FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Klemm, T
   Ebert, G
   Calleja, DJ
   Allison, CC
   Richardson, LW
   Bernardini, JP
   Lu, BGC
   Kuchel, NW
   Grohmann, C
   Shibata, Y
   Gan, ZY
   Cooney, JP
   Doerflinger, M
   Au, AE
   Blackmore, TR
   van Noort, GJV
   Geurink, PP
   Ovaa, H
   Newman, J
   Riboldi-Tunnicliffe, A
   Czabotar, PE
   Mitchell, JP
   Feltham, R
   Lechtenberg, BC
   Lowes, KN
   Dewson, G
   Pellegrini, M
   Lessene, G
   Komander, D
AF Klemm, Theresa
   Ebert, Gregor
   Calleja, Dale J.
   Allison, Cody C.
   Richardson, Lachlan W.
   Bernardini, Jonathan P.
   Lu, Bernadine G. C.
   Kuchel, Nathan W.
   Grohmann, Christoph
   Shibata, Yuri
   Gan, Zhong Yan
   Cooney, James P.
   Doerflinger, Marcel
   Au, Amanda E.
   Blackmore, Timothy R.
   van der Heden van Noort, Gerbrand J.
   Geurink, Paul P.
   Ovaa, Huib
   Newman, Janet
   Riboldi-Tunnicliffe, Alan
   Czabotar, Peter E.
   Mitchell, Jeffrey P.
   Feltham, Rebecca
   Lechtenberg, Bernhard C.
   Lowes, Kym N.
   Dewson, Grant
   Pellegrini, Marc
   Lessene, Guillaume
   Komander, David
TI Mechanism and inhibition of the papain-like protease, PLpro, of
   SARS-CoV-2
SO EMBO JOURNAL
LA English
DT Article
DE COVID-19; ISG15; papain-like protease; small molecule inhibitor;
   ubiquitin
ID RESPIRATORY-SYNDROME-CORONAVIRUS; UBIQUITIN RECOGNITION;
   CROSS-REACTIVITY; STRUCTURAL BASIS; MOLECULAR-BASIS; SPECIFICITY;
   ENZYMES; POTENT; ISG15
AB The SARS-CoV-2 coronavirus encodes an essential papain-like protease domain as part of its non-structural protein (nsp)-3, namely SARS2 PLpro, that cleaves the viral polyprotein, but also removes ubiquitin-like ISG15 protein modifications as well as, with lower activity, Lys48-linked polyubiquitin. Structures of PLpro bound to ubiquitin and ISG15 reveal that the S1 ubiquitin-binding site is responsible for high ISG15 activity, while the S2 binding site provides Lys48 chain specificity and cleavage efficiency. To identify PLpro inhibitors in a repurposing approach, screening of 3,727 unique approved drugs and clinical compounds against SARS2 PLpro identified no compounds that inhibited PLpro consistently or that could be validated in counterscreens. More promisingly, non-covalent small molecule SARS PLpro inhibitors also target SARS2 PLpro, prevent self-processing of nsp3 in cells and display high potency and excellent antiviral activity in a SARS-CoV-2 infection model.
C1 [Klemm, Theresa; Ebert, Gregor; Calleja, Dale J.; Allison, Cody C.; Richardson, Lachlan W.; Bernardini, Jonathan P.; Lu, Bernadine G. C.; Kuchel, Nathan W.; Grohmann, Christoph; Shibata, Yuri; Gan, Zhong Yan; Cooney, James P.; Doerflinger, Marcel; Au, Amanda E.; Blackmore, Timothy R.; Czabotar, Peter E.; Mitchell, Jeffrey P.; Feltham, Rebecca; Lechtenberg, Bernhard C.; Lowes, Kym N.; Dewson, Grant; Pellegrini, Marc; Lessene, Guillaume; Komander, David] Univ Melbourne, Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia.
   [Klemm, Theresa; Ebert, Gregor; Calleja, Dale J.; Allison, Cody C.; Richardson, Lachlan W.; Bernardini, Jonathan P.; Lu, Bernadine G. C.; Kuchel, Nathan W.; Grohmann, Christoph; Shibata, Yuri; Gan, Zhong Yan; Cooney, James P.; Doerflinger, Marcel; Au, Amanda E.; Blackmore, Timothy R.; Czabotar, Peter E.; Mitchell, Jeffrey P.; Feltham, Rebecca; Lechtenberg, Bernhard C.; Lowes, Kym N.; Dewson, Grant; Pellegrini, Marc; Lessene, Guillaume; Komander, David] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia.
   [Bernardini, Jonathan P.] Univ British Columbia, Dept Biochem & Mol Biol, Michael Smith Labs, Vancouver, BC, Canada.
   [van der Heden van Noort, Gerbrand J.; Geurink, Paul P.; Ovaa, Huib] Leiden Univ, Med Ctr, Oncode Inst, Leiden, Netherlands.
   [van der Heden van Noort, Gerbrand J.; Geurink, Paul P.; Ovaa, Huib] Leiden Univ, Med Ctr, Dept Cell & Chem Biol, Leiden, Netherlands.
   [Newman, Janet] CSIRO, Biomed Program, Parkville, Vic, Australia.
   [Riboldi-Tunnicliffe, Alan] Australian Synchrotron, ANSTO, Clayton, Vic, Australia.
   [Lessene, Guillaume] Univ Melbourne, Pharmacol & Therapeut Dept, Melbourne, Vic, Australia.
RP Pellegrini, M; Lessene, G; Komander, D (corresponding author), Univ Melbourne, Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia.; Pellegrini, M; Lessene, G; Komander, D (corresponding author), Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia.; Lessene, G (corresponding author), Univ Melbourne, Pharmacol & Therapeut Dept, Melbourne, Vic, Australia.
EM pellegrini@wehi.edu.au; glessene@wehi.edu.au; dk@wehi.edu.au
FU Walter and Eliza Hall Institute of Medical Research, an NHMRC/MRFF
   "VirDUB" grant [MRF2002119]; NWO (VIDI-grant)Netherlands Organization
   for Scientific Research (NWO); NWO (Off-road grant); NHMRCNational
   Health and Medical Research Council of Australia [GNT1178122,
   GNT0637350, GNT1117089]; NHMRC Independent Research Institutes
   Infrastructure Support Scheme grantNational Health and Medical Research
   Council of Australia [361646]; Victorian State Government Operational
   Infrastructure Support grant
FX We would like to thank Kanta Subbarao (Peter Doherty Institute,
   Melbourne) for live SARS-CoV-2 virus, Frederick P. (Fritz) Roth
   (University of Toronto) for providing the SARS2 nsp3 pENTRY plasmid,
   Thibault Major (University of British Columbia, Vancouver) for vectors
   and for supporting J. Bernardini, Sandra Nicholson, Peter Colman, Ian
   Wicks and Thomas Cotton (WEHI) for sharing expertise and reagents, and
   Jonathan O'Connell (FORMA Therapeutics) for advice on high-throughput
   assays. This work was funded by The Walter and Eliza Hall Institute of
   Medical Research, an NHMRC/MRFF "VirDUB" grant MRF2002119 (to DK, GL,
   MP, PEC), NWO (VIDI-grant and Off-road grant) to GJvdHvN, NHMRC
   Investigator Grants and Fellowships (GNT1178122 to DK, GNT0637350 to MP,
   and GNT1117089 to GL), NHMRC Independent Research Institutes
   Infrastructure Support Scheme grant (361646) and Victorian State
   Government Operational Infrastructure Support grant, and a generous
   donation by Hengyi Pacific Pty Ltd to support COVID-19 research.
CR Adams PD, 2011, METHODS, V55, P94, DOI 10.1016/j.ymeth.2011.07.005
   Akutsu M, 2011, P NATL ACAD SCI USA, V108, P2228, DOI 10.1073/pnas.1015287108
   Aragao D, 2018, J SYNCHROTRON RADIAT, V25, P885, DOI 10.1107/S1600577518003120
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Baez-Santos YM, 2014, J MED CHEM, V57, P2393, DOI 10.1021/jm401712t
   Bailey-Elkin BA, 2017, J MOL BIOL, V429, P3441, DOI 10.1016/j.jmb.2017.06.010
   Bailey-Elkin BA, 2014, J BIOL CHEM, V289, P34667, DOI 10.1074/jbc.M114.609644
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Bekes M, 2016, MOL CELL, V62, P572, DOI 10.1016/j.molcel.2016.04.016
   Bekes M, 2015, BIOCHEM J, V468, P215, DOI 10.1042/BJ20141170
   Berlin David A, 2020, N Engl J Med, V383, P2451, DOI 10.1056/NEJMcp2009575
   Berrow NS, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm047
   Caly L, 2020, MED J AUSTRALIA, V212, P459, DOI 10.5694/mja2.50569
   Chou CY, 2014, ACTA CRYSTALLOGR D, V70, P572, DOI 10.1107/S1399004713031040
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Chu Hin, 2020, Lancet Microbe, V1, pe14, DOI 10.1016/S2666-5247(20)30004-5
   Clasman JR, 2020, ANTIVIR RES, V174, DOI 10.1016/j.antiviral.2019.104661
   Clementz MA, 2010, J VIROL, V84, P4619, DOI 10.1128/JVI.02406-09
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Daczkowski CM, 2017, J VIROL, V91, DOI 10.1128/JVI.01067-17
   Daczkowski CM, 2017, J MOL BIOL, V429, P1661, DOI 10.1016/j.jmb.2017.04.011
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Dzimianski JV, 2019, J MOL BIOL, V431, P4203, DOI 10.1016/j.jmb.2019.03.013
   Ebner P, 2017, CRIT REV BIOCHEM MOL, V52, P425, DOI 10.1080/10409238.2017.1325829
   Ekkebus R, 2013, J AM CHEM SOC, V135, P2867, DOI 10.1021/ja309802n
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Evans PR, 2013, ACTA CRYSTALLOGR D, V69, P1204, DOI 10.1107/S0907444913000061
   Flierman D, 2016, CELL CHEM BIOL, V23, P472, DOI 10.1016/j.chembiol.2016.03.009
   Freitas BT, 2020, ACS INFECT DIS, V6, P2099, DOI 10.1021/acsinfecdis.0c00168
   Frias-Staheli N, 2007, CELL HOST MICROBE, V2, P404, DOI 10.1016/j.chom.2007.09.014
   Gersch M, 2017, NAT STRUCT MOL BIOL, V510, P370
   Geurink PP, 2019, METHOD ENZYMOL, V618, P357, DOI 10.1016/bs.mie.2018.12.037
   Geurink PP, 2012, CHEMBIOCHEM, V13, P293, DOI 10.1002/cbic.201100706
   Ghosh AK, 2020, CHEMMEDCHEM, V15, P907, DOI 10.1002/cmdc.202000223
   Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Heaton SM, 2016, J EXP MED, V213, P1, DOI 10.1084/jem.20151531
   Isaacson MK, 2009, CELL HOST MICROBE, V5, P559, DOI 10.1016/j.chom.2009.05.012
   Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581
   James TW, 2011, P NATL ACAD SCI USA, V108, P2222, DOI 10.1073/pnas.1013388108
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   KIM JC, 1995, VIROLOGY, V208, P1, DOI 10.1006/viro.1995.1123
   Kotschy A, 2016, NATURE, V538, P477, DOI 10.1038/nature19830
   Lee H, 2015, ACS CHEM BIOL, V10, P1456, DOI 10.1021/cb500917m
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Lindner HA, 2007, ARCH BIOCHEM BIOPHYS, V466, P8, DOI 10.1016/j.abb.2007.07.006
   Magis C, 2014, METHODS MOL BIOL, V1079, P117, DOI 10.1007/978-1-62703-646-7_7
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Mevissen TET, 2017, ANNU REV BIOCHEM, V86, P159, DOI 10.1146/annurev-biochem-061516-044916
   Mevissen TET, 2013, CELL, V154, P169, DOI 10.1016/j.cell.2013.05.046
   Michel MA, 2018, METHODS MOL BIOL, V1844, P73, DOI 10.1007/978-1-4939-8706-1_6
   Perng YC, 2018, NAT REV MICROBIOL, V16, P423, DOI 10.1038/s41579-018-0020-5
   Pruijssers AJ, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107940
   Ratia K, 2006, P NATL ACAD SCI USA, V103, P5717, DOI 10.1073/pnas.0510851103
   Ratia K, 2008, P NATL ACAD SCI USA, V105, P16119, DOI 10.1073/pnas.0805240105
   Ratia K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004113
   Rut Wioletta, 2020, bioRxiv, DOI 10.1101/2020.04.29.068890
   Shin D, 2020, NATURE, DOI 10.1038/s41586-020-2601-5
   Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048
   Swatek KN, 2018, P NATL ACAD SCI USA, V115, P2371, DOI 10.1073/pnas.1710617115
   Swatek KN, 2016, CELL RES, V26, P399, DOI 10.1038/cr.2016.39
   Turnbull AP, 2017, NATURE, V550, P481, DOI 10.1038/nature24451
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wilkinson KD, 2005, METHOD ENZYMOL, V399, P37, DOI 10.1016/S0076-6879(05)99003-4
   Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yau R, 2016, NAT CELL BIOL, V18, P579, DOI 10.1038/ncb3358
   Ye Y, 2011, EMBO REP, V12, P350, DOI 10.1038/embor.2011.17
   Zhang X, 2017, MOL CELL, V65, P1
NR 70
TC 0
Z9 0
U1 8
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
PD SEP 15
PY 2020
VL 39
IS 18
AR e106275
PG 17
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NS6LK
UT WOS:000572370300006
DA 2021-01-01
ER

PT J
AU Prommer, E
AF Prommer, Eric
TI Safety and Utility of Chloroquine/ Hydroxychloroquine in Palliative Care
   Patients
SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE
LA English
DT Article; Early Access
DE hydroxychloroquine; chloroquine; palliative care; pharmacology;
   antiviral; COVID-19
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; OLD DRUG; ENANTIOMERS; PHOSPHATE
AB The coronavirus disease 2019 (COVID-19) pandemic represents a significant healthcare challenge for the world. Many drugs have therapeutic potential. The aminoquinolones, hydroxychloroquine, and chloroquine are undergoing evaluation as a potential therapy against COVID -19. In vitro and in vivo studies suggest that these drugs affect viral adherence and modify inflammatory responses, which may provide some impact on the symptoms associated with COVID. As palliative care specialists encounter more COVID positive patients, palliative care specialists need to know how these drugs work, and importantly how they interact with palliative care drugs used for symptom control. At the same time, there is a need to reduce polypharmacy in any seriously ill patient population. The goals of this paper are to identify whether or not hydroxychloroquine/chloroquine improves symptoms in palliative care patients and whether or not these drugs are safe to use in the advanced illness population who have COVID.
C1 [Prommer, Eric] Greater Los Angeles Healthcare, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
RP Prommer, E (corresponding author), Greater Los Angeles Healthcare, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM eric.prommer@va.gov
CR Adedoyin A, 1998, BRIT J CLIN PHARMACO, V46, P215, DOI 10.1046/j.1365-2125.1998.00765.x
   ALI HM, 1985, J ANTIMICROB CHEMOTH, V15, P781, DOI 10.1093/jac/15.6.781
   American Society of Health-System Pharmacists, 2020, EARL REL INF EXT FOR
   [Anonymous], 2020, MICR DRUG INT HYDR C
   [Anonymous], 2020, CORONAVIRUS COVID 19
   [Anonymous], 2017, AR CHLOR PHOSPH
   [Anonymous], 2020, INF CLIN THER OPT CO
   Barlow A, 2020, PHARMACOTHERAPY, V40, P416, DOI 10.1002/phar.2398
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Chorin E, 2020, HEART RHYTHM
   Chorin E, 2020, QT INTERVAL PATIENTS, V2020, DOI [10.1101/2020.04.02.20047050, DOI 10.1101/2020.04.02.20047050]
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Cutler D J, 1988, Agents Actions Suppl, V24, P142
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   ETTE EI, 1987, J CLIN PHARMACOL, V27, P813, DOI 10.1002/j.1552-4604.1987.tb03002.x
   ETTE EI, 1987, DRUG INTEL CLIN PHAR, V21, P732, DOI 10.1177/106002808702100913
   Food and Drug Administration, 2020, FACT SHEET HLTH CAR
   Franken LG, 2016, EXPERT OPIN DRUG MET, V12, P669, DOI 10.1080/17425255.2016.1179281
   Galvan VG, 2007, CLIN RHEUMATOL, V26, P971, DOI 10.1007/s10067-006-0218-1
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Kaufmann AM, 2007, J PHARM SCI-US, V96, P729, DOI 10.1002/jps.20792
   Kuznik A, 2011, J IMMUNOL, V186, P4794, DOI 10.4049/jimmunol.1000702
   Lacerda M, 2020, CHLOROQUINE DIPHOSPH
   LEDEN I, 1982, ACTA MED SCAND, V211, P411
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Malaria WSGotCo, 1984, ADV MAL CHEM REP WHO
   McCreary EK, 2020, COVID 19 TREATMENT R
   MCELNAY JC, 1985, INT J PHARM, V26, P267, DOI 10.1016/0378-5173(85)90236-4
   MCLACHLAN AJ, 1991, J CHROMATOGR-BIOMED, V570, P119, DOI 10.1016/0378-4347(91)80206-R
   MCLACHLAN AJ, 1994, CHIRALITY, V6, P360, DOI 10.1002/chir.530060421
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Pati S., 2020, SYSTEMATIC REV ASSES, DOI [10.1101/2020.04.09.20056358, DOI 10.1101/2020.04.09.20056358]
   Perinel S, 2020, CLIN INFECT DIS
   Projean D, 2003, DRUG METAB DISPOS, V31, P748, DOI 10.1124/dmd.31.6.748
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Ramireddy A, 2020, EXPERIENCE HYDROXYCH, DOI [10.1101/2020.04.22.20075671, DOI 10.1101/2020.04.22.20075671]
   Ramireddy A, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.017144
   Ruiz-Irastorza G, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2764
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Shippey EA, 2018, CLEV CLIN J MED, V85, P459, DOI 10.3949/ccjm.85a.17034
   Sun LZ, 2016, MED HYPOTHESES, V93, P5, DOI 10.1016/j.mehy.2016.04.045
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Warhurst DC, 2003, J ANTIMICROB CHEMOTH, V52, P188, DOI 10.1093/jac/dkg319
   Wozniacka A, 2006, LUPUS, V15, P521, DOI 10.1191/0961203306lu2345oa
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yusuf IH, 2017, EYE, V31, P828, DOI 10.1038/eye.2016.298
NR 51
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1049-9091
EI 1938-2715
J9 AM J HOSP PALLIAT ME
JI Am. J. Hosp. Palliat. Med.
AR 1049909120952773
DI 10.1177/1049909120952773
EA SEP 2020
PG 9
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA NQ1LP
UT WOS:000570628700001
PM 32929975
DA 2021-01-01
ER

PT J
AU Larsson, E
   Brattstrom, O
   Agvald-Ohman, C
   Grip, J
   Jalde, FC
   Stralin, K
   Naucler, P
   Oldner, A
   Konrad, D
   Persson, BP
   Eriksson, LI
   Martensson, J
AF Larsson, Emma
   Brattstrom, Olof
   Agvald-Ohman, Christina
   Grip, Jonathan
   Campoccia Jalde, Francesca
   Stralin, Kristoffer
   Naucler, Pontus
   Oldner, Anders
   Konrad, David
   Persson, Bjorn P.
   Eriksson, Lars I.
   Martensson, Johan
CA Karolinska Intensive Care COVID-19
TI Characteristics and outcomes of patients with COVID-19 admitted to ICU
   in a tertiary hospital in Stockholm, Sweden
SO ACTA ANAESTHESIOLOGICA SCANDINAVICA
LA English
DT Article
DE ARDS; COVID-19; critical care; SARS-CoV-2
AB Background: Information on characteristics and outcomes of intensive care unit (ICU) patients with COVID-19 remains limited. We examined characteristics, clinical course and early outcomes of patients with COVID-19 admitted to ICU.
   Methods: We included all 260 patients with COVID-19 admitted to nine ICUs at the Karolinska University Hospital (Stockholm, Sweden) between 9 March and 20 April 2020. Primary outcome was in-hospital mortality among patients with definite outcomes (discharged from ICU or death), as of 30 April 2020 (study end point). Secondary outcomes included ICU length of stay, the proportion of patients receiving mechanical ventilation and renal replacement therapy, and hospital discharge destination.
   Results: Of 260 ICU patients with COVID-19, 208 (80.0%) were men, the median age was 59 (IQR 51-65) years, 154 (59.2%) had at least one comorbidity, and the median duration of symptoms preceding ICU admission was 11 (IQR 8-14) days. Sixty-two (23.8%) patients remained in ICU at study end point. Among the 198 patients with definite outcomes, ICU length of stay was 12 (IQR, 6-18) days, 163 (82.3%) received mechanical ventilation, 28 (14.1%) received renal replacement therapy, 60 (30.3%) died, 62 (31.3%) were discharged home, 47 (23.7%) were discharged to ward, and 29 (14.6%) were discharged to another health care facility. On multivariable logistic regression analysis, older age and admission from the emergency department was associated with higher mortality.
   Conclusion: This study presents detailed data on clinical characteristics and early outcomes of consecutive patients with COVID-19 admitted to ICU in a large tertiary hospital in Sweden.
C1 [Larsson, Emma; Brattstrom, Olof; Campoccia Jalde, Francesca; Oldner, Anders; Konrad, David; Persson, Bjorn P.; Eriksson, Lars I.; Martensson, Johan] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden.
   [Larsson, Emma; Brattstrom, Olof; Agvald-Ohman, Christina; Grip, Jonathan; Campoccia Jalde, Francesca; Oldner, Anders; Konrad, David; Persson, Bjorn P.; Eriksson, Lars I.; Martensson, Johan] Karolinska Univ Hosp, Dept Perioperat Med & Intens Care, SE-17176 Stockholm, Sweden.
   [Agvald-Ohman, Christina; Grip, Jonathan] Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Stockholm, Sweden.
   [Stralin, Kristoffer; Naucler, Pontus] Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden.
   [Stralin, Kristoffer] Karolinska Inst, Dept Med, Stockholm, Sweden.
   [Naucler, Pontus] Karolinska Inst, Dept Med, Div Infect Dis, Stockholm, Sweden.
RP Martensson, J (corresponding author), Karolinska Univ Hosp, Dept Perioperat Med & Intens Care, SE-17176 Stockholm, Sweden.
EM johan.martensson@sll.se
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Myers LC, 2020, JAMA-J AM MED ASSOC, V323, P2195, DOI 10.1001/jama.2020.7202
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Organization WH, BOOK COR DIS COVID 2
   Registry SIC Swedish Intensive Care Registry, BOOK SWED INT CAR RE
   Rhodes A, 2012, INTENS CARE MED, V38, P1647, DOI 10.1007/s00134-012-2627-8
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   United Nations Department of Economic and Social Affairs, WORLD POP PROSP 2019
   [World Health Organization Book World Health Organization], 2019, GEN GOV EXP HLTH PER
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 12
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-5172
EI 1399-6576
J9 ACTA ANAESTH SCAND
JI Acta Anaesthesiol. Scand.
PD JAN
PY 2021
VL 65
IS 1
BP 76
EP 81
DI 10.1111/aas.13694
EA SEP 2020
PG 6
WC Anesthesiology
SC Anesthesiology
GA PD7IT
UT WOS:000569389900001
PM 32892337
OA Other Gold
DA 2021-01-01
ER

PT J
AU Halpern, B
   Mancini, MC
AF Halpern, Bruno
   Mancini, Marcio C.
TI Type 2 diabetes and metabolic surgery guidelines and recommendations
   should urgently be unified
SO ACTA DIABETOLOGICA
LA English
DT Article; Early Access
DE Bariatric surgery; Metabolic surgery; Type 2 diabetes; Obesity;
   Cardiovascular disease; Guidelines; Diabetes treatment
ID LONG-TERM REMISSION; Y GASTRIC BYPASS; BARIATRIC SURGERY; POSITION
   STATEMENT; AMERICAN-COLLEGE; MEDICAL THERAPY; ASSOCIATION; MANAGEMENT;
   OUTCOMES; WEIGHT
AB Metabolic surgery has been studied in the last decades as an effective and safe treatment for type 2 diabetes (T2D), and randomized controlled trials generally found surgery superior when compared with medical treatment. In 2016, the DSS-II Joint Statement recognized the importance of metabolic surgery in the treatment of T2D and urged clinicians to discuss, recommend, or at least consider this procedure for their patients. Diabetes societies also cogitate metabolic surgery as an option for T2D patients in their guidelines. However, there are some differences in recommendations that could lead a careful reader to some confusion. This was potentialized in a recent document published by the same DSS-II group concerning prioritization for surgery after the COVID-19 pandemic, in which the criteria suggested for an expedited recommendation that is not exactly evidence-based, and collided substantially with several clinical guidelines worldwide, especially with regard to secondary prevention of cardiovascular disease. A more harmonious discussion and unified guidelines between clinicians and surgeons are needed in order to provide the same message for those who read different articles.
C1 [Halpern, Bruno; Mancini, Marcio C.] Univ Sao Paulo, Dept Endocrinol, Obes Grp, Hosp Clin, Sao Paulo, Brazil.
   [Halpern, Bruno] Brazilian Assoc Study Obes ABESO, Dept Epidemiol & Prevent, Sao Paulo, Brazil.
   [Mancini, Marcio C.] Brazilian Soc Endocrinol & Metab SBEM, Rio De Janeiro, Brazil.
RP Halpern, B (corresponding author), Univ Sao Paulo, Dept Endocrinol, Obes Grp, Hosp Clin, Sao Paulo, Brazil.; Halpern, B (corresponding author), Brazilian Assoc Study Obes ABESO, Dept Epidemiol & Prevent, Sao Paulo, Brazil.
EM brunohalpern@hotmail.com
CR Adams TD, 2007, NEW ENGL J MED, V357, P753, DOI 10.1056/NEJMoa066603
   Adams TD, 2015, CURR ATHEROSCLER REP, V17, DOI 10.1007/s11883-015-0551-4
   Alsabrook GD, 2006, OBES SURG, V16, P1272, DOI 10.1381/096089206778663779
   Aminian A, 2019, JAMA-J AM MED ASSOC, V322, P1271, DOI 10.1001/jama.2019.14231
   Arnett DK, 2019, CIRCULATION, V140, pE563, DOI 10.1161/CIR.0000000000000677
   Arterburn DE, 2013, OBES SURG, V23, P93, DOI 10.1007/s11695-012-0802-1
   Batterham RL, 2016, DIABETES CARE, V39, P893, DOI 10.2337/dc16-0145
   Bray GA, 2018, ENDOCR REV, V39, P79, DOI 10.1210/er.2017-00253
   Buchwald H, 2019, DIABETES CARE, V42, P331, DOI 10.2337/dc17-2654
   Buchwald H, 2009, AM J MED, V122, P248, DOI 10.1016/j.amjmed.2008.09.041
   Cosentino F, 2020, EUR HEART J, V41, P255, DOI 10.1093/eurheartj/ehz486
   Courcoulas AP, 2015, JAMA SURG, V150, P931, DOI 10.1001/jamasurg.2015.1534
   Cummings DE, 2016, DIABETES CARE, V39, P924, DOI 10.2337/dc16-0350
   Davies MJ, 2018, DIABETOLOGIA, V61, P2461, DOI 10.1007/s00125-018-4729-5
   Delling L, 2010, J OBES, V2010, DOI 10.1155/2010/102341
   DiGiorgi M, 2010, SURG OBES RELAT DIS, V6, P249, DOI 10.1016/j.soard.2009.09.019
   Eliasson B, 2015, LANCET DIABETES ENDO, V3, P847, DOI 10.1016/S2213-8587(15)00334-4
   Executive Council of ASMBS, 2020, SURG OBES RELAT DIS
   Funk LM, 2015, JAMA SURG, V150, P999, DOI 10.1001/jamasurg.2015.1250
   Garber AJ, 2020, ENDOCR PRACT, V26, P107, DOI 10.4158/CS-2019-0472
   Halpern B, 2016, DIABETES CARE, P924
   Halpern B, 2020, LANCET DIABETES ENDO, V8, P741, DOI 10.1016/S2213-8587(20)30276-X
   Halpern B, 2019, OBES REV, V20, P633, DOI 10.1111/obr.12837
   Herzog K, 2020, DIABETES
   Ikramuddin S, 2015, LANCET DIABETES ENDO, V3, P413, DOI 10.1016/S2213-8587(15)00089-3
   Inabnet WB, 2012, J AM COLL SURGEONS, V214, P550, DOI 10.1016/j.jamcollsurg.2011.12.019
   Inzucchi SE, 2015, DIABETOLOGIA, V58, P429, DOI 10.1007/s00125-014-3460-0
   Jackness C, 2013, DIABETES, V62, P3027, DOI 10.2337/db12-1762
   Jensen MD, 2014, J AM COLL CARDIOL, V63, P2985, DOI 10.1016/j.jacc.2013.11.004
   Kadera BE, 2009, SURG OBES RELAT DIS, V5, P305, DOI 10.1016/j.soard.2009.02.007
   Kristensen SL, 2019, LANCET DIABETES ENDO, V7, P776, DOI 10.1016/S2213-8587(19)30249-9
   Lean MEJ, 2019, LANCET DIABETES ENDO, V7, P344, DOI 10.1016/S2213-8587(19)30068-3
   Lean MEJ, 2018, LANCET, V391, P541, DOI 10.1016/S0140-6736(17)33102-1
   Lebovitz HE, 2013, OBES SURG, V23, P800, DOI 10.1007/s11695-013-0907-1
   Lingvay I, 2013, DIABETES CARE, V36, P2741, DOI 10.2337/dc12-2316
   Liu L, 2020, J MED VIROL, V92, P3327, DOI 10.1002/jmv.25718
   Lopez-Jimenez F, 2005, MAYO CLIN PROC, V80, P1157, DOI 10.4065/80.9.1157
   Madsbad S, 2014, LANCET DIABETES ENDO, V2, P152, DOI 10.1016/S2213-8587(13)70218-3
   Mingrone G, 2012, NEW ENGL J MED, V366, P1577, DOI 10.1056/NEJMoa1200111
   Miras AD, 2014, LANCET DIABETES ENDO, V2, P141, DOI 10.1016/S2213-8587(13)70158-X
   O'Rahilly S, 2016, CLIN MED, V16, P551, DOI 10.7861/clinmedicine.16-6-551
   Pirlet C, 2020, AM J CARDIOL, V125, P40, DOI 10.1016/j.amjcard.2019.09.041
   Pontiroli AE, 2020, OBES SURG, V30, P2487, DOI 10.1007/s11695-020-04530-3
   Pontiroli AE, 2020, ACTA DIABETOL, V57, P323, DOI 10.1007/s00592-019-01433-3
   Pontiroli AE, 2019, OBES SURG, V29, P935, DOI 10.1007/s11695-018-3601-5
   Riddle MC, 2020, DIABETES CARE, V43, P1378, DOI 10.2337/dci20-0024
   Rubino F, 2020, LANCET DIABET ENDOCR
   Rubino F, 2016, DIABETES CARE, V39, P861, DOI 10.2337/dc16-0236
   Sattar N, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0123-4
   Schauer PR, 2017, NEW ENGL J MED, V376, P641, DOI 10.1056/NEJMoa1600869
   Schauer PR, 2011, SURG OBES RELAT DIS, V7, P448, DOI 10.1016/j.soard.2011.05.015
   Sjoholm K, 2015, DIABETOLOGIA, V58, P1448, DOI 10.1007/s00125-015-3591-y
   Sjostrom L, 2013, J INTERN MED, V273, P219, DOI 10.1111/joim.12012
   Sjostrom L, 2014, JAMA-J AM MED ASSOC, V311, P2297, DOI 10.1001/jama.2014.5988
   Steven S, 2016, DIABETES CARE, V39, P158, DOI 10.2337/dc15-0750
   Taylor R, 2019, LANCET DIABETES ENDO, V7, P726, DOI 10.1016/S2213-8587(19)30076-2
   White MG, 2016, DIABETES CARE, V39, P2080, DOI 10.2337/dc16-0619
   Williamson EJ, 2020, NATURE
   Yoshino M, 2020, NEW ENGL J MED, V383, P721, DOI 10.1056/NEJMoa2003697
   Yumuk V, 2015, OBESITY FACTS, V8, P402, DOI 10.1159/000442721
   Zelniker TA, 2019, CIRCULATION, V139, P2022, DOI 10.1161/CIRCULATIONAHA.118.038868
   Zelniker TA, 2019, LANCET, V393, P31, DOI 10.1016/S0140-6736(18)32590-X
NR 62
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 0940-5429
EI 1432-5233
J9 ACTA DIABETOL
JI Acta Diabetol.
DI 10.1007/s00592-020-01603-8
EA SEP 2020
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NP3ZF
UT WOS:000570116400001
PM 32930887
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Jin, Z
   Liu, JY
   Feng, R
   Ji, L
   Jin, ZL
   Li, HB
AF Jin, Zhe
   Liu, Jing-Yi
   Feng, Rang
   Ji, Lu
   Jin, Zi-Li
   Li, Hai-Bo
TI Drug treatment of coronavirus disease 2019 (COVID-19) in China
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; Drug treatment; China
ID ELASTASE INHIBITOR SIVELESTAT; ACUTE LUNG INJURY; CONVALESCENT PLASMA;
   T-705 FAVIPIRAVIR; LOPINAVIR/RITONAVIR; CHLOROQUINE; RIBAVIRIN;
   GLUCOCORTICOIDS; MECHANISMS; INFECTION
AB Since December 2019, the coronavirus disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread throughout China as well as other countries. More than 8,700,000 confirmed COVID-19 cases have been recorded worldwide so far, with much more cases popping up overseas than those inside. As the initial epicenter in the world, China has been combating the epidemic for a relatively longer period and accumulated valuable experience in prevention and control of COVID-19. This article reviewed the clinical use, mechanism and efficacy of the clinically approved drugs recommended in the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (DTPNCP) released by National Health Commission of P.R. China, and the novel therapeutic agents now undergoing clinical trials approved by China National Medical Products Administration (NMPA) to evaluate experimental treatment for COVID-19. Reviewing the progress in drug development for the treatment against COVID-19 in China may provide insight into the epidemic control in other countries.
C1 [Jin, Zhe; Liu, Jing-Yi; Feng, Rang; Ji, Lu; Jin, Zi-Li; Li, Hai-Bo] Third Mil Med Univ, Coll Pharm, Natl Engn Res Ctr Immunol Prod, Dept Microbiol & Biochem Pharm, Chongqing 400038, Peoples R China.
RP Jin, ZL; Li, HB (corresponding author), Third Mil Med Univ, Coll Pharm, Chongqing 400038, Peoples R China.
EM jinzili@pku.edu.cn; lihaibo@tmmu.edu.cn
FU Chinese National Natural Science Foundation ProjectNational Natural
   Science Foundation of China (NSFC) [31670936/31400788]
FX This work was supported by Chinese National Natural Science Foundation
   Project (No. 31670936/31400788). We thank Prof. Shan Guan and Miss
   Xiaoqing Zhan (Third Military Medical University) for their linguistic
   assistance during the revison of this manuscript.
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Aikawa N, 2014, THER CLIN RISK MANAG, V10, P621, DOI 10.2147/TCRM.S65066
   Alzghari SK, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104380
   Antinori S, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102564
   Barratt-Due A, 2013, J IMMUNOL, V191, P819, DOI 10.4049/jimmunol.1201909
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Bian X.-W., 2020, NATL SCI REV, DOI [10.1093/nsr/nwaa123nwaa123, DOI 10.1093/NSR/NWAA123NWAA123]
   Bijker EM, 2013, P NATL ACAD SCI USA, V110, P7862, DOI 10.1073/pnas.1220360110
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Burnouf T, 2003, Hong Kong Med J, V9, P310
   Cai GJ, 2020, STEEL RES INT, DOI 10.1002/srin.202000269
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao HL, 2020, TRANSFUSION, V60, P1078, DOI 10.1111/trf.15797
   Chen Jiajia, 2020, Engineering (Beijing), V6, P1153, DOI 10.1016/j.eng.2020.02.006
   CHEN M, 2020, HER MED, V39, P483, DOI DOI 10.3870/j.issn.1004-0781.2020.04.010
   Cheng CY, 2020, J MICROBIOL IMMUNOL, V53, P488, DOI 10.1016/j.jmii.2020.03.032
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Delvecchio R, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8120322
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Fan ZY, 2020, CLIN GASTROENTEROL H, V18, P1561, DOI 10.1016/j.cgh.2020.04.002
   Ferreira LLG, 2019, DRUG DISCOV TODAY, V24, P1157, DOI 10.1016/j.drudis.2019.03.015
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Furuta Y, 2009, ANTIVIR RES, V82, P95, DOI 10.1016/j.antiviral.2009.02.198
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   GILBERT BE, 1986, ANTIMICROB AGENTS CH, V30, P201, DOI 10.1128/AAC.30.2.201
   Golchin A, 2020, STEM CELL REV REP, V16, P427, DOI 10.1007/s12015-020-09973-w
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Han V.D.W., 2003, NAT REV DRUG DISCOV, V2, P278
   Hendaus MA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1767691
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang M, 2020, PRELIMINARY EVIDENCE
   Hughes JP, 2011, BRIT J PHARMACOL, V162, P1239, DOI 10.1111/j.1476-5381.2010.01127.x
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Iwata K, 2010, INTERNAL MED, V49, P2423, DOI 10.2169/internalmedicine.49.4010
   Kadam RU, 2017, P NATL ACAD SCI USA, V114, P206, DOI 10.1073/pnas.1617020114
   Khalili JS, 2020, J MED VIROL, V92, P740, DOI 10.1002/jmv.25798
   Khambholja K, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101710
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li ZY, 2020, DRUG DISCOV THER, V14, P73, DOI 10.5582/ddt.2020.01015
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Liu SY, 2011, CURR OPIN IMMUNOL, V23, P57, DOI 10.1016/j.coi.2010.11.003
   Mizui T, 2010, J GASTROENTEROL, V45, P195, DOI 10.1007/s00535-009-0132-9
   Monsel A, 2016, EXPERT OPIN BIOL TH, V16, P859, DOI 10.1517/14712598.2016.1170804
   Montoya M, 2002, BLOOD, V99, P3263, DOI 10.1182/blood.V99.9.3263
   MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25
   Oestereich L, 2014, ANTIVIR RES, V105, P17, DOI 10.1016/j.antiviral.2014.02.014
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Pantziarka P, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k2701
   Pecheur EI, 2007, BIOCHEMISTRY-US, V46, P6050, DOI 10.1021/bi700181j
   Qin YY, 2020, CHINESE MED J-PEKING, V133, P1080, DOI 10.1097/CM9.0000000000000791
   Renu K, 2020, LIFE SCI, V255, DOI 10.1016/j.lfs.2020.117839
   Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Rocha-Pereira J, 2012, BIOCHEM BIOPH RES CO, V424, P777, DOI 10.1016/j.bbrc.2012.07.034
   Sachs RE, 2017, JAMA-J AM MED ASSOC, V318, P2421, DOI 10.1001/jama.2017.17535
   Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001
   Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8
   Scheinecker C, 2009, NAT REV DRUG DISCOV, V8, P273, DOI 10.1038/nrd2863
   Schultz KR, 1997, LEUKEMIA LYMPHOMA, V24, P201, DOI 10.3109/10428199709039008
   Shannon A, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104793
   Shi Chen, 2020, CHIN J HOSP PHARM, P1
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   van Griensven J, 2016, NEW ENGL J MED, V374, P33, DOI 10.1056/NEJMoa1511812
   Vankadari N, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105998
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang RX, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.28
   Wang X, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0169-8
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Wilckens T, 1997, IMMUNOL TODAY, V18, P418, DOI 10.1016/S0167-5699(97)01111-0
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Ye XT, 2020, EUR REV MED PHARMACO, V24, P3390, DOI 10.26355/eurrev_202003_20706
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Yuki K, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108427
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang LB, 2020, AGING-US, V12, P6536, DOI 10.18632/aging.103102
   ZHANG ZH, 2020, CHIN J HOSP PHARM, V40, P721, DOI DOI 10.13286/j.1001-5213.2020.07.01
   Zhao RCH, 2020, STEM CELLS DEV, V29, P679, DOI 10.1089/scd.2020.0071
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
   Zhou Hang, 2020, Histol Histopathol, V35, P1077, DOI 10.14670/HH-18-223
   Zhu Z, 2020, J INFECTION, V81, pE21, DOI 10.1016/j.jinf.2020.03.060
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 95
TC 1
Z9 1
U1 7
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD SEP 15
PY 2020
VL 883
AR 173326
DI 10.1016/j.ejphar.2020.173326
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NN9ZD
UT WOS:000569146600002
PM 32598953
OA Green Published
DA 2021-01-01
ER

PT J
AU Omolo, CA
   Soni, N
   Fasiku, VO
   Mackraj, I
   Govender, T
AF Omolo, Calvin A.
   Soni, Nikki
   Fasiku, Victoria Oluwaseun
   Mackraj, Irene
   Govender, Thirumala
TI Update on therapeutic approaches and emerging therapies for SARS-CoV-2
   virus
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV2; Re-purposing; Drug targets; Clinical trials;
   Vaccines
ID RESPIRATORY SYNDROME CORONAVIRUS; MONOCLONAL-ANTIBODY; FAVIPIRAVIR
   T-705; SARS CORONAVIRUS; COVID-19; INHIBITION; DRUGS; TOLERABILITY;
   INFECTION; VACCINES
AB The global pandemic of coronavirus disease 2019 (COVID-19), caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in over 7,273,958 cases with almost over 413,372 deaths worldwide as per the WHO situational report 143 on COVID-19. There are no known treatment regimens with proven efficacy and vaccines thus far, posing an unprecedented challenge to identify effective drugs and vaccines for prevention and treatment. The urgency for its prevention and cure has resulted in an increased number of proposed treatment options. The high rate and volume of emerging clinical trials on therapies for COVID-19 need to be compared and evaluated to provide scientific evidence for effective medical options. Other emerging non-conventional drug discovery techniques such as bioinformatics and cheminformatics, structure-based drug design, network-based methods for prediction of drug-target interactions, artificial intelligence (AI) and machine learning (ML) and phage technique could provide alternative routes to discovering potent Anti-SARS-CoV2 drugs. While drugs are being repurposed and discovered for COVID-19, novel drug delivery systems will be paramount for efficient delivery and avoidance of possible drug resistance. This review describes the proposed drug targets for therapy, and outcomes of clinical trials that have been reported. It also identifies the adopted treatment modalities that are showing promise, and those that have failed as drug candidates. It further highlights various emerging therapies and future strategies for the treatment of COVID-19 and delivery of Anti-SARS-CoV2 drugs.
C1 [Omolo, Calvin A.; Soni, Nikki; Govender, Thirumala] US Int Univ Africa, Sch Pharm & Hlth Sci, Dept Pharmaceut, POB 14634-00800, Nairobi, Kenya.
   [Omolo, Calvin A.; Fasiku, Victoria Oluwaseun] Univ KwaZulu Natal, Coll Hlth Sci, Discipline Pharmaceut Sci, Private Bag X54001, Durban, South Africa.
   [Mackraj, Irene] Univ KwaZulu Natal, Coll Hlth Sci, Sch Lab Med & Med Sci, Private Bag X54001, Durban, South Africa.
RP Omolo, CA; Govender, T (corresponding author), US Int Univ Africa, Sch Pharm & Hlth Sci, Dept Pharmaceut, POB 14634-00800, Nairobi, Kenya.
EM comolo@usiu.ac.ke; govenderth@ukzn.ac.za
OI Omolo, Calvin/0000-0002-4421-3783
FU University of KwaZulu-Natal (UKZN) South Africa; United States
   International University Africa Kenya
FX The authors acknowledge the University of KwaZulu-Natal (UKZN) South
   Africa and United States International University Africa Kenya for
   financial support.
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Anighoro A, 2014, J MED CHEM, V57, P7874, DOI 10.1021/jm5006463
   [Anonymous], 2020, IMP CAM MES COVID 19
   Anzctr, 2020, CHLOR CHEM COUNT COV
   Arabi YM, 2019, CLIN INFECT DIS
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Backer JA, 2020, EUROSURVEILLANCE, V25, P10, DOI 10.2807/1560-7917.ES.2020.25.5.2000062
   Bavishi C., 2020, JAMA CARDIOLOGY
   Beigel JH, 2018, LANCET INFECT DIS, V18, P410, DOI 10.1016/S1473-3099(18)30002-1
   BenevolentAI, 2020, POT TREATM COVID 19
   Berlin DA, 2020, N ENGL J MED
   Biontech, 2020, BIONTECH PFIZ ANN RE
   BJELLE A, 1983, CLIN RHEUMATOL, V2, P393, DOI 10.1007/BF02041561
   Borba MG, 2020, CHLOROQUINE DIPHOSPH
   Bordy R, 2018, NAT REV RHEUMATOL, V14, P404, DOI 10.1038/s41584-018-0022-8
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Cabut S., 2019, CORONAVIRUS SERIOUS
   Cai GJ, 2020, STEEL RES INT, DOI 10.1002/srin.202000269
   Cao B, 2020, NEW ENGL J MED, V382
   Cao W, 2020, CELL RES, V30, P367, DOI 10.1038/s41422-020-0327-4
   CDC, 2020, INT CLIN GUID MAN PA
   Chen A, 2020, STRESS RESILIENCE: MOLECULAR AND BEHAVIORAL ASPECTS, P1, DOI 10.1016/C2016-0-03233-3
   Chen L, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041193
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen ZW, 2020, EFFICACY HYDROXYCHLO
   clinicaltrials gov, 2020, SAF IMM STUD 2019 NC
   clinicaltrials gov, 2020, PATCH 2 3 PREV TREAT
   clinicaltrials gov, 2020, OUTC REL COVID 19 TR
   clinicaltrials gov, 2020, POST PROP PREEMPT TH
   clinicaltrials gov, 2020, HYDR OUTP AD COVID 1
   clinicaltrials gov, 2020, TREATM PAT SUSP CONF
   ClinicalTrialsgov, 2020, SEV 2019 NCOV REMD R
   ClinicalTrialsgov, 2020, EFF LOP PLUS RIT ARB
   ClinicalTrialsgov, 2020, NORW COR DIS 2019 ST
   ClinicalTrialsgov, 2020, MILD MOD 2019 NCOV R
   clinicaltrialsregister eu, 2020, COVID 19 EP SARS COV
   clinicaltrialsregister eu, 2020, RAND CLIN TRIAL EV E
   Colson PW, 2020, AIDS BEHAV, V24, P3436, DOI 10.1007/s10461-020-02901-6
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Coppola A, 2020, BLOOD TRANSFUS-ITALY, V18, P226, DOI 10.2450/2020.0113-20
   Cortegiani A, 2020, J CRIT CARE
   COVID-19 Treatment Guidelines Panel, 2020, COVID 19 TREATM GUID
   Crotti C., 2019, DRUGS, P1
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1168
   De Witt BJ, 2000, EUR J PHARMACOL, V404, P213, DOI 10.1016/S0014-2999(00)00612-9
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Duan K, 2020, FEASIBILITY CONVALES
   Edwards Geoffrey, 2003, Filaria J, V2 Suppl 1, pS8, DOI 10.1186/1475-2883-2-S1-S8
   EMA, 2020, B DTB
   Favalli EG, 2020, LANCET INFECT DIS
   Food and Drug Administration (FDA), 2020, REC INV COVID 19 CON
   Furuta Y, 2005, ANTIMICROB AGENTS CH, V49, P981, DOI 10.1128/AAC.49.3.981-986.2005
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Gao GS, 2020, INFECTION, DOI 10.1007/s15010-020-01485-6
   Gao J., 2020, BIOSCIENCE TRENDS
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Ge Y, 2020, BIORXIV
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gozes O., 2020, ARXIV200305037
   GSK, 2020, CLOV GSK ANN RES COL
   Gu HJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19840
   Guo D., 2020, VIROL SIN, P1
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Health M.o., 2018, REPORT DELIBERATION
   Henry B.M., 2020, CLIN CHIM ACTA
   Hoffmann M, 2020, CELL
   Hoffmann M., 2020, NOVEL CORONAVIRUS 20
   Hofmarcher M., 2020, LARGE SCALE LIGAND B
   Holmes KV, 2003, NEW ENGL J MED, V348, P1948, DOI 10.1056/NEJMp030078
   Hoth, 2020, HOTH THERAPEUTICS HO
   HOY T, 1990, PHARMACOL TOXICOL, V67, P307, DOI 10.1111/j.1600-0773.1990.tb00835.x
   Hu Y, 2012, RSC ADV, V2, P3481, DOI 10.1039/c2ra01345b
   Iba T., 2020, CRITICAL CARE MED
   Kadam RU, 2017, P NATL ACAD SCI USA, V114, P206, DOI 10.1073/pnas.1617020114
   Kai H, 2020, HYPERTENS RES, V43, P648, DOI 10.1038/s41440-020-0455-8
   Kennedy CJ, 2014, AQUAT TOXICOL, V146, P176, DOI 10.1016/j.aquatox.2013.10.035
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Kindrachuk J., 2014, ANTIMICROB AGENTS CH
   Kobayashi O, 2008, INT J INFECT DIS, V12, pE299, DOI 10.1016/j.ijid.2008.05.802
   Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kumar N., 2020, BIORXIV
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lane R, 2020, LANCET, V395, P1247, DOI 10.1016/S0140-6736(20)30796-0
   Lauer S.A., 2020, ANN INTERN MED
   Lauster D, 2020, NAT NANOTECHNOL, V15, P373, DOI 10.1038/s41565-020-0660-2
   Le T.T., 2020, NAT REV DRUG DISCOV, V10
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Leon C., 2020, ANTIVIR RES
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li L, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00661-z
   Li WL, 2019, EUR J PHARM BIOPHARM, V136, P120, DOI 10.1016/j.ejpb.2019.01.016
   Li X., 2020, NETWORK BIOINFORMATI
   Li X, 2020, J PHARM ANAL
   Li YX, 2020, SYST REV-LONDON, V9, DOI [10.1186/s13643-020-01432-4, 10.1186/s13643-020-01343-4]
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Liu C., 2020, RES DEV THERAPEUTIC
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu M, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104896
   Liu X., 2004, COCHRANE DATABASE SY
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo P., J MED VIROLOGY
   Magro C, 2020, TRANSL RES
   Mahase E., 2020, COVID 19 WHAT TREATM
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   Marotto D., 2020, AUTOIMMUN REV
   Mason RJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00607-2020
   Maxmen A, 2020, NATURE, V578, P347, DOI 10.1038/d41586-020-00444-3
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mifsud EJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104545
   Mina F., 2020, POTENTIAL DRUG CANDI
   Molina J.M., 2020, MED MALADIES INFECT
   Moore B.J.B., 2020, SCIENCE
   Morselli Gysi D., 2020, ARXIV200407229
   Murck H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01239
   Novavax, 2020, NOV ID COR VACC CAN
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Rensi S., 2020, HOMOLOGY MODELING TM
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Rocha-Pereira J, 2012, BIOCHEM BIOPH RES CO, V424, P777, DOI 10.1016/j.bbrc.2012.07.034
   Roche JA, 2020, FASEB J, V34, P7265, DOI 10.1096/fj.202000967
   Rockx B., 2020, SCIENCE
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Russell B., 2020, EECANCER MED SCI CAN
   Rynes RI, 1997, BRIT J RHEUMATOL, V36, P799
   Scott B., 2020, MEDSCAPE
   Senior AW, 2020, NATURE, V577, P706, DOI 10.1038/s41586-019-1923-7
   Shanmugaraj B, 2020, ASIAN PAC J ALLERGY, V38, P10, DOI 10.12932/AP-200220-0773
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shen C., 2020, J AM MED ASS
   sinovac, 2020, SIN ANN APPR HUM CLI
   Smith T., 2020, COVID 19 DRUG THERAP
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tang X, 2020, NATL SCI REV
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   ter Meulen J, 2004, LANCET, V363, P2139, DOI 10.1016/S0140-6736(04)16506-9
   Trump Tests China's Red Line on Taiwan Using Beijing's Playbook,, 2020, BLOOMBERG
   Trus E, 2020, CYTOKINE, V127, DOI 10.1016/j.cyto.2019.154939
   Tsantikos E, 2018, J CLIN INVEST, V128, P2406, DOI 10.1172/JCI98224
   Vaduganathan M, 2020, NEW ENGL J MED, V382
   Vankadari N, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105998
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walter J.D., 2020, BIORXIV
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Wang X, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0169-8
   Wang Y., 2020, ARXIV PREPRINT ARXIV
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Warren TK, 2014, NATURE, V508, P402, DOI 10.1038/nature13027
   WHO, 2020, PUBL HLTH EM SOL TRI
   WHO, 2020, WHO 2020BA DRAFT LAN
   WHO, 2020, US NONST ANT DRUGS N
   World Health Organization, 2020, COR DIS 2019 COVID 1, P72
   World Health Organization, 2020, WHO COR DIS COVID 19
   World Health Organization, 2017, WHO MOD LIST ESS MED
   World Health Organization, 2020, 143 WHO
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu Canrong, 2020, ACTA PHARM SIN B
   Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031
   Wu Z, 2018, FRONT PHARM, V9
   Xu J., 2020, COMPLEMENTARY THERAP
   Yang ND, 2020, INT J BIOL SCI, V16, P1724, DOI 10.7150/ijbs.45498
   Yasir M., 2019, CORTICOSTEROID ADVER
   Yuen KS, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00404-4
   Zeldin RK, 2004, J ANTIMICROB CHEMOTH, V53, P4, DOI 10.1093/jac/dkh029
   Zhang D., 2020, COVID 19 INFECT INDU
   Zhang H, 2020, INTENS CARE MED, V3, P1, DOI DOI 10.1016/S0140-6736(20)30627-9
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
   Zhavoronkov A., 2020, POTENTIAL COVID 2019, V307, pE1
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, BIORXIV
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu Y., 2020, DESIGN POTENT MEMBRA, V2020
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
   Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 185
TC 5
Z9 5
U1 15
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD SEP 15
PY 2020
VL 883
AR 173348
DI 10.1016/j.ejphar.2020.173348
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NN9ZD
UT WOS:000569146600006
PM 32634438
OA Green Published
DA 2021-01-01
ER

PT J
AU Samudrala, PK
   Kumar, P
   Choudhary, K
   Thakur, N
   Wadekar, GS
   Dayaramani, R
   Agrawal, M
   Alexander, A
AF Samudrala, Pavan Kumar
   Kumar, Pramod
   Choudhary, Kamlesh
   Thakur, Nagender
   Wadekar, Gaurav Suresh
   Dayaramani, Richa
   Agrawal, Mukta
   Alexander, Amit
TI Virology, pathogenesis, diagnosis and in-line treatment of COVID-19
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; Virology; Pathogenesis; Clinical features;
   Treatment strategies
ID CORONAVIRUS REPLICATION; SPIKE PROTEIN; SARS; AZITHROMYCIN; OUTBREAK;
   CHLOROQUINE; PNEUMONIA
AB SARS CoV-2, a newly emerged pathogen in December 2019, marked as one of the highly pathogenic Coronavirus, and altogether this is the third coronavirus attack that crossed the species barrier. As of 1st July 2020, it is spreading around 216 countries, areas or territories, and a total of 10,185,374 and 503,862 confirmed cases and death reports, respectively. The SARS-CoV-2 virus entered into the target cells by binding with the hACE2 receptors. Spike glycopmtein promotes the entry of the virus into host target cells. Literature reported a significant mutation in receptor binding sites and membrane proteins of the previous SARS-CoV to turned as SARS-CoV-2 virus, responsible for most dreadful pandemic COVID-19. These modifications may be the probable reason for the extreme transmission and pathogenicity of the virus. A hasty spread of COVID-19 throughout the world is highly threatening, but still, scientists do not have a proper therapeutic measure to fight with it. Scientists are endeavoring across the world to find effective therapy to combat COVID 19. Several drugs such as Remdesivir, Hydroxychloroquine, Chlomquine, Ribavirin, Ritonavir, Lopinavir, Favipiravir, Interferons, Bevacizumab, Azithromycin, etc. are currently under clinical trials. Vaccine development from various pharmaceutical companies and research institutes is under progress, and more than ten vaccine candidates are in the various phases of clinical trials. This review work highlighted the origin, emergence, structural features, pathogenesis, and clinical features of COVID-19. We have also discussed the in-line treatment strategies, preventive measures, and vaccines to combat the emergence of COVID-19.
C1 [Samudrala, Pavan Kumar; Choudhary, Kamlesh] Natl Inst Pharmaceut Educ & Res NIPER Guwahati, Minist Chem & Fertilizers Govt India, Dept Pharmaceut, Dept Pharmacol & Toxicol, Gauhati 781101, Assam, India.
   [Kumar, Pramod; Thakur, Nagender; Wadekar, Gaurav Suresh] Natl Inst Pharmaceut Educ & Res NIPER Guwahati, Minist Chem & Fertilizers Govt India, Dept Pharmaceut Anal, Dept Pharmaceut, Gauhati 781101, Assam, India.
   [Dayaramani, Richa] Khyati Coll Pharm, Ahmadabad 382115, Gujarat, India.
   [Agrawal, Mukta] Rungta Coll Pharmaceut Sci & Res, Kohka Kurud Rd, Bhilai 490024, Chhattisgarh, India.
   [Alexander, Amit] Natl Inst Pharmaceut Educ & Res NIPER Guwahati, Dept Pharmaceut, Minist Chem & Fertilizers Govt India, Gauhati 781101, Assam, India.
RP Kumar, P (corresponding author), Natl Inst Pharmaceut Educ & Res NIPER Guwahati, Minist Chem & Fertilizers Govt India, Dept Pharmaceut Anal, Dept Pharmaceut, Gauhati 781101, Assam, India.; Alexander, A (corresponding author), Natl Inst Pharmaceut Educ & Res NIPER Guwahati, Dept Pharmaceut, Minist Chem & Fertilizers Govt India, Gauhati 781101, Assam, India.
EM drpramodkumar14@gmail.com; amit.alexander@niperguwahati.ac.in
RI ; Alexander, Amit/U-1271-2019
OI DAYARAMANI, RICHA/0000-0002-8615-6529; Alexander,
   Amit/0000-0003-0391-7650; SAMUDRALA, PAVAN KUMAR/0000-0001-5496-6845;
   KUMAR, Dr. PRAMOD/0000-0002-0346-7242
FU National Institute of Pharmaceutical Education and Research (NIPER
   GUWAHATI), Department of Pharmaceuticals, Ministry of Chemicals and
   Fertilizers, Govt. of India, Changsari, Kamrup, Guwahati, Assam, India
FX The author wants to show his gratitude to National Institute of
   Pharmaceutical Education and Research (NIPER GUWAHATI), Department of
   Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt. of India,
   Changsari, Kamrup-781101, Guwahati, Assam, India for providing necessary
   facilities for the compilation of this review work and support.
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Alexander A, 2011, STAMFORD J PHARM SCI, V4, P91, DOI DOI 10.3329/sjps.v4i1.8878
   Alexander DJ, 2009, REV SCI TECH OIE, V28, P19, DOI 10.20506/rst.28.1.1856
   Alsaadi EAJ, 2019, FUTURE VIROL, V14, P275, DOI 10.2217/fvl-2018-0144
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   Angeletti S., COVID 2019 ROLE NSP2
   [Anonymous], 2020, GIL ANN RES PHAS 3 T
   Bagdonaite I, 2018, GLYCOBIOLOGY, V28, P443, DOI 10.1093/glycob/cwy021
   Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Berry M, 2015, VIRUSES-BASEL, V7, P996, DOI 10.3390/v7030996
   Bonilla-Aldana D.K., 2020, CORONAVIRUS INFECT R
   Cai GJ, 2020, STEEL RES INT, DOI 10.1002/srin.202000269
   Cameron MJ, 2008, VIRUS RES, V133, P13, DOI 10.1016/j.virusres.2007.02.014
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dai WC, 2020, CAN ASSOC RADIOL J, V71, P195, DOI 10.1177/0846537120913033
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Devices V.M., 2020, ROCHE CORONAVIRUS TE
   Dhama K., 2020, CORONAVIRUS DIS 2019
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Ghinai I, 2020, LANCET, V395, P1137, DOI 10.1016/S0140-6736(20)30607-3
   Guan W, 2020, CLIN CHARACTERISTICS
   He F, 2020, J MED VIROL, V92, P719, DOI [10.1002/jmv.25766, 10.3171/2020.3.JNS193202]
   Heymann DL, 2020, LANCET, V395, P542, DOI 10.1016/S0140-6736(20)30374-3
   Huang BH, 2007, PACE, V30, P1579, DOI 10.1111/j.1540-8159.2007.00912.x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang PK, 2020, RADIOLOGY, V295, P22, DOI 10.1148/radiol.2020200330
   Hulswit RJG, 2019, P NATL ACAD SCI USA, V116, P2681, DOI 10.1073/pnas.1809667116
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Iserson Kenneth V, 2021, Camb Q Healthc Ethics, V30, P59, DOI 10.1017/S096318012000047X
   Ito T, 2001, J VIROL, V75, P4439, DOI 10.1128/JVI.75.9.4439-4443.2001
   Kezerashvili A, 2007, J INTERV CARD ELECTR, V18, P243, DOI 10.1007/s10840-007-9124-y
   Knoops K, 2008, PLOS BIOL, V6, P1957, DOI 10.1371/journal.pbio.0060226
   Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P404, DOI 10.1016/j.jmii.2020.02.012
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lee IK, 2020, J HOSP INFECT, V105, P102, DOI 10.1016/j.jhin.2020.02.022
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li J, 2020, SEX DIFFERENCES CLIN
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1070, DOI 10.1515/cclm-2020-0285
   Liu C, 2015, J VIROL, V89, P6121, DOI 10.1128/JVI.00430-15
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Lv HB, 2020, EUR J IMMUNOL, V50, P939, DOI 10.1002/eji.202048663
   Mao L., 2020, CHINA RETROSPECTIVE
   Melbourne U.o., 2020, COR COVID 19 MAN STR
   Menachery VD, 2020, J VIROL, V94, DOI 10.1128/JVI.01774-19
   Park YJ, 2019, NAT STRUCT MOL BIOL, V26, P1151, DOI 10.1038/s41594-019-0334-7
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Peng QY, 2020, INTENS CARE MED, V46, P849, DOI 10.1007/s00134-020-05996-6
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pronker ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057755
   Ritchie AI, 2020, LANCET, V395, P1111, DOI 10.1016/S0140-6736(20)30691-7
   Roche's, 2020, ROCH COB SARS COV 2
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Shaik KM, 2020, CRIT REV ANAL CHEM, DOI 10.1080/10408347.2020.1788375
   Shang J, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008392
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Skariyachan S, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00569
   Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan Y., 2020, RECEPTOR RECOGNITION, V94
   Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748
   WHO, 2020, 144 WHO
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, COR DIS COVID 19 ADV
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu YC, 2020, J CHIN MED ASSOC, V83, P217, DOI 10.1097/JCMA.0000000000000270
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang YS, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102434
   Zhang B, 2020, CLIN CHARACTERISTICS
   Zhang L, 2018, EUR J PHARMACOL, V837, P64, DOI 10.1016/j.ejphar.2018.07.049
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490
NR 92
TC 1
Z9 1
U1 13
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD SEP 15
PY 2020
VL 883
AR 173375
DI 10.1016/j.ejphar.2020.173375
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NN9YX
UT WOS:000569146000001
PM 32682788
OA Green Published
DA 2021-01-01
ER

PT J
AU Atyeo, C
   Fischinger, S
   Zohar, T
   Slein, MD
   Burke, J
   Loos, C
   McCulloch, DJ
   Newman, KL
   Wolf, C
   Yu, JY
   Shuey, K
   Feldman, J
   Hauser, BM
   Caradonna, T
   Schmidt, AG
   Suscovich, TJ
   Linde, C
   Cai, YF
   Barouch, D
   Ryan, ET
   Charles, RC
   Lauffenburger, D
   Chu, H
   Alter, G
AF Atyeo, Caroline
   Fischinger, Stephanie
   Zohar, Tomer
   Slein, Matthew D.
   Burke, John
   Loos, Carolin
   McCulloch, Denise J.
   Newman, Kira L.
   Wolf, Caitlin
   Yu, Jingyou
   Shuey, Kiel
   Feldman, Jared
   Hauser, Blake Marie
   Caradonna, Tim
   Schmidt, Aaron G.
   Suscovich, Todd J.
   Linde, Caitlyn
   Cai, Yongfei
   Barouch, Dan
   Ryan, Edward T.
   Charles, Richelle C.
   Lauffenburger, Douglas
   Chu, Helen
   Alter, Galit
TI Distinct Early Serological Signatures Track with SARS-CoV-2 Survival
SO IMMUNITY
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; SARS-CORONAVIRUS; PASSIVE
   IMMUNOTHERAPY; ANTIBODY-RESPONSES; INFECTION; PROTEIN
AB As SARS-CoV-2 infections and death counts continue to rise, it remains unclear why some individuals recover from infection, whereas others rapidly progress and die. Although the immunological mechanisms that underlie different clinical trajectories remain poorly defined, pathogen-specific antibodies often point to immunological mechanisms of protection. Here, we profiled SARS-CoV-2-specific humoral responses in a cohort of 22 hospitalized individuals. Despite inter-individual heterogeneity, distinct antibody signatures resolved individuals with different outcomes. Although no differences in SARS-CoV-2-specific IgG levels were observed, spike-specific humoral responses were enriched among convalescent individuals, whereas functional antibody responses to the nucleocapsid were elevated in deceased individuals. Furthermore, this enriched immunodominant spike-specific antibody profile in convalescents was confirmed in a larger validation cohort. These results demonstrate that early antigen-specific and qualitative features of SARS-CoV-2-specific antibodies point to differences in disease trajectory, highlighting the potential importance of functional antigen-specific humoral immunity to guide patient care and vaccine development.
C1 [Atyeo, Caroline; Fischinger, Stephanie; Zohar, Tomer; Slein, Matthew D.; Burke, John; Loos, Carolin; Feldman, Jared; Hauser, Blake Marie; Caradonna, Tim; Schmidt, Aaron G.; Alter, Galit] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.
   [Atyeo, Caroline] Harvard Univ, Div Med Sci, PhD Program Virol, Boston, MA 02115 USA.
   [Fischinger, Stephanie] Univ Duisburg Essen, PhD Program Immunol & Virol, Essen, Germany.
   [Zohar, Tomer; Loos, Carolin; Lauffenburger, Douglas] MIT, Dept Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Newman, Kira L.; Shuey, Kiel; Chu, Helen] Univ Washington, Dept Med, Seattle, WA 98195 USA.
   [McCulloch, Denise J.; Wolf, Caitlin; Yu, Jingyou; Barouch, Dan] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA.
   [Ryan, Edward T.; Charles, Richelle C.] Massachusetts Gen Hosp, Infect Dis Div, Boston, MA 02114 USA.
   [Suscovich, Todd J.; Linde, Caitlyn] SeromYx Syst, Cambridge, MA USA.
   [Cai, Yongfei] Harvard Med Sch, Boston Childrens Hosp, Div Mol Med, Boston, MA 02115 USA.
   [Cai, Yongfei] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.
RP Alter, G (corresponding author), Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.; Chu, H (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.
EM helenchu@uw.edu; galter@partners.org
RI Cai, Yongfei/ABI-7748-2020
OI Cai, Yongfei/0000-0002-3628-3802; Slein, Matthew/0000-0001-8288-787X;
   Caradonna, Timothy/0000-0001-7138-4441; Yu, Jingyou/0000-0002-0775-6623;
   Newman, Kira/0000-0002-8279-1111; McCulloch, Denise/0000-0001-8755-6105;
   Hauser, Blake/0000-0002-0100-1684; Zohar, Tomer/0000-0001-9965-2559
FU Ragon Institute of MGH, MIT and Harvard; Massachusetts Consortium on
   Pathogen Readiness (MassCPR); Bill and Melinda Gates FoundationBill &
   Melinda Gates Foundation [235730]; NIAIDUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID) [U19
   AI135995]; Centers for Disease Control and PreventionUnited States
   Department of Health & Human ServicesCenters for Disease Control &
   Prevention - USA [CK000490]
FX We thank Bruce Walker, Nancy Zimmerman, Mark and Lisa Schwartz, an
   anonymous donor, and Terry and Susan Ragon for support. We would also
   like to thank Bing Chen for protein production efforts. We acknowledge
   support from the Ragon Institute of MGH, MIT and Harvard, the
   Massachusetts Consortium on Pathogen Readiness (MassCPR), the Bill and
   Melinda Gates Foundation (235730), the NIAID (U19 AI135995) and the
   Centers for Disease Control and Prevention (CK000490).
CR Ackerman ME, 2018, NAT MED, V24, P1590, DOI 10.1038/s41591-018-0161-0
   Altomare A, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9050367
   Barouch DH, 2015, SCIENCE, V349, P320, DOI 10.1126/science.aab3886
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Boudreau CM, 2020, J CLIN INVEST, V130, P662, DOI 10.1172/JCI129520
   Brown EP, 2017, J IMMUNOL METHODS, V443, P33, DOI 10.1016/j.jim.2017.01.010
   Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Chang SC, 2005, CLIN DIAGN LAB IMMUN, V12, P1455, DOI 10.1128/CDLI.12.12.1455-1457.2005
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Cobey S, 2017, CURR OPIN VIROL, V22, P105, DOI 10.1016/j.coviro.2016.12.004
   Cong JJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01416
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Fischinger S, 2019, J IMMUNOL METHODS, V473, DOI 10.1016/j.jim.2019.07.002
   Gunn BM, 2016, TRENDS MOL MED, V22, P969, DOI 10.1016/j.molmed.2016.09.002
   Guyon I., 2003, Journal of Machine Learning Research, V3, P1157, DOI 10.1162/153244303322753616
   Hauser A, 2020, ESTIMATION SARS COV, DOI [10.1101/2020.03.04.20031104, DOI 10.1101/2020.03.04.20031104]
   He YX, 2006, BIOCHEM BIOPH RES CO, V344, P106, DOI 10.1016/j.bbrc.2006.03.139
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Jegaskanda S, 2016, J INFECT DIS, V214, P945, DOI 10.1093/infdis/jiw262
   Kong P, 2020, BMC MICROBIOL, V20, DOI 10.1186/s12866-020-01904-6
   Lau KS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001338
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Li TS, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000024
   Lu LL, 2016, CELL, V167, P433, DOI 10.1016/j.cell.2016.08.072
   Ojala M, 2010, J MACH LEARN RES, V11, P1833
   Organization WH, 2020, 122 WHO, P122
   Pedregosa F, 2011, J MACH LEARN RES, V12, P2825
   Pittala S, 2019, MOL SYST BIOL, V15, DOI 10.15252/msb.20188747
   Quinlan B. D., 2020, BIORXIV, DOI [10.1101/2020.04.10.036418, DOI 10.1101/2020.04.10.036418]
   Saphire EO, 2018, NAT IMMUNOL, V19, P1169, DOI 10.1038/s41590-018-0233-9
   Shi YL, 2004, J CLIN VIROL, V31, P66, DOI 10.1016/j.jcv.2004.05.006
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Timani KA, 2004, J CLIN VIROL, V30, P309, DOI 10.1016/j.jcv.2004.01.001
   Tomaras GD, 2009, CURR OPIN HIV AIDS, V4, P373, DOI 10.1097/COH.0b013e32832f00c0
   van Erp EA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00548
   Wang Xiaoli, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa721
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Yasui F, 2014, VIROLOGY, V454, P157, DOI 10.1016/j.virol.2014.02.005
   Zhao JC, 2015, J VIROL, V89, P6117, DOI 10.1128/JVI.00446-15
   Zhao YK, 2017, ANTIVIR RES, V137, P125, DOI 10.1016/j.antiviral.2016.11.016
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 44
TC 14
Z9 13
U1 2
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD SEP 15
PY 2020
VL 53
IS 3
BP 524
EP +
DI 10.1016/j.immuni.2020.07.020
PG 13
WC Immunology
SC Immunology
GA NO9KZ
UT WOS:000569806100011
PM 32783920
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lakeman, R
   Crighton, J
AF Lakeman, R.
   Crighton, J.
TI The Impact of Social Distancing on People with Borderline Personality
   Disorder: The Views of Dialectical Behavioural Therapists
SO ISSUES IN MENTAL HEALTH NURSING
LA English
DT Article; Early Access
ID SUICIDE ATTEMPTS
AB Dialectical Behavioural Therapy (DBT) is an evidence-based treatment for borderline personality disorder and other problems associated with emotional dysregulation. It has traditionally been deployed as a face-to-face programme comprised of attendance at group skills training, individual therapy and phone coaching. Social distancing measures arising from the COVID-19 pandemic led to a cessation of therapeutic programmes in many places. This survey of DBT clinicians in a regional State mental health service in Australia explored the impact of the cessation of DBT programmes in the region and obstacles to engaging with people via online platforms. Clinicians have been able to engage in DBT informed care, but it was perceived that many people have experienced a clinical deterioration or have increased their use of crisis services, which is entirely appropriate, as group skills programmes have ceased. Movement to online platforms of delivery poses problems, as some people do not have the access to internet or privacy in their home environments to engage in online therapy. Ideally, clinicians need to be supported through education, supervision and coaching in the use of telehealth interventions. Social distancing requirements has enabled an opportunity to carefully consider how programmes can be adapted to enable the extension of these programmes to those who have traditionally been unable to access them.
C1 [Lakeman, R.] Southern Cross Univ, Sch Hlth & Human Sci, Gold Coast Campus,Southern Cross Dr, Bilinga, Qld 4225, Australia.
   [Crighton, J.] Northern NSW Local Hlth Dist, Lismore, NSW, Australia.
RP Lakeman, R (corresponding author), Southern Cross Univ, Sch Hlth & Human Sci, Gold Coast Campus,Southern Cross Dr, Bilinga, Qld 4225, Australia.
EM Richard.lakeman@scu.edu.au
OI Lakeman, Richard/0000-0002-4304-5431
CR Babeva K. N., 2020, HDB DIALECTICAL BEHA
   Bedics J. D., 2020, HDB DIALECTICAL BEHA
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]
   CAMPBELL K, 2020, INT J MENT HEAL 0519, DOI DOI https://doi.org/10.1111/inm.12737
   DeCou CR, 2019, BEHAV THER, V50, P60, DOI 10.1016/j.beth.2018.03.009
   Dixon LJ, 2020, COGN BEHAV THERAPY, V49, P181, DOI 10.1080/16506073.2019.1620324
   Dunster-Page C, 2017, J AFFECT DISORDERS, V223, P165, DOI 10.1016/j.jad.2017.07.040
   Finch EF, 2019, PERSONAL DISORD, V10, P491, DOI 10.1037/per0000353
   Goodman M, 2017, PERSONAL MENT HEALTH, V11, P157, DOI 10.1002/pmh.1375
   Haktanr A., 2020, RES ED PSYCHOL REP, V4
   Harvey LJ, 2019, BEHAV CHANGE, V36, P143, DOI 10.1017/bec.2019.9
   Hornor G, 2019, J PEDIATR HEALTH CAR, V33, P214, DOI 10.1016/j.pedhc.2018.09.009
   Howard KP, 2020, BEHAV COGN PSYCHOTH, V48, P116, DOI 10.1017/S1352465819000420
   KOTHGASSNER OD, 2020, BORDER PERS DIS EMOT, V7, DOI DOI https://doi.org/10.1186/s40479-020-00123-9
   Lakeman R, 2020, ADV MENT HEALTH, DOI 10.1080/18387357.2020.1761262
   LAKEMAN R, 2020, INT J MENT HEAL 0613, DOI DOI https://doi.org/10.1111/inm.12749
   Linehan M., 1993, COGNITIVE BEHAV TREA
   Linehan M. M., 2015, DBT SKILLS TRAINING
   Looi JCL, 2020, AUSTRALAS PSYCHIATRY, V28, P508, DOI 10.1177/1039856220930675
   Lopez Amy, 2020, Mhealth, V6, P13, DOI 10.21037/mhealth.2019.11.04
   MacPherson HA, 2013, CLIN CHILD FAM PSYCH, V16, P59, DOI 10.1007/s10567-012-0126-7
   Mattei SB, 2020, CLIN PSYCHOL-SCI PR, DOI 10.1111/cpsp.12354
   Meuldijk D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171592
   Murphy A, 2020, IRISH J MED SCI, V189, P415, DOI 10.1007/s11845-019-02091-8
   Ougrin D, 2015, J AM ACAD CHILD PSY, V54, P97, DOI 10.1016/j.jaac.2014.10.009
   Qualtrics Development Team, 2019, QUALTR VERS SEP 2019
   SCHROEDER J, 2018, P 2018 CHI C HUM, DOI DOI https://doi.org/10.1145/3173574.3173972
   Valentine SE, 2015, J CLIN PSYCHOL, V71, P1, DOI 10.1002/jclp.22114
   Wetzelaer P, 2017, J MENT HEALTH POLICY, V20, P177
   Zhou XY, 2020, TELEMED E-HEALTH, V26, P377, DOI 10.1089/tmj.2020.0068
NR 30
TC 0
Z9 0
U1 4
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0161-2840
EI 1096-4673
J9 ISSUES MENT HEALTH N
JI Issues Ment. Health Nurs.
DI 10.1080/01612840.2020.1817208
EA SEP 2020
PG 7
WC Nursing; Psychiatry
SC Nursing; Psychiatry
GA NO4EA
UT WOS:000569437100001
PM 32931341
OA Bronze
DA 2021-01-01
ER

PT J
AU Liu, STH
   Lin, HM
   Baine, I
   Wajnberg, A
   Gumprecht, JP
   Rahman, F
   Rodriguez, D
   Tandon, P
   Bassily-Marcus, A
   Bander, J
   Sanky, C
   Dupper, A
   Zheng, A
   Nguyen, FT
   Amanat, F
   Stadlbauer, D
   Altman, DR
   Chen, BK
   Krammer, F
   Mendu, DR
   Firpo-Betancourt, A
   Levin, MA
   Bagiella, E
   Casadevall, A
   Cordon-Cardo, C
   Jhang, JS
   Arinsburg, SA
   Reich, DL
   Aberg, JA
   Bouvier, NM
AF Liu, Sean T. H.
   Lin, Hung-Mo
   Baine, Ian
   Wajnberg, Ania
   Gumprecht, Jeffrey P.
   Rahman, Farah
   Rodriguez, Denise
   Tandon, Pranai
   Bassily-Marcus, Adel
   Bander, Jeffrey
   Sanky, Charles
   Dupper, Amy
   Zheng, Allen
   Nguyen, Freddy T.
   Amanat, Fatima
   Stadlbauer, Daniel
   Altman, Deena R.
   Chen, Benjamin K.
   Krammer, Florian
   Mendu, Damodara Rao
   Firpo-Betancourt, Adolfo
   Levin, Matthew A.
   Bagiella, Emilia
   Casadevall, Arturo
   Cordon-Cardo, Carlos
   Jhang, Jeffrey S.
   Arinsburg, Suzanne A.
   Reich, David L.
   Aberg, Judith A.
   Bouvier, Nicole M.
TI Convalescent plasma treatment of severe COVID-19: a propensity
   score-matched control study
SO NATURE MEDICINE
LA English
DT Article
AB Convalescent plasma for treatment of hospitalized patients with COVID-19 is associated with improved survival in a retrospective comparison with matched controls, supporting further study in randomized controlled trials.
   Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a new human disease with few effective treatments(1). Convalescent plasma, donated by persons who have recovered from COVID-19, is the acellular component of blood that contains antibodies, including those that specifically recognize SARS-CoV-2. These antibodies, when transfused into patients infected with SARS-CoV-2, are thought to exert an antiviral effect, suppressing virus replication before patients have mounted their own humoral immune responses(2,3). Virus-specific antibodies from recovered persons are often the first available therapy for an emerging infectious disease, a stopgap treatment while new antivirals and vaccines are being developed(1,2). This retrospective, propensity score-matched case-control study assessed the effectiveness of convalescent plasma therapy in 39 patients with severe or life-threatening COVID-19 at The Mount Sinai Hospital in New York City. Oxygen requirements on day 14 after transfusion worsened in 17.9% of plasma recipients versus 28.2% of propensity score-matched controls who were hospitalized with COVID-19 (adjusted odds ratio (OR), 0.86; 95% confidence interval (CI), 0.75-0.98; chi-square testPvalue = 0.025). Survival also improved in plasma recipients (adjusted hazard ratio (HR), 0.34; 95% CI, 0.13-0.89; chi-square testP = 0.027). Convalescent plasma is potentially effective against COVID-19, but adequately powered, randomized controlled trials are needed.
C1 [Liu, Sean T. H.; Gumprecht, Jeffrey P.; Rahman, Farah; Dupper, Amy; Altman, Deena R.; Chen, Benjamin K.; Aberg, Judith A.; Bouvier, Nicole M.] Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY 10029 USA.
   [Liu, Sean T. H.; Zheng, Allen; Amanat, Fatima; Stadlbauer, Daniel; Krammer, Florian; Bouvier, Nicole M.] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.
   [Lin, Hung-Mo; Bagiella, Emilia] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, New York, NY 10029 USA.
   [Baine, Ian; Nguyen, Freddy T.; Mendu, Damodara Rao; Firpo-Betancourt, Adolfo; Cordon-Cardo, Carlos; Jhang, Jeffrey S.; Arinsburg, Suzanne A.] Icahn Sch Med Mt Sinai, Dept Pathol Mol & Cell Based Med, New York, NY 10029 USA.
   [Wajnberg, Ania] Icahn Sch Med Mt Sinai, Dept Med, Div Gen Internal Med, New York, NY 10029 USA.
   [Rodriguez, Denise] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
   [Tandon, Pranai] Icahn Sch Med Mt Sinai, Dept Med, Div Pulm Crit Care & Sleep Med, New York, NY 10029 USA.
   [Bassily-Marcus, Adel] Icahn Sch Med Mt Sinai, Inst Crit Care Med, Dept Surg, New York, NY 10029 USA.
   [Bander, Jeffrey] Icahn Sch Med Mt Sinai, Dept Med, Div Cardiol, New York, NY 10029 USA.
   [Sanky, Charles] Icahn Sch Med Mt Sinai, Dept Med Educ, New York, NY 10029 USA.
   [Amanat, Fatima] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA.
   [Levin, Matthew A.; Reich, David L.] Icahn Sch Med Mt Sinai, Dept Anesthesiol Perioperat & Pain Med, New York, NY 10029 USA.
   [Casadevall, Arturo] Johns Hopkins Sch Med, Dept Mol Microbiol & Immunol, Baltimore, MD USA.
RP Bouvier, NM (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY 10029 USA.; Bouvier, NM (corresponding author), Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY 10029 USA.
EM nicole.bouvier@mssm.edu
RI Krammer, Florian/H-3237-2019; Zheng, Allen/ABD-8443-2020; Nguyen, Freddy
   T./X-2742-2019
OI Krammer, Florian/0000-0003-4121-776X; Zheng, Allen/0000-0003-1103-839X;
   Nguyen, Freddy T./0000-0003-0106-8114; Liu, Sean/0000-0002-3842-6838
FU MSH; ISMMS
FX This study was supported by internal funding from MSH and ISMMS. We
   thank all of the patients who participated in this study and their
   families. We also acknowledge the generosity of the thousands of
   anonymous tristate area residents who recovered from COVID-19 and then
   volunteered to donate convalescent plasma for the benefit of others. We
   thank the New York Blood Center, L.-A. Pirofski, T. Schneider, C. Seah,
   S. Srinivas, D. Tremblay, M. Geiger, C. Lebovits and J. Lustgarten. We
   acknowledge the assistance of ISMMS medical students: S. Ahsanuddin, A.
   Paasewe, R. Upadhyay, G. Mellgard, T. Martinson, B. Patil, C. Luo, S.
   Agrawal, A. Siddiqui, J. Schwarz, L. Piendel, J. Emerson, H. Kaplan, E.
   Klein, M. Garcia, J. Johnson, L. Maillie and E. Baldwin. We also
   appreciate the clinical expertise of the Mount Sinai Convalescent Plasma
   Squad: N. Shuman, D. Delbeau, D. Catamero, G. Sanchez, S. Aird, M. Mann,
   T. Broome, S. Kleiner-Arje, L. Wolf, A. Lee, L. Gaynes and K. Goodman.
   We dedicate this work to the New Yorkers who have lost their lives to
   COVID-19 with a special dedication to the health care workers who will
   always be remembered for their selflessness during this pandemic.
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Austin PC, 2014, STAT MED, V33, P1057, DOI 10.1002/sim.6004
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Cecil R L, 1932, Br Med J, V2, P657
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Choe PG, 2020, EMERG INFECT DIS, V26, P2484, DOI 10.3201/eid2610.202211
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   ENRIA DA, 1984, LANCET, V2, P255, DOI 10.1016/S0140-6736(84)90299-X
   Finland M, 1930, NEW ENGL J MED, V202, P1244, DOI 10.1056/NEJM193006262022605
   Gharbharan A, 2020, CONVALESCENT PLASMA, DOI DOI 10.1101/2020.07.01.20139857V1
   Hung IFN, 2013, CHEST, V144, P712, DOI 10.1378/chest.13-0571
   Joyner M. J, 2020, MAYO CLIN P
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Klein S, 2020, J CLIN INVEST, V130, P6141, DOI 10.1172/JCI142004
   Lee JS, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3980-9
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Perotti C, 2020, HAEMATOLOGICA
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Roback JD, 2020, JAMA-J AM MED ASSOC, V323, P1561, DOI 10.1001/jama.2020.4940
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Salazar E, 2020, AM J PATHOL, V190, P1680, DOI 10.1016/j.ajpath.2020.05.014
   Sharun K, 2020, EXPERT OPIN BIOL TH, V20, P1033, DOI 10.1080/14712598.2020.1796963
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Wajnberg A., 2020, SARS COV 2 INFECT IN
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 31
TC 11
Z9 11
U1 5
U2 5
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD NOV
PY 2020
VL 26
IS 11
BP 1708
EP +
DI 10.1038/s41591-020-1088-9
EA SEP 2020
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA OT0SR
UT WOS:000569723100001
PM 32934372
OA Bronze
DA 2021-01-01
ER

PT J
AU Molnar, MZ
   Bhalla, A
   Azhar, A
   Tsujita, M
   Talwar, M
   Balaraman, V
   Sodhi, A
   Kadaria, D
   Eason, JD
   Hayek, SS
   Coca, SG
   Shaefi, S
   Neyra, JA
   Gupta, S
   Leaf, DE
   Kovesdy, CP
AF Molnar, Miklos Z.
   Bhalla, Anshul
   Azhar, Ambreen
   Tsujita, Makoto
   Talwar, Manish
   Balaraman, Vasanthi
   Sodhi, Amik
   Kadaria, Dipen
   Eason, James D.
   Hayek, Salim S.
   Coca, Steven G.
   Shaefi, Shahzad
   Neyra, Javier A.
   Gupta, Shruti
   Leaf, David E.
   Kovesdy, Csaba P.
CA STOP-COVID Investigators
TI Outcomes of critically ill solid organ transplant patients with COVID-19
   in the United States
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE clinical research; practice; complication; infectious; infection and
   infectious agents - viral; infectious disease; kidney transplantation;
   nephrology; organ transplantation in general; patient survival
ID KIDNEY; CORONAVIRUS
AB National data on patient characteristics, treatment, and outcomes of critically ill coronavirus disease 2019 (COVID-19) solid organ transplant (SOT) patients are limited. We analyzed data from a multicenter cohort study of adults with laboratory-confirmed COVID-19 admitted to intensive care units (ICUs) at 68 hospitals across the United States from March 4 to May 8, 2020. From 4153 patients, we created a propensity score matched cohort of 386 patients, including 98 SOT patients and 288 non-SOT patients. We used a binomial generalized linear model (log-binomial model) to examine the association of SOT status with death and other clinical outcomes. Among the 386 patients, the median age was 60 years, 72% were male, and 41% were black. Death within 28 days of ICU admission was similar in SOT and non-SOT patients (40% and 43%, respectively; relative risk [RR] 0.92; 95% confidence interval [CI]: 0.70-1.22). Other outcomes and requirement for organ support including receipt of mechanical ventilation, development of acute respiratory distress syndrome, and receipt of vasopressors were also similar between groups. There was a trend toward higher risk of acute kidney injury requiring renal replacement therapy in SOT vs. non-SOT patients (37% vs. 27%; RR [95% CI]: 1.34 [0.97-1.85]). Death and organ support requirement were similar between SOT and non-SOT critically ill patients with COVID-19.
C1 [Molnar, Miklos Z.; Bhalla, Anshul; Azhar, Ambreen; Tsujita, Makoto; Talwar, Manish; Balaraman, Vasanthi; Eason, James D.] Methodist Univ Hosp, James D Eason Transplant Inst, Memphis, TN 38104 USA.
   [Molnar, Miklos Z.; Bhalla, Anshul; Azhar, Ambreen; Tsujita, Makoto; Talwar, Manish; Balaraman, Vasanthi; Eason, James D.] Univ Tennessee, Hlth Sci Ctr, Dept Surg, Memphis, TN 38163 USA.
   [Molnar, Miklos Z.; Kovesdy, Csaba P.] Univ Tennessee, Dept Med, Hlth Sci Ctr, Div Nephrol, Memphis, TN 38104 USA.
   [Sodhi, Amik; Kadaria, Dipen] Univ Tennessee, Dept Med, Hlth Sci Ctr, Div Pulm Crit Care & Sleep Med, Memphis, TN 38104 USA.
   [Hayek, Salim S.] Univ Michigan, Dept Med, Div Cardiol, Ann Arbor, MI 48109 USA.
   [Coca, Steven G.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
   [Shaefi, Shahzad] Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA.
   [Neyra, Javier A.] Univ Kentucky, Dept Med, Div Nephrol Bone & Mineral Metab, Lexington, KY 40506 USA.
   [Gupta, Shruti; Leaf, David E.] Brigham & Womens Hosp, Div Renal Med, 75 Francis St, Boston, MA 02115 USA.
   [Kovesdy, Csaba P.] Memphis VA Med Ctr, Nephrol Sect, Memphis, TN USA.
RP Molnar, MZ (corresponding author), Methodist Univ Hosp, James D Eason Transplant Inst, Memphis, TN 38104 USA.; Molnar, MZ (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Surg, Memphis, TN 38163 USA.; Molnar, MZ (corresponding author), Univ Tennessee, Dept Med, Hlth Sci Ctr, Div Nephrol, Memphis, TN 38104 USA.
EM mzmolnar@uthsc.edu
RI Hayek, Salim S./E-6932-2013; Azhar, Ambreen/ABA-8476-2020
OI Hayek, Salim S./0000-0003-0180-349X; Molnar, Miklos
   Z/0000-0002-9665-330X; Leaf, David/0000-0001-7875-090X
CR Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Akdur A, 2020, EXP CLIN TRANSPLANT, V18, P270, DOI 10.6002/ect.2020.0193
   Alberici F, 2020, KIDNEY INT, V97, P1083, DOI 10.1016/j.kint.2020.04.002
   Banerjee D, 2020, KIDNEY INT, V97, P1076, DOI 10.1016/j.kint.2020.03.018
   Bhasin A, 2020, J GEN INTERN MED, DOI 10.1007/s11606-020-05961-5
   Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Chan L, 2020, ACUTE KIDNEY INJURY
   Chaudhry ZS, 2020, AM J TRANSPLANT, V20, P3051, DOI 10.1111/ajt.16188
   Fernandez-Ruiz M, 2020, AM J TRANSPLANT, V20, P1849, DOI 10.1111/ajt.15929
   Fung M, 2020, AM J TRANSPLANT, V20, P3225, DOI 10.1111/ajt.16079
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Hirsch JS, 2020, KIDNEY INT
   Hoek RAS, 2020, TRANSPL INT, V33, P1099, DOI 10.1111/tri.13662
   Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372
   Manuel O, 2019, CLIN TRANSPLANT, V33, DOI 10.1111/ctr.13511
   Mohan S, 2020, J AM SOC NEPHROL, V31, P1150, DOI 10.1681/ASN.2020030375
   Nair V, 2020, AM J TRANSPLANT, V20, P1819, DOI 10.1111/ajt.15967
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Recoverytrial.net, 2020, LOW COST DEX RED DEA
   Richardson S., 2020, JAMA
   Ronco C, 2020, LANCET RESP MED, V8, P738, DOI 10.1016/S2213-2600(20)30229-0
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Travi G, 2020, AM J TRANSPLANT, V20, P2628, DOI 10.1111/ajt.16069
   Tschopp J, 2020, AM J TRANSPLANT, V20, P2876, DOI 10.1111/ajt.16062
   Wang DW, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02895-6
   Williams C, 2018, AM J TRANSPLANT, V18, P1481, DOI 10.1111/ajt.14638
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yi SG, 2020, TRANSPLANTATION
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
NR 31
TC 3
Z9 3
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD NOV
PY 2020
VL 20
IS 11
BP 3061
EP 3071
DI 10.1111/ajt.16280
EA SEP 2020
PG 11
WC Surgery; Transplantation
SC Surgery; Transplantation
GA OH7XN
UT WOS:000569197700001
PM 32844546
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Bharadwaj, S
   Lee, KE
   Dwivedi, VD
   Kang, SG
AF Bharadwaj, Shiv
   Lee, Kyung Eun
   Dwivedi, Vivek Dhar
   Kang, Sang Gu
TI Computational insights into tetracyclines as inhibitors against
   SARS-CoV-2 M-pro via combinatorial molecular simulation calculations
SO LIFE SCIENCES
LA English
DT Article
DE COVID-19; Tetracyclines; Drug repurposing; SARS-CoV-2 M-pro; Molecular
   simulation calculations
ID VIRUS-REPLICATION; SARS; MINOCYCLINE; DOCKING; DESIGN
AB The COVID-19 pandemic raised by SARS-CoV-2 is a public health emergency. However, lack of antiviral drugs and vaccine against human coronaviruses demands a concerted approach to challenge the SARS-CoV-2 infection. Under limited resource and urgency, combinatorial computational approaches to identify the potential inhibitor from known drugs could be applied against risen COVID-19 pandemic. Thereof, this study attempted to purpose the potent inhibitors from the approved drug pool against SARS-CoV-2 main protease (M-pro). To circumvent the issue of lead compound from available drugs as antivirals, antibiotics with broad spectrum of viral activity, i.e. doxycycline, tetracycline, demeclocycline, and minocycline were chosen for molecular simulation analysis against native ligand N3 inhibitor in SARS-CoV-2 M-pro crystal structure. Molecular docking simulation predicted the docking score > -7 kcal/mol with significant intermolecular interaction at the catalytic dyad (His41 and Cys145) and other essential substrate binding residues of SARS-CoV-2 M-pro. The best ligand conformations were further studied for complex stability and intermolecular interaction profiling with respect to time under 100 ns classical molecular dynamics simulation, established the significant stability and interactions of selected antibiotics by comparison to N3 inhibitor. Based on combinatorial molecular simulation analysis, doxycycline and minocycline were selected as potent inhibitor against SARS-CoV-2 M-pro which can used in combinational therapy against SARS-CoV-2 infection.
C1 [Bharadwaj, Shiv; Lee, Kyung Eun; Kang, Sang Gu] Yeungnam Univ, Coll Life & Appl Sci, Inst Biotechnol, Dept Biotechnol, 280 Daehak Ro, Gyongsan 38541, Gyeongbuk, South Korea.
   [Dwivedi, Vivek Dhar] Pathfinder Res & Training Fdn, Ctr Bioinformat Computat & Syst Biol, Greater Noida, India.
RP Kang, SG (corresponding author), Yeungnam Univ, Coll Life & Appl Sci, Inst Biotechnol, Dept Biotechnol, 280 Daehak Ro, Gyongsan 38541, Gyeongbuk, South Korea.; Dwivedi, VD (corresponding author), Pathfinder Res & Training Fdn, Ctr Bioinformat Computat & Syst Biol, Greater Noida, India.
EM vivek_bioinformatics@yahoo.com; kangsg@ynu.ac.kr
RI Dwivedi, Vivek Dhar/AAD-4206-2019; Bharadwaj, Shiv/F-9401-2013
OI Dwivedi, Vivek Dhar/0000-0003-0767-1328; Bharadwaj,
   Shiv/0000-0003-2832-8617
FU Yeungnam University [220A380070]
FX This work was supported by the 2020 Yeungnam University Research Grant
   220A380070.
CR Abuhammad A, 2017, J MOL RECOGNIT, V30, DOI 10.1002/jmr.2644
   Aman M.J., 2011, U.S. Patent, Patent No. [7,999,001, 7999001]
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   Bassetti M, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13326
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Bharadwaj S., 2019, SCI REP, V9, P1
   Bharadwaj S, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1747545, 10.1080/10799893.2020.1805626]
   Bowers K., 2006, P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   Cheng Feixiong, 2019, Methods Mol Biol, V1878, P243, DOI 10.1007/978-1-4939-8868-6_15
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Chukwudi CU, 2016, ANTIMICROB AGENTS CH, V60, P4433, DOI 10.1128/AAC.00594-16
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Du Toit A, 2020, NAT REV MICROBIOL, V18, P123, DOI 10.1038/s41579-020-0332-0
   DYALL J, 2017, DRUGS, V77, P1935, DOI [10.1007/s40265-017-0830-1, DOI 10.1007/S40265-017-0830-1]
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kaeppler U, 2005, J MED CHEM, V48, P6832, DOI 10.1021/jm0501782
   Karaman B, 2019, CURR MED CHEM, V26, P5389, DOI 10.2174/0929867325666180530100332
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Mani D, 2019, J YOUNG PHARM, V11, P117, DOI 10.5530/jyp.2019.11.26
   McIntosh K., 2015, DOUGLAS BENNETTS PRI, Ve2, P1928
   Michaelis M, 2007, J ANTIMICROB CHEMOTH, V60, P981, DOI 10.1093/jac/dkm307
   Mohankumar T., 2020, SCI REPORTS, V10, P1
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Nagarakanti S, 2016, BASIC CLIN PHARMACOL, V118, P4, DOI 10.1111/bcpt.12444
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Ren ZL, 2013, PROTEIN CELL, V4, P248, DOI 10.1007/s13238-013-2841-3
   Rothan HA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126360
   Rothan HA, 2014, ARCH VIROL, V159, P711, DOI 10.1007/s00705-013-1880-7
   Si QS, 2004, J NEUROVIROL, V10, P284, DOI 10.1080/13550280490499533
   Sodhi M, 2020, PHARMACOTHERAPY, V40, P487, DOI 10.1002/phar.2395
   Sturtz FG, 1998, METHOD FIND EXP CLIN, V20, P643, DOI 10.1358/mf.1998.20.8.487489
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vanhaelen Q, 2017, DRUG DISCOV TODAY, V22, P210, DOI 10.1016/j.drudis.2016.09.019
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang JM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000428
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu N., 2020, NEW ENGL J MED, V579, P270
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 51
TC 7
Z9 7
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD SEP 15
PY 2020
VL 257
AR 118080
DI 10.1016/j.lfs.2020.118080
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA NN3RM
UT WOS:000568708500005
PM 32653520
OA Green Published
DA 2021-01-01
ER

PT J
AU Hajivalili, M
   Hosseini, M
   Haji-Fatahaliha, M
AF Hajivalili, Mahsa
   Hosseini, Maryam
   Haji-Fatahaliha, Mostafa
TI Gaining insights on immune responses to the novel coronavirus, COVID-19
   and therapeutic challenges
SO LIFE SCIENCES
LA English
DT Article
DE CVID-19; Immune response; Cytokine storm; Inflammation
ID ACUTE RESPIRATORY SYNDROME; ANTIBODY-DEPENDENT ENHANCEMENT; T-CELL
   RESPONSES; SARS CORONAVIRUS; VIRUS-INFECTION; NITRIC-OXIDE; COV;
   EXPRESSION; PROTEIN; MACROPHAGES
AB SARS-CoV-2 is a new member of coronaviruses that its sudden spreading put the health care system of most countries in a tremendous shock. For controlling of the new infection, COVID-19, many efforts have been done and are ongoing to defeat this virus in the combat field. In this review, we focused on how the immune system behaves toward the virus and the relative possible consequences during their interactions. Then the therapeutic steps and potential vaccine candidates have been described in a hope to provide a better prospective of effective treatment and preventive strategies to the novel SARS-CoV in near future.
C1 [Hajivalili, Mahsa] Shahid Beheshti Univ Med Sci, Sch Med, Dept Immunol, Student Res Comm, Tehran, Iran.
   [Hajivalili, Mahsa] Shahid Beheshti Univ Med Sci, Fac Med, Dept Immunol, Tehran, Iran.
   [Hosseini, Maryam] Tarbiat Modares Univ, Fac Med, Dept Immunol, Tehran, Iran.
   [Hosseini, Maryam] Shahid Beheshti Univ Med Sci, Res Ctr Gastroenterol & Liver Dis, Tehran, Iran.
   [Haji-Fatahaliha, Mostafa] Tabriz Univ Med Sci, Fac Med, Dept Immunol, Tabriz, Iran.
RP Hosseini, M (corresponding author), Tarbiat Modares Univ, Fac Med, Dept Immunol, Tehran, Iran.
EM H_maryam@modares.ac.ir
CR Adedeji AO, 2013, J VIROL, V87, P8017, DOI 10.1128/JVI.00998-13
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Akerstrom S, 2005, J VIROL, V79, P1966, DOI 10.1128/JVI.79.3.1966-1969.2005
   Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014
   Arruvito L, 2014, J IMMUNOL, V193, P4469, DOI 10.4049/jimmunol.1401490
   Baden L.R., 2020, MASS MED SOC
   Barber GN, 2015, NAT REV IMMUNOL, V15, P760, DOI 10.1038/nri3921
   Barnes B.J., 2020, J EXP MED, P217
   Blanco-Melo D., 2020, CELL
   Cabrera-Benitez NE, 2014, ANESTHESIOLOGY, V121, P189, DOI 10.1097/ALN.0000000000000264
   Cai GJ, 2020, STEEL RES INT, DOI 10.1002/srin.202000269
   Cao B, 2020, NEW ENGL J MED, V382
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Channappanavar R., 2017, SEMINARS IMMUNOPATHO
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Chen C, 2020, THALIDOMIDE COMBINED
   Chen G, 2020, CLIN IMMUNOLOGIC FEA, DOI 10.1101/2020.02.16.20023903
   Chen J, 2007, ANNU REV IMMUNOL, V25, P443, DOI 10.1146/annurev.immunol.25.022106.141706
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Chen L., 2020, CARDIOVASC RES
   Chen LN, 2004, CLIN INFECT DIS, V39, P1531, DOI 10.1086/425357
   Chen X., 2020, DETECTABLE SERUM SAR
   Cheraghali A.M., 2020, IRANIAN J ALLERGY AS
   Chuquimia OD, 2013, INFECT IMMUN, V81, P381, DOI 10.1128/IAI.00950-12
   Cristiani L., 2020, EUR RESP SOC
   Cui J, 2018, J PATHOL, V245, P41, DOI 10.1002/path.5054
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dejnirattisai W., 2010, SCIENCE, P328
   Deng X, 2020, ARXIV200300751
   Dhama K., 2020, CORONAVIRUS DIS 2019
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Diao B, 2020, REDUCTION FUNCTIONAL
   Donnelly CA, 2004, LANCET INFECT DIS, V4, P672, DOI 10.1016/S1473-3099(04)01173-9
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Ehlert A, 2016, J NEUROSURG, V124, P51, DOI 10.3171/2014.12.JNS13846
   Elkin SR, 2016, TRAFFIC, V17, P1139, DOI 10.1111/tra.12425
   Evren E, 2020, IMMUNOLOGY, V160, P126, DOI 10.1111/imm.13154
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Fast E.C., 2020, BIORXIV
   Fox SE, 2020, PULMONARY CARDIAC PA
   Gao J., 2020, BIOSCIENCE TRENDS
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   Grifoni A., 2020, CELL
   Guan G W, 2020, Zhonghua Gan Zang Bing Za Zhi, V28, P100, DOI 10.3760/cma.j.issn.1007-3418.2020.02.002
   Guan W, 2020, CLIN CHARACTERISTICS
   Guo L., 2020, CLIN INFECT DIS
   Guzman MG, 2007, EMERG INFECT DIS, V13, P282, DOI 10.3201/eid1302.060539
   Hahm JB, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01785-19
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Herst C.V., 2020, BIORXIV
   Hoffmann M, 2020, CELL
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hussell T, 2014, NAT REV IMMUNOL, V14, P81, DOI 10.1038/nri3600
   Ingraham NE, 2020, LANCET RESP MED
   Inoue Y, 2007, J VIROL, V81, P8722, DOI 10.1128/JVI.00253-07
   Johnston R., 2017, OVERVIEW INNATE IMMU
   Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836
   Kindler E, 2016, ADV VIRUS RES, V96, P219, DOI 10.1016/bs.aivir.2016.08.006
   Kosugi T, 2015, NEPHROL DIAL TRANSPL, V30, P1097, DOI 10.1093/ndt/gfu302
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li M., 2020, GENERATION ANTIBODIE
   Li TS, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000024
   Li X, 2020, J PHARM ANAL
   Li Z, 2020, J MED VIROL
   Liao M., 2020, LANDSCAPE LUNG BRONC
   Liu J., 2020, NEUTROPHIL TO LYMPHO
   Liu J, 2020, LONGITUDINAL CHARACT
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Lu L, 2013, MICROBES INFECT, V15, P625, DOI 10.1016/j.micinf.2013.06.003
   Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0
   Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063
   Okba N.M.A., 2020, EMERG INFECT DIS, V26
   Pechkovsky DV, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-75
   Pichler K, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-100
   Qian ZH, 2013, AM J RESP CELL MOL, V48, P742, DOI 10.1165/rcmb.2012-0339OC
   Qing E., 2020, TRENDS IMMUNOL
   Ramachandran P, 2019, NATURE, V575, P512, DOI 10.1038/s41586-019-1631-3
   Reyfman PA, 2019, AM J RESP CRIT CARE, V199, P1517, DOI 10.1164/rccm.201712-2410OC
   Schneider C, 2014, NAT IMMUNOL, V15, P1026, DOI 10.1038/ni.3005
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Silveyra P, 2014, EXP LUNG RES, V40, P354, DOI 10.3109/01902148.2014.929757
   Smith T., 2020, COVID 19 DRUG THERAP
   Song YG, 2020, INFECT CHEMOTHER, V52, P110, DOI 10.3947/ic.2020.52.1.110
   Su HY, 2018, EXP MOL PATHOL, V104, P222, DOI 10.1016/j.yexmp.2018.05.001
   Sun WX, 2009, P NATL ACAD SCI USA, V106, P8653, DOI 10.1073/pnas.0900850106
   Takada A, 2003, REV MED VIROL, V13, P387, DOI 10.1002/rmv.405
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Thevarajan I., 2020, BREADTH CONCOMITANT
   Thorley AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021827
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Tirado SMC, 2003, VIRAL IMMUNOL, V16, P69, DOI 10.1089/088282403763635465
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang C, 2020, AVEOLAR MACROPHAGE A
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang H, 2020, BIORXIV
   Wang K, 2020, BIORXIV
   Wang R, 2015, EMERG MICROBES INFEC, V4, P1
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Wang ZF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7833
   Watanabe K, 2020, SOC SCI COMPUT REV, DOI 10.1177/0894439320907027
   Wu A, 2020, CELL HOST MICROBE
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Xiao AT, 2020, J INFECT
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang L., 2020, DISCOVERY POTENTIAL
   Yang Y, 2005, BIOCHEM J, V392, P135, DOI 10.1042/BJ20050698
   Yang Y., 2020, EXUBERANT ELEVATION
   Yang ZY, 2005, P NATL ACAD SCI USA, V102, P797, DOI 10.1073/pnas.0409065102
   Yoshikawa T, 2009, J VIROL, V83, P3039, DOI 10.1128/JVI.01792-08
   Yu XB, 2014, THERANOSTICS, V4, P808, DOI 10.7150/thno.8255
   Zhang C, 2020, LANCET GASTROENTEROL
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang D., 2020, COVID 19 INFECT INDU
   Zhang J, 2020, ELECTRON J DIFFER EQ
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhao B, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202002019
   Zhao JC, 2011, J CLIN INVEST, V121, P4921, DOI 10.1172/JCI59777
   Zhao Jing-min, 2003, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, V17, P217
   Zhao R, 2009, NAT PHYS, V5, P100, DOI 10.1038/NPHYS1152
   Zhao Z, 2020, CLIN LAB PROFILES 75
   Zheng M., 2020, CELL MOL IMMUNOL, P1
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou L, 2020, CHIN J TUBERC RESP D, V43, DOI DOI 10.3760/cma.j.issn.1001-0939.2020.0003
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Y., 2020, BIORXIV
   Zhu H, 2006, P NATL ACAD SCI USA, V103, P4011, DOI 10.1073/pnas.0510921103
   Zhu N, 2020, N ENGL J MED
   Ziegler C. G, 2020, CELL
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
   Zuidema A, 2020, BIOESSAYS, V42, DOI 10.1002/bies.202000119
   Zuo Y, 2020, NEUTROPHIL EXTRACELL
NR 137
TC 2
Z9 2
U1 10
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD SEP 15
PY 2020
VL 257
AR 118058
DI 10.1016/j.lfs.2020.118058
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA NN3TL
UT WOS:000568713600002
PM 32653518
OA Green Published
DA 2021-01-01
ER

PT J
AU Hazra, S
   Chaudhuri, AG
   Tiwary, BK
   Chakrabarti, N
AF Hazra, Suvojit
   Chaudhuri, Alok Ghosh
   Tiwary, Basant K.
   Chakrabarti, Nilkanta
TI Matrix metallopeptidase 9 as a host protein target of chloroquine and
   melatonin for immunoregulation in COVID-19: A network-based
   meta-analysis
SO LIFE SCIENCES
LA English
DT Article
DE COVID-19; SARS-CoV-2; Coronavirus; PPI-CPI network; MMP9; Chloroquine;
   Melatonin
ID ANGIOTENSIN-CONVERTING ENZYME-2; INHIBITORS; SARS; METALLOPROTEINASES;
   INFECTION; CORONAVIRUSES; INFLAMMATION; PNEUMONIA; PHOSPHATE; DISCOVERY
AB Aims: The molecular pathogenesis of COVID-19 is similar to other coronavirus (CoV) infections viz. severe acute respiratory syndrome (SARS) in human. Due to scarcity of the suitable treatment strategy, the present study was undertaken to explore host protein(s) targeted by potent repurposed drug(s) in COVID-19.
   Materials and methods: The differentially expressed genes (DEGs) were identified from microarray data repository of SARS-CoV patient blood. The repurposed drugs for COVID-19 were selected from available literature. Using DEGs and drugs, the protein-protein interaction (PPI) and chemo-protein interaction (CPI) networks were constructed and combined to develop an interactome model of PPI-CPI network. The top-ranked sub-network with its hub-bottleneck nodes were evaluated with their functional annotations.
   Key findings: A total of 120 DEGs and 65 drugs were identified. The PPI-CPI network (118 nodes and 293 edges) exhibited a top-ranked sub-network (35 nodes and 174 connectivities) with 12 hub-bottleneck nodes having two drugs chloroquine and melatonin in association with 10 proteins corresponding to six upregulated and four downregulated genes. Two drugs interacted directly with the hub-bottleneck node i.e. matrix metallopeptidase 9 (MMP9), a host protein corresponding to its upregulated gene. MMP9 showed functional annotations associated with neutrophil mediated immunoinflammation. Moreover, literature survey revealed that angiotensin converting enzyme 2, a membrane receptor of SARS-CoV-2 virus, might have functional cooperativity with MMP9 and a possible interaction with both drugs.
   Significance: The present study reveals that between chloroquine and melatonin, melatonin appears to be more promising repurposed drug against MMP9 for better immunocompromisation in COVID-19.
C1 [Hazra, Suvojit; Chakrabarti, Nilkanta] Univ Calcutta, CPEPA UGC Ctr Electrophysiol & Neuroimaging Studi, Kolkata, W Bengal, India.
   [Hazra, Suvojit; Chakrabarti, Nilkanta] Univ Calcutta, Dept Physiol, 92 Acharya Prafulla Chandra Rd, Kolkata 700009, W Bengal, India.
   [Chaudhuri, Alok Ghosh] Vidyasagar Coll, Dept Physiol, Kolkata, W Bengal, India.
   [Tiwary, Basant K.] Pondicherry Univ, Sch Life Sci, Ctr Bioinformat, Pondicherry 605014, India.
RP Chakrabarti, N (corresponding author), Univ Calcutta, Dept Physiol, 92 Acharya Prafulla Chandra Rd, Kolkata 700009, W Bengal, India.; Tiwary, BK (corresponding author), Pondicherry Univ, Sch Life Sci, Ctr Bioinformat, Pondicherry 605014, India.
EM basant68@email.com; ncphysiolcu@gmail.com
RI Chakrabarti, Nilkanta/AAX-1331-2020; Tiwary, Basant K/A-9617-2011
OI Tiwary, Basant K/0000-0002-8194-5860; Hazra, Suvojit/0000-0002-7925-098X
FU Department of Biotechnology (DBT), BINC (Bioinformatics National
   Certification), Ministry of Science and Technology, Government of India
   [BT/BI/10/078/2014]
FX The Senior Research Fellowship grant was funded by the Department of
   Biotechnology (DBT), BINC (Bioinformatics National Certification),
   Ministry of Science and Technology, Government of India, to Suvojit
   Hazra (Grant No.: BT/BI/10/078/2014).
CR Aitken EH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03005
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2
   Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Boga JA, 2012, REV MED VIROL, V22, P323, DOI 10.1002/rmv.1714
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Brann D, 2020, NONNEURAL EXPRESSION, DOI [10.1101/2020.03.25.009084, DOI 10.1101/2020.03.25.009084, 10.1101/2020.03.25.009084.]
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Camp JV, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00550
   Cangussu LM, 2009, PEPTIDES, V30, P1921, DOI 10.1016/j.peptides.2009.06.028
   Cassatella MA, 2019, TRENDS IMMUNOL, V40, P648, DOI 10.1016/j.it.2019.05.003
   Castillo R. R., 2020, MELATONIN RES, V3, P297, DOI [10.32794/mr11250063., DOI 10.32794/MR11250063]
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Chung FT, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091451
   Clarke NE, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/307315
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Djuric T., 2017, ROLE MATRIX MET HUM, V1, P3, DOI DOI 10.5772/INTECH0PEN.70265
   Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   Ferrario CM, 2010, ADV PHARMACOL, V59, P197, DOI 10.1016/S1054-3589(10)59007-0
   Fu LW, 2020, J INFECTION, V80, P656, DOI 10.1016/j.jinf.2020.03.041
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Gomez DE, 1997, EUR J CELL BIOL, V74, P111
   Gomez-Salinero JM, 2017, BLOOD, V130, P5, DOI 10.1182/blood-2017-04-776385
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hassan N, 2015, EUR RESPIR J, V46, DOI 10.1183/13993003.congress-2015.OA1467
   Hernandez AV, 2020, ANN INTERN MED, V173, P287, DOI 10.7326/M20-2496
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hofmann H, 2004, BIOCHEM BIOPH RES CO, V319, P1216, DOI 10.1016/j.bbrc.2004.05.114
   Holshue Michelle L, 2020, N Engl J Med, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang SH, 2019, J FUNCT FOODS, V58, P189, DOI 10.1016/j.jff.2019.04.062
   Iwata M., 2011, CURR ENZ INHIB, V7, P42, DOI DOI 10.2174/157340811795713756
   Jin Y, 2007, J MOL CELL CARDIOL, V43, P664, DOI 10.1016/j.yjmcc.2007.09.002
   Kapoor C, 2016, J CANCER RES THER, V12, P28, DOI 10.4103/0973-1482.157337
   Klein T, 2011, AMINO ACIDS, V41, P271, DOI 10.1007/s00726-010-0689-x
   Kuhn M, 2008, NUCLEIC ACIDS RES, V36, pD684, DOI 10.1093/nar/gkm795
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   LABRO MT, 1988, ANTIMICROB AGENTS CH, V32, P1124, DOI 10.1128/AAC.32.8.1124
   Lesiak A, 2010, LUPUS, V19, P683, DOI 10.1177/0961203309356455
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Loffek S, 2011, EUR RESPIR J, V38, P191, DOI 10.1183/09031936.00146510
   Lukassen S, 2020, EMBO J, DOI 10.15252/embj.20105114
   Mahevas M, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1844
   Nicastri E, 2020, INFECT DIS REP, V12, P3, DOI 10.4081/idr.2020.8543
   Nunes OD, 2008, J PINEAL RES, V44, P373, DOI 10.1111/j.1600-079X.2007.00538.x
   Pandi-Perumal SR, 2005, EXP GERONTOL, V40, P911, DOI 10.1016/j.exger.2005.08.009
   Patel VB, 2016, CIRC RES, V118, P1313, DOI 10.1161/CIRCRESAHA.116.307708
   Patil VM, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2020.117775
   Pliyev BK, 2012, APOPTOSIS, V17, P1050, DOI 10.1007/s10495-012-0738-x
   Potey PMD, 2019, J PATHOL, V247, P672, DOI 10.1002/path.5221
   R Core Team, 2013, R LANG ENV STAT COMP, V3, P201
   Radogna F, 2010, BIOCHEM PHARMACOL, V80, P1844, DOI 10.1016/j.bcp.2010.07.041
   Ray A, 2017, TRENDS IMMUNOL, V38, P942, DOI 10.1016/j.it.2017.07.003
   Reghunathan R, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-2
   Reiter RJ, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00226
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Rojas-Quintero J, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99022
   Romanelli F, 2004, CURR PHARM DESIGN, V10, P2643, DOI 10.2174/1381612043383791
   Rudra DS, 2013, J PINEAL RES, V54, P398, DOI 10.1111/jpi.12034
   Scardoni G, 2009, BIOINFORMATICS, V25, P2857, DOI 10.1093/bioinformatics/btp517
   Schindler C, 2007, VASC HEALTH RISK MAN, V3, P125
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shen L, 2019, J VIROL, V93, DOI 10.1128/JVI.00023-19
   Shimazu H, 2017, BLOOD, V130, P59, DOI 10.1182/blood-2016-09-738096
   Shneider A, 2020, INT REV IMMUNOL, V39, P153, DOI 10.1080/08830185.2020.1756284
   Silvestri M, 2013, ITAL J PEDIATR, V39, DOI 10.1186/1824-7288-39-61
   Simko F, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117902
   Silva ACSE, 2013, BRIT J PHARMACOL, V169, P477, DOI 10.1111/bph.12159
   Skariyachan S, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00569
   Smith SB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033174
   Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tan DX, 2014, J PINEAL RES, V57, P381, DOI 10.1111/jpi.12186
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Totura AL, 2012, CURR OPIN VIROL, V2, P264, DOI 10.1016/j.coviro.2012.04.004
   Tuomela J, 2013, ONCOL LETT, V6, P1665, DOI 10.3892/ol.2013.1602
   Vafadari B, 2016, J NEUROCHEM, V139, P91, DOI 10.1111/jnc.13415
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Vinetz JM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2018
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   WHO, 2020, WE HAV THER MAD ASS
   Williams AE, 2014, AM J PHYSIOL-LUNG C, V306, pL217, DOI 10.1152/ajplung.00311.2013
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yin YD, 2018, RESPIROLOGY, V23, P130, DOI 10.1111/resp.13196
   Yu CM, 2006, POSTGRAD MED J, V82, P140, DOI 10.1136/pgmj.2005.037515
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhang R, 2020, LIFE SCI, V250, DOI 10.1016/j.lfs.2020.117583
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Q, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01061
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 101
TC 3
Z9 3
U1 11
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD SEP 15
PY 2020
VL 257
AR 118096
DI 10.1016/j.lfs.2020.118096
PG 12
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA NN3RY
UT WOS:000568709700009
PM 32679150
OA Green Published
DA 2021-01-01
ER

PT J
AU Li, S
   Qu, YL
   Tu, MQ
   Guo, LY
   Zhang, QL
   Lv, CY
   Guo, RJ
AF Li, Shuo
   Qu, Ya-Li
   Tu, Mu-Qin
   Guo, Li-Yan
   Zhang, Qi-Li
   Lv, Chao-Yang
   Guo, Rui-Jun
TI Application of lung ultrasonography in critically ill patients with
   COVID-19
SO ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED
   TECHNIQUES
LA English
DT Article
DE lung consolidation; lung ultrasonography; severe and critical COVID-19
ID ULTRASOUND
AB Purpose Lung ultrasonography (LU) is useful to assess lung lesions and variations at bedside. To investigate the results of LU in severe and critical patients with coronavirus disease 2019 (COVID-19), we performed a single-institution study to evaluate the related lung lesions and variations, and prophylactic strategies, in a large referral and treatment center. Methods We included 91 adult patients with severe and critical COVID-19, namely 62 males and 29 females, with an average age of 59 +/- 11 years, who underwent LU. We collected the following patient information: sex, age, days in hospital, and days in ICU. In the ultrasound examinations, we recorded the presence of discrete B lines, confluent B lines, consolidation, pleural thickening, pleural effusion, and pneumothorax (PTX). Results Among the 91 severe and critical patients, 59 cases had scattered B lines, 56 cases had confluent B lines, 58 cases had alveolar-interstitial syndrome (AIS), 48 cases had lung consolidation, six cases had pleural thickening, 39 cases had pleural effusion (average depth of the pleural effusion: 1.0 +/- 1.5 cm), and 20 patients developed PTX. In the Cox multivariate analysis, there were significant differences in age, hospitalization days, ICU days, and lung consolidation. Conclusion Lung ultrasonography performed at the bedside can detect lung diseases, such as B lines, PTX, pulmonary edema, lung consolidation, pleural effusion, and variations of these findings. Our findings support the use of LU and measurements for estimating factors, and monitoring response to therapy in severe and critical COVID-19 patients.
C1 [Qu, Ya-Li; Tu, Mu-Qin; Guo, Li-Yan] Wuhan Jin Yin Tan Hosp, Dept Ultrasound Med, Wuhan, Peoples R China.
   [Li, Shuo; Zhang, Qi-Li; Lv, Chao-Yang; Guo, Rui-Jun] Capital Med Univ, Beijing Chaoyang Hosp, Dept Ultrasound Med, North Rd 8, Beijing 100020, Peoples R China.
RP Guo, RJ (corresponding author), Capital Med Univ, Beijing Chaoyang Hosp, Dept Ultrasound Med, North Rd 8, Beijing 100020, Peoples R China.
EM guodaoshi@126.com
CR Chen SW, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005826
   GAO YQ, 2019, CHIN PEDIAT EMERG ME, V26, P588
   Giwa Al, 2020, Emerg Med Pract, V22, P1
   Jambrik Z, 2004, AM J CARDIOL, V93, P1265, DOI 10.1016/j.amjcard.2004.02.012
   Konietzke P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230252
   Lichtenstein DA, 2019, CHEST, V156, P21, DOI 10.1016/j.chest.2019.02.332
   Liu JL, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-3199-1
   Liu J, 2019, J COMPUT CIVIL ENG, V33, DOI 10.1061/(ASCE)CP.1943-5487.0000816
   Mayo PH, 2019, INTENS CARE MED, V45, P1200, DOI 10.1007/s00134-019-05725-8
   National Health Commission, 2020, DIAGN TRATM PROGR NO
   Peng QY, 2020, INTENS CARE MED, V46, P849, DOI 10.1007/s00134-020-05996-6
   Raimondi F, 2016, J PEDIATR-US, V175, P74, DOI 10.1016/j.jpeds.2016.04.018
   Soummer A, 2012, CRIT CARE MED, V40, P2064, DOI 10.1097/CCM.0b013e31824e68ae
   Trezzi M, 2013, INTERN EMERG MED, V8, P409, DOI 10.1007/s11739-011-0625-4
   Vaeth M, 2004, STAT MED, V23, P1781, DOI 10.1002/sim.1753
NR 15
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0742-2822
EI 1540-8175
J9 ECHOCARDIOGR-J CARD
JI Echocardiography-J. Cardiovasc. Ultrasound Allied Tech.
PD NOV
PY 2020
VL 37
IS 11
BP 1838
EP 1843
DI 10.1111/echo.14849
EA SEP 2020
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OY0FS
UT WOS:000569190500001
PM 32931069
OA Other Gold
DA 2021-01-01
ER

PT J
AU Hamadeh, A
   Aldujeli, A
   Briedis, K
   Tecson, KM
   Sanz-Sanchez, J
   Al Dujeili, M
   Al-Obeidi, A
   Diez, JL
   Zaliunas, R
   Stoler, RC
   McCullough, PA
AF Hamadeh, Anas
   Aldujeli, Ali
   Briedis, Kasparas
   Tecson, Kristen M.
   Sanz-Sanchez, Jorge
   Al Dujeili, Montazar
   Al-Obeidi, Ammar
   Diez, Jose Luis
   Zaliunas, Remigijus
   Stoler, Robert C.
   McCullough, Peter A.
TI Characteristics and Outcomes in Patients Presenting With COVID-19 and
   ST-Segment Elevation Myocardial Infarction
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID GUIDELINES
AB There is limited information regarding clinical characteristics and outcomes of patients with SARS-CoV-2 (COVID-19) disease presenting with ST-segment elevation myocardial infarction (STEMI). In this multicenter retrospective study, we reviewed charts of patients admitted with symptomatic COVID-19 infection and STEMI to a total of 4 hospitals spanning Italy, Lithuania, Spain and Iraq from February 1, 2020 to April 15, 2020. A total of 78 patients were included in this study, 49 (63%) of whom were men, with a median age of 65 [58, 71] years, and high comorbidity burden. During hospitalization, 8 (10%) developed acute respiratory distress syndrome, and 14 (18%) required mechanical ventilation. 19 (24%) patients were treated with primary Percutaneous Coronary Intervention (PCI) and 59 (76%) were treated with fibrinolytic therapy. 13 (17%) patients required cardiac resuscitation, and 9 (11%) died. For the 19 patients treated with primary PCI, 8 (42%) required intubation and 8 (42%) required cardiac resuscitation; stent thrombosis occurred in 4 patients (21%). A total of 5 patients (26%) died during hospitalization. 50 (85%) of the 59 patients initially treated with fibrinolytic therapy had successful fibrinolysis. The median time to reperfusion was 27 minutes [20, 34]. Hemorrhagic stroke occurred in 5 patients (9%). Six patients (10%) required invasive mechanical ventilation; 5 (9%) required cardiac resuscitation, and 4 (7%) died. In conclusion, this is the largest case series to-date of COVID-19 positive patients presenting with STEMI and spans 4 countries. We found a high rate of stent thrombosis, indicating a possible need to adapt STEMI management for COVID-19 patients. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Hamadeh, Anas; Stoler, Robert C.; McCullough, Peter A.] Baylor Univ, Med Ctr, Dallas, TX 75246 USA.
   [Hamadeh, Anas; Stoler, Robert C.; McCullough, Peter A.] Baylor Scott & White Heart & Vasc Hosp, Dallas, TX 75226 USA.
   [Aldujeli, Ali; Briedis, Kasparas; Zaliunas, Remigijus] Lithuanian Univ Hlth Sci, Kaunas, Lithuania.
   [Tecson, Kristen M.; McCullough, Peter A.] Baylor Heart & Vasc Inst, Dallas, TX USA.
   [Sanz-Sanchez, Jorge] Humanitas Clin & Res Ctr IRCCS, Rozzano Milan, Italy.
   [Al Dujeili, Montazar] Univ Brescia, Brescia, Italy.
   [Al-Obeidi, Ammar] Al Kafeel Super Specialty Hosp, Karbala, Iraq.
   [Al-Obeidi, Ammar] Karbala Cardiac & Cardiosurg Ctr, Karbala, Iraq.
   [Diez, Jose Luis] Hosp Univ & Politecn La Fe, Valencia, Spain.
RP Hamadeh, A (corresponding author), Baylor Univ, Med Ctr, Dallas, TX 75246 USA.; Hamadeh, A (corresponding author), Baylor Scott & White Heart & Vasc Hosp, Dallas, TX 75226 USA.
EM Anas.Hamadeh@bswhealth.org
OI Sanz Sanchez, Jorge/0000-0003-4991-6549; Diez, Jose
   L./0000-0001-9921-8023; Hamadeh, Anas/0000-0001-8351-1276
FU Baylor Health Care System Foundation
FX This work was funded, in part, by the Baylor Health Care System
   Foundation.
CR [Anonymous], 2020, CLIN MAN SEV AC RESP
   Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Bangalore S, 2020, N ENGL J MED
   CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142
   Claeys MJ, 2015, ACTA CARDIOL, V70, P693, DOI [10.1080/AC.70.6.3120182, 10.2143/AC.70.6.3120182]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ibanez B, 2018, EUR HEART J, V39, P119, DOI 10.1093/eurheartj/ehx393
   Jing ZC, 2020, EUR HEART J
   Klok FA, 2020, THROMB RES
   Levine GN, 2012, CATHETER CARDIO INTE, V79, P453, DOI 10.1002/ccd.23438
   Patel MR, 2017, J AM COLL CARDIOL, V69, P570, DOI 10.1016/j.jacc.2016.10.034
   Stefanini GG, 2020, CIRCULATION, V141, P2113, DOI 10.1161/CIRCULATIONAHA.120.047525
   Szerlip M, 2020, CATHETER CARDIO INTE, V96, P586, DOI 10.1002/ccd.28887
   The Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, COR COVID 19 GLOB CA
   Thygesen K, 2019, EUR HEART J, V40, P237, DOI [10.1093/eurheartj/ehy462, 10.1016/j.jacc.2018.08.1038]
   Vasiljevic Z, 2008, SRP ARK CELOK LEK, V136, P84, DOI 10.2298/SARH08S2084V
   Warren-Gash C, 2012, J INFECT DIS, V206, P1652, DOI 10.1093/infdis/jis597
   Wolf G, 2002, AM J KIDNEY DIS, V39, P1, DOI 10.1053/ajkd.2002.29865
   Yin S, 2020, J THROMB THROMBOLYS, P1, DOI [10.1007/s11239-020-02106-8., DOI 10.1007/S11239-020-02106-8]
   Zeng J, 2020, INTENS CARE MED, V46, P1111, DOI 10.1007/s00134-020-05993-9
NR 20
TC 6
Z9 6
U1 0
U2 0
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
EI 1879-1913
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD SEP 15
PY 2020
VL 131
BP 1
EP 6
DI 10.1016/j.amjcard.2020.06.063
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NK0IN
UT WOS:000566425500001
PM 32732010
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ismail, S
   Ahmad, S
   Azam, SS
AF Ismail, Saba
   Ahmad, Sajjad
   Azam, Syed Sikander
TI Immunoinformatics characterization of SARS-CoV-2 spike glycoprotein for
   prioritization of epitope based multivalent peptide vaccine
SO JOURNAL OF MOLECULAR LIQUIDS
LA English
DT Article
DE COVID-19; SARS-CoV-2; Spike glycoprotein; Vaccine; Immuno-informatics;
   Multi-epitope peptide vaccine construct; Molecular dynamics simulation
ID NF-KAPPA-B; PROTEIN-STRUCTURE; SALT BRIDGES; CODON USAGE; CORONAVIRUS;
   ANTIBODIES; PREDICTION; STABILIZATION; RECOGNITION; REFINEMENT
AB The COVID-19 pandemic caused by SARS-CoV-2 is a public health emergency of international concern and thus calling for the development of effective and safe therapeutics and prophylactics particularly a vaccine to protect against the infection. SARS-CoV-2 spike glycoprotein is an attractive candidate for a vaccine, antibodies, and inhibitors development because of the many roles it plays in attachment, fusion and entry into the host cell. In the present investigation, we characterized the SARS-CoV-2 spike glycoprotein by immunoinformatics techniques to put forward potential B and T cell epitopes, followed by the use of epitopes in construction of a multi-epitope peptide vaccine construct (MEPVC). The MEPVC revealed robust host immune system simulation with high production of immunoglobulins, cytokines and interleukins. Stable conformation of the MEPVC with a representative innate immune TLR3 receptor was observed involving strong hydrophobic and hydrophilic chemical interactions, along with enhanced contribution from salt-bridges towards inter-molecular stability. Molecular dynamics simulation in aqueous milieu aided further in interpreting strong affinity of the MEPVC for TLR3. This stability is the attribute of several vital residues from both TLR3 and MEPVC as shown by radial distribution function (RDF) and a novel axial frequency distribution (AFD) analytical tool. Comprehensive binding free energies estimation was provided at the end that concluded major domination by electrostatic and minor from van der Waals. Summing all, the designed MEPVC has tremendous potential of providing protective immunity against COVID-19 and thus could be considered in experimental studies. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Ismail, Saba; Ahmad, Sajjad; Azam, Syed Sikander] Quaid I Azam Univ, Natl Ctr Bioinformat NCB, Computat Biol Lab, Islamabad 45320, Pakistan.
RP Azam, SS (corresponding author), Quaid I Azam Univ, Natl Ctr Bioinformat NCB, Islamabad 45320, Pakistan.
EM ssazam@qau.edu.pk
RI Ahmad, Sajjad/ABG-7863-2020
OI Ahmad, Sajjad/0000-0003-0754-1742; Ismail, saba/0000-0002-8793-2972
FU Pakistan-United States Science and Technology Cooperation Program
FX Authors are highly grateful to the Pakistan-United States Science and
   Technology Cooperation Program (Grant No. Pak-US/2017/360) for granting
   the financial assistance.
CR Abbasi S, 2016, J MOL LIQ, V221, P507, DOI 10.1016/j.molliq.2016.06.034
   Ahmad S, 2019, EUR J PHARM SCI, V132, P1, DOI 10.1016/j.ejps.2019.02.023
   Ahmad S, 2017, J MOL GRAPH MODEL, V77, P72, DOI 10.1016/j.jmgm.2017.07.024
   Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Ali M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09199-w
   Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639
   Andrusier N, 2007, PROTEINS, V69, P139, DOI 10.1002/prot.21495
   Angov E, 2011, BIOTECHNOL J, V6, P650, DOI 10.1002/biot.201000332
   Barh D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052773
   Bhattacharya M., 2020, J MED VIROL, V19, P149
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Bosshard HR, 2004, J MOL RECOGNIT, V17, P1, DOI 10.1002/jmr.657
   Brubaker SW, 2015, ANNU REV IMMUNOL, V33, P257, DOI 10.1146/annurev-immunol-032414-112240
   Bui HH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-361
   Cao WCC, 2007, NEW ENGL J MED, V357, P1162, DOI 10.1056/NEJMc070348
   Case D, 2014, AMBER, V14, P29
   Case D. A., 2016, AMBER16 PACKAGE
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen R, 2020, VIRUS RES, V276, DOI 10.1016/j.virusres.2019.197834
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cheng J, 2005, NUCLEIC ACIDS RES, V33, pW72, DOI 10.1093/nar/gki396
   Chung EH, 2014, CLIN EXP VACCINE RES, V3, P50, DOI 10.7774/cevr.2014.3.1.50
   Craig DB, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-346
   CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204
   Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
   Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30
   Dimitrov I, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S6-S4
   Dombkowski AA, 2014, FEBS LETT, V588, P206, DOI 10.1016/j.febslet.2013.11.024
   DONOHUE J, 1954, P NATL ACAD SCI USA, V40, P377, DOI 10.1073/pnas.40.6.377
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   FENG MF, 2010, BIOMED RES INT, V2010, DOI DOI 10.1155/2010/845984
   FERSHT AR, 1987, TRENDS BIOCHEM SCI, V12, P301, DOI 10.1016/0968-0004(87)90146-0
   Garg A, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-62
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505
   Goo J, 2020, VIRUS RES, V278, DOI 10.1016/j.virusres.2020.197863
   Greenwood D., 2012, MED MICROBIOLOGY E B
   Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376
   Guan PP, 2003, NUCLEIC ACIDS RES, V31, P3621, DOI 10.1093/nar/gkg510
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Gupta S, 2015, METHODS MOL BIOL, V1268, P143, DOI 10.1007/978-1-4939-2285-7_7
   Haq FU, 2017, J MOL GRAPH MODEL, V74, P143, DOI DOI 10.1016/j.jmgm.2017.03.002
   Hassan A, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2951-4
   HENDSCH ZS, 1994, PROTEIN SCI, V3, P211
   Heo L, 2013, NUCLEIC ACIDS RES, V41, pW384, DOI 10.1093/nar/gkt458
   Hewitt EW, 2003, IMMUNOLOGY, V110, P163, DOI 10.1046/j.1365-2567.2003.01738.x
   Hoffmann M, 2020, BIORXIV
   Hou T., 2011, ASSESSING PERFORMANC, V1, P69
   Hubbard R.E., 2001, HYDROGEN BONDS PROTE, V164, P2399
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Ikram A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34254-5
   Izaguirre JA, 2001, J CHEM PHYS, V114, P2090, DOI 10.1063/1.1332996
   Jelesarov Ilian, 2009, V490, P227, DOI 10.1007/978-1-59745-367-7_10
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Jones EY, 2006, NAT REV IMMUNOL, V6, P271, DOI 10.1038/nri1805
   Karplus M, 2002, NAT STRUCT BIOL, V9, P646, DOI 10.1038/nsb0902-646
   Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kouetcha DN, 2017, J SUPERCOMPUT, V73, P1629, DOI 10.1007/s11227-016-1854-0
   Krautler V, 2001, J COMPUT CHEM, V22, P501, DOI 10.1002/1096-987X(20010415)22:5<501::AID-JCC1021>3.0.CO;2-V
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li G, 2020, THERAPEUTIC OPTIONS
   Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Liu ZQ, 2005, IMMUNOL LETT, V97, P41, DOI 10.1016/j.imlet.2004.09.012
   Lobanov MY, 2008, MOL BIOL+, V42, P623, DOI 10.1134/S0026893308040195
   Maiorov V.N., 1994, SIGNIFICANCE ROOT ME
   Makhatadze GI, 2003, J MOL BIOL, V327, P1135, DOI 10.1016/S0022-2836(03)00233-X
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h
   Mittal A, 2020, INT J PEPT RES THER, V0, P1
   Morris G M, 2008, MOL MODELING PROTEIN, P365, DOI DOI 10.1007/978-1-59745-177-2_19
   Motamedi MJ, 2014, INT J PEPT RES THER, V20, P179, DOI 10.1007/s10989-013-9380-x
   Naz A, 2015, INFECT GENET EVOL, V32, P280, DOI 10.1016/j.meegid.2015.03.027
   Naz K, 2019, BMC BIOINFORMATICS, V20, DOI 10.1186/s12859-019-2713-9
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Pandey RK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19456-1
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   ProtParam E., 2017, EXPASY PROTPARAM TOO
   Rapin N., 2012, C IMMSIM 10 1 SERVER
   Raza S, 2018, J MOL MODEL, V24, DOI 10.1007/s00894-018-3601-3
   Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Solanki V, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41496-4
   Sugiarto H, 2004, BIOCHEM BIOPH RES CO, V323, P721, DOI 10.1016/j.bbrc.2004.08.162
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Wang P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-568
   Wizemann TM, 1999, EMERG INFECT DIS, V5, P395, DOI 10.3201/eid0503.990310
   Woo PCY, 2004, CLIN DIAGN LAB IMMUN, V11, P665, DOI 10.1128/CDLI.11.4.665-668.2004
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu J, 2020, NEUROCOMPUTING, V395, P78, DOI [10.1080/17435390.2020.1831639, 10.1016/j.neucom.2020.02.017]
   Yang YS, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102434
   Ye ZW, 2020, INT J BIOL SCI, V16, P1686, DOI 10.7150/ijbs.45472
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhang LF, 2018, CELL MOL IMMUNOL, V15, P182, DOI 10.1038/cmi.2017.92
   Zhou GY, 2020, INT J BIOL SCI, V16, P1718, DOI 10.7150/ijbs.45123
NR 104
TC 0
Z9 0
U1 19
U2 19
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0167-7322
EI 1873-3166
J9 J MOL LIQ
JI J. Mol. Liq.
PD SEP 15
PY 2020
VL 314
AR 113612
DI 10.1016/j.molliq.2020.113612
PG 15
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA ND4XT
UT WOS:000561905700053
PM 32834259
OA Green Published
DA 2021-01-01
ER

PT J
AU Rodler, S
   Apfelbeck, M
   Schulz, GB
   Ivanova, T
   Buchner, A
   Staehler, M
   Heinemann, V
   Stief, C
   Casuscelli, J
AF Rodler, Severin
   Apfelbeck, Maria
   Schulz, Gerald Bastian
   Ivanova, Troya
   Buchner, Alexander
   Staehler, Michael
   Heinemann, Volker
   Stief, Christian
   Casuscelli, Jozefina
TI Telehealth in Uro-oncology Beyond the Pandemic: Toll or Lifesaver?
SO EUROPEAN UROLOGY FOCUS
LA English
DT Article
DE COVID-19; Patient perspective; Telehealth; Uro-oncology
AB Background: Telehealth services are rapidly embraced in uro-oncology due to the current coronavirus disease 2019 (COVID-19) pandemic.
   Objective: To determine patients perspective on adoption of telehealth as a response to the pandemic and its sustainability in the future.
   Design, setting, and participants: Following a COVID-19 outbreak, 101 patients with advanced genitourinary cancers are currently managed virtually for therapy administration at our tertiary care unit. They were surveyed about the current situation, and current and long-term employment of telehealth.
   Intervention: Rapid implementation of virtual patient management.
   Outcome measurements and statistical analysis: Patients perception of anxiety of COVID-19 and cancer, perspective on telehealth measures as a reaction to the current COVID-19 pandemic, and long-term acceptance were used as outcomes. Wilcoxon matched-pair signed rank test, chi-square test, and Mann-Whitney U test were performed.
   Results and limitations: Of 101 patients, 92 answered the questionnaire, with 71 (77.2%) responding virtually by e-mail or phone call. Anxiety of cancer (6/10, interquartile range [IQR] 38) superseded that of COVID-19 (four/10, IQR 25.25, p < 0.001), and patients oppose temporary treatment interruption. Of the patients, 66.0% perceive their susceptibility to COVID-19 as equal to or lower than the general population and 52.2% believe that COVID-19 will not affect their therapy. In future, patients (62.6%) prefer to maintain in-person appointments as opposed to complete remote care, but accept remote care during the pandemic (eight/10, IQR 59). Beyond the crisis, maintaining telehealth has low preference rates (four/10, IQR 27), with high acceptance for external laboratory controls (60.9%) and online visit management (48.9%), but lower acceptance for remote treatment planning including staging discussions (44.6%) and for referral to secondary care oncologists (17.4%).
   Conclusions: Despite the pandemic, cancer remains the key concern and patients are not willing to compromise on their treatment. Rapid implementation of telehealth is tolerated well during the need of social distancing, with a clear red line concerning changes in existing patient-physician relationships. Balancing future implementation of telehealth while considering patients demand for personal relationships will ensure human dignity in uro-oncology.
   Patient summary: We queried patients with genitourinary cancers treated in an almost virtual setting following a local coronavirus outbreak. Acceptance of telehealth during the current situation is high; however, long-term implementation of the adapted services is less favored. We deduce that patient-physician relationship is crucial for cancer patients and needs to be balanced against measures for social distancing to forge the future management. (C) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
C1 [Rodler, Severin; Apfelbeck, Maria; Schulz, Gerald Bastian; Ivanova, Troya; Buchner, Alexander; Staehler, Michael; Stief, Christian; Casuscelli, Jozefina] Klinikum Univ Munchen, Klin & Poliklin Urol, Munich, Germany.
   [Rodler, Severin; Apfelbeck, Maria; Heinemann, Volker; Casuscelli, Jozefina] Klinikum Univ Munchen, Comprehens Canc Ctr, Munich, Germany.
   [Heinemann, Volker] Klinikum Univ Munchen, Med Klin 3, Munich, Germany.
RP Rodler, S (corresponding author), Klinikum Univ Munchen, Klin Urol, Marchioninistr 15, D-81377 Munich, Germany.
EM severin.rodler@med.uni-muenchen.de
OI Buchner, Alexander/0000-0001-7895-7070
CR American Society of Clinical Oncology (ASCO), COVID 19 PAT CAR INF
   Basch E, 2017, JAMA-J AM MED ASSOC, V318, P197, DOI 10.1001/jama.2017.7156
   Cohen S, 2015, PSYCHOL SCI, V26, P135, DOI 10.1177/0956797614559284
   Eschler Jordan, 2015, AMIA Annu Symp Proc, V2015, P543
   ESMO, CANC PAT MAN COVID 1
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Gillessen S, 2020, EUR UROL, V77, P667, DOI 10.1016/j.eururo.2020.03.026
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Indini A, 2020, EUR J CANCER, V132, P17, DOI 10.1016/j.ejca.2020.03.024
   Jimenez-Fonseca P, 2018, CLIN TRANSL ONCOL, V20, P1392, DOI 10.1007/s12094-018-1870-z
   Keesara S, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2005835
   Kruse CS, 2018, J TELEMED TELECARE, V24, P4, DOI 10.1177/1357633X16674087
   Leung K, 2020, LANCET, V395, P1382, DOI 10.1016/S0140-6736(20)30746-7
   Lewis MA, 2020, NEW ENGL J MED, V382, P2285, DOI 10.1056/NEJMp2006588
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017
   Robert Koch Institut, 2019, COR DIS 2019 COVID 1
   Rodler Severin, 2020, Clin Genitourin Cancer, DOI 10.1016/j.clgc.2020.03.018
   Rodler S, 2020, EUR J CANCER, V132, P136, DOI 10.1016/j.ejca.2020.04.003
   Rosenbaum L, 2020, NEW ENGL J MED, V382, P2368, DOI 10.1056/NEJMms2009984
   The Kidney Cancer Research Alliance, COVID 10 K CANC
   Tran VT, 2019, NPJ DIGIT MED, V2, DOI 10.1038/s41746-019-0132-y
   World Health Organization, COR DIS COVID 2019 S
NR 24
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2405-4569
J9 EUR UROL FOCUS
JI Eur. Urol. Focus
PD SEP 15
PY 2020
VL 6
IS 5
BP 1097
EP 1103
DI 10.1016/j.euf.2020.05.010
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA MY5NN
UT WOS:000558464000039
PM 32534969
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ciardi, MR
   Zingaropoli, MA
   Pasculli, P
   Perri, V
   Tartaglia, M
   Valeri, S
   Russo, G
   Conte, A
   Mastroianni, CM
AF Ciardi, Maria Rosa
   Zingaropoli, Maria Antonella
   Pasculli, Patrizia
   Perri, Valentina
   Tartaglia, Matteo
   Valeri, Serena
   Russo, Gianluca
   Conte, Antonella
   Mastroianni, Claudio Maria
TI The peripheral blood immune cell profile in a teriflunomide-treated
   multiple sclerosis patient with COVID-19 pneumonia
SO JOURNAL OF NEUROIMMUNOLOGY
LA English
DT Article
DE COVID-19; Flow cytometry; Disease-modifying therapies
AB A teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia was hospitalized and recovered in 15 days. The immunophenotyping analysis of peripheral blood cells was performed in two time points: the first was 1 month before (pre-infection) while the second was during COVID-19 pneumonia (infection). At the infection time point, no differences in the percentages of immune activation and immunesenescence of CD4 + and CD8 + T-cells were observed compared to the pre-infection time point. Our evaluation seems to confirm that teriflunomide controls T-cells immune activation and immunosenescence suggesting that teriflunomide should not be discontinued in MS patients with an active COVID-19 pneumonia.
C1 [Ciardi, Maria Rosa; Zingaropoli, Maria Antonella; Pasculli, Patrizia; Perri, Valentina; Valeri, Serena; Russo, Gianluca; Mastroianni, Claudio Maria] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
   [Tartaglia, Matteo; Conte, Antonella] Sapienza Univ Rome, Dept Human Neurosci, Viale Univ 30, I-00161 Rome, Italy.
   [Conte, Antonella] IRCCS Neuromed, Via Atinense 18, I-86077 Pozzilli, IS, Italy.
RP Zingaropoli, MA (corresponding author), Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
EM mariaantonella.zingaropoli@uniroma1.it
RI Russo, Gianluca/N-4362-2019
OI Russo, Gianluca/0000-0002-8764-7389
CR Bar-Or A, 2014, DRUGS, V74, P659, DOI 10.1007/s40265-014-0212-x
   Barzegar M, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000753
   Bowen JD, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000783
   Goodman A, 2017, NAT REV CLIN ONCOL, V14, P203, DOI 10.1038/nrclinonc.2016.168
   Iannetta M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160277
   Kaltsas A, 2012, CURR OPIN INFECT DIS, V25, P423, DOI 10.1097/QCO.0b013e328355660b
   Maghzi AH, 2020, J NEUROL, V267, P2790, DOI 10.1007/s00415-020-09944-8
   Medina S, 2019, ANN CLIN TRANSL NEUR, V6, P355, DOI 10.1002/acn3.711
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Merino J, 1998, CLIN EXP IMMUNOL, V112, P48
   Mills EA, 2018, MULT SCLER J, V24, P1014, DOI 10.1177/1352458518775550
   Novi G, 2019, MULT SCLER RELAT DIS, V36, DOI 10.1016/j.msard.2019.101430
   Oh J, 2014, THER ADV NEUROL DISO, V7, P239, DOI 10.1177/1756285614546855
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Sormani MP, 2020, LANCET NEUROL, V19, P481, DOI 10.1016/S1474-4422(20)30147-2
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
NR 20
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0165-5728
EI 1872-8421
J9 J NEUROIMMUNOL
JI J. Neuroimmunol.
PD SEP 15
PY 2020
VL 346
AR 577323
DI 10.1016/j.jneuroim.2020.577323
PG 4
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA MO6JV
UT WOS:000551630600026
PM 32688146
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wong, PTP
AF Wong, Paul T. P.
TI Existential positive psychology and integrative meaning therapy
SO INTERNATIONAL REVIEW OF PSYCHIATRY
LA English
DT Article; Early Access
DE Existential positive psychology (PP2; 0); meaning therapy; psychiatry;
   Viktor Frankl; logotherapy; existential psychology; positive psychology
ID PURPOSE; MODEL; LIFE
AB The unprecedented changes in our society because of COVID-19 and the fourth industrial revolution (4IR) shows that our healthcare system and the medical approach to psychotherapy can no longer meet the mental health needs of society. This paper first described the negative impact of COVID-19 and 4IR on our mental health. Then, following a brief critique of the medical model, this paper proposes that the future of psychotherapy needs to be based on the more inclusive and integrative framework of existential positive psychology (PP 2.0), which emphasizes flourishing through suffering. Finally, the paper emphasizes Viktor Frankl's cure and Wong's integrative meaning therapy. It concludes that integrative meaning therapy represents the future of psychotherapy, because it is situated in the area of interactions of at least three traditions: Clinical psychology, existential psychology, and positive psychology. This integrative model is holistic, recognising humans as bio-psycho-social-spiritual beings and considers several theoretical perspectives in both diagnosis and treatment.
C1 [Wong, Paul T. P.] Trent Univ, Dept Psychol, 13 Ballyconnor Ct, Peterborough, ON M2M 4C5, Canada.
RP Wong, PTP (corresponding author), Trent Univ, Dept Psychol, 13 Ballyconnor Ct, Peterborough, ON M2M 4C5, Canada.
EM drpaulwong@gmail.com
OI Wong, Paul/0000-0003-4982-8127
CR Adler A., 1938, SOCIAL INTEREST CHAL
   Akhtar S., 2014, SOURCES SUFFERING FE
   Allport G. W., 1981, PERSONALITY SOCIAL E
   Anderson J., 2018, 3 CONCERNS FUTURE PE, V3
   Antonovsky A., 1987, JOSSEY BASS SOCIAL B
   Bastian B., 2018, OTHER SIDE HAPPINESS
   BAUMEISTER RF, 1995, PSYCHOL BULL, V117, P497, DOI 10.1037/0033-2909.117.3.497
   Benning TB, 2016, BJPSYCH BULL, V40, P292, DOI 10.1192/pb.bp.115.053249
   Camus Albert, 1947, PLAGUE
   Centers for Disease Control and Prevention (CDC), 2016, WEB BAS INJ STAT QUE
   Deacon BJ, 2013, CLIN PSYCHOL REV, V33, P846, DOI 10.1016/j.cpr.2012.09.007
   European Center for Disease Prevention and Control, 2020, COVID 19 SIT UPD WOR
   Fowers B. J., 2017, FRAILTY SUFFERING VI
   Frankl V. E., 1985, MANS SEARCH MEANING
   Frankl V. E., 1946, YES LIFE SPITE EVERY
   Frankl V. E., 1977, UNHEARD CRY MEANING
   Frankl Viktor E., 1988, THE WILL TO MEANING
   Friedman Thomas L., 2016, THANK YOU BEING LATE
   Galer S., 2020, FORBES
   George LS, 2016, REV GEN PSYCHOL, V20, P205, DOI 10.1037/gpr0000077
   Gloag O., 2020, A CAMUS VERY SHORT I
   Goldsmith S. K., 2002, REDUCING SUICIDE NAT
   Huda AS, 2019, MED MODEL MENTAL HLT
   INPM, 2020, RES I FLOUR SUFF RIF
   Johnson J., 2020, MED NEWS TODAY
   Jyoti R., 2019, IDC FUTURESCAPE WEBC
   Kaufman S. B., 2020, TRANSCEND NEW SCI SE
   Martela F, 2016, J POSIT PSYCHOL, V11, P531, DOI 10.1080/17439760.2015.1137623
   McDonald M. J., 2012, HUMAN QUEST MEANING, V2, P357
   McGonigal K., 2015, UPSIDE STRESS WHY ST
   ODonnell Jayne, 2020, US TODAY
   PEACOCK EJ, 1990, STRESS MEDICINE, V6, P227, DOI 10.1002/smi.2460060308
   Peck M. S., 1978, ROAD LESS TRAVELLED
   Peterson J.B., 2018, 12 RULES LIFE ANTIDO
   Purtill J., 2020, ABC
   Pytell T., 2020, VIKTOR FRANKLS SEARC
   Roy L., 2020, FORBES
   Samoon A., 2020, KEVINMD
   Schwab K., 2018, BRITANNICA
   Swart M., 2020, ALJAZEERA
   Szasz T.S., 1961, MYTH MENTAL ILLNESS
   Takano Y., MEANING SHAME REVISI
   Twenge J., 2017, IGEN WHY TODAYS SUPE
   Vinayak V., 2019, OXFORD HUMAN RIGHTS
   Wan W., 2020, WASHINGTON POST
   Wong P. T. P., 2016, RES WORK GROUP M VIR
   Wong P. T. P., 2010, INT J EXISTENTIAL PS, V3, P1
   Wong P. T. P., 2020, EVOLUTIONARY STUDIES, V4, DOI [https://doi.org/10.26613/esic/4.1.170, DOI 10.26613/ESIC/4.1.170]
   Wong P. T. P., 2016, INT J EXIST PSYCHOL, V6
   Wong P. T. P., 2007, ANTHOLOGY VIKTOR FRA
   Wong P. T. P., 2017, SAGE ENCY ABNORMAL C, P1984
   Wong P. T. P., 2020, INT J WELLBEING, V10, P107, DOI [10.5502/ijw.v10i1.885., DOI 10.5502/IJW.V10I1.885]
   Wong P. T. P., 2016, LOGOTHERAPY EXISTENT, P311, DOI [10.1007/978-3-319-29424-7_27, DOI 10.1007/978-3-319-29424-7_27]
   Wong P. T. P., 2020, MADE RESILIENCE HAPP
   Wong PTP, 2011, CAN PSYCHOL, V52, P69, DOI 10.1037/a0022511
   Wong P, 2016, SCI REP-UK, V6, DOI 10.1038/srep24613
   WONG PTP, 2019, COUNS PSYCHOL Q 0930
   Yong EL, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2019.19706
   Yuval N. H., 2018, HOMO DEUS BRIEF HIST
NR 59
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0954-0261
EI 1369-1627
J9 INT REV PSYCHIATR
JI Int. Rev. Psych.
DI 10.1080/09540261.2020.1814703
EA SEP 2020
PG 14
WC Psychiatry
SC Psychiatry
GA NW8MZ
UT WOS:000575272200001
PM 33016788
OA Bronze
DA 2021-01-01
ER

PT J
AU Jeon, J
   Kim, H
   Yu, KS
AF Jeon, JuYeun
   Kim, Hyeikyoung
   Yu, Kyung-Sang
TI The Impact of COVID-19 on the Conduct of Clinical Trials for Medical
   Products in Korea
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article
DE COVID-19; Clinical Trial; Korea
AB Background: The number of clinical trials conducted in Korea continues to increase and an increasing proportion focus on severe and rare incurable diseases. After the start of the severe acute respiratory syndrome, coronavirus disease 2019 (COVID-19), Korea Centers for Disease Control and Prevention (KCDC) developed guidelines to prevent the spread of infection. This study evaluated the impact of COVID-19 and the KCDC guideline on the conduct of clinical research in Korea. The purpose was to develop recommendations on how to minimize the risk of infection while enabling subjects to take part in the trials if no better alternative treatment options were available.
   Methods: The impact on subject's scheduled visits and major milestones of clinical trials in Korea were measured by conducting a survey among clinical project manager (CPMs) working at global clinical research organization. The policy on monitor's access to hospital and site initiation meetings was investigated through correspondence with clinical trial center of 39 hospitals. The Top 25 pharmaceutical companies' official press and public clinical trial registry database were used to analyze companies' trial strategy during the pandemic and COVID-19 clinical research status, respectively.
   Results: Of 85 CPMs, 12% reported that trial subjects' scheduled visits had been affected in their project. Monitors' access to hospital for source data verification was restricted at all sites in February 2020. Accordingly, 43% of 105 CPMs reported that the COVID-19 epidemic had an effect on study major milestones and data cleaning and database lock accounted for > 60% of milestones affected. In addition, 87% sites advised not to have site initiation meetings and 52% pharmaceutical companies suspended recruitment or new study startup due to the pandemic. On the other hands, the number of COVID-19 related clinical trials increased rapidly in Korea and worldwide, with investigator-initiated trials accounting for 47% and 63% of all trials locally and globally, respectively. Most trials were phase 2 and were in the recruitment stage.
   Conclusion: The COVID-19 and the KCDC guideline influenced all parties involved in clinical trials in Korea. In order to ensure the safety and well-being of trial subjects during the pandemic, new approaches are required for clinical trials to respond to the impact actively. Method of non-contact is developed to replace and supplement the face-to-face contact and alternatives to reduce the travel is introduced to decrease the risk of infection for all trial participants in whole trial process. The relevant regulations should be developed and the guidelines for foreign countries need to be adopted in accordance with the situation in Korea. COVID-19 trial is rapidly increasing worldwide and continuous support of health authorities, regulation, and facilities is required for developing the treatments with protecting all trial participants.
C1 [Jeon, JuYeun; Yu, Kyung-Sang] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Clin Pharmacol & Therapeut, Coll Med, Seoul, South Korea.
   [Jeon, JuYeun; Kim, Hyeikyoung] IQVIA, Dept Project Leadership, 558 Songpa Daero, Seoul 05510, South Korea.
RP Kim, H (corresponding author), IQVIA, Dept Project Leadership, 558 Songpa Daero, Seoul 05510, South Korea.
EM hkandjh@gmail.com
OI Yu, Kyung-Sang/0000-0003-0921-7225
CR European Medicines Agency, GUID MAN CLIN TRIALS
   Korea Pharmaceutical and Bio-Pharma Manufacturers' Association, 2019, 2019 PHARM IND DAT B
   Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e112
   Ministry of Food and Drug Safety, CONS CLIN TRIALS SIT
   Ministry of Food and Drug Safety, NOT TRAIN CONS CLIN
   Ministry of Food and Drug Safety, PRES RES APPR CLIN T
   Ministry of Food and Drug Safety, INT DRUG INF SYST
   United Kingdom Medicines and Healthcare Products Regulatory Agency, SYN MHRA ADV MAN CLI
NR 8
TC 0
Z9 0
U1 2
U2 2
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
EI 1598-6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD SEP 14
PY 2020
VL 35
IS 36
AR e329
DI 10.3346/jkms.2020.35.e329
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA NU3OT
UT WOS:000573552500006
PM 32924344
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Moon, SS
   Lee, K
   Park, J
   Yun, S
   Lee, YS
   Lee, DS
AF Moon, Seong-Su
   Lee, Kwan
   Park, Jungi
   Yun, Seongcheol
   Lee, Yun Sik
   Lee, Dong Seok
TI Clinical Characteristics and Mortality Predictors of COVID-19 Patients
   Hospitalized at Nationally-Designated Treatment Hospitals
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article
DE Coronavirus; Mortality; Pandemics; Hospitals; Korea
ID CORONAVIRUS DISEASE 2019; ASSOCIATION; VACCINES; OUTCOMES; RISK
AB Background: Coronavirus disease 2019 (COVID-19) was first reported in December 2019 in China, and then it has disseminated worldwide. In Korea, a religious group-related super-spreading event triggered a sudden outbreak in Daegu city and Gyeongsangbuk-do in southeast Korea. This study was undertaken to document the clinical characteristics of patients hospitalized in Gyeongsangbuk-do.
   Methods: Three hundred and fifty-two patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection hospitalized at Dongguk University Gyeongju Hospital or at the Andong Medical Center between February 18th and June 30th were enrolled in this study. Medical records were reviewed and demographic and clinical features, including comorbidities, symptoms, radiological and laboratory findings on admission were analyzed. In addition, we sought to identify risk factors of mortality.
   Results: Mean age of the 352 study subjects was 56 years (range, 14-95). The mortality rate was 6.8% and mean age at death was 81 years (range, 57-91). The most common symptom was cough (31.8%) followed by a febrile sensation (28.4%), sputum (17.0%), sore throat (15.6%), and myalgia (13.1%). Eighty-one (23.0%) patients were asymptomatic, but a half of these patients exhibited pneumonic infiltration at presentation. Chest radiology showed no active lesion in 41.8% of the study subjects, bilateral pneumonia in 46.9%, and unilateral pneumonic infiltration in 11.4%. Among 24 patients that died, 18 subjects were transferred from a care facility. An age of >= 70 years, previous history of malignancy or diabetes, and fever (>= 37.5 degrees C) on admission were found to be significant risk factors of mortality.
   Conclusion: Patients aged >= 70 years, those with fever on admission, and patients with an underlying malignancy or diabetes were found to be more likely to succumb to COVID-19. Elderly in care facilities or hospitalized patients with an underlying disease should receive more attention and be considered for preventive quarantine.
C1 [Moon, Seong-Su; Park, Jungi] Dongguk Univ, Dept Internal Med, Coll Med, Gyeongju, South Korea.
   [Lee, Kwan] Dongguk Univ, Dept Prevent Med, Coll Med, Gyeongju, South Korea.
   [Yun, Seongcheol] Andong Med Ctr, Dept Internal Med, Andong, South Korea.
   [Lee, Yun Sik] Andong Med Ctr, Dept Gen Surg, Andong, South Korea.
   [Lee, Dong Seok] Dongguk Univ, Dept Pediat, Coll Med, Gyeongju, South Korea.
RP Moon, SS (corresponding author), Dongguk Univ, Gyeongju Hosp, Coll Med, Dept Internal Med, 87 Dongdae Ro, Gyeongju 38067, South Korea.
EM drmoonss@hanmail.net
OI Moon, Seong-su/0000-0001-8881-3927; Lee, Kwan/0000-0003-2554-4170
FU Gyeongsanbuk-do Medical Association; Dongguk University
FX This research was supported by the Gyeongsanbuk-do Medical Association
   and Dongguk University research fund (2020).
CR Ahn DG, 2020, J MICROBIOL BIOTECHN, V30, P313, DOI 10.4014/jmb.2003.03011
   Chen M, 2020, J MED VIROL, V92, P2146, DOI 10.1002/jmv.26002
   Chung SM, 2020, DIABETES METAB J, V44, P405, DOI 10.4093/dmj.2020.0105
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Dariya B, 2020, CYTOKINE GROWTH F R, V53, P43, DOI 10.1016/j.cytogfr.2020.05.001
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   El-Lababidi RM, 2020, IDCases, V21, DOI 10.1016/j.idcr.2020.e00837
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Hussain A, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108142
   Kim ES, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e142
   Kim JY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e61
   Kim SW, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e152
   Korea Center of Disease Control and Prevention, COVID 19 RESP KOR GO
   Korea Center of Disease Control and Prevention, CAS KOR
   Korea Center of Disease Control and Prevention, GLOB LOC COVID 19
   Korea Center of Disease Control and Prevention, COR DIS 2019
   Lan L, 2020, JAMA-J AM MED ASSOC, V323, P1502, DOI 10.1001/jama.2020.2783
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Noh J, 2020, DIABETES METAB J, V44, P372, DOI 10.4093/dmj.2020.0138
   Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P113, DOI DOI 10.46234/CCDCW2020.032
   Obukhov AG, 2020, DIABETES, V69, P1875, DOI 10.2337/dbi20-0019
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sun YXH, 2020, CLIN INFECT DIS, V71, P786, DOI 10.1093/cid/ciaa322
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Yan YL, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc-2020-001343
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 32
TC 0
Z9 0
U1 0
U2 0
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
EI 1598-6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD SEP 14
PY 2020
VL 35
IS 36
AR e328
DI 10.3346/jkms.2020.35.e328
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA NU3OT
UT WOS:000573552500005
PM 32924343
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Grant, OC
   Montgomery, D
   Ito, K
   Woods, RJ
AF Grant, Oliver C.
   Montgomery, David
   Ito, Keigo
   Woods, Robert J.
TI Analysis of the SARS-CoV-2 spike protein glycan shield reveals
   implications for immune recognition
SO SCIENTIFIC REPORTS
LA English
DT Article
ID RECEPTOR-BINDING DOMAIN; MOLECULAR-DYNAMICS SIMULATIONS; BIOMOLECULAR
   FORCE-FIELD; MERS-COV; STRUCTURAL DEFINITION; NEUTRALIZATION EPITOPE;
   GLYCOSYLATION; HEMAGGLUTININ; ANTIBODY; SPECIFICITY
AB Here we have generated 3D structures of glycoforms of the spike (S) glycoprotein from SARS-CoV-2, based on reported 3D structures and glycomics data for the protein produced in HEK293 cells. We also analyze structures for glycoforms representing those present in the nascent glycoproteins (prior to enzymatic modifications in the Golgi), as well as those that are commonly observed on antigens present in other viruses. These models were subjected to molecular dynamics (MD) simulation to determine the extent to which glycan microheterogeneity impacts the antigenicity of the S glycoprotein. Lastly, we have identified peptides in the S glycoprotein that are likely to be presented in human leukocyte antigen (HLA) complexes, and discuss the role of S protein glycosylation in potentially modulating the innate and adaptive immune response to the SARS-CoV-2 virus or to a related vaccine. The 3D structures show that the protein surface is extensively shielded from antibody recognition by glycans, with the notable exception of the ACE2 receptor binding domain, and also that the degree of shielding is largely insensitive to the specific glycoform. Despite the relatively modest contribution of the glycans to the total molecular weight of the S trimer (17% for the HEK293 glycoform) they shield approximately 40% of the protein surface.
C1 [Grant, Oliver C.; Montgomery, David; Ito, Keigo; Woods, Robert J.] Univ Georgia, Complex Carbohydrate Res Ctr, 315 Riverbend Rd, Athens, GA 30602 USA.
RP Woods, RJ (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, 315 Riverbend Rd, Athens, GA 30602 USA.
EM rwoods@ccrc.uga.edu
OI Woods, Robert/0000-0002-2400-6293
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U01 CA207824, P41
   GM103390]
FX R.J.W. thanks the National Institutes of Health (U01 CA207824 and P41
   GM103390) for financial support.
CR Altman MO, 2019, MBIO, V10, DOI 10.1128/mBio.00204-19
   Amaro RE, 2012, METHODS MOL BIOL, V819, P575, DOI 10.1007/978-1-61779-465-0_34
   An YM, 2019, J VIROL, V93, DOI 10.1128/JVI.01693-18
   An YM, 2013, J PROTEOME RES, V12, P3707, DOI 10.1021/pr400329k
   Avci FY, 2011, NAT MED, V17, P1602, DOI 10.1038/nm.2535
   Baum LG, 2017, GLYCOBIOLOGY, V27, P619, DOI 10.1093/glycob/cwx036
   Bonomelli C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023521
   Casadevall A, 2020, JAMA-J AM MED ASSOC, V324, P455, DOI 10.1001/jama.2020.10218
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Casals C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01998
   Case D.A., 2014, AMBER 14 COMPUTER PR
   Chang D, 2019, MOL CELL PROTEOMICS, V18, P2348, DOI 10.1074/mcp.R119.001491
   Chen Z, 2017, J INFECT DIS, V215, P1807, DOI 10.1093/infdis/jix209
   Cotter CR, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003831
   Crispin M, 2015, CURR OPIN VIROL, V11, P63, DOI 10.1016/j.coviro.2015.02.002
   Dall'Olio F, 2013, AGEING RES REV, V12, P685, DOI 10.1016/j.arr.2012.02.002
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Davies NG, 2020, NAT MED, V26, P1205, DOI 10.1038/s41591-020-0962-9
   Depetris RS, 2012, J BIOL CHEM, V287, P24239, DOI 10.1074/jbc.M112.371898
   Doores KJ, 2015, FEBS J, V282, P4679, DOI 10.1111/febs.13530
   Farrera L., 2020, IDENTIFICATION IMMUN, DOI [10.1101/2020.06.15.20131391, DOI 10.1101/2020.06.15.20131391]
   Gebrehiwot AG, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209515
   Gotz AW, 2012, J CHEM THEORY COMPUT, V8, P1542, DOI 10.1021/ct200909j
   Grant OC, 2016, GLYCOBIOLOGY, V26, P1027, DOI 10.1093/glycob/cww094
   Haji-Ghassemi O, 2015, GLYCOBIOLOGY, V25, P920, DOI 10.1093/glycob/cwv037
   Hang I, 2015, GLYCOBIOLOGY, V25, P1335, DOI 10.1093/glycob/cwv058
   Harbison A, 2020, GLYCOBIOLOGY, V30, P420, DOI 10.1093/glycob/cwz101
   Helle F, 2011, VIRUSES-BASEL, V3, P1909, DOI 10.3390/v3101909
   HOMANS SW, 1986, BIOCHEMISTRY-US, V25, P6342, DOI 10.1021/bi00368a076
   HOMANS SW, 1987, BIOCHEMISTRY-US, V26, P6571, DOI 10.1021/bi00395a001
   Horiya S, 2014, NAT CHEM BIOL, V10, P990, DOI 10.1038/nchembio.1685
   Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398
   Hubbard Simon J, 1993, NACCESS, V2, P1
   Hutter J, 2013, J IMMUNOL, V190, P220, DOI 10.4049/jimmunol.1201060
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Jo S, 2016, GLYCOBIOLOGY, V26, P19, DOI 10.1093/glycob/cwv083
   JORGENSEN WL, 1981, J AM CHEM SOC, V103, P335, DOI 10.1021/ja00392a016
   Khatri K, 2016, MOL CELL PROTEOMICS, V15, P1895, DOI 10.1074/mcp.M116.058016
   Kirschner KN, 2008, J COMPUT CHEM, V29, P622, DOI 10.1002/jcc.20820
   Kristic J, 2014, J GERONTOL A-BIOL, V69, P779, DOI 10.1093/gerona/glt190
   Kwong PD, 2000, STRUCTURE, V8, P1329, DOI 10.1016/S0969-2126(00)00547-5
   Lan J, 2020, BIORXIV, DOI [10.1101/2020.02.19.956235, DOI 10.1101/2020.02.19.956235]
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Li Y, 2015, CELL RES, V25, P1237, DOI 10.1038/cr.2015.113
   Li Y, 2013, J VIROL, V87, P9904, DOI 10.1128/JVI.01023-13
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Malaker SA, 2017, J PROTEOME RES, V16, P228, DOI 10.1021/acs.jproteome.6b00496
   Marth JD, 2008, NAT REV IMMUNOL, V8, P874, DOI 10.1038/nri2417
   Millett GA, 2020, ANN EPIDEMIOL, V47, P37, DOI 10.1016/j.annepidem.2020.05.003
   Nivedha AK, 2014, J COMPUT CHEM, V35, P526, DOI 10.1002/jcc.23517
   Pak JE, 2009, J MOL BIOL, V388, P815, DOI 10.1016/j.jmb.2009.03.042
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Pavic T, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1695-0
   Pejchal R, 2011, SCIENCE, V334, P1097, DOI 10.1126/science.1213256
   Peng WJ, 2017, CELL HOST MICROBE, V21, P23, DOI 10.1016/j.chom.2016.11.004
   Pereira MS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02754
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pinto Dora, 2020, bioRxiv, DOI 10.1101/2020.04.07.023903
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Reche PA, 2004, IMMUNOGENETICS, V56, P405, DOI 10.1007/s00251-004-0709-7
   Reche PA, 2002, HUM IMMUNOL, V63, P701, DOI 10.1016/S0198-8859(02)00432-9
   Rudman N, 2019, FEBS LETT, V593, P1598, DOI 10.1002/1873-3468.13495
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Salomon-Ferrer R, 2013, J CHEM THEORY COMPUT, V9, P3878, DOI 10.1021/ct400314y
   Sawen E, 2011, J PHYS CHEM B, V115, P7109, DOI 10.1021/jp2017105
   Singh A, 2016, CAN J CHEM, V94, P927, DOI 10.1139/cjc-2015-0606
   Stevens J, 2006, SCIENCE, V312, P404, DOI 10.1126/science.1124513
   Sun XJ, 2013, J VIROL, V87, P8756, DOI 10.1128/JVI.00593-13
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tate MD, 2014, VIRUSES-BASEL, V6, P1294, DOI 10.3390/v6031294
   Tessier MB, 2008, MOL SIMULAT, V34, P349, DOI 10.1080/08927020701710890
   Urbanowicz RA, 2019, J VIROL, V93, DOI 10.1128/JVI.01403-18
   Vigerust DJ, 2007, TRENDS MICROBIOL, V15, P211, DOI 10.1016/j.tim.2007.03.003
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wang LS, 2018, J VIROL, V92, DOI 10.1128/JVI.02002-17
   Wang LS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8712
   Wang NS, 2019, CELL REP, V28, P3395, DOI 10.1016/j.celrep.2019.08.052
   Watanabe Yasunori, 2020, bioRxiv, DOI 10.1101/2020.03.26.010322
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   WHO-World Health Organization, 2020, 77 WHO
   Woods RJ, 2018, CHEM REV, V118, P8005, DOI 10.1021/acs.chemrev.8b00032
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yamaguchi T, 2014, ANGEW CHEM INT EDIT, V53, P10941, DOI 10.1002/anie.201406145
   Ying TL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9223
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhang SY, 2018, CELL REP, V24, P441, DOI 10.1016/j.celrep.2018.06.041
   Zhou HX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10897-4
   Zhou TQ, 2007, NATURE, V445, P732, DOI 10.1038/nature05580
   Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114
NR 90
TC 4
Z9 4
U1 8
U2 8
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 14
PY 2020
VL 10
IS 1
AR 14991
DI 10.1038/s41598-020-71748-7
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NT9QB
UT WOS:000573274900003
PM 32929138
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Khan, FR
   Kazmi, SMR
   Iqbal, NT
   Iqbal, J
   Ali, ST
   Abbas, SA
AF Khan, Farhan Raza
   Kazmi, Syed Murtaza Raza
   Iqbal, Najeeha Talat
   Iqbal, Junaid
   Ali, Syed Tariq
   Abbas, Syed Akbar
TI A quadruple blind, randomised controlled trial of gargling agents in
   reducing intraoral viral load among hospitalised COVID-19 patients: A
   structured summary of a study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Article
DE COVID-19; randomised controlled trial; protocol; gargles; nasal lavage;
   viral load
AB Objectives1- To compare the effectiveness of 1% Hydrogen peroxide, 0.2% Povidone-Iodine, 2% hypertonic saline and a novel solution Neem extract (Azardirachta indica) in reducing intra-oral viral load in COVID-19 positive patients.2- To determine the salivary cytokine profiles of IL-2, IL-4, IL-6, IL-10, TNF-alpha, IFN-gamma and IL- 17 among COVID-19 patients subjected to 1% Hydrogen peroxide, 0.2% Povidone-Iodine, 2% hypertonic saline or Neem extract (Azardirachta indica) based gargles.Trial designThis will be a parallel group, quadruple blind-randomised controlled pilot trial with an add on laboratory based study.ParticipantsA non-probability, purposive sampling technique will be followed to identify participants for this study.The clinical trial will be carried out at the Aga Khan University Hospital (AKUH), Karachi, Pakistan. The viral PCR tests will be done at main AKUH clinical laboratories whereas the immunological tests (cytokine analysis) will be done at the Juma research laboratory of AKUH.The inclusion criteria are laboratory-confirmed COVID-19 positive patients, male or female, in the age range of 18-65 years, with mild to moderate disease, already admitted to the AKUH. Subjects with low Glasgow coma score, with a history of radiotherapy or chemotherapy, who are more than 7 days past the onset of COVID- 19 symptoms, or intubated or edentulous patients will be excluded. Patients who are being treated with any form of oral or parenteral antiviral therapy will be excluded, as well as patients with known pre-existing chronic mucosal lesions such as lichen planus.Intervention and comparatorGroup A (n=10) patients on 10 ml gargle and nasal lavage using 0.2% Povidone-Iodine (Betadiene (R) by Aviro Health Inc./ Pyodine (R) by Brooks Pharma Inc.) for 20-30 seconds, thrice daily for 6 days. Group B (n=10) patients will be subjected to 10 ml gargle and nasal lavage using 1% Hydrogen peroxide (HP (R) by Karachi Chemicals Products Inc./ ActiveOxy (R) by Boumatic Inc.) for 20-30 seconds, thrice daily for 6 days. Group C will comprised of (n=10) subjects on 10ml gargle and nasal lavage using Neem extract solution (Azardirachta indica) formulated by Karachi University (chemistry department laboratories) for 20-30 seconds, thrice daily for 6 days. Group D (n=10) patients will use 2% hypertonic saline (Plabottle (R) by Otsuka Inc.) gargle and nasal lavage for a similar time period. Group E (n=10) will serve as positive controls. These will be given simple distilled water gargles and nasal lavage for 20-30 seconds, thrice daily for six days. For nasal lavage, a special douche syringe will be provided to each participant. Its use will be thoroughly explained by the data collection officer. After each use, the patient is asked not to eat, drink, or rinse their mouth for the next 30 minutes.Main outcomesThe primary outcome is the reduction in the intra-oral viral load confirmed with real time quantitative PCR.RandomisationThe assignment to the study group/ allocation will be done using the sealed envelope method under the supervision of Clinical Trial Unit (CTU) of Aga Khan University, Karachi, Pakistan. The patients will be randomised to their respective study group (1:1:1:1:1 allocation ratio) immediately after the eligibility assessment and consent administration is done.Blinding (masking)The study will be quadruple-blinded. Patients, intervention provider, outcome assessor and the data collection officer will be blinded. The groups will be labelled as A, B, C, D or E.
   The codes of the intervention will be kept in lock & key at the CTU and will only be revealed at the end of study or if the study is terminated prematurely.Numbers to be randomised (sample size)As there is no prior work on this research question, so no assumptions for the sample size calculation could be made. The present study will serve as a pilot trial. We intend to study 50 patients in five study groups with 10 patients in each study group. For details, please refer to Fig. 1 for details.Trial StatusProtocol version is 7.0, approved by the department and institutional ethics committees and clinical trial unit of the university hospital. Recruitment is planned to start as soon as the funding is sanctioned. The total duration of the study is expected to be 6 months i.e. August 2020-January 2021.Trial registrationThis study protocol was registered at www.clinicaltrials.gov on 10 April 2020 NCT04341688.Full protocolThe full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
C1 [Khan, Farhan Raza; Kazmi, Syed Murtaza Raza; Abbas, Syed Akbar] Aga Khan Univ, Dept Surg, Karachi 74800, Pakistan.
   [Iqbal, Najeeha Talat; Iqbal, Junaid] Aga Khan Univ, Dept Pediat & Child Hlth, Karachi 74800, Pakistan.
   [Ali, Syed Tariq] Univ Karachi, Dept Chem, Karachi 75271, Pakistan.
RP Khan, FR (corresponding author), Aga Khan Univ, Dept Surg, Karachi 74800, Pakistan.
EM farhan.raza@aku.edu
OI khan, farhan/0000-0002-5650-6268
NR 0
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD SEP 14
PY 2020
VL 21
IS 1
AR 785
DI 10.1186/s13063-020-04634-2
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NS0KO
UT WOS:000571949400001
PM 32928313
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hou, W
AF Hou, Wei
TI Characterization of codon usage pattern in SARS-CoV-2
SO VIROLOGY JOURNAL
LA English
DT Article
DE COVID-19; Coronaviruses; SARS-CoV-2; Codon usage pattern
ID GENERATION; VIRUS; SARS
AB The outbreak of coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed significant threats to international health. The genetic traits as well as evolutionary processes in this novel coronavirus are not fully characterized, and their roles in viral pathogenesis are yet largely unknown. To get a better picture of the codon architecture of this newly emerging coronavirus, in this study we perform bioinformatic analysis, based on publicly available nucleotide sequences of SARS-CoV-2 along with those of other members of human coronaviruses as well as non-human coronaviruses in different hosts, to take a snapshot of the genome-wide codon usage pattern of SARS-CoV-2 and uncover that all over-represented codons end with A/U and this newly emerging coronavirus has a relatively low codon usage bias, which is shaped by both mutation pressure and natural selection. Additionally, there is slight variation in the codon usage pattern among the SARS-CoV-2 isolates from different geo-locations. Furthermore, the overall codon usage pattern of SARS-CoV-2 is generally similar to that of its phylogenetic relatives among non-human betacoronaviruses such as RaTG13. Taken together, we comprehensively analyze the characteristics of codon usage pattern in SARS-CoV-2 via bioinformatic approaches. The information from this research may not only be helpful to get new insights into the evolution of SARS-CoV-2, but also have potential value for developing coronavirus vaccines.
C1 [Hou, Wei] Tianjin Second Peoples Hosp, 7 Sudi South Rd, Tianjin 300192, Peoples R China.
   [Hou, Wei] Tianjin Inst Hepatol, 7 Sudi South Rd, Tianjin 300192, Peoples R China.
RP Hou, W (corresponding author), Tianjin Second Peoples Hosp, 7 Sudi South Rd, Tianjin 300192, Peoples R China.; Hou, W (corresponding author), Tianjin Inst Hepatol, 7 Sudi South Rd, Tianjin 300192, Peoples R China.
EM houweicn@163.com
OI Hou, Wei/0000-0001-9223-424X
CR Baker SF, 2015, FUTURE VIROL, V10, P715, DOI 10.2217/fvl.15.31
   Blanco-Lobo P, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020190
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chaney JL, 2015, ANNU REV BIOPHYS, V44, P143, DOI 10.1146/annurev-biophys-060414-034333
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dilucca M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050498
   Fan RLY, 2015, J VIROL, V89, P10762, DOI 10.1128/JVI.01443-15
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Gu HG, 2020, VIRUS EVOL, V6, DOI 10.1093/ve/veaa032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Kandeel M, 2020, J MED VIROL, V92, P660, DOI 10.1002/jmv.25754
   Khodary SM, 2020, INSIGHTS CODON USAGE
   Plotkin JB, 2011, NAT REV GENET, V12, P32, DOI 10.1038/nrg2899
   Puigbo P, 2008, BIOL DIRECT, V3, DOI 10.1186/1745-6150-3-38
   Tort FL, 2020, VIRUS RES, V283, DOI 10.1016/j.virusres.2020.197976
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1743-422X
J9 VIROL J
JI Virol. J.
PD SEP 14
PY 2020
VL 17
IS 1
AR 138
DI 10.1186/s12985-020-01395-x
PG 10
WC Virology
SC Virology
GA NS0NI
UT WOS:000571956600002
PM 32928234
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lopinto, J
   Teulier, M
   Milon, A
   Voiriot, G
   Fartoukh, M
AF Lopinto, Julien
   Teulier, Marion
   Milon, Audrey
   Voiriot, Guillaume
   Fartoukh, Muriel
TI Severe hemoptysis in post-tuberculosis bronchiectasis precipitated by
   SARS-CoV-2 infection
SO BMC PULMONARY MEDICINE
LA English
DT Article
DE SARS-CoV-2; Severe hemoptysis; Bronchiectasis; Case report
AB Background Since the beginning of SARS-CoV-2 outbreak in China, severe acute respiratory syndrome has been widely descripted. Hemoptysis has rarely been observed in SARS-CoV-2 infection. We report here a case of severe hemoptysis in post-tuberculosis bronchiectasis precipitated by SARS-CoV-2 infection and managed in a referral center. Case presentation A 58-year-old man was admitted to our intensive care unit for severe hemoptysis with history of post-tuberculosis bronchiectasis. At ICU admission the patient had fever and severe acute respiratory failure requiring high flow oxygen therapy. Respiratory tract sampling was positive for SARS-CoV-2. Multi-detector computed tomography angiography pointed out localized bronchiectasis on the left lower lobe and enlarged left bronchial and phrenic arteries; bronchial arteriography with distal embolization was performed with favorable outcome and no bleeding recurrence. Conclusions To our knowledge, this is the first case of acute exacerbation of bronchiectasis related to SARS-CoV-2 infection and complicated by severe hemoptysis. Whether the virus may play a role in the dysregulation of airway haemostasis, and contribute to episodes of hemoptysis in patients with chronic pulmonary diseases and predisposing factors might be investigated.
C1 [Lopinto, Julien; Teulier, Marion; Voiriot, Guillaume; Fartoukh, Muriel] Tenon Hosp, AP HP, Intens Care Unit, 4 Rue Chine, F-75020 Paris, France.
   [Milon, Audrey] Tenon Hosp, AP HP, Dept Radiol, Paris, France.
RP Lopinto, J (corresponding author), Tenon Hosp, AP HP, Intens Care Unit, 4 Rue Chine, F-75020 Paris, France.
EM julien.lopinto78100@gmail.com
CR Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
NR 5
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2466
J9 BMC PULM MED
JI BMC Pulm. Med.
PD SEP 14
PY 2020
VL 20
IS 1
AR 244
DI 10.1186/s12890-020-01285-6
PG 3
WC Respiratory System
SC Respiratory System
GA NQ4FZ
UT WOS:000570820500001
PM 32928157
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shu, ZX
   Zhou, YN
   Chang, K
   Liu, JF
   Min, XJ
   Zhang, Q
   Sun, J
   Xiong, YJ
   Zou, QS
   Zheng, QG
   Ji, JH
   Poon, J
   Liu, BY
   Zhou, XZ
   Li, XD
AF Shu, Zixin
   Zhou, Yana
   Chang, Kai
   Liu, Jifen
   Min, Xiaojun
   Zhang, Qing
   Sun, Jing
   Xiong, Yajuan
   Zou, Qunsheng
   Zheng, Qiguang
   Ji, Jinghui
   Poon, Josiah
   Liu, Baoyan
   Zhou, Xuezhong
   Li, Xiaodong
TI Clinical features and the traditional Chinese medicine therapeutic
   characteristics of 293 COVID-19 inpatient cases
SO FRONTIERS OF MEDICINE
LA English
DT Article; Early Access
DE COVID-19; traditional Chinese medicine; clinical features
ID NETWORK; CLASSIFICATION; DIAGNOSIS
AB Coronavirus disease 2019 (COVID-19) is now pandemic worldwide and has heavily overloaded hospitals in Wuhan City, China during the time between late January and February. We reported the clinical features and therapeutic characteristics of moderate COVID-19 cases in Wuhan that were treated via the integration of traditional Chinese medicine (TCM) and Western medicine. We collected electronic medical record (EMR) data, which included the full clinical profiles of patients, from a designated TCM hospital in Wuhan. The structured data of symptoms and drugs from admission notes were obtained through an information extraction process. Other key clinical entities were also confirmed and normalized to obtain information on the diagnosis, clinical treatments, laboratory tests, and outcomes of the patients. A total of 293 COVID-19 inpatient cases, including 207 moderate and 86 (29.3%) severe cases, were included in our research. Among these cases, 238 were discharged, 31 were transferred, and 24 (all severe cases) died in the hospital. Our COVID-19 cases involved elderly patients with advanced ages (57 years on average) and high comorbidity rates (61%). Our results reconfirmed several well-recognized risk factors, such as age, gender (male), and comorbidities, as well as provided novel laboratory indications (e.g., cholesterol) and TCM-specific phenotype markers (e.g., dull tongue) that were relevant to COVID-19 infections and prognosis. In addition to antiviral/antibiotics and standard supportive therapies, TCM herbal prescriptions incorporating 290 distinct herbs were used in 273 (93%) cases. The cases that received TCM treatment had lower death rates than those that did not receive TCM treatment (17/273 = 6.2% vs. 7/20= 35%,P= 0.0004 for all cases; 17/77= 22% vs. 7/9= 77.7%,P= 0.002 for severe cases). The TCM herbal prescriptions used for the treatment of COVID-19 infections mainly consisted of Pericarpium Citri Reticulatae, Radix Scutellariae, Rhizoma Pinellia, and their combinations, which reflected the practical TCM principles (e.g., clearing heat and dampening phlegm). Lastly, 59% of the patients received treatment, including antiviral, antibiotics, and Chinese patent medicine, before admission. This situation might have some effects on symptoms, such as fever and dry cough. By using EMR data, we described the clinical features and therapeutic characteristics of 293 COVID-19 cases treated via the integration of TCM herbal prescriptions and Western medicine. Clinical manifestations and treatments before admission and in the hospital were investigated. Our results preliminarily showed the potential effectiveness of TCM herbal prescriptions and their regularities in COVID-19 treatment.
C1 [Shu, Zixin; Chang, Kai; Zou, Qunsheng; Zheng, Qiguang; Ji, Jinghui; Zhou, Xuezhong] Beijing Jiaotong Univ, Inst Med Intelligence, Sch Comp & Informat Technol, Beijing 100044, Peoples R China.
   [Zhou, Yana; Liu, Jifen; Min, Xiaojun; Zhang, Qing; Sun, Jing; Xiong, Yajuan; Li, Xiaodong] Hubei Prov Hosp Tradit Chinese Med, Wuhan 430061, Peoples R China.
   [Li, Xiaodong] Hubei Prov Acad Tradit Chinese Med, Inst Liver Dis, Wuhan 430061, Peoples R China.
   [Poon, Josiah] Univ Sydney, Sch Comp Sci, Sydney, NSW 2006, Australia.
   [Poon, Josiah] USYD, Analyt & Clin Cooperat Lab Integrat Med, Sydney, NSW 2006, Australia.
   [Poon, Josiah] CUHK, Sydney, NSW 2006, Australia.
   [Liu, Baoyan] China Acad Chinese Med Sci, Beijing 100700, Peoples R China.
RP Zhou, XZ (corresponding author), Beijing Jiaotong Univ, Inst Med Intelligence, Sch Comp & Informat Technol, Beijing 100044, Peoples R China.; Li, XD (corresponding author), Hubei Prov Hosp Tradit Chinese Med, Wuhan 430061, Peoples R China.; Li, XD (corresponding author), Hubei Prov Acad Tradit Chinese Med, Inst Liver Dis, Wuhan 430061, Peoples R China.; Poon, J (corresponding author), Univ Sydney, Sch Comp Sci, Sydney, NSW 2006, Australia.; Poon, J (corresponding author), USYD, Analyt & Clin Cooperat Lab Integrat Med, Sydney, NSW 2006, Australia.; Poon, J (corresponding author), CUHK, Sydney, NSW 2006, Australia.; Liu, BY (corresponding author), China Acad Chinese Med Sci, Beijing 100700, Peoples R China.
EM josiah.poon@sydney.edu.au; liuby5505@139.com; xzzhou@bjtu.edu.cn;
   lixiaodong555@126.com
FU National Key Research and Development Program [2017YFC1703506,
   2017YFC1703505, 2017YFC1703502, 2020YFC0841600]; Special Programs of
   Traditional Chinese Medicine [JDZX2015168, JDZX2015171, JDZX2015170];
   Fundamental Research Funds for the Central public welfare research
   institutes [ZZ10-005, 2018JBZ006]
FX This work is partially supported by the National Key Research and
   Development Program (Nos. 2017YFC1703506, 2017YFC1703505,
   2017YFC1703502, and 2020YFC0841600), the Special Programs of Traditional
   Chinese Medicine (Nos. JDZX2015168, JDZX2015171, and JDZX2015170) and
   the Fundamental Research Funds for the Central public welfare research
   institutes (Nos. ZZ10-005 and 2018JBZ006).
CR [Anonymous], 2020, LANCET, V395, P311, DOI 10.1016/S0140-6736(20)30186-0
   Baclawski K, 2004, LECT NOTES COMPUT SC, V3298, P650
   Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918
   Cao WJ, 2019, CLIN LAB, V65, P2377, DOI 10.7754/Clin.Lab.2019.190525
   Chakrabarty B, 2020, NETWORK BASED ANAL F, DOI [10.26434/chemrxiv.12136470.v1, DOI 10.26434/CHEMRXIV.12136470.V1]
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chand K, 2020, ARAB J CHEM, V13, P8248, DOI [10.1142/S0192415X20500378, 10.1016/j.arabjc.2020.01.009]
   FitzGerald GA, 2020, SCIENCE, V367, P1434, DOI 10.1126/science.abb8034
   [何黎黎 He Lili], 2020, [中草药, Chinese Traditional and Herbal Drugs], V51, P1375
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang MX, 2020, FRONT MED-PRC, V14, P357, DOI 10.1007/s11684-019-0699-3
   Jiang F, 2020, J GEN INTERN MED, V35, P1545, DOI 10.1007/s11606-020-05762-w
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Li SY, 2005, ANTIVIR RES, V67, P18, DOI 10.1016/j.antiviral.2005.02.007
   Liang T., 2020, HDB COVID 19 PREVENT
   Ling CQ, 2020, J INTEGR MED-JIM, V18, P87, DOI 10.1016/j.joim.2020.02.004
   Lu YF, 2020, J SHANGHAI U TRADIT, V2020, P17
   Maddaloni E, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3321
   Muller B., 2012, NEURAL NETWORKS INTR
   National Health Commission & State Administration of Traditional Chinese Medicine, 2020, DIAGN TREATM PROT NO
   Rabby MII, 2020, J PHARM PHARM SCI, V23, P58, DOI 10.18433/jpps31002
   Ran J, 2020, J EMERG TRADIT CHIN, V29, P753
   Reed GM, 2010, PROF PSYCHOL-RES PR, V41, P457, DOI 10.1037/a0021701
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Schroeder C, 2010, SUBCELL BIOCHEM, V51, P77, DOI 10.1007/978-90-481-8622-8_3
   Shu ZX, 2019, COMPUT METH PROG BIO, V174, P41, DOI 10.1016/j.cmpb.2018.02.014
   [孙宏源 Sun Hongyuan], 2020, [中医杂志, Journal of Traditional Chinese Medicine], V61, P837
   Takano T, 2017, ANTIVIR RES, V145, P96, DOI 10.1016/j.antiviral.2017.07.022
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang PX, 2020, ADV OPT MATER, V8, DOI 10.1002/adom.202000524
   Wang YS, 2018, J BIOMED INFORM, V77, P34, DOI 10.1016/j.jbi.2017.11.011
   [杨家耀 Yang Jiayao], 2020, [中医杂志, Journal of Traditional Chinese Medicine], V61, P645
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang Y, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00489
   Zeng SP, 2020, CLASSICAL CHIN MED R, V3, P36
   Zhang DH, 2020, J INTEGR MED-JIM, V18, P152, DOI 10.1016/j.joim.2020.02.005
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhang Yin, 2017, Zhongguo Zhong Yao Za Zhi, V42, P2900, DOI 10.19540/j.cnki.cjcmm.20170705.009
   [郑文科 Zheng Wenke], 2020, [中医杂志, Journal of Traditional Chinese Medicine], V61, P277
   Zhou XZ, 2018, EBIOMEDICINE, V31, P79, DOI 10.1016/j.ebiom.2018.04.002
   Zhou XZ, 2014, FRONT MED-PRC, V8, P337, DOI 10.1007/s11684-014-0349-8
NR 41
TC 1
Z9 1
U1 7
U2 7
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2095-0217
EI 2095-0225
J9 FRONT MED-PRC
JI Front. Med.
DI 10.1007/s11684-020-0803-8
EA SEP 2020
PG 16
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA NO9GF
UT WOS:000569793600001
PM 32926319
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Stifter, J
   Terry, A
   Phillips, J
   Heitschmidt, M
AF Stifter, Janet
   Terry, Allison
   Phillips, Janice
   Heitschmidt, Mary
TI A short report on an interprofessional mobilizer team: innovation and
   impact during the COVID-19 pandemic
SO JOURNAL OF INTERPROFESSIONAL CARE
LA English
DT Article
DE Incident command; Covid-19; pandemic; response; interprofessional
   collaboration; mobilizer team
AB The response to a pandemic crisis requires strong preparedness and an action plan that is well defined yet flexible enough to address the uncertainties that accompany an infectious disease outbreak. Interprofessional collaboration is an integral component when implementing a robust and comprehensive response to such a crisis. As the needs of our academic medical center evolved during the COVID-19 pandemic, the COVID-19 Mobilizer Team used an interprofessional approach to respond to the diverse and complex needs of the organization. Team members included employees deployed from diverse departments such as Physical and Occupational Therapy, Nursing Education, Hospital Operations, and Advance Practice Providers. The team's function transitioned from ensuring compliance with infection control policy and procedure and use of personal protective equipment to ensuring a two way channel of communication between front line staff and the Hospital Incident Command System (HICS) concerning testing and isolation procedures, supplies, visitor restrictions, and staff wellness issues. The Mobilizer Team members became integral contributors to the HICS and provided members of our staff outside of the COVID-19 care units an opportunity to partner with colleagues from professions they may have never worked with and the chance to contribute to the COVID-19 pandemic response.
C1 [Stifter, Janet] Rush Univ, Med Ctr, Nursing Adm, Profess Nursing Practice, 1620 W Harrison St, Chicago, IL 60612 USA.
   [Terry, Allison] Rush Univ, Med Ctr, APP Inpatient Orthoped, Chicago, IL 60612 USA.
   [Phillips, Janice] Rush Univ, Med Ctr, Nursing Adm, Nursing Res & Hlth Equ, Chicago, IL 60612 USA.
   [Heitschmidt, Mary] Rush Univ, Med Ctr, Ctr Clin Res & Scholarship, Clin Res, Chicago, IL 60612 USA.
RP Stifter, J (corresponding author), Rush Univ, Med Ctr, Nursing Adm, Profess Nursing Practice, 1620 W Harrison St, Chicago, IL 60612 USA.
EM janet_stifter@rush.edu
CR Bryson JM, 2015, PUBLIC ADMIN REV, V75, P647, DOI 10.1111/puar.12432
   Chicago Department of Public Health, LAT DAT
   Filice CE, 2013, ACAD EMERG MED, V20, P54, DOI 10.1111/acem.12061
   Houghton C, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013582
   Jankouskas Tara, 2007, Simul Healthc, V2, P96, DOI 10.1097/SIH.0b013e31805d8b0d
   Johns Hopkins University, COVID 19 DASHB CTR S
   Khorram-Manesh A, 2017, EUR J TRAUMA EMERG S, V43, P595, DOI 10.1007/s00068-017-0778-6
   McCallin A, 2001, J CLIN NURS, V10, P419, DOI 10.1046/j.1365-2702.2001.00495.x
   U.S. Department of Health and Human Services, 2017, PAND INFL PLAN 2017
NR 9
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1356-1820
EI 1469-9567
J9 J INTERPROF CARE
JI J. Interprofessional Care
PD SEP 2
PY 2020
VL 34
IS 5
SI SI
BP 716
EP 718
DI 10.1080/13561820.2020.1813696
EA SEP 2020
PG 3
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA OI9JA
UT WOS:000569468300001
PM 32935613
DA 2021-01-01
ER

PT J
AU Alvarez, MAL
   Revuelta, JR
   Portero, BO
   Mendez, CP
   Montero, GS
   Alfonso, AL
AF Lara Alvarez, Miguel Angel
   Rogado Revuelta, Jacobo
   Obispo Portero, Berta
   Pangua Mendez, Cristina
   Serrano Montero, Gloria
   Lopez Alfonso, Ana
TI Covid-19 mortality in cancer patients in a Madrid hospital during the
   first 3 weeks of the epidemic
SO MEDICINA CLINICA
LA Spanish
DT Article
DE Covid-19; Cancer; Mortality
AB Background and objective: The covid-19 pandemic especially affects cancer patients with higher incidence and mortality according to published series of original pandemic foci. The study aims to determine the mortality in our center due to covid-19 in cancer patients during the first 3 weeks of the epidemic.
   Material and methods: The cancer patients who died of covid-19 during the analysis period have been reviewed describing the oncological and the covid-19 infection characteristics and the treatments established.
   Results: Confirmed cases covid-19: 1069 with 132 deaths (12.3%). With cancer 36 patients (3.4%), 15 deceased (41.6%). Of the deceased, only 6 patients (40%) were in active treatment. The most frequent associated tumor was lung (8/15 patients, 53.3%), 11 with metastatic disease (11/15, 73.3%). No specific treatment was established in 40% (6/15) of the patients. The rest of them received treatments with the active protocols.
   Conclusion: Covid-19 mortality in cancer patients is almost four times higher than that of the general population. Until we have effective treatments or an effective vaccine, the only possibility to protect our patients is to prevent the infection with the appropriate measures. (C) 2020 Elsevier Espana, S.L.U. All rights reserved.
C1 [Lara Alvarez, Miguel Angel; Rogado Revuelta, Jacobo; Obispo Portero, Berta; Pangua Mendez, Cristina; Serrano Montero, Gloria; Lopez Alfonso, Ana] Hosp Univ Infanta Leonor, Secc Oncol Med, Madrid, Spain.
   [Lara Alvarez, Miguel Angel] Univ Complutense Madrid, Madrid, Spain.
RP Alvarez, MAL (corresponding author), Hosp Univ Infanta Leonor, Secc Oncol Med, Madrid, Spain.; Alvarez, MAL (corresponding author), Univ Complutense Madrid, Madrid, Spain.
EM lara.miguelangel@gmail.com
CR Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Ji M, 2020, CLIN TRANSL ONCOL, DOI 10.1007/s12094-020-02417-4
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   World Health Organization, DIS OUTBREAK NE 0208
   Yu J, 2020, JAMA ONCOL, V25
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 6
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER ESPANA SLU
PI BARCELONA
PA AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN
SN 0025-7753
EI 1578-8989
J9 MED CLIN-BARCELONA
JI Med. Clin.
PD SEP 14
PY 2020
VL 155
IS 5
BP 202
EP 204
DI 10.1016/j.medcli.2020.05.005
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA NN7VO
UT WOS:000568995200004
PM 32507536
OA Green Published
DA 2021-01-01
ER

PT J
AU Aly, AA
   Hassan, AA
   Mohamed, AH
   Osman, EM
   Brase, S
   Nieger, M
   Ibrahim, MAA
   Mostafa, SM
AF Aly, Ashraf A.
   Hassan, Alaa A.
   Mohamed, Asmaa H.
   Osman, Esraa M.
   Braese, Stefan
   Nieger, Martin
   Ibrahim, Mahmoud A. A.
   Mostafa, Sara M.
TI Synthesis of 3,3 '-methylenebis(4-hydroxyquinolin-2(1H)-ones) of
   prospective anti-COVID-19 drugs
SO MOLECULAR DIVERSITY
LA English
DT Article; Early Access
DE Formylation; 3,3 '-methylenebis(4-hydroxyquinolin-2(1H)-ones); X-ray;
   Anti-form; Molecular docking; COVID-19
ID DERIVATIVES; INHIBITORS; MECHANISM
AB During formylation of 2-quinolones by DMF/Et3N mixture, the unexpected 3,3 '-methylenebis(4-hydroxyquinolin-2(1H)-ones) were formed. The discussed mechanism was proved as due to the formation of 4-formyl-2-quinolone as intermediate. Reaction of the latter compound with the parent quinolone under the same reaction condition gave also the same product. The structure of the obtained products was elucidated via NMR, IR and mass spectra. X-ray structure analysis proved theanti-form of the obtained compounds, which were stabilized by the formation hydrogen bond. Molecular docking calculations showed that most of the synthesized compounds possessed good binding affinity to the SARS-CoV-2 main protease (M-pro) in comparable to Darunavir.
   [GRAPHICS]
   .
C1 [Aly, Ashraf A.; Hassan, Alaa A.; Mohamed, Asmaa H.; Osman, Esraa M.; Ibrahim, Mahmoud A. A.; Mostafa, Sara M.] Menia Univ, Fac Sci, Dept Chem, Al Minya 61519, Egypt.
   [Braese, Stefan] Karlsruhe Inst Technol, Inst Organ Chem, D-76131 Karlsruhe, Germany.
   [Braese, Stefan] Karlsruhe Inst Technol, Inst Biol & Chem Syst IBCS FMS, Eggenstein Leopoldshafen, Germany.
   [Nieger, Martin] Univ Helsinki, Dept Chem, AI Virtasenaukio 1,POB 55, Helsinki 00014, Finland.
RP Aly, AA (corresponding author), Menia Univ, Fac Sci, Dept Chem, Al Minya 61519, Egypt.
EM ashrafaly63@yahoo.com
RI Ibrahim, Mahmoud/J-2936-2014; Brase, Stefan/B-9057-2008
OI Ibrahim, Mahmoud/0000-0003-4819-2040; Brase, Stefan/0000-0003-4845-3191
FU DFG Collaborative Center "3MET", Karlsruhe Institute of Technology,
   Karlsruhe, Germany; Science and Technology Development Fund, STDF,
   EgyptScience and Technology Development Fund (STDF) [5480, 7972]
FX The authors thank DFG Collaborative Center "3MET", Karlsruhe Institute
   of Technology, Karlsruhe, Germany for financial support to Prof Aly
   enabling him to carry out analyses in the aforesaid Institute. The
   computational work was completed with resources supported by the Science
   and Technology Development Fund, STDF, Egypt, Grants No. 5480 & 7972.
CR Aly AA, 2020, J MOL STRUCT, V1207, DOI 10.1016/j.molstruc.2020.127798
   Aly AA, 2020, MONATSH CHEM, V151, P223, DOI 10.1007/s00706-019-02541-0
   Aly AA, 2019, CHEM PAP, V73, P27, DOI 10.1007/s11696-018-0561-0
   Aly AA, 2019, BIOORG CHEM, V82, P290, DOI 10.1016/j.bioorg.2018.10.044
   Aly AA, 2018, BIOORG CHEM, V81, P700, DOI 10.1016/j.bioorg.2018.09.017
   Aly AA, 2018, MONATSH CHEM, V149, P635, DOI 10.1007/s00706-017-2078-6
   Bhudevi B, 2009, INDIAN J CHEM B, V48, P255
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   BUCKLE DR, 1975, J MED CHEM, V18, P726, DOI 10.1021/jm00241a017
   Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8
   Chin YW, 2008, J NAT PROD, V71, P390, DOI 10.1021/np070584j
   Choudhary CD, 2008, ORIENT J CHEM, V24, P259
   De Meyer S, 2020, LACK ANTIVIRAL ACTIV, DOI [10.1101/2020.04.03.20052548, DOI 10.1101/2020.04.03.20052548]
   FUCIK K, 1951, CHEM LISTY, V45, P23
   Fujio M, 2001, PCT INT APPL WO CHEM, Patent No. 066546
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2
   Gordon JC, 2005, NUCLEIC ACIDS RES, V33, pW368, DOI 10.1093/nar/gki464
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Han L, 2019, J MAT ENV SCI, V10, P182
   Hu HJ, 2006, J NAT PROD, V69, P1672, DOI 10.1021/np0603830
   HUNT RG, 1975, TETRAHEDRON LETT, P2327
   Jayashree A, 2010, J INDIAN CHEM SOC, V87, P325
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kaminski K, 2008, EUR J MED CHEM, V43, P53, DOI 10.1016/j.ejmech.2007.02.024
   Koeller S, 1999, TETRAHEDRON LETT, V40, P7043, DOI 10.1016/S0040-4039(99)01453-7
   Kumar R, 2010, HETEROCYCL COMMUN, V16, P201
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   MENTZER C, 1945, Bull Soc Chim Fr, V12, P430
   Meunier P, 1943, B SOC CHIM BIOL, V25, P384
   MOHAMED EA, 1994, CHEM PAP-CHEM ZVESTI, V48, P285
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Muzart J, 2009, TETRAHEDRON, V65, P8313, DOI 10.1016/j.tet.2009.06.091
   Nakao Kaoru, 2008, JAPANESE JOURNAL OF NEUROPSYCHOPHARMACOLOGY, V28, P75
   Obniska Jolanta, 2006, Acta Pol Pharm, V63, P101
   Obniska J, 2006, PHARMACOL REP, V58, P207
   Palaska E, 2001, EUR J MED CHEM, V36, P539, DOI 10.1016/S0223-5234(01)01243-0
   Park HB, 2007, ARCH PHARM, V340, P530, DOI 10.1002/ardp.200700060
   Pawar MJ, 2009, ARKIVOC, P97, DOI 10.3998/ark.5550190.0010.d08
   RAO VS, 1988, SYNTHETIC COMMUN, V18, P2267, DOI 10.1080/00397918808082369
   Sarma BK, 2010, J AM CHEM SOC, V132, P5364, DOI 10.1021/ja908080u
   Schick H, 2006, PCT INT APPL WO CHEM, Patent No. 122769
   Seah I, 2020, OCUL IMMUNOL INFLAMM, V28, P391, DOI 10.1080/09273948.2020.1738501
   Sheldrick GM, 2015, ACTA CRYSTALLOGR C, V71, P3, DOI 10.1107/S2053229614024218
   Wu YH, 2017, CELL CHEM BIOL, V24, P1437, DOI 10.1016/j.chembiol.2017.08.024
   Yuan ML, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230548
NR 45
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1381-1991
EI 1573-501X
J9 MOL DIVERS
JI Mol. Divers.
DI 10.1007/s11030-020-10140-z
EA SEP 2020
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Applied; Chemistry,
   Medicinal; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA NO1UZ
UT WOS:000569273100001
PM 32926254
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Wang, QQ
   Kaelber, DC
   Xu, R
   Volkow, ND
AF Wang, Quan Qiu
   Kaelber, David C.
   Xu, Rong
   Volkow, Nora D.
TI COVID-19 risk and outcomes in patients with substance use disorders:
   analyses from electronic health records in the United States
SO MOLECULAR PSYCHIATRY
LA English
DT Article; Early Access
ID DRUGS
AB The global pandemic of COVID-19 is colliding with the epidemic of opioid use disorders (OUD) and other substance use disorders (SUD) in the United States (US). Currently, there is limited data on risks, disparity, and outcomes for COVID-19 in individuals suffering from SUD. This is a retrospective case-control study of electronic health records (EHRs) data of 73,099,850 unique patients, of whom 12,030 had a diagnosis of COVID-19. Patients with a recent diagnosis of SUD (within past year) were at significantly increased risk for COVID-19 (adjusted odds ratio or AOR = 8.699 [8.411-8.997],P < 10(-30)), an effect that was strongest for individuals with OUD (AOR = 10.244 [9.107-11.524],P < 10(-30)), followed by individuals with tobacco use disorder (TUD) (AOR = 8.222 ([7.925-8.530],P < 10(-30)). Compared to patients without SUD, patients with SUD had significantly higher prevalence of chronic kidney, liver, lung diseases, cardiovascular diseases, type 2 diabetes, obesity and cancer. Among patients with recent diagnosis of SUD, African Americans had significantly higher risk of COVID-19 than Caucasians (AOR = 2.173 [2.01-2.349],P < 10(-30)), with strongest effect for OUD (AOR = 4.162 [3.13-5.533],P < 10(-25)). COVID-19 patients with SUD had significantly worse outcomes (death: 9.6%, hospitalization: 41.0%) than general COVID-19 patients (death: 6.6%, hospitalization: 30.1%) and African Americans with COVID-19 and SUD had worse outcomes (death: 13.0%, hospitalization: 50.7%) than Caucasians (death: 8.6%, hospitalization: 35.2%). These findings identify individuals with SUD, especially individuals with OUD and African Americans, as having increased risk for COVID-19 and its adverse outcomes, highlighting the need to screen and treat individuals with SUD as part of the strategy to control the pandemic while ensuring no disparities in access to healthcare support.
C1 [Wang, Quan Qiu; Xu, Rong] Case Western Reserve Univ, Sch Med, Ctr Artificial Intelligence Drug Discovery, Cleveland, OH 44106 USA.
   [Kaelber, David C.] MetroHlth Syst, Dept Internal Med, Cleveland, OH USA.
   [Kaelber, David C.] MetroHlth Syst, Dept Pediat, Cleveland, OH USA.
   [Kaelber, David C.] MetroHlth Syst, Ctr Clin Informat Res & Educ, Cleveland, OH USA.
   [Volkow, Nora D.] NIDA, NIH, Bethesda, MD 20892 USA.
RP Xu, R (corresponding author), Case Western Reserve Univ, Sch Med, Ctr Artificial Intelligence Drug Discovery, Cleveland, OH 44106 USA.; Volkow, ND (corresponding author), NIDA, NIH, Bethesda, MD 20892 USA.
EM rxx@case.edu; nvolkow@nida.nih.gov
FU Eunice Kennedy Shriver National Institute of Child Health & Human
   Development of the National Institutes of Health under the NIH
   Director's New Innovator Award [DP2HD084068]; NIH National Institute on
   AgingUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)
   [R01 AG057557, R01 AG061388, R56 AG062272]; American Cancer Society
   Research Scholar GrantAmerican Cancer Society [RSG-16-049-01-MPC];
   Clinical and Translational Science Collaborative (CTSC) of Cleveland
   [1UL1TR002548-01]
FX RX acknowledges support from Eunice Kennedy Shriver National Institute
   of Child Health & Human Development of the National Institutes of Health
   under the NIH Director's New Innovator Award number DP2HD084068, NIH
   National Institute on Aging R01 AG057557, R01 AG061388, R56 AG062272,
   American Cancer Society Research Scholar Grant RSG-16-049-01-MPC, The
   Clinical and Translational Science Collaborative (CTSC) of Cleveland
   1UL1TR002548-01.
CR Ahmad FS, 2017, CIRCULATION, V136, P1207, DOI 10.1161/CIRCULATIONAHA.117.027436
   Alexander GC, 2020, ANN INTERN MED, V173, P57, DOI 10.7326/M20-1141
   American Psychiatric Association, DIAGNOSTIC STAT MANU, V4th
   Bahorik AL, 2017, J ADDICT MED, V11, P3, DOI 10.1097/ADM.0000000000000260
   Becker WC, 2020, ANN INTERN MED, V173, P59, DOI 10.7326/M20-1210
   Berlin I, 2020, NICOTINE TOB RES, V22, P1650, DOI 10.1093/ntr/ntaa059
   Bodenreider O, 2004, NUCLEIC ACIDS RES, V32, pD267, DOI 10.1093/nar/gkh061
   Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   Coorevits P, 2013, J INTERN MED, V274, P547, DOI 10.1111/joim.12119
   Cowie MR, 2017, CLIN RES CARDIOL, V106, P1, DOI 10.1007/s00392-016-1025-6
   Creamer MR, 2019, MMWR-MORBID MORTAL W, V68, P1013, DOI 10.15585/mmwr.mm6845a2
   Friedman H, 2003, CLIN MICROBIOL REV, V16, P209, DOI 10.1128/CMR.16.2.209-219.2003
   Friedman H, 2006, FEMS IMMUNOL MED MIC, V47, P330, DOI 10.1111/j.1574-695X.2006.00097.x
   Kaelber DC, 2012, J AM MED INFORM ASSN, V19, P965, DOI 10.1136/amiajnl-2011-000782
   KURITZ SJ, 1988, ANNU REV PUBL HEALTH, V9, P123, DOI 10.1146/annurev.pu.09.050188.001011
   National Institute on Drug Abuse, 2020, HLTH CONS DRUG MIS
   National Institute on Drug Abuse, HLTH CONS DRUG MIS H
   Owen WF, 2020, JAMA-J AM MED ASSOC, V323, P1905, DOI 10.1001/jama.2020.6547
   Patanavanich R, 2020, NICOTINE TOB RES, V22, P1653, DOI 10.1093/ntr/ntaa082
   Patel VN, 2014, J BIOMED INFORM, V52, P36, DOI 10.1016/j.jbi.2013.10.009
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   SNOMED International, SYST NOM MED CLIN TE
   The Centers for Disease Control and Prevention (CDC), 2020, GROUPS HIGH RISK COV
   The Substance Abuse and Mental Health Services Administration (SAMHSA) of the U.S. Department of Health and Human Services, KEY SUBST US MENT HL
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Volkow ND, 2020, ANN INTERN MED, V173, P61, DOI 10.7326/M20-1212
   Wadhera RK, 2020, JAMA-J AM MED ASSOC, V323, P2192, DOI 10.1001/jama.2020.7197
   Williams DR, 2020, JAMA-J AM MED ASSOC, V323, P2478, DOI 10.1001/jama.2020.8051
   Winhusen T, 2019, ADDICTION, V114, P1462, DOI 10.1111/add.14607
   Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou MS, 2020, BIOINFORMATICS, V36, P436, DOI 10.1093/bioinformatics/btaa451
   Zhou MS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229819
NR 33
TC 2
Z9 2
U1 4
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1359-4184
EI 1476-5578
J9 MOL PSYCHIATR
JI Mol. Psychiatr.
DI 10.1038/s41380-020-00880-7
EA SEP 2020
PG 10
WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry
SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry
GA NO2BO
UT WOS:000569290300001
PM 32929211
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rieder, M
   Zahn, T
   Benk, C
   Lother, A
   Bode, C
   Staudacher, D
   Duerschmied, D
   Supady, A
AF Rieder, Marina
   Zahn, Timm
   Benk, Christoph
   Lother, Achim
   Bode, Christoph
   Staudacher, Dawid
   Duerschmied, Daniel
   Supady, Alexander
TI Cytokine adsorption in a patient with severe coronavirus disease 2019
   related acute respiratory distress syndrome requiring extracorporeal
   membrane oxygenation therapy: A case report
SO ARTIFICIAL ORGANS
LA English
DT Letter; Early Access
ID COVID-19
C1 [Rieder, Marina; Zahn, Timm; Lother, Achim; Bode, Christoph; Staudacher, Dawid; Duerschmied, Daniel; Supady, Alexander] Univ Freiburg, Dept Med Interdisciplinary Med Intens Care 3, Med Ctr, Fac Med, Freiburg, Germany.
   [Rieder, Marina; Zahn, Timm; Lother, Achim; Bode, Christoph; Staudacher, Dawid; Duerschmied, Daniel; Supady, Alexander] Univ Freiburg, Dept Cardiol & Angiol 1, Ctr Heart, Freiburg, Germany.
   [Benk, Christoph] Univ Freiburg, Dept Cardiovasc Surg, Ctr Heart, Freiburg, Germany.
   [Lother, Achim] Univ Freiburg, Inst Expt & Clin Pharmacol & Toxicol, Fac Med, Freiburg, Germany.
   [Supady, Alexander] Heidelberg Univ, Heidelberg Inst Global Hlth, Heidelberg, Germany.
RP Supady, A (corresponding author), Univ Freiburg, Dept Med Intens Care Med 3, Med Ctr, Hugstetter Str 55, D-79106 Freiburg, Germany.
EM alexander.supady@universitaets-herzzentrum.de
RI Duerschmied, Daniel/K-8182-2015
OI Duerschmied, Daniel/0000-0001-5249-4012; Supady,
   Alexander/0000-0003-4056-3652
FU Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG)
   [413517907] Funding Source: Medline
CR Bemtgen X, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02217-1
   Bonavia A, 2018, BLOOD PURIFICAT, V46, P337, DOI 10.1159/000492379
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   EuroELSO, 2020, EUROELSO SURV ECMO U
   Falcoz PE, 2020, AM J RESP CRIT CARE, V202, P460, DOI 10.1164/rccm.202004-1370LE
   Fengmin S, 2020, ARTIF ORGANS
   Hartman ME, 2020, ASAIO J, V66, P603, DOI 10.1097/MAT.0000000000001177
   Hawchar F, 2019, J CRIT CARE, V49, P172, DOI 10.1016/j.jcrc.2018.11.003
   Henry BM, 2020, J CRIT CARE, V58, P27, DOI 10.1016/j.jcrc.2020.03.011
   Honore PM, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0530-y
   Jacobs JP, 2020, ASAIO J, V66, P722, DOI 10.1097/MAT.0000000000001185
   Melhuish TM, 2020, AM J EMERG MED
   Poli EC, 2019, INTENS CARE MED, V45, P236, DOI 10.1007/s00134-018-5464-6
   Rieder M, 2020, J THROMB THROMBOLYS, V50, P558, DOI 10.1007/s11239-020-02202-8
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Shekar K, 2020, ASAIO J
   Swol J, 2020, ARTIF ORGANS, V44, P918, DOI 10.1111/aor.13748
NR 17
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0160-564X
EI 1525-1594
J9 ARTIF ORGANS
JI Artif. Organs
DI 10.1111/aor.13805
EA SEP 2020
PG 4
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA NN7MD
UT WOS:000568968500001
PM 32929761
OA Bronze
DA 2021-01-01
ER

PT J
AU Molinelli, E
   Diotallevi, F
   Simonetti, O
   Brisigotti, V
   Sapigni, C
   Radi, G
   Campanati, A
   Offidani, A
AF Molinelli, Elisa
   Diotallevi, Federico
   Simonetti, Oriana
   Brisigotti, Valerio
   Sapigni, Claudia
   Radi, Giulia
   Campanati, Anna
   Offidani, Annamaria
TI Management of patients with hidradenitis suppurativa during the COVID-19
   pandemic: Risk and benefit of immunomodulatory therapy
SO DERMATOLOGIC THERAPY
LA English
DT Article; Early Access
DE adalimumab; biologic therapy; coronavirus; COVID-19; dermatology;
   hidradenitis suppurativa; SARS-CoV-2; skin diseases
ID ADALIMUMAB; BIOLOGICS; ERA
AB Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by a new coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Italy has been the first nation affected by the coronavirus pandemic and is the second in the number of reported deaths in the European Union. In the United Hospital of Ancona, a specialist outpatient clinic dealing with diagnosis and treatment of immunomediated skin diseases has been operating since 1985, and 291 patients with hidradenitis suppurativa (HS) are currently being treated. Several cutaneous immunomediated diseases, including HS, are treated with biologic and nonbiologic immunosuppressive and immunomodulatory drugs. Since the end of February 2020, when the SARS-CoV-2 pandemic had already spread in most of Italy, a task force comprised of seven specialists has been set up with the aim of addressing problems relating to the specific risk for this class of patients in relation to SARS-CoV-2 infection and immunosuppressive ongoing therapy. In this article, the management of HS disease during the COVID-19 pandemic is discussed. The main goal was to evaluate the risk/benefit in modulating treatment taking into consideration patients' risk of exposure to SARS-CoV-2 virus.
C1 [Molinelli, Elisa; Diotallevi, Federico; Simonetti, Oriana; Brisigotti, Valerio; Sapigni, Claudia; Radi, Giulia; Campanati, Anna; Offidani, Annamaria] Polytech Marche Univ, Dermatol Unit, Dept Clin & Mol Sci, Ancona, Italy.
RP Molinelli, E (corresponding author), Polytech Marche Univ, Dermatol Unit, Dept Clin & Mol Sci, Ancona, Italy.
EM molinelli.elisa@gmail.com
OI Brisigotti, Valerio/0000-0002-3033-8024; CAMPANATI,
   ANNA/0000-0002-3740-0839; DIOTALLEVI, FEDERICO/0000-0003-2274-1742
CR Blaszczak A, 2020, J AM ACAD DERMATOL, V83, pE31, DOI 10.1016/j.jaad.2020.04.030
   Kimball AB, 2016, NEW ENGL J MED, V375, P422, DOI 10.1056/NEJMoa1504370
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Marasca C, 2020, J DERMATOL TREAT, DOI [10.1080/09546634.2020.1769828, 10.1080/09546634.2020.1809625]
   Marzano AV, 2020, BRIT J DERMATOL, DOI 10.1111/bjd.18983
   Megna M, 2020, J DERMATOL TREAT, DOI [10.1080/09546634.2020.1781044, 10.1080/09546634.2020.1757605]
   Offidani A, 2019, J EUR ACAD DERMATOL, V33, P28, DOI 10.1111/jdv.15827
   Price KN, 2020, J AM ACAD DERMATOL, V82, pE173, DOI 10.1016/j.jaad.2020.03.046
   Seltzer JA, 2020, J AM ACAD DERMATOL, V83, pE153, DOI 10.1016/j.jaad.2020.05.012
   Torres T, 2020, AM J CLIN DERMATOL, V10, P1
   Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021
NR 11
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
AR e14256
DI 10.1111/dth.14256
EA SEP 2020
PG 4
WC Dermatology
SC Dermatology
GA NN7KF
UT WOS:000568962800001
PM 32860474
OA Bronze
DA 2021-01-01
ER

PT J
AU Ramakrishnan, VS
   Kim, YK
   Yung, W
   Mayur, P
AF Ramakrishnan, Venkata Subramanian
   Kim, Young Kwang
   Yung, Wanda
   Mayur, Prashanth
TI ECT in the time of the COVID-19 pandemic
SO AUSTRALASIAN PSYCHIATRY
LA English
DT Article
DE COVID-19; electroconvulsive therapy; personal protective equipment;
   aerosol-generating procedure
AB Objective: The recent and ongoing COVID-19 pandemic outbreak has placed a huge burden on healthcare systems worldwide. This emergent situation applies invariably to mental health services, and policy makers have issued new directives to adequately deal with this crisis. The COVID-19 outbreak poses special challenges to the administration of electroconvulsive therapy (ECT) since the anaesthetic induction is an aerosol-generating process. The report provides a narrative account of modifications to the ECT practice at a tertiary care psychiatric hospital to mitigate the risk of COVID-19 transmission. Conclusion: We emphasise two main modifications: use of personal protective equipment (PPE) during the ECT and modifications in the anaesthetic procedure to mitigate potential transmission.
C1 [Ramakrishnan, Venkata Subramanian; Kim, Young Kwang; Yung, Wanda; Mayur, Prashanth] Cumberland Hosp, 1-11 Hainsworth St, Westmead, NSW 2145, Australia.
   [Mayur, Prashanth] Univ Sydney, Discipline Psychiat, Sydney, NSW, Australia.
RP Kim, YK (corresponding author), Cumberland Hosp, 1-11 Hainsworth St, Westmead, NSW 2145, Australia.
EM young.kim1@health.nsw.gov.au
CR Australian and New Zealand College of Anaesthetists, 2020, ANZCA STAT PERS PROT
   Chen Y, 2020, LANCET INFECT DIS, V20, P515, DOI 10.1016/S1473-3099(20)30235-8
   Espinoza RT, 2020, J ECT, DOI [10.1097/YCT.00000000000000689., DOI 10.1097/YCT.00000000000000689.]
   Fox GJ, 2020, MED J AUSTRALIA, V212, P468, DOI 10.5694/mja2.50606
   Galea S, 2020, JAMA INTERN MED, V180, P817, DOI 10.1001/jamainternmed.2020.1562
   Tor PC, 2020, J ECT, DOI [10.1097/YCT.00000000000000690., DOI 10.1097/YCT.00000000000000690.]
   World Health Organization, 2019, STAT 2 M INT HLTH RE
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 8
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1039-8562
EI 1440-1665
J9 AUSTRALAS PSYCHIATRY
JI Australas. Psychiatry
PD OCT
PY 2020
VL 28
IS 5
BP 527
EP 529
AR 1039856220953705
DI 10.1177/1039856220953705
EA SEP 2020
PG 3
WC Psychiatry
SC Psychiatry
GA NV8ET
UT WOS:000570173100001
PM 32924540
OA Bronze
DA 2021-01-01
ER

PT J
AU Rife, E
   Gedalia, A
AF Rife, Eileen
   Gedalia, Abraham
TI Kawasaki Disease: an Update
SO CURRENT RHEUMATOLOGY REPORTS
LA English
DT Article
DE Kawasaki disease; Kawasaki review; Kawasaki treatment; Kawasaki workup;
   Kawasaki differential; Kawasaki diagnosis; Multi system inflammatory
   syndrome; Kawasaki-like disease
ID CORONARY-ARTERY ABNORMALITIES; LONG-TERM MANAGEMENT; INTRAVENOUS
   IMMUNOGLOBULIN; CARDIOVASCULAR-DISEASE; SCIENTIFIC STATEMENT;
   HEALTH-PROFESSIONALS; TROPOSPHERIC WINDS; RANDOMIZED-TRIAL; PRIMARY
   THERAPY; HIGH-RISK
AB Purpose of Review Provide the most recent updates on the epidemiology, pathogenesis, and treatment advances in Kawasaki disease. Recent Findings Treatment advances in complex, IVIG-refractory cases of Kawasaki disease. Multisystem inflammatory syndrome, a newly reported inflammatory condition with Kawasaki-like features and an association with the 2019 Coronavirus (COVID-19). Kawasaki disease (KD) is a rare systemic inflammatory disease that predominately affects children less than 5 years of age. Pathogenesis of KD remains unknown; the leading theory is that an unknown stimulus triggers an immune-mediated inflammatory cascade in a genetically susceptible child. Classic KD is a clinical diagnosis based on set criteria and excluding other similar clinical entities. Patients who do not fulfill complete diagnostic criteria for KD are often referred to as atypical (or incomplete) KD. The most feared complication of KD is coronary artery abnormality development, and patients with atypical KD are also at risk. Administration of intravenous immunoglobulin (IVIG) and aspirin has greatly reduced the incidence of coronary lesions in affected children. Several other immune-modulating therapies have recently been utilized in complex or refractory cases.
C1 [Rife, Eileen] Louisiana State Univ, New Orleans, LA 70112 USA.
   [Gedalia, Abraham] Childrens Hosp, Div Pediat Rheumatol, 2000 Henry Clay Ave, New Orleans, LA 70118 USA.
   [Gedalia, Abraham] LSU Hlth Sci Ctr, 2000 Henry Clay Ave, New Orleans, LA 70118 USA.
RP Rife, E (corresponding author), Louisiana State Univ, New Orleans, LA 70112 USA.; Gedalia, A (corresponding author), Childrens Hosp, Div Pediat Rheumatol, 2000 Henry Clay Ave, New Orleans, LA 70118 USA.; Gedalia, A (corresponding author), LSU Hlth Sci Ctr, 2000 Henry Clay Ave, New Orleans, LA 70118 USA.
EM erife@lsuhsc.edu; AGedal@lsuhsc.edu
CR Abrams JY, 2015, VACCINE, V33, P382, DOI 10.1016/j.vaccine.2014.10.044
   Alphonse MP, 2016, J IMMUNOL, V197, P3481, DOI 10.4049/jimmunol.1600388
   [Anonymous], 1984, REP SUB STAND DIAGN
   Anzai F, 2020, J MOL CELL CARDIOL, V138, P185, DOI 10.1016/j.yjmcc.2019.11.158
   Ashouri N, 2008, J PEDIATR-US, V153, P365, DOI 10.1016/j.jpeds.2008.03.014
   Baker MA, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002844
   Baumer JH, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004175.pub2
   Beiser AS, 1998, AM J CARDIOL, V81, P1116, DOI 10.1016/S0002-9149(98)00116-7
   Belhadjer Z, 2020, CIRCULATION, V142, P429, DOI 10.1161/CIRCULATIONAHA.120.048360
   BELL DM, 1983, AM J DIS CHILD, V137, P211, DOI 10.1001/archpedi.1983.02140290003001
   Burns JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074529
   Centers for Disease Control and Prevention Health Alert Network (HAN), MULT INFL SYDR CHILD
   Chen SJ, 2016, JAMA PEDIATR, V170, P1156, DOI 10.1001/jamapediatrics.2016.2055
   Chen SJ, 2013, HEART, V99, P76, DOI 10.1136/heartjnl-2012-302126
   Cohen S, 2012, ANN RHEUM DIS, V71, P2059, DOI 10.1136/annrheumdis-2012-201658
   Dahdah N, 2009, PEDIATR CARDIOL, V30, P810, DOI 10.1007/s00246-009-9441-2
   Dergun M, 2005, ARCH PEDIAT ADOL MED, V159, P876, DOI 10.1001/archpedi.159.9.876
   Doi M, 2010, J INVEST ALLERG CLIN, V20, P413
   ElAdawy M, 2011, PEDIATR INFECT DIS J, V30, P141, DOI 10.1097/INF.0b013e3181f6fe2a
   Franco A, 2014, AUTOIMMUNITY, V47, P95, DOI 10.3109/08916934.2013.860524
   Franco A, 2010, AUTOIMMUNITY, V43, P317, DOI 10.3109/08916930903405891
   FUJITA Y, 1989, PEDIATRICS, V84, P666
   Gedalia A, 2007, CURR RHEUMATOL REP, V9, P336, DOI 10.1007/s11926-007-0053-7
   Ha KS, 2013, EUR J PEDIATR, V172, P343, DOI 10.1007/s00431-012-1891-5
   Hall GC, 2016, PHARMACOEPIDEM DR S, V25, P1331, DOI 10.1002/pds.4108
   Hamada H, 2019, LANCET, V393, P1128, DOI 10.1016/S0140-6736(18)32003-8
   HARADA F, 1986, AM J HUM GENET, V39, P537
   Hayasaka S, 2003, J EPIDEMIOL, V13, P246, DOI 10.2188/jea.13.246
   Hokosaki T, 2012, PEDIATR INT, V54, P99, DOI 10.1111/j.1442-200X.2011.03487.x
   Holman Robert C, 2010, Hawaii Med J, V69, P194
   Huang SM, 2008, CIRC J, V72, P1583, DOI 10.1253/circj.CJ-08-0121
   Inoue Y, 2006, J PEDIATR-US, V149, P336, DOI 10.1016/j.jpeds.2006.05.025
   Jaggi P, 2013, CLIN INFECT DIS, V56, P58, DOI 10.1093/cid/cis807
   Jorquera H, 2015, ENVIRON INT, V78, P32, DOI 10.1016/j.envint.2015.02.007
   Kato H, 1996, CIRCULATION, V94, P1379, DOI 10.1161/01.CIR.94.6.1379
   Kavey REW, 2006, CIRCULATION, V114, P2710, DOI 10.1161/CIRCULATIONAHA.106.179568
   Kil HR, 2017, PEDIATR RHEUMATOL, V15, DOI 10.1186/s12969-017-0192-y
   Kimura M, 2017, PEDIATR INT, V59, P397, DOI 10.1111/ped.13190
   Kobayashi T, 2012, LANCET, V379, P1613, DOI 10.1016/S0140-6736(11)61930-2
   Kone-Paut I, 2018, AUTOIMMUN REV, V17, P768, DOI 10.1016/j.autrev.2018.01.024
   Kottek A, 2011, PEDIATR INFECT DIS J, V30, P1114, DOI 10.1097/INF.0b013e31822ac4ff
   Kwon H, 2016, EUR J PEDIATR, V175, P1997, DOI 10.1007/s00431-016-2798-3
   L'Huillier AG, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00524
   Lee TJ, 2008, YONSEI MED J, V49, P714, DOI 10.3349/ymj.2008.49.5.714
   LEUNG DYM, 1986, J EXP MED, V164, P1958, DOI 10.1084/jem.164.6.1958
   Li X, 2018, EUR J PEDIATR, V177, P1279, DOI 10.1007/s00431-018-3182-2
   Lin KH, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006703
   Lindquist ME, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081834
   Maddox RA, 2015, CIRCULATION S2, V131
   Maddox RA, 2015, PEDIATR INT, V57, P1116, DOI 10.1111/ped.12733
   Makino N, 2019, PEDIATR INT, V61, P397, DOI 10.1111/ped.13809
   Makino N, 2015, J EPIDEMIOL, V25, P239, DOI 10.2188/jea.JE20140089
   McCrindle BW, 2017, CIRCULATION, V135, pE927, DOI 10.1161/CIR.0000000000000484
   Mori Masaaki, 2004, Mod Rheumatol, V14, P361, DOI 10.1007/s10165-004-0324-3
   Newburger JW, 2007, NEW ENGL J MED, V356, P663, DOI 10.1056/NEJMoa061235
   Newburger JW, 2004, PEDIATRICS, V114, P1708, DOI 10.1542/peds.2004-2182
   NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601
   Nozawa T, 2017, NEW ENGL J MED, V377, P1894, DOI 10.1056/NEJMc1709609
   Okada S, 2016, PEDIATR INT, V58, P295, DOI 10.1111/ped.12778
   Onouchi Y, 2008, NAT GENET, V40, P35, DOI 10.1038/ng.2007.59
   Onouchi Y, 2012, CIRC J, V76, P1581, DOI 10.1253/circj.CJ-12-0568
   Onouchi Y, 2012, NAT GENET, V44, P517, DOI 10.1038/ng.2220
   Onouchi Y, 2010, HUM MOL GENET, V19, P2898, DOI 10.1093/hmg/ddq176
   Portman MA, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-3675
   Riphagen S, 2020, LANCET, P31094, DOI [10.1016/S0140-6736, DOI 10.1016/S0140-6736(20)31094]
   Rodo X, 2014, P NATL ACAD SCI USA, V111, P7952, DOI 10.1073/pnas.1400380111
   Rodo X, 2011, SCI REP-UK, V1, DOI 10.1038/srep00152
   Rowley AH, 2000, J INFECT DIS, V182, P1183, DOI 10.1086/315832
   Rowley AH, 1997, J IMMUNOL, V159, P5946
   Royal College of Paediatrics and Child Health Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19, 2020, NEWL DESCR KAW LIK D
   Sauvaget E, 2012, J PEDIATR-US, V160, P875, DOI 10.1016/j.jpeds.2012.01.018
   Shafferman A, 2014, PEDIATR RHEUMATOL, V12, DOI 10.1186/1546-0096-12-26
   Shike H, 2009, PEDIATR INFECT DIS J, V28, P440, DOI 10.1097/INF.0b013e318193ec8e
   Son MB, 2011, J PEDIATR-US, V158, P644, DOI 10.1016/j.jpeds.2010.10.012
   Sundel RP, 2003, J PEDIATR-US, V142, P611, DOI 10.1067/mpd.2003.191
   Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0
   Toubina J, 2020, OUTBREAK KAWASAKI DI, DOI [10.1101/2020.05.10.20097394., DOI 10.1101/2020.05.10.20097394, 10.1101/2020.05.10.20097394]
   Tremoulet AH, 2019, J PEDIATR-US, V215, P107, DOI 10.1016/j.jpeds.2019.07.064
   Tremoulet AH, 2014, LANCET, V383, P1731, DOI 10.1016/S0140-6736(13)62298-9
   Tremoulet AH, 2012, J PEDIATR-US, V161, P506, DOI 10.1016/j.jpeds.2012.02.048
   Tremoulet AH, 2011, PEDIATR INFECT DIS J, V30, P1022, DOI 10.1097/INF.0b013e31822d4f56
   Uehara R, 2004, ARCH PEDIAT ADOL MED, V158, P1166, DOI 10.1001/archpedi.158.12.1166
   Uehara R, 2003, ACTA PAEDIATR, V92, P694, DOI 10.1080/08035320310002768
   Uehara R, 2012, J EPIDEMIOL, V22, P79, DOI 10.2188/jea.JE20110131
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Wardle AJ, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011188.pub2
   Wu MH, 2012, CIRC-CARDIOVASC QUAL, V5, P566, DOI 10.1161/CIRCOUTCOMES.112.965194
   Yanagawa H, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.6.e65
   Yi LY, 2020, J INTERF CYTOK RES, V40, P159, DOI 10.1089/jir.2019.0141
   Zheng XL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217274
NR 90
TC 0
Z9 0
U1 9
U2 9
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1523-3774
EI 1534-6307
J9 CURR RHEUMATOL REP
JI Curr. Rheumatol. Rep.
PD SEP 13
PY 2020
VL 22
IS 10
AR 75
DI 10.1007/s11926-020-00941-4
PG 10
WC Rheumatology
SC Rheumatology
GA NN2WZ
UT WOS:000568655000001
PM 32924089
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Gerotziafas, GT
   Catalano, M
   Colgan, MP
   Pecsvarady, Z
   Wautrecht, JC
   Fazeli, B
   Olinic, DM
   Farkas, K
   Elalamy, I
   Falanga, A
   Fareed, J
   Papageorgiou, C
   Arellano, RS
   Agathagelou, P
   Antic, D
   Auad, L
   Banfic, L
   Bartolomew, JR
   Benczur, B
   Bernardo, MB
   Boccardo, F
   Cifkova, R
   Cosmi, B
   De Marchi, S
   Dimakakos, E
   Dimopoulos, MA
   Dimitrov, G
   Durand-Zaleski, I
   Edmonds, M
   El Nazar, EA
   Erer, D
   Esponda, OL
   Gresele, P
   Gschwandtner, M
   Gu, YQ
   Heinzmann, M
   Hamburg, NM
   Hamade, A
   Jatoi, NA
   Karahan, O
   Karetova, D
   Karplus, T
   Klein-Weigel, P
   Kolossvary, E
   Kozak, M
   Lefkou, E
   Lessiani, G
   Liew, A
   Marcoccia, A
   Marshang, P
   Marakomichelakis, G
   Matuska, J
   Moraglia, L
   Pillon, S
   Poredos, P
   Prior, M
   Salvador, DRK
   Schlager, O
   Schernthaner, G
   Sieron, A
   Spaak, J
   Spyropoulos, A
   Sprynger, M
   Suput, D
   Stanek, A
   Stvrtinova, V
   Szuba, A
   Tafur, A
   Vandreden, P
   Vardas, PE
   Vasic, D
   Vikkula, M
   Wennberg, P
   Zhai, ZG
AF Gerotziafas, Grigoris T.
   Catalano, Mariella
   Colgan, Mary-Paula
   Pecsvarady, Zsolt
   Wautrecht, Jean Claude
   Fazeli, Bahare
   Olinic, Dan-Mircea
   Farkas, Katalin
   Elalamy, Ismail
   Falanga, Anna
   Fareed, Jawed
   Papageorgiou, Chryssa
   Arellano, Rosella S.
   Agathagelou, Petros
   Antic, Darco
   Auad, Luciana
   Banfic, Ljiljana
   Bartolomew, John R.
   Benczur, Bela
   Bernardo, Melissa B.
   Boccardo, Francesco
   Cifkova, Renate
   Cosmi, Benilde
   De Marchi, Sergio
   Dimakakos, Evangelos
   Dimopoulos, Meletios A.
   Dimitrov, Gabriel
   Durand-Zaleski, Isabelle
   Edmonds, Michael
   El Nazar, Essam Abo
   Erer, Dilek
   Esponda, Omar L.
   Gresele, Paolo
   Gschwandtner, Michael
   Gu, Yongquan
   Heinzmann, Monica
   Hamburg, Naomi M.
   Hamade, Amer
   Jatoi, Noor-Ahmed
   Karahan, Oguz
   Karetova, Debora
   Karplus, Thomas
   Klein-Weigel, Peter
   Kolossvary, Endre
   Kozak, Matija
   Lefkou, Eleftheria
   Lessiani, Gianfranco
   Liew, Aaron
   Marcoccia, Antonella
   Marshang, Peter
   Marakomichelakis, George
   Matuska, Jiri
   Moraglia, Luc
   Pillon, Sergio
   Poredos, Pavel
   Prior, Manlio
   Salvador, David Raymund K.
   Schlager, Oliver
   Schernthaner, Gerit
   Sieron, Alexander
   Spaak, Jonas
   Spyropoulos, Alex
   Sprynger, Muriel
   Suput, Dusan
   Stanek, Agata
   Stvrtinova, Viera
   Szuba, Andrzej
   Tafur, Alfonso
   Vandreden, Patrick
   Vardas, Panagiotis E.
   Vasic, Dragan
   Vikkula, Miikka
   Wennberg, Paul
   Zhai, Zhenguo
CA Scientific Reviewer Comm
TI Guidance for the Management of Patients with Vascular Disease or
   Cardiovascular Risk Factors and COVID-19: Position Paper from
   VAS-European Independent Foundation in Angiology/Vascular Medicine
SO THROMBOSIS AND HAEMOSTASIS
LA English
DT Article; Early Access
DE COVID-19; cardiovascular disease; peripheral artery disease; deep vein
   thrombosis; antithrombotic; antiplatelets; anticoagulants;
   low-molecular-weight heparin; DOAC
ID MOLECULAR-WEIGHT HEPARINS; VENOUS THROMBOEMBOLISM PROPHYLAXIS;
   ENDOTHELIAL-CELL DYSFUNCTION; FACTOR XA; SARS CORONAVIRUS; THROMBOSIS;
   PREVENTION; EFFICACY; PLACEBO; THROMBOPROPHYLAXIS
AB COVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation, microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing risk factors to severe COVID-19 are male sex, underlying cardiovascular disease, or cardiovascular risk factors including noncontrolled diabetes mellitus or arterial hypertension, obesity, and advanced age. The VAS-European Independent Foundation in Angiology/Vascular Medicine draws attention to patients with vascular disease (VD) and presents an integral strategy for the management of patients with VD or cardiovascular risk factors (VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary health care network for patients with VD-CVR for identification of patients with VD-CVR in the community and patients' education for disease symptoms, use of eHealth technology, adherence to the antithrombotic and vascular regulating treatments, and (2) close medical follow-up for efficacious control of VD progression and prompt application of physical and social distancing measures in case of new epidemic waves. For patients with VD-CVR who receive home treatment for COVID-19, VAS recommends assessment for (1) disease worsening risk and prioritized hospitalization of those at high risk and (2) VTE risk assessment and thromboprophylaxis with rivaroxaban, betrixaban, or low-molecular-weight heparin (LMWH) for those at high risk. For hospitalized patients with VD-CVR and COVID-19, VAS recommends (1) routine thromboprophylaxis with weight-adjusted intermediate doses of LMWH (unless contraindication); (2) LMWH as the drug of choice over unfractionated heparin or direct oral anticoagulants for the treatment of VTE or hypercoagulability; (3) careful evaluation of the risk for disease worsening and prompt application of targeted antiviral or convalescence treatments; (4) monitoring of D-dimer for optimization of the antithrombotic treatment; and (5) evaluation of the risk of VTE before hospital discharge using the IMPROVE-D-dimer score and prolonged post-discharge thromboprophylaxis with rivaroxaban, betrixaban, or LMWH.
C1 [Gerotziafas, Grigoris T.; Elalamy, Ismail] Sorbonne Univ, Hop Univ Est Parisien, Hop Tenon, AP HP,Fac Med,Hematol & Thrombosis Ctr, Paris, France.
   [Gerotziafas, Grigoris T.; Elalamy, Ismail; Vandreden, Patrick] Sorbonne Univ, Ctr Rech St Antoine, Inst Univ Cancerol,U938,Fac Med, Res Grp Canc,Haemostasis & Angiogenesis,INSERM, Paris, France.
   [Catalano, Mariella; Dimitrov, Gabriel] Univ Milan, L Sacco Hosp, Res Ctr Vasc Dis, Milan, Italy.
   [Catalano, Mariella; Dimitrov, Gabriel] Univ Milan, L Sacco Hosp, Angiol Unit, Dept Biomed Sci, Milan, Italy.
   [Colgan, Mary-Paula] Trinity Coll Dublin, St Jamess Hosp, Dept Vasc Surg, Dublin, Ireland.
   [Pecsvarady, Zsolt] Flor Ferenc Teaching Hosp, Dept Vasc Med, Kistarcsa, Hungary.
   [Wautrecht, Jean Claude] Univ Libre Bruxelle, Hop ERASME, Serv Pathol Vasc, Brussels, Belgium.
   [Fazeli, Bahare] Mashhad Univ Med Sci, Avicenna BuAli Res Inst, Dept Immunol, Mashhad, Razavi Khorasan, Iran.
   [Olinic, Dan-Mircea] Univ Med & Pharm, Med Clin 1, Cluj Napoca, Romania.
   [Farkas, Katalin; Kolossvary, Endre] St Imre Univ Teaching Hosp, Dept Angiol, Budapest, Hungary.
   [Elalamy, Ismail] Sechenov Univ, IM Sechenov First Moscow State Med Univ, Dept Obstet & Gynecol, Moscow, Russia.
   [Falanga, Anna] Hosp Papa Giovanni XXIII, Dept Immunohematol & Transfus Med, Bergamo, Italy.
   [Falanga, Anna] Hosp Papa Giovanni XXIII, Ctr Thrombosis & Hemostasis, Bergamo, Italy.
   [Fareed, Jawed] Loyola Univ Med Ctr, Dept Pathol, Maywood, IL 60153 USA.
   [Papageorgiou, Chryssa] Sorbonne Univ, Hop Univ Est Parisien, Serv Anesthesie Reanimat & Med Perioperatoire, Hop Tenon,AP HP,Fac Med, Paris, France.
   [Arellano, Rosella S.; Bernardo, Melissa B.; Salvador, David Raymund K.] Philippine Soc Vasc Med, Manila, Philippines.
   [Agathagelou, Petros] Amer Heart Inst Cyprus, Dept Inrtervent Cardiol, Nicosia, Cyprus.
   [Antic, Darco] Univ Belgrade, Clin Ctr Serbia, Fac Med, Clin Hematol, Belgrade, Serbia.
   [Auad, Luciana; Heinzmann, Monica] Univ Catolica Cordoba, Sanatorio Allende Cordoba, Ciencias Med, Med Vasc, Cordoba, Argentina.
   [Banfic, Ljiljana] Univ Zagreb, Sch Med, Univ Hosp Ctr, Zagreb, Croatia.
   [Bartolomew, John R.] Cleveland Clin, Cleveland, OH 44106 USA.
   [Benczur, Bela] Balassa Janos Cty Hosp, Univ Med Sch, Szeged, Hungary.
   [Boccardo, Francesco] Univ Genoa, S Martino Hosp, Dept Cardiothoracvasc & Endovasc Surg, Unit Lymphat Surg,IRCCS, Genoa, Italy.
   [Cifkova, Renate] Thomayer Teaching Hosp, Dept Prevent Cardiol, Prague, Czech Republic.
   [Cosmi, Benilde] Univ Bologna, S Orsola Malpighi Univ Hosp, Dept Specialty Diagnost & Expt Med, Angiol & Blood Coagulat, Bologna, Italy.
   [De Marchi, Sergio] Verona Univ Hosp, Angiol Unit, Cardiovasc & Thorac & Med Dept, Verona, Italy.
   [Dimakakos, Evangelos] Natl & Kapodistrian Univ Athens, Sotiria Hosp, Dept Internal Med 3, Vasc Unit, Athens, Greece.
   [Dimopoulos, Meletios A.] Hellen Soc Hematol, Athens, Greece.
   [Dimopoulos, Meletios A.] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece.
   [Durand-Zaleski, Isabelle] Univ Paris, Hop Hotel Dieu, AP HP, CRESS,INSERM,INRA,URCEco, Paris, France.
   [Edmonds, Michael] Kings Coll Hosp London, Diabet Foot Clin, London, England.
   [El Nazar, Essam Abo] Minist Hlth, Dept Surg, Riyadh, Saudi Arabia.
   [Erer, Dilek] Gazi Univ, Fac Med, Dept Cardiovasc Surg, Besevler, Turkey.
   [Esponda, Omar L.] Hosp Perea, Dept Internal Med, Mayaguez, PR USA.
   [Gresele, Paolo] Univ Perugia, Dept Med, Sect Internal & Cardiovasc Med, Perugia, Italy.
   [Gschwandtner, Michael] Med Univ Wien, Univ Klin Innere Med 2, Vienna, Austria.
   [Gu, Yongquan] Capital Med Univ, Xuanwu Hosp, Dept Vasc Surg, Beijing, Peoples R China.
   [Hamburg, Naomi M.] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Dept Med, Boston, MA 02118 USA.
   [Hamade, Amer] Imam Abdulrahman Bin Faisal Univ, King Fahad Univ Hosp, Dept Internal Med, Vasc Med Unit, Dammam, Saudi Arabia.
   [Jatoi, Noor-Ahmed] Mulhouse Hosp Ctr, Dept Vasc Med, Mulhouse, France.
   [Karahan, Oguz] Alaaddin Keykubat Univ, Sch Med, Dept Cardiovasc Surg, Alanya, Turkey.
   [Karetova, Debora] Charles Univ Prague, Dept Cardiovasc Med, Dept Med 2, Prague, Czech Republic.
   [Karplus, Thomas] Concord Repatriat Gen Hosp, Dept Vasc Med, Sydney, NSW, Australia.
   [Klein-Weigel, Peter] Ernst von Bergmann Klinikum, Zentrum Innere Med 2, Klin Angiol, Potsdam, Germany.
   [Kozak, Matija] Univ Med Ctr Ljubljana, Med Fac Ljubljana, Dept Vasc Dis, Ljubljana, Slovenia.
   [Lefkou, Eleftheria] Inst Study & Educ Thrombosis & Antithrombot Thera, Athens, Greece.
   [Lessiani, Gianfranco] Citta St Angelo Hosp, AUSL 03, Dept Internal Med, Angiol Unit, Pescara, Italy.
   [Liew, Aaron] Natl Univ Ireland Galway NUIG, Soalta Univ Hlth Care Grp, Portiuncula Univ Hosp, Galway, Ireland.
   [Marcoccia, Antonella] CRIIS Ctr Riferimento Interdisciplinare Sclerosi, Unita Med Vasc & Autoimmunita, Rome, Italy.
   [Marshang, Peter] Cent Hosp Bolzano, Dept Internal Med, Bolzano, Italy.
   [Marakomichelakis, George] Evangelismos Gen Hosp, Angiol Unit, Athens, Greece.
   [Matuska, Jiri] Private Angiol Facil, MATMED Sro, Hodonin, Czech Republic.
   [Moraglia, Luc] Med Vasc Travail, Angiol Ctr Cours Medoc, Bordeaux, France.
   [Pillon, Sergio] Natl Hlth Inst ISS, San Camillo Forlanini Hosp, UOSD Angiol, Rome, Italy.
   [Poredos, Pavel] Slovenian Med Acad, Slovenia Acad Res Ctr, Med Assoc Slovenia & SMA, Ljubljana, Slovenia.
   [Prior, Manlio] Azienda Osped Univ Integrata Verona, Angiol Unit, Verona, Italy.
   [Schlager, Oliver; Schernthaner, Gerit] Med Univ Vienna, Dept Internal Med 2, Div Angiol, Vienna, Austria.
   [Sieron, Alexander] Med Univ Silesia, Dept Internal Med Angiol & Phys Med, Katowice, Poland.
   [Sieron, Alexander] Jan Dlugosz Univ, Specialist Hosp, Czestochowa, Poland.
   [Spaak, Jonas] Karolinska Inst, Danderyd Hosp, Div Cardiovasc Med, Dept Clin Sci, Stockholm, Sweden.
   [Spyropoulos, Alex] Feinstein Inst Med Res, Donald & Barbara Zucker Sch Med Hofstra Northwell, Northwell Hlth Lenox Hill Hosp, Dept Med Anticoagulat & Clin Thrombosis Serv, New York, NY USA.
   [Sprynger, Muriel] Univ Hosp Sart Tilman, Dept Cardiol, Liege, Belgium.
   [Suput, Dusan] Univ Ljubljana, Fac Med, Ctr Clin Physiol, Ljubljana, Slovenia.
   [Stanek, Agata] Med Univ Silesia, Fac Med Sci Zabrze, Dept Internal Med Angiol & Phys Med, Bytom, Poland.
   [Stvrtinova, Viera] Comenius Univ, Fac Med, Bratislava, Slovakia.
   [Szuba, Andrzej] Wroclaw Med Univ, Dept Angiol Hypertens & Diabetol, Wroclaw, Poland.
   [Tafur, Alfonso] US Army, Vasc Med Univ Chicago, Northshore Cardiovasc Inst, Skokie, IL USA.
   [Vardas, Panagiotis E.] Univ Crete, Med Sch Crete, Athens, Greece.
   [Vardas, Panagiotis E.] Hellen Healthcare Grp, Heart Sect, Athens, Greece.
   [Vasic, Dragan] Clin Ctr Serbia, Clin Vasc & Endovasc Surg, Dept Noninvas Vasc Lab, Belgrade, Serbia.
   [Vikkula, Miikka] Univ Louvain, de Duve Inst, Human Mol Genet, Brussels, Belgium.
   [Wennberg, Paul] Mayo Clin, Gonda Vasc Ctr, Dept Cardiovasc Med, Rochester, MN USA.
   [Zhai, Zhenguo] Capital Med Univ, Peking Univ Hlth Sci Ctr, China Japan Friendship Hosp, Dept Pulm & Crit Care Med,Ctr Resp Med, Beijing, Peoples R China.
   [Zhai, Zhenguo] Chinese Acad Med Sci, Inst Resp Med, Beijing, Peoples R China.
RP Gerotziafas, GT (corresponding author), Hop St Antoine, VAS European Independent Fdn Angiol Vasc Med, INSERM U938, VAS Board, Batiment Kourilsky,34 Rue Crozatier, F-75012 Paris, France.
EM grigorios.gerotziafas@inserm.fr
RI Karahan, Oguz/ABH-5155-2020; sprynger, muriel/ABB-2766-2020; Stanek,
   Agata/N-8179-2017; CATALANO, MARIA/F-2708-2017
OI Karahan, Oguz/0000-0003-0044-9476; Stanek, Agata/0000-0001-6939-9898;
   Marschang, Peter/0000-0002-8239-3447; CATALANO,
   MARIA/0000-0002-8355-0344
CR Abdulai I, 2020, AGR SYST, V181, DOI 10.1016/j.agsy.2020.102812
   Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Aimes RT, 2003, THROMB HAEMOSTASIS, V89, P561
   Al-Ani F, 2020, THROMB RES, V192, P152, DOI 10.1016/j.thromres.2020.05.039
   Al-Samkari H, 2020, BLOOD, V136, P489, DOI 10.1182/blood.2020006520
   Alramthan A, 2020, CLIN EXP DERMATOL, V45, P746, DOI 10.1111/ced.14243
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Artifoni M, 2020, J THROMB THROMBOLYS, V50, P211, DOI 10.1007/s11239-020-02146-z
   Atiq F, 2015, EUR J CLIN PHARMACOL, V71, P921, DOI 10.1007/s00228-015-1880-5
   Auld SC, 2020, CRIT CARE MED, V48, pE799, DOI 10.1097/CCM.0000000000004457
   Ayerbe L, 2020, J THROMB THROMBOLYS, V50, P298, DOI 10.1007/s11239-020-02162-z
   Bae YS, 2020, J MED INTERNET RES, V22, DOI 10.2196/19938
   Baker CJ, 2019, RES PRACT THROMB HAE, V3, P18, DOI 10.1002/rth2.12162
   Bangash MN, 2020, LANCET GASTROENTEROL, V5, P529, DOI 10.1016/S2468-1253(20)30084-4
   Barnes GD, 2020, J THROMB THROMBOLYS, V50, P72, DOI 10.1007/s11239-020-02138-z
   Barrett CD, 2020, J TRAUMA ACUTE CARE, V89, P453, DOI 10.1097/TA.0000000000002786
   Bellosta Raffaello, 2020, J Vasc Surg, V72, P1864, DOI 10.1016/j.jvs.2020.04.483
   Beun R, 2020, INT J LAB HEMATOL, V42, P19, DOI 10.1111/ijlh.13230
   Biembengut IV, 2020, MEM I OSWALDO CRUZ, V115, DOI 10.1590/0074-02760200179
   Bikdeli B, 2020, THROMB HAEMOSTASIS, V120, P1004, DOI 10.1055/s-0040-1713152
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Calabrese F, 2020, VIRCHOWS ARCH, V477, P359, DOI 10.1007/s00428-020-02886-6
   Cantador E, 2020, J THROMB THROMBOLYS, V50, P543, DOI 10.1007/s11239-020-02176-7
   Cao XL, 2020, AM J PHYSIOL-ENDOC M, V319, pE197, DOI 10.1152/ajpendo.00255.2020
   Carsana L, 2020, LANCET INFECT DIS, V20, P1135, DOI 10.1016/S1473-3099(20)30434-5
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Christie DB, 2020, J TRAUMA ACUTE CARE, V89, P448, DOI 10.1097/TA.0000000000002787
   Cohen AT, 2016, NEW ENGL J MED, V375, P534, DOI 10.1056/NEJMoa1601747
   Cohen AT, 2013, NEW ENGL J MED, V368, P513, DOI 10.1056/NEJMoa1111096
   Cohen AT, 2006, BMJ-BRIT MED J, V332, P325, DOI 10.1136/bmj.38733.466748.7C
   Cohen G., 2007, Archives of Physiology and Biochemistry, V113, P259, DOI 10.1080/13813450701783513
   Cohoon KP, 2018, J THROMB HAEMOST, V16, P1278, DOI 10.1111/jth.14146
   Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819
   Colmenero I, 2020, BRIT J DERMATOL, V183, P729, DOI 10.1111/bjd.19327
   Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000
   Cromwell William C, 2004, Curr Atheroscler Rep, V6, P381, DOI 10.1007/s11883-004-0050-5
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254
   Darien BJ, 1998, SHOCK, V9, P274, DOI 10.1097/00024382-199804000-00007
   de Vries AAF, 2020, NETH HEART J, V28, P396, DOI 10.1007/s12471-020-01439-5
   Deng Y, 2020, CHINESE MED J-PEKING, V133, P1261, DOI 10.1097/CM9.0000000000000824
   Di Castelnuovo A, 2014, THROMB HAEMOSTASIS, V112, P941, DOI 10.1160/TH14-04-0297
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Du LY, 2007, BIOCHEM BIOPH RES CO, V359, P174, DOI 10.1016/j.bbrc.2007.05.092
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Duarte-Neto AN, 2020, HISTOPATHOLOGY, V77, P186, DOI 10.1111/his.14160
   Edler C, 2020, INT J LEGAL MED, V134, P1275, DOI 10.1007/s00414-020-02317-w
   Eleftheriou P, 2020, MOLECULES, V25, DOI 10.3390/molecules25112529
   Estebanez A, 2020, J EUR ACAD DERMATOL, V34, pE250, DOI 10.1111/jdv.16474
   Fareed J, 2000, SEMIN THROMB HEMOST, V26, P5, DOI 10.1055/s-2000-9498
   Fareed J, 2008, CLIN APPL THROMB-HEM, V14, P385, DOI 10.1177/1076029608319881
   Felice C, 2020, AM J HYPERTENS, V33, P944, DOI 10.1093/ajh/hpaa096
   Fogarty H, 2020, BRIT J HAEMATOL, V189, P1060, DOI 10.1111/bjh.16791
   Fogarty H, 2020, BRIT J HAEMATOL, V189, P1044, DOI 10.1111/bjh.16749
   Fox SE, 2020, LANCET RESP MED, V8, P681, DOI 10.1016/S2213-2600(20)30243-5
   Fried JA, 2020, CIRCULATION, V141, P1930, DOI 10.1161/CIRCULATIONAHA.120.047164
   Galeano-Valle F, 2020, THROMB RES, V192, P113, DOI 10.1016/j.thromres.2020.05.017
   Gerotziafas GT, 2007, J THROMB HAEMOST, V5, P955, DOI 10.1111/j.1538-7836.2007.02477.x
   Gerotziafas GT, 2020, THROMB HAEMOSTASIS, DOI 10.1055/s-0040-1716544
   Gerotziafas GT, 2018, THROMB RES, V164, pS62, DOI 10.1016/j.thromres.2018.02.004
   Gimbrone MA, 2016, CIRC RES, V118, P620, DOI 10.1161/CIRCRESAHA.115.306301
   Glatthaar-Saalmuller B, 2017, INFLUENZA OTHER RESP, V11, P85, DOI 10.1111/irv.12421
   Grillet F, 2020, RADIOLOGY, V296, pE186, DOI 10.1148/radiol.2020201544
   Gris JC, 2020, J THROMB HAEMOST, V18, P2066, DOI 10.1111/jth.14876
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Harenberg J, 2020, CLIN CHEM LAB MED, V58, P1029, DOI 10.1515/cclm-2020-0502
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Henry D, 2020, J EUR ACAD DERMATOL, V34, pE244, DOI 10.1111/jdv.16472
   Hohlfelder Benjamin, 2019, Am J Ther, DOI 10.1097/MJT.0000000000001113
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hull RD, 2010, ANN INTERN MED, V153, P8, DOI 10.7326/0003-4819-153-1-201007060-00004
   Iba T, 2020, CRIT CARE MED, V48, P1358, DOI 10.1097/CCM.0000000000004458
   Itkonen MK, 2019, CLIN PHARMACOL THER, V105, P219, DOI 10.1002/cpt.1099
   Jin WZ, 2020, RESP CARE, V65, P1039, DOI 10.4187/respcare.07177
   Kahn SR, 2012, CHEST, V141, pE195S, DOI 10.1378/chest.11-2296
   Khera Rohan, 2020, medRxiv, DOI 10.1101/2020.05.17.20104943
   Khider L, 2020, J THROMB HAEMOST, V18, P2391, DOI 10.1111/jth.14968
   Khurshid S, 2018, CIRC-ARRHYTHMIA ELEC, V11, DOI 10.1161/CIRCEP.118.006273
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Kolivras Athanassios, 2020, JAAD Case Rep, V6, P489, DOI 10.1016/j.jdcr.2020.04.011
   Kollias A, 2020, BRIT J HAEMATOL, V189, P846, DOI 10.1111/bjh.16727
   Krupinski J, 2007, INT J CARDIOL, V116, P174, DOI 10.1016/j.ijcard.2006.02.014
   Lang M, 2020, LANCET INFECT DIS
   Langer F, 2020, HAMOSTASEOLOGIE, V40, P264, DOI 10.1055/a-1178-3551
   Laskier V, 2019, J MED ECON, V22, P1063, DOI 10.1080/13696998.2019.1645679
   Lee KCH, 2020, INT J INFECT DIS, V96, P615, DOI 10.1016/j.ijid.2020.05.115
   Leizorovicz A, 2004, CIRCULATION, V110, P874, DOI 10.1161/01.CIR.0000138928.83266.24
   Leonard-Lorant I, 2020, RADIOLOGY, V296, pE189, DOI 10.1148/radiol.2020201561
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Levy JH, 2016, THROMB HAEMOSTASIS, V115, P712, DOI 10.1160/TH15-08-0687
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Liu J, 2020, RES PRACT THROMB HAE, V4, P518, DOI 10.1002/rth2.12353
   Liu XQ, 2020, ANN HEMATOL, V99, P1421, DOI 10.1007/s00277-020-04103-5
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Long B, 2020, AM J EMERG MED, V38, P1504, DOI 10.1016/j.ajem.2020.04.048
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Maas C, 2018, BLOOD, V131, P1903, DOI 10.1182/blood-2017-04-569111
   Maglakelidze N, 2020, PULM THER, DOI [10.1007/s41030-020-00118-5, DOI 10.1007/S41030-020-00118-5]
   Mahe A, 2020, J EUR ACAD DERMATOL, V34, pE246, DOI 10.1111/jdv.16471
   Manalo IF, 2020, J AM ACAD DERMATOL, V83, pE157, DOI [10.1016/j.jaad.2020.04.018, 10.1016/j.jaad.2020.05.001]
   Manfredi AA, 2017, PHARMACOL RES, V123, P146, DOI 10.1016/j.phrs.2016.08.008
   Marsousi N, 2018, CLIN PHARMACOKINET, V57, P1347, DOI 10.1007/s40262-018-0637-6
   McLaughlin K, 2019, CLIN APPL THROMB-HEM, V25, DOI 10.1177/1076029619876030
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Menter T, 2020, HISTOPATHOLOGY, V77, P198, DOI 10.1111/his.14134
   Mezger M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01731
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Milos Scott, 2016, Biochem Biophys Rep, V7, P180, DOI 10.1016/j.bbrep.2016.06.009
   Moores LK, 2020, CHEST, V158, P1143, DOI 10.1016/j.chest.2020.05.559
   Mousa S A, 2005, CHEM BIOL HEPARIN HE, P571
   Mulloy B, 2016, PHARMACOL REV, V68, P76, DOI 10.1124/pr.115.011247
   Nyssen A, 2020, VASA, V49, P133, DOI 10.1024/0301-1526/a000838
   Olie RH, 2017, NEPHRON, V137, P113, DOI 10.1159/000477474
   Olinic DM, 2018, INT ANGIOL, V37, P327, DOI 10.23736/S0392-9590.18.03996-2
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Papageorgiou C, 2018, CLIN APPL THROMB-HEM, V24, p8S, DOI 10.1177/1076029618806424
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Partridge L. J., 2020, UNFRACTIONATED HEPAR, P1, DOI [10.1101/2020.05.21.107870, DOI 10.1101/2020.05.21.107870, 10. 1101/2020.05.21.107870.]
   Perini P, 2020, LANCET, V395, P1546, DOI 10.1016/S0140-6736(20)31051-5
   Pirillo A, 2018, CURR ATHEROSCLER REP, V20, DOI 10.1007/s11883-018-0715-0
   Pons S, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03062-7
   Projean D, 2019, THROMB RES, V174, P48, DOI 10.1016/j.thromres.2018.11.031
   Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Reiner Z, 2020, ARCH MED SCI, V16, P490, DOI 10.5114/aoms.2020.94655
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Roncon L, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104354
   Rosenberg D, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001152
   Roth GA, 2017, J AM COLL CARDIOL, V70, P1, DOI 10.1016/j.jacc.2017.04.052
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Salta S, 2018, RES PRACT THROMB HAE, V2, P696, DOI 10.1002/rth2.12120
   Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103
   Schunemann HJ, 2018, BLOOD ADV, V2, P3198, DOI 10.1182/bloodadvances.2018022954
   Sharma P, 2020, J AM SOC NEPHROL, V31, P1948, DOI 10.1681/ASN.2020050699
   Song WY, 2020, COMPUT IND ENG, V140, DOI 10.1016/j.cie.2020.106279
   Spyropoulos AC, 2020, J THROMB HAEMOST, V18, P1859, DOI 10.1111/jth.14929
   Spyropoulos Alex C, 2020, TH Open, V4, pe59, DOI 10.1055/s-0040-1705137
   Spyropoulos AC, 2018, NEW ENGL J MED, V379, P1118, DOI 10.1056/NEJMoa1805090
   Spyropoulos AC, 2011, CHEST, V140, P706, DOI 10.1378/chest.10-1944
   Su CJ, 2020, J EUR ACAD DERMATOL, V34, pE251, DOI 10.1111/jdv.16469
   Suchonwanit P, 2020, J AM ACAD DERMATOL, V83, pE57, DOI 10.1016/j.jaad.2020.04.094
   Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Testa S, 2020, J THROMB HAEMOST, V18, P1320, DOI 10.1111/jth.14871
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Thachil J, 2020, J THROMB HAEMOST, V18, P2058, DOI 10.1111/jth.14866
   Ufer M, 2010, THROMB HAEMOSTASIS, V103, P572, DOI 10.1160/TH09-09-0659
   Vaarala MH, 2001, J PATHOL, V193, P134, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH743>3.0.CO;2-T
   van Dam LF, 2020, THROMB RES, V193, P86, DOI 10.1016/j.thromres.2020.06.010
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Viecca M, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104950
   Violi F, 2020, THROMB HAEMOSTASIS, V120, P949, DOI 10.1055/s-0040-1710317
   Wada H, 2013, J THROMB HAEMOST, V11, P2078, DOI 10.1111/jth.12366
   Wan MX, 2001, INFLAMM RES, V50, P581, DOI 10.1007/PL00000237
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang H, 2020, PREPRINT, DOI [10.1101/2020.05.09.086249. Preprint, DOI 10.1101/2020.05.09.086249]
   Wang J, 2020, J THROMB HAEMOST, V18, P1752, DOI 10.1111/jth.14828
   Wang LC, 2002, J CLIN INVEST, V110, P127, DOI 10.1172/JCI200214996
   Wang Y., 2018, J APPL ELECTROCHEM, V22, P1
   Warren BL, 2001, JAMA-J AM MED ASSOC, V286, P1869, DOI 10.1001/jama.286.15.1869
   Watson RA, 2020, HOSP PRACT, V48, P169, DOI 10.1080/21548331.2020.1772639
   White D, 2020, J THROMB THROMBOLYS, V50, P287, DOI 10.1007/s11239-020-02145-0
   WHO, 2020, CLIN MAN SEV AC RESP
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu J H, 2020, Zhonghua Bing Li Xue Za Zhi, V49, P568, DOI 10.3760/cma.j.cn112151-20200405-00291
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Zhai ZG, 2020, THROMB HAEMOSTASIS, V120, P937, DOI 10.1055/s-0040-1710019
   Zhang LT, 2020, J THROMB HAEMOST, V18, P2067, DOI 10.1111/jth.14899
   Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859
   Zhang XQ, 2020, POSTGRAD MED J, V96, P403, DOI 10.1136/postgradmedj-2020-137935
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
   Zierfuss B, 2020, ATHEROSCLEROSIS, V293, P92, DOI 10.1016/j.atherosclerosis.2019.11.006
   Zulfiqar A A, N ENGL J MED, V382, pe43
   Zuo Yu, 2020, medRxiv, DOI 10.1101/2020.04.30.20086736
   Zuo Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138999
   2013, INT ANGIOL, V32, P111
NR 187
TC 2
Z9 2
U1 3
U2 3
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0340-6245
EI 2567-689X
J9 THROMB HAEMOSTASIS
JI Thromb. Haemost.
DI 10.1055/s-0040-1715798
EA SEP 2020
PG 32
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA NN5GZ
UT WOS:000568818300003
PM 32920811
OA Bronze
DA 2021-01-01
ER

PT J
AU Qin, M
   Cao, Z
   Wen, J
   Yu, QS
   Liu, CY
   Wang, F
   Zhang, JN
   Yang, FM
   Li, YY
   Fishbein, G
   Yan, S
   Xu, B
   Hou, Y
   Ning, ZB
   Nie, KL
   Jiang, N
   Liu, Z
   Wu, J
   Yu, YT
   Li, H
   Zheng, HW
   Li, J
   Jin, WH
   Pang, S
   Wang, S
   Chen, JF
   Gan, ZH
   He, ZL
   Lu, YF
AF Qin, Meng
   Cao, Zheng
   Wen, Jing
   Yu, Qingsong
   Liu, Chaoyong
   Wang, Fang
   Zhang, Jianjun
   Yang, Fengmei
   Li, Yanyan
   Fishbein, Gregory
   Yan, Sen
   Xu, Bin
   Hou, Yi
   Ning, Zhenbo
   Nie, Kaili
   Jiang, Ni
   Liu, Zhen
   Wu, Jun
   Yu, Yanting
   Li, Heng
   Zheng, Huiwen
   Li, Jing
   Jin, Weihua
   Pang, Shen
   Wang, Shuai
   Chen, Jianfeng
   Gan, Zhihua
   He, Zhanlong
   Lu, Yunfeng
TI An Antioxidant Enzyme Therapeutic for COVID-19
SO ADVANCED MATERIALS
LA English
DT Article
DE anti-inflammation; catalase; immunosuppression; SARS-Cov-2
ID HYDROGEN-PEROXIDE; OXIDATIVE STRESS
AB The COVID-19 pandemic has taken a significant toll on people worldwide, and there are currently no specific antivirus drugs or vaccines. Herein it is a therapeutic based on catalase, an antioxidant enzyme that can effectively breakdown hydrogen peroxide and minimize the downstream reactive oxygen species, which are excessively produced resulting from the infection and inflammatory process, is reported. Catalase assists to regulate production of cytokines, protect oxidative injury, and repress replication of SARS-CoV-2, as demonstrated in human leukocytes and alveolar epithelial cells, and rhesus macaques, without noticeable toxicity. Such a therapeutic can be readily manufactured at low cost as a potential treatment for COVID-19.
C1 [Qin, Meng; Yu, Qingsong; Liu, Chaoyong; Wang, Fang; Zhang, Jianjun; Hou, Yi; Ning, Zhenbo; Nie, Kaili; Jiang, Ni; Liu, Zhen; Wu, Jun; Yu, Yanting; Chen, Jianfeng; Gan, Zhihua] Beijing Univ Chem Technol, Coll Life Sci & Technol, Beijing Adv Innovat Ctr Soft Matter Sci & Engn, State Key Lab Organicinorgan Composites, Beijing 100029, Peoples R China.
   [Cao, Zheng; Wen, Jing; Fishbein, Gregory; Xu, Bin; Lu, Yunfeng] Univ Calif Los Angeles, Dept Chem & Biomol Engn, Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.
   [Cao, Zheng; Wen, Jing; Fishbein, Gregory; Xu, Bin; Lu, Yunfeng] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   [Yang, Fengmei; Li, Yanyan; Li, Heng; Jin, Weihua; He, Zhanlong] Chinese Acad Med Sci, Peking Union Med Coll, Yunnan Key Lab Vaccine Res Dev Severe Infect Dis, Inst Med Biol, Kunming 650118, Yunnan, Peoples R China.
   [Yan, Sen] Jinan Univ, Guangdong Hongkong Macau Inst CNS Regenerat, Guangzhou 510632, Guangdong, Peoples R China.
   [Pang, Shen; Wang, Shuai] Univ Calif Los Angeles, Vivibaba Inc, 570 Westwood Plaza, Los Angeles, CA 90095 USA.
RP Chen, JF; Gan, ZH (corresponding author), Beijing Univ Chem Technol, Coll Life Sci & Technol, Beijing Adv Innovat Ctr Soft Matter Sci & Engn, State Key Lab Organicinorgan Composites, Beijing 100029, Peoples R China.; Lu, YF (corresponding author), Univ Calif Los Angeles, Dept Chem & Biomol Engn, Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.; Lu, YF (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.; He, ZL (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll, Yunnan Key Lab Vaccine Res Dev Severe Infect Dis, Inst Med Biol, Kunming 650118, Yunnan, Peoples R China.
EM chenjf@mail.buct.edu.cn; zhgan@mail.buct.edu.cn; hzl@imbcams.com.cn;
   luucla@ucla.edu
FU Beijing Science Sun Pharmaceutical Co Ltd
FX M.Q., Z.C., J.W. contributed equally to this work. The authors greatly
   appreciated the help and support from the Beijing Science Sun
   Pharmaceutical Co Ltd, President Dr. Biao Ma, particularly, for the
   assistance in the manufacture of catalase nanocapsules and the in-depth
   discussion during the COVID-19 pandemic. The studies in rhesus macaques
   were conducted in a BSL-3 laboratory in the Institute of Medical
   Biology, Chinese Academy of Medical Sciences (BSL number SWAQ20200404,
   animal protocol number DWSP202001020). The studies with mice were
   conducted at the same Institute (Permit number: SYXK(Dian)K2015-0006).
   The animal protocols were approved by the Institutional Animal Care and
   Use Committee (IACUC) at the Chinese Academy of Medical Sciences and
   Peking Union Medical College. Human leukocytes were separated from whole
   blood provided by the China-Japan Friendship Hospital, Beijing. Human
   pulmonary alveolar epithelial cells (HPAEpiC) were purchased from Bnbio.
CR Amatore D, 2015, CELL MICROBIOL, V17, P131, DOI 10.1111/cmi.12343
   Gong J., 2020, MEDRXIV, DOI [10.1101/2020.02.25.20025643, DOI 10.1101/2020.02.25.20025643]
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Guo KJ, 2014, BONE JOINT J, V96B, P259, DOI 10.1302/0301-620X.96B2.31935
   Hardy RS, 2020, NAT REV RHEUMATOL, V16, P133, DOI 10.1038/s41584-020-0371-y
   Hill GR, 2000, BLOOD, V95, P2754, DOI 10.1182/blood.V95.9.2754.009k25_2754_2759
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8
   Kupferschmidt K, 2020, SCIENCE, DOI [10.1126/science.abd3683, DOI 10.1126/SCIENCE.ABD3683]
   La Rosee F, 2020, LEUKEMIA, V34, P1805, DOI 10.1038/s41375-020-0891-0
   Liang S, 2016, NANO RES, V9, P1022, DOI 10.1007/s12274-016-0991-3
   Liu Q, 2016, CELL MOL IMMUNOL, V13, P3, DOI 10.1038/cmi.2015.74
   Majewska E, 2004, RESP MED, V98, P669, DOI 10.1016/j.rmed.2003.08.015
   Marchesoni A, 2009, ANN NY ACAD SCI, V1173, P837, DOI 10.1111/j.1749-6632.2009.04621.x
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149
   Nathan C, 2013, NAT REV IMMUNOL, V13, P349, DOI 10.1038/nri3423
   Nguyen AA, 2020, CLIN IMMUNOL, V216, DOI 10.1016/j.clim.2020.108459
   Niethammer P, 2009, NATURE, V459, P996, DOI 10.1038/nature08119
   Nishikawa M, 2009, ADV DRUG DELIVER REV, V61, P319, DOI 10.1016/j.addr.2009.01.001
   O'Shea JJ, 2002, NAT REV IMMUNOL, V2, P37, DOI 10.1038/nri702
   Patlevic P, 2016, INTEGR MED RES, V5, P250, DOI 10.1016/j.imr.2016.07.004
   Phaniendra A, 2015, INDIAN J CLIN BIOCHE, V30, P11, DOI 10.1007/s12291-014-0446-0
   Roshanravan Neda, 2020, Arch Med Res, V51, P608, DOI 10.1016/j.arcmed.2020.06.012
   Scavone C, 2020, BRIT J PHARMACOL, V177, P4813, DOI 10.1111/bph.15072
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034
   Sebastiano M, 2016, CURR ZOOL, V62, P325, DOI 10.1093/cz/zow019
   Shi XL, 2013, APPL MICROBIOL BIOT, V97, P10025, DOI 10.1007/s00253-013-4775-3
   Sies H, 2020, NAT REV MOL CELL BIO, DOI 10.1038/s41580-020-0230-3
   Slimen IB, 2014, INT J HYPERTHER, V30, P513, DOI 10.3109/02656736.2014.971446
   Sterner RM, 2019, BLOOD, V133, P697, DOI 10.1182/blood-2018-10-881722
   Tang C, 2020, LANCET, V395, P1759, DOI 10.1016/S0140-6736(20)30749-2
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Vlahos R, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001271
   Wen J, 2019, NAT BIOMED ENG, V3, P706, DOI 10.1038/s41551-019-0434-z
   Wu D, 2019, ADV MATER, V31, DOI 10.1002/adma.201807557
   Xu D, 2019, ADV MATER, V31, DOI 10.1002/adma.201900727
   Yan M, 2010, NAT NANOTECHNOL, V5, P48, DOI [10.1038/NNANO.2009.341, 10.1038/nnano.2009.341]
NR 40
TC 1
Z9 1
U1 26
U2 26
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0935-9648
EI 1521-4095
J9 ADV MATER
JI Adv. Mater.
PD OCT 27
PY 2020
VL 32
IS 43
AR 2004901
DI 10.1002/adma.202004901
EA SEP 2020
PG 9
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA OK9AV
UT WOS:000568725100001
PM 32924219
OA Bronze
DA 2021-01-01
ER

PT J
AU Sano, T
   Kimizuka, Y
   Fujikura, Y
   Hisada, T
   Watanabe, C
   Suematsu, R
   Izumi, K
   Sugiura, H
   Miyata, J
   Shinmoto, H
   Nagata, M
   Kawana, A
AF Sano, Tomoya
   Kimizuka, Yoshifumi
   Fujikura, Yuji
   Hisada, Tetsuya
   Watanabe, Chie
   Suematsu, Ryohei
   Izumi, Kaori
   Sugiura, Hiroaki
   Miyata, Jun
   Shinmoto, Hiroshi
   Nagata, Masayoshi
   Kawana, Akihiko
TI COVID-19 in older adults: Retrospective cohort study in a tertiary
   hospital in Japan
SO GERIATRICS & GERONTOLOGY INTERNATIONAL
LA English
DT Article
DE anticoagulation therapy; ciclesonide; COVID-19; favipiravir; nafamostat
ID PNEUMONIA
AB Aim We aimed to describe the clinical characteristics, treatment and outcomes of patients with COVID-19 pneumonia, in particular older patients, admitted to tertiary and partner hospitals in Saitama, Japan. Methods We retrospectively reviewed the medical records of patients with COVID-19 pneumonia admitted to tertiary and partner hospitals in Saitama, Japan. Twenty-six patients with COVID-19 were categorized into two groups, i.e., older (>= 75 years) and younger adults (<= 74 years). We evaluated the clinical characteristics, comorbidities, symptoms, laboratory test results, treatments and outcomes of the patients. Results The majority of the older patients had comorbidities, such as dementia, cardiovascular disease and bone fractures. Comorbidities were significantly more frequent in older patients than younger patients. No association was found between age and body temperature or the incidence of respiratory failure. White blood cell count was significantly lower in older patients (P= 0.018) and the decrease in lymphocytes was greater in younger patients (P= 0.009). Computed tomography (CT) of all patients showed non-segmental, peripherally dominant ground-glass opacities consistent with COVID-19 pneumonia. In older patients, antiviral drugs, anticoagulants and anti-inflammatory drugs were administered on a compassionate use basis. The difference in mortality between the older and the younger patients was not statistically significant. Conclusions In older patients, typical clinical symptoms and blood test changes were often absent; however, CT always contained typical findings of COVID-19, suggesting that CT may be a useful diagnostic tool. Our report illustrates that appropriate treatment, taking patient background into consideration, may improve their condition regardless of age.Geriatr Gerontol Int center dot center dot; center dot center dot: center dot center dot-center dot center dot Geriatr Gerontol Int 2020; center dot center dot: center dot center dot-center dot center dot.
C1 [Sano, Tomoya; Kimizuka, Yoshifumi; Fujikura, Yuji; Watanabe, Chie; Suematsu, Ryohei; Izumi, Kaori; Miyata, Jun; Nagata, Masayoshi; Kawana, Akihiko] Natl Def Med Coll, Dept Internal Med, Div Infect Dis & Resp Med, Saitama, Japan.
   [Hisada, Tetsuya] Iruma Heart Hosp, Internal Med, Saitama, Japan.
   [Sugiura, Hiroaki; Shinmoto, Hiroshi] Natl Def Med Coll, Dept Radiol, Saitama, Japan.
RP Kimizuka, Y (corresponding author), Natl Def Med Coll, Dept Internal Med, Div Infect Dis & Resp Med, 3-2,Namiki, Tokorozawa, Saitama 3598513, Japan.
EM ykimizuka@ndmc.ac.jp
CR Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   Cummings MJ, 2020, LANCET, V395, P1763, DOI 10.1016/S0140-6736(20)31189-2
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iwabuchi K, 2020, J INFECT CHEMOTHER, V26, P625, DOI 10.1016/j.jiac.2020.04.007
   Johns Hopkins University & Medicine Coronavirus Resource Center, 2020, COVID 19 CAS TRACK
   Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621
   Ouchi Y, 2017, GERIATR GERONTOL INT, V17, P1045, DOI 10.1111/ggi.13118
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Statistics Bureau of Japan, 2015, POP CENS
   Sun HY, 2020, J AM GERIATR SOC, V68, pE19, DOI 10.1111/jgs.16533
   The Japanese Association for Infectious Diseases, 2019, CONC DRUG TREATM COV
   United Nations Department of Economic and Social Affairs, 2019, POP DYN WORLD POP PR
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yamamoto M, 2020, BIORXIV, DOI [10.1101/2020.04.22.054981, DOI 10.1101/2020.04.22.054981]
NR 21
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1444-1586
EI 1447-0594
J9 GERIATR GERONTOL INT
JI Geriatr. Gerontol. Int.
PD NOV
PY 2020
VL 20
IS 11
BP 1044
EP 1049
DI 10.1111/ggi.14034
EA SEP 2020
PG 6
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA OJ0NY
UT WOS:000568624800001
PM 32924229
OA Bronze
DA 2021-01-01
ER

PT J
AU Moyses, V
AF Moyses, Valerie
TI Make covid-19 vaccines mandatory to go overseas?
SO NEW SCIENTIST
LA English
DT Letter
NR 0
TC 0
Z9 0
U1 0
U2 0
PU REED BUSINESS INFORMATION LTD
PI SUTTON
PA QUADRANT HOUSE THE QUADRANT, SUTTON SM2 5AS, SURREY, ENGLAND
SN 0262-4079
J9 NEW SCI
JI New Sci.
PD SEP 12
PY 2020
VL 245
IS 3299
BP 28
EP 28
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NR0UN
UT WOS:000571279200019
DA 2021-01-01
ER

PT J
AU King, S
AF King, Steven
TI Make covid-19 vaccines mandatory to go overseas?
SO NEW SCIENTIST
LA English
DT Letter
NR 0
TC 0
Z9 0
U1 0
U2 0
PU REED BUSINESS INFORMATION LTD
PI SUTTON
PA QUADRANT HOUSE THE QUADRANT, SUTTON SM2 5AS, SURREY, ENGLAND
SN 0262-4079
J9 NEW SCI
JI New Sci.
PD SEP 12
PY 2020
VL 245
IS 3299
BP 28
EP 28
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NR0UN
UT WOS:000571279200020
DA 2021-01-01
ER

PT J
AU Ishay, Y
   Kessler, A
   Schwarts, A
   Ilan, Y
AF Ishay, Yuval
   Kessler, Asa
   Schwarts, Asaf
   Ilan, Yaron
TI Antibody Response to Severe Acute Respiratory Syndrome- Corona Virus 2,
   Diagnostic and Therapeutic Implications
SO HEPATOLOGY COMMUNICATIONS
LA English
DT Article
ID HUMAN MONOCLONAL-ANTIBODY; ALLEVIATES INSULIN-RESISTANCE; SYNDROME SARS
   CORONAVIRUS; ORAL IMMUNE REGULATION; REGULATORY T-CELLS; CONVALESCENT
   PLASMA; NEUTRALIZING ANTIBODIES; POTENT NEUTRALIZATION; AFFINITY
   MATURATION; PNEUMONIA OUTBREAK
AB The immune response against severe acute respiratory syndrome-corona virus 2 (SARS-CoV-2) is comprised of both cellular and humoral arms. While current diagnostic methods are mainly based on polymerase chain reaction, they suffer from insensitivity. Therefore, antibody-based serologic tests are being developed to achieve higher sensitivity and specificity. Current efforts in treating SARS-CoV-2 infection include blocking of viral entry into the host cells, prohibiting viral replication and survival in the host cells, and reducing the exaggerated host immune response. Administration of convalescent plasma containing antiviral antibodies was proposed to improve the outcome in severe cases. In this paper, we review some of the aspects associated with the development of antibodies against SARS-CoV-2 and their potential use for improved diagnosis and therapy.
C1 [Ishay, Yuval; Kessler, Asa; Schwarts, Asaf; Ilan, Yaron] Hebrew Univ Hadassah Med Ctr, Dept Med, Jerusalem, Israel.
RP Ilan, Y (corresponding author), Hebrew Univ Hadassah Med Ctr, Dept Med, Jerusalem, Israel.
EM ilan@hadassah.org.il
CR Adar T, 2012, CLIN EXP IMMUNOL, V167, P252, DOI 10.1111/j.1365-2249.2011.04511.x
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Arabi Y, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1490-9
   Barderas R, 2008, P NATL ACAD SCI USA, V105, P9029, DOI 10.1073/pnas.0801221105
   Cao WCC, 2007, NEW ENGL J MED, V357, P1162, DOI 10.1056/NEJMc070348
   Carbone J, 2016, TRANSPLANTATION, V100, pS11, DOI 10.1097/TP.0000000000001095
   Catalan-Dibene Jovani, 2020, Nat Rev Immunol, V20, P350, DOI 10.1038/s41577-020-0313-6
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen XY, 2020, CELL MOL IMMUNOL, V17, P647, DOI 10.1038/s41423-020-0426-7
   Chen XJ, 2014, PROTEIN CELL, V5, P369, DOI 10.1007/s13238-014-0026-3
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P339
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P333, DOI 10.23812/Editorial-Conti-2
   Corman VM, 2016, CLIN INFECT DIS, V62, P477, DOI 10.1093/cid/civ951
   Coughlin M, 2007, VIROLOGY, V361, P93, DOI 10.1016/j.virol.2006.09.029
   Deeks JJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013652
   Du LY, 2017, EXPERT OPIN THER TAR, V21, P131, DOI 10.1080/14728222.2017.1271415
   Duan JZ, 2005, BIOCHEM BIOPH RES CO, V333, P186, DOI 10.1016/j.bbrc.2005.05.089
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Dunmire GB, 1893, JAMA-J AM MED ASSOC, VXXI, P853
   Elshabrawy HA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050366
   Epstein J, 2020, VOX SANG, V115, P485, DOI 10.1111/vox.12939
   Florescu DF, 2015, CLIN INFECT DIS, V61, P969, DOI 10.1093/cid/civ395
   FRAME JD, 1984, T ROY SOC TROP MED H, V78, P319, DOI 10.1016/0035-9203(84)90107-X
   Fu W, 2020, J MED VIROL, V92, P2298, DOI 10.1002/jmv.25968
   Gabriella D, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106519
   Gelman R, 2020, EMERG MICROBES INFEC, V9, P1397, DOI 10.1080/22221751.2020.1776161
   Greenough TC, 2005, J INFECT DIS, V191, P507, DOI 10.1086/427242
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   Hahm JB, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.01785-19
   Halota W, 2015, J VIRAL HEPATITIS, V22, P651, DOI 10.1111/jvh.12369
   Hanson BJ, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-126
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hsueh PR, 2004, CLIN MICROBIOL INFEC, V10, P1062, DOI 10.1111/j.1469-0691.2004.01009.x
   Hung IFN, 2013, CHEST, V144, P712, DOI 10.1378/chest.13-0571
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Ilan Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01143
   Ilan Y, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1798-2
   Ilan Y, 2010, P NATL ACAD SCI USA, V107, P9765, DOI 10.1073/pnas.0908771107
   Infantino M, 2020, ISR MED ASSOC J, V22, P203
   Irwin KK, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew014
   Israeli E, 2004, LIVER INT, V24, P295, DOI 10.1111/j.1478-3231.2004.0935.x
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Jawhara S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072272
   Jensen T, 2018, J HEPATOL, V68, P1063, DOI 10.1016/j.jhep.2018.01.019
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Jiang SB, 2020, EMERG MICROBES INFEC, V9, P275, DOI 10.1080/22221751.2020.1723441
   Jin YJ, 2020, INT J INFECT DIS, V94, P49, DOI 10.1016/j.ijid.2020.03.065
   Kenig A, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01542
   Khoury T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02726
   Klasse PJ, 2014, ADV BIOL, V2014, P1, DOI DOI 10.1155/2014/157895
   Kraft CS, 2015, CLIN INFECT DIS, V61, P496, DOI 10.1093/cid/civ334
   Kruse Robert L, 2020, F1000Res, V9, P72, DOI 10.12688/f1000research.22211.2
   Lai ST, 2005, EUR J CLIN MICROBIOL, V24, P583, DOI 10.1007/s10096-005-0004-z
   Lambrecht BN, 2012, ANNU REV IMMUNOL, V30, P243, DOI 10.1146/annurev-immunol-020711-075021
   Li DZ, 2017, BIOCHEM BIOPH RES CO, V485, P446, DOI 10.1016/j.bbrc.2017.02.058
   Li G, 2003, NEW ENGL J MED, V349, P508, DOI 10.1056/NEJM200307313490520
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1156, DOI 10.1515/cclm-2020-0473
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Lou B, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00763-2020
   Lu CL, 2016, SCIENCE, V352, P1001, DOI 10.1126/science.aaf1279
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Makris S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00259
   Marston HD, 2018, NEW ENGL J MED, V378, P1469, DOI 10.1056/NEJMp1802256
   Matson MA, 2020, HUM VACC IMMUNOTHER, V16, P452, DOI 10.1080/21645515.2019.1656967
   Mizrahi M, 2008, VACCINE, V26, P2589, DOI 10.1016/j.vaccine.2008.03.026
   Mizrahi M, 2012, J INFLAMM RES, V5, P141, DOI 10.2147/JIR.S35227
   Nguyen A, 2020, J VIROL, V94, DOI 10.1128/JVI.00510-20
   Nigro G, 2017, EXPERT REV ANTI-INFE, V15, P977, DOI 10.1080/14787210.2017.1398081
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Boas LCPV, 2019, CELL MOL LIFE SCI, V76, P3525, DOI 10.1007/s00018-019-03138-w
   Perez-Garcia F, 2020, RAPID DIAGNOSIS SARS, DOI [10.1101/2020.04.11.20062158, DOI 10.1101/2020.04.11.20062158]
   Pia L, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0333-2
   Quinti I, 2020, J ALLERGY CLIN IMMUN, V146, P211, DOI 10.1016/j.jaci.2020.04.013
   Roback JD, 2020, JAMA-J AM MED ASSOC, V323, P1561, DOI 10.1001/jama.2020.4940
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Rockx B, 2008, J VIROL, V82, P3220, DOI 10.1128/JVI.02377-07
   Rokni M, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2107
   Safadi R, 2003, AM J GASTROENTEROL, V98, P2505, DOI 10.1111/j.1572-0241.2003.07700.x
   Saylor C, 2009, VACCINE, V27, pG38, DOI 10.1016/j.vaccine.2009.09.105
   Schoofs T, 2016, SCIENCE, V352, P997, DOI 10.1126/science.aaf0972
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Sheridan C, 2020, NAT BIOTECHNOL, V38, P655, DOI 10.1038/d41587-020-00011-1
   Shetty Rohit, 2020, Indian J Ophthalmol, V68, P693, DOI 10.4103/ijo.IJO_639_20
   Simchoni N, 2015, J IMMUNOL, V194, P3035, DOI 10.4049/jimmunol.1402690
   Smith K, 2009, NAT PROTOC, V4, P372, DOI 10.1038/nprot.2009.3
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Tang T, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104792
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Tiberghien P, 2020, VOX SANG, V115, P488, DOI 10.1111/vox.12926
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   Ueno H, 2010, IMMUNOL CELL BIOL, V88, P376, DOI 10.1038/icb.2010.28
   Vogel FR, 2000, CLIN INFECT DIS, V30, pS266, DOI 10.1086/313883
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Wasserman RL, 2017, EXPERT REV CLIN IMMU, V13, P1107, DOI 10.1080/1744666X.2017.1389647
   WHO, 2014, US CONV WHOL BLOOD P
   Winter AK, 2020, LANCET INFECT DIS, V20, P758, DOI 10.1016/S1473-3099(20)30322-4
   Woo PCY, 2004, CLIN DIAGN LAB IMMUN, V11, P665, DOI 10.1128/CDLI.11.4.665-668.2004
   Wosen JE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02144
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xiang F, 2020, CLIN INFECT DIS, V71, P1930, DOI 10.1093/cid/ciaa461
   Xiang J, 2020, EVALUATION ENZYME LI, DOI [10.1101/2020.02.27.20028787, DOI 10.1101/2020.02.27.20028787, 10.1101/2020.02.27. 20028787]
   Ye MX, 2020, J MED VIROL, V92, P1890, DOI 10.1002/jmv.25882
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zeng ZK, 2020, J INFECTION, V81, pE80, DOI 10.1016/j.jinf.2020.03.052
   Zhang LB, 2020, AGING-US, V12, P6536, DOI 10.18632/aging.103102
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang YC, 2020, EMERG MICROBES INFEC, V9, P833, DOI 10.1080/22221751.2020.1756699
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhao Q, 2015, LEUKEMIA, V29, P2238, DOI 10.1038/leu.2015.125
   Zhao Q, 2015, J BIOL CHEM, V290, P13017, DOI 10.1074/jbc.M115.650903
   Zhao Q, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104358
   Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359
   Zhou GY, 2020, INT J BIOL SCI, V16, P1718, DOI 10.7150/ijbs.45123
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
NR 128
TC 0
Z9 0
U1 3
U2 3
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
EI 2471-254X
J9 HEPATOL COMMUN
JI Hepatol. Commun.
PD DEC
PY 2020
VL 4
IS 12
BP 1731
EP 1743
DI 10.1002/hep4.1600
EA SEP 2020
PG 13
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OZ6QK
UT WOS:000570698300001
PM 32904861
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Choubey, A
   Dehury, B
   Kumar, S
   Medhi, B
   Mondal, P
AF Choubey, Abhinav
   Dehury, Budheswar
   Kumar, Sunil
   Medhi, Bikash
   Mondal, Prosenjit
TI Naltrexone a potential therapeutic candidate for COVID-19
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; drug repurposing; molecular docking; naltrexone; SARS-CoV-2;
   structural bioinformatics
ID INVOLVEMENT; LDN
AB Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the cause of Coronavirus Disease (COVID-19) that has resulted in a global pandemic. At the time of writing, approximately 16.06 million cases have been reported worldwide. Like other coronaviruses, SARS-CoV-2 relies on the surface Spike glycoprotein to access the host cells, mainly through the interaction of its Receptor Binding Domain (RBD) with the host receptor Angiotensin-Converting Enzyme2 (ACE2). SARS-CoV-2 infection induces a profound downstream pro-inflammatory cytokine storm. This release of the pro-inflammatory cytokines is underpinning lung tissue damage, respiratory failure, and eventually multiple organ failure in COVID-19 patients. The phosphorylation status of ERK1/2 is positively correlated with virus load and ERK1/2 inhibition suppressed viral replication and viral infectivity. Therefore, molecular entities able to interfere with binding of the SARS-CoV-2 Spike protein to ACE2, or damping hyperinflammatory cytokines storm, blocking ERK1/2 phosphorylation have a great potential to inhibit viral entry along with viral infectivity. Herein, we report that the FDA-approved non-peptide opioid antagonist drug, naltrexone suppresses high fat/LPS induced pro-inflammatory cytokine release both from macrophage cells and Adipose Tissue Macrophage. Moreover, Low Dose Naltrexone (LDN) also showed its activity as an ERK1/2 inhibitor. Notably, virtual docking and simulation data also suggest LDN may disrupt the interaction of ACE2 with RBD. LDN may be considered as a target as the treatment and (or) adjuvant therapy for coronavirus infection. Clinical toxicity measurements may not be required for LDN since naltrexone was previously tested and is an approved drug by the FDA. Communicated by Ramaswamy H. Sarma
C1 [Choubey, Abhinav; Mondal, Prosenjit] Indian Inst Technol Mandi, Sch Basic Sci, Mandi 175005, HP, India.
   [Dehury, Budheswar] Kalinga Inst Ind Technol KIIT, Sch Biotechnol, Bhubaneswar, India.
   [Kumar, Sunil] ICAR Indian Agr Stat Res Inst, PUSA, New Delhi, India.
   [Medhi, Bikash] Post Grad Inst Med Educ & Res, Dept Pharmacol, Chandigarh, India.
RP Mondal, P (corresponding author), Indian Inst Technol Mandi, Sch Basic Sci, Mandi 175005, HP, India.
EM prosenjit@iitmandi.ac.in
FU Department of Science & Technology (DST) INSPIRE fellowshipDepartment of
   Science & Technology (India)Department of Science & Technology (DOST),
   Philippines
FX We sincerely thank the BioX Centre of IIT Mandi for use of different
   analytical instruments. AC thank Department of Science & Technology
   (DST) INSPIRE fellowship, for his research fellowship. The authors
   received no funding from an external source.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Adedeji AO, 2013, J VIROL, V87, P8017, DOI 10.1128/JVI.00998-13
   [Anonymous], 2020, NATURAL MED J
   Cai YY, 2007, J VIROL, V81, P446, DOI 10.1128/JVI.01705-06
   CANT R, 2017, FRONT IMMUNOL, V8, DOI DOI https://doi.org/10.3389/fimmu.2017.00809
   Coperchini F, 2020, CYTOKINE GROWTH F R, V53, P25, DOI 10.1016/j.cytogfr.2020.05.003
   Cornish JW, 1997, J SUBST ABUSE TREAT, V14, P529, DOI 10.1016/S0740-5472(97)00020-2
   Dehury B, 2017, J MOL GRAPH MODEL, V71, P154, DOI 10.1016/j.jmgm.2016.11.012
   Dehury B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097852
   Dogra S, 2019, NANOMED-NANOTECHNOL, V17, P210, DOI 10.1016/j.nano.2019.01.013
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Girdhar K, 2019, J BIOMOL STRUCT DYN, V37, P3976, DOI 10.1080/07391102.2018.1532818
   GOLD MS, 1982, MED RES REV, V2, P211, DOI 10.1002/med.2610020302
   GONZALEZ JP, 1988, DRUGS, V35, P192, DOI 10.2165/00003495-198835030-00002
   Hersoug LG, 2016, OBES REV, V17, P297, DOI 10.1111/obr.12370
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hussain A, 2020, EUR PHYS J PLUS, V135, DOI 10.1140/epjp/s13360-020-00394-9
   Hutchinson MR, 2008, EUR J NEUROSCI, V28, P20, DOI 10.1111/j.1460-9568.2008.06321.x
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li ZJ, 2018, INT IMMUNOPHARMACOL, V61, P178, DOI 10.1016/j.intimp.2018.05.020
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286
   Mizutani T, 2010, MOLECULAR BIOLOGY OF THE SARS-CORONAVIRUS, P305, DOI 10.1007/978-3-642-03683-5_19
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Parkitny L, 2017, BIOMEDICINES, V5, DOI 10.3390/biomedicines5020016
   Patil S., 2020, DRUG REPURPOSING COV, DOI [10.26434/chemrxiv.12482435.v1, DOI 10.26434/CHEMRXIV.12482435.V1]
   Rahmati M., 2020, EURASIAN J MED ONCOL, V4, DOI [10.14744/ejmo.2020.72142., DOI 10.14744/EJMO.2020.72142, 10.14744/ejmo.2020.72142]
   Ramos-Benitez MJ, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00548-18
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Toljan K., 2018, MED SCI, V6
   Vanommeslaeghe K, 2012, J CHEM INF MODEL, V52, P3144, DOI 10.1021/ci300363c
   Vickers AP, 2006, BMJ-BRIT MED J, V332, P132, DOI 10.1136/bmj.332.7534.132
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4
   Wang X, 2016, BRIT J PHARMACOL, V173, P856, DOI 10.1111/bph.13394
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Younger J, 2014, CLIN RHEUMATOL, V33, P451, DOI 10.1007/s10067-014-2517-2
   Zaim S, 2020, CURR PROB CARDIOLOGY, V45, DOI 10.1016/j.cpcardiol.2020.100618
   Zha L, 2020, MED J AUSTRALIA, V212, P416, DOI 10.5694/mja2.50577
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhao M, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105982
NR 44
TC 1
Z9 1
U1 2
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1820379
EA SEP 2020
PG 8
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NO0TU
UT WOS:000569200400001
PM 32930058
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Fadaka, AO
   Sibuyi, NRS
   Madiehe, AM
   Meyer, M
AF Fadaka, Adewale Oluwaseun
   Sibuyi, Nicole Remaliah Samantha
   Madiehe, Abram Madimabe
   Meyer, Mervin
TI Computational insight of dexamethasone against potential targets of
   SARS-CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Dexamethasone; COVID-19; interleukins; glucocorticoid; SARS-CoV-2; main
   protease
ID MOLECULAR-DYNAMICS; RECEPTOR DIMERIZATION; CRYSTAL-STRUCTURE; BINDING;
   DOCKING; PROTEIN; SIMULATIONS; EXPRESSION; INHIBITORS; MODE
AB The health sector has been on the race to find a potent therapy for coronavirus disease (COVID)-19, a diseases caused by severe acute respiratory syndrome coronavirus (SARS-CoV)-2. Repurposed anti-viral drugs have played a huge role in combating the virus, and most recently, dexamethasone (Dex) have shown its therapeutic activity in severe cases of COVID-19 patients. The study sought to provide insights on the anti-COVID-19 mechanism of Dex at both atomic and molecular level against SARS-CoV-2 targets. Computational methods were employed to predict the binding affinity of Dex to SARS-CoV-2 using the Schrodinger suite (v2020-2). The target molecules and ligand (Dex) were retrieved from PDB and PubChem, respectively. The selected targets were SARS-CoV-2 main protease (Mpro), and host secreted molecules glucocorticoid receptor, and Interleukin-6 (IL-6). Critical analyses such as Protein and ligand preparation, molecular docking, molecular dynamic (MD) simulations, and absorption, distribution, metabolism, excretion (ADME), and toxicity analyses were performed using the targets and the ligand as inputs. Dex showed stronger affinity to its theoretical (glucocorticoid) receptor with a superior docking score of -14.7 and a good binding energy value of -147.48 kcal/mol; while short hydrogen bond distances were observed in both Mpro and IL-6 when compared to glucocorticoid receptor. Based on these findings, Dex-target complexes were used to perform MD simulations to analyze Dex stability at 50 ns. This study demonstrates that Dex could bind to both the viral and host receptors as a potential drug candidate for COVID-19. To ascertain the biological fitness of this study, other SARS-CoV-2 targets should be explored. Also, thein vitrostudies of dexamethasone against several SARS-CoV-2 targets warrant further investigation. Communicated by Ramaswamy H. Sarma
C1 [Fadaka, Adewale Oluwaseun; Sibuyi, Nicole Remaliah Samantha; Madiehe, Abram Madimabe; Meyer, Mervin] Univ Western Cape, Dept Biotechnol, Mintek Nanotechnol Innovat Ctr, Biolabels Node,Fac Nat Sci,Dept Sci & Innovat, Bellville, South Africa.
   [Madiehe, Abram Madimabe] Univ Western Cape, Dept Biotechnol, Nanobiotechnol Res Grp, Fac Nat Sci, Bellville, South Africa.
RP Fadaka, AO; Meyer, M (corresponding author), Univ Western Cape, Dept Biotechnol, Mintek Nanotechnol Innovat Ctr, Biolabels Node,Fac Nat Sci,Dept Sci & Innovat, Bellville, South Africa.
EM afadaka@uwc.ac.za; memeyer@uwc.ac.za
RI ADEWALE, FADAKA/O-8760-2017
OI ADEWALE, FADAKA/0000-0002-3952-2098; MADIEHE, ABRAM/0000-0002-3935-467X;
   Meyer, Mervin/0000-0002-8296-4860
CR Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1652, DOI 10.1111/bph.12448
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6
   Blessy JJ, 2015, J BIOMOL STRUCT DYN, V33, P1126, DOI 10.1080/07391102.2014.931825
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Borhani DW, 2012, J COMPUT AID MOL DES, V26, P15, DOI 10.1007/s10822-011-9517-y
   Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   DOWTON SB, 1991, PEDIATR RES, V30, P444, DOI 10.1203/00006450-199111000-00010
   Durrant JD, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-71
   EAVES CJ, 1991, BLOOD, V78, P110
   Edman K, 2015, STRUCTURE, V23, P2280, DOI 10.1016/j.str.2015.09.012
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elmezayen AD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758791
   Enayatkhani M, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1756411
   Enmozhi SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760136
   Group RC, 2020, NEW ENGLAND J MED
   Gupta VK, 2005, INVEST OPHTH VIS SCI, V46
   Hayes JM, 2012, MOL DYNAMICS STUDIES, P171
   Healthcare  G, 2020, DEXAMETHASONE UNEXPE
   Herr I, 2006, LANCET ONCOL, V7, P425, DOI 10.1016/S1470-2045(06)70694-5
   Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood-2004-01-0037
   HOLLANDER JL, 1960, JAMA-J AM MED ASSOC, V172, P306, DOI 10.1001/jama.1960.03020040004002
   Hollingsworth SA, 2018, NEURON, V99, P1129, DOI 10.1016/j.neuron.2018.08.011
   HOOVER WG, 1985, PHYS REV A, V31, P1695, DOI 10.1103/PhysRevA.31.1695
   Isidori AM, 2020, J ENDOCRINOL INVEST, V43, P1141, DOI 10.1007/s40618-020-01266-w
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Klebe G, 1997, J RECEPT SIGNAL TR R, V17, P459, DOI 10.3109/10799899709036621
   Li Bo, 2006, J Huazhong Univ Sci Technolog Med Sci, V26, P25
   Li JN, 2011, PROTEINS, V79, P2794, DOI 10.1002/prot.23106
   Liu L., 2017, CELL DEATH DIS, V8, pe3054
   Liuzzi JP, 2005, P NATL ACAD SCI USA, V102, P6843, DOI 10.1073/pnas.0502257102
   Mahmud-Al-Rafat A, 2019, CYTOKINE, V115, P13, DOI 10.1016/j.cyto.2018.12.008
   Matsuda T, 1989, Int Rev Immunol, V5, P97, DOI 10.3109/08830188909061976
   Mittal L, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768151
   Nayeem S. M., 2020, RES SQUARE, P1
   Nemeth E, 2004, J CLIN INVEST, V113, P1271, DOI 10.1172/JCI200420945
   Nishimoto N, 2005, BLOOD, V106, P2627, DOI 10.1182/blood-2004-12-4602
   Organization WH, 1977, SEL ESS DRUGS REP WH
   Pace CN, 2014, FEBS LETT, V588, P2177, DOI 10.1016/j.febslet.2014.05.006
   RATHNAYAKE S, 2018, J MOL MODEL, V24, DOI DOI https://doi.org/10.1007/s00894-018-3879-1
   Roy S, 2015, METHODS, V83, P105, DOI 10.1016/j.ymeth.2015.04.021
   RUPPRECHT R, 1993, EUR J PHARM-MOLEC PH, V247, P145, DOI 10.1016/0922-4106(93)90072-H
   Schett G, 2020, NAT REV RHEUMATOL, V16, P465, DOI 10.1038/s41584-020-0451-z
   Sharma J., 2011, J COMPUT METH MOL DE, V1, P44
   Somers W, 1997, EMBO J, V16, P989, DOI 10.1093/emboj/16.5.989
   Sorbera LA, 2020, DRUG FUTURE, V45, P239, DOI 10.1358/dof.2020.45.4.3150676
   STOLL BA, 1960, CANCER, V13, P1074, DOI 10.1002/1097-0142(196009/10)13:5<1074::AID-CNCR2820130531>3.0.CO;2-9
   Subhani S, 2015, BIOMED PHARMACOTHER, V71, P37, DOI 10.1016/j.biopha.2015.02.009
   Sze CI, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/628094
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Ullah W, 2020, ENG COMPUTATION, DOI 10.1108/EC-04-2020-0201
   Vijayakumar S, 2018, J PHARM ANAL, V8, P413, DOI 10.1016/j.jpha.2017.07.006
   Villar J, 2020, CRIT CARE EXPL, V2
   Volden PA, 2013, BRAIN BEHAV IMMUN, V30, pS26, DOI 10.1016/j.bbi.2012.10.022
   Xu MJ, 2003, CHINESE MED J-PEKING, V116, P392
   Xue XY, 2008, J VIROL, V82, P2515, DOI 10.1128/JVI.02114-07
   ZHANG CW, 2006, BMC CANCER, V6, DOI DOI https://doi.org/10.1186/1471-2407-6-61
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang XN, 2020, INFLAMMOPHARMACOLOGY, V28, P1269, DOI 10.1007/s10787-020-00696-5
   Zhavoronkov A, 2020, POTENTIAL COVID 2019, P1, DOI [10.26434/chemrxiv.11829102.v1, DOI 10.26434/CHEMRXIV.11829102.V2]
NR 63
TC 1
Z9 1
U1 6
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1819880
EA SEP 2020
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NO1AK
UT WOS:000569217600001
PM 32924825
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kelleni, MT
AF Kelleni, Mina T.
TI ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of
   the mirror
SO INFLAMMOPHARMACOLOGY
LA English
DT Article
DE COVID-19; SARS CoV-2; Aceis; Arbs; Ibuprofen
ID ANTIHYPERTENSIVE DRUGS; CORONAVIRUS; HYPERTENSION; EXPRESSION; RISK
AB During the COVID-19 pandemic, a correspondence, published at the Lancet Respiratory Medicine, that linked angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and ibuprofen to a higher risk of SARS CoV-2 infection and complications, has influenced, when adopted by official health authorities, the practical management of COVID-19 with regard to non-steroidal anti-inflammatory drugs that were avoided in all COVID-19 management protocols all over the world. This manuscript discusses, from a pharmacological point of view, the points of weakness in the mentioned correspondence and it also lists some important contradictory review articles as well as clinical results that refuted its claims. The author chose to argue against each claim represented in the mentioned correspondence to confirm that ACEIs, ARBs and NSAIDs including ibuprofen should not be considered hazardous to be administered for COVID-19 patients and to warn against any future adoption of such unproved claims.
C1 [Kelleni, Mina T.] Menia Univ, Dept Pharmacol, Coll Med, Al Minya, Egypt.
RP Kelleni, MT (corresponding author), Menia Univ, Dept Pharmacol, Coll Med, Al Minya, Egypt.
EM mina.kelleni@mu.edu.eg
RI Kelleni, Mina/L-5463-2018
OI Kelleni, Mina/0000-0001-6290-6025
CR American College of Cardiology, 2020, HFSA ACC AHA STAT AD
   Banu N, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117905
   Bean D, 2020, TREATMENT ACEINHIBIT
   Brown JD, 2020, LANCET RESP MED, V8, pE28, DOI 10.1016/S2213-2600(20)30158-2
   Chen C, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P567, DOI 10.3760/cma.j.cn112148-20200225-00123
   Deng SQ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020575
   Devaux CA, 2020, J MICROBIOL IMMUNOL, V53, P425, DOI 10.1016/j.jmii.2020.04.015
   European Medicines Agency, 2020, EMA ADV CONT MED HYP
   Fang L, 2020, LANCET RESP MED, V8, pE32, DOI 10.1016/S2213-2600(20)30159-4
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Fosbol EL, 2020, JAMA-J AM MED ASSOC, V324, P168, DOI 10.1001/jama.2020.11301
   Hoffmann M, 2020, CELL
   Kelleni M, 2020, IBUPROFEN POTENTIAL
   Kelleni M, 2018, PHARM PHARM INT J, V6, P297
   Kelleni M, 2020, BREAKTHROUGH IBUPROF
   Kelleni M, 2020, ACEIS ARBS IBUPROFEN
   Koitka A, 2008, CLIN EXP PHARMACOL P, V35, P420, DOI 10.1111/j.1440-1681.2008.04889.x
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Li XC, 2017, PHARMACOL RES, V125, P21, DOI 10.1016/j.phrs.2017.06.005
   Moore N, 2020, DRUG SAFETY, V43, P611, DOI 10.1007/s40264-020-00953-0
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   Qiao WL, 2015, CARDIOLOGY, V131, P97, DOI 10.1159/000375362
   Rinott E, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.06.003
   Smart L, 2020, INFLAMMOPHARMACOLOGY, V28, P1141, DOI 10.1007/s10787-020-00745-z
   The Local, 2020, THE LOCAL
   University of Basel, 2020, IB COVID 19
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wakahara S, 2007, ENDOCRINOLOGY, V148, P2453, DOI 10.1210/en.2006-1287
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang JJQ, 2020, PHARMACOL THERAPEUT, V215, DOI 10.1016/j.pharmthera.2020.107628
   WHO, 2020, Q CLOUD IB WORS DIS
   Wong DW, 2007, AM J PATHOL, V171, P438, DOI 10.2353/ajpath.2007.060977
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 34
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 0925-4692
EI 1568-5608
J9 INFLAMMOPHARMACOLOGY
JI Inflammopharmacology
PD DEC
PY 2020
VL 28
IS 6
BP 1477
EP 1480
DI 10.1007/s10787-020-00755-x
EA SEP 2020
PG 4
WC Immunology; Pharmacology & Pharmacy; Toxicology
SC Immunology; Pharmacology & Pharmacy; Toxicology
GA OE5OE
UT WOS:000568631100002
PM 32920716
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Verma, YK
   Verma, R
   Tyagi, N
   Behl, A
   Kumar, S
   Gangenahalli, GU
AF Verma, Yogesh Kumar
   Verma, Ranjan
   Tyagi, Nishant
   Behl, Amanpreet
   Kumar, Subodh
   Gangenahalli, Gurudutta U.
TI COVID-19 and its Therapeutics: Special Emphasis on Mesenchymal Stem
   Cells Based Therapy
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article; Early Access
DE SARS-CoV-2; Cytokine storm; Repurposed drugs; MSCs transplantation;
   Antimicrobial peptides
ID INTERNATIONAL-SOCIETY; STROMAL CELLS; SARS; INFECTION; PROTEASE;
   MECHANISMS; INHIBITOR; VIRUS; DRUG; TRANSPLANTATION
AB The novel virus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) caused the Corona Virus Disease-2019 (COVID-19) outbreak in Wuhan, Hubei province of China. This virus disseminated rapidly and reached to an unprecedented pandemic proportion in more than 213 nations with a large number of fatalities. The hypersecretion of pro-inflammatory cytokines is the main cause of mortality and morbidity due to COVID-19, therefore strategies that avert the cytokine storm may play a crucial role in abating the severity of COVID-19. This review highlights the minute details of SARS-CoV-2, its genomic organization, genomic variations within structural and non-structural proteins and viral progression mechanism in human beings. The approaches like antiviral strategies are discussed, including drugs that obstruct viral propagation and suppress the pro-inflammatory cytokines. This compilation emphasizes Mesenchymal Stem Cells (MSCs) based therapy alone or in combination with other therapeutics as an attractive curative approach for COVID-19 pandemic. The MSCs and its secretome, including antimicrobial peptides (AMPs) have various capabilities, for instance, immunomodulation, regeneration, antimicrobial properties, potential for attenuating the cytokine storm and bare minimum chances of being infected with SARS-CoV-2 virus. The immunomodulatory property of MSCs affects inflammatory state and regulates immune response during SARS-CoV-2 infection. However, as of now, there is no WHO-approved MSCs based therapy for the treatment of COVID-19 infection.
C1 [Verma, Yogesh Kumar; Verma, Ranjan; Tyagi, Nishant; Behl, Amanpreet; Kumar, Subodh; Gangenahalli, Gurudutta U.] Inst Nucl Med & Allied Sci INMAS, Div Stem Cell & Gene Therapy Res, Brig SK Mazumdar Rd, Delhi 110054, India.
RP Gangenahalli, GU (corresponding author), Inst Nucl Med & Allied Sci INMAS, Div Stem Cell & Gene Therapy Res, Brig SK Mazumdar Rd, Delhi 110054, India.
EM gugdutta@rediffmail.com
FU Defence Research Development Organisation, IndiaDefence Research &
   Development Organisation (DRDO) [ST/18-19/INM-323]
FX We thank Director, INMAS, for his continuous support. This work was
   funded by the Defence Research Development Organisation, India, project
   no. S&T/18-19/INM-323. Images are created with BioRender.com.
CR Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559
   Alcayaga-Miranda F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00339
   Alvarez E, 2010, VIROLOGY, V402, P281, DOI 10.1016/j.virol.2010.03.015
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   [Anonymous], 2020, COR CAS, DOI [10.1101/2020.01.23.20018549V2, DOI 10.1101/2020.01.23.20018549V2]
   Atluri S, 2020, PAIN PHYSICIAN, V23, pE71
   Baden LR, 2020, NEW ENGL J MED, V382, P1851, DOI 10.1056/NEJMe2005477
   Balamurugan K, 2006, AM J PHYSIOL-CELL PH, V291, pC189, DOI 10.1152/ajpcell.00594.2005
   Banerjee A, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010041
   Bari E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040924
   Basiri A, 2020, STEM CELL REV REP, DOI 10.1007/s12015-020-09994-5
   Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Bouffi C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014247
   Campbell EA, 2001, CELL, V104, P901, DOI 10.1016/S0092-8674(01)00286-0
   Carapagnoli C., 2000, BLOOD, V96, P2396
   Castaneda-Sanchez J. I., 2016, EXPRESSION ANTIMICRO, DOI [10.1159/000446282, DOI 10.1159/000446282]
   Chan JL, 2006, BLOOD, V107, P4817, DOI 10.1182/blood-2006-01-0057
   Currie SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073659
   Das A, 2007, PROTEIN PEPTIDE LETT, V14, P565
   De Clercq E, 2009, INT J ANTIMICROB AG, V33, P307, DOI 10.1016/j.ijantimicag.2008.10.010
   De Meyer S, 2005, ANTIMICROB AGENTS CH, V49, P2314, DOI 10.1128/AAC.49.6.2314-2321.2005
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   de Witte SFH, 2018, STEM CELLS, V36, P602, DOI 10.1002/stem.2779
   Deng P, 2013, ANTIMICROB AGENTS CH, V57, P1743, DOI 10.1128/AAC.02282-12
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   English K, 2009, CLIN EXP IMMUNOL, V156, P149, DOI 10.1111/j.1365-2249.2009.03874.x
   Esfandiyari R, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02652
   Pachon-Ibanez ME, 2017, FEMS MICROBIOL REV, V41, P323, DOI 10.1093/femsre/fux012
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Gang EJ, 2004, STEM CELLS, V22, P617, DOI 10.1634/stemcells.22-4-617
   Gangenahalli G., 2011, NATURE PRECEDINGS, P1, DOI [10.1038/npre.2011.5512.1, DOI 10.1038/NPRE.2011.5512.1]
   Gao F, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.327
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Genovese MC, 2016, NEW ENGL J MED, V374, P1243, DOI 10.1056/NEJMoa1507247
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Golchin A, 2020, STEM CELL REV REP, V16, P427, DOI 10.1007/s12015-020-09973-w
   Han KH, 2011, TRANSPL IMMUNOL, V25, P7, DOI 10.1016/j.trim.2011.05.004
   Hayden FG, 2019, CURR OPIN INFECT DIS, V32, P176, DOI 10.1097/QCO.0000000000000532
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234
   Hsieh IN, 2016, PHARMACEUTICALS-BASE, V9, DOI 10.3390/ph9030053
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hull MW, 2011, ANN MED, V43, P375, DOI 10.3109/07853890.2011.572905
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jones EA, 2002, ARTHRITIS RHEUM-US, V46, P3349, DOI 10.1002/art.10696
   Jorgensen C, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt15
   Karussis D, 2010, ARCH NEUROL-CHICAGO, V67, P1187, DOI 10.1001/archneurol.2010.248
   Khan F. A., 2020, MODS SIRS SUSTAINABL, DOI 10.1016/j.scs.2020.102018
   Kim JW, 2014, INTEST RES, V12, P266, DOI [10.5217/ir.2014.12.1.20, 10.5217/ir.2014.12.4.266]
   Kim J, 2019, TISSUE ENG REGEN MED, V16, P59, DOI 10.1007/s13770-018-0163-5
   Kitani A, 2003, J EXP MED, V198, P1179, DOI 10.1084/jem.20030917
   Kumar GN, 1999, DRUG METAB DISPOS, V27, P86
   Kuriya B, 2017, THER ADV MUSCULOSKEL, V9, P37, DOI 10.1177/1759720X16687481
   Lee JW, 2013, AM J RESP CRIT CARE, V187, P751, DOI 10.1164/rccm.201206-0990OC
   Lee Seoung Hoon, 2018, Osteoporos Sarcopenia, V4, P150, DOI 10.1016/j.afos.2018.11.083
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li CF, 2017, EBIOMEDICINE, V24, P189, DOI 10.1016/j.ebiom.2017.09.034
   Li HJ, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/9671206
   Li Y, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0395-z
   Liang S., 2020, CLIN REMISSION CRITI, V16, P9179, DOI [DOI 10.3969/J.ISSN.2095-4344.2012.49.011, 10.3969,4issn.2095-4344. 2012.49.011]
   Liu W, 2006, J INFECT DIS, V193, P792, DOI 10.1086/500469
   Liu Y, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01112-2020
   Louie J. K., 2009, TREATMENT NEURAMINID, DOI [10.1093/cid/cis636, DOI 10.1093/CID/CIS636]
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lukomska B, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/9628536
   Luo C, 2004, BIOCHEM BIOPH RES CO, V321, P557, DOI 10.1016/j.bbrc.2004.07.003
   Mallapaty S, 2020, NATURE, V582, P467, DOI 10.1038/d41586-020-01738-2
   Matsumura T, 2016, HEPATOL RES, V46, P924, DOI 10.1111/hepr.12627
   Mielech AM, 2014, VIROLOGY, V450, P64, DOI 10.1016/j.virol.2013.11.040
   Mousavizadeh Leila, 2020, J Microbiol Immunol Infect, DOI 10.1016/j.jmii.2020.03.022
   Muroi K, 2016, INT J HEMATOL, V103, P243, DOI 10.1007/s12185-015-1915-9
   Musial-Wysocka A, 2019, CELL TRANSPLANT, V28, P801, DOI 10.1177/0963689719837897
   Neuman BW, 2011, J STRUCT BIOL, V174, P11, DOI 10.1016/j.jsb.2010.11.021
   Ning H, 2008, LEUKEMIA, V22, P593, DOI 10.1038/sj.leu.2405090
   O'Shea JJ, 2013, ANN RHEUM DIS, V72, P111, DOI 10.1136/annrheumdis-2012-202576
   Pervushin K, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000511
   Podesta MA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01287
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Putra Agung, 2018, Open Access Maced J Med Sci, V6, P1779, DOI 10.3889/oamjms.2018.404
   Raza SS, 2020, STEM CELL REV REP, DOI 10.1007/s12015-020-09999-0
   Regmi S, 2019, EUR J CELL BIOL, V98, DOI 10.1016/j.ejcb.2019.04.002
   Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Shetty AK, 2020, AGING DIS, V11, P462, DOI 10.14336/AD.2020.0301
   Shippey EA, 2018, CLEV CLIN J MED, V85, P459, DOI 10.3949/ccjm.85a.17034
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Stadler K, 2008, AM J RESP CELL MOL, V39, P142, DOI 10.1165/rcmb.2007-0217OC
   Sundquist WI, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006924
   Sung DK, 2016, CELL MICROBIOL, V18, P424, DOI 10.1111/cmi.12522
   Takano T, 2014, LAB INVEST, V94, P286, DOI 10.1038/labinvest.2013.152
   Takeshita K, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0550-1
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Tremblay Cecile L, 2008, Ther Clin Risk Manag, V4, P759
   Tupin A, 2010, INT J ANTIMICROB AG, V35, P519, DOI 10.1016/j.ijantimicag.2009.12.017
   Ullah I, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150025
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Venkataraman S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020076
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Villain-Guillot P, 2007, DRUG DISCOV TODAY, V12, P200, DOI 10.1016/j.drudis.2007.01.005
   Volarevic V, 2018, INT J MED SCI, V15, P36, DOI 10.7150/ijms.21666
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang Q, 2020, CELL, V182, P417, DOI 10.1016/j.cell.2020.05.034
   Wang XB, 2020, MATH PHYS ANAL GEOM, V23, DOI 10.1007/s11040-020-09347-1
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Westover JB, 2018, ANTIVIR RES, V156, P38, DOI 10.1016/j.antiviral.2018.05.013
   WHITE RJ, 1971, J BACTERIOL, V108, P737, DOI 10.1128/JB.108.2.737-741.1971
   WHO, 2015, SUMM PROB SARS CAS O
   Wilson L, 2006, VIROLOGY, V353, P294, DOI 10.1016/j.virol.2006.05.028
   World Health Organization, 2020, MIDDL E RESP SYNDR C
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yagi H, 2010, CELL TRANSPLANT, V19, P667, DOI 10.3727/096368910X508762
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhang LJ, 2016, CURR BIOL, V26, pR14, DOI 10.1016/j.cub.2015.11.017
   Zhang Y, 2004, EXP HEMATOL, V32, P657, DOI 10.1016/j.exphem.2004.04.001
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 120
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629-3269
EI 2629-3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
DI 10.1007/s12015-020-10037-2
EA SEP 2020
PG 19
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
SC Cell Biology; Research & Experimental Medicine
GA NN2QO
UT WOS:000568637500001
PM 32920752
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Olson, B
   Cruz, A
   Chen, LY
   Ghattas, M
   Ji, Y
   Huang, KH
   Ayoub, S
   Luchko, T
   McKay, DJ
   Kurtzman, T
AF Olson, Brian
   Cruz, Anthony
   Chen, Lieyang
   Ghattas, Mossa
   Ji, Yeonji
   Huang, Kunhui
   Ayoub, Steven, Jr.
   Luchko, Tyler
   McKay, Daniel J.
   Kurtzman, Tom
TI An online repository of solvation thermodynamic and structural maps of
   SARS-CoV-2 targets
SO JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
LA English
DT Article
DE COVID-19; Solvation thermodynamics; Virtual screening; Rational lead
   modification; Drug discovery
ID INHOMOGENEOUS FLUID APPROACH; MOLECULAR-DYNAMICS; PROTEIN; WATER;
   PARAMETERS; DISCOVERY
AB SARS-CoV-2 recently jumped species and rapidly spread via human-to-human transmission to cause a global outbreak of COVID-19. The lack of effective vaccine combined with the severity of the disease necessitates attempts to develop small molecule drugs to combat the virus. COVID19_GIST_HSA is a freely available online repository to provide solvation thermodynamic maps of COVID-19-related protein small molecule drug targets. Grid inhomogeneous solvation theory maps were generated using AmberTools cpptraj-GIST, 3D reference interaction site model maps were created with AmberTools rism3d.snglpnt and hydration site analysis maps were created using SSTMap code. The resultant data can be applied to drug design efforts: scoring solvent displacement for docking, rational lead modification, prioritization of ligand- and protein- based pharmacophore elements, and creation of water-based pharmacophores. Herein, we demonstrate the use of the solvation thermodynamic mapping data. It is hoped that this freely provided data will aid in small molecule drug discovery efforts to defeat SARS-CoV-2.
C1 [Cruz, Anthony; Chen, Lieyang; Ghattas, Mossa; Ji, Yeonji; Huang, Kunhui; Kurtzman, Tom] Lehman Coll, Dept Chem, 205 W Bedford Pk Blvd, Bronx, NY 10468 USA.
   [Cruz, Anthony; Ghattas, Mossa; Kurtzman, Tom] CUNY, Grad Ctr, PhD Program Chem, 365 5th Ave, New York, NY 10016 USA.
   [Olson, Brian; Chen, Lieyang; Ji, Yeonji; Huang, Kunhui; Kurtzman, Tom] CUNY, Grad Ctr, PhD Program Biochem, 365 5th Ave, New York, NY 10016 USA.
   [Olson, Brian] Cty Coll Morris, Dept Biol & Chem, 214 Ctr Grove Rd, Randolph, NJ 07869 USA.
   [McKay, Daniel J.] Ventus Therapeut, Montreal, PQ H9S 2A1, Canada.
   [Ayoub, Steven, Jr.] Calif State Univ Northridge, Dept Chem & Biochem, 18111 Nordhoff St, Northridge, CA 91330 USA.
   [Luchko, Tyler] Calif State Univ Northridge, Dept Phys & Astron, Ctr Biol Phys, 18111 Nordhoff St, Northridge, CA 91330 USA.
RP Kurtzman, T (corresponding author), Lehman Coll, Dept Chem, 205 W Bedford Pk Blvd, Bronx, NY 10468 USA.; Kurtzman, T (corresponding author), CUNY, Grad Ctr, PhD Program Chem, 365 5th Ave, New York, NY 10016 USA.; Kurtzman, T (corresponding author), CUNY, Grad Ctr, PhD Program Biochem, 365 5th Ave, New York, NY 10016 USA.
EM thomas.kurtzman@lehman.cuny.edu
OI Kurtzman, Tom/0000-0003-0900-772X; Olson, Brian/0000-0002-7632-703X
FU USA National Institutes of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R01GM100946];
   National Science FoundationNational Science Foundation (NSF) [1566638];
   Research Corporation for Science Advancement (RCSA) Cottrell Scholar
   Award [23967]
FX This research was supported by the USA National Institutes of Health
   R01GM100946, National Science Foundation Grant No. 1566638 and the
   Research Corporation for Science Advancement (RCSA) Cottrell Scholar
   Award #23967.
CR Abel R, 2008, J AM CHEM SOC, V130, P2817, DOI 10.1021/ja0771033
   Abel R, 2017, CURR OPIN STRUC BIOL, V43, P38, DOI 10.1016/j.sbi.2016.10.007
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   [Anonymous], 2017, SCHR REL 2017 3
   Balius TE, 2017, P NATL ACAD SCI USA, V114, pE6839, DOI 10.1073/pnas.1703287114
   Bayly C, 2010, INFORMAL AMBER SMALL
   Case D., 2016, AMBER 16
   Case D. A., 2019, AMBER 2019
   Collin MP, 2018, CHEMMEDCHEM, V13, P437, DOI 10.1002/cmdc.201700718
   Haider K, 2018, J CHEM THEORY COMPUT, V14, P418, DOI 10.1021/acs.jctc.7b00592
   Haider K, 2016, J PHYS CHEM B, V120, P8743, DOI 10.1021/acs.jpcb.6b01094
   Harriman G, 2016, P NATL ACAD SCI USA, V113, pE1796, DOI 10.1073/pnas.1520686113
   Hu BJ, 2012, J CHEM INF MODEL, V52, P1046, DOI 10.1021/ci200620h
   Izadi S, 2014, J PHYS CHEM LETT, V5, P3863, DOI 10.1021/jz501780a
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Johnson J, 2016, J PHYS-CONDENS MAT, V28, DOI 10.1088/0953-8984/28/34/344002
   Jung SW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28546-z
   Kast SM, 2008, J CHEM PHYS, V129, DOI 10.1063/1.3041709
   Kraml J, 2019, J CHEM THEORY COMPUT, V15, P5872, DOI 10.1021/acs.jctc.9b00742
   Lazaridis T, 1998, J PHYS CHEM B, V102, P3531, DOI 10.1021/jp9723574
   Lazaridis T, 1998, J PHYS CHEM B, V102, P3542, DOI 10.1021/jp972358w
   Luchko T, 2010, J CHEM THEORY COMPUT, V6, P607, DOI 10.1021/ct900460m
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   MORITA T, 1961, PROG THEOR PHYS, V25, P537, DOI 10.1143/PTP.25.537
   Murphy RB, 2016, J MED CHEM, V59, P4364, DOI 10.1021/acs.jmedchem.6b00131
   Nguyen C, 2011, ARXIV11084876
   Nguyen C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219473
   Nguyen CN, 2014, J CHEM THEORY COMPUT, V10, P2769, DOI 10.1021/ct401110x
   Nguyen CN, 2012, J CHEM PHYS, V137, DOI 10.1063/1.4733951
   PERKYNS J, 1992, J CHEM PHYS, V97, P7656, DOI 10.1063/1.463485
   Ramsey S, 2016, J COMPUT CHEM, V37, P2029, DOI 10.1002/jcc.24417
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Shi JH, 2006, FEBS J, V273, P1035, DOI 10.1111/j.1742-4658.2006.05130.x
   Uehara S, 2016, MOLECULES, V21, DOI 10.3390/molecules21111604
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   Young T, 2007, P NATL ACAD SCI USA, V104, P808, DOI 10.1073/pnas.0610202104
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 40
TC 0
Z9 0
U1 5
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0920-654X
EI 1573-4951
J9 J COMPUT AID MOL DES
JI J. Comput.-Aided Mol. Des.
PD DEC
PY 2020
VL 34
IS 12
BP 1219
EP 1228
DI 10.1007/s10822-020-00341-x
EA SEP 2020
PG 10
WC Biochemistry & Molecular Biology; Biophysics; Computer Science,
   Interdisciplinary Applications
SC Biochemistry & Molecular Biology; Biophysics; Computer Science
GA OH8UK
UT WOS:000568465700001
PM 32918236
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Beretta, F
   Dassie, F
   Parolin, M
   Boscari, F
   Barbot, M
   Busetto, L
   Mioni, R
   De Carlo, E
   Scaroni, C
   Fallo, F
   Vettor, R
   Maffei, P
AF Beretta, Federica
   Dassie, Francesca
   Parolin, Matteo
   Boscari, Federico
   Barbot, Mattia
   Busetto, Luca
   Mioni, Roberto
   De Carlo, Eugenio
   Scaroni, Carla
   Fallo, Francesco
   Vettor, Roberto
   Maffei, Pietro
TI Practical Considerations for the Management of Cushing's Disease and
   COVID-19: A Case Report
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE SARS-Cov-2; Cushing's disease; pituitary; rare diseases;
   hypercortisolism
AB Introduction:Italy, since the end of February 2020, is experiencing the corona virus disease 2019 (COVID-19) pandemic that may present as an acute respiratory infection. We report on COVID-19 pneumonia in the context of a complex case of Cushing's disease (CD). Case Report:A 67-year-old man with CD, who was admitted to our hospital, presented with signs and symptoms of adrenal insufficiency with persistent hypotension and glycemia toward the lower limits. We progressively withdrew almost all treatments for diabetes and CD (pasireotide and metyrapone), and i.v. hydrocortisone was necessary. A tendency to hyperkalemia was probably associated to enoxaparin. We summarized the many possible interactions between medications of Cushing's syndrome (CS) and COVID-19. Conclusion:Adrenal insufficiency might be a clinical challenge that needs a prompt treatment also in CS patients during COVID-19 infection. We should consider the possibility to titrate or temporary halt medical therapies of CS in the context of COVID-19 infection. Unexpected hyperkalemia in CS patients under treatment with heparin might be the signal of aldosterone suppression.
C1 [Beretta, Federica; Dassie, Francesca; Parolin, Matteo; Busetto, Luca; Mioni, Roberto; De Carlo, Eugenio; Fallo, Francesco; Vettor, Roberto; Maffei, Pietro] Univ Padua, Dept Med, Clin Med 3, Padua, Italy.
   [Boscari, Federico] Univ Padua, Dept Med, Div Metab Dis, Padua, Italy.
   [Barbot, Mattia; Scaroni, Carla] Univ Padua, Dept Med, Endocrinol Unit, Padua, Italy.
RP Dassie, F (corresponding author), Univ Padua, Dept Med, Clin Med 3, Padua, Italy.
EM francesca.dasse@libero.it
CR Bornstein SR, 2020, LANCET DIABETES ENDO, V8, P546, DOI 10.1016/S2213-8587(20)30152-2
   Caccese M, 2020, ANTI-CANCER DRUG, V31, P199, DOI 10.1097/CAD.0000000000000856
   Contini C, 2020, J INFECT DEV COUNTR, V14, P254, DOI 10.3855/jidc.12671
   Feelders RA, 2019, LANCET DIABETES ENDO, V7, P300, DOI 10.1016/S2213-8587(18)30155-4
   Isidori AM, 2020, J ENDOCRINOL INVEST, V43, P1141, DOI 10.1007/s40618-020-01266-w
   Italian Society of Infectious and Tropical Diseases (SIMIT), 2020, LOMB REG SECT VAD TH
   Kakodkar P, 2020, CUREUS, V12, DOI 10.7759/cureus.7560
   Kollias A, 2020, BRIT J HAEMATOL, V189, P846, DOI 10.1111/bjh.16727
   Li MY, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00662-x
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Newell-Price J, 2020, EUR J ENDOCRINOL, V183, pG1, DOI 10.1530/EJE-20-0352
   OSTER JR, 1995, AM J MED, V98, P575, DOI 10.1016/S0002-9343(99)80017-5
   Pal R, 2020, ENDOCRINE, V68, P251, DOI 10.1007/s12020-020-02325-1
   Pivonello R, 2016, LANCET DIABETES ENDO, V4, P611, DOI 10.1016/S2213-8587(16)00086-3
   Puig-Domingo M, 2020, ENDOCRINE, V68, P2, DOI 10.1007/s12020-020-02294-5
   Wang X, 2020, INT J INFECT DIS, V94, P107, DOI 10.1016/j.ijid.2020.04.023
   Zhai ZG, 2020, THROMB HAEMOSTASIS, V120, P937, DOI 10.1055/s-0040-1710019
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 18
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD SEP 11
PY 2020
VL 11
AR 554
DI 10.3389/fendo.2020.00554
PG 7
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NX8KL
UT WOS:000575952800001
PM 33071957
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Camelo, AE
   Silva, AMS
   Estephan, EP
   Zambon, AA
   Mendonca, RH
   Souza, PVS
   Pinto, WBVR
   Oliveira, ASB
   Dangoni, I
   Pouza, AFP
   Valerio, BCO
   Zanoteli, E
AF Camelo-Filho, Antonio E.
   Silva, Andre M. S.
   Estephan, Eduardo P.
   Zambon, Antonio A.
   Mendonca, Rodrigo H.
   Souza, Paulo V. S.
   Pinto, Wladimir B. V. R.
   Oliveira, Acary S. B.
   Dangoni-Filho, Iron
   Pouza, Ana F. P.
   Valerio, Berenice C. O.
   Zanoteli, Edmar
TI Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE Myasthenia Gravis; COVID-19; SARS-CoV-2; neuromuscular disorders;
   immunosuppression
AB Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may be a risk factor for severe COVID-19. We conducted an observational retrospective study with 15 consecutive adult MG patients admitted with COVID-19 at four hospitals in Sao Paulo, Brazil. Most patients with MG hospitalized for COVID-19 had severe courses of the disease: 87% were admitted in the intensive care unit, 73% needed mechanical ventilation, and 30% died. Immunoglobulin use and the plasma exchange procedure were safe. Immunosuppressive therapy seems to be associated with better outcomes, as it might play a protective role.
C1 [Camelo-Filho, Antonio E.; Silva, Andre M. S.; Estephan, Eduardo P.; Zambon, Antonio A.; Mendonca, Rodrigo H.; Dangoni-Filho, Iron; Pouza, Ana F. P.; Zanoteli, Edmar] Univ Sao Paulo, Fac Med, Dept Neurol, Sao Paulo, Brazil.
   [Estephan, Eduardo P.] Fac Med Santa Marceline, Dept Neurol, Sao Paulo, Brazil.
   [Souza, Paulo V. S.; Pinto, Wladimir B. V. R.; Oliveira, Acary S. B.] Univ Fed Sao Paulo, Dept Neurol & Neurosurg, Sao Paulo, Brazil.
   [Pouza, Ana F. P.] Inst Assistencia Mod Ao Servidor Publ Estadual, Dept Neurol, Sao Paulo, Brazil.
   [Valerio, Berenice C. O.] Fac Ciencias Med Santa Casa Sao Paulo, Dept Internal Med, Sao Paulo, Brazil.
RP Zanoteli, E (corresponding author), Univ Sao Paulo, Fac Med, Dept Neurol, Sao Paulo, Brazil.
EM edmar.zanoteli@usp.br
OI Estephan, Eduardo/0000-0002-6807-1951
CR Anand P, 2020, MUSCLE NERVE, V62, P254, DOI 10.1002/mus.26918
   Delly F, 2020, J NEUROL SCI, V414, DOI 10.1016/j.jns.2020.116888
   Guidon AC, 2020, NEUROLOGY, V94, P959, DOI 10.1212/WNL.0000000000009566
   Jaretzki A, 2000, NEUROLOGY, V55, P16, DOI 10.1212/WNL.55.1.16
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Ministerio da Saude Brazil, 2020, SRAG 2020 BANC DAD S
   Novi G, 2019, MULT SCLER RELAT DIS, V36, DOI 10.1016/j.msard.2019.101430
   Ramaswamy Swathi Beladakere, 2020, J Neuromuscul Dis, V7, P361, DOI 10.3233/JND-200520
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Romero-Sanchez CM, 2020, NEUROLOGY, V95, pE1060, DOI 10.1212/WNL.0000000000009937
   Valencia-Sanchez C, 2020, MULT SCLER RELAT DIS, V42, DOI 10.1016/j.msard.2020.102182
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 15
TC 2
Z9 2
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD SEP 11
PY 2020
VL 11
AR 1053
DI 10.3389/fneur.2020.01053
PG 5
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NX8YG
UT WOS:000575988800001
PM 33013676
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Conversano, C
   Di Giuseppe, M
   Miccoli, M
   Ciacchini, R
   Gemignani, A
   Orru, G
AF Conversano, Ciro
   Di Giuseppe, Mariagrazia
   Miccoli, Mario
   Ciacchini, Rebecca
   Gemignani, Angelo
   Orru, Graziella
TI Mindfulness, Age and Gender as Protective Factors Against Psychological
   Distress During COVID-19 Pandemic
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE mindfulness; COVID-19; pandemic; meditation; psychological distress;
   SCL-90; MAAS; adjustment
ID DISPOSITIONAL MINDFULNESS; MENTAL-HEALTH; SELF-REPORT;
   DEFENSE-MECHANISMS; COGNITIVE THERAPY; BIPOLAR DISORDER; STRESS;
   RESILIENCE; INTERVENTION; DEPRESSION
AB Objective Mindfulness disposition is associated with various psychological factors and prevents emotional distress in chronic diseases. In the present study, we analyzed the key role of mindfulness dispositions in protecting the individual against psychological distress consequent to COVID-19 social distancing and quarantining. Methods An online survey was launched on March 13, 2020, with 6,412 responses by April 6, 2020. Socio-demographic information, exposure to the pandemic, and quarantining were assessed together with psychological distress and mindfulness disposition. Multivariate linear regression analysis was performed to study the influence of predictive factors on psychological distress and quality of life in Italian responders during the early days of lockdown. Pearson correlations were calculated to study the relationship between mindfulness and psychiatric symptoms. Results Multivariate linear regression run on socio-demographics, COVID-19-related variables, and mindfulness disposition as moderators of overall psychological distress showed that mindfulness was the best predictor of psychological distress (beta = -0.504;p< 0.0001). High negative correlations were found between mindfulness disposition and the overall Global Severity Index (r= -0.637;p< 0.0001), while moderate to high associations were found between mindfulness and all SCL-90 sub-scales. Discussion Findings showed that high dispositional mindfulness enhances well-being and helps in dealing with stressful situations such as the COVID-19 pandemic. Mindfulness-based mental training could represent an effective intervention to stem post-traumatic psychopathological beginnings and prevent the onset of chronic mental disorders.
C1 [Conversano, Ciro; Di Giuseppe, Mariagrazia; Ciacchini, Rebecca; Gemignani, Angelo; Orru, Graziella] Univ Pisa, Dept Surg Med & Mol Pathol, Crit & Care Med, Pisa, Italy.
   [Miccoli, Mario] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy.
RP Di Giuseppe, M (corresponding author), Univ Pisa, Dept Surg Med & Mol Pathol, Crit & Care Med, Pisa, Italy.
EM Mariagrazia.digiuseppe@gmail.com
RI Conversano, Ciro/ABE-1007-2020
OI Conversano, Ciro/0000-0002-0726-3634
CR Doorn KAV, 2020, COUNS PSYCHOL Q, DOI 10.1080/09515070.2020.1773404
   Abenavoli R. M., 2013, PSYCHOL ED REV, V37, P57
   Acierno R, 2006, AM J GERIAT PSYCHIAT, V14, P1051, DOI 10.1097/01.JGP.0000221327.97904.b0
   Alon T.M., 2020, W26947 NAT BUR EC RE
   Baer RA, 2006, ASSESSMENT, V13, P27, DOI 10.1177/1073191105283504
   Baer RA, 2004, ASSESSMENT, V11, P191, DOI 10.1177/1073191104268029
   Baer RA, 2003, CLIN PSYCHOL-SCI PR, V10, P125, DOI 10.1093/clipsy/bpg015
   Bao XM, 2015, PERS INDIV DIFFER, V78, P48, DOI 10.1016/j.paid.2015.01.007
   Black DS, 2012, ASSESSMENT, V19, P42, DOI 10.1177/1073191111415365
   Bonicatto S, 1997, SOC PSYCH PSYCH EPID, V32, P332, DOI 10.1007/BF00805438
   Bradbury-Jones C, 2020, J CLIN NURS, V29, P2047, DOI 10.1111/jocn.15296
   Branstrom R, 2011, BRIT J HEALTH PSYCH, V16, P300, DOI 10.1348/135910710X501683
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822
   Carmassi C, 2018, ANN GEN PSYCHIATR, V17, DOI 10.1186/s12991-018-0184-4
   Carmassi C, 2014, ANN GEN PSYCHIATR, V13, DOI 10.1186/s12991-014-0028-9
   Cassano G., 1999, REPERTORIO SCALE VAL, P325
   Catalano A, 2019, CLIN DRUG INVEST, V39, P97, DOI 10.1007/s40261-018-0720-7
   Cellini N, 2020, J SLEEP RES, V29, DOI 10.1111/jsr.13074
   Chang VY, 2004, STRESS HEALTH, V20, P141, DOI 10.1002/smi.1011
   Chu CS, 2018, J AFFECT DISORDERS, V225, P234, DOI 10.1016/j.jad.2017.08.025
   Conversano C, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.01683
   Conversano C, 2020, CLIN NEUROPSYCHIATR, V17, P94, DOI 10.36131/CN20200212
   Conversano C, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.02727
   Costa P., 2008, SAGE HDB PERSONALITY, V2, P179, DOI DOI 10.4135/9781849200479.N9
   Davidson RJ, 2003, PSYCHOSOM MED, V65, P564, DOI 10.1097/01.PSY.0000077505.67574.E3
   de Frias CM, 2015, AGING MENT HEALTH, V19, P201, DOI 10.1080/13607863.2014.924090
   Dell'Osso L, 2012, ANN GEN PSYCHIATR, V11, DOI 10.1186/1744-859X-11-27
   Deng YQ, 2014, MINDFULNESS, V5, P124, DOI 10.1007/s12671-012-0157-7
   DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13
   DEROGATIS LR, 1977, J CLIN PSYCHOL, V33, P981, DOI 10.1002/1097-4679(197710)33:4<981::AID-JCLP2270330412>3.0.CO;2-0
   DEROGATIS LR, 1976, BRIT J PSYCHIAT, V128, P280, DOI 10.1192/bjp.128.3.280
   Di Giuseppe M., 2020, J NERV MENT DIS, V8, DOI [10.1080/00332747.2019.1579595, DOI 10.1080/00332747.2019.1579595]
   Di Giuseppe M, 2020, MEDITERR J CLIN PSYC, V8, DOI 10.6092/2282-1619/mjcp-2515
   Di Giuseppe M, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00870
   Di Giuseppe M, 2020, MEDITERR J CLIN PSYC, V8, DOI 10.6092/2282-1619/mjcp-2384
   Di Giuseppe M, 2020, CLIN NEUROPSYCHIATR, V17, P85, DOI 10.36131/CN20200210
   Di Giuseppe M, 2019, EUR J ONCOL NURS, V40, P104, DOI 10.1016/j.ejon.2019.04.003
   Di Giuseppe M, 2019, PSYCHIATRY, V82, P128, DOI 10.1080/00332747.2019.1579595
   Di Giuseppe M, 2018, J PSYCHOSOM RES, V115, P76, DOI 10.1016/j.jpsychores.2018.10.016
   Dixon HC, 2016, J SOC CLIN PSYCHOL, V35, P255, DOI 10.1521/jscp.2016.35.3.255
   Evans S, 2008, J ANXIETY DISORD, V22, P716, DOI 10.1016/j.janxdis.2007.07.005
   Fisher S, 2020, COUNS PSYCHOL, DOI [10.1080/09515070.2020.1777535, DOI 10.1080/09515070.2020.1777535]
   Fonagy P, 2016, COMPR PSYCHIAT, V64, P59, DOI 10.1016/j.comppsych.2015.11.006
   Fuller-Iglesias H, 2008, RES HUM DEV, V5, P181, DOI 10.1080/15427600802274043
   Geng LN, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16020248
   Helbig S, 2006, SOC PSYCH PSYCH EPID, V41, P889, DOI 10.1007/s00127-006-0113-8
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Idusohan-Moizer H, 2015, J INTELL DISABIL RES, V59, P93, DOI 10.1111/jir.12082
   Jha AP, 2017, MINDFULNESS, V8, P46, DOI 10.1007/s12671-015-0465-9
   Jha AP, 2010, EMOTION, V10, P54, DOI 10.1037/a0018438
   Jones P., 2013, BRIT J PSYCHIAT S54, V202, P5, DOI DOI 10.1192/bjp.bp.112.119164
   Kabat-Zinn J, 2003, CLIN PSYCHOL-SCI PR, V10, P144, DOI 10.1093/clipsy/bpg016
   Kabat-Zinn J, 2015, MINDFULNESS, V6, P1481, DOI 10.1007/s12671-015-0456-x
   Kessler RC, 2007, WORLD PSYCHIATRY, V6, P168
   Kwon J., 2020, DEFINING FACETS SOCI, DOI [10.1101/2020.04.26.20080937, DOI 10.1101/2020.04.26.20080937]
   Lam AHY, 2020, NEUROPSYCH DIS TREAT, V16, P729, DOI 10.2147/NDT.S231877
   Lara Muñoz Carmen, 2005, Salud Ment, V28, P42
   Lenzo V, 2020, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.02875
   Li SJ, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17062032
   Lingiardi V, 2010, RICERCA PSICOTERAPIA, V2, P97, DOI DOI 10.4081/ripppo.2010.36
   Maffei C, 1995, J PERS DISORD, V9, P330, DOI 10.1521/pedi.1995.9.4.330
   Manuell ME, 2011, DISASTERS, V35, P417, DOI 10.1111/j.1467-7717.2010.01219.x
   Marazziti D, 2008, NEUROPSYCHOBIOLOGY, V57, P38, DOI 10.1159/000129665
   Marazziti D, 2020, PSYCHOL TRAUMA-US, V12, P531, DOI 10.1037/tra0000687
   Marazziti D, 2015, J INT NEUROPSYCH SOC, V21, P670, DOI 10.1017/S135561771500082X
   Marchi L, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.01735
   Mariagrazia D, 2019, HEALTH PSYCHOL OPEN, V6, DOI 10.1177/2055102919854667
   Martino G, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230681
   Martino G, 2020, FRONT PSYCHOL, V11, DOI 10.3389/fpsyg.2020.00267
   Martino G, 2019, MEDITERR J CLIN PSYC, V7, DOI 10.6092/2282-1619/2019.7.2328
   Martino G, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.02502
   Martino G, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.01779
   Matti H., 2003, HELSINGIN YLIOPISTO, V15, P203
   Maunder R, 2003, CAN MED ASSOC J, V168, P1245
   Merlo EM, 2019, MEDITERR J CLIN PSYC, V7, DOI 10.6092/2282-1619/2019.7.2341
   Mula M, 2008, J ANXIETY DISORD, V22, P1421, DOI 10.1016/j.janxdis.2008.02.004
   Muratori P, 2020, CLIN NEUROPSYCHIATR, V17, P131, DOI 10.36131/CN20200219
   Nelson SK, 2014, PSYCHOL BULL, V140, P846, DOI 10.1037/a0035444
   Orru G, 2020, CLIN NEUROPSYCHIATR, V17, P76, DOI 10.36131/CN20200208
   Orru G, 2020, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.02970
   Orru G, 2020, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00319
   Pearl J, 2010, INT J BIOSTAT, V6, DOI 10.2202/1557-4679.1203
   Piccinni A, 2012, J AFFECT DISORDERS, V138, P160, DOI 10.1016/j.jad.2011.12.042
   Poli A, 2020, CLIN NEUROPSYCHIATR, V17, P112, DOI 10.36131/CN20200216
   Prout TA, 2019, J CONTEMP PSYCHOTHER, V49, P235, DOI 10.1007/s10879-019-09423-w
   Rasmussen MK, 2011, ANXIETY STRESS COPIN, V24, P227, DOI 10.1080/10615806.2010.515681
   Rosenfield S., 2013, HDB SOCIOLOGY MENTAL, P277, DOI DOI 10.1007/978-94-007-4276-5_14
   Rosenfield S., 1999, HDB STUDY MENTAL HLT, P348
   Ryan RM, 2000, AM PSYCHOL, V55, P68, DOI 10.1037/0003-066X.55.1.68
   Salovey P., 1995, EMOTION DISCLOSURE H, P125, DOI [10.1037/10182-006, DOI 10.1037/10182-006]
   Sartori G., 2017, DETECTION MALINGERIN, P330
   Seedat S, 2009, ARCH GEN PSYCHIAT, V66, P785, DOI 10.1001/archgenpsychiatry.2009.36
   Segal ZV, 2018, MINDFULNESS BASED CO
   Shear Jonathan, 1999, J CONSCIOUSNESS STUD, V6, P189
   Soysa CK, 2015, MINDFULNESS, V6, P217, DOI 10.1007/s12671-013-0247-1
   Strauss C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096110
   Tang YY, 2015, NAT REV NEUROSCI, V16, P213, DOI 10.1038/nrn3916
   Taub A., 2020, NEW COVID 19 CRISIS
   Teasdale JD, 2000, J CONSULT CLIN PSYCH, V68, P615, DOI 10.1037/0022-006X.68.4.615
   Veltri A, 2012, CLIN EXP RHEUMATOL, V30, pS136
   Veneziani CA, 2015, MINDFULNESS, V6, P373, DOI 10.1007/s12671-013-0270-2
   Walsh JJ, 2009, PERS INDIV DIFFER, V46, P94, DOI 10.1016/j.paid.2008.09.008
   Wang CY, 2020, BRAIN BEHAV IMMUN, V87, P40, DOI 10.1016/j.bbi.2020.04.028
   Westphal M, 2015, J AFFECT DISORDERS, V175, P79, DOI 10.1016/j.jad.2014.12.038
   Xu M, 2017, CONSCIOUS COGN, V51, P157, DOI 10.1016/j.concog.2017.03.009
   Zhang MF, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000897
NR 107
TC 8
Z9 8
U1 6
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD SEP 11
PY 2020
VL 11
AR 1900
DI 10.3389/fpsyg.2020.01900
PG 9
WC Psychology, Multidisciplinary
SC Psychology
GA NX3YY
UT WOS:000575648800001
PM 33013503
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Taguchi, YH
   Turki, T
AF Taguchi, Y-H
   Turki, Turki
TI A new advancedin silicodrug discovery method for novel coronavirus
   (SARS-CoV-2) with tensor decomposition-based unsupervised feature
   extraction
SO PLOS ONE
LA English
DT Article
ID VIRUS; REPLICATION; INHIBITION; APOPTOSIS; AGENTS
AB Background: COVID-19 is a critical pandemic that has affected human communities worldwide, and there is an urgent need to develop effective drugs. Although there are a large number of candidate drug compounds that may be useful for treating COVID-19, the evaluation of these drugs is time-consuming and costly. Thus, screening to identify potentially effective drugs prior to experimental validation is necessary. Method: In this study, we applied the recently proposed method tensor decomposition (TD)-based unsupervised feature extraction (FE) to gene expression profiles of multiple lung cancer cell lines infected with severe acute respiratory syndrome coronavirus 2. We identified drug candidate compounds that significantly altered the expression of the 163 genes selected by TD-based unsupervised FE. Results: Numerous drugs were successfully screened, including many known antiviral drug compounds such as C646, chelerythrine chloride, canertinib, BX-795, sorafenib, sorafenib, QL-X-138, radicicol, A-443654, CGP-60474, alvocidib, mitoxantrone, QL-XII-47, geldanamycin, fluticasone, atorvastatin, quercetin, motexafin gadolinium, trovafloxacin, doxycycline, meloxicam, gentamicin, and dibromochloromethane. The screen also identified ivermectin, which was first identified as an anti-parasite drug and recently the drug was included in clinical trials for SARS-CoV-2. Conclusions: The drugs screened using our strategy may be effective candidates for treating patients with COVID-19.
C1 [Taguchi, Y-H] Chuo Univ, Dept Phys, Tokyo, Japan.
   [Turki, Turki] King Abdulaziz Univ, Dept Comp Sci, Jeddah, Saudi Arabia.
RP Taguchi, YH (corresponding author), Chuo Univ, Dept Phys, Tokyo, Japan.
EM tag@granular.com
RI Taguchi, Y-h./E-1474-2011
OI Taguchi, Y-h./0000-0003-0867-8986
FU KAKENHIMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for
   Scientific Research (KAKENHI) [19H05270, 20H04848, 20K12067]; Deanship
   of Scientific Research (DSR) at King Abdulaziz University, Jeddah
   [KEP-8-611-38]
FX This work was supported by KAKENHI [grant numbers 19H05270, 20H04848,
   and 20K12067] to YT and Deanship of Scientific Research (DSR) at King
   Abdulaziz University, Jeddah [grant number KEP-8-611-38] to TT.
CR [Anonymous], 2007, NUTR BUSINESS J, V12, P1
   [Anonymous], 2017, KIDNEY INT S, V7, P1, DOI DOI 10.1016/j.kisu.2017.04.001
   Blanco-Melo D., 2020, SARS COV 2 LAUNCHES
   Brahms A, 2017, J VIROLOGY, V91
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chan CM, 2007, ARCH BIOCHEM BIOPHYS, V459, P197, DOI 10.1016/j.abb.2007.01.012
   Connor JH, 2007, VIROLOGY, V362, P109, DOI 10.1016/j.virol.2006.12.026
   Culita DC, 2012, REV CHIM-BUCHAREST, V63, P384
   de Wispelaere M, 2017, ANTIVIR RES, V139, P171, DOI 10.1016/j.antiviral.2016.12.017
   Deng L, 2007, J VIROL, V81, P13392, DOI 10.1128/JVI.00770-07
   Episcopio D, 2019, FASEB J, V33, P9516, DOI 10.1096/fj.201900428RR
   FISCHER AB, 1975, MED MICROBIOL IMMUN, V161, P23, DOI 10.1007/BF02120767
   Gordon DE, 2020, SARS COV 2 HUMAN PRO
   He B, 2020, REPURPOSED DRUGS TRE
   Huang CT, 2019, ISCIENCE, V15, P291, DOI 10.1016/j.isci.2019.04.039
   Iorio F, 2010, P NATL ACAD SCI USA, V107, P14621, DOI 10.1073/pnas.1000138107
   Jeong GU, 2019, ANTIVIR RES, V170, DOI 10.1016/j.antiviral.2019.104572
   Kubota N, 2016, WORLD J HEPATOL, V8, P282, DOI 10.4254/wjh.v8.i5.282
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Li YH, 2004, ANTIMICROB AGENTS CH, V48, P867, DOI 10.1128/AAC.48.3.867-872.2004
   Perez OD, 2002, P NATL ACAD SCI USA, V99, P2270, DOI 10.1073/pnas.261711499
   Perwitasari O, 2015, ASSAY DRUG DEV TECHN, V13, P638, DOI 10.1089/adt.2015.0003.drrr
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robson B, 2020, COMPUT BIOL MED, V119, DOI 10.1016/j.compbiomed.2020.103670
   Singanayagam Aran, 2015, Lancet, V385 Suppl 1, pS88, DOI 10.1016/S0140-6736(15)60403-2
   Sirota M, 2011, SCI TRANSL MED, V3, p96ra77
   Su AR, 2017, ACTA PHARMACOL SIN, V38, P402, DOI 10.1038/aps.2016.160
   Sultan I, 2020, DRUG REPOSITIONING S
   Taguchi YH, 2019, CURR PHARM DESIGN, V25, P4589, DOI 10.2174/1381612825666191210160906
   Taguchi Y, 2019, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2395-8
   Taguchi YH, 2020, UNSUPERVISED FEATURE
   Taguchi YH, 2020, NOVEL METHOD DETECTI
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Ubani A, 2020, MOL DOCKING ANAL SOM
   Wu C, 2020, ACTA PHARM SINICA B
   Wu ZC, 2015, FEMS MICROBIOL LETT, V362, DOI 10.1093/femsle/fnv195
   Yang HL, 2005, J CLIN INVEST, V115, P379, DOI 10.1172/jc1200523200
   Yi L, 2004, J VIROL, V78, P11334, DOI 10.1128/JVI.78.20.11334-11339.2004
   Zhao DM, 2016, ANTIMICROB AGENTS CH, V60, P1902, DOI 10.1128/AAC.02055-15
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   2018, CURR OPIN TOXICOL, V10
NR 42
TC 1
Z9 1
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 11
PY 2020
VL 15
IS 9
AR e0238907
DI 10.1371/journal.pone.0238907
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NR9MU
UT WOS:000571887500065
PM 32915876
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zeng, MJ
   Li, LJ
   Wu, ZQ
AF Zeng, Mengjie
   Li, Linjun
   Wu, Zhiquan
TI Traditional Chinese medicine Lianhua Qingwen treating corona virus
   disease 2019(COVID-19): Meta-analysis of randomized controlled trials
SO PLOS ONE
LA English
DT Article
AB Introduction As the global epidemic continues to spread, countries have tapped effective drugs to treat new coronavirus pneumonia. The therapeutic effect of the traditional Chinese medicine Lianhua Qingwen in this new coronary pneumonia epidemic has attracted attention from all walks of life, and relevant research reports continue to appear. Therefore, we conducted a systematic review of the clinical efficacy and safety of the traditional Chinese medicine Lianhua Qingwen in the treatment of new coronavirus pneumonia (COVID-19) (referred to as "new coronary pneumonia"), and evaluated the overall level of research quality. Methods We searched seven databases and retrieved the Chinese Journal Full-text Database (CNKI), Vip Database (VIP), China Biomedicine (SinoMed), Wanfang Database and PubMed, Cochrane Central, EMBASE from October 2019 to May 2020 Literature references. We included randomized controlled trials (RCTs) that tested the efficacy of the traditional Chinese medicine lotus clearing plague in the treatment of new coronavirus pneumonia. The authors extracted data and independently assessed quality. We used Stata15.1 software to analyze the data of randomized trials. Results A total of 2 articles were identified, including 154 patients. All the participating patients were diagnosed with new coronavirus pneumonia (COVID-19). The meta-analysis results showed that the disappearance rate of the main clinical symptoms of Chinese medicine Lianhua Qingwen in the treatment of new coronavirus pneumonia was significantly higher than that of the control group [OR = 3.34, 95% CI (2.06, 5.44), P <0.001]; the disappearance rate of other clinical secondary symptoms is significantly higher than the control group [OR = 6.54, 95% CI (3.59, 11.90), P <0.001]. The duration of fever was significantly lower than that of the control group [OR = -1.04, 95% CI (-1.60, -0.49), P <0.001]. It is confirmed that the traditional Chinese medicine Lianhua Qingwen treatment improves the clinical effectiveness, and also has certain advantages in relieving cough and fever. Conclusion The treatment of new pneumonia with traditional Chinese medicine lotus clearing plague can be used as an effective therapy to improve the clinical symptoms of new coronary pneumonia. More rigorous design, multi-center, and prospective RCTs are necessary to further determine the effectiveness and safety of the traditional Chinese medicine lotus decoction in the treatment of new pneumonia.
C1 [Zeng, Mengjie] Macau Univ Sci & Technol, Dept Tradit Chinese Med, Macau, Peoples R China.
   [Li, Linjun] Yunnan Univ Tradit Chinese Med, Dept Acupuncture & Tuina, Kunming, Yunnan, Peoples R China.
   [Wu, Zhiquan] Sanya Cent Hosp, Dept Rehabil Med, Sanya, Peoples R China.
RP Wu, ZQ (corresponding author), Sanya Cent Hosp, Dept Rehabil Med, Sanya, Peoples R China.
EM 513376829@qq.com
RI Wu, Zhiquan/ABD-2420-2020
FU Sanya medical science and technology innovation project [2017YW06]
FX This work was supported by Sanya medical science and technology
   innovation project, No.: 2017YW06
CR [Anonymous], 2013, PANCREATOLOGY, V13, pe1
   [Anonymous], 2020, J TIANJIN U TRADITIO, V39, P121
   [Anonymous], 2017, EPLASTY, V17, pic25
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Dezhong Cheng, TIANJIN CHINESE MED, V30, P1
   Dong Liang, 2014, EVID-BASED COMPL ALT, V2014
   Higgins J, 2011, COCHRANE COLLAB, V5, P1, DOI DOI 10.1002/9780470712184
   Lin Wang, 2020, CHINESE HERBAL MED, P1
   Shuming Gao, 2020, TIANJIN CHINESE MED, V37, P121
   WANG SH, 2019, CHINA J CHIN MAT MED, V44, P113
   Xiaoying Ling, 2020, CHINESE HERBAL MED, V51, P1723
   Yao K.T., 2020, CHIN J EXP TRADIT ME, DOI [10.13422/j.cnki.syfjx.20201099, DOI 10.13422/J.CNKI.SYFJX.20201099]
   Yingying Jiao, 2020, J GUANGDONG PHARM U, V36, P169
NR 13
TC 0
Z9 0
U1 6
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 11
PY 2020
VL 15
IS 9
AR e0238828
DI 10.1371/journal.pone.0238828
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NR9MU
UT WOS:000571887500136
PM 32915877
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Saul, S
   Einav, S
AF Saul, Sirle
   Einav, Shirit
TI Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19
SO ACS INFECTIOUS DISEASES
LA English
DT Article
DE antiviral drugs; repurposing; COVID-19; SARS-CoV-2; small molecule
   inhibitors; anti-inflammatory drugs; direct acting antivirals;
   host-targeted approaches
ID RESPIRATORY SYNDROME CORONAVIRUS; EBOLA-VIRUS; KINASE INHIBITORS; DENGUE
   VIRUS; INFECTION; REPLICATION; FAVIPIRAVIR; CHLOROQUINE; EFFICACY;
   RECEPTOR
AB There is a large global unmet need for effective countermeasures to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19). The development of novel antiviral drugs is expensive and too slow to meet the immediate need. The repurposing of drugs that are approved or are under advanced clinical investigation provides a cost- and time-effective therapeutic solution. This review summarizes the major repurposed approaches that have been proposed or are already being studied in clinical trials for COVID-19. Among these approaches are drugs that aim to reduce SARS-CoV-2 replication by targeting either viral enzymatic functions or cellular factors required for the viral life cycle. Drugs that modulate the host immune response to SARS-CoV-2 infection by boosting it to enhance viral clearance or by suppressing it to prevent excessive inflammation and tissue injury represent another category. Lastly, we discuss means to discover repurposed drugs and the ongoing challenges associated with the off-label use of existing drugs in the context of the COVID-19 outbreak.
C1 [Saul, Sirle; Einav, Shirit] Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Dept Med, Stanford, CA 94305 USA.
   [Saul, Sirle; Einav, Shirit] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.
RP Einav, S (corresponding author), Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Dept Med, Stanford, CA 94305 USA.; Einav, S (corresponding author), Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA.
EM seinav@stanford.edu
FU Defense Threat Reduction AgencyUnited States Department of
   DefenseDefense Threat Reduction Agency [HDTRA11810039]; Department of
   Defense office of the Congressionally Directed Medical Research Programs
   (CDMRP), Peer Reviewed Medical Research Program (PRMRP)
   [W81XWH-16-1-0691]
FX This research was supported by grant HDTRA11810039 from the Defense
   Threat Reduction Agency and by an InvestigatorInitiated Research Award
   (W81XWH-16-1-0691) from the Department of Defense office of the
   Congressionally Directed Medical Research Programs (CDMRP), Peer
   Reviewed Medical Research Program (PRMRP) to S.E. The authors
   acknowledge all the contributions in the field that could not be
   included in the review.
CR Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099
   Azad GK, 2014, MOL BIOL REP, V41, P2717, DOI 10.1007/s11033-014-3181-y
   Bai CQ, 2016, CLIN INFECT DIS, V63, P1288, DOI 10.1093/cid/ciw571
   Barker AD, 2009, CLIN PHARMACOL THER, V86, P97, DOI 10.1038/clpt.2009.68
   Barnard Dale L., 2006, Antiviral Chemistry & Chemotherapy, V17, P275
   Beckman JA, 2016, AM J PHYSIOL-HEART C, V311, pH1431, DOI 10.1152/ajpheart.00504.2016
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bekerman E, 2017, J CLIN INVEST, V127, P1338, DOI 10.1172/JCI89857
   Bekerman E, 2015, SCIENCE, V348, P282, DOI 10.1126/science.aaa3778
   Berry SM, 2016, CLIN TRIALS, V13, P22, DOI 10.1177/1740774515621721
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Borges MC, 2013, MEM I OSWALDO CRUZ, V108, P596, DOI 10.1590/S0074-02762013000500010
   Bouhaddou M, 2020, CELL, V182, P685, DOI 10.1016/j.cell.2020.06.034
   Broggi A, 2020, J EXP MED, V217, DOI 10.1084/jem.20190295
   Cai GJ, 2020, STEEL RES INT, DOI 10.1002/srin.202000269
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Cai XM, 2013, CHEM BIOL, V20, P912, DOI 10.1016/j.chembiol.2013.05.010
   Cantini F, 2020, J INFECTION, V81, P318, DOI 10.1016/j.jinf.2020.04.017
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Chen W, 2017, CELL SIGNAL, V41, P89, DOI 10.1016/j.cellsig.2017.04.001
   Chu H, 2020, CLIN INFECT DIS
   Chu JJH, 2007, P NATL ACAD SCI USA, V104, P3520, DOI 10.1073/pnas.0611681104
   Clark MJ, 2016, CELL CHEM BIOL, V23, P443, DOI 10.1016/j.chembiol.2016.03.010
   Coleman CM, 2016, J VIROL, V90, P8924, DOI 10.1128/JVI.01429-16
   De Clercq E, 2015, BIOCHEM PHARMACOL, V93, P1, DOI 10.1016/j.bcp.2014.11.008
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   de Wispelaere M, 2013, J VIROL, V87, P7367, DOI 10.1128/JVI.00632-13
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Dean NE, 2020, NEW ENGL J MED, V382, P1366, DOI 10.1056/NEJMsb1905390
   DiMasi JA, 2016, J HEALTH ECON, V47, P20, DOI 10.1016/j.jhealeco.2016.01.012
   Du YX, 2020, CLIN PHARMACOL THER, V108, P242, DOI 10.1002/cpt.1844
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Frayha GJ, 1997, GEN PHARMACOL, V28, P273, DOI 10.1016/S0306-3623(96)00149-8
   Furuta Y, 2017, P JPN ACAD B-PHYS, V93, P449, DOI 10.2183/pjab.93.027
   Gassen N.C., 2019, FRONT PSYCHIATRY, V10, P1
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gibo J, 2005, LAB INVEST, V85, P75, DOI 10.1038/labinvest.3700203
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Hamming OJ, 2013, EMBO J, V32, P3055, DOI 10.1038/emboj.2013.232
   Haqqani AA, 2013, ANTIVIR RES, V98, P158, DOI 10.1016/j.antiviral.2013.03.017
   Hardie WD, 2008, AM J PHYSIOL-LUNG C, V294, pL1217, DOI 10.1152/ajplung.00020.2008
   He G, 2020, HERZ, V45, P335, DOI 10.1007/s00059-018-4732-0
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00754-20
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Ju MJ, 2019, MOL MED REP, V20, P3347, DOI 10.3892/mmr.2019.10561
   Kassiri Z, 2009, CIRC-HEART FAIL, V2, P446, DOI 10.1161/CIRCHEARTFAILURE.108.840124
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Khajah M. A., 2016, PLOS ONE, V11
   Kil J, 2017, LANCET, V390, P969, DOI 10.1016/S0140-6736(17)31791-9
   Kim YJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104558
   Kindrachuk J, 2015, ANTIMICROB AGENTS CH, V59, P1088, DOI 10.1128/AAC.03659-14
   Krichel B, 2020, BIOCHEM J, V477, P1009, DOI 10.1042/BCJ20200029
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kubo S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01510
   Kumari G, 2020, BIORXIV, DOI [10.1101/2020.03.07.982264, DOI 10.1101/2020.03.07.982264]
   Li H, 2020, LEUKEMIA, V34, P1503, DOI 10.1038/s41375-020-0848-3
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu RX, 2014, J GASTROEN HEPATOL, V29, P1328, DOI 10.1111/jgh.12584
   Loutfy MR, 2003, JAMA-J AM MED ASSOC, V290, P3222, DOI 10.1001/jama.290.24.3222
   Lupberger J, 2011, NAT MED, V17, P589, DOI 10.1038/nm.2341
   Madelain V, 2016, CLIN PHARMACOKINET, V55, P907, DOI 10.1007/s40262-015-0364-1
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   Matt U, 2017, INT J ANTIMICROB AG, V50, P55, DOI 10.1016/j.ijantimicag.2017.02.022
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   MCCHESNEY EW, 1983, AM J MED, V75, P11, DOI 10.1016/0002-9343(83)91265-2
   Mita MM, 2017, BRIT J CANCER, V117, P1258, DOI 10.1038/bjc.2017.288
   Mizutani T, 2004, BIOCHEM BIOPH RES CO, V319, P1228, DOI 10.1016/j.bbrc.2004.05.107
   Mordstein M, 2010, J VIROL, V84, P5670, DOI 10.1128/JVI.00272-10
   Muir AJ, 2014, J HEPATOL, V61, P1238, DOI 10.1016/j.jhep.2014.07.022
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Oestereich L, 2014, ANTIVIR RES, V105, P17, DOI 10.1016/j.antiviral.2014.02.014
   Ohashi H., 2020, BIORXIV, DOI [10.1101/2020.04.14.039925., DOI 10.1101/2020.04.14.039925, 10.1101/ 2020.04.14.039925.]
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Pagano Mario Angelo, 2013, World J Virol, V2, P71, DOI 10.5501/wjv.v2.i2.71
   Pastick KA, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa130
   Prokunina-Olsson L, 2020, J EXP MED, V217, DOI 10.1084/jem.20200653
   Reeves PM, 2011, J VIROL, V85, P21, DOI 10.1128/JVI.01814-10
   Roschewski M, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd0110
   Rossotti R, 2020, J INFECTION, V81, pE11, DOI 10.1016/j.jinf.2020.07.008
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Schor S, 2018, DNA CELL BIOL, V37, P63, DOI 10.1089/dna.2017.4033
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Shin JS, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10060283
   Shirato K, 2013, J VIROL, V87, P12552, DOI 10.1128/JVI.01890-13
   Shiryaev SA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15467-6
   Farias KJS, 2015, VIRAL IMMUNOL, V28, P161, DOI 10.1089/vim.2014.0090
   Silva ACSE, 2013, BRIT J PHARMACOL, V169, P477, DOI 10.1111/bph.12159
   Somers E. C., 2020, CLIN INFECT DIS
   South AM, 2020, NAT REV NEPHROL, V16, P305, DOI 10.1038/s41581-020-0279-4
   Spagnolo P, 2020, LANCET RESP MED, V8, P750, DOI 10.1016/S2213-2600(20)30222-8
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Titanji BK, 2020, CLIN INFECT DIS, V95
   Tricou Vianney, 2010, PLoS Negl Trop Dis, V4, pe785, DOI 10.1371/journal.pntd.0000785
   Venkataraman T, 2017, J VIROL, V91, DOI 10.1128/JVI.00182-17
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang HF, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01370
   Wang M, 2018, LANCET, V391, P659, DOI 10.1016/S0140-6736(17)33108-2
   Wang WK, 2017, EXP THER MED, V14, P2497, DOI 10.3892/etm.2017.4824
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Warren TK, 2016, NATURE, V531, P381, DOI 10.1038/nature17180
   Warren TK, 2014, NATURE, V508, P402, DOI 10.1038/nature13027
   Williamson Brandi N, 2020, bioRxiv, DOI 10.1101/2020.04.15.043166
   Wu CJ, 2004, ANTIMICROB AGENTS CH, V48, P2693, DOI 10.1128/AAC.48.7.2693-2696.2004
   Xu JB, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020244
   Xu JM, 2020, ACS INFECT DIS, V6, P909, DOI 10.1021/acsinfecdis.0c00052
   Yaekura A, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106549
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Yan YW, 2013, CELL RES, V23, P300, DOI 10.1038/cr.2012.165
   Yao X, 2020, CLIN INFECT DIS
   Zhang XY, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-019-0968-6
   Zhou Q, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01061
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
NR 131
TC 0
Z9 0
U1 3
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373-8227
J9 ACS INFECT DIS
JI ACS Infect. Dis.
PD SEP 11
PY 2020
VL 6
IS 9
BP 2304
EP 2318
DI 10.1021/acsinfecdis.0c00343
PG 15
WC Chemistry, Medicinal; Infectious Diseases
SC Pharmacology & Pharmacy; Infectious Diseases
GA NR4FU
UT WOS:000571520200002
PM 32687696
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Cao, RY
   Hu, HR
   Li, YF
   Wang, X
   Xu, MY
   Liu, J
   Zhang, HY
   Yan, YZ
   Zhao, L
   Li, W
   Zhang, TH
   Xiao, D
   Guo, XJ
   Li, YX
   Yang, JJ
   Hu, ZH
   Wang, ML
   Zhong, W
AF Cao, Ruiyuan
   Hu, Hengrui
   Li, Yufeng
   Wang, Xi
   Xu, Mingyue
   Liu, Jia
   Zhang, Huanyu
   Yan, Yunzheng
   Zhao, Lei
   Li, Wei
   Zhang, Tianhong
   Xiao, Dian
   Guo, Xiaojia
   Li, Yuexiang
   Yang, Jingjing
   Hu, Zhihong
   Wang, Manli
   Zhong, Wu
TI Anti-SARS-CoV-2 Potential of Artemisinins In Vitro
SO ACS INFECTIOUS DISEASES
LA English
DT Article
DE artemisinin; SARS-CoV-2; COVID-19; antiviral drug; drug repurposing
ID HUMAN CYTOMEGALOVIRUS; ANTIVIRAL ACTIVITY; ARTESUNATE
AB The discovery of novel drug candidates with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) potential is critical for the control of the global COVID-19 pandemic. Artemisinin, an old antimalarial drug derived from Chinese herbs, has saved millions of lives. Artemisinins are a cluster of artemisinin-related drugs developed for the treatment of malaria and have been reported to have multiple pharmacological activities, including anticancer, antiviral, and immune modulation. Considering the reported broad-spectrum antiviral potential of artemisinins, researchers are interested in whether they could be used to combat COVID-19. We systematically evaluated the anti-SARS-CoV-2 activities of nine artemisinin-related compounds in vitro and carried out a time-of-drug-addition assay to explore their antiviral mode of action. Finally, a pharmacokinetic prediction model was established to predict the therapeutic potential of selected compounds against COVID-19. Arteannuin B showed the highest antiSARS-CoV-2 potential with an EC50 of 10.28 +/- 1.12 mu M. Artesunate and dihydroartemisinin showed similar EC50 values of 12.98 +/- 5.30 mu M and 13.31 +/- 1.24 mu M, respectively, which could be clinically achieved in plasma after intravenous administration. Interestingly, although an EC50 of 23.17 +/- 3.22 mu M was not prominent among the tested compounds, lumefantrine showed therapeutic promise due to high plasma and lung drug concentrations after multiple dosing. Further mode of action analysis revealed that arteannuin B and lumefantrine acted at the post-entry step of SARS-CoV-2 infection. This research highlights the anti-SARS-CoV-2 potential of artemisinins and provides leading candidates for anti-SARS-CoV-2 drug research and development.
C1 [Cao, Ruiyuan; Yan, Yunzheng; Zhao, Lei; Li, Wei; Zhang, Tianhong; Xiao, Dian; Guo, Xiaojia; Li, Yuexiang; Yang, Jingjing; Zhong, Wu] Beijing Inst Pharmacol & Toxicol, Natl Engn Res Ctr Emergency Drug, Beijing 100850, Peoples R China.
   [Hu, Hengrui; Li, Yufeng; Wang, Xi; Xu, Mingyue; Liu, Jia; Zhang, Huanyu; Hu, Zhihong; Wang, Manli] Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Peoples R China.
   [Hu, Hengrui; Li, Yufeng; Xu, Mingyue; Zhang, Huanyu] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Zhang, Tianhong] Guoke Excellence Beijing Med Technol Res Co Ltd, Beijing 100176, Peoples R China.
RP Zhong, W (corresponding author), Beijing Inst Pharmacol & Toxicol, Natl Engn Res Ctr Emergency Drug, Beijing 100850, Peoples R China.; Hu, ZH; Wang, ML (corresponding author), Chinese Acad Sci, Ctr Biosafety Megasci, Wuhan Inst Virol, State Key Lab Virol, Wuhan 430071, Peoples R China.
EM huzh@wh.iov.cn; vangml@wh.iov.cn; zhongwu@bmi.ac.cn
FU National Science and Technology Major Projects [2018ZX09711003];
   National Key Research and Development Project [2020YFC0841700]
FX This research was supported by grants from the National Science and
   Technology Major Projects (2018ZX09711003) and the National Key Research
   and Development Project (2020YFC0841700). We thank Jia Wu, Hao Tang, and
   Jun Liu from BSL-3 Laboratory from the Core Faculty of Wuhan Institute
   of Virology for their critical support.
CR Afolabi B. B, 2004, COCHRANE DB SYST REV, V2004
   Baroni A, 2007, J DERMATOL SCI, V47, P253, DOI 10.1016/j.jdermsci.2007.05.009
   Borrmann S, 2010, TROP MED INT HEALTH, V15, P434, DOI 10.1111/j.1365-3156.2010.02477.x
   Cai GJ, 2020, STEEL RES INT, DOI 10.1002/srin.202000269
   Cheong DHJ, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104901
   Efferth T, 2002, J MOL MED-JMM, V80, P233, DOI 10.1007/s00109-001-0300-8
   Efferth T, 2008, CLIN INFECT DIS, V47, P804, DOI 10.1086/591195
   Eickhoff J, 2004, J BIOL CHEM, V279, P9642, DOI 10.1074/jbc.M312893200
   FDA, 2020, COARTEM ART LUM TABL
   Flobinus A, 2014, J ANTIMICROB CHEMOTH, V69, P34, DOI 10.1093/jac/dkt346
   Han YS, 2019, J MED VIROL, V91, P1182, DOI 10.1002/jmv.25440
   Hedya SA, 2019, BEHAV BRAIN RES, V365, P82, DOI 10.1016/j.bbr.2019.02.033
   Ho WE, 2014, PHARMACOL THERAPEUT, V142, P126, DOI 10.1016/j.pharmthera.2013.12.001
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ilett KF, 2002, BRIT J CLIN PHARMACO, V53, P23, DOI 10.1046/j.0306-5251.2001.01519.x
   Kaptein SJF, 2006, ANTIVIR RES, V69, P60, DOI 10.1016/j.antiviral.2005.10.003
   Lee J, 2012, J CELL BIOCHEM, V113, P2488, DOI 10.1002/jcb.24124
   Malakar S, 2018, VIRUS RES, V255, P171, DOI 10.1016/j.virusres.2018.07.018
   National Institutes of Health, 2020, COR DIS 2019 2019 NC
   Oiknine-Djian E, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.00288-18, 10.1128/aac.00288-18]
   Oiknine-Djian E, 2019, ANTIVIR RES, V172, DOI 10.1016/j.antiviral.2019.104639
   Peymani P, 2016, CAN J PHYSIOL PHARM, V94, P613, DOI 10.1139/cjpp-2015-0507
   Raffetin A, 2018, MED MALADIES INFECT, V48, P238, DOI 10.1016/j.medmal.2018.01.004
   Romero MR, 2006, PLANTA MED, V72, P1169, DOI 10.1055/s-2006-947198
   Romero MR, 2005, ANTIVIR RES, V68, P75, DOI 10.1016/j.antiviral.2005.07.005
   Shapira MY, 2008, CLIN INFECT DIS, V46, P1455, DOI 10.1086/587106
   Sinclair D., 2009, COCHRANE DB SYST REV, V2009
   Uzun T, 2020, CHIN MED-UK, V15, DOI 10.1186/s13020-020-00336-8
   Waknine-Grinberg JH, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-227
   World Health Organization, 2020, COR DIS COVID 2019 S
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 32
TC 1
Z9 1
U1 4
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373-8227
J9 ACS INFECT DIS
JI ACS Infect. Dis.
PD SEP 11
PY 2020
VL 6
IS 9
BP 2524
EP 2531
DI 10.1021/acsinfecdis.0c00522
PG 8
WC Chemistry, Medicinal; Infectious Diseases
SC Pharmacology & Pharmacy; Infectious Diseases
GA NR4FU
UT WOS:000571520200020
PM 32786284
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Abhinand, CS
   Nair, AS
   Krishnamurthy, A
   Oommen, OV
   Sudhakaran, PR
AF Abhinand, Chandran S.
   Nair, Achuthsankar S.
   Krishnamurthy, Anand
   Oommen, Oommen V.
   Sudhakaran, Perumana R.
TI Potential protease inhibitors and their combinations to block SARS-CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE COVID-19; spike protein; main protease; TMPRSS2; molecular docking
ID MAIN PROTEASE; CORONAVIRUS; LOPINAVIR/RITONAVIR; TMPRSS2; SERINE; SITE;
   SARS
AB COVID-19, which has emerged recently as a pandemic viral infection caused by SARS-coronavirus 2 has spread rapidly around the world, creating a public health emergency. The current situation demands an effective therapeutic strategy to control the disease using drugs that are approved, or by inventing new ones. The present study examines the possible repurposing of existing anti-viral protease inhibitor drugs. For this, the structural features of the viral spike protein, the substrate for host cell protease and main protease of the available SARS CoV-2 isolates were established by comparing with related viruses for which antiviral drugs are effective. The results showed 97% sequence similarity among SARS and SARS-CoV-2 main protease and has same cleavage site positions and ACE2 receptor binding region as in the SARS-CoV spike protein. Though both are N-glycosylated, unlike SARS-CoV, human SARS-CoV-2 S-protein was O-glycosylated as well. Molecular docking studies were done to explore the role of FDA approved protease inhibitors to control SARS-CoV-2 replication. The results indicated that, Ritonavir has the highest potency to block SARS-CoV-2 main protease and human TMPRSS2, a host cell factor that aids viral infection. Other drugs such as Indinavir and Atazanavir also showed favourable binding with Cathepsin B/L that helped viral fusion with the host cell membrane. Further molecular dynamics simulation and MM-PBSA binding free energy calculations confirmed the stability of protein-drug complexes. These results suggest that protease inhibitors particularly Ritonavir, either alone or in combination with other drugs such as Atazanavir, have the potential to treat COVID 19. Communicated by Ramaswamy H. Sarma
C1 [Abhinand, Chandran S.; Nair, Achuthsankar S.; Oommen, Oommen V.; Sudhakaran, Perumana R.] Univ Kerala, Dept Computat Biol & Bioinformat, Thiruvananthapuram 6995581, Kerala, India.
   [Krishnamurthy, Anand] Dassault Syst India Pvt Ltd, Chennai, Tamil Nadu, India.
RP Sudhakaran, PR (corresponding author), Univ Kerala, Dept Computat Biol & Bioinformat, Thiruvananthapuram 6995581, Kerala, India.
EM prslab@gmail.com
FU SIUCEB at the Department of Computational Biology and Bioinformatics,
   University of Kerala, India; ISCA, Kolkata
FX This study was supported by the SIUCEB at the Department of
   Computational Biology and Bioinformatics, University of Kerala, India.
   P.R.S. was supported by ISCA, Kolkata by Asutosh Mookerjee Fellowship.
CR Bagdonaite I, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004784
   Bhardwaj VK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1766572
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chen J, 1998, CELL, V95, P409, DOI 10.1016/S0092-8674(00)81771-7
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dereeper A, 2008, NUCLEIC ACIDS RES, V36, pW465, DOI 10.1093/nar/gkn180
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Gupta Ramneek, 2002, Pac Symp Biocomput, P310
   HAVRANEK B, 2020, J BIOMOL STRUCT 0615, DOI DOI https://doi.org/10.1080/07391102.2020.1776158
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Jin YH, 2020, MILITARY MED RES, V7
   Julenius K, 2005, GLYCOBIOLOGY, V15, P153, DOI 10.1093/glycob/cwh151
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   KHAN SA, 2020, J BIOMOL STRUCT 0411, DOI DOI https://doi.org/10.1080/07391102.2020.1751298
   Lai ST, 2005, EUR J CLIN MICROBIOL, V24, P583, DOI 10.1007/s10096-005-0004-z
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Molina JM, 2008, LANCET, V372, P646, DOI 10.1016/S0140-6736(08)61081-8
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Patick AK, 1998, CLIN MICROBIOL REV, V11, P614, DOI 10.1128/CMR.11.4.614
   POLI G, 2020, MOLECULES, V25, DOI DOI https://doi.org/10.3390/molecules25081971
   Rao SN, 2007, J CHEM INF MODEL, V47, P2159, DOI 10.1021/ci6004299
   Reinke LM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179177
   Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2
   Sanche S, 2020, EMERG INFECT DIS, V26, P1470, DOI 10.3201/eid2607.200282
   Shirato K, 2018, VIROLOGY, V517, P9, DOI 10.1016/j.virol.2017.11.012
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Simossis VA, 2005, NUCLEIC ACIDS RES, V33, pW289, DOI 10.1093/nar/gki390
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Watanabe Y, 2019, BBA-GEN SUBJECTS, V1863, P1480, DOI 10.1016/j.bbagen.2019.05.012
   Wilson S, 2005, BIOCHEM J, V388, P967, DOI 10.1042/BJ20041066
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Yang HT, 2006, CURR PHARM DESIGN, V12, P4573, DOI 10.2174/138161206779010369
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
NR 52
TC 0
Z9 0
U1 5
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1819881
EA SEP 2020
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NO0XK
UT WOS:000569209800001
PM 32924827
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Mutlu, O
   Ugurel, OM
   Sariyer, E
   Ata, O
   Inci, TG
   Ugurel, E
   Kocer, S
   Turgut-Balik, D
AF Mutlu, Ozal
   Ugurel, Osman Mutluhan
   Sariyer, Emrah
   Ata, Oguz
   Inci, Tugba Gul
   Ugurel, Erennur
   Kocer, Sinem
   Turgut-Balik, Dilek
TI Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with approved and
   investigational drugs: anin silicostructure-based approach
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; COVID-19; mutation analysis; RNA-dependent RNA polymerase;
   Nsp12; drug repositioning
ID RESPIRATORY SYNDROME CORONAVIRUS; MULTIPLE SEQUENCE ALIGNMENT; DEPENDENT
   RNA-POLYMERASE; MOLECULAR-DYNAMICS; ACCURATE DOCKING; PROTEIN;
   REPLICATION; FENOTEROL; EFFICACY; COMPLEX
AB In this study, the Nsp12-Nsp8 complex of SARS-CoV-2 was targeted with structure-based and computer-aided drug design approach because of its vital role in viral replication. Sequence analysis of RNA-dependent RNA polymerase (Nsp12) sequences from 30,366 different isolates were analysed for possible mutations. FDA-approved and investigational drugs were screened for interaction with both mutant and wild-type Nsp12-Nsp8 interfaces. Sequence analysis revealed that 70.42% of Nsp12 sequences showed conserved P323L mutation, located in the Nsp8 binding cleft. Compounds were screened for interface interaction, any with XP GScores lower than -7.0 kcal/mol were considered as possible interface inhibitors. RX-3117 (fluorocyclopentenyl cytosine) and Nebivolol had the highest binding affinities in both mutant and wild-type enzymes, therefore they were selected and resultant protein-ligand complexes were simulated for analysis of stability over 100 ns. Although the selected ligands had partial mobility in the binding cavity, they were not removed from the binding pocket after 100 ns. The ligand RX-3117 remained in the same position in the binding pocket of the mutant and wild-type enzyme after 100 ns MD simulation. However, the ligand Nebivolol folded and embedded in the binding pocket of mutant Nsp12 protein. Overall, FDA-approved and investigational drugs are able to bind to the Nsp12-Nsp8 interaction interface and prevent the formation of the Nsp12-Nsp8 complex. Interruption of viral replication by drugs proposed in this study should be further tested to pave the way forin vivostudies towards the treatment of COVID-19. Communicated by Ramaswamy H. Sarma
C1 [Mutlu, Ozal] Marmara Univ, Dept Biol, Fac Arts & Sci, Istanbul, Turkey.
   [Ugurel, Osman Mutluhan; Inci, Tugba Gul; Ugurel, Erennur; Turgut-Balik, Dilek] Yildiz Tech Univ, Dept Bioengn, Fac Chem & Met Engn, Davutpasa Campus, TR-34210 Istanbul, Turkey.
   [Ugurel, Osman Mutluhan] Altinbas Univ, Sch Engn & Nat Sci, Dept Basic Sci, Istanbul, Turkey.
   [Sariyer, Emrah] Artvin Coruh Univ, Med Lab Tech, Vocat Sch Hlth Serv, Artvin, Turkey.
   [Ata, Oguz] Altinbas Univ, Dept Software Engn, Sch Engn & Nat Sci, Istanbul, Turkey.
   [Kocer, Sinem] Istanbul Yeni Yuzyil Univ, Dept Pharmaceut Biotechnol, Fac Pharm, Istanbul, Turkey.
RP Turgut-Balik, D (corresponding author), Yildiz Tech Univ, Dept Bioengn, Fac Chem & Met Engn, Davutpasa Campus, TR-34210 Istanbul, Turkey.
EM dilekbalik@gmail.com
RI ; Ata, Oguz/O-2961-2016
OI SARIYER, Emrah/0000-0003-1721-0314; Kocer, Sinem/0000-0003-0517-7422;
   Ata, Oguz/0000-0003-4511-7694; mutlu, ozal/0000-0003-4551-5780
CR Ahn DG, 2012, ARCH VIROL, V157, P2095, DOI 10.1007/s00705-012-1404-x
   [Anonymous], 2020, 51 WHO
   BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307
   Benson DA, 2003, NUCLEIC ACIDS RES, V31, P23, DOI 10.1093/nar/gkg057
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Betts M.J., 2003, BIOINFORMATICS GENET, V317, P289, DOI [10.1002/0470867302.ch14, DOI 10.1002/0470867302.CH14]
   Bornot A, 2011, PROTEINS, V79, P839, DOI 10.1002/prot.22922
   Chakrabortya H. J., 2020, NATURE RESOUR, DOI [10.21203/rs.3.rs-22079/v1, DOI 10.21203/RS.3.RS-22079/V1]
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Choi WJ, 2012, J MED CHEM, V55, P4521, DOI 10.1021/jm3004009
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Davidchack RL, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3149788
   de Wilde AH, 2014, ANTIMICROB AGENTS CH, V58, P4875, DOI 10.1128/AAC.03011-14
   Deejai N, 2017, ANIM BIOTECHNOL, V28, P120, DOI 10.1080/10495398.2016.1232268
   DESIMONE J, 1985, AM J HEMATOL, V18, P283, DOI 10.1002/ajh.2830180310
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Farag A. B., 2018, GENE REGULATION META, DOI [10.7551/mitpress/3215.003.0017, DOI 10.7551/MITPRESS/3215.003.0017]
   FLETCHER R, 1963, COMPUT J, V6, P163, DOI 10.1093/comjnl/6.2.163
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Funamizu N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037424
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563
   Giles TD, 2017, J HYPERTENS, V35, P1758, DOI 10.1097/HJH.0000000000001412
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   HEEL RC, 1978, DRUGS, V15, P3, DOI 10.2165/00003495-197815010-00002
   Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jakher H, 2019, DIABET METAB SYND OB, V12, P209, DOI 10.2147/DMSO.S184437
   Jiang CL, 2015, STEROIDS, V102, P27, DOI 10.1016/j.steroids.2015.06.015
   Kaushal S, 2014, N AM J MED SCI, V6, P107, DOI 10.4103/1947-2714.128471
   KIRCHDOERFER RN, 2019, NAT COMMUN, V10, DOI DOI https://doi.org/10.1038/s41467-019-10280-3
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Lehninger, 2004, LEHNINGER PRINCIPLES
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Liu Chao, 2020, J Pharm Anal, DOI 10.1016/j.jpha.2020.08.002
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Mark P, 2001, J PHYS CHEM A, V105, P9954, DOI 10.1021/jp003020w
   MARKETOU M, 2017, CURR HYPERTENS REP, V19, DOI DOI https://doi.org/10.1007/s11906-017-0716-3
   MARQUEZ VE, 1988, J MED CHEM, V31, P1687, DOI 10.1021/jm00117a004
   Martinez L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119264
   Moen MD, 2006, DRUGS, V66, P1389, DOI 10.2165/00003495-200666100-00007
   MOLLER MF, 1993, NEURAL NETWORKS, V6, P525, DOI 10.1016/S0893-6080(05)80056-5
   Molokie R, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002382
   NARAYANAN N, 2020, IUBMB LIFE 0818, DOI DOI https://doi.org/10.20944/preprints202003.0347.v1
   National Center for Biotechnology Information, 2020, PUBCHEM DAT DOB
   National Center for Biotechnology Information, 2020, PUBCHEM DAT SAQ
   NORTH TW, 1981, J VIROL, V37, P987, DOI 10.1128/JVI.37.3.987-993.1981
   PACHETTI M, 2020, J TRANSL MED, V18, DOI DOI https://doi.org/10.1186/s12967-020-02344-6
   PEABODY DS, 1989, J BIOL CHEM, V264, P5031
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pillaiyar T, 2020, DRUG DISCOV TODAY, V25, P668, DOI 10.1016/j.drudis.2020.01.015
   Posthuma CC, 2017, VIRUS RES, V234, P58, DOI 10.1016/j.virusres.2017.01.023
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   ROMANO M, 2020, CELLS BASEL, V9, DOI DOI https://doi.org/10.3390/cells9051267
   RUAN Z, 2020, J MED VIROL 0709, DOI DOI https://doi.org/10.20944/preprints202003.0024.v1
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Sexton NR, 2016, J VIROL, V90, P7415, DOI 10.1128/JVI.00080-16
   SHANNON A, 2020, ANTIVIR RES, V178, DOI DOI https://doi.org/10.1016/j.antiviral.2020.104793
   Song GY, 2001, J MED CHEM, V44, P3985, DOI 10.1021/jm010256v
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Subissi L, 2014, P NATL ACAD SCI USA, V111, pE3900, DOI 10.1073/pnas.1323705111
   SVEDMYR N, 1985, PHARMACOTHERAPY, V5, P109
   THOMAS BJ, 2014, SCI REP UK, V4, DOI DOI https://doi.org/10.1038/srep07176
   Ugurel OM, 2020, TURK J BIOL, V44, P157, DOI 10.3906/biy-2005-111
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Velthuis AJWT, 2012, NUCLEIC ACIDS RES, V40, P1737, DOI 10.1093/nar/gkr893
   Velthuis AJWT, 2010, NUCLEIC ACIDS RES, V38, P203, DOI 10.1093/nar/gkp904
   Volkamer A, 2012, J CHEM INF MODEL, V52, P360, DOI 10.1021/ci200454v
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   WONG CS, 1990, LANCET, V336, P1396, DOI 10.1016/0140-6736(90)93099-B
   World Health Organization, 2020, 198 WHO
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xu C., 2020, SYSTEMIC SILICO SCRE, DOI [10.26434/chemrxiv.12058143.v1, DOI 10.26434/CHEMRXIV.12058143.V1]
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Zhai YJ, 2005, NAT STRUCT MOL BIOL, V12, P980, DOI 10.1038/nsmb999
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 82
TC 1
Z9 1
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1819882
EA SEP 2020
PG 13
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NO4JX
UT WOS:000569452400001
PM 32933378
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Mitchell, EJ
   Ahmed, K
   Breeman, S
   Cotton, S
   Constable, L
   Ferry, G
   Goodman, K
   Hickey, H
   Meakin, G
   Mironov, K
   Quann, N
   Wakefield, N
   McDonald, A
AF Mitchell, Eleanor J.
   Ahmed, Khaled
   Breeman, Suzanne
   Cotton, Seonaidh
   Constable, Lynda
   Ferry, Gillian
   Goodman, Kirsteen
   Hickey, Helen
   Meakin, Garry
   Mironov, Katy
   Quann, Niamh
   Wakefield, Natalie
   McDonald, Alison
TI It is unprecedented: trial management during the COVID-19 pandemic and
   beyond
SO TRIALS
LA English
DT Article
DE COVID-19; Pandemic; Clinical trial; Trial management
AB The COVID-19 pandemic has presented unique challenges for the clinical trial community, both in the rapid establishment of COVID-19 clinical trials and many existing non-COVID-19 studies either being temporarily paused (whether that is a complete pause or pause in some activities) and/or adapting their processes. Trial managers have played a key role in decision-making, undertaking risk assessments and adapting trial processes, working closely with other members of the research team. This article presents some of the ways in which trial management processes have been altered and the key role that trial managers have played. It has been born out of discussions between trial managers in the UK who are members of the UK Trial Managers' Network (UKTMN), a national network of trial management professionals managing non-commercial trials.In these unprecedented times, clinical trials have faced many uncertainties and broad-ranging challenges encompassing a range of activities including prioritising patient safety amidst the pandemic, consenting and recruiting new participants into trials, data collection and management and intervention delivery. In many cases, recruitment has been paused whilst mitigations have been put in place to continue data collection. Innovative solutions have been implemented to ensure we continue, where possible, to deliver high-quality clinical trials. Technology has provided many solutions to these challenges, and trial managers have adapted to new ways of working whilst continuing to deliver their clinical trials. Trial management groups are now faced with new uncertainties around re-starting clinical trials, and it is unclear currently how this will go, though working together with sponsors, funders and site teams is clearly a priority.Clinical trial teams have worked together to ensure their trials have adapted quickly whilst ensuring participant safety is given utmost importance. There are clear examples where the trial community have come together to share experiences and expertise, and this should continue in the future to ensure the innovative practices developed become embedded in the design and conduct of clinical trials in the future.
C1 [Mitchell, Eleanor J.; Meakin, Garry; Wakefield, Natalie] Univ Nottingham, Nottingham Clin Trials Unit, Bldg 42,Univ Pk, Nottingham NG7 2RD, England.
   [Ahmed, Khaled] Univ Birmingham, Inst Appl Hlth Res, Coll Med & Dent Sci, Birmingham Clin Trials Unit BCTU, Publ Hlth Bldg, Birmingham B15 2TT, W Midlands, England.
   [Breeman, Suzanne; Cotton, Seonaidh; Constable, Lynda; Ferry, Gillian; McDonald, Alison] Univ Aberdeen, Ctr Healthcare Randomised Trials CHaRT, Hlth Sci Bldg,Foresterhill, Aberdeen AB25 2ZD, Scotland.
   [Goodman, Kirsteen] Glasgow Caledonian Univ, NMAHP Res Unit, Cowcaddens Rd, Glasgow G4 0BA, Lanark, Scotland.
   [Hickey, Helen] Univ Liverpool, Liverpool Clin Trials Ctr, Liverpool L69 3BX, Merseyside, England.
   [Hickey, Helen] Liverpool Hlth Partners, Liverpool L69 3BX, Merseyside, England.
   [Mironov, Katy] Univ Oxford, John Radcliffe Hosp, Kadoorie Ctr, Oxford Trauma,NDORMS, Level 3, Oxford OX3 9DU, England.
   [Quann, Niamh] Univ Leicester, Coll Life Sci, Leicester Clin Trials Unit, Univ Rd, Leicester LE1 7RH, Leics, England.
RP Mitchell, EJ (corresponding author), Univ Nottingham, Nottingham Clin Trials Unit, Bldg 42,Univ Pk, Nottingham NG7 2RD, England.
EM eleanor.mitchell@nottingham.ac.uk
OI Mitchell, Eleanor/0000-0002-6998-4533
FU Nuffield Department of Population Health (NDPH) at the University of
   Oxford
FX UKTMN is funded by the Nuffield Department of Population Health (NDPH)
   at the University of Oxford. The funder had no role in any aspect of the
   design of the study, collection, analysis and interpretation of data or
   in writing the manuscript.
CR ALTMAN DG, 1994, BRIT MED J, V308, P283, DOI 10.1136/bmj.308.6924.283
   [Anonymous], 2020, URG PUBL HLTH COVID
   [Anonymous], 2020, Q A IMP COVID 19 RES
   [Anonymous], 2020, COVID 19 RES 2020
   [Anonymous], 2020, REST FRAM
   [Anonymous], 2016, ICH HARM GUID INT AD
   BioMed Central ISRCTN registry, ISRCTN16912075 REC R
   BioMed Central ISRCTN Registry, ISRCTN89654042 FLUID
   BioMed Central ISRCTN Registry, ISRCTN10497306 BIS C
   BioMed Central ISRCTN Registry, FOR FRACT REC CHILDR
   BioMed Central ISRCTN Registry, ISRCTN15236311 SMOK
   BioMed Central ISRCTN registry, ISRCTN63268739 FEM U
   Chalmers Iain, 2000, Curr Control Trials Cardiovasc Med, V1, P3, DOI 10.1186/CVM-1-1-003
   Crowley E, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04388-x
   European Medicines Agency, 2020, GUID MAN CLIN TRIALS
   Farrell B, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-78
   Health Research Authority, 2019, INF PART SEEK CONS
   Jefferson L, 2018, J CLIN EPIDEMIOL, V100, P13, DOI 10.1016/j.jclinepi.2018.04.011
   National Institute for Health Research, 2020, DHSC ISS GUID IMP CO
   Nuffield Department of Population Health University of Oxford, SET TRIAL 9 DAYS
   Townsend D, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0908-6
   UK Trial Managers' Network, GUID EFF TRIAL MAN V
NR 22
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD SEP 11
PY 2020
VL 21
IS 1
AR 784
DI 10.1186/s13063-020-04711-6
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NR8AI
UT WOS:000571781700005
PM 32917258
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Roehrig, S
   Hssain, AA
   Shallik, NA
   Elsaid, IMA
   Mustafa, SF
   Smain, OAM
   Molokhia, AA
   Lance, MD
AF Roehrig, Stefan
   Hssain, Ali Ait
   Shallik, Nabil Al Hamid
   Elsaid, Ingi Mohamed A.
   Mustafa, Salma Faisal
   Smain, Osama A. M.
   Molokhia, Ashraf Abdulla
   Lance, Marcus D.
TI Flow controlled ventilation in Acute Respiratory Distress Syndrome
   associated with COVID-19: A structured summary of a study protocol for a
   randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; randomised controlled trial; protocol; ARDS; Flow Controlled
   Ventilation; Mechanical ventilation
AB ObjectivesThis study aims to demonstrate the positive effects on oxygenation of flow-controlled ventilation compared to conventionally ventilated patients in patients suffering from Acute respiratory distress syndrome (ARDS) associated with COVID-19.We define ARDS according to the "Berlin" definition integrating the oxygenation index (P/F ratio), the level of Positive End Expiratory Pressure (PEEP), radiological and clinical findings.
   Trial design This is a prospective, randomized (1:1 ratio), parallel group feasibility study in adult patients with proven COVID-19 associated ARDS.
   Participants All adult patients admitted to the ICU of Hamad Medical Corporation facilities in Qatar because of COVID-19 infection who develop moderate to severe ARDS are eligible. The inclusion criteria are above 18 years of age, proven COVID-19 infection, respiratory failure necessitating intubation and mechanical ventilation, ARDS with a P/F ratio of at least 200mmHg or less and a minimum PEEP 5cmH2O, BMI less 30 kg/ m2. The following exclusion criteria: no written consent, chronic respiratory disease, acute or chronic cardiovascular disease, pregnancy or need for special therapy (prone position and/or Extracorporeal membrane oxygenation).
   Intervention and comparator After randomisation, the group A patients will be ventilated with the test-device for 48 hours. The settings will be started with the pre-existing-PEEP. The upper pressure will be determined to achieve a tidal volume of 6 ml/kg lean body mass, while the respiratory rate will be set to maintain an arterial pH above 7.2.
   In group B, the ventilator settings will be adjusted by the attending ICU team in accordance with lung-protective ventilation strategy.
   All other treatment will be unchanged and according to our local policies/guidelines.
   Main outcomes The primary end point is PaO2. As this is a dynamic parameter, we will record it every 6-8 hours and analyse it sequentially.
   Randomisation The study team screens the ventilated patients who fulfil the inclusion criteria and randomise using a 1:1 allocation ratio after consenting using a closed envelope method. The latter were prepared and sealed in advance by an independent person.
   Blinding (masking) Due to the technical nature of the study (use of a specific ventilator) blinding is only possible for the data-analysts and the patients.
   Numbers to be randomised (sample size) The sample size calculation based on the assumption of an effect size (change in PaO2) of 1.5 SDS in the primary endpoint (PaO2), an intended power of 80%, an alpha error of 5% and an equal sample ratio results in n=7 patients needed to treat. However, to compensate for dropouts we will include 10 patients in each group, which means in total 20 patients.
   Trial Status The local registration number is MRC-05-018 with the protocol version number 3. The date of approval is 14(th) April 2020. Recruitment began 28th May 2020 and is expected to end in September 2020.
   Trial registration The protocol was registered before starting subject recruitment under the title: "Flow controlled ventilation in ARDS associated with COVID-19" in ClinicalTrials.org with the registration number: NCT04399317. Registered on 22 May 2020.
   Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Roehrig, Stefan; Shallik, Nabil Al Hamid; Lance, Marcus D.] Hamad Med Corp HMC, Dept Anesthesiol Intens Care & Perioperat Med, Al Rayyan Rd, Doha, Qatar.
   [Hssain, Ali Ait; Molokhia, Ashraf Abdulla] Hamad Med Corp HMC, Dept Med Intens Care, Al Rayyan Rd, Doha, Qatar.
   [Elsaid, Ingi Mohamed A.; Mustafa, Salma Faisal; Smain, Osama A. M.] Hamad Med Corp HMC, Dept Med Educ, Al Rayyan Rd, Doha, Qatar.
RP Lance, MD (corresponding author), Hamad Med Corp HMC, Dept Anesthesiol Intens Care & Perioperat Med, Al Rayyan Rd, Doha, Qatar.
EM Mlance@hamad.qa
FU HMC
FX This project was supported by HMC only. However, there was no influence
   regarding the study design and execution by HMC.
NR 0
TC 0
Z9 0
U1 6
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD SEP 11
PY 2020
VL 21
IS 1
AR 781
DI 10.1186/s13063-020-04708-1
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NR8AI
UT WOS:000571781700002
PM 32917259
OA DOAJ Gold, Green Accepted
DA 2021-01-01
ER

PT J
AU Alzaid, F
   Julla, JB
   Diedisheim, M
   Potier, C
   Potier, L
   Velho, G
   Gaborit, B
   Manivet, P
   Germain, S
   Vidal-Trecan, T
   Roussel, R
   Riveline, JP
   Dalmas, E
   Venteclef, N
   Gautier, JF
AF Alzaid, Fawaz
   Julla, Jean-Baptiste
   Diedisheim, Marc
   Potier, Charline
   Potier, Louis
   Velho, Gilberto
   Gaborit, Benedicte
   Manivet, Philippe
   Germain, Stephane
   Vidal-Trecan, Tiphaine
   Roussel, Ronan
   Riveline, Jean-Pierre
   Dalmas, Elise
   Venteclef, Nicolas
   Gautier, Jean-Francois
TI Monocytopenia, monocyte morphological anomalies and hyperinflammation
   characterise severeCOVID-19 in type 2 diabetes
SO EMBO MOLECULAR MEDICINE
LA English
DT Article; Early Access
DE COVID-19; inflammation; monocyte; SARS-CoV-2; type 2 diabetes
ID SUBSETS; IRF5; COVID-19
AB Early in theCOVID-19 pandemic, type 2 diabetes (T2D) was marked as a risk factor for severe disease and mortality. Inflammation is central to the aetiology of both conditions where variations in immune responses can mitigate or aggravate disease course. Identifying at-risk groups based on immunoinflammatory signatures is valuable in directing personalised care and developing potential targets for precision therapy. This observational study characterised immunophenotypic variation associated withCOVID-19 severity in T2D. Broad-spectrum immunophenotyping quantified 15 leucocyte populations in peripheral circulation from a cohort of 45 hospitalisedCOVID-19 patients with and without T2D. Lymphocytopenia and specific loss of cytotoxicCD8(+)lymphocytes were associated with severeCOVID-19 and requirement for intensive care in both non-diabetic and T2D patients. A morphological anomaly of increased monocyte size and monocytopenia restricted to classicalCD14(Hi)CD16(-)monocytes was specifically associated with severeCOVID-19 in patients with T2D requiring intensive care. Increased expression of inflammatory markers reminiscent of the type 1 interferon pathway (IL6,IL8,CCL2,INFB1) underlaid the immunophenotype associated with T2D. These immunophenotypic and hyperinflammatory changes may contribute to increased voracity ofCOVID-19 in T2D. These findings allow precise identification of T2D patients with severeCOVID-19 as well as provide evidence that the type 1 interferon pathway may be an actionable therapeutic target for future studies.
C1 [Alzaid, Fawaz; Julla, Jean-Baptiste; Diedisheim, Marc; Potier, Charline; Potier, Louis; Velho, Gilberto; Roussel, Ronan; Riveline, Jean-Pierre; Dalmas, Elise; Venteclef, Nicolas; Gautier, Jean-Francois] Univ Paris, Sorbonne Univ, IMMEDIAB Lab, Cordeliers Res Ctr,INSERM, Paris, France.
   [Julla, Jean-Baptiste; Vidal-Trecan, Tiphaine; Riveline, Jean-Pierre; Gautier, Jean-Francois] Lariboisiere Hosp, AP HP, Dept Diabet, Clin Invest Ctr CIC 9504, Paris, France.
   [Diedisheim, Marc] Univ Paris, Cochin Hosp, AP HP, Dept Diabetol, Paris, France.
   [Potier, Louis; Roussel, Ronan] Hop Xavier Bichat, AP HP, Dept Diabetol Endocrinol & Nutr, Paris, France.
   [Gaborit, Benedicte] Aix Marseille Univ, INSERM, INRA, C2VN, Marseille, France.
   [Gaborit, Benedicte] AP HM, Endocrinol Metab Dis & Nutr Dept, Marseille, France.
   [Manivet, Philippe] Univ Paris, Hop Lariboisiere, Ctr Ressources Biol Biobank Lariboisiere, BB 0033 00064,AP HP,Paris Diderot, Paris, France.
   [Germain, Stephane] Paris Sci & Lettres PSL Res Univ, Ctr Interdisciplinary Res Biol CIRB, Coll France, CNRS,INSERM, Paris, France.
RP Alzaid, F; Gautier, JF (corresponding author), Univ Paris, Sorbonne Univ, IMMEDIAB Lab, Cordeliers Res Ctr,INSERM, Paris, France.; Gautier, JF (corresponding author), Lariboisiere Hosp, AP HP, Dept Diabet, Clin Invest Ctr CIC 9504, Paris, France.
EM fawaz.alzaid@gmail.com; jean-francois.gautier@aphp.fr
RI GABORIT, Benedicte/AAK-3842-2020; Diedisheim, Marc/ABC-6996-2020
OI GABORIT, Benedicte/0000-0002-4180-158X; Alzaid,
   Fawaz/0000-0003-3056-3640
FU French National Agency of Research (ANR)French National Research Agency
   (ANR) [ANR-19-CE14-0005]; European Foundation for the Study of Diabetes
   (EFSD)/LillyEli Lilly; French National Agency of Research (GLUTADIAB);
   French National Agency of Research (ANGIOSAFE); European Foundation for
   Diabetes (EFSD); European UnionEuropean Union (EU) [ERC-EpiFAT 725790];
   Assistance Publique des Hopitaux de Paris (ANR-DGOS Project AngioSafe
   T2D); ASSERADT (a non-profit patient association); French Foundation for
   Diabetes (SFD)
FX F.A. was supported by grants from the French National Agency of Research
   (ANR) for ANR MitoFLAME (ANR-19-CE14-0005) and the European Foundation
   for the Study of Diabetes (EFSD)/Lilly grant (Characterisation of
   monocyte metabolism and bioenergetic responses in type-2 diabetes and
   risk of cardiovascular disease). N.V. was supported by grants from the
   French National Agency of Research (GLUTADIAB and ANGIOSAFE), the
   European Foundation for Diabetes (EFSD) and the European Union H2020
   Framework (ERC-EpiFAT 725790). The human study was performed at the
   Clinical Investigation Centre (Groupe Hospitalier
   Saint-Louis/Lariboisiere, Paris) and was supported by Assistance
   Publique des Hopitaux de Paris (ANR-DGOS Project AngioSafe T2D; J.-F.G.,
   principal investigator) and ASSERADT (a non-profit patient association).
   E.D was supported by grants from the French and European Foundation for
   Diabetes (SFD and EFSD). The authors would like to thank Helene
   Fohrer-Ting of the Centre for Cytometry, Histology and Cellular Imaging
   (CHIC) core facility of the Cordeliers Research Centre (CRC), for her
   guidance, patience and support. The authors thank the Unite de Recherche
   Clinique of Lariboisiere/Fernand Widal (Pr Eric Vicaut & Dr Veronique
   Jouis); the Delegation a la Recherche Clinique de Paris-Ile de France;
   and the Direction de la Recherche Sante de Marseille for their
   administrative support. The authors also thank Nassima Haddadi, Djamila
   Bellili and Hanane Mersel for their technical support, and nurses and
   patients who accepted to be involved in these studies. The authors also
   thank Jagadeesh Bayry and Anupama Karnam for their generous gift of the
   IL-8 ELISA Kit.
CR Alzaid F, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88689
   Autissier P, 2010, J IMMUNOL METHODS, V360, P119, DOI 10.1016/j.jim.2010.06.017
   Coates BM, 2018, J IMMUNOL, V200, P2391, DOI 10.4049/jimmunol.1701543
   Codo AC, 2020, CELL METAB, V32, P437, DOI 10.1016/j.cmet.2020.07.007
   Corbin AL, 2019, BIORXIV, DOI [10.1101/601963, DOI 10.1101/601963]
   Dalmas E, 2015, NAT MED, V21, P610, DOI 10.1038/nm.3829
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Forbester JL, 2020, J VIROL, V94, DOI 10.1128/JVI.00121-20
   Friedrich K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01874
   Gruber C, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0335-0
   Hadjadj J., 2020, IMPAIRED TYPE 1 INTE, DOI [10.1101/2020.04.19.20068015, DOI 10.1101/2020.04.19.20068015]
   Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008-1091
   Hijdra D, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00339
   Hoeve MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029443
   Jardine L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09913-4
   Julla Jean-Baptiste, 2019, Methods Mol Biol, V1951, P33, DOI 10.1007/978-1-4939-9130-3_3
   Kim D, 2017, CELL REP, V20, P832, DOI 10.1016/j.celrep.2017.06.088
   Koressaar T, 2007, BIOINFORMATICS, V23, P1289, DOI 10.1093/bioinformatics/btm091
   Koutsakos M, 2019, NAT IMMUNOL, V20, P613, DOI 10.1038/s41590-019-0320-6
   Laviada-Molina HA, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00514
   Melzer S, 2015, CYTOM PART B-CLIN CY, V88, P270, DOI 10.1002/cyto.b.21234
   Menart-Houtermans B, 2014, DIABETES CARE, V37, P2326, DOI 10.2337/dc14-0316
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Park Matthew D, 2020, Nat Rev Immunol, V20, P351, DOI 10.1038/s41577-020-0317-2
   R Core Team, 2013, R LANG ENV STAT COMP
   Rogacev KS, 2012, J AM COLL CARDIOL, V60, P1512, DOI 10.1016/j.jacc.2012.07.019
   Sanchez-Torres C, 2001, INT IMMUNOL, V13, P1571, DOI 10.1093/intimm/13.12.1571
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596
   van der Maaten L, 2008, J MACH LEARN RES, V9, P2579
   Vangeti S, 2019, J IMMUNOL, V202, P2069, DOI 10.4049/jimmunol.1801191
   Wang QM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz7086
   Wang ZZ, 2020, DIABETES RES CLIN PR, V164, DOI 10.1016/j.diabres.2020.108214
   Weiss M, 2015, P NATL ACAD SCI USA, V112, P11001, DOI 10.1073/pnas.1506254112
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yang LS, 2012, J IMMUNOL, V189, P3741, DOI 10.4049/jimmunol.1201162
   Yu YRA, 2020, J IMMUNOL, V204, P1474, DOI 10.4049/jimmunol.1900239
   Zhang D., 2020, COVID 19 INFECT INDU, DOI [10.1101/2020.03.24, DOI 10.1101/2020.03.24.20042655, 10.1101/2020.03.24.20042655]
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
NR 41
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
AR e13038
DI 10.15252/emmm.202013038
EA SEP 2020
PG 12
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NN8HV
UT WOS:000569028600001
PM 32816392
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Peng, Y
   Du, N
   Lei, YQ
   Dorje, S
   Qi, JX
   Luo, TR
   Gao, GF
   Song, H
AF Peng, Ya
   Du, Ning
   Lei, Yuqing
   Dorje, Sonam
   Qi, Jianxun
   Luo, Tingrong
   Gao, George F.
   Song, Hao
TI Structures of theSARS-CoV-2 nucleocapsid and their perspectives for drug
   design
SO EMBO JOURNAL
LA English
DT Article; Early Access
DE 2019-nCoV; antivirals; dimerization; nucleocapsid; RNAbinding
ID RESPIRATORY SYNDROME-CORONAVIRUS; N-TERMINAL DOMAIN; CRYSTAL-STRUCTURE;
   PROTEIN; IDENTIFICATION; DIFFRACTION; ANTIBODIES; OUTBREAK; MODEL
AB COVID-19, caused bySARS-CoV-2, has resulted in severe and unprecedented economic and social disruptions in the world. Nucleocapsid (N) protein, which is the major structural component of the virion and is involved in viral replication, assembly and immune regulation, plays key roles in the viral life cycle. Here, we solved the crystal structures of the N- and C-terminal domains (N-NTDand N-CTD) ofSARS-CoV-2 N protein, at 1.8 and 1.5 angstrom resolution, respectively. Both structures show conserved features from other CoV N proteins. The binding sites targeted by small molecules againstHCoV-OC43 andMERS-CoV, which inhibit viral infection by blocking theRNA-binding activity or normal oligomerization of N protein, are relatively conserved in our structure, indicating N protein is a promising drug target. In addition, certain areas of N-NTDand N-CTDdisplay distinct charge distribution patterns inSARS-CoV-2, which may alter theRNA-binding modes. The specific antigenic characteristics are critical for developing specific immune-based rapid diagnostic tests. Our structural information can aid in the discovery and development of antiviral inhibitors againstSARS-CoV-2 in the future.
C1 [Peng, Ya; Luo, Tingrong] Guangxi Univ, Coll Anim Sci & Vet Med, Lab Anim Infect Dis, Nanning, Peoples R China.
   [Peng, Ya; Lei, Yuqing; Dorje, Sonam; Qi, Jianxun; Gao, George F.] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China.
   [Du, Ning; Gao, George F.; Song, Hao] Chinese Acad Sci, Beijing Inst Life Sci, Res Network Immun & Hlth RNIH, Beijing, Peoples R China.
   [Lei, Yuqing; Dorje, Sonam; Qi, Jianxun; Gao, George F.] Univ Chinese Acad Sci, Beijing, Peoples R China.
RP Gao, GF (corresponding author), Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China.; Gao, GF; Song, H (corresponding author), Chinese Acad Sci, Beijing Inst Life Sci, Res Network Immun & Hlth RNIH, Beijing, Peoples R China.; Gao, GF (corresponding author), Univ Chinese Acad Sci, Beijing, Peoples R China.
EM gaof@im.ac.cn; songhao@im.ac.cn
OI Dorje, Sonam/0000-0002-1885-3007; Reis, AlessanRSS/0000-0001-8486-7469
FU Ministry of Science and Technology of the People's Republic of
   ChinaMinistry of Science and Technology, China [2020YFC0845900];
   National Science and Technology Major Project [2018ZX10733403]; National
   Natural Science Foundation of China (NSFC)National Natural Science
   Foundation of China (NSFC) [81702015]; Youth Innovation Promotion
   Association CAS [2017117]; COVID-19 Emergency Project of CAS; External
   Cooperation Program of CAS [153211KYSB20160001]
FX We thank the staff of BL19U1 beamlines at Shanghai Synchrotron Radiation
   Facility. We thank Qian Wang (Institute of Microbiology CAS) for help
   with analytical ultracentrifugation experiment. This work was supported
   by the Ministry of Science and Technology of the People's Republic of
   China (2020YFC0845900), the National Science and Technology Major
   Project (2018ZX10733403), and the National Natural Science Foundation of
   China (NSFC) (81702015). H.S. is supported by the Youth Innovation
   Promotion Association CAS (2017117). G.F.G. is supported partly by the
   COVID-19 Emergency Project of CAS and the External Cooperation Program
   of CAS (153211KYSB20160001).
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Ashkenazy H, 2016, NUCLEIC ACIDS RES, V44, pW344, DOI 10.1093/nar/gkw408
   Barcena M, 2009, P NATL ACAD SCI USA, V106, P582, DOI 10.1073/pnas.0805270106
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Burbelo PD, 2020, J INFECT DIS, V222, P206, DOI 10.1093/infdis/jiaa273
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cavalcanti AB, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2019014, DOI 10.1056/NEJM0A2019014]
   Chang CK, 2016, MOL BIOSYST, V12, P59, DOI 10.1039/c5mb00582e
   Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   Che XY, 2004, J CLIN MICROBIOL, V42, P2629, DOI 10.1128/JCM.42.6.2629-2635.2004
   Chen CY, 2007, J MOL BIOL, V368, P1075, DOI 10.1016/j.jmb.2007.02.069
   Cong YY, 2020, J VIROL, V94, DOI 10.1128/JVI.01925-19
   Cong YY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06062-w
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Gui M, 2017, PROTEIN CELL, V8, P219, DOI 10.1007/s13238-016-0352-8
   Horber S, 2020, CLIN CHEM LAB MED, V58, P2113, DOI 10.1515/cclm-2020-0975
   Hoffmann M, 2020, NATURE, V585, P588, DOI 10.1038/s41586-020-2575-3
   Jiang SB, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30419-0
   Kang SS, 2020, ACTA PHARMACOL SIN B, V10, P1228, DOI 10.1016/j.apsb.2020.04.009
   Klein S., 2020, SARS COV 2 STRUCTURE, DOI [10.1101/2020.06.23.167064., DOI 10.1101/2020.06.23.167064]
   Li CY, 2019, MBIO, V10, DOI 10.1128/mBio.02483-19
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lin SM, 2020, J MED CHEM, V63, P3131, DOI 10.1021/acs.jmedchem.9b01913
   Lin SY, 2014, J MED CHEM, V57, P2247, DOI 10.1021/jm500089r
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lu XL, 2011, VIRUS GENES, V42, P37, DOI 10.1007/s11262-010-0544-x
   Maisonnasse P, 2020, NATURE, V585, P584, DOI 10.1038/s41586-020-2558-4
   Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949
   Mu JF, 2020, SCI CHINA LIFE SCI, DOI 10.1007/s11427-020-1692-1
   Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255
   Neuman BW, 2006, J VIROL, V80, P7918, DOI 10.1128/JVI.00645-06
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Papageorgiou N, 2016, ACTA CRYSTALLOGR D, V72, P192, DOI 10.1107/S2059798315024328
   Peng TY, 2008, FEBS J, V275, P4152, DOI 10.1111/j.1742-4658.2008.06564.x
   Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471
   Saikatendu KS, 2007, J VIROL, V81, P3913, DOI 10.1128/JVI.02236-06
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Surjit M, 2006, J BIOL CHEM, V281, P10669, DOI 10.1074/jbc.M509233200
   Surjit M, 2004, BIOCHEM J, V383, P13, DOI 10.1042/BJ20040984
   Szelazek B, 2017, J VIROL, V91, DOI 10.1128/JVI.02503-16
   Tan W, 2020, CHINA CDC WEEKLY, V2, P61, DOI DOI 10.46234/ccdcw2020.017
   Nguyen THV, 2019, ACTA CRYSTALLOGR D, V75, P8, DOI 10.1107/S2059798318014948
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang HY, 2017, SCI CHINA LIFE SCI, V60, P1403, DOI 10.1007/s11427-017-9238-8
   Wang JL, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01744-7
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Wu YL, 2020, CELL HOST MICROBE, V27, P891, DOI 10.1016/j.chom.2020.04.023
   Xiang F, 2020, CLIN INFECT DIS, V71, P1930, DOI 10.1093/cid/ciaa461
   Ye QZ, 2020, PROTEIN SCI, V29, P1890, DOI 10.1002/pro.3909
   Yu IM, 2006, J BIOL CHEM, V281, P17134, DOI 10.1074/jbc.M602107200
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang XN, 2020, NATURE, V583, P437, DOI 10.1038/s41586-020-2355-0
   Zhou H, 2020, CURR BIOL, V30, P2196, DOI 10.1016/j.cub.2020.05.023
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zuniga S, 2010, J VIROL, V84, P2169, DOI 10.1128/JVI.02011-09
NR 60
TC 0
Z9 0
U1 15
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0261-4189
EI 1460-2075
J9 EMBO J
JI Embo J.
AR e105938
DI 10.15252/embj.2020105938
EA SEP 2020
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NN4CD
UT WOS:000568736500001
PM 32914439
DA 2021-01-01
ER

PT J
AU Bollmann, A
   Hohenstein, S
   Konig, S
   Meier-Hellmann, A
   Kuhlen, R
   Hindricks, G
AF Bollmann, Andreas
   Hohenstein, Sven
   Koenig, Sebastian
   Meier-Hellmann, Andreas
   Kuhlen, Ralf
   Hindricks, Gerhard
TI In-hospital mortality in heart failure in Germany during the Covid-19
   pandemic
SO ESC HEART FAILURE
LA English
DT Article; Early Access
DE Heart failure; In-hospital mortality; Covid-19
AB Aims The Covid-19 pandemic affects care for cardiovascular conditions, but data on heart failure (HF) are scarce. This study aims to analyse HF care and in-hospital outcomes during the pandemic in Germany. Methods and results A total of 9452 HF admissions were studied using claims data of 65 Helios hospitals; 1979 in the study period (13 March 30 April 2020) and 4691 and 2782 in two control periods (13 March to 30 April 2019 and 1 January to 12 March 2020). HF admissions declined compared with both control periods by 29-38%. Cardiac resynchronization therapy was implanted in 0.55% during the study period, 0.32% [odds ratio (OR) 1.66, 95% confidence interval (CI) 0.68-4.04,P = 0.27] in the previous year and 0.43% (OR 1.35, 95% CI 0.64-2.84,P = 0.43) in the same year control. Intensive care treatment was 6.22% during the study period, 4.49% in the previous year (OR 1.46, 95% CI 1.13-1.89,P < 0.01), and 5.27% in the same year control (OR 1.19, 95% CI 0.96-1.49,P = 0.12). Length of hospital stay was 7.0 +/- 5.0 days in the study and 7.8 +/- 5.6 (P < 0.01) and 7.3 +/- 5.1 days (P = 0.07) in the control periods. In-hospital mortality was 7.0% in the study and 5.5% in both control periods (P < 0.05). Conclusions During the early phase of the Covid-19 pandemic in Germany, HF treatment pathways seem not to be affected, but hospital stay shortened and in-hospital mortality increased. As the pandemic continues, this early signal demands close monitoring and further investigation of potential causes.
C1 [Bollmann, Andreas; Hohenstein, Sven; Koenig, Sebastian; Hindricks, Gerhard] Univ Leipzig, Heart Ctr Leipzig, Strumpellstr 39, D-04289 Leipzig, Germany.
   [Bollmann, Andreas; Hohenstein, Sven; Koenig, Sebastian; Hindricks, Gerhard] Leipzig Heart Inst, Strumpellstr 39, D-04289 Leipzig, Germany.
   [Meier-Hellmann, Andreas] Helios Kliniken, Berlin, Germany.
   [Kuhlen, Ralf] Helios Hlth, Berlin, Germany.
RP Bollmann, A (corresponding author), Univ Leipzig, Heart Ctr Leipzig, Strumpellstr 39, D-04289 Leipzig, Germany.; Bollmann, A (corresponding author), Leipzig Heart Inst, Strumpellstr 39, D-04289 Leipzig, Germany.
EM andreas.bollmann@helios-gesundheit.de
OI Reis, AlessanRSS/0000-0001-8486-7469; Hohenstein,
   Sven/0000-0002-9708-1593
CR Abraham WT, 2008, J AM COLL CARDIOL, V52, P347, DOI 10.1016/j.jacc.2008.04.028
   Andersson C, 2020, CIRC-HEART FAIL, V13, P4, DOI 10.1161/CIRCHEARTFAILURE.120.007274
   Bhatt AS, 2020, J AM COLL CARDIOL, V76, P280, DOI 10.1016/j.jacc.2020.05.038
   Colivicchi F, 2020, J CARD FAIL, V26, P464, DOI 10.1016/j.cardfail.2020.05.007
   Cox ZL, 2020, EUR J HEART FAIL, V22, P1045, DOI 10.1002/ejhf.1921
   De Filippo O, 2020, NEW ENGL J MED, V383, P88, DOI 10.1056/NEJMc2009166
   De Rosa S, 2020, EUR HEART J, V41, P2083, DOI 10.1093/eurheartj/ehaa409
   Garcia S, 2020, J AM COLL CARDIOL, V75, P2871, DOI 10.1016/j.jacc.2020.04.011
   Hall ME, 2020, J CARD FAIL, V26, P462, DOI 10.1016/j.cardfail.2020.05.005
   Konig S, 2018, EUR HEART J, V39, P3947, DOI 10.1093/eurheartj/ehy528
   Metzler B, 2020, EUR HEART J, V41, P1852, DOI 10.1093/eurheartj/ehaa314
NR 11
TC 0
Z9 0
U1 0
U2 0
PU WILEY PERIODICALS, INC
PI SAN FRANCISCO
PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA
SN 2055-5822
J9 ESC HEART FAIL
JI ESC Heart Fail.
DI 10.1002/ehf2.13011
EA SEP 2020
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NM2ST
UT WOS:000567952400001
PM 32915516
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Nessaibia, I
   Siciliano, D
   Tahraoui, A
AF Nessaibia, Issam
   Siciliano, Dafne
   Tahraoui, Abdelkrim
TI Why nobody discusses the adverse psychiatric effects of chloroquine in
   case it might become the future treatment againstCOVID-19?
SO INTERNATIONAL JOURNAL OF HEALTH PLANNING AND MANAGEMENT
LA English
DT Article
DE anxiety; chloroquine; COVID-19; mental care; psychiatric side-effects
AB Chloroquine represents at least a basic prototype antimalarial drug, widely applied in several branches of medicine and also recently against a new zoonotic origin coronavirus. At present, there is little awareness of chloroquine's psychiatric side effects, which appear to be overlooked by the Scientific Committee, although they may manifest in a worryingly wide range of symptoms. This is likely to interfere with the course of specifically long-term (high-dose) COVID-19 treatment in some aggravated forms (25% of coronavirus patients were still carrying the virus 6 days after taking hydroxychloroquine). Besides, symptoms of infection, adverse effects from the 600 mg hydroxychloroquine daily plus azithromycin, including insomnia, headaches, skin reactions, digestive upset with nausea, vomiting, and diarrhea, blurred vision, and local pain, may lead to increased anxiety and mental distress.
C1 [Nessaibia, Issam; Tahraoui, Abdelkrim] Badji Mokhtar Univ, Lab Appl Neuroendocrinol, Annaba, Algeria.
   [Nessaibia, Issam; Siciliano, Dafne] Gabinetto Psicol REFLETO, Via Francesco Saverio Nitti 28, Rome, Italy.
RP Nessaibia, I (corresponding author), Badji Mokhtar Univ, Lab Appl Neuroendocrinol, Annaba, Algeria.
EM issamland@yahoo.fr
OI Reis, AlessanRSS/0000-0001-8486-7469; Nessaibia,
   Issam/0000-0002-2597-1183
CR Bogaczewicz A, 2017, PSYCHIATR PSYCHOL KL, V17, P111, DOI 10.15557/PiPK.2017.0012
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Hu TY, 2020, NAT NANOTECHNOL, V15, P247, DOI 10.1038/s41565-020-0674-9
   Javed B, 2020, INT J HEALTH PLAN M, V35, P993, DOI 10.1002/hpm.3008
   Paton C., 2020, INT J HEALTH PLAN MA, P1
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   SCHMIDT H, 1987, EUR J PHARMACOL, V133, P83, DOI 10.1016/0014-2999(87)90208-1
   Thompson AJ, 2013, TRENDS PHARMACOL SCI, V34, P100, DOI 10.1016/j.tips.2012.12.002
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
NR 10
TC 0
Z9 0
U1 5
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0749-6753
EI 1099-1751
J9 INT J HEALTH PLAN M
JI Int. J. Health Plan. Manag.
PD NOV
PY 2020
VL 35
IS 6
BP 1311
EP 1313
DI 10.1002/hpm.3057
EA SEP 2020
PG 3
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA OU3CY
UT WOS:000567815100001
PM 32914465
OA Bronze
DA 2021-01-01
ER

PT J
AU Zhang, LY
   Fang, XN
   Liu, XB
   Ou, HC
   Zhang, HY
   Wang, JJ
   Li, Q
   Cheng, HY
   Zhang, WY
   Luo, ZF
AF Zhang, Liyun
   Fang, Xiaona
   Liu, Xingbo
   Ou, Huichao
   Zhang, Haiyan
   Wang, Jinjun
   Li, Qian
   Cheng, Huanyi
   Zhang, Wenyi
   Luo, Zhaofeng
TI Discovery of sandwich type COVID-19 nucleocapsid protein DNA aptamers
SO CHEMICAL COMMUNICATIONS
LA English
DT Article
AB Here, we report for the first time DNA aptamers targeted toward the COVID-19 nucleocapsid protein (Np). Np is one of the most abundant structural proteins and it serves as a diagnostic marker for the accurate and sensitive detection of COVID-19. After five rounds of selection, we obtained four DNA sequences with an affinity below 5 nM. The best one displayed a superb binding performance toward Np with aK(d)value of 0.49 nM. Interestingly, we found that the four pairs of aptamers could bind to Np successively, suggesting a sandwich-type interaction. Using these sandwiched aptamers in ELISA and colloidal gold immunochromatographic strips, we were able to detect Np at the tens of pM level. The results demonstrate that aptamers are powerful molecular tools for virus detection, diagnosis, and antiviral therapy.
C1 [Zhang, Liyun; Wang, Jinjun; Li, Qian] Nankai Univ, Coll Life Sci, State Key Lab Med Chem Biol, Tianjin 300350, Peoples R China.
   [Fang, Xiaona; Ou, Huichao; Zhang, Haiyan; Luo, Zhaofeng] Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China.
   [Liu, Xingbo; Cheng, Huanyi; Zhang, Wenyi] Abace Biotechnol Co LTD, Beijing 100176, Peoples R China.
RP Zhang, LY (corresponding author), Nankai Univ, Coll Life Sci, State Key Lab Med Chem Biol, Tianjin 300350, Peoples R China.; Luo, ZF (corresponding author), Univ Sci & Technol China, Sch Life Sci, Hefei 230027, Anhui, Peoples R China.
EM liyunzhang@nankai.edu.cn; lzf@ustc.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31570755, 5197021057]; COVID-19 emergency
   science and technology special fund [YD2070002016]; Nankai university
   [019157]; Natural Science Foundation of TianjinNatural Science
   Foundation of Tianjin [19JCZDJC33400]
FX We acknowledge the financial support from the National Natural Science
   Foundation of China (No. 31570755 and 5197021057) and the COVID-19
   emergency science and technology special fund (YD2070002016). L. Zhang
   thanks Nankai university for the support of the hundred youth program
   (019157) and acknowledges the funding support from the Natural Science
   Foundation of Tianjin (19JCZDJC33400).
CR Ahn DG, 2009, ANALYST, V134, P1896, DOI 10.1039/b906788d
   Basso CR, 2019, TALANTA, V197, P482, DOI 10.1016/j.talanta.2019.01.058
   Bhardwaj J, 2019, ANAL CHIM ACTA, V1064, P94, DOI 10.1016/j.aca.2019.03.005
   Chang CK, 2014, ANTIVIR RES, V103, P39, DOI 10.1016/j.antiviral.2013.12.009
   Chen ZQ, 2020, VIROL SIN, V35, P351, DOI 10.1007/s12250-020-00236-z
   Cho SJ, 2011, J BIOSCI BIOENG, V112, P535, DOI 10.1016/j.jbiosc.2011.08.014
   Famulok M, 2014, CHEM BIOL, V21, P1055, DOI 10.1016/j.chembiol.2014.08.003
   Hmila I, 2017, J VIROL METHODS, V243, P83, DOI 10.1016/j.jviromet.2017.01.024
   Hong SL, 2019, ANAL CHEM, V91, P3367, DOI 10.1021/acs.analchem.8b04623
   Lao YH, 2015, ACS NANO, V9, P2235, DOI 10.1021/nn507494p
   Lin SY, 2014, J MED CHEM, V57, P2247, DOI 10.1021/jm500089r
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo ZF, 2017, ANALYST, V142, P3136, DOI 10.1039/c7an01131h
   Pang YF, 2015, BIOSENS BIOELECTRON, V66, P527, DOI 10.1016/j.bios.2014.10.052
   Roh C, 2011, J CHEM TECHNOL BIOT, V86, P1475, DOI 10.1002/jctb.2721
   Santosh B, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/540451
   Seo G, 2020, ACS NANO, V14, P5135, DOI 10.1021/acsnano.0c02823
   Udugama B, 2020, ACS NANO, V14, P3822, DOI 10.1021/acsnano.0c02624
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhang SY, 2014, ANALYST, V139, P439, DOI 10.1039/c3an01835k
   Zhu GZ, 2018, ADV DRUG DELIVER REV, V134, P65, DOI 10.1016/j.addr.2018.08.005
   Zou XR, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01462
   Zu ZY, 2020, RADIOLOGY, V296, pE15, DOI 10.1148/radiol.2020200490
NR 23
TC 4
Z9 4
U1 24
U2 24
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1359-7345
EI 1364-548X
J9 CHEM COMMUN
JI Chem. Commun.
PD SEP 11
PY 2020
VL 56
IS 70
BP 10235
EP 10238
DI 10.1039/d0cc03993d
PG 4
WC Chemistry, Multidisciplinary
SC Chemistry
GA NH1UX
UT WOS:000564463200027
PM 32756614
DA 2021-01-01
ER

PT J
AU Singh, P
   Cumberland, WG
   Ugarte, D
   Bruckner, TA
   Young, SD
AF Singh, Parvati
   Cumberland, William G.
   Ugarte, Dominic
   Bruckner, Tim-Allen
   Young, Sean D.
TI Association Between Generalized Anxiety Disorder Scores and Online
   Activity Among US Adults During the COVID-19 Pandemic: Cross-Sectional
   Analysis
SO JOURNAL OF MEDICAL INTERNET RESEARCH
LA English
DT Article
DE online activity; COVID-19; anxiety; generalized anxiety disorder; GAD;
   scores; stress; internet; survey; cross-sectional
ID THREAT
AB Background: Evidence from past pandemics suggests that fear, uncertainty, and loss of control during large-scale public health crises may lead to increased pandemic-related information seeking, particularly among persons predisposed to high anxiety. In such groups, a greater consumption of information pertaining to the COVID-19 pandemic may increase anxiety.
   Objective: In this study, we examine the association between online activity and Generalized Anxiety Disorder 7 (GAD-7) scores in the United States. Methods: We recruited participants for an online survey through advertisements on various platforms such as Google, Facebook, and Reddit. A total of 406 adult US participants with moderate to severe (>= 10) GAD-7 scores met the inclusion criteria and completed the survey. Anxiety levels measured using the GAD-7 scale formed our primary outcome. Our key independent variables were average daily time spent online and average daily time spent online searching about COVID-19 within the past 14 days. We used as controls potential confounders of the relation between our key independent variables and GAD-7 scores, namely, sleep quality, the COVID-19 Fear Inventory scale, binge drinking, substance use, prescription drug abuse, and sociodemographic attributes.
   Results: Linear multivariate regression analyses showed that GAD-7 scores were higher among those who spent >4 hours online (per day) searching for information about COVID-19 (coefficient 1.29, P=.002), controlling for all other covariates. The total time spent online was not statistically associated with GAD-7 scores.
   Conclusions: Results from this study indicate that limiting pandemic-related online information seeking may aid anxiety management in our study population.
C1 [Singh, Parvati; Young, Sean D.] Univ Calif Irvine, Inst Predict Technol, Irvine, CA 92697 USA.
   [Cumberland, William G.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA USA.
   [Ugarte, Dominic] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA.
   [Bruckner, Tim-Allen] Univ Calif Irvine, Program Publ Hlth, Irvine, CA 92717 USA.
RP Singh, P (corresponding author), Univ Calif Irvine, Inst Predict Technol, Irvine, CA 92697 USA.
EM parvatis@uci.edu
OI Young, Sean D./0000-0001-6052-4875; Ugarte, Dominic
   Arjuna/0000-0003-3984-7324
CR [Anonymous], 2020, BBC NEWS
   Blakey SM, 2015, COGNITIVE THER RES, V39, P816, DOI 10.1007/s10608-015-9701-9
   Choi EPH, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17103740
   Czeisler ME, 2020, MMWR-MORBID MORTAL W, V69, P1049, DOI [10.15585/mmwr.mm6932a1, 10.1101/2020.04.22.20076141v1]
   Eysenbach G, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.2.e13
   Galea S, 2020, JAMA INTERN MED, V180, P817, DOI 10.1001/jamainternmed.2020.1562
   Gao JL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231924
   Gostin LO, 2020, JAMA-J AM MED ASSOC, V323, P2137, DOI 10.1001/jama.2020.5460
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954
   Kriplean Travis, 2014, P 17 ACM C COMP SUPP, P1188, DOI [10.1145/2531602.2531677, DOI 10.1145/2531602.2531677]
   Lai J, 2020, JAMA NETW OPEN, V3, DOI DOI 10.1001/JAMANETW0RK0PEN.2020.3976
   Misiak B, 2020, BRAIN BEHAV IMMUN, V87, P126, DOI 10.1016/j.bbi.2020.04.083
   Salari N, 2020, GLOBALIZATION HEALTH, V16, DOI 10.1186/s12992-020-00589-w
   Shahid A, 2011, STOP ONE 100 OTHER S, P219
   Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092
   Stanton R, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17114065
   StataCorp, 2015, STAT STAT SOFTW REL
   Taha SA, 2013, J HEALTH COMMUN, V18, P278, DOI 10.1080/10810730.2012.727960
   Taylor S, 2020, FEM PSYCHOL, V30, P63, DOI 10.1177/0959353519864390
   Yip L, 2020, MMWR-MORBID MORTAL W, V69, P1070, DOI 10.15585/mmwr.mm6932e1
NR 21
TC 0
Z9 0
U1 1
U2 1
PU JMIR PUBLICATIONS, INC
PI TORONTO
PA 130 QUEENS QUAY E, STE 1102, TORONTO, ON M5A 0P6, CANADA
SN 1438-8871
J9 J MED INTERNET RES
JI J. Med. Internet Res.
PD SEP 10
PY 2020
VL 22
IS 9
AR e21490
DI 10.2196/21490
PG 7
WC Health Care Sciences & Services; Medical Informatics
SC Health Care Sciences & Services; Medical Informatics
GA OC9TD
UT WOS:000579497400001
PM 32841152
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cheng, LL
   Guan, WJ
   Duan, CY
   Zhang, NF
   Lei, CL
   Hu, Y
   Chen, AL
   Li, SY
   Zhuo, C
   Deng, XL
   Cheng, FJ
   Gao, Y
   Zhang, JH
   Xie, JX
   Peng, H
   Li, YX
   Wu, XX
   Liu, W
   Peng, H
   Wang, J
   Xiao, GM
   Chen, PY
   Wang, CY
   Yang, ZF
   Zhao, JC
   Zhong, NS
AF Cheng, Lin-ling
   Guan, Wei-jie
   Duan, Chong-yang
   Zhang, Nuo-fu
   Lei, Chun-liang
   Hu, Yu
   Chen, Ai-lan
   Li, Shi-yue
   Zhuo, Chao
   Deng, Xi-long
   Cheng, Fan-jun
   Gao, Yong
   Zhang, Jian-heng
   Xie, Jia-xing
   Peng, Hong
   Li, Ying-xian
   Wu, Xiao-xiong
   Liu, Wen
   Peng, Hui
   Wang, Jian
   Xiao, Guang-ming
   Chen, Ping-yan
   Wang, Chun-yan
   Yang, Zi-feng
   Zhao, Jin-cun
   Zhong, Nan-shan
TI Effect of Recombinant Human Granulocyte Colony-Stimulating Factor for
   Patients With Coronavirus Disease 2019 (COVID-19) and Lymphopenia A
   Randomized Clinical Trial
SO JAMA INTERNAL MEDICINE
LA English
DT Article; Early Access
ID G-CSF; RECONSTITUTION
AB IMPORTANCE Lymphopenia is common and correlates with poor clinical outcomes in patients with coronavirus disease 2019 (COVID-19).
   OBJECTIVE To determine whether a therapy that increases peripheral blood leukocyte and lymphocyte cell counts leads to clinical improvement in patients with COVID-19.
   DESIGN, SETTING AND PARTICIPANTS Between February 18 and April 10, 2020, we conducted an open-label, multicenter, randomized clinical trial at 3 participating centers in China. The main eligibility criteria were pneumonia, a blood lymphocyte cell count of 800 per mu L (to convert to x10(9)/L, multiply by 0.001) or lower, and no comorbidities. Severe acute respiratory syndrome coronavirus 2 infection was confirmed with reverse-transcription polymerase chain reaction testing.
   EXPOSURES Usual care alone, or usual care plus 3 doses of recombinant human granulocyte colony-stimulating factor (rhG-CSF, 5 mu g/kg, subcutaneously at days 0-2).
   MAIN OUTCOMES AND MEASURES The primary end point was the time from randomization to improvement of at least 1 point on a 7-category disease severity score.
   RESULTS Of 200 participants, 112 (56%) were men and the median (interquartile range [IQR]) age was 45 (40-55) years. There was random assignment of 100 patients (50%) to the rhG-CSF group and 100 (50%) to the usual care group. Time to clinical improvement was similar between groups (rhG-CSF group median of 12 days (IQR, 10-16 days) vs usual care group median of 13 days (IQR, 11-17 days); hazard ratio, 1.28; 95% CI, 0.95-1.71;P = .06). For secondary end points, the proportion of patients progressing to acute respiratory distress syndrome, sepsis, or septic shock was lower in the rhG-CSF group (rhG-CSF group, 2% vs usual care group, 15%; difference, -13%; 95%CI, -21.4% to -5.4%). At 21 days, 2 patients (2%) had died in the rhG-CSF group compared with 10 patients (10%) in the usual care group (hazard ratio, 0.19; 95%CI, 0.04-0.88). At day 5, the lymphocyte cell count was higher in the rhG-CSF group (rhG-CSF group median of 1050/mu L vs usual care group median of 620/mu L; Hodges-Lehmann estimate of the difference in medians, 440; 95% CI, 380-490). Serious adverse events, such as sepsis or septic shock, respiratory failure, and acute respiratory distress syndrome, occurred in 29 patients (14.5%) in the rhG-CSF group and 42 patients (21%) in the usual care group.
   CONCLUSION AND RELEVANCE In preliminary findings from a randomized clinical trial, rhG-CSF treatment for patients with COVID-19 with lymphopenia but no comorbidities did not accelerate clinical improvement, but the number of patients developing critical illness or dying may have been reduced. Larger studies that include a broader range of patients with COVID-19 should be conducted.
C1 [Cheng, Lin-ling; Guan, Wei-jie; Zhang, Nuo-fu; Zhuo, Chao; Zhang, Jian-heng; Xie, Jia-xing; Peng, Hong; Li, Ying-xian; Yang, Zi-feng; Zhao, Jin-cun; Zhong, Nan-shan] Guangzhou Med Univ, Natl Clin Res Ctr Resp Dis, State Key Lab Resp Dis, Guangzhou Inst Resp Hlth,Affiliated Hosp 1, 151 Yanjiang Rd, Guangzhou 510120, Guangdong, Peoples R China.
   [Cheng, Lin-ling; Lei, Chun-liang; Li, Shi-yue; Peng, Hui; Wang, Jian; Xiao, Guang-ming] Guangzhou Med Univ, Guangzhou Peoples Hosp 8, Guangzhou, Peoples R China.
   [Duan, Chong-yang; Chen, Ping-yan] Southern Med Univ, State Key Lab Organ Failure Res, Natl Clin Res Ctr Kidney Dis, Dept Biostat,Sch Publ Hlth, Guangzhou, Peoples R China.
   [Hu, Yu; Cheng, Fan-jun; Liu, Wen] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Hubei, Peoples R China.
   [Chen, Ai-lan; Zhang, Jian-heng; Xie, Jia-xing; Li, Ying-xian] Hankou Hosp Wuhan City, Med Dept, Wuhan, Peoples R China.
   [Wang, Chun-yan] Guangzhou Med Univ, Affiliated Hosp 1, Dept Haematol, Guangzhou, Peoples R China.
RP Zhong, NS (corresponding author), Guangzhou Med Univ, Natl Clin Res Ctr Resp Dis, State Key Lab Resp Dis, Guangzhou Inst Resp Hlth,Affiliated Hosp 1, 151 Yanjiang Rd, Guangzhou 510120, Guangdong, Peoples R China.
EM nanshan@vip.163.com
OI Reis, AlessanRSS/0000-0001-8486-7469
FU Guangzhou Institute for Respiratory Health
FX The study was supported by grants related to the prevention and
   management of coronavirus disease 2019 and Guangzhou Institute for
   Respiratory Health. We thank Kyowa Hakko Kirin China Pharmaceutical Co
   Ltd for their provision of the recombinant human granulocyte
   colony-stimulating factor.
CR Ang CC, 2011, INT J DERMATOL, V50, P1570, DOI 10.1111/j.1365-4632.2011.05007.x
   [Anonymous], COR DIS COVID 2019
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   HODGES JL, 1963, ANN MATH STAT, V34, P598, DOI 10.1214/aoms/1177704172
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   KIMURA S, 1990, AIDS, V4, P1251, DOI 10.1097/00002030-199012000-00011
   Koizumi T, 1997, EXP LUNG RES, V23, P393, DOI 10.3109/01902149709039234
   Li JG, 2004, YI SHI JIN XIU ZA ZH, V27, P21, DOI [10.3760/cma.j.issn.1673-4904.2004.23.008, DOI 10.3760/CMA.J.ISSN.1673-4904.2004.23.008]
   Melve GK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00845
   Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I
   Piccirillo N, 2009, AM J HEMATOL, V84, P381, DOI 10.1002/ajh.21418
   Rondelli D, 1998, BONE MARROW TRANSPL, V22, P631, DOI 10.1038/sj.bmt.1701413
   SanMiguel JF, 1996, BRIT J HAEMATOL, V94, P140, DOI 10.1046/j.1365-2141.1996.d01-1756.x
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   World Health Organization, WHO COR DIS COVID 19
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhao HX, 2013, J RADIAT RES, V54, P83, DOI 10.1093/jrr/rrs082
   Zhao SS, 2018, J CONTEMP CHINA, V27, P1, DOI 10.1080/10670564.2017.1363012
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 23
TC 12
Z9 12
U1 2
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6106
EI 2168-6114
J9 JAMA INTERN MED
JI JAMA Intern. Med.
DI 10.1001/jamainternmed.2020.5503
EA SEP 2020
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA NS6OK
UT WOS:000572378200002
PM 32910179
OA Bronze
DA 2021-01-01
ER

PT J
AU Ibarrondo, FJ
   Fulcher, JA
   Yang, OO
AF Ibarrondo, F. Javier
   Fulcher, Jennifer A.
   Yang, Otto O.
TI Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
ID CORONAVIRUS
AB Among 34 volunteers who had recovered from mild Covid-19 illness, antiviral antibodies to the receptor-binding domain of the viral spike protein declined with a mean half-life of approximately 36 days after recovery. Whether these results predict the duration of viral immunity in persons recovering from more severe cases of Covid-19 or those exposed to vaccines is unknown.
C1 [Ibarrondo, F. Javier; Fulcher, Jennifer A.; Yang, Otto O.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Yang, OO (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
EM oyang@mednet.ucla.edu
FU AIDS Healthcare Foundation; Doris Duke Charitable FoundationDoris Duke
   Charitable Foundation (DDCF) [2019086]; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [AI124979, AI131879, AI140775,
   AI068616, AI068632, AI106716]; James B. Pendleton Charitable Trust;
   McCarthy Family Foundation
FX Supported by grants from the AIDS Healthcare Foundation, the Doris Duke
   Charitable Foundation (2019086), the National Institutes of Health
   (AI124979, AI131879, AI140775, AI068616, AI068632, and AI106716), the
   James B. Pendleton Charitable Trust, and the McCarthy Family Foundation.
CR Cao WCC, 2007, NEW ENGL J MED, V357, P1162, DOI 10.1056/NEJMc070348
   Chang SC, 2005, CLIN DIAGN LAB IMMUN, V12, P1455, DOI 10.1128/CDLI.12.12.1455-1457.2005
   Long QQ, 2020, REPROD BIOL ENDOCRIN, V18, DOI 10.1186/s12958-020-00600-4
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   2012, SURG OBES RELAT DIS, V8, pE1002
NR 5
TC 46
Z9 46
U1 3
U2 3
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD SEP 10
PY 2020
VL 383
IS 11
BP 1085
EP 1087
DI 10.1056/NEJMc2025179
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA NR8KA
UT WOS:000571807800025
PM 32706954
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Avidan, MS
   Dehbi, HM
   Delany-Moretlwe, S
AF Avidan, Michael S.
   Dehbi, Hakim-Moulay
   Delany-Moretlwe, Sinead
TI Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
AB To the Editor: The window for postexposure prophylaxis against Covid-19 is narrow.(1-3) Therapy that is initiated up to 4 days after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is early treatment, not postexposure prophylaxis. The trial described in the article by Boulware et al. (published online on June 3 at NEJM.org)(4) was therefore largely about the prevention of symptoms in persons who may already have been infected. The trial was designed to detect a 50% relative reduction in new cases of symptomatic Covid-19; this estimate was overly optimistic. The trial was not powered to detect an important, but . . .
C1 [Avidan, Michael S.] Washington Univ, Sch Med, St Louis, MO 63130 USA.
   [Dehbi, Hakim-Moulay] UCL, London, England.
   [Delany-Moretlwe, Sinead] Univ Witwatersrand, Johannesburg, South Africa.
RP Avidan, MS (corresponding author), Washington Univ, Sch Med, St Louis, MO 63130 USA.
CR [Anonymous], 2020, STAND SURV CAS DEF N
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 SYMPT B
   DWORZACK DL, 1988, ANTIMICROB AGENTS CH, V32, P1740, DOI 10.1128/AAC.32.11.1740
   Ferretti L, 2020, SCIENCE, V368, P619, DOI 10.1126/science.abb6936
   Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205
   Hafner CM, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17113827
   Harrington D, 2019, NEW ENGL J MED, V381, P285, DOI 10.1056/NEJMe1906559
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Kong W, 2020, TRAVEL MED INFECT DI
   Kucirka LM, 2020, ANN INTERN MED
   La Scola B, 2020, EUR J CLIN MICROBIOL, V39, P1059, DOI 10.1007/s10096-020-03913-9
   Linton NM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020538
   Pitt B, 2003, NEW ENGL J MED, V348, P1309, DOI 10.1056/NEJMoa030207
   Tavazzi L, 2008, LANCET, V372, P1223, DOI 10.1016/S0140-6736(08)61239-8
   Wasserstein RL, 2019, AM STAT, V73, P1, DOI 10.1080/00031305.2019.1583913
NR 16
TC 1
Z9 1
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD SEP 10
PY 2020
VL 383
IS 11
BP 1087
EP 1088
DI 10.1056/NEJMc2023617
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA NR8KA
UT WOS:000571807800026
OA Bronze
DA 2021-01-01
ER

PT J
AU ElDahshan, KA
   AlHabshy, AA
   Abutaleb, GE
AF ElDahshan, Kamal A.
   AlHabshy, AbdAllah A.
   Abutaleb, Gaber E.
TI Data in the time of COVID-19: a general methodology to select and secure
   a NoSQL DBMS for medical data
SO PEERJ COMPUTER SCIENCE
LA English
DT Article
DE NoSQL databases; Database security; Key-value stores NoSQL systems;
   Document-based stores NoSQL systems; Column-based stores NoSQL systems;
   Graph stores NoSQL systems; Object Store NoSQL systems; COVID-19
   patients' data
AB Background. As the COVID-19 crisis endures and the virus continues to spread globally, the need for collecting epidemiological data and patient information also grows exponentially. The race against the clock to find a cure and a vaccine to the disease means researchers require storage of increasingly large and diverse types of information; for doctors following patients, recording symptoms and reactions to treatments, the need for storage flexibility is only surpassed by the necessity of storage security. The volume, variety, and variability of COVID-19 patient data requires storage in NoSQL database management systems (DBMSs). But with a multitude of existing NoSQL DBMSs, there is no straightforward way for institutions to select the most appropriate. And more importantly, they suffer from security flaws that would render them inappropriate for the storage of confidential patient data.
   Motivation. This paper develops an innovative solution to remedy the aforementioned shortcomings. COVID-19 patients, as well as medical professionals, could be subjected to privacy-related risks, from abuse of their data to community bullying regarding their medical condition. Thus, in addition to being appropriately stored and analyzed, their data must imperatively be highly protected against misuse.
   Methods. This paper begins by explaining the five most popular categories of NoSQL databases. It also introduces the most popular NoSQL DBMS types related to each one of them. Moreover, this paper presents a comparative study of the different types of NoSQL DBMS, according to their strengths and weaknesses. This paper then introduces an algorithm that would assist hospitals, and medical and scientific authorities to choose the most appropriate type for storing patients' information. This paper subsequently presents a set of functions, based on web services, offering a set of endpoints that include authentication, authorization, auditing, and encryption of information. These functions are powerful and effective, making them appropriate to store all the sensitive data related to patients.
   Results and Contributions. This paper presents an algorithm to select the most convenient NoSQL DBMS for COVID-19 patients, medical staff, and organizations data. In addition, the paper proposes innovative security solutions that eliminate the barriers to utilizing NoSQL DBMSs to store patients' data. The proposed solutions resolve several security problems including authentication, authorization, auditing, and encryption. After implementing these security solutions, the use of NoSQL DBMSs will become a much more appropriate, safer, and affordable solution to storing and analyzing patients' data, which would contribute greatly to the medical and research effort against COVID-19. This solution can be implemented for all types of NoSQL DBMSs; implementing it would result in highly securing patients' data, and protecting them from any downsides related to data leakage.
C1 [ElDahshan, Kamal A.; AlHabshy, AbdAllah A.; Abutaleb, Gaber E.] Al Azhar Univ, Fac Sci, Math Dept, Cairo, Egypt.
RP Abutaleb, GE (corresponding author), Al Azhar Univ, Fac Sci, Math Dept, Cairo, Egypt.
EM gaber_abutaleb@azhar.edu.eg
OI Elhabshy, Abd Allah/0000-0002-5258-6109
CR Abed AH, 2020, INT J ADV NETWORKING, V11, p4321~4329
   Angles R., 2012, 2012 IEEE 28 INT C D, p171~177
   Arora R, 2013, INT J ADV STUDIES CO, V2, p6~12
   Chang F, 2008, ACM T COMPUT SYST, V26, DOI 10.1145/1365815.1365816
   Chen M, 2014, MOBILE NETW APPL, V19, P171, DOI 10.1007/s11036-013-0489-0
   Chodorow K., 2013, MONGODB DEFINITIVE G, p1~432
   Dayan N, 2018, ACM T DATABASE SYST, V43, DOI 10.1145/3276980
   Deka G., 2013, IT PROFESSIONAL, V16, P50
   Dindoliwala VJ, 2017, INT J ADV RES COMPUT, V8, p333~338
   ELMASRI R, 2017, FUNDAMENTALS DATABAS
   Franz Inc, 2020, ALLEGROGRAPH
   George S., 2013, INT J ENTERPRISE COM, V2, p1~11
   Grolinger K, 2013, J CLOUD COMPUT-ADV S, V2, DOI 10.1186/2192-113X-2-22
   Hong W, 2011, I C WIREL COMM NETW
   Internet Engineering Task Force (IETF), 2020, JSON WEB TOK INTR
   Jim T, 2007, P 16 INT C WORLD WID, p601~610
   Kaur K, 2013, IEEE INT CONF BIG DA
   Khasawneh T, 2020, 11 INT C INF COMM SY
   Kobrix Software Inc, 2020, HYPERGRAPHDB
   Lakshman Avinash, 2010, Operating Systems Review, V44, P35, DOI 10.1145/1773912.1773922
   Lasisi AN, 2012, COMMUNICATIONS, V2, p354~362
   Lourenco J. R., 2015, J BIG DATA, V2, P18, DOI [10.1186/s40537-015-0025-0, DOI 10.1186/s40537-015-0025-0, DOI 10.1186/S40537-015-0025-0]
   Meier A, 2019, SQL NOSQL DATABASES
   Moniruzzaman A. B. M., 2013, INT J DATABASE THEOR, V6, P1
   Nayak A, 2013, INT J APPL INFORM SY, V5, P16, DOI DOI 10.5120/IJAIS12-450888
   Noiumkar P, 2014, 9 INT C INF TECHN AP, P6
   Ozsu MT, 2020, PRINCIPLES DISTRIBUT, p519~557
   Paterson J, 2006, DEFINITIVE GUIDE DB4, P485
   Sahafizadeh E., 2015, ADV COMPUTER SCI INT, V4, P68
   SecurityFocus, 2020, AP COUCHDB UN UN IDE
   Son S., 2013, P 2013 ACM SIGSAC C, P1181, DOI DOI 10.1145/2508859.2516696
   Strauch C, 2011, LECT NOTES, P20
   Sullivan P, 2011, ADV ENERGY MATER, V1, P352, DOI 10.1002/aenm.201100036
   Tudorica BG, 2011, 2011 ROEDUNET INT C
   VMware Inc., 2020, SPRING BOOT
   Zahid A, 2014, 2014 C INF ASS CYB S
   Zugaj W., 2019, AM J INF SCI TECHNOL, V3, P41
NR 37
TC 0
Z9 0
U1 0
U2 0
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2376-5992
J9 PEERJ COMPUT SCI
JI PeerJ Comput. Sci.
PD SEP 10
PY 2020
AR e297
DI 10.7717/peerj-cs.297
PG 32
WC Computer Science, Artificial Intelligence; Computer Science, Information
   Systems; Computer Science, Theory & Methods
SC Computer Science
GA NO9YH
UT WOS:000569840900001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU de la Cruz-benito, B
   Rivas-Pollmar, MI
   Roman, MTA
   Trelles-Martinez, R
   Martin-Salces, M
   Lazaro-del Campo, P
   Ramirez-Lopez, A
   Garcia-Barcenilla, S
   Cebanu, T
   Acuna-Butta, P
   Monzon-Manzano, E
   Gonzalez-Zorrilla, E
   Jimenez-Yuste, V
   Butta, NV
AF de la Cruz-Benito, Beatriz
   Rivas-Pollmar, Maria I.
   Alvarez Roman, Maria T.
   Trelles-Martinez, Roberto
   Martin-Salces, Monica
   Lazaro-del Campo, Paula
   Ramirez-Lopez, Andres
   Garcia-Barcenilla, Sara
   Cebanu, Tamara
   Acuna-Butta, Paula
   Monzon-Manzano, Elena
   Gonzalez-Zorrilla, Elena
   Jimenez-Yuste, Victor
   Butta, Nora V.
TI Paradoxical effect of SARS-CoV-2 infection in patients with immune
   thrombocytopenia
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article; Early Access
DE immune thrombocytopenia; COVID-19; SARS-CoV-2; thrombocytosis;
   lymphopenia
ID ACUTE RESPIRATORY SYNDROME
AB Thrombocytopenia has been identified as a common complication of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in the general population. In an attempt to determine the impact of coronavirus disease 2019 (COVID-19) in patients with immune thrombocytopenia (ITP), a retrospective single-centre study was performed. Thrombocytosis was observed in patients with chronic ITP after SARS-CoV-2 infection, frequently needing treatment adjustment or even discontinuation of therapy. Relapses and newly diagnosed cases showed a fast response after initial treatment compared to ITP. Reduced immune activity due to lymphopenia during COVID-19 could explain this paradoxical effect, although further studies are needed.
C1 [de la Cruz-Benito, Beatriz; Rivas-Pollmar, Maria I.; Alvarez Roman, Maria T.; Trelles-Martinez, Roberto; Martin-Salces, Monica; Lazaro-del Campo, Paula; Ramirez-Lopez, Andres; Garcia-Barcenilla, Sara; Cebanu, Tamara; Acuna-Butta, Paula; Monzon-Manzano, Elena; Gonzalez-Zorrilla, Elena; Jimenez-Yuste, Victor; Butta, Nora V.] La Paz Univ Hosp IdiPAZ, Unit Thrombosis & Hemostasis, Dept Hematol, Madrid, Spain.
   [Jimenez-Yuste, Victor] Univ Autonoma Madrid, Madrid, Spain.
RP Roman, MTA (corresponding author), Hosp Univ La Paz, Dept Hematol, Paseo Castellana 261, Madrid 28046, Spain.
EM talvarezroman@gmail.com
FU FIS-Fondos FEDEREuropean Union (EU) [PI19/00772]
FX Beatriz de la Cruz-Benito, Maria I. Rivas-Pollmar, Maria T. Alvarez
   Roman, Victor Jimenez-Yuste and Nora V. Butta designed the study.
   Beatriz de la Cruz-Benito, Maria I. RivasPollmar, Monica Martin-Salces,
   Roberto Trelles-Martinez, Paula Lazaro-del Campo, Andres Ramirez-Lopez,
   Sara Garcia-Barcenilla, Tamara Cebanu, Paula Acuna-Butta, Elena
   Monzon-Manzano and Elena Gonzalez-Zorrilla performed the follow-up of
   patients with ITP. Maria T. Alvarez Roman and Nora V. Butta wrote the
   paper. All authors approved the manuscript. This work was supported by
   FIS-Fondos FEDER: PI19/00772
CR Bomhof G, 2020, BRIT J HAEMATOL, V190, pE61, DOI 10.1111/bjh.16850
   Despotovic JM, 2018, HEMATOL-AM SOC HEMAT, P405, DOI 10.1182/asheducation-2018.1.405
   Gao ZW, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102557
   Khellaf M, 2014, AM J HEMATOL, V89, P194, DOI 10.1002/ajh.23609
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Liu Yang, 2020, Zhongguo Meijieshengwuxue Ji Kongzhi Zazhi, V31, P490
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Swinkels M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00880
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Wong RSM, 2003, BRIT MED J, V326, P1358, DOI 10.1136/bmj.326.7403.1358
   Xu PY, 2020, ANN HEMATOL, V99, P1205, DOI 10.1007/s00277-020-04019-0
   Yang M, 2005, HEMATOLOGY, V10, P101, DOI 10.1080/10245330400026170
   Yang XB, 2020, J THROMB HAEMOST, V18, P1469, DOI 10.1111/jth.14848
   Zhao XF, 2020, EPMA J, V11, P139, DOI 10.1007/s13167-020-00208-z
   Zulfiqar AA, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2010472
NR 16
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
DI 10.1111/bjh.17077
EA SEP 2020
PG 5
WC Hematology
SC Hematology
GA NN5IP
UT WOS:000568822500001
PM 33280085
DA 2021-01-01
ER

PT J
AU Marchese, V
   Crosato, V
   Gulletta, M
   Castelnuovo, F
   Cristini, G
   Matteelli, A
   Castelli, F
AF Marchese, Valentina
   Crosato, Verena
   Gulletta, Maurizio
   Castelnuovo, Filippo
   Cristini, Graziella
   Matteelli, Alberto
   Castelli, Francesco
TI Strongyloidesinfection manifested during immunosuppressive therapy for
   SARS-CoV-2 pneumonia
SO INFECTION
LA English
DT Article; Early Access
DE Strongyloides stercoralis; Tocilizumab; SARS-CoV-2; Immunosuppression
ID STRONGYLOIDIASIS; INFECTION
AB Background SARS-CoV-2 pandemic has posed formidable public health and clinical challenges. The use of immunosuppressive agents, such as high dose corticosteroids and cytokine inhibitors (e.g., Tocilizumab) has been suggested to contrast the hyperinflammatory process involved in the pathogenesis of the severe disease, with conflicting evidence. Among the drawbacks of immunosuppressive therapy, the risk of reactivation of latent infections, including parasitic infestations, is to be considered. Case presentation We report a case of a 59-year-old Italian patient treated with high dose intravenous dexamethasone and two intravenous doses of Tocilizumab for interstitial bilateral pneumonia associated with SARS-CoV-2 infection who developed itching, abdominal pain, and an increased eosinophil count. Stool examination confirmed the presence ofS. stercoralislarvae. The patient was treated with a 4-day course of Ivermectin with full recovery. Discussion We report the first case ofS. stercoralisinfection following an 11-day treatment with high-dose steroids and Tocilizumab for severe COVID-19. Clinicians should be aware of the risk of strongyloidiasis as a complication of the treatment for severe COVID-19.
C1 [Marchese, Valentina] Univ Brescia, ASST Spedali Civili Hosp, Specialist Consultat Serv ASST Spedali Civili, Brescia, Italy.
   [Marchese, Valentina; Gulletta, Maurizio; Castelnuovo, Filippo; Cristini, Graziella; Matteelli, Alberto; Castelli, Francesco] Univ Brescia, ASST Spedali Civili Hosp, Univ Div Infect & Trop Dis, Brescia, Italy.
   [Crosato, Verena] Univ Brescia, ASST Spedali Civili Hosp, Univ Dept Infect & Trop Dis, Brescia, Italy.
RP Marchese, V (corresponding author), Univ Brescia, ASST Spedali Civili Hosp, Specialist Consultat Serv ASST Spedali Civili, Brescia, Italy.; Marchese, V (corresponding author), Univ Brescia, ASST Spedali Civili Hosp, Univ Div Infect & Trop Dis, Brescia, Italy.
EM v.marchese@unibs.it
OI Reis, AlessanRSS/0000-0001-8486-7469
FU UniversitA degli Studi di Brescia
FX Open access funding provided by UniversitA degli Studi di Brescia within
   the CRUI-CARE Agreement. This research received no specific grant from
   any funding agency in the public, commercial, or not-for-profit sectors.
CR Brotherton H, 2020, LANCET GLOB HEALTH, V8, pE1125, DOI 10.1016/S2214-109X(20)30318-1
   Buonfrate D, 2016, EUROSURVEILLANCE, V21, P9, DOI 10.2807/1560-7917.ES.2016.21.31.30310
   Buonfrate D, 2019, LANCET INFECT DIS, V19, P1181, DOI 10.1016/S1473-3099(19)30289-0
   Buonfrate D, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-78
   CDC, 2020, PAR STRONG RES HLTH
   Downey C, 2016, INT J RHEUM DIS, V19, P536, DOI 10.1111/1756-185X.12659
   Fardet L, 2006, CLIN MICROBIOL INFEC, V12, P945, DOI 10.1111/j.1469-0691.2006.01443.x
   Greaves D, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4610
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Kassalik M, 2011, GASTROENTEROL EPATOL, V7
   Lan SH, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106103
   Li RQ, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104363
   Mafort TT, 2017, AM J RESP CRIT CARE, V195
   Mejia R, 2012, CURR OPIN INFECT DIS, V25, P458, DOI 10.1097/QCO.0b013e3283551dbd
   Montes M, 2010, CURR OPIN INFECT DIS, V23, P500, DOI 10.1097/QCO.0b013e32833df718
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Requena-Mendez A, 2017, AM J TROP MED HYG, V97, P645, DOI 10.4269/ajtmh.16-0923
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Stauffer WM, 2020, JAMA-J AM MED ASSOC, V324, P623, DOI 10.1001/jama.2020.13170
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Veronese N, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00170
   Wang Y, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0158-2
   Winthrop KL, 2018, CLIN MICROBIOL INFEC, V24, pS21, DOI 10.1016/j.cmi.2018.02.002
   World Health Organization, STRONGYLOIDIASIS
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9
NR 27
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0300-8126
EI 1439-0973
J9 INFECTION
JI Infection
DI 10.1007/s15010-020-01522-4
EA SEP 2020
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA NN3IX
UT WOS:000568686000001
PM 32910321
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rotenberg, LD
   Nascimento, C
   Khafif, TC
   Dias, RS
   Lafer, B
AF de Siqueira Rotenberg, Luisa
   Nascimento, Camila
   Cohab Khafif, Tatiana
   Silva Dias, Rodrigo
   Lafer, Beny
TI Psychological therapies and psychoeducational recommendations for
   bipolar disorder treatment during COVID-19 pandemic
SO BIPOLAR DISORDERS
LA English
DT Article
C1 [de Siqueira Rotenberg, Luisa; Nascimento, Camila; Cohab Khafif, Tatiana; Silva Dias, Rodrigo; Lafer, Beny] Univ Sao Paulo, Sch Med, Dept Psychiat, Bipolar Disorder Program PROMAN, Sao Paulo, Brazil.
RP Rotenberg, LD (corresponding author), Rua Dr Ovidio Pires de Campos 785, BR-01060970 Sao Paulo, SP, Brazil.
EM rotenbergluisa@gmail.com
RI Nascimento, Camila/ABC-6200-2020; Lafer, Beny/C-1055-2012
OI Nascimento, Camila/0000-0002-8170-7635; de Siqueira Rotenberg,
   Luisa/0000-0001-9175-7567; Cohab Khafif, Tatiana/0000-0003-0806-1249;
   Lafer, Beny/0000-0002-6132-9999
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [17/07089-8, 2017/07089-8];
   Coordenacao de Aperfeicoamento de Pessoal de Nivel SuperiorCAPES [CAPES
   PROEX 88887.461435/2019-00, CAPES PROEX 88887.475730/2020-00]
FX Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Grant/Award
   Number: 17/07089-8 and 2017/07089-8; Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior, Grant/Award Number: CAPES PROEX
   88887.461435/2019-00 and CAPES PROEX 88887.475730/2020-00
CR Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Faurholt-Jepsen M, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0713-0
   Gottlieb JF, 2019, BIPOLAR DISORD, V21, P741, DOI 10.1111/bdi.12847
   Pavlova B, 2015, LANCET PSYCHIAT, V2, P710, DOI 10.1016/S2215-0366(15)00112-1
   Yatham LN, 2018, BIPOLAR DISORD, V20, P97, DOI 10.1111/bdi.12609
NR 5
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-5647
EI 1399-5618
J9 BIPOLAR DISORD
JI Bipolar Disord.
PD SEP
PY 2020
VL 22
IS 6
BP 644
EP 646
DI 10.1111/bdi.12981
EA SEP 2020
PG 3
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA NQ2AD
UT WOS:000568730300001
PM 32780503
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Murray, G
   Gottlieb, J
   Swartz, HA
AF Murray, Greg
   Gottlieb, John
   Swartz, Holly A.
TI Maintaining Daily Routines to Stabilize Mood: Theory, Data, and
   Potential Intervention for Circadian Consequences of COVID-19
SO CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
LA English
DT Article; Early Access
DE COVID-19; major depressive disorder; bipolar disorders; circadian
   system; social rhythms; social rhythm therapy
ID BIPOLAR SPECTRUM DISORDERS; SOCIAL RHYTHM DISRUPTION; STRESSFUL LIFE
   EVENTS; ONSET; ZEITGEBER; EPISODES
C1 [Murray, Greg] Swinburne Univ Technol, Ctr Mental Hlth, Melbourne, Vic, Australia.
   [Gottlieb, John] Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, Chicago, IL 60611 USA.
   [Swartz, Holly A.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
RP Murray, G (corresponding author), Swinburne Univ Technol, Ctr Mental Hlth, John St, Hawthorn, Vic 3122, Australia.
EM gwm@swin.edu.au
CR Boland EM, 2016, CLIN PSYCHOL SCI, V4, P418, DOI 10.1177/2167702615603368
   Boland EM, 2012, J AFFECT DISORDERS, V139, P264, DOI 10.1016/j.jad.2012.01.038
   Bullock B, 2011, J AFFECT DISORDERS, V135, P384, DOI 10.1016/j.jad.2011.06.006
   Clark DM, 2018, LANCET, V391, P679, DOI 10.1016/S0140-6736(17)32133-5
   Crowe M, 2016, J PSYCHIATR MENT HLT, V23, P3, DOI 10.1111/jpm.12271
   Crowe M, 2020, BIPOLAR DISORD, V22, P121, DOI 10.1111/bdi.12840
   Fletcher K, 2018, J MED INTERNET RES, V20, DOI 10.2196/11160
   Fletcher K, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1805-9
   Frank E, 2005, TREATING BIPOLAR DIS
   Gottlieb JF, 2019, BIPOLAR DISORD, V21, P741, DOI 10.1111/bdi.12847
   Grandin LD, 2006, CLIN PSYCHOL REV, V26, P679, DOI 10.1016/j.cpr.2006.07.001
   HEALY D, 1987, PSYCHOPHARMACOLOGY, V93, P271
   Huhne A, 2018, ANN MED, V50, P637, DOI 10.1080/07853890.2018.1530449
   Inder ML, 2015, BIPOLAR DISORD, V17, P128, DOI 10.1111/bdi.12273
   International Society for Bipolar Disorders CTF, 2020, COVID 19 PAND EM WEL
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Logan RW, 2019, NAT REV NEUROSCI, V20, P49, DOI 10.1038/s41583-018-0088-y
   Malkoff-Schwartz S, 1998, ARCH GEN PSYCHIAT, V55, P702, DOI 10.1001/archpsyc.55.8.702
   Malkoff-Schwartz S, 2000, PSYCHOL MED, V30, P1005, DOI 10.1017/S0033291799002706
   Margraf J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150312
   Melo MCA, 2017, SLEEP MED REV, V34, P46, DOI 10.1016/j.smrv.2016.06.007
   Monk TH, 2002, J SLEEP RES, V11, P183, DOI 10.1046/j.1365-2869.2002.00300.x
   Morton E, 2020, CLIN PSYCHOL PSYCHOT, V27, P364, DOI 10.1002/cpp.2433
   Murray G, 2020, BIPOLAR DISORD, V22, P693, DOI 10.1111/bdi.12963
   Murray G, 2019, AUST NZ J PSYCHIAT, V53, P597, DOI 10.1177/0004867419847279
   Scott J, 2017, JAMA PSYCHIAT, V74, P189, DOI 10.1001/jamapsychiatry.2016.3459
   Shen GH, 2008, BIPOLAR DISORD, V10, P520, DOI 10.1111/j.1399-5618.2008.00583.x
   Swartz HA, 2018, BIPOLAR DISORD, V20, P63, DOI [10.1111/bdi.12619, DOI 10.1111/BDI.12619]
   Sylvia LG, 2009, BEHAV THER, V40, P131, DOI 10.1016/j.beth.2008.04.003
   Tahkamo L, 2019, CHRONOBIOL INT, V36, P151, DOI 10.1080/07420528.2018.1527773
NR 30
TC 0
Z9 0
U1 5
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0706-7437
EI 1497-0015
J9 CAN J PSYCHIAT
JI Can. J. Psychiat.-Rev. Can. Psychiat.
AR 0706743720957825
DI 10.1177/0706743720957825
EA SEP 2020
PG 5
WC Psychiatry
SC Psychiatry
GA NN1WH
UT WOS:000568580400001
PM 32909832
DA 2021-01-01
ER

PT J
AU Zhang, LK
   Liu, J
   Cao, RY
   Xu, MY
   Wu, Y
   Shang, WJ
   Wang, X
   Zhang, HY
   Jiang, XM
   Sun, Y
   Hu, HR
   Li, YF
   Zou, G
   Zhang, M
   Zhao, L
   Li, W
   Guo, XJ
   Zhuang, XM
   Yang, XL
   Shi, ZL
   Deng, F
   Hu, ZH
   Xiao, GF
   Wang, ML
   Zhong, W
AF Zhang, Leike
   Liu, Jia
   Cao, Ruiyuan
   Xu, Mingyue
   Wu, Yan
   Shang, Weijuan
   Wang, Xi
   Zhang, Huanyu
   Jiang, Xiaming
   Sun, Yuan
   Hu, Hengrui
   Li, Yufeng
   Zou, Gang
   Zhang, Min
   Zhao, Lei
   Li, Wei
   Guo, Xiaojia
   Zhuang, Xiaomei
   Yang, Xing-Lou
   Shi, Zheng-Li
   Deng, Fei
   Hu, Zhihong
   Xiao, Gengfu
   Wang, Manli
   Zhong, Wu
TI Comparative Antiviral Efficacy of Viral Protease Inhibitors against the
   Novel SARS-CoV-2In Vitro
SO VIROLOGICA SINICA
LA English
DT Article; Early Access
DE Respiratory pharmacology; COVID-19; SARS-CoV-2; Protease inhibitor
ID CORONAVIRUS; LOPINAVIR/RITONAVIR; MANAGEMENT; BINDING; DESIGN
AB The recent outbreak of novel coronavirus pneumonia (COVID-19) caused by a new coronavirus has posed a great threat to public health. Identifying safe and effective antivirals is of urgent demand to cure the huge number of patients. Virus-encoded proteases are considered potential drug targets. The human immunodeficiency virus protease inhibitors (lopinavir/ritonavir) has been recommended in the global Solidarity Trial in March launched by World Health Organization. However, there is currently no experimental evidence to support or against its clinical use. We evaluated the antiviral efficacy of lopinavir/ritonavir along with other two viral protease inhibitorsin vitro, and discussed the possible inhibitory mechanismin silico. Thein vitrotoin vivoextrapolation was carried out to assess whether lopinavir/ritonavir could be effective in clinical. Among the four tested compounds, lopinavir showed the best inhibitory effect against the novel coronavirus infection. However, furtherin vitrotoin vivoextrapolation of pharmacokinetics suggested that lopinavir/ritonavir could not reach effective concentration under standard dosing regimen [marketed as Kaletra(R), contained lopinavir/ritonavir (200 mg/50 mg) tablets, recommended dosage is 400 mg/10 mg (2 tablets) twice daily]. This research concluded that lopinavir/ritonavir should be stopped for clinical use due to the huge gap betweenin vitroIC(50)and free plasma concentration. Nevertheless, the structure-activity relationship analysis of the four inhibitors provided further information forde noveldesign of future viral protease inhibitors of SARS-CoV-2.
C1 [Zhang, Leike; Liu, Jia; Xu, Mingyue; Wu, Yan; Shang, Weijuan; Wang, Xi; Zhang, Huanyu; Jiang, Xiaming; Sun, Yuan; Hu, Hengrui; Li, Yufeng; Yang, Xing-Lou; Shi, Zheng-Li; Deng, Fei; Hu, Zhihong; Xiao, Gengfu; Wang, Manli] Chinese Acad Sci, State Key Lab Virol, Wuhan Inst Virol, Ctr Biosafety Mega Sci, Wuhan 430071, Peoples R China.
   [Cao, Ruiyuan; Zhang, Min; Zhao, Lei; Li, Wei; Guo, Xiaojia; Zhuang, Xiaomei; Zhong, Wu] Beijing Inst Pharmacol & Toxicol, Natl Engn Res Ctr Emergency Drug, Beijing 100850, Peoples R China.
   [Zou, Gang] Chinese Acad Sci, Inst Pasteur Shanghai, CAS Key Lab Mol Virol & Immunol, Shanghai 200031, Peoples R China.
RP Xiao, GF; Wang, ML (corresponding author), Chinese Acad Sci, State Key Lab Virol, Wuhan Inst Virol, Ctr Biosafety Mega Sci, Wuhan 430071, Peoples R China.; Zhong, W (corresponding author), Beijing Inst Pharmacol & Toxicol, Natl Engn Res Ctr Emergency Drug, Beijing 100850, Peoples R China.
EM xiaogf@wh.iov.cn; wangml@wh.iov.cn; zhongwu@bmi.ac.cn
OI Reis, AlessanRSS/0000-0001-8486-7469; , Yuan/0000-0001-8244-7436
FU National Science and Technology Major Projects [2018ZX09711003];
   National Key Research and Development Project [2020YFC0841700]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [31621061]; Hubei Science and Technology Project
   [2020FCA003]
FX We thank Hao Tang, Jia Wu, Jun Liu and Tao Du from BSL-3 Laboratory of
   Wuhan Institute of Virology for their critical support. This work was
   supported in part by grants from the National Science and Technology
   Major Projects (Grant Number 2018ZX09711003), National Key Research and
   Development Project (2020YFC0841700), the National Natural Science
   Foundation of China (Grant Number 31621061), and the Hubei Science and
   Technology Project (Grant Number 2020FCA003).
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Croxtall JD, 2010, DRUGS, V70, P1885, DOI 10.2165/11204950-000000000-00000
   Cvetkovic RS, 2003, DRUGS, V63, P769, DOI 10.2165/00003495-200363080-00004
   Dragovich PS, 1999, J MED CHEM, V42, P1213, DOI 10.1021/jm9805384
   Gulati A, 2009, DRUG METAB DISPOS, V37, P1572, DOI 10.1124/dmd.109.026708
   Kuo CJ, 2009, FEBS LETT, V583, P549, DOI 10.1016/j.febslet.2008.12.059
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Murphy RL, 2001, AIDS, V15, pF1, DOI 10.1097/00002030-200101050-00002
   Patick AK, 2005, ANTIMICROB AGENTS CH, V49, P2267, DOI 10.1128/AAC.49.6.2267-2275.2005
   Smith DA, 2010, NAT REV DRUG DISCOV, V9, P929, DOI 10.1038/nrd3287
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 16
TC 1
Z9 1
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1674-0769
EI 1995-820X
J9 VIROL SIN
JI Virol. Sin.
DI 10.1007/s12250-020-00288-1
EA SEP 2020
PG 9
WC Virology
SC Virology
GA NM6UT
UT WOS:000568231600001
PM 32910347
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU de la Cruz-Benito, B
   Lazaro-del Campo, P
   Ramirez-Lopez, A
   de Soto-Alvarez, T
   Sanchez-Vadillo, I
   Garcia-Perez, E
   Dos Santos-Ortas, A
   Humala-Barbier, K
   Lopez-de la Guia, A
   Casado-Abad, G
   Jimenez-Yuste, V
   Canales-Albendea, M
AF de la Cruz-Benito, Beatriz
   Lazaro-del Campo, Paula
   Ramirez-Lopez, Andres
   de Soto-Alvarez, Teresa
   Sanchez-Vadillo, Irene
   Garcia-Perez, Eduardo
   Dos Santos-Ortas, Abel
   Humala-Barbier, Karem
   Lopez-de la Guia, Ana
   Casado-Abad, Gema
   Jimenez-Yuste, Victor
   Canales-Albendea, Miguel
TI Managing the front-line treatment for diffuse large B cell lymphoma and
   high-grade B cell lymphoma during the COVID-19 outbreak
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE B cell lymphoma; COVID-19; high-grade; haematological malignancies;
   SARS-CoV-2
AB The COVID-19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment who represent a vulnerable population for SARS-CoV-2 infection. Aggressive lymphoid neoplasms, such as diffuse large B cell lymphoma and high-grade B cell lymphoma, need to be treated without delay in order to get the best disease outcome. Because of that, our clinical practice was changed to minimise the risk of SARS-CoV-2 infection while continuing haematological treatment. In this report, we analyse the management of front-line therapy in 18 patients during the COVID-19 outbreak, as well as the results of the implemented measures in their outcome.
C1 [de la Cruz-Benito, Beatriz; Lazaro-del Campo, Paula; Ramirez-Lopez, Andres; de Soto-Alvarez, Teresa; Sanchez-Vadillo, Irene; Garcia-Perez, Eduardo; Dos Santos-Ortas, Abel; Humala-Barbier, Karem; Lopez-de la Guia, Ana; Jimenez-Yuste, Victor; Canales-Albendea, Miguel] La Paz Univ Hosp, Haematol Dept, Madrid, Spain.
   [Casado-Abad, Gema] La Paz Univ Hosp, Pharm Dept, Madrid, Spain.
RP de la Cruz-benito, B (corresponding author), Hosp Univ La Paz, Hematol Dept, Paseo Castellana 261, Madrid 28046, Spain.
EM beatriz.delacruz@salud.madrid.org
OI Canales Albendea, Miguel Angel/0000-0002-6550-2621; Lazaro del Campo,
   Paula/0000-0001-9089-4789; de la Cruz-Benito,
   Beatriz/0000-0002-3223-0121
CR Di Ciaccio P, 2020, INTERN MED J, V50, P667, DOI 10.1111/imj.14859
   Perini GF, 2020, HEMATOL TRANSF CELL, V42, P103, DOI 10.1016/j.htct.2020.04.002
   Robilotti EV, 2020, NAT MED, V26, P1218, DOI 10.1038/s41591-020-0979-0
   Shah V, 2020, BRIT J HAEMATOL, V190, pE279, DOI 10.1111/bjh.16935
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Weinkove R, 2020, MED J AUSTRALIA, V212, P481, DOI 10.5694/mja2.50607
   Willan J, 2020, BRIT J HAEMATOL, V189, pE224, DOI 10.1111/bjh.16782
   Willan J, 2020, BRIT J HAEMATOL, V189, P241, DOI 10.1111/bjh.16620
NR 9
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
EI 1365-2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD NOV
PY 2020
VL 191
IS 3
BP 386
EP 389
DI 10.1111/bjh.17066
EA SEP 2020
PG 4
WC Hematology
SC Hematology
GA PF3LO
UT WOS:000567697700001
PM 32762043
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Tatlow, D
   Tatlow, C
   Tatlow, S
   Tatlow, S
AF Tatlow, Dean
   Tatlow, Corinne
   Tatlow, Scarlet
   Tatlow, Savanah
TI A novel concept for treatment and vaccination against Covid-19 with an
   inhaled chitosan-coated DNA vaccine encoding a secreted spike protein
   portion
SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
LA English
DT Article
DE ACE2; coronavirus; Covid-19; plasmid DNA; spike proteins; treatment;
   vaccine
ID IMMUNOGENICITY; NANOPARTICLES; PROTECTION
AB A novel concept in DNA vaccine design is the creation of an inhaled DNA plasmid construct containing a portion of the coronavirus spike protein for treatment and vaccination. The secretion of a spike protein portion will function as a competitive antagonist by interfering with the binding of coronavirus to the angiotensin-converting enzyme 2 (ACE2) receptor. The secreted protein binding to the ACE2 receptor provides a unique mechanism of action for treatment to all strains of coronavirus in naive patients, by blocking the ACE2 receptor site. An inhaled plasmid DNA vaccine replicates the route of lung infection taken by coronavirus with transfected cells secreting spike protein portions to induce immunity. Unlike most DNA vaccines with intracellular antigen presentation through MHC I, the current vaccine relies on the secreted proteins presentation through MHC II as well as MHC I to induce immunity. Lung specific production of vaccine particles by inhaled plasmid DNA is appealing since it may have limited systemic side effects, and may induce both humoral and cytotoxic immunity. Finally, the ease and ability to rapidly produce this plasmid construct makes this an ideal solution for managing the emerging threat of coronavirus.
C1 [Tatlow, Dean] 60 Woodbrook Close SW, Calgary, AB T2W 4E9, Canada.
RP Tatlow, D (corresponding author), 60 Woodbrook Close SW, Calgary, AB T2W 4E9, Canada.
EM dtatlow16@gmail.com
OI , Dean/0000-0001-5871-4573
CR Cheng MA, 2018, HUM GENE THER, V29, P971, DOI 10.1089/hum.2017.197
   Diamond MS, 2019, ANNU REV MED, V70, P121, DOI 10.1146/annurev-med-040717-051127
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gaudinski MR, 2018, LANCET, V391, P552, DOI 10.1016/S0140-6736(17)33105-7
   Grodeland G, 2013, J IMMUNOL, V191, P3221, DOI 10.4049/jimmunol.1300504
   Hellfritzsch M, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080375
   Huang T, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0337-2
   Kimura S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01323
   Kodama Y, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12060540
   Liu MA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020037
   Neuman BW, 2008, J VIROL, V82, P5279, DOI 10.1128/JVI.02631-07
   Raghuwanshi D, 2012, MOL PHARMACEUT, V9, P946, DOI 10.1021/mp200553x
   Reuten R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152386
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302
   Weaver EA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040144
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Xu Yingying, 2014, Pharmaceutics, V6, P378, DOI 10.3390/pharmaceutics6030378
   Yang ZY, 2005, P NATL ACAD SCI USA, V102, P797, DOI 10.1073/pnas.0409065102
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
NR 20
TC 1
Z9 1
U1 7
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0305-1870
EI 1440-1681
J9 CLIN EXP PHARMACOL P
JI Clin. Exp. Pharmacol. Physiol.
PD NOV
PY 2020
VL 47
IS 11
BP 1874
EP 1878
DI 10.1111/1440-1681.13393
EA SEP 2020
PG 5
WC Pharmacology & Pharmacy; Physiology
SC Pharmacology & Pharmacy; Physiology
GA OM4AC
UT WOS:000567698400001
PM 32881059
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU de Snyder, VNS
   Garcia, D
   Pineda, R
   Calderon, J
   Diaz, D
   Morales, A
   Perez, B
AF Snyder, V. Nelly Salgado de
   Garcia, Deliana
   Pineda, Roxana
   Calderon, Jessica
   Diaz, Dania
   Morales, Alondra
   Perez, Brenda
TI Exploring Why Adult Mexican Males Do Not Get Vaccinated: Implications
   for COVID-19 Preventive Actions
SO HISPANIC JOURNAL OF BEHAVIORAL SCIENCES
LA English
DT Article
DE vaccines; males; Mexican; preventive medicine; COVID-19
ID HEALTH-CARE; INFLUENZA
AB Vaccination is the single most important preventive medicine action worldwide. However, there are inequalities in the procurement of vaccines particularly among US ethnic and racial minority males when compared to the rest of the US population. This study explored the reasons given by adult Mexican-origin males residing in Texas, for obtaining or not, immunizations. This was a cross-sectional, exploratory study with a sample of convenience of 401 adult males (age range 18-79) who were invited to participate in the study while waiting their turn to receive administrative services at the Mexican Consulate in Austin Texas. Data was collected in Spanish with a seven-item multiple choice questionnaire, using electronic tablets. The majority of respondents received their last vaccination longer than 5 years earlier. A higher percentage of individuals in the older age groups received a vaccine in the last year, as opposed to their younger counterparts who obtained their last immunization 3 to 5 years earlier. Among the reasons given for not getting vaccinated were lack of time or money, feared injections and side effects, insufficient information, interest or motivation. Others did not get vaccines because they perceived themselves to be healthy and did not feel sick. Findings from this study have important implications for future preventive medicine and vaccination practices that reach socially excluded groups in times of COVID-19. Recommendations are made to facilitate access to vaccines to the target group of this study and other socially disadvantaged populations in the global health context.
C1 [Snyder, V. Nelly Salgado de] Inst Nacl Salud Publ Mexico, Global Hlth Program, Cuernavaca, Morelos, Mexico.
   [Garcia, Deliana; Pineda, Roxana; Calderon, Jessica; Diaz, Dania; Morales, Alondra] Migrant Clinicians Network, Austin, TX USA.
   [Perez, Brenda] Austin Publ Hlth, Neighborhood Serv Unit, Austin, TX USA.
RP de Snyder, VNS (corresponding author), Inst Nacl Salud Publ Mexico, Ave Univ 655, Cuernavaca 62100, Mor, Mexico.
EM nelly.salgado@insp.mx
CR Aguayo-Mazzucato C, 2019, DIABETES-METAB RES, V35, DOI 10.1002/dmrr.3097
   Baker P, 2020, LANCET, V395, P1886, DOI 10.1016/S0140-6736(20)31303-9
   Caballero AE, 2011, AM J MED, V124, pS10, DOI 10.1016/j.amjmed.2011.07.018
   Centers for Disease Control and Prevention, 2020, HLTH EQ CONS RAC ETH
   Damnjanovic K, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00735
   De Keijzer B., 2003, SALUD COMO DERECHO C
   de Snyder VNS, 2005, SALUD PUBLICA MEXICO, V47, P294, DOI 10.1590/s0036-36342005000400007
   Derose KP, 2007, HEALTH AFFAIR, V26, P1258, DOI 10.1377/hlthaff.26.5.1258
   DuBard CA, 2008, AM J PUBLIC HEALTH, V98, P2021, DOI 10.2105/AJPH.2007.119008
   Ejebe IH, 2015, PREV MED, V71, P57, DOI 10.1016/j.ypmed.2014.12.004
   Ferris DG, 2009, J AM BOARD FAM MED, V22, P34, DOI 10.3122/jabfm.2009.01.080008
   Hughes MM, 2018, AM J PUBLIC HEALTH, V108, P517, DOI 10.2105/AJPH.2017.304257
   Johnson DR, 2008, AM J MED, V121, pS28, DOI 10.1016/j.amjmed.2008.05.005
   Kaul I, 2001, B WORLD HEALTH ORGAN, V79, P869
   Gutierrez-Robledo LM, 2017, GAC MED MEX, V153, P5
   Moyce Sally C, 2017, Curr Environ Health Rep, V4, P349, DOI 10.1007/s40572-017-0152-1
   Orenstein WA, 2017, P NATL ACAD SCI USA, V114, P4031, DOI 10.1073/pnas.1704507114
   Cruz-Hervert LP, 2013, SALUD PUBLICA MEXICO, V55, pS300
   Rodriguez-Diaz Carlos E, 2020, Ann Epidemiol, V52, P46, DOI 10.1016/j.annepidem.2020.07.007
   Sobralske MC, 2006, J TRANSCULT NURS, V17, P129, DOI 10.1177/1043659606286767
   Staff writer, 2020, UN NEWS
   US Department of Health and Human Services Office of Minority Health, IMM HISSSSSP AM
   Wang LS, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105948
   Wexler D., 2009, MCN STREAMLINE MIGRA, V15, P5
   Williams WW, 2014, MMWR SURVEILL SUMM, V65, P1, DOI DOI 10.15585/MMWR.SS6501A1
NR 25
TC 0
Z9 0
U1 4
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0739-9863
EI 1552-6364
J9 HISPANIC J BEHAV SCI
JI Hisp. J. Behav. Sci.
PD NOV
PY 2020
VL 42
IS 4
BP 515
EP 527
AR 0739986320956913
DI 10.1177/0739986320956913
EA SEP 2020
PG 13
WC Psychology, Multidisciplinary
SC Psychology
GA NX6OF
UT WOS:000568325300001
OA Bronze
DA 2021-01-01
ER

PT J
AU Chen, P
   Zeng, ZH
   Du, HW
AF Chen, Peng
   Zeng, Zehua
   Du, Hongwu
TI Establishment and validation of a drug-target microarray for SARS-CoV-2
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE COVID-19; SARS-CoV-2; Drug target; Microarray
ID TRADITIONAL CHINESE MEDICINE; INFLAMMATION
AB COVID-19 has become one of the worst epidemic in the world, currently already more than four million people have been infected, which probably co-exist with human beings, and has a significant impact on the global economy and political order. In the process of fighting against the epidemic in China, the clinical value of a variety of herbal medicines has been recognized and written into the clinical application guide. However, their effective molecular mechanism and potential targets are still not clear. Pathology and pharmacology research will gradually attract attention in the post-epidemic outbreak term. Here, we constructed a COVID-19 protein microarray of potential therapy targets, which contains the main drug targets to the SARS-CoV-2 virus and the anti-virus, anti-inflammatory cellar targets of the host. Series of quality controls test has been carried out, which showed that it could be applied for drug target screening of bio-active natural products. The establishment of this microarray will provide a useful tool for the study of the molecular pharmacology of natural products. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Chen, Peng] China Acad Chinese Med Sci, Beijing Key Lab Tradit Chinese Med Basic Res Prev, Expt Res Ctr, Beijing, Peoples R China.
   [Zeng, Zehua; Du, Hongwu] Univ Sci & Technol Beijing, Sch Chem & Biol Engn, Beijing, Peoples R China.
RP Du, HW (corresponding author), Univ Sci & Technol Beijing, Sch Chem & Biol Engn, Beijing, Peoples R China.
EM hwdu93@126.com
OI Zehua, Zeng/0000-0002-2109-0418
FU Hebei Provincial Department of Science and Technology [19942410G];
   Fundamental Research Funds for the Central public welfare research
   institutes of China [ZZ13-YQ-082, ZZ2018007]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81903893]
FX This work was supported by Hebei Provincial Department of Science and
   Technology (No.19942410G), and grants from the Fundamental Research
   Funds for the Central public welfare research institutes of China
   (ZZ13-YQ-082; ZZ2018007), National Natural Science Foundation of China
   (81903893).
CR Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Cartwright T, 2016, FEBS J, V283, P1812, DOI 10.1111/febs.13627
   Du HZ, 2020, CHIN J NAT MEDICINES, V18, P206, DOI [10.3724/SP.J.1009.2019.000000, 10.1016/S1875-5364(20)30022-4]
   Fang YT, 2010, MOL IMMUNOL, V47, P1000, DOI 10.1016/j.molimm.2009.11.019
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Lei YL, 2019, CLIN SCI, V133, P789, DOI 10.1042/CS20180687
   Li RS, 2016, MED RES REV, V36, P3, DOI 10.1002/med.21380
   Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI [10.3724/SP.J.1009.2013.00110, 10.1016/S1875-5364(13)60037-0]
   Liang JH, 2015, PROTEIN PEPTIDE LETT, V22, P504, DOI 10.2174/0929866522666150428121442
   Liu XX, 2020, SCI CHINA LIFE SCI, V63, P1006, DOI 10.1007/s11427-020-1705-0
   Qu LH, 2019, MED SCI MONITOR, V25, P1828, DOI 10.12659/MSM.912867
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Ren Yue, 2020, Zhongguo Zhong Yao Za Zhi, V45, P1225, DOI 10.19540/j.cnki.cjcmm.20200224.405
   Tauler J, 2009, CURR OPIN PHARMACOL, V9, P384, DOI 10.1016/j.coph.2009.06.004
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tu Youyou, 2013, ANGEW CHEM INT EDIT, P10210
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Ulrich H, 2020, STEM CELL REV REP, V16, P434, DOI 10.1007/s12015-020-09976-7
   Wang CH, 2016, MOL BIOSYST, V12, P606, DOI 10.1039/c5mb00448a
   Weiss R, 2016, J AUTOIMMUN, V73, P92, DOI 10.1016/j.jaut.2016.06.011
   Wong C.K., 2018, BMC COMPLEM ALTERN M, V18, P2696, DOI [10.1186/s12906-018-2216-7, DOI 10.1186/S12906-018-2216-7]
   Wright MH, 2016, NAT PROD REP, V33, P681, DOI 10.1039/c6np00001k
   Xia YF, 2004, J IMMUNOL, V173, P4207, DOI 10.4049/jimmunol.173.6.4207
   Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538
   Zhang HN, 2015, P NATL ACAD SCI USA, V112, P15084, DOI 10.1073/pnas.1521316112
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhu H, 2003, CURR OPIN CHEM BIOL, V7, P55, DOI 10.1016/S1367-5931(02)00005-4
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 29
TC 1
Z9 1
U1 3
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 10
PY 2020
VL 530
IS 1
BP 4
EP 9
DI 10.1016/j.bbrc.2020.05.217
PG 6
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NI2KL
UT WOS:000565184300002
PM 32828312
OA Green Published
DA 2021-01-01
ER

PT J
AU Tomar, PPS
   Arkin, IT
AF Tomar, Prabhat Pratap Singh
   Arkin, Isaiah T.
TI SARS-CoV-2 E protein is a potential ion channel that can be inhibited by
   Gliclazide and Memantine
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE COVID-19; Bacterial assays; Anti-virals
ID RESPIRATORY SYNDROME CORONAVIRUS; INFECTIOUS-BRONCHITIS VIRUS; ENVELOPE
   PROTEIN; TRANSMEMBRANE DOMAIN; STRAIN A59; IMMUNIZATION; RESISTANCE;
   RELEASE; PORE; PH
AB COVID-19 is one of the most impactful pandemics in recorded history. As such, the identification of inhibitory drugs against its etiological agent, SARS-CoV-2, is of utmost importance, and in particular, repurposing may provide the fastest route to curb the disease. As the first step in this route, we sought to identify an attractive and viable target in the virus for pharmaceutical inhibition. Using three bacteria-based assays that were tested on known viroporins, we demonstrate that one of its essential components, the E protein, is a potential ion channel and, therefore, is an excellent drug target. Channel activity was demonstrated for E proteins in other coronaviruses, providing further emphasis on the importance of this functionally to the virus' pathogenicity. The results of a screening effort involving a repurposing drug library of ion channel blockers yielded two compounds that inhibit the E protein: Gliclazide and Memantine. In conclusion, as a route to curb viral virulence and abate COVID-19, we point to the E protein of SARS-CoV-2 as an attractive drug target and identify off-label compounds that inhibit it. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Tomar, Prabhat Pratap Singh; Arkin, Isaiah T.] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Edmond J Safra Campus Givat Ram, IL-91904 Jerusalem, Israel.
RP Arkin, IT (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Edmond J Safra Campus Givat Ram, IL-91904 Jerusalem, Israel.
EM arkin@huji.ac.il
OI Arkin, Isaiah/0000-0002-7659-1746
FU United states -Israel binational science foundationUS-Israel Binational
   Science Foundation [2013618]; Israel Science FoundationIsrael Science
   Foundation [948/19]; Israel minstry of science [66257]
FX United states -Israel binational science foundation grant number
   2013618. Israel Science Foundation grant number 948/19. Israel minstry
   of science 66257.
CR Assa D, 2016, J MOL BIOL, V428, P4209, DOI 10.1016/j.jmb.2016.08.007
   Astrahan P, 2011, BBA-BIOMEMBRANES, V1808, P394, DOI 10.1016/j.bbamem.2010.08.021
   Corse E, 2000, J VIROL, V74, P4319, DOI 10.1128/JVI.74.9.4319-4326.2000
   DeDiego ML, 2007, J VIROL, V81, P1701, DOI 10.1128/JVI.01467-06
   Fett C, 2013, J VIROL, V87, P6551, DOI 10.1128/JVI.00087-13
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Lamirande EW, 2008, J VIROL, V82, P7721, DOI 10.1128/JVI.00304-08
   Lim KP, 2001, J BIOL CHEM, V276, P17515, DOI 10.1074/jbc.M009731200
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Masters P.S., 2013, FIELDS VIROLOGY
   Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190
   Nal B, 2005, J GEN VIROL, V86, P1423, DOI 10.1099/vir.0.80671-0
   Netland J, 2010, VIROLOGY, V399, P120, DOI 10.1016/j.virol.2010.01.004
   Nguyen VP, 1997, J VIROL, V71, P9278, DOI 10.1128/JVI.71.12.9278-9284.1997
   Nieto-Torres JL, 2015, VIROLOGY, V485, P330, DOI 10.1016/j.virol.2015.08.010
   Nieto-Torres JL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004077
   Parthasarathy K, 2008, BIOPHYS J, V95, pL39, DOI 10.1529/biophysj.108.133041
   Pervushin K, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000511
   PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I
   Raamsman MJB, 2000, J VIROL, V74, P2333, DOI 10.1128/JVI.74.5.2333-2342.2000
   Regla-Nava JA, 2015, J VIROL, V89, P3870, DOI 10.1128/JVI.03566-14
   Ruch TR, 2011, J VIROL, V85, P675, DOI 10.1128/JVI.01570-10
   Sakaguchi T, 1996, J CELL BIOL, V133, P733, DOI 10.1083/jcb.133.4.733
   Santner P, 2018, BIOCHEMISTRY-US, V57, P5949, DOI 10.1021/acs.biochem.8b00721
   Santner P, 2018, BIOCHEMISTRY-US, V57, P5957, DOI 10.1021/acs.biochem.8b00722
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Stauffer S, 2014, J VIROL, V88, P13029, DOI 10.1128/JVI.01430-14
   Stumpe S, 1997, ARCH MICROBIOL, V167, P126, DOI 10.1007/s002030050425
   Surya W, 2015, VIRUS RES, V201, P61, DOI 10.1016/j.virusres.2015.02.023
   TAKEUCHI K, 1994, J VIROL, V68, P911, DOI 10.1128/JVI.68.2.911-919.1994
   Taube R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105387
   To J, 2017, J VIROL, V91, DOI 10.1128/JVI.02158-16
   Tomar PPS, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11070632
   TOOZE J, 1985, EUR J CELL BIOL, V37, P203
   Torres J, 2007, PROTEIN SCI, V16, P2065, DOI 10.1110/ps.062730007
   Torres J, 2006, BIOPHYS J, V91, P938, DOI 10.1529/biophysj.105.080119
   Verdia-Baguena C, 2012, VIROLOGY, V432, P485, DOI 10.1016/j.virol.2012.07.005
   Wilson L, 2004, VIROLOGY, V330, P322, DOI 10.1016/j.virol.2004.09.033
   Wilson L, 2006, VIROLOGY, V353, P294, DOI 10.1016/j.virol.2006.05.028
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
NR 40
TC 3
Z9 3
U1 13
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 10
PY 2020
VL 530
IS 1
BP 10
EP 14
DI 10.1016/j.bbrc.2020.05.206
PG 5
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NI2KL
UT WOS:000565184300003
PM 32828269
OA Green Published
DA 2021-01-01
ER

PT J
AU Muraca, M
   Pessina, A
   Pozzobon, M
   Dominici, M
   Galderisi, U
   Lazzari, L
   Parolini, O
   Lucarelli, E
   Perilongo, G
   Baraldi, E
AF Muraca, Maurizio
   Pessina, Augusto
   Pozzobon, Michela
   Dominici, Massimo
   Galderisi, Umberto
   Lazzari, Lorenza
   Parolini, Ornella
   Lucarelli, Enrico
   Perilongo, Giorgio
   Baraldi, Eugenio
TI Mesenchymal stromal cells and their secreted extracellular vesicles as
   therapeutic tools for COVID-19 pneumonia?
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
ID MSC-DERIVED EXOSOMES; ACUTE LUNG INJURY; STEM-CELLS; SARS CORONAVIRUS;
   IMMUNOMODULATION; TRANSPLANTATION; MICROVESICLES; INFLAMMATION;
   CLEARANCE; RECEPTOR
AB The COVID-19 epidemic represents an unprecedented global health emergency, further aggravated by the lack of effective therapies. For this reason, several clinical trials are testing different off-label drugs, already approved for other pathologies. Mesenchymal stem/stromal cells (MSCs) have been tested during the last two decades for the treatment of various pathologic conditions, including acute and chronic lung diseases, both in animal models and in patients. In particular, promising results have been obtained in the experimental therapy of acute respiratory distress syndrome, which represents the most threatening complication of COVID-19 infection. Furthermore, more recently, great interest has been devoted to the possible clinical applications of extracellular vesicles secreted by MSCs, nanoparticles that convey much of the biological effects and of the therapeutic efficacy of their cells of origin. This review summarizes the experimental evidence underlying the possible use of MSCs and of MSC-EVs in severe COVID-19 infection and underlines the need to evaluate the possible efficacy of these therapeutic approaches through controlled studies under the supervision of the Regulatory Authorities.
C1 [Muraca, Maurizio; Pozzobon, Michela; Perilongo, Giorgio; Baraldi, Eugenio] Univ Padua, Dept Womens & Childrens Hlth, Padua, Italy.
   [Pessina, Augusto] Univ Milan, Dept Biomed Surg & Dent Sci, CRC StaMeTec, Via Pascal 36, I-20133 Milan, Italy.
   [Dominici, Massimo] Univ Hosp Modena & Reggio Emilia, Lab Cellular Therapy, Modena, Italy.
   [Galderisi, Umberto] Luigi Vanvitelli Univ, Dept Expt Med, Naples, Italy.
   [Lazzari, Lorenza] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Trasfus Med & Hematol, Lab Regenerat Med Cell Factory, Milan, Italy.
   [Parolini, Ornella] Univ Cattolica Sacro Cuore, Dept Life Sci & Publ Hlth, Rome, Italy.
   [Parolini, Ornella] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy.
   [Lucarelli, Enrico] IRCCS Ist Ortoped Rizzoli, Osteoarticolar Regenerat Lab, Bologna, Italy.
RP Pessina, A (corresponding author), Univ Milan, Dept Biomed Surg & Dent Sci, CRC StaMeTec, Via Pascal 36, I-20133 Milan, Italy.
EM augusto.pessina@unimi.it
RI PAROLINI, ORNELLA/ABI-7862-2020; Lucarelli, Enrico/G-3588-2015
OI Lucarelli, Enrico/0000-0002-6681-6374
CR [Anonymous], 2019, CASE MED RES, DOI [10.31525/ct1-nct03857841, DOI 10.31525/CT1-NCT03857841]
   Armstrong JPK, 2017, ACS NANO, V11, P69, DOI 10.1021/acsnano.6b07607
   de Oliveira PWB, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00039
   Braun RK, 2018, BIOCHEM BIOPH RES CO, V503, P2653, DOI 10.1016/j.bbrc.2018.08.019
   Brown C, 2019, J TISSUE ENG REGEN M, V13, P1738, DOI 10.1002/term.2914
   Budoni M, 2013, CELL TRANSPLANT, V22, P369, DOI 10.3727/096368911X582769
   Cappariello A, 2018, J BONE MINER RES, V33, P517, DOI 10.1002/jbmr.3332
   Cargnoni A, 2009, CELL TRANSPLANT, V18, P405, DOI 10.3727/096368909788809857
   Chen CM, 2018, AM J TRANSL RES, V10, P2628
   de Girolamo L, 2013, CURR PHARM DESIGN, V19, P2459, DOI 10.2174/1381612811319130015
   Del Fattore A, 2015, CELL TRANSPLANT, V24, P2615, DOI 10.3727/096368915X687543
   Di Trapani M, 2016, SCI REP-UK, V6, DOI 10.1038/srep24120
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Doorn J, 2012, TISSUE ENG PART B-RE, V18, P101, DOI [10.1089/ten.teb.2011.0488, 10.1089/ten.TEB.2011.0488]
   El-Hashim AZ, 2012, BRIT J PHARMACOL, V166, P1964, DOI 10.1111/j.1476-5381.2012.01905.x
   FDA Center for Biologics Evaluation and Research, 2011, POT TESTS CELL GEN T
   Fierabracci A, 2015, CELL TRANSPLANT, V24, P133, DOI 10.3727/096368913X675728
   Galderisi U, 2014, MED RES REV, V34, P1100, DOI 10.1002/med.21322
   Gao F, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.327
   Gennai S, 2015, AM J TRANSPLANT, V15, P2404, DOI 10.1111/ajt.13271
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Glowacka I, 2010, J VIROL, V84, P1198, DOI 10.1128/JVI.01248-09
   Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826
   Gotts JE, 2011, CRIT CARE CLIN, V27, P719, DOI 10.1016/j.ccc.2011.04.004
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Herold S, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00065
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   ISSCR, 2020, ISSCR STAT REG MARK
   Jee Y, 2020, EPIDEMIOL HEALTH, V42, DOI 10.4178/epih.e2020013
   Khatri M, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-0774-8
   Kordelas L, 2014, LEUKEMIA, V28, P970, DOI 10.1038/leu.2014.41
   Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113
   Kowal J, 2014, CURR OPIN CELL BIOL, V29, P116, DOI 10.1016/j.ceb.2014.05.004
   Krasnodembskaya A, 2010, STEM CELLS, V28, P2229, DOI 10.1002/stem.544
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Laffey JG, 2017, AM J RESP CRIT CARE, V196, P266, DOI 10.1164/rccm.201701-0107CP
   Le Blanc K, 2007, J INTERN MED, V262, P509, DOI 10.1111/j.1365-2796.2007.01844.x
   Lee JH, 2019, TRANSFUSION, V59, P876, DOI 10.1111/trf.14838
   Lee JW, 2009, P NATL ACAD SCI USA, V106, P16357, DOI 10.1073/pnas.0907996106
   Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Li JW, 2014, INT WOUND J, V11, P114, DOI 10.1111/iwj.12202
   Liu L.L.F.-P., 2017, CHIN MED, V125
   Lloyd-Williams H, 2020, BRIT J CLIN PHARMACO, DOI 10.1111/bcp.14275
   Lv HJ, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.105
   Mansouri N, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128060
   Matthay MA, 2019, LANCET RESP MED, V7, P154, DOI 10.1016/S2213-2600(18)30418-1
   Matthay Michael A, 2015, Ann Am Thorac Soc, V12 Suppl 1, pS54, DOI 10.1513/AnnalsATS.201406-254MG
   Matthay MA, 2010, CRIT CARE MED, V38, pS569, DOI 10.1097/CCM.0b013e3181f1ff1d
   McIntyre LA, 2018, AM J RESP CRIT CARE, V197, P337, DOI 10.1164/rccm.201705-1006OC
   Mei SHJ, 2010, AM J RESP CRIT CARE, V182, P1047, DOI 10.1164/rccm.201001-0010OC
   Monsel A, 2015, AM J RESP CRIT CARE, V192, P324, DOI 10.1164/rccm.201410-1765OC
   Morse MA, 2005, J TRANSL MED, V3
   Muraca M, 2018, AM J RESP CRIT CARE, V197, P969, DOI 10.1164/rccm.201709-1851LE
   Muraca M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051021
   Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905
   Nicholls J, 2005, NAT MED, V11, P821, DOI 10.1038/nm0805-821
   Norgren L, 2019, EUR J VASC ENDOVASC, V57, P538, DOI 10.1016/j.ejvs.2018.11.008
   Park J, 2019, THORAX, V74, P43, DOI 10.1136/thoraxjnl-2018-211576
   Park JS, 2011, BIOMATERIALS, V32, P8139, DOI 10.1016/j.biomaterials.2011.07.043
   Pascucci L, 2014, J CONTROL RELEASE, V192, P262, DOI 10.1016/j.jconrel.2014.07.042
   Patel DB, 2018, BIOTECHNOL ADV, V36, P2051, DOI 10.1016/j.biotechadv.2018.09.001
   Phinney DG, 2017, STEM CELLS, V35, P851, DOI 10.1002/stem.2575
   Pittenger MF, 2019, NPJ REGEN MED, V4, DOI 10.1038/s41536-019-0083-6
   Porzionato A, 2019, AM J PHYSIOL-LUNG C, V316, pL6, DOI 10.1152/ajplung.00109.2018
   Ragni E, 2017, STEM CELLS, V35, P1093, DOI 10.1002/stem.2557
   Rahmati M., 2020, EURASIAN J MED ONCOL, V4, DOI [10.14744/ejmo.2020.72142., DOI 10.14744/EJMO.2020.72142, 10.14744/ejmo.2020.72142]
   Ringden O, 2011, BEST PRACT RES CL HA, V24, P65, DOI 10.1016/j.beha.2011.01.003
   SCMP Editorial, 2020, S CHINA MORNING POST
   Sengupta V, 2020, STEM CELLS DEV, V29, P747, DOI 10.1089/scd.2020.0080
   Shah TG, 2019, CLIN TRANSL MED, V8, DOI 10.1186/s40169-019-0242-9
   Sheng GH, 2020, CHEST, V157, P1175, DOI 10.1016/j.chest.2019.10.032
   Silachev DN, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030258
   Silini AR, 2017, CELL TRANSPLANT, V26, P531, DOI 10.3727/096368916X693699
   Simonson O.E., 2020, 5 YEAR FOLLOW MSC BA, P1, DOI [10.1164/rccm.202003-0544LE., DOI 10.1164/RCCM.202003-0544LE]
   Simonson OE, 2015, STEM CELL TRANSL MED, V4, P1199, DOI 10.5966/sctm.2015-0021
   STEMNET Scientific Board, 2020, STEMNET POS US CELL
   Thery C., 2018, MINIMAL INFORM STUDI, P1
   Thompson Mary, 2020, EClinicalMedicine, V19, P100249, DOI 10.1016/j.eclinm.2019.100249
   Tkach M, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0479
   Tsiapalis D, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040991
   Tufan A, 2020, TURK J MED SCI, V50, P620, DOI 10.3906/sag-2004-168
   Vader P, 2016, ADV DRUG DELIVER REV, V106, P148, DOI 10.1016/j.addr.2016.02.006
   van der Meel R, 2014, J CONTROL RELEASE, V195, P72, DOI 10.1016/j.jconrel.2014.07.049
   Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017
   Wang B, 2016, MOL THER, V24, P1290, DOI 10.1038/mt.2016.90
   Wecht S, 2016, RESPIROLOGY, V21, P1366, DOI 10.1111/resp.12911
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wiklander OPB, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav8521
   Willis GR, 2018, AM J RESP CRIT CARE, V197, P104, DOI 10.1164/rccm.201705-0925OC
   Winkler T, 2018, J CACHEXIA SARCOPENI, V9, P880, DOI 10.1002/jcsm.12316
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zemans RL, 2017, THORAX, V72, P1, DOI 10.1136/thoraxjnl-2016-209170
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang PX, 2020, BONE RES, V8, DOI 10.1038/s41413-020-0084-5
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 97
TC 3
Z9 3
U1 15
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD SEP 10
PY 2020
VL 325
BP 135
EP 140
DI 10.1016/j.jconrel.2020.06.036
PG 6
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
SC Chemistry; Pharmacology & Pharmacy
GA ND7VY
UT WOS:000562112400003
PM 32622963
OA Green Published
DA 2021-01-01
ER

PT J
AU Chaudhary, S
   Natt, B
   Bime, C
   Knox, KS
   Glassberg, MK
AF Chaudhary, Sachin
   Natt, Bhupinder
   Bime, Christian
   Knox, Kenneth S.
   Glassberg, Marilyn K.
TI Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE antifibrotics; COVID; 19; ARDS; fibrosis; SARS; CoV-2; SARS; MERS
   (Middle East respiratory syndrome)
ID RESPIRATORY-DISTRESS-SYNDROME; QUALITY-OF-LIFE; PULMONARY-FUNCTION;
   EXERCISE CAPACITY; FIBROSIS; VENTILATION; IMPACT; INJURY; COHORT
AB After decades of research, two therapies for chronic fibrotic lung disease are now approved by the FDA, with dozens more anti-fibrotic therapies in the pipeline. A great deal of enthusiasm has been generated for the use of these drugs, which are by no means curative but clearly have a favorable impact on lung function decline over time. Amidst a flurry of newly developed and repurposed drugs to treat the coronavirus disease 2019 (COVID-19) and its accompanying acute respiratory distress syndrome (ARDS), few have emerged as effective. Historically, survivors of severe viral pneumonia and related acute lung injury with ARDS often have near full recovery of lung function. While the pathological findings of the lungs of patients with COVID-19 can be diverse, current reports have shown significant lung fibrosis predominantly in autopsy studies. There is growing enthusiasm to study anti-fibrotic therapy for inevitable lung fibrosis, and clinical trials are underway using currently FDA-approved anti-fibrotic therapies. Given the relatively favorable outcomes of survivors of virus-mediated ARDS and the low prevalence of clinically meaningful lung fibrosis in survivors, this perspective examines if there is a rationale for testing these repurposed antifibrotic agents in COVID-19-associated lung disease.
C1 [Chaudhary, Sachin; Natt, Bhupinder; Bime, Christian; Knox, Kenneth S.] Univ Arizona, Coll Med, Interstitial Lung Dis Program, Tucson, AZ 85721 USA.
   [Knox, Kenneth S.; Glassberg, Marilyn K.] Banner Univ, Med Div, Phoenix, AZ USA.
RP Chaudhary, S (corresponding author), Univ Arizona, Coll Med, Interstitial Lung Dis Program, Tucson, AZ 85721 USA.
EM sachin@deptofmed.arizona.edu
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Alsaad KO, 2018, HISTOPATHOLOGY, V72, P516, DOI 10.1111/his.13379
   Arish N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122996
   Batawi S, 2019, HEALTH QUAL LIFE OUT, V17, DOI 10.1186/s12955-019-1165-2
   Bein T, 2018, CURR OPIN CRIT CARE, V24, P35, DOI 10.1097/MCC.0000000000000476
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801
   Cabrera-Benitez NE, 2014, ANESTHESIOLOGY, V121, P189, DOI 10.1097/ALN.0000000000000264
   Carsana L, 2020, LANCET INFECT DIS, V20, P1135, DOI 10.1016/S1473-3099(20)30434-5
   Caulfield Timothy, 2020, Nature, DOI 10.1038/d41586-020-01266-z
   Chang YC, 2005, RADIOLOGY, V236, P1067, DOI 10.1148/radiol.2363040958
   Chen JJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17497-6
   Copin MC, 2020, INTENS CARE MED, V46, P1124, DOI 10.1007/s00134-020-06057-8
   Courtwright AM, 2019, ANN AM THORAC SOC, V16, P175, DOI 10.1513/AnnalsATS.201808-508CME
   Das Karuna M, 2017, Indian J Radiol Imaging, V27, P342, DOI 10.4103/ijri.IJRI_469_16
   Forel JM, 2015, INTENS CARE MED, V41, P1, DOI 10.1007/s00134-014-3524-0
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   George PM, 2020, LANCET RESP MED, V8, P807, DOI 10.1016/S2213-2600(20)30225-3
   Gu J, 2007, AM J PATHOL, V170, P1136, DOI 10.2353/ajpath.2007.061088
   Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2005, CHEST, V128, P2247, DOI 10.1378/chest.128.4.2247
   Lederer DJ, 2018, NEW ENGL J MED, V378, P1811, DOI 10.1056/NEJMra1705751
   Liu TJ, 2013, AM J RESP CELL MOL, V49, P260, DOI 10.1165/rcmb.2012-0514OC
   Luks AM, 2020, ANN AM THORAC SOC, V17, P918, DOI 10.1513/AnnalsATS.202004-327CME
   Luyt CE, 2012, CHEST, V142, P583, DOI 10.1378/chest.11-2196
   MARTIN C, 1995, CHEST, V107, P196, DOI 10.1378/chest.107.1.196
   Masclans JR, 2011, CHEST, V139, P1340, DOI 10.1378/chest.10-2438
   Mineo G, 2012, RADIOL MED, V117, P185, DOI 10.1007/s11547-011-0740-3
   Mo XN, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01217-2020
   Ngai JC, 2010, RESPIROLOGY, V15, P543, DOI 10.1111/j.1440-1843.2010.01720.x
   Pallett LJ, 2019, CLIN EXP IMMUNOL, V197, P143, DOI 10.1111/cei.13308
   Park WB, 2018, J KOREAN MED SCI, V33, DOI 10.3346/jkms.2018.33.e169
   Paton NI, 2011, LANCET INFECT DIS, V11, P677, DOI 10.1016/S1473-3099(11)70065-2
   Piantadosi CA, 2004, ANN INTERN MED, V141, P460, DOI 10.7326/0003-4819-141-6-200409210-00012
   Polak SB, 2020, MODERN PATHOL, V33, P2128, DOI 10.1038/s41379-020-0603-3
   Schaller T, 2020, JAMA-J AM MED ASSOC, V323, P2518, DOI 10.1001/jama.2020.8907
   Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707
   Solomon JJ, 2015, J INTENSIVE CARE MED, V30, P392, DOI 10.1177/0885066613516579
   Spagnolo P, 2020, LANCET RESP MED, V8, P750, DOI 10.1016/S2213-2600(20)30222-8
   Tashiro J, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00118
   Thille AW, 2013, LANCET RESP MED, V1, P395, DOI 10.1016/S2213-2600(13)70053-5
   Venkataraman T, 2017, ANTIVIR RES, V143, P142, DOI 10.1016/j.antiviral.2017.03.022
   Xie LX, 2005, CHEST, V127, P2119, DOI 10.1378/chest.127.6.2119
   Zhang PX, 2020, BONE RES, V8, DOI 10.1038/s41413-020-0084-5
NR 46
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD SEP 9
PY 2020
VL 7
AR 539
DI 10.3389/fmed.2020.00539
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA NY3FD
UT WOS:000576279000001
PM 33072773
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cagnin, A
   Di Lorenzo, R
   Marra, C
   Bonanni, L
   Cupidi, C
   Lagana, V
   Rubino, E
   Vacca, A
   Provero, P
   Isella, V
   Vanacore, N
   Agosta, F
   Appollonio, I
   Caffarra, P
   Pettenuzzo, I
   Sambati, R
   Quaranta, D
   Guglielmi, V
   Logroscino, G
   Filippi, M
   Tedeschi, G
   Ferrarese, C
   Rainero, I
   Bruni, AC
AF Cagnin, Annachiara
   Di Lorenzo, Raffaele
   Marra, Camillo
   Bonanni, Laura
   Cupidi, Chiara
   Lagana, Valentina
   Rubino, Elisa
   Vacca, Alessandro
   Provero, Paolo
   Isella, Valeria
   Vanacore, Nicola
   Agosta, Federica
   Appollonio, Ildebrando
   Caffarra, Paolo
   Pettenuzzo, Ilaria
   Sambati, Renato
   Quaranta, Davide
   Guglielmi, Valeria
   Logroscino, Giancarlo
   Filippi, Massimo
   Tedeschi, Gioacchino
   Ferrarese, Carlo
   Rainero, Innocenzo
   Bruni, Amalia C.
CA SINdem COVID 19 Study Grp
TI Behavioral and Psychological Effects of Coronavirus Disease-19
   Quarantine in Patients With Dementia
SO FRONTIERS IN PSYCHIATRY
LA English
DT Article
DE behavioral and psychological symptoms; behavioral symptoms;
   psychological symptoms; quarantine; dementia; caregiver; coronavirus
   disease; gender
ID DEPRESSIVE SYMPTOMS; CAREGIVER BURDEN; SARS
AB Background In March 2020, the World Health Organization declared a global pandemic due to the novel coronavirus SARS-CoV-2 and several governments planned a national quarantine in order to control the virus spread. Acute psychological effects of quarantine in frail elderly subjects with special needs, such as patients with dementia, have been poorly investigated. The aim of this study was to assess modifications of neuropsychiatric symptoms during quarantine in patients with dementia and their caregivers. Methods This is a sub-study of a multicenter nation-wide survey. A structured telephone interview was delivered to family caregivers of patients with diagnosis of Alzheimer disease (AD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), and vascular dementia (VD), followed regularly at 87 Italian memory clinics. Variations in behavioral and psychological symptoms (BPSD) were collected after 1 month since quarantine declaration and associations with disease type, severity, gender, and caregiver's stress burden were analyzed. Results A total of 4,913 caregivers participated in the survey. Increased BPSD was reported in 59.6% of patients as worsening of preexisting symptoms (51.9%) or as new onset (26%), and requested drug modifications in 27.6% of these cases. Irritability, apathy, agitation, and anxiety were the most frequently reported worsening symptoms and sleep disorder and irritability the most frequent new symptoms. Profile of BPSD varied according to dementia type, disease severity, and patients' gender. Anxiety and depression were associated with a diagnosis of AD (OR 1.35, CI: 1.12-1.62), mild to moderate disease severity and female gender. DLB was significantly associated with a higher risk of worsening hallucinations (OR 5.29, CI 3.66-7.64) and sleep disorder (OR 1.69, CI 1.25-2.29), FTD with wandering (OR 1.62, CI 1.12-2.35), and change of appetite (OR 1.52, CI 1.03-2.25). Stress-related symptoms were experienced by two-thirds of caregivers and were associated with increased patients' neuropsychiatric burden (p<0.0001). Conclusion Quarantine induces a rapid increase of BPSD in approximately 60% of patients and stress-related symptoms in two-thirds of caregivers. Health services need to plan a post-pandemic strategy in order to address these emerging needs.
C1 [Cagnin, Annachiara; Pettenuzzo, Ilaria] Univ Padua, Dept Neurosci DNS, Padua, Italy.
   [Di Lorenzo, Raffaele; Lagana, Valentina; Bruni, Amalia C.] ASP CZ, Reg Neurogenet Ctr, Dept Primary Care, Catanzaro, Italy.
   [Marra, Camillo; Quaranta, Davide; Guglielmi, Valeria] IRCCS Univ, Memory Clin, Fdn Policlin Gemelli, Cattolica Sacro Cuore, Rome, Italy.
   [Bonanni, Laura] Univ G dAnnunzio, Dept Neurosci Imaging & Clin Sci, Chieti, Italy.
   [Cupidi, Chiara] AUSL Ferrara, CDCD Osped Delta, Ferrara, Italy.
   [Rubino, Elisa] AOU Citta Salute & Sci Torino, Dept Neurosci & Mental Hlth, Turin, Italy.
   [Vacca, Alessandro; Rainero, Innocenzo] Univ Torino, Dept Neurosci, Aging Brain & Memory Clin, Turin, Italy.
   [Provero, Paolo] Univ Torino, Dept Mol Biotechnol & Hlth Sci, Turin, Italy.
   [Provero, Paolo] IRCCS San Raffaele Sci Inst, Ctr Om Sci, Milan, Italy.
   [Isella, Valeria; Appollonio, Ildebrando; Ferrarese, Carlo] Univ Milano Bicocca, Dept Med & Surg, Monza, Italy.
   [Isella, Valeria; Appollonio, Ildebrando; Ferrarese, Carlo] Univ Milano Bicocca, Milan Ctr Neurosci NeuroMi, Monza, Italy.
   [Vanacore, Nicola] Natl Inst Hlth, Rome, Italy.
   [Agosta, Federica; Filippi, Massimo] IRCCS San Raffaele Sci Inst, Div Neurosci, Milan, Italy.
   [Agosta, Federica; Filippi, Massimo] Univ Vita Salute San Raffaele, Milan, Italy.
   [Caffarra, Paolo] Univ Parma, Unit Neurosci, Parma, Italy.
   [Sambati, Renato; Logroscino, Giancarlo] Univ Bari, Ctr Neurodegenerat Dis & Aging Brain, Dept Clin Res Neurol, Bari, Italy.
   [Sambati, Renato; Logroscino, Giancarlo] Univ Aldo Moro Bari, Dept Basic Med Neurosci & Sense Organs, Bari, Italy.
   [Tedeschi, Gioacchino] Univ Campania Luigi Vanvitelli, Dept Med & Surg Sci, Naples, Italy.
RP Cagnin, A (corresponding author), Univ Padua, Dept Neurosci DNS, Padua, Italy.
EM annachiara.cagnin@unipd.it
RI Filippi, Massimo/K-1755-2018; Guglielmi, Valeria/ABC-2000-2020; Di Fede,
   Giuseppe/A-4471-2019; Agosta, Federica/J-9908-2016
OI Filippi, Massimo/0000-0002-5485-0479; Guglielmi,
   Valeria/0000-0002-1245-5227; Di Fede, Giuseppe/0000-0003-3537-6713;
   Agosta, Federica/0000-0003-3121-4979; Porcari, Desiree
   Estela/0000-0003-4338-1547; Cuffaro, Luca/0000-0002-6853-1284
CR Aguirre E, 2013, AGEING RES REV, V12, P253, DOI 10.1016/j.arr.2012.07.001
   Alzheimers Assoc, 2015, ALZHEIMERS DEMENT, V11, P332, DOI 10.1016/j.jalz.2015.02.003
   Armitage R, 2020, LANCET PUBLIC HEALTH, V5, pE256, DOI 10.1016/S2468-2667(20)30061-X
   Barbisch D, 2015, DISASTER MED PUBLIC, V9, P547, DOI 10.1017/dmp.2015.38
   Bianchetti A, 2020, J NUTR HEALTH AGING, V24, P560, DOI 10.1007/s12603-020-1389-1
   Bostanciklioglu Mehmet, 2020, Curr Neurovasc Res, V17, P342, DOI 10.2174/1567202617666200522220509
   Bressan V, 2020, HEALTH SOC CARE COMM, V28, P1942, DOI 10.1111/hsc.13048
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Brown EE, 2020, AM J GERIAT PSYCHIAT, V28, P712, DOI 10.1016/j.jagp.2020.04.010
   COHEN D, 1993, J AM GERIATR SOC, V41, P229, DOI 10.1111/j.1532-5415.1993.tb06697.x
   Colombo D, 2018, J WOMENS HEALTH, V27, P1368, DOI 10.1089/jwh.2017.6420
   Fofana NK, 2020, PSYCHIAT RES, V291, DOI 10.1016/j.psychres.2020.113230
   Forte G, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17114151
   Fratiglioni L, 2004, LANCET NEUROL, V3, P343, DOI 10.1016/S1474-4422(04)00767-7
   Gaugler JE, 2009, PSYCHOL AGING, V24, P385, DOI 10.1037/a0016052
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hawryluck L, 2004, EMERG INFECT DIS, V10, P1206, DOI 10.3201/eid1007.030703
   Ho CS, 2020, ANN ACAD MED SINGAPO, V49, P155
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Hsieh SW, 2020, AGING MENT HEALTH, V24, P1342, DOI 10.1080/13607863.2019.1590311
   Jia RX, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1175-2
   Kwok YT, 2011, ARCH GERONTOL GERIAT, V52, P60, DOI 10.1016/j.archger.2010.01.021
   Lara B, 2020, EUR J NEUROL, V27, P1744, DOI 10.1111/ene.14339
   LAZARUS LW, 1987, AM J PSYCHIAT, V144, P41
   Le Heron C, 2018, NEUROPSYCHOLOGIA, V118, P54, DOI 10.1016/j.neuropsychologia.2017.07.003
   Le Heron C, 2019, J NEUROL NEUROSUR PS, V90, P302, DOI 10.1136/jnnp-2018-318265
   Lee J, 2017, ASIAN J PSYCHIATR, V26, P124, DOI 10.1016/j.ajp.2017.01.027
   Leigh-Hunt N, 2017, PUBLIC HEALTH, V152, P157, DOI 10.1016/j.puhe.2017.07.035
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu J, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00459
   McKeith IG, 2017, NEUROLOGY, V89, P88, DOI 10.1212/WNL.0000000000004058
   Ngandu T, 2015, LANCET, V385, P2255, DOI 10.1016/S0140-6736(15)60461-5
   Nussbaumer-Streit B, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013574
   Ott BR, 1999, J GEND SPECIF MED, V2, P63
   Pinquart M, 2003, J GERONTOL B-PSYCHOL, V58, pP112, DOI 10.1093/geronb/58.2.P112
   Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339
   Qiu JY, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100213
   Rascovsky K, 2011, BRAIN, V134, P2456, DOI 10.1093/brain/awr179
   Resnick B, 2020, J WOMEN AGING, DOI 10.1080/08952841.2020.1735925
   Royall DR, 2020, INT J GERIATR PSYCH, V35, P1341, DOI 10.1002/gps.5371
   Santini ZI, 2020, LANCET PUBLIC HEALTH, V5, pE62, DOI 10.1016/S2468-2667(19)30230-0
   Serafini G, 2020, QJM-INT J MED, V113, P529, DOI 10.1093/qjmed/hcaa201
   Shahid Z, 2020, J AM GERIATR SOC, V68, P926, DOI 10.1111/jgs.16472
   Sheridan MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04381-8
   Sheridan MA, 2014, TRENDS COGN SCI, V18, P580, DOI 10.1016/j.tics.2014.09.001
   Song H, 2020, JAMA NEUROL, V77, P700, DOI 10.1001/jamaneurol.2020.0117
   Steinman MA, 2020, JAMA INTERN MED, V180, P819, DOI 10.1001/jamainternmed.2020.1661
   Thompson C, 2010, INT PSYCHOGERIATR, V22, P300, DOI 10.1017/S1041610209991220
   Vik-Mo AO, 2020, BRIT J PSYCHIAT, V216, P43, DOI 10.1192/bjp.2019.195
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang HL, 2020, LANCET, V395, P1190, DOI 10.1016/S0140-6736(20)30755-8
   Weintraub D, 2020, ANN CLIN TRANSL NEUR, V7, P449, DOI 10.1002/acn3.51022
   Wu LL, 2020, PSYCHOL TRAUMA-US, V12, pS3, DOI 10.1037/tra0000609
NR 53
TC 1
Z9 1
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD SEP 9
PY 2020
VL 11
AR 578015
DI 10.3389/fpsyt.2020.578015
PG 15
WC Psychiatry
SC Psychiatry
GA NV6PI
UT WOS:000574440500001
PM 33033486
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Majmundar, M
   Kansara, T
   Lenik, JM
   Park, H
   Ghosh, K
   Doshi, R
   Shah, P
   Kumar, A
   Amin, H
   Chaudhari, S
   Habtes, I
AF Majmundar, Monil
   Kansara, Tikal
   Lenik, Joanna Marta
   Park, Hansang
   Ghosh, Kuldeep
   Doshi, Rajkumar
   Shah, Palak
   Kumar, Ashish
   Amin, Hossam
   Chaudhari, Shobhana
   Habtes, Imnett
TI Efficacy of corticosteroids in non-intensive care unit patients with
   COVID-19 pneumonia from the New York Metropolitan region
SO PLOS ONE
LA English
DT Article
ID RESPIRATORY SYNDROME; THERAPY; GLUCOCORTICOIDS
AB Introduction
   The role of systemic corticosteroid as a therapeutic agent for patients with COVID-19 pneumonia is controversial.
   Objective
   The purpose of this study was to evaluate the effect of corticosteroids in non-intensive care unit (ICU) patients with COVID-19 pneumonia complicated by acute hypoxemic respiratory failure (AHRF).
   Methods
   This was a single-center retrospective cohort study, from 16(th) March, 2020 to 30(th) April, 2020; final follow-up on 10(th) May, 2020. 265 patients consecutively admitted to the non-ICU wards with laboratory-confirmed COVID-19 pneumonia were screened for inclusion. 205 patients who developed AHRF (SpO(2)/FiO(2)<= 440 or PaO2/FiO(2)<= 300) were only included in the final study. Direct admission to the Intensive care unit (ICU), patients developing composite primary outcome within 24 hours of admission, and patients who never became hypoxic during their stay in the hospital were excluded. Patients were divided into two cohorts based on corticosteroid. The primary outcome was a composite of ICU transfer, intubation, or in-hospital mortality. Secondary outcomes were ICU transfer, intubation, in-hospital mortality, discharge, length of stay, and daily trend of SpO(2)/FiO(2)(SF) ratio from the index date. Cox-proportional hazard regression was implemented to analyze the time to event outcomes.
   Result
   Among 205 patients, 60 (29.27%) were treated with corticosteroid. The mean age was similar to 57 years, and similar to 75% were men. Thirteen patients (22.41%) developed a primary composite outcome in the corticosteroid cohort vs. 54 (37.5%) patients in the non-corticosteroid cohort (P = 0.039). The adjusted hazard ratio (HR) for the development of the composite primary outcome was 0.15 (95% CI, 0.07-0.33; P <0.001). The adjusted hazard ratio for ICU transfer was 0.16 (95% CI, 0.07 to 0.34; P < 0.001), intubation was 0.31 (95% CI, 0.14 to 0.70; P- 0.005), death was 0.53 (95% CI, 0.22 to 1.31; P- 0.172), composite of death or intubation was 0.31 (95% CI, 0.15 to 0.66; P- 0.002) and discharge was 3.65 (95% CI, 2.20 to 6.06; P<0.001). The corticosteroid cohort had increasing SpO(2)/FiO(2) over time compared to the non-corticosteroid cohort who experience decreasing SpO(2)/FiO(2) over time.
   Conclusion
   Among non-ICU patients hospitalized with COVID-19 pneumonia complicated by AHRF, treatment with corticosteroid was associated with a significantly lower risk of the primary composite outcome of ICU transfer, intubation, or in-hospital death, composite of intubation or death and individual components of the primary outcome.
C1 [Majmundar, Monil; Kansara, Tikal; Lenik, Joanna Marta; Park, Hansang; Ghosh, Kuldeep; Shah, Palak; Chaudhari, Shobhana] New York Med Coll, Metropolitan Hosp, Dept Internal Med, New York, NY 10595 USA.
   [Doshi, Rajkumar] Univ Nevada, Reno Sch Med, Dept Internal Med, Reno, NV 89557 USA.
   [Kumar, Ashish] St Johns Med Coll Hosp, Dept Crit Care Med, Bengaluru, Karnataka, India.
   [Amin, Hossam; Habtes, Imnett] New York Med Coll, Metropolitan Hosp, Dept Internal Med, Div Pulm & Crit Care, New York, NY USA.
RP Majmundar, M (corresponding author), New York Med Coll, Metropolitan Hosp, Dept Internal Med, New York, NY 10595 USA.
EM monilmajmundar1804@gmail.com
RI Majmundar, Monil/AAA-3148-2020; Kumar, Ashish/X-5704-2018
OI Majmundar, Monil/0000-0002-5389-5878; Kumar, Ashish/0000-0003-4249-0055
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Auyeung TW, 2005, J INFECTION, V51, P98, DOI 10.1016/j.jinf.2004.09.008
   Cain DW, 2017, NAT REV IMMUNOL, V17, P233, DOI 10.1038/nri.2017.1
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Czock D, 2005, CLIN PHARMACOKINET, V44, P61, DOI 10.2165/00003088-200544010-00003
   Gangopadhyay KK, 2020, ROLE CORTICOSTEROIDS, DOI 10.1101/2020.04.17.20069773
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hui DS, 2018, AM J RESP CRIT CARE, V197, P700, DOI 10.1164/rccm.201712-2371ED
   Li H, 2017, INFLUENZA OTHER RESP, V11, P345, DOI 10.1111/irv.12456
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Siemieniuk RAC, 2015, ANN INTERN MED, V163, P519, DOI 10.7326/M15-0715
   Stern A, 2017, COCHRANE DB SYST REV, P1, DOI 10.1002/14651858.CD007720.pub3
   Thompson BT, 2003, CRIT CARE MED, V31, pS253, DOI 10.1097/01.CCM.0000057900.19201.55
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, GLOB SURV HUM INF CO
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhao J P, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P183, DOI 10.3760/cma.j.issn.1001-0939.2020.03.008
   Zhou Y, 2020, SCI REP-UK, V10, DOI [10.1038/s41598-020-59732-7, 10.1038/s41598-020-58796-9]
NR 23
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 9
PY 2020
VL 15
IS 9
AR e0238827
DI 10.1371/journal.pone.0238827
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NR4MY
UT WOS:000571539500014
PM 32903258
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Freij, BJ
   Gebara, BM
   Tariq, R
   Wang, AM
   Gibson, J
   El-Wiher, N
   Krasan, G
   Patek, PM
   Levasseur, KA
   Amin, M
   Fullmer, JM
AF Freij, Bishara J.
   Gebara, Bassam M.
   Tariq, Rabail
   Wang, Ay-Ming
   Gibson, John
   El-Wiher, Nidal
   Krasan, Graham
   Patek, Paul M.
   Levasseur, Kelly A.
   Amin, Mitual
   Fullmer, Joseph M.
TI Fatal central nervous system co-infection with SARS-CoV-2 and
   tuberculosis in a healthy child
SO BMC PEDIATRICS
LA English
DT Article
DE SARS-CoV-2; CNS tuberculosis; Meningoencephalitis; Pediatric infections;
   Case report
ID DIAGNOSIS
AB BackgroundCentral and peripheral nervous system symptoms and complications are being increasingly recognized among individuals with pandemic SARS-CoV-2 infections, but actual detection of the virus or its RNA in the central nervous system has rarely been sought or demonstrated. Severe or fatal illnesses are attributed to SARS-CoV-2, generally without attempting to evaluate for alternative causes or co-pathogens.Case presentationA five-year-old girl with fever and headache was diagnosed with acute SARS-CoV-2-associated meningoencephalitis based on the detection of its RNA on a nasopharyngeal swab, cerebrospinal fluid analysis, and magnetic resonance imaging findings. Serial serologic tests for SARS-CoV-2 IgG and IgA showed seroconversion, consistent with an acute infection. Mental status and brain imaging findings gradually worsened despite antiviral therapy and intravenous dexamethasone. Decompressive suboccipital craniectomy for brain herniation with cerebellar biopsy on day 30 of illness, shortly before death, revealed SARS-CoV-2 RNA in cerebellar tissue using the Centers for Disease Control and Prevention 2019-nCoV Real-Time Reverse Transcriptase-PCR Diagnostic Panel. On histopathology, necrotizing granulomas with numerous acid-fast bacilli were visualized, and Mycobacterium tuberculosis complex DNA was detected by PCR. Ventricular cerebrospinal fluid that day was negative for mycobacterial DNA. Tracheal aspirate samples for mycobacterial DNA and culture from days 22 and 27 of illness were negative by PCR but grew Mycobacterium tuberculosis after 8weeks, long after the child's passing. She had no known exposures to tuberculosis and no chest radiographic findings to suggest it. All 6 family members had normal chest radiographs and negative interferon-gamma release assay results. The source of her tuberculous infection was not identified, and further investigations by the local health department were not possible because of the State of Michigan-mandated lockdown for control of SARS-CoV-2 spread.ConclusionThe detection of SARS-CoV-2 RNA in cerebellar tissue and the demonstration of seroconversion in IgG and IgA assays was consistent with acute SARS-CoV-2 infection of the central nervous infection. However, the cause of death was brain herniation from her rapidly progressive central nervous system tuberculosis. SARS-CoV-2 may mask or worsen occult tuberculous infection with severe or fatal consequences.
C1 [Freij, Bishara J.; Gebara, Bassam M.; Tariq, Rabail; El-Wiher, Nidal; Krasan, Graham] Beaumont Hlth, Beaumont Childrens Hosp, 3601 West 13 Mile Rd, Royal Oak, MI 48073 USA.
   [Wang, Ay-Ming] Beaumont Hlth, Dept Neuroradiol, Royal Oak, MI USA.
   [Gibson, John; Amin, Mitual; Fullmer, Joseph M.] Beaumont Hlth, Dept Pathol, Royal Oak, MI USA.
   [Patek, Paul M.; Levasseur, Kelly A.] Beaumont Hlth, Dept Emergency Med, Royal Oak, MI USA.
RP Freij, BJ (corresponding author), Beaumont Hlth, Beaumont Childrens Hosp, 3601 West 13 Mile Rd, Royal Oak, MI 48073 USA.
EM Bishara.Freij@beaumont.org
OI Freij, Bishara/0000-0002-5870-4356
CR Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Bodro M, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000821
   Chiang SS, 2014, LANCET INFECT DIS, V14, P947, DOI 10.1016/S1473-3099(14)70852-7
   Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680
   Goussard P, 2020, PEDIATR PULM, V55, P2201, DOI 10.1002/ppul.24927
   He GQ, 2020, J MED VIROL, V92, P1802, DOI 10.1002/jmv.25943
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Kunchok A, 2019, CURR OPIN NEUROL, V32, P452, DOI 10.1097/WCO.0000000000000676
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Lin DC, 2020, SCI CHINA LIFE SCI, V63, P606, DOI 10.1007/s11427-020-1668-5
   Liu WY, 2020, NEW ENGL J MED, V382, P1370, DOI 10.1056/NEJMc2003717
   Mandal N, 2017, CRIT REV MICROBIOL, V43, P466, DOI [10.1080/1040841x.2016.1262813, 10.1080/1040841X.2016.1262813]
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Marais S, 2010, LANCET INFECT DIS, V10, P803, DOI 10.1016/S1473-3099(10)70138-9
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Paniz-Mondolfi A, 2020, J MED VIROL, V92, P699, DOI 10.1002/jmv.25915
   Panteleev AV, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00963
   Pathak S, 2010, INFECT IMMUN, V78, P4022, DOI 10.1128/IAI.00106-10
   Rawson Timothy M, 2020, Clin Infect Dis, V71, P2459, DOI 10.1093/cid/ciaa530
   Redford PS, 2014, J INFECT DIS, V209, P270, DOI 10.1093/infdis/jit424
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Scriba TJ, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.TBTB2-0016-2016
   Solomons RS, 2015, INT J TUBERC LUNG D, V19, P200, DOI 10.5588/ijtld.14.0634
   Stochino C, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01708-2020
   Tadolini M, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01398-2020
   Tham SM, 2020, EMERG INFECT DIS, V26, P2763, DOI 10.3201/eid2611.202752
   Trouillet-Assant S, 2020, J ALLERGY CLIN IMMUN, V146, P206, DOI 10.1016/j.jaci.2020.04.029
   Wei L., 2020, SSRN, DOI [10.2139/ssrn.3555695, DOI 10.2139/SSRN.3555695]
   Whittaker E, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00233
   Wu YS, 2020, BRAIN BEHAV IMMUN, V87, P18, DOI 10.1016/j.bbi.2020.03.031
   Yousaf Z, 2020, AM J PHYSIOL-ENDOC M, V318, pE882, DOI 10.1152/ajpendo.00178.2020
   Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P355, DOI 10.1097/INF.0000000000002660
NR 32
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2431
J9 BMC PEDIATR
JI BMC Pediatr.
PD SEP 9
PY 2020
VL 20
IS 1
AR 429
DI 10.1186/s12887-020-02308-1
PG 7
WC Pediatrics
SC Pediatrics
GA NR7YX
UT WOS:000571777500002
PM 32907595
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Atallah, B
   El Nekidy, W
   Mallah, SI
   Cherfan, A
   AbdelWareth, L
   Mallat, J
   Hamed, F
AF Atallah, Bassam
   El Nekidy, Wasim
   Mallah, Saad I.
   Cherfan, Antoine
   AbdelWareth, Laila
   Mallat, Jihad
   Hamed, Fadi
TI Thrombotic events following tocilizumab therapy in critically ill
   COVID-19 patients: a Facade for prognostic markers
SO THROMBOSIS JOURNAL
LA English
DT Article
DE COVID-19; Tocilizumab; Thrombosis; D-dimers; Prognostic markers
AB Background Hospitals in the Middle East Gulf region have experienced an influx of COVID-19 patients to their medical wards and intensive care units. The hypercoagulability of these patients has been widely reported on a global scale. However, many of the experimental treatments used to manage the various complications of COVID-19 have not been widely studied in this context. The effect of the current treatment protocols on patients' diagnostic and prognostic biomarkers may thus impact the validity of the algorithms adopted. Case presentation In this case series, we report four cases of venous thromboembolism and 1 case of arterial thrombotic event, in patients treated with standard or intensified prophylactic doses of unfractionated heparin or low molecular weight heparin at our institution. Tocilizumab has been utilized as an add-on therapy to the standard of care to treat patients with SARS-CoV-2 associated acute respiratory distress syndrome, in order to dampen the hyperinflammatory response. It is imperative to be aware that this drug may be masking the inflammatory markers (e.g. IL6, CRP, fibrinogen, and ferritin), without reducing the risk of thrombotic events in this population, creating instead a facade of an improved prognostic outcome. However, the D-dimer levels remained prognostically reliable in these cases, as they were not affected by the drug and continued to be at the highest level until event occurrence. Conclusions In the setting of tocilizumab therapy, traditional prognostic markers of worsening infection and inflammation, and thus potential risk of acute thrombosis, should be weighed carefully as they may not be reliable for prognosis and may create a facade of an improved prognostic outcome insteasd. Additionally, the fact that thrombotic events continued to be observed despite decrease in inflammatory markers and the proactive anticoagulative approach adopted, raises more questions about the coagulative mechanisms at play in COVID-19, and the appropriate management strategy.
C1 [Atallah, Bassam; El Nekidy, Wasim; Cherfan, Antoine] Cleveland Clin Abu Dhabi, Dept Pharm Serv, Abu Dhabi, U Arab Emirates.
   [Atallah, Bassam; El Nekidy, Wasim; Mallat, Jihad] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA.
   [Mallah, Saad I.] Royal Coll Surg Ireland Bahrain, Sch Med, Al Sayh, Bahrain.
   [AbdelWareth, Laila] Cleveland Clin Abu Dhabi, Dept Clin Pathol, Abu Dhabi, U Arab Emirates.
   [Mallat, Jihad; Hamed, Fadi] Cleveland Clin Abu Dhabi, Crit Care Inst, Abu Dhabi, U Arab Emirates.
   [Mallat, Jihad] Normandy Univ, UNICAEN ED 497, Caen, France.
RP Atallah, B (corresponding author), Cleveland Clin Abu Dhabi, Dept Pharm Serv, Abu Dhabi, U Arab Emirates.; Atallah, B (corresponding author), Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA.
EM Atallab@clevelandclinicabudhabi.ae
RI Mallah, Saad I./AAO-7502-2020
OI Mallah, Saad I./0000-0002-2234-1530
CR [Anonymous], 2019, ACT TOC PACK INS
   [Anonymous], 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2015432, DOI 10.1056/NEJMOA2015432]
   [Anonymous], 2020, WHO COR DIS COVID 19
   Atallah B, 2020, EUR HEART J-CARD PHA, V6, P260, DOI 10.1093/ehjcvp/pvaa036
   Bowles L, 2020, N ENGL J MED
   Chan KH, TOCILIZUMAB THROMBOE
   Devreese KM, 2020, J THROMB HAEMOST, P3
   Fogarty H, 2020, BR J HAEMATOL, P24
   Guaraldi G, 2020, LANCET RHEUMATOLOGY, P24
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Imamura H, 2018, MOD RHEUMATOL, V28, P976, DOI 10.1080/14397595.2018.1428041
   Isaacs JD, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4397
   Jin S, 2020, THROMB HAEMOST, P17
   Kotch C, 2019, EXPERT REV CLIN IMMU, V15, P813, DOI 10.1080/1744666X.2019.1629904
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Price CC, 2020, CHEST, P15
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Xiong M, 2019, BRIT J H
NR 18
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1477-9560
J9 THROMB J
JI Thromb. J.
PD SEP 9
PY 2020
VL 18
IS 1
AR 22
DI 10.1186/s12959-020-00236-9
PG 6
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA NR7ZC
UT WOS:000571778100001
PM 32922212
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Barco, S
   Bingisser, R
   Colucci, G
   Frenk, A
   Gerber, B
   Held, U
   Mach, F
   Mazzolai, L
   Righini, M
   Rosemann, T
   Sebastian, T
   Spescha, R
   Stortecky, S
   Windecker, S
   Kucher, N
AF Barco, Stefano
   Bingisser, Roland
   Colucci, Giuseppe
   Frenk, Andre
   Gerber, Bernhard
   Held, Ulrike
   Mach, Francois
   Mazzolai, Lucia
   Righini, Marc
   Rosemann, Thomas
   Sebastian, Tim
   Spescha, Rebecca
   Stortecky, Stefan
   Windecker, Stephan
   Kucher, Nils
TI Enoxaparin for primary thromboprophylaxis in ambulatory patients with
   coronavirus disease-2019 (the OVID study): a structured summary of a
   study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; enoxaparin;
   anticoagulation; elderly; venous thromboembolism; thrombosis; prevention
AB Objectives: The OVID study will demonstrate whether prophylactic-dose enoxaparin improves survival and reduces hospitalizations in symptomatic ambulatory patients aged 50 or older diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.
   Trial design: The OVID study is conducted as a multicentre open-label superiority randomised controlled trial.
   Participants: Inclusion Criteria
   1. Signed patient informed consent after being fully informed about the study's background.
   2. Patients aged 50 years or older with a positive test for SARS-CoV2 in the past 5 days and eligible for ambulatory treatment.
   3. Presence of respiratory symptoms (i.e. cough, sore throat, or shortness of breath) or body temperature >37.5 degrees C.
   4. Ability of the patient to travel to the study centre by private transportation, performed either by an accompanying person from the same household or by the patient themselves
   5. Ability to comply with standard hygiene requirements at the time of in-hospital visit, including a face mask and hand disinfectant.
   6. Ability to walk from car to study centre or reach it by wheelchair transport with the help of an accompanying person from the same household also complying with standard hygiene requirements.
   7. Ability to self-administer prefilled enoxaparin injections after instructions received at the study centre or availability of a person living with the patient to administer enoxaparin.
   Exclusion Criteria
   1. Any acute or chronic condition posing an indication for anticoagulant treatment, e.g. atrial fibrillation, prior venous thromboembolism (VTE), acute confirmed symptomatic VTE, acute coronary syndrome.
   2. Anticoagulant thromboprophylaxis deemed necessary in view of the patient's history, comorbidity or predisposing strong risk factors for thrombosis:
   a. Any of the following events occurring in the prior 30 days: fracture of lower limb, hospitalization for heart failure, hip/knee replacement, major trauma, spinal cord injury, stroke,
   b. previous VTE,
   c. histologically confirmed malignancy, which was diagnosed or treated (surgery, chemotherapy, radiotherapy) in the past 6 months, or recurrent, or metastatic, or inoperable.
   3. Any clinically relevant bleeding (defined as bleeding requiring hospitalization, transfusion, surgical intervention, invasive procedures, occurring in a critical anatomical site, or causing disability) within 30 days prior to randomization or sign of acute bleeding.
   4. Intracerebral bleeding at any time in the past or signs/symptoms consistent with acute intracranial haemorrhage.
   5. Haemoglobin <8 g/dL and platelet count <50 x 10(9)cells/L confirmed by recent laboratory test (<90 days).
   6. Subjects with any known coagulopathy or bleeding diathesis, including known significant liver disease associated with coagulopathy.
   7. Severe renal insufficiency (baseline creatinine clearance <30 mL/min calculated using the Cockcroft-Gault formula) confirmed by recent laboratory test (<90 days).
   8. Contraindications to enoxaparin therapy, including prior heparin-induced thrombocytopenia and known hypersensitivity.
   9. Current use of dual antiplatelet therapy.
   10. Participation in other interventional studies over the past 30 days.
   11. Non-compliance or inability to adhere to treatment or lack of a family environment or support system for home treatment.
   12. Cognitive impairment and/or inability to understand information provided in the study information.
   Patient enrolment will take place at seven Swiss centres, including five university hospitals and two large cantonal hospitals.
   Intervention and comparator
   Patients randomized to the intervention group will receive subcutaneous enoxaparin at the recommended dose of 4,000 IU anti-Xa activity (40 mg/0.4 ml) once daily for 14 days. Patients randomized to the comparator group will receive no anticoagulation.
   Main outcomes Primary outcome: a composite of any hospitalization or all-cause death occurring within 30 days of randomization.
   Secondary outcomes: (i) a composite of cardiovascular events, including deep vein thrombosis (including catheter-associated), pulmonary embolism, myocardial infarction/myocarditis, arterial ischemia including mesenteric and extremities, acute splanchnic vein thrombosis, or ischemic stroke within 14 days, 30 days, and 90 days of randomization; (ii) each component of the primary efficacy outcome, within 14 days, 30 days, and 90 days of randomization; (iii) net clinical benefit (accounting for the primary efficacy outcome, composite cardiovascular events, and major bleeding), within 14 days, 30 days, and 90 days of enrolment; (iv) primary efficacy outcome, within 14 days, and 90 days of enrolment; (v) disseminated intravascular coagulation (ISTH criteria, in-hospital diagnosis) within 14 days, 30 days, and 90 days of enrolment.
   Randomisation: Patients will undergo block stratified randomization (by age: 50-70 vs. >70 years; and by study centre) with a randomization ratio of 1:1 with block sizes varying between 4 and 8. Randomization will be performed after the signature of the informed consent for participation and the verification of the eligibility criteria using the electronic data capture software (REDCAP, Vanderbilt University, v9.1.24).
   Blinding (masking): In this open-label study, no blinding procedures will be used.
   Numbers to be randomised (sample size): The sample size calculation is based on the parameters alpha = 0.05 (2-sided), power: 1-beta = 0.8, event rate in experimental group, pexp = 0.09 and event rate in control group, pcon = 0.15. The resulting total sample size is 920. To account for potential dropouts, the total sample size was fixed to 1000 with 500 patients in the intervention group and 500 in the control group.
   Trial Status Protocol version 1.0, 14 April 2020. Protocol version 3.0, 18 May 2020
   Recruiting start date: June 2020.
   Last Patient Last Visit: March 2021.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Barco, Stefano; Sebastian, Tim; Spescha, Rebecca; Kucher, Nils] Univ Hosp Zurich, Clin Angiol, Zurich, Switzerland.
   [Bingisser, Roland] Univ Basel Hosp, Emergency Dept, Basel, Switzerland.
   [Colucci, Giuseppe] Clin Luganese Moncucco, Serv Haematol, Lugano, Switzerland.
   [Frenk, Andre; Stortecky, Stefan; Windecker, Stephan] Univ Bern, Dept Cardiol, Inselspital Bern, Bern, Switzerland.
   [Gerber, Bernhard] Oncol Inst Southern Switzerland, Clin Haematol, Bellinzona, Switzerland.
   [Held, Ulrike] Univ Zurich, Epidemiol Biostat & Prevent Inst, Zurich, Switzerland.
   [Mach, Francois] Geneva Univ Hosp, Cardiol Div, Geneva, Switzerland.
   [Mazzolai, Lucia] Lausanne Univ Hosp, Dept Angiol, Lausanne, Switzerland.
   [Righini, Marc] Geneva Univ Hosp, Div Angiol & Haemostasis, Dept Med Specialties, Geneva, Switzerland.
   [Rosemann, Thomas] Univ Zurich, Inst Primary Care, Zurich, Switzerland.
RP Kucher, N (corresponding author), Univ Hosp Zurich, Clin Angiol, Zurich, Switzerland.
EM nils.kucher@usz.ch
RI Barco, Stefano/V-4901-2017
OI Barco, Stefano/0000-0002-2618-347X
FU Schweizerischer Nationalfonds (SNF; NFP 78 Covid-19)Swiss National
   Science Foundation (SNSF) [198352, 98352]; Innovation Pool of the
   University Hospital Zurich; "Forschungsforderungs" from the University
   Zurich; Durrmuller Bol Foundation
FX The authors received public funding from the Schweizerischer
   Nationalfonds (SNF; NFP 78 Covid-19; Project ID 198352;
   https://data.snf.ch/covid-19/snsf/1 98352), the Innovation Pool of the
   University Hospital Zurich and from the "Forschungsforderungs" from the
   University Zurich, respectively. Additionally, a private funding from
   the Durrmuller Bol Foundation was obtained. Funding was used to design
   and set up the study, including the payment of collaborators. The
   funding bodies had no influence on the study design and will have no
   influence on the study conductance or publication decisions.
NR 0
TC 2
Z9 2
U1 7
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD SEP 9
PY 2020
VL 21
IS 1
AR 770
DI 10.1186/s13063-020-04678-4
PG 3
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NR8CX
UT WOS:000571788400001
PM 32907635
OA DOAJ Gold, Green Accepted, Green Published
DA 2021-01-01
ER

PT J
AU Garcia-Vicuna, R
   Abad-Santos, F
   Gonzalez-Alvaro, I
   Ramos-Lima, F
   Sanz, JS
AF Garcia-Vicuna, Rosario
   Abad-Santos, Francisco
   Gonzalez-Alvaro, Isidoro
   Ramos-Lima, Francisco
   Sanz, Jesus Sanz
TI Subcutaneous Sarilumab in hospitalised patients with moderate-severe
   COVID-19 infection compared to the standard of care (SARCOVID): a
   structured summary of a study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; Open label trial; protocol;
   SARS-CoV-2; Coronavirus infections; Sarilumab; IL-6 receptor inhibitors
AB Objectives: The main aim of the study is to evaluate the efficacy of a single dose of sarilumab, in subcutaneous administration, in hospitalised patients with moderate to early severe COVID-19 infection compared to the current standard of care, to prevent progression to systemic hyperinflammatory status. Our hypothesis is that use of subcutaneous sarilumab in early stages (window of opportunity) of COVID-19 moderate-severe pneumonia can prevent higher oxygenation requirements through non-invasive and invasive mechanical ventilation and decrease in-hospital stays, as well as death rate.
   The secondary objectives of the study are to evaluate the safety of sarilumab through hospitalisation and up to day 14 after discharge, compared to the control arm as assessed by incidence of serious and non serious adverse events (SAEs).
   In addition, as an exploratory objective, to compare the baseline clinical and biological parameters, including serum IL-6 levels, of the intervention population against controls of the same pandemic outbreak (using a propensity score) to search for markers that identify the best candidates for the treatment with subcutaneous IL-6R inhibitors and to attempt an approximation in the temporal frame of the "window of opportunity"
   Trial design: SARCOVID is an investigator-initiated single center randomised proof of concept study.
   Participants: Patients treated at the Hospital Universitario La Princesa, Madrid, Spain requiring hospitalisation will be consecutively recruited, meeting all inclusion criteria and none of the exclusion criteria
   Inclusion criteria
   a. Age >18, <80 years old
   b. COVID-19 infection documented by a positive RT-PCR test or, in absence of a RT-PCR positive test, case definition of COVID 19 infection/pneumonia as per local protocol and the presence of a positive serologic test (IgM/IgA by ELISA)
   c. Documented interstitial pneumonia requiring admission and at least two of the following parameters:
   1) Fever >= 37.8 degrees C (tympanic)
   2) IL-6 in serum >= 25 pg/mL (in the absence of a previous dose of prednisone or equivalent> 1 mg / kg) or PCR> 5mg/dL
   3) Lymphocytes <600 cells/mm(3)
   4) Ferritin> 300 mu g/L that doubles in 24 hours
   5) Ferritin> 600 mu g/L in the first determination and LDH> 250 U/L
   6) D-dimer (> 1 mg/L)
   d. Informed verbal consent or requested under urgent conditions, documented in the electronic medical record.
   Exclusion criteria
   a. Patients who require mechanical ventilation at the time of inclusion.
   b. AST / ALT values > 5 folds the ULN.
   c. Absolute neutrophil count below 500 cells/mm(3)
   d. Absolute platelet count below 50,000 cells/mm(3)
   e. Documented sepsis or high suspicion of superimposed infection by pathogens other than COVID-19.
   f. Presence of comorbidities that can likely lead to an unfavourable result according to clinical judgment.
   g. Complicated diverticulitis or intestinal perforation.
   h. Current skin infection (eg, uncontrolled dermopiodermitis).
   i. Immunosuppressive anti-rejection therapy.
   j. Pregnancy or lactation.
   k. Previous treatment with tocilizumab or sarilumab.
   l. Patients participating in another clinical trial for SARS-CoV-2 infection.
   m. Patients with known hypersensitivity or contraindication to sarilumab or excipients.
   Intervention and comparator
   The intervention group, sarilumab plus standard of care, will receive 400 mg single dose treatment with Sarilumab (Kevzara), 2 subcutaneous injections 200mg each in a pre-filled syringe.
   Treatment with drugs or procedures in routine clinical practice that the clinician responsible for the patient deems necessary is allowed.
   The control group will receive drugs or procedures in routine clinical practice according to the best standard of care as per local protocol.
   Main outcomes: Primary Outcome Measures
   1. Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation compared to baseline (Score ranges 1-7)
   1. Death;
   2. Hospitalised, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO);
   3. Hospitalised, requiring non-invasive ventilation or high flow oxygen devices;
   4. Hospitalised, requiring supplemental oxygen;
   5. Hospitalised, not requiring supplemental oxygen - but in need of ongoing medical care (COVID-19 related or otherwise)
   6. Hospitalised, not requiring supplemental oxygen - no longer requires ongoing medical care (independent)
   7. Not hospitalised
   2. Duration of hospitalisation: Days from the date of enrolment to the date of discharge
   3. Number of deaths at the end of study
   Randomisation: Randomisation to treatment arms sarilumab plus standard of care or standard of care in a 2:1 ratio will be performed by the Clinical Research and Clinical Trials Unit (CRCTU) at the Hospital using a table of random numbers, an internet-based randomisation tool. After checking that all inclusion criteria are met and none of the exclusion criteria, CRCTU will communicate the recruiting investigator the assigned treatment.
   Blinding (masking): This study is unblinded.
   Numbers to be randomised (sample size): 30 patients treated by COVID-19 infection who require hospitalisation: 20 will receive sarilumab plus Standard of Care and 10 will receive Standard of Care.
   Trial Status: The Protocol version number is 2, as of 6(th)April 2020, with amendment 1, as of 7(th)May 2020. The recruitment is ongoing. Recruitment started on April 13(th)2020 and is anticipated to be completed by November 2020.
   Trial registration: This trial was first registered in the European Union Clinical Trials Register on 4 April 2020, EudraCT Number 2020-001634-36. Then, posted on ClinicalTrials.gov on 22 April 2020, Identifier: NCT04357808.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
   The study protocol has been reported in accordance with the International Council Harmonization guidelines:. https://www.ich.org/page/efficacy-guidelines.
C1 [Garcia-Vicuna, Rosario; Gonzalez-Alvaro, Isidoro] Hosp Univ Princesa, Rheumatol Dept, Madrid, Spain.
   [Garcia-Vicuna, Rosario; Abad-Santos, Francisco] Univ Autonoma Madrid UAM, Fac Med, Madrid, Spain.
   [Garcia-Vicuna, Rosario; Abad-Santos, Francisco; Gonzalez-Alvaro, Isidoro; Sanz, Jesus Sanz] Inst Invest Sanitaria La Princesa IIS IP, Madrid, Spain.
   [Abad-Santos, Francisco] Hosp Univ Princesa, Clin Pharmacol Dept, Unidad Invest Clin & Ensayos Clin UICEC, Plataforma SCReN Spanish Clin Res Network, Madrid, Spain.
   [Ramos-Lima, Francisco] Sanofi Spain, Med Affairs Dept, Immunol Area, Madrid, Spain.
   [Sanz, Jesus Sanz] Hosp Univ Princesa, Div Infect Dis, Internal Med Dept, Madrid, Spain.
RP Garcia-Vicuna, R (corresponding author), Hosp Univ Princesa, Rheumatol Dept, Madrid, Spain.; Garcia-Vicuna, R (corresponding author), Univ Autonoma Madrid UAM, Fac Med, Madrid, Spain.; Garcia-Vicuna, R (corresponding author), Inst Invest Sanitaria La Princesa IIS IP, Madrid, Spain.
EM mariadelrosario.garcia@salud.madrid.org
RI de VicuAa, Rosario Garcia/ABD-7892-2020
OI de VicuAa, Rosario Garcia/0000-0001-9096-3780
NR 0
TC 2
Z9 2
U1 7
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD SEP 9
PY 2020
VL 21
IS 1
AR 772
DI 10.1186/s13063-020-04588-5
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NR8CX
UT WOS:000571788400003
PM 32907638
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kahan, BC
   Morris, TP
   White, IR
   Tweed, CD
   Cro, S
   Dahly, D
   Pham, TM
   Esmail, H
   Babiker, A
   Carpenter, JR
AF Kahan, Brennan C.
   Morris, Tim P.
   White, Ian R.
   Tweed, Conor D.
   Cro, Suzie
   Dahly, Darren
   Pham, Tra My
   Esmail, Hanif
   Babiker, Abdel
   Carpenter, James R.
TI Treatment estimands in clinical trials of patients hospitalised for
   COVID-19: ensuring trials ask the right questions
SO BMC MEDICINE
LA English
DT Article
DE COVID-19; Estimand; Randomised trial; Intercurrent events;
   Truncation-by-death
AB When designing a clinical trial, explicitly defining the treatment estimands of interest (that which is to be estimated) can help to clarify trial objectives and ensure the questions being addressed by the trial are clinically meaningful. There are several challenges when defining estimands. Here, we discuss a number of these in the context of trials of treatments for patients hospitalised with COVID-19 and make suggestions for how estimands should be defined for key outcomes. We suggest that treatment effects should usually be measured as differences in proportions (or risk or odds ratios) for outcomes such as death and requirement for ventilation, and differences in means for outcomes such as the number of days ventilated. We further recommend that truncation due to death should be handled differently depending on whether a patient- or resource-focused perspective is taken; for the former, a composite approach should be used, while for the latter, a while-alive approach is preferred. Finally, we suggest that discontinuation of randomised treatment should be handled from a treatment policy perspective, where non-adherence is ignored in the analysis (i.e. intention to treat).
C1 [Kahan, Brennan C.; Morris, Tim P.; White, Ian R.; Tweed, Conor D.; Pham, Tra My; Esmail, Hanif; Babiker, Abdel; Carpenter, James R.] MRC Clin Trials Unit UCL, London, England.
   [Cro, Suzie] Imperial Coll London, Imperial Clin Trials Unit, London, England.
   [Dahly, Darren] HRB Clin Res Facil Cork, Cork, Ireland.
   [Dahly, Darren] Univ Coll Cork, Sch Publ Hlth, Cork, Ireland.
   [Esmail, Hanif] UCL, Inst Global Hlth, London, England.
RP Kahan, BC (corresponding author), MRC Clin Trials Unit UCL, London, England.
EM b.kahan@ucl.ac.uk
OI Morris, Tim/0000-0001-5850-3610; White, Ian/0000-0002-6718-7661
FU UK MRCMedical Research Council UK (MRC) [MC_UU_12023/21, MC_UU_12023/29]
FX BCK, TPM, IRW, TMP, AB, and JRC are funded by the UK MRC, grants
   MC_UU_12023/21 and MC_UU_12023/29.
CR Akach M, 2017, STAT MED, V36, P5, DOI 10.1002/sim.7033
   Akacha M, 2017, CLIN PHARMACOL THER, V102, P894, DOI 10.1002/cpt.872
   Aroda VR, 2019, DIABETES OBES METAB, V21, P2203, DOI 10.1111/dom.13804
   Benkeser D, 2020, IMPROVING PRECISION
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Colantuoni E, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5748
   COMET Initiative, MET COS RES COVID 19
   Cro S, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01590-1
   Cytel, GLOB COR COVID 19 CL
   Degtyarev E, 2020, STAT BIOPHARM RES, V12, P427, DOI 10.1080/19466315.2020.1785543
   Dufouil C, 2004, STAT MED, V23, P2215, DOI 10.1002/sim.1821
   Finkelstein DM, 1999, STAT MED, V18, P1341, DOI 10.1002/(SICI)1097-0258(19990615)18:11&lt;1341::AID-SIM129&gt;3.0.CO;2-7
   Harhay MO, 2019, MED CARE, V57, pE53, DOI 10.1097/MLR.0000000000001059
   Holzhauer B, 2015, PHARM STAT, V14, P433, DOI 10.1002/pst.1705
   ICH E9 working group, ICH E9 R1 ADD EST SE
   Initiative C, 2020, COR OUTC SET DEV RES
   Jin X, 2020, ENGINEERING BEIJING
   Leuchs AK, 2017, PHARM STAT, V16, P12, DOI 10.1002/pst.1791
   Mallinckrodt CH, 2020, THER INNOV REGUL SCI, V54, P353, DOI 10.1007/s43441-019-00063-9
   Mallinckrodt C, 2017, PHARM STAT, V16, P29, DOI 10.1002/pst.1765
   Meyer RD, 2020, STAT BIOPHARM RES, V12, P399, DOI 10.1080/19466315.2020.1779122
   Min T, 2020, LANCET DIABETES ENDO, V8, P181, DOI 10.1016/S2213-8587(19)30407-3
   Organisation WH, WHO R D BLUEPR COVID
   Petavy F, 2020, BRIT J CLIN PHARMACO, V86, P1235, DOI 10.1111/bcp.14195
   Pocock SJ, 2012, EUR HEART J, V33, P176, DOI 10.1093/eurheartj/ehr352
   Qiu R., 2020, OUTCOME REPORTING PR
   Qiu RJ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00781
   Ratitch B, 2020, THER INNOV REGUL SCI, V54, P370, DOI 10.1007/s43441-019-00065-7
   Rufibach K, 2019, PHARM STAT, V18, P145, DOI 10.1002/pst.1917
   Schulz KF, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000251
   Thorlund K, 2020, LANCET DIGIT HEALTH, V2, pE286, DOI 10.1016/S2589-7500(20)30086-8
   White IR, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d40
NR 32
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1741-7015
J9 BMC MED
JI BMC Med.
PD SEP 9
PY 2020
VL 18
IS 1
AR 286
DI 10.1186/s12916-020-01737-0
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA NQ5VC
UT WOS:000570935600001
PM 32900372
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chen, XX
   Zhang, GQ
   Tang, YT
   Peng, ZY
   Pan, HQ
AF Chen, Xiaoxing
   Zhang, Guqin
   Tang, Yueting
   Peng, Zhiyong
   Pan, Huaqin
TI The coronavirus diseases 2019 (COVID-19) pneumonia with spontaneous
   pneumothorax: a case report
SO BMC INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; SARS-CoV-2 virus; Pneumonia; Pneumothorax
AB BackgroundThe outbreak of the novel coronavirus (COVID-19) that was firstly reported in Wuhan, China, with cases now confirmed in more than 100 countries. However, COVID-19 pneumonia with spontaneous pneumothorax is unknown.Case presentationWe reported a case of 66-year-old man infected with COVID-19, presenting with fever, cough and myalgia; The patient received supportive and empirical treatment including antiviral treatment, anti-inflammatory treatment, oxygen supply and inhalation therapy; The symptoms, CT images, laboratory results got improved after the treatments, and a throat swab was negative for COVID-19 PCR test; However, on the hospital day 30, the patient presented with a sudden chest pain and dyspnea. CT showed a 30-40% left-sided pneumothorax. Immediate thoracic closed drainage was performed and his dyspnea was rapidly improved. With five more times negative PCR tests for SARS-CoV-2 virus, the patient was discharged and home quarantine.ConclusionThis case highlights the importance for clinicians to pay attention to the appearance of spontaneous pneumothorax, especially patients with severe pulmonary damage for a long course, as well as the need for early image diagnose CT and effective treatment once pneumothorax occurs.
C1 [Chen, Xiaoxing] Wuhan Univ, Renmin Hosp, Dept Geriatr, Wuhan, Peoples R China.
   [Zhang, Guqin] Wuhan Univ, Zhongnan Hosp, Dept Resp & Crit Care Med, Wuhan 430071, Peoples R China.
   [Tang, Yueting] Wuhan Univ, Zhongnan Hosp, Dept Clin Lab, Wuhan 430071, Peoples R China.
   [Peng, Zhiyong; Pan, Huaqin] Wuhan Univ, Zhongnan Hosp, Dept Crit Care Med, 169 Eastlake Rd, Wuhan 430071, Hubei, Peoples R China.
RP Pan, HQ (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Crit Care Med, 169 Eastlake Rd, Wuhan 430071, Hubei, Peoples R China.
EM phq2012@whu.edu.cn
OI Pan, Huaqin/0000-0002-1572-2781
CR BINTCLIFFE O, 2014, BMJ-BRIT MED J, V348, DOI DOI 10.1136/BMJ.G2928
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Sihoe ADL, 2004, CHEST, V125, P2345, DOI 10.1378/chest.125.6.2345
   Ucpinar BA, 2020, J INFECT PUBLIC HEAL, V13, P887, DOI 10.1016/j.jiph.2020.05.012
   Wang W, 2020, J TRAVEL MED, V27
   World Health Organization, 2020, 72EBOL WHO
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xiang CL, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020208
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 10
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2334
J9 BMC INFECT DIS
JI BMC Infect. Dis.
PD SEP 9
PY 2020
VL 20
IS 1
AR 662
DI 10.1186/s12879-020-05384-x
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA NQ6DI
UT WOS:000570959900001
PM 32907540
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU van de Plassche, MAT
   Barniol-Xicota, M
   Verhelst, SHL
AF van de Plassche, Merel A. T.
   Barniol-Xicota, Marta
   Verhelst, Steven H. L.
TI Peptidyl Acyloxymethyl Ketones as Activity-Based Probes for the Main
   Protease of SARS-CoV-2
SO CHEMBIOCHEM
LA English
DT Article
DE activity-based protein profiling; enzymes; fluorescent probes;
   proteases; viruses
ID CORONAVIRUS; SARS; CYSTEINE; INHIBITORS; DESIGN; DISCOVERY; ENZYMES
AB The global pandemic caused by SARS-CoV-2 calls for the fast development of antiviral drugs against this particular coronavirus. Chemical tools to facilitate inhibitor discovery as well as detection of target engagement by hit or lead compounds from high-throughput screens are therefore in urgent need. We here report novel, selective activity-based probes that enable detection of the SARS-CoV-2 main protease. The probes are based on acyloxymethyl ketone reactive electrophiles combined with a peptide sequence including unnatural amino acids that targets the nonprimed site of the main protease substrate binding cleft. They are the first activity-based probes for the main protease of coronaviruses and display target labeling within a human proteome without background. We expect that these reagents will be useful in the drug-development pipeline, not only for the current SARS-CoV-2, but also for other coronaviruses.
C1 [van de Plassche, Merel A. T.; Barniol-Xicota, Marta; Verhelst, Steven H. L.] Univ Leuven, KU Leuven, Dept Cellular & Mol Med, Biol Chem Lab, Herestr 49,Box 802, B-3000 Leuven, Belgium.
   [Verhelst, Steven H. L.] AG Chem Prote, Leibniz Inst Analyt Sci ISAS, Otto Hahn Str 6b, D-44227 Dortmund, Germany.
RP Verhelst, SHL (corresponding author), Univ Leuven, KU Leuven, Dept Cellular & Mol Med, Biol Chem Lab, Herestr 49,Box 802, B-3000 Leuven, Belgium.; Verhelst, SHL (corresponding author), AG Chem Prote, Leibniz Inst Analyt Sci ISAS, Otto Hahn Str 6b, D-44227 Dortmund, Germany.
OI Verhelst, Steven/0000-0002-7400-1319; Barniol-Xicota,
   Marta/0000-0001-7957-2199
FU Research Foundation Flanders FWOFWO [G0D8617N, 12Y0720N]; Ministerium
   fur Kultur und Wissenschaft des Landes Nordrhein-Westfalen; Regierende
   Burgermeister von Berlin inkl. Wissenschaft und Forschung;
   Bundesministerium fur Bildung und ForschungFederal Ministry of Education
   & Research (BMBF)
FX We thank Dr. Ladan Khodaparast and Dr. Laleh Khodaparast (Switch
   laboratory) for providing access to and help with the Avestin
   Emulsiflex, Prof. Rolf Hilgenfeld for kind donation of the plasmid for
   SARS-CoV-2 Mpro expression, Dr. Linlin Zhang for useful discussions on
   expression and purification, Peptides International for donation of the
   fluorogenic substrate, Prof. Wim De Borggraeve and Bart Van Huffel for
   NMR measurements. We acknowledge financial support from Research
   Foundation Flanders FWO (project number G0D8617N to SHLV and
   post-doctoral fellowship 12Y0720N to MBX), the Ministerium fur Kultur
   und Wissenschaft des Landes Nordrhein-Westfalen, the Regierende
   Burgermeister von Berlin inkl. Wissenschaft und Forschung, and the
   Bundesministerium fur Bildung und Forschung.
CR Akaji K, 2011, J MED CHEM, V54, P7962, DOI 10.1021/jm200870n
   Aleshin AE, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.388678
   Bianco G, 2016, PROTEIN SCI, V25, P295, DOI 10.1002/pro.2733
   Bogyo M, 2000, CHEM BIOL, V7, P27, DOI 10.1016/S1074-5521(00)00061-2
   Chakrabarty S, 2019, CURR TOP MICROBIOL, V420, P253, DOI 10.1007/82_2018_138
   Chuck CP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027228
   Cravatt BF, 2008, ANNU REV BIOCHEM, V77, P383, DOI 10.1146/annurev.biochem.75.101304.124125
   Dai W., 2020, SCIENCE
   Delano WL, 2002, PYMOL MOL GRAPHICS S
   Desrochers GF, 2019, CURR TOP MICROBIOL, V420, P131, DOI 10.1007/82_2018_139
   Greenbaum D, 2000, CHEM BIOL, V7, P569, DOI 10.1016/S1074-5521(00)00014-4
   HAMRE D, 1966, P SOC EXP BIOL MED, V121, P190, DOI 10.3181/00379727-121-30734
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Jin Z., 2020, BIORXIV PREPRINT
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kato D, 2005, NAT CHEM BIOL, V1, P33, DOI 10.1038/nchembio707
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Nomura DK, 2010, NAT REV CANCER, V10, P630, DOI 10.1038/nrc2901
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Powers JC, 2002, CHEM REV, V102, P4639, DOI 10.1021/cr010182v
   Rawlings ND, 2018, NUCLEIC ACIDS RES, V46, pD624, DOI 10.1093/nar/gkx1134
   Rut W., 2020, BIORXIV
   Rut W, 2020, ANTIVIR RES, V175, DOI 10.1016/j.antiviral.2020.104731
   Rut W, 2017, ANTIVIR RES, V139, P88, DOI 10.1016/j.antiviral.2016.12.018
   Sanman LE, 2014, ANNU REV BIOCHEM, V83, P249, DOI 10.1146/annurev-biochem-060713-035352
   Serim S, 2012, CHEMMEDCHEM, V7, P1146, DOI 10.1002/cmdc.201200057
   Sharifzadeh S, 2019, CURR TOP MICROBIOL, V420, P23, DOI 10.1007/82_2018_135
   Takahashi K, 2009, BIOL PHARM BULL, V32, P475, DOI 10.1248/bpb.32.475
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   TYRRELL DA, 1966, LANCET, V1, P76
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang HZ, 2006, J MED CHEM, V49, P1198, DOI 10.1021/jm0507678
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziebuhr J, 2004, CURR OPIN MICROBIOL, V7, P412, DOI 10.1016/j.mib.2004.06.007
NR 37
TC 0
Z9 0
U1 3
U2 3
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1439-4227
EI 1439-7633
J9 CHEMBIOCHEM
JI ChemBioChem
PD DEC 1
PY 2020
VL 21
IS 23
BP 3383
EP 3388
DI 10.1002/cbic.202000371
EA SEP 2020
PG 6
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA OZ6HE
UT WOS:000568708200001
PM 32717117
DA 2021-01-01
ER

PT J
AU Diez, JM
   Romero, C
   Vergara-Alert, J
   Bello-Perez, M
   Rodon, J
   Honrubia, JM
   Segales, J
   Sola, I
   Enjuanes, L
   Gajardo, R
AF Maria Diez, Jose
   Romero, Carolina
   Vergara-Alert, Julia
   Bello-Perez, Melissa
   Rodon, Jordi
   Manuel Honrubia, Jose
   Segales, Joaquim
   Sola, Isabel
   Enjuanes, Luis
   Gajardo, Rodrigo
TI Cross-neutralization activity against SARS-CoV-2 is present in currently
   available intravenous immunoglobulins
SO IMMUNOTHERAPY
LA English
DT Article
DE COVID-19; cross-neutralization; intravenous immunoglobulin; MERS-CoV;
   SARS-CoV; SARS-CoV-2
ID RECEPTOR-BINDING DOMAIN; SPIKE GLYCOPROTEIN; SARS CORONAVIRUS;
   ANTIBODIES; REACTIVITY; COVID-19; SERA
AB Background:Cross-reactivity against human coronaviruses with Flebogamma(R)DIF and Gamunex(R)-C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV).Materials & methods:Neutralization capacity of lots of IVIG manufactured prior to COVID-19 pandemic was assessed against these viruses in cell culture. Infectivity neutralization was quantified by percent reduction in plaque-forming units and/or cytopathic/cytotoxic methods.Results:All IVIG preparations showed neutralization of SARS-CoV-2 isolates. All IVIG lots produced neutralization of SARS-CoV. No IVIG preparation showed significant neutralizing activity against MERS-CoV.Conclusion:The tested IVIG contain antibodies with significantin vitrocross-neutralization capacity against SARS-CoV-2 and SARS-CoV, but not MERS-CoV. These preparations are currently under evaluation as potential therapies for COVID-19.
C1 [Maria Diez, Jose; Romero, Carolina; Gajardo, Rodrigo] Grifols, Biosci Res & Dev, Barcelona, Spain.
   [Vergara-Alert, Julia; Rodon, Jordi] IRTA UAB, Ctr Recerca Sanitat Anim CReSA, IRTA, Campus Univ Autonoma Barcelona UAB, Barcelona, Spain.
   [Bello-Perez, Melissa; Manuel Honrubia, Jose; Sola, Isabel; Enjuanes, Luis] CNB CSIC, Dept Biol Mol & Celular, Lab Coronavirus, Madrid, Spain.
   [Segales, Joaquim] UAB, CReSA IRTA UAB, Campus Univ Autonoma Barcelona UAB, Barcelona, Spain.
   [Segales, Joaquim] Univ Autonoma Barcelona UAB, Fac Vet, Dept Sanitat & Anat Anim, Barcelona, Spain.
RP Diez, JM (corresponding author), Grifols, Biosci Res & Dev, Barcelona, Spain.
EM josemaria.diez@grifols.com
RI Rodon Aldrufeu, Jordi/T-6532-2018
OI Rodon Aldrufeu, Jordi/0000-0002-1032-9091; Sola,
   Isabel/0000-0002-5704-1917
FU Grifols
FX Neutralization experiments were funded by Grifols, the manufacturer of
   Flebogamma DIF and Gamunex-C. JM Diez, C Romero and R Gajardo are
   full-time employees of Grifols. J Vergara-Alert, J Rodon, M Bello-Perez
   and JM Honrubia, J Segales and L Enjuanes declare having no other
   conflict of interest. The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript apart from those disclosed.
CR Almazan F, 2006, J VIROL, V80, P10900, DOI 10.1128/JVI.00385-06
   Almazan F, 2013, MBIO, V4, DOI 10.1128/mBio.00650-13
   Anderson DE, 2020, EMERG MICROBES INFEC, V9, P900, DOI 10.1080/22221751.2020.1761267
   [Anonymous], 2020, EFFICACY INTRAVENOUS
   Anthony SJ, 2017, VIRUS EVOL, V3, DOI 10.1093/ve/vex012
   Bianchi M, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4389089
   Bozzo J, 2017, EXPERT REV ANTI-INFE, V15, P585, DOI 10.1080/14787210.2017.1328278
   Cao W, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa102
   Chakraborty C, 2020, EUR REV MED PHARMACO, V24, P4016, DOI 10.26355/eurrev_202004_20871
   Chakraborty C, 2020, ASIAN PAC J TROP MED, V13, P242, DOI 10.4103/1995-7645.281613
   Chan KS, 2003, RESPIROLOGY, V8, pS36, DOI 10.1046/j.1440-1843.2003.00522.x
   Chan KH, 2013, J INFECTION, V67, P130, DOI 10.1016/j.jinf.2013.03.015
   Che XY, 2005, J INFECT DIS, V191, P2033, DOI 10.1086/430355
   Diez JM, 2020, IMMUNOTHERAPY-UK, V12, P571, DOI 10.2217/imt-2020-0095
   European Centre for Disease Prevention and Control, 2020, COVID 19 SIT UPD WOR
   Greenberg SB, 2016, SEMIN RESP CRIT CARE, V37, P555, DOI 10.1055/s-0036-1584797
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   Jaimes JA, 2020, J MOL BIOL, V432, P3309, DOI 10.1016/j.jmb.2020.04.009
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Laupland K. B., 2002, Canadian Journal of Infectious Diseases, V13, P100
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Patrick David M, 2006, Can J Infect Dis Med Microbiol, V17, P330
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Qian ZH, 2015, J VIROL, V89, P8816, DOI 10.1128/JVI.03737-14
   Rabaan Ali A, 2020, Infez Med, V28, P174
   Rodon J, 2020, SEARCH SARS COV 2 IN, DOI [10.1101/2020.04.23.055756, DOI 10.1101/2020.04.23.055756]
   Schmaljohn AL, 2013, CURR HIV RES, V11, P345, DOI 10.2174/1570162X113116660057
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Tang B S F, 2009, Hong Kong Med J, V15 Suppl 9, P23
   Tay MZ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00332
   Uddin M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050526
   van Boheemen S, 2012, MBIO, V3, DOI 10.1128/mBio.00473-12
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Xie Y, 2020, J INFECTION, V81, P340, DOI 10.1016/j.jinf.2020.03.044
   Zhang QF, 2004, J MED VIROL, V73, P332, DOI 10.1002/jmv.20095
   Zumla A, 2015, LANCET, V386, P995, DOI 10.1016/S0140-6736(15)60454-8
NR 41
TC 1
Z9 1
U1 4
U2 4
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-743X
EI 1750-7448
J9 IMMUNOTHERAPY-UK
JI Immunotherapy
PD DEC
PY 2020
VL 12
IS 17
BP 1247
EP 1255
DI 10.2217/imt-2020-0220
EA SEP 2020
PG 9
WC Immunology
SC Immunology
GA OI4EP
UT WOS:000567797200001
PM 32900263
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Seshiah, V
   Balaji, V
   Banerjee, S
   Sahay, R
   Divakar, H
   Jain, R
   Chawla, R
   Das, AK
   Gupta, S
   Krishnan, D
AF Seshiah, Veeraswamy
   Balaji, Vijayam
   Banerjee, Samar
   Sahay, Rakesh
   Divakar, Hema
   Jain, Rajesh
   Chawla, Rajeev
   Das, Ashok Kumar
   Gupta, Sunil
   Krishnan, Dharani
TI Diagnosis and principles of management of gestational diabetes mellitus
   in the prevailing COVID-19 pandemic
SO INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES
LA English
DT Article
DE Gestational diabetes mellitus (GDM); Medical nutrition therapy (MNT);
   Oral hypoglycemic agent (OHA); Postprandial plasma glucose(PPPG);
   Fasting plasma glucose (FPG); Ministry of Health and Family Welfare;
   Government of India (MHFW-GOI)
ID PREGNANCY; CLASSIFICATION; HYPERGLYCEMIA; CRITERIA; GLUCOSE
AB Background Limited medical facilities are available due to Covid-19 pandemic. Nevertheless, all efforts should be made in planning judicial and possible methods of delivering health care, particularly to pregnant woman with GDM. GDM may play a crucial role in the increasing prevalence of diabetes and obesity and also may be the origin of cardiometabolic diseases.
   Methods It is mandatary to diagnose and care pregnant woman with GDM. The test suggested to diagnose GDM has to be evidence based and in this regard "a single test procedure" evaluated meets this requirement. This doable test has been accepted by the Diabetes in Pregnancy Study Group India (DIPSI) and approved by MHFW-GOI, WHO, International Diabetes Federation, and International Federation of Obstetricians and Gynecologists. MHFW-GOI also recommends testing at first antenatal visit and then at 24-28 weeks of gestation. This opportunity can also be utilized for performing ultrasonography for assessing fetal development.
   Result The first-line management is MNT and life style modifications. Non-responders may require insulin or OHA. The target glycemic control is FPG similar to 5.0 mmol/dl (90 mg/dl) and 2 h PPPG similar to 6.7 mmol/dl (120 mg/dl). The goal is to obtain newborns birth weight appropriate for gestational age between 2.5 and 3.5 kg, a step to prevent offspring developing diabetes.
   Conclusion The essential precaution required during COVID pandemic is to wear face mask, avoid crowded places, and maintain social distancing. Finally, the economical and evidence based "single test procedure" of DIPSI is most appropriate for screening during the COVID pandemic.
C1 [Seshiah, Veeraswamy; Balaji, Vijayam] Dr Balaji Diabet Care Ctr, Chennai 600029, Tamil Nadu, India.
   [Seshiah, Veeraswamy; Balaji, Vijayam] Dr Seshiah Diabet Res Inst, Chennai 600029, Tamil Nadu, India.
   [Banerjee, Samar] Vivekananda Inst Med Sci, Calcuta, India.
   [Sahay, Rakesh] Osmania Med Coll & Hosp, Dept Endocrinol, Hyderabad, India.
   [Sahay, Rakesh] Osmania Gen Hosp, Hyderabad, India.
   [Divakar, Hema] Divakars Specialty Hosp, Bengaluru, India.
   [Jain, Rajesh] Jain Hosp, Kanpur, Uttar Pradesh, India.
   [Chawla, Rajeev] Diabet Pregnancy Study Grp India, Delhi, India.
   [Das, Ashok Kumar] Pondicherry Inst Med Sci, Pondicherry, India.
   [Gupta, Sunil] Diabet Pregnancy Study Grp India, Nagpur, Maharashtra, India.
RP Seshiah, V (corresponding author), Dr Balaji Diabet Care Ctr, Chennai 600029, Tamil Nadu, India.; Seshiah, V (corresponding author), Dr Seshiah Diabet Res Inst, Chennai 600029, Tamil Nadu, India.
EM vseshiah@gmail.com
CR Anderson V, 2013, J OBSTET GYNAECOL CA, V35, P515, DOI 10.1016/S1701-2163(15)30909-9
   Anjalakshi C, 2009, ACTA DIABETOL, V46, P51, DOI 10.1007/s00592-008-0060-9
   [Anonymous], 2011, DIABETES RES CLIN PR, V93, P299, DOI 10.1016/j.diabres.2011.03.012
   [Anonymous], 1991, DIABETES S2, V40, P126
   Bain ES, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-195
   Brown JE, 2002, AM J CLIN NUTR, V76, P205
   Colagiuri S, 2014, DIABETES RES CLIN PR, V103, P364, DOI 10.1016/j.diabres.2014.02.012
   Crowther CA, 2005, NEW ENGL J MED, V352, P2477, DOI 10.1056/NEJMoa042973
   Crowther CA, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002398
   Docherty A.B., 2020, FEATURES 16749 HOSP, DOI [10.1101/2020.04.23.20076042thisversion, DOI 10.1101/2020.04.23.20076042]
   Ferrara A, 2007, DIABETES CARE, V30, pS141, DOI 10.2337/dc07-s206
   Fiore K, 2014, SCREENING
   Franks PW, 2006, DIABETES, V55, P460, DOI 10.2337/diabetes.55.02.06.db05-0823
   Gayle C, 2010, DIABETOLOGIA, V53, pS435
   Hod M, 2015, INT J GYNAECOL OB S3, V131, pS173
   Institute of Medicine, 2002, US DIET REF INT EN C
   International Diabetes Federation (IDF), 2018, ATLAS
   Lapolla A, 2018, ACTA DIABETOL, V55, P885, DOI 10.1007/s00592-018-1146-7
   McIntyre HD, 2020, DIABETES CARE, V43, P1433, DOI 10.2337/dci20-0026
   Metzger BE, 2010, DIABETES CARE, V33, P676, DOI 10.2337/dc09-1848
   Mor G, 2010, AM J REPROD IMMUNOL, V63, P425, DOI 10.1111/j.1600-0897.2010.00836.x
   National Institute for Health and Care Excellence, 2015, DIAB PREGN MAN PREC
   Nelison KK, 2017, BMC PREGNANCY CHILDB
   Poon LC, 2020, INT J GYNECOL OBSTET, V149, P273, DOI 10.1002/ijgo.13156
   Purandare CN, 2017, IDF C AB DHAB 6 DEC
   Riaz M, 2019, CLIN EPIDEMIOL GLOB, V7, P218, DOI 10.1016/j.cegh.2018.06.003
   Sandesh Panthi, 2015, JCD, V2
   Seshiah V, 2019, J ASS PHYS INDIA, V67
   Shan ZL, 2013, RESP MED, V107, P321, DOI 10.1016/j.rmed.2012.12.001
   Simmons D, 2005, DIABETIC MED, V22, P207, DOI 10.1111/j.1464-5491.2004.01378.x
   Singh N, 2017, INDIAN J MED RES, V145, P622, DOI 10.4103/ijmr.IJMR_1358_15
   Smith V, 2020, PLOS ONE, V15
   Susman E., 2020, MED PAGE TODAY  0710
   Wong VW, 2012, DIABETIC MED, V29, P366, DOI 10.1111/j.1464-5491.2011.03439.x
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 35
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0973-3930
EI 1998-3832
J9 INT J DIABETES DEV C
JI Int. Diabetes Dev. Ctries.
PD SEP
PY 2020
VL 40
IS 3
BP 329
EP 334
DI 10.1007/s13410-020-00860-1
EA SEP 2020
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NS7PB
UT WOS:000567731300001
PM 32929316
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Portelli, S
   Olshansky, M
   Rodrigues, CHM
   D'Souza, EN
   Myung, Y
   Silk, M
   Alavi, A
   Pires, DEV
   Ascher, DB
AF Portelli, Stephanie
   Olshansky, Moshe
   Rodrigues, Carlos H. M.
   D'Souza, Elston N.
   Myung, Yoochan
   Silk, Michael
   Alavi, Azadeh
   Pires, Douglas E., V
   Ascher, David B.
TI Exploring the structural distribution of genetic variation in SARS-CoV-2
   with the COVID-3D online resource
SO NATURE GENETICS
LA English
DT Article
ID MUTATIONS; SERVER
AB The emergence of the COVID-19 pandemic has spurred a global rush to uncover basic biological mechanisms to inform effective vaccine and drug development. Despite the novelty of the virus, global sequencing efforts have already identified genomic variation across isolates. To enable easy exploration and spatial visualization of the potential implications of SARS-CoV-2 mutations in infection, host immunity and drug development, we have developed COVID-3D ().
C1 [Portelli, Stephanie; Olshansky, Moshe; Rodrigues, Carlos H. M.; D'Souza, Elston N.; Myung, Yoochan; Silk, Michael; Alavi, Azadeh; Pires, Douglas E., V; Ascher, David B.] Univ Melbourne, Bio21 Inst, Struct Biol & Bioinformat, Melbourne, Vic, Australia.
   [Portelli, Stephanie; Olshansky, Moshe; Rodrigues, Carlos H. M.; D'Souza, Elston N.; Myung, Yoochan; Silk, Michael; Alavi, Azadeh; Pires, Douglas E., V; Ascher, David B.] Baker Heart & Diabet Inst, Computat Biol & Clin Informat, Melbourne, Vic, Australia.
   [Pires, Douglas E., V] Univ Melbourne, Sch Comp & Informat Syst, Melbourne, Vic, Australia.
   [Ascher, David B.] Univ Cambridge, Dept Biochem, Cambridge, England.
RP Ascher, DB (corresponding author), Univ Melbourne, Bio21 Inst, Struct Biol & Bioinformat, Melbourne, Vic, Australia.; Ascher, DB (corresponding author), Baker Heart & Diabet Inst, Computat Biol & Clin Informat, Melbourne, Vic, Australia.; Ascher, DB (corresponding author), Univ Cambridge, Dept Biochem, Cambridge, England.
EM david.ascher@unimelb.edu.au
RI Pires, Douglas/ABC-7445-2020
OI Pires, Douglas/0000-0002-3004-2119; Olshansky,
   Moshe/0000-0003-2085-9851; D'Souza, Elston/0000-0002-5394-7260; Ascher,
   David/0000-0003-2948-2413
FU Melbourne Research Scholarship; Newton Fund RCUK-CONFAP Grant; Medical
   Research Council (MRC)Medical Research Council UK (MRC); Fundacao de
   Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)Minas Gerais State
   Research Foundation (FAPEMIG) [MR/M026302/1]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Jack Brockhoff
   Foundation [JBF 4186]; Wellcome TrustWellcome Trust [200814/Z/16/Z];
   National Health and Medical Research Council (NHMRC) of
   AustraliaNational Health and Medical Research Council of Australia
   [GNT1174405]; Victorian Government's OIS Program
FX We thank N. Thanh Binh (Bioinformatics Institute, A*STAR, Singapore) for
   help with molecular dynamics simulations. S.P., C.H.M.R. and Y.M. were
   supported by a Melbourne Research Scholarship. D.B.A. and D.E.V.P. were
   funded by a Newton Fund RCUK-CONFAP Grant awarded by The Medical
   Research Council (MRC) and Fundacao de Amparo a Pesquisa do Estado de
   Minas Gerais (FAPEMIG; MR/M026302/1) and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq). D.B.A. was funded by
   the Jack Brockhoff Foundation (JBF 4186, 2016); the Wellcome Trust
   (200814/Z/16/Z) and an Investigator Grant from the National Health and
   Medical Research Council (NHMRC) of Australia (GNT1174405). This work
   was supported in part by the Victorian Government's OIS Program. This
   research has been conducted using the UK Biobank Resource under
   Application Number 50000.
CR Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Jubb HC, 2017, J MOL BIOL, V429, P365, DOI 10.1016/j.jmb.2016.12.004
   Kawabata T, 2010, PROTEINS, V78, P1195, DOI 10.1002/prot.22639
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   MacGowan S. A., 2020, PREPRINT BIORXIV, DOI [10.1101/2020.05.03.074781, DOI 10.1101/2020.05.03.074781]
   Pandurangan AP, 2017, NUCLEIC ACIDS RES, V45, pW229, DOI 10.1093/nar/gkx439
   Petrovski S, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003709
   Pires D, 2016, SCI REP-UK, V6, DOI 10.1038/srep32247
   Pires DEV, 2020, BIOINFORMATICS, V36, P4200, DOI 10.1093/bioinformatics/btaa480
   Pires DEV, 2014, NUCLEIC ACIDS RES, V42, pW314, DOI 10.1093/nar/gku411
   Pires DEV, 2014, BIOINFORMATICS, V30, P335, DOI 10.1093/bioinformatics/btt691
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Portelli S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33370-6
   Radoux CJ, 2016, J MED CHEM, V59, P4314, DOI 10.1021/acs.jmedchem.5b01980
   Rodrigues CHM, 2019, NUCLEIC ACIDS RES, V47, pW338, DOI 10.1093/nar/gkz383
   Rodrigues CHM, 2018, NUCLEIC ACIDS RES, V46, pW350, DOI 10.1093/nar/gky300
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Silk M, 2019, NUCLEIC ACIDS RES, V47, pW121, DOI 10.1093/nar/gkz457
NR 18
TC 1
Z9 1
U1 3
U2 3
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD OCT
PY 2020
VL 52
IS 10
BP 999
EP 1001
DI 10.1038/s41588-020-0693-3
EA SEP 2020
PG 3
WC Genetics & Heredity
SC Genetics & Heredity
GA NV5GP
UT WOS:000567756100002
PM 32908256
OA Bronze
DA 2021-01-01
ER

PT J
AU Huo, JD
   Zhao, YG
   Ren, JS
   Zhou, DM
   Duyvesteyn, HME
   Ginn, HM
   Carrique, L
   Malinauskas, T
   Ruza, RR
   Shah, PNM
   Tan, TK
   Rijal, P
   Coombes, N
   Bewley, KR
   Tree, JA
   Radecke, J
   Paterson, NG
   Supasa, P
   Mongkolsapaya, J
   Screaton, GR
   Carroll, M
   Townsend, A
   Fry, EE
   Owens, RJ
   Stuart, DI
AF Huo, Jiandong
   Zhao, Yuguang
   Ren, Jingshan
   Zhou, Daming
   Duyvesteyn, Helen M. E.
   Ginn, Helen M.
   Carrique, Loic
   Malinauskas, Tomas
   Ruza, Reinis R.
   Shah, Pranav N. M.
   Tan, Tiong Kit
   Rijal, Pramila
   Coombes, Naomi
   Bewley, Kevin R.
   Tree, Julia A.
   Radecke, Julika
   Paterson, Neil G.
   Supasa, Piyada
   Mongkolsapaya, Juthathip
   Screaton, Gavin R.
   Carroll, Miles
   Townsend, Alain
   Fry, Elizabeth E.
   Owens, Raymond J.
   Stuart, David, I
TI Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike
SO CELL HOST & MICROBE
LA English
DT Article
ID NANOLITRE CRYSTALLIZATION EXPERIMENTS; CRYO-EM STRUCTURE; SARS
   CORONAVIRUS; TRANSIENT EXPRESSION; MONOCLONAL-ANTIBODIES; PROTEIN;
   SYSTEM
AB There are as yet no licensed therapeutics for the COVID-19 pandemic. The causal coronavirus (SARS-CoV-2) binds host cells via a trimeric spike whose receptor binding domain (RBD) recognizes angiotensin-converting enzyme 2, initiating conformational changes that drive membrane fusion. We find that the monoclonal antibody CR3022 binds the RBD tightly, neutralizing SARS-CoV-2, and report the crystal structure at 2.4 angstrom of the Fab/RBD complex. Some crystals are suitable for screening for entry-blocking inhibitors. The highly conserved, structure-stabilizing CR3022 epitope is inaccessible in the prefusion spike, suggesting that CR3022 binding facilitates conversion to the fusion-incompetent post-fusion state. Cryogenic electron microscopy (cryo-EM) analysis confirms that incubation of spike with CR3022 Fab leads to destruction of the prefusion trimer. Presentation of this cryptic epitope in an RBD-based vaccine might advantageously focus immune responses. Binders at this epitope could be useful therapeutically, possibly in synergy with an antibody that blocks receptor attachment.
C1 [Huo, Jiandong; Zhao, Yuguang; Ren, Jingshan; Zhou, Daming; Duyvesteyn, Helen M. E.; Carrique, Loic; Malinauskas, Tomas; Ruza, Reinis R.; Shah, Pranav N. M.; Fry, Elizabeth E.; Owens, Raymond J.; Stuart, David, I] Univ Oxford, Wellcome Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England.
   [Huo, Jiandong; Owens, Raymond J.] Rosalind Franklin Inst, Harwell Campus, Didcot OX11 0FA, Oxon, England.
   [Huo, Jiandong; Owens, Raymond J.] Prot Prod UK, Res Complex Harwell, Harwell Sci & Innovat Campus, Didcot OX11 0FA, Oxon, England.
   [Tan, Tiong Kit; Rijal, Pramila; Townsend, Alain] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford OX3 9DS, England.
   [Coombes, Naomi; Bewley, Kevin R.; Tree, Julia A.; Carroll, Miles] Publ Hlth England, Natl Infect Serv, Salisbury SP4 0JG, Wilts, England.
   [Ginn, Helen M.; Radecke, Julika; Paterson, Neil G.; Stuart, David, I] Diamond Light Source Ltd, Harwell Sci & Innovat Campus, Didcot OX11 0DE, DE, England.
   [Supasa, Piyada; Mongkolsapaya, Juthathip; Screaton, Gavin R.; Carroll, Miles] Univ Oxford, Wellcome Ctr Human Genet, Nuffield Dept Med, Oxford OX3 7BN, England.
   [Mongkolsapaya, Juthathip] Mahidol Univ, Siriraj Hosp, Fac Med, Dengue Hemorrhag Fever Res Unit,Off Res & Dev, Bangkok 73170, Thailand.
   [Stuart, David, I] Instruct ERIC, Oxford House,Pkwy Court,John Smith Dr, Oxford OX4 2JY, England.
   [Rijal, Pramila; Townsend, Alain] Univ Oxford, Chinese Acad Med Sci Oxford Inst, Ctr Translat Immunol, Oxford OX3 7FZ, England.
RP Ren, JS; Stuart, DI (corresponding author), Univ Oxford, Wellcome Ctr Human Genet, Div Struct Biol, Oxford OX3 7BN, England.; Stuart, DI (corresponding author), Diamond Light Source Ltd, Harwell Sci & Innovat Campus, Didcot OX11 0DE, DE, England.; Stuart, DI (corresponding author), Instruct ERIC, Oxford House,Pkwy Court,John Smith Dr, Oxford OX4 2JY, England.
EM ren@strubi.ox.ac.uk; dave@strubi.ox.ac.uk
RI Malinauskas, Tomas/H-3133-2012
OI Malinauskas, Tomas/0000-0002-4847-5529; Carrique,
   Loic/0000-0001-5332-8593; Shah, Pranav NM/0000-0003-1212-904X; Ren,
   Jingshan/0000-0003-4015-1404; Zhao, Yuguang/0000-0001-8916-8552
FU CAMS-Oxford Institute; Wellcome TrustWellcome Trust [101122/Z/13/Z,
   095541/A/11/Z, 090532/Z/09/Z]; Cancer Research UKCancer Research UK
   [C375/A17721, C20724/A14414, C20724/A26752]; UK Medical Research
   CouncilMedical Research Council UK (MRC) [MR/N00065X/1]; EPA
   Cephalosporin Fund; Rosalind Franklin Institute EPSRC grant
   [EP/S025243/1]; Chinese Academy of Medical Sciences (CAMS) Innovation
   Fund for Medical Science (CIFMS) [2018-I2M-2-002]; National Institutes
   for Health Research Biomedical Research Centre Funding Scheme
FX This work was supported by a grant from the CAMS-Oxford Institute to
   D.I.S. E.E.F., H.M.E.D., and J. Ren are supported by the Wellcome Trust
   (101122/Z/13/Z); Y.Z. by Cancer Research UK (C375/A17721); and D.I.S.
   and E.E.F. by the UK Medical Research Council (MR/N00065X/1). J.H. is
   supported by a grant from the EPA Cephalosporin Fund. Protein Production
   UK (PPUK) is funded by the Rosalind Franklin Institute EPSRC grant no.
   EP/S025243/1. The National Institutes for Health Research Biomedical
   Research Centre Funding Scheme supports G.R.S. together with the Chinese
   Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science
   (CIFMS) (grant number: 2018-I2M-2-002), which also supports D.I.S.
   G.R.S. is also supported as a Wellcome Trust Senior Investigator (grant
   095541/A/11/Z). T.M. is supported by Cancer Research UK grants
   C20724/A14414 and C20724/A26752 to Christian Siebold. This is a
   contribution from the UK Instruct-ERIC Centre. The Wellcome Centre for
   Human Genetics is supported by the Wellcome Trust (grant 090532/Z/09/Z).
   The virus used for the neutralization assays was a gift from Julian
   Druce, Doherty Centre, Melbourne, Australia. We acknowledge Diamond
   Light Source for time on Beamline I03 under Proposal mx19946 and for
   electron microscope time at the UK national electron bio-imaging center
   (eBIC), proposal BI26983-2, both COVID-19 Rapid Access. Huge thanks to
   the teams, especially at the Diamond Light Source and Department of
   Structural Biology, Oxford University that have enabled work to continue
   during the pandemic.
CR Aricescu AR, 2006, ACTA CRYSTALLOGR D, V62, P1243, DOI 10.1107/S0907444906029799
   Baud D., 2020, LANCET INFECT DIS
   Caly L, 2020, MED J AUSTRALIA, V212, P459, DOI 10.5694/mja2.50569
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Grist N. R., 1966, DIAGNOSTIC METHODS C
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Johnson RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054092
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lu RM, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-019-0592-z
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Neffleship Joanne E., 2009, V498, P245, DOI 10.1007/978-1-59745-196-3_16
   Nettleship JE, 2008, PROTEIN EXPRES PURIF, V62, P83, DOI 10.1016/j.pep.2008.06.017
   Nettleship JE, 2015, METHODS MOL BIOL, V1258, P209, DOI 10.1007/978-1-4939-2205-5_11
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Perlman S, 2005, NAT REV IMMUNOL, V5, P917, DOI 10.1038/nri1732
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Qiu XG, 2014, NATURE, V514, P47, DOI 10.1038/nature13777
   Rijal P, 2019, CELL REP, V27, P172, DOI 10.1016/j.celrep.2019.03.020
   Roy S., 2020, DYNAMICAL ASYMMETRY, DOI [10.1101/2020.04.20.052290, DOI 10.1101/2020.04.20.052290]
   Salazar G, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0019-3
   Saphire EO, 2018, CELL, V174, P938, DOI 10.1016/j.cell.2018.07.033
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Teplyakov A, 2016, MABS-AUSTIN, V8, P1045, DOI 10.1080/19420862.2016.1190060
   Teplyakov A, 2014, PROTEINS, V82, P1563, DOI 10.1002/prot.24554
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Thomson CA, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00087
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walter TS, 2005, ACTA CRYSTALLOGR D, V61, P651, DOI 10.1107/S0907444905007808
   Walter TS, 2003, J APPL CRYSTALLOGR, V36, P308, DOI 10.1107/S0021889803001997
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Winter G, 2010, J APPL CRYSTALLOGR, V43, P186, DOI 10.1107/S0021889809045701
   Winter G, 2018, ACTA CRYSTALLOGR D, V74, P85, DOI 10.1107/S2059798317017235
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhang K, 2016, J STRUCT BIOL, V193, P1, DOI 10.1016/j.jsb.2015.11.003
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
NR 53
TC 21
Z9 18
U1 13
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1931-3128
EI 1934-6069
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD SEP 9
PY 2020
VL 28
IS 3
BP 445
EP +
DI 10.1016/j.chom.2020.06.010
PG 16
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA NL8GW
UT WOS:000567648000014
PM 32585135
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, N
   Zhan, Y
   Zhu, LY
   Hou, ZB
   Liu, F
   Song, PH
   Qiu, F
   Wang, XL
   Zou, XF
   Wan, DY
   Qian, XS
   Wang, SS
   Guo, YB
   Yu, H
   Cui, M
   Tong, GL
   Xu, YS
   Zheng, ZH
   Lu, YY
   Hong, P
AF Wang, Nan
   Zhan, Yan
   Zhu, Linyu
   Hou, Zhibing
   Liu, Feng
   Song, Pinhong
   Qiu, Feng
   Wang, Xiaolin
   Zou, Xiafei
   Wan, Deyun
   Qian, Xiaosong
   Wang, Shanshan
   Guo, Yabi
   Yu, Hao
   Cui, Miao
   Tong, Gangling
   Xu, Yunsheng
   Zheng, Zhihua
   Lu, Yingying
   Hong, Peng
TI Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is
   Associated with Favorable Clinical Responses in COVID-19 Patients
SO CELL HOST & MICROBE
LA English
DT Article
ID CORONAVIRUS; RIBAVIRIN; PNEUMONIA
AB Interferons (IFNs) are widely used in treating coronavirus disease 2019 (COVID-19) patients. However, a recent report of ACE2, the host factor mediating SARS-Cov-2 infection, identifying it as interferon-stimulated raised considerable safety concern. To examine the association between the use and timing of IFN-alpha 2b and clinical outcomes, we analyzed in a retrospective multicenter cohort study of 446 COVID-19 patients in Hubei, China. Regression models estimated that early administration (<= 5 days after admission) of IFN-alpha 2b was associated with reduced in-hospital mortality in comparison with no admission of IFN-alpha 2b, whereas late administration of IFN-alpha 2b was associated with increased mortality. Among survivors, early IFN-alpha 2b was not associated with hospital discharge or computed tomography (CT) scan improvement, whereas late IFN-alpha 2b was associated with delayed recovery. Additionally, early IFN-alpha 2b and umifenovir alone or together were associated with reduced mortality and accelerated recovery in comparison with treatment with lopinavir/ritonavir (LPV/r) alone. We concluded that administration of IFN-alpha 2b during the early stage of COVID-19 could induce favorable clinical responses.
C1 [Wang, Nan; Xu, Yunsheng; Lu, Yingying; Hong, Peng] Sun Yat Sen Univ SYSU, Dept Res, Hosp 7, Shenzhen 518107, Guangdong, Peoples R China.
   [Zhan, Yan; Wang, Shanshan; Guo, Yabi; Yu, Hao] Xiangyang Cent Hosp, Dept Rehabil Med, Xiangyang 441021, Hubei, Peoples R China.
   [Zhan, Yan] Hubei Univ Arts & Sci, Coll Med, Xiangyang 441053, Hubei, Peoples R China.
   [Zhu, Linyu; Xu, Yunsheng] SYSU, Dept Dermatol, Hosp 7, Shenzhen 518107, Guangdong, Peoples R China.
   [Hou, Zhibing] Xiangyang Cent Blood Stn, Div Qual Control, Xiangyang 441000, Hubei, Peoples R China.
   [Liu, Feng; Song, Pinhong; Qiu, Feng] Suizhou Zengdu Hosp, Dept Infect Dis, Fever Clin, Suizhou 441300, Hubei, Peoples R China.
   [Wang, Xiaolin; Zou, Xiafei] Suizhou Zengdu Hosp, Intens Care Unit, Suizhou 441300, Hubei, Peoples R China.
   [Wan, Deyun; Qian, Xiaosong] Suizhou Zengdu Hosp, Dept Resp Med, Suizhou 441300, Hubei, Peoples R China.
   [Cui, Miao] Mt Sinai St Lukes Roosevelt Hosp Ctr, Dept Pathol, New York, NY 10025 USA.
   [Tong, Gangling] Peking Univ, Dept Oncol, Shenzhen Hosp, Shenzhen 518036, Guangdong, Peoples R China.
   [Zheng, Zhihua] SYSU, Ctr Nephrol & Urol, Dept Nephrol, Hosp 7, Shenzhen 518107, Guangdong, Peoples R China.
   [Lu, Yingying] City Univ Hong Kong, Dept Biomed Sci, Kowloon, Hong Kong, Peoples R China.
   [Hong, Peng] US Dept Vet Affairs New York Harbor Healthcare Sy, Div Res & Dev, Brooklyn, NY 11209 USA.
   [Hong, Peng] State Univ New York Downstate Hlth Sci Univ, Dept Cell Biol, Brooklyn, NY 11203 USA.
RP Hong, P (corresponding author), Sun Yat Sen Univ SYSU, Dept Res, Hosp 7, Shenzhen 518107, Guangdong, Peoples R China.; Hong, P (corresponding author), US Dept Vet Affairs New York Harbor Healthcare Sy, Div Res & Dev, Brooklyn, NY 11209 USA.; Hong, P (corresponding author), State Univ New York Downstate Hlth Sci Univ, Dept Cell Biol, Brooklyn, NY 11203 USA.
EM peng.hong@downstate.edu
OI Hong, Peng/0000-0002-3879-303X; Lu, Yingying/0000-0002-5423-9522
FU US Department of Veterans AffairsUS Department of Veterans Affairs
   [5I01BX001353]; Sun Yat-sen University Seventh Hospital [393003]
FX We thank Drs. Tianhao Su (Beijing Friendship Hospital), Kui Li, Zhengyan
   Wang, and Bo Zou (Suizhou Central Hospital), who did not receive any
   specific compensation for their contributions, for expert opinions on
   clinical findings. This study was supported by US Department of Veterans
   Affairs (5I01BX001353) and Sun Yat-sen University Seventh Hospital
   (393003).
CR Acharya D, 2020, NAT REV IMMUNOL, V20, P397, DOI 10.1038/s41577-020-0346-x
   [Anonymous], 2020, CHIN GUID COVID 19 V
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Cai GJ, 2020, STEEL RES INT, DOI 10.1002/srin.202000269
   Channappanavar R, 2019, J CLIN INVEST, V129, P3625, DOI 10.1172/JCI126363
   Channappanavar R, 2016, CELL HOST MICROBE, V19, P181, DOI 10.1016/j.chom.2016.01.007
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Mantlo E, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104811
   McKechnie JL, 2020, CELL HOST MICROBE, V27, P863, DOI 10.1016/j.chom.2020.05.009
   Nile SH, 2020, CYTOKINE GROWTH F R, V53, P66, DOI 10.1016/j.cytogfr.2020.05.002
   Park A, 2020, CELL HOST MICROBE, V27, P870, DOI 10.1016/j.chom.2020.05.008
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Su S, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0185-z
   Xie Xiangyang, 2020, Antivir Ther, DOI 10.3851/IMP3362
   Zeng YM, 2020, CHINESE MED J-PEKING, V133, P1132, DOI 10.1097/CM9.0000000000000790
   Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Q, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01061
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
   Zuo Y, 2020, J MED VIROL, V92, P2666, DOI 10.1002/jmv.26127
NR 22
TC 14
Z9 14
U1 2
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1931-3128
EI 1934-6069
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD SEP 9
PY 2020
VL 28
IS 3
BP 455
EP +
DI 10.1016/j.chom.2020.07.005
PG 12
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA NL8GW
UT WOS:000567648000015
PM 32707096
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Case, JB
   Rothlauf, PW
   Chen, RE
   Kafai, NM
   Fox, JM
   Smith, BK
   Shrihari, S
   McCune, BT
   Harvey, IB
   Keeler, SP
   Bloyet, LM
   Zhao, HY
   Ma, MS
   Adams, LJ
   Winkler, ES
   Holtzman, MJ
   Fremont, DH
   Whelan, SPJ
   Diamond, MS
AF Case, James Brett
   Rothlauf, Paul W.
   Chen, Rita E.
   Kafai, Natasha M.
   Fox, Julie M.
   Smith, Brittany K.
   Shrihari, Swathi
   McCune, Broc T.
   Harvey, Ian B.
   Keeler, Shamus P.
   Bloyet, Louis-Marie
   Zhao, Haiyan
   Ma, Meisheng
   Adams, Lucas J.
   Winkler, Emma S.
   Holtzman, Michael J.
   Fremont, Daved H.
   Whelan, Sean P. J.
   Diamond, Michael S.
TI Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects
   against SARS-CoV-2-Mediated Pathogenesis in Mice
SO CELL HOST & MICROBE
LA English
DT Article
ID MESSENGER-RNA; RHESUS-MONKEYS; EBOLA; INFECTION; IMMUNOGENICITY;
   GLYCOPROTEIN; EXPRESSION; HAMSTERS; TRIAL; CDNA
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of human infections, and an effective vaccine is critical to mitigate coronavirus-induced disease 2019 (COVID-19). Previously, we developed a replication-competent vesicular stomatitis virus (VSV) expressing a modified form of the SARS-CoV-2 spike gene in place of the native glycoprotein gene (VSV-eGFP-SARS-CoV-2). Here, we show that vaccination with VSV-eGFP-SARS-CoV-2 generates neutralizing immune responses and protects mice from SARS-CoV-2. Immunization of mice with VSV-eGFP-SARS-CoV-2 elicits high antibody titers that neutralize SARS-CoV-2 and target the receptor binding domain that engages human angiotensin-conveiling enzyme-2 (ACE2). Upon challenge with a human isolate of SARS-CoV-2. mice that expressed human ACE2 and were immunized with VSV-eGFP-SARS-CoV-2 show profoundly reduced viral infection and inflammation in the lung, indicating protection against pneumonia. Passive transfer of sera from VSV-eGFP-SARS-CoV-2-immunized animals also protects naive mice from SARS-CoV-2 challenge. These data support development of VSV-SARS-CoV-2 as an attenuated, replication-competent vaccine against SARS-CoV-2.
C1 [Case, James Brett; Chen, Rita E.; Kafai, Natasha M.; Fox, Julie M.; Shrihari, Swathi; McCune, Broc T.; Keeler, Shamus P.; Winkler, Emma S.; Holtzman, Michael J.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Rothlauf, Paul W.; Bloyet, Louis-Marie; Fremont, Daved H.; Whelan, Sean P. J.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   [Chen, Rita E.; Kafai, Natasha M.; Smith, Brittany K.; Harvey, Ian B.; Zhao, Haiyan; Ma, Meisheng; Adams, Lucas J.; Winkler, Emma S.; Fremont, Daved H.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
   [Fremont, Daved H.] Washington Univ, Sch Med, Biochem & Mol Biophys, St Louis, MO USA.
   [Fremont, Daved H.; Diamond, Michael S.] Washington Univ, Sch Med, Andrew M & Jane M Bursky Ctr Human Immunol & Immu, St Louis, MO 63110 USA.
   [Keeler, Shamus P.; Holtzman, Michael J.] Washington Univ, Sch Med, Div Pulm & Crit Care Med, St Louis, MO USA.
   [Rothlauf, Paul W.] Harvard Med Sch, Program Virol, Boston, MA 02115 USA.
RP Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Whelan, SPJ; Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.; Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.; Diamond, MS (corresponding author), Washington Univ, Sch Med, Andrew M & Jane M Bursky Ctr Human Immunol & Immu, St Louis, MO 63110 USA.
EM spjwhelan@wustl.edu; diamond@wusm.wustl.edu
RI Keeler, Shamus/ABC-1774-2020
OI Keeler, Shamus/0000-0002-1301-0852; Adams, Lucas/0000-0002-1724-8120;
   Rothlauf, Paul/0000-0002-0941-4467; Harvey, Ian/0000-0002-5444-8287;
   Kafai, Natasha/0000-0002-3115-3400; Fox, Julie/0000-0003-0567-738X
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [75N93019C00062, HHSN272201700060C, R01
   AI127828, R37 AI059371, U01 AI151810, HR001117S0019, R01 AI130591, R35
   HL145242]; Defense Advanced Research Project AgencyUnited States
   Department of DefenseDefense Advanced Research Projects Agency (DARPA)
   [HR001117S0019]; Washington University Institute of Clinical and
   Translational Sciences from the National Center for Advancing
   Translational Sciences (NCATS) of the National Institutes of Health
   (NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [UL1TR002345]; Helen Hay Whitney
   Foundation postdoctoral fellowship
FX This study was supported by NIH contracts and grants (75N93019C00062,
   HHSN272201700060C and R01 AI127828, R37 AI059371, and U01 AI151810), the
   Defense Advanced Research Project Agency (HR001117S0019), NIH R01
   AI130591 and R35 HL145242, the Washington University Institute of
   Clinical and Translational Sciences grant UL1TR002345 from the National
   Center for Advancing Translational Sciences (NCATS) of the National
   Institutes of Health (NIH), and gifts to Washington University. J.B.C.
   is supported by a Helen Hay Whitney Foundation postdoctoral fellowship.
   We thank Natalie Thornburg for providing the clinical isolate of
   SARS-CoV-2, Ahmed Hassan for amplifying the AdV-hACE2 stocks, James
   Earnest for providing cell culture support, and the Washington
   University School of Medicine Pulmonary Morphology Core. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official view of the NIH. Some of the figures were created
   by using BioRender.com.
CR Alsoussi WB, 2020, J IMMUNOL, V205, P915, DOI 10.4049/jimmunol.2000583
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Ball LA, 1999, J VIROL, V73, P4705, DOI 10.1128/JVI.73.6.4705-4712.1999
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Barouch DH, 2004, J IMMUNOL, V172, P6290, DOI 10.4049/jimmunol.172.10.6290
   Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831
   Brown KS, 2011, J VIROL, V85, P12781, DOI 10.1128/JVI.00794-11
   Buchholz UJ, 1999, J VIROL, V73, P251, DOI 10.1128/JVI.73.1.251-259.1999
   Case J.B., 2020, CELL HOST MICROBE
   Casimiro DR, 2003, J VIROL, V77, P6305, DOI 10.1128/JVI.77.11.6305-6313.2003
   Chandran K, 2005, SCIENCE, V308, P1643, DOI 10.1126/science.1110656
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   CLINE BL, 1976, AM J TROP MED HYG, V25, P875, DOI 10.4269/ajtmh.1976.25.875
   Dutta A, 2016, SCI REP-UK, V6, DOI 10.1038/srep32973
   Fathi A, 2019, HUM VACC IMMUNOTHER, V15, P2269, DOI 10.1080/21645515.2019.1649532
   FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122
   Furuyama W, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-019-0155-z
   Garbutt M, 2004, J VIROL, V78, P5458, DOI 10.1128/JVI.78.10.5458-5465.2004
   Geisbert TW, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000225
   Geisbert TW, 2005, PLOS MED, V2, P537, DOI 10.1371/journal.pmed.0020183
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Gu J, 2007, AM J PATHOL, V170, P1136, DOI 10.2353/ajpath.2007.061088
   Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011
   Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6
   Henao-Restrepo AM, 2015, LANCET, V386, P857, DOI 10.1016/S0140-6736(15)61117-5
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huttner A, 2015, LANCET INFECT DIS, V15, P1156, DOI 10.1016/S1473-3099(15)00154-1
   Imai M, 2020, P NATL ACAD SCI USA, V117, P16587, DOI [10.1073/pnas.2009799117/-/DCSupplemental., 10.1073/pnas.2009799117]
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   Jiang RD, 2020, CELL, V182, P50, DOI 10.1016/j.cell.2020.05.027
   JOHNSON KM, 1966, AM J TROP MED HYG, V15, P244, DOI 10.4269/ajtmh.1966.15.244
   Jones SM, 2005, NAT MED, V11, P786, DOI 10.1038/nm1258
   Kapadia SU, 2008, VIROLOGY, V376, P165, DOI 10.1016/j.virol.2008.03.002
   Kennedy SB, 2017, NEW ENGL J MED, V377, P1438, DOI 10.1056/NEJMoa1614067
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li JR, 2006, P NATL ACAD SCI USA, V103, P8493, DOI 10.1073/pnas.0509821103
   Lichty BD, 2004, TRENDS MOL MED, V10, P210, DOI 10.1016/j.molmed.2004.03.003
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Ma YM, 2014, J VIROL, V88, P2913, DOI 10.1128/JVI.03420-13
   Martinez I, 2003, J VIROL, V77, P8039, DOI 10.1128/JVI.77.14.8039-8047.2003
   McCray PB, 2007, J VIROL, V81, P813, DOI 10.1128/JVI.02012-06
   Mire CE, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001567
   Muik A, 2014, CANCER RES, V74, P3567, DOI 10.1158/0008-5472.CAN-13-3306
   Mukherjee S, 2016, VIROLOGY, V497, P33, DOI 10.1016/j.virol.2016.06.022
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   RABINOWITZ SG, 1981, INFECT IMMUN, V33, P120, DOI 10.1128/IAI.33.1.120-125.1981
   Roberts A, 1999, J VIROL, V73, P3723, DOI 10.1128/JVI.73.5.3723-3732.1999
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Santra S, 2007, J VIROL, V81, P8563, DOI 10.1128/JVI.00744-07
   Sheehan KCF, 2006, J INTERF CYTOK RES, V26, P804, DOI 10.1089/jir.2006.26.804
   Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5
   Stanifer ML, 2011, J VIROL, V85, P8105, DOI 10.1128/JVI.00735-11
   Sun SH, 2020, CELL HOST MICROBE, V28, P124, DOI 10.1016/j.chom.2020.05.020
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   van den Pol AN, 2017, J VIROL, V91, DOI 10.1128/JVI.02154-16
   Wang BY, 2015, MBIO, V6, DOI 10.1128/mBio.00237-15
   Whelan SPJ, 2000, J VIROL, V74, P8268, DOI 10.1128/JVI.74.18.8268-8276.2000
   WHELAN SPJ, 1995, P NATL ACAD SCI USA, V92, P8388, DOI 10.1073/pnas.92.18.8388
   Wollmann G, 2015, J VIROL, V89, P6711, DOI 10.1128/JVI.00709-15
   Xu ZJ, 2020, GEROSCIENCE, DOI 10.1007/s11357-020-00209-w
   Yao Bai Y, 2020, JAMA
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 64
TC 8
Z9 7
U1 2
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1931-3128
EI 1934-6069
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD SEP 9
PY 2020
VL 28
IS 3
BP 465
EP +
DI 10.1016/j.chom.2020.07.018
PG 14
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA NL8GW
UT WOS:000567648000016
PM 32798445
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Case, JB
   Rothlauf, PW
   Chen, RE
   Liu, ZM
   Zhao, HY
   Kim, AS
   Bloyet, LM
   Zeng, QR
   Tahan, S
   Droit, L
   Ilagan, MXG
   Tartell, MA
   Amarasinghe, G
   Henderson, JP
   Miersch, S
   Ustav, M
   Sidhu, S
   Virgin, HW
   Wang, D
   Ding, SY
   Corti, D
   Theel, ES
   Fremont, DH
   Diamond, MS
   Whelan, SPJ
AF Case, James Brett
   Rothlauf, Paul W.
   Chen, Rita E.
   Liu, Zhuoming
   Zhao, Haiyan
   Kim, Arthur S.
   Bloyet, Louis-Marie
   Zeng, Qiru
   Tahan, Stephen
   Droit, Lindsay
   Ilagan, Ma Xenia G.
   Tartell, Michael A.
   Amarasinghe, Gaya
   Henderson, Jeffrey P.
   Miersch, Shane
   Ustav, Mart
   Sidhu, Sachdev
   Virgin, Herbert W.
   Wang, David
   Ding, Siyuan
   Corti, Davide
   Theel, Elitza S.
   Fremont, Daved H.
   Diamond, Michael S.
   Whelan, Sean P. J.
TI Neutralizing Antibody and Soluble ACE2 Inhibition of a
   Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of
   SARS-CoV-2
SO CELL HOST & MICROBE
LA English
DT Article
ID EBOLA-VIRUS GLYCOPROTEIN; FUNCTIONAL RECEPTOR; SARS CORONAVIRUS; ENTRY
   REQUIRES; STOMATITIS; CELLS; ALIGNMENT; ENVELOPE; DOMAIN; ASSAY
AB Antibody-based interventions against SARS-CoV-2 could limit morbidity, mortality, and possibly transmission. An anticipated correlate of such countermeasures is the level of neutralizing antibodies against the SARS-CoV-2 spike protein, which engages with host ACE2 receptor for entry. Using an infectious molecular clone of vesicular stomatitis virus (VSV) expressing eGFP as a marker of infection, we replaced the glycoprotein gene (G) with the spike protein of SARS-CoV-2 (VSV-eGFP-SARS-CoV-2) and developed a high-throughput-imaging-based neutralization assay at biosafety level 2. We also developed a focus-reduction neutralization test with a clinical isolate of SARS-CoV-2 at biosafety level 3. Comparing the neutralizing activities of various antibodies and ACE2-Fc soluble decoy protein in both assays revealed a high degree of concordance. These assays will help define correlates of protection for antibody-based countermeasures and vaccines against SARS-CoV-2. Additionally, replication-competent VSV-eGFP-SARS-CoV-2 provides a tool for testing inhibitors of SARS-CoV-2 mediated entry under reduced biosafety containment.
C1 [Case, James Brett; Chen, Rita E.; Kim, Arthur S.; Henderson, Jeffrey P.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Rothlauf, Paul W.; Liu, Zhuoming; Bloyet, Louis-Marie; Zeng, Qiru; Tahan, Stephen; Droit, Lindsay; Tartell, Michael A.; Amarasinghe, Gaya; Wang, David; Ding, Siyuan; Fremont, Daved H.; Diamond, Michael S.; Whelan, Sean P. J.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   [Chen, Rita E.; Zhao, Haiyan; Kim, Arthur S.; Amarasinghe, Gaya; Wang, David; Fremont, Daved H.; Diamond, Michael S.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
   [Ilagan, Ma Xenia G.; Amarasinghe, Gaya; Fremont, Daved H.] Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.
   [Fremont, Daved H.; Diamond, Michael S.] Washington Univ, Andrew M & Jane M Bursky Ctr Human Immunol & Immu, Sch Med, St Louis, MO 63110 USA.
   [Rothlauf, Paul W.; Tartell, Michael A.] Harvard Med Sch, Program Virol, Boston, MA 02115 USA.
   [Miersch, Shane; Ustav, Mart; Sidhu, Sachdev] Univ Toronto, Donnelly Ctr, Toronto, ON, Canada.
   [Virgin, Herbert W.] Vir Biotechnol, San Francisco, CA USA.
   [Corti, Davide] Humabs BioMed SA, CH-6500 Bellinzona, Switzerland.
   [Theel, Elitza S.] Mayo Clin, Div Clin Microbiol, Dept Lab Med & Pathol, Rochester, MN USA.
RP Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.; Diamond, MS; Whelan, SPJ (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.; Diamond, MS (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.; Diamond, MS (corresponding author), Washington Univ, Andrew M & Jane M Bursky Ctr Human Immunol & Immu, Sch Med, St Louis, MO 63110 USA.
EM diamond@wusm.wustl.edu; spjwhelan@wustl.edu
OI Rothlauf, Paul/0000-0002-0941-4467; Virgin, Herbert/0000-0001-8580-7628;
   Liu, Zhuoming/0000-0001-8198-0976; Tahan, Stephen/0000-0002-5895-8698;
   Tartell, Michael/0000-0002-4518-4187; Kim, Arthur/0000-0003-4101-6642
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [75N93019C00062, HHSN272201700060C, R01
   AI127828, R37 AI059371, U01 AI151810]; Defense Advanced Research Project
   AgencyUnited States Department of DefenseDefense Advanced Research
   Projects Agency (DARPA) [HR001117S0019]; Helen Hay Whitney Foundation
   postdoctoral fellowship
FX This study was supported by NIH contracts and grants (75N93019C00062,
   HHSN272201700060C, R01 AI127828, R37 AI059371, and U01 AI151810), the
   Defense Advanced Research Project Agency (HR001117S0019), and gifts from
   Washington University in Saint Louis. J.B.C. is supported by a Helen Hay
   Whitney Foundation postdoctoral fellowship. We thank Natalie Thornburg
   for providing the clinical isolate of SARS-CoV-2, James Rini for
   providing RBD used to detect phage display mAbs, Jan Carette for
   providing A549 and H1Hela cells, Harry Greenberg for providing Huh7.5.1
   and MA104 cells, and Stanley Perlman for providing Calu-3 cells. We also
   thank Wandy Beatty and the Molecular Microbiology Imaging Facility at
   the Washington University School of Medicine for taking the electron
   microscopy pictures. Some of the figures were created using
   BioRender.com.
CR Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Bankevich A, 2012, J COMPUT BIOL, V19, P455, DOI 10.1089/cmb.2012.0021
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Brown KS, 2011, J VIROL, V85, P12781, DOI 10.1128/JVI.00794-11
   Buchholz UJ, 1999, J VIROL, V73, P251, DOI 10.1128/JVI.73.1.251-259.1999
   Bushnell B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185056
   Carette JE, 2011, NATURE, V477, P340, DOI 10.1038/nature10348
   Chandran K, 2005, SCIENCE, V308, P1643, DOI 10.1126/science.1110656
   Chen J, 2015, SCIENCE, V349, P191, DOI 10.1126/science.aaa9804
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen SF, 2018, BIOINFORMATICS, V34, P884, DOI 10.1093/bioinformatics/bty560
   Delcher AL, 2002, NUCLEIC ACIDS RES, V30, P2478, DOI 10.1093/nar/30.11.2478
   Denison MR, 2011, RNA BIOL, V8, P270, DOI 10.4161/rna.8.2.15013
   Dieterle ME, 2020, CELL HOST MICROBE, V28, P486, DOI 10.1016/j.chom.2020.06.020
   FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122
   Fukushi S, 2005, J GEN VIROL, V86, P2269, DOI 10.1099/vir.0.80955-0
   Fukushi S, 2006, J MED VIROL, V78, P1509, DOI 10.1002/jmv.20732
   Furuyama W, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-019-0155-z
   Garbutt M, 2004, J VIROL, V78, P5458, DOI 10.1128/JVI.78.10.5458-5465.2004
   Geisbert TW, 2005, PLOS MED, V2, P537, DOI 10.1371/journal.pmed.0020183
   Giroglou T, 2004, J VIROL, V78, P9007, DOI 10.1128/JVI.78.17.9007-9015.2004
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jae LT, 2014, SCIENCE, V344, P1506, DOI 10.1126/science.1252480
   Jones SM, 2005, NAT MED, V11, P786, DOI 10.1038/nm1258
   Kobinger GP, 2007, HUM GENE THER, V18, P413, DOI 10.1089/hum.2006.194
   Kruse Robert L, 2020, F1000Res, V9, P72, DOI 10.12688/f1000research.22211.2
   Lei CH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16048-4
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li JR, 2006, P NATL ACAD SCI USA, V103, P8493, DOI 10.1073/pnas.0509821103
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lontok E, 2004, J VIROL, V78, P5913, DOI 10.1128/JVI.78.11.5913-5922.2004
   McBride CE, 2007, J VIROL, V81, P2418, DOI 10.1128/JVI.02146-06
   Miersch S., 2020, SYNTHETIC ANTIBODIES, DOI [10.1101/2020.06.05.137349, DOI 10.1101/2020.06.05.137349]
   Moore MJ, 2004, J VIROL, V78, P10628, DOI 10.1128/JVI.78.19.10628-10635.2004
   Mukherjee S, 2016, VIROLOGY, V497, P33, DOI 10.1016/j.virol.2016.06.022
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Persson H, 2013, J MOL BIOL, V425, P803, DOI 10.1016/j.jmb.2012.11.037
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Ruch TR, 2012, VIRUSES-BASEL, V4, P363, DOI 10.3390/v4030363
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Stanifer ML, 2011, J VIROL, V85, P8105, DOI 10.1128/JVI.00735-11
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Takada A, 2003, J VIROL, V77, P1069, DOI 10.1128/JVI.77.2.1069-1074.2003
   Tao Y, 2019, ELIFE, V8, DOI 10.7554/eLife.46134
   ter Meulen J, 2006, PLOS MED, V3, P1071, DOI 10.1371/journal.pmed.0030237
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   van den Pol AN, 2017, J VIROL, V91, DOI 10.1128/JVI.02154-16
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Watanabe Y., 2020, SCIENCE
   WHELAN SPJ, 1995, P NATL ACAD SCI USA, V92, P8388, DOI 10.1073/pnas.92.18.8388
   Wrapp D., 2020, SCIENCE
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 61
TC 5
Z9 5
U1 3
U2 3
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1931-3128
EI 1934-6069
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD SEP 9
PY 2020
VL 28
IS 3
BP 475
EP +
DI 10.1016/j.chom.2020.06.021
PG 16
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA NL8GW
UT WOS:000567648000017
PM 32735849
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Dieterle, ME
   Haslwanter, D
   Bortz, RH
   Wirchnianski, AS
   Lasso, G
   Vergnolle, O
   Abbasi, SA
   Fels, JM
   Laudermilch, E
   Florez, C
   Mengotto, A
   Kimmel, D
   Malonis, RJ
   Georgiev, G
   Quiroz, J
   Barnhill, J
   Pirofski, LA
   Daily, JP
   Dye, JM
   Lai, JR
   Herbert, AS
   Chandran, K
   Jangra, RK
AF Dieterle, M. Eugenia
   Haslwanter, Denise
   Bortz, Robert H., III
   Wirchnianski, Ariel S.
   Lasso, Gorka
   Vergnolle, Olivia
   Abbasi, Shawn A.
   Fels, J. Maximilian
   Laudermilch, Ethan
   Florez, Catalina
   Mengotto, Amanda
   Kimmel, Duncan
   Malonis, Ryan J.
   Georgiev, George
   Quiroz, Jose
   Barnhill, Jason
   Pirofski, Liise-anne
   Daily, Johanna P.
   Dye, John M.
   Lai, Jonathan R.
   Herbert, Andrew S.
   Chandran, Kartik
   Jangra, Rohit K.
TI A Replication-Competent Vesicular Stomatitis Virus for Studies of
   SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition
SO CELL HOST & MICROBE
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; NEUTRALIZING ANTIBODY; RETRIEVAL
   SIGNAL; INFLUENZA-VIRUS; PROTEIN; SARS; INFECTION; EXPRESSION;
   RESPONSES; POTENT
AB There is an urgent need for vaccines and therapeutics to prevent and treat COVID-19, Rapid SARS-CoV-2 countermeasure development is contingent on the availability of robust, scalable, and readily deployable surrogate viral assays to screen antiviral humoral responses, define correlates of immune protection, and down-select candidate antivirals. Here, we generate a highly infectious recombinant vesicular stomatitis virus (VSV) bearing the SARS-CoV-2 spike glycoprotein S as its sole entry glycoprotein and show that this recombinant virus, rVSV-SARS-CoV-2 S, closely resembles SARS-CoV-2 in its entry-related properties. The neutralizing activities of a large panel of COVID-19 convalescent sera can be assessed in a high-throughput fluorescent reporter assay with rVSV-SARS-CoV-2 S, and neutralization of rVSV-SARS-CoV-2 S and authentic SARS-CoV-2 by spike-specific antibodies in these antisera is highly correlated. Our findings underscore the utility of rVSV-SARS-CoV-2 S for the development of spike-specific therapeutics and for mechanistic studies of viral entry and its inhibition.
C1 [Dieterle, M. Eugenia; Haslwanter, Denise; Bortz, Robert H., III; Wirchnianski, Ariel S.; Lasso, Gorka; Fels, J. Maximilian; Laudermilch, Ethan; Florez, Catalina; Pirofski, Liise-anne; Daily, Johanna P.; Chandran, Kartik; Jangra, Rohit K.] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA.
   [Wirchnianski, Ariel S.; Vergnolle, Olivia; Malonis, Ryan J.; Georgiev, George; Lai, Jonathan R.] Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA.
   [Abbasi, Shawn A.; Dye, John M.; Herbert, Andrew S.] US Army Med Res Inst Infect Dis, Frederick, MD 21702 USA.
   [Florez, Catalina; Barnhill, Jason] US Mil Acad, Dept Chem & Life Sci, West Point, NY 10996 USA.
   [Mengotto, Amanda; Kimmel, Duncan; Quiroz, Jose; Pirofski, Liise-anne; Daily, Johanna P.] Albert Einstein Coll Med, Dept Med, Div Infect Dis, Bronx, NY 10461 USA.
   [Mengotto, Amanda; Kimmel, Duncan; Quiroz, Jose; Pirofski, Liise-anne; Daily, Johanna P.] Montefiore Med Ctr, Bronx, NY 10461 USA.
   [Herbert, Andrew S.] Geneva Fdn, 917 Pacific Ave, Tacoma, WA 98402 USA.
RP Chandran, K; Jangra, RK (corresponding author), Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA.; Herbert, AS (corresponding author), US Army Med Res Inst Infect Dis, Frederick, MD 21702 USA.; Herbert, AS (corresponding author), Geneva Fdn, 917 Pacific Ave, Tacoma, WA 98402 USA.
EM andrew.s.herbert4.ctr@mail.mil; kartik.chandran@einsteinmed.org;
   rohit.jangra@einsteinmed.org
RI Cabrera, Gorka Lasso/ABD-1962-2020
OI Cabrera, Gorka Lasso/0000-0001-5355-323X; Florez,
   Catalina/0000-0002-0407-861X; Haslwanter, Denise/0000-0003-2727-0468
FU National Institutes of Health (NIH)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [U19AI142777,
   R01AI132633, R01AI143453, R01AI123654, R01AI125462, R21AI141367]; Pew
   Charitable Trusts; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [2T32GM007288-45]
FX We thank I. Gutierrez, E. Valencia, L. Polanco, and S. Diaz for
   laboratory management and technical support. We thank J. McLellan for
   his generous gifts of wild-type and recombinant SARS-CoV-2 spike
   constructs. We also thank F. Krammer, H. Choe, and R. Reeves for their
   generous gifts of SARS-CoV-2 RBD, hACE2, and TMPRSS2 constructs,
   respectively. We are grateful to J. Carette for his generous gift of
   Huh-7.5.1 cells and to S. Anthony, E. Choi, B. Gomperts, B. Maniccasamy,
   K. Stapleford, and C. Sen for their generous gifts of airway epithelial
   cell lines. This work was supported in part by National Institutes of
   Health (NIH) grants U19AI142777 and R01AI132633 (to K.C.), R01AI143453
   and R01AI123654 (to L.P.), R01AI125462 (to J.R.L.) and R21AI141367 (to
   J.P.D). M.E.D. is a Latin American Fellow in the Biomedical Sciences,
   supported by the Pew Charitable Trusts. R.H.B. and R.J.M. were partially
   supported by NIH training grant 2T32GM007288-45 (Medical Scientist
   Training Program) at Albert Einstein College of Medicine. Opinions,
   conclusions, interpretations, and recommendations are those of the
   authors and are not necessarily endorsed by the U.S. Army. The mention
   of trade names or commercial products does not constitute endorsement or
   recommendation for use by the Department of the Army or the Department
   of Defense.
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Bestle D., 2020, BIORXIV, DOI [10.1101/2020.04.15.042085, DOI 10.1101/2020.04.15.042085]
   Bottcher-Friebertshauser E, 2014, CURR TOP MICROBIOL, V385, P3, DOI 10.1007/82_2014_384
   Bottcher-Friebertshauser E, 2010, J VIROL, V84, P5605, DOI 10.1128/JVI.00140-10
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Cai YY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00856
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Case J.B., 2020, CELL HOST MICROBE
   Chaipan C, 2009, J VIROL, V83, P3200, DOI 10.1128/JVI.02205-08
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Choi SY, 2009, TRENDS MOL MED, V15, P303, DOI 10.1016/j.molmed.2009.05.003
   Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Fukushi S, 2005, J GEN VIROL, V86, P2269, DOI 10.1099/vir.0.80955-0
   Fukushi S, 2006, J MED VIROL, V78, P1509, DOI 10.1002/jmv.20732
   Harcourt J, 2020, EMERG INFECT DIS, V26, P1266, DOI 10.3201/eid2606.200516
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Hui K.P.Y., 2020, LANCET RESP MED
   Jae LT, 2013, SCIENCE, V340, P479, DOI 10.1126/science.1233675
   Jangra RK, 2018, NATURE, V563, P559, DOI 10.1038/s41586-018-0702-1
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   Kapadia SU, 2008, VIROLOGY, V376, P165, DOI 10.1016/j.virol.2008.03.002
   Kapadia SU, 2005, VIROLOGY, V340, P174, DOI 10.1016/j.virol.2005.06.016
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Kleinfelter LM, 2015, MBIO, V6, DOI 10.1128/mBio.00801-15
   Lei CH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16048-4
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Limburg H, 2019, J VIROL, V93, DOI 10.1128/JVI.00649-19
   Liu RQ, 2018, ANTIVIR RES, V150, P30, DOI 10.1016/j.antiviral.2017.12.007
   Maier KE, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.32
   McBride CE, 2007, J VIROL, V81, P2418, DOI 10.1128/JVI.02146-06
   MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587
   Mossel EC, 2005, J VIROL, V79, P3846, DOI 10.1128/JVI.79.6.3846-3850.2005
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Nimishakavi S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141169
   NYU Langone Health/Albert Einstein College of Medicine, 2020, CONV PLASM LIM COVID
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Pu T, 2020, J MED VIROL, V92, P1609, DOI 10.1002/jmv.25865
   Raaben M, 2017, CELL HOST MICROBE, V22, P688, DOI 10.1016/j.chom.2017.10.002
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Shen LW, 2017, BIOCHIMIE, V142, P1, DOI 10.1016/j.biochi.2017.07.016
   Slough MM, 2019, MBIO, V10, DOI 10.1128/mBio.02372-18
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803
   Tan C.W., 2020, SARS COV 2 SURROGATE, DOI [10.1002/jmv.25865, DOI 10.1002/JMV.25865]
   Ujike M, 2016, J GEN VIROL, V97, P1853, DOI 10.1099/jgv.0.000494
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424
   WHELAN SPJ, 1995, P NATL ACAD SCI USA, V92, P8388, DOI 10.1073/pnas.92.18.8388
   WHO, 2020, 147 WHO
   Witko SE, 2006, J VIROL METHODS, V135, P91, DOI 10.1016/j.jviromet.2006.02.006
   Wong AC, 2010, J VIROL, V84, P163, DOI 10.1128/JVI.01832-09
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Xiong H-L, 2020, BIORXIV, DOI [10.1101/2020.04.08.026948, DOI 10.1101/2020.04.08.026948]
   Yang X., 2020, IDENTIFICATION SUPER, DOI [10.1101/2020.04.19, DOI 10.1101/2020.04.19]
   Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zost Seth J, 2020, bioRxiv, DOI 10.1101/2020.05.12.091462
NR 69
TC 7
Z9 7
U1 7
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1931-3128
EI 1934-6069
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD SEP 9
PY 2020
VL 28
IS 3
BP 486
EP +
DI 10.1016/j.chom.2020.06.020
PG 17
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA NL8GW
UT WOS:000567648000018
PM 32738193
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Catala, A
   Galvan-Casas, C
   Carretero-Hernandez, G
   Rodriguez-Jimenez, P
   Fernandez-Nieto, D
   Rodriguez-Villa, A
   Navarro-Fernandez, I
   Ruiz-Villaverde, R
   Falkenhain-Lopez, D
   Llamas-Velasco, M
   Carnero-Gonzalez, L
   Garcia-Gavin, J
   Baniandres, O
   Gonzalez-Cruz, C
   Morillas-Lahuerta, V
   Cubiro, X
   Figueras, I
   Selda-Enriquez, G
   Fusta-Novell, X
   Roncero-Riesco, M
   Burgos-Blasco, P
   Romani, J
   Sola-Ortigosa, J
   Garcia-Doval, I
AF Catala, Alba
   Galvan-Casas, Cristina
   Carretero-Hernandez, Gregorio
   Rodriguez-Jimenez, Pedro
   Fernandez-Nieto, Daniel
   Rodriguez-Villa, Ana
   Navarro-Fernandez, Inigo
   Ruiz-Villaverde, Ricardo
   Falkenhain-Lopez, Daniel
   Llamas-Velasco, Mar
   Carnero-Gonzalez, Lucia
   Garcia-Gavin, Juan
   Baniandres, Ofelia
   Gonzalez-Cruz, Carlos
   Morillas-Lahuerta, Victor
   Cubiro, Xavier
   Figueras, Ignasi
   Selda-Enriquez, Gerald
   Fusta-Novell, Xavier
   Roncero-Riesco, Monica
   Burgos-Blasco, Patricia
   Romani, Jorge
   Sola-Ortigosa, Joaquim
   Garcia-Doval, Ignacio
TI Maculopapular eruptions associated toCOVID-19: A subanalysis of
   theCOVID-Pielstudy
SO DERMATOLOGIC THERAPY
LA English
DT Article; Early Access
DE coronavirus; COVID-19; cutaneous manifestations; skin
ID RASH; COVID-19
AB A previous study has defined the maculopapular subtype of manifestations of COVID-19. The objective of our study was to describe and classify maculopapular eruptions associated with COVI-19. We carried out a subanalysis of the maculopapular cases found in the previous cross-sectional study. Using a consensus, we defined seven clinical patterns. We described patient demographics, the therapy received by the patient and the characteristics of each pattern. Consensus lead to the description of seven major maculopapular patterns: morbilliform (45.5%), other maculopapular (20.0%), purpuric (14.2%), erythema multiforme-like (9.7%), pytiriasis rosea-like (5.7%), erythema elevatum diutinum-like (2.3%), and perifollicular (2.3%). In most cases, maculopapular eruptions were coincident (61.9%) or subsequent (34.1%) to the onset of other COVID-19 manifestations. The most frequent were cough (76%), dyspnea (72%), fever (88%), and astenia (62%). Hospital admission due to pneumonia was frequent (61%). Drug intake was frequent (78%). Laboratory alterations associated with maculo-papular eruptions were high C-reactive protein, high D-Dimer, lymphopenia, high ferritin, high LDH, and high IL-6. The main limitation of our study was the impossibility to define the cause-effect relationship of each pattern. In conclusion, we provide a description of the cutaneous maculopapular manifestations associated with COVID-19. The cutaneous manifestations of COVID-19 are wide-ranging and can mimic other dermatoses.
C1 [Catala, Alba] Hosp Plato, Barcelona, Spain.
   [Galvan-Casas, Cristina] Hosp Univ Mostoles, Madrid, Spain.
   [Carretero-Hernandez, Gregorio] Hosp Univ Gran Canaria Dr Negrin, Las Palmas Gran Canaria, Spain.
   [Rodriguez-Jimenez, Pedro; Llamas-Velasco, Mar] Hosp Univ Princesa, Madrid, Spain.
   [Fernandez-Nieto, Daniel; Selda-Enriquez, Gerald; Burgos-Blasco, Patricia] Hosp Univ Ramon y Cajal, Madrid, Spain.
   [Rodriguez-Villa, Ana] Hosp Univ Principe Asturias, Madrid, Spain.
   [Navarro-Fernandez, Inigo] Hosp Univ Marques de Valdecilla, Santander, Spain.
   [Ruiz-Villaverde, Ricardo] Hosp Univ Clin San Cecilio, Granada, Spain.
   [Falkenhain-Lopez, Daniel] Hosp Univ 12 Octubre, Madrid, Spain.
   [Carnero-Gonzalez, Lucia] HUA Santiago, Vitoria, Spain.
   [Garcia-Gavin, Juan] Gavin Dermatologos, Vigo, Spain.
   [Baniandres, Ofelia] Hosp Gen Univ Gregorio Maranon, Madrid, Spain.
   [Gonzalez-Cruz, Carlos] Hosp Univ Vall dHebron, Barcelona, Spain.
   [Morillas-Lahuerta, Victor] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain.
   [Cubiro, Xavier] Hosp Santa Creu & Sant Pau, Barcelona, Spain.
   [Figueras, Ignasi] Hosp Univ Bellvitge, Barcelona, Spain.
   [Fusta-Novell, Xavier] Xarxa Assistencial Univ Manresa, Althaia, Barcelona, Spain.
   [Roncero-Riesco, Monica] Complejo Asistencial Univ Salamanca, Salamanca, Spain.
   [Romani, Jorge] Sabadell, Consorci Sanitari Parc Tauli, Barcelona, Spain.
   [Sola-Ortigosa, Joaquim] Hosp Gen Granollers, Barcelona, Spain.
   [Garcia-Doval, Ignacio] Fdn Piel Sana Acad Espanola Dermatol & Venereol, Res Unit, Madrid, Spain.
RP Catala, A (corresponding author), Acad Espanola Dermatol & Venereol, C Ferraz 100, Madrid 28008, Spain.
EM alba.catala@hospitalplato.com
RI Garcia-Doval, Ignacio/A-3703-2009; Romani, Jorge/AAE-3312-2020;
   Ruiz-Villaverde, Ricardo/F-5007-2016
OI Garcia-Doval, Ignacio/0000-0002-6881-5260; Romani,
   Jorge/0000-0002-6134-5155; Ruiz-Villaverde, Ricardo/0000-0002-0381-6174;
   Navarro-Fernandez, Inigo/0000-0001-7599-3949; Fernandez-Nieto,
   Diego/0000-0003-4461-1770; RODRIGUEZ-VILLA LARIO,
   ANA/0000-0001-6156-4115; Romani, Jorge/0000-0002-5161-5078;
   Morillas-Lahuerta, Victor/0000-0003-3281-7309
CR Ahouach B, 2020, BRIT J DERMATOL, V183, pE31, DOI 10.1111/bjd.19168
   Moreno RA, 2020, J EUR ACAD DERMATOL, V34, pE307, DOI 10.1111/jdv.16531
   Castelnovo L, 2020, J EUR ACAD DERMATOL, V34, pE362, DOI 10.1111/jdv.16589
   Diaz-Guimaraens Borja, 2020, JAMA Dermatol, V156, P820, DOI 10.1001/jamadermatol.2020.1741
   Ehsani AH, 2020, J EUR ACAD DERMATOL, V34, pE436, DOI 10.1111/jdv.16579
   Elmas OF, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13696
   Fernandez-Nieto D, 2020, J AM ACAD DERMATOL, V83, pE61, DOI 10.1016/j.jaad.2020.04.093
   Casas CG, 2020, BRIT J DERMATOL, V183, P71, DOI 10.1111/bjd.19163
   Gaspari V, 2020, J EUR ACAD DERMATOL, V34, pE552, DOI 10.1111/jdv.16693
   Gianotti Raffaele, 2020, Acta Derm Venereol, V100, padv00124, DOI 10.2340/00015555-3490
   Grandolfo M, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13499
   Harel L, 2002, CLIN INFECT DIS, V35, P1558, DOI 10.1086/344773
   Herrero-Moyano M, 2020, J EUR ACAD DERMATOL, V34, pE460, DOI 10.1111/jdv.16631
   Hunt Madison, 2020, Clin Pract Cases Emerg Med, V4, P219, DOI 10.5811/cpcem.2020.3.47349
   Jimenez-Cauhe J, 2020, CLIN EXP DERMATOL, V45, P892, DOI 10.1111/ced.14281
   Joob B, 2020, J AM ACAD DERMATOL, V82, pE177, DOI 10.1016/j.jaad.2020.03.036
   Lopez DF, 2020, MED CLIN-BARCELONA, V155, P92, DOI 10.1016/j.medcli.2020.04.003
   Macedo-Perez M, 2020, INT J DERMATOL, V59, P872, DOI 10.1111/ijd.14958
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Mahe A, 2020, J EUR ACAD DERMATOL, V34, pE246, DOI 10.1111/jdv.16471
   Marzano AV, 2020, BRIT J DERMATOL, V183, P431, DOI 10.1111/bjd.19264
   Mayor-Ibarguren A, 2020, J EUR ACAD DERMATOL, V34, pE541, DOI 10.1111/jdv.16670
   Najarian David James, 2020, JAAD Case Rep, V6, P493, DOI 10.1016/j.jdcr.2020.04.015
   Petrosino MI, 2016, ARCH MED SCI, V12, P684, DOI 10.5114/aoms.2016.59943
   Reymundo A, 2020, J EUR ACAD DERMATOL, DOI 10.1111/jdv.16707
   Rivera-Oyola Ryan, 2020, JAAD Case Rep, V6, P537, DOI 10.1016/j.jdcr.2020.04.027
   Rodriguez-Jimenez P, 2020, J EUR ACAD DERMATOL, V34, pE459, DOI 10.1111/jdv.16618
   Romani J, 2020, ACTAS DERMO-SIFILOGR, V111, P426, DOI 10.1016/j.ad.2020.04.002
   Sanchez A, 2020, JAMA DERMATOL, V156, P819, DOI 10.1001/jamadermatol.2020.1704
   Suchonwanit P, 2020, J AM ACAD DERMATOL, V83, pE57, DOI 10.1016/j.jaad.2020.04.094
   Taskin B, 2020, J EUR ACAD DERMATOL, V34, pE534, DOI 10.1111/jdv.16662
   Torrelo A, 2020, PEDIATR DERMATOL, V37, P442, DOI 10.1111/pde.14246
   Velavan TP, 2020, INT J INFECT DIS, V95, P304, DOI 10.1016/j.ijid.2020.04.061
   Zulfiqar AA, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2010472
NR 34
TC 3
Z9 3
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
AR e14170
DI 10.1111/dth.14170
EA SEP 2020
PG 10
WC Dermatology
SC Dermatology
GA NL4RT
UT WOS:000567405800001
PM 32779280
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Justice, JN
   Gubbi, S
   Kulkarni, AS
   Bartley, JM
   Kuchel, GA
   Barzilai, N
AF Justice, Jamie N.
   Gubbi, Sriram
   Kulkarni, Ameya S.
   Bartley, Jenna M.
   Kuchel, George A.
   Barzilai, Nir
TI A geroscience perspective on immune resilience and infectious diseases:
   a potential case for metformin
SO GEROSCIENCE
LA English
DT Article; Early Access
DE Metformin; Aging; Geroscience; Immunity; COVID-19
ID CHRONIC HEPATITIS-C; T-HELPER 17; DNA-DAMAGE; HEPATOCELLULAR-CARCINOMA;
   DIABETES-MELLITUS; MAMMALIAN TARGET; GUT MICROBIOTA; LIFE-SPAN; AMPK;
   MORTALITY
AB We are in the midst of the global pandemic. Though acute respiratory coronavirus (SARS-COV2) that leads to COVID-19 infects people of all ages, severe symptoms and mortality occur disproportionately in older adults. Geroscience interventions that target biological aging could decrease risk across multiple age-related diseases and improve outcomes in response to infectious disease. This offers hope for a new host-directed therapeutic approach that could (i) improve outcomes following exposure or shorten treatment regimens; (ii) reduce the chronic pathology associated with the infectious disease and subsequent comorbidity, frailty, and disability; and (iii) promote development of immunological memory that protects against relapse or improves response to vaccination. We review the possibility of this approach by examining available evidence in metformin: a generic drug with a proven safety record that will be used in a large-scale multicenter clinical trial. Though rigorous translational research and clinical trials are needed to test this empirically, metformin may improve host immune defenses and confer protection against long-term health consequences of infectious disease, age-related chronic diseases, and geriatric syndromes.
C1 [Justice, Jamie N.] Wake Forest Sch Med, Sticht Ctr Hlth Aging & Alzheimers Prevent Intern, Med Ctr Blvd, Winston Salem, NC 27157 USA.
   [Gubbi, Sriram] NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20814 USA.
   [Kulkarni, Ameya S.; Barzilai, Nir] Albert Einstein Coll Med, Dept Med, Div Endocrinol, Bronx, NY 10461 USA.
   [Kulkarni, Ameya S.; Barzilai, Nir] Albert Einstein Coll Med, Inst Aging Res, Bronx, NY 10461 USA.
   [Bartley, Jenna M.; Kuchel, George A.] Univ Connecticut, Sch Med, Ctr Aging, Farmington, CT 06030 USA.
   [Bartley, Jenna M.] Univ Connecticut, Sch Med, Dept Immunol, Farmington, CT 06030 USA.
RP Justice, JN (corresponding author), Wake Forest Sch Med, Sticht Ctr Hlth Aging & Alzheimers Prevent Intern, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM jnjustic@wakehealth.edu
RI Gubbi, Sriram/AAL-6801-2020
OI Gubbi, Sriram/0000-0002-9263-1381; Kulkarni, Ameya/0000-0003-4495-8838;
   JUSTICE, JAMIE/0000-0003-2953-4404
FU American Federation of Aging Research; Glenn Center for the Biology of
   Human Aging; National Institutes of Health (NIH)United States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA [K01
   AG059837, P30 AG021332, R33 AG061456, R21 AG063528, R56 AG060746, R35
   GM124922, U01 AI124297, R21 AG060018, R01 AG058814, R01 AI142086, UH3
   AG056925, P30AG038072]
FX The authors acknowledge the support by the American Federation of Aging
   Research (JMB, Irene Diamond AFAR award), the Glenn Center for the
   Biology of Human Aging (NB), and the National Institutes of Health
   (NIH): JNJ (K01 AG059837, P30 AG021332); GAK (R33 AG061456, R21
   AG063528, R56 AG060746, R35 GM124922, U01 AI124297, R21 AG060018, R01
   AG058814, R01 AI142086, UH3 AG056925); NB (P30AG038072).Data
   availabilityNot applicable.
CR Aatsinki SM, 2014, BRIT J PHARMACOL, V171, P2351, DOI 10.1111/bph.12585
   Agarwal D, 2018, IMMUN AGEING, V15, DOI 10.1186/s12979-018-0124-9
   Ahmadi S, 2020, J GERONTOL A-BIOL, V75, pE9, DOI 10.1093/gerona/glaa056
   Ajaimy M, 2020, CLIN J AM SOC NEPHRO, V15, P1087, DOI 10.2215/CJN.09730620
   Algire C, 2012, CANCER PREV RES, V5, P536, DOI 10.1158/1940-6207.CAPR-11-0536
   Ba W, 2019, CELL BIOCHEM FUNCT, V37, P4, DOI 10.1002/cbf.3367
   Bailey CJ, 2017, DIABETOLOGIA, V60, P1566, DOI 10.1007/s00125-017-4318-z
   Bartley JM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01164
   Barzilai N, 2016, CELL METAB, V23, P1060, DOI 10.1016/j.cmet.2016.05.011
   Bauer PV, 2018, CELL METAB, V27, P101, DOI 10.1016/j.cmet.2017.09.019
   Ben Sahra I, 2011, CANCER RES, V71, P4366, DOI 10.1158/0008-5472.CAN-10-1769
   Ben-Yehuda A, 1992, Clin Geriatr Med, V8, P701
   Blagih J, 2015, IMMUNITY, V42, P41, DOI 10.1016/j.immuni.2014.12.030
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bramante C, 2020, OBSERVATIONAL STUDY
   Bridgeman SC, 2018, DIABETES OBES METAB, V20, P1553, DOI 10.1111/dom.13262
   Brima W, 2015, DIABETES-METAB RES, V31, P346, DOI 10.1002/dmrr.2636
   Cabreiro F, 2013, CELL, V153, P228, DOI 10.1016/j.cell.2013.02.035
   Cameron AR, 2016, CIRC RES, V119, P652, DOI 10.1161/CIRCRESAHA.116.308445
   Campbell JM, 2017, AGEING RES REV, V40, P31, DOI 10.1016/j.arr.2017.08.003
   Canto C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Cawthon P, 2020, J GERONTOL A
   Channappanavar R, 2019, J CLIN INVEST, V129, P3625, DOI 10.1172/JCI126363
   Chen CI, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000462
   Chen C, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000559
   Chen TM, 2011, J GASTROEN HEPATOL, V26, P858, DOI 10.1111/j.1440-1746.2011.06664.x
   Chen X, 2019, J INFECT DIS, V220, P1892, DOI 10.1093/infdis/jiz413
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chiasson JL, 2003, JAMA-J AM MED ASSOC, V290, P486, DOI 10.1001/jama.290.4.486
   Cuyas E, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00657
   Dagenais-Lussier X, 2015, CYTOKINE GROWTH F R, V26, P603, DOI 10.1016/j.cytogfr.2015.09.001
   De Haes W, 2014, P NATL ACAD SCI USA, V111, pE2501, DOI 10.1073/pnas.1321776111
   Degner NR, 2018, CLIN INFECT DIS, V66, P198, DOI 10.1093/cid/cix819
   del Campo JA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191805
   Diaz A, 2017, VACCINE, V35, P2694, DOI 10.1016/j.vaccine.2017.03.078
   Dillon SM, 2017, AIDS, V31, P510, DOI 10.1097/QAD.0000000000001366
   Diman A, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600031
   Ding L, 2015, ONCOTARGET, V6, P36441, DOI 10.18632/oncotarget.5541
   Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008-5472.CAN-07-2310
   Doyle MA, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1454-6
   DuGoff EH, 2014, MED CARE, V52, P688, DOI 10.1097/MLR.0000000000000166
   Dutta NK, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00652-17
   Eikawa S, 2015, P NATL ACAD SCI USA, V112, P1809, DOI 10.1073/pnas.1417636112
   El-Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223
   Espinoza SE, 2020, J GERONTOL A-BIOL, V75, P102, DOI 10.1093/gerona/glz078
   Fang JQ, 2018, AGING CELL, V17, DOI 10.1111/acel.12765
   Fatt M, 2015, STEM CELL REP, V5, P988, DOI 10.1016/j.stemcr.2015.10.014
   Forslund K, 2015, NATURE, V528, P262, DOI 10.1038/nature15766
   GARCIA E Y, 1950, J Philipp Med Assoc, V26, P287
   Garnett JP, 2014, CELL MOL LIFE SCI, V71, P4665, DOI 10.1007/s00018-014-1635-y
   Garnett JP, 2013, THORAX, V68, P835, DOI 10.1136/thoraxjnl-2012-203178
   Gill SK, 2016, SCI REP-UK, V6, DOI 10.1038/srep27636
   Gonzalez-Hernandez LA, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3867-9
   Gregoire M, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.02590-2017
   Ruivo MTG, 2016, CELL REP, V16, P2539, DOI 10.1016/j.celrep.2016.08.001
   Guo T, 2020, JAMA CARDIOL
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hammerstad SS, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00134
   Hansson I., 2020, J GERONTOL B
   Harris K, 2013, ANN PHARMACOTHER, V47, P1348, DOI 10.1177/1060028013503108
   Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420
   Hofmeister MG, 2019, HEPATOLOGY, V69, P1020, DOI 10.1002/hep.30297
   Howell JJ, 2017, CELL METAB, V25, P463, DOI 10.1016/j.cmet.2016.12.009
   Hwangbo DS, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041194
   Jiang Xue, 2020, Oxid Med Cell Longev, V2020, P8708236, DOI 10.1155/2020/8708236
   Jiang Z, 2018, J CELL BIOCHEM, V119, P4482, DOI 10.1002/jcb.26555
   Johnson SC, 2013, NATURE, V493, P338, DOI 10.1038/nature11861
   Justice JN, 2018, CARDIOVASC ENDOCR ME, V7, P80, DOI 10.1097/XCE.0000000000000159
   Kajiwara C, 2018, J IMMUNOL, V200, P623, DOI 10.4049/jimmunol.1700474
   Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014
   Kalsi KK, 2019, J CELL MOL MED, V23, P317, DOI 10.1111/jcmm.13929
   Kato M, 2019, NAT REV NEPHROL, V15, P327, DOI 10.1038/s41581-019-0135-6
   Kim JH, 2013, KOREAN J PHYSIOL PHA, V17, P455, DOI 10.4196/kjpp.2013.17.5.455
   Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512
   Kulkarni AS, 2020, CELL METAB, V32, P15, DOI 10.1016/j.cmet.2020.04.001
   Lachmandas E, 2019, J INFECT DIS, V220, P139, DOI 10.1093/infdis/jiz064
   Lai SW, 2012, AM J GASTROENTEROL, V107, P46, DOI 10.1038/ajg.2011.384
   Lamarca K, 2016, EXPERT OPIN PHARMACO, V17, P1327, DOI 10.1080/14656566.2016.1187133
   Lee H, 2014, APPL ENVIRON MICROB, V80, P5935, DOI 10.1128/AEM.01357-14
   Lee SY, 2017, J IMMUNOL, V198, P2661, DOI 10.4049/jimmunol.1403088
   Lee YS, 2016, ONCOL REP, V35, P3735, DOI 10.3892/or.2016.4740
   Li HB, 2020, CIRC RES, V126, P533, DOI 10.1161/CIRCRESAHA.119.315889
   Lindner D, 2020, JAMA CARDIOL
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Luo P, 2020, AM J TROP MED HYG, V103, P69, DOI 10.4269/ajtmh.20-0375
   Ma W, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01336
   Malik F, 2018, DIABETES-METAB RES, V34, DOI 10.1002/dmrr.2975
   Mallia P, 2018, J ALLERGY CLIN IMMUN, V142, P815, DOI 10.1016/j.jaci.2017.10.017
   Mannick JB, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaq1564
   Mannick JB, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009892
   Marcucci F, 2020, TRENDS PHARMACOL SCI, V41, P162, DOI 10.1016/j.tips.2020.01.003
   Martin-Montalvo A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3192
   Meftahi GH, 2020, INFLAMM RES, V69, P825, DOI 10.1007/s00011-020-01372-8
   Mehla R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011160
   Michalak I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030479
   Mitchell SJ, 2019, CELL METAB, V29, P221, DOI 10.1016/j.cmet.2018.08.011
   Miyakoda M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02942
   Moiseeva O, 2013, AGING CELL, V12, P489, DOI 10.1111/acel.12075
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Mortensen E, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.congress-2018.PA2639
   Moseley CE, 2010, INFLUENZA OTHER RESP, V4, P307, DOI 10.1111/j.1750-2659.2010.00155.x
   Na HJ, 2018, BIOCHEM BIOPH RES CO, V498, P18, DOI 10.1016/j.bbrc.2018.02.191
   Na HJ, 2013, MECH AGEING DEV, V134, P381, DOI 10.1016/j.mad.2013.07.003
   Naicker N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00435
   Nakashima K, 2011, MICROBIOL IMMUNOL, V55, P774, DOI 10.1111/j.1348-0421.2011.00382.x
   Neumann B, 2019, CELL STEM CELL, V25, P473, DOI 10.1016/j.stem.2019.08.015
   Nikolich-Zugich J, 2020, GEROSCIENCE, V42, P505, DOI 10.1007/s11357-020-00186-0
   Nkontchou G, 2011, J CLIN ENDOCR METAB, V96, P2601, DOI 10.1210/jc.2010-2415
   Noren Hooten N, 2016, AGING CELL, V15, P572, DOI 10.1111/acel.12469
   Onken B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008758
   Ouyang J, 2020, AIDS RES THER, V17, DOI 10.1186/s12981-020-00267-2
   Park MJ, 2016, TRANSL RES, V173, P115, DOI 10.1016/j.trsl.2016.03.006
   Patkee WRA, 2016, J CELL MOL MED, V20, P758, DOI 10.1111/jcmm.12784
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Pereira Felipe V, 2018, Oncotarget, V9, P25808, DOI 10.18632/oncotarget.25380
   Pollak M, 2017, DIABETOLOGIA, V60, P1662, DOI 10.1007/s00125-017-4352-x
   Promislow DEL, 2020, J GERONTOL A
   Qing LM, 2019, AM J TRANSL RES, V11, P655
   Rangarajan S, 2018, NAT MED, V24, P1121, DOI 10.1038/s41591-018-0087-6
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rodriguez-Carlos A, 2020, MICROBES INFECT, V22, P111, DOI 10.1016/j.micinf.2019.10.002
   Romero-Gomez M, 2009, HEPATOLOGY, V50, P1702, DOI 10.1002/hep.23206
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Routy JP, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028444
   Sarfstein R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061537
   Sato Y, 2019, NAT REV NEPHROL, V15, P625, DOI 10.1038/s41581-019-0185-9
   Schuiveling M, 2018, CURR DRUG TARGETS, V19, P945, DOI 10.2174/1389450118666170613081730
   Sharifi Amir Houshang, 2014, Middle East J Dig Dis, V6, P13
   Shen C, 2016, ONCOTARGET, V7, P62647, DOI 10.18632/oncotarget.11591
   Sheth SH, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-183
   Shikuma CM, 2020, AIDS RES HUM RETROV, V36, P303, DOI [10.1089/aid.2019.0078, 10.1089/AID.2019.0078]
   Shin NR, 2014, GUT, V63, P727, DOI 10.1136/gutjnl-2012-303839
   Sierra F, 2020, J AM GERIATR SOC, V68, P951, DOI 10.1111/jgs.16489
   Singhal A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009885
   Soukas AA, 2019, TRENDS ENDOCRIN MET, V30, P745, DOI 10.1016/j.tem.2019.07.015
   Statistics C.N, 2020, COVID 19 DEATH DAT R
   Sun YF, 2016, J NEUROIMMUNOL, V292, P58, DOI 10.1016/j.jneuroim.2016.01.014
   The OpenSAFELY Collaborative, 2020, OPENSAFELY FACT ASS
   Tizazu AM, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00572
   Tsai HH, 2017, ONCOTARGET, V8, P13832, DOI 10.18632/oncotarget.14640
   Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8
   Uehara T, 2019, INT IMMUNOL, V31, P187, DOI 10.1093/intimm/dxy079
   Vasamsetti SB, 2015, DIABETES, V64, P2028, DOI 10.2337/db14-1225
   Vazquez-Martin A, 2011, CELL CYCLE, V10, P1499, DOI 10.4161/cc.10.9.15423
   Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383
   Vera IM, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127441
   Wang CP, 2017, J DIABETES COMPLICAT, V31, P679, DOI [10.1016/jjdiacomp.2017.01.013, 10.1016/j.jdiacomp.2017.01.013]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang GY, 2017, INT J MED SCI, V14, P698, DOI 10.7150/ijms.19800
   Wang GZ, 2016, EXP THER MED, V12, P1551, DOI 10.3892/etm.2016.3465
   Wang Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0731-5
   Wheaton WW, 2014, ELIFE, V3, DOI 10.7554/eLife.02242
   Wu H, 2017, NAT MED, V23, P850, DOI 10.1038/nm.4345
   Wu J, 2020, CLIN J AM SOC NEPHRO, V15, P1139, DOI 10.2215/CJN.04160320
   Xiao Y, 2020, VIRULENCE, V11, P39, DOI 10.1080/21505594.2019.1706305
   Xun YH, 2014, J VIRAL HEPATITIS, V21, P597, DOI 10.1111/jvh.12187
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Yen FS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67338-2
   Yew WW, 2019, TUBERCULOSIS, V115, P76, DOI 10.1016/j.tube.2019.02.004
   Yoshikawa TT, 2000, CLIN INFECT DIS, V30, P931, DOI 10.1086/313792
   Yousefzadeh MJ, 2018, EBIOMEDICINE, V36, P18, DOI 10.1016/j.ebiom.2018.09.015
   Yu JW, 2012, INT J INFECT DIS, V16, pE436, DOI 10.1016/j.ijid.2012.02.004
   Yu LL, 2018, EUR REV MED PHARMACO, V22, P5355, DOI 10.26355/eurrev_201808_15737
   Zhang CS, 2016, CELL METAB, V24, P521, DOI 10.1016/j.cmet.2016.09.003
   Zhang XY, 2015, SCI REP-UK, V5, DOI 10.1038/srep09940
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zmijewski JW, 2008, AM J RESP CRIT CARE, V178, P168, DOI 10.1164/rccm.200710-1602OC
   Zumla A, 2020, INT J INFECT DIS, V96, P431, DOI 10.1016/j.ijid.2020.05.040
NR 168
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2509-2715
EI 2509-2723
J9 GEROSCIENCE
JI GeroScience
DI 10.1007/s11357-020-00261-6
EA SEP 2020
PG 20
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA NL9IT
UT WOS:000567721900002
PM 32902818
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Wang, Q
   Zhao, Y
   Chen, XJ
   Hong, A
AF Wang, Qiang
   Zhao, Ying
   Chen, Xiaojia
   Hong, An
TI Virtual screening of approved clinic drugs with main protease (3CL(pro))
   reveals potential inhibitory effects on SARS-CoV-2
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE SARS-CoV-2; 3CL(pro); approved drugs; virtual screening; molecular
   dynamics
ID SARS; CORONAVIRUS; DISCOVERY; LOPINAVIR/RITONAVIR; GROMACS; MODEL; TOOL
AB 3CL(pro)is the main protease of the novel coronavirus (SARS-CoV-2) responsible for their intracellular duplication. Based on virtual screening technology and molecular dynamics simulation, we found 23 approved clinical drugs such as Viomycin, Capastat, Carfilzomib and Saquinavir, which showed high affinity with the 3CL(pro)active sites. These findings showed that there were potential drugs that inhibit SARS-Cov-2's 3CL(pro)in the current clinical drug library, and these drugs can be further tested or chemically modified for the treatment of COVID-19. Communicated by Ramaswamy H. Sarma
C1 [Wang, Qiang; Zhao, Ying; Chen, Xiaojia; Hong, An] Jinan Univ, Inst Biomed, Guangzhou, Peoples R China.
   [Wang, Qiang; Zhao, Ying; Chen, Xiaojia; Hong, An] Jinan Univ, Dept Cell Biol, Guangzhou, Peoples R China.
   [Wang, Qiang; Zhao, Ying; Chen, Xiaojia; Hong, An] Natl Engn Res Ctr Genet Med, Guangzhou, Peoples R China.
   [Wang, Qiang; Zhao, Ying; Chen, Xiaojia; Hong, An] Guangdong Prov Key Lab Bioengn Med, Guangzhou, Peoples R China.
   [Wang, Qiang; Zhao, Ying; Chen, Xiaojia; Hong, An] Guangdong Prov Engn Res Ctr Biotechnol, Guangzhou, Peoples R China.
   [Wang, Qiang; Zhao, Ying; Chen, Xiaojia; Hong, An] Minist Educ, Engn Res Ctr Genet Med, Guangzhou, Peoples R China.
RP Chen, XJ; Hong, A (corresponding author), Jinan Univ, Inst Biomed, Guangzhou, Peoples R China.; Chen, XJ; Hong, A (corresponding author), Jinan Univ, Dept Cell Biol, Guangzhou, Peoples R China.
EM tchenxj@jnu.edu.cn; tha@jnu.edu.cn
FU Operating Fund of Guangdong Provincial Key Laboratory of Bioengineering
   Medicine [2014B030301050]
FX This work was supported by Operating Fund of Guangdong Provincial Key
   Laboratory of Bioengineering Medicine [No. 2014B030301050].
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Bienert S, 2017, NUCLEIC ACIDS RES, V45, pD313, DOI 10.1093/nar/gkw1132
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chan K. S., 2003, HONG KONG MED J, V9
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lee CC, 2007, FEBS LETT, V581, P5454, DOI 10.1016/j.febslet.2007.10.048
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Zhang N, 2016, BIOORG MED CHEM LETT, V26, P3594, DOI 10.1016/j.bmcl.2016.06.013
   Zhao HT, 2014, BIOORG MED CHEM LETT, V24, P1523, DOI 10.1016/j.bmcl.2014.01.083
   Zoete V, 2011, J COMPUT CHEM, V32, P2359, DOI 10.1002/jcc.21816
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 27
TC 3
Z9 3
U1 4
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1817786
EA SEP 2020
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NM3FS
UT WOS:000567986400001
PM 32909528
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Borcsa, M
   Pomini, V
   Saint-Mont, U
AF Borcsa, Maria
   Pomini, Valeria
   Saint-Mont, Uwe
TI Digital systemic practices in Europe: a survey before the Covid-19
   pandemic
SO JOURNAL OF FAMILY THERAPY
LA English
DT Article; Early Access
DE Covid-19; digital systemic couple and family therapy; Europe;
   information and communication technology (ICT); survey
ID E-MENTAL HEALTH; COMMUNICATION TECHNOLOGIES; PSYCHOLOGICAL TREATMENTS;
   ETHICAL-ISSUES; FAMILY-THERAPY; INFORMATION; TELEHEALTH; MARRIAGE
AB Knowledge regarding digital practices in the field of systemic therapy is poor. A few surveys have been conducted in non-European countries investigating the provision of digitally based therapy, counselling, training, and supervision by systemic family and couple therapists (SCFTs). Thus, a survey aiming to investigate the use of information and communication technology (ICT) among European SCFTs was launched in 2017. A sample of 220 SCFTs was included in the survey. The majority were residents in Greece, France and Italy. Descriptive analysis compared SCFTs' digital practices and concerns from the above three countries with those from the rest of Europe. Results showed that 81.4 per cent of European SCFTs used ICT for clinical purposes and 47.7 per cent in training and supervision. Main concerns among European SCFTs related to the quality of therapeutic relationship, ethical and legal issues, and a lack of national and transnational regulation. Practitioner points
   ICT use and e-therapy increase access to mental health services and maintain therapeutic contact Systemic individual therapy, supervision and training are workable online settings Legislation regulating ICT use in therapy, supervision and training (e.g. General Data Protection Regulation) has to be respected Training and continuous education in online practices enhance therapists' and clients' options, and ensure digital safeness and effective treatment
C1 [Borcsa, Maria] Univ Appl Sci Nordhausen, Inst Social Med Rehabil Sci & Healthcare Res, Clin Psychol, Nordhausen, Germany.
   [Pomini, Valeria] Natl & Kapodistrian Univ Athens, Athens, Greece.
   [Pomini, Valeria] Univ Mental Hlth Res Inst Costas Stefanis UMHRI, Athens, Greece.
   [Saint-Mont, Uwe] Univ Appl Sci Nordhausen, Inst Social Med Rehabil Sci & Healthcare Res, Informat Sci & Stat, Nordhausen, Germany.
RP Borcsa, M (corresponding author), Univ Appl Sci Nordhausen, Inst Social Med Rehabil Sci & Healthcare Res, Clin Psychol, Nordhausen, Germany.
OI Saint-Mont, Uwe/0000-0001-6801-3658
FU Projekt DEAL
FX Open access funding enabled and organized by Projekt DEAL.
CR Akyil Y, 2017, J FAM PSYCHOTHER, V28, P99, DOI 10.1080/08975353.2017.1285654
   Anderson SC, 2013, J TECHNOL HUMAN SERV, V31, P112, DOI 10.1080/15228835.2013.775901
   Andersson G, 2019, WORLD PSYCHIATRY, V18, P20, DOI 10.1002/wps.20610
   Apolinario-Hagen J, 2018, JMIR MENT HEALTH, V5, DOI 10.2196/10735
   Apolinario-Hagen J, 2017, JMIR MENT HEALTH, V4, DOI 10.2196/mental.6375
   Bacigalupe G, 2014, J FAM THER, V36, P339, DOI 10.1111/1467-6427.12042
   Bacigalupe G, 2011, FAM PROCESS, V50, P12, DOI 10.1111/j.1545-5300.2010.01343.x
   Balaouras P., 2018, THERAPY 2 0 COUNSELL
   Banbury A, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.8090
   Batterham PJ, 2017, JMIR MENT HEALTH, V4, DOI 10.2196/mental.7722
   Blumer MLC, 2015, CONTEMP FAM THER, V37, P113, DOI 10.1007/s10591-015-9330-1
   Borcsa M., 2020, CLINICA WEB RISORSE, P37
   Borcsa M., 2018, 2018 ENCY COUPLE FAM, DOI [10.1007/978-3-319-15877-8_1069-1, DOI 10.1007/978-3-319-15877-8_1069-1]
   Borcsa M, 2017, CONTEMP FAM THER, V39, P239, DOI 10.1007/s10591-017-9446-6
   Caldwell B. E., 2017, BEST PRACTICES ONLIN
   Cipolletta S, 2018, PSYCHOTHER RES, V28, P909, DOI 10.1080/10503307.2016.1259533
   Crisp DA, 2014, DEPRESS RES TREAT, V2014, P1, DOI DOI 10.1155/2014/
   Dores A. R, 2017, 10 C INT 15 NAC PSIC
   Drda-Kuhn K., 2018, E BERATUNGS J, V14
   European Commission, 2020, E HTLH ACT PLAN 2020
   Fairburn CG, 2017, BEHAV RES THER, V88, P19, DOI 10.1016/j.brat.2016.08.012
   Gagnon MP, 2012, J MED SYST, V36, P241, DOI 10.1007/s10916-010-9473-4
   Gibson K., 2009, NRC PUBLICATIONS ARC
   Gibson K, 2011, J TELEMED TELECARE, V17, P263, DOI 10.1258/jtt.2011.101011
   Glueckauf RL, 2018, PROF PSYCHOL-RES PR, V49, P205, DOI 10.1037/pro0000188
   Granja C, 2018, J MED INTERNET RES, V20, DOI 10.2196/10235
   Hertlein KM, 2014, CONTEMP FAM THER, V36, P58, DOI 10.1007/s10591-013-9284-0
   Hertlein KM, 2015, FAM J, V23, P5, DOI 10.1177/1066480714547184
   Jensen EJ, 2018, CONTEMP FAM THER, V40, P309, DOI 10.1007/s10591-018-9460-3
   Lal S, 2014, PSYCHIAT SERV, V65, P24, DOI 10.1176/appi.ps.201300009
   Lazuras L, 2016, TECHNOL SOC, V44, P10, DOI 10.1016/j.techsoc.2015.11.002
   Lindegaard T, 2020, INTERNET INTERV, V20, DOI 10.1016/j.invent.2020.100316
   Manfrida G., 2020, CLIN WEB RISORSE TEC
   Mar MY, 2014, J TECHNOL HUMAN SERV, V32, P312, DOI 10.1080/15228835.2014.943457
   Markowitz J, 2020, LANCET PSYCHIAT, V7, P388, DOI 10.1016/S2215-0366(20)30140-1
   McCoy M, 2013, J COUPLE RELATSH THE, V12, P339, DOI 10.1080/15332691.2013.836053
   Menon GM, 2011, J TECHNOL HUMAN SERV, V29, P133, DOI 10.1080/15228835.2011.595262
   Mucic D., 2016, E MENTAL HLTH, DOI [10.1007/978-3-319-20852-7, DOI 10.1007/978-3-319-20852-7]
   Mucic D, 2016, E MENTAL HLTH, P77, DOI DOI 10.1007/978-3-319-20852-7_5
   Negretti MA, 2001, CONTEMP FAM THER, V23, P275, DOI 10.1023/A:1011178915547
   Orru G, 2020, CLIN NEUROPSYCHIATR, V17, P76, DOI 10.36131/CN20200208
   Patel V, 2018, LANCET, V392, P1553, DOI 10.1016/S0140-6736(18)31612-X
   Perle JG, 2014, J TECHNOL HUMAN SERV, V32, P158, DOI 10.1080/15228835.2014.894488
   Perle JG, 2013, J TECHNOL HUMAN SERV, V31, P22, DOI 10.1080/15228835.2012.760332
   Pomini V., 2016, HUMAN SYSTEMS, V27, P21
   Rahimi K, 2019, LANCET DIGIT HEALTH, V1, pE108, DOI 10.1016/S2589-7500(19)30056-1
   Roddy MK, 2018, FAM PROCESS, V57, P293, DOI 10.1111/famp.12291
   Schweitzer J., 2020, EFTA BOOK SERIES, V4, P1, DOI DOI 10.1007/978-3-030-36560-8
   Shoemaker EZ, 2016, E MENTAL HLTH, P43, DOI DOI 10.1007/978-3-319-20852-7
   Sprenger M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180867
   Twist MLC, 2015, J FEM FAM THER, V27, P116, DOI 10.1080/08952833.2015.1065651
   Twist MLC, 2016, CONTEMP FAM THER, V38, P424, DOI 10.1007/s10591-016-9391-9
   Wells M, 2007, CYBERPSYCHOL BEHAV, V10, P453, DOI 10.1089/cpb.2006.9933
   Wilcoxon SA, 2015, AUST NZ J FAM THER, V36, P480, DOI 10.1002/anzf.1128
   Wrape ER, 2019, J MARITAL FAM THER, V45, P296, DOI 10.1111/jmft.12319
   Zhou XY, 2020, TELEMED E-HEALTH, V26, P377, DOI 10.1089/tmj.2020.0068
NR 56
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0163-4445
EI 1467-6427
J9 J FAM THER
JI J. Fam. Ther.
DI 10.1111/1467-6427.12308
EA SEP 2020
PG 23
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA NL5CW
UT WOS:000567434700001
OA Other Gold
DA 2021-01-01
ER

PT J
AU Plumereau, C
   Cho, TH
   Buisson, M
   Amaz, C
   Cappucci, M
   Derex, L
   Ong, E
   Fontaine, J
   Rascle, L
   Riva, R
   Schiavo, D
   Benhamed, A
   Douplat, M
   Bony, T
   Tazarourte, K
   Tuttle, C
   Eker, OF
   Berthezene, Y
   Ovize, M
   Nighoghossian, N
   Mechtouff, L
AF Plumereau, Cecile
   Cho, Tae-Hee
   Buisson, Marielle
   Amaz, Camille
   Cappucci, Matteo
   Derex, Laurent
   Ong, Elodie
   Fontaine, Julia
   Rascle, Lucie
   Riva, Roberto
   Schiavo, David
   Benhamed, Axel
   Douplat, Marion
   Bony, Thomas
   Tazarourte, Karim
   Tuttle, Celia
   Eker, Omer Faruk
   Berthezene, Yves
   Ovize, Michel
   Nighoghossian, Norbert
   Mechtouff, Laura
TI Effect of the COVID-19 pandemic on acute stroke reperfusion therapy:
   data from the Lyon Stroke Center Network
SO JOURNAL OF NEUROLOGY
LA English
DT Article; Early Access
DE Stroke; Thrombolysis; Thrombectomy; COVID-19
AB Background The coronavirus disease 2019 (COVID-19) pandemic would have particularly affected acute stroke care. However, its impact is clearly inherent to the local stroke network conditions. We aimed to assess the impact of COVID-19 pandemic on acute stroke care in the Lyon comprehensive stroke center during this period. Methods We conducted a prospective data collection of patients with acute ischemic stroke (AIS) treated with intravenous thrombolysis (IVT) and/or mechanical thrombectomy (MT) during the COVID-19 period (from 29/02/2020 to 10/05/2020) and a control period (from 29/02/2019 to 10/05/2019). The volume of reperfusion therapies and pre and intra-hospital delays were compared during both periods. Results A total of 208 patients were included. The volume of IVT significantly decreased during the COVID-period [55 (54.5%) vs 74 (69.2%);p = 0.03]. The volume of MT remains stable over the two periods [72 (71.3%) vs 65 (60.8%);p = 0.14], but the door-to-groin puncture time increased in patients transferred for MT (237 [187-339] vs 210 [163-260];p < 0.01). The daily number of Emergency Medical Dispatch calls considerably increased (1502 [1133-2238] vs 1023 [960-1410];p < 0.01). Conclusions Our study showed a decrease in the volume of IVT, whereas the volume of MT remained stable although intra-hospital delays increased for transferred patients during the COVID-19 pandemic. These results contrast in part with the national surveys and suggest that the impact of the pandemic may depend on local stroke care networks.
C1 [Plumereau, Cecile; Schiavo, David; Benhamed, Axel; Douplat, Marion; Bony, Thomas; Tazarourte, Karim] Hosp Civils Lyon, Emergency Dept, Lyon, France.
   [Plumereau, Cecile; Cho, Tae-Hee; Derex, Laurent; Ong, Elodie; Fontaine, Julia; Rascle, Lucie; Nighoghossian, Norbert; Mechtouff, Laura] Hosp Civils Lyon, Stroke Ctr, Dept Neurol, Lyon, France.
   [Cho, Tae-Hee; Ong, Elodie; Ovize, Michel; Nighoghossian, Norbert; Mechtouff, Laura] Univ Lyon 1, CarMeN Lab, INSERM U1060, Lyon, France.
   [Buisson, Marielle; Amaz, Camille; Ovize, Michel] Hosp Civils Lyon, Clin Invest Ctr, INSERM 1407, Lyon, France.
   [Cappucci, Matteo; Riva, Roberto; Tuttle, Celia; Eker, Omer Faruk; Berthezene, Yves] Hosp Civils Lyon, Neuroradiol Dept, Lyon, France.
   [Derex, Laurent; Tazarourte, Karim] Claude Bernard Lyon 1 Univ, Hlth Serv & Performance Res, EA HESPER 7425, Lyon, France.
   [Berthezene, Yves] Univ Lyon 1, CREATIS, INSERM U1044, CNRS UMR 5220, Lyon, France.
RP Mechtouff, L (corresponding author), Hosp Civils Lyon, Stroke Ctr, Dept Neurol, Lyon, France.; Mechtouff, L (corresponding author), Univ Lyon 1, CarMeN Lab, INSERM U1060, Lyon, France.
EM laura.mechtouff@chu-lyon.fr
RI EKER, Omer F/H-1930-2019; BENHAMED, Axel/A-6264-2019; Cho,
   Tae-Hee/I-5491-2014
OI EKER, Omer F/0000-0002-5696-5368; BENHAMED, Axel/0000-0001-8784-5273;
   Cho, Tae-Hee/0000-0001-8677-2447
CR Baracchini C, 2020, NEUROL SCI, V41, P1003, DOI 10.1007/s10072-020-04375-9
   Barber PA, 2000, LANCET, V355, P1670, DOI 10.1016/S0140-6736(00)02237-6
   De Coninck D, 2020, PUBLIC HEALTH, V183, P65, DOI 10.1016/j.puhe.2020.05.011
   Frisullo G, 2020, NEUROL SCI, V41, P2309, DOI 10.1007/s10072-020-04545-9
   Gurley KL, 2019, ACAD EMERG MED, V26, P1273, DOI 10.1111/acem.13830
   Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9
   Hoyer C, 2020, STROKE, V51, P2224, DOI 10.1161/STROKEAHA.120.030395
   Hsiao J, 2020, STROKE, V51, pE211, DOI 10.1161/STROKEAHA.120.030499
   Kerleroux B, 2020, STROKE, V51, P2012, DOI 10.1161/STROKEAHA.120.030373
   Perlini S, 2020, INTERN EMERG MED, V15, P825, DOI 10.1007/s11739-020-02390-4
   Pop R, 2020, EUR J NEUROL, V27, P1783, DOI 10.1111/ene.14316
   Rudilosso S, 2020, STROKE, V51, P1991, DOI 10.1161/STROKEAHA.120.030329
   Zedde M, 2020, EUR STROKE J, V5, P222, DOI 10.1177/2396987320942622
   Zhao J, 2020, STROKE, V51, P1996, DOI 10.1161/STROKEAHA.120.030225
NR 14
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
DI 10.1007/s00415-020-10199-6
EA SEP 2020
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA NL9LH
UT WOS:000567728500002
PM 32902732
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Schmid, M
   Escher, F
   Clevert, DA
AF Schmid, M.
   Escher, F.
   Clevert, D. -A.
TI Lung ultrasonography in COVID-19 pneumonia
SO RADIOLOGE
LA German
DT Article
DE Lung ultrasound; Screening; Follow up; Emergency sonography; Intensive
   care unit
ID ACUTE RESPIRATORY-FAILURE; INTENSIVE-CARE; ULTRASOUND; EMERGENCY; CT
AB Background Point-of-care ultrasound (POCUS) of the lung in patients with COVID-19 plays a key role in the emergency room and intensive care unit. Lung ultrasound is able to depict typical pulmonary findings of COVID-19 and is therefore suitable for diagnosis and follow-up of these patients. Clinical/methodological issue Lung ultrasound in COVID-19 patients in the emergency room and intensive care unit. Standard radiological methods Computed tomography (low-dose CT) and X-ray of the lung. Methodological innovations Lung ultrasound in COVID-19 patients. Recommendations Lung ultrasound in patients with COVID-19 offers similar performance as CT and is superior when compared to X-ray in evaluating pneumonia and acute respiratory distress syndrome (ARDS). Lung ultrasound plays an important role in the emergency room and intensive care unit. POCUS reduces exposure to radiation, therapy delays, and minimizes transport of high-risk patients. Differential diagnoses can also be clarified.
C1 [Escher, F.; Clevert, D. -A.] Klinikum Ludwig Maximilians Univ Munchen, Klin & Poliklin Radiol, Interdisziplinares Ultraschallzentrum, Campus Grosshadern,Marchioninistr 15, D-81377 Munich, Germany.
   [Schmid, M.] Munchen Klin Harlaching, Klin Gastroenterol Pneumol Internist Akut & Inten, Munich, Germany.
RP Clevert, DA (corresponding author), Klinikum Ludwig Maximilians Univ Munchen, Klin & Poliklin Radiol, Interdisziplinares Ultraschallzentrum, Campus Grosshadern,Marchioninistr 15, D-81377 Munich, Germany.
EM Dirk.Clevert@med.uni-muenchen.de
CR Armbruster W, 2019, ANASTH INTENSIV NOTF, V54, P108, DOI 10.1055/a-0664-5700
   Bai HX, 2020, RADIOLOGY, V296, pE46, DOI 10.1148/radiol.2020200823
   Bouhemad B, 2010, CRIT CARE MED, V38, P84, DOI 10.1097/CCM.0b013e3181b08cdb
   Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149
   Brogi E, 2017, CARDIOVASC ULTRASOUN, V15, DOI 10.1186/s12947-017-0113-8
   Convissar DL, 2020, ANESTH ANALG, V131, P345, DOI 10.1213/ANE.0000000000004929
   Dietrich CF, 2016, J THORAC DIS, V8, DOI 10.21037/jtd.2016.04.55
   Dietrich CF, 2015, ULTRASOUND MED BIOL, V41, P351, DOI 10.1016/j.ultrasmedbio.2014.10.002
   Gardelli G, 2012, RESP CARE, V57, P773, DOI 10.4187/respcare.01743
   Gargani L, 2020, EUR HEART J-CARD IMG, V21, P941, DOI 10.1093/ehjci/jeaa163
   Gargani L, 2015, CARDIOVASC ULTRASOUN, V13, DOI 10.1186/s12947-015-0033-4
   Gargani L, 2015, CRIT ULTRASOUND J, V7, DOI 10.1186/s13089-015-0020-x
   Gargani L, 2011, CARDIOVASC ULTRASOUN, V9, DOI 10.1186/1476-7120-9-6
   Goffi A, 2018, CAN J ANESTH, V65, P399, DOI 10.1007/s12630-018-1062-x
   Havelock T, 2010, THORAX, V65, P61, DOI 10.1136/thx.2010.137026
   Johri AM, 2020, J AM SOC ECHOCARDIOG, V33, P670, DOI 10.1016/j.echo.2020.04.017
   Kluge S, 2020, EMPFEHLUNGEN INTENSI
   Lesser TG, 2017, ULTRASCHALL MED, V38, P592, DOI 10.1055/s-0043-119873
   Lichtenstein D, 2004, ANESTHESIOLOGY, V100, P9, DOI 10.1097/00000542-200401000-00006
   Lichtenstein DA, 2008, CHEST, V134, P117, DOI 10.1378/chest.07-2800
   Lichtenstein DA, 2017, ACUTE CRIT CARE, V32, P1, DOI 10.4266/kjccm.2016.00955
   Lichtenstein DA, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/2110-5820-4-1
   Lichtenstein DA, 2009, CHEST, V136, P1014, DOI 10.1378/chest.09-0001
   Mathis G, 2010, CHEST, V137, P233, DOI 10.1378/chest.08-2601
   Mayo PH, 2019, INTENS CARE MED, V45, P1200, DOI 10.1007/s00134-019-05725-8
   Michels G, 2014, DEUT MED WOCHENSCHR, V139, P2301, DOI 10.1055/s-0034-1387309
   Mongodi S, 2020, ULTRASOUND MED BIOL, V46, P2090, DOI 10.1016/j.ultrasmedbio.2020.04.033
   Oks M, 2014, CHEST, V146, P1574, DOI 10.1378/chest.14-0728
   Peng QY, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02856-z
   Piscaglia F, 2012, ULTRASCHALL MED, V33, P33, DOI 10.1055/s-0031-1281676
   Smargiassi A, 2020, J ULTRASOUND, V23, P449, DOI 10.1007/s40477-020-00501-7
   Sultan LR, 2020, DIAGNOSTICS BASEL
   Tan GL, 2020, ULTRASOUND MED BIOL, V46, P2651, DOI 10.1016/j.ultrasmedbio.2020.05.006
   TECCE PM, 1994, RADIOGRAPHICS, V14, P973, DOI 10.1148/radiographics.14.5.7991827
   Volpicelli G, 2013, J ULTRAS MED, V32, P165
   Volpicelli G, 2012, INTENS CARE MED, V38, P577, DOI 10.1007/s00134-012-2513-4
   Wu J, 2020, EUR RADIOL, V30, P5455, DOI 10.1007/s00330-020-06915-5
   Wujtewicz M, 2020, ANAESTHESIOL INTENSI
   Zhao W, 2020, AJR AM J ROENTGENOL
   Zhou S, 2020, AJR AM J ROENTGENOL
   ZISKIN MC, 1982, J ULTRAS MED, V1, P1
NR 41
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0033-832X
EI 1432-2102
J9 RADIOLOGE
JI Radiologe
PD OCT
PY 2020
VL 60
IS 10
SI SI
BP 919
EP 926
DI 10.1007/s00117-020-00747-6
EA SEP 2020
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA NU7LP
UT WOS:000567726600001
PM 32909049
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Trevino, KM
   Raghunathan, N
   Latte-Naor, S
   Polubriaginof, FCG
   Jensen, C
   Atkinson, TM
   Emard, N
   Seluzicki, CM
   Ostroff, JS
   Mao, JJ
AF Trevino, Kelly M.
   Raghunathan, Nirupa
   Latte-Naor, Shelly
   Polubriaginof, Fernanda C. G.
   Jensen, Claus
   Atkinson, Thomas M.
   Emard, Nicholas
   Seluzicki, Christina M.
   Ostroff, Jamie S.
   Mao, Jun J.
TI Rapid deployment of virtual mind-body interventions during the COVID-19
   outbreak: feasibility, acceptability, and implications for future care
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article; Early Access
DE Fitness; Meditation; Yoga; Stress; Virtual; Cancer
AB Introduction COVID-19 increased stress levels while reducing access to mind-body services in patients with cancer. We describe the rapid deployment of remotely delivered mind-body services to people with cancer during COVID-19, rates of participation, and acceptability from patients' perspectives. Methods Eligible participants were patients with cancer age >= 18 years enrolled in a single academic cancer center's online patient portal. Interventions included mind-body group therapy sessions in fitness, meditation, yoga, dance, tai chi, and music delivered using Zoom video conferencing. Sessions were 30-45 min and led by an integrative medicine clinician. Following each session, participants were asked to complete a three-item questionnaire assessing (1) satisfaction with the class session, (2) reduction in stress/anxiety, and (3) likelihood of recommending the class to others. Patients could also provide comments in real-time using the Zoom chat function. Results Among 5948 unique visits, the most frequently attended classes were fitness (n= 2513, 42.2%) followed by meditation (n= 1176, 19.8%) and yoga (n= 909, 15.3%). Of these visits, 3902 (65.6%) had an associated completed questionnaire. Across class types, a large majority of participants reported being extremely satisfied (n= 3733, 95.7%), experiencing extreme reductions in anxiety/stress (n= 3268, 83.8%), and being extremely likely to recommend the class to others (n= 3605, 92.4%). Fitness had the highest endorsement among class types (allpvalues < 0.001). Themes from the chat responses included gratitude, expressions of helpfulness, and feelings of connection. Conclusion High utilization of and satisfaction with these virtual mind-body services demonstrate the significant potential of remote delivery to facilitate patient access to services.
C1 [Trevino, Kelly M.; Raghunathan, Nirupa; Latte-Naor, Shelly; Polubriaginof, Fernanda C. G.; Jensen, Claus; Atkinson, Thomas M.; Emard, Nicholas; Seluzicki, Christina M.; Ostroff, Jamie S.; Mao, Jun J.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
RP Mao, JJ (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
EM maoj@mskcc.org
FU National Institutes of Health/National Cancer Institute Cancer
   CenterUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30
   CA008748]; Translational and Integrative Medicine Research Fund at
   Memorial Sloan Kettering Cancer Center
FX This manuscript is supported in part by a grant from the National
   Institutes of Health/National Cancer Institute Cancer Center (P30
   CA008748) and the Translational and Integrative Medicine Research Fund
   at Memorial Sloan Kettering Cancer Center.
CR [Anonymous], 2011, STAT STAT SOFTW REL
   Chan A, 2020, SUPPORT CARE CANCER, V28, P3485, DOI 10.1007/s00520-020-05544-4
   Cillessen L, 2018, ACTA ONCOL, V57, P1293, DOI 10.1080/0284186X.2018.1479071
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hong YR, 2020, JMIR PUBLIC HLTH SUR, V6, P168, DOI 10.2196/18961
   Kramer A, 2020, J VOCAT BEHAV, V119, DOI 10.1016/j.jvb.2020.103442
   Kubo A, 2019, INTEGR CANCER THER, V18, DOI 10.1177/1534735419850634
   Latte-Naor S, 2019, J ONCOL PRACT, V15, P7, DOI 10.1200/JOP.18.00554
   Linden W, 2012, J AFFECT DISORDERS, V141, P343, DOI 10.1016/j.jad.2012.03.025
   Russell L, 2019, SUPPORT CARE CANCER, V27, P2735, DOI 10.1007/s00520-018-4574-6
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Wang C, 2019, INT C ELECTR MACH SY, P17
   Young AM, 2020, SUPPORT CARE CANCER, V28, P4001, DOI 10.1007/s00520-020-05604-9
NR 13
TC 0
Z9 0
U1 11
U2 11
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0941-4355
EI 1433-7339
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
DI 10.1007/s00520-020-05740-2
EA SEP 2020
PG 4
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA NL9JF
UT WOS:000567723100001
PM 32902712
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU da Costa, CM
   de Souza, ZS
   Salgues, ACR
   Harada, G
   Ayres, PPMR
   Nunes, DBV
   Katz, A
   Munhoz, RR
AF da Costa, Cesar Martins
   de Souza, Zenaide Silva
   Real Salgues, Alessandra Corte
   Harada, Guilherme
   Marino Rodrigues Ayres, Pedro Paulo
   Vieira Nunes, Daniela Bulhoes
   Katz, Artur
   Munhoz, Rodrigo Ramella
TI COVID-19 in a patient with advanced Merkel cell carcinoma receiving
   immunotherapy
SO IMMUNOTHERAPY
LA English
DT Article
DE anti-PD-1 therapy; coronavirus; COVID-19; immune-related adverse events;
   immunotherapy; Merkel cell carcinoma; oncology; pandemic; SARS-CoV-2;
   skin cancer
ID MANAGEMENT
AB Background:Little is known about the 2019 novel coronavirus disease (COVID-19) course and outcomes in patients receiving immunotherapy. Here we describe a metastatic Merkel cell carcinoma patient with a severe acute respiratory syndrome coronavirus 2 infection while receiving pembrolizumab.Case presentation:A 66-year-old man, with a metastatic Merkel cell carcinoma receiving pembrolizumab, presented with fever. Chest computed tomography (CT) showed pulmonary ground-glass opacities, suggesting viral or immuno-related etiology. On day 7, the patient was hospitalized due to dyspnea and worsening of the radiological findings. Real time polymerase chain reaction (RT-PCR) testing confirmed COVID-19. The patient developed acute respiratory distress syndrome and acute kidney injury. Hydroxychloroquine was administered for 5 days, but discontinued after supraventricular extrasystoles. Clinical improvement allowed the patient's discharge after 81 days of hospitalization.Conclusion:A careful evaluation of oncologic patients receiving immunotherapy during the COVID-19 pandemic is of utmost importance.
C1 [da Costa, Cesar Martins; de Souza, Zenaide Silva; Real Salgues, Alessandra Corte; Harada, Guilherme; Katz, Artur; Munhoz, Rodrigo Ramella] Hosp Sirio Libanes HSL, Oncol Ctr, Sao Paulo, SP, Brazil.
   [Marino Rodrigues Ayres, Pedro Paulo; Vieira Nunes, Daniela Bulhoes] Hosp Sirio Libanes HSL, Intens Care Med, Sao Paulo, SP, Brazil.
RP Munhoz, RR (corresponding author), Hosp Sirio Libanes HSL, Oncol Ctr, Sao Paulo, SP, Brazil.
EM rodrigo.rmunhoz@hsl.org.br
OI Reis, AlessanRSS/0000-0001-8486-7469; Costa, Cesar/0000-0003-1753-6840;
   Munhoz, Rodrigo/0000-0001-8898-2798
CR Artigas C, 2020, CLIN NUCL MED, V45, pE381, DOI 10.1097/RLU.0000000000003152
   ASCO, 2020, ASCO SPEC REP GUID C
   Baumann BC, 2020, CANCER-AM CANCER SOC, V126, P3900, DOI 10.1002/cncr.32969
   Chuzi S, 2017, CANCER MANAG RES, V9, P207, DOI 10.2147/CMAR.S136818
   Davis AP, 2020, IMMUNOTHERAPY-UK, V12, P545, DOI 10.2217/imt-2020-0096
   Delaunay M, 2019, EUR RESPIR REV, V28, DOI 10.1183/16000617.0012-2019
   Fox TA, 2020, BRIT J HAEMATOL, V191, P194, DOI 10.1111/bjh.17027
   Friedrich MJ, 2019, JAMA-J AM MED ASSOC, V321, P131, DOI 10.1001/jama.2018.18306
   Fumet JD, 2018, BRIT J CANCER, V119, P950, DOI 10.1038/s41416-018-0220-9
   Garassino MC, 2020, LANCET ONCOL, V21, P914, DOI 10.1016/S1470-2045(20)30314-4
   Gentileschi S, 2020, EJSO-EUR J SURG ONC, V46, P1194, DOI 10.1016/j.ejso.2020.04.048
   Gosain R, 2020, CURR ONCOL REP, V22, DOI 10.1007/s11912-020-00934-7
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lu S, 2019, JAMA ONCOL, V5, P1195, DOI 10.1001/jamaoncol.2019.1549
   Luo J, 2020, CANCER DISCOV, V10, P1121, DOI 10.1158/2159-8290.CD-20-0596
   Rashdan S, 2018, LANCET RESP MED, V6, P472, DOI 10.1016/S2213-2600(18)30172-3
   Robilotti EV, 2020, NAT MED, V26, P1218, DOI 10.1038/s41591-020-0979-0
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Wang DY, 2018, JAMA ONCOL, V4, P1721, DOI 10.1001/jamaoncol.2018.3923
   World Health Organization, 2020, COR DIS 2019
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhang Q, 2018, NAT IMMUNOL, V19, P723, DOI 10.1038/s41590-018-0132-0
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
NR 25
TC 1
Z9 1
U1 1
U2 1
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-743X
EI 1750-7448
J9 IMMUNOTHERAPY-UK
JI Immunotherapy
PD OCT
PY 2020
VL 12
IS 15
BP 1133
EP 1138
DI 10.2217/imt-2020-0193
EA SEP 2020
PG 6
WC Immunology
SC Immunology
GA NU8CD
UT WOS:000566957500001
PM 32900245
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Choudry, FA
   Hamshere, SM
   Rathod, KS
   Akhtar, MM
   Archbold, RA
   Guttman, OP
   Woldman, S
   Jain, AK
   Knight, CJ
   Baumbach, A
   Mathur, A
   Jones, DA
AF Choudry, Fizzah A.
   Hamshere, Stephen M.
   Rathod, Krishnaraj S.
   Akhtar, Mohammed M.
   Archbold, R. Andrew
   Guttman, Oliver P.
   Woldman, Simon
   Jain, Ajay K.
   Knight, Charles J.
   Baumbach, Andreas
   Mathur, Anthony
   Jones, Daniel A.
TI High Thrombus Burden in Patients With COVID-19 Presenting With
   ST-Segment Elevation Myocardial Infarction
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE COVID-19; primary percutaneous coronary intervention; ST-segment
   elevation myocardial infarction; thrombosis
ID INFLAMMATION
AB BACKGROUND Coronavirus disease-2019 (COVID-19) is thought to predispose patients to thrombotic disease. To date there are few reports of ST-segment elevation myocardial infarction (STEMI) caused by type 1 myocardial infarction in patients with COVID-19.
   OBJECTIVES The aim of this study was to describe the demographic, angiographic, and procedural characteristics alongside clinical outcomes of consecutive cases of COVID-19-positive patients with STEMI compared with COVID-19-negative patients.
   METHODS This was a single-center, observational study of 115 consecutive patients admitted with confirmed STEMS treated with primary percutaneous coronary intervention at Barts Heart Centre between March 1, 2020, and May 20, 2020.
   RESULTS Patients with STEMS presenting with concurrent COVID-19 infection had higher levels of troponin T and tower lymphocyte count, but elevated D-dimer and C-reactive protein. There were significantly higher rates of multivessel thrombosis, stent thrombosis, higher modified thrombus grade post first device with consequently higher use of glycoprotein Ilb/Illa inhibitors and thrombus aspiration. Myocardial blush grade and left ventricular function were significantly tower in patients with COVID-19 with STEMI. Higher doses of heparin to achieve therapeutic activated dotting times were also noted. Importantly, patients with STEMS presenting with COVID-19 infection had a longer in-patient admission and higher rates of intensive care admission.
   CONCLUSIONS In patients presenting with STEMS and concurrent COVID-19 infection, there is a strong signal toward higher thrombus burden and poorer outcomes. This supports the need for establishing COVID-19 status in all STEMS cases. Further work is required to understand the mechanism of increased thrombosis and the benefit of aggressive antithrombotic therapy in selected cases. (C) 2020 by the American College of Cardiology Foundation.
C1 [Choudry, Fizzah A.; Hamshere, Stephen M.; Rathod, Krishnaraj S.; Akhtar, Mohammed M.; Archbold, R. Andrew; Guttman, Oliver P.; Woldman, Simon; Jain, Ajay K.; Knight, Charles J.; Baumbach, Andreas; Mathur, Anthony; Jones, Daniel A.] St Bartholomews Hosp, Barts Heart Ctr, Dept Cardiol, London, England.
   [Choudry, Fizzah A.; Hamshere, Stephen M.; Rathod, Krishnaraj S.; Akhtar, Mohammed M.; Guttman, Oliver P.; Woldman, Simon; Jain, Ajay K.; Knight, Charles J.; Baumbach, Andreas; Mathur, Anthony; Jones, Daniel A.] Queen Mary Univ London, Ctr Cardiovasc Med & Devices, William Harvey Res Inst, London, England.
RP Jones, DA (corresponding author), Barts Heart Ctr, London EC1A 7BE, England.
EM dan.jones8@nhs.net
FU Barts Charity
FX Dr. Jones is funded from The Barts Charity. All other authors have
   reported that they have no relationships relevant to the contents of
   this paper to disclose.
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bangalore S, 2020, NEW ENGL J MED, V382, P2478, DOI 10.1056/NEJMc2009020
   Beyrouti R, 2020, J NEUROL NEUROSURG P
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Chieffo A, 2020, EUR HEART J, V41, P1839, DOI 10.1093/eurheartj/ehaa381
   Curzen Nick, 2020, Interv Cardiol, V15, pe01, DOI 10.15420/icr.2020.10
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Fan BE, 2020, AM J HEMATOL, V95, pE131, DOI 10.1002/ajh.25774
   Inciardi RM, 2020, JAMA CARDIOL
   Jing ZC, 2020, EUR HEART J, V41, P1791, DOI 10.1093/eurheartj/ehaa258
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kwong JC, 2018, NEW ENGL J MED, V378, P345, DOI 10.1056/NEJMoa1702090
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Libby P, 2009, J AM COLL CARDIOL, V54, P2129, DOI 10.1016/j.jacc.2009.09.009
   Masi P, 2020, CIRCULATION, V142, P611, DOI 10.1161/CIRCULATIONAHA.120.048925
   Paranjpe I, 2020, J AM COLL CARDIOL
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Saltiel AR, 2017, J CLIN INVEST, V127, P1, DOI [10.1172/JCI92035, 10.1172/jci92035]
   Sianos G, 2010, J INVASIVE CARDIOL, V22, p6B
   Stefanini GG, 2020, CIRCULATION, V141, P2113, DOI 10.1161/CIRCULATIONAHA.120.047525
   Tall AR, 2015, NAT REV IMMUNOL, V15, P104, DOI 10.1038/nri3793
   van't Hof AWJ, 1998, CIRCULATION, V97, P2302, DOI 10.1161/01.CIR.97.23.2302
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zidar DA, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.16526
NR 27
TC 8
Z9 8
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0735-1097
EI 1558-3597
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD SEP 8
PY 2020
VL 76
IS 10
BP 1168
EP 1176
DI 10.1016/j.jacc.2020.07.022
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NX6DE
UT WOS:000575798600003
PM 32679155
DA 2021-01-01
ER

PT J
AU Crisan-Dabija, R
   Grigorescu, C
   Pavel, CA
   Artene, B
   Popa, IV
   Cernomaz, A
   Burlacu, A
AF Crisan-Dabija, Radu
   Grigorescu, Cristina
   Pavel, Cristina-Alice
   Artene, Bogdan
   Popa, Iolanda Valentina
   Cernomaz, Andrei
   Burlacu, Alexandru
TI Tuberculosis and COVID-19: Lessons from the Past Viral Outbreaks and
   Possible Future Outcomes
SO CANADIAN RESPIRATORY JOURNAL
LA English
DT Article
ID ACUTE RESPIRATORY SYNDROME; CORONAVIRUS; INFECTION; MYCOBACTERIAL;
   COINFECTION; STRATEGIES; RESISTANT; VACCINES; BCG
AB Background. The threat of contagious infectious diseases is constantly evolving as demographic explosion, travel globalization, and changes in human lifestyle increase the risk of spreading pathogens, leading to accelerated changes in disease landscape. Of particular interest is the aftermath of superimposing viral epidemics (especially SARS-CoV-2) over long-standing diseases, such as tuberculosis (TB), which remains a significant disease for public health worldwide and especially in emerging economies. Methods and Results. The PubMed electronic database was systematically searched for relevant articles linking TB, influenza, and SARS-CoV viruses and subsequently assessed eligibility according to inclusion criteria. Using a data mining approach, we also queried the COVID-19 Open Research Dataset (CORD-19). We aimed to answer the following questions: What can be learned from other coronavirus outbreaks (focusing on TB patients)? Is coinfection (TB and SARS-CoV-2) more severe? Is there a vaccine for SARS-CoV-2? How does the TB vaccine affect COVID-19? How does one diagnosis affect the other? Discussions. Few essential elements about TB and SARS-CoV coinfections were discussed. First, lessons from past outbreaks (other coronaviruses) and influenza pandemic/seasonal outbreaks have taught the importance of infection control to avoid the severe impact on TB patients. Second, although challenging due to data scarcity, investigating the pathological pathways linking TB and SARS-CoV-2 leads to the idea that their coexistence might yield a more severe clinical evolution. Finally, we addressed the issues of vaccination and diagnostic reliability in the context of coinfection. Conclusions. Because viral respiratory infections and TB impede the host's immune responses, it can be assumed that their lethal synergism may contribute to more severe clinical evolution. Despite the rapidly growing number of cases, the data needed to predict the impact of the COVID-19 pandemic on patients with latent TB and TB sequelae still lies ahead. The trial is registered with NCT04327206, NCT01829490, and NCT04121494.
C1 [Crisan-Dabija, Radu] Univ Med & Pharm Grigore T Popa Iasi, Pulmonol Dept, Clin Pulm Dis, Iasi, Romania.
   [Grigorescu, Cristina] Univ Med & Pharm Grigore T Popa Iasi, Hosp Pulm Dis Iasi, Dept Thorac Surg, Clin Thorac Surg Iasi, Iasi, Romania.
   [Pavel, Cristina-Alice] Clin Pulm Dis, Iasi, Romania.
   [Artene, Bogdan; Burlacu, Alexandru] Cardiovasc Dis Inst, Dept Intervent Cardiol, Iasi, Romania.
   [Popa, Iolanda Valentina] Inst Gastroenterol & Hepatol, Iasi, Romania.
   [Popa, Iolanda Valentina; Burlacu, Alexandru] Grigore T Popa Univ Med, Iasi, Romania.
   [Cernomaz, Andrei] Univ Med & Pharm Grigore T Popa Iasi, Inst Oncol, Pulmonol Dept, Iasi, Romania.
RP Popa, IV (corresponding author), Inst Gastroenterol & Hepatol, Iasi, Romania.; Popa, IV (corresponding author), Grigore T Popa Univ Med, Iasi, Romania.
EM radu.dabija@umfiasi.ro; cpislariu@hotmail.com; alice.tarus@yahoo.com;
   bogdan.artene@yahoo.com; iolivp@gmail.com; a_cernomaz@yahoo.com;
   alexandru.burlacu@umfiasi.ro
RI Burlacu, Alexandru/AAM-4168-2020; CRISAN-DABIJA, Radu/AAE-8846-2019
OI Burlacu, Alexandru/0000-0002-3424-1588; CRISAN-DABIJA,
   Radu/0000-0003-3732-0350; Popa, Iolanda Valentina/0000-0002-0597-8839;
   Artene, Bogdan/0000-0002-3201-1105
FU Romanian Academy of MedAcademy of Medical Sciences; European Regional
   Development FundEuropean Union (EU) [MySMIS 107124: Funding Contract
   2/Axa 1/31.07.2017/107124 SMIS]
FX This study was funded by the Romanian Academy of MedAcademy of Medical
   Sciences and European Regional Development Fund (MySMIS 107124: Funding
   Contract 2/Axa 1/31.07.2017/107124 SMIS).
CR Aaby P, 2012, P NATL ACAD SCI USA, V109, P17317, DOI 10.1073/pnas.1215761109
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Alfaraj SH, 2017, INTERVIROLOGY, V60, P53, DOI 10.1159/000477908
   Amimo F, 2020, TROP MED HEALTH, V48, DOI 10.1186/s41182-020-00219-6
   Andersen P, 2005, NAT REV MICROBIOL, V3, P656, DOI 10.1038/nrmicro1211
   Angelidou A, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00332
   Beaute J., 2017, TUBERCULOSIS SURVEIL, V150
   Brode SK, 2015, THORAX, V70, P677, DOI 10.1136/thoraxjnl-2014-206470
   Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P321
   Chu DK, 2020, LANCET, V395, P1973, DOI 10.1016/S0140-6736(20)31142-9
   Co DO, 2006, J IMMUNOL, V177, P8456, DOI 10.4049/jimmunol.177.12.8456
   Coker RJ, 2004, TROP MED INT HEALTH, V9, P25, DOI 10.1046/j.1365-3156.2003.01156.x
   Covian C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02806
   Curtis N, 2020, LANCET, V395, P1545, DOI 10.1016/S0140-6736(20)31025-4
   Dheda K, 2014, LANCET RESP MED, V2, P321, DOI 10.1016/S2213-2600(14)70031-1
   Di L, 2018, J CLIN LAB ANAL, V32, DOI 10.1002/jcla.22273
   Eriksson KK, 2006, CLIN DEV IMMUNOL, V13, P353, DOI 10.1080/17402520600579168
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Gao Y, 2020, J MED VIROL, DOI 10.1002/jmv.26311
   Golli AL, 2019, INT J TUBERC LUNG D, V23, P226, DOI 10.5588/ijtld.18.0270
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Harding E, 2020, LANCET RESP MED, V8, P19, DOI 10.1016/S2213-2600(19)30418-7
   Harris J, 2010, CLIN EXP IMMUNOL, V161, P1, DOI 10.1111/j.1365-2249.2010.04146.x
   Hollm-Delgado MG, 2014, PEDIATRICS, V133, pE73, DOI 10.1542/peds.2013-2218
   Hotchkiss JR, 2006, EMERG INFECT DIS, V12, P159
   Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001
   Kuate S, 2007, VIROLOGY, V362, P26, DOI 10.1016/j.virol.2006.12.011
   Kwon YS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129792
   Li JY, 2020, MICROBES INFECT, V22, P80, DOI 10.1016/j.micinf.2020.02.002
   Li TS, 2004, J INFECT DIS, V189, P648, DOI 10.1086/381535
   Li Z, 2020, CHIN MANAG STUD, DOI 10.1108/CMS-01-2020-0001
   Liu W, 2006, EMERG INFECT DIS, V12, P707, DOI 10.3201/eid1204.050264
   Low JGH, 2004, CLIN INFECT DIS, V38, pE123, DOI 10.1086/421396
   Lu LL, 2019, NAT MED, V25, P977, DOI 10.1038/s41591-019-0441-3
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Manyazewal T, 2020, NAT MED, V26, P811, DOI 10.1038/s41591-020-0917-1
   Mayer-Barber KD, 2015, IMMUNOL REV, V264, P264, DOI 10.1111/imr.12249
   Motta I, 2020, PULMONOLOGY, V26, P233, DOI 10.1016/j.pulmoe.2020.05.002
   Nitu FM, 2017, ROM J MORPHOL EMBRYO, V58, P385
   Noymer A, 2011, VACCINE, V29, pB38, DOI 10.1016/j.vaccine.2011.02.053
   Oei W, 2012, COMPUT MATH METHOD M, DOI 10.1155/2012/124861
   Organisation W. H, 2009, WHO INF TUB PAND INF
   Organization W. H, 2019, COR DIS COVID 19 PAN
   Organization W. H, 2020, MERS SIT UPD
   Organization W. H, 2020, ADDR NEEDS VULN POP
   Pang JX, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030623
   Pollard AJ, 2017, ARCH DIS CHILD, V102, P1077, DOI 10.1136/archdischild-2015-310282
   Raoult D, 2020, CELL STRESS, V4, P66, DOI 10.15698/cst2020.04.216
   Redford PS, 2014, J INFECT DIS, V209, P270, DOI 10.1093/infdis/jit424
   Rello J, 2020, ANAESTH CRIT CARE PA, V39, P167, DOI 10.1016/j.accpm.2020.03.001
   Robson B, 2020, COMPUT BIOL MED, V119, DOI 10.1016/j.compbiomed.2020.103670
   Roth S, 2013, INFLUENZA OTHER RESP, V7, P244, DOI 10.1111/j.1750-2659.2012.00413.x
   Rusen ID, 2020, TROP MED INFECT DIS, V5, DOI 10.3390/tropicalmed5020086
   Salehi S, 2020, AM J ROENTGENOL, V215, P87, DOI [10.2214/AJR.20.23034, 10.2214/AJR.20.23034S.]
   Small CL, 2010, J IMMUNOL, V184, P2048, DOI 10.4049/jimmunol.0902772
   Soto JA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02875
   Stochino C, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01708-2020
   Tadolini M, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01398-2020
   Walaza S, 2020, INFLUENZA OTHER RESP, V14, P77, DOI 10.1111/irv.12670
   Walaza S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129173
   Wang N, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00298
   Whittaker E, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00233
   Yamasue M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58459-9
   Yasri Sora, 2020, Indian J Tuberc, V67, P264, DOI 10.1016/j.ijtb.2020.02.004
   Zhang NR, 2014, EXPERT REV VACCINES, V13, P761, DOI 10.1586/14760584.2014.912134
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zignol M, 2012, B WORLD HEALTH ORGAN, V90, P111, DOI 10.2471/BLT.11.092585
NR 68
TC 0
Z9 0
U1 5
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1198-2241
EI 1916-7245
J9 CAN RESPIR J
JI Can. Respir. J.
PD SEP 8
PY 2020
VL 2020
AR 1401053
DI 10.1155/2020/1401053
PG 10
WC Respiratory System
SC Respiratory System
GA NU9WX
UT WOS:000573987000001
PM 32934758
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kang, SJ
   Tanaka, T
   Inoue, H
   Ono, C
   Hashimoto, S
   Kioi, Y
   Matsumoto, H
   Matsuura, H
   Matsubara, T
   Shimizu, K
   Ogura, H
   Matsuura, Y
   Kishimoto, T
AF Kang, Sujin
   Tanaka, Toshio
   Inoue, Hitomi
   Ono, Chikako
   Hashimoto, Shoji
   Kioi, Yoshiyuki
   Matsumoto, Hisatake
   Matsuura, Hiroshi
   Matsubara, Tsunehiro
   Shimizu, Kentaro
   Ogura, Hiroshi
   Matsuura, Yoshiharu
   Kishimoto, Tadamitsu
TI IL-6 trans-signaling induces plasminogen activator inhibitor-1 from
   vascular endothelial cells in cytokine release syndrome
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE IL-6; tocilizumab; endothelial cell; cytokine release syndrome; COVID-19
ID INFLAMMATORY RESPONSE; RECEPTOR; INTERLEUKIN-6; SEPSIS; MARKER; SERUM
AB Cytokine release syndrome (CRS) is a life-threatening complication induced by systemic inflammatory responses to infections, including bacteria and chimeric antigen receptor T cell therapy. There are currently no immunotherapies with proven clinical efficacy and understanding of the molecular mechanisms of CRS pathogenesis is limited. Here, we found that patients diagnosed with CRS from sepsis, acute respiratory distress syndrome (ARDS), or burns showed common manifestations: strikingly elevated levels of the four proinflammatory cytokines interleukin (IL)-6, IL-8, monocyte chemotactic protein-1 (MCP-1), and IL-10 and the coagulation cascade activator plasminogen activator inhibitor-1 (PAI-1). Our in vitro data indicate that endothelial IL-6 trans-signaling formed an inflammation circuit for robust IL-6, IL-8, and MCP-1 production and promoted PAI-1 production; additionally, an IL-6 signaling blockade by the human monoclonal antibody tocilizumab blunted endothelial cell activation. Plasma from severe COVID-19 patients similarly exhibited increased IL-6, IL-10, and MCP-1 levels, but these levels were not as high as those in patients with CRS from other causes. In contrast, the PAI-1 levels in COVID-19 patients were as highly elevated as those in patients with bacterial sepsis or ARDS. Tocilizumab treatment decreased the PAI-1 levels and alleviated critical illness in severe COVID-19 patients. Our findings suggest that distinct levels of cytokine production are associated with CRS induced by bacterial infection and COVID-19, but both CRS types are accompanied by endotheliopathy through IL-6 trans-signaling. Thus, the present study highlights the crucial role of IL-6 signaling in endothelial dysfunction during bacterial infection and COVID-19.
C1 [Kang, Sujin; Inoue, Hitomi; Kioi, Yoshiyuki; Kishimoto, Tadamitsu] Osaka Univ, Immunol Frontier Res Ctr, Dept Immune Regulat, Suita, Osaka 5650871, Japan.
   [Tanaka, Toshio] Osaka Habikino Med Ctr, Med Affairs Bur, Osaka 5838588, Japan.
   [Ono, Chikako; Matsuura, Yoshiharu] Osaka Univ, Microbial Dis Res Inst, Dept Mol Virol, Suita, Osaka 5650871, Japan.
   [Hashimoto, Shoji] Osaka Habikino Med Ctr, Dept Clin Lab, Osaka 5838588, Japan.
   [Matsumoto, Hisatake; Matsuura, Hiroshi; Matsubara, Tsunehiro; Shimizu, Kentaro; Ogura, Hiroshi] Osaka Univ, Grad Sch Med, Dept Traumatol & Acute Crit Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
RP Kishimoto, T (corresponding author), Osaka Univ, Immunol Frontier Res Ctr, Dept Immune Regulat, Suita, Osaka 5650871, Japan.
EM kishimoto@ifrec.osaka-u.ac.jp
OI Matsubara, Tsunehiro/0000-0002-0910-3124
FU Ono Medical Research Foundation; Takeda Science FoundationTakeda Science
   Foundation (TSF); Kishimoto Foundation
FX We thank M. Okawa for secretarial assistance and Mitchell Arico, Melissa
   Crawford, PhD, and Katie Oakley, PhD, from Edanz Group for editing a
   draft of this manuscript. We thank A. Osuka (Japan Community Health Care
   Organization Chukyo Hospital) for providing the sera of patients with
   burns. This work was supported by research grants from the Ono Medical
   Research Foundation (to S.K.), Takeda Science Foundation (to S.K.), and
   Kishimoto Foundation.
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Bonetti PO, 2003, ARTERIOSCL THROM VAS, V23, P168, DOI 10.1161/01.ATV.0000051384.43104.FC
   Esmon CT, 1999, HAEMATOLOGICA, V84, P254
   Fink MP, 2014, NAT REV DRUG DISCOV, V13, P741, DOI 10.1038/nrd4368
   Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kang SJ, 2019, IMMUNITY, V50, P1007, DOI 10.1016/j.immuni.2019.03.026
   Lord JM, 2014, LANCET, V384, P1455, DOI 10.1016/S0140-6736(14)60687-5
   Lu ZY, 2012, ARTERIOSCL THROM VAS, V32, P1696, DOI 10.1161/ATVBAHA.112.251181
   Matsumoto H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32275-8
   Matsuura H, 2019, SHOCK, V51, P185, DOI 10.1097/SHK.0000000000001152
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Nishimoto N, 2008, BLOOD, V112, P3959, DOI 10.1182/blood-2008-05-155846
   Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4
   Pierrakos C, 2010, CRIT CARE, V14, DOI 10.1186/cc8872
   PRALONG G, 1989, THROMB HAEMOSTASIS, V61, P459
   Ranieri VM, 2012, NEW ENGL J MED, V366, P2055, DOI 10.1056/NEJMoa1202290
   Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9
   Rose-John S, 2017, CLIN PHARMACOL THER, V102, P591, DOI 10.1002/cpt.782
   Stearns-Kurosawa DJ, 2011, ANNU REV PATHOL-MECH, V6, P19, DOI 10.1146/annurev-pathol-011110-130327
   Teachey DT, 2013, BLOOD, V121, P5154, DOI 10.1182/blood-2013-02-485623
   Terpstra ML, 2014, CRIT CARE MED, V42, P691, DOI 10.1097/01.ccm.0000435669.60811.24
   van der Poll T, 2017, NAT REV IMMUNOL, V17, P407, DOI 10.1038/nri.2017.36
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333
   Wang ZG, 2018, BIOMARK RES, V6, DOI 10.1186/s40364-018-0116-0
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Zegeye MM, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0268-4
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 32
TC 1
Z9 1
U1 2
U2 2
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 8
PY 2020
VL 117
IS 36
BP 22351
EP 22356
DI 10.1073/pnas.2010229117
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NT5GH
UT WOS:000572968600006
PM 32826331
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Xia, SL
   Duan, K
   Zhang, YT
   Zhao, DY
   Zhang, HJ
   Xie, ZQ
   Li, XG
   Peng, C
   Zhang, YB
   Zhang, W
   Yang, YK
   Chen, W
   Gao, XX
   You, WY
   Wang, XW
   Wang, ZJ
   Shi, ZL
   Wang, YX
   Yang, XQ
   Zhang, LH
   Huang, LL
   Wang, Q
   Lu, J
   Yang, YL
   Guo, J
   Zhou, W
   Wan, X
   Wu, C
   Wang, WH
   Huang, SH
   Du, JH
   Meng, ZY
   Pan, A
   Yuan, ZM
   Shen, S
   Guo, WS
   Yang, XM
AF Xia, Shengli
   Duan, Kai
   Zhang, Yuntao
   Zhao, Dongyang
   Zhang, Huajun
   Xie, Zhiqiang
   Li, Xinguo
   Peng, Cheng
   Zhang, Yanbo
   Zhang, Wei
   Yang, Yunkai
   Chen, Wei
   Gao, Xiaoxiao
   You, Wangyang
   Wang, Xuewei
   Wang, Zejun
   Shi, Zhengli
   Wang, Yanxia
   Yang, Xuqin
   Zhang, Lianghao
   Huang, Lili
   Wang, Qian
   Lu, Jia
   Yang, Yongli
   Guo, Jing
   Zhou, Wei
   Wan, Xin
   Wu, Cong
   Wang, Wenhui
   Huang, Shihe
   Du, Jianhui
   Meng, Ziyan
   Pan, An
   Yuan, Zhiming
   Shen, Shuo
   Guo, Wanshen
   Yang, Xiaoming
TI Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and
   Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID CORONAVIRUS; VIRUS
AB This interim analysis of 2 randomized trials compares adverse reactions and neutralizing antibody responses to inactivated coronavirus disease 2019 (COVID-19) vs adjuvant-only control vaccination, and compares the outcomes at varying vaccine doses among healthy adults in China.
   Question What are the safety and immunogenicity of an inactivated vaccine against coronavirus disease 2019 (COVID-19)? Findings This was an interim analysis of 2 randomized placebo-controlled trials. In 96 healthy adults in a phase 1 trial of patients randomized to aluminum hydroxide (alum) only and low, medium, and high vaccine doses on days 0, 28, and 56, 7-day adverse reactions occurred in 12.5%, 20.8%, 16.7%, and 25.0%, respectively; geometric mean titers of neutralizing antibodies at day 14 after the third injection were 316, 206 and 297 in the low-, medium-, and high-dose groups, respectively. In 224 healthy adults randomized to the medium dose, 7-day adverse reactions occurred in 6.0% and 14.3% of the participants who received injections on days 0 and 14 vs alum only, and 19.0% and 17.9% who received injections on days 0 and 21 vs alum only, respectively; geometric mean titers of neutralizing antibodies in the vaccine groups at day 14 after the second injection were 121 vs 247, respectively. Meaning This inactivated COVID-19 vaccine had a low rate of adverse reactions and demonstrated immunogenicity, but longer-term assessment of safety and efficacy will require phase 3 trials.
   Importance A vaccine against coronavirus disease 2019 (COVID-19) is urgently needed. Objective To evaluate the safety and immunogenicity of an investigational inactivated whole-virus COVID-19 vaccine in China. Interventions In the phase 1 trial, 96 participants were assigned to 1 of the 3 dose groups (2.5, 5, and 10 mu g/dose) and an aluminum hydroxide (alum) adjuvant-only group (n = 24 in each group), and received 3 intramuscular injections at days 0, 28, and 56. In the phase 2 trial, 224 adults were randomized to 5 mu g/dose in 2 schedule groups (injections on days 0 and 14 [n = 84] vs alum only [n = 28], and days 0 and 21 [n = 84] vs alum only [n = 28]). Design, Setting, and Participants Interim analysis of ongoing randomized, double-blind, placebo-controlled, phase 1 and 2 clinical trials to assess an inactivated COVID-19 vaccine. The trials were conducted in Henan Province, China, among 96 (phase 1) and 224 (phase 2) healthy adults aged between 18 and 59 years. Study enrollment began on April 12, 2020. The interim analysis was conducted on June 16, 2020, and updated on July 27, 2020. Main Outcomes and Measures The primary safety outcome was the combined adverse reactions 7 days after each injection, and the primary immunogenicity outcome was neutralizing antibody response 14 days after the whole-course vaccination, which was measured by a 50% plaque reduction neutralization test against live severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Results Among 320 patients who were randomized (mean age, 42.8 years; 200 women [62.5%]), all completed the trial up to 28 days after the whole-course vaccination. The 7-day adverse reactions occurred in 3 (12.5%), 5 (20.8%), 4 (16.7%), and 6 (25.0%) patients in the alum only, low-dose, medium-dose, and high-dose groups, respectively, in the phase 1 trial; and in 5 (6.0%) and 4 (14.3%) patients who received injections on days 0 and 14 for vaccine and alum only, and 16 (19.0%) and 5 (17.9%) patients who received injections on days 0 and 21 for vaccine and alum only, respectively, in the phase 2 trial. The most common adverse reaction was injection site pain, followed by fever, which were mild and self-limiting; no serious adverse reactions were noted. The geometric mean titers of neutralizing antibodies in the low-, medium-, and high-dose groups at day 14 after 3 injections were 316 (95% CI, 218-457), 206 (95% CI, 123-343), and 297 (95% CI, 208-424), respectively, in the phase 1 trial, and were 121 (95% CI, 95-154) and 247 (95% CI, 176-345) at day 14 after 2 injections in participants receiving vaccine on days 0 and 14 and on days 0 and 21, respectively, in the phase 2 trial. There were no detectable antibody responses in all alum-only groups. Conclusions and Relevance In this interim report of the phase 1 and phase 2 trials of an inactivated COVID-19 vaccine, patients had a low rate of adverse reactions and demonstrated immunogenicity; the study is ongoing. Efficacy and longer-term adverse event assessment will require phase 3 trials.
C1 [Xia, Shengli; Zhao, Dongyang; Xie, Zhiqiang; Zhang, Wei; You, Wangyang; Wang, Yanxia; Huang, Lili; Guo, Wanshen] Henan Ctr Dis Control & Prevent, Zhengzhou, Henan, Peoples R China.
   [Duan, Kai; Li, Xinguo; Chen, Wei; Wang, Zejun; Zhang, Lianghao; Lu, Jia; Guo, Jing; Zhou, Wei; Wan, Xin; Wu, Cong; Wang, Wenhui; Huang, Shihe; Du, Jianhui; Meng, Ziyan; Shen, Shuo; Yang, Xiaoming] Wuhan Inst Biol Prod Co Ltd, Natl Engn Technol Res Ctr Combined Vaccines, Wuhan, Hubei, Peoples R China.
   [Zhang, Yuntao; Yang, Yunkai; Wang, Xuewei; Yang, Xuqin; Wang, Qian; Yang, Xiaoming] China Natl Biotec Grp Co Ltd, 4 Hui Xin E St, Beijing, Peoples R China.
   [Zhang, Huajun; Peng, Cheng; Gao, Xiaoxiao; Shi, Zhengli; Yuan, Zhiming] Chinese Acad Sci, Wuhan Inst Virol, Key Lab Special Pathogens, Ctr Biosafety Mega Sci, Wuhan, Hubei, Peoples R China.
   [Zhang, Yanbo; Pan, An] Huazhong Univ Sci & Technol, Key Lab Environm & Hlth, Dept Epidemiol & Biostat, Minist Educ, Wuhan, Hubei, Peoples R China.
   [Zhang, Yanbo; Pan, An] Huazhong Univ Sci & Technol, State Key Lab Environm Hlth Incubat, Sch Publ Hlth, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Yang, Yongli] Zhengzhou Univ, Dept Epidemiol & Biostat, Coll Publ Hlth, Zhengzhou, Henan, Peoples R China.
   [Pan, An] Huazhong Univ Sci & Technol, Natl Med Ctr Major Publ Hlth Events, Wuhan, Hubei, Peoples R China.
RP Pan, A (corresponding author), Huazhong Univ Sci & Technol, Sch Publ Hlth, Tongji Med Coll, 13 Hangkong Rd, Wuhan, Peoples R China.; Yang, XM (corresponding author), China Natl Biotec Grp Co Ltd, 4 Hui Xin E St, Beijing, Peoples R China.
EM panan@hust.edu.cn; yangxiaoming@sinopharm.com
RI Zhang, Yan-Bo/N-5858-2019; Pan, An/C-5572-2011
OI Zhang, Yan-Bo/0000-0003-1054-9657; Pan, An/0000-0002-1089-7945
FU National Program on Key Research Project of China [2020YFC0842100];
   Major Science and Technology Project of the National New Drug
   Development of China [2018ZX09734-004]; China National Biotec Group Co
   Ltd; Wuhan Institute of Biological Products Co Ltd.
FX This study was supported by the National Program on Key Research Project
   of China (2020YFC0842100) and Major Science and Technology Project of
   the National New Drug Development of China (2018ZX09734-004). The
   vaccine was developed and the study was sponsored by the China National
   Biotec Group Co Ltd and the Wuhan Institute of Biological Products Co
   Ltd.
CR [Anonymous], 2020, DRAFT LANDSC COVID 1
   Cao WCC, 2007, NEW ENGL J MED, V357, P1162, DOI 10.1056/NEJMc070348
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671
   Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Eroshenko N, 2020, NAT BIOTECHNOL, V38, P789, DOI 10.1038/s41587-020-0577-1
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   FULGINITI VA, 1967, J AMER MED ASSOC, V202, P1075, DOI 10.1001/jama.202.12.1075
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Hotez PJ, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0358-6
   Hotez PJ, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0323-4
   Ibarrondo FJ, 2020, NEW ENGL J MED, V383, P1085, DOI 10.1056/NEJMc2025179
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955
   Le Bert N, 2020, NATURE, DOI 10.1038/s41586-020-2550-z
   Lin JT, 2007, ANTIVIR THER, V12, P1107
   Liu T, 2020, PREVALENCE IGG ANTIB, DOI [DOI 10.1101/2020.06.13.20130252, 10.1101/2020.06.13.20130252]
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Luchsinger Larry L, 2020, medRxiv, DOI 10.1101/2020.06.08.20124792
   Martin JE, 2008, VACCINE, V26, P6338, DOI 10.1016/j.vaccine.2008.09.026
   Mulligan M. J., 2020, PHASE 1 2 STUDY DESC, DOI [10.1101/2020.06.30.20142570, DOI 10.1101/2020.06.30.20142570]
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Sahin U, 2020, CONCURRENT HUMAN ANT, DOI [10.1101/2020.07.17.20140533, DOI 10.1101/2020.07.17.20140533]
   Stern PL, 2020, ANN ALLERG ASTHMA IM, V125, P17, DOI 10.1016/j.anai.2020.01.025
   Wang H, 2020, CELL, V182, P713, DOI 10.1016/j.cell.2020.06.008
   Wang Xiaoli, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa721
   World Health Organization, WHO COR DIS COVID 19
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 34
TC 22
Z9 21
U1 16
U2 16
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD SEP 8
PY 2020
VL 324
IS 10
BP 951
EP 960
DI 10.1001/jama.2020.15543
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA NR9EX
UT WOS:000571867000018
PM 32789505
OA Bronze
DA 2021-01-01
ER

PT J
AU Valle-Suarez, RM
   Calderon-Mendoza, GL
   Lanza-Sorto, NA
   Ponce-Rodriguez, HD
AF Valle-Suarez, R. M.
   Calderon-Mendoza, G. L.
   Lanza-Sorto, N. A.
   Ponce-Rodriguez, H. D.
TI Teaching Instrumental Analytical Chemistry in the Framework of COVID-19:
   Experiences and Outlook
SO JOURNAL OF CHEMICAL EDUCATION
LA English
DT Article
DE Upper-Division Undergraduate; Analytical Chemistry; Distance
   Learning/Self Instruction; Drugs/Pharmaceuticals
AB Significant changes in the teaching-learning process have occurred since the appearance of the COVID-19 pandemic caused by the SARS-CoV 2 coronavirus, due to the limited mobility and closure of university education centers. In this context, essential challenges were presented for teachers and to finish the academic courses by addressing the programmatic;contents without undermining the learning quality. Likewise,en the teaching of upper-division undergraduate. subjects with a high academic load in laboratory practices represents a greater difficulty, since these competencies are acquired in the classroom teaching system. In this communication, the authors present the experiences, difficulties, and results obtained in the teaching of instrumental' analytical chemistry and its applications for biological samples analysis, focused on the access to technology, learning of practical; skills, and evaluation of student learning of a public university, in the context of COVID-19 disease.
C1 [Valle-Suarez, R. M.; Calderon-Mendoza, G. L.; Lanza-Sorto, N. A.; Ponce-Rodriguez, H. D.] Univ Nacl Autonoma Honduras, Dept Control Quim, Fac Ciencias Quim & Farm, Ciudad Univ, Tegucigalpa 11101, Honduras.
RP Ponce-Rodriguez, HD (corresponding author), Univ Nacl Autonoma Honduras, Dept Control Quim, Fac Ciencias Quim & Farm, Ciudad Univ, Tegucigalpa 11101, Honduras.
EM henry.ponce@unah.edu.hn
OI Ponce-Rodriguez, Henry Daniel/0000-0002-8949-7679
FU UNAH Faculty of Chemistry and Pharmacy
FX The research reported here was supported by the UNAH Faculty of
   Chemistry and Pharmacy. We are grateful to laboratory assistants R. I.
   Esponda-Velasquez and B. A. RiveraMartinez.
CR [Anonymous], SIM CHROM DAT
   Blackburn RAR, 2019, J CHEM EDUC, V96, P153, DOI 10.1021/acs.jchemed.8b00549
   Boswell PG, 2013, J CHEM EDUC, V90, P198, DOI 10.1021/ed300117b
   Bowers W. G., 1924, J CHEM EDUC, V1, P205
   Durovic-Pejcev RD, 2019, J AOAC INT, V102, P46, DOI 10.5740/jaoacint.18-0296
   Gas Chromatography, 2019, QUICK BIOCH BASICS
   Giammatteo L., 2018, SCI ED INT, V29, P103
   Martinez-Lara JM, 2017, REV INT CONTAM AMBIE, V33, P559, DOI 10.20937/rica.2017.33.04.02
   Martin-Fernandez B, 2016, PROFESORADO, V20, P140
   Ram P, 1999, J CHEM EDUC, V76, P1122, DOI 10.1021/ed076p1122
   Vosegaard T, 2018, J CHEM EDUC, V95, P97, DOI 10.1021/acs.jchemed.7b00482
NR 11
TC 0
Z9 0
U1 6
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-9584
EI 1938-1328
J9 J CHEM EDUC
JI J. Chem. Educ.
PD SEP 8
PY 2020
VL 97
IS 9
BP 2723
EP 2726
DI 10.1021/acs.jchemed.0c00707
PG 4
WC Chemistry, Multidisciplinary; Education, Scientific Disciplines
SC Chemistry; Education & Educational Research
GA NP2MX
UT WOS:000570016400047
DA 2021-01-01
ER

PT J
AU Peng, P
   Barham, GR
   Hunnicutt, W
   Li, LM
   Moment, AJ
AF Peng, Peng
   Barham, Gabriella Reis
   Hunnicutt, William
   Li, Liming
   Moment, Aaron J.
TI Designing a Hybrid Biopharmaceutical Laboratory Course to Enhance
   Content Flexibility and Access
SO JOURNAL OF CHEMICAL EDUCATION
LA English
DT Article
DE Upper-Division Undergraduate; Graduate Education/Research; Chemical
   Engineering; Laboratory Instruction;
   Interdisciplinlry/Multidisciplinary; Internet/Web-Based Learning;
   Hands-on LearniNg/Manipulatives; Drugs/Pharrnacetiticals;
   Crystals/Crystallography; Transport Properties
AB Herein we report the design of an upper-level hybrid laboratory course in the area of applied biopharmaceuticals, which has high scheduling flexibility, and utilizes both virtual and in-person educational elements to enhance students learning experience. This newly developed course applies chemical engineering knowledge, practical and theoretical, in the bioprocess and pharmaceutical industry, including crystallization, chromatography, and mass transport. During the COVID-19 pandemic, we transferred this lab course to a completely virtual mode during midsemester of Spring 2020. Despite the lack of in-person experiments during the second half of the semester, we introduced various additional elements including modeling, simulation, literature review, and added lectures to the virtual version of the course to improve students learning experience. These additional elements introduced during the virtual period enriched the course content and exposed students to more advanced applications of the knowledge in this course, which can be implemented in future hybrid modes. Although the student performance on quizzes and lab reports remained consistent after the transition to online format, the instructors noticed students struggling with data mined from previous groups. The root cause of this was not being able to create and observe their own data in real time, which could be improved by developing better remote data collection methods. Another lesson we learned during this experience is the value of keeping an experimental video archive for all of our laboratory modules, regardless of plans for remote learning.
C1 [Peng, Peng; Barham, Gabriella Reis; Moment, Aaron J.] Columbia Univ, Dept Chem Engn, New York, NY 10027 USA.
   [Peng, Peng] Columbia Univ, Dept Earth & Environm Engn, New York, NY 10027 USA.
   [Hunnicutt, William; Li, Liming] Columbia Univ, Dept Civil Engn & Engn Mech, Robert AW Carleton Strength Mat Lab, New York, NY 10027 USA.
RP Moment, AJ (corresponding author), Columbia Univ, Dept Chem Engn, New York, NY 10027 USA.
EM ajm2293@columbia.edu
OI Peng, Peng/0000-0001-6554-2247; Moment, Aaron/0000-0002-1220-927X
CR ALBAL RS, 1983, CHEM ENG J BIOCH ENG, V27, P61, DOI 10.1016/0300-9467(83)80053-7
   Andrews JL, 2020, J CHEM EDUC, V97, P1887, DOI 10.1021/acs.jchemed.0c00483
   Bao Wei, 2020, Hum Behav Emerg Technol, V2, P113, DOI 10.1002/hbe2.191
   Bernstein J., 2002, POLYMORPH MOL CRYST, P1
   Dunmire E., 2016, 2016 ASEE ANN C EXP
   Dyrberg NR, 2017, J BIOL EDUC, V51, P358, DOI 10.1080/00219266.2016.1257498
   Enneking KM, 2019, J CHEM EDUC, V96, P1058, DOI 10.1021/acs.jchemed.8b00637
   ERWIN DK, 1991, J CHEM EDUC, V68, P862, DOI 10.1021/ed068p862
   Fair JD, 2014, J CHEM EDUC, V91, P2084, DOI 10.1021/ed400570f
   Geankoplis C. J, 2003, TRANSPORT PROCESSES
   Hall S., 2015, INT J TEACHING LEARN, V27, P69
   Hansen SJR, 2016, J CHEM EDUC, V93, P663, DOI 10.1021/acs.jchemed.5b00710
   He Y, 2012, J CHEM EDUC, V89, P1128, DOI 10.1021/ed200685p
   Konig L, 2015, COMPLEX BEHAVIOR IN EVOLUTIONARY ROBOTICS, P35
   O'Sullivan JW, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.2064
   Olney D, 1997, J CHEM EDUC, V74, P1343, DOI 10.1021/ed074p1343
   Peng A. S., 2014, 2014 ASEE N MIDW SEC, DOI [10.17077/aseenmw2014.1047, DOI 10.17077/ASEENMW2014.1047]
   Ray S., 2020, J PROTEINS PROTEOMIC, V11, P1
   Rose J., 2019, MAXIMIZING STUDENT E
   Sun CC, 2008, INT J PHARMACEUT, V346, P93, DOI 10.1016/j.ijpharm.2007.06.017
   SZMANT HH, 1985, J CHEM EDUC, V62, P736, DOI 10.1021/ed062p736
   Turner J., 2008, J TEACHING SCI, V54, P20
   Tuysuz C, 2010, INT ONLINE J ED SCI, V2, P37
   Wang CY, 2020, J RISK FINANC MANAG, V13, DOI 10.3390/jrfm13020036
   White C., 2006, J CHEM EDUC, V83, P353
   Young-Suk Shin, 2004, International Journal of Distance Education Technologies, V2, P62
NR 26
TC 0
Z9 0
U1 3
U2 3
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-9584
EI 1938-1328
J9 J CHEM EDUC
JI J. Chem. Educ.
PD SEP 8
PY 2020
VL 97
IS 9
BP 3121
EP 3128
DI 10.1021/acs.jchemed.0c00564
PG 8
WC Chemistry, Multidisciplinary; Education, Scientific Disciplines
SC Chemistry; Education & Educational Research
GA NP2MX
UT WOS:000570016400122
DA 2021-01-01
ER

PT J
AU Purtill, D
   Antonenas, V
   Chiappini, P
   Tong, DC
   O'Flaherty, E
   Bajel, A
   Kabani, K
   Larsen, S
   Tan, S
   Hutchins, C
   Curtis, DJ
   Kennedy, GA
   Watson, AM
   Bai, LJ
   Greenwood, M
   Gottlieb, DJ
   Hamad, N
AF Purtill, Duncan
   Antonenas, Vicki
   Chiappini, Paul
   Tong, Daochen
   O'Flaherty, Elizabeth
   Bajel, Ashish
   Kabani, Karieshma
   Larsen, Stephen
   Tan, Suikeat
   Hutchins, Cheryl
   Curtis, David J.
   Kennedy, Glen A.
   Watson, Anne-Marie
   Bai, LiJun
   Greenwood, Matthew
   Gottlieb, David J.
   Hamad, Nada
TI Variable CD34(+) recovery of cryopreserved allogeneic HPC products:
   transplant implications during the COVID-19 pandemic
SO BLOOD ADVANCES
LA English
DT Article
ID HEMATOPOIETIC-CELL TRANSPLANTATION; ENGRAFTMENT; IMPACT
AB Donor registries and transplantation societies recommend cryopreservation of unrelated donor hemopoietic progenitor cell (HPC) products before the recipient commences conditioning therapy to mitigate the donor and travel risks associated with the COVID-19 pandemic. However, little is known regarding the postthaw quality of such allogeneic products or the effect of precryopreservation storage and processing on these characteristics. We investigated the postthaw CD34(+) cell recovery and viability of 305 allogeneic HPC products cryopreserved at 9 laboratories across Australia. Median postthaw CD34(+) cell recovery was 76% and ranged from 6% to 122%. Longer transit time before cryopreservation, white cell count (WCC) during storage, and complex product manipulation before cryopreservation were independently associated with inferior postthaw CD34(+) cell recovery. Longer precryopreservation transit time and WCC were also associated with inferior postthaw CD34(+) cell viability. We conclude that although postthaw CD34(+) cell recovery and viability of cryopreserved allogeneic HPC is generally acceptable, there is a significant risk of poor postthaw product quality, associated with prolonged storage time, higher WCC, and complex product manipulation precryopreservation. Awareness of expected postthaw recovery and practices that influence it will assist collection, processing, and transplant centers in optimizing outcomes for transplant recipients.
C1 [Purtill, Duncan] Fiona Stanley Hosp, 11 Robin Warren Dr, Murdoch, WA 6150, Australia.
   [Purtill, Duncan] PathWest Lab Med, Murdoch, WA, Australia.
   [Antonenas, Vicki; Tong, Daochen; Gottlieb, David J.] Westmead Hosp, Sydney, NSW, Australia.
   [Chiappini, Paul; O'Flaherty, Elizabeth; Bajel, Ashish] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
   [O'Flaherty, Elizabeth; Bajel, Ashish] Royal Melbourne Hosp, Melbourne, Vic, Australia.
   [Kabani, Karieshma; Larsen, Stephen] Royal Prince Alfred Hosp, Sydney, NSW, Australia.
   [Larsen, Stephen; Greenwood, Matthew; Gottlieb, David J.] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia.
   [Tan, Suikeat; Hamad, Nada] St Vincents Hosp, Darlinghurst, NSW, Australia.
   [Hutchins, Cheryl; Kennedy, Glen A.] Royal Brisbane & Womans Hosp, Herston, Qld, Australia.
   [Curtis, David J.] Alfred Hlth, Melbourne, Vic, Australia.
   [Curtis, David J.] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic, Australia.
   [Watson, Anne-Marie] Liverpool Hosp, Liverpool, NSW, Australia.
   [Bai, LiJun; Greenwood, Matthew] Royal North Shore Hosp, St Leonards, NSW, Australia.
   [Hamad, Nada] Univ New South Wales, Fac Med, Sydney, NSW, Australia.
RP Purtill, D (corresponding author), Fiona Stanley Hosp, 11 Robin Warren Dr, Murdoch, WA 6150, Australia.
EM duncan.purtill@health.wa.gov.au
RI Hamad, Nada/AAR-9461-2020
OI Hamad, Nada/0000-0001-7929-1450; Purtill, Duncan/0000-0002-0408-8455
CR Australian Bone Marrow Donor Registry, 2019, ABMDR STD NCU 10 TRA
   Avery S, 2011, BLOOD, V117, P3277, DOI 10.1182/blood-2010-08-300491
   Berens C, 2016, CYTOTHERAPY, V18, P1325, DOI 10.1016/j.jcyt.2016.06.014
   Eapen M, 2020, BIOL BLOOD MARROW TR, V26, pE161, DOI 10.1016/j.bbmt.2020.04.027
   European Society for Blood and Marrow Transplantation, 2020, COR DIS COVID 19 EMB
   Fisher V, 2014, TRANSFUSION, V54, P1088, DOI 10.1111/trf.12428
   Hamad N., 2020, BONE MARROW TRANSPLA
   Hamadani M, 2020, BIOL BLOOD MARROW TR, V26, P1312, DOI 10.1016/j.bbmt.2020.04.001
   Medd P, 2013, BONE MARROW TRANSPL, V48, P243, DOI 10.1038/bmt.2012.118
   National Marrow Donor Program, DON PROD CRYOPR
   Patton WN, 2017, BIOL BLOOD MARROW TR, V23, P147, DOI 10.1016/j.bbmt.2016.09.026
   Purtill D, 2014, BLOOD, V124, P2905, DOI 10.1182/blood-2014-03-566216
   World Marrow Donor Association, 2020, SPEAR RAP AL
NR 13
TC 1
Z9 1
U1 1
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 2473-9529
EI 2473-9537
J9 BLOOD ADV
JI Blood Adv.
PD SEP 8
PY 2020
VL 4
IS 17
BP 4147
EP 4150
DI 10.1182/bloodadvances.2020002431
PG 4
WC Hematology
SC Hematology
GA NL4ZO
UT WOS:000567426100012
PM 32886750
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Fischer, T
AF Fischer, Thomas
TI Data monitoring committees-state of the art and perspectives for the
   future
SO BUNDESGESUNDHEITSBLATT-GESUNDHEITSFORSCHUNG-GESUNDHEITSSCHUTZ
LA German
DT Article
DE Data monitoring committees; Statistical analysis; BfArM databank; New
   study designs; COVID-19
ID MASTER PROTOCOLS; CLINICAL-TRIALS; EU REGULATION
AB Background The classic randomized and controlled clinical trial is facing new challenges with complex study designs and disease interception concepts. For this reason, data monitoring committees (DMCs) can take on a central function if professionally integrated into the methodical procedure of clinical trials. On this basis, the responsible competent authority and the responsible ethics committee have to verify the substantial charter document in the implicit/explicit approval procedure reflecting the working process of the independent committee. Objectives The frequencies and conditions under which DMCs are used in clinical trials was investigated. Methods The database of the Federal Institute for Drugs and Medical Devices (BfArM) was the basis for statistical analysis concerning the frequency of implementation of data monitoring committees with different criteria over an observation period of more than 15 years. Results In total, 4152 DMCs have been used in 14,135 clinical trials with drugs. The independent expert committee was mostly integrated by commercial sponsors in phase III of the clinical development. The ethics committees were involved with different absolute frequencies. Discussion Sponsors demonstrate an increasing willingness to integrate DMCs in the methodical conduct of clinical trials especially in the case of new study designs. DMCs could be an important scientific aid in order to assess the implications of coronavirus SARS-CoV-2 on clinical trials.
C1 [Fischer, Thomas] Bundesinst Arzneimittel Med Prod, Fachgebiet Klin Prufung Klin, Kurt Georg Kiesinger Allee 3, D-53175 Bonn, Germany.
RP Fischer, T (corresponding author), Bundesinst Arzneimittel Med Prod, Fachgebiet Klin Prufung Klin, Kurt Georg Kiesinger Allee 3, D-53175 Bonn, Germany.
EM Thomas.Fischer@bfarm.de
FU Projekt DEAL
FX Open Access funding provided by Projekt DEAL.
CR [Anonymous], 2005, OP GUID EST FUNCT DA
   [Anonymous], 2018, EMA4920102018
   [Anonymous], 2005, GUID DAT MON COMM
   [Anonymous], 2006, GUID CLIN TRIAL SPON
   CANNER PL, 1981, CONTROL CLIN TRIALS, V1, P363
   DeMets DL, 2016, NEW ENGL J MED, V375, P1365, DOI 10.1056/NEJMra1510066
   Ellenberg SS, 2004, STAT MED, V23, P1503, DOI 10.1002/sim.1784
   Ellenberg SS, 2015, CLIN TRIALS, V12, P530, DOI 10.1177/1740774515597697
   EMA, 2020, GUID MAN CLIN TRIALS
   European Medicines Agency (EMA), 2020, POINTS CONS IMPL COR
   Fischer T, 2008, BUNDESGESUNDHEITSBLA, V51, P793, DOI 10.1007/s00103-008-0588-4
   FISCHER T, 2009, BRIT J CLIN PHARM S1, V68, P37
   Fleming TR, 2018, CLIN TRIALS, V15, P321, DOI 10.1177/1740774518764855
   Fleming TR, 2017, CLIN TRIALS, V14, P115, DOI 10.1177/1740774516688915
   Fleming TR, 2014, J BIOPHARM STAT, V24, P968, DOI 10.1080/10543406.2014.925719
   Grant AM, 2005, LANCET, V365, P711
   Hasford J, 2017, BUNDESGESUNDHEITSBLA, V60, P830, DOI 10.1007/s00103-017-2580-3
   Hazenberg A, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0222-6
   Kielmansegg S, 2019, BUNDESGESUNDHEITSBLA, V62, P706
   Levin GP, 2014, BIOMETRICS, V70, P556, DOI 10.1111/biom.12168
   Neaton JD, 2018, CLIN TRIALS, V15, P359, DOI 10.1177/1740774518764449
   Nickel L, 2017, BUNDESGESUNDHEITSBLA, V60, P804, DOI 10.1007/s00103-017-2574-1
   Sartor O, 2015, UROL ONCOL-SEMIN ORI, V33, P143, DOI 10.1016/j.urolonc.2014.12.013
   Stegert M, 2016, J CLIN EPIDEMIOL, V69, P152, DOI 10.1016/j.jclinepi.2015.05.023
   Sudhop T, 2019, LANCET ONCOL, V20, pE336, DOI 10.1016/S1470-2045(19)30271-2
   Wan H, 2015, STAT MED, V34, P27, DOI 10.1002/sim.6311
   Woodcock J, 2017, NEW ENGL J MED, V377, P62, DOI 10.1056/NEJMra1510062
NR 27
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1436-9990
EI 1437-1588
J9 BUNDESGESUNDHEITSBLA
JI Bundesgesundheitsblatt-Gesund.
PD DEC
PY 2020
VL 63
IS 12
SI SI
BP 1511
EP 1518
DI 10.1007/s00103-020-03212-w
EA SEP 2020
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OV3UD
UT WOS:000567373100002
PM 32897407
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ong, WY
   Go, ML
   Wang, DY
   Cheah, IKM
   Halliwell, B
AF Ong, Wei-Yi
   Go, Mei-Lin
   Wang, De-Yun
   Cheah, Irwin Kee-Mun
   Halliwell, Barry
TI Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for
   Treatment of COVID-19-Related Neurologic Complications
SO MOLECULAR NEUROBIOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; COVID; SARS; Coronavirus; Antimalarials; Statins;
   Chloroquine; Hydroxychloroquine; Quinacrine; Aminoacridine; Cytosolic
   phospholipase A(2); cPLA(2); Secretory phospholipase A(2); sPLA(2)IID;
   TNF-alpha; DMT1; Iron transport; Arachidonic acid; Eicosanoids;
   Inflammation; Neuroinflammation; Microglia; Lysosomes; Oxidative stress;
   Free radical damage; Carotid body; Aortic body; Nucleus of the tractus
   solitarius; Glossopharyngeal nerve; Vagus nerve; Respiratory centre;
   Hippocampus; Stroke; Microvessels; Microcirculation; Brain endothelial
   cells; Vascular dementia
ID CYTOPLASMIC PHOSPHOLIPASE A(2); DIVALENT METAL TRANSPORTER-1;
   NF-KAPPA-B; RAT HIPPOCAMPUS; PLASMA 7-KETOCHOLESTEROL; ARACHIDONIC-ACID;
   APOLIPOPROTEIN D; NEURONAL DEATH; QUINACRINE; CORONAVIRUS
AB The SARS-CoV-2 virus that is the cause of coronavirus disease 2019 (COVID-19) affects not only peripheral organs such as the lungs and blood vessels, but also the central nervous system (CNS)-as seen by effects on smell, taste, seizures, stroke, neoropathological findings and possibly, loss of control of respiration resulting in silent hypoxemia. COVID-19 induces an inflammatory response and, in severe cases, a cytokine storm that can damage the CNS. Antimalarials have unique properties that distinguish them from other anti-inflammatory drugs. (A) They are very lipophilic, which enhances their ability to cross the blood-brain barrier (BBB). Hence, they have the potential to act not only in the periphery but also in the CNS, and could be a useful addition to our limited armamentarium against the SARS-CoV-2 virus. (B) They are non-selective inhibitors of phospholipase A(2) isoforms, including cytosolic phospholipase A(2)(cPLA(2)). The latter is not only activated by cytokines but itself generates arachidonic acid, which is metabolized by cyclooxygenase (COX) to pro-inflammatory eicosanoids. Free radicals are produced in this process, which can lead to oxidative damage to the CNS. There are at least 4 ways that antimalarials could be useful in combating COVID-19. (1) They inhibit PLA(2.)(2) They are basic molecules capable of affecting the pH of lysosomes and inhibiting the activity of lysosomal enzymes. (3) They may affect the expression and Fe2+/H+ symporter activity of iron transporters such as divalent metal transporter 1 (DMT1), hence reducing iron accumulation in tissues and iron-catalysed free radical formation. (4) They would affect viral replication. The latter may be related to their effect on inhibition of PLA(2) isoforms. Inhibition of cPLA(2) impairs an early step of coronavirus replication in cell culture. In addition, a secretory PLA(2)(sPLA(2)) isoform, PLA2G2D, has been shown to be essential for the lethality of SARS-CoV in mice. It is important to take note of what ongoing clinical trials on chloroquine and hydroxychloroquine can eventually tell us about the use of antimalarials and other anti-inflammatory agents, not only for the treatment of COVID-19, but also for neurovascular disorders such as stroke and vascular dementia.
C1 [Ong, Wei-Yi] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 119260, Singapore.
   [Ong, Wei-Yi; Cheah, Irwin Kee-Mun; Halliwell, Barry] Natl Univ Singapore, Life Sci Inst, Neurobiol Programme, Singapore 119260, Singapore.
   [Go, Mei-Lin] Natl Univ Singapore, Fac Sci, Dept Pharm, Singapore 119260, Singapore.
   [Wang, De-Yun] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Otolaryngol, Singapore 119260, Singapore.
   [Cheah, Irwin Kee-Mun; Halliwell, Barry] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Biochem, Singapore 119260, Singapore.
RP Ong, WY (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 119260, Singapore.; Ong, WY; Halliwell, B (corresponding author), Natl Univ Singapore, Life Sci Inst, Neurobiol Programme, Singapore 119260, Singapore.
EM antongwy@nus.edu.sg; bchbh@nus.edu.sg
OI Ong, Wei-Yi/0000-0001-9756-7772
FU Ministry of Education, SingaporeMinistry of Education, Singapore
FX This work was supported by a grant from the Ministry of Education,
   Singapore.
CR Aboughdir M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050527
   Agarwal S, 2020, STROKE, V51, P2649, DOI 10.1161/STROKEAHA.120.030940
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Balasubramanian SK, 2013, BIOMATERIALS, V34, P5439, DOI 10.1016/j.biomaterials.2013.03.080
   Beauverd Y, 2020, EUR J HAEMATOL, V105, P357, DOI 10.1111/ejh.13432
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Bondeson J, 1998, GEN PHARMACOL, V30, P357, DOI 10.1016/S0306-3623(97)00269-3
   Bosetti F, 2003, J NEUROCHEM, V87, P1471, DOI 10.1046/j.1471-4159.2003.02118.x
   Burdo JR, 2001, J NEUROSCI RES, V66, P1198, DOI 10.1002/jnr.1256.abs
   Butowt R, 2020, ACS CHEM NEUROSCI, V11, P1200, DOI 10.1021/acschemneuro.0c00172
   CABIRAC GF, 1994, MICROB PATHOGENESIS, V16, P349, DOI 10.1006/mpat.1994.1035
   Cataldi M, 2020, NEUROBIOL DIS, V143, DOI 10.1016/j.nbd.2020.105007
   Chuang DY, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0419-0
   Clark DE, 2003, DRUG DISCOV TODAY, V8, P927, DOI 10.1016/S1359-6446(03)02827-7
   Colafrancesco S, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102573
   Cooper KW, 2020, NEURON, V107, P219, DOI 10.1016/j.neuron.2020.06.032
   Danta CC, 2020, ACS CHEM NEUROSCI, V11, P2137, DOI 10.1021/acschemneuro.0c00335
   De Felice FG, 2020, TRENDS NEUROSCI, V43, P355, DOI 10.1016/j.tins.2020.04.004
   De Santis G, 2020, BRAIN BEHAV IMMUN, V87, P95, DOI 10.1016/j.bbi.2020.04.066
   Divani AA, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104941
   Do Carmo S, 2008, J NEUROSCI, V28, P10330, DOI 10.1523/JNEUROSCI.2644-08.2008
   DUBIN NH, 1982, FERTIL STERIL, V38, P735
   Farooqui AA, 2006, PHARMACOL REV, V58, P591, DOI 10.1124/pr.58.3.7
   Farooqui Akhlaq A, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P85, DOI 10.2174/1568006043481239
   Feng W, 2017, APOPTOSIS, V22, P696, DOI 10.1007/s10495-017-1363-5
   Fotuhi M, 2020, J ALZHEIMERS DIS, V76, P3, DOI 10.3233/JAD-200581
   Gane SB, 2020, RHINOLOGY, V58, P299, DOI 10.4193/Rhin20.114
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Halliwell B., 2015, FREE RADICALS BIOL M
   Han WK, 2003, J BIOL CHEM, V278, P24153, DOI 10.1074/jbc.M300424200
   Harberts E, 2011, P NATL ACAD SCI USA, V108, P13734, DOI 10.1073/pnas.1105143108
   He X, 2009, NEUROSCI LETT, V455, P183, DOI 10.1016/j.neulet.2009.03.038
   HOMEWOOD CA, 1972, NATURE, V235, P50, DOI 10.1038/235050a0
   HOSTETLER KY, 1989, MOL CELL BIOCHEM, V88, P77
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang MX, 2020, J MOL CELL BIOL, V12, P322, DOI 10.1093/jmcb/mjaa014
   JONES R, 1994, FORENSIC SCI INT, V68, P29, DOI 10.1016/0379-0738(94)90376-X
   Kishi F, 1998, BIOCHEM BIOPH RES CO, V251, P775, DOI 10.1006/bbrc.1998.9415
   Koka S, 2017, REDOX BIOL, V13, P336, DOI 10.1016/j.redox.2017.06.004
   Larrayoz IM, 2010, INVEST OPHTH VIS SCI, V51, P4942, DOI 10.1167/iovs.09-4854
   Laurendon T, 2020, NEUROLOGY, V95, P224, DOI 10.1212/WNL.0000000000009850
   Lee CYJ, 2009, ANTIOXID REDOX SIGN, V11, P407, DOI [10.1089/ars.2008.2179, 10.1089/ARS.2008.2179]
   Lee IT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072783
   Lee KCH, 2020, INT J INFECT DIS, V96, P615, DOI 10.1016/j.ijid.2020.05.115
   Lee PL, 1998, BLOOD CELL MOL DIS, V24, P199, DOI 10.1006/bcmd.1998.0186
   Li D, 2016, DRUG LIKE PROPERTIES
   Li YC, 2020, J MED VIROL, V92, P552, DOI 10.1002/jmv.25728
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Lobell M, 2003, J PHARM SCI-US, V92, P360, DOI 10.1002/jps.10282
   Loke SY, 2013, NEUROSCIENCE, V245, P179, DOI 10.1016/j.neuroscience.2013.04.008
   Lu XR, 2001, FREE RADICAL BIO MED, V30, P1263, DOI 10.1016/S0891-5849(01)00528-7
   Lu XR, 2001, EXP BRAIN RES, V138, P500, DOI 10.1007/s002210100737
   Luo SF, 2008, TOXICOL APPL PHARM, V232, P396, DOI 10.1016/j.taap.2008.07.019
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P4539, DOI 10.26355/eurrev_202004_21038
   Million M, 2020, New Microbes New Infect, V38, P100709, DOI 10.1016/j.nmni.2020.100709
   Muller C, 2018, J VIROL, V92, DOI 10.1128/JVI.01463-17
   Murakami H, 2000, LIPIDS, V35, P333, DOI 10.1007/s11745-000-0530-1
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Ong WY, 2015, ACS CHEM NEUROSCI, V6, P814, DOI 10.1021/acschemneuro.5b00073
   Ong WY, 2005, J ALZHEIMERS DIS, V8, P183
   Ong WY, 1999, J NEUROCHEM, V72, P1574, DOI 10.1046/j.1471-4159.1999.721574.x
   Ong WY, 2003, EXP NEUROL, V183, P449, DOI 10.1016/S0014-4886(03)00174-2
   Ong WY, 2003, EXP BRAIN RES, V148, P521, DOI 10.1007/s00221-002-1315-2
   Palasca O, 2018, DATABASE-OXFORD, DOI 10.1093/database/bay028
   Paniz-Mondolfi A, 2020, J MED VIROL, V92, P699, DOI 10.1002/jmv.25915
   PATERSON S, 1984, J CELL PHYSIOL, V120, P225, DOI 10.1002/jcp.1041200217
   Pham YT, 1999, INT J CLIN PHARM TH, V37, P58
   Politi LS, 2020, JAMA NEUROL, V77, P1028, DOI 10.1001/jamaneurol.2020.2125
   Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187
   Rey A, 1998, BBA-LIPID LIPID MET, V1393, P244, DOI 10.1016/S0005-2760(98)00080-0
   Rodrigues-Diez RR, 2020, BRIT J PHARMACOL, V177, P4873, DOI 10.1111/bph.15166
   Roldan EQ, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104904
   Sardu C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051417
   Sharma OP, 1998, ARCH NEUROL-CHICAGO, V55, P1248, DOI 10.1001/archneur.55.9.1248
   Shawki A, 2012, CURR TOP MEMBR, V70, P169, DOI 10.1016/B978-0-12-394316-3.00005-3
   Song JY, 2017, CIRC RES, V120, P1622, DOI 10.1161/CIRCRESAHA.117.311049
   Stuhlmeier KM, 2000, BBA-GEN SUBJECTS, V1524, P57, DOI 10.1016/S0304-4165(00)00140-9
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Thi HTN, 2008, BIOORGAN MED CHEM, V16, P6737, DOI 10.1016/j.bmc.2008.05.060
   Nguyen T, 2011, EUR J MED CHEM, V46, P2917, DOI 10.1016/j.ejmech.2011.04.016
   Van Gool WA, 2001, LANCET, V358, P455, DOI 10.1016/S0140-6736(01)05623-9
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Vespignani H, 2020, ANN NEUROL, V88, P626, DOI 10.1002/ana.25814
   Vijay R, 2015, J EXP MED, V212, P1851, DOI 10.1084/jem.20150632
   von Weyhern CH, 2020, LANCET, V395, pE109, DOI 10.1016/S0140-6736(20)31282-4
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang M, 2017, HEART, V103, P1788, DOI 10.1136/heartjnl-2016-310914
   Wang XS, 2003, NEUROSCIENCE, V120, P21, DOI 10.1016/S0306-4522(03)00293-8
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yang C, 2019, EXP EYE RES, V189, DOI 10.1016/j.exer.2019.107849
   Yu LE, 2007, NANOTOXICOLOGY, V1, P235, DOI 10.1080/17435390701763108
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhang XJ, 2020, CELL METAB, V32, P176, DOI 10.1016/j.cmet.2020.06.015
   Zhang XW, 2019, J NEUROCHEM, V148, P499, DOI 10.1111/jnc.14640
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
   Zhou LY, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101642
   Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017
   ZIDOVETZKI R, 1993, J PARASITOL, V79, P565, DOI 10.2307/3283384
   Zubair AS, 2020, JAMA NEUROL, V77, P1018, DOI 10.1001/jamaneurol.2020.2065
NR 102
TC 1
Z9 1
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0893-7648
EI 1559-1182
J9 MOL NEUROBIOL
JI Mol. Neurobiol.
PD JAN
PY 2021
VL 58
IS 1
BP 106
EP 117
DI 10.1007/s12035-020-02093-z
EA SEP 2020
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA PE6QW
UT WOS:000567450900001
PM 32897518
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Michel, S
   Witt, C
   Gottlieb, J
   Aigner, C
AF Michel, Sebastian
   Witt, Christian
   Gottlieb, Jens
   Aigner, Clemens
CA German Transplantation Soc
TI Impact of COVID-19 on Lung Transplant Activity in Germany-A
   Cross-Sectional Survey
SO THORACIC AND CARDIOVASCULAR SURGEON
LA English
DT Article; Early Access
DE transplantation; lung; infection; intensive care
AB The current COVID-19 pandemia affects health care systems worldwide, however, to a variable extent depending on the caseload in each country. We aimed to provide a cross-sectional overview of current limitations or adaptions in lung transplant programs in Germany in from January to May 2020 due to the COVID-19 pandemia caused by severe acute respiratory syndrome coronavirus 2. A cross-sectional survey assessing various aspects of lung transplant activity was sent to all active lung transplant programs ( n =12) in Germany. Eight centers (66%) responded to the survey within the requested time frame. Four centers (50%) reported their activity is not restricted at all and four centers (50%) reported on moderate general limitations. The overall lung transplant activity in Germany from January to May 2020 contains 128 bilateral and 11 single lung transplantations, which is similar to the same period in the year 2019 (126 bilateral transplantations and 12 single lung transplantations). The results suggest that the influence of the COVID-19 pandemia on lung transplantation activity in Germany has been moderate so far. Nevertheless, adaptions such as extensive testing of donors and recipients were introduced to reduce the likelihood of infections and increase patient safety. Alertness to changes in COVID-19 reproduction rates might be required until effective antiviral therapy or vaccination is available.
C1 [Michel, Sebastian] LMU Munchen, Dept Cardiac Surg, Munich, Bayern, Germany.
   [Witt, Christian] Charite, Dept Resp Med, Berlin, Germany.
   [Gottlieb, Jens] MHH, Dept Resp Med, Hannover, Niedersachsen, Germany.
   [Gottlieb, Jens] MHH, German Ctr Lung Res, Hannover, Niedersachsen, Germany.
   [Aigner, Clemens] Univ Duisburg Essen, Dept Thorac Surg, Med Fak, Essen, Germany.
RP Aigner, C (corresponding author), Univ Duisburg Essen, Dept Thorac Surg, Univ Med Essen, Ruhrlandklin, Essen, Germany.
EM clemens.aigner@rlk.uk-essen.de
CR Aigner C, 2020, J HEART LUNG TRANSPL, V39, P610, DOI 10.1016/j.healun.2020.04.004
   Akalin E, 2020, NEW ENGL J MED, V382, P2475, DOI 10.1056/NEJMc2011117
   Angelico R, 2020, AM J TRANSPLANT, V20, P1780, DOI 10.1111/ajt.15904
   Carbajo-Lozoya J, 2012, VIRUS RES, V165, P112, DOI 10.1016/j.virusres.2012.02.002
   de Vries APJ, 2020, TRANSPL IMMUNOL, V61, DOI 10.1016/j.trim.2020.101304
   Kates OS, 2020, AM J TRANSPLANT, V20, P1885, DOI 10.1111/ajt.15944
   Li F, 2020, AM J TRANSPLANT, V20, P1859
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 8
TC 0
Z9 0
U1 1
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0171-6425
EI 1439-1902
J9 THORAC CARDIOV SURG
JI Thorac. Cardiovasc. Surg.
DI 10.1055/s-0040-1715436
EA SEP 2020
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA NK8CR
UT WOS:000566959400003
PM 32898894
DA 2021-01-01
ER

PT J
AU Zhao, R
   Zhou, Q
   Wang, XW
   Liu, CH
   Wang, M
   Yang, Q
   Zhai, YH
   Zhu, DQ
   Chen, J
   Fang, XY
   Tang, XS
   Zhang, H
   Shen, Q
   Xu, H
AF Zhao, Rui
   Zhou, Qing
   Wang, Xiao-Wen
   Liu, Cui-Hua
   Wang, Mo
   Yang, Qing
   Zhai, Yi-Hui
   Zhu, Da-Qian
   Chen, Jing
   Fang, Xiao-Yan
   Tang, Xiao-Shan
   Zhang, Hui
   Shen, Qian
   Xu, Hong
TI COVID-19 Outbreak and Management Approach for Families with Children on
   Long-Term Kidney Replacement Therapy
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
DE Renal replacement therapy; COVID-19; SARS-CoV-2; End-stage kidney
   disease; Caregivers; Families; Mainland China; Children
ID DEPRESSIVE SYMPTOMS; VERSION; PHQ-9
AB Background and objectives During the coronavirus disease 2019 outbreak, the treatment of families with children on long-term KRT is challenging. This study was conducted to identify the current difficulties, worries regarding the next 2 months, and mental distress experienced by families with children on long-term KRT during the coronavirus disease 2019 outbreak and to deliver possible management approaches to ensure uninterrupted treatment for children on long-term KRT.
   Design, setting, participants, & measurements A multicenter online survey was conducted between February 10 and 15, 2020, among the families with children on long-term KRT from five major pediatric dialysis centers in mainland China. The primary caregivers of children currently on long-term KRT were eligible and included. Demographic information, severe acute respiratory syndrome coronavirus 2 infection status, current difficulties, and worries regarding the next 2 months were surveyed using a self-developed questionnaire. The Patient Health Questionnaire-9 and the General Anxiety Disorder Scale-7 were used to screen for depressive symptoms and anxiety, respectively.
   Results Among the children in the 220 families included in data analysis, 113 (51%) children were on dialysis, and the other 107 (49%) had kidney transplants. No families reported confirmed or suspected cases of coronavirus disease 2019. Overall, 135 (61%) and 173 (79%) caregivers reported having difficulties now and havingworries regarding thenext 2 months, respectively. Dialysis supply shortage (dialysis group) and hard to have blood tests (kidney transplantation group) weremost commonly reported. A total of 29 (13%) caregivers had depressive symptoms, and 24 (11%) had anxiety. After the survey, we offered online and offline interventions to address their problems. At the time of the submission of this paper, no treatment interruption had been reported.
   Conclusions The coronavirus disease 2019 outbreak has had physical, mental, logistical, and financial effects on families with children on long-term KRT.
C1 [Zhao, Rui; Zhou, Qing; Zhai, Yi-Hui; Chen, Jing; Fang, Xiao-Yan; Tang, Xiao-Shan; Zhang, Hui; Shen, Qian; Xu, Hong] Fudan Univ, Childrens Hosp, Dept Nephrol, Lane 399 Wanyuan Rd, Shanghai 201102, Peoples R China.
   [Wang, Xiao-Wen] Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan Childrens Hosp, Dept Nephrol, Wuhan, Peoples R China.
   [Liu, Cui-Hua] Zhengzhou Univ, Affiliated Childrens Hosp, Dept Nephrol & Rheumatol, Zhengzhou, Peoples R China.
   [Wang, Mo] Chongqing Med Univ, Childrens Hosp, Dept Nephrol, Chongqing, Peoples R China.
   [Yang, Qing] Wenzhou Med Univ, Affiliated Hosp 2, Dept Nephrol, Wenzhou, Peoples R China.
   [Yang, Qing] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
   [Zhu, Da-Qian] Fudan Univ, Childrens Hosp, Dept Psychol, Shanghai, Peoples R China.
RP Shen, Q; Xu, H (corresponding author), Fudan Univ, Childrens Hosp, Dept Nephrol, Lane 399 Wanyuan Rd, Shanghai 201102, Peoples R China.
EM shenqian@shmu.edu; hxu@shmu.edu.cn
FU Emergency COVID-19 Research Funding of Children's Hospital of Fudan
   University [EKXGZX005]
FX This work was supported by Emergency COVID-19 Research Funding of
   Children's Hospital of Fudan University grant EKXGZX005.
CR Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen TM, 2006, PSYCHIAT SERV, V57, P976, DOI 10.1176/appi.ps.57.7.976
   Chin WY, 2016, ANN FAM MED, V14, P47, DOI 10.1370/afm.1854
   Chinese Medical Doctor Association of Youth Pediatric Nephrology, 2020, CHIN J EVID BASED PE, V15, P15
   He C, 2020, PSYCHOTHER PSYCHOSOM, V89, P25, DOI 10.1159/000502294
   He X, 2010, SHANGHAI ARCH PSYCHI, V22, P200, DOI DOI 10.3969/J.ISSN.1002-0829.2010.04.002
   Lima Angélica Godoy Torres, 2019, Braz. J. Nephrol., V41, P356, DOI [10.1590/2175-8239-jbn-2018-0039, 10.1590/2175-8239-JBN-2018-0039]
   Luo ZC, 2019, GEN HOSP PSYCHIAT, V60, P50, DOI 10.1016/j.genhosppsych.2019.07.008
   Montag C, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02247
   Shen Q, 2020, PEDIATR NEPHROL, V35, P1351, DOI 10.1007/s00467-020-04555-x
   Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Tsai TC, 2006, KIDNEY INT, V70, P1983, DOI 10.1038/sj.ki.5001811
   Wang WZ, 2014, GEN HOSP PSYCHIAT, V36, P539, DOI 10.1016/j.genhosppsych.2014.05.021
   World Health Organization, 2020, 152 WHO
   World Health Organization, 2020, 11 WHO
   World Health Organization, 2020, WHO CHIN JOINT MISS
   Wu Z, JAMA, DOI 10.1001/jama.2020.2648 32091533
   Yu XN, 2012, COMPR PSYCHIAT, V53, P95, DOI 10.1016/j.comppsych.2010.11.002
NR 19
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555-9041
EI 1555-905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD SEP 7
PY 2020
VL 15
IS 9
BP 1259
EP 1266
DI 10.2215/CJN.03630320
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA NQ5YT
UT WOS:000570946300010
PM 32665227
OA Bronze
DA 2021-01-01
ER

PT J
AU Kharma, N
   Roehrig, S
   Shible, AA
   Elshafei, MS
   Osman, D
   Elsaid, IM
   Mustafa, SF
   Aldabi, A
   Smain, OAM
   Lance, MD
AF Kharma, Nadir
   Roehrig, Stefan
   Shible, Ahmed Atef
   Elshafei, Moustafa Sayed
   Osman, Dema
   Elsaid, Ingi Mohamed
   Mustafa, Salma Faisal
   Aldabi, Asjad
   Smain, Osamah A. M.
   Lance, Marcus D.
TI Anticoagulation in critically ill patients on mechanical ventilation
   suffering from COVID-19 disease, The ANTI-CO trial: A structured summary
   of a study protocol for a randomised controlled trial
SO TRIALS
LA English
DT Letter
DE COVID-19; randomised controlled trial; protocol; anticoagulation;
   thrombosis; Anti-Co trial
AB Objectives: To assess the effect of anticoagulation with bivalirudin administered intravenously on gas-exchange in patients with COVID-19 and respiratory failure using invasive mechanical ventilation.
   Trial design: This is a single centre parallel group, superiority, randomized (1:1 allocation ratio) controlled trial.
   Participants: All patients admitted to the Hamad Medical Corporation -ICU in Qatar for COVID-19 associated respiratory distress and in need of mechanical ventilation are screened for eligibility. Inclusion criteria: all adult patients admitted to the ICU who test positive for COVID-19 by PCR-test and in need for mechanical ventilation are eligible for inclusion. Upon crossing the limit of D-dimers (1.2 mg/L) these patients are routinely treated with an increased dose of anticoagulant according to our local protocol. This will be the start of randomization.
   Exclusion criteria: pregnancy, allergic to the drug, inherited coagulation abnormalities, no informed consent.
   Intervention and comparator: The intervention group will receive the anticoagulant bivalirudin intravenously with a target aPTT of 45-70 sec for three days while the control group will stay on the standard treatment with low-molecular-weight heparins /unfractionated heparin subcutaneously (see scheme in Additional file1).
   All other treatment will be unchanged and left to the attending physicians.
   Main outcomes: As a surrogate parameter for clinical improvement and primary outcome we will use the PaO2/FiO2 (P/F) ratio.
   Randomisation: After inclusion, the patients will be randomized using a closed envelope method into the conventional treatment group, which uses the standard strategy and the experimental group which receives anticoagulation treatment with bivalirudin using an allocation ratio of 1:1.
   Blinding (masking): Due to logistical and safety reasons (assessment of aPTT to titrate the study drug) only the data-analyst will be blinded to the groups.
   Numbers to be randomised (sample size): We performed a sample size calculation and assumed the data for P/F ratio (according to literature) is normally distributed and used the mean which would be: 160 and SD is 80. We expect the treatment will improve this by 30%. In order to reach a power of 80% we would need 44 patients per group (in total 88 patients). Taking approximately 10% of dropout into account we will include 100 patients (50 in each group).
   Trial Status: The local registration number is MRC-05-082 with the protocol version number 2. The date of approval is 18th June 2020. Recruitment started on 28(th)June and is expected to end in November 2020.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file2). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Kharma, Nadir; Elshafei, Moustafa Sayed] Hamad Med Corp HMC, Dept Med Intens Care, Al Rayyan Rd, Doha, Qatar.
   [Roehrig, Stefan; Lance, Marcus D.] Hamad Med Corp HMC, Dept Anesthesiol Intens Care & Perioperat Med, Al Rayyan Rd, Doha, Qatar.
   [Shible, Ahmed Atef] Hamad Med Corp HMC, Dept Pharm, Al Rayyan Rd, Doha, Qatar.
   [Osman, Dema; Elsaid, Ingi Mohamed; Mustafa, Salma Faisal; Aldabi, Asjad; Smain, Osamah A. M.] Hamad Med Corp HMC, Dept Med Educ, Al Rayyan Rd, Doha, Qatar.
RP Lance, MD (corresponding author), Hamad Med Corp HMC, Dept Anesthesiol Intens Care & Perioperat Med, Al Rayyan Rd, Doha, Qatar.
EM Mlance@hamad.qa
OI Shible, Ahmed/0000-0002-7901-7686
FU HMC
FX This project was supported by HMC only. HMC plays no part in study
   design; collection, management, analysis, and interpretation of data;
   writing this summary; and decisions to submit a report for publication.
NR 0
TC 2
Z9 2
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD SEP 7
PY 2020
VL 21
IS 1
AR 769
DI 10.1186/s13063-020-04689-1
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NQ5ZS
UT WOS:000570949100003
PM 32895056
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mi, BB
   Chen, L
   Tong, DK
   Panayi, AC
   Ji, F
   Guo, JF
   Hou, ZY
   Zhang, YZ
   Xiong, Y
   Liu, GH
AF Mi, Bobin
   Chen, Lang
   Tong, Dake
   Panayi, Adriana C.
   Ji, Fang
   Guo, Junfei
   Hou, Zhiyong
   Zhang, Yingze
   Xiong, Yuan
   Liu, Guohui
TI Delayed surgery versus nonoperative treatment for hip fractures in
   post-COVID-19 arena: a retrospective study of 145 patients
SO ACTA ORTHOPAEDICA
LA English
DT Article; Early Access
AB Background and purpose - Following the outbreak of COVID-19 in December 2019, in China, many hip fracture patients were unable to gain timely admission and surgery. We assessed whether delayed surgery improves hip joint function and reduces major complications better than nonoperative therapy. Patients and methods - In this retrospective observational study, we collected data from 24 different hospitals from January 1, 2020, to July 20, 2020. 145 patients with hip fractures aged 65 years or older were eligible. Clinical data was extracted from electronic medical records. The primary outcomes were visual analogue scale (VAS) score and Harris Hip Score. Major complications, including deep venous thrombosis (DVT) and pneumonia within 1 month and 3 months, were collected for further analysis. Results - Of the 145 hip fracture patients 108 (median age 72; 70 females) received delayed surgery and 37 (median age 74; 20 females) received nonoperative therapy. The median time from hip fracture injury to surgery was 33 days (IQR 24-48) in the delayed surgery group. Hypertension, in about half of the patients in both groups, and cerebral infarction, in around a quarter of patients in both groups, were the most common comorbidities. Both VAS score and Harris Hip Score were superior in the delayed surgery group. At the 3-month follow-up, the median VAS score was 1 in the delayed surgery group and 2.5 in the nonoperative group (p < 0.001). Also, the percentage of complications was higher in the nonoperative group (p = 0.004 for DVT, p < 0.001 for pulmonary infection). Interpretation - In hip fracture patients, delayed surgery compared with nonoperative therapy significantly improved hip function and reduced various major complications.
C1 [Mi, Bobin; Chen, Lang; Xiong, Yuan; Liu, Guohui] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthoped, Wuhan, Peoples R China.
   [Panayi, Adriana C.] Harvard Med Coll, Brigham & Womens Hosp, Dept Plast Surg, Boston, MA USA.
   [Tong, Dake] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Orthoped, Sch Med, Shanghai, Peoples R China.
   [Ji, Fang] Changhai Hosp, Dept Orthoped, Shanghai, Peoples R China.
   [Guo, Junfei; Hou, Zhiyong; Zhang, Yingze] Hebei Med Univ, Dept Orthopaed Surg, Hosp 3, Shijiazhuang, Hebei, Peoples R China.
RP Liu, GH (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthoped, Wuhan, Peoples R China.
EM liuguohui@hust.edu.cn
RI Panayi, Adriana C./AAF-1817-2020
OI Panayi, Adriana C./0000-0003-4053-9855
CR Ekeloef S, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l6395
   Forster R, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004179.pub2
   Goh EL, 2020, INJURY, V51, P1331, DOI 10.1016/j.injury.2020.03.031
   Neuman MD, 2014, JAMA INTERN MED, V174, P1273, DOI 10.1001/jamainternmed.2014.2362
   NHCC . National Health Commission of China, 2020, STAT COUNC JOINT PRE
   Papadimitriou N, 2017, LANCET PUBLIC HEALTH, V2, pE239, DOI 10.1016/S2468-2667(17)30046-4
   Prommik P, 2019, ACTA ORTHOP, V90, P159, DOI 10.1080/17453674.2018.1562816
   Sasabuchi Y, 2018, INJURY, V49, P1848, DOI 10.1016/j.injury.2018.07.026
   Shin WC, 2016, J BONE JOINT SURG AM, V98, P2089, DOI 10.2106/JBJS.15.01329
   Sinvani L, 2020, J AM GERIATR SOC, V68, P1706, DOI 10.1111/jgs.16483
   Spandorfer J, 2015, ANN INTERN MED, V162, DOI 10.7326/AITC201505050
   Xing F, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891-018-2371-5
NR 12
TC 1
Z9 1
U1 2
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1745-3674
EI 1745-3682
J9 ACTA ORTHOP
JI Acta Orthop.
DI 10.1080/17453674.2020.1816617
EA SEP 2020
PG 5
WC Orthopedics
SC Orthopedics
GA NL1QM
UT WOS:000567198400001
PM 32896189
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Kumar, A
   Kumar, P
   Saumya, KU
   Kapuganti, SK
   Bhardwaj, T
   Giri, R
AF Kumar, Amit
   Kumar, Prateek
   Saumya, Kumar Udit
   Kapuganti, Shivani K.
   Bhardwaj, Taniya
   Giri, Rajanish
TI Exploring the SARS-CoV-2 structural proteins for multi-epitope vaccine
   development: anin-silicoapproach
SO EXPERT REVIEW OF VACCINES
LA English
DT Article
DE SARS-CoV-2; vaccine; epitopes; spike glycoprotein; nucleocapsid;
   envelope
ID ACUTE RESPIRATORY SYNDROME; NUCLEOCAPSID PROTEIN; SARS; PREDICTION;
   CORONAVIRUSES; DISCOVERY; INTERACTS; RESPONSES; MEMBRANE; DISORDER
AB Introduction The ongoing life-threatening pandemic of coronavirus disease 2019 (COVID-19) has extensively affected the world. During this global health crisis, it is fundamentally crucial to find strategies to combat SARS-CoV-2. Despite several efforts in this direction and continuing clinical trials, no vaccine has been approved for it yet. Methods To find a preventive measure, we have computationally designed a multi-epitopic subunit vaccine using immuno-informatic approaches. Results The structural proteins of SARS-CoV-2 involved in its survival and pathogenicity were used to predict antigenic epitopes. The antigenic epitopes were capable of eliciting a strong humoral as well as cell-mediated immune response, our predictions suggest. The final vaccine was constructed by joining the all epitopes with specific linkers and to enhance their stability and immunogenicity. The physicochemical property of the vaccine was assessed. The vaccine 3D structure prediction and validation were done and docked with the human TLR-3 receptor. Furthermore, molecular dynamics simulations of the vaccine-TLR-3 receptor complex are employed to assess its dynamic motions and binding stabilityin-silico. Conclusion Based on this study, we strongly suggest synthesizing this vaccine, which further can be testedin-vitroandin-vivoto check its potency in a cure for COVID-19.
C1 [Kumar, Amit; Kumar, Prateek; Saumya, Kumar Udit; Kapuganti, Shivani K.; Bhardwaj, Taniya; Giri, Rajanish] Indian Inst Technol Mandi, Sch Basic Sci, Mandi 175005, Himachal Prades, India.
RP Giri, R (corresponding author), Indian Inst Technol Mandi, Sch Basic Sci, Mandi 175005, Himachal Prades, India.
EM rajanishgiri@iitmandi.ac.in
RI ; Giri, Rajanish/Q-6530-2018
OI kumar, amit/0000-0001-9118-7971; Bhardwaj, Taniya/0000-0002-7226-6348;
   Kumar, Prateek/0000-0001-7392-5045; Giri, Rajanish/0000-0002-2046-836X
FU DBT, Govt. of IndiaDepartment of Biotechnology (DBT) India
   [BT/11/IYBA/2018/06]; MHRD-India; ICMR SRF fellowship; DST INSPIRE PhD
   fellowship
FX The authors would like to thank IIT Mandi for research facilities. RG is
   thankful to DBT, Govt. of India (BT/11/IYBA/2018/06) to RG. AK is
   supported from DBT, Govt. of India grant (BT/11/IYBA/2018/06). PK and SK
   were supported by MHRD-India for their funding. KUS and TB are grateful
   to the ICMR SRF and DST INSPIRE PhD fellowships, respectively.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   [Anonymous], WHO COR DIS COVID 20
   Belouzard S, 2012, VIRUSES-BASEL, V4, P1011, DOI 10.3390/v4061011
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Buchan DWA, 2019, NUCLEIC ACIDS RES, V47, pW402, DOI 10.1093/nar/gkz297
   Bzowka M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093099
   Cascella M, 2020, FEATURES EVALUATION
   Chakraborty C, 2020, EUR REV MED PHARMACO, V24, P4016, DOI 10.26355/eurrev_202004_20871
   Chakraborty C, 2020, J MED VIROL, V92, P2314, DOI 10.1002/jmv.25997
   Chan JFW, 2012, J INFECTION, V65, P477, DOI 10.1016/j.jinf.2012.10.002
   Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chuang GY, 2008, BIOPHYS J, V95, P4217, DOI 10.1529/biophysj.108.135814
   COLLINS AR, 1994, IMMUNOL INVEST, V23, P313, DOI 10.3109/08820139409066826
   de Haan CAA, 2006, J VIROL, V80, P10909, DOI 10.1128/JVI.00950-06
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30
   Dimitrov I, 2014, BIOINFORMATICS, V30, P846, DOI 10.1093/bioinformatics/btt619
   Dimitrov I, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S6-S4
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Gadhave K, 2020, CELL MOL LIFE SCI, V77, P4163, DOI 10.1007/s00018-019-03414-9
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Giri R, 2020, CELL MOL LIFE SCI, DOI 10.1007/s00018-020-03603-x
   Guy AJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141729
   He RT, 2004, BIOCHEM BIOPH RES CO, V316, P476, DOI 10.1016/j.bbrc.2004.02.074
   Hulswit RJG, 2019, P NATL ACAD SCI USA, V116, P2681, DOI 10.1073/pnas.1809667116
   India State Level Disease Burden Initiative Road Injury Collaborators, 2020, LANCET PUBLIC HLTH, V5, pe86
   Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091
   Kozakov D, 2006, PROTEINS, V65, P392, DOI 10.1002/prot.21117
   Kumar A, 2020, ARCH BIOCHEM BIOPHYS, V684, DOI 10.1016/j.abb.2020.108342
   Kumar D, 2020, INT J BIOL MACROMOL, V144, P892, DOI 10.1016/j.ijbiomac.2019.09.166
   Kuo L, 2016, J VIROL, V90, P4357, DOI 10.1128/JVI.03212-15
   Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li W., 2017, P NATL ACAD SCI US, V114, pE8508, DOI 10.1073/pnas
   Liao Y, 2006, VIROLOGY, V349, P264, DOI 10.1016/j.virol.2006.01.028
   Lin Y, 2003, CELL RES, V13, P141, DOI 10.1038/sj.cr.7290158
   Magnan CN, 2010, BIOINFORMATICS, V26, P2936, DOI 10.1093/bioinformatics/btq551
   Meszaros B, 2018, NUCLEIC ACIDS RES, V46, pW329, DOI 10.1093/nar/gky384
   Namvar A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51679-8
   Nielsen M, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-296
   Obradovic Z, 2003, PROTEINS, V53, P566, DOI 10.1002/prot.10532
   Obradovic Z, 2005, PROTEINS, V61, P176, DOI 10.1002/prot.20735
   Ojha R, 2019, ACS OMEGA, V4, P13069, DOI 10.1021/acsomega.9b00944
   Pandey RK, 2018, J CELL BIOCHEM, V119, P7631, DOI 10.1002/jcb.27110
   Peng H, 2006, VIROLOGY, V351, P466, DOI 10.1016/j.virol.2006.03.036
   Saha A, 2020, ARCH MED RES
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490
   Teoh KT, 2010, MOL BIOL CELL, V21, P3838, DOI 10.1091/mbc.E10-04-0338
   Tilocca B, 2020, MICROBES INFECT, V22, P188, DOI 10.1016/j.micinf.2020.04.002
   Tilocca B, 2020, MICROBES INFECT, V22, P218, DOI 10.1016/j.micinf.2020.03.002
   Tseng CT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035421
   Vennema H, 1996, EMBO J, V15, P2020, DOI 10.1002/j.1460-2075.1996.tb00553.x
   Wilson L, 2004, VIROLOGY, V330, P322, DOI 10.1016/j.virol.2004.09.033
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu X, 2020, BMJ, V368
   Xue B, 2010, BBA-PROTEINS PROTEOM, V1804, P996, DOI 10.1016/j.bbapap.2010.01.011
   Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 64
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1476-0584
EI 1744-8395
J9 EXPERT REV VACCINES
JI Expert Rev. Vaccines
PD SEP 1
PY 2020
VL 19
IS 9
BP 887
EP 898
DI 10.1080/14760584.2020.1813576
EA SEP 2020
PG 12
WC Immunology
SC Immunology
GA OU3GD
UT WOS:000567512600001
PM 32815406
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rocha, JLM
   de Oliveira, WCF
   Noronha, NC
   dos Santos, NCD
   Covas, DT
   Picanco-Castro, V
   Swiech, K
   Malmegrim, KCR
AF Martins Rocha, Jose Lucas
   Ferreira de Oliveira, Waldir Cesar
   Noronha, Nadia Cassia
   Dias dos Santos, Natalia Cristine
   Covas, Dimas Tadeu
   Picanco-Castro, Virginia
   Swiech, Kamilla
   Ribeiro Malmegrim, Kelen Cristina
TI Mesenchymal Stromal Cells in Viral Infections: Implications for COVID-19
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article; Early Access
DE Mesenchymal stromal cells; Viral infections; COVID-19; Immunomodulation;
   SARS-CoV-2; Cell therapy; Viral diseases; Acute respiratory distress
   syndrome
ID HUMAN UMBILICAL-CORD; CHRONIC LIVER-FAILURE; HUMAN BONE-MARROW;
   STEM-CELLS; TRANSPLANTATION; DIFFERENTIATION; INJURY; MSCS;
   ANGIOGENESIS; MACROPHAGES
AB Mesenchymal stromal cells (MSCs) constitute a heterogeneous population of stromal cells with immunomodulatory and regenerative properties that support their therapeutic use. MSCs isolated from many tissue sources replicate vigorously in vitro and maintain their main biological properties allowing their widespread clinical application. To date, most MSC-based preclinical and clinical trials targeted immune-mediated and inflammatory diseases. Nevertheless, MSCs have antiviral properties and have been used in the treatment of various viral infections in the last years. Here, we revised in detail the biological properties of MSCs and their preclinical and clinical applications in viral diseases, including the disease caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection (COVID-19). Notably, rapidly increasing numbers of MSC-based therapies for COVID-19 have recently been reported. MSCs are theoretically capable of reducing inflammation and promote lung regeneration in severe COVID-19 patients. We critically discuss the rationale, advantages and disadvantages of MSC-based therapies for viral infections and also specifically for COVID-19 and point out some directions in this field. Finally, we argue that MSC-based therapy may be a promising therapeutic strategy for severe COVID-19 and other emergent respiratory tract viral infections, beyond the viral infection diseases in which MSCs have already been clinically applied.
C1 [Martins Rocha, Jose Lucas; Ferreira de Oliveira, Waldir Cesar; Noronha, Nadia Cassia; Dias dos Santos, Natalia Cristine; Covas, Dimas Tadeu; Picanco-Castro, Virginia; Swiech, Kamilla; Ribeiro Malmegrim, Kelen Cristina] Univ Sao Paulo, Ctr Cell Based Therapy, Reg Blood Ctr Ribeirao Preto, Ribeirao Preto Med Sch, Ribeirao Preto, Brazil.
   [Martins Rocha, Jose Lucas] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem & Immunol, Basic & Appl Immunol Program, Ribeirao Preto, Brazil.
   [Ferreira de Oliveira, Waldir Cesar; Noronha, Nadia Cassia; Dias dos Santos, Natalia Cristine] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal Toxicol & Food Sci, Biosci & Biotecnol Program, Ribeirao Preto, SP, Brazil.
   [Swiech, Kamilla; Ribeiro Malmegrim, Kelen Cristina] Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Av Cafe S-N, BR-14040903 Ribeirao Preto, SP, Brazil.
RP Malmegrim, KCR (corresponding author), Univ Sao Paulo, Ctr Cell Based Therapy, Reg Blood Ctr Ribeirao Preto, Ribeirao Preto Med Sch, Ribeirao Preto, Brazil.; Malmegrim, KCR (corresponding author), Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Av Cafe S-N, BR-14040903 Ribeirao Preto, SP, Brazil.
EM kelenfarias@fcfrp.usp.br
RI Malmegrim, Kelen/H-1016-2015
OI Malmegrim, Kelen/0000-0002-9303-0086; Reis,
   AlessanRSS/0000-0001-8486-7469
FU Sao Paulo Research Foundation (Center for Cell-Based Research,
   CTC-CEPID-FAPESP) [2013/08135-2]; Coordination for the Improvement of
   Higher Education Personnel (CAPES)CAPES [001]
FX This study was financed by two Brazilian foundations: Sao Paulo Research
   Foundation (Center for Cell-Based Research, CTC-CEPID-FAPESP, Process
   number 2013/08135-2) and the Coordination for the Improvement of Higher
   Education Personnel (CAPES; Finance Code 001).
CR Abumaree MH, 2013, STEM CELL REV REP, V9, P620, DOI 10.1007/s12015-013-9455-2
   Ahmadi AR, 2019, BURNS, V45, P1014, DOI 10.1016/j.burns.2018.10.017
   Akiyama K, 2012, CELL STEM CELL, V10, P544, DOI 10.1016/j.stem.2012.03.007
   Alcayaga-Miranda F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00339
   Androulidaki A, 2009, IMMUNITY, V31, P220, DOI 10.1016/j.immuni.2009.06.024
   Atluri S, 2020, PAIN PHYSICIAN, V23, pE71
   Aziz J, 2019, CYTOTHERAPY, V21, P1112, DOI 10.1016/j.jcyt.2019.08.004
   Bai LP, 2016, ACTA HISTOCHEM, V118, P761, DOI 10.1016/j.acthis.2016.09.006
   Bailey CC, 2014, ANNU REV VIROL, V1, P261, DOI 10.1146/annurev-virology-031413-085537
   Behnke J, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030682
   Berlin David A, 2020, N Engl J Med, V383, P2451, DOI 10.1056/NEJMcp2009575
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Budgude P, 2020, CELL BIOL INT, V44, P1078, DOI 10.1002/cbin.11313
   Cesario A, 2011, CURR MED CHEM, V18, P2263, DOI 0929-8673/11 $58.00+.00
   Chan MCW, 2016, P NATL ACAD SCI USA, V113, P3621, DOI 10.1073/pnas.1601911113
   Chen C, 2017, INT IMMUNOPHARMACOL, V44, P234, DOI 10.1016/j.intimp.2017.01.024
   Chen K, 2010, CLIN IMMUNOL, V135, P448, DOI 10.1016/j.clim.2010.01.015
   Chen L, 2020, CARDIOVASC RES, V116, P1097, DOI 10.1093/cvr/cvaa078
   Chen X, 2020, J INFECTION, V81, P652, DOI 10.1016/j.jinf.2020.05.020
   Cheung TS, 2019, HAEMATOLOGICA, V104, pE438, DOI 10.3324/haematol.2018.214767
   Cheung TS, 2018, SEMIN IMMUNOL, V35, P59, DOI 10.1016/j.smim.2018.01.002
   Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353
   Collino Federica, 2019, Cell Physiol Biochem, V52, P1463, DOI 10.33594/000000102
   Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326
   Corliss BA, 2016, MICROCIRCULATION, V23, P95, DOI 10.1111/micc.12259
   Ding DC, 2016, CELL TRANSPLANT, V25, P217, DOI 10.3727/096368915X688182
   Du J, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01699-3
   Du WJ, 2016, STEM CELLS DEV, V25, P1454, DOI 10.1089/scd.2016.0022
   Dyer DP, 2016, J BIOL CHEM, V291, P12627, DOI 10.1074/jbc.M116.720953
   Enes SR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09127-y
   English K, 2009, CLIN EXP IMMUNOL, V156, P149, DOI 10.1111/j.1365-2249.2009.03874.x
   Fajardo-Orduna GR, 2015, ARCH MED RES, V46, P589, DOI 10.1016/j.arcmed.2015.10.001
   Fang XQ, 2018, J GASTROEN HEPATOL, V33, P774, DOI 10.1111/jgh.14081
   Ferreira JR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02837
   Foronjy Robert F, 2012, Cells, V1, P874
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365-2184.1970.tb00347.x
   Golchin A, 2020, STEM CELL REV REP, V16, P427, DOI 10.1007/s12015-020-09973-w
   Gomez-Salazar M, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00148
   Harrell CR, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/4236973
   Hart M, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1295-1
   Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-12
   HAYAISHI O, 1976, J BIOCHEM-TOKYO, V79, pP13
   Hillman Y, 2016, J IMMUNOL, V196, P5156, DOI 10.4049/jimmunol.1502701
   Khatibi SMH, 2020, J CELL PHYSIOL, V235, P7731, DOI 10.1002/jcp.29728
   Hung CF, 2019, ADV EXP MED BIOL, V1122, P41, DOI 10.1007/978-3-030-11093-2_3
   Hung Chi F, 2017, American journal of physiology. Lung cellular and molecular physiology, V312, pL556, DOI 10.1152/ajplung.00349.2016
   Hyvarinen K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00771
   Jeon YK, 2010, WOUND REPAIR REGEN, V18, P655, DOI 10.1111/j.1524-475X.2010.00636.x
   Jiang DS, 2016, STEM CELLS, V34, P2393, DOI 10.1002/stem.2417
   Jiang XX, 2005, BLOOD, V105, P4120, DOI 10.1182/blood-2004-02-0586
   Kachgal S, 2011, ANGIOGENESIS, V14, P47, DOI 10.1007/s10456-010-9194-9
   Kane M, 2016, CELL HOST MICROBE, V20, P392, DOI 10.1016/j.chom.2016.08.005
   Kaur S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33899-6
   Kehl D, 2019, NPJ REGEN MED, V4, DOI 10.1038/s41536-019-0070-y
   Kerkela E, 2016, STEM CELLS, V34, P781, DOI 10.1002/stem.2280
   Khoury M, 2020, CYTOTHERAPY, V22, P602, DOI 10.1016/j.jcyt.2020.04.089
   Khoury M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00858-2020
   Klimczak A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/4285215
   Kong PR, 2013, BIOCHEM BIOPH RES CO, V438, P410, DOI 10.1016/j.bbrc.2013.07.088
   Kouroupis D, 2019, TISSUE ENG PART B-RE, V25, P55, DOI [10.1089/ten.TEB.2018.0118, 10.1089/ten.teb.2018.0118]
   Kumar M, 2011, J ALLERGY CLIN IMMUN, V128, P1077, DOI 10.1016/j.jaci.2011.04.034
   Laporte C, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1190-4
   Leaf IA, 2017, NEPHROL DIAL TRANSPL, V32, P89, DOI 10.1093/ndt/gfw388
   Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228
   Leyendecker A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02056
   Li D, 2015, INT J MOL MED, V35, P1309, DOI 10.3892/ijmm.2015.2137
   Li YH, 2016, STEM CELL REV REP, V12, P645, DOI 10.1007/s12015-016-9683-3
   Lin BL, 2017, HEPATOLOGY, V66, P209, DOI 10.1002/hep.29189
   Liu JJ, 2015, INT J LOW EXTR WOUND, V14, P63, DOI 10.1177/1534734615573660
   Liu S, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01678-8
   Liu Y, 2014, BIOCHEM BIOPH RES CO, V450, P1409, DOI 10.1016/j.bbrc.2014.07.001
   Loy H, 2019, J INFECT DIS, V219, P186, DOI 10.1093/infdis/jiy478
   Luo XY, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-018-1122-8
   Luz-Crawford P, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt216
   Ma S, 2014, CELL DEATH DIFFER, V21, P216, DOI 10.1038/cdd.2013.158
   Mao RC, 2011, J VIROL, V85, P1048, DOI 10.1128/JVI.01998-10
   Martin I, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat2189
   Mas-Bargues C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051195
   McIntyre LA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147170
   Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002
   Meisel R, 2004, BLOOD, V103, P4619, DOI 10.1182/blood-2003-11-3909
   Meisel R, 2011, LEUKEMIA, V25, P648, DOI 10.1038/leu.2010.310
   Morrison TJ, 2017, AM J RESP CRIT CARE, V196, P1275, DOI 10.1164/rccm.201701-0170OC
   Motegi S, 2017, J DERMATOL SCI, V86, P83, DOI 10.1016/j.jdermsci.2016.11.005
   Naji A, 2019, CELL MOL LIFE SCI, V76, P3323, DOI 10.1007/s00018-019-03125-1
   Nauta AJ, 2006, J IMMUNOL, V177, P2080, DOI 10.4049/jimmunol.177.4.2080
   Noronha ND, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1259-0
   Obojes K, 2005, J VIROL, V79, P7768, DOI 10.1128/JVI.79.12.7768-7776.2005
   Obradovic H, 2019, PLACENTA, V82, P25, DOI 10.1016/j.placenta.2019.05.005
   Paine A, 2010, BIOCHEM PHARMACOL, V80, P1895, DOI 10.1016/j.bcp.2010.07.014
   Pittenger MF, 2019, NPJ REGEN MED, V4, DOI 10.1038/s41536-019-0083-6
   Qian F, 2009, CANCER RES, V69, P5498, DOI 10.1158/0008-5472.CAN-08-2106
   Qian XJ, 2016, STEM CELL TRANSL MED, V5, P1190, DOI 10.5966/sctm.2015-0348
   Qin H, 2020, PROTEIN CELL, V11, P707, DOI 10.1007/s13238-020-00738-2
   Qu MM, 2017, STEM CELLS DEV, V26, P818, DOI 10.1089/scd.2016.0348
   Rajarshi Keshav, 2020, Biotechnology Reports, V26, pe00467, DOI 10.1016/j.btre.2020.e00467
   Romieu-Mourez R, 2009, J IMMUNOL, V182, P7963, DOI 10.4049/jimmunol.0803864
   Ryan JM, 2007, CLIN EXP IMMUNOL, V149, P353, DOI 10.1111/j.1365-2249.2007.03422.x
   Schoggins JW, 2019, ANNU REV VIROL, V6, P567, DOI 10.1146/annurev-virology-092818-015756
   Schulte LN, 2011, EMBO J, V30, P1977, DOI 10.1038/emboj.2011.94
   Selmani Z, 2008, STEM CELLS, V26, P212, DOI 10.1634/stemcells.2007-0554
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Shetty AK, 2020, AGING DIS, V11, P462, DOI 10.14336/AD.2020.0301
   Shi YF, 2018, NAT REV NEPHROL, V14, P493, DOI 10.1038/s41581-018-0023-5
   Shin L, 2013, STEM CELL TRANSL MED, V2, P33, DOI 10.5966/sctm.2012-0041
   Simonson OE, 2015, STEM CELL TRANSL MED, V4, P1199, DOI 10.5966/sctm.2015-0021
   Sinclair K, 2013, RESPIROLOGY, V18, P397, DOI 10.1111/resp.12050
   South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020
   Sveiven SN, 2020, AM J PHYSIOL-LUNG C, V319, pL197, DOI 10.1152/ajplung.00049.2020
   Tao HY, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1314709
   Teklemariam T, 2014, BIOCHEM BIOPH RES CO, V452, P753, DOI 10.1016/j.bbrc.2014.08.152
   Thanunchai M, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/860950
   Van Linthout S, 2011, EUR HEART J, V32, P2168, DOI 10.1093/eurheartj/ehq467
   Vasandan AB, 2016, SCI REP-UK, V6, DOI 10.1038/srep38308
   Walter J, 2014, LANCET RESP MED, V2, P1016, DOI 10.1016/S2213-2600(14)70217-6
   Wang G, 2018, CELL DEATH DIFFER, V25, P1209, DOI 10.1038/s41418-017-0006-2
   Wang J, 2020, Zhonghua Shao Shang Za Zhi, V36, P691, DOI 10.3760/cma.j.cn501120-20200307-00132
   Wang Y, 2014, NAT IMMUNOL, V15, P1009, DOI 10.1038/ni.3002
   Whiteside TL, 2018, SEMIN IMMUNOL, V35, P69, DOI 10.1016/j.smim.2017.12.003
   World Health Organization, 2020, MAN ETH ISS INF DIS
   Wu XF, 2018, CELL, V172, P423, DOI 10.1016/j.cell.2017.11.018
   Xu LM, 2014, J GASTROEN HEPATOL, V29, P1620, DOI 10.1111/jgh.12653
   Yang LL, 2012, J EXP MED, V209, P1655, DOI 10.1084/jem.20112218
   Yen BLJ, 2020, STEM CELL TRANSL MED, V9, P1163, DOI 10.1002/sctm.20-0186
   Yin JQ, 2019, NAT BIOMED ENG, V3, P90, DOI 10.1038/s41551-018-0325-8
   Yu FG, 2020, STEM CELL RES, V46, DOI 10.1016/j.scr.2020.101859
   Zhang YX, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01725-4
   Zhao RCH, 2020, STEM CELLS DEV, V29, P679, DOI 10.1089/scd.2020.0071
   Zhou M, 2020, FRONT MED-PRC, V14, P126, DOI 10.1007/s11684-020-0767-8
   Zhou YY, 2019, J CLIN MED, V8, DOI 10.3390/jcm8071025
   Zumla A, 2020, INT J INFECT DIS, V96, P431, DOI 10.1016/j.ijid.2020.05.040
NR 131
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 2629-3269
EI 2629-3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
DI 10.1007/s12015-020-10032-7
EA SEP 2020
PG 23
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
SC Cell Biology; Research & Experimental Medicine
GA NK7FF
UT WOS:000566898000001
PM 32895900
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Poulsen, NN
   von Brunn, A
   Hornum, M
   Jensen, MB
AF Poulsen, Nadia Nicholine
   von Brunn, Albrecht
   Hornum, Mads
   Blomberg Jensen, Martin
TI Cyclosporine and COVID-19: Risk or favorable?
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE clinical research; practice; immunosuppressant - calcineurin inhibitor
   (CNI); immunosuppression; immune modulation; infection and infectious
   agents - viral; infectious disease; organ transplantation in general
ID RESPIRATORY SYNDROME CORONAVIRUS; TRANSPLANT RECIPIENTS; CALCINEURIN
   INHIBITORS; CYCLOPHILIN INHIBITORS; INTERFERON-ALPHA; STEM-CELL;
   IN-VITRO; REPLICATION; INFECTION; MERS
AB The coronavirus disease 2019 (COVID-19) pandemic is declared a global health emergency. COVID-19 is triggered by a novel coronavirus: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Baseline characteristics of admitted patients with COVID-19 show that adiposity, diabetes, and hypertension are risk factors for developing severe disease, but so far immunosuppressed patients who are listed as high-risk patients have not been more susceptible to severe COVID-19 than the rest of the population. Multiple clinical trials are currently being conducted, which may identify more drugs that can lower mortality, morbidity, and burden on the society. Several independent studies have convincingly shown that cyclosporine inhibit replication of several different coronaviruses in vitro. The cyclosporine-analog alisporivir has recently been shown to inhibit SARS-CoV-2 in vitro. These findings are intriguing, although there is no clinical evidence for a protective effect to reduce the likelihood of severe COVID-19 or to treat the immune storm or acute respiratory distress syndrome (ARDS) that often causes severe morbidity. Here, we review the putative link between COVID-19 and cyclosporine, while we await more robust clinical data.
C1 [Poulsen, Nadia Nicholine; Blomberg Jensen, Martin] Rigshosp, Grp Skeletal Mineral & Gonadal Endocrinol, Dept Growth & Reprod, Copenhagen, Denmark.
   [von Brunn, Albrecht] Ludwig Maximilians Univ Munchen, German Ctr Infect Res DZIF, Max von Pettenkofer Inst, Munich, Germany.
   [Hornum, Mads] Rigshosp, Dept Nephrol, Copenhagen, Denmark.
   [Hornum, Mads] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark.
   [Blomberg Jensen, Martin] HSDM HMS Harvard Univ, Div Bone & Mineral Res, Boston, MA 02115 USA.
RP Jensen, MB (corresponding author), Rigshosp, Grp Skeletal Mineral & Gonadal Endocrinol, Dept Growth & Reprod, Copenhagen, Denmark.; Jensen, MB (corresponding author), HSDM HMS Harvard Univ, Div Bone & Mineral Res, Boston, MA 02115 USA.
EM blombergjensen@gmail.com
RI Jensen, Martin Blomberg/U-3338-2017
OI Jensen, Martin Blomberg/0000-0003-3800-4253; Poulsen, Nadia
   Nicholine/0000-0002-0625-1770
FU Lundbech Foundation [R187-2015-2148]
FX Clinical Research Associate Professorship grant from the Lundbech
   Foundation, Grant/Award Number: R187-2015-2148
CR ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P
   AlGhamdi M, 2015, AM J TRANSPLANT, V15, P1101, DOI 10.1111/ajt.13085
   Anders HJ, 2020, NEPHROL DIAL TRANSPL, V35, P920, DOI 10.1093/ndt/gfaa112
   [Anonymous], 2020, ICNARC REPORT COVID
   Baud D, 2020, LANCET INFECT DIS, V20, P773, DOI 10.1016/S1473-3099(20)30195-X
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bendickova K, 2017, EMBO MOL MED, V9, P990, DOI 10.15252/emmm.201707698
   CALNE RY, 1978, LANCET, V2, P1323
   Cao YH, 2020, J MED VIROL, V92, P1449, DOI [10.1002/jmv.25822, 10.1080/10962247.2020.1815895]
   Carbajo-Lozoya J, 2014, VIRUS RES, V184, P44, DOI 10.1016/j.virusres.2014.02.010
   Carbajo-Lozoya J, 2012, VIRUS RES, V165, P112, DOI 10.1016/j.virusres.2012.02.002
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chemaly RF, 2006, MEDICINE, V85, P278, DOI 10.1097/01.md.0000232560.22098.4e
   Chen J, 2020, J INFECTION, V80, pE1, DOI 10.1016/j.jinf.2020.03.004
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Cung TT, 2015, NEW ENGL J MED, V373, P1021, DOI 10.1056/NEJMoa1505489
   de Wilde AH, 2018, VIROLOGY, V522, P46, DOI 10.1016/j.virol.2018.06.011
   de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25
   de Wilde AH, 2017, VIRUS RES, V228, P7, DOI 10.1016/j.virusres.2016.11.011
   de Wilde AH, 2013, J GEN VIROL, V94, P1749, DOI 10.1099/vir.0.052910-0
   de Wilde AH, 2013, J VIROL, V87, P1454, DOI 10.1128/JVI.02078-12
   de Wilde AH, 2011, J GEN VIROL, V92, P2542, DOI 10.1099/vir.0.034983-0
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Enderby C, 2015, AM J MANAG CARE, V21, pS12
   Fan Y, 2009, J HEART LUNG TRANSPL, V28, P58, DOI 10.1016/j.healun.2008.10.004
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Flisiak R, 2008, HEPATOLOGY, V47, P817, DOI 10.1002/hep.22131
   Gabutti G, 2020, INFECT DIS THER, V9, P241, DOI 10.1007/s40121-020-00295-5
   Garcia-Serradilla M, 2019, VIRUS RES, V264, P22, DOI 10.1016/j.virusres.2019.02.011
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guba M, 2008, NEW ENGL J MED, V358, P2518, DOI 10.1056/NEJMc080067
   Guery B, 2013, LANCET, V381, P2265, DOI 10.1016/S0140-6736(13)60982-4
   Guillen E, 2020, AM J TRANSPLANT, V20, P1875, DOI 10.1111/ajt.15874
   Hamada H, 2019, LANCET, V393, P1128, DOI 10.1016/S0140-6736(18)32003-8
   Han QM, 2020, J INFECTION, V80, P373, DOI 10.1016/j.jinf.2020.02.010
   Holzhauser L, 2020, AM J TRANSPLANT, V20, P2916, DOI 10.1111/ajt.15982
   Hopkins S, 2015, BBA-GEN SUBJECTS, V1850, P2103, DOI 10.1016/j.bbagen.2014.11.011
   Hopkins S, 2012, J HEPATOL, V57, P47, DOI 10.1016/j.jhep.2012.02.024
   Horby P, 2020, EFFECT DEXAMETHASONE, DOI [10.1101/2020.06.22.20137273, DOI 10.1101/2020.06.22.20137273]
   Hornum M, 2007, NEPHROL DIAL TRANSPL, V22, P3616, DOI 10.1093/ndt/gfm478
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iacono A, 2019, ERJ OPEN RES, V5, DOI 10.1183/23120541.00167-2019
   Iacono AT, 2006, NEW ENGL J MED, V354, P141, DOI 10.1056/NEJMoa043204
   Kim YJ, 2007, SEMIN RESP CRIT CARE, V28, P222, DOI 10.1055/s-2007-976494
   Kronbichler A, 2020, NAT REV NEPHROL, V16, P365, DOI 10.1038/s41581-020-0305-6
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P404, DOI 10.1016/j.jmii.2020.02.012
   Lawitz E, 2011, ANTIVIR RES, V89, P238, DOI 10.1016/j.antiviral.2011.01.003
   Li F, 2020, J HEART LUNG TRANSPL, V39, P496, DOI 10.1016/j.healun.2020.03.006
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Li HS, 2018, ANTIVIR RES, V155, P89, DOI 10.1016/j.antiviral.2018.05.007
   Liu KC, 2020, EUR J RADIOL, V126, DOI 10.1016/j.ejrad.2020.108941
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luo C, 2004, BIOCHEM BIOPH RES CO, V321, P557, DOI 10.1016/j.bbrc.2004.07.003
   Ma-Lauer Y, 2020, ANTIVIR RES, V173, DOI 10.1016/j.antiviral.2019.104620
   Matsuda S, 2000, IMMUNOPHARMACOLOGY, V47, P119, DOI 10.1016/S0162-3109(00)00192-2
   McAlister VC, 2006, AM J TRANSPLANT, V6, P1578, DOI 10.1111/j.1600-6143.2006.01360.x
   Mitruka SN, 2000, J HEART LUNG TRANSPL, V19, P969, DOI 10.1016/S1053-2498(00)00176-5
   Montagud-Marrahi E, 2020, AM J TRANSPLANT, V20, P2958, DOI 10.1111/ajt.15970
   Naesens M, 2009, CLIN J AM SOC NEPHRO, V4, P481, DOI 10.2215/CJN.04800908
   Nagy PD, 2011, VIROLOGY, V411, P374, DOI 10.1016/j.virol.2010.12.061
   Ogando NS, 2020, J GEN VIROL, V101, P925, DOI 10.1099/jgv.0.001453
   Omae T, 2015, PEDIATR INT, V57, P773, DOI 10.1111/ped.12644
   Paraskevis D, 2020, INFECT GENET EVOL, V79, DOI 10.1016/j.meegid.2020.104212
   Peck AJ, 2007, BLOOD, V110, P1681, DOI 10.1182/blood-2006-12-060343
   Pereira MR, 2020, AM J TRANSPLANT, V20, P1800, DOI 10.1111/ajt.15941
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   PTACHCINSKI RJ, 1986, CLIN PHARMACOKINET, V11, P107, DOI 10.2165/00003088-198611020-00002
   Rehman S, 2020, SAUDI J BIOL SCI, V27, P2567, DOI 10.1016/j.sjbs.2020.05.024
   Rodriguez-Cubillo B, 2020, AM J TRANSPLANT, V20, P3173, DOI 10.1111/ajt.16141
   Romanelli A, 2020, CRUCIAL ASPECTS MANA, P0, DOI [10.20944/PREPRINTS202003.0434.V1, DOI 10.20944/PREPRINTS202003.0434.V1]
   Russell CD, 2013, J INFECTION, V67, P84, DOI 10.1016/j.jinf.2013.01.004
   Schaller T, 2020, JAMA-J AM MED ASSOC, V323, P1
   Schiff J, 2007, CLIN J AM SOC NEPHRO, V2, P374, DOI 10.2215/CJN.03791106
   SCHILTKNECHT E, 1985, CELL IMMUNOL, V91, P227, DOI 10.1016/0008-8749(85)90046-2
   SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J
   Sharkey L, 2011, J CROHNS COLITIS, V5, P91, DOI 10.1016/j.crohns.2010.10.004
   Softic L, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00876-20
   STARZL TE, 1989, LANCET, V2, P1000
   Tanaka Y, 2013, VIRUSES-BASEL, V5, P1250, DOI 10.3390/v5051250
   Travi G, 2020, AM J TRANSPLANT, V20, P2628, DOI 10.1111/ajt.16069
   Tschopp J, 2020, AM J TRANSPLANT, V20, P2876, DOI 10.1111/ajt.16062
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   von Brunn A, 2015, CURR OPIN VIROL, V14, P56, DOI 10.1016/j.coviro.2015.08.004
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yuan S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.367
   Zhang H, 2020, EUR UROL, V77, P742, DOI 10.1016/j.eururo.2020.03.030
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zimmermann S, 2017, JAMA DERMATOL, V153, P514, DOI 10.1001/jamadermatol.2016.5668
NR 94
TC 2
Z9 2
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD NOV
PY 2020
VL 20
IS 11
BP 2975
EP 2982
DI 10.1111/ajt.16250
EA SEP 2020
PG 8
WC Surgery; Transplantation
SC Surgery; Transplantation
GA OH7XN
UT WOS:000566720800001
PM 32777170
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hayakawa, J
   Takakura, H
   Mizukawa, Y
   Shiohara, T
AF Hayakawa, J.
   Takakura, H.
   Mizukawa, Y.
   Shiohara, T.
TI COVID-19-related cutaneous manifestations associated with multiple drug
   sensitization as shown by lymphocyte transformation test
SO JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
LA English
DT Letter; Early Access
C1 [Hayakawa, J.; Mizukawa, Y.; Shiohara, T.] Kosei Hosp, Div Dermatol, Tokyo, Japan.
   [Takakura, H.] Kosei Hosp, Div Resp Med, Tokyo, Japan.
   [Mizukawa, Y.; Shiohara, T.] Kyorin Univ, Dept Dermatol, Sch Med, Tokyo, Japan.
RP Hayakawa, J (corresponding author), Kosei Hosp, Div Dermatol, Tokyo, Japan.
EM jun.hayakawa@kosei-hp.or.jp
OI Mizukawa, Yoshiko/0000-0002-9035-1298
CR Aoyama Yumi, 2017, JAAD Case Rep, V3, P301, DOI 10.1016/j.jdcr.2017.03.005
   Mahe A, 2020, J EUR ACAD DERMATOL, V34, pE246, DOI 10.1111/jdv.16471
   Marzano AV, 2020, BRIT J DERMATOL, V183, P431, DOI 10.1111/bjd.19264
   Mockenhaupt M, 2008, J INVEST DERMATOL, V128, P35, DOI 10.1038/sj.jid.5701033
   Pichler WJ, 2004, ALLERGY, V59, P809, DOI 10.1111/j.1398-9995.2004.00547.x
   Takahashi R, 2009, J IMMUNOL, V182, P8071, DOI 10.4049/jimmunol.0804002
   Tammaro A, 2020, J EUR ACAD DERMATOL, V34, pE306, DOI 10.1111/jdv.16530
   Weiss Doris, 2019, JAAD Case Rep, V5, P89, DOI 10.1016/j.jdcr.2018.10.015
   Wollina U, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13549
NR 9
TC 2
Z9 2
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0926-9959
EI 1468-3083
J9 J EUR ACAD DERMATOL
JI J. Eur. Acad. Dermatol. Venereol.
DI 10.1111/jdv.16878
EA SEP 2020
PG 2
WC Dermatology
SC Dermatology
GA NK2DL
UT WOS:000566547500001
PM 32810920
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lee, KA
   Ma, WJ
   Sikavi, DR
   Drew, DA
   Nguyen, LH
   Bowyer, RCE
   Cardoso, MJ
   Fall, T
   Freidin, MB
   Gomez, M
   Graham, M
   Guo, CG
   Joshi, AD
   Kwon, S
   Lo, CH
   Lochlainn, MN
   Menni, C
   Murray, B
   Mehta, R
   Song, MY
   Sudre, CH
   Bataille, V
   Varsavsky, T
   Visconti, A
   Franks, PW
   Wolf, J
   Steves, CJ
   Ourselin, S
   Spector, TD
   Chan, AT
AF Lee, Karla A.
   Ma, Wenjie
   Sikavi, Daniel R.
   Drew, David A.
   Nguyen, Long H.
   Bowyer, Ruth C. E.
   Cardoso, M. Jorge
   Fall, Tove
   Freidin, Maxim B.
   Gomez, Maria
   Graham, Mark
   Guo, Chuan-Guo
   Joshi, Amit D.
   Kwon, Sohee
   Lo, Chun-Han
   Lochlainn, Mary Ni
   Menni, Cristina
   Murray, Benjamin
   Mehta, Raaj
   Song, Mingyang
   Sudre, Carole H.
   Bataille, Veronique
   Varsavsky, Thomas
   Visconti, Alessia
   Franks, Paul W.
   Wolf, Jonathan
   Steves, Claire J.
   Ourselin, Sebastien
   Spector, Tim D.
   Chan, Andrew T.
CA COPE Consortium
TI Cancer and Risk ofCOVID-19 Through a General Community Survey
SO ONCOLOGIST
LA English
DT Article; Early Access
ID COVID-19
AB Individuals with cancer may be at high risk for coronavirus disease 2019 (COVID-19) and adverse outcomes. However, evidence from large population-based studies examining whether cancer and cancer-related therapy exacerbates the risk of COVID-19 infection is still limited. Data were collected from the COVID Symptom Study smartphone application since March 29 through May 8, 2020. Among 23,266 participants with cancer and 1,784,293 without cancer, we documented 10,404 reports of a positive COVID-19 test. Compared with participants without cancer, those living with cancer had a 60% increased risk of a positive COVID-19 test. Among patients with cancer, current treatment with chemotherapy or immunotherapy was associated with a 2.2-fold increased risk of a positive test. The association between cancer and COVID-19 infection was stronger among participants >65 years and males. Future studies are needed to identify subgroups by tumor types and treatment regimens who are particularly at risk for COVID-19 infection and adverse outcomes.
C1 [Lee, Karla A.; Bowyer, Ruth C. E.; Freidin, Maxim B.; Lochlainn, Mary Ni; Menni, Cristina; Bataille, Veronique; Visconti, Alessia; Steves, Claire J.; Spector, Tim D.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England.
   [Cardoso, M. Jorge; Graham, Mark; Murray, Benjamin; Sudre, Carole H.; Varsavsky, Thomas; Ourselin, Sebastien] Kings Coll London, Sch Biomed Engn & Imaging Sci, London, England.
   [Ma, Wenjie; Drew, David A.; Nguyen, Long H.; Guo, Chuan-Guo; Joshi, Amit D.; Kwon, Sohee; Lo, Chun-Han; Mehta, Raaj; Song, Mingyang; Chan, Andrew T.] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA 02114 USA.
   [Ma, Wenjie; Drew, David A.; Nguyen, Long H.; Guo, Chuan-Guo; Joshi, Amit D.; Kwon, Sohee; Lo, Chun-Han; Mehta, Raaj; Song, Mingyang; Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
   [Sikavi, Daniel R.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
   [Sikavi, Daniel R.] Harvard Med Sch, 100 Cambridge St,15th Floor, Boston, MA 02114 USA.
   [Fall, Tove; Gomez, Maria] Lund Univ, Dept Clin Sci, Malmo, Sweden.
   [Fall, Tove] Uppsala Univ, Mol Epidemiol & Sci Life Lab, Dept Med Sci, Uppsala, Sweden.
   [Wolf, Jonathan] Zoe Global Ltd, London, England.
   [Chan, Andrew T.] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA USA.
   [Chan, Andrew T.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
RP Chan, AT (corresponding author), Harvard Med Sch, 100 Cambridge St,15th Floor, Boston, MA 02114 USA.; Chan, AT (corresponding author), Massachusetts Gen Hosp, 100 Cambridge St,15th Floor, Boston, MA 02114 USA.
EM achan@mgh.harvard.edu
RI Lo, Chun-Han/AAT-4992-2020; Visconti, Alessia/B-9974-2015
OI Lo, Chun-Han/0000-0001-8202-4513; Lee, Karla/0000-0001-5904-5586;
   Steves, Claire/0000-0002-4910-0489; Visconti,
   Alessia/0000-0003-4144-2019; Kwon, Sohee/0000-0002-4201-9522; Sudre,
   Carole/0000-0001-5753-428X
FU Wellcome TrustWellcome Trust; EPSRCEngineering & Physical Sciences
   Research Council (EPSRC) [WT212904/Z/18/Z, WT203148/Z/16/Z,
   T213038/Z/18/Z]; NIHR GSTT/KCL Biomedical Research Centre, MRC/BHF
   [MR/M016560/1]; Alzheimer's Society [AS-JF-17-011]; Seerave Foundation;
   Massachusetts Consortium on Pathogen Readiness (MassCPR); Swedish
   Foundation for Strategic ResearchSwedish Foundation for Strategic
   Research [LUDC-IRC 15-0067]; Swedish Heart-Lung FoundationSwedish
   Heart-Lung Foundation; Swedish research CouncilSwedish Research Council;
   NHS
FX We thank the more than 3 million contributing citizen scientists who
   have downloaded the COVID Symptom Study, including participants of
   cohort studies within the COronavirus Pandemic Epidemiology (COPE)
   Consortium. We also thank the investigators of the cohort studies
   enrolled in the COPE Consortium; the MGH Clinical and Translational
   Epidemiology Unit Clinical Research Coordination team; Sophie Papa, Paul
   Nathan, and Heather Shaw for development of cancer-related questions;
   the staff of Zoe Global Ltd for providing technical support for the app;
   and Stand Up to Cancer for their assistance in media and social media
   outreach. Zoe provided in-kind support for all aspects of building,
   running, and supporting the app and service to all users worldwide.
   King's College of London investigators (K.A.L., C.J.S., T.D.S.) were
   supported by the Wellcome Trust and EPSRC (WT212904/Z/18/Z,
   WT203148/Z/16/Z, T213038/Z/18/Z), the NIHR GSTT/KCL Biomedical Research
   Centre, MRC/BHF (MR/M016560/1), and the Alzheimer's Society
   (AS-JF-17-011). K.A.L. was supported by the Seerave Foundation. A.T.C.
   is the Stuart and Suzanne Steele MGH Research Scholar and Stand Up to
   Cancer scientist. The Massachusetts Consortium on Pathogen Readiness
   (MassCPR) and Mark and Lisa Schwartz also supported MGH investigators
   (W.M., D.R.S., D.A.D., L.H.N., C.G.G., A.D.J., S.K., C.H.L., R.M., M.S.,
   A.T.C.). Support was also received from the Swedish Foundation for
   Strategic Research (LUDC-IRC 15-0067), the Swedish Heart-Lung
   Foundation, and the Swedish research Council. In the U.K., the App
   Ethics has been approved by KCL ethics Committee REMAS ID 18210, review
   reference LRS-19/20-18210, and all subscribers provided consent. In the
   U.S, ethics approval was provided by the Human Research Committee at
   Mass General Brigham. In Sweden, ethics approval for the study was
   provided by the central ethics committee (DNR 2020-01803). Data
   collected in the app are being shared with other health researchers
   through the NHS-funded Health Data Research U.K. (HDRUK)/SAIL
   consortium, housed in the U.K. Secure e-Research Platform (UKSeRP) in
   Swansea. Anonymized data collected by the symptom tracker app can be
   shared with bonafide researchers via HDRUK, provided the request is made
   according to their protocols and is in the public interest (see
   https://healthdatagateway.org/detail/9b604483-9cdc-41b2-b82c-14ee3dd705f
   6).
CR Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Drew DA, 2020, SCIENCE, V368, P1362, DOI 10.1126/science.abc0473
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Menni C, 2020, NAT MED, V26, P1037, DOI 10.1038/s41591-020-0916-2
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   Robilotti EV, 2020, NAT MED, V26, P1218, DOI 10.1038/s41591-020-0979-0
NR 8
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
DI 10.1634/theoncologist.2020-0572
EA SEP 2020
PG 4
WC Oncology
SC Oncology
GA NK1VE
UT WOS:000566526000001
PM 32845538
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Adhikari, P
   Li, N
   Shin, M
   Steinmetz, NF
   Twarock, R
   Podgornik, R
   Ching, WY
AF Adhikari, Puja
   Li, Neng
   Shin, Matthew
   Steinmetz, Nicole F.
   Twarock, Reidun
   Podgornik, Rudolf
   Ching, Wai-Yim
TI Intra- and intermolecular atomic-scale interactions in the receptor
   binding domain of SARS-CoV-2 spike protein: implication for ACE2
   receptor binding
SO PHYSICAL CHEMISTRY CHEMICAL PHYSICS
LA English
DT Article
ID ELECTRONIC-STRUCTURE; CHARGE-DISTRIBUTION; INFECTION
AB The COVID-19 pandemic poses a severe threat to human health with unprecedented social and economic disruption. Spike (S) glycoprotein in the SARS-CoV-2 virus is pivotal in understanding the virus anatomy, since it initiates the early contact with the ACE2 receptor in the human cell. The subunit S1 in chain A of S-protein has four structural domains: the receptor binding domain (RBD), the n-terminal domain (NTD) and two subdomains (SD1, SD2). We report details of the intra- and inter-molecular binding mechanism of RBD using density functional theory, including electronic structure, interatomic bonding and partial charge distribution. We identify five strong hydrogen bonds and analyze their roles in binding. This provides a pathway to a quantum-chemical understanding of the interaction between the S-protein and the ACE2 receptor with insights into the function of conserved features in the ACE2 receptor binding domain that could inform vaccine and drug development.
C1 [Adhikari, Puja; Ching, Wai-Yim] Univ Missouri, Dept Phys & Astron, Kansas City, MO 64110 USA.
   [Li, Neng] Wuhan Univ Technol, Sch Mat Sci & Engn, 122 Luoshi Rd, Wuhan 430070, Peoples R China.
   [Shin, Matthew; Steinmetz, Nicole F.] Univ Calif San Diego, Dept NanoEngn, 9500 Gilman Dr, La Jolla, CA 92039 USA.
   [Steinmetz, Nicole F.] Univ Calif San Diego, Bioengn, 9500 Gilman Dr, La Jolla, CA 92039 USA.
   [Steinmetz, Nicole F.] Univ Calif San Diego, Radiol, 9500 Gilman Dr, La Jolla, CA 92039 USA.
   [Steinmetz, Nicole F.] Univ Calif San Diego, Moores Canc Ctr, 9500 Gilman Dr, La Jolla, CA 92039 USA.
   [Steinmetz, Nicole F.] Univ Calif San Diego, Ctr Nanoimmunoengn, 9500 Gilman Dr, La Jolla, CA 92039 USA.
   [Twarock, Reidun] Univ York, Dept Math & Biol, York YO10 5GE, N Yorkshire, England.
   [Twarock, Reidun] Univ York, York Cross Disciplinary Ctr Syst Anal, York YO10 5GE, N Yorkshire, England.
   [Podgornik, Rudolf] Univ Chinese Acad Sci, Sch Phys Sci, Beijing 100049, Peoples R China.
   [Podgornik, Rudolf] Univ Chinese Acad Sci, Kavli Inst Theoret Sci, Beijing 100049, Peoples R China.
   [Podgornik, Rudolf] Chinese Acad Sci, Inst Phys, CAS Key Lab Soft Matter Phys, Beijing 100090, Peoples R China.
   [Podgornik, Rudolf] Univ Ljubljana, Fac Math & Phys, Dept Phys, SI-1000 Ljubljana, Slovenia.
RP Ching, WY (corresponding author), Univ Missouri, Dept Phys & Astron, Kansas City, MO 64110 USA.
EM ChingW@umkc.edu
RI Ching, Wai-Yim/B-4686-2009; Li, Neng/S-1296-2017
OI Ching, Wai-Yim/0000-0001-7738-8822; Shin, Matthew/0000-0002-2516-5712;
   Li, Neng/0000-0001-9633-6702
FU DOEUnited States Department of Energy (DOE) [DE-AC03-76SF00098];
   Research Computing Support Services (RCSS) of the University of Missouri
   System; University of Missouri-Kansas City, School of Graduate Studies;
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [11604249]; Fok Ying-Tong Education
   Foundation for Young Teachers in the Higher Education Institutions of
   ChinaFok Ying Tung Education Foundation [161008]; Basic Research Program
   of Shenzhen [JCYJ20190809120015163]; Overseas Expertise Introduction
   Project (111 project) for Discipline Innovation of China [B18038]; CBI
   training program NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [T32GM135142];
   EPSRCEngineering & Physical Sciences Research Council (EPSRC)
   [EP/R023204/1]; National Science Foundation RAPID [CMMI-2027668,
   CBET-2032196, DMR/CMMT-2028803]; EPSRC Established Career Fellowship
   [EP/R023204/1]; Royal Society Wolfson Fellowship [RSWF\R1\180009];
   Wellcome TrustWellcome Trust [110145, 110146]; 1000-Talents Program of
   the Chinese Foreign Experts Bureau; University of the Chinese Academy of
   Sciences, Beijing
FX This research used the resources of the National Energy Research
   Scientific Computing Center supported by DOE under Contract No.
   DE-AC03-76SF00098 and the Research Computing Support Services (RCSS) of
   the University of Missouri System. PA was supported in part from funds
   provided by the University of Missouri-Kansas City, School of Graduate
   Studies. NL is supported by the National Natural Science Foundation of
   China (Grant No. 11604249), the Fok Ying-Tong Education Foundation for
   Young Teachers in the Higher Education Institutions of China (Grant No.
   161008), the Basic Research Program of Shenzhen (Grant No.
   JCYJ20190809120015163), the Overseas Expertise Introduction Project (111
   project) for Discipline Innovation of China (B18038). M. S. was
   supported in part by CBI training program NIH T32GM135142. NS is
   supported for work on SARS-CoV-2 by the National Science Foundation
   RAPID CMMI-2027668 and CBET-2032196. RT acknowledges funding via an
   EPSRC Established Career Fellowship (EP/R023204/1), a Royal Society
   Wolfson Fellowship (RSWF\R1\180009) and a Joint Wellcome Trust
   Investigator Award (110145 & 110146). RP would like to acknowledge the
   support of the 1000-Talents Program of the Chinese Foreign Experts
   Bureau, and of the University of the Chinese Academy of Sciences,
   Beijing. WC is supported for work on SARS-CoV-2 by the National Science
   Foundation RAPID DMR/CMMT-2028803.
CR Adhikari P, 2016, J PHYS CHEM C, V120, P15362, DOI 10.1021/acs.jpcc.6b06337
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   [Anonymous], 2020, COR DIS 2019 COVID 2
   Becker O. M., 2001, COMPUTATIONAL BIOCH
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Brookes JC, 2017, P ROY SOC A-MATH PHY, V473, DOI 10.1098/rspa.2016.0822
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen WH, 2020, HUM VACC IMMUNOTHER, V16, P1239, DOI 10.1080/21645515.2020.1740560
   Chen WH, 2017, J PHARM SCI-US, V106, P1961, DOI 10.1016/j.xphs.2017.04.037
   Ching W.-Y., 2012, ELECT STRUCTURE METH
   Eifler J, 2016, INT J QUANTUM CHEM, V116, P681, DOI 10.1002/qua.25089
   Eriksson L. A., 2001, THEORETICAL BIOCH PR
   Fang LQ, 2015, VIRUSES-BASEL, V7, P333, DOI 10.3390/v7010333
   French RH, 2010, REV MOD PHYS, V82, P1887, DOI 10.1103/RevModPhys.82.1887
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Lowdin P.-O., 1962, QUANTUM GENETICS APE
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ma H., 2020, MEDRXIV, DOI [10.1101/2020.04.17.20064907, DOI 10.1101/2020.04.17.20064907]
   Matta C. F., 2010, QUANTUM BIOCH ELECT
   Nap RJ, 2014, BIOPHYS J, V107, P1970, DOI 10.1016/j.bpj.2014.08.032
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Parsegian VA, 2011, CURR OPIN COLLOID IN, V16, P618, DOI 10.1016/j.cocis.2011.06.010
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Poudel L, 2017, J PHYS CHEM B, V121, P6321, DOI 10.1021/acs.jpcb.7b02569
   Poudel L, 2016, PHYS CHEM CHEM PHYS, V18, P21573, DOI 10.1039/c6cp04357g
   Poudel L, 2015, CHEMPHYSCHEM, V16, P1451, DOI 10.1002/cphc.201402893
   Quinlan B. D., 2020, IMMUNITY, P1, DOI [10.2139/ssrn.3575134, DOI 10.2139/SSRN.3575134]
   Roy S., 2020, BIORXIV, P1, DOI [10.1101/2020.04.20.052290, DOI 10.1101/2020.04.20.052290]
   Smith M., 2020, REPURPOSING THERAPEU, DOI [10.26434/chemrxiv.11871402.v4, DOI 10.26434/CHEMRXIV.11871402.V4]
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang HY, 2020, J CHEM RES, DOI 10.1177/1747519820923277
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   Wiler E., US ARMYS VIRUS RES L
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zandi R, 2020, PHYS REP, V847, P1, DOI 10.1016/j.physrep.2019.12.005
   Zavadlav J, 2015, J CHEM THEORY COMPUT, V11, P5035, DOI 10.1021/acs.jctc.5b00596
   Zhang B., 2020, MEDRXIV, P1, DOI [10.1101/2020.03.12.20035048, DOI 10.1101/2020.03.12.20035048]
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
   Zou J., 2020, CHEMRXIV, P1, DOI [10.26434/chemrxiv.11902623.v2, DOI 10.26434/CHEMRXIV.11902623.V2]
   2020, CLIN INFECT DIS, P1, DOI DOI 10.1093/CID/CIAA344.
NR 45
TC 1
Z9 1
U1 6
U2 6
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1463-9076
EI 1463-9084
J9 PHYS CHEM CHEM PHYS
JI Phys. Chem. Chem. Phys.
PD SEP 7
PY 2020
VL 22
IS 33
BP 18272
EP 18283
DI 10.1039/d0cp03145c
PG 12
WC Chemistry, Physical; Physics, Atomic, Molecular & Chemical
SC Chemistry; Physics
GA NI2AH
UT WOS:000565157900047
PM 32756685
OA Other Gold
DA 2021-01-01
ER

PT J
AU Ali, I
AF Ali, Inayat
TI Impact of COVID-19 on vaccination programs: adverse or positive?
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article
DE COVID-19; 2019-nCoV; pandemic; immunization; vaccination;
   vaccine-preventable disease; VPDs; outbreaks; refusals; anxiety;
   suspicion; hesitancy
ID REEMERGING INFECTIOUS-DISEASES; RESPIRATORY SYNDROME; OUTBREAK; QUALITY;
   FLU
AB The COVID-19 pandemic has posed multiple substantial challenges, affecting not only public health but also economic systems, socio-cultural patterns, and political institutions. Studies have focused on the relationships between complex emergencies and natural disasters with outbreaks of infectious diseases. However, there is a dearth of relevant literature on the impact of a global pandemic on vaccination programs - an important topic because delays or stops in such programs are likely to result in outbreaks and epidemics of other infectious diseases. Thus, this article discusses the negative and positive impacts that the COVID-19 pandemic may exert on vaccination for vaccine-preventable diseases (VPDs). Negative impacts include the increased risk of VPD outbreaks in low-resource countries where vaccination programs must be temporarily halted to prevent the spread of infection. Positive effects include the strong possibility that the universally-recognized need for a coronavirus vaccine may increase people's appreciation for vaccines in general, resulting in improved vaccination uptake once the pandemic passes. Concerned stakeholders, such as governments and the World Health Organization (WHO), should seize this moment to effectively build on these positive impacts by planning renewed and revitalized post-COVID vaccination programs.
C1 [Ali, Inayat] Univ Vienna, Dept Social & Cultural Anthropol, Vienna, Austria.
RP Ali, I (corresponding author), Room D0418,NIG 4 Stock,Univ Str 7, A-1010 Vienna, Austria.
EM inayat_qau@yahoo.com
RI Ali, Inayat/ABA-4426-2020
OI Ali, Inayat/0000-0003-1659-8492; Reis, AlessanRSS/0000-0001-8486-7469
CR Abbott A, 2004, NATURE, V427, P472, DOI 10.1038/427472a
   Ali I, 2020, CONSTRUCTION NEGOTIA
   Ali I, 2020, MED ANTHROPOL, V39, P376, DOI 10.1080/01459740.2020.1745481
   AlJazeera, 2013, ALJAZEERA
   Aye HNN, 2018, VACCINE, V36, P7542, DOI 10.1016/j.vaccine.2018.10.051
   Barrett R, 1998, ANNU REV ANTHROPOL, V27, P247, DOI 10.1146/annurev.anthro.27.1.247
   Blume S, 2006, SOC SCI MED, V62, P628, DOI 10.1016/j.socscimed.2005.06.020
   Butt M, 2020, RISK MANAG HEALTHC P, V13, P111, DOI 10.2147/RMHP.S211170
   Chaib F, 2017, SUBSTANTIAL DECLINE
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Closser S, 2010, CHASING POLIO PAKIST
   Crosby AW, 2003, AM FORGOTTEN PANDEMI, V1918
   Culver A, 2017, CONFL HEALTH, V11, DOI 10.1186/s13031-017-0135-8
   Fairhead J, 2012, VACCINE ANXIETIES GL
   Farmer P, 1996, EMERG INFECT DIS, V2, P259, DOI 10.3201/eid0204.960402
   Feldman-Savelsberg P, 2000, MED ANTHROPOL Q, V14, P159, DOI 10.1525/maq.2000.14.2.159
   Feldman-Savelsberg P, 2017, RUMOR BEGETS RUMOR C
   Flu: KG, 2001, STORY GREAT INFLUENZ
   Gao GF, 2018, CELL, V172, P1157, DOI 10.1016/j.cell.2018.02.025
   Gatherer D, 2009, J CLIN VIROL, V45, P174, DOI 10.1016/j.jcv.2009.06.004
   Ghinai I, 2013, GLOB PUBLIC HEALTH, V8, P1138, DOI 10.1080/17441692.2013.859720
   Global Polio Eradication Initiative (GPEI), 2020, PAKISTAN
   Heidebrecht CL, 2014, BMC MED INFORM DECIS, V14, DOI 10.1186/1472-6947-14-5
   Hein A, 2019, FOX NEWS
   Hinman A, 1999, ANNU REV PUBL HEALTH, V20, P211, DOI 10.1146/annurev.publhealth.20.1.211
   Holmberg C, 2017, SOC HIST MEDIC, P1
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Independent, 2018, INDEPENDENT
   Iqbal S, 2020, HUM VACC IMMUNOTHER, V16, P1529, DOI 10.1080/21645515.2019.1705693
   Kazi AM, 2017, INT J MED INFORM, V107, P48, DOI 10.1016/j.ijmedinf.2017.09.004
   Kazi AM, 2018, JMIR PUBLIC HLTH SUR, V4, P333, DOI 10.2196/publichealth.7026
   Khan MH, 2014, SINDHS MEASLES NIGHT
   Kouadio IK, 2012, EXPERT REV ANTI-INFE, V10, P95, DOI [10.1586/eri.11.155, 10.1586/ERI.11.155]
   Larson HJ, 2018, LANCET, V392, P2244, DOI 10.1016/S0140-6736(18)32608-4
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Ligon B Lee, 2006, Semin Pediatr Infect Dis, V17, P36, DOI 10.1053/j.spid.2006.01.002
   Lim SS, 2016, VACCINE BOOK, 2ND EDITION, pXXIX
   Lindmeier C, 2018, MEASLES CASES SPIKE
   Lyren A, 2006, CLIN PEDIATR, V45, P399, DOI 10.1177/0009922806289581
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   McGirk T, 2015, NATL GEOGRAPHIC
   Mohd HA, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0544-0
   Mutale W, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-S2-S9
   Paquet C, 1998, B I PASTEUR, V96, P3, DOI 10.1016/S0020-2452(98)80024-9
   Paules CI, 2017, JAMA-J AM MED ASSOC, V317, P691, DOI 10.1001/jama.2016.21079
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Renne EP, 2010, POLITICS POLIO NO NI
   Roberts L, 2020, SCIENCE, V368, P116, DOI 10.1126/science.368.6487.116
   Saint-Victor DS, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0148
   Spiegel Paul B, 2007, Confl Health, V1, P2, DOI 10.1186/1752-1505-1-2
   Taubenberger JK, 2000, VIROLOGY, V274, P241, DOI 10.1006/viro.2000.0495
   Tilahun B, 2018, HEALTH RES POLICY SY, V16, DOI 10.1186/s12961-018-0312-2
   Trilla A, 2008, CLIN INFECT DIS, V47, P668, DOI 10.1086/590567
   United Nations International Emergency Fund Zaidi A., 2020, UNITED NATIONS  0426
   Walton S, 2017, VACCINE, V35, P7166, DOI 10.1016/j.vaccine.2017.10.085
   Waring Stephen C, 2005, Disaster Manag Response, V3, P41, DOI 10.1016/j.dmr.2005.02.003
   Watson JT, 2007, EMERG INFECT DIS, V13, P1, DOI 10.3201/eid1301.060779
   WHO, 2019, MIDDL E RESP SYNDR C
   World Health Organisation, 2018, REP CAS SEL VACC PRE
   World Health Organization, 2013, MEASL RUB IN ANN REP
   World Health Organization, 2020, WHO REC ROUT IMM SUM
NR 61
TC 0
Z9 0
U1 3
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
PD NOV 1
PY 2020
VL 16
IS 11
BP 2594
EP 2600
DI 10.1080/21645515.2020.1787065
EA SEP 2020
PG 7
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA PC2WP
UT WOS:000571928200001
PM 32961081
DA 2021-01-01
ER

PT J
AU Zeng, J
   Xie, MH
   Yang, J
   Chao, SW
   Xu, EL
AF Zeng, Jia
   Xie, Ming-Hui
   Yang, Jing
   Chao, Sheng-Wu
   Xu, Er-Li
TI Clinical efficacy of tocilizumab treatment in severe and critical
   COVID-19 patients
SO WORLD JOURNAL OF CLINICAL CASES
LA English
DT Article
DE COVID-19; Cytokine storm; Tocilizumab; Interleukin-6
AB BACKGROUND
   The main pathophysiological basis of coronavirus disease 2019 (COVID-19) causing respiratory failure is a cytokine storm and interleukin-6 (IL-6) is an important component of the COVID-19 cytokine storm. As a specific antagonist of IL-6, tocilizumab may block the cytokine storm of COVID-19. The Diagnosis and Treatment Guidelines of New Coronavirus Pneumonia (7(th)Edition) includes tocilizumab as a recommended drug for immunotherapy in severe and critical COVID-19 patients. However, the specific clinical efficacy of tocilizumab in the treatment of COVID-19 patients is worth studying.
   AIM
   To determine the clinical efficacy of tocilizumab in inhibiting the cytokine storm in COVID-19.
   METHODS
   In total, 19 severe and critical COVID-19 patients were enrolled in this study, and were treated with tocilizumab in Optical Valley Campus of Hubei Maternal and Child Health Care Hospital from February 20 to March 31, 2020. The imaging manifestations and clinical data before and after treatment were analyzed retrospectively, including routine peripheral venous blood tests, routine blood biochemical tests, coagulation test, C-reactive protein (CRP), IL-6, and arterial blood gas analysis.
   RESULTS
   Of the 19 patients in this group, 13 (68.4%) had significantly improved symptoms of COVID-19 (5 patients were discharged directly and 8 patients were transferred after improvement) following treatment. One case was invalid, 1 case was exacerbated, and 4 deaths (21.1%) were observed (all critical cases). The lymphocyte count, CRP, lactic acid, oxygenation index, fibrinogen (FIB) and IL-6 levels were significantly different in the improved group.
   CONCLUSION
   Tocilizumab treatment is effective against IL-6 in COVID-19 patients, but it does not completely inhibit the inflammation and cytokine storm in all patients with COVID-19.In the clinical treatment of COVID-19 patients, attention should be paid to the timing of drug administration and other adjuvant treatments.
C1 [Zeng, Jia; Xu, Er-Li] Naval Med Ctr PLA, Dept Aviat Dis, 338 Huaihai West Rd, Shanghai 200052, Peoples R China.
   [Zeng, Jia; Xie, Ming-Hui; Yang, Jing; Chao, Sheng-Wu] Hubei Maternal & Child Hlth Care Hosp, Dept Infect 1, Opt Valley Campus, Wuhan 430073, Hubei, Peoples R China.
   [Xie, Ming-Hui] Second Mil Med Univ, Affiliated Hosp 1, Dept Intervent Therapy, Shanghai 200433, Peoples R China.
   [Yang, Jing] Naval Med Ctr PLA, Dept Nephrol, Shanghai 200052, Peoples R China.
   [Chao, Sheng-Wu] Naval Med Ctr PLA, Dept Cardiovasc Med, Shanghai 200052, Peoples R China.
RP Xu, EL (corresponding author), Naval Med Ctr PLA, Dept Aviat Dis, 338 Huaihai West Rd, Shanghai 200052, Peoples R China.
EM yijiacheng455@163.com
CR Buonaguro FM, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02333-9
   Ceribelli A, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102442
   Chiappelli F, 2020, BIOINFORMATION, V16, P219, DOI [10.6026/97320630016222, 10.6026/97320630016219]
   Choudhury R, 2020, WORLD J EMERG SURG, V15, DOI 10.1186/s13017-020-00305-4
   Cure E, 2020, DIABETES METAB SYND, V14, P349, DOI 10.1016/j.dsx.2020.04.019
   Fu BQ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02339-3
   Gattinoni L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02880-z
   Hu Y, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104371
   Li GP, 2020, J AUTOIMMUN, V112, DOI 10.1016/j.jaut.2020.102463
   Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125
   Michot JM, 2020, ANN ONCOL, V31, P961, DOI 10.1016/j.annonc.2020.03.300
   Yang H, 2020, J INFECTION, V81, pE40, DOI 10.1016/j.jinf.2020.04.003
   Zhang XH, 2020, BLOOD ADV, V4, P1307, DOI 10.1182/bloodadvances.2020001907
NR 13
TC 1
Z9 1
U1 0
U2 0
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 2307-8960
J9 WORLD J CLIN CASES
JI World J. Clin. Cases
PD SEP 6
PY 2020
VL 8
IS 17
BP 3763
EP 3773
DI 10.12998/wjcc.v8.i17.3763
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA NR8BZ
UT WOS:000571786000012
PM 32953852
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Miyoshi, A
   Ueda, Y
   Kimura, T
AF Miyoshi, Ai
   Ueda, Yutaka
   Kimura, Tadashi
TI Contemplating HPV vaccination in Japan during the time of COVID-19
SO HUMAN VACCINES & IMMUNOTHERAPEUTICS
LA English
DT Article; Early Access
DE HPV vaccine; suspension; Covid-19; infection; mortality; bias
AB The Coronavirus Disease 2019 (COVID-19) pandemic has been growing, including in Japan where it has been estimated that as many as 3.1% of patients positive for new CoV strain SARS-CoV-2 might die of COVID-19-related respiratory failure. Meanwhile, human papillomavirus (HPV) is spreading in Japan. The fatality rate for HPV-associated cancers after infection with HPV is as much as that for COVID-19 in Japan, although the time to disease is much longer for HPV. Among advanced countries, the cervical cancer screening rate in Japanese females is very low. The Japanese Ministry of Health, Labor and Welfare (MHLW) suspended its official recommendation for HPV vaccination in June 2013 due to alleged adverse post-vaccination events in several young girls, such as chronic pain and motor impairment, which were repeatedly reported in the media. Subsequently, the rate for vaccinating girls plummeted from approximately 70% to the current rate of 1% or less. Women should accept HPV vaccination for the eventual prevention of cervical cancer with the same passion they are for COVID-19 testing.
C1 [Miyoshi, Ai; Ueda, Yutaka; Kimura, Tadashi] Osaka Univ, Dept Obstet & Gynecol, Grad Sch Med, Suita, Osaka 5670871, Japan.
RP Ueda, Y (corresponding author), Osaka Univ, Dept Obstet & Gynecol, Grad Sch Med, Suita, Osaka 5670871, Japan.
EM ZVF03563@nifty.ne.jp
OI Reis, AlessanRSS/0000-0001-8486-7469
CR Chesson HW, 2014, SEX TRANSM DIS, V41, P660, DOI 10.1097/OLQ.0000000000000193
   Ikeda S, 2019, EXPERT REV VACCINES, V18, P323, DOI 10.1080/14760584.2019.1584040
   Yagi A, 2017, VACCINE, V35, P6931, DOI 10.1016/j.vaccine.2017.10.064
NR 3
TC 0
Z9 0
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2164-5515
EI 2164-554X
J9 HUM VACC IMMUNOTHER
JI Human Vaccines Immunother.
DI 10.1080/21645515.2020.1801318
EA SEP 2020
PG 2
WC Biotechnology & Applied Microbiology; Immunology
SC Biotechnology & Applied Microbiology; Immunology
GA NS0FU
UT WOS:000571937000001
PM 32961077
OA Bronze
DA 2021-01-01
ER

PT J
AU Li, J
   Bao, L
   Xia, ZJ
   Wang, SL
   Zhou, X
   Ding, KY
   Zhang, WH
   Yang, W
   Li, BZ
   Fu, CC
   Chen, B
   Hua, LM
   Wang, L
   Luo, J
   Yang, Y
   Xu, TH
   Wang, WD
   Huang, Y
   Wu, GL
   Liu, P
AF Li, Jing
   Bao, Li
   Xia, Zhongjun
   Wang, Sili
   Zhou, Xin
   Ding, Kaiyang
   Zhang, Wenhao
   Yang, Wei
   Li, Bingzong
   Fu, Chengcheng
   Chen, Bing
   Hua, Luoming
   Wang, Liang
   Luo, Jun
   Yang, Yang
   Xu, Tianhong
   Wang, Weida
   Huang, Yun
   Wu, Guolin
   Liu, Peng
TI Ixazomib-based frontline therapy in patients with newly diagnosed
   multiple myeloma in real-life practice showed comparable efficacy and
   safety profile with those reported in clinical trial: a multi-center
   study
SO ANNALS OF HEMATOLOGY
LA English
DT Article
DE Myeloma; Frontline; Ixazomib; Real-world
ID ORAL IXAZOMIB; OPEN-LABEL; DOUBLE-BLIND; DEXAMETHASONE; LENALIDOMIDE;
   BORTEZOMIB; CRITERIA; TRANSPLANTATION; CONSENSUS; WORLD
AB The induction therapy containing ixazomib, an oral proteasome inhibitor, has shown favorable efficacy and safety in clinical trials, but its experience in real-life remains limited. In routine practice, few patients received ixazomib-based induction therapy due to reasons including (1) patients' preference on oral regimens, (2) concerns on adverse events (AEs) of other intravenous/subcutaneous regimens, (3) requirements for less center visits, and (4) fears of COVID-19 and other infectious disease exposures. With the aim of assessing the real-life effectiveness and safety of ixazomib-based induction therapy, we performed this multi-center, observational study on 85 newly diagnosed multiple myeloma (NDMM) patients from 14 medical centers. Ixazomib-based regimens included ixazomib-lenalidomide-dexamethasone (IRd) in 44.7% of patients, ixazomib-dexamethasone (Id) in 29.4%, and Id plus another agent (doxorubicin, cyclophosphamide, thalidomide, or daratumumab) in 25.9%. Different ixazomib-based therapies were applied due to (1) financial burdens or limitations on local health insurance coverage, (2) concerns on treatment tolerance, and (3) drug accessibility issue. Ten patients received ixazomib maintenance. The median age was 67 years; 43.5% had ISS stage III disease; 48.2% had an Eastern Cooperative Oncology Group performance score >= 2; and 17.6% with high-risk cytogenetic abnormalities. Overall response rate for all 85 patients was 95.3%, including 65.9% very good partial response or better and 29.5% complete responses. The median time to response was 30 days. The response rate was similar across different ixazomib-based regimens. Median progression-free survival was not reached. Severe AEs (>= grade 3) were reported in 29.4% of patients. No grade 3/4 peripheral neuropathy (PN) occurred. Patients received a median of 6 (range 1-20) cycles of ixazomib treatment; 56.6% remained on treatment at data cutoff; 15.3% discontinued treatment due to intolerable AEs. These results support that the ixazomib-based frontline therapy was highly effective with acceptable toxicity in routine practice and the ixazomib oral regimens could be good alternative options for NDMM patients.
C1 [Li, Jing; Yang, Yang; Xu, Tianhong; Liu, Peng] Fudan Univ, Zhongshan Hosp, Dept Hematol, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
   [Bao, Li] Beijing Jishuitan Hosp, Dept Hematol, Beijing, Peoples R China.
   [Xia, Zhongjun; Wang, Weida] Sun Yat Sen Univ, Dept Hematol Oncol, Canc Ctr, Guangzhou, Peoples R China.
   [Wang, Sili; Huang, Yun] Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China.
   [Zhou, Xin] Wuxi People Hosp, Wuxi, Jiangsu, Peoples R China.
   [Ding, Kaiyang; Wu, Guolin] Anhui Prov Canc Hosp, Hefei, Peoples R China.
   [Zhang, Wenhao] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Shanghai, Peoples R China.
   [Yang, Wei] China Med Univ, Shengjing Hosp, Shengjing, Peoples R China.
   [Li, Bingzong] Soochow Univ, Affiliated Hosp 2, Suzhou, Jiangsu, Peoples R China.
   [Fu, Chengcheng] Soochow Univ, Jiangsu Inst Hematol, Affiliated Hosp 1, Dept Hematol, Suzhou, Peoples R China.
   [Chen, Bing] Nanjing Univ, Med Sch, Dept Hematol, Affiliated Nanjing Drum Tower Hosp, Nanjing, Peoples R China.
   [Hua, Luoming] Hebei Univ, Affiliated Hosp, Baoding, Peoples R China.
   [Wang, Liang] Southern Med Univ, Dept Hematol, ZhuJiang Hosp, Guangzhou, Peoples R China.
   [Luo, Jun] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Peoples R China.
RP Liu, P (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Hematol, 180 Fenglin Rd, Shanghai 200032, Peoples R China.
EM liu.peng@zs-hospital.sh.cn
FU National Key New Drug Creation Special Programs [2017ZX09304-021]
FX This study has been partially supported by the National Key New Drug
   Creation Special Programs (2017ZX09304-021).
CR Al Saleh AS, 2020, ACTA HAEMATOL-BASEL, V143, P410, DOI [10.1159/000507690, 10.1007/978-3-030-44584-3_1]
   Attal M, 2017, NEW ENGL J MED, V376, P1311, DOI 10.1056/NEJMoa1611750
   Bergin K, 2017, CL LYMPH MYELOM LEUK, V17, P133, DOI 10.1016/j.clml.2016.12.002
   Dimopoulos MA, 2019, LANCET, V393, P253, DOI 10.1016/S0140-6736(18)33003-4
   Dimopoulos MA, 2019, EUR J CANCER, V106, P89, DOI 10.1016/j.ejca.2018.09.011
   Durie BGM, 2017, LANCET, V389, P519, DOI 10.1016/S0140-6736(16)31594-X
   Engelhardt M, 2020, HAEMATOLOGICA, V105, P2872, DOI 10.3324/haematol.2020.262758
   Hou J, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0501-4
   Kumar SK, 2014, LEUKEMIA, V28, P1122, DOI 10.1038/leu.2013.313
   Kumar S, 2016, LANCET ONCOL, V17, pE328, DOI 10.1016/S1470-2045(16)30206-6
   Kumar SK, 2019, LEUKEMIA, V33, P1736, DOI 10.1038/s41375-019-0384-1
   Kumar SK, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0106-3
   Kumar SK, 2014, LANCET ONCOL, V15, P1503, DOI 10.1016/S1470-2045(14)71125-8
   Lu J, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.55
   Ludwig H, 2012, BLOOD, V119, P3003, DOI 10.1182/blood-2011-11-374249
   Mateos MV, 2020, LANCET, V395, P132, DOI 10.1016/S0140-6736(19)32956-3
   Merola D, 2018, J MANAG CARE SPEC PH, V24, P1019, DOI 10.18553/jmcp.2018.24.10.1019
   Mian H, 2020, J GERIATR ONCOL, V11, P764, DOI 10.1016/j.jgo.2020.04.008
   Morawska M, 2015, HEMATOL ONCOL, V33, P113, DOI 10.1002/hon.2149
   Moreau P, 2016, NEW ENGL J MED, V374, P1621, DOI 10.1056/NEJMoa1516282
   Palumbo A, 2015, J CLIN ONCOL, V33, P3459, DOI 10.1200/JCO.2014.60.2466
   Rajkumar SV, 2019, HEMATOL ONCOL, V37, P62, DOI 10.1002/hon.2586
   Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5
   Ross FM, 2012, HAEMATOL-HEMATOL J, V97, P1272, DOI 10.3324/haematol.2011.056176
   Shah JJ, 2017, CL LYMPH MYELOM LEUK, V17, P575, DOI 10.1016/j.clml.2017.06.013
   Terpos E, 2020, LEUKEMIA, V34, P2000, DOI 10.1038/s41375-020-0876-z
   Terpos E, 2020, ANN HEMATOL, V99, P1049, DOI 10.1007/s00277-020-03981-z
   Yong K, 2016, BRIT J HAEMATOL, V175, P252, DOI 10.1111/bjh.14213
   Zweegman S, 2020, HAEMATOLOGICA, DOI [10.3324/haematol.2019.240374, DOI 10.3324/HAEMAT0L.2019.240374]
NR 29
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0939-5555
EI 1432-0584
J9 ANN HEMATOL
JI Ann. Hematol.
PD NOV
PY 2020
VL 99
IS 11
BP 2589
EP 2598
DI 10.1007/s00277-020-04234-9
EA SEP 2020
PG 10
WC Hematology
SC Hematology
GA NW6KY
UT WOS:000566306500002
PM 32892275
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Gupta, AK
   Quinlan, EM
   Williams, KL
AF Gupta, Aditya K.
   Quinlan, Emma M.
   Williams, Ken L.
TI The shifting preferences of patients and physicians in nonsurgical hair
   loss treatment
SO JOURNAL OF COSMETIC DERMATOLOGY
LA English
DT Article; Early Access
DE Google; hair growth; hair loss; ISHRS; laser treatment; minoxidil
AB Background: There are multiple etiologies for hair thinning and loss, including genetic, hormonal, immune, scaring, and infectious. Hair loss treatment involves both surgical intervention and nonsurgical therapies such as pharmaceuticals, haircare products, vitamins, and low-level laser therapy (LLLT). While pharmaceuticals have been extensively researched, the efficacy of other therapies remains inconclusive. With so many available treatments, consumers often research their options using search engines such as Google and/or seek help from hair restoration physicians.
   Aims: To identify and analyze changing trends in international consumer and physician interest in nonsurgical hair loss therapies.
   Methods: Worldwide trends in Google searches of hair loss products (2004-2020) were compared with product prescription frequency surveys from members of the International Society of Hair Restoration Surgery (2004-2019, similar to 29% response rate).
   Results: Minoxidil and finasteride were the most prescribed hair loss treatments, while "minoxidil" was the most "Googled" term. Generic products were searched more often than their brand counterparts. Nutritionals and haircare prescriptions increased over time. LLLT was also increasingly prescribed, with Internet searches increasing following government regulation announcements. The COVID-19 pandemic initially negatively affected hair loss treatment searches, which have since returned to, and surpassed, pre-pandemic levels.
   Conclusion: Regulations and social media have influence on consumer interest in hair loss products. A weak economy and coronavirus fears may persuade consumers to turn to cheaper hair loss treatment alternatives. Hair restoration specialists need to keep abreast of online trends to communicate effectively with their patients. Patients should be cognizant of the safety and efficacy of hair restoration treatments.
C1 [Gupta, Aditya K.; Quinlan, Emma M.] Mediprobe Res Inc, London, ON, Canada.
   [Gupta, Aditya K.] Univ Toronto, Dept Dermatol, Fac Med, Toronto, ON, Canada.
   [Williams, Ken L.] Orange Cty Hair Restorat, Irvine, CA USA.
RP Gupta, AK (corresponding author), 645 Windermere Rd, London, ON N5X 2P1, Canada.
EM agupta@execulink.com
OI Quinlan, Emma/0000-0002-1806-5561; Gupta, Aditya/0000-0002-8664-7723
CR Ablon G, 2016, J COSMET DERMATOL-US, V15, P358, DOI 10.1111/jocd.12265
   Dodd EM, 2018, J COSMET LASER THER, V20, P159, DOI 10.1080/14764172.2017.1383613
   Evans M, 2020, J AM COLL NUTR, V39, P422, DOI 10.1080/07315724.2019.1684398
   FDA, 2008, DRUG APPR PACK MENS
   Gary Goldenberg, 2013, J Clin Aesthet Dermatol, V6, P44
   Guo Emily L, 2017, Dermatol Pract Concept, V7, P1, DOI 10.5826/dpc.0701a01
   Gupta AK, 2019, J DERMATOL TREAT, DOI 10.1080/09546634.2019.1688755
   Gupta AK, 2020, J DERMATOL TREAT, DOI 10.1080/09546634.2020.1749547
   Hairmax, 2020, FDA CLEAR
   Hirshburg Jason M, 2016, J Clin Aesthet Dermatol, V9, P56
   ISHRS, 2017, ISHRS
   ISHRS, 2017, STAT RES
   Kelly Y, 2016, DRUGS, V76, P1349, DOI 10.1007/s40265-016-0629-5
   Merck & Co. Inc, 2012, PROPECIA FIN TABL OR
   Picard C., 2019, GOOD HOUSEKEEPING
   Post-Finasteride Syndrome Foundation, 2020, HOM WELC POSTF FDN
   Randolph Michael, 2020, J Am Acad Dermatol, DOI 10.1016/j.jaad.2020.06.1009
   Theradome, FDA CLEAR ARCH
   Thompson Katherine G, 2020, J Am Acad Dermatol, DOI 10.1016/j.jaad.2020.04.123
   Wagner CL, 2019, NUTRIENTS, V11, DOI 10.3390/nu11051023
   World Health Organization, 2020, TIM WHOS RESP COVID
   York K, 2020, EXPERT OPIN PHARMACO, V21, P603, DOI 10.1080/14656566.2020.1721463
NR 22
TC 2
Z9 2
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1473-2130
EI 1473-2165
J9 J COSMET DERMATOL-US
JI J. Cosmet. Dermatol.
DI 10.1111/jocd.13681
EA SEP 2020
PG 8
WC Dermatology
SC Dermatology
GA NJ8CS
UT WOS:000566272400001
PM 32892459
DA 2021-01-01
ER

PT J
AU Fonseca, E
   Quintana, M
   Lallana, S
   Restrepo, JL
   Abraira, L
   Santamarina, E
   Seijo-Raposo, I
   Toledo, M
AF Fonseca, Elena
   Quintana, Manuel
   Lallana, Sofia
   Luis Restrepo, Juan
   Abraira, Laura
   Santamarina, Estevo
   Seijo-Raposo, Ivan
   Toledo, Manuel
TI Epilepsy in time of COVID-19: A survey-based study
SO ACTA NEUROLOGICA SCANDINAVICA
LA English
DT Article
DE coronavirus; epilepsy; pandemics; quality of life; seizures
AB Objectives Collateral damage may occur in epilepsy management during the coronavirus (COVID-19) pandemic. We aimed to establish the impact of this pandemic on epilepsy patients in terms of patient-reported seizure control and emerging symptoms. Materials & Methods This is a cross-sectional study including consecutive patients assessed by telephone contact in an epilepsy clinic during the first month of confinement. Demographic and clinical characteristics were recorded, and a 19-item questionnaire was systematically completed. Data regarding the impact of confinement, economic effects of the pandemic, and subjective perception of telemedicine were recorded. Additional clinical data were obtained in patients with a COVID-19 diagnosis. Results Two hundred and fifty-five patients were recruited: mean age 48.2 +/- 19.8 years, 121 (47.5%) women. An increase in seizure frequency was reported by 25 (9.8%) patients. Sixty-eight (26.7%) patients reported confinement-related anxiety, 22 (8.6%) depression, 31 (12.2%) both, and 72 (28.2%) insomnia. Seventy-three (28.6%) patients reported a reduction in economic income. Logistic regression analysis showed that tumor-related epilepsy etiology [OR = 7.36 (95% CI 2.17-24.96)], drug-resistant epilepsy [OR = 3.44 (95% CI 1.19-9.95)], insomnia [OR = 3.25 (95% CI 1.18-8.96)], fear of epilepsy [OR = 3.26 (95% CI 1.09-9.74)], and income reduction [OR = 3.65 (95% CI 1.21-10.95)] were associated with a higher risk of increased seizure frequency. Telemedicine was considered satisfactory by 214 (83.9%) patients. Five patients were diagnosed with COVID-19, with no changes in seizure frequency. Conclusions The COVID-19 pandemic has effects in epilepsy patients. Patients with tumor-related, drug-resistant epilepsy, insomnia, and economic difficulties are at a higher risk of increased seizure frequency. Telemedicine represents a suitable tool in this setting.
C1 [Fonseca, Elena; Quintana, Manuel; Lallana, Sofia; Luis Restrepo, Juan; Abraira, Laura; Santamarina, Estevo; Seijo-Raposo, Ivan; Toledo, Manuel] Vall dHebron Univ Hosp, Epilepsy Unit, Neurol Dept, Barcelona, Spain.
   [Fonseca, Elena; Quintana, Manuel; Lallana, Sofia; Luis Restrepo, Juan; Abraira, Laura; Santamarina, Estevo; Seijo-Raposo, Ivan; Toledo, Manuel] Univ Autonoma Barcelona, Med Dept, Barcelona, Spain.
   [Fonseca, Elena; Quintana, Manuel; Abraira, Laura; Santamarina, Estevo; Seijo-Raposo, Ivan; Toledo, Manuel] Vall dHebron Res Inst VHIR, Epilepsy Res Grp, Barcelona, Spain.
RP Santamarina, E (corresponding author), Vall dHebron Univ Hosp, Epilepsy Unit, Passeig Vall dHebron 119-129, Barcelona, Spain.
EM esantama@vhebron.net
OI Fonseca, Elena/0000-0002-3895-1237; Quintana, Manuel/0000-0003-0288-9088
CR American Psychiatric Association, DIAGN STAT MAN MENT
   Ammar A, 2020, ACAD MED, V95, P1495, DOI 10.1097/ACM.0000000000003440
   Banks JL, 2007, STROKE, V38, P1091, DOI 10.1161/01.STR.0000258355.23810.c6
   Chi NC, 2015, J TELEMED TELECARE, V21, P37, DOI 10.1177/1357633X14562734
   Espinosa-Jovel C, 2018, SEIZURE-EUR J EPILEP, V56, P67, DOI 10.1016/j.seizure.2018.02.002
   Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550
   French JA, 2020, NEUROLOGY, V94, P1032, DOI 10.1212/WNL.0000000000009632
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hao XT, 2020, EPILEPSIA, V61, P1166, DOI 10.1111/epi.16544
   Hitiris N, 2007, EPILEPSY RES, V75, P192, DOI 10.1016/j.eplepsyres.2007.06.003
   Hu Y, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104371
   Kalilani L, 2018, EPILEPSIA, V59, P2179, DOI 10.1111/epi.14596
   Keesara S, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2005835
   Lu L, 2020, EPILEPSIA, V61, pE49, DOI 10.1111/epi.16524
   Miller WR, 2020, EPILEPSY BEHAV, V111, DOI 10.1016/j.yebeh.2020.107238
   MOOTS PL, 1995, ARCH NEUROL-CHICAGO, V52, P717, DOI 10.1001/archneur.1995.00540310091021
   Novakova B, 2013, EPILEPSIA, V54, P1866, DOI 10.1111/epi.12377
   Petrovski S, 2010, NEUROLOGY, V75, P1015, DOI 10.1212/WNL.0b013e3181f25b16
   Scheffer IE, 2017, EPILEPSIA, V58, P512, DOI 10.1111/epi.13709
   Steer S, 2014, EPILEPSIA, V55, P1634, DOI 10.1111/epi.12763
   Tschamper MK, 2019, J CLIN NURS, V28, P1506, DOI 10.1111/jocn.14755
   Verelst F, 2020, EUROSURVEILLANCE, V25, P13, DOI 10.2807/1560-7917.ES.2020.25.13.2000323
   WHO-China Joint Mission, REP WHO CHIN JOINT M
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Zhang J, 2020, CLIN MICROBIOL INFEC, V26, P767, DOI 10.1016/j.cmi.2020.04.012
NR 25
TC 1
Z9 1
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6314
EI 1600-0404
J9 ACTA NEUROL SCAND
JI Acta Neurol. Scand.
PD DEC
PY 2020
VL 142
IS 6
BP 545
EP 554
DI 10.1111/ane.13335
EA SEP 2020
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA OI6MZ
UT WOS:000566152000001
PM 32799337
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Favalli, EG
   Monti, S
   Ingegnoli, F
   Balduzzi, S
   Caporali, R
   Montecucco, C
AF Favalli, Ennio Giulio
   Monti, Sara
   Ingegnoli, Francesca
   Balduzzi, Silvia
   Caporali, Roberto
   Montecucco, Carlomaurizio
TI Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With
   Targeted Immunosuppressive Drugs: What Can We Learn From Observational
   Data?
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID ARTHRITIS; INFECTION; RISK
AB Objective To describe the incidence and severity of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases treated with targeted synthetic or biologic disease-modifying antirheumatic drugs (DMARDs) compared with that in the general population living in the same Italian region. Methods Patients followed up at 2 rheumatology referral centers in Lombardy from February 25, 2020 to April 10, 2020 were invited to participate in a survey designed to identify patients who had confirmed COVID-19, close contact with others with confirmed COVID-19, or symptoms of the infection, and to detect changes in work, behavior, and disease management made in an attempt to prevent infection. The incidence of COVID-19 in the Lombardy population was obtained from the National Institute of Statistics. COVID-19 cases were confirmed by nasopharyngeal swab. Results The survey was given to 955 patients (531 patients with rheumatoid arthritis, 203 patients with psoriatic arthritis, 181 patients with spondyloarthritis, and 40 patients with connective tissue diseases, vasculitides, or autoinflammatory diseases). These patients had a mean age of 53.7 years, and 67.4% were women. The rate of response to the survey was 98.05%, and the incidence of confirmed COVID-19 cases was consistent with that in the general population (0.62% versus 0.66%;P= 0.92). None of the patients had severe complications or required intensive care treatment, and all of the patients who tested positive for COVID-19 temporarily discontinued ongoing targeted synthetic drug or biologic DMARD therapy. Almost all patients took precautions to prevent the COVID-19 infection (90.6%), and almost all continued treatment with targeted synthetic drugs or biologic DMARDs (93.2%). Disease activity remained stable in 89.5% of patients. Conclusion Our results reflected the attitude of patients with rheumatic diseases regarding the prevention of the infection while maintaining their long-term treatment regimens. The incidence and severity of COVID-19 in patients treated with targeted synthetic drugs or biologic DMARDs was not significantly different from that in the general population in the same region.
C1 [Favalli, Ennio Giulio; Caporali, Roberto] ASST Gaetano Pini CTO Inst, Milan, Italy.
   [Monti, Sara; Balduzzi, Silvia; Montecucco, Carlomaurizio] Fdn IRCCS Policlin San Matteo, Pavia, Italy.
   [Ingegnoli, Francesca; Caporali, Roberto] Univ Milan, Milan, Italy.
RP Favalli, EG (corresponding author), ASST Gaetano Pini CTO Inst, Div Clin Rheumatol, Piazza Cardinale Andrea Ferrari 1, I-20122 Milan, Italy.
EM enniofavalli@me.com
RI Ingegnoli, Francesca/B-6226-2017; Monti, Sara/D-4505-2019
OI Ingegnoli, Francesca/0000-0002-6727-1273; Monti,
   Sara/0000-0002-1800-6772; Favalli, Ennio Giulio/0000-0003-1471-6467
FU Italian Ministry of HealthMinistry of Health, Italy [RF-2018-12365439]
FX Supported in part by the Italian Ministry of Health (grant
   RF-2018-12365439).
CR Accortt NA, 2018, ARTHRIT CARE RES, V70, P679, DOI 10.1002/acr.23426
   Blumentals WA, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-158
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Doran MF, 2002, ARTHRITIS RHEUM, V46, P2287, DOI 10.1002/art.10524
   Favalli EG, 2020, ANN RHEUM DIS
   Favalli EG, 2020, J RHEUMATOL, V47, P1296, DOI 10.3899/jrheum.200507
   Favalli EG, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102523
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Haberman R, 2020, N ENGL J MED
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Listing J, 2013, RHEUMATOLOGY, V52, P53, DOI 10.1093/rheumatology/kes305
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Singh JA, 2015, LANCET, V386, P258, DOI 10.1016/S0140-6736(14)61704-9
NR 15
TC 6
Z9 6
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD OCT
PY 2020
VL 72
IS 10
BP 1600
EP 1606
DI 10.1002/art.41388
EA SEP 2020
PG 7
WC Rheumatology
SC Rheumatology
GA NT0ST
UT WOS:000566162500001
PM 32506699
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Pierzynowska, K
   Gaffke, L
   Wegrzyn, G
AF Pierzynowska, Karolina
   Gaffke, Lidia
   Wegrzyn, Grzegorz
TI Transcriptomic analyses suggest that mucopolysaccharidosis patients may
   be less susceptible to COVID-19
SO FEBS LETTERS
LA English
DT Article
DE COVID-19; mucopolysaccharidosis; transcriptomic analyses
ID ENZYME REPLACEMENT THERAPY; RAPID CESSATION; MOLECULE
AB We used transcriptomic (RNA-seq) analyses to determine whether patients suffering from all types and subtypes of mucopolysaccharidosis (MPS), a severe inherited metabolic disease, may be more susceptible to coronavirus disease 2019 (COVID-19). The expression levels of genes encoding proteins potentially involved in SARS-CoV-2 development were estimated in MPS cell lines. Four genes (GTF2F2, RAB18, TMEM97,PDE4DIP) coding for proteins potentially facilitating virus development were down-regulated, while two genes (FBN1,MFGE8), the products of which potentially interfere with virus propagation, were up-regulated in most MPS types. Although narrowing of respiratory tract and occurrence of thick mucus, characteristic of MPS, are risk factors for COVID-19, transcriptomic analyses suggest that MPS cells might be less, rather than more, susceptible to SARS-CoV-2 infection.
C1 [Pierzynowska, Karolina; Gaffke, Lidia; Wegrzyn, Grzegorz] Univ Gdansk, Dept Mol Biol, Wita Stwosza 59, PL-80308 Gdansk, Poland.
RP Wegrzyn, G (corresponding author), Univ Gdansk, Dept Mol Biol, Wita Stwosza 59, PL-80308 Gdansk, Poland.
EM grzegorz.wegrzyn@biol.ug.edu.pl
OI Pierzynowska, Karolina/0000-0003-3634-6567; Wegrzyn,
   Grzegorz/0000-0003-4042-7466; Gaffke, Lidia/0000-0002-0820-7204
FU National Science Center, PolandNational Science Centre, PolandNational
   Science Center, Poland [2017/25/B/NZ2/00414]
FX This work was supported by National Science Center, Poland (project
   grant no. 2017/25/B/NZ2/00414).
CR Akhmerov A, 2020, CIRC RES, V126, P1443, DOI 10.1161/CIRCRESAHA.120.317055
   Ather A, 2020, J ENDODONT, V46, P584, DOI 10.1016/j.joen.2020.03.008
   Brokowska J, 2020, CELL BIOL INT, DOI 10.1002/cbin.11332
   Chariot A, 1998, INT J BIOCHEM CELL B, V30, P651, DOI 10.1016/S1357-2725(97)00136-2
   Cheng LC, 2019, NUCLEUS-PHILA, V10, P126, DOI 10.1080/19491034.2019.1618175
   Ciotti M, 2020, CHEMOTHERAPY, V64, P215, DOI [10.1159/000507423, 10.1080/10408363.2020.1783198]
   Dejgaard SY, 2019, CELL MOL LIFE SCI, V76, P1935, DOI 10.1007/s00018-019-03050-3
   Fecarotta S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072515
   Fornerod M, 1997, EMBO J, V16, P807, DOI 10.1093/emboj/16.4.807
   Gabutti G, 2020, INFECT DIS THER, V9, P241, DOI 10.1007/s40121-020-00295-5
   Gaffke L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041204
   Gaffke L, 2020, CELL BIOL INT, DOI 10.1002/cbin.11275
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Guzzi PH, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040982
   Ihara M, 2008, BIOL REPROD, V79, P906, DOI 10.1095/biolreprod.108.070474
   Jurecka A, 2014, MOL GENET METAB, V111, P212, DOI 10.1016/j.ymgme.2013.08.019
   Jurecka A, 2012, MOL GENET METAB, V107, P508, DOI 10.1016/j.ymgme.2012.08.013
   Kaminska A, 2018, VASC PHARMACOL, V101, P21, DOI 10.1016/j.vph.2017.11.006
   Ketteler J, 2018, INT J CANCER, V143, P2092, DOI 10.1002/ijc.31369
   Kochi AN, 2020, J CARDIOVASC ELECTR, V31, P1003, DOI 10.1111/jce.14479
   Kolifarhood G, 2020, ARCH ACAD EMERG MED, V8
   Lou J, 2020, EUR REV MED PHARMACO, V24, P3411, DOI 10.26355/eurrev_202003_20712
   Muthu ML, 2020, J CELL COMMUN SIGNAL, V14, P159, DOI 10.1007/s12079-020-00566-3
   Ng SC, 2020, GUT, V69, P973, DOI 10.1136/gutjnl-2020-321195
   Oyer HM, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01141
   Pierzynowska K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031156
   Piotrowska E, 2009, ACTA PAEDIATR, V98, P743, DOI 10.1111/j.1651-2227.2008.01153.x
   PURRELLO M, 1995, CYTOGENET CELL GENET, V69, P75, DOI 10.1159/000133942
   Sears TK, 2017, ONCOTARGET, V8, P84595, DOI 10.18632/oncotarget.21102
   Shapshak P, 2012, BIOINFORMATION, V8, P740, DOI 10.6026/97320630008740
   Sharma A, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13398
   Wegrzyn G, 2007, AM J MED GENET A, V143A, P1925, DOI 10.1002/ajmg.a.31831
   Zhou J, 2020, INTRACTABLE RARE DIS, V9, P1, DOI 10.5582/irdr.2020.01011
NR 33
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-5793
EI 1873-3468
J9 FEBS LETT
JI FEBS Lett.
PD OCT
PY 2020
VL 594
IS 20
BP 3363
EP 3370
DI 10.1002/1873-3468.13908
EA SEP 2020
PG 8
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA OH3WV
UT WOS:000566269800001
PM 32880920
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Barthels, F
   Schirmeister, T
   Kersten, C
AF Barthels, Fabian
   Schirmeister, Tanja
   Kersten, Christian
TI BAN Delta IT: B'-factor Analysis for Drug Design and Structural Biology
SO MOLECULAR INFORMATICS
LA English
DT Article; Early Access
DE B-factor; Protein flexibility; Molecular modeling; Drug design;
   Bioinformatics
ID PROTEIN FLEXIBILITY; CRYSTAL-STRUCTURES; PDZ DOMAIN; BINDING; DYNAMICS;
   INSIGHTS; CONFORMATION; PREDICTION; PARAMETERS; RECEPTOR
AB The analysis of B-factor profiles from X-ray protein structures can be utilized for structure-based drug design since protein mobility changes have been associated with the quality of protein-ligand interactions. With the BAN Delta IT (B'-factor analysis and Delta B' interpretation toolkit), we have developed a JavaScript-based browser application that provides a graphical user interface for the normalization and analysis of B'-factor profiles. To emphasize the usability for rational drug design applications, we have analyzed a selection of crystallographic protein-ligand complexes and have given exemplary conclusions for further drug optimization including the development of a B'-factor-supported pharmacophore model for SARS CoV-2 main protease inhibitors. BAN Delta IT is available online at https://bandit.uni-mainz.de. The source code can be downloaded from https://github.com/FBarthels/BANDIT.
C1 [Barthels, Fabian; Schirmeister, Tanja; Kersten, Christian] Johannes Gutenberg Univ Mainz, Inst Pharmaceut & Biomed Sci, Staudingerweg 5, D-55128 Mainz, Germany.
RP Kersten, C (corresponding author), Johannes Gutenberg Univ Mainz, Inst Pharmaceut & Biomed Sci, Staudingerweg 5, D-55128 Mainz, Germany.
EM kerstec@uni-mainz.de
OI Barthels, Fabian/0000-0001-7950-2158
FU Johannes Gutenberg-Universitat Mainz
FX This work has been supported by the Johannes Gutenberg-Universitat
   Mainz.
CR Baszczyk J., 2014, BIOCH ANAL BIOCH, V3, P1
   Blankenbecler R, 2003, P NATL ACAD SCI USA, V100, P11936, DOI 10.1073/pnas.1635048100
   Carlson HA, 2000, MOL PHARMACOL, V57, P213
   Carugo O, 1997, PROTEIN ENG, V10, P777, DOI 10.1093/protein/10.7.777
   Clore GM, 2006, J MOL BIOL, V355, P879, DOI 10.1016/j.jmb.2005.11.042
   Collier JH, 2017, BIOINFORMATICS, V33, P1005, DOI 10.1093/bioinformatics/btw757
   Dhulesia A, 2008, J AM CHEM SOC, V130, P8931, DOI 10.1021/ja0752080
   Iglewicz B., 1993, DETECT HANDLE OUTLIE
   Jiang C, 2017, J CHEM INF MODEL, V57, P2407, DOI 10.1021/acs.jcim.7b00434
   Johnson TW, 2018, ACS MED CHEM LETT, V9, P878, DOI 10.1021/acsmedchemlett.8b00147
   Jubb H, 2015, PROG BIOPHYS MOL BIO, V119, P2, DOI 10.1016/j.pbiomolbio.2015.01.009
   KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768
   Li X, 2017, J BIOL CHEM, V292, P11618, DOI 10.1074/jbc.M117.789024
   Liu Q., 2014, BMC BIOINFORMATICS, V15, P3
   Liu Q, 2013, J CHEM INF MODEL, V53, P3076, DOI 10.1021/ci400450h
   Lovell SC, 1999, P NATL ACAD SCI USA, V96, P400, DOI 10.1073/pnas.96.2.400
   Meyers L.S., 2013, PERFORMING DATA ANAL
   NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4
   Paasche A, 2014, BIOCHEMISTRY-US, V53, P5930, DOI 10.1021/bi400604t
   Parthasarathy S, 1997, PROTEIN SCI, V6, P2561, DOI 10.1002/pro.5560061208
   Patel D, 2014, PROG BIOPHYS MOL BIO, V116, P92, DOI 10.1016/j.pbiomolbio.2014.08.004
   Phadke M, 2020, DRUG DEVELOP RES, V81, P541, DOI 10.1002/ddr.21666
   Ran X, 2018, CURR OPIN CHEM BIOL, V44, P75, DOI 10.1016/j.cbpa.2018.06.004
   Rodgers TL, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-183
   Rose AS, 2018, BIOINFORMATICS, V34, P3755, DOI 10.1093/bioinformatics/bty419
   Schneider B, 2014, ACTA CRYSTALLOGR D, V70, P2413, DOI 10.1107/S1399004714014631
   Siglioccolo A, 2010, BIOPHYS CHEM, V153, P104, DOI 10.1016/j.bpc.2010.10.009
   Smith DK, 2003, PROTEIN SCI, V12, P1060, DOI 10.1110/ps.0236203
   Sun ZT, 2019, CHEM REV, V119, P1626, DOI 10.1021/acs.chemrev.8b00290
   Teague SJ, 2003, NAT REV DRUG DISCOV, V2, P527, DOI 10.1038/nrd1129
   Tong L, 1996, J MOL BIOL, V256, P601, DOI 10.1006/jmbi.1996.0112
   Tronrud DE, 1996, J APPL CRYSTALLOGR, V29, P100, DOI 10.1107/S002188989501421X
   Trueblood KN, 1996, ACTA CRYSTALLOGR A, V52, P770, DOI 10.1107/S0108767396005697
   van Montfort R. L. M., 2017, ESSAYS BIOCHEM, V61, P453
   van Westen GJP, 2010, PROTEIN SCI, V19, P742, DOI 10.1002/pro.350
   VIHINEN M, 1994, PROTEINS, V19, P141, DOI 10.1002/prot.340190207
   Waldron TT, 2003, BIOCHEMISTRY-US, V42, P5058, DOI 10.1021/bi034212v
   Wang NX, 2008, DRUG NEWS PERSPECT, V21, P137, DOI 10.1358/dnp.2008.21.3.1203409
   Ward JM, 2010, J AM CHEM SOC, V132, P11058, DOI 10.1021/ja910535j
   Yuan Z, 2003, PROTEIN ENG, V16, P109, DOI 10.1093/proeng/gzg014
   Zhang J, 2010, BIOCHEMISTRY-US, V49, P9280, DOI 10.1021/bi101131f
NR 41
TC 0
Z9 0
U1 0
U2 0
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1868-1743
EI 1868-1751
J9 MOL INFORM
JI Mol. Inf.
DI 10.1002/minf.202000144
EA SEP 2020
PG 7
WC Chemistry, Medicinal; Computer Science, Interdisciplinary Applications;
   Mathematical & Computational Biology
SC Pharmacology & Pharmacy; Computer Science; Mathematical & Computational
   Biology
GA NK1KJ
UT WOS:000566497900001
PM 32830452
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Dashraath, P
   Nielsen-Saines, K
   Madhi, SA
   Baud, D
AF Dashraath, Pradip
   Nielsen-Saines, Karin
   Madhi, Shabir A.
   Baud, David
TI COVID-19 vaccines and neglected pregnancy
SO LANCET
LA English
DT Letter
C1 [Dashraath, Pradip] Natl Univ Singapore Hosp, Div Maternal Fetal Med, Dept Obstet & Gynecol, Singapore, Singapore.
   [Nielsen-Saines, Karin] David Geffen UCLA Sch Med, Div Infect Dis, Dept Pediat, Los Angeles, CA USA.
   [Madhi, Shabir A.] Univ Witwatersrand, Vaccine Preventable Dis, Dept Sci & Technol, Natl Res Fdn, Johannesburg, South Africa.
   [Madhi, Shabir A.] Univ Witwatersrand, South African Med Res Council, Vaccines & Infect Dis Analyt Res Unit, Johannesburg, South Africa.
   [Baud, David] Lausanne Univ Hosp, Maternofetal & Obstet Res Unit, Dept Woman Mother Child, CH-1011 Lausanne, Switzerland.
RP Baud, D (corresponding author), Lausanne Univ Hosp, Maternofetal & Obstet Res Unit, Dept Woman Mother Child, CH-1011 Lausanne, Switzerland.
EM david.baud@chuv.ch
OI Baud, David/0000-0001-9914-6496
FU NIAID NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01 AI140718] Funding Source: Medline
CR Collin J, 2020, ACTA OBSTET GYN SCAN, V99, P819, DOI 10.1111/aogs.13901
   Ellington S, 2020, MMWR-MORBID MORTAL W, V69, P769, DOI 10.15585/mmwr.mm6925a1externalicon
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Hassan AO, 2019, CELL REP, V28, P2634, DOI 10.1016/j.celrep.2019.08.005
   Khalil A, 2020, JAMA-J AM MED ASSOC, V324, P705, DOI 10.1001/jama.2020.12746
   Stedman A, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0138-0
   World Health Organization, 2020, GLOB FRAM ENS EQ FAI
   Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6
NR 8
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD SEP 5
PY 2020
VL 396
IS 10252
BP E22
EP E22
DI 10.1016/S0140-6736(20)31822-5
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA OC4OX
UT WOS:000579138700001
PM 32861313
OA Green Accepted, Bronze
DA 2021-01-01
ER

PT J
AU Jiang, S
   Li, QY
   Li, CQ
   Liu, SS
   He, XM
   Wang, T
   Li, H
   Corpe, C
   Zhang, XY
   Xu, JQ
   Wang, J
AF Jiang, Shuo
   Li, Qiuyue
   Li, Chaoqun
   Liu, Shanshan
   He, Xiaomeng
   Wang, Tao
   Li, Hua
   Corpe, Christopher
   Zhang, Xiaoyan
   Xu, Jianqing
   Wang, Jin
TI Mathematical models for devising the optimal SARS-CoV-2 strategy for
   eradication in China, South Korea, and Italy
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; Mathematical models; Hospital isolation
ID TRANSMISSION; SARS; CORONAVIRUS; EPIDEMIOLOGY; INFLUENZA; OUTBREAK; MERS
AB Background Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), spreads rapidly and has attracted worldwide attention. Methods To improve the forecast accuracy and investigate the spread of SARS-CoV-2, we constructed four mathematical models to numerically estimate the spread of SARS-CoV-2 and the efficacy of eradication strategies. Results Using the Susceptible-Exposed-Infected-Removed (SEIR) model, and including measures such as city closures and extended leave policies implemented by the Chinese government that effectively reduced the beta value, we estimated that the beta value and basic transmission number,R-0, of SARS-CoV-2 was 0.476/6.66 in Wuhan, 0.359/5.03 in Korea, and 0.400/5.60 in Italy. Considering medicine and vaccines, an advanced model demonstrated that the emergence of vaccines would greatly slow the spread of the virus. Our model predicted that 100,000 people would become infected assuming that the isolation rate alpha in Wuhan was 0.30. If quarantine measures were taken from March 10, 2020, and the quarantine rate of alpha was also 0.3, then the final number of infected people was predicted to be 11,426 in South Korea and 147,142 in Italy. Conclusions Our mathematical models indicate that SARS-CoV-2 eradication depends on systematic planning, effective hospital isolation, and SARS-CoV-2 vaccination, and some measures including city closures and leave policies should be implemented to ensure SARS-CoV-2 eradication.
C1 [Jiang, Shuo; Li, Qiuyue; Li, Chaoqun; Liu, Shanshan; He, Xiaomeng; Zhang, Xiaoyan; Xu, Jianqing; Wang, Jin] Fudan Univ, Shanghai Publ Hlth Clin Ctr, 2901 Caolang Rd, Shanghai 201508, Peoples R China.
   [Wang, Tao] Wuhan Acad Social Sci, Wuhan, Hubei, Peoples R China.
   [Li, Hua] Shanghai Jiao Tong Univ, Sch Biomed Engn, State Key Lab Oncogenes, Shanghai, Peoples R China.
   [Li, Hua] Shanghai Jiao Tong Univ, Sch Biomed Engn, BioID Ctr, Shanghai, Peoples R China.
   [Corpe, Christopher] Kings Coll London, Nutr Sci Dept, 150 Stamford St, London SE19NH, England.
RP Wang, J (corresponding author), Fudan Univ, Shanghai Publ Hlth Clin Ctr, 2901 Caolang Rd, Shanghai 201508, Peoples R China.
EM wjincityu@yahoo.com
FU National Special Research Program of China for Important Infectious
   Diseases [2018ZX10302103-003];  [81672383]
FX The work is supported partially by a grant (2018ZX10302103-003) from the
   National Special Research Program of China for Important Infectious
   Diseases and a grant from the National Natural Science Foundation of
   China (81672383).
CR Al-Tawfiq JA, 2020, J HOSP INFECT, V105, P111, DOI 10.1016/j.jhin.2020.04.002
   ANDERSON RM, 1988, J ACQ IMMUN DEF SYND, V1, P241
   Bai YP, 2005, CHAOS SOLITON FRACT, V26, P559, DOI 10.1016/j.chaos.2005.01.064
   Bishop MT, 2006, LANCET NEUROL, V5, P393, DOI 10.1016/S1474-4422(06)70413-6
   Cauchemez S, 2013, EUROSURVEILLANCE, V18, P7
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chowell G, 2016, PHYS LIFE REV, V18, P66, DOI 10.1016/j.plrev.2016.07.005
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Ferguson NM, 2005, NATURE, V437, P209, DOI 10.1038/nature04017
   Ferguson NM, 1997, PHILOS T R SOC B, V352, P803, DOI 10.1098/rstb.1997.0063
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Han XN, 2009, TROP MED INT HEALTH, V14, P92, DOI 10.1111/j.1365-3156.2009.02244.x
   Hu B, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0422-1
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Letko M, 2020, FUNCTIONAL ASSESSMEN
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Liu J, 2020, EMERGING INFECT DIS, V26
   Liu T, 2020, TIME VARYING TRANSMI, V2020
   Liu Y, 2020, LANCET, V395, pE47, DOI 10.1016/S0140-6736(20)30462-1
   Longini IM, 2005, SCIENCE, V309, P1083, DOI 10.1126/science.1115717
   Majumder M, 2020, EARLY TRANSMISSIBILI
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Riou J, 2020, PATTERN EARLY HUMAN, V25
   Tang S Y, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P480, DOI 10.3760/cma.j.cn112338-20200216-00107
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang LF, 2006, EMERG INFECT DIS, V12, P1834
   Wang WD, 2004, J THEOR BIOL, V227, P369, DOI 10.1016/j.jtbi.2003.11.014
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Xu S, BEWARE 2 WAVE COVID
   Zhang C, 2020, MRCA TIME EPIDEMIC D
   Zhang Z, 2020, NUCLEIC ACIDS RES, V48, pD24, DOI 10.1093/nar/gkz913
   Zhou P, 2020, DISCOVERY NOVEL CORO
NR 34
TC 0
Z9 0
U1 9
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD SEP 5
PY 2020
VL 18
IS 1
AR 345
DI 10.1186/s12967-020-02513-7
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NM9ST
UT WOS:000568430900002
PM 32891155
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kaddam, L
   Babiker, R
   Ali, S
   Satti, S
   Ali, N
   Elamin, M
   Mukhtar, M
   Elnimeiri, M
   Saeed, A
AF Kaddam, Lamis
   Babiker, Rasha
   Ali, Sara
   Satti, Shahinaz
   Ali, Nour
   Elamin, Maha
   Mukhtar, Mowaia
   Elnimeiri, Mustafa
   Saeed, Amal
TI Potential Role of Acacia Senegal (Gum Arabic) as Immunomodulatory Agent
   among newly diagnosed COVID 19 Patients: A structured summary of a
   protocol for a randomised, controlled, clinical trial
SO TRIALS
LA English
DT Letter
DE COVID-19; Randomised controlled trial; protocol; Gum Arabic; cytokines;
   Immunomodulation
AB Objectives: To investigate the potential efficacy of Acacia Senegal extract Gum Arabic (GA) supplementation as immunomodulatory and anti-inflammatory dietary intervention among newly diagnosed COVID 19 Sudanese patients. To study the effect of GA on the level of cytokines, TNFa, IL8, IL6 IL10, CRP and the viral load. Secondary outcomes will be the effect of GA oral intake on mortality rate and days of hospital admission.
   Trial design: Quadruple blind, randomized placebo-controlled clinical trial Phase II & III. Prospective, two-arm, parallel-group, randomised (1:1 allocation ratio) superiority trial of oral GA among seropositive COVID-19 patients.
   Participants: Inclusion criteria: C
   OVID-19 infected (newly diagnosed) as proved by real-time PCR within 72 hours of PCR.
   Age 8-90 years
   Both genders
   Exclusion criteria:
   Intubated patients on parenteral treatment
   Allergy to Gum Arabic
   The study will be conducted in COVID Isolation Centres and Soba University Hospital Khartoum State Sudan.
   Intervention and comparator: Experimental: Intervention Group
   This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose once daily for four weeks Placebo Comparator: Control group: This group will be provided with pectin powder provided as one-gram-dose once daily for four weeks
   Both GA and placebo will be in addition to standard care treatment based on local clinical guidelines.
   Main outcomes: Mean change from baseline score of Immune Response to end of the trial. Changes of the level of Tumor Necrosis Factor (TNF alpha), interleukin IL8, IL6, and IL10 from the baseline values (Four weeks from the start of randomization).
   Mortality rate: The percentage of deaths among COVID 19 patients received Gum Arabic compared to placebo (Four weeks from the start of randomization]).
   Randomisation: Randomization (1:1 allocation ratio) and will be conducted using a sequence of computer-generated random numbers by an independent individual.
   Each participating centre will be assigned a special code generated by the computer. The randomization will be kept by the PI and a research assistant.
   Blinding (masking): Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Numbers to be randomised (sample size): 110 eligible patients will be randomly assigned to either GA (n=55) or placebo (n=55) groups.
   Trial Status: Protocol Version no 2, 30th June 2020. Recruitment will start on 15th September 2020. The intended completion date is 15th January 2021.
   Trial registration: ClinicalTrials.gov Identifier: NCT04381871. Date of trial registration: 11 May 2020.
   Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
C1 [Kaddam, Lamis; Satti, Shahinaz] Alneelain Univ Khartoum, Fac Med, Dept Physiol, POB 11121, Khartoum 12702, Sudan.
   [Kaddam, Lamis] King Abdulaziz Univ, Dept Physiol, Fac Med, Rabigh, Saudi Arabia.
   [Babiker, Rasha] Natl Univ Sudan, Dept Physiol, Fac Med, Khartoum, Sudan.
   [Ali, Sara] Int Univ Africa, Fac Med Lab Sci, Dept Microbiol, Khartoum, Sudan.
   [Ali, Nour] Nile Univ, Dept Physiol, Fac Med, Khartoum, Sudan.
   [Elamin, Maha] Alneelain Univ, Dept Biochem, Fac Med, Khartoum, Sudan.
   [Mukhtar, Mowaia] Univ Khartoum, Inst Endem Dis, Fac Med, Khartoum, Sudan.
   [Elnimeiri, Mustafa] Alneelain Univ, Dept Community Med, Fac Med, Khartoum, Sudan.
   [Saeed, Amal] Univ Khartoum, Dept Physiol, Fac Med, Khartoum, Sudan.
RP Kaddam, L (corresponding author), Alneelain Univ Khartoum, Fac Med, Dept Physiol, POB 11121, Khartoum 12702, Sudan.; Kaddam, L (corresponding author), King Abdulaziz Univ, Dept Physiol, Fac Med, Rabigh, Saudi Arabia.
EM lamiskaddam@hotmail.com
RI Kaddam, Lamis/AAI-6891-2020
OI Babiker, Rasha/0000-0002-9456-2033
FU Higher Education and Scientific Research Ministry in Sudan
FX This research is funded by a grant from Higher Education and Scientific
   Research Ministry in Sudan to LK and ME
NR 0
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD SEP 5
PY 2020
VL 21
IS 1
AR 766
DI 10.1186/s13063-020-04707-2
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NM9SO
UT WOS:000568430400002
PM 32891160
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Williams, L
   Gallant, AJ
   Rasmussen, S
   Nicholls, LAB
   Cogan, N
   Deakin, K
   Young, D
   Flowers, P
AF Williams, Lynn
   Gallant, Allyson J.
   Rasmussen, Susan
   Nicholls, Louise A. Brown
   Cogan, Nicola
   Deakin, Karen
   Young, David
   Flowers, Paul
TI Towards intervention development to increase the uptake of COVID-19
   vaccination among those at high risk: Outlining evidence-based and
   theoretically informed future intervention content
SO BRITISH JOURNAL OF HEALTH PSYCHOLOGY
LA English
DT Article
DE behaviour change techniques; beliefs about consequences; COVID-19;
   pandemic; theoretical domains framework; vaccination
ID INFLUENZA VACCINATION; BEHAVIOR
AB Objectives. Development of a vaccine against COVID-19 will be key to controlling the pandemic. We need to understand the barriers and facilitators to receiving a future COVID-19 vaccine so that we can provide recommendations for the design of interventions aimed at maximizing public acceptance.
   Design. Cross-sectional UK survey with older adults and patients with chronic respiratory disease.
   Methods. During the UK's early April 2020 'lockdown' period, 527 participants (311 older adults, mean age = 70.4 years; 216 chronic respiratory participants, mean age = 43.8 years) completed an online questionnaire assessing willingness to receive a COVID-19 vaccine, perceptions of COVID-19, and intention to receive influenza and pneumococcal vaccinations. A free text response (n = 502) examined barriers and facilitators to uptake. The Behaviour Change Wheel informed the analysis of these responses, which were coded to the Theoretical Domains Framework (TDF). Behaviour change techniques (BCTs) were identified.
   Results. Eighty-six per cent of respondents want to receive a COVID-19 vaccine. This was positively correlated with the perception that COVID-19 will persist over time, and negatively associated with perceiving the media to have over-exaggerated the risk. The majority of barriers and facilitators were mapped onto the 'beliefs about consequences' TDF domain, with themes relating to personal health, health consequences to others, concerns of vaccine safety, and severity of COVID-19.
   Conclusions. Willingness to receive a COVID-19 vaccination is currently high among high-risk individuals. Mass media interventions aimed at maximizing vaccine uptake should utilize the BCTs of information about health, emotional, social and environmental consequences, and salience of consequences.
C1 [Williams, Lynn; Gallant, Allyson J.; Rasmussen, Susan; Nicholls, Louise A. Brown; Cogan, Nicola; Deakin, Karen; Young, David; Flowers, Paul] Univ Strathclyde, Glasgow, Lanark, Scotland.
RP Williams, L (corresponding author), Univ Strathclyde, Sch Psychol Sci & Hlth, 40 George St, Glasgow G1 1QE, Lanark, Scotland.
EM lynn.williams@strath.ac.uk
OI Brown Nicholls, Louise A./0000-0003-3520-6175; Flowers,
   Paul/0000-0001-6239-5616; Young, David/0000-0002-3652-0513; Cogan,
   Nicola/0000-0003-0861-5133; Rasmussen, Susan/0000-0001-6408-0028;
   Williams, Lynn/0000-0003-2735-9219
FU Chief Scientist Office in Scotland [HIPS/18/37, CGA/19/52]
FX The University of Strathclyde supported the COVID-19 phase of data
   collection upon which the current paper is based. The funding for the
   initial phase of this research on general vaccination behaviour came
   from the Chief Scientist Office in Scotland (REF: HIPS/18/37 and
   CGA/19/52).
CR Atkins L, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0605-9
   Bish A, 2011, VACCINE, V29, P6472, DOI 10.1016/j.vaccine.2011.06.107
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]
   Brewer NT, 2007, HEALTH PSYCHOL, V26, P136, DOI 10.1037/0278-6133.26.2.136
   Brien S, 2012, VACCINE, V30, P1255, DOI 10.1016/j.vaccine.2011.12.089
   Cane J, 2015, BRIT J HEALTH PSYCH, V20, P130, DOI 10.1111/bjhp.12102
   Cane J, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-37
   Davis M, 2020, SOC SCI MED, V256, DOI 10.1016/j.socscimed.2020.113032
   Davis MDM, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1756-8
   Dodd Rachael H, 2020, Lancet Infect Dis, DOI 10.1016/S1473-3099(20)30559-4
   Fabry P, 2011, VACCINE, V29, P1824, DOI 10.1016/j.vaccine.2010.12.109
   Han YKJ, 2016, PREV MED, V84, P57, DOI 10.1016/j.ypmed.2015.12.018
   Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687
   Jorgensen P, 2018, VACCINE, V36, P442, DOI 10.1016/j.vaccine.2017.12.019
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Michie S. F., 2014, BEHAV CHANGE WHEEL G
   Michie S, 2013, ANN BEHAV MED, V46, P81, DOI 10.1007/s12160-013-9486-6
   Michie S, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-10
   Oliver K, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7389-6
   Peretti-Watel P, 2020, LANCET INFECT DIS, V20, P769, DOI 10.1016/S1473-3099(20)30426-6
   ROGERS RW, 1975, J PSYCHOL, V91, P93, DOI 10.1080/00223980.1975.9915803
   ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P328, DOI 10.1177/109019817400200403
   Rubin GJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2651
   Seale H, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-99
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Wellcome Trust, 2019, WELLC GLOB MON 2018
   Williams L, 2012, PSYCHOL HEALTH MED, V17, P383, DOI 10.1080/13548506.2011.626564
   Wu JT, 2010, CLIN INFECT DIS, V51, P1184, DOI 10.1086/656740
NR 28
TC 3
Z9 3
U1 11
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1359-107X
EI 2044-8287
J9 BRIT J HEALTH PSYCH
JI Br. J. Health Psychol.
PD NOV
PY 2020
VL 25
IS 4
BP 1039
EP 1054
DI 10.1111/bjhp.12468
EA SEP 2020
PG 16
WC Psychology, Clinical
SC Psychology
GA OJ3NA
UT WOS:000566520600001
PM 32889759
OA Other Gold, Green Accepted
DA 2021-01-01
ER

PT J
AU Hansmann, G
   Bezzerides, V
AF Hansmann, Georg
   Bezzerides, Vassilios
TI Paediatric/congenital cardiology physician scientists-An endangered
   species
SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
DE adults; children; clinician innovator; clinician scientist; congenital
   heart disease; early career development; mentoring; paediatric
   cardiology; physician scientist
ID CRITICAL-CARE; MEDICINE
AB Producing excellent physician scientists starts with the active discovery of talent and dedication, supported by the strong belief that physician involvement in biomedical research is essential to make fundamental discoveries that improve human health. The revolution of surgical and interventional therapy of structural heart disease has had 'profoundly positive effects on survival and quality of life over the decades. ( horizontal ellipsis ) Small increments in clinical improvement will still be possible in the future, but for the most part, the potential for major advancement using these techniques has been exhausted' (Frank Hanley, MD; Stanford). Personalized medicine, rapid genetic diagnostics, RNA and extracellular vesicle biology, epigenetics, gene editing, gene and stem cell-derived therapy are exemplary areas where specialized training for paediatric/congenital cardiology physician scientists will be increasingly needed to further advance the field. About a decade ago, a series in Circulation discussed academic career models and highlighted the major challenges facing the cardiovascular 'clinician scientist' (syn. physician scientist), which have not abated since. To develop the skills and expertise in both clinical congenital cardiology and basic research, the training of fellows must be focused and integrated. The current pandemic COVID-19 puts additional pressure and hurdles on fellows-in-training (FIT) and early career investigators (ECI) who aim to establish, consolidate or expand their own research group. Here, we discuss the major challenges, opportunities and necessary changes for academic institutions to sustain and recruit physician scientists in paediatric/congenital cardiology in the years to come.
C1 [Hansmann, Georg] Hannover Med Sch, Dept Paediat Cardiol & Crit Care, Carl Neuberg Str 1, D-30625 Hannover, Germany.
   [Bezzerides, Vassilios] Harvard Med Sch, Boston Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA.
RP Hansmann, G (corresponding author), Hannover Med Sch, Dept Paediat Cardiol & Crit Care, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM georg.hansmann@gmail.com
OI Hansmannn, Georg/0000-0003-0709-3935
FU German Research Foundation (DFG)German Research Foundation (DFG)
   [HA4348/2-2, HA4348/6-2 KFO311]; Federal Ministry of Education and
   Research (BMBF)Federal Ministry of Education & Research (BMBF) [ViP +
   03VP08053, 01KC2001B]; European Pediatric Pulmonary Vascular Disease
   Network; K08 grant from the NIH [K08HL140197]
FX GH receives financial support from the German Research Foundation (DFG;
   HA4348/2-2 and HA4348/6-2 KFO311), the Federal Ministry of Education and
   Research (BMBF ViP + 03VP08053; BMBF 01KC2001B) and the European
   Pediatric Pulmonary Vascular Disease Network (www.pvdne twork.org). VJB
   is supported by a K08 grant from the NIH, K08HL140197.
CR Agarwal S, 2018, CIRC RES, V122, P1330, DOI 10.1161/CIRCRESAHA.118.312999
   Alon U, 2010, MOL CELL, V37, P151, DOI 10.1016/j.molcel.2010.01.011
   Bonhoeffer P, 2000, LANCET, V356, P1403, DOI 10.1016/S0140-6736(00)02844-0
   Chang AC, 2019, ANN PEDIAT CARDIOL, V12, P191, DOI 10.4103/apc.APC_55_19
   Dittrich HC, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002489
   Fuster V, 2009, CIRCULATION, V119, P754, DOI 10.1161/CIRCULATIONAHA.108.792564
   Hanley F, 2019, STRATEGIC VISION BAS
   Hansmann G, 2012, J CLIN EXP CARDIOLOG, V22, P1
   Jain MK, 2019, NEW ENGL J MED, V381, P399, DOI 10.1056/NEJMp1904482
   Kalra A, 2019, EUR HEART J, V40, P3885, DOI 10.1093/eurheartj/ehz846
   Mahle WT, 2015, J AM COLL CARDIOL, V66, P740, DOI 10.1016/j.jacc.2015.03.006
   Majmudar MD, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.001990
   Mandalenakis Z, 2020, SURVIVAL CHILDREN CO
   Martin DM, 2018, J CLIN INVEST, V128, P3204, DOI 10.1172/JCI122099
   Oishi PE, 2013, J PEDIATR-US, V163, P616, DOI 10.1016/j.jpeds.2013.05.047
   Reinhardt Z, 2018, CARDIOL YOUNG, V28, P1295, DOI 10.1017/S1047951118001221
   Romfh A, 2012, J CLIN EXP CARDIO S8
   Sallmon H, 2019, CARDIOL YOUNG, V29, P1323, DOI 10.1017/S104795111900235X
   Whitelaw S, 2020, EUR HEART J, V41, P9, DOI 10.1093/eurheartj/ehz886
NR 19
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2972
EI 1365-2362
J9 EUR J CLIN INVEST
JI Eur. J. Clin. Invest.
PD OCT
PY 2020
VL 50
IS 10
AR e13367
DI 10.1111/eci.13367
EA SEP 2020
PG 6
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA NW6XF
UT WOS:000565964100001
PM 32735699
OA Other Gold
DA 2021-01-01
ER

PT J
AU Ziade, N
   el Kibbi, L
   Hmamouchi, I
   Abdulateef, N
   Halabi, H
   Hamdi, W
   Abutiban, F
   el Rakawi, M
   Eissa, M
   Masri, B
AF Ziade, Nelly
   el Kibbi, Lina
   Hmamouchi, Ihsane
   Abdulateef, Nizar
   Halabi, Hussein
   Hamdi, Wafa
   Abutiban, Fatemah
   el Rakawi, Manal
   Eissa, Mervat
   Masri, Basel
TI Impact of the COVID-19 pandemic on patients with chronic rheumatic
   diseases: A study in 15 Arab countries
SO INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
LA English
DT Article
DE access to care; adherence; COVID-19; persistency
ID RECOMMENDATIONS; MANAGEMENT; ARTHRITIS
AB Aim To evaluate the impact of the coronavirus disease 2019 pandemic (COVID-19) on the access to rheumatology care for patients with chronic rheumatic diseases (CRD) in the Arab countries. Method A web-based cross-sectional survey was designed by the Arab Adult Arthritis Awareness group (AAAA) consisting of 16 rheumatologists representing countries from the Arab League of Associations for Rheumatology (ArLAR) and was validated by the ArLAR scientific committee. The survey was disseminated online through social media and patients' association channels between May 8 and May 22, 2020. The steering committee developed recommendations to improve the care of patients with CRD during the COVID-19 pandemic. Results A total of 2163 patients were included in the analysis; 72% were female; mean age was 40 years (SD 11.9). The Levant, the Gulf, and North Africa contributed almost equally to the sample. The pandemic had a significant negative impact on rheumatology visits in 82% of cases, access to hydroxychloroquine (47%), and chronic medication persistency (28%). The negative impact on rheumatology visits was associated with female gender, country, medication non-persistency, isolation due to COVID-19, and impact on mental health. Sixty-one patients (2.8%) stated that they had COVID-19, 5% said that a close contact was infected, and 47% were in isolation because of COVID-19. Conclusion The current study highlights the deleterious consequences of the COVID-19 pandemic on the continuity of rheumatology care. Therefore, an action plan, including establishing a telemedicine platform, securing drug availability, and promoting medication persistence through the appropriate communication channels, is strongly recommended.
C1 [Ziade, Nelly] St Joseph Univ, Hotel Dieu France Hosp, Beirut, Lebanon.
   [el Kibbi, Lina] Specialized Med Ctr, Riyadh, Saudi Arabia.
   [Hmamouchi, Ihsane] Mohammed V Univ, Lab Biostat Clin Res & Epidemiol LBRCE, Fac Med & Pharm, Temara Hosp, Rabat, Morocco.
   [Abdulateef, Nizar] Univ Baghdad, Coll Med, Dept Med, Rheumatol Unit, Baghdad, Iraq.
   [Halabi, Hussein] King Faisal Specialist Hosp & Res Ctr, Jeddah, Saudi Arabia.
   [Hamdi, Wafa] Tunis El Manar Univ, Dept Rheumatol, UR17SP04, Fac Med Tunis,Kassab Inst Orthoped, Tunis, Tunisia.
   [Abutiban, Fatemah] Jaber Alahmed Alsabah Hosp, Dept Med, Rheumatol Unit, Kuwait, State Of Kuwait, Kuwait.
   [el Rakawi, Manal] Douera Hosp, Fac Med, Dept Rheumatol, Blida, Algeria.
   [Eissa, Mervat] Cairo Univ, Rheumatol Dept, Cairo, Egypt.
   [Masri, Basel] Jordan Hosp, Amman, Jordan.
RP Ziade, N (corresponding author), Hotel Dieu France Hosp, 6th Floor,Alfred Naccache Blvd, Beirut, Lebanon.
EM nellziade@yahoo.fr
OI Eissa, Mervat/0000-0001-7999-3401; hamdi, wafa/0000-0003-3045-4831
CR [Anonymous], RHEUMATOLOGY AC ACR
   ArLAR, 2020, COVID 19 FAQ
   Associations AL of R, ASS AL R ARAB ADULT
   Bedaiwi M, 2019, RHEUMATOL INT, V39, P1321, DOI 10.1007/s00296-019-04319-3
   Benucci Maurizio, 2020, Rev Rhum Ed Fr, V87, P150, DOI 10.1016/j.rhum.2020.03.010
   D'Silva KM, 2020, ANN RHEUM DIS, V2019, P1
   El Zorkany B, 2013, CLIN RHEUMATOL, V32, P151, DOI 10.1007/s10067-012-2153-7
   European League Against Rheumatism, 2020, EULAR GUID PAT COVID, P3
   Eurosurveillance Editorial Team, 2020, EUROSURVEILLANCE, V25, P2019, DOI DOI 10.2807/1560-7917.ES.2020.25.5.200131E
   Eysenbach G, 2004, J MED INTERNET RES, V6, P12, DOI 10.2196/jmir.6.3.e34
   Favalli EG, 2020, J RHEUMATOL, V47, P1296, DOI 10.3899/jrheum.200507
   Fernandez-gutierrez Benjamin, 2020, MEDRXIV, DOI 10.1101/2020.05.21.20108696
   Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P175
   Freites Nunez DD, 2020, ANN RHEUMATIC DIS, DOI 10.1136/annrheumdis-2020-217984
   Gianfrancesco M, 2020, ANN RHEUM DIS, P1
   Gianfrancesco MA, 2020, LANCET RHEUMATOL, V9913, P19
   Government MBRS of, 2017, GOVT MBRS ARAB SOCIA
   Graef ER, 2020, ANN RHEUM DIS, V79, P734, DOI 10.1136/annrheumdis-2020-217480
   Michaud Kaleb, 2020, ACR Open Rheumatol, V2, P335, DOI 10.1002/acr2.11148
   Mikuls TR, 2020, ARTHRITIS RHEUMATOL, V72, P1241, DOI 10.1002/art.41301
   Mohn N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01059
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Schulze-Koops H, 2020, ANN RHEUM DIS, V79, P840, DOI 10.1136/annrheumdis-2020-217628
   Tang DL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008536
   The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P1, DOI DOI 10.5194/GCHRON-2-1-2020
   Wendy E, 2020, NEW ENGL J MED, V28, P1, DOI DOI 10.1056/NEJMP2002125
   WHO, 2020, WHO COVID 19 DASHB
   World Health Organization (WHO), 2020, WHO ANN COVID 19 OUT
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Ye C, 2020, ANN RHEUM DIS, V79, P1007, DOI 10.1136/annrheumdis-2020-217627
NR 30
TC 1
Z9 1
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1756-1841
EI 1756-185X
J9 INT J RHEUM DIS
JI Int. J. Rheum. Dis.
PD NOV
PY 2020
VL 23
IS 11
BP 1550
EP 1557
DI 10.1111/1756-185X.13960
EA SEP 2020
PG 8
WC Rheumatology
SC Rheumatology
GA OU1RY
UT WOS:000566045900001
PM 32892516
OA Bronze
DA 2021-01-01
ER

PT J
AU Chang, WT
   Ragazzi, E
   Liu, PY
   Wu, SN
AF Chang, Wei-Ting
   Ragazzi, Eugenio
   Liu, Ping-Yen
   Wu, Sheng-Nan
TI Effective block by pirfenidone, an antifibrotic pyridone compound
   (5-methyl-1-phenylpyridin-2[H-1]-one), on hyperpolarization-activated
   cation current: An additional but distinctive target
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Pirfenidone; Hyperpolarization-activated cation current; K+ current;
   Ca2+ current; Voltage hysteresis; Membrane potential; Pituitary cell
ID HCN CHANNELS; DYSFUNCTION; FIBROSIS; CELLS
AB Pirfenidone (PFD), a pyridone compound, is well recognized as an antifibrotic agent tailored for the treatment of idiopathic pulmonary fibrosis. Recently, through its anti-inflammatory and anti-oxidant effects, PFD based clinical trial has also been launched for the treatment of coronavirus disease (COVID-19). To what extent this drug can perturb membrane ion currents remains largely unknown. Herein, the exposure to PFD was observed to depress the amplitude of hyperpolarization-activated cation current (I-h) in combination with a considerable slowing in the activation time of the current in pituitary GH(3) cells. In the continued presence of ivabradine or zatebradine, subsequent application of PFD decreased I-h amplitude further. The presence of PFD resulted in a leftward shift in I-h activation curve without changes in the gating charge. The addition of this compound also led to a reduction in area of voltage-dependent hysteresis evoked by long-lasting inverted triangular (downsloping and upsloping) ramp pulse. Neither the amplitude of M-type nor erg-mediated K+ current was altered by its presence. In whole-cell potential recordings, addition of PFD reduced the firing frequency, and this effect was accompanied by the depression in the amplitude of sag voltage elicited by hyperpolarizing current stimulus. Overall, this study highlights evidence that PFD is capable of perturbing specific ionic currents, revealing a potential additional impact on functional activities of different excitable cells.
C1 [Chang, Wei-Ting; Liu, Ping-Yen] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan 70101, Taiwan.
   [Chang, Wei-Ting] Chi Mei Med Ctr, Div Cardiol, Internal Med, Tainan 71004, Taiwan.
   [Chang, Wei-Ting] Southern Taiwan Univ Sci & Technol, Dept Biotechnol, Tainan 71004, Taiwan.
   [Ragazzi, Eugenio] Univ Padua, Dept Pharmaceut & Pharmacol Sci, I-35131 Padua, Italy.
   [Liu, Ping-Yen] Natl Cheng Kung Univ Hosp, Coll Med, Div Cardiol, Internal Med, Tainan 70401, Taiwan.
   [Wu, Sheng-Nan] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan.
   [Wu, Sheng-Nan] Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan, Taiwan.
   [Wu, Sheng-Nan] China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung, Taiwan.
RP Wu, SN (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Physiol, 1 Univ Rd, Tainan 70101, Taiwan.
EM cmcvecho2@gmail.com; larry@mail.ncku.edu.tw; snwu@mail.ncku.edu.tw
RI Wu, Sheng-Nan/B-9224-2009
OI Wu, Sheng-Nan/0000-0002-5208-3253
FU National Cheng Kung University, Taiwan [NCKUH-10709001]; Ministry of
   Education, TaiwanMinistry of Education, Taiwan [D108-F2507]; Ministry of
   Science and Technology, TaiwanMinistry of Science and Technology, Taiwan
   [MOST-108-2314-B-006-094]
FX The work described in this manuscript is supported jointly by National
   Cheng Kung University (NCKUH-10709001), Ministry of Education
   (D108-F2507), and Ministry of Science and Technology
   (MOST-108-2314-B-006-094), Taiwan.
CR Aimo A, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104694
   Antoniu Sabina A, 2006, Expert Opin Investig Drugs, V15, P823, DOI 10.1517/13543784.15.7.823
   Balestro L, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091469
   Barbuti A, 2012, J MOL CELL CARDIOL, V53, P187, DOI 10.1016/j.yjmcc.2012.05.013
   Barthel L, 2016, CELL PHYSIOL BIOCHEM, V38, P2079, DOI 10.1159/000445566
   Busseuil D, 2010, CARDIOLOGY, V117, P234, DOI 10.1159/000322905
   Chang WT, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020396
   Chang WT, 2019, MOLECULES, V24, DOI 10.3390/molecules24234256
   Ciotu CI, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184572
   Collins BF, 2019, EUR RESPIR REV, V28, DOI 10.1183/16000617.0022-2019
   Castro-Torres RD, 2014, J MOL NEUROSCI, V52, P193, DOI 10.1007/s12031-013-0121-6
   Datunashvili M, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00369
   DiFrancesco JC, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00071
   Fang L, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00186
   Figueroa SM, 2020, PHARM RES-DORDR, V37, DOI 10.1007/s11095-020-2783-4
   Furst O, 2015, SCI REP-UK, V5, DOI 10.1038/srep14270
   Greenwood IA, 2001, J PHYSIOL-LONDON, V534, P395, DOI 10.1111/j.1469-7793.2001.00395.x
   Hsu HT, 2014, BMC NEUROSCI, V15, DOI 10.1186/s12868-014-0135-1
   Huang MH, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00566
   Huang MH, 2011, TOXICOLOGY, V280, P1, DOI 10.1016/j.tox.2010.10.010
   IRISAWA H, 1993, PHYSIOL REV, V73, P197
   Ji TJ, 2017, ACS NANO, V11, P8668, DOI 10.1021/acsnano.7b01026
   Kanayama M, 2020, SURG TODAY, V50, P469, DOI 10.1007/s00595-019-01923-5
   Korolkova YV, 2001, J BIOL CHEM, V276, P9868, DOI 10.1074/jbc.M005973200
   Kramer M, 2020, CELL SIGNAL, V65, DOI 10.1016/j.cellsig.2019.109432
   Lee E, 2017, BIOCHEM BIOPH RES CO, V485, P328, DOI 10.1016/j.bbrc.2017.02.082
   Lo YK, 2001, PFLUG ARCH EUR J PHY, V442, P547, DOI 10.1007/s004240100576
   Mannikko R, 2005, J GEN PHYSIOL, V125, P305, DOI 10.1085/jgp.200409130
   Nguyen DT, 2010, HEART RHYTHM, V7, P1438, DOI 10.1016/j.hrthm.2010.04.030
   Pattnaik BR, 2012, AM J PHYSIOL-CELL PH, V302, pC821, DOI 10.1152/ajpcell.00269.2011
   Peng L, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00636
   Qu YS, 2011, J PHARMACOL EXP THER, V337, P2, DOI 10.1124/jpet.110.176883
   Ramos-Mondragon R, 2012, CARDIOVASC RES, V96, P244, DOI 10.1093/cvr/cvs248
   Romanelli MN, 2016, CURR TOP MED CHEM, V16, P1764, DOI 10.2174/1568026616999160315130832
   Romanelli MN, 2005, BIOORGAN MED CHEM, V13, P1211, DOI 10.1016/j.bmc.2004.11.017
   Saito S, 2019, J THORAC DIS, V11, pS1740, DOI 10.21037/jtd.2019.04.62
   Selyanko AA, 1999, J NEUROSCI, V19, P7742
   SIMASKO SM, 1997, AM J PHYSIOL, V272, pE40
   So EC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030657
   Stojilkovic SS, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00126
   Tanguay J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37116-2
   Togami K, 2015, BIOPHARM DRUG DISPOS, V36, P205, DOI 10.1002/bdd.1932
   Van Bogaert PP, 2003, EUR J PHARMACOL, V478, P161, DOI 10.1016/j.ejphar.2003.08.083
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Wu SN, 2017, J CELL PHYSIOL, V232, P3409, DOI 10.1002/jcp.25788
   Wu SN, 2003, J CELL PHYSIOL, V195, P298, DOI 10.1002/jcp.10244
   Zhang Y, 2008, DIABETOLOGIA, V51, P2290, DOI 10.1007/s00125-008-1166-x
NR 47
TC 0
Z9 0
U1 6
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD SEP 5
PY 2020
VL 882
AR 173237
DI 10.1016/j.ejphar.2020.173237
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NB6ZK
UT WOS:000560663000006
PM 32525005
OA Green Published
DA 2021-01-01
ER

PT J
AU d'Ettorre, G
   Recchia, G
   Ridolfi, M
   Siccardi, G
   Pinacchio, C
   Innocenti, GP
   Santinelli, L
   Frasca, F
   Bitossi, C
   Ceccarelli, G
   Borrazzo, C
   Antonelli, G
   Scagnolari, C
   Mastroianni, CM
AF d'Ettorre, Gabriella
   Recchia, Gregorio
   Ridolfi, Marco
   Siccardi, Guido
   Pinacchio, Claudia
   Innocenti, Giuseppe Pietro
   Santinelli, Letizia
   Frasca, Federica
   Bitossi, Camilla
   Ceccarelli, Giancarlo
   Borrazzo, Cristian
   Antonelli, Guido
   Scagnolari, Carolina
   Mastroianni, Claudio Maria
TI Analysis of type I IFN response and T cell activation in severe
   COVID-19/HIV-1 coinfection A case report
SO MEDICINE
LA English
DT Article
DE human immunodeficiency virus-1; interferon; protease inhibitor; severe
   acute respiratory syndrome coronavirus-2; T cell activation
ID HIV
AB Rationale: Complex immune dysregulation in interferon (IFN) and T cell response has been observed in human immunodeficiency virus (HIV-1)-infected patients as well as in coronavirus disease-2019 (COVID-19) patients. However, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)/HIV-1 coinfection has been described in only few cases worldwide and no data are available on immunological outcomes in HIV-1-patients infected with SARS-CoV-2. Hence, this study aims to compare type I IFN response and T cell activation levels between a SARS-CoV-2/HIV-1-coinfected female patient and age-matched HIV-1-positive or uninfected women. Patient concerns: A 52-year-old woman diagnosed with SARS-CoV-2/HIV-1 coinfection, ten HIV-1-positive women and five age-matched-healthy individuals were enrolled in this study. Diagnoses: SARS-CoV-2 infection caused severe pneumonia in the second week of illness in HIV-1-positive patient under protease inhibitors. Chest high-resolution computed tomography images of the SARS-CoV-2/HIV-1-coinfected patient showed bilateral ground-glass opacities. Interventions: SARS-CoV-2/HIV-1-coinfected female patient under darunavir/cobicistat regimen received a 7-days hydroxychloroquine therapy. Analysis of IFN alpha/beta mRNA levels and CD4 and CD8 T cell (CD38, human leukocyte antigen-DR [HLA-DR], CD38 HLA-DR) frequencies were performed by RT/real-time PCR assays and flow cytometry, respectively. Median relative difference (MRD) was calculated for each immunological variable. For values greater than reference, MRD should be a positive number and for values that are smaller, MRD should be negative. Outcomes: The severe pneumonia observed in SARS-CoV-2/HIV-1-positive patient under protease inhibitors was reversed by a 7-days hydroxychloroquine therapy. At the end of treatment, on day 7, patient reported resolution of fever, normalization of respiratory rate (14 breaths/min), and improved oxygen arterial pressure with a F(i)O(2)of 30%. MRD values for IFN alpha/beta and CD4 and CD8 T cells expressing CD38 and/or HLA-DR found in SARS-CoV-2-/HIV-1-coinfected woman were approximatively equal to 0 when refereed respectively to HIV-1-positive female patients [MRDs IFN alpha/beta: median -0.2545 (range: -0.5/0.1); T cells: median -0.11 (range: -0.8/1.3)] and >= 6 when referred to healthy individuals [MRDs IFN alpha/beta: median 28.45 (range: 15/41.9); T cells: median 10 (range 6/22)]. Lessons: These results indicate that SARS-CoV-2 infection in HIV-1-positive female patient was associated with increased levels of IFN alpha/beta-mRNAs and T cell activation compared to healthy individuals.
C1 [d'Ettorre, Gabriella; Recchia, Gregorio; Ridolfi, Marco; Siccardi, Guido; Pinacchio, Claudia; Innocenti, Giuseppe Pietro; Santinelli, Letizia; Ceccarelli, Giancarlo; Borrazzo, Cristian; Mastroianni, Claudio Maria] Sapienza Univ Rome, Dept Publ Hlth & Infect Dis, Viale Policlin 155, Rome, Italy.
   [Frasca, Federica; Bitossi, Camilla; Antonelli, Guido; Scagnolari, Carolina] Sapienza Univ, Ist Pasteur Italia, Dept Mol Med, Lab Virol,Cenci Bolognetti Fdn, Rome, Italy.
   [Antonelli, Guido] Sapienza Univ, Hosp Policlin Umberto I, Microbiol & Virol Unit, Rome, Italy.
RP Mastroianni, CM (corresponding author), Sapienza Univ, Aziende Osped Univ Policlin Umberto I, Dept Publ Hlth & Infect Dis, Viale Policlin 155, I-00161 Rome, Italy.
EM claudio.mastroianni@uniroma1.it
RI Ceccarelli, Giancarlo/ABD-8347-2020; Ceccarelli, Giancarlo/K-6454-2016
OI Ceccarelli, Giancarlo/0000-0001-5921-3180; Ceccarelli,
   Giancarlo/0000-0001-5921-3180
FU Sapienza University of Rome, Progetti di Ricerca (Piccoli) 2019
   [RP11916B6EC60AF3]; PRIN 2017Ministry of Education, Universities and
   Research (MIUR)Research Projects of National Relevance (PRIN)
   [20179JHAMZ_002]; Sapienza University of Rome, Medie Attrezzature
   Scientifiche [MA218164304DC6DC]; Ministero della SaluteMinistry of
   Health, Italy [COVID2020-12371817]; Sapienza University of Rome,
   Progetti di Ricerca Medi [RM1181642D1A5219]
FX This work was partially supported by grants to Carolina Scagnolari
   (Sapienza University of Rome, Progetti di Ricerca (Piccoli) 2019, Prot.
   RP11916B6EC60AF3), to Guido Antonelli (PRIN 2017, 20179JHAMZ_002;
   Sapienza University of Rome, Medie Attrezzature
   Scientifiche-MA218164304DC6DC; Ministero della Salute,
   COVID2020-12371817) and to Gabriella d'Ettorre (Sapienza University of
   Rome, Progetti di Ricerca Medi, RM1181642D1A5219).
CR [Anonymous], 2020, SOCIETA ITALIANA MAL
   Antonelli G, 2020, J CLIN VIROL, V128, DOI 10.1016/j.jcv.2020.104450
   Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2013, J INFECTION, V67, P606, DOI 10.1016/j.jinf.2013.09.029
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410
   Ferdinand KC, 2020, J AM COLL CARDIOL, V75, P2746, DOI 10.1016/j.jacc.2020.04.040
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gervasoni Cristina, 2020, Clin Infect Dis, V71, P2276, DOI 10.1093/cid/ciaa579
   Alvarez DAG, 2016, EXPERT REV RESP MED, V10, P463, DOI 10.1586/17476348.2016.1157474
   Harter G, 2020, INFECTION, V48, P681, DOI 10.1007/s15010-020-01438-z
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Laurencin CT, 2020, J RACIAL ETHN HEALTH, V7, P398, DOI 10.1007/s40615-020-00756-0
   Milam Adam J, 2020, Health Equity, V4, P139, DOI 10.1089/heq.2020.0015
   Paiardini M, 2013, IMMUNOL REV, V254, P78, DOI 10.1111/imr.12079
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Santinelli L, 2020, BIOL SEX DIFFER, V11, DOI 10.1186/s13293-020-00302-x
   Santinelli L, 2019, CYTOKINE, V120, P273, DOI 10.1016/j.cyto.2019.01.012
   Scagnolari C, 2018, CYTOKINE GROWTH F R, V40, P19, DOI 10.1016/j.cytogfr.2018.03.003
   Statzu M, 2019, MED MICROBIOL IMMUN, V208, P679, DOI 10.1007/s00430-018-0574-x
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Wang MM, 2020, INT J INFECT DIS, V96, P148, DOI 10.1016/j.ijid.2020.04.060
   Wen W, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0168-9
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Zhu F, 2020, J MED VIROL, V92, P529, DOI 10.1002/jmv.25732
   Zhuo Z, 2020, CELL HOST MICROBE, V27
NR 29
TC 2
Z9 2
U1 4
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD SEP 4
PY 2020
VL 99
IS 36
DI 10.1097/MD.0000000000021803
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA OC8ZH
UT WOS:000579444200021
PM 32899009
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, MM
   Li, T
   Qiao, F
   Wang, LX
   Li, CL
   Gong, YP
AF Wang, Maomao
   Li, Ting
   Qiao, Fan
   Wang, Laixing
   Li, Chunlin
   Gong, Yanping
TI Coronavirus disease 2019 associated with aggressive neurological and
   mental abnormalities confirmed based on cerebrospinal fluid antibodies A
   case report
SO MEDICINE
LA English
DT Article
DE antibodies; cerebrospinal fluid; coronavirus disease 2019; mental
   abnormalities; neurological injuries
AB Introduction: Coronavirus disease (COVID-19) is spreading worldwide. The reported possible neurological symptoms are varied and range from subtle neurologic deficits to unconsciousness. Knowledge regarding the detection, diagnosis, treatment, and follow-up of COVID-19-associated neurological damage is still limited. We report a case of serious neurological damage and mental abnormalities in a patient who was finally confirmed to have COVID-19 based on IgM and IgG antibodies in the cerebrospinal fluid (CSF). Patient concerns: A 68-year-old man had slight flu-like symptoms and transient loss of consciousness in early February. Exaggerated unconsciousness and deteriorating mental abnormalities occurred over the next month without severe respiratory symptoms. Craniocerebral computed tomography showed normal results, but antibodies against severe acute respiratory syndrome coronavirus 2 were 100 times higher in the CSF than in the serum; tests for viral ribonucleic acid showed negative results with both a nasopharyngeal swab and CSF sample. Diagnosis: COVID-19 pneumonia was diagnosed based on symptoms and positive results for IgM and IgG in the CSF. Interventions: Antiviral, fluid, and nutritional support were administered for 30 days before admission without obvious improvement. A further 18 days of routine antiviral therapy, immunoglobulin therapy (10 g per day for 5 days), and antipsychotic drug treatment were administered. Outcomes: The patient's neurological and mental abnormalities were greatly ameliorated. He was discharged with mild irritability, slight shaking of the hands, and walking fatigue. These symptoms have persisted up to our last follow-up (May 4, 2020). Conclusion: We believe this is the first case involving neural system injury in a patient who confirmed COVID-19 based on CSF antibody test results. Negative ribonucleic acid test results, strong positivity for antibodies, and high protein levels in the CSF suggest the possibility of autoimmune encephalitis secondary to COVID-19. This case highlights additional novel symptoms of COVID-19, and these data are important for the assessment and follow-up of COVID-19 patients.
C1 [Wang, Maomao; Qiao, Fan; Wang, Laixing] Second Mil Med Univ, Chang Hai Hosp, Dept Neurosurg, Shanghai, Peoples R China.
   [Wang, Maomao; Qiao, Fan] Huo Shen Shan Hosp, Wuhan, Peoples R China.
   [Li, Ting; Li, Chunlin; Gong, Yanping] Peoples Liberat Army Gen Hosp, Med Ctr 2, Dept Endocrinol, Beijing, Peoples R China.
RP Gong, YP (corresponding author), Peoples Liberat Army Gen Hosp, Med Ctr 2, Dept Endocrinol, Beijing, Peoples R China.
EM gypmrp@163.com
CR Al Saiegh F, 2020, J NEUROL NEUROSURG P
   Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597
   Kim JE, 2017, J CLIN NEUROL, V13, P227, DOI 10.3988/jcn.2017.13.3.227
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu KM, 2020, J NEUROL NEUROSUR PS, V91, P669, DOI 10.1136/jnnp-2020-323177
   Morfopoulou S, 2016, NEW ENGL J MED, V375, P497, DOI 10.1056/NEJMc1509458
   Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187
   Stainsby Brynne, 2011, J Can Chiropr Assoc, V55, P32
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Zhao H, 2020, LANCET NEUROL, V19, P383, DOI 10.1016/S1474-4422(20)30109-5
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 11
TC 1
Z9 1
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD SEP 4
PY 2020
VL 99
IS 36
DI 10.1097/MD.0000000000021428
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA OC8ZH
UT WOS:000579444200005
PM 32898993
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, M
   Yang, XH
   Yang, F
   Zhu, XX
   Sun, ZB
   Bao, PL
   Yan, YM
AF Wang, Min
   Yang, Xiaohong
   Yang, Fang
   Zhu, Xinxin
   Sun, Zhibing
   Bao, Peiling
   Yan, Yimin
TI Convalescent plasma therapy in critically ill coronavirus disease 2019
   patients with persistently positive nucleic acid test, case series
   report
SO MEDICINE
LA English
DT Article
DE case series; convalescent plasma therapy; coronavirus disease 2019;
   convalescent plasma therapy; nucleic acid test
AB Introduction: Globally, the coronavirus disease 2019 (COVID-19) is still spreading rapidly. At present, there are no specifically approved therapeutic agents or vaccines for its treatment. Previous studies have shown that the convalescent plasma therapy (CPT) is effective in patients with COVID-19. However, its efficacy in patients with persistently positive nucleic acid test is unknown. Patient concerns: In this report, we present the clinical data of 5 critically ill COVID-19 patients admitted, between January 16 and February 26, 2020, in intensive care unit of Xiaogan Central Hospital. Diagnosis and interventions: All these patients had a persistently positive nucleic acid test and received CPT. All 5 patients had severe respiratory failure, and thus, required invasive mechanical ventilation. The median time from the onset of symptoms to initiating the CPT was 37 (Interquartile range, 34-44) days. Outcomes: Only 2 patients were cured and subsequently discharged, while 3 patients succumbed due to multiple organ failure. Conclusion: The time of initiating the CPT may be an important factor affecting its efficacy, and its therapeutic effect in the treatment of COVID-19, in the late stage, is limited.
C1 [Wang, Min; Yang, Fang; Zhu, Xinxin; Yan, Yimin] Wuhan Univ Sci & Technol, Med Coll, Wuhan, Peoples R China.
   [Yang, Xiaohong; Sun, Zhibing; Yan, Yimin] Wuhan Univ Sci & Technol, Cent Hosp Xiaogan, Dept Internal Med, Xiaogan Hosp, Xiaogan, Hubei, Peoples R China.
   [Bao, Peiling] Wuhan Univ Sci & Technol, Cent Hosp Xiaogan, Blood Purificat Ctr, Xiaogan Hosp, Xiaogan, Hubei, Peoples R China.
RP Bao, PL (corresponding author), Wuhan Univ Sci & Technol, Blood Purificat Ctr, Xiaogan Hosp, 6 Plaza St, Xiaogan 432000, Hubei, Peoples R China.; Yan, YM (corresponding author), Wuhan Univ Sci & Technol, Dept Internal Med, Xiaogan Hosp, 6 Plaza St, Xiaogan 432000, Hubei, Peoples R China.
EM bpl112902@163.com; yanyimin180@163.com
FU Hubei Health Commission Joint Fund [WJ2019H170]
FX Fund Program: Hubei Health Commission Joint Fund (WJ2019H170).
CR [Anonymous], 2020, Chin Med J (Engl), DOI 10.1097/CM9.0000000000000819
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Mair-Jenkins J, 2015, J INFECT DIS, V211, P80, DOI 10.1093/infdis/jiu396
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   National Health Commission of the People's Republic of China, THER SCHED NOV COR P
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou M, 2020, FRONT MED-PRC, V14, P126, DOI 10.1007/s11684-020-0767-8
NR 12
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD SEP 4
PY 2020
VL 99
IS 36
DI 10.1097/MD.0000000000021596
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA OC8ZH
UT WOS:000579444200008
PM 32898996
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Xu, WX
   Wang, MJ
   Yu, DM
   Zhang, XX
AF Xu, Wenxin
   Wang, Mingjie
   Yu, Demin
   Zhang, Xinxin
TI Variations in SARS-CoV-2 Spike Protein Cell Epitopes and Glycosylation
   Profiles During Global Transmission Course of COVID-19
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE SARS-CoV-2; spike protein; cell epitope; glycosylation; variation
ID SARS-COV; CORONAVIRUS; GLYCOPROTEIN; TARGETS; VACCINE
AB Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to an outbreak of a pandemic worldwide. For better understanding the viral spike (S) protein variations and its potential effects on the interaction with the host immune system and also in vaccine development, the cell epitopes, glycosylation profile and their changes during the global transmission course were characterized and compared with SARS-CoV for their glycosylation profile. We analyzed totally 7,813 sequences screened from 8,897 whole genome sequences on GISAID database up to April 26, and 18 S protein amino acid variations with relatively high frequency (>= 10(-3)) were identified. A total of 228 sequences of variants had multiple variations, of note, most of them harboring the D614G mutation. Among the predicted 69 linear B cell epitopes, 175 discontinuous B cell epitopes and 41 cytotoxic T lymphocyte epitopes in the viral S protein, we found that the protein structure and its potential function of some sites changed, such as the linear epitope length shortened and discontinuous epitope disappeared of G476S. In addition, we detected 9 predicted N-glycosylation sites and 3 O-glycosylation sites unique to SARS-CoV-2, but no evidently observed variation of the glycan sites so far. Our findings provided an important snapshot of temporal and geographical distributions on SARS-CoV-2 S protein cell epitopes and glycosylation sites, which would be an essential basis for the selection of vaccine candidates.
C1 [Xu, Wenxin; Yu, Demin; Zhang, Xinxin] Shanghai Jiao Tong Univ, Natl Res Ctr Translat Med, Ruijin Hosp, Dept Infect Dis,Res Lab Clin Virol,Sch Med, Shanghai, Peoples R China.
   [Wang, Mingjie] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp North, Dept Digest Dis, Shanghai, Peoples R China.
   [Zhang, Xinxin] Shanghai Jiao Tong Univ, Ruijin Hosp North, Sch Med, Clin Res Ctr, Shanghai, Peoples R China.
RP Yu, DM; Zhang, XX (corresponding author), Shanghai Jiao Tong Univ, Natl Res Ctr Translat Med, Ruijin Hosp, Dept Infect Dis,Res Lab Clin Virol,Sch Med, Shanghai, Peoples R China.; Zhang, XX (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp North, Sch Med, Clin Res Ctr, Shanghai, Peoples R China.
EM ydm11367@rjh.com.cn; zhangx@shsmu.edu.cn
FU Shanghai Scientific & Technology Committee for Epidemiological study on
   SARSCoV-2 [20JC1410200]
FX This work was funded by a grant from Shanghai Scientific & Technology
   Committee for Epidemiological study on SARSCoV-2 (20JC1410200).
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Bagdonaite I, 2018, GLYCOBIOLOGY, V28, P443, DOI 10.1093/glycob/cwy021
   Baum LG, 2017, GLYCOBIOLOGY, V27, P619, DOI 10.1093/glycob/cwx036
   Becerra-Flores M, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13525
   Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Grant Oliver C, 2020, bioRxiv, DOI 10.1101/2020.04.07.030445
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Le Bert N, 2020, NATURE, DOI 10.1038/s41586-020-2550-z
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Parsons LM, 2019, J BIOL CHEM, V294, P7797, DOI 10.1074/jbc.RA119.007532
   Paul Sinu, 2016, Curr Protoc Immunol, V114, DOI 10.1002/cpim.12
   Paul S, 2013, J IMMUNOL, V191, P5831, DOI 10.4049/jimmunol.1302101
   PENG Y, 2020, NAT IMMUNOL 0904, DOI DOI 10.1101/2020.06.05.134551
   Poh CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16638-2
   Shajahan Asif, 2020, Glycobiology, V30, P981, DOI 10.1093/glycob/cwaa042
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Vigerust DJ, 2007, TRENDS MICROBIOL, V15, P211, DOI 10.1016/j.tim.2007.03.003
   Wang MJ, 2020, BMC GENOMICS, V21, DOI 10.1186/s12864-020-6744-4
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Watanabe Y, 2019, BBA-GEN SUBJECTS, V1863, P1480, DOI 10.1016/j.bbagen.2019.05.012
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yang TJ, 2020, P NATL ACAD SCI USA, V117, P1438, DOI 10.1073/pnas.1908898117
   Zhang BZ, 2020, CELL RES, V30, P702, DOI 10.1038/s41422-020-0366-x
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 33
TC 1
Z9 1
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD SEP 4
PY 2020
VL 11
AR 565278
DI 10.3389/fimmu.2020.565278
PG 12
WC Immunology
SC Immunology
GA NU4IB
UT WOS:000573605000001
PM 33013929
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Qian, SZ
   Hong, WD
   Lingjie-mao
   Chenfeng-lin
   Zhendong-fang
   Pan, JY
AF Qian, Song-Zan
   Hong, Wan-dong
   Lingjie-mao
   Chenfeng-lin
   Zhendong-fang
   Pan, Jing-Ye
TI Clinical Characteristics and Outcomes of Severe and Critical Patients
   With 2019 Novel Coronavirus Disease (COVID-19) in Wenzhou: A
   Retrospective Study
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE COVID-19; infection; severity; critically ill; outcome
ID PNEUMONIA; SEPSIS
AB Information about severe cases of 2019 novel coronavirus disease (COVID-19) infection is scarce. The aim of this study was to report the clinical characteristics and outcomes of severe and critical patients with confirmed COVID-19 infection in Wenzhou city. In this single-centered, retrospective cohort study, we consecutively enrolled 37 RT-PCR confirmed positive severe or critical patients from January 28 to February 16, 2020 in a tertiary hospital. Outcomes were followed up until 28-day mortality. Fifteen severe and 22 critical adult patients with the COVID-19 infection were included. Twenty-six (68.4%) were men. Echocardiography data results suggest that normal or increased cardiac output and diastolic dysfunction are the most common manifestations. Compared with severe patients, critical patients were older, more likely to exhibit low platelet counts and high blood urea nitrogen, and were in hospital for longer. Most patients had organ dysfunction during hospitalization, including 11 (29.7%) with ARDS, 8 (21.6%) with acute kidney injury, 17 (45.9%) with acute cardiac injury, and 33 (89.2%) with acute liver dysfunction. Eighteen (48.6%) patients were treated with high-flow ventilation, 9 (13.8%) with non-invasive ventilation, 10 (15.4%) with invasive mechanical ventilation, 7 (18.9%) with prone position ventilation, 6 (16.2%) with extracorporeal membrane oxygenation (ECMO), and 3 (8.1%) with renal replacement therapy. Only 1 (2.7%) patient had died in the 28-day follow up in our study. All patients had bilateral infiltrates on their chest CT scan. Twenty-one (32.3%) patients presented ground glass opacity (GGO) with critical patients more localized in the periphery and the center. The mortality of critical patients with the COVID-19 infection is low in our study. Cardiac function was enhanced in the early stage and less likely to develop into acute cardiac injury, but most patients suffered with acute liver injury. The CT imaging presentations of COVID-19 in critical patients were more likely with consolidation and bilateral lung involvement.
C1 [Qian, Song-Zan; Pan, Jing-Ye] Wenzhou Med Univ, Affiliated Hosp 1, Dept Intens Care Unit, Wenzhou, Peoples R China.
   [Qian, Song-Zan; Pan, Jing-Ye] Wenzhou Key Lab Crit Care & Artificial Intelligen, Wenzhou, Peoples R China.
   [Hong, Wan-dong] Wenzhou Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Wenzhou, Peoples R China.
   [Lingjie-mao; Chenfeng-lin; Zhendong-fang] Wenzhou Med Univ, Sch Clin Med Sci 1, Wenzhou, Peoples R China.
RP Pan, JY (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Intens Care Unit, Wenzhou, Peoples R China.; Pan, JY (corresponding author), Wenzhou Key Lab Crit Care & Artificial Intelligen, Wenzhou, Peoples R China.
EM wmupanjingye@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81671968]; Medical Innovation Discipline of
   Zhejiang Province; Ministry of Science and Technology [WKJ-ZJ-1909]
FX This work was supported by the National Natural Science Foundation of
   China (81671968), the Medical Innovation Discipline of Zhejiang Province
   (Critical Care Medicine, Y2015), and the Major project co-founded by
   Zhejiang Province and Ministry of Science and Technology (WKJ-ZJ-1909).
CR Arabi YM, 2014, ANN INTERN MED, V160, P389, DOI 10.7326/M13-2486
   Chai X, 2020, SPECIFIC ACE2 EXPRES, DOI [10.1101/2020.02.03.931766, DOI 10.1101/2020.02.03.931766]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui H, 2020, CLIN RADIOGRAPHIC FE, DOI [10.1101/2020.02.24.20027052, DOI 10.1101/2020.02.24.20027052]
   Kohlmeier JE, 2009, ANNU REV IMMUNOL, V27, P61, DOI 10.1146/annurev.immunol.021908.132625
   Opal SM, 2005, CLIN INFECT DIS, V41, pS504, DOI 10.1086/432007
   Rello J, 2020, ANAESTH CRIT CARE PA, V39, P167, DOI 10.1016/j.accpm.2020.03.001
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Turner AJ, 2004, TRENDS PHARMACOL SCI, V25, P291, DOI 10.1016/j.tips.2004.04.001
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Xu YH, 2020, J INFECTION, V80, P394, DOI 10.1016/j.jinf.2020.02.017
   Yang WJ, 2020, J INFECTION, V80, P388, DOI 10.1016/j.jinf.2020.02.016
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 18
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD SEP 4
PY 2020
VL 7
AR 552002
DI 10.3389/fmed.2020.552002
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA NU6TH
UT WOS:000573774300001
PM 33015108
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Almahboub, SA
   Algaissi, A
   Alfaleh, MA
   ElAssouli, MZ
   Hashem, AM
AF Almahboub, Sarah A.
   Algaissi, Abdullah
   Alfaleh, Mohamed A.
   ElAssouli, M-Zaki
   Hashem, Anwar M.
TI Evaluation of Neutralizing Antibodies Against Highly Pathogenic
   Coronaviruses: A Detailed Protocol for a Rapid Evaluation of
   Neutralizing Antibodies Using Vesicular Stomatitis Virus
   Pseudovirus-Based Assay
SO FRONTIERS IN MICROBIOLOGY
LA English
DT Article
DE coronaviruses; Middle East respiratory syndrome coronavirus; severe
   acute respiratory syndrome coronavirus 2; serological assay; vesicular
   stomatitis virus pseudovirus
ID MERS-COV
AB Emerging highly pathogenic human coronaviruses (CoVs) represent a serious ongoing threat to the public health worldwide. The spike (S) proteins of CoVs are surface glycoproteins that facilitate viral entry into host cells via attachment to their respective cellular receptors. The S protein is believed to be a major immunogenic component of CoVs and a target for neutralizing antibodies (nAbs) and most candidate vaccines. Development of a safe and convenient assay is thus urgently needed to determine the prevalence of CoVs nAbs in the population, to study immune response in infected individuals, and to aid in vaccines and viral entry inhibitor evaluation. While live virus-based neutralization assays are used as gold standard serological methods to detect and measure nAbs, handling of highly pathogenic live CoVs requires strict bio-containment conditions in biosafety level-3 (BSL-3) laboratories. On the other hand, use of replication-incompetent pseudoviruses bearing CoVs S proteins could represent a safe and useful method to detect nAbs in serum samples under biosafety level-2 (BSL-2) conditions. Here, we describe a detailed protocol of a safe and convenient assay to generate vesicular stomatitis virus (VSV)-based pseudoviruses to evaluate and measure nAbs against highly pathogenic CoVs. The protocol covers methods to produce VSV pseudovirus bearing the S protein of the Middle East respiratory syndrome-CoV (MERS-CoV) and the severe acute respiratory syndrome-CoV-2 (SARS-CoV-2), pseudovirus titration, and pseudovirus neutralization assay. Such assay could be adapted by different laboratories and researchers working on highly pathogenic CoVs without the need to handle live viruses in the BSL-3 environment.
C1 [Almahboub, Sarah A.; Algaissi, Abdullah; Alfaleh, Mohamed A.; ElAssouli, M-Zaki; Hashem, Anwar M.] King Abdulaziz Univ, King Fahd Med Res Ctr, Vaccines & Immunotherapy Unit, Jeddah, Saudi Arabia.
   [Algaissi, Abdullah] Jazan Univ, Coll Appl Med Sci, Dept Med Labs Technol, Jazan, Saudi Arabia.
   [Algaissi, Abdullah] Jazan Univ, Med Res Ctr, Jazan, Saudi Arabia.
   [Alfaleh, Mohamed A.] King Abdulaziz Univ, Fac Pharm, Jeddah, Saudi Arabia.
   [Hashem, Anwar M.] King Abdulaziz Univ, Fac Med, Dept Med Microbiol & Parasitol, Jeddah, Saudi Arabia.
RP Hashem, AM (corresponding author), King Abdulaziz Univ, King Fahd Med Res Ctr, Vaccines & Immunotherapy Unit, Jeddah, Saudi Arabia.; Hashem, AM (corresponding author), King Abdulaziz Univ, Fac Med, Dept Med Microbiol & Parasitol, Jeddah, Saudi Arabia.
EM amhashem@kau.edu.sa
RI Hashem, Anwar M/B-2301-2017
OI Hashem, Anwar M/0000-0002-8471-7011
FU King Abdulaziz City for Science and Technology (KACST) [09-1]
FX This work was supported by King Abdulaziz City for Science and
   Technology (KACST) through research grant program (number 09-1), which
   is a part of the Targeted Research Program.
CR Al-amri SS, 2017, SCI REP-UK, V7, DOI 10.1038/srep44875
   Algaissi Abdullah, 2020, Methods Mol Biol, V2099, P107, DOI 10.1007/978-1-0716-0211-9_9
   Almasaud Abdulrahman, 2020, Methods Mol Biol, V2099, P117, DOI 10.1007/978-1-0716-0211-9_10
   Case James Brett, 2020, bioRxiv, DOI 10.1101/2020.05.18.102038
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Degnah AA, 2020, J INFECT PUBLIC HEAL, V13, P697, DOI 10.1016/j.jiph.2020.01.001
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Fukushi S, 2005, J GEN VIROL, V86, P2269, DOI 10.1099/vir.0.80955-0
   Grehan K, 2015, METHODSX, V2, P379, DOI 10.1016/j.mex.2015.09.003
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Kandeel M, 2020, J MED VIROL, V92, P660, DOI 10.1002/jmv.25754
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lester Sandra, 2019, Access Microbiol, V1, pe000057, DOI 10.1099/acmi.0.000057
   Liu RQ, 2018, ANTIVIR RES, V150, P30, DOI 10.1016/j.antiviral.2017.12.007
   Ma CQ, 2020, MICROBES INFECT, V22, P245, DOI 10.1016/j.micinf.2020.05.004
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Padron-Regalado E, 2020, INFECT DIS THER, V9, P255, DOI 10.1007/s40121-020-00300-x
   Rodriguez LL, 2002, VIRUS RES, V85, P211, DOI 10.1016/S0168-1702(02)00026-6
   Ruedas JB, 2017, METHODS MOL BIOL, V1581, P203, DOI 10.1007/978-1-4939-6869-5_12
   Tani H, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2011.00272
   Tse LV, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00658
   Whitt MA, 2010, J VIROL METHODS, V169, P365, DOI 10.1016/j.jviromet.2010.08.006
   Wu D, 2020, INT J INFECT DIS, V94, P44, DOI 10.1016/j.ijid.2020.03.004
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 25
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-302X
J9 FRONT MICROBIOL
JI Front. Microbiol.
PD SEP 4
PY 2020
VL 11
AR 2020
DI 10.3389/fmicb.2020.02020
PG 12
WC Microbiology
SC Microbiology
GA NS4PJ
UT WOS:000572245100001
PM 33013745
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lamontagne, F
   Agoritsas, T
   Macdonald, H
   Leo, YS
   Diaz, J
   Agarwal, A
   Appiah, JA
   Arabi, Y
   Blumberg, L
   Calfee, CS
   Cao, B
   Cecconi, M
   Cooke, G
   Dunning, J
   Geduld, H
   Gee, P
   Manai, H
   Hui, DS
   Kanda, S
   Kawano-Dourado, L
   Kim, YJ
   Kissoon, N
   Kwizera, A
   Laake, JH
   Machado, FR
   Qadir, N
   Sarin, R
   Shen, YZ
   Zeng, LN
   Brignardello-Petersen, R
   Lytvyn, L
   Siemieniuk, R
   Zeraatkar, D
   Bartoszko, J
   Ge, L
   Maguire, B
   Rochwerg, B
   Guyatt, G
   Vandvik, PO
AF Lamontagne, Francois
   Agoritsas, Thomas
   Macdonald, Helen
   Leo, Yee-Sin
   Diaz, Janet
   Agarwal, Arnav
   Appiah, John Adabie
   Arabi, Yaseen
   Blumberg, Lucille
   Calfee, Carolyn S.
   Cao, Bin
   Cecconi, Maurizio
   Cooke, Graham
   Dunning, Jake
   Geduld, Heike
   Gee, Patrick
   Manai, Hela
   Hui, David S.
   Kanda, Seema
   Kawano-Dourado, Leticia
   Kim, Yae-Jean
   Kissoon, Niranjan
   Kwizera, Arthur
   Laake, Jon Henrik
   Machado, Flavia R.
   Qadir, Nida
   Sarin, Rohit
   Shen, Yinzhong
   Zeng, Linan
   Brignardello-Petersen, Romina
   Lytvyn, Lyubov
   Siemieniuk, Reed
   Zeraatkar, Dena
   Bartoszko, Jessica
   Ge, Long
   Maguire, Brittany
   Rochwerg, Bram
   Guyatt, Gordon
   Vandvik, Per Olav
TI A living WHO guideline on drugs for covid-19
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Article
AB CLINICAL QUESTION
   What is the role of drug interventions in the treatment and prevention of covid-19?
   RECOMMENDATIONS The first version on this living guidance focuses on corticosteroids. It contains a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19, and a weak or conditional recommendation against systemic corticosteroids in patients with non-severe covid-19. Corticosteroids are inexpensive and are on the World Health Organisation list of essential medicines.
   HOW
   this guideline was created This guideline reflects an innovative collaboration between the WHO and the MAGIC Evidence Ecosystem Foundation, driven byan urgent need for global collaboration to provide trustworthy and living covid-19 guidance. A standing international panel of content experts, patients, clinicians, and methodologists, free from relevant conflicts of interest, produce recommendations for clinical practice. The panel follows standards, methods, processes, and platforms for trustworthy guideline development using the GRADE approach. We apply an individual patient perspective while considering contextual factors (that is, resources, feasibility, acceptability, equity) for countries and healthcare systems.
   THE EVIDENCE
   A living systematic review and network meta-analysis, supported by a prospective meta-analysis, with data from eight randomised trials (7184 participants) found that systemic corticosteroids probably reduce 28 day mortality in patients with critical covid-19 (moderate certainty evidence; 87 fewer deaths per 1000 patients (95% confidence interval 124 fewer to 41 fewer)), and also in those with severe disease (moderate certainty evidence; 67 fewer deaths per 1000 patients (100 fewer to 27 fewer)). In contrast, systemic corticosteroids may increase the risk of death in patients without severe covid-19 (low certainty evidence; absolute effect estimate 39 more per 1000 patients, (12 fewer to 107 more)). Systemic corticosteroids probably reduce the need for invasive mechanical ventilation, and harms are likely to be minor (indirect evidence).
   UNDERSTANDING THE RECOMMENDATIONS
   The panel made a strong recommendation for use of corticosteroids in severe and critical covid-19 because there is a lower risk of death among people treated with systemic corticosteroids (moderate certainty evidence), and they believe that all or almost all fully informed patients with severe and critical covid-19 would choose this treatment. In contrast, the panel concluded that patients with non-severe covid-19 would decline this treatment because they would be unlikely to benefit and may be harmed. Moreover, taking both a public health and a patient perspective, the panel warned that indiscriminate use of any therapy for covid-19 would potentially rapidly deplete global resources and deprive patients who may benefit from it most as potentially lifesaving therapy.
   UPDATES
   This is a living guideline. Work is under way to evaluate other interventions. New recommendations will be published as updates to this guideline.
   READERS NOTE
   This is version 1 of the living guideline, published on 4 September (BMJ 2020;370:m3379) version 1. Updates will be labelled as version 2, 3 etc. When citing this article, please cite the version number.
   SUBMITTED
   August 28
   ACCEPTED
   August 31
C1 [Lamontagne, Francois] Univ Sherbrooke, 3001 12e Ave N, Sherbrooke, PQ J1H 5N4, Canada.
   [Lamontagne, Francois] CHU Sherbrooke, Ctr Rech, Sherbrooke, PQ, Canada.
   [Agoritsas, Thomas; Zeng, Linan; Brignardello-Petersen, Romina; Lytvyn, Lyubov; Siemieniuk, Reed; Zeraatkar, Dena; Bartoszko, Jessica; Ge, Long; Rochwerg, Bram; Guyatt, Gordon] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.
   [Agoritsas, Thomas] Univ Hosp Geneva, Div Gen Internal Med, Geneva, Switzerland.
   [Agoritsas, Thomas] Univ Hosp Geneva, Div Clin Epidemiol, Geneva, Switzerland.
   [Agoritsas, Thomas; Zeng, Linan; Brignardello-Petersen, Romina; Lytvyn, Lyubov; Siemieniuk, Reed; Guyatt, Gordon; Vandvik, Per Olav] MAGIC Evidence Ecosyst Fdn, Oslo, Norway.
   [Leo, Yee-Sin] Natl Ctr Infect Dis, Singapore, Singapore.
   [Diaz, Janet] WHO, Geneva, Switzerland.
   [Agarwal, Arnav] Univ Toronto, Dept Med, Toronto, ON, Canada.
   [Appiah, John Adabie] Kwame Nkrumah Univ Sci & Technol, Kumasi, Ghana.
   [Arabi, Yaseen] King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia.
   [Arabi, Yaseen] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia.
   [Blumberg, Lucille] Natl Inst Communicable Dis, Johannesburg, South Africa.
   [Calfee, Carolyn S.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Cao, Bin] China Japan Friendship Hosp, Beijing, Peoples R China.
   [Cecconi, Maurizio] IRCCS, Dept Anesthesia & Intens Care Med, Humanitas Clin & Res Ctr, Via Manzoni 56, I-20089 Rozzano, MI, Italy.
   [Cecconi, Maurizio] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini 4, I-20090 Pieve Emanuele Milan, Italy.
   [Cooke, Graham] Imperial Coll London, London, England.
   [Dunning, Jake] Publ Hlth England, London, England.
   [Geduld, Heike] Stellenbosch Univ, Div Emergency Med, Fac Med & Hlth Sci, Cape Town, South Africa.
   [Manai, Hela] Emergency Med Serv, Fac Med, Tunis, Tunisia.
   [Hui, David S.] Chinese Univ Hong Kong, Stanley Ho Ctr Emerging Infect Dis, Hong Kong, Peoples R China.
   [Kanda, Seema] McMaster Univ Alumnus, Hamilton, ON, Canada.
   [Kawano-Dourado, Leticia] Univ Sao Paulo, Heart Inst InCor, Med Sch, Pulm Div,HCFMUSP, Sao Paulo, Brazil.
   [Kawano-Dourado, Leticia] Hosp Coracao HCor, Res Inst, Sao Paulo, Brazil.
   [Kim, Yae-Jean] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea.
   [Kissoon, Niranjan] Univ British Columbia, Dept Paediat & Emergency Med, Vancouver, BC, Canada.
   [Kwizera, Arthur] Makerere Univ, Dept Anaesthesia & Crit Care, Coll Hlth Sci, Kampala, Uganda.
   [Laake, Jon Henrik] Rikshospitalet Med Ctr, Crit Care & Emergencies, Oslo, Norway.
   [Machado, Flavia R.] Univ Fed Sao Paulo, Anesthesiol Pain & Intens Care, Sao Paulo, Brazil.
   [Qadir, Nida] Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA.
   [Sarin, Rohit] Natl Inst TB & Resp Dis, New Delhi, India.
   [Shen, Yinzhong] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai, Peoples R China.
   [Zeng, Linan] Sichuan Univ, West China Univ Hosp 2, Pharm Dept, Evidence Based Pharm Ctr, Chengdu, Peoples R China.
   [Ge, Long] Lanzhou Univ, Sch Publ Hlth, Evidence Based Social Sci Res Ctr, Lanzhou, Peoples R China.
   [Ge, Long] Lanzhou Univ, Sch Publ Hlth, Dept Social Med & Hlth Management, Lanzhou, Peoples R China.
   [Maguire, Brittany] Univ Oxford, Nuffield Dept Med, Ctr Trop Med & Global Hlth, Infect Dis Data Observ IDDO, Oxford, England.
   [Rochwerg, Bram] McMaster Univ, Dept Med, Hamilton, ON, Canada.
   [Guyatt, Gordon] Univ Miami, Miller Sch Med, Div Pulm Crit Care & Sleep Med, Miami, FL 33136 USA.
   [Vandvik, Per Olav] Univ Oslo, Inst Hlth & Soc, Dept Hlth Econ & Hlth Management, Oslo, Norway.
RP Lamontagne, F (corresponding author), Univ Sherbrooke, 3001 12e Ave N, Sherbrooke, PQ J1H 5N4, Canada.
EM Francois.Lamontagne@usherbrooke.ca
RI Arabi, Yaseen/ABF-3316-2020; Agoritsas, Thomas/F-4321-2014
OI Arabi, Yaseen/0000-0001-5735-6241; Reis, AlessanRSS/0000-0001-8486-7469;
   Kissoon, Niranjan/0000-0001-8847-9973; Agoritsas,
   Thomas/0000-0002-6182-9969
FU World Health OrganizationWorld Health Organization [001] Funding Source:
   Medline
CR Angus DC, 2020, JAMA-J AM MED ASSOC, V324, P1317, DOI 10.1001/jama.2020.17022
   Corral L, 2020, GLUCOCOVID CONTROLLE
   Dequin PF, 2020, JAMA-J AM MED ASSOC, V324, P1298, DOI 10.1001/jama.2020.16761
   Maguire Brittany J, 2020, Wellcome Open Res, V5, P60, DOI 10.12688/wellcomeopenres.15821.1
   Qaseem A, 2012, ANN INTERN MED, V156, P525, DOI 10.7326/0003-4819-156-7-201204030-00009
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Rochwerg B, 2018, CRIT CARE MED, V46, P1411, DOI 10.1097/CCM.0000000000003262
   Schandelmaier S, DEV NEW INSTRUMENT A
   Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980
   Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023
   Tomazini BM, 2020, JAMA-J AM MED ASSOC, V324, P1307, DOI 10.1001/jama.2020.17021
   World Health Organization, 2011, HOSP CAR AD AD GUID
   World Health Organization, 2008, HDB GUID DEV
   World Health Organization, 2020, Q A DEX COVID 19
   World Health Organization, 2020, WHO COR DIS COVID 19
   World Health Organization, 2020, CLIN MAN COVID 19 IN
   Ye ZK, 2020, CAN MED ASSOC J, V192, pE756, DOI 10.1503/cmaj.200645
NR 17
TC 12
Z9 12
U1 5
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD SEP 4
PY 2020
VL 370
AR m3379
DI 10.1136/bmj.m3379
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA NR3FF
UT WOS:000571447500002
PM 32887691
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Parray, HA
   Chiranjivi, AK
   Asthana, S
   Yadav, N
   Shrivastava, T
   Mani, S
   Sharma, C
   Vishwakarma, P
   Das, S
   Pindari, K
   Sinha, S
   Samal, S
   Ahmed, S
   Kumar, R
AF Parray, Hilal Ahmad
   Chiranjivi, Adarsh Kumar
   Asthana, Shailendra
   Yadav, Naveen
   Shrivastava, Tripti
   Mani, Shailendra
   Sharma, Chandresh
   Vishwakarma, Preeti
   Das, Supratik
   Pindari, Kamal
   Sinha, Subrata
   Samal, Sweety
   Ahmed, Shubbir
   Kumar, Rajesh
TI Identification of an anti-SARS-CoV-2 receptor-binding domain-directed
   human monoclonal antibody from a naive semisynthetic library
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE RBD; scFv; ACE2; mAb; IgG1; monoclonal antibody; virus; phage display;
   infectious disease; antigen
ID NEUTRALIZING ANTIBODIES
AB There is a desperate need for safe and effective vaccines, therapies, and diagnostics for SARS- coronavirus 2 (CoV-2), the development of which will be aided by the discovery of potent and selective antibodies against relevant viral epitopes. Human phage display technology has revolutionized the process of identifying and optimizing antibodies, providing facile entry points for further applications. Herein, we use this technology to search for antibodies targeting the receptor-binding domain (RBD) of CoV-2. Specifically, we screened a naive human semisynthetic phage library against RBD, leading to the identification of a high-affinity single-chain fragment variable region (scFv). The scFv was further engineered into two other antibody formats (scFv-Fc and IgG1). All three antibody formats showed high binding specificity to CoV-2 RBD and the spike antigens in different assay systems. Flow cytometry analysis demonstrated specific binding of the IgG1 format to cells expressing membrane-bound CoV-2 spike protein. Docking studies revealed that the scFv recognizes an epitope that partially overlaps with angiotensin-converting enzyme 2 (ACE2)-interacting sites on the CoV-2 RBD. Given its high specificity and affinity, we anticipate that these anti-CoV-2 antibodies will be useful as valuable reagents for accessing the antigenicity of vaccine candidates, as well as developing antibody-based therapeutics and diagnostics for CoV-2.
C1 [Parray, Hilal Ahmad; Chiranjivi, Adarsh Kumar; Asthana, Shailendra; Yadav, Naveen; Shrivastava, Tripti; Mani, Shailendra; Sharma, Chandresh; Vishwakarma, Preeti; Das, Supratik; Pindari, Kamal; Samal, Sweety; Ahmed, Shubbir; Kumar, Rajesh] NCR Biotech Sci Cluster, Translat Hlth Sci & Technol Inst, Faridabad, Haryana, India.
   [Sinha, Subrata] All India Inst Med Sci, Dept Biochem, New Delhi, India.
RP Ahmed, S; Kumar, R (corresponding author), NCR Biotech Sci Cluster, Translat Hlth Sci & Technol Inst, Faridabad, Haryana, India.
EM sahmed@thsti.res.in; rajesh@thsti.res.in
OI Das, Supratik/0000-0002-7279-938X; Mani, Shailendra/0000-0001-8541-8315
FU Department of Biotechnology; Translational Health Science & Technology
   Institute core grant
FX This work was supported by the Department of Biotechnology and by a
   Translational Health Science & Technology Institute core grant.
CR Abou El-Magd RM, 2016, J IMMUNOL METHODS, V428, P9, DOI 10.1016/j.jim.2015.11.006
   Bagheri S, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695924
   Benjathummarak S, 2018, BIOLOGICALS, V56, P54, DOI 10.1016/j.biologicals.2018.10.003
   Bertoglio F, 2020, SARS COV 2 NEUTRALIZ, DOI [10.1101/2020.06.05.135921, DOI 10.1101/2020.06.05.135921]
   Brown BL, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102790
   Burnouf T, 2014, TRANSFUS APHER SCI, V51, P120, DOI 10.1016/j.transci.2014.10.003
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Excler JL, 2014, CLIN VACCINE IMMUNOL, V21, P1023, DOI 10.1128/CVI.00230-14
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Haynes BF, 2006, VIROLOGY, V345, P44, DOI 10.1016/j.virol.2005.08.042
   Hey A, 2015, MICROBIOL SPECTR, V3, DOI 10.1128/microbiolspec.AID-0026-2014
   Kanwal A, 2016, DRUG DES DEV THER, V10, P2929, DOI 10.2147/DDDT.S105482
   Kumar R, 2020, APPL MICROBIOL BIOT, V104, P3209, DOI 10.1007/s00253-020-10437-x
   Kumar R, 2019, INT J BIOL MACROMOL, V135, P907, DOI 10.1016/j.ijbiomac.2019.06.006
   Kumar R, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-87
   Marano G, 2016, BLOOD TRANSFUS-ITALY, V14, P152, DOI 10.2450/2015.0131-15
   Mattapally Saidulu, 2018, Oncotarget, V9, P13713, DOI 10.18632/oncotarget.24459
   Ngono AE, 2018, ANNU REV IMMUNOL, V36, P279, DOI 10.1146/annurev-immunol-042617-053142
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413
   PRINCE GA, 1987, J VIROL, V61, P1851, DOI 10.1128/JVI.61.6.1851-1854.1987
   Qian ZH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076469
   Sankhyan A, 2016, SCI REP-UK, V6, DOI 10.1038/srep21240
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Spriestersbach A, 2015, METHOD ENZYMOL, V559, P1, DOI 10.1016/bs.mie.2014.11.003
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
NR 29
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 4
PY 2020
VL 295
IS 36
BP 12814
EP 12821
DI 10.1074/jbc.AC120.014918
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA NQ9DL
UT WOS:000571166700020
PM 32727845
OA Bronze
DA 2021-01-01
ER

PT J
AU Nundoochan, A
AF Nundoochan, Ajoy
TI Improving public hospital efficiency and fiscal space implications: the
   case of Mauritius
SO INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH
LA English
DT Article
DE Technical efficiency; Stochastic frontier analysis; Fiscal space
ID STOCHASTIC FRONTIER ANALYSIS; TECHNICAL EFFICIENCY; HEALTH-CARE
AB Background General Government Health Expenditure (GGHE) in Mauritius accounted for only 10% of General Government Expenditure for the fiscal year 2018. This is less than the pledge taken under the Abuja 2001 Declaration to allocate at least 15% of national budget to the health sector. The latest National Health Accounts also urged for an expansion in the fiscal space for health. As public hospitals in Mauritius absorb 70% of GGHE, maximising returns of hospitals is essential to achieve Universal Health Coverage. More so, as Mauritius is bracing for its worst recession in 40 years in the aftermath of the COVID-19 pandemic public health financing will be heavily impacted. A thorough assessment of hospital efficiency and its implications on effective public health financing and fiscal space creation is, therefore, vital to inform ongoing health reform agenda. Objectives This paper aims to examine the trend in hospital technical efficiency over the period 2001-2017, to measure the elasticity of hospital output to changes in inputs variables and to assess the impact of improved hospital technical efficiency in terms of fiscal space creation. Methods Annual health statistics released by the Ministry of Health and Wellness and national budget of the Ministry of Finance, Economic Planning and Development were the principal sources of data. Applying Stochastic Frontier Analysis, technical efficiency of public regional hospitals was estimated under Cobb-Douglas, Translog and Multi-output distance functions, using STATA 11. Hospital beds, doctors, nurses and non-medical staff were used as input variables. Output variable combined inpatients and outpatients seen at Accident Emergency, Sorted and Unsorted departments. Efficiency scores were used to determine potential efficiency savings and fiscal space creation. Findings Mean technical efficiency scores, using the Cobb Douglas, Translog and Multi-output functions, were estimated at 0.83, 0.84 and 0.89, respectively. Nurses and beds are the most important factors in hospital production, as a 1% increase in the number of beds and nurses, result in an increase in hospital outputs by 0.73 and 0.51%, respectively. If hospitals are to increase their inputs by 1%, their outputs will increase by 1.16%. Hospital output process has an increasing return to scale. With technical efficiencies improving to scores of 0.95 and 1.0 in 2021-2022, potential savings and fiscal space creation at hospital level, would amount to MUR 633 million (US$ 16.2 million) and MUR 1161 million (US$ 29.6 million), respectively. Conclusion Fiscal space creation through full technical efficiency, is estimated to represent 8.9 and 9.2% of GGHE in fiscal year 2021-2022 and 2022-2023, respectively. This will allow without any restrictions the funding of the national response for HIV, vaccine preventable diseases as well as building a resilient health system to mitigate impact of emerging infectious diseases as experienced with COVID-19.
C1 [Nundoochan, Ajoy] WHO, Country Off, Port Louis, Mauritius.
RP Nundoochan, A (corresponding author), WHO, Country Off, Port Louis, Mauritius.
EM nundoochana@who.int
OI NUNDOOCHAN, Ajoy/0000-0001-6495-8056
FU World Health OrganizationWorld Health Organization [001] Funding Source:
   Medline
CR Abou El-Seoud M, 2013, INT J EC MANAGE SCI, V2, P44
   Aigner D., 1977, J ECONOMETRICS, V6, P21, DOI DOI 10.1016/0304-4076(77)90052-5
   Atilgan E, 2016, J EC BUSINESS FINANC, V5, P17, DOI DOI 10.17261/PRESSACADEMIA.2016116550
   Battese G. E., 1995, EMPIR ECON, V20, P325, DOI DOI 10.1007/BF01205442
   Battese G. E., 1992, J PROD ANAL, V3, P153, DOI DOI 10.1007/BF00158774
   BATTESE GE, 1988, J ECONOMETRICS, V38, P387, DOI 10.1016/0304-4076(88)90053-X
   Blatnik P, 2017, OPEN MED-WARSAW, V12, P214, DOI 10.1515/med-2017-0031
   Chisholm D, 2010, IMPROVING HLTH SYSTE
   Coelli TJ, 2005, INTRO INEFFICIENCY P
   Debreu G, 1951, ECONOMETRICA, V19, P273, DOI 10.2307/1906814
   Durairaj V, 2010, FISCAL SPACE HLTH RE
   Evans DB, 2001, BRIT MED J, V323, P307, DOI 10.1136/bmj.323.7308.307
   FARRELL MJ, 1957, J R STAT SOC SER A-G, V120, P253, DOI 10.2307/2343100
   Giancotti M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174533
   Goudarzi R, 2014, INT J HEALTH POLICY, V3, P91, DOI 10.15171/ijhpm.2014.66
   Greene W, 2005, J ECONOMETRICS, V126, P269, DOI 10.1016/j.jeconom.2004.05.003
   Greene William, 2008, MEASUREMENT PRODUCTI, P92, DOI DOI 10.1093/ACPROF:OSO/9780195183528.003.0002
   Nguyen H, 2013, INT J HEALTH PLAN M, V28, P3, DOI 10.1002/hpm.2114
   Hamidi S, 2016, COST EFFECT RESOUR A, V14, DOI 10.1186/s12962-016-0052-5
   Heller PS, 2006, HEALTH POLICY PLANN, V21, P75, DOI 10.1093/heapol/czj013
   Hernandez de Cos P, 2011, BANK SPAIN OCCASIONA
   Herr A, 2008, HEALTH ECON, V17, P1057, DOI 10.1002/hec.1388
   International Monetary Fund, IMF COUNTR INF
   Jowett M, 2016, 1 WHO
   Khalid F, 2020, HEALTH SYST REFORM, V6, DOI 10.1080/23288604.2019.1617026
   Koopmans T.C, 1951, ACTIVITY ANALYSIS PR, P359
   Kumbhakar S, J INT ASS AGR EC, V38, P99
   Lin LC, 2005, PROC E ASIA SOC TRAN, V5, P592
   Ludwig M, 2008, THESIS
   Ministry of Finance and Economic Development Republic of Mauritius., NAT BUDG
   Ministry of Health & Quality of Life Republic of Mauritius., SURV REP 2015 HOUS O
   Ministry of Health & Quality of Life Republic of Mauritius., 2017, NAT HLTH ACC
   Ministry of Health & Quality of Life Republic of Mauritius., HLTH STAT REP 2018
   Ministry of Health & Quality of Life Republic of Mauritius, 2019, REP MAUR COMPR MULT
   Ministry of Health & Quality of Life Republic of Mauritius European Union and WHO, NAT ASS HLTH SYST CH
   Novignon J, 2015, AFR J HLTH EC, V4, P1
   Novignon J, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2347-4
   Nundoochan A, 2019, INT J EQUITY HEALTH, V18, DOI 10.1186/s12939-019-0959-5
   Orendi J, 2008, LANCET, V371, P1401, DOI 10.1016/S0140-6736(08)60610-8
   Preston S H, 1985, Popul Bull UN, P34
   Ravaghi H, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4701-1
   Roh CY, 2010, PUBLIC PERFORM MANAG, P1, DOI 10.2753/PMR1530-9576340102?needAccess=true
   Rosko MD, 2008, MED CARE RES REV, V65, P131, DOI 10.1177/1077558707307580
   Shahhoseini R, 2011, HEALTH SERV MANAG RE, V24, P75, DOI 10.1258/hsmr.2010.010017
   Valdois J, 2018, REV EXCISE TAXES CIG
   WHO, WORLD HLTH REP 2000
   WHO, GLOB HLTH EXP DAT GH
   WHO (World Health Organization), 2008, INT HLTH REG
   World Health Organization, WORLD HLTH REP 2010
   World Health Organization, TRACK UN HLTH COV 20
   World Health Organization (WHO), 2006, WORLD HLTH REP 2006
   Worthington AC, 2004, MED CARE RES REV, V61, P135, DOI 10.1177/1077558704263796
   Yong K, 1999, EFFICIENCY HOSP VICT
NR 53
TC 1
Z9 1
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-9276
J9 INT J EQUITY HEALTH
JI Int. J. Equity Health
PD SEP 4
PY 2020
VL 19
IS 1
AR 152
DI 10.1186/s12939-020-01262-9
PG 16
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NO9BO
UT WOS:000569781500002
PM 32887629
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fu, LF
   Ye, F
   Feng, Y
   Yu, F
   Wang, QS
   Wu, Y
   Zhao, C
   Sun, H
   Huang, BY
   Niu, PH
   Song, H
   Shi, Y
   Li, XB
   Tan, WJ
   Qi, JX
   Gao, GF
AF Fu, Lifeng
   Ye, Fei
   Feng, Yong
   Yu, Feng
   Wang, Qisheng
   Wu, Yan
   Zhao, Cheng
   Sun, Huan
   Huang, Baoying
   Niu, Peihua
   Song, Hao
   Shi, Yi
   Li, Xuebing
   Tan, Wenjie
   Qi, Jianxun
   Gao, George Fu
TI Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting
   its main protease
SO NATURE COMMUNICATIONS
LA English
DT Article
ID CORONAVIRUS; SCH-503034; DISCOVERY; OUTBREAK
AB COVID-19 was declared a pandemic on March 11 by WHO, due to its great threat to global public health. The coronavirus main protease (M-pro, also called 3CLpro) is essential for processing and maturation of the viral polyprotein, therefore recognized as an attractive drug target. Here we show that a clinically approved anti-HCV drug, Boceprevir, and a pre-clinical inhibitor against feline infectious peritonitis (corona) virus (FIPV), GC376, both efficaciously inhibit SARS-CoV-2 in Vero cells by targeting M-pro. Moreover, combined application of GC376 with Remdesivir, a nucleotide analogue that inhibits viral RNA dependent RNA polymerase (RdRp), results in sterilizing additive effect. Further structural analysis reveals binding of both inhibitors to the catalytically active side of SARS-CoV-2 protease M-pro as main mechanism of inhibition. Our findings may provide critical information for the optimization and design of more potent inhibitors against the emerging SARS-CoV-2 virus. Coronavirus main protease is essential for viral polyprotein processing and maturation. Here Fu et al. report efficient inhibition of SARS-CoV-2 replication using two inhibitors - Boceprevir and GC376 - targeting the active site of the main viral protease.
C1 [Fu, Lifeng; Feng, Yong; Zhao, Cheng; Sun, Huan; Shi, Yi; Li, Xuebing; Qi, Jianxun; Gao, George Fu] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China.
   [Fu, Lifeng; Shi, Yi] Chinese Acad Sci, Ctr Influenza Res & Early Warning CASCIRE, CAS TWAS Ctr Excellence Emerging Infect Dis CEEID, Beijing 100101, Peoples R China.
   [Ye, Fei; Huang, Baoying; Niu, Peihua; Tan, Wenjie] China CDC, Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, NHC Key Lab Biosafety, Beijing 102206, Peoples R China.
   [Feng, Yong; Li, Xuebing] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Yu, Feng; Wang, Qisheng] Chinese Acad Sci, Shanghai Adv Res Inst, Shanghai Synchrotron Radiat Facil, Shanghai 201204, Peoples R China.
   [Wu, Yan; Song, Hao] Chinese Acad Sci, Beijing Inst Life Sci, Res Network Immun & Hlth RNIH, Beijing 100101, Peoples R China.
   [Wu, Yan] Capital Med Univ, Sch Basic Med Sci, Dept Pathogen Microbiol, Beijing 100069, Peoples R China.
   [Shi, Yi; Qi, Jianxun] Univ Chinese Acad Sci, Savaid Med Sch, Beijing 100049, Peoples R China.
RP Li, XB; Qi, JX; Gao, GF (corresponding author), Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China.; Tan, WJ (corresponding author), China CDC, Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, NHC Key Lab Biosafety, Beijing 102206, Peoples R China.; Li, XB (corresponding author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.; Qi, JX (corresponding author), Univ Chinese Acad Sci, Savaid Med Sch, Beijing 100049, Peoples R China.
EM lixb@im.ac.cn; tanwj@ivdc.chinacdc.cn; jxqi@im.ac.cn; gaof@im.ac.cn
OI Fu, Lifeng/0000-0003-0431-5424
FU Strategic Priority Research Program of CAS [XDB29010202]; National Key
   Research and Development Program of China [2016YFD0500300,
   2016YFE0205800]; National Science and Technology Major Project
   [2018ZX10733403]; National Natural Science Foundation of China
   (NSFC)National Natural Science Foundation of China (NSFC) [81673358,
   21807109]
FX We thank the staff of BL17U beamlines at Shanghai Synchrotron Radiation
   Facility. We also thank Mr. Yi Han at the Institute of Biophysics
   Core-Facility for the support during in-house data collection. We also
   thank Hanxing Zhang and Guoxia Liu from the Institute of Microbiology,
   Chinese Academy of Sciences for help in enzyme activity analysis. This
   work was supported by the Strategic Priority Research Program of CAS
   (XDB29010202), the National Key Research and Development Program of
   China (2016YFD0500300, 2016YFE0205800), the National Science and
   Technology Major Project (2018ZX10733403), and National Natural Science
   Foundation of China (NSFC) (81673358 and 21807109).
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Agbowuro AA, 2018, MED RES REV, V38, P1295, DOI 10.1002/med.21475
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cummings MD, 2010, ANGEW CHEM INT EDIT, V49, P1652, DOI 10.1002/anie.200906696
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Jiang SB, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30419-0
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kim Y, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005531
   Kim Y, 2012, J VIROL, V86, P11754, DOI 10.1128/JVI.01348-12
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lin C., 2006, Infectious Disorders - Drug Targets, V6, P3, DOI 10.2174/187152606776056706
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Malcolm BA, 2006, ANTIMICROB AGENTS CH, V50, P1013, DOI 10.1128/AAC.50.3.1013-1020.2006
   Ni L, 2020, FRONT MED-PRC, V14, P210, DOI 10.1007/s11684-020-0757-x
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Pedersen NC, 2018, J FELINE MED SURG, V20, P378, DOI 10.1177/1098612X17729626
   Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272
   Prongay AJ, 2007, J MED CHEM, V50, P2310, DOI 10.1021/jm060173k
   Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471
   Romano KP, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002832
   Soumana DI, 2014, ACS CHEM BIOL, V9, P2485, DOI 10.1021/cb5006118
   Tan W, 2020, CHINA CDC WEEKLY, V2, P61, DOI DOI 10.46234/ccdcw2020.017
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   WHO, 2020, WHO COR DIS COVID 20
   Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xue XY, 2007, J MOL BIOL, V366, P965, DOI 10.1016/j.jmb.2006.11.073
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang HT, 2005, PLOS BIOL, V3, P1742, DOI 10.1371/journal.pbio.0030324
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 43
TC 2
Z9 2
U1 9
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD SEP 4
PY 2020
VL 11
IS 1
AR 4417
DI 10.1038/s41467-020-18233-x
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NP0CO
UT WOS:000569852000006
PM 32887884
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Perkins, TA
   Espana, G
AF Perkins, T. Alex
   Espana, Guido
TI Optimal Control of the COVID-19 Pandemic with Non-pharmaceutical
   Interventions
SO BULLETIN OF MATHEMATICAL BIOLOGY
LA English
DT Article
DE Coronavirus; Epidemic; Infectious disease dynamics; Ordinary
   differential equations; Pontryagin's Maximum Principle
ID MODEL; STRATEGIES; INFLUENZA
AB The COVID-19 pandemic has forced societies across the world to resort to social distancing to slow the spread of the SARS-CoV-2 virus. Due to the economic impacts of social distancing, there is growing desire to relax these measures. To characterize a range of possible strategies for control and to understand their consequences, we performed an optimal control analysis of a mathematical model of SARS-CoV-2 transmission. Given that the pandemic is already underway and controls have already been initiated, we calibrated our model to data from the USA and focused our analysis on optimal controls from May 2020 through December 2021. We found that a major factor that differentiates strategies that prioritize lives saved versus reduced time under control is how quickly control is relaxed once social distancing restrictions expire in May 2020. Strategies that maintain control at a high level until at least summer 2020 allow for tapering of control thereafter and minimal deaths, whereas strategies that relax control in the short term lead to fewer options for control later and a higher likelihood of exceeding hospital capacity. Our results also highlight that the potential scope for controlling COVID-19 until a vaccine is available depends on epidemiological parameters about which there is still considerable uncertainty, including the basic reproduction number and the effectiveness of social distancing. In light of those uncertainties, our results do not constitute a quantitative forecast and instead provide a qualitative portrayal of possible outcomes from alternative approaches to control.
C1 [Perkins, T. Alex; Espana, Guido] 100 Galvin Life Sci Ctr, Dept Biol Sci, Notre Dame, IN 46556 USA.
   [Perkins, T. Alex; Espana, Guido] 100 Galvin Life Sci Ctr, Eck Inst Global Hlth, Notre Dame, IN 46556 USA.
RP Perkins, TA (corresponding author), 100 Galvin Life Sci Ctr, Dept Biol Sci, Notre Dame, IN 46556 USA.; Perkins, TA (corresponding author), 100 Galvin Life Sci Ctr, Eck Inst Global Hlth, Notre Dame, IN 46556 USA.
EM taperkins@nd.edu; guido.espana@nd.edu
OI Perkins, Alex/0000-0002-7518-4014
FU RAPID Grant from the National Science Foundation [DEB 2027718]
FX The authors were supported by a RAPID Grant from the National Science
   Foundation (DEB 2027718).
CR Agusto FB, 2018, MATH BIOSCI, V305, P102, DOI 10.1016/j.mbs.2018.09.007
   Aledort JE, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-208
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   [Anonymous], 2020, LANCET, V395, P1229, DOI 10.1016/S0140-6736(20)30863-1
   [Anonymous], 2010, 2009 H1N1 PAND TIM
   [Anonymous], 2020, NY TIMES
   [Anonymous], 2010, 2009 H1N1 FLU VACC
   Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   Berry I, 2020, CAN MED ASSOC J, V192, pE420, DOI 10.1503/cmaj.75262
   Blayneh KW, 2010, B MATH BIOL, V72, P1006, DOI 10.1007/s11538-009-9480-0
   Britton T, 2020, SCIENCE, V369, P846, DOI 10.1126/science.abc6810
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P465, DOI 10.15585/mmwr.mm6915e4
   CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6912e2
   Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757
   Choi S, 2014, B MATH BIOL, V76, P1566, DOI 10.1007/s11538-014-9962-6
   Cowling BJ, 2020, LANCET PUBLIC HEALTH, V5, pE279, DOI 10.1016/S2468-2667(20)30090-6
   Davies N, 2020, EFFECT NONPHARMACEUT
   Djidjou-Demasse R., 2020, OPTIMAL COVID 19 EPI, DOI [10.1101/2020.04.02.20049189, DOI 10.1101/2020.04.02.20049189, 10.1101/2020.04.02.20049189.]
   Ferguson N, 2020, REPORT 9 IMPACT NONP
   Flaxman S., 2020, REPORT 13 ESTIMATING
   Gilbert M, 2020, LANCET, V395, P871, DOI 10.1016/S0140-6736(20)30411-6
   Gondim J, 2020, CHAOS SOLITON FRACT
   Head Jennifer R, 2020, medRxiv, DOI 10.1101/2020.08.06.20169797
   Hilton J, 2020, ESTIMATION COUNTRY L, DOI [DOI 10.1101/2020.02.26.20028167, 10.1101/2020.02.26.20028167]
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Jarvis C.I., 2020, QUANTIFYING IMPACT P, DOI [10.1101/2020.03.31.20049023, DOI 10.1101/2020.03.31.20049023]
   Keeling M., 2007, MODELING INFECT DIS
   Kissler SM, 2020, SCIENCE, DOI DOI 10.1101/2020.03.04.20031112
   Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218
   Lai Shengjie, 2020, medRxiv, DOI 10.1101/2020.03.03.20029843
   Lenhart S., 2007, OPTIMAL CONTROL APPL
   Lin F, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-32
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Mallela A, 2020, OPTIMAL CONTROL APPL, DOI [10.1101/2020.04.10.20061069, DOI 10.1101/2020.04.10.20061069]
   Martin J, 2019, CATHOL U LAW REV, V68, P1
   Mizumoto K, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.10.2000180
   Morris D. H., 2020, ARXIV200402209
   Murray C, 2020, FORECASTING COVID 19, V03, DOI [10.1101/2020.03.27.20043752, DOI 10.1101/2020.03.27.20043752]
   nCoV 2019 Data Working Group, 2020, NCOV 2019 DATA WORKI
   Neilan RLM, 2010, B MATH BIOL, V72, P2004, DOI 10.1007/s11538-010-9521-8
   Ngonghala CN, 2020, MATH ASSESSMENT IMPA, DOI [10.1101/2020.04.15.20066480, DOI 10.1101/2020.04.15.20066480]
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Park SW, 2020, RECONCILING EARLY OU, DOI [10.1101/2020.01.30.20019877, DOI 10.1101/2020.01.30.20019877]
   Patterson-Lomba O, 2020, OPTIMAL TIMING SOCIA, DOI [10.1101/2020.03.30.20048132, DOI 10.1101/2020.03.30.20048132]
   Perkins T, 2019, EPIDEMICS, P100357
   Perkins T. A., 2020, ESTIMATING UNOBSERVE, DOI [10.1101/2020.03.15.20036582, DOI 10.1101/2020.03.15.20036582]
   Piguillem F., 2020, EIEF WORKING PAPERS, V2004
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Richard Q, 2020, AGE STRUCTURED NONPH
   Shah N, 2020, CONTROL STRATEGIES C, DOI [10.1101/2020.04.04.20053173, DOI 10.1101/2020.04.04.20053173]
   Shim E, 2013, MATH BIOSCI ENG, V10, P1615, DOI 10.3934/mbe.2013.10.1615
   Soetaert K, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i09
   Tchuenche JM, 2011, ACTA BIOTHEOR, V59, P1, DOI 10.1007/s10441-010-9095-8
   van den Driessche P, 2008, LECT NOTES MATH, V1945, P159
   Yap W, 2020, TIME VARIANT STRATEG, DOI [10.1101/2020.04.13.20063248, DOI 10.1101/2020.04.13.20063248]
NR 55
TC 2
Z9 2
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0092-8240
EI 1522-9602
J9 B MATH BIOL
JI Bull. Math. Biol.
PD SEP 4
PY 2020
VL 82
IS 9
AR 118
DI 10.1007/s11538-020-00795-y
PG 24
WC Biology; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA NM9HR
UT WOS:000568402100002
PM 32888118
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Babar, Z
   Khan, M
   Zahra, M
   Anwar, M
   Noor, K
   Hashmi, HF
   Suleman, M
   Waseem, M
   Shah, A
   Ali, S
   Ali, SS
AF Babar, Zainib
   Khan, Mazhar
   Zahra, Mubeen
   Anwar, Munazza
   Noor, Kashif
   Hashmi, Huma Farooque
   Suleman, Muhammad
   Waseem, Muhammad
   Shah, Abdullah
   Ali, Shahid
   Ali, Syed Shujait
TI Drug similarity and structure-based screening of medicinal compounds to
   target macrodomain-I from SARS-CoV-2 to rescue the host immune system: a
   molecular dynamics study
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Macrodomain-I; immune system; SARs-CoV-2; drug similarity; free energy
ID FREE-ENERGY CALCULATIONS; ADP-RIBOSE; REPLICATION; BINDING;
   CORONAVIRUSES; SOFTWARE; DOCKING; AMBER
AB The outbreak of the recent coronavirus (SARS-CoV-2), which causes a severe pneumonia infection, first identified in Wuhan, China, imposes significant risks to public health. Around the world, researchers are continuously trying to identify small molecule inhibitors or vaccine candidates by targeting different drug targets. The SARs-CoV-2 macrodomain-I, which helps in viral replication and hijacking the host immune system, is also a potential drug target. Hence, this study targeted viral macrodomain-I by using drug similarity, virtual screening, docking and re-docking approaches. A total of 64,043 compounds were screened, and potential hits were identified based on the docking score and interactions with the key residues. The top six hits were subjected to molecular dynamics simulation and Free energy calculations and repeated three times each. The per-residue energy decomposition analysis reported that these compounds significantly interact with Asp22, Ala38, Asn40, Val44, Phe144, Gly46, Gly47, Leu127, Ser128, Gly130, Ile131, Phe132 and Ala155 which are the critical active site residues. Here, we also used ADPr as a positive control to compare our results. Our results suggest that our identified hits by using such a complicated computational pipeline could inhibit the SARs-CoV-2 by targeting the macrodomain-1. We strongly recommend the experimental testing of these compounds, which could rescue the host immune system and could help to contain the disease caused by SARs-CoV-2. Communicated by Ramaswamy H. Sarma
C1 [Babar, Zainib; Zahra, Mubeen] Univ Agr Faisalabad, Dept Bot, Faisalabad, Punjab, Pakistan.
   [Khan, Mazhar] Univ Sci & Technol China USTC, CAS Ctr Excellence Mol Cell Sci, Collaborat Innovat Ctr Genet & Dev,Hefei Natl Lab, Sch Life Sci,CAS Key Lab Innate Immun & Chron Dis, Hefei, Anhui, Peoples R China.
   [Anwar, Munazza] Quaid I Azam Univ, Fac Biol Sci, Dept Biochem, Islamabad, Pakistan.
   [Noor, Kashif] Univ Agr Faisalabad, Dept Plant Breeding & Genet, Punjab, Pakistan.
   [Suleman, Muhammad; Ali, Shahid; Ali, Syed Shujait] Univ Swat, Ctr Biotechnol & Microbiol, Swat, Khyber Pakhtunk, Pakistan.
   [Shah, Abdullah] Shaheed Benazir Bhutto Univ, Dept Biotechnol, Sheringal, Dir, Pakistan.
   [Hashmi, Huma Farooque] Shandong Univ, Sch Life Sci, Jinan, Shandong, Peoples R China.
   [Waseem, Muhammad] Riphah Int Univ, Fac Rehabil & Allied Hlth Sci, Islamabad, Pakistan.
RP Ali, S; Ali, SS (corresponding author), Univ Swat, Ctr Biotechnol & Microbiol, Swat, Khyber Pakhtunk, Pakistan.
EM shahidali@uswat.edu.pk; shujaitswati@uswat.edu.pk
CR Anandakrishnan R, 2012, NUCLEIC ACIDS RES, V40, pW537, DOI 10.1093/nar/gks375
   Angeletti S, 2020, J MED VIROL, V92, P584, DOI 10.1002/jmv.25719
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chatterjee A, 2009, J VIROL, V83, P1823, DOI 10.1128/JVI.01781-08
   Chen CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015939
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Davidchack RL, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3149788
   DeLano WL, 2002, CCP4 NEWSLETT PROTEI, V40, P1
   Egloff MP, 2006, J VIROL, V80, P8493, DOI 10.1128/JVI.00713-06
   Eriksson KK, 2008, J VIROL, V82, P12325, DOI 10.1128/JVI.02082-08
   Fehr AR, 2018, TRENDS MICROBIOL, V26, P598, DOI 10.1016/j.tim.2017.11.011
   Fehr AR, 2016, MBIO, V7, DOI 10.1128/mBio.01721-16
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Junaid M, 2019, J BIOMOL STRUCT DYN, V37, P4035, DOI 10.1080/07391102.2018.1537895
   Khan A, 2020, INTERDISCIP SCI, V12, P335, DOI 10.1007/s12539-020-00381-9
   Khan A, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1779128, 10.1080/01634372.2020.1787575]
   Khan A, 2020, FRONT MOL BIOSCI, V6, DOI 10.3389/fmolb.2019.00159
   Khan A, 2019, RSC ADV, V9, P10326, DOI 10.1039/c9ra01007f
   Khan A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196484
   Khan A, 2018, J MOL GRAPH MODEL, V82, P37, DOI 10.1016/j.jmgm.2018.03.004
   Khan MT, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1769733
   Krautler V, 2001, J COMPUT CHEM, V22, P501, DOI 10.1002/1096-987X(20010415)22:5<501::AID-JCC1021>3.0.CO;2-V
   Kusov Y, 2015, VIROLOGY, V484, P313, DOI 10.1016/j.virol.2015.06.016
   Land H., 2018, YASARA TOOL OBTAIN S
   Lei J, 2018, ANTIVIR RES, V149, P58, DOI 10.1016/j.antiviral.2017.11.001
   Lin YQ, 2017, J CHEM PHYS, V146, DOI 10.1063/1.4978807
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Ntie-Kang F, 2017, J NAT PROD, V80, P2067, DOI 10.1021/acs.jnatprod.7b00283
   PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D
   Piotrowski Y, 2009, PROTEIN SCI, V18, P6, DOI 10.1002/pro.15
   Putics A, 2005, J VIROL, V79, P12721, DOI 10.1128/JVI.79.20.12721-12731.2005
   Quimque MTJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1776639
   Raoult D, 2020, CELL STRESS, V4, P66, DOI 10.15698/cst2020.04.216
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Santhanam Vijayasri, 2017, Journal of Applied Pharmaceutical Science, V7, P74
   Shimizu JF, 2020, ACTA TROP, V207, DOI 10.1016/j.actatropica.2020.105490
   Sumoza-Toledo A, 2011, J PHYSIOL-LONDON, V589, P1515, DOI 10.1113/jphysiol.2010.201855
   Sun HY, 2014, PHYS CHEM CHEM PHYS, V16, P16719, DOI 10.1039/c4cp01388c
   Toukmaji A, 2000, J CHEM PHYS, V113, P10913, DOI 10.1063/1.1324708
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vassetti D, 2019, J CHEM THEORY COMPUT, V15, P1983, DOI 10.1021/acs.jctc.8b01039
   Vilar S, 2008, CURR TOP MED CHEM, V8, P1555, DOI 10.2174/156802608786786624
   WANG JM, 2001, ABSTR PAP AM CHEM 1, V222
   Wang YQ, 2019, J BIOMOL STRUCT DYN, V37, P4051, DOI 10.1080/07391102.2018.1537896
   Wu YT, 2020, LANCET, V395, P949, DOI 10.1016/S0140-6736(20)30557-2
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zoete V., 2016, SWISSSIMILARITY WEB
NR 50
TC 1
Z9 1
U1 8
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1815583
EA SEP 2020
PG 15
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NL6YG
UT WOS:000567558000001
PM 32897173
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Majumder, R
   Mandal, M
AF Majumder, Ranabir
   Mandal, Mahitosh
TI Screening of plant-based natural compounds as a potential COVID-19 main
   protease inhibitor: anin silicodocking and molecular dynamics simulation
   approach
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Coronavirus (SARS-CoV-2); COVID-19 main protease (Mpro); natural
   compounds; in silicomolecular docking (Autodock vina); molecular
   dynamics (MD) simulation (Gromacs)
ID BIOAVAILABILITY; ANTHOCYANINS; CORONAVIRUS; FLAVONOIDS; PROGRAM;
   GROMACS; TOOL
AB A new strain of coronavirus (CoV) has been identified as SARS-CoV-2, which is responsible for the recent COVID-19 pandemic. Currently, there is no approved vaccine or drug available to combat the pandemic. COVID-19 main protease (M-pro) is a key CoV enzyme, which plays an important role in triggering viral replication and transcription, turns it into an attractive target. Therefore, we aim to screen natural products library to find out potential COVID-19 M(pro)inhibitors. Plant-based natural compounds from Sigma-Aldrich plant profiler chemical library have been screened through virtual molecular docking and molecular dynamics simulation to identify potential inhibitors of COVID M-pro. Our virtual molecular docking results have shown that there are twenty-eight natural compounds with a greater binding affinity toward the COVID-19 M(pro)inhibition site as compared to the co-crystal native ligand Inhibitor N3 (-7.9 kcal/mol). Also, molecular dynamics simulation results have confirmed that Peonidin 3-O-glucoside, Kaempferol 3-O-beta-rutinoside, 4-(3,4-Dihydroxyphenyl)-7-methoxy-5-[(6-O-beta-D-xylopyranosyl-beta-D-glucopyranosyl)oxy]-2H-1-benzopyran-2-one, Quercetin-3-D-xyloside, and Quercetin 3-O-alpha-L-arabinopyranoside (selected based on the docking score) possess a significant amount of dynamic properties such as stability, flexibility and binding energy. OurIn silcoresults suggests that all the above mention natural compounds have the potential to be developed as a COVID-19 M(pro)inhibitor. But before that, it must go through under the proper preclinical and clinical trials for further scientific validation. Communicated by Ramaswamy H. Sarma
C1 [Majumder, Ranabir; Mandal, Mahitosh] Indian Inst Technol Kharagpur, Sch Med Sci & Technol, Kharagpur 721302, W Bengal, India.
RP Mandal, M (corresponding author), Indian Inst Technol Kharagpur, Sch Med Sci & Technol, Kharagpur 721302, W Bengal, India.
EM mahitosh@smst.iitkgp.ac.in
OI Majumder, Ranabir/0000-0003-3585-3276
FU Indian Institute of Technology Kharagpur, India; Indian Council of
   Medical ResearchIndian Council of Medical Research (ICMR); Council of
   Scientific and Industrial ResearchCouncil of Scientific & Industrial
   Research (CSIR) - India; J C Bose Fellowship (SERB, India)
FX We would like to acknowledge the Indian Institute of Technology
   Kharagpur, India, Indian Council of Medical Research, Council of
   Scientific and Industrial Research, and J C Bose Fellowship (SERB,
   India) for providing structural and financial support.
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   BAEK NI, 1994, PHYTOCHEMISTRY, V36, P513, DOI 10.1016/S0031-9422(00)97105-X
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   Cristians S, 2009, J NAT PROD, V72, P408, DOI 10.1021/np800642d
   DAS P, 2020, J BIOMOL STRUCT 0723, DOI DOI https://doi.org/10.1080/07391102.2020.1796799
   De Abreu MB, 2011, CHEM BIODIVERS, V8, P2126, DOI 10.1002/cbdv.201000334
   Camargo LMD, 2012, PHYTOCHEM LETT, V5, P427, DOI 10.1016/j.phytol.2012.03.015
   Diaz JG, 2008, PLANTA MED, V74, P171, DOI 10.1055/s-2008-1034278
   Ferreira ACF, 2006, CHEM RES TOXICOL, V19, P351, DOI 10.1021/tx0501684
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   GRZEGORCZYKKAROLAK, 2016, ACTA PHYSIOL PLANT, V38, DOI DOI https://doi.org/10.1007/s11738-015-2024-3
   GUPTA S. R., 1952, PROC INDIAN ACAD SCI SEC A, V35, P242
   Habtemariam S., 2019, MED FOODS POTENTIAL, P1049
   Hernandez F, 1999, EUR FOOD RES TECHNOL, V210, P39, DOI 10.1007/s002170050529
   Jackson RS, 2017, WINE TASTING: A PROFESSIONAL HANDBOOK, 3RD EDITION, P19, DOI 10.1016/B978-0-12-801813-2.00002-1
   Jang GH, 2018, SAUDI J BIOL SCI, V25, P1622, DOI 10.1016/j.sjbs.2016.08.001
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Ju WT, 2018, J FOOD SCI TECH MYS, V55, P1789, DOI 10.1007/s13197-018-3093-2
   Kamenickova A, 2013, TOXICOL LETT, V221, P1, DOI 10.1016/j.toxlet.2013.05.007
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Landrault N, 2001, J AGR FOOD CHEM, V49, P3341, DOI 10.1021/jf010128f
   Li SY, 2005, J AGR FOOD CHEM, V53, P32, DOI 10.1021/jf0484780
   Liu PZ, 2011, FOOD CHEM, V127, P1370, DOI 10.1016/j.foodchem.2011.01.103
   Majumder R, 2020, NAT PROD RES, V34, P2363, DOI 10.1080/14786419.2018.1534848
   MATA R, 1992, PHYTOCHEMISTRY, V31, P3199, DOI 10.1016/0031-9422(92)83474-D
   Meyer H, 2006, ANN NUTR METAB, V50, P167, DOI 10.1159/000090736
   Mullen W, 2008, J AGR FOOD CHEM, V56, P713, DOI 10.1021/jf072000p
   Panda PK, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb8097
   Patel K., 2019, BIOACTIVE FOOD DIETA, V2, P457, DOI DOI 10.1016/B978-0-12-813820-5.00026-X
   Peng B, 2016, J ASIAN NAT PROD RES, V18, P59, DOI 10.1080/10286020.2015.1121853
   Rao SN, 2007, J CHEM INF MODEL, V47, P2159, DOI 10.1021/ci6004299
   Refaat J., 2015, INT J PHARMACOGN, V2, P102, DOI DOI 10.13040/IJPSR.0975-8232.IJP.2(3).102-109
   Roshchin Y. V., 1977, CHEM NAT COMPD, V13, DOI https://doi.org/10.1007/BF00565849
   Sadiqud M. U. E., 2016, IOSR J APPL CHEM IOS, V9, DOI [https://doi.org/10.9790/5736-0904021217, DOI 10.9790/5736-0904021217]
   Trott O., 2009, J COMPUT CHEM, V31, pNA461
   vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047
   Weng XC, 2000, FOOD CHEM, V71, P489, DOI 10.1016/S0308-8146(00)00191-6
   WHO-World Health Organization, 2020, 77 WHO
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu SS, 2011, CHIN J CHROMATOGR, V29, P1244, DOI 10.3724/SP.J.1123.2011.01244
   Xu XY, 2011, J AGR FOOD CHEM, V59, P1205, DOI 10.1021/jf104387y
   Yoon EK, 2015, BMB REP, V48, P577, DOI 10.5483/BMBRep.2015.48.10.044
   Zanwar A. A., 2013, POLYPHENOLS HUMAN HL, V2, DOI [10.1016/B978-0-12-398456-2.00076-1, DOI 10.1016/B978-0-12-398456-2.00076-1]
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zoete V, 2016, J CHEM INF MODEL, V56, P1399, DOI 10.1021/acs.jcim.6b00174
NR 46
TC 1
Z9 1
U1 8
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1817787
EA SEP 2020
PG 16
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NL6ZB
UT WOS:000567560100001
PM 32897138
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Jin, YH
   Zhan, QY
   Peng, ZY
   Ren, XQ
   Yin, XT
   Cai, L
   Yuan, YF
   Yue, JR
   Zhang, XC
   Yang, QW
   Ji, JG
   Xia, J
   Li, YR
   Zhou, FX
   Gao, YD
   Yu, Z
   Xu, F
   Tu, ML
   Tan, LM
   Yang, M
   Chen, F
   Zhang, XJ
   Zeng, M
   Zhu, Y
   Liu, XC
   Yang, J
   Zhao, DC
   Ding, YF
   Hou, N
   Wang, FB
   Chen, H
   Zhang, YG
   Li, W
   Chen, W
   Shi, YX
   Yang, XZ
   Wang, XJ
   Zhong, YJ
   Zhao, MJ
   Li, BH
   Ma, LL
   Zi, H
   Wang, N
   Wang, YY
   Yu, SF
   Li, LY
   Huang, Q
   Weng, H
   Ren, XY
   Luo, LS
   Fan, MR
   Huang, D
   Xue, HY
   Yu, LX
   Gao, JP
   Deng, T
   Zeng, XT
   Li, HJ
   Cheng, ZS
   Yao, XM
   Wang, XH
AF Jin, Ying-Hui
   Zhan, Qing-Yuan
   Peng, Zhi-Yong
   Ren, Xue-Qun
   Yin, Xun-Tao
   Cai, Lin
   Yuan, Yu-Feng
   Yue, Ji-Rong
   Zhang, Xiao-Chun
   Yang, Qi-Wen
   Ji, Jianguang
   Xia, Jian
   Li, Yi-Rong
   Zhou, Fu-Xiang
   Gao, Ya-Dong
   Yu, Zhui
   Xu, Feng
   Tu, Ming-Li
   Tan, Li-Ming
   Yang, Min
   Chen, Fang
   Zhang, Xiao-Ju
   Zeng, Mei
   Zhu, Yu
   Liu, Xin-Can
   Yang, Jian
   Zhao, Dong-Chi
   Ding, Yu-Feng
   Hou, Ning
   Wang, Fu-Bing
   Chen, Hao
   Zhang, Yong-Gang
   Li, Wei
   Chen, Wen
   Shi, Yue-Xian
   Yang, Xiu-Zhi
   Wang, Xue-Jun
   Zhong, Yan-Jun
   Zhao, Ming-Juan
   Li, Bing-Hui
   Ma, Lin-Lu
   Zi, Hao
   Wang, Na
   Wang, Yun-Yun
   Yu, Shao-Fu
   Li, Lu-Yao
   Huang, Qiao
   Weng, Hong
   Ren, Xiang-Ying
   Luo, Li-Sha
   Fan, Man-Ru
   Huang, Di
   Xue, Hong-Yang
   Yu, Lin-Xin
   Gao, Jin-Ping
   Deng, Tong
   Zeng, Xian-Tao
   Li, Hong-Jun
   Cheng, Zhen-Shun
   Yao, Xiaomei
   Wang, Xing-Huan
CA Evidence Based Med
   CRHA
TI Chemoprophylaxis, diagnosis, treatments, and discharge management of
   COVID-19: An evidence-based clinical practice guideline (updated
   version)
SO MILITARY MEDICAL RESEARCH
LA English
DT Article
DE COVID-19; SARS-CoV-2; Recommendation; Chemoprophylaxis; Diagnosis;
   Treatment; Discharge management; Traditional Chinese medicine; guideline
ID RESPIRATORY-DISTRESS-SYNDROME; CORONAVIRUS DISEASE 2019; MANIFESTATIONS;
   INVOLVEMENT; CHINA
AB The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of a rapidly spreading illness, coronavirus disease 2019 (COVID-19), affecting more than seventeen million people around the world. Diagnosis and treatment guidelines for clinicians caring for patients are needed. In the early stage, we have issued "A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)"; now there are many direct evidences emerged and may change some of previous recommendations and it is ripe for develop an evidence-based guideline. We formed a working group of clinical experts and methodologists. The steering group members proposed 29 questions that are relevant to the management of COVID-19 covering the following areas: chemoprophylaxis, diagnosis, treatments, and discharge management. We searched the literature for direct evidence on the management of COVID-19, and assessed its certainty generated recommendations using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. Recommendations were either strong or weak, or in the form of ungraded consensus-based statement. Finally, we issued 34 statements. Among them, 6 were strong recommendations for, 14 were weak recommendations for, 3 were weak recommendations against and 11 were ungraded consensus-based statement. They covered topics of chemoprophylaxis (including agents and Traditional Chinese Medicine (TCM) agents), diagnosis (including clinical manifestations, reverse transcription-polymerase chain reaction (RT-PCR), respiratory tract specimens, IgM and IgG antibody tests, chest computed tomography, chest x-ray, and CT features of asymptomatic infections), treatments (including lopinavir-ritonavir, umifenovir, favipiravir, interferon, remdesivir, combination of antiviral drugs, hydroxychloroquine/chloroquine, interleukin-6 inhibitors, interleukin-1 inhibitors, glucocorticoid, qingfei paidu decoction, lianhua qingwen granules/capsules, convalescent plasma, lung transplantation, invasive or noninvasive ventilation, and extracorporeal membrane oxygenation (ECMO)), and discharge management (including discharge criteria and management plan in patients whose RT-PCR retesting shows SARS-CoV-2 positive after discharge). We also created two figures of these recommendations for the implementation purpose. We hope these recommendations can help support healthcare workers caring for COVID-19 patients.
C1 [Jin, Ying-Hui; Zhao, Ming-Juan; Li, Bing-Hui; Ma, Lin-Lu; Zi, Hao; Wang, Yun-Yun; Yu, Shao-Fu; Li, Lu-Yao; Huang, Qiao; Weng, Hong; Ren, Xiang-Ying; Luo, Li-Sha; Fan, Man-Ru; Huang, Di; Xue, Hong-Yang; Yu, Lin-Xin; Gao, Jin-Ping; Deng, Tong; Zeng, Xian-Tao; Wang, Xing-Huan] Wuhan Univ, Ctr Evidence Based & Translat Med, Zhongnan Hosp, Wuhan 430071, Peoples R China.
   [Zhan, Qing-Yuan] China Japan Friendship Hosp, Natl Clin Res Ctr Resp Dis, Beijing 100029, Peoples R China.
   [Zhan, Qing-Yuan] China Japan Friendship Hosp, Dept Pulm & Crit Care Med, Beijing 10029, Peoples R China.
   [Peng, Zhi-Yong; Cai, Lin; Zhang, Xiao-Chun; Xia, Jian; Li, Yi-Rong; Zeng, Xian-Tao; Cheng, Zhen-Shun; Wang, Xing-Huan] Leishenshan Hosp Wuhan, Wuhan 430200, Peoples R China.
   [Peng, Zhi-Yong] Wuhan Univ, Dept Crit Care Med, Zhongnan Hosp, Wuhan 430071, Peoples R China.
   [Ren, Xue-Qun; Ma, Lin-Lu; Wang, Na] Henan Univ, Inst Evidence based Med & Knowledge Translat, Kaifeng 475000, Henan, Peoples R China.
   [Yin, Xun-Tao] Guizhou Prov Peoples Hosp, Dept Med Imaging, Guiyang 550002, Peoples R China.
   [Cai, Lin] Wuhan Univ, Dept Orthoped, Zhongnan Hosp, Wuhan 430071, Peoples R China.
   [Yuan, Yu-Feng] Wuhan Univ, Dept Hepatobiliary Surg, Zhongnan Hosp, Wuhan 430071, Peoples R China.
   [Yue, Ji-Rong] Sichuan Univ, Natl Clin Res Ctr Geriatr, West China Hosp, Chengdu 610041, Peoples R China.
   [Yue, Ji-Rong] Sichuan Univ, Dept Geriatr, West China Hosp, Chengdu 610041, Peoples R China.
   [Zhang, Xiao-Chun] Wuhan Univ, Dept Radiol, Zhongnan Hosp, Wuhan 430071, Peoples R China.
   [Yang, Qi-Wen] Chinese Acad Med Sci CAMS, Peking Union Med Coll Hosp PUMCH, Peking Union Med Coll, Dept Clin Lab, Beijing 100730, Peoples R China.
   [Ji, Jianguang; Xia, Jian] Lund Univ & Region Skane, Ctr Primary Hlth Care Res, S-25002 Malmo, Sweden.
   [Xia, Jian] Wuhan Univ, Emergency Ctr, Zhongnan Hosp, Wuhan 403371, Peoples R China.
   [Li, Yi-Rong] Wuhan Univ, Dept Allergol, Zhongnan Hosp, Wuhan 430071, Peoples R China.
   Wuhan Univ, Dept Radiat & Med Oncol, Zhongnan Hosp, Wuhan 43071, Peoples R China.
   [Zhou, Fu-Xiang] Wuhan Univ, Dept Crit Care Med, Zhongnan Hosp, Wuhan 430060, Peoples R China.
   [Xu, Feng] Shandong Univ, Dept Emergency Med, Qilu Hosp, Jinan 250002, Peoples R China.
   [Xu, Feng] Shandong Univ, Chest Pain Ctr, Qilu Hosp, Jinan 250002, Peoples R China.
   [Tu, Ming-Li] Hubei Univ Med, Suizhou Cent Hosp, Dept Resp & Crit Care Med, Suizhou 441300, Hubei, Peoples R China.
   [Tu, Ming-Li] Second Peoples Hosp Huaihua City, Dept Clin Pharm, Huaihua 418000, Hunan, Peoples R China.
   [Yang, Min] Anhui Med Univ, Dept Intens Care Unit, Affiliated Hosp 2, Hefei 230601, Peoples R China.
   [Chen, Fang] Zhengzhou Univ Hosp, Dept Internal Med, Zhengzhou 450001, Peoples R China.
   [Zhang, Xiao-Ju] Henan Prov Peoples Hosp, Dept Resp & Crit Care Med, Zhengzhou 450003, Peoples R China.
   [Zeng, Mei] Fudan Univ, Dept Infect Dis, Childrens Hosp, Shanghai 201102, Peoples R China.
   [Zhu, Yu] Sichuan Univ, West China Hosp 2, Dept Infect Dis, Chengdu 610041, Peoples R China.
   [Liu, Xin-Can] Henan Univ Chinese Med, Dept Cardiol, Zhengzhou 450000, Peoples R China.
   [Yang, Jian] Three Gorges Univ, Renmin Hosp China, Dept Cardiol, Yichang 443000, Hubei, Peoples R China.
   [Zhao, Dong-Chi] Wuhan Univ, Dept Pediat, Zhongnan Hosp, Wuhan 430071, Peoples R China.
   [Ding, Yu-Feng] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Pharm, Wuhan 430030, Peoples R China.
   [Hou, Ning] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Prov Hosp, Dept Pharm, Jinan 250021, Peoples R China.
   [Chen, Hao] Nanjing Univ Chinese Med, Lab Integrated Acupuncture & Drugs, Nanjing 210023, Peoples R China.
   [Zhang, Yong-Gang] Sichuan Univ, West China Hosp, Dept Period Press, Chengdu 610041, Peoples R China.
   [Li, Wei] Qingdao Univ, Yantai Yuhuangding Hosp, Dept Clin Lab, Yantai 264000, Shandong, Peoples R China.
   [Chen, Wen] Hubei Univ Med, Taihe Hosp, Dept Radiol, Shiyan 442000, Hubei, Peoples R China.
   [Shi, Yue-Xian] Peking Univ, Sch Nursing, Beijing 100191, Peoples R China.
   [Yang, Xiu-Zhi] Kaifeng Cent Hosp, Dept Resp & Crit Care Med, Kaifeng 475000, Henan, Peoples R China.
   [Wang, Xue-Jun] Beijing Elect Power Hosp, Dept Emergency, Beijing 100073, Peoples R China.
   [Zhong, Yan-Jun] Cent South Univ, Second Xiangya Hosp, ICU Ctr, Changsha 410008, Peoples R China.
   [Li, Bing-Hui; Wang, Xing-Huan] Wuhan Univ, Dept Urol, Zhongnan Hosp, Wuhan 430071, Peoples R China.
   [Ma, Lin-Lu] Wuhan Univ, Zhongnan Hosp, Dept Haematol, Wuhan 430071, Peoples R China.
   [Wang, Na] Henan Univ, Henan Med Sch, Coll Nursing & Hlth, Kaifeng 475000, Henan, Peoples R China.
   [Gao, Jin-Ping] Shanxi Med Univ, Sch Nursing, Taiyuan 030001, Peoples R China.
   [Li, Hong-Jun] Capital Med Univ, Beijing Youan Hosp, Dept Diagnost Radiol, Beijing 100069, Peoples R China.
   [Cheng, Zhen-Shun] Wuhan Univ, Dept Resp Med, Zhongnan Hosp, Wuhan 430071, Peoples R China.
   [Yao, Xiaomei] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON L8S 4L8, Canada.
RP Zeng, XT; Wang, XH (corresponding author), Wuhan Univ, Ctr Evidence Based & Translat Med, Zhongnan Hosp, Wuhan 430071, Peoples R China.; Zeng, XT; Cheng, ZS; Wang, XH (corresponding author), Leishenshan Hosp Wuhan, Wuhan 430200, Peoples R China.; Wang, XH (corresponding author), Wuhan Univ, Dept Urol, Zhongnan Hosp, Wuhan 430071, Peoples R China.; Li, HJ (corresponding author), Capital Med Univ, Beijing Youan Hosp, Dept Diagnost Radiol, Beijing 100069, Peoples R China.; Cheng, ZS (corresponding author), Wuhan Univ, Dept Resp Med, Zhongnan Hosp, Wuhan 430071, Peoples R China.; Yao, XM (corresponding author), McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON L8S 4L8, Canada.
EM zengxiantao1128@163.com; lihongjun00113@126.com; chzs1990@163.com;
   yaoxia@mcmaster.ca; wangxinghuan1965@163.com
RI , 月月/ABF-7551-2020; Ji, Jianguang/E-9579-2011
OI Reis, AlessanRSS/0000-0001-8486-7469; Ji, Jianguang/0000-0003-0324-9496
FU National Key Research and Development Program of China [2020YFC0845500];
   Special Project for Emergency of Hubei Province [2020FCA008]; First
   Level Funding of the Second Medical Leading Talent Project in Hubei
   Province
FX This work was supported (in part) by the National Key Research and
   Development Program of China (2020YFC0845500), the Special Project for
   Emergency of Hubei Province (2020FCA008), and the First Level Funding of
   the Second Medical Leading Talent Project in Hubei Province. The funding
   organizations had no role in the design and conduct of the study
   collection, management, analysis, and interpretation of the data;
   preparation, review, or approval of the manuscript; and decision to
   submit the manuscript for publication.
CR Alonso-Coello P, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2016
   Altmayer S, 2020, EUR RADIOL, V30, P6485, DOI 10.1007/s00330-020-07018-x
   An J., 2020, CLIN CHARACTERISTICS, DOI [10.1101/2020.03.26.20044222, DOI 10.1101/2020.03.26.20044222]
   Bhattacharya R, 2020, PREEXPOSURE HYDROXYC, DOI [10.1101/2020.06.09.20116806, DOI 10.1101/2020.06.09.20116806]
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Boregowda U, 2020, ADDITION TOCILIZUMAB, DOI [10.1101/2020.07.10.20150680, DOI 10.1101/2020.07.10.20150680]
   Borsetto D, 2020, Rhinology, V58, P430, DOI 10.4193/Rhin20.185
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Cai Qingxian, 2020, Engineering (Beijing), V6, P1192, DOI 10.1016/j.eng.2020.03.007
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cao YH, 2020, J MED VIROL, V92, P1449, DOI [10.1002/jmv.25822, 10.1080/10962247.2020.1815895]
   Carvalho V, 2020, EFFECTS TOCILIZUMAB, DOI [10.1101/2020.07.13.20149328, DOI 10.1101/2020.07.13.20149328]
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   Chen J., 2020, CHINESE J INFECT DIS, V38, pE008, DOI [10.3760/cma.j.cn311365-20200210-00050, DOI 10.3760/CMA.J.CN311365-20200210-00050]
   Chen JY, 2020, CHINESE MED J-PEKING, V133, P1390, DOI 10.1097/CM9.0000000000000839
   Chen LW, 2020, ACTA OPHTHALMOL, V98, pE951, DOI 10.1111/aos.14472
   Chen WY, 2020, J MED VIROL, V92, P2702, DOI 10.1002/jmv.26142
   Cheng D.Z., 2020, TIANJIN J TRADITIONA, P1
   Cheung KS, 2020, GASTROENTEROLOGY, V159, P81, DOI 10.1053/j.gastro.2020.03.065
   Corral L, 2020, CONTROLLED TRIAL MET, DOI [10.1101/2020.06.17.20133579, DOI 10.1101/2020.06.17.20133579]
   Davoudi-Monfared E, 2020, ANTIMICROB AGENTS CH, V64, DOI [10.1128/AAC.01061-2032661006, DOI 10.1101/2020.05.28.20116467]
   Deeks JJ, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013652
   Della-Torre E, 2020, ANN RHEUM DIS, V79, P1277, DOI [10.1136/annrheumdis-2020-218122, 10.1136/annrheumdis-2020-218759, 10.1136/annrheumdis-2020-218724]
   Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002
   Deng Z, 2020, CHIN J RADIOL
   Elavarasi A, 2020, CHLOROQUINE HYDROXYC, DOI [10.1101/2020.07.04.20146381, DOI 10.1101/2020.07.04.20146381]
   EQUATOR Network, AGR REP CHECKL TOOL
   Estebanez M., 2020, CLIN EVALUATION IFN, DOI [10.1101/2020.05.15.20084293, DOI 10.1101/2020.05.15.20084293]
   Fernandez Cruz A, 2020, MEDRXIV, V64, pe01168, DOI [10.1128/AAC.01168-20, DOI 10.1128/AAC.01168-20]
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Fu LW, 2020, J INFECTION, V80, P656, DOI 10.1016/j.jinf.2020.03.041
   Gharbharan A, 2020, CONVALESCENT PLASMA, DOI DOI 10.1101/2020.07.01.20139857V1
   Grant MC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234765
   Gritti G, 2020, IL 6 SIGNALLING PATH, DOI [10.1101/2020.04.01.20048561, DOI 10.1101/2020.04.01.20048561]
   Gupta M, 2020, GLOB HEALTH RES POL, V5, DOI 10.1186/s41256-020-00159-y
   Han WL, 2020, ANN SURG, V272, pE33, DOI 10.1097/SLA.0000000000003955
   HERNANDEZ AV, 2020, ANN INTERN MED, DOI DOI 10.7326/M20-2496.
   Hoang MP, 2020, ASIAN PAC J ALLERGY, V38, P162, DOI 10.12932/AP-210520-0853
   Hong N, 2020, ACTA OPHTHALMOL, V98, pE649, DOI 10.1111/aos.14445
   Hu K. E., 2020, PHYTOMEDICINE, P153242, DOI [10.1016/j.phymed.2020.153242, DOI 10.1016/J.PHYMED.2020.153242]
   Hu R, 2020, JAMA NETW OPEN, P3, DOI [10.1001/jamanetworkopen.2020.104757256666, DOI 10.1001/JAMANETWORKOPEN.2020.104757256666]
   Huang DZ, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-2124
   Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Jin YH, 2020, YIXUE XINZHI ZAZHI, V30, P209
   JIN YH, 2020, MILITARY MED RES, V7, DOI DOI 10.1186/S40779-020-0233-67003341
   Kim H, 2020, RADIOLOGY, V296, pE145, DOI 10.1148/radiol.2020201343
   Koh J, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00295
   Kronbichler A, 2020, INT J INFECT DIS, V98, P180, DOI 10.1016/j.ijid.2020.06.052
   Lan X, 2020, LOPINAVIR RITONAVIR, DOI [10.1101/2020.04.25.20079079, DOI 10.1101/2020.04.25.20079079]
   [李旷宇 Li Kuangyu], 2020, [中草药, Chinese Traditional and Herbal Drugs], V51, P2046
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Li X, 2020, WORLD CHIN MED, P1
   Li Y, 2020, EXPLORATORY RANDOMIZ, DOI [10.1101/2020.03.19.20038984, DOI 10.1101/2020.03.19.20038984]
   Lian N, 2020, CLIN MICROBIOL INFEC, V26, P917, DOI 10.1016/j.cmi.2020.04.026
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Liu R, 2020, CLIN CHIM ACTA, V505, P172, DOI 10.1016/j.cca.2020.03.009
   Lu J, 2020, CLIN IMMUNOLOGICAL V, DOI [10.1101/2020.06.15.20131748, DOI 10.1101/2020.06.15.20131748]
   Lv RB, 2020, J TRADIT CHIN MED
   Ma LL, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00242
   Ma LL, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00238-8
   Magagnoli J, 2020, MED, DOI [10.1016/j.medj.2020.06.001, DOI 10.1016/J.MEDJ.2020.06.001]
   Majmundar M, 2020, EFFICACY CORTICOSTER, DOI [10.1101/2020.07.02.20145565, DOI 10.1101/2020.07.02.20145565]
   Malla C, 2018, GLOB HEALTH RES POL, V3, DOI 10.1186/s41256-018-0084-9
   Mao R, 2020, LANCET GASTROENTEROL, V5, P426, DOI 10.1016/S2468-1253(20)30076-5
   Marfella R, 2020, DIABETES METAB, V46, P403, DOI 10.1016/j.diabet.2020.05.005
   Mei Q, 2020, LANCET INFECT DIS, V20, P1004, DOI 10.1016/S1473-3099(20)30433-3
   Mohammadi Abbas, 2020, medRxiv, DOI 10.1101/2020.05.14.20102038
   Ni Q, 2020, CHIN J CLIN INFECT D, DOI 10.3760/cma.j.cn115673?20200225?00072
   Norris Susan L, 2018, J Evid Based Med, V11, P133, DOI 10.1111/jebm.12314
   Park JH, 2020, CLIN EXP OTORHINOLAR, V13, P95, DOI 10.21053/ceo.2020.00570
   Pereda R, 2020, THERAPEUTIC EFFECTIV, DOI [10.1101/2020.05.29.20109199, DOI 10.1101/2020.05.29.20109199]
   Piechotta V, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD013600.pub2
   Pormohammad A, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2112
   Rasheed AM, 2020, THERAPEUTIC EFFECTIV, DOI [10.1101/2020.06.24.20121905v2, DOI 10.1101/2020.06.24.20121905V2]
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Rokkas T, 2020, ANN GASTROENTEROL, V33, P355, DOI 10.20524/aog.2020.0506
   Roshanshad A, 2020, REMDESIVIR EFFICACY, DOI [10.1101/2020.06.15.20131227, DOI 10.1101/2020.06.15.20131227]
   Rossi B, 2020, MEDRXIV, DOI [10.1101/2020.06.06.20122341, DOI 10.1101/2020.06.06.20122341]
   Rossotti R, 2020, J INFECTION, V81, pE11, DOI 10.1016/j.jinf.2020.07.008
   Salton F., 2020, PROLONGED LOW DOSE M, DOI [10.1101/2020.06.17.20134031, DOI 10.1101/2020.06.17.20134031]
   Herrero FS, 2020, J INTERN MED, DOI 10.1111/joim.13145
   Schiaffino S, 2020, J THORAC IMAG, V35, pW105, DOI 10.1097/RTI.0000000000000533
   Schunemann HJ, 2007, PLOS MED, V4, P786, DOI 10.1371/journal.pmed.0040119
   Singh AK, 2020, DIABETES METAB SYND, V14, P971, DOI 10.1016/j.dsx.2020.06.054
   Su Y, 2020, CLIN CHARACTERISTICS, DOI [10.1101/2020.06.23.20138149, DOI 10.1101/2020.06.23.20138149]
   Sun PF, 2020, J MED VIROL, V92, P612, DOI 10.1002/jmv.25735
   Suresh Kumar Vishnu Charan, 2020, BMJ Open Gastroenterol, V7, DOI 10.1136/bmjgast-2020-000417
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   von Bartheld Christopher S, 2020, medRxiv, DOI 10.1101/2020.06.15.20132134
   Wang D, 2020, NO CLEAR BENEFIT USE, DOI [10.1101/2020.04.21.20066258., DOI 10.1101/2020.04.21.20066258, 10.1101/2020.04.21.20066258]
   Wang M, 2020, CHIN J LAB MED, V4, P341
   Wang Yanxue, 2020, MECH BASED DES STRUC, P1, DOI DOI 10.3897/ZOOKEYS.922.49141
   Wang YY, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00245-9
   Wei R, 2020, CHIN J CLIN INFECT D
   WHO, WHO COR DIS COV 19
   Wong J, 2020, J MED VIROL, V92, P2847, DOI 10.1002/jmv.26199
   Wu FQ, 2020, BRIT J HOSP MED, V81, DOI 10.12968/hmed.2020.0156
   Wu P, 2020, JAMA OPHTHALMOL, V138, P575, DOI 10.1001/jamaophthalmol.2020.1291
   Xu K, 2020, CLIN EFFICACY ARBIDO
   Xu P, 2020, MICROBES INFECT, V22, P200, DOI 10.1016/j.micinf.2020.05.012
   XU ZH, 2020, AM J INFECT CONTROL, DOI DOI 10.1016/J.AJIC.2020.06.008
   Xuan TM, 2020, J ZHEJIANG UNIV-SC B, V21, P411, DOI 10.1631/jzus.B2000182
   Yan D, 2020, FACTORS ASS PROLONGE, DOI [10.1101/2020.03.22.20040832, DOI 10.1101/2020.03.22.20040832]
   Yang C, 2020, VIRAL RNA LEVEL SERU, DOI [10.1101/2020.07.21.20125138, DOI 10.1101/2020.07.21.20125138]
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yao K.T., 2020, CHIN J EXP TRADIT ME, DOI [10.13422/j.cnki.syfjx.20201099, DOI 10.13422/J.CNKI.SYFJX.20201099]
   Ye XT, 2020, EUR REV MED PHARMACO, V24, P3390, DOI 10.26355/eurrev_202003_20706
   Yu AR, 2020, HERALD MED, P1
   Yu P, 2020, EFFECTS LIANHUA QING, V55, P1042
   Yuan Mingli, 2020, Shock, V54, P638, DOI 10.1097/SHK.0000000000001574
   ZENG JH, 2020, CLIN INFECT DIS, DOI DOI 10.1093/CID/CIAA398
   Zhang JN, 2020, CURR MED SCI, V40, P480, DOI 10.1007/s11596-020-2203-3
   Zhao Q, 2020, J EUR ACAD DERMATOL, DOI 10.1111/jdv.16778
   Zheng Y, 2020, J MED VIROL, DOI 10.1002/jmv.26218
   Zhou Q, 2020, INTERFERON A2B TREAT, DOI [10.1101/2020.04.06.20042580, DOI 10.1101/2020.04.06.20042580]
   Zhou YY, 2020, OPHTHALMOLOGY, V127, P982, DOI 10.1016/j.ophtha.2020.04.028
   Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6
   Zhu H, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23392
   Zhu JY, 2020, J MED VIROL, V92, P1902, DOI 10.1002/jmv.25884
   Zhu Z, 2020, J INFECTION, V81, pE21, DOI 10.1016/j.jinf.2020.03.060
NR 122
TC 1
Z9 2
U1 12
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2095-7467
EI 2054-9369
J9 MILITARY MED RES
JI MILITARY MED. RES.
PD SEP 4
PY 2020
VL 7
IS 1
AR 41
DI 10.1186/s40779-020-00270-8
PG 33
WC Medicine, General & Internal
SC General & Internal Medicine
GA NM8SX
UT WOS:000568363700001
PM 32887670
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mathew, D
   Giles, JR
   Baxter, AE
   Oldridge, DA
   Greenplate, AR
   Wu, JE
   Alanio, C
   Kuri-Cervantes, L
   Pampena, MB
   D'Andrea, K
   Manne, S
   Chen, ZY
   Huang, YJ
   Reilly, JP
   Weisman, AR
   Ittner, CAG
   Kuthuru, O
   Dougherty, J
   Nzingha, K
   Han, N
   Kim, J
   Pattekar, A
   Goodwin, EC
   Anderson, EM
   Weirick, ME
   Gouma, S
   Arevalo, CP
   Bolton, MJ
   Chen, F
   Lacey, SF
   Ramage, H
   Cherry, S
   Hensley, SE
   Apostolidis, SA
   Huang, AC
   Vella, LA
   Betts, MR
   Meyer, NJ
   Wherry, EJ
AF Mathew, Divij
   Giles, Josephine R.
   Baxter, Amy E.
   Oldridge, Derek A.
   Greenplate, Allison R.
   Wu, Jennifer E.
   Alanio, Cecile
   Kuri-Cervantes, Leticia
   Pampena, M. Betina
   D'Andrea, Kurt
   Manne, Sasikanth
   Chen, Zeyu
   Huang, Yinghui Jane
   Reilly, John P.
   Weisman, Ariel R.
   Ittner, Caroline A. G.
   Kuthuru, Oliva
   Dougherty, Jeanette
   Nzingha, Kito
   Han, Nicholas
   Kim, Justin
   Pattekar, Ajinkya
   Goodwin, Eileen C.
   Anderson, Elizabeth M.
   Weirick, Madison E.
   Gouma, Sigrid
   Arevalo, Claudia P.
   Bolton, Marcus J.
   Chen, Fang
   Lacey, Simon F.
   Ramage, Holly
   Cherry, Sara
   Hensley, Scott E.
   Apostolidis, Sokratis A.
   Huang, Alexander C.
   Vella, Laura A.
   Betts, Michael R.
   Meyer, Nuala J.
   Wherry, E. John
CA UPenn COVID Proc Unit
TI Deep immune profiling of COVID-19 patients reveals distinct immunotypes
   with therapeutic implications
SO SCIENCE
LA English
DT Article
ID VIRUS-INFECTION; T-CELLS; RESPONSES; FEVER
AB Coronavirus disease 2019 (COVID-19) is currently a global pandemic, but human immune responses to the virus remain poorly understood. We used high-dimensional cytometry to analyze 125 COVID-19 patients and compare them with recovered and healthy individuals. Integrated analysis of similar to 200 immune and similar to 50 clinical features revealed activation of T cell and B cell subsets in a proportion of patients. A subgroup of patients had T cell activation characteristic of acute viral infection and plasmablast responses reaching >30% of circulating B cells. However, another subgroup had lymphocyte activation comparable with that in uninfected individuals. Stable versus dynamic immunological signatures were identified and linked to trajectories of disease severity change. Our analyses identified three immunotypes associated with poor clinical trajectories versus improving health. These immunotypes may have implications for the design of therapeutics and vaccines for COVID-19.
C1 [Mathew, Divij; Giles, Josephine R.; Baxter, Amy E.; Oldridge, Derek A.; Greenplate, Allison R.; Wu, Jennifer E.; Alanio, Cecile; Kuri-Cervantes, Leticia; Pampena, M. Betina; Manne, Sasikanth; Chen, Zeyu; Huang, Yinghui Jane; Kuthuru, Oliva; Dougherty, Jeanette; Nzingha, Kito; Han, Nicholas; Kim, Justin; Pattekar, Ajinkya; Goodwin, Eileen C.; Anderson, Elizabeth M.; Weirick, Madison E.; Gouma, Sigrid; Arevalo, Claudia P.; Bolton, Marcus J.; Cherry, Sara; Hensley, Scott E.; Apostolidis, Sokratis A.; Huang, Alexander C.; Vella, Laura A.; Betts, Michael R.; Wherry, E. John] Univ Penn, Inst Immunol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Mathew, Divij; Giles, Josephine R.; Baxter, Amy E.; Greenplate, Allison R.; Wu, Jennifer E.; Alanio, Cecile; Manne, Sasikanth; Chen, Zeyu; Huang, Yinghui Jane; Kuthuru, Oliva; Dougherty, Jeanette; Nzingha, Kito; Han, Nicholas; Kim, Justin; Wherry, E. John] Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA.
   [Giles, Josephine R.; Wu, Jennifer E.; Alanio, Cecile; Huang, Alexander C.; Wherry, E. John] Univ Penn, Parker Inst Canc Immunotherapy, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Oldridge, Derek A.; Lacey, Simon F.; Cherry, Sara] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Kuri-Cervantes, Leticia; Pampena, M. Betina; Goodwin, Eileen C.; Anderson, Elizabeth M.; Weirick, Madison E.; Gouma, Sigrid; Arevalo, Claudia P.; Bolton, Marcus J.; Hensley, Scott E.; Betts, Michael R.] Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [D'Andrea, Kurt] Univ Penn, Div Translat Med & Human Genet, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Reilly, John P.; Weisman, Ariel R.; Ittner, Caroline A. G.] Univ Penn, Div Pulm Allergy & Crit Care Med, Perelman Sch Med, Ctr Translat Lung Biol,Lung Biol Inst,Dept Med, Philadelphia, PA 19104 USA.
   [Pattekar, Ajinkya] Univ Penn, Div Gastroenterol, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.
   [Chen, Fang; Lacey, Simon F.] Univ Penn, Ctr Cellular Immunotherapies, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Ramage, Holly] Thomas Jefferson Univ, Dept Microbiol, Philadelphia, PA 19107 USA.
   [Apostolidis, Sokratis A.] Univ Penn, Perelman Sch Med, Div Rheumatol, Dept Med, Philadelphia, PA 19104 USA.
   [Huang, Alexander C.] Univ Penn, Perelman Sch Med, Div Hematol & Oncol, Dept Med, Philadelphia, PA 19104 USA.
   [Vella, Laura A.] Childrens Hosp Philadelphia, Div Infect Dis, Dept Pediat, Philadelphia, PA 19104 USA.
   [Meyer, Nuala J.] Univ Penn, Dept Med, Div Pulm & Crit Care Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Betts, MR; Wherry, EJ (corresponding author), Univ Penn, Inst Immunol, Perelman Sch Med, Philadelphia, PA 19104 USA.; Wherry, EJ (corresponding author), Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA 19104 USA.; Wherry, EJ (corresponding author), Univ Penn, Parker Inst Canc Immunotherapy, Perelman Sch Med, Philadelphia, PA 19104 USA.; Betts, MR (corresponding author), Univ Penn, Dept Microbiol, Perelman Sch Med, Philadelphia, PA 19104 USA.; Meyer, NJ (corresponding author), Univ Penn, Dept Med, Div Pulm & Crit Care Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
EM betts@pennmedicine.upenn.edu; nuala.meyer@pennmedicine.upenn.edu;
   wherry@pennmedicine.upenn.edu
RI Wherry, John/ABI-1280-2020; Greenplate, Allison/F-7360-2015
OI Bolton, Marcus/0000-0002-6933-0548; Alanio, Cecile/0000-0003-2785-7445;
   Baxter, Amy/0000-0002-1555-0713; Gouma, Sigrid/0000-0002-7853-8340;
   Shah, Jennifer/0000-0001-9908-9874; Greenplate,
   Allison/0000-0002-2614-3072; Weisman, Ariel/0000-0002-7187-304X; Shilan,
   Jakee/0000-0003-2112-1189; Omran, Dalia/0000-0003-4323-2621; Pampena,
   Maria Betina/0000-0001-6665-4865
FU University of Pennsylvania Institute for Immunology Glick COVID-19
   research award; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [CA234842, AI105343,
   AI082630, HL137006, H137915, CA230157, T32 CA009140]; Allen Institute
   for Immunology; NHLBI StARR [1R38HL143613]; Athersys, Inc.; Biomarck,
   Inc.; Marcus Foundation for Research; Parker Institute for Cancer
   Immunotherapy
FX This work was supported by the University of Pennsylvania Institute for
   Immunology Glick COVID-19 research award (M.R.B.), NIH grants AI105343
   and AI082630 and the Allen Institute for Immunology (E.J.W.), and NIH
   grants HL137006 and H137915 (N.J.M.). A.C.H. was funded by grant
   CA230157 from the NIH. D.M. and J.R.G. were funded by NIH grant T32
   CA009140. Z.C. was funded by NIH grant CA234842. D.A.O. was funded by
   NHLBI StARR: 1R38HL143613. N.J.M. reports funding to her institution
   from Athersys, Inc., Biomarck, Inc., and the Marcus Foundation for
   Research. J.R.G. is a Cancer Research Institute-Mark Foundation Fellow.
   J.R.G., J.E.W., C.A., A.C.H., and E.J.W. are supported by the Parker
   Institute for Cancer Immunotherapy, which supports the Cancer Immunology
   program at the University of Pennsylvania.
CR Adams E.R., 2020, EVALUATION ANTIBODY, DOI [10.1101/2020.04.15.20066407, DOI 10.1101/2020.04.15.20066407]
   Agrati C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.55
   Akondy RS, 2017, NATURE, V552, P362, DOI 10.1038/nature24633
   Blanchard-Rohner G, 2009, BLOOD, V114, P4998, DOI 10.1182/blood-2009-03-211052
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Braun J., 2020, PRESENCE SARS COV 2, DOI [10.1101/2020.04.17.20061440, 10.1101/2020.04.17.20061440., DOI 10.1101/2020.04.17.20061440]
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Flannery D. D., 2020, RES SQUARE, DOI [10.21203/rs.3.rs-27402/v1, DOI 10.21203/RS.3.RS-27402/V1]
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Greenplate AR, 2019, CANCER IMMUNOL RES, V7, P86, DOI 10.1158/2326-6066.CIR-17-0692
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Guo C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17834-w
   Gupta PK, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005177
   Herati R. S., 2019, VACCINE INDUCED ICOS
   Herati RS, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aag2152
   Herati RS, 2014, J IMMUNOL, V193, P3528, DOI 10.4049/jimmunol.1302503
   Huang AC, 2017, NATURE, V545, P60, DOI 10.1038/nature22079
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   HUIZINGA JD, 2020, GENES DIS, DOI DOI 10.1016/J.GENDIS.2020.03.008
   Iype E, 2020, UNDERSTANDING ASYMME, V2004, DOI [10.1101/2020.04.21.20073791, DOI 10.1101/2020.04.21.20073791]
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Kotecha N, 2010, CURR PROTOC CYTOM, V53, DOI DOI 10.1002/0471142956.CY1017S53
   Kuri-Cervantes L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd7114
   Lagunas-Rangel FA, 2020, J MED VIROL, V92, P1733, DOI 10.1002/jmv.25819
   Laing AG, 2020, CONSENSUS COVID 19 I, DOI DOI 10.1101/2020.06.08.20125112
   Lee FEH, 2011, J IMMUNOL, V186, P5514, DOI 10.4049/jimmunol.1002932
   Lei Shaoqing, 2020, EClinicalMedicine, V21, P100331, DOI 10.1016/j.eclinm.2020.100331
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Ma H, 2020, COVID 19 DIAGNOSIS S, DOI [10.1101/2 020.04.17.20064907, DOI 10.1101/2020.04.17.20064907]
   McElroy AK, 2015, P NATL ACAD SCI USA, V112, P4719, DOI 10.1073/pnas.1502619112
   McLane LM, 2019, ANNU REV IMMUNOL, V37, P457, DOI 10.1146/annurev-immunol-041015-055318
   Miller JD, 2008, IMMUNITY, V28, P710, DOI 10.1016/j.immuni.2008.02.020
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Ndhlovu ZM, 2015, IMMUNITY, V43, P591, DOI 10.1016/j.immuni.2015.08.012
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Orlova DY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151859
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Reed DS, 2004, VIRAL IMMUNOL, V17, P390, DOI 10.1089/vim.2004.17.390
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625
   Weiskopf D, 2020, PHENOTYPE SARS COV 2, DOI [10.1101/2020.04.11.20062349, DOI 10.1101/2020.04.11.20062349]
   Wen W, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0168-9
   Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612
   Wrammert J, 2012, J VIROL, V86, P2911, DOI 10.1128/JVI.06075-11
   Wu F., 2020, NEUTRALIZING ANTIBOD, DOI [10.2139/ssrn.3566211, DOI 10.2139/SSRN.3566211]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang Y., 2020, EXUBERANT ELEVATION, DOI [10.1101/2020.03.02.20029975, DOI 10.1101/2020.03.02.20029975]
   Zhang B., 2020, VIEW ORCID PROFILE J, DOI [10.1101/2020.02.26.20028191, DOI 10.1101/2020.02.26.20028191]
   Zhao QW, 2020, INT J INFECT DIS, V96, P131, DOI 10.1016/j.ijid.2020.04.086
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zhou Y, 2020, BIORXIV, DOI [10.1101/2020.02.12.945576, DOI 10.1101/2020.02.12.945576]
NR 61
TC 56
Z9 54
U1 17
U2 17
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD SEP 4
PY 2020
VL 369
IS 6508
SI SI
BP 1209
EP +
AR eabc8511
DI 10.1126/science.abc8511
PG 42
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NL6LT
UT WOS:000567525400046
PM 32669297
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Thoms, M
   Buschauer, R
   Ameismeier, M
   Koepke, L
   Denk, T
   Hirschenberger, M
   Kratzat, H
   Hayn, M
   Mackens-Kiani, T
   Cheng, JD
   Straub, JH
   Sturzel, CM
   Frohlich, T
   Berninghausen, O
   Becker, T
   Kirchhoff, F
   Sparrer, KMJ
   Beckmann, R
AF Thoms, Matthias
   Buschauer, Robert
   Ameismeier, Michael
   Koepke, Lennart
   Denk, Timo
   Hirschenberger, Maximilian
   Kratzat, Hanna
   Hayn, Manuel
   Mackens-Kiani, Timur
   Cheng, Jingdong
   Straub, Jan H.
   Sturzel, Christina M.
   Frohlich, Thomas
   Berninghausen, Otto
   Becker, Thomas
   Kirchhoff, Frank
   Sparrer, Konstantin M. J.
   Beckmann, Roland
TI Structural basis for translational shutdown and immune evasion by the
   Nsp1 protein of SARS-CoV-2
SO SCIENCE
LA English
DT Article
ID HOST GENE-EXPRESSION; CORONAVIRUS; INTERFERON; SARS; ALPHACORONAVIRUS;
   ACTIVATION; CELLS
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the current coronavirus disease 2019 (COVID-19) pandemic. A major virulence factor of SARS-CoVs is the nonstructural protein 1 (Nsp1), which suppresses host gene expression by ribosome association. Here, we show that Nsp1 from SARS-CoV-2 binds to the 40S ribosomal subunit, resulting in shutdown of messenger RNA (mRNA) translation both in vitro and in cells. Structural analysis by cryo-electron microscopy of in vitro-reconstituted Nsp1-40S and various native Nsp1-40S and -80S complexes revealed that the Nsp1 C terminus binds to and obstructs the mRNA entry tunnel. Thereby, Nsp1 effectively blocks retinoic acid-inducible gene I-dependent innate immune responses that would otherwise facilitate clearance of the infection. Thus, the structural characterization of the inhibitory mechanism of Nsp1 may aid structure-based drug design against SARS-CoV-2.
C1 [Thoms, Matthias; Buschauer, Robert; Ameismeier, Michael; Denk, Timo; Kratzat, Hanna; Mackens-Kiani, Timur; Cheng, Jingdong; Berninghausen, Otto; Becker, Thomas; Beckmann, Roland] Univ Munich, Gene Ctr Munich, Dept Biochem, Munich, Germany.
   [Koepke, Lennart; Hirschenberger, Maximilian; Hayn, Manuel; Straub, Jan H.; Sturzel, Christina M.; Kirchhoff, Frank; Sparrer, Konstantin M. J.] Ulm Univ, Inst Mol Virol, Med Ctr, Ulm, Germany.
   [Frohlich, Thomas] Univ Munich, Lab Funct Genome Anal, Munich, Germany.
RP Beckmann, R (corresponding author), Univ Munich, Gene Ctr Munich, Dept Biochem, Munich, Germany.; Sparrer, KMJ (corresponding author), Ulm Univ, Inst Mol Virol, Med Ctr, Ulm, Germany.
EM konstantin.sparrer@uni-ulm.de; beckmann@genzentrum.lmu.de
RI Frohlich, Thomas/ABA-3627-2020
OI Koepke, Lennart/0000-0001-9788-1972; Denk, Timo/0000-0002-0761-3294;
   Frohlich, Thomas/0000-0002-4709-3211; Mackens-Kiani,
   Timur/0000-0003-0385-5875
FU Boehringer Ingelheim FondsBoehringer Ingelheim; DFGGerman Research
   Foundation (DFG) [SFB/TRR-174, BE1814/15-1, BE1814/1-1, CRC-1279,
   SPP-1923, SP1600/4-1, RestrictSARS-CoV2]; BMBFFederal Ministry of
   Education & Research (BMBF) [CRC-1279, SPP-1923, RestrictSARS-CoV2];
   University Ulm Medical Center [L.SBN.0150]
FX This study was supported by a Ph.D. fellowship by Boehringer Ingelheim
   Fonds to R.Bu., grants by the DFG to R.Be. (SFB/TRR-174, BE1814/15-1,
   BE1814/1-1), grants by the DFG to K.M.J.S. (CRC-1279, SPP-1923,
   SP1600/4-1), and grants by the DFG and BMBF to F.K. (CRC-1279, SPP-1923,
   RestrictSARS-CoV2), as well as intramural funding by University Ulm
   Medical Center (L.SBN.0150) to K.M.J.S.
CR Almeida MS, 2007, J VIROL, V81, P3151, DOI 10.1128/JVI.01939-06
   Ameismeier M, 2018, NATURE, V558, P249, DOI 10.1038/s41586-018-0193-0
   Becker T, 2012, NATURE, V482, P501, DOI 10.1038/nature10829
   Bhaskar V, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.03.037
   Brown A, 2015, NATURE, V524, P493, DOI 10.1038/nature14896
   Brzozka K, 2005, J VIROL, V79, P7673, DOI 10.1128/JVI.79.12.7673-7681.2005
   Burnley T, 2017, ACTA CRYSTALLOGR D, V73, P469, DOI 10.1107/S2059798317007859
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   des Georges A, 2015, NATURE, V525, P491, DOI 10.1038/nature14891
   Devaux P, 2007, VIROLOGY, V360, P72, DOI 10.1016/j.virol.2006.09.049
   Di Rienzo M, 2019, AUTOPHAGY, V15, P1674, DOI 10.1080/15548627.2019.1635385
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235
   Hashem Y, 2013, CELL, V153, P1108, DOI 10.1016/j.cell.2013.04.036
   Heuer A, 2017, ELIFE, V6, DOI 10.7554/eLife.30189
   Hu Y, 2017, J VIROL, V91, DOI 10.1128/JVI.02143-16
   Huang C, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002433
   Huang C, 2011, J VIROL, V85, P638, DOI 10.1128/JVI.01806-10
   Jauregui AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062416
   Kamitani W, 2009, NAT STRUCT MOL BIOL, V16, P1134, DOI 10.1038/nsmb.1680
   Kratzat H., 2020, BIORXIV, DOI [10.1101/2020.07.09.194902, DOI 10.1101/2020.07.09.194902]
   Lei L., 2013, PLOS ONE, V8
   Lim Yvonne Xinyi, 2016, Diseases, V4, DOI 10.3390/diseases4030026
   Lin L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061166
   Llacer JL, 2015, MOL CELL, V59, P399, DOI 10.1016/j.molcel.2015.06.033
   Lokugamage KG, 2012, J VIROL, V86, P13598, DOI 10.1128/JVI.01958-12
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Matheisl S, 2015, NUCLEIC ACIDS RES, V43, P8615, DOI 10.1093/nar/gkv909
   Miyazawa N, 2014, GENES CELLS, V19, P273, DOI 10.1111/gtc.12129
   Narayananj K, 2008, J VIROL, V82, P4471, DOI 10.1128/JVI.02472-07
   Passmore LA, 2007, MOL CELL, V26, P41, DOI 10.1016/j.molcel.2007.03.018
   Preis A, 2014, CELL REP, V8, P59, DOI 10.1016/j.celrep.2014.04.058
   Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]
   Robertson MP, 2005, PLOS BIOL, V3, P86, DOI 10.1371/journal.pbio.0030005
   Rohou A, 2015, J STRUCT BIOL, V192, P216, DOI 10.1016/j.jsb.2015.08.008
   Sarkar S, 2013, COMMUN COMPUT PHYS, V13, P269, DOI 10.4208/cicp.300611.201011s
   Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2
   Sharma A, 2010, METHODS MOL BIOL, V619, P339, DOI 10.1007/978-1-60327-412-8_20
   Sidrauski C, 2015, ELIFE, V4, DOI 10.7554/eLife.05033
   Sparrer KMJ, 2017, NAT MICROBIOL, V2, P1543, DOI 10.1038/s41564-017-0017-2
   Sparrer KMJ, 2015, CURR OPIN MICROBIOL, V26, P1, DOI 10.1016/j.mib.2015.03.001
   Sparrer KMJ, 2012, J VIROL, V86, P796, DOI 10.1128/JVI.05899-11
   Straehle L, 2007, J VIROL, V81, P12227, DOI 10.1128/JVI.01300-07
   Tanaka T, 2012, J VIROL, V86, P11128, DOI 10.1128/JVI.01700-12
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Tohya Y, 2009, J VIROL, V83, P5282, DOI 10.1128/JVI.02485-08
   van der Hoek L, 2007, ANTIVIR THER, V12, P651
   van der Hoek L, 2006, FEMS MICROBIOL REV, V30, P760, DOI 10.1111/j.1574-6976.2006.00032.x
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wathelet MG, 2007, J VIROL, V81, P11620, DOI 10.1128/JVI.00702-07
   Weiss SR, 2005, MICROBIOL MOL BIOL R, V69, P635, DOI 10.1128/MMBR.69.4.635-664.2005
   Wells J. N., 2020, BIORXIV, DOI [10.1101/2020.02.12.944066, DOI 10.1101/2020.02.12.944066]
   Woo PCY, 2012, J VIROL, V86, P3995, DOI 10.1128/JVI.06540-11
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yan C, 2019, J VIROL, V93, DOI 10.1128/JVI.00769-19
   Yang CH, 2019, J VIROL, V93, DOI 10.1128/JVI.00183-19
   Zhang K, 2016, J STRUCT BIOL, V193, P1, DOI 10.1016/j.jsb.2015.11.003
   Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zivanov J, 2020, IUCRJ, V7, P253, DOI 10.1107/S2052252520000081
   Zivanov J, 2018, ELIFE, V7, DOI 10.7554/eLife.42166
   Zong WH, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2004506
   ZONG WH, 2018, PLOS BIOL, V16, DOI DOI 10.1371/JOURNAL.PBIO.2005903
NR 65
TC 25
Z9 24
U1 8
U2 8
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD SEP 4
PY 2020
VL 369
IS 6508
SI SI
BP 1249
EP +
DI 10.1126/science.abc8665
PG 31
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NL6LT
UT WOS:000567525400054
PM 32680882
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Li, Y
   Yang, XN
   Wang, N
   Wang, HY
   Yin, B
   Yang, XP
   Jiang, WQ
AF Li, Yue
   Yang, Xinai
   Wang, Na
   Wang, Haiyan
   Yin, Bin
   Yang, Xiaoping
   Jiang, Wenqing
TI GC usage of SARS-CoV-2 genes might adapt to the environment of human
   lung expressed genes
SO MOLECULAR GENETICS AND GENOMICS
LA English
DT Article
DE SARS-CoV-2; GC content; Lung expressed genes; Adaptation
ID CORONAVIRUS OUTBREAK; GLOBAL HEALTH; CODON USAGE
AB Understanding how SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) efficiently reproduces itself by taking resources from the human host could facilitate the development of drugs against the virus. SARS-CoV-2 translates its own proteins by using the host tRNAs, so that its GC or codon usage should fit that of the host cells. It is necessary to study both the virus and human genomes in the light of evolution and adaptation. The SARS-CoV-2 virus has significantly lower GC content and GC3 as compared to human. However, when we selected a set of human genes that have similar GC properties to SARS-CoV-2, we found that these genes were enriched in particular pathways. Moreover, these human genes have the codon composition perfectly correlated with the SARS-CoV-2, and were extraordinarily highly expressed in human lung tissues, demonstrating that the SARS-CoV-2 genes have similar GC usage as compared to the lung expressed human genes. RSCU (relative synonymous codon usage) and CAI (codon adaptation index) profiles further support the matching between SARS-CoV-2 and lungs. Our study indicates that SARS-CoV-2 might have adapted to the human lung environment by observing the high correlation between GC usage of SARS-CoV-2 and human lung genes, which suggests the GC content of SARS-CoV-2 is optimized to take advantage of human lung tissues.
C1 [Li, Yue; Yang, Xinai; Wang, Na; Wang, Haiyan; Yin, Bin; Yang, Xiaoping; Jiang, Wenqing] Qingdao Haici Hosp, Dept Resp Dis, Qingdao, Peoples R China.
RP Jiang, WQ (corresponding author), Qingdao Haici Hosp, Dept Resp Dis, Qingdao, Peoples R China.
EM qdhospit87@163.com
FU Qingdao Haici Medical Group [2019-WJZD051]
FX This study was funded by Qingdao Haici Medical Group (Grant number
   2019-WJZD051).
CR Argueso CT, 2019, PLANT DIRECT, V3, DOI 10.1002/pld3.133
   Berkhout B, 2015, VIRUS RES, V202, P41, DOI 10.1016/j.virusres.2014.11.031
   Carpenter JA, 2009, BMC GENET, V10, DOI 10.1186/1471-2156-10-75
   Cowling BJ, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.6.2000110
   Edelstein M, 2015, FUTURE VIROL, V10, P497, DOI [10.2217/FVL.15.20, 10.2217/fvl.15.20]
   Feng C, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-732
   Fung TS, 2018, FUTURE VIROL, V13, P405, DOI 10.2217/fvl-2018-0008
   Harrison RJ, 2011, MOL BIOL EVOL, V28, P117, DOI 10.1093/molbev/msq191
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jiao XL, 2012, BIOINFORMATICS, V28, P1805, DOI 10.1093/bioinformatics/bts251
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li Y, 2020, FUTURE VIROL, V15, P341, DOI 10.2217/fvl-2020-0066
   Plotkin JB, 2011, NAT REV GENET, V12, P32, DOI 10.1038/nrg2899
   SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281
   Sheahan TP, 2018, FUTURE VIROL, V13, P143, DOI 10.2217/fvl-2017-0143
   Taghinezhad S, 2017, FUTURE VIROL, V12, P499, DOI 10.2217/fvl-2017-0032
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang HC, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-S1-S6
   Wei L, 2020, EVOL BIOINFORM, V16, DOI 10.1177/1176934320916794
   Zhao ZM, 2004, BMC EVOL BIOL, V4, DOI 10.1186/1471-2148-4-21
NR 20
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1617-4615
EI 1617-4623
J9 MOL GENET GENOMICS
JI Mol. Genet. Genomics
PD NOV
PY 2020
VL 295
IS 6
BP 1537
EP 1546
DI 10.1007/s00438-020-01719-0
EA SEP 2020
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA NV4HG
UT WOS:000566044800001
PM 32888056
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Peng, YC
   Mentzer, AJ
   Liu, GH
   Yao, X
   Yin, ZX
   Dong, DN
   Dejnirattisai, W
   Rostron, T
   Supasa, P
   Liu, C
   Lopez-Camacho, C
   Slon-Campos, J
   Zhao, YG
   Stuart, DI
   Paesen, GC
   Grimes, JM
   Antson, AA
   Bayfield, OW
   Hawkins, DEDP
   Ker, DS
   Wang, BB
   Turtle, L
   Subramaniam, K
   Thomson, P
   Zhang, P
   Dold, C
   Ratcliff, J
   Simmonds, P
   de Silva, T
   Sopp, P
   Wellington, D
   Rajapaksa, U
   Chen, YL
   Salio, M
   Napolitani, G
   Paes, W
   Borrow, P
   Kessler, BM
   Fry, JW
   Schwabe, NF
   Semple, MG
   Baillie, JK
   Moore, SC
   Openshaw, PJM
   Ansari, MA
   Dunachie, S
   Barnes, E
   Frater, J
   Kerr, G
   Goulder, P
   Lockett, T
   Levin, R
   Zhang, YH
   Jing, RH
   Ho, LP
   Cornall, RJ
   Conlon, CP
   Klenerman, P
   Screaton, GR
   Mongkolsapaya, J
   McMichael, A
   Knight, JC
   Ogg, G
   Dong, T
AF Peng, Yanchun
   Mentzer, Alexander J.
   Liu, Guihai
   Yao, Xuan
   Yin, Zixi
   Dong, Danning
   Dejnirattisai, Wanwisa
   Rostron, Timothy
   Supasa, Piyada
   Liu, Chang
   Lopez-Camacho, Cesar
   Slon-Campos, Jose
   Zhao, Yuguang
   Stuart, David, I
   Paesen, Guido C.
   Grimes, Jonathan M.
   Antson, Alfred A.
   Bayfield, Oliver W.
   Hawkins, Dorothy E. D. P.
   Ker, De-Sheng
   Wang, Beibei
   Turtle, Lance
   Subramaniam, Krishanthi
   Thomson, Paul
   Zhang, Ping
   Dold, Christina
   Ratcliff, Jeremy
   Simmonds, Peter
   de Silva, Thushan
   Sopp, Paul
   Wellington, Dannielle
   Rajapaksa, Ushani
   Chen, Yi-Ling
   Salio, Mariolina
   Napolitani, Giorgio
   Paes, Wayne
   Borrow, Persephone
   Kessler, Benedikt M.
   Fry, Jeremy W.
   Schwabe, Nikolai F.
   Semple, Malcolm G.
   Baillie, J. Kenneth
   Moore, Shona C.
   Openshaw, Peter J. M.
   Ansari, M. Azim
   Dunachie, Susanna
   Barnes, Eleanor
   Frater, John
   Kerr, Georgina
   Goulder, Philip
   Lockett, Teresa
   Levin, Robert
   Zhang, Yonghong
   Jing, Ronghua
   Ho, Ling-Pei
   Cornall, Richard J.
   Conlon, Christopher P.
   Klenerman, Paul
   Screaton, Gavin R.
   Mongkolsapaya, Juthathip
   McMichael, Andrew
   Knight, Julian C.
   Ogg, Graham
   Dong, Tao
CA Oxford Immunology Network Covid-19
   ISARIC4C Investigators
TI Broad and strong memory CD4(+)and CD8(+)T cells induced by SARS-CoV-2 in
   UK convalescent individuals following COVID-19
SO NATURE IMMUNOLOGY
LA English
DT Article
ID T-CELLS; RESPONSES; CORONAVIRUSES; REPLICATION; PROTECTION; PHENOTYPE;
   H5N1
AB The development of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines and therapeutics will depend on understanding viral immunity. We studied T cell memory in 42 patients following recovery from COVID-19 (28 with mild disease and 14 with severe disease) and 16 unexposed donors, using interferon-gamma-based assays with peptides spanning SARS-CoV-2 except ORF1. The breadth and magnitude of T cell responses were significantly higher in severe as compared with mild cases. Total and spike-specific T cell responses correlated with spike-specific antibody responses. We identified 41 peptides containing CD4(+)and/or CD8(+)epitopes, including six immunodominant regions. Six optimized CD8(+)epitopes were defined, with peptide-MHC pentamer-positive cells displaying the central and effector memory phenotype. In mild cases, higher proportions of SARS-CoV-2-specific CD8(+)T cells were observed. The identification of T cell responses associated with milder disease will support an understanding of protective immunity and highlights the potential of including non-spike proteins within future COVID-19 vaccine design.
   Questions have arisen as to whether patients with severe COVID-19 disease can generate a T cell response against SARS-CoV-2. Tao Dong and colleagues report that convalescent patients with COVID-19 harbor functional memory CD4(+)and CD8(+)T cells that recognize multiple epitopes that span the viral proteome. CD4(+)T cells predominated the memory response in patients with severe disease, whereas higher proportions of CD8(+)T cells were found in patients with mild disease.
C1 [Peng, Yanchun; Yao, Xuan; Yin, Zixi; Wellington, Dannielle; Chen, Yi-Ling; Salio, Mariolina; Napolitani, Giorgio; Ho, Ling-Pei; Cornall, Richard J.; Ogg, Graham; Dong, Tao] Univ Oxford, MRC Weatherall Inst Mol Med, Radcliffe Dept Med, MRC Human Immunol Unit, Oxford, England.
   [Peng, Yanchun; Liu, Guihai; Yao, Xuan; Yin, Zixi; Dong, Danning; Liu, Chang; Stuart, David, I; Wang, Beibei; Wellington, Dannielle; Rajapaksa, Ushani; Kessler, Benedikt M.; Zhang, Yonghong; Ho, Ling-Pei; Conlon, Christopher P.; Mongkolsapaya, Juthathip; McMichael, Andrew; Knight, Julian C.; Ogg, Graham; Dong, Tao] Univ Oxford, Oxford Inst COI, Chinese Acad Med Sci CAMS, Oxford, England.
   [Mentzer, Alexander J.; Lopez-Camacho, Cesar; Stuart, David, I; Paesen, Guido C.; Grimes, Jonathan M.; Knight, Julian C.] Univ Oxford, Wellcome Ctr Human Genet, Oxford, England.
   [Mentzer, Alexander J.; Liu, Guihai; Yao, Xuan; Dong, Danning; Dejnirattisai, Wanwisa; Supasa, Piyada; Liu, Chang; Lopez-Camacho, Cesar; Slon-Campos, Jose; Zhao, Yuguang; Stuart, David, I; Grimes, Jonathan M.; Wang, Beibei; Zhang, Ping; Ratcliff, Jeremy; Simmonds, Peter; Rajapaksa, Ushani; Paes, Wayne; Borrow, Persephone; Kessler, Benedikt M.; Ansari, M. Azim; Dunachie, Susanna; Barnes, Eleanor; Frater, John; Kerr, Georgina; Goulder, Philip; Ho, Ling-Pei; Cornall, Richard J.; Conlon, Christopher P.; Klenerman, Paul; Screaton, Gavin R.; Mongkolsapaya, Juthathip; McMichael, Andrew; Knight, Julian C.; Dong, Tao] Univ Oxford, Nuffield Dept Med, Oxford, England.
   [Mentzer, Alexander J.; Dunachie, Susanna; Barnes, Eleanor; Frater, John; Goulder, Philip; Lockett, Teresa; Cornall, Richard J.; Conlon, Christopher P.; Klenerman, Paul; Screaton, Gavin R.; Knight, Julian C.; Ogg, Graham] Oxford Univ Hosp NHS Fdn Trust, Oxford, England.
   [Liu, Guihai; Zhang, Yonghong; Jing, Ronghua] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China.
   [Dong, Danning] Xinjiang Med Univ, Xinjiang Tumor Hosp, CAMS Key Lab Tumor Immunol & Radiat Therapy, Urumqi, Xinjiang, Peoples R China.
   [Rostron, Timothy; Sopp, Paul] Univ Oxford, Weatherall Inst Mol Med, Sequencing & Flow Cytometry Facil, Oxford, England.
   [Stuart, David, I; Grimes, Jonathan M.] Diamond Light Source, Didcot, Oxon, England.
   [Antson, Alfred A.; Bayfield, Oliver W.; Hawkins, Dorothy E. D. P.; Ker, De-Sheng] Univ York, Dept Chem, York Struct Biol Lab, York, N Yorkshire, England.
   [Turtle, Lance] Liverpool Univ Hosp NHS Fdn Trust, Trop & Infect Dis Unit, Liverpool, Merseyside, England.
   [Turtle, Lance; Subramaniam, Krishanthi; Thomson, Paul; Semple, Malcolm G.; Moore, Shona C.] Univ Liverpool, Inst Infect Vet & Ecol Sci, NIHR Hlth Protect Res Unit Emerging & Zoonot Infe, Liverpool, Merseyside, England.
   [Dold, Christina] Univ Oxford, Dept Paediat, Oxford Vaccine Grp, Oxford, England.
   [Dold, Christina] Univ Oxford, NIHR Oxford Biomed Res Ctr, Ctr Clin Vaccinol & Trop Med, Oxford, England.
   [de Silva, Thushan] Univ Sheffield, Dept Infect Immun & Cardiovasc Dis, Florey Inst Host Pathogen Interact, Sheffield, S Yorkshire, England.
   [Fry, Jeremy W.; Schwabe, Nikolai F.] ProImmune, Oxford, England.
   [Semple, Malcolm G.] Alder Hey Childrens Hosp, Resp Med, Inst Pk, Liverpool, Merseyside, England.
   [Baillie, J. Kenneth] Univ Edinburgh, Anaesthesia Crit Care & Pain Med Div Hlth Sci, Edinburgh, Midlothian, Scotland.
   [Openshaw, Peter J. M.] Imperial Coll London, Fac Med, Natl Heart & Lung Inst, London, England.
   [Barnes, Eleanor; Ho, Ling-Pei; Klenerman, Paul; Screaton, Gavin R.; Mongkolsapaya, Juthathip; Ogg, Graham] NIHR Oxford Biomed Res Ctr, Oxford, England.
   [Levin, Robert] Worthing Dist Hosp, Worthing, England.
   [Mongkolsapaya, Juthathip] Mahidol Univ, Siriraj Hosp, Fac Med, Off Res & Dev,Dengue Hemorrhag Fever Res Unit, Bangkok, Thailand.
RP Dong, T (corresponding author), Univ Oxford, MRC Weatherall Inst Mol Med, Radcliffe Dept Med, MRC Human Immunol Unit, Oxford, England.; Dong, T (corresponding author), Univ Oxford, Oxford Inst COI, Chinese Acad Med Sci CAMS, Oxford, England.; Dong, T (corresponding author), Univ Oxford, Nuffield Dept Med, Oxford, England.
EM tao.dong@imm.ox.ac.uk
RI Semple, Malcolm/A-8790-2008
OI Semple, Malcolm/0000-0001-9700-0418; Mentzer,
   Alexander/0000-0002-4502-2209; Moore, Shona/0000-0001-8610-2806; Slon
   Campos, Jose Luis/0000-0002-0012-5247; Barnes,
   Eleanor/0000-0002-0860-0831; Ansari, M. Azim/0000-0003-2790-8353;
   McDonald, Sarah/0000-0003-2776-7415; Bayfield, Oliver
   William/0000-0003-1421-7780
FU Oxford Immunology Network COVID-19 Response T Cell Consortium
   (Supplementary Table 4); UK Medical Research CouncilMedical Research
   Council UK (MRC); Chinese Academy of Medical Sciences (CAMS) Innovation
   Fund for Medical Sciences (CIFMS), China [2018-I2M-2-002]; National
   Institutes of Health, National Key R&D Program of ChinaUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [2020YFE0202400]; China Scholarship CouncilChina Scholarship
   Council; National Institute for Health Research (NIHR)National Institute
   for Health Research (NIHR) [CO-CIN-01]; Medical Research CouncilMedical
   Research Council UK (MRC) [MC_PC_19059]; Wellcome TrustWellcome Trust;
   Department for International Development [215091/Z/18/Z]; Bill and
   Melinda Gates FoundationBill & Melinda Gates Foundation [OPP1209135];
   NIHR Oxford Biomedical Research CentreNational Institute for Health
   Research (NIHR); Health Protection Research Unit in Respiratory
   Infections [NIHR200927/WHRG_P82523]; NIHR Senior Investigator Award
   [NIHR201385/WHRR P84026]; Imperial College Biomedical Research Centre
   [IS-BRC-1215-20013]; National Institute of Allergy and Infectious
   Diseases (Consortium for HIV/AIDS Vaccine Development) [UM1 AI 144371,
   R01 AI 118549]; NIHR Health Protection Research Unit (HPRU) in Emerging
   and Zoonotic Infections at the University of Liverpool [NIHR200907];
   Public Health England (PHE); Schmidt Futures; Liverpool School of
   Tropical Medicine; University of Oxford; Wellcome TrustWellcome Trust
   [205228/Z/16/Z, 110058/Z/15/Z, 206377, 095541/A/11/Z]
FX We are grateful to all of the participants for donating their samples
   and data for these analyses, and to the research teams involved in the
   consenting, recruitment and sampling of these participants. We
   acknowledge the support of the Oxford Immunology Network COVID-19
   Response T Cell Consortium (Supplementary Table 4) and ISARIC4C
   Investigators (Supplementary Table 5). This work is supported by the UK
   Medical Research Council (to T.D., G.O., Y.P., M.S., G.N. and Y.-L.C.);
   Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical
   Sciences (CIFMS), China (grant number 2018-I2M-2-002 to T.D., Y.P.,
   X.Y., G.L., D.D., D.I.S., J.M. and G.R.S.); National Institutes of
   Health, National Key R&D Program of China (2020YFE0202400 to T.D., Y.
   Zhang and R.J.); China Scholarship Council (Z.Y., G.L. and C.L.);
   National Institute for Health Research (NIHR) (award CO-CIN-01 to
   M.G.S.); Medical Research Council (grant MC_PC_19059 to M.G.S.);
   Wellcome Trust and Department for International Development
   (215091/Z/18/Z to M.G.S.); and the Bill and Melinda Gates Foundation
   (OPP1209135 to M.G.S.). The study is also funded by the NIHR Oxford
   Biomedical Research Centre (to L.-P.H., G.O., P.K., E.B. and G.R.S.),
   Senior Investigator Award (to G.O.), Clinical Research Network (to
   G.O.), Schmidt Futures (G.R.S.), Health Protection Research Unit in
   Respiratory Infections (NIHR200927/WHRG_P82523 to P.J.M.O.), NIHR Senior
   Investigator Award (NIHR201385/WHRR P84026 to P.J.M.O.), Imperial
   College Biomedical Research Centre (IS-BRC-1215-20013 to P.J.M.O.) and
   National Institute of Allergy and Infectious Diseases (Consortium for
   HIV/AIDS Vaccine Development UM1 AI 144371 to P.B. and A.M. and R01 AI
   118549 to P.B.). L.T., P.K. and P. Simmonds are supported by the NIHR
   Health Protection Research Unit (HPRU) in Emerging and Zoonotic
   Infections (NIHR200907) at the University of Liverpool in partnership
   with Public Health England (PHE), in collaboration with the Liverpool
   School of Tropical Medicine and University of Oxford. L.T. is based at
   the University of Liverpool. P.K. and P. Simmonds are based at the
   University of Oxford. L.T., T.d.S. and A.A.A. are supported by the
   Wellcome Trust (grant numbers 205228/Z/16/Z to L.T., 110058/Z/15/Z to
   T.d.S. and 206377 to A.A.A.). G.R.S. is supported as a Wellcome Trust
   Senior Investigator (grant 095541/A/11/Z). P.B. and A.M. are Jenner
   Institute investigators. This work uses data provided by patients and
   collected by the NHS as part of their care, and supports the Data Saves
   Lives initiative. The views expressed are those of the authors and not
   necessarily those of the Department of Health and Social Care, DID,
   NIHR, MRC, Wellcome Trust or PHE.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9
   Campion SL, 2014, J EXP MED, V211, P1273, DOI 10.1084/jem.20130555
   de Silva TI, 2013, BLOOD, V121, P4330, DOI 10.1182/blood-2012-12-472787
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Dong T, 2011, BLOOD, V118, P98, DOI 10.1182/blood-2010-06-291963
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Feng Z, 2020, NOVEL SEVERE ACUTE R, DOI [10.1101/2020.03.27.20045427, DOI 10.1101/2020.03.27.20045427]
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hayward AC, 2015, AM J RESP CRIT CARE, V191, P1422, DOI 10.1164/rccm.201411-1988OC
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Le Bert N, 2020, NATURE, DOI 10.1038/s41586-020-2550-z
   Lee LYH, 2008, J CLIN INVEST, V118, P3478, DOI 10.1172/JCI32460
   Li CKF, 2008, J IMMUNOL, V181, P5490, DOI 10.4049/jimmunol.181.8.5490
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Lillie PJ, 2012, CLIN INFECT DIS, V55, P19, DOI 10.1093/cid/cis327
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Ogg GS, 1998, AIDS, V12, P1561, DOI 10.1097/00002030-199812000-00026
   Peng YC, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00287
   Pereira BI, 2020, NAT IMMUNOL, V21, P684, DOI 10.1038/s41590-020-0643-3
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Pizzolla A, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aam6970
   Powell TJ, 2012, J INFECT DIS, V205, P20, DOI 10.1093/infdis/jir689
   Sekine T, 2020, CELL, V183, P158, DOI [10.10160.cell.2020.08.017, 10.1016/j.cell.2020.08.017]
   Sette A, 2020, NAT REV IMMUNOL, V20, P457, DOI 10.1038/s41577-020-0389-z
   Shomuradova A. S., 2020, SARS COV 2 EPITOPES, DOI [10.1101/2020.05.20.20107813, DOI 10.1101/2020.05.20.20107813]
   St John AL, 2019, NAT REV IMMUNOL, V19, P218, DOI 10.1038/s41577-019-0123-x
   Su LF, 2013, IMMUNOL REV, V255, P95, DOI 10.1111/imr.12095
   Turner DL, 2014, MUCOSAL IMMUNOL, V7, P501, DOI 10.1038/mi.2013.67
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yoshizawa A, 2018, EUR J IMMUNOL, V48, P128, DOI 10.1002/eji.201747174
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 37
TC 16
Z9 16
U1 19
U2 19
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1529-2908
EI 1529-2916
J9 NAT IMMUNOL
JI Nat. Immunol.
PD NOV
PY 2020
VL 21
IS 11
BP 1336
EP +
DI 10.1038/s41590-020-0782-6
EA SEP 2020
PG 16
WC Immunology
SC Immunology
GA OD0BT
UT WOS:000566073200001
PM 32887977
DA 2021-01-01
ER

PT J
AU Teh, J
   O'Connor, E
   Coles-Black, J
   Lawrentschuk, N
AF Teh, Jiasian
   O'Connor, Ellen
   Coles-Black, Jasamine
   Lawrentschuk, Nathan
TI Clinical trials in urological oncology: COVID-19 and the potential need
   for a new perspective
SO WORLD JOURNAL OF UROLOGY
LA English
DT Article; Early Access
DE COVID-19; Urologic oncology; Clinical trial
AB The COVID-19 pandemic has led to the suspension, termination or alteration of thousands of clinical trials as the health emergency escalated globally. Whilst the rapid suspension of certain clinical trials was necessary to ensure the safety of high-risk or vulnerable trial participants as well as healthcare workers, the long-term ramifications that this delay will have on the field of urologic oncology is unknown. The COVID-19 pandemic has highlighted the need to plan for and implement new strategies to advance our understanding of unmet areas of need in urologic oncology. The COVID-19 pandemic has led to the suspension, termination or alteration of thousands of clinical trials as the health emergency escalated globally. Whilst the rapid suspension of certain clinical trials was necessary to ensure the safety of high-risk or vulnerable trial participants as well as healthcare workers, the long-term ramifications that this delay will have on the field of urologic oncology is unknown. The COVID-19 pandemic has highlighted the need to plan for and implement new strategies to advance our understanding of unmet areas of need in urologic oncology.
C1 [Teh, Jiasian; O'Connor, Ellen; Lawrentschuk, Nathan] Peter MacCallum Ctr, Div Canc Surg, Melbourne, Vic, Australia.
   [Teh, Jiasian; O'Connor, Ellen; Coles-Black, Jasamine] Univ Melbourne, Austin Hosp, Dept Surg, Melbourne, Vic, Australia.
   [Lawrentschuk, Nathan] Univ Melbourne, Dept Surg, Dept Urol, Melbourne, Vic, Australia.
   [Lawrentschuk, Nathan] Royal Melbourne Hosp, Melbourne, Vic, Australia.
   [Lawrentschuk, Nathan] Epworth Healthcare, EJ Whitten Prostate Canc Res Ctr, Melbourne, Vic, Australia.
RP Teh, J (corresponding author), Peter MacCallum Ctr, Div Canc Surg, Melbourne, Vic, Australia.; Teh, J (corresponding author), Univ Melbourne, Austin Hosp, Dept Surg, Melbourne, Vic, Australia.
EM jiasian@gmail.com
OI Teh, Jiasian/0000-0002-7882-5155
CR Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2
   Chen RC, 2020, CHEST, V158, P97, DOI 10.1016/j.chest.2020.04.010
   Gostin LO, 2020, HASTINGS CENT REP, V50, P8, DOI 10.1002/hast.1090
   Institute NC, CAN GEN ATL PROGR 20
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Parmar MKB, 2008, JNCI-J NATL CANCER I, V100, P1204, DOI 10.1093/jnci/djn267
NR 6
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0724-4983
EI 1433-8726
J9 WORLD J UROL
JI World J. Urol.
DI 10.1007/s00345-020-03416-4
EA SEP 2020
PG 3
WC Urology & Nephrology
SC Urology & Nephrology
GA NJ5CS
UT WOS:000566061600001
PM 32886143
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Gulotta, MR
   Lombino, J
   Perricone, U
   De Simone, G
   Mekni, N
   De Rosa, M
   Diana, P
   Padova, A
AF Gulotta, Maria Rita
   Lombino, Jessica
   Perricone, Ugo
   De Simone, Giada
   Mekni, Nedra
   De Rosa, Maria
   Diana, Patrizia
   Padova, Alessandro
TI Targeting SARS-CoV-2 RBD Interface: a Supervised Computational
   Data-Driven Approach to Identify Potential Modulators
SO CHEMMEDCHEM
LA English
DT Article
DE COVID-19; docking; pharmacophore; molecular dynamics; protein-protein
   interactions
ID CORONAVIRUS SPIKE PROTEIN; RECEPTOR-BINDING DOMAIN; HOT-SPOTS; ACCURATE
   DOCKING; SARS-COV; DETERMINANTS; PREDICTION; GLIDE; MODEL;
   IDENTIFICATION
AB Coronavirus disease 2019 (COVID-19) has spread out as a pandemic threat affecting over 2 million people. The infectious process initiates via binding of SARS-CoV-2 Spike (S) glycoprotein to host angiotensin-converting enzyme 2 (ACE2). The interaction is mediated by the receptor-binding domain (RBD) of S glycoprotein, promoting host receptor recognition and binding to ACE2 peptidase domain (PD), thus representing a promising target for therapeutic intervention. Herein, we present a computational study aimed at identifying small molecules potentially able to target RBD. Although targeting PPI remains a challenge in drug discovery, our investigation highlights that interaction between SARS-CoV-2 RBD and ACE2 PD might be prone to small molecule modulation, due to the hydrophilic nature of the bi-molecular recognition process and the presence of druggable hot spots. The fundamental objective is to identify, and provide to the international scientific community, hit molecules potentially suitable to enter the drug discovery process, preclinical validation and development.
C1 [Gulotta, Maria Rita; Lombino, Jessica; Perricone, Ugo; De Simone, Giada; Mekni, Nedra; De Rosa, Maria; Padova, Alessandro] Ri MED Fdn, Mol Informat Unit, Via Bandiera 11, I-90133 Palermo, Italy.
   [Gulotta, Maria Rita; Lombino, Jessica; Diana, Patrizia] Univ Palermo, Dept STEBICEF, Viale Sci,Bldg 16, I-90128 Palermo, Italy.
RP Gulotta, MR; Perricone, U (corresponding author), Ri MED Fdn, Mol Informat Unit, Via Bandiera 11, I-90133 Palermo, Italy.; Gulotta, MR (corresponding author), Univ Palermo, Dept STEBICEF, Viale Sci,Bldg 16, I-90128 Palermo, Italy.
EM mrgulotta@fondazionerimed.com; uperricone@fondazionerimed.com
OI Gulotta, Maria Rita/0000-0001-5032-4888
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   [Anonymous], 2020, MOL DYNAMICS SIMULAT
   Beard H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082849
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Bettinetti L., 2013, DISRUPT PROTEIN PROT, P1
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Bowers K., 2006, P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   Chanphai P, 2015, EUR POLYM J, V67, P224, DOI 10.1016/j.eurpolymj.2015.03.069
   Corti D, 2015, P NATL ACAD SCI USA, V112, P10473, DOI 10.1073/pnas.1510199112
   Cukuroglu E, 2014, PROG BIOPHYS MOL BIO, V116, P165, DOI 10.1016/j.pbiomolbio.2014.06.003
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Ekins S, 2020, DRUG DISCOV TODAY, V25, P928, DOI 10.1016/j.drudis.2020.03.019
   Elshabrawy HA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050366
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gallagher TM, 2001, VIROLOGY, V279, P371, DOI 10.1006/viro.2000.0757
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Greenwood JR, 2010, J COMPUT AID MOL DES, V24, P591, DOI 10.1007/s10822-010-9349-1
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Heald-Sargent T, 2012, VIRUSES-BASEL, V4, P557, DOI 10.3390/v4040557
   Hu B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006698
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kortemme T, 2002, P NATL ACAD SCI USA, V99, P14116, DOI 10.1073/pnas.202485799
   Kortemme T., 2004, SCI STKE, P12, DOI DOI 10.1126/STKE.2192004PL2
   Krovat EM, 2005, J CHEM INF MODEL, V45, P146, DOI 10.1021/ci049778k
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li JW, 2014, INT J GRID HIGH PERF, V6, P72, DOI 10.4018/ijghpc.2014100105
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Li Y, 2015, CELL RES, V25, P1237, DOI 10.1038/cr.2015.113
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Mark P, 2001, J PHYS CHEM A, V105, P9954, DOI 10.1021/jp003020w
   Masters SL, 2010, NAT IMMUNOL, V11, P897, DOI 10.1038/ni.1935
   Mekni N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20204974
   Metz A, 2012, CURR PHARM DESIGN, V18, P4630, DOI 10.2174/138161212802651553
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Mustafa S, 2018, J INFECT PUBLIC HEAL, V11, P9, DOI 10.1016/j.jiph.2017.08.009
   NOREL R, 1994, BIOPOLYMERS, V34, P933, DOI 10.1002/bip.360340711
   Olsson MHM, 2011, J CHEM THEORY COMPUT, V7, P525, DOI 10.1021/ct100578z
   Pandey P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1796811
   Perricone U, 2018, MEDCHEMCOMM, V9, P920, DOI 10.1039/c8md00166a
   Poli G, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00229
   Prabakaran P, 2004, BIOCHEM BIOPH RES CO, V314, P235, DOI 10.1016/j.bbrc.2003.12.081
   Sabir JSM, 2016, SCIENCE, V351, P81, DOI 10.1126/science.aac8608
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822-007-9133-z
   Steindl TM, 2007, J CHEM INF MODEL, V47, P563, DOI 10.1021/ci600321m
   Steindl TM, 2006, J COMPUT AID MOL DES, V20, P703, DOI 10.1007/s10822-006-9066-y
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Sushko I, 2012, J CHEM INF MODEL, V52, P2310, DOI 10.1021/ci300245q
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Traggiai E, 2004, NAT MED, V10, P871, DOI 10.1038/nm1080
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293
   Wan Y, 2020, J COASTAL RES, P1, DOI 10.2112/SI99-001.1
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Wolber G, 2005, J CHEM INF MODEL, V45, P160, DOI 10.1021/ci049885e
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu KL, 2011, J VIROL, V85, P5331, DOI 10.1128/JVI.02274-10
   Wu Renyi, 2020, Curr Pharmacol Rep, P1, DOI 10.1007/s40495-020-00216-7
   Xiong X., 2018, J VIROL, V92, P1
   Xu D., 2012, PROTEINS STRUCT FUNC, Vn/a-n/a
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Yan R., 2020, 20200217951848 BIORI
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang XL, 2016, J VIROL, V90, P3253, DOI 10.1128/JVI.02582-15
   Ying TL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9223
   YU X, 2015, SCI REP, V5, P1, DOI DOI 10.1038/SREP11533
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zerbe BS, 2012, J CHEM INF MODEL, V52, P2236, DOI [10.1021/cI300175u, 10.1021/ci300175u]
   Zhou GY, 2020, INT J BIOL SCI, V16, P1718, DOI 10.7150/ijbs.45123
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhou YC, 2012, EXPERT REV ANTI-INFE, V10, P1129, DOI [10.1586/ERI.12.104, 10.1586/eri.12.104]
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 85
TC 0
Z9 0
U1 3
U2 3
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860-7179
EI 1860-7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD OCT 19
PY 2020
VL 15
IS 20
BP 1921
EP 1931
DI 10.1002/cmdc.202000259
EA SEP 2020
PG 11
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OF2FX
UT WOS:000565712500001
PM 32700795
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Wintjens, R
   Bifani, AM
   Bifani, P
AF Wintjens, Rene
   Bifani, Amanda Makha
   Bifani, Pablo
TI Impact of glycan cloud on the B-cell epitope prediction of SARS-CoV-2
   Spike protein
SO NPJ VACCINES
LA English
DT Article
ID GLYCOSYLATION; ANTIBODY; NEUTRALIZATION; SHIELD
AB The SARS-CoV-2 outbreak originated in China in late 2019 and has since spread to pandemic proportions. Diagnostics, therapeutics and vaccines are urgently needed. We model the trimeric Spike protein, including flexible loops and all N-glycosylation sites, in order to elucidate accessible epitopes for antibody-based diagnostics, therapeutics and vaccine development. Based on published experimental data, six homogeneous glycosylation patterns and two heterogeneous ones were used for the analysis. The glycan chains alter the accessible surface areas on the S-protein, impeding antibody-antigen recognition. In presence of glycan, epitopes on the S1 subunit, that notably contains the receptor binding domain, remain mostly accessible to antibodies while those present on the S2 subunit are predominantly inaccessible. We identify 28 B-cell epitopes in the Spike structure and group them as non-affected by the glycan cloud versus those which are strongly masked by the glycan cloud, resulting in a list of favourable epitopes as targets for vaccine development, antibody-based therapy and diagnostics.
C1 [Wintjens, Rene] Univ Libre Bruxelles, Fac Pharm, Dept Res Drug Dev RD3, Unit Microbiol Bioorgan & Macromol Chem, B-1050 Brussels, Belgium.
   [Bifani, Amanda Makha] Duke NUS Med Sch, Programme Emerging Infect Dis, Singapore 169857, Singapore.
   [Bifani, Pablo] ASTAR, Singapore Immunol Network SIgN, 8A Biomed Grove,Immunos Bldg, Singapore 138648, Singapore.
   [Bifani, Pablo] Natl Univ Singapore, Infect Dis Programme, Singapore 119077, Singapore.
   [Bifani, Pablo] Natl Univ Singapore, Dept Microbiol & Immunol, Yong Loo Lin Sch Med, Singapore 119077, Singapore.
   [Bifani, Pablo] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Infect Biol, London, England.
RP Wintjens, R (corresponding author), Univ Libre Bruxelles, Fac Pharm, Dept Res Drug Dev RD3, Unit Microbiol Bioorgan & Macromol Chem, B-1050 Brussels, Belgium.; Bifani, P (corresponding author), ASTAR, Singapore Immunol Network SIgN, 8A Biomed Grove,Immunos Bldg, Singapore 138648, Singapore.; Bifani, P (corresponding author), Natl Univ Singapore, Infect Dis Programme, Singapore 119077, Singapore.; Bifani, P (corresponding author), Natl Univ Singapore, Dept Microbiol & Immunol, Yong Loo Lin Sch Med, Singapore 119077, Singapore.; Bifani, P (corresponding author), London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Infect Biol, London, England.
EM rene.wintjens@ulb.ac.be; micpb@nus.edu.sg
FU Duke-NUS; Singapore Ministry of Education Tier 3 grant,
   SingaporeMinistry of Education, Singapore; National University of
   Singapore Start-up FundsNational University of Singapore; Singapore
   Immunology Network (SIgN)Agency for Science Technology & Research
   (ASTAR); Agency for Science Technology and Research, SingaporeAgency for
   Science Technology & Research (ASTAR)
FX R.W. is a Research Associate with the Belgian National Funds for
   Scientific Research (FRS-FNRS). A.M.B. is supported by graduate
   scholarships from Duke-NUS and Singapore Ministry of Education Tier 3
   grant, Singapore. P.B. is supported by the National University of
   Singapore Start-up Funds, and the Singapore Immunology Network (SIgN);
   Agency for Science Technology and Research, Singapore. Schematics were
   generated using BioRender.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698
   Bohm M, 2019, NUCLEIC ACIDS RES, V47, pD1195, DOI 10.1093/nar/gky994
   Bohne-Lang A, 2005, NUCLEIC ACIDS RES, V33, pW214, DOI 10.1093/nar/gki385
   Bolmstedt A, 2001, VACCINE, V20, P397, DOI 10.1016/S0264-410X(01)00358-9
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Dearlove B. L., 2020, BIORXIV, DOI [10.1101/2020.04.27.064774, DOI 10.1101/2020.04.27.064774]
   Doores KJ, 2015, FEBS J, V282, P4679, DOI 10.1111/febs.13530
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Gugliotta A, 2017, EUR J PHARM BIOPHARM, V112, P119, DOI 10.1016/j.ejpb.2016.11.012
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Mitternacht Simon, 2016, F1000Res, V5, P189, DOI 10.12688/f1000research.7931.1
   Mizumoto K., 2020, ESTIMATING ASYMPTOMA, DOI [10.1101/2020.02.20.20025866, DOI 10.1101/2020.02.20.20025866]
   NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P226, DOI 10.1073/pnas.83.2.226
   NOVOTNY J, 1984, NUCLEIC ACIDS RES, V12, P243, DOI 10.1093/nar/12.1Part1.243
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pak JE, 2009, J MOL BIOL, V388, P815, DOI 10.1016/j.jmb.2009.03.042
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Poh CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16638-2
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Ravichandran S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc3539
   Ruhaak LR, 2015, J PROTEOME RES, V14, P4538, DOI 10.1021/acs.jproteome.5b00255
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Shajahan Asif, 2020, Glycobiology, V30, P981, DOI 10.1093/glycob/cwaa042
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Vashi Y, 2020, INFECT GENET EVOL, V84, DOI 10.1016/j.meegid.2020.104382
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.00127-20
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470
   Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330
   World Health Organization, 2020, 66 WHO
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zhang Y., 2020, BIORXIV, DOI [10.1101/2020.03.28.013276, DOI 10.1101/2020.03.28.013276]
   Zost Seth J, 2020, bioRxiv, DOI 10.1101/2020.05.22.111005
NR 42
TC 0
Z9 0
U1 2
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2059-0105
J9 NPJ VACCINES
JI npj Vaccines
PD SEP 4
PY 2020
VL 5
IS 1
AR 81
DI 10.1038/s41541-020-00237-9
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA NJ2MM
UT WOS:000565880600001
PM 32944295
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Diorio, C
   Anderson, EM
   McNerney, KO
   Goodwin, EC
   Chase, JC
   Bolton, MJ
   Arevalo, CP
   Weirick, ME
   Gouma, S
   Vella, LA
   Henrickson, SE
   Chiotos, K
   Fitzgerald, JC
   Kilbaugh, TJ
   John, ARO
   Blatz, AM
   Lambert, MP
   Sullivan, KE
   Tartaglione, MR
   Zambrano, D
   Martin, M
   Lee, JH
   Young, P
   Friedman, D
   Sesok-Pizzini, DA
   Hensley, SE
   Behrens, EM
   Bassiri, H
   Teachey, DT
AF Diorio, Caroline
   Anderson, Elizabeth M.
   McNerney, Kevin O.
   Goodwin, Eileen C.
   Chase, Julie C.
   Bolton, Marcus J.
   Arevalo, Claudia P.
   Weirick, Madison E.
   Gouma, Sigrid
   Vella, Laura A.
   Henrickson, Sarah E.
   Chiotos, Kathleen
   Fitzgerald, Julie C.
   Kilbaugh, Todd J.
   John, Audrey R. Odom
   Blatz, Allison M.
   Lambert, Michele P.
   Sullivan, Kathleen E.
   Tartaglione, Margaret R.
   Zambrano, Danielle
   Martin, Meghan
   Lee, Jessica H.
   Young, Pampee
   Friedman, David
   Sesok-Pizzini, Deborah A.
   Hensley, Scott E.
   Behrens, Edward M.
   Bassiri, Hamid
   Teachey, David T.
TI Convalescent plasma for pediatric patients with SARS-CoV-2-associated
   acute respiratory distress syndrome
SO PEDIATRIC BLOOD & CANCER
LA English
DT Article
DE convalescent plasma; COVID-19; pediatrics; SARS-CoV-2
ID INFECTION
AB There are no proven safe and effective therapies for children who develop life-threatening complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Convalescent plasma (CP) has demonstrated potential benefit in adults with SARS-CoV-2, but has theoretical risks.We present the first report of CP in children with life-threatening coronavirus disease 2019 (COVID-19), providing data on four pediatric patients with acute respiratory distress syndrome. We measured donor antibody levels and recipient antibody response prior to and following CP infusion. Infusion of CP was not associated with antibody-dependent enhancement (ADE) and did not suppress endogenous antibody response. We found CP was safe and possibly efficacious. Randomized pediatric trials are needed.
C1 [Diorio, Caroline; McNerney, Kevin O.; Chase, Julie C.; Vella, Laura A.; Henrickson, Sarah E.; Fitzgerald, Julie C.; Lambert, Michele P.; Sullivan, Kathleen E.; Lee, Jessica H.; Behrens, Edward M.; Bassiri, Hamid; Teachey, David T.] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat,Perelman Sch Med, Immune Dysregulat Frontier Program, Philadelphia, PA 19104 USA.
   [Diorio, Caroline; McNerney, Kevin O.; Tartaglione, Margaret R.; Zambrano, Danielle; Martin, Meghan; Teachey, David T.] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Div Oncol,Perelman Sch Med, 3008 CTRB,3501 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
   [Anderson, Elizabeth M.; Goodwin, Eileen C.; Bolton, Marcus J.; Arevalo, Claudia P.; Weirick, Madison E.; Gouma, Sigrid; Hensley, Scott E.] Univ Penn, Perelman Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA.
   [Chase, Julie C.; Behrens, Edward M.] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Div Rheumatol,Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Vella, Laura A.; John, Audrey R. Odom; Blatz, Allison M.; Bassiri, Hamid] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Div Infect Dis,Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Henrickson, Sarah E.; Sullivan, Kathleen E.] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Div Allergy & Immunol,Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Chiotos, Kathleen; Fitzgerald, Julie C.; Kilbaugh, Todd J.] Univ Penn, Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Div Crit Care Med,Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Lambert, Michele P.; Friedman, David] Univ Penn, Childrens Hosp Philadelphia, Div Hematol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Young, Pampee] Amer Red Cross, Washington, DC 20006 USA.
   [Friedman, David; Sesok-Pizzini, Deborah A.] Univ Penn, Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Teachey, DT (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Div Oncol,Perelman Sch Med, 3008 CTRB,3501 Civ Ctr Blvd, Philadelphia, PA 19104 USA.
EM teacheyd@email.chop.edu
RI Bassiri, Hamid/B-9840-2014
OI Bassiri, Hamid/0000-0001-6532-8478; Gouma, Sigrid/0000-0002-7853-8340;
   McNerney, Kevin/0000-0002-4359-3569; Blatz, Allison/0000-0003-2525-1212
FU Children's Hospital of Philadelphia Frontiers Program Immune
   Dysregulation Team, National Institute of Allergy and Infectious
   Diseases (NIAID) (US) [R01AI121250, R01AI103280, R01AI123433,
   R21AI144472, K08 AI136660, K08AI135091]; Agency for Healthcare Research
   and Quality (AHRQ)United States Department of Health & Human
   ServicesAgency for Healthcare Research & Quality [5K12HS026393];
   National Cancer Institute (NCI) (US) [R01CA193776, X01HD100702-01,
   5UG1CA233249, R01A1123538]; Leukemia and Lymphoma SocietyLeukemia and
   Lymphoma Society; Cookies for Kids Cancer; Alex's Lemonade Stand
   Foundation for Childhood Cancer; Stand UP 2 Cancer; Kate Amato
   Foundations; Burroughs Wellcome Fund CAMS and PATHBurroughs Wellcome
   Fund; Clinical Immunology Society; American Academy of Allergy, Asthma,
   and Immunology; University of Pennsylvania; Institute for
   TranslationalMedicine and Therapeutics of the Perelman School of
   Medicine at the University of Pennsylvania; Children's Oncology Group;
   Team Connor; NIH Training in VirologyUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA
   [T32-AI-007324]
FX Children's Hospital of Philadelphia Frontiers Program Immune
   Dysregulation Team, National Institute of Allergy and Infectious
   Diseases (NIAID) (US): R01AI121250, R01AI103280, R01AI123433,
   R21AI144472, K08 AI136660, and K08AI135091; Agency for Healthcare
   Research and Quality (AHRQ): 5K12HS026393; National Cancer Institute
   (NCI) (US): R01CA193776, X01HD100702-01, 5UG1CA233249, and R01A1123538;
   NIH Training in Virology: T32-AI-007324; Leukemia and Lymphoma Society;
   Cookies for Kids Cancer; Alex's Lemonade Stand Foundation for Childhood
   Cancer; Children's Oncology Group; Stand UP 2 Cancer; Team Connor; and
   Kate Amato Foundations. Burroughs Wellcome Fund CAMS and PATH; Clinical
   Immunology Society; and American Academy of Allergy, Asthma, and
   Immunology; Institutional funds from the University of Pennsylvania;
   Institute for TranslationalMedicine and Therapeutics of the Perelman
   School of Medicine at the University of Pennsylvania
CR Agrawal AS, 2016, HUM VACC IMMUNOTHER, V12, P2351, DOI 10.1080/21645515.2016.1177688
   Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Chao JY, 2020, J PEDIATR-US, V223, P14, DOI 10.1016/j.jpeds.2020.05.006
   Diorio C, 2020, J CLIN INVEST, V130, P5967, DOI 10.1172/JCI140970
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Flannery D, 2020, SARS COV 2 SEROPREVA
   Hachim A, 2020, NAT IMMUNOL, V21, P1293, DOI 10.1038/s41590-020-0773-7
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Leung DTM, 2004, J INFECT DIS, V190, P379, DOI 10.1086/422040
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P1, DOI DOI 10.1001/jama.2020.10044
   Liu WY, 2020, NEW ENGL J MED, V382, P1370, DOI 10.1056/NEJMc2003717
   Lv HB, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107725
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090
   Yip MS, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-82
   Zachariah P, 2020, JAMA PEDIATR, V174, DOI 10.1001/jamapediatrics.2020.2430
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
NR 22
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
EI 1545-5017
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD NOV
PY 2020
VL 67
IS 11
AR e28693
DI 10.1002/pbc.28693
EA SEP 2020
PG 6
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA NY3VA
UT WOS:000565671700001
PM 32885904
OA Other Gold
DA 2021-01-01
ER

PT J
AU Meza, HT
   Gil, AL
   Saldana, AS
   Martinez-Zabaleta, M
   Lopetegui, EG
   Martinez, ELC
   Apilanez, MC
   Isasi, MH
   Enguita, JM
   Gomez-Vicente, B
   Arenillas, JF
   Basterrechea, NA
   Fernandez, JJT
   Herrero, JS
   Montero, JLM
   Rodrigo, MC
   Fernandez-Coud, D
   Menendez, IC
   Fernandez, MTT
   Freijo, M
   Luna, A
   Portilla, EJP
   Lopez, YJ
   Rodriguez-Castro, E
   Rodriguez-Yanez, M
   Garcia, JT
   Rodriguez, IB
   Julian-Villaverde, F
   Garcia, MPM
   Gabriel-Galan, JMT
   Iniguez, AE
   Lazaro, CP
   Perez, MPN
   Moreno, JM
AF Tejada Meza, H.
   Lambea Gil, A.
   Sancho Saldana, A.
   Martinez-Zabaleta, M.
   Garmendia Lopetegui, E.
   Lopez-Cancio Martinez, E.
   Castanon Apilanez, M.
   Herrera Isasi, M.
   Marta Enguita, J.
   Gomez-Vicente, B.
   Arenillas, J. F.
   Arenaza Basterrechea, N.
   Timiraos Fernandez, J. J.
   Sanchez Herrero, J.
   Macineiras Montero, J. L.
   Rodrigo, M. Castellanos
   Fernandez-Coud, D.
   Casado Menendez, I
   Temprano Fernandez, M. T.
   Freijo, M.
   Luna, A.
   Palacio Portilla, E. J.
   Jimenez Lopez, Y.
   Rodriguez-Castro, E.
   Rodriguez-Yanez, M.
   Tejada Garcia, J.
   Beltran Rodriguez, I
   Julian-Villaverde, F.
   Moreno Garcia, M. P.
   Trejo Gabriel-Galan, J. M.
   Echavarria Iniguez, A.
   Perez Lazaro, C.
   Navarro Perez, M. P.
   Marta Moreno, J.
CA NORDICTUS Investigators
TI Impact of COVID-19 outbreak in reperfusion therapies of acute ischaemic
   stroke in northwest Spain
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Article
DE acute stroke therapy; cerebral infarction; ischaemic stroke;
   thrombolysis; Spain; COVID-19; thrombectomy
AB Background and purpose Spain has been one of the countries more heavily stricken by SARS-CoV-2, which has had huge implications for stroke care. The aim was to analyse the impact of the COVID-19 epidemic outbreak on reperfusion therapies for acute ischaemic stroke in the northwest of Spain. Methods This was a Spanish multicentre retrospective observational study based on data from tertiary hospitals of the NORDICTUS network. All patients receiving reperfusion therapy for ischaemic stroke between 30 December 2019 and 3 May 2020 were recorded, and their baseline, clinical and radiological characteristics, extra- and intra-hospital times of action, Code Stroke activation pathway, COVID-19 status, reperfusion rate, and short-term outcome before and after the setting of the emergency state were analysed. Results A total of 796 patients received reperfusion therapies for ischaemic stroke. There was a decrease in the number of patients treated per week (46.5 patients per week vs. 39.0 patients per week,P = 0.043) and a delay in out-of-hospital (95.0 vs. 110.0 min,P = 0.001) and door-to-needle times (51.0 vs. 55.0,P = 0.038). Patients receiving endovascular therapy obtained less successful reperfusion rates (92.9% vs. 86.6%,P = 0.016). COVID-19 patients had more in-hospital mortality. Conclusion A decrease in the number of patients benefiting from reperfusion therapies was found, with a delay in out-of-hospital and door-to-needle times and worse reperfusion rates in northwest Spain. COVID-19 patients had more in-hospital mortality.
C1 [Tejada Meza, H.; Lambea Gil, A.; Sancho Saldana, A.; Marta Moreno, J.] Hosp Univ Miguel Servet, Dept Neurol, Stroke Unit, Zaragoza, Spain.
   [Tejada Meza, H.] Hosp Univ Miguel Servet, Dept Radiol, Intervent Neuroradiol Unit, Zaragoza, Spain.
   [Tejada Meza, H.; Lambea Gil, A.; Sancho Saldana, A.; Marta Moreno, J.] Inst Invest Sanitaria Aragon IIS Aragon, Zaragoza, Spain.
   [Martinez-Zabaleta, M.] Donostia Univ Hosp, Dept Neurol, San Sebastian, Spain.
   [Garmendia Lopetegui, E.] Donostia Univ Hosp, Dept Neuroradiol, San Sebastian, Spain.
   [Lopez-Cancio Martinez, E.; Castanon Apilanez, M.] Hosp Univ Cent Asturias, Dept Neurol, Oviedo, Spain.
   [Herrera Isasi, M.; Marta Enguita, J.; Beltran Rodriguez, I] Complejo Hosp Navarra, Dept Neurol, Pamplona, Spain.
   [Gomez-Vicente, B.; Arenillas, J. F.] Hosp Clin Univ Valladolid, Dept Neurol, Valladolid, Spain.
   [Arenillas, J. F.] Univ Valladolid, Inst Biol & Genet Mol, Neurovasc Res Lab, CSIC, Madrid, Spain.
   [Arenaza Basterrechea, N.; Timiraos Fernandez, J. J.] Hosp Univ Araba, Dept Neurol, Stroke Unit, Vitoria, Spain.
   [Sanchez Herrero, J.; Macineiras Montero, J. L.] Complejo Hosp Univ Vigo, Dept Neurol, Vigo, Spain.
   [Rodrigo, M. Castellanos; Fernandez-Coud, D.] Complexo Hosp Univ A Coruna, Dept Neurol, A Coruna Biomed Res Inst, La Coruna, Spain.
   [Casado Menendez, I; Temprano Fernandez, M. T.] Hosp Univ Cabuenes, Dept Neurol, Stroke Unit, Gijon, Spain.
   [Freijo, M.; Luna, A.] Hosp Univ Cruces, Neurovasc Dept, Biocruces Bizkaia Hlth Res Inst, Osakidetza, Baracaldo, Spain.
   [Palacio Portilla, E. J.; Jimenez Lopez, Y.] Hosp Univ Marques Valdecilla, Dept Neurol, Santander, Spain.
   [Rodriguez-Castro, E.; Rodriguez-Yanez, M.] Complejo Hosp Univ Santiago, Dept Neurol, Santiago De Compostela, Spain.
   [Tejada Garcia, J.] Complejo Asistencial Univ Leon, Dept Neurol, Leon, Spain.
   [Julian-Villaverde, F.; Moreno Garcia, M. P.] Hosp San Pedro, Dept Neurol, Logrono, Spain.
   [Trejo Gabriel-Galan, J. M.; Echavarria Iniguez, A.] Complejo Asistencial Univ Burgos, Dept Neurol, Burgos, Spain.
   [Perez Lazaro, C.; Navarro Perez, M. P.] Hosp Clin Lozano Blesa, Dept Neurol, Zaragoza, Spain.
RP Meza, HT (corresponding author), Hosp Univ Miguel Servet, Dept Neurol, Dept Radiol, Stroke Unit,Intervent Neuroradiol, Paseo Isabel La Catolica 1-3, Zaragoza 50009, Spain.
EM htmeza@gmail.com
RI Rodriguez-Yanez, Manuel/ABI-1283-2020; Lambea-Gil, Alvaro/AAS-4568-2020;
   Meza, Herbert Tejada/AAW-1598-2020
OI Rodriguez-Yanez, Manuel/0000-0002-5381-8557; Lambea-Gil,
   Alvaro/0000-0003-1785-9201; Meza, Herbert Tejada/0000-0002-6506-1037
CR [Anonymous], 2020, SIT COVID 19 ESP
   Boehme AK, 2018, ANN CLIN TRANSL NEUR, V5, P456, DOI 10.1002/acn3.545
   Centro Nacional de Epidemiologia Instituto de Salud Carlos III, 2020, DAT AGR NOT CCAA MIN
   Conselleria de Sanidade Xunta de Galiza, 2020, DAT NOT CAS GAL
   COVIDsurg Collaborative, 2020, LANCET, V396, P27, DOI 10.1016/S0140-6736(20)31182-X
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Mahase Elisabeth, 2020, BMJ, V368, pm1282, DOI 10.1136/bmj.m1282
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401
   Meza HT, 2020, INT J STROKE, V15, P755, DOI 10.1177/1747493020938301
   Montaner J, 2020, STROKE, V51, P2307, DOI 10.1161/STROKEAHA.120.030106
   Pranata R, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104949
   Rudilosso S, 2020, STROKE, V51, P1991, DOI 10.1161/STROKEAHA.120.030329
   Meza HT, 2020, EUR J NEUROL, V27, P1788, DOI 10.1111/ene.14327
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Zhao J, 2020, STROKE, V51, P1996, DOI 10.1161/STROKEAHA.120.030225
NR 19
TC 1
Z9 1
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD DEC
PY 2020
VL 27
IS 12
BP 2491
EP 2498
DI 10.1111/ene.14467
EA SEP 2020
PG 8
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OO3VR
UT WOS:000565793900001
PM 32761981
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Fulgencio-Barbarin, J
   Puerta-Pena, M
   Ortiz-Romero, P
   Garcia-Donoso, C
   Rivera-Diaz, R
AF Fulgencio-Barbarin, Jon
   Puerta-Pena, Mario
   Ortiz-Romero, Pablo
   Garcia-Donoso, Carmen
   Rivera-Diaz, Raquel
TI COVID-19 and systemic therapies in psoriasis: experience of a tertiary
   hospital in Madrid
SO INTERNATIONAL JOURNAL OF DERMATOLOGY
LA English
DT Letter
C1 [Fulgencio-Barbarin, Jon; Puerta-Pena, Mario; Ortiz-Romero, Pablo; Garcia-Donoso, Carmen; Rivera-Diaz, Raquel] 12 Octubre Univ Hosp, Madrid, Spain.
RP Fulgencio-Barbarin, J (corresponding author), 12 Octubre Univ Hosp, Madrid, Spain.
EM jonfulgencio@hotmail.com
OI , Jon/0000-0002-5620-0541; Puerta-Pena, Mario/0000-0001-6273-0613
CR Gisondi P, 2020, BRIT J DERMATOL, V183, P373, DOI 10.1111/bjd.19158
   Instituto de Salud Carlos III Centro Nacional de Epidemiologia Red Nacional de Vigilancia Epidemiologica, INF SIT COVID 19 ESP
   Lebwohl M, 2020, J AM ACAD DERMATOL, V82, P1217, DOI 10.1016/j.jaad.2020.03.031
   Price KN, 2020, J AM ACAD DERMATOL, V82, pE173, DOI 10.1016/j.jaad.2020.03.046
NR 4
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0011-9059
EI 1365-4632
J9 INT J DERMATOL
JI Int. J. Dermatol.
PD NOV
PY 2020
VL 59
IS 11
BP 1425
EP 1426
DI 10.1111/ijd.15157
EA SEP 2020
PG 2
WC Dermatology
SC Dermatology
GA OE6TY
UT WOS:000565788400001
PM 32886364
OA Bronze
DA 2021-01-01
ER

PT J
AU Cunningham, LS
   McFadden, JP
   Basketter, DA
   Ferguson, FJ
   White, IR
   Kimber, I
AF Cunningham, Louise S.
   McFadden, John P.
   Basketter, David A.
   Ferguson, Felicity J.
   White, Ian R.
   Kimber, Ian
TI Harnessing co-operative immune augmentation by contact allergens to
   enhance the efficacy of viral vaccines
SO CONTACT DERMATITIS
LA English
DT Article
DE adjuvant; contact allergens; co-operative immune augmentation;
   co-sensitization; COVID; diphenylcyclopropenone; vaccine
ID ALOPECIA-AREATA; DERMATITIS; DIPHENYLCYCLOPROPENONE; CONSTITUENTS;
   VACCINATION; THIMEROSAL; EXPRESSION; PERFORIN; EXPOSURE
AB Although the development of successful vaccines against coronaviruses may be achieved, for some individuals the immune response that they stimulate may prove to be insufficient for effective host defence. The principle that a relatively strong contact allergen will have an enhancing effect on sensitization compared with a less potent contact allergen if they are co-administered, may not, at first, appear relevant to this issue. However, this augmentation effect is thought to be due to the sharing of common or complementary pathways. Here, we briefly consider aspects of the shared and complementary pathways between skin sensitization induced by exposure to a contact allergen and the immune response to viruses, with particular reference to COVID-19. The relationship leads us to explore whether this principle, which we name here as "co-operative immune augmentation" may be extended to include viral vaccination. We consider evidence that even relatively weak contact allergens, used in vaccines for other purposes, can show enhanced sensitization, which is in keeping with a co-operative augmentation principle. Finally, we consider how the potent contact allergen diphenylcyclopropenone could be employed safely as an enhancer of vaccine responses.
C1 [Cunningham, Louise S.; McFadden, John P.; Ferguson, Felicity J.; White, Ian R.] Guys & St Thomas Hosp, St Johns Inst Dermatol, Dept Cutaneous Allergy, London, England.
   [Basketter, David A.] DABMEB Consultancy Ltd, Sharnbrook, Beds, England.
   [Kimber, Ian] Univ Manchester, Fac Biol Med & Hlth, Manchester, Lancs, England.
RP Cunningham, LS (corresponding author), Guys & St Thomas Hosp, St Johns Inst Dermatol, Dept Cutaneous Allergy, London, England.
EM lcunningham73@gmail.com
OI Cunningham, Louise/0000-0002-2009-3588
CR Bergfors E, 2014, EUR J PEDIATR, V173, P1297, DOI 10.1007/s00431-014-2318-2
   Bonefeld CM, 2017, CONTACT DERMATITIS, V77, P133, DOI 10.1111/cod.12847
   Bonefeld CM, 2015, EXP DERMATOL, V24, P229, DOI 10.1111/exd.12634
   Bonefeld CM, 2011, CONTACT DERMATITIS, V65, P336, DOI 10.1111/j.1600-0536.2011.01945.x
   Bordoni Veronica, 2020, Clin Infect Dis, V71, P2272, DOI 10.1093/cid/ciaa577
   Bruze M, 2008, CONTACT DERMATITIS, V59, DOI 10.1111/j.1600-0536.2008.01394.x
   Carbone T, 2010, J IMMUNOL, V184, P1102, DOI 10.4049/jimmunol.0902518
   Choe SJ, 2018, J AM ACAD DERMATOL, V78, P515, DOI 10.1016/j.jaad.2017.10.042
   Choi Y, 2013, ANN DERMATOL, V25, P434, DOI 10.5021/ad.2013.25.4.434
   COX NH, 1988, CONTACT DERMATITIS, V18, P143, DOI 10.1111/j.1600-0536.1988.tb04500.x
   Cunningham L, 2020, J ALLERGY CLIN IMMUN, V146, P52, DOI 10.1016/j.jaci.2020.05.007
   Enjuanes L, 2016, ADV VIRUS RES, V96, P245, DOI 10.1016/bs.aivir.2016.08.003
   Jowsey IR, 2008, CONTACT DERMATITIS, V59, P90, DOI 10.1111/j.1600-0536.2008.01349.x
   Lavelle EC, 2011, EXPERT REV VACCINES, V10, P255, DOI [10.1586/ERV.11.12, 10.1586/erv.11.12]
   Leventhal JS, 2012, DERMATITIS, V23, P102, DOI 10.1097/DER.0b013e31825228cf
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   McFadden JP, 2013, BRIT J DERMATOL, V168, P692, DOI 10.1111/bjd.12145
   Mullard A, 2020, LANCET, V395, P1751, DOI 10.1016/S0140-6736(20)31252-6
   OSAWA J, 1991, CONTACT DERMATITIS, V24, P178, DOI 10.1111/j.1600-0536.1991.tb01694.x
   RIETSCHEL RL, 1990, DERMATOL CLIN, V8, P161, DOI 10.1016/S0733-8635(18)30543-6
   Salsberg JM, 2012, ARCH DERMATOL, V148, P1084, DOI 10.1001/archdermatol.2012.1622
   Schmidt M, 2010, NAT IMMUNOL, V11, P814, DOI 10.1038/ni.1919
   Yawalkar N, 2001, AM J PATHOL, V158, P803, DOI 10.1016/S0002-9440(10)64027-8
   Zhao CY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00211
NR 24
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-1873
EI 1600-0536
J9 CONTACT DERMATITIS
JI Contact Dermatitis
PD NOV
PY 2020
VL 83
IS 5
BP 432
EP 435
DI 10.1111/cod.13685
EA SEP 2020
PG 4
WC Allergy; Dermatology
SC Allergy; Dermatology
GA OS5OX
UT WOS:000565678700001
PM 32880961
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ahmetolan, S
   Bilge, AH
   Demirci, A
   Peker-Dobie, A
   Ergonul, O
AF Ahmetolan, Semra
   Bilge, Ayse Humeyra
   Demirci, Ali
   Peker-Dobie, Ayse
   Ergonul, Onder
TI What Can We Estimate From Fatality and Infectious Case Data Using the
   Susceptible-Infected-Removed (SIR) Model? A Case Study of Covid-19
   Pandemic
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE COVID-19; SIR model; parameter estimation; mathematical models;
   epidemiology
ID EPIDEMIC
AB The rapidly spreading Covid-19 that affected almost all countries, was first reported at the end of 2019. As a consequence of its highly infectious nature, countries all over the world have imposed extremely strict measures to control its spread. Since the earliest stages of this major pandemic, academics have done a huge amount of research in order to understand the disease, develop medication, vaccines and tests, and model its spread. Among these studies, a great deal of effort has been invested in the estimation of epidemic parameters in the early stage, for the countries affected by Covid-19, hence to predict the course of the epidemic but the variability of the controls over the course of the epidemic complicated the modeling processes. In this article, the determination of the basic reproduction number, the mean duration of the infectious period, the estimation of the timing of the peak of the epidemic wave is discussed using early phase data. Daily case reports and daily fatalities for China, South Korea, France, Germany, Italy, Spain, Iran, Turkey, the United Kingdom and the United States over the period January 22, 2020-April 18, 2020 are evaluated using the Susceptible-Infected-Removed (SIR) model. For each country, the SIR models fitting cumulative infective case data within 5% error are analyzed. It is observed that the basic reproduction number and the mean duration of the infectious period can be estimated only in cases where the spread of the epidemic is over (for China and South Korea in the present case). Nevertheless, it is shown that the timing of the maximum and timings of the inflection points of the proportion of infected individuals can be robustly estimated from the normalized data. The validation of the estimates by comparing the predictions with actual data has shown that the predictions were realized for all countries except USA, as long as lock-down measures were retained.
C1 [Ahmetolan, Semra; Demirci, Ali; Peker-Dobie, Ayse] Istanbul Tech Univ, Fac Sci & Letters, Dept Math, Istanbul, Turkey.
   [Bilge, Ayse Humeyra; Peker-Dobie, Ayse] Kadir Has Univ, Fac Engn & Nat Sci, Dept Ind Engn, Istanbul, Turkey.
   [Ergonul, Onder] Koc Univ, Sch Med, Infect Dis & Clin Microbiol Dept, Istanbul, Turkey.
RP Demirci, A (corresponding author), Istanbul Tech Univ, Fac Sci & Letters, Dept Math, Istanbul, Turkey.
EM demircial@itu.edu.tr
RI ahmetolan, semra/Q-8760-2016; Demirci, Ali/P-8777-2014; Dobie, Ayse
   Peker/ABB-4876-2020
OI ahmetolan, semra/0000-0003-1003-7918; Demirci, Ali/0000-0001-9780-0132;
   Dobie, Ayse Peker/0000-0002-5228-7694
CR Batista M., 2020, ESTIMATION FINAL SIZ, DOI [10.1101/2020.02.16.20023606, DOI 10.1101/2020.02.16.20023606]
   Bilge AH, 2018, INT J BIOMATH, V11, DOI 10.1142/S1793524518500213
   Bilge AH, 2015, J MATH BIOL, V71, P767, DOI 10.1007/s00285-014-0838-z
   Cassaro FAM, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138834
   Danon L, 2020, SPATIAL MODEL COVID, DOI [10.1101/2020.02.12.20022566, DOI 10.1101/2020.02.12.20022566]
   Dobie AP, 2019, ARXIV190911317
   Fanelli D, 2020, CHAOS SOLITON FRACT, V134, DOI 10.1016/j.chaos.2020.109761
   Fugitive Literacies Collective, 2020, ENGLISH ED, V52, pN3
   HETHCOTE H W, 1976, Mathematical Biosciences, V28, P335, DOI 10.1016/0025-5564(76)90132-2
   Jia WP, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00169
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Li LX, 2020, INFECT DIS MODEL, V5, P282, DOI 10.1016/j.idm.2020.03.002
   Mangoni L, 2020, EPIDEMIC ANAL COVID
   Perc M, 2020, FRONT PHYS-LAUSANNE, V8, DOI 10.3389/fphy.2020.00127
   Read J. M., 2020, NOVEL CORONAVIRUS 20, DOI [10.1101/2020.01.23.20018549, DOI 10.1101/2020.01.23.20018549]
   Roda WC, 2020, INFECT DIS MODEL, V5, P271, DOI 10.1016/j.idm.2020.03.001
   Roosa K, 2020, INFECT DIS MODEL, V5, P256, DOI 10.1016/j.idm.2020.02.002
   Samanlioglu F, 2012, ARXIV12052497
   Shen M, 2020, MODELLING EPIDEMIC T, DOI [10.1101/2020.01.23.916726, DOI 10.1101/2020.01.23.916726, 10.1101/2020.01.23.916726.]
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
   Tizzoni M, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-165
   Zhang XL, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109829
   Zhao S, 2020, INT J INFECT DIS, V92, P214, DOI 10.1016/j.ijid.2020.01.050
NR 23
TC 1
Z9 1
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD SEP 3
PY 2020
VL 7
AR 556366
DI 10.3389/fmed.2020.556366
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA NS8LJ
UT WOS:000572507000001
PM 33015109
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ramtohul, T
   Cabel, L
   Paoletti, X
   Chiche, L
   Moreau, P
   Noret, A
   Vuagnat, P
   Cherel, P
   Tardivon, A
   Cottu, P
   Bidard, FC
   Servois, V
AF Ramtohul, Toulsie
   Cabel, Luc
   Paoletti, Xavier
   Chiche, Laurent
   Moreau, Pauline
   Noret, Aurelien
   Vuagnat, Perrine
   Cherel, Pascal
   Tardivon, Anne
   Cottu, Paul
   Bidard, Francois-Clement
   Servois, Vincent
TI Quantitative CT Extent of Lung Damage in COVID-19 Pneumonia Is an
   Independent Risk Factor for Inpatient Mortality in a Population of
   Cancer Patients: A Prospective Study
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE COVID-19 pneumonia; quantitative chest CT extent; cancer patients; risk
   factor for mortality; prognostic performance
AB Background:CT lung extent has emerged as a potential risk factor of COVID-19 pneumonia severity with mainly semiquantitative assessment, and outcome was not assessed in the specific oncology setting. The main goal was to evaluate the prognostic role of quantitative assessment of the extent of lung damage for early mortality of patients with COVID-19 pneumonia in cancer patients. Methods:We prospectively included consecutive cancer patients with recent onset of COVID-19 pneumonia assessed by chest CT between March 15, 2020, and April 20, 2020, and followed until May 1, 2020. Demographic, clinical, laboratory test data and imaging findings were recorded. Quantitative chest CT assessment of COVID-19 pneumonia was based on the density distribution of lung lesions using a freely available software recently released (Myrian XP-Lung). The association between extent of lung damage and overall survival was studied by univariate and multivariate Cox analysis. The Uno C-index was used to assess the discriminatory value of the quantitative CT extent of lung damage. Results:Seventy cancer patients with chest CT evidence of COVID-19 were included. After a median follow-up of 25 days, 17 patients (24%) had died. The median quantitative chest CT extent of COVID-19 was 20% (IQR = 14-35, range = 3-59) for non-survivors vs. 10% (IQR = 6-15, range = 2-55) for survivors (p= 0.002). The extent of COVID-19 pneumonia was correlated with inpatient management (p= 0.003) and oxygen therapy requirements (p< 0.001). Independent factors associated with death were performance status (PS) >= 2 (HR = 3.9, 95% CI = [1.1-13.8]p= 0.04) and extent of COVID-19 pneumonia >= 30% (HR = 12.0, 95% CI = [2.2-64.4]p= 0.004). No differences were found regarding the histology of cancer, cancer stage, metastases sites, or type of oncologic treatment between the survivor and non-survivor groups. The cross-validated Uno C-index of the model including PS and extent of COVID-19 pneumonia was 0.83, 95% CI = [0.73-0.93]. Conclusions:The quantitative chest CT extent of COVID-19 pneumonia was a strong independent prognostic factor of early inpatient mortality in a population of cancer patients.
C1 [Ramtohul, Toulsie; Chiche, Laurent; Cherel, Pascal; Tardivon, Anne; Servois, Vincent] Inst Curie Paris & St Cloud, Dept Radiol, Paris, France.
   [Cabel, Luc; Moreau, Pauline; Noret, Aurelien; Vuagnat, Perrine; Cottu, Paul; Bidard, Francois-Clement] Inst Curie Paris & St Cloud, Dept Med Oncol, Paris, France.
   [Paoletti, Xavier] Inst Curie Paris & St Cloud, INSERM STAMPM Team U900, Paris, France.
   [Paoletti, Xavier; Bidard, Francois-Clement] Univ Paris Saclay, UVSQ, St Cloud, France.
RP Ramtohul, T (corresponding author), Inst Curie Paris & St Cloud, Dept Radiol, Paris, France.
EM toulsie.ramtohul@curie.fr
RI Cottu, Paul/ABC-8595-2020
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Bai HX, 2020, RADIOLOGY, V296, pE46, DOI 10.1148/radiol.2020200823
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chassagnon G, 2020, AI DRIVEN CTBASED QU, DOI [10.1101/2020.04.17.20069187, DOI 10.1101/2020.04.17.20069187]
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Colombi D, 2020, RADIOLOGY, V296, pE86, DOI 10.1148/radiol.2020201433
   European Centre for Disease Prevention and Control, 2020, SIT UPD EU EEA UK 7
   Gencer B, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-9
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang L, 2020, RADIOLOGY CARDIOTHOR, V2, P2, DOI DOI 10.1148/RYCT.2020200075
   Institut Curie, 2018, I CUR HAS WON EUR LA
   Li KH, 2020, INVEST RADIOL, V55, P327, DOI 10.1097/RLI.0000000000000672
   Li KW, 2020, EUR RADIOL, V30, P4407, DOI 10.1007/s00330-020-06817-6
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lyu PJ, 2020, INVEST RADIOL, V55, P412, DOI 10.1097/RLI.0000000000000689
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   Prokop M, 2020, RADIOLOGY, V296, pE97, DOI 10.1148/radiol.2020201473
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Shin SH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39671-8
   SPF, 2020, COVID 19 POINT EP 7
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wang YH, 2020, RADIOLOGY, V296, pE55, DOI 10.1148/radiol.2020200843
   Wu J, 2020, INVEST RADIOL, V55, P257, DOI 10.1097/RLI.0000000000000670
   Xu X, 2020, EUR J NUCL MED MOL I, V47, P1275, DOI 10.1007/s00259-020-04735-9
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang R, 2020, RADIOLOGY CARDIOTHOR, V2, P2, DOI DOI 10.1148/RYCT.2020200047
   Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 32
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD SEP 3
PY 2020
VL 10
AR 1560
DI 10.3389/fonc.2020.01560
PG 11
WC Oncology
SC Oncology
GA NS8KN
UT WOS:000572504800001
PM 33014804
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Khan, MI
   Khan, ZA
   Baig, MH
   Ahmad, I
   Farouk, AE
   Song, YG
   Dong, JJ
AF Khan, Mohd Imran
   Khan, Zainul A.
   Baig, Mohammad Hassan
   Ahmad, Irfan
   Farouk, Abd-ElAziem
   Song, Young Goo
   Dong, Jae-Jun
TI Comparative genome analysis of novel coronavirus (SARS-CoV-2) from
   different geographical locations and the effect of mutations on major
   target proteins: Anin silicoinsight
SO PLOS ONE
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; SARS-CORONAVIRUS; SPIKE PROTEIN;
   RECEPTOR; DOMAIN; PNEUMONIA; STABILITY; COV
AB A novel severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) causing COVID-19 pandemic in humans, recently emerged and has exported in more than 200 countries as a result of rapid spread. In this study, we have made an attempt to investigate the SARS-CoV-2 genome reported from 13 different countries, identification of mutations in major coronavirus proteins of these different SARS-CoV-2 genomes and compared with SARS-CoV. These thirteen complete genome sequences of SARS-CoV-2 showed high identity (>99%) to each other, while they shared 82% identity with SARS-CoV. Here, we performed a very systematic mutational analysis of SARS-CoV-2 genomes from different geographical locations, which enabled us to identify numerous unique features of this viral genome. This includes several important country-specific unique mutations in the major proteins of SARS-CoV-2 namely, replicase polyprotein, spike glycoprotein, envelope protein and nucleocapsid protein. Indian strain showed mutation in spike glycoprotein at R408I and in replicase polyprotein at I671T, P2144S and A2798V,. While the spike protein of Spain & South Korea carried F797C and S221W mutation, respectively. Likewise, several important country specific mutations were analyzed. The effect of mutations of these major proteins were also investigated using variousin silicoapproaches. Main protease (Mpro), the therapeutic target protein of SARS with maximum reported inhibitors, was thoroughly investigated and the effect of mutation on the binding affinity and structural dynamics of Mpro was studied. It was found that the R60C mutation in Mpro affects the protein dynamics, thereby, affecting the binding of inhibitor within its active site. The implications of mutation on structural characteristics were determined. The information provided in this manuscript holds great potential in further scientific research towards the design of potential vaccine candidates/small molecular inhibitor against COVID19.
C1 [Khan, Mohd Imran] All India Inst Med Sci, Dept Biophys, New Delhi, India.
   [Khan, Zainul A.] Univ Delhi, Dept Plant Mol Biol, South Campus, New Delhi, India.
   [Baig, Mohammad Hassan; Dong, Jae-Jun] Yonsei Univ, Dept Family Med, Coll Med, Seoul, South Korea.
   [Ahmad, Irfan] King Khalid Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Abha, Saudi Arabia.
   [Ahmad, Irfan] King Khalid Univ, Res Ctr Adv Mat Sci, Abha, Saudi Arabia.
   [Farouk, Abd-ElAziem] Taif Univ, Fac Sci, Dept Biotechnol, At Taif, Saudi Arabia.
   [Song, Young Goo] Yonsei Univ, Gangnam Severance Hosp, Dept Infect Dis, Coll Med, Seoul, South Korea.
RP Dong, JJ (corresponding author), Yonsei Univ, Dept Family Med, Coll Med, Seoul, South Korea.; Song, YG (corresponding author), Yonsei Univ, Gangnam Severance Hosp, Dept Infect Dis, Coll Med, Seoul, South Korea.
EM IMFELL@yush.ac; S82TONIGHT@yush.ac
RI Ahmad, Irfan/AAU-4179-2020
OI Ahmad, Irfan/0000-0002-9500-4623; Song, Young Goo/0000-0002-0733-4156;
   Baig, Mohd Hassan/0000-0001-8227-4838; Dong,
   Jaejune/0000-0002-2420-2155; Reis, AlessanRSS/0000-0001-8486-7469
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Angeletti S, 2020, J MED VIROL, V92, P584, DOI 10.1002/jmv.25719
   Babcock GJ, 2004, J VIROL, V78, P4552, DOI 10.1128/JVI.78.9.4552-4560.2004
   Baig MH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112456
   Beauchamp KA, 2012, J CHEM THEORY COMPUT, V8, P1409, DOI 10.1021/ct2007814
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Cheng JL, 2006, PROTEINS, V62, P1125, DOI 10.1002/prot.20810
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Duffy S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.3000003
   Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3, 10.1002/cpps.20]
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Gurung AB, 2020, LIFE SCI, V255, DOI 10.1016/j.lfs.2020.117831
   Guvench O, 2011, J CHEM THEORY COMPUT, V7, P3162, DOI 10.1021/ct200328p
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Hsin WC, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0449-x
   Hu B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006698
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Joshi T, 2020, EUR REV MED PHARMACO, V24, P4529, DOI 10.26355/eurrev_202004_21036
   Kan B, 2005, J VIROL, V79, P11892, DOI 10.1128/JVI.79.18.11892-11900.2005
   Kuhn JH, 2004, CELL MOL LIFE SCI, V61, P2738, DOI 10.1007/s00018-004-4242-5
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Lindner HA, 2005, J VIROL, V79, P15199, DOI 10.1128/JVI.79.24.15199-15208.2005
   Lindorff-Larsen K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032131
   Lo YS, 2013, FEBS LETT, V587, P120, DOI 10.1016/j.febslet.2012.11.016
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Masters PS, 2006, ADV VIRUS RES, V66, P193, DOI 10.1016/S0065-3527(06)66005-3
   Masters PS, 2019, VIROLOGY, V537, P198, DOI 10.1016/j.virol.2019.08.031
   Memish ZA, 2013, EMERG INFECT DIS, V19, P1819, DOI 10.3201/eid1911.131172
   Mihindukulasuriya KA, 2008, J VIROL, V82, P5084, DOI 10.1128/JVI.02722-07
   Mortola E, 2004, FEBS LETT, V576, P174, DOI 10.1016/j.febslet.2004.09.009
   Nieto-Torres JL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004077
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Ruch TR, 2012, VIRUSES-BASEL, V4, P363, DOI 10.3390/v4030363
   Salemi M, 2004, J VIROL, V78, P1602, DOI 10.1128/JVI.78.3.1602-1603.2004
   Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Shimamoto Y, 2015, BIOORGAN MED CHEM, V23, P876, DOI 10.1016/j.bmc.2014.12.028
   Stoye J, 2011, ICTV 9 REPORT
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Velthuis AJWT, 2010, NUCLEIC ACIDS RES, V38, P203, DOI 10.1093/nar/gkp904
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Wang C, 2017, ONCOTARGET, V8, P12686, DOI 10.18632/oncotarget.8475
   Wang L, 1998, PROTEINS, V32, P438, DOI 10.1002/(SICI)1097-0134(19980901)32:4<438::AID-PROT4>3.0.CO;2-C
   Wang M, 2005, EMERG INFECT DIS, V11, P1860, DOI 10.3201/eid1112.041293
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Woo PCY, 2009, J VIROL, V83, P908, DOI 10.1128/JVI.01977-08
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 53
TC 2
Z9 2
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 3
PY 2020
VL 15
IS 9
AR e0238344
DI 10.1371/journal.pone.0238344
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NQ7QD
UT WOS:000571063300049
PM 32881907
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rodriguez-Molinero, A
   Perez-Lopez, C
   Galvez-Barron, C
   Minarro, A
   Macho, O
   Lopez, GF
   Robles, MT
   Dapena, MD
   Martinez, S
   Rodriguez, E
   Collado, I
AF Rodriguez-Molinero, Alejandro
   Perez-Lopez, Carlos
   Galvez-Barron, Cesar
   Minarro, Antonio
   Macho, Oscar
   Lopez, Gabriela F.
   Teresa Robles, Maria
   Dolores Dapena, Maria
   Martinez, Sergi
   Rodriguez, Ezequiel
   Collado, Isabel
CA COVID-19 Res Grp CSAPG
TI Observational study of azithromycin in hospitalized patients with
   COVID-19
SO PLOS ONE
LA English
DT Article
AB Background The rapid spread of the disease caused by the novel SARS-CoV-2 virus has led to the use of multiple therapeutic agents whose efficacy has not been previously demonstrated. The objective of this study was to analyze whether there is an association between the use of azithromycin and the evolution of the pulmonary disease or the time to discharge, in patients hospitalized with COVID-19. Methods This was an observational study on a cohort of 418 patients admitted to three regional hospitals in Catalonia, Spain. As primary outcomes, we studied the evolution of SAFI ratio (oxygen saturation/fraction of inspired oxygen) in the first 48 hours of treatment and the time to discharge. The results were compared between patients treated and untreated with the study drug through subcohort analyses matched for multiple clinical and prognostic factors, as well as through analysis of non-matched subcohorts, using Cox multivariate models adjusted for prognostic factors. Results There were 239 patients treated with azithromycin. Of these, 29 patients treated with azithromycin could be matched with an equivalent number of control patients. In the analysis of these matched subcohorts, SAFI at 48h had no significant changes associated to the use of azithromycin, though azithromycin treatment was associated with a longer time to discharge (10.0 days vs 6.7 days; log rank: p = 0.039). However, in the unmatched cohorts, the increased hospital stay associated to azithromycin use, was no significant after adjustment using Multivariate Cox regression models: hazard ratio 1.45 (IC95%: 0.88-2.41; p = 0.150). This study is limited by its small sample size and its observational nature; despite the strong pairing of the matched subcohorts and the adjustment of the Cox regression for multiple factors, the results may be affected by residual confusion. Conclusions We did not find a clinical benefit associated with the use of azithromycin, in terms of lung function 48 hours after treatment or length of hospital stay.
C1 [Rodriguez-Molinero, Alejandro; Galvez-Barron, Cesar; Macho, Oscar; Lopez, Gabriela F.; Teresa Robles, Maria; Dolores Dapena, Maria; Martinez, Sergi; Rodriguez, Ezequiel; Collado, Isabel] Consorci Sanitari Alt Penedes & Garraf CSAPG, Res Area, Barcelona, Spain.
   [Perez-Lopez, Carlos] Univ Politecn Cataluna, Tech Res Ctr Dependency Care & Autonomous Living, Vilanova and La Geltru, Spain.
   [Minarro, Antonio] Univ Barcelona, Sch Biol, Dept Genet Microbiol & Stat, Barcelona, Spain.
RP Rodriguez-Molinero, A (corresponding author), Consorci Sanitari Alt Penedes & Garraf CSAPG, Res Area, Barcelona, Spain.
EM rodriguez.molinero@gmail.com
RI Minarro, Antonio/G-1740-2015
OI Minarro, Antonio/0000-0001-7747-5299; Galvez-Barron,
   Cesar/0000-0001-5333-3317; Rodriguez-Molinero,
   Alejandro/0000-0002-9678-2654
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   American Institute of Ultrasound in Medicine, 2020, J ULTRASOUND MED, V21, pE1
   Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099
   Bhimraj A, 2020, CLIN INFECT DIS
   Cavalcanti AB, 2020, N ENGL J MED
   Tran DH, 2019, J ANTIBIOT, V72, P759, DOI 10.1038/s41429-019-0204-x
   Di Gennaro F, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082690
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Geleris J, 2020, N ENGL J MED
   Kawamura K, 2018, INT J ANTIMICROB AG, V51, P918, DOI 10.1016/j.ijantimicag.2018.02.009
   Kuo CH, 2019, J MICROBIOL IMMUNOL, V52, P872, DOI 10.1016/j.jmii.2019.10.001
   Lagier J-C, 2020, TRAVEL MED INFECT DI, P101791, DOI 10.1016/j.tmaid.2020.101791
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Li C, 2019, ANTIMICROB AGENTS CH
   Lu XF, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01455-4
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Million M, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101738
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Parra-Lara LG, 2020, J GLOB ANTIMICROB RE
   Rice TW, 2007, CHEST, V132, P410, DOI 10.1378/chest.07-0617
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   Rosenberg ES, 2020, JAMA
   Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x
   Zhang Y, 2019, MICROBIOL IMMUNOL, V63, P343, DOI 10.1111/1348-0421.12726
NR 26
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 3
PY 2020
VL 15
IS 9
AR e0238681
DI 10.1371/journal.pone.0238681
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NQ7QD
UT WOS:000571063300066
PM 32881982
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mato, AR
   Roeker, LE
   Lamanna, N
   Allan, JN
   Leslie, L
   Pagel, JM
   Patel, K
   Osterborg, A
   Wojenski, D
   Kamdar, M
   Huntington, SF
   Davids, MS
   Brown, JR
   Antic, D
   Jacobs, R
   Ahn, IE
   Pu, J
   Isaac, KM
   Barr, PM
   Ujjani, CS
   Geyer, MB
   Berman, E
   Zelenetz, AD
   Malakhov, N
   Furman, RR
   Koropsak, M
   Bailey, N
   Hanson, L
   Perini, GF
   Ma, S
   Ryan, CE
   Wiestner, A
   Portell, CA
   Shadman, M
   Chong, EA
   Brander, DM
   Sundaram, S
   Seddon, AN
   Seymour, E
   Patel, M
   Martinez-Calle, N
   Munir, T
   Walewska, R
   Broom, A
   Walter, H
   El-Sharkawi, D
   Parry, H
   Wilson, MR
   Patten, PEM
   Hernandez-Rivas, JA
   Miras, F
   Escalada, NF
   Ghione, P
   Nabhan, C
   Lebowitz, S
   Bhavsar, E
   Lopez-Jimenez, J
   Naya, D
   Garcia-Marco, JA
   Skanland, SS
   Cordoba, R
   Eyre, TA
AF Mato, Anthony R.
   Roeker, Lindsey E.
   Lamanna, Nicole
   Allan, John N.
   Leslie, Lori
   Pagel, John M.
   Patel, Krish
   Osterborg, Anders
   Wojenski, Daniel
   Kamdar, Manali
   Huntington, Scott F.
   Davids, Matthew S.
   Brown, Jennifer R.
   Antic, Darko
   Jacobs, Ryan
   Ahn, Inhye E.
   Pu, Jeffrey
   Isaac, Krista M.
   Barr, Paul M.
   Ujjani, Chaitra S.
   Geyer, Mark B.
   Berman, Ellin
   Zelenetz, Andrew D.
   Malakhov, Nikita
   Furman, Richard R.
   Koropsak, Michael
   Bailey, Neil
   Hanson, Lotta
   Perini, Guilherme F.
   Ma, Shuo
   Ryan, Christine E.
   Wiestner, Adrian
   Portell, Craig A.
   Shadman, Mazyar
   Chong, Elise A.
   Brander, Danielle M.
   Sundaram, Suchitra
   Seddon, Amanda N.
   Seymour, Erlene
   Patel, Meera
   Martinez-Calle, Nicolas
   Munir, Talha
   Walewska, Renata
   Broom, Angus
   Walter, Harriet
   El-Sharkawi, Dima
   Parry, Helen
   Wilson, Matthew R.
   Patten, Piers E. M.
   Hernandez-Rivas, Jose-angel
   Miras, Fatima
   Escalada, Noemi Fernandez
   Ghione, Paola
   Nabhan, Chadi
   Lebowitz, Sonia
   Bhavsar, Erica
   Lopez-Jimenez, Javier
   Naya, Daniel
   Garcia-Marco, Jose Antonio
   Skanland, Sigrid S.
   Cordoba, Raul
   Eyre, Toby A.
TI Outcomes of COVID-19 in patients with CLL: a multicenter international
   experience
SO BLOOD
LA English
DT Article
ID CANCER
AB Given advanced age, comorbidities, and immune dysfunction, chronic lymphocytic leukemia (CLL) patients may be at particularly high risk of infection and poor outcomes related to coronavirus disease 2019 (COVID-19). Robust analysis of outcomes for CLL patients, particularly examining effects of baseline characteristics and CLL-directed therapy, is critical to optimally manage CLL patients through this evolving pandemic. CLL patients diagnosed with symptomatic COVID-19 across 43 international centers (n = 198) were included. Hospital admission occurred in 90%. Median age at COVI D-19 diagnosis was 70.5 years. Median Cumulative Illness Rating Scale score was 8 (range, 4-32). Thirty-nine percent were treatment naive ("watch and wait"), while 61% had received >= 1 CLL-directed therapy (median, 2; range, 1-8). Ninety patients (45%) were receiving active CLL therapy at COVID-19 diagnosis, most commonly Bruton tyrosine kinase inhibitors (BTKi's; n = 68/90 [76%]). At a median follow-up of 16 days, the overall case fatality rate was 33%, though 25% remain admitted. Watch-and-wait and treated cohorts had similar rates of admission (89% vs 90%), intensive care unit admission (35% vs 36%), intubation (33% vs 25%), and mortality (37% vs 32%). CLL-directed treatment with BTKi's at COVID-19 diagnosis did not impact survival (case fatality rate, 34% vs 35%), though the BTKi was held during the COVID-19 course for most patients. These data suggest that the subgroup of CLL patients admitted with COVID-19, regardless of disease phase or treatment status, are at high risk of death. Future epidemiologic studies are needed to assess severe acute respiratory syndrome coronavirus 2 infection risk, these data should be validated independently, and randomized studies of BTKi's in COVID-19 are needed to provide definitive evidence of benefit.
C1 [Mato, Anthony R.; Roeker, Lindsey E.; Geyer, Mark B.; Berman, Ellin; Zelenetz, Andrew D.; Ghione, Paola; Lebowitz, Sonia] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.
   [Lamanna, Nicole] Columbia Univ, Med Ctr, New York, NY USA.
   [Allan, John N.; Bhavsar, Erica] Weill Cornell Med, New York Presbyterian Hosp, New York, NY USA.
   [Leslie, Lori] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA.
   [Pagel, John M.; Patel, Krish] Swedish Canc Inst, Seattle, WA USA.
   [Osterborg, Anders] Karolinska Inst, Solna, Sweden.
   [Wojenski, Daniel] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
   [Kamdar, Manali] Univ Colorado, Ctr Canc, Aurora, CO USA.
   [Huntington, Scott F.] Yale Univ, Dept Internal Med, Div Hematol & Oncol, New Haven, CT USA.
   [Davids, Matthew S.; Brown, Jennifer R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Antic, Darko] Univ Belgrade, Clin Ctr Serbia, Belgrade, Serbia.
   [Jacobs, Ryan] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA.
   [Ahn, Inhye E.] NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA.
   [Pu, Jeffrey] Upstate Canc Ctr, Syracuse, NY USA.
   [Isaac, Krista M.] Emily Couric Clin Canc Ctr, Charlottesville, VA USA.
   [Barr, Paul M.] Univ Rochester, Wilmot Canc Inst, Rochester, NY USA.
   [Ujjani, Chaitra S.; Shadman, Mazyar] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
   [Perini, Guilherme F.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Chong, Elise A.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
   [Brander, Danielle M.] Duke Univ, Sch Med, Dept Internal Med, Div Hematol & Oncol, Durham, NC USA.
   [Sundaram, Suchitra] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA.
   [Seddon, Amanda N.] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
   [Seymour, Erlene; Patel, Meera] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
   [Martinez-Calle, Nicolas] Nottingham Univ Hosp NHS Trust, Nottingham, England.
   [Munir, Talha] St James Univ Hosp, Leeds, W Yorkshire, England.
   [Walewska, Renata] Royal Bournemouth Hosp, Bournemouth, Dorset, England.
   [Broom, Angus] Western Gen Hosp, Edinburgh, Midlothian, Scotland.
   [Walter, Harriet] Leicester Royal Infirm, Leicester, Leics, England.
   [El-Sharkawi, Dima] Royal Marsden Hosp, London, England.
   [Parry, Helen] Univ Birmingham, Dept Internal Med, Div Hematol & Oncol, Birmingham, W Midlands, England.
   [Wilson, Matthew R.] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland.
   [Patten, Piers E. M.] Kings Coll London, Comprehens Canc Ctr, London, England.
   [Hernandez-Rivas, Jose-angel] Hosp Univ Infanta Leonor, Madrid, Spain.
   [Miras, Fatima] Univ Hosp Doce Octubre, Madrid, Spain.
   [Escalada, Noemi Fernandez] Marques Valdecilla Univ Hosp, Santander, Spain.
   [Nabhan, Chadi] Caris Life Sci, Irving, TX USA.
   [Garcia-Marco, Jose Antonio] Univ Hosp Ramon & Cajal, Madrid, Spain.
   [Naya, Daniel] Univ Hosp Infanta Elena, Madrid, Spain.
   [Garcia-Marco, Jose Antonio] Puerta Hierra Majadahonda Univ Hosp, Madrid, Spain.
   [Skanland, Sigrid S.] Univ Oslo, Inst Canc Res, Dept Canc Immunol, Oslo, Norway.
   [Cordoba, Raul] Fdn Jimenez Diaz Univ Hosp, Madrid, Spain.
   [Eyre, Toby A.] Oxford Univ Hosp NHS Fdn Trust, Dept Haematol, Oxford, England.
RP Mato, AR (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA.
EM matoa@mskcc.org
RI Lamanna, Nicole/ABB-7835-2020; Pu, Jeffrey/ABG-3867-2020; ghione,
   paola/AAB-7391-2020; Martinez-Calle, Nicolas/ABE-4394-2020; Barr,
   Paul/V-2574-2019
OI Pu, Jeffrey/0000-0001-7498-3159; ghione, paola/0000-0001-6986-7954;
   Martinez-Calle, Nicolas/0000-0002-5184-9464; Barr,
   Paul/0000-0002-9733-401X; Bailey, Neil/0000-0002-3809-3236;
   Hernandez-Rivas, Jose-Angel/0000-0003-4550-757X; Roeker,
   Lindsey/0000-0002-3806-059X
FU National Institutes of Health/National Cancer Institute (Cancer Center
   Support Grant) [P30 CA008748]; Intramural Program of the National Heart,
   Lung, and Blood Institute; American Society of Hematology Scholar Award;
   Oxford NIHR Biomedical Research CentreNational Institute for Health
   Research (NIHR)
FX This research was supported in part by the National Institutes of
   Health/National Cancer Institute (Cancer Center Support Grant P30
   CA008748). L.E.R. recognizes support from the American Society of
   Hematology Research Training Award for Fellows outside of the submitted
   work. I.E.A. receives research support from the Intramural Program of
   the National Heart, Lung, and Blood Institute and an American Society of
   Hematology Scholar Award. T.A.E. recognizes support from the Oxford NIHR
   Biomedical Research Centre.
CR Baumann T, 2020, LEUKEMIA, V34, P1954, DOI 10.1038/s41375-020-0870-5
   Chong EA, 2020, CLIN CANCER RES, V26, P3514, DOI 10.1158/1078-0432.CCR-20-1427
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Forconi F, 2015, BLOOD, V126, P573, DOI 10.1182/blood-2015-03-567388
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   He WJ, 2020, LEUKEMIA, V34, P1637, DOI 10.1038/s41375-020-0836-7
   Horby P, 2020, STATEMENT CHIEF INVE
   Jin XH, 2020, LANCET HAEMATOL, V7, pE351, DOI 10.1016/S2352-3026(20)30074-0
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Malard F, 2020, BONE MARROW TRANSPL, V55, P2180, DOI 10.1038/s41409-020-0931-4
   Martin-Moro F, 2020, BRIT J HAEMATOL, V190, pE16, DOI 10.1111/bjh.16801
   MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N
   National Cancer Institute, 2020, COR GUID
   Paneesha S, 2020, LEUKEMIA RES, V93, DOI 10.1016/j.leukres.2020.106366
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Robilotti EV, 2020, NAT MED, V26, P1218, DOI 10.1038/s41591-020-0979-0
   Roschewski M, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd0110
   Shadman M, 2020, COVID 19 CLL FREQUEN
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Solodky ML, 2020, ANN ONCOL          S, P39793, DOI [10.1016/j.annonc.2020.04, DOI 10.1016/J.ANNONC.2020.04]
   Strati P, 2015, BLOOD, V126, P454, DOI 10.1182/blood-2015-02-585059
   Treon SP, 2020, BLOOD, V135, P1912, DOI 10.1182/blood.2020006288
   UK CLL Forum, 2020, PRACT GUID MAN CLL C
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 29
TC 7
Z9 7
U1 5
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD SEP 3
PY 2020
VL 136
IS 10
BP 1134
EP 1143
DI 10.1182/blood.2020006965
PG 10
WC Hematology
SC Hematology
GA NR3EW
UT WOS:000571446600007
PM 32688395
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Zhang, NN
   Li, XF
   Deng, YQ
   Zhao, H
   Huang, YJ
   Yang, G
   Huang, WJ
   Gao, P
   Zhou, C
   Zhang, RR
   Guo, Y
   Sun, SH
   Fan, H
   Zu, SL
   Chen, Q
   He, Q
   Cao, TS
   Huang, XY
   Qiu, HY
   Nie, JH
   Jiang, YH
   Yan, HY
   Ye, Q
   Zhong, X
   Xue, XL
   Zha, ZY
   Zhou, DS
   Yang, X
   Wang, YC
   Ying, B
   Qin, CF
AF Zhang, Na-Na
   Li, Xiao-Feng
   Deng, Yong-Qiang
   Zhao, Hui
   Huang, Yi-Jiao
   Yang, Guan
   Huang, Wei-Jin
   Gao, Peng
   Zhou, Chao
   Zhang, Rong-Rong
   Guo, Yan
   Sun, Shi-Hui
   Fan, Hang
   Zu, Shu-Long
   Chen, Qi
   He, Qi
   Cao, Tian-Shu
   Huang, Xing-Yao
   Qiu, Hong-Ying
   Nie, Jian-Hui
   Jiang, Yuhang
   Yan, Hua-Yuan
   Ye, Qing
   Zhong, Xia
   Xue, Xia-Lin
   Zha, Zhen-Yu
   Zhou, Dongsheng
   Yang, Xiao
   Wang, You-Chun
   Ying, Bo
   Qin, Cheng-Feng
TI A Thermostable mRNA Vaccine against COVID-19
SO CELL
LA English
DT Article
ID CORONAVIRUS; INFECTION
AB There is an urgent need for vaccines against coronavirus disease 2019 (COVID-19) because of the ongoing SARS-CoV-2 pandemic. Among all approaches, a messenger RNA (mRNA)-based vaccine has emerged as a rapid and versatile platform to quickly respond to this challenge. Here, we developed a lipid nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of SARS-CoV-2 as a vaccine candidate (called ARCoV). Intramuscular immunization of ARCoV mRNA-LNP elicited robust neutralizing antibodies against SARS-CoV-2 as well as a Th1-biased cellular response in mice and non-human primates. Two doses of ARCoV immunization in mice conferred complete protection against the challenge of a SARS-CoV-2 mouse-adapted strain. Additionally, ARCoV is manufactured as a liquid formulation and can be stored at room temperature for at least 1 week. ARCoV is currently being evaluated in phase 1 clinical trials.
C1 [Zhang, Na-Na; Li, Xiao-Feng; Deng, Yong-Qiang; Zhao, Hui; Huang, Yi-Jiao; Zhou, Chao; Zhang, Rong-Rong; Guo, Yan; Sun, Shi-Hui; Fan, Hang; Zu, Shu-Long; Chen, Qi; Cao, Tian-Shu; Huang, Xing-Yao; Qiu, Hong-Ying; Ye, Qing; Zhou, Dongsheng; Qin, Cheng-Feng] Acad Mil Med Sci, Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China.
   [Zhang, Na-Na] Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China.
   [Yang, Guan; He, Qi; Yang, Xiao] Beijing Inst Life, Natl Ctr Prot Sci Beijing, Beijing Proteome Res Ctr, State Key Lab Prote, Beijing 102206, Peoples R China.
   [Huang, Wei-Jin; Nie, Jian-Hui; Wang, You-Chun] Natl Inst Food & Drug Control NIFDC, Inst Biol Prod Control, Div HIV AIDS & Sex Transmitted Virus Vaccines, Beijing 102629, Peoples R China.
   [Gao, Peng; Jiang, Yuhang; Yan, Hua-Yuan; Zhong, Xia; Xue, Xia-Lin; Zha, Zhen-Yu; Ying, Bo] Suzhou Abogen Biosci Co Ltd, Suzhou 215123, Peoples R China.
RP Qin, CF (corresponding author), Acad Mil Med Sci, Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China.; Wang, YC (corresponding author), Natl Inst Food & Drug Control NIFDC, Inst Biol Prod Control, Div HIV AIDS & Sex Transmitted Virus Vaccines, Beijing 102629, Peoples R China.; Ying, B (corresponding author), Suzhou Abogen Biosci Co Ltd, Suzhou 215123, Peoples R China.
EM wangyc@nifdc.org.cn; bo.ying@abogenbio.com; qincf@bmi.ac.cn
RI Li, Xiao-Feng/ABF-5188-2020; Qin, Cheng-Feng/I-6839-2019
OI Qin, Cheng-Feng/0000-0002-0632-2807; Huang, Weijin/0000-0002-4246-8889
FU National Key Research and Development Project of China [2020YFC0842200,
   2020YFA0707801, 2016YFD0500304]; special grant from AMS [JK2020NC002];
   National Science Fund for Distinguished Young ScholarsNational Natural
   Science Foundation of China (NSFC)National Science Fund for
   Distinguished Young Scholars [81925025]; Innovative Research Group from
   the NSFC [81621005]; Innovation Fund for Medical Sciences from the
   Chinese Academy of Medical Sciences [2019-I2M-5-049]
FX We thank Drs. Chunyun Sun, Jing Ma, and Qiang Gao for critical materials
   and helpful discussions. This work was supported by the National Key
   Research and Development Project of China (2020YFC0842200,
   2020YFA0707801, and 2016YFD0500304) and a special grant from AMS
   (JK2020NC002). C.-F.Q. was supported by the National Science Fund for
   Distinguished Young Scholars (81925025), the Innovative Research Group
   (81621005) from the NSFC, and the Innovation Fund for Medical Sciences
   (2019-I2M-5-049) from the Chinese Academy of Medical Sciences.
CR Alameh Mohamad-Gabriel, 2020, Curr Top Microbiol Immunol, DOI 10.1007/82_2020_202
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Bahl K, 2017, MOL THER, V25, P1316, DOI 10.1016/j.ymthe.2017.03.035
   Becerra-Flores M, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13525
   CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Corbett K.S., 2020, BIORXIV, DOI [10.1101/2020.06.11, DOI 10.1101/2020.06.11]
   Erhart F, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0621-2
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Gu H., 2020, BIORXIV, DOI [10.1101/2020.05.02.073411, DOI 10.1101/2020.05.02.073411]
   HAMILTON MA, 1977, ENVIRON SCI TECHNOL, V11, P714, DOI 10.1021/es60130a004
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ickenstein LM, 2019, EXPERT OPIN DRUG DEL, V16, P1205, DOI 10.1080/17425247.2019.1669558
   Jackson NAC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0159-8
   Jiang SB, 2020, NATURE, V579, P321, DOI 10.1038/d41586-020-00751-9
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Korber B, 2020, SPIKE MUTATION PIPEL, V12, P122, DOI [10.1101/2020.04.29.069054, DOI 10.1101/2020.04.29.069054]
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li XF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02975-w
   Lindsay KE, 2019, NAT BIOMED ENG, V3, P371, DOI 10.1038/s41551-019-0378-3
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Lu S, 2020, COMP SARS COV 2 INFE, DOI [10.1101/2020.04.08.031807, DOI 10.1101/2020.04.08.031807]
   Maruggi G, 2019, MOL THER, V27, P757, DOI 10.1016/j.ymthe.2019.01.020
   Mascola JR, 2020, NAT REV IMMUNOL, V20, P87, DOI 10.1038/s41577-019-0243-3
   Maugeri M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12275-6
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   OLSEN CW, 1992, J VIROL, V66, P956, DOI 10.1128/JVI.66.2.956-965.1992
   Pardi Norbert, 2020, Curr Opin Immunol, V65, P14, DOI 10.1016/j.coi.2020.01.008
   Pardi N, 2015, J CONTROL RELEASE, V217, P345, DOI 10.1016/j.jconrel.2015.08.007
   Quinlan B. D., 2020, BIORXIV, DOI [10.1101/2020.04.10.036418, DOI 10.1101/2020.04.10.036418]
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Rodriguez-Ruiz ME, 2018, ANN ONCOL, V29, P1312, DOI 10.1093/annonc/mdy089
   Ruckwardt TJ, 2019, IMMUNITY, V51, P429, DOI 10.1016/j.immuni.2019.08.007
   Semple SC, 2010, NAT BIOTECHNOL, V28, P172, DOI 10.1038/nbt.1602
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Stitz L, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006108
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   van Doremalen N., 2020, CHADOX1 NCOV 19 VACC, DOI [10.1101/2020.05.13, DOI 10.1101/2020.05.13]
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Wu LP, 2007, EMERG INFECT DIS, V13, P1562, DOI 10.3201/eid1310.070576
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 48
TC 9
Z9 9
U1 20
U2 20
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD SEP 3
PY 2020
VL 182
IS 5
BP 1271
EP +
DI 10.1016/j.cell.2020.07.024
PG 29
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NR3DG
UT WOS:000571442200016
PM 32795413
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Li, QQ
   Wu, JJ
   Nie, JH
   Zhang, L
   Hao, H
   Liu, S
   Zhao, CY
   Zhang, Q
   Liu, H
   Nie, LL
   Qin, HY
   Wang, M
   Lu, Q
   Li, XY
   Sun, QY
   Liu, JK
   Zhang, LQ
   Li, XG
   Huang, WJ
   Wang, YC
AF Li, Qianqian
   Wu, Jiajing
   Nie, Jianhui
   Zhang, Li
   Hao, Huan
   Liu, Shuo
   Zhao, Chenyan
   Zhang, Qi
   Liu, Huan
   Nie, Lingling
   Qin, Haiyang
   Wang, Meng
   Lu, Qiong
   Li, Xiaoyu
   Sun, Qiyu
   Liu, Junkai
   Zhang, Linqi
   Li, Xuguang
   Huang, Weijin
   Wang, Youchun
TI The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and
   Antigenicity
SO CELL
LA English
DT Article
ID SARS CORONAVIRUS; GLYCAN SHIELD; EBOLA-VIRUS; HIV-1 GP120; PROTEIN;
   GLYCOSYLATION; GLYCOPROTEIN; ANTIBODIES; 2019-NCOV; TARGET
AB The spike protein of SARS-CoV-2 has been undergoing mutations and is highly glycosylated. It is critically important to investigate the biological significance of these mutations. Here, we investigated 80 variants and 26 glycosylation site modifications for the infectivity and reactivity to a panel of neutralizing antibodies and sera from convalescent patients. D614G, along with several variants containing both D614G and another amino acid change, were significantly more infectious. Most variants with amino acid change at receptor binding domain were less infectious, but variants including A475V, L452R, V483A, and F490L became resistant to some neutralizing antibodies. Moreover, the majority of glycosylation deletions were less infectious, whereas deletion of both N331 and N343 glycosylation drastically reduced infectivity, revealing the importance of glycosylation for viral infectivity. Interestingly, N234Q was markedly resistant to neutralizing antibodies, whereas N165Q became more sensitive. These findings could be of value in the development of vaccine and therapeutic antibodies.
C1 [Li, Qianqian; Wu, Jiajing; Nie, Jianhui; Zhang, Li; Hao, Huan; Liu, Shuo; Zhao, Chenyan; Liu, Huan; Nie, Lingling; Qin, Haiyang; Wang, Meng; Lu, Qiong; Li, Xiaoyu; Sun, Qiyu; Liu, Junkai; Huang, Weijin; Wang, Youchun] Natl Inst Food & Drug Control NIFDC, Inst Biol Prod Control, Div HIV AIDS & Sex Transmitted Virus Vaccines, 31 Huatuo St, Beijing 102629, Peoples R China.
   [Li, Qianqian; Wu, Jiajing; Nie, Jianhui; Zhang, Li; Hao, Huan; Liu, Shuo; Zhao, Chenyan; Liu, Huan; Nie, Lingling; Qin, Haiyang; Wang, Meng; Lu, Qiong; Li, Xiaoyu; Sun, Qiyu; Liu, Junkai; Huang, Weijin; Wang, Youchun] WHO Collaborating Ctr Standardizat & Evaluat Biol, 31 Huatuo St, Beijing 102629, Peoples R China.
   [Li, Qianqian; Wang, Youchun] Peking Union Med Coll, Grad Sch, 9 Dongdan Santiao, Beijing 100730, Peoples R China.
   [Zhang, Qi; Zhang, Linqi] Tsinghua Univ, Ctr Global Hlth & Infect Dis, Comprehens AIDS Res Ctr, Sch Med, Beijing 100084, Peoples R China.
   [Zhang, Qi; Zhang, Linqi] Tsinghua Univ, Beijing Adv Innovat Ctr Struct Biol, Sch Med, Beijing 100084, Peoples R China.
   [Li, Xuguang] Hlth Canada, Ctr Vaccine Evaluat, HPFB, Biol & Genet Therapies Directorate, Ottawa, ON K1A 0K9, Canada.
   [Li, Xuguang] WHO Collaborating Ctr Standardizat & Evaluat Biol, Ottawa, ON K1A 0K9, Canada.
RP Huang, WJ; Wang, YC (corresponding author), Natl Inst Food & Drug Control NIFDC, Inst Biol Prod Control, Div HIV AIDS & Sex Transmitted Virus Vaccines, 31 Huatuo St, Beijing 102629, Peoples R China.; Huang, WJ; Wang, YC (corresponding author), WHO Collaborating Ctr Standardizat & Evaluat Biol, 31 Huatuo St, Beijing 102629, Peoples R China.; Wang, YC (corresponding author), Peking Union Med Coll, Grad Sch, 9 Dongdan Santiao, Beijing 100730, Peoples R China.
EM huangweijin@nifdc.org.cn; wangyc@nifdc.org.cn
OI Huang, Weijin/0000-0002-4246-8889
FU National Science and Technology Major Projects of Drug Discovery
   [2018ZX09101001]; National Science and Technology Major Projects of
   Infectious Disease [2017ZX10304402]; Bill and Melinda Gates
   FoundationBill & Melinda Gates Foundation [INV-006379]
FX We would like to thank Prof. X. Sunney Xie of Peking University for
   providing mAb X593; Prof. JinghuaYan of the Institute of Microbiology,
   Chinese Academy of Sciences for mAbs CA1 and CB6; Dr. Liangzhi Xie from
   Sino Biological Company for mAbs H014 and H00S022 and the 293T-hACE2
   cell line; Prof. Linqi Zhang of Tsinghua University for mAbs P2C-1F11,
   P2B-2F6, AB35, 261-262, 157, and 247; and Prof. Yan Wu of the Institute
   of Microbiology, Chinese Academy of Sciences for H4 and B38. We would
   like to thank Dr. Xiaoming Yang from China National Biotec Group Company
   Ltd. for providing convalescent sera (CS1, CS2, CS3, CS4, CS6, CS7, CS8,
   and CS10) and Ms. Fangyu Dong from China Biologic Products Holdings,
   Inc. for convalescent sera CS86 and CS87. This work was supported by the
   National Science and Technology Major Projects of Drug Discovery
   (2018ZX09101001), the National Science and Technology Major Projects of
   Infectious Disease (2017ZX10304402), and the Bill and Melinda Gates
   Foundation (INV-006379).
CR Becerra-Flores M, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13525
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Dawood AA, 2020, NEW MICROB NEW INFEC, V35, DOI 10.1016/j.nmni.2020.100673
   Deng WK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111988
   Diehl WE, 2016, CELL, V167, P1088, DOI 10.1016/j.cell.2016.10.014
   Doores KJ, 2015, FEBS J, V282, P4679, DOI 10.1111/febs.13530
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Duffy S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.3000003
   Francois KO, 2011, J BIOL CHEM, V286, P42900, DOI 10.1074/jbc.M111.274456
   He YX, 2004, J IMMUNOL, V173, P4050, DOI 10.4049/jimmunol.173.6.4050
   Herfst S, 2012, SCIENCE, V336, P1534, DOI 10.1126/science.1213362
   Huang Y, 2020, J VIROL, V94, DOI 10.1128/JVI.01432-19
   Hulswit RJG, 2016, ADV VIRUS RES, V96, P29, DOI 10.1016/bs.aivir.2016.08.004
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Kong L, 2015, PROTEINS, V83, P590, DOI 10.1002/prot.24747
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Kumar Swatantra, 2020, VirusDisease, V31, DOI 10.1007/s13337-020-00571-5
   Lauring AS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001005
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li Y, 2008, J VIROL, V82, P638, DOI 10.1128/JVI.01691-07
   Lv M, 2020, EUROSURVEILLANCE, V25, P14, DOI 10.2807/1560-7917.ES.2020.25.15.2000125
   Lv Z., 2020, BIORXIV, DOI [10.1101/2020.06.02.129098, DOI 10.1101/2020.06.02.129098]
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Ning TT, 2019, J INFECT DIS, V219, P19, DOI 10.1093/infdis/jiy408
   Petrie JG, 2019, J INFECT DIS, V219, P3, DOI 10.1093/infdis/jiy409
   Saha P, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20201312
   Sheikh JA, 2020, INFECT GENET EVOL, V84, DOI 10.1016/j.meegid.2020.104330
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Tsetsarkin KA, 2007, PLOS PATHOG, V3, P1895, DOI 10.1371/journal.ppat.0030201
   Urbanowicz RA, 2016, CELL, V167, P1079, DOI 10.1016/j.cell.2016.10.013
   Utachee P, 2010, J VIROL, V84, P4311, DOI 10.1128/JVI.02619-09
   van Dorp L, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104351
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang WB, 2015, JAIDS-J ACQ IMM DEF, V69, P270, DOI 10.1097/QAI.0000000000000595
   Wang WB, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-14
   Watanabe Y, 2020, SCIENCE, V369, P330, DOI 10.1126/science.abb9983
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yang XL, 2019, NAT MICROBIOL, V4, P390, DOI 10.1038/s41564-018-0328-y
   Zhang XJ, 2015, J GEN VIROL, V96, P1248, DOI 10.1099/vir.0.000082
NR 45
TC 27
Z9 27
U1 13
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD SEP 3
PY 2020
VL 182
IS 5
BP 1284
EP +
DI 10.1016/j.cell.2020.07.012
PG 20
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NR3DG
UT WOS:000571442200017
PM 32730807
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Starr, TN
   Greaney, AJ
   Hilton, SK
   Ellis, D
   Crawford, KHD
   Dingens, AS
   Navarro, MJ
   Bowen, JE
   Tortorici, MA
   Walls, AC
   King, NP
   Veesler, D
   Bloom, JD
AF Starr, Tyler N.
   Greaney, Allison J.
   Hilton, Sarah K.
   Ellis, Daniel
   Crawford, Katharine H. D.
   Dingens, Adam S.
   Navarro, Mary Jane
   Bowen, John E.
   Tortorici, M. Alejandra
   Walls, Alexandra C.
   King, Neil P.
   Veesler, David
   Bloom, Jesse D.
TI Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals
   Constraints on Folding and ACE2 Binding
SO CELL
LA English
DT Article
ID POTENT NEUTRALIZING ANTIBODIES; SARS-LIKE CORONAVIRUS; AFFINITY
   MATURATION; VIRAL DETERMINANTS; STRUCTURAL BASIS; SURFACE DISPLAY; SPIKE
   PROTEIN; EVOLUTION; ESCAPE; STABILITY
AB The receptor binding domain (RBD) of the SARS-CoV-2 spike glycoprotein mediates viral attachment to ACE2 receptor and is a major determinant of host range and a dominant target of neutralizing antibodies. Here, we experimentally measure how all amino acid mutations to the RBD affect expression of folded protein and its affinity for ACE2. Most mutations are deleterious for RBD expression and ACE2 binding, and we identify constrained regions on the RBD's surface that may be desirable targets for vaccines and antibody-based therapeutics. But a substantial number of mutations are well tolerated or even enhance ACE2 binding, including at ACE2 interface residues that vary across SARS-related coronaviruses. However, we find no evidence that these ACE2-affinity-enhancing mutations have been selected in current SARS-CoV-2 pandemic isolates. We present an interactive visualization and open analysis pipeline to facilitate use of our dataset for vaccine design and functional annotation of mutations observed during viral surveillance.
C1 [Starr, Tyler N.; Greaney, Allison J.; Hilton, Sarah K.; Crawford, Katharine H. D.; Dingens, Adam S.; Bloom, Jesse D.] Fred Hutchinson Canc Res Ctr, Basic Sci Div, Seattle, WA 98109 USA.
   [Starr, Tyler N.; Greaney, Allison J.; Hilton, Sarah K.; Crawford, Katharine H. D.; Dingens, Adam S.; Bloom, Jesse D.] Fred Hutchinson Canc Res Ctr, Computat Biol Program, Seattle, WA 98109 USA.
   [Greaney, Allison J.; Hilton, Sarah K.; Crawford, Katharine H. D.; Bloom, Jesse D.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
   [Greaney, Allison J.; Crawford, Katharine H. D.] Univ Washington, Med Scientist Training Program, Seattle, WA 98195 USA.
   [Ellis, Daniel; King, Neil P.] Univ Washington, Inst Prot Design, Seattle, WA 98195 USA.
   [Ellis, Daniel; Navarro, Mary Jane; Bowen, John E.; Tortorici, M. Alejandra; Walls, Alexandra C.; King, Neil P.; Veesler, David] Univ Washington, Dept Biochem, Seattle, WA 98195 USA.
   [Ellis, Daniel] Univ Washington, Grad Program Mol & Cellular Biol, Seattle, WA 98195 USA.
   [Bloom, Jesse D.] Howard Hughes Med Inst, Seattle, WA 98109 USA.
RP Bloom, JD (corresponding author), Fred Hutchinson Canc Res Ctr, Basic Sci Div, Seattle, WA 98109 USA.; Bloom, JD (corresponding author), Fred Hutchinson Canc Res Ctr, Computat Biol Program, Seattle, WA 98109 USA.; Bloom, JD (corresponding author), Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.; Bloom, JD (corresponding author), Howard Hughes Med Inst, Seattle, WA 98109 USA.
EM jbloom@fredhutch.org
OI Crawford, Katharine/0000-0002-6223-4019; Dingens,
   Adam/0000-0001-9603-9409; Bowen, John/0000-0003-3590-9727; Tortorici, M.
   Alejandra/0000-0002-2260-2577; Greaney, Allison/0000-0001-7202-3349;
   Hilton, Sarah/0000-0001-9278-3644
FU NIAID/NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [R01AI141707, R01AI12893, HHSN272201700059C,
   F30AI149928, T32AI083203]; Pew Biomedical Scholars Award; Burroughs
   Wellcome Investigators in the Pathogenesis of Infectious Diseases;
   NIGMS/NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R01GM120553]; Bill & Melinda Gates
   FoundationBill & Melinda Gates Foundation [OPP1156262]; Fast Grants;
   Damon Runyon Cancer Research Foundation [DRG-2381-19]
FX We thank Keara Malone for experimental assistance, Katherine Xue for
   helpful suggestions, and Frederick Matsen for intellectual support and
   hospitality. We thank the Flow Cytometry and Genomics core facilities at
   the Fred Hutchinson Cancer Research Center for experimental support as
   well as Mike Murphy, Deleah Pettie, and the Mammalian Production Core at
   the Institute for Protein Design for assistance with protein
   purification. This work was supported by the NIAID/NIH (R01AI141707 and
   R01AI12893 to J.D.B., HHSN272201700059C to D.V., F30AI149928 to
   K.H.D.C., and T32AI083203 to A.J.G.), NIGMS/NIH (R01GM120553 to D.V.), a
   Pew Biomedical Scholars Award to D.V., Burroughs Wellcome Investigators
   in the Pathogenesis of Infectious Diseases awards to D.V. and J.D.B.,
   the Bill & Melinda Gates Foundation (OPP1156262 to D.V. and N.P.K.),
   Fast Grants to N.P.K. and D.V., and a generous gift from the Open
   Philanthropy Project to N.P.K. T.N.S. is a Washington Research
   Foundation Innovation Fellow at the University of Washington Institute
   for Protein Design and a Howard Hughes Medical Institute Fellow of the
   Damon Runyon Cancer Research Foundation (DRG-2381-19). J.D.B. is an
   Investigator of the Howard Hughes Medical Institute.
CR Adams RM, 2016, ELIFE, V5, DOI 10.7554/eLife.23156
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831
   Becker MM, 2008, P NATL ACAD SCI USA, V105, P19944, DOI 10.1073/pnas.0808116105
   Bedford Trevor, 2020, medRxiv, DOI 10.1101/2020.04.02.20051417
   Bloom JD, 2014, MOL BIOL EVOL, V31, P1956, DOI 10.1093/molbev/msu173
   Bloom JD, 2010, SCIENCE, V328, P1272, DOI 10.1126/science.1187816
   Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553
   Bolles M, 2011, CURR OPIN VIROL, V1, P624, DOI 10.1016/j.coviro.2011.10.012
   Boni MF, 2020, NAT MICROBIOL, V5, P1408, DOI 10.1038/s41564-020-0771-4
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Callaway H.M., 2018, J VIROL, V92
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Chen Wen-Hsiang, 2020, bioRxiv, DOI 10.1101/2020.05.15.098079
   Chen WH, 2020, CURR TROP MED REP, V7, P61, DOI 10.1007/s40475-020-00201-6
   Chen WH, 2017, J PHARM SCI-US, V106, P1961, DOI 10.1016/j.xphs.2017.04.037
   Chen WH, 2014, HUM VACC IMMUNOTHER, V10, P648, DOI 10.4161/hv.27464
   Crawford K.H.D., 2019, J OPEN SOURCE SOFTW, V4, P1915
   Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Davenport TM, 2016, STRUCTURE, V24, P1346, DOI 10.1016/j.str.2016.06.012
   Dean AM, 2007, NAT REV GENET, V8, P675, DOI 10.1038/nrg2160
   Delignette-Muller ML, 2015, J STAT SOFTW, V64, P1, DOI 10.18637/jss.v064.i04
   Demogines A, 2012, J VIROL, V86, P6350, DOI 10.1128/JVI.00311-12
   Dingens AS, 2019, IMMUNITY, V50, P520, DOI 10.1016/j.immuni.2018.12.017
   Dingens AS, 2017, CELL HOST MICROBE, V21, P777, DOI 10.1016/j.chom.2017.05.003
   Duan HY, 2018, IMMUNITY, V49, P301, DOI 10.1016/j.immuni.2018.07.005
   Eggink D, 2014, J VIROL, V88, P699, DOI 10.1128/JVI.02608-13
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   FANE B, 1991, J BIOL CHEM, V266, P11640
   Fauver JR, 2020, CELL, V181, P990, DOI 10.1016/j.cell.2020.04.021
   Fowler DM, 2014, NAT METHODS, V11, P801, DOI [10.1038/NMETH.3027, 10.1038/nmeth.3027]
   Frank Hannah K, 2020, bioRxiv, DOI 10.1101/2020.04.20.051656
   Friedrich TC, 2004, J VIROL, V78, P2581, DOI 10.1128/JVI.78.5.2581-2585.2004
   Frieman M, 2012, J VIROL, V86, P884, DOI 10.1128/JVI.05957-11
   Gietz RD, 2007, NAT PROTOC, V2, P31, DOI 10.1038/nprot.2007.13
   Gong LI, 2013, ELIFE, V2, DOI 10.7554/eLife.00631
   Hamilton SR, 2003, SCIENCE, V301, P1244, DOI 10.1126/science.1088166
   Handford C, 2014, EXTREME PHYSIOL MED, V3, DOI 10.1186/2046-7648-3-7
   Harms MJ, 2013, NAT REV GENET, V14, P559, DOI 10.1038/nrg3540
   Hensley SE, 2009, SCIENCE, V326, P734, DOI 10.1126/science.1178258
   Hiatt JB, 2010, NAT METHODS, V7, P119, DOI [10.1038/NMETH.1416, 10.1038/nmeth.1416]
   Hilton S.K., 2020, J OPEN SOURCE SOFTWA, V5, P2353
   Hilton SK, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vey033
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006698
   Huo JD, 2020, CELL HOST MICROBE, V28, P445, DOI 10.1016/j.chom.2020.06.010
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Jardine JG, 2016, SCIENCE, V351, P1458, DOI 10.1126/science.aad9195
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Julian MC, 2017, SCI REP-UK, V7, DOI 10.1038/srep45259
   KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kowalski JM, 1998, BIOCHEMISTRY-US, V37, P1264, DOI 10.1021/bi9722397
   Kowalski JM, 1998, J BIOL CHEM, V273, P19453, DOI 10.1074/jbc.273.31.19453
   Kulp DW, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01549-6
   Kutter JS, 2018, CURR OPIN VIROL, V28, P142, DOI 10.1016/j.coviro.2018.01.001
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lang Y., 2020, CORONAVIRUS HEMAGGLU, DOI [10.1101/2020.04.03.003699, DOI 10.1101/2020.04.03.003699]
   Latinne Alice, 2020, bioRxiv, DOI 10.1101/2020.05.31.116061
   Lee JM, 2019, ELIFE, V8, DOI 10.7554/eLife.49324
   Lee JM, 2018, P NATL ACAD SCI USA, V115, pEB276, DOI 10.1073/pnas.1806133115
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2008, J VIROL, V82, P6984, DOI 10.1128/JVI.00442-08
   Li H, 2018, BIOINFORMATICS, V34, P3094, DOI 10.1093/bioinformatics/bty191
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li WH, 2005, EMBO J, V24, P1634, DOI 10.1038/sj.emboj.7600640
   Louz D, 2013, CRIT REV MICROBIOL, V39, P325, DOI 10.3109/1040841X.2012.711740
   Lynch RM, 2015, J VIROL, V89, P4201, DOI 10.1128/JVI.03608-14
   MacLean Oscar A, 2020, bioRxiv, DOI 10.1101/2020.05.28.122366
   Matreyek KA, 2018, NAT GENET, V50, P874, DOI 10.1038/s41588-018-0122-z
   Menachery VD, 2016, P NATL ACAD SCI USA, V113, P3048, DOI 10.1073/pnas.1517719113
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   Mulligan M. J., 2020, PHASE 1 2 STUDY DESC, DOI [10.1101/2020.06.30.20142570, DOI 10.1101/2020.06.30.20142570]
   Otwinowski J, 2018, P NATL ACAD SCI USA, V115, pE7550, DOI 10.1073/pnas.1804015115
   Ovchinnikov V, 2018, ELIFE, V7, DOI 10.7554/eLife.33038
   Pak JE, 2009, J MOL BIOL, V388, P815, DOI 10.1016/j.jmb.2009.03.042
   Peterman N, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2533-5
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Pollock DD, 2012, P NATL ACAD SCI USA, V109, pE1352, DOI 10.1073/pnas.1120084109
   Poteete AR, 1997, PROTEIN SCI, V6, P2418
   Povolotskaya IS, 2010, NATURE, V465, P922, DOI 10.1038/nature09105
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413
   Pybus OG, 2007, MOL BIOL EVOL, V24, P845, DOI 10.1093/molbev/msm001
   Qu XX, 2005, J BIOL CHEM, V280, P29588, DOI 10.1074/jbc.M500662200
   Quinlan B. D., 2020, BIORXIV, DOI [10.1101/2020.04.10.036418, DOI 10.1101/2020.04.10.036418]
   Ravichandran S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc3539
   Ren W, 2008, J VIROL, V82, P1899, DOI 10.1128/JVI.01085-07
   Rockx B, 2010, J INFECT DIS, V201, P946, DOI 10.1086/651022
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Scanlon TC, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-95
   Schmidt AG, 2013, P NATL ACAD SCI USA, V110, P264, DOI 10.1073/pnas.1218256109
   Schwehm JM, 1998, BIOCHEMISTRY-US, V37, P6939, DOI 10.1021/bi9725069
   Seydoux E, 2020, IMMUNITY, V53, P98, DOI 10.1016/j.immuni.2020.06.001
   Shah P, 2015, P NATL ACAD SCI USA, V112, pE3226, DOI 10.1073/pnas.1412933112
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sheahan T, 2008, J VIROL, V82, P8721, DOI 10.1128/JVI.00818-08
   Sheahan T, 2008, J VIROL, V82, P2274, DOI 10.1128/JVI.02041-07
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Shusta EV, 1999, J MOL BIOL, V292, P949, DOI 10.1006/jmbi.1999.3130
   Smith DJ, 2004, SCIENCE, V305, P371, DOI 10.1126/science.1097211
   Soskine M, 2010, NAT REV GENET, V11, P572, DOI 10.1038/nrg2808
   Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033
   Starr TN, 2018, P NATL ACAD SCI USA, V115, P4453, DOI 10.1073/pnas.1718133115
   Starr TN, 2016, PROTEIN SCI, V25, P1204, DOI 10.1002/pro.2897
   Suthar Mehul S, 2020, Cell Rep Med, V1, P100040, DOI 10.1016/j.xcrm.2020.100040
   Tareen A, 2020, BIOINFORMATICS, V36, P2272, DOI 10.1093/bioinformatics/btz921
   Tien MZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080635
   Tokuriki N, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000002
   Tong SX, 2009, EMERG INFECT DIS, V15, P482, DOI 10.3201/eid1503.081013
   Trkola A, 2005, NAT MED, V11, P615, DOI 10.1038/nm1244
   van Dorp L, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104351
   VANDERPLAS J, 2018, J OPEN SOURCE SOFTW, V3, P1057, DOI DOI 10.21105/JOSS.01057
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang XJ, 2002, J MOL BIOL, V320, P85, DOI 10.1016/S0022-2836(02)00400-X
   Weidenbacher PA, 2019, P NATL ACAD SCI USA, V116, P9947, DOI 10.1073/pnas.1822062116
   Weile J, 2018, HUM GENET, V137, P665, DOI 10.1007/s00439-018-1916-x
   Wentz AE, 2007, APPL ENVIRON MICROB, V73, P1189, DOI 10.1128/AEM.02427-06
   Wrapp D, 2020, CELL, V181, P1004, DOI 10.1016/j.cell.2020.04.031
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wrobel AG, 2020, NAT STRUCT MOL BIOL, V27, P763, DOI 10.1038/s41594-020-0468-7
   Wu KL, 2012, J BIOL CHEM, V287, P8904, DOI 10.1074/jbc.M111.325803
   Wu NC, 2020, SCIENCE, V368, P1335, DOI 10.1126/science.aaz5143
   Wu NC, 2017, CELL HOST MICROBE, V21, P742, DOI 10.1016/j.chom.2017.05.011
   Wu XL, 2010, SCIENCE, V329, P856, DOI 10.1126/science.1187659
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Xue KS, 2020, VIRUS EVOL, V6, DOI 10.1093/ve/veaa010
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang J, 2020, ADV OPT MATER, V8, DOI 10.1002/adom.202000290
   Yuan M, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101273
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zang J, 2020, IMMUNIZATION RECEPTO, DOI [10.1101/2020.05.21.107565, DOI 10.1101/2020.05.21.107565]
   Zhang BZ, 2020, CELL RES, V30, P702, DOI 10.1038/s41422-020-0366-x
   Zhou H, 2020, CURR BIOL, V30, P2196, DOI 10.1016/j.cub.2020.05.023
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou Tongqing, 2020, bioRxiv, DOI 10.1101/2020.06.22.166033
   Zost SJ, 2020, NATURE, DOI 10.1038/s41586-020-2548-6
NR 142
TC 9
Z9 9
U1 7
U2 7
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD SEP 3
PY 2020
VL 182
IS 5
BP 1295
EP +
DI 10.1016/j.cell.2020.08.012
PG 36
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA NR3DG
UT WOS:000571442200018
PM 32841599
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Remy, KE
   Mazer, M
   Striker, DA
   Ellebedy, AH
   Walton, AH
   Unsinger, J
   Blood, TM
   Mudd, PA
   Yi, DJ
   Mannion, DA
   Osborne, DF
   Martin, RS
   Anand, NJ
   Bosanquet, JP
   Blood, J
   Drewry, AM
   Caldwell, CC
   Turnbull, IR
   Brakenridge, SC
   Moldwawer, LL
   Hotchkiss, RS
AF Remy, Kenneth E.
   Mazer, Monty
   Striker, David A.
   Ellebedy, Ali H.
   Walton, Andrew H.
   Unsinger, Jacqueline
   Blood, Teresa M.
   Mudd, Philip A.
   Yi, Daehan J.
   Mannion, Daniel A.
   Osborne, Dale F.
   Martin, R. Scott
   Anand, Nitin J.
   Bosanquet, James P.
   Blood, Jane
   Drewry, Anne M.
   Caldwell, Charles C.
   Turnbull, Isaiah R.
   Brakenridge, Scott C.
   Moldwawer, Lyle L.
   Hotchkiss, Richard S.
TI Severe immunosuppression and not a cytokine storm characterizes COVID-19
   infections
SO JCI INSIGHT
LA English
DT Article
ID SEPTIC SHOCK; CELLS; EXPRESSION; IMMUNITY; SEPSIS; IL-6
AB COVID-19-associated morbidity and mortality have been attributed to a pathologic host response. Two divergent hypotheses have been proposed: hyperinflammatory cytokine storm; and failure of host protective immunity that results in unrestrained viral dissemination and organ injury. A key explanation for the inability to address this controversy has been the lack of diagnostic tools to evaluate immune function in COVID-19 infections. ELISpot, a highly sensitive, functional immunoassay, was employed in 27 patients with COVID-19, 51 patients with sepsis, 18 critically ill nonseptic (CINS) patients, and 27 healthy control volunteers to evaluate adaptive and innate immune status by quantitating T cell IFN-gamma and monocyte TFN-alpha production. Circulating T cell subsets were profoundly reduced in COVID-19 patients. Additionally, stimulated blood mononuclear cells produced less than 40%-50% of the IFN-gamma and TNF-alpha observed in septic and CINS patients, consistent with markedly impaired immune effector cell function. Approximately 25% of COVID-19 patients had increased IL-6 levels that were not associated with elevations in other canonical proinflammatory cytokines. Collectively, these findings support the hypothesis that COVID-19 suppresses host functional adaptive and innate immunity. Importantly, IL-7 administered ex vivo restored T cell IFN-gamma production in COVID-19 patients. Thus, ELISpot may functionally characterize host immunity in COVID-19 and inform prospective therapies.
C1 [Remy, Kenneth E.; Mazer, Monty; Yi, Daehan J.; Mannion, Daniel A.] Washington Univ, Sch Med St Louis, Dept Pediat, St Louis, MO 63110 USA.
   [Remy, Kenneth E.; Hotchkiss, Richard S.] Washington Univ, Sch Med St Louis, Dept Internal Med, St Louis, MO 63110 USA.
   [Remy, Kenneth E.; Mazer, Monty; Walton, Andrew H.; Unsinger, Jacqueline; Blood, Teresa M.; Osborne, Dale F.; Blood, Jane; Drewry, Anne M.; Hotchkiss, Richard S.] Washington Univ, Sch Med St Louis, Dept Anesthesiol, 660 South Euclid Ave, St Louis, MO 63110 USA.
   [Striker, David A.; Martin, R. Scott; Anand, Nitin J.; Bosanquet, James P.] Missouri Baptist Med Ctr, Dept Crit Care, St Louis, MO USA.
   [Ellebedy, Ali H.] Washington Univ, Sch Med St Louis, Dept Pathol & Immunol, St Louis, MO 63110 USA.
   [Mudd, Philip A.] Washington Univ, Sch Med St Louis, Dept Emergency Med, St Louis, MO 63110 USA.
   [Mannion, Daniel A.] St Louis Univ, Sch Med, St Louis, MO USA.
   [Caldwell, Charles C.] Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH USA.
   [Turnbull, Isaiah R.; Hotchkiss, Richard S.] Washington Univ, Sch Med St Louis, Dept Surg, 660 South Euclid Ave, St Louis, MO 63110 USA.
   [Brakenridge, Scott C.; Moldwawer, Lyle L.] Univ Florida, Coll Med, Dept Surg, Sepsis & Crit Illness Res Ctr, Gainesville, FL USA.
RP Hotchkiss, RS (corresponding author), Washington Univ, Sch Med St Louis, Dept Anesthesiol, 660 South Euclid Ave, St Louis, MO 63110 USA.; Hotchkiss, RS (corresponding author), Washington Univ, Sch Med St Louis, Dept Surg, 660 South Euclid Ave, St Louis, MO 63110 USA.; Hotchkiss, RS (corresponding author), Washington Univ, Sch Med St Louis, Dept Med, 660 South Euclid Ave, St Louis, MO 63110 USA.
EM richardshotchkiss@wustl.edu
OI Blood, Teresa/0000-0001-8623-5684; Mudd, Philip/0000-0002-3860-5473
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [CTSA-WUSTL KL2 TR002346, CTSA-UF-FSU
   UL1 TR001427 NIH GM129763, GM126928, GM008721, GM133756, GM111153,
   AG056444, AI139813]
FX The authors would like to acknowledge the nurses and staff at
   Barnes-Jewish Hospital and Missouri Baptist Medical Center. We would
   also like to acknowledge the patients and their families during this
   difficult pandemic. Additional support is provided by NIH grants
   CTSA-WUSTL KL2 TR002346, CTSA-UF-FSU UL1 TR001427 NIH GM129763,
   GM126928, GM008721, GM133756, GM111153, AG056444, and AI139813.
CR Aouba A, 2020, ANN RHEUM DIS, V79, P1381, DOI 10.1136/annrheumdis-2020-217706
   Chatterjee Pranab, 2020, Indian J Med Res, V151, P147, DOI 10.4103/ijmr.IJMR_519_20
   Chen XH, 2020, CLIN INFECT DIS, V71, P1937, DOI 10.1093/cid/ciaa449
   Ciotti M, 2020, CHEMOTHERAPY, V64, P215, DOI [10.1159/000507423, 10.1080/10408363.2020.1783198]
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Drewry AM, 2018, SHOCK, V50, P381, DOI 10.1097/SHK.0000000000001083
   Du RH, 2020, ANN AM THORAC SOC, V17, P839, DOI 10.1513/AnnalsATS.202003-225OC
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Francois B, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98960
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hanley B, 2020, J CLIN PATHOL, V73, P239, DOI 10.1136/jclinpath-2020-206522
   Hayashi N, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222403
   Hotchkiss RS, 2020, NEW ENGL J MED, V382, P1270, DOI 10.1056/NEJMcibr1917242
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ijiri T, 2020, HUM MOVEMENT SCI, V69, DOI 10.1016/j.humov.2019.102567
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Kang YJ, 2020, DISASTER MED PUBLIC, V14, P384, DOI [10.1017/dmp.2020.60, 10.1017/dmp.2020.141]
   Liu M., 2020, PHASE 2 2 STUDY UNIV
   Liu Q, 2020, Fa Yi Xue Za Zhi, V36, P21, DOI 10.12116/j.issn.1004-5619.2020.01.005
   Matsukura S, 1996, J ALLERGY CLIN IMMUN, V98, P1080, DOI 10.1016/S0091-6749(96)80195-3
   Mazer M, 2019, J IMMUNOL, V203, P2088, DOI 10.4049/jimmunol.1900637
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Menter T, 2020, HISTOPATHOLOGY, V77, P198, DOI 10.1111/his.14134
   Oberholzer A, 2005, SHOCK, V23, P488, DOI 10.1097/01.shk.0000163802.46355.59
   Parra-Lopez CA, 2020, PHASE 1 2 CLIN STUDY
   Peterson D, 2020, J AM ACAD DERMATOL, V83, pE67, DOI 10.1016/j.jaad.2020.04.097
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Remy KE, 2020, LANCET RESP MED, V8, P946, DOI 10.1016/S2213-2600(20)30217-4
   Roback JD, 2020, JAMA-J AM MED ASSOC, V323, P1561, DOI 10.1001/jama.2020.4940
   Ruscitti P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102562
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, P1, DOI 10.3332/ecancer.2020.1022
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Sereti I, 2009, BLOOD, V113, P6304, DOI 10.1182/blood-2008-10-186601
   Shah P, 2020, J AM ACAD DERMATOL, V82, pE203, DOI 10.1016/j.jaad.2020.03.056
   Sharma NK, 2017, SHOCK, V47, P17, DOI 10.1097/SHK.0000000000000698
   Spinelli FR, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc5367
   Swain SL, 2012, NAT REV IMMUNOL, V12, P136, DOI 10.1038/nri3152
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Thampy LK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199497
   Tveito K., 2020, TIDSSKR NOR LAEGEFOR, V140
   Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678
   WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wong HR, 2009, CRIT CARE MED, V37, P1558, DOI 10.1097/CCM.0b013e31819fcc08
   Wright David J M, 2021, Lancet Infect Dis, V21, P25, DOI 10.1016/S1473-3099(20)30376-5
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zheng Y, STUDY LYMPHOCYTE CHA, DOI [10.1101/2020.02.19.20024, DOI 10.1101/2020.02.19.20024]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 55
TC 7
Z9 7
U1 0
U2 0
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379-3708
J9 JCI INSIGHT
JI JCI Insight
PD SEP 3
PY 2020
VL 5
IS 17
AR e140329
DI 10.1172/jci.insight.140329
PG 15
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NO0XJ
UT WOS:000569209700002
PM 32687484
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wilson, JG
   Simpson, LJ
   Ferreira, AM
   Rustagi, A
   Roque, J
   Asuni, A
   Ranganath, T
   Grant, PM
   Subramanian, A
   Rosenberg-Hasson, Y
   Maecker, HT
   Holmes, SP
   Levitt, JE
   Blish, CA
   Rogers, AJ
AF Wilson, Jennifer G.
   Simpson, Laura J.
   Ferreira, Anne-Maud
   Rustagi, Arjun
   Roque, Jonasel
   Asuni, Adijat
   Ranganath, Thanmayi
   Grant, Philip M.
   Subramanian, Aruna
   Rosenberg-Hasson, Yael
   Maecker, Holden T.
   Holmes, Susan P.
   Levitt, Joseph E.
   Blish, Catherine A.
   Rogers, Angela J.
TI Cytokine profile in plasma of severe COVID-19 does not differ from ARDS
   and sepsis
SO JCI INSIGHT
LA English
DT Article
ID STORM
AB BACKGROUND. Elevated levels of inflammatory cytokines have been associated with poor outcomes among COVID-19 patients. It is unknown, however, how these levels compare with those observed in critically ill patients with acute respiratory distress syndrome (ARDS) or sepsis due to other causes.
   METHODS. We used a Luminex assay to determine expression of 76 cytokines from plasma of hospitalized COVID-19 patients and banked plasma samples from ARDS and sepsis patients. Our analysis focused on detecting statistical differences in levels of 6 cytokines associated with cytokine storm (IL-1 beta, IL-1RA, IL-6, IL-8, IL-18, and TNF-alpha) between patients with moderate COVID-19, severe COVID-19, and ARDS or sepsis.
   RESULTS. Fifteen hospitalized COVID-19 patients, 9 of whom were critically ill, were compared with critically ill patients with ARDS (n = 12) or sepsis (n = 16). There were no statistically significant differences in baseline levels of IL-1 beta, IL-1RA, IL-6, IL-8, IL-18, and TNF-alpha between patients with COVID-19 and critically ill controls with ARDS or sepsis.
   CONCLUSION. Levels of inflammatory cytokines were not higher in severe COVID-19 patients than in moderate COVID-19 or critically ill patients with ARDS or sepsis in this small cohort. Broad use of immunosuppressive therapies in ARDS has failed in numerous Phase 3 studies; use of these therapies in unselected patients with COVID-19 may be unwarranted.
C1 [Wilson, Jennifer G.] Stanford Univ, Sch Med, Dept Emergency Med, Stanford, CA USA.
   [Simpson, Laura J.; Rustagi, Arjun; Roque, Jonasel; Asuni, Adijat; Ranganath, Thanmayi; Grant, Philip M.; Subramanian, Aruna; Levitt, Joseph E.; Blish, Catherine A.; Rogers, Angela J.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA.
   [Ferreira, Anne-Maud; Holmes, Susan P.] Stanford Univ, Dept Stat, Stanford, CA 94305 USA.
   [Rosenberg-Hasson, Yael; Maecker, Holden T.; Blish, Catherine A.] Stanford Univ, Inst Immun Transplantat & Infect, Sch Med, Stanford, CA USA.
   [Blish, Catherine A.] Chan Zuckerberg Biohub, San Francisco, CA USA.
RP Rogers, AJ (corresponding author), 300 Pasteur Dr H3143, Stanford, CA 94305 USA.
EM ajrogers@stanford.edu
RI Ranganath, Thanmayi/N-8616-2019
OI Ranganath, Thanmayi/0000-0001-9865-2119; , Jonasel/0000-0001-7818-6958;
   Rustagi, Arjun/0000-0002-6921-1012
FU NHLBIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [K23 HL125663]; Bill and Melinda Gates FoundationBill
   & Melinda Gates Foundation [OPP1113682]; Burroughs Wellcome Fund
   Investigators in the Pathogenesis of Infectious DiseasesBurroughs
   Wellcome Fund [1016687 NIH/NIAID U19AI057229-16]; Stanford Maternal
   Child Health Research Institute; Chan Zuckerberg Biohub
FX Funding was received from NHLBI K23 HL125663 (AJR); The Bill and Melinda
   Gates Foundation OPP1113682 (AJR and CAB); Burroughs Wellcome Fund
   Investigators in the Pathogenesis of Infectious Diseases #1016687
   NIH/NIAID U19AI057229-16; Stanford Maternal Child Health Research
   Institute; and Chan Zuckerberg Biohub (CAB). The authors thank all of
   the patients, families, and care providers who supported this work. We
   also acknowledge the many people who collected and processed the
   specimens.
CR Breen EJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep26996
   Calfee CS, 2018, LANCET RESP MED, V6, P691, DOI 10.1016/S2213-2600(18)30177-2
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Cheung CY, 2002, LANCET, V360, P1831, DOI 10.1016/S0140-6736(02)11772-7
   Coperchini F, 2020, CYTOKINE GROWTH F R, V53, P25, DOI 10.1016/j.cytogfr.2020.05.003
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Maecker HT, 2020, J IMMUNOL, V204, P3425, DOI 10.4049/jimmunol.2000017
   Mayhew MB, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14975-w
   MEDURI GU, 1995, CHEST, V107, P1062, DOI 10.1378/chest.107.4.1062
   Ritchie AI, 2020, LANCET, V395, P1111, DOI 10.1016/S0140-6736(20)30691-7
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Santacruz CA, 2019, CRIT CARE MED, V47, P1680, DOI 10.1097/CCM.0000000000004000
   Sinha P, 2018, INTENS CARE MED, V44, P1859, DOI 10.1007/s00134-018-5378-3
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 15
TC 11
Z9 11
U1 2
U2 2
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
EI 2379-3708
J9 JCI INSIGHT
JI JCI Insight
PD SEP 3
PY 2020
VL 5
IS 17
AR e140289
DI 10.1172/jci.insight.140289
PG 6
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NO0WM
UT WOS:000569207400006
PM 32706339
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Batra, R
   Chan, H
   Kamath, G
   Ramprasad, R
   Cherukara, MJ
   Sankaranarayanan, SKRS
AF Batra, Rohit
   Chan, Henry
   Kamath, Ganesh
   Ramprasad, Rampi
   Cherukara, Mathew J.
   Sankaranarayanan, Subramanian K. R. S.
TI Screening of Therapeutic Agents for COVID-19 Using Machine Learning and
   Ensemble Docking Studies
SO JOURNAL OF PHYSICAL CHEMISTRY LETTERS
LA English
DT Article
AB The current pandemic demands a search for therapeutic agents against the novel coronavirus SARS-CoV-2. Here, we present an efficient computational strategy that combines machine learning (ML)-based models and high-fidelity ensemble docking studies to enable rapid screening of possible therapeutic ligands. Targeting the binding affinity of molecules for either the isolated SARS-CoV-2 S-protein at its host receptor region or the S-protein:human ACE2 interface complex, we screen ligands from drug and biomolecule data sets that can potentially limit and/or disrupt the host-virus interactions. Top scoring one hundred eighty-seven ligands (with 75 approved by the Food and Drug Administration) are further validated by all atom docking studies. Important molecular descriptors ((2)chi(n), topological surface area, and ring count) and promising chemical fragments (oxolane, hydroxy, and imidazole) are identified to guide future experiments. Overall, this work expands our knowledge of small-molecule treatment against COVID-19 and provides a general screening pathway (combining quick ML models with expensive high-fidelity simulations) for targeting several chemical/biochemical problems.
C1 [Batra, Rohit; Chan, Henry; Cherukara, Mathew J.; Sankaranarayanan, Subramanian K. R. S.] Argonne Natl Lab, Ctr Nanoscale Mat, Lemont, IL 60439 USA.
   [Chan, Henry; Sankaranarayanan, Subramanian K. R. S.] Univ Illinois, Dept Mech & Ind Engn, Chicago, IL 60607 USA.
   [Kamath, Ganesh] Dalzielfiver LLC, El Sobrante, CA 94803 USA.
   [Ramprasad, Rampi] Georgia Inst Technol, Sch Mat Sci & Engn, Atlanta, GA 30332 USA.
RP Batra, R; Sankaranarayanan, SKRS (corresponding author), Argonne Natl Lab, Ctr Nanoscale Mat, Lemont, IL 60439 USA.; Sankaranarayanan, SKRS (corresponding author), Univ Illinois, Dept Mech & Ind Engn, Chicago, IL 60607 USA.
EM rohitbatra1989@gmail.com; skrssank@uic.edu
RI Ramprasad, Rampi/ABE-7556-2020; Batra, Rohit/ABB-9972-2020
OI Ramprasad, Rampi/0000-0003-4630-1565; Batra, Rohit/0000-0002-1098-7035;
   Cherukara, Mathew/0000-0002-1475-6998
FU U.S. Department of Energy, Office of Science, Office of Basic Energy
   SciencesUnited States Department of Energy (DOE) [DE-AC02-06CH11357];
   UIC
FX Use of the Center for Nanoscale Materials and Advanced Photon Source,
   both Office of Science user facilities, was supported by the U.S.
   Department of Energy, Office of Science, Office of Basic Energy
   Sciences, under Contract No. DE-AC02-06CH11357. The authors thank Naina
   Zachariah for useful discussions and for reviewing the manuscript. SKRS
   is thankful for a UIC Start-up faculty grant for supporting this work.
   The authors dedicate this research to the millions of lives affected by
   the COVID pandemic.
CR Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Bung N, 2020, NOVO DESIGN NEW CHEM
   Degen J, 2008, CHEMMEDCHEM, V3, P1503, DOI 10.1002/cmdc.200800178
   Gilson MK, 2016, NUCLEIC ACIDS RES, V44, pD1045, DOI 10.1093/nar/gkv1072
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Hall L.H., 1991, REV COMPUTATIONAL CH, VII, P367, DOI DOI 10.1002/9780470125793.CH
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   Mardirossian N., 2020, ARXIV200408725
   Nguyen Duc Duy, 2020, bioRxiv, DOI 10.1101/2020.02.05.936013
   Nguyen NT, 2020, J CHEM INF MODEL, V60, P204, DOI 10.1021/acs.jcim.9b00778
   Novick PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079568
   Pedregosa F, 2011, J MACH LEARN RES, V12, P2825
   Sen FG, 2015, J MATER CHEM A, V3, P18970, DOI 10.1039/c5ta04678e
   Smith M., 2020, REPURPOSING THERAPEU, DOI 10.26434/chemrxiv.11871402.v3
   Sun PF, 2020, J MED VIROL, V92, P548, DOI 10.1002/jmv.25722
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Ursu O, 2017, NUCLEIC ACIDS RES, V45, pD932, DOI 10.1093/nar/gkw993
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu Z., 2020, NELFINAVIR WAS PREDI, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Yu WB, 2020, ZOOL RES, V41, P247, DOI 10.24272/j.issn.2095-8137.2020.022
NR 24
TC 3
Z9 3
U1 1
U2 1
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7185
J9 J PHYS CHEM LETT
JI J. Phys. Chem. Lett.
PD SEP 3
PY 2020
VL 11
IS 17
BP 7058
EP 7065
DI 10.1021/acs.jpclett.0c02278
PG 8
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Atomic, Molecular & Chemical
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA NO3HF
UT WOS:000569375400018
PM 32787328
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Gao, J
   Zhang, L
   Liu, XD
   Li, FD
   Ma, RS
   Zhu, ZL
   Zhang, JH
   Wu, JH
   Shi, YY
   Pan, YY
   Ge, YS
   Ruan, K
AF Gao, Jia
   Zhang, Liang
   Liu, Xiaodan
   Li, Fudong
   Ma, Rongsheng
   Zhu, Zhongliang
   Zhang, Jiahai
   Wu, Jihui
   Shi, Yunyu
   Pan, Yueyin
   Ge, Yushu
   Ruan, Ke
TI Repurposing Low-Molecular-Weight Drugs against the Main Protease of
   Severe Acute Respiratory Syndrome Coronavirus 2
SO JOURNAL OF PHYSICAL CHEMISTRY LETTERS
LA English
DT Article
ID SARS; MONOMER; MECHANISM
AB The coronavirus disease pandemic caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected the global healthcare system. As low-molecular-weight drugs have high potential to completely match interactions with essential SARS-CoV-2 targets, we propose a strategy to identify such drugs using the fragment-based approach. Herein, using ligand- and protein-observed fragment screening approaches, we identified niacin and hit 1 binding to the catalytic pocket of the main protease (M-pro) of SARS-CoV-2, thereby modestly inhibiting the enzymatic activity of M-pro. We further searched for low-molecular-weight drugs containing niacin or hit 1 pharmacophores with enhanced inhibiting activity, e.g., carmofur, bendamustine, triclabendazole, emedastine, and omeprazole, in which omeprazole is the only one binding to the C-terminal domain of SARS-CoV-2 M-pro. Our study demonstrates that the fragment-based approach is a feasible strategy for identifying low-molecular-weight drugs against the SARS-CoV-2 and other potential targets lacking specific drugs.
C1 [Gao, Jia; Zhang, Liang; Liu, Xiaodan; Li, Fudong; Ma, Rongsheng; Zhu, Zhongliang; Zhang, Jiahai; Wu, Jihui; Shi, Yunyu; Pan, Yueyin; Ge, Yushu; Ruan, Ke] Univ Sci & Technol China, Div Life Sci & Med, Key Lab Membrane Less Organelles & Cellular Dynam, Hefei Natl Lab Phys Sci Microscale,Minist Educ, Hefei 230027, Anhui, Peoples R China.
RP Ge, YS; Ruan, K (corresponding author), Univ Sci & Technol China, Div Life Sci & Med, Key Lab Membrane Less Organelles & Cellular Dynam, Hefei Natl Lab Phys Sci Microscale,Minist Educ, Hefei 230027, Anhui, Peoples R China.
EM geyushu@ustc.edu.cn; kruan@ustc.edu.cn
OI Ruan, Ke/0000-0001-9358-0451; zhang, liang/0000-0002-8338-784X
FU Ministry of Science and Technology of ChinaMinistry of Science and
   Technology, China [2019YFA0508400, 2016YFA0500700]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [21874123, 21703254, 21807095]; Fundamental Research Funds for
   the Central UniversitiesFundamental Research Funds for the Central
   Universities [WK2060190086]; Hefei National Science Center Pilot Project
   Funds
FX Part of our nuclear magnetic resonance study was performed at the
   National Center for Protein Science Shanghai and the High Magnetic Field
   Laboratory of the Chinese Academy of Sciences. We thank the Ministry of
   Science and Technology of China (2019YFA0508400 and 2016YFA0500700), the
   National Natural Science Foundation of China (21874123, 21703254, and
   21807095), the Fundamental Research Funds for the Central Universities
   (WK2060190086), Hefei National Science Center Pilot Project Funds for
   the financial support, and we acknowledge supercomputing resources from
   the Bioinformatics Center of the University of Science and Technology of
   China, School of Life Sciences.
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Gao J, 2017, ANGEW CHEM INT EDIT, V56, P12982, DOI 10.1002/anie.201707114
   Gao J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088098
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Jin ZM, 2020, NAT STRUCT MOL BIOL, V27, P529, DOI 10.1038/s41594-020-0440-6
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Kang X, 2012, P NATL ACAD SCI USA, V109, P14900, DOI 10.1073/pnas.1205241109
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu JY, 2017, BBA-GEN SUBJECTS, V1861, P3061, DOI 10.1016/j.bbagen.2016.10.003
   Liu S, 2020, BIOINFORMATICS, V36, P1066, DOI 10.1093/bioinformatics/btz725
   Ma CL, 2020, CELL RES, V30, P678, DOI 10.1038/s41422-020-0356-z
   Malik S, 2013, EUR J MED CHEM, V67, P1, DOI [10.1016/j.ejmech.2013.06.026, 10.1016/j.ejmech.2012.10.053]
   Murray CW, 2009, NAT CHEM, V1, P187, DOI [10.1038/NCHEM.217, 10.1038/nchem.217]
   Nshogoza G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133230
   Ortega JT, 2020, EXCLI J, V19, P400, DOI 10.17179/excli2020-1189
   Shi JH, 2008, J VIROL, V82, P4620, DOI 10.1128/JVI.02680-07
   Wu CG, 2013, ACTA CRYSTALLOGR D, V69, P747, DOI 10.1107/S0907444913001315
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu DF, 2018, J PHYS CHEM LETT, V9, P3361, DOI 10.1021/acs.jpclett.8b01443
   Zhang DH, 2020, J INTEGR MED-JIM, V18, P152, DOI 10.1016/j.joim.2020.02.005
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhang LL, 2020, J MED CHEM, V63, P4562, DOI 10.1021/acs.jmedchem.9b01828
   Zhang SN, 2011, BIOMOL NMR ASSIGN, V5, P143, DOI 10.1007/s12104-010-9287-9
NR 28
TC 1
Z9 1
U1 6
U2 6
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-7185
J9 J PHYS CHEM LETT
JI J. Phys. Chem. Lett.
PD SEP 3
PY 2020
VL 11
IS 17
BP 7267
EP 7272
DI 10.1021/acs.jpclett.0c01894
PG 6
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Atomic, Molecular & Chemical
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA NO3HF
UT WOS:000569375400047
PM 32787337
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Deming, ME
   Michael, NL
   Robb, M
   Cohen, MS
   Neuzil, KM
AF Deming, Meagan E.
   Michael, Nelson L.
   Robb, Merlin
   Cohen, Myron S.
   Neuzil, Kathleen M.
TI Accelerating Development of SARS-CoV-2 Vaccines - The Role for
   Controlled Human Infection Models
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
AB Controlled human infection models have been proposed as a strategy for accelerating SARS-CoV-2 vaccine development. But scientific and technical factors make CHIMs unlikely to accelerate the establishment of vaccine efficacy.
C1 [Deming, Meagan E.; Neuzil, Kathleen M.] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA.
   [Michael, Nelson L.] Walter Reed Army Inst Res, Ctr Infect Dis Res, Silver Spring, MD USA.
   [Robb, Merlin] Henry Jackson Fdn, Bethesda, MD USA.
   [Cohen, Myron S.] Univ N Carolina, Sch Med, Inst Global Hlth & Infect Dis, Chapel Hill, NC 27515 USA.
RP Deming, ME (corresponding author), Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, Baltimore, MD 21201 USA.
OI Deming, Meagan/0000-0003-2574-0542
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA
FX Drs. Michael, Robb, Cohen, and Neuzil are members of the Accelerating
   COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Vaccines Working
   Group, a publicprivate partnership sponsored by the National Institutes
   of Health; its other members are Paula Annunziato, M.D., Ann Arvin,
   M.D., Beth Bell, M.D., Susan Buchbinder, M.D., Marco Cavaleri, Ph.D.,
   Lawrence Corey, M. D., Mark Davis, Ph.D., Emilio Emini, Ph.D., Gregory
   M. Glenn, M.D., Emmanuel Hanon, Ph.D., Barton Haynes, M.D., Peter Hotez,
   M.D., Ph.D., Kathrin Jansen, Ph.D. (cochair), Antonio Lanzavecchia,
   M.D., Douglas R. Lowy, M. D. (cochair), Peter Marks, M.D., Ph.D., John
   Mascola, M. D., Nancy Messonier, M.D., Nelson Michael, M.D., Ph.D., Paul
   Offit, M.D., Hanneke Schuitemaker, Ph.D., Jonathan Seals, Ph.D., Jim
   Tartaglia, Ph.D., and Tal Zaks, M.D., Ph.D.
CR BRADBURNE AF, 1967, BMJ-BRIT MED J, V3, P767, DOI 10.1136/bmj.3.5568.767
   Eyal N, 2020, J INFECT DIS, V221, P1752, DOI 10.1093/infdis/jiaa152
   Plotkin SA, 2020, VACCINE, V38, P3987, DOI 10.1016/j.vaccine.2020.04.039
   Shah SK, 2020, SCIENCE, V368, P832, DOI 10.1126/science.abc1076
   World Health Organization Advisory Group on Human Challenge Studies, 2020, FEAS POT VAL LIM EST
NR 5
TC 13
Z9 13
U1 4
U2 4
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD SEP 3
PY 2020
VL 383
IS 10
AR e63
DI 10.1056/NEJMp2020076
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA NO9YO
UT WOS:000569841600002
PM 32610006
OA Bronze
DA 2021-01-01
ER

PT J
AU Wagner, DN
   Marcon, AR
   Caulfield, T
AF Wagner, Darren N.
   Marcon, Alessandro R.
   Caulfield, Timothy
TI "Immune Boosting" in the time of COVID: selling immunity on Instagram
SO ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY
LA English
DT Letter
DE Immune boosting; Social media; COVID-19; Instagram; Immunity
AB "Immune boosting" is a trending topic during the COVID-19 pandemic. The concept of "immune boosting" is scientifically misleading and often used to market unproven products and therapies. This paper presents an analysis of popular immune-boosting posts from Instagram. Of the sampled posts, all promoted "immune boosting" as beneficial, nearly all involved commercial interests, and many used scientific and medical rhetoric in their messaging.
C1 [Wagner, Darren N.; Marcon, Alessandro R.; Caulfield, Timothy] Univ Alberta, Hlth Law Inst, Fac Law, Ctr Law, Edmonton, AB T6G 2H5, Canada.
RP Caulfield, T (corresponding author), Univ Alberta, Hlth Law Inst, Fac Law, Ctr Law, Edmonton, AB T6G 2H5, Canada.
EM caulfield@ualberta.ca
FU Canadian Institutes for Health ResearchCanadian Institutes of Health
   Research (CIHR); Alberta Innovates; Ministry of Economic Development,
   Trade and Tourism; Government of CanadaCGIAR; Government of Alberta
FX The authors would like to thank the Canadian Institutes for Health
   Research, Alberta Innovates, the Ministry of Economic Development, Trade
   and Tourism, the Government of Alberta and the Government of Canada for
   their generous support of the following projects: (1) Coronavirus
   Outbreak: Mapping and Countering Misinformation, and: (2) Critical
   Thinking in the Digital Age: Countering Coronavirus Misinformation.
CR Assarroudi A, 2018, J RES NURS, V23, P42, DOI 10.1177/1744987117741667
   Gorvett Z, 2020, BBC FUTURE
   Haard J, 2004, HEALTH COMMUN, V16, P411, DOI 10.1207/s15327027hc1604_2
   Hendriks H, 2020, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.02991
   Holland G, 2017, INT J EAT DISORDER, V50, P76, DOI 10.1002/eat.22559
   Laato S, 2020, EUR J INFORM SYST, V29, P288, DOI 10.1080/0960085X.2020.1770632
   Laestadius LI, 2019, ADDICT BEHAV, V91, P119, DOI 10.1016/j.addbeh.2018.09.008
   Macedo AC, 2019, FRONT MED-LAUSANNE, V6, DOI 10.3389/fmed.2019.00165
   Marcon AR, 2019, MATERN CHILD NUTR, V15, DOI 10.1111/mcn.12658
   Marwick AE, 2015, PUBLIC CULTURE, V27, P137, DOI 10.1215/08992363-2798379
   Muralidhara S, 2018, JMIR PUBLIC HLTH SUR, V4, P148, DOI 10.2196/10150
   Ofli F, 2017, PROCEEDINGS OF THE 26TH INTERNATIONAL CONFERENCE ON WORLD WIDE WEB (WWW'17), P509, DOI 10.1145/3038912.3052663
   Rachul C, 2020, COVID 19 IMMUNE BOOS
   Rambukkana N., 2015, HASHTAG PUBLICS POWE
   Tangcharoensathien V, 2020, J MED INTERNET RES, V22
   Turner PG, 2017, EAT WEIGHT DISORD-ST, V22, P277, DOI 10.1007/s40519-017-0364-2
NR 16
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1710-1492
J9 ALLERGY ASTHMA CL IM
JI Allerg Asthma Clin. Immunol.
PD SEP 3
PY 2020
VL 16
IS 1
AR 76
DI 10.1186/s13223-020-00474-6
PG 5
WC Allergy; Immunology
SC Allergy; Immunology
GA NN1QH
UT WOS:000568564800001
PM 32905318
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cava, C
   Bertoli, G
   Castiglioni, I
AF Cava, Claudia
   Bertoli, Gloria
   Castiglioni, Isabella
TI A protein interaction map identifies existing drugs targeting SARS-CoV-2
SO BMC PHARMACOLOGY & TOXICOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; Drug; Network; In silico analysis; Molecular
   docking
ID CORONAVIRUS INFECTION; REPLICATION; INHIBITION
AB Background Severe acute respiratory syndrome coronavirus (SARS-CoV-2), an emerging Betacoronavirus, is the causative agent of COVID-19. Angiotensin converting enzyme 2 (ACE2), being the main cell receptor of SARS-CoV-2, plays a role in the entry of the virus into the cell. Currently, there are neither specific antiviral drugs for the treatment or preventive drugs such as vaccines. Methods We proposed a bioinformatics analysis to test in silico existing drugs as a fast way to identify an efficient therapy. We performed a differential expression analysis in order to identify differentially expressed genes in COVID-19 patients correlated with ACE-2 and we explored their direct relations with a network approach integrating also drug-gene interactions. The drugs with a central role in the network were also investigated with a molecular docking analysis. Results We found 825 differentially expressed genes correlated with ACE2. The protein-protein interactions among differentially expressed genes identified a network of 474 genes and 1130 interactions. Conclusions The integration of drug-gene interactions in the network and molecular docking analysis allows us to obtain several drugs with antiviral activity that, alone or in combination with other treatment options, could be considered as therapeutic approaches against COVID-19.
C1 [Cava, Claudia; Bertoli, Gloria] Natl Res Council IBFM CNR, Inst Mol Bioimaging & Physiol, Via F Cervi 93, I-20090 Milan, Italy.
   [Castiglioni, Isabella] Univ Milano Bicocca, Dept Phys Giuseppe Occhialini, Piazza Ateneo Nuovo 1, I-20126 Milan, Italy.
RP Cava, C (corresponding author), Natl Res Council IBFM CNR, Inst Mol Bioimaging & Physiol, Via F Cervi 93, I-20090 Milan, Italy.
EM claudia.cava@ibfm.cnr.it
RI Cava, Claudia/P-2257-2018
OI Cava, Claudia/0000-0002-5540-4104
FU Italian Ministry of University and Research (MIUR) SYSBIONET-Italian
   ROADMAP ESFRI InfrastructuresMinistry of Education, Universities and
   Research (MIUR)
FX This work was supported by Italian Ministry of University and Research
   (MIUR) SYSBIONET-Italian ROADMAP ESFRI Infrastructures.
CR Al Saleh AS, 2020, ACTA HAEMATOL-BASEL, V143, P410, DOI [10.1159/000507690, 10.1007/978-3-030-44584-3_1]
   BDassault Systemes BIOVIA, 2020, DISC STUD MOD ENV RE
   Bowman LJ, 2018, TRANSPLANTATION, V102, pS50, DOI [10.1097/TP.0000000000001777, 10.1097/tp.0000000000001777]
   Brown EE, 2020, AM J GERIAT PSYCHIAT, V28, P712, DOI 10.1016/j.jagp.2020.04.010
   Budden KF, 2017, NAT REV MICROBIOL, V15, P55, DOI 10.1038/nrmicro.2016.142
   Cava C, 2020, COMPUT BIOL CHEM, V87, DOI 10.1016/j.compbiolchem.2020.107313
   Cava C, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040404
   Cava C, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1535-2
   Cava C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020274
   Chang CC, 2005, J GEN VIROL, V86, P2513, DOI 10.1099/vir.0.81123-0
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Clauset A, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.066111
   Colaprico A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv1507
   DYALL J, 2017, DRUGS, V77, P1935, DOI [10.1007/s40265-017-0830-1, DOI 10.1007/S40265-017-0830-1]
   Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47
   Fung SY, 2020, EMERG MICROBES INFEC, V9, P558, DOI 10.1080/22221751.2020.1736644
   Gao QY, 2020, J DIGEST DIS, V21, P125, DOI 10.1111/1751-2980.12851
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   He Y, 2017, CRIT REV MICROBIOL, V43, P81, DOI [10.1080/1040841X.2016.1176988, 10.1080/1040841x.2016.1176988]
   Huber W, 2015, NAT METHODS, V12, P115, DOI [10.1038/NMETH.3252, 10.1038/nmeth.3252]
   Hwang YC, 2008, ANTIVIR RES, V77, P232, DOI 10.1016/j.antiviral.2007.12.009
   Jawhara S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072272
   Jelski W, 2018, ARCH MED SCI, V14, P281, DOI 10.5114/aoms.2016.60406
   Ji D, 2020, J HEPATOL, V73, P451, DOI 10.1016/j.jhep.2020.03.044
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Kindrachuk J, 2015, ANTIMICROB AGENTS CH, V59, P1088, DOI 10.1128/AAC.03659-14
   Koenigsknecht-Talboo J, 2005, J NEUROSCI, V25, P8240, DOI 10.1523/JNEUROSCI.1808-05.2005
   Lehrer Steven, 2020, World Acad Sci J, V2, DOI 10.3892/wasj.2020.42
   Li H, 2020, LEUKEMIA, V34, P1503, DOI 10.1038/s41375-020-0848-3
   Maiese K, 2020, CURR NEUROVASC RES, V17, P332, DOI 10.2174/1567202617666200425205122
   Matricardi PM, 2020, PEDIAT ALLERG IMM-UK, V31, P454, DOI 10.1111/pai.13271
   Morris Garrett M, 2008, Curr Protoc Bioinformatics, VChapter 8, DOI 10.1002/0471250953.bi0814s24
   Murray James L., 2012, Antiviral Chemistry & Chemotherapy, V22, P205, DOI 10.3851/IMP2080
   Nakhleh A, 2020, DIABETES METAB SYND, V14, P509, DOI 10.1016/j.dsx.2020.04.040
   Nedu ME, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10040223
   NORTHROP RL, 1969, J VIROL, V4, P133, DOI 10.1128/JVI.4.2.133-140.1969
   Pal R, 2020, DIABETES RES CLIN PR, V163, DOI 10.1016/j.diabres.2020.108146
   Pirola CJ, 2020, LIVER INT, V40, P2038, DOI 10.1111/liv.14500
   Prins GH, 2020, LIVER INT, V40, P2568, DOI 10.1111/liv.14484
   Quintana VM, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104749
   Raaben M, 2010, J VIROL, V84, P7869, DOI 10.1128/JVI.00485-10
   RAMABHADRAN TV, 1980, J VIROL, V34, P293, DOI 10.1128/JVI.34.1.293-296.1980
   Rizvi SMD, 2013, EXCLI J, V12, P831
   Salentin S, 2015, NUCLEIC ACIDS RES, V43, pW443, DOI 10.1093/nar/gkv315
   Schneider M, 2012, J VIROL, V86, P10112, DOI 10.1128/JVI.01001-12
   Wagner AH, 2016, NUCLEIC ACIDS RES, V44, pD1036, DOI 10.1093/nar/gkv1165
   Wang YC, 2019, J MED VIROL, V91, P2059, DOI 10.1002/jmv.25538
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
NR 49
TC 1
Z9 1
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2050-6511
J9 BMC PHARMACOL TOXICO
JI BMC Pharmacol. Toxicol.
PD SEP 3
PY 2020
VL 21
IS 1
AR 65
DI 10.1186/s40360-020-00444-z
PG 11
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA NM6QK
UT WOS:000568220200001
PM 32883368
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shivanika, C
   Kumar, SD
   Ragunathan, V
   Tiwari, P
   Sumitha, A
   Devi, PB
AF Shivanika, C.
   Kumar, Deepak S.
   Ragunathan, Venkataraghavan
   Tiwari, Pawan
   Sumitha, A.
   Devi, Brindha P.
TI Molecular docking, validation, dynamics simulations, and pharmacokinetic
   prediction of natural compounds against the SARS-CoV-2 main-protease
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Antiviral phytocompounds; SARS-CoV-2; main-protease; COVID-19; decoy
   ligands; pharmacokinetic properties; molecular dynamics simulations
ID COV 3CL PROTEASE; ANTIVIRAL ACTIVITIES; LIGAND DOCKING; VIRUS;
   CORONAVIRUS; IDENTIFICATION; INHIBITORS; COVID-19; ROBUSTAFLAVONE;
   ANTIINFLUENZA
AB The study aims to evaluate the potency of two hundred natural antiviral phytocompounds against the active site of the Severe Acquired Respiratory Syndrome - Coronavirus - 2 (SARS-CoV-2) Main-Protease (M-pro) using AutoDock 4.2.6. The three- dimensional crystal structure of the M-pro(PDB Id: 6LU7) was retrieved from the Protein Data Bank (PDB), the active site was predicted using MetaPocket 2.0. Food and Drug Administration (FDA) approved viral protease inhibitors were used as standards for comparison of results. The compounds theaflavin-3-3'-digallate, rutin, hypericin, robustaflavone, and (-)-solenolide A with respective binding energy of -12.41 (Ki = 794.96 pM); -11.33 (Ki = 4.98 nM); -11.17 (Ki = 6.54 nM); -10.92 (Ki = 9.85 nM); and -10.82 kcal/mol (Ki = 11.88 nM) were ranked top as Coronavirus Disease - 2019 (COVID-19) M(pro)inhibitors. The interacting amino acid residues were visualized using Discovery Studio 3.5 to elucidate the 2-dimensional and 3-dimensional interactions. The study was validated by i) re-docking the N3-peptide inhibitor-M(pro)and superimposing them onto co-crystallized complex and ii) docking decoy ligands to M-pro. The ligands that showed low binding energy were further predicted for and pharmacokinetic properties and Lipinski's rule of 5 and the results are tabulated and discussed. Molecular dynamics simulations were performed for 50 ns for those compounds using the Desmond package, Schrodinger to assess the conformational stability and fluctuations of protein-ligand complexes during the simulation. Thus, the natural compounds could act as a lead for the COVID-19 regimen afterin-vitroandin- vivoclinical trials. Communicated by Ramaswamy H. Sarma
C1 [Shivanika, C.; Devi, Brindha P.] Vels Inst Sci Technol & Adv Studies, Sch Engn, Dept Bioengn, Chennai, Tamil Nadu, India.
   [Kumar, Deepak S.] Rajalakshmi Engn Coll, Dept Biotechnol, Thandalam, Tamil Nadu, India.
   [Ragunathan, Venkataraghavan] Anna Univ, Alagappa Coll Technol, Dept Chem Engn, Chennai, Tamil Nadu, India.
   [Tiwari, Pawan] Kumaun Univ, Dept Pharmaceut Sci, Naini Tal, Uttarakhand, India.
   [Sumitha, A.] ACS Med Coll & Hosp, Dept Pharmacol, Chennai, Tamil Nadu, India.
RP Devi, PB (corresponding author), Vels Inst Sci Technol & Adv Studies, Dept Bioengn, Chennai 600117, Tamil Nadu, India.
EM hodb.techbiotech@velsuniv.ac.in
RI Ragunathan, Venkataraghavan/AAY-9550-2020; Parthiban, Brindha
   Devi/ABF-1829-2020
OI Ragunathan, Venkataraghavan/0000-0003-2487-9972; Parthiban, Brindha
   Devi/0000-0003-2859-4659
CR Aier I, 2016, SCI REP-UK, V6, DOI 10.1038/srep34984
   Al-Khodairy F. M., 2013, AM J BIOINFORMATICS, V3, P62
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Andrade BS, 2020, F1000RESEARCH, V9, P514, DOI [10.12688/f1000research.23829.1, DOI 10.12688/F1000RESEARCH.23829.1]
   Ardalan Mohammad-Reza, 2013, J Nephropharmacol, V2, P11
   Battegay M, 2020, SWISS MED WKLY, V150, DOI [10.4414/smw.w20203, 10.4414/smw.2020.20203]
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Bekhit A. E. D., 2014, STUDIES NATURAL PROD, V42, DOI [DOI 10.1016/B978-0-444-63281-4.00007-0, 10.1016/b978-0-444-63281-4.00007-0]
   Benet LZ, 2016, ADV DRUG DELIVER REV, V101, P89, DOI 10.1016/j.addr.2016.05.007
   Benfenati E, 2009, J ENVIRON SCI HEAL C, V27, P57, DOI 10.1080/10590500902885593
   Beura S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772111
   Boopathi S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758788
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Brandman R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029377
   Cao DY, 2012, J CHEM INF MODEL, V52, P1132, DOI 10.1021/ci300112j
   Cereto-Massague A, 2012, BIOINFORMATICS, V28, P1661, DOI 10.1093/bioinformatics/bts249
   Chen CN, 2005, EVID-BASED COMPL ALT, V2, P209, DOI 10.1093/ecam/neh081
   Chen HJ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01272
   Chowdhury P., 2018, THEAFLAVINS POLYPHEN
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Daina A, 2016, CHEMMEDCHEM, V11, P1117, DOI 10.1002/cmdc.201600182
   Daina A, 2014, J CHEM INF MODEL, V54, P3284, DOI 10.1021/ci500467k
   Dang VT, 2011, J GEN VIROL, V92, P627, DOI 10.1099/vir.0.025247-0
   de Oliveira A, 2015, ANTIVIR RES, V118, P56, DOI 10.1016/j.antiviral.2015.03.009
   Ding YP, 2020, INT J FOOD SCI TECH, V55, P1531, DOI 10.1111/ijfs.14429
   Ding YP, 2017, FOOD NUTR RES, V61, DOI 10.1080/16546628.2017.1400340
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Forli S, 2016, NAT PROTOC, V11, P905, DOI 10.1038/nprot.2016.051
   Ganeshpurkar A, 2017, SAUDI PHARM J, V25, P149, DOI 10.1016/j.jsps.2016.04.025
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Gentile D, 2020, MAR DRUGS, V18, DOI 10.3390/md18040225
   Grubaugh ND, 2018, CELL, V172, P1160, DOI 10.1016/j.cell.2018.02.027
   Gupta MK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1751300
   Hagar M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113922
   Han DP, 2006, VIROLOGY, V350, P15, DOI 10.1016/j.virol.2006.01.029
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Hatada R., 2020, FRAGMENT MOL ORBITAL, DOI [10.26434/chemrxiv.11988120.v1, DOI 10.26434/CHEMRXIV.11988120.V1]
   HAYASHI K, 1992, ANTIMICROB AGENTS CH, V36, P1890, DOI 10.1128/AAC.36.9.1890
   He  Yun, 2016, IAENG INT J COMPUT S, V43, P7
   Hibasami H., 2003, Journal of Herbs, Spices & Medicinal Plants, V10, P29, DOI 10.1300/J044v10n04_04
   Hollingsworth SA, 2018, NEURON, V99, P1129, DOI 10.1016/j.neuron.2018.08.011
   Hospital Adam, 2015, Adv Appl Bioinform Chem, V8, P37, DOI 10.2147/AABC.S70333
   Huang BD, 2009, OMICS, V13, P325, DOI 10.1089/omi.2009.0045
   Huang F, 2003, ANGEW CHEM INT EDIT, V42, P2269, DOI 10.1002/anie.200250684
   Huang N, 2006, J MED CHEM, V49, P6789, DOI 10.1021/jm0608356
   Ibrahim MT, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03158
   Islam R., 2020, J BIOMOLECULAR STRUC, V7, P1
   Jackson L. A., 2020, NEW ENGLAND J MED
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001
   Joshi T, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1719200
   Keivan Zandi, 2014, Journal of Medicinal Plants Research, V8, P307
   Kernan MR, 1997, J NAT PROD, V60, P635, DOI 10.1021/np960613i
   Khan S, 2020, MITOCHONDRIAL DNA A, DOI [10.1080/24701394.2020.1845323, 10.1016/B978-0-12-816960-5.00001-X]
   Khodarahmi G, 2015, RSC ADV, V5, P58055, DOI 10.1039/c5ra10097f
   Kirchmair J, 2008, J COMPUT AID MOL DES, V22, P213, DOI 10.1007/s10822-007-9163-6
   KOCA J, 1994, J MOL STRUC-THEOCHEM, V112, P157
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kumar KS, 2018, HELIYON, V4, DOI 10.1016/j.heliyon.2018
   Kumar P, 2015, MOLECULES, V20, P135, DOI 10.3390/molecules20010135
   LALANI S, 2020, VIRUSES BASEL, V12, DOI DOI https://doi.org/10.3390/v12020184
   Lillie PJ, 2020, J INFECTION, V80, P600, DOI 10.1016/j.jinf.2020.02.020
   Lin LC, 2000, J NAT PROD, V63, P627, DOI 10.1021/np990538m
   Lin YM, 1999, PLANTA MED, V65, P120, DOI 10.1055/s-1999-13971
   Lin YM, 1997, BIOORG MED CHEM LETT, V7, P2325, DOI 10.1016/S0960-894X(97)00422-8
   Lipinski CA, 2000, J PHARMACOL TOX MET, V44, P235, DOI 10.1016/S1056-8719(00)00107-6
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007
   LIU K, 2020, CELL DISCOV, V6, DOI DOI https://doi.org/10.1038/s41421-019-0132-8
   LIU P, 2019, VIRUSES BASEL, V11, DOI DOI https://doi.org/10.3390/v11110979
   Lung JH, 2020, J MED VIROL, V92, P693, DOI 10.1002/jmv.25761
   MERUELO D, 1988, P NATL ACAD SCI USA, V85, P5230, DOI 10.1073/pnas.85.14.5230
   Mesch GS, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02016
   Miki K, 2007, BIOORG MED CHEM LETT, V17, P772, DOI 10.1016/j.bmcl.2006.10.075
   Mirza MU, 2020, J PHARM ANAL, V10, P320, DOI 10.1016/j.jpha.2020.04.008
   Mishra S, 2020, INT J RF MICROW C E, V30, DOI 10.1002/mmce.22001
   Morris Garrett M, 2008, Curr Protoc Bioinformatics, VChapter 8, DOI 10.1002/0471250953.bi0814s24
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Muralidharan N, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1752802
   Mysinger MM, 2012, J MED CHEM, V55, P6582, DOI 10.1021/jm300687e
   Namendys-Silva SA, 2020, LANCET RESP MED, V8, pE18, DOI 10.1016/S2213-2600(20)30110-7
   Odhar HA, 2020, BIOINFORMATION, V16, P375, DOI 10.6026/97320630016375
   Pant S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1757510
   PATEL A, 2019, PHARMACEUTICS, V11, DOI DOI https://doi.org/10.3390/pharmaceutics11070345
   Peng X, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0075-9
   Perez RM, 2003, PHARM BIOL, V41, P107, DOI 10.1076/phbi.41.2.107.14240
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Pu Xiu-ying, 2009, Virologica Sinica, V24, P19, DOI 10.1007/s12250-009-2983-x
   Ravindranath PA, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004586
   Riet-Correa F, 2013, RES VET SCI, V95, P200, DOI 10.1016/j.rvsc.2013.03.008
   Roccatano D, 2007, BIOPOLYMERS, V85, P407, DOI 10.1002/bip.20690
   SALAZARBOOKAMAN MM, 1994, J OCUL PHARMACOL, V10, P217, DOI 10.1089/jop.1994.10.217
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Schuck AG, 2008, TOXICOL IN VITRO, V22, P598, DOI 10.1016/j.tiv.2007.11.021
   Shie JJ, 2005, J MED CHEM, V48, P4469, DOI 10.1021/jm050184y
   Silva ARA, 2011, J VENOM ANIM TOXINS, V17, P406, DOI [10.1590/S1678-91992011000400007, 10.1590/S1678-91992011000400018]
   Singh AK, 2020, DIABETES METAB SYND, V14, P241, DOI 10.1016/j.dsx.2020.03.011
   Sousa SF, 2006, PROTEINS, V65, P15, DOI 10.1002/prot.21082
   Teixeira da Silva Jaime A, 2020, Med J Armed Forces India, V76, P236, DOI 10.1016/j.mjafi.2020.04.006
   Ngoc TM, 2019, NAT PROD RES, V33, P360, DOI 10.1080/14786419.2018.1452004
   Verdonk ML, 2004, J CHEM INF COMP SCI, V44, P793, DOI 10.1021/ci034289q
   Visalli RJ, 2015, BIOORG MED CHEM LETT, V25, P3168, DOI 10.1016/j.bmcl.2015.05.099
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wallace DJ, 2012, NAT REV RHEUMATOL, V8, P522, DOI 10.1038/nrrheum.2012.106
   Wen CC, 2007, J MED CHEM, V50, P4087, DOI 10.1021/jm070295s
   Xu GH, 2009, ARCH PHARM RES, V32, P275, DOI 10.1007/s12272-009-1233-y
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yi L, 2004, J VIROL, V78, P11334, DOI 10.1128/JVI.78.20.11334-11339.2004
   Yin R, 2020, J BIOINF COMPUT BIOL, V18, DOI 10.1142/S0219720020400028
   Yu R, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106012
   Zakaryan H, 2017, ARCH VIROL, V162, P2539, DOI 10.1007/s00705-017-3417-y
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zembower DE, 1998, ANTIVIR RES, V39, P81, DOI 10.1016/S0166-3542(98)00033-3
   Zengion A. H., 2011, HERBAL NUTR SUPPLEME, P187
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhang ZM, 2011, BIOINFORMATICS, V27, P2083, DOI 10.1093/bioinformatics/btr331
   Zhavoronkov A., 2020, INSILICO MED HONG A, V307, pE1
   Zheng XW, 2010, EUR J PHARM SCI, V41, P43, DOI 10.1016/j.ejps.2010.05.013
   Zoete V, 2009, J CELL MOL MED, V13, P238, DOI 10.1111/j.1582-4934.2008.00665.x
NR 120
TC 2
Z9 2
U1 6
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1815584
EA SEP 2020
PG 27
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NL7JA
UT WOS:000567586000001
PM 32897178
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Khan, RJ
   Jha, RK
   Singh, E
   Jain, M
   Amera, GM
   Singh, RP
   Muthukumaran, J
   Singh, AK
AF Khan, Rameez Jabeer
   Jha, Rajat Kumar
   Singh, Ekampreet
   Jain, Monika
   Amera, Gizachew Muluneh
   Singh, Rashmi Prabha
   Muthukumaran, Jayaraman
   Singh, Amit Kumar
TI Identification of promising antiviral drug candidates against
   non-structural protein 15 (NSP15) from SARS-CoV-2: anin silicoassisted
   drug-repurposing study
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Drug repurposing; SARS-CoV-2; NSP15; Molecular Docking; MD simulation;
   MM; PBSA
ID BOLTZMANN SURFACE-AREA; CORONAVIRUS; DYNAMICS; ACCURACY; GROMACS;
   MODELS; TOOL
AB The recent COVID-19 pandemic caused by SARS-CoV-2 has recorded a high number of infected people across the globe. The virulent nature of the virus makes it necessary for us to identify promising therapeutic agents in a time-sensitive manner. The current study utilises anin silicobased drug repurposing approach to identify potential anti-viral drug candidates targeting non-structural protein 15 (NSP15), i.e. a uridylate specific endoribonuclease of SARS-CoV-2 which plays an indispensable role in RNA processing and viral immune evasion from the host immune system. The NSP15 protein was screened against an in-house library of 123 antiviral drugs obtained from the DrugBank database from which three promising drug candidates were identified based on their estimated binding affinities (Delta G), estimated inhibition constants (Ki), the orientation of drug molecules in the active site and the key interacting residues of NSP15. Molecular dynamics (MD) simulations were performed for the screened drug candidates in complex with NSP15 as well as the apo form of NSP15 to mimic their physiological states. Based on the stable MD simulation trajectories, the binding free energies of the screened NSP15-drug complexes were calculated using the MM/PBSA approach. Two candidate drugs, Simeprevir and Paritaprevir, achieved the lowest binding free energies for NSP15, with a value of -259.522 +/- 17.579 and -154.051 +/- 33.628 kJ/mol, respectively. In addition, their complexes with NSP15 also exhibited the strongest structural stabilities. Taken together, we propose that Simeprevir and Paritaprevir are promising drug candidates to inhibit NSP15 and may act as potential therapeutic agents against SARS-CoV-2. Communicated by Ramaswamy H. Sarma
C1 [Khan, Rameez Jabeer; Jha, Rajat Kumar; Singh, Ekampreet; Jain, Monika; Amera, Gizachew Muluneh; Muthukumaran, Jayaraman; Singh, Amit Kumar] Sharda Univ, Sch Engn & Technol, Dept Biotechnol, Greater Noida 201310, UP, India.
   [Singh, Rashmi Prabha] IILM Coll Engn & Technol, Dept Biotechnol, Greater Noida, UP, India.
RP Muthukumaran, J; Singh, AK (corresponding author), Sharda Univ, Sch Engn & Technol, Dept Biotechnol, Greater Noida 201310, UP, India.
EM j.muthukumaran@sharda.ac.in; amitk.singh@sharda.ac.in
RI ; MUTHUKUMARAN, JAYARAMAN/M-1509-2013
OI Jha, Rajat Kumar/0000-0002-8557-4219; MUTHUKUMARAN,
   JAYARAMAN/0000-0002-0953-1196
FU College of Natural Science, Wollo University, Dessie, Ethiopia; Sharda
   University, Greater Noida, India
FX Dr. Amit Kumar Singh thanks the Department of Science and Technology
   (DST), Indian National Science Academy (INSA), Indian Council of Medical
   Research (ICMR), New Delhi, India. Gizachew Muluneh Amera thanks the
   College of Natural Science, Wollo University, Dessie, Ethiopia for the
   sponsorship. The authors thank Sharda University, Greater Noida, India
   for support.
CR Amera GM, 2020, J MOL GRAPH MODEL, V100, DOI 10.1016/j.jmgm.2020.107675
   Amera GM, 2020, MICROB PATHOGENESIS, V147, DOI 10.1016/j.micpath.2020.104205
   Amera GM, 2020, J BIOMOL STRUCT DYN, V38, P5230, DOI 10.1080/07391102.2019.1700167
   Amera GM, 2019, INFORM MED UNLOCKED, V16, P100216, DOI [DOI 10.1016/J.IMU.2019.100216, 10.1016/j.imu.2019.100216]
   Berman H. M., 2000, NUCL ACIDS RES, V28, pD235, DOI DOI HTTPS://DOI.ORG/10.1093/NAR/28.1.235
   Bhardwaj K, 2008, J BIOL CHEM, V283, P3655, DOI 10.1074/jbc.M708375200
   Bhardwaj VK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1766572
   Biovia D.S., 2019, DISCOVERY STUDIO VIS
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Csse J. H., 2020, CORONAVIRUS COVID 19
   de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25
   Deng XF, 2017, P NATL ACAD SCI USA, V114, pE4251, DOI 10.1073/pnas.1618310114
   Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1758789
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Fan KQ, 2004, J BIOL CHEM, V279, P1637, DOI 10.1074/jbc.M310875200
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Hackbart M, 2020, P NATL ACAD SCI USA, V117, P8094, DOI 10.1073/pnas.1921485117
   Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hollingsworth SA, 2018, NEURON, V99, P1129, DOI 10.1016/j.neuron.2018.08.011
   Homeyer N, 2012, MOL INFORM, V31, P114, DOI 10.1002/minf.201100135
   Huang XQ, 2020, AGING-US, V12, P11263, DOI 10.18632/aging.103416
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kang H, 2007, J VIROL, V81, P13587, DOI 10.1128/JVI.00547-07
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Kim Y., 2020, BIORXIV, DOI [10.1101/2020.03.02.968388, DOI 10.1101/2020.03.02.968388, 10.1101/2020.03.02.968388.]
   Kim Y, 2020, PROTEIN SCI, V29, P1596, DOI 10.1002/pro.3873
   Krieger E, 2009, PROTEINS, V77, P114, DOI 10.1002/prot.22570
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   LEI Y, 2009, PLOS ONE, V4, DOI DOI https://doi.org/10.1371/journal.pone.0005466
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mark P, 2001, J PHYS CHEM A, V105, P9954, DOI 10.1021/jp003020w
   Martins LC, 2018, J COMPUT AID MOL DES, V32, P591, DOI 10.1007/s10822-018-0112-3
   Mohammad T, 2020, MOLECULES, V25, DOI 10.3390/molecules25040823
   Naider F, 2009, CURR OPIN STRUC BIOL, V19, P473, DOI 10.1016/j.sbi.2009.07.003
   Pol-Fachin L, 2009, CARBOHYD RES, V344, P491, DOI 10.1016/j.carres.2008.12.025
   Posthuma CC, 2006, J VIROL, V80, P1653, DOI 10.1128/JVI.80.4.1653-1661.2006
   Qiu Y., 2020, STEMEDICINE, V1, pe39
   REN W, 2015, SCI REP UK, V5, DOI DOI https://doi.org/10.1038/srep12632
   Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Thiel V, 2001, J VIROL, V75, P6676, DOI 10.1128/JVI.75.14.6676-6681.2001
   Tian X., 2020, ELECTRONICS, V9, P1, DOI DOI 10.1080/22221751.2020.1729069
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wl D., 2002, PYMOL MOL GRAPHICS S
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xue J, 2019, RSC ADV, V9, P13868, DOI 10.1039/c9ra02406a
   Yuen CK, 2020, EMERG MICROBES INFEC, V9, P1418, DOI 10.1080/22221751.2020.1780953
   Zhang LQ, 2018, J VIROL, V92, DOI 10.1128/JVI.00893-18
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 56
TC 0
Z9 1
U1 4
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2020.1814870
EA SEP 2020
PG 11
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA NK4BG
UT WOS:000566677000001
PM 32885740
OA Bronze
DA 2021-01-01
ER

PT J
AU Du, H
   Dong, X
   Zhang, JJ
   Cao, YY
   Akdis, M
   Huang, PQ
   Chen, HW
   Li, Y
   Liu, GH
   Akdis, CA
   Lu, XX
   Gao, YD
AF Du, Hui
   Dong, Xiang
   Zhang, Jin-jin
   Cao, Yi-yuan
   Akdis, Mubeccel
   Huang, Pei-qi
   Chen, Hong-wei
   Li, Ying
   Liu, Guang-hui
   Akdis, Cezmi A.
   Lu, Xiao-xia
   Gao, Ya-dong
TI Clinical characteristics of 182 pediatric COVID-19 patients with
   different severities and allergic status
SO ALLERGY
LA English
DT Article; Early Access
DE allergy; children; COVID-19; lymphocyte subsets; pneumonia; SARS-CoV-2
ID UNITED-STATES; CHILDREN; CORONAVIRUS; ASTHMA; PREVALENCE; RHINITIS
AB Background The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has made widespread impact recently. We aim to investigate the clinical characteristics of COVID-19 children with different severities and allergic status. Methods Data extracted from the electronic medical records, including demographics, clinical manifestations, comorbidities, laboratory and immunological results, and radiological images of 182 hospitalized COVID-19 children, were summarized and analyzed. Results The median age was 6 years, ranging from 3 days to 15 years, and there were more boys (male-female ratio about 2:1) within the studied 182 patients. Most of the children were infected by family members. Fever (43.4%) and dry cough (44.5%) were common symptoms, and gastrointestinal manifestations accounted for 11.0%, including diarrhea, abdominal discomfort, and vomiting. 71.4% had abnormal chest computed tomography (CT) scan images, and typical signs of pneumonia were ground-glass opacity and local patchy shadowing on admission. Laboratory results were mostly within normal ranges, and only a small ratio of lymphopenia (3.9%) and eosinopenia (29.5%) were observed. The majority (97.8%) of infected children were not severe, and 24 (13.2%) of them had asymptomatic infections. Compared to children without pneumonia (manifested as asymptomatic and acute upper respiratory infection), children with pneumonia were associated with higher percentages of the comorbidity history, symptoms of fever and cough, and increased levels of serum procalcitonin, alkaline phosphatase, and serum interleukins (IL)-2, IL-4, IL-6, IL-10, and TNF-alpha. There were no differences in treatments, duration of hospitalization, time from first positive to first negative nucleic acid testing, and outcomes between children with mild pneumonia and without pneumonia. All the hospitalized COVID-19 children had recovered except one death due to intussusception and sepsis. In 43 allergic children with COVID-19, allergic rhinitis (83.7%) was the major disease, followed by drug allergy, atopic dermatitis, food allergy, and asthma. Demographics and clinical features were not significantly different between allergic and nonallergic groups. Allergic patients showed less increase in acute phase reactants, procalcitonin, D-dimer, and aspartate aminotransferase levels compared with all patients. Immunological profiles including circulating T, B, and NK lymphocyte subsets, total immunoglobulin and complement levels, and serum cytokines did not show any difference in allergic and pneumonia groups. Neither eosinophil counts nor serum total immunoglobulin E (IgE) levels showed a significant correlation with other immunological measures, such as other immunoglobulins, complements, lymphocyte subset numbers, and serum cytokine levels. Conclusion Pediatric COVID-19 patients tended to have a mild clinical course. Patients with pneumonia had higher proportion of fever and cough and increased inflammatory biomarkers than those without pneumonia. There was no difference between allergic and nonallergic COVID-19 children in disease incidence, clinical features, and laboratory and immunological findings. Allergy was not a risk factor for developing and severity of SARS-CoV-2 infection and hardly influenced the disease course of COVID-19 in children.
C1 [Du, Hui; Huang, Pei-qi; Chen, Hong-wei; Li, Ying; Lu, Xiao-xia] Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan Childrens Hosp, Dept Resp Med, Hongkong Rd 100, Wuhan 430015, Hubei, Peoples R China.
   [Dong, Xiang; Zhang, Jin-jin; Liu, Guang-hui; Gao, Ya-dong] Wuhan Univ, Zhongnan Hosp, Dept Allergol, Wuhan 430071, Hubei, Peoples R China.
   [Cao, Yi-yuan] Wuhan Univ, Dept Radiol, Zhongnan Hosp, Wuhan, Peoples R China.
   [Akdis, Mubeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Herman Burchard Str 9, CH-7265 Davos, Wolfgang, Switzerland.
RP Lu, XX (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan Childrens Hosp, Dept Resp Med, Hongkong Rd 100, Wuhan 430015, Hubei, Peoples R China.; Gao, YD (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Allergol, Wuhan 430071, Hubei, Peoples R China.; Akdis, CA (corresponding author), Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Herman Burchard Str 9, CH-7265 Davos, Wolfgang, Switzerland.
EM akdisca@siaf.uzh.ch; akdisca@siaf.uzh.ch; gaoyadong@whu.edu.cn
OI Dong, Xiang/0000-0002-5241-4307
CR Akinbami LJ, 2016, J ASTHMA, V53, P356, DOI 10.3109/02770903.2015.1126848
   [Anonymous], 2020, RESP COMM SPREAD COV
   Bauchner H, 2020, JAMA-J AM MED ASSOC, V323, P1256, DOI 10.1001/jama.2020.3980
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Bousquet J, 2020, ALLERGY, V75, P2440, DOI 10.1111/all.14302
   Bush A, 2020, ALLERGY, V75, P2711, DOI 10.1111/all.14172
   Cai JH, 2020, CLIN INFECT DIS, V71, P1547, DOI 10.1093/cid/ciaa198
   Cai QX, 2020, ALLERGY, V75, P1742, DOI 10.1111/all.14309
   Chao JY, 2020, J PEDIATR-US, V223, P14, DOI 10.1016/j.jpeds.2020.05.006
   Chen F, 2020, Zhonghua Er Ke Za Zhi, V58, P179, DOI [10.3760/cma.j.issn.0578-1310.2020.0005, 10.3760/cma.j.issn.0578-1310.2020.03.003]
   Coronaviridae Study Group of the International Committee on Taxomony of Viruses, 2020, NATURE MICROBIOLOGY, V5, P536, DOI DOI 10.1038/s41564-020-0695-z
   DeBiasi RL, 2020, J PEDIATR-US, V223, P199, DOI 10.1016/j.jpeds.2020.05.007
   Dong X, 2020, ALLERGY, V75, P1699, DOI 10.1111/all.14289
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Duan YN, 2020, EUR RADIOL, V30, P4427, DOI 10.1007/s00330-020-06860-3
   Ducharme FM, 2014, LANCET, V383, P1593, DOI 10.1016/S0140-6736(14)60615-2
   Erdem SB, 2018, ALLERGOL IMMUNOPATH, V46, P119, DOI 10.1016/j.aller.2017.04.003
   Gilles S, 2020, ALLERGY, V75, P576, DOI 10.1111/all.14047
   Greenberg SB, 2016, SEMIN RESP CRIT CARE, V37, P555, DOI 10.1055/s-0036-1584797
   Han MY, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10120682
   Hong H, 2020, PEDIATR NEONATOL, V61, P131, DOI 10.1016/j.pedneo.2020.03.001
   Hu XW, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138812
   Jackson DJ, 2020, J ALLERGY CLIN IMMUN, V146, P203, DOI 10.1016/j.jaci.2020.04.009
   Lei Y, 2016, ASIA PAC ALLERGY, V6, P101, DOI 10.5415/apallergy.2016.6.2.101
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Liu ZM, 2020, J INFECTION, V81, P331, DOI 10.1016/j.jinf.2020.03.054
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   National Cooperative Group on Childhood Asthma, 2013, Zhonghua Er Ke Za Zhi, V51, P729
   Papadopoulos NG, 2011, ALLERGY, V66, P458, DOI 10.1111/j.1398-9995.2010.02505.x
   Pawankar R, 2014, WORLD ALLERGY ORGAN, V7, DOI 10.1186/1939-4551-7-12
   Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Shen KL, 2020, WORLD J PEDIATR, V16, P223, DOI 10.1007/s12519-020-00343-7
   Turunen R, 2014, PEDIAT ALLERG IMM-UK, V25, P796, DOI 10.1111/pai.12318
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Wong GWK, 2018, PEDIAT ALLERG IMM-UK, V29, P127, DOI 10.1111/pai.12819
   World Health Organization, COR DIS COVID 2019 S
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Wuhan Municipal Health Commission, 2019, REP CLUST PNEUM UNKN
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Zahran HS, 2018, MMWR-MORBID MORTAL W, V67, P149, DOI 10.15585/mmwr.mm6705e1
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang Y, 2019, ALLERGY ASTHMA IMMUN, V11, P156, DOI 10.4168/aair.2019.11.2.156
   Zheng F, 2020, CHINA CURR MED SCI, V40, P1
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   姜毅, 2020, [中华实用儿科临床杂志, Chinese Journal of Applied Clinical Pediatrics], V35, P143
NR 48
TC 10
Z9 12
U1 3
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0105-4538
EI 1398-9995
J9 ALLERGY
JI Allergy
DI 10.1111/all.14452
EA SEP 2020
PG 23
WC Allergy; Immunology
SC Allergy; Immunology
GA NJ9KK
UT WOS:000566362500001
PM 32524611
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Ul Haq, E
   Yu, JF
   Guo, JC
AF Ul Haq, Ehtisham
   Yu, Jifeng
   Guo, Jiancheng
TI Frontiers in the COVID-19 vaccines development
SO EXPERIMENTAL HEMATOLOGY & ONCOLOGY
LA English
DT Letter
DE COVID-19; Vaccine development; RNA and DNA vaccine
AB Novel corona virus caused pneumonia first reported in December, 2019 in Wuhan, China was later named COVID-19. Due to its special pathogenicity, COVID-19 transmitted with high speed beyond borders and has significantly affected normal life. Currently, no specific drugs, treatment or vaccines are available. Vaccine development for COVID-19 is a highly complex process involving viral genomic studies, identification of target for vaccine, vaccine design, manufacturing, storage and distribution, preclinical and clinical safety and efficacy studies. The high levels of efforts and global collaboration at this scale is unprecedented. The World Health Organization (WHO) has documented 160 different COVID-19 vaccine candidates as of July 13, 2020 with 26 currently on clinical evaluation while 137 vaccines on preclinical evaluation. COVID-19 vaccine efforts mark the first use of mRNA-type vaccines ever evaluated. Numerous research organizations have successfully initiated clinical evaluation of COVID-19 vaccines. This review aims to summarize the advances and challenges for COVID-19 vaccines development.
C1 [Ul Haq, Ehtisham] Zhengzhou Univ, Sch Basic Hlth Sci, 100 Sci Ave, Zhengzhou 450001, Peoples R China.
   [Yu, Jifeng] Zhengzhou Univ, Affiliated Hosp 1, 1 East Jianshe Rd, Zhengzhou 450052, Peoples R China.
   [Yu, Jifeng; Guo, Jiancheng] Zhengzhou Univ, Acad Med & Pharmaceut Sci, 40 Daxue Rd, Zhengzhou 450052, Peoples R China.
   [Guo, Jiancheng] Zhengzhou Univ, Precis Med Ctr, 40 Daxue Rd, Zhengzhou 450052, Peoples R China.
   [Guo, Jiancheng] Zhengzhou Univ, Dept Mol Pathol, Affiliated Hosp 2, 2 Jingba Rd, Zhengzhou 450052, Peoples R China.
RP Yu, JF (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, 1 East Jianshe Rd, Zhengzhou 450052, Peoples R China.; Yu, JF; Guo, JC (corresponding author), Zhengzhou Univ, Acad Med & Pharmaceut Sci, 40 Daxue Rd, Zhengzhou 450052, Peoples R China.
EM Yujifengzzu@163.com; gjc@zzu.edu.cn
RI Yu, Jifeng/AAB-8399-2020
OI Yu, Jifeng/0000-0003-1217-4385
FU Key Scientific Research Project of Henan Provincial Education Department
   [20A320062]; Special Talents Project Fund of the First Affiliated
   Hospital of Zhengzhou University, Zhengzhou, China
FX This study was funded by the Key Scientific Research Project of Henan
   Provincial Education Department (20A320062) and Special Talents Project
   Fund of the First Affiliated Hospital of Zhengzhou University,
   Zhengzhou, China. The funding bodies did not participate in study
   design, in data collection, analysis, and interpretation, and in writing
   the manuscript.
CR Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li H, 2020, J CELL MOL MED, V24, P6558, DOI 10.1111/jcmm.15364
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Ong E, 2020, BIORXIV, V64, P608
   Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195
   Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543
   Yang JY, 2020, NATURE, V586, P572, DOI 10.1038/s41586-020-2599-8
   Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 15
TC 0
Z9 0
U1 18
U2 18
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2162-3619
J9 EXP HEMATOL ONCOL
JI Exp. Hematol. Oncol.
PD SEP 3
PY 2020
VL 9
IS 1
AR 24
DI 10.1186/s40164-020-00180-4
PG 6
WC Oncology; Hematology
SC Oncology; Hematology
GA NN1QO
UT WOS:000568565500003
PM 32901214
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Vrachatis, DA
   Giotaki, SG
   Giannopoulos, G
   Deftereos, S
   Reimers, B
AF Vrachatis, Dimitrios A.
   Giotaki, Sotiria G.
   Giannopoulos, George
   Deftereos, Spyridon
   Reimers, Bernhard
TI Comment on: "Pharmaco-Immunomodulatory Therapy in COVID-19"
SO DRUGS
LA English
DT Letter
C1 [Vrachatis, Dimitrios A.; Reimers, Bernhard] IRCCS, Humanitas Clin & Res Ctr, Via Alessandro Mazoni 56, Milan, Italy.
   [Vrachatis, Dimitrios A.; Giotaki, Sotiria G.; Deftereos, Spyridon] Natl & Kapodistrian Univ Athens, Dept Cardiol 2, Athens, Greece.
   [Giannopoulos, George] Gen Hosp Athens G Gennimatas, Dept Cardiol, Athens, Greece.
RP Vrachatis, DA (corresponding author), IRCCS, Humanitas Clin & Res Ctr, Via Alessandro Mazoni 56, Milan, Italy.; Vrachatis, DA (corresponding author), Natl & Kapodistrian Univ Athens, Dept Cardiol 2, Athens, Greece.
EM dvrachatis@gmail.com
OI Reimers, Bernhard/0000-0002-9890-5582; Vrachatis,
   Dimitrios/0000-0002-2385-5365
FU Hellenic Society of Cardiology (Athens, Greece)
FX DV is supported by a scholarship from Hellenic Society of Cardiology
   (Athens, Greece).
CR Cure MC, 2020, CLIN RHEUMATOL, V39, P2101, DOI 10.1007/s10067-020-05144-x
   Deftereos SG, 2020, NETHERLANDS HELLENIC
   Deftereos S, 2020, EUR HEART J-CARD PHA, V6, P255, DOI 10.1093/ehjcvp/pvaa033
   Deftereos SG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13136
   Gendelman O, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102566
   Giannopoulos G, 2020, US JAMA CARDIOL
   Kobak S, 2020, CLIN RHEUMATOL, V39, P2487, DOI 10.1007/s10067-020-05233-x
   Parra-Medina R, 2020, CLIN RHEUMATOL, P2487
   Piantoni S, 2020, CLIN RHEUMATOL, V39, P2489, DOI 10.1007/s10067-020-05232-y
   Rizk JG, 2020, DRUGS, V80, P1267, DOI 10.1007/s40265-020-01367-z
NR 10
TC 1
Z9 1
U1 1
U2 1
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0012-6667
EI 1179-1950
J9 DRUGS
JI Drugs
PD SEP
PY 2020
VL 80
IS 14
BP 1499
EP 1500
DI 10.1007/s40265-020-01395-9
EA SEP 2020
PG 2
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA NT9NP
UT WOS:000565825800001
PM 32880807
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Rizk, JG
   Kalantar-Zadeh, K
   Mehra, MR
   Lavie, CJ
   Rizk, Y
   Forthal, DN
AF Rizk, John G.
   Kalantar-Zadeh, Kamyar
   Mehra, Mandeep R.
   Lavie, Carl J.
   Rizk, Youssef
   Forthal, Donald N.
TI Authors' Reply to Vrachatis et al. "Pharmaco-Immunomodulatory Therapy in
   COVID-19"
SO DRUGS
LA English
DT Letter
ID COLCHICINE
C1 [Rizk, John G.] Arizona State Univ, Edson Coll, Phoenix, AZ 85004 USA.
   [Kalantar-Zadeh, Kamyar] Univ Calif Irvine, Sch Med, Div Nephrol Hypertens & Kidney Transplantat, Irvine, CA 92717 USA.
   [Kalantar-Zadeh, Kamyar] Univ Calif Los Angeles, UCLA Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA.
   [Kalantar-Zadeh, Kamyar] Tibor Rubin VA Long Beach Healthcare Syst, Long Beach, CA USA.
   [Mehra, Mandeep R.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
   [Mehra, Mandeep R.] Harvard Med Sch, Boston, MA 02115 USA.
   [Lavie, Carl J.] Univ Queensland, Sch Med, Ochsner Clin Sch, John Ochsner Heart & Vasc Inst, New Orleans, LA USA.
   [Rizk, Youssef] Amer Univ Beirut, Dept Family Med, Med Ctr, Beirut, Lebanon.
   [Forthal, Donald N.] Univ Calif Irvine, Sch Med, Dept Med, Div Infect Dis, Irvine, CA 92717 USA.
   [Forthal, Donald N.] Univ Calif Irvine, Sch Med, Dept Mol Biol & Biochem, Irvine, CA 92717 USA.
RP Rizk, JG (corresponding author), Arizona State Univ, Edson Coll, Phoenix, AZ 85004 USA.
EM john.rizk@lau.edu
OI Rizk, John/0000-0002-5216-8695; Kalantar-Zadeh,
   Kamyar/0000-0002-8666-0725
CR [Anonymous], 2009, COLCR PACK INS
   Ben-Chetrit E, 2018, TXB AUTOINFLAMM, DOI [10.1007/978-3-319-98605-0_40, DOI 10.1007/978-3-319-98605-0_40]
   Deftereos SG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13136
   Finkelstein Y, 2010, CLIN TOXICOL, V48, P407, DOI 10.3109/15563650.2010.495348
   Gupta A, 2020, NAT MED, V26, P1017, DOI 10.1038/s41591-020-0968-3
   Hirayama Ichiro, 2018, J Med Case Rep, V12, P191, DOI 10.1186/s13256-018-1737-5
   Hung IFN, 2005, CLIN INFECT DIS, V41, P291, DOI 10.1086/431592
   MACLEOD JG, 1947, ANN RHEUM DIS, V6, P224, DOI 10.1136/ard.6.4.224
   Rizk JG, 2020, DRUGS, V80, P1267, DOI 10.1007/s40265-020-01367-z
   Slobodnick Anastasia, 2018, Rheumatology (Oxford), V57, pi4, DOI 10.1093/rheumatology/kex453
   Tardif JC, 2019, NEW ENGL J MED, V381, P2497, DOI 10.1056/NEJMoa1912388
   Vrachatis DA, 2020, DRUGS, V80, P1499, DOI 10.1007/s40265-020-01395-9
   Zagler Bernhard, 2009, Cases J, V2, P6602, DOI 10.1186/1757-1626-2-6602
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 0012-6667
EI 1179-1950
J9 DRUGS
JI Drugs
PD SEP
PY 2020
VL 80
IS 14
BP 1501
EP 1503
DI 10.1007/s40265-020-01396-8
EA SEP 2020
PG 3
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA NT9NP
UT WOS:000565825800003
PM 32880806
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Zadow, EK
   Wundersitz, DWT
   Hughes, DL
   Adams, MJ
   Kingsley, MIC
   Blacklock, HA
   Wu, SSX
   Benson, AC
   Dutheil, F
   Gordon, BA
AF Zadow, Emma Kate
   Wundersitz, Daniel William Taylor
   Hughes, Diane Louise
   Adams, Murray John
   Kingsley, Michael Ian Charles
   Blacklock, Hilary Anne
   Wu, Sam Shi Xuan
   Benson, Amanda Clare
   Dutheil, Frederic
   Gordon, Brett Ashley
TI Coronavirus (COVID-19), Coagulation, and Exercise: Interactions That May
   Influence Health Outcomes
SO SEMINARS IN THROMBOSIS AND HEMOSTASIS
LA English
DT Article
DE coronavirus; pharmaceutical medications; coagulation; fibrinolysis;
   physical activity
ID PHYSICAL-ACTIVITY; FIBRINOLYTIC-ACTIVITY; BLOOD-COAGULATION; VENOUS
   THROMBOEMBOLISM; SINGLE BOUT; D-DIMER; MARKERS; DISEASE; RESPONSES;
   FITNESS
AB The proinflammatory cytokine storm associated with coronavirus disease 2019 (COVID-19) negatively affects the hematological system, leading to coagulation activation and endothelial dysfunction and thereby increasing the risk of venous and arterial thrombosis. Coagulopathy has been reported as associated with mortality in people with COVID-19 and is partially reflected by enhanced D-dimer levels. Poor vascular health, which is associated with the cardiometabolic health conditions frequently reported in people with severer forms of COVID-19, might exacerbate the risk of coagulopathy and mortality. Sedentary lifestyles might also contribute to the development of coagulopathy, and physical activity participation has been inherently lowered due to at-home regulations established to slow the spread of this highly infectious disease. It is possible that COVID-19, coagulation, and reduced physical activity may contribute to generate a "perfect storm," where each fuels the other and potentially increases mortality risk. Several pharmaceutical agents are being explored to treat COVID-19, but potential negative consequences are associated with their use. Exercise is known to mitigate many of the identified side effects from the pharmaceutical agents being trialled but has not yet been considered as part of management for COVID-19. From the limited available evidence in people with cardiometabolic health conditions, low- to moderate-intensity exercise might have the potential to positively influence biochemical markers of coagulopathy, whereas high-intensity exercise is likely to increase thrombotic risk. Therefore, low- to moderate-intensity exercise could be an adjuvant therapy for people with mild-to-moderate COVID-19 and reduce the risk of developing severe symptoms of illness that are associated with enhanced mortality.
C1 [Zadow, Emma Kate; Wundersitz, Daniel William Taylor; Hughes, Diane Louise; Kingsley, Michael Ian Charles; Gordon, Brett Ashley] La Trobe Univ, Holsworth Res Initiat, La Trobe Rural Hlth Sch, Edwards Rd,Flora Hill, Bendigo, Vic 3550, Australia.
   [Hughes, Diane Louise] La Trobe Univ, Sch Mol Sci, Dept Pharm & Biomed Sci, Bendigo, Vic, Australia.
   [Adams, Murray John] Murdoch Univ, Coll Sci Hlth Engn & Educ, Murdoch, WA, Australia.
   [Kingsley, Michael Ian Charles] Univ Auckland, Dept Exercise Sci, Auckland, New Zealand.
   [Blacklock, Hilary Anne] Middlemore Hosp, Dept Haematol, Auckland, New Zealand.
   [Wu, Sam Shi Xuan; Benson, Amanda Clare] Swinburne Univ Technol, Dept Hlth & Med Sci, Hawthorn, Vic, Australia.
   [Dutheil, Frederic] Univ Clermont Auvergne, Univ Hosp Clermont Ferrand, CHU Clermont Ferrand,LaPSCo, CNRS,Prevent & Occupatl Med,Physiol & Psychosocia, Clermont Ferrand, France.
RP Zadow, EK (corresponding author), La Trobe Univ, Holsworth Res Initiat, La Trobe Rural Hlth Sch, Edwards Rd,Flora Hill, Bendigo, Vic 3550, Australia.
EM e.zadow@latrobe.edu.au
RI Stefanadis, Christodoulos/ABH-2232-2020; Adams, Murray/G-4269-2011
OI Stefanadis, Christodoulos/0000-0001-5974-6454; Wundersitz,
   Daniel/0000-0002-7316-6373; Gordon, Brett/0000-0001-8864-2128; Adams,
   Murray/0000-0002-7743-4515; Benson, Amanda Clare/0000-0003-2959-8969;
   Wu, Sam/0000-0003-1466-939X
CR Abd El-Aziz TM, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104327
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bhimraj A, 2020, CLIN INFECT DIS, V2000, pciaa478
   Bikdeli B, 2020, THROMB HAEMOSTASIS, V120, P1004, DOI 10.1055/s-0040-1713152
   Braschi A, 2019, PLATELETS, V30, P675, DOI 10.1080/09537104.2019.1615611
   Cannegieter SC, 2020, RES PRACT THROMB HAE, V4, P439, DOI 10.1002/rth2.12350
   Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1
   Chen PJ, 2020, J SPORT HEALTH SCI, V9, P103, DOI 10.1016/j.jshs.2020.02.001
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Chodzko-Zajko WJ, 2009, MED SCI SPORT EXER, V41, P1510, DOI 10.1249/MSS.0b013e3181a0c95c
   Chutaputti A, 2000, J GASTROEN HEPATOL, V15, pE156, DOI 10.1046/j.1440-1746.2000.02114.x
   Cuzzolin L, 2000, INT J SPORTS MED, V21, P289, DOI 10.1055/s-2000-13308
   DeSouza CA, 1997, J APPL PHYSIOL, V82, P1765
   Dutheil F, 2018, J INT MED RES, V46, P2082, DOI 10.1177/0300060517706578
   ElSayed MS, 1996, SPORTS MED, V22, P282, DOI 10.2165/00007256-199622050-00002
   ELSAYED MS, 1990, MED SCI SPORT EXER, V22, P494
   Eriksson-Berg M, 2002, THROMB RES, V105, P481, DOI 10.1016/S0049-3848(02)00063-4
   Evidation Health, COVID 19 PULS STUD
   FERGUSON EW, 1987, J APPL PHYSIOL, V62, P1416
   FitbitStaff, IMP COR GLOB ACT
   Franchini M, 2020, SEMIN THROMB HEMOST, V46, P804, DOI 10.1055/s-0040-1713433
   Friis-Moller N, 2007, NEW ENGL J MED, V356, P1723
   Gaertner F, 2016, SEMIN IMMUNOL, V28, P561, DOI 10.1016/j.smim.2016.10.010
   Gao Y, 2020, J MED VIROL, V92, P791, DOI 10.1002/jmv.25770
   Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb
   Goldhaber SZ, 2012, LANCET, V379, P1835, DOI 10.1016/S0140-6736(11)61904-1
   Gonzales F, 1996, J SPORT MED PHYS FIT, V36, P112
   Gram AS, 2018, J OBES, V2018, DOI 10.1155/2018/7140754
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Gregson J, 2019, JAMA CARDIOL, V4, P163, DOI 10.1001/jamacardio.2018.4537
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gunga HC, 2002, INT J SPORTS MED, V23, P495, DOI 10.1055/s-2002-35070
   Gupta N, 2019, THROMB RES, V181, P77, DOI 10.1016/j.thromres.2019.07.013
   Halabchi F, 2020, ASIAN J SPORTS MED, DOI [10.5812/asjsm.102630, DOI 10.5812/ASJSM.102630]
   Hashemi A, 2020, SEMIN THROMB HEMOST, V46, P789, DOI 10.1055/s-0040-1714273
   Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI 10.1249/mss.0b013e3180616b27
   Hendren NS, 2020, CIRCULATION, V141, P1903, DOI 10.1161/CIRCULATIONAHA.120.047349
   Henke PK, 2010, PHLEBOLOGY, V25, P219, DOI 10.1258/phleb.2010.010018
   Henry BM, 2020, CLIN CHEM LAB MED, V58, P1021, DOI 10.1515/cclm-2020-0369
   Hilberg T, 2003, THROMB RES, V109, P271, DOI 10.1016/S0049-3848(03)00283-4
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DY, 2003, PROG LIPID RES, V42, P81, DOI 10.1016/S0163-7827(02)00046-2
   Hull CM, 2013, CIRCULATION, V128, pE469, DOI 10.1161/CIRCULATIONAHA.113.004586
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Ivey FM, 2003, MED SCI SPORT EXER, V35, P193, DOI 10.1249/01.MSS.0000048634.89370.06
   Jahangir M, 2020, INT J PHARMACEUT, V4, P2581
   Karampour S, 2018, J SPORT MED PHYS FIT, V58, P120, DOI 10.23736/S0022-4707.17.06822-0
   Kelly J, 2002, ARCH INTERN MED, V162, P747, DOI 10.1001/archinte.162.7.747
   Kleinegris MC, 2012, POL ARCH MED WEWN, V122, P557, DOI 10.20452/pamw.1464
   Koehler KS, 2014, MIL MED, V179, P225, DOI 10.7205/MILMED-D-13-00384
   Kupchak BR, 2013, THROMB RES, V131, pE227, DOI 10.1016/j.thromres.2013.02.014
   Kvernmo HD, 1997, THROMB RES, V87, P559, DOI 10.1016/S0049-3848(97)00185-0
   Kwaan HC, 2020, SEMIN THROMB HEMOST, V46, P841, DOI 10.1055/s-0040-1709996
   Larsen JB, 2020, SEMIN THROMB HEMOST, V46, P823, DOI 10.1055/s-0040-1710006
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Lippi G, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.157
   Lippi G, 2020, DIAGNOSIS, V7, P85, DOI 10.1515/dx-2020-0041
   Lippi G, 2020, EUR J PREV CARDIOL, V27, P906, DOI 10.1177/2047487320916823
   Lippi G, 2020, THROMB HAEMOSTASIS, V120, P876, DOI 10.1055/s-0040-1709650
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Lippi G, 2018, SEMIN THROMB HEMOST, V44, P747, DOI 10.1055/s-0038-1667115
   Lippi G, 2018, SEMIN THROMB HEMOST, V44, P780, DOI 10.1055/s-0038-1661334
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Lowe GDO, 2003, PATHOPHYSIOL HAEMO T, V33, P455, DOI 10.1159/000083845
   Marrelli MT, 2016, MALARIA J, V15, P1
   Menzel K, 2011, EUR J APPL PHYSIOL, V111, P253, DOI 10.1007/s00421-010-1640-2
   Mondy KE, 2011, CLIN INFECT DIS, V52, P378, DOI 10.1093/cid/ciq066
   Monroe DM, 2006, ARTERIOSCL THROM VAS, V26, P41, DOI 10.1161/01.ATV.0000193624.28251.83
   Monto AS, 2003, VACCINE, V21, P1796, DOI 10.1016/S0264-410X(03)00075-6
   Morris PJ, 2003, OBES RES, V11, P1333, DOI 10.1038/oby.2003.180
   Nguyen NT, 2001, ARCH SURG-CHICAGO, V136, P909, DOI 10.1001/archsurg.136.8.909
   Page MJ, 2020, SEMIN THROMB HEMOST, V46, P302, DOI 10.1055/s-0040-1708827
   Pallister C J, 2010, HAEMATOLOGY
   Panagiotakos DB, 2005, PREV MED, V40, P432, DOI 10.1016/j.ypmed.2004.07.010
   Parker BA, 2012, AM J CARDIOL, V109, P282, DOI [10.1016/j.amjcard.2012.01.369, 10.1016/j.amjcard.2011.08.045]
   Peng Y D, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P450, DOI 10.3760/cma.j.cn112148-20200220-00105
   Pitsavos C, 2005, EUR J CARDIOV PREV R, V12, P151, DOI 10.1097/00149831-200504000-00010
   Pollock ML, 1998, MED SCI SPORT EXER, V30, P975, DOI 10.1097/00005768-199806000-00032
   Polman R, 2007, J SPORT MED PHYS FIT, V47, P103
   Posthuma JJ, 2015, BLOOD REV, V29, P171, DOI 10.1016/j.blre.2014.10.005
   Prchal JT, 2018, BLOOD, V132, P348, DOI 10.1182/blood-2018-06-854976
   Prisco D, 1998, THROMB RES, V89, P73, DOI 10.1016/S0049-3848(97)00293-4
   Rocker L, 1996, THROMB HAEMOSTASIS, V75, P612
   Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034
   Schobersberger W, 1996, FIBRINOLYSIS, V10, P37, DOI 10.1016/S0268-9499(05)80074-8
   Schulman S, 2020, SEMIN THROMB HEMOST, V46, P772, DOI 10.1055/s-0040-1710337
   Sebba A, 2008, AM J HEALTH-SYST PH, V65, P1413, DOI 10.2146/ajhp070449
   Shetty Rohit, 2020, Indian J Ophthalmol, V68, P693, DOI 10.4103/ijo.IJO_639_20
   Siahkouhian M, 2013, BIOL SPORT, V30, P125, DOI 10.5604/20831862.1044457
   SZYMANSKI LM, 1994, ARTERIOSCLER THROMB, V14, P1746, DOI 10.1161/01.ATV.14.11.1746
   SZYMANSKI LM, 1994, J APPL PHYSIOL, V77, P2305
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   Thachil J, 2020, SEMIN THROMB HEMOST, V46, P777, DOI 10.1055/s-0040-1712155
   Thrall G, 2007, THROMB RES, V120, P819, DOI 10.1016/j.thromres.2007.01.004
   UNCTAD, COR CAN POL AV TRILL
   Veinot JP, 1998, J RHEUMATOL, V25, P1221
   Verhamme P, 2006, ACTA CLIN BELG, V61, P213, DOI 10.1179/acb.2006.036
   VERNY C, 1992, PRESSE MED, V21, P800
   Versteeg HH, 2013, PHYSIOL REV, V93, P327, DOI 10.1152/physrev.00016.2011
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Weiss C, 1998, MED SCI SPORT EXER, V30, P1205, DOI 10.1097/00005768-199808000-00004
   Wells PS, 2003, NEW ENGL J MED, V349, P1227, DOI 10.1056/NEJMoa023153
   Wen J, 2020, ANATOLIA, V31, P331, DOI [10.1142/S0192415X21500014, 10.1080/13032917.2020.1730621]
   Womack CJ, 2001, MED SCI SPORT EXER, V33, P214
   World Health Organization, WHO COR DIS COVID 19
   Yeung RR, 1996, J PSYCHOSOM RES, V40, P123, DOI 10.1016/0022-3999(95)00554-4
   Yu WC, 2004, THORAX, V59, P643, DOI 10.1136/thx.2003.017665
   Zadow EK, 2018, EUR J SPORT SCI, V18, P367, DOI 10.1080/17461391.2017.1420237
   Zbinden-Foncea H, 2020, OBESITY SILVER SPRIN, P23
   Zebrowska A, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/7315714
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 112
TC 1
Z9 1
U1 5
U2 5
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 0094-6176
EI 1098-9064
J9 SEMIN THROMB HEMOST
JI Semin. Thromb. Hemost.
PD OCT
PY 2020
VL 46
IS 07
BP 807
EP 814
DI 10.1055/s-0040-1715094
EA SEP 2020
PG 8
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA OG3XQ
UT WOS:000565660000002
PM 32882720
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Tostanoski, LH
   Wegmann, F
   Martinot, AJ
   Loos, C
   McMahan, K
   Mercado, NB
   Yu, JY
   Chan, CN
   Bondoc, S
   Starke, CE
   Nekorchuk, M
   Busman-Sahay, K
   Piedra-Mora, C
   Wrijil, LM
   Ducat, S
   Custers, J
   Atyeo, C
   Fischinger, S
   Burke, JS
   Feldman, J
   Hauser, BM
   Caradonna, TM
   Bondzie, EA
   Dagotto, G
   Gebre, MS
   Jacob-Dolan, C
   Lin, ZJ
   Mahrokhian, SH
   Nampanya, F
   Nityanandam, R
   Pessaint, L
   Porto, M
   Ali, V
   Benetiene, D
   Tevi, K
   Andersen, H
   Lewis, MG
   Schmidt, AG
   Lauffenburger, DA
   Alter, G
   Estes, JD
   Schuitemaker, H
   Zahn, R
   Barouch, DH
AF Tostanoski, Lisa H.
   Wegmann, Frank
   Martinot, Amanda J.
   Loos, Carolin
   McMahan, Katherine
   Mercado, Noe B.
   Yu, Jingyou
   Chan, Chi N.
   Bondoc, Stephen
   Starke, Carly E.
   Nekorchuk, Michael
   Busman-Sahay, Kathleen
   Piedra-Mora, Cesar
   Wrijil, Linda M.
   Ducat, Sarah
   Custers, Jerome
   Atyeo, Caroline
   Fischinger, Stephanie
   Burke, John S.
   Feldman, Jared
   Hauser, Blake M.
   Caradonna, Timothy M.
   Bondzie, Esther A.
   Dagotto, Gabriel
   Gebre, Makda S.
   Jacob-Dolan, Catherine
   Lin, Zijin
   Mahrokhian, Shant H.
   Nampanya, Felix
   Nityanandam, Ramya
   Pessaint, Laurent
   Porto, Maciel
   Ali, Vaneesha
   Benetiene, Dalia
   Tevi, Komlan
   Andersen, Hanne
   Lewis, Mark G.
   Schmidt, Aaron G.
   Lauffenburger, Douglas A.
   Alter, Galit
   Estes, Jacob D.
   Schuitemaker, Hanneke
   Zahn, Roland
   Barouch, Dan H.
TI Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in
   hamsters
SO NATURE MEDICINE
LA English
DT Article
ID INFECTION; TRANSMISSION; IMMUNITY; WUHAN; CHINA; SARS
AB Coronavirus disease 2019 (COVID-19) in humans is often a clinically mild illness, but some individuals develop severe pneumonia, respiratory failure and death(1-4). Studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in hamsters(5-7)and nonhuman primates(8-10)have generally reported mild clinical disease, and preclinical SARS-CoV-2 vaccine studies have demonstrated reduction of viral replication in the upper and lower respiratory tracts in nonhuman primates(11-13). Here we show that high-dose intranasal SARS-CoV-2 infection in hamsters results in severe clinical disease, including high levels of virus replication in tissues, extensive pneumonia, weight loss and mortality in a subset of animals. A single immunization with an adenovirus serotype 26 vector-based vaccine expressing a stabilized SARS-CoV-2 spike protein elicited binding and neutralizing antibody responses and protected against SARS-CoV-2-induced weight loss, pneumonia and mortality. These data demonstrate vaccine protection against SARS-CoV-2 clinical disease. This model should prove useful for preclinical studies of SARS-CoV-2 vaccines, therapeutics and pathogenesis.
   A single immunization with an adenovirus vector-based vaccine expressing a stabilized SARS-CoV-2 spike protein induces protection against SARS-CoV-2-induced weight loss, pneumonia and mortality in hamsters.
C1 [Tostanoski, Lisa H.; Martinot, Amanda J.; McMahan, Katherine; Mercado, Noe B.; Yu, Jingyou; Piedra-Mora, Cesar; Bondzie, Esther A.; Dagotto, Gabriel; Gebre, Makda S.; Jacob-Dolan, Catherine; Lin, Zijin; Mahrokhian, Shant H.; Nampanya, Felix; Nityanandam, Ramya; Barouch, Dan H.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02115 USA.
   [Wegmann, Frank; Custers, Jerome; Schuitemaker, Hanneke; Zahn, Roland] Janssen Vaccines & Prevent BV, Leiden, Netherlands.
   [Martinot, Amanda J.; Piedra-Mora, Cesar; Wrijil, Linda M.; Ducat, Sarah] Tufts Univ, Cummings Sch Vet Med, 200 Westboro Rd, North Grafton, MA 01536 USA.
   [Loos, Carolin; Atyeo, Caroline; Fischinger, Stephanie; Burke, John S.; Feldman, Jared; Hauser, Blake M.; Caradonna, Timothy M.; Schmidt, Aaron G.; Alter, Galit; Barouch, Dan H.] Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.
   [Loos, Carolin; Lauffenburger, Douglas A.] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Chan, Chi N.; Bondoc, Stephen; Starke, Carly E.; Nekorchuk, Michael; Busman-Sahay, Kathleen; Estes, Jacob D.] Oregon Hlth & Sci Univ, Beaverton, OR USA.
   [Atyeo, Caroline; Fischinger, Stephanie; Feldman, Jared; Hauser, Blake M.; Caradonna, Timothy M.; Dagotto, Gabriel; Gebre, Makda S.; Jacob-Dolan, Catherine; Schmidt, Aaron G.; Barouch, Dan H.] Harvard Med Sch, Boston, MA 02115 USA.
   [Pessaint, Laurent; Porto, Maciel; Ali, Vaneesha; Benetiene, Dalia; Tevi, Komlan; Andersen, Hanne; Lewis, Mark G.] Bioqual, Rockville, MD USA.
   [Schmidt, Aaron G.; Alter, Galit; Barouch, Dan H.] Massachusetts Consortium Pathogen Readiness, Boston, MA 02115 USA.
RP Barouch, DH (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02115 USA.; Barouch, DH (corresponding author), Ragon Inst MGH MIT & Harvard, Cambridge, MA 02139 USA.; Barouch, DH (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.; Barouch, DH (corresponding author), Massachusetts Consortium Pathogen Readiness, Boston, MA 02115 USA.
EM dbarouch@bidmc.harvard.edu
RI Mercado, Noe/ABE-8247-2020
OI Mercado, Noe/0000-0001-7769-7326; Tostanoski, Lisa/0000-0001-9255-5684;
   Piedra-Mora, Cesar/0000-0003-1146-7717; Starke, Carly
   Elizabeth/0000-0002-9548-9368; Mahrokhian, Shant/0000-0003-4094-8739;
   Jacob-Dolan, Catherine/0000-0001-6641-0342; Ducat,
   Sarah/0000-0002-5285-7642; Martinot, Amanda/0000-0001-6237-6191;
   Wegmann, Frank/0000-0002-9821-1492; Hauser, Blake/0000-0002-0100-1684
FU Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR
   [INV-006131]; Janssen Vaccines Prevention BV; Ragon Institute of MGH,
   MIT and Harvard; Mark and Lisa Schwartz Foundation; Massachusetts
   Consortium on Pathogen Readiness; National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [OD024917, AI129797, AI124377, AI128751, AI126603,
   AI007387, AI146779, AI135098, OD011092, OD025002]; Department of Health
   and Human Services Biomedical Advanced Research and Development
   Authority [HHS0100201700018C]; Emergent Ventures, Mercatus Center at
   George Mason University
FX We thank J. van Hoof, M. Mammon, P. Stoffels, D. van Manen, T. Kwaks, K.
   Bauer, N. Callaham, L. Mistretta, A. Thomas, A. Chandrashekar, L. Peter,
   L. Maxfield, M. Lifton, E. Borducchi, M. Silva, A. Richardson and C.
   Caron for generous advice, assistance and reagents. We acknowledge
   support from the Bill & Melinda Gates Foundation (INV-006131), Janssen
   Vaccines & Prevention BV, the Ragon Institute of MGH, MIT and Harvard,
   the Mark and Lisa Schwartz Foundation, the Massachusetts Consortium on
   Pathogen Readiness and the National Institutes of Health (OD024917,
   AI129797, AI124377, AI128751, AI126603 to D.H.B.; AI007387 to L.H.T.;
   AI146779 to A.G.S.; AI135098 to A.J.M.; and OD011092, OD025002 to
   J.D.E.). This project was funded, in part, by the Department of Health
   and Human Services Biomedical Advanced Research and Development
   Authority under contract HHS0100201700018C. We also acknowledge a Fast
   Grant, Emergent Ventures, Mercatus Center at George Mason University to
   A.J.M.
CR Abbink P, 2007, J VIROL, V81, P4654, DOI 10.1128/JVI.02696-06
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Brown EP, 2012, J IMMUNOL METHODS, V386, P117, DOI 10.1016/j.jim.2012.09.007
   Chan Jasper Fuk-Woo, 2020, Clin Infect Dis, V71, P2428, DOI 10.1093/cid/ciaa325
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chung AW, 2015, CELL, V163, P988, DOI 10.1016/j.cell.2015.10.027
   Fischinger S, 2019, J IMMUNOL METHODS, V473, DOI 10.1016/j.jim.2019.07.002
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai M, 2020, P NATL ACAD SCI USA, V117, P16587, DOI [10.1073/pnas.2009799117/-/DCSupplemental., 10.1073/pnas.2009799117]
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Mercado NB, 2020, NATURE, DOI 10.1038/s41586-020-2607-z
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5
   Sun SH, 2020, CELL HOST MICROBE, V28, P124, DOI 10.1016/j.chom.2020.05.020
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yang ZY, 2004, NATURE, V428, P561, DOI 10.1038/nature02463
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 26
TC 1
Z9 1
U1 8
U2 8
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD NOV
PY 2020
VL 26
IS 11
BP 1694
EP +
DI 10.1038/s41591-020-1070-6
EA SEP 2020
PG 20
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA OT0SR
UT WOS:000566411600001
PM 32884153
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU McGregor, R
   Whitcombe, AL
   Sheen, CR
   Dickson, JM
   Day, CL
   Carlton, LH
   Sharma, P
   Lott, JS
   Koch, B
   Bennett, J
   Baker, MG
   Ritchie, SR
   Fox-Lewis, S
   Morpeth, SC
   Taylor, SL
   Roberts, SA
   Webb, RH
   Moreland, NJ
AF McGregor, Reuben
   Whitcombe, Alana L.
   Sheen, Campbell R.
   Dickson, James M.
   Day, Catherine L.
   Carlton, Lauren H.
   Sharma, Prachi
   Lott, J. Shaun
   Koch, Barbara
   Bennett, Julie
   Baker, Michael G.
   Ritchie, Stephen R.
   Fox-Lewis, Shivani
   Morpeth, Susan C.
   Taylor, Susan L.
   Roberts, Sally A.
   Webb, Rachel H.
   Moreland, Nicole J.
TI Collaborative networks enable the rapid establishment of serological
   assays for SARS-CoV-2 during nationwide lockdown in New Zealand
SO PEERJ
LA English
DT Article
DE COVID-19; Serology; SARS-CoV-2; Neutralising antibodies; Spike protein
AB Background: Serological assays that detect antibodies to SARS-CoV-2 are critical for determining past infection and investigating immune responses in the COVID-19 pandemic. We established ELISA-based immunoassays using locally produced antigens when New Zealand went into a nationwide lockdown and the supply chain of diagnostic reagents was a widely held domestic concern. The relationship between serum antibody binding measured by ELISA and neutralising capacity was investigated using a surrogate viral neutralisation test (sVNT).
   Methods: A pre-pandemic sera panel (n = 113), including respiratory infections with symptom overlap with COVID-19, was used to establish assay specificity. Sera from PCR-confirmed SARS-CoV-2 patients (n = 21), and PCR-negative patients with respiratory symptoms suggestive of COVID-19 (n = 82) that presented to the two largest hospitals in Auckland during the lockdown period were included. A two-step IgG ELISA based on the receptor binding domain (RBD) and spike protein was adapted to determine seropositivity, and neutralising antibodies that block the RBD/ hACE-2 interaction were quantified by sVNT.
   Results: The calculated cut-off (>0.2) in the two-step ELISA maximised specificity by classifying all pre-pandemic samples as negative. Sera from all PCR-confirmed COVID-19 patients were classified as seropositive by ELISA >= 7 days after symptom onset. There was 100% concordance between the two-step ELISA and the sVNT with all 7+ day sera from PCR-confirmed COVID-19 patients also classified as positive with respect to neutralising antibodies. Of the symptomatic PCR-negative cohort, one individual with notable travel history was classified as positive by two-step ELISA and sVNT, demonstrating the value of serology in detecting prior infection.
   Conclusions: These serological assays were established and assessed at a time when human activity was severely restricted in New Zealand. This was achieved by generous sharing of reagents and technical expertise by the international scientific community, and highly collaborative efforts of scientists and clinicians across the country. The assays have immediate utility in supporting clinical diagnostics, understanding transmission in high-risk cohorts and underpinning longer-term 'exit strategies based on effective vaccines and therapeutics.
C1 [McGregor, Reuben; Whitcombe, Alana L.; Carlton, Lauren H.; Sharma, Prachi; Ritchie, Stephen R.; Webb, Rachel H.; Moreland, Nicole J.] Univ Auckland, Fac Med & Hlth Sci, Auckland, New Zealand.
   [McGregor, Reuben; Whitcombe, Alana L.; Lott, J. Shaun; Roberts, Sally A.; Moreland, Nicole J.] Univ Auckland, Maurice Wilkins Ctr, Auckland, New Zealand.
   [Sheen, Campbell R.; Koch, Barbara] Callaghan Innovat, Prot Sci & Engn, Christchurch, New Zealand.
   [Dickson, James M.; Lott, J. Shaun] Univ Auckland, Sch Biol Sci, Auckland, New Zealand.
   [Day, Catherine L.] Univ Otago, Dept Biochem, Dunedin, New Zealand.
   [Bennett, Julie; Baker, Michael G.] Univ Otago, Dept Publ Hlth, Wellington, New Zealand.
   [Ritchie, Stephen R.] Auckland City Hosp, Infect Dis Dept, Auckland, New Zealand.
   [Fox-Lewis, Shivani; Roberts, Sally A.] Auckland City Hosp, Dept Microbiol, LabPLUS, Auckland, New Zealand.
   [Morpeth, Susan C.; Taylor, Susan L.] Middlemore Hosp, Auckland, New Zealand.
   [Webb, Rachel H.] Starship Childrens Hosp, Auckland, New Zealand.
RP Moreland, NJ (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Auckland, New Zealand.; Moreland, NJ (corresponding author), Univ Auckland, Maurice Wilkins Ctr, Auckland, New Zealand.
EM n.moreland@auckland.ac.nz
OI Lott, Shaun/0000-0003-3660-452X; Moreland, Nicole/0000-0001-6548-637X
FU School of Medicine Foundation (University of Auckland); COVID-19
   Innovation Acceleration Fund (Ministry of Business, Innovation and
   Employment); Callaghan Innovation Strategic Investment Fund
FX This work was funded by the School of Medicine Foundation (University of
   Auckland), the COVID-19 Innovation Acceleration Fund (Ministry of
   Business, Innovation and Employment) and Callaghan Innovation Strategic
   Investment Fund. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abbasi J, 2020, JAMA-J AM MED ASSOC, V323, P1881, DOI 10.1001/jama.2020.6170
   Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Anderson DE, 2020, EMERG MICROBES INFEC, V9, P900, DOI 10.1080/22221751.2020.1761267
   Baker MG, 2020, MED J AUSTRALIA, V213, P198, DOI 10.5694/mja2.50735
   Beavis KG, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104468
   Bennett J, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4126-9
   Bryan A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00941-20
   Bryant JE, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc6347
   Chen XY, 2020, CELL MOL IMMUNOL, V17, P647, DOI 10.1038/s41423-020-0426-7
   Diamond MS, 2020, CELL HOST MICROBE, V27, P699, DOI 10.1016/j.chom.2020.04.021
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Garcia-Basteiro AL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17318-x
   Huang Angkana T, 2020, medRxiv, DOI 10.1101/2020.04.14.20065771
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Juno JA, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0995-0
   Krammer F, 2020, SCIENCE, V368, P1060, DOI 10.1126/science.abc1227
   Long Q-X, 2020, NAT MED, V62, P477, DOI [10.1038/d41586-020-00094-5, DOI 10.1038/D41586-020-00094-5]
   Meyer B, 2020, CLIN MICROBIOL INFEC, V26, P1386, DOI 10.1016/j.cmi.2020.06.024
   Petherick A, 2020, LANCET, V395, P1101, DOI 10.1016/S0140-6736(20)30788-1
   Sethuraman N, 2020, JAMA-J AM MED ASSOC, V323, P2249, DOI 10.1001/jama.2020.8259
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Yong SEF, 2020, LANCET INFECT DIS, V20, P809, DOI 10.1016/S1473-3099(20)30273-5
NR 24
TC 1
Z9 1
U1 3
U2 3
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD SEP 3
PY 2020
VL 8
AR e9863
DI 10.7717/peerj.9863
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NI6IJ
UT WOS:000565454500009
PM 32953275
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Naeem, S
   Gohh, R
   Bayliss, G
   Cosgrove, C
   Farmakiotis, D
   Merhi, B
   Morrissey, P
   Osband, A
   Bailey, JA
   Sweeney, J
   Rogers, R
AF Naeem, Syed
   Gohh, Reginald
   Bayliss, George
   Cosgrove, Christopher
   Farmakiotis, Dimitrios
   Merhi, Basma
   Morrissey, Paul
   Osband, Adena
   Bailey, Jeffrey A.
   Sweeney, Joseph
   Rogers, Ralph
TI Successful recovery from COVID-19 in three kidney transplant recipients
   who received convalescent plasma therapy
SO TRANSPLANT INFECTIOUS DISEASE
LA English
DT Article; Early Access
DE convalescent plasma; COVID-19; immunosuppression; kidney transplant
   recipient; viral pneumonia
ID ANTIBODIES
AB Novel coronavirus disease 2019 (COVID-19) is a highly infectious, rapidly spreading viral disease that typically presents with greater severity in patients with underlying medical conditions or those who are immunosuppressed. We present a novel case series of three kidney transplant recipients with COVID-19 who recovered after receiving COVID-19 convalescent plasma (CCP) therapy. Physicians should be aware of this potentially useful treatment option. Larger clinical registries and randomized clinical trials should be conducted to further explore the clinical and allograft outcomes associated with CCP use in this population.
C1 [Naeem, Syed; Gohh, Reginald; Bayliss, George; Cosgrove, Christopher; Merhi, Basma; Morrissey, Paul; Osband, Adena] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Div Renal Transplantat, Providence, RI 02903 USA.
   [Farmakiotis, Dimitrios; Rogers, Ralph] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Div Infect Dis, Providence, RI 02903 USA.
   [Bailey, Jeffrey A.; Sweeney, Joseph] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Dept Pathol & Transfus Med, Providence, RI 02903 USA.
RP Naeem, S (corresponding author), Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Div Renal Transplantat, Providence, RI 02903 USA.
EM Naeem.syedsaad@gmail.com
OI Rogers, Ralph/0000-0003-0268-0188; Farmakiotis,
   Dimitrios/0000-0001-8489-108X
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Arabi YM, 2016, EMERG INFECT DIS, V22, P1554, DOI 10.3201/eid2209.151164
   Cao WCC, 2007, NEW ENGL J MED, V357, P1162, DOI 10.1056/NEJMc070348
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Crowe JE, 2001, J IMMUNOL, V167, P3910, DOI 10.4049/jimmunol.167.7.3910
   Cucinotta D, 2020, ACTA BIOMED, V91, P157, DOI [10.23750/abm.v91i1.9397, DOI 10.23750/ABM.V91I1.9397]
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Garraud O, 2016, TRANSFUS CLIN BIOL, V23, P39, DOI 10.1016/j.tracli.2015.12.003
   Hassan S, 2019, AM J TRANSPLANT, V19, P1720, DOI 10.1111/ajt.15233
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P365, DOI 10.1016/j.jmii.2020.02.001
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lunemann JD, 2015, NAT REV NEUROL, V11, P80, DOI 10.1038/nrneurol.2014.253
   Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633
   Nixon CP, 2015, TRANSFUSION, V55, P1825, DOI 10.1111/trf.13142
   Pandey S, 2012, TRANSFUSION, V52, p65S, DOI 10.1111/j.1537-2995.2012.03663.x
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Vlaar APJ, 2019, TRANSFUSION, V59, P2465, DOI 10.1111/trf.15311
   Wilson N, 2020, EMERG INFECT DIS, V26, P1339, DOI 10.3201/eid2606.200320
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
NR 22
TC 1
Z9 1
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1398-2273
EI 1399-3062
J9 TRANSPL INFECT DIS
JI Transpl. Infect. Dis.
AR e13451
DI 10.1111/tid.13451
EA SEP 2020
PG 6
WC Immunology; Infectious Diseases; Transplantation
SC Immunology; Infectious Diseases; Transplantation
GA NI4WK
UT WOS:000565353800001
PM 32815238
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Kochhar, S
   Excler, JL
   Kim, D
   Robertson, JS
   Fast, PE
   Condit, RC
   Drew, S
   Wood, D
   Gurwith, M
   Klug, B
   Whelan, M
   Khuri-Bulos, N
   Moore, TM
   Smith, ER
   Chen, RT
AF Kochhar, Sonali
   Excler, Jean-Louis
   Kim, Denny
   Robertson, James S.
   Fast, Patricia E.
   Condit, Richard C.
   Drew, Stephen
   Wood, David
   Gurwith, Marc
   Klug, Bettina
   Whelan, Mike
   Khuri-Bulos, Najwa
   Moore, Tamala Mallett
   Smith, Emily R.
   Chen, Robert T.
CA Brighton Collaboration Viral Vecto
TI The Brighton Collaboration standardized template for collection of key
   information for benefit-risk assessment of inactivated viral vaccines
SO VACCINE
LA English
DT Article
DE Brighton Collaboration; CEPI; COVID-19; Vaccine; Benefit-risk; Safety;
   Inactivated; Virus; Template
ID VIRUS-VACCINES
AB Inactivated viral vaccines have long been used in humans for diseases of global health threat and are now among the vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of inactivated viral vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of the vaccine platform. The standardized and structured assessment provided by the template would also help to contribute to improved communica-tion and support public acceptance of licensed inactivated viral vaccines. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Kochhar, Sonali] Global Healthcare Consulting, New Delhi, India.
   [Kochhar, Sonali] Univ Washington, Seattle, WA 98195 USA.
   [Excler, Jean-Louis] Int Vaccine Inst, Seoul, South Korea.
   [Kim, Denny] Janssen Pharmaceut, Titusville, NJ USA.
   [Fast, Patricia E.] Int AIDS Vaccine Initiat, New York, NY USA.
   [Fast, Patricia E.] Stanford Sch Med, Palo Alto, CA USA.
   [Condit, Richard C.] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL USA.
   [Gurwith, Marc; Smith, Emily R.; Chen, Robert T.] Brighton Collaborat, Decatur, GA 30030 USA.
   [Klug, Bettina] Paul Ehrlich Inst, Fed Inst Vaccines & Biomed, Langen, Germany.
   [Whelan, Mike] CEPI, London, England.
   [Khuri-Bulos, Najwa] Univ Jordan, Amman, Jordan.
   [Moore, Tamala Mallett] Sanofi Pasteur, Swiftwater, PA USA.
RP Chen, RT (corresponding author), Brighton Collaborat, Decatur, GA 30030 USA.
FU Coalition for Epidemic Preparedness Innovations (CEPI); Brighton
   Collaboration, a program of the Task Force for Global Health, Decatur,
   GA
FX We acknowledge the financial support provided by the Coalition for
   Epidemic Preparedness Innovations (CEPI) for our work under a service
   order entitled Safety Platform for Emergency vACcines (SPEAC) Project
   with the Brighton Collaboration, a program of the Task Force for Global
   Health, Decatur, GA.
CR [Anonymous], 2020, DRAFT LANDSC COVID 1
   Barrett PN, 2017, EXPERT REV VACCINES, V16, P883, DOI 10.1080/14760584.2017.1357471
   Bonhoeffer J, 2002, VACCINE, V21, P298, DOI 10.1016/S0264-410X(02)00449-8
   Bonhoeffer J, 2009, VACCINE, V27, P2282, DOI 10.1016/j.vaccine.2008.11.036
   Chen RT, 2015, VACCINE, V33, P73, DOI 10.1016/j.vaccine.2014.09.035
   Chen RT, VACCINE
   Clarke DK, 2016, VACCINE, V34, P6597, DOI 10.1016/j.vaccine.2016.06.071
   Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001
   Delrue I, 2012, EXPERT REV VACCINES, V11, P695, DOI [10.1586/ERV.12.38, 10.1586/erv.12.38]
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Monath TP, 2015, VACCINE, V33, P62, DOI 10.1016/j.vaccine.2014.10.004
   Monath TP, 2019, VACCINE, V1, DOI [10.1016/j.jvacx.2019.100009100009, DOI 10.1016/J.JVACX.2019.100009100009]
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   World Health Organization, 2020, WKLY EPIDEM REC, V95, P28
NR 14
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD SEP 3
PY 2020
VL 38
IS 39
BP 6184
EP 6189
DI 10.1016/j.vaccine.2020.07.028
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA NG8WA
UT WOS:000564260700014
PM 32747214
OA Other Gold
DA 2021-01-01
ER

PT J
AU Ledford, H
AF Ledford, Heidi
TI WHAT THE IMMUNE RESPONSE TO THE CORONAVIRUS SAYS ABOUT THE PROSPECTS FOR
   A VACCINE
SO NATURE
LA English
DT Article
DE Medical research; SARS-CoV-2; Immunology
AB How strong is the immune response to COVID-19 infection? Viral immunologists say that results so far have been predictable - here's why that's good news.
   Viral immunologists say that results so far have been predictable - here's why that's good news.
CR CALLOW KA, 1990, EPIDEMIOL INFECT, V105, P435, DOI 10.1017/S0950268800048019
   Kumar Rajesh, 2018, Ther Adv Vaccines Immunother, V6, P61, DOI 10.1177/2515135518800689
   Le Bert N, 2020, NATURE, DOI 10.1038/s41586-020-2550-z
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871
   Rodda L. B., 2020, PREPRINT MEDRXIV, DOI [10.1101/2020.08.11.20171843, DOI 10.1101/2020.08.11.20171843]
   Seow J., 2020, PREPRINT MEDRXIV, DOI [10.1101/2020.07.09.20148429, DOI 10.1101/2020.07.09.20148429]
   Sette A, 2020, NAT REV IMMUNOL, V20, P457, DOI 10.1038/s41577-020-0389-z
   Wu F., 2020, PREPRINT MEDRXIV, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
NR 9
TC 0
Z9 0
U1 7
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD SEP 3
PY 2020
VL 585
IS 7823
BP 20
EP 21
DI 10.1038/d41586-020-02400-7
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NF6TB
UT WOS:000563427200005
PM 32811981
OA Bronze
DA 2021-01-01
ER

PT J
AU Grewal, S
   Jankelson, L
   van den Broek, MPH
   Cour, M
   Bachmann, G
   Kostis, JB
   Misra, K
AF Grewal, Sarah
   Jankelson, Lior
   van den Broek, Marcel P. H.
   Cour, Martin
   Bachmann, Gloria
   Kostis, John B.
   Misra, Kamana
TI QTc Prolongation Risk Evaluation in Female COVID-19 Patients Undergoing
   Chloroquine and Hydroxychloroquine With/Without Azithromycin Treatment
SO FRONTIERS IN CARDIOVASCULAR MEDICINE
LA English
DT Article
DE COVID; QTc changes; hydroxychloroquine; chloroquin; azithromycin (AZM);
   QTc; hydroxychloroquine (HCQ); women
ID TORSADE-DE-POINTES; INTERVAL PROLONGATION; GENDER; SEX; WOMEN
AB Women have higher risk for developing TdP in response to ventricular repolarization prolonging drugs. Hundreds of trials are administering chloroquine and hydroxychloroquine with/without azithromycin to COVID-19 patients. While an overall prolonged QTc has been reported in COVID-19 patients undergoing these treatments, the question on even higher QTc elevation risk in thousands of female COVID-19 patients undergoing these treatments remains unanswered. We therefore explore data reported and shared with us to evaluate safety and efficacy of antimalaria pharmacotherapies in female COVID-19 patients. Although we observed longer mean QTc intervals in female patients in 2 of the 3 cohorts reviewed, the sex disproportionality in COVID-19 hospitalizations precludes a clear sex mediated QTc interval elevation risk association in the female COVID-19 patients undergoing acute treatment regimens. Adoption of study designs that include observation of sex mediated differential triggering of cardiac electrical activity by these drugs is warranted.
C1 [Grewal, Sarah; Misra, Kamana] ContraRx, Pharmacovigilance, Edison, NJ 08817 USA.
   [Jankelson, Lior] NYU, Sch Med, NYU Langone Hlth, New York, NY USA.
   [van den Broek, Marcel P. H.] St Antonius Hosp, Dept Clin Pharm, Utrecht, Netherlands.
   [Cour, Martin] Hop Edouard Herriot, Hosp Civils Lyon, Serv Med Intens Reanimat, Lyon, France.
   [Bachmann, Gloria] Rutgers Robert Wood Johnson Med Sch, Womens Hlth Inst, New Brunswick, NJ USA.
   [Kostis, John B.] Rutgers Robert Wood Johnson Med Sch, Cardiovasc Inst, New Brunswick, NJ USA.
RP Misra, K (corresponding author), ContraRx, Pharmacovigilance, Edison, NJ 08817 USA.
EM Kamana@contrarx.com
CR Bednar MM, 2002, AM J CARDIOL, V89, P1316, DOI 10.1016/S0002-9149(02)02337-8
   Bessiere F, 2020, JAMA CARDIOL, V5, P1067, DOI 10.1001/jamacardio.2020.1787
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Chorin E, 2020, HEART RHYTHM, V17, P1425, DOI 10.1016/j.hrthm.2020.05.014
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Darpo B, 2014, BRIT J CLIN PHARMACO, V77, P522, DOI 10.1111/bcp.12201
   Drici MD, 2001, DRUG SAFETY, V24, P575, DOI 10.2165/00002018-200124080-00002
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Hancox JC, 2013, THER ADV INFECT DIS, V1, P155, DOI 10.1177/2049936113501816
   Hreiche R, 2008, GENDER MED, V5, P124, DOI 10.1016/j.genm.2008.05.005
   Kannankeril P, 2010, PHARMACOL REV, V62, P760, DOI 10.1124/pr.110.003723
   Lehmann MH, 1996, CIRCULATION, V94, P2535, DOI 10.1161/01.CIR.94.10.2535
   MAKKAR RR, 1993, JAMA-J AM MED ASSOC, V270, P2590, DOI 10.1001/jama.270.21.2590
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   MERRI M, 1989, CIRCULATION, V80, P1301, DOI 10.1161/01.CIR.80.5.1301
   Misra K, 2020, CV NETWORK, V19, P12
   Nachimuthu S, 2012, THER ADV DRUG SAF, V3, P241, DOI 10.1177/2042098612454283
   Nakagawa M, 2006, PACE, V29, P607, DOI 10.1111/j.1540-8159.2006.00407.x
   Negoescu Thornback A, 2013, LONG QT HYDROXYCHLOR
   Owens RC, 2001, PHARMACOTHERAPY, V21, P301, DOI 10.1592/phco.21.3.301.34206
   Pham TV, 2002, CARDIOVASC RES, V53, P740, DOI 10.1016/S0008-6363(01)00429-1
   Projean D, 2003, DRUG METAB DISPOS, V31, P748, DOI 10.1124/dmd.31.6.748
   RAUTAHARJU PM, 1992, CAN J CARDIOL, V8, P690
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Saito T, 2009, CIRC RES, V105, P343, DOI 10.1161/CIRCRESAHA.108.190041
   Schwartz PJ, 2001, CIRCULATION, V103, P89
   Sedlak T, 2013, ANN NONINVAS ELECTRO, V18, P389, DOI 10.1111/anec.12050
   Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178
   van den Broek MPH, 2020, NETH HEART J, V28, P406, DOI 10.1007/s12471-020-01429-7
   Varshneya Meera, 2020, medRxiv, DOI 10.1101/2020.05.21.20109397
   Yang ZJ, 2017, CIRC-ARRHYTHMIA ELEC, V10, DOI 10.1161/CIRCEP.115.003560
NR 32
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2297-055X
J9 FRONT CARDIOVASC MED
JI Front. Cardiovasc. Med.
PD SEP 2
PY 2020
VL 7
AR 152
DI 10.3389/fcvm.2020.00152
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NS7ZM
UT WOS:000572476100001
PM 33102533
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Johnson, AS
   Fatemi, R
   Winlow, W
AF Johnson, Andrew S.
   Fatemi, Rouholah
   Winlow, William
TI SARS-CoV-2 Bound Human Serum Albumin and Systemic Septic Shock
SO FRONTIERS IN CARDIOVASCULAR MEDICINE
LA English
DT Article
DE human serum albumin; septic shock; coronavirus; endothelial glycocalyx
   layer; acute respiratory distress syndrome; albumin therapy
ID ENDOTHELIAL GLYCOCALYX; CLINICAL CHARACTERISTICS; BINDING; SEPSIS;
   HYPOALBUMINEMIA; HOMEOSTASIS; MANAGEMENT; COVID-19; DISEASE; MODES
AB The emergence of the COVID-19 virus and the subsequent pandemic have driven a great deal of research activity. The effects of COVID-19 are caused by the severe respiratory syndrome coronavirus 2 (SARS-CoV-2) and it is the underlying actions of SARs-CoV-2 virions on the endothelial glycocalyx that we consider here. One of the key factors in COVID-19 infection is its almost unique age-related profile, with a doubling in mortality every 10 years after the age of 50. The endothelial glycocalyx layer is essential in maintaining normal fluid homeostasis, but is fragile and prone to pathophysiological damage. It is physiologically significant in capillary microcirculation and in fluid distribution to the tissues. Human serum albumin (HSA), the most abundant protein in plasma, is created in the liver which also maintains its concentration, but this reduces by 10-15% after 50 years of age. HSA transports hormones, free fatty acids and maintains oncotic pressure, but SARS-CoV-2 virions bind competitively to HSA diminishing its normal transport function. Furthermore, hypoalbuminemia is frequently observed in patients with such conditions as diabetes, hypertension, and chronic heart failure, i.e., those most vulnerable to SARS-CoV-2 infection. Hypoalbuminemia, coagulopathy, and vascular disease have been linked in COVID-19 and have been shown to predict outcome independent of age and morbidity. Hypoalbuminemia is also known factor in sepsis and Acute respiratory distress syndrome (ARDS) occurs when fluids build-up in the alveoli and it is associated with sepsis, whose mechanism is systemic, being associated with the fluid and logistic mechanisms of the circulation. Glycocalyx damage is associated with changes plasma protein concentration, particularly HSA and blockage of albumin transport can produce the systemic symptoms seen in SARS-CoV-2 infection and sepsis. We therefore conclude that albumin binding to SARS-CoV-2 virions may inhibit the formation of the endothelial glycocalyx by inhibition of albumin transport binding sites. We postulate that albumin therapy to replace bound albumin might alleviate some of the symptoms leading to sepsis and that clinical trials to test this postulation should be initiated as a matter of urgency.
C1 [Johnson, Andrew S.; Winlow, William] Univ Naples Federico II, Dipartimento Biol, Naples, Italy.
   [Fatemi, Rouholah] Ahvaz Jundishapur Univ Med Sci, Sch Med, Physiol Res Ctr PRC, Ahwaz, Iran.
   [Winlow, William] Univ Liverpool, Inst Ageing & Chron Dis, Apex Bldg, Liverpool, Merseyside, England.
RP Winlow, W (corresponding author), Univ Naples Federico II, Dipartimento Biol, Naples, Italy.; Winlow, W (corresponding author), Univ Liverpool, Inst Ageing & Chron Dis, Apex Bldg, Liverpool, Merseyside, England.
EM bill.winlow@gmail.com
OI Johnson, Andrew/0000-0002-5228-6587
CR Adachi T, 2020, EMERG INFECT DIS, V26, P2157, DOI 10.3201/eid2609.201353
   Allen Sara J, 2014, J Extra Corpor Technol, V46, P28
   Alphonsus CS, 2014, ANAESTHESIA, V69, P777, DOI 10.1111/anae.12661
   Andersen JT, 2011, J BIOL CHEM, V286, P5234, DOI 10.1074/jbc.M110.164848
   Arner P, 2015, OBESITY FACTS, V8, P147, DOI 10.1159/000381224
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Baker ME, 1998, FEBS LETT, V439, P9, DOI 10.1016/S0014-5793(98)01346-5
   Barelli S, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00091
   Barochia AV, 2010, CRIT CARE MED, V38, P668, DOI 10.1097/CCM.0b013e3181cb0ddf
   Becker BF, 2010, CARDIOVASC RES, V87, P300, DOI 10.1093/cvr/cvq137
   Begum T, 2019, J CURR ADV MED RES, V6, P83, DOI [10.3329/jcamr.v6i2.42976, DOI 10.3329/JCAMR.V6I2.42976]
   Berg Daniela, 2018, F1000Res, V7, DOI 10.12688/f1000research.15758.1
   Bhattacharyya C, 2020, GLOBAL SPREAD SARS C, DOI [10.1101/2020.05.04.075911, DOI 10.1101/2020.05.04.075911]
   Burrell LM, 2004, TRENDS ENDOCRIN MET, V15, P166, DOI 10.1016/j.tem.2004.03.001
   Carvalho JR, 2018, ANN HEPATOL, V17, P547, DOI 10.5604/01.3001.0012.0916
   Chang R, 2016, SHOCK, V46, P17, DOI 10.1097/SHK.0000000000000577
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chuang VTG, 2002, PHARMACEUT RES, V19, P569
   Cohen J, 2015, LANCET INFECT DIS, V15, P581, DOI 10.1016/S1473-3099(15)70112-X
   Cortese-Krott MM, 2014, REDOX BIOL, V2, P251, DOI 10.1016/j.redox.2013.12.027
   Czub MP, 2019, CHEM SCI, V10, P1607, DOI 10.1039/c8sc04397c
   DOWEIKO JP, 1994, JPEN-PARENTER ENTER, V18, P516, DOI 10.1177/0148607194018006516
   Durand Pierre M., 2019, Biology Theory, V14, P30, DOI 10.1007/s13752-018-0311-0
   Elsadek B, 2012, J CONTROL RELEASE, V157, P4, DOI 10.1016/j.jconrel.2011.09.069
   Evoli S, 2016, PHYS CHEM CHEM PHYS, V18, P32358, DOI 10.1039/c6cp05680f
   Fatemi R, 2020, EJBPS, V7, P126
   Fliesler N, 2020, COVID 19 SERIOUS INF
   Fuchs Y, 2015, NAT REV MOL CELL BIO, V16, P329, DOI 10.1038/nrm3999
   Furman D, 2015, VACCINE, V33, P5271, DOI 10.1016/j.vaccine.2015.06.117
   Gattinoni L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02880-z
   Gomi I, 2007, J NUTR SCI VITAMINOL, V53, P37, DOI 10.3177/jnsv.53.37
   Gonzalez D, 2013, CLIN MICROBIOL REV, V26, P274, DOI 10.1128/CMR.00092-12
   Guo C, 2019, BIOPHYS J, V116, P248, DOI 10.1016/j.bpj.2018.11.3133
   Hastie CE, 2020, DIABETES METAB SYND, V14, P561, DOI 10.1016/j.dsx.2020.04.050
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang Y, 2020, CLIN CHARACTERISTICS, DOI [10.1101/2020.02.27.20029009, DOI 10.1101/2020.02.27.20029009]
   Ilie PC, 2020, AGING CLIN EXP RES, V32, P1195, DOI 10.1007/s40520-020-01570-8
   Jacobi J, 2002, AM J HEALTH-SYST PH, V59, pS3, DOI 10.1093/ajhp/59.suppl_1.S3
   Kelly JM, 2019, J NUCL MED, V60, P656, DOI 10.2967/jnumed.118.221150
   Kundra P, 2019, INDIAN J ANAESTH, V63, P6, DOI 10.4103/ija.IJA_751_18
   Laird E, 2020, Ir Med J, V113, P81
   LAMOLA AA, 1981, BIOCHEM J, V196, P693, DOI 10.1042/bj1960693
   Levitt DG, 2016, INT J GEN MED, V9, P229, DOI 10.2147/IJGM.S102819
   Li HY, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/aac.02168-16, 10.1128/AAC.02168-16]
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Lippi G, 2020, HEMATOL TRANSF CELL, V42, P116, DOI 10.1016/j.htct.2020.03.001
   Lippi G, 2020, THROMB HAEMOSTASIS, V120, P876, DOI 10.1055/s-0040-1709650
   Litus EA, 2018, CELL BIOCHEM BIOPHYS, V76, P39, DOI 10.1007/s12013-017-0785-6
   Liu W., 2020, COVID 19 ATTACKS 1 B
   Loflin R, 2017, EMERG MED CLIN N AM, V35, P59, DOI 10.1016/j.emc.2016.08.001
   Martinez ML, 2020, J THORAC DIS, V12, P1007, DOI 10.21037/jtd.2020.01.47
   Mittendorfer B, 2005, J NUTR, V135, P681
   Franco DM, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011811.pub2
   Moman R. N., 2020, STATPEARLS
   Neligan PJ, 2010, EVIDENCE BASED PRACT, P198, DOI [10.1016/b978-1-4160-5476-4.00030-4, DOI 10.1016/B978-1-4160-5476-4.00030-4]
   Niedzwiedz CL, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01640-8
   Port M, 2005, INVEST RADIOL, V40, P565, DOI 10.1097/01.rli.0000175388.98721.9b
   RASMUSSEN LF, 1976, J PEDIATR-US, V89, P475, DOI 10.1016/S0022-3476(76)80557-4
   Remy KE, 2020, LANCET RESP MED, V8, P946, DOI 10.1016/S2213-2600(20)30217-4
   Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Sanjuan R, 2016, CELL MOL LIFE SCI, V73, P4433, DOI 10.1007/s00018-016-2299-6
   Sedov I, 2020, INT J PHARMACEUT, V583, DOI 10.1016/j.ijpharm.2020.119362
   Seedher N, 2013, LUMINESCENCE, V28, P562, DOI 10.1002/bio.2494
   Sharma YP, 2020, BMJ-BRIT MED J, V368, pm810, DOI [10.1136/bmj.m810, DOI 10.1136/BMJ.M810]
   Sheu CC, 2010, CHEST, V138, P559, DOI 10.1378/chest.09-2933
   Siddall E, 2017, KIDNEY INT, V92, P37, DOI 10.1016/j.kint.2016.11.029
   Sun JK, 2015, PEERJ, V3, DOI 10.7717/peerj.1267
   Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4
   Tanaka R, 2014, MOL PHARMACEUT, V11, P1228, DOI 10.1021/mp400690v
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Violi F, 2020, CIRC RES, V127, P400, DOI 10.1161/CIRCRESAHA.120.317173
   Wu D, 2020, NATL SCI REV, V7, P1157, DOI 10.1093/nsr/nwaa086
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Yilmaz O, 2019, CLIN KIDNEY J, V12, P611, DOI 10.1093/ckj/sfz042
   Zhang N, 2005, CELL RES, V15, P749, DOI 10.1038/sj.cr.7290345
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 78
TC 0
Z9 0
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2297-055X
J9 FRONT CARDIOVASC MED
JI Front. Cardiovasc. Med.
PD SEP 2
PY 2020
VL 7
AR 153
DI 10.3389/fcvm.2020.00153
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NS7ZR
UT WOS:000572476600001
PM 33088822
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ma, LL
   Yin, X
   Li, BH
   Yang, JY
   Jin, YH
   Huang, D
   Deng, T
   Wang, YY
   Ren, XQ
   Ji, JG
   Zeng, XT
AF Ma, Lin-Lu
   Yin, Xuan
   Li, Bing-Hui
   Yang, Jia-Yu
   Jin, Ying-Hui
   Huang, Di
   Deng, Tong
   Wang, Yun-Yun
   Ren, Xue-Qun
   Ji, Jianguang
   Zeng, Xian-Tao
TI Coronavirus Disease 2019 Related Clinical Studies: A Cross-Sectional
   Analysis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE coronavirus disease 2019; SARS-CoV-2; clinical trial; registration;
   ClinicalTrials; gov
ID RANDOMIZED TRIALS
AB Objective The quality and rationality of many recently registered clinical studies related to coronavirus disease 2019 (COVID-19) needs to be assessed. Hence, this study aims to evaluate the current status of COVID-19 related registered clinical trial. Methods We did an electronic search of COVID-19 related clinical studies registered between December 1, 2019 and February 21, 2020 (updated to May 28, 2020) from theClinicalTrials.gov, and collected registration information, study details, recruitment status, characteristics of the subjects, and relevant information about the trial implementation process. Results A total of 1,706 studies were included 10.0% of which (n=171) were from France, 943 (55.3%) used an interventional design, and 600 (35.2%) used an observational design. Most of studies (73.6%) aimed to recruit fewer than 500 people. Interferon was the main prevention program, and antiviral drugs were the main treatment program. Hydroxychloroquine and chloroquine (230/943, 24.4%) were widely studied. Some registered clinical trials are incomplete in content, and 37.4% of the 1,706 studies may have had insufficient sample size. Conclusion The quality of COVID-19 related studies needs to be improved by strengthening the registration process and improving the quality of clinical study protocols so that these clinical studies can provide high-quality clinical evidence related to COVID-19.
C1 [Ma, Lin-Lu; Li, Bing-Hui; Yang, Jia-Yu; Jin, Ying-Hui; Huang, Di; Wang, Yun-Yun; Zeng, Xian-Tao] Wuhan Univ, Zhongnan Hosp, Ctr Evidence Based & Translat Med, Wuhan, Peoples R China.
   [Yin, Xuan] Hubei Univ Med, Taihe Hosp, Dept Rehabil, Shiyan, Peoples R China.
   [Li, Bing-Hui; Deng, Tong; Ren, Xue-Qun] Henan Univ, Inst Evidence Based Med & Knowledge Translat, Kaifeng, Peoples R China.
   [Yang, Jia-Yu] Wuhan Univ, Zhongnan Hosp, Wuhan, Peoples R China.
   [Ji, Jianguang] Lund Univ Reg Skane, Ctr Primary Hlth Care Res, Adm Off Hosp Director, Malmo, Sweden.
RP Zeng, XT (corresponding author), Wuhan Univ, Zhongnan Hosp, Ctr Evidence Based & Translat Med, Wuhan, Peoples R China.; Ren, XQ (corresponding author), Henan Univ, Inst Evidence Based Med & Knowledge Translat, Kaifeng, Peoples R China.; Ji, JG (corresponding author), Lund Univ Reg Skane, Ctr Primary Hlth Care Res, Adm Off Hosp Director, Malmo, Sweden.
EM renxuequn001@163.com; jianguang.ji@med.lu.se; zengxiantao1128@163.com
RI Ji, Jianguang/E-9579-2011
OI Ji, Jianguang/0000-0003-0324-9496
FU National Key Research and Development Program of China [2020YFC0845500]
FX This work was supported (in part) by the National Key Research and
   Development Program of China (2020YFC0845500).
CR Aslam A, 2013, N AM J MED SCI, V5, P713, DOI 10.4103/1947-2714.123266
   Bauchner H, 2020, JAMA-J AM MED ASSOC, V323, P2262, DOI 10.1001/jama.2020.8115
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bhatt DL, 2016, NEW ENGL J MED, V375, P65, DOI 10.1056/NEJMra1510061
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Chu DKW, 2020, CLIN CHEM, V66, P549, DOI 10.1093/clinchem/hvaa029
   Esbin MN, 2020, RNA, V26, P771, DOI 10.1261/rna.076232.120
   Fang YC, 2020, RADIOLOGY, V296, pE115, DOI 10.1148/radiol.2020200432
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gheorghe A, 2019, GLOB HEALTH RES POL, V4, DOI 10.1186/s41256-019-0103-5
   GOLDACRE B, 2017, BMJ-BRIT MED J, V357, DOI DOI 10.1136/BMJ.J2816
   Gupta M, 2020, GLOB HEALTH RES POL, V5, DOI 10.1186/s41256-020-00159-y
   Haagmans BL, 2004, NAT MED, V10, P290, DOI 10.1038/nm1001
   Hou YP, 2019, MILITARY MED RES, V6, DOI 10.1186/s40779-019-0228-3
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Johns Hopkins University, 2020, COVID 19 DASHB CTR S
   Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727
   Lim J, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e79
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Ma LL, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00238-8
   Mehta HB, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2020-039978
   Mustafa S, 2018, J INFECT PUBLIC HEAL, V11, P9, DOI 10.1016/j.jiph.2017.08.009
   National Institutes of Health, 2020, COR DIS 2019 COVID 1
   NIH, 2020, NIH HALTS CLIN TRIAL
   Norris Susan L, 2019, J Evid Based Med, V12, P218, DOI 10.1111/jebm.12347
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Ruberg SJ, 2017, CLIN PHARMACOL THER, V102, P917, DOI 10.1002/cpt.869
   Sarma P, 2020, J MED VIROL, V92, P776, DOI 10.1002/jmv.25898
   Schulz KF, 2002, LANCET, V359, P614, DOI 10.1016/S0140-6736(02)07750-4
   Schulz KF, 2002, LANCET, V359, P696, DOI 10.1016/S0140-6736(02)07816-9
   Sessler DI, 2015, ANESTH ANALG, V121, P1052, DOI 10.1213/ANE.0000000000000862
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Shirato Kazuya, 2020, Jpn J Infect Dis, V73, P304, DOI 10.7883/yoken.JJID.2020.061
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   To KKW, 2020, CLIN INFECT DIS, V71, P841, DOI 10.1093/cid/ciaa149
   Wang W, 2020, YIXUE XINZHI, V30, P7, DOI DOI 10.12173/j.issn.1004-5511.2020.01.04
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   WHO, 2020, WHO DISC HYDR LOP RI
   Yu F, 2020, MICROBES INFECT, V22, P74, DOI 10.1016/j.micinf.2020.01.003
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang RY, 2020, P NATL ACAD SCI USA, V117, P14857, DOI 10.1073/pnas.2009637117
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou SS, 2018, J THORAC DIS, V10, P2059, DOI 10.21037/jtd.2018.03.103
NR 48
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 2
PY 2020
VL 11
AR 540187
DI 10.3389/fphar.2020.540187
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NS8HX
UT WOS:000572498000001
PM 32982751
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Xu, C
   Xu, YJ
   Xu, S
   Zhang, QH
   Liu, XT
   Shao, YF
   Xu, XX
   Peng, L
   Li, M
AF Xu, Chen
   Xu, Yanjun
   Xu, Song
   Zhang, Qianhui
   Liu, Xiaotong
   Shao, Yifan
   Xu, Xiaoxiao
   Peng, Li
   Li, Min
TI Cognitive Reappraisal and the Association Between Perceived Stress and
   Anxiety Symptoms in COVID-19 Isolated People
SO FRONTIERS IN PSYCHIATRY
LA English
DT Article
DE perceived stress; emotion regulation; cognitive reappraisal; anxiety
   symptoms; COVID-19 isolated people
ID EMOTION REGULATION STRATEGIES; DEPRESSIVE SYMPTOMS;
   INDIVIDUAL-DIFFERENCES; APPRAISAL; HEALTH; LONELINESS; RESPONSES;
   THERAPY
AB The purpose of this study is to examine how the emotion regulation strategy, cognitive reappraisal, affects the association between perceived stress and anxiety symptoms in COVID-19 isolated people. Data for this cross-sectional study come from a community-based online survey of COVID-19 isolated people (N = 328), who are not infected with the 2019-nCoV virus. We applied correlation and moderating effect for data analysis and found that cognitive reappraisal negatively moderated the relationship between perceived stress and anxiety symptoms. These results give us a new perspective on understanding the relationship between anxiety symptoms and perceived stress by clarifying the protective function of cognitive reappraisal. It buffers the induced negative emotion when COVID-19 isolated people perceive overpressure, and thus instigates future research into targeted clinical interventions, which aim to cultivate cognitive reappraisal skills for those isolated people in the face of stressful events or crisis events.
C1 [Xu, Chen; Xu, Yanjun; Zhang, Qianhui; Liu, Xiaotong; Shao, Yifan; Xu, Xiaoxiao; Peng, Li; Li, Min] Army Med Univ, Fac Med Psychol, Dept Mil Psychol, Chongqing, Peoples R China.
   [Xu, Song] Chinese PLA, Dept Psychol, Hosp 991, Xiangyang, Peoples R China.
RP Li, M (corresponding author), Army Med Univ, Fac Med Psychol, Dept Mil Psychol, Chongqing, Peoples R China.
EM limin52267@tmmu.edu.cn
CR Aiken L.S., 1991, MULTIPLE REGRESSION
   Alhurani AS, 2018, HEART LUNG, V47, P205, DOI 10.1016/j.hrtlng.2018.03.008
   American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU
   Beck AT, 1983, TREATMENT DEPRESSION, P265, DOI DOI 10.1017/S0141347300012106
   Cacioppo JT, 2006, PSYCHOL AGING, V21, P140, DOI 10.1037/0882-7974.21.1.140
   Caporali P, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00195
   COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404
   Duan QQ, 2012, ZHONGGUO XIN LI WEI, V26, P676, DOI DOI 10.3969/J.ISSN.1000-6729.2012.09.007
   Ehring T, 2006, BEHAV RES THER, V44, P1699, DOI 10.1016/j.brat.2005.11.013
   Fan LB, 2015, OCCUP MED-OXFORD, V65, P110, DOI 10.1093/occmed/kqu181
   FOLKMAN S, 1985, J PERS SOC PSYCHOL, V48, P150, DOI 10.1037/0022-3514.48.1.150
   GARBEE WH, 1980, J AM DENT ASSOC, V100, P853, DOI 10.14219/jada.archive.1980.0279
   Garnefski N, 2006, PERS INDIV DIFFER, V40, P1659, DOI 10.1016/j.paid.2005.12.009
   Garnefski N, 2004, PERS INDIV DIFFER, V36, P267, DOI 10.1016/S0191-8869(03)00083-7
   Garnefski N, 2002, EUR J PERSONALITY, V16, P403, DOI 10.1002/per.458
   Gross J. J., 2007, HDB EMOTION REGULATI, P3, DOI DOI 10.1080/00140130600971135
   Gross JJ, 2015, PSYCHOL INQ, V26, P1, DOI 10.1080/1047840X.2014.940781
   GROSS JJ, 1995, CLIN PSYCHOL-SCI PR, V2, P151, DOI 10.1111/j.1468-2850.1995.tb00036.x
   Gross JJ, 2003, J PERS SOC PSYCHOL, V85, P348, DOI 10.1037/0022-3514.85.2.348
   Hallion LS, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00539
   Hattar-Pollara M, 2006, J TRANSCULT NURS, V17, P349, DOI 10.1177/1043659606291543
   Holt-Lunstad J, 2015, PERSPECT PSYCHOL SCI, V10, P227, DOI 10.1177/1745691614568352
   Jamieson JP, 2012, J EXP PSYCHOL GEN, V141, P417, DOI 10.1037/a0025719
   Jeong H, 2016, EPIDEMIOL HEALTH, V38, DOI 10.4178/epih.e2016048
   Jones-Bitton A, 2020, SOC PSYCH PSYCH EPID, V55, P229, DOI 10.1007/s00127-019-01738-2
   Joormann J, 2016, BEHAV RES THER, V86, P35, DOI 10.1016/j.brat.2016.07.007
   Kashdan TB, 2006, BEHAV RES THER, V44, P1301, DOI 10.1016/j.brat.2005.10.003
   Kivity Y, 2016, J CONSULT CLIN PSYCH, V84, P269, DOI 10.1037/ccp0000075
   Krishnan V, 2008, NATURE, V455, P894, DOI 10.1038/nature07455
   Lau Y, 2014, ARCH PSYCHIAT NURS, V28, P305, DOI 10.1016/j.apnu.2014.05.009
   Lazarus R. S., 1987, EUROPEAN J PERSONALI, V1, P141, DOI DOI 10.1002/PER.2410010304
   Lu F, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00260
   Lynch TR, 2007, ANNU REV CLIN PSYCHO, V3, P181, DOI 10.1146/annurev.clinpsy.2.022305.095229
   Mauss IB, 2007, INT J PSYCHOPHYSIOL, V66, P116, DOI 10.1016/j.ijpsycho.2007.03.017
   Mennin D, 2007, CLIN PSYCHOL-SCI PR, V14, P329, DOI 10.1111/j.1468-2850.2007.00094.x
   Moltrecht B, 2020, EUR CHILD ADOLES PSY, DOI 10.1007/s00787-020-01498-4
   Moore SA, 2008, BEHAV RES THER, V46, P993, DOI 10.1016/j.brat.2008.05.001
   Morey JN, 2015, CURR OPIN PSYCHOL, V5, P13, DOI 10.1016/j.copsyc.2015.03.007
   Olatunji BO, 2010, PSYCHIAT CLIN N AM, V33, P557, DOI 10.1016/j.psc.2010.04.002
   PARKES KR, 1984, J PERS SOC PSYCHOL, V46, P655, DOI 10.1037/0022-3514.46.3.655
   Parkinson B, 1999, COGNITION EMOTION, V13, P277, DOI 10.1080/026999399379285
   Pereira-Morales AJ, 2019, CURR PSYCHOL, V38, P66, DOI 10.1007/s12144-017-9587-7
   Pidgeon A.M., 2014, OPEN J SOC SCI, V2, P23, DOI DOI 10.4236/JSS.2014.211004
   Preacher KJ, 2006, J EDUC BEHAV STAT, V31, P437, DOI 10.3102/10769986031004437
   Pun VC, 2018, ENVIRON HEALTH-GLOB, V17, DOI 10.1186/s12940-018-0381-2
   Sachs-Ericsson N, 2019, AGING MENT HEALTH, DOI 10.1080/13607863.2019.1698516
   SAFRAN JD, 1982, COGNITIVE THER RES, V6, P251, DOI 10.1007/BF01173574
   Sanders Anne E, 2002, J Dent Educ, V66, P75
   SARASON IG, 1984, J PERS SOC PSYCHOL, V46, P929, DOI 10.1037/0022-3514.46.4.929
   SCHAUBROECK J, 1992, J APPL PSYCHOL, V77, P322, DOI 10.1037/0021-9010.77.3.322
   Segerstrom SC, 2004, PSYCHOL BULL, V130, P601, DOI 10.1037/0033-2909.130.4.601
   Shin LM, 2010, NEUROPSYCHOPHARMACOL, V35, P169, DOI 10.1038/npp.2009.83
   Smith A, 2019, INT J DENT, V2019, DOI 10.1155/2019/5864591
   Stewart-Brown S, 2000, J PUBLIC HEALTH MED, V22, P492, DOI 10.1093/pubmed/22.4.492
   Troy AS, 2010, EMOTION, V10, P783, DOI 10.1037/a0020262
   Wang L., 2007, CHINA J HLTH PSYCHOL, V15, P503, DOI DOI 10.13342/J.CNKI.CJHP.2007.06.012
   Xiang YT, 2020, LANCET PSYCHIAT, V7, P228, DOI 10.1016/S2215-0366(20)30046-8
   Yang Ting-zhong, 2003, Zhonghua Liu Xing Bing Xue Za Zhi, V24, P760
   [周浩 Zhou Hao], 2004, [心理科学进展, ADVANCES IN PSYCHOLOGICAL SCIENCE], V12, P942
   ZUNG WWK, 1971, PSYCHOSOMATICS, V12, P371
NR 60
TC 1
Z9 1
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-0640
J9 FRONT PSYCHIATRY
JI Front. Psychiatry
PD SEP 2
PY 2020
VL 11
AR 858
DI 10.3389/fpsyt.2020.00858
PG 8
WC Psychiatry
SC Psychiatry
GA NQ1UK
UT WOS:000570651800001
PM 32982809
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zeng, CX
   Hou, XC
   Yan, JY
   Zhang, CX
   Li, WQ
   Zhao, WY
   Du, S
   Dong, YZ
AF Zeng, Chunxi
   Hou, Xucheng
   Yan, Jingyue
   Zhang, Chengxiang
   Li, Wenqing
   Zhao, Weiyu
   Du, Shi
   Dong, Yizhou
TI Leveraging mRNA Sequences and Nanoparticles to Deliver SARS-CoV-2
   Antigens In Vivo
SO ADVANCED MATERIALS
LA English
DT Article
DE lipid-derived nanoparticles; mRNA engineering; mRNA vaccines;
   SARS-CoV-2; untranslated regions
ID TRANSLATION; PROTEIN; PREDICTION; VACCINES; REGIONS; DESIGN; GENES;
   CODON; STEM
AB SARS-CoV-2 has become a pandemic worldwide; therefore, an effective vaccine is urgently needed. Recently, messenger RNAs (mRNAs) have emerged as a promising platform for vaccination. In this work, the untranslated regions (UTRs) of mRNAs are systematically engineered in order to enhance protein production. Through a comprehensive analysis of endogenous gene expression and de novo design of UTRs, the optimal combination of 5 ' and 3 ' UTR are identified and termed NASAR, which are 5- to 10-fold more efficient than the tested endogenous UTRs. More importantly, NASAR mRNAs delivered by lipid-derived TT3 nanoparticles trigger a dramatic expression of potential SARS-CoV-2 antigens. The antigen-specific antibodies induced by TT3-nanoparticles and NASAR mRNAs are over two orders of magnitude more than that induced by the FDA-approved lipid nanoparticle material MC3 in vaccinated mice. These NASAR mRNAs merit further development as alternative SARS-CoV-2 vaccines.
C1 [Zeng, Chunxi; Hou, Xucheng; Yan, Jingyue; Zhang, Chengxiang; Li, Wenqing; Zhao, Weiyu; Du, Shi; Dong, Yizhou] Ohio State Univ, Coll Pharm, Div Pharmaceut & Pharmacol, 500 W 12Th Ave, Columbus, OH 43210 USA.
   [Dong, Yizhou] Ohio State Univ, Dept Biomed Engn, Comprehens Canc Ctr,Dept Radiat Oncol, Dorothy M Davis Heart & Lung Res Inst,Ctr Clin &, Columbus, OH 43210 USA.
RP Dong, YZ (corresponding author), Ohio State Univ, Coll Pharm, Div Pharmaceut & Pharmacol, 500 W 12Th Ave, Columbus, OH 43210 USA.; Dong, YZ (corresponding author), Ohio State Univ, Dept Biomed Engn, Comprehens Canc Ctr,Dept Radiat Oncol, Dorothy M Davis Heart & Lung Res Inst,Ctr Clin &, Columbus, OH 43210 USA.
EM dong.525@osu.edu
RI Zeng, Chunxi/AAF-7195-2019; Dong, Yizhou/O-9057-2015
OI Dong, Yizhou/0000-0001-5786-0659
FU National Institutes of Health (NIH) through the Maximizing
   Investigators' Research Award of the National Institute of General
   Medical Sciences [R35GM119679]; College of Pharmacy at Ohio State
   University
FX The OSU Campus Microscopy & Imaging Facility is acknowledged for
   providing the instruments and services. Y.D. acknowledges the support
   from the National Institutes of Health (NIH) through the Maximizing
   Investigators' Research Award R35GM119679 of the National Institute of
   General Medical Sciences as well as the start-up fund from the College
   of Pharmacy at Ohio State University. All mouse studies were approved by
   the Institutional Animal Care and Use Committee (approval number:
   2014A00000106-R1) at The Ohio State University and complied with local,
   state, and federal regulations.
CR Akinc A, 2019, NAT NANOTECHNOL, V14, P1084, DOI 10.1038/s41565-019-0591-y
   Babendure JR, 2006, RNA, V12, P851, DOI 10.1261/rna.2309906
   Bai Y, 2013, NUCLEIC ACIDS RES, V41, P7861, DOI 10.1093/nar/gkt543
   Chatterjee S, 2009, BIOL CELL, V101, P251, DOI 10.1042/BC20080104
   Chen SJ, 2008, ANNU REV BIOPHYS, V37, P197, DOI 10.1146/annurev.biophys.37.032807.125957
   Chen YH, 2020, NUCLEIC ACIDS RES, V48, pD127, DOI 10.1093/nar/gkz757
   Ferizi M, 2016, SCI REP-UK, V6, DOI 10.1038/srep39149
   Fernandez N, 2011, NUCLEIC ACIDS RES, V39, P8572, DOI 10.1093/nar/gkr560
   Galarneau A, 2005, NAT STRUCT MOL BIOL, V12, P691, DOI 10.1038/nsmb963
   Geyer PE, 2016, CELL SYST, V2, P185, DOI 10.1016/j.cels.2016.02.015
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Hentze MW, 2018, NAT REV MOL CELL BIO, V19, P327, DOI 10.1038/nrm.2017.130
   Hinnebusch AG, 2017, TRENDS BIOCHEM SCI, V42, P589, DOI 10.1016/j.tibs.2017.03.004
   Hinnebusch AG, 2016, SCIENCE, V352, P1413, DOI 10.1126/science.aad9868
   Huang PS, 2016, NATURE, V537, P320, DOI 10.1038/nature19946
   Jackson NAC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0159-8
   Jayaraman M, 2012, ANGEW CHEM INT EDIT, V51, P8529, DOI 10.1002/anie.201203263
   Jiang SB, 2005, EMERG INFECT DIS, V11, P1016, DOI 10.3201/1107.050219
   Klauer AA, 2012, WIRES RNA, V3, P649, DOI 10.1002/wrna.1124
   Korostelev AA, 2014, CELL, V159, P475, DOI 10.1016/j.cell.2014.10.005
   KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9
   Lee J, 2017, J CLIN INVEST, V127, P2433, DOI 10.1172/JCI92030
   Leung DTM, 2004, J INFECT DIS, V190, P379, DOI 10.1086/422040
   Li B, 2018, NAT PROTOC, V13, P899, DOI 10.1038/nprot.2018.004
   Li B, 2015, NANO LETT, V15, P8099, DOI 10.1021/acs.nanolett.5b03528
   Li WQ, 2020, BIOCONJUGATE CHEM, V31, P542, DOI 10.1021/acs.bioconjchem.0c00062
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mann M, 2017, NUCLEIC ACIDS RES, V45, pW435, DOI 10.1093/nar/gkx279
   Maruggi G, 2019, MOL THER, V27, P757, DOI 10.1016/j.ymthe.2019.01.020
   Mascola JR, 2020, NAT REV IMMUNOL, V20, P87, DOI 10.1038/s41577-019-0243-3
   Mayr C, 2017, ANNU REV GENET, V51, P171, DOI 10.1146/annurev-genet-120116-024704
   Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243
   Ricci EP, 2013, NUCLEIC ACIDS RES, V41, P586, DOI 10.1093/nar/gks1076
   Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017
   Sample PJ, 2019, NAT BIOTECHNOL, V37, P803, DOI 10.1038/s41587-019-0164-5
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Schrom E, 2017, MOL THER-NUCL ACIDS, V7, P350, DOI 10.1016/j.omtn.2017.04.006
   Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098
   Sokoloski KJ, 2010, CELL HOST MICROBE, V8, P196, DOI 10.1016/j.chom.2010.07.003
   Terenin IM, 2013, NUCLEIC ACIDS RES, V41, P1807, DOI 10.1093/nar/gks1282
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Thorlund K, 2020, LANCET DIGIT HEALTH, V2, pE286, DOI 10.1016/S2589-7500(20)30086-8
   Topisirovic I, 2009, MOL CELL BIOL, V29, P1152, DOI 10.1128/MCB.01532-08
   Trepotec Z, 2019, TISSUE ENG PT A, V25, P69, DOI [10.1089/ten.tea.2017.0485, 10.1089/ten.TEA.2017.0485]
   WHO, 145 WHO
   Yamagishi R, 2016, NUCLEIC ACIDS RES, V44, P2475, DOI 10.1093/nar/gkw118
   Yamashita R, 2008, NUCLEIC ACIDS RES, V36, P3707, DOI 10.1093/nar/gkn248
   Yoshihama M, 2002, GENOME RES, V12, P379, DOI 10.1101/gr.214202
   Zearfoss NR, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001269
   Zhang L, 2015, EXPERT REV VACCINES, V14, P1509, DOI 10.1586/14760584.2015.1081067
NR 50
TC 0
Z9 0
U1 8
U2 8
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0935-9648
EI 1521-4095
J9 ADV MATER
JI Adv. Mater.
PD OCT
PY 2020
VL 32
IS 40
AR 2004452
DI 10.1002/adma.202004452
EA SEP 2020
PG 8
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA OB5MI
UT WOS:000567317300001
PM 32875709
OA Bronze
DA 2021-01-01
ER

PT J
AU Guimon, J
   Narula, R
AF Guimon, Jose
   Narula, Rajneesh
TI Ending the COVID-19 Pandemic Requires More International Collaboration
SO RESEARCH-TECHNOLOGY MANAGEMENT
LA English
DT Article
DE COVID-19; Vaccine; Collaboration; Globalization; Techno-nationalism
AB Overview:Global scientific collaboration to find a vaccine is not enough to end the pandemic. International cooperation is also necessary to produce a successful vaccine affordably and distribute it equitably worldwide. Commercial and national interests threaten to thwart the universal immunization needed to curtail the pandemic. International institutions such as the World Health Organization are essential to the solution.
C1 [Guimon, Jose] Autonomous Univ Madrid UAM, Econ, Madrid, Spain.
   [Narula, Rajneesh] Univ Reading, Henley Business Sch, Int Business Regulat, Reading, Berks, England.
RP Guimon, J (corresponding author), Autonomous Univ Madrid UAM, Econ, Madrid, Spain.
EM jose.guimon@uam.es; r.narula@henley.ac.uk
RI Guimon, Jose/J-7645-2017
OI Guimon, Jose/0000-0002-7391-7659
CR Chesbrough H, 2020, IND MARKET MANAG, V88, P410, DOI 10.1016/j.indmarman.2020.04.010
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Hosangadi D, 2020, VACCINE, V38, P4167, DOI 10.1016/j.vaccine.2020.04.037
   Khamsi R, 2020, NATURE, V580, P578, DOI 10.1038/d41586-020-01063-8
   Knaus C., 2020, GUARDIAN
   Maxmen Amy, 2020, Nature, V582, P17, DOI 10.1038/d41586-020-01586-0
   Milne M., 2020, FINANCIAL TIMES
   Narula R., 2003, GLOBALIZATION TECHNO
   Organization for Economic Cooperation and Development, 2020, WHY OP SCI IS CRIT C
   Organization for Economic Cooperation and Development, 2020, STIP COV 19 WATCH OE
   Petricevic O, 2019, J INT BUS STUD, V50, P1487, DOI 10.1057/s41267-019-00269-x
   Wellcome, 2020, SHAR RES DAT FIND RE
   Yamey G, 2020, LANCET, V395, P1405, DOI 10.1016/S0140-6736(20)30763-7
NR 13
TC 1
Z9 1
U1 2
U2 2
PU INDUSTRIAL RESEARCH INST, INC
PI ARLINGTON
PA 2300 CLARENDON BLVD, STE 400, ARLINGTON, VA 22201 USA
SN 0895-6308
EI 1930-0166
J9 RES TECHNOL MANAGE
JI Res.-Technol. Manage.
PD SEP 2
PY 2020
VL 63
IS 5
BP 38
EP 41
DI 10.1080/08956308.2020.1790239
PG 4
WC Business; Engineering, Industrial; Management
SC Business & Economics; Engineering
GA NL0MN
UT WOS:000567120400006
OA Bronze
DA 2021-01-01
ER

PT J
AU Chung, GR
   Lanier, P
   Wong, PYJ
AF Chung, Gerard
   Lanier, Paul
   Wong, Peace Yuh Ju
TI Mediating Effects of Parental Stress on Harsh Parenting and Parent-Child
   Relationship during Coronavirus (COVID-19) Pandemic in Singapore
SO JOURNAL OF FAMILY VIOLENCE
LA English
DT Article; Early Access
DE Coronavirus (COVID-19); Singapore; Parental stress; Harsh parenting;
   Relationship
ID EXTERNALIZING BEHAVIOR; INTERACTION THERAPY; SPANKING; OUTCOMES
AB Because of the Coronavirus (COVID-19) pandemic, "Circuit-breaker" safety distancing was implemented in Singapore from April to May 2020. Schools and workplaces were closed and parents had to balance telecommuting with parenting responsibilities. Coupled with the high degree of economic uncertainty and reduced social support, these circumstances are hypothesized to increase parenting stress. Based on the Parental Stress Model, this study aims to understand how parents' perceived impact of COVID-19 increased harsh parenting and reduced parent-child relationship closeness through the mediating effects of parenting stress. We collected data from 258 parents living in Singapore using online surveys disseminated through Facebook and community organizations. Our predictor was the perceived impact of COVID-19. Parental stress (mediator) was measured with the Parental Stress Scale. Two outcomes were used: parent-child relationship closeness and harsh parenting (spanking, yelling). Using mediation analysis in the SEM framework, we tested the indirect effects using bias-corrected bootstrap confidence intervals. Our results indicated that parenting stress was a significant mediator in the relationship between the perceived impact of COVID-19 and (a) parent-child closeness (indirect effect = -.30, Bootstrap 99% CI[-.59, -.11]) and (b) harsh parenting (indirect effect = .58, Bootstrap 99% CI[.25, .94]). The impact of COVID-19 and stay-home orders can increase parenting stress. This, in turn, has a negative impact on parenting by affecting parents' relationship with their children and increasing the use of harsh parenting. Given that these are risk factors for potential child abuse, supporting parents and mitigating the impact of COVID-19 are important.
C1 [Chung, Gerard; Lanier, Paul] Univ N Carolina, Sch Social Work, Tate Turner Kuralt Bldg,325 Pittsboro St CB 3550, Chapel Hill, NC 27599 USA.
   [Wong, Peace Yuh Ju] Natl Univ Singapore, Dept Social Work, BLK AS3 Level 4,3 Arts Link Singapore, Singapore 117570, Singapore.
RP Chung, GR (corresponding author), Univ N Carolina, Sch Social Work, Tate Turner Kuralt Bldg,325 Pittsboro St CB 3550, Chapel Hill, NC 27599 USA.
EM gcsk1982@live.unc.edu
OI Chung, Siew Keong Gerard/0000-0002-7852-1848
CR ABIDIN RR, 1992, J CLIN CHILD PSYCHOL, V21, P407, DOI 10.1207/s15374424jccp2104_12
   Agrawal N., 2020, NY TIMES
   [Anonymous], 2020, PSYCH POD OTH ALL HL
   [Anonymous], 2020, CHANNEL NEWS ASIA
   [Anonymous], 2020, SING EX CIRC BREAK J
   [Anonymous], 2020, NY TIMES
   Azhari A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47810-4
   Bendheim-Thoman Center for Research on Child Wellbeing, 2018, US GUID FRAG FAM CHI
   Berkovits MD, 2010, BEHAV THER, V41, P375, DOI 10.1016/j.beth.2009.11.002
   BERRY JO, 1995, J SOC PERS RELAT, V12, P463, DOI 10.1177/0265407595123009
   Bornstein MH, 2018, DEV PSYCHOPATHOL, V30, P399, DOI 10.1017/S0954579417000931
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Brooks-Gunn J, 2013, CHILD ABUSE NEGLECT, V37, P721, DOI 10.1016/j.chiabu.2013.08.004
   Brown S. M, 2020, STRESS PARENTING GLO, DOI [10.31234/osf.io/ucezm, DOI 10.31234/OSF.IO/UCEZM]
   Campbell AM, 2020, FORENSIC SCI INT REP, V2, DOI [10.1016/j.fsir.2020.100089, DOI 10.1016/J.FSIR.2020.100089]
   Chang L, 2003, J FAM PSYCHOL, V17, P598, DOI 10.1037/0893-3200.17.4.598
   Cheng I., 2020, COVID 19 BUDGET WHAT
   Cheung SK, 2000, PSYCHOLOGIA, V43, P253
   Chng GS, 2018, CHILD ABUSE NEGLECT, V79, P465, DOI 10.1016/j.chiabu.2018.02.029
   Chung G, 2020, ASS WORK FAMILY BALA, DOI [10.31219/osf.io/nz9s8, DOI 10.31219/OSF.IO/NZ9S8]
   Chung G, 2020, FAM PROCESS, V59, P772, DOI 10.1111/famp.12450
   Cluver L, 2020, LANCET, V395, pE64, DOI 10.1016/S0140-6736(20)30736-4
   Conway L. G, 2020, SOCIAL PSYCHOL MEASU, DOI [10.31234/osf.io/z2x9a, DOI 10.31234/OSF.IO/Z2X9A, 10.31234/osf.io/z2x9a.]
   Coyne L. W, 2020, 1 THINGS 1 PARENT PS, DOI [10.31219/osf.io/pyge2, DOI 10.31219/OSF.IO/PYGE2]
   Crnic KA, 2005, INFANT CHILD DEV, V14, P117, DOI 10.1002/icd.384
   Deater-Deckard K, 1998, CLIN PSYCHOL-SCI PR, V5, P314, DOI 10.1111/j.1468-2850.1998.tb00152.x
   DOS, 2019, POP TRENDS 2019
   DOS, 2020, AV MED MONTHL HOUS I
   Driscoll K., 2011, J EARLY CHILDHOOD IN, V7, P1
   Eltanamly H, 2021, TRAUMA VIOLENCE ABUS, V22, P147, DOI 10.1177/1524838019833001
   Fontanesi L, 2020, PSYCHOL TRAUMA-US, V12, pS79, DOI 10.1037/tra0000672
   Gershoff ET, 2018, PSYCHOL SCI, V29, P110, DOI 10.1177/0956797617729816
   Hayes A.F., 2018, INTRO MEDIATION MODE
   Holly LE, 2019, J CLIN CHILD ADOLESC, V48, P685, DOI 10.1080/15374416.2019.1639515
   Jackson AP, 2018, J FAMILY MED COMMUNI, V5, P3
   Koh X. H, 2016, STRAITS TIMES
   Lanier P, 2011, RES SOCIAL WORK PRAC, V21, P689, DOI 10.1177/1049731511406551
   Lazarus RS, 1984, STRESS APPRAISAL COP
   Lee SJ, 2014, CHILD ABUSE NEGLECT, V38, P875, DOI 10.1016/j.chiabu.2014.01.018
   Li C, 2013, STATA J, V13, P795, DOI 10.1177/1536867X1301300407
   Liu L, 2015, CHILD ABUSE NEGLECT, V43, P73, DOI 10.1016/j.chiabu.2015.01.014
   Lutz WJ, 2007, AM J ORTHOPSYCHIAT, V77, P86, DOI 10.1037/0002-9432.77.1.86
   MacKenzie MJ, 2015, J YOUTH ADOLESCENCE, V44, P658, DOI 10.1007/s10964-014-0114-y
   Mohan M., 2020, CHANNEL NEWS ASIA
   National Academies of Sciences Engineering and Medicine, 2016, PAR MATT SUPP PAR CH, DOI [10.17226/21868, DOI 10.17226/21868]
   Ostberg M, 2000, J CLIN CHILD PSYCHOL, V29, P615, DOI 10.1207/S15374424JCCP2904_13
   Pinquart M, 2017, DEV PSYCHOL, V53, P873, DOI 10.1037/dev0000295
   Romero E., 2020, TESTING EFFECTS COVI, DOI [10.31234/osf.io/spxtw, DOI 10.31234/OSF.IO/SPXTW]
   Salloum A., 2010, TRAUMATOLOGY, V16, P31, DOI [10.1177/1534765609348240, DOI 10.1177/1534765609348240]
   Sanders M R, 1999, Clin Child Fam Psychol Rev, V2, P71, DOI 10.1023/A:1021843613840
   Shulruf B, 2009, CHILD YOUTH SERV REV, V31, P526, DOI 10.1016/j.childyouth.2008.10.010
   Sim TN, 2005, J MARRIAGE FAM, V67, P85
   Singapore Social Lifestyle and Infection Networks Group, 2020, IMP WORK PATT WAG
   Tang S., 2020, CNA
   Tarver J, 2014, EUR CHILD ADOLES PSY, V23, P1123, DOI 10.1007/s00787-014-0556-5
   Thomas R, 2007, J ABNORM CHILD PSYCH, V35, P475, DOI 10.1007/s10802-007-9104-9
   Tong C. K, 1996, PUBLIC PERCEPTIONS C
   Weems CF, 2020, PANDEMIC FORECAST, DOI [10.13140/RG.2.2.21601.45926, DOI 10.13140/RG.2.2.21601.45926]
   World Health Organization, 2020, 2 M INT HLTH REG 200
   Yip C, 2020, CNA
   Zhuo T., 2020, STRAITS TIMES
NR 61
TC 1
Z9 1
U1 8
U2 8
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0885-7482
EI 1573-2851
J9 J FAM VIOLENCE
JI J. Fam. Violence
DI 10.1007/s10896-020-00200-1
EA SEP 2020
PG 12
WC Psychology, Clinical; Family Studies
SC Psychology; Family Studies
GA NK0OP
UT WOS:000566441300002
PM 32895601
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Aschendorff, A
   Arndt, S
   Kroger, S
   Wesarg, T
   Ketterer, MC
   Kirchem, P
   Pixner, S
   Hassepass, F
   Beck, R
AF Aschendorff, A.
   Arndt, S.
   Kroeger, S.
   Wesarg, T.
   Ketterer, M. C.
   Kirchem, P.
   Pixner, S.
   Hassepass, F.
   Beck, R.
TI Quality of cochlear implant rehabilitation under COVID-19 conditions.
   German version
SO HNO
LA German
DT Article
DE Speech therapy; Aftercare; Severe acute respiratory syndrome coronavirus
   2; Quality assurance; Standard of care
AB Background The rehabilitation process following cochlear implant (CI) surgery is carried out in a multimodal therapy according to German national guidelines and includes technical and medical aftercare. In times of the corona pandemic surgery and rehabilitation appointments were cancelled or delayed leading to a more difficult access to auditory rehabilitation. Newly implemented hygiene modalities due to the SARS-CoV-2 pandemic have changed medical aftercare and the rehabilitation process. The aim of this study was to evaluate the quality of rehabilitation under corona conditions. Material and methods An anonymous survey of adult cochlear implant patients was carried out by a non-standardized questionnaire. Demographics were analyzed and the quality of medical aftercare, speech therapy, technical aftercare, psychological support and the hygiene modalities were compared to previous rehabilitation stays. Results In total 109 patients completed the questionnaire. The quality of rehabilitation and individual therapy were rated as qualitatively similar or improved. The threat of the pandemic and fear of corona were rated unexpectedly high with 68% and 50%, respectively. The hygiene measures during the rehabilitation stay eased subjective fears at the same time. The majority of patients were annoyed by wearing face masks but visors, protection shields and social distancing were more tolerated. Conclusion The implementation of the new hygiene modalities within the therapeutic rehabilitation setting was well-accepted by patients allowing access to auditory rehabilitation. A successful rehabilitation should ensure a fear-free environment by adhering to the necessary hygiene modalities.
C1 [Aschendorff, A.; Arndt, S.; Kroeger, S.; Wesarg, T.; Ketterer, M. C.; Kirchem, P.; Pixner, S.; Hassepass, F.; Beck, R.] Albert Ludwigs Univ Freiburg Breisgau, Klin Hals Nasen & Ohrenheilkunde, Killianstr 5, D-79106 Freiburg, Germany.
RP Aschendorff, A (corresponding author), Albert Ludwigs Univ Freiburg Breisgau, Klin Hals Nasen & Ohrenheilkunde, Killianstr 5, D-79106 Freiburg, Germany.
EM antje.aschendorff@uniklinik-freiburg.de
FU Projekt DEAL
FX Open Access funding provided by Projekt DEAL.
CR [Anonymous], 2020, COCHL IMPL VERS ZENT
   Baungaard LH, 2019, DAN MED J, V66
   Bhangu A, 2020, BRIT J SURG, DOI [10.1002/bjs.11746, DOI 10.1002/BJS.11746]
   Blom A., 2020, MANNHEIMER CORONA ST
   Carlson ML, 2020, NEW ENGL J MED, V382, P1531, DOI 10.1056/NEJMra1904407
   Fu Qian-Jie, 2004, Cochlear Implants Int, V5 Suppl 1, P84, DOI 10.1179/cim.2004.5.Supplement-1.84
   Green T, 2019, TRENDS HEAR, V23, DOI 10.1177/2331216519843878
   Illg A, 2017, HNO, V65, P552, DOI 10.1007/s00106-016-0311-y
   Korzilius H, 2020, DTSCH ARZTEBL, V117, pA
   Luryi AL, 2020, OTOL NEUROTOL, V41, pE330, DOI 10.1097/MAO.0000000000002551
   Naumann E, 2020, MANNHEIMER CORONA ST
   Reis M, 2019, EAR HEARING, V40, P1445, DOI 10.1097/AUD.0000000000000724
   Zeh R, 2015, HNO, V63, P557, DOI 10.1007/s00106-015-0037-2
NR 13
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0017-6192
EI 1433-0458
J9 HNO
JI HNO
PD NOV
PY 2020
VL 68
IS 11
BP 847
EP 853
DI 10.1007/s00106-020-00922-0
EA SEP 2020
PG 7
WC Otorhinolaryngology
SC Otorhinolaryngology
GA OK4UE
UT WOS:000565476400002
PM 32876719
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sengupta, S
   Brooks, TG
   Grant, GR
   FitzGerald, GA
AF Sengupta, Shaon
   Brooks, Thomas G.
   Grant, Gregory R.
   FitzGerald, Garret A.
TI Accounting for Time: Circadian Rhythms in the Time of COVID-19
SO JOURNAL OF BIOLOGICAL RHYTHMS
LA English
DT Article; Early Access
DE vaccines; translational medicine; chronotherapy; COVID-19; circadian;
   immunity
ID GENE-EXPRESSION; REV-ERB; CLOCK; IMMUNITY; INNATE; MOUSE
AB The COVID-19 pandemic has necessitated novel approaches and collaborative efforts across multiple disciplines. It is known that various aspects of our physiology and response to pathogens are under tight clock control. However, the assimilation of circadian biology into our clinical and research practices is still evolving. Using a focused review of the literature and original analyses of the UK Biobank, we discuss how circadian biology may inform our diagnostic and therapeutic strategies in this pandemic.
C1 [Sengupta, Shaon] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
   [Sengupta, Shaon] Childrens Hosp Philadelphia, Div Neonatol, Philadelphia, PA 19104 USA.
   [Sengupta, Shaon; Brooks, Thomas G.; Grant, Gregory R.; FitzGerald, Garret A.] Univ Penn, Inst Translat Med & Therapeut ITMAT, Philadelphia, PA 19104 USA.
   [Sengupta, Shaon; FitzGerald, Garret A.] Univ Penn, Chronobiol & Sleep Inst, Philadelphia, PA 19104 USA.
   [Grant, Gregory R.] Univ Penn, Perelman Sch Med, Dept Genet, Philadelphia, PA 19104 USA.
   [FitzGerald, Garret A.] Univ Penn, Perelman Sch Med, Syst Pharmacol, Philadelphia, PA 19104 USA.
RP Sengupta, S (corresponding author), Childrens Hosp Philadelphia, Div Neonatol, 2NW27, Philadelphia, PA 19104 USA.
EM SenguptaS@email.chop.edu
OI Brooks, Thomas/0000-0002-6980-0079
FU NHLBIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [K08HL132053]; NIH/NCRRUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Center for Research Resources (NCRR) [RR023567]; American Heart
   AssociationAmerican Heart Association; Volkswagen FoundationVolkswagen;
   NCATSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Advancing
   Translational Sciences (NCATS) [5UL1TR000003]; UK Biobank Resource
   [50398];  [5T32MH106442-04]
FX This work was supported by the NHLBI-K08HL132053 (to S.S.), NIH/NCRR
   RR023567 (to G.A.F.), a Merit Award from the American Heart Association
   (to G.A.F.), a grant from the Volkswagen Foundation (to G.A.F.), and
   5T32MH106442-04 and NCATS-5UL1TR000003 (to T.G.B. and G.R.G). Dr.
   FitzGerald is the McNeil Professor of Translational Medicine and
   Therapeutics and a senior advisor to Calico Laboratories. This research
   has been conducted using the UK Biobank Resource under project ID 50398.
   We thank Kaitlyn Forrest for her help with the graphics.
CR Adrover JM, 2019, IMMUNITY, V50, P390, DOI 10.1016/j.immuni.2019.01.002
   Benedict C, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-1
   Bonten TN, 2015, HYPERTENSION, V65, P743, DOI 10.1161/HYPERTENSIONAHA.114.04980
   BROWN R, 1989, Regional Immunology, V2, P321
   Buurma M, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00084
   Chen LH, 2018, ARTERIOSCL THROM VAS, V38, P2819, DOI 10.1161/ATVBAHA.118.311296
   Cobey S, 2017, CURR OPIN VIROL, V22, P105, DOI 10.1016/j.coviro.2016.12.004
   Curtis AM, 2014, IMMUNITY, V40, P178, DOI 10.1016/j.immuni.2014.02.002
   Doherty A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169649
   Druzd D, 2017, IMMUNITY, V46, P120, DOI 10.1016/j.immuni.2016.12.011
   Early JO, 2018, P NATL ACAD SCI USA, V115, pE8460, DOI 10.1073/pnas.1800431115
   Ehlers A, 2018, MUCOSAL IMMUNOL, V11, P97, DOI 10.1038/mi.2017.24
   Erkekoglu P, 2012, J RES PHARM PRACT, V1, P3, DOI 10.4103/2279-042X.99670
   Farias T, 2019, CELLS, P8
   Gibbs JE, 2012, P NATL ACAD SCI USA, V109, P582, DOI 10.1073/pnas.1106750109
   Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Prado NJ, 2018, CURR HYPERTENS REP, V20, DOI 10.1007/s11906-018-0842-6
   Keller M, 2009, P NATL ACAD SCI USA, V106, P21407, DOI 10.1073/pnas.0906361106
   Kojetin DJ, 2014, NAT REV DRUG DISCOV, V13, P197, DOI 10.1038/nrd4100
   Loef B, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54816-5
   Long JE, 2016, VACCINE, V34, P2679, DOI 10.1016/j.vaccine.2016.04.032
   Man K, 2016, SCIENCE, V354, P999, DOI 10.1126/science.aah4966
   Mathew Divij, 2020, bioRxiv, DOI 10.1101/2020.05.20.106401
   Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731
   Nobis CC, 2019, P NATL ACAD SCI USA, V116, P20077, DOI 10.1073/pnas.1905080116
   Nonaka H, 2001, CIRCULATION, V104, P1746, DOI 10.1161/hc4001.098048
   Ohashi N, 2017, HYPERTENS RES, V40, P413, DOI 10.1038/hr.2016.166
   Sengupta S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11400-9
   Shay T, 2013, P NATL ACAD SCI USA, V110, P2946, DOI 10.1073/pnas.1222738110
   Silver AC, 2012, IMMUNITY, V36, P251, DOI 10.1016/j.immuni.2011.12.017
   Skarke C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17362-6
   Smith MR, 2012, NAT SCI SLEEP, V4, P111, DOI 10.2147/NSS.S10372
   Spiegel K, 2002, JAMA-J AM MED ASSOC, V288, P1471, DOI 10.1001/jama.288.12.1471-a
   Stone EF, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002445
   Sulli G, 2018, TRENDS PHARMACOL SCI, V39, P812, DOI 10.1016/j.tips.2018.07.003
   Suzuki K, 2016, J EXP MED, V213, P2567, DOI 10.1084/jem.20160723
   Takahashi JS, 2017, NAT REV GENET, V18, P164, DOI 10.1038/nrg.2016.150
   Waltenburg MA, 2020, MMWR-MORBID MORTAL W, V69, P887, DOI 10.15585/mmwr.mm6927e2
   Willetts M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26174-1
   WITTING W, 1990, BIOL PSYCHIAT, V27, P563, DOI 10.1016/0006-3223(90)90523-5
   Yang GR, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007225
   Yu XF, 2013, SCIENCE, V342, P727, DOI 10.1126/science.1243884
   Zhang R, 2014, P NATL ACAD SCI USA, V111, P16219, DOI 10.1073/pnas.1408886111
   Zhuang XD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08299-7
NR 45
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0748-7304
EI 1552-4531
J9 J BIOL RHYTHM
JI J. Biol. Rhythms
AR 0748730420953335
DI 10.1177/0748730420953335
EA SEP 2020
PG 5
WC Biology; Physiology
SC Life Sciences & Biomedicine - Other Topics; Physiology
GA NI9MN
UT WOS:000565669900001
PM 32875944
OA Bronze
DA 2021-01-01
ER

PT J
AU Ganesh, R
   Lucocq, J
   Ekpete, NO
   Ul Ain, N
   Lim, SK
   Alwash, A
   Bibi, S
   Alijani, A
AF Ganesh, Radhakrishnan
   Lucocq, James
   Ekpete, Neville Ogbonnia
   Ul Ain, Noor
   Lim, Su Kwan
   Alwash, Al
   Bibi, Saira
   Alijani, Afshin
TI Management of appendicitis during COVID-19 pandemic; short-term outcomes
SO SCOTTISH MEDICAL JOURNAL
LA English
DT Article
DE Appendicitis; COVID-19; antibiotic; CT scan
ID COMPUTED-TOMOGRAPHY; ANTIBIOTIC-THERAPY; APPENDECTOMY
AB Background and aim COVID-19 pandemic has predisposed patients undergoing surgery to post-operative infection and resultant complications. Appendicitis is frequently managed by appendicectomy. After the onset of the pandemic, selected cases of appendicitis were managed with antibiotics which is a recognised treatment option. Our objective was to compare the management of appendicitis and post-operative outcomes between pre- and post-COVID-19. Methods Ninety-six patients were identified from before the onset of the pandemic (November 2019) to after the onset of the pandemic (May 2020). Data were collected retrospectively from electronic records including demographics, investigations, treatment, duration of inpatient stay, complications, readmissions and compared between pre- and post-COVID-19 groups. Results One hundred percent underwent surgical treatment before the onset of pandemic, compared with 56.3% from the onset of the pandemic. A greater percentage of patients were investigated with imaging post-COVID-19 (100% versus 60.9%; p < 0.00001). There was no significant difference in the outcomes between the two groups. Conclusion CT/MRI scan was preferred to laparoscopy in diagnosing appendicitis and conservative management of uncomplicated appendicitis was common practice after the onset of pandemic. Health boards can adapt their management of surgical conditions during pandemics without adverse short-term consequences. Long term follow-up of this cohort will identify patients suitable for conservative management.
C1 [Ganesh, Radhakrishnan; Lucocq, James; Ekpete, Neville Ogbonnia; Ul Ain, Noor; Lim, Su Kwan; Alwash, Al; Bibi, Saira; Alijani, Afshin] Ninewells Hosp, Dept Gen Surg, Dundee, Scotland.
RP Ganesh, R (corresponding author), 43 Lister Court, Dundee DD2 1UY, Scotland.
EM r.ganesh@nhs.net
OI Lucocq, James/0000-0002-6979-7818
CR Alkatout I, 2017, J GYNECOL SURG, V33, P81, DOI 10.1089/gyn.2016.0111
   [Anonymous], STAT US CT CHEST SCR
   Bagherzadeh S, 2018, INT J RADIAT BIOL, V94, P454, DOI 10.1080/09553002.2018.1450536
   Behrns K., 2012, YB SURG, V2012, P258
   Cervellin G, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.09.10
   Chiang DT, 2008, ANN ROY COLL SURG, V90, P17, DOI 10.1308/003588408X242259
   DORIA A, 2009, PEDIATR RADIOL, V39, P144
   Gaskill CE, 2018, CURR PROBL DIAGN RAD, V47, P6, DOI 10.1067/j.cpradiol.2016.12.002
   Gorter RR, 2016, SURG ENDOSC, V30, P4668, DOI 10.1007/s00464-016-5245-7
   Hansson J, 2009, BRIT J SURG, V96, P473, DOI 10.1002/bjs.6482
   Hensgens MPM, 2012, J ANTIMICROB CHEMOTH, V67, P742, DOI 10.1093/jac/dkr508
   Lai HW, 2006, J GASTROEN HEPATOL, V21, P1693, DOI 10.1111/j.1440-1746.2006.04426.x
   Moletta L, 2020, INT J SURG, V79, P180, DOI 10.1016/j.ijsu.2020.05.061
   Rosen MP, 2011, J AM COLL RADIOL, V8, P749, DOI 10.1016/j.jacr.2011.07.010
   Royal College of Surgeons, UPD INT GEN SURG GUI
   Salminen P, 2015, JAMA-J AM MED ASSOC, V313, P2340, DOI 10.1001/jama.2015.6154
   Schroeder M, 2017, GENES-BASEL, V8, DOI 10.3390/genes8010039
   Shogilev DJ, 2014, WEST J EMERG MED, V15, P859, DOI 10.5811/westjem.2014.9.21568
   Sippola S, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023623
   Styrud J, 2006, WORLD J SURG, V30, P1033, DOI 10.1007/s00268-005-0304-6
NR 20
TC 2
Z9 2
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0036-9330
EI 2045-6441
J9 SCOT MED J
JI Scott. Med. J.
PD NOV
PY 2020
VL 65
IS 4
BP 144
EP 148
AR 0036933020956316
DI 10.1177/0036933020956316
EA SEP 2020
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA OA7YH
UT WOS:000566176400001
PM 32878574
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Li, Q
   Li, WX
   Jin, YP
   Xu, W
   Huang, CL
   Li, L
   Huang, YX
   Fu, QC
   Chen, L
AF Li, Qiang
   Li, Weixia
   Jin, Yinpeng
   Xu, Wei
   Huang, Chenlu
   Li, Li
   Huang, Yuxian
   Fu, Qingchun
   Chen, Liang
TI Efficacy Evaluation of Early, Low-Dose, Short-Term Corticosteroids in
   Adults Hospitalized with Non-Severe COVID-19 Pneumonia: A Retrospective
   Cohort Study
SO INFECTIOUS DISEASES AND THERAPY
LA English
DT Article
DE 2019 novel coronavirus disease; Corticosteroids; Efficacy evaluation;
   Non-severe COVID-19 infections; Severe acute respiratory syndrome
   coronavirus 2
AB Objectives This study aimed to observe the efficacy of corticosteroids in non-severe COVID-19 pneumonia. Methods A retrospective study based on propensity score matching was designed to explore the effects of corticosteroids. Primary outcomes included the rate of patients who developed severe disease and mortality. Secondary outcomes included duration of fever, virus clearance time, length of hospital stay, and the use of antibiotics. Results A total of 475 patients with non-severe COVID-19 pneumonia were enrolled, 55 patients received early, low-dose, and short-term corticosteroids therapy, 420 patients received non-corticosteroids therapy. Compared to the non-corticosteroids group, there was a prolonged duration of fever (median 5 vs 3 days,p < 0.001), virus clearance time (median 18 vs 11 days,p < 0.001), and length of hospital stay (median 23 vs 15 days,p < 0.001) in the corticosteroids group. The percentages of antibiotics therapy (89.1% vs 23.6%,p < 0.001), use of at least two antibiotics (38.2% vs 12.7%,p = 0.002), and antifungal therapy (7.3% vs 0,p = 0.042) were higher in the corticosteroids group than those in the non-corticosteroids group. Compared to the non-corticosteroids group, more patients developed severe disease (12.7% vs 1.8%,p = 0.028) in the corticosteroids group. There was no significant difference between the two groups in mortality (1.8% vs 0,p = 0.315). Conclusion In adult patients with non-severe COVID-19 pneumonia, early, low-dose, and short-term corticosteroids therapy was associated with worse clinical outcomes.
C1 [Li, Qiang; Jin, Yinpeng; Xu, Wei; Huang, Chenlu; Li, Li; Huang, Yuxian; Fu, Qingchun; Chen, Liang] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Liver Dis, Shanghai, Peoples R China.
   [Li, Weixia] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Infect Dis, Shanghai, Peoples R China.
RP Fu, QC; Chen, L (corresponding author), Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Liver Dis, Shanghai, Peoples R China.
EM fuqingchun@shphc.org.cn; chenliang@shphc.org.cn
OI Yuxian, Huang/0000-0001-9934-3588
FU Shanghai Association for Science and Technology [17411969700]; Shanghai
   Sailing Plan Program [19YF1441200]
FX This study was supported by grant no. 17411969700 from Shanghai
   Association for Science and Technology and grant no. 19YF1441200 from
   Shanghai Sailing Plan Program. The Rapid Service Fees were funded by the
   authors. The funding organizations are public institutions and had no
   role in the design and conduct of the study; collection, management, and
   analysis of the data; or preparation, review, and approval of the
   manuscript.
CR Benedetto U, 2018, EUR J CARDIO-THORAC, V53, P1112, DOI 10.1093/ejcts/ezy167
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen RC, 2006, CHEST, V129, P1441, DOI 10.1378/chest.129.6.1441
   Goursaud S, 2020, J INFECTION, V81, pE89, DOI 10.1016/j.jinf.2020.05.023
   Han YY, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108413
   Haukoos JS, 2015, JAMA-J AM MED ASSOC, V314, P1637, DOI 10.1001/jama.2015.13480
   Horby P, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2021436, DOI 10.1056/NEJM0A2021436]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim SH, 2011, AM J RESP CRIT CARE, V183, P1207, DOI 10.1164/rccm.201101-0110OC
   Li H, 2020, LEUKEMIA, V34, P1503, DOI 10.1038/s41375-020-0848-3
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Ma SQ, 2020, J MED VIROL, V92, P2396, DOI 10.1002/jmv.26086
   National Health Commision of the People's Republic of China, 2020, NEW COR PNEUM PREV C
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1023
   Tang C, 2020, LANCET, V395, P1759, DOI 10.1016/S0140-6736(20)30749-2
   Veronese N, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00170
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2019, 166 WHO, V166
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang SS, 2020, CAN J ANESTH, V67, P1462, DOI 10.1007/s12630-020-01700-w
   Yang ZW, 2020, J INFECTION, V81, pE13, DOI 10.1016/j.jinf.2020.03.062
   Ye ZK, 2020, CAN MED ASSOC J, V192, pE756, DOI 10.1503/cmaj.200645
   Yuan Mingli, 2020, Shock, V54, P638, DOI 10.1097/SHK.0000000000001574
   Zha L, 2020, MED J AUSTRALIA, V212, P416, DOI 10.5694/mja2.50577
NR 25
TC 9
Z9 9
U1 1
U2 1
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 2193-8229
EI 2193-6382
J9 INFECT DIS THER
JI Infect. Dis. Ther.
PD DEC
PY 2020
VL 9
IS 4
BP 823
EP 836
DI 10.1007/s40121-020-00332-3
EA SEP 2020
PG 14
WC Infectious Diseases
SC Infectious Diseases
GA OU0TA
UT WOS:000565471500001
PM 32880102
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bhandari, S
   Rankawat, G
   Singh, A
   Gupta, V
   Kakkar, S
AF Bhandari, Sudhir
   Rankawat, Govind
   Singh, Ajeet
   Gupta, Vishal
   Kakkar, Shivankan
TI Impact of glycemic control in diabetes mellitus on management of
   COVID-19 infection
SO INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES
LA English
DT Article
DE COVID-19; Diabetes mellitus; HbA1c; Glycemic control; Management
ID SARS CORONAVIRUS; WUHAN
AB Background Diabetes mellitus may be associated with increased severity and enhanced mortality in COVID-19 infections. The present study was undertaken to evaluate the clinical presentation, laboratory parameters, radiological imaging, management, and outcome of COVID-19 infection in patients of diabetes mellitus and its association with glycemic control. Methods The present study was designed to evaluate the difference between uncontrolled and controlled diabetes for COVID-19 manifestations by enrolling 80 admitted COVID-19 patients. Patients were categorized into two groups, where group 1 had patients with uncontrolled diabetes as indicated by HbA1c > 8 g% and group 2 had patients with controlled diabetes as indicated by HbA1c < 8 g%. Information concerning medical history, clinical manifestations, laboratory findings, radiological imaging, management, and outcome was extracted from medical records for evaluation, interpretation, and association among both the groups. Results COVID-19 patients with uncontrolled diabetes exhibited a severe symptomatic presentation, excessive uncontrolled inflammatory responses, and hypercoagulable state. Total leukocyte count, neutrophil-lymphocyte ratio, serum levels of IL-6, FDP, and D-dimer were significantly raised (p < 0.05) in case of uncontrolled diabetes as compared with controlled diabetes. Radiological findings detected by chest radiograph and computed tomography chest suggested severe lung involvement in uncontrolled diabetes. COVID-19 patients with uncontrolled diabetes required intensive treatment as compared with controlled diabetes group in terms of insulin therapy (p = 0.0226) and non-invasive ventilation (p = 0.0292). Patients with uncontrolled diabetes had higher mortality (p = 0.0375) and required prolonged hospitalization (p = 0.0479) as compared with controlled diabetes group. Conclusion From the current study, it can be concluded that uncontrolled diabetic condition might be a risk factor for severity and morbidity of COVID-19 patients. Uncontrolled diabetes mellitus might be responsible for an overall higher susceptibility for COVID-19 infection and severity in terms of symptomatic presentation, inflammatory storm, rapid pulmonary invasion, requirement of more intensive treatment, and a poor outcome.
C1 [Bhandari, Sudhir; Rankawat, Govind; Singh, Ajeet; Gupta, Vishal] SMS Med Coll & Attached Grp Hosp, Dept Gen Med, Jaipur, Rajasthan, India.
   [Kakkar, Shivankan] SMS Med Coll & Attached Grp Hosp, Dept Pharmacol, Jaipur, Rajasthan, India.
RP Rankawat, G (corresponding author), SMS Med Coll & Attached Grp Hosp, Dept Gen Med, Jaipur, Rajasthan, India.
EM drs_bhandari@yahoo.com; govindrankawat@gmail.com;
   dr.ajeetsingh@yahoo.com; drvishalguptamd@rediffmail.com;
   drshivankan@gmail.com
CR Anjana RM, 2017, LANCET DIABETES ENDO, V5, P585, DOI 10.1016/S2213-8587(17)30174-2
   [Anonymous], COR DIS COVID 19 DAS
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Hodgson K, 2015, IMMUNOLOGY, V144, P171, DOI 10.1111/imm.12394
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Knapp S, 2013, GERONTOLOGY, V59, P99, DOI 10.1159/000345107
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Meshkani R, 2016, CLIN CHIM ACTA, V462, P77, DOI 10.1016/j.cca.2016.08.015
   Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633
   Peng QY, 2020, INTENS CARE MED, V46, P849, DOI 10.1007/s00134-020-05996-6
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Shu CJ, 2012, SEMIN IMMUNOL, V24, P436, DOI 10.1016/j.smim.2012.12.001
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Tikellis Chris, 2012, Int J Pept, V2012, P256294, DOI 10.1155/2012/256294
   Warren MA, 2018, THORAX, V73, P840, DOI 10.1136/thoraxjnl-2017-211280
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
   Yang JK, 2010, ACTA DIABETOL, V47, P193, DOI 10.1007/s00592-009-0109-4
NR 20
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0973-3930
EI 1998-3832
J9 INT J DIABETES DEV C
JI Int. Diabetes Dev. Ctries.
PD SEP
PY 2020
VL 40
IS 3
BP 340
EP 345
DI 10.1007/s13410-020-00868-7
EA SEP 2020
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NS7PB
UT WOS:000565500000001
PM 32905072
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Isoletta, E
   Vassallo, C
   Brazzelli, V
   Giorgini, C
   Tomasini, CF
   Sabena, A
   Perlini, S
   De Silvestri, A
   Barruscotti, S
AF Isoletta, Eugenio
   Vassallo, Camilla
   Brazzelli, Valeria
   Giorgini, Chiara
   Tomasini, Carlo Francesco
   Sabena, Anna
   Perlini, Stefano
   De Silvestri, Annalisa
   Barruscotti, Stefania
TI Emergency accesses in Dermatology Department during the Covid-19
   pandemic in a referral third level center in the north of Italy
SO DERMATOLOGIC THERAPY
LA English
DT Article; Early Access
DE Covid-19; dermatology; emergency consultations; emergency department;
   SARS-CoV-2
AB During the lockdown period, most planned visits have been postponed and the number of accesses to emergency department (ED) has dramatically reduced. The aim of our study is to analyze the impact of the lockdown on the number, type, and severity of Dermatological ED diagnosis. We performed a retrospective review of all dermatological consultations in the ED of IRCSS San Matteo during the lockdown period in Italy (February 22-May 3 2020) and compared them with those from the same period in 2019. We noticed a sharply reduction in the number of dermatological consultations requested in the ED: from 164 patients in 2019 to 33 in 2020. Some diagnostic categories showed a significant difference with a higher incidence of vasculopathic lesions (0.6% vs 12.1%,P< .0001), urticarial rashes (8.5% vs 21.2%,P= .03), and scabies (3% vs 12.1%,P= .023). We observed an increase in the proportion of patients starting medications, before coming to the ED 26.2% in 2019 vs 66.7% in 2020 (P< .001). Furthermore, we noticed a significant increase in the average complexity of cases presenting to the ED in 2020, as proven by the increased need for biopsies and systemic therapy.
C1 [Isoletta, Eugenio; Vassallo, Camilla; Brazzelli, Valeria; Giorgini, Chiara; Tomasini, Carlo Francesco; Barruscotti, Stefania] IRCCS Fdn Policlin San Matteo, Inst Dermatol, Dept Clin Surg Diagnost & Pediat Sci, I-27100 Pavia, Italy.
   [Sabena, Anna; Perlini, Stefano] IRCCS Fdn Policlin San Matteo, Emergency Dept, Pavia, Italy.
   [Sabena, Anna; Perlini, Stefano] Univ Pavia, Internal Med Dept, Pavia, Italy.
   [De Silvestri, Annalisa] IRCCS Fdn Policlin San Matteo, Clin Epidemiol & Biometry Unit, Pavia, Italy.
   [Barruscotti, Stefania] Univ Pavia, PhD Expt Med, Viale Golgi 19, I-27100 Pavia, Italy.
RP Barruscotti, S (corresponding author), IRCCS Fdn Policlin San Matteo, Inst Dermatol, Dept Clin Surg Diagnost & Pediat Sci, I-27100 Pavia, Italy.; Barruscotti, S (corresponding author), Univ Pavia, PhD Expt Med, Viale Golgi 19, I-27100 Pavia, Italy.
EM stefania.barruscotti@hotmail.it
RI De Silvestri, Annalisa/I-6024-2014
OI De Silvestri, Annalisa/0000-0003-3128-8441
CR Asperges E, 2020, J HOSP INFECT, V105, P477, DOI 10.1016/j.jhin.2020.03.020
   Bouaziz JD, 2020, J EUR ACAD DERMATOL, V34, pE451, DOI 10.1111/jdv.16544
   Cao YB, 2020, ACAD EMERG MED, V27, P309, DOI 10.1111/acem.13951
   De Filippo O, 2020, NEW ENGL J MED, V383, P88, DOI 10.1056/NEJMc2009166
   Giacalone S, 2020, INT J DERMATOL, V59, pE269, DOI 10.1111/ijd.15005
   Giacalone S, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13630
   Henry D, 2020, J EUR ACAD DERMATOL, V34, pE244, DOI 10.1111/jdv.16472
   Masroor S, 2020, J CARDIAC SURG, V35, P1345, DOI 10.1111/jocs.14638
   Metzler B, 2020, EUR HEART J, V41, P1852, DOI 10.1093/eurheartj/ehaa314
   Nunez JH, 2020, INJURY, V51, P1414, DOI 10.1016/j.injury.2020.05.016
   Pelloni L, 2019, DERMATOLOGY, V235, P243, DOI 10.1159/000498850
   Rubegni P, 2015, J EUR ACAD DERMATOL, V29, P164, DOI 10.1111/jdv.12513
   Wee LE, 2020, ACAD EMERG MED, V27, P379, DOI 10.1111/acem.13984
   Wollina U, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13549
NR 14
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1396-0296
EI 1529-8019
J9 DERMATOL THER
JI Dermatol. Ther.
AR e14027
DI 10.1111/dth.14027
EA SEP 2020
PG 3
WC Dermatology
SC Dermatology
GA NI5GQ
UT WOS:000565380400001
PM 32681752
OA Green Accepted, Bronze
DA 2021-01-01
ER

PT J
AU Baldassarre, A
   Paolini, A
   Bruno, SP
   Felli, C
   Tozzi, AE
   Masotti, A
AF Baldassarre, Antonella
   Paolini, Alessandro
   Bruno, Stefania Paola
   Felli, Cristina
   Tozzi, Alberto Eugenio
   Masotti, Andrea
TI Potential use of noncoding RNAs and innovative therapeutic strategies to
   target the 5'UTR of SARS-CoV-2
SO EPIGENOMICS
LA English
DT Article
DE 5'UTR; COVID-19; GapmeRs; miRNAs; RNAi; SARS-CoV; SARS-CoV-2
ID 5'-UNTRANSLATED REGION; SARS CORONAVIRUS; GENOME SEQUENCE; STEM-LOOP;
   VIRUS; EXPRESSION; SIRNAS; REPLICATION; MIPOMERSEN; INHIBITION
AB After the increasing number of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections all over the world, researchers and clinicians are struggling to find a vaccine or innovative therapeutic strategies to treat this viral infection. The severe acute respiratory syndrome coronavirus infection that occurred in 2002, Middle East respiratory syndrome (MERS) and other more common infectious diseases such as hepatitis C virus, led to the discovery of many RNA-based drugs. Among them, siRNAs and antisense locked nucleic acids have been demonstrated to have effective antiviral effects both in animal models and humans. Owing to the high genomic homology of SARS-CoV-2 and severe acute respiratory syndrome coronavirus (80-82%) the use of these molecules could be employed successfully also to target this emerging coronavirus. Trying to translate this approach to treat COVID-19, we analyzed the common structural features of viral 5'UTR regions that can be targeted by noncoding RNAs and we also identified miRNAs binding sites suitable for designing RNA-based drugs to be employed successfully against SARS-CoV-2.
C1 [Baldassarre, Antonella; Paolini, Alessandro; Bruno, Stefania Paola; Felli, Cristina; Tozzi, Alberto Eugenio; Masotti, Andrea] Childrens Hosp Bambino Gesu IRCCS, Res Labs, Vle San Paolo 15, I-00146 Rome, Italy.
   [Baldassarre, Antonella; Paolini, Alessandro; Bruno, Stefania Paola; Felli, Cristina; Tozzi, Alberto Eugenio; Masotti, Andrea] Multifactorial & Complex Phenotype Res Area, Vle San Paolo 15, I-00146 Rome, Italy.
RP Masotti, A (corresponding author), Childrens Hosp Bambino Gesu IRCCS, Res Labs, Vle San Paolo 15, I-00146 Rome, Italy.; Masotti, A (corresponding author), Multifactorial & Complex Phenotype Res Area, Vle San Paolo 15, I-00146 Rome, Italy.
EM andrea.masotti@opbg.net
RI Tozzi, Alberto Eugenio/F-9494-2012; Paolini, Alessandro/H-2905-2016
OI Tozzi, Alberto Eugenio/0000-0002-6884-984X; Paolini,
   Alessandro/0000-0003-4354-9100; Bruno, Stefania
   Paola/0000-0002-0478-6296
FU Italian Ministry of HealthMinistry of Health, Italy
FX The authors thank the Italian Ministry of Health for financing (Ricerca
   Corrente 2020). The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript apart from those disclosed.
CR Adams D, 2018, NEW ENGL J MED, V379, P11, DOI 10.1056/NEJMoa1716153
   Adams D, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0948-5
   Alfano LN, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015858
   Bates JT, 2016, VACCINE, V34, P950, DOI 10.1016/j.vaccine.2015.12.045
   Benson MD, 2019, AMYLOID, V26, P27, DOI 10.1080/13506129.2019.1582497
   Boyer DS, 2014, BRIT J OPHTHALMOL, V98, P1543, DOI 10.1136/bjophthalmol-2013-304075
   Brian DA, 2005, CURR TOP MICROBIOL, V287, P1, DOI 10.1007/3-540-26765-4_1
   Brinton MA, 2019, CURR OPIN VIROL, V35, pIII, DOI [10.1016/j.coviro.2019.05.011, 10.1016/j.coyiro.2019.05.011]
   Bruscella P, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00824
   Cameron CE, 2009, VIRAL GENOME REPLICATION, P1, DOI 10.1007/b135974
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chang Z, 2006, GENE THER, V13, P871
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chiriboga CA, 2016, NEUROLOGY, V86, P890, DOI 10.1212/WNL.0000000000002445
   Cohn L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00255
   de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310
   Du Pont V, 2019, CURR OPIN VIROL, V35, P1, DOI 10.1016/j.coviro.2018.12.009
   Duell PB, 2016, J CLIN LIPIDOL, V10, P1011, DOI 10.1016/j.jacl.2016.04.013
   Dutkiewicz M, 2008, FEBS LETT, V582, P3061, DOI 10.1016/j.febslet.2008.07.051
   Edwards MR, 2019, CURR OPIN VIROL, V35, P42, DOI 10.1016/j.coviro.2019.03.001
   Fields BN, 2001, FIELDS VIROLOGY
   Finkel RS, 2016, LANCET, V388, P3017, DOI 10.1016/S0140-6736(16)31408-8
   Grabbe S, 2016, NANOMEDICINE-UK, V11, P2723, DOI 10.2217/nnm-2016-0275
   Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791
   Haupenthal J, 2006, BIOCHEM PHARMACOL, V71, P702, DOI 10.1016/j.bcp.2005.11.015
   Iwamoto N, 2017, NAT BIOTECHNOL, V35, P845, DOI 10.1038/nbt.3948
   Janssen HLA, 2013, NEW ENGL J MED, V368, P1685, DOI 10.1056/NEJMoa1209026
   Kernan NA, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.27269
   Kernan NA, 2018, BRIT J HAEMATOL, V181, P816, DOI 10.1111/bjh.15267
   Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135
   Khvorova A, 2017, NAT BIOTECHNOL, V35, P238, DOI 10.1038/nbt.3765
   Lai MMC, 1997, ADV VIRUS RES, V48, P1, DOI 10.1016/S0065-3527(08)60286-9
   Laxton C, 2011, ANTIMICROB AGENTS CH, V55, P3105, DOI 10.1128/AAC.00222-11
   Levanova A, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02151
   Li BJ, 2005, NAT MED, V11, P944, DOI 10.1038/nm1280
   Li LC, 2008, J MOL BIOL, V377, P790, DOI 10.1016/j.jmb.2008.01.068
   Li T, 2005, GENE THER, V12, P751, DOI 10.1038/sj.gt.3302479
   Liu PH, 2007, RNA, V13, P763, DOI 10.1261/rna.261807
   Ludwig N, 2016, NUCLEIC ACIDS RES, V44, P3865, DOI 10.1093/nar/gkw116
   Lundstrom K, 2018, MOLECULES, V23, DOI 10.3390/molecules23123310
   Lundstrom K, 2016, FUTURE VIROL, V11, P345, DOI 10.2217/fvl-2016-0028
   Machlin ES, 2011, P NATL ACAD SCI USA, V108, P3193, DOI 10.1073/pnas.1012464108
   Madhugiri R, 2018, VIROLOGY, V517, P44, DOI 10.1016/j.virol.2017.11.025
   MAKINO S, 1986, P NATL ACAD SCI USA, V83, P4204, DOI 10.1073/pnas.83.12.4204
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Mendell JR, 2013, ANN NEUROL, V74, P637, DOI 10.1002/ana.23982
   Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428
   Perche F, 2013, J DRUG DELIV, V2013, DOI 10.1155/2013/705265
   Presloid JB, 2015, VIRUSES-BASEL, V7, P3226, DOI 10.3390/v7062768
   Pruijssers AJ, 2019, CURR OPIN VIROL, V35, P57, DOI 10.1016/j.coviro.2019.04.002
   Raal FJ, 2016, J CLIN LIPIDOL, V10, P860, DOI 10.1016/j.jacl.2016.02.018
   Richardson PG, 2016, BLOOD, V127, P1656, DOI 10.1182/blood-2015-10-676924
   Rinaldi M, 2013, RETINA-J RET VIT DIS, V33, P397, DOI 10.1097/IAE.0b013e318261a73c
   Sardh E, 2019, NEW ENGL J MED, V380, P549, DOI 10.1056/NEJMoa1807838
   Sawicki SG, 1998, ADV EXP MED BIOL, V440, P215
   SAWICKI SG, 1990, J VIROL, V64, P1050, DOI 10.1128/JVI.64.3.1050-1056.1990
   Sawicki SG, 2007, J VIROL, V81, P20, DOI 10.1128/JVI.01358-06
   Setten RL, 2019, NAT REV DRUG DISCOV, V18, P421, DOI 10.1038/s41573-019-0017-4
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shen W, 2019, NAT BIOTECHNOL, V37, P640, DOI 10.1038/s41587-019-0106-2
   Shen XL, 2018, NUCLEIC ACIDS RES, V46, P1584, DOI 10.1093/nar/gkx1239
   Solomon SD, 2019, CIRCULATION, V139, P431, DOI 10.1161/CIRCULATIONAHA.118.035831
   Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775
   Stanton R, 2012, NUCLEIC ACID THER, V22, P344, DOI 10.1089/nat.2012.0366
   Suhr OB, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0326-6
   Swayze EE, 2007, NUCLEIC ACIDS RES, V35, P687, DOI 10.1093/nar/gkl1071
   Taiaroa G, 2020, BIORXIV, DOI [10.1101/2020.03.05.976167, DOI 10.1101/2020.03.05.976167]
   Tan YW, 2012, NUCLEIC ACIDS RES, V40, P5065, DOI 10.1093/nar/gks165
   Te Helen S, 2007, Gastroenterol Hepatol (N Y), V3, P218
   van Poelgeest EP, 2013, AM J KIDNEY DIS, V62, P796, DOI 10.1053/j.ajkd.2013.02.359
   Voshavar C, 2019, CURR TOP MED CHEM, V19, P1571, DOI 10.2174/1568026619666190619115243
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang Y, 2010, MOLECULES, V15, P7197, DOI 10.3390/molecules15107197
   Wu CJ, 2006, EXPERT OPIN INV DRUG, V15, P89, DOI 10.1517/13543784.15.2.89
   Wu CJ, 2005, ANTIVIR RES, V65, P45, DOI 10.1016/j.antiviral.2004.09.005
   Yang D, 2015, VIRUS RES, V206, P120, DOI 10.1016/j.virusres.2015.02.025
   Zeng FY, 2003, EXP BIOL MED, V228, P866, DOI 10.1177/15353702-0322807-13
   Zhang Jian-jun, 2006, Sichuan Da Xue Xue Bao Yi Xue Ban, V37, P5
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhang S, 2018, INFORMATICS-BASEL, V5, DOI 10.3390/informatics5010004
   Zhang YJ, 2004, FEBS LETT, V560, P141, DOI 10.1016/S0014-5793(04)00087-0
   Zheng BJ, 2004, ANTIVIR THER, V9, P365
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zou J, 2019, CURR OPIN VIROL, V35, P19, DOI 10.1016/j.coviro.2019.01.005
NR 85
TC 3
Z9 3
U1 4
U2 4
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-1911
EI 1750-192X
J9 EPIGENOMICS-UK
JI Epigenomics
PD AUG
PY 2020
VL 12
IS 15
DI 10.2217/epi-2020-0162
EA SEP 2020
PG 14
WC Genetics & Heredity
SC Genetics & Heredity
GA NN3MV
UT WOS:000565250900001
PM 32875809
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Vasanthakumar, N
AF Vasanthakumar, Natesan
TI Beta-Adrenergic Blockers as a Potential Treatment for COVID-19 Patients
SO BIOESSAYS
LA English
DT Article
DE ACE2; ARDS; beta-adrenergic blockers; COVID-19; pulmonary embolism;
   SARS-CoV-2; septic shock
ID PROPRANOLOL; EXPRESSION; INTERLEUKIN-6; PROTEIN; NOREPINEPHRINE;
   ACTIVATION; OXYGEN; SHOCK; ARDS; ECMO
AB More than 15 million people have been affected by coronavirus disease 2019 (COVID-19) and it has caused 640 016 deaths as of July 26, 2020. Currently, no effective treatment option is available for COVID-19 patients. Though many drugs have been proposed, none of them has shown particular efficacy in clinical trials. In this article, the relationship between the Adrenergic system and the renin-angiotensin-aldosterone system (RAAS) is focused in COVID-19 and a vicious circle consisting of the Adrenergic system-RAAS-Angiotensin converting enzyme 2 (ACE2)-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (which is referred to as the "ARAS loop") is proposed. Hyperactivation of the ARAS loop may be the underlying pathophysiological mechanism in COVID-19, and beta-adrenergic blockers are proposed as a potential treatment option. Beta-adrenergic blockers may decrease the SARS-CoV-2 cellular entry by decreasing ACE2 receptors expression and cluster of differentiation 147 (CD147) in various cells in the body. Beta-adrenergic blockers may decrease the morbidity and mortality in COVID-19 patients by preventing or reducing acute respiratory distress syndrome (ARDS) and other complications. Retrospective and prospective clinical trials should be conducted to check the validity of the hypothesis. Also see the video abstract here .
C1 [Vasanthakumar, Natesan] SASTRA Deemed Univ, Sch Chem & Biotechnol, Thanjavur 613401, Tamil Nadu, India.
RP Vasanthakumar, N (corresponding author), SASTRA Deemed Univ, Sch Chem & Biotechnol, Thanjavur 613401, Tamil Nadu, India.
EM vasanth.dr@gmail.com
CR Al-Qadi MO, 2015, AM J RESP CRIT CARE, V191
   Ali-Saleh M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158652
   Bunge JJH, 2019, J CRIT CARE, V53, P248, DOI 10.1016/j.jcrc.2019.06.024
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Chen C, 2012, BRIT J PHARMACOL, V166, P676, DOI 10.1111/j.1476-5381.2011.01785.x
   Chen IY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00050
   Chen Y, 2003, J BIOL CHEM, V278, P17036, DOI 10.1074/jbc.M210429200
   Coppola S, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0803-2
   Deftereos SG, 2020, HELL J CARDIOL, V61, P42, DOI 10.1016/j.hjc.2020.03.002
   Deten A, 2003, MOL CELL BIOCHEM, V251, P127, DOI 10.1023/A:1025498319598
   Doerschug KC, 2010, CRIT CARE, V14, DOI 10.1186/cc8887
   Doo YC, 2001, AM J CARDIOL, V88, P422, DOI 10.1016/S0002-9149(01)01693-9
   Esler M, 2020, J HYPERTENS, V38, P781, DOI 10.1097/HJH.0000000000002450
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Gandhi RT, 2020, N ENGL J MED
   Greene KE, 1999, AM J RESP CRIT CARE, V160, P1843, DOI 10.1164/ajrccm.160.6.9901117
   Grillet F, 2020, RADIOLOGY, V296, pE186, DOI 10.1148/radiol.2020201544
   GROVES AC, 1973, ANN SURG, V178, P102, DOI 10.1097/00000658-197307000-00020
   Gruszecki M, 2001, POL J PHARMACOL, V53, P5
   Hajighasemi Fatemeh, 2016, Int J Hematol Oncol Stem Cell Res, V10, P99
   Henry BM, 2020, J CRIT CARE, V58, P27, DOI 10.1016/j.jcrc.2020.03.011
   Henry BM, 2020, LANCET RESP MED, V8, pE24, DOI 10.1016/S2213-2600(20)30119-3
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoppener MR, 2004, J THROMB HAEMOST, V2, P1316, DOI 10.1111/j.1538-7836.2004.00851.x
   KHAMBATTA HJ, 1987, BRIT J ANAESTH, V59, P1171, DOI 10.1093/bja/59.9.1171
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Leonard-Lorant I, 2020, RADIOLOGY, V296, pE189, DOI 10.1148/radiol.2020201561
   Mac Sweeney R, 2016, LANCET, V388, P2416, DOI 10.1016/S0140-6736(16)00578-X
   Martin C, 2015, SHOCK, V44, P305, DOI 10.1097/SHK.0000000000000426
   MASON JW, 1979, J HUM STRESS, V5, P18, DOI 10.1080/0097840X.1979.9934524
   Matsumura Takayoshi, 2002, J Cardiol, V39, P253
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Namendys-Silva SA, 2020, HEART LUNG, V49, P348, DOI 10.1016/j.hrtlng.2020.03.012
   Natesan V., 2018, INT J CLIN EXP PHYSL, V5, P3
   Nielsen Anne Orholm, 2019, EClinicalMedicine, V7, P21, DOI 10.1016/j.eclinm.2019.01.004
   Noveanu M, 2010, CRIT CARE, V14, DOI 10.1186/cc9317
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430
   Qian GD, 2020, INT J NEUROSCI, DOI [10.1080/00207454.2020.1758088, 10.1080/23744235.2020.1748705]
   Rabelo LA, 2011, HYPERTENS RES, V34, P154, DOI 10.1038/hr.2010.235
   Rassler B, 2012, SCIENTIFICA, V2012, DOI 10.6064/2012/829504
   Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Singer M, 2007, LANCET, V370, P636, DOI 10.1016/S0140-6736(07)61317-8
   Siu KL, 2019, FASEB J, V33, P8865, DOI 10.1096/fj.201802418R
   Snyder EM, 2011, PHARMACOTHERAPY, V31, P748, DOI 10.1592/phco.31.8.748
   Stolk RF, 2016, AM J RESP CRIT CARE, V194, P550, DOI 10.1164/rccm.201604-0862CP
   Tan KQ, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2562-y
   Ulrich H, 2020, STEM CELL REV REP, V16, P434, DOI 10.1007/s12015-020-09976-7
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   VINCENT JL, 1985, CHEST, V88, P558, DOI 10.1378/chest.88.4.558
   von Kanel R, 2000, EUR J HAEMATOL, V65, P357, DOI 10.1034/j.1600-0609.2000.065006357.x
   Wang CF, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102833
   Wang K, 2020, SARS COV 2 INVADES H
   Woiciechowsky C, 2004, MED SCI MONITOR, V10, pBR325
   Wong WT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01920
   Wood G, 1997, CRIT CARE MED, V25, P1807, DOI 10.1097/00003246-199711000-00017
   Wu C., 2014, ACTA PHARM SIN B, V10, P766
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xie W, 2013, BRIT J DERMATOL, V168, P739, DOI 10.1111/bjd.12193
   Yamamoto T, 1997, JPN J PHARMACOL, V73, P33, DOI 10.1254/jjp.73.33
   Yang Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1413-8
   Yu J, 2019, SHOCK, V51, P557, DOI 10.1097/SHK.0000000000001244
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang HL, 2020, ANN INTERN MED, V172, P629, DOI 10.7326/M20-0533
   Zhang X, 2007, VIROLOGY, V365, P324, DOI 10.1016/j.virol.2007.04.009
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhou YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097788
   Zhu Z, 2020, INT J INFECT DIS, V95, P332, DOI 10.1016/j.ijid.2020.04.041
NR 70
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0265-9247
EI 1521-1878
J9 BIOESSAYS
JI Bioessays
PD NOV
PY 2020
VL 42
IS 11
AR 2000094
DI 10.1002/bies.202000094
EA SEP 2020
PG 9
WC Biochemistry & Molecular Biology; Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA OK3HY
UT WOS:000564908800001
PM 32815593
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Srinivasan, P
   Smolke, CD
AF Srinivasan, Prashanth
   Smolke, Christina D.
TI Biosynthesis of medicinal tropane alkaloids in yeast
SO NATURE
LA English
DT Article
ID IDENTIFICATION; EXPRESSION; SCOPOLAMINE; PLATFORM; ACYLTRANSFERASE;
   HYOSCYAMINE; TRANSPORTER; MULTIDRUG; LITTORINE; NICOTINE
AB The alkaloid drugs hyoscyamine and scopolamine are synthesized from sugars and amino acids in yeast, using 26 genes from yeast, plants, bacteria and animals, protein engineering and a vacuole transporter to enable functional expression of a key acyltransferase.
   Tropane alkaloids from nightshade plants are neurotransmitter inhibitors that are used for treating neuromuscular disorders and are classified as essential medicines by the World Health Organization(1,2). Challenges in global supplies have resulted in frequent shortages of these drugs(3,4). Further vulnerabilities in supply chains have been revealed by events such as the Australian wildfires(5)and the COVID-19 pandemic(6). Rapidly deployable production strategies that are robust to environmental and socioeconomic upheaval(7,8)are needed. Here we engineered baker's yeast to produce the medicinal alkaloids hyoscyamine and scopolamine, starting from simple sugars and amino acids. We combined functional genomics to identify a missing pathway enzyme, protein engineering to enable the functional expression of an acyltransferase via trafficking to the vacuole, heterologous transporters to facilitate intracellular routing, and strain optimization to improve titres. Our integrated system positions more than twenty proteins adapted from yeast, bacteria, plants and animals across six sub-cellular locations to recapitulate the spatial organization of tropane alkaloid biosynthesis in plants. Microbial biosynthesis platforms can facilitate the discovery of tropane alkaloid derivatives as new therapeutic agents for neurological disease and, once scaled, enable robust and agile supply of these essential medicines.
C1 [Srinivasan, Prashanth; Smolke, Christina D.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.
   [Smolke, Christina D.] Chan Zuckerberg Biohub, San Francisco, CA USA.
RP Smolke, CD (corresponding author), Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA.; Smolke, CD (corresponding author), Chan Zuckerberg Biohub, San Francisco, CA USA.
EM csmolke@stanford.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA; Natural Sciences and
   Engineering Research Council of CanadaNatural Sciences and Engineering
   Research Council of CanadaCGIAR
FX We thank A. Cravens for the yeast multiplex CRISPR-Cas9/sgRNA plasmids
   (pCS3410, 3411, 3414 and 3700-3703); T. Lozanoski (Jarosz laboratory)
   for a plasmid containing yeast codon-optimized mVenus; J. Payne for
   assistance with the generation of DFT energy-optimized ligand structures
   for docking studies; P. Dykstra for assistance with fluorescence
   microscopy and the Stanford Cell Sciences Imaging Facility for access to
   microscopy equipment and training; R. Nett for suggestions regarding de
   novo transcriptome assembly using Trinity; W. Cody and the Sattely
   laboratory for providing N. benthamiana plants, Agrobacterium strains, a
   pEAQ-HT binary vector backbone plasmid, and suggestions for tobacco
   agroinfiltration experiments; D. Endy and J. Payne for discussions and
   feedback in the preparation of this manuscript. This work was supported
   by the National Institutes of Health and the Natural Sciences and
   Engineering Research Council of Canada (doctoral postgraduate
   scholarship to P.S.).
CR Agrawal G., 2020, WINNING COVID 19 IMP
   Alberti S, 2007, YEAST, V24, P913, DOI 10.1002/yea.1502
   Allen F, 2014, NUCLEIC ACIDS RES, V42, pW94, DOI 10.1093/nar/gku436
   Amberg DC, 2006, COLD SPRING HARB PRO, V2006, ppdbprot4165
   American Society of Anesthesiologists (ASA), 2020, ASA URG FED GOV TAK
   Bedewitz MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07671-3
   Bomati EK, 2005, PLANT CELL, V17, P1598, DOI 10.1105/tpc.104.029983
   Bontpart T, 2015, NEW PHYTOL, V208, P695, DOI 10.1111/nph.13498
   Brown S, 2015, P NATL ACAD SCI USA, V112, P3205, DOI 10.1073/pnas.1423555112
   Bryant DM, 2017, CELL REP, V18, P762, DOI 10.1016/j.celrep.2016.12.063
   Cardillo AB, 2017, BIOCHEM ENG J, V125, P180, DOI 10.1016/j.bej.2017.06.013
   Carqueijeiro I, 2018, METHODS PROTOCOLS, P33
   Cravens A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09848-w
   Dastmalchi M, 2019, PLANT PHYSIOL, V181, P916, DOI 10.1104/pp.19.00565
   Entian KD, 2007, METHOD MICROBIOL, V36, P629, DOI 10.1016/S0580-9517(06)36025-4
   Fujii T, 2011, BBA-PROTEINS PROTEOM, V1814, P1669, DOI 10.1016/j.bbapap.2011.05.024
   Galanie S, 2015, SCIENCE, V349, P1095, DOI 10.1126/science.aac9373
   Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883
   Grynkiewicz G, 2008, PHARMACOL REP, V60, P439
   Guijas C, 2018, ANAL CHEM, V90, P3156, DOI 10.1021/acs.analchem.7b04424
   Haas BJ, 2013, NAT PROTOC, V8, P1494, DOI 10.1038/nprot.2013.084
   Hahn S. M, 2020, FDA STATEMENT CORONA
   HASHIMOTO T, 1993, FEBS LETT, V329, P35, DOI 10.1016/0014-5793(93)80187-Y
   Hu Y, 2018, METAB ENG, V45, P51, DOI 10.1016/j.ymben.2017.11.008
   Kallberg M, 2012, NAT PROTOC, V7, P1511, DOI 10.1038/nprot.2012.085
   Kohnen KL, 2018, PLANT CELL PHYSIOL, V59, P107, DOI 10.1093/pcp/pcx165
   Kohnen-Johannsen KL, 2019, MOLECULES, V24, DOI 10.3390/molecules24040796
   Kushnirov VV, 2000, YEAST, V16, P857, DOI 10.1002/1097-0061(20000630)16:9<857::AID-YEA561>3.0.CO;2-B
   KWIATKOWSKI TJ, 1990, NUCLEIC ACIDS RES, V18, P7191, DOI 10.1093/nar/18.23.7191
   LESUISSE E, 1990, BIOCHIM BIOPHYS ACTA, V1038, P253, DOI 10.1016/0167-4838(90)90213-Y
   Li JF, 2018, J BIOTECHNOL, V281, P193, DOI 10.1016/j.jbiotec.2018.05.011
   Li R, 2006, CHEM BIOL, V13, P513, DOI 10.1016/j.chembiol.2006.03.005
   Liu L, 2008, PROTEIN EXPRES PURIF, V62, P21, DOI 10.1016/j.pep.2008.07.010
   Matasci N, 2014, GIGASCIENCE, V3, DOI 10.1186/2047-217X-3-17
   MATSUDA J, 1991, J BIOL CHEM, V266, P9460
   Michigan State University, MED PLANT GEN RES
   Morita M, 2009, P NATL ACAD SCI USA, V106, P2447, DOI 10.1073/pnas.0812512106
   Nasomjai P, 2009, CHEMBIOCHEM, V10, P2382, DOI 10.1002/cbic.200900318
   NIH, MED PLANT RNA SEQ DA
   Ping Y, 2019, ACS SYNTH BIOL, V8, P1257, DOI 10.1021/acssynbio.9b00152
   Qiu F, 2020, NEW PHYTOL, V225, P1906, DOI 10.1111/nph.16317
   Qiu F, 2018, ORG LETT, V20, P7807, DOI 10.1021/acs.orglett.8b03236
   Redford K. H., 2019, GENETIC FRONTIERS CO
   Ro DK, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-83
   ROBERTS CJ, 1992, J CELL BIOL, V119, P69, DOI 10.1083/jcb.119.1.69
   Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004
   Ryan OW, 2014, ELIFE, V3, DOI 10.7554/eLife.03703
   Sainsbury F, 2009, PLANT BIOTECHNOL J, V7, P682, DOI 10.1111/j.1467-7652.2009.00434.x
   Sevin DC, 2017, NAT METHODS, V14, P187, DOI [10.1038/NMETH.4103, 10.1038/nmeth.4103]
   Shoji T, 2009, PLANT PHYSIOL, V149, P708, DOI 10.1104/pp.108.132811
   Srinivasan P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11588-w
   Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1
   Stehle F, 2008, FEBS J, V275, P775, DOI 10.1111/j.1742-4658.2007.06244.x
   Strasser R, 2016, GLYCOBIOLOGY, V26, P926, DOI 10.1093/glycob/cww023
   The Climate Council of Australia, 2019, THIS IS NOT NORM CLI
   Thodey K, 2014, NAT CHEM BIOL, V10, P837, DOI [10.1038/NCHEMBIO.1613, 10.1038/nchembio.1613]
   U.S. Food and Drug Administration, 2020, FDA DRUG SHORT ATR S
   U.S. Food and Drug Administration, FDA DRUG SHORT SCOP
   U.S. Food and Drug Administration, 2020, COR COV 19 UPD TAK F
   Ullrich SF, 2017, PHYTOCHEM REV, V16, P333, DOI 10.1007/s11101-016-9477-x
   Wallace W, 2001, BIOTECHNIQUES, V31, P1076, DOI 10.2144/01315bi01
   Wang HM, 2016, MICROB CELL FACT, V15, DOI 10.1186/s12934-016-0535-2
   Wang ZY, 2018, MICROB CELL FACT, V17, DOI 10.1186/s12934-018-0907-x
   Weigel D, 2006, CSH PROTOC, V2006, P4666, DOI DOI 10.1093/mp/sst004
   World Health Organisation, 2015, WHO MOD LIST ESS MED
   Zhang XQ, 2014, FEMS MICROBIOL LETT, V356, P89, DOI 10.1111/1574-6968.12483
   Zheng ZJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019030
NR 67
TC 4
Z9 4
U1 23
U2 23
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD SEP 24
PY 2020
VL 585
IS 7826
BP 614
EP +
DI 10.1038/s41586-020-2650-9
EA SEP 2020
PG 23
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NS9DW
UT WOS:000565516400001
PM 32879484
OA Bronze
DA 2021-01-01
ER

PT J
AU Mares, J
   Hartung, HP
AF Mares, Jan
   Hartung, Hans-Peter
TI Multiple sclerosis and COVID-19
SO BIOMEDICAL PAPERS-OLOMOUC
LA English
DT Article
DE coronavirus; COVID-19; multiple sclerosis; immunomodulatory therapy
AB This paper reviews currently available data on the novel coronavirus and clinical features of COVID-19, followed by a detailed section on possible modifications of immunomodulatory therapy in multiple sclerosis patients with COVID-19, based on what we know so far.There are discussed: (i) The COVID-19 disease (Epidemiological background SARS-CoV-1 coronavirus; Autoimmune response to COVID-19; Asymptomatic course; SARS-CoV-2 test; COVID-19 symptoms), (ii) Treatment of COVID-19 (Experimental plasma treatment; Antiviral therapy; Antimalarial treatment scheme; Biological treatment; Corticosteroid treatment; Symptomatic treatment; Vaccine preparation) and (iii) Multiple sclerosis and SARS-CoV-2 infection (Epidemiological recommendation).
C1 [Mares, Jan] Palacky Univ Olomouc, Fac Med & Dent, Dept Neurol, Olomouc, Czech Republic.
   [Mares, Jan] Univ Hosp Olomouc, Olomouc, Czech Republic.
   [Hartung, Hans-Peter] Heinrich Heine Univ Duesseldorf, Klin Neurol, Dusseldorf, Germany.
RP Mares, J (corresponding author), Palacky Univ Olomouc, Fac Med & Dent, Dept Neurol, Olomouc, Czech Republic.; Mares, J (corresponding author), Univ Hosp Olomouc, Olomouc, Czech Republic.
EM jan.mares@fnol.cz
CR American Chemical Society, 2020, MISS LINK COR JUMP B
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   [Anonymous], 2020, GRIFOLS          MAR
   [Anonymous], 2020, TREATMENTS COVID 19
   [Anonymous], 2020, SCI NEWS
   [Anonymous], 2020, WIKIPROJEKT SARS COV
   [Anonymous], 2020, MED XPRESS       MAR
   Assistance Publique-Hopitaux de Paris, 2020, COHORT MULTIPLE RAND
   Baker S., 2020, BUSINESS INSIDER
   Baumann Kreuziger L, 2020, COVID 19 VTE ANTICOA
   Belgium-FPS Health-DGM, 2020, PROSPECTIVE RANDOMIZ
   Botao X, 2020, RES GATE
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cha AE, 2020, WASHINGTON POST
   Chen S, 2020, S CHINA MORNING POST
   CTK, 2020, NOVINKY          MAR
   Cyranoski D, 2017, NATURE, V552, P15, DOI 10.1038/d41586-017-07766-9
   Cytodyn, 2020, SEV ILL COVID 19 PAT
   Dahm T, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/8562805
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Giovannoni G, 2020, MULT SCLER RELAT DIS, V39, DOI 10.1016/j.msard.2020.102073
   Gorbalenya AE, 2020, SEVERE ACUTE RESP SY, V5, P536, DOI [10.1101/2020.02.07.937862, DOI 10.1101/2020.02.07.937862]
   Hennigan Stephanie, 2008, Ther Clin Risk Manag, V4, P767
   Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008
   InflaRx GmbH, 2020, PRAGM AD OP LAB RAND
   Jin HJ, 2020, STROKE VASC NEUROL, V5, P146, DOI [10.1136/svn-2020-000382, 10.1136/svn-2020-000482]
   Kekrt L., 2020, CZECH SIGHT      FEB
   Khaliq R., 2020, ANADOLU AGENCY   APR
   Menachery VD, 2015, NAT MED, V21, P1508, DOI 10.1038/nm.3985
   MS Ireland, 2020, COVID 19 MS
   MS Trust, 2020, COR COVID 19 MULT SC
   Neurologicka sekce CSL JEP, 2020, AKTIVNI ZIVOT
   Nextrain team, 2020, GEN EP NOV COR GLOB
   Nishiura H, 2020, INT J INFECT DIS, V94, P154, DOI 10.1016/j.ijid.2020.03.020
   Paul Ehrlich Institute, 2020, 1 CLIN TRIAL COVID 1
   Qiu J., 2020, SCI AM
   RTDS Verein Engl. RTDS Asscociation, 2020, EXPL SAF TOL CLIN EF
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1023
   Scarborough R., 2020, WASHINGTON TIMES
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   SUKL, 2020, PREHL HODN LEC NEM C
   Swedish Orphan Biovitrum, 2020, SWEDISH ORPHAN BIOVI
   Taylor A., 2020, WASHINGTON POST
   University of Oxford, 2020, RAND EV COVID 19 THE
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wadman M, 2020, SCIENCE
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Weise E, 2020, US TODAY
   WHO, 2020, LAB TEST STRAT REC C
   WHO, 2020, 102 WHO
   WHO, 2020, Q A COR COVID 19
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xiao SY, 2020, J MED VIROL, V92, P464, DOI 10.1002/jmv.25702
   Yuen KS, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00404-4
   Zhang MY, 2005, CURR OPIN MOL THER, V7, P151
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 58
TC 0
Z9 0
U1 0
U2 0
PU PALACKY UNIV, MEDICAL FAC
PI OLOMOUC
PA CENTRAL LIBRARY, HNEVOTINSKA 3, OLOMOUC, 00000, CZECH REPUBLIC
SN 1213-8118
EI 1804-7521
J9 BIOMED PAP
JI Biomed. Pap-Olomouc
PD SEP
PY 2020
VL 164
IS 3
BP 217
EP 225
DI 10.5507/bp.2020.033
PG 9
WC Engineering, Biomedical; Medicine, Research & Experimental
SC Engineering; Research & Experimental Medicine
GA PA4ZK
UT WOS:000595645600001
PM 32686774
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Gurnani, B
   Kaur, K
AF Gurnani, Bharat
   Kaur, Kirandeep
TI Changing drug regimen during COVID-19 pandemic lockdown: An experience
   from a Tertiary Eye Care Hospital as a cornea specialist
SO INDIAN JOURNAL OF PHARMACOLOGY
LA English
DT Letter
C1 [Gurnani, Bharat] Aravind Eye Hosp & Post Grad Inst Ophthalmol, Dept Cornea & Refract Serv, Pondicherry, India.
   [Kaur, Kirandeep] Aravind Eye Hosp & Post Grad Inst Ophthalmol, Dept Pediat Ophthalmol & Strabismus, Pondicherry, India.
RP Gurnani, B (corresponding author), Aravind Eye Hosp & Post Grad Inst Ophthalmol, Cornea & Refract Serv, Pondicherry 05007, India.
EM drgurnanibharat25@gmail.com
CR Costedoat-Chalumeau N, 2015, CLIN REV ALLERG IMMU, V49, P317, DOI 10.1007/s12016-015-8469-8
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1168
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Narasimhan TE., BUSINESS STANDARD
NR 4
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0253-7613
EI 1998-3751
J9 INDIAN J PHARMACOL
JI Indian J. Pharmacol.
PD SEP-OCT
PY 2020
VL 52
IS 5
BP 435
EP 436
DI 10.4103/ijp.IJP_688_20
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA PG7UA
UT WOS:000599934900012
PM 33283776
DA 2021-01-01
ER

PT J
AU Ferrara, F
   La Porta, R
   Santilli, P
   D'Aiuto, V
   Vitiello, A
AF Ferrara, Francesco
   La Porta, Raffaele
   Santilli, Priscilla
   D'Aiuto, Vilma
   Vitiello, Antonio
TI Are multiple sclerosis therapies safe in severe acute respiratory
   syndrome coronavirus 2 times?
SO INDIAN JOURNAL OF PHARMACOLOGY
LA English
DT Letter
C1 [Ferrara, Francesco; Santilli, Priscilla; D'Aiuto, Vilma; Vitiello, Antonio] Usl Umbria 1, Dept Pharmaceut, Perugia, Italy.
   [La Porta, Raffaele] Asur Marche, Dept Clin Pathol, Macerata, Italy.
RP Ferrara, F (corresponding author), Usl Umbria 1, Dept Pharmaceut, Perugia, Italy.
EM francesco.ferrara@uslumbria1.it
CR Ferrara F, 2020, EUR J CLIN PHARMACOL, V76, P1615, DOI 10.1007/s00228-020-02947-4
   Vitiello A, 2020, EUR J PHARMACOL, V883, DOI 10.1016/j.ejphar.2020.173373
   Vitiello Antonio, 2020, BMJ Evid Based Med, DOI [10.1136/bmjebm-2020-111497, 10.1136/bmjebm-2020-111589]
   Vitiello A, 2020, ITAL J MED, V14, P88, DOI 10.4081/itjm.2020.1284
   Wijnands JMA, 2017, MULT SCLER J, V23, P1506, DOI 10.1177/1352458516681198
NR 5
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0253-7613
EI 1998-3751
J9 INDIAN J PHARMACOL
JI Indian J. Pharmacol.
PD SEP-OCT
PY 2020
VL 52
IS 5
BP 441
EP 442
DI 10.4103/ijp.IJP_417_20
PG 2
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA PG7UA
UT WOS:000599934900015
PM 33283779
DA 2021-01-01
ER

PT J
AU Velayos-Ortega, G
   Lopez-Carreno, R
AF Velayos-Ortega, Gema
   Lopez-Carreno, Rosana
TI Most cited journals in coronavirus patents according to Lens.org
SO PROFESIONAL DE LA INFORMACION
LA Spanish
DT Article
DE Patents; Citations; References; Impact; Non patent literature; Scholarly
   publications; NPL; Patent search engines; Lens; JCR; Coronavirus;
   Covid-19
AB The scientific literature cited in patents on coronaviruses is analyzed with the aim of determining its characteristics, identifying the main journals, and evaluating the possible correspondence between the impact of these publications in the scientific and technological fields. For this purpose, the Lens.org patent search engine and its two predefined sets of patents on coronaviruses were used, one of a general nature and the other more specific (on treatments and vaccines). Among the results, the use of persistent identifiers and bibliographic metadata extracted from other academic-scientific platforms such as Microsoft Academic or PubMed, among others, stands out. However, debugging and standardization of the bibliographic data in Lens is required, because duplications have been detected. Although the most cited journals, namely the Journal of Virology and the Proceedings of the National Academy of Sciences of the USA, do present a similarity in their positioning in the top positions of the rankings of Journal Citation Reports (JCR) and Lens, the rest of the journals that are most cited in patents on coronaviruses do not have high impact according to the JCR index of the Web of Science. Inequalities are evident when comparing the scientific with the technological impact of the journals cited in patents, and indicators other than traditional bibliometrics are needed to evaluate scientific journals cited in patents from the technological perspective.
C1 [Velayos-Ortega, Gema; Lopez-Carreno, Rosana] Univ Murcia, Fac Informac & Documentac, Dept Informac & Documentac, Campus Univ, Murcia 30100, Spain.
RP Velayos-Ortega, G (corresponding author), Univ Murcia, Fac Informac & Documentac, Dept Informac & Documentac, Campus Univ, Murcia 30100, Spain.
EM g.velayosortega@um.es; rosanalc@um.es
CR Aguado-Cortes Cesar, 2020, TRANSLATIONAL KNOWLE
   Codina Lluis, 2019, MICROSOFT ACAD ECOSI
   Guerrero-Bote VP, 2019, PROF INFORM, V28, DOI 10.3145/epi.2019.jul.01
   Haleem A, 2020, AM J EMERG MED, V38, P1524, DOI 10.1016/j.ajem.2020.04.022
   Jefferson OA, 2018, NAT BIOTECHNOL, V36, P31, DOI 10.1038/nbt.4049
   Jurgens B, 2018, WORLD PAT INF, V52, P9, DOI 10.1016/j.wpi.2018.01.001
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Machuca-Martinez F, 2020, DATA BRIEF, V30, DOI 10.1016/j.dib.2020.105551
   Mariani MS, 2019, TECHNOL FORECAST SOC, V146, P644, DOI 10.1016/j.techfore.2018.01.036
   Nasab Fateme-Rafiei, 2020, BIBLIOMETRIC ANAL GL, DOI DOI 10.1101/2020.03.19.20038752
   OBrien Nicolas, 2020, REV CHILENA ANESTESI, V49, P408, DOI [10.25237/reychilanestv49n03.020, DOI 10.25237/REVCHILANESTV49N03.020]
   Plaza L.M., 2004, REV ESP DOC CIENT, V27, P212
   Ram Shri, 2020, Science & Technology Libraries, V39, DOI 10.1080/0194262X.2020.1742270
   Torres-Salinas D, 2020, PROF INFORM, V29, DOI 10.3145/epi.2020.mar.15
NR 14
TC 0
Z9 0
U1 0
U2 0
PU  EDICIONES PROFESIONALES INFORMACION SL-EPI
PI BARCELONA
PA MISTRAL, 36, BARCELONA, ALBOLOTE, SPAIN
SN 1386-6710
J9 PROF INFORM
JI Prof. Inf.
PD SEP-OCT
PY 2020
VL 29
IS 5
AR e290519
DI 10.3145/epi.2020.sep.19
PG 9
WC Communication; Information Science & Library Science
SC Communication; Information Science & Library Science
GA OV7WI
UT WOS:000592414700008
DA 2021-01-01
ER

PT J
AU Mann, ER
   Menon, M
   Knight, SB
   Konkel, JE
   Jagger, C
   Shaw, TN
   Krishnan, S
   Rattray, M
   Ustianowski, A
   Bakerly, ND
   Dark, P
   Lord, GM
   Simpson, A
   Felton, T
   Ho, LP
   Feldmann, M
   Grainger, JR
   Hussell, T
AF Mann, Elizabeth R.
   Menon, Madhvi
   Knight, Sean Blandin
   Konkel, Joanne E.
   Jagger, Christopher
   Shaw, Tovah N.
   Krishnan, Siddharth
   Rattray, Magnus
   Ustianowski, Andrew
   Bakerly, Nawar Diar
   Dark, Paul
   Lord, Graham M.
   Simpson, Angela
   Felton, Timothy
   Ho, Ling-Pei
   Feldmann, Marc
   Grainger, John R.
   Hussell, Tracy
CA NIHR Resp TRC
   CIRCO
TI Longitudinal immune profiling reveals key myeloid signatures associated
   with COVID-19
SO SCIENCE IMMUNOLOGY
LA English
DT Article
ID CORONAVIRUS; NEUTROPHIL; PNEUMONIA; CYCLOOXYGENASE-2; EXPRESSION;
   CHEMOKINES; INFECTION; CELLS
AB COVID-19 pathogenesis is associated with an exaggerated immune response. However, the specific cellular mediators and inflammatory components driving diverse clinical disease outcomes remain poorly understood. We undertook longitudinal immune profiling on both whole blood and peripheral blood mononuclear cells of hospitalized patients during the peak of the COVID-19 pandemic in the United Kingdom. Here, we report key immune signatures present shortly after hospital admission that were associated with the severity of COVID-19. Immune signatures were related to shifts in neutrophil to T cell ratio, elevated serum IL-6, MCP-1, and IP-10 and modulation of CD14(+) monocyte phenotype and function. Modified features of CD14(+) monocytes included poor induction of the prostaglandin-producing enzyme, COX-2, and enhanced expression of the cell cycle marker Ki-67. Longitudinal analysis revealed reversion of some immune features back to the healthy median level in patients with a good eventual outcome. These findings identify previously unappreciated alterations in the innate immune compartment of patients with COVID-19 and lend support to the idea that therapeutic strategies targeting release of myeloid cells from bone marrow should be considered in this disease. Moreover, they demonstrate that features of an exaggerated immune response are present early after hospital admission, suggesting that immunomodulating therapies would be most beneficial at early time points.
C1 [Mann, Elizabeth R.; Menon, Madhvi; Knight, Sean Blandin; Konkel, Joanne E.; Jagger, Christopher; Shaw, Tovah N.; Krishnan, Siddharth; Lord, Graham M.; Grainger, John R.; Hussell, Tracy] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Sch Biol Sci,Div Infect Immun & Resp Med,Lydia Be, Room 2-16,Core Technol Facil,46 Grafton St, Manchester M13 9PL, Lancs, England.
   [Mann, Elizabeth R.] Univ Manchester, Fac Biol Med & Hlth, Sch Med Sci, Maternal & Fetal Hlth Ctr,Div Dev Biol, 5th Floor St Marys Hosp,Oxford Rd, Manchester M13 9WL, Lancs, England.
   [Knight, Sean Blandin; Bakerly, Nawar Diar] Salford Royal NHS Fdn Trust, Resp Dept, Stott Lane, Salford M6 8HD, Lancs, England.
   [Rattray, Magnus] Univ Manchester, Fac Biol Med & Hlth, Div Informat Imaging & Data Sci, Manchester M13 9PL, Lancs, England.
   [Ustianowski, Andrew] North Manchester Gen Hosp, Reg Infect Dis Unit, Manchester, Lancs, England.
   [Dark, Paul; Simpson, Angela; Felton, Timothy] Wythenshawe Hosp, Educ & Res Ctr, Manchester NIHR BRC, Div Infect Immun & Resp Med, Manchester, Lancs, England.
   [Dark, Paul] Salford Royal NHS Fdn Trust, Intens Care Dept, Stott Lane, Salford M6 8HD, Lancs, England.
   [Ho, Ling-Pei] Univ Oxford, Weatherall Inst Mol Med, MRC Human Immunol Unit, Oxford, England.
   [Feldmann, Marc] Kennedy Inst Rheumatol, Botnar Res Ctr, Nuffield Dept Orthoped Rheumatol & Musculoskeleta, Windmill Rd, Oxford OX3 7LD, England.
RP Grainger, JR; Hussell, T (corresponding author), Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Sch Biol Sci,Div Infect Immun & Resp Med,Lydia Be, Room 2-16,Core Technol Facil,46 Grafton St, Manchester M13 9PL, Lancs, England.
EM john.grainger-2@manchester.ac.uk; tracy.hussell@manchester.ac.uk
RI ; Rattray, Magnus/B-4393-2009; Porter, Joanna/C-7162-2009
OI Knight, Sean/0000-0003-4773-6843; Krishnan,
   Siddharth/0000-0002-9270-7083; Dark, Paul/0000-0003-3309-0164; Menon,
   Madhvi/0000-0003-2516-9438; Chenery, Alistair/0000-0001-8755-461X;
   Rattray, Magnus/0000-0001-8196-5565; Shaw, Tovah/0000-0002-8107-2836;
   Porter, Joanna/0000-0002-7307-169X; Diar Bakerly,
   Nawar/0000-0003-2102-1997; Pearmain, Laurence/0000-0003-1288-3026
FU Kennedy Trust for Rheumatology Research; Wellcome TrustWellcome Trust
   [202865/Z/16/Z, 106898/A/15/Z]; Wellcome Trust/Royal Society
   [206206/Z/17/Z]; Lister Institute; BBSRCBiotechnology and Biological
   Sciences Research Council (BBSRC) [BB/M025977/1, BB/S01103X/1]; Oxford
   and Manchester NIHR BRC
FX This work was supported by The Kennedy Trust for Rheumatology Research
   that provided a Rapid Response Award for costs associated with the
   laboratory analysis of the immune response in patients with COVID-19 to
   J.R.G., The Wellcome Trust (T.H., 202865/Z/16/Z; 106898/A/15/Z, which
   helped support some CIRCO members), The Wellcome Trust/Royal Society
   (E.R.M., 206206/Z/17/Z), the Lister Institute (J.E.K.), and BBSRC
   (J.E.K., BB/M025977/1; T.N.S., BB/S01103X/1). The Oxford and Manchester
   NIHR BRC provided support for study design and sample collection. Author
   contributions: E.R.M., M.M., S.B.K., J.E.K., C.J., T.N.S., J.R.G., and
   T.H. designed the study and performed tissue processing, data
   collection, data analysis, data interpretation, and manuscript writing.
   S.K. and M.R. performed data analysis and generated the figures. A.U.,
   N.D.B., P.D., A.S., and T.F. performed sample collection and biobanking.
   A.U., A.S., and T.F. contributed to data interpretation, presentation of
   clinical data, and paper construction. L.-P.H., NIHR Respiratory TRC,
   G.M.L., CIRCO, and M.F. contributed to study design, patient consent and
   sample collection, and manuscript preparation. CIRCO performed tissue
   processing, data collection, and data analysis.
CR Agostini C, 2000, AM J RESP CRIT CARE, V162, P1466, DOI 10.1164/ajrccm.162.4.2003130
   Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652
   Bermejo-Martin JF, 2010, CRIT CARE, V14, DOI 10.1186/cc9259
   Boettcher S, 2017, TRENDS IMMUNOL, V38, P345, DOI 10.1016/j.it.2017.01.004
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cole SL, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91868
   Coward WR, 2014, FASEB J, V28, P3183, DOI 10.1096/fj.13-241760
   FitzGerald GA, 2020, SCIENCE, V367, P1434, DOI 10.1126/science.abb8034
   Fu JH, 2020, THROMB RES, V192, P3, DOI 10.1016/j.thromres.2020.05.006
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Guilliams M, 2018, IMMUNITY, V49, P595, DOI 10.1016/j.immuni.2018.10.005
   Hadjadj J, 2020, SCIENCE, V369, P718, DOI 10.1126/science.abc6027
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   KURLAND JI, 1978, J EXP MED, V147, P952, DOI 10.1084/jem.147.3.952
   Lagunas-Rangel FA, 2020, J MED VIROL, V92, P1733, DOI 10.1002/jmv.25819
   Laing A. G., 2020, CONSENSUS COVID 19 I
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Liu JY, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02374-0
   Lucas C, 2020, NATURE, DOI 10.1038/s41586-020-2588-y
   Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511
   McElroy AK, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137260
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Nemeth T, 2020, NAT REV DRUG DISCOV, V19, P253, DOI 10.1038/s41573-019-0054-z
   O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537
   Ojima M, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-00444-5
   Orr Y, 2005, BRIT J HAEMATOL, V131, P508, DOI 10.1111/j.1365-2141.2005.05794.x
   Page TH, 2010, J IMMUNOL, V185, P3694, DOI 10.4049/jimmunol.1000906
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Rinaldi S, 2017, AGING-US, V9, P1307, DOI 10.18632/aging.101229
   Risitano AM, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0320-7
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Smith MA, 2014, ANN PHARMACOTHER, V48, P77, DOI 10.1177/1060028013510698
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Terpos E, 2020, AM J HEMATOL, V95, P834, DOI 10.1002/ajh.25829
   To KKW, 2010, CLIN INFECT DIS, V50, P850, DOI 10.1086/650581
   Woodruff Matthew, 2020, medRxiv, DOI 10.1101/2020.04.29.20083717
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yan XH, 2006, INT J BIOCHEM CELL B, V38, P1417, DOI 10.1016/j.biocel.2006.02.003
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
   Zhou J, 2014, J INFECT DIS, V209, P1331, DOI 10.1093/infdis/jit504
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zuo Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138999
NR 47
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2470-9468
J9 SCI IMMUNOL
JI Sci. Immunol.
PD SEP
PY 2020
VL 5
IS 51
AR eabd6197
DI 10.1126/sciimmunol.abd6197
PG 11
WC Immunology
SC Immunology
GA PB0RU
UT WOS:000596036300006
PM 32943497
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nagaraja, BS
   Ramesh, KN
   Dhar, D
   Mondal, MS
   Dey, T
   Saha, S
   Khan, MA
   Rutul, SD
   Pratik, K
   Manjula, J
   Sangeeth, TA
   Singh, V
AF Nagaraja, Bada Sharanappa
   Ramesh, Kalhalli Narayanaswamy
   Dhar, Debjyoti
   Mondal, Mahammad Samim
   Dey, Treshita
   Saha, Subhrakamal
   Khan, Mumtaz Ali
   Rutul, Shah Dhiren
   Pratik, Kishore
   Manjula, Jayaram
   Sangeeth, Thuppanattumadam Ananthasubramanian
   Singh, Vikram
TI HyPE study: hydroxychloroquine prophylaxis-related adverse events'
   analysis among healthcare workers during COVID-19 pandemic: a rising
   public health concern
SO JOURNAL OF PUBLIC HEALTH
LA English
DT Article
DE adverse effects; COVID-19; hydroxychloroquine; prophylaxis
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; CHLOROQUINE
AB Background The rising burden of Coronavirus disease (COVID-19) has led to the mass use of hydroxychloroquine by healthcare workers (HCWs). Adverse event profile of this drug when used as prophylaxis is not well known in the literature.
   Methods A retrospective, cross-sectional study was conducted across the country using semi-structured web-based questionnaire among COVID-19 negative and asymptomatic healthcare workers, taking hydroxychloroquine prophylaxis. Descriptive and multivariate logistic-regression models were applied for analysis.
   Results Of the 166 participants, at least one adverse event was experienced by 37.9% participants, gastrointestinal being the most common (30.7%). Risk was higher in participants <40 years age (odd's ratio (OR): 2.44, 95% confidence interval (CI): 1.18-5.05) and after first dose of hydroxychloroquine (51.2%, OR: 2.38, 95%CI: 1.17-4.84). Hydroxychloroquine prophylaxis was initiated without electrocardiography by 80.1% of HCWs. Only 21.6% of those with cardiovascular disease could get prior ECG.
   Conclusions A higher incidence of adverse events was observed when results were compared with studies involving patients on long-term hydroxychloroquine therapy. Younger age and first dose were associated with greater incidence of adverse events though all were self-limiting. Monitoring prior and during prophylaxis was inadequate even among those with cardiovascular disease and risk-factors. However, no serious cardiovascular events were reported.
C1 [Nagaraja, Bada Sharanappa; Ramesh, Kalhalli Narayanaswamy; Khan, Mumtaz Ali] Bowring & Lady Curzon Hosp, Dept Internal Med, Bangalore 560001, Karnataka, India.
   [Dhar, Debjyoti; Mondal, Mahammad Samim; Rutul, Shah Dhiren; Pratik, Kishore; Sangeeth, Thuppanattumadam Ananthasubramanian; Singh, Vikram] Natl Inst Mental Hlth & Neurosci, Dept Neurol, Bangalore 560029, Karnataka, India.
   [Dey, Treshita] Postgrad Inst Med Educ & Res, Dept Radiat Oncol, Chandigarh 160012, India.
   [Saha, Subhrakamal] Jawaharlal Nehru Hosp & Res Ctr, Dept Internal Med, Sect 9, Bhilai 490001, India.
   [Dhar, Debjyoti; Mondal, Mahammad Samim; Manjula, Jayaram; Sangeeth, Thuppanattumadam Ananthasubramanian; Singh, Vikram] Bangalore Med Coll & Res Inst, Dept Internal Med, Bangalore 560002, Karnataka, India.
RP Mondal, MS (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Neurol, Bangalore 560029, Karnataka, India.; Mondal, MS (corresponding author), Bangalore Med Coll & Res Inst, Dept Internal Med, Bangalore 560002, Karnataka, India.
EM msmondal788@gmail.com
OI Dey, Treshita/0000-0001-7795-3596; dhar, debjyoti/0000-0002-4835-4698
CR Abubakar AR, 2014, J APPL PHARM SCI, V4, P117
   [Anonymous], 2020, LANCET, V395, P922, DOI [10.1016/S0140-6736(20)30627-9, 10.1016/S0140-6736(20)30644-9]
   BRUCECHWATT LJ, 1988, BRIT MED J, V296, P1486, DOI 10.1136/bmj.296.6635.1486
   Chen Z, 2020, EFFICACY HYDROXYCHLO, V7
   Clark P, 1993, RANDOMIZED CONTROLLE
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Costedoat-Chalumeau N, 2007, RHEUMATOLOGY, V46, P808, DOI 10.1093/rheumatology/kel402
   Culp WC, 2020, A A PRACT, V14, DOI 10.1213/XAA.0000000000001218
   FDA, 2020, HYDR FACT SHEET HLTH, V1, P7
   FDA / CDER, 2017, PLAQ HYDR SULF TABL
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu M, 2020, JAMA INT MED
   MORAND EF, 1992, ANN RHEUM DIS, V51, P1318, DOI 10.1136/ard.51.12.1318
   Rathi S, 2020, LANCET INFECT DIS, V20, P1118, DOI 10.1016/S1473-3099(20)30313-3
   Rayhan Rakib U, 2013, Appl Med Inform, V33, P12
   Ruiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766
   Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP), RISK POP SHARP COVID
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Tangtavorn N, 2016, CLIN OPHTHALMOL, V10, P2179, DOI 10.2147/OPTH.S119872
   The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)-Full Text View, PATCH TRIAL PREV TRE
   van Gelder MMHJ, 2010, AM J EPIDEMIOL, V172, P1292, DOI 10.1093/aje/kwq291
   van Jaarsveld CH, 2000, RHEUMATOLOGY
   Wang CC, 1999, J RHEUMATOL, V26, P808
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Will Hydroxychloroquine Impede or Prevent COVID-19-Full Text View, WILL HYDR IMP PREV C
   Wozniacka A, 2006, LUPUS, V15, P521, DOI 10.1191/0961203306lu2345oa
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yao X, 2020, CLIN INFECT DIS, V2, P1, DOI DOI 10.1093/CID/CIAA237
   ZHANG MH, 2020, NEW ENGL J MED, DOI DOI 10.1159/000511207
NR 30
TC 4
Z9 4
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1741-3842
EI 1741-3850
J9 J PUBLIC HEALTH-UK
JI J. Public Health
PD SEP
PY 2020
VL 42
IS 3
BP 493
EP 503
DI 10.1093/pubmed/fdaa074
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OW8AM
UT WOS:000593102400036
PM 32490532
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Dean, E
   Jones, A
   Yu, HPM
   Gosselink, R
   Skinner, M
AF Dean, Elizabeth
   Jones, Alice
   Yu, Homer Peng-Ming
   Gosselink, Rik
   Skinner, Margot
TI Translating COVID-19 Evidence to Maximize Physical Therapists' Impact
   and Public Health Response
SO PHYSICAL THERAPY
LA English
DT Article
ID CLINICAL-PRACTICE; ADHERENCE; RECOMMENDATIONS; PHYSIOTHERAPY; EXERCISE;
   SUMMIT; DIET
AB Coronavirus disease 2019 (COVID-19) has sounded alarm bells throughout global health systems. As of late May, 2020, over 100,000 COVID-19-related deaths were reported in the United States, which is the highest number of any country. This article describes COVID-19 as the next historical turning point in the physical therapy profession's growth and development. The profession has had over a 100-year tradition of responding to epidemics, including poliomyelitis; 2 world wars and geographical regions experiencing conflicts and natural disasters; and, the epidemic of noncommunicable diseases (NCDs). The evidence-based role of noninvasive interventions (nonpharmacological/nonsurgical) that hallmark physical therapist practice has emerged as being highly relevant today in addressing COVID-19 in 2 primary ways. First, despite some unique features, COVID-19 presents as acute respiratory distress syndrome in its severe acute stage. Acute respiratory distress syndrome is very familiar to physical therapists in intensive care units. Body positioning and mobilization, prescribed based on comprehensive assessments/examinations, counter the negative sequelae of recumbency and bedrest; augment gas exchange and reduce airway closure, deconditioning, and critical illness complications; and maximize long-term functional outcomes. Physical therapists have an indisputable role across the contiuum of COVID-19 care. Second, over 90% of individuals who die from COVID-19 have comorbidities, most notably cardiovascular disease, hypertension, chronic lung disease, type 2 diabetes mellitus, and obesity. Physical therapists need to redouble their efforts to address NCDs by assessing patients for risk factors and manifestations and institute evidence-based health education (smoking cessation, whole-food plant-based nutrition, weight control, physical activity/exercise), and/or support patients' efforts when these are managed by other professionals. Effective health education is a core competency for addressing risk of death by COVID-19 as well as NCDs. COVID-19 is a wake-up call to the profession, an opportunity to assert its role throughout the COVID-19 care continuum, and augment public health initiatives by reducing the impact of the current pandemic.
C1 [Dean, Elizabeth] Univ British Columbia, Fac Med, Dept Phys Therapy, 212 Friedman Bldg,2177 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.
   [Jones, Alice] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld, Australia.
   [Yu, Homer Peng-Ming] Sichuan Univ, West China Hosp, Rehabil Med Ctr, Chengdu, Sichuan, Peoples R China.
   [Yu, Homer Peng-Ming] Sichuan Univ, Fac Phys Therapy, Rehabil Med Coll, Chengdu, Sichuan, Peoples R China.
   [Gosselink, Rik] Katholieke Univ Leuven, Fac Movement & Rehabil Sci, Dept Rehabil Sci, Leuven, Belgium.
   [Skinner, Margot] Univ Otago, Sch Physiotherapy, Div Hlth Sci, Dunedin, New Zealand.
RP Dean, E (corresponding author), Univ British Columbia, Fac Med, Dept Phys Therapy, 212 Friedman Bldg,2177 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.
EM elizabeth.dean@ubc.ca
CR Ajimsha MS, ACUTE CARE PHYSIOTHE
   Akbaraly TN, 2015, AM J MED, V128, P152, DOI 10.1016/j.amjmed.2014.10.002
   American College of Lifestyle Medicine, JAMA PHYS COMP PRESC
   American Physical Therapy Association, CARD PULM SECT
   Amundadottir OR, 2017, EUR J PHYSIOTHER, V21, P296
   [Anonymous], 2018, HARVARD MED SCH GUID
   Azoulay E, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1887-7
   Beaglehole R, 2011, LANCET, V378, P449, DOI 10.1016/S0140-6736(11)60879-9
   Booth FW, 2012, COMPR PHYSIOL, V2, P1143, DOI 10.1002/cphy.c110025
   Buck D., 2012, CLUSTERING UNHEALTHY
   Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   Centers for Disease Control and Prevention, PROT YOURS OTH
   Dean E, 2012, CARDIOVASCULAR PULMO, P544
   Dean E, 2019, PHYS THER, V99, P1242, DOI 10.1093/ptj/pzz087
   Dean E, 2016, PHYS THER, V96, P940, DOI 10.2522/ptj.20150141
   Dean E, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-717
   Dean E, 2014, PHYSIOTHER THEOR PR, V30, P261, DOI 10.3109/09593985.2013.856977
   Dean Elizabeth, 2011, Physiotherapy Theory and Practice, V27, P531, DOI 10.3109/09593985.2010.544052
   Dean Elizabeth, 2009, Physiother Theory Pract, V25, P328
   Dempsey PC, 2015, CURR DIABETES REP, V15, DOI 10.1007/s11892-014-0522-0
   Desai SV, 2011, CRIT CARE MED, V39, P371, DOI 10.1097/CCM.0b013e3181fd66e5
   Elven M, 2015, PHYSIOTHER THEOR PR, V31, P231, DOI 10.3109/09593985.2014.994250
   Food Planet Health, HLTH DIETS SUST FOOD
   Ford ES, 2009, ARCH INTERN MED, V169, P1355, DOI 10.1001/archinternmed.2009.237
   Gosselink R, 2008, INTENS CARE MED, V34, P1188, DOI 10.1007/s00134-008-1026-7
   Greger M., 2015, NOT DIE
   Greger M., 2019, NOT DIET
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Hagan KA, 2016, J NUTR, V146, P1341, DOI 10.3945/jn.115.227900
   Hecht EM, 2020, AM J PREV MED, V59, P270, DOI 10.1016/j.amepre.2020.02.013
   Hill AD, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1248-y
   Lazzeri M, 2009, MONALDI ARCH CHEST D, V13, pR153
   Lee CM, 2009, CRIT CARE, V13, DOI 10.1186/cc8053
   Lein DH, 2017, PHYS THER, V97, P1169, DOI 10.1093/ptj/pzx090
   Maddock J, 2018, BRIT J NUTR, V119, P581, DOI 10.1017/S0007114517003877
   Makary MA, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2139
   Needham DM, 2010, TOP STROKE REHABIL, V17, P271, DOI 10.1310/tsr1704-271
   Ngai JC, 2010, RESPIROLOGY, V15, P543, DOI 10.1111/j.1440-1843.2010.01720.x
   Ornish D, 1998, AM J CARDIOL, V82, p72T
   Ornish D, 1998, JAMA, V280
   Percy Edward, 2020, Can J Cardiol, V36, P956, DOI 10.1016/j.cjca.2020.04.006
   Ricker MA, 2017, NUTR CLIN PRACT, V32, P318, DOI 10.1177/0884533617700353
   SARS-CoV-2 Surveillance Group,. Istituto Superiore di Sanita, 2020, CHAR SARS COV 2 PAT
   Schaller T, 2020, JAMA-J AM MED ASSOC, V323, P2518, DOI 10.1001/jama.2020.8907
   Schulze MB, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k2396
   Smith JM, 2020, PHYS THER, V100, P1062, DOI 10.1093/ptj/pzaa059
   Thomas P, 2020, J PHYSIOTHER, V66, P73, DOI 10.1016/j.jphys.2020.03.011
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wannamethee SG, 2001, DIABETES CARE, V24, P1590, DOI 10.2337/diacare.24.9.1590
   World Health Organization, COVID 19 ADV PUBL
   World Health Organization, WHO TOOLS PREV CONTR
   World Health Organization, COVID 19 SIGN IMP HL
   World Health Organization and others, 2013, GLOB ACT PLAN PREV C
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 57
TC 2
Z9 2
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0031-9023
EI 1538-6724
J9 PHYS THER
JI Phys. Ther.
PD SEP
PY 2020
VL 100
IS 9
BP 1458
EP 1464
DI 10.1093/ptj/pzaa115
PG 7
WC Orthopedics; Rehabilitation
SC Orthopedics; Rehabilitation
GA OX3MJ
UT WOS:000593472700005
PM 32589718
OA Green Published, Green Accepted, Bronze
DA 2021-01-01
ER

PT J
AU Abbott, FM
   Reichman, JH
AF Abbott, Frederick M.
   Reichman, Jerome H.
TI Facilitating Access to Cross-Border Supplies of Patented
   Pharmaceuticals: The Case of the COVID-19 Pandemic
SO JOURNAL OF INTERNATIONAL ECONOMIC LAW
LA English
DT Article
AB The COVID-19 pandemic has brought into stark relief the gaps in global preparedness to address widespread outbreaks of deadly viral infections. This article proposes legal mechanisms for addressing critical issues facing the international community in terms of providing equitable access to vaccines, treatments, diagnostics, and medical equipment. On the supply side, the authors propose the establishment of mandatory patent pools ('Licensing Facilities') on a global or regional, or even national basis, depending upon the degree of cooperation that may be achieved. The authors also discuss the importance of creating shared production facilities. On the demand side, the authors propose the establishment of Regional Pharmaceutical Supply Centers (RPSCs) for the collective procurement of products, and the need to coordinate the issuance of necessary compulsory licenses for production and/or importation, depending on relevant circumstances. The authors envisage that centralized coordination by RPSCs should assist in overcoming difficulties individual countries may encounter in addressing administrative and technical issues in procuring supplies, as well as creating improved bargaining leverage with potential suppliers. The authors finally address the problem created by the decision of various high-income countries to 'opt out' as eligible importing countries under the World Trade Organization TRIPS Agreement Article 31bis amendment that addresses the predominant export of pharmaceutical products under compulsory licenses.
C1 [Abbott, Frederick M.] Florida State Univ, Coll Law, Law, Tallahassee, FL 32306 USA.
   [Reichman, Jerome H.] Duke Law Sch, Law, Durham, NC USA.
RP Abbott, FM (corresponding author), Florida State Univ, Coll Law, Law, Tallahassee, FL 32306 USA.
CR Abbott FM, 2005, AM J INT LAW, V99, P317, DOI 10.2307/1562501
   Abbott FM, 2002, J INT ECON LAW, V5, P469, DOI 10.1093/jiel/5.2.469
   Abbott Frederick M., 2016, U C IRVINE L REV, V6, P281
   Abbott Frederick M., 2002, 2A UK COMM INT PROP
   Abboud L, 2020, FINANCIAL TIMES
   [Anonymous], 2020, REUTERS
   Bale Jr Harvey E., 1996, WORKSH ID CART MARCH
   Bauman Valerie, 2020, BLOOMBERG HLTH  0422
   Branswell Helen, 2020, STAT HLTH       0315
   Cattoor Steven, 2020, LEXGO           0508
   Decker Susan, 2020, BLOOMBERG IP NE 0409
   Emmott Robin, 2020, REUTERS WORLD N 0504
   Fletcher Elaine Ruth, 2020, HLTH POLICY WAT 0519
   from Canada Communication, 2005, IPCW464 COMM CAN
   Frontieres Medecins Sans, 2006, NEITH EXP NOR SOL WT
   Fuchs Sebastian, 2020, BIRD BIRD        MAY
   Gathi James Thuo, 2016, GEORGIA J INT COMP L, V44, P499
   Hahn Jim, 2007, RL33782 CRS
   Helfer Laurence R., 2017, WORLD BLIND UNION GU
   Jerome H., 2003, 5 ICTSDUNCTAD
   Knowledge Ecology International, 2016, NEED GLOB NEG AGR FU
   Kremer Michael, 2004, STRONG MED CREATING
   Lasswell Harold D., 1935, WORLD POLITICS PERSO
   Love James, 2005, ADDIS ABABA     0303
   Outterson K, 2006, AM J LAW MED, V32, P159, DOI 10.1177/009885880603200202
   Pecoul Bernard, 2020, EURACTIV
   Sampath Padmashree Gehl, 2020, WORKING PAPER
   Silverman Ed, 2020, STAT PHARMALOT  0406
   Sykes Alan O, 2002, Chic J Int Law, V3, P47
   Vijay Svet Lustig, 2020, HLTH POLICY WATC MAY
   WIPO Secretariat, 2019, SCP303 WIPO SECR
   World Health Organization World Intellectual Property Organization & World Trade Organization, 2020, PROM ACC MED TECHN I
   WTO Member and effectively nonjusticiable, 2019, WTDS512R WTO
NR 33
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1369-3034
EI 1464-3758
J9 J INT ECON LAW
JI J. Int. Econ. Law
PD SEP
PY 2020
VL 23
IS 3
BP 535
EP 561
DI 10.1093/jiel/jgaa022
PG 27
WC Law
SC Government & Law
GA OW7SL
UT WOS:000593081500002
DA 2021-01-01
ER

PT J
AU Dajti, E
   Cristini, F
   Tamanini, G
   Cescon, M
   Bazzoli, F
   Tame, M
AF Dajti, Elton
   Cristini, Francesco
   Tamanini, Giacomo
   Cescon, Matteo
   Bazzoli, Franco
   Tame, Mariarosa
TI COVID-19 in a young liver transplant recipient: caution for drug-drug
   interactions
SO JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES
LA English
DT Letter
C1 [Dajti, Elton; Tamanini, Giacomo; Cescon, Matteo; Bazzoli, Franco; Tame, Mariarosa] Univ Bologna, Dept Med & Surg Sci DIMEC, Bologna, Italy.
   [Cristini, Francesco] Rimini Forli Cesena Hosp, Infect Dis Unit, Rimini, Italy.
RP Tame, M (corresponding author), Univ Bologna, Dept Med & Surg Sci DIMEC, Bologna, Italy.
EM mariarosa.tame@aosp.bo.it
CR Boettler Tobias, 2020, JHEP Rep, V2, P100113, DOI 10.1016/j.jhepr.2020.100113
   Fix OK, 2020, HEPATOLOGY, V72, P287, DOI 10.1002/hep.31281
   Huang JF, 2020, AM J TRANSPLANT, V20, P1879, DOI 10.1111/ajt.15896
   Ritschl PV, 2020, AM J TRANSPLANT, V20, P1826, DOI 10.1111/ajt.15933
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
NR 5
TC 0
Z9 0
U1 0
U2 0
PU MEDICAL UNIV PRESS
PI CLUJ-NAPOCA
PA 3RD MEDICAL CLINIC, STR CROITORILOR NO 19-21, CLUJ-NAPOCA, 400162,
   ROMANIA
SN 1841-8724
EI 1842-1121
J9 J GASTROINTEST LIVER
JI J. Gastrointest. Liver Dis.
PD SEP
PY 2020
VL 29
IS 3
BP 470
EP 470
DI 10.15403/jgld-2672
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OR6LK
UT WOS:000589580000031
PM 32830825
OA Other Gold
DA 2021-01-01
ER

PT J
AU Randazzo, W
   Cuevas-Ferrando, E
   Sanjuan, R
   Domingo-Calap, P
   Sanchez, G
AF Randazzo, Walter
   Cuevas-Ferrando, Enric
   Sanjuan, Rafael
   Domingo-Calap, Pilar
   Sanchez, Gloria
TI Metropolitan wastewater analysis for COVID-19 epidemiological
   surveillance
SO INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH
LA English
DT Article
DE Epidemiological surveillance; SARS-CoV-2; COVID-19; Early warning
ID SARS-COV-2; SPECIMENS; VIRUSES; SEWAGE; RNA
AB The COVID-19 disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a rapidly emerging pandemic which has enforced extreme containment measures worldwide. In the absence of a vaccine or efficient treatment, cost-effective epidemiological surveillance strategies are urgently needed. Here, we have used RT-qPCR for SARS-CoV-2 detection in a series of longitudinal metropolitan wastewaters samples collected from February to April 2020, during the earliest stages of the epidemic in the Region of Valencia, Spain. We were able to consistently detect SARS-CoV-2 RNA in samples taken in late February, when communicated cases in that region were only incipient. We also find that the wastewater viral RNA context increased rapidly and anticipated the subsequent ascent in the number of declared cases. Our results strongly suggest that the virus was undergoing community transmission earlier than previously believed, and suggest that wastewater analysis could be sensitive and cost-effective strategy for COVID-19 epidemiological surveillance. Routine implementation of this surveillance tool would significantly improve our preparedness against new or re-occurring viral outbreaks.
C1 [Randazzo, Walter; Cuevas-Ferrando, Enric; Sanchez, Gloria] Consejo Super Invest Cient IATA CSIC, Dept Preservat & Food Safety Technol, Inst Agroquim & Tecnol Alimentos, Av Agustin Escardino 7, Valencia 46980, Spain.
   [Randazzo, Walter] Univ Valencia, Dept Microbiol & Ecol, Av Dr Moliner 50, Valencia 46100, Spain.
   [Sanjuan, Rafael; Domingo-Calap, Pilar] Univ Valencia, CSIC, I2SysBio, Inst Integrat Syst Biol, Paterna 46980, Spain.
   [Domingo-Calap, Pilar] Univ Valencia, Dept Genet, Paterna 46980, Spain.
RP Sanchez, G (corresponding author), Consejo Super Invest Cient IATA CSIC, Dept Preservat & Food Safety Technol, Inst Agroquim & Tecnol Alimentos, Av Agustin Escardino 7, Valencia 46980, Spain.; Domingo-Calap, P (corresponding author), Univ Valencia, CSIC, I2SysBio, Inst Integrat Syst Biol, Paterna 46980, Spain.
EM pilar.domingo@uv.es; gloriasanchez@iata.csic.es
RI ; Domingo-Calap, Pilar/B-3570-2019
OI Cuevas, Enric/0000-0002-0799-009X; Domingo-Calap,
   Pilar/0000-0003-2829-8809
FU CSICConsejo Superior de Investigaciones Cientificas (CSIC) [202070E101];
   Valencian Innovation Agency/GV [210152]; Spanish Ministry of Science,
   Innovation and Universities [AGL201782909]; ERCEuropean Research Council
   (ERC) [724519Vis-a-Vis]; Instituto de Salud Carlos IIIInstituto de Salud
   Carlos III [COV20/00210]; MICINNSpanish Government;  [APOSTD/2018/150]
FX We thank the Generalitat Valenciana and the Empresa Publica de
   Saneamiento de Aguas Residuales (EPSAR) for providing access to
   wastewater. This research was funded by CSIC 202070E101 grant, 210152
   project of Valencian Innovation Agency/GV, and AGL201782909 (AEI/FEDER,
   UE) funded by Spanish Ministry of Science, Innovation and Universities
   to G.S., ERC Consolidator Grant 724519Vis-`a-Vis to R.S. and
   FONDO-COVID19 COV20/00210 funded by Instituto de Salud Carlos III to
   P.D-C. W.R. was supported by APOSTD/2018/150 postdoctoral fellowship,
   and E.C-F. was supported by a predoctoral contract from the MICINN, Call
   2018.
CR Ahmed W, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138764
   [Anonymous], 2018, AM J PUBLIC HEALTH, DOI [10.2105/SMWW.2882.202., DOI 10.2105/SMWW.2882.202]
   Bivins A, 2020, ENVIRON SCI TECHNOL, V54, P7754, DOI 10.1021/acs.est.0c02388
   Chen YF, 2020, J MED VIROL, V92, P833, DOI 10.1002/jmv.25825
   Cheung KS, 2020, GASTROENTEROLOGY, V159, P81, DOI 10.1053/j.gastro.2020.03.065
   Chin AWH, 2020, LANCET MICROBE, V1, pe10, DOI [DOI 10.1101/2020.03.15.20036673, heresAdoi. moll 0.10161 S2666-5247(20130003-3, 10.1016/S2666-5247(20)130003-3]
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Cuevas-Ferrando E, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02937
   Duan SM, 2003, BIOMED ENVIRON SCI, V16, P246
   Haramoto E, 2020, SCI TOTAL ENVIRON, V737, DOI 10.1016/j.scitotenv.2020.140405
   Haramoto E, 2018, WATER RES, V135, P168, DOI 10.1016/j.watres.2018.02.004
   Heijnen L, 2011, J WATER HEALTH, V9, P434, DOI 10.2166/wh.2011.019
   Hellmer M, 2014, APPL ENVIRON MICROB, V80, P6771, DOI 10.1128/AEM.01981-14
   Hovi T, 2012, EPIDEMIOL INFECT, V140, P1, DOI 10.1017/S095026881000316X
   La Rosa G, 2020, SCI TOTAL ENVIRON, V736, DOI 10.1016/j.scitotenv.2020.139652
   Lescure FX, 2020, LANCET INFECT DIS, V20, P697, DOI 10.1016/S1473-3099(20)30200-0
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Lo IL, 2020, INT J BIOL SCI, V16, P1698, DOI 10.7150/ijbs.45357
   Lodder W, 2020, LANCET GASTROENTEROL, V5, P533, DOI 10.1016/S2468-1253(20)30087-X
   Medema G., 2020, ENVIRON SCI TECH LET, V7, P511, DOI DOI 10.1021/ACS.ESTLETT.0C00357
   Ministerio de Sanidad, CONS BIEN SOC PROF E
   Nalla AK, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00557-20
   Randazzo W, 2020, WATER RES, V181, DOI 10.1016/j.watres.2020.115942
   Randazzo W, 2019, FOOD ENVIRON VIROL, V11, P350, DOI 10.1007/s12560-019-09392-2
   Santiso-Bellon C, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8030458
   Sun J, 2020, EMERG MICROBES INFEC, V9, P991, DOI 10.1080/22221751.2020.1760144
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wu YJ, 2020, LANCET GASTROENTEROL, V5, P434, DOI 10.1016/S2468-1253(20)30083-2
   Xing YH, 2020, J MICROBIOL IMMUNOL, V53, P473, DOI 10.1016/j.jmii.2020.03.021
   Zhang TQ, 2020, J MED VIROL, V92, P909, DOI 10.1002/jmv.25795
NR 30
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 1438-4639
EI 1618-131X
J9 INT J HYG ENVIR HEAL
JI Int. J. Hyg. Environ. Health.
PD SEP
PY 2020
VL 230
AR 113621
DI 10.1016/j.ijheh.2020.113621
PG 4
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA OK1CW
UT WOS:000584390300011
PM 32911123
OA Green Published
DA 2021-01-01
ER

PT J
AU Vivas, D
   Roldan, V
   Esteve-Pastor, MA
   Roldan, I
   Tello-Montoliu, A
   Ruiz-Nodar, JM
   Cosin-Sales, J
   Gamez, JM
   Consuegra, L
   Ferreiro, JL
   Marin, F
   Arrarte, V
   Anguita, M
   Cequier, A
   Perez-Villacastin, J
AF Vivas, David
   Roldan, Vanessa
   Asuncion Esteve-Pastor, Maria
   Roldan, Inmaculada
   Tello-Montoliu, Antonio
   Miguel Ruiz-Nodar, Juan
   Cosin-Sales, Juan
   Maria Gamez, Jose
   Consuegra, Luciano
   Luis Ferreiro, Jose
   Marin, Francisco
   Arrarte, Vicente
   Anguita, Manuel
   Cequier, Angel
   Perez-Villacastin, Julian
TI Recommendations on antithrombotic treatment during the COVID-19
   pandemic. Position statement of the Working Group on Cardiovascular
   Thrombosis of the Spanish Society of Cardiology
SO REVISTA ESPANOLA DE CARDIOLOGIA
LA Spanish
DT Article
DE COVID-19; Coronavirus; SARS-CoV-2; Thrombosis; Antithrombotics
ID DUAL ANTIPLATELET THERAPY; FOCUSED UPDATE; COAGULATION; DISEASE; ESC
AB The new coronavirus SARS-CoV-2, which gives rise to the highly contagious COVID-19 disease, has caused a pandemic that is overwhelming health care systems worldwide. Affected patients have been reported to have a heightened inflammatory state that increases their thrombotic risk. However, there is very scarce information on the management of thrombotic risk, coagulation disorders, and anticoagulant therapy. In addition, the situation has also greatly influenced usual care in patients not infected with COVID-19. This article by the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology aims to summarize the available information and to provide a practical approach to the management of antithrombotic therapy. (C) 2020 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved.
C1 [Vivas, David; Perez-Villacastin, Julian] Hosp Clin San Carlos, Inst Cardiovasc, Madrid, Spain.
   [Roldan, Vanessa] Univ Murcia, Hosp Univ Morales Meseguer, IMIB Arrixaca, CIBERCV,Serv Hematol, Murcia, Spain.
   [Asuncion Esteve-Pastor, Maria; Tello-Montoliu, Antonio; Marin, Francisco] Univ Murcia, Hosp Clin Univ Virgen Arrixaca, IMIB Arrixaca, CIBERCV,Serv Cardiol, Murcia, Spain.
   [Roldan, Inmaculada] Hosp Gen Univ La Paz, Serv Cardiol, CIBERCV, Madrid, Spain.
   [Miguel Ruiz-Nodar, Juan; Arrarte, Vicente] Univ Miguel Hernandez, Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Serv Cardiol,CIBERCV, Alicante, Spain.
   [Cosin-Sales, Juan] Hosp Arnau Vilanova, Serv Cardiol, Valencia, Spain.
   [Cosin-Sales, Juan] Univ Cardenal Herrera CEU, Fac Ciencias Salud, Dept Med, Valencia, Spain.
   [Maria Gamez, Jose] Univ Islas Baleares, Hosp Univ Son Llatzer, Fac Med, Dept Med,Serv Cardiol, Palma De Mallorca, Spain.
   [Consuegra, Luciano] Hosp Gen Univ Santa Lucia, Serv Cardiol, Murcia, Spain.
   [Luis Ferreiro, Jose; Cequier, Angel] Hosp Univ Bellvitge IDIBELL, CIBERCV, Serv Cardiol, Barcelona, Spain.
   [Anguita, Manuel] Hosp Univ Reina Sofia, Serv Cardiol, Cordoba, Spain.
RP Marin, F (corresponding author), Hosp Clin Univ Virgen Arrixaca, Serv Cardiol, Ctra Madrid Cartagena S-N, Murcia 30120, Spain.
EM fcomarino@hotmail.com
OI Gamez/0000-0002-9362-6947
CR Agencia Espanola de Medicamentos y Productos Sanitarios, TRAT DISP MAN INF RE
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Baumgartner H, 2017, EUR HEART J, V38, P2739, DOI 10.1093/eurheartj/ehx391
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen J, LANCET INFECT DIS FI
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Driggin E, 2020, J AM COLL CARDIOL, V75, P2352, DOI 10.1016/j.jacc.2020.03.031
   Esmon CT, 2009, BLOOD REV, V23, P225, DOI 10.1016/j.blre.2009.07.002
   Gaertner F, 2016, SEMIN IMMUNOL, V28, P561, DOI 10.1016/j.smim.2016.10.010
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Hunt B, 2020, THROMBOSIS UK ISTH I
   Idell S, 2003, CRIT CARE MED, V31, pS213, DOI 10.1097/01.CCM.0000057846.21303.AB
   Navarro MJ, 2018, REV ESP CARDIOL, V71, P6, DOI 10.1016/j.recesp.2017.11.011
   Keragala CB, 2018, BRIT J HAEMATOL, V180, P782, DOI 10.1111/bjh.15062
   Li JL, 2018, INT J CLIN EXP MED, V11, P414
   Lillicrap D, 2020, J THROMB HAEMOST, V18, P786, DOI 10.1111/jth.14781
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Ferreiro JL, 2019, THROMB RES, V175, P95, DOI 10.1016/j.thromres.2019.01.021
   Mousavi S, 2015, ADV PHARMACOL SCI, V2015, DOI 10.1155/2015/507151
   Mueck W, 2013, BRIT J CLIN PHARMACO, V76, P455, DOI 10.1111/bcp.12075
   Rodriguez-Leor O., 2020, REC INTERVENTIONAL C, DOI [10.24875/RECICE.M20000123., DOI 10.24875/RECICE.M20000123, 10.24875/recice.m20000123]
   Romaguera R, 2020, NIH CONSENSUS STATE, DOI [10.24875/RECICE.M20000121, DOI 10.24875/RECICE.M20000121]
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   University of Liverpool, EV DRUG DRUG INT RIS
   Valgimigli M, 2018, EUR HEART J, V39, P213, DOI 10.1093/eurheartj/ehx419
   Vivas D, 2018, REV ESP CARDIOL, V71, P553, DOI 10.1016/j.rec.2018.01.029
   Wang L, 2020, RISK ASSESSMENT VENO, DOI [10.2139/ssrn.3548771, DOI 10.2139/SSRN.3548771]
   Yin SY, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02105-8
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 32
TC 10
Z9 11
U1 0
U2 0
PU EDICIONES DOYMA S A
PI BARCELONA
PA TRAV DE GRACIA 17-21, 08021 BARCELONA, SPAIN
SN 0300-8932
EI 1579-2242
J9 REV ESP CARDIOL
JI Rev. Esp. Cardiol.
PD SEP
PY 2020
VL 73
IS 9
BP 749
EP 757
DI 10.1016/j.recesp.2020.04.006
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OM0DN
UT WOS:000585699600011
PM 32327870
OA Green Published
DA 2021-01-01
ER

PT J
AU Collins, CD
   West, N
   Sudekum, DM
   Hecht, JP
AF Collins, Curtis D.
   West, Nina
   Sudekum, David M.
   Hecht, Jason P.
TI Perspectives from the frontline: A pharmacy department's response to the
   COVID-19 pandemic
SO AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
LA English
DT Article
DE antimicrobial stewardship; care bundles; COVID-19; pandemics;
   pharmacists; organization & administration; pharmacy
ID CRITICALLY-ILL; CARE BUNDLE; IMPACT; MANAGEMENT
AB Purpose. The global coronavirus disease 2019 (COVID-19) pandemic has created unprecedented strains on healthcare systems around the world. Challenges surrounding an overwhelming influx of patients with COVID-19 and changes in care dynamics prompt the need for care models and processes that optimize care in this medically complex patient population. The purpose of this report is to describe our institution's strategy to deploy pharmacy resources and standardize pharmacy processes to optimize the management of patients with COVID-19.
   Methods. This retrospective, descriptive report characterizes documented pharmacy interventions in the acute care of patients admitted for COVID-19 during the period April 1 to April 15, 2020. Patient monitoring, interprofessional communication, and intervention documentation by pharmacy staff was facilitated through the development of a COVID-19-specific care bundle integrated into the electronic medical record.
   Results. A total of 1,572 pharmacist interventions were documented in 197 patients who received a total of 15,818 medication days of therapy during the study period. The average number of interventions per patient was 8. The most common interventions were regimen simplification (15.9%), timing and dosing adjustments (15.4%), and antimicrobial therapy and COVID-19 treatment adjustments (15.2%). Patients who were admitted to an intensive care unit care at any point during their hospital stay accounted for 66.7% of all interventions documented.
   Conclusion. A pharmacy department's response to the COVID-19 pandemic was optimized through standardized processes. Pharmacists intervened to address a wide scope of medication-related issues, likely contributing to improved management of COVID-19 patients. Results of our analysis demonstrate the vital role pharmacists play as members of multidisciplinary teams during times of crisis.
C1 [Collins, Curtis D.; West, Nina; Sudekum, David M.; Hecht, Jason P.] St Joseph Mercy Hlth Syst, Dept Pharm Serv, Ann Arbor, MI 48197 USA.
RP Collins, CD (corresponding author), St Joseph Mercy Hlth Syst, Dept Pharm Serv, Ann Arbor, MI 48197 USA.
EM curtis.collins@stjoeshealth.org
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Alkhalili M, 2017, DISASTER MED PUBLIC, V11, P496, DOI 10.1017/dmp.2016.172
   American Association of Colleges of Pharmacy House of Delegates, OATH PHARM
   [Anonymous], 2003, AM J HEALTH-SYST PH, V60, P1993, DOI DOI 10.1093/AJHP/60.19.1993
   Antworth A, 2013, PHARMACOTHERAPY, V33, P137, DOI 10.1002/phar.1186
   ASHP Expert Panel on Drug Product Shortages, 2009, Am J Health Syst Pharm, V66, P1399, DOI 10.2146/ajhp090026
   Barlam TF, 2016, CLIN INFECT DIS, V62, pE51, DOI 10.1093/cid/ciw118
   Bhimraj A, 2020, INFECT DIS SOC AM GU
   Bond CA, 1999, PHARMACOTHERAPY, V19, P556, DOI 10.1592/phco.19.8.556.31531
   Brumley PE, 2016, J ANTIMICROB CHEMOTH, V71, P836, DOI 10.1093/jac/dkv404
   Collins CD, 2016, INFECT CONT HOSP EP, V37, P1499, DOI 10.1017/ice.2016.199
   Einav S, 2014, CHEST, V146, pE17S, DOI 10.1378/chest.14-0734
   Gross AE, 2020, J AM COLL CLIN PHARM, V3, P564, DOI DOI 10.1002/JAC5.1231
   Hammond DA, 2019, PHARMACOTHERAPY, V39, P215, DOI 10.1002/phar.2224
   Han QM, 2020, J INFECTION, V80, P373, DOI 10.1016/j.jinf.2020.02.010
   Ijo Immanuel, 2011, Pharm Pract (Granada), V9, P106
   Leape LL, 1999, JAMA-J AM MED ASSOC, V282, P267, DOI 10.1001/jama.282.3.267
   Lee H, 2019, CRIT CARE MED, V47, P1243, DOI 10.1097/CCM.0000000000003830
   Leguelinel-Blache G, 2018, CRIT CARE MED, V46, P199, DOI 10.1097/CCM.0000000000002827
   Liu S, 2020, INT J CLIN PHARM-NET, V42, P299, DOI 10.1007/s11096-020-01017-0
   Luo MQ, 2020, ANESTHESIOLOGY, V132, P1616, DOI 10.1097/ALN.0000000000003288
   MacLaren R, 2008, CRIT CARE MED, V36, P3184, DOI 10.1097/CCM.0b013e31818f2269
   Miller S, 2012, J AM PHARM ASSOC, V52, P763, DOI 10.1331/JAPhA.2012.11003
   Paskovaty A, 2014, AM J HEALTH-SYST PH, V71, P2014, DOI 10.2146/ajhp130661
   Rivkin A, 2011, J CRIT CARE, V26, DOI 10.1016/j.jcrc.2010.04.014
   Singh Preet Mohinder, 2013, J Emerg Trauma Shock, V6, P241, DOI 10.4103/0974-2700.120363
   Song Zaiwei, 2021, Res Social Adm Pharm, V17, P2027, DOI 10.1016/j.sapharm.2020.03.027
   Stringer KA, 2020, PHARMACOTHERAPY, V40, P382, DOI 10.1002/phar.2394
   US Food and Drug Administration, FDA DRUG SHORT
NR 29
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1079-2082
EI 1535-2900
J9 AM J HEALTH-SYST PH
JI Am. J. Health-Syst. Pharm.
PD SEP 1
PY 2020
VL 77
IS 17
BP 1409
EP 1416
DI 10.1093/ajhp/zxaa176
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OF1KE
UT WOS:000580975100011
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hu, HJ
   Sun, Q
AF Hu, Huijun
   Sun, Qiang
TI Hyperbaric oxygen therapy for COVID-19: A potential choice for improving
   COVID-19-related hypoxemia
SO KUWAIT MEDICAL JOURNAL
LA English
DT Letter
C1 [Hu, Huijun; Sun, Qiang] Peoples Liberat Army Gen Hosp, Med Ctr 6, Dept Hyperbar Med, Beijing 100048, Peoples R China.
RP Sun, Q (corresponding author), Peoples Liberat Army Gen Hosp, Med Ctr 6, 6 Fucheng Rd, Beijing 100048, Peoples R China.
EM sunqiang83@gmail.com
CR Bedford J, 2020, LANCET, V395, P1015, DOI 10.1016/S0140-6736(20)30673-5
   BOEREMA I, 1960, Ned Tijdschr Geneeskd, V104, P949
   Geiderman JM, 1996, NEW ENGL J MED, V335, P1684
   Jain KK, 2017, TXB HYPERBARIC MED
   Kanne JP, 2020, RADIOLOGY, V296, pE113, DOI 10.1148/radiol.2020200527
   Kliff S, NY TIMES
   Liu W, COVID 19 ATTACKS 1 B
   Mehta Vandana, 2009, J PAKISTHAN ASS DERM, V19, P164
   Thom SR, 2011, PLAST RECONSTR SURG, V127, p131S, DOI 10.1097/PRS.0b013e3181fbe2bf
   who.int [Internet]. National Health Protection Committee, NTR
   World Health Organization, NTR
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhong X, OUTCOMES HYPERBARIC
NR 13
TC 0
Z9 0
U1 0
U2 0
PU KUWAIT MEDICAL ASSOC
PI SAFAT
PA PO BOX 1202, SAFAT, 13013, KUWAIT
SN 0023-5776
J9 KUWAIT MED J
JI Kuwait Med. J.
PD SEP
PY 2020
VL 52
IS 3
BP 326
EP 327
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA OS8QD
UT WOS:000590422500019
DA 2021-01-01
ER

PT J
AU Bakhshaliyev, N
   Uluganyan, M
   Enhos, A
   Karacop, E
   Ozdemir, R
AF Bakhshaliyev, Nijad
   Uluganyan, Mahmut
   Enhos, Asim
   Karacop, Erdem
   Ozdemir, Ramazan
TI The effect of 5-day course of hydroxychloroquine and azithromycin
   combination on QT interval in non-ICU COVID19(+) patients
SO JOURNAL OF ELECTROCARDIOLOGY
LA English
DT Article
DE Hydroxychloroquine; Azithromycin; Electrocardiography; Coronavirus
   disease 2019; QT interval
ID PROLONGATION; PHARMACOKINETICS; REPOLARIZATION; ASSOCIATION; POINTES;
   RISK
AB Background: The combination of Hydroxychloroquine (HCQ) and azithromycin showed effectiveness as a treat-ment for COVID-19 and is being used widely all around the world. Despite that those drugs are known to cause prolonged QT interval individually there is no study assessing the impact of this combination on electrocardiography (ECG). This study aimed to assess the impact of a 5-day course of HCQ and azithromycin combination on ECG in non-ICU COVID19(+) patients.
   Methods: In this retrospective observational study, we enrolled 109 COVID19(+) patients who required non-ICU hospitalization. All patients received 5-day protocol of HCQ and azithromycin combination. On-treatment ECGs were repeated 3-6 h after the second HCQ loading dose and 48-72 h after the first dose of the combination. ECGs were assessed in terms of rhythm, PR interval, QRS duration, QT and QTc intervals. Baseline and on treatment ECG findings were compared. Demographic characteristics, laboratory results were recorded. Daily phone call-visit or bed-side visit were performed by attending physician.
   Results: Of the 109 patients included in the study, the mean age was 57.3 +/- 14.4 years and 48 (44%) were male. Mean baseline PR interval was 158.47 +/- 25.10 ms, QRS duration was 94.00 +/- 20.55 ms, QTc interval was 435.28 +/- 32.78 ms, 415.67 +/- 28.51, 412.07 +/- 25.65 according to Bazett's, Fridericia's and Framingham Heart Study formulas respectively. APR was -2.94 +/- 19.93 ms (p = .55), AQRS duration was 5.18 +/- 8.94 ms (p = .03). AQTc interval was 6.64 +/- 9.60 ms (p = .5), 10.67 +/- 9.9 ms (p = .19), 14.14 +/- 9.68 ms (p = .16) according to Bazett's, Fridericia's and Framingham Heart Study formulas respectively. There were no statistically significant differences between QTc intervals. No ventricular tachycardia, ventricular fibrillation or significant conduction delay was seen during follow-up. There was no death or worsening heart function.
   Conclusion: The 5-day course of HCQAZM combination did not lead to clinically significant QT prolongation and other conduction delays compared to baseline ECG in non-ICU COVID19(+) patients. (c) 2020 Elsevier Inc. All rights reserved.
C1 [Bakhshaliyev, Nijad; Uluganyan, Mahmut; Enhos, Asim; Karacop, Erdem; Ozdemir, Ramazan] Bezmialem Vakif Univ, Dept Cardiol, Istanbul, Turkey.
RP Bakhshaliyev, N (corresponding author), Bezmialem Vakif Univ Hosp, Adnan Menderes Bulvari, TR-34093 Istanbul, Turkey.
EM bnijad@bezmialem.edu.tr
RI Bakhshaliyev, Nijad/AAW-3940-2020
CR Anderson ME, 2002, AM HEART J, V144, P769, DOI 10.1067/mhj.2002.125804
   [Anonymous], 2020, WHO DIR GEN OP REM M
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Chiang G, 1996, CLIN THER, V18, P1080, DOI 10.1016/S0149-2918(96)80063-4
   CLEMESSY JL, 1995, LANCET, V346, P877, DOI 10.1016/S0140-6736(95)92711-5
   De Bruin ML, 2005, EUR HEART J, V26, P590, DOI 10.1093/eurheartj/ehi092
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Fleet JL, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002857
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gupta A, 2007, AM HEART J, V153, P891, DOI 10.1016/j.ahj.2007.01.040
   Huang BH, 2007, PACE, V30, P1579, DOI 10.1111/j.1540-8159.2007.00912.x
   Kezerashvili A, 2007, J INTERV CARD ELECTR, V18, P243, DOI 10.1007/s10840-007-9124-y
   Lee JY, 2016, ARTHRITIS RHEUMATOL, V68, P184, DOI 10.1002/art.39402
   LODE H, 1991, EUR J CLIN MICROBIOL, V10, P807, DOI 10.1007/BF01975832
   Matsunaga N, 2003, NZ MED J, V116
   Milberg P, 2002, J PHARMACOL EXP THER, V303, P218, DOI 10.1124/jpet.102.037911
   Mortensen EM, 2014, JAMA-J AM MED ASSOC, V311, P2199, DOI 10.1001/jama.2014.4304
   Owens RC, 2006, CLIN INFECT DIS, V43, P1603
   Pruchnicki S, 1996, J TOXICOL-CLIN TOXIC, V33, P582
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Roden DM, 2020, CIRCULATION
   Russo Vincenzo, 2006, Acta Biomed, V77, P30
   SINGLAS E, 1995, PATHOL BIOL, V43, P505
   Svanstrom H, 2013, NEW ENGL J MED, V368, P1704, DOI 10.1056/NEJMoa1300799
   TETT S, 1993, AGENT ACTION SUPPL, V44, P145
   Wang LF, 2015, J INTERF CYTOK RES, V35, P143, DOI 10.1089/jir.2014.0038
   Yogasundaram H, 2014, CAN J CARDIOL, V30, P1706, DOI 10.1016/j.cjca.2014.08.016
   Zhu N, 2019, N ENGL J MED, P2020
NR 31
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 0022-0736
EI 1532-8430
J9 J ELECTROCARDIOL
JI J. Electrocardiol.
PD SEP-OCT
PY 2020
VL 62
BP 59
EP 64
DI 10.1016/j.jelectrocard.2020.08.008
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA OT1KK
UT WOS:000590611900014
PM 32827987
OA Green Published
DA 2021-01-01
ER

PT J
AU Vanachayangkul, P
   Im-erbsin, R
   Tungtaeng, A
   Kodchakorn, C
   Roth, A
   Adams, J
   Chaisatit, C
   Saingam, P
   Sciotti, RJ
   Reichard, GA
   Nolan, CK
   Pybus, BS
   Black, CC
   Lugo-Roman, LA
   Wegner, MD
   Smith, PL
   Wojnarski, M
   Vesely, BA
   Kobylinski, KC
AF Vanachayangkul, Pattaraporn
   Im-erbsin, Rawiwan
   Tungtaeng, Anchalee
   Kodchakorn, Chanikarn
   Roth, Alison
   Adams, John
   Chaisatit, Chaiyaporn
   Saingam, Piyaporn
   Sciotti, Richard J.
   Reichard, Gregory A.
   Nolan, Christina K.
   Pybus, Brandon S.
   Black, Chad C.
   Lugo-Roman, Luis A.
   Wegner, Matthew D.
   Smith, Philip L.
   Wojnarski, Mariusz
   Vesely, Brian A.
   Kobylinski, Kevin C.
TI Safety, Pharmacokinetics, and Activity of High-Dose Ivermectin and
   Chloroquine against the Liver Stage of Plasmodium cynomolgi Infection in
   Rhesus Macaques
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
DE COVID-19; Plasmodium; SARS-CoV-2; chloroquine; ivermectin; macaque;
   pharmacokinetics; safety
ID MALARIA TRANSMISSION; TISSUE DISTRIBUTION; IN-VITRO; EFFICACY;
   HYDROXYCHLOROQUINE
AB Previously, ivermectin (1 to 10 mg/kg of body weight) was shown to inhibit the liver-stage development of Plasmodium berghei in orally dosed mice. Here, ivermectin showed inhibition of the in vitro development of Plasmodium cynomolgi schizonts (50% inhibitory concentration [IC50], 10.42 mu M) and hypnozoites (IC50, 29.24 mu M) in primary macaque hepatocytes when administered as a high dose prophylactically but not when administered in radical cure mode. The safety, pharmacokinetics, and efficacy of oral ivermectin (0.3, 0.6, and 1.2 mg/kg) with and without chloroquine (10 mg/kg) administered for 7 consecutive days were evaluated for prophylaxis or radical cure of P. cynomolgi liver stages in rhesus macaques. No inhibition or delay to blood-stage P. cynomolgi parasitemia was observed at any ivermectin dose (0.3, 0.6, and 1.2 mg/kg). Ivermectin (0.6 and 1.2 mg/kg) and chloroquine (10 mg/kg) in combination were well-tolerated with no adverse events and no significant pharmacokinetic drug-drug interactions observed. Repeated daily ivermectin administration for 7 days did not inhibit ivermectin bioavailability. It was recently demonstrated that both ivermectin and chloroquine inhibit replication of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro. Further ivermectin and chloroquine trials in humans are warranted to evaluate their role in Plasmodium vivax control and as adjunctive therapies against COVID-19 infections.
C1 [Vanachayangkul, Pattaraporn; Kodchakorn, Chanikarn; Chaisatit, Chaiyaporn; Saingam, Piyaporn; Smith, Philip L.; Wojnarski, Mariusz; Vesely, Brian A.] Armed Forces Res Inst Med Sci, Dept Bacterial & Parasit Dis, Bangkok, Thailand.
   [Im-erbsin, Rawiwan; Tungtaeng, Anchalee; Lugo-Roman, Luis A.; Wegner, Matthew D.] Armed Forces Res Inst Med Sci, Dept Vet Med, Bangkok, Thailand.
   [Roth, Alison; Sciotti, Richard J.; Reichard, Gregory A.; Nolan, Christina K.; Pybus, Brandon S.; Black, Chad C.] Walter Reed Army Inst Res, Dept Drug Discovery, Expt Therapeut Branch, Silver Spring, MD USA.
   [Roth, Alison; Adams, John] Univ S Florida, Coll Publ Hlth, Ctr Global Hlth & Infect Dis Res, Tampa, FL 33620 USA.
   [Kobylinski, Kevin C.] Armed Forces Res Inst Med Sci, Dept Entomol, Bangkok, Thailand.
RP Kobylinski, KC (corresponding author), Armed Forces Res Inst Med Sci, Dept Entomol, Bangkok, Thailand.
EM kobylinskikevin@yahoo.com
RI Adams, John/G-1800-2015
OI Adams, John/0000-0003-3707-7979; Roth, Alison/0000-0001-6917-3485
FU Military Infectious Disease Research Program; Defense Malaria Assistance
   Program; University of South Florida College of Public Health Graduate
   Fellowship
FX We thank the AFRIMS Department of Veterinary Medicine for conducting the
   macaque trial, especially Laksanee Inamnuay, Kesara Chumpolkulwong,
   Natthasorn Komchareon, Chardchai Burom, Noppon Popruk, Sujitra Tayamun,
   Mana Saithasao, Alongkorn Hanrujirakomjorn, Nuttawat Wongpim, Khrongsak
   Saengpha, Phakorn Wilaisri, Chakkapat Detpattanan, Rachata Jecksaeng,
   Siwakorn Sirisrisopa, Yongyuth Kongkaew, Sakda Wosawanonkul, Sonchai
   Jansuwan, Amnart Andaeng, Chaisit Pornkhunviwat, Manas Kaewsurind,
   Wuthichai Puenchompu, Sawaeng Sripakdee, Dejmongkol Onchompoo, Thanaphon
   Rattanathan, Paitoon Hintong, and Siwadol Samano. We also thank the
   Department of Entomology Malariology and Insectary Sections, especially
   Ratawan Ubalee and Siriporn Phasomkusolsil, for supporting the
   sporozoite production. Monoclonal antibody 7.2 (anti-GAPDH) was obtained
   from The European Malaria Reagent Repository
   (http://www.malariaresearch.eu).; Funding sources include the Military
   Infectious Disease Research Program and the Defense Malaria Assistance
   Program. Funding support was provided by the University of South Florida
   College of Public Health Graduate Fellowship to A.R. The funders had no
   role in study design, data collection and interpretation, or the
   decision to submit the work for publication.
CR Alberich M, 2014, EUR J PHARMACOL, V740, P428, DOI 10.1016/j.ejphar.2014.06.052
   Alout H, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-417
   Bellinger AM, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag2374
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Chaccour C, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0618-2
   Chaccour C, 2010, J INFECT DIS, V202, P113, DOI 10.1086/653208
   Chhonker YS, 2018, J CHROMATOGR B, V1072, P320, DOI 10.1016/j.jchromb.2017.11.026
   Chua ACY, 2019, BIOMATERIALS, V216, DOI 10.1016/j.biomaterials.2019.05.032
   da Cruz FP, 2012, J INFECT DIS, V205, P1278, DOI 10.1093/infdis/jis184
   DiTusa C, 2014, J PARASITOL, V100, P671, DOI 10.1645/13-480.1
   Dufour JP, 2006, J MED PRIMATOL, V35, P172, DOI 10.1111/j.1600-0684.2006.00154.x
   Foy BD, 2019, LANCET, V393, P1517, DOI 10.1016/S0140-6736(18)32321-3
   Gupta DK, 2019, ELIFE, V8, DOI 10.7554/eLife.43362
   Gural N, 2018, CELL HOST MICROBE, V23, P395, DOI 10.1016/j.chom.2018.01.002
   Guzzo CA, 2002, J CLIN PHARMACOL, V42, P1122, DOI 10.1177/009127002401382731
   Institute for Laboratory Animal Research (U.S.), 2011, GUIDE CARE USE LAB A
   JOSEPH BE, 1984, LAB ANIM SCI, V34, P360
   Kobylinski KC, 2020, CLIN PHARMACOL THER, V107, P1221, DOI 10.1002/cpt.1716
   Lankas G. R., 1989, Ivermectin and abamectin., P89
   Lespine A, 2005, VET PARASITOL, V128, P251, DOI 10.1016/j.vetpar.2004.11.028
   Lifschitz A, 2000, VET PARASITOL, V87, P327, DOI 10.1016/S0304-4017(99)00175-2
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Mader D, 1979, LAB ANIM, V13, P275, DOI [10.1258/002367779780937834, DOI 10.1258/002367779780937834]
   MCCHESNEY EW, 1967, TOXICOL APPL PHARM, V10, P501, DOI 10.1016/0041-008X(67)90089-0
   Mendes AM, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.02005-16
   Merck Research Laboratories, 1996, STROM NEW DRUG APPL
   Metzger WG, 2020, TROP MED INT HEALTH, V25, P380, DOI 10.1111/tmi.13357
   Moudgil AD, 2018, J MED PRIMATOL, V47, P388, DOI 10.1111/jmp.12358
   National Research Council of Thailand, 2015, AN SCI PURP ACT
   Office of New Drugs in the Center for Drug Evaluation and Research (CDER), 2005, GUID IND EST MAX SAF
   Ouedraogo AL, 2015, CLIN INFECT DIS, V60, P357, DOI 10.1093/cid/ciu797
   Pinilla YT, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006221
   ROSENBERG R, 1990, T ROY SOC TROP MED H, V84, P209, DOI 10.1016/0035-9203(90)90258-G
   Roth A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04221-9
   Smit MR, 2018, LANCET INFECT DIS, V18, P615, DOI 10.1016/S1473-3099(18)30163-4
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang T, 2008, VET PARASITOL, V153, P121, DOI 10.1016/j.vetpar.2008.01.012
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
NR 38
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD SEP
PY 2020
VL 64
IS 9
AR e00741-20
DI 10.1128/AAC.00741-20
PG 11
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA OS5PP
UT WOS:000590216000046
PM 32660993
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Grover, S
   Mehra, A
   Sahoo, S
   Avasthi, A
   Tripathi, A
   D'Souza, A
   Saha, G
   Jagadhisha, A
   Gowda, M
   Vaishnav, M
   Singh, O
   Dalal, PK
   Kumar, P
AF Grover, Sandeep
   Mehra, Aseem
   Sahoo, Swapnajeet
   Avasthi, Ajit
   Tripathi, Adarsh
   D'Souza, Avinash
   Saha, Gautam
   Jagadhisha, A.
   Gowda, Mahesh
   Vaishnav, Mrugesh
   Singh, Omprakash
   Dalal, P. K.
   Kumar, Parmod
TI Impact of COVID-19 pandemic and lockdown on the state of mental health
   services in the private sector in India
SO INDIAN JOURNAL OF PSYCHIATRY
LA English
DT Article
DE COVID-19; lockdown; mental health services; pandemic; private sector
ID PSYCHOLOGICAL IMPACT
AB Background: No information is available about the impact of lockdown and COVID-19 pandemic on the mental health services in the private practice in India.
   Aim: The current study is aimed to assess the impact of the COVID-19 pandemic and lockdown on the state of Mental Health Services in the Private Sector in India.
   Materials and Methods: An online survey was carried out using the Survey Monkey platform during the period of 1st to 15th May 2020 among the members of the Indian Psychiatric Society.
   Results: Three hundred and ninety six responses were analysed. There was a reduction in revenue generation by about 70%. All kinds of services, including outpatient services, inpatient services, psychotherapy services, consultation-liaison, and electroconvulsive therapy (ECT) services, were severely affected. One-third of the participants were using the teleservices during the pandemic. The most common problem faced in running the services included modifying the psychological treatment to maintain social distancing, and managing the staff. Besides providing clinical care to the patients, the majority of the mental health professionals reported that they were involved in increasing awareness about the mental health consequences of pandemic and the lockdown and addressing myths related to the spread of infection.
   Conclusion: The pandemic and the lockdown have markedly impacted mental health services in the private sector. ECT services, inpatient services, psychotherapy services and outpatient services are the most affected. However, the COVID-19 pandemic and lockdown have led to the expansion of teleconsultation services.
C1 [Grover, Sandeep; Mehra, Aseem; Sahoo, Swapnajeet] Post Grad Inst Med Educ & Res, Dept Psychiat, Chandigarh, India.
   [Avasthi, Ajit] Fortis Hosp, Mohali, Punjab, India.
   [Avasthi, Ajit] CMC, Chandigarh, India.
   [Tripathi, Adarsh; Dalal, P. K.] King Georges Med Univ, Dept Psychiat, Lucknow, Uttar Pradesh, India.
   [D'Souza, Avinash] Lokmanya Tilak Municipal Gen Hosp & Med Coll, Dept Psychiat, Mumbai, Maharashtra, India.
   [Saha, Gautam] Clin Brain Neuropsychiat Inst & Res Ctr, Bengaluru, India.
   [Jagadhisha, A.] Abhaya Hosp, Bengaluru, India.
   [Gowda, Mahesh] Spandana Hlth Care, Bengaluru, Karnataka, India.
   [Vaishnav, Mrugesh] Samvedana Grp Hosp & Res Ctr, Ahmadabad, Gujarat, India.
   [Singh, Omprakash] NRS Med Coll, Dept Psychiat, Kolkata, W Bengal, India.
   [Kumar, Parmod] Dr Parmod Clin, Chandigarh, India.
RP Grover, S (corresponding author), Post Grad Inst Med Educ & Res, Dept Psychiat, Chandigarh, India.
EM drsandeepg2002@yahoo.com
OI Grover, Sandeep/0000-0002-2714-2055
CR Board of governors Medical council of India, 2020, TEL PRACT GUID
   Bojdani E, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113069
   D'Agostino A, 2020, LANCET PSYCHIAT, V7, P385, DOI 10.1016/S2215-0366(20)30133-4
   Grover S, 2020, INDIAN J PSYCHOL MED, V42, P473
   Grover S, 2020, INDIAN J PSYCHIAT, V62, P354, DOI 10.4103/psychiatry.IndianJPsychiatry_427_20
   Grover S, 2020, INDIAN J PSYCHIAT, V62, P363, DOI 10.4103/psychiatry.IndianJPsychiatry_567_20
   Grover S, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102147
   Hooda SK, 2015, PRIVATE SECTOR HEALT
   Kavoor AR, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102051
   Khanna RC, 2020, INDIAN J OPHTHALMOL, V68, P994, DOI 10.4103/ijo.IJO_1458_20
   Li ZY, 2020, BRAIN BEHAV IMMUN, V88, P916, DOI 10.1016/j.bbi.2020.03.007
   Sahoo S, 2020, ASIAN J PSYCHIATR, V54
   Xiang YT, 2020, LANCET, V395, P684, DOI 10.1016/S0140-6736(20)30375-5
NR 13
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0019-5545
EI 1998-3794
J9 INDIAN J PSYCHIAT
JI Indian J. Psychiatry
PD SEP-OCT
PY 2020
VL 62
IS 5
BP 488
EP 493
DI 10.4103/psychiatry.IndianJPsychiatry_568_20
PG 6
WC Psychiatry
SC Psychiatry
GA OI5HB
UT WOS:000583308300006
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Grover, S
   Sinha, P
   Sahoo, S
   Arumugham, S
   Baliga, S
   Chakrabarti, S
   Thirthalli, J
AF Grover, Sandeep
   Sinha, Preeti
   Sahoo, Swapnajeet
   Arumugham, Shyamsundar
   Baliga, Sachin
   Chakrabarti, Subho
   Thirthalli, Jagadisha
TI Electroconvulsive therapy during the COVID-19 pandemic
SO INDIAN JOURNAL OF PSYCHIATRY
LA English
DT Article
DE COVID-19; electroconvulsive therapy; pandemic
AB The COVID-19 pandemic has forced substantial changes in the practice of psychiatry, including that of electroconvulsive therapy (ECT). There is higher risk of transmission of the SARS-CoV-2 virus during ECT unless due care is taken. However, in many cases, ECT cannot be avoided. In this paper, we discuss various measures that may be adapted to reduce the risk of transmission of the virus during ECT. We also suggest certain modifications to the practice of ECT in order to achieve a balance between risks and benefits of the procedure during the pandemic.
C1 [Grover, Sandeep; Sahoo, Swapnajeet; Chakrabarti, Subho] Post Grad Inst Med Educ & Res, Dept Psychiat, Chandigarh, India.
   [Sinha, Preeti; Arumugham, Shyamsundar; Thirthalli, Jagadisha] Natl Inst Mental Hlth & Neurosci, Dept Psychiat, Bengaluru 560029, Karnataka, India.
   [Baliga, Sachin] TN Med Coll & BYL Nair Charitable Hosp, Dept Psychiat, Mumbai, Maharashtra, India.
RP Thirthalli, J (corresponding author), Natl Inst Mental Hlth & Neurosci, Dept Psychiat, Bengaluru 560029, Karnataka, India.
EM jagatth@yahoo.com
OI Grover, Sandeep/0000-0002-2714-2055
CR Cai J, 2020, EMERG INFECT DIS, V26, P1343, DOI 10.3201/eid2606.200412
   Colbert SA, 2020, J ECT, V36, P86, DOI 10.1097/YCT.0000000000000688
   Tran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035797
   Tor PC, 2020, J ECT, V36, P80, DOI 10.1097/YCT.0000000000000690
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
NR 5
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0019-5545
EI 1998-3794
J9 INDIAN J PSYCHIAT
JI Indian J. Psychiatry
PD SEP-OCT
PY 2020
VL 62
IS 5
BP 582
EP 584
DI 10.4103/psychiatry.IndianJPsychiatry_335_20
PG 3
WC Psychiatry
SC Psychiatry
GA OI5HB
UT WOS:000583308300020
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Kar, SK
   Menon, V
   Arafat, SMY
AF Kar, Sujita Kumar
   Menon, Vikas
   Arafat, S. M. Yasir
TI Online group cognitive behavioral therapy for panic buying:
   Understanding the usefulness in COVID-19 context
SO INDIAN JOURNAL OF PSYCHIATRY
LA English
DT Letter
C1 [Kar, Sujita Kumar] King Georges Med Univ, Dept Psychiat, Lucknow, Uttar Pradesh, India.
   [Menon, Vikas] Jawaharlal Inst Postgrad Med Educ & Res, Dept Psychiat, Pondicherry, India.
   [Arafat, S. M. Yasir] Enam Med Coll & Hosp, Dept Psychiat, Dhaka, Bangladesh.
RP Menon, V (corresponding author), Jawaharlal Inst Postgrad Med Educ & Res, Dept Psychiat, Pondicherry, India.
EM drvmenon@gmail.com
RI Kar, Sujita Kumar/R-3249-2019; Arafat, S M Yasir/P-9260-2015
OI Kar, Sujita Kumar/0000-0003-1107-3021; Arafat, S M
   Yasir/0000-0003-0521-5708
CR Arafat SMY, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00320-1
   Arafat SMY, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113061
   Bergstrom J, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-54
   Moore, 1996, ADV PSYCHIAT TREAT, V2, P17
   Sim K, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.113015
   Whitfield G, 2010, ADV PSYCHIAT TREAT, V16, P219, DOI DOI 10.1192/APT.BP.108.005744
   Wright B, 2002, ADV PSYCHIAT TREAT, V8, P307
NR 7
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0019-5545
EI 1998-3794
J9 INDIAN J PSYCHIAT
JI Indian J. Psychiatry
PD SEP-OCT
PY 2020
VL 62
IS 5
BP 607
EP +
DI 10.4103/psychiatry.IndianJPsychiatry_610_20
PG 3
WC Psychiatry
SC Psychiatry
GA OI5HB
UT WOS:000583308300036
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Flanders, WD
   Flanders, WD
   Goodman, M
AF Flanders, W. Dana
   Flanders, William D.
   Goodman, Michael
TI The association of voter turnout with county-level coronavirus disease
   2019 occurrence early in the pandemic
SO ANNALS OF EPIDEMIOLOGY
LA English
DT Article
DE COVID-19; Risk factors; Social distancing; Voting
ID TRANSMISSION; SARS-COV-2; CHINA
AB Purpose: The ongoing coronavirus disease 2019 (COVID-19) severely impacted both health and the economy. Absent an effective vaccine, preventive measures used, some of which are being relaxed, have included school closures, restriction of movement, and banning of large gatherings. Our goal was to estimate the association of voter turnout with county-level COVID-19 risks.
   Methods: We used publicly available data on voter turnout in the March 10 primary in three states, COVID-19 confirmed cases by day and county, and county-level census data. We used zero-inflated negative binomial regression to estimate the association of voter turnout with COVID-19 incidence, adjusted for county-level population density and proportions: over age 65 years, female, Black, with college education, with high school education, poor, obese, and smokers.
   Results: COVID-19 risk was associated with voter turnout, most strongly in Michigan during the week starting 3 days postelection (risk ratio, 1.24; 95% confidence interval, 1.16-1.33). For longer periods, the association was progressively weaker (risk ratio 0.98-1.03).
   Conclusions: Despite increased absentee-ballot voting in the primary, our results suggest an association of voter turnout in at least one state with a detectable increase in risks associated with and perhaps due to greater exposures related to the primary. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Flanders, W. Dana; Goodman, Michael] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd, Atlanta, GA 30322 USA.
   [Flanders, William D.] Wisconsin Inst Law & Liberty, Milwaukee, WI USA.
RP Flanders, WD (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, 1518 Clifton Rd, Atlanta, GA 30322 USA.
EM wflande@emory.edu
OI Flanders, W. Dana/0000-0003-4069-3262
CR [Anonymous], 2020, OPEN LETT US SENATE
   Backer JA, 2020, EUROSURVEILLANCE, V25, P10, DOI 10.2807/1560-7917.ES.2020.25.5.2000062
   CDC, 2020, PREV COVID 19 CAS DA
   Chen SM, 2020, LANCET, V395, P764, DOI 10.1016/S0140-6736(20)30421-9
   CSSE: JHU-CSSE, 2020, TIM SER SUMM CSSE CO
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Ebrahim SH, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101617
   Flanders WD, 2011, EPIDEMIOLOGY, V22, P59, DOI 10.1097/EDE.0b013e3181fdcabe
   Flanders WD, 2009, EPIDEMIOLOGY, V20, pS44, DOI 10.1097/01.ede.0000362312.45024.53
   Ghinai I, 2020, MMWR-MORBID MORTAL W, V69, P446, DOI 10.15585/mmwr.mm6915e1
   GREENLAND S, 1994, AM J EPIDEMIOL, V139, P747, DOI 10.1093/oxfordjournals.aje.a117069
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Haw DJ, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006600
   He X, 2020, NAT MED NAT RES, V1, P4
   John A, 2020, AGING MENT HEALTH, DOI 10.1080/13607863.2020.1758916
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Lasry A, 2020, MMWR-MORBID MORTAL W, V69, P451, DOI 10.15585/mmwr.mm6915e2
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Lessler J, 2017, AM J TROP MED HYG, V96, P1270, DOI 10.4269/ajtmh.16-0427
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Linton NM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020538
   Lipsitch M, 2010, EPIDEMIOLOGY, V21, P383, DOI 10.1097/EDE.0b013e3181d61eeb
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130
   Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026
   Rothman KJ, 2008, MODERN EPIDEMIOLOGY
   Sjodin H, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.13.2000280
   Tindale L, 2020, TRANSMISSION INTERVA
   USAFacts, 2020, COV CONF US
   Wei WE, 2020, MMWR-MORBID MORTAL W, V69, P411, DOI 10.15585/mmwr.mm6914e1
   Wu D, 2020, INT J INFECT DIS, V94, P44, DOI 10.1016/j.ijid.2020.03.004
   Wu J, 2020, NEUROCOMPUTING, V395, P78, DOI [10.1080/17435390.2020.1831639, 10.1016/j.neucom.2020.02.017]
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 34
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1047-2797
EI 1873-2585
J9 ANN EPIDEMIOL
JI Ann. Epidemiol.
PD SEP
PY 2020
VL 49
BP 42
EP 49
DI 10.1016/j.annepidem.2020.06.011
PG 8
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA OG1QS
UT WOS:000581668200007
PM 32951804
OA Green Published
DA 2021-01-01
ER

PT J
AU Kapepula, PM
   Kabengele, JK
   Kingombe, M
   Van Bambeke, F
   Tulkens, PM
   Kishabongo, AS
   Decloedt, E
   Zumla, A
   Tiberi, S
   Suleman, F
   Tshilolo, L
   Muyembe-TamFum, JJ
   Zumla, A
   Nachega, JB
AF Kapepula, Paulin M.
   Kabengele, Jimmy K.
   Kingombe, Micheline
   Van Bambeke, Francoise
   Tulkens, Paul M.
   Kishabongo, Antoine Sadiki
   Decloedt, Eric
   Zumla, Adam
   Tiberi, Simon
   Suleman, Fatima
   Tshilolo, Leon
   Muyembe-TamFum, Jean-Jacques
   Zumla, Alimuddin
   Nachega, Jean B.
TI Artemisia Spp. Derivatives for COVID-19 Treatment: Anecdotal Use,
   Political Hype, Treatment Potential, Challenges, and Road Map to
   Randomized Clinical Trials
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID ANTIVIRAL ACTIVITIES; ANNUA L.; FLAVONOIDS; MALARIA
AB The world is currently facing a novel COVID-19 pandemic caused by SARS-CoV-2 that, as of July 12, 2020, has caused a reported 12,322,395 cases and 556,335 deaths. To date, only two treatments, remdesivir and dexamethasone, have demonstrated clinical efficacy through randomized controlled trials (RCTs) in seriously ill patients. The search for new or repurposed drugs for treatment of COVID-19 continues. We have witnessed anecdotal use of herbal medicines, including Artemisia spp. extracts, in low-income countries, and exaggerated claims of their efficacies that are not evidence based, with subsequent political controversy. These events highlight the urgent need for further research on herbal compounds to evaluate efficacy through RCTs, and, when efficacious compounds are identified, to establish the active ingredients, develop formulations and dosing, and define pharmacokinetics, toxicology, and safety to enable drug development. Derivatives from the herb Artemisia annua have been used as traditional medicine over centuries for the treatment of fevers, malaria, and respiratory tract infections. We review the bioactive compounds, pharmacological and immunological effects, and traditional uses for Artemisia spp. derivatives, and discuss the challenges and controversies surrounding current efforts and the scientific road map to advance them to prevent or treat COVID-19.
C1 [Kapepula, Paulin M.; Kabengele, Jimmy K.] Univ Kinshasa, Fac Pharmaceut Sci, Ctr Etud Subst Nat Origine Vegetale CESNOV, Kinshasa, DEM REP CONGO.
   [Kingombe, Micheline] Minist Publ Hlth, Natl Program Promot Tradit Med & Med Plants PNMT, Kinshasa, DEM REP CONGO.
   [Van Bambeke, Francoise; Tulkens, Paul M.] Univ Catholique Louvain UCLouvain, Louvain Drug Res Inst, Pharmacol Cellulaire & Mol, Brussels, Belgium.
   [Kishabongo, Antoine Sadiki] Univ Catholique Bukavu UCB, Dept Clin Biol, Bukavu, DEM REP CONGO.
   [Decloedt, Eric] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Med, Div Clin Pharmacol, Cape Town, South Africa.
   [Zumla, Adam; Tiberi, Simon] Queen Mary Univ London, Barts & London Sch Med & Dent, London, England.
   [Suleman, Fatima] Univ KwaZulu Natal, Pharmaceut Sci, Durban, South Africa.
   [Tshilolo, Leon] Monkole Hosp Ctr, Unit Sickle Cell Dis & Clin Res, Kinshasa, DEM REP CONGO.
   [Tshilolo, Leon] Ctr Hosp Monkole, Le Ctr Format & Appui Sanit CEFA, Kinshasa, DEM REP CONGO.
   [Tshilolo, Leon] Official Univ Mbuji Mayi UOM, Dept Pediat, Kinshasa, DEM REP CONGO.
   [Muyembe-TamFum, Jean-Jacques] Natl Inst Biomed Res INRB, Kinshasa, DEM REP CONGO.
   [Muyembe-TamFum, Jean-Jacques] Univ Kinshasa, Fac Med, Dept Med Microbiol & Virol, Kinshasa, DEM REP CONGO.
   [Zumla, Alimuddin] UCL, Ctr Clin Microbiol, Dept Infect, Div Infect & Immun, London, England.
   [Zumla, Alimuddin] UCL, Hosp, Natl Inst Hlth Res Biomed Res Ctr, London, England.
   [Nachega, Jean B.] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Med & Ctr Infect Dis, Cape Town, South Africa.
   [Nachega, Jean B.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
   [Nachega, Jean B.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
   [Nachega, Jean B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, 130 DeSoto St,Crabtree Hall A531, Pittsburgh, PA 15260 USA.
   [Nachega, Jean B.] Univ Pittsburgh, Dept Infect Dis, Grad Sch Publ Hlth, 130 DeSoto St,Crabtree Hall A531, Pittsburgh, PA 15260 USA.
   [Nachega, Jean B.] Univ Pittsburgh, Dept Microbiol, Grad Sch Publ Hlth, 130 DeSoto St,Crabtree Hall A531, Pittsburgh, PA 15260 USA.
   [Nachega, Jean B.] Univ Pittsburgh, Ctr Global Hlth, Grad Sch Publ Hlth, 130 DeSoto St,Crabtree Hall A531, Pittsburgh, PA 15260 USA.
RP Nachega, JB (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, 130 DeSoto St,Crabtree Hall A531, Pittsburgh, PA 15260 USA.; Nachega, JB (corresponding author), Univ Pittsburgh, Dept Infect Dis, Grad Sch Publ Hlth, 130 DeSoto St,Crabtree Hall A531, Pittsburgh, PA 15260 USA.; Nachega, JB (corresponding author), Univ Pittsburgh, Dept Microbiol, Grad Sch Publ Hlth, 130 DeSoto St,Crabtree Hall A531, Pittsburgh, PA 15260 USA.; Nachega, JB (corresponding author), Univ Pittsburgh, Ctr Global Hlth, Grad Sch Publ Hlth, 130 DeSoto St,Crabtree Hall A531, Pittsburgh, PA 15260 USA.
EM garaphmutwal@yahoo.fr; jimmykabeya2014@gmail.com; bilungula@gmail.com;
   francoise.vanbambeke@uclouvain.be; tulkens@facm.ucl.ac.be;
   santoines@yahoo.fr; ericdecloedt@sun.ac.za; adam.zumla@nhs.net;
   simon.tiberi@nhs.net; sulemanf@ukzn.ac.za; leon.tshilolo2012@gmail.com;
   jjmuyembet@gmail.com; a.zumla@ucl.ac.uk; jbn16@pitt.edu
OI Zumla, Professor Sir Alimuddin/0000-0002-5111-5735
FU U.S. National Institutes of Health (NIH)/National Institutes of Allergy
   and Infectious Diseases [5U01AI069521]; NIH/Fogarty International
   CenterUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)
   [1R25TW011217-01, 1D43TW01093701A1]; EU Horizon 2020 Framework Program
   for Research and Innovation; Fogarty International Center (FIC)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Fogarty International Center (FIC); NIH Common
   FundUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; Office of Strategic Coordination,
   Office of the Director (OD/OSC/CF/NIH), Office of AIDS Research, Office
   of the Director (OAR/NIH); National Institute of Mental Health
   (NIMH/NIH) of the National Institutes of Health [D43TW010131]
FX J. B. N. is an infectious diseases internist and epidemiologist
   supported by the U.S. National Institutes of Health (NIH)/National
   Institutes of Allergy and Infectious Diseases (Grant number
   5U01AI069521) (Stellenbosch University Clinical Trial Unit of the AIDS
   Clinical Trial Group) as well as NIH/Fogarty International Center (Grant
   numbers 1R25TW011217-01 [African Association for Health Professions
   Education and Research] and 1D43TW01093701A1 [University of Pittsburgh
   HIV Comorbidities Research Training Program in South Africa]), and A. Z.
   is funded by the EU Horizon 2020 Framework Program for Research and
   Innovation. F. S. is a public health pharmacist supported by a
   NIH/Fogarty International Center (Grant number 1R25TW011217-01) (African
   Association for Health Professions Education and Research) as well as
   the Fogarty International Center (FIC); NIH Common Fund; Office of
   Strategic Coordination, Office of the Director (OD/OSC/CF/NIH), Office
   of AIDS Research, Office of the Director (OAR/NIH); and the National
   Institute of Mental Health (NIMH/NIH) of the National Institutes of
   Health under award number D43TW010131. Publication charges for this
   article were waived due to the ongoing pandemic of COVID-19.
CR [Anonymous], 2020, 166 WHO
   Bhakuni RS, 2001, CURR SCI INDIA, V80, P35
   Bhatt S, 2015, NATURE, V526, P207, DOI 10.1038/nature15535
   Bilia AR, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/159819
   Cheong DHJ, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104901
   Desrosiers MR, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020254
   Efferth T, 2008, CLIN INFECT DIS, V47, P804, DOI 10.1086/591195
   Ferreira JFS, 2010, MOLECULES, V15, P3135, DOI 10.3390/molecules15053135
   Kanyinda JNM, 2020, EUR J MED HLTH SCI, V2, P1
   KHAN MMAA, 1991, PLANT SCI, V75, P161, DOI 10.1016/0168-9452(91)90230-6
   Kim WS, 2015, KOREAN J PHYSIOL PHA, V19, P21, DOI 10.4196/kjpp.2015.19.1.21
   Li SY, 2005, ANTIVIR RES, V67, P18, DOI 10.1016/j.antiviral.2005.02.007
   Li YJ, 2015, TOXICOL APPL PHARM, V286, P151, DOI 10.1016/j.taap.2015.04.005
   Liu CX, 2020, CHIN HERB MED, V12, P97, DOI 10.1016/j.chmed.2020.03.004
   Mukherjee P. K., 2019, QUALITY CONTROL EVAL, P599
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Suryanarayana L, 2020, INT J RES ENG SCI MA, V3, P675
   van der Kooy F, 2013, J ETHNOPHARMACOL, V150, P1, DOI 10.1016/j.jep.2013.08.021
   van der Kooy F, 2011, PLANTA MED, V77, P1754, DOI 10.1055/s-0030-1271065
   Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5
   Wagner H, 2016, CHROMATOGRAPHIC FING, V4, P247
   Wang XG, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104810
   Willcox M, 2004, TRA HERB, V4, P43
   World Health Organization, 2015, GUID TREATM MAL
   World Health Organization Africa, 2020, WHO SUPP SCI PROV TR
   Zeyuan L, 2018, ARTEMISININ BASED OT, P129
NR 26
TC 2
Z9 2
U1 3
U2 3
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD SEP
PY 2020
VL 103
IS 3
BP 960
EP 964
DI 10.4269/ajtmh.20-0820
PG 5
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA OE8XL
UT WOS:000580806400012
PM 32705976
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Solis, JG
   Pineda, AE
   Minutti, PA
   Sanchez, AA
AF Gabriel Solis, Jose
   Esquivel Pineda, Alejandra
   Alberti Minutti, Paolo
   Albarran Sanchez, Alejandra
TI Case Report: Rhabdomyolysis in a Patient with COVID-19: A Proposed
   Diagnostic-Therapeutic Algorithm
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
AB COVID-19 represents the greatest health challenge of modern years. The spectrum of illness comprises respiratory and non-respiratory manifestations. We report the case of an adult man with COVID-19 who presented with rhabdomyolysis as a principal extrapulmonary manifestation. Our patient presented with dyspnea, fever, and muscle pain. After a comprehensive approach, the diagnosis of COVID-19 and rhabdomyolysis was made. He developed acute kidney injury requiring renal replacement therapy without reversibility, despite optimal treatment. We performed a literature search for similar cases, discuss the potential mechanisms implied, and propose a diagnostic-therapeutic algorithm.
C1 [Gabriel Solis, Jose; Esquivel Pineda, Alejandra; Alberti Minutti, Paolo; Albarran Sanchez, Alejandra] Inst Mexicano Seguro Social IMSS, Ctr Med Nacl Siglo XXI, Internal Med Dept, Cuauhtemoc Ave 330, Mexico City 06720, DF, Mexico.
RP Minutti, PA (corresponding author), Inst Mexicano Seguro Social IMSS, Ctr Med Nacl Siglo XXI, Internal Med Dept, Cuauhtemoc Ave 330, Mexico City 06720, DF, Mexico.
EM gabrielsolismd@gmail.com; esquivelpinedaalejandra@gmail.com;
   paolo.alberti@gmail.com; albarranalejandra@gmail.com
OI Albarran, Alejandra/0000-0003-2693-4031; Solis, Jose
   Gabriel/0000-0003-3532-6062; Alberti Minutti, Paolo/0000-0003-3998-3924
CR Batlle D, 2020, J AM SOC NEPHROL, V31, P1
   Chan KH, 2020, AM J EMERG MED, V38, DOI 10.1016/j.ajem.2020.05.015
   Chavez LO, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1314-5
   Chen LL, 2005, INT J CLIN PRACT, V59, P1162, DOI 10.1111/j.1368-5031.2005.00540.x
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Crum-Cianflone NF, 2008, CLIN MICROBIOL REV, V21, P473, DOI 10.1128/CMR.00001-08
   Desdouits M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079628
   Duarte-Neto AN, 2020, HISTOPATHOLOGY, V77, P186, DOI 10.1111/his.14160
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Heyne N, 2009, NEW ENGL J MED, V361, P1412
   Jin M, 2020, EMERG INFECT DIS, V26, P1618, DOI 10.3201/eid2607.200445
   Khan FY, 2009, NETH J MED, V67, P272
   Petejova N, 2014, CRIT CARE, V18, DOI 10.1186/cc13897
   Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
   Ronco C, 2020, NAT REV NEPHROL, V16, P308, DOI 10.1038/s41581-020-0284-7
   Saad M, 2014, INT J INFECT DIS, V29, P301, DOI 10.1016/j.ijid.2014.09.003
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Suwanwongse K, 2020, CUREUS, V12, DOI 10.7759/cureus.7561
   Wang JL, 2003, AM J MED, V115, P421, DOI 10.1016/S0002-9343(03)00448-0
   Worldometer.Info, 2020, COR CAS 2020 JUL 15
   Zhang Q, 2020, CUREUS, V12, DOI 10.7759/cureus.8074
NR 21
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PD SEP
PY 2020
VL 103
IS 3
BP 1158
EP 1161
DI 10.4269/ajtmh.20-0692
PG 4
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA OE8XL
UT WOS:000580806400047
PM 32729460
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Eldanasory, OA
   Rabaan, AA
   Al-Tawfiq, JA
AF Eldanasory, Omar Abdelhay
   Rabaan, Ali A.
   Al-Tawfiq, Jaffar A.
TI Can influenza vaccine modify COVID-19 clinical course?
SO TRAVEL MEDICINE AND INFECTIOUS DISEASE
LA English
DT Letter
DE Influenza vaccine; COVID-19; Immunity; Prophylaxis; SARS-CoV-2
C1 [Eldanasory, Omar Abdelhay] AL Azhar Univ, Al Zahraa Hosp, Fac Med, Neurosurg, Cairo, Egypt.
   [Rabaan, Ali A.] Johns Hopkins Aramco Healthcare, Mol Diagnost Lab, Dhahran, Saudi Arabia.
   [Al-Tawfiq, Jaffar A.] Johns Hopkins Aramco Healthcare, Specialty Internal Med & Qual Dept, Dhahran, Saudi Arabia.
   [Al-Tawfiq, Jaffar A.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
   [Al-Tawfiq, Jaffar A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
RP Al-Tawfiq, JA (corresponding author), Johns Hopkins Aramco Healthcare, Dhahran Hlth Ctr, POB 76,Room A-428Bldg 61, Dhahran 31311, Saudi Arabia.
EM jaffar.tawfiq@jhah.com
OI eldanasory, omar/0000-0001-5289-7452
CR Coudeville L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-18
   Fink G, 2020, INACTIVATED TRIVALEN, DOI [10.1101/2020.06.29.20142505, DOI 10.1101/2020.06.29.20142505]
   Hui KPY, 2020, LANCET RESP MED, V8, P687, DOI 10.1016/S2213-2600(20)30193-4
   Jehi L, 2020, CHEST, V158, P1364, DOI 10.1016/j.chest.2020.05.580
   Poulas K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01373
   Zanettini C, 2020, INFLUENZA VACCINATIO, P2020, DOI [10.1101/2020.06.24.20129817.06.24.20129817, DOI 10.1101/2020.06.24.20129817.06.24.20129817]
NR 6
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1477-8939
EI 1873-0442
J9 TRAVEL MED INFECT DI
JI Travel Med. Infect. Dis.
PD SEP-OCT
PY 2020
VL 37
AR 101872
DI 10.1016/j.tmaid.2020.101872
PG 2
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA OE4BD
UT WOS:000580476900086
PM 32896672
DA 2021-01-01
ER

PT J
AU Gendrot, M
   Andreani, J
   Boxberger, M
   Jardot, P
   Fonta, I
   Le Bideau, M
   Duflot, I
   Mosnier, J
   Rolland, C
   Bogreau, H
   Hutter, S
   La Scola, B
   Pradines, B
AF Gendrot, Mathieu
   Andreani, Julien
   Boxberger, Manon
   Jardot, Priscilla
   Fonta, Isabelle
   Le Bideau, Marion
   Duflot, Isabelle
   Mosnier, Joel
   Rolland, Clara
   Bogreau, Herve
   Hutter, Sebastien
   La Scola, Bernard
   Pradines, Bruno
TI Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro
   evaluation
SO TRAVEL MEDICINE AND INFECTIOUS DISEASE
LA English
DT Article
DE SARS-CoV-2; COVID-19; Antiviral; Antimalarial drugs; In vitro
ID CHLOROQUINE; HYDROXYCHLOROQUINE; BLOOD; PYRONARIDINE; AMODIAQUINE;
   COMBINATION; MEFLOQUINE
AB In December 2019, a new severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing coronavirus diseases 2019 (COVID-19) emerged in Wuhan, China. African countries see slower dynamic of COVID-19 cases and deaths. One of the assumptions that may explain this later emergence in Africa, and more particularly in malaria endemic areas, would be the use of antimalarial drugs. We investigated the in vitro antiviral activity against SARS-CoV-2 of several antimalarial drugs. Chloroquine (EC50 = 2.1 mu M and EC90 = 3.8 mu M), hydroxychloroquine (EC50 = 1.5 mu M and EC90 = 3.0 mu M), ferroquine (EC50 = 1.5 mu M and EC90 = 2.4 mu M), desethylamodiaquine (EC50 = 0.52 mu M and EC90 = 1.9 mu M), mefloquine (EC50 = 1.8 mu M and EC90 = 8.1 mu M), pyronaridine (EC50 = 0.72 mu M and EC90 = 0.75 mu M) and quinine (EC50 = 10.7 mu M and EC90 = 38.8 mu M) showed in vitro antiviral effective activity with IC50 and IC90 compatible with drug oral uptake at doses commonly administered in malaria treatment. The ratio C-lung/EC90 ranged from 5 to 59. Lumefantrine, piperaquine and dihydroartemisinin had IC50 and IC90 too high to be compatible with expected plasma concentrations (ratio C-max/EC90 < 0.05). Based on our results, we would expect that countries which commonly use artesunate-amodiaquine or artesunate-mefloquine report fewer cases and deaths than those using artemether-lumefantrine or dihydroartemisinin-piperaquine. It could be necessary now to compare the antimalarial use and the dynamics of COVID-19 country by country to confirm this hypothesis.
C1 [Gendrot, Mathieu; Fonta, Isabelle; Mosnier, Joel; Bogreau, Herve; Pradines, Bruno] Inst Rech Biomed Armees, Dept Microbiol & Malad Infect, Unite Parasitol & Entomol, Marseille, France.
   [Gendrot, Mathieu; Fonta, Isabelle; Mosnier, Joel; Bogreau, Herve; Hutter, Sebastien; Pradines, Bruno] Aix Marseille Univ, AP HM, VITROME, SSA,IRD, Marseille, France.
   [Gendrot, Mathieu; Andreani, Julien; Boxberger, Manon; Jardot, Priscilla; Fonta, Isabelle; Le Bideau, Marion; Duflot, Isabelle; Mosnier, Joel; Rolland, Clara; Bogreau, Herve; Hutter, Sebastien; La Scola, Bernard; Pradines, Bruno] IHU Mediterranee Infect, Marseille, France.
   [Andreani, Julien; Boxberger, Manon; Jardot, Priscilla; Le Bideau, Marion; Duflot, Isabelle; Rolland, Clara; La Scola, Bernard] Aix Marseille Univ, AP HM, MEPHI, IRD, Marseille, France.
   [Fonta, Isabelle; Mosnier, Joel; Bogreau, Herve; Pradines, Bruno] Ctr Natl Reference Paludisme, Marseille, France.
RP La Scola, B; Pradines, B (corresponding author), Inst Rech Biomed Armees, Unite Parasitol & Entomol, IHU Mediterranee Infect, 19-21 Blvd Jean Moulin, F-13005 Marseille, France.; Pradines, B (corresponding author), IHU Mediterranee Infect, MEPHI, 19-21 Blvd Jean Moulin, F-13005 Marseille, France.
EM bruno.pradines@gmail.com; bernard.la-scola@univ-amu.fr
RI Gendrot, Mathieu/ABI-6205-2020
FU Institut Hospitalo-Universitaire (IHU) Mediterranee Infection, the
   National Research Agency under the program "Investissements
   d'avenir"French National Research Agency (ANR) [ANR-10-IAHU-03]
FX This study was supported by the Institut Hospitalo-Universitaire (IHU)
   Mediterranee Infection, the National Research Agency under the program
   "Investissements d'avenir", reference ANR-10-IAHU-03.
CR Abd-Elsalam S, 2020, AM J TROP MED HYG, DOI [10.4269/ajtmh.20.0873, DOI 10.4269/AJTMH.20.0873]
   Acharya Y, 2020, THER ADV INFECT DIS, V7, DOI 10.1177/2049936120947517
   Adedeji ON, 2015, ANTIMICROB AGENTS CH, V59, P5114, DOI 10.1128/AAC.04957-14
   Adehin A, 2019, CURR THER RES CLIN E, V91, P33, DOI 10.1016/j.curtheres.2019.100567
   Alkadi HO, 2007, CHEMOTHERAPY, V53, P385, DOI 10.1159/000109767
   Amrane S, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101632
   Andreani J, 2020, MICROB PATHOGENESIS, V145, DOI 10.1016/j.micpath.2020.104228
   Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099
   Barnard Dale L., 2006, Antiviral Chemistry & Chemotherapy, V17, P275
   Biot C, 2006, J MED CHEM, V49, P2845, DOI 10.1021/jm0601856
   Boonyasuppayakorn S, 2014, ANTIVIR RES, V106, P125, DOI 10.1016/j.antiviral.2014.03.014
   Cairoli E, 2020, MED CLIN-BARCELONA, V155, P134, DOI 10.1016/j.medcli.2020.05.006
   Cao YN, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0147-1
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Chhonker YS, 2018, J CHROMATOGR B, V1072, P320, DOI 10.1016/j.jchromb.2017.11.026
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Croft SL, 2012, MALARIA J, V11, P170
   Fan HH, 2020, CHINESE MED J-PEKING, V133, P1051, DOI [10.1097/CM9.0000000000000797, 10.1080/15384047.2020.1792218]
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Frolich T, 2018, CHEMISTRY, V24, P8103
   FU S, 1991, PARASITOL TODAY, V7, P310, DOI 10.1016/0169-4758(91)90267-R
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Gendrot M, 2020, INT J INFECT DIS, DOI [10.1016/j.ijid.2020.08.0.2, DOI 10.1016/J.IJID.2020.08.0.2]
   Gendrot M, 2020, IN VITRO ANTIVIRAL A
   Gendrot M, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105980
   Hong KS, 2020, INFECT CHEMOTHER, V52, P396, DOI 10.3947/ic.2020.52.3.396
   JONES R, 1994, FORENSIC SCI INT, V68, P29, DOI 10.1016/0379-0738(94)90376-X
   Lagier JC, 2020, TRAVEL MED INFECT DI, V36, DOI 10.1016/j.tmaid.2020.101791
   Lane TR, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007890
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu W, 2020, PREPRINT, DOI [10.26434/chemrxiv.11938173.v6., DOI 10.26434/CHEMRXIV.11938173.V6]
   Lopez A, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106136
   Maisonnasse P, 2020, NATURE, V585, P584, DOI 10.1038/s41586-020-2558-4
   McCarthy JS, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1511-3
   Michel R, 2010, T ROY SOC TROP MED H, V104, P290, DOI 10.1016/j.trstmh.2009.10.001
   Million M, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101738
   MINCHIN RF, 1981, J PHARM PHARMACOL, V33, P464, DOI 10.1111/j.2042-7158.1981.tb13835.x
   Mitja Oriol, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1009
   Morris CA, 2015, EUR J DRUG METAB PH, V40, P75, DOI 10.1007/s13318-014-0182-0
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Mwebaza N, 2013, BASIC CLIN PHARMACOL, V113, P66, DOI 10.1111/bcpt.12065
   Oiknine-Djian E, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.00288-18, 10.1128/aac.00288-18]
   Paccoud Olivier, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa791
   Park SH, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/590707
   Popert A J, 1976, Rheumatol Rehabil, V15, P235, DOI 10.1093/rheumatology/15.3.235
   Potasman I, 2000, J TRAVEL MED, V7, P5
   Pradines B, 2001, J ANTIMICROB CHEMOTH, V48, P179, DOI 10.1093/jac/48.2.179
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Reuter SE, 2015, CLIN DRUG INVEST, V35, P559, DOI 10.1007/s40261-015-0312-8
   Roy S, 2015, ANTIMICROB AGENTS CH, V59, P3870, DOI 10.1128/AAC.00262-15
   Schlagenhauf P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101658
   Servonnet A, 2005, ANN TOXICOL ANAL, V17, P87
   Silva-Pinto A, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1698-y
   Touret F, 2020, ANTIVIR RES, V177, DOI 10.1016/j.antiviral.2020.104762
   vandenBorne BEEM, 1997, J RHEUMATOL, V24, P55
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wernsdorfer WH, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-443
   WINSTANLEY PA, 1988, J PHARM PHARMACOL, V40, P343, DOI 10.1111/j.2042-7158.1988.tb05264.x
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xue HY, 2020, J MED VIROL, V92, P2523, DOI 10.1002/jmv.26193
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yu B, 2020, SCI CHINA LIFE SCI, DOI 10.1007/s11427-020-1782-1
NR 68
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1477-8939
EI 1873-0442
J9 TRAVEL MED INFECT DI
JI Travel Med. Infect. Dis.
PD SEP-OCT
PY 2020
VL 37
AR 101873
DI 10.1016/j.tmaid.2020.101873
PG 6
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA OE4BD
UT WOS:000580476900087
PM 32916297
OA Green Published
DA 2021-01-01
ER

PT J
AU Magro, G
AF Magro, Giuseppe
TI SARS-CoV-2 and COVID-19: What are our options? Where should we focus our
   attention on to find new drugs and strategies?
SO TRAVEL MEDICINE AND INFECTIOUS DISEASE
LA English
DT Letter
DE SARS-CoV-2; COVID-19; Therapies; Drugs; Strategies; Targets; SARS-CoV;
   Coronavirus; Coronaviruses; Corona virus cycle; Baricitinib;
   Hydroxychloroquine; Remdesivir; Tocilizumab
C1 [Magro, Giuseppe] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy.
RP Magro, G (corresponding author), Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy.
EM g1us3pp3m4gr0@gmail.com
OI Magro, Giuseppe/0000-0002-8187-8354
CR de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Zhang X, 2007, VIROLOGY, V365, P324, DOI 10.1016/j.virol.2007.04.009
NR 6
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1477-8939
EI 1873-0442
J9 TRAVEL MED INFECT DI
JI Travel Med. Infect. Dis.
PD SEP-OCT
PY 2020
VL 37
AR 101685
DI 10.1016/j.tmaid.2020.101685
PG 2
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA OE4BD
UT WOS:000580476900020
PM 32334088
OA Green Published
DA 2021-01-01
ER

PT J
AU Bertolaccini, L
   Spaggiari, L
AF Bertolaccini, Luca
   Spaggiari, Lorenzo
TI Opening and closing the doors of the lockdown in Italy without
   forgetting lung cancer patients
SO INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY
LA English
DT Article
DE Coronavirus; Coronavirus disease-19; SARS-CoV-2; Lung cancer; Healthcare
   reorganization; Biostatistics
AB Coronavirus disease-19 (COVID-19) has rapidly spread to more than 200 countries all around the world, which are facing challenges in controlling its spread. The Italian Government initiated an unprecedented public health intervention to contain the epidemic by shutting down all people movements. Two weeks after the start of the lockdown period, the daily rate of patient admissions to hospitals significantly decreased. After 2 months, the quarantine progressively came to an end. A practical issue at this time is when and how the lockdown interventions should be relaxed since, without an effective vaccine, the general public still remains vulnerable. However, patient should not be placed at an increased risk of dying of lung cancer just to avoid COVID-19. Attention must be paid to all types of cancers and people should not hesitate to go to the hospital to be treated in time. All necessary actions should be taken by hospitals to minimize the risks of potential contagion, by designating differentiated routes and areas for patients potentially affected by COVID-19, while maintaining the highest standard of oncological care. If this 'cancer amnesia' situation persists, the mortality from lung neoplasms would far exceed that directly associated with the COVID-19 pandemic.
C1 [Bertolaccini, Luca; Spaggiari, Lorenzo] European Inst Oncol IRCCS, Dept Thorac Surg, IEO, Via Ripamonti 435, I-20141 Milan, Italy.
   [Spaggiari, Lorenzo] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy.
RP Bertolaccini, L (corresponding author), European Inst Oncol IRCCS, Dept Thorac Surg, IEO, Via Ripamonti 435, I-20141 Milan, Italy.
EM luca.bertolaccini@gmail.com
RI Bertolaccini, Luca/I-8309-2015
OI Bertolaccini, Luca/0000-0002-1153-3334; Spaggiari,
   Lorenzo/0000-0002-1068-3541
FU Italian Ministry of HealthMinistry of Health, Italy
FX This work was partially supported by the Italian Ministry of Health with
   Ricerca Corrente and 5x1000 funds.
CR Bertolaccini L, 2020, INTERACT CARDIOV TH, V30, P801, DOI 10.1093/icvts/ivaa076
   Dipartimento della Protezione Civile, COVID 19 SIT IT
   Garassino M., 2020, AM ASS CANC RES VIRT
   Ji T, 2020, CLIN INFECT DIS, V71, P1454, DOI 10.1093/cid/ciaa390
   Lau H, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa037
   Samson P, 2017, ANN THORAC SURG, V103, P1070, DOI 10.1016/j.athoracsur.2016.09.053
   Samson P, 2015, ANN THORAC SURG, V99, P1906, DOI 10.1016/j.athoracsur.2015.02.022
NR 7
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1569-9293
EI 1569-9285
J9 INTERACT CARDIOV TH
JI Interact Cardiovasc. Thorac. Surg.
PD SEP
PY 2020
VL 31
IS 3
BP 339
EP 341
DI 10.1093/icvts/ivaa106
PG 3
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA OK2PN
UT WOS:000584493100007
PM 32728692
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Gonzalez, SE
   Regairaz, L
   Ferrando, NS
   Martinez, VVG
   Salazar, MR
   Estenssor, E
AF Gonzalez, Soledad E.
   Regairaz, Lorena
   Ferrando, Noelia S.
   Gonzalez Martinez, Veronica V.
   Salazar, Martin R.
   Estenssor, Elisa
TI Convalescent plasma therapy in COVID-19 patients, in the Province of
   Buenos Aires
SO MEDICINA-BUENOS AIRES
LA Spanish
DT Article
DE COVID-19; convalescent plasma; expanded access program
AB This is a preliminary, multicenter, retrospective cohort study, including 272 consecutive patients with COVID-19 admitted to hospitals in Buenos Aires Province, between May 15th and July 1st, 2020, included in an expanded access program to convalescent plasma. Our objectives were to analyze mortality and its independent risk factors, and to assess the occurrence of a favorable evolution, defined as hospital discharge, or stay at the ward, or transfer from ICU to ward. Patients were stratified into 4 subgroups: admission to the ward with pneumonia and/or oxygen requirement (WARD; n = 100); ICU admission (ICU; n = 87); ICU admission with requirement of mechanical ventilation (ICU-MV; n = 56), and ICU-MV plus septic shock (ICU-MV-SS; N = 29). Mortality at 28 days was 26.1% for the entire group, 14.0% for WARD group, 18.4% for ICU, 44.6% for ICU-MV, and 55.2% for ICU-MV-SS. Mean survival time (days) was 25.6 +/- 0.6 (WARD); 25.3 +/- 0.7 (ICU); 20.8 +/- 1.2 (ICU-MV) and 18.2 +/- 1.8 (ICU-MV-SS). Independent predictors of mortality were MV, septic shock and weight. A favorable evolution occurred in 81.4% of WARD patients; in 70.9% of ICU; in 39.6% of ICU-MV and in 27.6% of ICU-MV-SS patients. Severity of illness on admission, age, weight and heart rate were independently associated with evolution. No major adverse effects were recorded. The lack of a control group precluded the estimation of efficacy. However, our 26% mortality rate was higher than that of the treatment arm of clinical trials comparing plasma with usual treatment, which might be ascribed to higher proportion of patients with MV and septic shock in our cohort.
C1 [Gonzalez, Soledad E.] Minist Salud Prov Buenos Aires, La Plata, Argentina.
   [Regairaz, Lorena] Hosp Interzonal Agudos Especializado Pediat Sor M, Serv Inmunol, La Plata, Argentina.
   [Ferrando, Noelia S.] Minist Salud Prov Buenos Aires, Inst Hemoterapia, La Plata, Argentina.
   [Gonzalez Martinez, Veronica V.] Minist Salud Prov Buenos Aires, Direcc Invest & Cooperac Tecn, La Plata, Argentina.
   [Salazar, Martin R.] Hosp Interzonal Agudos San Martin, Serv Docencia & Invest, La Plata, Argentina.
   [Estenssor, Elisa] Hosp Interzonal Agudos San Martin, Terapia Intens, La Plata, Argentina.
RP Gonzalez, SE (corresponding author), Ave 51 N 1120 Entre 17 & 18, RA-1900 La Plata, Argentina.
EM sole.estrella.gonzalez@gmail.com
CR Abolghasemi H, 2020, TRANSFUS APHER SCI, V59, DOI 10.1016/j.transci.2020.102875
   Arabi YM, 2016, EMERG INFECT DIS, V22, P1554, DOI 10.3201/eid2209.151164
   CASADEVALL A, 1995, CLIN INFECT DIS, V21, P150, DOI 10.1093/clinids/21.1.150
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Estenssoro E, 2018, CRIT CARE MED, V46, P1276, DOI 10.1097/CCM.0000000000003208
   Gharbharan A, 2020, CONVALESCENT PLASMA, DOI [10.1101/2020.07.01.20139857, DOI 10.1101/2020.07.01.20139857, 10.1101/2020.07.01.20139857.]
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Joyner MJ, 2020, MAYO CLIN PROC, V95, P1888, DOI 10.1016/j.mayocp.2020.06.028
   Kalligeros M, 2020, OBESITY, V28, P1200, DOI 10.1002/oby.22859
   Laffey JG, 2017, LANCET RESP MED, V5, P627, DOI [10.1016/S2213-2600(17)30213-8, 10.1016/s2213-2600(17)30213-8]
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Liu STH, 2020, CONVALESCENT PLASMA, DOI [10.1101/2020.05.20.20102236, DOI 10.1101/2020.05.20.20102236]
   Machado FR, 2017, LANCET INFECT DIS, V17, P1180, DOI 10.1016/S1473-3099(17)30322-5
   MAIZTEGUI JI, 1979, LANCET, V2, P1216
   McAllister F, 2020, MEDICINA-BUENOS AIRE, V80, P82
   Narick C, 2012, TRANSFUSION, V52, P160, DOI 10.1111/j.1537-2995.2011.03247.x
   Rasheed AM, THERAPEUTIC EFFECTIV, DOI [10.1101/2020.06.24.20121905, DOI 10.1101/2020.06.24.20121905]
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Xai CC, 2020, INT J ANTIMICROB AG, V55
   Xia XY, 2020, BLOOD, V136, P755, DOI 10.1182/blood.2020007079
NR 25
TC 0
Z9 0
U1 1
U2 1
PU MEDICINA (BUENOS AIRES)
PI BUENOS AIRES
PA DONATO ALVAREZ 3150, 1427 BUENOS AIRES, ARGENTINA
SN 0025-7680
EI 1669-9106
J9 MEDICINA-BUENOS AIRE
JI Med.-Buenos Aires
PD SEP-OCT
PY 2020
VL 80
IS 5
BP 417
EP 424
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA OL2SG
UT WOS:000585191500001
PM 33048783
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Pulido, L
   Solis-Aramayo, MA
   Ibarrola, M
   Heres, M
   Falco, J
   Tomaszuk, G
   Churin, L
   Maggio, P
   Martin, V
   Hernandez, M
   Garcia-Zamora, S
   Ouadrelli, S
AF Pulido, Laura
   Solis-Aramayo, Marco A.
   Ibarrola, Manuel
   Heres, Marcela
   Falco, Jimena
   Tomaszuk, Giselle
   Churin, Lisandro
   Maggio, Patricia
   Martin, Vanina
   Hernandez, Marcos
   Garcia-Zamora, Sebastian
   Ouadrelli, Silvia
TI Initial experience in the attention of patients with COVID-19 in a
   private third-level hospital in Buenos Aires city
SO MEDICINA-BUENOS AIRES
LA Spanish
DT Article
DE SARS-CoV-2 infection; coronavirus-19; hospitalization; mortality
AB Infection with the SARS coronavirus type 2 (COVID-19) has a variety of presentations, with little data on the evolution of affected patients in Argentina. This is a retrospective and observational study of patients with virological confirmation of coronavirus treated during the months of March to May in a private third-level university hospital in Buenos Aires. One hundred and fifty-five adult patients were included, of which 30.3% attended only for a swab; 59.4% were admitted to the hospital and 10.3% were hospitalized at home with daily telephone follow-up. Fifty-four point two percent of participants were women and the median age was 35 years (ICQ 29 to 50). About 59.3% of patients had some risk factor, including age (65 years old or more), underlying chronic disease, were health workers or personneVresidents in a nursing home. The most frequent symptom was fever (75.9%), followed by cough (65.7%), and odynophagia (48.2%). Globally, 93.5% experienced some symptoms while 17.6% of the participants presented some symptoms but without fever. Chest tomographies were performed to 5 patients. Their chest radiograph was normal or non-diagnostic. Fourteen patients required intensive therapy and 6 of them required mechanical ventilation, 4 of them died. The remaining 2 patients were referred to chronic care centers. No patient with home hospitalization required admission to hospital or died. While this observation is encouraging, it will need to be confirmed with new studies.
C1 [Pulido, Laura; Solis-Aramayo, Marco A.; Ibarrola, Manuel; Heres, Marcela; Falco, Jimena; Tomaszuk, Giselle; Churin, Lisandro; Maggio, Patricia; Martin, Vanina; Hernandez, Marcos; Ouadrelli, Silvia] Fdn Sanatorio Guemes, Serv Neumonol, Buenos Aires, DF, Argentina.
   [Garcia-Zamora, Sebastian] Serv Cardiodiagnost, Invest Med, Buenos Aires, DF, Argentina.
RP Solis-Aramayo, MA (corresponding author), Francisco Acuna de Figueroa 1240, RA-1180 Buenos Aires, DF, Argentina.
EM msolisaramayo@yahoo.com.ar
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Barrett Emily S, 2020, medRxiv, DOI 10.1101/2020.04.20.20072470
   Basbus L, 2020, MEDICINA-BUENOS AIRE, V80, P31
   Carboni Bisso Indalecio, 2020, Medicina (B. Aires), V80, P25
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chou R, 2020, ANN INTERN MED, V173, P120, DOI 10.7326/M20-1632
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Goodyear MDE, 2007, BRIT MED J, V335, P624, DOI 10.1136/bmj.39339.610000.BE
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kluytmans-van Den Bergh MFQ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.9673
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Price-Haywood EG, 2020, NEW ENGL J MED, V382, P2534, DOI 10.1056/NEJMsa2011686
   Rearte A, 2020, REV ARGENT SALUD PUB, V12, pe5
   Wainer P, 2020, MEDICINA-BUENOS AIRE, V80, P193
   Wang DW, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02895-6
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 18
TC 0
Z9 0
U1 0
U2 0
PU MEDICINA (BUENOS AIRES)
PI BUENOS AIRES
PA DONATO ALVAREZ 3150, 1427 BUENOS AIRES, ARGENTINA
SN 0025-7680
EI 1669-9106
J9 MEDICINA-BUENOS AIRE
JI Med.-Buenos Aires
PD SEP-OCT
PY 2020
VL 80
IS 5
BP 433
EP 438
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA OL2SG
UT WOS:000585191500003
PM 33048785
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Vecchio, G
   Zapico, V
   Catanzariti, A
   Bisso, IC
   Heras, ML
AF Vecchio, Gisela
   Zapico, Valeria
   Catanzariti, Alejandro
   Carboni Bisso, Indalecio
   Las Heras, Marcos
TI Adverse effects of lopinavir/ritonavir in critically ill patients with
   COVID-19
SO MEDICINA-BUENOS AIRES
LA Spanish
DT Article
DE critical care; COVID-19; Argentina; lopinavir; ritonavir
AB During the SARS-CoV-2 pandemic many drugs have been used as potential treatments in order to improve the clinical outcome and reduce the mortality. But since it is a currently unknown disease, the evidence about efficacy and safety is built as the drugs are prescribed. In this context, intensive pharmacovigilance allows early detection of adverse events, and thereby infer the safety profile of the indication. We conducted an observational, retrospective, single-center study involving adult patients with severe SARS-CoV-2 infection. All adverse events detected in 23 patients in the Intensive Care Unit between March 15 and June 15, 2020 were registered. We describe type and severity of the adverse events and if treatment suspension was needed. The results show a high rate of adverse events (10/23, 43%) in treatment with lopinavir/ritonavir. In most cases early treatment suspension was required. Even though the limitations of our study derived from the small sample size, these results could help in building evidence about the safety of using lopinavir/ritonavir for severe SARS-CoV-2 infection.
C1 [Vecchio, Gisela; Zapico, Valeria; Catanzariti, Alejandro] Hosp Italiano Buenos Aires, Farm, Buenos Aires, DF, Argentina.
   [Vecchio, Gisela; Carboni Bisso, Indalecio; Las Heras, Marcos] Hosp Italiano Buenos Aires, Terapia Intens Adultos, Buenos Aires, DF, Argentina.
RP Vecchio, G (corresponding author), Hosp Italian Buenos Aires, Tte Gral JD Peron 4190, RA-1199 Buenos Aires, DF, Argentina.
EM gisela.vecchio@hospitalitaliano.org.ar
OI Carboni Bisso, Indalecio/0000-0002-4834-4676
CR ANMAT, GUIA BUEN PRACT FARM
   [Anonymous], TRAT FARM ESP LOP RI
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chandler RE, 2020, DRUG SAFETY, V43, P511, DOI 10.1007/s40264-020-00941-4
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Gemelli Nicolas Alejandro, 2020, Disaster Med Public Health Prep, P1, DOI 10.1017/dmp.2020.116
   Li Y, 2020, MED, V1, P1
   NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154
   Tobaiqy M, 2020, 061620133298 MEDRXIV
NR 9
TC 0
Z9 0
U1 0
U2 0
PU MEDICINA (BUENOS AIRES)
PI BUENOS AIRES
PA DONATO ALVAREZ 3150, 1427 BUENOS AIRES, ARGENTINA
SN 0025-7680
EI 1669-9106
J9 MEDICINA-BUENOS AIRE
JI Med.-Buenos Aires
PD SEP-OCT
PY 2020
VL 80
IS 5
BP 439
EP 441
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA OL2SG
UT WOS:000585191500004
PM 33048786
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Davidescu, EI
   Odajiu, I
   Ilie, MD
   Bunea, T
   Sandu, G
   Stratan, L
   Iftode, N
   Arama, V
   Popescu, BO
AF Davidescu, Eugenia Irene
   Odajiu, Irina
   Ilie, Mirela Dumitrita
   Bunea, Teodora
   Sandu, Georgiana
   Stratan, Laurentiu
   Iftode, Nicoleta
   Arama, Victoria
   Popescu, Bogdan Ovidiu
TI INFLUENCE OF TOCILIZUMAB ON THE OUTCOME OF PATIENTS WITH COVID-19.
   RETROSPECTIVE OBSERVATIONAL STUDY
SO FARMACIA
LA English
DT Article
DE COVID-19; severe form; tocilizumab
ID CORONAVIRUS; RECEPTOR; PNEUMONIA; ANTIBODY; EFFICACY
AB Cytokine storm seems to be one of the main culprits for developing a severe form of COVID-19, IL-6 being one of its basic components. Therefore, currently, tocilizumab is widely studied as a powerful treatment in patients with severe forms of COVID-19. Our aim was to determine whether it could potentiate a favourable outcome in such patients. We conducted a retrospective observational study including all consecutive admitted patients with confirmed SARS-CoV-2 infection that received treatment with tocilizumab in the period between 01.05-23.08.2020 in "Matei Bal." National Institute for Infectious Diseases and Neurology Department of the Colentina Clinical Hospital in Bucharest, Romania. 22 patients were enrolled with a severe form of COVID-19, predominantly women, with an average age of of 61.72 +/- 14.5 years. The fatality rate was 31.81%. It was observed that following tocilizumab administration, patients presented improvement in the majority of the studied parameters, statistically significant in the case of fibrinogen, C reactive protein and blood oxygen level (p < 0.05). Tocilizumab might be regarded as a valuable drug in the management of severe SARS-CoV-2 infection.
C1 [Davidescu, Eugenia Irene; Odajiu, Irina; Ilie, Mirela Dumitrita; Bunea, Teodora; Sandu, Georgiana; Popescu, Bogdan Ovidiu] Colentina Clin Hosp, Neurol Dept, Bucharest, Romania.
   [Davidescu, Eugenia Irene; Stratan, Laurentiu; Arama, Victoria; Popescu, Bogdan Ovidiu] Carol Davila Univ Med & Pharm, Bucharest, Romania.
   [Popescu, Bogdan Ovidiu] Victor Babes Natl Inst Pathol, Lab Cell Biol Neurosci & Expt Myol, Bucharest, Romania.
   [Stratan, Laurentiu; Iftode, Nicoleta; Arama, Victoria] Matei Bals Natl Inst Infect Dis, Bucharest, Romania.
RP Davidescu, EI (corresponding author), Colentina Clin Hosp, Neurol Dept, Bucharest, Romania.; Davidescu, EI (corresponding author), Carol Davila Univ Med & Pharm, Bucharest, Romania.
EM eugenia.davidescu@umfcd.ro
CR Alattar R, 2020, J MED VIROL, P1
   Araki M, 2014, NEUROLOGY, V82, P1302, DOI 10.1212/WNL.0000000000000317
   Aziz M, 2020, J MED VIROL, V92, P2283, DOI 10.1002/jmv.25948
   Blejan IE, 2020, FARMACIA, V68, P512, DOI 10.31925/farmacia.2020.3.17
   Campochiaro C, 2020, EUR J INTERN MED, V76, P43, DOI 10.1016/j.ejim.2020.05.021
   Cantini F, 2017, MEDIAT INFLAMM, V2017, P1
   Capra R, 2020, EUR J INTERN MED, V76, P31, DOI 10.1016/j.ejim.2020.05.009
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Colaneri M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050695
   Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ito H, 2004, GASTROENTEROLOGY, V126, P989, DOI 10.1053/j.gastro.2004.01.012
   Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Martinez-Sanz J, 2020, CLIN MICROBIOL INFEC, P1
   Mikulska M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237831
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Oldfield V, 2009, DRUGS, V69, P609, DOI 10.2165/00003495-200969050-00007
   Perrone F, 2020, TOCILIZUMAB PATIENTS, P1
   Radbel J, 2020, CHEST, V158, pE15, DOI 10.1016/j.chest.2020.04.024
   Schiff MH, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3455
   Somers EC, 2020, CLIN INFECT DIS, V11, P1
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 30
TC 0
Z9 0
U1 0
U2 0
PU SOC STIINTE FARMACEUTICE ROMANIA
PI BUCURESTI
PA BUCURESTI, STR TRAIAN VUIA 6, SECT 1, BUCURESTI, 020956, ROMANIA
SN 0014-8237
EI 2065-0019
J9 FARMACIA
JI Farmacia
PD SEP-OCT
PY 2020
VL 68
IS 5
BP 792
EP 799
DI 10.31925/farmacia.2020.5.4
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OI4LJ
UT WOS:000583251900004
OA Bronze
DA 2021-01-01
ER

PT J
AU Machado, C
   Nicolini, KP
   Nicolini, J
AF Machado, Clodoaldo
   Nicolini, Keller P.
   Nicolini, Jaqueline
TI QSAR STUDIES FOR SARS-CoV-2
SO QUIMICA NOVA
LA Portuguese
DT Article
DE QSAR; drug repositioning; mathematical model; SARS-CoV-2
ID MATHEMATICAL-MODEL; 3CL PROTEASE; INHIBITORS; COVID-19
AB The generation of mathematical models through the quantitative relationship between the chemical structure and the biological activity (QSARs) of compounds was used in this investigation. Mathematical models were generated from compounds available in literature that predicting the biological activity against SARS-CoV-2. The data indicate that the parameters that most interfere and allow to validate the equations are: number of hydrogen bonding donors, maximum projection radius and length perpendicular to the minimum area. This allows us to infer that there is synergism between the basic capacity of the cysteine protein action site present in the virus and the geometric conditions for the three-dimensional alignment to potential compounds with anti-SARS-CoV-2 action. The authors highlight that mathematical models assist in chemical research, but do not replace evaluation of the efficacy in vitro, in vivo, pre-clinical and clinical studies, which are essential for dosage, release or authorization to use any medication or supplement.
C1 [Machado, Clodoaldo] Inst Fed Educ Ciencia & Tecnol Santa Catarina, BR-89251000 Jaragua Do Sul, SC, Brazil.
   [Nicolini, Keller P.; Nicolini, Jaqueline] Inst Fed Educ Ciencia & Tecnol Parana, Dept Quim, BR-85555000 Palmas, PR, Brazil.
RP Nicolini, J (corresponding author), Inst Fed Educ Ciencia & Tecnol Parana, Dept Quim, BR-85555000 Palmas, PR, Brazil.
EM jaqueline.nicolini@ifpr.edu.br
RI Nicolini, Jaqueline/J-7884-2015
OI Nicolini, Jaqueline/0000-0002-3446-9275
CR Ashby M., 1996, US Pat., Patent No. [5,569,588, 5569588]
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Bondonno NP, 2019, NAT COMMUN, V10, DOI [10.1038/s41467-019-11622-x, 10.1038/s41467-019-11622-X]
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Clososki GC, 2020, J BRAZIL CHEM SOC, V31, P1552, DOI 10.21577/0103-5053.20200106
   Cohen Ted, 2009, Expert Rev Respir Med, V3, P67, DOI 10.1586/17476348.3.1.67
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   de Castilho TS, 2018, FOOD SCI HUM WELL, V7, P215, DOI 10.1016/j.fshw.2018.08.001
   Domling A, 2020, CHEM-US, V6, P1283, DOI 10.1016/j.chempr.2020.04.023
   DosSantos C.d.M. R., 2019, ENG AGR ENV FOOD, V12, P534
   Dowdy DW, 2008, P NATL ACAD SCI USA, V105, P11293, DOI 10.1073/pnas.0800965105
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Ferreira MMC, 2002, QUIM NOVA, V25, P439, DOI 10.1590/S0100-40422002000300017
   Gaudio AC, 2001, QUIM NOVA, V24, P658, DOI 10.1590/S0100-40422001000500013
   Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9
   Hsu JTA, 2004, FEBS LETT, V574, P116, DOI 10.1016/j.febslet.2004.08.015
   Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Karuppannan AK, 2012, ANTIVIR RES, V94, P188, DOI 10.1016/j.antiviral.2012.03.008
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Martins JPA, 2013, QUIM NOVA, V36, P554, DOI 10.1590/S0100-40422013000400013
   Mohan DK, 2006, BIOSENS BIOELECTRON, V21, P1804, DOI 10.1016/j.bios.2005.09.008
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Mounce BC, 2017, ANTIVIR RES, V142, P148, DOI 10.1016/j.antiviral.2017.03.014
   Pandey A, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117883
   Ramajayam R, 2011, BIOCHEM SOC T, V39, P1371, DOI 10.1042/BST0391371
   Ren ZL, 2013, PROTEIN CELL, V4, P248, DOI 10.1007/s13238-013-2841-3
   Stebbing J, 2020, LANCET INFECT DIS, V20, P400, DOI 10.1016/S1473-3099(20)30132-8
   Sugibayashi K, 2010, PHARM RES-DORD, V27, P134, DOI 10.1007/s11095-009-9987-y
   Tavares LC, 2004, QUIM NOVA, V27, P631, DOI 10.1590/S0100-40422004000400018
NR 32
TC 0
Z9 0
U1 0
U2 0
PU SOC BRASILEIRA QUIMICA
PI SAO PAULO
PA CAIXA POSTAL 26037, 05599-970 SAO PAULO, BRAZIL
SN 0100-4042
EI 1678-7064
J9 QUIM NOVA
JI Quim. Nova
PD SEP
PY 2020
VL 43
IS 9
BP 1258
EP 1263
DI 10.21577/0100-4042.20170600
PG 6
WC Chemistry, Multidisciplinary
SC Chemistry
GA OI3GQ
UT WOS:000583171900010
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Baay, M
   Neels, P
AF Baay, Marc
   Neels, Pieter
TI SARS-CoV-2 controlled human infection models: Ethics, challenge agent
   production and regulatory issues
SO BIOLOGICALS
LA English
DT Article
DE SARS-CoV-2; Controlled human infection models; Ethics; CMC
AB This second International Alliance for Biological Standardization COVID-19 webinar brought together a broad range of international stakeholders, including academia, regulators, funders and industry, with a considerable participation from low- and middle-income countries, to discuss the use of controlled human infection models to accelerate development and market authorization assessment of a vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
C1 [Baay, Marc] P95 Epidemiol & Pharmacovigilance, Leuven, Belgium.
   [Neels, Pieter] Int Alliance Biol Standardizat IABS, Geneva, Switzerland.
RP Neels, P (corresponding author), Int Alliance Biol Standardizat IABS, Geneva, Switzerland.
EM marc.baay@p-95.com; Pieter.neels@vaccine-advice.be
FU Wellcome TrustWellcome Trust
FX The authors are grateful for the support by a grant of Wellcome Trust to
   organize the webinar; and would like to thank Madinina Cox and Abigail
   Charlet (International Alliance for Biological Standardization) for
   logistic management.
CR Baay M, 2020, BIOLOGICALS, V66, P35, DOI 10.1016/j.biologicals.2020.06.005
   Bekeredjian-Ding I, 2020, BIOLOGICALS, V66, P53, DOI 10.1016/j.biologicals.2020.04.005
   Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283
   Jamrozik E, 2020, LANCET INFECT DIS, V20, pE198, DOI 10.1016/S1473-3099(20)30438-2
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Ren LL, 2015, SCI REP-UK, V5, DOI 10.1038/srep11451
   Shah SK, 2020, SCIENCE, V368, P832, DOI 10.1126/science.abc1076
   WHO Advisory Group on Human Challenge Studies, ADVISORY GROUP HUMAN
   WHO Working Group for Guidance on Human Challenge Studies in COVID-19, WORKING GROUP GUIDAN
NR 9
TC 1
Z9 1
U1 1
U2 1
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1045-1056
EI 1095-8320
J9 BIOLOGICALS
JI Biologicals
PD SEP
PY 2020
VL 67
BP 69
EP 74
DI 10.1016/j.biologicals.2020.08.006
PG 6
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Pharmacology & Pharmacy
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Pharmacology & Pharmacy
GA OH2GL
UT WOS:000582387700010
PM 32829985
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Vizcaychipi, MP
   Shovlin, CL
   McCarthy, A
   Godfrey, A
   Patel, S
   Shah, PL
   Hayes, M
   Keays, RT
   Beveridge, I
   Davies, G
AF Vizcaychipi, Marcela P.
   Shovlin, Claire L.
   McCarthy, Alex
   Godfrey, Andrew
   Patel, Sheena
   Shah, Pallav L.
   Hayes, Michelle
   Keays, Richard T.
   Beveridge, Iain
   Davies, Gary
CA ChelWest Covid19 Consortium
TI Increase in COVID-19 inpatient survival following detection of
   Thromboembolic and Cytokine storm risk from the point of admission to
   hospital by a near real time Traffic-light System (TraCe-Tic)
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Anticoagulation; C-reactive protein; D-dimer; Discharge; Ferritin;
   Mortality; SARS-CoV2
AB Introduction: Our goal was to evaluate if traffic-light driven personalized care for COVID-19 was associated with improved survival in acute hospital settings.
   Methods: Discharge outcomes were evaluated before and after prospective implementation of a real-time dashboard with feedback to ward-based clinicians. Thromboembolism categories were "medium-risk" (D-dimer >1000 ng/mL or CRP >200 mg/L); "high-risk" (D-dimer >3000 ng/mL or CRP >250 mg/L) or "suspected" (D-dimer >5000 ng/mL). Cytokine storm risk was categorized by ferritin.
   Results: 939/1039 COVID-19 positive patients (median age 67 years, 563/939 (60%) male) completed hospital encounters to death or discharge by 21st May 2020. Thromboembolism flag criteria were reached by 568/939 (60.5%), including 238/275 (86.6%) of the patients who died, and 330/664 (49.7%) of the patients who survived to discharge, p <0.0001. Cytokine storm flag criteria were reached by 212 (22.6%) of admissions, including 80/275 (29.1%) of the patients who died, and 132/664 (19.9%) of the patients who survived, p < 0.0001. The maximum thromboembolism flag discriminated completed encounter mortality (no flag: 37/371 [9.97%] died; medium-risk: 68/239 [28.5%]; high -risk: 105/205 [51.2%]; and suspected thromboembolism: 65/124 [52.4%], p <0.0001). Flag criteria were reached by 535 consecutive COVID-19 positive patients whose hospital encounter completed before traffic-light introduction: 173/535 (32.3% [95% confidence intervals 28.0, 36.0]) died. For the 200 consecutive admissions after implementation of real-time traffic light flags, 46/200 (23.0% [95% confidence intervals 17.1, 28.9]) died, p = 0.013. Adjusted for age and sex, the probability of death was 0.33 (95% confidence intervals 0.30, 0.37) before traffic light implementation, 0.22 (0.17, 0.27) after implementation, p < 0.001. In subgroup analyses, older patients, males, and patients with hypertension (p <= 0.01), and/or diabetes (p = 0.05) derived the greatest benefit from admission under the traffic light system.
   Conclusion: Personalized early interventions were associated with a 33% reduction in early mortality. We suggest benefit predominantly resulted from early triggers to review/enhance anticoagulation management, without exposing lower-risk patients to potential risks of full anticoagulation therapy. (C) 2020 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U.
C1 [Vizcaychipi, Marcela P.; Hayes, Michelle; Keays, Richard T.] Chelsea & Westminster Hosp NHS Fdn Trust, Anaesthesia & Intens Care, London, England.
   [Vizcaychipi, Marcela P.; Keays, Richard T.] Imperial Coll London, Dept Surg & Canc, London, England.
   [Shovlin, Claire L.] Imperial Coll London, NHLI Vasc Sci, London, England.
   [McCarthy, Alex] Chelsea & Westminster Hosp NHS Fdn Trust, Informat Data Qual & Clin Coding, London, England.
   [Godfrey, Andrew] Chelsea & Westminster Hosp NHS Fdn Trust, Haematol, London, England.
   [Patel, Sheena] Chelsea & Westminster Hosp NHS Fdn Trust, Pharm, London, England.
   [Shah, Pallav L.; Davies, Gary] Chelsea & Westminster Hosp NHS Fdn Trust, Resp Med, London, England.
   [Beveridge, Iain] West Middlesex Univ Hosp NHS Fdn Trust, Dept Anaesthesia & Intens Care Med, Isleworth, England.
RP Vizcaychipi, MP (corresponding author), Chelsea & Westminster Hosp NHS Fdn Trust, Anaesthesia & Intens Care, London, England.; Vizcaychipi, MP (corresponding author), Imperial Coll London, Dept Surg & Canc, London, England.; Shovlin, CL (corresponding author), Imperial Coll London, NHLI Vasc Sci, London, England.
EM Marcela.Vizcaychipi@chelwest.nhs.uk; c.shovlin@imperial.ac.uk;
   Alex.McCarthy@chelwest.nhs.uk
RI ; Vizcaychipi, Marcela/H-5487-2011
OI Shovlin, Claire/0000-0001-9007-5775; Vizcaychipi,
   Marcela/0000-0001-7894-873X
CR Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432
   Alberca RW, 2020, CRIT REV FOOD SCI, DOI 10.1080/10408398.2020.1775546
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Cattaneo M, 2020, BLOOD TRANSFUS, DOI DOI 10.7450/7020.0109-70
   Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   Chen C, 2020, Zhonghua Shao Shang Za Zhi, V36, P471, DOI 10.3760/cma.j.cn501120-20200224-00088
   Costa FF, 2020, DIABETES METAB SYND, V14, P809, DOI 10.1016/j.dsx.2020.06.016
   Doherty AB, 2020, BMJ-BRIT MED J, V369, P1985
   El Taguri A, 2020, LIBYAN J MED, V15, DOI 10.1080/19932820.2020.1770518
   Fox SE, 2020, LANCET RESP MED, V8, P681, DOI 10.1016/S2213-2600(20)30243-5
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Habib AMG, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4555-5
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iba T, 2019, J THROMB HAEMOST, V17, P1989, DOI 10.1111/jth.14578
   ICNARC, 2020, ICNARC REP COVID 19
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Liang WH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00562-2020
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Marietta M, 2020, BLOOD TRANSFUS, DOI DOI 10.7450/2020.0083-20
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Patel BV, 2020, AM J RESP CRIT CARE, DOI DOI 10.1164/RCCM.202004-14120C
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Shovlin Claire L, 2020, QJM, DOI 10.1093/qjmed/hcaa241
   Shovlin CL, 2020, EMERG MED J, V37, P332, DOI 10.1136/emermed-2020-209791
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Vizcaychipi M. P., 2020, EARLY DETECTION SEVE
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   World Health Organisation, R D BLUEPR COVID 19
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang Yimin, 2020, Engineering (Beijing), DOI 10.1016/j.eng.2020.03.006
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 38
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD SEP-OCT
PY 2020
VL 24
IS 5
BP 412
EP 421
DI 10.1016/j.bjid.2020.07.010
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA OH5ID
UT WOS:000582615500006
PM 32857990
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cipolat, MM
   Sprinz, E
AF Cipolat, Murillo Machado
   Sprinz, Eduardo
TI COVID-19 pneumonia in an HIV-positive woman on antiretroviral therapy
   and undetectable viral load in Porto Alegre, Brazil
SO BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE SARS-CoV-2; COVID-19; HIV; AIDS
ID SARS-COV-2
AB COVID-19 pandemic has been a problem worldwide. It is important to identify people at risk of progressing to severe complications and to investigate if some existing antivirals could have any action against SARS-CoV-2. In this context, HIV-infected individuals and antiretroviral drugs might be included, respectively. Herein we present the case of a 63 year-old HIV-infected woman with undetectable viral load, on dolutegravir, tenofovir and lamivudine, who was hospitalized due to COVID-19 pneumonia. In spite of having some clinical markers of severity on admission, the patient improved and was discharged after a week. To our knowledge, this is the first report of severe SARS-CoV-2 infection in an HIV-infected individual in Brazil. (C) 2020 Sociedade Brasileira de Infectologia. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommon.org/licenses/by-nc-nd/4.0/).
C1 [Cipolat, Murillo Machado; Sprinz, Eduardo] Hosp Clin Porto Alegre, Infect Dis Serv, Porto Alegre, RS, Brazil.
   [Sprinz, Eduardo] Univ Fed Rio Grande do Sul, Fac Med, Porto Alegre, RS, Brazil.
RP Sprinz, E (corresponding author), Hosp Clin Porto Alegre, Infect Dis Serv, Porto Alegre, RS, Brazil.; Sprinz, E (corresponding author), Univ Fed Rio Grande do Sul, Fac Med, Porto Alegre, RS, Brazil.
EM esprinz@hcpa.edu.br
RI sprinz, eduardo/V-7961-2019
OI sprinz, eduardo/0000-0003-4343-8304
CR Ballester-Arnal R, 2020, AIDS BEHAV, V24, P2253, DOI 10.1007/s10461-020-02877-3
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Clososki GC, 2020, J BRAZIL CHEM SOC, P1, DOI [10.71577/0103-5053.70700106, DOI 10.71577/0103-5053.70700106]
   del Amo J, 2020, ANN INTERN MED, V173, P536, DOI 10.7326/M20-3689
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Harter G, 2020, INFECTION, V48, P681, DOI 10.1007/s15010-020-01438-z
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Mascolo S, 2020, J MED VIROL, V92, P1777, DOI 10.1002/jmv.25881
   Park SJ, 2020, MBIO, V11, DOI 10.1128/mBio.01114-20
   Patel RH, 2020, J MED VIROL, DOI [10.1002/jmv.26049, DOI 10.1002/JNW.26049]
   Ridgway JP, 2020, AIDS PATIENT CARE ST, V34, P331, DOI 10.1089/apc.2020.0103
   World Health Organization, 2020, Q A COVID 19 HIV ANT
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER BRAZIL
PI RIO DE JANEIRO
PA R SETE SETEMBRO, 111-16, RIO DE JANEIRO, RJ 20050-006, BRAZIL
SN 1413-8670
EI 1678-4391
J9 BRAZ J INFECT DIS
JI Braz. J. Infect. Dis.
PD SEP-OCT
PY 2020
VL 24
IS 5
BP 455
EP 457
DI 10.1016/j.bjid.2020.07.009
PG 3
WC Infectious Diseases
SC Infectious Diseases
GA OH5ID
UT WOS:000582615500011
PM 32866436
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Konakci, G
   Uran, BNO
   Erkin, O
AF Konakci, Gulbin
   Uran, Berna Nilgun Ozgursoy
   Erkin, Ozum
TI In the Turkish News: Coronavirus and "Alternative & complementary"
   medicine methods
SO COMPLEMENTARY THERAPIES IN MEDICINE
LA English
DT Article
DE COVID-19; Newspaper; News; Coronavirus; Complementary and alternative
   medicine
ID HERBAL MEDICINES; CANCER-PATIENTS; INFORMATION; COVERAGE; DRUGS; USAGE
AB Background and Object: The object of this study is to analyze the complementary and alternative treatments for the prevention of COVID-19/Coronavirus in the Turkish news.
   Material and Method: The sample of this descriptive study consisted of 160 news articles published between 11 March and 11 April 2020 on the websites of the three highest-circulating newspapers throughout the nation. A quantitative media context analysis method, consisting of 14 questions and 2 sections was employed to evaluate news on the newspapers. The data was analyzed using SPSS 21.0 statistical package program using numbers and percentages.
   Results: Forty percent of the news analyzed within the scope of the study were obtained from the newspaper's own news, reporter or columnist, 56.9 % were informative, 6.3 % were advisory and critical against the CAT methods. 95 % of the news included preventive or protective methods against COVID-19. 77.5 % of the complementary and alternative medicine methods mentioned in the news were biologically-based, 20.6 % were mind-body practices. It was determined that 85.0 % of the benefits, harm and side effects of the methods mentioned in the news were announced, but their impact on COVID-19 is not clarified (78.1 %), and there was insufficient information provided about the method and dosage of the method. It was seen that all news contained information on protection against COVID-19 or prevention of COVID19.
   Conclusion: It was concluded that the sources and methods and the number of news items changed from one newspaper to another, the news lacked a scientific basis, and as a result, it might lead to misinterpretations among the public. There were different opinions among the experts in the proposed or criticized complementary and alternative medicine methods. It was observed that there was an increase in the number of news items related to using complementary and alternative medicine methods for the treatment of COVID19, a clear and easily understandable language was used in the news, but the content and sources of the news were insufficient in conveying the correct and scientific information. It was reported by previous literature potential interactions between herbal remedies/dietary supplements and prescribed drugs, complications of medical conditions and some adverse effects cause of CAM usage
C1 [Konakci, Gulbin; Erkin, Ozum] Izmir Democracy Univ, Hlth Sci Fac, Izmir, Turkey.
   [Uran, Berna Nilgun Ozgursoy] Izmir Katip Celebi Univ, Hlth Sci Fac, Izmir, Turkey.
RP Konakci, G (corresponding author), Izmir Democracy Univ, Hlth Sci Fac, Izmir, Turkey.
EM ygulbin@gmail.com
RI ERKIN, Ozum/H-9624-2019; KONAKCI, GULBIN/N-2196-2018
OI ERKIN, Ozum/0000-0002-0977-2854; KONAKCI, GULBIN/0000-0002-6913-4256;
   Ozgursoy Uran, Berna Nilgun/0000-0002-4096-4619
CR Ali A, 2015, AM J PREV MED, V49, pS230, DOI 10.1016/j.amepre.2015.07.019
   Ang L, 2020, COMPLEMENT THER CLIN, V39, DOI 10.1016/j.ctcp.2020.101174
   [Anonymous], 2020, TRADITIONAL MED
   [Anonymous], 2012, J SOC SCI, V2, P122, DOI [10.16990/SOBIDER.29., DOI 10.16990/SOBIDER.29]
   [Anonymous], 2020, NEW INDIAN EXPRESS
   [Anonymous], 2020, NATL CTR COMPLEMENTA
   Araz A., 2007, Turk Silahli Kuvvetleri,  Koruyucu Hekimlik Bulteni, V6, P112
   Balcik P. Y., 2014, Turk Silahli Kuvvetleri,  Koruyucu Hekimlik Bulteni, V13, P321
   Barry CL, 2010, PEDIATRICS, V125, P88, DOI 10.1542/peds.2009-0792
   Bello Nusirat, 2012, Pharmacy Practice (Internet), V10, P125, DOI 10.4321/s1886-36552012000300002
   Bent S, 2004, AM J MED, V116, P478, DOI 10.1016/j.amjmed.2003.10.036
   BICER I, 2019, HACETTEPE SAGLIK IDA, V22, P245
   Bilgin N., 2014, SIYASAL KITABEVI 3 B
   Bonevski B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002406
   Cakmak S, 2017, TURKIYE KLINIKLERI J, V3, P5764
   Chen AT, 2018, INTERACT J MED RES, V7, DOI 10.2196/ijmr.9803
   Corbin J. M., 2007, BASICS QUALITATIVE R
   Dissiz G, 2016, COMPLEMENT THER CLIN, V23, P34, DOI 10.1016/j.ctcp.2016.02.004
   Dunne A, 2010, AUST FAM PHYSICIAN, V39, P671
   Ernst E, 2002, J INTERN MED, V252, P107, DOI 10.1046/j.1365-2796.2002.00999.x
   Hargreaves J, 2003, BETTER MAP SCI PUBLI
   Huebner J, 2014, ANTICANCER RES, V34, P943
   Ilgaz A, 2016, DEUHFED, V9, P67
   Institute of medicine (US), 2005, I MED US COMMITTEE U
   Karaman E, 2018, J PAK MED ASSOC, V68, P587
   Kava R, 2002, J HEALTH COMMUN, V7, P13, DOI 10.1080/10810730252801165
   Kes D, 2016, TJCN, V7, P40
   Kim SN, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/7648237
   Kiroglu F, 2020, MEYAD AKADEMI DERGIS, V1, P9
   Koithan Mary, 2009, J Nurse Pract, V5, P18
   Korkmaz M, 2016, HOLIST NURS PRACT, V30, P88, DOI 10.1097/HNP.0000000000000121
   Kucukoner M, 2013, AFR J TRADIT COMPLEM, V10, P21, DOI 10.4314/ajtcam.v10i1.4
   Lavorgna A, 2018, EUR J CRIMINOL, V15, P421, DOI 10.1177/1477370817748589
   Liu WH, 2020, WORLD J ACUPUNCT-MOX, V30, P1, DOI 10.1016/j.wjam.2020.03.005
   Miles M., 1994, QUALITATIVE DATA ANA
   Nissen M, 2012, CRIT THEOR PRACT, P105
   Ozbas S., 2010, Turk Silahli Kuvvetleri,  Koruyucu Hekimlik Bulteni, V9, P541
   Ozdemir A., 2019, ANN MED RES, V26, P658
   Ozdemir AA, 2009, THESIS
   Pirkis J, 2012, MENTAL ILLNESS NEWS
   Polat G, 2014, INT J HUMAN SCI, V11, P814, DOI [10.14687/ijhs.v11i1.2732., DOI 10.14687/IJHS.V11I1.2732]
   Saglik Bakanligi TC, 2020, 11 MART 2020 COVID 1
   Schifano F, 2010, RIV PSICHIATR, V45, P88
   Seker Muzaffer, 2020, COVID 19 PAND RAP AN
   Sharma V, 2016, METHOD INFORM MED, V55, P322, DOI 10.3414/ME15-01-0154
   Sirois FM, 2018, AM J CARDIOL, V122, P170, DOI 10.1016/j.amjcard.2018.03.014
   Surette R, 2016, ADV CRIMINOLOGY CRIM
   Tabish SA, 2008, INT J HLTH SCI QASSI, V2, pV
   Tasdemir A, 2011, EDUC SCI-THEOR PRACT, V11, P1
   Taskin SC, 2014, TAHUD, V18, P35
   Tillu G, 2020, J ALTERN COMPLEM MED, V26, P360, DOI 10.1089/acm.2020.0129
   Walsh MC, 2010, J HEALTH COMMUN, V15, P445, DOI 10.1080/10810731003753109
   Yarney J, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-16
   Yasar D, 2006, THESIS
   Yumlu K., 1994, KITLE ILETISIM KURAM
   Zhu HB, 2020, GLOB HEALTH RES POL, V5, DOI 10.1186/s41256-020-00135-6
NR 56
TC 0
Z9 0
U1 0
U2 0
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0965-2299
EI 1873-6963
J9 COMPLEMENT THER MED
JI Complement. Ther. Med.
PD SEP
PY 2020
VL 53
AR 102545
DI 10.1016/j.ctim.2020.102545
PG 8
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA OH4YR
UT WOS:000582584000024
PM 33066867
OA Green Published
DA 2021-01-01
ER

PT J
AU Fiorino, G
   Allocca, M
   Furfaro, F
   Gilardi, D
   Zilli, A
   Radice, S
   Spinelli, A
   Danese, S
AF Fiorino, Gionata
   Allocca, Mariangela
   Furfaro, Federica
   Gilardi, Daniela
   Zilli, Alessandra
   Radice, Simona
   Spinelli, Antonino
   Danese, Silvio
TI Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The
   Humanitas, Milan, Experience
SO JOURNAL OF CROHNS & COLITIS
LA English
DT Article
DE Coronavirus; COVID-19; inflammatory bowel disease; quality of care;
   pandemic
ID CORONAVIRUS; PNEUMONIA
AB The outbreak of the COVID-19 caused by coronavirus SARS-CoV2, is rapidly spreading worldwide. This is the first pandemic caused by a coronavirus in history. More than 150 000 confirmed cases worldwide are reported involving the SARS-CoV2, with more than 5000 COVID-19-related deaths on March 14, 2020. Fever, chills, cough, shortness of breath, generalised myalgia, malaise, drowsiness, diarrhoea, confusion, dyspnoea, and bilateral interstitial pneumonia are the common symptoms. No therapies are available, and the only way to contain the virus spread is to regularly and thoroughly clean one's hands with an alcohol-based hand rub or wash them with soap and water, to maintain at least 1 m [3 feet] distance from anyone who is coughing or sneezing, to avoid touching eyes, nose, and mouth, and to stay home if one feels unwell. No data are available on the risk of COVID-19 and outcomes in inflammatory bowel disease [IBD] patients. Outbreak restrictions can impact on the IBD care. We aim to give a viewpoint on how operationally to manage IBD patients and ensure quality of care in the current pandemic era.
C1 [Fiorino, Gionata; Allocca, Mariangela; Furfaro, Federica; Gilardi, Daniela; Zilli, Alessandra; Radice, Simona; Danese, Silvio] Humanitas Clin & Res Inst, Dept Gastroenterol, Milan, Italy.
   [Fiorino, Gionata; Allocca, Mariangela; Spinelli, Antonino; Danese, Silvio] Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini, Milan, Italy.
   [Spinelli, Antonino] Humanitas Clin & Res Inst, Div Colon & Rectal Surg, Milan, Italy.
RP Danese, S (corresponding author), Humanitas Univ, Dept Biomed Sci, Via Rita Levi Montalcini, Milan, Italy.
EM sdanese@hotmail.com
RI Spinelli, Antonino/ABI-1441-2020; Danese, Silvio/ABH-9571-2020
OI Spinelli, Antonino/0000-0002-1493-1768; Danese,
   Silvio/0000-0001-7341-1351
CR Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Fiorino G, 2020, J CROHNS COLITIS, V14, pS102
   International Organization for the study of Inflammatory Bowel Disease [IOIBD], 2020, IOIBD UPDATE COVID19
   Jin YH, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-0233-6
   Johns Hopkins University Coronavirus Resource Center, 2020, CORONAVIRUS COVID 19
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Mao R, 2020, LANCET GASTROENTEROL, V5, P426, DOI 10.1016/S2468-1253(20)30076-5
   Meo SA, 2020, EUR REV MED PHARMACO, V24, P2012, DOI 10.26355/eurrev_202002_20379
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   World Health Organization, 2020, CORONAVIRUS
   World Health Organization, 2020, Q CORONAVIRUSES COVI
   Xiao F, EVIDENCE GASTROINTES
   Xie CB, 2020, INT J INFECT DIS, V93, P264, DOI 10.1016/j.ijid.2020.02.050
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Yang YS, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102434
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou W, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0127-9
NR 20
TC 19
Z9 19
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1873-9946
EI 1876-4479
J9 J CROHNS COLITIS
JI J. Crohns Colitis
PD SEP 1
PY 2020
VL 14
IS 9
BP 1330
EP 1333
DI 10.1093/ecco-jcc/jjaa058
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OH1BY
UT WOS:000582308300018
PM 32211765
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Monteleone, G
   Ardizzone, S
AF Monteleone, Giovanni
   Ardizzone, Sandro
TI Are Patients with Inflammatory Bowel Disease at Increased Risk for
   Covid-19 Infection?
SO JOURNAL OF CROHNS & COLITIS
LA English
DT Article
DE Crohn's disease; ulcerative colitis; Covid-19; ACE2; viral infection
ID CORONAVIRUS; RECEPTOR; PROTEIN; ACE2
AB Crohn's disease [CD] and ulcerative colitis [UC], the main inflammatory bowel diseases [IBD] in humans, are chronic, immune-inflammatory diseases, the pathogenesis of which suggests a complex interaction between environmental factors and genetic susceptibility. These disabling conditions affect millions of individuals and, together with the drugs used to treat them, can put patients at risk of developing complications and other conditions. This is particularly relevant today, as coronavirus disease [Covid-19] has rapidly spread from China to countries where IBD are more prevalent, and there is convincing evidence that Covid-19-mediated morbidity and mortality are higher in subjects with comorbidities. The primary objectives of this Viewpoint are to provide a focused overview of the factors and mechanisms by which the novel severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] infects cells and to illustrate the link between such determinants and intestinal inflammation. We also provide clues about the reasons why the overall IBD population might have no increased risk of developing SARS-CoV-2 infection and highlight the potential of cytokine blockers, used to treat IBD patients, to prevent Covid-driven pneumonia.
C1 [Monteleone, Giovanni] Univ Roma Tor Vergata, Dept Syst Med, Via Montpellier 1, I-00133 Rome, Italy.
   [Ardizzone, Sandro] Univ Milan, ASST Fatebenefratelli Sacco, Gastrointestinal Unit, Dept Biochem & Clin Sci L Sacco, Milan, Italy.
RP Monteleone, G (corresponding author), Univ Roma Tor Vergata, Dept Syst Med, Via Montpellier 1, I-00133 Rome, Italy.
EM Gi.Monteleone@Med.uniroma2.it
CR Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163
   Chen C, 2020, Zhonghua Shao Shang Za Zhi, V36, P471, DOI 10.3760/cma.j.cn501120-20200224-00088
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Dulai PS, 2014, CLIN GASTROENTEROL H, V12, P1443, DOI 10.1016/j.cgh.2014.01.021
   Garg M, 2020, GUT, V69, P841, DOI 10.1136/gutjnl-2019-318512
   Garg M, 2015, J RENIN-ANGIO-ALDO S, V16, P559, DOI 10.1177/1470320314521086
   Govani SM, 2010, J CROHNS COLITIS, V4, P444, DOI 10.1016/j.crohns.2010.02.009
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Harmer D, 2002, FEBS LETT, V532, P107, DOI 10.1016/S0014-5793(02)03640-2
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Ibrahim IM, 2020, J INFECTION, V80, P554, DOI 10.1016/j.jinf.2020.02.026
   Jablaoui A, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00021
   MacDonald TT, 2005, SCIENCE, V307, P1920, DOI 10.1126/science.1106442
   Maude SL, 2014, CANCER J, V20, P119, DOI 10.1097/PPO.0000000000000035
   Monteleone G, 2011, CURR OPIN PHARMACOL, V11, P640, DOI 10.1016/j.coph.2011.09.013
   Ning LG, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/3950628
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wysocki J, 2010, HYPERTENSION, V55, P90, DOI 10.1161/HYPERTENSIONAHA.109.138420
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 21
TC 36
Z9 36
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1873-9946
EI 1876-4479
J9 J CROHNS COLITIS
JI J. Crohns Colitis
PD SEP 1
PY 2020
VL 14
IS 9
BP 1334
EP 1336
DI 10.1093/ecco-jcc/jjaa061
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA OH1BY
UT WOS:000582308300019
PM 32215548
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kluger, BM
   Vaughan, CL
   Robinson, MT
   Creutzfeldt, C
   Subramanian, I
   Holloway, RG
AF Kluger, Benzi M.
   Vaughan, Christina L.
   Robinson, Maisha T.
   Creutzfeldt, Claire
   Subramanian, Indu
   Holloway, Robert G.
TI Neuropalliative care essentials for the COVID-19 crisis
SO NEUROLOGY
LA English
DT Article
ID LIFE EVENTS
AB The coronavirus disease 2019 (COVID-19) pandemic is profoundly affecting neurology patients, families, and providers through direct neurologic complications,(1)indirect consequences of COVID-19 on healthcare delivery,(2)and the consequences of social distancing.As-3 frontline providers, neurologists see both the medical consequences of COVID-19 and its toll in heightening personal suffering ranging from interruptions or changes in standard therapies(4)to patients facing isolation in the hospital and even the prospect of dying without the family being present.(5)Almost instantly, the calculus of risks and benefits have changed to include concerns of COVID-19 during routine office visits, procedures, and hospital admissions. This affects patients desire to seek medical care and may explain the dramatic drop in acute hospitalizations and outpatient referrals. Neurologists also face challenges in providing ongoing care for persons with chronic illness, responding to novel clinical situations and hosting an increasing number of difficult conversations, often via telehealth.(6)
C1 [Kluger, Benzi M.; Holloway, Robert G.] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA.
   [Kluger, Benzi M.; Holloway, Robert G.] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA.
   [Vaughan, Christina L.] Univ Colorado, Dept Neurol, Anschutz Med Campus, Aurora, CO USA.
   [Vaughan, Christina L.] Univ Colorado, Dept Med, Anschutz Med Campus, Aurora, CO USA.
   [Robinson, Maisha T.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA.
   [Robinson, Maisha T.] Mayo Clin, Dept Family Med, Jacksonville, FL 32224 USA.
   [Creutzfeldt, Claire] Univ Washington, Harborview Med Ctr, Dept Neurol, 325 9Th Ave, Seattle, WA 98104 USA.
   [Subramanian, Indu] Univ Calif Los Angeles, Geffen Sch Med, Dept Neurol, Los Angeles, CA 90024 USA.
   [Subramanian, Indu] West Vet Affairs Med Ctr, Los Angeles, CA USA.
RP Kluger, BM (corresponding author), Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA.; Kluger, BM (corresponding author), Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA.
EM benzi_kluger@urmc.rochester.edu
CR [Anonymous], 2020, LANCET, V395, P1168, DOI 10.1016/S0140-6736(20)30823-0
   Arya A, 2020, CAN MED ASSOC J, V192, pE400, DOI 10.1503/cmaj.200465
   Back A, 2009, MASTERING COMMUNICAT
   Baile W F, 2000, Oncologist, V5, P302, DOI 10.1634/theoncologist.5-4-302
   Cheshire WP, 2020, J TELEMED TELECARE, DOI 10.1177/1357633X19899237
   Creutzfeldt CJ, 2018, NEUROLOGY, V91, P217, DOI 10.1212/WNL.0000000000005916
   Creutzfeldt CJ, 2016, NEUROL-CLIN PRACT, V6, P40, DOI 10.1212/CPJ.0000000000000213
   Curtis JR, 2020, JAMA-J AM MED ASSOC, V323, P1771, DOI 10.1001/jama.2020.4894
   Fausto J, J PAIN SYMPTOM MANAG
   Gostin L, 2006, JAMA-J AM MED ASSOC, V295, P1700, DOI 10.1001/jama.295.14.1700
   Goyal P, 2020, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2020/02/020
   Grossman P, 2010, NEUROLOGY, V75, P1141, DOI 10.1212/WNL.0b013e3181f4d80d
   Hatcher-Martin JM, 2020, NEUROLOGY, V94, P30, DOI 10.1212/WNL.0000000000008708
   IAHPC, RESOURCES RELEVANT P
   Jess M, 2019, PALLIATIVE MED, V33, P942, DOI 10.1177/0269216319854938
   Katz RS, 2016, PROFESSIONALS WEEP E, P3
   Kent EE, J PAIN SYMPTOM MANAG
   Luthar SS, 2007, DEV PSYCHOPATHOL, V19, P931, DOI 10.1017/S0954579407000454
   Marmura MJ, 2018, CURR PAIN HEADACHE R, V22, DOI 10.1007/s11916-018-0734-0
   Meng Y, 2020, MEAS SCI TECHNOL, V31, DOI 10.1088/1361-6501/ab4a66
   Mills J, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0318-0
   Mohile NA, NEUROONCOL
   Mohr DC, 2004, BMJ-BRIT MED J, V328, P731, DOI 10.1136/bmj.38041.724421.55
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Pfefferbaum B, N ENGL J MED
   Pleasure SJ, 2020, JAMA NEUROL, V77, P679, DOI 10.1001/jamaneurol.2020.1065
   Ripp J, ACAD MED
   Rosa RG, 2019, JAMA-J AM MED ASSOC, V322, P216, DOI 10.1001/jama.2019.8766
   Rosenbaum L, 2020, NEW ENGL J MED, V382, P2368, DOI 10.1056/NEJMms2009984
   Rosenbaum L, 2020, NEW ENGL J MED, V382, P1873, DOI 10.1056/NEJMp2005492
   Rosenberg AR, JAMA PEDIAT
   Sheth K, 2020, WASHINGTON POST
   Shore JC, 2016, J HOSP PALLIAT NURS, V18, P15, DOI 10.1097/NJH.0000000000000208
   Shpancer N., LESSONS CORONAVIRUS
   Stulberg B., BECOME MORE RESILIEN
   Tiet QQ, 1998, J AM ACAD CHILD PSY, V37, P1191, DOI 10.1097/00004583-199811000-00020
   Wakam GK, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2007781
   Wallace CL, J PAIN SYMPTOM MANAG
   Webster P, 2020, LANCET, V395, P1180, DOI 10.1016/S0140-6736(20)30818-7
   Wolfe B., 2013, ADV CARE PLANNING CO
   Worster B, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0600-y
NR 41
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD SEP 1
PY 2020
VL 95
IS 9
BP 394
EP 398
DI 10.1212/WNL.0000000000010211
PG 5
WC Clinical Neurology
SC Neurosciences & Neurology
GA OH2DA
UT WOS:000582378800005
PM 32591476
OA Bronze
DA 2021-01-01
ER

PT J
AU Ni, JQ
   Xu, XS
AF Ni, Jianqiang
   Xu, Xingshun
TI Editors' note: Miller Fisher syndrome and polyneuritis cranialis in
   COVID-19
SO NEUROLOGY
LA English
DT Letter
AB We read with great interest the case reports about patients with COVID-19 with Miller Fisher syndrome and polyneuritis cranialis by Gutierrez-Ortiz et al.,(1) which provided a link between these diseases and the symptom spectrum of SARS-CoV-2 infection. As we know, the Miller Fisher syndrome and polyneuritis cranialis are an autoimmune neuropathy triggered by autoantibodies specific for the polysialogangliosides GQ1b and GT1a in axonal terminals and causes the inflammation and demyelination of the peripheral and cranial nerves.(2) A recent article also proposed that autoimmune injury may be involved in the mechanisms of nervous system symptoms of COVID-19.(3) In addition, Zika virus-another coronavirus-is also associated with autoimmune peripheral neuropathy.(4,5) These thus support the connection of Miller Fisher syndrome and polyneuritis cranialis with SARS-CoV-2 infection. We wonder whether the authors examined the presence of SARS-CoV-2 RNA and antibodies for SARS-CoV-2 in CSF and ruled out the infection by other common viruses in 2 patients with COVID-19? This will provide more convincing evidence to support SARS-CoV-2 infection-induced autoimmune injury on peripheral nerves, and immunoglobulin therapy may be considered for some patients with COVID-19.
CR Brasil P, 2016, LANCET, V387, P1482, DOI 10.1016/S0140-6736(16)30058-7
   Gutierrez-Ortiz C, 2020, NEUROLOGY, V95, pE601, DOI 10.1212/WNL.0000000000009619
   Li H, 2020, NEUROTOX RES, V38, P1, DOI 10.1007/s12640-020-00219-8
   Parra B, 2016, NEW ENGL J MED, V375, P1513, DOI 10.1056/NEJMoa1605564
   Rodella U, 2016, NEUROBIOL DIS, V96, P95, DOI 10.1016/j.nbd.2016.09.005
NR 5
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD SEP 1
PY 2020
VL 95
IS 9
BP 408
EP 408
DI 10.1212/WNL.0000000000010401
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA OH2DA
UT WOS:000582378800009
PM 32868475
DA 2021-01-01
ER

PT J
AU Ng, B
AF Ng, Bernardo
TI Solutions to prevent and address physician burnout during the pandemic
   in Mexico
SO INDIAN JOURNAL OF PSYCHIATRY
LA English
DT Article
DE Burn out; Mexican healthcare personnel; Mexico; pandemic; stress
AB Background: The COVID-19 pandemic has tested the level of preparedness and readiness of governments globally. The demand for services exceeding the capacity of the health systems in both developed and developing countries has been the rule rather than the exception. Physicians and the rest of the health-care personnel have been put through unprecedented levels of demand, within a field of uncertainty, from an evolving and insufficient understanding of the pathophysiology of the viral process, the unclear benefit of face coverings used by the general public, numerous pharmacological candidates, insufficient personal protection equipment, and the highly expected vaccine. Aims and Objectives: Design a program to address the emotional and psychiatric needs of COVID-19 first response Healthcare personnel in Mexico. Materials: in march 2020, the Mexican Psychiatric Association was invited to be part of the Workgroup for the fortification of Mental Health during Disasters of the Ministry of Health in Mexico. The charge was to develop a program to address the needs and prevent burn out in physicians and the rest of healthcare personal. The details of how this program was planned, implemented, and launched will be presented. Results: The program was launched in two phases. Phase A through a chat with text messaging capability was launched on 25 April, 2020. B through telepsychiatric video calls, was launched on 15 June, 2020. Phase A had a very limited demand. Phase B also had a very limited demand until the month 5 September, 2020. Conclusions: from the time of program launch through the first four months, the demand was very low, what may be explained due to "normalization" of stress and/or stigma among healthcare professionals. Our personnel deserve the utmost support from their society.
C1 [Ng, Bernardo] Mexican Psychiat Assoc, Mexico City, DF, Mexico.
   [Ng, Bernardo] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
RP Ng, B (corresponding author), Mexican Psychiat Assoc, Mexico City, DF, Mexico.
EM mrugeshvaishnav@gmail.com
CR Agren D, 2020, LANCET, V395, P1601, DOI 10.1016/S0140-6736(20)31198-3
   Gazelle G, 2015, J GEN INTERN MED, V30, P508, DOI 10.1007/s11606-014-3144-y
   Shah K, 2020, CUREUS, V12, DOI 10.7759/cureus.7538
NR 3
TC 0
Z9 0
U1 1
U2 1
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0019-5545
EI 1998-3794
J9 INDIAN J PSYCHIAT
JI Indian J. Psychiatry
PD SEP
PY 2020
VL 62
IS 9
SU 3
BP 467
EP 469
DI 10.4103/psychiatry.IndianJPsychiatry_840_20
PG 3
WC Psychiatry
SC Psychiatry
GA OG2GO
UT WOS:000581709400025
PM 33227061
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sultanov, S
   Khodzhaeva, N
   Ashurov, Z
   Lyan, Y
   Shadmanova, L
AF Sultanov, Shokhrukh
   Khodzhaeva, Nazira
   Ashurov, Zarifjon
   Lyan, Yekaterina
   Shadmanova, Lola
TI Features of minor depressive disorder subtypes in conditions of COVID-19
   pandemic
SO INDIAN JOURNAL OF PSYCHIATRY
LA English
DT Article
DE Anxiety; COVID-19; depression
AB Background: The continuous research on minor depressive disorder is one of the pressing issues in the context of the COVID-19 pandemic. We studied the features of minor depressive disorder subtypes in conditions of the COVID-19 pandemic. Materials and Methods: Sixty-two patients were observed with the administration of clinical follow-up research method. Results: The following major subtypes of minor depressive disorder were identified: Asthenic, hysterical, hypochondriacal, apathetic, and minor depressive disorder with obsessive-compulsive symptoms. Conclusions: The COVID-19 pandemic lead to an increase in the development of the minor depressive disorder with a predominance of asthenic and obsessive-phobic symptoms. Therapy of minor depressive disorder requires the involvement of a wide range of specialists, preferably with the inclusion of community-based treatment.
C1 [Sultanov, Shokhrukh; Khodzhaeva, Nazira; Ashurov, Zarifjon; Lyan, Yekaterina; Shadmanova, Lola] Tashkent Med Acad, Dept Psychiat & Narcol, Tashkent, Uzbekistan.
RP Sultanov, S (corresponding author), Tashkent Med Acad, Dept Psychiat & Narcol, Tashkent, Uzbekistan.
EM mrugeshvaishnav@gmail.com
CR Corfield EC, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.99
   Gonzalez HM, 2010, ARCH GEN PSYCHIAT, V67, P37, DOI 10.1001/archgenpsychiatry.2009.168
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   MacQueen G, 2017, CAN J PSYCHIAT, V62, P11, DOI 10.1177/0706743716664885
   Roy D, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102083
   ten Have M, 2017, ACTA PSYCHIAT SCAND, V136, P300, DOI 10.1111/acps.12753
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
NR 7
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0019-5545
EI 1998-3794
J9 INDIAN J PSYCHIAT
JI Indian J. Psychiatry
PD SEP
PY 2020
VL 62
IS 9
SU 3
BP 476
EP 478
DI 10.4103/psychiatry.IndianJPsychiatry_847_20
PG 3
WC Psychiatry
SC Psychiatry
GA OG2GO
UT WOS:000581709400027
PM 33227070
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pajevic, I
   Hasanovic, M
   Avdibegovic, E
   Dzubur-Kulenovic, A
   Burgic-Radmanovic, M
   Babic, D
   Mehic-Basara, N
   Zivlak-Radulovic, N
   Racetovic, G
AF Pajevic, Izet
   Hasanovic, Mevludin
   Avdibegovic, Esmina
   Dzubur-Kulenovic, Alma
   Burgic-Radmanovic, Marija
   Babic, Dragan
   Mehic-Basara, Nermana
   Zivlak-Radulovic, Nera
   Racetovic, Goran
TI Organization of mental healthcare in Bosnia and Herzegovina during
   coronavirus disease 2019 pandemic
SO INDIAN JOURNAL OF PSYCHIATRY
LA English
DT Article
DE Attitude and practice; comorbidities; coronavirus disease 2019; online
   survey; stress and depression
ID COVID-19; SERVICES
AB Background: Coronavirus disease 2019 (COVID-19), like any other pandemic, has imposed an unprecedented threat to physical and mental health to all nations, worldwide. There is no enough evidence in the literature in this area. The present study has been done to explore the organization of psychiatric services in Bosnia and Herzegovina (BH) to meet mental health needs of BH citizens during the particular restrictive measures caused by COVID-19 pandemic. Materials and Methods: This online survey has been done for BH psychiatric institutions. Data were collected from psychiatric institutions in the mental health network of BH. A total of 38 complete responses have been received. Results: Of 38 study participants, three were the departments of psychiatry in university clinical centers, two were psychiatric hospitals, four were psychiatric wards in general hospitals, 27 were community mental health centers, and two were institutes for alcoholism and drug addiction. During the pandemic, all services functioned on a reduced scale, adhering to measures to protect and self-protect both staff and service users. Protective equipment was provided to staff in some institutions in a timely and complete manner and in some in an untimely and incomplete manner. Consultative psychiatric examinations were mainly performed through telephone and online, where it exists as a standard patient monitoring protocol. The application of long-acting antipsychotics was continuous with adherence to restricted and protective measures. In opiate addiction replacement therapy services, substitution therapy was provided for a longer period to reduce frequent contacts between staff and patients. Individual and group psychotherapy continued in reduced number using online technologies, although this type of service was not administratively regulated. An initiative has been given to regulate and administratively recognize telepsychiatry by health insurance funds in the country. A number of psychological problems associated with restrictive measures and fear of illness have been reported by patients as well as by the professionals in mental healthcare teams. There were no COVID-19-positive patients seeking help from institutions that responded to the questionnaire. In one center, infected people with COVID-19 from abroad sought help through the phone. Only one involuntary hospitalization was reported. The involvement of mental health professionals in the work of crisis headquarters during the design of the COVID-19 pandemic control measures varies from satisfactory to insufficient. Education of staff, patients, and citizens was regular with direct instructions through meetings, press, and electronic media. Conclusions: During the COVID-19 pandemic in BH, all psychiatric services functioned on a reduced scale, adhering to measures to protect and self-protect staff and service users. All patients who asked for help have been adequately treated in direct inpatient or outpatient mental healthcare or online, despite telepsychiatric services not being recognized in health system in BH. There were neither infected patients nor staff with COVID-19 in the psychiatric institutions who responded in this research. A large-scale, multicenter study needs to be performed to get a broader picture and to guide us for future better service planning and delivery.
C1 [Pajevic, Izet; Hasanovic, Mevludin; Avdibegovic, Esmina] Univ Clin Ctr Tuzla, Dept Psychiat, Ul Rate Dugonjica BB, Tuzla 75000, Bosnia & Herceg.
   [Dzubur-Kulenovic, Alma] Univ Sarajevo, Clin Ctr, Dept Psychiat, Sarajevo, Bosnia & Herceg.
   [Mehic-Basara, Nermana] Publ Inst Addict Disorders Canton Sarajevo, Sarajevo, Bosnia & Herceg.
   [Burgic-Radmanovic, Marija; Zivlak-Radulovic, Nera] Univ Clin Ctr Republ Srpska, Dept Psychiat, Banja Luka, Bosnia & Herceg.
   [Babic, Dragan] Univ Clin Hosp Mostar, Dept Psychiat, Mostar, Bosnia & Herceg.
   [Racetovic, Goran] Hlth Ctr Prijedor, Community Mental Hlth Ctr, Prijedor, Bosnia & Herceg.
RP Hasanovic, M (corresponding author), Univ Clin Ctr Tuzla, Dept Psychiat, Ul Rate Dugonjica BB, Tuzla 75000, Bosnia & Herceg.
EM dr.mevludin.hasanovic@gmail.com
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Arapovic J, 2020, BOSNIAN J BASIC MED, V20, P396, DOI 10.17305/bjbms.2020.4838
   Bakioglu F, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00331-y
   Ceric I, 2001, Med Arh, V55, P5
   Dar KA, 2017, ASIAN J PSYCHIATR, V29, P129, DOI 10.1016/j.ajp.2017.04.017
   Duan L, 2020, LANCET PSYCHIAT, V7, P300, DOI 10.1016/S2215-0366(20)30073-0
   Dzubur Kulenovic A., 2020, BRZA TRANKVILIZACIJA
   Farre L, 2015, 9235 IZA
   Gunnell D, 2020, LANCET PSYCHIAT, V7, P468, DOI 10.1016/S2215-0366(20)30171-1
   Hermann Alison, 2020, JAMA Psychiatry, DOI 10.1001/jamapsychiatry.2020.1947
   Hodzic N, 2020, PSYCHIAT DANUB, V32, P294, DOI 10.24869/psyd.2020.294
   Jakovljevic M, 2020, PSYCHIAT DANUB, V32, P3, DOI 10.24869/psyd.2020.3
   Johns Hopkins University, COVID 19 DASHB CTR S
   Kalin ML, 2020, AM J PSYCHIAT, V177, P636, DOI 10.1176/appi.ajp.2020.20040372
   Kallivayali RA, 2020, HINDU
   Kang LJ, 2020, LANCET PSYCHIAT, V7, pE14, DOI 10.1016/S2215-0366(20)30047-X
   Keshvardoost S, 2020, TELEMED E-HEALTH, V26, P850, DOI 10.1089/tmj.2020.0105
   Kucukalic A, 2005, PSYCHIAT SERV, V56, P1455, DOI 10.1176/appi.ps.56.11.1455
   Lazzari C, 2020, PSYCHIAT DANUB, V32, P229, DOI 10.24869/psyd.2020.229
   Li C, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.112935
   Li LM, 2020, PSYCHIAT SERV, V71, P873, DOI 10.1176/appi.ps.71803
   Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125
   Medalia A, 2020, PSYCHIAT SERV, V71, P872, DOI 10.1176/appi.ps.71705
   Mehic-Basara N., 2020, POSTUPANJE S OVISNIC
   Moreno C, 2020, LANCET PSYCHIAT, V7, P813, DOI 10.1016/S2215-0366(20)30307-2
   Nicomedes CJ, 2020, ANAL PANIC FILIPINOS
   Pajevic I, 2020, MENTAL HLTH PROTECTI
   Percudani M, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112980
   Roncero C, 2020, PSYCHIAT RES, V291, DOI 10.1016/j.psychres.2020.113252
   Ruddin F., 2020, PSIKOISLAMICA, V17, P17
   Sinanovic O., 2020, SARS COV 2 PANDEMIJA
   Sinanovic Osman, 2009, Int Psychiatry, V6, P10
   Spagnolo PA, 2020, AM J PSYCHIAT, V177, P805, DOI 10.1176/appi.ajp.2020.20040417
   Sun NN, 2020, AM J INFECT CONTROL, V48, P592, DOI 10.1016/j.ajic.2020.03.018
   Thakur V, 2020, BRAIN BEHAV IMMUN, V88, P952, DOI 10.1016/j.bbi.2020.04.062
   World Health Organization, 2020, 2 M INT HLTH REG 200
   Xiang YT, 2020, INT J BIOL SCI, V16, P1741, DOI 10.7150/ijbs.45072
   Yao H, 2020, LANCET PSYCHIAT, V7, pE21, DOI 10.1016/S2215-0366(20)30090-0
   Zhang J, 2020, PRECISION CLIN MED, V3, P3, DOI [10.1093/pcmedi/pbaa006, DOI 10.1093/pcmedi/pbaa006]
   Zhu YH, 2020, NEUROSCI BULL, V36, P299, DOI 10.1007/s12264-020-00476-9
NR 40
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0019-5545
EI 1998-3794
J9 INDIAN J PSYCHIAT
JI Indian J. Psychiatry
PD SEP
PY 2020
VL 62
IS 9
SU 3
BP 479
EP 491
DI 10.4103/psychiatry.IndianJPsychiatry_1044_20
PG 13
WC Psychiatry
SC Psychiatry
GA OG2GO
UT WOS:000581709400028
PM 33227053
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Irfan, M
   Naeem, F
   Afridi, MI
   Javed, A
AF Irfan, Muhammad
   Naeem, Farooq
   Afridi, Muhammad Iqbal
   Javed, Afzal
TI Prevention of occupational stress in health-care workers during COVID-19
   pandemic
SO INDIAN JOURNAL OF PSYCHIATRY
LA English
DT Article
DE COVID-19; healthcare workers; occupational stress
ID RESILIENCE
AB In a humanitarian crisis, healthcare workers are on the frontline in providing their services. Despite being crisis management personnel, healthcare workers may get exposed to occupational stress due to unprecedented circumstances, challenges in delivery of high-quality care, lack of resources, and most importantly for being at high risk to suffer from the impact of the situation itself. Therefore, it is imperative to maintain the mental health of healthcare workers on a regular basis and more so during a pandemic like COVID-19. For addressing the occupational stress in healthcare workers, a Cognitive Behaviour Therapy (CBT) based intervention is suggested, also supported by a Cochrane review, which can build/ improve/ enhance resilience, needed to shield individuals against the development of psychopathology, at the public health level in humanitarian crises. In addition to developing resilience, which will be helpful in combating anxiety, depression, somatization, and incapacitation, CBT will also help in dealing with the social isolation which has been part and parcel of COVID-19 and similar pandemic situations.
C1 [Irfan, Muhammad] Riphah Int Univ, Peshawar Med Coll, Dept Mental Hlth Psychiat & Behav Sci, Islamabad, Pakistan.
   [Afridi, Muhammad Iqbal] Jinnah Postgrad Med Ctr, Psychiat, Karachi, Pakistan.
   [Naeem, Farooq] Univ Toronto, Toronto, ON, Canada.
   [Naeem, Farooq] Ctr Addict & Mental Hlth, Toronto, ON, Canada.
   [Javed, Afzal] Univ Warwick, Warwick Med Sch, Warwick, England.
RP Irfan, M (corresponding author), Riphah Int Univ, Peshawar Med Coll, Dept Mental Hlth Psychiat & Behav Sci, Islamabad, Pakistan.
EM mirfan78@yahoo.com
CR Arnetz J, 2013, J NERV MENT DIS, V201, P167, DOI 10.1097/NMD.0b013e3182848afe
   Chen QN, 2020, LANCET PSYCHIAT, V7, pE15, DOI 10.1016/S2215-0366(20)30078-X
   Familoni OB, 2008, NIGER HOSP PRACT, V2, P102
   Marine A, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002892.pub2
   Maunder RG, 2008, CAN J PUBLIC HEALTH, V99, P486, DOI 10.1007/BF03403782
   Norte CE, 2011, REV PSIQ CLIN-BRAZIL, V38, P43
   WILLIAMSON AM, 1994, INT J IND ERGONOM, V14, P171, DOI 10.1016/0169-8141(94)90014-0
NR 7
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0019-5545
EI 1998-3794
J9 INDIAN J PSYCHIAT
JI Indian J. Psychiatry
PD SEP
PY 2020
VL 62
IS 9
SU 3
BP 495
EP 497
DI 10.4103/psychiatry.IndianJPsychiatry_844_20
PG 3
WC Psychiatry
SC Psychiatry
GA OG2GO
UT WOS:000581709400030
PM 33227042
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Sugiyama, Y
   Tsuchiya, T
   Tanaka, R
   Ouchi, A
   Motoyama, A
   Takamoto, T
   Hara, N
   Yanagawa, Y
AF Sugiyama, Yohsuke
   Tsuchiya, Takaaki
   Tanaka, Ryota
   Ouchi, Aiko
   Motoyama, Arata
   Takamoto, Takeshi
   Hara, Natsumi
   Yanagawa, Yoshitaka
TI Cerebral venous thrombosis in COVID-19-associated coagulopathy: A case
   report
SO JOURNAL OF CLINICAL NEUROSCIENCE
LA English
DT Article
DE COVID-19; Cerebral venous thrombosis; Pulmonary thromboembolism;
   D-dimer; Edoxaban
AB COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first reported in Wuhan, China in December 2019, and is ongoing pandemic. While a majority of patients with SARS-CoV-2 infection shows asymptomatic or mild disease, hospitalized patients can develop critical condition, such as pneumonia, sepsis, and respiratory failure. Some cases deteriorate into sever systemic disease and multiorgan failure. Many patients of severe COVID-19 show hypercoagulable state and complicate with venous thromboembolism and atrial thrombosis. We herein reported a case of COVID-19 who developed cerebral venous thrombosis (CVT) co-incidence with pulmonary thromboembolism (PTE). A 56-year-old Japanese man was presented with fever and malaise and diagnosed with COVID-19. He was treated with ciclesonide and azithromycin, but his respiratory condition deteriorated. Thus, systemic corticosteroids and favipiravir were initiated and these treatments resulted in afebrile state, improving malaise and respiratory failure. However, he suddenly developed severe headache and vomiting with increased concentration of D-dimer. Brain CT and MRI showed typical images of CVT in the left transvers sinus and CT pulmonary angiography showed PE. Administration of unfractionated heparin followed by edoxaban treatment reduced the levels of D-dimer and improved his clinical presentation and thrombosis. Monitoring coagulopathy is important in COVID-19 patients and in case of venous thromboembolism, including cerebral venous system, appropriate anticoagulant therapy should be initiated. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Sugiyama, Yohsuke; Tsuchiya, Takaaki; Ouchi, Aiko; Hara, Natsumi; Yanagawa, Yoshitaka] Natl Hosp Org Kobe Med Ctr, Dept Resp Med, Kobe, Hyogo, Japan.
   [Tanaka, Ryota] Jichi Med Univ, Stroke Ctr, Shimotsuke, Tochigi, Japan.
   [Tanaka, Ryota] Jichi Med Univ, Dept Med, Div Neurol, Shimotsuke, Tochigi, Japan.
   [Motoyama, Arata] Natl Hosp Org Kobe Med Ctr, Dept Radiol, Kobe, Hyogo, Japan.
   [Takamoto, Takeshi] Natl Hosp Org Kobe Med Ctr, Dept Neurosurg, Kobe, Hyogo, Japan.
RP Sugiyama, Y (corresponding author), Natl Hosp Org Kobe Med Ctr, Dept Resp, Suma Ku, 3-1-1 Nishiochiai, Kobe, Hyogo 6540155, Japan.
EM m05047ys@jichi.ac.jp
CR Al-Ani F, 2020, THROMB RES, V192, P152, DOI 10.1016/j.thromres.2020.05.039
   Al-Samkari H, 2020, BLOOD, V136, P489, DOI 10.1182/blood.2020006520
   Capecchi M, 2018, J THROMB HAEMOST, V16, P1918, DOI 10.1111/jth.14210
   Leonard-Lorant I, 2020, RADIOLOGY, V296, pE189, DOI 10.1148/radiol.2020201561
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Moores LK, 2020, CHEST, V158, P1143, DOI 10.1016/j.chest.2020.05.559
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Romoli M, 2020, EUR J NEUROL, V27, P1712, DOI 10.1111/ene.14382
NR 8
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0967-5868
EI 1532-2653
J9 J CLIN NEUROSCI
JI J. Clin. Neurosci.
PD SEP
PY 2020
VL 79
BP 30
EP 32
DI 10.1016/j.jocn.2020.07.038
PG 3
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA OG5ML
UT WOS:000581927800005
PM 33070913
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Steinbach, R
   Prell, T
   Gaur, N
   Stubendorff, B
   Roediger, A
   Ilse, B
   Witte, OW
   Grosskreutz, J
AF Steinbach, Robert
   Prell, Tino
   Gaur, Nayana
   Stubendorff, Beatrice
   Roediger, Annekathrin
   Ilse, Benjamin
   Witte, Otto W.
   Grosskreutz, Julian
TI Triage of Amyotrophic Lateral Sclerosis Patients during the COVID-19
   Pandemic: An Application of the D50 Model
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE amyotrophic lateral sclerosis; disease progression; D50; COVID-19;
   SARS-CoV-2; triage; gastrostomy; assisted ventilation
ID NONINVASIVE VENTILATION; CARE; GASTROSTOMY; MANAGEMENT
AB Amyotrophic lateral sclerosis (ALS) is a progressive neuromuscular disease, the management of which requires the continuous provision of multidisciplinary therapies. Owing to the novel coronavirus disease (COVID-19) pandemic, regular contact with ALS patients at our center was severely restricted and patient care was at risk by delay of supportive therapies. We established a triage system based on the D50 disease progression model and were thus able to identify a prospective cohort with high disease aggressiveness (D50 < 30). Thirty-seven patients with highly aggressive disease were actively offered follow-up, either via telephone or on-site, depending on their disease-specific needs and abilities. We describe here the procedures, obstacles, and results of these prescient efforts during the restrictions caused by COVID-19 in the period between March and June 2020. In conclusion, four patients with highly aggressive disease were initiated with non-invasive ventilation and two received a gastrostomy. We could show that a comparable amount of advanced care was induced in a retrospective cohort within a similar time period one year prior to the COVID-19 outbreak. Our workflow to identify high-risk patients via D50 model metrics can be easily implemented and integrated within existing centers. It helped to maintain a high quality of advanced care planning for our ALS patients.
C1 [Steinbach, Robert; Prell, Tino; Gaur, Nayana; Stubendorff, Beatrice; Roediger, Annekathrin; Ilse, Benjamin; Witte, Otto W.; Grosskreutz, Julian] Jena Univ Hosp, Hans Berger Dept Neurol, D-07747 Jena, Germany.
   [Prell, Tino; Witte, Otto W.; Grosskreutz, Julian] Jena Univ Hosp, Ctr Hlth Ageing, D-07747 Jena, Germany.
RP Steinbach, R (corresponding author), Jena Univ Hosp, Hans Berger Dept Neurol, D-07747 Jena, Germany.
EM Robert.Steinbach@med.uni-jena.de; Tino.Prell@med.uni-jena.de;
   Nayana.Gaur@med.uni-jena.de; Beatrice.Stubendorff@med.uni-jena.de;
   Annekathrin.Roediger@med.uni-jena.de; Benjamin.Ilse@med.uni-jena.de;
   Otto.Witte@med.uni-jena.de; Julian.Grosskreutz@med.uni-jena.de
RI ; , Otto/P-4127-2018; Grosskreutz, Julian/G-2293-2010
OI Prell, Tino/0000-0002-6423-3108; , Otto/0000-0003-2101-4105; Ilse,
   Benjamin/0000-0002-2260-0803; Steinbach, Robert/0000-0003-3936-6010;
   Grosskreutz, Julian/0000-0001-9525-1424
FU German Bundesministerium fur Bildung und Forschung (BMBF) grant
   SOPHIAFederal Ministry of Education & Research (BMBF); ONWebDUALS under
   the aegis of the EU Joint Programme Neurodegenerative Disease Research
   (JPND); BMBF grant PYRAMID; Bundesministerium fur Bildung und
   ForschungFederal Ministry of Education & Research (BMBF) [01GY1804];
   Motor Neurone Disease Association (MNDA); Deutsche Gesellschaft fur
   Muskelkranke (DGM); Deutsche Forschungsgemeinschaft (DFG)German Research
   Foundation (DFG) [WI 830/12-1]; Graduate Academy of Friedrich Schiller
   University, Jena, Germany; state of Thuringia
FX The present study was supported by the German Bundesministerium fur
   Bildung und Forschung (BMBF) grant SOPHIA and ONWebDUALS to J.G. under
   the aegis of the EU Joint Programme Neurodegenerative Disease Research
   (JPND) and a BMBF grant PYRAMID to J.G. in the framework of the ERANET
   E-RARE program. T.P. was supported by a Bundesministerium fur Bildung
   und Forschung grant (01GY1804). Support was received from the Motor
   Neurone Disease Association (MNDA) and Deutsche Gesellschaft fur
   Muskelkranke (DGM). R.S. and A.R. are supported by the Deutsche
   Forschungsgemeinschaft (DFG) with a clinician scientist program (WI
   830/12-1). N.G. is supported by a doctoral scholarship
   (Landesgraduiertenstipendien) from the Graduate Academy of Friedrich
   Schiller University, Jena, Germany and the state of Thuringia.
CR Andersen PM, 2018, J NEUROL, V265, P1600, DOI 10.1007/s00415-018-8861-4
   Andersen PM, 2012, EUR J NEUROL, V19, P360, DOI 10.1111/j.1468-1331.2011.03501.x
   Andrews JA, 2020, MUSCLE NERVE, V62, P182, DOI 10.1002/mus.26989
   Boentert M, 2015, J NEUROL, V262, P2073, DOI 10.1007/s00415-015-7822-4
   Bond L, 2020, BEHAV SCI, V10, DOI 10.3390/bs10010033
   Bond L, 2019, BRAIN SCI, V9, DOI 10.3390/brainsci9090223
   do Nascimento IB, 2020, J CLIN MED, V9, DOI 10.3390/jcm9040941
   Burkhardt C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177555
   Capozzo R, 2020, AMYOTROPH LAT SCL FR, V21, P542, DOI 10.1080/21678421.2020.1773502
   Cedarbaum JM, 1999, J NEUROL SCI, V169, P13, DOI 10.1016/S0022-510X(99)00210-5
   Chio A, 2011, J NEUROL NEUROSUR PS, V82, P740, DOI 10.1136/jnnp.2010.235952
   Clark A, 2020, LANCET GLOB HEALTH, V8, P1003, DOI 10.1016/S2214-109X(20)30264-3
   de Carvalho M, 2017, NEUROLOGY, V89, P1435, DOI 10.1212/WNL.0000000000004547
   De Marchi F, 2020, NEUROL SCI, V41, P1365, DOI 10.1007/s10072-020-04457-8
   Demetriou CA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220246
   Dorst J, 2017, THER ADV NEUROL DISO, V11, P1, DOI 10.1177/1756285617734734
   Foley G, 2012, AMYOTROPH LATERAL SC, V13, P11, DOI 10.3109/17482968.2011.607500
   Gordon J, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101578
   Greenaway LP, 2015, J NEUROL, V262, P1002, DOI 10.1007/s00415-015-7665-z
   Gromicho M, 2020, ANN CLIN TRANSL NEUR, V7, P1181, DOI 10.1002/acn3.51098
   Helleman J, 2020, AMYOTROPH LAT SCL FR, V21, P167, DOI 10.1080/21678421.2019.1706581
   Hobson EV, 2016, NAT REV NEUROL, V12, P526, DOI 10.1038/nrneurol.2016.111
   Khamankar N, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00578
   Kiernan MC, 2011, LANCET, V377, P942, DOI 10.1016/S0140-6736(10)61156-7
   Logroscino G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195821
   Martin NH, 2016, QUAL HEALTH RES, V26, P1366, DOI 10.1177/1049732315583661
   Meyer T, 2020, J NEUROL NEUROSUR PS, V91, P783, DOI 10.1136/jnnp-2020-322938
   Miller RG, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001447.pub2
   Miller RG, 2009, NEUROLOGY, V73, P1218, DOI 10.1212/WNL.0b013e3181bc0141
   Mishra-Kalyani PS, 2016, SCI REP-UK, V6, DOI 10.1038/srep33431
   Niedermeyer S, 2019, CHEST, V155, P401, DOI 10.1016/j.chest.2018.06.035
   Paipa AJ, 2019, J MULTIDISCIP HEALTH, V12, P465, DOI 10.2147/JMDH.S205313
   Petrov D, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00068
   Poesen K, 2017, NEUROLOGY, V88, P2302, DOI 10.1212/WNL.0000000000004029
   Prell T, 2020, HEALTH QUAL LIFE OUT, V18, DOI 10.1186/s12955-020-01372-6
   Prell T, 2016, J NEUROL NEUROSUR PS, V87, P1022, DOI 10.1136/jnnp-2015-312185
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Rosenbohm A, 2018, J NEUROL, V265, P774, DOI 10.1007/s00415-018-8735-9
   Schoser B., 2020, DGNEUROLOGIE, V3, P310, DOI [10.1007/s42451-020-00198-2, DOI 10.1007/S42451-020-00198-2]
   Seeber AA, 2019, BMC PALLIAT CARE, V18, DOI 10.1186/s12904-019-0433-6
   Simon NG, 2014, ANN NEUROL, V76, P643, DOI 10.1002/ana.24273
   Sole G, 2020, REV NEUROL-FRANCE, V176, P507, DOI 10.1016/j.neurol.2020.04.004
   Steinbach R, 2020, NEUROIMAGE-CLIN, V25, DOI 10.1016/j.nicl.2019.102094
   Westeneng HJ, 2018, LANCET NEUROL, V17, P423, DOI 10.1016/S1474-4422(18)30089-9
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 45
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD SEP
PY 2020
VL 9
IS 9
AR 2873
DI 10.3390/jcm9092873
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA OG9CA
UT WOS:000582171600001
PM 32899481
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Milenkovic, A
   Jankovic, D
   Rajkovic, P
AF Milenkovic, Aleksandar
   Jankovic, Dragan
   Rajkovic, Petar
TI Extensions and adaptations of existing medical information system in
   order to reduce social contacts during COVID-19 pandemic
SO INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS
LA English
DT Article
DE COVID-19; Coronavirus; Pandemic; Social contacts; Medical information
   system
ID CRITICAL-CARE; HEALTH-CARE; LESSONS; TRIAGE; CORONAVIRUS
AB Objective: The main objective of this paper is the reduction of the COVID-19 pandemic spread by increasing the degree of social distancing by using and upgrading the existing Medical Information System (MIS).
   Material and methods: The existing MIS MEDIS.NET, currently used in the largest health center in the Balkans, has been adapted and further developed.
   Results: During the adaptation of existing MIS MEDIS.NET 4 new and 9 existing modules were developed. A quick questionnaire for the smart triage of patients was also implemented.
   Discussion: The adapted MIS successfully influenced the reduction of social contacts within the Health Center Nis. The need for the arrival of children and their parents to receive appropriate health certificates for the school enrolment is reduced. The therapy of chronic patients has been prolonged for 6 months via an electronic prescription. An online service for the communication between patients and the chosen physicians is provided. Possible social contacts and exposure to the viral environment of patients are reduced by making appointments in extended slots and at determined physical locations. Patients are notified per SMS or email about the availability of chosen and physician on duty. The social distancing of patients and physicians is also established by sending laboratory analyses per email or SMS. Keeping the central registry for COVID-19 is enabled throughout the country.
   Conclusion: The smart adaptation of MIS, and its collaboration with other state systems can significantly influence the reduction of social contacts and thus mitigate the consequences of COVID-19 pandemic.
C1 [Milenkovic, Aleksandar; Jankovic, Dragan; Rajkovic, Petar] Univ Nis, Fac Elect Engn, Lab Med Informat, Aleksandra Medvedeva St 14,Lab 534, Nish 18000, Serbia.
RP Milenkovic, A (corresponding author), Univ Nis, Fac Elect Engn, Lab Med Informat, Aleksandra Medvedeva St 14,Lab 534, Nish 18000, Serbia.
EM aleksandar.milenkovic@elfak.ni.ac.rs; dragan.jankovic@elfak.ni.ac.rs;
   petar.rajkovic@elfak.ni.ac.rs
FU Ministry of Education, Science and Technological Development of the
   Republic of Serbia [ON174026]
FX This work has been supported by the Ministry of Education, Science and
   Technological Development of the Republic of Serbia (Project number:
   ON174026).
CR Adalja AA, 2020, JAMA-J AM MED ASSOC, V323, P1343, DOI 10.1001/jama.2020.3413
   Agarwal B., 2020, DEEP LEARNING TECHNI, DOI [10.1016/C2018-0-04781-7., DOI 10.1016/C2018-0-04781-7]
   Aleksic D, 2017, J BIOMED INFORM, V69, P188, DOI 10.1016/j.jbi.2017.04.012
   [Anonymous], 2020, COVID 19 COR DAT
   [Anonymous], 2020, APPLE GOOGLE DETAIL
   Arango C, 2020, BIOL PSYCHIAT, V88, pE33, DOI 10.1016/j.biopsych.2020.04.003
   Tran BX, 2020, SAFETY SCI, V129, DOI 10.1016/j.ssci.2020.104811
   Bandayrel K, 2013, DISASTER MED PUBLIC, V7, P287, DOI 10.1001/dmp.2011.45
   Boas SJ, 2014, HEALTHCARE, V2, P103, DOI 10.1016/j.hjdsi.2013.10.003
   Boccia S, 2020, JAMA INTERN MED, V180, P927, DOI 10.1001/jamainternmed.2020.1447
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Christian MD, 2006, CAN MED ASSOC J, V175, P1377, DOI 10.1503/cmaj.060911
   Cooper D., 2020, PAN EUROPEAN PRIVACY
   Dai B, 2018, INT SYMP COMP CONS, P449, DOI 10.1109/IS3C.2018.00119
   Danquah LO, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4354-z
   Dordevic A., 2020, 10 INT C INF SOC TEC
   European Centre for Disease Prevention and Control, 2020, COVID 19 SIT UPD WOR
   Ferretti L, 2020, SCIENCE, V368, P619, DOI 10.1126/science.abb6936
   Hao FY, 2020, BRAIN BEHAV IMMUN, V87, P100, DOI 10.1016/j.bbi.2020.04.069
   Hayward Andrew C, 2020, Wellcome Open Res, V5, P54, DOI 10.12688/wellcomeopenres.15795.1
   Hook L., 2020, FT MAGAZINE
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jankovic D., 2012, ACTA MED MEDIAN, P73, DOI [10.5633/amm.2012.0113., DOI 10.5633/AMM.2012.0113]
   Judson TJ, 2020, J AM MED INFORM ASSN, V27, P860, DOI 10.1093/jamia/ocaa051
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Liu HC, 2008, INT C WAVEL ANAL PAT, P287, DOI 10.1109/ICWAPR.2008.4635791
   Markovic I., 2012, ICEST 2012, V2012, P178
   Mason R., 2020, GUARDIAN
   Milenkovic A., 2014, YUINFO 2013, P507
   Milic E, 2018, ADV INTELL SYST, V665, P173, DOI 10.1007/978-3-319-68855-8_17
   Morens DM, 2020, NEW ENGL J MED, V382, P1293, DOI 10.1056/NEJMp2002106
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Pyne S., 2015, BIG DATA APPL HLTH S, P171, DOI [10.1016/B978-0-444-63492-4.00008-3, DOI 10.1016/B978-0-444-63492-4.00008-3]
   Rajagopalan A, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7110150
   Rajkovic P, 2013, COMPUT SCI INF SYST, V10, P1429, DOI 10.2298/CSIS120523056R
   Reeves JJ, 2020, J AM MED INFORM ASSN, V27, P853, DOI 10.1093/jamia/ocaa037
   Tan WQ, 2020, BRAIN BEHAV IMMUN, V87, P84, DOI 10.1016/j.bbi.2020.04.055
   Tian S., 2019, GLOB HLTH J, V3, P62, DOI [10.1016/j.glohj.2019.07.001, DOI 10.1016/J.GLOHJ.2019.07.001]
   Walker P., 2020, GLOBAL IMPACT COVID, DOI [DOI 10.25561/77735, 10.25561/77735]
   Wang CY, 2020, BRAIN BEHAV IMMUN, V87, P40, DOI 10.1016/j.bbi.2020.04.028
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, EM US ICD COD COVID
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   World Health Organization, 2014, INF PREV CONTR EP PA
   World Health Organization, 2020, COVID 19 STRAT UPD
   Worldometer, 2020, COVID 19 COR PAND
   Wosik J, 2020, J AM MED INFORM ASSN, V27, P957, DOI 10.1093/jamia/ocaa067
   Xie MX, 2020, INT J INFECT DIS, V94, P119, DOI 10.1016/j.ijid.2020.03.071
   Zhang MW, 2016, TECHNOL HEALTH CARE, V24, P139, DOI 10.3233/THC-151099
   Zhang MWB, 2016, TECHNOL HEALTH CARE, V24, P769, DOI 10.3233/THC-161165
   Zhang MWB, 2015, TECHNOL HEALTH CARE, V23, P737, DOI 10.3233/THC-151026
NR 53
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1386-5056
EI 1872-8243
J9 INT J MED INFORM
JI Int. J. Med. Inform.
PD SEP
PY 2020
VL 141
AR 104224
DI 10.1016/j.ijmedinf.2020.104224
PG 11
WC Computer Science, Information Systems; Health Care Sciences & Services;
   Medical Informatics
SC Computer Science; Health Care Sciences & Services; Medical Informatics
GA OD3VH
UT WOS:000579780700038
PM 32570196
OA Green Published
DA 2021-01-01
ER

PT J
AU Fong, CHY
   Cai, JP
   Dissanayake, TK
   Chen, LL
   Choi, CYK
   Wong, LH
   Ng, ACK
   Pang, PKP
   Ho, DTY
   Poon, RWS
   Chung, TWH
   Sridhar, S
   Chan, KH
   Chan, JFW
   Hung, IFN
   Yuen, KY
   To, KKW
AF Fong, Carol Ho-Yan
   Cai, Jian-Piao
   Dissanayake, Thrimendra Kaushika
   Chen, Lin-Lei
   Choi, Charlotte Yee-Ki
   Wong, Lok-Hin
   Ng, Anthony Chin-Ki
   Pang, Polly K. P.
   Ho, Deborah Tip-Yin
   Poon, Rosana Wing-Shan
   Chung, Tom Wai-Hin
   Sridhar, Siddharth
   Chan, Kwok-Hung
   Chan, Jasper Fuk-Woo
   Hung, Ivan Fan-Ngai
   Yuen, Kwok-Yung
   To, Kelvin Kai-Wang
TI Improved Detection of Antibodies against SARS-CoV-2 by Microsphere-Based
   Antibody Assay
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE COVID-19; SARS-CoV-2; serology; flow cytometry; antibody assay
ID IMMUNOASSAY; CORONAVIRUS; VIRUS
AB Currently available COVID-19 antibody tests using enzyme immunoassay (EIA) or immunochromatographic assay have variable sensitivity and specificity. Here, we developed and evaluated a novel microsphere-based antibody assay (MBA) for detecting immunoglobulin G (IgG) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleoprotein (NP) and spike protein receptor binding domain (RBD). The seropositive cutoff value was set using a cohort of 294 anonymous serum specimens collected in 2018. The specificity was assessed using serum specimens collected from organ donors or influenza patients before 2020. Seropositive rate was determined among COVID-19 patients. Time-to-seropositivity and signal-to-cutoff (S/CO) ratio were compared between MBA and EIA. MBA had a specificity of 100% (93/93; 95% confidence interval (CI), 96-100%) for anti-NP IgG, 98.9% (92/93; 95% CI 94.2-100%) for anti-RBD IgG. The MBA seropositive rate for convalescent COVID-19 patients was 89.8% (35/39) for anti-NP IgG and 79.5% (31/39) for anti-RBD IgG. The time-to-seropositivity was shorter with MBA than EIA. MBA could better differentiate between COVID-19 patients and negative controls with higher S/CO ratio for COVID-19 patients, lower S/CO ratio with negative controls and fewer specimens in the equivocal range. MBA is robust, simple and is suitable for clinical microbiology laboratory for the accurate determination of anti-SARS-CoV-2 antibodies for diagnosis, serosurveillance, and vaccine trials.
C1 [Fong, Carol Ho-Yan; Cai, Jian-Piao; Dissanayake, Thrimendra Kaushika; Chen, Lin-Lei; Choi, Charlotte Yee-Ki; Wong, Lok-Hin; Ng, Anthony Chin-Ki; Pang, Polly K. P.; Ho, Deborah Tip-Yin; Sridhar, Siddharth; Chan, Kwok-Hung; Chan, Jasper Fuk-Woo; Yuen, Kwok-Yung; To, Kelvin Kai-Wang] Univ Hong Kong, Li Ka Shing Fac Med, Carol Yu Ctr Infect,State Key Lab Emerging Infect, Dept Microbiol,Pokfulam, Hong Kong, Peoples R China.
   [Poon, Rosana Wing-Shan; Chung, Tom Wai-Hin] Queen Mary Hosp, Dept Microbiol, Hong Kong, Peoples R China.
   [Hung, Ivan Fan-Ngai] Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Pokfulam, Hong Kong, Peoples R China.
RP To, KKW (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Carol Yu Ctr Infect,State Key Lab Emerging Infect, Dept Microbiol,Pokfulam, Hong Kong, Peoples R China.
EM chyfong@hku.hk; caijuice@163.com; thrimendra@gmail.com;
   chenlinlei2346@gmail.com; yeekic@hku.hk; wallacewongg@gmail.com;
   anthonyng912@gmail.com; pollypang833@gmail.com; tipyinho@hku.hk;
   rosanapws@yahoo.com.hk; stwh.chung@gmail.com; sid8998@hku.hk;
   chankh2@hku.hk; jfwchan@hku.hk; ivanhung@hku.hk; kyyuen@hku.hk;
   kelvinto@hku.hk
RI ; Chan, Jasper Fuk-Woo/D-8007-2013; Sridhar, Siddharth/J-4061-2019
OI Cai, Jian-Piao/0000-0003-4077-3852; Chan, Jasper
   Fuk-Woo/0000-0001-6336-6657; Sridhar, Siddharth/0000-0002-2022-8307;
   /0000-0003-1771-8249
FU Public Sector Trial Scheme for the Prevention and Control of Coronavirus
   Disease 2019 (COVID-19) in Hong Kong [SST/115/20GP]
FX This study was supported by the Public Sector Trial Scheme for the
   Prevention and Control of Coronavirus Disease 2019 (COVID-19) in Hong
   Kong (SST/115/20GP), and donations of Richard Yu and Carol Yu, May Tam
   Mak Mei Yin, the Shaw Foundation Hong Kong, Michael Seak-Kan Tong,
   Respiratory Viral Research Foundation Limited, Hui Ming, Hui Hoy and
   Chow Sin Lan Charity Fund Limited, Chan Yin Chuen Memorial Charitable
   Foundation, Marina Man-Wai Lee, the Jessie & George Ho Charitable
   Foundation, Perfect Shape Medical Limited, and Kai Chong Tong; The
   funding sources had no role in the study design, data collection,
   analysis, interpretation, or writing of the report.
CR Abbasi J, 2020, JAMA-J AM MED ASSOC, V323, P1881, DOI 10.1001/jama.2020.6170
   Basile AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075670
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen LL, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268819001717
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Demey B, 2020, J INFECTION, V81, pE6, DOI 10.1016/j.jinf.2020.04.033
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Imai K, 2020, J CLIN VIROL, V128
   Kranz LM, 2019, J IMMUNOL METHODS, V466, P47, DOI 10.1016/j.jim.2019.01.007
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Montesinos I, 2020, J CLIN VIROL, V128
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Perera Ranawaka Apm, 2020, Euro Surveill, V25, DOI 10.2807/1560-7917.ES.2020.25.16.2000421
   Petherick A, 2020, LANCET, V395, P1101, DOI 10.1016/S0140-6736(20)30788-1
   Rogier EW, 2018, EMERG INFECT DIS, V24, P995, DOI 10.3201/eid2406.171447
   Smits GP, 2012, CLIN VACCINE IMMUNOL, V19, P396, DOI 10.1128/CVI.05537-11
   To Kelvin Kai-Wang, 2020, Lancet Microbe, V1, pe111, DOI 10.1016/S2666-5247(20)30053-7
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   To KKW, 2020, CLIN INFECT DIS, V71, P841, DOI 10.1093/cid/ciaa149
   Trivedi SU, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37747-5
   Zhang YG, 2014, J VIROL METHODS, V206, P55, DOI 10.1016/j.jviromet.2014.05.008
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
NR 23
TC 1
Z9 1
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2020
VL 21
IS 18
AR 6595
DI 10.3390/ijms21186595
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA OG2ED
UT WOS:000581703100001
PM 32916926
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Joyner, MJ
   Wright, RS
   Fairweather, D
   Senefeld, JW
   Bruno, KA
   Klassen, SA
   Carter, RE
   Klompas, AM
   Wiggins, CC
   Shepherd, JRA
   Rea, RF
   Whelan, ER
   Clayburn, AJ
   Spiegel, MR
   Johnson, PW
   Lesser, ER
   Baker, SE
   Larson, KF
   Ripoll, JG
   Andersen, KJ
   Hodge, DO
   Kunze, KL
   Buras, MR
   Vogt, MNP
   Herasevich, V
   Dennis, JJ
   Regimbal, RJ
   Bauer, PR
   Blair, JE
   van Buskirk, CM
   Winters, JL
   Stubbs, JR
   Paneth, NS
   Verdun, NC
   Marks, P
   Casadevall, A
AF Joyner, Michael J.
   Wright, R. Scott
   Fairweather, DeLisa
   Senefeld, Jonathon W.
   Bruno, Katelyn A.
   Klassen, Stephen A.
   Carter, Rickey E.
   Klompas, Allan M.
   Wiggins, Chad C.
   Shepherd, John R. A.
   Rea, Robert F.
   Whelan, Emily R.
   Clayburn, Andrew J.
   Spiegel, Matthew R.
   Johnson, Patrick W.
   Lesser, Elizabeth R.
   Baker, Sarah E.
   Larson, Kathryn F.
   Ripoll, Juan G.
   Andersen, Kylie J.
   Hodge, David O.
   Kunze, Katie L.
   Buras, Matthew R.
   Vogt, Matthew N. P.
   Herasevich, Vitaly
   Dennis, Joshua J.
   Regimbal, Riley J.
   Bauer, Philippe R.
   Blair, Janis E.
   van Buskirk, Camille M.
   Winters, Jeffrey L.
   Stubbs, James R.
   Paneth, Nigel S.
   Verdun, Nicole C.
   Marks, Peter
   Casadevall, Arturo
TI Early safety indicators of COVID-19 convalescent plasma in 5000 patients
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID ACUTE LUNG INJURY
AB BACKGROUND. Convalescent plasma is the only antibody-based therapy currently available for patients with coronavirus disease 2019 (COVID-19). It has robust historical precedence and sound biological plausibility. Although promising, convalescent plasma has not yet been shown to be safe as a treatment for COVID-19.
   METHODS. Thus, we analyzed key safety metrics after transfusion of ABO-compatible human COVID-19 convalescent plasma in 5000 hospitalized adults with severe or life-threatening COVID-19, with 66% in the intensive care unit, as part of the US FDA expanded access program for COVID-19 convalescent plasma.
   RESULTS. The incidence of all serious adverse events (SAEs), including mortality rate (0.3%), in the first 4 hours after transfusion was <1%. Of the 36 reported SAEs, there were 25 reported incidences of related SAEs, including mortality (n = 4), transfusion-associated circulatory overload (n = 7), transfusion-related acute lung injury (n = 11), and severe allergic transfusion reactions (n = 3). However, only 2 of 36 SAEs were judged as definitely related to the convalescent plasma transfusion by the treating physician. The 7-day mortality rate was 14.9%.
   CONCLUSION. Given the deadly nature of COVID-19 and the large population of critically ill patients included in these analyses, the mortality rate does not appear excessive. These early indicators suggest that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19.
C1 [Joyner, Michael J.; Senefeld, Jonathon W.; Klassen, Stephen A.; Klompas, Allan M.; Wiggins, Chad C.; Shepherd, John R. A.; Clayburn, Andrew J.; Baker, Sarah E.; Ripoll, Juan G.; Andersen, Kylie J.; Vogt, Matthew N. P.; Herasevich, Vitaly; Dennis, Joshua J.; Regimbal, Riley J.] Mayo Clin, Dept Anesthesiol & Perioperat Med, Rochester, MN 55905 USA.
   [Wright, R. Scott; Rea, Robert F.; Larson, Kathryn F.] Mayo Clin, Dept Cardiovasc Med, Rochester, MN 55905 USA.
   [Wright, R. Scott] Mayo Clin, Human Res Protect Program, Rochester, MN 55905 USA.
   [Fairweather, DeLisa; Bruno, Katelyn A.; Whelan, Emily R.] Mayo Clin, Dept Cardiovasc Med, Jacksonville, FL 32224 USA.
   [Carter, Rickey E.; Spiegel, Matthew R.; Johnson, Patrick W.; Lesser, Elizabeth R.; Hodge, David O.] Mayo Clin, Dept Hlth Sci Res, Jacksonville, FL 32224 USA.
   [Kunze, Katie L.; Buras, Matthew R.] Mayo Clin, Dept Hlth Sci Res, Scottsdale, AZ USA.
   [Bauer, Philippe R.] Mayo Clin, Div Pulm & Crit Care Med, Dept Internal Med, Rochester, MN 55905 USA.
   [Blair, Janis E.] Mayo Clin, Div Infect Dis, Dept Internal Med, Phoenix, AZ USA.
   [van Buskirk, Camille M.; Winters, Jeffrey L.; Stubbs, James R.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA.
   [Paneth, Nigel S.] Michigan State Univ, Coll Human Med, Dept Epidemiol & Biostat, E Lansing, MI 48824 USA.
   [Paneth, Nigel S.] Michigan State Univ, Coll Human Med, Dept Pediat & Human Dev, E Lansing, MI 48824 USA.
   [Verdun, Nicole C.; Marks, Peter] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA.
   [Casadevall, Arturo] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA.
RP Joyner, MJ (corresponding author), Mayo Clin, 200 First St SW, Rochester, MN 55905 USA.
EM joyner.michael@mayo.edu
RI Senefeld, Jack/ABF-1286-2020; Johnson, Patrick/ABE-9597-2020; Carter,
   Rickey/A-1594-2012
OI Johnson, Patrick/0000-0001-8365-1375; Andersen,
   Kylie/0000-0001-8668-2871; Baker, Sarah/0000-0001-9647-7660; Senefeld,
   Jonathon/0000-0001-8116-3538; Vogt, Matthew/0000-0003-0721-8451; Carter,
   Rickey/0000-0002-0818-273X; Klompas, Allan/0000-0001-8852-4666;
   Regimbal, Riley/0000-0002-0195-5875; Bruno, Katelyn/0000-0001-8980-6059
FU US Department of Health and Human Services Biomedical Advanced Research
   and Development Authority [75A50120C00096]; National Center for
   Advancing Translational SciencesUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Advancing Translational Sciences (NCATS) [UL1TR002377];
   National Heart, Lung, and Blood Institute grantUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [5R35HL139854]; National
   Institute of Diabetes and Digestive and Kidney DiseasesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK) [5T32DK07352]; Natural Sciences and Engineering Research Council
   of CanadaNatural Sciences and Engineering Research Council of
   CanadaCGIAR [PDF-532926-2019]; National Institute of Allergy and
   Infectious DiseaseUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R21 AI145356, R21 AI152318,
   R01 AI1520789]; National Heart, Lung, and Blood InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL059842];
   Schwab Charitable Fund; United Health Group; National Basketball
   Association; Millennium PharmaceuticalsTakeda Pharmaceutical Company
   Ltd; Octapharma USA Inc.; Mayo Clinic
FX This study was supported in part by a US Department of Health and Human
   Services Biomedical Advanced Research and Development Authority contract
   (75A50120C00096, to MJJ), a National Center for Advancing Translational
   Sciences grant (UL1TR002377), a National Heart, Lung, and Blood
   Institute grant (5R35HL139854, to MJJ), the National Institute of
   Diabetes and Digestive and Kidney Diseases (5T32DK07352, to JWS and
   CCW), the Natural Sciences and Engineering Research Council of Canada
   (PDF-532926-2019, to SAK), the National Institute of Allergy and
   Infectious Disease (R21 AI145356 and R21 AI152318, to DF; R01 AI1520789,
   to AC), the National Heart, Lung, and Blood Institute (R01 HL059842, to
   AC), the Schwab Charitable Fund (Eric E. Schmidt and Wendy Schmidt
   donors), the United Health Group, the National Basketball Association,
   Millennium Pharmaceuticals, Octapharma USA Inc., and the Mayo Clinic. We
   thank the members of the Mayo Clinic IRB, the Mayo Clinic Office of
   Human Research Protection; the Mayo Clinic Office of Research Regulatory
   Support and in particular Mark Wentworth; the Executive Dean of Research
   at Mayo Clinic, Gregory Gores, and the CEO of Mayo Clinic, Gianrico
   Farrugia, for their support and assistance; and the independent Data and
   Safety Monitoring Board for their work and oversight of the EAP, Allan
   S. Jaffe (chair), David O. Warner, William G. Morice II, Paula J.
   Santrach, Robert L. Frye, Lawrence J Appel, and Taimur Sher. We thank
   the members of the National COVID-19 Convalescent Plasma Project
   (http://ccpp19.org) for their intellectual contributions and support. We
   thank the participating medical centers and medical teams and blood
   centers for their rigorous efforts necessary to make this program
   possible. We also thank the donors for providing COVID-19 convalescent
   plasma.
CR Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bierbaum BE, 1999, J BONE JOINT SURG AM, V81A, P2, DOI 10.2106/00004623-199901000-00002
   Bosboom JJ, 2019, TRANSFUS MED REV, V33, P69, DOI 10.1016/j.tmrv.2019.01.003
   CASADEVALL A, 1995, CLIN INFECT DIS, V21, P150, DOI 10.1093/clinids/21.1.150
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   CDC, COR DIS 2019 COVID 1
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   de Alwis R, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102768
   Division of Healthcare Quality Promotion Nation- al Center for Emerging and Zoonotic Infectious Diseases CDC, 2018, NAT HEALTHC SAF NETW
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Dzik S, 2020, TRANSFUS MED REV
   Gajic O, 2007, AM J RESP CRIT CARE, V176, P886, DOI 10.1164/rccm.200702-271OC
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Jancar S, 2005, TRENDS IMMUNOL, V26, P48, DOI 10.1016/j.it.2004.11.007
   Kam YW, 2007, VACCINE, V25, P729, DOI 10.1016/j.vaccine.2006.08.011
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Lutz HU, 2012, ADV EXP MED BIOL, V750, P186, DOI 10.1007/978-1-4614-3461-0_14
   Marshall AL, 2016, J THROMB HAEMOST, V14, P324, DOI 10.1111/jth.13212
   Poles D, 2019, 2018 ANN SHOT REPORT
   Rajgor DD, 2020, LANCET INFECT DIS, V20, P776, DOI 10.1016/S1473-3099(20)30244-9
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Vlaar APJ, 2019, TRANSFUSION, V59, P2465, DOI 10.1111/trf.15311
   Vlaar APJ, 2010, CRIT CARE MED, V38, P771, DOI 10.1097/CCM.0b013e3181cc4d4b
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang K, 2020, INTENS CARE MED, V46, P1472, DOI 10.1007/s00134-020-06047-w
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yip MS, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-82
   Zhang B, 2020, CHEST, V158, pE9, DOI 10.1016/j.chest.2020.03.039
   Zhang JS, 2005, J MED VIROL, V77, P147, DOI 10.1002/jmv.20431
NR 33
TC 47
Z9 47
U1 1
U2 2
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD SEP 1
PY 2020
VL 130
IS 9
BP 4791
EP 4797
DI 10.1172/JCI140200
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA OC8QJ
UT WOS:000579421000002
PM 32525844
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Fiumara, A
   Lanzafame, G
   Arena, A
   Sapuppo, A
   Raudino, F
   Pratico, A
   Pavone, P
   Barone, R
AF Fiumara, Agata
   Lanzafame, Giuseppina
   Arena, Alessia
   Sapuppo, Annamaria
   Raudino, Federica
   Pratico, Andrea
   Pavone, Piero
   Barone, Rita
TI COVID-19 Pandemic Outbreak and its Psychological Impact on Patients with
   Rare Lysosomal Diseases
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE COVID-19 pandemic; ERT; lysosomal storage disease; psychological impact
AB Background: Lysosomal storage disorders (LSDs) are rare, chronic, progressive multisystem diseases implying severe medical issues and psychological burden. Some of these disorders are susceptible to a treatment, which is administered weekly or every other week, in a hospital. During the COVID-19 (Corona Virus Disease 2019) pandemic lockdown, patients with LSDs on enzyme replacement therapy (ERT) missed their scheduled access to the Day Hospital to get their treatment. Methods: Based on the feeling that our patients were experiencing profound distress, we designed a structured telephone interview with the aim to evaluate how, and to which extent, the pandemic outbreak was changing their behavior and feelings about their chronic disease, the impact on therapies, and future expectations. The same interview was administered to an age-matched control group. Results: All interviewed people experienced an increase of anxiety, worries, and uncertainty fostered by incessant media updates. Moreover, a striking similarity emerged between the groups regarding forced home reclusion and the profound feeling to be excluded by normal life, well-known to those affected by a chronic rare disease. Conclusions: Although no statistically significant difference was found compared to controls, we felt that the reactions were qualitatively different, underlining the fragility and isolation of such patients.
C1 [Fiumara, Agata; Lanzafame, Giuseppina; Arena, Alessia; Sapuppo, Annamaria; Raudino, Federica; Pratico, Andrea; Pavone, Piero] Univ Catania, Reg Referral Ctr Inborn Errors Metab, Dept Clin & Expt Med, Pediat Clin, I-95123 Catania, Italy.
   [Barone, Rita] Univ Catania, Dept Clin & Expt Med, Child Neuropsychiat, I-95123 Catania, Italy.
RP Fiumara, A (corresponding author), Univ Catania, Reg Referral Ctr Inborn Errors Metab, Dept Clin & Expt Med, Pediat Clin, I-95123 Catania, Italy.
EM fiumara@policlinico.unict.it; giusylanz@virgilio.it;
   alessia.arena@gmail.com; annamaria.pan@hotmail.it;
   federica.raudino@tiscali.it; andrea.pratico@unict.it; ppavone@unict.it;
   rbarone@unict.it
OI Sapuppo, Annamaria/0000-0001-9433-026X; Pavone,
   Piero/0000-0002-5600-9560; Barone, Rita/0000-0001-6302-2686
CR [Anonymous], 2020, LANCET PSYCHIAT, V7, P371, DOI 10.1016/S2215-0366(20)30156-5
   Brooks FB, 1996, MOD LANG J, V80, P555, DOI 10.2307/329757
   Dyer C., 2006, RES PSYCHOL PRACTICA
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Platt FM, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0025-4
   Sechi A, 2020, MOL GENET METAB, V130, P170, DOI 10.1016/j.ymgme.2020.04.002
NR 6
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD SEP
PY 2020
VL 9
IS 9
AR 2716
DI 10.3390/jcm9092716
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA OF8PE
UT WOS:000581461400001
PM 32842622
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Savastano, A
   Crincoli, E
   Savastano, MC
   Younis, S
   Gambini, G
   De Vico, U
   Cozzupoli, GM
   Culiersi, C
   Rizzo, S
AF Savastano, Alfonso
   Crincoli, Emanuele
   Savastano, Maria Cristina
   Younis, Saad
   Gambini, Gloria
   De Vico, Umberto
   Cozzupoli, Grazia Maria
   Culiersi, Carola
   Rizzo, Stanislao
CA Gemelli COVID-19 Post-Acute Care S
TI Peripapillary Retinal Vascular Involvement in Early Post-COVID-19
   Patients
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE OCT angiography; peripapillary capillary perfusion; personalized
   medicine; SARS-CoV-2
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; CAPILLARY DENSITY
AB The ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 ' s) to cause multi-organ ischemia and coronavirus-induced posterior segment eye diseases in mammals gave concern about potential sight-threatening ischemia in post coronavirus disease 2019 patients. The radial peripapillary capillary plexus (RPCP) is a sensitive target due to the important role in the vascular supply of the peripapillary retinal nerve fiber layer (RNFL). Eighty patients one month after SARS-CoV-2 infection and 30 healthy patients were selected to undergo structural OCT (optical coherence tomography) and OCTA (optical coherence tomography angiography) exams. Primary outcome was a difference in RPCP perfusion density (RPCP-PD) and RPCP flow index (RPCP-FI). No significant difference was observed in age, sex, intraocular pressure (IOP) and prevalence of myopia. RPCP-PD was lower in post SARS-CoV-2 patients compared to controls. Within the post-COVID-19 group, patients with systemic arterial hypertension had lower RPCP-FI and age was inversely correlated to both RPCP-FI and RPCP-PD. Patients treated with lopinavir + ritonavir or antiplatelet therapy during admission had lower RPCP-FI and RPCP-PD. RNFL average thickness was linearly correlated to RPCP-FI and RPCP-PD within post-COVID-19 group. Future studies will be needed to address the hypothesis of a microvascular retinal impairment in individuals who recovered from SARS-CoV-2 infection.
C1 [Savastano, Alfonso; Crincoli, Emanuele; Savastano, Maria Cristina; Gambini, Gloria; De Vico, Umberto; Cozzupoli, Grazia Maria; Culiersi, Carola; Rizzo, Stanislao] Fdn Policlin Univ A Gemelli IRCCS, Ophthalmol Unit, I-00196 Rome, Italy.
   [Savastano, Alfonso; Crincoli, Emanuele; Savastano, Maria Cristina; Gambini, Gloria; De Vico, Umberto; Cozzupoli, Grazia Maria; Culiersi, Carola; Rizzo, Stanislao] Univ Cattolica Sacro Cuore, Dept Ophthalmol, I-00168 Rome, Italy.
   [Younis, Saad] Imperial Coll Healthcare NHS Trust, Western Eye Hosp, Dept Ophthalmol, London NW1 5QH, England.
   [Rizzo, Stanislao] CNR, Ist Neurosci, Neurosci Inst, I-56124 Pisa, Italy.
RP Savastano, MC (corresponding author), Fdn Policlin Univ A Gemelli IRCCS, Ophthalmol Unit, I-00196 Rome, Italy.; Savastano, MC (corresponding author), Univ Cattolica Sacro Cuore, Dept Ophthalmol, I-00168 Rome, Italy.
EM asavastano21@gmail.com; emanuelecrincolil@gmail.com;
   mariacristina.savastano@gmail.com; saad.younis@nhs.net;
   gambini.gloria@gmail.com; umbertodevico@gmail.com;
   mgcozzupoli@gmail.com; c.carola@live.it; stanislao.rizzo@gmail.com
RI ; Savastano, Maria Cristina/I-5355-2015
OI Savastano, Alfonso/0000-0003-1575-6567; Savastano, Maria
   Cristina/0000-0003-1397-4333; Crincoli, Emanuele/0000-0001-9996-9871; De
   Vico, Umberto/0000-0001-8557-3964; , Carola/0000-0003-3221-3791
CR Amesty MA, 2020, OPHTHALMOL THER, DOI 10.1007/s40123-020-00260-y
   [Anonymous], 2020, WHO DIR GEN OP REM M
   Atum M, 2020, OCUL IMMUNOL INFLAMM, V28, P745, DOI 10.1080/09273948.2020.1775261
   Augstburger E, 2018, INVEST OPHTH VIS SCI, V59, P870, DOI 10.1167/iovs.17-22996
   Bayyoud Tarek, 2020, Am J Ophthalmol Case Rep, V19, P100805, DOI 10.1016/j.ajoc.2020.100805
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Cerda-Ibanez M, 2017, OPHTHALMOL EYE DIS, V9, P1, DOI 10.1177/1179172117702889
   Chandrasekera E, 2018, INVEST OPHTH VIS SCI, V59, P4327, DOI 10.1167/iovs.18-24105
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chu ZD, 2016, J BIOMED OPT, V21, DOI 10.1117/1.JBO.21.6.066008
   Connor DE, 2020, PHLEBOLOGY, V35, P566, DOI 10.1177/0268355520913384
   Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001
   DOHERTY MJ, 1971, J AM VET MED ASSOC, V159, P417
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   Guemes-Villahoz N, 2020, J MED VIROL, DOI 10.1002/jmv.26219
   Jia YL, 2017, INVEST OPHTH VIS SCI, V58, P5188, DOI 10.1167/iovs.17-22593
   Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372
   Jung F, 2020, CLIN HEMORHEOL MICRO, V75, P1, DOI 10.3233/CH-209100
   Li YJ, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/3490962
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Liu XQ, 2020, ANN HEMATOL, V99, P1421, DOI 10.1007/s00277-020-04103-5
   Loon SC, 2013, BRIT J OPHTHALMOL, V97, P1217, DOI 10.1136/bjophthalmol-2013-303596
   Mammo Z, 2016, AM J OPHTHALMOL, V170, P41, DOI 10.1016/j.ajo.2016.07.015
   Mansoori T, 2017, J GLAUCOMA, V26, P438, DOI 10.1097/IJG.0000000000000649
   Mansoori T, 2017, J GLAUCOMA, V26, P241, DOI 10.1097/IJG.0000000000000594
   Marchetti M, 2020, ANN HEMATOL, V99, P1701, DOI 10.1007/s00277-020-04138-8
   Martini Nello, 2020, Recenti Prog Med, V111, P198, DOI 10.1701/3347.33180
   Mazzaccaro D, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061781
   Nelson AJ, 2019, INVEST OPHTH VIS SCI, V60, P3368, DOI 10.1167/iovs.19-27035
   Oudkerk M, 2020, RADIOLOGY, V297, pE216, DOI 10.1148/radiol.2020201629
   Olivares-de Emparan JP, 2020, ARQ BRAS OFTALMOL, V83, P250, DOI [10.5935/0004-2749.20200067, 10.5935/0004-2749.20200067.]
   Provis JM, 2001, PROG RETIN EYE RES, V20, P799, DOI 10.1016/S1350-9462(01)00012-X
   Rabiolo A, 2016, EXPERT REV OPHTHALMO, V11, P243, DOI 10.1080/17469899.2016.1209409
   Rispoli M., 2020, RETINA, DOI [10.1097/IAE.0000000000002810, DOI 10.1097/IAE.0000000000002810]
   ROBBINS SG, 1990, ADV EXP MED BIOL, V276, P519
   Rodriguez FJ, 2018, GRAEF ARCH CLIN EXP, V256, P2019, DOI 10.1007/s00417-018-4109-3
   Romacho T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62190-w
   Seah I, 2020, OCUL IMMUNOL INFLAMM, V28, P391, DOI 10.1080/09273948.2020.1738501
   SNODDERLY DM, 1992, J NEUROSCI, V12, P1169
   Song JT, 2020, BIOCHEM BIOPH RES CO, V525, P812, DOI 10.1016/j.bbrc.2020.02.151
   Statement on the second meeting of the International Health Regulations, 2005, EM COMM REG OUTBR NO
   Su W, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00202
   Valente Paola, 2020, J AAPOS, V24, P212, DOI 10.1016/j.jaapos.2020.05.002
   Wang J, 2017, BIOMED OPT EXPRESS, V8, P1536, DOI 10.1364/BOE.8.001536
   WHO, 2002, SUMM TABL SARS CAS C
   WHO, 2020, ORG WH COR DIS 2019
   Yin SY, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02105-8
NR 47
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD SEP
PY 2020
VL 9
IS 9
AR 2895
DI 10.3390/jcm9092895
PG 16
WC Medicine, General & Internal
SC General & Internal Medicine
GA OF7CD
UT WOS:000581359900001
PM 32911619
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Posteraro, B
   Torelli, R
   Vella, A
   Leone, PM
   De Angelis, G
   De Carolis, E
   Ventura, G
   Sanguinetti, M
   Fantoni, M
AF Posteraro, Brunella
   Torelli, Riccardo
   Vella, Antonietta
   Leone, Paolo Maria
   De Angelis, Giulia
   De Carolis, Elena
   Ventura, Giulio
   Sanguinetti, Maurizio
   Fantoni, Massimo
TI Pan-Echinocandin-Resistant Candida glabrata Bloodstream Infection
   Complicating COVID-19: A Fatal Case Report
SO JOURNAL OF FUNGI
LA English
DT Article
DE SARS-CoV-2; coinfection; diabetes; bloodstream infection; Candida
   glabrata; echinocandin resistance; FKS mutation
ID INVASIVE CANDIDIASIS; FKS2; SUSCEPTIBILITY; MUTATIONS; OUTCOMES;
   FAILURE; GLUCOSE; RISK
AB Coinfections with bacteria or fungi may be a frequent complication of COVID-19, but coinfections with Candida species in COVID-19 patients remain rare. We report the 53-day clinical course of a complicated type-2 diabetes patient diagnosed with COVID-19, who developed bloodstream infections initially due to methicillin-resistant Staphylococcus aureus, secondly due to multidrug-resistant Gram-negative bacteria, and lastly due to a possibly fatal Candida glabrata. The development of FKS-associated pan-echinocandin resistance in the C. glabrata isolated from the patient after 13 days of caspofungin treatment aggravated the situation. The patient died of septic shock shortly before the prospect of receiving potentially effective antifungal therapy. This case emphasizes the importance of early diagnosis and monitoring for antimicrobial drug-resistant coinfections to reduce their unfavorable outcomes in COVID-19 patients.
C1 [Posteraro, Brunella; Sanguinetti, Maurizio] Univ Cattolica Sacro Cuore, Clin Intensivol & Perioperatorie, Dipartimento Sci Biotecnol Base, I-00168 Rome, Italy.
   [Posteraro, Brunella; Leone, Paolo Maria] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Gastroenterol Endocrinometab & N, I-00168 Rome, Italy.
   [Torelli, Riccardo; Vella, Antonietta; De Angelis, Giulia; De Carolis, Elena; Ventura, Giulio; Sanguinetti, Maurizio; Fantoni, Massimo] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Lab & Infettivol, I-00168 Rome, Italy.
   [Ventura, Giulio; Fantoni, Massimo] Univ Cattolica Sacro Cuore, Dipartimento Sicurezza & Bioet, I-00168 Rome, Italy.
RP Sanguinetti, M (corresponding author), Univ Cattolica Sacro Cuore, Clin Intensivol & Perioperatorie, Dipartimento Sci Biotecnol Base, I-00168 Rome, Italy.; Sanguinetti, M (corresponding author), Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Lab & Infettivol, I-00168 Rome, Italy.
EM brunella.posteraro@unicatt.it; riccardo.torelli@policlinicogemelli.it;
   antonietta.vella@policlinicogemelli.it;
   paolomaria.leone@policlinicogemelli.it; giulia.deangelis78@gmail.com;
   elena.decarolis@policlinicogemelli.it; giulio.ventura@unicatt.it;
   maurizio.sanguinetti@unicatt.it; massimo.fantoni@unicatt.it
RI De Angelis, Giulia/G-1905-2018; Vella, Antonietta/ABH-7693-2020;
   Sanguinetti, Maurizio/A-1453-2019; Vella, Antonietta/K-2816-2018
OI De Angelis, Giulia/0000-0002-7087-7399; Sanguinetti,
   Maurizio/0000-0002-9780-7059; Vella, Antonietta/0000-0002-0495-8959
CR Agnelli C, 2019, REV ESP QUIM, V32, P395
   Alexander BD, 2013, CLIN INFECT DIS, V56, P1724, DOI 10.1093/cid/cit136
   Bordallo-Cardona MA, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.02004-18
   Bordallo-Cardona MA, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.01542-16
   Arastehfar A, 2020, J FUNGI, V6, DOI 10.3390/jof6030138
   Arastehfar Amir, 2020, Med Mycol, DOI 10.1093/mmy/myaa059
   Arastehfar A, 2020, J FUNGI, V6, DOI 10.3390/jof6020091
   Arastehfar A, 2020, MYCOSES, V63, P911, DOI 10.1111/myc.13104
   Arendrup MC, 2014, CURR OPIN INFECT DIS, V27, P484, DOI 10.1097/QCO.0000000000000111
   Castanheira M, 2010, ANTIMICROB AGENTS CH, V54, P2655, DOI 10.1128/AAC.01711-09
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Clancy Cornelius J, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa524
   Clinical and Laboratory Standards Institute, 2017, M60 CLIN LAB STAND I
   CLSI, 2008, M27A3 CLSI
   CLSI, 2018, M59 CLSI
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   De Angelis G, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0226467
   De Carolis E, 2014, J CLIN MICROBIOL, V52, P1453, DOI 10.1128/JCM.03355-13
   Erener S, 2020, MOL METAB, V39, DOI 10.1016/j.molmet.2020.101044
   Gangneux JP, 2020, J MYCOL MED, V30, DOI 10.1016/j.mycmed.2020.100971
   Garcia-Effron G, 2009, ANTIMICROB AGENTS CH, V53, P3690, DOI 10.1128/AAC.00443-09
   Healey KR, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.01412-17
   Healey KR, 2011, ANTIMICROB AGENTS CH, V55, P3947, DOI 10.1128/AAC.00044-11
   Hou X, 2019, EMERG MICROBES INFEC, V8, P1619, DOI 10.1080/22221751.2019.1684209
   Iacob S, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01676
   Katiyar SK, 2012, ANTIMICROB AGENTS CH, V56, P6304, DOI 10.1128/AAC.00813-12
   Kox M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02896-5
   Lee KK, 2012, ANTIMICROB AGENTS CH, V56, P208, DOI 10.1128/AAC.00683-11
   Lewis James S 2nd, 2013, Antimicrob Agents Chemother, V57, P4559, DOI 10.1128/AAC.01144-13
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   McCarty TP, 2018, J ANTIMICROB CHEMOTH, V73, P1677, DOI 10.1093/jac/dky059
   Ostrosky-Zeichner L, 2017, INFECT DIS CLIN N AM, V31, P475, DOI 10.1016/j.idc.2017.05.005
   Pappas PG, 2016, CLIN INFECT DIS, V62, P409, DOI 10.1093/cid/civ1194
   Perlin DS, 2017, LANCET INFECT DIS, V17, pE383, DOI 10.1016/S1473-3099(17)30316-X
   Pfaller MA, 2019, OPEN FORUM INFECT DI, V6, pS79, DOI 10.1093/ofid/ofy358
   Rawson Timothy M, 2020, Clin Infect Dis, V71, P2459, DOI 10.1093/cid/ciaa530
   Ren D, 2020, INTENS CARE MED, V46, P1630, DOI 10.1007/s00134-020-06084-5
   Rodrigues CF, 2014, EUR J CLIN MICROBIOL, V33, P673, DOI 10.1007/s10096-013-2009-3
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Seshasai SRK, 2011, NEW ENGL J MED, V364, P829, DOI 10.1056/NEJMoa1008862
   Shields RK, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.01692-18
   Shields RK, 2014, ANTIMICROB AGENTS CH, V58, P7601, DOI 10.1128/AAC.04134-14
   Shields RK, 2013, ANTIMICROB AGENTS CH, V57, P3528, DOI 10.1128/AAC.00136-13
   Shields RK, 2012, ANTIMICROB AGENTS CH, V56, P4862, DOI 10.1128/AAC.00027-12
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Thaiss CA, 2018, SCIENCE, V359, P1376, DOI 10.1126/science.aar3318
   World Health Organization, 2020, TEST COR DIS COVID 1
   World Health Organization (WHO), 2020, 183 WHO
   Wright WF, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.00512-19
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Zhai B, 2020, NAT MED, V26, P59, DOI 10.1038/s41591-019-0709-7
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 55
TC 2
Z9 2
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2309-608X
J9 J FUNGI
JI J. Fungi
PD SEP
PY 2020
VL 6
IS 3
AR 163
DI 10.3390/jof6030163
PG 11
WC Microbiology; Mycology
SC Microbiology; Mycology
GA OG3FZ
UT WOS:000581775800001
PM 32899996
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Akiyama, T
   Hirata, T
   Fujimoto, T
   Hatakeyama, S
   Yamazaki, R
   Nomura, T
AF Akiyama, Tomohiro
   Hirata, Takamichi
   Fujimoto, Takahiro
   Hatakeyama, Shinnosuke
   Yamazaki, Ryuhei
   Nomura, Tomohiro
TI The Natural-Mineral-Based Novel Nanomaterial IFMC Increases
   Intravascular Nitric Oxide without Its Intake: Implications for COVID-19
   and beyond
SO NANOMATERIALS
LA English
DT Article
DE SARS-CoV-2; COVID-19; natural-mineral-based nanomaterial; nitric oxide;
   haemoglobin; blood flow promotion
ID ACUTE RESPIRATORY SYNDROME; NEAR-DEATH EXPERIENCE; HYPERPOLARIZING
   FACTOR; HYPOXIC VASODILATION; BIOAVAILABILITY; CORONAVIRUS; EXPRESSION;
   DISCOVERY; INFECTION; CYTOKINES
AB There are currently no promising therapy strategies for either the treatment or prevention of novel coronavirus disease 2019 (COVID-19), despite the urgent need. In addition to respiratory diseases, vascular complications are rapidly emerging as a key threat of COVID-19. Existing nitric oxide (NO) therapies have been shown to improve the vascular system; however, they have different limitations in terms of safety, usability and availability. In light of this, we hypothesise that a natural-mineral-based novel nanomaterial, which was developed based on NO therapy, might be a viable strategy for the treatment and prevention of COVID-19. The present study examined if it could induce an increase of intravascular NO, vasodilation and the consequent increase of blood flow rate and temperature in a living body. The intravascular NO concentration in the hepatic portal of rats was increased by 0.17 nM over 35.2 s on average after its application. An ultrasonic Doppler flow meter showed significant increases in the blood flow rate and vessel diameter, but no difference in the blood flow velocity. These were corroborated by measurements of human hand surface temperature. To our knowledge, this result is the first evidence where an increase of intravascular NO and vasodilation were induced by bringing a natural-mineral-based nanomaterial into contact with or close to a living body. The precise mechanisms remain a matter for further investigation; however, we may assume that endothelial NO synthase, haemoglobin and endothelium-derived hyperpolarising factor are deeply involved in the increase of intravascular NO.
C1 [Akiyama, Tomohiro; Hirata, Takamichi; Fujimoto, Takahiro] Tokyo City Univ, Adv Res Labs, Tokyo 1588557, Japan.
   [Akiyama, Tomohiro] Kobe Inst Comp, Grad Sch Informat Technol, Kobe, Hyogo 6500001, Japan.
   [Akiyama, Tomohiro] Kyoto Univ, Grad Sch Educ, Kyoto 6068501, Japan.
   [Akiyama, Tomohiro] Sophia Univ, Grad Sch Global Environm Studies, Tokyo 1028554, Japan.
   [Hirata, Takamichi; Hatakeyama, Shinnosuke; Yamazaki, Ryuhei] Tokyo City Univ, Grad Sch Integrat Sci & Engn Elect Engn & Chem, Tokyo 1588557, Japan.
   [Fujimoto, Takahiro] Clin F Laser Med & Surg, Tokyo 1020083, Japan.
   [Nomura, Tomohiro] Osaka City Univ, Osaka 5588585, Japan.
RP Akiyama, T; Hirata, T (corresponding author), Tokyo City Univ, Adv Res Labs, Tokyo 1588557, Japan.; Akiyama, T (corresponding author), Kobe Inst Comp, Grad Sch Informat Technol, Kobe, Hyogo 6500001, Japan.; Akiyama, T (corresponding author), Kyoto Univ, Grad Sch Educ, Kyoto 6068501, Japan.; Akiyama, T (corresponding author), Sophia Univ, Grad Sch Global Environm Studies, Tokyo 1028554, Japan.; Hirata, T (corresponding author), Tokyo City Univ, Grad Sch Integrat Sci & Engn Elect Engn & Chem, Tokyo 1588557, Japan.
EM akiyamat@tcu.ac.jp; thirata@tcu.ac.jp; fujimoto@clinic-f.com;
   g1981258@tcu.ac.jp; g1981268@tcu.ac.jp; t.nomura@abeam.ocn.ne.jp
OI Fujimoto, Takahiro/0000-0002-4491-837X; Akiyama,
   Tomohiro/0000-0002-6720-8995; Hirata, Takamichi/0000-0003-1882-0552
CR Akerstrom S, 2005, J VIROL, V79, P1966, DOI 10.1128/JVI.79.3.1966-1969.2005
   Allen BW, 2006, AM J PHYSIOL-HEART C, V291, pH1507, DOI 10.1152/ajpheart.00310.2006
   Angeli F, 2020, EUR J INTERN MED, V71, P15, DOI 10.1016/j.ejim.2019.10.031
   Arsene AL, 2020, FARMACIA, V68, P185, DOI 10.31925/farmacia.2020.2.1
   BARNES PJ, 1995, ANN MED, V27, P389, DOI 10.3109/07853899509002592
   Berra L, 2020, PROTOCOL RANDOMIZED
   Bianco S, 2019, J HUMANIST PSYCHOL, DOI 10.1177/0022167819892107
   Brunt VE, 2016, J APPL PHYSIOL, V121, P716, DOI 10.1152/japplphysiol.00424.2016
   Calina D, 2020, INT J MOL MED, V46, P3, DOI 10.3892/ijmm.2020.4596
   CHEN G, 1988, BRIT J PHARMACOL, V95, P1165, DOI 10.1111/j.1476-5381.1988.tb11752.x
   Chen LN, 2004, CLIN INFECT DIS, V39, P1531, DOI 10.1086/425357
   CULOTTA E, 1992, SCIENCE, V258, P1862, DOI 10.1126/science.1361684
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Furchgott RF, 1999, BIOSCIENCE REP, V19, P235, DOI 10.1023/A:1020537506008
   Ghimire K, 2017, AM J PHYSIOL-CELL PH, V312, pC254, DOI 10.1152/ajpcell.00315.2016
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Helms C, 2013, FREE RADICAL BIO MED, V61, P464, DOI 10.1016/j.freeradbiomed.2013.04.028
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hsu CH, 2015, CLIN INTERV AGING, V10, P907, DOI 10.2147/CIA.S82026
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ignarro LJ, 1999, BIOSCIENCE REP, V19, P51, DOI 10.1023/A:1020150124721
   Ignarro LJ, 2020, BRIT J PHARMACOL, V177, P3848, DOI 10.1111/bph.15085
   Ikeda Y, 2005, CIRC J, V69, P722, DOI 10.1253/circj.69.722
   Imanishi T, 2006, HYPERTENSION, V48, P1058, DOI 10.1161/01.HYP.0000248920.16956.d8
   Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372
   Kakodkar P, 2020, CUREUS, V12, DOI 10.7759/cureus.7560
   Karaarslan F, 2018, INT J BIOMETEOROL, V62, P833, DOI 10.1007/s00484-017-1484-0
   Keyaerts E, 2004, INT J INFECT DIS, V8, P223, DOI 10.1016/j.ijid.2004.04.012
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kobayashi J, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00681-9
   Kuba K, 2013, CIRC J, V77, P301, DOI 10.1253/circj.CJ-12-1544
   Kume T, 2009, CIRC J, V73, P562, DOI 10.1253/circj.CJ-08-0789
   Lake MA, 2020, CLIN MED, V20, P124, DOI 10.7861/clinmed.2019-coron
   Lakshminrusimha S, 2009, PEDIATR CRIT CARE ME, V10, P106, DOI 10.1097/PCC.0b013e3181936aee
   Lebrun R, 2018, NATURE, V561, P222, DOI 10.1038/s41586-018-0490-7
   Lei C, 2020, PROTOCOL RANDOMIZED
   Li YY, 2013, TOXICOLOGY, V312, P132, DOI 10.1016/j.tox.2013.08.008
   Liu Z., 2020, COVID 19 CAUSES RECO
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Martial C, 2020, TRENDS COGN SCI, V24, P173, DOI 10.1016/j.tics.2019.12.010
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mochizuki S, 2003, BIOCHEM BIOPH RES CO, V306, P505, DOI 10.1016/S0006-291X(03)00985-9
   Mohammad FS, 2020, FARMACIA, V68, P384, DOI 10.31925/farmacia.2020.3.2
   Murad F, 1999, BIOSCIENCE REP, V19, P133, DOI 10.1023/A:1020265417394
   Nakagawa A, 2012, BRIT J SURG, V99, P1120, DOI 10.1002/bjs.8817
   Neishi Y, 2005, P NATL ACAD SCI USA, V102, P11456, DOI 10.1073/pnas.0501392102
   Oyama J, 2013, HEART VESSELS, V28, P173, DOI 10.1007/s00380-011-0220-7
   Ozkor MA, 2011, CARDIOL RES PRACT, V2011, DOI 10.4061/2011/156146
   Patel VB, 2016, CIRC RES, V118, P1313, DOI 10.1161/CIRCRESAHA.116.307708
   Pieretti JC, 2020, BIOCHEM PHARMACOL, V176, DOI 10.1016/j.bcp.2019.113740
   Roosterman D, 2006, PHYSIOL REV, V86, P1309, DOI 10.1152/physrev.00026.2005
   Rouda U., 2005, PROSPECTS DEMOCRACY, P71
   Scheel P, 2000, ULTRASOUND MED BIOL, V26, P1261, DOI 10.1016/S0301-5629(00)00293-3
   Sobajima M, 2011, AM J PHYSIOL-HEART C, V301, pH548, DOI 10.1152/ajpheart.00103.2011
   Straub AC, 2012, NATURE, V491, P473, DOI 10.1038/nature11626
   Su H, 2018, J APPL TOXICOL, V38, P3, DOI 10.1002/jat.3476
   Suzuki M, 2014, ACUTE MED SURG, V1, P101, DOI 10.1002/ams2.18
   Takaki A, 2008, J EXP MED, V205, P2053, DOI 10.1084/jem.20080106
   Takamura Y, 1999, J CARDIOVASC PHARM, V34, P381, DOI 10.1097/00005344-199909000-00010
   Islam MT, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00281
   Tsutsui C, 2014, JPN J APPL PHYS, V53, DOI 10.7567/JJAP.53.060309
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Turnbull AV, 1999, PHYSIOL REV, V79, P1, DOI 10.1152/physrev.1999.79.1.1
   Turner AJ, 2004, TRENDS PHARMACOL SCI, V25, P291, DOI 10.1016/j.tips.2004.04.001
   Uozumi Y, 2010, LASER SURG MED, V42, P566, DOI 10.1002/lsm.20938
   VALLET B, 1994, J APPL PHYSIOL, V76, P1256
   van Dorp L, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104351
   van Lommel P, 2001, LANCET, V358, P2039, DOI 10.1016/S0140-6736(01)07100-8
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Venter Z.S., 2020, COVID 19 LOCKDOWNS C
   Wadman M, 2020, SCIENCE, V368, P356, DOI 10.1126/science.368.6489.356
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Yang CC, 2015, CHINESE J PHYSIOL, V58, P420, DOI 10.4077/CJP.2015.BAD324
   Ye WNN, 2020, ARTIF ORGANS, V44, P680, DOI 10.1111/aor.13659
   Zhang DH, 2020, J INTEGR MED-JIM, V18, P152, DOI 10.1016/j.joim.2020.02.005
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang L, 2020, J MED VIROL, V92, P479, DOI 10.1002/jmv.25707
   Zhao Z., 2020, BIORXIV
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
NR 80
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2079-4991
J9 NANOMATERIALS-BASEL
JI Nanomaterials
PD SEP
PY 2020
VL 10
IS 9
AR 1699
DI 10.3390/nano10091699
PG 18
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
SC Science & Technology - Other Topics; Materials Science
GA OF4XI
UT WOS:000581212200001
PM 32872395
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Olvera, A
   Noguera-Julian, M
   Kilpelainen, A
   Romero-Martin, L
   Prado, JG
   Brander, C
AF Olvera, Alex
   Noguera-Julian, Marc
   Kilpelainen, Athina
   Romero-Martin, Luis
   Prado, Julia G.
   Brander, Christian
TI SARS-CoV-2 Consensus-Sequence and Matching Overlapping Peptides Design
   for COVID19 Immune Studies and Vaccine Development
SO VACCINES
LA English
DT Article
DE COVID-19; SARS-CoV-2; consensus sequence; T cell immunity; overlapping
   peptides set
ID T-CELL RESPONSES; HUMAN-IMMUNODEFICIENCY-VIRUS; EPSTEIN-BARR-VIRUS;
   VIRAL DIVERSITY; R-PACKAGE; EPITOPES; CD8; RECOGNITION; INFECTION;
   PRESSURE
AB Synthetic antigens based on consensus sequences that represent circulating viral isolates are sensitive, time saving and cost-effective tools for in vitro immune monitoring and to guide immunogen design. When based on a representative sequence database, such consensus sequences can effectively be used to test immune responses in exposed and infected individuals at the population level. To accelerate immune studies in SARS-CoV-2 infection, we here describe a SARS-CoV-2 2020 consensus sequence (CoV-2-cons) which is based on more than 1700 viral genome entries in NCBI and encompasses all described SARS-CoV-2 open reading frames (ORF), including recently described frame-shifted and length variant ORF. Based on these sequences, we created curated overlapping peptide (OLP) lists containing between 1500 to 3000 peptides of 15 and 18 amino acids in length, overlapping by 10 or 11 residues, as ideal tools for the assessment of SARS-CoV-2-specific T cell immunity. In addition, CoV-2-cons sequence entropy values are presented along with variant sequences to provide increased coverage of the most variable sections of the viral genome. The identification of conserved protein fragments across the coronavirus family and the corresponding OLP facilitate the identification of T cells potentially cross-reactive with related viruses. This new CoV-2-cons sequence, together with the peptides sets, should provide the basis for SARS-CoV-2 antigen synthesis to facilitate comparability between ex-vivo immune analyses and help to accelerate research on SARS-CoV-2 immunity and vaccine development.
C1 [Olvera, Alex; Noguera-Julian, Marc; Kilpelainen, Athina; Romero-Martin, Luis; Prado, Julia G.; Brander, Christian] Hosp Univ Germans Trias i Pujol, IrsiCaixa AIDS Res Inst HIVACAT, Badalona 08916, Spain.
   [Olvera, Alex] Univ Vic Cent Catalunya UVic UCC, Fac Sci & Technol, Vic 08500, Spain.
   [Noguera-Julian, Marc; Brander, Christian] Univ Vic Cent Catalunya UVic UCC, Fac Med, Vic 08500, Spain.
   [Prado, Julia G.] Germans Trias i Pujol Res Inst IGTP, Barcelona 08196, Spain.
   [Brander, Christian] Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona 08010, Spain.
RP Prado, JG; Brander, C (corresponding author), Hosp Univ Germans Trias i Pujol, IrsiCaixa AIDS Res Inst HIVACAT, Badalona 08916, Spain.; Brander, C (corresponding author), Univ Vic Cent Catalunya UVic UCC, Fac Med, Vic 08500, Spain.; Prado, JG (corresponding author), Germans Trias i Pujol Res Inst IGTP, Barcelona 08196, Spain.; Brander, C (corresponding author), Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona 08010, Spain.
EM aolvera@irsicaixa.es; mnoguera@irsicaixa.es; akilpelainen@irsicaixa.es;
   lromero@irsicaixa.es; jgarcia@irsicaixa.es; cbrander@irsicaixa.es
RI Noguera-Julian, Marc/F-8651-2016
OI Noguera-Julian, Marc/0000-0002-6194-1395
FU National Health Institute Carlos III (ISCIII) (European Regional
   Development Fund/European Social Fund) [COV20/00660, PI17/000164, RETIC
   RD16/0025/0041]; Grifols; crowdfunding initiative YoMeCorono
FX This study was supported in part by grants from the National Health
   Institute Carlos III (ISCIII) COV20/00660, PI17/000164 and RETIC
   RD16/0025/0041 (Co-funded by European Regional Development Fund/European
   Social Fund) for J.G.P. The funders had no role in study design, data
   collection and analysis, the decision to publish or drafting of the
   manuscript. This study has received partial funding from Grifols and the
   crowdfunding initiative YoMeCorono.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Almeida RR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045267
   Altfeld M, 2003, J VIROL, V77, P7330, DOI 10.1128/JVI.77.13.7330-7340.2003
   Arenas M, 2010, CURR HIV RES, V8, P613, DOI 10.2174/157016210794088263
   Bansal A, 2006, AIDS, V20, P353, DOI 10.1097/01.aids.0000206501.16783.67
   Bansal A, 2010, J EXP MED, V207, P51, DOI 10.1084/jem.20092060
   Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698
   Berger CT, 2010, J EXP MED, V207, P61, DOI 10.1084/jem.20091808
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Bigaut K, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000785
   Brander C, 2007, CURR OPIN HIV AIDS, V2, P183, DOI 10.1097/COH.0b013e3280f3bfe2
   Braun J., 2020, PRESENCE SARS COV 2, DOI [10.1101/2020.04.17.20061440, 10.1101/2020.04.17.20061440., DOI 10.1101/2020.04.17.20061440]
   Cardinaud S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002049
   Carlson TL, 2010, VIRAL IMMUNOL, V23, P577, DOI 10.1089/vim.2010.0057
   Carragher DM, 2008, J IMMUNOL, V181, P4168, DOI 10.4049/jimmunol.181.6.4168
   Chan JL, 2020, CAN J NEUROL SCI, V47, P560, DOI [10.1017/cjn.2020.42, 10.1017/cjn.2020.106]
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   De Groot AS, 2004, METHODS, V34, P476, DOI 10.1016/j.ymeth.2004.06.003
   DECAMPOSLIMA PO, 1993, SCIENCE, V260, P98, DOI 10.1126/science.7682013
   Draenert R, 2004, AIDS, V18, P871, DOI 10.1097/00002030-200404090-00004
   Draenert R, 2003, J IMMUNOL METHODS, V275, P19, DOI 10.1016/S0022-1759(02)00541-0
   Finkel Y, 2020, CODING CAPACITY SARS, DOI [10.1101/2020.05.07.082909, DOI 10.1101/2020.05.07.082909]
   Fonseca SG, 2006, AIDS, V20, P2263, DOI 10.1097/01.aids.0000253353.48331.5f
   Frahm N, 2004, J VIROL, V78, P2187, DOI 10.1128/JVI.78.5.2187-2200.2004
   Frahm N, 2008, AIDS, V22, P447, DOI 10.1097/QAD.0b013e3282f42412
   Frahm N, 2007, J IMMUNOL, V179, P6638, DOI 10.4049/jimmunol.179.10.6638
   Gallais F., 2020, INTRAFAMILIAL EXPOSU, DOI [10.1101/2020.06.21.20132449, DOI 10.1101/2020.06.21.20132449]
   Gao Ang, 2020, bioRxiv, DOI 10.1101/2020.05.14.095885
   Grant BJ, 2006, BIOINFORMATICS, V22, P2695, DOI 10.1093/bioinformatics/btl461
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Gutierrez MI, 1998, BLOOD, V92, P600, DOI 10.1182/blood.V92.2.600.414k33_600_606
   Honeyborne I, 2010, J VIROL, V84, P11279, DOI 10.1128/JVI.01144-10
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kesturu GS, 2006, VIROLOGY, V348, P437, DOI 10.1016/j.virol.2005.11.055
   Koita OA, 2006, HUM VACCINES, V2, P119, DOI 10.4161/hv.2869
   Kothe DL, 2006, VIROLOGY, V352, P438, DOI 10.1016/j.virol.2006.05.011
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Lascano AM, 2020, EUR J NEUROL, V27, P1751, DOI 10.1111/ene.14368
   Le Bert N, 2020, NATURE, DOI 10.1038/s41586-020-2550-z
   Li Xiaojun, 2020, bioRxiv, DOI 10.1101/2020.03.20.000885
   Liu WJ, 2017, ANTIVIR RES, V137, P82, DOI 10.1016/j.antiviral.2016.11.006
   Llano A, 2019, HIV MOL IMMUNOLOGY
   Lucchese G, 2020, CELL MOL IMMUNOL, V17, P539, DOI 10.1038/s41423-020-0377-z
   Malhotra U, 2007, VACCINE, V25, P381, DOI 10.1016/j.vaccine.2006.07.045
   Ng K., 2020, PREEXISTING NOVO HUM, V15, DOI [10.1101/2020.05.14.095414, DOI 10.1101/2020.05.14.095414]
   Nickle DC, 2007, PLOS COMPUT BIOL, V3, P754, DOI 10.1371/journal.pcbi.0030075
   Peng Y., 2020, BROAD STRONG MEMORY, DOI [10.1101/2020.06.05.134551, DOI 10.1101/2020.06.05.134551]
   Prado JG, 2009, J VIROL, V83, P1018, DOI 10.1128/JVI.01882-08
   Riva N, 2020, J NEUROL, V267, P2492, DOI 10.1007/s00415-020-09907-z
   Rivino L, 2013, J IMMUNOL, V191, P4010, DOI 10.4049/jimmunol.1301507
   Robbiani Davide F, 2020, bioRxiv, DOI 10.1101/2020.05.13.092619
   Rolland M, 2007, J VIROL, V81, P8507, DOI 10.1128/JVI.02683-06
   Rolland M, 2013, J VIROL, V87, P5461, DOI 10.1128/JVI.03033-12
   Ross HA, 2006, EVOL BIOINFORM, V2, P53
   Rutebemberwa A, 2005, AIDS, V19, P1165, DOI 10.1097/01.aids.0000176216.02743.98
   Sekine T, 2020, CELL IMMUNITY CONVAL, DOI [10.1101/2020.06.29.174888, DOI 10.1101/2020.06.29.174888]
   Seow G., 2020, LONGITUDINAL EVALUAT, DOI [10.1101/2020.07.09.20148429., 10.1101/2020.07.09.20148429, DOI 10.1101/2020.07.09.20148429]
   Silva-Arrieta S, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008607
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Wagih O, 2017, BIOINFORMATICS, V33, P3645, DOI 10.1093/bioinformatics/btx469
   Wu F., 2020, NEUTRALIZING ANTIBOD, DOI [10.2139/ssrn.3566211, DOI 10.2139/SSRN.3566211]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yerly D, 2008, J VIROL, V82, P3147, DOI 10.1128/JVI.02252-07
   Zhao JX, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan5393
NR 66
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-393X
J9 VACCINES-BASEL
JI Vaccines
PD SEP
PY 2020
VL 8
IS 3
AR 444
DI 10.3390/vaccines8030444
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OG7DD
UT WOS:000582039200001
PM 32781672
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ranga, V
   Niemela, E
   Tamirat, MZ
   Eriksson, JE
   Airenne, TT
   Johnson, MS
AF Ranga, Vipin
   Niemela, Erik
   Tamirat, Mahlet Z.
   Eriksson, John E.
   Airenne, Tomi T.
   Johnson, Mark S.
TI Immunogenic SARS-CoV-2 Epitopes: In Silico Study Towards Better
   Understanding of COVID-19 Disease-Paving the Way for Vaccine Development
SO VACCINES
LA English
DT Article
DE SARS-CoV-2; COVID-19; SARS-CoV; in silico analysis; MHC class I
   epitopes; HLA; viral peptides; antigen presentation; vaccine
   development; immunoinformatics; homology modeling; molecular dynamics
   simulations; structural biology
ID PEPTIDE; CORONAVIRUS; RESPONSES; PREDICTION; STABILITY; OUTBREAK
AB The emergence of the COVID-19 outbreak at the end of 2019, caused by the novel coronavirus SARS-CoV-2, has, to date, led to over 13.6 million infections and nearly 600,000 deaths. Consequently, there is an urgent need to better understand the molecular factors triggering immune defense against the virus and to develop countermeasures to hinder its spread. Using in silico analyses, we showed that human major histocompatibility complex (MHC) class I cell-surface molecules vary in their capacity for binding different SARS-CoV-2-derived epitopes, i.e., short sequences of 8-11 amino acids, and pinpointed five specific SARS-CoV-2 epitopes that are likely to be presented to cytotoxic T-cells and hence activate immune responses. The identified epitopes, each one of nine amino acids, have high sequence similarity to the equivalent epitopes of SARS-CoV virus, which are known to elicit an effective T cell response in vitro. Moreover, we give a structural explanation for the binding of SARS-CoV-2-epitopes to MHC molecules. Our data can help us to better understand the differences in outcomes of COVID-19 patients and may aid the development of vaccines against SARS-CoV-2 and possible future outbreaks of novel coronaviruses.
C1 [Ranga, Vipin; Tamirat, Mahlet Z.; Airenne, Tomi T.; Johnson, Mark S.] Abo Akad Univ, Fac Sci & Engn, Struct Bioinformat Lab, Biochem, Turku 20520, Finland.
   [Niemela, Erik; Eriksson, John E.] Abo Akad Univ, Fac Sci & Engn, Cell Biol, Turku 20520, Finland.
   [Niemela, Erik; Eriksson, John E.] Univ Turku, Turku Biosci Ctr, Turku 20520, Finland.
   [Niemela, Erik; Eriksson, John E.] Abo Akad Univ, Turku 20520, Finland.
RP Johnson, MS (corresponding author), Abo Akad Univ, Fac Sci & Engn, Struct Bioinformat Lab, Biochem, Turku 20520, Finland.
EM vipin.ranga@abo.fi; erik.niemela@abo.fi; mahlet.tamirat@abo.fi;
   john.eriksson@abo.fi; tomi.airenne@abo.fi; mark.s.johnson@abo.fi
OI Ranga, Vipin/0000-0003-4835-8661; Niemela, Erik/0000-0003-4059-0837
FU Swedish Cultural Foundation; Academy of FinlandAcademy of Finland
   [308317]; Sigrid Juselius FoundationSigrid Juselius Foundation; Magnus
   Ehrnrooth Foundation; Joe, Pentti, and Tor Borg Memorial Fund; Doctoral
   School of Abo Akademi University; Foundation of Abo Akademi University
FX This research was funded by the Swedish Cultural Foundation, the Academy
   of Finland (grant number 308317), Sigrid Juselius Foundation, Magnus
   Ehrnrooth Foundation, Joe, Pentti, and Tor Borg Memorial Fund, Doctoral
   School of Abo Akademi University, and Foundation of Abo Akademi
   University.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Al Awaidy Salah T, 2019, Oman Med J, V34, P181, DOI 10.5001/omj.2019.36
   Alicia SM, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20248
   Anft M., 2020, ALLERGY IMMUNOL, DOI [10.1101/2020.04.28.20083089, DOI 10.1101/2020.04.28.20083089]
   Bettencourt P, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-019-0148-y
   Blum JS, 2013, ANNU REV IMMUNOL, V31, P443, DOI 10.1146/annurev-immunol-032712-095910
   Boyle LH, 2004, IMMUNOLOGY, V112, P54, DOI 10.1111/j.1365-2567.2004.01857.x
   Braun J., 2020, PRESENCE SARS COV 2, DOI [10.1101/2020.04.17.20061440, 10.1101/2020.04.17.20061440., DOI 10.1101/2020.04.17.20061440]
   Brister JR, 2015, NUCLEIC ACIDS RES, V43, pD571, DOI 10.1093/nar/gku1207
   Case D.A., 2018, AMBER
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Chowell D, 2015, P NATL ACAD SCI USA, V112, pE1754, DOI 10.1073/pnas.1500973112
   Colleton BA, 2009, J VIROL, V83, P6288, DOI 10.1128/JVI.02611-08
   Crux NB, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00832
   Denesyuk AI, 2020, INT J BIOL MACROMOL, V153, P399, DOI 10.1016/j.ijbiomac.2020.03.025
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Drozdetskiy A, 2015, NUCLEIC ACIDS RES, V43, pW389, DOI 10.1093/nar/gkv332
   Fan E, 2018, JAMA-J AM MED ASSOC, V319, P698, DOI 10.1001/jama.2017.21907
   Fleri W, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00278
   Funke J, 2011, AIDS REV, V13, P67
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Harndahl M, 2012, EUR J IMMUNOL, V42, P1405, DOI 10.1002/eji.201141774
   Heymann DL, 2020, LANCET, V395, P469, DOI 10.1016/S0140-6736(20)30184-7
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Ishizuka J, 2009, J IMMUNOL, V183, P4337, DOI 10.4049/jimmunol.0901607
   Johnson M, 2008, NUCLEIC ACIDS RES, V36, pW5, DOI 10.1093/nar/gkn201
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Kohyama S, 2009, ANTIVIR RES, V84, P168, DOI 10.1016/j.antiviral.2009.09.004
   Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Lin Marie, 2003, BMC Med Genet, V4, P9, DOI 10.1186/1471-2350-4-9
   Liu JX, 2011, EUR J IMMUNOL, V41, P2097, DOI 10.1002/eji.201041370
   Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
   London N, 2011, NUCLEIC ACIDS RES, V39, pW249, DOI 10.1093/nar/gkr431
   Lund O, 2004, IMMUNOGENETICS, V55, P797, DOI 10.1007/s00251-004-0647-4
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Negandaripour M, 2017, BIOTECHNOL ADV, V35, P575, DOI 10.1016/j.biotechadv.2017.05.002
   Ng M H L, 2010, Hong Kong Med J, V16, P29
   Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063
   Nguyen A, 2020, J VIROL, V94, DOI 10.1128/JVI.00510-20
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Piai A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16165-0
   Rasmussen M, 2016, J IMMUNOL, V197, P1517, DOI 10.4049/jimmunol.1600582
   Robinson J, 2020, NUCLEIC ACIDS RES, V48, pD948, DOI 10.1093/nar/gkz950
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Rose PW, 2013, NUCLEIC ACIDS RES, V41, pD475, DOI 10.1093/nar/gks1200
   Shajahan Asif, 2020, Glycobiology, V30, P981, DOI 10.1093/glycob/cwaa042
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1
   Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
   Sohrabi C, 2020, INT J SURG, V77, P217, DOI 10.1016/j.ijsu.2020.03.036
   Srinivasan S, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040360
   Tamirat MZ, 2020, JOVE-J VIS EXP, DOI 10.3791/61125
   Tsao YP, 2006, BIOCHEM BIOPH RES CO, V344, P63, DOI 10.1016/j.bbrc.2006.03.152
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
   Watanabe Yasunori, 2020, bioRxiv, DOI 10.1101/2020.03.26.010322
   Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071
   Yang XB, 2017, J BIOL CHEM, V292, P18618, DOI 10.1074/jbc.M117.810382
   Zhang Y., 2020, BIORXIV, DOI [10.1101/2020.03.28.013276, DOI 10.1101/2020.03.28.013276]
   Zhao WL, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006457
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zipeto D, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-39
NR 67
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-393X
J9 VACCINES-BASEL
JI Vaccines
PD SEP
PY 2020
VL 8
IS 3
AR 408
DI 10.3390/vaccines8030408
PG 19
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OF8OV
UT WOS:000581460500001
PM 32717854
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, DL
   Mai, JH
   Zhou, WF
   Yu, WT
   Zhan, Y
   Wan, ND
   Epstein, ND
   Yang, Y
AF Wang, Dongliang
   Mai, Jinhui
   Zhou, Wenfeng
   Yu, Wanting
   Zhan, Yang
   Wan, Naidong
   Epstein, Neal D.
   Yang, Yi
TI Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2
   Vaccine Design
SO VACCINES
LA English
DT Article
DE SARS-CoV-2; S protein; B-cell and T-cell epitopes; vaccine
ID SYNDROME SARS CORONAVIRUS; SPIKE PROTEIN; FUNCTIONAL RECEPTOR;
   STRUCTURAL BASIS; S2 DOMAIN; IDENTIFICATION; NEUTRALIZATION; RESPONSES;
   ENTRY; COV
AB Currently, there is limited knowledge about the immunological profiles of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). We used computer-based immunoinformatic analysis and the newly resolved 3-dimensional (3D) structures of the SARS-CoV-2 S trimeric protein, together with analyses of the immunogenic profiles of SARS-CoV, to anticipate potential B-cell and T-cell epitopes of the SARS-CoV-2 S protein for vaccine design, particularly for peptide-driven vaccine design and serological diagnosis. Nine conserved linear B-cell epitopes and multiple discontinuous B-cell epitopes composed of 69 residues on the surface of the SARS-CoV-2 trimeric S protein were predicted to be highly antigenic. We found that the SARS-CoV-2 S protein has a different antigenic profile than that of the SARS-CoV S protein due to the variations in their primary and 3D structures. Importantly, SARS-CoV-2 may exploit an immune evasion mechanism through two point mutations in the critical and conserved linear neutralization epitope (overlap with fusion peptide) around a sparsely glycosylated area. These mutations lead to a significant decrease in the antigenicity of this epitope in the SARS-CoV-2 S protein. In addition, 62 T-cell epitopes in the SARS-CoV-2 S protein were predicted in our study. The structure-based immunoinformatic analysis for the SARS-CoV-2 S protein in this study may improve vaccine design, diagnosis, and immunotherapy against the pandemic of COVID-19.
C1 [Wang, Dongliang; Mai, Jinhui; Zhou, Wenfeng; Yu, Wanting; Zhan, Yang; Wan, Naidong; Yang, Yi] Hunan Agr Univ, Coll Vet Med, Res Ctr Reverse Vaccinol RCRV, Hunan Prov Key Lab Prot Engn Anim Vaccines,Lab Fu, Changsha 410128, Peoples R China.
   [Yu, Wanting] Peking Univ, Biodynam Opt Imaging Ctr BIOPIC, Sch Life Sci, State Key Lab Membrane Biol, Beijing 100871, Peoples R China.
   [Epstein, Neal D.] NHLBI, Cell & Dev Biol Ctr, NIH, Bldg 10, Bethesda, MD 20892 USA.
RP Yang, Y (corresponding author), Hunan Agr Univ, Coll Vet Med, Res Ctr Reverse Vaccinol RCRV, Hunan Prov Key Lab Prot Engn Anim Vaccines,Lab Fu, Changsha 410128, Peoples R China.; Epstein, ND (corresponding author), NHLBI, Cell & Dev Biol Ctr, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM dongliangwang@stu.hunau.edu.cn; jinhuimai@stu.hunau.edu.cn;
   wenfengzhou@stu.hunau.edu.cn; 1906390265@pku.edu.cn;
   yangzhan@hunau.edu.cn; naidongwang@hunau.edu.cn; epsteinn@nhlbi.nih.gov;
   yiyang@hunau.edu.cn
OI Yang, Yi/0000-0003-2502-1011
FU Hunan Provincial Key Laboratory of Protein Engineering in Animal Vaccine
   [2017TP1014]; Hunan Education Department's Science & Research Project
   [18B092]; Hunan Provincial Natural Science Foundation of ChinaNatural
   Science Foundation of Hunan Province [2018JJ2177]; Double first-class
   construction project of Hunan Agricultural University [SYL2019048];
   Intramural Institute of the NHLBI, NIH, Bethesda, MD, USA
FX This research was funded by the Hunan Provincial Key Laboratory of
   Protein Engineering in Animal Vaccine, grant number 2017TP1014; the
   Hunan Education Department's Science & Research Project, grant number
   18B092; the Hunan Provincial Natural Science Foundation of China, grant
   number 2018JJ2177; and the Double first-class construction project of
   Hunan Agricultural University, grant number SYL2019048. N.D.E. was
   supported by the Intramural Institute of the NHLBI, NIH, Bethesda, MD,
   USA.
CR Andrusier N, 2007, PROTEINS, V69, P139, DOI 10.1002/prot.21495
   Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Czub M, 2005, VACCINE, V23, P2273, DOI 10.1016/j.vaccine.2005.01.033
   De Groot AS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00442
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Graham RL, 2013, NAT REV MICROBIOL, V11, P836, DOI 10.1038/nrmicro3143
   Gutierrez AH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159237
   He YX, 2004, J IMMUNOL, V173, P4050, DOI 10.4049/jimmunol.173.6.4050
   Hewitt JS, 2019, VACCINE, V37, P4302, DOI 10.1016/j.vaccine.2019.06.044
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu HB, 2005, J COMB CHEM, V7, P648, DOI 10.1021/cc0500607
   Hwang WC, 2006, J BIOL CHEM, V281, P34610, DOI 10.1074/jbc.M603275200
   Lamiable A, 2016, NUCLEIC ACIDS RES, V44, pW449, DOI 10.1093/nar/gkw329
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li F, 2005, SCIENCE, V309, P1864, DOI 10.1126/science.1116480
   Li F, 2006, J VIROL, V80, P6794, DOI 10.1128/JVI.02744-05
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu C, 2015, J VIROL, V89, P6121, DOI 10.1128/JVI.00430-15
   Lv YB, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-61
   Mashiach E, 2008, NUCLEIC ACIDS RES, V36, pW229, DOI 10.1093/nar/gkn186
   Paul S, 2015, J IMMUNOL METHODS, V422, P28, DOI 10.1016/j.jim.2015.03.022
   Poh CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16638-2
   Prabakaran P, 2006, J BIOL CHEM, V281, P15829, DOI 10.1074/jbc.M600697200
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Song PP, 2020, CLIN CHIM ACTA, V509, P280, DOI 10.1016/j.cca.2020.06.017
   Sui JH, 2004, P NATL ACAD SCI USA, V101, P2536, DOI 10.1073/pnas.0307140101
   Tsao YP, 2006, BIOCHEM BIOPH RES CO, V344, P63, DOI 10.1016/j.bbrc.2006.03.152
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang BM, 2004, BLOOD, V104, P200, DOI 10.1182/blood-2003-11-4072
   Wang Q, 2020, CELL, V182, P417, DOI 10.1016/j.cell.2020.05.034
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xu XJ, 2004, CELL MOL IMMUNOL, V1, P119
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang JB, 2009, INT IMMUNOL, V21, P63, DOI 10.1093/intimm/dxn124
   Yong CY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01781
   Zhang H, 2004, J VIROL, V78, P6938, DOI 10.1128/JVI.78.13.6938-6945.2004
   Zhao JC, 2007, VIROLOGY, V359, P362, DOI 10.1016/j.virol.2006.09.022
   Zhong XF, 2005, J VIROL, V79, P3401, DOI 10.1128/JVI.79.6.3401-3408.2005
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu ZY, 2007, P NATL ACAD SCI USA, V104, P12123, DOI 10.1073/pnas.0701000104
NR 52
TC 2
Z9 2
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-393X
J9 VACCINES-BASEL
JI Vaccines
PD SEP
PY 2020
VL 8
IS 3
AR 355
DI 10.3390/vaccines8030355
PG 15
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OF5HN
UT WOS:000581238700001
PM 32635180
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Wang, JH
   Jing, RZ
   Lai, XZ
   Zhang, HJ
   Lyu, Y
   Knoll, MD
   Fang, H
AF Wang, Jiahao
   Jing, Rize
   Lai, Xiaozhen
   Zhang, Haijun
   Lyu, Yun
   Knoll, Maria Deloria
   Fang, Hai
TI Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China
SO VACCINES
LA English
DT Article
DE SARS-CoV-2; COVID-19; immunization; vaccine acceptance; vaccine
   preference
ID VACCINES; ATTITUDES; IMPACT
AB Background: Faced with the coronavirus disease 2019 (COVID-19) pandemic, the development of COVID-19 vaccines has been progressing at an unprecedented rate. This study aimed to evaluate the acceptance of COVID-19 vaccination in China and give suggestions for vaccination strategies and immunization programs accordingly. Methods: In March 2020, an anonymous cross-sectional survey was conducted online among Chinese adults. The questionnaire collected socio-demographic characteristics, risk perception, the impact of COVID-19, attitudes, acceptance and attribute preferences of vaccines against COVID-19 during the pandemic. Multivariate logistic regression was performed to identify the influencing factors of vaccination acceptance. Results: Of the 2058 participants surveyed, 1879 (91.3%) stated that they would accept COVID-19 vaccination after the vaccine becomes available, among whom 980 (52.2%) wanted to get vaccinated as soon as possible, while others (47.8%) would delay the vaccination until the vaccine's safety was confirmed. Participants preferred a routine immunization schedule (49.4%) to emergency vaccination (9.0%) or either of them (41.6%). Logistic regression showed that being male, being married, perceiving a high risk of infection, being vaccinated against influenza in the past season, believing in the efficacy of COVID-19 vaccination or valuing doctor's recommendations could increase the probability of accepting COVID-19 vaccination as soon as possible, while having confirmed or suspected cases in local areas, valuing vaccination convenience or vaccine price in decision-making could hinder participants from immediate vaccination. Conclusion: During the pandemic period, a strong demand for and high acceptance of COVID-19 vaccination has been shown among the Chinese population, while concerns about vaccine safety may hinder the promotion of vaccine uptake. To expand vaccination coverage, immunization programs should be designed to remove barriers in terms of vaccine price and vaccination convenience, and health education and communication from authoritative sources are important ways to alleviate public concerns about vaccine safety.
C1 [Wang, Jiahao; Jing, Rize; Lai, Xiaozhen; Zhang, Haijun; Lyu, Yun] Peking Univ, Sch Publ Hlth, Beijing 100083, Peoples R China.
   [Wang, Jiahao; Jing, Rize; Lai, Xiaozhen; Zhang, Haijun; Lyu, Yun; Fang, Hai] Peking Univ, China Ctr Hlth Dev Studies, Beijing 100083, Peoples R China.
   [Knoll, Maria Deloria] Johns Hopkins Univ, Int Vaccine Access Ctr, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.
   [Fang, Hai] Peking Univ Hlth Sci Ctr Chinese Ctr Dis Control, Beijing 100083, Peoples R China.
   [Fang, Hai] Natl Hlth Commiss Peoples Republ China, Key Lab Reprod Hlth, Beijing 100083, Peoples R China.
RP Fang, H (corresponding author), Peking Univ, China Ctr Hlth Dev Studies, Beijing 100083, Peoples R China.; Fang, H (corresponding author), Peking Univ Hlth Sci Ctr Chinese Ctr Dis Control, Beijing 100083, Peoples R China.; Fang, H (corresponding author), Natl Hlth Commiss Peoples Republ China, Key Lab Reprod Hlth, Beijing 100083, Peoples R China.
EM jiahaowang@pku.edu.cn; rzjing2015@hsc.pku.edu.cn;
   laixiaozhen@pku.edu.cn; haijunzhang@pku.edu.cn; lydialu1217@hotmail.com;
   mkno112@jhu.edu; hfang@hsc.pku.edu.cn
OI Jing, Rize/0000-0002-1469-909X
FU Special Research Fund of the PKU for the Prevention and Control of
   COVID-19; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
FX This research was funded by the Special Research Fund of the PKU for the
   Prevention and Control of COVID-19 and the Fundamental Research Funds
   for the Central Universities.
CR Bone A, 2010, VACCINE, V28, P8157, DOI 10.1016/j.vaccine.2010.09.096
   Cheney MK, 2013, SAGE OPEN, V3, DOI 10.1177/2158244013484732
   Determann D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102505
   Dube E, 2016, VACCINE BOOK, 2ND EDITION, P507, DOI 10.1016/B978-0-12-802174-3.00026-6
   Eastwood K, 2010, MED J AUSTRALIA, V192, P33, DOI 10.5694/j.1326-5377.2010.tb03399.x
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   GAVI, DOES COVID 19 COMPAR
   Henrich N., 2009, EMERG HLTH THREAT J, V2, P7088, DOI [10.3402/ehtj.v2i0.7088, DOI 10.3402/EHTJ.V2I0.7088]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Irwin KL, 2017, VACCINE, V35, P6915, DOI 10.1016/j.vaccine.2017.06.026
   Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218
   Kwok KO, 2020, J INFECTION, V80, pE32, DOI 10.1016/j.jinf.2020.03.027
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8
   Lau JTF, 2010, VACCINE, V28, P4632, DOI 10.1016/j.vaccine.2010.04.076
   Leung K, 2020, LANCET, V395, P1382, DOI 10.1016/S0140-6736(20)30746-7
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   MADDUX JE, 1983, J EXP SOC PSYCHOL, V19, P469, DOI 10.1016/0022-1031(83)90023-9
   Maurer J, 2010, PREV MED, V51, P185, DOI 10.1016/j.ypmed.2010.05.008
   Maurer J, 2009, VACCINE, V27, P5732, DOI 10.1016/j.vaccine.2009.07.080
   Nguyen Trang, 2011, Infect Drug Resist, V4, P197, DOI 10.2147/IDR.S23174
   Raude Jocelyn, 2010, PLoS Curr, V2, pRRN1188, DOI 10.1371/currents.RRN1188
   Rosenstock I. M., 1990, HLTH BEHAV HLTH ED T, P39
   ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P354, DOI 10.1177/109019817400200405
   Rubin GJ, 2010, HEALTH TECHNOL ASSES, V14, P183, DOI 10.3310/hta14340-03
   Schwarzinger M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010199
   Seale H, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-99
   SYPSA V, 2009, EUROSURVEILLANCE, V14, P2
   Tian HY, 2020, SCIENCE, V368, P638, DOI 10.1126/science.abb6105
   Ughasoro MD, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003838
   Wang Q, 2018, VACCINE, V36, P7262, DOI 10.1016/j.vaccine.2018.10.045
   World Health Organization, WHO DIRECTOR GENERAL
   World Health Organization, Q INFLUENZA COVID 19
   World Health Organization, WHO CORONAVIRUS DIS
   World Health Organization, REPORT SAGE WORKING
   World Health Organization, DRAFT LANDSCAPE COVI
   Xinhua Net, UPDATE CHINA MAKE CO
   Yang YS, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102434
   Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018
   Zijtregtop EAM, 2009, VACCINE, V28, P207, DOI 10.1016/j.vaccine.2009.09.099
NR 40
TC 0
Z9 0
U1 7
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-393X
J9 VACCINES-BASEL
JI Vaccines
PD SEP
PY 2020
VL 8
IS 3
AR 482
DI 10.3390/vaccines8030482
PG 14
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OF6UY
UT WOS:000581341200001
PM 32867224
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Awasthi, M
   Gulati, S
   Sarkar, DP
   Tiwari, S
   Kateriya, S
   Ranjan, P
   Verma, SK
AF Awasthi, Mayanka
   Gulati, Sahil
   Sarkar, Debi P.
   Tiwari, Swasti
   Kateriya, Suneel
   Ranjan, Peeyush
   Verma, Santosh Kumar
TI The Sialoside-Binding Pocket of SARS-CoV-2 Spike Glycoprotein
   Structurally Resembles MERS-CoV
SO VIRUSES-BASEL
LA English
DT Article
DE SARS-CoV-2; N-terminal domain; spike glycoprotein; MERS-CoV
ID CORONAVIRUS; IDENTIFICATION; PREDICTION; ACE2
AB COVID-19 novel coronavirus (CoV) disease caused by severe acquired respiratory syndrome (SARS)-CoV-2 manifests severe lethal respiratory illness in humans and has recently developed into a worldwide pandemic. The lack of effective treatment strategy and vaccines against the SARS-CoV-2 poses a threat to human health. An extremely high infection rate and multi-organ secondary infection within a short period of time makes this virus more deadly and challenging for therapeutic interventions. Despite high sequence similarity and utilization of common host-cell receptor, human angiotensin-converting enzyme-2 (ACE2) for virus entry, SARS-CoV-2 is much more infectious than SARS-CoV. Structure-based sequence comparison of the N-terminal domain (NTD) of the spike protein of Middle East respiratory syndrome (MERS)-CoV, SARS-CoV, and SARS-CoV-2 illustrate three divergent loop regions in SARS-CoV-2, which is reminiscent of MERS-CoV sialoside binding pockets. Comparative binding analysis with host sialosides revealed conformational flexibility of SARS-CoV-2 divergent loop regions to accommodate diverse glycan-rich sialosides. These key differences with SARS-CoV and similarity with MERS-CoV suggest an evolutionary adaptation of SARS-CoV-2 spike glycoprotein reciprocal interaction with host surface sialosides to infect host cells with wide tissue tropism.
C1 [Awasthi, Mayanka; Ranjan, Peeyush] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA.
   [Gulati, Sahil] Gatan Inc, Pleasanton, CA 94588 USA.
   [Sarkar, Debi P.] Univ Delhi, Dept Biochem, South Campus, New Delhi 110021, India.
   [Tiwari, Swasti; Verma, Santosh Kumar] Sanjay Gandhi Postgrad Inst Med Sci, Dept Mol Med & Biotechnol, Lucknow 226014, Uttar Pradesh, India.
   [Kateriya, Suneel] Jawaharlal Nehru Univ, Sch Biotechnol, New Delhi 110067, India.
RP Ranjan, P (corresponding author), Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA.; Verma, SK (corresponding author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Mol Med & Biotechnol, Lucknow 226014, Uttar Pradesh, India.
EM awasthi9@umd.edu; s.gulati@case.edu; dpsarkar59@gmail.com;
   tiwari.pgi@gmail.com; skateriya@jnu.ac.in; rpeeyush@umd.edu;
   santoshkv@sgpgi.ac.in
OI Verma, Santosh Kumar/0000-0001-6058-6494; AWASTHI,
   MAYANKA/0000-0002-4395-0589; Gulati, Sahil/0000-0002-8255-479X; Sarkar,
   Debi P/0000-0002-8886-8415; Kateriya, Suneel/0000-0001-5428-4297
FU Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS),
   Lucknow, India [A-21-PGI/IMP/80/2019]; SERB/DST Gov. of India (GOI), as
   JC Bose National Fellowship [SR/S2/JCB-08/2010]; UGC/SAP (GOI) [F
   3.3/2016]; SGPGIMS, Lucknow, India
FX This research was funded by intramural research grant from Sanjay Gandhi
   Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India to
   S.K.V vide grant number A-21-PGI/IMP/80/2019 and DPS is grateful for
   financial assistance from SERB/DST Gov. of India (GOI), as JC Bose
   National Fellowship vide grant number JC Bose, SR/S2/JCB-08/2010 and
   grants from UGC/SAP (GOI) to the Department of Biochemistry, University
   of Delhi, India vide grant file number F 3.3/2016. The APC was funded by
   SGPGIMS, Lucknow, India.
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Behloul N, 2020, VIRUS RES, V286, DOI 10.1016/j.virusres.2020.198058
   Breiman A, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008556
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chiodo F., 2020, BIORXIV, DOI [10.1101/2020.05.13.092478, DOI 10.1101/2020.05.13.092478]
   Cohen M, 2009, BLOOD, V114, P3668, DOI 10.1182/blood-2009-06-227041
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216
   Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3, 10.1002/cpps.20]
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Gui M, 2017, CELL RES, V27, P119, DOI 10.1038/cr.2016.152
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jiang X, 2020, J MED VIROL, V92, P476, DOI 10.1002/jmv.25708
   Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Li WT, 2017, P NATL ACAD SCI USA, V114, pE8508, DOI 10.1073/pnas.1712592114
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Milanetti E., 2020, BIORXIV, DOI [10.1101/2020.03.24.006197, DOI 10.1101/2020.03.24.006197]
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Othman H, 2020, BIOCHEM BIOPH RES CO, V527, P702, DOI 10.1016/j.bbrc.2020.05.028
   Pallesen J, 2017, P NATL ACAD SCI USA, V114, pE7348, DOI 10.1073/pnas.1707304114
   Park YJ, 2019, NAT STRUCT MOL BIOL, V26, P1151, DOI 10.1038/s41594-019-0334-7
   Ponder JW, 2003, ADV PROTEIN CHEM, V66, P27
   Qiang XL, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00649-8
   Ravindranath PA, 2016, BIOINFORMATICS, V32, P3142, DOI 10.1093/bioinformatics/btw367
   Robson B, 2020, COMPUT BIOL MED, V122, DOI 10.1016/j.compbiomed.2020.103849
   Roussel Y, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105947
   Schwegmann-Wessels C, 2006, GLYCOCONJUGATE J, V23, P51, DOI 10.1007/s10719-006-5437-9
   Shen MY, 2006, PROTEIN SCI, V15, P2507, DOI 10.1110/ps.062416606
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   Song WF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007236
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Uhlen M, 2020, PROTEIN EXPRES PURIF, DOI [10.1101/2020.03.31.016048., DOI 10.1101/2020.03.31.016048]
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Zhao J, 2020, RELATIONSHIP ABO BLO, DOI [10.1101/2020.03.11.20031096, DOI 10.1101/2020.03.11.20031096, 10.1101/2020.03.11.20031096.]
   Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 40
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD SEP
PY 2020
VL 12
IS 9
AR 909
DI 10.3390/v12090909
PG 10
WC Virology
SC Virology
GA OG6XI
UT WOS:000582024100001
PM 32825063
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tzou, PL
   Tao, KM
   Nouhin, J
   Rhee, SY
   Hu, BND
   Pai, ST
   Parkin, N
   Shafer, RW
AF Tzou, Philip L.
   Tao, Kaiming
   Nouhin, Janin
   Rhee, Soo-Yon
   Hu, Benjamin D.
   Pai, Shruti
   Parkin, Neil
   Shafer, Robert W.
TI Coronavirus Antiviral Research Database (CoV-RDB): An Online Database
   Designed to Facilitate Comparisons between Candidate Anti-Coronavirus
   Compounds
SO VIRUSES-BASEL
LA English
DT Article
DE coronavirus; COVID-19; SARS-CoV-2; SARS-CoV; MERS-CoV; antiviral therapy
ID POTENT NEUTRALIZING ANTIBODIES; LENGTH INFECTIOUS CDNA; REVERSE
   GENETICS; ANIMAL-MODELS; SARS-COV-2; SARS; MERS; INHIBITION;
   PATHOGENESIS; REPLICATION
AB Background: To prioritize the development of antiviral compounds, it is necessary to compare their relative preclinical activity and clinical efficacy. Methods: We reviewed in vitro, animal model, and clinical studies of candidate anti-coronavirus compounds and placed extracted data in an online relational database. Results: As of August 2020, the Coronavirus Antiviral Research Database (CoV-RDB; covdb.stanford.edu) contained over 2800 cell culture, entry assay, and biochemical experiments, 259 animal model studies, and 73 clinical studies from over 400 published papers. SARS-CoV-2, SARS-CoV, and MERS-CoV account for 85% of the data. Approximately 75% of experiments involved compounds with known or likely mechanisms of action, including monoclonal antibodies and receptor binding inhibitors (21%), viral protease inhibitors (17%), miscellaneous host-acting inhibitors (10%), polymerase inhibitors (9%), interferons (7%), fusion inhibitors (5%), and host protease inhibitors (5%). Of 975 compounds with known or likely mechanism, 135 (14%) are licensed in the U.S. for other indications, 197 (20%) are licensed outside the U.S. or are in human trials, and 595 (61%) are pre-clinical investigational compounds. Conclusion: CoV-RDB facilitates comparisons between different candidate antiviral compounds, thereby helping scientists, clinical investigators, public health officials, and funding agencies prioritize the most promising compounds and repurposed drugs for further development.
C1 [Tzou, Philip L.; Tao, Kaiming; Nouhin, Janin; Rhee, Soo-Yon; Shafer, Robert W.] Stanford Univ, Sch Med, Div Infect Dis, Stanford, CA 94305 USA.
   [Hu, Benjamin D.] Stanford Univ, Undergrad Sch Humanities & Sci, Stanford, CA 94305 USA.
   [Pai, Shruti] Univ Calif Berkeley, Undergrad Studies, Berkeley, CA 94720 USA.
   [Parkin, Neil] Data First Consulting Inc, Sebastopol, CA 95472 USA.
RP Tzou, PL; Shafer, RW (corresponding author), Stanford Univ, Sch Med, Div Infect Dis, Stanford, CA 94305 USA.
EM philiptz@stanford.edu; kaiming.tao@stanford.edu; jnouhin@stanford.edu;
   syrhee@stanford.edu; benhu8@stanford.edu; shrutipai@berkeley.edu;
   nparkin34@gmail.com; rshafer@stanford.edu
OI Shafer, Robert/0000-0003-2513-2643; Parkin, Neil/0000-0001-5824-3388;
   Tzou, Philip Lei/0000-0002-2876-1552; Nouhin, Janin/0000-0003-4985-8377
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [NIH/NIAID
   R24AI136618]
FX R.W.S., P.L.T, K.T., and S.-Y.R. were supported, in part, by grants from
   the National Institutes of Health (NIH/NIAID R24AI136618).
CR Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Almazan F, 2014, VIRUS RES, V189, P262, DOI 10.1016/j.virusres.2014.05.026
   Alsoussi WB, 2020, J IMMUNOL, V205, P915, DOI 10.4049/jimmunol.2000583
   Anthony SJ, 2017, VIRUS EVOL, V3, DOI 10.1093/ve/vex012
   Bakowski M.A, 2020, BIORXIV, DOI [10.1101/2020.06.16.153403, DOI 10.1101/2020.06.16.153403]
   Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Baum A., 2020, BIORXIV, DOI [10.1101/2020.08.02.233320, DOI 10.1101/2020.08.02.233320]
   Baum A, 2020, SCIENCE, V369, P1014, DOI 10.1126/science.abd0831
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bojkova D., 2020, SARS COV 2 SARS COV, DOI [10.1101/2020.04.03.024257., DOI 10.1101/2020.04.03.024257, 10.1101/2020.04.03.024257]
   Bolles M, 2011, CURR OPIN VIROL, V1, P624, DOI 10.1016/j.coviro.2011.10.012
   Bouhaddou M, 2020, CELL, V182, P685, DOI 10.1016/j.cell.2020.06.034
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Brimacombe Kyle R, 2020, bioRxiv, DOI 10.1101/2020.06.04.135046
   Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902
   Cao LX, 2019, MOL CANCER THER, V18, P3, DOI 10.1158/1535-7163.MCT-18-0863
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Cavalcanti A.B., 2020, ENGL J MED, DOI [10.1056/NEJMoa2019014 32706953, DOI 10.1056/NEJMOA2019014]
   Chan JFW, 2015, J INFECT DIS, V212, P1904, DOI 10.1093/infdis/jiv392
   Chan JFW, 2013, J INFECT DIS, V207, P1743, DOI 10.1093/infdis/jit123
   Channappanavar R, 2015, J INFECT DIS, V212, P1894, DOI 10.1093/infdis/jiv325
   Chen Catherine Z, 2020, bioRxiv, DOI 10.1101/2020.08.18.255877
   Cheung NN, 2017, J GEN VIROL, V98, P946, DOI 10.1099/jgv.0.000758
   Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Dittmar M, 2020, DRUG REPURPOSING SCR, DOI [10.1101/2020.06.19.161042, DOI 10.1101/2020.06.19.161042]
   Ejemel M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18058-8
   Ellinger B, 2020, RES SQUARE, DOI [10.21203/rs.3.rs-23951/v1, DOI 10.21203/RS.3.RS-23951/V1]
   EMENY JM, 1979, J GEN VIROL, V43, P247, DOI 10.1099/0022-1317-43-1-247
   Falzarano D, 2013, NAT MED, V19, P1313, DOI 10.1038/nm.3362
   Felgenhauer U, 2020, J BIOL CHEM, V295, P13958, DOI 10.1074/jbc.AC120.013788
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Greenough TC, 2005, AM J PATHOL, V167, P455, DOI 10.1016/S0002-9440(10)62989-6
   Gretebeck LM, 2015, CURR OPIN VIROL, V13, P123, DOI 10.1016/j.coviro.2015.06.009
   Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827
   Hempel T, 2020, MOL MECH SARS COV 2, DOI [10.1101/2020.07.21.214098, DOI 10.1101/2020.07.21.214098]
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00754-20
   Horby P, 2020, EFFECT HYDROXYCHLORO, DOI [10.1101/2020.07.15.20151852, DOI 10.1101/2020.07.15.20151852]
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Huo JD, 2020, CELL HOST MICROBE, V28, P445, DOI 10.1016/j.chom.2020.06.010
   Huo JD, 2020, NAT STRUCT MOL BIOL, V27, P846, DOI 10.1038/s41594-020-0469-6
   Imai M, 2020, P NATL ACAD SCI USA, V117, P16587, DOI [10.1073/pnas.2009799117/-/DCSupplemental., 10.1073/pnas.2009799117]
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Jiang RD, 2020, CELL, V182, P50, DOI 10.1016/j.cell.2020.05.027
   Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z
   Kang YL, 2020, P NATL ACAD SCI USA, V117, P20803, DOI 10.1073/pnas.2007837117
   Kaye M, 2006, EMERG INFECT DIS, V12, P128, DOI 10.3201/eid1201.050496
   Khan A, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1823-x
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Ko M, 2020, BIORXIV, DOI [10.1101/2020.05.12.090035, DOI 10.1101/2020.05.12.090035]
   Ko M, 2020, J MED VIROL, DOI 10.1002/jmv.26397
   Kuhn JH, 2013, ARCH VIROL, V158, P301, DOI 10.1007/s00705-012-1454-0
   Kumari G, 2020, BIORXIV, DOI [10.1101/2020.03.07.982264, DOI 10.1101/2020.03.07.982264]
   Lawler JV, 2006, PLOS MED, V3, P677, DOI 10.1371/journal.pmed.0030149
   Lei CH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16048-4
   Liu Q, 2020, CELL CHEM BIOL, V27, P668, DOI 10.1016/j.chembiol.2020.05.002
   Luban Jeremy, 2020, bioRxiv, DOI 10.1101/2020.08.05.238394
   Lutz C, 2020, HUM GENOMICS, V14, DOI 10.1186/s40246-020-00272-6
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Mantlo E, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104811
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   McAuliffe J, 2004, VIROLOGY, V330, P8, DOI 10.1016/j.virol.2004.09.030
   Milewska A, 2020, J VIROL, V94, DOI 10.1128/JVI.00957-20
   Mirabelli Carmen, 2020, bioRxiv, DOI 10.1101/2020.05.27.117184
   Mitja O., 2020, CLUSTER RANDOMIZED T, DOI [10.1101/2020.07.20.20157651, DOI 10.1101/2020.07.20.20157651]
   Mitja Oriol, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa1009
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Ogando NS, 2020, J GEN VIROL, V101, P925, DOI 10.1099/jgv.0.001453
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Park A, 2020, CELL HOST MICROBE, V27, P870, DOI 10.1016/j.chom.2020.05.008
   Park SJ, 2020, MBIO, V11, DOI 10.1128/mBio.01114-20
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Pizzorno A, 2020, BIORXIV, DOI [10.1101/2020.03.31.017889, DOI 10.1101/2020.03.31.017889]
   Pruijssers AJ, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107940
   Raybould Matthew I J, 2020, Bioinformatics, DOI 10.1093/bioinformatics/btaa739
   Riva L, 2020, NATURE, V586, P113, DOI 10.1038/s41586-020-2577-1
   Riva Laura, 2020, bioRxiv, DOI 10.1101/2020.04.16.044016
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Roberts A, 2006, ADV EXP MED BIOL, V581, P463
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Rogers Thomas F, 2020, bioRxiv, DOI 10.1101/2020.05.11.088674
   Scobey T, 2013, P NATL ACAD SCI USA, V110, P16157, DOI 10.1073/pnas.1311542110
   Seydoux E, 2020, IMMUNITY, V53, P98, DOI 10.1016/j.immuni.2020.06.001
   Shan C, 2020, CELL RES, V30, P670, DOI 10.1038/s41422-020-0364-z
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Shrimp Jonathan H, 2020, ACS Pharmacol Transl Sci, V3, P997, DOI 10.1021/acsptsci.0c00106
   Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5
   Skipper CP, 2020, ANN INTERN MED, V173, P623, DOI 10.7326/M20-4207
   Tang T, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104792
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Thao TTN, 2020, NATURE, V582, P561, DOI 10.1038/s41586-020-2294-9
   U.S. Centers for Disease Control and Prevention (CDC), SB THACK CDC LIB COV
   Vanderheiden A, 2020, J VIROL, V94, DOI 10.1128/JVI.00985-20
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Wang Q., 2020, EFFICACY SAFETY LEFL, DOI [10.1101/2020.05.29.20114223, DOI 10.1101/2020.05.29.20114223]
   Wec AZ, 2020, SCIENCE, V369, P731, DOI 10.1126/science.abc7424
   Weisblum Yiska, 2020, bioRxiv, DOI 10.1101/2020.07.21.214759
   Wettstein L, 2020, ALPHA 1 ANTITRYPSIN, DOI [10.1101/2020.07.02.183764, DOI 10.1101/2020.07.02.183764]
   WILLIAMSON BN, 2020, NATURE 0609, DOI DOI 10.1038/S41586-020-2423-5
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Xie XP, 2020, CELL HOST MICROBE, V27, P841, DOI 10.1016/j.chom.2020.04.004
   Yamamoto M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060629
   Yang M, 2020, INTEGR MED RES, V9, DOI 10.1016/j.imr.2020.100426
   Yount B, 2003, P NATL ACAD SCI USA, V100, P12995, DOI 10.1073/pnas.1735582100
   Zhao JC, 2015, J VIROL, V89, P6117, DOI 10.1128/JVI.00446-15
   Zheng F, 2020, INT J INFECT DIS, V99, P84, DOI 10.1016/j.ijid.2020.07.053
   Zost SJ, 2020, NATURE, DOI 10.1038/s41586-020-2548-6
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 114
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD SEP
PY 2020
VL 12
IS 9
AR 1006
DI 10.3390/v12091006
PG 21
WC Virology
SC Virology
GA OG6WF
UT WOS:000582021200001
PM 32916958
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Abate, G
   Memo, M
   Uberti, D
AF Abate, Giulia
   Memo, Maurizio
   Uberti, Daniela
TI Impact of COVID-19 on Alzheimer's Disease Risk: Viewpoint for Research
   Action
SO HEALTHCARE
LA English
DT Article
DE SARS-CoV-2 infection; neuroinvasivness; ACE2; Alzheimer's disease risk
ID MILD COGNITIVE IMPAIRMENT; SIMPLEX-VIRUS TYPE-1; NOREPINEPHRINE RELEASE;
   CORONAVIRUS INFECTION; TISSUE DISTRIBUTION; OXIDATIVE STRESS;
   ANGIOTENSIN-(1-7); BRAIN; RECEPTOR; ACE2
AB In the middle of the coronavirus disease 19 (COVID-19) outbreak, the main efforts of the scientific community are rightly all focused on identifying efficient pharmacological treatments to cure the acute severe symptoms and developing a reliable vaccine. On the other hand, we cannot exclude that, in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) positive subjects, the virus infection could have long-term consequences, leading to chronic medical conditions such as dementia and neurodegenerative disease. Considering the age of SARS-CoV-2 infected subjects, the neuroinvasive potential might lead/contribute to the development of neurodegenerative diseases. Here, we analyzed a possible link between SARS-CoV-2 infection and Alzheimer's disease risk, hypothesizing possible mechanisms at the base of disease development. This reflection raises the need to start to experimentally investigating today the mechanistic link between Alzheimer's disease (AD) and COVID-19 to be ready tomorrow.
C1 [Abate, Giulia; Memo, Maurizio; Uberti, Daniela] Univ Brescia, Dept Mol & Translat Med, I-25123 Brescia, Italy.
RP Abate, G (corresponding author), Univ Brescia, Dept Mol & Translat Med, I-25123 Brescia, Italy.
EM giulia.abate@unibs.it; maurizio.memo@unibs.it; daniela.uberti@unibs.it
OI Abate, Giulia/0000-0001-9161-3475
FU Ministero dell'Istruzione, dell'Universita e della RicercaMinistry of
   Education, Universities and Research (MIUR) [University intramural
   funding grant to D. Uberti.] Funding Source: Medline
CR Abate G, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/7039816
   Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X
   Alenina N, 2019, NEUROCHEM RES, V44, P1323, DOI 10.1007/s11064-018-2679-4
   Asiimwe N, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7205747
   Benussi Alberto, 2020, Neurology, V95, pe910, DOI 10.1212/WNL.0000000000009848
   Bomtempo CAS, 1998, J HYPERTENS, V16, P1797, DOI 10.1097/00004872-199816120-00013
   Butterfield DA, 2006, EUR J PHARMACOL, V545, P39, DOI 10.1016/j.ejphar.2006.06.026
   Cahill S, 2020, AGING MENT HEALTH, V24, P197, DOI 10.1080/13607863.2018.1544213
   CAMPAGNOLESANTOS MJ, 1992, AM J PHYSIOL, V263, pR89
   Chang MC, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8020145
   Chen R., 2020, SPATIAL CELL TYPE DI, DOI [10.1101/2020.04.07.030650, DOI 10.1101/2020.04.07.030650]
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   Cummings Jeffrey, 2017, Alzheimers Dement (N Y), V3, P367, DOI 10.1016/j.trci.2017.05.002
   Dobruch J, 2003, J PHYSIOL PHARMACOL, V54, P371
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Doobay MF, 2007, AM J PHYSIOL-REG I, V292, pR373, DOI 10.1152/ajpregu.00292.2006
   Ellul MA, 2020, LANCET NEUROL, V19, P767, DOI 10.1016/S1474-4422(20)30221-0
   Evans CE, 2020, ACTA NEUROPATHOL, V139, P485, DOI 10.1007/s00401-019-02098-6
   Feng YM, 2008, CIRC RES, V102, P729, DOI 10.1161/CIRCRESAHA.107.169110
   Fotuhi M, 2020, J ALZHEIMERS DIS, V76, P3, DOI 10.3233/JAD-200581
   Gironacci MM, 2000, HYPERTENSION, V35, P1248, DOI 10.1161/01.HYP.35.6.1248
   Gironacci MM, 2004, HYPERTENSION, V44, P783, DOI 10.1161/01.HYP.0000143850.73831.9d
   Hajjar I, 2012, ARCH INTERN MED, V172, P442, DOI 10.1001/archinternmed.2011.1391
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Harris SA, 2015, J ALZHEIMERS DIS, V48, P319, DOI 10.3233/JAD-142853
   Hellner K, 2005, MOL CELL NEUROSCI, V29, P427, DOI 10.1016/j.mcn.2005.03.012
   Heneka MT, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00640-3
   Hocht C, 2008, REGUL PEPTIDES, V146, P58, DOI 10.1016/j.regpep.2007.08.001
   Hort J, 2010, EUR J NEUROL, V17, P1236, DOI 10.1111/j.1468-1331.2010.03040.x
   Hu JG, 1998, BRAIN RES, V785, P195, DOI 10.1016/S0006-8993(97)01318-8
   Itzhaki RF, 1997, LANCET, V349, P241, DOI 10.1016/S0140-6736(96)10149-5
   Itzhaki RF, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00324
   Jack CR, 2018, ALZHEIMERS DEMENT, V14, P535, DOI 10.1016/j.jalz.2018.02.018
   Jeong HH, 2019, NEURON, V104, P1034, DOI 10.1016/j.neuron.2019.11.009
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Kuo CL, 2020, J GERONTOL A-BIOL, V75, P2231, DOI 10.1093/gerona/glaa131
   Lane CA, 2018, EUR J NEUROL, V25, P59, DOI 10.1111/ene.13439
   Lazaroni TLN, 2012, NEUROBIOL LEARN MEM, V97, P113, DOI 10.1016/j.nlm.2011.10.003
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
   LEE SC, 1993, J NEUROIMMUNOL, V46, P19, DOI 10.1016/0165-5728(93)90229-R
   Li K, 2016, J INFECT DIS, V213, P712, DOI 10.1093/infdis/jiv499
   Li NC, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5465
   Li Y, 2004, J VIROL, V78, P3398, DOI 10.1128/JVI.78.7.3398-3406.2004
   Li YC, 2013, J COMP NEUROL, V521, P203, DOI 10.1002/cne.23171
   Li YC, 2012, VIRUS RES, V163, P628, DOI 10.1016/j.virusres.2011.12.021
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Lu J, 2008, BRAIN RES, V1219, P127, DOI 10.1016/j.brainres.2008.04.057
   Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Matsuda K, 2004, VET PATHOL, V41, P101, DOI 10.1354/vp.41-2-101
   Minett T, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0601-z
   Montagne A, 2020, NATURE, V581, P70, DOI 10.1038/s41586-020-2247-3
   MORIGUCHI A, 1995, HYPERTENSION, V25, P1260, DOI 10.1161/01.HYP.25.6.1260
   MORIGUCHI A, 1994, AM J PHYSIOL, V267, pR786
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Netland J, 2008, J VIROL, V82, P7264, DOI 10.1128/JVI.00737-08
   Ortiz JMP, 2019, BRIT J PHARMACOL, V176, P3489, DOI 10.1111/bph.14585
   Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x
   Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X
   Prince M., 2015, WORLD ALZHEIMER REPO
   Prince M, 2016, ALZHEIMERS RES THER, V8, DOI 10.1186/s13195-016-0188-8
   Racchi Marco, 2008, Immun Ageing, V5, P7, DOI 10.1186/1742-4933-5-7
   Regenhardt RW, 2014, CLIN SCI, V126, P195, DOI 10.1042/CS20130324
   Rozzini L, 2006, INT J GERIATR PSYCH, V21, P550, DOI 10.1002/gps.1523
   Santos RAS, 2003, P NATL ACAD SCI USA, V100, P8258, DOI 10.1073/pnas.1432869100
   Selkoe DJ, 2016, EMBO MOL MED, V8, P595, DOI 10.15252/emmm.201606210
   Serrano-Pozo A, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006189
   Soscia SJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009505
   Sriramula S, 2011, CARDIOVASC RES, V92, P401, DOI 10.1093/cvr/cvr242
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Swomley AM, 2014, BBA-MOL BASIS DIS, V1842, P1248, DOI 10.1016/j.bbadis.2013.09.015
   Tian MJ, 2012, FEBS LETT, V586, P3737, DOI 10.1016/j.febslet.2012.09.004
   To KF, 2004, J PATHOL, V203, P740, DOI 10.1002/path.1597
   Tramutola A, 2017, BRAIN RES BULL, V133, P88, DOI 10.1016/j.brainresbull.2016.06.005
   Tramutola A, 2018, FREE RADICAL BIO MED, V129, P430, DOI 10.1016/j.freeradbiomed.2018.10.414
   Tzioras M, 2019, NEUROPATH APPL NEURO, V45, P327, DOI 10.1111/nan.12529
   van den Pol AN, 2009, NEURON, V64, P17, DOI 10.1016/j.neuron.2009.09.023
   von Bernhardi R, 2004, BRAIN RES, V1025, P186, DOI 10.1016/j.brainres.2004.07.084
   Wahl D, 2019, NEUROBIOL DIS, V130, DOI 10.1016/j.nbd.2019.104481
   WAN S, 2020, BRIT J HAEMATOL 0420, DOI DOI 10.1101/2020.02.10.20021832
   Wharton W, 2015, J AM GERIATR SOC, V63, P1749, DOI 10.1111/jgs.13627
   Wozniak Matthew A, 2010, Ther Adv Neurol Disord, V3, P141, DOI 10.1177/1756285610370069
   Xia HJ, 2009, HYPERTENSION, V53, P210, DOI 10.1161/HYPERTENSIONAHA.108.123844
   Xie W, 2014, BRAIN RES, V1573, P44, DOI 10.1016/j.brainres.2014.05.019
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Zheng JL, 2014, CNS NEUROSCI THER, V20, P452, DOI 10.1111/cns.12233
NR 86
TC 1
Z9 1
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9032
J9 HEALTHCARE-BASEL
JI Healthcare
PD SEP
PY 2020
VL 8
IS 3
AR 286
DI 10.3390/healthcare8030286
PG 10
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA OF6HO
UT WOS:000581306400001
PM 32839380
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Muller, C
   Schibli, R
   Maurer, B
AF Muller, Cristina
   Schibli, Roger
   Maurer, Britta
TI Can Nuclear Imaging of Activated Macrophages with Folic Acid-Based
   Radiotracers Serve as a Prognostic Means to Identify COVID-19 Patients
   at Risk?
SO PHARMACEUTICALS
LA English
DT Article
DE COVID-19; imaging biomarker; macrophages; folate receptor-beta (FR
   beta); positron emission tomography (PET); inflammation; folate-based
   F-18-PET tracer
ID INTERSTITIAL LUNG-DISEASES; TOCILIZUMAB
AB Herein, we discuss the potential role of folic acid-based radiopharmaceuticals for macrophage imaging to support clinical decision-making in patients with COVID-19. Activated macrophages play an important role during coronavirus infections. Exuberant host responses, i.e., a cytokine storm with increase of macrophage-related cytokines, such as TNF alpha, IL-1 beta, and IL-6 can lead to life-threatening complications, such as acute respiratory distress syndrome (ARDS), which develops in approximately 20% of the patients. Diverse immune modulating therapies are currently being tested in clinical trials. In a preclinical proof-of-concept study in experimental interstitial lung disease, we showed the potential of F-18-AzaFol, an F-18-labeled folic acid-based radiotracer, as a specific novel imaging tool for the visualization and monitoring of macrophage-driven lung diseases. F-18-AzaFol binds to the folate receptor-beta (FR beta) that is expressed on activated macrophages involved in inflammatory conditions. In a recent multicenter cancer trial, F-18-AzaFol was successfully and safely applied (NCT03242993). It is supposed that the visualization of activated macrophage-related disease processes by folate radiotracer-based nuclear imaging can support clinical decision-making by identifying COVID-19 patients at risk of a severe disease progression with a potentially lethal outcome.
C1 [Muller, Cristina; Schibli, Roger] Paul Scherrer Inst, Ctr Radiopharmaceut Sci, CH-5232 Villigen, Switzerland.
   [Muller, Cristina; Schibli, Roger] Swiss Fed Inst Technol, Dept Chem & Appl Biosci, CH-8093 Zurich, Switzerland.
   [Maurer, Britta] Univ Hosp Zurich, Ctr Expt Rheumatol, Dept Rheumatol, CH-8091 Zurich, Switzerland.
RP Maurer, B (corresponding author), Univ Hosp Zurich, Ctr Expt Rheumatol, Dept Rheumatol, CH-8091 Zurich, Switzerland.
EM cristina.mueller@psi.ch; roger.schibli@psi.ch; britta.maurer@usz.ch
OI Mueller, Cristina/0000-0001-9357-9688; Schibli,
   Roger/0000-0002-1537-3833
FU Innosuisse [13877.1 PFLS-LS]; Personalized Health and Related
   Technologies (PHRT) [512]; Swiss National Science FoundationSwiss
   National Science Foundation (SNSF) [CRSII3_154490, 310030_156803]; Prof.
   Max Cloetta Foundation
FX B.M. was supported by the Prof. Max Cloetta Foundation. The development
   of 18F-AzaFol was funded by Innosuisse: grant no.: CTI-Project 13877.1
   PFLS-LS (PI: RS) and from the "Personalized Health and Related
   Technologies (PHRT)" grant no. 512 (PI: RS). In addition, the
   preclinical work was supported by the Swiss National Science Foundation:
   grant no.: CRSII3_154490 (PI: RS) and grant no.: 310030_156803 (PI: CM).
CR Amini H, 2020, EUR J NUCL MED MOL I, V47, P1771, DOI 10.1007/s00259-020-04821-y
   Ayala-Lopez W, 2010, J NUCL MED, V51, P768, DOI 10.2967/jnumed.109.071324
   Basu S, 2009, SEMIN NUCL MED, V39, P124, DOI 10.1053/j.semnuclmed.2008.10.006
   Betzel T, 2013, BIOCONJUGATE CHEM, V24, P205, DOI 10.1021/bc300483a
   Byrne AJ, 2016, TRENDS MOL MED, V22, P303, DOI 10.1016/j.molmed.2016.02.004
   Chandrupatla DMSH, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1325-x
   Channappanavar Rudragouda, 2020, Methods Mol Biol, V2099, P195, DOI 10.1007/978-1-0716-0211-9_15
   Chen L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE005, DOI [10.3760/cma.j.issn.1001-0939.2020.03.013, 10.3760/cma.j.issn.1001-0939.2020.0005]
   Czernin J, 2020, J NUCL MED, V61, P626, DOI 10.2967/jnumed.120.245738
   Czernin Johannes, 2013, Curr Radiol Rep, V1, P177
   Dai WC, 2020, CAN ASSOC RADIOL J, V71, P195, DOI 10.1177/0846537120913033
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Gao Y, 2020, J MED VIROL, V92, P791, DOI 10.1002/jmv.25770
   Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009
   Gibson GJ, 2013, EUR RESPIR J, V42, P559, DOI 10.1183/09031936.00105513
   Gnesin S, 2020, EJNMMI RES, V10, DOI 10.1186/s13550-020-00624-2
   Hansell DM, 2015, LANCET RESP MED, V3, P483, DOI 10.1016/S2213-2600(15)00096-X
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jager NA, 2014, J NUCL MED, V55, P1945, DOI 10.2967/jnumed.114.143180
   Khanna D, 2018, ANN RHEUM DIS, V77, P212, DOI 10.1136/annrheumdis-2017-211682
   Khanna D, 2016, LANCET, V387, P2630, DOI 10.1016/S0140-6736(16)00232-4
   Kraus VB, 2016, OSTEOARTHR CARTILAGE, V24, P1613, DOI 10.1016/j.joca.2016.04.010
   Lee HW, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/1946585
   Li Y, 2020, ACROSS LANG CULT, V21, P1, DOI [10.1556/084.2020.00001, 10.2214/AJR.20.22954]
   Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158
   Low PS, 2008, ACCOUNTS CHEM RES, V41, P120, DOI 10.1021/ar7000815
   Maher TM, 2007, EUR RESPIR J, V30, P835, DOI 10.1183/09031936.00069307
   Mahoney JM, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004005
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Muller A, 2014, MOL IMAGING, V13, DOI 10.2310/7290.2013.00074
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Piscaer TM, 2011, ARTHRITIS RHEUM-US, V63, P1898, DOI 10.1002/art.30363
   Qi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Qin CX, 2020, EUR J NUCL MED MOL I, V47, P1281, DOI 10.1007/s00259-020-04734-w
   Sakkas LI, 2016, DRUG DES DEV THER, V10, P2723, DOI 10.2147/DDDT.S99696
   Schniering J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02724
   Setti L, 2020, EUR J NUCL MED MOL I, V47, P1649, DOI 10.1007/s00259-020-04819-6
   Shen JY, 2013, MOL PHARMACEUT, V10, P1918, DOI 10.1021/mp3006962
   Silvola JMU, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27618-4
   Singh AS, 2010, Q J NUCL MED MOL IM, V54, P281
   Sun D, 2020, WORLD J PEDIATR, V16, P251, DOI 10.1007/s12519-020-00354-4
   Taroni JN, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0417-1
   Thomeer MJ, 2004, RESP MED, V98, P567, DOI 10.1016/j.rmed.2003.10.015
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Venneti S, 2013, GLIA, V61, P10, DOI 10.1002/glia.22357
   Verweij NJF, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57841-x
   Vivash L, 2016, J NUCL MED, V57, P165, DOI 10.2967/jnumed.114.141713
   Wang ZL, 2020, CLIN INFECT DIS, V71, P769, DOI 10.1093/cid/ciaa272
   Wells AU, 2014, NAT REV RHEUMATOL, V10, P728, DOI 10.1038/nrrheum.2014.149
   Werry EL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133161
   Winkel LCJ, 2014, MOL IMAGING, V13, DOI 10.2310/7290.2013.00061
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xia W, 2009, BLOOD, V113, P438, DOI 10.1182/blood-2008-04-150789
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Yi YS, 2016, IMMUNE NETW, V16, P337, DOI 10.4110/in.2016.16.6.337
   Zou SJ, 2020, RADIOLOGY, V296, pE118, DOI 10.1148/radiol.2020200770
NR 57
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1424-8247
J9 PHARMACEUTICALS-BASE
JI Pharmaceuticals
PD SEP
PY 2020
VL 13
IS 9
AR 238
DI 10.3390/ph13090238
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OF6ME
UT WOS:000581318400001
PM 32916949
OA DOAJ Gold, Green Published, Green Accepted
DA 2021-01-01
ER

PT J
AU Rasaeifar, B
   Gomez-Gutierrez, P
   Perez, JJ
AF Rasaeifar, Bahareh
   Gomez-Gutierrez, Patricia
   Perez, Juan J.
TI Molecular Features of Non-Selective Small Molecule Antagonists of the
   Bradykinin Receptors
SO PHARMACEUTICALS
LA English
DT Article
DE bradykinin receptors; bradykinin pharmacophore; non-peptide bradykinin
   antagonists; bradykinin repurposing; Covid-19 therapy
ID STEREOCHEMICAL REQUIREMENTS; PROTEIN; ACE2; PHARMACOLOGY; RALOXIFENE;
   INSIGHTS
AB Angiotensin converting enzyme 2 (ACE2) downregulation is a key negative factor for the severity of lung edema and acute lung failure observed in patients infected with SARS-CoV-2. ACE2 downregulation affects the levels of diverse peptide mediators of the renin-agiotensin-aldestosterone and kallikrein-kinin systems, compromising vascular hemostasis. Increasing evidence suggests that the inflammatory response observed in covid-19 patients is initiated by the action of kinins on the bradykinin receptors. Accordingly, the use of bradykinin antagonists should be considered as a strategy for therapeutic intervention against covid-19 illness progression. Presently, icatibant is the only bradykinin antagonist drug approved. In the present report, we investigated the molecular features characterizing non-selective antagonists targeting the bradykinin receptors and carried out a in silico screening of approved drugs, aimed at the identification of compounds with a non-selective bradykinin antagonist profile that can be evaluated for drug repurposing. The study permitted to identify eight compounds as prospective non-selective antagonists of the bradykinin receptors, including raloxifene; sildenafil; cefepime; cefpirome; imatinib; ponatinib; abemaciclib and entrectinib.
C1 [Rasaeifar, Bahareh; Gomez-Gutierrez, Patricia; Perez, Juan J.] Univ Politecn Cataluna, Dept Chem Engn, ETSEIB, Av Diagonal 647, Barcelona 08028, Spain.
RP Perez, JJ (corresponding author), Univ Politecn Cataluna, Dept Chem Engn, ETSEIB, Av Diagonal 647, Barcelona 08028, Spain.
EM bahareh.rasaeifar@upc.edu; ondopasa@gmail.com; juan.jesus.perez@upc.edu
RI Perez, Juan J/E-3710-2010
OI Perez, Juan J/0000-0002-0748-8147; Rasaeifar,
   Bahareh/0000-0002-0496-1242; Reis, AlessanRSS/0000-0001-8486-7469
CR [Anonymous], 2020, MOLECULAR OPERATING
   Bernstein KE, 2013, PHARMACOL REV, V65, P1, DOI 10.1124/pr.112.006809
   Bork K, 2008, NAT REV DRUG DISCOV, V7, P801, DOI 10.1038/nrd2694
   Crowley SD, 2012, EXP CELL RES, V318, P1049, DOI 10.1016/j.yexcr.2012.02.023
   Dagnino APA, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13090215
   de Maat S, 2020, SEMIN THROMB HEMOST, V46, P835, DOI 10.1055/s-0040-1712960
   Flores-Munoz M, 2012, HYPERTENSION, V59, P300, DOI 10.1161/HYPERTENSIONAHA.111.177485
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Gelbert LM, 2014, INVEST NEW DRUG, V32, P825, DOI 10.1007/s10637-014-0120-7
   Golias Ch, 2007, Hippokratia, V11, P124
   Hamazaki Hiroyuki, 1997, Japanese Journal of Antibiotics, V50, P12
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Leeb-Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2
   Lupala CS, 2018, J BIOMOL STRUCT DYN, V36, P2436, DOI 10.1080/07391102.2017.1357503
   Lupala CS, 2016, J MOL GRAPH MODEL, V68, P184, DOI 10.1016/j.jmgm.2016.06.010
   Lupala CS, 2016, J COMPUT AID MOL DES, V30, P85, DOI 10.1007/s10822-015-9890-z
   Mahmudpour M, 2020, CYTOKINE, V133, DOI 10.1016/j.cyto.2020.155151
   Marceau F, 2004, NAT REV DRUG DISCOV, V3, P845, DOI 10.1038/nrd1522
   Marceau F, 2020, INT IMMUNOPHARMACOL, V82, DOI 10.1016/j.intimp.2020.106305
   Ni WT, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03120-0
   Patel HB, 2019, J PHARM PRACT, V32, P458, DOI 10.1177/0897190017743134
   Pretorius M, 2010, J PHARMACOL EXP THER, V332, P291, DOI 10.1124/jpet.109.160168
   Rameshrad M, 2020, N-S ARCH PHARMACOL, V393, P1137, DOI 10.1007/s00210-020-01901-6
   Rasaeifar B, 2019, BIOORG MED CHEM LETT, V29, P11, DOI 10.1016/j.bmcl.2018.11.026
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   REGOLI D, 1980, PHARMACOL REV, V32, P1
   Rolfo C, 2015, EXPERT OPIN INV DRUG, V24, P1493, DOI 10.1517/13543784.2015.1096344
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Santos RAS, 2003, P NATL ACAD SCI USA, V100, P8258, DOI 10.1073/pnas.1432869100
   Schmaier AH, 2002, J CLIN INVEST, V109, P1007, DOI 10.1172/JCI200215490
   Scott JA, 1999, AM FAM PHYSICIAN, V60, P1131
   Sodhi CP, 2018, AM J PHYSIOL-LUNG C, V314, pL17, DOI 10.1152/ajplung.00498.2016
   Sree GNSH, 2019, BIOMED PHARMACOTHER, V110, P700, DOI 10.1016/j.biopha.2018.11.127
   Su JB, 2014, J RENIN-ANGIO-ALDO S, V15, P319, DOI 10.1177/1470320312474854
   TOLOUIAN R, 2020, J RENAL INJ PREV, V9, pe19, DOI DOI 10.34172/JRIP.2020.19
   Unegbu C, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-1450
   Van De Veerdonk FL, 2020, KININS CYTOKINES COV, DOI [10.20944/preprints202004.0023.v1, DOI 10.20944/PREPRINTS202004.0023.V1]
   van de Veerdonk FL, 2020, ELIFE, V9, DOI 10.7554/eLife.57555
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wassmann S, 2002, CIRCULATION, V105, P2083, DOI 10.1161/01.CIR.0000014618.91633.67
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   World Health Organization, 2020, GENERALS OPENING REM
   Wu BL, 2010, SCIENCE, V330, P1066, DOI 10.1126/science.1194396
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou TJ, 2011, CHEM BIOL DRUG DES, V77, P1, DOI 10.1111/j.1747-0285.2010.01054.x
NR 49
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1424-8247
J9 PHARMACEUTICALS-BASE
JI Pharmaceuticals
PD SEP
PY 2020
VL 13
IS 9
AR 259
DI 10.3390/ph13090259
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA OF6FF
UT WOS:000581300300001
PM 32967280
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU De Francesco, MA
   Alberici, F
   Bossini, N
   Scolari, F
   Pascucci, F
   Tomasoni, G
   Caruso, A
AF De Francesco, Maria A.
   Alberici, Federico
   Bossini, Nicola
   Scolari, Francesco
   Pascucci, Federico
   Tomasoni, Gabriele
   Caruso, Arnaldo
TI Pneumocystis jirevocii and SARS-CoV-2 Co-Infection: A Common Feature in
   Transplant Recipients?
SO VACCINES
LA English
DT Article
DE COVID-19; pneumonia; immunosuppression
ID PNEUMONIA; CORONAVIRUS
AB COVID-19 might potentially give rise to a more severe infection in solid organ transplant recipients due to their chronic immunosuppression. These patients are at a higher risk of developing concurrent or secondary bacterial and fungal infections. Co-infections can increase systemic inflammation influencing the prognosis and the severity of the disease, and can in turn lead to an increased need of mechanical ventilation, antibiotic therapy and to a higher mortality. Here we describe, for the first time in Europe, a fatal case of co-infection between SARS-CoV-2 and Pneumocystis jirevocii in a kidney transplant recipient.
C1 [De Francesco, Maria A.; Caruso, Arnaldo] Univ Brescia, Inst Microbiol, Dept Mol & Translat Med, ASST Spedali Civili Brescia, I-25123 Brescia, Italy.
   [Alberici, Federico; Scolari, Francesco] Univ Brescia, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, I-25123 Brescia, Italy.
   [Alberici, Federico; Bossini, Nicola; Scolari, Francesco] ASST Spedali Civili Brescia, Nephrol Unit, Spedali Civili Hosp, I-25123 Brescia, Italy.
   [Pascucci, Federico; Tomasoni, Gabriele] ASST Spedali Civili Brescia, Div Anesthesiol 1, I-25123 Brescia, Italy.
   [Pascucci, Federico; Tomasoni, Gabriele] ASST Spedali Civili Brescia, Intens Care Unit, I-25123 Brescia, Italy.
RP De Francesco, MA (corresponding author), Univ Brescia, Inst Microbiol, Dept Mol & Translat Med, ASST Spedali Civili Brescia, I-25123 Brescia, Italy.
EM maria.defrancesco@unibs.it; federico.alberici@unibs.it;
   bossini-nicola@libero.it; francesco.scolari@unibs.it;
   pas.fede@gmail.com; gabriele.tomasoni@asst-spedalicivili.it;
   arnaldo.caruso@unibs.it
RI ; De Francesco, Maria Antonia/H-3456-2019
OI Alberici, Federico/0000-0002-1686-5709; De Francesco, Maria
   Antonia/0000-0003-2221-6286
CR Buchacz K, 2010, AIDS, V24, P1549, DOI 10.1097/QAD.0b013e32833a3967
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   de Wilde AH, 2018, CURR TOP MICROBIOL, V419, P1, DOI 10.1007/82_2017_25
   ECDC, 2020, COR DIS 2019 COVID 1
   Festic E, 2005, CHEST, V128, P573, DOI 10.1378/chest.128.2.573
   Gill JR, 2010, ARCH PATHOL LAB MED, V134, P235, DOI 10.1043/1543-2165-134.2.235
   Gong J., 2020, CELL HOST MICROBE, V27, P992
   Kaplan JE, 2000, CLIN INFECT DIS, V30, pS5, DOI 10.1086/313843
   Kim SJ, 2014, J INFECTION, V69, P88, DOI 10.1016/j.jinf.2014.02.015
   Li MC, 2014, J MICROBIOL IMMUNOL, V47, P42, DOI 10.1016/j.jmii.2012.08.024
   Magira EE, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz247
   Matsumura Y, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-76
   Menon AA, 2020, AM J RESP CRIT CARE, V202, P136, DOI 10.1164/rccm.202003-0766LE
   Monnet X, 2008, CRIT CARE, V12, DOI 10.1186/cc6806
   Netea MG, 2020, CELL, V181, P969, DOI 10.1016/j.cell.2020.04.042
   Pittet LA, 2010, AM J RESP CELL MOL, V42, P450, DOI 10.1165/rcmb.2007-0417OC
   Roblot F, 2002, EUR J CLIN MICROBIOL, V21, P523, DOI 10.1007/s10096-002-0758-5
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Sun PF, 2020, J MED VIROL, V92, P548, DOI 10.1002/jmv.25722
   Thompson GR, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa242
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   Werbel WA, 2018, TRANSPL INFECT DIS, V20, DOI 10.1111/tid.12876
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Xu Z, 2020, LANCET, V395, P947, DOI 10.1016/S0140-6736(20)30308-1
   Yuan ML, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230548
   Zhang BC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235458
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou PC, 2020, INFECT CONT HOSP EP, V41, P1124, DOI 10.1017/ice.2020.156
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 30
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-393X
J9 VACCINES-BASEL
JI Vaccines
PD SEP
PY 2020
VL 8
IS 3
AR 544
DI 10.3390/vaccines8030544
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OF5GZ
UT WOS:000581237300001
PM 32962148
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rahman, N
   Ali, F
   Basharat, Z
   Shehroz, M
   Khan, MK
   Jeandet, P
   Nepovimova, E
   Kuca, K
   Khan, H
AF Rahman, Noor
   Ali, Fawad
   Basharat, Zarrin
   Shehroz, Muhammad
   Khan, Muhammad Kazim
   Jeandet, Philippe
   Nepovimova, Eugenie
   Kuca, Kamil
   Khan, Haroon
TI Vaccine Design from the Ensemble of Surface Glycoprotein Epitopes of
   SARS-CoV-2: An Immunoinformatics Approach
SO VACCINES
LA English
DT Article
DE vaccine; multi-epitopes; antigenicity; allergenicity; coronavirus;
   pneumonia
ID PEPTIDE VACCINE; PROTEIN; CORONAVIRUS; PREDICTION; FLAGELLIN; IMPROVES;
   SERVER; TLR7
AB The present study aimed to work out a peptide-based multi-epitope vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We predicted different B-cell and T-cell epitopes by using the Immune Epitopes Database (IEDB). Homology modeling of the construct was done using SWISS-MODEL and then docked with different toll-like-receptors (TLR4, TLR7, and TLR8) using PatchDock, HADDOCK, and FireDock, respectively. From the overlapped epitopes, we designed five vaccine constructs C1-C5. Based on antigenicity, allergenicity, solubility, different physiochemical properties, and molecular docking scores, we selected the vaccine construct 1 (C1) for further processing. Docking of C1 with TLR4, TLR7, and TLR8 showed striking interactions with global binding energy of -43.48, -65.88, and -60.24 Kcal/mol, respectively. The docked complex was further simulated, which revealed that both molecules remain stable with minimum RMSF. Activation of TLRs induces downstream pathways to produce pro-inflammatory cytokines against viruses and immune system simulation shows enhanced antibody production after the booster dose. In conclusion, C1 was the best vaccine candidate among all designed constructs to elicit an immune response SARS-CoV-2 and combat the coronavirus disease (COVID-19).
C1 [Rahman, Noor] Univ Karachi, Int Ctr Chem & Biol Sci, HEJ Res Inst Chem, Karachi 75270, Pakistan.
   [Ali, Fawad] Hazara Univ, Dept Biochem, Mansehra 21120, Pakistan.
   [Basharat, Zarrin] Univ Karachi, Jamil Ur Rahman Ctr Genome Res, ICCBS, PCMD, Karachi 75270, Pakistan.
   [Shehroz, Muhammad] Virtual Univ Pakistan, Dept Biotechnol, Lahore 54000, Pakistan.
   [Khan, Muhammad Kazim] Univ Punjab, Ctr Appl Mol Biol, Lahore 53700, Pakistan.
   [Jeandet, Philippe] Univ Reims, Fac Sci, F-51687 Reims 2, France.
   [Nepovimova, Eugenie; Kuca, Kamil] Univ Hradec Kralove, Fac Sci, Dept Chem, Hradec Kralove 50005, Czech Republic.
   [Khan, Haroon] Abdul Wali Khan Univ Mardan, Dept Pharm, Mardan 23200, Pakistan.
RP Kuca, K (corresponding author), Univ Hradec Kralove, Fac Sci, Dept Chem, Hradec Kralove 50005, Czech Republic.; Khan, H (corresponding author), Abdul Wali Khan Univ Mardan, Dept Pharm, Mardan 23200, Pakistan.
EM noorbiochemist@gmail.com; fawwadali792@gmail.com; zarrin.iiui@gmail.com;
   muhammad.shehroz@vu.edu.pk; kazimbt@gmail.com;
   philippe.jeandet@univ-reims.fr; eugenie.nepovimova@uhk.cz;
   kamil.kuca@uhk.cz; haroonkhan@awkum.edu.pk
RI Khan, Haroon/AAY-1785-2020; Kuca, Kamil/D-1396-2011; /D-5805-2014
OI Khan, Haroon/0000-0002-1736-4404; Kuca, Kamil/0000-0001-9664-1109; Ali,
   Fawad/0000-0002-5331-7816; /0000-0003-1785-3803; Rahman,
   Noor/0000-0002-7062-2302
FU University of Hradec Kralove (Faculty of Science) [VT2019-2021]
FX It was supported by the University of Hradec Kralove (Faculty of
   Science, VT2019-2021).
CR Ahmad T. A., 2016, TRIALS VACCINOLOGY, V5, P71, DOI DOI 10.1016/J.TRIVAC.2016.04.003
   Craft N, 2005, J IMMUNOL, V175, P1983, DOI 10.4049/jimmunol.175.3.1983
   Doytchinova I. A, 2008, OPEN VACCINE J, V1, P4, DOI DOI 10.2174/1875035400801010022
   El-Manzalawy Y, 2008, J MOL RECOGNIT, V21, P243, DOI 10.1002/jmr.893
   Ferris LK, 2013, J INVEST DERMATOL, V133, P460, DOI 10.1038/jid.2012.319
   Fleri W, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00278
   Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Ghaffari-Nazari H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142563
   Gnjatic S, 2010, CANCER J, V16, P382, DOI 10.1097/PPO.0b013e3181eaca65
   Gorden KB, 2005, J IMMUNOL, V174, P1259, DOI 10.4049/jimmunol.174.3.1259
   Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376
   GURUPRASAD K, 1990, PROTEIN ENG, V4, P155, DOI 10.1093/protein/4.2.155
   Haagmans BL, 2014, LANCET INFECT DIS, V14, P140, DOI 10.1016/S1473-3099(13)70690-X
   Hajighahramani N, 2017, INFECT GENET EVOL, V48, P83, DOI 10.1016/j.meegid.2016.12.010
   Jespersen MC, 2017, NUCLEIC ACIDS RES, V45, pW24, DOI 10.1093/nar/gkx346
   Jung ID, 2011, CANCER RES, V71, P2858, DOI 10.1158/0008-5472.CAN-10-3487
   Kaba SA, 2018, VACCINE, V36, P906, DOI 10.1016/j.vaccine.2017.12.001
   Kim Y, 2012, NUCLEIC ACIDS RES, V40, pW525, DOI 10.1093/nar/gks438
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Lester SN, 2014, J MOL BIOL, V426, P1246, DOI 10.1016/j.jmb.2013.11.024
   Li ZJ, 2019, ELIFE, V8, DOI 10.7554/eLife.51230
   Lu GW, 2015, TRENDS MICROBIOL, V23, P468, DOI 10.1016/j.tim.2015.06.003
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Magnan CN, 2009, BIOINFORMATICS, V25, P2200, DOI 10.1093/bioinformatics/btp386
   Mashiach E, 2008, NUCLEIC ACIDS RES, V36, pW229, DOI 10.1093/nar/gkn186
   Miyazawa S, 1996, J MOL BIOL, V256, P623, DOI 10.1006/jmbi.1996.0114
   Mizel SB, 2010, J IMMUNOL, V185, P5677, DOI 10.4049/jimmunol.1002156
   Modelos C., 2016, NAT PROTOC, V10, P845, DOI [10.1038/nprot.2015-053, DOI 10.1038/NPROT.2015-053]
   Mohan R, 2012, BIOINFORMATION, V8, P722, DOI 10.6026/97320630008722
   Muhammad I, 2020, RECENT PAT ANTI-CANC, V15, P154, DOI 10.2174/1574892815666200226112506
   Nezafat N, 2014, J THEOR BIOL, V349, P121, DOI 10.1016/j.jtbi.2014.01.018
   Olejnik J, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007390
   Park HJ, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0539-7
   Rahman N, 2020, GENOMICS, V112, P3473, DOI 10.1016/j.ygeno.2020.06.026
   Rahman N, 2020, MOLECULES, V25, DOI 10.3390/molecules25102271
   Rahman N, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9100544
   Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862
   Rosa DS, 2004, IMMUNOL LETT, V92, P259, DOI 10.1016/j.imlet.2004.01.006
   Saha S, 2006, NUCLEIC ACIDS RES, V34, pW202, DOI 10.1093/nar/gkl343
   Sanchita, 2014, MOL BIOL REP, V41, P7323, DOI 10.1007/s11033-014-3618-3
   Shey RA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40833-x
   Solanki V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26689-7
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Le TT, 2020, NAT REV DRUG DISCOV, V19, P305, DOI 10.1038/d41573-020-00073-5
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988
   Wang P, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000048
   Wilkins MR, 1999, METH MOL B, V112, P531
   Wille-Reece U, 2005, P NATL ACAD SCI USA, V102, P15190, DOI 10.1073/pnas.0507484102
   Yang Y, 2015, HUM VACC IMMUNOTHER, V11, P795, DOI 10.1080/21645515.2015.1012017
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zheng M, 2020, CELL MOL IMMUNOL, V17, P536, DOI 10.1038/s41423-020-0385-z
NR 54
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-393X
J9 VACCINES-BASEL
JI Vaccines
PD SEP
PY 2020
VL 8
IS 3
AR 423
DI 10.3390/vaccines8030423
PG 17
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OF4VO
UT WOS:000581207600001
PM 32731461
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rohaim, MA
   Clayton, E
   Sahin, I
   Vilela, J
   Khalifa, ME
   Al-Natour, MQ
   Bayoumi, M
   Poirier, AC
   Branavan, M
   Tharmakulasingam, M
   Chaudhry, NS
   Sodi, R
   Brown, A
   Burkhart, P
   Hacking, W
   Botham, J
   Boyce, J
   Wilkinson, H
   Williams, C
   Whittingham-Dowd, J
   Shaw, E
   Hodges, M
   Butler, L
   Bates, MD
   La Ragione, R
   Balachandran, W
   Fernando, A
   Munir, M
AF Rohaim, Mohammed A.
   Clayton, Emily
   Sahin, Irem
   Vilela, Julianne
   Khalifa, Manar E.
   Al-Natour, Mohammad Q.
   Bayoumi, Mahmoud
   Poirier, Aurore C.
   Branavan, Manoharanehru
   Tharmakulasingam, Mukunthan
   Chaudhry, Nouman S.
   Sodi, Ravinder
   Brown, Amy
   Burkhart, Peter
   Hacking, Wendy
   Botham, Judy
   Boyce, Joe
   Wilkinson, Hayley
   Williams, Craig
   Whittingham-Dowd, Jayde
   Shaw, Elisabeth
   Hodges, Matt
   Butler, Lisa
   Bates, Michelle D.
   La Ragione, Roberto
   Balachandran, Wamadeva
   Fernando, Anil
   Munir, Muhammad
TI Artificial Intelligence-Assisted Loop Mediated Isothermal Amplification
   (AI-LAMP) for Rapid Detection of SARS-CoV-2
SO VIRUSES-BASEL
LA English
DT Article
DE SARS-CoV-2; diagnosis; LAMP; point of care; artificial intelligence
ID CORONAVIRUS; PNEUMONIA; ASSAY
AB Until vaccines and effective therapeutics become available, the practical solution to transit safely out of the current coronavirus disease 19 (CoVID-19) lockdown may include the implementation of an effective testing, tracing and tracking system. However, this requires a reliable and clinically validated diagnostic platform for the sensitive and specific identification of SARS-CoV-2. Here, we report on the development of a de novo, high-resolution and comparative genomics guided reverse-transcribed loop-mediated isothermal amplification (LAMP) assay. To further enhance the assay performance and to remove any subjectivity associated with operator interpretation of results, we engineered a novel hand-held smart diagnostic device. The robust diagnostic device was further furnished with automated image acquisition and processing algorithms and the collated data was processed through artificial intelligence (AI) pipelines to further reduce the assay run time and the subjectivity of the colorimetric LAMP detection. This advanced AI algorithm-implemented LAMP (ai-LAMP) assay, targeting the RNA-dependent RNA polymerase gene, showed high analytical sensitivity and specificity for SARS-CoV-2. A total of similar to 200 coronavirus disease (CoVID-19)-suspected NHS patient samples were tested using the platform and it was shown to be reliable, highly specific and significantly more sensitive than the current gold standard qRT-PCR. Therefore, this system could provide an efficient and cost-effective platform to detect SARS-CoV-2 in resource-limited laboratories.
C1 [Rohaim, Mohammed A.; Clayton, Emily; Sahin, Irem; Vilela, Julianne; Khalifa, Manar E.; Al-Natour, Mohammad Q.; Bayoumi, Mahmoud; Whittingham-Dowd, Jayde; Shaw, Elisabeth; Hodges, Matt; Butler, Lisa; Bates, Michelle D.; Munir, Muhammad] Univ Lancaster, Fac Hlth & Med, Div Biomed & Life Sci, Lancaster LA1 4YW, England.
   [Poirier, Aurore C.; La Ragione, Roberto] Univ Surrey, Sch Vet Med, Dept Pathol & Infect Dis, Guildford GU2 7AL, Surrey, England.
   [Branavan, Manoharanehru; Balachandran, Wamadeva] Brunel Univ London, Coll Engn Design & Phys Sci, Kingston Lane, Uxbridge UB8 3PH, Middx, England.
   [Tharmakulasingam, Mukunthan; Chaudhry, Nouman S.; Fernando, Anil] Univ Surrey, Ctr Vis Speech & Signal Proc, Guildford GU2 7XH, Surrey, England.
   [Sodi, Ravinder] Poole & Bournemouth Hosp NHS Trust, Dept Biochem, Longfleet Rd, Poole BH15 2JB, Dorset, England.
   [Brown, Amy; Burkhart, Peter; Hacking, Wendy; Botham, Judy; Boyce, Joe; Wilkinson, Hayley; Williams, Craig] Univ Hosp Morecambe Bay NHS Fdn Trust, Royal Lancaster Infirm, Kendal LA9 7RG, England.
RP Munir, M (corresponding author), Univ Lancaster, Fac Hlth & Med, Div Biomed & Life Sci, Lancaster LA1 4YW, England.
EM m.a.rohaim@lancaster.ac.uk; e.clayton3@lancaster.ac.uk;
   i.sahin@lancaster.ac.uk; j.vilela@lancaster.ac.uk;
   m.khalifa@lancaster.ac.uk; m.al-natour@lancaster.ac.uk;
   m.bayoumi@lancaster.ac.uk; a.poirier@surrey.ac.uk;
   manoharanehru.branavan@brunel.ac.uk; m.tharmakulasingam@surrey.ac.uk;
   n.chaudhry@surrey.ac.uk; r.sodi@nhs.net; Amy.Brown@mbht.nhs.uk;
   Peter.Burkhart@mbht.nhs.uk; Wendy.Hacking@mbht.nhs.uk;
   Judy.Botham@mbht.nhs.uk; Joe.Boyce@mbht.nhs.uk;
   hayley.wilkinson@mbht.nhs.uk; craig.williams@mbht.nhs.uk;
   j.whittingham-dowd@lancaster.ac.uk; e.shaw1@lancaster.ac.uk;
   m.hodges@lancaster.ac.uk; l.butler1@lancaster.ac.uk;
   m.bates@lancaster.ac.uk; r.laragione@surrey.ac.uk;
   wamadeva.balachandran@brunel.ac.uk; W.Fernando@surrey.ac.uk;
   muhammad.munir@lancaster.ac.uk
RI Rohaim, Mohammed A./AAM-7476-2020; Poirier, Aurore/O-3846-2014
OI Rohaim, Mohammed A./0000-0002-6941-9294; Rohaim, Mohammed Abdelmohsen
   Shahaat/0000-0003-1798-7086; Hodges, Matthew David
   John/0000-0002-6815-751X; Clayton, Emily/0000-0002-6840-1105; Munir,
   Muhammad/0000-0002-7889-1398; Vilela, Julianne/0000-0002-1730-9720;
   Bayoumi, Mahmoud/0000-0002-1265-3047; Poirier,
   Aurore/0000-0002-9041-7605; Chaudhry, Nouman/0000-0003-2746-6081;
   Whittingham-Dowd, Jayde/0000-0002-7939-6081; Sodi,
   Ravinder/0000-0002-7219-5957; Tharmakulasingam,
   Mukunthan/0000-0002-2081-7865; Shaw, Elisabeth Jane/0000-0002-5653-0145
FU BBSRCBiotechnology and Biological Sciences Research Council (BBSRC)
   [BB/R012695/1, BB/M008681/1, BBS/E/I/00001852]; British Council at
   Division of Biomedical and Life Sciences, Lancaster University, UK
   [172710323, 332228521]; Brunel University London; University of Surrey
FX The authors wish to express our sincere appreciation to the BBSRC for
   allowing us to repurpose the LAMP prototypes produced in the grant
   BB/R012695/1 to be used for SARS-CoV-2 laboratory testing at The
   University of Lancaster. We would like to thank the support of BBSRC
   (BB/M008681/1 and BBS/E/I/00001852) and British Council (172710323 and
   332228521) at Division of Biomedical and Life Sciences, Lancaster
   University, UK. We would also like to thank Brunel University London and
   the University of Surrey for providing some financial support to rapidly
   produce these devices.
CR Afshan G, 2019, PAK J ZOOL, V51, P2311, DOI 10.17582/journal.pjz/2019.51.6.2311.2322
   Al-Tairi ZH, 2014, J INF PROCESS SYST, V10, P283, DOI 10.3745/JIPS.02.0002
   Cao ZG, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00554
   Chan JFW, 2015, CLIN MICROBIOL REV, V28, P465, DOI 10.1128/CMR.00102-14
   Chan JFW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00310-20
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chen LJ, 2020, EMERG MICROBES INFEC, V9, P313, DOI 10.1080/22221751.2020.1725399
   Cheng VCC, 2007, CLIN MICROBIOL REV, V20, P660, DOI 10.1128/CMR.00023-07
   Chotiwan N, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag0538
   Decaro N, 2020, VET MICROBIOL, V244, DOI 10.1016/j.vetmic.2020.108693
   Ganguli A, 2017, BIOMED MICRODEVICES, V19, DOI 10.1007/s10544-017-0209-9
   Ge YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069941
   Javaid A, 2019, PAK J ZOOL, V51, P1987, DOI 10.17582/journal.pjz/2019.51.5.sc8
   Kaarj K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30797-9
   Kashir J, 2020, MED HYPOTHESES, V141, DOI 10.1016/j.mehy.2020.109786
   Katoh K, 2019, BRIEF BIOINFORM, V20, P1160, DOI 10.1093/bib/bbx108
   Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011
   Kurosaki Y, 2010, J CLIN MICROBIOL, V48, P2330, DOI 10.1128/JCM.01224-09
   Kwallah AO, 2013, J VIROL METHODS, V193, P23, DOI 10.1016/j.jviromet.2013.05.004
   Liu S, 2010, PROCEEDINGS OF 2010 INTERNATIONAL SYMPOSIUM ON IMAGE ANALYSIS AND SIGNAL PROCESSING, P266
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mahony J, 2013, J CLIN MICROBIOL, V51, P2696, DOI 10.1128/JCM.00662-13
   Mori Y, 2020, J INFECT CHEMOTHER, V26, P13, DOI 10.1016/j.jiac.2019.07.020
   Nguyen T, 2020, MICROMACHINES-BASEL, V11, DOI 10.3390/mi11030306
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Shahid M, 2019, PAK J ZOOL, V51, P1971, DOI 10.17582/journal.pjz/2019.51.5.sc4
   Sharif M, 2019, J EXP THEOR ARTIF IN, V1, P23, DOI [10.1080/0952813X.2019.1572657, DOI 10.1080/0952813X.2019.1572657]
   Sodi R, 2017, CLIN CHIM ACTA, V466, P13, DOI 10.1016/j.cca.2016.12.031
   Sun YY, 2019, IEEE ACCESS, V7, P28392, DOI 10.1109/ACCESS.2019.2901943
   Vogels CBF, 2020, NAT MICROBIOL, V5, P1299, DOI 10.1038/s41564-020-0761-6
   Wei M, 2020, JAMA-J AM MED ASSOC, V323, P1313, DOI 10.1001/jama.2020.2131
   WHO, 2020, COR DIS COVID 19 PAN
   World Health Organization (WHO), 2020, NOV COR CHIN
   Xu CP, 2016, ARCH VIROL, V161, P1125, DOI 10.1007/s00705-016-2763-5
   Yan C, 2020, CLIN MICROBIOL INFEC, V26, P773, DOI 10.1016/j.cmi.2020.04.001
   Yang W., 2020, RAPID DETECTION SARS, DOI [10.1101/2020.03.02.20030130, DOI 10.1101/2020.03.02.20030130]
   Yu L, 2020, CLIN CHEM, V66, P975, DOI 10.1093/clinchem/hvaa102
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 40
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD SEP
PY 2020
VL 12
IS 9
AR 972
DI 10.3390/v12090972
PG 19
WC Virology
SC Virology
GA OF7JO
UT WOS:000581379200001
PM 32883050
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Stoddard, SV
   Stoddard, SD
   Oelkers, BK
   Fitts, K
   Whalum, K
   Whalum, K
   Hemphill, AD
   Manikonda, J
   Martinez, LM
   Riley, EG
   Roof, CM
   Sarwar, N
   Thomas, DM
   Ulmer, E
   Wallace, FE
   Pandey, P
   Roy, S
AF Stoddard, Shana, V
   Stoddard, Serena D.
   Oelkers, Benjamin K.
   Fitts, Kennedi
   Whalum, Kellen
   Whalum, Kaylah
   Hemphill, Alexander D.
   Manikonda, Jithin
   Martinez, Linda Michelle
   Riley, Elizabeth G.
   Roof, Caroline M.
   Sarwar, Nowreen
   Thomas, Doni M.
   Ulmer, Emily
   Wallace, Felissa E.
   Pandey, Pankaj
   Roy, Sudeshna
TI Optimization Rules for SARS-CoV-2 M-pro Antivirals: Ensemble Docking and
   Exploration of the Coronavirus Protease Active Site
SO VIRUSES-BASEL
LA English
DT Article
DE coronaviruses; molecular docking; inhibitor design; molecular
   interactions; COVID-19; molecular dynamics; SARS-CoV-2 main protease;
   SARS-CoV-2 M-pro
ID MOLECULAR DOCKING; IDENTIFICATION; DISCOVERY; CONSURF; DESIGN; SARS
AB Coronaviruses are viral infections that have a significant ability to impact human health. Coronaviruses have produced two pandemics and one epidemic in the last two decades. The current pandemic has created a worldwide catastrophe threatening the lives of over 15 million as of July 2020. Current research efforts have been focused on producing a vaccine or repurposing current drug compounds to develop a therapeutic. There is, however, a need to study the active site preferences of relevant targets, such as the SARS-CoV-2 main protease (SARS-CoV-2 M-pro), to determine ways to optimize these drug compounds. The ensemble docking and characterization work described in this article demonstrates the multifaceted features of the SARS-CoV-2 M-pro active site, molecular guidelines to improving binding affinity, and ultimately the optimization of drug candidates. A total of 220 compounds were docked into both the 5R7Z and 6LU7 SARS-CoV-2 M-pro crystal structures. Several key preferences for strong binding to the four subsites (S1, S1 ', S2, and S4) were identified, such as accessing hydrogen binding hotspots, hydrophobic patches, and utilization of primarily aliphatic instead of aromatic substituents. After optimization efforts using the design guidelines developed from the molecular docking studies, the average docking score of the parent compounds was improved by 6.59 -log(10)(Kd) in binding affinity which represents an increase of greater than six orders of magnitude. Using the optimization guidelines, the SARS-CoV-2 M-pro inhibitor cinanserin was optimized resulting in an increase in binding affinity of 4.59 -log(10)(Kd) and increased protease inhibitor bioactivity. The results of molecular dynamic (MD) simulation of cinanserin-optimized compounds CM02, CM06, and CM07 revealed that CM02 and CM06 fit well into the active site of SARS-CoV-2 M-pro [Protein Data Bank (PDB) accession number 6LU7] and formed strong and stable interactions with the key residues, Ser-144, His-163, and Glu-166. The enhanced binding affinity produced demonstrates the utility of the design guidelines described. The work described herein will assist scientists in developing potent COVID-19 antivirals.
C1 [Stoddard, Shana, V; Stoddard, Serena D.; Oelkers, Benjamin K.; Fitts, Kennedi; Whalum, Kellen; Whalum, Kaylah; Hemphill, Alexander D.; Manikonda, Jithin; Martinez, Linda Michelle; Riley, Elizabeth G.; Roof, Caroline M.; Sarwar, Nowreen; Thomas, Doni M.; Ulmer, Emily; Wallace, Felissa E.] Rhodes Coll, Dept Chem, 2000 North Pkwy, Memphis, TN 38112 USA.
   [Stoddard, Serena D.] Tuskegee Univ, Coll Vet Med, 201 Frederick D Patterson Dr, Tuskegee, AL 36088 USA.
   [Wallace, Felissa E.] Walnut Hills High Sch, 3250 Victory Pkwy, Cincinnati, OH 45207 USA.
   [Pandey, Pankaj] Univ Mississippi, Natl Ctr Nat Prod Res, University, MS 38677 USA.
   [Roy, Sudeshna] Univ Mississippi, Sch Pharm, Dept BioMol Sci, University, MS 38677 USA.
RP Stoddard, SV (corresponding author), Rhodes Coll, Dept Chem, 2000 North Pkwy, Memphis, TN 38112 USA.
EM stoddards@rhodes.edu; sstoddard7607@tuskegee.edu; oelbk-23@rhodes.edu;
   fitke-21@rhodes.edu; whakt2-21@rhodes.edu; whakt-21@rhodes.edu;
   hemal-23@rhodes.edu; manve-23@rhodes.edu; martinezlinda367@gmail.com;
   rileg-22@rhodes.edu; roocm-21@rhodes.edu; sarno-23@rhodes.edu;
   donithomas10@gmail.com; ulmea-22@rhodes.edu; emmaleewallac@gmail.com;
   ppandey@olemiss.edu; roy@olemiss.edu
OI Stoddard, Shana/0000-0002-0721-084X
FU Rhodes College Chemistry department
FX We would like to acknowledge the Rhodes College Chemistry department for
   support of the research project during the Spring 2020 semester.
CR Arun KG, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/10799893.2020.1715432, 10.1080/07391102.2020.1779819]
   Balasubramaniam S, 2020, BEILSTEIN J ORG CHEM, V16, P628, DOI 10.3762/bjoc.16.59
   Chan JFW, 2012, J INFECTION, V65, P477, DOI 10.1016/j.jinf.2012.10.002
   Chaurasiya ND, 2019, MOLECULES, V24, DOI 10.3390/molecules24040810
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Dyall J, 2014, ANTIMICROB AGENTS CH, V58, P4885, DOI 10.1128/AAC.03036-14
   Ertl P, 2000, J MED CHEM, V43, P3714, DOI 10.1021/jm000942e
   Glaser F, 2003, BIOINFORMATICS, V19, P163, DOI 10.1093/bioinformatics/19.1.163
   Gullapelli K., 2017, EGYPT J BASIC APPL S, V4, P303, DOI [10.1016/j.ejbas.2017.09.002, DOI 10.1016/J.EJBAS.2017.09.002]
   Guy RK, 2020, SCIENCE, V368, P829, DOI 10.1126/science.abb9332
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Huber RG, 2014, J CHEM INF MODEL, V54, P1371, DOI 10.1021/ci500183u
   Jain AN, 2007, J COMPUT AID MOL DES, V21, P281, DOI 10.1007/s10822-007-9114-2
   Jain AN, 2003, J MED CHEM, V46, P499, DOI 10.1021/jm020406h
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   JORGENSEN WL, 1981, J AM CHEM SOC, V103, P335, DOI 10.1021/ja00392a016
   KHAN RJ, 2020, J BIOMOL STRUCT 0418, DOI DOI 10.1080/07391102.2020.1753577
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Landau M, 2005, NUCLEIC ACIDS RES, V33, pW299, DOI 10.1093/nar/gki370
   Liu GY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051436
   Miceli LA, 2013, MAR DRUGS, V11, P4127, DOI 10.3390/md11114127
   Molinspiration Cheminformatics Free Web Services, FREE WEB SERV MOL PR
   Odhar HA, 2020, BIOINFORMATION, V16, P236, DOI 10.6026/97320630016236
   Patel Mehul M, 2014, ScientificWorldJournal, V2014, P897187, DOI 10.1155/2014/897187
   Pawar AY, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105984
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Shaw D.E., 2019, SHAW RES DESM MOL DY
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Stoddard SV, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010219
   Stoddard SV, 2019, MOL INFORM, V38, DOI 10.1002/minf.201800080
   Tetko IV, 2005, J COMPUT AID MOL DES, V19, P453, DOI 10.1007/s10822-005-8694-y
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yu R, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106012
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 39
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD SEP
PY 2020
VL 12
IS 9
AR 942
DI 10.3390/v12090942
PG 34
WC Virology
SC Virology
GA OF5OX
UT WOS:000581257900001
PM 32859008
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rehman, HM
   Mirza, MU
   Ahmad, MA
   Saleem, M
   Froeyen, M
   Ahmad, S
   Gul, R
   Alghamdi, HA
   Aslam, MS
   Sajjad, M
   Bhinder, MA
AF Rehman, Hafiz Muzzammel
   Mirza, Muhammad Usman
   Ahmad, Mian Azhar
   Saleem, Mahjabeen
   Froeyen, Matheus
   Ahmad, Sarfraz
   Gul, Roquyya
   Alghamdi, Huda Ahmed
   Aslam, Muhammad Shahbaz
   Sajjad, Muhammad
   Bhinder, Munir Ahmad
TI A Putative Prophylactic Solution for COVID-19: Development of Novel
   Multiepitope Vaccine Candidate against SARS-COV-2 by Comprehensive
   Immunoinformatic and Molecular Modelling Approach
SO BIOLOGY-BASEL
LA English
DT Article
DE COVID-19; SARS-CoV-2; spike protein; multiepitope vaccine; molecular
   modeling
ID MULTI-EPITOPE VACCINE; PROTEIN-STRUCTURE; HARNESSING BIOINFORMATICS;
   ANTIGENIC DETERMINANTS; RATIONAL DESIGN; PEPTIDE VACCINE; CORONAVIRUS;
   IDENTIFICATION; MICE; IMMUNOGENICITY
AB Simple Summary COVID-19, caused by a novel coronavirus, SARS-CoV-2, first emerged in China in December 2019, and then spread around the globe with more than 29 million confirmed infections. Immunoinformatics and molecular modelling techniques are time-efficient methods that are used to accelerate the discovery and design of the candidate peptides for vaccine development against SARS-COV-2. Recently, the use of multiepitope vaccines has proved to be a promising immunization strategy against different viruses and other pathogens. In the current study a comprehensive in silico strategy was used to design stable multiepitope vaccine construct (MVC) from B-cell and T-cell epitopes of essential SARS-CoV-2 proteins which include, spike, main protease, non-structural protein 12 (polymerase), and Nsp13 (helicase) with the help of adjuvants and linkers. Molecular dynamics studies revealed that the MVC displayed favourable molecular interactions with human Toll-like receptors (TLRs), which are known in triggering an innate and adaptive immune response. Furthermore, the MVC was checked for its recombinant production in Escherichia coli using a well-known expression system. The MVC showed a stable three-dimensional structure and could serve as a potential candidate for vaccine production, which warrant further experimental research for validation. The outbreak of 2019-novel coronavirus (SARS-CoV-2) that causes severe respiratory infection (COVID-19) has spread in China, and the World Health Organization has declared it a pandemic. However, no approved drug or vaccines are available, and treatment is mainly supportive and through a few repurposed drugs. The urgency of the situation requires the development of SARS-CoV-2-based vaccines. Immunoinformatic and molecular modelling are time-efficient methods that are generally used to accelerate the discovery and design of the candidate peptides for vaccine development. In recent years, the use of multiepitope vaccines has proved to be a promising immunization strategy against viruses and pathogens, thus inducing more comprehensive protective immunity. The current study demonstrated a comprehensive in silico strategy to design stable multiepitope vaccine construct (MVC) from B-cell and T-cell epitopes of essential SARS-CoV-2 proteins with the help of adjuvants and linkers. The integrated molecular dynamics simulations analysis revealed the stability of MVC and its interaction with human Toll-like receptors (TLRs), which trigger an innate and adaptive immune response. Later, the in silico cloning in a known pET28a vector system also estimated the possibility of MVC expression inEscherichia coli. Despite that this study lacks validation of this vaccine construct in terms of its efficacy, the current integrated strategy encompasses the initial multiple epitope vaccine design concepts. After validation, this MVC can be present as a better prophylactic solution against COVID-19.
C1 [Rehman, Hafiz Muzzammel; Saleem, Mahjabeen; Aslam, Muhammad Shahbaz] Univ Punjab, Inst Biochem & Biotechnol, Lahore 54590, Punjab, Pakistan.
   [Rehman, Hafiz Muzzammel; Ahmad, Mian Azhar; Bhinder, Munir Ahmad] Univ Hlth Sci, Dept Human Genet & Mol Biol, Lahore 54590, Punjab, Pakistan.
   [Mirza, Muhammad Usman; Froeyen, Matheus] Univ Leuven, Dept Pharmaceut & Pharmacol Sci, Rega Inst Med Res, Med Chem, B-3000 Leuven, Belgium.
   [Ahmad, Mian Azhar] Govt Punjab, Dept Hlth, Lahore 54590, Punjab, Pakistan.
   [Ahmad, Sarfraz] Univ Malaya, Dept Chem, Fac Sci, Drug Design & Dev Res Grp DDDRG, Kuala Lumpur 50603, Malaysia.
   [Gul, Roquyya] Fac Life Sci, Gulab Devi Educ Complex, Lahore 54590, Punjab, Pakistan.
   [Alghamdi, Huda Ahmed] King Khalid Univ, Dept Biol, Coll Sci, Abha 61413, Saudi Arabia.
   [Sajjad, Muhammad] Univ Punjab, Sch Biol Sci, Quaid E Azam Campus, Lahore 54590, Punjab, Pakistan.
RP Saleem, M (corresponding author), Univ Punjab, Inst Biochem & Biotechnol, Lahore 54590, Punjab, Pakistan.
EM muzzammel.phd.ibb@pu.edu.pk; muhammadusman.mirza@kuleuven.be;
   drmianazharahmad@gmail.com; mahjabeen.ibb@pu.edu.pk;
   mathy.froeyen@kuleuven.be; sarfraz.ahmad@um.edu.my;
   roquyya.gul@gdec.edu.pk; hudaghamdi@kku.edu.sa; shahbaz.ibb@pu.edu.pk;
   sajjad.sbs@pu.edu.pk; munirbhinder@uhs.edu.pk
RI Ahmad, Sarfraz/ABG-7957-2020; Mirza, Muhammad Usman/I-5970-2019
OI Ahmad, Sarfraz/0000-0003-0059-477X; Mirza, Muhammad
   Usman/0000-0001-9120-2414
FU Deanship of Scientific Research at King Khalid University
   [R.G.P-2/49/40]
FX The authors extend their appreciation to the Deanship of Scientific
   Research at King Khalid University for funding this work through
   research groups program under Grant No.R.G.P-2/49/40. The authors would
   like to thank Prof. Dr. Niaz Ahmad Akhtar, Vice chancellor, University
   of the Punjab, and the Institute of Biochemistry and Biotechnology for
   providing all necessities in order to complete this work.
CR Abdulla F, 2019, MICROB PATHOGENESIS, V137, DOI 10.1016/j.micpath.2019.103791
   Abu-Saleh A.A.-A.A., 2020, COMPUTATIONAL DESIGN
   Alberts B, 2002, MOL BIOL CELL
   Arai R, 2001, PROTEIN ENG, V14, P529, DOI 10.1093/protein/14.8.529
   Arnon R, 2003, INT IMMUNOPHARMACOL, V3, P1195, DOI 10.1016/S1567-5769(03)00016-X
   Azhar EI, 2019, INFECT DIS CLIN N AM, V33, P891, DOI 10.1016/j.idc.2019.08.001
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930
   Benvenuto D, 2020, J MED VIROL, V92, P455, DOI 10.1002/jmv.25688
   Bergmann CC, 1996, J IMMUNOL, V157, P3242
   Bhatnager R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1787227
   Buchholz UJ, 2004, P NATL ACAD SCI USA, V101, P9804, DOI 10.1073/pnas.0403492101
   Cao YM, 2017, ANTIVIR RES, V140, P133, DOI 10.1016/j.antiviral.2017.01.023
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Channappanavar R., 2020, MERS CORONAVIRUS MET, P195
   Chen JH, 2007, PROTEINS, V67, P922, DOI 10.1002/prot.21345
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Comeau SR, 2004, NUCLEIC ACIDS RES, V32, pW96, DOI 10.1093/nar/gkh354
   Craig DB, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-346
   Damfo SA, 2017, J MOL GRAPH MODEL, V78, P195, DOI 10.1016/j.jmgm.2017.10.004
   Davies MN, 2007, DRUG DISCOV TODAY, V12, P389, DOI 10.1016/j.drudis.2007.03.010
   Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216
   Tosta SFD, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2019.1707120
   Depla E, 2008, J VIROL, V82, P435, DOI 10.1128/JVI.01505-07
   Dorosti H, 2019, J BIOMOL STRUCT DYN, V37, P3524, DOI 10.1080/07391102.2018.1519460
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985
   FIESER TM, 1987, P NATL ACAD SCI USA, V84, P8568, DOI 10.1073/pnas.84.23.8568
   Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI DOI 10.1385/1-59259-890-0:571
   Goodman AG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025938
   Green DR, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc7428
   Grote A, 2005, NUCLEIC ACIDS RES, V33, pW526, DOI 10.1093/nar/gki376
   Guo L, 2014, APPL MICROBIOL BIOT, V98, P3495, DOI 10.1007/s00253-013-5408-6
   Havranek B, 2020, J BIOMOL STRUCT DYN, DOI [10.1080/07391102.2020.1776158, 10.1080/07391102.2020.1805018]
   Hughes JP, 2011, BRIT J PHARMACOL, V162, P1239, DOI 10.1111/j.1476-5381.2010.01127.x
   IKAI A, 1980, J BIOCHEM-TOKYO, V88, P1895
   Ikram N, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9040124
   Iman K, 2018, CNS NEUROL DISORD-DR, V17, P54, DOI 10.2174/1871527317666180115162422
   Jabbar B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03000
   Jia ZH, 2019, NUCLEIC ACIDS RES, V47, P6538, DOI 10.1093/nar/gkz409
   Jiang PF, 2017, VACCINE, V35, P3096, DOI 10.1016/j.vaccine.2017.04.031
   Kallberg M, 2012, NAT PROTOC, V7, P1511, DOI 10.1038/nprot.2012.085
   KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768
   Kathwate G.H., 2020, SILICO DESIGN CHARAC, DOI [10.1101/2020.06.03.131755, DOI 10.1101/2020.06.03.131755]
   Kavoosi M, 2007, BIOTECHNOL BIOENG, V98, P599, DOI 10.1002/bit.21396
   Khatoon N, 2019, J BIOMOL STRUCT DYN, V37, P2381, DOI 10.1080/07391102.2018.1484815
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kohlgraf KG, 2010, FUTURE MICROBIOL, V5, P99, DOI 10.2217/FMB.09.104
   KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   Lennerz V, 2014, CANCER IMMUNOL IMMUN, V63, P381, DOI 10.1007/s00262-013-1516-5
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li TS, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000024
   Livingston B, 2002, J IMMUNOL, V168, P5499, DOI 10.4049/jimmunol.168.11.5499
   Ma JZ, 2013, BIOINFORMATICS, V29, P257, DOI 10.1093/bioinformatics/btt210
   Mahmoodi S, 2016, CURR PHARM BIOTECHNO, V17, P1100, DOI 10.2174/1389201017666160914191106
   McGillewie L, 2016, MOL BIOSYST, V12, P1457, DOI 10.1039/c6mb00077k
   Michel-Todo L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02698
   Mirjalili V, 2014, PROTEINS, V82, P196, DOI 10.1002/prot.24336
   Mirza MU, 2020, J PHARM ANAL, V10, P320, DOI 10.1016/j.jpha.2020.04.008
   Mirza MU, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43129-2
   Mirza MU, 2016, SCI REP-UK, V6, DOI 10.1038/srep37313
   Mirza MU, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111748
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Nair DT, 2002, J IMMUNOL, V168, P2371, DOI 10.4049/jimmunol.168.5.2371
   Nezafat N, 2017, MOL BIOSYST, V13, P699, DOI 10.1039/c6mb00772d
   Nielsen M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-238
   Nielsen M, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-296
   Nosrati M, 2019, J BIOMED INFORM, V93, DOI 10.1016/j.jbi.2019.103160
   Park MS, 2018, BIOMOL THER, V26, P242, DOI 10.4062/biomolther.2017.172
   PARRY J, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M236
   Perlman S, 2020, NEW ENGL J MED, V382, P760, DOI 10.1056/NEJMe2001126
   Ponomarenko J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-514
   Rapin N, 2011, BIOINFORMATICS, V27, P2013, DOI 10.1093/bioinformatics/btr335
   Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862
   Rappuoli R, 2000, CURR OPIN MICROBIOL, V3, P445, DOI 10.1016/S1369-5274(00)00119-3
   Raval A, 2012, PROTEINS, V80, P2071, DOI 10.1002/prot.24098
   RICHMOND TJ, 1984, J MOL BIOL, V178, P63, DOI 10.1016/0022-2836(84)90231-6
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   Saadi M, 2017, INFECT GENET EVOL, V51, P227, DOI 10.1016/j.meegid.2017.04.009
   Sabetian S, 2019, J BIOMOL STRUCT DYN, V37, P2546, DOI 10.1080/07391102.2018.1491890
   Saha S, 2006, NUCLEIC ACIDS RES, V34, pW202, DOI 10.1093/nar/gkl343
   Sanchez-Felipe L., 2020, BIORXIV, DOI [10.1101/2020.07.08.193045, DOI 10.1101/2020.07.08.193045]
   Scheiblhofer S, 2017, EXPERT REV VACCINES, V16, P479, DOI 10.1080/14760584.2017.1306441
   Shahid F, 2020, INFECT GENET EVOL, V80, DOI 10.1016/j.meegid.2020.104199
   Shang WL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0170-0
   Sindhu T, 2015, RSC ADV, V5, P14202, DOI 10.1039/c4ra16617e
   Slingluff CL, 2013, CLIN CANCER RES, V19, P4228, DOI 10.1158/1078-0432.CCR-13-0002
   Srivastava S, 2019, J BIOMOL STRUCT DYN, V37, P4345, DOI 10.1080/07391102.2018.1548977
   Sunita, 2020, HUM VACC IMMUNOTHER, V16, P723, DOI 10.1080/21645515.2019.1670035
   Taylor R., 1983, J MOL GRAPHICS, V1, P30
   THORNTON JM, 1986, EMBO J, V5, P409, DOI 10.1002/j.1460-2075.1986.tb04226.x
   Toledo H, 2001, VACCINE, V19, P4328, DOI 10.1016/S0264-410X(01)00111-6
   Ul Qamar MT, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2116-8
   Vajda S, 2017, PROTEINS, V85, P435, DOI 10.1002/prot.25219
   van Duin D, 2006, TRENDS IMMUNOL, V27, P49, DOI 10.1016/j.it.2005.11.005
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Weinberg A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00294
   World Health Organization, COR DIS 2019 COVID 1
   Xu D, 1997, PROTEIN ENG, V10, P999, DOI 10.1093/protein/10.9.999
   Xu JB, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020244
   Yang HM, 2005, INT J EMERG ELECTR P, V3, DOI 10.2202/1553-779X.1069
   Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213
   Yano A, 2005, VACCINE, V23, P2322, DOI 10.1016/j.vaccine.2005.01.031
   Yin DH, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1552-9
   Yu K, 2015, BIOTECHNOL ADV, V33, P155, DOI 10.1016/j.biotechadv.2014.11.005
   Zakhartchouk AN, 2007, VACCINE, V25, P136, DOI 10.1016/j.vaccine.2006.06.084
   Zhang LF, 2018, CELL MOL IMMUNOL, V15, P182, DOI 10.1038/cmi.2017.92
   Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40
   Zhi Y, 2005, VIROLOGY, V335, P34, DOI 10.1016/j.virol.2005.01.050
   Zhou WY, 2009, VACCINE, V27, P5013, DOI 10.1016/j.vaccine.2009.05.009
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu SL, 2014, APPL MICROBIOL BIOT, V98, P4107, DOI 10.1007/s00253-014-5517-x
NR 116
TC 1
Z9 1
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2079-7737
J9 BIOLOGY-BASEL
JI Biology-Basel
PD SEP
PY 2020
VL 9
IS 9
AR 296
DI 10.3390/biology9090296
PG 28
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA OD8CN
UT WOS:000580074900001
PM 32962156
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Perisic, O
AF Perisic, Ognjen
TI Recognition of Potential COVID-19 Drug Treatments through the Study of
   Existing Protein-Drug and Protein-Protein Structures: An Analysis of
   Kinetically Active Residues
SO BIOMOLECULES
LA English
DT Article
DE COVID-19; proteins; normal-modes; protein-drug interactions;
   chloroquine; ivermectin; remdesivir; sofosbuvir; boceprevir;
   alpha-difluoromethylornithine (DMFO); spike glycoprotein
ID HOT-SPOTS; BINDING; CHLOROQUINE; DYNAMICS; MOTIONS; IDENTIFICATION;
   INSIGHTS
AB We report the results of our in silico study of approved drugs as potential treatments for COVID-19. The study is based on the analysis of normal modes of proteins. The drugs studied include chloroquine, ivermectin, remdesivir, sofosbuvir, boceprevir, and alpha-difluoromethylornithine (DMFO). We applied the tools we developed and standard tools used in the structural biology community. Our results indicate that small molecules selectively bind to stable, kinetically active residues and residues adjoining them on the surface of proteins and inside protein pockets, and that some prefer hydrophobic sites over other active sites. Our approach is not restricted to viruses and can facilitate rational drug design, as well as improve our understanding of molecular interactions, in general.
C1 [Perisic, Ognjen] Big Blue Genom, Vojvode Brane 32, Belgrade 11000, Serbia.
RP Perisic, O (corresponding author), Big Blue Genom, Vojvode Brane 32, Belgrade 11000, Serbia.
EM ognjen.perisic@gmail.com
OI Reis, AlessanRSS/0000-0001-8486-7469
CR [Anonymous], 2020, MEDINCELL HAS LAUNCH
   Appleby TC, 2015, SCIENCE, V347, P771, DOI 10.1126/science.1259210
   Bahar I, 1998, PHYS REV LETT, V80, P2733, DOI 10.1103/PhysRevLett.80.2733
   Bahar I, 1999, J MOL BIOL, V285, P1023, DOI 10.1006/jmbi.1998.2371
   Bahar I, 1997, FOLD DES, V2, P173, DOI 10.1016/S1359-0278(97)00024-2
   Beck Bo Ram, 2020, Comput Struct Biotechnol J, V18, P784, DOI 10.1016/j.csbj.2020.03.025
   Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843
   Brendel W., ARXIV190400760
   Calligari P, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040445
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Davis IW, 2009, J MOL BIOL, V385, P381, DOI 10.1016/j.jmb.2008.11.010
   de Oliveira OV, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772885
   Demirel MC, 1998, PROTEIN SCI, V7, P2522, DOI 10.1002/pro.5560071205
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Ducharme J, 1996, CLIN PHARMACOKINET, V31, P257, DOI 10.2165/00003088-199631040-00003
   Elfiky AA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761882
   Webb Benjamin, 2016, Curr Protoc Protein Sci, V86, DOI [10.1002/0471140864.ps0209s50, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3, 10.1002/cpps.20]
   Flavio B., 2018, METHOD MOL BIOL, P67
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Geirhos R., 2018, ADV NEURAL INFORM PR, P7549, DOI DOI 10.5555/3327757.3327854
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gunasekaran K, 2007, J MOL BIOL, V365, P257, DOI 10.1016/j.jmb.2006.09.062
   Haliloglu T, 2005, BIOPHYS J, V88, P1552, DOI 10.1529/biophysj.104.051342
   Haliloglu T, 1997, PHYS REV LETT, V79, P3090, DOI 10.1103/PhysRevLett.79.3090
   Henry BM, 2020, AM J EMERG MED, V38, P1722, DOI 10.1016/j.ajem.2020.05.073
   Hibbs RE, 2011, NATURE, V474, P54, DOI 10.1038/nature10139
   Huang X, 2017, STRUCTURE, V25, P945, DOI 10.1016/j.str.2017.04.007
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Huta BP, 2016, CHEMMEDCHEM, V11, P277, DOI 10.1002/cmdc.201500494
   Igloi Z, 2015, J VIROL, V89, P4023, DOI 10.1128/JVI.02946-14
   Jackson LK, 2003, J BIOL CHEM, V278, P22037, DOI 10.1074/jbc.M300188200
   Kirchdoerfer RN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34171-7
   Kitchen DB, 2004, NAT REV DRUG DISCOV, V3, P935, DOI 10.1038/nrd1549
   Kozakov D, 2011, P NATL ACAD SCI USA, V108, P13528, DOI 10.1073/pnas.1101835108
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lise S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016774
   Lise S, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-365
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Lu H, 2003, BIOPHYS J, V84, P1895, DOI 10.1016/S0006-3495(03)74997-2
   Ma CL, 2020, CELL RES, V30, P678, DOI 10.1038/s41422-020-0356-z
   Moreira IS, 2007, PROTEINS, V68, P803, DOI 10.1002/prot.21396
   Moscona A, 2009, NEW ENGL J MED, V360, P953, DOI 10.1056/NEJMp0900648
   National Center for Biotechnology Information (NCBI), ACE2 ANG 1 CONV ENZ
   Noh SY, 2020, J CHEM PHYS, V153, DOI 10.1063/5.0016114
   O'Hara S., ARXIV11013354
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Palmieri L, 2020, CHARACTERISTICS COVI
   Perisic O, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11010029
   Perisic O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101810
   Perisic O, 2013, PHYS REV E, V87, DOI 10.1103/PhysRevE.87.013303
   Perisic O, 2011, PHYS REV E, V84, DOI 10.1103/PhysRevE.84.056705
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Press W.H., 2002, NUMERICAL RECIPES C
   Prussia A, 2011, INT J MOL SCI, V12, P4027, DOI 10.3390/ijms12064027
   Raveh B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018934
   Read JA, 1999, J BIOL CHEM, V274, P10213, DOI 10.1074/jbc.274.15.10213
   Sadeghi A., SOFOSBUVIR DACLATASV
   Santos-Filho Osvaldo A., 2020, J. Braz. Chem. Soc., V31, P2638, DOI 10.21577/0103-5053.20200139
   Senior AW, 2020, NATURE, V577, P706, DOI 10.1038/s41586-019-1923-7
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Tuncbag N, 2011, NAT PROTOC, V6, P1341, DOI 10.1038/nprot.2011.367
   Tuncbag N, 2009, BIOINFORMATICS, V25, P1513, DOI 10.1093/bioinformatics/btp240
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wang K, 2011, BBA-BIOMEMBRANES, V1808, P510, DOI 10.1016/j.bbamem.2010.05.006
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Weisstein E.W., SINGULAR VALUE DECOM
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xiong XL, 2018, J VIROL, V92
   Yan CH, 2020, INT FORUM ALLERGY RH, V10, P806, DOI 10.1002/alr.22579
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang LW, 2007, STRUCTURE, V15, P741, DOI 10.1016/j.str.2007.04.014
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Yu R, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106012
NR 76
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD SEP
PY 2020
VL 10
IS 9
AR 1346
DI 10.3390/biom10091346
PG 26
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA OE2BC
UT WOS:000580341600001
PM 32967116
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Bertuzzi, AF
   Marrari, A
   Gennaro, N
   Cariboni, U
   Ciccarelli, M
   Giordano, L
   Quagliuolo, VL
   Santoro, A
AF Bertuzzi, Alexia Francesca
   Marrari, Andrea
   Gennaro, Nicolo
   Cariboni, Umberto
   Ciccarelli, Michele
   Giordano, Laura
   Quagliuolo, Vittorio Lorenzo
   Santoro, Armando
TI Low Incidence of SARS-CoV-2 in Patients with Solid Tumours on Active
   Treatment: An Observational Study at a Tertiary Cancer Centre in
   Lombardy, Italy
SO CANCERS
LA English
DT Article
DE COVID-19; SARS-CoV-2; cancer care; chemotherapy; immunotherapy;
   treatment safety
ID COVID-19; MORTALITY
AB Background:The incidence and prognosis of SARS-CoV-2-positive cancer patients on active oncologic treatment remain unknown. Retrospective data from China reported higher incidence and poorer outcomes with respect to the general population. We aimed to describe the real-word incidence of SARS-CoV-2 in cancer patients and the impact of oncologic therapies on the infection.Materials & Methods:In this study, we analysed all consecutive cancer patients with solid tumours undergoing active intravenous treatment (chemotherapy, immunotherapy, targeted therapy, alone or in combination) between 21 February and 30 April 2020, in a high-volume cancer centre in Lombardy, Italy. We focused on SARS-CoV-2-positive patients, reporting on the clinical characteristics of the cancer and the infection.Results:We registered 17 SARS-CoV-2-positive patients among 1267 cancer patients on active treatment, resulting in an incidence of 1.3%. The median age was 69.5 years (range 43-79). Fourteen patients (82%) required hospitalisation for COVID-19 with a median in-hospital stay of 11.5 days (range 3-58). Fourteen of the seventeen (82%) were treated for locally advanced or metastatic disease. We could not demonstrate any correlation between SARS-CoV-2 infection and tumour or treatment type. The COVID-19-related fatality rate was 29% (5/17), which was higher than that of the general population cared for in our centre (20%).Conclusions:Active oncologic treatments do not represent a risk factor for SARS-CoV-2 infection in cancer patients. However, the prognosis of infected cancer patients appears to be worse compared with that of the non-oncologic population. Given the low number of SARS-CoV-2-positive cases and the uncertainties in risk factors that may have an impact on the prognosis, we advocate for the continuum of cancer care even during the current pandemic.
C1 [Bertuzzi, Alexia Francesca; Marrari, Andrea; Santoro, Armando] IRCCS, Med Oncol & Hematol Unit, Humanitas Clin & Res Ctr, I-20089 Milan, Italy.
   [Marrari, Andrea; Gennaro, Nicolo; Santoro, Armando] Humanitas Univ, Dept Biomed Sci, I-20072 Milan, Italy.
   [Gennaro, Nicolo] IRCCS, Radiol Unit, Humanitas Clin & Res Ctr, I-20089 Milan, Italy.
   [Cariboni, Umberto] IRCCS, Thorac Surg Unit, Humanitas Clin & Res Ctr, I-20089 Milan, Italy.
   [Ciccarelli, Michele] IRCCS, Pneumol Unit, Humanitas Clin & Res Ctr, I-20089 Milan, Italy.
   [Giordano, Laura] IRCCS, Biostat Unit, Humanitas Clin & Res Ctr, I-20089 Milan, Italy.
   [Quagliuolo, Vittorio Lorenzo] IRCCS, Sarcoma Melanoma & Rare Tumors Surg Unit, Humanitas Clin & Res Ctr, I-20089 Milan, Italy.
RP Santoro, A (corresponding author), IRCCS, Med Oncol & Hematol Unit, Humanitas Clin & Res Ctr, I-20089 Milan, Italy.; Santoro, A (corresponding author), Humanitas Univ, Dept Biomed Sci, I-20072 Milan, Italy.
EM alexia.bertuzzi@humanitas.it; andrea.marrari@humanitas.it;
   nicolo.gennaro@st.hunimed.eu; umberto.cariboni@humanitas.it;
   michele.ciccarelli@humanitas.it; laura.giordano@humanitas.it;
   vittorio.quagliuolo@humanitas.it;
   armando.santoro@cancercenter.humanitas.it
RI Santoro, Armando/J-9594-2018
OI Santoro, Armando/0000-0003-1709-9492; cariboni,
   umberto/0000-0002-8391-948X; Bertuzzi, Alexia
   Francesca/0000-0002-8933-9929; Gennaro, Nicolo/0000-0001-7259-6980
CR Francone M, 2020, EUR RADIOL, V30, P6808, DOI 10.1007/s00330-020-07033-y
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Lee LYW, 2020, LANCET, V395, P1919, DOI 10.1016/S0140-6736(20)31173-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Mei H, 2020, LANCET ONCOL, V21, P634, DOI 10.1016/S1470-2045(20)30238-2
   Ofori-Asenso R, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1047
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Watson J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1808
   Yang KY, 2020, LANCET ONCOL, V21, P904, DOI 10.1016/S1470-2045(20)30310-7
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
NR 14
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD SEP
PY 2020
VL 12
IS 9
AR 2352
DI 10.3390/cancers12092352
PG 9
WC Oncology
SC Oncology
GA OE9TR
UT WOS:000580864600001
PM 32825295
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Singh, SRK
   Thanikachalam, K
   Jabbour-Aida, H
   Poisson, LM
   Khan, G
AF Singh, Sunny R. K.
   Thanikachalam, Kannan
   Jabbour-Aida, Hiba
   Poisson, Laila M.
   Khan, Gazala
TI COVID-19 and Cancer: Lessons Learnt from a Michigan Hotspot
SO CANCERS
LA English
DT Article
DE COVID-19; Sars-CoV-2; cancer; health care disparity
AB (1) Background: Outcomes with coronavirus disease 2019 (COVID-19) have been worse in those with comorbidities and amongst minorities. In our study, we describe outcomes amongst cancer patients in Detroit, a major COVID-19 hotspot with a predominant inner-city population. (2) Methods: We retrospectively analyzed 85 patients with active invasive cancers who were infected with COVID-19. The primary outcome was death or transition to hospice. (3) Results: The majority were males (55.3%, n = 47), <= 70 years old (58.5%, n = 50), and African Americans (65.5%, n = 55). The most common primary site was prostate (18.8%, n = 16). Inpatient admission was documented in 85.5% (n = 73), ICU admission in 35.3% (n = 30), and primary outcome in 43.8% (n = 32) of hospitalized patients. On a multivariate analysis, factors associated with increased odds of a primary outcome included an age of >70 years versus <= 70 years (OR 4.7,p= 0.012) and of male gender (OR 4.8,p= 0.008). Recent cancer-directed therapy was administered in 66.7% (n = 20) of ICU admissions versus 39.5% (n = 17) of general floor admissions (Chi-squarep-value of 0.023). (4) Conclusions: High rates of mortality/transition to hospice and ICU utilization were noted amongst our patients with active invasive cancer, following a COVID-19 infection. Men and those of >70 years of age had a greater than four-fold increase in odds of death or transition to hospice.
C1 [Singh, Sunny R. K.; Thanikachalam, Kannan; Jabbour-Aida, Hiba; Khan, Gazala] Henry Ford Hlth Syst, Div Hematol & Med Oncol, Detroit, MI 48202 USA.
   [Poisson, Laila M.] Henry Ford Hosp, Dept Publ Hlth Sci, Detroit, MI 48202 USA.
RP Singh, SRK (corresponding author), Henry Ford Hlth Syst, Div Hematol & Med Oncol, Detroit, MI 48202 USA.
EM ssingh15@hfhs.org; kannanmbbs@gmail.com; hjabbou1@hfhs.org;
   lpoisso1@hfhs.org; gkhan1@hfhs.org
OI Jabbour-Aida, Hiba/0000-0001-6416-4694; Thanikachalam,
   Kannan/0000-0001-5379-8966
FU  [F11102]
FX The APC was funded by U CAN-CER VIVE (Grant number F11102).
CR Arshad S, 2020, INT J INFECT DIS, V97, P396, DOI 10.1016/j.ijid.2020.06.099
   Crawford J, 2004, CANCER-AM CANCER SOC, V100, P228, DOI 10.1002/cncr.11882
   Dai MY, 2020, CANCER DISCOV, V10, P783, DOI 10.1158/2159-8290.CD-20-0422
   Desai Aakash, 2020, JCO Glob Oncol, V6, P557, DOI 10.1200/GO.20.00097
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   He WJ, 2020, LEUKEMIA, V34, P1637, DOI 10.1038/s41375-020-0836-7
   Henry BM, 2020, CLIN CHEM LAB MED, V58, P1021, DOI 10.1515/cclm-2020-0369
   Henry BM, 2020, INT UROL NEPHROL, V52, P1193, DOI 10.1007/s11255-020-02451-9
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Inciardi RM, 2020, EUR HEART J, V41, P1821, DOI 10.1093/eurheartj/ehaa388
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Marone EM, 2020, J VASC SURG-VENOUS L, V8, P694, DOI 10.1016/j.jvsv.2020.04.004
   Martin-Moro F, 2020, BRIT J HAEMATOL, V190, pE16, DOI 10.1111/bjh.16801
   Mehta V, 2020, CANCER DISCOV, V10, P935, DOI 10.1158/2159-8290.CD-20-0516
   Miyashita H, 2020, ANN ONCOL, V31, P1088, DOI 10.1016/j.annonc.2020.04.006
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Ruan QR, 2020, INTENS CARE MED, V46, P1294, DOI 10.1007/s00134-020-06028-z
   Tian JB, 2020, LANCET ONCOL, V21, P893, DOI 10.1016/S1470-2045(20)30309-0
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu PY, 2020, ANN HEMATOL, V99, P1205, DOI 10.1007/s00277-020-04019-0
   Zhang L, 2020, ANN ONCOL, V31, P894, DOI 10.1016/j.annonc.2020.03.296
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 26
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD SEP
PY 2020
VL 12
IS 9
AR 2377
DI 10.3390/cancers12092377
PG 13
WC Oncology
SC Oncology
GA OE9TW
UT WOS:000580865100001
PM 32842584
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Morales, P
   Curtis, NL
   Zarate, SG
   Bastida, A
   Bolanos-Garcia, VM
AF Morales, Paula
   Curtis, Natalie L.
   Zarate, Sandra G.
   Bastida, Agatha
   Bolanos-Garcia, Victor M.
TI Interfering with mRNA Methylation by the 2 ' O-Methyltransferase (NSP16)
   from SARS-CoV-2 to Tackle the COVID-19 Disease
SO CATALYSTS
LA English
DT Article
DE SARS-CoV-2; drug target; NSP16/NSP10; 2 ' O-Methyltransferase
   inhibition; virtual screening
ID DRUG; PREDICTION; SOLUBILITY; MOLECULES; PAINS
AB The pandemic associated to Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2) has resulted in a huge number of deaths and infected people. Although several vaccine programmes are currently underway and have reached phase 3, and a few small size drugs repurposed to aid treatment of severe cases of COVID-19 infections, effective therapeutic options for this disease do not currently exist. NSP16 is a S-adenosyl-L-Methionine (SAM) dependent 2 ' O-Methyltransferase that converts mRNA cap-0 into cap-1 structure to prevent virus detection by cell innate immunity mechanisms. NSP16 methylates the ribose 2 ' O-position of the first nucleotide of the mRNA only in the presence of an interacting partner, the protein NSP10. This feature suggests that inhibition of the NSP16 may represent a therapeutic window to treat COVID-19. To test this idea, we performed comparative structural analyses of the NSP16 present in human coronaviruses and developed a sinefungin (SFG) similarity-based virtual screening campaign to assess the druggability of the SARS-CoV-2 NSP16 enzyme. Through these studies, we identified the SFG analogue44601604as a promising more potent inhibitor of NSP16 to limit viral replication in infected cells, favouring viral clearance.
C1 [Morales, Paula] CSIC, Inst Quim Med IQM, Juan De La Cierva 3, Madrid 28006, Spain.
   [Curtis, Natalie L.; Bolanos-Garcia, Victor M.] Oxford Brookes Univ, Fac Hlth & Life Sci, Dept Biol & Med Sci, Oxford OX3 OBP, England.
   [Zarate, Sandra G.] Univ Mayor Real & Pontifice San Francisco Xavier, Fac Tecnol, Carrera Ingn Quim, Regimiento Campos 180,Casilla 60, Sucre, Bolivia.
   [Bastida, Agatha] CSIC, Dept Quim Bioorgan, Inst Quim Organ Gen IQOG, Juan De La Cierva 3, Madrid 28006, Spain.
RP Bolanos-Garcia, VM (corresponding author), Oxford Brookes Univ, Fac Hlth & Life Sci, Dept Biol & Med Sci, Oxford OX3 OBP, England.; Bastida, A (corresponding author), CSIC, Dept Quim Bioorgan, Inst Quim Organ Gen IQOG, Juan De La Cierva 3, Madrid 28006, Spain.
EM paula.morales@iqm.csic.es; 17083926@brookes.ac.uk;
   zarate.sandra@usfx.bo; agatha.bastida@csic.es;
   vbolanos-garcia@brookes.ac.uk
RI Morales, Paula/H-5887-2015; Morales, Paula/R-9647-2019
OI Morales, Paula/0000-0002-6209-8600; Morales, Paula/0000-0002-6209-8600;
   Bastida, Agatha/0000-0002-5141-9595; Bolanos-Garcia, Victor
   M./0000-0003-2700-1479
FU CSICConsejo Superior de Investigaciones Cientificas (CSIC)
   [CSIC-COV19-013]; MICINNSpanish Government [PID2019-105337RB-C21]
FX This research was funded by CSIC (CSIC-COV19-013) and MICINN
   (PID2019-105337RB-C21).
CR Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Capuzzi SJ, 2017, J CHEM INF MODEL, V57, P417, DOI 10.1021/acs.jcim.6b00465
   Chen Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002294
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Decroly E, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002059
   Deng Z, 2004, J MED CHEM, V47, P337, DOI 10.1021/jm030331x
   European Central Bank, 2020, EMA ADV CONT US MED, P1
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Greenwood JR, 2010, J COMPUT AID MOL DES, V24, P591, DOI 10.1007/s10822-010-9349-1
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Hyde JL, 2015, VIROLOGY, V479, P66, DOI 10.1016/j.virol.2015.01.019
   Jorgensen WL, 2002, ADV DRUG DELIVER REV, V54, P355, DOI 10.1016/S0169-409X(02)00008-X
   Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951
   Krafcikova P., 2020, STRUCTURAL ANAL SARS, V11, P1
   Lipinski CA, 2000, J PHARMACOL TOX MET, V44, P235, DOI 10.1016/S1056-8719(00)00107-6
   Perlman S, 2009, NAT REV MICROBIOL, V7, P439, DOI 10.1038/nrmicro2147
   Ramanathan A, 2016, NUCLEIC ACIDS RES, V44, P7511, DOI 10.1093/nar/gkw551
   Robert X, 2014, NUCLEIC ACIDS RES, V42, pW320, DOI 10.1093/nar/gku316
   Rosas-Lemus M., 2020, STRUCTURE SARS COV 2, P1
   Snijder EJ, 2016, ADV VIRUS RES, V96, P59, DOI 10.1016/bs.aivir.2016.08.008
   Warren GL, 2006, J MED CHEM, V49, P5912, DOI 10.1021/jm050362n
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
NR 23
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4344
J9 CATALYSTS
JI Catalysts
PD SEP
PY 2020
VL 10
IS 9
AR 1023
DI 10.3390/catal10091023
PG 13
WC Chemistry, Physical
SC Chemistry
GA OE7GW
UT WOS:000580695700001
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Siewert, CD
   Haas, H
   Cornet, V
   Nogueira, SS
   Nawroth, T
   Uebbing, L
   Ziller, A
   Al-Gousous, J
   Radulescu, A
   Schroer, MA
   Blanchet, CE
   Svergun, DI
   Radsak, MP
   Sahin, U
   Langguth, P
AF Siewert, Christian D.
   Haas, Heinrich
   Cornet, Vera
   Nogueira, Sara S.
   Nawroth, Thomas
   Uebbing, Lukas
   Ziller, Antje
   Al-Gousous, Jozef
   Radulescu, Aurel
   Schroer, Martin A.
   Blanchet, Clement E.
   Svergun, Dmitri, I
   Radsak, Markus P.
   Sahin, Ugur
   Langguth, Peter
TI Hybrid Biopolymer and Lipid Nanoparticles with Improved Transfection
   Efficacy for mRNA
SO CELLS
LA English
DT Article
DE vaccination; Covid-19; cancer immunotherapy; RNA; cationic polymer;
   cationic lipid; lipid-polymer hybrid nanoparticles; small angle
   scattering
ID X-RAY-SCATTERING; ANGLE NEUTRON-SCATTERING; GENE DELIVERY; IN-VITRO;
   DNA; COMPLEXES; CRYSTALLOGRAPHY; NANOSTRUCTURE; VACCINES; PLATFORM
AB Hybrid nanoparticles from lipidic and polymeric components were assembled to serve as vehicles for the transfection of messenger RNA (mRNA) using different portions of the cationic lipid DOTAP (1,2-Dioleoyl-3-trimethylammonium-propane) and the cationic biopolymer protamine as model systems. Two different sequential assembly approaches in comparison with a direct single-step protocol were applied, and molecular organization in correlation with biological activity of the resulting nanoparticle systems was investigated. Differences in the structure of the nanoparticles were revealed by thorough physicochemical characterization including small angle neutron scattering (SANS), small angle X-ray scattering (SAXS), and cryogenic transmission electron microscopy (cryo-TEM). All hybrid systems, combining lipid and polymer, displayed significantly increased transfection in comparison to lipid/mRNA and polymer/mRNA particles alone. For the hybrid nanoparticles, characteristic differences regarding the internal organization, release characteristics, and activity were determined depending on the assembly route. The systems with the highest transfection efficacy were characterized by a heterogenous internal organization, accompanied by facilitated release. Such a system could be best obtained by the single step protocol, starting with a lipid and polymer mixture for nanoparticle formation.
C1 [Siewert, Christian D.; Cornet, Vera; Nawroth, Thomas; Uebbing, Lukas; Ziller, Antje; Al-Gousous, Jozef; Langguth, Peter] Johannes Gutenberg Univ Mainz, Dept Pharmaceut & Biopharmaceut, D-55131 Mainz, Germany.
   [Haas, Heinrich; Nogueira, Sara S.; Sahin, Ugur] BioNTech RNA Pharmaceut, D-55131 Mainz, Germany.
   [Radulescu, Aurel] Heinz Maier Leibnitz Ctr MLZ, Julich Ctr Neutron Sci JCNS, D-85748 Garching, Germany.
   [Schroer, Martin A.; Blanchet, Clement E.; Svergun, Dmitri, I] European Mol Biol Lab EMBL Hamburg Outstn, Deutsch Elektronen Synchrotron DESY, D-22603 Hamburg, Germany.
   [Radsak, Markus P.] Johannes Gutenberg Univ Mainz, Johannes Gutenberg Univ Med Ctr, Dept Med 3, D-55131 Mainz, Germany.
   [Sahin, Ugur] Johannes Gutenberg Univ Mainz, Johannes Gutenberg Univ Med Ctr, Dept Med 3, Exp Oncol, D-55131 Mainz, Germany.
RP Siewert, CD (corresponding author), Johannes Gutenberg Univ Mainz, Dept Pharmaceut & Biopharmaceut, D-55131 Mainz, Germany.
EM csiewert@uni-mainz.de; Heinrich.Haas@biontech.de; vcornet@uni-mainz.de;
   Sara.Nogueira@biontech.de; nawroth@uni-mainz.de; L.uebbing@uni-mainz.de;
   Zillerantje@web.de; joalgous@uni-mainz.de; a.radulescu@fz-juelich.de;
   martin.schroer@embl-hamburg.de; clement.blanchet@embl-hamburg.de;
   dmitri.svergun@embl-hamburg.de; radsak@uni-mainz.de; sahin@uni-mainz.de;
   langguth@uni-mainz.de
RI ; Radsak, Markus/L-3651-2013
OI Schroer, Martin/0000-0002-0747-3965; Uebbing, Lukas/0000-0003-0568-9540;
   Radulescu, Aurel/0000-0002-6050-0176; Radsak,
   Markus/0000-0002-3991-5721; Siewert, Christian/0000-0001-9246-6673;
   Haas, Heinrich/0000-0002-5517-5970
FU Max Planck Graduate Center (MPGC-Mainz); BMBFFederal Ministry of
   Education & Research (BMBF) [FKZ: 131A026C]; Deutsche
   ForschungsgemeinschaftGerman Research Foundation (DFG) [SFB 1066]
FX This work was supported by Max Planck Graduate Center (MPGC-Mainz), the
   BMBF (FKZ: 131A026C), and the "Deutsche Forschungsgemeinschaft" (SFB
   1066).
CR Aied A, 2013, DRUG DISCOV TODAY, V18, P1090, DOI 10.1016/j.drudis.2013.06.014
   Akinc A, 2019, NAT NANOTECHNOL, V14, P1084, DOI 10.1038/s41565-019-0591-y
   Arangoa MA, 2003, GENE THER, V10, P5, DOI 10.1038/sj.gt.3301840
   Ashkar R, 2018, ACTA CRYSTALLOGR D, V74, P1129, DOI 10.1107/S2059798318017503
   Badwaik VD, 2016, BIOMATERIALS, V84, P86, DOI 10.1016/j.biomaterials.2015.11.032
   Bellettini IC, 2017, SOFT MATTER, V13, P2609, DOI 10.1039/c6sm02835g
   Blanchet CE, 2015, J APPL CRYSTALLOGR, V48, P431, DOI 10.1107/S160057671500254X
   Blanchet CE, 2013, ANNU REV PHYS CHEM, V64, P37, DOI 10.1146/annurev-physchem-040412-110132
   Corsi J, 2010, LANGMUIR, V26, P12119, DOI 10.1021/la101448m
   Dave V, 2019, J MICROBIOL METH, V160, P130, DOI 10.1016/j.mimet.2019.03.017
   Franke D, 2012, NUCL INSTRUM METH A, V689, P52, DOI 10.1016/j.nima.2012.06.008
   GAST FU, 1991, BIOCHEMISTRY-US, V30, P4268, DOI 10.1021/bi00231a024
   Grabbe S, 2016, NANOMEDICINE-UK, V11, P2723, DOI 10.2217/nnm-2016-0275
   Grudzien-Nogalska Ewa, 2013, Methods Mol Biol, V969, P55, DOI 10.1007/978-1-62703-260-5_4
   Guan S, 2017, GENE THER, V24, P133, DOI 10.1038/gt.2017.5
   Hadinoto K, 2013, EUR J PHARM BIOPHARM, V85, P427, DOI 10.1016/j.ejpb.2013.07.002
   Hammouda B, 2010, J APPL CRYSTALLOGR, V43, P716, DOI 10.1107/S0021889810015773
   Hart S, 2017, GENE THER, V24, P121, DOI 10.1038/gt.2017.15
   Hoerr I, 2000, EUR J IMMUNOL, V30, P1
   IBEL K, 1975, J MOL BIOL, V93, P255, DOI 10.1016/0022-2836(75)90131-X
   Islam MA, 2015, BIOMATER SCI-UK, V3, P1519, DOI 10.1039/c5bm00198f
   JACROT B, 1976, REP PROG PHYS, V39, P911, DOI 10.1088/0034-4885/39/10/001
   Kauffman KJ, 2016, J CONTROL RELEASE, V240, P227, DOI 10.1016/j.jconrel.2015.12.032
   Keswani RK, 2013, MOL PHARMACEUT, V10, P1725, DOI 10.1021/mp300561y
   Kiselev MA, 2017, BBA-GEN SUBJECTS, V1861, P3700, DOI 10.1016/j.bbagen.2016.04.022
   KNOLL W, 1981, J APPL CRYSTALLOGR, V14, P191, DOI 10.1107/S0021889881009102
   Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78
   Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779
   Kranz LM, 2016, NATURE, V534, P396, DOI 10.1038/nature18300
   KRATKY O, 1949, RECL TRAV CHIM PAY B, V68, P1106
   Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426
   Kucerka N, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.051903
   Kuhn AN, 2010, GENE THER, V17, P961, DOI 10.1038/gt.2010.52
   Kuntsche J, 2011, INT J PHARMACEUT, V417, P120, DOI 10.1016/j.ijpharm.2011.02.001
   Li S, 1998, GENE THER, V5, P930, DOI 10.1038/sj.gt.3300683
   Li S, 1997, GENE THER, V4, P891, DOI 10.1038/sj.gt.3300482
   MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077
   Mandal B, 2013, NANOMED-NANOTECHNOL, V9, P474, DOI 10.1016/j.nano.2012.11.010
   Midoux P, 2015, EXPERT REV VACCINES, V14, P221, DOI 10.1586/14760584.2015.986104
   Mukherjee A, 2019, INT J NANOMED, V14, P1937, DOI 10.2147/IJN.S198353
   Nchinda Godwin, 2002, BMC Biotechnol, V2, P12, DOI 10.1186/1472-6750-2-12
   Pabst G, 2010, CHEM PHYS LIPIDS, V163, P460, DOI 10.1016/j.chemphyslip.2010.03.010
   Pascolo Steve, 2008, V183, P221
   Peng SF, 2010, BIOMATERIALS, V31, P5660, DOI 10.1016/j.biomaterials.2010.03.059
   POROD G, 1951, KOLLOID Z Z POLYM, V124, P83, DOI 10.1007/BF01512792
   Pozzi D, 2013, MOL PHARMACEUT, V10, P4654, DOI 10.1021/mp400470p
   Putnam CD, 2007, Q REV BIOPHYS, V40, P191, DOI 10.1017/S0033583507004635
   Qian S., 2013, PLOS ONE, V8, DOI [10.1371/annotation/3e3f4f53-4492-4c6e-8426-364bd585b9b8, DOI 10.1371/ANNOTATION/3E3F4F53-4492-4C6E-8426-364BD585B9B8]
   Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810
   Radulescu A, 2012, J PHYS CONF SER, V351, DOI 10.1088/1742-6596/351/1/012026
   Reichmuth AM, 2016, THER DELIV, V7, P319, DOI 10.4155/tde-2016-0006
   Rosenblum D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03705-y
   Rosigkeit S, 2018, MOL PHARMACEUT, V15, P3909, DOI 10.1021/acs.molpharmaceut.8b00370
   Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003
   Scheel B, 2005, EUR J IMMUNOL, V35, P1557, DOI 10.1002/eji.200425656
   Sears V.F., 2006, NEUTRON NEWS, V3, P26, DOI [DOI 10.1080/10448639208218770, 10.1080/10448639208218770]
   Siewert C, 2019, BIOMATERIALS, V192, P612, DOI 10.1016/j.biomaterials.2018.10.020
   Sorgi FL, 1997, GENE THER, V4, P961, DOI 10.1038/sj.gt.3300484
   Stuhrmann HB, 2008, ACTA CRYSTALLOGR A, V64, P181, DOI 10.1107/S0108767307046569
   Tavernier G, 2011, J CONTROL RELEASE, V150, P238, DOI 10.1016/j.jconrel.2010.10.020
   Thaplyal P, 2014, METHOD ENZYMOL, V549, P189, DOI 10.1016/B978-0-12-801122-5.00009-X
   Ueno NT, 2002, CANCER RES, V62, P6712
   Wang YH, 2013, MOL THER, V21, P358, DOI 10.1038/mt.2012.250
   Weisman S, 2004, BIOPHYS J, V87, P609, DOI 10.1529/biophysj.103.033480
   Yang B, 2015, BIOMACROMOLECULES, V16, P457, DOI 10.1021/bm501519u
   Zhang Y, 2014, J CONTROL RELEASE, V174, P7, DOI 10.1016/j.jconrel.2013.11.006
   Ziller A, 2018, MOL PHARMACEUT, V15, P642, DOI 10.1021/acs.molpharmaceut.7b01022
   Zohra FT, 2009, BIOMATERIALS, V30, P4006, DOI 10.1016/j.biomaterials.2009.02.050
   Zohra FT, 2012, BIOL PHARM BULL, V35, P111, DOI 10.1248/bpb.35.111
NR 69
TC 0
Z9 0
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD SEP
PY 2020
VL 9
IS 9
AR 2034
DI 10.3390/cells9092034
PG 19
WC Cell Biology
SC Cell Biology
GA OE7IH
UT WOS:000580699400001
PM 32899484
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Esam, Z
AF Esam, Zohreh
TI A proposed mechanism for the possible therapeutic potential of Metformin
   in COVID-19
SO DIABETES RESEARCH AND CLINICAL PRACTICE
LA English
DT Letter
DE Metformin; COVID-19; SARS-CoV-2; V-ATPase; eNHEs
AB The whole world is facing a tough time these days struggling against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). There is not any specific effective drug for this viral infection. Thus, we are trying to treat patients with non-specific drug cocktails. Metformin, as a strong base, a potential regulator of Vacuolar ATPase (V-ATPase) and endosomal Na+/H+ exchangers (eNHEs), additionally a regenerative agent for lung fibrosis, seems to be beneficial for patients in acute, chronic and recovery phases of COVID-19. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Esam, Zohreh] Mazandaran Univ Med Sci, Dept Med Chem, Pharmaceut Sci Res Ctr, Sari, Iran.
   [Esam, Zohreh] Islamic Azad Univ, Fac Pharm, Dept Med Chem, Ayatollah Amoli Branch, Amol, Iran.
RP Esam, Z (corresponding author), Mazandaran Univ Med Sci, Dept Med Chem, Pharmaceut Sci Res Ctr, Sari, Iran.
EM z.esam@mazums.ac.ir
CR Chatterjee Pranab, 2020, Indian J Med Res, V151, P147, DOI 10.4103/ijmr.IJMR_519_20
   Glossmann HH, 2019, GERONTOLOGY, V65, P581, DOI 10.1159/000502257
   HO TJ, 2020, CHIN MED J, V15, DOI DOI 10.1097/CM9.0000000000000839
   Kim J, 2017, IUBMB LIFE, V69, P459, DOI 10.1002/iub.1633
   KROGSTAD DJ, 1987, AM J TROP MED HYG, V36, P213, DOI 10.4269/ajtmh.1987.36.213
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Magro G, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101685
   Rangarajan S, 2018, NAT MED, V24, P1121, DOI 10.1038/s41591-018-0087-6
   Sharma S, J PREPROOFS, DOI [10.1016/j.diabres.2020.108183., DOI 10.1016/J.DIABRES.2020.108183]
   Zhang CS, 2016, CELL METAB, V24, P521, DOI 10.1016/j.cmet.2016.09.003
NR 10
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0168-8227
EI 1872-8227
J9 DIABETES RES CLIN PR
JI Diabetes Res. Clin. Pract.
PD SEP
PY 2020
VL 167
AR 108282
DI 10.1016/j.diabres.2020.108282
PG 2
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA OD8AL
UT WOS:000580069500002
PM 32592841
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Liu, DF
   Lan, LJ
   Luo, DX
   Zhao, BN
   Wei, G
   He, YS
   Zhang, RQ
   Liu, YL
AF Liu, Dafeng
   Lan, Lijuan
   Luo, Dongxia
   Zhao, Bennan
   Wei, Guo
   He, Yinsheng
   Zhang, Renqing
   Liu, Yaling
TI Lymphocyte subsets with the lowest decline at baseline and the slow
   lowest rise during recovery in COVID-19 critical illness patients with
   diabetes mellitus
SO DIABETES RESEARCH AND CLINICAL PRACTICE
LA English
DT Article
DE Coronavirus disease 2019 (COVID-19); Diabetes mellitus; Lymphocyte
   subsets; Dynamic change
ID T-CELLS; MOUSE MODEL; RESPONSES; PROTEIN
AB Background: Host dysregulation of immune response was highly involved in the pathological process of Coronavirus disease 2019 (COVID-19), especially COVID-19 severe cases with DM.
   Aim: In this study we aimed at the dynamic change of peripheral lymphocyte and subsets during COVID-19 covery.
   Methods: The peripheral lymphocyte and subsets of 95 confirmed cases with COVID-19 from baseline to four weeks were compared between critical illness and non-critical illness cases with or without DM.
   Results: The dynamic characteristics of lymphocyte and subsets in COVID-19 patients was that it reduced significantly at one week, rapidly elevated to the peak at two weeks after onset, then gradually declined during recovery. The COVID-19 critical illness patients with DM had the lowest decline at one week and the slow lowest rise at two weeks after onset, while COVID-19 non-critical illness patients with DM had the rapid highest rise at two weeks after onset, both of them had similar lymphocyte and subsets at five weeks after onset and lower than those patients without DM.
   Conclusions: These findings provide a reference for clinicians that for COVID-19 patients with DM and the lowest decline of lymphocyte and subsets, immunomodulatory therapy as soon as possible might avoid or slow down disease progression; moreover for COVID-19 critical illness patients with or without DM and non-critical illness patients with DM, continuous immunomodulatory therapy in later stages of disease might speed up virus clearance, shorten hospital stay, improve disease prognosis in COVID-19 critical illness patients with DM. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Liu, Dafeng; Lan, Lijuan; Zhao, Bennan; He, Yinsheng; Liu, Yaling] Publ & Hlth Clin Ctr Chengdu, Dept Internal Med, Chengdu, Peoples R China.
   [Luo, Dongxia] Publ & Hlth Clin Ctr Chengdu, Dept Sci & Educ, Chengdu, Peoples R China.
   [Wei, Guo] Publ & Hlth Clin Ctr Chengdu, Dept Surg Ward 2, Chengdu, Peoples R China.
   [Zhang, Renqing] Publ & Hlth Clin Ctr Chengdu, Dept Vice Headmasters Off, Chengdu, Peoples R China.
RP Liu, DF; Liu, YL (corresponding author), Publ & Hlth Clin Ctr Chengdu, Dept Internal Med, Chengdu, Peoples R China.; Zhang, RQ (corresponding author), Publ & Hlth Clin Ctr Chengdu, Dept Vice Headmasters Off, Chengdu, Peoples R China.
EM ldf312@126.com; cdzrq33@163.com; cdlyl@sina.com
FU Thirteenth Five-Year Project on Tackling Key Problems of National
   Science and Technology [2017ZX10305501008]; Sichuan Science and
   Technology Program [2020YFS0564]; Chengdu Municipal Science and
   Technology Bureau Science and Technology Huimin Major Demonstration
   Project [00092]; Sichuan Province Health Commission [17PJ070]; Chengdu
   Municipal Health Commission [2019079]
FX This research was supported by the Thirteenth Five-Year Project on
   Tackling Key Problems of National Science and Technology
   (2017ZX10305501008), Sichuan Science and Technology Program
   (2020YFS0564), Chengdu Municipal Science and Technology Bureau Science
   and Technology Huimin Major Demonstration Project (00092), the Sichuan
   Province Health Commission (17PJ070), Chengdu Municipal Health
   Commission (2019079).
CR Bunte K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143394
   Cecere TE, 2012, VIRUSES-BASEL, V4, P833, DOI 10.3390/v4050833
   Channappanavar R, 2014, J VIROL, V88, P11034, DOI 10.1128/JVI.01505-14
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   [中华医学会糖尿病学分会 Chinese Diabetes Society], 2018, [中国实用内科杂志, Chinese Journal of Practical Internal Medicine], V38, P292
   Dutzan N, 2019, ADV EXP MED BIOL, V1197, P107, DOI 10.1007/978-3-030-28524-1_9
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Ji W, 2020, J MED VIROL, V92, P433, DOI 10.1002/jmv.25682
   Liu DF, 2020, BMC INFECT DIS, DOI 10.21203/rs.3.rs-20385/v1
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Maloir Q, 2018, Rev Med Liege, V73, P370
   Manni ML, 2014, EXPERT REV RESP MED, V8, P25, DOI 10.1586/17476348.2014.854167
   Mubarak A, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/6491738
   National Health Commission of the People's Republic of China, 7 TRIAL VERS NOV COR
   National Health Commission of the People's Republic of China, 2020, UPD EP SIT NEW COR P
   Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063
   Pascal KE, 2015, P NATL ACAD SCI USA, V112, P8738, DOI 10.1073/pnas.1510830112
   Qin C, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa248., DOI 10.1093/CID/CIAA248.]
   WAMG Xiao-mei, 2003, J CHIN PHYS, V5, P1308
   World Health Organization, 2020, 89 WHO
   Yang Y, 2005, BIOCHEM J, V392, P135, DOI 10.1042/BJ20050698
   Zhao JC, 2014, P NATL ACAD SCI USA, V111, P4970, DOI 10.1073/pnas.1323279111
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0168-8227
EI 1872-8227
J9 DIABETES RES CLIN PR
JI Diabetes Res. Clin. Pract.
PD SEP
PY 2020
VL 167
AR 108341
DI 10.1016/j.diabres.2020.108341
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA OD8AL
UT WOS:000580069500009
PM 32707212
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Majeed, J
   Ajmera, P
   Goyal, RK
AF Majeed, Jaseela
   Ajmera, Puneeta
   Goyal, Ramesh K.
TI Delineating clinical characteristics and comorbidities among 206
   COVID-19 deceased patients in India: Emerging significance of renin
   angiotensin system derangement
SO DIABETES RESEARCH AND CLINICAL PRACTICE
LA English
DT Article
DE COVID-19; Angiotensin Converting Enzyme 2 (ACE-2); Renin Angiotensin
   System (RAS); Hypertension; Diabetes; Cardiovascular diseases
AB Aim: While there are rampant deaths reported worldwide due to novel corona virus (COVID-19) on one side, hypertension, diabetes and renal failure are emerging comorbidities with mortality risk due to respiratory failure on the other side. The link of these morbidities with renin angiotensin system (RAS) and angiotensin converting enzyme-2 (ACE2) as the site of the multiplication of COVID-19 has widely been accepted. The objective of this research report was to delineate the clinical characteristics with COVID-19 infection with RAS and to consider its significance not just for the search of novel antiviral drugs, but for the management and prevention of death of patients with COVID-19.
   Methods: It was a retrospective case series analysis of demographic and clinical data with associated comorbidities of 206 deaths reported in India up to 10th April 2020. The data were available from the official release from Ministry of Health and Family welfare, Government of India. This was followed by a literature search to correlate the available evidence for their possible relationship with RAS.
   Results: The demographic data were consistent with those reported from other countries. The death (53.4%) was more common in patients with age above 60 years and men (69.3%) were more susceptible as compared to women (30.68%).We found that 50.5% of the deceased patients had pre-existing comorbidities. Diabetes and hypertension were the major comorbidities in 27.8% and 22.1% of the deceased cases respectively. Although respiratory and cardiac problems were prevalent at the time of death, the pre-existing pulmonary disease was comparatively less prevalent. Only 13.6% of the deceased were having pre-existing respiratory problems and 6.2% had cardiac ailments. We could correlate the reports that RAS plays a significant role in the prognosis of the disease.
   Conclusions: Patients with cardiovascular diseases, diabetes mellitus and hypertension are at greater risk for developing COVID-19 infection. There may be massive derangement of the entire RAS after the attack of COVID-19 and hence, patients with these pre-existing comorbidities and on ACE inhibitors or angiotensin receptor blockers should be monitored carefully considering the role of RAS in the prognosis of COVID-19 infections. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Majeed, Jaseela] Delhi Pharmaceut Sci & Res Univ, Sch Allied Hlth Sci, Dept Pharmaceut Management, New Delhi, India.
   [Ajmera, Puneeta] Delhi Pharmaceut Sci & Res Univ, Sch Allied Hlth Sci, Dept Publ Hlth, New Delhi, India.
   [Goyal, Ramesh K.] Delhi Pharmaceut Sci & Res Univ, Sch Pharmaceut Sci, Dept Pharmacol, New Delhi, India.
RP Goyal, RK (corresponding author), Delhi Pharmaceut Sci, Pharmacol, New Delhi, India.
EM vc@dpsru.edu.in
CR [Anonymous], 2020, NEWYORK TIMES   0123
   Badawi A, 2016, INT J INFECT DIS, V49, P129, DOI 10.1016/j.ijid.2016.06.015
   Chen T, 2019, BMJ-BRIT MED J, V2020, P368
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Corley MJ, 2020, DNA METHYLATION ANAL
   Fang L., 2020, LANCET RESP MED
   Ferrario CM, 2014, CLIN SCI, V126, P461, DOI 10.1042/CS20130400
   Fisher D, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01533-w
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gumbrecht J, PANDEMIC WHO SAYS CO
   HSU CW, 2014, NAT COMMUN, V5, DOI DOI 10.1038/NCOMMS4594
   John Hopkins University, 2020, COVID 19 DASH BOARD
   Jordan RE, 2020, COVID 19 RISK FACTOR
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Li XC, 2017, PHARMACOL RES, V125, P21, DOI 10.1016/j.phrs.2017.06.005
   Mullen B., COVID 19 CLIN GUIDAN
   Patel VB, 2016, CIRC RES, V118, P1313, DOI 10.1161/CIRCRESAHA.116.307708
   Ramzy A, 2020, NY TIMES
   Sawalha AH, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108410
   SUN ZD, 2020, NAT REV CARDIOL, P1, DOI DOI 10.1145/3377644.3377649
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Tikellis Chris, 2012, Int J Pept, V2012, P256294, DOI 10.1155/2012/256294
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   World of meters.com, 2020, COVID 19 COR OV BAS
   Worldometer, 2020, COR CAS DEATHS MORT
   Wu J, 2020, NEUROCOMPUTING, V395, P78, DOI [10.1080/17435390.2020.1831639, 10.1016/j.neucom.2020.02.017]
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0168-8227
EI 1872-8227
J9 DIABETES RES CLIN PR
JI Diabetes Res. Clin. Pract.
PD SEP
PY 2020
VL 167
AR 108349
DI 10.1016/j.diabres.2020.108349
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA OD8AL
UT WOS:000580069500011
PM 32712124
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Yan, AF
   Sun, XM
   Zheng, JG
   Mi, BB
   Zuo, H
   Ruan, GR
   Hussain, A
   Wang, YF
   Shi, ZM
AF Yan, Alice F.
   Sun, Xiaomin
   Zheng, Jinge
   Mi, Baibing
   Zuo, Hui
   Ruan, Guorui
   Hussain, Akhtar
   Wang, Youfa
   Shi, Zumin
TI Perceived risk, behavior changes and Health-related outcomes during
   COVID-19 pandemic: Findings among adults with and without diabetes in
   China
SO DIABETES RESEARCH AND CLINICAL PRACTICE
LA English
DT Article
DE COVID-19; Pandemic; Diabetes; Lifestyle; China
ID CORONAVIRUS; OBESITY; PREVENTION; ALCOHOL
AB Aims: To examine perceived infection risk of COVID-19 and the health and related behavior changes among people with diabetes, compared with people without diabetes, and to examine factors associated with self-reported health during the national quarantine period in China.
   Methods: The 2020 China COVID-19 Survey is an anonymous 74-item survey administered via social media across China. A national sample of 10,545 adults in all 31 provinces in mainland China provided data on sociodemographic characteristics, awareness, attitudes towards COVID-19, lifestyle factors, and health outcomes during the quarantine. Regression models tested associations among study variables adjusting for covariates.
   Results: Among the 9,016 total participants (42.6% men and 57.4% women), 585 reported having diagnosed diabetes and 8,431 had no diabetes. Participants with diabetes perceived themselves to be at higher risk and were more worried about being infected with COVID-19 when compared to non-diabetic individuals (p < 0.001). During the COVID-19 pandemic, participants with diabetes were more likely to experience food and drug shortages and to increase their physical activity, compared to their counterparts. Among diabetic respondents, a high proportion of current smokers (74.1%) and drinkers (68.5%) reported increased amounts of smoking and drinking. People with diabetes were 11% less likely to report excellent or very good health. Having 150 min/week physical activity was positively associated with excellent or very good health (prevalence ratio, PR = 1.14, 95%CI 1.11-1.16).
   Conclusions: A high proportion of people with diabetes perceived risk of COVID-19 infection and increased their smoking and drinking during the pandemic. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Yan, Alice F.] Med Coll Wisconsin, Dept Med, Div Gen Internal Med, Ctr Adv Populat Sci, Milwaukee, WI 53226 USA.
   [Sun, Xiaomin; Zheng, Jinge; Mi, Baibing; Ruan, Guorui; Wang, Youfa] Xi An Jiao Tong Univ, Sch Publ Hlth, Global Hlth Inst, Xian, Peoples R China.
   [Mi, Baibing] Xi An Jiao Tong Univ, Hlth Sci Ctr, Xian, Peoples R China.
   [Zuo, Hui] Soochow Univ, Sch Publ Hlth, Med Coll, Suzhou, Jiangsu, Peoples R China.
   [Hussain, Akhtar] Nord Univ, N-8049 Bodo, Norway.
   [Wang, Youfa] Ball State Univ, Coll Hlth, Fisher Inst Hlth & Well Being, Syst Oriented Global Childhood Obes Intervent Pro, Muncie, IN 47306 USA.
   [Shi, Zumin] Qatar Univ, Coll Hlth Sci, Human Nutr Dept, QU Hlth, Doha, Qatar.
RP Wang, YF (corresponding author), Xi An Jiao Tong Univ, Sch Publ Hlth, Global Hlth Inst, Xian, Peoples R China.; Shi, ZM (corresponding author), Qatar Univ, Coll Hlth Sci, QU Hlth, Doha, Qatar.
EM youfawant@gmail.com; zumin@qu.edu.qa
RI Shi, Zumin/A-1093-2009; Yan, Alice/AAC-4224-2019
OI Shi, Zumin/0000-0002-3099-3299; Yan, Alice/0000-0002-3162-3687
FU China Medical Board [16-262]; Xi'an Jiaotong University Global Health
   Institute
FX The project is supported in part by research grants from the China
   Medical Board (Grant number: 16-262) and Xi'an Jiaotong University
   Global Health Institute.
CR American Diabetes Association, 2020, COVID 19 IMP PEOPL D
   Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21
   Bornstein SR, 2020, LANCET DIABETES ENDO, V8, P546, DOI 10.1016/S2213-8587(20)30152-2
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen ZM, 2005, INT J EPIDEMIOL, V34, P1243, DOI 10.1093/ije/dyi174
   Cullmann M, 2012, DIABETIC MED, V29, P441, DOI 10.1111/j.1464-5491.2011.03450.x
   Da BL., 2020, HEPATOLOGY
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Dryhurst S, 2020, J RISK RES, V23, P994, DOI 10.1080/13669877.2020.1758193
   Engin AB, 2020, ENVIRON TOXICOL PHAR, V78, DOI 10.1016/j.etap.2020.103411
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Gupta R, 2020, DIABETES METAB SYND, V14, P211, DOI 10.1016/j.dsx.2020.03.002
   Hays RD, 2015, J GEN INTERN MED, V30, P1511, DOI 10.1007/s11606-015-3290-x
   Hu C, 2018, DIABETES, V67, P3, DOI 10.2337/dbi17-0013
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iqbal M., 2020, WECHAT REVENUE USAGE
   Lee PH, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-115
   Najibi N, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7236-9
   Parascandola M, 2019, TRANSL LUNG CANCER R, V8, pS21, DOI 10.21037/tlcr.2019.03.12
   Petersen MR, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-9
   Pietraszek A, 2010, NUTR METAB CARDIOVAS, V20, P366, DOI 10.1016/j.numecd.2010.05.001
   Saeedi P, 2019, GLOBAL REGIONAL DIAB, P157
   Sarkar D, 2015, ALCOHOL RES-CURR REV, V37, P153
   Tamara A, 2020, DIABETES METAB SYND, V14, P655, DOI 10.1016/j.dsx.2020.05.020
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang LM, 2017, JAMA-J AM MED ASSOC, V317, P2515, DOI 10.1001/jama.2017.7596
   Wang Y, 2017, EUR J CLIN NUTR, V71, P149, DOI 10.1038/ejcn.2016.171
   Wang Youfa, 2019, Zhonghua Yufang Yixue Zazhi, V53, P875, DOI 10.3760/cma.j.issn.0253-9624.2019.09.003
   Wang YF, 2019, LANCET GLOB HEALTH, V7, pE1166, DOI 10.1016/S2214-109X(19)30276-1
   Wolf MS, 2020, ANN INTERN MED
   Yan Y, 2020, BMJ OPEN DIAB RES CA, V8
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yao Y, 2019, INT J EQUITY HEALTH, V18, DOI 10.1186/s12939-019-0986-2
   Zhang Y, 2020, DIABETES OBES METAB
   Zhou Beifan, 2002, Zhonghua Liu Xing Bing Xue Za Zhi, V23, P5
   Zubrod A, 2020, J LANG SOC PSYCHOL, DOI 10.1177/0261927X20958439
NR 36
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0168-8227
EI 1872-8227
J9 DIABETES RES CLIN PR
JI Diabetes Res. Clin. Pract.
PD SEP
PY 2020
VL 167
AR 108350
DI 10.1016/j.diabres.2020.108350
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA OD8AL
UT WOS:000580069500012
PM 32710996
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Henry, BM
   Benoit, JL
   Benoit, S
   Pulvino, C
   Berger, BA
   de Olivera, MHS
   Crutchfield, CA
   Lippi, G
AF Henry, Brandon Michael
   Benoit, Justin Lee
   Benoit, Stefanie
   Pulvino, Christina
   Berger, Brandon A.
   de Olivera, Maria Helena Santos
   Crutchfield, Christopher A.
   Lippi, Giuseppe
TI Red Blood Cell Distribution Width (RDW) Predicts COVID-19 Severity: A
   Prospective, Observational Study from the Cincinnati SARS-CoV-2
   Emergency Department Cohort
SO DIAGNOSTICS
LA English
DT Article
DE diagnostics; hematology; red blood cells; anisocytosis; infections;
   acute kidney injury
ID MORTALITY
AB Since previous evidence has demonstrated that red blood cell distribution width (RDW) may be a useful prognostic parameter in many critical illnesses and infectious diseases, we investigated the utility of RDW for monitoring patients with coronavirus disease 2019 (COVID-19). The study population consisted of 49 COVID-19 patients, including 16 (32.6%) with severe illness, 12 (24.5%) with severe acute kidney injury (AKI), and 8 (16.3%) requiring renal replacement therapy (RRT). The predictive value of blood tests, performed during emergency department evaluation, was then addressed. A progressive increase of RDW was observed with advancing COVID-19 severity. The area under the curve (AUC) of RDW was 0.73 for predicting severe illness, 0.80 for severe AKI, and 0.83 for RRT, respectively. In multivariate analysis, elevated RDW was associated with 9-fold and 16-fold increased odds of severe COVID-19 and AKI, respectively. The results of this study suggest that RDW should be part of routine laboratory assessment and monitoring of COVID-19.
C1 [Henry, Brandon Michael] Cincinnati Childrens Hosp Med Ctr, Cardiac Intens Care Unit, Inst Heart, Cincinnati, OH 45229 USA.
   [Benoit, Justin Lee; Pulvino, Christina; Berger, Brandon A.] Univ Cincinnati, Dept Emergency Med, Cincinnati, OH 45221 USA.
   [Benoit, Stefanie] Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH 45229 USA.
   [Benoit, Stefanie] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45229 USA.
   [de Olivera, Maria Helena Santos] Univ Fed Parana, Dept Stat, BR-80060000 Curitiba, Parana, Brazil.
   [Crutchfield, Christopher A.] Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45219 USA.
   [Lippi, Giuseppe] Univ Verona, Dept Neurosci Biomed & Movement, Clin Biochem Sect, I-37129 Verona, Italy.
RP Henry, BM (corresponding author), Cincinnati Childrens Hosp Med Ctr, Cardiac Intens Care Unit, Inst Heart, Cincinnati, OH 45229 USA.
EM brandon.henry@cchmc.org; benoitjn@ucmail.uc.edu;
   stefanie.benoit@cchmc.org; christina.pulvino@uc.edu;
   bergerbd@ucmail.uc.edu; mariaholiveira34@gmail.com;
   crutchcs@ucmail.uc.edu; giuseppe.lippi@univr.it
RI ; Lippi, Giuseppe/X-7198-2018; Benoit, Justin/A-2329-2015
OI Benoit, Stefanie/0000-0002-4203-1978; Lippi,
   Giuseppe/0000-0001-9523-9054; Oliveira, Maria
   Helena/0000-0003-1180-7224; Benoit, Justin/0000-0002-0669-2963
FU University of Cincinnati College of Medicine Special Coronavirus
   (COVID-19) Research Pilot Grant Program
FX This study was funded by the University of Cincinnati College of
   Medicine Special Coronavirus (COVID-19) Research Pilot Grant Program.
CR Abate SM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235653
   Angileri F, 2020, BRIT J HAEMATOL, V190, pE92, DOI 10.1111/bjh.16883
   Cheruiyot Isaac, 2020, Acta Biomed, V91, pe2020029, DOI 10.23750/abm.v91i3.10222
   Cowling BJ, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.6.2000110
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8
   Favaloro EJ, 2020, SEMIN THROMB HEMOST, V46, P379, DOI 10.1055/s-0040-1709498
   Hedley BD, 2011, INT J LAB HEMATOL, V33, P45, DOI 10.1111/j.1751-553X.2010.01239.x
   Henry BM, 2020, CLIN CHEM LAB MED, V58, P1021, DOI 10.1515/cclm-2020-0369
   Hu ZD, 2020, CLIN BIOCHEM, V77, P1, DOI 10.1016/j.clinbiochem.2020.01.001
   Lazarian G, 2020, BRIT J HAEMATOL, V190, P29, DOI 10.1111/bjh.16794
   Lee JH, 2013, AM J EMERG MED, V31, P72, DOI 10.1016/j.ajem.2012.06.004
   Lippi G, 2020, CLIN CHEM LAB MED, V58, pE311, DOI 10.1515/cclm-2020-1121
   Lippi G, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-3989
   Lippi G, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.157
   Lippi Giuseppe, 2016, Acta Biomed, V87, P323
   Luo RB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167000
   Martinelli N, 2020, THROMB RES, V193, P170, DOI 10.1016/j.thromres.2020.07.034
   Otero TMN, 2018, J INTENSIVE CARE MED, V33, P241, DOI 10.1177/0885066616652612
   Patel KV, 2010, J GERONTOL A-BIOL, V65, P258, DOI 10.1093/gerona/glp163
   Prieto-Perez L, 2020, MODERN PATHOL, V33, P2139, DOI 10.1038/s41379-020-0613-1
   Salvagno GL, 2015, CRIT REV CL LAB SCI, V52, P86, DOI 10.3109/10408363.2014.992064
   Thomas Tiffany, 2020, medRxiv, DOI 10.1101/2020.06.29.20142703
   Wang CZ, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-3391
   Wurmb T, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03104-0
   Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328
   Yu XS, 2020, HEART LUNG, V49, P641, DOI 10.1016/j.hrtlng.2020.04.008
   Zhang L, 2020, BMC IMMUNOL, V21, DOI 10.1186/s12865-020-00369-6
NR 27
TC 2
Z9 2
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4418
J9 DIAGNOSTICS
JI Diagnostics
PD SEP
PY 2020
VL 10
IS 9
AR 618
DI 10.3390/diagnostics10090618
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA OD8YZ
UT WOS:000580133300001
PM 32825629
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lee, D
   Heo, Y
   Kim, K
AF Lee, Doyeon
   Heo, Yoseob
   Kim, Keunhwan
TI A Strategy for International Cooperation in the COVID-19 Pandemic Era:
   Focusing on National Scientific Funding Data
SO HEALTHCARE
LA English
DT Article
DE coronavirus; international cooperation; national scientific funds;
   cluster analysis; pandemic; health policy
ID EPIDEMIC; PATENT
AB The coronavirus crisis may lead to a deeper understanding of international collaborations for developing antivirals and vaccines that are essential to protect us from current and future health security threats. Beyond technical solutions, the government of South Korea needs to establish a timely strategic investment in coronavirus-related research and development (R&D) in order to enhance the capabilities for managing this new uncertainty in regard to the domestic health crisis. Thus, this study aims to provide useful information about the status of global coronavirus-related research from the South Korean government's perspective. National funded projects stemmed from leading nations such as the United States, countries of the European Union, and Japan between 2012 and 2018. Six research fields were derived by clustering analysis and an expert-based approach, and then matched to those of South Korea. The comparative analysis among them allowed for the identification of the nations' strengths and weaknesses, thereby laying the groundwork for strategic international research collaborations.
C1 [Lee, Doyeon; Kim, Keunhwan] Korea Inst Sci & Technol Informat KISTI, Div Data Anal, Seoul 02456, South Korea.
   [Heo, Yoseob] Korea Inst Sci & Technol Informat KISTI, Div Data Anal, Busan Branch, Busan 48058, South Korea.
RP Kim, K (corresponding author), Korea Inst Sci & Technol Informat KISTI, Div Data Anal, Seoul 02456, South Korea.
EM dylee@kisti.re.kr; joseph87@kisti.re.kr; dylee@kisti.re.kr
OI Heo, Yoseob/0000-0002-5477-9561
FU Korea Institute of Science and Technology Information (KISTI); Korean
   governmentKorean Government [K-20-L03-C03-S01]
FX This work was supported by the Korea Institute of Science and Technology
   Information (KISTI) granted by the Korean government (No.
   K-20-L03-C03-S01).
CR Borrell J., 2020, POLICY BRIEF POST CO
   Carlson Colin J, 2020, Lancet Microbe, V1, pe6, DOI 10.1016/S2666-5247(20)30002-1
   Chung MY, 2015, WORLD DEV, V66, P678, DOI 10.1016/j.worlddev.2014.09.010
   Criscuolo P, 2006, SCIENTOMETRICS, V66, P23, DOI 10.1007/s11192-006-0003-6
   Destoumieux-Garzon D, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00014
   Fitchett JR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105722
   Gates B, 2020, NEW ENGL J MED, V382, P1677, DOI 10.1056/NEJMp2003762
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Greene Christopher J, 2020, J Am Coll Emerg Physicians Open, DOI 10.1002/emp2.12040
   Heo Y, 2019, SUSTAINABILITY-BASEL, V11, DOI 10.3390/su11154120
   Her Minyoung, 2020, Disaster Med Public Health Prep, V14, P684, DOI 10.1017/dmp.2020.69
   Hoon J., 2011, EXPERT SYST APPL, V38, P15159, DOI [10.1016/j.eswa.2011.05.088, DOI 10.1016/J.ESWA.2011.05.088]
   Khan N., 2020, SSRN ELECT J, DOI [10.2139/ssrn.3532001, DOI 10.2139/SSRN.3532001]
   Li JY, 2020, MICROBES INFECT, V22, P80, DOI 10.1016/j.micinf.2020.02.002
   Matthiessen L, 2017, VACCINE, V35, pA20, DOI 10.1016/j.vaccine.2016.10.031
   Meirmans S, 2019, J EVOLUTION BIOL, V32, P754, DOI 10.1111/jeb.13497
   Pan XC, 2020, MICROBES INFECT, V22, P86, DOI 10.1016/j.micinf.2020.02.004
   Park SC, 2020, PSYCHIAT INVEST, V17, P85, DOI 10.30773/pi.2020.0058
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Sarngadharan M., 2011, FINANCIAL ANAL MANAG
   Sedighi M, 2016, LIBR REV, V65, P52, DOI 10.1108/LR-07-2015-0075
   Seok J, 2015, CLUSTER COMPUT, V18, P783, DOI 10.1007/s10586-015-0445-9
   Shim W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159249
   Sridhar D, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3841
   Sweileh WM, 2017, GLOBALIZATION HEALTH, V13, DOI 10.1186/s12992-017-0233-9
   Van Eck N.J., 2014, MEASURING SCHOLARLY, P285, DOI [10.1007/978-3-319-10377-8_13, DOI 10.1007/978-3-319-10377-8_13]
   van Eck NJ, 2010, SCIENTOMETRICS, V84, P523, DOI 10.1007/s11192-009-0146-3
   Waltman L, 2010, J INFORMETR, V4, P629, DOI 10.1016/j.joi.2010.07.002
   WHO, COR DIS
   WHO, 2020, COORD GLOB RES ROADM
   WHO Timeline - COVID-19, WHO TIM COVID 19
NR 31
TC 1
Z9 1
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9032
J9 HEALTHCARE-BASEL
JI Healthcare
PD SEP
PY 2020
VL 8
IS 3
AR 204
DI 10.3390/healthcare8030204
PG 18
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA OE3DX
UT WOS:000580416500001
PM 32659997
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Matiz, A
   Fabbro, F
   Paschetto, A
   Cantone, D
   Paolone, AR
   Crescentini, C
AF Matiz, Alessio
   Fabbro, Franco
   Paschetto, Andrea
   Cantone, Damiano
   Paolone, Anselmo Roberto
   Crescentini, Cristiano
TI Positive Impact of Mindfulness Meditation on Mental Health of Female
   Teachers during the COVID-19 Outbreak in Italy
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE COVID-19; longitudinal study; mindfulness meditation; resilience; school
   teachers; self-reports; women's mental health
ID STRESS REDUCTION; HOSPITAL ANXIETY; COGNITIVE THERAPY; RESILIENCE;
   INTERVENTIONS; DEPRESSION; METAANALYSIS; TEMPERAMENT; CHARACTER;
   VALIDITY
AB The Covid-19 pandemic and subsequent public health measures were shown to impact negatively on people's mental health. In particular, women were reported to be at higher risk than men of developing symptoms of stress/anxiety/depression, and resilience was considered a key factor for positive mental health outcomes. In the present study, a sample of Italian female teachers (n= 66, age: 51.5 +/- 7.9 years) was assessed with self-report instruments one month before and one month after the start of the Covid-19 lockdown: mindfulness skills, empathy, personality profiles, interoceptive awareness, psychological well-being, emotional distress and burnout levels were measured. Meanwhile, they received an 8-week Mindfulness-Oriented Meditation (MOM) course, through two group meetings and six individual video-lessons. Based on baseline personality profiles, analyses of variance were performed in a low-resilience (LR,n= 32) and a high-resilience (HR,n= 26) group. The LR and HR groups differed at baseline in most of the self-report measures. Pre-post MOM significant improvements were found in both groups in anxiety, depression, affective empathy, emotional exhaustion, psychological well-being, interoceptive awareness, character traits and mindfulness levels. Improvements in depression and psychological well-being were higher in the LR vs. HR group. We conclude that mindfulness-based training can effectively mitigate the psychological negative consequences of the Covid-19 outbreak, helping in particular to restore well-being in the most vulnerable individuals.
C1 [Matiz, Alessio; Fabbro, Franco; Paschetto, Andrea; Paolone, Anselmo Roberto; Crescentini, Cristiano] Univ Udine, Dept Languages & Literatures Commun Educ & Soc, I-33100 Udine, Italy.
   [Fabbro, Franco] Scuola Super Sant Anna, Perceptual Robot PERCRO Lab, I-56010 Pisa, Italy.
   [Cantone, Damiano] Univ Roma La Sapienza, Dept Psychol, I-00185 Rome, Italy.
RP Matiz, A (corresponding author), Univ Udine, Dept Languages & Literatures Commun Educ & Soc, I-33100 Udine, Italy.
EM alessio.matiz@uniud.it; franco.fabbro@uniud.it;
   andrea.paschetto@uniud.it; cantonedamiano@hotmail.com;
   anselmo.paolone@uniud.it; cristiano.crescentini@uniud.it
OI CRESCENTINI, CRISTIANO/0000-0002-3154-3687; Matiz,
   Alessio/0000-0001-6785-3102
FU Prevention Department of Regione Autonoma Friuli Venezia Giulia
FX This research was funded by the Prevention Department of Regione
   Autonoma Friuli Venezia Giulia.
CR Abbott RA, 2014, J PSYCHOSOM RES, V76, P341, DOI 10.1016/j.jpsychores.2014.02.012
   Baer RA, 2006, ASSESSMENT, V13, P27, DOI 10.1177/1073191105283504
   Baiano C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17165928
   Bandura A., 1990, SELF REGULATION MOTI, V69, P164
   Behan C., 2020, J PSYCHOL MED, P1, DOI [10.1017/ipm.2020.38, DOI 10.1017/IPM.2020.38]
   Birnie K, 2010, STRESS HEALTH, V26, P359, DOI 10.1002/smi.1305
   Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3
   Brennan C, 2010, J PSYCHOSOM RES, V69, P371, DOI 10.1016/j.jpsychores.2010.04.006
   Broche-Perez Y, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00343-8
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Brown KW, 2003, J PERS SOC PSYCHOL, V84, P822, DOI 10.1037/0022-3514.84.4.822
   Cali G, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01202
   Campanella F, 2014, COMPR PSYCHIAT, V55, P1269, DOI 10.1016/j.comppsych.2014.03.009
   Cao WJ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112934
   Carmody J, 2008, J PSYCHOSOM RES, V64, P393, DOI 10.1016/j.jpsychores.2007.06.015
   Carmody J, 2008, J BEHAV MED, V31, P23, DOI 10.1007/s10865-007-9130-7
   Casagrande M, 2020, SLEEP MED, V75, P12, DOI 10.1016/j.sleep.2020.05.011
   Chiesa A, 2011, J CLIN PSYCHOL, V67, P404, DOI 10.1002/jclp.20776
   Chiesa A, 2009, J ALTERN COMPLEM MED, V15, P593, DOI 10.1089/acm.2008.0495
   CLONINGER CR, 1993, ARCH GEN PSYCHIAT, V50, P975, DOI 10.1001/archpsyc.1993.01820240059008
   Cloninger CR, 1994, TEMPERAMENT CHARACTE
   Cobb M.R., 2012, OXFORD TXB SPIRITUAL
   Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113
   Cooke GPE, 2013, BMC MED EDUC, V13, DOI 10.1186/1472-6920-13-2
   Costantini M, 1999, SUPPORT CARE CANCER, V7, P121, DOI 10.1007/s005200050241
   Crescentini Cristiano, 2018, Int J MS Care, V20, P101, DOI 10.7224/1537-2073.2016-093
   Crescentini C, 2015, J ADDICT DIS, V34, P75, DOI 10.1080/10550887.2014.991657
   Crescentini C, 2014, CONSCIOUS COGN, V30, P266, DOI 10.1016/j.concog.2014.09.013
   Davico C, 2020, LANCET, DOI [10.2139/ssrn.3576933, DOI 10.2139/SSRN.3576933]
   Davydov DM, 2010, CLIN PSYCHOL REV, V30, P479, DOI 10.1016/j.cpr.2010.03.003
   Delvecchio G, 2016, J AFFECT DISORDERS, V204, P83, DOI 10.1016/j.jad.2016.06.014
   Di Girolamo M, 2019, J PERS ASSESS, V101, P159, DOI 10.1080/00223891.2017.1389745
   Duan L, 2020, LANCET PSYCHIAT, V7, P300, DOI 10.1016/S2215-0366(20)30073-0
   Eley DS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160028
   Eley DS, 2013, PEERJ, V1, DOI 10.7717/peerj.216
   Fabbro A, 2020, PERCEPT MOTOR SKILL, V127, P515, DOI 10.1177/0031512520908708
   Fabbro F, 2016, RICERCHE PSICOLOGIA, V4, P457, DOI DOI 10.3280/RIP2016-004001
   Favieri F, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3576804, DOI 10.2139/SSRN.3576804]
   Ferrell BR, 2020, J PAIN SYMPTOM MANAG, V60, pE7, DOI 10.1016/j.jpainsymman.2020.06.034
   Fessell D, 2020, J AM COLL RADIOL, V17, P746, DOI 10.1016/j.jacr.2020.03.013
   Fischer R., 2020, PSYARXIV, DOI [10.31234/osf.io/ndyf4, DOI 10.31234/OSF.IO/NDYF4]
   Forbes L, 2018, MINDFULNESS, V9, P271, DOI 10.1007/s12671-017-0772-4
   Galbraith Niall, 2020, BJPsych Bull, P1, DOI 10.1192/bjb.2020.44
   Galea S, 2020, JAMA INTERN MED, V180, P817, DOI 10.1001/jamainternmed.2020.1562
   Gawande R, 2019, J GEN INTERN MED, V34, P293, DOI 10.1007/s11606-018-4739-5
   Gentilini U, 2020, SOCIAL PROTECTION JO
   Geoffroy PA, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00511
   Giovannini C, 2014, J PSYCHOPATHOL BEHAV, V36, P415, DOI 10.1007/s10862-013-9403-0
   Goldberg SB, 2018, CLIN PSYCHOL REV, V59, P52, DOI 10.1016/j.cpr.2017.10.011
   Hartigan J. A., 1979, Applied Statistics, V28, P100, DOI 10.2307/2346830
   Hasse L, 2016, BIOL PSYCHOL, V113, P37, DOI 10.1016/j.biopsycho.2015.11.004
   Hayes SC, 2007, PSYCHOL INQ, V18, P242, DOI 10.1080/10478400701598314
   Hjemdal O, 2011, CLIN PSYCHOL PSYCHOT, V18, P314, DOI 10.1002/cpp.719
   Ho CSH, 2020, ANN ACAD MED SINGAP, V49, P155
   Hofmann SG, 2010, J CONSULT CLIN PSYCH, V78, P169, DOI 10.1037/a0018555
   Hu TQ, 2015, PERS INDIV DIFFER, V76, P18, DOI 10.1016/j.paid.2014.11.039
   Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954
   Kabat-Zinn J, 2003, CLIN PSYCHOL-SCI PR, V10, P144, DOI 10.1093/clipsy/bpg016
   Kabat-Zinn J., 1990, FULL CATASTROPHE LIV
   Karreman A, 2012, PERS INDIV DIFFER, V53, P821, DOI 10.1016/j.paid.2012.06.014
   Keye M.D., 2013, OPEN J SOCIAL SCI, V1, P1, DOI DOI 10.4236/JSS.2013.16001
   Khoury B, 2013, CLIN PSYCHOL REV, V33, P763, DOI 10.1016/j.cpr.2013.05.005
   Killgore WDS, 2020, PSYCHIAT RES, V291, DOI 10.1016/j.psychres.2020.113216
   Kim JW, 2013, COMPR PSYCHIAT, V54, P1105, DOI 10.1016/j.comppsych.2013.05.005
   Kwon CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17124477
   Lai JB, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.3976
   Lamothe M, 2016, COMPLEMENT THER MED, V24, P19, DOI 10.1016/j.ctim.2015.11.001
   LI ZH, 2020, GEN HOSP PSYCHIAT
   Liu NQ, 2020, PSYCHIAT RES, V287, DOI 10.1016/j.psychres.2020.112921
   Liu S, 2020, LANCET PSYCHIAT, V7, pE17, DOI 10.1016/S2215-0366(20)30077-8
   Logie CH, 2020, AIDS BEHAV, V24, P2003, DOI 10.1007/s10461-020-02856-8
   Luken M, 2016, AM J OCCUP THER, V70, DOI 10.5014/ajot.2016.016956
   Luo M, 2020, PSYCHIAT RES, V291, DOI 10.1016/j.psychres.2020.113190
   Mantzios M, 2014, APPL PSYCHOL-HLTH WE, V6, P173, DOI 10.1111/aphw.12023
   MASLACH C, 1981, J OCCUP BEHAV, V2, P99, DOI 10.1002/job.4030020205
   Maslach C., 1986, MASLACH BURNOUT INVE
   Matiz A, 2020, EUR J INTEGR MED, V37, DOI 10.1016/j.eujim.2020.101168
   Matiz A, 2018, MINDFULNESS, V9, P1236, DOI 10.1007/s12671-017-0865-0
   Mazza C, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093165
   Mehling WE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048230
   Moccia L, 2020, BRAIN BEHAV IMMUN, V87, P75, DOI 10.1016/j.bbi.2020.04.048
   Morice-Ramat A, 2018, INT J MED EDUC, V9, P122, DOI 10.5116/ijme.5ac6.44ba
   Nam SW, 2016, INT J MENT HEALTH AD, V14, P969, DOI 10.1007/s11469-016-9667-1
   OECD, 2020, TALIS 2018 RES, VII
   Oshio A, 2018, PERS INDIV DIFFER, V127, P54, DOI 10.1016/j.paid.2018.01.048
   Parsons CE, 2017, BEHAV RES THER, V95, P29, DOI 10.1016/j.brat.2017.05.004
   Pfefferbaum B, 2020, NEW ENGL J MED, V383, P510, DOI 10.1056/NEJMp2008017
   Polizzi C, 2020, CLIN NEUROPSYCHIATR, V17, P59, DOI 10.36131/CN20200204
   Reniers RLEP, 2011, J PERS ASSESS, V93, P84, DOI 10.1080/00223891.2010.528484
   Ribeiro L, 2018, MINDFULNESS, V9, P401, DOI 10.1007/s12671-017-0781-3
   RYFF CD, 1995, J PERS SOC PSYCHOL, V69, P719, DOI 10.1037/0022-3514.57.6.1069
   Sagone E., 2014, AM J ED RES, V2, P463, DOI DOI 10.12691/education-2-7-5
   Sekhon M, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2031-8
   Sevilla-Llewellyn-Jones J, 2018, JMIR MENT HEALTH, V5, DOI 10.2196/10278
   Shaw SCK, 2020, NURSE EDUC PRACT, V44, DOI 10.1016/j.nepr.2020.102780
   Simeon D, 2007, PSYCHONEUROENDOCRINO, V32, P1149, DOI 10.1016/j.psyneuen.2007.08.005
   Sirigatti S., 2009, B PSICOLOGIA APPL, V259, P30
   Southwick S.M., 2018, RESILIENCE SCI MASTE
   Spijkerman MPJ, 2016, CLIN PSYCHOL REV, V45, P102, DOI 10.1016/j.cpr.2016.03.009
   Sun L, 2020, PREVALENCE RISK FACT, V2020, p200620032425, DOI [10.1101/ 2020.03.06.20032425, DOI 10.1101/2020.03.06.20032425, 10.1101/2020.03.06.20032425]
   Szczeniak D., 2020, PROG NEUROPSYCHOPHAR, V104, DOI 10.1016/j.pnpbp.2020.11004632730915
   Thera N., 2014, HEART BUDDHIST MEDIT
   Urgesi C, 2010, NEURON, V65, P309, DOI 10.1016/j.neuron.2010.01.026
   van Agteren J, 2020, JMIR MENT HEALTH, V7, DOI 10.2196/20696
   Vindegaard N, 2020, BRAIN BEHAV IMMUN, V89, P531, DOI 10.1016/j.bbi.2020.05.048
   Viola MM, 2016, CAREER DEV Q, V64, P387, DOI 10.1002/cdq.12073
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Yang Lei, 2020, Psychol Med, P1, DOI 10.1017/S0033291720001385
   Zhou XB, 2020, PSYCHIAT RES, V286, DOI 10.1016/j.psychres.2020.112895
   Zhou XY, 2020, TELEMED E-HEALTH, V26, P377, DOI 10.1089/tmj.2020.0068
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 112
TC 2
Z9 2
U1 6
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD SEP
PY 2020
VL 17
IS 18
AR 6450
DI 10.3390/ijerph17186450
PG 22
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA OE6WE
UT WOS:000580667900001
PM 32899739
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Albani, F
   Fusina, F
   Giovannini, A
   Ferretti, P
   Granato, A
   Prezioso, C
   Divizia, D
   Sabaini, A
   Marri, M
   Malpetti, E
   Natalini, G
AF Albani, Filippo
   Fusina, Federica
   Giovannini, Alessia
   Ferretti, Pierluigi
   Granato, Anna
   Prezioso, Chiara
   Divizia, Danilo
   Sabaini, Alessandra
   Marri, Marco
   Malpetti, Elena
   Natalini, Giuseppe
TI Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality
   in COVID-19
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE azithromycin; hydroxychloroquine; SARS-CoV-2
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has led to widespread use of hydroxychloroquine and azithromycin despite the lack of conclusive evidence for their safety and efficacy. We evaluated the association between treatment with hydroxychloroquine and/or azithromycin and hospital mortality as the primary outcome. We compared the hospital mortality of patients treated with hydroxychloroquine alone, azithromycin alone, or their combination to the mortality of patients who received neither drug. A logistic multivariate model with overlap weight propensity score was used for estimation of odds ratios (ORs) with 95% confidence intervals (95% CIs). One thousand four hundred and three patients with SARS-CoV-2 infection were admitted to the hospital. At the time of the analysis, the outcome was available for 1376 (98%) of them. Five hundred and eighty-seven patients (42%) received azithromycin and 377 patients (27%) received hydroxychloroquine, alone or in combination. In-hospital mortality was 26%. After the adjusted analysis, azithromycin alone was associated with lower mortality (OR 0.60, 95% CI 0.42-0.85) compared to no treatment. Hydroxychloroquine alone (OR 0.76, 95% CI 0.53-1.08) and the combination of azithromycin and hydroxychloroquine (OR 1.13, 95% CI 0.77-1.69) were not associated with hospital mortality. In this cohort of patients, azithromycin alone was associated with lower hospital mortality but hydroxychloroquine was not associated with increased or reduced mortality. While we await randomized clinical trials, these data support the use of azithromycin in novel coronavirus disease 2019 (COVID-19) and can contribute to better understanding of its role in further meta-analyses.
C1 [Albani, Filippo; Fusina, Federica; Giovannini, Alessia; Ferretti, Pierluigi; Granato, Anna; Prezioso, Chiara; Divizia, Danilo; Sabaini, Alessandra; Malpetti, Elena; Natalini, Giuseppe] Fdn Poliambulanza Ist Osped, Dept Anesthesia Intens Care & Pain Med, I-25124 Brescia, Italy.
   [Prezioso, Chiara] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli, Dept Intens Care Med & Anaesthesiol, I-00168 Rome, Italy.
   [Marri, Marco] Fdn Poliambulanza Ist Osped, Dept Informat & Commun Technol, I-25124 Brescia, Italy.
RP Albani, F (corresponding author), Fdn Poliambulanza Ist Osped, Dept Anesthesia Intens Care & Pain Med, I-25124 Brescia, Italy.
EM filippo.albani@poliambulanza.it; f.fusina@gmail.com;
   alessia.giovannini@poliambulanza.it;
   pierluigi.ferretti@poliambulanza.it; anna.granato@poliambulanza.it;
   c.prezioso89@gmail.com; danilo.divizia@poliambulanza.it;
   alessandra.sabaini@poliambulanza.it; marco.marri@poliambulanza.it;
   elena.malpetti@poliambulanza.it; giuseppe.natalini@poliambulanza.it
OI Albani, Filippo/0000-0001-7116-5740; Natalini,
   Giuseppe/0000-0002-0408-1966; Fusina, Federica/0000-0002-3341-5793
CR Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Chorin E, 2020, HEART RHYTHM, V17, P1425, DOI 10.1016/j.hrthm.2020.05.014
   Craney T. A., 2002, Quality Engineering, V14, P391, DOI 10.1081/QEN-120001878
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Hsieh FY, 1998, STAT MED, V17, P1623, DOI 10.1002/(SICI)1097-0258(19980730)17:14<1623::AID-SIM871>3.0.CO;2-S
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   Kissler SM, 2020, SCIENCE, V368, P860, DOI 10.1126/science.abb5793
   Madrid PB, 2015, ACS INFECT DIS, V1, P317, DOI 10.1021/acsinfecdis.5b00030
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3
   Retallack H, 2016, P NATL ACAD SCI USA, V113, P14408, DOI 10.1073/pnas.1618029113
   Rosenberg E.S., 2020, JAMA-J AM MED ASSOC, V324, P617
   Thomas L, 2020, JAMA-J AM MED ASSOC, V323, P466, DOI 10.1001/jama.2019.21558
   Thomas LE, 2020, JAMA-J AM MED ASSOC, V323, P2417, DOI 10.1001/jama.2020.7819
   Touret F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70143-6
   VanderWeele TJ, 2017, ANN INTERN MED, V167, P268, DOI 10.7326/M16-2607
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 22
TC 2
Z9 2
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD SEP
PY 2020
VL 9
IS 9
AR 2800
DI 10.3390/jcm9092800
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA OE8QR
UT WOS:000580788800001
PM 32872629
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fredi, M
   Cavazzana, I
   Moschetti, L
   Andreoli, L
   Franceschini, F
AF Fredi, Micaela
   Cavazzana, Ilaria
   Moschetti, Liala
   Andreoli, Laura
   Franceschini, Franco
CA Brescia Rheumatology COVID-19 Stud
TI COVID-19 in patients with rheumatic diseases in northern Italy: a
   single-centre observational and case-control study
SO LANCET RHEUMATOLOGY
LA English
DT Article
ID CLINICAL-COURSE; SERIES
AB Background The highest number of COVID-19 cases in Italy have been reported in Lombardy a region in northern Italy. We aimed to analyse the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with rheumatic and musculoskeletal diseases living in a district of Lombardy with a high prevalence of COVID-19.
   Methods We did a single-centre observational study at the Azienda Socio Sanitaria Territoriale (ASST) Spedali Civili of Brescia, Italy. We collected data from patients with rheumatic and musculoskeletal diseases enrolled in our outpatient clinic to identify confirmed or possible cases of SARS-CoV-2 infection. Data were collected through a survey that was administered via telephone or in the outpatient clinic by rheumatologists. We also did a case control study of all patients with confirmed COVID-19 pneumonia and rheumatic and musculoskeletal diseases who were admitted to the ASST Spedali Civili of Brescia during the study period. Cases were matched by age, sex, and month of hospital admission to at least two controls admitted to the same hospital for COVID-19 pneumonia during the study period.
   Findings Between Feb 24 and May 1,2020, we collected data from 1525 patients with rheumatic and musculoskeletal diseases: 117 (8%) presented with symptoms that were compatible with COVID-19.65 patients had a swab confirmation of SARS-CoV-2 infection, whereas 52 presented with a spectrum of symptoms indicative of COVI D-19 but were not swab tested. Patients with confirmed COVID-19 were older than those with suspected COVID-19 (median age 68 [IQR 55-76] years vs 57 [49-67] years; p=0.0010) and more likely to have arterial hypertension (33 [51%] vs 14 [27%] patients; odds ratio [OR] 2.8 [95% CI 1.3-6.1]; p=0.031) and obesity (11 [17%] vs 1 [2%]; OR 11.0 [1.3-83.4]; p=0.0059). We found no differences in rheumatological disease or background therapy between confirmed and suspected COVID-19 cases. 47 (72%) of the 65 patients with confirmed COVID-19 developed pneumonia that required admission to hospital. 12 (10%) deaths occurred among the 117 patients with confirmed or suspected COVID-19 (ten in those with confirmed COVID-19 and two in those with suspected COVID-19). Deceased patients with confirmed COVID-19 were older than survivors (median age 78.8 years [IQR 75.3-81.3] vs 65-5 years [53.3-74.0]; p=0.0002). We observed no differences in sex, comorbidities, or therapies between the deceased patients and survivors. The case control study comprised 26 patients with rheumatic and musculoskeletal diseases and COVID-19 pneumonia and 62 matched controls. We found no significant differences between cases and controls in duration of COVI D-19 symptoms before admission, duration of stay in hospital, or the local chest X-ray scoring system. Glucocorticoids were used for severe respiratory manifestations related to lung involvement in 17 (65%) of 26 cases and tocilizumab in six (23%) of 26; thrombotic events occurred in four (15%) of 26 cases. Four (15%) of 26 cases and six (10%) of 62 controls died during the study period.
   Interpretation In this cohort of patients with rheumatic and musculoskeletal diseases in a geographical region with a high prevalence of COVID-19, a poor outcome from COVID-19 seems to be associated with older age and the presence of comorbidities rather than the type of rheumatic disease or the degree of pharmacological immunosuppression.
C1 [Fredi, Micaela; Cavazzana, Ilaria; Moschetti, Liala; Andreoli, Laura; Franceschini, Franco] ASST Spedali Civili Brescia, Rheumatol & Clin Immunol Unit, Brescia, Italy.
   [Fredi, Micaela; Moschetti, Liala; Andreoli, Laura; Franceschini, Franco] Univ Brescia, Dept Clin & Expt Sci, Brescia, Italy.
RP Fredi, M (corresponding author), ASST Spedali Civili, Dept Clin & Expt Sci, Rheumatol & Clin Immunol Unit, I-25100 Brescia, Italy.; Fredi, M (corresponding author), Univ Brescia, I-25100 Brescia, Italy.
EM fredi.micaela@gmail.com
CR Borghesi A, 2020, RADIOL MED, V125, P509, DOI 10.1007/s11547-020-01200-3
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen RC, 2020, CHEST, V158, P97, DOI 10.1016/j.chest.2020.04.010
   Damiani G, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13475
   Emmi G, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102575
   European Centre for Disease Prevention and Control, 2020, CAS DEF COR DIS 2019
   Favalli Ennio Giulio, 2020, Ann Rheum Dis, DOI [10.1136/annrheumdis-2020-217615, 10.1136/annrheumdis-2020-217787]
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Gianfrancesco MA, 2020, LANCET RHEUMATOL, V2, pE250, DOI 10.1016/S2665-9913(20)30095-3
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285
   Mathian A, 2020, ANN RHEUM DIS, V79, P837, DOI 10.1136/annrheumdis-2020-217566
   Mikuls TR, 2020, ARTHRITIS RHEUMATOL, V72, P1241, DOI 10.1002/art.41301
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Piva S, 2020, J CRIT CARE, V58, P29, DOI 10.1016/j.jcrc.2020.04.004
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 23
TC 7
Z9 7
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2665-9913
J9 LANCET RHEUMATOL
JI Lancet Rheumatol.
PD SEP
PY 2020
VL 2
IS 9
BP E549
EP E556
DI 10.1016/S2665-9913(20)30169-7
PG 8
WC Rheumatology
SC Rheumatology
GA OD7WV
UT WOS:000580060100021
PM 32838307
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Zhong, JX
   Shen, GF
   Yang, HQ
   Huang, AB
   Chen, XQ
   Dong, L
   Wu, B
   Zhang, AB
   Su, LC
   Hou, XQ
   Song, SL
   Li, HL
   Zhou, WY
   Zhou, T
   Huang, Q
   Chu, AC
   Braunstein, Z
   Rao, XQ
   Ye, C
   Dong, LL
AF Zhong, Jixin
   Shen, Guifen
   Yang, Huiqin
   Huang, Anbin
   Chen, Xiaoqi
   Dong, Li
   Wu, Bin
   Zhang, Anbin
   Su, Linchong
   Hou, Xiaoqiang
   Song, Shulin
   Li, Huiling
   Zhou, Wenyu
   Zhou, Tao
   Huang, Qin
   Chu, Aichun
   Braunstein, Zachary
   Rao, Xiaoquan
   Ye, Cong
   Dong, Lingli
TI COVID-19 in patients with rheumatic disease in Hubei province, China: a
   multicentre retrospective observational study
SO LANCET RHEUMATOLOGY
LA English
DT Article
ID CORONAVIRUS; PNEUMONIA
AB Background In the ongoing COVID-19 pandemic, the susceptibility of patients with rheumatic diseases to COVID-19 remains unclear. We aimed to investigate susceptibility to COVID-19 in patients with autoimmune rheumatic diseases during the ongoing COVID-19 pandemic.
   Methods We did a multicentre retrospective study of patients with autonnmune rheumatic diseases in Hubei province, the epicentre of the COVID-19 outbreak in China. Patients with rheumatic diseases were contacted through an automated telephone-based survey to investigate their susceptibility to COVID-19. Data about COVID-19 exposure or diagnosis were collected. Families with a documented history of COVID-19 exposure, as defined by having at least one family member diagnosed with COVID-19, were followed up by medical professionals to obtain detailed information, including sex, age, smoking history, past medical history, use of medications, and information related to COVID-19.
   Findings Between March 20 and March 30, 2020, 6228 patients with autoimmune rheumatic diseases were included in the study. The overall rate of COVI D-19 in patients with an autoimmune rheumatic disease in our study population was 0"43% (27 of 6228 patients). We identified 42 families in which COVID-19 was diagnosed between Dec 20, 2019, and March 20, 2020, in either patients with a rheumatic disease or in a family member residing at the same physical address during the outbreak. Within these 42 families, COVID-19 was diagnosed in 27 (63%) of 43 patients with a rheumatic disease and in 28 (34%) of 83 of their family members with no rheumatic disease (adjusted odds ratio [OR] 2.68 [95% CI 1.14-6- 27]; p=0.023). Patients with rheumatic disease who were taking hydroxychloroquine had a lower risk of COVID-19 infection than patients taking other disease-modifying anti-rheumatic drugs (OR 0.09 [95% CI 0- 01-0. 94]; p=0. 044). Additionally, the risk of COVID-19 was increased with age (adjusted OR 1.04 [95% CI 1 01-1. 06]; p=0.0081).
   Interpretation Patients with autoimmune rheumatic disease might be more susceptible to COVID-19 infection than the general population. Funding National Natural
C1 [Zhong, Jixin; Shen, Guifen; Ye, Cong; Dong, Lingli] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Rheumatol & Immunol, Wuhan 430030, Hubei, Peoples R China.
   [Yang, Huiqin] Wuhan 1 Hosp, Dept Rheumatol & Immunol, Wuhan, Hubei, Peoples R China.
   [Huang, Anbin] Huazhong Univ Sci & Technol, Union Hosp, Dept Rheumatol & Immunol, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   [Chen, Xiaoqi] Wuhan Univ, Dept Rheumatol, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
   [Dong, Li] Jingzhou City Cent Hosp Hubei Prov, Dept Rheumatol & Immunol, Jingzhou, Hubei, Peoples R China.
   [Wu, Bin] First Peoples Hosp Jingzhou, Dept Rheumatol & Immunol, Jingzhou, Hubei, Peoples R China.
   [Zhang, Anbin] Xiangyang Cent Hosp, Dept Rheumatol & Immunol, Xiangyang, Hubei, Peoples R China.
   [Su, Linchong] Hubei Minzu Univ, Dept Rheumatol & Immunol, Minda Hosp, Enshi, Peoples R China.
   [Hou, Xiaoqiang] China Three Gorges Univ, Coll Clin Med Sci 1, Yichang, Hubei, Peoples R China.
   [Song, Shulin] First Peoples Hosp Yichang, Dept Rheumatol & Immunol, Yichang, Hubei, Peoples R China.
   [Li, Huiling] Tradit Chinese Med Hosp Hubei Prov, Dept Rheumatol & Immunol, Wuhan, Hubei, Peoples R China.
   [Zhou, Wenyu] Huazhong Univ Sci & Technol, Wuhan Hosp 4, Tongji Med Coll, Dept Rheumatol & Immunol,Puai Hosp, Wuhan, Hubei, Peoples R China.
   [Zhou, Tao] Wuhan Univ Sci & Technol, Dept Rheumatol & Immunol, Wuhan Puren Hosp, Wuhan, Hubei, Peoples R China.
   [Huang, Qin] Enshi Tujia & Miao Autonomous Prefecture Cent Hos, Dept Nephrol & Rheumatol, Enshi, Hubei, Peoples R China.
   [Chu, Aichun] Wuhan Univ, Dept Prevent & Hlth Care, Renmin Hosp, Wuhan, Hubei, Peoples R China.
   [Braunstein, Zachary] Ohio State Univ, Dept Med, Columbus, OH 43210 USA.
   [Rao, Xiaoquan] Oregon Hlth & Sci Univ, Oregon Inst Occupat Hlth Sci, Portland, OR 97201 USA.
RP Dong, LL (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Rheumatol & Immunol, Wuhan 430030, Hubei, Peoples R China.
EM tjhdongll@163.com
RI Zhong, Jixin/ABE-3768-2020
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81974254, 81670431, 817717541]; Tongji
   Hospital Clinical Research Flagship Program [2019C13206]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81974254, 81670431, and 817717541 and the Tongji
   Hospital Clinical Research Flagship Program (number 2019C13206).
CR Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Caporali R, 2008, AUTOIMMUN REV, V8, P139, DOI 10.1016/j.autrev.2008.05.001
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Davies NG, 2020, NAT MED, V26, P1205, DOI 10.1038/s41591-020-0962-9
   Figueroa-Parra G, 2020, ANN RHEUM DIS, V79, P839, DOI 10.1136/annrheumdis-2020-217322
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Goyal R, 2009, CURR OPIN RHEUMATOL, V21, P78, DOI 10.1097/BOR.0b013e32831cb939
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang MX, 2020, NATL SCI REV, V7, P1428, DOI 10.1093/nsr/nwaa113
   Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Mahevas M, 2020, NO EVIDENCE CLIN EFF, P369, DOI [10.1101/2020.04.10.20060699, DOI 10.1101/2020.04.10.20060699]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Monti S, 2020, ANN RHEUM DIS, V79, DOI [10.1136/annrheumdis-2020-217800, 10.1136/annrheumdis-2020-217915, 10.1136/annrheumdis-2020-217957, 10.1136/annrheumdis-2020-217524, 10.1136/annrheumdis-2020-217738]
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   Thevarajan I, 2020, NAT MED, DOI 10.1038/s41591-020-0819-2
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang RR, 2020, INT J INFECT DIS, V95, P421, DOI 10.1016/j.ijid.2020.03.070
   Ye C, 2020, ANN RHEUM DIS, V79, P1007, DOI 10.1136/annrheumdis-2020-217627
   Zhang LB, 2020, AGING-US, V12, P6536, DOI 10.18632/aging.103102
   Zhong JX, 2020, LANCET RHEUMATOL, V2, pE428, DOI 10.1016/S2665-9913(20)30120-X
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 33
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2665-9913
J9 LANCET RHEUMATOL
JI Lancet Rheumatol.
PD SEP
PY 2020
VL 2
IS 9
BP E557
EP E564
DI 10.1016/S2665-9913(20)30227-7
PG 8
WC Rheumatology
SC Rheumatology
GA OD7WV
UT WOS:000580060100022
PM 32838309
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Azad, T
   Singaravelu, R
   Crupi, MJF
   Jamieson, T
   Dave, J
   Brown, EEF
   Rezaei, R
   Taha, Z
   Boulton, S
   Martin, NT
   Surendran, A
   Poutou, J
   Ghahremani, M
   Nouri, K
   Whelan, JT
   Duong, J
   Tucker, S
   Diallo, JS
   Bell, JC
   Ilkow, CS
AF Azad, Taha
   Singaravelu, Ragunath
   Crupi, Mathieu J. F.
   Jamieson, Taylor
   Dave, Jaahnavi
   Brown, Emily E. F.
   Rezaei, Reza
   Taha, Zaid
   Boulton, Stephen
   Martin, Nikolas T.
   Surendran, Abera
   Poutou, Joanna
   Ghahremani, Mina
   Nouri, Kazem
   Whelan, Jack T.
   Duong, Jessie
   Tucker, Sarah
   Diallo, Jean-Simon
   Bell, John C.
   Ilkow, Carolina S.
TI Implications for SARS-CoV-2 Vaccine Design: Fusion of Spike Glycoprotein
   Transmembrane Domain to Receptor-Binding Domain Induces Trimerization
SO MEMBRANES
LA English
DT Article
DE trimerization; spike protein; receptor-binding domain; transmembrane
   domain; SARS-CoV-2; vaccine development
ID SEARCH
AB The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic presents an urgent need for an effective vaccine. Molecular characterization of SARS-CoV-2 is critical to the development of effective vaccine and therapeutic strategies. In the present study, we show that the fusion of the SARS-CoV-2 spike protein receptor-binding domain to its transmembrane domain is sufficient to mediate trimerization. Our findings may have implications for vaccine development and therapeutic drug design strategies targeting spike trimerization. As global efforts for developing SARS-CoV-2 vaccines are rapidly underway, we believe this observation is an important consideration for identifying crucial epitopes of SARS-CoV-2.
C1 [Azad, Taha; Singaravelu, Ragunath; Crupi, Mathieu J. F.; Jamieson, Taylor; Dave, Jaahnavi; Brown, Emily E. F.; Rezaei, Reza; Taha, Zaid; Boulton, Stephen; Martin, Nikolas T.; Surendran, Abera; Poutou, Joanna; Whelan, Jack T.; Duong, Jessie; Tucker, Sarah; Diallo, Jean-Simon; Bell, John C.; Ilkow, Carolina S.] Ottawa Hosp Res Inst, Ottawa, ON K1H 8L6, Canada.
   [Azad, Taha; Singaravelu, Ragunath; Crupi, Mathieu J. F.; Jamieson, Taylor; Dave, Jaahnavi; Brown, Emily E. F.; Rezaei, Reza; Taha, Zaid; Boulton, Stephen; Martin, Nikolas T.; Surendran, Abera; Poutou, Joanna; Whelan, Jack T.; Duong, Jessie; Tucker, Sarah; Diallo, Jean-Simon; Bell, John C.; Ilkow, Carolina S.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada.
   [Ghahremani, Mina] Univ Ottawa, Dept Biol, Ottawa, ON K1N 6N5, Canada.
   [Nouri, Kazem] Princess Margaret Canc Ctr, Univ Hlth Network, Toronto, ON M5G 2C1, Canada.
RP Ilkow, CS (corresponding author), Ottawa Hosp Res Inst, Ottawa, ON K1H 8L6, Canada.; Ilkow, CS (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada.
EM tazad@ohri.ca; rsingaravelu@ohri.ca; mcrupi@ohri.ca; tjamieson@ohri.ca;
   jdave@ohri.ca; emibrown@ohri.ca; Reza.Rezaei@uottawa.ca; ztaha@ohri.ca;
   sboulton@ohri.ca; nikmartin@ohri.ca; asure077@uottawa.ca;
   ypoutoupaumier@ohri.ca; mghahre2@uottawa.ca; kazem.nouri@gmail.com;
   jwhelan@ohri.ca; jduong@ohri.ca; satucker@ohri.ca; jsdiallo@gmail.com;
   jbell@ohri.ca; cilkow@ohri.ca
OI Brown, Emily/0000-0002-7849-6021; Azad, Taha/0000-0002-9498-0657; Taha,
   Zaid/0000-0002-2660-0560; Nouri, Kazem/0000-0001-7787-1304; Rezaei,
   Reza/0000-0001-9652-9328
FU Ottawa Hospital Foundation; Canadian Institutes of Health
   ResearchCanadian Institutes of Health Research (CIHR) [448323]; Fast
   Grant for COVID-19 Science; Ontario Together Grant; CIHRCanadian
   Institutes of Health Research (CIHR); CIHR Frederick Banting and Charles
   Best CanadaCanadian Institutes of Health Research (CIHR)
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   funded by the generous support from the Ottawa Hospital Foundation and a
   grant from the Canadian Institutes of Health Research (#448323) to
   J.C.B., C.S.I. and J-S.D. This work was also supported by a Fast Grant
   for COVID-19 Science to J.C.B. and C.S.I. as well as an Ontario Together
   Grant to J-S-D. T.A. is funded by a CIHR Banting Fellowship. R.S. is
   funded by a CIHR postdoctoral fellowship and a cluster MITACs
   fellowship. T.R.J. is funded by a CIHR Frederick Banting and Charles
   Best Canada and Graduate Scholarship and an Ontario Graduate
   Scholarship. E.E.F.B. is funded by a CIHR Frederick Banting and Charles
   Best Canada Graduate Scholarship and a Lebovic Fellowship. A.S. and S.T.
   were supported by NSERC Graduate Scholarships. M.J.F.C., J.D., S.B.,
   N.T.M., J.P., J.T.W, J.D. and S.T. are funded by cluster MITACs
   fellowships. Finally, we would like to thank the excellent technical
   assistance of Xiaohong He, Ricardo Marius, Julia Petryk and Christiano
   Tanese De Souza.
CR Abdel-Magid Ahmed F, 2015, ACS Med Chem Lett, V6, P104, DOI 10.1021/ml5005365
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   [Anonymous], 2020, DRAFT LANDSC COVID 1
   Broer R, 2006, J VIROL, V80, P1302, DOI 10.1128/JVI.80.3.1302-1310.2006
   Cai YF, 2020, SCIENCE, V369, P1586, DOI 10.1126/science.abd4251
   Conn PJ, 2009, NAT REV DRUG DISCOV, V8, P41, DOI 10.1038/nrd2760
   Corver J, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-230
   Madeira F, 2019, NUCLEIC ACIDS RES, V47, pW636, DOI 10.1093/nar/gkz268
   Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841
   Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413
   States D J, 1994, J Comput Biol, V1, P39
   Tai WB, 2016, VIROLOGY, V499, P375, DOI 10.1016/j.virol.2016.10.005
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xiong XL, 2020, NAT STRUCT MOL BIOL, DOI 10.1038/s41594-020-0478-5
   Zhou YS, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010060
NR 17
TC 1
Z9 1
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0375
J9 MEMBRANES-BASEL
JI Membranes
PD SEP
PY 2020
VL 10
IS 9
AR 215
DI 10.3390/membranes10090215
PG 8
WC Biochemistry & Molecular Biology; Engineering, Chemical; Materials
   Science, Multidisciplinary; Polymer Science
SC Biochemistry & Molecular Biology; Engineering; Materials Science;
   Polymer Science
GA OE1YO
UT WOS:000580335000001
PM 32872641
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Byrnes, JR
   Zhou, XX
   Lui, I
   Elledge, SK
   Glasgow, JE
   Lim, SA
   Loudermilk, RP
   Chiu, CY
   Wang, TT
   Wilson, MR
   Leung, KK
   Wells, JA
AF Byrnes, James R.
   Zhou, Xin X.
   Lui, Irene
   Elledge, Susanna K.
   Glasgow, Jeff E.
   Lim, Shion A.
   Loudermilk, Rita P.
   Chiu, Charles Y.
   Wang, Taia T.
   Wilson, Michael R.
   Leung, Kevin K.
   Wells, James A.
TI Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the
   Spike Receptor-Binding Domain Compete for ACE2 Binding
SO MSPHERE
LA English
DT Article
DE COVID-19; SARS-CoV-2; angiotensin-converting enzyme 2; immunoserology;
   neutralizing antibodies; receptor-binding domain; serology
AB As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread around the world, there is an urgent need for new assay formats to characterize the humoral response to infection. Here, we present an efficient, competitive serological assay that can simultaneously determine an individual's seroreactivity against the SARS-CoV-2 Spike protein and determine the proportion of anti-Spike antibodies that block interaction with the human angiotensin-converting enzyme 2 (ACE2) required for viral entry. In this approach based on the use of enzyme-linked immunosorbent assays (ELISA), we present natively folded viral Spike protein receptor-binding domain (RBD)-containing antigens via avidin-biotin interactions. Sera are then competed with soluble ACE2-Fc, or with a higher-affinity variant thereof, to determine the proportion of ACE2 blocking anti-RBD antibodies. Assessment of sera from 144 SARS-CoV-2 patients ultimately revealed that a remarkably consistent and high proportion of antibodies in the anti-RBD pool targeted the epitope responsible for ACE2 engagement (83% +/- 11%; 50% to 107% signal inhibition in our largest cohort), further underscoring the importance of tailoring vaccines to promote the development of such antibodies.
   IMPORTANCE With the emergence and continued spread of the SARS-CoV-2 virus, and of the associated disease, coronavirus disease 2019 (COVID-19), there is an urgent need for improved understanding of how the body mounts an immune response to the virus. Here, we developed a competitive SARS-CoV-2 serological assay that can simultaneously determine whether an individual has developed antibodies against the SARS-CoV-2 Spike protein receptor-binding domain (RBD) and measure the proportion of these antibodies that block interaction with the human angiotensin-converting enzyme 2 (ACE2) required for viral entry. Using this assay and 144 SARSCoV-2 patient serum samples, we found that a majority of anti-RBD antibodies compete for ACE2 binding. These results not only highlight the need to design vaccines to generate such blocking antibodies but also demonstrate the utility of this assay to rapidly screen patient sera for potentially neutralizing antibodies.
C1 [Byrnes, James R.; Zhou, Xin X.; Lui, Irene; Elledge, Susanna K.; Glasgow, Jeff E.; Lim, Shion A.; Leung, Kevin K.; Wells, James A.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.
   [Loudermilk, Rita P.; Wilson, Michael R.] Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA 94143 USA.
   [Loudermilk, Rita P.; Wilson, Michael R.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
   [Chiu, Charles Y.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.
   [Chiu, Charles Y.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
   [Wang, Taia T.; Wells, James A.] Chan Zuckerberg Biohub, San Francisco, CA 94158 USA.
   [Wang, Taia T.] Stanford Univ, Dept Med, Med Sch, Stanford, CA 94305 USA.
   [Wang, Taia T.] Stanford Univ, Dept Microbiol & Immunol, Med Sch, Stanford, CA 94305 USA.
   [Wells, James A.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.
RP Wells, JA (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.; Wells, JA (corresponding author), Chan Zuckerberg Biohub, San Francisco, CA 94158 USA.; Wells, JA (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.
EM jim.wells@ucsf.edu
OI Chiu, Charles/0000-0003-2915-2094; , Taia/0000-0002-3894-685X; Lui,
   Irene/0000-0002-6171-5443; Wilson, Michael/0000-0002-8705-5084; Zhou,
   Xin/0000-0002-8198-2856; Byrnes, James/0000-0003-0297-1209
FU Harry and Dianna Hind Endowed Professorship in Pharmaceutical Sciences;
   Chan Zuckerberg Biohub; National Institutes of Health National Cancer
   Institute F32 grant [5F32CA239417]; Merck Fellowship from the Damon
   Runyon Research Foundation [DRG-2297-17]; Merck Postdoctoral Research
   Fellowship from the Helen Hay Whitney Foundation; National Science
   Foundation Graduate Research Fellowship ProgramNational Science
   Foundation (NSF) [DGE 1650113]; National Institutes of Health from the
   National Heart, Lung, and Blood InstituteUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Heart Lung & Blood Institute (NHLBI) [R01-HL105704]; National
   Institute of Allergy and Infectious DiseasesUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R33-129077]; Charles and Helen Schwab Foundation; Rachleff family for
   an endowment; Fast Grants; CEND COVID Catalyst Fund; NIH/NIAIDUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [U19AI111825, R01AI139119]
FX We thank the members of the Wells Lab, especially those involved in our
   COVID-19 research program. We also acknowledge Michel Nussenzweig,
   Marina Caskey, and Christian Gaebler (Rockefeller University) as well as
   Colin Zamecnik and Joseph DeRisi (UCSF) for providing the cohort of 99
   patient sera. We thank Peter Kim and Abigail Powell for helpful
   discussions. We thank Anum Glasgow (UCSF) for her contributions to the
   high-affinity ACE2-Fc design. We also thank John Pak (Chan Zuckerberg
   Initiative Biohub) and Florian Krammer (Mt. Sinai Icahn School of
   Medicine) for providing the FL Spike plasmid for cloning a version
   containing an Avi tag for biotinylation. We thank Kanishka Koshal and
   Kelsey Zorn for their assistance with patient consenting and enrollment.
   We thank the patients for their participation in this study. J.A.W. is
   grateful for funding from the Harry and Dianna Hind Endowed
   Professorship in Pharmaceutical Sciences and the Chan Zuckerberg Biohub
   that helped support this work. Postdoctoral Fellowship support included
   a National Institutes of Health National Cancer Institute F32 grant
   (5F32CA239417 to J.R.B.), a Merck Fellowship from the Damon Runyon
   Research Foundation (DRG-2297-17 to X.X.Z.), and a Merck Postdoctoral
   Research Fellowship from the Helen Hay Whitney Foundation (S.A.L.). The
   National Science Foundation Graduate Research Fellowship Program
   supported I.L. and S.K.E. (DGE 1650113). Study enrollment and collection
   of patient and control sera were supported in part by National
   Institutes of Health grant R01-HL105704 (to C.Y.C.) from the National
   Heart, Lung, and Blood Institute and grant R33-129077 (to C.Y.C.) from
   the National Institute of Allergy and Infectious Diseases and a grant
   from the Charles and Helen Schwab Foundation (to C.Y.C.). M.R.W. also
   thanks the Rachleff family for an endowment for support. Research
   reported here was also supported, in part, by Fast Grants, the CEND
   COVID Catalyst Fund, and the NIH/NIAID (U19AI111825 to T.T.W. and
   R01AI139119 to T.T.W.). J.R.B. designed the research, performed
   experiments, and analyzed data. X.X.Z., I.L., J.E.G., S.K.E., S.A.L.,
   and K.K.L. designed research and helped with protein design, expression,
   and purification. R.P.L., C.Y.C., T.T.W., and M.R.W. provided patient
   and control sera. J.A.W. supervised the research. J.R.B., X.X.Z.,
   K.K.L., and J.A.W. cowrote the manuscript, and all of us provided edits
   and approved the final version.
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   Berry JD, 2010, MABS-AUSTIN, V2, P53, DOI 10.4161/mabs.2.1.10788
   Carter LJ, 2020, ACS CENTRAL SCI, V6, P591, DOI 10.1021/acscentsci.0c00501
   Chen XY, 2020, CELL MOL IMMUNOL, V17, P647, DOI 10.1038/s41423-020-0426-7
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Glasgow Anum, 2020, bioRxiv, DOI 10.1101/2020.07.31.231746
   Grant Oliver C, 2020, bioRxiv, DOI 10.1101/2020.04.07.030445
   He YX, 2004, BIOCHEM BIOPH RES CO, V325, P445, DOI 10.1016/j.bbrc.2004.10.052
   Lui I., 2020, TRIMERIC SARS COV 2, DOI [10.1101/2020.05.21.109157, DOI 10.1101/2020.05.21.109157]
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Sekine T, 2020, CELL, V183, P158, DOI [10.10160.cell.2020.08.017, 10.1016/j.cell.2020.08.017]
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4
   Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z
   Theel ES, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00797-20
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Whitman Jeffrey D, 2020, medRxiv, DOI 10.1101/2020.04.25.20074856
NR 18
TC 1
Z9 1
U1 2
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2379-5042
J9 MSPHERE
JI mSphere
PD SEP-OCT
PY 2020
VL 5
IS 5
AR e00802-20
DI 10.1128/mSphere.00802-20
PG 11
WC Microbiology
SC Microbiology
GA OC7VK
UT WOS:000579365500008
PM 32938700
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Loos, C
   Atyeo, C
   Fischinger, S
   Burke, J
   Slein, MD
   Streeck, H
   Lauffenburger, D
   Ryan, ET
   Charles, RC
   Alter, G
AF Loos, Carolin
   Atyeo, Caroline
   Fischinger, Stephanie
   Burke, John
   Slein, Matthew D.
   Streeck, Hendrik
   Lauffenburger, Douglas
   Ryan, Edward T.
   Charles, Richelle C.
   Alter, Galit
TI Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity
SO MSPHERE
LA English
DT Article
DE Fc-receptor binding; SARS-CoV-2; antibody response; cross-reactivity
ID ACUTE-RESPIRATORY-SYNDROME; REACTIVITY; RESPONSES
AB The novel coronavirus, SARS-coronavirus (CoV)-2 (SARS-CoV-2), has caused over 17 million infections in just a few months, with disease manifestations ranging from largely asymptomatic infection to critically severe disease. The remarkable spread and unpredictable disease outcomes continue to challenge management of this infection. Among the hypotheses to explain the heterogeneity of symptoms is the possibility that exposure to other coronaviruses (CoVs), or overall higher capability to develop immunity against respiratory pathogens, may influence the evolution of immunity to SARS-CoV-2. Thus, we profiled the immune response across multiple coronavirus receptor binding domains (RBDs), respiratory viruses, and SARS-CoV-2, to determine whether heterologous immunity to other CoV-RBDs or other infections influenced the evolution of the SARS-CoV-2 humoral immune response. Overall changes in subclass, isotype, and Fc-receptor binding were profiled broadly across a cohort of 43 individuals against different coronaviruses-RBDs of SARS-CoV-2 and the more common HKU1 and NL63 viruses. We found rapid functional evolution of responses to SARS-CoV-2 over time, along with broad but relatively more time-invariant responses to the more common CoVs. Moreover, there was little evidence of correlation between SARS-CoV-2 responses and HKU1, NL63, and respiratory infection (influenza and respiratory syncytial virus) responses. These findings suggest that common viral infections including common CoV immunity, targeting the receptor binding domain involved in viral infection, do not appear to influence the rapid functional evolution of SARS-CoV-2 immunity, and thus should not impact diagnostics or shape vaccine-induced immunity.
   IMPORTANCE A critical step to ending the spread of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the ability to detect, diagnose, and understand why some individuals develop mild and others develop severe disease. For example, defining the early evolutionary patterns of humoral immunity to SARS-CoV-2, and whether prevalent coronaviruses or other common infections influence the evolution of immunity, remains poorly understood but could inform diagnostic and vaccine development. Here, we deeply profiled the evolution of SARS-CoV-2 immunity, and how it is influenced by other coinfections. Our data suggest an early and rapid rise in functional humoral immunity in the first 2 weeks of infection across antigen-specific targets, which is negligibly influenced by cross-reactivity to additional common coronaviruses or common respiratory infections. These data suggest that preexisting receptor binding domain-specific immunity does not influence or bias the evolution of immunity to SARS-CoV-2 and should have negligible influence on shaping diagnostic or vaccine-induced immunity.
C1 [Loos, Carolin; Atyeo, Caroline; Fischinger, Stephanie; Burke, John; Slein, Matthew D.; Alter, Galit] MGH MIT & Harvard, Ragon Inst, Cambridge, MA 02139 USA.
   [Loos, Carolin; Lauffenburger, Douglas] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
   [Atyeo, Caroline] Harvard Virol Program, Boston, MA USA.
   [Fischinger, Stephanie] Univ Duisburg Essen, Virol & Immunol Program, Essen, Germany.
   [Streeck, Hendrik] Univ Hosp Bonn, Dept Virol, Bonn, Germany.
   [Ryan, Edward T.; Charles, Richelle C.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
   [Ryan, Edward T.; Charles, Richelle C.] Harvard Med Sch, Boston, MA 02115 USA.
   [Ryan, Edward T.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA.
RP Alter, G (corresponding author), MGH MIT & Harvard, Ragon Inst, Cambridge, MA 02139 USA.; Charles, RC (corresponding author), Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.; Charles, RC (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.
EM rcharles@mgh.harvard.edu; galter@partners.org
OI Slein, Matthew/0000-0001-8288-787X
FU Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [U01CK000490]; National Institutes of HealthUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [3R37AI080289-11S1]; National Institute of Allergy and Infectious
   DiseasesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [U19 AI135995]
FX We also thank the MassCPR, Nancy Zimmerman, an anonymous financial
   donor, and the SAMANA Kay MGH Scholar Program. This work was supported
   in part by the Centers for Disease Control and Prevention U01CK000490
   (R.C.C., E.T.R.), the National Institutes of Health (3R37AI080289-11S1),
   and the National Institute of Allergy and Infectious Diseases (U19
   AI135995).
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Ben Mkaddem S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00811
   Benson DA, 2008, NUCLEIC ACIDS RES, V36, pD25, DOI 10.1093/nar/gkm929
   Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9
   Brown EP, 2012, J IMMUNOL METHODS, V386, P117, DOI 10.1016/j.jim.2012.09.007
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001
   Damelang T, 2019, TRENDS IMMUNOL, V40, P197, DOI 10.1016/j.it.2019.01.005
   Denner J, 2020, J CLIN VIROL, V128, DOI 10.1016/j.jcv.2020.104424
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Haveri A, 2020, EUROSURVEILLANCE, V25, P16, DOI 10.2807/1560-7917.ES.2020.25.11.2000266
   Huang Angkana T, 2020, medRxiv, DOI 10.1101/2020.04.14.20065771
   Iyer Anita S, 2020, medRxiv, DOI 10.1101/2020.07.18.20155374
   Krammer F, 2020, SCIENCE, V368, P1060, DOI 10.1126/science.abc1227
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Poh CM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16638-2
   Prevost Jeremie, 2020, bioRxiv, DOI 10.1101/2020.06.08.140244
   Rokni M, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2107
   Sun BQ, 2020, EMERG MICROBES INFEC, V9, P940, DOI 10.1080/22221751.2020.1762515
   Sun ZF, 2004, J CLIN MICROBIOL, V42, P2351, DOI 10.1128/JCM.42.5.2351-2352.2004
   Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490
   Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520
   Vlasova AN, 2007, J VIROL, V81, P13365, DOI 10.1128/JVI.01169-07
   Wang HH, 2020, EUR J CLIN MICROBIOL, V39, P1629, DOI 10.1007/s10096-020-03899-4
   Wu F, 2020, NEUTRALIZING ANTIBOD, DOI [10.1101/2020.03.30.20047365, DOI 10.1101/2020.03.30.20047365]
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Ye ZW, 2020, INT J BIOL SCI, V16, P1686, DOI 10.7150/ijbs.45472
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhu FC, 2020, LANCET, V395, P1845, DOI 10.1016/S0140-6736(20)31208-3
NR 30
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2379-5042
J9 MSPHERE
JI mSphere
PD SEP-OCT
PY 2020
VL 5
IS 5
AR e00622-20
DI 10.1128/mSphere.00622-20
PG 10
WC Microbiology
SC Microbiology
GA OC7VK
UT WOS:000579365500032
PM 32878931
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mugisha, CS
   Vuong, HR
   Puray-Chavez, M
   Bailey, AL
   Fox, JM
   Chen, RE
   Wessel, AW
   Scott, JM
   Harastani, HH
   Boon, ACM
   Shin, H
   Kutluay, SB
AF Mugisha, Christian Shema
   Vuong, Hung R.
   Puray-Chavez, Maritza
   Bailey, Adam L.
   Fox, Julie M.
   Chen, Rita E.
   Wessel, Alex W.
   Scott, Jason M.
   Harastani, Houda H.
   Boon, Adrianus C. M.
   Shin, Haina
   Kutluay, Sebla B.
TI A Simplified Quantitative Real-Time PCR Assay for Monitoring SARS-CoV-2
   Growth in Cell Culture
SO MSPHERE
LA English
DT Article
DE SARS-CoV-2; antivirals; assay development; viral entry; virus
   replication
ID CORONAVIRUS
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions within just a few months, causing severe respiratory disease and mortality. Assays to monitor SARS-CoV-2 growth in vitro depend on time-consuming and costly RNA extraction steps, hampering progress in basic research and drug development efforts. Here, we developed a simplified quantitative real-time PCR assay that bypasses viral RNA extraction steps and can monitor SARS-CoV-2 growth from a small amount of cell culture supernatants. In addition, we show that this approach is easily adaptable to numerous other RNA and DNA viruses. Using this assay, we screened the activities of a number of compounds that were predicted to alter SAR-SCoV-2 entry and replication as well as HIV-1-specific drugs in a proof-of-concept study. We found that E64D (inhibitor of endosomal proteases cathepsin B and L) and apilimod (endosomal trafficking inhibitor) potently decreased the amount of SARS-CoV-2 RNA in cell culture supernatants with minimal cytotoxicity. Surprisingly, we found that the macropinocytosis inhibitor ethylisopropylamiloride (EIPA) similarly decreased SARS-CoV-2 RNA levels in supernatants, suggesting that entry may additionally be mediated by an alternative pathway. HIV-1-specific inhibitors nevirapine (a nonnucleoside reverse transcriptase inhibitor (NNRTI)), amprenavir (a protease inhibitor), and allosteric integrase inhibitor 2 (ALLINI-2) modestly inhibited SARS-CoV-2 replication, albeit the 50% inhibitory concentration (IC50) values were much higher than that required for HIV-1. Taking the data together, this simplified assay will expedite basic SARS-CoV-2 research, be amenable to mid-throughput screening assays (i.e., drug, CRISPR, small interfering RNA [siRNA], etc.), and be applicable to a broad number of RNA and DNA viruses.
   IMPORTANCE Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of the coronavirus disease 2019 (COVID-19) pandemic, is continuing to cause immense respiratory disease and social and economic disruptions. Conventional assays that monitor SARS-CoV-2 growth in cell culture rely on costly and time-consuming RNA extraction procedures, hampering progress in basic SARS-CoV-2 research and development of effective therapeutics. Here, we developed a simple quantitative real-time PCR assay to monitor SARS-CoV-2 growth in cell culture supernatants that does not necessitate RNA extraction and that is as accurate and sensitive as existing methods. In a proof-of-concept screen, we found that E64D, apilimod, EIPA, and remdesivir can substantially impede SARS-Cov-2 replication, providing novel insight into viral entry and replication mechanisms. In addition, we show that this approach is easily adaptable to numerous other RNA and DNA viruses. This simplified assay will undoubtedly expedite basic SARS-CoV-2 and virology research and be amenable to use in drug screening platforms to identify therapeutics against SARS-CoV-2.
C1 [Mugisha, Christian Shema; Vuong, Hung R.; Puray-Chavez, Maritza; Boon, Adrianus C. M.; Kutluay, Sebla B.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
   [Bailey, Adam L.; Chen, Rita E.; Wessel, Alex W.; Boon, Adrianus C. M.] Washington Univ, Dept Pathol & Immunol, Sch Med, St Louis, MO USA.
   [Fox, Julie M.; Chen, Rita E.; Wessel, Alex W.; Scott, Jason M.; Harastani, Houda H.; Boon, Adrianus C. M.; Shin, Haina] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
RP Kutluay, SB (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
EM Kutluay@wustl.edu
OI Harastani, Houda/0000-0002-1234-6194
FU Washington University startup funds; NIHUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [U54AI150470]; NSFNational Science Foundation (NSF) [DGE-1745038];
   Stephen I. Morse fellowship;  [1U01AI151810-01]
FX We thank members of the Whelan, Diamond, and Amarasinghe labs for their
   generosity in providing reagents and support. This study was supported
   by Washington University startup funds to S.B.K., NIH grant U54AI150470
   (the Center for HIV RNA Studies) to S.B.K., 1U01AI151810-01 to A.C.M.B.,
   NSF grant DGE-1745038 to H.R.V., and a Stephen I. Morse fellowship to
   M.P.-C. The Boon laboratory has scientific research agreements with AI
   Therapeutics, Greenlight Biosciences, and Nano Targeting & Therapy
   Biopharma Inc.
CR Chan JFW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00310-20
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Kang Yuan-Lin, 2020, bioRxiv, DOI 10.1101/2020.04.21.053058
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Pizzato M, 2009, J VIROL METHODS, V156, P1, DOI 10.1016/j.jviromet.2008.10.012
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 10
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2379-5042
J9 MSPHERE
JI mSphere
PD SEP-OCT
PY 2020
VL 5
IS 5
AR e00658-20
DI 10.1128/mSphere.00658-20
PG 7
WC Microbiology
SC Microbiology
GA OC7VK
UT WOS:000579365500052
PM 32878932
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Galmes, S
   Serra, F
   Palou, A
AF Galmes, Sebastia
   Serra, Francisca
   Palou, Andreu
TI Current State of Evidence: Influence of Nutritional and Nutrigenetic
   Factors on Immunity in the COVID-19 Pandemic Framework
SO NUTRIENTS
LA English
DT Article
DE immunity; micronutrient; COVID-19; SARS-CoV-2; genetic variant;
   nutrigenetics; epidemiology
ID GENOME-WIDE ASSOCIATION; VITAMIN-C; SELENIUM; PLASMA; DEFICIENCY; SARS;
   IRON; SUPPLEMENTATION; POLYMORPHISMS; INHIBITION
AB The pandemic caused by the new coronavirus has caused shock waves in many countries, producing a global health crisis worldwide. Lack of knowledge of the biological mechanisms of viruses, plus the absence of effective treatments against the disease (COVID-19) and/or vaccines have pulled factors that can compromise the proper functioning of the immune system to fight against infectious diseases into the spotlight. The optimal status of specific nutrients is considered crucial to keeping immune components within their normal activity, helping to avoid and overcome infections. Specifically, the European Food Safety Authority (EFSA) evaluated and deems six vitamins (D, A, C, Folate, B-6, B-12) and four minerals (zinc, iron, copper and selenium) to be essential for the normal functioning of the immune system, due to the scientific evidence collected so far. In this report, an update on the evidence of the contribution of nutritional factors as immune-enhancing aspects, factors that could reduce their bioavailability, and the role of the optimal status of these nutrients within the COVID-19 pandemic context was carried out. First, a non-systematic review of the current state of knowledge regarding the impact of an optimal nutritional status of these nutrients on the proper functioning of the immune system as well as their potential role in COVID-19 prevention/treatment was carried out by searching for available scientific evidence in PubMed and LitCovid databases. Second, a compilation from published sources and an analysis of nutritional data from 10 European countries was performed, and the relationship between country nutritional status and epidemiological COVID-19 data (available in the Worldometers database) was evaluated following an ecological study design. Furthermore, the potential effect of genetics was considered through the selection of genetic variants previously identified in Genome-Wide Association studies (GWAs) as influencing the nutritional status of these 10 considered nutrients. Therefore, access to genetic information in accessible databases (1000genomes, by Ensembl) of individuals from European populations enabled an approximation that countries might present a greater risk of suboptimal status of the nutrients studied. Results from the review approach show the importance of maintaining a correct nutritional status of these 10 nutrients analyzed for the health of the immune system, highlighting the importance of Vitamin D and iron in the context of COVID-19. Besides, the ecological study demonstrates that intake levels of relevant micronutrients-especially Vitamins D, C, B-12, and iron-are inversely associated with higher COVID-19 incidence and/or mortality, particularly in populations genetically predisposed to show lower micronutrient status. In conclusion, nutrigenetic data provided by joint assessment of 10 essential nutrients for the functioning of the immune system and of the genetic factors that can limit their bioavailability can be a fundamental tool to help strengthen the immune system of individuals and prepare populations to fight against infectious diseases such as COVID-19.
C1 [Galmes, Sebastia; Serra, Francisca; Palou, Andreu] Univ Illes Balears, NUO Grp, Lab Mol Biol Nutr & Biotechnol, Palma De Mallorca 07122, Spain.
   [Galmes, Sebastia; Serra, Francisca; Palou, Andreu] CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Madrid 28029, Spain.
   [Galmes, Sebastia; Serra, Francisca; Palou, Andreu] Inst Invest Sanitaria Illes Balears IdISBa, Palma De Mallorca 07120, Spain.
   [Galmes, Sebastia; Serra, Francisca] Univ Balearic Isl, Alimentom SL, Palma De Mallorca 07121, Spain.
RP Serra, F (corresponding author), Univ Illes Balears, NUO Grp, Lab Mol Biol Nutr & Biotechnol, Palma De Mallorca 07122, Spain.; Serra, F (corresponding author), CIBER Fisiopatol Obesidad & Nutr CIBEROBN, Madrid 28029, Spain.; Serra, F (corresponding author), Inst Invest Sanitaria Illes Balears IdISBa, Palma De Mallorca 07120, Spain.; Serra, F (corresponding author), Univ Balearic Isl, Alimentom SL, Palma De Mallorca 07121, Spain.
EM s.galmes@uib.cat; francisca.serra@uib.es; andreu.palou@uib.es
RI GalmA©s, SebastiA/ABB-1742-2020; Serra, Francisca/B-8641-2008; Palou,
   Andreu/K-9881-2014
OI GalmA©s, SebastiA/0000-0002-4243-9527; Serra,
   Francisca/0000-0002-8307-9732; Palou, Andreu/0000-0002-0295-4452
CR Abobaker A, 2020, EUR J CLIN PHARMACOL, V76, P1619, DOI 10.1007/s00228-020-02942-9
   Agoro R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196921
   Agostoni C, 2010, EFSA J, V8, DOI 10.2903/j.efsa.2010.1459
   Alipio M., 2020, SSRN ELECT J, DOI [10.2139/ssrn.3571484, DOI 10.2139/SSRN.3571484]
   Allayee H, 2009, J NUTRIGENET NUTRIGE, V2, P140, DOI 10.1159/000235562
   Allende A, 2015, EFSA J, V13, DOI 10.2903/j.efsa.2015.4330
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Alvarez BV, 2013, BMC CARDIOVASC DISOR, V13, DOI 10.1186/1471-2261-13-2
   Amrein K, 2020, EUR J CLIN NUTR, V74, P1498, DOI 10.1038/s41430-020-0558-y
   Andreoletti O, 2014, EFSA J, V12, DOI 10.2903/j.efsa.2014.3782
   Andreou A, 2020, IN VIVO, V34, P1567, DOI 10.21873/invivo.11946
   [Anonymous], 2009, EFSA J, V7, P1225, DOI [10.2903/j.efsa.2009.1225, DOI 10.2903/J.EFSA.2009.1225]
   [Anonymous], 2009, EFSA J, V7, P1220, DOI [10.2903/j.efsa.2009.1220, DOI 10.2903/J.EFSA.2009.1220]
   [Anonymous], 2009, EFSA J, V7, P1211, DOI [10.2903/j.efsa.2009.1211, DOI 10.2903/J.EFSA.2009.1211]
   [Anonymous], 2009, EFSA J, V7, P1229, DOI [10.2903/j.efsa.2009.1229, DOI 10.2903/J.EFSA.2009.1229]
   Arnaud L, 2015, FEBS LETT, V589, P3624, DOI 10.1016/j.febslet.2015.09.029
   Astle WJ, 2016, CELL, V167, P1415, DOI 10.1016/j.cell.2016.10.042
   ATHERTON JG, 1978, ARCH VIROL, V56, P195, DOI 10.1007/BF01317848
   Axelrod A.E., 1981, DIET RESISTANCE DISE, P93
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Baum L, 2004, CLIN CHEM LAB MED, V42, P1370, DOI 10.1515/CCLM.2004.256
   Beck MA, 2003, J NUTR, V133, p1463S, DOI 10.1093/jn/133.5.1463S
   Benford D, 2015, EFSA J, V13, DOI 10.2903/j.efsa.2015.4140
   Benyamin B, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5926
   Berry DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037465
   Bertoldi G, 2020, ALIMENT PHARM THER, V52, P577, DOI 10.1111/apt.15895
   Besold AN, 2016, J BIOL INORG CHEM, V21, P137, DOI 10.1007/s00775-016-1335-1
   Bolondi G, 2020, WORLD J EMERG SURG, V15, DOI 10.1186/s13017-020-00323-2
   Bonet ML, 2020, BBA-MOL CELL BIOL L, V1865, DOI 10.1016/j.bbalip.2020.158676
   Boretti A, 2020, PHARMANUTRITION, V12, DOI 10.1016/j.phanu.2020.100190
   Brasiel PGD, 2020, CLIN NUTR ESPEN, V38, P65, DOI 10.1016/j.clnesp.2020.06.003
   Bresson JL, 2015, EFSA J, V13, DOI 10.2903/j.efsa.2015.4254
   Bresson JL, 2016, EFSA J, V14, DOI 10.2903/j.efsa.2016.4547
   Bresson JL, 2016, EFSA J, V14, DOI 10.2903/j.efsa.2016.4485
   Brigham EP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117545
   BROWN GM, 1959, J BIOL CHEM, V234, P370
   Buniello A, 2019, NUCLEIC ACIDS RES, V47, pD1005, DOI 10.1093/nar/gky1120
   Carr AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02851-4
   Carr AC, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2538-y
   Chen KH, 2020, J CHIN MED ASSOC, V83, P817, DOI 10.1097/JCMA.0000000000000375
   CHEW BP, 1993, J DAIRY SCI, V76, P2804, DOI 10.3168/jds.S0022-0302(93)77619-5
   Cifre M, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600353
   Biancatelli RMLC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01451
   Cornelis MC, 2015, HUM MOL GENET, V24, P1469, DOI 10.1093/hmg/ddu546
   D'Adamo CR, 2016, J NUTRIGENET NUTRIGE, V9, P254, DOI 10.1159/000452890
   D'Adamo CR, 2016, NUTRIENTS, V8, DOI 10.3390/nu8020082
   D'Amico F, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051536
   D'Lima NG, 2017, NAT CHEM BIOL, V13, P174, DOI [10.1038/nchembio.2249, 10.1038/NCHEMBIO.2249]
   Daneshkhah A., 2020, ROLE VITAMIN D SUPPR, DOI [10.1101/2020.04.08.20058578, DOI 10.1101/2020.04.08.20058578]
   Derwand R, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109815
   Dhar D, 2020, VIRUS RES, V285, DOI 10.1016/j.virusres.2020.198018
   Doboszewska U, 2020, BRIT J PHARMACOL, V177, P4887, DOI 10.1111/bph.15199
   Ducker GS, 2017, CELL METAB, V25, P27, DOI 10.1016/j.cmet.2016.08.009
   EFSA, 2013, EFSA J, V11, P1
   Ehret GB, 2011, NATURE, V478, P103, DOI 10.1038/nature10405
   Elmadfa I, 2009, FORUM NUTR, V62, P1, DOI [10.1159/000244607, 10.1159/000242367]
   European Food Safety Authority (EFSA), DRV FIND
   European Food Safety Authority (EFSA), DIET REF VAL VIT A A
   Evans DM, 2013, HUM MOL GENET, V22, P3998, DOI 10.1093/hmg/ddt239
   Farhat G, 2019, PUBLIC HEALTH, V167, P70, DOI 10.1016/j.puhe.2018.10.016
   Ferrucci L, 2009, AM J HUM GENET, V84, P123, DOI 10.1016/j.ajhg.2008.12.019
   Finzi E, 2020, INT J INFECT DIS, V99, P307, DOI 10.1016/j.ijid.2020.06.006
   Fogarty H, 2020, BRIT J HAEMATOL, V189, P1044, DOI 10.1111/bjh.16749
   Fowler AA, 2019, JAMA-J AM MED ASSOC, V322, P1261, DOI 10.1001/jama.2019.11825
   Galmes S, 2019, NUTRIENTS, V11, DOI 10.3390/nu11020298
   Galmes S, 2018, NUTRIENTS, V10, DOI 10.3390/nu10121919
   Garcia OP, 2012, P NUTR SOC, V71, P290, DOI 10.1017/S0029665112000079
   Gombart AF, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010236
   Gong J, 2013, NUTRIENTS, V5, P1706, DOI 10.3390/nu5051706
   GOODMAN DS, 1966, J BIOL CHEM, V241, P1929
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Hadizadeh Fatemeh, 2020, Nutr Rev, DOI 10.1093/nutrit/nuaa081
   Hastie CE, 2020, DIABETES METAB SYND, V14, P561, DOI 10.1016/j.dsx.2020.04.050
   Hemila H, 1997, PEDIATR INFECT DIS J, V16, P836, DOI 10.1097/00006454-199709000-00003
   Hemila H, 2017, NUTRIENTS, V9, DOI 10.3390/nu9040339
   Hiedra R, 2020, EXPERT REV ANTI-INFE, V18, P1259, DOI 10.1080/14787210.2020.1794819
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hiraoka M, 2017, CONGENIT ANOM, V57, P142, DOI 10.1111/cga.12232
   Hong J, 2018, J CLIN ENDOCR METAB, V103, P1380, DOI 10.1210/jc.2017-01802
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ilie PC, 2020, AGING CLIN EXP RES, V32, P1195, DOI 10.1007/s40520-020-01570-8
   Institute of Medicine (US), 2001, PAN MICR DIET REF IN
   Jayawardena R, 2020, DIABETES METAB SYND, V14, P367, DOI 10.1016/j.dsx.2020.04.015
   Jiang X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02662-2
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kampe A, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008530
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Kantoch Miroslaw, 2002, Rocz Panstw Zakl Hig, V53, P385
   Katsarou M.S, 2019, HEMOCHROMATOSIS HERE, V110
   Kaur B, 2014, MICRONUTRIENT STATUS, V71
   Kehoe L, 2019, P NUTR SOC, V78, P221, DOI 10.1017/S0029665118002744
   Kieliszek M, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109878
   Kobylecki CJ, 2018, RHEUMATOLOGY, V57, P1769, DOI 10.1093/rheumatology/key171
   Kuras R, 2018, J TRACE ELEM MED BIO, V49, P43, DOI 10.1016/j.jtemb.2018.04.032
   Lietz G, 2012, J NUTR, V142, p161S, DOI 10.3945/jn.111.140756
   Maggini S., 2008, CAB Reviews: Perspectives in Agriculture, Veterinary Science, Nutrition and Natural Resources, V3, P1, DOI 10.1079/PAVSNNR20083098
   Maggini S, 2007, BRIT J NUTR, V98, pS29, DOI 10.1017/S0007114507832971
   May JM, 2011, BRIT J PHARMACOL, V164, P1793, DOI 10.1111/j.1476-5381.2011.01350.x
   McLaren CE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017390
   Mensink GBM, 2013, BRIT J NUTR, V110, P755, DOI 10.1017/S000711451200565X
   Minandri F, 2016, INFECT IMMUN, V84, P2324, DOI 10.1128/IAI.00098-16
   Mondul AM, 2011, HUM MOL GENET, V20, P4724, DOI 10.1093/hmg/ddr387
   Moy KA, 2014, AM J CLIN NUTR, V99, P1424, DOI 10.3945/ajcn.113.080309
   Moyersoen I, 2017, NUTRIENTS, V9, DOI 10.3390/nu9080860
   NDA EFSA, 2012, EFSA J, V10, DOI [10.2903/j.efsa.2012.2815, DOI 10.2903/J.EFSA.2012.2815]
   NDA EFSA, 2010, EFSA J, V8, DOI [10.2903/j.efsa.2010.1458, DOI 10.2903/J.EFSA.2010.1458]
   NDA EFSA, 2014, EFSA J, V12, P3844, DOI [10.2903/j.efsa.2014.3844, DOI 10.2903/J.EFSA.2014.3844]
   Nongmaithem SS, 2017, HUM MOL GENET, V26, P2551, DOI 10.1093/hmg/ddx071
   Panel E, 2009, EFSA J, V7, P1215, DOI [10.2903/j.efsa.2009.1215, DOI 10.2903/J.EFSA.2009.1215]
   Panel E., 2011, EFSA J, V9, P2079, DOI [10.2903/j.efsa.2011.2079, DOI 10.2903/J.EFSA.2011.2079]
   Percival SS, 1998, AM J CLIN NUTR, V67, p1064S, DOI 10.1093/ajcn/67.5.1064S
   Perricone C, 2020, IMMUNOL RES, V68, P213, DOI 10.1007/s12026-020-09145-5
   Pichler I, 2011, HUM MOL GENET, V20, P1232, DOI 10.1093/hmg/ddq552
   Pilling LC, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.k5222
   Raffield LM, 2017, HUM MOL GENET, V26, P1966, DOI 10.1093/hmg/ddx082
   Raha S, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109814
   Razzaque MS, 2020, TOHOKU J EXP MED, V251, P175, DOI 10.1620/tjem.251.175
   Rippin HL, 2017, NUTRIENTS, V9, DOI 10.3390/nu9121288
   Rocha FAC, 2020, PHYTOTHER RES, V34, P2085, DOI 10.1002/ptr.6745
   Rogero MM, 2020, FREE RADICAL BIO MED, V156, P190, DOI 10.1016/j.freeradbiomed.2020.07.005
   Vinas BR, 2011, ANN NUTR METAB, V59, P84, DOI 10.1159/000332762
   Rousseau S, 2020, CRIT REV FOOD SCI, V60, P826, DOI 10.1080/10408398.2018.1552243
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Saeed F, 2016, FOOD AGR IMMUNOL, V27, P205, DOI 10.1080/09540105.2015.1079600
   Sassi F, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111656
   Satia JA, 2006, ANN EPIDEMIOL, V16, P53, DOI 10.1016/j.annepidem.2005.02.011
   Seale LA, 2020, AM J CLIN NUTR, V112, P447, DOI 10.1093/ajcn/nqaa177
   Semba RD, 1999, P NUTR SOC, V58, P719, DOI 10.1017/S0029665199000944
   Shane B, 2018, AM J CLIN NUTR, V108, P1334, DOI 10.1093/ajcn/nqy209
   Sheybani Z, 2020, ROLE FOLIC ACID MANA, DOI [10.26434/chemrxiv, DOI 10.26434/CHEMRXIV]
   Simonson W, 2020, GERIATR NURS, V41, P331, DOI 10.1016/j.gerinurse.2020.05.002
   Singh Y, 2020, DERMATOL THER, DOI 10.1111/dth.13871
   Sobczak AIS, 2019, BIOMETALS, V32, P123, DOI 10.1007/s10534-018-00167-z
   Sobiecki JG, 2016, NUTR RES, V36, P464, DOI 10.1016/j.nutres.2015.12.016
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Strahle W.C., 1978, CELL HOST MICROBE, V13, P509, DOI [10.1016/j.chom.2013.04.010, DOI 10.1016/J.CHOM.2013.04.010]
   Stubbs Brianna J, 2020, Med (N Y), V1, P43, DOI 10.1016/j.medj.2020.06.008
   Tanaka T, 2009, AM J HUM GENET, V84, P477, DOI 10.1016/j.ajhg.2009.02.011
   TEVELTHUIS AJW, 2010, PLOS PATHOG, V0006
   Thomas-Valdes S, 2017, CRIT REV FOOD SCI, V57, P3332, DOI 10.1080/10408398.2015.1117413
   Timpson NJ, 2013, AM J CLIN NUTR, V98, P253, DOI 10.3945/ajcn.113.065342
   Topilski I, 2004, EUR J IMMUNOL, V34, P1068, DOI 10.1002/eji.200324532
   Toti E, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4637861
   Trasino SE, 2020, CLIN EXP PHARMACOL P, V47, P1765, DOI 10.1111/1440-1681.13354
   Troen AM, 2006, J NUTR, V136, P189
   Tuerk MJ, 2009, CURR OPIN GASTROEN, V25, P136, DOI 10.1097/MOG.0b013e328321b395
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   van Meurs JBJ, 2013, AM J CLIN NUTR, V98, P668, DOI 10.3945/ajcn.112.044545
   Vavougios George D, 2020, Free Radic Biol Med, DOI 10.1016/j.freeradbiomed.2020.07.014
   Villamor E, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.1.e6
   Vural Z, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041072
   Wahedi HM, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762743
   Wallace TC, 2020, J AM COLL NUTR, V39, P685, DOI 10.1080/07315724.2020.1785971
   Wang TJ, 2010, LANCET, V376, P180, DOI 10.1016/S0140-6736(10)60588-0
   Weir EK, 2020, CLIN MED, V20, pE107, DOI 10.7861/clinmed.2020-0301
   Wishart K, 2017, VITAMIN MINER, V6, P166, DOI [10.4172/2376-1318.1000166, DOI 10.4172/2376-1318.1000166]
   World Health Organization, WHO COR DIS COVID 19
   Wyss A, 2001, BIOCHEM J, V354, P521, DOI 10.1042/0264-6021:3540521
   Xu J, 2017, MOL MED REP, V16, P7432, DOI 10.3892/mmr.2017.7546
   Zahedipour F, 2020, PHYTOTHER RES, V34, P2911, DOI 10.1002/ptr.6738
   Zhang JS, 2020, AM J CLIN NUTR, V111, P1297, DOI 10.1093/ajcn/nqaa095
   Zhao K., 2020, OPEN FORUM INFECT DI, P1, DOI [10.1093/ofid/ofaa250, DOI 10.1093/OFID/OFAA250]
NR 162
TC 0
Z9 0
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD SEP
PY 2020
VL 12
IS 9
AR 2738
DI 10.3390/nu12092738
PG 33
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA OG6ML
UT WOS:000581995400001
PM 32911778
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hassan, Y
   Ogg, S
   Ge, H
AF Hassan, Yasser
   Ogg, Sherry
   Ge, Hui
TI Novel Binding Mechanisms of Fusion Broad Range Anti-Infective Protein
   Ricin A Chain Mutant-Pokeweed Antiviral Protein 1 (RTAM-PAP1) against
   SARS-CoV-2 Key Proteins in Silico
SO TOXINS
LA English
DT Article
DE fusion proteins; ricin; pokeweed antiviral protein; COVID-19;
   SARS-CoV-2; antiviral agent; ribosome-inactivating proteins
ID INHIBITION; VIRUS; REPLICATION; INFECTION; TOXICITY; DOCKING; TISSUE;
   VITRO; VIVO
AB The deadly pandemic named COVID-19, caused by a new coronavirus (SARS-CoV-2), emerged in 2019 and is still spreading globally at a dangerous pace. As of today, there are no proven vaccines, therapies, or even strategies to fight off this virus. Here, we describe the in silico docking results of a novel broad range anti-infective fusion protein RTAM-PAP1 against the various key proteins of SARS-CoV-2 using the latest protein-ligand docking software. RTAM-PAP1 was compared against the SARS-CoV-2 B38 antibody, ricin A chain, a pokeweed antiviral protein from leaves, and the lectin griffithsin using the special CoDockPP COVID-19 version. These experiments revealed novel binding mechanisms of RTAM-PAP1 with a high affinity to numerous SARS-CoV-2 key proteins. RTAM-PAP1 was further characterized in a preliminary toxicity study in mice and was found to be a potential therapeutic candidate. These findings might lead to the discovery of novel SARS-CoV-2 targets and therapeutic protein structures with outstanding functions.
C1 [Hassan, Yasser] Ophiuchus Med Inc, Vancouver, BC V6B 0M3, Canada.
   [Ogg, Sherry] Johns Hopkins Univ, Biotechnol, AAP, Baltimore, MD 21218 USA.
   [Ge, Hui] AscentGene Inc, Gaithersburg, MD 20878 USA.
RP Hassan, Y (corresponding author), Ophiuchus Med Inc, Vancouver, BC V6B 0M3, Canada.
EM yhassan@ophiuchus.institute; slojac@gmail.com; hge@ascentgene.com
RI Hassan, Yasser/ABE-3309-2020
OI Hassan, Yasser/0000-0001-6828-3092
FU Ophiuchus Medicine
FX This work was funded by Ophiuchus Medicine which owns the rights to the
   patent pending of the fusion protein described in this study. The entire
   study was done at the request of, by, and for Ophiuchus Medicine.
CR Amawi H, 2020, THER DELIV, V11, P245, DOI 10.4155/tde-2020-0035
   BARBIERI L, 1990, XENOBIOTICA, V20, P1331, DOI 10.3109/00498259009046631
   BATTELLI MG, 1990, APMIS, V98, P585, DOI 10.1111/j.1699-0463.1990.tb04975.x
   Domashevskiy AV, 2015, TOXINS, V7, P274, DOI 10.3390/toxins7020274
   Hassan Y., 2019, The World Intellectual Property Organization (WIPO), VWO/2019/204902, Patent No. 2019204902
   Hassan Y, 2018, BMC BIOTECHNOL, V18, DOI 10.1186/s12896-018-0458-6
   Ishag HZA, 2013, VIRUS RES, V171, P89, DOI 10.1016/j.virusres.2012.10.032
   Ko SM, 2015, J FOOD PROTECT, V78, P1046, DOI 10.4315/0362-028X.JFP-14-540
   Kong R., 2020, ARXIV200300163V1
   Kong R, 2019, J CHEM INF MODEL, V59, P3556, DOI 10.1021/acs.jcim.9b00445
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Mani JS, 2020, VIRUS RES, V284, DOI 10.1016/j.virusres.2020.197989
   O'Keefe BR, 2010, J VIROL, V84, P2511, DOI 10.1128/JVI.02322-09
   OLSON MC, 1991, AIDS RES HUM RETROV, V7, P1025, DOI 10.1089/aid.1991.7.1025
   Othman H, 2020, BIOCHEM BIOPH RES CO, V527, P702, DOI 10.1016/j.bbrc.2020.05.028
   Pierce BG, 2014, BIOINFORMATICS, V30, P1771, DOI 10.1093/bioinformatics/btu097
   TELTOW GJ, 1983, ANTIMICROB AGENTS CH, V23, P390, DOI 10.1128/AAC.23.3.390
   TOMLINSON JA, 1974, J GEN VIROL, V22, P225, DOI 10.1099/0022-1317-22-2-225
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Uckun FM, 1999, J PHARMACOL EXP THER, V291, P1301
   USSERY MA, 1977, ANN NY ACAD SCI, V284, P431, DOI 10.1111/j.1749-6632.1977.tb21979.x
   van Zundert GCP, 2016, J MOL BIOL, V428, P720, DOI 10.1016/j.jmb.2015.09.014
   Wassenaar TA, 2012, J GRID COMPUT, V10, P743, DOI 10.1007/s10723-012-9246-z
   Wu Y, 2020, SCIENCE, V368, P1274, DOI 10.1126/science.abc2241
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
NR 25
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6651
J9 TOXINS
JI Toxins
PD SEP
PY 2020
VL 12
IS 9
AR 602
DI 10.3390/toxins12090602
PG 10
WC Food Science & Technology; Toxicology
SC Food Science & Technology; Toxicology
GA OD9TX
UT WOS:000580187700001
PM 32957454
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Amato, M
   Werba, JP
   Frigerio, B
   Coggi, D
   Sansaro, D
   Ravani, A
   Ferrante, P
   Veglia, F
   Tremoli, E
   Baldassarre, D
AF Amato, Mauro
   Werba, Jose Pablo
   Frigerio, Beatrice
   Coggi, Daniela
   Sansaro, Daniela
   Ravani, Alessio
   Ferrante, Palma
   Veglia, Fabrizio
   Tremoli, Elena
   Baldassarre, Damiano
TI Relationship between Influenza Vaccination Coverage Rate and COVID-19
   Outbreak: An Italian Ecological Study
SO VACCINES
LA English
DT Article
DE influenza vaccination coverage rate; COVID-19; coronavirus spread
AB Background:The lack of specific vaccines or drugs against coronavirus disease 2019 (COVID-19) warrants studies focusing on alternative clinical approaches to reduce the spread of this pandemic disease. In this study, we investigated whether anti-influenza vaccination plays a role in minimizing the diffusion of COVID-19 in the Italian population aged 65 and over.Methods:Four COVID-19 outcomes were used: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence, hospitalizations for COVID-19 symptoms, admissions to intensive care units for reasons related to SARS-CoV-2, and deaths attributable to COVID-19.Results:At univariate analyses, the influenza vaccination coverage rates correlated negatively with all COVID-19 outcomes (Beta ranging from -134 to -0.61; allp< 0.01). At multivariable analyses, influenza vaccination coverage rates correlated independently with SARS-CoV-2 seroprevalence (Beta (95% C.I.): -130 (-198, -62);p= 0.001), hospitalizations for COVID-19 symptoms (Beta (95% C.I.): -4.16 (-6.27, -2.05);p= 0.001), admission to intensive care units for reasons related to SARS-CoV-2 (Beta (95% C.I.): -0.58 (-1.05, -0.12);p= 0.017), and number of deaths attributable to COVID-19 (Beta (95% C.I.): -3.29 (-5.66, -0.93);p= 0.010). The R(2)observed in the unadjusted analysis increased from 82% to 159% for all the considered outcomes after multivariable analyses.Conclusions:In the Italian population, the coverage rate of the influenza vaccination in people aged 65 and over is associated with a reduced spread and a less severe clinical expression of COVID-19. This finding warrants ad hoc studies to investigate the role of influenza vaccination in preventing the spread of COVID-19.
C1 [Amato, Mauro; Werba, Jose Pablo; Frigerio, Beatrice; Coggi, Daniela; Sansaro, Daniela; Ravani, Alessio; Ferrante, Palma; Veglia, Fabrizio; Tremoli, Elena; Baldassarre, Damiano] IRCCS, Ctr Cardiol Monzino, I-20138 Milan, Italy.
   [Coggi, Daniela] Univ Milan, Dipartimento Sci Farmacol & Biomol, I-20133 Milan, Italy.
   [Baldassarre, Damiano] Univ Milan, Dept Med Biotechnol & Translat Med, I-20129 Milan, Italy.
RP Baldassarre, D (corresponding author), IRCCS, Ctr Cardiol Monzino, I-20138 Milan, Italy.; Baldassarre, D (corresponding author), Univ Milan, Dept Med Biotechnol & Translat Med, I-20129 Milan, Italy.
EM mauro.amato@ccfm.it; pablo.werba@ccfm.it; beatrice.frigerio@ccfm.it;
   daniela.coggi@ccfm.it; daniela.sansaro@ccfm.it; alessio.ravani@ccfm.it;
   ferrante.palma@cardiologicomonzino.it; fabrizio.veglia@ccfm.it;
   elena.tremoli@ccfm.it; damiano.baldassarre@unimi.it
RI Werba, Jose Pablo/AAC-8973-2019; Amato, Mauro/J-3289-2016; Coggi,
   Daniela/F-3926-2018; Baldassarre, Damiano/J-3295-2016; Veglia,
   Fabrizio/K-1958-2016; Ravani, Alessio Luigi/J-8193-2016
OI Werba, Jose Pablo/0000-0001-7188-1157; Amato, Mauro/0000-0002-0118-5719;
   Coggi, Daniela/0000-0003-3857-298X; Baldassarre,
   Damiano/0000-0002-2766-8882; Veglia, Fabrizio/0000-0002-9378-8874;
   Ravani, Alessio Luigi/0000-0003-4894-7685
CR Adebowale V, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2514
   Aidoud A, 2020, VACCINE, V38, P4944, DOI 10.1016/j.vaccine.2020.05.070
   [Anonymous], 2020, 51 WHO
   Asfahan S, 2020, MONALDI ARCH CHEST D, V90, P313, DOI 10.4081/monaldi.2020.1325
   Bontempi E, 2020, ENVIRON RES, V188, DOI 10.1016/j.envres.2020.109775
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Consortium E, 2020, COVID 19 SEV EUR US, DOI [10.2139/ssrn.3621446, DOI 10.2139/SSRN.3621446]
   Costantino C, 2016, J Prev Med Hyg, V57, pE13
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Espinosa OA, 2020, REV INST MED TROP SP, V62, DOI [10.1590/S1678-9946202062043, 10.1590/s1678-9946202062043]
   Fink G, 2020, INACTIVATED TRIVALEN, DOI [10.1101/2020.06.29.20142505, DOI 10.1101/2020.06.29.20142505]
   Hashemi SA, 2020, J MED VIROL, DOI 10.1002/jmv.26364
   Horns F, 2020, CELL REP, V30, P905, DOI 10.1016/j.celrep.2019.12.063
   Iqbal MM, 2020, SCI TOTAL ENVIRON, V739, DOI 10.1016/j.scitotenv.2020.140101
   Khan K, 2005, EMERG INFECT DIS, V11, P191, DOI 10.3201/eid1102.040524
   Kim D, 2020, JAMA-J AM MED ASSOC, V323, P2085, DOI 10.1001/jama.2020.6266
   Kleinnijenhuis J, 2014, J INNATE IMMUN, V6, P152, DOI 10.1159/000355628
   Lau H, 2020, J MICROBIOL IMMUNOL, V53, P467, DOI 10.1016/j.jmii.2020.03.026
   Li Q, 2020, MATH BIOSCI, V325, DOI 10.1016/j.mbs.2020.108378
   MacIntyre CR, 2016, HEART, V102, P1953, DOI 10.1136/heartjnl-2016-309983
   Mandal CC, 2020, PUBLIC HEALTH, V185, P72, DOI 10.1016/j.puhe.2020.05.065
   Marin-Hernandez D, 2020, J MED VIROL, DOI 10.1002/jmv.26120
   Miller A, 2020, CORRELATION UNIVERSA, DOI [DOI 10.1101/2020.03.24.20042937, 10.1101/2020.03.24.20042937]
   Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   Pani SK, 2020, SCI TOTAL ENVIRON, V740, DOI 10.1016/j.scitotenv.2020.140112
   Petersen E, 2020, LANCET INFECT DIS, V20, pE238, DOI 10.1016/S1473-3099(20)30484-9
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Rieckmann A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031415
   Stokes EK, 2020, MMWR-MORBID MORTAL W, V69, P759, DOI 10.15585/mmwr.mm6924e2
   Washio M, 2008, VACCINE, V26, P6470, DOI 10.1016/j.vaccine.2008.06.037
   WISE J, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2294
   Wolff GG, 2020, VACCINE, V38, P350, DOI 10.1016/j.vaccine.2019.10.005
   Worby CJ, 2015, EPIDEMICS-NETH, V13, P10, DOI 10.1016/j.epidem.2015.04.003
   World Health Organization, 2003, PREV CONTR INFL PAND
   Wu HH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219172
   Zanettini Claudio, 2020, medRxiv, DOI 10.1101/2020.06.24.20129817
   Zeng Q, 2007, MATH BIOSCI ENG, V4, P739
   Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021
NR 39
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-393X
J9 VACCINES-BASEL
JI Vaccines
PD SEP
PY 2020
VL 8
IS 3
AR 535
DI 10.3390/vaccines8030535
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OD7HV
UT WOS:000580021100001
PM 32947988
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Corral-Lugo, A
   Lopez-Siles, M
   Lopez, D
   McConnell, MJ
   Martin-Galiano, AJ
AF Corral-Lugo, Andres
   Lopez-Siles, Mireia
   Lopez, Daniel
   McConnell, Michael J.
   Martin-Galiano, Antonio J.
TI Identification and Analysis of Unstructured, Linear B-Cell Epitopes in
   SARS-CoV-2 Virion Proteins for Vaccine Development
SO VACCINES
LA English
DT Article
DE coronavirus; COVID-19; epitope prediction; epitope switch;
   immunoinformatics; unfolded protein response; SARS-CoV
ID CORONAVIRUS SPIKE PROTEIN; NUCLEOCAPSID PROTEIN; MONOCLONAL-ANTIBODY;
   MEMBRANE-PROTEIN; SARS; PEPTIDES; SEQUENCE; OUTBREAK; MUTATIONS;
   VIRULENCE
AB The efficacy of SARS-CoV-2 nucleic acid-based vaccines may be limited by proteolysis of the translated product due to anomalous protein folding. This may be the case for vaccines employing linear SARS-CoV-2 B-cell epitopes identified in previous studies since most of them participate in secondary structure formation. In contrast, we have employed a consensus of predictors for epitopic zones plus a structural filter for identifying 20 unstructured B-cell epitope-containing loops (uBCELs) in S, M, and N proteins. Phylogenetic comparison suggests epitope switching with respect to SARS-CoV in some of the identified uBCELs. Such events may be associated with the reported lack of serum cross-protection between the 2003 and 2019 pandemic strains. Incipient variability within a sample of 1639 SARS-CoV-2 isolates was also detected for 10 uBCELs which could cause vaccine failure. Intermediate stages of the putative epitope switch events were observed in bat coronaviruses in which additive mutational processes possibly facilitating evasion of the bat immune system appear to have taken place prior to transfer to humans. While there was some overlap between uBCELs and previously validated SARS-CoV B-cell epitopes, multiple uBCELs had not been identified in prior studies. Overall, these uBCELs may facilitate the development of biomedical products for SARS-CoV-2.
C1 [Corral-Lugo, Andres; Lopez-Siles, Mireia; McConnell, Michael J.; Martin-Galiano, Antonio J.] Inst Salud Carlos III ISCIII, Natl Ctr Microbiol, Intrahosp Infect Unit, Madrid 28220, Spain.
   [Lopez, Daniel] Inst Salud Carlos III, Immune Presentat & Regulat Unit, Madrid 28220, Spain.
RP McConnell, MJ; Martin-Galiano, AJ (corresponding author), Inst Salud Carlos III ISCIII, Natl Ctr Microbiol, Intrahosp Infect Unit, Madrid 28220, Spain.
EM acorral@isciii.es; mireia.lopez@isciii.es; dlopez@isciii.es;
   michael.mcconnell@isciii.es; mgaliano@isciii.es
RI Lopez-Siles, Mireia/K-3717-2017; Lopez, Daniel/I-2632-2014
OI Lopez-Siles, Mireia/0000-0002-5805-8446; Lopez,
   Daniel/0000-0003-0268-5878
FU Accion Estrategica en Salud from the ISCIII [MPY 380/18, MPY 388/18, MPY
   509/19]
FX This research was supported by Accion Estrategica en Salud from the
   ISCIII, grants MPY 380/18, MPY 388/18, and MPY 509/19. A.C.-L. is the
   recipient of a Comunidad de Madrid contract by the ISCIII. M.L.-S. is
   the recipient of a Sara Borrell contract by the ISCIII. A.J.M.-G. is the
   recipient of a Miguel Servet contract by the ISCIII.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742
   Baruah V, 2020, J MED VIROL, V92, P495, DOI 10.1002/jmv.25698
   Bussmann BM, 2006, VIRUS RES, V122, P119, DOI 10.1016/j.virusres.2006.07.005
   Buus S, 2012, MOL CELL PROTEOMICS, V11, P1790, DOI 10.1074/mcp.M112.020800
   Carpentier GS, 2005, J MED VIROL, V77, P558, DOI 10.1002/jmv.20492
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Che XY, 2004, EMERG INFECT DIS, V10, P1947, DOI 10.3201/eid1011.040516
   Chen CY, 2007, J MOL BIOL, V368, P1075, DOI 10.1016/j.jmb.2007.02.069
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cheng ZKJ, 2020, INFECTION, V48, P155, DOI 10.1007/s15010-020-01401-y
   Cheung YK, 2007, VACCINE, V25, P6070, DOI 10.1016/j.vaccine.2007.05.025
   Chow SCS, 2006, J CLIN PATHOL, V59, P468, DOI 10.1136/jcp.2005.029868
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Du LY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13473
   Enjuanes L, 2016, ADV VIRUS RES, V96, P245, DOI 10.1016/bs.aivir.2016.08.003
   Goo L, 2018, VIROLOGY, V515, P191, DOI 10.1016/j.virol.2017.12.032
   Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002
   Guo JP, 2004, VIROLOGY, V324, P251, DOI 10.1016/j.virol.2004.04.017
   He YX, 2006, VACCINE, V24, P5498, DOI 10.1016/j.vaccine.2006.04.054
   He YX, 2006, J VIROL, V80, P5757, DOI 10.1128/JVI.00083-06
   He YX, 2005, J CLIN MICROBIOL, V43, P3718, DOI 10.1128/JCM.43.8.3718-3726.2005
   Hu D, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0155-5
   Hu HB, 2005, J COMB CHEM, V7, P648, DOI 10.1021/cc0500607
   Hua RH, 2004, BIOCHEM BIOPH RES CO, V319, P929, DOI 10.1016/j.bbrc.2004.05.066
   Ibrahim IM, 2019, LIFE SCI, V226, P156, DOI 10.1016/j.lfs.2019.04.022
   Kalinina OV, 2004, PROTEIN SCI, V13, P443, DOI 10.1110/ps.03191704
   Kannan S, 2020, EUR REV MED PHARMACO, V24, P2006, DOI 10.26355/eurrev_202002_20378
   Kumar Swatantra, 2020, VirusDisease, V31, DOI 10.1007/s13337-020-00571-5
   Li ZH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07199-6
   Lien SP, 2007, BIOCHEM BIOPH RES CO, V358, P716, DOI 10.1016/j.bbrc.2007.04.164
   Liu J, 2010, J INFECT DIS, V202, P1171, DOI 10.1086/656315
   Lu W, 2005, FEBS LETT, V579, P2130, DOI 10.1016/j.febslet.2005.02.070
   Marra MA, 2003, SCIENCE, V300, P1399, DOI 10.1126/science.1085953
   Ng OW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102415
   Patil S, 2016, J VIROL, V90, P3446, DOI 10.1128/JVI.03090-15
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Plant EP, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010125
   Potocnakova L, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/6760830
   Qian C, 2006, VIRUS GENES, V33, P147, DOI 10.1007/s11262-005-0050-8
   Qin E, 2003, CHINESE SCI BULL, V48, P941, DOI 10.1007/BF03184203
   Qu PK, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-019-0140-8
   Rauch S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01963
   Robson B, 2020, COMPUT BIOL MED, V119, DOI 10.1016/j.compbiomed.2020.103670
   Rubinchik E, 2000, VACCINE, V18, P2312, DOI 10.1016/S0264-410X(99)00554-X
   Schoeman D, 2019, VIROL J, V16, DOI 10.1186/s12985-019-1182-0
   Shang WL, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0170-0
   Sher G, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-4024-8
   Shin GC, 2006, VIRUS RES, V122, P109, DOI 10.1016/j.virusres.2006.07.004
   Sun PP, 2019, CURR TOP MED CHEM, V19, P105, DOI 10.2174/1568026619666181130111827
   Tilocca B, 2020, MICROBES INFECT, V22, P218, DOI 10.1016/j.micinf.2020.03.002
   TYRRELL DA, 1966, LANCET, V1, P76
   Van Regenmortal Marc H. V., 1996, Methods (Orlando), V9, P465, DOI 10.1006/meth.1996.0054
   Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Walls AC, 2016, NAT STRUCT MOL BIOL, V23, P899, DOI 10.1038/nsmb.3293
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang XH, 2008, IMMUNOL LETT, V119, P71, DOI 10.1016/j.imlet.2008.04.005
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xu LF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00477-9
   Yu H, 2007, VIROLOGY, V359, P264, DOI 10.1016/j.virol.2006.09.016
   Yu XF, 2005, IMMUNOL LETT, V100, P177, DOI 10.1016/j.imlet.2005.03.015
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Zheng M, 2020, CELL MOL IMMUNOL, V17, P536, DOI 10.1038/s41423-020-0385-z
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 66
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-393X
J9 VACCINES-BASEL
JI Vaccines
PD SEP
PY 2020
VL 8
IS 3
AR 397
DI 10.3390/vaccines8030397
PG 21
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OD8AF
UT WOS:000580068900001
PM 32698423
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Klinger, D
   Blass, I
   Rappoport, N
   Linial, M
AF Klinger, Danielle
   Blass, Ido
   Rappoport, Nadav
   Linial, Michal
TI Significantly Improved COVID-19 Outcomes in Countries with Higher BCG
   Vaccination Coverage: A Multivariable Analysis
SO VACCINES
LA English
DT Article
DE epidemiology; SARS-CoV-2; multivariable regression; tuberculosis;
   demography; coronavirus; MMR vaccine
ID PREVENTION
AB The COVID-19 pandemic that started in China has spread within 3 months to the entire globe. We tested the hypothesis that the vaccination against tuberculosis by Bacille Calmette-Guerin vaccine (BCG) correlates with a better outcome for COVID-19 patients. Our analysis covers 55 countries complying with predetermined thresholds on the population size and number of deaths per million (DPM). We found a strong negative correlation between the years of BCG administration and the DPM along with the progress of the pandemic, corroborated by permutation tests. The results from multivariable regression tests with 23 economic, demographic, health-related, and pandemic restriction-related quantitative properties, substantiate the dominant contribution of BCG years to the COVID-19 outcomes. The analysis of countries according to an age-group partition reveals that the strongest correlation is attributed to the coverage in BCG vaccination of the young population (0-24 years). Furthermore, a strong correlation and statistical significance are associated with the degree of BCG coverage for the most recent 15 years, but no association was observed in these years for other broadly used vaccination protocols for measles and rubella. We propose that BCG immunization coverage, especially among the most recently vaccinated population, contribute to attenuation of the spread and severity of the COVID-19 pandemic.
C1 [Klinger, Danielle; Linial, Michal] Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.
   [Blass, Ido] Hebrew Univ Jerusalem, Rachel & Selim Benin Sch Comp Sci & Engn, IL-91904 Jerusalem, Israel.
   [Rappoport, Nadav] Ben Gurion Univ Negev, Dept Software & Informat Syst Engn, Fac Engn Sci, IL-84105 Beer Sheva, Israel.
RP Linial, M (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.; Rappoport, N (corresponding author), Ben Gurion Univ Negev, Dept Software & Informat Syst Engn, Fac Engn Sci, IL-84105 Beer Sheva, Israel.
EM danielle.klinger@mail.huji.ac.il; ido.blass@mail.huji.ac.il;
   nadavrap@bgu.ac.il; michall@cc.huji.ac.il
RI Rappoport, Nadav/AAA-3769-2019; Linial, Michal/AAQ-9259-2020
OI Rappoport, Nadav/0000-0002-7218-2558; Linial, Michal/0000-0002-9357-4526
FU Center for Interdisciplinary Data Science (CIDR), at the Hebrew
   University
FX This research received no external funding. The Center for
   Interdisciplinary Data Science (CIDR), at the Hebrew University
   partially contributed D.K and I.B fellowship.
CR Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   Angelidou A, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00332
   Ayoub BM, 2020, PHARMAZIE, V75, P159, DOI 10.1691/ph.2020.0444
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Bank W, POP AG 65 AB TOT POP
   Basilaia G., 2020, PEDAGOGICAL RES, V5, DOI [DOI 10.29333/PR/7937, 10.29333/pr/7937]
   Bi QF, 2020, LANCET INFECT DIS, V20, P911, DOI 10.1016/S1473-3099(20)30287-5
   Bloom B.R., 2018, VALUE BCG TNF AUTOIM, P1
   Bluhm R., 2020, FRB N STAFF REP, V5, P926, DOI [10.2139/ssrn.3604314, DOI 10.2139/SSRN.3604314]
   Bodova K., 2020, TIME ADJUSTED ANAL S, DOI [10.1101/2020.05.01.20087809, DOI 10.1101/2020.05.01.20087809]
   Boldog P, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020571
   BREWER TF, 1995, CLIN INFECT DIS, V20, P126, DOI 10.1093/clinids/20.1.126
   Butkeviciute E, 2018, FUTURE MICROBIOL, V13, P1193, DOI 10.2217/fmb-2018-0026
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cohen J, 2020, SCIENCE, V367, P1287, DOI 10.1126/science.367.6484.1287
   Davies NG, 2020, NAT MED, V26, P1205, DOI 10.1038/s41591-020-0962-9
   Dijkman K, 2019, NAT MED, V25, P255, DOI 10.1038/s41591-018-0319-9
   Dockrell HM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01134
   Dowd JB, 2020, P NATL ACAD SCI USA, V117, P9696, DOI 10.1073/pnas.2004911117
   Ebrahim SH, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1066
   Gilbert M, 2020, LANCET, V395, P871, DOI 10.1016/S0140-6736(20)30411-6
   Glaziou P, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017798
   Gursel M, 2020, MED HYPOTHESES, DOI [10.1016/j.mehy.2020.109707, DOI 10.1016/J.MEHY.2020.109707]
   HART PD, 1977, BRIT MED J, V2, P293, DOI 10.1136/bmj.2.6082.293
   Hopman J, 2020, JAMA-J AM MED ASSOC, V323, P1549, DOI 10.1001/jama.2020.4169
   Jung SM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020523
   Kaufmann E, 2018, CELL, V172, P176, DOI 10.1016/j.cell.2017.12.031
   Kelvin AA, 2020, LANCET INFECT DIS, V20, P633, DOI 10.1016/S1473-3099(20)30236-X
   Kleinnijenhuis J, 2014, J INNATE IMMUN, V6, P152, DOI 10.1159/000355628
   Linehan MF, 2007, J ALLERGY CLIN IMMUN, V119, P1079, DOI 10.1016/j.jaci.2006.12.672
   Liu Yang, 2020, EClinicalMedicine, V22, P100354, DOI 10.1016/j.eclinm.2020.100354
   Ma Shujuan, 2020, EPIDEMIOLOGICAL PARA, DOI [10.1101/2020.03.21.20040329, DOI 10.1101/2020.03.21.20040329]
   Moorlag SJCFM, 2019, CLIN MICROBIOL INFEC, V25, P1473, DOI 10.1016/j.cmi.2019.04.020
   Netea MG, 2014, SEMIN IMMUNOL, V26, P512, DOI 10.1016/j.smim.2014.09.006
   O'Neill LAJ, 2020, NAT REV IMMUNOL, V20, P335, DOI 10.1038/s41577-020-0337-y
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Orme IM, 1999, MOL MED TODAY, V5, P487, DOI 10.1016/S1357-4310(99)01594-4
   Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130
   Pareek M, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0595-5
   Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5
   R Core Team, 2013, R LANG ENV STAT COMP
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Salman S, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109689
   Salman S, 2019, J AM ACAD DERMATOL, V80, P922, DOI 10.1016/j.jaad.2018.07.003
   Shim E, 2020, INT J INFECT DIS, V93, P339, DOI 10.1016/j.ijid.2020.03.031
   Subbaraman Nidhi, 2020, Nature, DOI 10.1038/d41586-020-01008-1
   Tanner R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01317
   van Rossum G., 1995, CSR9526 CWI AMST NET
   Viner RM, 2020, LANCET CHILD ADOLESC, V4, P397, DOI 10.1016/S2352-4642(20)30095-X
   Vrieze J., 2020, SCIENCE, DOI [10.1126/science.abb8297, 10.1126/science.abb8297., DOI 10.1126/SCIENCE.ABB8297]
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Wang YX, 2020, J MED VIROL, V92, P568, DOI 10.1002/jmv.25748
   Wardhana, 2011, Acta Med Indones, V43, P185
   World Health Organization (WHO), 2019, REP EST BCG COV
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zwerling A, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001012
NR 58
TC 6
Z9 6
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-393X
J9 VACCINES-BASEL
JI Vaccines
PD SEP
PY 2020
VL 8
IS 3
AR 378
DI 10.3390/vaccines8030378
PG 14
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OD9IK
UT WOS:000580157800001
PM 32664505
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Noale, M
   Trevisan, C
   Maggi, S
   Incalzi, RA
   Pedone, C
   Di Bari, M
   Adorni, F
   Jesuthasan, N
   Sojic, A
   Galli, M
   Giacomelli, A
   Molinaro, S
   Bianchi, F
   Mastroianni, C
   Prinelli, F
AF Noale, Marianna
   Trevisan, Caterina
   Maggi, Stefania
   Antonelli Incalzi, Raffaele
   Pedone, Claudio
   Di Bari, Mauro
   Adorni, Fulvio
   Jesuthasan, Nithiya
   Sojic, Aleksandra
   Galli, Massimo
   Giacomelli, Andrea
   Molinaro, Sabrina
   Bianchi, Fabrizio
   Mastroianni, Claudio
   Prinelli, Federica
CA EPICOVID19 Working Grp
TI The Association between Influenza and Pneumococcal Vaccinations and
   SARS-Cov-2 Infection: Data from the EPICOVID19 Web-Based Survey
SO VACCINES
LA English
DT Article
DE SARS-CoV-2; COVID-19; web-based survey; nasopharyngeal swab testing;
   influenza vaccination; pneumococcal vaccination
ID VACCINES; EFFICACY; RESPONSES
AB The present study aims to evaluate whether influenza and pneumococcal vaccinations are associated with positive nasopharyngeal swab (NPS) testing to detect SARS-CoV-2. Data from the Italian cross-sectional web-based survey (EPICOVID19), based on a self-selection sample of individuals aged >= 18, were considered. The probability of a positive SARS-CoV-2 NPS test result as a function of influenza or anti-pneumococcal vaccination was evaluated using multivariable logistic regression, stratifying analysis by age (<65 years, >= 65 years). From April 2020, 170,731 individuals aged <65 years and 28,097 >= 65 years filled out the EPICOVID19 questionnaire. Influenza and anti-pneumococcal vaccinations were received, respectively, by 16% and 2% of those <65 years, and by 53% and 13% of those >= 65 years. SARS-CoV-2 NPS testing was reported by 6680 participants. Anti-pneumococcal and influenza vaccinations were associated with a decreased probability of a SARS-CoV-2 NPS positive test in the younger participants (OR = 0.61, 95% CI 0.41-0.91; OR = 0.85, 95%CI 0.74-0.98; respectively). A significantly lower probability of a positive test result was detected in the individuals >= 65 years who received anti-pneumococcal vaccination (OR = 0.56, 95%CI 0.33-0.95). These results need to be confirmed by further investigations, but they are relevant given the probable coexistence of influenza, bacterial infections, and COVID-19 over the coming autumn-winter season.
C1 [Noale, Marianna; Trevisan, Caterina; Maggi, Stefania] CNR, Neurosci Inst, Aging Branch, Via Vincenzo Maria Gallucci 16, I-35128 Padua, Italy.
   [Trevisan, Caterina] Univ Padua, Dept Med DIMED, Geriatr Unit, Via Giustiniani 2, I-35128 Padua, Italy.
   [Antonelli Incalzi, Raffaele; Pedone, Claudio] Biomed Campus Rome, Dept Med, Unit Geriatr, Via Alvaro Portillo 21, I-00128 Rome, Italy.
   [Di Bari, Mauro] Univ Florence, Geriatr Intens Care Med, Viale Peraccini 18, I-50139 Florence, Italy.
   [Di Bari, Mauro] Azienda Osped Univ Careggi, Viale Peraccini 18, I-50139 Florence, Italy.
   [Adorni, Fulvio; Jesuthasan, Nithiya; Sojic, Aleksandra; Prinelli, Federica] CNR, Inst Biomed Technol, Epidemiol Unit, Via Fratelli Cervi 93, I-20090 Segrate, Italy.
   [Galli, Massimo; Giacomelli, Andrea] Univ Milan, Dept Biomed & Clin Sci L Sacco, Infect Dis Unit, ASST Fatebenefratelli Sacco, I-20157 Milan, Italy.
   [Molinaro, Sabrina] CNR, Inst Clin Physiol, Epidemiol & Hlth Res Lab, Via G Moruzzi 1, I-56124 Pisa, Italy.
   [Bianchi, Fabrizio] CNR, Inst Clin Physiol, Dept Environm Epidemiol & Dis Registries, Via G Moruzzi 1, I-56124 Pisa, Italy.
   [Mastroianni, Claudio] Sapienza Univ, Publ Hlth & Infect Dis Dept, Piazzale Aldo Moro 1, I-00185 Rome, Italy.
RP Noale, M (corresponding author), CNR, Neurosci Inst, Aging Branch, Via Vincenzo Maria Gallucci 16, I-35128 Padua, Italy.
EM marianna.noale@in.cnr.it; caterina.trevisan.5@studenti.unipd.it;
   stefania.maggi@in.cnr.it; r.antonelli@unicampus.it;
   claudio.pedone@gmail.com; mauro.dibari@unifi.it;
   fulvio.adorni@itb.cnr.it; nithiya.jesuthasan@itb.cnr.it;
   aleksandra.sojic@itb.cnr.it; massimo.galli@unimi.it;
   andrea.giacomelli@unimi.it; sabrina.molinaro@ifc.cnr.it;
   fabriepi@ifc.cnr.it; claudio.mastroianni@uniroma1.it;
   federica.prinelli@itb.cnr.it
RI Giacomelli, Andrea/AAA-4642-2019; Adorni, Fulvio/P-7064-2018;
   Jesuthasan, Nithiya/ABD-7719-2020; molinaro, sabrina/B-3710-2013;
   Bianchi, Fabrizio/F-7900-2015; Sojic, Aleksandra/K-7574-2015; Prinelli,
   Federica/J-6538-2016
OI Giacomelli, Andrea/0000-0003-3685-4289; Adorni,
   Fulvio/0000-0001-6264-6876; Jesuthasan, Nithiya/0000-0001-7286-7234;
   Trevisan, Caterina/0000-0002-9221-6997; molinaro,
   sabrina/0000-0001-7221-0873; Pedone, Claudio/0000-0003-1847-9032;
   MASTROIANNI, Claudio Maria/0000-0002-1286-467X; Bianchi,
   Fabrizio/0000-0002-3459-9301; Noale, Marianna/0000-0001-7115-139X;
   Sojic, Aleksandra/0000-0003-2318-4511; Prinelli,
   Federica/0000-0002-9093-7643
CR Adorni F, 2020, JMIR PUBLIC HLTH SUR, V6, P461, DOI 10.2196/21866
   Benn CS, 2013, TRENDS IMMUNOL, V34, P431, DOI 10.1016/j.it.2013.04.004
   Cho E, 2020, IEEE T APPL SUPERCON, V30, DOI 10.1109/TASC.2020.2981302
   Ciabattini A, 2018, SEMIN IMMUNOL, V40, P83, DOI 10.1016/j.smim.2018.10.010
   de Bree LCJ, 2018, SEMIN IMMUNOL, V39, P35, DOI 10.1016/j.smim.2018.06.002
   Endrich MM, 2009, VACCINE, V27, P4018, DOI 10.1016/j.vaccine.2009.04.029
   Fink G, 2020, INACTIVATED TRIVALEN, DOI [10.1101/2020.06.29.20142505, DOI 10.1101/2020.06.29.20142505]
   Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Gostin LO, 2020, JAMA-J AM MED ASSOC, V324, P335, DOI 10.1001/jama.2020.10802
   Grech V, 2020, EARLY HUM DEV, V148, DOI 10.1016/j.earlhumdev.2020.105116
   Grundy EJ, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/124788
   Hosmer D.W., APPL LOGISTIC REGRES
   ISTAT, POP RES GENN
   ISTAT, POP 15 ANN OLTR TIT
   Istituto Superiore di Sanita Dati E, 2013, ANT PNEUM NEI SOGG R
   Jefferson T, 2005, LANCET, V366, P1165, DOI 10.1016/S0140-6736(05)67339-4
   Jehi L, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237419
   Marin-Hernandez D, 2020, J MED VIROL, DOI 10.1002/jmv.26120
   Melegaro A, 2004, EUR J EPIDEMIOL, V19, P353, DOI 10.1023/B:EJEP.0000024701.94769.98
   Napoli C, 2020, ARCH GERONTOL GERIAT, V90, DOI 10.1016/j.archger.2020.104174
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X
   Pawelec G, 2020, IMMUN AGEING, V17, DOI 10.1186/s12979-020-00180-2
   Pera A, 2015, MATURITAS, V82, P50, DOI 10.1016/j.maturitas.2015.05.004
   Siegrist CA, 2009, NAT REV IMMUNOL, V9, P185, DOI 10.1038/nri2508
   Smith AM, 2018, VIRAL IMMUNOL, V31, P159, DOI 10.1089/vim.2017.0138
   Vojtek I, 2019, VACCINE, V37, P539, DOI 10.1016/j.vaccine.2018.12.005
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Weinberger B, 2008, CLIN INFECT DIS, V46, P1078, DOI 10.1086/529197
   Zanettini Claudio, 2020, medRxiv, DOI 10.1101/2020.06.24.20129817
NR 31
TC 2
Z9 2
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-393X
J9 VACCINES-BASEL
JI Vaccines
PD SEP
PY 2020
VL 8
IS 3
AR 471
DI 10.3390/vaccines8030471
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OE2VL
UT WOS:000580394500001
PM 32842505
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Rohaim, MA
   Munir, M
AF Rohaim, Mohammed A.
   Munir, Muhammad
TI A Scalable Topical Vectored Vaccine Candidate against SARS-CoV-2
SO VACCINES
LA English
DT Article
DE newcastle disease virus; recombinant vaccine; SARS-CoV-2; CoVID-19;
   pandemic
ID NEWCASTLE-DISEASE VIRUS; SERUM ANTIBODY-RESPONSES; NEUTRALIZING
   ANTIBODIES; FUSION PROTEIN; SPIKE PROTEIN; CLEAVAGE SITE; CELL;
   IMMUNIZATION; MICE; MACROPHAGES
AB The severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) caused an ongoing unprecedented global public health crises of coronavirus disease in 2019 (CoVID-19). The precipitously increased death rates, its impact on livelihood and trembling economies warrant the urgent development of a SARS-CoV-2 vaccine which would be safe, efficacious and scalable. Owing to unavailability of the vaccine, we propose a de novo synthesized avian orthoavulavirus 1 (AOaV-1)-based topical respiratory vaccine candidate against CoVID-19. Avirulent strain of AOaV-1 was engineered to express full length spike (S) glycoprotein which is highly neutralizing and a major protective antigen of the SARS-CoV-2. Broad-scale in vitro characterization of a recombinant vaccine candidate demonstrated efficient co-expression of the hemagglutinin-neuraminidase (HN) of AOaV-1 and S protein of SARS-CoV-2, and comparable replication kinetics were observed in a cell culture model. The recombinant vaccine candidate virus actively replicated and spread within cells independently of exogenous trypsin. Interestingly, incorporation of S protein of SARS-CoV-2 into the recombinant AOaV-1 particles attributed the sensitivity to anti-SARS-CoV-2 antiserum and more prominently to anti-AOaV-1 antiserum. Finally, our results demonstrated that the recombinant vaccine vector stably expressed S protein after multiple propagations in chicken embryonated eggs, and this expression did not significantly impact the in vitro growth characteristics of the recombinant. Taken together, the presented respiratory vaccine candidate is highly attenuated in primates per se, safe and lacking pre-existing immunity in human, and carries the potential for accelerated vaccine development against CoVID-19 for clinical studies.
C1 [Rohaim, Mohammed A.; Munir, Muhammad] Univ Lancaster, Fac Hlth & Med, Div Biomed & Life Sci, Lancaster LA1 4YG, England.
RP Munir, M (corresponding author), Univ Lancaster, Fac Hlth & Med, Div Biomed & Life Sci, Lancaster LA1 4YG, England.
EM m.a.rohaim@lancaster.ac.uk; muhammad.munir@lancaster.ac.uk
RI Rohaim, Mohammed A./AAM-7476-2020
OI Rohaim, Mohammed A./0000-0002-6941-9294; Rohaim, Mohammed Abdelmohsen
   Shahaat/0000-0003-1798-7086
FU Biotechnology and Biological Sciences Research Council
   (BBSRC)Biotechnology and Biological Sciences Research Council (BBSRC)
   [BB/M008681/2]
FX This study was supported by the Biotechnology and Biological Sciences
   Research Council (BBSRC) grant BB/M008681/2.
CR Atasoy MO, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040207
   Avki S, 2004, VET IMMUNOL IMMUNOP, V98, P9, DOI 10.1016/j.vetimm.2003.10.003
   Ayllon J, 2013, JOVE-J VIS EXP, DOI 10.3791/50830
   BLACH-OLSZEWSKA Z, 1970, Archivum Immunologiae et Therapiae Experimentalis, V18, P418
   BREHM G, 1986, J INTERFERON RES, V6, P21, DOI 10.1089/jir.1986.6.21
   Bukreyev A, 2005, J VIROL, V79, P13275, DOI 10.1128/JVI.79.21.13275-13284.2005
   Bukreyev A, 2008, CURR OPIN MOL THER, V10, P46
   Carnero E, 2009, J VIROL, V83, P584, DOI 10.1128/JVI.01443-08
   Corbett Kizzmekia S, 2020, Nature, V586, P567, DOI 10.1038/s41586-020-2622-0
   Corbett Kizzmekia S, 2020, bioRxiv, DOI 10.1101/2020.06.11.145920
   DiNapoli JM, 2007, P NATL ACAD SCI USA, V104, P9788, DOI 10.1073/pnas.0703584104
   DiNapoli JM, 2010, VACCINE, V29, P17, DOI 10.1016/j.vaccine.2010.10.024
   DiNapoli JM, 2010, J VIROL, V84, P1489, DOI 10.1128/JVI.01946-09
   Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   Ge JY, 2007, J VIROL, V81, P150, DOI 10.1128/JVI.01514-06
   Ge JY, 2011, J VIROL, V85, P8241, DOI 10.1128/JVI.00519-11
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Haas C, 1998, CLIN CANCER RES, V4, P721
   Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Janke M, 2008, INT J ONCOL, V33, P823, DOI 10.3892/ijo_00000070
   Karcher J, 2004, CANCER RES, V64, P8057, DOI 10.1158/0008-5472.CAN-04-1545
   Khalid Z, 2020, PAK J ZOOL, V52, P2377, DOI 10.17582/journal.pjz/20200608144416
   Khattar SK, 2011, J VIROL, V85, P10529, DOI 10.1128/JVI.05050-11
   Khattar SK, 2010, VACCINE, V28, P3159, DOI 10.1016/j.vaccine.2010.02.051
   Kim SH, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8070183
   Kong DN, 2012, VIROLOGY, V432, P327, DOI 10.1016/j.virol.2012.06.001
   Kortekaas J, 2010, VACCINE, V28, P4394, DOI 10.1016/j.vaccine.2010.04.048
   Kortekaas J, 2010, VACCINE, V28, P2271, DOI 10.1016/j.vaccine.2010.01.001
   Lu LQ, 2004, J CLIN MICROBIOL, V42, P1570, DOI 10.1128/JCM.42.4.1570-1576.2004
   Montomoli E, 2012, EXPERT REV VACCINES, V11, P587, DOI [10.1586/ERV.12.24, 10.1586/erv.12.24]
   NELSON CB, 1952, AM J PUBLIC HEALTH, V42, P672
   Ockert D, 1996, CLIN CANCER RES, V2, P21
   OIE, 2012, NEWC DIS MAN DIAGN T, P555
   Panda A, 2004, MICROB PATHOGENESIS, V36, P1, DOI 10.1016/j.micpath.2003.07.003
   Pecora AL, 2002, J CLIN ONCOL, V20, P2251, DOI 10.1200/JCO.2002.08.042
   Peeters BPH, 1999, J VIROL, V73, P5001, DOI 10.1128/JVI.73.6.5001-5009.1999
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   RUSSELL PH, 1983, J GEN VIROL, V64, P2069, DOI 10.1099/0022-1317-64-9-2069
   Skiadopoulos MH, 2003, J VIROL, V77, P1141, DOI 10.1128/JVI.77.2.1141-1148.2003
   Termeer CC, 2000, CANCER GENE THER, V7, P316, DOI 10.1038/sj.cgt.7700109
   Umansky V, 1996, INT IMMUNOL, V8, P491, DOI 10.1093/intimm/8.4.491
   Van Doremalen N., 2020, PREPR SERV BIOL, DOI [10.1101/2020.05.13.093195, DOI 10.1101/2020.05.13.093195]
   Walsh E, 2012, PROCEEDINGS OF THE ASME INTERNATIONAL MECHANICAL ENGINEERING CONGRESS AND EXPOSITION, 2011, VOL 10, PTS A AND B, P1
   Wise MG, 2004, J CLIN MICROBIOL, V42, P329, DOI 10.1128/JCM.42.1.329-338.2004
   World Health Organization, 2020, DRAFT LANDSC COVID 1
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xia SL, 2020, JAMA-J AM MED ASSOC, V324, P951, DOI 10.1001/jama.2020.15543
   Yu Q, 2015, BRIT J VIROL, V2, P15
   Zhao W, 2015, J GEN VIROL, V96, P40, DOI 10.1099/vir.0.068437-0
   Zhu FC, 2020, LANCET, V396, P479, DOI 10.1016/S0140-6736(20)31605-6
NR 52
TC 2
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-393X
J9 VACCINES-BASEL
JI Vaccines
PD SEP
PY 2020
VL 8
IS 3
AR 472
DI 10.3390/vaccines8030472
PG 16
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OD8MX
UT WOS:000580101900001
PM 32846910
OA DOAJ Gold, Green Published, Green Accepted
DA 2021-01-01
ER

PT J
AU Saso, A
   Skirrow, H
   Kampmann, B
AF Saso, Anja
   Skirrow, Helen
   Kampmann, Beate
TI Impact of COVID-19 on Immunization Services for Maternal and Infant
   Vaccines: Results of a Survey Conducted by Imprint-The Immunising
   Pregnant Women and Infants Network
SO VACCINES
LA English
DT Article
DE COVID-19; pandemic; vaccines; maternal immunization; global health;
   questionnaire; survey; qualitative; neonatal; infant; IMPRINT
AB The COVID-19 pandemic response has caused disruption to healthcare services globally, including to routine immunizations. To understand immunization service interruptions specifically for maternal, neonatal and infant vaccines, we captured the local experiences of members of the Immunising Pregnant Women and Infants Network (IMPRINT) by conducting an online survey over 2-weeks in April 2020. IMPRINT is a global network of clinicians and scientists working in maternal and neonatal vaccinology. The survey included discrete questions to quantify the extent of disruption as well as free-text options to explore the reasons behind reported disruptions. Of the 48 responses received, the majority (75%) were from low-and-middle-income countries (LMICs). Of all respondents, 50% or more reported issues with vaccine delivery within their country. Thematic analysis identified three key themes behind immunization disruption: "access" issues, e.g., logistical barriers, "provider" issues, e.g., staff shortages and user "concern" about attending immunization appointments due to COVID-19 fear. Access and provider issues were more commonly reported by LMIC respondents. Overall, respondents reported uncertainty among parents and healthcare providers regarding routine immunization. We conclude that further quantification of routine vaccination disruption is needed, alongside health service prioritization, logistical support and targeted communication strategies to reinforce routine immunizations during the COVID-19 response.
C1 [Saso, Anja; Kampmann, Beate] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Vaccine Ctr, London WC1 7HT, England.
   [Saso, Anja; Kampmann, Beate] MRC Unit Gambia LSHTM, Vaccines & Immun Theme, POB 273, Banjul 273, Gambia.
   [Skirrow, Helen] Imperial Coll London, Sch Publ Hlth, Dept Primary Care & Publ Hlth, London W6 8RP, England.
RP Kampmann, B (corresponding author), London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Vaccine Ctr, London WC1 7HT, England.; Kampmann, B (corresponding author), MRC Unit Gambia LSHTM, Vaccines & Immun Theme, POB 273, Banjul 273, Gambia.
EM anja.saso@lshtm.ac.uk; h.skirrow@imperial.ac.uk;
   beate.kampmann@lshtm.ac.uk
OI Skirrow, Helen/0000-0002-4383-0616; Kampmann, Beate/0000-0002-6546-4709
FU UKRI/MRC/BBSRC Immunising Pregnant Women and Infants Network (IMPRINT)
   [MR/R005990/1, MC_PC_17221]; Wellcome Trust Global Health Clinical Ph.D.
   FellowshipWellcome Trust [220565/Z/20/Z]; MRC program grant
   [MC_UP_A900/1122, MC_UP_A900/115, MR/K007602/1]; Immunising Pregnant
   Women and Infants Network (IMPRINT)
FX We acknowledge funding from UKRI/MRC/BBSRC Immunising Pregnant Women and
   Infants Network (IMPRINT), which supported this research (MR/R005990/1
   and MC_PC_17221). A.S. declares funding from Wellcome Trust Global
   Health Clinical Ph.D. Fellowship (220565/Z/20/Z). B.K. was funded by an
   MRC program grant (MC_UP_A900/1122; MC_UP_A900/115; and MR/K007602/1).
   H.S. is funded by Immunising Pregnant Women and Infants Network
   (IMPRINT). B.K.'s institution receives funding from a variety of donors,
   including industry for the conduct of vaccine-related research in women
   and children.
CR Abbas K, 2020, LANCET GLOB HEALTH, V8, pE1264, DOI [10.1016/52214-109X(20)30308-9, 10.1016/S2214-109X(20)30308-9]
   Chandir S, 2020, LANCET GLOB HEALTH, V8, pE1118, DOI 10.1016/S2214-109X(20)30290-4
   Corner J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002316
   Depoux A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa031
   DYER O, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1596
   DYER O, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2219
   GAVI, VACC ALL WORLD LEAD
   Harrison EA, 2020, EUR J EPIDEMIOL, V35, P325, DOI 10.1007/s10654-020-00634-3
   Hoang Ansel, 2020, EClinicalMedicine, V24, P100433, DOI 10.1016/j.eclinm.2020.100433
   Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687
   Hussain D., CHILDHOOD IMMUNISATI
   Isenor JE, 2016, VACCINE, V34, P5708, DOI 10.1016/j.vaccine.2016.08.085
   JCVI, STAT JOINT COMM VACC
   Kelley K, 2003, INT J QUAL HEALTH C, V15, P261, DOI 10.1093/intqhc/mzg031
   Larson HJ, 2020, NAT REV IMMUNOL, V20, P449, DOI 10.1038/s41577-020-0380-8
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Martinez-Alvarez M, 2020, LANCET GLOB HEALTH, V8, pE631, DOI 10.1016/S2214-109X(20)30123-6
   McDonald HI, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.19.2000848
   Ministry of Health and Family Welfare, 2020, GOV IND EN DEL ESS H
   O'Brien BC, 2014, ACAD MED, V89, P1245, DOI 10.1097/ACM.0000000000000388
   Oyo-Ita A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008145.pub3
   RCGP Royal College of General Practitioners, 2020, GUID WORKL PRIOR COV
   RCN Royal College of Nursing, 2020, OV PRINC MAINT NAT I
   RCPCH, 2020, COVID 19 GUID PAED S
   Ribacke KJB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150080
   Richards SH, 2009, MED EDUC, V43, P757, DOI 10.1111/j.1365-2923.2009.03416.x
   Roberton T, 2020, LANCET GLOB HEALTH, V8, pE901, DOI 10.1016/S2214-109X(20)30229-1
   Roberts L, 2020, NATURE, V580, P446, DOI 10.1038/d41586-020-01011-6
   Santoli JM, 2020, MMWR-MORBID MORTAL W, V69, P591, DOI 10.15585/mmwr.mm6919e2
   SAXENA S, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2392
   Shepherd J, 2020, CLIN INFECT DIS, V71, P1564, DOI 10.1093/cid/ciaa772
   Suk JE, 2016, EMERG INFECT DIS, V22, P1106, DOI 10.3201/eid2206.151652
   UNICEF, GEN PAL BRIEF NOT IM
   Vaismoradi M, 2013, NURS HEALTH SCI, V15, P398, DOI 10.1111/nhs.12048
   WHO, 2019 GLOB SUMM
   WHO, 2020, FRAM DEC MAK IMPL MA
   Williamson E., 2020, OPENSAFELY FACTORS A, DOI [10.1101/2020.05.06.20092999, DOI 10.1101/2020.05.06.20092999]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 38
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-393X
J9 VACCINES-BASEL
JI Vaccines
PD SEP
PY 2020
VL 8
IS 3
AR 556
DI 10.3390/vaccines8030556
PG 15
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OE1KS
UT WOS:000580299000001
PM 32972015
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Zettl, F
   Meister, TL
   Vollmer, T
   Fischer, B
   Steinmann, J
   Krawczyk, A
   V'kovski, P
   Todt, D
   Steinmann, E
   Pfaender, S
   Zimmer, G
AF Zettl, Ferdinand
   Meister, Toni Luise
   Vollmer, Tanja
   Fischer, Bastian
   Steinmann, Joerg
   Krawczyk, Adalbert
   V'kovski, Philip
   Todt, Daniel
   Steinmann, Eike
   Pfaender, Stephanie
   Zimmer, Gert
TI Rapid Quantification of SARS-CoV-2-Neutralizing Antibodies Using
   Propagation-Defective Vesicular Stomatitis Virus Pseudotypes
SO VACCINES
LA English
DT Article
DE SARS-CoV-2; neutralizing antibodies; pseudovirus; vaccine; passive
   immunization
ID RESPIRATORY SYNDROME CORONAVIRUS; GLYCOPROTEIN; NEUTRALIZATION;
   SARS-COV-2; PREVENTION
AB Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2, a new member of the genusBetacoronavirus, is a pandemic virus, which has caused numerous fatalities, particularly in the elderly and persons with underlying morbidities. At present, there are no approved vaccines nor antiviral therapies available. The detection and quantification of SARS-CoV-2-neutralizing antibodies plays a crucial role in the assessment of the immune status of convalescent COVID-19 patients, evaluation of recombinant therapeutic antibodies, and the evaluation of novel vaccines. To detect SARS-CoV-2-neutralizing antibodies, classically, a virus-neutralization test has to be performed at biosafety level 3, considerably limiting the general use of this test. In the present work, a biosafety level 1 pseudotype virus assay based on a propagation-incompetent vesicular stomatitis virus (VSV) has been used to determine the neutralizing antibody titers in convalescent COVID-19 patients. The neutralization titers in serum of two independently analyzed patient cohorts were available within 18 h and correlated well with those obtained with a classical SARS-CoV-2 neutralization test (Pearson correlation coefficients of r = 0.929 and r = 0.939, respectively). Most convalescent COVID-19 patients had only low titers of neutralizing antibodies (ND50 < 320). The sera of convalescent COVID-19 patients also neutralized pseudotype virus displaying the SARS-CoV-1 spike protein on their surface, which is homologous to the SARS-CoV-2 spike protein. In summary, we report a robust virus-neutralization assay, which can be used at low biosafety level 1 to rapidly quantify SARS-CoV-2-neutralizing antibodies in convalescent COVID-19 patients and vaccinated individuals.
C1 [Zettl, Ferdinand; V'kovski, Philip; Zimmer, Gert] Inst Virol & Immunol IVI, Abt Virol, CH-3147 Mittelhausern, Switzerland.
   [Meister, Toni Luise; Todt, Daniel; Steinmann, Eike; Pfaender, Stephanie] Ruhr Univ Bochum, Dept Mol & Med Virol, Univ Str 150, D-44801 Bochum, Germany.
   [Vollmer, Tanja; Fischer, Bastian] Ruhr Univ Bochum, Univ Klin, Inst Lab & Transfus Med Herz & Diabet Zentrum, D-32545 Bad Oeynhausen, Germany.
   [Steinmann, Joerg] Univ Hosp Essen, Inst Med Microbiol, D-45147 Essen, Germany.
   [Steinmann, Joerg] Paracelsus Med Univ, Gen Hosp Nurnberg, Inst Clin Hyg Med Microbiol & Infectiol, D-90419 Nurnberg, Germany.
   [Krawczyk, Adalbert] Univ Duisburg Essen, Univ Hosp Essen, West German Ctr Infect Dis, Dept Infect Dis, D-45147 Essen, Germany.
   [Krawczyk, Adalbert] Univ Duisburg Essen, Univ Hosp Essen, Inst Virol, D-45147 Essen, Germany.
   [V'kovski, Philip; Zimmer, Gert] Univ Bern, Vetsuisse Fac, Dept Infect Dis & Pathobiol DIP, CH-3012 Bern, Switzerland.
RP Zimmer, G (corresponding author), Inst Virol & Immunol IVI, Abt Virol, CH-3147 Mittelhausern, Switzerland.; Pfaender, S (corresponding author), Ruhr Univ Bochum, Dept Mol & Med Virol, Univ Str 150, D-44801 Bochum, Germany.; Zimmer, G (corresponding author), Univ Bern, Vetsuisse Fac, Dept Infect Dis & Pathobiol DIP, CH-3012 Bern, Switzerland.
EM ferdinand.zettl@yahoo.de; toni.meister@rub.de; tvollmer@hdz-nrw.de;
   bfischer@hdz-nrw.de; joerg.steinmann@uk-essen.de;
   adalbert.krawczyk@uni-due.de; philip.vkovski@vetsuisse.unibe.ch;
   daniel.todt@rub.de; eike.steinmann@rub.de;
   stephanie.pfaender@ruhr-uni-bochum.de; gert.zimmer@ivi.admin.ch
RI Todt, Daniel/W-9362-2019; Krawczyk, Adalbert/ABD-7193-2020
OI Todt, Daniel/0000-0002-3564-1014; Krawczyk,
   Adalbert/0000-0001-9502-9903; Pfaender, Stephanie/0000-0002-3957-5448;
   Zimmer, Gert/0000-0002-2708-2507; V'kovski, Philip/0000-0002-8366-1220;
   Zettl, Ferdinand/0000-0003-2802-3813; Meister, Toni
   Luise/0000-0001-8962-9443; Steinmann, Eike/0000-0002-3654-9965
CR Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364
   Bisht H, 2004, P NATL ACAD SCI USA, V101, P6641, DOI 10.1073/pnas.0401939101
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   European Commission, EU PROGR COVID 19 CO
   Fukushi S, 2005, J GEN VIROL, V86, P2269, DOI 10.1099/vir.0.80955-0
   Gasparyan AY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e176
   Ge JY, 2006, ANN NY ACAD SCI, V1081, P246, DOI 10.1196/annals.1373.030
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Griffin DE, 2018, VIRAL IMMUNOL, V31, P86, DOI 10.1089/vim.2017.0143
   Hanika A, 2005, J GEN VIROL, V86, P1455, DOI 10.1099/vir.0.80788-0
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Keller MA, 2000, CLIN MICROBIOL REV, V13, P602, DOI 10.1128/CMR.13.4.602-614.2000
   LEFRANCOIS L, 1982, VIROLOGY, V121, P157, DOI 10.1016/0042-6822(82)90125-8
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Meyer B, 2020, CLIN MICROBIOL INFEC, V26, P1386, DOI 10.1016/j.cmi.2020.06.024
   Moeschler S, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8090254
   Rentsch MB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025858
   Sawyer LA, 2000, ANTIVIR RES, V47, P57, DOI 10.1016/S0166-3542(00)00111-X
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Sicca F, 2018, EXPERT REV VACCINES, V17, P785, DOI 10.1080/14760584.2018.1516553
   Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004
   Suzuki T, 2015, P NATL ACAD SCI USA, V112, P7809, DOI 10.1073/pnas.1503885112
   Teramichi T, 2019, J VET MED SCI, V81, P1887, DOI 10.1292/jvms.19-0436
   Walker LM, 2018, NAT REV IMMUNOL, V18, P297, DOI 10.1038/nri.2017.148
   Wulff Niels H, 2012, J Clin Bioinforma, V2, P5, DOI 10.1186/2043-9113-2-5
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 28
TC 2
Z9 2
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-393X
J9 VACCINES-BASEL
JI Vaccines
PD SEP
PY 2020
VL 8
IS 3
AR 386
DI 10.3390/vaccines8030386
PG 13
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA OD6OQ
UT WOS:000579971200001
PM 32679691
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ling, JX
   Hickman, RA
   Li, JL
   Lu, X
   Lindahl, JF
   Lundkvist, A
   Jarhult, JD
AF Ling, Jiaxin
   Hickman, Rachel A.
   Li, Jinlin
   Lu, Xi
   Lindahl, Johanna F.
   Lundkvist, Ake
   Jarhult, Josef D.
TI Spatio-Temporal Mutational Profile Appearances of Swedish SARS-CoV-2
   during the Early Pandemic
SO VIRUSES-BASEL
LA English
DT Article
DE SARS-CoV-2; evolution; mutation; spike protein
ID CORONAVIRUS; VIRUS; SARS; SEQUENCE; SPIKE
AB Background: During the COVID-19 pandemic, the virus evolved, and we therefore aimed to provide an insight into which genetic variants were enriched, and how they spread in Sweden. Methods: We analyzed 348 Swedish SARS-CoV-2 sequences freely available from GISAID obtained from 7 February 2020 until 14 May 2020. Results: We identified 14 variant sites >= 5% frequency in the population. Among those sites, the D936Y substitution in the viral Spike protein was under positive selection. The variant sites can distinguish 11 mutational profiles in Sweden. Nine of the profiles appeared in Stockholm in March 2020. Mutational profiles 3 (B.1.1) and 6 (B.1), which contain the D936Y mutation, became the predominant profiles over time, spreading from Stockholm to other Swedish regions during April and the beginning of May. Furthermore, Bayesian phylogenetic analysis indicated that SARS-CoV-2 could have emerged in Sweden on 27 December 2019, and community transmission started on February 1st with an evolutionary rate of 1.5425 x 10(-3)substitutions per year. Conclusions: Our study provides novel knowledge on the spatio-temporal dynamics of Swedish SARS-CoV-2 variants during the early pandemic. Characterization of these viral variants can provide precious insights on viral pathogenesis and can be valuable for diagnostic and drug development approaches.
C1 [Ling, Jiaxin; Hickman, Rachel A.; Li, Jinlin; Lindahl, Johanna F.; Lundkvist, Ake] Uppsala Univ, Zoonosis Sci Ctr, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden.
   [Li, Jinlin] Karolinska Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden.
   [Lu, Xi] Sun Yat Sen Univ, Sch Life Sci, Guangzhou 510275, Peoples R China.
   [Lindahl, Johanna F.] Int Livestock Res Inst, Nairobi 00100, Kenya.
   [Lindahl, Johanna F.] Swedish Univ Agr Res, SE-75007 Uppsala, Sweden.
   [Jarhult, Josef D.] Uppsala Univ, Zoonosis Sci Ctr, Dept Med Sci, SE-75123 Uppsala, Sweden.
RP Ling, JX; Hickman, RA (corresponding author), Uppsala Univ, Zoonosis Sci Ctr, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden.
EM jiaxin.ling@imbim.uu.se; rachel.hickman@medsci.uu.se;
   lijinlinwhu@gmail.com; shindowfeather@gmail.com;
   Johanna.Lindahl@imbim.uu.se; ake.lundkvist@imbim.uu.se;
   josef.jarhult@medsci.uu.se
RI Jarhult, Josef D./ABE-8149-2020
OI Jarhult, Josef D./0000-0002-7075-1059; Hickman,
   Rachel/0000-0002-0290-1836; Lindahl, Johanna/0000-0002-1175-0398
FU Swedish Research CouncilSwedish Research Council [VR: 2016-02606,
   2017-05807, 2018-02569]; Knut and Alice Wallenberg FoundationKnut &
   Alice Wallenberg Foundation; Science for Life Laboratory Uppsala
   (project "Nevermore Covid")
FX This work was supported by grants from The Swedish Research Council (VR:
   2016-02606, 2017-05807, and 2018-02569) and Knut and Alice Wallenberg
   Foundation and Science for Life Laboratory Uppsala (project "Nevermore
   Covid").
CR Boni MF, 2020, NAT MICROBIOL, V5, P1408, DOI 10.1038/s41564-020-0771-4
   Cavallo L., 2020, D936Y OTHER MUTATION, DOI [10.1101/2020.06.08.140152, DOI 10.1101/2020.06.08.140152]
   Chibo D, 2006, J GEN VIROL, V87, P1203, DOI 10.1099/vir.0.81662-0
   Cyranoski D, 2020, NATURE, V581, P22, DOI 10.1038/d41586-020-01315-7
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018
   Folkhalsomyndigheten Helgenomsekvensering av Svenska, 2020, 2 FOLKH
   Folkhalsomyndigheten Helgenomsekvensering av Svenska, 2020, 1 FOLKH
   Grubaugh ND, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0690-4
   Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139
   Guarner J, 2020, AM J CLIN PATHOL, V153, P420, DOI 10.1093/ajcp/aqaa029
   Hilgenfeld R, 2013, ANTIVIR RES, V100, P286, DOI 10.1016/j.antiviral.2013.08.015
   Kamerlin Shina C L, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa864
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Koyama T, 2020, B WORLD HEALTH ORGAN, V98, P495, DOI 10.2471/BLT.20.253591
   Lai A, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12080798
   Lauring AS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001005
   Martin DP, 2010, BIOINFORMATICS, V26, P2462, DOI 10.1093/bioinformatics/btq467
   Membrebe JV, 2019, MOL BIOL EVOL, V36, P1793, DOI 10.1093/molbev/msz094
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Rambaut Andrew, 2020, Nat Microbiol, V5, P1403, DOI 10.1038/s41564-020-0770-5
   Rambaut A, 2016, VIRUS EVOL, V2, DOI 10.1093/ve/vew007
   Ren LL, 2015, SCI REP-UK, V5, DOI 10.1038/srep11451
   Speed D, 2012, AM J HUM GENET, V91, P1011, DOI 10.1016/j.ajhg.2012.10.010
   Stamatakis A, 2014, BIOINFORMATICS, V30, P1312, DOI 10.1093/bioinformatics/btu033
   Sui JH, 2005, J VIROL, V79, P5900, DOI 10.1128/JVI.79.10.5900-5906.2005
   Tang XC, 2014, P NATL ACAD SCI USA, V111, pE2018, DOI 10.1073/pnas.1402074111
   Team R.C, 2020, R LANG ENV STAT COMP
   Phan T, 2020, INFECT GENET EVOL, V81, DOI 10.1016/j.meegid.2020.104260
   Urbanowicz RA, 2016, CELL, V167, P1079, DOI 10.1016/j.cell.2016.10.013
   Vijgen L, 2005, VIROLOGY, V337, P85, DOI 10.1016/j.virol.2005.04.010
   Walker PGT, 2020, SCIENCE, V369, P413, DOI 10.1126/science.abc0035
   Wang GT, 2014, AM J HUM GENET, V94, P770, DOI 10.1016/j.ajhg.2014.04.004
   Warnock RCM, 2012, BIOL LETTERS, V8, P156, DOI 10.1098/rsbl.2011.0710
   Weaver S, 2018, MOL BIOL EVOL, V35, P773, DOI 10.1093/molbev/msx335
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yuan L, 2017, SCIENCE, V358, P933, DOI 10.1126/science.aam7120
NR 39
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD SEP
PY 2020
VL 12
IS 9
AR 1026
DI 10.3390/v12091026
PG 14
WC Virology
SC Virology
GA OE8WQ
UT WOS:000580804300001
PM 32937868
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Loes, AN
   Gentles, LE
   Greaney, AJ
   Crawford, KHD
   Bloom, JD
AF Loes, Andrea N.
   Gentles, Lauren E.
   Greaney, Allison J.
   Crawford, Katharine H. D.
   Bloom, Jesse D.
TI Attenuated Influenza Virions Expressing the SARS-CoV-2 Receptor-Binding
   Domain Induce Neutralizing Antibodies in Mice
SO VIRUSES-BASEL
LA English
DT Article
DE SARS-CoV-2; influenza; intranasal; live attenuated vaccine; spike; RBD
ID A VIRUS; LIVE; NEURAMINIDASE; GENERATION; PROTECTION; IMMUNIZATION;
   VACCINATION; MUTANT; MODEL; CELL
AB An effective vaccine is essential for controlling the spread of the SARS-CoV-2 virus. Here, we describe an influenza virus-based vaccine for SARS-CoV-2. We incorporated a membrane-anchored form of the SARS-CoV-2 spike receptor binding domain (RBD) in place of the neuraminidase (NA) coding sequence in an influenza virus also possessing a mutation that reduces the affinity of hemagglutinin for its sialic acid receptor. The resulting Delta NA(RBD)-Flu virus can be generated by reverse genetics and grown to high titers in cell culture. A single-dose intranasal inoculation of mice with Delta NA(RBD)-Flu elicits serum neutralizing antibody titers against SAR-CoV-2 comparable to those observed in humans following natural infection (similar to 1:200). Furthermore, Delta NA(RBD)-Flu itself causes no apparent disease in mice. It might be possible to produce a vaccine similar to Delta NA(RBD)-Flu at scale by leveraging existing platforms for the production of influenza vaccines.
C1 [Loes, Andrea N.; Gentles, Lauren E.; Greaney, Allison J.; Crawford, Katharine H. D.; Bloom, Jesse D.] Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.
   [Loes, Andrea N.; Gentles, Lauren E.; Greaney, Allison J.; Crawford, Katharine H. D.; Bloom, Jesse D.] Fred Hutchinson Canc Res Ctr, Computat Biol Program, Seattle, WA 98109 USA.
   [Loes, Andrea N.; Bloom, Jesse D.] Howard Hughes Med Inst, Seattle, WA 98103 USA.
   [Gentles, Lauren E.; Bloom, Jesse D.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.
   [Greaney, Allison J.; Crawford, Katharine H. D.; Bloom, Jesse D.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
   [Greaney, Allison J.; Crawford, Katharine H. D.] Univ Washington, Med Scientist Training Program, Seattle, WA 98195 USA.
RP Bloom, JD (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.; Bloom, JD (corresponding author), Fred Hutchinson Canc Res Ctr, Computat Biol Program, Seattle, WA 98109 USA.; Bloom, JD (corresponding author), Howard Hughes Med Inst, Seattle, WA 98103 USA.; Bloom, JD (corresponding author), Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.; Bloom, JD (corresponding author), Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
EM aloes@fredhutch.org; lgentles@uw.edu; agreaney@uw.edu;
   kdusenbu@fredhutch.org; jbloom@fredhutch.org
RI ; Bloom, Jesse/C-6837-2013
OI Gentles, Lauren/0000-0002-2532-412X; Bloom, Jesse/0000-0003-1267-3408
FU NIAID of the NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI141707, R01AI127893,
   F30AI149928]; NSF predoctoral fellowshipNational Science Foundation
   (NSF) [DGE-1762114]
FX This research was supported by the following grants from the NIAID of
   the NIH: R01AI141707 and R01AI127893 (J.D.B.), F30AI149928 (to
   K.H.D.C.), and an NSF predoctoral fellowship to L.E.G. (DGE-1762114).
   J.D.B. is an Investigator of the Howard Hughes Medical Institute.
CR Addetia A., 2020, J CLIN MICROBIOL, DOI [10.1128/JCM.02107-2032826322, DOI 10.1128/JCM.02107-2032826322]
   Blazevic V, 2000, HUM IMMUNOL, V61, P845, DOI 10.1016/S0198-8859(00)00170-1
   Breen M, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8070179
   Cao YL, 2020, CELL, V182, P73, DOI 10.1016/j.cell.2020.05.025
   Chen Wen-Hsiang, 2020, bioRxiv, DOI 10.1101/2020.05.15.098079
   Chen ZY, 2014, J VIROL, V88, P7016, DOI 10.1128/JVI.00100-14
   Crawford KHD, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12050513
   Crawford KH, 2020, DYNAMICS NEUTRALIZIN, DOI [10.1101/2020.08.06.20169367, DOI 10.1101/2020.08.06.20169367]
   Doud MB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03665-3
   Fujii Y, 2003, P NATL ACAD SCI USA, V100, P2002, DOI 10.1073/pnas.0437772100
   Gao QS, 2009, P NATL ACAD SCI USA, V106, P15891, DOI 10.1073/pnas.0908897106
   Gentles LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060597
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Harding AT, 2017, MBIO, V8, DOI 10.1128/mBio.00669-17
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697
   Hooper KA, 2013, J VIROL, V87, P12531, DOI 10.1128/JVI.01889-13
   Imai M, 2020, P NATL ACAD SCI USA, V117, P16587, DOI [10.1073/pnas.2009799117/-/DCSupplemental., 10.1073/pnas.2009799117]
   Lee JM, 2019, ELIFE, V8, DOI 10.7554/eLife.49324
   Lee JM, 2018, P NATL ACAD SCI USA, V115, pEB276, DOI 10.1073/pnas.1806133115
   Li JW, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00170
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li ZN, 2005, J VIROL, V79, P10003, DOI 10.1128/JVI.79.15.10003-10012.2005
   Lin YC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075084
   Martin J, 1998, VIROLOGY, V241, P101, DOI 10.1006/viro.1997.8958
   Martina BEE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018995
   Meisner J, 2008, J VIROL, V82, P5079, DOI 10.1128/JVI.01958-07
   Mercado NB, 2020, NATURE, DOI 10.1038/s41586-020-2607-z
   Mishin VR, 2005, VACCINE, V23, P2922, DOI 10.1016/j.vaccine.2004.11.058
   Mohn KGI, 2017, J INFECT DIS, V215, P1527, DOI 10.1093/infdis/jix165
   Mohn KGI, 2015, J INFECT DIS, V211, P1541, DOI 10.1093/infdis/jiu654
   Moreno-Fierros L, 2020, EXPERT OPIN BIOL TH, V20, P831, DOI 10.1080/14712598.2020.1767062
   Mulligan M. J., 2020, PHASE 1 2 STUDY DESC, DOI [10.1101/2020.06.30.20142570, DOI 10.1101/2020.06.30.20142570]
   MUSTER T, 1995, J VIROL, V69, P6678, DOI 10.1128/JVI.69.11.6678-6686.1995
   Neumann G, 1999, P NATL ACAD SCI USA, V96, P9345, DOI 10.1073/pnas.96.16.9345
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Ravichandran S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc3539
   Rimmelzwaan GF, 2007, VIRUS RES, V129, P175, DOI 10.1016/j.virusres.2007.07.007
   Shi R, 2020, NATURE, V584, P120, DOI 10.1038/s41586-020-2381-y
   Shinya K, 2004, J VIROL, V78, P3083, DOI 10.1128/JVI.78.6.3083-3088.2004
   Smith A, 2020, J VIROL, V94, DOI 10.1128/JVI.01065-19
   Starr TN, 2020, CELL, V182, P1295, DOI 10.1016/j.cell.2020.08.012
   Stokes EK, 2020, MMWR-MORBID MORTAL W, V69, P759, DOI 10.15585/mmwr.mm6924e2
   Sun Weina, 2020, bioRxiv, DOI 10.1101/2020.07.26.221861
   Suthar Mehul S, 2020, Cell Rep Med, V1, P100040, DOI 10.1016/j.xcrm.2020.100040
   Tian XL, 2020, EMERG MICROBES INFEC, V9, P382, DOI 10.1080/22221751.2020.1729069
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang LL, 2017, CELL HOST MICROBE, V21, P334, DOI 10.1016/j.chom.2017.02.007
   World Health Organization (WHO), 2020, 183 WHO
   Wu F., 2020, NEUTRALIZING ANTIBOD, DOI [10.2139/ssrn.3566211, DOI 10.2139/SSRN.3566211]
   Yang JN, 2020, NAT PROD RES, DOI 10.1080/14786419.2019.1709189
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
NR 52
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4915
J9 VIRUSES-BASEL
JI Viruses-Basel
PD SEP
PY 2020
VL 12
IS 9
AR 987
DI 10.3390/v12090987
PG 12
WC Virology
SC Virology
GA OE2BN
UT WOS:000580342700001
PM 32899480
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mancini, L
   Quinzi, V
   Mummolo, S
   Marzo, G
   Marchetti, E
AF Mancini, Leonardo
   Quinzi, Vincenzo
   Mummolo, Stefano
   Marzo, Giuseppe
   Marchetti, Enrico
TI Angiotensin-Converting Enzyme 2 as a Possible Correlation between
   COVID-19 and Periodontal Disease
SO APPLIED SCIENCES-BASEL
LA English
DT Article
DE periodontitis; COVID-19; ACE2; cytokines; inflammation
ID NECROSIS-FACTOR-ALPHA; ADHESION MOLECULE; SARS CORONAVIRUS;
   EPITHELIAL-CELLS; SPIKE PROTEIN; RECEPTOR AXIS; INFLAMMATION;
   EXPRESSION; ACE2; ACTIVATION
AB SARS-CoV-2 propagation in the world has led to rapid growth and an acceleration in the discoveries and publications of various interests. The main focus of a consistent number of studies has been the role of angiotensin-converting enzyme 2 (ACE2) in binding the virus and its role in expression of the inflammatory response after transmission. ACE2 is an enzyme involved in the renin-angiotensin system (RAS), whose key role is to regulate and counter angiotensin-converting enzyme (ACE), reducing the amount of angiotensin II and increasing angiotensin 1-7 (Ang1-7), making it a promising drug target for treating cardiovascular diseases. The classical RAS axis, formed by ACE, angiotensin II (Ang II), and angiotensin receptor type 1 (AT1), activates several cell functions and molecular signalling pathways related to tissue injury and inflammation. In contrast, the RAS axis composed of ACE2, Ang1-7, and Mas receptor (MasR) exerts the opposite effect concerning the inflammatory response and tissue fibrosis. Recent studies have shown the presence of the RAS system in periodontal sites where osteoblasts, fibroblasts, and osteoclasts are involved in bone remodelling, suggesting that the role of ACE2 might have a fundamental function in the under- or overexpression of cytokines such as interleukin-6 (IL-6), interleukin-7 (IL-7), tumour necrosis factor alpha (TNF-alpha), interleukin-2 (IL-2), interleukin-1 beta (IL-1 beta), monocyte chemoattractant protein-1 (MCP-1), and transforming growth factor-beta (TGF-beta), associated with a periodontal disorder, mainly during coinfection with SARS-CoV-2, where ACE2 is underexpressed and cannot form the ACE2-Ang1-7-MasR axis. This renders the patient unresponsive to an inflammatory process, facilitating periodontal loss.
C1 [Mancini, Leonardo; Quinzi, Vincenzo; Mummolo, Stefano; Marzo, Giuseppe; Marchetti, Enrico] Univ Aquila, Dept Life Hlth & Environm Sci, Piazzale Salvatore Tommasi 1, I-67100 Laquila, Italy.
RP Mancini, L (corresponding author), Univ Aquila, Dept Life Hlth & Environm Sci, Piazzale Salvatore Tommasi 1, I-67100 Laquila, Italy.
EM leonardo.mancini@student.univaq.it; vincenzo.quinzi@univaq.it;
   stefano.mummolo@cc.univaq.it; giuseppe.marzo@univaq.it;
   enrico.marchetti@univaq.it
OI MARCHETTI, ENRICO/0000-0001-6461-7876; Mancini,
   Leonardo/0000-0002-7030-155X; quinzi, vincenzo/0000-0002-3184-6899
CR Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8
   Basso FG, 2016, J PERIODONTOL, V87, P990, DOI 10.1902/jop.2016.150713
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Ben-Sasson SZ, 2009, P NATL ACAD SCI USA, V106, P7119, DOI 10.1073/pnas.0902745106
   Burrell LM, 2004, TRENDS ENDOCRIN MET, V15, P166, DOI 10.1016/j.tem.2004.03.001
   Capettini LSA, 2012, CURR PHARM DESIGN, V18, P963
   Carson SD, 2001, REV MED VIROL, V11, P219, DOI 10.1002/rmv.318
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Cheng WC, 2014, J CLIN PERIODONTOL, V41, P541, DOI 10.1111/jcpe.12238
   De Benedetti F, 2006, ARTHRITIS RHEUM, V54, P3551, DOI 10.1002/art.22175
   Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1
   Dutzan N, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat0797
   Ebersole JL, 2016, PERIODONTOL 2000, V72, P54, DOI 10.1111/prd.12135
   Ebersole JL, 2014, J CLIN PERIODONTOL, V41, P853, DOI 10.1111/jcpe.12286
   Fraga-Silva RA, 2013, HYPERTENSION, V61, P1233, DOI 10.1161/HYPERTENSIONAHA.111.00627
   Fujihara R, 2014, J PERIODONTAL RES, V49, P508, DOI 10.1111/jre.12131
   Gabriele LG, 2017, J PERIODONTOL, V88, pE1, DOI 10.1902/jop.2016.160354
   Halpin DMG, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01009-2020
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   HANAZAWA S, 1993, INFECT IMMUN, V61, P5219, DOI 10.1128/IAI.61.12.5219-5224.1993
   Hienz SA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/615486
   Hoehl S, 2020, NEW ENGL J MED, V382, P1278, DOI 10.1056/NEJMc2001899
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Isola G, 2020, CLIN ORAL INVEST, DOI 10.1007/s00784-020-03397-z
   Isola G, 2020, J PERIODONTOL, V91, P1076, DOI 10.1002/JPER.19-0446
   Kawai T, 2006, AM J PATHOL, V169, P987, DOI 10.2353/ajpath.2006.060180
   Kortekaas KE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111952
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lang Niklaus P, 2003, Oral Health Prev Dent, V1, P7
   Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu YX, 2020, SCI CHINA LIFE SCI, V63, P364, DOI 10.1007/s11427-020-1643-8
   Marchetti E, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1901-z
   Mark LL, 2000, J PERIODONTAL RES, V35, P172, DOI 10.1034/j.1600-0765.2000.035003172.x
   Marshall RP, 2003, CURR PHARM DESIGN, V9, P715, DOI 10.2174/1381612033455431
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Meyle J, 2015, PERIODONTOL 2000, V69, P7, DOI 10.1111/prd.12104
   Moutsopoulos NM, 2012, J AUTOIMMUN, V39, P294, DOI 10.1016/j.jaut.2012.03.003
   Okui T, 2012, J DENT RES, V91, P574, DOI 10.1177/0022034512446341
   Patini R, 2020, J INT SOC PREV COMMU, V10, P237, DOI 10.4103/jispcd.JISPCD_202_20
   Pietropaoli D, 2018, HYPERTENSION, V72, P1365, DOI 10.1161/HYPERTENSIONAHA.118.11528
   Qian GQ, 2020, CLIN INFECT DIS, V71, P861, DOI 10.1093/cid/ciaa316
   Queiroz CM, 2019, BONE, V128, DOI 10.1016/j.bone.2019.115041
   Rabaan Ali A, 2020, Infez Med, V28, P174
   Prestes TRR, 2017, CURR DRUG TARGETS, V18, P1301, DOI 10.2174/1389450117666160727142401
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Saccomanno S, 2020, EUR J PAEDIATR DENT, V21, P157, DOI 10.23804/ejpd.2020.21.02.12
   Sahni V., 2020, COVID 19 PERIODONTIT
   Santos CF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134601
   Sardu C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051417
   Silhol F, 2020, HYPERTENS RES, V43, P854, DOI 10.1038/s41440-020-0476-3
   Silva ACSE, 2013, BRIT J PHARMACOL, V169, P477, DOI 10.1111/bph.12159
   Soltani P, 2020, SCIENTOMETRICS, V125, P819, DOI 10.1007/s11192-020-03661-9
   Santos RAS, 2018, PHYSIOL REV, V98, P505, DOI 10.1152/physrev.00023.2016
   STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2
   Sukumaran V, 2011, INT J BIOL SCI, V7, P154, DOI 10.7150/ijbs.7.154
   Turkoglu O, 2014, J PERIODONTOL, V85, P908, DOI 10.1902/jop.2013.130346
   Villalobos LA, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00482
   Woelfel R., 2020, CLIN PRESENTATION VI
   Wu Q, 2017, CELL PHYSIOL BIOCHEM, V41, P1360, DOI 10.1159/000465455
   Wylie LA, 2020, SALIVA IS MORE SENSI, DOI [10.1101/2020.04.16.20067835, DOI 10.1101/2020.04.16.20067835]
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Yamada Y, 2009, J VIROL, V83, P8744, DOI 10.1128/JVI.00613-09
   Zenobia C, 2015, PERIODONTOL 2000, V69, P142, DOI 10.1111/prd.12083
   Zhao Y., 2020, BIORXIV
NR 65
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3417
J9 APPL SCI-BASEL
JI Appl. Sci.-Basel
PD SEP
PY 2020
VL 10
IS 18
AR 6224
DI 10.3390/app10186224
PG 10
WC Chemistry, Multidisciplinary; Engineering, Multidisciplinary; Materials
   Science, Multidisciplinary; Physics, Applied
SC Chemistry; Engineering; Materials Science; Physics
GA OE3PH
UT WOS:000580446100001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Lee, YH
   Choi, KJ
   Choi, SH
   Lee, SY
   Kim, KC
   Kim, EJ
   Lee, J
AF Lee, Yong Hoon
   Choi, Keum-Ju
   Choi, Sun Ha
   Lee, Shin Yup
   Kim, Kyung Chan
   Kim, Eun Jin
   Lee, Jaehee
TI Clinical Significance of Timing of Intubation in Critically Ill Patients
   with COVID-19: A Multi-Center Retrospective Study
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE COVID-19; acute respiratory distress syndrome; intubation; respiratory
   failure; mortality; intensive care units
ID HIGH-FLOW OXYGEN; PNEUMONIA; THERAPY
AB The effect of intubation timing on the prognosis of critically ill patients with coronavirus 2019 (COVID-19) is not yet well understood. We investigated whether early intubation is associated with the survival of COVID-19 patients with acute respiratory distress syndrome (ARDS). This multicenter, retrospective, observational study was done on 47 adult COVID-19 patients with ARDS who were admitted to the intensive care unit (ICU) in Daegu, Korea between February 17 and April 23, 2020. Clinical characteristics and in-hospital mortality were compared between the early intubation and initially non-intubated groups, and between the early and late intubation groups, respectively. Of the 47 patients studied, 23 (48.9%) were intubated on the day of meeting ARDS criteria (early intubation), while 24 (51.1%) were not initially intubated. Eight patients were never intubated during the in-hospital course. Median follow-up duration was 46 days, and 21 patients (44.7%) died in the hospital. No significant difference in in-hospital mortality rate was noted between the early group and initially non-intubated groups (56.5% vs. 33.3%,p= 0.110). Furthermore, the risk of in-hospital death in the early intubation group was not significantly different compared to the initially non-intubated group on multivariate adjusted analysis (p= 0.385). Results were similar between early and late intubation in the subgroup analysis of 39 patients treated with mechanical ventilation. In conclusion, in this study of critically ill COVID-19 patients with ARDS, early intubation was not associated with improved survival. This result may help in the efficient allocation of limited medical resources, such as ventilators.
C1 [Lee, Yong Hoon; Choi, Sun Ha; Lee, Shin Yup; Lee, Jaehee] Kyungpook Natl Univ, Sch Med, Div Pulm & Crit Care Med, Dept Internal Med, Daegu 41944, South Korea.
   [Choi, Keum-Ju] Daegu Vet Hosp, Dept Internal Med, Daegu 42835, South Korea.
   [Kim, Kyung Chan; Kim, Eun Jin] Daegu Catholic Univ, Sch Med, Dept Internal Med, Daegu 42472, South Korea.
RP Lee, J (corresponding author), Kyungpook Natl Univ, Sch Med, Div Pulm & Crit Care Med, Dept Internal Med, Daegu 41944, South Korea.; Kim, EJ (corresponding author), Daegu Catholic Univ, Sch Med, Dept Internal Med, Daegu 42472, South Korea.
EM yhlee2020@knu.ac.kr; tvbogo@naver.com; sunha20@knu.ac.kr;
   shinyup@knu.ac.kr; solar903@chol.com; ejkim77@cu.ac.kr; jaelee@knu.ac.kr
RI Kim, Eun Jin/L-6480-2018
OI Kim, Eun Jin/0000-0001-9791-8077
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Arulkumaran N, 2020, LANCET RESP MED, V8, pE45, DOI 10.1016/S2213-2600(20)30181-8
   Bonten MJM, 2004, CLIN INFECT DIS, V38, P1141, DOI 10.1086/383039
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Fowler RA, 2004, AM J RESP CRIT CARE, V169, P1198, DOI 10.1164/rccm.200305-715OC
   Kangelaris KN, 2016, CRIT CARE MED, V44, P120, DOI 10.1097/CCM.0000000000001359
   Leung CCH, 2019, J HOSP INFECT, V101, P84, DOI 10.1016/j.jhin.2018.10.007
   Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713
   Messika J, 2015, RESP CARE, V60, P162, DOI 10.4187/respcare.03423
   Parke RL, 2011, RESP CARE, V56, P265, DOI 10.4187/respcare.00801
   Quah P, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03006-1
   Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Roca O, 2010, RESP CARE, V55, P408
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Sztrymf B, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.07.075
   Sztrymf B, 2011, INTENS CARE MED, V37, P1780, DOI 10.1007/s00134-011-2354-6
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wells CR, 2020, LANCET INFECT DIS, V20, P1123, DOI 10.1016/S1473-3099(20)30315-7
   World Health Organization, 2020, CLIN MAN SEV AC RESP, P21
   World Health Organization, 2020, 192 WHO
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 25
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD SEP
PY 2020
VL 9
IS 9
AR 2847
DI 10.3390/jcm9092847
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA OD6MH
UT WOS:000579965100001
PM 32887462
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Hogan, AB
   Jewell, BL
   Sherrard-Smith, E
   Vesga, JF
   Watson, OJ
   Whittaker, C
   Hamlet, A
   Smith, JA
   Winskill, P
   Verity, R
   Baguelin, M
   Lees, JA
   Whittles, LK
   Ainslie, KEC
   Bhatt, S
   Boonyasiri, A
   Brazeau, NF
   Cattarino, L
   Cooper, LV
   Coupland, H
   Cuomo-Dannenburg, G
   Dighe, A
   Djaafara, BA
   Donnelly, CA
   Eaton, JW
   van Elsland, SL
   FitzJohn, RG
   Fu, H
   Gaythorpe, KAM
   Green, W
   Haw, DJ
   Hayes, S
   Hinsley, W
   Imai, N
   Laydon, DJ
   Mangal, TD
   Mellan, TA
   Mishra, S
   Nedjati-Gilani, G
   Parag, KV
   Thompson, HA
   Unwin, HJT
   Vollmer, MAC
   Walters, CE
   Wang, HW
   Wang, YR
   Xi, XY
   Ferguson, NM
   Okell, LC
   Churcher, TS
   Arinaminpathy, N
   Ghani, AC
   Walker, PGT
   Hallett, TB
AF Hogan, Alexandra B.
   Jewell, Britta L.
   Sherrard-Smith, Ellie
   Vesga, Juan F.
   Watson, Oliver J.
   Whittaker, Charles
   Hamlet, Arran
   Smith, Jennifer A.
   Winskill, Peter
   Verity, Robert
   Baguelin, Marc
   Lees, John A.
   Whittles, Lilith K.
   Ainslie, Kylie E. C.
   Bhatt, Samir
   Boonyasiri, Adhiratha
   Brazeau, Nicholas F.
   Cattarino, Lorenzo
   Cooper, Laura, V
   Coupland, Helen
   Cuomo-Dannenburg, Gina
   Dighe, Amy
   Djaafara, Bimandra A.
   Donnelly, Christl A.
   Eaton, Jeff W.
   van Elsland, Sabine L.
   FitzJohn, Richard G.
   Fu, Han
   Gaythorpe, Katy A. M.
   Green, William
   Haw, David J.
   Hayes, Sarah
   Hinsley, Wes
   Imai, Natsuko
   Laydon, Daniel J.
   Mangal, Tara D.
   Mellan, Thomas A.
   Mishra, Swapnil
   Nedjati-Gilani, Gemma
   Parag, Kris, V
   Thompson, Hayley A.
   Unwin, H. Juliette T.
   Vollmer, Michaela A. C.
   Walters, Caroline E.
   Wang, Haowei
   Wang, Yuanrong
   Xi, Xiaoyue
   Ferguson, Neil M.
   Okell, Lucy C.
   Churcher, Thomas S.
   Arinaminpathy, Nimalan
   Ghani, Azra C.
   Walker, Patrick G. T.
   Hallett, Timothy B.
TI Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and
   malaria in low-income and middle-income countries: a modelling study
SO LANCET GLOBAL HEALTH
LA English
DT Article
AB Background COVID-19 has the potential to cause substantial disruptions to health services, due to cases overburdening the health system or response measures limiting usual programmatic activities. We aimed to quantify the extent to which disruptions to services for HIV, tuberculosis, and malaria in low-income and middle-income countries with high burdens of these diseases could lead to additional loss of life over the next 5 years.
   Methods Assuming a basic reproduction number of 3.0, we constructed four scenarios for possible responses to the COVID-19 pandemic: no action, mitigation for 6 months, suppression for 2 months, or suppression for 1 year. We used established transmission models of HIV, tuberculosis, and malaria to estimate the additional impact on health that could be caused in selected settings, either due to COVID-19 interventions limiting activities, or due to the high demand on the health system due to the COVID-19 pandemic.
   Findings In high-burden settings, deaths due to HIV, tuberculosis, and malaria over 5 years could increase by up to 10%, 20%, and 36%, respectively, compared with if there was no COVID-19 pandemic. The greatest impact on HIV was estimated to be from interruption to antiretroviral therapy, which could occur during a period of high health system demand. For tuberculosis, the greatest impact would be from reductions in timely diagnosis and treatment of new cases, which could result from any prolonged period of COVID-19 suppression interventions. The greatest impact on malaria burden could be as a result of interruption of planned net campaigns. These disruptions could lead to a loss of life-years over 5 years that is of the same order of magnitude as the direct impact from COVID-19 in places with a high burden of malaria and large HIV and tuberculosis epidemics.
   Interpretation Maintaining the most critical prevention activities and health-care services for HIV, tuberculosis, and malaria could substantially reduce the overall impact of the COVID-19 pandemic. Copyright (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Hogan, Alexandra B.; Jewell, Britta L.; Sherrard-Smith, Ellie; Vesga, Juan F.; Watson, Oliver J.; Whittaker, Charles; Hamlet, Arran; Smith, Jennifer A.; Winskill, Peter; Verity, Robert; Baguelin, Marc; Lees, John A.; Whittles, Lilith K.; Ainslie, Kylie E. C.; Bhatt, Samir; Boonyasiri, Adhiratha; Brazeau, Nicholas F.; Cattarino, Lorenzo; Cooper, Laura, V; Coupland, Helen; Cuomo-Dannenburg, Gina; Dighe, Amy; Djaafara, Bimandra A.; Donnelly, Christl A.; Eaton, Jeff W.; van Elsland, Sabine L.; FitzJohn, Richard G.; Fu, Han; Gaythorpe, Katy A. M.; Green, William; Haw, David J.; Hayes, Sarah; Hinsley, Wes; Imai, Natsuko; Laydon, Daniel J.; Mangal, Tara D.; Mellan, Thomas A.; Mishra, Swapnil; Nedjati-Gilani, Gemma; Parag, Kris, V; Thompson, Hayley A.; Unwin, H. Juliette T.; Vollmer, Michaela A. C.; Walters, Caroline E.; Wang, Haowei; Wang, Yuanrong; Xi, Xiaoyue; Ferguson, Neil M.; Okell, Lucy C.; Churcher, Thomas S.; Arinaminpathy, Nimalan; Ghani, Azra C.; Walker, Patrick G. T.; Hallett, Timothy B.] Imperial Coll London, Med Res Council Ctr Global Infect Dis Anal, Abdul Latif Jameel Inst Dis & Emergency Analyt, London W2 1PG, England.
   [Donnelly, Christl A.] Univ Oxford, Dept Stat, Oxford, England.
RP Hallett, TB (corresponding author), Imperial Coll London, Med Res Council Ctr Global Infect Dis Anal, Abdul Latif Jameel Inst Dis & Emergency Analyt, London W2 1PG, England.
EM timothy.hallett@imperial.ac.uk
RI Parag, Kris/ABE-5722-2020; Bhatt, Samir/ABE-7938-2020
OI Parag, Kris/0000-0002-7806-3605; Okell, Lucy/0000-0001-7202-6873;
   Watson, Oliver/0000-0003-2374-0741; Hallett,
   Timothy/0000-0002-9681-0424; Unwin, Juliette/0000-0002-9120-4003;
   Gaythorpe, Katy/0000-0003-3734-9081; Mellan, Thomas/0000-0003-4185-9930;
   Smith, Jennifer/0000-0002-8809-8553
FU Bill & Melinda Gates FoundationBill & Melinda Gates FoundationCGIAR;
   Wellcome TrustWellcome Trust; UK Department for International
   Development; Medical Research CouncilMedical Research Council UK (MRC)
FX Bill & Melinda Gates Foundation, Wellcome Trust, UK Department for
   International Development, and Medical Research Council.
CR [Anonymous], 2020, PEPFAR TECHN GUID CO
   Black JRM, 2020, LANCET, V395, P1418, DOI 10.1016/S0140-6736(20)30917-X
   Cilloni L, 2020, POTENTIAL IMPACT COV, DOI [10.1101/2020.05.16.20104075, DOI 10.1101/2020.05.16.20104075]
   Griffi JT, 2016, LANCET INFECT DIS, V16, P465, DOI 10.1016/S1473-3099(15)00423-5
   Jewell BL, 2020, POTENTIAL IMPACT INT, DOI [10.1101/2020.04.22.20075861, DOI 10.1101/2020.04.22.20075861]
   Joint United Nations Programme on HIV/AIDS (UNAIDS), 2019, UNAIDS DAT 2019
   Kruk ME, 2015, LANCET, V385, P1910, DOI 10.1016/S0140-6736(15)60755-3
   Plucinski MM, 2015, LANCET INFECT DIS, V15, P1017, DOI 10.1016/S1473-3099(15)00061-4
   Sherrard-Smith E, 2020, REPORT 18 POTENTIAL
   Smith JA, 2016, LANCET HIV, V3, pE289, DOI 10.1016/S2352-3018(16)30036-4
   The Global Fund, 2020, GLOB FUND SURV MAJ H
   THORNTON J, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1401
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Vesga JF, 2019, LANCET GLOB HEALTH, V7, pE585, DOI 10.1016/S2214-109X(19)30037-3
   Walker PGT, 2020, SCIENCE, V369, P413, DOI 10.1126/science.abc0035
   WHO, 2019, GLOB TUB REP 2019
   WHO Expert Committee on Malaria, 2019, WORLD MAL REP 2019
NR 17
TC 23
Z9 23
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2214-109X
J9 LANCET GLOB HEALTH
JI Lancet Glob. Health
PD SEP
PY 2020
VL 8
IS 9
BP E1132
EP E1141
DI 10.1016/S2214-109X(20)30288-6
PG 10
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NZ8CD
UT WOS:000577328800018
PM 32673577
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Duijf, PHG
AF Duijf, Pascal H. G.
TI Low Baseline Pulmonary Levels of Cytotoxic Lymphocytes as a Predisposing
   Risk Factor for Severe COVID-19
SO MSYSTEMS
LA English
DT Article
DE COVID-19; SARS-CoV-2; ACE2; TMPRSS2; T cells; NK cells
ID ANGIOTENSIN-CONVERTING ENZYME-2; FUNCTIONAL RECEPTOR; SARS CORONAVIRUS;
   DENDRITIC CELLS; T-CELLS; EXPRESSION; ACE2; LUNG; INFECTION; HOMOLOG
AB Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and currently has detrimental human health, community, and economic impacts around the world. It is unclear why some SARS-CoV2-positive individuals remain asymptomatic, while others develop severe symptoms. Baseline pulmonary levels of antiviral leukocytes, already residing in the lung prior to infection, may orchestrate an effective early immune response and prevent severe symptoms. Here, "in silico flow cytometry" was used to deconvolute the levels of all seven types of antiviral leukocytes in 1,927 human lung tissues. Baseline levels of CD8(+) T cells, resting NK cells, and activated NK cells, as well as cytokines that recruit these cells, are significantly lower in lung tissues with high expression of the SARS-CoV-2 entry receptor angiotensin-converting enzyme 2 (ACE2). This is observed in univariate analyses, in multivariate analyses, and in two independent data sets. Importantly, ACE2 mRNA and protein levels very strongly correlate in human cells and tissues. The above findings also largely apply to the SARS-CoV-2 entry protease TMPRSS2. Both SARS-CoV-2-infected lung cells and COVID-19 lung tissues show upregulation of CD8(+) T cell- and NK cell-recruiting cytokines. Moreover, tissue-resident CD8(+) T cells and inflammatory NK cells are significantly more abundant in bronchoalveolar lavage fluids from mildly affected COVID-19 patients compared to severe cases. This suggests that these lymphocytes are important for preventing severe symptoms. Elevated ACE2 expression increases sensitivity to coronavirus infection. Thus, the results suggest that some individuals may be exceedingly susceptible to develop severe COVID-19 due to concomitant high preexisting ACE2 and TMPRSS expression and low baseline cytotoxic lymphocyte levels in the lung.
   IMPORTANCE COVID-19 is caused by the highly contagious coronavirus SARS-CoV-2 and currently has detrimental human health, community, and economic impacts around the world. It is unclear why some SARS-CoV-2-positive individuals develop severe COVID-19 symptoms, which can be fatal, while others only develop mild symptoms. In the absence of an effective and widely available vaccine, it is of paramount importance that we identify risk factors for development of severe symptoms to be able to improve treatment approaches. The ACE2 gene encodes the receptor on human cells that the virus uses to infect these cells. This study finds that if the lungs of healthy individuals have high levels of ACE2, they typically have low levels of the immune cells that eliminate viruses. Therefore, some individuals may develop severe COVID-19 due to simultaneous high levels of the virus receptor and low levels of immune cells that eradicate the virus in their lungs.
C1 [Duijf, Pascal H. G.] Queensland Univ Technol QUT, Fac Hlth, Sch Biomed Sci, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia.
   [Duijf, Pascal H. G.] Queensland Univ Technol QUT, Ctr Data Sci, Brisbane, Qld, Australia.
   [Duijf, Pascal H. G.] Univ Queensland, Diamantina Inst, Translat Res Inst, Brisbane, Qld, Australia.
RP Duijf, PHG (corresponding author), Queensland Univ Technol QUT, Fac Hlth, Sch Biomed Sci, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia.; Duijf, PHG (corresponding author), Queensland Univ Technol QUT, Ctr Data Sci, Brisbane, Qld, Australia.; Duijf, PHG (corresponding author), Univ Queensland, Diamantina Inst, Translat Res Inst, Brisbane, Qld, Australia.
EM pascal.duijf@qut.edu.au
RI Duijf, Pascal/E-7110-2012
OI Duijf, Pascal/0000-0001-8646-9843
FU School of Biomedical Sciences, Queensland University of Technology;
   Common Fund of the Office of the Director of the National Institutes of
   Health; NCIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI);
   NHGRIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Human Genome Research
   Institute (NHGRI); NHLBIUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI); NIDAUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA); NIMHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH); NCI\Leidos Biomedical Research, Inc.
   [10XS170, 10XS171, X10S172]; NINDSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Neurological Disorders & Stroke (NINDS); Leidos Biomedical
   Research, Inc. [10ST1035];  [DA006227];  [MH090941];  [MH101814]; 
   [MH090951];  [MH090937];  [MH101825];  [MH101820];  [MH090936]; 
   [MH101819];  [MH090948];  [MH101782];  [MH101810];  [MH101822]; 
   [HHSN268201000029C]
FX This work was supported by the School of Biomedical Sciences, Queensland
   University of Technology. This study used publicly available and
   controlled data from the Genotype-Tissue Expression (GTEx) Project. GTEx
   was supported by the Common Fund of the Office of the Director of the
   National Institutes of Health (commonfund. nih.gov/GTEx). Additional
   funds were provided by the NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS.
   Donors were enrolled at Biospecimen Source Sites funded by NCI\Leidos
   Biomedical Research, Inc. subcontracts to the National Disease Research
   Interchange (10XS170), Roswell Park Cancer Institute (10XS171), and
   Science Care, Inc. (X10S172). The Laboratory, Data Analysis, and
   Coordinating Center (LDACC) was funded through a contract
   (HHSN268201000029C) to the Broad Institute, Inc., Biorepository
   operations were funded through a Leidos Biomedical Research, Inc.
   subcontract to Van Andel Research Institute (10ST1035). Additional data
   repository and project management were provided by Leidos Biomedical
   Research, Inc. (HHSN261200800001E). The Brain Bank was supported by
   supplements to University of Miami grant DA006227. Statistical Methods
   development grants were made to the University of Geneva (MH090941 and
   MH101814), the University of Chicago (MH090951, MH090937, MH101825, and
   MH101820), the University of North Carolina-Chapel Hill (MH090936),
   North Carolina State University (MH101819), Harvard University
   (MH090948), Stanford University (MH101782), Washington University
   (MH101810), and to the University of Pennsylvania (MH101822).
CR Aguet F, 2017, NATURE, V550, P204, DOI 10.1038/nature24277
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Brown CE, 2007, J IMMUNOL, V179, P3332, DOI 10.4049/jimmunol.179.5.3332
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chu Hin, 2020, Lancet Microbe, V1, pe14, DOI 10.1016/S2666-5247(20)30004-5
   Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410
   Cook PC, 2016, SEMIN IMMUNOPATHOL, V38, P449, DOI 10.1007/s00281-016-0571-3
   Crouse J, 2015, NAT REV IMMUNOL, V15, P231, DOI 10.1038/nri3806
   DeLuca DS, 2012, BIOINFORMATICS, V28, P1530, DOI 10.1093/bioinformatics/bts196
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Fan ZS, 2006, BLOOD, V107, P1342, DOI 10.1182/blood-2005-08-3485
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Forrest ARR, 2014, NATURE, V507, P462, DOI 10.1038/nature13182
   Galani IE, 2015, J LEUKOCYTE BIOL, V98, P557, DOI 10.1189/jlb.4VMR1114-555R
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Guo JY, 2020, J AM HEART ASSOC, V9, DOI 10.1161/JAHA.120.016219
   Hammer Q, 2018, NAT IMMUNOL, V19, P800, DOI 10.1038/s41590-018-0163-6
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Harmer D, 2002, FEBS LETT, V532, P107, DOI 10.1016/S0014-5793(02)03640-2
   Harper RW, 2017, AM J RESP CELL MOL, V57, P145, DOI 10.1165/rcmb.2017-0153ED
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hofmann H, 2004, BIOCHEM BIOPH RES CO, V319, P1216, DOI 10.1016/j.bbrc.2004.05.114
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim MS, 2014, NATURE, V509, P575, DOI 10.1038/nature13302
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Liu J, 2015, ACCIDENT ANAL PREV, V85, P157, DOI 10.1016/j.aap.2015.09.004
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Lloyd-Sherlock P, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1052
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Mossel EC, 2005, J VIROL, V79, P3846, DOI 10.1128/JVI.79.6.3846-3850.2005
   Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]
   Newton AH, 2016, SEMIN IMMUNOPATHOL, V38, P471, DOI 10.1007/s00281-016-0558-0
   Nusinow DP, 2020, CELL, V180, P387, DOI 10.1016/j.cell.2019.12.023
   Obeidat M, 2015, LANCET RESP MED, V3, P782, DOI 10.1016/S2213-2600(15)00380-X
   Sant AJ, 2012, J EXP MED, V209, P1391, DOI 10.1084/jem.20121517
   Schmidt ME, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00678
   Serody JS, 2000, BLOOD, V96, P2973
   Smith JC, 2020, DEV CELL, V53, P514, DOI 10.1016/j.devcel.2020.05.012
   Spranger S, 2017, CANCER CELL, V31, P711, DOI 10.1016/j.ccell.2017.04.003
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Thul PJ, 2017, SCIENCE, V356, DOI 10.1126/science.aal3321
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507
   Wauters E, 2020, DISCRIMINATING MILD, DOI [10.1101/2020.07.09.196519, DOI 10.1101/2020.07.09.196519]
   Wendel M, 2008, CANCER RES, V68, P8437, DOI 10.1158/0008-5472.CAN-08-1440
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CL, 2016, NUCLEIC ACIDS RES, V44, pD313, DOI 10.1093/nar/gkv1104
   Xie MX, 2020, INT J INFECT DIS, V94, P119, DOI 10.1016/j.ijid.2020.03.071
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhuang MW, 2020, J MED VIROL, V92, P2693, DOI 10.1002/jmv.26139
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
   Zumwalt TJ, 2015, ONCOTARGET, V6, P2981, DOI 10.18632/oncotarget.3205
NR 62
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2379-5077
J9 MSYSTEMS
JI mSystems
PD SEP-OCT
PY 2020
VL 5
IS 5
AR e00741-20
DI 10.1128/mSystems.00741-20
PG 13
WC Microbiology
SC Microbiology
GA OC7WM
UT WOS:000579368300005
PM 32873611
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shekhar, N
   Sarma, P
   Prajapat, M
   Avti, P
   Kaur, H
   Raja, A
   Singh, H
   Bhattacharya, A
   Sharma, S
   Kumar, S
   Prakash, A
   Medhi, B
AF Shekhar, Nishant
   Sarma, Phulen
   Prajapat, Manisha
   Avti, Pramod
   Kaur, Hardeep
   Raja, Anupam
   Singh, Harvinder
   Bhattacharya, Anusuya
   Sharma, Saurabh
   Kumar, Subodh
   Prakash, Ajay
   Medhi, Bikash
TI In Silico Structure-Based Repositioning of Approved Drugs for Spike
   Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from
   Molecular Dynamics and Binding Free Energy Calculations
SO MSYSTEMS
LA English
DT Article
DE severe acute respiratory syndrome coronavirus 2; fusion peptide;
   molecular dynamics simulation; molecular mechanics/generalized Born
   model and solvent accessibility; S2 fusion peptide-containing domain;
   coronavirus; docking; drug discovery; free energy; fusion peptide;
   molecular dynamics; repurposing; repositioning; spike protein
ID SARS-COV; MEMBRANE-FUSION; PROTEIN; VIRUS; IDENTIFICATION; ENTRY
AB The membrane-anchored spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a pivotal role in directing the fusion of the virus particle mediated by the host cell receptor angiotensin-converting enzyme 2 (ACE-2). The fusion peptide region of the S protein S2 domain provides SARSCoV-2 with the biological machinery needed for direct fusion to the host lipid membrane. In our present study, computer-aided drug design strategies were used for the identification of FDA-approved small molecules using the optimal structure of the S2 domain, which exhibits optimal interaction ratios, structural features, and energy variables, which were evaluated based on their performances in molecular docking, molecular dynamics simulations, molecular mechanics/generalized Born model and solvent accessibility binding free energy calculations of molecular dynamics trajectories, and statistical inferences. Among the 2,625 FDA-approved small molecules, chloramphenicol succinate, imipenem, and imidurea turned out to be the molecules that bound the best at the fusion peptide hydrophobic pocket. The principal interactions of the selected molecules suggest that the potential binding site at the fusion peptide region is centralized amid the Lys790, Thr791, Lys795, Asp808, and Gln872 residues.
   IMPORTANCE The present study provides the structural identification of the viable binding residues of the SARS-CoV-2 S2 fusion peptide region, which holds prime importance in the virus's host cell fusion and entry mechanism. The classical molecular mechanics simulations were set on values that mimic physiological standards for a good approximation of the dynamic behavior of selected drugs in biological systems. The drug molecules screened and analyzed here have relevant antiviral properties, which are reported here and which might hint toward their utilization in the coronavirus disease 2019 (COVID-19) pandemic owing to their attributes of binding to the fusion protein binding region shown in this study.
C1 [Shekhar, Nishant; Sarma, Phulen; Prajapat, Manisha; Kaur, Hardeep; Raja, Anupam; Singh, Harvinder; Sharma, Saurabh; Kumar, Subodh; Prakash, Ajay; Medhi, Bikash] PGIMER, Dept Pharmacol, Chandigarh, India.
   [Avti, Pramod] PGIMER, Dept Biophys, Chandigarh, India.
   [Bhattacharya, Anusuya] Govt Med Coll & Hosp, Dept Ophthalmol, Chandigarh, India.
RP Medhi, B (corresponding author), PGIMER, Dept Pharmacol, Chandigarh, India.
EM dr.bikash.us@yahoo.com
OI Singh, Harvinder/0000-0002-6349-3143; Reis,
   AlessanRSS/0000-0001-8486-7469
CR [Anonymous], 2015, VERS 3 4
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Bowers K., 2006, P 2006 ACM IEEE C SU, P43, DOI [DOI 10.1109/SC.2006.54, 10.1109/SC.2006.54]
   Calligari P, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040445
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   EVANS DJ, 1985, J CHEM PHYS, V83, P4069, DOI 10.1063/1.449071
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Grant BJ, 2006, BIOINFORMATICS, V22, P2695, DOI 10.1093/bioinformatics/btl461
   Guillen J, 2009, MOL MEMBR BIOL, V26, P236, DOI 10.1080/09687680902926203
   Halgren T, 2007, CHEM BIOL DRUG DES, V69, P146, DOI 10.1111/j.1747-0285.2007.00483.x
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jendele L, 2019, NUCLEIC ACIDS RES, V47, pW345, DOI 10.1093/nar/gkz424
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Madu IG, 2009, J VIROL, V83, P7411, DOI 10.1128/JVI.00079-09
   MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468
   Millet JK, 2018, VIROLOGY, V517, P3, DOI 10.1016/j.virol.2017.12.015
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Peddi SR, 2018, J BIOMOL STRUCT DYN, V36, P486, DOI 10.1080/07391102.2017.1281762
   Prajapat M, 2020, INDIAN J PHARMACOL, V52, P56, DOI 10.4103/ijp.IJP_115_20
   Racine JS, 2012, J APPL ECONOMET, V27, P167, DOI 10.1002/jae.1278
   Sainz B, 2005, J VIROL, V79, P7195, DOI 10.1128/JVI.79.11.7195-7206.2005
   Sarma P, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753580
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   White JM, 2008, CRIT REV BIOCHEM MOL, V43, P189, DOI 10.1080/10409230802058320 
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Xu YH, 2004, J BIOL CHEM, V279, P49414, DOI 10.1074/jbc.M408782200
NR 35
TC 1
Z9 1
U1 4
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2379-5077
J9 MSYSTEMS
JI mSystems
PD SEP-OCT
PY 2020
VL 5
IS 5
AR e00382-20
DI 10.1128/mSystems.00382-20
PG 16
WC Microbiology
SC Microbiology
GA OC7WM
UT WOS:000579368300021
PM 32963099
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mertz, L
AF Mertz, Leslie
TI Developing Antibody Defenses
SO IEEE PULSE
LA English
DT Article
DE Vaccines; Viruses (medical); COVID-19; Proteins; Immune system; Blood;
   Pandemics
AB Long before the coronavirus-2019 (COVID-19) pandemic began, four research groups-two at universities and two at biotechnology companies-were preparing for it by tackling a seemingly outlandish challenge proffered by the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense: find a stopgap defense against emerging pathogens, so people would have protection until a longer-term solution, notably a vaccine, became available. Under the challenge, called the Pandemic Prevention Platform (P3) program, the groups were to develop technology that would generate a treatment within 60 days of a virus being identified, and have that treatment begin to confer protection within three days of it being administered [1].
EM lmertz@nasw.org
CR Kose N, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw6647
   Sempowski GD, 2020, CELL, V181, P1458, DOI 10.1016/j.cell.2020.05.041
   Zost SJ, 2020, NATURE, DOI 10.1038/s41586-020-2548-6
   Zost SJ, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0998-x
NR 4
TC 0
Z9 0
U1 0
U2 0
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2154-2287
EI 2154-2317
J9 IEEE PULSE
JI IEEE Pulse
PD SEP
PY 2020
VL 11
IS 5
BP 2
EP 6
DI 10.1109/MPULS.2020.3022137
PG 5
WC Engineering, Biomedical
SC Engineering
GA OC7KU
UT WOS:000579336200001
OA Bronze
DA 2021-01-01
ER

PT J
AU Mertz, L
AF Mertz, Leslie
TI New, At-Home Antibody Test for Detecting, Tracking COVID-19
SO IEEE PULSE
LA English
DT Article
DE COVID-19; Blood; Forestry; Immune system; Companies; Viruses (medical)
AB An at-home test for coronavirus disease 2019 (COVID-19) could be released commercially as early as August, according to Scanwell Health of Los Angeles. A combination of a finger-prick blood sample and a smart-phone app, the test is designed to detect the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19. The company hopes to receive Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) by the end of summer, and make its first commercially available tests soon after.
CR Scanwell Health, IMPR SCREEN MON KIDN
   Scanwell Health, TEST TREAT UTIS YOUR
NR 2
TC 0
Z9 0
U1 0
U2 0
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2154-2287
EI 2154-2317
J9 IEEE PULSE
JI IEEE Pulse
PD SEP
PY 2020
VL 11
IS 5
BP 28
EP 31
DI 10.1109/MPULS.2020.3022203
PG 4
WC Engineering, Biomedical
SC Engineering
GA OC7KU
UT WOS:000579336200007
PM 33064642
OA Bronze
DA 2021-01-01
ER

PT J
AU Perez-Belmonte, LM
   Lopez-Carmona, MD
   Quevedo-Marin, JL
   Ricci, M
   Martin-Carmona, J
   Sanz-Canovas, J
   Lopez-Sampalo, A
   Martin-Escalante, MD
   Bernal-Lopez, MR
   Gomez-Huelgas, R
AF Perez-Belmonte, Luis M.
   Lopez-Carmona, Maria D.
   Quevedo-Marin, Juan L.
   Ricci, Michele
   Martin-Carmona, Jesica
   Sanz-Canovas, Jaime
   Lopez-Sampalo, Almudena
   Martin-Escalante, Maria D.
   Bernal-Lopez, M. Rosa.
   Gomez-Huelgas, Ricardo
TI Differences between Clinical Protocols for the Treatment of Coronavirus
   Disease 2019 (COVID-19) in Andalusia, Spain
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE coronavirus disease 2019; management; clinical protocol; differences;
   antiviral agent; corticosteroids; anakinra; heparin
ID PNEUMONIA
AB Our objective was to compare clinical protocols for the treatment of the novel coronavirus disease 2019 (COVID-19) among different hospitals in Andalusia, Spain. We reviewed the current COVID-19 protocols of the 15 largest hospitals in Andalusia. Antiviral treatment, empirical antibacterial agents, adjunctive therapies, anticoagulant treatment, supportive care, hospital organization, and discharge recommendations were analyzed. All protocols included were the latest updates as of July 2020. Hydroxychloroquine in monotherapy was the most frequent antiviral drug recommended for mild respiratory illness with clinical risk factors (33.3%). Combined hydroxychloroquine with azithromycin or lopinavir/ritonavir was found in 40% of protocols. The recommended treatment for patients with mild and moderate pneumonias was different antiviral combinations including hydroxychloroquine plus azithromycin (93.3%) or hydroxychloroquine plus lopinavir/ritonavir (79.9%). Different combinations of hydroxychloroquine and lopinavir/ritonavir (46.7%) and triple therapy with hydroxychloroquine, azithromycin, and lopinavir/ritonavir (40%) were the most recommended treatments for patients with severe pneumonia. There were five corticosteroid regimens, which used dexamethasone, methylprednisolone, or prednisone, with different doses and treatment durations. Anakinra was included in seven protocols with six different regimens. All protocols included prophylactic heparin and therapeutic doses for thromboembolism. Higher prophylactic doses of heparin for high-risk patients and therapeutic doses for patients in critical condition were included in 53.3% and 33.3% of protocols, respectively. This study showed that COVID-19 protocols varied widely in several aspects (antiviral treatment, corticosteroids, anakinra, and anticoagulation for high risk of thrombosis or critical situation). Rigorous randomized clinical trials on the proposed treatments are needed to provide consistent evidence.
C1 [Perez-Belmonte, Luis M.; Lopez-Carmona, Maria D.; Ricci, Michele; Martin-Carmona, Jesica; Sanz-Canovas, Jaime; Lopez-Sampalo, Almudena; Bernal-Lopez, M. Rosa.; Gomez-Huelgas, Ricardo] Univ Malaga UMA, Inst Invest Biomed Malaga IBIMA, Hosp Reg Univ Malaga, Serv Med Interna, Malaga 29010, Spain.
   [Perez-Belmonte, Luis M.] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Cardiovasc CIB, Madrid 28029, Spain.
   [Quevedo-Marin, Juan L.] Univ Rey Juan Carlos, Dept Bioquim, Madrid 28933, Spain.
   [Martin-Escalante, Maria D.] Hosp Costa Sol, Serv Med Interna, Marbella 29603, Spain.
   [Bernal-Lopez, M. Rosa.; Gomez-Huelgas, Ricardo] Inst Salud Carlos III, Ctr Invest Biomed Red Fisiopatol Obesidad & Nutr, Madrid 28029, Spain.
RP Perez-Belmonte, LM; Lopez-Carmona, MD (corresponding author), Univ Malaga UMA, Inst Invest Biomed Malaga IBIMA, Hosp Reg Univ Malaga, Serv Med Interna, Malaga 29010, Spain.; Perez-Belmonte, LM (corresponding author), Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Cardiovasc CIB, Madrid 28029, Spain.
EM lmiguel.perez.sspa@juntadeandalucia.es;
   mariad.lopez.carmona.sspa@juntadeandalucia.es;
   mariad.m.escalante@juntadeandalucia.es;
   michele.ricci.sspa@juntadeandalucia.es;
   jessica.martin.sspa@juntadeandalucia.es;
   jaime.sanz.sspa@juntadeandalucia.es;
   almudena.lopez.sampalo.sspa@juntadeandalucia.es;
   mariad.m.escalante@juntadeandalucia.es; rosa.bernal@ibima.eu; rgh@uma.es
RI Bernal Lopez, M Rosa/N-3564-2016
OI Bernal Lopez, M Rosa/0000-0002-0238-0890; Gomez Huelgas,
   Ricardo/0000-0002-9909-3555; Martin Escalante, Maria
   Dolores/0000-0003-1932-8682
FU Sociedad Andaluza de Medicina Interna
FX We thank all hospital COVID-19 teams for the protocol developments and
   updates, Sociedad Andaluza de Medicina Interna for the coordination, and
   Claire Conrad for her help with the final English-language version.
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   [Anonymous], 2020, COVID 19 GUIDELINES
   [Anonymous], 2020, COVID 19 VTE ANT FRE
   [Anonymous], 2020, COVID 19 RAP GUID MA
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bhimraj A, 2020, INFECT DIS SOC AM GU
   Corral L., 2020, GLUCOCOVID CONTROLLE, DOI [10.1101/2020.06.17.20133579, DOI 10.1101/2020.06.17.20133579]
   COVID-19 RISK and Treatments (CORIST) Collaboration, 2020, Eur J Intern Med, V82, P38, DOI 10.1016/j.ejim.2020.08.019
   Di Castelnuovo A, 2020, NUTR METAB CARDIOVAS, V30, P1899, DOI 10.1016/j.numecd.2020.07.031
   Di Gennaro F, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082690
   Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Hewitt-Taylor Jaquelina, 2004, Intensive Crit Care Nurs, V20, P45, DOI 10.1016/j.iccn.2003.08.002
   Horby P, 2020, EFFECT HYDROXYCHLORO, DOI [10.1101/2020.07.15.20151852, DOI 10.1101/2020.07.15.20151852]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kruse Robert L, 2020, F1000Res, V9, P72, DOI 10.12688/f1000research.22211.2
   Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Monteagudo Luke Adam, 2020, ACR Open Rheumatol, V2, P276, DOI 10.1002/acr2.11135
   National Health Commission & State Administration of Traditional Chinese Medicine, DIAGN TREATM PROT NO
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Scavone C, 2020, BRIT J PHARMACOL, V177, P4813, DOI 10.1111/bph.15072
   Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980
   Teijaro JR, 2017, SEMIN IMMUNOPATHOL, V39, P501, DOI 10.1007/s00281-017-0640-2
   Wang T, 2020, LANCET HAEMATOL, V7, pE362, DOI 10.1016/S2352-3026(20)30109-5
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   World Health Organization, CLIN MAN SEV AC RESP
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yan D, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00799-2020
   Ye ZK, 2020, CAN MED ASSOC J, V192, pE536, DOI 10.1503/cmaj.200648
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 34
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD SEP
PY 2020
VL 17
IS 18
AR 6845
DI 10.3390/ijerph17186845
PG 12
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA OD6OS
UT WOS:000579971400001
PM 32961675
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nollace, L
   Cravero, C
   Abbou, A
   Mazda-Walter, B
   Bleibtreu, A
   Pereirra, N
   Sainte-Marie, M
   Cohen, D
   Giannitelli, M
AF Nollace, Leslie
   Cravero, Cora
   Abbou, Alice
   Mazda-Walter, Brice
   Bleibtreu, Alexandre
   Pereirra, Nathalie
   Sainte-Marie, Myriam
   Cohen, David
   Giannitelli, Marianna
TI Autism and COVID-19: A Case Series in a Neurodevelopmental Unit
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE COVID-19; autism; intellectual disability; challenging behaviors
AB Background: COVID-19 has become pandemic and can impact individuals with autism as well. Here, we report a case series admitted to a neurobehavioral unit dedicated to challenging behaviors in patients with autism. Methods: We describe 16 patients (mean age 20.8 years; range 12-43 years; 76% male) with autism hospitalized between March 2020 and mid-April 2020 for challenging behaviors, for which COVID-19 disease has been suspected and who needed both psychiatric and medical care. A close cooperation with the Infectious and Tropical Diseases Department was organized to limit viral spread and training sessions (e.g., hygiene, clinical COVID-19 monitoring, virus testing) were given to staff members. Results: Most patients had severe autism and severe/moderate intellectual disability. Eleven patients were already in the unit when it was hit by the pandemic, and five were admitted from the community. Based on a virus search via reverse transcriptase polymerase chain reaction (RT-PCR) or serology at the 2-month follow-up, we had 11 confirmed COVID-19 cases. The main COVID-19 symptoms included benign upper respiratory infection signs (N= 9, 81.8%), diarrhea (N= 7, 63.6%), fatigue (N= 7, 63.6%), and respiratory signs (N= 5, 45.5%), including one patient who needed oxygen therapy. Three patients remained asymptomatic and COVID-19-free (including two under immunosuppressive treatments). Among the symptomatic patients, five showed atypical behaviors that we understood as idiosyncratic manifestations (e.g., irrepressible licking behavior). On day 14, only one patient with respiratory dysfunction still had a positive RT-PCR SARS-CoV-2 test. Conclusions: Organizing a COVID+ unit for patients with autism is realistic and requires close collaboration with infectologists. We believe that this initiative should be promoted to limit both the spread of the virus and the ostracism of patients with autism and challenging behaviors.
C1 [Nollace, Leslie; Cravero, Cora; Abbou, Alice; Mazda-Walter, Brice; Pereirra, Nathalie; Sainte-Marie, Myriam; Cohen, David; Giannitelli, Marianna] Sorbonne Univ, APHP, Reference Ctr Rare Psychiat Dis, Dept Child & Adolescent Psychiat, F-75013 Paris, France.
   [Cravero, Cora] Elan Retrouve Fdn, Interdept Mobile Unit Complex Situat Autism UMI 7, UMI 75, F-75009 Paris, France.
   [Bleibtreu, Alexandre] Sorbonne Univ, APHP, Pitie Salpetriere Hosp, Dept Infect Dis, F-75013 Paris, France.
   [Cohen, David] Sorbonne Univ, CNRS UMR 7222, Inst Syst Intelligents & Robot ISIR, F-75005 Paris, France.
RP Cohen, D (corresponding author), Sorbonne Univ, APHP, Reference Ctr Rare Psychiat Dis, Dept Child & Adolescent Psychiat, F-75013 Paris, France.; Cohen, D (corresponding author), Sorbonne Univ, CNRS UMR 7222, Inst Syst Intelligents & Robot ISIR, F-75005 Paris, France.
EM leslie.nollace@aphp.fr; cora.cravero@aphp.fr; alice.abbou@aphp.fr;
   BRICE.MAZDA-WALTER@aphp.fr; alexandre.bleibtreu@aphp.fr;
   nathalie.pereirra@aphp.fr; myriam.saintemarie@aphp.fr;
   david.cohen@aphp.fr; marianna.giannitelli@aphp.fr
OI CRAVERO, Cora/0000-0002-8345-079X; Bleibtreu,
   Alexandre/0000-0001-5145-4174
CR [Anonymous], 2020, SANTE PUBLIQUE FRANC
   Arango C, 2020, BIOL PSYCHIAT, V88, pE33, DOI 10.1016/j.biopsych.2020.04.003
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Cheung KS, 2020, GASTROENTEROLOGY, V159, P81, DOI 10.1053/j.gastro.2020.03.065
   Chevance A, 2020, ENCEPHALE, V46, pS3, DOI 10.1016/j.encep.2020.03.001
   Choi Soo-Han, 2020, Clin Exp Pediatr, V63, P125, DOI 10.3345/cep.2020.00535
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   COVID19 APHP Grp, 2020, LANCET, V395, P1760, DOI 10.1016/S0140-6736(20)31210-1
   Cravero Cora, 2017, Case Rep Psychiatry, V2017, P7582780, DOI 10.1155/2017/7582780
   Cravero Cora, 2016, BMJ Case Rep, V2016, DOI 10.1136/bcr-2015-210925
   Deslandes A, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.106006
   Guinchat V., 2020, HDB NEUROCOGNITIVE D
   Guinchat V, 2015, RES DEV DISABIL, V38, P242, DOI 10.1016/j.ridd.2014.12.020
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Hyman SL, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2019-3447
   Levine J, 2019, J MOL NEUROSCI, V68, P321, DOI 10.1007/s12031-019-01333-9
   Narzisi A, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10040207
   Stoecklin SB, 2020, EUROSURVEILLANCE, V25, P20, DOI 10.2807/1560-7917.ES.2020.25.6.2000094
   The Royal College of Physicians, NAT EARL WARN SCOR N, V2
   Xie MX, 2020, INT J INFECT DIS, V94, P119, DOI 10.1016/j.ijid.2020.03.071
NR 20
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD SEP
PY 2020
VL 9
IS 9
AR 2937
DI 10.3390/jcm9092937
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA OD6SD
UT WOS:000579980300001
PM 32932951
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Busnadiego, I
   Fernbach, S
   Pohl, MO
   Karakus, U
   Huber, M
   Trkola, A
   Stertz, S
   Hale, BG
AF Busnadiego, Idoia
   Fernbach, Sonja
   Pohl, Marie O.
   Karakus, Umut
   Huber, Michael
   Trkola, Alexandra
   Stertz, Silke
   Hale, Benjamin G.
TI Antiviral Activity of Type I, II, and III Interferons Counterbalances
   ACE2 Inducibility and Restricts SARS-CoV-2
SO MBIO
LA English
DT Article
DE ACE2; COVID-19; SARS-CoV-2; coronavirus; immunotherapy; interferons;
   receptors
ID CORONAVIRUS; RECEPTOR
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), is a recently emerged respiratory coronavirus that has infected >23 million people worldwide with >800,000 deaths. Few COVID-19 therapeutics are available, and the basis for severe infections is poorly understood. Here, we investigated properties of type I (/3), II (y), and III (A1) interferons (IFNs), potent immune cytokines that are normally produced during in-fection and that upregulate IFN-stimulated gene (ISG) effectors to limit virus replication. IFNs are already in clinical trials to treat COVID-19. However, recent studies highlight the potential for IFNs to enhance expression of host angiotensin-converting enzyme 2 (ACE2), suggesting that IFN therapy or natural coinfections could exacerbate COVID-19 by upregulating this critical virus entry receptor. Using a cell line model, we found that beta interferon (IFN-/3) strongly upregulated expression of canonical antiviral ISGs, as well as ACE2 at the mRNA and cell surface protein levels. Strikingly, IFN-A1 upregulated antiviral ISGs, but ACE2 mRNA was only marginally elevated and did not lead to detectably increased ACE2 protein at the cell surface. IFN-y induced the weakest ISG response but clearly enhanced surface expression of ACE2. Importantly, all IFN types inhibited SARS-CoV-2 replication in a dose-dependent manner, and IFN-/3 and IFN-A1 exhibited potent antiviral activity in primary human bronchial epithelial cells. Our data imply that type-specific mechanisms or kinetics shape IFN-enhanced ACE2 transcript and cell surface levels but that the antiviral action of IFNs against SARS-CoV-2 counterbalances any proviral effects of ACE2 induction. These insights should aid in evaluating the benefits of specific IFNs, particularly IFN-A, as repurposed therapeutics.
   IMPORTANCE Repurposing existing, clinically approved, antiviral drugs as COVID-19 therapeutics is a rapid way to help combat the SARS-CoV-2 pandemic. Interferons (IFNs) usually form part of the body's natural innate immune defenses against viruses, and they have been used with partial success to treat previous new viral threats, such as HIV, hepatitis C virus, and Ebola virus. Nevertheless, IFNs can have undesirable side effects, and recent reports indicate that IFNs upregulate the expression of host ACE2 (a critical entry receptor for SARS-CoV-2), raising the possibility that IFN treatments could exacerbate COVID-19. Here, we studied the antiviraland ACE2-inducing properties of different IFN types in both a human lung cell line model and primary human bronchial epithelial cells. We observed differences between IFNs with respect to their induction of antiviral genes and abilities to enhance the cell surface expression of ACE2. Nevertheless, all the IFNs limited SARS-CoV-2 replication, suggesting that their antiviral actions can counterbalance increased ACE2.
C1 [Busnadiego, Idoia; Fernbach, Sonja; Pohl, Marie O.; Karakus, Umut; Huber, Michael; Trkola, Alexandra; Stertz, Silke; Hale, Benjamin G.] Univ Zurich, Inst Med Virol, Zurich, Switzerland.
   [Fernbach, Sonja] ETH, Life Sci Zurich Grad Sch, Zurich, Switzerland.
   [Fernbach, Sonja] Univ Zurich, Zurich, Switzerland.
RP Stertz, S; Hale, BG (corresponding author), Univ Zurich, Inst Med Virol, Zurich, Switzerland.
EM stertz.silke@virology.uzh.ch; hale.ben@virology.uzh.ch
RI Hale, Benjamin G./D-4958-2015; Busnadiego, Idoia/O-8641-2016; Huber,
   Michael/B-8509-2015
OI Hale, Benjamin G./0000-0002-3891-9480; Busnadiego,
   Idoia/0000-0002-8781-9099; Huber, Michael/0000-0002-0384-0000; Fernbach,
   Sonja/0000-0002-3362-3832; Reis, AlessanRSS/0000-0001-8486-7469
FU University of Zurich (Forschungskredit) [FK-18-044]; Swiss National
   Science FoundationSwiss National Science Foundation (SNSF)
   [31003A_182464]
FX This work was partially supported by the University of Zurich
   (Forschungskredit grant FK-18-044 to I.B.) and the Swiss National
   Science Foundation (grant 31003A_182464 to B.G.H.).
CR Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bunyavanich S, 2020, JAMA-J AM MED ASSOC, V323, P2427, DOI 10.1001/jama.2020.8707
   Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045
   Davidson S, 2016, EMBO MOL MED, V8, P1099, DOI 10.15252/emmm.201606413
   Felgenhauer U, 2020, J BIOL CHEM, V295, P13958, DOI 10.1074/jbc.AC120.013788
   Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Klinkhammer J, 2018, ELIFE, V7, DOI 10.7554/eLife.33354
   Lazear HM, 2019, IMMUNITY, V50, P907, DOI 10.1016/j.immuni.2019.03.025
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Lukassen S, 2020, EMBO J, DOI 10.15252/embj.20105114
   Park A, 2020, CELL HOST MICROBE, V27, P870, DOI 10.1016/j.chom.2020.05.008
   Pinto BGG, 2020, J INFECT DIS, V222, P556, DOI 10.1093/infdis/jiaa332
   Sims AC, 2005, J VIROL, V79, P15511, DOI 10.1128/JVI.79.24.15511-15524.2005
   Smith JC, 2020, DEV CELL, V53, P514, DOI 10.1016/j.devcel.2020.05.012
   Stanifer ML, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107863
   Vanderheiden A, 2020, J VIROL, V94, DOI 10.1128/JVI.00985-20
   Venkatakrishnan AJ, 2020, ELIFE, V9, DOI 10.7554/eLife.58040
   Wang N, 2020, CELL HOST MICROBE, V28, P455, DOI 10.1016/j.chom.2020.07.005
   World Health Organization, 2020, COR DIS 19 COVID 19
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhuang MW, 2020, J MED VIROL, V92, P2693, DOI 10.1002/jmv.26139
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
NR 26
TC 1
Z9 1
U1 3
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD SEP-OCT
PY 2020
VL 11
IS 5
AR e01928-20
DI 10.1128/mBio.01928-20
PG 10
WC Microbiology
SC Microbiology
GA OC4EX
UT WOS:000579111800009
PM 32913009
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Guimaraes, TT
   dos Santos, HMB
   Sanctos, RTM
AF Guimaraes, Thiago Teixeira
   Brito dos Santos, Henrique Mariano
   Mattos Sanctos, Rodrigo Terra
TI PHYSICAL INACTIVITY, CHRONIC DISEASES, IMMUNITY AND COVID-19
SO REVISTA BRASILEIRA DE MEDICINA DO ESPORTE
LA English
DT Article
DE Pandemic; Physical exercise; Inflammation; SARS-CoV-2
ID EXERCISE; CYTOKINE; SYSTEM; INTEGRATION; ADAPTATION; RESPONSES;
   MODERATE; STRESS
AB Complications arising from COVID-19 reflect an abnormal immune response in people previously diagnosed with chronic, non-communicable diseases (NCD), such as cardiovascular, metabolic and pulmonary conditions. Physical inactivity is recognized as a condition that affects the development of chronic low-grade inflammation, NCD, and susceptibility to cell infections. Anxiety and mental stress, poor nutritional status, drug use and circadian rhythm disturbances can further aggravate the harm caused by physical inactivity. Therefore, the purpose of the review is to invite health professionals, their respective regulatory boards, universities, research promotion foundations, media, political authorities and lay citizens to raise awareness of immunity and health in the medium- to long-term control of the current pandemic.
C1 [Guimaraes, Thiago Teixeira; Brito dos Santos, Henrique Mariano; Mattos Sanctos, Rodrigo Terra] Excess Exercise Res Grp GPEEx, Rio De Janeiro, RJ, Brazil.
   [Mattos Sanctos, Rodrigo Terra] Brazilian Air Force DIRENS FAB, Directorate Educ, Colegio Brigadeiro Newton Braga CBNB, Rio De Janeiro, RJ, Brazil.
RP Guimaraes, TT (corresponding author), Av Lucio Costa 3550, BR-22630010 Rio De Janeiro, RJ, Brazil.
EM thiagotguimaraes@yahoo.com.br
OI Terra, Rodrigo/0000-0001-8418-2654; Teixeira Guimaraes,
   Thiago/0000-0001-6457-5098
CR Abbas AK, 2019, IMUNOLOGIA CELULAR M
   Ahmadpoor P, 2020, TRANSPL INT, V33, P824, DOI 10.1111/tri.13611
   Bassit RA, 2000, MED SCI SPORT EXER, V32, P1214, DOI 10.1097/00005768-200007000-00005
   Booth FW, 2002, J PHYSIOL-LONDON, V543, P399, DOI 10.1113/jphysiol.2002.019265
   Bratman GN, 2015, P NATL ACAD SCI USA, V112, P8567, DOI 10.1073/pnas.1510459112
   Braun WA, 2004, NUTRITION, V20, P645, DOI 10.1016/j.nut.2004.04.013
   Dickerson SS, 2004, PSYCHOL BULL, V130, P355, DOI 10.1037/0033-2909.130.3.355
   Dorshkind K, 2009, NAT REV IMMUNOL, V9, P57, DOI 10.1038/nri2471
   Farhangimaleki N, 2009, J SPORT SCI MED, V8, P600
   Fiuza-Luces C, 2013, PHYSIOLOGY, V28, P330, DOI 10.1152/physiol.00019.2013
   Gholamnezhad Z, 2014, IRAN J BASIC MED SCI, V17, P1
   Gleeson M, 2011, NAT REV IMMUNOL, V11, P607, DOI 10.1038/nri3041
   Guimaraes T, 2019, AN 31 C BRAS MED EX, V25, P3
   Guimarães Thiago Teixeira, 2017, Motri., V13, P69, DOI 10.6063/motricidade.10049
   Hallal PC, 2012, LANCET, V380, P247, DOI 10.1016/S0140-6736(12)60646-1
   Handschin C, 2008, NATURE, V454, P463, DOI 10.1038/nature07206
   Hasan KMM, 2012, AGE, V34, P1421, DOI 10.1007/s11357-011-9319-0
   Heinonen I, 2014, PHYSIOLOGY, V29, P421, DOI 10.1152/physiol.00067.2013
   Lee IM, 2012, LANCET, V380, P219, DOI 10.1016/S0140-6736(12)61031-9
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Micic Dragan D., 2011, Glas Srpska Akademija Nauka i Umetnosti Odeljenje Meditsinskikh Nauka, V417, P5
   Ministerio da Saude, 2011, PLAN AC ESTR ENF DOE
   Murphy KM, 2014, IMUNBIOLOGIA JANEWAY
   Organization WH, 2018, WORLD HLTH STAT 2018
   Pedersen BK, 2000, PHYSIOL REV, V80, P1055
   Radak Z, 2008, FREE RADICAL BIO MED, V44, P153, DOI 10.1016/j.freeradbiomed.2007.01.029
   Ram H, 2019, INT MICROBIOL, V22, P1, DOI 10.1007/s10123-018-00049-x
   Rowbottom DG, 1996, SPORTS MED, V21, P80, DOI 10.2165/00007256-199621020-00002
   Schmitt V, 2013, EXP GERONTOL, V48, P1379, DOI 10.1016/j.exger.2013.09.003
   Shearer GM, 1997, MECH AGEING DEV, V94, P1
   Shephard RJ, 2010, EXERC IMMUNOL REV, V16, P194
   Simpson Richard J, 2020, Exerc Immunol Rev, V26, P8
   Stefan N, 2020, NAT REV ENDOCRINOL, V16, P341, DOI 10.1038/s41574-020-0364-6
   Terra R, 2013, INT J SPORTS MED, V34, P661, DOI 10.1055/s-0032-1329992
   Terra R, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00115
   Terra R, 2012, REV BRAS MED ESPORTE, V18, P208, DOI 10.1590/S1517-86922012000300015
   Wang R, 2009, INT J BIOL SCI, V5, P338
   WHO, 2014, NONC DIS COUNTR PROF
   Zhao GG, 2012, EXERC IMMUNOL REV, V18, P98
NR 39
TC 0
Z9 0
U1 1
U2 1
PU SOC BRASILEIRA MED ESPORTE
PI SAO PAULO SP
PA AV BRIGADEIRO LUIS ANTONIO, 278, 6 AND, SAO PAULO SP, 01318 901, BRAZIL
SN 1517-8692
EI 1806-9940
J9 REV BRAS MED ESPORTE
JI Rev. Bras. Med. Esporte
PD SEP-OCT
PY 2020
VL 26
IS 5
BP 378
EP 381
DI 10.1590/1517-8692202026052019_0040
PG 4
WC Physiology; Sport Sciences
SC Physiology; Sport Sciences
GA OC3LF
UT WOS:000579058700002
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Corte, ACRE
   de Sousa, JPG
   de Sousa, IFG
   Garcia, RM
   Stancati, J
AF Ramos e Corte, Ana Carolina
   Grava de Sousa, Joaquim Paulo
   Grava de Sousa, Ivan Furlan
   Garcia, Raquel Muarrek
   Stancati, Julio
TI COVID-19 SAFETY RECOMMENDATIONS FOR THE REOPENING OF THE DR. JOAQUIM
   GRAVA CORINTHIANS TRAINING FACILITY
SO REVISTA BRASILEIRA DE MEDICINA DO ESPORTE
LA English
DT Article
DE SARS-CoV-2; Soccer; COVID-19
ID INJURIES
AB Since December 2019, the world has been fighting the SARS-CoV2 virus (severe acute respiratory syndrome coronavirus 2). Little is known about vaccines and forms of treatment at this point. However, the importance of preventing transmission is very clear, and one of the main measures is social isolation. Major sports tournaments, including soccer championships, have been suspended or cancelled due to COVID-19, on the grounds of our understanding of the importance of social isolation. Accordingly, large clubs have handed over their stadiums for the construction of field hospitals, and have encouraged health care by providing guidance on hygiene and social distancing. The involvement of soccer in the prevention of this pandemic is due to the fact that its managers understand the importance of this sport in the process, and its influence on fans and players. Over the years, soccer has incorporated scientific and technological knowledge into the game, which has frequently served as a role model for other types of sport and for the population. Therefore, in these extreme times of the COVID-19 pandemic, there is no reason to believe it would be any different, and standpoints taken by soccer teams serve as an example and reiterate their role in the educational commitment to society and respect for government authorities. As a result, a protocol was drawn up for the resumption of training, in which all recommendations to be followed by players, managers/backroom staff and employees are in accordance with official health agencies of the national and international government. In other words, the resumption of training is subject to the authorization of government authorities.
C1 [Ramos e Corte, Ana Carolina; Grava de Sousa, Joaquim Paulo; Grava de Sousa, Ivan Furlan; Garcia, Raquel Muarrek; Stancati, Julio] SC Corinthians Paulista, Sao Paulo, SP, Brazil.
RP Corte, ACRE (corresponding author), Av Dr Gastao Vidigal 1132,Apto 131 A, BR-05314000 Sao Paulo, SP, Brazil.
EM anacarolinacorte@gmail.com
CR Andersen TE, 2004, BRIT J SPORT MED, V38, P626, DOI 10.1136/bjsm.2003.007955
   Baggish A, 2020, BR J SPORTS MED, P2020
   Brazil. Ministry of Health. Health Surveillance Department, 2020, GUIA VIG EP EM SAUD
   Centers for Disease Control and Prevention, INF HEALTHC PROF COR
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cohen M, 1997, REV BRAS ORTOP, V32, P940
   Ehrmann FE, 2016, J STRENGTH COND RES, V30, P360, DOI 10.1519/JSC.0000000000001093
   Ekstrand J, 2011, AM J SPORT MED, V39, P1226, DOI 10.1177/0363546510395879
   Finnoff J., 2020, USOPC SPORTS MED
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Iaia FM, 2009, INTJ SPORT PHYSIOL, V4, P291, DOI 10.1123/ijspp.4.3.291
   Kampf G, 2020, J HOSP INFECT, V104, P246, DOI 10.1016/j.jhin.2020.01.022
   Lago-Penas C, 2010, J SPORT SCI MED, V9, P288
   Larcom AB, 2020, 18 SAFETY CONSIDERAT
   Schultz JC, 2015, MARKETING PROVISIONI, P303
NR 15
TC 0
Z9 0
U1 1
U2 1
PU SOC BRASILEIRA MED ESPORTE
PI SAO PAULO SP
PA AV BRIGADEIRO LUIS ANTONIO, 278, 6 AND, SAO PAULO SP, 01318 901, BRAZIL
SN 1517-8692
EI 1806-9940
J9 REV BRAS MED ESPORTE
JI Rev. Bras. Med. Esporte
PD SEP-OCT
PY 2020
VL 26
IS 5
BP 382
EP 385
DI 10.1590/1517-8692202026052019_0044
PG 4
WC Physiology; Sport Sciences
SC Physiology; Sport Sciences
GA OC3LF
UT WOS:000579058700016
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Di Michele, A
   Schoubben, A
   Varfaj, I
   D'Arpino, A
   Mercolini, L
   Sardella, R
   Ricci, M
   Tiacci, E
AF Di Michele, Alessandro
   Schoubben, Aurelie
   Varfaj, Ina
   D'Arpino, Alessandro
   Mercolini, Laura
   Sardella, Roccaldo
   Ricci, Maurizio
   Tiacci, Enrico
TI Improved Achiral and Chiral HPLC-UV Analysis of Ruxolitinib in Two
   Different Drug Formulations
SO SEPARATIONS
LA English
DT Article
DE chiral chromatography; COVID-19; enantioseparation; ICH guidelines;
   pharmaceutical formulations; quantitative analysis; system suitability
   parameters
ID COLUMNS APPROACH; RAT PLASMA
AB In this paper, two new reversed-phase (RP) HPLC-UV methods enabling the quantitative achiral and chiral analysis of ruxolitinib in commercial tablets (containing 20 mg of active pharmaceutical ingredient, API) and not commercially available galenic capsules (with 5 mg of API) are described. For the achiral method based on the use of a water/acetonitrile [70:30,v/v; with 0.1% (v) formic acid] eluent, a "research validation" study was performed mostly following the "International Council for Harmonization" guidelines. All the system suitability parameters were within the acceptance criteria: tailing factor, between 1.7 and 2.0; retention factor, 2.2; number of theoretical plates, >9000. The linearity curve showed R-2= 0.99 (R-xv(2)= 0.99), while trueness (expressed as recovery) was between 96.3 and 106.3%. Coefficient of variations (CVs) (repeatability: CV(w)and intermediate precision: CVIP) did not exceed 1.3% and 2.9%, respectively. Moreover, the use of the enantiomeric Whelk-O1 chiral stationary phases operated under similar RP eluent conditions as for the achiral analyses, and the "inverted chirality columns approach (ICCA)" allowed us to establish that the enantiomeric purity of ruxolitinib is retained upon reformulation from tablets to capsules. The two developed methods can allow accurate determinations of ruxolitinib in drug formulations for medical use.
C1 [Di Michele, Alessandro] Univ Perugia, Dept Phys & Geol, Via Pascoli 1, I-06123 Perugia, Italy.
   [Schoubben, Aurelie; Varfaj, Ina; Sardella, Roccaldo; Ricci, Maurizio] Univ Perugia, Dept Pharmaceut Sci, Via Fabretti 48, I-06123 Perugia, Italy.
   [D'Arpino, Alessandro] Santa Maria Misericordia Hosp, Hosp Pharm Unit, I-06132 Perugia, Italy.
   [Mercolini, Laura] Univ Bologna, Alma Mater Studiorum, Dept Pharm & Biotechnol FaBiT, Via Belmeloro 6, I-40126 Bologna, Italy.
   [Tiacci, Enrico] Univ & Hosp Perugia, Inst Haematol, I-06129 Perugia, Italy.
   [Tiacci, Enrico] Univ & Hosp Perugia, Ctr Haematooncol Res CREO, I-06129 Perugia, Italy.
RP Sardella, R (corresponding author), Univ Perugia, Dept Pharmaceut Sci, Via Fabretti 48, I-06123 Perugia, Italy.
EM alessandro.dimichele@collaboratori.unipg.it; aurelie.schoubben@unipg.it;
   ina.varfaj@outlook.com; alessandro.darpino@ospedale.perugia.it;
   laura.mercolini@unibo.it; roccaldo.sardella@unipg.it;
   maurizio.ricci@unipg.it; enrico.tiacci@unipg.it
RI ; Sardella, Roccaldo/Q-1181-2016
OI MERCOLINI, LAURA/0000-0002-0644-9461; Di Michele,
   Alessandro/0000-0002-0357-2608; Sardella, Roccaldo/0000-0001-9856-0230
FU grant on classical Hodgkin lymphoma to Enrico Tiacci from AIRC (IG 2019)
   [23732]
FX This work was supported in part by a grant on classical Hodgkin lymphoma
   to Enrico Tiacci from AIRC (IG 2019-ID. 23732 project-P.I. Tiacci
   Enrico).
CR Abraham J., 2010, HDB TRANSNATIONAL EC, P1041
   Badaloni E, 2007, ANAL CHEM, V79, P6013, DOI 10.1021/ac070776j
   Biswal S., 2019, PHARM METHODS, V10, P53, DOI [10.5530/phm.2019.2.10, DOI 10.5530/PHM.2019.2.10]
   Charlier B, 2019, ANAL LETT, V52, P1328, DOI 10.1080/00032719.2018.1537283
   Dalvi AV, 2018, J CHROMATOGR B, V1102, P74, DOI 10.1016/j.jchromb.2018.10.014
   Ianni F, 2019, TALANTA, V203, P147, DOI 10.1016/j.talanta.2019.05.045
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   Koller D, 2020, TALANTA, V208, DOI 10.1016/j.talanta.2019.120450
   Malavolta M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040909
   McKee S., PHARM TIMES
   Mehta N, 2020, AM J EMERG MED, V38, P1488, DOI [10.1016/j.ajem.2020.03.011, 10.1016/j.ajem.2020.04.035]
   Merienne C, 2018, J PHARMACEUT BIOMED, V150, P112, DOI 10.1016/j.jpba.2017.11.060
   Pucciarini L, 2020, J PHARMACEUT BIOMED, V180, DOI 10.1016/j.jpba.2019.113066
   Pucciarini L, 2019, J CHROMATOGR B, V1126, DOI 10.1016/j.jchromb.2019.121747
   Rood JJM, 2016, J PHARMACEUT BIOMED, V130, P244, DOI 10.1016/j.jpba.2016.06.037
   Satyanarayana P.V.V., 2012, J AT MOL, V2, P223
   Shabir GA, 2003, J CHROMATOGR A, V987, P57, DOI 10.1016/S0021-9673(02)01536-4
   Veeraraghavan S, 2014, J PHARMACEUT BIOMED, V94, P125, DOI 10.1016/j.jpba.2014.01.040
   Welch CJ, 1997, J CHROMATOGR A, V758, P93, DOI 10.1016/S0021-9673(96)00569-9
NR 19
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2297-8739
J9 SEPARATIONS
JI Separations
PD SEP
PY 2020
VL 7
IS 3
AR 47
DI 10.3390/separations7030047
PG 11
WC Chemistry, Analytical
SC Chemistry
GA OC5YF
UT WOS:000579230800001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Li, YN
   Li, M
   Wang, MD
   Zhou, YF
   Chang, J
   Xian, Y
   Wang, D
   Mao, L
   Jin, HJ
   Hu, B
AF Li, Yanan
   Li, Man
   Wang, Mengdie
   Zhou, Yifan
   Chang, Jiang
   Xian, Ying
   Wang, David
   Mao, Ling
   Jin, Huijuan
   Hu, Bo
TI Acute cerebrovascular disease following COVID-19: a single center,
   retrospective, observational study
SO STROKE AND VASCULAR NEUROLOGY
LA English
DT Article
DE stroke; Cerebrovascular disease; COVID-19; Anticoagulation therapy;
   Thromboembolic events
ID STROKE; RISK
AB Background and purpose COVID-19 is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Apart from respiratory complications, acute cerebrovascular disease (CVD) has been observed in some patients with COVID-19. Therefore, we described the clinical characteristics, laboratory features, treatment and outcomes of CVD complicating SARS-CoV-2 infection. Materials and methods Demographic and clinical characteristics, laboratory findings, treatments and clinical outcomes were collected and analysed. Clinical characteristics and laboratory findings of patients with COVID-19 with or without new-onset CVD were compared. Results Of 219 patients with COVID-19, 10 (4.6%) developed acute ischaemic stroke and 1 (0.5%) had intracerebral haemorrhage. COVID-19 with new onset of CVD were significantly older (75.7 +/- 10.8 years vs 52.1 +/- 15.3 years, p<0.001), more likely to present with severe COVID-19 (81.8% vs 39.9%, p<0.01) and were more likely to have cardiovascular risk factors, including hypertension, diabetes and medical history of CVD (all p<0.05). In addition, they were more likely to have increased inflammatory response and hypercoagulable state as reflected in C reactive protein (51.1 (1.3-127.9) vs 12.1 (0.1-212.0) mg/L, p<0.05) and D-dimer (6.9 (0.3-20.0) vs 0.5 (0.1-20.0) mg/L, p<0.001). Of 10 patients with ischemic stroke; 6 received antiplatelet treatment with aspirin or clopidogrel; and 3 of them died. The other four patients received anticoagulant treatment with enoxaparin and 2 of them died. As of 24 March 2020, six patients with CVD died (54.5%). Conclusion Acute CVD is not uncommon in COVID-19. Our findings suggest that older patients with risk factors are more likely to develop CVD. The development of CVD is an important negative prognostic factor which requires further study to identify optimal management strategy to combat the COVID-19 outbreak.
C1 [Li, Yanan; Li, Man; Wang, Mengdie; Zhou, Yifan; Mao, Ling; Jin, Huijuan; Hu, Bo] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurol, Wuhan, Peoples R China.
   [Chang, Jiang] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat,Key Lab Environm & Hlth, Wuhan, Peoples R China.
   [Xian, Ying] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
   [Xian, Ying] Duke Univ, Med Ctr, Dept Neurol, Durham, NC USA.
   [Wang, David] St Joseph Hosp Med Ctr, Barrow Neurol Inst, Dept Neurol, Neurovasc Div, Phoenix, AZ USA.
RP Jin, HJ; Hu, B (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Neurol, Wuhan, Peoples R China.
EM jinhuijuan1983@163.com; hubo@mail.hust.edu.cn
FU National Key Research and Development Program of China [2018YFC1312200];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81820108010]
FX This study was funded by the National Key Research and Development
   Program of China (number 2018YFC1312200 to BH) and the National Natural
   Science Foundation of China (number 81820108010 to BH).
CR Aggarwal G, 2020, INT J STROKE, V15, P385, DOI 10.1177/1747493020921664
   Arabi YM, 2015, INFECTION, V43, P495, DOI 10.1007/s15010-015-0720-y
   Avula A, 2020, BRAIN BEHAV IMMUN, V87, P115, DOI 10.1016/j.bbi.2020.04.077
   China NHCotPsRo, 2020, UPD OUTBR COR DIS 20
   Ding PW, 2018, INT IMMUNOPHARMACOL, V57, P132, DOI 10.1016/j.intimp.2018.02.006
   Goldberg MF, 2020, AM J NEURORADIOL, V41, P1170, DOI 10.3174/ajnr.A6588
   Grau AJ, 1998, NEUROLOGY, V50, P196, DOI 10.1212/WNL.50.1.196
   Horvei LD, 2016, J THROMB HAEMOST, V14, P1561, DOI 10.1111/jth.13369
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399
   Mao L, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3544840, DOI 10.2139/SSRN.3544840]
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST
   Pranata R, 2020, J STROKE CEREBROVASC, V29, DOI 10.1016/j.jstrokecerebrovasdis.2020.104949
   Tsai LK, 2004, ARCH NEUROL-CHICAGO, V61, P1669, DOI 10.1001/archneur.61.11.1669
   Tunc A, 2020, J CLIN NEUROSCI, V77, P227, DOI 10.1016/j.jocn.2020.05.018
   Umapathi T, 2004, J NEUROL, V251, P1227, DOI 10.1007/s00415-004-0519-8
   Valderrama EV, 2020, STROKE, V51, pE124, DOI 10.1161/STROKEAHA.120.030153
   Vonck K, 2020, EUR J NEUROL, V27, P1578, DOI 10.1111/ene.14329
   W-j G, 2020, NEW ENGL J MED
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, 78 WHO
   Xu J, 2005, CLIN INFECT DIS, V41, P1089, DOI 10.1086/444461
   Yaghi S, 2020, STROKE, V51, P2002, DOI 10.1161/STROKEAHA.120.030335
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 26
TC 48
Z9 48
U1 4
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2059-8688
EI 2059-8696
J9 STROKE VASC NEUROL
JI Stroke Vasc. Neurol.
PD SEP
PY 2020
VL 5
IS 3
BP 279
EP 284
DI 10.1136/svn-2020-000431
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA OB7BO
UT WOS:000578622800007
PM 32616524
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU AlShoaibi, NA
   Maghrabi, K
   Alanazi, H
   Al Harbi, M
   Alghamdi, S
AF AlShoaibi, Naeem A.
   Maghrabi, Khadijah
   Alanazi, Haitham
   Al Harbi, Mousa
   Alghamdi, Saleh
TI Saudi Heart Rhythm Society Task Force on Management of Potential
   Arrhythmogenicity Associated with Pharmacotherapy for COVID-19
SO ANNALS OF SAUDI MEDICINE
LA English
DT Article
ID QT INTERVAL PROLONGATION; TORSADE-DE-POINTES; SCIENTIFIC STATEMENT;
   DRUGS; RISK; SCORE
AB Evidence of cardiovascular complications associated with the COVID-19 global pandemic continues to evolve. These include direct and indirect myocardial injury with subsequent acute myocardial ischemia, and cardiac arrhythmia. Some results from a limited number of trials of antiviral medications, along with chloroquine/hydroxychloroquine and azithromycin, have been beneficial. However, these pharmacotherapies may cause drug-induced QT prolongation leading to ventricular arrhythmias and sudden cardiac death. Mitigation of the potential risk in these susceptible patients may prove exceptionally challenging. The Saudi Heart Rhythm Society established a task force to perform a review of this subject based on has recently published reports, and studies and recommendations from major medical organizations. The objective of this review is to identify high-risk patients, and to set clear guidelines for management of patients receiving these pharmacotherapies.
C1 [AlShoaibi, Naeem A.] King Abdulaziz Univ, Dept Med, Jeddah 21441, Saudi Arabia.
   [Maghrabi, Khadijah] King Abdulaziz Univ, Dept Pediat, Jeddah, Saudi Arabia.
   [Alanazi, Haitham; Alghamdi, Saleh] King Abdulaziz Cardiac Ctr, Dept Cardiol, Riyadh, Saudi Arabia.
   [Al Harbi, Mousa] King Fahad Specialist Hosp Dammam, Dept Cardiol, Dammam, Saudi Arabia.
RP AlShoaibi, NA (corresponding author), King Abdulaziz Univ, Dept Med, Jeddah 21441, Saudi Arabia.
EM neema.alshoaibi@gmail.com
CR Al-Khatib Sana M, 2018, J Am Coll Cardiol, V72, pe91, DOI 10.1016/j.jacc.2017.10.054
   [Anonymous], 2020, GUIDANCE CCS COVID 1
   [Anonymous], 2013, KALETRA R OR FILM CO
   Bazett HC, 1920, HEART-J STUD CIRC, V7, P353
   Bessiere F, 2020, JAMA CARDIOL, V5, P1067, DOI 10.1001/jamacardio.2020.1787
   Choi Y, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1574806
   Chorin E, 2020, HEART RHYTHM, V17, P1425, DOI 10.1016/j.hrthm.2020.05.014
   Costedoat-Chalumeau N, 2007, RHEUMATOLOGY, V46, P808, DOI 10.1093/rheumatology/kel402
   D Wang, 2020, JAMA
   De Yang F, 2011, PSYCHOPHARMACOLOGY, V216, P9, DOI 10.1007/s00213-011-2188-5
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Drew BJ, 2010, J AM COLL CARDIOL, V55, P934, DOI 10.1016/j.jacc.2010.01.001
   Fogarty H, 2020, BRIT J HAEMATOL, V189, P1044, DOI 10.1111/bjh.16749
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Giudicessi JR, 2020, MAYO CLIN P, V95
   Goldenberg I, 2006, J CARDIOVASC ELECTR, V17, P333, DOI 10.1111/j.1540-8167.2006.00408.x
   Haugaa KH, 2013, MAYO CLIN PROC, V88, P315, DOI 10.1016/j.mayocp.2013.01.013
   Hnatkova K, 2006, PACE, V29, P1277, DOI 10.1111/j.1540-8159.2006.00532.x
   Kim Y, 2014, YONSEI MED J, V55, P517, DOI 10.3349/ymj.2014.55.2.517
   Li B, 2020, CLIN RES CARDIOL, V109, P531, DOI 10.1007/s00392-020-01626-9
   Liu K, 2020, CHIN MED J
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Mitra Raman L, 2020, HeartRhythm Case Rep, V6, P244, DOI 10.1016/j.hrcr.2020.03.016
   Nachimuthu S, 2012, THER ADV DRUG SAF, V3, P241, DOI 10.1177/2042098612454283
   Nicastri E, 2020, INFECT DIS REP, V12, P3, DOI 10.4081/idr.2020.8543
   Page RL, 2016, CIRCULATION, V134, pE32, DOI 10.1161/CIR.0000000000000426
   Panicker GK, 2014, J ELECTROCARDIOL, V47, P155, DOI 10.1016/j.jelectrocard.2013.11.004
   Panicker GK, 2009, J ELECTROCARDIOL, V42, P348, DOI 10.1016/j.jelectrocard.2009.01.003
   Panicker GK, 2009, ANN NONINVAS ELECTRO, V14, P19, DOI 10.1111/j.1542-474X.2008.00269.x
   Porta-Sanchez A, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.007724
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Schachtele S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155649
   Sharma S, 2018, EUR HEART J, V39, P1466, DOI 10.1093/eurheartj/ehw631
   Singh AK, 2020, DIABETES METAB SYND, V14, P589, DOI 10.1016/j.dsx.2020.05.017
   Tisdale JE, 2013, CIRC-CARDIOVASC QUAL, V6, P479, DOI 10.1161/CIRCOUTCOMES.113.000152
   TZIVONI D, 1988, CIRCULATION, V77, P392, DOI 10.1161/01.CIR.77.2.392
   US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER), 2005, E14 CLIN EV QT QTC I
   Vink AS, 2018, CIRCULATION, V138, P2345, DOI 10.1161/CIRCULATIONAHA.118.033943
   White NJ, 2007, LANCET INFECT DIS, V7, P549, DOI 10.1016/S1473-3099(07)70187-1
   World Health Organization, 2016, NLM CLASS WA
   Xiong T.-Y., 2020, EUR HEART J
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zeltser D, 2003, MEDICINE, V82, P282, DOI 10.1097/00005792-200307000-00007
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 47
TC 0
Z9 0
U1 1
U2 1
PU K FAISAL SPEC HOSP RES CENTRE
PI RIYADH
PA PUBLICATIONS OFFICE PO BOX 3354, RIYADH 11211, SAUDI ARABIA
SN 0256-4947
EI 1319-9226
J9 ANN SAUDI MED
JI Ann. Saudi Med.
PD SEP-OCT
PY 2020
VL 40
IS 5
BP 365
EP 372
DI 10.5144/0256-4947.2020.365
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA NZ5GM
UT WOS:000577127900001
PM 32954790
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Alfinito, E
   Beccaria, M
   Ciccarese, M
AF Alfinito, Eleonora
   Beccaria, Matteo
   Ciccarese, Mariangela
TI Biosensing Cytokine IL-6: A Comparative Analysis of Natural and
   Synthetic Receptors
SO BIOSENSORS-BASEL
LA English
DT Article
DE IL-6 cytokine; biosensors; Proteotronics; aptamers; topological analysis
ID LABEL-FREE; CRYSTAL-STRUCTURE; INTERLEUKIN-6; CANCER; APTAMERS;
   ANTIBODY; APTASENSOR; TUMOR; NANOPARTICLES; INFLAMMATION
AB Cytokines are a family of proteins which play a major role in the regulation of the immune system and the development of several diseases, from rheumatoid arthritis to cancer and, more recently, COVID-19. Therefore, many efforts are currently being developed to improve therapy and diagnosis, as well as to produce inhibitory drugs and biosensors for a rapid, minimally invasive, and effective detection. In this regard, even more efficient cytokine receptors are under investigation. In this paper we analyze a set of IL-6 cytokine receptors, investigating their topological features by means of a theoretical approach. Our results suggest a topological indicator that may help in the identification of those receptors having the highest complementarity with the protein, a feature expected to ensure a stable binding. Furthermore, we propose and discuss the use of these receptors in an idealized experimental setup.
C1 [Alfinito, Eleonora] Univ Salento, Dept Innovat Engn, Piazza Tancredi, I-73100 Lecce, Italy.
   [Beccaria, Matteo] Univ Salento, Dept Math & Phys Ennio de Giorgi, Piazza Tancredi, I-73100 Lecce, Italy.
   [Beccaria, Matteo] Natl Inst Nucl Phys, Lecce Unit, I-73100 Lecce, Italy.
   [Ciccarese, Mariangela] Vito Fazzi Hosp Lecce, Oncol Unit, I-73100 Lecce, Italy.
RP Alfinito, E (corresponding author), Univ Salento, Dept Innovat Engn, Piazza Tancredi, I-73100 Lecce, Italy.
EM eleonora.alfinito@unisalento.it; matteo.beccaria@unisalento.it;
   mari.ciccarese75@gmail.com
OI Beccaria, Matteo/0000-0002-2152-3738
FU Italian Ministry of Education, University and Research (MIUR)Ministry of
   Education, Universities and Research (MIUR)
FX This research was supported in part by the Italian Ministry of
   Education, University and Research (MIUR), with the grant Project FFABR
   2017.
CR Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47
   Alfinito E., 2015, PROTEOTRONICS DEV PR, P1
   Alfinito E, 2017, NANOTECHNOLOGY, V28, DOI 10.1088/1361-6528/aa510f
   Alfinito E, 2015, PHYS REV E, V91, DOI 10.1103/PhysRevE.91.032702
   Alfinito E, 2011, RSC ADV, V1, P123, DOI 10.1039/c1ra00025j
   Baraket A, 2017, BIOSENS BIOELECTRON, V93, P170, DOI 10.1016/j.bios.2016.09.023
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bini A, 2011, BIOSENS BIOELECTRON, V26, P4411, DOI 10.1016/j.bios.2011.04.053
   Bizzarri AR, 2010, CHEM SOC REV, V39, P734, DOI 10.1039/b811426a
   Blanchetot C, 2016, J BIOL CHEM, V291, P13846, DOI 10.1074/jbc.M115.695528
   Bochet L, 2011, BIOCHEM BIOPH RES CO, V411, P102, DOI 10.1016/j.bbrc.2011.06.101
   Bonanni B, 2005, BIOPHYS J, V89, P2783, DOI 10.1529/biophysj.105.064097
   Boulanger MJ, 2003, SCIENCE, V300, P2101, DOI 10.1126/science.1083901
   Bromberg J, 2009, CANCER CELL, V15, P79, DOI 10.1016/j.ccr.2009.01.009
   Cataldo R, 2019, J PHYS CHEM B, V123, P1265, DOI 10.1021/acs.jpcb.8b11456
   Cataldo R, 2018, COMPUT BIOL CHEM, V77, P123, DOI 10.1016/j.compbiolchem.2018.09.014
   Cataldo R, 2020, CURR PHARM DESIGN, V26, P363, DOI 10.2174/1381612826666200114095027
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Crivianu-Gaita V, 2016, BIOSENS BIOELECTRON, V85, P32, DOI 10.1016/j.bios.2016.04.091
   Gelinas AD, 2016, CURR OPIN STRUC BIOL, V36, P122, DOI 10.1016/j.sbi.2016.01.009
   Gelinas AD, 2014, J BIOL CHEM, V289, P8720, DOI 10.1074/jbc.M113.532697
   Ghandadi M, 2016, CURR PHARM DESIGN, V22, P518, DOI 10.2174/1381612822666151124234417
   Gold L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015004
   Grivennikov S, 2008, CANCER CELL, V13, P7, DOI 10.1016/j.ccr.2007.12.020
   Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007
   Gupta S, 2014, J BIOL CHEM, V289, P8706, DOI 10.1074/jbc.M113.532580
   HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621
   Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551
   Hirota M, 2016, NUCLEIC ACID THER, V26, P10, DOI 10.1089/nat.2015.0567
   Hosseini F, 2017, CANCER MED-US, V6, P640, DOI 10.1002/cam4.1013
   Huang JF, 2013, PROCEDIA ENGINEER, V60, P195, DOI 10.1016/j.proeng.2013.07.042
   Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153
   Jo H, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.44
   Jones SA, 2011, J CLIN INVEST, V121, P3375, DOI 10.1172/JCI57158
   Kishimoto T, 2005, ANNU REV IMMUNOL, V23, P1, DOI 10.1146/annurev.immunol.23.021704.115806
   Klarenbeek A, 2016, PROTEIN ENG DES SEL, V29, P123, DOI 10.1093/protein/gzw003
   Kobilka BK, 2007, TRENDS PHARMACOL SCI, V28, P397, DOI 10.1016/j.tips.2007.06.003
   Kontzias A, 2012, CURR OPIN PHARMACOL, V12, P464, DOI 10.1016/j.coph.2012.06.008
   Kovacevic KD, 2018, ADV DRUG DELIVER REV, V134, P36, DOI 10.1016/j.addr.2018.10.008
   Kumari N, 2016, TUMOR BIOL, V37, P11553, DOI 10.1007/s13277-016-5098-7
   Li T, 2011, SENSOR ACTUAT B-CHEM, V158, P361, DOI 10.1016/j.snb.2011.06.035
   Lu H, 2010, CURR OPIN CHEM BIOL, V14, P467, DOI 10.1016/j.cbpa.2010.06.176
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Nasonov E, 2019, ARTHRITIS RHEUMATOL, V71
   Russo Krauss I, 2012, NUCLEIC ACIDS RES, V40, P8119, DOI 10.1093/nar/gks512
   SATO K, 1993, CANCER RES, V53, P851
   Sciascia S, 2020, CLIN EXP RHEUMATOL, V38, P529
   Shaw S, 2014, MABS-AUSTIN, V6, P773, DOI 10.4161/mabs.28612
   Somers W, 1997, EMBO J, V16, P989, DOI 10.1093/emboj/16.5.989
   Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142
   Tertis M, 2019, BIOSENS BIOELECTRON, V137, P123, DOI 10.1016/j.bios.2019.05.012
   Tertis M, 2017, ELECTROCHIM ACTA, V258, P1208, DOI 10.1016/j.electacta.2017.11.176
   Tombelli S, 2007, BIOMOL ENG, V24, P191, DOI 10.1016/j.bioeng.2007.03.003
   Toniati P, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102568
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Varghese JN, 2002, P NATL ACAD SCI USA, V99, P15959, DOI 10.1073/pnas.232432399
   White UA, 2011, CURR PHARM DESIGN, V17, P340
   Wolf J, 2014, CYTOKINE, V70, P11, DOI 10.1016/j.cyto.2014.05.024
   Yang T, 2013, SENSOR ACTUAT B-CHEM, V178, P310, DOI 10.1016/j.snb.2012.12.107
NR 60
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2079-6374
J9 BIOSENSORS-BASEL
JI Biosensors-Basel
PD SEP
PY 2020
VL 10
IS 9
AR 106
DI 10.3390/bios10090106
PG 19
WC Chemistry, Analytical
SC Chemistry
GA OB2EU
UT WOS:000578287300001
PM 32847008
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Codo, AC
   Davanzo, GG
   Monteiro, LD
   de Souza, GF
   Muraro, SP
   Virgilio-da-Silva, JV
   Prodonoff, JS
   Carregari, VC
   de Biagi, CAO
   Crunfli, F
   Restrepo, JLJ
   Vendramini, PH
   Reis-de-Oliveira, G
   dos Santos, KB
   Toledo-Teixeira, DA
   Parise, PL
   Martini, MC
   Marques, RE
   Carmo, HR
   Borin, A
   Coimbra, LD
   Boldrini, VO
   Brunetti, NS
   Vieira, AS
   Mansour, E
   Ulaf, RG
   Bernardes, AF
   Nunes, TA
   Ribeiro, LC
   Palma, AC
   Agrela, MV
   Moretti, ML
   Sposito, AC
   Pereira, FB
   Velloso, LA
   Vinolo, MAR
   Damasio, A
   Proenca-Modena, JL
   Carvalho, RF
   Mori, MA
   Martins-de-Souza, D
   Nakaya, HI
   Farias, AS
   Moraes-Vieira, PM
AF Codo, Ana Campos
   Davanzo, Gustavo Gastao
   Monteiro, Lauar de Brito
   de Souza, Gabriela Fabiano
   Muraro, Stefanie Primon
   Virgilio-da-Silva, Joao Victor
   Prodonoff, Juliana Silveira
   Carregari, Victor Corasolla
   Oliveira de Biagi Junior, Carlos Alberto
   Crunfli, Fernanda
   Jimenez Restrepo, Jeffersson Leandro
   Vendramini, Pedro Henrique
   Reis-de-Oliveira, Guilherme
   dos Santos, Karina Bispo
   Toledo-Teixeira, Daniel A.
   Parise, Pierina Lorencini
   Martini, Matheus Cavalheiro
   Marques, Rafael Elias
   Carmo, Helison R.
   Borin, Alexandre
   Coimbra, Lais Durco
   Boldrini, Vinicius O.
   Brunetti, Natalia S.
   Vieira, Andre S.
   Mansour, Eli
   Ulaf, Raisa G.
   Bernardes, Ana F.
   Nunes, Thyago A.
   Ribeiro, Luciana C.
   Palma, Andre C.
   Agrela, Marcus, V
   Moretti, Maria Luiza
   Sposito, Andrei C.
   Pereira, Fabricio Biscaro
   Velloso, Licio Augusto
   Ramirez Vinolo, Marco Aurelio
   Damasio, Andre
   Proenca-Modena, Jose Luiz
   Carvalho, Robson Francisco
   Mori, Marcelo A.
   Martins-de-Souza, Daniel
   Nakaya, Helder, I
   Farias, Alessandro S.
   Moraes-Vieira, Pedro M.
TI Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response
   through a HIF-1 alpha/Glycolysis-Dependent Axis
SO CELL METABOLISM
LA English
DT Article
ID SUCCINATE
AB COVID-19 can result in severe lung injury. It remained to be determined why diabetic individuals with uncontrolled glucose levels are more prone to develop the severe form of COVID-19. The molecular mechanism underlying SARS-CoV-2 infection and what determines the onset of the cytokine storm found in severe COVID-19 patients are unknown. Monocytes and macrophages are the most enriched immune cell types in the lungs of COVID-19 patients and appear to have a central role in the pathogenicity of the disease. These cells adapt their metabolism upon infection and become highly glycolytic, which facilitates SARS-CoV-2 replication. The infection triggers mitochondrial ROS production, which induces stabilization of hypoxia-inducible factor-1 alpha (HIF-1 alpha) and consequently promotes glycolysis. HIF-1 alpha-induced changes in monocyte metabolism by SARSCoV-2 infection directly inhibit T cell response and reduce epithelial cell survival. Targeting HIF-1 alpha may have great therapeutic potential for the development of novel drugs to treat COVID-19.
C1 [Codo, Ana Campos; Davanzo, Gustavo Gastao; Monteiro, Lauar de Brito; Virgilio-da-Silva, Joao Victor; Prodonoff, Juliana Silveira; Moraes-Vieira, Pedro M.] Univ Estadual Campinas, Lab Immunometab, Dept Genet Evolut Microbiol & Immunol, Inst Biol, Campinas, SP, Brazil.
   [de Souza, Gabriela Fabiano; Muraro, Stefanie Primon; dos Santos, Karina Bispo; Toledo-Teixeira, Daniel A.; Parise, Pierina Lorencini; Martini, Matheus Cavalheiro; Boldrini, Vinicius O.; Brunetti, Natalia S.; Ramirez Vinolo, Marco Aurelio; Proenca-Modena, Jose Luiz; Farias, Alessandro S.] Univ Estadual Campinas, Inst Biol, Dept Genet Evolut Microbiol & Immunol, Campinas, SP, Brazil.
   [Carregari, Victor Corasolla; Crunfli, Fernanda; Vendramini, Pedro Henrique; Reis-de-Oliveira, Guilherme; Damasio, Andre; Mori, Marcelo A.; Martins-de-Souza, Daniel] Univ Estadual Campinas, Inst Biol, Dept Biochem & Tissue Biol, Campinas, SP, Brazil.
   [Oliveira de Biagi Junior, Carlos Alberto] Univ Sao Paulo, Dept Genet, Ribeirao Preto Med Sch, Ribeirao Preto, SP, Brazil.
   [Jimenez Restrepo, Jeffersson Leandro; Nakaya, Helder, I] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo, Brazil.
   [Marques, Rafael Elias; Borin, Alexandre; Coimbra, Lais Durco] Brazilian Biosci Natl Lab LNBio, Campinas, SP, Brazil.
   [Vieira, Andre S.] Univ Estadual Campinas, Inst Biol, Dept Anim Biol, Campinas, SP, Brazil.
   [Mansour, Eli; Ulaf, Raisa G.; Bernardes, Ana F.; Nunes, Thyago A.; Ribeiro, Luciana C.; Palma, Andre C.; Agrela, Marcus, V; Moretti, Maria Luiza; Velloso, Licio Augusto] Univ Estadual Campinas, Sch Med Sci, Dept Internal Med, Campinas, SP, Brazil.
   [Carmo, Helison R.; Sposito, Andrei C.] Univ Estadual Campinas, Sch Med Sci, Dept Clin Med, Campinas, SP, Brazil.
   [Pereira, Fabricio Biscaro] Univ Estadual Campinas, Hematol & Hemotherapy Ctr, Campinas, SP, Brazil.
   [Velloso, Licio Augusto; Mori, Marcelo A.; Moraes-Vieira, Pedro M.] Univ Estadual Campinas, Obes & Comorbid Res Ctr OCRC, Sao Paulo, Brazil.
   [Ramirez Vinolo, Marco Aurelio; Damasio, Andre; Mori, Marcelo A.; Martins-de-Souza, Daniel; Farias, Alessandro S.; Moraes-Vieira, Pedro M.] Univ Estadual Campinas, Expt Med Res Cluster EMRC, Sao Paulo, Brazil.
   [Carvalho, Robson Francisco] Sao Paulo State Univ UNESP, Inst Biosci, Dept Struct & Funct Biol, Botucatu, SP, Brazil.
   [Martins-de-Souza, Daniel] DOr Inst Res & Educ IDOR, Sao Paulo, Brazil.
   [Martins-de-Souza, Daniel] Conselho Nacl Desenvolvimento Cient & Tecnol, Inst Nacl Biomarcadores Neuropsiquiatria, Sao Paulo, Brazil.
RP Moraes-Vieira, PM (corresponding author), Univ Estadual Campinas, Lab Immunometab, Dept Genet Evolut Microbiol & Immunol, Inst Biol, Campinas, SP, Brazil.; Moraes-Vieira, PM (corresponding author), Univ Estadual Campinas, Obes & Comorbid Res Ctr OCRC, Sao Paulo, Brazil.; Moraes-Vieira, PM (corresponding author), Univ Estadual Campinas, Expt Med Res Cluster EMRC, Sao Paulo, Brazil.
EM pmvieira@unicamp.br
RI Moraes-Vieira, Pedro M/C-8701-2014; Carregari, Victor
   Corasolla/ABB-6071-2020; Proenca-Modena, Jose Luiz/AAU-7622-2020;
   Toledo-Teixeira, Daniel A./C-6940-2017; da Silva, Joao Victor
   Virgilio/ABG-7665-2020; Sposito, Andrei C/G-4116-2013; Mansour,
   Eli/AAD-2841-2019; de Biagi, Carlos Alberto Oliveira/W-7117-2018
OI Moraes-Vieira, Pedro M/0000-0002-8263-786X; Carregari, Victor
   Corasolla/0000-0001-6863-1333; Proenca-Modena, Jose
   Luiz/0000-0002-4996-3153; da Silva, Joao Victor
   Virgilio/0000-0002-7846-7386; Sposito, Andrei C/0000-0001-7127-2052;
   Mansour, Eli/0000-0001-6450-6930; de Biagi, Carlos Alberto
   Oliveira/0000-0003-0700-3135; Monteiro, Lauar/0000-0003-1258-6857;
   Campos Codo, Ana/0000-0001-9036-5772
FU Sao Paulo Research Foundation -FAPESPFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2015/15626-8, 2016/23328-0, 2016/18031-8,
   2018/22505-0, 20/04579-7, 2020/04746-0, 2019/06372-3, 2020/04558-0,
   2020/04919-2, 2020/04583-4, 2017/01184-9, 2020/04522-5, 2019/00098-7];
   Fundo de Apoio ao Ensino, Pesquisa e Extensao (FAEPEX), Unicamp
   [2274/20]; Brazilian National Council for Scientific and Technological
   Development - CNPqNational Council for Scientific and Technological
   Development (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior - Brazil (CAPES)CAPES [001]
FX We thank the Hematology and Hemotherapy Center of Unicamp (Campinas, Sao
   Paulo, Brazil) and Nelson Cabral Junior and Regina Amelia Moraes for
   providing the buffy coats used for peripheral blood mononuclear cell
   isolation in this study. We thank Edson Durigon for providing the
   SARS-CoV-2 and Eurico Arruda for providing RSV and IAV. We thank Elzira
   E. Saviani for technical support. We would like to thank Aline Mika
   Matsuguma for designing our schematic figures. We gratefully acknowledge
   Dr. Catherine A. Reardon from the Committee on Molecular Metabolism and
   Nutrition, University of Chicago and from Ben May Department for Cancer
   Research, University of Chicago, Chicago, IL, USA, for revising the
   manuscript. We thank the Sao Paulo Research Foundation -FAPESP (grant
   numbers 2015/15626-8, 2016/23328-0, 2016/18031-8, 2018/22505-0,
   20/04579-7, 2020/04746-0, 2019/06372-3, 2020/04558-0, 2020/04919-2,
   2020/04583-4, 2017/01184-9, 2020/04522-5, and 2019/00098-7); Fundo de
   Apoio ao Ensino, Pesquisa e Extensao (FAEPEX), Unicamp (grant number
   2274/20); the Brazilian National Council for Scientific and
   Technological Development - CNPq; and the Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior - Brazil (CAPES) (Finance Code 001) for
   funding this project.
CR Aguer C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028536
   Baardman J, 2018, CELL REP, V25, P2044, DOI 10.1016/j.celrep.2018.10.092
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bojkova D, 2020, NATURE, V583, P469, DOI 10.1038/s41586-020-2332-7
   Bost P, 2020, CELL, V181, P1475, DOI 10.1016/j.cell.2020.05.006
   Buck MD, 2016, CELL, V166, P63, DOI 10.1016/j.cell.2016.05.035
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128
   Chouchani ET, 2014, NATURE, V515, P431, DOI 10.1038/nature13909
   de Marcken M., 2019, SCI SIGNAL
   Breda CND, 2019, REDOX BIOL, V26, DOI 10.1016/j.redox.2019.101255
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Distler U, 2016, NAT PROTOC, V11, P795, DOI 10.1038/nprot.2016.042
   Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319
   Hammer J, 1997, PEDIATR PULM, V23, P176, DOI 10.1002/(SICI)1099-0496(199703)23:3<176::AID-PPUL2>3.0.CO;2-M
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   Medeiros AI, 2002, SCAND J IMMUNOL, V56, P392, DOI 10.1046/j.1365-3083.2002.01142.x
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Mills EL, 2016, CELL, V167, P457, DOI 10.1016/j.cell.2016.08.064
   Neumann G, 1999, P NATL ACAD SCI USA, V96, P9345, DOI 10.1073/pnas.96.16.9345
   Otasek D, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1758-4
   Ribeiro SA, 2010, J BRAS PNEUMOL, V36, P386, DOI 10.1590/S1806-37132010000300017
   Rodriguez AE, 2019, CELL METAB, V29, P1003, DOI 10.1016/j.cmet.2019.01.014
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Simko TWaV, 2017, R PACKAGE CORRPLOT V
   Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x
   Wang YH, 2020, RADIOLOGY, V296, pE55, DOI 10.1148/radiol.2020200843
   Won J, 2020, EXP NEUROBIOL, V29, P107, DOI [10.5607/en20009, 10.5607/en2009]
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou GY, 2019, NUCLEIC ACIDS RES, V47, pW234, DOI 10.1093/nar/gkz240
   Zhu LH, 2020, CELL METAB, V31, P1068, DOI 10.1016/j.cmet.2020.04.021
NR 37
TC 14
Z9 14
U1 1
U2 1
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD SEP 1
PY 2020
VL 32
IS 3
BP 437
EP +
DI 10.1016/j.cmet.2020.07.007
PG 15
WC Cell Biology; Endocrinology & Metabolism
SC Cell Biology; Endocrinology & Metabolism
GA OA6GM
UT WOS:000577881100004
PM 32697943
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Leist, SR
   Schafer, A
   Martinez, DR
AF Leist, Sarah R.
   Schafer, Alexandra
   Martinez, David R.
TI Cell and animal models of SARS-CoV-2 pathogenesis and immunity
SO DISEASE MODELS & MECHANISMS
LA English
DT Article
DE SARS-CoV; SARS-CoV-2; MERS-CoV; Cell models; Animal models
ID CORONAVIRUS; INFECTION; PNEUMONIA; COVID-19; SARS; MERS
AB The spread of the novel virus SARS coronavirus 2 (SARS-CoV-2) was explosive, with cases first identified in December 2019, and >22 million people infected and >775,000 deaths as of August 2020. SARS-CoV-2 can cause severe respiratory disease in humans leading to coronavirus disease 2019 (COVID-19). The development of effective clinical interventions, such as antivirals and vaccines that can limit or even prevent the burden and spread of SARS-CoV-2, is a global health priority. Testing of leading antivirals, monoclonal antibody therapies and vaccines against SARS-CoV-2 will require robust animal and cell models of viral pathogenesis. In this Special Article, we discuss the cell-based and animal models of SARS-CoV-2 infection and pathogenesis that have been described as of August 2020. We also outline the outstanding questions for which researchers can leverage animal and cell-based models to improve our understanding of SARS-CoV-2 pathogenesis and protective immunity. Taken together, the refinement of models of SARS-CoV-2 infection will be critical to guide the development of therapeutics and vaccines against SARS-CoV-2 to end the COVID-19 pandemic.
C1 [Leist, Sarah R.; Schafer, Alexandra; Martinez, David R.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
RP Martinez, DR (corresponding author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
EM david.rafael.martinez@gmail.com
OI Martinez, David/0000-0002-2940-8961
FU National Institutes of Health (NIH)/National Institute of Allergy and
   Infectious DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [T32 AI007151]; NIHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [F32 AI152296]; Burroughs Wellcome Fund Postdoctoral
   Enrichment Program AwardBurroughs Wellcome Fund
FX D.R.M. is funded by National Institutes of Health (NIH)/National
   Institute of Allergy and Infectious Diseases T32 AI007151, NIH F32
   AI152296 and a Burroughs Wellcome Fund Postdoctoral Enrichment Program
   Award. The conclusions and opinions expressed in this article are those
   of the authors and do not necessarily reflect those of the NIH or US
   Department of Health and Human Services.
CR Bao LN, 2020, NATURE, V583, P830, DOI 10.1038/s41586-020-2312-y
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Bolles M, 2011, J VIROL, V85, P12201, DOI 10.1128/JVI.06048-11
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Bradley BT, 2020, LANCET, V396, P320, DOI 10.1016/S0140-6736(20)31305-2
   Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014
   Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chua RL, 2020, NAT BIOTECHNOL, V38, P970, DOI 10.1038/s41587-020-0602-4
   Cockrell AS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28900-1
   Cockrell AS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2016.226
   Corbett Kizzmekia S, 2020, Nature, V586, P567, DOI 10.1038/s41586-020-2622-0
   Corbett KS, 2020, NEW ENGL J MED, V383, P1544, DOI 10.1056/NEJMoa2024671
   Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343
   Dinnon KH, 2020, NATURE, DOI 10.1038/s41586-020-2708-8
   Finch Courtney L, 2020, bioRxiv, DOI 10.1101/2020.05.14.096727
   Hassan AO, 2020, CELL, V182, P744, DOI 10.1016/j.cell.2020.06.011
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hou YXJ, 2020, CELL, V182, P429, DOI 10.1016/j.cell.2020.05.042
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Imai M, 2020, P NATL ACAD SCI USA, V117, P16587, DOI [10.1073/pnas.2009799117/-/DCSupplemental., 10.1073/pnas.2009799117]
   Israelow Benjamin, 2020, J Exp Med, V217, DOI 10.1084/jem.20201241
   Jiang RD, 2020, CELL, V182, P50, DOI 10.1016/j.cell.2020.05.027
   Kim YI, 2020, CELL HOST MICROBE, V27, P704, DOI 10.1016/j.chom.2020.03.023
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0
   Lamers MM, 2020, SCIENCE, V369, P50, DOI 10.1126/science.abc1669
   Lawler JV, 2006, PLOS MED, V3, P677, DOI 10.1371/journal.pmed.0030149
   Leist SR, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2483-y
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu SY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00269-6
   Lucas C, 2020, NATURE, DOI 10.1038/s41586-020-2588-y
   Maisonnasse P, 2020, NATURE, V585, P584, DOI 10.1038/s41586-020-2558-4
   Mercado NB, 2020, NATURE, DOI 10.1038/s41586-020-2607-z
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Mossel EC, 2008, VIROLOGY, V372, P127, DOI 10.1016/j.virol.2007.09.045
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Richard M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17367-2
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520
   Rosenke Kyle, 2020, bioRxiv, DOI 10.1101/2020.06.10.145144
   Salahudeen Ameen A, 2020, bioRxiv, DOI 10.1101/2020.07.27.212076
   Scobey T, 2013, P NATL ACAD SCI USA, V110, P16157, DOI 10.1073/pnas.1311542110
   Shi JZ, 2020, SCIENCE, V368, P1016, DOI 10.1126/science.abb7015
   Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5
   Sims AC, 2005, J VIROL, V79, P15511, DOI 10.1128/JVI.79.24.15511-15524.2005
   van Doremalen N, 2020, NATURE, V586, P578, DOI 10.1038/s41586-020-2608-y
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WILLIAMSON BN, 2020, NATURE 0609, DOI DOI 10.1038/S41586-020-2423-5
   Woolsey C. B., 2020, ESTABLISHMENT AFRICA
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yao YF, 2014, J INFECT DIS, V209, P236, DOI 10.1093/infdis/jit590
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zang RC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc3582
   Zhao XS, 2020, J VIROL, V94, DOI 10.1128/JVI.00940-20
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17796-z
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Ziegler CGK, 2020, CELL, V181, P1016, DOI 10.1016/j.cell.2020.04.035
   Zost SJ, 2020, NATURE, DOI 10.1038/s41586-020-2548-6
NR 66
TC 1
Z9 1
U1 1
U2 1
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 1754-8403
EI 1754-8411
J9 DIS MODEL MECH
JI Dis. Model. Mech.
PD SEP
PY 2020
VL 13
IS 9
AR dmm046581
DI 10.1242/dmm.046581
PG 6
WC Cell Biology; Pathology
SC Cell Biology; Pathology
GA NZ0KI
UT WOS:000576780200007
PM 32887790
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Chang, D
   Zhao, P
   Zhang, DW
   Dong, JH
   Xu, Z
   Yang, G
   Li, BY
   Liu, HX
   Li, BA
   Qin, CF
   Peng, XH
   Wang, FS
   Xie, LX
   Chen, Z
   Dela Cruz, CS
   Sharma, L
   Qin, EQ
AF Chang, De
   Zhao, Peng
   Zhang, Dawei
   Dong, Jing-Hui
   Xu, Zhe
   Yang, Guang
   Li, Bo-Yu
   Liu, Hong-Xia
   Li, Bo-An
   Qin, Cheng-Feng
   Peng, Xiao-Hua
   Wang, Fu-Sheng
   Xie, Li-Xin
   Chen, Zhu
   Dela Cruz, Charles S.
   Sharma, Lokesh
   Qin, En-Qiang
TI Persistent Viral Presence Determines the Clinical Course of the Disease
   in COVID-19
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Article
DE COVID-19; Viral persistence; Disease severity; Viral clearance; Host
   recovery
ID CORONAVIRUS PNEUMONIA; D-DIMER; OUTBREAK
AB BACKGROUND: The clinical management of coronavirus disease 2019 (COVID-19) is dependent on understanding the underlying factors that contribute to the disease severity. In the absence of effective antiviral therapies, other host immunomodulatory therapies such as targeting inflammatory response are currently being used without clear evidence of their effectiveness. Because inflammation is an essential component of host antiviral mechanisms, therapies targeting inflammation may adversely affect viral clearance and disease outcome.
   OBJECTIVE: To understand whether the persistent presence of the virus is a key determinant in the disease severity during COVID-19 and to determine whether the viral reactivation in some patients is associated with infectious viral particles.
   METHODS: The data for patients were available including the onset of the disease, duration of viral persistence, measurements of inflammatory markers such as IL-6 and C-reactive protein, chest imaging, disease symptoms, and their durations among others. Follow-up tests were performed to determine whether the viral negative status persists after their recovery.
   RESULTS: Our data show that patients with persistent viral presence (>16 days) have more severe disease outcomes including extensive lung involvement and requirement of respiratory support. Two patients who died of COVID-19 were virus-positive at the time of their death. Four patients demonstrated virus-positive status on the follow-up tests, and these patient samples were sent to viral culture facility where virus culture could not be established.
   CONCLUSIONS: These data suggest that viral persistence is the key determining factor of the disease severity. Therapies that may impair the viral clearance may impair the host recovery from COVID-19. (C) 2020 American Academy of Allergy, Asthma & Immunology.
C1 [Chang, De; Xie, Li-Xin] Chinese Peoples Liberat Army Gen Hosp, Coll Pulm & Crit Care Med, Beijing, Peoples R China.
   [Zhao, Peng; Zhang, Dawei; Dong, Jing-Hui; Xu, Zhe; Yang, Guang; Li, Bo-Yu; Liu, Hong-Xia; Li, Bo-An; Wang, Fu-Sheng; Chen, Zhu; Qin, En-Qiang] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing 100039, Peoples R China.
   [Qin, Cheng-Feng] Acad Mil Med Sci AMMS, Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China.
   [Peng, Xiao-Hua; Dela Cruz, Charles S.; Sharma, Lokesh] Yale Univ, Sch Med, Dept Med, Sect Pulm & Crit Care & Sleep Med, New Haven, CT 06510 USA.
RP Chen, Z; Qin, EQ (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing 100039, Peoples R China.
EM chenzhuren264@126.com; qeq2004@sina.com
RI Qin, Cheng-Feng/I-6839-2019
OI Qin, Cheng-Feng/0000-0002-0632-2807; Sharma, Lokesh/0000-0003-3040-9029
FU Beijing Nova Program Interdisciplinary Cooperation Project
   [Z191100001119021]; China 13th Five-year National Key Grant
   [2018ZX09201013]; China Scholarship CouncilChina Scholarship Council
   [201809112037]; Beijing Nova ProgramBeijing Municipal Science &
   Technology Commission [Z171100001117012]
FX This study was supported by funding from Beijing Nova Program
   Interdisciplinary Cooperation Project (grant no. Z191100001119021 to
   D.C.), China 13th Five-year National Key Grant (grant no. 2018ZX09201013
   to L.X.X.), China Scholarship Council (grant no. 201809112037), and
   Beijing Nova Program (grant no. Z171100001117012 to D.C.).
CR Aspinall Richard, 2007, Immun Ageing, V4, P9, DOI 10.1186/1742-4933-4-9
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chang D, 2020, AM J RESP CRIT CARE, V201, P1150, DOI 10.1164/rccm.202003-0524LE
   Chang D, 2020, JAMA-J AM MED ASSOC, V323, P1092, DOI 10.1001/jama.2020.1623
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   China National Health Commission, CHIN CLIN GUID COVID
   Dienz O, 2012, MUCOSAL IMMUNOL, V5, P258, DOI 10.1038/mi.2012.2
   Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   Kyrle PA, 2018, CIRCULATION, V138, P724, DOI 10.1161/CIRCULATIONAHA.118.033670
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Stein PD, 2004, ANN INTERN MED, V140, P589, DOI 10.7326/0003-4819-140-8-200404200-00005
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang X, 2020, CLIN EXP HYPERTENS, V42, P531, DOI 10.1080/10641963.2020.1723615
   World Health Organization, COR DIS 2019 COVID 1
   Ye GM, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.001
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhao JY, 2020, CHINESE MED J-PEKING, V133, P1347, DOI 10.1097/CM9.0000000000000866
NR 25
TC 4
Z9 4
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD SEP
PY 2020
VL 8
IS 8
BP 2585
EP +
DI 10.1016/j.jaip.2020.06.015
PG 8
WC Allergy; Immunology
SC Allergy; Immunology
GA OA6KH
UT WOS:000577891000019
PM 32574840
OA Green Published
DA 2021-01-01
ER

PT J
AU Dominguez-Ortega, J
   Lopez-Carrasco, V
   Barranco, P
   Ifim, M
   Luna, JA
   Romero, D
   Quirce, S
AF Dominguez-Ortega, Javier
   Lopez-Carrasco, Valentin
   Barranco, Pilar
   Ifim, Mihaela
   Luna, Juan Alberto
   Romero, David
   Quirce, Santiago
TI Early experiences of SARS-CoV-2 infection in severe asthmatics receiving
   biologic therapy
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
LA English
DT Letter
C1 [Dominguez-Ortega, Javier; Lopez-Carrasco, Valentin; Barranco, Pilar; Ifim, Mihaela; Luna, Juan Alberto; Quirce, Santiago] La Paz Univ Hosp, Dept Allergy, IdiPAZ, Paseo Castellana 261, Madrid 28046, Spain.
   [Dominguez-Ortega, Javier; Barranco, Pilar; Luna, Juan Alberto; Romero, David; Quirce, Santiago] CIBERES, CIBER Resp Dis, Madrid, Spain.
   [Romero, David] La Paz Univ Hosp, Dept Pulmonol, IdiPAZ, Madrid, Spain.
RP Dominguez-Ortega, J (corresponding author), La Paz Univ Hosp, Dept Allergy, IdiPAZ, Paseo Castellana 261, Madrid 28046, Spain.
EM javier.dominguez@idipaz.es
CR [Anonymous], GLOB STRAT ASTHM MAN
   Borobia AM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061733
   Brake SJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030841
   Chung KF, INT ERS ATS GUIDELIN
   Long CQ, 2020, EUR J RADIOL, V126, DOI 10.1016/j.ejrad.2020.108961
   Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, 2020, CHINA CDC WEEKLY, V2, P113, DOI DOI 10.46234/CCDCW2020.032
   Spanish Health Ministry, MAP PROV ANT IGG ANT
   Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
NR 9
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2198
EI 2213-2201
J9 J ALLER CL IMM-PRACT
JI J. Allergy Clin. Immunol.-Pract.
PD SEP
PY 2020
VL 8
IS 8
BP 2784
EP 2786
DI 10.1016/j.jaip.2020.06.027
PG 3
WC Allergy; Immunology
SC Allergy; Immunology
GA OA6KH
UT WOS:000577891000048
PM 32592790
OA Green Published
DA 2021-01-01
ER

PT J
AU Li, MT
   Wang, Y
   Xu, H
   Liu, CL
   Shi, L
   Ye, Q
   Wang, J
   Li, SC
   Mei, Y
   Gao, LL
AF Li, Mengting
   Wang, Yang
   Xu, Hua
   Liu, Changlin
   Shi, Liang
   Ye, Qi
   Wang, Jun
   Li, Sichan
   Mei, Yan
   Gao, Liuliu
TI Existing drug treatments cannot significantly shorten the clinical cure
   time of children with COVID-19
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE Coronavirus disease 2019; pediatric patients; different treatment
   agents; cure rate
AB Introduction: COVID-19 has become a global health security issue, it has caused more than half a million deaths worldwide so far, the treatment strategies are the most concerned issues for clinicians. In this study, the treatments and outcomes in 40 pediatric patients diagnosed with COVID-19 and treated with different drugs were evaluated.
   Methodology: All cases were diagnosed with COVID-19 nucleic acid positive by using RT-PCR or clinical manifestations, imaging specific characteristics and epidemiological clinical diagnosis. The biological information and first symptom of all cases were collect. A variety of treatments were employed and the outcomes were evaluated by Cox regression analysis. Multivariable analysis was performed to evaluate cure rate at 14 days with different drug treatment.
   Results: The average length of hospital stay was 10.4 days. The cure rate was increased with the treatment time extended and 90% of pediatric patients were cured and discharged after 14 days' treatment. And multivariable analysis results proved that none of the covariates were related to the cure rate at 14 days with different drug treatment since p values were over 0.05.
   Conclusions: Multivariable analysis suggested that the present drug treatments cannot significantly shorten the clinical cure time and improve the cure rate of children with COVID-19.
C1 [Li, Mengting; Wang, Yang; Xu, Hua; Liu, Changlin; Ye, Qi; Wang, Jun; Li, Sichan; Mei, Yan; Gao, Liuliu] Huazhong Univ Sci & Technol, Wuhan Childrens Hosp, Wuhan Meternal & Child Healthcare Hosp, Dept Clin Pharm,Tongji Med Coll, Wuhan, Peoples R China.
RP Gao, LL (corresponding author), Wuhan Childrens Hosp, Dept Clin Pharm, Hong Kong Rd 100, Wuhan 430016, Peoples R China.
EM 2577588761@qq.com
FU China National Natural Science Foundation Youth Funding Project
   [81600123]
FX The work was supported by China National Natural Science Foundation
   Youth Funding Project (Grant Agreement number: 81600123).
CR Arabi YM, 2019, CLIN INFECT DIS, V70, P1837, DOI DOI 10.1093/cid/ciz544
   [陈军 Chen Jun], 2020, [中华传染病杂志, Chinese Journal of Infections Diseases], V38, P86
   Contini C, 2020, J INFECT DEV COUNTR, V14, P254, DOI 10.3855/jidc.12671
   Fang F, 2020, Zhonghua Er Ke Za Zhi, V58, P81, DOI 10.3760/cma.j.issn.0578-1310.2020.02.001
   Kevin RM, 2006, J ALLERGY CLIN IMMUN, V8, P1815
   Li H, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE002, DOI 10.3760/cma.j.issn.1001-0939.2020.0002
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Shen KL, 2020, WORLD J PEDIATR, V16, P223, DOI 10.1007/s12519-020-00343-7
   Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343
   Strayer David R., 2014, Infectious Disorders - Drug Targets, V14, P37
   [朱月玲 Zhu Yueling], 2020, [中草药, Chinese Traditional and Herbal Drugs], V51, P883
NR 12
TC 0
Z9 0
U1 0
U2 0
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD SEP
PY 2020
VL 14
IS 9
BP 963
EP 967
DI 10.3855/jidc.13491
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA OC1CA
UT WOS:000578899400005
PM 33031081
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Calderon, JM
   Flores, MDF
   Coria, LP
   Garduno, JCB
   Figueroa, JM
   Contreras, MJV
   Avila, LD
   Meza, SD
   Chacon, RR
   Padmanabhan, S
   Zeron, HM
AF Calderon, Jose Meneses
   Flores, Ma. del Rocio Figueroa
   Coria, Leopoldo Paniagua
   Garduno, Jesus Carlos Briones
   Figueroa, Jazmin Meneses
   Contreras, Maria Jose Vargas
   Avila, Lilia de la Cruz
   Meza, Salvador Diaz
   Chacon, Reynaldo Ramirez
   Padmanabhan, Srivatsan
   Zeron, Hugo Mendieta
TI Nitazoxanide against COVID-19 in three explorative scenarios
SO JOURNAL OF INFECTION IN DEVELOPING COUNTRIES
LA English
DT Article
DE Ambulatory treatment; internal medicine; nitazoxanide; pregnancy;
   SARS-CoV-2
ID INFECTIONS
AB Introduction: Nitazoxanide has shown efficacy in vitro against coronavirus infections (MERS, SARS, SARS-CoV-2). The aim of this report is to describe the results of treating COVID-19 positive patients with nitazoxanide in three clinical settings: pregnancy/puerperium, hospitalized patients in an Internal Medicine Service and in an ambulatory setting.
   Methodology: This was a prospective follow-up and report of COVID-19 cases in three different situations, pregnant women, hospitalized patients receiving medical attention in an Internal Medicine Service and ambulatory patients residing in Toluca City, and Mexico City.
   Results: The experience with a first group of 20 women, pregnant (17) or in immediate puerperium (3) was successful in 18 cases with two unfortunate deaths. The five cases treated in an Internal Medicine service showed a positive outcome with two patients weaned from mechanical ventilation. Of the remaining 16 patients treated in an ambulatory setting, all got cured. Nitazoxanide seems to be useful against SARS-CoV-2, not only in an early intervention but also in critical condition as well as in pregnancy without undesired effects for the babies. As an adjunctive therapy budesonide was used that seems to contribute to the clinical improvement.
   Conclusions: Nitazoxanide could be useful against COVID-19 as a safe and available regimen to be tested in a massive way immediately.
C1 [Calderon, Jose Meneses; Coria, Leopoldo Paniagua; Garduno, Jesus Carlos Briones; Avila, Lilia de la Cruz; Zeron, Hugo Mendieta] Monica Pretelini Saenz Maternal Perinatal Hosp HM, Toluca, Mexico.
   [Calderon, Jose Meneses; Figueroa, Jazmin Meneses; Contreras, Maria Jose Vargas; Zeron, Hugo Mendieta] Autonomous Univ State Mexico UAEMex, Fac Med, Toluca, Mexico.
   [Meza, Salvador Diaz] Dr Nicolas San Juan Gen Hosp, Toluca, Mexico.
   [Chacon, Reynaldo Ramirez] Inst Seguridad Social Serv Trabajadores Estado IS, Mexico City, Tabasco, Mexico.
   [Padmanabhan, Srivatsan] St Joseph Med Ctr, Tacoma, WA USA.
   [Zeron, Hugo Mendieta] Cipres Grp Med CGM, Toluca, Mexico.
RP Zeron, HM (corresponding author), Monica Pretelini Saenz Maternal Perinatal Hosp, Res Dept, Paseo Tollocan S-N, Toluca 50010, Mexico.
EM drmendietaz@yahoo.com
CR Acter T, 2020, SCI TOTAL ENVIRON, V730, DOI 10.1016/j.scitotenv.2020.138996
   Arshad U, 2020, CLIN PHARMACOL THER, V108, P775, DOI 10.1002/cpt.1909
   Barlow A, 2020, PHARMACOTHERAPY, V40, P416, DOI 10.1002/phar.2398
   Bhimraj A, 2020, CLIN INFECT DIS
   Cabello RR, 1997, T ROY SOC TROP MED H, V91, P701, DOI 10.1016/S0035-9203(97)90531-9
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cao JZ, 2015, ANTIVIR RES, V114, P1, DOI 10.1016/j.antiviral.2014.11.010
   Chan PS, 2020, CIRC-CARDIOVASC QUAL, V13
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Gilles HM, 2002, TRENDS PARASITOL, V18, P95, DOI 10.1016/S1471-4922(01)02205-X
   Haffizulla J, 2014, LANCET INFECT DIS, V14, P609, DOI 10.1016/S1473-3099(14)70717-0
   Hemphill A, 2006, EXPERT OPIN PHARMACO, V7, P953, DOI 10.1517/14656566.7.7.953
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kelleni MT, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104874
   Mahmoud Dina B., 2020, Journal of Genetic Engineering and Biotechnology, V18, P35, DOI 10.1186/s43141-020-00055-5
   National Center for Biotechnology Information, 2020, PUBCHEM COMP SUMM CI
   Parazzini F, 2020, INT J GYNECOL OBSTET, V150, P41, DOI 10.1002/ijgo.13166
   Rajoli RK, 2020, DOSE PREDICTION REPU
   Rossignol JF, 2014, ANTIVIR RES, V110, P94, DOI 10.1016/j.antiviral.2014.07.014
   Rossingol JF, 2016, J INFECT PUBLIC HEAL, V9, P227, DOI 10.1016/j.jiph.2016.04.001
   Serafin MB, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105969
   Wei JP, 2020, KOREAN J RADIOL, V21, P501, DOI 10.3348/kjr.2020.0112
   Zareifopoulos N, 2020, MONALDI ARCH CHEST D, V90, P191
   Zhang RR, 2018, ARTIF CELL NANOMED B, V46, pS1123, DOI 10.1080/21691401.2018.1446442
NR 24
TC 0
Z9 0
U1 1
U2 1
PU J INFECTION DEVELOPING COUNTRIES
PI TRAMANIGLIO
PA JIDC CENT OFF PORTO CONTE RICERCHE RES CTR, S P 55, PORTO CONTE CAPO
   CACCIA KM 8.400 LOC, TRAMANIGLIO, 07041, ITALY
SN 1972-2680
J9 J INFECT DEV COUNTR
JI J. Infect. Dev. Ctries.
PD SEP
PY 2020
VL 14
IS 9
BP 982
EP 986
DI 10.3855/jidc.13274
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA OC1CA
UT WOS:000578899400009
PM 33031085
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Clementi, N
   Ferrarese, R
   Criscuolo, E
   Diotti, RA
   Castelli, M
   Scagnolari, C
   Burioni, R
   Antonelli, G
   Clementi, M
   Mancini, N
AF Clementi, Nicola
   Ferrarese, Roberto
   Criscuolo, Elena
   Diotti, Roberta Antonia
   Castelli, Matteo
   Scagnolari, Carolina
   Burioni, Roberto
   Antonelli, Guido
   Clementi, Massimo
   Mancini, Nicasio
TI Interferon-beta-1a Inhibition of Severe Acute Respiratory
   Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE SARS-CoV-2; IFN-beta-1a; COVID-19 clinical trial
ID SARS
AB The ongoing coronavirus disease 2019 pandemic has forced the clinical and scientific community to try drug repurposing of existing antiviral agents as a quick option against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). Under this scenario, interferon (IFN) beta-1a, whose antiviral potential is already known, and which is a drug currently used in the clinical management of multiple sclerosis, may represent as a potential candidate. In this report, we demonstrate that IFN-beta-1a was highly effective in inhibiting in vitro SARS-CoV-2 replication at clinically achievable concentration when administered after virus infection.
C1 [Clementi, Nicola; Ferrarese, Roberto; Criscuolo, Elena; Diotti, Roberta Antonia; Castelli, Matteo; Burioni, Roberto; Clementi, Massimo; Mancini, Nicasio] Univ Vita Salute San Raffaele, Lab Microbiol & Virol, Milan, Italy.
   [Scagnolari, Carolina; Antonelli, Guido] Sapienza Univ, Lab Virol, Dept Mol Med, Rome, Italy.
   [Scagnolari, Carolina; Antonelli, Guido] Sapienza Univ, Inst Pasteur, Italia Cenci Bolognetti Fdn, Rome, Italy.
   [Clementi, Nicola; Clementi, Massimo; Mancini, Nicasio] IRCCS Osped San Raffaele, Lab Microbiol & Virol, Milan, Italy.
RP Clementi, N (corresponding author), Univ Vita Salute San Raffaele, Via Olgettina 58, I-20132 Milan, Italy.
EM clementi.nicola@hsr.it
RI Clementi, Nicola/AAT-7697-2020; Clementi, Massimo/F-6646-2013
OI Clementi, Nicola/0000-0002-1822-9861; Criscuolo,
   Elena/0000-0003-0185-3147
CR Cinatl J, 2003, LANCET, V362, P293, DOI 10.1016/S0140-6736(03)13973-6
   Franco Evelyn J., 2018, Antiviral Chemistry & Chemotherapy, V26, p2040206618807580, DOI 10.1177/2040206618807580
   GUTTERMAN JU, 1982, ANN INTERN MED, V96, P549, DOI 10.7326/0003-4819-96-5-549
   Hensley LE, 2004, EMERG INFECT DIS, V10, P317, DOI 10.3201/eid1002.030482
   Khan RJ, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1753577
   Limmroth Volker, 2011, Ther Adv Neurol Disord, V4, P281, DOI 10.1177/1756285611413825
   Mantlo E, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104811
   Ogando NS, 2020, J GEN VIROL, V101, P925, DOI 10.1099/jgv.0.001453
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Scagnolari C, 2018, CYTOKINE GROWTH F R, V40, P19, DOI 10.1016/j.cytogfr.2018.03.003
   Schneider M, 2012, J VIROL, V86, P10112, DOI 10.1128/JVI.01001-12
   Smits SL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000756
   Stroher U, 2004, J INFECT DIS, V189, P1164, DOI 10.1086/382597
   Yuan LZ, 2020, EMERG MICROBES INFEC, V9, P949, DOI 10.1080/22221751.2020.1764871
   Zhou Q, 2020, INTERFERON A2B TREAT, DOI [10.1101/2020.04.06.200425, DOI 10.1101/2020.04.06.200425]
NR 15
TC 2
Z9 2
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD SEP 1
PY 2020
VL 222
IS 5
BP 722
EP 725
DI 10.1093/infdis/jiaa350
PG 4
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA NZ5VQ
UT WOS:000577173700006
PM 32559285
OA Green Published
DA 2021-01-01
ER

PT J
AU Sakai, T
   Hoshino, C
   Yamaguchi, R
   Hirao, M
   Nakahara, R
   Okawa, A
AF SAKAI, Tomoko
   HOSHINO, Chisato
   YAMAGUCHI, Reiko
   HIRAO, Masanobu
   NAKAHARA, Rui
   OKAWA, Atsushi
TI REMOTE REHABILITATION FOR PATIENTS WITH COVID-19
SO JOURNAL OF REHABILITATION MEDICINE
LA English
DT Article
DE coronavirus; early ambulation; infection; pulmonary embolism;
   rehabilitation; risk management
AB Objective: To describe the effectiveness and risk management of remote rehabilitation for coronavirus disease (COVID-19) patients in general wards.
   Design: Single-centre, retrospective, observational study.
   Patients: COVID-19 patients undergoing rehabilitation (24 April to 24 May 2020).
   Methods: All COVID-19 inpatients undergoing rehabilitation in the general ward of Tokyo Medical and Dental University were assessed. Data were collected on age, sex, physical ability, rehabilitation modality (remote/direct), need for intubation or extracorporeal membrane oxygenation, degree of pneumonia, oxygen therapy from the start of rehabilitation, D-dimer and C-reactive protein levels, and rehabilitation-related complications. Activities of daily living were measured using the Barthel Index.
   Results: Out of a total of 43 patients, 14 were initially provided with remote rehabilitation and 29 with direct (hands-on) rehabilitation. Four patients were switched from direct to remote rehabilitation during the study, thus at the end of the study there were 18 in the remote rehabilitation group and 25 in the direct rehabilitation group. Patients in remote rehabilitation were significantly younger than those in direct rehabilitation. Of 12 patients who required intubation, 3 were given remote rehabilitation. One extracorporeal membrane oxygenation survivor underwent direct rehabilitation. All patients on remote rehabilitation were discharged home or to a hotel. Twelve out of 29 patients on direct rehabilitation were transferred to a rehabilitation hospital due to delayed recovery of activities of daily living. No serious adverse events occurred.
   Conclusion: Effective and safe remote rehabilitation was performed in 41.9% of COVID-19 patients in this study, which resulted in which facilitated rehabilitation in COVID-19 specialized general wards.
C1 [SAKAI, Tomoko; HOSHINO, Chisato; YAMAGUCHI, Reiko; HIRAO, Masanobu; NAKAHARA, Rui] Tokyo Med & Dent Univ, Dept Rehabil Med, Tokyo, Japan.
   [OKAWA, Atsushi] Tokyo Med & Dent Univ, Dept Orthoped Surg, Tokyo, Japan.
RP Sakai, T (corresponding author), Tokyo Med & Dent Univ, Dept Orthoped, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.
EM t_sakai.orth@tmd.ac.jp
CR [Anonymous], 2020, MANAGEMENT COVID PAT
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bailey P, 2007, CRIT CARE MED, V35, P139, DOI 10.1097/01.CCM.0000251130.69568.87
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kabrhel C, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d3867
   Panigada M, 2020, J THROMB HAEMOST, V18, P1738, DOI 10.1111/jth.14850
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sakai T, 2019, PROG REHABIL MED, V4
   Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Spiezia L, 2020, THROMB HAEMOSTASIS, V120, P998, DOI 10.1055/s-0040-1710018
   Stam HJ, 2020, J REHABIL MED, V52, DOI 10.2340/16501977-2677
   Thomas P, 2020, J PHYSIOTHER, V66, P73, DOI 10.1016/j.jphys.2020.03.011
   World Health Organization (WHO), 2020, 132 WHO
NR 16
TC 1
Z9 1
U1 0
U2 0
PU FOUNDATION REHABILITATION INFORMATION
PI UPPSALA
PA TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN
SN 1650-1977
EI 1651-2081
J9 J REHABIL MED
JI J. Rehabil. Med.
PD SEP
PY 2020
VL 52
IS 9
AR jrm00095
DI 10.2340/16501977-2731
PG 8
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA NZ4UU
UT WOS:000577092200001
PM 32871014
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Stierli, S
   Buss, I
   Redecker, H
   Baumberger, M
   Blattler, E
   Selb, M
   Hinter, S
   Ischer, B
   Schwegler, H
AF STIERLI, Sarah
   BUSS, Irene
   REDECKER, Hermann
   BAUMBERGER, Michael
   BLaeTTLER, Erika
   SELB, Melissa
   HINTER, Sandra
   ISCHER, Barbara
   SCHWEGLER, Hans
TI INSIGHTS FROM AN INTERPROFESSIONAL POST-COVID-19 REHABILITATION UNIT: A
   SPEECH AND LANGUAGE THERAPY AND RESPIRATORY MEDICINE PERSPECTIVE
SO JOURNAL OF REHABILITATION MEDICINE
LA English
DT Article
DE Covid-19; post intensive care syndrome; speech and language therapy;
   swallowing; rehabilitation; tracheostomy management; speaking valve
ID MECHANICAL VENTILATION; SPEAKING VALVE
AB Objective: We present a case report that complements the conclusion of Stam et al. in their call to rehabilitation facilities to anticipate and prepare to address post intensive care syndrome in post-Covid-19 patients.
   Methods: The case report presented here provides insight into treating mechanically ventilated post-Covid-19 patients.
   Results: Early intervention with dysphagia therapy and speech therapy and ventilator-compatible speaking valves, provided within an interprofessional collaborative team, can mitigate the potentially negative consequences of prolonged intubation, long-term use of cuffed tracheostomy, and post intensive care syndrome resulting from Covid-19.
   Conclusion: Such a treatment approach can be used to address what is important to patients: to be able to speak with family and friends, eat what they want, and breathe spontaneously.
C1 [STIERLI, Sarah; BUSS, Irene; HINTER, Sandra; ISCHER, Barbara; SCHWEGLER, Hans] Swiss Parapleg Ctr, Speech & Language Therapy, Nottwil, Switzerland.
   [REDECKER, Hermann; BLaeTTLER, Erika] Swiss Parapleg Ctr, Intens Care Med & Resp Rehabil, Nottwil, Switzerland.
   [BAUMBERGER, Michael] Swiss Parapleg Ctr, Spinal Cord & Rehabil Med, Nottwil, Switzerland.
   [SELB, Melissa] Swiss Parapleg Res, Nottwil, Switzerland.
RP Buss, I (corresponding author), Swiss Parapleg Ctr, Speech & Language Therapy, Nottwil, Switzerland.
EM irene.buss@paraplegie.ch
CR Acosta P, 2007, CRIT CARE CLIN, V23, P251, DOI 10.1016/j.ccc.2006.12.012
   Bader CA, 2017, LARYNGO RHINO OTOL, V96, P280, DOI 10.1055/s-0043-103279
   Frajkova Z, 2020, DYSPHAGIA, V35, P549, DOI 10.1007/s00455-020-10139-6
   Freeman-Sanderson AL, 2016, J CRIT CARE, V33, P186, DOI 10.1016/j.jcrc.2016.01.012
   Heidler MD, 2015, MED KLIN-INTENSIVMED, V110, P55, DOI 10.1007/s00063-014-0397-5
   Heidler M. D., 2007, NEUROLOGIE REHABILIT, V13, P3
   Heidler MD, 2011, FORUM LOGOPADIE, V25, P22
   Hernandez G, 2013, INTENS CARE MED, V39, P1063, DOI 10.1007/s00134-013-2870-7
   Kowalski S, 2017, CAN J ANESTH, V64, P1286, DOI 10.1007/s12630-017-0964-3
   Macht M, 2014, CHEST, V146, P1681, DOI 10.1378/chest.14-1133
   Pandian V, 2014, ORL HEAD NECK NURS, V32, P10
   Pandian Vinciya, 2014, ORL Head Neck Nurs, V32, P6
   Schwegler H., 2020, TRACHEALKANULENMANAG
   Stam HJ, 2020, J REHABIL MED, V52, DOI 10.2340/16501977-2677
   Sutt AL, 2017, J CRIT CARE, V40, P164, DOI 10.1016/j.jcrc.2017.04.001
   Sutt AL, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1249-x
   Zielske J, 2014, EUR ARCH OTO-RHINO-L, V271, P3085, DOI 10.1007/s00405-014-3148-6
NR 17
TC 0
Z9 0
U1 0
U2 0
PU FOUNDATION REHABILITATION INFORMATION
PI UPPSALA
PA TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN
SN 1650-1977
EI 1651-2081
J9 J REHABIL MED
JI J. Rehabil. Med.
PD SEP
PY 2020
VL 52
IS 9
AR jrm00100
DI 10.2340/16501977-2735
PG 4
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA NZ4UU
UT WOS:000577092200004
PM 32896863
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Beaudoin-Bussieres, G
   Laumaea, A
   Anand, SP
   Prevost, J
   Gasser, R
   Goyette, G
   Medjahed, H
   Perreault, J
   Tremblay, T
   Lewin, A
   Gokool, L
   Morrisseau, C
   Begin, P
   Tremblay, C
   Martel-Laferriere, V
   Kaufmann, DE
   Richard, J
   Bazin, R
   Finzi, A
AF Beaudoin-Bussieres, Guillaume
   Laumaea, Annemarie
   Anand, Sai Priya
   Prevost, Jeremie
   Gasser, Romain
   Goyette, Guillaume
   Medjahed, Halima
   Perreault, Josee
   Tremblay, Tony
   Lewin, Antoine
   Gokool, Laurie
   Morrisseau, Chantal
   Begin, Philippe
   Tremblay, Cecile
   Martel-Laferriere, Valerie
   Kaufmann, Daniel E.
   Richard, Jonathan
   Bazin, Renee
   Finzi, Andres
TI Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent
   Individuals
SO MBIO
LA English
DT Letter
DE coronavirus; COVID-19; SARS-CoV-2; Spike glycoproteins; RBD; ELISA; IgA;
   IgM; IgG; neutralization; cross-reactivity; convalescent plasma
ID PLASMA; THERAPY
AB In the absence of effective vaccines and with limited therapeutic options, convalescent plasma is being collected across the globe for potential transfusion to coronavirus disease 2019 (COVID-19) patients. The therapy has been deemed safe, and several clinical trials assessing its efficacy are ongoing. While it remains to be formally proven, the presence of neutralizing antibodies is thought to play a positive role in the efficacy of this treatment. Indeed, neutralizing titers of >= 1: 160 have been recommended in some convalescent plasma trials for inclusion. Here, we performed repeated analyses at 1-month intervals on 31 convalescent individuals to evaluate how the humoral responses against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoprotein, including neutralization, evolve over time. We observed that the levels of receptorbinding-domain ( RBD)- specific IgG and IgA slightly decreased between 6 and 10 weeks after the onset of symptoms but that RBD-specific IgM levels decreased much more abruptly. Similarly, we observed a significant decrease in the capacity of convalescent plasma to neutralize pseudoparticles bearing wild-type SARS-CoV-2 S or its D614G variant. If neutralization activity proves to be an important factor in the clinical efficacy of convalescent plasma transfer, our results suggest that plasma from convalescent donors should be recovered rapidly after resolution of symptoms.
   IMPORTANCE While waiting for an efficient vaccine to protect against SARS-CoV-2 infection, alternative approaches to treat or prevent acute COVID-19 are urgently needed. Transfusion of convalescent plasma to treat COVID-19 patients is currently being explored; neutralizing activity in convalescent plasma is thought to play a central role in the efficacy of this treatment. Here, we observed that plasma neutralization activity decreased a few weeks after the onset of the symptoms. If neutralizing activity is required for the efficacy of convalescent plasma transfer, our results suggest that convalescent plasma should be recovered rapidly after the donor recovers from active infection.
C1 [Beaudoin-Bussieres, Guillaume; Laumaea, Annemarie; Anand, Sai Priya; Prevost, Jeremie; Gasser, Romain; Goyette, Guillaume; Medjahed, Halima; Gokool, Laurie; Morrisseau, Chantal; Begin, Philippe; Tremblay, Cecile; Martel-Laferriere, Valerie; Kaufmann, Daniel E.; Richard, Jonathan; Finzi, Andres] Ctr Rech CHUM, Quebec City, PQ, Canada.
   [Beaudoin-Bussieres, Guillaume; Laumaea, Annemarie; Prevost, Jeremie; Gasser, Romain; Tremblay, Cecile; Martel-Laferriere, Valerie; Richard, Jonathan; Finzi, Andres] Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada.
   [Anand, Sai Priya; Finzi, Andres] McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada.
   [Perreault, Josee; Tremblay, Tony; Lewin, Antoine; Bazin, Renee] Hema Quebec, Affaires Med & Innovat, Montreal, PQ, Canada.
   [Begin, Philippe] CHU Ste Justine, Montreal, PQ, Canada.
   [Kaufmann, Daniel E.] Univ Montreal, Dept Med, Montreal, PQ, Canada.
RP Finzi, A (corresponding author), Ctr Rech CHUM, Quebec City, PQ, Canada.; Finzi, A (corresponding author), Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada.; Finzi, A (corresponding author), McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada.
EM andres.finzi@umontreal.ca
FU Ministere de l'Economie et de l'Innovation du Quebec, Program de soutien
   aux organismes de recherche et d'innovation; Fondation du CHUM; Canadian
   Institutes of Health Research (via the Immunity Task Force)Canadian
   Institutes of Health Research (CIHR); American Foundation for AIDS
   Research (amfAR); CIHR FoundationCanadian Institutes of Health Research
   (CIHR) [352417]; CIHRCanadian Institutes of Health Research (CIHR);
   Canada Research Chair on Retroviral Entry [RCHS0235 950-232424]; CIHR
   fellowshipsCanadian Institutes of Health Research (CIHR); MITACS
   Acceleration postdoctoral fellowship; FRQS
FX We thank the convalescent plasma donors who participated in this study;
   the Hema-Quebec team involved in convalescent donor recruitment and
   plasma collection; the staff members of the CRCHUM BSL3 and Flow
   Cytometry Platforms for technical assistance; Stefan Pohlmann
   (Georg-August University, Germany) for the plasmids coding for
   SARS-CoV-2 S, 229E S and NL63 S glycoproteins; Marcelline Cote
   (University of Ottawa) for the OC43 S expressor; and M. Gordon Joyce
   (U.S. Military HIV Research Program [MHRP]) for the CR3022 monoclonal
   antibody. This work was supported by le Ministere de l'Economie et de
   l'Innovation du Quebec, Program de soutien aux organismes de recherche
   et d'innovation (A. Finzi), by the Fondation du CHUM (A. Finzi), and by
   the Canadian Institutes of Health Research (via the Immunity Task
   Force), the American Foundation for AIDS Research (amfAR) (A. Finzi and
   D. E. Kaufmann). This work was also supported by CIHR Foundation grant
   352417 to A. Finzi and by CIHR COVID-19 Rapid Research Funding to A.
   Finzi, R. Bazin, and P. Begin. A. Finzi is the recipient of a Canada
   Research Chair on Retroviral Entry (RCHS0235 950-232424). G.
   Beaudoin-Bussieres, S. P. Anand, and J. Prevost are supported by CIHR
   fellowships. R. Gasser is supported by a MITACS Acceleration
   postdoctoral fellowship. V. Martel-Laferriere and P. Begin are supported
   by FRQS salary awards. D. E. Kaufmann is a FRQS Merit Research Scholar.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Adams E.R., 2020, ANTIBODY TESTING COV, DOI [10.1101/2020.04.15.20066407, DOI 10.1101/2020.04.15.20066407, 10.1101/2020.04.15.20066407.]
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Casadevall A, 2020, JAMA-J AM MED ASSOC, V324, P455, DOI 10.1001/jama.2020.10218
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Deng W, 2020, SCIENCE, V369, P818, DOI 10.1126/science.abc5343
   Duan K, 2020, P NATL ACAD SCI USA, V117, P12529, DOI [10.1073/pnas.2007408117, 10.1073/pnas.2004168117]
   Hung IFN, 2011, CLIN INFECT DIS, V52, P447, DOI 10.1093/cid/ciq106
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Ko JH, 2018, ANTIVIR THER, V23, P617, DOI 10.3851/IMP3243
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Payne DC, 2020, MMWR-MORBID MORTAL W, V69, P714, DOI [10.15585/mmwr.mm6923e4, 10.15585/mmwr.mm6923e4externalicon]
   Perreault Josee, 2020, Blood, V136, P2588, DOI 10.1182/blood.2020008367
   Prevost Jeremie, 2020, Cell Rep Med, V1, P100126, DOI 10.1016/j.xcrm.2020.100126
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Schmidt F, 2020, J EXP MED, V217, DOI 10.1084/jem.20201181
   Seow G., 2020, LONGITUDINAL EVALUAT, DOI [10.1101/2020.07.09.20148429., 10.1101/2020.07.09.20148429, DOI 10.1101/2020.07.09.20148429]
   Sterlin D, 2020, IGA DOMINATES EARLY, DOI [10.1101/2020.06.10.20126532, DOI 10.1101/2020.06.10.20126532]
   Zhang Lizhou, 2020, bioRxiv, DOI 10.1101/2020.06.12.148726
NR 23
TC 3
Z9 3
U1 2
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD SEP-OCT
PY 2020
VL 11
IS 5
AR e02590-20
DI 10.1128/mBio.02590-20
PG 7
WC Microbiology
SC Microbiology
GA OC9VF
UT WOS:000579503600086
PM 33067385
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fidel, PL
   Noverr, MC
AF Fidel, Paul L., Jr.
   Noverr, Mairi C.
TI Reply to Ozdemir, "Measles-Mumps-Rubella Vaccine and COVID-19
   Relationship"
SO MBIO
LA English
DT Letter
C1 [Fidel, Paul L., Jr.] Louisiana State Univ Hlth, Sch Dent, Dept Oral & Craniofacial Biol, New Orleans, LA 70112 USA.
   [Noverr, Mairi C.] Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA.
RP Fidel, PL (corresponding author), Louisiana State Univ Hlth, Sch Dent, Dept Oral & Craniofacial Biol, New Orleans, LA 70112 USA.
EM pfidel@lsuhsc.edu
OI Reis, AlessanRSS/0000-0001-8486-7469; Fidel, Paul/0000-0001-8066-5763
CR de Vrieze J., 2020, SCIENCE
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Esher SK, 2019, J FUNGI, V5, DOI 10.3390/jof5020037
   Fidel PL, 2020, MBIO, V11, DOI 10.1128/mBio.00907-20
   Franklin R., 2020, HOMOLOGOUS PROTEIN D, DOI [10.1101/2020.04.10.20053207, DOI 10.1101/2020.04.10.20053207]
   Gold JE, 2020, RESEARCHGATE
   Klinger D, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030378
   Lilly EA, 2019, INFECT IMMUN, V87, DOI [10.1128/IAI.00348-19, 10.1128/iai.00348-19]
   Lilly EA, 2018, MBIO, V9, DOI 10.1128/mBio.01472-17
   Liu WY, 2020, NEW ENGL J MED, V382, P1370, DOI 10.1056/NEJMc2003717
   Pawlowski C., 2020, EXPLORATORY ANAL IMM, DOI [10.1101/2020.07.27.20161976, DOI 10.1101/2020.07.27.20161976]
NR 11
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD SEP-OCT
PY 2020
VL 11
IS 5
AR e02465-20
DI 10.1128/mBio.02465-20
PG 2
WC Microbiology
SC Microbiology
GA OC9VF
UT WOS:000579503600083
PM 32963010
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Nchioua, R
   Kmiec, D
   Muller, JA
   Conzelmann, C
   Gro, R
   Swanson, CM
   Neil, SJD
   Stenger, S
   Sauter, D
   Munch, J
   Sparrer, KMJ
   Kirchhoff, F
AF Nchioua, Rayhane
   Kmiec, Dorota
   Mueller, Janis A.
   Conzelmann, Carina
   Gro, Rudiger
   Swanson, Chad M.
   Neil, Stuart J. D.
   Stenger, Steffen
   Sauter, Daniel
   Muench, Jan
   Sparrer, Konstantin M. J.
   Kirchhoff, Frank
TI SARS-CoV-2 Is Restricted by Zinc Finger Antiviral Protein despite
   Preadaptation to the Low-CpG Environment in Humans
SO MBIO
LA English
DT Article
DE COVID-19; CpG suppression; SARS-CoV-2; ZAP; evolution; interferon
ID CLEAVAGE SITE; CORONAVIRUS; RECOMBINATION; REPLICATION; MECHANISM;
   GENOTYPE; REVEALS
AB Recent evidence shows that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is sensitive to interferons (IFNs). However, the most effective types of IFNs and the underlying antiviral effectors remain to be defined. Here, we show that zinc finger antiviral protein (ZAP), which preferentially targets CpG dinucleotides in viral RNA sequences, restricts SARS-CoV-2. We further demonstrate that ZAP and its cofactors KHNYN and TRIM25 are expressed in human lung cells. Type I, II, and III IFNs all strongly inhibited SARS-CoV-2 and further induced ZAP expression. Comprehensive sequence analyses revealed that SARS-CoV-2 and its closest relatives from horseshoe bats showed the strongest CpG suppression among all known human and bat coronaviruses, respectively. Nevertheless, endogenous ZAP expression restricted SARS-CoV-2 replication in human lung cells, particularly upon treatment with IFN-alpha or IFN-gamma. Both the long and the short isoforms of human ZAP reduced SARS-CoV-2 RNA expression levels, but the former did so with greater efficiency. Finally, we show that the ability to restrict SARS-CoV-2 is conserved in ZAP orthologues of the reservoir bat and potential intermediate pangolin hosts of human coronaviruses. Altogether, our results show that ZAP is an important effector of the innate response against SARS-CoV-2, although this pandemic pathogen emerged from zoonosis of a coronavirus that was preadapted to the low-CpG environment in humans.
   IMPORTANCE Although interferons inhibit SARS-CoV-2 and have been evaluated for treatment of coronavirus disease 2019 (COVID-19), the most effective types and antiviral effectors remain to be defined. Here, we show that IFN-gamma is particularly potent in restricting SARS-CoV-2 and in inducing expression of the antiviral factor ZAP in human lung cells. Knockdown experiments revealed that endogenous ZAP significantly restricts SARS-CoV-2. We further show that CpG dinucleotides which are specifically targeted by ZAP are strongly suppressed in the SARS-CoV-2 genome and that the two closest horseshoe bat relatives of SARS-CoV-2 show the lowest genomic CpG content of all coronavirus sequences available from this reservoir host. Nonetheless, both the short and long isoforms of human ZAP reduced SARS-CoV-2 RNA levels, and this activity was conserved in horseshoe bat and pangolin ZAP orthologues. Our findings indicating that type II interferon is particularly efficient against SARS-CoV-2 and that ZAP restricts this pandemic viral pathogen might promote the development of effective immune therapies against COVID-19.
C1 [Nchioua, Rayhane; Kmiec, Dorota; Mueller, Janis A.; Conzelmann, Carina; Gro, Rudiger; Sauter, Daniel; Muench, Jan; Sparrer, Konstantin M. J.; Kirchhoff, Frank] Ulm Univ, Inst Mol Virol, Med Ctr, Ulm, Germany.
   [Kmiec, Dorota; Swanson, Chad M.; Neil, Stuart J. D.] Kings Coll London, Sch Immunol & Microbial Sci, Dept Infect Dis, London, England.
   [Stenger, Steffen] Ulm Univ, Inst Med Microbiol & Hyg, Med Ctr, Ulm, Germany.
RP Kirchhoff, F (corresponding author), Ulm Univ, Inst Mol Virol, Med Ctr, Ulm, Germany.
EM frank.kirchhoff@uni-ulm.de
OI Swanson, Chad/0000-0002-6650-3634
FU DFGGerman Research Foundation (DFG) [CRC 1279, SPP 1923, KM 5/1-1,
   SP1600/4-1]; EU Horizon 2020 research and innovation program
   [101003555]; Ulm University Medical Center [L.SBN.0150]; Ministry for
   Science, Research and Arts of Baden-Wuerttemberg; BMBFFederal Ministry
   of Education & Research (BMBF); International Graduate School in
   Molecular Medicine Ulm
FX This study was supported by DFG grants to F. Kirchhoff, J. Munch, D.
   Kmiec, D. Sauter, S. Stenger, and K. M. J. Sparrer (CRC 1279, SPP 1923,
   KM 5/1-1, and SP1600/4-1) and by an EU Horizon 2020 research and
   innovation program grant to J. Munch (Fight-nCoV, 101003555) as well as
   by intramural funding provided by the Ulm University Medical Center
   (L.SBN.0150) to K. M. J. Sparrer. F. Kirchhoff, J. Munch, J. Muller, and
   D. Sauter were also supported by COVID-19 research grants of the
   Ministry for Science, Research and Arts of Baden-Wuerttemberg.
   Furthermore, the BMBF supported the present study with grants to F.
   Kirchhoff and D. Sauter (Restrict SARS-CoV-2 and protACT, respectively).
   C. Conzelmann and R. Gross are part of and R. Gross is funded by a
   scholarship from the International Graduate School in Molecular Medicine
   Ulm.
CR Andrea CG, 2020, EXPERT REV ANTICANC, V20, P63, DOI [10.1080/22221751.2020.1806735, 10.1080/14737140.2020.1712198]
   Atkinson NJ, 2014, NUCLEIC ACIDS RES, V42, P4527, DOI 10.1093/nar/gku075
   Banerjee A, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010041
   Bermingham A, 2012, EUROSURVEILLANCE, V17, P6
   Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026
   Boni MF, 2020, NAT MICROBIOL, V5, P1408, DOI 10.1038/s41564-020-0771-4
   Charron G, 2013, P NATL ACAD SCI USA, V110, P11085, DOI 10.1073/pnas.1302564110
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chu Hin, 2020, Lancet Microbe, V1, pe14, DOI 10.1016/S2666-5247(20)30004-5
   Corman VM, 2018, ADV VIRUS RES, V100, P163, DOI 10.1016/bs.aivir.2018.01.001
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   di Gioacchino Andrea, 2020, bioRxiv, DOI 10.1101/2020.05.06.074039
   Digard Paul, 2020, Virus Evol, V6, pveaa057, DOI 10.1093/ve/veaa057
   Dominguez SR, 2012, J GEN VIROL, V93, P2387, DOI 10.1099/vir.0.044628-0
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Ficarelli M, 2019, ELIFE, V8, DOI 10.7554/eLife.46767
   Ghimire D, 2018, J GEN VIROL, V99, P435, DOI 10.1099/jgv.0.001026
   Graham RL, 2010, J VIROL, V84, P3134, DOI 10.1128/JVI.01394-09
   Greenbaum BD, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000079
   Gross R, 2020, LANCET, V395, P1757, DOI 10.1016/S0140?6736(20)31181?8
   Gu HG, 2020, VIRUS EVOL, V6, DOI 10.1093/ve/veaa032
   Hayakawa S, 2011, NAT IMMUNOL, V12, P37, DOI 10.1038/ni.1963
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   i L, 2020, IMPAIRED CELLULAR IM, DOI [10.1101/2020.08.10.20171371, DOI 10.1101/2020.08.10.20171371]
   Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011
   Kmiec D, 2020, MBIO, V11, DOI 10.1128/mBio.02903-19
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Lemoine F, 2019, NUCLEIC ACIDS RES, V47, pW260, DOI 10.1093/nar/gkz303
   Letunic I, 2019, NUCLEIC ACIDS RES, V47, pW256, DOI 10.1093/nar/gkz239
   Li MMH, 2019, J VIROL, V93, DOI 10.1128/JVI.00715-19
   Li MMH, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006145
   Luo X, 2020, CELL REP, V30, P46, DOI 10.1016/j.celrep.2019.11.116
   MacLean Oscar A, 2020, bioRxiv, DOI 10.1101/2020.05.28.122366
   Mantlo E, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104811
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Meagher JL, 2019, P NATL ACAD SCI USA, V116, P24303, DOI 10.1073/pnas.1913232116
   Odon V, 2019, NUCLEIC ACIDS RES, V47, P8061, DOI 10.1093/nar/gkz581
   Ogando NS, 2020, J GEN VIROL, V101, P925, DOI 10.1099/jgv.0.001453
   Park A, 2020, CELL HOST MICROBE, V27, P870, DOI 10.1016/j.chom.2020.05.008
   Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Sallard E, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104791
   Saxonov S, 2006, P NATL ACAD SCI USA, V103, P1412, DOI 10.1073/pnas.0510310103
   Schwerk J, 2019, NAT IMMUNOL, V20, P1610, DOI 10.1038/s41590-019-0527-6
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Stanifer ML, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107863
   Takata MA, 2017, NATURE, V550, P124, DOI 10.1038/nature24039
   Thoms M, 2020, SCIENCE, V369, P1249, DOI 10.1126/science.abc8665
   Totura AL, 2012, CURR OPIN VIROL, V2, P264, DOI 10.1016/j.coviro.2012.04.004
   Tse LV, 2014, J VIROL, V88, P1673, DOI 10.1128/JVI.02648-13
   van der Hoek L, 2004, NAT MED, V10, P368, DOI 10.1038/nm1024
   Woo PCY, 2007, VIROLOGY, V369, P431, DOI 10.1016/j.virol.2007.08.010
   Woo PCY, 2006, J VIROL, V80, P7136, DOI 10.1128/JVI.00509-06
   Xia XH, 2020, MOL BIOL EVOL, V37, P2699, DOI 10.1093/molbev/msaa094
   Xiao KP, 2020, NATURE, V583, P286, DOI 10.1038/s41586-020-2313-x
   Ye ZW, 2020, INT J BIOL SCI, V16, P1686, DOI 10.7150/ijbs.45472
   Zhang BG, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01912
   Zheng HY, 2020, CELL MOL IMMUNOL, V17, P541, DOI 10.1038/s41423-020-0401-3
   Zheng XJ, 2017, J VIROL, V91, DOI [10.1128/JVI.00088-17, 10.1128/jvi.00088-17]
   Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021
   Zhou H, 2020, CURR BIOL, V30, P2196, DOI 10.1016/j.cub.2020.05.023
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 67
TC 1
Z9 1
U1 1
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD SEP-OCT
PY 2020
VL 11
IS 5
AR e01930-20
DI 10.1128/mBio.01930-20
PG 19
WC Microbiology
SC Microbiology
GA OC9VF
UT WOS:000579503600037
PM 33067384
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Outlaw, VK
   Bovier, FT
   Mears, MC
   Cajimat, MN
   Zhu, Y
   Lin, MJ
   Addetia, A
   Lieberman, NAP
   Peddu, V
   Xie, XP
   Shi, PY
   Greninger, AL
   Gellman, SH
   Bente, DA
   Moscona, A
   Porotto, M
AF Outlaw, Victor K.
   Bovier, Francesca T.
   Mears, Megan C.
   Cajimat, Maria N.
   Zhu, Yun
   Lin, Michelle J.
   Addetia, Amin
   Lieberman, Nicole A. P.
   Peddu, Vikas
   Xie, Xuping
   Shi, Pei-Yong
   Greninger, Alexander L.
   Gellman, Samuel H.
   Bente, Dennis A.
   Moscona, Anne
   Porotto, Matteo
TI Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a
   Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein
   HRC Domain
SO MBIO
LA English
DT Article
DE SARS-CoV-2; spike protein; fusion inhibitor; lipopeptide
ID TYPE-3 HEMAGGLUTININ-NEURAMINIDASE; MEASLES-VIRUS INFECTION; VIRAL
   MEMBRANE-FUSION; CELL ENTRY; PROTEIN; MECHANISMS
AB The emergence of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), the etiological agent of the 2019 coronavirus disease (COVID-19), has erupted into a global pandemic that has led to tens of millions of infections and hundreds of thousands of deaths worldwide. The development of therapeutics to treat infection or as prophylactics to halt viral transmission and spread is urgently needed. SARS-CoV-2 relies on structural rearrangements within a spike (S) glycoprotein to mediate fusion of the viral and host cell membranes. Here, we describe the development of a lipopeptide that is derived from the C-terminal heptad repeat (HRC) domain of SARS-CoV-2 S that potently inhibits infection by SARS-CoV-2. The lipopeptide inhibits cell-cell fusion mediated by SARS-CoV-2 S and blocks infection by live SARS-CoV-2 in Vero E6 cell monolayers more effectively than previously described lipopeptides. The SARS-CoV-2 lipopeptide exhibits broad-spectrum activity by inhibiting cell-cell fusion mediated by SARS-CoV-1 and Middle East respiratory syndrome coronavirus (MERS-CoV) and blocking infection by live MERS-CoV in cell monolayers. We also show that the SARS-CoV-2 HRC-derived lipopeptide potently blocks the spread of SARS-CoV-2 in human airway epithelial (HAE) cultures, an ex vivo model designed to mimic respiratory viral propagation in humans. While viral spread of SARS-CoV-2 infection was widespread in untreated airways, those treated with SARS-CoV-2 HRC lipopeptide showed no detectable evidence of viral spread. These data provide a framework for the development of peptide therapeutics for the treatment of or prophylaxis against SARS-CoV-2 as well as other coronaviruses.
   IMPORTANCE SARS-CoV-2, the causative agent of COVID-19, continues to spread globally, placing strain on health care systems and resulting in rapidly increasing numbers of cases and mortalities. Despite the growing need for medical intervention, no FDA-approved vaccines are yet available, and treatment has been limited to supportive therapy for the alleviation of symptoms. Entry inhibitors could fill the important role of preventing initial infection and preventing spread. Here, we describe the design, synthesis, and evaluation of a lipopeptide that is derived from the HRC domain of the SARS-CoV-2 S glycoprotein that potently inhibits fusion mediated by SARS-CoV-2 S glycoprotein and blocks infection by live SARS-CoV-2 in both cell monolayers (in vitro) and human airway tissues (ex vivo). Our results highlight the SARS-CoV-2 HRC-derived lipopeptide as a promising therapeutic candidate for SARS-CoV-2 infections.
C1 [Outlaw, Victor K.; Gellman, Samuel H.] Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA.
   [Bovier, Francesca T.; Zhu, Yun; Xie, Xuping; Shi, Pei-Yong; Moscona, Anne; Porotto, Matteo] Columbia Univ, Dept Pediat, Med Ctr, New York, NY 10027 USA.
   [Bovier, Francesca T.; Zhu, Yun; Moscona, Anne; Porotto, Matteo] Columbia Univ, Ctr Host Pathogen Interact, Med Ctr, New York, NY 10027 USA.
   [Bovier, Francesca T.; Porotto, Matteo] Univ Campania Luigi Vanvitelli, Dept Expt Med, Caserta, Italy.
   [Mears, Megan C.; Cajimat, Maria N.; Bente, Dennis A.] Univ Texas Med Branch, Galveston Natl Lab, Galveston, TX 77555 USA.
   [Mears, Megan C.; Cajimat, Maria N.] Univ Texas Med Branch, Dept Expt Pathol, Galveston, TX 77555 USA.
   [Zhu, Yun] Capital Med Univ, Beijing Childrens Hosp, Beijing Pediat Res Inst, Beijing, Peoples R China.
   [Lin, Michelle J.; Addetia, Amin; Lieberman, Nicole A. P.; Peddu, Vikas; Greninger, Alexander L.] Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98195 USA.
   [Xie, Xuping; Shi, Pei-Yong] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.
   [Greninger, Alexander L.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Bente, Dennis A.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
   [Moscona, Anne] Columbia Univ, Dept Microbiol & Immunol, Med Ctr, New York, NY 10027 USA.
   [Moscona, Anne] Columbia Univ, Dept Physiol & Cellular Biophys, Med Ctr, New York, NY 10027 USA.
RP Gellman, SH (corresponding author), Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA.; Moscona, A; Porotto, M (corresponding author), Columbia Univ, Dept Pediat, Med Ctr, New York, NY 10027 USA.; Moscona, A; Porotto, M (corresponding author), Columbia Univ, Ctr Host Pathogen Interact, Med Ctr, New York, NY 10027 USA.; Porotto, M (corresponding author), Univ Campania Luigi Vanvitelli, Dept Expt Med, Caserta, Italy.; Bente, DA (corresponding author), Univ Texas Med Branch, Galveston Natl Lab, Galveston, TX 77555 USA.; Bente, DA (corresponding author), Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.; Moscona, A (corresponding author), Columbia Univ, Dept Microbiol & Immunol, Med Ctr, New York, NY 10027 USA.; Moscona, A (corresponding author), Columbia Univ, Dept Physiol & Cellular Biophys, Med Ctr, New York, NY 10027 USA.
EM gellman@chem.wisc.edu; dabente@UTMB.EDU; am939@cumc.columbia.edu;
   mp3509@cumc.columbia.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI146980, AI121349,
   NS091263, AI114736, GM056414]; Sharon Golub Fund at Columbia University
   Medical Center; Department of Laboratory Medicine at the University of
   Washington School of Medicine; NIH/NCI Cancer Center Support Grant
   [P30CA013696]; Genomics and High Throughput Screening Shared Resource
FX This work was supported by funding from the National Institutes of
   Health (AI146980, AI121349, and NS091263 to M.P., AI114736 to A.M., and
   GM056414 to S.H.G.), the Sharon Golub Fund at Columbia University
   Medical Center, and the Department of Laboratory Medicine at the
   University of Washington School of Medicine. This research was funded in
   part through the NIH/NCI Cancer Center Support Grant P30CA013696 and
   used the Genomics and High Throughput Screening Shared Resource.
CR Baldwin CE, 2004, J VIROL, V78, P12428, DOI 10.1128/JVI.78.22.12428-12437.2004
   Biswas NK, 2020, INDIAN J MED RES, V151, P450, DOI 10.4103/ijmr.IJMR_1125_20
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Bottom-Tanzer SF, 2019, MBIO, V10, DOI 10.1128/mBio.02900-18
   Channappanavar R, 2015, J INFECT DIS, V212, P1894, DOI 10.1093/infdis/jiv325
   Chong HH, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007552
   Chong HH, 2018, J VIROL, V92, DOI 10.1128/JVI.00775-18
   Chong HH, 2017, J VIROL, V91, DOI 10.1128/JVI.00288-17
   Corbett AJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01961
   Daniloski Zharko, 2020, bioRxiv, DOI 10.1101/2020.06.14.151357
   Deng XF, 2014, J VIROL METHODS, V195, P112, DOI 10.1016/j.jviromet.2013.10.012
   Ding XH, 2017, J VIROL, V91, DOI 10.1128/JVI.00831-17
   Eaaswarkhanth M, 2020, INT J INFECT DIS, V96, P459, DOI 10.1016/j.ijid.2020.05.071
   Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777
   Figueira TN, 2018, BIOCONJUGATE CHEM, V29, P3362, DOI 10.1021/acs.bioconjchem.8b00527
   Figueira TN, 2017, J VIROL, V91, DOI 10.1128/JVI.01554-16
   Figueira TN, 2018, ACS NANO, V12, P9855, DOI 10.1021/acsnano.8b01422
   Gong YQ, 2020, EPIDEMIOL INFECT, V148, DOI [10.1017/S0950268820000771, 10.1080/22221751.2020.1782271]
   Greninger AL, 2017, J CLIN MICROBIOL, V55, P177, DOI 10.1128/JCM.01881-16
   Harrison SC, 2008, NAT STRUCT MOL BIOL, V15, P690, DOI 10.1038/nsmb.1456
   Hernandez LD, 1996, ANNU REV CELL DEV BI, V12, P627, DOI 10.1146/annurev.cellbio.12.1.627
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hsieh Ching-Lin, 2020, bioRxiv, DOI 10.1101/2020.05.30.125484
   Iketani S, 2018, MBIO, V9, DOI 10.1128/mBio.00898-18
   Karacan I, 2020, NORTH CLIN ISTANB, V7, P203, DOI 10.14744/nci.2020.90532
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Kim SJ, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020220
   Koyama T, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9050324
   Lee KK, 2011, J BIOL CHEM, V286, P42141, DOI 10.1074/jbc.M111.254243
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Lin MJ, 2019, BIORXIV, DOI [10.1101/2019.12.17.879320., DOI 10.1101/2019.12.17.879320.]
   Looi K, 2018, CLIN EXP ALLERGY, V48, P513, DOI 10.1111/cea.13097
   Maitra A, 2020, J BIOSCIENCES, V45, DOI 10.1007/s12038-020-00046-1
   Mathieu C, 2015, J VIROL, V89, P1143, DOI 10.1128/JVI.02417-14
   Mathieu C, 2019, J VIROL, V93, DOI 10.1128/JVI.01862-18
   Mathieu C, 2017, SCI REP-UK, V7, DOI 10.1038/srep43610
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331
   MOSCONA A, 1993, J VIROL, V67, P6463, DOI 10.1128/JVI.67.11.6463-6468.1993
   Moscona A, 2010, J INFECT DIS, V202, P234, DOI 10.1086/653621
   Moscona A, 2009, NEW ENGL J MED, V360, P953, DOI 10.1056/NEJMp0900648
   Murrell MT, 2001, J VIROL, V75, P6310, DOI 10.1128/JVI.75.14.6310-6320.2001
   Navaratnarajah CK, 2020, J BIOL CHEM, V295, P2771, DOI 10.1074/jbc.REV119.009961
   Outlaw VK, 2019, J AM CHEM SOC, V141, P12648, DOI 10.1021/jacs.9b04615
   Palermo LM, 2009, J VIROL, V83, P6900, DOI 10.1128/JVI.00475-09
   Palmer SG, 2014, J VIROL, V88, P13495, DOI 10.1128/JVI.01965-14
   Park JE, 2017, VIROLOGY, V511, P9, DOI 10.1016/j.virol.2017.07.033
   Pessi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036833
   Porotto M, 2019, MBIO, V10, DOI 10.1128/mBio.00723-19
   Porotto M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001168
   Porotto M, 2010, J VIROL, V84, P6760, DOI 10.1128/JVI.00135-10
   Rezaee F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181876
   Schamberger AC, 2014, AM J RESP CELL MOL, V50, P1040, DOI 10.1165/rcmb.2013-0090OC
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Su S, 2019, MOLECULES, V24, DOI 10.3390/molecules24061134
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Welsch JC, 2013, J VIROL, V87, P13785, DOI 10.1128/JVI.02436-13
   White JM, 2008, CRIT REV BIOCHEM MOL, V43, P189, DOI 10.1080/10409230802058320 
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Xia Shuai, 2015, Yaoxue Xuebao, V50, P1513
   Xie XP, 2020, CELL HOST MICROBE, V27, P841, DOI 10.1016/j.chom.2020.04.004
   Yu DW, 2020, J VIROL, V94, DOI 10.1128/JVI.00384-20
   Zhang Lizhou, 2020, bioRxiv, DOI 10.1101/2020.06.12.148726
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zhu N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17796-z
   Zhu YZ, 2012, J VIROL, V86, P13407, DOI 10.1128/JVI.00903-12
   Zhu YM, 2019, J VIROL, V93, DOI 10.1128/JVI.02312-18
NR 68
TC 1
Z9 1
U1 5
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD SEP-OCT
PY 2020
VL 11
IS 5
AR e01935-20
DI 10.1128/mBio.01935-20
PG 14
WC Microbiology
SC Microbiology
GA OC9VF
UT WOS:000579503600038
PM 33082259
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ozdemir, O
AF Ozdemir, Oner
TI Measles-Mumps-Rubella Vaccine and COVID-19 Relationship
SO MBIO
LA English
DT Letter
C1 [Ozdemir, Oner] Sakarya Univ, Res & Training Hosp, Dept Pediat, Div Allergy & Immunol, Adapazari, Sakarya, Turkey.
RP Ozdemir, O (corresponding author), Sakarya Univ, Res & Training Hosp, Dept Pediat, Div Allergy & Immunol, Adapazari, Sakarya, Turkey.
EM ozdemir_oner@hotmail.com
OI Reis, AlessanRSS/0000-0001-8486-7469
CR de Bree CLCJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00869
   Fidel PL, 2020, MBIO, V11, DOI 10.1128/mBio.00907-20
   Kantor IN, 2020, MEDICINA-BUENOS AIRE, V80, P292
   Kleinnijenhuis J, 2014, J INNATE IMMUN, V6, P152, DOI 10.1159/000355628
   Lin Marie, 2003, BMC Med Genet, V4, P9, DOI 10.1186/1471-2350-4-9
   Macedo A, 2020, MED HYPOTHESES, V142, DOI 10.1016/j.mehy.2020.109816
NR 6
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD SEP-OCT
PY 2020
VL 11
IS 5
AR e01832-20
DI 10.1128/mBio.01832-20
PG 2
WC Microbiology
SC Microbiology
GA OC9VF
UT WOS:000579503600031
PM 32963005
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Richman, DD
AF Richman, Douglas D.
TI Antiviral Drug Discovery To Address the COVID-19 Pandemic
SO MBIO
LA English
DT Article
DE coronavirus; COVID-19; SARS-CoV-2; antiviral agents; drug resistance;
   hepatitis C virus; human immunodeficiency virus; protease inhibitors
AB The magnitude of the morbidity and mortality inflicted upon the global population in less than 1 year has driven the inescapable conclusion that the discovery and development of effective antiviral drugs for COVID-19 are urgent and should be prioritized. The antiviral drug discovery programs that emerged for HIV and hepatitis C virus have enabled technology and expertise to accelerate this process for SARS-CoV-2. The description of candidate lead inhibitors for the viral main protease (Mpro) exemplifies this accelerated approach and reminds us of the needs and opportunities for addressing this pandemic.
C1 [Richman, Douglas D.] Univ Calif San Diego, Pathol & Med, La Jolla, CA 92093 USA.
   [Richman, Douglas D.] Univ Calif San Diego, HIV Inst, La Jolla, CA 92093 USA.
   [Richman, Douglas D.] Univ Calif San Diego, San Diego Ctr AIDS Res, Florence Seeley Riford Chair AIDS Res, La Jolla, CA 92093 USA.
RP Richman, DD (corresponding author), Univ Calif San Diego, Pathol & Med, La Jolla, CA 92093 USA.; Richman, DD (corresponding author), Univ Calif San Diego, HIV Inst, La Jolla, CA 92093 USA.; Richman, DD (corresponding author), Univ Calif San Diego, San Diego Ctr AIDS Res, Florence Seeley Riford Chair AIDS Res, La Jolla, CA 92093 USA.
EM drichman@ucsd.edu
OI richman, douglas/0000-0003-0962-9254
CR Berliba E, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.01201-19
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   Good S, 2020, BIORXIV, DOI [10.1101/2020.08.11.242834., DOI 10.1101/2020.08.11.242834]
   Hattori S, 2020, MBIO, V11, DOI 10.1128/mBio.01833-20
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Koh Y, 2003, ANTIMICROB AGENTS CH, V47, P3123, DOI 10.1128/AAC.47.10.3123-3129.2003
   McKechnie JL, 2020, CELL HOST MICROBE, V27, P863, DOI 10.1016/j.chom.2020.05.009
   MITSUYA H, 1986, P NATL ACAD SCI USA, V83, P1911, DOI 10.1073/pnas.83.6.1911
   Ohrui Hiroshi, 2006, Nucleic Acids Symp Ser (Oxf), P1
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
NR 12
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD SEP-OCT
PY 2020
VL 11
IS 5
AR e02134-20
DI 10.1128/mBio.02134-20
PG 3
WC Microbiology
SC Microbiology
GA OC9VF
UT WOS:000579503600061
PM 32978312
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Westmeier, J
   Paniskaki, K
   Karakose, Z
   Werner, T
   Sutter, K
   Dolff, S
   Overbeck, M
   Limmer, A
   Liu, J
   Zheng, X
   Brenner, T
   Berger, MM
   Witzke, O
   Trilling, M
   Lu, MJ
   Yang, DL
   Babel, N
   Westhoff, T
   Dittmer, U
   Zelinskyy, G
AF Westmeier, Jaana
   Paniskaki, Krystallenia
   Karakoese, Zehra
   Werner, Tanja
   Sutter, Kathrin
   Dolff, Sebastian
   Overbeck, Marvin
   Limmer, Andreas
   Liu, Jia
   Zheng, Xin
   Brenner, Thorsten
   Berger, Marc M.
   Witzke, Oliver
   Trilling, Mirko
   Lu, Mengji
   Yang, Dongliang
   Babel, Nina
   Westhoff, Timm
   Dittmer, Ulf
   Zelinskyy, Gennadiy
TI Impaired Cytotoxic CD8(+) T Cell Response in Elderly COVID-19 Patients
SO MBIO
LA English
DT Article
DE COVID-19; SARS-CoV-2; cytotoxic T cells; CD8(+); CD4(+); PD-1; granzyme;
   perforin; aging
ID VIRUS; PERFORIN; MICE
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection induces a T cell response that most likely contributes to virus control in COVID-19 patients but may also induce immunopathology. Until now, the cytotoxic T cell response has not been very well characterized in COVID-19 patients. Here, we analyzed the differentiation and cytotoxic profile of T cells in 30 cases of mild COVID-19 during acute infection. SARS-CoV-2 infection induced a cytotoxic response of CD8(+) T cells, but not CD4(+) T cells, characterized by the simultaneous production of granzyme A and B as well as perforin within different effector CD8(+) T cell subsets. PD-1-expressing CD8(+) T cells also produced cytotoxic molecules during acute infection, indicating that they were not functionally exhausted. However, in COVID-19 patients over the age of 80 years, the cytotoxic T cell potential was diminished, especially in effector memory and terminally differentiated effector CD8(+) cells, showing that elderly patients have impaired cellular immunity against SARS-CoV-2. Our data provide valuable information about T cell responses in COVID-19 patients that may also have important implications for vaccine development.
   IMPORTANCE Cytotoxic T cells are responsible for the elimination of infected cells and are key players in the control of viruses. CD8(+) T cells with an effector phenotype express cytotoxic molecules and are able to perform target cell killing. COVID-19 patients with a mild disease course were analyzed for the differentiation status and cytotoxic profile of CD8(+) T cells. SARS-CoV-2 infection induced a vigorous cytotoxic CD8(+) T cell response. However, this cytotoxic profile of T cells was not detected in COVID-19 patients over the age of 80 years. Thus, the absence of a cytotoxic response in elderly patients might be a possible reason for the more frequent severity of COVID-19 in this age group than in younger patients.
C1 [Westmeier, Jaana; Karakoese, Zehra; Werner, Tanja; Sutter, Kathrin; Trilling, Mirko; Lu, Mengji; Dittmer, Ulf; Zelinskyy, Gennadiy] Univ Duisburg Essen, Univ Hosp Essen, Inst Virol, Essen, Germany.
   [Paniskaki, Krystallenia; Babel, Nina] Ruhr Univ Bochum, Univ Hosp, Marien Hosp Herne, Ctr Translat Med,Med Dept 1, Herne, Germany.
   [Dolff, Sebastian; Witzke, Oliver] Univ Duisburg Essen, Univ Hosp Essen, West German Ctr Infect Dis, Dept Infect Dis, Essen, Germany.
   [Overbeck, Marvin; Limmer, Andreas; Brenner, Thorsten; Berger, Marc M.] Univ Duisburg Essen, Univ Hosp Essen, Dept Anesthesiol, Essen, Germany.
   [Liu, Jia; Zheng, Xin; Yang, Dongliang] Huazhong Univ Sci & Technol, Tonji Med Coll, Union Hosp, Dept Infect Dis, Wuhan, Peoples R China.
   [Sutter, Kathrin; Liu, Jia; Zheng, Xin; Trilling, Mirko; Lu, Mengji; Yang, Dongliang; Dittmer, Ulf; Zelinskyy, Gennadiy] HUST, Joint Int Lab Infect & Immun, Wuhan, Peoples R China.
   [Babel, Nina] Charite Univ Med Berlin, Berlin, Germany.
   [Babel, Nina] Free Univ Berlin, Berlin, Germany.
   [Babel, Nina] Humboldt Univ, Berlin, Germany.
   [Babel, Nina] Berlin Brandenburg Ctr Regenerat Therapies, Berlin Inst Hlth, Berlin, Germany.
   [Westhoff, Timm] Ruhr Univ Bochum, Univ Hosp, Marien Hosp Herne, Med Dept 1, Bochum, Germany.
RP Dittmer, U; Zelinskyy, G (corresponding author), Univ Duisburg Essen, Univ Hosp Essen, Inst Virol, Essen, Germany.; Dittmer, U; Zelinskyy, G (corresponding author), HUST, Joint Int Lab Infect & Immun, Wuhan, Peoples R China.
EM ulf.dittmer@uni-due.de; gennadiy.zelinskyy@uni-due.de
RI Lu, Mengji/ABF-9410-2020; Sutter, Kathrin/AAE-9019-2020
OI Sutter, Kathrin/0000-0001-6397-6551; Berger, Marc
   Moritz/0000-0001-6771-3193
FU Stiftung Universitatsmedizin Essen of University Hospital Essen
FX We are grateful to the Stiftung Universitatsmedizin Essen of University
   Hospital Essen for financial support of this study.
CR Anft M., 2020, ALLERGY IMMUNOL, DOI [10.1101/2020.04.28.20083089, DOI 10.1101/2020.04.28.20083089]
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chikuma S, 2009, J IMMUNOL, V182, P6682, DOI 10.4049/jimmunol.0900080
   David P, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008340
   David P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00054
   Di Cosimo S, 2020, EUR J CANCER, V135, P62, DOI 10.1016/j.ejca.2020.05.026
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Dietze KK, 2011, P NATL ACAD SCI USA, V108, P2420, DOI 10.1073/pnas.1015148108
   Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hasenkrug KJ, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006776
   Huppert FA, 1998, EXP GERONTOL, V33, P593, DOI 10.1016/S0531-5565(98)00033-3
   Jubel JM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00487
   Le Bert N, 2020, NATURE, DOI 10.1038/s41586-020-2550-z
   Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Liu K, 2020, J INFECTION, V80, pE14, DOI 10.1016/j.jinf.2020.03.005
   Malyshkina A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08578-7
   Melendi GA, 2007, J VIROL, V81, P11461, DOI 10.1128/JVI.02423-06
   Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
   Nie S, 2020, METABOLIC DISTURBANC, DOI [10.1101/2020.03.24.20042283, DOI 10.1101/2020.03.24.20042283]
   Odak I, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102885
   Phetsouphanh C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01729
   Schmidt ME, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00678
   Simon S, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1364828
   Snow AL, 2010, IMMUNOL REV, V236, P68, DOI 10.1111/j.1600-065X.2010.00917.x
   Thieme C. J., 2020, SARS COV 2 T CELL IM, DOI [10.1101/2020.05.13.20100636, DOI 10.1101/2020.05.13.20100636]
   Topham DJ, 1997, J IMMUNOL, V159, P5197
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Vicente R, 2016, AGING CELL, V15, P400, DOI 10.1111/acel.12455
   Voskoboinik I, 2015, NAT REV IMMUNOL, V15, P388, DOI 10.1038/nri3839
   Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071
   Wiesel M, 2009, APMIS, V117, P356, DOI 10.1111/j.1600-0463.2009.02459.x
   Xu WL, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081742
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zelinskyy G, 2011, J IMMUNOL, V187, P3730, DOI 10.4049/jimmunol.1101612
NR 38
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD SEP-OCT
PY 2020
VL 11
IS 5
AR e02243-20
DI 10.1128/mBio.02243-20
PG 13
WC Microbiology
SC Microbiology
GA OC9VF
UT WOS:000579503600067
PM 32948688
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ye, CJ
   Chiem, K
   Park, JG
   Oladunni, F
   Platt, RN
   Anderson, T
   Almazan, F
   de la Torre, JC
   Martinez-Sobrido, L
AF Ye, Chengjin
   Chiem, Kevin
   Park, Jun-Gyu
   Oladunni, Fatai
   Platt, Roy Neal, II
   Anderson, Tim
   Almazan, Fernando
   de la Torre, Juan Carlos
   Martinez-Sobrido, Luis
TI Rescue of SARS-CoV-2 from a Single Bacterial Artificial Chromosome
SO MBIO
LA English
DT Article
DE BAC; COVID-19; SARS-CoV-2; coronavirus; hamsters; recombinant virus;
   reverse genetics
ID VIRUS; CORONAVIRUS; RNA; GENOME
AB Infectious coronavirus (CoV) disease 2019 (COVID-19) emerged in the city of Wuhan (China) in December 2019, causing a pandemic that has dramatically impacted public health and socioeconomic activities worldwide. A previously unknown coronavirus, severe acute respiratory syndrome CoV-2 (SARS-CoV-2), has been identified as the causative agent of COVID-19. To date, there are no U.S. Food and Drug Administration (FDA)-approved vaccines or therapeutics available for the prevention or treatment of SARS-CoV-2 infection and/or associated COVID-19 disease, which has triggered a large influx of scientific efforts to develop countermeasures to control SARS-CoV-2 spread. To contribute to these efforts, we have developed an infectious cDNA clone of the SARS-CoV-2 USA-WA1/2020 strain based on the use of a bacterial artificial chromosome (BAC). Recombinant SARS-CoV-2 (rSARS-CoV-2) was readily rescued by transfection of the BAC into Vero E6 cells. Importantly, BAC-derived rSARS-CoV-2 exhibited growth properties and plaque sizes in cultured cells comparable to those of the natural SARS-CoV-2 isolate. Likewise, rSARS-CoV-2 showed levels of replication similar to those of the natural isolate in nasal turbinates and lungs of infected golden Syrian hamsters. This is, to our knowledge, the first BAC-based reverse genetics system for the generation of infectious rSARS-CoV-2 that displays features in vivo similar to those of a natural viral isolate. This SARS-CoV-2 BAC-based reverse genetics will facilitate studies addressing several important questions in the biology of SARS-CoV-2, as well as the identification of antivirals and development of vaccines for the treatment of SARS-CoV-2 infection and associated COVID-19 disease.
   IMPORTANCE The pandemic coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome CoV-2 (SARS-CoV-2) is a major threat to global human health. To date, there are no approved prophylactics or therapeutics available for COVID-19. Reverse genetics is a powerful approach to understand factors involved in viral pathogenesis, antiviral screening, and vaccine development. In this study, we describe the feasibility of generating recombinant SARS-CoV-2 (rSARS-CoV-2) by transfection of a single bacterial artificial chromosome (BAC). Importantly, rSARS-CoV-2 possesses the same phenotype as the natural isolate in vitro and in vivo. This is the first description of a BAC-based reverse genetics system for SARS-CoV-2 and the first time that an rSARS-CoV-2 isolate has been shown to be phenotypically identical to a natural isolate in a validated animal model of SARS-CoV-2 infection. The BAC-based reverse genetics approach will facilitate the study of SARS-CoV-2 and the development of prophylactics and therapeutics for the treatment of COVID-19.
C1 [Ye, Chengjin; Chiem, Kevin; Park, Jun-Gyu; Oladunni, Fatai; Platt, Roy Neal, II; Anderson, Tim; Martinez-Sobrido, Luis] Texas Biomed Res Inst, San Antonio, TX 78227 USA.
   [Oladunni, Fatai] Univ Ilorin, Dept Vet Microbiol, Ilorin, Nigeria.
   [Almazan, Fernando] CSIC, Dept Mol & Cell Biol, Ctr Nacl Biotecnol CNB, Madrid, Spain.
   [de la Torre, Juan Carlos] Scripps Res Inst, Dept Immunol & Microbiol, La Jolla, CA USA.
RP Martinez-Sobrido, L (corresponding author), Texas Biomed Res Inst, San Antonio, TX 78227 USA.
EM lmartinez@txbiomed.org
RI Almazan, Fernando/K-8781-2015
OI Almazan, Fernando/0000-0002-5752-8469; Martinez-Sobrido,
   Luis/0000-0001-7084-0804
CR Almazan F, 2000, P NATL ACAD SCI USA, V97, P5516, DOI 10.1073/pnas.97.10.5516
   Almazan F, 2013, MBIO, V4, DOI 10.1128/mBio.00650-13
   Avila-Perez G, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57545-2
   Avila-Perez G, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56291-4
   Avila-Perez G, 2019, JOVE-J VIS EXP, DOI 10.3791/59537
   AVILAPEREZ G, 2018, VIRUSES-BASEL, V10, DOI DOI 10.3390/V10110597
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Cheng BYH, 2013, JOVE-J VIS EXP, DOI 10.3791/50662
   Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695
   Ciotti M, 2020, CHEMOTHERAPY, V64, P215, DOI [10.1159/000507423, 10.1080/10408363.2020.1783198]
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Jensen EC, 2013, ANAT REC, V296, P378, DOI 10.1002/ar.22641
   Jones L, 2020, CONTACT LENS ANTERIO, V43, P196, DOI 10.1016/j.clae.2020.03.012
   Khan S, 2020, CLIN MICROBIOL INFEC, V26, P399, DOI 10.1016/j.cmi.2020.02.005
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lopez-Ortiz E, 2020, GAC MED MEX, V156, P132, DOI 10.24875/GMM.M20000346
   Marquez-Jurado S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10100547
   Martinez-Sobrido L, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030258
   Nogales A, 2014, J VIROL, V88, P10525, DOI 10.1128/JVI.01565-14
   Pedersen BS, 2018, BIOINFORMATICS, V34, P867, DOI 10.1093/bioinformatics/btx699
   Polo S, 1997, J VIROL, V71, P5366, DOI 10.1128/JVI.71.7.5366-5374.1997
   Pu SY, 2011, J VIROL, V85, P2927, DOI 10.1128/JVI.01986-10
   Qian X, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00650-1
   Qin JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010611
   Ralph R, 2020, J INFECT DEV COUNTR, V14, P3, DOI 10.3855/jidc.12425
   Roberts A, 2005, J VIROL, V79, P503, DOI 10.1128/JVI.79.1.503-511.2005
   Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   St-Jean JR, 2006, J VIROL, V80, P3670, DOI 10.1128/JVI.80.7.3670-3674.2006
   Stoye Emma, 2020, Nature, DOI 10.1038/d41586-020-01048-7
   SUMIYOSHI H, 1992, J VIROL, V66, P5425, DOI 10.1128/JVI.66.9.5425-5431.1992
   Thao TTN, 2020, NATURE, V582, P561, DOI 10.1038/s41586-020-2294-9
   Tsetsarkin KA, 2016, MBIO, V7, DOI 10.1128/mBio.01114-16
   Vellingiri B, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138277
   Wilm A, 2012, NUCLEIC ACIDS RES, V40, P11189, DOI 10.1093/nar/gks918
   Xie XP, 2020, CELL HOST MICROBE, V27, P841, DOI 10.1016/j.chom.2020.04.004
   Ye Chengjin, 2020, Curr Opin Virol, V44, P66, DOI 10.1016/j.coviro.2020.06.011
NR 38
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 2150-7511
J9 MBIO
JI mBio
PD SEP-OCT
PY 2020
VL 11
IS 5
AR e02168-20
DI 10.1128/mBio.02168-20
PG 10
WC Microbiology
SC Microbiology
GA OC9VF
UT WOS:000579503600063
PM 32978313
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kipshidze, N
   Yeo, NI
   Kipshidze, N
AF Kipshidze, Nicholas
   Yeo, Nicholas
   Kipshidze, Nodar
TI Photodynamic and sonodynamic therapy of acute hypoxemic respiratory
   failure in patients with COVID-19
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Letter
C1 [Kipshidze, Nicholas] New York Cardiovasc Res, New York, NY 10019 USA.
   [Yeo, Nicholas] UCL Sch Pharm, London, England.
   [Kipshidze, Nodar] NYU Langone Hlth, New York, NY USA.
RP Kipshidze, N (corresponding author), New York Cardiovasc Res, New York, NY 10019 USA.
EM nicholas02@msn.com
CR Beigel J.H., 2020, N ENGL J MED, P22
   Dondorp AMHM, 2020, AM J TROP MED HYG, DOI 10.4269/ajtmh20-0283
   Kharkwal GB, 2011, LASER SURG MED, V43, P755, DOI 10.1002/lsm.21080
   Liu W, 2020, B ENG GEOL ENVIRON, V79, P2189, DOI 10.1007/s10064-019-01717-6
   Majiya H, 2018, J PHOTOCH PHOTOBIO B, V189, P87, DOI 10.1016/j.jphotobiol.2018.10.009
   Marini J. J., 2020, JAMA
   MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x
   Patel BK, 2020, JAMA-J AM MED ASSOC, V324, P43, DOI 10.1001/jama.2020.9611
   Read R.J., 2020, PREPRINT
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Richardson S., 2020, JAMA
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Slutsky AS, 2013, NEW ENGL J MED, V369, P2126, DOI 10.1056/NEJMra1208707
   von Tappeiner H., 1900, MUNCHEN MED WOCHEN, V47, P5
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wiehe A, 2019, PHOTOCH PHOTOBIO SCI, V18, P2565, DOI 10.1039/c9pp00211a
   Wiersinga WJ, 2020, JAMA-J AM MED ASSOC, V324, P782, DOI 10.1001/jama.2020.12839
   Young BE, 2020, JAMA
NR 18
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD SEP
PY 2020
VL 31
AR 101961
DI 10.1016/j.pdpdt.2020.101961
PG 2
WC Oncology
SC Oncology
GA NZ2QS
UT WOS:000576941800005
PM 32818638
OA Green Published
DA 2021-01-01
ER

PT J
AU Moghissi, K
   Dixon, K
   Gibbins, S
AF Moghissi, K.
   Dixon, Kate
   Gibbins, Sally
TI Does PDT have potential in the treatment of COVID 19 patients?
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE PDT, Respiratory infection; Nebulizer; Respiratory tract; COVID 19
   respiratory infection; Photodynamic Therapy
AB The corona virus pandemic has ignited a proliferation of research aimed at prevention of spread, early diagnosis and treatment.
   Coincidentally, in recent years the Yorkshire Laser Centre has been engaged in developing the methodology of applying PDT in chronic bronchiectasis. Our methodology is based on Methylene Blue (MB) mediated PDT used topically within the airway.
   The novelty of the method is the use of a nebulizer to deliver the photosensitizer.
   We suggest that our protocol and methodology could be modulated for use in respiratory infections of COVID-19.
C1 [Moghissi, K.; Dixon, Kate; Gibbins, Sally] Goole & Dist Hosp, Yorkshire Laser Ctr, Goole DN14 6RX, England.
RP Dixon, K (corresponding author), Goole & Dist Hosp, Yorkshire Laser Ctr, Goole DN14 6RX, England.
EM kdixon@yorkshirelasercentre.org
CR Acter T, 2020, SCI TOTAL ENVIRON, V730, DOI 10.1016/j.scitotenv.2020.138996
   Amawi H, 2020, THER DELIV, V11, P245, DOI 10.4155/tde-2020-0035
   Dhama K, 2020, TRAVEL MED INFECT DI, V37, DOI 10.1016/j.tmaid.2020.101755
   Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P404, DOI 10.1016/j.jmii.2020.02.012
   Moghissi K, 2015, SURG J-NY, V1, pE1, DOI 10.1055/s-0035-1565246
   Moghissi K, 2019, PHOTODIAGN PHOTODYN, V27, pA3, DOI 10.1016/j.pdpdt.2019.04.029
   Renwick M. J., 2016, HLTH POLICY SERIES, V45
   Tobaiqy M, 2020, INFECT PREVENTION PR, V100061, DOI [10.1016/j.infpip.2020.100061, DOI 10.1016/J.INFPIP.2020.100061]
   Wainwright M, 2009, PHOTODIAGN PHOTODYN, V6, P167, DOI 10.1016/j.pdpdt.2009.10.007
NR 9
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD SEP
PY 2020
VL 31
AR 101889
DI 10.1016/j.pdpdt.2020.101889
PG 2
WC Oncology
SC Oncology
GA NZ2QS
UT WOS:000576941800009
PM 32592911
OA Green Published
DA 2021-01-01
ER

PT J
AU Politano, G
   Benso, A
AF Politano, Gianfranco
   Benso, Alfredo
TI IL6-mediated HCoV-host interactome regulatory network and GO/Pathway
   enrichment analysis
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID DISCOVERY
AB Author summary In this paper we provide data about the HCoV-host interactome that can be extracted from the integration of several public available databases. We used the initial interactome published by Zhou et al. and analyzed if there are already known and validated interactions. We also looked into possible known miRNAs and drugs interactions to suggest possible biomarker candidates and treatment options. We also performed a Gene Ontology and a Pathways enrichment analysis to understand which are the pathways most likely involved in the proteins targeted by SARS-CoV-2. This paper not only provides a set of validated and reliable data that could help researchers in their fight against the COVID-19 disease outbreak, but also demonstrates how Systems Biology can be effectively used to quickly gather preliminary but still significant data without resorting only to expensive lab experiments.
   During these days of global emergency for the COVID-19 disease outbreak, there is an urgency to share reliable information able to help worldwide life scientists to get better insights and make sense of the large amount of data currently available. In this study we used the results presented in [1] to perform two different Systems Biology analyses on the HCoV-host interactome. In the first one, we reconstructed the interactome of the HCoV-host proteins, integrating it with highly reliable miRNA and drug interactions information. We then added the IL-6 gene, identified in recent publications [2] as heavily involved in the COVID-19 progression and, interestingly, we identified several interactions with the reconstructed interactome. In the second analysis, we performed a Gene Ontology and a Pathways enrichment analysis on the full set of the HCoV-host interactome proteins and on the ones belonging to a significantly dense cluster of interacting proteins identified in the first analysis. Results of the two analyses provide a compact but comprehensive glance on some of the current state-of-the-art regulations, GO, and pathways involved in the HCoV-host interactome, and that could support all scientists currently focusing on SARS-CoV-2 research.
C1 [Politano, Gianfranco; Benso, Alfredo] Politecn Torino, Comp Sci & Automat Dept, Turin, Italy.
RP Benso, A (corresponding author), Politecn Torino, Comp Sci & Automat Dept, Turin, Italy.
EM alfredo.benso@polito.it
CR [Anonymous], 2019, CIRCULATION, V2019
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Chau DHW, 2007, APOPTOSIS, V12, P513, DOI 10.1007/s10495-006-0013-0
   Chen X., 2020, DETECTABLE SERUM SAR
   Cotto Kelsy C, 2018, Nucleic Acids Res, V46, pD1068, DOI 10.1093/nar/gkx1143
   Gu J., 2020, GASTROENTEROLOGY
   Henke A, 2000, J VIROL, V74, P4284, DOI 10.1128/JVI.74.9.4284-4290.2000
   Hinske LCG, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-533
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Licata L, 2020, NUCLEIC ACIDS RES, V48, pD504, DOI 10.1093/nar/gkz949
   NCBI Resource Coordinators, 2018, NUCLEIC ACIDS RES, V46, pD8
   Poortahmasebi V, 2016, HEPAT MON, V16, DOI 10.5812/hepatmon.36005
   Rajan Rajesh, 2020, CARDIOVASCULAR COMPL
   Slenter DN, 2018, NUCLEIC ACIDS RES, V46, pD661, DOI 10.1093/nar/gkx1064
   Team R Core, 2016, R FDN STAT COMP
   Waxman AB, 2009, AM J RESP CELL MOL, V41, P385, DOI 10.1165/rcmb.2008-0302OC
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wu XW, 2002, FRONT BIOSCI, V7, pD151, DOI 10.2741/wu1
   Zeng JH, 2020, 1 CASE COVID 19 INFE, V2020
   Zhou Y, 2020, NATL SCI REV
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 23
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-734X
EI 1553-7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD SEP
PY 2020
VL 16
IS 9
AR e1008238
DI 10.1371/journal.pcbi.1008238
PG 8
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA NZ4TA
UT WOS:000577087300004
PM 32997660
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gray, CM
   Peter, J
   Mendelson, M
   Madhi, SA
   Blackburn, JM
AF Gray, C. M.
   Peter, J.
   Mendelson, M.
   Madhi, S. A.
   Blackburn, J. M.
TI COVID-19 antibody testing: From hype to immunological reality
SO SAMJ SOUTH AFRICAN MEDICAL JOURNAL
LA English
DT Article
AB The potential role for serological tests in the current COVID-19 pandemic has generated very considerable recent interest across many sectors worldwide, inter alia pathologists seeking additional weapons for their armoury of diagnostic tests; epidemiologists seeking tools to gain seroprevalence data that will inform improved models of the spread of disease; research scientists seeking tools to study the natural history of COVID-19 disease; vaccine developers seeking tools to assess vaccine efficacy in clinical trials; and companies and governments seeking tools to aid return-to-work decision-making. However, much of the local debate to date has centred on questions surrounding whether regulatory approval processes are limiting access to serological tests, and has not paused to consider the intrinsically limiting impact of underlying fundamental biology and immunology on where and how different COVID-19 serological tests can usefully be deployed in the response to the current pandemic. We review, from an immunological perspective, recent experimental evidence on the time-dependency of adaptive immune responses following SARS-CoV-2 infection and the impact of this on the sensitivity and specificity of COVID-19 antibody tests made at different time points post infection. We interpret this scientific evidence in terms of mooted clinical applications for current COVID-19 antibody tests in identifying acute infections, in confirming recent or past infections at the individual and population level, and in detecting re-infection and protective immunity. We conclude with guidance on where current COVID-19 antibody tests can make a genuine impact in the pandemic.
C1 [Gray, C. M.; Blackburn, J. M.] Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, Rondebosch, South Africa.
   [Gray, C. M.] Univ Cape Town, Fac Hlth Sci, Dept Pathol, Div Immunol, Rondebosch, South Africa.
   [Gray, C. M.] Univ Cape Town, Fac Hlth Sci, Natl Hlth Lab Serv, Rondebosch, South Africa.
   [Peter, J.] Univ Cape Town, Fac Hlth Sci, Dept Med, Div Allergy & Clin Immunol, Rondebosch, South Africa.
   [Mendelson, M.] Univ Cape Town, Groote Schuur Hosp, Dept Med, Div Infect Dis & HIV Med, Rondebosch, South Africa.
   [Mendelson, M.] Univ Cape Town, Fac Hlth Sci, Rondebosch, South Africa.
   [Madhi, S. A.] Univ Witwatersrand, MRC Vaccines & Infect Dis Analyt Res Unit, Johannesburg, South Africa.
   [Blackburn, J. M.] Univ Cape Town, Fac Hlth Sci, Dept Integrat Biomed Sci, Div Chem & Syst Biol, Rondebosch, South Africa.
RP Blackburn, JM (corresponding author), Univ Cape Town, Fac Hlth Sci, Inst Infect Dis & Mol Med, Rondebosch, South Africa.; Blackburn, JM (corresponding author), Univ Cape Town, Fac Hlth Sci, Dept Integrat Biomed Sci, Div Chem & Syst Biol, Rondebosch, South Africa.
EM jonathan.blackburn@uct.ac.za
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01AI135937-01,
   R01HD102050-01, 1U01AI131302-01, K43TW011178-02]; European Developing
   Clinical Trials Partnership; SA National Research Foundation; Medical
   Research CouncilMedical Research Council UK (MRC); National Research
   Foundation
FX CMG receives financial support from the National Institutes of Health,
   awards R01HD102050-01 and 1U01AI131302-01. JP receives financial support
   from the National Institutes of Health, award K43TW011178-02, the
   European Developing Clinical Trials Partnership and the SA National
   Research Foundation and Medical Research Council. JMB thanks the
   National Research Foundation for a SARChI grant and receives financial
   support from the National Institutes of Health, award R01AI135937-01.
CR Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   Bastos ML, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2516
   Edridge AWD, 2020, CORONAVIRUS PROTECTI, DOI [10.1101/2020.05.11.20086439, DOI 10.1101/2020.05.11.20086439]
   Feldstein LR, 2020, NEW ENGL J MED, V383, P334, DOI 10.1056/NEJMoa2021680
   Fierz W, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01120
   FIND, 2020, SARS COV 2 DIAGN PIP
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
   Kew G, 2020, DAILY MAVERICK
   Lee CYP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00879
   Leung DTM, 2004, J INFECT DIS, V190, P379, DOI 10.1086/422040
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Mo HY, 2006, RESPIROLOGY, V11, P49, DOI 10.1111/j.1440-1843.2006.00783.x
   Muruato Antonio E, 2020, bioRxiv, DOI 10.1101/2020.05.21.109546
   Ng K., 2020, PREEXISTING NOVO HUM, V15, DOI [10.1101/2020.05.14.095414, DOI 10.1101/2020.05.14.095414]
   Pollan M, 2020, LANCET, V396, P535, DOI 10.1016/S0140-6736(20)31483-5
   Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9
   Rosenberg E.S., 2020, CUMULATIVE INCIDENCE, DOI [10.1101/2020.05.25.20113050, DOI 10.1101/2020.05.25.20113050]
   Sekine T, 2020, ROBUST T CELL IMMUNI, DOI [10.1101/2020.06.29.174888, DOI 10.1101/2020.06.29.174888]
   Seow G., 2020, LONGITUDINAL EVALUAT, DOI [10.1101/2020.07.09.20148429., 10.1101/2020.07.09.20148429, DOI 10.1101/2020.07.09.20148429]
   South African Health Products Authority (SAHPRA), 2020, SPEC CRIT COVID 19 S
   Vardas E, 2020, DAILY MAVERICK
   Wang J, 2020, J CLIN TRANSL SCI, P1, DOI [DOI 10.1017/CTS.2020.39, 10.1017/cts.2020.39]
   Wang Xiaoli, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa721
   Weinstein MC, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2017739
   WHO, 2020, ADV US POINT CAR IMM
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
NR 27
TC 1
Z9 1
U1 1
U2 1
PU SA MEDICAL ASSOC
PI PRETORIA
PA BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
   PRETORIA, 0002, SOUTH AFRICA
SN 0256-9574
EI 2078-5135
J9 SAMJ S AFR MED J
JI SAMJ S. Afr. Med. J.
PD SEP
PY 2020
VL 110
IS 9
BP 837
EP 841
DI 10.7196/SAMJ.2020.v110i9.15155
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA NZ4WQ
UT WOS:000577097500009
PM 32880263
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Mayne, ES
   Scott, L
   Semete, B
   Julsing, A
   Jugwanth, S
   Mampeule, N
   David, A
   Gededzha, MP
   Goga, A
   Hardie, D
   Preiser, W
   Chetty, K
   Rees, H
   Sanne, I
   Mlisana, K
   George, JA
   Stevens, W
AF Mayne, E. S.
   Scott, L.
   Semete, B.
   Julsing, A.
   Jugwanth, S.
   Mampeule, N.
   David, A.
   Gededzha, M. P.
   Goga, A.
   Hardie, D.
   Preiser, W.
   Chetty, K.
   Rees, H.
   Sanne, I
   Mlisana, K.
   George, J. A.
   Stevens, W.
TI The role of serological testing in the SARS-CoV-2 outbreak
SO SAMJ SOUTH AFRICAN MEDICAL JOURNAL
LA English
DT Article
ID COVID-19
AB Antibody tests for the novel coronavirus, SARS-CoV2, have been developed both as rapid diagnostic assays and for high-throughput formal serology platforms. Although these tests may be a useful adjunct to a diagnostic strategy, they have a number of limitations. Because of the antibody and viral dynamics of the coronavirus, their sensitivity can be variable, especially at early time points after symptom onset. Additional data are required on the performance of the tests in the South African population, especially with regard to development and persistence of antibody responses and whether antibodies are protective against reinfection. These tests may, however, be useful in guiding the public health response, providing data for research (including seroprevalence surveys and vaccine initiatives) and development of therapeutic strategies.
C1 [Mayne, E. S.; Jugwanth, S.; Mampeule, N.; Gededzha, M. P.] Univ Witwatersrand, Fac Hlth Sci, Dept Immunol, Johannesburg, South Africa.
   [Mayne, E. S.; Scott, L.; Jugwanth, S.; Mampeule, N.; Gededzha, M. P.; Hardie, D.; Preiser, W.; Chetty, K.; Mlisana, K.; Stevens, W.] Natl Hlth Lab Serv, Johannesburg, South Africa.
   [Scott, L.; David, A.; Stevens, W.] Univ Witwatersrand, Fac Hlth Sci, Dept Mol Med & Haematol, Johannesburg, South Africa.
   [Semete, B.; Julsing, A.] South African Hlth Prod Regulatory Author, Pretoria, South Africa.
   [Goga, A.] South African Med Res Council, Pretoria, South Africa.
   [Goga, A.] Univ Pretoria, Steve Biko Hosp, Dept Paediat, Pretoria, South Africa.
   [Goga, A.] Univ Pretoria, Fac Hlth Sci, Sch Med, Pretoria, South Africa.
   [Hardie, D.] Univ Cape Town, Fac Hlth Sci, Dept Med Virol, Rondebosch, South Africa.
   [Preiser, W.] Stellenbosch Univ, Fac Med & Hlth Sci, Div Med Virol, Cape Town, South Africa.
   [Rees, H.] Univ Witwatersrand, Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa.
   [Sanne, I] Univ Witwatersrand, Fac Hlth Sci, Dept Med, Clin HIV Res Unit, Johannesburg, South Africa.
   [George, J. A.] Univ Witwatersrand, Fac Hlth Sci, Dept Chem Pathol, Johannesburg, South Africa.
RP Mayne, ES (corresponding author), Univ Witwatersrand, Fac Hlth Sci, Dept Immunol, Johannesburg, South Africa.; Mayne, ES (corresponding author), Natl Hlth Lab Serv, Johannesburg, South Africa.
EM elizabeth.mayne@nhls.ac.za
RI Sanne, Ian/ABH-2231-2020; Mlisana, Koleka/N-6204-2013
OI Mlisana, Koleka/0000-0002-8436-3268; Gededzha, Maemu/0000-0003-0686-1293
FU EQUIP grant [AID-OAA-A-15-00070]; iLEAD BMGF (i-LEAD) grant [OPP1171455]
FX EQUIP grant AID-OAA-A-15-00070 - Antiretroviral Therapy
   Simplification-Optimization of Programs and Services (ART-OPS) COVID
   supplement, and through iLEAD BMGF (i-LEAD) grant ID OPP1171455.
CR Adhikari SP, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00646-x
   Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5
   Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   Bryan A, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00941-20
   Chen YX, 2020, J INFECTION, V81, P420, DOI 10.1016/j.jinf.2020.05.067
   Ebrahim SH, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1066
   Evelyne B, 2020, SWISS MED WKLY, V150, DOI 10.4414/smw.2020.20216
   Furukawa Nathan W, 2020, Emerg Infect Dis, V26, DOI 10.3201/eid2607.201595
   Gupta Nivedita, 2020, Indian J Med Res, V151, P210, DOI 10.4103/ijmr.IJMR_1166_20
   Hijnen D, 2020, EMERG INFECT DIS, V26, P1935, DOI 10.3201/eid2608.201235
   Huang Angkana T, 2020, medRxiv, DOI 10.1101/2020.04.14.20065771
   IACOBUCCI G, 2020, BMJ-BRIT MED J, V369, P76638, DOI DOI 10.1136/BMJ.M1845
   IACOBUCCI G, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1118
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Kontou PI, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10050319
   Korth J, 2020, J CLIN VIROL, V128
   Kruttgen A, 2020, J CLIN VIROL, V128
   Lake MA, 2020, CLIN MED, V20, P124, DOI 10.7861/clinmed.2019-coron
   Law SK, 2020, HONG KONG MED J, V26, P264, DOI 10.12809/hkmj208601
   Lee CYP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00879
   Li P, 2020, INT J INFECT DIS, V96, P452, DOI 10.1016/j.ijid.2020.03.027
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1063, DOI 10.1515/cclm-2020-0240
   Liu WD, 2020, J INFECTION, V81, P329, DOI 10.1016/j.jinf.2020.03.063
   Liu YJ, 2020, J FORMOS MED ASSOC, V119, P1555, DOI 10.1016/j.jfma.2020.05.004
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Lu YY, 2020, PEDIATR INFECT DIS J, V39, pE95, DOI 10.1097/INF.0000000000002729
   Ma LXX, 2020, J CLIN ONCOL, V38
   MAHASE E, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M2066
   Montesinos I, 2020, J CLIN VIROL, V128
   Ong J, 2020, GUT, V69, P1144, DOI [10.1136/gutjnl-2020-321051, 10.1136/gutjnl-2020-321154]
   Parodi SM, 2020, JAMA-J AM MED ASSOC, V323, P1441, DOI 10.1001/jama.2020.3882
   Qi L, 2020, INT J INFECT DIS, V96, P531, DOI 10.1016/j.ijid.2020.05.045
   Siedner Mark J, 2020, medRxiv, DOI 10.1101/2020.05.15.20103226
   Slifka MK, 2020, ARCH PATHOL LAB MED, V144, P1161, DOI 10.5858/arpa.2020-0255-LE
   Stowell SR, 2020, CLIN INFECT DIS, V71, P1935, DOI 10.1093/cid/ciaa510
   Tang YW, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00512-20
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Traugott M, 2020, J INFECT DIS, V222, P362, DOI 10.1093/infdis/jiaa305
   Widders A, 2020, INFECT DIS HEALTH, V25, P210, DOI 10.1016/j.idh.2020.05.002
   Winter AK, 2020, LANCET INFECT DIS, V20, P758, DOI 10.1016/S1473-3099(20)30322-4
   Xu X, 2020, NAT MED, V26, P1193, DOI 10.1038/s41591-020-0949-6
   Yu Pin, 2020, Animal Model Exp Med, V3, P93, DOI 10.1002/ame2.12108
   Zeng QL, 2020, J INFECT DIS, V222, P38, DOI 10.1093/infdis/jiaa228
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhang WW, 2020, EMERG INFECT DIS, V26, P1924, DOI 10.3201/eid2608.201142
   Zhang YC, 2020, EMERG MICROBES INFEC, V9, P833, DOI 10.1080/22221751.2020.1756699
NR 46
TC 0
Z9 0
U1 2
U2 2
PU SA MEDICAL ASSOC
PI PRETORIA
PA BLOCK F CASTLE WALK CORPORATE PARK, NOSSOB STREET, ERASMUSKLOOF EXT3,
   PRETORIA, 0002, SOUTH AFRICA
SN 0256-9574
EI 2078-5135
J9 SAMJ S AFR MED J
JI SAMJ S. Afr. Med. J.
PD SEP
PY 2020
VL 110
IS 9
BP 842
EP 845
DI 10.7196/SAMJ.2020.v110i9.15098
PG 4
WC Medicine, General & Internal
SC General & Internal Medicine
GA NZ4WQ
UT WOS:000577097500010
PM 32880264
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Zha, LL
   Xu, X
   Wang, DY
   Qiao, GB
   Zhuang, WT
   Huang, SJ
AF Zha, Lulu
   Xu, Xi
   Wang, Dongya
   Qiao, Guibin
   Zhuang, Weitao
   Huang, Shujie
TI Modified rehabilitation exercises for mild cases of COVID-19
SO ANNALS OF PALLIATIVE MEDICINE
LA English
DT Article
DE Coronavirus disease 2019 (COVTD-19); severe acute respiratory syndrome
   coronavirus 2 (SARS-CoV-2); rehabilitation; exercise therapy
AB Background: Coronavirus disease 2019 (COVID-19) caused by a new Betacoronavirus severe acute respiratory syndrome coronavirus 2 (SA RS-CoV-2) is currently a global pandemic. Gathered clinicopathological evidence in COVID-19 patients shows that alveoli injuries and interstitial changes are the major mechanisms of impaired 02/CO2 exchange. Few rehabilitation exercises concerning COVID-19 patients were reported. Here, we present a modified version of rehabilitation exercises based on the underlying mechanism of the disease to mild cases of COVID-19. These exercises aimed to improve the pulmonary function of patients and ease the expectoration process. Additionally, an essential branch of Traditional Chinese Medicine (TCM) named acupressure was integrated into the exercises to facilitate the recovery and maintenance of pulmonary function.
   Methods: From March 4, 2020 to May 5, 2020, a total of 60 COVID-19 patients who completed the full course of MRF. were enrolled in this observational study The diagnostic and classification criteria were based on the 7th edition of Diagnosis and Treatment Guideline of COVID-19 published by the National Health Commission of the People's Republic of China. We prospectively gathered patients' reported outcomes concerning respiration-related symptoms at four different time points, including: (I) at admission; (II) at the time of hospital discharge; (III) two weeks after discharge; (TV) four weeks after discharge. The reported respiratory symptoms included dry cough, productive cough, difficulty in expectoration, and dyspnea.
   Results: In total, 60 confirmed mild COVID-19 cases were enrolled with a median age of 54 years old. The baseline prevalence for dry cough, productive cough, difficulty in expectoration, and dyspnea were 41.7%, 43.3%, 35.0%, and 50.0%, respectively. The pronounced decline in symptom prevalence was recorded over time. Interestingly, four weeks after discharge, we noticed a lower remission rate in productive cough and difficulty in expectoration.
   Conclusions: The modified rehabilitation exercises were retrieved from the Eight-Sertion Brocade, and are specifically designed for rehabilitation of COVID-19 patients at home or health facilities. Based on current findings on pronouncedly improved remission rate in respiratory- symptoms, we recommend the M as suitable rehabilitation exercise to smooth respiration and case the expectoration process in mild COVID-19 cases.
C1 [Zha, Lulu; Xu, Xi; Wang, Dongya] Gen Hosp Southern Theater Command, Chinese Peoples Liberat Army, Guangzhou, Peoples R China.
   [Zha, Lulu; Xu, Xi; Wang, Dongya] Huoshenshan Hosp, Wuhan, Peoples R China.
   [Qiao, Guibin; Zhuang, Weitao; Huang, Shujie] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Thorac Surg, 106 Zhongshan Second Rd, Guangzhou, Peoples R China.
   [Qiao, Guibin; Zhuang, Weitao; Huang, Shujie] Shantou Univ, Med Coll, Shantou, Peoples R China.
RP Zhuang, WT; Huang, SJ (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Thorac Surg, 106 Zhongshan Second Rd, Guangzhou, Peoples R China.
EM wtzhuang1@163.com; 15sjhuang2@stu.edu.cn
CR Cecins N, 2017, CHRON RESP DIS, V14, P3, DOI 10.1177/1479972316654287
   Greening NJ, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4315
   Khanghah AG, 2019, J ACUPUNCT MERIDIAN, V12, P103, DOI 10.1016/j.jams.2019.07.003
   Klijn P, 2013, AM J RESP CRIT CARE, V188, P193, DOI 10.1164/rccm.201210-1829OC
   Lopez-Lopez L, 2019, CLIN REHABIL, V33, P1757, DOI 10.1177/0269215519859930
   Lv W, 2019, FRONT PSYCHOL, V10, DOI 10.3389/fpsyg.2019.02348
   National Health Commission of People's Republic of China, 2020, DIAGN TREATM GUID CO
   Pan YY, 2020, EUR RADIOL, V30, P3306, DOI 10.1007/s00330-020-06731-x
   van der Lee L, 2018, AUST CRIT CARE, V31, P349, DOI 10.1016/j.aucc.2017.10.001
   Wang Fang, 2008, J Tradit Chin Med, V28, P101
   World Health Organization, 2020, 11 WHO
   World Health Organization, 2020, COR DIS COVID 19 OUT
   World Health Organization, 2002, 51 WHO
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhao W, 2020, AM J ROENTGENOL, V214, P1072, DOI 10.2214/AJR.20.22976
   Zhu YR, 2020, SURG INFECT, DOI 10.1089/sur.2019.355
NR 17
TC 0
Z9 0
U1 1
U2 1
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2224-5820
EI 2224-5839
J9 ANN PALLIAT MED
JI Ann. Pallliat. Med.
PD SEP
PY 2020
VL 9
IS 5
BP 3100
EP 3106
DI 10.21037/apm-20-753
PG 7
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA NY8YP
UT WOS:000576670500075
PM 32787373
OA Other Gold
DA 2021-01-01
ER

PT J
AU Guo, H
   Zheng, JY
   Huang, G
   Xiang, Y
   Lang, CH
   Li, BQ
   Huang, DQ
   Sun, QY
   Luo, YL
   Zhang, YL
   Huang, L
   Fang, W
   Zheng, Y
   Wan, SX
AF Guo, Hu
   Zheng, Jiangyuan
   Huang, Gu
   Xiang, Yi
   Lang, Chunhui
   Li, Boqun
   Huang, Daoqiu
   Sun, Qiuyan
   Luo, Yaling
   Zhang, Yulian
   Huang, Liang
   Fang, Wei
   Zheng, Yu
   Wan, Suxin
TI Xuebijing injection in the treatment of COVID-19: a retrospective
   case-control study
SO ANNALS OF PALLIATIVE MEDICINE
LA English
DT Article
DE Xuebijing injection; coronavirus disease 2019 (COVID-19); effect;
   interleukin 6 (IL-6)
ID PNEUMONIA
AB Background: Neither a vaccine nor specific therapeutic drugs against 2019 novel coronavirus have been developed. Some studies have shown that Xuebijing injection (XBJ) can exert an anti-inflammatory effect by inhibiting the production of interleukin-6 (IL-6), tumor necrosis factor alpha TNF-alpha), and other cytokines. This study aimed to investigate the effect of XBJ on coronavirus disease 2019 (COVID-19) and its effects on IL-6 and tumor necrosis alpha TNF-alpha.
   Methods: A total of 42 patients, who were diagnosed with COVID-19 and treated with XBJ combined with routine treatment at Chongqing University Three Gorges Hospital between January 20, 2020, and March 11, 2020, were selected as the observation group. A control group comprising 16 patients who received routine treatment was also established, and cases were matched from the observation group on a 1:1 basis according to age, comorbidities, and mild and severe disease. The clinical symptoms, laboratory test indexes, and changes in computed tomography (CT) scans of patients in the two groups were observed at the time of admission and 7 days after treatment, and the time taken for the patients to produce a negative nucleic acid test was also recorded.
   Results: There were no significant differences in baseline data between the two groups. After treatment, there were significant improvements in IL-6 levels and body temperature in the observation group as compared with the control group. Particularly in severe patients, the reduction in body temperature in the observation group was greater than that in the control group (P<0.05). A higher number of patients in the observation group showed improved CT imaging results compared with the control group, and the time taken to produce a negative nucleic acid test was shorter in the observation group than in the control group; however, the differences were not statistically significant (P>0.05). Furthermore, there were no significant differences in TNF-alpha and IL-10 between the two groups.
   Conclusions: The results of this study suggest that routine treatment combined with XBF can better improve the clinical outcomes of COVID-19 patients.
C1 [Guo, Hu; Huang, Gu; Li, Boqun; Huang, Daoqiu; Sun, Qiuyan; Zhang, Yulian; Fang, Wei; Wan, Suxin] Chongqing Univ, Three Gorges Hosp, Chongqing Three Gorges Cent Hosp, Pharmaceut Dept, Chongqing, Peoples R China.
   [Zheng, Jiangyuan; Luo, Yaling] Chongqing Med Univ, Coll Med Informat, Chongqing, Peoples R China.
   [Xiang, Yi] Chongqing Univ, Three Gorges Hosp, Chongqing Three Gorges Cent Hosp, Yu An Branch,Liver Ctr, Chongqing, Peoples R China.
   [Lang, Chunhui] Chongqing Univ, Three Gorges Hosp, Chongqing Three Gorges Cent Hosp, Res & Foreign Affairs Dept, Chongqing, Peoples R China.
   [Huang, Liang] Chongqing Univ, Cardiol Chongqing Three Gorges Cent Hosp, Three Gorges Hosp, Chongqing, Peoples R China.
   [Zheng, Yu] Chengdu Univ Tradit Chinese Med, Pharm Coll, Key Lab Standardizat Chinese Herbal Med,Key Lab B, Minist Educ,Key Lab Systemat Res Dev & Utilizat C, Chongqing, Peoples R China.
RP Fang, W; Wan, SX (corresponding author), Chongqing Univ, Three Gorges Hosp, Chongqing Three Gorges Cent Hosp, Pharmaceut Dept, Chongqing, Peoples R China.; Zheng, Y (corresponding author), Chengdu Univ Tradit Chinese Med, Pharm Coll, Key Lab Standardizat Chinese Herbal Med,Key Lab B, Minist Educ,Key Lab Systemat Res Dev & Utilizat C, Chongqing, Peoples R China.
EM 239491815@qq.com; yuzheng1@cdutcm.edu.cn; wansuxin@foxmail.com
FU National Social Science Foundation [15BGL191]
FX This work is supported by the National Social Science Foundation (No.
   15BGL191).
CR Arabi YM, 2018, TRIALS, V19, DOI 10.1186/s13063-017-2427-0
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen SG, 2016, AM J THER, V23, pE1819, DOI 10.1097/MJT.0000000000000296
   China Association Of Integrative Medicine Emergency Medicine Committee, 2019, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V31, P1317, DOI 10.3760/cma.j.issn.2095-4352.2019.11.002
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   General Office of the National Health and Family Planning Commission, 2020, CHIN J INTEGR TRADIT, P1
   Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   He XD, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/804940
   Huang YX, 2020, AGING-US, V12, P11224, DOI 10.18632/aging.103370
   Jiang M, 2013, J ETHNOPHARMACOL, V147, P426, DOI 10.1016/j.jep.2013.03.032
   LI C, 2020, WORLD SCI TECHNOLOGY, V28, P242
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li ST, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/2710782
   Long QX, 2020, NAT MED, V26, P1200, DOI 10.1038/s41591-020-0965-6
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Monteleone G, 2020, LANCET RHEUMATOL, V2, pE255, DOI 10.1016/S2665-9913(20)30092-8
   Organization WH, 2020, CLIN MAN SEV AC RESP
   Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
   Shi H, 2017, AM J EMERG MED, V35, P285, DOI 10.1016/j.ajem.2016.11.007
   Song YL, 2019, CRIT CARE MED, V47, pE735, DOI 10.1097/CCM.0000000000003842
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Wan SX, 2020, BRIT J HAEMATOL, V189, P428, DOI 10.1111/bjh.16659
   Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783
   Wang Q, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/860259
   Wang YP, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/2720369
   Wong JEL, 2020, JAMA-J AM MED ASSOC, V323, P1243, DOI 10.1001/jama.2020.2467
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Zhang Shu-wen, 2006, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V18, P673
   Zheng R, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2018.09.26
   Zhou L, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P281, DOI 10.3760/cma.j.cn112147-20200229-00219
   Zhou Y, 2020, BIORXIV, DOI [10.1101/2020.02.12.945576, DOI 10.1101/2020.02.12.945576]
NR 33
TC 0
Z9 0
U1 3
U2 3
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2224-5820
EI 2224-5839
J9 ANN PALLIAT MED
JI Ann. Pallliat. Med.
PD SEP
PY 2020
VL 9
IS 5
BP 3235
EP 3248
DI 10.21037/apm-20-1478
PG 14
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA NY8YP
UT WOS:000576670500090
PM 32954754
OA Other Gold
DA 2021-01-01
ER

PT J
AU Zhang, HQ
   Lin, JY
   Guo, Y
   Pang, S
   Jiang, R
   Cheng, QJ
AF Zhang, Hai-Qin
   Lin, Jia-Yuan
   Guo, Yi
   Pang, Shuai
   Jiang, Ren
   Cheng, Qi-Jian
TI Medication adherence among patients with chronic obstructive pulmonary
   disease treated in a primary general hospital during the COVID-19
   pandemic
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Chronic obstructive pulmonary disease (COPD); medication; adherence;
   COVID-19
ID MAINTENANCE MEDICATIONS; OLDER-ADULTS; COPD; DEPRESSION; MANAGEMENT
AB Background: The objective of this study was to investigate medication adherence and the associated influencing factors in patients with chronic obstructive pulmonary disease (COPD) who were treated in a primary general hospital in Shanghai China during the 2019 novel coronavirus (COVID-19) pandemic.
   Methods: From March to April 2020, all of the COPD patients treated in our department in the last 7 years were interviewed by telephone. The basic patient data and each questionnaire item were collected, and influencing factors were analyzed by the Chi-square test, U test, and univariate and multivariate logistic regression analyses.
   Results: A total of 191 patients with COPD were queried, and 84 (44.0%) valid questionnaires were obtained. Among them, individuals with group B symptoms were most represented (45.2%); 53.6% had Medical Research Council (MRC) dyspnea levels of 2 or above. Chronic obstructive pulmonary disease assessment test (CAT) had an average of 9 [3, 13], and 52.4% of patients used two-drug combination therapy. Medication adherence was both good in ordinary times and over the past 2 months of the pandemic, and 88.8% of patients had no acute exacerbation during the pandemic. The CAT scores of male patients <70 years old, and patients with general outpatient follow-up and regular gargling were reduced (P<0.05). Drug combination and doctor's supervision were favorable factors affecting medication adherence during the 2 months of the pandemic, while possible depression was an unfavorable factor (P<0.05).
   Conclusions: During the pandemic, medication adherence in patients with COPD was similar to that in regular times, and was significantly related to drug combination, doctor's supervision, and accompanying mood disorders. An effective way to improve patient adherence and disease control could be strengthening follow-up education and diagnosing and treating depression and other complications.
C1 [Zhang, Hai-Qin; Guo, Yi; Pang, Shuai; Jiang, Ren; Cheng, Qi-Jian] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pulm & Crit Care Med, 197 Ruijin Er Rd, Shanghai, Peoples R China.
   [Lin, Jia-Yuan] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pharm, Shanghai, Peoples R China.
RP Cheng, QJ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pulm & Crit Care Med, 197 Ruijin Er Rd, Shanghai, Peoples R China.
EM chengqijian@aliyun.com
FU Youth Foundation of Shanghai Municipal Commission of Health and Family
   Planning [20174Y0184]
FX This work was supported by the Youth Foundation of Shanghai Municipal
   Commission of Health and Family Planning (No. 20174Y0184).
CR Abdulsalim S, 2018, RES SOC ADMIN PHARM, V14, P909, DOI 10.1016/j.sapharm.2017.10.008
   Albrecht JS, 2017, RESP MED, V129, P53, DOI 10.1016/j.rmed.2017.06.002
   Albrecht JS, 2016, ANN AM THORAC SOC, V13, P1497, DOI 10.1513/AnnalsATS.201602-136OC
   Alton Sarah, 2018, Br J Community Nurs, V23, P214, DOI 10.12968/bjcn.2018.23.6.214
   [Anonymous], 2013, CHIN J TUBERC RESP D, V36, P255
   Baiardini I, 2019, INT J CHRONIC OBSTR, V14, P1, DOI 10.2147/COPD.S179784
   Barja-Martinez E, 2019, ENFERM CLIN, V29, P34, DOI 10.1016/j.enfcli.2018.09.003
   Blakemore A, 2019, INT J CHRONIC OBSTR, V14, P1343, DOI 10.2147/COPD.S179109
   Blasi F, 2015, COPD, V12, P227, DOI 10.3109/15412555.2014.933796
   Duarte-de-Araujo A, 2018, INT J CHRONIC OBSTR, V13, P2767, DOI 10.2147/COPD.S160982
   Gregoriano C, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0936-3
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Hesso I, 2016, RESP MED, V118, P22, DOI 10.1016/j.rmed.2016.07.010
   Horvat N, 2018, ACTA PHARMACEUT, V68, P117, DOI 10.2478/acph-2018-0006
   Humenberger M, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0724-3
   Ilic AD, 2016, INT J CHRONIC OBSTR, V11, P2509, DOI 10.2147/COPD.S114576
   Jenkins CR, 2017, CHEST, V151, P686, DOI 10.1016/j.chest.2016.10.031
   Kayhan F, 2018, PERSPECT PSYCHIATR C, V54, P6, DOI 10.1111/ppc.12169
   Lin Jia-Yuan, 2017, J CLIN PULMONARY MED, V22, P658
   Lopez-Campos JL, 2019, INT J CHRONIC OBSTR, V14, P1503, DOI 10.2147/COPD.S170848
   Miravitlles M, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0548-3
   Mirza S, 2018, MAYO CLIN PROC, V93, P1488, DOI 10.1016/j.mayocp.2018.05.026
   Price D, 2018, INT J CHRONIC OBSTR, V13, P695, DOI 10.2147/COPD.S149404
   Scalone G, 2018, PULM PHARMACOL THER, V53, P68, DOI 10.1016/j.pupt.2018.09.001
   Scullion J, 2018, CAN RESPIR J, V2018, DOI 10.1155/2018/2525319
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Taylor TE, 2018, CHEST, V153, P710, DOI 10.1016/j.chest.2017.08.1162
   Tottenborg SS, 2016, RESP MED, V119, P160, DOI 10.1016/j.rmed.2016.09.007
   Underner M, 2018, REV MAL RESPIR, V35, P604, DOI 10.1016/j.rmr.2018.04.004
   van Boven JFM, 2018, NPJ PRIM CARE RESP M, V28, DOI 10.1038/s41533-018-0092-8
   Wang C, 2018, LANCET, V391, P1706, DOI [10.1016/S0140-6736(18)30841-9, 10.1016/s0140-6736(18)30841-9]
   Wei YJ, 2018, INT J GERIATR PSYCH, V33, pE212, DOI 10.1002/gps.4772
   Wu CX, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019425
   Xiao T, 2018, BMC PSYCHIATRY, V18, DOI 10.1186/s12888-018-1671-5
NR 34
TC 0
Z9 0
U1 0
U2 0
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD SEP
PY 2020
VL 8
IS 18
AR 1179
DI 10.21037/atm-20-6016
PG 10
WC Oncology; Medicine, Research & Experimental
SC Oncology; Research & Experimental Medicine
GA NZ1DR
UT WOS:000576832600001
PM 33241028
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Kang, Y
   Wang, H
   Chen, H
   Wang, B
   Yang, YY
   Zhao, X
   Ran, QH
   Wei, JF
AF Kang, Yu
   Wang, Hui
   Chen, Hong
   Wang, Bo
   Yang, Yingying
   Zhao, Xuan
   Ran, Qihui
   Wei, Jiafu
TI Suspected Hydroxychloroquine-Induced Sinus Bradycardia and QTc
   Prolongation in a Patient with COVID-19
SO INTERNATIONAL HEART JOURNAL
LA English
DT Article
DE Coronavirus infections; Antiviral agents; Adverse effects
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS
AB An 84-year-old woman with hypertension, Alzheimer's disease, and chronic kidney disease presented with fever and was diagnosed with corona virus disease 2019 (COVID-19). During the hospitalization, she experienced unexpected sinus bradycardia with prolonged QTc, which was thought to be closely related to the short-term use of hydroxychloroquine (HCQ), an old drug used to treat malaria and autoimmune diseases, but now used against COVID-19. The cardiac side effects of HCQ were rare, seen with short-term and low-dose use. With the COV1D-19 pandemic, this case alerts clinicians to be aware of the arrhythmogenic effects of HCQ when it is used as an antiviral drug, especially in patients with preexisting cardiovascular diseases.
C1 [Kang, Yu; Wang, Hui; Wei, Jiafu] Sichuan Univ, West China Hosp, Dept Cardiol, Chengdu 610041, Sichuan, Peoples R China.
   [Chen, Hong; Zhao, Xuan; Ran, Qihui] Publ Hlth Clin Ctr Chengdu, Dept Intens Care Unit, Chengdu, Peoples R China.
   [Wang, Bo] Sichuan Univ, West China Hosp, Dept Intens Care Unit, Chengdu, Peoples R China.
   [Yang, Yingying] Sichuan Univ, West China Hosp, Dept Nephrol, Chengdu, Peoples R China.
RP Wei, JF (corresponding author), Sichuan Univ, West China Hosp, Dept Cardiol, Chengdu 610041, Sichuan, Peoples R China.
EM weijiafu@163.com
CR Ajayi AAL, 2002, BRIT J CLIN PHARMACO, V53, P404, DOI 10.1046/j.1365-2125.2002.01572_2.x
   Cairoli E, 2015, LUPUS, V24, P1204, DOI 10.1177/0961203315580870
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Comin-Colet J, 2001, LUPUS, V10, P59, DOI 10.1191/096120301673172543
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   US Food Drug and Administration, FACT SHEET HLTH CAR
   Xiong T.-Y., 2020, EUR HEART J
NR 7
TC 1
Z9 1
U1 1
U2 1
PU INT HEART JOURNAL ASSOC
PI TOKYO
PA UNIV TOKYO, GRADUATE SCHOOL MEDICINE, DEPT CARDIOVASCULAR MEDICINE,
   HONGO 7-3-1, BUNKYO-KU, TOKYO, 113-8655, JAPAN
SN 1349-2365
EI 1349-3299
J9 INT HEART J
JI Int. Heart J.
PD SEP
PY 2020
VL 61
IS 5
BP 1056
EP 1058
DI 10.1536/ihj.20-271
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NY9ET
UT WOS:000576688600028
PM 32921678
OA Bronze
DA 2021-01-01
ER

PT J
AU Bestle, D
   Heindl, MR
   Limburg, H
   Van, TVL
   Pilgram, O
   Moulton, H
   Stein, DA
   Hardes, K
   Eickmann, M
   Dolnik, O
   Rohde, C
   Klenk, HD
   Garten, W
   Steinmetzer, T
   Bottcher-Friebertshauser, E
AF Bestle, Dorothea
   Heindl, Miriam Ruth
   Limburg, Hannah
   Thuy Van Lam Van
   Pilgram, Oliver
   Moulton, Hong
   Stein, David A.
   Hardes, Kornelia
   Eickmann, Markus
   Dolnik, Olga
   Rohde, Cornelius
   Klenk, Hans-Dieter
   Garten, Wolfgang
   Steinmetzer, Torsten
   Boettcher-Friebertshaeuser, Eva
TI TMPRSS2 and furin are both essential for proteolytic activation of
   SARS-CoV-2 in human airway cells
SO LIFE SCIENCE ALLIANCE
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; MORPHOLINO OLIGOMERS; PROTEASE
   INHIBITORS; VIRUS-INFECTIONS; SPIKE PROTEIN; INFLUENZA-VIRUSES; SERINE;
   FUSION; ENTRY; MICE
AB The novel emerged SARS-CoV-2 has rapidly spread around the world causing acute infection of the respiratory tract (COVID-19) that can result in severe disease and lethality. For SARS-CoV-2 to enter cells, its surface glycoprotein spike (S) must be cleaved at two different sites by host cell proteases, which therefore represent potential drug targets. In the present study, we show that S can be cleaved by the proprotein convertase furin at the S1/S2 site and the transmembrane serine protease 2 (TMPRSS2) at the S29 site. We demonstrate that TMPRSS2 is essential for activation of SARS-CoV-2 S in Calu-3 human airway epithelial cells through antisense-mediated knockdown of TMPRSS2 expression. Furthermore, SARS-CoV-2 replication was also strongly inhibited by the synthetic furin inhibitor MI-1851 in human airway cells. In contrast, inhibition of endosomal cathepsins by E64d did not affect virus replication. Combining various TMPRSS2 inhibitors with furin inhibitor MI-1851 produced more potent antiviral activity against SARS-CoV-2 than an equimolar amount of any single serine protease inhibitor. Therefore, this approach has considerable therapeutic potential for treatment of COVID-19.
C1 [Bestle, Dorothea; Heindl, Miriam Ruth; Limburg, Hannah; Eickmann, Markus; Dolnik, Olga; Rohde, Cornelius; Klenk, Hans-Dieter; Garten, Wolfgang; Boettcher-Friebertshaeuser, Eva] Philipps Univ, Inst Virol, Marburg, Germany.
   [Thuy Van Lam Van; Pilgram, Oliver; Hardes, Kornelia; Steinmetzer, Torsten] Philipps Univ, Inst Pharmaceut Chem, Marburg, Germany.
   [Moulton, Hong; Stein, David A.] Oregon State Univ, Carlson Coll Vet Med, Dept Biomed Sci, Corvallis, OR 97331 USA.
   [Hardes, Kornelia] Fraunhofer Inst Mol Biol & Appl Ecol, Giessen, Germany.
   [Eickmann, Markus; Dolnik, Olga; Rohde, Cornelius] Philipps Univ, German Ctr Infect Res DZIF, Emerging Infect Unit, Marburg Giessen Langen Site, Marburg, Germany.
RP Bottcher-Friebertshauser, E (corresponding author), Philipps Univ, Inst Virol, Marburg, Germany.
EM friebertshaeuser@staff.uni-marburg.de
FU LOEWE Center DRUID [D1]; German Center for Infection Research (DZIF);
   Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)German
   Research Foundation (DFG) [SFB 1021]
FX We are grateful to Christian Drosten for providing the virus. We thank
   Iris Lindberg for providing recombinant furin. We also thank Stephan
   Becker for support of this study. This work was funded by the LOEWE
   Center DRUID (project D1), by the German Center for Infection Research
   (DZIF), and by the Deutsche Forschungsgemeinschaft (DFG, German Research
   Foundation) SFB 1021 (project B07). We thank Diana Kruhl and Dirk Becker
   for excellent technical assistance.
CR Abes S, 2006, J CONTROL RELEASE, V116, P304, DOI 10.1016/j.jconrel.2006.09.011
   Baron J, 2013, J VIROL, V87, P1811, DOI 10.1128/JVI.02320-12
   Belouzard S, 2009, P NATL ACAD SCI USA, V106, P5871, DOI 10.1073/pnas.0809524106
   Bottcher-Friebertshauser E, 2012, VACCINE, V30, P7374, DOI 10.1016/j.vaccine.2012.10.001
   Bottcher-Friebertshauser E, 2011, J VIROL, V85, P1554, DOI 10.1128/JVI.01294-10
   Bosch BJ, 2008, J VIROL, V82, P8887, DOI 10.1128/JVI.00415-08
   Bottcher E, 2006, J VIROL, V80, P9896, DOI 10.1128/JVI.01118-06
   Bottcher-Friebertshauser E., 2018, ACTIVATION VIRUSES H, P153, DOI [10.1007/978-3-319-75474-1_8, DOI 10.1007/978-3-319-75474-1_8]
   Bugge TH, 2009, J BIOL CHEM, V284, P23177, DOI 10.1074/jbc.R109.021006
   Burkard C, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004502
   Cheng JL, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100972
   Coutard B, 2020, ANTIVIR RES, V176, DOI 10.1016/j.antiviral.2020.104742
   Follis KE, 2006, VIROLOGY, V350, P358, DOI 10.1016/j.virol.2006.02.003
   Gabriel G, 2008, J GEN VIROL, V89, P939, DOI 10.1099/vir.0.83449-0
   Garten W., 2018, ACTIVATION VIRUSES H, P205, DOI [10.1007/978-3-319-75474-1_9., DOI 10.1007/978-3-319-75474-1_9]
   Garten W, 2015, EUR J CELL BIOL, V94, P375, DOI 10.1016/j.ejcb.2015.05.013
   Garten Wolfgang, 2008, V27, P156
   Gierer S, 2015, J INFECT DIS, V211, P889, DOI 10.1093/infdis/jiu407
   Hammami M, 2012, MEDCHEMCOMM, V3, P807, DOI 10.1039/c2md20074k
   Hardes K, 2015, CHEMMEDCHEM, V10, P1218, DOI 10.1002/cmdc.201500103
   Hardes K, 2013, ANAL BIOCHEM, V442, P223, DOI 10.1016/j.ab.2013.07.043
   Hatesuer B, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003774
   Heald-Sargent T, 2012, VIRUSES-BASEL, V4, P557, DOI 10.3390/v4040557
   Hierholzer J, 1996, VIROLOGY METHODS MAN, P24
   Hoffmann M, 2018, ACTIVATION VIRUSES H, P71, DOI DOI 10.1007/978-3-319-75474-1_4
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Kacprzak MM, 2004, J BIOL CHEM, V279, P36788, DOI 10.1074/jbc.M400484200
   KASSELL B, 1965, BIOCHEM BIOPH RES CO, V18, P255, DOI 10.1016/0006-291X(65)90749-7
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Kim TS, 2006, MOL CELL BIOL, V26, P965, DOI 10.1128/MCB.26.3.965-975.2006
   Klenk Hans-Dieter, 1994, Trends in Microbiology, V2, P39, DOI 10.1016/0966-842X(94)90123-6
   Kruger N, 2018, CELL REP, V25, P312, DOI 10.1016/j.celrep.2018.09.018
   Lai SH, 2008, MOL THER, V16, P1120, DOI 10.1038/mt.2008.81
   Limburg H, 2019, J VIROL, V93, DOI 10.1128/JVI.00649-19
   Lu YH, 2015, ANTIVIR RES, V120, P89, DOI 10.1016/j.antiviral.2015.05.006
   Lupfer C, 2008, ARCH VIROL, V153, P929, DOI 10.1007/s00705-008-0067-0
   Madu IG, 2009, J VIROL, V83, P7411, DOI 10.1128/JVI.00079-09
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Matsuyama S, 2018, J VIROL, V92, DOI 10.1128/JVI.00683-18
   Meyer D, 2013, BIOCHEM J, V452, P331, DOI 10.1042/BJ20130101
   MIDGLEY I, 1994, XENOBIOTICA, V24, P79, DOI 10.3109/00498259409043223
   Millet JK, 2015, VIRUS RES, V202, P120, DOI 10.1016/j.virusres.2014.11.021
   Millet JK, 2014, P NATL ACAD SCI USA, V111, P15214, DOI 10.1073/pnas.1407087111
   Moulton HM, 2010, BBA-BIOMEMBRANES, V1798, P2296, DOI 10.1016/j.bbamem.2010.02.012
   Opriessnig T, 2011, ANTIVIR RES, V91, P36, DOI 10.1016/j.antiviral.2011.04.012
   Park JE, 2016, P NATL ACAD SCI USA, V113, P12262, DOI 10.1073/pnas.1608147113
   Rensi S., 2020, HOMOLOGY MODELING TM, DOI [10.26434/chemrxiv.12009582, DOI 10.26434/CHEMRXIV.12009582]
   Rockwell NC, 2002, CHEM REV, V102, P4525, DOI 10.1021/cr010168i
   Sakai K, 2014, J VIROL, V88, P5608, DOI 10.1128/JVI.03677-13
   Sarac MS, 2004, INFECT IMMUN, V72, P602, DOI 10.1128/IAI.72.1.602-605.2004
   Sarac MS, 2002, INFECT IMMUN, V70, P7136, DOI 10.1128/IAI.70.12.7136-7139.2002
   Shirato K, 2018, VIROLOGY, V517, P9, DOI 10.1016/j.virol.2017.11.012
   Shirato K, 2017, J VIROL, V91, DOI [10.1128/JVI.01387-16, 10.1128/jvi.01387-16]
   Shirato K, 2013, J VIROL, V87, P12552, DOI 10.1128/JVI.01890-13
   Simmons G, 2005, P NATL ACAD SCI USA, V102, P11876, DOI 10.1073/pnas.0505577102
   Singh S, 2002, LETT PEPT SCI, V9, P221
   Stein DA, 2008, CURR PHARM DESIGN, V14, P2619, DOI 10.2174/138161208786071290
   Steinmetzer T, 2018, ACTIVATION VIRUSES H, P279
   Steinmetzer T, 2020, J MED CHEM, V63, P1445, DOI 10.1021/acs.jmedchem.9b01060
   Tanaka N, 1979, Adv Exp Med Biol, V120B, P367
   Tarnow C, 2014, J VIROL, V88, P4744, DOI 10.1128/JVI.03799-13
   Van TVL, 2019, CHEMMEDCHEM, V14, P673, DOI 10.1002/cmdc.201800807
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2016, NATURE, V531, P114, DOI 10.1038/nature16988
   Zhirnov OP, 2011, ANTIVIR RES, V92, P27, DOI 10.1016/j.antiviral.2011.07.014
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
NR 67
TC 14
Z9 14
U1 0
U2 0
PU LIFE SCIENCE ALLIANCE LLC
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
EI 2575-1077
J9 LIFE SCI ALLIANCE
JI Life Sci. Alliance
PD SEP
PY 2020
VL 3
IS 9
AR e202000786
DI 10.26508/lsa.202000786
PG 14
WC Biology
SC Life Sciences & Biomedicine - Other Topics
GA NZ1EH
UT WOS:000576834200007
PM 32703818
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shalayel, MH
   Al-Mazaideh, GM
   Aladadeh, SH
   Al-Swailmi, FK
   Al-Thiabat, MG
AF Shalayel, Mohammed H.
   Al-Mazaideh, Ghassab M.
   Aladadeh, Saleem H.
   Al-Swailmi, Farhan K.
   Al-Thiabat, Mohammad G.
TI Vitamin D is a potential inhibitor of COVID-19: In silico molecular
   docking to the binding site of SARS-CoV-2 endoribonuclease Nsp15
SO PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Vitamin D; COVID-19; SARS-CoV-2; endoribonuclease Nsp15; docking
   studies; pharmaceutics
ID PROTEIN; CORONAVIRUSES; INFECTIONS; OUTBREAK; WUHAN
AB Novel coronavirus disease (COVID-19) has become a pandemic threat to public health. Vaccines and targeted therapeutics to prevent infections and stop virus proliferation are currently lacking. Endoribonuclease Nsp15 plays a vital role in the life cycle, including replication and transcription as well as virulence of the virus. Here, we investigated Vitamin D for its in silico potential inhibition of the binding sites of SARS-CoV-2 endoribonuclease Nsp15. In this study, we selected Remdesivir, Chloroquine, Hydroxychloroquine and Vitamin D to study the potential binding affinity with the putative binding sites of endoribonuclease Nsp15 of COVID-19. The docking study was applied to rationalize the possible interactions of the target compounds with the active site of endoribonuclease Nsp 15. Among the results, Vitamin D was found to have the highest potency with strongest interaction in terms of LBE, lowest RMSD, and lowest inhibition intensity Ki than the other standard compounds. The investigation results of endoribonuclease Nsp15 on the PrankWeb server showed that there are three prospective binding sites with the ligands. The singularity of Vitamin D interaction with the three pockets, particularly in the second pocket, may write down Vitamin D as a potential inhibitor of COVID-19 Nsp15 endoribonuclease binding sites and favour addition of Vitamin D in the treatment plan for COVID-19 alone or in combination with the other used drugs in this purpose, which deserves exploration in further in vitro and in vivo studies.
C1 [Shalayel, Mohammed H.; Aladadeh, Saleem H.; Al-Swailmi, Farhan K.] Univ Hafr Al Batin, Coll Pharm, Dept Pharm Practice, Hafar al Batin, Saudi Arabia.
   [Al-Mazaideh, Ghassab M.] Univ Hafr Al Batin, Coll Pharm, Dept Pharmaceut Chem, Hafar al Batin, Saudi Arabia.
   [Al-Thiabat, Mohammad G.] Univ Sains Malaysia, Sch Pharmaceut Sci, Gelugor, Malaysia.
RP Al-Mazaideh, GM (corresponding author), Univ Hafr Al Batin, Coll Pharm, Dept Pharmaceut Chem, Hafar al Batin, Saudi Arabia.
EM gmazaideh@uhb.edu.sa
CR Abbad MM, 2009, INT J EMERG TECHNOL, V4, P4, DOI 10.3991/ijet.v4i4.928
   Abou-Zeid LA, 2020, SILICO FAVIPIRAVIR I
   Jimenez-Sousa MA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00458
   Cao YC, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101647
   Chen DL, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1501240
   Cheng K, 2020, DEV COMP IMMUNOL, V107, DOI 10.1016/j.dci.2020.103644
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Deng XF, 2018, VIROLOGY, V517, P157, DOI 10.1016/j.virol.2017.12.024
   Deng XF, 2017, P NATL ACAD SCI USA, V114, pE4251, DOI 10.1073/pnas.1618310114
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Ferner RE, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1432
   Friedl C, 2017, INT J NEPHROL RENOV, V10, P109, DOI 10.2147/IJNRD.S97637
   Gonzalez Paz LA, 2020, MOL DOCKING MOL DYNA
   Grant WB, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040988
   Gunville Cameron F., 2013, Inflammation & Allergy Drug Targets, V12, P239
   Holick MF, 2006, MAYO CLIN PROC, V81, P353, DOI 10.4065/81.3.353
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Jamkhande P.G, 2017, B FACULTY PHARM, V55, P203, DOI [DOI 10.1016/J.BFOPCU.2017.10.001, 10.1016/j.bfopcu.2017.10.001]
   Jat KR, 2017, TROP DOCT, V47, P77, DOI 10.1177/0049475516644141
   Jendele L, 2019, NUCLEIC ACIDS RES, V47, pW345, DOI 10.1093/nar/gkz424
   Jimenez J, 2017, BIOINFORMATICS, V33, P3036, DOI 10.1093/bioinformatics/btx350
   Jin ZM, 2020, NAT STRUCT MOL BIOL, V27, P529, DOI 10.1038/s41594-020-0440-6
   Joshi G, 2020, VIRTUAL SCREENING EN
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI 10.20944/preprints202003.0226.v1
   Khan MF, 2020, RES SQUARE
   Kim Y, 2020, PROTEIN SCI
   Krivak R, 2018, J CHEMINFORMATICS, V10, DOI 10.1186/s13321-018-0285-8
   Liu XR, 2019, MOL IMMUNOL, V114, P100, DOI 10.1016/j.molimm.2019.07.003
   Mavromoustakos T, 2011, CURR MED CHEM, V18, P2517, DOI 10.2174/092986711795933731
   Panarese A, 2020, ALIMENT PHARM THER, V51, P993, DOI 10.1111/apt.15752
   Ricagno S, 2006, P NATL ACAD SCI USA, V103, P11892, DOI 10.1073/pnas.0601708103
   Rizvi SMD, 2013, EXCLI J, V12, P831
   Saber-Ayad M, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13050096
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Shalayel MHF, 2018, BR BIOMED B, V6, P311
   Talluri S., 2020, VIRTUAL HIGH THROUGH
   Telcian AG, 2017, ANTIVIR RES, V137, P93, DOI 10.1016/j.antiviral.2016.11.004
   Wang FH, 2016, SCI REP-UK, V6, DOI 10.1038/srep22677
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wen F, 2020, J INFECTION, V80, P679, DOI 10.1016/j.jinf.2020.02.027
   Wu Canrong, 2020, ACTA PHARM SIN B
   Yu F, 2020, MICROBES INFECT, V22, P74, DOI 10.1016/j.micinf.2020.01.003
   Zhang LQ, 2018, J VIROL, V92, DOI 10.1128/JVI.00893-18
NR 44
TC 0
Z9 0
U1 1
U2 1
PU UNIV KARACHI
PI KARACHI
PA UNIV CAMPUS, FAC PHARMACY, KARACHI, 75270, PAKISTAN
SN 1011-601X
J9 PAK J PHARM SCI
JI Pak. J. Pharm. Sci.
PD SEP
PY 2020
VL 33
IS 5
BP 2179
EP 2186
DI 10.36721/PJPS.2020.33.5.REG.2179-2186.1
PG 8
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NZ0PV
UT WOS:000576795600016
DA 2021-01-01
ER

PT J
AU Qadir, MI
AF Qadir, Muhammad Imran
TI QadirVID-19: A fusion inhibitor against Novel Coronavirus-2019 for
   specific management of COVID-19
SO PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Coronavirus; peptide; QadirVID-19
ID SPIKE PROTEIN
AB With the emergence of COVID-19 (Corona virus Disease 19), the workers tried to search the drug/s for its management. Chloroquine, hydroxychloroquine and protease inhibitors including Ritonavir have been tested. But the safety and efficacy of these drugs for the treatment of COVID-19 were not very strong. Fusion inhibitors may be used for the management or prophylaxis of viral diseases. Objective of the present study was to design a fusion inhibitor for specific management of COVID-19. A series of BLAST was performed to get an optimized and conservative region of the spike protein of the virus which is used in fusion process. Based on the recent data available, residue 1160-1189 of spike protein of Novel coronavirus-2019 (2019-nCoV) was found highly conserved region with 100% similarity, with maximum score of 99.5 and with an E-value of 5e(-24). Thus, this sequence was selected as a drug. This drug is a synthetic peptide composed of 30 amino acids of Heptad Repeat 2 (HR2) region of spike protein of 2019-nCoV and was named as QadirVID-19 (Qadir, name of the scientist who developed it and VID-19 from COVID-19).
C1 [Qadir, Muhammad Imran] Bahauddin Zakariya Univ, Inst Mol Biol & Biotechnol, Multan, Pakistan.
RP Qadir, MI (corresponding author), Bahauddin Zakariya Univ, Inst Mol Biol & Biotechnol, Multan, Pakistan.
EM mrimranqadir@hotmail.com
CR Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Dorward J., 2020, LOPINAVIR RITONAVIR
   Gao J, 2020, BIOSCI TRENDS
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hulswit RJG, 2016, ADV VIRUS RES, V96, P29, DOI 10.1016/bs.aivir.2016.08.004
   Liu SW, 2004, LANCET, V363, P938, DOI 10.1016/S0140-6736(04)15788-7
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Qadir MI, 2011, AIDS RES HUM RETROV, V27, P57, DOI 10.1089/aid.2010.0098
   Qadir MI, 2010, REV MED VIROL, V20, P23, DOI 10.1002/rmv.631
   Qadir MI, 2011, PAK J PHARM SCI, V24, P593
   Quinn K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09230-0
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
NR 15
TC 0
Z9 0
U1 0
U2 0
PU UNIV KARACHI
PI KARACHI
PA UNIV CAMPUS, FAC PHARMACY, KARACHI, 75270, PAKISTAN
SN 1011-601X
J9 PAK J PHARM SCI
JI Pak. J. Pharm. Sci.
PD SEP
PY 2020
VL 33
IS 5
BP 2187
EP 2191
DI 10.36721/PJPS.2020.33.5.REG.2187-2191.1
PG 5
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NZ0PV
UT WOS:000576795600017
DA 2021-01-01
ER

PT J
AU Yu, X
   Li, N
AF Yu, Xiang
   Li, Na
TI Observation on China's efficient mobilization and external dependencies
   in COVID-19 detection reagents, vaccines and drugs development
SO PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Corona virus disease 2019; drug; authority; development; legal
ID CORONAVIRUS; SARS
AB Respiratory infectious diseases had happened in China in recent years, and the outbreak of Corona Virus Disease 2019(COVID-19) had drawn worldwide attention. In order to control such high-mortality infectious diseases, the work of the Chinese government and the medical community in detection reagents, drugs, and vaccines had been speeded up. This research extensively searched the medical data of drugs, vaccines and kits development, the company's business report and the government's policy documents and conducted case analysis. We found some national mobilization measures had been put on the agenda and some special marketing authorization measures had been adopted. Due to the limitations of biotechnology research and the pharmaceutical industry, some key technologies and drugs still had a high external dependence. In the process of development, it was necessary to attach importance to scientific, ethical, and safety construction, and to strengthen international cooperation.
C1 [Yu, Xiang] Fujian Jiangxia Univ, Publ Affairs, 2 St Xiyuangong Rd, Fuzhou, Fujian, Peoples R China.
   [Li, Na] Ningbo Univ, Law, 818st Fenghua Rd, Ningbo, Zhejiang, Peoples R China.
RP Li, N (corresponding author), Ningbo Univ, Law, 818st Fenghua Rd, Ningbo, Zhejiang, Peoples R China.
EM nali321@126.com
CR Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chinese Center for Disease Prevention and Control, 2020, EP UPD RISK ASS 2019
   Chinese National Health Commission, 2020, DYN REP COVID 19 EP
   Chinese National Medical Products Administration, 2020, CHINA MED NEWS  0226
   Chinese National Medical Products Administration, 2020, NEWS C COVID 19 DRUG
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Coomes EA, 2020, J ANTIMICROB CHEMOTH, V75, P2013, DOI 10.1093/jac/dkaa171
   Expert Group on Prevention and Control of COVID-19 of Chinese Preventive Medicine Association, 2020, CHINESE J EPIDEMIOL, V41, P3
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Morgenstern B, 2005, BIOCHEM BIOPH RES CO, V326, P905, DOI 10.1016/j.bbrc.2004.11.128
   Pfefferle S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002331
   Shan X, 2020, GUANGMING DAILY
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   State Council Information Office of China, 2020, FIGHT CIV 19 CHIN AC
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Wang J, 2020, PHARM BIOTECHNOL, V1, P8
   Xu K, 2020, CLIN EFFICACY ARBIDO
   Yu X, 2019, BIOTECHNOL LAW REP, V38, P165, DOI 10.1089/blr.2019.29117.xy
   Yu X, 2018, BIOTECHNOL LAW REP, V37, P79, DOI 10.1089/blr.2018.29061.xy
   Zhang N, 2020, BEIJING DAILY   0324
NR 25
TC 0
Z9 0
U1 2
U2 2
PU UNIV KARACHI
PI KARACHI
PA UNIV CAMPUS, FAC PHARMACY, KARACHI, 75270, PAKISTAN
SN 1011-601X
J9 PAK J PHARM SCI
JI Pak. J. Pharm. Sci.
PD SEP
PY 2020
VL 33
IS 5
BP 2193
EP 2198
DI 10.36721/PJPS.2020.33.5.REG.2193-2198.1
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NZ0PV
UT WOS:000576795600018
DA 2021-01-01
ER

PT J
AU Rasool, MS
   Siddiqui, F
   Hassan, MA
   Hafiz, S
AF Rasool, Muhammad Salman
   Siddiqui, Fraz
   Hassan, Muhammad Akbar
   Hafiz, Saleem
TI Novel Coronavirus-2019 (2019-nCoV): Perspectives of emergence,
   prophylaxis and predicted treatment approaches
SO PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Emergence of 2019-nCoV; SARS coronavirus-2; 2019-nCoV; COVID-19;
   anti-coronavirus agents; Thymoquinone
ID RESPIRATORY-TRACT INFECTION; MESSENGER-RNA; SARS; PNEUMONIA; EXERCISE;
   CELLS; DISEASE; CHINA; EBOLA; SPIKE
AB Emergence of novel coronavirus-2019 has become an international health concern. The objective of this review is to focus on 2019-nCoV emergence, prophylaxis and to predict the treatment approaches. The first case of 2019-nCoV was noted in Wuhan, China. The WHO has announced this epidemic as pandemic. The 2019-nCoV has +ve ssRNA (29903bp), lipid-bilayer envelope spiked with glycoprotein and bears genome sequences similar to bat coronavirus RaTG13. Antiviral agents like Interferon, Darunavir, Ribavirin, Lopinavir, Remdesivir, Chloroquine and Camostat mesylate may be considered for clinical trials. Chinese herbals may be effective against 2019-nCoV. These include Saikosaponins (triterpene glycosides), Amentoflavone, Scutellarein, Myricetin, extracts of Isatis indigotica, and Houttuynia cordata. Another treatment approach is to administer plasma from COVID-19 recovered patients. RNA vaccines, recombinant vector based vaccine and ACE-2 receptor like molecules may be employed for immunization against COVID-19. Moreover, immunity can be boosted against 2019-nCoV by regular exercise. We have checked Thymoquinone as ligand for various targets of 2019-nCoV (receptor binding domain of spike, RNA polymerase, protease, Nsp9 RNA binding protein, nucleocapsid phosphoprotein, endoribonuclease) by protein-ligand docking server SwissDoc. Thymoquinone can bind effectively to the targets of 2019-nCoV. Hence, it may be an effective candidate for the treatment of COVID-19.
C1 [Rasool, Muhammad Salman] DJ Sindh Govt Sci Coll, Karachi, Pakistan.
   [Siddiqui, Fraz; Hafiz, Saleem] Sindh Inst Urol & Transplantat SLUT, Karachi, Pakistan.
   [Hassan, Muhammad Akbar] Baqai Med Univ, Karachi, Pakistan.
RP Rasool, MS (corresponding author), DJ Sindh Govt Sci Coll, Karachi, Pakistan.
EM sangimsr@yahoo.com
CR Adams GR, 2011, BRAIN BEHAV IMMUN, V25, P658, DOI 10.1016/j.bbi.2011.01.002
   Arbabi-Ghahroudi M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01589
   Bigley AB, 2014, BRAIN BEHAV IMMUN, V39, P160, DOI 10.1016/j.bbi.2013.10.030
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cheng PW, 2006, CLIN EXP PHARMACOL P, V33, P612, DOI 10.1111/j.1440-1681.2006.04415.x
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Cyranoski D., 2020, NATURE
   Diken M, 2017, CURR ISSUES MOL BIOL, V22, P113, DOI 10.21775/cimb.022.113
   Du X, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020144
   Elshabrawy HA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050366
   Faber M, 2005, J GEN VIROL, V86, P1435, DOI 10.1099/vir.0.80844-0
   Falzarano D, 2013, SCI REP, V3, P1
   Fan Y, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030210
   Fendrick AM, 2003, ARCH INTERN MED, V163, P487, DOI 10.1001/archinte.163.4.487
   Forouzanfar F, 2014, IRAN J BASIC MED SCI, V17, P929
   Gao GF, 2018, CELL, V172, P1157, DOI 10.1016/j.cell.2018.02.025
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kim Y, 2020, PROTEIN SCI, V29, P1596, DOI 10.1002/pro.3873
   Kraft CS, 2015, CLIN INFECT DIS, V61, P496, DOI 10.1093/cid/civ334
   Kruger N, 2020, BIORXIV, DOI [10.1101/2020.01.31.929042, DOI 10.1101/2020.01.31.929042]
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lau KM, 2008, J ETHNOPHARMACOL, V118, P79, DOI 10.1016/j.jep.2008.03.018
   Li SY, 2005, ANTIVIR RES, V67, P18, DOI 10.1016/j.antiviral.2005.02.007
   Lin CW, 2005, ANTIVIR RES, V68, P36, DOI 10.1016/j.antiviral.2005.07.002
   Lin Liang-Tzung, 2014, J Tradit Complement Med, V4, P24, DOI 10.4103/2225-4110.124335
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Malau N. D., 2020, Journal of Physics: Conference Series, V1428, DOI 10.1088/1742-6596/1428/1/012057
   Martin SA, 2009, EXERC SPORT SCI REV, V37, P157, DOI 10.1097/JES.0b013e3181b7b57b
   Maxmen A, 2020, NATURE, V578, P347, DOI 10.1038/d41586-020-00444-3
   McGettigan JP, 2001, J VIROL, V75, P8724, DOI 10.1128/JVI.75.18.8724-8732.2001
   Moore MJ, 2004, J VIROL, V78, P10628, DOI 10.1128/JVI.78.19.10628-10635.2004
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Nieman DC, 2019, J SPORT HEALTH SCI, V8, P201, DOI 10.1016/j.jshs.2018.09.009
   Nieman DC, 2011, BRIT J SPORT MED, V45, P987, DOI 10.1136/bjsm.2010.077875
   Peterhans E, 1997, J NUTR, V127, pS962, DOI 10.1093/jn/127.5.962S
   Rabi FA, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9030231
   Ramsey ML, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3606-y
   Reilly JP, 2019, SEMIN RESP CRIT CARE, V40, P19, DOI 10.1055/s-0039-1684049
   Ryu YB, 2010, BIOORGAN MED CHEM, V18, P7940, DOI 10.1016/j.bmc.2010.09.035
   Sahin U, 2014, NAT REV DRUG DISCOV, V13, P759, DOI 10.1038/nrd4278
   Simpson RJ, 2017, EXERC SPORT SCI REV, V45, P163, DOI 10.1249/JES.0000000000000114
   Tan W, 2020, CHINA CDC WEEKLY, V2, P61, DOI DOI 10.46234/ccdcw2020.017
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Walker LM, 2018, NAT REV IMMUNOL, V18, P297, DOI 10.1038/nri.2017.148
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wax RS, 2020, CAN J ANESTH, V67, P568, DOI 10.1007/s12630-020-01591-x
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   Wong G, 2015, CELL HOST MICROBE, V18, P398, DOI 10.1016/j.chom.2015.09.013
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Yamawaki H, 2019, DIGESTION, V99, P283, DOI 10.1159/000492813
   Yu MS, 2012, BIOORG MED CHEM LETT, V22, P4049, DOI 10.1016/j.bmcl.2012.04.081
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou P, 2018, NATURE, V556, P255, DOI 10.1038/s41586-018-0010-9
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 66
TC 0
Z9 0
U1 4
U2 4
PU UNIV KARACHI
PI KARACHI
PA UNIV CAMPUS, FAC PHARMACY, KARACHI, 75270, PAKISTAN
SN 1011-601X
J9 PAK J PHARM SCI
JI Pak. J. Pharm. Sci.
PD SEP
PY 2020
VL 33
IS 5
BP 2199
EP 2207
DI 10.36721/PJPS.2020.33.5.REG.2199-2207.1
PG 9
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NZ0PV
UT WOS:000576795600019
DA 2021-01-01
ER

PT J
AU Dias, LD
   Blanco, KC
   Bagnato, VS
AF Dias, Lucas D.
   Blanco, Kate C.
   Bagnato, Vanderlei S.
TI COVID-19: Beyond the virus. The use of photodynamic therapy for the
   treatment of infections in the respiratory tract
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Letter
C1 [Dias, Lucas D.; Blanco, Kate C.; Bagnato, Vanderlei S.] Univ Sao Paulo, Sao Carlos Inst Phys, Ave Trabalhador Sancarlense,400 Ctr, Sao Carlos, SP, Brazil.
   [Bagnato, Vanderlei S.] Texas A&M Univ, Dept Biomed Engn, College Stn, TX 77843 USA.
RP Dias, LD (corresponding author), Univ Sao Paulo, Sao Carlos Inst Phys, Ave Trabalhador Sancarlense,400 Ctr, Sao Carlos, SP, Brazil.
EM lucasdanillodias@gmail.com
RI Blanco, Kate/ABG-6865-2020
OI Blanco, Kate/0000-0003-0361-9725
CR Blanco KC, 2017, PHOTODIAGN PHOTODYN, V18, P138, DOI 10.1016/j.pdpdt.2017.01.187
   Geralde M.C., 2017, PHYSL REP, V5, P7
   Hu XQ, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01299
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kassab G, 2019, J BIOPHOTONICS, V12, DOI 10.1002/jbio.201800189
   Neville T, 2002, LIBR J, V127, P203
   Wiehe A, 2019, PHOTOCH PHOTOBIO SCI, V18, P2565, DOI 10.1039/c9pp00211a
NR 7
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD SEP
PY 2020
VL 31
AR 101804
DI 10.1016/j.pdpdt.2020.101804
PG 2
WC Oncology
SC Oncology
GA NZ2QQ
UT WOS:000576941600015
PM 32437972
OA Green Published
DA 2021-01-01
ER

PT J
AU McLellan, LJ
   Morelli, M
   Simeone, E
   Khazova, M
   Ibbotson, SH
   Eadie, E
AF McLellan, Luke J.
   Morelli, Marco
   Simeone, Emilio
   Khazova, Marina
   Ibbotson, Sally H.
   Eadie, Ewan
TI SmartPDT (R): Smartphone enabled real-time dosimetry via satellite
   observation for daylight photodynamic therapy
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Article
DE Daylight photodynamic therapy; Photodynamic therapy; Dosimetry; Live
   dosimetry
ID ACTINIC KERATOSIS; METHYL AMINOLEVULINATE; PREVALENCE; GUIDELINES;
   DELIVERY; DAMAGE; CREAM; FACE; CARE
AB Background: Actinic keratosis (AK) affects one quarter of over 60 year olds in Europe with the risk of transforming into invasive squamous cell carcinoma. Daylight photodynamic therapy (dPDT) is an effective and patient preferred treatment that uses sunlight to clear AK. Currently, there is no standardised method for measuring the light received during treatment.
   Methods: SmartPDT (R) is a smartphone-based application and web-portal, developed by siHealth Ltd, enabling remote delivery of dPDT. It uses satellite imagery and computational algorithms to provide real-time determination of exposure to PpIX-effective solar radiation ("light dose"). The application also provides forecast of expected radiant exposures for 24- and 48-hs prior to the treatment period. Validation of the real-time and forecasted radiant exposure algorithms was performed against direct ground-based measurement under all weather conditions in Chilton, UK.
   Results: Agreement between direct ground measurements and satellite-determined radiant exposure for 2-h treatment was excellent at - 0.1 % +/- 5.1 % (mean +/- standard deviation). There was also excellent agreement between weather forecasted radiant exposure and ground measurement, 1.8 % +/- 17.7 % at 24-hs and 1.6 % +/- 25.2 % at 48-hs. Relative Root Mean Square of the Error (RMSEr) demonstrated that agreement improved as time to treatment reduced (RMSEr = 22.5 % (48 -hs), 11.2 % (24-hs), 5.2 % (real-time)).
   Conclusion: Agreement between satellite-determined, weather-forecasted and ground-measured radiant exposure was better than any existing published literature for dPDT. The SmartPDT (R) application and web-portal has excellent potential to assist with remote delivery of dPDT, an important factor in reducing risk in an elderly patient population during the Covid-19 pandemic.
C1 [McLellan, Luke J.; Ibbotson, Sally H.] Univ Dundee, Sch Med, Dundee DD1 9SY, Scotland.
   [Morelli, Marco; Simeone, Emilio] RAL, SiHlth Ltd, Bldg R104,Harwell Campus, Didcot OX11 0QX, Oxon, England.
   [Khazova, Marina] Publ Hlth England, Didcot OX11 0RQ, Oxon, England.
   [Ibbotson, Sally H.; Eadie, Ewan] Ninewells Hosp, Scottish Photodynam Therapy Ctr, Dundee DD1 9SY, Scotland.
   [Ibbotson, Sally H.; Eadie, Ewan] Ninewells Hosp, NHS Tayside, Photobiol Unit, Dundee DD1 9SY, Scotland.
RP McLellan, LJ (corresponding author), Univ Dundee, Sch Med, Dundee DD1 9SY, Scotland.
EM l.j.y.mclellan@dundee.ac.uk
OI Ibbotson, Sally/0000-0001-5685-752X; Eadie, Ewan/0000-0002-7824-5580;
   McLellan, Luke/0000-0002-3603-6123
FU Innovate UK award; Medical Laser Research Fund [SC037390]
FX L. J. M's salary is supported by an Innovate UK award and by the Medical
   Laser Research Fund (registered charity SC037390).
CR Aculinin A, 2016, REMOTE SENS-BASEL, V8, DOI 10.3390/rs8070537
   Champeau M, 2019, J PHOTOCH PHOTOBIO B, V197, DOI 10.1016/j.jphotobiol.2019.111544
   Chetty P, 2015, DERMATOLOGY THER, V5, P19, DOI 10.1007/s13555-015-0070-9
   Cordey H, 2017, SCOT MED J, V62, P48, DOI 10.1177/0036933017695156
   de Berker D, 2017, BRIT J DERMATOL, V176, P20, DOI 10.1111/bjd.15107
   ELSHARABASY MMH, 1992, BRIT J CANCER, V65, P409, DOI 10.1038/bjc.1992.83
   Fargnoli MC, 2018, J EUR ACAD DERMATOL, V32, P757, DOI 10.1111/jdv.14691
   Flohil SC, 2013, J INVEST DERMATOL, V133, P1971, DOI 10.1038/jid.2013.134
   Grinblat BM, 2015, PHOTODERMATOL PHOTO, V31, P54, DOI 10.1111/phpp.12127
   Jebar MAA, 2018, PHOTOCHEM PHOTOBIOL, V94, P1281, DOI 10.1111/php.12948
   Krzyscin JW, 2018, J PHOTOCH PHOTOBIO B, V184, P27, DOI 10.1016/j.jphotobiol.2018.05.012
   Lacour JP, 2015, J EUR ACAD DERMATOL, V29, P2342, DOI 10.1111/jdv.13228
   LaRochelle EPM, 2020, PHOTOCHEM PHOTOBIOL, V96, P320, DOI 10.1111/php.13170
   Manley M, 2018, PHYS MED BIOL, V63, DOI 10.1088/1361-6560/aa9ea7
   Marra K, 2018, PHOTOCHEM PHOTOBIOL, V94, P1049, DOI 10.1111/php.12923
   McLellan LJ, 2019, BRIT J DERMATOL, V181, P834, DOI 10.1111/bjd.17920
   McLellan LJ, 2019, PHOTODIAGN PHOTODYN, V27, P19, DOI 10.1016/j.pdpdt.2019.05.020
   Memon AA, 2000, BRIT J DERMATOL, V142, P1154, DOI 10.1046/j.1365-2133.2000.03541.x
   Morelli M, 2016, PHOTOCH PHOTOBIO SCI, V15, P1170, DOI 10.1039/c6pp00129g
   Morton CA, 2013, J EUR ACAD DERMATOL, V27, P536, DOI 10.1111/jdv.12031
   Nyamsi WW, 2017, ATMOS MEAS TECH, V10, DOI 10.5194/amt-10-4965-2017
   O'Mahoney P, 2017, BRIT J DERMATOL, V176, P1607, DOI 10.1111/bjd.15146
   O'Mahoney P, 2019, PHARMACEUTICALS-BASE, V12, DOI 10.3390/ph12040143
   Philipp-Dormston WG, 2016, J EUR ACAD DERMATOL, V30, P8, DOI 10.1111/jdv.13327
   Rosen T, 2013, J AM ACAD DERMATOL, V68, pS2, DOI 10.1016/j.jaad.2012.09.052
   Rubel DM, 2014, BRIT J DERMATOL, V171, P1164, DOI 10.1111/bjd.13138
   See JA, 2016, AUSTRALAS J DERMATOL, V57, P167, DOI 10.1111/ajd.12354
   Szeimies RM, 1996, J PHOTOCH PHOTOBIO B, V36, P213, DOI 10.1016/S1011-1344(96)07375-7
   Taniguchi M, 2018, PHOTOCHEM PHOTOBIOL, V94, P290, DOI 10.1111/php.12860
   Wald L., 2018, SIMPLE ALGORITHM COM, P1
   Werner RN, 2013, BRIT J DERMATOL, V169, P502, DOI 10.1111/bjd.12420
   Wiegell SR, 2012, J EUR ACAD DERMATOL, V26, P673, DOI 10.1111/j.1468-3083.2011.04386.x
   Wiegell SR, 2012, BRIT J DERMATOL, V166, P1327, DOI 10.1111/j.1365-2133.2012.10833.x
   Wiegell SR, 2011, BRIT J DERMATOL, V164, P1083, DOI 10.1111/j.1365-2133.2011.10209.x
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD SEP
PY 2020
VL 31
AR 101914
DI 10.1016/j.pdpdt.2020.101914
PG 6
WC Oncology
SC Oncology
GA NZ2RB
UT WOS:000576942700011
PM 32645436
OA Green Published
DA 2021-01-01
ER

PT J
AU Imami, AS
   O'Donovan, SM
   Creeden, JF
   Wu, XJ
   Eby, H
   McCullumsmith, CB
   Uvnas-Moberg, K
   McCullumsmith, RE
   Andari, E
AF Imami, Ali S.
   O'Donovan, Sinead M.
   Creeden, Justin F.
   Wu, Xiaojun
   Eby, Hunter
   McCullumsmith, Cheryl B.
   Uvnas-Moberg, Kerstin
   McCullumsmith, Robert E.
   Andari, Elissar
TI Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a
   transcriptomic signature-based approach
SO PHYSIOLOGICAL GENOMICS
LA English
DT Article
DE COVID19; oxytocin; immune; LINCS; transcriptomic signature
ID ATRIAL-NATRIURETIC-PEPTIDE; IN-VITRO; CONNECTIVITY MAP; COMPLEMENT; CD46
AB The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide pandemic, infecting over 16 million people worldwide with a significant mortality rate. However, there is no current Food and Drug Administration-approved drug that treats coronavirus disease 2019 (COVID-19). Damage to T lymphocytes along with the cytokine storm are important factors that lead to exacerbation of clinical cases. Here, we are proposing intravenous oxytocin (OXT) as a candidate for adjunctive therapy for COVID-19. OXT has antiinflammatory and proimmune adaptive functions. Using the Library of Integrated Network-Based Cellular Signatures (LINCS), we used the transcriptomic signature for carbetocin, an OXT agonist, and compared it to gene knockdown signatures of inflammatory (such as interleukin IL-1 beta and IL-6) and proimmune markers (including T cell and macrophage cell markers like CD40 and ARG1). We found that carbetocin's transcriptomic signature has a pattern of concordance with inflammation and immune marker knockdown signatures that are consistent with reduction of inflammation and promotion and sustaining of immune response. This suggests that carbetocin may have potent effects in modulating inflammation, attenuating T cell inhibition, and enhancing T cell activation. Our results also suggest that carbetocin is more effective at inducing immune cell responses than either lopinavir or hydroxychloroquine, both of which have been explored for the treatment of COVID-19.
C1 [Imami, Ali S.; O'Donovan, Sinead M.; Creeden, Justin F.; Wu, Xiaojun; Eby, Hunter; McCullumsmith, Robert E.] Univ Toledo, Dept Neurosci, Coll Med & Life Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.
   [McCullumsmith, Cheryl B.; Andari, Elissar] Univ Toledo, Dept Psychiat, Coll Med & Life Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.
   [Uvnas-Moberg, Kerstin] Swedish Univ Agr Sci, Dept Anim Environm & Hlth, Skara, Sweden.
   [McCullumsmith, Robert E.] ProMedica, Neurosci Inst, Toledo, OH USA.
RP Andari, E (corresponding author), Univ Toledo, Dept Psychiat, Coll Med & Life Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.
EM elissar.andari@utoledo.edu
OI Imami, Ali/0000-0003-3684-3539
FU University of Toledo Medical Research Society pilot grant on oxytocin
   and COVID-19 [207014]
FX E. Andari acknowledges the University of Toledo Medical Research Society
   pilot grant on oxytocin and COVID-19 (#207014).
CR Akerstrom S, 2005, J VIROL, V79, P1966, DOI 10.1128/JVI.79.3.1966-1969.2005
   An XN, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39349-1
   Astier AL, 2008, IMMUNOLOGY, V124, P149, DOI 10.1111/j.1365-2567.2008.02821.x
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen JJ, 2007, BMC BIOINFORMATICS, V8, P1, DOI 10.1186/1471-2105-8-412
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Clodi M, 2008, AM J PHYSIOL-ENDOC M, V295, pE686, DOI 10.1152/ajpendo.90263.2008
   Deing V, 2013, EXP DERMATOL, V22, P399, DOI 10.1111/exd.12155
   Dembele D, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-14
   Detillion CE, 2004, PSYCHONEUROENDOCRINO, V29, P1004, DOI 10.1016/j.psyneuen.2003.10.003
   Favaretto AIV, 1997, PEPTIDES, V18, P1377, DOI 10.1016/S0196-9781(97)00209-X
   Garrido-Urbani S, 2018, DIABETES METAB, V44, P292, DOI 10.1016/j.diabet.2017.10.004
   Gimpl G, 2001, PHYSIOL REV, V81, P629
   Guo L, 2006, NAT BIOTECHNOL, V24, P1162, DOI 10.1038/nbt1238
   Gutkowska J, 1997, P NATL ACAD SCI USA, V94, P11704, DOI 10.1073/pnas.94.21.11704
   Han ZW, 2020, INVEST NEW DRUG, V38, P1888, DOI 10.1007/s10637-020-00955-w
   Hua ZL, 2013, CELL MOL IMMUNOL, V10, P103, DOI 10.1038/cmi.2012.61
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iseri SO, 2005, J SURG RES, V126, P73, DOI 10.1016/j.jss.2005.01.021
   Jankowski M, 2016, BMC ENDOCR DISORD, V16, DOI 10.1186/s12902-016-0110-1
   Jonasson Aino Fianu, 2011, Menopause Int, V17, P120, DOI 10.1258/mi.2011.011030
   Kallak Theodora K, 2017, Post Reprod Health, V23, P6, DOI 10.1177/2053369117693148
   Keenan AB, 2019, ANNU REV BIOMED DA S, V2, P69, DOI 10.1146/annurev-biodatasci-072018-021211
   Keenan AB, 2018, CELL SYST, V6, P13, DOI 10.1016/j.cels.2017.11.001
   Keyaerts E, 2004, INT J INFECT DIS, V8, P223, DOI 10.1016/j.ijid.2004.04.012
   Lai JH, 2018, EMBO REP, V19, DOI 10.15252/embr.201846182
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lee AYS, 2019, IMMUNOBIOLOGY, V224, P449, DOI 10.1016/j.imbio.2019.01.005
   Liszewski MK, 2019, J IMMUNOL, V203, P3, DOI 10.4049/jimmunol.1900527
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Newton MA, 2007, ANN APPL STAT, V1, P85, DOI 10.1214/07-AOAS104
   Nielsen EI, 2017, J CLIN PHARMACOL, V57, P1573, DOI 10.1002/jcph.961
   O'Donovan Sinead M, 2020, Res Sq, DOI 10.21203/rs.3.rs-25643/v1
   Petersson M, 1996, PHYSIOL BEHAV, V60, P1311, DOI 10.1016/S0031-9384(96)00261-2
   Petersson M, 2001, PEPTIDES, V22, P1479, DOI 10.1016/S0196-9781(01)00469-7
   PETTY MA, 1985, EUR J PHARMACOL, V112, P203, DOI 10.1016/0014-2999(85)90497-2
   Pilarczyk M, 2019, BIORXIV, DOI [10.1101/826271., DOI 10.1101/826271]
   Plantone D, 2018, CLIN DRUG INVEST, V38, P653, DOI 10.1007/s40261-018-0656-y
   Poutahidis T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078898
   Shevach EM, 2014, IMMUNOL REV, V259, P88, DOI 10.1111/imr.12160
   Shi LM, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-S2-S12
   Skorobogatykh Yu. I., 2010, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, P3
   Stromback L, 2006, BRIEF BIOINFORM, V7, P331, DOI 10.1093/bib/bbl039
   Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049
   Tang Y, 2019, CLIN SCI, V133, P1977, DOI 10.1042/CS20190756
   Thibonnier M, 1999, ENDOCRINOLOGY, V140, P1301, DOI 10.1210/en.140.3.1301
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Vonderheide RH, 2018, CANCER CELL, V33, P563, DOI 10.1016/j.ccell.2018.03.008
   Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150
   Wang ZC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12846
   West EE, 2020, IMMUNOL REV, V295, P68, DOI 10.1111/imr.12852
   West Erin E, 2019, Immunometabolism, V1, pe190006, DOI 10.20900/immunometab20190006
   World Health Organization, ROLL UPD COR DIS COV
   Xagorari Angeliki, 2008, Open Microbiol J, V2, P49, DOI 10.2174/1874285800802010049
   Zyzak J, 2020, J INNATE IMMUN, V12, P387, DOI 10.1159/000504542
NR 56
TC 0
Z9 0
U1 0
U2 0
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 1094-8341
EI 1531-2267
J9 PHYSIOL GENOMICS
JI Physiol. Genomics
PD SEP
PY 2020
VL 52
IS 9
BP 401
EP 407
DI 10.1152/physiolgenomics.00095.2020
PG 7
WC Cell Biology; Genetics & Heredity; Physiology
SC Cell Biology; Genetics & Heredity; Physiology
GA NY4HR
UT WOS:000576353200004
PM 32809918
OA Bronze
DA 2021-01-01
ER

PT J
AU Alvez, F
AF Alvez, F.
TI SARS-CoV2 coronavirus: so far polite with children. Debatable
   immunological and non-immunological evidence
SO ALLERGOLOGIA ET IMMUNOPATHOLOGIA
LA English
DT Article
DE SARS-CoV2; COVID-19; Innate; Adaptive; ACE2; Melatonin
ID VIRUS; INFECTIONS; MELATONIN; RESPONSES; COVID-19; VACCINE; DISEASE;
   IMPACT
AB The reasons for the relative resistance of children to certain infections such as that caused by coronavirus SARS-CoV2 are not yet fully clear. Deciphering these differences can provide important information about the pathogenesis of the disease. Regarding the SARS-CoV2 virus, children are at the same risk of infection as the general population of all ages, with the most serious cases being found in infants. However, it has been reported that the disease is much less frequent than in adults and that most cases are benign or moderate (even with high viral loads), provided there are no other risk factors or underlying diseases. It is not clear why they have lower morbidity and virtually no mortality. A series of findings, relationships and behavioral patterns between the infectious agent and the child host may account for the lower incidence and a greatly attenuated clinical presentation of the disease in children. (C) 2020 SEICAP. Published by Elsevier Espana, S.L.U. All rights reserved.
C1 [Alvez, F.] Univ Clin Hosp, Infect Dis & Vaccines Unit UNIV, Vaccines & Pediat Infect GENVIP, Santiago De Compostela, Spain.
   [Alvez, F.] Spanish Soc Pediat Infectol, Madrid, Spain.
RP Alvez, F (corresponding author), Univ Clin Hosp, Infect Dis & Vaccines Unit UNIV, Vaccines & Pediat Infect GENVIP, Santiago De Compostela, Spain.; Alvez, F (corresponding author), Spanish Soc Pediat Infectol, Madrid, Spain.
EM fernanalvez@hotmail.com
CR [Anonymous], 2020, MMWR-MORBID MORTAL W, V69, P422, DOI [10.15585/mmwr.mm6914e4externalicon, DOI 10.15585/MMWR.MM6914E4EXTERNALICON]
   Blay A, 2007, VACCINE, V25, P1071, DOI 10.1016/j.vaccine.2006.09.056
   Castagnoli R, 2020, JAMA PEDIAT, DOI [10.1001/jamapediatrics.2020.1467, DOI 10.1001/JAMAPEDIATRICS.7070.1467.PUBLISHED]
   Chan CM, 2009, J CLIN VIROL, V45, P54, DOI 10.1016/j.jcv.2009.02.011
   Che XY, 2005, J INFECT DIS, V191, P2033, DOI 10.1086/430355
   Chen J, 2010, J VIROL, V84, P1289, DOI 10.1128/JVI.01281-09
   Chen Y, 2020, ASIANS OTHER RACES E, DOI [10.2.0944/preprints2.02002.0758.v1, DOI 10.20944/PREPRINTS2.02002.0758.V1]
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   ECDC, 2020, COR DIS 2019 COVID 1
   Fathima P, 2018, CLIN INFECT DIS, V66, P1075, DOI 10.1093/cid/cix923
   Green RJ, 2020, VIRAL INFECT CHILDRE, V1, P193
   He X, 2020, NAT MED, DOI [10.1038/541591-020-0869-5, DOI 10.1038/541591-020-0869-5]
   Heimdal I, 2019, J INFECT DIS, V219, P1198, DOI 10.1093/infdis/jiy646
   Jia HP, 2016, SHOCK, V46, P239, DOI 10.1097/SHK.0000000000000633
   Kikkert M, 2020, J INNATE IMMUN, V12, P4, DOI 10.1159/000503030
   Lambert L, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01570
   Lee PI, 2020, J MICROBIOL IMMUNOL, V53, P371, DOI 10.1016/j.jmii.2020.02.011
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Madhi SA, 2004, NAT MED, V10, P811, DOI 10.1038/nm1077
   Monto AS, 2020, J INFECT DIS, V222, P9, DOI 10.1093/infdis/jiaa161
   Pathak EB, 2020, J PUBLIC HEALTH MAN, V26, P325, DOI 10.1097/PHH.0000000000001190
   Pinky L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155589
   Pohanka M, 2013, CENT EUR J MED, V8, P369, DOI 10.2478/s11536-013-0177-2
   Shafinoori S, 2005, PEDIATR INFECT DIS J, V24, P10, DOI 10.1097/01.inf.0000148930.41928.0d
   Shi YF, 2020, CELL DEATH DIFFER, V27, P1451, DOI 10.1038/s41418-020-0530-3
   Shinjoh M, 2000, ACTA VIROL, V44, P91
   Shneider A, 2020, INT REV IMMUNOL, V39, P153, DOI 10.1080/08830185.2020.1756284
   Song RF, 2012, PEDIATR RES, V71, P13, DOI 10.1038/pr.2011.7
   Su L, 2020, EMERG MICROBES INFEC, V9, P707, DOI 10.1080/22221751.2020.1744483
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang R, 2020, LIFE SCI, V250, DOI 10.1016/j.lfs.2020.117583
   Zhang Y, 2016, J PINEAL RES, V60, P405, DOI 10.1111/jpi.12322
   Zhao JC, 2010, J VIROL, V84, P9318, DOI 10.1128/JVI.01049-10
   Zimmermann P, 2020, PEDIATR INFECT DIS J, V39, P355, DOI 10.1097/INF.0000000000002660
   Zou Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4594
NR 39
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER ESPANA SLU
PI BARCELONA
PA AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN
SN 0301-0546
EI 1578-1267
J9 ALLERGOL IMMUNOPATH
JI Allergol. Immunopath.
PD SEP-OCT
PY 2020
VL 48
IS 5
BP 500
EP 506
DI 10.1016/j.aller.2020.05.003
PG 7
WC Allergy; Immunology
SC Allergy; Immunology
GA NX5ZD
UT WOS:000575788100014
PM 32771236
OA Green Published
DA 2021-01-01
ER

PT J
AU Yu, JM
   Zhang, LS
   Fu, YH
   Ji, FM
   Xu, HL
   Huang, JQ
   Peng, XL
   Zheng, YP
   Zhang, Y
   He, JS
AF Yu, Jie-Mei
   Zhang, Li-Shu
   Fu, Yuan-Hui
   Ji, Feng-Min
   Xu, Han-Li
   Huang, Jia-Qiang
   Peng, Xiang-Lei
   Zheng, Yan-Peng
   Zhang, Ying
   He, Jin-Sheng
TI Analysis of Continuous Mutation and Evolution on Circulating SARS-CoV-2
SO EVOLUTIONARY BIOINFORMATICS
LA English
DT Article
DE SARS-CoV-2; mutation dynamics; SNP; evolution; clusters
ID CORONAVIRUS
AB Monitoring the mutation and evolution of the virus is important for tracing its ongoing transmission and facilitating effective vaccine development. A total of 342 complete genomic sequences of SARS-CoV-2 were analyzed in this study. Compared to the reference genome reported in December 2019, 465 mutations were found, among which, 347 occurred in only 1 sequence, while 26 occurred in more than 5 sequences. For these 26 further identified as SNPs, 14 were closely linked and were grouped into 5 profiles. Phylogenetic analysis revealed the sequences formed 2 major groups. Most of the sequences in late period (March and April) constituted the Cluster II, while the sequences before March in this study and the reported S/L and A/B/C types in previous studies were all in Cluster I. The distributions of some mutations were specific geographically or temporally, the potential effect of which on the transmission and pathogenicity of SARS-CoV-2 deserves further evaluation and monitoring. Two mutations were found in the receptor-binding domain (RBD) but outside the receptor-binding motif (RBM), indicating that mutations may only have marginal biological effects but merit further attention. The observed novel sequence divergence is of great significance to the study of the transmission, pathogenicity, and development of an effective vaccine for SARS-CoV-2.
C1 [Yu, Jie-Mei; Zhang, Li-Shu; Fu, Yuan-Hui; Ji, Feng-Min; Xu, Han-Li; Huang, Jia-Qiang; Peng, Xiang-Lei; Zheng, Yan-Peng; Zhang, Ying; He, Jin-Sheng] Beijing Jiaotong Univ, Coll Life Sci & Bioengn, Beijing 100044, Peoples R China.
RP He, JS (corresponding author), Beijing Jiaotong Univ, Coll Life Sci & Bioengn, Beijing 100044, Peoples R China.
EM jshhe@bjtu.edu.cn
OI Xu, Hanli/0000-0002-2082-2197; Yu, Jiemei/0000-0003-2988-384X
FU Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [2020RC016]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by "the Fundamental Research Funds for the Central
   Universities" (2020RC016).
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   Ferron F, 2018, P NATL ACAD SCI USA, V115, pE162, DOI 10.1073/pnas.1718806115
   Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117
   Korber B, 2020, BIORXIV PREPRINT
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li F, 2015, J VIROL, V89, P1954, DOI 10.1128/JVI.02615-14
   Li XJ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb9153
   Pachetti M, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02344-6
   Sanjuan R, 2010, J VIROL, V84, P9733, DOI 10.1128/JVI.00694-10
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Tang X, 2020, NATL SCI REV, V6, P6
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Zhou H, 2020, CURR BIOL, V30, P2196, DOI 10.1016/j.cub.2020.05.023
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 16
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1176-9343
J9 EVOL BIOINFORM
JI Evol. Bioinform.
PD SEP
PY 2020
VL 16
AR 1176934320954870
DI 10.1177/1176934320954870
PG 6
WC Evolutionary Biology; Mathematical & Computational Biology
SC Evolutionary Biology; Mathematical & Computational Biology
GA NY4MW
UT WOS:000576366700001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Schwartz, RA
   Sharma, A
   Lotti, T
   Szepietowski, JC
   Sandhu, S
   Goldust, M
AF Schwartz, Robert A.
   Sharma, Aseem
   Lotti, Torello
   Szepietowski, Jacek C.
   Sandhu, Sunmeet
   Goldust, Mohamad
TI Systemic Medications of Dermatological Importance in COVID-19
SO JOURNAL OF DRUGS IN DERMATOLOGY
LA English
DT Article
AB Early December 2019 witnessed an international outbreak of a novel coronavirus (COVID 19) designated severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). Since then, a number of therapeutic molecules have been explored to have potential efficacy against the SARS-Cov-2 per se or its sequelae. There are no Food and Drug Administration specific therapies approved so far; however, numerous drugs based on varying levels of evidence, in vitro studies and compassionate drug trials are being established as therapeutic agents, especially drugs approved for previous emergence of the severe acute respiratory syndrome (SARS-CoV-1) and Middle east respiratory syndrome coronavirus (MERS-Cov). Numerous active clinical trials for COVID-19 with more than 150 drugs and products are under study. Needless to say, many dermatological drugs are being employed to mitigate this pandemic threat. We aim to review drugs with potential against SARS-Cov-2 widely used in dermatology practice. Additionally, rampant and overzealous use of these drugs as well as introduction of new molecules might lead to emergence of adverse effects associated with these agents. Dermatologists must be on lookout for any cutaneous adverse effects of these drugs.
C1 [Schwartz, Robert A.] Rutgers New Jersey Med Sch, Newark, NJ USA.
   [Sharma, Aseem] Skin Saga Ctr Dermatol, Mumbai, Maharashtra, India.
   [Lotti, Torello] Univ Guglielmo Marconi, Rome, Italy.
   [Szepietowski, Jacek C.] Wroclaw Med Univ, Wroclaw, Poland.
   [Sandhu, Sunmeet] Armed Forces Med Coll, Pune, Maharashtra, India.
   [Goldust, Mohamad] Univ Hosp Basel, Basel, Switzerland.
RP Goldust, M (corresponding author), Univ Hosp Basel, Basel, Switzerland.
EM mohamad.goldust@usb.ch
RI Sharma, Aseem/AAF-4443-2020
OI Sharma, Aseem/0000-0001-5873-227X
CR Abdelmaksoud A, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13482
   Almutairi N, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13544
   Amici C, 2006, ANTIVIR THER, V11, P1021
   [Anonymous], EM US AUTH
   Arora G, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13359
   Borras-Blasco J, 2008, J ANTIMICROB CHEMOTH, V62, P879, DOI 10.1093/jac/dkn292
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Cao B, 2020, NEW ENGL J MED, V382
   Coulombe J, 2017, CAN MED ASSOC J, V189, pE212, DOI 10.1503/cmaj.150622
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Ghosn J, 2005, CLIN INFECT DIS, V41, P1360, DOI 10.1086/497075
   Goldust M, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13523
   Murrell DF, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13538
   Nutho B, 2020, BIOCHEMISTRY-US, V59, P1769, DOI 10.1021/acs.biochem.0c00160
   Patri A, 2020, J AM ACAD DERMATOL, V82, pE221, DOI 10.1016/j.jaad.2020.04.017
   ROSA SGV, 2020, REV PANAM SALUD PUBL, V44, DOI DOI 10.26633/RPSP2020.40
   Rudnicka L, 2020, J AM ACAD DERMATOL, pS0190
   Rudnicka L, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13361
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Schwartz RA, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13785
   Schwartz RA, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13380
   Schwartz RA, 2020, INT J DERMATOL, V59, P1065, DOI 10.1111/ijd.14614
   Sharma A, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13398
   Sodhi M, 2020, PHARMACOTHERAPY, V40, P487, DOI 10.1002/phar.2395
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WHO, 2020, CLIN MAN SEV AC RESP
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zha L, 2020, MED J AUSTRALIA, V212, P416, DOI 10.5694/mja2.50577
   Zhao J P, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, P183, DOI 10.3760/cma.j.issn.1001-0939.2020.03.008
NR 30
TC 0
Z9 0
U1 0
U2 0
PU JOURNAL OF DRUGS IN DERMATOLOGY
PI NEW YORK
PA 377 PARK AVE SOUTH, 6TH FLOOR, NEW YORK, NY 10016 USA
SN 1545-9616
J9 J DRUGS DERMATOL
JI J. Drugs Dermatol.
PD SEP
PY 2020
VL 19
IS 9
BP 889
EP 892
DI 10.36849/JDD.2020.5323
PG 4
WC Dermatology
SC Dermatology
GA NP1EL
UT WOS:000569924500010
PM 33026746
OA Bronze
DA 2021-01-01
ER

PT J
AU Gostin, LO
   Karim, SA
   Meier, BM
AF Gostin, Lawrence O.
   Karim, Safura Abdool
   Meier, Benjamin Mason
TI Facilitating Access to a COVID-19 Vaccine through Global Health Law
SO JOURNAL OF LAW MEDICINE & ETHICS
LA English
DT Article
C1 [Gostin, Lawrence O.] Georgetown Univ, Washington, DC 20057 USA.
   [Gostin, Lawrence O.] Georgetown Univ, Linda Timothy ONeill Prof Global Hlth Law, Law Ctr, Washington, DC 20057 USA.
   [Gostin, Lawrence O.] WHO, Ctr Natl & Global Hlth Law, Washington, DC 20037 USA.
   [Karim, Safura Abdool] Wits Sch Publ Hlth, SAMRC Ctr Hlth Econ & Decis Sci Priceless S, Johannesburg, South Africa.
   [Meier, Benjamin Mason] Univ N Carolina, Global Hlth Policy, Chapel Hill, NC USA.
   [Meier, Benjamin Mason] ONeill Inst Natl & Global Hlth Law, Washington, DC USA.
RP Gostin, LO (corresponding author), Georgetown Univ, Washington, DC 20057 USA.; Gostin, LO (corresponding author), Georgetown Univ, Linda Timothy ONeill Prof Global Hlth Law, Law Ctr, Washington, DC 20057 USA.; Gostin, LO (corresponding author), WHO, Ctr Natl & Global Hlth Law, Washington, DC 20037 USA.
FU World Health OrganizationWorld Health Organization [001] Funding Source:
   Medline
CR [Anonymous], 2020, LANCET, V395, P1883, DOI 10.1016/S0140-6736(20)31405-7
   Ball P, 2020, NATURE, V581, P251, DOI 10.1038/d41586-020-01423-4
   Bollyky TJ, 2020, JAMA-J AM MED ASSOC, V323, P2462, DOI 10.1001/jama.2020.6641
   Capretta J.C., 2020, THE BULWARK     0729
   Cueto M., 2019, WHO HIST
   Dellepiane N, 2015, VACCINE, V33, P52, DOI 10.1016/j.vaccine.2013.11.066
   Duclos P, 2010, VACCINE, V28, pA18, DOI 10.1016/j.vaccine.2010.02.027
   Ghedamu TB, 2019, J LAW MED ETHICS, V47, P412, DOI 10.1177/1073110519876174
   GOSTIN LO, 2020, FDN GLOBAL HLTH HUMA
   Graham BS, 2020, SCIENCE, V368, P945, DOI 10.1126/science.abb8923
   Huddart S, 2017, J HLTH SPECIALTIES, V5, P30
   Islam MD, 2019, GLOBALIZATION HEALTH, V15, DOI 10.1186/s12992-019-0528-0
   Makenga G., 2019, FRONTIERS PUBLIC HLT
   Meier BM, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.20305
   Moon S, 2017, HEALTH ECON POLICY L, V12, P195, DOI [10.1017/S1744133116000451, 10.1017/s1744133116000451]
   Moran M, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000411
   Perehudoff K., COVID 19 TECHNOLOGY
   Petchesky R.P., 2006, GLOBAL PRESCRIPTIONS
   The Medicines Patent Pool, 2019, MED PAT POOL
   United Nations Committee on Economic Social and Cultural Rights, 2000, SUBST ISS AR IMPL IN
   Usher AD, 2020, LANCET, V395, P1822, DOI 10.1016/S0140-6736(20)31354-4
   WHO Regional Office for South-East Asia, 2005, 23 M HLTH MIN COUNTR
   World Health Organisation, PREQ
   World Health Organisation, COVID 19 TECHN ACC P
   World Health Organization, PAND INFL PREP PIP F
NR 25
TC 1
Z9 1
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1073-1105
EI 1748-720X
J9 J LAW MED ETHICS
JI J. Law Med. Ethics
PD SEP
PY 2020
VL 48
IS 3
SI SI
BP 622
EP 626
DI 10.1177/1073110520958892
PG 5
WC Ethics; Law; Medical Ethics; Medicine, Legal
SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal
   Medicine
GA NX6PL
UT WOS:000575830600030
PM 33021168
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Del Papa, N
   Sambataro, G
   Minniti, A
   Maglione, W
   Pignataro, F
   Caminati, A
   Harari, S
   Sambataro, D
   Vitali, C
   Caporali, RF
AF Papa, Nicoletta Del
   Sambataro, Gianluca
   Minniti, Antonina
   Maglione, Wanda
   Pignataro, Francesca
   Caminati, Antonella
   Harari, Sergio
   Sambataro, Domenico
   Vitali, Claudio
   Caporali, Roberto Felice
TI Impact of COVID-19 outbreak in an Italian cohort of patients with
   systemic sclerosis
SO THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
LA English
DT Article
DE coronavirus; interstitial lung disease; mortality; outbreak; SARS 2;
   systemic sclerosis; viral infection
ID ALTERNATIVELY ACTIVATED MACROPHAGES; TYPE-1 INTERFERON; CORONAVIRUS;
   PATHOGENESIS; MECHANISMS; SARS; CLASSIFICATION; DISEASE
AB Background: Mortality rate in patients infected by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) can be related to the presence of comorbidities like diabetes, cardiovascular and pulmonary diseases. On the contrary, few data exist on the impact of CoronaVirus Disease 2019 (COVID-19) on patients with rheumatic disorders, namely in those having pulmonary involvement and treated with immunosuppressive agents. The present survey is aimed at knowing the impact of COVID-19 in a cohort of patients with systemic sclerosis (SSc).
   Methods: Telephone interviews were carried out during the COVID-19 outbreak in patients with SSc followed in a Rheumatic Disease Unit in Italy. Patients were asked for confirmed SARS-CoV-2 infection, symptoms suggestive of COVID-19, and modification of their therapy.
   Results: A total number of 526 patients with SSc were contacted and interviewed. Of them, 270 and 256 had limited cutaneous and diffuse cutaneous SSc, respectively. Interstitial lung disease (ILD) was present in 45% of patients and most of them (68.2%) were treated with immunosuppressive therapy. Only two patients were hospitalized for COVID-19-related pneumonia, and one of them died despite invasive ventilator support. An additional 11 patients reported flu-like symptoms compatible with a mild form of COVID-19. Nobody modified the therapy during the COVID-19 outbreak.
   Conclusion: Despite the large prevalence of ILD and immunosuppressive therapies, which can be considered risk factors for the occurrence and severity of incidental viral infections, the impact of COVID-19, in terms of mortality rate and morbidity, does not appear particularly severe in this large cohort of patients with SSc. Possible mechanisms influencing this figure are discussed.
C1 [Papa, Nicoletta Del; Minniti, Antonina; Maglione, Wanda; Pignataro, Francesca; Caporali, Roberto Felice] G Pini Hosp, Dept Rheumatol, Via Pini, I-20122 Milan 9, Italy.
   [Sambataro, Gianluca; Sambataro, Domenico] Univ Catania, Reg Referral Ctr Rare Lung Dis, Dept Clin & Expt Med, Catania, Italy.
   [Caminati, Antonella; Harari, Sergio] San Giuseppe Hosp MultiMed, IRCCS, Dept Med Sci, Milan, Italy.
   [Caminati, Antonella; Harari, Sergio] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
   [Vitali, Claudio] Mater Domini Humanitas Hosp, Rheumatol Outpatient Clin, Castellanza, Italy.
   [Caporali, Roberto Felice] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
   [Caporali, Roberto Felice] Univ Milan, Res Ctr Pediat & Adult Rheumat Dis RECAP RD, Milan, Italy.
RP Del Papa, N (corresponding author), G Pini Hosp, Dept Rheumatol, Via Pini, I-20122 Milan 9, Italy.
EM nicoletta.delpapa@asst-pini-cto.it
RI Sambataro, Gianluca/K-9528-2016
OI Sambataro, Gianluca/0000-0001-9933-1202; Pignataro,
   Francesca/0000-0003-2772-3308
CR Avouac Jerome, 2020, Ann Rheum Dis, DOI 10.1136/annrheumdis-2020-217864
   Booth CM, 2003, JAMA-J AM MED ASSOC, V289, P2801, DOI 10.1001/jama.289.21.JOC30885
   Carminati A, 2017, EUR RESPIR REV, V26, P170047
   Cottin V, 2019, RESP RES, V20, DOI 10.1186/s12931-019-0980-7
   Del Papa N, 2015, BEST PRACT RES CL RH, V29, P756, DOI 10.1016/j.berh.2016.02.004
   Deng SQ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020575
   Frieman M, 2008, MICROBIOL MOL BIOL R, V72, P672, DOI 10.1128/MMBR.00015-08
   Gabrielli A, 2009, NEW ENGL J MED, V360, P1989, DOI 10.1056/NEJMra0806188
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Hensley LE, 2004, EMERG INFECT DIS, V10, P317, DOI 10.3201/eid1002.030482
   Khanna D, 2018, ANN RHEUM DIS, V77, P212, DOI 10.1136/annrheumdis-2017-211682
   Khanolkar A, 2009, J VIROL, V83, P8946, DOI 10.1128/JVI.01857-08
   LEROY EC, 1988, J RHEUMATOL, V15, P202
   Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633
   Ma WT, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01140
   Martinez Fernando O, 2014, F1000Prime Rep, V6, P13, DOI 10.12703/P6-13
   Mihai C, 2020, ANN RHEUM DIS, V79, P668, DOI 10.1136/annrheumdis-2020-217442
   Page C, 2012, J VIROL, V86, P13334, DOI 10.1128/JVI.01689-12
   Perelas A, 2020, LANCET RESP MED, V8, P304, DOI 10.1016/S2213-2600(19)30480-1
   Reusken CBEM, 2016, CURR OPIN VIROL, V16, P55, DOI 10.1016/j.coviro.2016.01.004
   Roofeh D, 2020, CURR OPIN RHEUMATOL, V32, P228, DOI 10.1097/BOR.0000000000000711
   Russell B, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1023
   Sang Y. M., 2015, Journal of Clinical and Cellular Immunology, V6, P311
   Shirey KA, 2010, MUCOSAL IMMUNOL, V3, P291, DOI 10.1038/mi.2010.6
   Stifano G, 2016, CURR RHEUMATOL REP, V18, DOI 10.1007/s11926-015-0554-8
   Stroher U, 2004, J INFECT DIS, V189, P1164, DOI 10.1086/382597
   Totura AL, 2012, CURR OPIN VIROL, V2, P264, DOI 10.1016/j.coviro.2012.04.004
   van den Hoogen F, 2013, ANN RHEUM DIS, V72, P1747, DOI 10.1136/annrheumdis-2013-204424
   Wan SX, 2020, BRIT J HAEMATOL, V189, P428, DOI 10.1111/bjh.16659
   Who Mers-Cov Research Group, 2013, PLoS Curr, V5, DOI 10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8
   World Health Organization, COR DIS 2019 COVID 1
   Wu MH, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00266
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhao JC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000636
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 36
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1759-720X
EI 1759-7218
J9 THER ADV MUSCULOSKEL
JI Ther. Adv. Musculoskelet. Dis.
PD SEP
PY 2020
VL 12
AR 1759720X20953356
DI 10.1177/1759720X20953356
PG 8
WC Rheumatology
SC Rheumatology
GA NX9ZZ
UT WOS:000576061600001
PM 33029203
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Otoom, M
   Otoum, N
   Alzubaidi, MA
   Etoom, Y
   Banihani, R
AF Otoom, Mwaffaq
   Otoum, Nesreen
   Alzubaidi, Mohammad A.
   Etoom, Yousef
   Banihani, Rudaina
TI An IoT-based framework for early identification and monitoring of
   COVID-19 cases
SO BIOMEDICAL SIGNAL PROCESSING AND CONTROL
LA English
DT Article
DE COVID-19; Coronaviruses; Early identification or prediction; Internet of
   Things; Real-time monitoring; Treatment response
ID INTERNET; THINGS; DEVICES
AB The world has been facing the challenge of COVID-19 since the end of 2019. It is expected that the world will need to battle the COVID-19 pandemic with precautions measures, until an effective vaccine is developed. This paper proposes a real-time COVID-19 detection and monitoring system. The proposed system would employ an Internet of Things (IoTs) framework to collect real-time symptom data from users to early identify suspected coronaviruses cases, to monitor the treatment response of those who have already recovered from the virus, and to understand the nature of the virus by collecting and analyzing relevant data. The framework consists of five main components: Symptom Data Collection and Uploading (using wearable sensors), Quarantine/Isolation Center, Data Analysis Center (that uses machine learning algorithms), Health Physicians, and Cloud Infrastructure. To quickly identify potential coronaviruses cases from this real-time symptom data, this work proposes eight machine learning algorithms, namely Support Vector Machine (SVM), Neural Network, Naive Bayes, K-Nearest Neighbor (K-NN), Decision Table, Decision Stump, OneR, and ZeroR. An experiment was conducted to test these eight algorithms on a real COVID-19 symptom dataset, after selecting the relevant symptoms. The results show that five of these eight algorithms achieved an accuracy of more than 90 %. Based on these results we believe that real-time symptom data would allow these five algorithms to provide effective and accurate identification of potential cases of COVID-19, and the framework would then document the treatment response for each patient who has contracted the virus.
C1 [Otoom, Mwaffaq; Alzubaidi, Mohammad A.] Yarmouk Univ, Comp Engn Dept, Irbid, Jordan.
   [Otoum, Nesreen] Univ Petra, Software Engn Dept, Amman, Jordan.
   [Etoom, Yousef; Banihani, Rudaina] Univ Toronto, Fac Med, Dept Pediat, Toronto, ON, Canada.
   [Etoom, Yousef] Hosp Sick Children, Sick Kids Res Inst, Dept Pediat, Toronto, ON, Canada.
   [Etoom, Yousef] Hosp Sick Children, Sick Kids Res Inst, Div Pediat Emergency Med, Toronto, ON, Canada.
   [Etoom, Yousef] St Josephs Hlth Ctr, Dept Pediat, Toronto, ON, Canada.
   [Banihani, Rudaina] Sunnybrook Hlth Sci Ctr, Dept Newborn & Dev Pediat, Toronto, ON, Canada.
RP Otoom, M (corresponding author), Yarmouk Univ, Comp Engn Dept, Irbid, Jordan.
EM mof.otoom@yu.edu.jo
CR Ahmed E, 2017, COMPUT NETW, V129, P459, DOI 10.1016/j.comnet.2017.06.013
   Al-Fuqaha A, 2015, IEEE COMMUN SURV TUT, V17, P2347, DOI 10.1109/COMST.2015.2444095
   Al-Garadi MA, 2020, IEEE COMMUN SURV TUT, V22, P1646, DOI 10.1109/COMST.2020.2988293
   Allam Z, 2020, HEALTHCARE-BASEL, V8, DOI 10.3390/healthcare8010046
   Alshraideh H, 2015, J MED SYST, V39, DOI 10.1007/s10916-015-0290-7
   Altawy H, 2016, IEEE ACCESS, V4, P959, DOI 10.1109/ACCESS.2016.2521727
   Alzubaidi M.A., 2020, NOVEL COMPUTATIONAL
   [Anonymous], 2020, COR COVID 19 GLOB CA
   [Anonymous], 2020, NEW YORK POST
   [Anonymous], 2020, COVID 19 OPEN RES DA, DOI 10.5281/zenodo.3715506
   Askarian B., 2019, SENSORS, V19
   Camara C, 2015, J BIOMED INFORM, V55, P272, DOI 10.1016/j.jbi.2015.04.007
   Cerina L., 2017, P IEEE 3 INT FOR RES, P1, DOI 10.1109/RTSI.2017.8065939
   Darwish A, 2019, J AMB INTEL HUM COMP, V10, P4151, DOI 10.1007/s12652-017-0659-1
   Dastjerdi AV, 2016, COMPUTER, V49, P112, DOI 10.1109/MC.2016.245
   Din S, 2019, FUTURE GENER COMP SY, V91, P611, DOI 10.1016/j.future.2017.12.059
   Dinesen B, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5257
   Fatima S.A., 2020, INT J ADV RES IDEAS, V6
   Gaidhani A, 2017, SENSORS-BASEL, V17, DOI 10.3390/s17122932
   Hamidi H, 2019, FUTURE GENER COMP SY, V91, P434, DOI 10.1016/j.future.2018.09.024
   Hlaing P.M., 2018, DIGITAL MED, V4, P117, DOI 10.4103/digm.digm_25_18.
   Ichwana D, 2018, INT C INF TECH SYST, P497, DOI 10.1109/ICITSI.2018.8696039
   Kelly MP, 2016, AM J PREV MED, V51, P861, DOI 10.1016/j.amepre.2016.06.012
   Lorena LHN, 2015, J INTELL ROBOT SYST, V80, pS227, DOI 10.1007/s10846-014-0101-2
   Maghdid H. S., 2020, ARXIV200307434
   Medina J, 2018, COMPUT ELECTR ENG, V65, P400, DOI 10.1016/j.compeleceng.2017.03.012
   Nguyen T.T., 2020, PREPRINT
   Otoom M, 2015, J MED SYST, V39, DOI 10.1007/s10916-015-0301-8
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Perera C, 2014, IEEE COMMUN SURV TUT, V16, P414, DOI 10.1109/SURV.2013.042313.00197
   Rath M, 2019, INT J HUM RIGHTS HEA, V12, P148, DOI 10.1108/IJHRH-01-2018-0007
   Sethi P, 2017, J ELECTR COMPUT ENG, V2017, DOI 10.1155/2017/9324035
   Rao ASRS, 2020, INFECT CONT HOSP EP, V41, P826, DOI 10.1017/ice.2020.61
   Tan P.-N., 2018, INTRO DATA MINING, V2nd ed
   Umayahara Y, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18113810
   Usak M, 2020, INT J COMMUN SYST, V33, DOI 10.1002/dac.4179
   WHO, 2020, DIR GEN OP REM MED B
   Witten I., 2016, WEKA WORKBENCH ONLIN
   Wu F, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19010021
   Zhao K, 2013, 2013 9TH INTERNATIONAL CONFERENCE ON COMPUTATIONAL INTELLIGENCE AND SECURITY (CIS), P663, DOI 10.1109/CIS.2013.145
   Zhong C.-L., 2020, MEASUREMENT, V159
NR 41
TC 3
Z9 3
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1746-8094
EI 1746-8108
J9 BIOMED SIGNAL PROCES
JI Biomed. Signal Process. Control
PD SEP
PY 2020
VL 62
AR 102149
DI 10.1016/j.bspc.2020.102149
PG 9
WC Engineering, Biomedical
SC Engineering
GA NW9ZQ
UT WOS:000575379700003
PM 32834831
OA Green Published
DA 2021-01-01
ER

PT J
AU Schredl, M
   Bulkeley, K
AF Schredl, Michael
   Bulkeley, Kelly
TI Dreaming and the COVID-19 Pandemic: A Survey in a US Sample
SO DREAMING
LA English
DT Article
DE dream recall; dream emotions; COVID-19 pandemic
ID SLEEP DURATION; RECALL; THERAPY; IMAGERY; STATE
AB This study analyzes the responses of 3,031 U.S. adults who, in early May of 2020, completed an online survey regarding their dreams and the COVID-19 outbreak. The results indicate that those people most strongly affected by the pandemic also reported the strongest effects on their dream life (heightened dream recall, more negatively toned dreams, and pandemic-related dreams). Pronounced negative effects of the pandemic on dreaming were also found to be more likely among women and people with higher levels of education. These findings support the notion that changes in the frequency, tone, and contents of dreaming can help identify specific people who may be most at risk for mental health problems during the COVID-19 outbreak.
C1 [Schredl, Michael] Cent Inst Mental Hlth, Sleep Lab, Mannheim, Germany.
   [Schredl, Michael] Heidelberg Univ, Med Fac Mannheim, Heidelberg, Germany.
   [Bulkeley, Kelly] Sleep & Dream Database, Portland, OR USA.
RP Schredl, M (corresponding author), Zent Inst Seel Gesundheit, Schlaflab, Postfach 12 21 20, D-68072 Mannheim, Germany.
EM Michael.Schredl@zi-mannheim.de
OI Schredl, Michael/0000-0002-8031-6608
CR Bulkeley K, 2010, DREAMING, V20, P77, DOI 10.1037/a0019773
   Bulkeley K, 2008, CONSCIOUS COGN, V17, P1248, DOI 10.1016/j.concog.2008.07.001
   Cartwright R., 2011, PRINCIPLES PRACTICE, P620, DOI 10.1016/B978-1-4160-6645-3.00054-2
   Cellini N, 2020, J SLEEP RES, V29, DOI 10.1111/jsr.13074
   COHEN DB, 1974, J CONSULT CLIN PSYCH, V42, P699, DOI 10.1037/h0036948
   David D, 1997, DREAMING, V7, P209, DOI 10.1037/h0094475
   Domhoff GW, 2018, EMERGENCE DREAMING M
   Gupta MA, 2020, J CLIN SLEEP MED, V16, P1419, DOI 10.5664/jcsm.8562
   Hartmann E, 2003, DREAMING, V13, P61, DOI 10.1023/A:1023398924124
   Hartmann E, 2011, NATURE FUNCTIONS DRE
   Hill CE, 2001, DREAMING, V11, P53, DOI 10.1023/A:1009420619940
   Hill CE, 2010, INT REV NEUROBIOL, V92, P291, DOI 10.1016/S0074-7742(10)92013-8
   HOLLAN D, 1989, ETHOS, V17, P166, DOI 10.1525/eth.1989.17.2.02a00020
   Krakow B, 2010, SLEEP MED CLIN, V5, P289, DOI 10.1016/j.jsmc.2010.01.004
   Kramer M., 2007, DREAM EXPERIENCE SYS
   Mageo J, 2019, DREAMING, V29, P370, DOI 10.1037/drm0000120
   PAGEL JF, 1995, DREAMING, V5, P43, DOI 10.1037/h0094422
   Pappa S, 2020, BRAIN BEHAV IMMUN, V88, P901, DOI 10.1016/j.bbi.2020.05.026
   Pesant N, 2004, CLIN PSYCHOL REV, V24, P489, DOI 10.1016/j.cpr.2004.05.002
   Revonsuo A., 2015, OPEN MIND, P1
   Schredl M, 1998, J SLEEP RES, V7, P191, DOI 10.1046/j.1365-2869.1998.00113.x
   Schredl M, 2005, PERCEPT MOTOR SKILL, V101, P613
   Schredl M., 2016, INT J DREAM RES, V9, P82
   Schredl M., 2012, INT J DREAM RES, V5, P1
   Schredl M., 2018, RES DREAMS FUNDAMENT, DOI [10.1007/978-3-319-95453-0, DOI 10.1007/978-3-319-95453-0]
   Schredl M., 2003, SLEEP HYPNOSIS, V5, P38
   Schredl M, 2008, J SLEEP RES, V17, P125, DOI 10.1111/j.1365-2869.2008.00626.x
   Schredl M, 2008, PERCEPT MOTOR SKILL, V106, P633, DOI 10.2466/PMS.106.2.633-636
   Sheriff RE, 2017, ETHOS, V45, P532, DOI 10.1111/etho.12179
   Siegel A., 1996, TRAUMA DREAMS, P159
   Tedlock B., 1987, DREAMING ANTHR PSYCH, P1
   Torales J, 2020, INT J SOC PSYCHIATR, V66, P317, DOI 10.1177/0020764020915212
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang HY, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233410
   WOOD JM, 1992, J ABNORM PSYCHOL, V101, P219, DOI 10.1037/0021-843X.101.2.219
   Zhang CX, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00306
NR 36
TC 0
Z9 0
U1 6
U2 6
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1053-0797
EI 1573-3351
J9 DREAMING
JI Dreaming
PD SEP
PY 2020
VL 30
IS 3
BP 189
EP 198
DI 10.1037/drm0000146
PG 10
WC Psychology, Multidisciplinary
SC Psychology
GA NX0ZF
UT WOS:000575446700001
DA 2021-01-01
ER

PT J
AU Amporndanai, K
   Rogers, M
   Watanabe, S
   Yamanaka, K
   O'Neill, PM
   Hasnain, SS
AF Amporndanai, Kangsa
   Rogers, Michael
   Watanabe, Seiji
   Yamanaka, Koji
   O'Neill, Paul M.
   Hasnain, S. Samar
TI Novel Selenium-based compounds with therapeutic potential for
   SOD1-linked amyotrophic lateral sclerosis
SO EBIOMEDICINE
LA English
DT Article
DE SOD1; Ebselen; Drug design; Neurodegeneration; Motor neuron disease;
   COVID-19
ID SUPEROXIDE-DISMUTASE; EBSELEN; SOD1; ANTIOXIDANT; MODEL; AGGREGATION;
   INSTABILITY; IMPAIRMENT; EFFICACY; DISEASE
AB Background: Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease as well as Lou Gehrig's disease, is a progressive neurological disorder selectively affecting motor neurons with no currently known cure. Around 20% of the familial ALS cases arise from dominant mutations in the sod1 gene encoding super-oxide dismutasel (SOD1) enzyme. Aggregation of mutant SOD1 in familial cases and of wild-type SOD1 in at least some sporadic ALS cases is one of the known causes of the disease. Riluzole, approved in 1995 and edaravone in 2017 remain the only drugs with limited therapeutic benefits.
   Methods: We have utilised the ebselen template to develop novel compounds that redeem stability of mutant SOD1 dimer and prevent aggregation. Binding modes of compounds have been visualised by crystallography. In vitro neuroprotection and toxicity of lead compounds have been performed in mouse neuronal cells and disease onset delay of ebselen has been demonstrated in transgenic ALS mice model.
   Finding: We have developed a number of ebselen-based compounds with improvements in A4V SOD1 stabilisation and in vitro therapeutic effects with significantly better potency than edaravone. Structure-activity relationship of hits has been guided by high resolution structures of ligand-bound A4V SOD1. We also show clear disease onset delay of ebselen in transgenic ALS mice model holding encouraging promise for potential therapeutic compounds.
   Interpretation: Our finding established the new generation of organo-selenium compounds with better in vitro neuroprotective activity than edaravone. The potential of this class of compounds may offer an alternative therapeutic agent for ALS treatment. The ability of these compounds to target cysteine 111 in SOD may have wider therapeutic applications targeting cysteines of enzymes involved in pathogenic and viral diseases including main protease of SARS-Cov-2 (COVID-19). (C) 2020 The Authors. Published by Elsevier B.V.
C1 [Amporndanai, Kangsa; Hasnain, S. Samar] Univ Liverpool, Fac Hlth & Life Sci, Inst Syst Mol & Integrat Biol, Dept Biochem & Syst Biol,Mol Biophys Grp, Liverpool L69 7ZB, Merseyside, England.
   [Rogers, Michael; O'Neill, Paul M.] Univ Liverpool, Fac Sci & Engn, Dept Chem, Liverpool L69 7ZD, Merseyside, England.
   [Watanabe, Seiji; Yamanaka, Koji] Nagoya Univ, Res Inst Environm Med, Dept Neurosci & Pathobiol, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.
   [Watanabe, Seiji; Yamanaka, Koji] Nagoya Univ, Dept Neurosci & Pathobiol, Grad Sch Med, Nagoya, Aichi 4668550, Japan.
RP Hasnain, SS (corresponding author), Univ Liverpool, Fac Hlth & Life Sci, Inst Syst Mol & Integrat Biol, Dept Biochem & Syst Biol,Mol Biophys Grp, Liverpool L69 7ZB, Merseyside, England.
RI Yamanaka, Koji/ABD-1034-2020; Yamanaka, Koji/H-5806-2011
OI Yamanaka, Koji/0000-0003-4655-0035; Yamanaka, Koji/0000-0003-4655-0035;
   Watanabe, Seiji/0000-0001-8038-7919; Hasnain, Samar/0000-0002-2854-4718
FU ALS Association grant [WA1128]; Ministry of Education, Culture, Sports,
   Science and Technology (MEXT), JapanMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT) [19KK0214]
FX This work was supported by the ALS Association grant awarded to S.S.H.
   and P.O.N. (WA1128) supporting K.A. and M.R. for compound synthesis, DSF
   screens and crystallographic study and Fostering Joint International
   Research (19KK0214) from the Ministry of Education, Culture, Sports,
   Science and Technology (MEXT), Japan awarded to S. W. and K.Y for
   cell-based and animal model studies. We acknowledge the help and support
   of the staff and management of the Diamond Light Source for the
   beamtimes and operation of the facility (proposal: mx21970). We would
   also like to thank members of the molecular biophysics group
   particularly Dr Antonyuk for her interest and help. We also acknowledge
   discussions with Professor Carolyn Young and for her encouragement.
CR Abe K, 2014, AMYOTROPH LAT SCL FR, V15, P610, DOI 10.3109/21678421.2014.959024
   Alvarez-Zaldiernas C, 2016, J BIOL CHEM, V291, P17197, DOI 10.1074/jbc.M115.708230
   Auclair JR, 2010, P NATL ACAD SCI USA, V107, P21394, DOI 10.1073/pnas.1015463107
   Azad GK, 2014, MOL BIOL REP, V41, P2717, DOI 10.1007/s11033-014-3181-y
   Banci L, 2012, J AM CHEM SOC, V134, P7009, DOI 10.1021/ja211591n
   Capper MJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04114-x
   Cardoso RMF, 2002, J MOL BIOL, V324, P247, DOI 10.1016/S0022-2836(02)01090-2
   Chantadul V, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0826-3
   Chen XP, 2012, NEUROCHEM RES, V37, P835, DOI 10.1007/s11064-011-0679-8
   Chio A, 2013, NEUROEPIDEMIOLOGY, V41, P118, DOI 10.1159/000351153
   Deng HX, 2006, P NATL ACAD SCI USA, V103, P7142, DOI 10.1073/pnas.0602046103
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158
   Evans PR, 2011, ACTA CRYSTALLOGR D, V67, P282, DOI 10.1107/S090744491003982X
   Fang T, 2018, LANCET NEUROL, V17, P416, DOI 10.1016/S1474-4422(18)30054-1
   FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051
   Galaleldeen A, 2009, ARCH BIOCHEM BIOPHYS, V492, P40, DOI 10.1016/j.abb.2009.09.020
   GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258
   Hough MA, 2004, P NATL ACAD SCI USA, V101, P5976, DOI 10.1073/pnas.0305143101
   Jaiswal MK, 2019, MED RES REV, V39, P733, DOI 10.1002/med.21528
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Juneja T, 1997, NEUROLOGY, V48, P55, DOI 10.1212/WNL.48.1.55
   Kalayci M, 2005, NEUROCHEM RES, V30, P403, DOI 10.1007/s11064-005-2615-2
   Lebedev AA, 2012, ACTA CRYSTALLOGR D, V68, P431, DOI 10.1107/S090744491200251X
   Martini F, 2019, J PSYCHIATR RES, V109, P107, DOI 10.1016/j.jpsychires.2018.11.021
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Pansarasa O, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051345
   Rakhit R, 2004, J BIOL CHEM, V279, P15499, DOI 10.1074/jbc.M313295200
   Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43
   Saccon RA, 2013, BRAIN, V136, P2342, DOI 10.1093/brain/awt097
   Schmidlin T, 2009, BIOPHYS J, V97, P1709, DOI 10.1016/j.bpj.2009.06.043
   Takasago T, 1997, BRIT J PHARMACOL, V122, P1251, DOI 10.1038/sj.bjp.0701426
   Vagin A, 2010, ACTA CRYSTALLOGR D, V66, P22, DOI 10.1107/S0907444909042589
   Wager TT, 2016, ACS CHEM NEUROSCI, V7, P767, DOI 10.1021/acschemneuro.6b00029
   Wang Q, 2008, PLOS BIOL, V6, P1508, DOI 10.1371/journal.pbio.0060170
   Watanabe S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.459
   Watanabe S, 2016, EMBO MOL MED, V8, P1421, DOI 10.15252/emmm.201606403
   Winter G, 2018, ACTA CRYSTALLOGR D, V74, P85, DOI 10.1107/S2059798317017235
   Witan H, 2008, HUM MOL GENET, V17, P1373, DOI 10.1093/hmg/ddn025
   Wood-Allum CA, 2006, BRAIN, V129, P1693, DOI 10.1093/brain/awl118
   Wright GSA, 2016, SCI REP-UK, V6, DOI 10.1038/srep27691
   Wright GSA, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2750
   Xu WC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0106-4
NR 42
TC 0
Z9 0
U1 9
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD SEP
PY 2020
VL 59
AR 102980
DI 10.1016/j.ebiom.2020.102980
PG 12
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA NX1CR
UT WOS:000575455700013
PM 32862101
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Louapre, C
   Collongues, N
   Stankoff, B
   Giannesini, C
   Papeix, C
   Bensa, C
   Deschamps, R
   Creange, A
   Wahab, A
   Pelletier, J
   Heinzlef, O
   Labauge, P
   Guilloton, L
   Ahle, G
   Goudot, M
   Bigaut, K
   Laplaud, DA
   Vukusic, S
   Lubetzki, C
   De Seze, JM
AF Louapre, Celine
   Collongues, Nicolas
   Stankoff, Bruno
   Giannesini, Claire
   Papeix, Caroline
   Bensa, Caroline
   Deschamps, Romain
   Creange, Alain
   Wahab, Abir
   Pelletier, Jean
   Heinzlef, Olivier
   Labauge, Pierre
   Guilloton, Laurent
   Ahle, Guido
   Goudot, Mathilde
   Bigaut, Kevin
   Laplaud, David-Axel
   Vukusic, Sandra
   Lubetzki, Catherine
   De Seze, Jerome
CA Covisep Investigators
TI Clinical Characteristics and Outcomes in Patients With Coronavirus
   Disease 2019 and Multiple Sclerosis
SO JAMA NEUROLOGY
LA English
DT Article
AB Importance Risk factors associated with the severity of coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (MS) are unknown. Disease-modifying therapies (DMTs) may modify the risk of developing a severe COVID-19 infection, beside identified risk factors such as age and comorbidities. Objective To describe the clinical characteristics and outcomes in patients with MS and COVID-19 and identify factors associated with COVID-19 severity. Design, Setting, and Participants The Covisep registry is a multicenter, retrospective, observational cohort study conducted in MS expert centers and general hospitals and with neurologists collaborating with MS expert centers and members of the Societe Francophone de la Sclerose en Plaques. The study included patients with MS presenting with a confirmed or highly suspected diagnosis of COVID-19 between March 1, 2020, and May 21, 2020. Exposures COVID-19 diagnosed with a polymerase chain reaction test on a nasopharyngeal swab, thoracic computed tomography, or typical symptoms. Main Outcomes and Measures The main outcome was COVID-19 severity assessed on a 7-point ordinal scale (ranging from 1 [not hospitalized with no limitations on activities] to 7 [death]) with a cutoff at 3 (hospitalized and not requiring supplemental oxygen). We collected demographics, neurological history, Expanded Disability Severity Scale score (EDSS; ranging from 0 to 10, with cutoffs at 3 and 6), comorbidities, COVID-19 characteristics, and outcomes. Univariate and multivariate logistic regression models were used to estimate the association of collected variables with COVID-19 outcomes. Results A total of 347 patients (mean [SD] age, 44.6 [12.8] years, 249 women; mean [SD] disease duration, 13.5 [10.0] years) were analyzed. Seventy-three patients (21.0%) had a COVID-19 severity score of 3 or more, and 12 patients (3.5%) died of COVID-19. The median EDSS was 2.0 (range, 0-9.5), and 284 patients (81.8%) were receiving DMT. There was a higher proportion of patients with a COVID-19 severity score of 3 or more among patients with no DMT relative to patients receiving DMTs (46.0% vs 15.5%; P < .001). Multivariate logistic regression models determined that age (odds ratio per 10 years: 1.9 [95% CI, 1.4-2.5]), EDSS (OR for EDSS >= 6, 6.3 [95% CI. 2.8-14.4]), and obesity (OR, 3.0 [95% CI, 1.0-8.7]) were independent risk factors for a COVID-19 severity score of 3 or more (indicating hospitalization or higher severity). The EDSS was associated with the highest variability of COVID-19 severe outcome (R-2, 0.2), followed by age (R-2, 0.06) and obesity (R-2, 0.01). Conclusions and Relevance In this registry-based cohort study of patients with MS, age, EDSS, and obesity were independent risk factors for severe COVID-19; there was no association found between DMTs exposure and COVID-19 severity. The identification of these risk factors should provide the rationale for an individual strategy regarding clinical management of patients with MS during the COVID-19 pandemic.
   Question What are the risk factors for developing a severe form of coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (MS)? Findings In this cohort study of 347 patients with MS, risk factors for severe forms of COVID-19 were neurological disability, age, and obesity, but no association was found between disease-modifying therapies exposure and COVID-19 severity. Meaning The identification of these risk factors could provide a rationale for an individual strategy of clinical management in patients with MS during the COVID-19 pandemic.
   This cohort study describes the clinical characteristics and outcomes in patients with multiple sclerosis who contract COVID-19 and identifies factors associated with COVID-19 severity.
C1 [Louapre, Celine; Stankoff, Bruno; Papeix, Caroline; Lubetzki, Catherine] Sorbonne Univ, Inst Cerveau & Moelle Epiniere, Hop Pitie Salpetriere, CNRS,INSERM,AP HP,Clin Invest Ctr Neurosci, Paris, France.
   [Collongues, Nicolas; Bigaut, Kevin; De Seze, Jerome] CHU Strasbourg, Clin Invest Ctr Inst Natl Sante & Rech Med 1434, Serv Neurol, Strasbourg, France.
   [Stankoff, Bruno; Giannesini, Claire] Hop St Antoine, AP HP, Paris, France.
   [Bensa, Caroline; Deschamps, Romain] Hop Fdn Adolphe Rothschild, Dept Neurol, Paris, France.
   [Creange, Alain; Wahab, Abir] Univ Paris Est Creteil, Grp Hosp Henri Mondor, Ctr Ressources & Competences Sclerose Plaques, Serv Neurol,AP HP, Creteil, France.
   [Pelletier, Jean] Aix Marseille Univ, Hop Timone, AP HM, Serv Neurol,Pole Neurosci Clin, Marseille, France.
   [Heinzlef, Olivier] Ctr Hosp Poissy, Dept Neurol, St Germain En Laye, France.
   [Labauge, Pierre] CHU Montpellier, Dept Neurol, Montpellier, France.
   [Guilloton, Laurent] Assoc Neurologues Liberaux Langue Francaise, Bergerac, France.
   [Ahle, Guido] Hop Civils Colmar, Dept Neurol, Colmar, France.
   [Goudot, Mathilde] Grp Hosp Reg Mulhouse, Serv Neurol, Mulhouse, France.
   [Laplaud, David-Axel] CHU Nantes, Ctr Rech Transplantat & Immunol, INSERM, Clin Invest Ctr 1413,U1064,Serv Neurol, Nantes, France.
   [Vukusic, Sandra] Hosp Civils Lyon, Hop Neurol Pierre Wertheimer, Lyon, France.
RP Louapre, C (corresponding author), Sorbonne Univ, Inst Cerveau & Moelle Epiniere, Hop Pitie Salpetriere,Clin Invest Ctr Neurosci, CNRS,INSERM,AP HP,UMR S 1127,UMR 7225, F-75013 Paris, France.
EM celine.louapre@aphp.fr
RI Ahle, Guido/ABI-1028-2020
OI Ahle, Guido/0000-0002-0877-2289; Ciron, Jonathan/0000-0002-3386-6308;
   Bigaut, Kevin/0000-0002-5176-580X; Laplaud, David/0000-0001-6113-6938
FU French State; Agence Nationale de la RechercheFrench National Research
   Agency (ANR) [ANR-10-COHO-002]; Fondation d'Aide pour la Recherche sur
   la Sclerose en Plaques (ARSEP); Eugene Devic EDMUS Foundation Against
   Multiple Sclerosis; ARSEP Foundation
FX This study did not receive specific funding. The French Clinical
   Research Infrastructure Network for Multiple Sclerosis is supported by a
   grant provided by the French State and handled by the Agence Nationale
   de la Recherche, within the framework of the Investments for the Future
   program, and support from the Fondation d'Aide pour la Recherche sur la
   Sclerose en Plaques (ARSEP). Paris Brain Institute Clinical Research
   Infrastructure Network is supported by a grant provided by the French
   State and handled by the Agence Nationale de la Recherche, within the
   framework of the Institut Hospitalo-Universitaire program. The
   Observatoire Francais de la Sclerose en Plaques is supported by a grant
   provided by the French State and handled by the Agence Nationale de la
   Recherche, within the framework of the Investments for the Future
   program (ANR-10-COHO-002), the Eugene Devic EDMUS Foundation Against
   Multiple Sclerosis, and the ARSEP Foundation.
CR Brownlee W, 2020, NEUROLOGY, V94, P949, DOI 10.1212/WNL.0000000000009507
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Gianfrancesco MA, 2020, LANCET RHEUMATOL, V2, pE250, DOI 10.1016/S2665-9913(20)30095-3
   Giovannoni G, 2020, MULT SCLER RELAT DIS, V39, DOI 10.1016/j.msard.2020.102073
   Levy J, 2017, EUR J NEUROL, V24, P497, DOI 10.1111/ene.13231
   Louapre C, 2020, REV NEUROL-FRANCE, V176, P522, DOI 10.1016/j.neurol.2020.04.009
   Multiple Sclerosis International Federation, 2020, COR MS UPD GLOB ADV
   Novi G, 2019, MULT SCLER RELAT DIS, V36, DOI 10.1016/j.msard.2019.101430
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Salje H, 2020, SCIENCE, V369, P208, DOI 10.1126/science.abc3517
   Stokmaier D, 2018, NEUROLOGY, V90
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Yan CRH, 2020, INT FORUM ALLERGY RH, V10, P821, DOI 10.1002/alr.22592
   Zheng KI, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154244
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 17
TC 21
Z9 23
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6149
EI 2168-6157
J9 JAMA NEUROL
JI JAMA Neurol.
PD SEP
PY 2020
VL 77
IS 9
BP 1079
EP 1088
DI 10.1001/jamaneurol.2020.2581
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA NW2DP
UT WOS:000574820700006
PM 32589189
OA Bronze
DA 2021-01-01
ER

PT J
AU Korytkowski, M
   Antinori-Lent, K
   Drincic, A
   Hirsch, IB
   McDonnell, ME
   Rushakoff, R
   Muniyappa, R
AF Korytkowski, Mary
   Antinori-Lent, Kellie
   Drincic, Andjela
   Hirsch, Irl B.
   McDonnell, Marie E.
   Rushakoff, Robert
   Muniyappa, Ranganath
TI A Pragmatic Approach to Inpatient Diabetes Management during the
   COVID-19 Pandemic
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE COVID-19; diabetes; hyperglycemia; insulin; Sars-CoV-2; hospital
ID HOSPITALIZED-PATIENTS; INSULIN THERAPY; GLYCEMIC CONTROL; GLUCOSE
   CONTROL; GENERAL MEDICINE; SURGERY PATIENTS; BOLUS INSULIN; CARE;
   HYPERGLYCEMIA; INFUSION
AB The pandemic of COVID-19 has presented new challenges to hospital personnel providing care for infected patients with diabetes who represent more than 20% of critically ill patients in intensive care units. Appropriate glycemic management contributes to a reduction in adverse clinical outcomes in acute illness but also requires intensive patient interactions for bedside glucose monitoring, intravenous and subcutaneous insulin administration, as well as rapid intervention for hypoglycemia events. These tasks are required at a time when minimizing patient interactions is recommended as a way of avoiding prolonged exposure to COVID-19 by health care personnel who often practice in settings with limited supplies of personal protective equipment. The purpose of this manuscript is to provide guidance for clinicians for reconciling recommended standards of care for infected hospitalized patients with diabetes while also addressing the daily realities of an overwhelmed health care system in many areas of the country. The use of modified protocols for insulin administration, bedside glucose monitoring, and medications such as glucocorticoids and hydroxychloroquine that may affect glycemic control are discussed. Continuous glucose monitoring systems have been proposed as an option for reducing time spent with patients, but there are important issues that need to be addressed if these are used in hospitalized patients. On-site and remote glucose management teams have potential to provide guidance in areas where there are shortages of personnel who have expertise in inpatient glycemic management.
C1 [Korytkowski, Mary] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA.
   [Antinori-Lent, Kellie] Univ Pittsburgh, Med Ctr, Shadyside Hosp, Pittsburgh, PA 15213 USA.
   [Drincic, Andjela] Univ Nebraska, Med Ctr, Omaha, NE 68198 USA.
   [Hirsch, Irl B.] Univ Washington, Seattle, WA 98195 USA.
   [McDonnell, Marie E.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
   [McDonnell, Marie E.] Harvard Med Sch, Boston, MA 02115 USA.
   [Rushakoff, Robert] Univ Calif San Francisco, San Francisco, CA 94143 USA.
   [Muniyappa, Ranganath] NIDDK, Diabet Endocrinol & Obes Branch, NIH, Bethesda, MD 20892 USA.
RP Korytkowski, M (corresponding author), Univ Pittsburgh, Div Endocrinol & Metab, Med, 3601 Fifth Ave,Suite 3B, Pittsburgh, PA 15213 USA.
EM mtk7@pitt.edu
OI Muniyappa, Ranganath/0000-0003-4198-1055; Korytkowski,
   Mary/0000-0001-7131-8903
CR Aggarwal A, 2011, ENDOCR PRACT, V17, P558, DOI 10.4158/EP10354.OR
   Ali H, 2020, RENAL FAILURE, V42, P393, DOI 10.1080/0886022X.2020.1756323
   Amer Diabet Assoc, 2020, DIABETES CARE, V43, pS193, DOI 10.2337/dc20-S015
   Angus DC, 2020, ANN AM THORAC SOC, V17, P879, DOI 10.1513/AnnalsATS.202003-192SD
   [Anonymous], HOM US BLOOD GLUC ME
   Baldwin D, 2013, CURR DIABETES REP, V13, P114, DOI 10.1007/s11892-012-0339-7
   Baldwin D, 2012, DIABETES CARE, V35, P1970, DOI 10.2337/dc12-0578
   Bardia A, 2019, CURR OPIN ANESTHESIO, V32, P80, DOI 10.1097/ACO.0000000000000674
   Baretic M, 2020, DIABETES METAB SYND, V14, P355, DOI 10.1016/j.dsx.2020.04.014
   Brunner GA, 2000, DIABETIC MED, V17, P371, DOI 10.1046/j.1464-5491.2000.00289.x
   Curll M, 2010, QUAL SAF HEALTH CARE, V19, P355, DOI 10.1136/qshc.2008.027441
   Danese Elisa, 2015, J Diabetes Sci Technol, V9, P169, DOI 10.1177/1932296814567227
   Desouza CV, 2020, J CLIN ENDOCR METAB, V105, P677, DOI 10.1210/clinem/dgz087
   Deusenberry CM, 2012, PHARMACOTHERAPY, V32, P613, DOI 10.1002/j.1875-9114.2011.01088.x
   Donihi AC, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0876-1
   Donihi Amy Calabrese, 2006, Endocr Pract, V12, P358
   Drincic AT, 2018, CURR DIABETES REP, V18, DOI 10.1007/s11892-018-0972-x
   Drincic AT, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0882-3
   Drucker DJ, 2020, ENDOCR REV, V41, P457, DOI 10.1210/endrev/bnaa011
   Dungan KM, 2013, DIABETES CARE, V36, P3476, DOI 10.2337/dc13-0121
   Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625
   Flanagan D, 2018, DIABETIC MED, V35, P992, DOI 10.1111/dme.13677
   Fleming N, 2020, J CLIN ENDOCR METAB, V105, P2475, DOI 10.1210/clinem/dgaa200
   Flory JH, 2020, DIABETES CARE, V43, P244, DOI 10.2337/dc19-0923
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Grommesh B, 2016, ENDOCR PRACT, V22, P180, DOI 10.4158/EP15818.OR
   Healy SJ, 2017, ENDOCRINE, V56, P90, DOI 10.1007/s12020-016-1220-2
   Hood KK, 2020, DIABETES CARE, V43, P19, DOI 10.2337/dci19-0054
   Hsia E, 2012, J CLIN ENDOCR METAB, V97, P3132, DOI 10.1210/jc.2012-1244
   Hsia E, 2011, NUTR CLIN PRACT, V26, P714, DOI 10.1177/0884533611420727
   Huhmann MB, 2018, NUTR DIABETES, V8, DOI 10.1038/s41387-018-0053-x
   Iacobellis G, 2020, DIABETES RES CLIN PR, V162, DOI 10.1016/j.diabres.2020.108125
   James Steven, 2016, J Diabetes Sci Technol, V10, P1115, DOI 10.1177/1932296816660326
   Jia XM, 2018, CURR DIABETES REP, V18, DOI 10.1007/s11892-018-1038-9
   Kaiser UB, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgaa148
   Klonoff DC, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154224
   Klonoff DC, 2018, DIABETES CARE, V41, P1681, DOI 10.2337/dc17-1960
   Korytkowski MT, 2009, DIABETES CARE, V32, P594, DOI 10.2337/dc08-1436
   Koufakis T, 2020, J CLIN PHARM THER, V45, P883, DOI 10.1111/jcpt.13107
   Leonhardi Brenda J, 2008, J Diabetes Sci Technol, V2, P948
   Mabrey Melanie E, 2015, J Diabetes Sci Technol, V9, P1152, DOI 10.1177/1932296815590827
   Maiorino MI, 2020, DIABETES CARE, V43, P1146, DOI 10.2337/dc19-1459
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Menchine MD, 2011, ACAD EMERG MED, V18, P326, DOI 10.1111/j.1553-2712.2011.01014.x
   Michaud TL, 2018, POPUL HEALTH MANAG, V21, P387, DOI 10.1089/pop.2017.0175
   Moghissi ES, 2009, DIABETES CARE, V32, P1119, DOI 10.2337/dc09-9029
   Montero AR, 2019, WORLD J DIABETES, V10, P473, DOI 10.4239/wjd.v10.i9.473
   Muniyappa R, 2020, AM J PHYSIOL-ENDOC M, V318, pE736, DOI 10.1152/ajpendo.00124.2020
   Munshi MN, 2019, DIABETES CARE, V42, P1129, DOI 10.2337/dc18-1631
   Nair BG, 2020, DIABETES CARE, V43, pE168, DOI 10.2337/dc20-0670
   Noschese ML, 2009, ENDOCR PRACT, V15, P415, DOI 10.4158/EP09063.ORR
   Pasquel FJ, 2019, CURR DIABETES REP, V19, DOI 10.1007/s11892-019-1184-8
   Pasquel FJ, 2017, LANCET DIABETES ENDO, V5, P125, DOI 10.1016/S2213-8587(16)30402-8
   Perez-Belmonte LM, 2019, ANN MED, V51, P252, DOI 10.1080/07853890.2019.1613672
   Rea RS, 2007, AM J HEALTH-SYST PH, V64, P385, DOI 10.2146/ajhp060014
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rushakoff RJ, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0896-x
   Rushakoff RJ, 2017, ANN INTERN MED, V166, P621, DOI 10.7326/M16-1413
   Sardu C, 2020, DIABETES CARE, V43, P1408, DOI 10.2337/dc20-0723
   Schmeltz Lowell R, 2006, Endocr Pract, V12, P641
   Schnipper JL, 2008, J HOSP MED, V3, pS66, DOI 10.1002/jhm.356
   Scirica BM, 2013, NEW ENGL J MED, V369, P1317, DOI 10.1056/NEJMoa1307684
   Seggelke SA, 2011, J HOSP MED, V6, P175, DOI 10.1002/jhm.874
   Shah Arti D, 2015, J Diabetes Sci Technol, V9, P1155, DOI 10.1177/1932296815586581
   Siminerio L, 2014, DIABETES EDUCATOR, V40, P797, DOI 10.1177/0145721714551993
   Singh Lakshmi G, 2020, J Diabetes Sci Technol, V14, P783, DOI 10.1177/1932296819889640
   Slattery D, 2018, DIABETIC MED, V35, P306, DOI 10.1111/dme.13525
   Smiley D, 2010, J HOSP MED, V5, P212, DOI 10.1002/jhm.646
   Spanakis Elias K, 2018, J Diabetes Sci Technol, V12, P20, DOI 10.1177/1932296817748964
   Spanakis Elias K, 2014, Hosp Pract (1995), V42, P23, DOI 10.3810/hp.2014.04.1100
   Thabit H, 2014, J CLIN ENDOCR METAB, V99, P2225, DOI 10.1210/jc.2013-4519
   Thompson B, 2018, CURR DIABETES REP, V18, DOI 10.1007/s11892-018-1056-7
   Thompson Bithika, 2018, J Diabetes Sci Technol, V12, P880, DOI 10.1177/1932296818769933
   Toh S, 2016, ANN INTERN MED, V164, P705, DOI 10.7326/M15-2568
   Umpierrez GE, 2018, DIABETES CARE, V41, P1579, DOI 10.2337/dci18-0002
   Umpierrez GE, 2013, DIABETES CARE, V36, P3430, DOI 10.2337/dc13-0277
   Umpierrez GE, 2013, DIABETES CARE, V36, P2112, DOI 10.2337/dc12-2233
   Umpierrez GE, 2012, J CLIN ENDOCR METAB, V97, P16, DOI 10.1210/jc.2011-2098
   Umpierrez GE, 2011, DIABETES CARE, V34, P256, DOI 10.2337/dc10-1407
   Umpierrez GE, 2007, DIABETES CARE, V30, P2181, DOI 10.2337/dc07-0295
   Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300
   van der Crabben SN, 2009, J CLIN ENDOCR METAB, V94, P463, DOI 10.1210/jc.2008-0761
   Vellanki P, 2019, DIABETES OBES METAB, V21, P837, DOI 10.1111/dom.13587
   Wallia Amisha, 2017, J Diabetes Sci Technol, V11, P1036, DOI 10.1177/1932296817706151
   Wang CCL, 2016, ENDOCR PRACT, V22, P271, DOI 10.4158/EP151101.CO
   Wasko MCM, 2015, DIABETOLOGIA, V58, P2336, DOI 10.1007/s00125-015-3689-2
   Wondafrash DZ, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/5214751
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
NR 89
TC 6
Z9 6
U1 0
U2 0
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD SEP
PY 2020
VL 105
IS 9
BP 3076
EP 3087
DI 10.1210/clinem/dgaa342
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA NW2UY
UT WOS:000574866500074
PM 32498085
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Smith, E
   Zhen, W
   Manji, R
   Schron, D
   Duong, S
   Berry, GJ
AF Smith, Elizabeth
   Zhen, Wei
   Manji, Ryhana
   Schron, Deborah
   Duong, Scott
   Berry, Gregory J.
TI Analytical and Clinical Comparison of Three Nucleic Acid Amplification
   Tests for SARS-CoV-2 Detection
SO JOURNAL OF CLINICAL MICROBIOLOGY
LA English
DT Article
DE SARS-CoV-2; COVID-19; EUA; molecular diagnostics; TMA; PCR; quantified
   virus
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in December 2019 and has quickly become a worldwide pandemic. In response, many diagnostic manufacturers have developed molecular assays for SARS-CoV-2 under the Food and Drug Administration (FDA) Emergency Use Authorization (EUA) pathway. This study compared three of these assays, the Hologic Panther Fusion SARS-CoV-2 assay (Fusion), the Hologic Aptima SARS-CoV-2 assay (Aptima), and the BioFire Defense COVID-19 test (BioFire), to determine analytical and clinical performance as well as workflow. All three assays showed similar limits of detection (LODs) using inactivated virus, with 100% detection, ranging from 500 to 1,000 genome equivalents/ml, whereas use of a quantified RNA transcript standard showed the same trend but had values ranging from 62.5 to 125 copies/ml, confirming variability in absolute quantification of reference standards. The clinical correlation found that the Fusion and BioFire assays had a positive percent agreement (PPA) of 98.7%, followed by the Aptima assay at 94.7%, compared to the consensus result. All three assays exhibited 100% negative percent agreement (NPA). Analysis of discordant results revealed that all four samples missed by the Aptima assay had cycle threshold (C-t) values of >37 by the Fusion assay. In conclusion, while all three assays showed similar relative LODs, we showed differences in absolute LODs depending on which standard was employed. In addition, the Fusion and BioFire assays showed better clinical performance, while the Aptima assay showed a modest decrease in overall PPA. These findings should be kept in mind when making platform testing decisions.
C1 [Smith, Elizabeth; Zhen, Wei; Manji, Ryhana; Duong, Scott; Berry, Gregory J.] Northwell Hlth Labs, Infect Dis Diagnost, Lake Success, NY 11042 USA.
   [Schron, Deborah; Duong, Scott; Berry, Gregory J.] Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Pathol & Lab Med, Hempstead, NY 11549 USA.
RP Berry, GJ (corresponding author), Northwell Hlth Labs, Infect Dis Diagnost, Lake Success, NY 11042 USA.; Berry, GJ (corresponding author), Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Pathol & Lab Med, Hempstead, NY 11549 USA.
EM gberry1@northwell.edu
CR Aslam MM, 2020, DIS MARKERS, V2020, DOI 10.1155/2020/1910215
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Hogan CA, 2020, J CLIN VIROL, V128, DOI 10.1016/j.jcv.2020.104410
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lieberman JA, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00821-20
   McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031
   R Core Team, 2017, R LANG ENV STAT COMP
   WHO, 2020, REP WHO CHIN JOINT M
   Zhen W, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00743-20
   Zhen W, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00783-20
NR 11
TC 5
Z9 5
U1 4
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0095-1137
EI 1098-660X
J9 J CLIN MICROBIOL
JI J. Clin. Microbiol.
PD SEP
PY 2020
VL 58
IS 9
AR e01134-20
DI 10.1128/JCM.01134-20
PG 8
WC Microbiology
SC Microbiology
GA NW6HX
UT WOS:000575116900011
PM 32571894
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Salehi, N
   Amiri-Yekta, A
   Totonchi, M
AF Salehi, Najmeh
   Amiri-Yekta, Amir
   Totonchi, Mehdi
TI Profiling of Initial Available SARS-CoV-2 Sequences from Iranian Related
   COVID-19 Patients
SO CELL JOURNAL
LA English
DT Article
DE COVID-19; Nonsynonymous Mutations; SARS-CoV-2; S Protein
ID SARS; CORONAVIRUS; OUTBREAK
AB The etiologic agent SARS-CoV-2 has caused the outbreak of COVID-19 which is spread widely around the world. It is vital to uncover and investigate the full genome sequence of SARS-CoV-2 throughout the world to track changes in this virus. To this purpose, SARS-CoV-2 full genome sequence profiling of 20 patients in Iran and different countries that already had a travel history to Iran or contacts with Iranian cases were provided from the GISAID database. The bioinformatics analysis showed 44 different nucleotide mutations that caused 26 nonsynonymous mutations in protein sequences with regard to the reference full genome of the SARS-CoV-2 sequence (NC_045512.2). R207C, V3781, M27961, L3606F, and A6407V in ORF1ab were common mutations in these sequences. Also, some of the detected mutations only were found in Iranian data in comparison with all the available sequences of SARS-CoV-2. The position of S protein mutations showed they were far from the binding site of this protein with angiotensin-converting enzyme-2 (ACE2) as the host cell receptor. These results can be helpful to design specific diagnostic tests, trace the SARS-CoV-2 sequence changes in Iran, and explore therapeutic drugs and vaccines.
C1 [Salehi, Najmeh; Amiri-Yekta, Amir; Totonchi, Mehdi] ACECR, Dept Genet, Reprod Biomed Res Ctr, Royan Inst Reprod Biomed, POB 16635-148, Tehran, Iran.
   [Salehi, Najmeh] Univ Tehran, Inst Biochem & Biophys, Dept Bioinformat, Tehran, Iran.
   [Totonchi, Mehdi] ACECR, Royan Inst Stem Cell Biol & Technol, Dept Stem Cells & Dev Biol, Cell Sci Res Ctr, Tehran, Iran.
RP Totonchi, M (corresponding author), ACECR, Dept Genet, Reprod Biomed Res Ctr, Royan Inst Reprod Biomed, POB 16635-148, Tehran, Iran.
EM m.totonchi@royaninstitute.org
OI Salehi, Najmeh/0000-0002-7337-4404
FU Genetic Department of Royan Institute
FX The authors would like to thank the Genetic Department of Royan
   Institute for financially support. There is no conflict of interest.
CR Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Lu L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4067
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Sherwin WB, 2010, ENTROPY-SWITZ, V12, P1765, DOI 10.3390/e12071765
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Su S, 2016, TRENDS MICROBIOL, V24, P490, DOI 10.1016/j.tim.2016.03.003
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   World Health Organization, 2020, SUMM PROB SARS CAS O
   Xiao K, BIORXIV, DOI DOI 10.1101/2020.02.17.951335V1
   Zhang J, 2020, J INFECT
   Zhang T, 2020, CURR BIOL, V30, P1346, DOI 10.1016/j.cub.2020.03.022
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ROYAN INST
PI TEHRAN
PA PO BOX 19395-4644, TEHRAN, 00000, IRAN
SN 2228-5806
EI 2228-5814
J9 CELL J
JI Cell J.
PD FAL
PY 2020
VL 22
SU 1
BP 148
EP 150
DI 10.22074/cellj.2020.7524
PG 3
WC Cell Biology
SC Cell Biology
GA NW3QD
UT WOS:000574924300018
PM 32779445
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Ghavami, SHB
   Shahrokh, SH
   Hossein-Khannazer, N
   Shpichka, A
   Aghdaei, HA
   Timashev, P
   Vosough, M
AF Ghavami, S. Haghayegh Baradaran
   Shahrokh, S. Habnam
   Hossein-Khannazer, Nikoo
   Shpichka, Anastasia
   Aghdaei, Hamid Asadzadeh
   Timashev, Peter
   Vosough, Massoud
TI IBD Patients Could Be Silent Carriers for Novel Coronavirus and Less
   Prone to its Severe Adverse Events: True or False?
SO CELL JOURNAL
LA English
DT Article
DE Anti-TNF-alpha; COVID-19; Crohn's Disease; IBD; Ulcerative Colitis
ID INFLAMMATORY-BOWEL-DISEASE; RENIN-ANGIOTENSIN SYSTEM; SARS-COV;
   IFN-ALPHA; INTERFERON; RECEPTOR; TNF
AB Inflammatory bowel diseases (IBDs) are chronic disorders of the gastrointestinal tract. The goal of IBD treatment is to reduce the inflammation period and induce long-term remission. Use of anti-inflammatory drugs including corticosteroids, immunosuppressants and biologicals, is often the first step in the treatment of IBD. Therefore, IBD patients in pandemic of infectious diseases are considered a high-risk group. The public believes that IBD patients are at a higher risk in the current coronavirus 2 pandemic. Nevertheless, these patients may experience mild or moderate complications compared to healthy people. This might be because of particular anti-TNF-alpha treatment or any immunosuppressant that IBD patients receive. Moreover, these patients might be silent carrier for the virus.
C1 [Ghavami, S. Haghayegh Baradaran; Shahrokh, S. Habnam; Aghdaei, Hamid Asadzadeh] Shahid Beheshti Univ Med Sci, Basic & Mol Epidemiol Gastrointestinal Disorders, Res Inst Gastroenterol & Liver Dis, Tehran, Iran.
   [Ghavami, S. Haghayegh Baradaran; Shahrokh, S. Habnam; Hossein-Khannazer, Nikoo; Aghdaei, Hamid Asadzadeh] Shahid Beheshti Univ Med Sci, Gastroenterol & Liver Dis Res Ctr, Res Inst Gastroenterol & Liver Dis, Tehran, Iran.
   [Hossein-Khannazer, Nikoo] Shahid Beheshti Univ Med Sci, Sch Med, Dept Immunol, Tehran, Iran.
   [Shpichka, Anastasia; Timashev, Peter] Sechenov Univ, Inst Regenerat Med, Moscow, Russia.
   [Shpichka, Anastasia; Timashev, Peter] Lomonosov Moscow State Univ, Dept Chem, Moscow, Russia.
   [Vosough, Massoud] ACECR, Royan Inst Stem Cell Biol & Technol, Dept Regenerat Med, Cell Sci Res Ctr, POB 16635-148, Tehran, Iran.
RP Vosough, M (corresponding author), ACECR, Royan Inst Stem Cell Biol & Technol, Dept Regenerat Med, Cell Sci Res Ctr, POB 16635-148, Tehran, Iran.
EM masvos@royaninstitute.org
OI , Massoud/0000-0001-5924-4366
FU Royan institute and Research Institute for Gastroenterology and Liver
   Diseases, Shahid Beheshti University of Medical Sciences
FX The authors would like to express their gratitude to Royan institute and
   Research Institute for Gastroenterology and Liver Diseases, Shahid
   Beheshti University of Medical Sciences, for their support throughout
   the course of this work. There is no conflict of interest.
CR Actis Giovanni C, 2017, World J Gastrointest Pharmacol Ther, V8, P114, DOI 10.4292/wjgpt.v8.i2.114
   Batlle D, 2020, CLIN SCI, V134, P543, DOI 10.1042/CS20200163
   Burgueno JF, 2020, INFLAMM BOWEL DIS, V26, P797, DOI 10.1093/ibd/izaa085
   Castilletti C, 2005, VIROLOGY, V341, P163, DOI 10.1016/j.virol.2005.07.015
   Chen C, 2020, Zhonghua Shao Shang Za Zhi, V36, P471, DOI 10.3760/cma.j.cn501120-20200224-00088
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   D'Amico Ferdinando, 2020, Gastroenterology, V158, P2302, DOI 10.1053/j.gastro.2020.04.032
   Frieman M, 2008, VIRUS RES, V133, P101, DOI 10.1016/j.virusres.2007.03.015
   Garg M, 2012, ALIMENT PHARM THER, V35, P414, DOI 10.1111/j.1365-2036.2011.04971.x
   Garg M, 2020, GUT, V69, P841, DOI 10.1136/gutjnl-2019-318512
   Garg M, 2015, J RENIN-ANGIO-ALDO S, V16, P559, DOI 10.1177/1470320314521086
   Gembardt F, 2005, PEPTIDES, V26, P1270, DOI 10.1016/j.peptides.2005.01.009
   Haga S, 2010, ANTIVIR RES, V85, P551, DOI 10.1016/j.antiviral.2009.12.001
   HANAUER SB, 2006, INFLAMM BOWEL DIS S1, V12, pS, DOI DOI 10.1097/01.MIB.0000195385.19268.68
   Hiscott J, 2006, BIOCHEM PHARMACOL, V72, P1477, DOI 10.1016/j.bcp.2006.06.030
   Hume Georgia E, 2008, Expert Rev Gastroenterol Hepatol, V2, P645, DOI 10.1586/17474124.2.5.645
   Katze MG, 2002, NAT REV IMMUNOL, V2, P675, DOI 10.1038/nri888
   Khajah MA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150861
   Lambert DW, 2005, J BIOL CHEM, V280, P30113, DOI 10.1074/jbc.M505111200
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Monteleone G, 2020, J CROHNS COLITIS, V14, P1334, DOI 10.1093/ecco-jcc/jjaa061
   Palucka AK, 2005, P NATL ACAD SCI USA, V102, P3372, DOI 10.1073/pnas.0408506102
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Salmenkari H, 2018, J PHYSIOL PHARMACOL, V69, DOI 10.26402/jpp.2018.4.07
   Subramanian CR, 2016, GASTROENTEROL REP, V4, P261, DOI 10.1093/gastro/gow032
   Wong E, 2016, SCI REP-UK, V6, DOI 10.1038/srep35598
   Xiao F, 2020, GASTROENTEROLOGY, V158, P1831, DOI 10.1053/j.gastro.2020.02.055
   Younis N, 2020, MOL BIOL REP, V47, P3053, DOI 10.1007/s11033-020-05318-5
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ROYAN INST
PI TEHRAN
PA PO BOX 19395-4644, TEHRAN, 00000, IRAN
SN 2228-5806
EI 2228-5814
J9 CELL J
JI Cell J.
PD FAL
PY 2020
VL 22
SU 1
BP 151
EP 154
DI 10.22074/cellj.2020.7603
PG 4
WC Cell Biology
SC Cell Biology
GA NW3QD
UT WOS:000574924300019
PM 32779446
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Li, YP
   Tahamtani, Y
   Totonchi, M
   Chen, CS
   Hashemian, SMR
   Amoozegar, F
   Zhang, JS
   Gholampour, Y
   Li, XK
AF Li, Yuping
   Tahamtani, Yaser
   Totonchi, Mehdi
   Chen, Chengshui
   Hashemian, Seyed Mohammad Reza
   Amoozegar, Fatemeh
   Zhang, Jin-San
   Gholampour, Yousef
   Li, Xiaokun
TI Challenges of Iranian Clinicians in Dealing with COVID-19: Taking
   Advantages of The Experiences in Wenzhou
SO CELL JOURNAL
LA English
DT Article
DE Anti-inflammatory Drug; Antiviral Drug; COVID-19; Diagnosis; SARS-CoV-2
AB The novel coronavirus has been spreading since December 2019. It was initially reported in Wuhan, Hubei province of China. Coronavirus disease 2019 (COVID-19) has currently become a pandemic affecting over seven million people worldwide, and the number is still rising. Wenzhou, as the first hit city out of Hubei Province, achieved a remarkable success in effectively containing the disease. A great record was also observed in Wenzhou for the clinical management of COVID-19 patients, leading to one of the lowest death rates in China. Researchers and clinical specialists proposed and formulated combined approaches such as computerized tomography (CT)-scans and molecular assays, as well as using both allopathic and traditional medications to mitigate its effects. Iranian and Chinese specialists and scientists had a communication in clinical, molecular and pharmaceutical aspects of COVID-19. A proper guideline was prepared according to the experiences of Chinese clinicians in managing the full spectrum of COVID-19 patients, from relatively mild to highly complex cases. The purpose of this guideline is to serve a reference in the hospital for specialists so that they may better diagnose cases and provide effective therapies and proposed antiviral and anti-inflammatory drugs for patients.
C1 [Li, Yuping; Chen, Chengshui; Zhang, Jin-San; Li, Xiaokun] Wenzhou Med Univ, Dept Pulm & Crit Care Med, Affiliated Hosp 1, Wenzhou 325000, Peoples R China.
   [Tahamtani, Yaser] ACECR, Royan Inst Stem Cell Biol & Technol, Dept Diabet Obes & Metab, Cell Sci Res Ctr, Tehran, Iran.
   [Tahamtani, Yaser; Totonchi, Mehdi] ACECR, Royan Inst Stem Cell Biol & Technol, Dept Stem Cells & Dev Biol, Cell Sci Res Ctr, Tehran, Iran.
   [Totonchi, Mehdi] ACECR, Royan Inst Reprod Biomed, Dept Genet, Reprod Biomed Res Ctr, Tehran, Iran.
   [Hashemian, Seyed Mohammad Reza] Shahid Beheshti Univ Med Sci, Chron Resp Dis Res Ctr, Natl Res Inst TB & Lung Dis NRITLD, Tehran, Iran.
   [Amoozegar, Fatemeh] Fasa Univ Med Sci, Noncommunicable Dis Res Ctr, Fasa, Iran.
   [Zhang, Jin-San] Wenzhou MedicalUniv, Int Collaborat Ctr Growth Factor Res, Wenzhou, Peoples R China.
   [Zhang, Jin-San] Wenzhou MedicalUniv, Sch Pharmaceut Sci, Wenzhou, Peoples R China.
   [Gholampour, Yousef] Fasa Univ Med Sci, Sch Med, Dept Internal Med, Fasa, Iran.
   [Li, Xiaokun] Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou, Peoples R China.
   [Li, Xiaokun] Wenzhou Biomed Collaborat Innovat Ctr, Wenzhou, Peoples R China.
RP Zhang, JS; Gholampour, Y; Li, XK (corresponding author), Wenzhou Med Univ, Dept Pulm & Crit Care Med, Affiliated Hosp 1, Wenzhou 325000, Peoples R China.; Zhang, JS; Gholampour, Y; Li, XK (corresponding author), Fasa Univ Med Sci, Sch Med, Dept Internal Med, Fasa, Iran.; Zhang, JS; Gholampour, Y; Li, XK (corresponding author), Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou, Peoples R China.; Zhang, JS; Gholampour, Y; Li, XK (corresponding author), Wenzhou Biomed Collaborat Innovat Ctr, Wenzhou, Peoples R China.
EM Zhang_JinSan@wmu.edu.cn; Y.gholampoor@fums.ac.ir; Xiaokunli@wmu.edu.cn
FU Wenzhou Medical University, China; Fasa University of Medical Sciences,
   Iran; Royan Institute, Iran
FX This work has been supported by Wenzhou Medical University, China, Fasa
   University of Medical Sciences, Iran and Royan Institute, Iran. We
   express our appreciation to all members of Chronic Respiratory Diseases
   Research Center at Shahid Beheshti University of Medical Sciences for
   their helpful deliberations and consultation during this work. The
   authors declare that there is no financially support and conflict of
   interest.
CR [Anonymous], 2020, CORONAVIRUS DIS 2019
   [Anonymous], 2020, COVID 19 CORONAVIRUS
   Cai Q, 2020, ENGINEERING
   Gattinoni L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02880-z
   Gong FH, 2020, FRONT MED-PRC, V14, P220, DOI 10.1007/s11684-020-0755-z
   Guarner J, 2020, CLIN INFECT DIS
   Hong XY, 2020, INT J INFECT DIS, V94, P78, DOI 10.1016/j.ijid.2020.03.058
   Hossein-khannazer N, 2020, J MOL MED, V98, P789, DOI 10.1007/s00109-020-01927-6
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jia X, 2020, CLIN SIGNIFICANCE LG
   Li J, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00892-2020
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li SR, 2020, EUR J CLIN MICROBIOL, V39, P1021, DOI 10.1007/s10096-020-03883-y
   Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001
   Manandhar S, 2020, N AM ACAD RES, V3, P473
   Nasibova EM, 2020, J ANESTHESIA SURG, V3, P1
   Nguyen A, 2020, J VIROL, V94, DOI 10.1128/JVI.00510-20
   Ottestad W, 2020, TIDSSKRIFT NORSKE LE
   Pan L, 2020, AM J GASTROENTEROL, V115, P766, DOI 10.14309/ajg.0000000000000620
   Phelan AL, 2020, JAMA-J AM MED ASSOC, V323, P709, DOI 10.1001/jama.2020.1097
   Poe FL, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109862
   Sartini C, 2020, JAMA-J AM MED ASSOC, V323, P2338, DOI 10.1001/jama.2020.7861
   Surveillances V., 2020, ZHONGHUA LIU XING BI, V2, P113, DOI [DOI 10.3760/CMA.J.ISSN.0254-6450.2020.02.003, 10.46234/ccdcw2020.032]
   Veronese N, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00170
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Xu WX, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/4130757
   Yuan H, 2020, LANCET, DOI [10.2139/ssrn.3551344, DOI 10.2139/SSRN.3551344]
   Yuki K, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108427
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 29
TC 0
Z9 0
U1 2
U2 2
PU ROYAN INST
PI TEHRAN
PA PO BOX 19395-4644, TEHRAN, 00000, IRAN
SN 2228-5806
EI 2228-5814
J9 CELL J
JI Cell J.
PD FAL
PY 2020
VL 22
SU 1
BP 155
EP 165
DI 10.22074/cellj.2020.7604
PG 11
WC Cell Biology
SC Cell Biology
GA NW3QD
UT WOS:000574924300020
PM 32779447
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Samsky, MD
   DeVore, AD
   McIlvennan, CK
   Granger, CB
   Granger, BB
   Hernandez, AF
   Felker, GM
   Fonarow, GC
   Albert, NM
   Pina, IL
   Lanfear, D
   Allen, LA
AF Samsky, Marc D.
   DeVore, Adam D.
   McIlvennan, Colleen K.
   Granger, Christopher B.
   Granger, Bradi B.
   Hernandez, Adrian F.
   Felker, G. Michael
   Fonarow, Gregg C.
   Albert, Nancy M.
   Pina, Ileana L.
   Lanfear, David
   Allen, Larry A.
TI Heart Failure Clinical Trial Operations During the COVID-19 Pandemic
   Results From a Multicenter Survey
SO CIRCULATION-HEART FAILURE
LA English
DT Letter
DE COVID-19; clinical trials; heart failure; outcomes research
C1 [Samsky, Marc D.; DeVore, Adam D.; Granger, Christopher B.; Hernandez, Adrian F.; Felker, G. Michael] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA.
   [Samsky, Marc D.; DeVore, Adam D.; Granger, Christopher B.; Granger, Bradi B.; Hernandez, Adrian F.; Felker, G. Michael] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
   [McIlvennan, Colleen K.; Allen, Larry A.] Univ Colorado, Sch Med, Div Cardiol, Aurora, CO USA.
   [Granger, Bradi B.] Duke Coll Nursing, Durham, NC USA.
   [Fonarow, Gregg C.] Ronald Reagan UCLA Med Ctr, Ahmanson UCLA Cardiomyopathy Ctr, Los Angeles, CA USA.
   [Albert, Nancy M.] Cleveland Clin, Kaufman Ctr Heart Failure, Cleveland, OH 44106 USA.
   [Pina, Ileana L.] Wayne State Univ, Detroit, MI USA.
   [Lanfear, David] Wayne State Univ, Dept Med, Detroit, MI 48202 USA.
RP Samsky, MD (corresponding author), Duke Clin Res Inst, POB 17969, Durham, NC 27701 USA.
EM marc.samsky@duke.edu
OI DeVore, Adam/0000-0002-4679-2221; Albert, Nancy/0000-0002-3619-966X;
   Samsky, Marc/0000-0001-7524-5174
FU Novartis Pharmaceuticals Corporation (East Hanover, NJ) [CLCZ-696BUS05T]
FX The CONNECT-HF study is funded by Novartis Pharmaceuticals Corporation
   (East Hanover, NJ) through an investigator-initiated trial program
   (CLCZ-696BUS05T).
CR Bagiella E, 2020, J AM COLL CARDIOL, V76, P342, DOI 10.1016/j.jacc.2020.05.041
   DeVore AD, 2020, AM HEART J, V220, P41, DOI 10.1016/j.ahj.2019.09.012
   Solomon MD, 2020, NEW ENGL J MED, V383, P691, DOI 10.1056/NEJMc2015630
   US Food and Drug Administration, FDA GUID COND CLIN T
NR 4
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1941-3289
EI 1941-3297
J9 CIRC-HEART FAIL
JI Circ.-Heart Fail.
PD SEP
PY 2020
VL 13
IS 9
DI 10.1161/CIRCHEARTFAILURE.120.007456
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NW3AA
UT WOS:000574879900013
PM 32700547
DA 2021-01-01
ER

PT J
AU Mjaess, G
   Karam, A
   Aoun, F
   Albisinni, S
   Roumeguere, T
AF Mjaess, G.
   Karam, A.
   Aoun, F.
   Albisinni, S.
   Roumeguere, T.
TI COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the
   androgen receptor
SO PROGRES EN UROLOGIE
LA English
DT Article
DE COVID-19; Angiotensin-Converting Enzyme 2; Type II Transmembrane Serine
   Protease; androgen receptor
AB COVID-19 is the pandemic that hit the world starting December 2019. Recent studies and international statistics have shown an increased prevalence, morbidity as well as mortality of this disease in male patients compared to female patients. The aim of this brief communication is to describe the pathophysiology of this sex-discrepancy, based on the infectivity mechanism of the coronavirus including the Angiotensin-Converting Enzyme 2 (ACE2), the Type II transmembrane Serine Protease (TMPRSS2), and the androgen receptor. This could help understand the susceptibility of urological patients, especially those receiving androgen deprivation therapy for prostate cancer, and testosterone replacement therapy. (C) 2020 Elsevier Masson SAS. All rights reserved.
C1 [Mjaess, G.; Albisinni, S.; Roumeguere, T.] Univ Libre Bruxelles, Univ Clin Brussels, Erasme Hosp, Urol Dept, Brussels, Belgium.
   [Mjaess, G.; Karam, A.; Aoun, F.] Univ St Joseph, Hotel Dieu France, Beirut, Lebanon.
   [Aoun, F.; Roumeguere, T.] Inst Jules Bordet, Urol Dept, Brussels, Belgium.
RP Roumeguere, T (corresponding author), Univ Libre Bruxelles, Erasme Hosp, Urol Dept, Brussels, Belgium.
EM thierry.roumeguere@erasme.ulb.ac.be
OI Mjaess, Georges/0000-0002-8703-4611; Karam, Aya/0000-0003-3105-1604
CR Bahrami F, 2011, IRAN J PSYCHIATRY BE, V5, P83
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Jin J.-M., 2020, GENDER DIFFERENCES P, DOI [10.1101/2020.02.23.20026864, DOI 10.1101/2020.02.23.20026864]
   Karlberg J, 2004, AM J EPIDEMIOL, V159, P229, DOI 10.1093/aje/kwh056
   Li DG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8292
   Lin BY, 1999, CANCER RES, V59, P4180
   Lucas J, 2008, J PATHOL, V215, P118, DOI 10.1002/path.2330
   Montopoli M, 2020, ANN ONCOL OFF J EUR
   Santema BT, 2020, EUR HEART J
   Shen LW, 2017, BIOCHIMIE, V142, P1, DOI 10.1016/j.biochi.2017.07.016
   Smith J.C., 2020, CIGARETTE SMOKE TRIG
   Song C, 2020, DETECTION 2019 NOVEL
   Song H, 2020, EUR UROL
   Stopsack KH, 2020, CANC DISCOV
NR 15
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER MASSON, CORP OFF
PI PARIS
PA 65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE
SN 1166-7087
J9 PROG UROL
JI Prog. Urol.
PD SEP
PY 2020
VL 30
IS 10
BP 484
EP 487
DI 10.1016/j.purol.2020.05.007
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA NV8WD
UT WOS:000574593500002
PM 32620366
OA Green Published
DA 2021-01-01
ER

PT J
AU Alivernini, S
   Petricca, L
   Perniola, S
   Fedele, AL
   Gigante, MR
   Capacci, A
   Paglionico, A
   Varriano, V
   De Lorenzis, E
   Lanzo, L
   Melpignano, F
   Rubortone, P
   Tanti, G
   Tur, C
   Bruno, D
   Gigante, L
   Natalello, G
   Verardi, L
   Di Mario, C
   Tolusso, B
   Mirone, L
   Lizzio, MM
   Zoli, A
   Peluso, G
   Bosello, SL
   Gremese, E
AF Alivernini, Stefano
   Petricca, Luca
   Perniola, Simone
   Fedele, Anna Laura
   Gigante, Maria Rita
   Capacci, Annunziata
   Paglionico, Annamaria
   Varriano, Valentina
   De Lorenzis, Enrico
   Lanzo, Lucia
   Melpignano, Fabrizio
   Rubortone, Pietro
   Tanti, Giacomo
   Tur, Carlo
   Bruno, Dario
   Gigante, Laura
   Natalello, Gerlando
   Verardi, Lucrezia
   Di Mario, Clara
   Tolusso, Barbara
   Mirone, Luisa
   Lizzio, Marco Maria
   Zoli, Angelo
   Peluso, Giusy
   Bosello, Silvia Laura
   Gremese, Elisa
TI No higher risk of respiratory symptoms in Italian rheumatological
   patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic
SO RHEUMATOLOGY
LA English
DT Letter
C1 [Alivernini, Stefano; Petricca, Luca; Perniola, Simone; Fedele, Anna Laura; Gigante, Maria Rita; Capacci, Annunziata; Paglionico, Annamaria; Tolusso, Barbara; Mirone, Luisa; Lizzio, Marco Maria; Zoli, Angelo; Peluso, Giusy; Bosello, Silvia Laura; Gremese, Elisa] Fdn Policlin Univ A Gemelli IRCCS, Div Rheumatol, Rome, Italy.
   [Alivernini, Stefano; Varriano, Valentina; De Lorenzis, Enrico; Lanzo, Lucia; Melpignano, Fabrizio; Rubortone, Pietro; Tanti, Giacomo; Bruno, Dario; Natalello, Gerlando; Verardi, Lucrezia; Di Mario, Clara; Mirone, Luisa; Zoli, Angelo; Gremese, Elisa] Univ Cattolica Sacro Cuore, Inst Rheumatol, Rome, Italy.
RP Gremese, E (corresponding author), Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Rheumatol, Largo Francesco Vito 1, I-00168 Rome, Italy.
EM elisa.gremese@unicatt.it
OI Bruno, Dario/0000-0002-6647-9208; Natalello,
   Gerlando/0000-0001-7333-371X; Perniola, Simone/0000-0001-6918-4731;
   ALIVERNINI, STEFANO/0000-0002-7383-4212; De Lorenzis,
   Enrico/0000-0001-9819-105X; Di Mario, Clara/0000-0001-9459-3326
CR Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen HL, 2019, FRONT MED-PRC, V13, P610, DOI 10.1007/s11684-019-0714-8
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
NR 5
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-0324
EI 1462-0332
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD SEP
PY 2020
VL 59
IS 9
BP 2644
EP 2646
DI 10.1093/rheumatology/keaa388
PG 4
WC Rheumatology
SC Rheumatology
GA NV5XR
UT WOS:000574394600065
PM 32728733
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Giordano, F
   Scarlata, E
   Baroni, M
   Gentile, E
   Puntillo, F
   Brienza, N
   Gesualdo, L
AF Giordano, Filippo
   Scarlata, Elide
   Baroni, Mariagrazia
   Gentile, Eleonora
   Puntillo, Filomena
   Brienza, Nicola
   Gesualdo, Loreto
TI Receptive music therapy to reduce stress and improve wellbeing in
   Italian clinical staff involved in COVID-19 pandemic: A preliminary
   study
SO ARTS IN PSYCHOTHERAPY
LA English
DT Article
DE Music therapy; Covid-19; Support; Clinical staff; Stress
ID CORONAVIRUS; OUTBREAK; CARE
AB The influence of music therapy (MT) as a support intervention to reduce stress and improve wellbeing in Clinical Staff (CS) working with COVID-19 patients was evaluated. Participants were enrolled as a result of spontaneous agreement (n = 34) and were given remote receptive MT intervention over a 5-week period. Their levels of tiredness, sadness, fear and worry were measured with MTC-Q1 before and after MT intervention. An immediate significant variation in the CS emotional status was observed. The results seem to confirm that in an emergency situation, it is possible to put in place a remote MT support intervention for CS exposed to highly stressful situations.
C1 [Giordano, Filippo] Univ Bari, Sch Med, Piazza G Cesare 11, I-70124 Bari, Italy.
   [Scarlata, Elide] ASP Trapani Sicilia, Dept Mental Hlth, I-91100 Trapani, Italy.
   [Baroni, Mariagrazia] Hosp Madonna Uliveto Fdn, I-42020 Reggio Emilia, Italy.
   [Gentile, Eleonora] Univ Bari, Appl Neurophysiol & Pain Unit, SMBNOS Dept, I-70124 Bari, Italy.
   [Puntillo, Filomena] Univ Bari, Div Anesthesia & Intens Care Unit, Dept Interdisciplinary Med, I-70124 Bari, Italy.
   [Brienza, Nicola] Univ Bari, Div Div Anesthesia & Intens Care Unit, Dept Emergency & Organ Transplantat, I-70124 Bari, Italy.
   [Gesualdo, Loreto] Univ Bari, Nephrol Dialysis & Transplantat Unit, Dept Emergency & Organ Transplantat, I-70124 Bari, Italy.
RP Giordano, F (corresponding author), Univ Bari, Sch Med, Piazza G Cesare 11, I-70124 Bari, Italy.
EM filippo.giordano@uniba.it
RI Gentile, Eleonora/AAM-5563-2020
OI Gentile, Eleonora/0000-0002-1556-8518; Scarlata,
   Elide/0000-0001-5229-3800; Giordano, Filippo/0000-0002-6106-1187
CR ALLEN K, 1994, JAMA-J AM MED ASSOC, V272, P1724
   [Anonymous], 2020, LANCET, V395, P922, DOI [10.1016/S0140-6736(20)30627-9, 10.1016/S0140-6736(20)30644-9]
   Bonny H., 2002, MUSIC CONSCIOUSNESS
   Bradt J, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006911.pub3
   Bradt J, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006908.pub2
   Bruscia K., 2002, GUIDED IMAGERY MUSIC
   Bruscia KE, 1998, DEFINING MUSIC THERA
   Chanda ML, 2013, TRENDS COGN SCI, V17, P179, DOI 10.1016/j.tics.2013.02.007
   Chlan LL, 2018, CRIT CARE MED, V46, pE1085, DOI 10.1097/CCM.0000000000003408
   Chung BPM, 2005, J CLIN NURS, V14, P510, DOI 10.1111/j.1365-2702.2004.01072.x
   Dileo C., 2007, PRINCIPLES PRACTICE, P519
   Fallek R, 2020, PALLIAT SUPPORT CARE, V18, P47, DOI 10.1017/S1478951519000294
   Ferreri L, 2019, P NATL ACAD SCI USA, V116, P3793, DOI 10.1073/pnas.1811878116
   Geipel J, 2018, J AFFECT DISORDERS, V225, P647, DOI 10.1016/j.jad.2017.08.035
   George S. A. S., 2011, J ANAESTHESIOLOGY CL
   Giordano F, 2020, ART PSYCHOTHER, V68, DOI 10.1016/j.aip.2020.101649
   Grocke D., 2007, RECEPTIVE METHODS MU
   Honey M, 2013, NURS CRIT CARE, V18, P63, DOI 10.1111/j.1478-5153.2012.00520.x
   Kang L., 2020, LANCET PSYCHIAT, V2020
   Kim Y, 2018, AM J INFECT CONTROL, V46, P781, DOI 10.1016/j.ajic.2018.01.012
   Liu CZ, 2019, Int J Nurs Sci, V6, P187, DOI 10.1016/j.ijnss.2019.03.007
   Luk SJ, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1507600
   McConnell T, 2017, PALLIAT SUPPORT CARE, V15, P454, DOI 10.1017/S1478951516000663
   Mofredj A, 2016, J CRIT CARE, V35, P195, DOI 10.1016/j.jcrc.2016.05.021
   Pfeifer E, 2019, ART PSYCHOTHER, V63, P68, DOI 10.1016/j.aip.2019.02.006
   Raglio Alfredo, 2017, G Ital Med Lav Ergon, V38, P257
   Robb SL, 2011, J HEALTH PSYCHOL, V16, P342, DOI 10.1177/1359105310374781
   Schmid W, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0286-4
   Su JA, 2009, STRESS HEALTH, V25, P423, DOI 10.1002/smi.1261
   Tan P, 2020, ART PSYCHOTHER, V69, DOI 10.1016/j.aip.2020.101660
   Trifiletti E, 2014, J APPL SOC PSYCHOL, V44, P768, DOI 10.1111/jasp.12267
   Van Bortel T, 2016, B WORLD HEALTH ORGAN, V94, P210, DOI 10.2471/BLT.15.158543
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   WHO, 2020, TRATT ROLL UPD COR D
   Wigram T., 2019, COMPREHENSIVE GUIDE, P204
   Xiang YT, 2020, LANCET PSYCHIAT
   Zaka A, 2020, J HEALTH PSYCHOL, V25, P883, DOI 10.1177/1359105320925148
   Zanin GM, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17093024
   Zhang CX, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.00306
NR 39
TC 0
Z9 0
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0197-4556
EI 1873-5878
J9 ART PSYCHOTHER
JI Arts Psychother.
PD SEP
PY 2020
VL 70
AR 101688
DI 10.1016/j.aip.2020.101688
PG 5
WC Psychology, Clinical; Rehabilitation
SC Psychology; Rehabilitation
GA NW2UL
UT WOS:000574865200001
PM 32834302
OA Green Published
DA 2021-01-01
ER

PT J
AU Arpino, G
   De Angelis, C
   De Placido, P
   Pietroluongo, E
   Formisano, L
   Bianco, R
   Fiore, G
   Montella, E
   Forestieri, V
   Lauria, R
   Cardalesi, C
   Vozzella, EA
   Iervolino, A
   Giuliano, M
   De Placido, S
AF Arpino, Grazia
   De Angelis, Carmine
   De Placido, Pietro
   Pietroluongo, Erica
   Formisano, Luigi
   Bianco, Roberto
   Fiore, Giovanni
   Montella, Emma
   Forestieri, Valeria
   Lauria, Rossella
   Cardalesi, Cinzia
   Vozzella, Emilia Anna
   Iervolino, Anna
   Giuliano, Mario
   De Placido, Sabino
TI Optimising triage procedures for patients with cancer needing active
   anticancer treatment in the COVID-19 era
SO ESMO OPEN
LA English
DT Article
DE covid-19; cancer; SARS-CoV-2
AB Background Immunosuppression induced by anticancer therapy in a COVID-19-positive asymptomatic patient with cancer may have a devastating effect and, eventually, be lethal. To identify asymptomatic cases among patients receiving active cancer treatment, the Federico II University Hospital in Naples performs rapid serological tests in addition to hospital standard clinical triage for COVID-19 infection. Methods From 6 to 17 April 2020, all candidates for chemotherapy, radiotherapy or target/immunotherapy, if negative at the standard clinical triage on the day scheduled for anticancer treatment, received a rapid serological test on peripheral blood for COVID-19 IgM and IgG detection. In case of COVID-19 IgM and/or IgG positivity, patients underwent a real-time PCR (RT-PCR) SARS-CoV-2 test to confirm infection, and active cancer treatment was delayed. Results Overall 466 patients, negative for COVID-19 symptoms, underwent serological testing in addition to standard clinical triage. The average age was 61 years (range 25-88 years). Most patients (190, 40.8%) had breast cancer, and chemotherapy with or without immunotherapy was administered in 323 (69.3%) patients. Overall 433 (92.9%) patients were IgG-negative and IgM-negative, and 33 (7.1%) were IgM-positive and/or IgG-positive. Among the latter patients, 18 (3.9%), 11 (2.4%) and 4 (0.9%) were IgM-negative/IgG-positive, IgM-positive/IgG-negative and IgM-positive/IgG-positive, respectively. All 33 patients with a positive serological test, tested negative for RT-PCR SARS-CoV-2 test. No patient in our cohort developed symptoms suggestive of active COVID-19 infection. Conclusion Rapid serological testing at hospital admission failed to detect active asymptomatic COVID-19 infection. Moreover, it entailed additional economic and human resources, delayed therapy administrationand increased hospital accesses.
C1 [Arpino, Grazia; De Angelis, Carmine; De Placido, Pietro; Pietroluongo, Erica; Formisano, Luigi; Bianco, Roberto; Fiore, Giovanni; Forestieri, Valeria; Lauria, Rossella; Cardalesi, Cinzia; Giuliano, Mario; De Placido, Sabino] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy.
   [Montella, Emma] Univ Naples Federico II, Dept Publ Hlth, Naples, Italy.
   [Vozzella, Emilia Anna] Azienda Osped Univ Federico II, Direz Sanit, Naples, Italy.
   [Iervolino, Anna] Azienda Osped Univ Federico II, Direz Gen, Naples, Italy.
RP Giuliano, M (corresponding author), Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy.
EM m.giuliano@unina.it
OI Arpino, Grazia/0000-0002-4074-2530
CR Aeppli S, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000852
   Cortiula F, 2020, ANN ONCOL, V31, P553, DOI 10.1016/j.annonc.2020.03.286
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1165
   Kuderer NM, 2020, LANCET, V395, P1907, DOI 10.1016/S0140-6736(20)31187-9
   Lambertini M, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000759
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Li RY, 2020, SCIENCE, V368, P489, DOI 10.1126/science.abb3221
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Magno S, 2020, BREAST J, V26, P1597, DOI 10.1111/tbj.13889
   Marandino L, 2020, EUR UROL, V78, pE27, DOI 10.1016/j.eururo.2020.04.004
   Meattini I, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000779
   Moujaess E, 2020, CRIT REV ONCOL HEMAT, V150, DOI 10.1016/j.critrevonc.2020.102972
   National Health Commission of the People's Republic of China, NEW COR PNEUM DIAGN
   Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683
   Poggio Francesca, 2020, JCO Oncol Pract, V16, pe1304, DOI 10.1200/OP.20.00297
   Soldati G, 2020, J ULTRAS MED, V39, P1413, DOI 10.1002/jum.15285
   Tagliamento Marco, 2020, ESMO Open, V4, DOI 10.1136/esmoopen-2020-000683
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   Ueda M, 2020, J NATL COMPR CANC NE, V18, P366, DOI 10.6004/jnccn.2020.7560
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 20
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
EI 2059-7029
J9 ESMO OPEN
JI ESMO Open
PD SEP
PY 2020
VL 5
IS 5
AR e000885
DI 10.1136/esmoopen-2020-000885
PG 6
WC Oncology
SC Oncology
GA NV8WU
UT WOS:000574595200001
PM 32958531
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ogawa, F
   Kato, H
   Nakajima, K
   Nakagawa, T
   Matsumura, R
   Oi, Y
   Sakai, K
   Uchiyama, M
   Ohyama, Y
   Abe, T
   Takeuchi, I
AF Ogawa, Fumihiro
   Kato, Hideaki
   Nakajima, Kento
   Nakagawa, Tomoki
   Matsumura, Reo
   Oi, Yasufumi
   Sakai, Kazuya
   Uchiyama, Munehito
   Ohyama, Yutaro
   Abe, Takeru
   Takeuchi, Ichiro
TI Therapeutic strategy for severe COVID-19 pneumonia from clinical
   experience
SO EUROPEAN JOURNAL OF INFLAMMATION
LA English
DT Article
DE ciclesonide; COVID-19; lopinavir; ritonavir; mechanical ventilation;
   therapeutic strategy
ID COMMUNITY-ACQUIRED PNEUMONIA; CORONAVIRUS DISEASE; CICLESONIDE;
   DIAGNOSIS; WUHAN
AB Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was first identified in December 2019 in Wuhan, China, and has resulted in global pandemic. There is currently no effective therapeutic strategy for the management of mechanical ventilation or antiviral drugs for the treatment of this disease. As such, the development of a therapeutic strategy is urgently needed and should be established as soon as possible. In this case series, a therapeutic strategy was initially developed based on previous treatment methods used for the treatment of SARS and MERS in the absence of treatment options for COVID-19 due to a lack of information. During the search for a potential treatment, clinical findings were obtained from patients with severe COVID-19, and one therapeutic strategy was established. This therapeutic strategy was then applied to severe COVID-19 patients. In addition, we can require some interesting clinical features and characteristics of COVID-19 from blood analysis and physical findings. Here, we reported on the clinical features and characteristics of a therapeutic strategy for the treatment of severe COVID-19 pneumonia at our institution.
C1 [Ogawa, Fumihiro; Nakajima, Kento; Nakagawa, Tomoki; Matsumura, Reo; Oi, Yasufumi; Sakai, Kazuya; Uchiyama, Munehito; Ohyama, Yutaro; Abe, Takeru; Takeuchi, Ichiro] Yokohama City Univ, Sch Med, Dept Emergency Med, Yokohama, Kanagawa, Japan.
   [Kato, Hideaki] Yokohama City Univ Med, Infect Prevent & Control Dept, Yokohama, Kanagawa, Japan.
RP Ogawa, F (corresponding author), Yokohama City Univ, Sch Med, Dept Emergency Med, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.
EM fumihiro@yokohama-cu.ac.jp
RI ; Abe, Takeru/J-9512-2014
OI Ogawa, Fumihiro/0000-0002-7069-9334; Abe, Takeru/0000-0003-3496-1953
CR Baranova IN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175824
   Behrens K, 2018, GROWTH FACTORS, V36, P89, DOI 10.1080/08977194.2018.1498487
   Bernheim A, 2020, RADIOLOGY, V295, P3
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Connolly M, 2016, ANN RHEUM DIS, V75, P1392, DOI 10.1136/annrheumdis-2015-207655
   Deeks ED, 2008, DRUGS, V68, P1741, DOI 10.2165/00003495-200868120-00010
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Fu Y, 2012, J INFECTION, V64, P438, DOI 10.1016/j.jinf.2011.12.019
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Habibzadeh P, 2020, INT J OCCUP ENV MED, V11, P65, DOI 10.15171/ijoem.2020.1921
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Li H, 2020, J INFECTION, V80, P646, DOI 10.1016/j.jinf.2020.03.035
   Metlay JP, 2019, AM J RESP CRIT CARE, V200, pE45, DOI 10.1164/rccm.201908-1581ST
   Nakajima K, 2020, MAYO CLIN PROC, V95, P1297
   Nambu A, 2014, WORLD J RADIOL, V6, P779, DOI 10.4329/wjr.v6.i10.779
   Newman S, 2006, RESP MED, V100, P375, DOI 10.1016/j.rmed.2005.09.027
   Nguyen TM, 2020, CELL RES, V30, P189, DOI 10.1038/s41422-020-0290-0
   Sack GH, 2018, MOL MED, V24, DOI 10.1186/s10020-018-0047-0
   Salehi S, 2020, AM J ROENTGENOL, V215, P87, DOI [10.2214/AJR.20.23034, 10.2214/AJR.20.23034S.]
   Shekar K, 2020, ASAIO J, V66, P707, DOI 10.1097/MAT.0000000000001193
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Stoeck M, 2004, J PHARMACOL EXP THER, V309, P249, DOI 10.1124/jpet.103.059592
   Villar J, 2011, INTENS CARE MED, V37, P1932, DOI 10.1007/s00134-011-2380-4
   Wang CY, 2014, INTENS CARE MED, V40, P388, DOI 10.1007/s00134-013-3186-3
   Wang L, 2020, MED MALADIES INFECT, V50, P332, DOI 10.1016/j.medmal.2020.03.007
   World Health Organization (WHO), 2020, COUNTRY TECHNICAL GU
   Yang RZ, 2006, PLOS MED, V3, P884, DOI 10.1371/journal.pmed.0030287
   Yao TT, 2020, J MED VIROL, V92, P556, DOI 10.1002/jmv.25729
   Ye RD, 2015, J LEUKOCYTE BIOL, V98, P923, DOI 10.1189/jlb.3VMR0315-080R
   Yuki K, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108427
NR 32
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1721-727X
EI 2058-7392
J9 EUR J INFLAMM
JI Eur. J. Inflamm.
PD SEP
PY 2020
VL 18
AR 2058739220961591
DI 10.1177/2058739220961591
PG 10
WC Immunology
SC Immunology
GA NV6NL
UT WOS:000574435600001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Dang, JZ
   Zhu, GY
   Yang, YJ
   Zheng, F
AF Dang, Jian-zhong
   Zhu, Gang-yan
   Yang, Ying-jie
   Zheng, Fang
TI Clinical characteristics of coronavirus disease 2019 in patients aged 80
   years and older
SO JOURNAL OF INTEGRATIVE MEDICINE-JIM
LA English
DT Article
DE Coronavirus; 2019-nCoV; SARS-CoV-2; COVID-19; Older patients
AB Objective: Coronavirus disease 2019 (COVID-19) has raised concern around the world as an epidemic or pandemic. As data on COVID-19 has grown, it has become clear that older adults have a disproportionately high rate of death from COVID-19. This study describes the early clinical characteristics of COVID-19 in patients with more than 80 years of age.
   Methods: Epidemiological, clinical, laboratory, radiological, and treatment data from 17 patients diagnosed with COVID-19 between January 20 and February 20, 2020 were collected and analyzed retrospectively. Treatment outcomes among subgroups of patients with non-severe and severe symptoms of COVID-19 were compared.
   Results: Of the 17 hospitalized patients with COVID-19, the median age was 88.0 years (interquartile range, 86.6-90.0 years; range, 80.0-100.0 years) and 12 (70.6%) were men. The age distribution of patients was not significantly different between non-severe group and severe group. All patients had chronic pre-existing conditions. Hypertension and cardiovascular diseases were the most common chronic conditions in both subgroups. The most common symptoms at the onset of COVID-19 were fever (n = 13; 76.5%), fatigue (n = 11; 64.7%), and cough (n = 5; 29.4%). Lymphopenia was observed in all patients, and lymphopenia was significantly more severe in the severe group than that in non-severe group (0.4 x 10(9)/L vs 1.2 x 10(9)/L, P = 0.014). The level of serum creatinine was higher in the severe group than in the non-severe group (99.0 mu mol/L, vs 62.5 mu mol/L, P = 0.038). The most common features of chest computed tomography images were nodular foci in 10 (58.8%) patients and pleural thickening in 7 (41.2%) patients. All patients received antiviral therapy, while some patients also received intravenous antibiotics therapy (76.5%), Chinese medicinal preparation therapy (Lianhuaqingwen capsule, 64.7%), corticosteroids (35.3%) or immunoglobin (29.4%). Eight patients (47.1%) were transferred to the intensive care unit because of complications. Ten patients (58.8%) received intranasal oxygen, while 3 (17.6%) received non-invasive mechanical ventilation, and 4 (23.5%) received high-flow oxygen. As of June 20, 7 (41.2%) patients had been discharged and 10 (58.8% of this cohort, 77.8% of severe patients) had died.
   Conclusion: The mortality of patients aged 80 years and older with severe COVID-19 symptoms was high. Lymphopenia was a characteristic laboratory result in these patients, and the severity of lymphopenia was indicative of the severity of COVID-19. However, the majority of patients with COVID-19 in this age cohort had atypical symptoms, and early diagnosis depends on prompt use of a viral nucleic acid test. (C) 2020 Shanghai Changhai Hospital. Published by ELSEVIER B.V. All rights reserved.
C1 [Dang, Jian-zhong; Zhu, Gang-yan; Yang, Ying-jie] Wuhan Univ, Dept Geriatr, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China.
   [Zheng, Fang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Pediat, Wuhan 430022, Hubei, Peoples R China.
RP Dang, JZ (corresponding author), Wuhan Univ, Dept Geriatr, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China.
EM dangjianzhong2007@163.com
FU National Nature Sciences Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81500639]
FX This work was supported by grant from the National Nature Sciences
   Foundation of China (No. 81500639).
CR Alqahtani FY, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268818002923
   Alsolamy S, 2015, CRIT CARE MED, V43, P1283, DOI 10.1097/CCM.0000000000000966
   Assiri A, 2013, LANCET INFECT DIS, V13, P752, DOI 10.1016/S1473-3099(13)70204-4
   Chan TY, 2004, J AM GERIATR SOC, V52, P1321, DOI 10.1111/j.1532-5415.2004.52362.x
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chew NWS, 2020, BRAIN BEHAV IMMUN, V88, P559, DOI 10.1016/j.bbi.2020.04.049
   Chu H, 2016, J INFECT DIS, V213, P904, DOI 10.1093/infdis/jiv380
   Duan ZP, 2011, CHINESE MED J-PEKING, V124, P2925, DOI 10.3760/cma.j.issn.0366-6999.2011.18.024
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hao FY, 2020, BRAIN BEHAV IMMUN, V87, P100, DOI 10.1016/j.bbi.2020.04.069
   Hu K. E., 2020, PHYTOMEDICINE, P153242, DOI [10.1016/j.phymed.2020.153242, DOI 10.1016/J.PHYMED.2020.153242]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jia Weina, 2015, ScientificWorldJournal, V2015, P731765, DOI 10.1155/2015/731765
   Li X., 2019, STEADY GROWTH OF POP
   National Health Commission of the People's Republic of China, 2015, ZHONGGUO BING DU BIN, V5, P352
   National Health Commission of the People's Republic of China National Administration of Traditional Chinese Medicine, 2020, QUAN KE YI XUE LIN C, V18, P100
   Tan BYQ, 2020, ANN INTERN MED, V173, P317, DOI 10.7326/M20-1083
   Tan WQ, 2020, BRAIN BEHAV IMMUN, V87, P84, DOI 10.1016/j.bbi.2020.04.055
   The Center for Systems Science and Engineering at Johns Hopkins University, 2020, COVID 19 GLOB MAP
   van den Berg KS, 2019, AGING MENT HEALTH, DOI 10.1080/13607863.2019.1699900
   Walker ER, 2015, JAMA PSYCHIAT, V72, P334, DOI 10.1001/jamapsychiatry.2014.2502
   Wang CY, 2020, BRAIN BEHAV IMMUN, V87, P40, DOI 10.1016/j.bbi.2020.04.028
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m606, 10.1136/bmj.m792]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang JC, 2020, BRAIN BEHAV IMMUN, V87, P59, DOI 10.1016/j.bbi.2020.04.046
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
NR 28
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2095-4964
J9 J INTEGR MED-JIM
JI J. Integr. Med.-JIM
PD SEP
PY 2020
VL 18
IS 5
BP 395
EP 400
DI 10.1016/j.joim.2020.07.002
PG 6
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA NV7SC
UT WOS:000574515400004
PM 32690444
OA Green Published
DA 2021-01-01
ER

PT J
AU Gonzalez, HA
   Myers, S
   Whitehead, E
   Pattinson, A
   Stamp, K
   Turnbull, J
   Fory, R
   Featherstone, B
   Wilkinson, A
   Lisle, J
   Haire, G
   Henderson, E
   Sebastia, S
AF Gonzalez, Haidee A.
   Myers, Sally
   Whitehead, Emma
   Pattinson, Alisson
   Stamp, Katie
   Turnbull, Jack
   Fory, Rebecca
   Featherstone, Bethia
   Wilkinson, Amy
   Lisle, Jessica
   Haire, Greg
   Henderson, Eileen
   Sebastia, Shaji
TI React, reset and restore: Adaptation of a large inflammatory bowel
   disease service during COVID-19 pandemic
SO CLINICAL MEDICINE
LA English
DT Article
DE IBD; COVID-19; adaptations
ID ENDOSCOPY; OUTBREAK
AB Introduction
   Healthcare organisations have had to make adaptations to reduce the impact of the Coronavirus 2019 (COVID-19) pandemic. This has necessitated urgent reconfiguration within inflammatory bowel disease (IBD) services to ensure safety of patients and staff and seamless continuity of care provision.
   Aim
   To describe the adaptations made by a large inflammatory bowel disease service, caring for over 3,500 IBD patients, in response to the COVID-19 pandemic.
   Methods
   A diary record of responses to the pandemic were logged, and meeting minutes were reviewed. Data were recorded from IBD advice lines, multidisciplinary team (MDT) meeting minutes, infusion unit attendances, and electronic referral systems for the 8-week period from 9 March 2020 until 2 May 2020. Descriptive analysis was performed.
   Results
   The IBD service at Hull University Teaching Hospitals NHS Trust (IBD Hull) instituted rapid structural and functional changes to the service. Outpatient services were suspended and substituted by virtual consultations, and inpatient services were reduced and moved to ambulatory care where possible. The delivery of biologic and immunomodulatory therapies was significantly modified to ensure patient and staff safety. There was a substantial increase in IBD advice line calls.
   Conclusion
   The rapidly evolving COVID-19 pandemic required a prompt response, regular reassessment and planning, and continues to do so. We share our experience in of the successful adaptations made to our IBD service.
C1 [Gonzalez, Haidee A.; Myers, Sally; Whitehead, Emma; Pattinson, Alisson; Stamp, Katie; Turnbull, Jack; Fory, Rebecca; Featherstone, Bethia; Wilkinson, Amy; Lisle, Jessica; Haire, Greg; Henderson, Eileen; Sebastia, Shaji] Hull Univ Teaching Hosp NHS Trust, Kingston Upon Hull, N Humberside, England.
RP Sebastia, S (corresponding author), Hull Univ Teaching Hosp NHS Trust, IBD Unit, Dept Gastroenterol, Hull Royal Infirm, Anlaby Rd, Kingston Upon Hull HU3 2JZ, N Humberside, England.
EM shaji.sebastian@hey.nhs.uk
CR Allocca M, 2020, CLIN GASTROENTEROL H, V18, P1882, DOI 10.1016/j.cgh.2020.04.028
   [Anonymous], 2020, LANCET, V395, P1011, DOI DOI 10.1016/S0140-6736(20)30686-3
   Bezzio C, 2020, GUT, V69, P1213, DOI 10.1136/gutjnl-2020-321411
   Crohn's on Colitis UK, COR COVID 19 FAQS PE
   Cross RK, 2019, AM J GASTROENTEROL, V114, P472, DOI 10.1038/s41395-018-0272-8
   D'Amico F, 2020, GASTROENTEROLOGY, V159, P14, DOI 10.1053/j.gastro.2020.04.059
   Danese S, 2020, GUT, V69, P981, DOI 10.1136/gutjnl-2020-321143
   Danese S, 2020, NAT REV GASTRO HEPAT, V17, P253, DOI 10.1038/s41575-020-0294-8
   Iacucci M, 2020, LANCET GASTROENTEROL, V5, P598, DOI 10.1016/S2468-1253(20)30119-9
   Kennedy NA, 2020, FRONTLINE GASTROENTE, V11, P343, DOI 10.1136/flgastro-2020-101520
   Kennedy NA, 2020, GUT, V69, P984, DOI 10.1136/gutjnl-2020-321244
   Maurice JB, 2020, LANCET GASTROENTEROL, V5, P636, DOI 10.1016/S2468-1253(20)30157-6
   Monteleone G, 2020, J CROHNS COLITIS, V14, P1334, DOI 10.1093/ecco-jcc/jjaa061
   Norsa L, 2020, GASTROENTEROLOGY, V159, P371, DOI [10.1053/j.gastro.2020.03.062, 10.1053/j.gastro.2020.03.06]
   Rodriguez-Lago I, 2020, GASTROENTEROLOGY, V159, P781, DOI 10.1053/j.gastro.2020.04.043
   Rubin DT, 2020, GASTROENTEROLOGY, V159, P6, DOI 10.1053/j.gastro.2020.04.002
   Sebastian S, 2020, J CROHNS COLITIS, V14, P1632, DOI 10.1093/ecco-jcc/jjaa120
   Sebastian S, SERVICE SUCCESS STOR
   Taxonera C, 2020, ALIMENT PHARM THER, V52, P276, DOI 10.1111/apt.15804
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ROY COLL PHYS LONDON EDITORIAL OFFICE
PI LONDON
PA 11 ST ANDREWS PLACE REGENTS PARK, LONDON NW1 4LE, ENGLAND
SN 1470-2118
EI 1473-4893
J9 CLIN MED
JI Clin. Med.
PD SEP
PY 2020
VL 20
IS 5
BP E183
EP E188
DI 10.7861/clinmed.2020-0369
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA NU3TR
UT WOS:000573566000011
PM 32719036
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Knights, H
   Mayor, N
   Millar, K
   Cox, M
   Bunova, E
   Hughes, M
   Baker, J
   Mathew, S
   Russell-Jones, D
   Kotwica, A
AF Knights, Harry
   Mayor, Nikhil
   Millar, Kristina
   Cox, Matthew
   Bunova, Evgeniya
   Hughes, Morgan
   Baker, Jack
   Mathew, Sanju
   Russell-Jones, David
   Kotwica, Aleksandra
TI Characteristics and outcomes of patients with COVID-19 at a district
   general hospital in Surrey, UK
SO CLINICAL MEDICINE
LA English
DT Article
DE Coronavirus; SARS-CoV-2; frailty; COVID-19; Clinical Frailty Scale
AB Background
   This retrospective cohort study aims to define the clinical findings and outcomes of every patient admitted to a district general hospital in Surrey with COVID-19 in March 2020, providing a snapshot of the first wave of infection in the UK. This study is the first detailed insight into the impact of frailty markers on patient outcomes and provides the infection rate among healthcare workers.
   Methods
   Data were obtained from medical records. Outcome measures were level of oxygen therapy, discharge and death. Patients were followed up until 21 April 2020.
   Results
   108 patients were included. 34 (31%) died in hospital or were discharged for palliative care. 43% of patients aged over 65 died. The commonest comorbidities were hypertension (49; 45%) and diabetes (25; 23%). Patients who died were older (mean difference +/- SEM, 13.76 +/- 3.12 years; p<0.0001) with a higher NEWS2 score (median 6, IQR 2.5-7.5 vs median 2, IQR 2-6) and worse renal function (median differences: urea 2.7 mmol/L, p<0.01; creatinine 4 mu mol/L, p<0.05; eGFR 14 mL/min, p<0.05) on admission compared with survivors. Frailty markers were identified as risk factors for death. Clinical Frailty Scale (CFS) was higher in patients over 65 who died than in survivors (median 5, IQR 4-6 vs 3.5, IQR 2-5; p<0.01). Troponin and creatine kinase levels were higher in patients who died than in those who recovered (p<0.0001). Lymphopenia was common (median 0.8, IQR 0.6-1.2; p<0.005). Every patient with heart failure died (8). 26 (24%) were treated with continuous positive airway pressure (CPAP; median 3 days, IQR 2-7.3) and 9 (8%) were intubated (median 14 days, IQR 7-21). All patients who died after discharge (4; 6%) were care home residents. 276 of 699 hospital staff tested were positive for COVID-19.
   Conclusions
   This study identifies older patients with frailty as being particularly vulnerable and reinforces government policy to protect this group at all costs.
C1 [Knights, Harry; Mayor, Nikhil; Millar, Kristina; Cox, Matthew; Bunova, Evgeniya; Hughes, Morgan; Baker, Jack; Mathew, Sanju; Kotwica, Aleksandra] Royal Surrey Cty Hosp, Guildford, Surrey, England.
   [Russell-Jones, David] Royal Surrey Cty Hosp, Diabet & Endocrinol, Guildford, Surrey, England.
   [Russell-Jones, David] Univ Surrey, Guildford, Surrey, England.
RP Kotwica, A (corresponding author), Royal Surrey NHS Fdn Trust, Royal Surrey Cty Hosp, Egerton Rd, Guildford GU2 7XX, Surrey, England.
EM a.kotwica@doctors.org.uk
CR BBC News, 2020, BBC NEWS
   British Institute of Radiology, COVID 19 CXR ADV SHE
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Department of Health and Social Care, 2020, COR COVID 19 GETT TE
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Hanlon P, 2018, LANCET PUBLIC HEALTH, V3, pE323, DOI 10.1016/S2468-2667(18)30091-4
   NHS, ROY SURR COUNT HOSP
   Office for National Statistics, 2017, OV UK POP JUL 2017
   Public Health England, 2020, COVID 19 REV DISP RI
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051
   South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020
   Surrey-i, 2019, GUID WAV PLAC BAS PR
   Surrey-i, 2019, EC IND SURV
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 15
TC 1
Z9 1
U1 3
U2 3
PU ROY COLL PHYS LONDON EDITORIAL OFFICE
PI LONDON
PA 11 ST ANDREWS PLACE REGENTS PARK, LONDON NW1 4LE, ENGLAND
SN 1470-2118
EI 1473-4893
J9 CLIN MED
JI Clin. Med.
PD SEP
PY 2020
VL 20
IS 5
BP E148
EP E153
DI 10.7861/clinmed.2020-0303
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA NU3TR
UT WOS:000573566000003
PM 32709637
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Slater, TA
   Straw, S
   Drozd, M
   Kamalathasan, S
   Cowley, A
   Witte, KK
AF Slater, Thomas A.
   Straw, Sam
   Drozd, Michael
   Kamalathasan, Stephe
   Cowley, Alice
   Witte, Klaus K.
TI Dying 'due to' or 'with' COVID-19: a cause of death analysis in
   hospitalised patients
SO CLINICAL MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; coronavirus
AB The SARS-CoV-2 pandemic is accompanied by an everrising death toll attributed to coronavirus disease 2019 (COVID-19), but questions have persisted regarding deaths formally attributed to COVID-19. We aimed to provide an independent review of clinical features of patients who died during hospitalisation with a positive PCR test for SARS-CoV-2 and relate these to the reported cause of death. Between 23 March and 28 April 2020, a total of 162 patients with a positive SARS-CoV-2 PCR died in our NHS trust. COVID-19 infection was documented as the direct cause of death in 150 (93%). Review of the records revealed 138 (92%) patients had pulmonary infiltrates on chest radiography, and 146 (97%) required oxygen therapy. This retrospective review of cause of death has demonstrated that the overwhelming majority of hospitalised patients with positive SARS-CoV-2 PCR died as a direct consequence of COVID-19 infection.
C1 [Slater, Thomas A.; Straw, Sam; Drozd, Michael; Witte, Klaus K.] Univ Leeds, Leeds, W Yorkshire, England.
   [Kamalathasan, Stephe; Cowley, Alice; Witte, Klaus K.] Leeds Gen Infirm, Leeds, W Yorkshire, England.
RP Witte, KK (corresponding author), Univ Leeds, Leeds Inst Cardiovasc & Metab Med, Clarendon Way, Leeds LS2 9DA, W Yorkshire, England.
EM k.k.witte@leeds.ac.uk
OI Straw, Sam/0000-0002-2942-4574
CR Cahlmers V, 2020, DAILY MAIL
   Elezkurtaj S, 2020, CAUSES DEATH COMORBI
   Lee J, 2020, SPECTATOR
   Office for National Statistics, DEATHS REG WEEKL ENG
   Public Health England, 2020, PHE DAT SER DEATHS P
   Richardson R., 2020, US TODAY
NR 6
TC 0
Z9 0
U1 1
U2 1
PU ROY COLL PHYS LONDON EDITORIAL OFFICE
PI LONDON
PA 11 ST ANDREWS PLACE REGENTS PARK, LONDON NW1 4LE, ENGLAND
SN 1470-2118
EI 1473-4893
J9 CLIN MED
JI Clin. Med.
PD SEP
PY 2020
VL 20
IS 5
BP E189
EP E190
DI 10.7861/clinmed.2020-0440
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA NU3TR
UT WOS:000573566000012
PM 32753516
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Lehrer, S
   Rheinstein, PH
AF Lehrer, Steven
   Rheinstein, Peter H.
TI Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain
   Attached to ACE2
SO IN VIVO
LA English
DT Article
DE COVID-19; ivermectin; ACE2; spike protein
AB Background/Aim: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). One drug that has attracted interest is the antiparasitic compound ivermectin, a macrocyclic lactone derived from the bacterium Streptomyces avermitilis. We carried out a docking study to determine if ivermectin might be able to attach to the SARS-CoV-2 spike receptor-binding domain bound with ACE2. Materials and Methods: We used the program AutoDock Vina Extended to perform the docking study. Results: Ivermectin docked in the region of leucine 91 of the spike and histidine 378 of the ACE2 receptor. The binding energy of ivermectin to the spike-ACE2 complex was-18 kcal/mol and binding constant was 5.8 e-08. Conclusion: The ivermectin docking we identified may interfere with the attachment of the spike to the human cell membrane. Clinical trials now underway should determine whether ivermectin is an effective treatment for SARS-Cov2 infection.
C1 [Lehrer, Steven] Icahn Sch Med Mt Sinai, Dept Radiat Oncol, New York, NY 10029 USA.
   [Rheinstein, Peter H.] Severn Hlth Solut, Severna Pk, MD USA.
RP Lehrer, S (corresponding author), Icahn Sch Med Mt Sinai, Dept Radiat Oncol, Mt Sinai Med Ctr, 1 Gustave L Levy Pl,Box 1236, New York, NY 10029 USA.
EM steven.lehrer@mssm.edu
CR Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   GOA KL, 1991, DRUGS, V42, P640, DOI 10.2165/00003495-199142040-00007
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Mossel EC, 2005, J VIROL, V79, P3846, DOI 10.1128/JVI.79.6.3846-3850.2005
   Mothay Dipti, 2020, VirusDisease, V31, DOI 10.1007/s13337-020-00585-z
   Rayner CR, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104805
   Serseg Talia, 2020, Curr Comput Aided Drug Des, DOI 10.2174/1573409916666200422075440
   Servick K, 2020, SCIENCE, V368, P1041, DOI 10.1126/science.368.6495.1041
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Yu R, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106012
NR 12
TC 1
Z9 2
U1 0
U2 0
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258-851X
EI 1791-7549
J9 IN VIVO
JI In Vivo
PD SEP-OCT
PY 2020
VL 34
IS 5
BP 3023
EP 3026
DI 10.21873/invivo.12134
PG 4
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NU2LW
UT WOS:000573474400031
PM 32871846
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Smetana, K
   Rosel, D
   BrAbek, J
AF Smetana Jr, Karel
   Rosel, Daniel
   BrAbek, Jan
TI Raloxifene and Bazedoxifene Could Be Promising Candidates for Preventing
   the COVID-19 Related Cytokine Storm, ARDS and Mortality
SO IN VIVO
LA English
DT Article
DE SARS-CoV-2; lung failure; cytokine storm; IL6; COVID-19 therapy;
   bazedoxifene; raloxifene
AB The FDA-approved drugs raloxifene and bazedoxifene could be among the best candidates to prevent mortality in severe COVID-19 patients. Raloxifene and bazedoxifene inhibit IL-6 signaling at therapeutic doses, suggesting they have the potential to prevent the cytokine storm, ARDS and mortality in severe COVID-19 patients, as is being shown with humanized antibodies blocking IL-6 signaling. In addition, raloxifene and bazedoxifene are selective estrogen receptor modulators with strong antiviral activity.
C1 [Smetana Jr, Karel] Charles Univ Prague, Fac Med 1, Inst Anat, U Nemocnice 3, Prague 12800 2, Czech Republic.
   [Smetana Jr, Karel; Rosel, Daniel; BrAbek, Jan] BIOCEV, Prumyslova 595, Vestec 25250, Czech Republic.
   [Rosel, Daniel; BrAbek, Jan] Charles Univ Prague, Fac Sci, Dept Cell Biol, Prague, Czech Republic.
RP Smetana, K (corresponding author), Charles Univ Prague, Fac Med 1, Inst Anat, U Nemocnice 3, Prague 12800 2, Czech Republic.; Smetana, K; BrAbek, J (corresponding author), BIOCEV, Prumyslova 595, Vestec 25250, Czech Republic.
EM karel.smetana@lf1.cuni.cz; jan.brabek@natur.cuni.cz
RI Rosel, Daniel/J-7507-2017
OI Rosel, Daniel/0000-0001-7221-8672
CR Andersson A, 2016, RHEUMATOLOGY, V55, P553, DOI 10.1093/rheumatology/kev355
   Bakowski M.A, 2020, BIORXIV, DOI [10.1101/2020.06.16.153403, DOI 10.1101/2020.06.16.153403]
   Brabek J, 2020, SCIENCE, V368, P473, DOI [10.1126/science.abb8925, DOI 10.1126/SCIENCE.ABB8925]
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Li HM, 2014, J MED CHEM, V57, P632, DOI 10.1021/jm401144z
   Ma HY, 2019, CANCER SCI, V110, P950, DOI 10.1111/cas.13940
   Smetana K, 2020, IN VIVO, V34, P1589, DOI 10.21873/invivo.11947
   Thilakasiri P, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809539
NR 8
TC 3
Z9 3
U1 3
U2 3
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258-851X
EI 1791-7549
J9 IN VIVO
JI In Vivo
PD SEP-OCT
PY 2020
VL 34
IS 5
BP 3027
EP 3028
DI 10.21873/invivo.12135
PG 2
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA NU2LW
UT WOS:000573474400032
PM 32871847
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Brailovskaia, J
   Margraf, J
AF Brailovskaia, Julia
   Margraf, Juergen
TI Predicting adaptive and maladaptive responses to the Coronavirus
   (COVID-19) outbreak: A prospective longitudinal study
SO INTERNATIONAL JOURNAL OF CLINICAL AND HEALTH PSYCHOLOGY
LA English
DT Article
DE COVID-19; Burden; Depression, Anxiety, and Stress symptoms; Positive
   mental health; Descriptive survey study
ID POSITIVE MENTAL-HEALTH; DEPRESSION; ANXIETY; RESILIENCE; STRESS;
   IDEATION; SENSE; MODEL; RISK
AB Background/Objective: The outbreak of COVID-19 and the lack of vaccine made extraordinary actions such as social distancing necessary. While some individuals experience the restrictions on daily life as a heavy burden, others adapt to the situation and try to make the best of it. The present longitudinal study investigated the extent and predictors of the burden induced by the outbreak of COVID-19 in Germany.
   Method: Data were assessed in October 2019 using the DASS-21 and the PMH-Scale, and in March 2020 adding a six-item measure of burden and a 2-item rating of sense of control.
   Results: In a sample of 436 participants, about 28% stayed in self-quarantine, 22 persons had relevant symptoms and one person was positively tested for COVID-19. Most participants experienced medium to high levels of burden but tried to make the best of it. Stress symptoms in 2019 predicted a higher level of burden and PMH predicted a lower level of burden in March 2020. Remarkably, depression and anxiety symptoms did not significantly predict burden. The protective effect of PMH and the negative impact of stress symptoms were mediated by perceived sense of control.
   Conclusions: The results emphasize the protective effect of PMH in extraordinary situations such as the current outbreak of COVID-19. (C) 2020 Asociacion Espanola de Psicologia Conductual. Published by Elsevier Espana, S.L.U.
C1 [Brailovskaia, Julia; Margraf, Juergen] Ruhr Univ Bochum, Mental Hlth Res & Treatment Ctr, Dept Psychol, Bochum, Germany.
RP Brailovskaia, J (corresponding author), Ruhr Univ Bochum, Mental Hlth Res & Treatment Ctr, Massenbergstr 9-13, D-44787 Bochum, Germany.
EM Julia.Brailovskaia@rub.de
FU DFG Open Access Publication Funds of the Ruhr-Universitat Bochum
FX The DFG Open Access Publication Funds of the Ruhr-Universitat Bochum
   provided financial support for the publication of the present study.
CR Andrews B, 2004, BRIT J PSYCHOL, V95, P509, DOI 10.1348/0007126042369802
   Assari S, 2017, ARCH MED SCI, V13, P1233, DOI 10.5114/aoms.2016.59740
   Bonnett G. D., 2010, Proceedings of the 2010 Conference of the Australian Society of Sugar Cane Technologists held at Bundaberg, Queensland, Australia, 11-14 May 2010, P1
   Brailovskaia J, 2020, CYBERPSYCH BEH SOC N, V23, P346, DOI 10.1089/cyber.2019.0563
   Brailovskaia J, 2020, CRISIS, V41, P383, DOI 10.1027/0227-5910/a000652
   Brailovskaia J, 2019, J BEHAV ADDICT, V8, P703, DOI 10.1556/2006.8.2019.63
   Brailovskaia J, 2018, PSYCHIAT RES, V267, P240, DOI 10.1016/j.psychres.2018.05.074
   Brailovskaia J, 2019, CURR PSYCHOL, V38, P421, DOI 10.1007/s12144-017-9627-3
   DIENER E, 1995, J PERS SOC PSYCHOL, V68, P653, DOI 10.1037/0022-3514.69.1.120
   Fredrickson BL, 2013, ADV EXP SOC PSYCHOL, V47, P1, DOI 10.1016/B978-0-12-407236-7.00001-2
   GaIatzer-Levy IR, 2018, CLIN PSYCHOL REV, V63, P41, DOI 10.1016/j.cpr.2018.05.008
   Gorday JY, 2018, J PSYCHIATR RES, V107, P97, DOI 10.1016/j.jpsychires.2018.10.004
   Hayes A., 2018, INTRO MEDIATION MODE
   Hoorelbeke K, 2016, J AFFECT DISORDERS, V195, P96, DOI 10.1016/j.jad.2016.02.001
   Iasiello M, 2019, J AFFECT DISORDERS, V251, P227, DOI 10.1016/j.jad.2019.03.065
   Katon W, 2007, GEN HOSP PSYCHIAT, V29, P147, DOI 10.1016/j.genhosppsych.2006.11.005
   Keyes CLM, 2005, J CONSULT CLIN PSYCH, V73, P539, DOI 10.1037/0022-006X.73.3.539
   Lachman ME, 1998, J PERS SOC PSYCHOL, V74, P763, DOI 10.1037/0022-3514.74.3.763
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U
   Lukat J, 2017, CLIN PSYCHOL PSYCHOT, V24, P322, DOI 10.1002/cpp.2026
   Lukat Justina, 2016, BMC Psychol, V4, P8, DOI 10.1186/s40359-016-0111-x
   Lyubomirsky S, 1999, SOC INDIC RES, V46, P137, DOI 10.1023/A:1006824100041
   Manz R, 2001, SOZ PRAVENTIV MED, V46, P115, DOI 10.1007/BF01299728
   Margraf J., 2017, BOCHUM OPTIMISM MENT
   Mayr S, 2007, TUTOR QUANT METHODS, V3, P51, DOI 10.20982/tqmp.03.2.p051
   McKean M., 2000, AM J HLTH STUDIES, V16, P41, DOI DOI 10.4236/CE.2015.61007
   Michael T., 2007, PSYCHIATRY, V6, P136, DOI DOI 10.1016/J.MPPSY.2007.01.007
   Niemeyer H, 2019, SSM-POPUL HLTH, V7, DOI 10.1016/j.ssmph.2019.100392
   Ren P, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.01634
   RYFF CD, 1995, J PERS SOC PSYCHOL, V69, P719, DOI 10.1037/0022-3514.57.6.1069
   Siegmann P, 2018, CLIN PSYCHOL PSYCHOT, V25, pE1, DOI 10.1002/cpp.2118
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Spasojevic J, 2001, EMOTION, V1, P25, DOI 10.1037/1528-3542.1.1.25
   Suldo SM, 2008, SCHOOL PSYCHOL REV, V37, P52
   Teismann T, 2019, INT J CLIN HLTH PSYC, V19, P165, DOI 10.1016/j.ijchp.2019.02.003
   Teismann T, 2018, BEHAV RES THER, V108, P40, DOI 10.1016/j.brat.2018.06.006
   Teismann T, 2018, INT J CLIN HLTH PSYC, V18, P1, DOI 10.1016/j.ijchp.2017.08.001
   Toukhsati SR, 2017, EUR J CARDIOVASC NUR, V16, P64, DOI 10.1177/1474515116640412
   Truskauskaite-Kuneviciene I, 2020, CURR PSYCHOL, DOI 10.1007/s12144-020-00714-3
   Urban D, 2006, REGRESSIONSANALYSE T
   WATSON D, 1989, PSYCHOL REV, V96, P234, DOI 10.1037/0033-295X.96.2.234
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yu XB, 2018, SOC BEHAV PERSONAL, V46, P831, DOI 10.2224/sbp.6912
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 45
TC 1
Z9 1
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1697-2600
EI 1576-7329
J9 INT J CLIN HLTH PSYC
JI Int. J. Clin. Health Psychol.
PD SEP-DEC
PY 2020
VL 20
IS 3
BP 183
EP 191
DI 10.1016/j.ijchp.2020.06.002
PG 9
WC Psychology, Clinical
SC Psychology
GA NU9NJ
UT WOS:000573962200001
PM 32837518
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mehta, N
   Kalra, A
   Nowacki, AS
   Anjewierden, S
   Han, ZY
   Bhat, P
   Carmona-Rubio, AE
   Jacob, M
   Procop, GW
   Harrington, S
   Milinovich, A
   Svensson, LG
   Jehi, L
   Young, JB
   Chung, MK
AF Mehta, Neil
   Kalra, Ankur
   Nowacki, Amy S.
   Anjewierden, Scott
   Han, Zheyi
   Bhat, Pavan
   Carmona-Rubio, Andres E.
   Jacob, Miriam
   Procop, Gary W.
   Harrington, Susan
   Milinovich, Alex
   Svensson, Lars G.
   Jehi, Lara
   Young, James B.
   Chung, Mina K.
TI Association of Use of Angiotensin-Converting Enzyme Inhibitors and
   Angiotensin II Receptor Blockers With Testing Positive for Coronavirus
   Disease 2019 (COVID-19)
SO JAMA CARDIOLOGY
LA English
DT Article
AB This cohort study assesses the association between use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with the likelihood of testing positive for coronavirus disease 2019 (COVID-19).
   Importance The role of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) in the setting of the coronavirus disease 2019 (COVID-19) pandemic is hotly debated. There have been recommendations to discontinue these medications, which are essential in the treatment of several chronic disease conditions, while, in the absence of clinical evidence, professional societies have advocated their continued use. Objective To study the association between use of ACEIs/ARBs with the likelihood of testing positive for COVID-19 and to study outcome data in subsets of patients taking ACEIs/ARBs who tested positive with severity of clinical outcomes of COVID-19 (eg, hospitalization, intensive care unit admission, and requirement for mechanical ventilation). Design, Setting, and Participants Retrospective cohort study with overlap propensity score weighting was conducted at the Cleveland Clinic Health System in Ohio and Florida. All patients tested for COVID-19 between March 8 and April 12, 2020, were included. Exposures History of taking ACEIs or ARBs at the time of COVID-19 testing. Main Outcomes and Measures Results of COVID-19 testing in the entire cohort, number of patients requiring hospitalizations, intensive care unit admissions, and mechanical ventilation among those who tested positive. Results A total of 18472 patients tested for COVID-19. The mean (SD) age was 49 (21) years, 7384 (40%) were male, and 12725 (69%) were white. Of 18472 patients who underwent COVID-19 testing, 2285 (12.4%) were taking either ACEIs or ARBs. A positive COVID-19 test result was observed in 1735 of 18472 patients (9.4%). Among patients who tested positive, 421 (24.3%) were admitted to the hospital, 161 (9.3%) were admitted to an intensive care unit, and 111 (6.4%) required mechanical ventilation. Overlap propensity score weighting showed no significant association of ACEI and/or ARB use with COVID-19 test positivity (overlap propensity score-weighted odds ratio, 0.97; 95% CI, 0.81-1.15). Conclusions and Relevance This study found no association between ACEI or ARB use and COVID-19 test positivity. These clinical data support current professional society guidelines to not discontinue ACEIs or ARBs in the setting of the COVID-19 pandemic. However, further study in larger numbers of hospitalized patients receiving ACEI and ARB therapy is needed to determine the association with clinical measures of COVID-19 severity.
   Question What is the association of use of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB) with testing positive for coronavirus disease 2019 (COVID-19)? Findings In this cohort study of 18472 patients, 1322 (7.2%) were taking ACEIs and 982 (5.3%) were taking ARBs. A positive COVID-19 test result was observed in 1735 (9.4%) tested patients, and among all patients with positive test results, 116 (6.7%) were taking ACEIs, and 98 (5.6%) were taking ARBs; there was no association between ACEI/ARB use and testing positive for COVID-19 (overlap propensity score-weighted odds ratio, 0.97; 95% CI, 0.81-1.15). Meaning These data support various society guidelines to continue current treatment of chronic disease conditions with either ACEI or ARB during the COVID-19 pandemic.
C1 [Mehta, Neil; Anjewierden, Scott; Han, Zheyi; Young, James B.] Case Western Reserve Univ, Dept Med, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA.
   [Kalra, Ankur; Bhat, Pavan; Carmona-Rubio, Andres E.; Jacob, Miriam; Young, James B.; Chung, Mina K.] Cleveland Clin, Dept Cardiac Med, Heart Vasc & Thorac Inst, 224 West Exchange St,Ste 225, Cleveland, OH 44302 USA.
   [Kalra, Ankur] Cleveland Clin Akron Gen, Vasc & Thorac Dept, Sect Cardiovasc Res Heart, Akron, OH USA.
   [Nowacki, Amy S.; Milinovich, Alex] Cleveland Clin, Dept Quantitat Hlth Sci, Lerner Res Inst, Cleveland, OH 44106 USA.
   [Procop, Gary W.; Harrington, Susan] Cleveland Clin, Dept Lab Med, Pathol & Lab Med Inst, Cleveland, OH 44106 USA.
   [Svensson, Lars G.] Cleveland Clin, Dept Thorac & Cardiovasc Surg, Heart Vasc & Thorac Inst, Cleveland, OH 44106 USA.
   [Jehi, Lara] Cleveland Clin, Cleveland, OH 44106 USA.
   [Chung, Mina K.] Cleveland Clin, Dept Cardiovasc & Metab Sci, Lerner Res Inst, Cleveland, OH 44106 USA.
RP Kalra, A (corresponding author), Cleveland Clin, Dept Cardiac Med, Heart Vasc & Thorac Inst, 224 West Exchange St,Ste 225, Cleveland, OH 44302 USA.
EM kalraa@ccf.org
RI Milinovich, Alex/AAA-7353-2019
OI Milinovich, Alex/0000-0003-0585-1480; Bhat, Pavan/0000-0001-8955-1586
FU National Institutes of Health/National Center for Advancing
   Translational Sciences [UL1TR002548]
FX This study was supported by the Cleveland Clinic Lerner Research
   Institute (operations account) and National Institutes of
   Health/National Center for Advancing Translational Sciences (grant
   UL1TR002548).
CR Bavishi C, 2020, JAMA CARDIOL, V5, P745, DOI 10.1001/jamacardio.2020.1282
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Ferrario CM, 2005, CIRCULATION, V111, P2605, DOI 10.1161/CIRCULATIONAHA.104.510461
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Ishiyama Y, 2004, HYPERTENSION, V43, P970, DOI 10.1161/01.HYP.0000124667.34652.1a
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Li F, 2019, AM J EPIDEMIOL, V188, P250, DOI 10.1093/aje/kwy201
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Liu Y, 2020, ANTIHYPERTENSIVE ANG, DOI [10.1101/2020.03.20.20039586, DOI 10.1101/2020.03.20.20039586]
   Milinovich A, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.01.13
   Rafiq M, 2020, ACS APPL POLYM MATER, V2, P12, DOI 10.1021/acsapm.9b00859
   Sommerstein R, 2020, BMJ-BRIT MED J, V368, pm810, DOI [10.1136/bmj.m810, DOI 10.1136/BMJ.M810]
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 20
TC 71
Z9 72
U1 6
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2380-6583
EI 2380-6591
J9 JAMA CARDIOL
JI JAMA Cardiol.
PD SEP
PY 2020
VL 5
IS 9
BP 1020
EP 1026
DI 10.1001/jamacardio.2020.1855
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NU8ZL
UT WOS:000573925800013
PM 32936273
OA Green Published
DA 2021-01-01
ER

PT J
AU Mercuro, NJ
   Yen, CF
   Shim, DJ
   Maher, TR
   McCoy, CM
   Zimetbaum, PJ
   Gold, HS
AF Mercuro, Nicholas J.
   Yen, Christina F.
   Shim, David J.
   Maher, Timothy R.
   McCoy, Christopher M.
   Zimetbaum, Peter J.
   Gold, Howard S.
TI Risk of QT Interval Prolongation Associated With Use of
   Hydroxychloroquine With or Without Concomitant Azithromycin Among
   Hospitalized Patients Testing Positive for Coronavirus Disease 2019
   (COVID-19)
SO JAMA CARDIOLOGY
LA English
DT Article
AB Importance Administration of hydroxychloroquine with or without azithromycin for the treatment of coronavirus disease 2019 (COVID-19)-associated pneumonia carries increased risk of corrected QT (QTc) prolongation and cardiac arrhythmias. Objective To characterize the risk and degree of QT prolongation in patients with COVID-19 in association with their use of hydroxychloroquine with or without concomitant azithromycin. Design, Setting, and Participants This was a cohort study performed at an academic tertiary care center in Boston, Massachusetts, of patients hospitalized with at least 1 positive COVID-19 nasopharyngeal polymerase chain reaction test result and clinical findings consistent with pneumonia who received at least 1 day of hydroxychloroquine from March 1, 2020, through April 7, 2020. Main Outcomes and Measures Change in QT interval after receiving hydroxychloroquine with or without azithromycin; occurrence of other potential adverse drug events. Results Among 90 patients given hydroxychloroquine, 53 received concomitant azithromycin; 44 (48.9%) were female, and the mean (SD) body mass index was 31.5 (6.6). Hypertension (in 48 patients [53.3%]) and diabetes mellitus (in 26 patients [28.9%]) were the most common comorbid conditions. The overall median (interquartile range) baseline QTc was 455 (430-474) milliseconds (hydroxychloroquine, 473 [454-487] milliseconds vs hydroxychloroquine and azithromycin, 442 [427-461] milliseconds; P < .001). Those receiving concomitant azithromycin had a greater median (interquartile range) change in QT interval (23 [10-40] milliseconds) compared with those receiving hydroxychloroquine alone (5.5 [-15.5 to 34.25] milliseconds; P = .03). Seven patients (19%) who received hydroxychloroquine monotherapy developed prolonged QTc of 500 milliseconds or more, and 3 patients (8%) had a change in QTc of 60 milliseconds or more. Of those who received concomitant azithromycin, 11 of 53 (21%) had prolonged QTc of 500 milliseconds or more and 7 of 53 (13 %) had a change in QTc of 60 milliseconds or more. The likelihood of prolonged QTc was greater in those who received concomitant loop diuretics (adjusted odds ratio, 3.38 [95% CI, 1.03-11.08]) or had a baseline QTc of 450 milliseconds or more (adjusted odds ratio, 7.11 [95% CI, 1.75-28.87]). Ten patients had hydroxychloroquine discontinued early because of potential adverse drug events, including intractable nausea, hypoglycemia, and 1 case of torsades de pointes. Conclusions and Relevance In this cohort study, patients who received hydroxychloroquine for the treatment of pneumonia associated with COVID-19 were at high risk of QTc prolongation, and concurrent treatment with azithromycin was associated with greater changes in QTc. Clinicians should carefully weigh risks and benefits if considering hydroxychloroquine and azithromycin, with close monitoring of QTc and concomitant medication usage.
   This cohort study examines the association of hydroxychloroquine or hydroxychloroquine and azithromycin with QT prolongation in adult patients hospitalized with coronavirus disease 2019.
   Question In hospitalized patients with coronavirus disease 2019 (COVID-19), what is the risk of corrected QT (QTc) prolongation when taking hydroxychloroquine with or without azithromycin? Findings In a cohort study of 90 hospitalized patients with coronavirus disease 2019, use of hydroxychloroquine with or without azithromycin for treatment of COVID-19 was associated with frequent QTc prolongation, and those taking hydroxychloroquine and azithromycin had greater QT prolongation than those taking hydroxychloroquine alone. One patient developed torsades de pointes. Meaning Clinicians should carefully weigh risks and benefits if considering hydroxychloroquine and azithromycin, with close monitoring of QTc and concomitant medication usage.
C1 [Mercuro, Nicholas J.; McCoy, Christopher M.] Beth Israel Deaconess Med Ctr, Dept Pharm, Boston, MA 02215 USA.
   [Yen, Christina F.; Gold, Howard S.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Infect Dis, 330 Brookline Ave,MASCO 426, Boston, MA 02215 USA.
   [Shim, David J.; Zimetbaum, Peter J.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Boston, MA 02115 USA.
   [Maher, Timothy R.; Zimetbaum, Peter J.] Beth Israel Deaconess Med, Div Cardiovasc Med, Harvard Thorndike Elect Inst, Boston, MA USA.
RP Gold, HS (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Infect Dis, 330 Brookline Ave,MASCO 426, Boston, MA 02215 USA.
EM pzimetba@bidmc.harvard.edu
CR Bhimraj A, 2020, INFECT DIS SOC AM GU
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Chorin E, QT INTERVAL PATIENTS, DOI 10.1101/2020.04.02.20047050v1
   Clerkin KJ, 2020, CIRCULATION, V141, P1648, DOI 10.1161/CIRCULATIONAHA.120.046941
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grayson ML, 2017, KUCERS USE ANTIBIOTI, P3030
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Pfizer Inc, 2019, ZITHR
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   Roden DM, 2020, J AM COLL CARDIOL, V75, P2623, DOI 10.1016/j.jacc.2020.04.016
   Tisdale JE, 2013, CIRC-CARDIOVASC QUAL, V6, P479, DOI 10.1161/CIRCOUTCOMES.113.000152
   US Department of Health & Human Services Centers for Disease Control and Prevention, 2020, COR COVID 19
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   World Health Organization, 2017, CARD ANT MAL POL ADV
NR 15
TC 116
Z9 116
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2380-6583
EI 2380-6591
J9 JAMA CARDIOL
JI JAMA Cardiol.
PD SEP
PY 2020
VL 5
IS 9
BP 1036
EP 1041
DI 10.1001/jamacardio.2020.1834
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA NU8ZL
UT WOS:000573925800015
PM 32936252
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Le, MP
   Peiffer-Smadja, N
   Guedj, J
   Neant, N
   Mentre, F
   Ader, F
   Yazdanpanah, Y
   Peytavin, G
AF Le, Minh Patrick
   Peiffer-Smadja, Nathan
   Guedj, Jeremie
   Neant, Nadege
   Mentre, France
   Ader, Florence
   Yazdanpanah, Yazdan
   Peytavin, Gilles
CA C-20-15 DisCoVeRy French Steering
TI Rationale of a loading dose initiation for hydroxychloroquine treatment
   in COVID-19 infection in the DisCoVeRy trial
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
ID PHARMACOKINETICS; DISPOSITION
AB Around the world, several dose regimens of hydroxychloroquine have been used for COVID-19 infection treatment, with the objective of identifying a short-term course. Hydroxychloroquine was found to decrease the viral replication in a concentration-dependent manner in vitro and to be more active when added prior to the viral challenge. A loading dose is used to rapidly attain a target drug concentration, which is usually considered as approximately the steady-state concentration. With a loading dose, the minimum effective concentration is reached much more rapidly than when using only the maintenance dose from the start. Thus, we propose a hydroxychloroquine sulphate dose regimen of 400mg twice daily at Day 1 then 400mg once daily from Day 2 to Day 10. We aimto evaluate this in the C-20-15 DisCoVeRy trial.
C1 [Le, Minh Patrick; Peytavin, Gilles] Bichat Claude Bernard Hosp, AP HP, Pharmacol Toxicol Dept, F-75018 Paris, France.
   [Le, Minh Patrick] Univ Paris, INSERM, UMRS 1144, F-75006 Paris, France.
   [Peiffer-Smadja, Nathan; Yazdanpanah, Yazdan] Bichat Claude Bernard Hosp, AP HP, Trop & Infect Dis Dept, F-75018 Paris, France.
   [Peiffer-Smadja, Nathan; Guedj, Jeremie; Neant, Nadege; Mentre, France; Yazdanpanah, Yazdan; Peytavin, Gilles] Univ Paris, UMRS1137, INSERM, IAME, F-75018 Paris, France.
   [Ader, Florence] Hosp Civils Lyon, Croix Rousse Hosp, Dept Infect Dis, 104 Grande Rue Croix Rousse, F-69004 Lyon, France.
   [Ader, Florence] Univ Claude Bernard Lyon 1, Ctr Int Rech Infectiol CIRI UCBL1 1111, INSERM, Lyon, France.
RP Le, MP (corresponding author), Bichat Claude Bernard Hosp, AP HP, Pharmacol Toxicol Dept, F-75018 Paris, France.; Le, MP (corresponding author), Univ Paris, INSERM, UMRS 1144, F-75006 Paris, France.
EM minh.le@aphp.fr
OI Lescure, Xavier/0000-0002-2828-125X; lina, bruno/0000-0002-8959-2123
FU Institut National de la Sante Et de la Recherche Medicale (INSERM),
   FranceInstitut National de la Sante et de la Recherche Medicale (Inserm)
   [C-20-15]
FX This trial C-20-15 DisCoVeRy (NCT04315948) was funded by the Institut
   National de la Sante Et de la Recherche Medicale (INSERM), France.
CR DUCHARME J, 1995, BRIT J CLIN PHARMACO, V40, P127, DOI 10.1111/j.1365-2125.1995.tb05768.x
   Furst DE, 1999, ARTHRITIS RHEUM, V42, P357, DOI 10.1002/1529-0131(199902)42:2<357::AID-ANR19>3.0.CO;2-J
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu LH, 2019, J INFECTION, V78, P178, DOI 10.1016/j.jinf.2018.12.003
   MACINTYRE AC, 1988, BIOPHARM DRUG DISPOS, V9, P513, DOI 10.1002/bod.2510090602
   MCCHESNEY EW, 1983, AM J MED, V75, P11, DOI 10.1016/0002-9343(83)91265-2
   MCLACHLAN AJ, 1994, CHIRALITY, V6, P360, DOI 10.1002/chir.530060421
   Pesko L, 1993, AM DRUGGIST, P207
   Tanaka E, 2004, BEST PRACT RES CL RH, V18, P233, DOI 10.1016/j.berh.2004.02.006
   TETT SE, 1988, BRIT J CLIN PHARMACO, V26, P303, DOI 10.1111/j.1365-2125.1988.tb05281.x
   TETT SE, 1989, BRIT J CLIN PHARMACO, V27, P771, DOI 10.1111/j.1365-2125.1989.tb03439.x
   United States Food and Drug Administration, DRUGS FDA FDA APPR D
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhou D, 2020, J ANTIMICROB CHEMOTH, V75, P1667, DOI 10.1093/jac/dkaa114
NR 14
TC 4
Z9 4
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD SEP
PY 2020
VL 75
IS 9
BP 2376
EP 2380
DI 10.1093/jac/dkaa191
PG 5
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA NV5NC
UT WOS:000574367100002
PM 32473020
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Siccardi, M
   Schapiro, J
   Di Perri, G
   Back, DJ
AF Siccardi, Marco
   Schapiro, Jonathan
   Di Perri, Giovanni
   Back, David J.
TI The challenging pathway towards the identification of
   SARS-CoV-2/COVID-19 therapeutics
SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
LA English
DT Article
ID PHARMACOKINETICS
AB The development of therapeutic agents against SARS-CoV-2/COVID-19 faces numerous barriers and a multidisciplinary approach to evaluating drug efficacy and toxicity is essential. Experimental and preclinical data should be integrated into a comprehensive analysis, where drug potency, the timing of therapy initiation, drug combinations, variability in systemic and local drug exposure and short- and long-term toxicities represent fundamental factors for the rational identification of candidates and prioritization of clinical investigations. Although the identification of SARS-CoV-2 therapeutics is a priority, rigorous and transparent methodologies are crucial to ensure that accelerated research programmes result in high-quality and reproducible findings.
C1 [Siccardi, Marco; Back, David J.] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England.
   [Schapiro, Jonathan] Natl Hemophilia Ctr, Tel Aviv, Israel.
   [Di Perri, Giovanni] Univ Turin, Amedeo Hosp, Dept Clin Infect Dis, Turin, Italy.
RP Siccardi, M (corresponding author), Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England.
EM m.siccardi@liverpool.ac.uk
FU JanssenJohnson & Johnson USAJanssen Biotech Inc; ViiV; AbbVie; MSD;
   GileadGilead Sciences; MerckMerck & Company; Bristol-Myers
   SquibbBristol-Myers Squibb
FX M.S. has received research grant funding from Janssen and ViiV. J.S. has
   received an honorariumfromor served as an advisor, consultant or
   advisory board member of the following companies: AbbVie, Bristol-Myers
   Squibb, Gilead, GlaxoSmithKline, ViiV Healthcare, Teva, Virology
   Education and Janssen-Cilag. G.D.P. has received research grants from,
   received fees for lectures from and served as an advisor of AbbVie, MSD,
   Gilead, ViiV and Jansen. D.J.B. has served as an advisory board/speakers
   bureau member of and has received an honorarium from Gilead, Merck,
   AbbVie, Bristol-Myers Squibb and Janssen, has received research grant
   funding from Gilead, Merck, AbbVie, Bristol-Myers Squibb and Janssen,
   and has received travel sponsorship fromAbbVie
CR Martinez-Rojas MA, 2020, AM J PHYSIOL-RENAL, V318, pF1454, DOI 10.1152/ajprenal.00160.2020
   Bloom PP, 2020, HEPATOLOGY, DOI 10.1002/hep.31326
   Chorin E, 2020, HEART RHYTHM, V17, P1425, DOI 10.1016/j.hrthm.2020.05.014
   EMA, 2017, ASS REP MAV
   Everaert BR, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13270
   FDA, 2016, HIGHL PRESCR INF OS
   Finsterer J, 2020, J MED VIROL, V92, P2316, DOI 10.1002/jmv.26000
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Lambert-Niclot S, 2010, HIV MED, V11, P666, DOI 10.1111/j.1468-1293.2010.00839.x
   Orioli L, 2020, ANN ENDOCRINOL-PARIS, V81, P101, DOI 10.1016/j.ando.2020.05.001
   Razonable RR, 2011, MAYO CLIN PROC, V86, P1009, DOI 10.4065/mcp.2011.0309
   Reddy YS, 2002, J INFECT DIS, V186, P1339, DOI 10.1086/344311
   Sheldon T, 2018, NATURE, V559, P445, DOI 10.1038/d41586-018-05789-4
   Spinner CD, 2017, J ANTIMICROB CHEMOTH, V72, P2679, DOI 10.1093/jac/dkx105
   Tadic M, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104906
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Wang YM, 2020, J INFECT DIS, V221, P1688, DOI 10.1093/infdis/jiz656
   Xu TM, 2020, INT J INFECT DIS, V94, P68, DOI 10.1016/j.ijid.2020.03.022
   Yoshinaga T, 2015, ANTIMICROB AGENTS CH, V59, P397, DOI 10.1128/AAC.03909-14
   Yu X, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02893-8
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
NR 21
TC 0
Z9 0
U1 2
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-7453
EI 1460-2091
J9 J ANTIMICROB CHEMOTH
JI J. Antimicrob. Chemother.
PD SEP
PY 2020
VL 75
IS 9
BP 2381
EP 2383
DI 10.1093/jac/dkaa272
PG 3
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA NV5NC
UT WOS:000574367100003
PM 32591771
OA Green Published
DA 2021-01-01
ER

PT J
AU Behbehani, S
   Garg, N
   Wasson, M
AF Behbehani, Sadikah
   Garg, Nisha
   Wasson, Megan
TI Regarding "Understanding the 'Scope' of the Problem: Why Laparoscopy Is
   Considered Safe during the COVID-19 Pandemic" Reply
SO JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY
LA English
DT Letter
ID HORMONE REPLACEMENT THERAPY
CR Angloli R, 2018, CRIT REV ONCOL HEMAT, V124, P51, DOI 10.1016/j.critrevonc.2018.02.005
   Garg N, 2020, J MINIM INVASIVE GYN, VS1553-4650, P30124
   Li D, 2015, GYNECOL ONCOL, V139, P355, DOI 10.1016/j.ygyno.2015.07.109
   Marchetti C, 2018, CRIT REV ONCOL HEMAT, V132, P111, DOI 10.1016/j.critrevonc.2018.09.018
NR 4
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1553-4650
EI 1553-4669
J9 J MINIM INVAS GYN
JI J. Minim. Invasive Gynecol.
PD SEP-OCT
PY 2020
VL 27
IS 6
BP 1426
EP 1426
DI 10.1016/j.jmig.2020.04.024
PG 1
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA NU7CX
UT WOS:000573799300044
PM 32344033
DA 2021-01-01
ER

PT J
AU Ohman, JW
   Annest, SJ
   Azizzadeh, A
   Burt, BM
   Caputo, FJ
   Chan, C
   Donahue, DM
   Freischlag, JA
   Gelabert, HA
   Humphries, MD
   Illig, KA
   Lee, JT
   Lum, YW
   Meyer, RD
   Pearl, GJ
   Ransom, EF
   Sanders, RJ
   Teijink, JAW
   Vaccaro, PS
   van Sambeek, MRHM
   Vemuri, C
   Thompson, RW
AF Ohman, J. Westley
   Annest, Stephen J.
   Azizzadeh, Ali
   Burt, Bryan M.
   Caputo, Francis J.
   Chan, Colin
   Donahue, Dean M.
   Freischlag, Julie A.
   Gelabert, Hugh A.
   Humphries, Misty D.
   Illig, Karl A.
   Lee, Jason T.
   Lum, Ying Wei
   Meyer, Richard D.
   Pearl, Gregory J.
   Ransom, Erin F.
   Sanders, Richard J.
   Teijink, Joep A. W.
   Vaccaro, Patrick S.
   van Sambeek, Marc R. H. M.
   Vemuri, Chandu
   Thompson, Robert W.
TI Evaluation and treatment of thoracic outlet syndrome during the global
   pandemic due to SARS-CoV-2 and COVID-19
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Article
DE Coronavirus; Hospital resources; Upper extremity; Neurogenic; Brachial
   plexus; Subclavian vein; Deep venous thrombosis; Axillary artery;
   Subclavian artery; Thromboembolism; Triage; Endovascular treatment;
   Surgical treatment; Telemedicine; Teleconference; Consensus
ID CORONAVIRUS
AB The global SARS-CoV-2/COVID-19 pandemic has required a reduction in nonemergency treatment for a variety of disorders. This report summarizes conclusions of an international multidisciplinary consensus group assembled to address evaluation and treatment of patients with thoracic outlet syndrome (TOS), a group of conditions characterized by extrinsic compression of the neurovascular structures serving the upper extremity. The following recommendations were developed in relation to the three defined types of TOS (neurogenic, venous, and arterial) and three phases of pandemic response (preparatory, urgent with limited resources, and emergency with complete diversion of resources).
   In-person evaluation and treatment for neurogenic TOS (interventional or surgical) are generally postponed during all pandemic phases, with telephone/telemedicine visits and at-home physical therapy exercises recommended when feasible.
   Venous TOS presenting with acute upper extremity deep venous thrombosis (Paget-Schroetter syndrome) is managed primarily with anticoagulation, with percutaneous interventions for venous TOS (thrombolysis) considered in early phases (I and II) and surgical treatment delayed until pandemic conditions resolve. Catheter-based interventions may also be considered for selected patients with central subclavian vein obstruction and threatened hemodialysis access in all pandemic phases, with definitive surgical treatment postponed.
   Evaluation and surgical treatment for arterial TOS should be reserved for limb-threatening situations, such as acute upper extremity ischemia or acute digital embolization, in all phases of pandemic response. In late pandemic phases, surgery should be restricted to thrombolysis or brachial artery thromboembolectomy, with more definitive treatment delayed until pandemic conditions resolve.
C1 [Ohman, J. Westley; Thompson, Robert W.] Washington Univ, Sch Med, Dept Surg, Ctr Thorac Outlet Syndrome, St Louis, MO 63110 USA.
   [Ohman, J. Westley; Thompson, Robert W.] Washington Univ, Sch Med, Dept Surg, Vasc Surg Sect, St Louis, MO 63110 USA.
   [Annest, Stephen J.] Presbyterian St Lukes Hosp, Vasc Surg, Denver, CO USA.
   [Annest, Stephen J.] St Joseph Hosp, Denver, CO USA.
   [Azizzadeh, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Vasc Surg, Los Angeles, CA 90048 USA.
   [Burt, Bryan M.] Baylor Coll Med, Michael E DeBakey Dept Surg, Div Thorac Surg, Houston, TX 77030 USA.
   [Caputo, Francis J.] Cleveland Clin Fdn, Dept Vasc Surg, Sydell & Arnold Miller Heart & Vasc Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
   [Chan, Colin] Wirral Univ Teaching Hosp, Dept Vasc Surg, Chester, Cheshire, England.
   [Chan, Colin] Countess Chester Hosp NHS Fdn Trust, Chester, Cheshire, England.
   [Donahue, Dean M.] Massachusetts Gen Hosp, Dept Surg, Div Thorac Surg, Boston, MA 02114 USA.
   [Donahue, Dean M.] Harvard Med Sch, Boston, MA 02115 USA.
   [Freischlag, Julie A.] Wake Forest Sch Med, Wake Forest Baptist Med Ctr, Winston Salem, NC 27101 USA.
   [Gelabert, Hugh A.] Univ Calif Los Angeles, David Geffen Sch Med, Gonda Goldschmied Vasc Ctr, Div Vasc Surg, Los Angeles, CA 90095 USA.
   [Humphries, Misty D.] Univ Calif Davis, Med Ctr, Div Vasc Surg, Sacramento, CA 95817 USA.
   [Illig, Karl A.] Reg Med Ctr, Dialysis Access Inst, Orangeburg, NY USA.
   [Lee, Jason T.] Stanford Hosp & Clin, Dept Surg, Div Vasc Surg, Stanford, CA USA.
   [Lum, Ying Wei] Johns Hopkins Univ, Sch Med, Div Vasc Surg & Endovasc Therapy, Baltimore, MD USA.
   [Meyer, Richard D.; Ransom, Erin F.] Univ Alabama Birmingham, Dept Orthopaed Surg, Birmingham, AL USA.
   [Pearl, Gregory J.] Baylor Univ, Med Ctr, Div Vasc Surg, Dallas, TX USA.
   [Pearl, Gregory J.] Baylor Scott & White Heart & Vasc Hosp, Dallas, TX USA.
   [Sanders, Richard J.] Univ Colorado, Hlth Sci Ctr, Dept Surg, Aurora, CO USA.
   [Teijink, Joep A. W.; van Sambeek, Marc R. H. M.] Catharina Hosp, Dept Vasc Surg, Eindhoven, Netherlands.
   [Teijink, Joep A. W.] Maastricht Univ, Fac Hlth Med & Life Sci, CAPHRI Sch Publ Hlth & Primary Care, Dept Epidemiol, Maastricht, Netherlands.
   [Vaccaro, Patrick S.] Ohio State Univ, Coll Med, Div Vasc Dis & Surg, Columbus, OH 43210 USA.
   [van Sambeek, Marc R. H. M.] Univ Technol Eindhoven, Dept Biomed Technol, Eindhoven, Netherlands.
   [Vemuri, Chandu] Univ Michigan, Dept Surg, Sect Vasc Surg, Michigan Med, Ann Arbor, MI 48109 USA.
RP Thompson, RW (corresponding author), Washington Univ, Sch Med, Sect Vasc Surg, Ctr Thorac Outlet Syndrome, Campus Box 8109, St Louis, MO 63110 USA.
EM rwthompson@wustl.edu
CR American College of Surgeons, CLIN ISS GUID
   American College of Surgeons, REC MAN EL SURG PROC
   American College of Surgeons, COVID 19 GUID TRIAG
   American College of Surgeons, GUID TRIAG NON SURG
   Brownie ER, 2020, J VASC SURG-VENOUS L, V8, P118, DOI 10.1016/j.jvsv.2019.08.011
   Centers for Medicare & Medicaid Services, CMS REL REC AD EL SU
   Forrester JD, 2020, J AM COLL SURGEONS, V230, P1098, DOI 10.1016/j.jamcollsurg.2020.03.030
   Ghinai I, 2020, LANCET, V395, P1137, DOI 10.1016/S0140-6736(20)30607-3
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Humphries MD, VESS TELEMEDICINE ST
   Illig KA, 2013, THORACIC OUTLET SYND
   Illig KA, 2016, J VASC SURG, V64, pE23, DOI 10.1016/j.jvs.2016.04.039
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Moghadas SM, 2020, P NATL ACAD SCI USA, V117, P9122, DOI 10.1073/pnas.2004064117
   Murray CJ, FORECASTING COVID 19
   Prachand VN, 2020, J AM COLL SURGEONS, V231, P281, DOI 10.1016/j.jamcollsurg.2020.04.011
   Society for Vascular Surgery, VASC SURG TRIAG TIER
   Starnes BW, LETT SEATTLE COVID 1
   Vascular and Endovascular Surgery Society, VESS COVID 19 STAT
   WHO, WHO CHAR COVID 19 PA
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 22
TC 0
Z9 0
U1 2
U2 2
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD SEP
PY 2020
VL 72
IS 3
BP 790
EP 798
DI 10.1016/j.jvs.2020.05.048
PG 9
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA NU9OZ
UT WOS:000573966400006
PM 32497747
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Zhao, ZQ
   Sokhansanj, BA
   Malhotra, C
   Zheng, K
   Rosen, GL
AF Zhao, Zhengqiao
   Sokhansanj, Bahrad A.
   Malhotra, Charvi
   Zheng, Kitty
   Rosen, Gail L.
TI Genetic grouping of SARS-CoV-2 coronavirus sequences using informative
   subtype markers for pandemic spread visualization
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID IDENTIFICATION; PNEUMONIA
AB We propose an efficient framework for genetic subtyping of SARS-CoV-2, the novel coronavirus that causes the COVID-19 pandemic. Efficient viral subtyping enables visualization and modeling of the geographic distribution and temporal dynamics of disease spread. Subtyping thereby advances the development of effective containment strategies and, potentially, therapeutic and vaccine strategies. However, identifying viral subtypes in real-time is challenging: SARS-CoV-2 is a novel virus, and the pandemic is rapidly expanding. Viral subtypes may be difficult to detect due to rapid evolution; founder effects are more significant than selection pressure; and the clustering threshold for subtyping is not standardized. We propose to identify mutational signatures of available SARS-CoV-2 sequences using a population-based approach: an entropy measure followed by frequency analysis. These signatures, Informative Subtype Markers (ISMs), define a compact set of nucleotide sites that characterize the most variable (and thus most informative) positions in the viral genomes sequenced from different individuals. Through ISM compression, we find that certain distant nucleotide variants covary, including non-coding and ORF1ab sites covarying with the D614G spike protein mutation which has become increasingly prevalent as the pandemic has spread. ISMs are also useful for downstream analyses, such as spatiotemporal visualization of viral dynamics. By analyzing sequence data available in the GISAID database, we validate the utility of ISM-based subtyping by comparing spatiotemporal analyses using ISMs to epidemiological studies of viral transmission in Asia, Europe, and the United States. In addition, we show the relationship of ISMs to phylogenetic reconstructions of SARS-CoV-2 evolution, and therefore, ISMs can play an important complementary role to phylogenetic tree-based analysis, such as is done in the Nextstrain project. The developed pipeline dynamically generates ISMs for newly added SARS-CoV-2 sequences and updates the visualization of pandemic spatiotemporal dynamics, and is available on Github at https://github.com/EESI/ISM (Jupyter notebook), https://github.com/EESI/ncov_ism (command line tool) and via an interactive website at https://covid19-ism.coe.drexel.edu/.
C1 [Zhao, Zhengqiao; Sokhansanj, Bahrad A.; Rosen, Gail L.] Drexel Univ, Coll Engn, Dept Elect & Comp Engn, Ecol & Evolutionary Signal Proc & Informat Lab, Philadelphia, PA 19104 USA.
   [Malhotra, Charvi; Zheng, Kitty] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA.
RP Zhao, ZQ (corresponding author), Drexel Univ, Coll Engn, Dept Elect & Comp Engn, Ecol & Evolutionary Signal Proc & Informat Lab, Philadelphia, PA 19104 USA.
EM zz374@drexel.edu
OI Sokhansanj, Bahrad/0000-0002-5050-5926; Malhotra,
   Charvi/0000-0002-3371-8399
FU National Science Foundation (NSF)National Science Foundation (NSF)
   [1919691, ACI-1548562]; Drexel's University Research Computing Facility
   (URCF)
FX GR received National Science Foundation (NSF: https://www.nsf.gov/)
   grant #1919691. GR received computational resources support from Extreme
   Science and Engineering Discovery Environment (XSEDE:
   https://www.xsede.org/) and XSEDE is supported by National Science
   Foundation (NSF: https://www.nsf.gov/) grant number #ACI-1548562. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.; We downloaded
   all SARS-Cov-2 sequences available from and acknowledge the
   contributions of the Global Initiative on Sharing All Influenza Data
   (GISAID) EpiFlu database, which has made accessible novel coronavirus
   sequencing data, including from the NIH Genbank resource [5]. We would
   also like to acknowledge the authors, originating and submitting
   laboratories of the sequences from GISAID's EpiFlu Database on which
   this research is based, as well as all future SARS-CoV-2 sequence
   contributors in GISAID's EpiFlu Database. A list of contributors to the
   data used in this paper is included in S7 File. This work was partially
   supported by Drexel's University Research Computing Facility (URCF).
CR [Anonymous], 2020, BBC NEWS
   Batista MVA, 2011, INFECT GENET EVOL, V11, P2026, DOI 10.1016/j.meegid.2011.09.013
   BEALS EW, 1984, ADV ECOL RES, V14, P1, DOI 10.1016/S0065-2504(08)60168-3
   Benvenuto D, 2020, PATHOG GLOB HEALTH, V114, P64, DOI 10.1080/20477724.2020.1725339
   Bhattacharyya C., 2020, BIORXIV
   Bhowmik D, 2020, BIORXIV
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Clarridge JE, 2004, CLIN MICROBIOL REV, V17, P840, DOI 10.1128/CMR.17.4.840-862.2004
   Cole JR, 2014, NUCLEIC ACIDS RES, V42, pD633, DOI 10.1093/nar/gkt1244
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   Dawy Z, 2006, IEEE ACM T COMPUT BI, V3, P47, DOI 10.1109/TCBB.2006.9
   Deng XD, 2020, SCIENCE, V369, P582, DOI 10.1126/science.abb9263
   Eren AM, 2013, METHODS ECOL EVOL, V4, P1111, DOI 10.1111/2041-210X.12114
   Fauver JR, 2020, CELL, V181, P990, DOI 10.1016/j.cell.2020.04.021
   Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117
   Gonzalez-Reiche AS, 2020, INTR EARLY SPREAD SA
   Grubaugh ND, 2019, NAT MICROBIOL, V4, P10, DOI 10.1038/s41564-018-0296-2
   Grubaugh ND, CELL, VXXXX, DOI [10.1016/j.cell.2020.06.040, DOI 10.1016/J.CELL.2020.06.04032697970]
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Hodcroft EB, 2020, YEAR LETTER GENETIC
   Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55
   Isabel S, 2020, BIORXIV
   Jia YY, 2020, J INFECTION, V81, pE96, DOI 10.1016/j.jinf.2020.05.016
   Karacan I, 2020, NORTH CLIN ISTANB, V7, P203, DOI 10.14744/nci.2020.90532
   Karamitros T, 2020, BIORXIV, DOI [10.1016/j.jcv.2020.104585, DOI 10.1016/J.JCV.2020.10458532818852]
   Katoh K, 2013, MOL BIOL EVOL, V30, P772, DOI 10.1093/molbev/mst010
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Korber B, 2020, BIORXIV
   Korber B, 2020, CELL, V182, P812, DOI 10.1016/j.cell.2020.06.043
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Legendre P, 2008, NUMERICAL ECOLOGY, V24
   LEWONTIN RC, 1988, GENETICS, V120, P849
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li XJ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb9153
   Lorenzo-Redondo R, 2020, UNIQUE CLADE SARS CO
   McDonald D, 2018, MSYSTEMS, V3, DOI 10.1128/mSystems.00031-18
   McDonald D, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0117-2
   Miller D, 2020, FULL GENOME VIRAL SE
   Moya A, 2004, NAT REV MICROBIOL, V2, P279, DOI 10.1038/nrmicro863
   Nomenclature for incompletely specified bases in nucleic acid sequences, 1986, P NATL ACAD SCI USA, V83, P4
   Novembre J, 2008, NATURE, V456, P98, DOI 10.1038/nature07331
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Plotly Technologies Inc, 2015, COLL DAT SCI
   Price MN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009490
   Rambaut A, 2020, BIORXIV
   Robinson ER, 2013, GENOME MED, V5, DOI 10.1186/gm440
   Rosenberg A., 2007, EMNLP CONLL, V7, P410, DOI DOI 10.7916/D80V8N84
   Sanjuan R, 2010, J VIROL, V84, P9733, DOI 10.1128/JVI.00694-10
   Sekizuka T, 2020, P NATL ACAD SCI USA, V117, P20198, DOI 10.1073/pnas.2006824117
   SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x
   Shen ZJ, 2020, CLIN INFECT DIS, V71, P713, DOI 10.1093/cid/ciaa203
   Shu YL, 2017, EUROSURVEILLANCE, V22, P2, DOI 10.2807/1560-7917.ES.2017.22.13.30494
   Tan W, 2020, CHINA CDC WEEKLY, V2, P61, DOI DOI 10.46234/ccdcw2020.017
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   To KK, 2020, LANCET INFECT DIS
   Towns J, 2014, COMPUT SCI ENG, V16, P62, DOI 10.1109/MCSE.2014.80
   Villabona-Arenas CJ, 2020, NAT MICROBIOL, V5, P876, DOI 10.1038/s41564-020-0738-5
   Walls AC, CELL, VXXXX, DOI [10.1016/j.cell.2020.02.058, DOI 10.1016/J.CELL.2020.02.05832155444]
   Wang CT, 2020, J MED VIROL, V92, P667, DOI 10.1002/jmv.25762
   Wang MJ, 2020, J VIROL, V94, DOI 10.1128/JVI.00567-20
   WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/JB.173.2.697-703.1991
   Worobey M, 2020, BIORXIV, DOI [10.1101/2020.05.21.109322, DOI 10.1101/2020.05.21.10932232511416]
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yu IM, 2005, J BIOL CHEM, V280, P23280, DOI 10.1074/jbc.M501015200
   Yu WB, 2020, ZOOL RES, V41, P247, DOI 10.24272/j.issn.2095-8137.2020.022
   Yuen KS, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00404-4
   Zhang L, 2020, BIORXIV, DOI [10.1101/2020.06.12.148726, DOI 10.1101/2020.06.12.14872632587973]
   Zhao Wenming, 2020, Yichuan, V42, P212, DOI 10.16288/j.yczz.20-030
NR 69
TC 0
Z9 0
U1 4
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-734X
EI 1553-7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD SEP
PY 2020
VL 16
IS 9
AR e1008269
DI 10.1371/journal.pcbi.1008269
PG 32
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA NU7XO
UT WOS:000573853000004
PM 32941419
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Alamdari, NM
   Afaghi, S
   Rahimi, FS
   Tarki, FE
   Tavana, S
   Zali, A
   Fathi, M
   Besharat, S
   Bagheri, L
   Pourmotahari, F
   Irvani, SSN
   Dabbagh, A
   Mousavi, SA
AF Alamdari, Nasser Malekpour
   Afaghi, Siamak
   Rahimi, Fatemeh Sadat
   Tarki, Farzad Esmaeili
   Tavana, Sasan
   Zali, Alireza
   Fathi, Mohammad
   Besharat, Sara
   Bagheri, Leyla
   Pourmotahari, Fatemeh
   Irvani, Seyed Sina Naghibi
   Dabbagh, Ali
   Mousavi, Seyed Ali
TI Mortality Risk Factors among Hospitalized COVID-19 Patients in a Major
   Referral Center in Iran
SO TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
DE COVID-19; Iran; prognosis; risk factor; SARS-CoV-2
ID CORONAVIRUS; HYDROXYCHLOROQUINE; AZITHROMYCIN; ASSOCIATION; PREVALENCE;
   PREDICTORS; SEVERITY; CHINA; SARS
AB The Coronavirus Disease 2019 (COVID-19) pandemic has killed many people worldwide since December 2019, and Iran has been among the most affected countries. In this retrospective study, we aimed to determine the prognostic factors associated with mortality in COVID-19 patients by analyzing 396 survived and 63 non-survived patients in Shahid Modarres Hospital, Tehran, Iran, from January 30th until April 5th, 2020. As the results, the BMI > 35 (p = 0.0003), lung cancer (p = 0.007), chronic kidney disease (p = 0.002), Immunocompromised condition (p = 0.003), and diabetes (p = 0.018) were more frequently observed in the expired group. The history of statins use was more common in the discharged group (p = 0.002), while there was no significant difference in the drug history of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, nonsteroidal anti-inflammatory drugs, aspirin, and/or steroids, and in the past-year influenza vaccination. Multivariable regression demonstrated rising odds of in-hospital death related with age (odds ratio (OR) = 1.055, p = 0.002), levels of C-reactive protein (CRP) (OR = 2.915, p < 0.001), creatinine (OR = 1.740, p = 0.023), lymphocyte count (OR = 0.999, p = 0.008), and magnesium level (OR = 0.032, p < 0.001) on admission. In conclusion, the patients with older age and higher BMI with lymphopenia, hypomagnesemia, elevated CRP and/or raised creatinine on admission are at higher risk of mortality due to the COVID-19 infection, which requires the physicians to use timely and strong therapeutic measures for such patients.
C1 [Alamdari, Nasser Malekpour] Shahid Beheshti Univ Med Sci, Shahid Modarres Hosp, Crit Care Qual Improvement Res Ctr, Dept Gen Surg, Tehran, Iran.
   [Afaghi, Siamak; Rahimi, Fatemeh Sadat; Tarki, Farzad Esmaeili; Bagheri, Leyla] Shahid Beheshti Univ Med Sci, Shahid Modarres Hosp, Dept Internal Med, Tehran, Iran.
   [Tavana, Sasan] Shahid Beheshti Univ Med Sci, Shahid Modarres Hosp, Clin Res & Dev Ctr, Dept Pulm Med, Tehran, Iran.
   [Zali, Alireza] Shahid Beheshti Univ Med Sci, Shahid Modarres Hosp, Funct Neurosurg Res Ctr, Tehran, Iran.
   [Fathi, Mohammad] Shahid Beheshti Univ Med Sci, Shahid Modarres Hosp, Crit Care Qual Improvement Res Ctr, Dept Anesthesiol, Tehran, Iran.
   [Besharat, Sara; Pourmotahari, Fatemeh] Shahid Beheshti Univ Med Sci, Shahid Modarres Hosp, Clin Res & Dev Ctr, Dept Radiol, Tehran, Iran.
   [Irvani, Seyed Sina Naghibi] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Arabi Ave, Tehran 1985717443, Iran.
   [Dabbagh, Ali] Shahid Beheshti Univ Med Sci, Anesthesiol Res Ctr, Tehran, Iran.
   [Mousavi, Seyed Ali] Univ Tehran Med Sci, Shariati Hosp, Hematol Oncol & Hematopoiet Stem Cell Transplant, Tehran, Iran.
RP Irvani, SSN (corresponding author), Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Arabi Ave, Tehran 1985717443, Iran.
EM sina.irvani@gmail.com
RI Sciences, Functional Neurosurgery Research Center Shahid Beheshti
   University of Medical/AAN-2817-2020
CR Abdi M, 2020, INFECT CONT HOSP EP, V41, P754, DOI 10.1017/ice.2020.86
   Alraddadi BM, 2016, EMERG INFECT DIS, V22, P49, DOI 10.3201/eid2201.151340
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Casey K., 2020, AM J EMERG MED, V38, P1544
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P339
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Dai XF, 2020, EUR J PREV CARDIOL, V27, P1436, DOI 10.1177/2047487320922370
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Duwe Susanne, 2017, GMS Infect Dis, V5, pDoc04, DOI 10.3205/id000030
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Goldwasser P, 1997, J CLIN EPIDEMIOL, V50, P693, DOI 10.1016/S0895-4356(97)00015-2
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   HELFANT RH, 1986, AM J MED, V80, P13, DOI 10.1016/0002-9343(86)90336-0
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hong KH, 2018, THORAX, V73, P286, DOI 10.1136/thoraxjnl-2016-209313
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2018, LANCET INFECT DIS, V18, pE217, DOI 10.1016/S1473-3099(18)30127-0
   Hulme KD, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00861
   Jia N, 2009, TROP MED INT HEALTH, V14, P21, DOI 10.1111/j.1365-3156.2008.02147.x
   Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152
   Joyce E, 2013, EUR HEART J-ACUTE CA, V2, P77, DOI 10.1177/2048872612471215
   Kanne JP, 2020, RADIOLOGY, V296, pE113, DOI 10.1148/radiol.2020200527
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Lippi G, 2020, EUR J INTERN MED, V75, P107, DOI 10.1016/j.ejim.2020.03.014
   Mackenzie J.S., 2020, MICROBIOL AUST
   Milbrandt EB, 2009, MOL MED, V15, P438, DOI 10.2119/molmed.2009.00091
   Oostra M, 2006, J VIROL, V80, P2326, DOI 10.1128/JVI.80.5.2326-2336.2006
   Plein LM, 2018, BRIT J PHARMACOL, V175, P2717, DOI 10.1111/bph.13750
   Rao GA, 2014, ANN FAM MED, V12, P121, DOI 10.1370/afm.1601
   Rizzo P, 2020, BASIC RES CARDIOL, V115, DOI 10.1007/s00395-020-0791-5
   Rodelo JR, 2012, AM J EMERG MED, V30, P1991, DOI 10.1016/j.ajem.2012.04.033
   RUBEIZ GJ, 1993, CRIT CARE MED, V21, P203, DOI 10.1097/00003246-199302000-00010
   Salimi V, 2013, CRIT CARE MED, V41, P205, DOI 10.1097/CCM.0b013e31826767a8
   Sarnak MJ, 2001, CHEST, V120, P1883, DOI 10.1378/chest.120.6.1883
   Shahverdi Ehsan, 2016, Immunohematology, V32, P135
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Syedmoradi L, 2011, ANN HUM BIOL, V38, P150, DOI 10.3109/03014460.2010.500472
   Wang H, 2020, J HYDROMETEOROL, V21, P881, DOI 10.1175/JHM-D-19-0195.1
   WHO, 2020, CLIN MAN SEV AC RESP
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Yan CH, 2020, INT FORUM ALLERGY RH, V10, P806, DOI 10.1002/alr.22579
   Yang JK, 2006, DIABETIC MED, V23, P623, DOI 10.1111/j.1464-5491.2006.01861.x
   Yang PH, 2020, CELL MOL IMMUNOL, V17, P555, DOI 10.1038/s41423-020-0407-x
   Yuan S, 2015, MBIO, V6, DOI 10.1128/mBio.01120-15
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 49
TC 1
Z9 1
U1 1
U2 1
PU TOHOKU UNIV MEDICAL PRESS
PI SENDAI
PA 2-1, SEIRYO-MACHI, AOBA-KU, SENDAI, MIYAGI 980-8575, JAPAN
SN 0040-8727
EI 1349-3329
J9 TOHOKU J EXP MED
JI Tohoku J. Exp. Med.
PD SEP
PY 2020
VL 252
IS 1
BP 73
EP 84
DI 10.1620/tjem.252.73
PG 12
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA NU9QZ
UT WOS:000573971600009
PM 32908083
OA Other Gold
DA 2021-01-01
ER

PT J
AU Sweiss, NJ
   Korsten, P
   Syed, HJ
   Syed, A
   Baughman, RP
   Yee, AMF
   Culver, DA
   Sosenko, T
   Azuma, A
   Bonella, F
   Costabel, U
   Drake, WP
   Drent, M
   Lower, EE
   Israel-Biet, D
   Mostard, RLM
   Nunes, H
   Rottoli, P
   Spagnolo, P
   Wells, AU
   Wuyts, WA
   Judson, MA
AF Sweiss, Nadera J.
   Korsten, Peter
   Syed, Huzaefah J.
   Syed, Aamer
   Baughman, Robert P.
   Yee, Arthur M. F.
   Culver, Daniel A.
   Sosenko, Teresa
   Azuma, Arata
   Bonella, Francesco
   Costabel, Ulrich
   Drake, Wonder P.
   Drent, Marjolein
   Lower, Elyse E.
   Israel-Biet, Dominique
   Mostard, Remy L. M.
   Nunes, Hilario
   Rottoli, Paola
   Spagnolo, Paolo
   Wells, Athol U.
   Wuyts, Wim A.
   Judson, Marc A.
TI When the Game Changes Guidance to Adjust Sarcoidosis Management During
   the Coronavirus Disease 2019 Pandemic
SO CHEST
LA English
DT Letter
DE coronavirus disease; diffuse lung disease; immunosuppressives;
   sarcoidosis; SARS; severe acute respiratory syndrome
ID RHEUMATOID-ARTHRITIS; INFECTION; EFFICACY; THERAPY
C1 [Sweiss, Nadera J.; Sosenko, Teresa] Univ Illinois, Div Rheumatol, Chicago, IL USA.
   [Korsten, Peter] Univ Med Ctr Gottingen, Dept Nephrol & Rheumatol, Gottingen, Germany.
   [Syed, Huzaefah J.; Syed, Aamer] VCU Hlth, Dept Internal Med, Richmond, VA USA.
   [Baughman, Robert P.; Lower, Elyse E.] Univ Cincinnati, Med Ctr, Dept Med, Cincinnati, OH 45221 USA.
   [Yee, Arthur M. F.] Weill Cornell Med, Hosp Special Surg, Div Rheumatol, New York, NY USA.
   [Culver, Daniel A.] Cleveland Clin, Crit Care Med, Cleveland, OH 44106 USA.
   [Azuma, Arata] Univ Duisburg Essen, Nippon Med Sch, Ruhrlandklin, Dept Pneumol,Univ Hosp, Essen, Germany.
   [Bonella, Francesco; Costabel, Ulrich] Univ Duisburg Essen, Ctr Interstitial & Rare Lung Dis, Dept Pneumol, Ruhrlandklin,Univ Hosp, Essen, Germany.
   [Drake, Wonder P.] Vanderbilt Univ, Div Infect Dis, Dept Pulmonol, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Drent, Marjolein] St Antonius Hosp, ILD Ctr Excellence, Nieuwegein, Netherlands.
   [Israel-Biet, Dominique] Univ Paris, Hop Europeen Georges Pompidou, Paris, France.
   [Mostard, Remy L. M.] Zuyderland Med Ctr, Dept Resp Med, Heerlen, Netherlands.
   [Nunes, Hilario] Avicenne Hosp, Dept Pulmonol, Bobigny, France.
   [Rottoli, Paola] Univ Siena, Dept Med Surg & Neurol Sci, Siena, Italy.
   [Spagnolo, Paolo] Univ Padua, Resp Dis Unit, Padua, Italy.
   [Wells, Athol U.] Royal Brompton Hosp, London, England.
   [Wuyts, Wim A.] Univ Hosp Leuven, Dept Pulm Med, Leuven, Belgium.
   [Judson, Marc A.] Albany Med Coll, Div Pulm & Crit Care Med, Albany, NY 12208 USA.
RP Sweiss, NJ (corresponding author), Div Rheumatol, 840 South Wood St, Chicago, IL 60612 USA.
EM nsweiss@uic.edu
RI Korsten, med. Peter/H-3562-2019
OI Korsten, med. Peter/0000-0001-6065-5680; Azuma,
   Arata/0000-0003-0506-9966
CR Baughman RP, 2001, AM J RESP CRIT CARE, V164, P1885, DOI 10.1164/ajrccm.164.10.2104046
   Baughman RP, 2005, QJM-INT J MED, V98, P451, DOI 10.1093/qjmed/hci073
   Doran MF, 2002, ARTHRITIS RHEUM, V46, P2294, DOI 10.1002/art.10529
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grunewald J, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0096-x
   Ibrahim A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010015
   Judson MA, 2016, RHEUM DIS CLIN N AM, V42, P119, DOI 10.1016/j.rdc.2015.08.012
   Judson MA, 2014, EUR RESPIR J, V44, P1296, DOI 10.1183/09031936.00000914
   McKinzie BP, 2010, AM J MED SCI, V339, P1, DOI 10.1097/MAJ.0b013e3181b97635
   Schaeverbeke T, 2016, RHEUMATOLOGY, V55, P210, DOI 10.1093/rheumatology/kev277
   Singh JA, 2015, LANCET, V386, P258, DOI 10.1016/S0140-6736(14)61704-9
NR 12
TC 7
Z9 7
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0012-3692
EI 1931-3543
J9 CHEST
JI Chest
PD SEP
PY 2020
VL 158
IS 3
BP 892
EP 895
DI 10.1016/j.chest.2020.04.033
PG 4
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA NT9NA
UT WOS:000573265100023
PM 32360495
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Phipps, MM
   Barraza, LH
   LaSota, ED
   Sobieszczyk, ME
   Pereira, MR
   Zheng, EX
   Fox, AN
   Zucker, J
   Verna, EC
AF Phipps, Meaghan M.
   Barraza, Luis H.
   LaSota, Elijah D.
   Sobieszczyk, Magdalena E.
   Pereira, Marcus R.
   Zheng, Elizabeth X.
   Fox, Alyson N.
   Zucker, Jason
   Verna, Elizabeth C.
TI Acute Liver Injury in COVID-19: Prevalence and Association with Clinical
   Outcomes in a Large US Cohort
SO HEPATOLOGY
LA English
DT Article
AB Background and Aims Coronavirus disease 2019 (COVID-19) has been associated with acute liver injury (ALI) manifested by increased liver enzymes in reports worldwide. Prevalence of liver injury and associated clinical characteristics are not well defined. We aim to identify the prevalence of and risk factors for development of COVID-19-associated ALI in a large cohort in the United States. Approach and Results In this retrospective cohort study, all patients who underwent SARS-CoV-2 testing at three hospitals in the NewYork-Presbyterian network were assessed. Of 3,381 patients, 2,273 tested positive and had higher initial and peak alanine aminotransferase (ALT) than those who tested negative. ALI was categorized as mild if ALT was greater than the upper limit of normal (ULN) but <2 times ULN, moderate if ALT was between 2 and 5 times the ULN, and severe if ALT was >5 times the ULN. Among patients who tested positive, 45% had mild, 21% moderate, and 6.4% severe liver injury (SLI). In multivariable analysis, severe ALI was significantly associated with elevated inflammatory markers, including ferritin (odds ratio [OR], 2.40;P < 0.001) and interleukin-6 (OR, 1.45;P = 0.009). Patients with SLI had a more severe clinical course, including higher rates of intensive care unit admission (69%), intubation (65%), renal replacement therapy (RRT; 33%), and mortality (42%). In multivariable analysis, peak ALT was significantly associated with death or discharge to hospice (OR, 1.14;P = 0.044), controlling for age, body mass index, diabetes, hypertension, intubation, and RRT. Conclusions ALI is common in patients who test positive for SARS-CoV-2, but is most often mild. However, among the 6.4% of patients with SLI, a severe disease course should be anticipated.
C1 [Phipps, Meaghan M.; Barraza, Luis H.; Zheng, Elizabeth X.; Fox, Alyson N.; Verna, Elizabeth C.] Columbia Univ, Dept Med, Div Digest & Liver Dis, Irving Med Ctr, New York, NY USA.
   [LaSota, Elijah D.; Sobieszczyk, Magdalena E.; Pereira, Marcus R.; Zucker, Jason] Columbia Univ, Dept Med, Div Infect Dis, Irving Med Ctr, New York, NY USA.
   [Zheng, Elizabeth X.; Fox, Alyson N.; Verna, Elizabeth C.] Columbia Univ, Ctr Liver Dis & Transplantat, Irving Med Ctr, New York, NY USA.
RP Verna, EC (corresponding author), Columbia Univ, Ctr Liver Dis & Transplantat, Vagelos Coll Phys & Surg, 622 West 168th St,Ph 14-105, New York, NY 10032 USA.
EM ev77@cumc.columbia.edu
CR Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326
   Chai X, 2020, SPECIFIC ACE2 EXPRES, DOI [10.1101/2020.02.03.931766, DOI 10.1101/2020.02.03.931766]
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Cure E, 2020, J MED VIROL, V92, P1423, DOI 10.1002/jmv.25848
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kasarala George, 2016, Clin Liver Dis (Hoboken), V8, P13, DOI 10.1002/cld.562
   Lee IC, 2020, J CHIN MED ASSOC, V83, P521, DOI 10.1097/JCMA.0000000000000319
   Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sun J, 2020, LIVER INT, V40, P1278, DOI 10.1111/liv.14470
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu J, 2020, CLIN INFECT DIS, V71, P706, DOI 10.1093/cid/ciaa199
   Xie HS, 2020, LIVER INT, V40, P1321, DOI 10.1111/liv.14449
   Xu XW, 2020, BMJ, V19, pm606
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 21
TC 24
Z9 24
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
EI 1527-3350
J9 HEPATOLOGY
JI Hepatology
PD SEP
PY 2020
VL 72
IS 3
BP 807
EP 817
DI 10.1002/hep.31404
PG 11
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NT8GZ
UT WOS:000573173400004
PM 32473607
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kim, EJ
   Choi, SH
   Park, JS
   Kwon, YS
   Lee, J
   Kim, Y
   Lee, SY
   Choi, EY
AF Kim, Eun Jin
   Choi, Sun Ha
   Park, Jae Seok
   Kwon, Yong Shik
   Lee, Jaehee
   Kim, Yeonjae
   Lee, Shin Yup
   Choi, Eun Young
TI Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill
   Patients with SARS-CoV-2 Infection
SO YONSEI MEDICAL JOURNAL
LA English
DT Article
DE Coronavirus disease 2019; severe acute respiratory syndrome coronavirus
   2; darunavir-cobicistat
AB We retrospectively reviewed patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections who were admitted to an intensive care unit in Daegu, South Korea. The outcomes of patients who did (cases) or did not (controls) receive darunavir-cobicistat (800-150 mg) therapy were compared. Fourteen patients received darunavir-cobicistat treatment, and 96 received other antiviral therapy (controls). Overall, the darunavir-cobicistat group comprised patients with milder illness, and the crude mortality rate of all patients in the darunavir-cobicistat group was lower than that in the controls [odds ratio (OR) 0.20, 95% confidence interval (CI) 0.04-0.89, p.0.034 After 1:2 propensity-score matching, there were 14 patients in the darunavir-cobicistet group, and 28 patients in the controls. In propensity score-matched analysis, the darunavir-cobicistat group had lower mortality than the controls (OR 0.07, 95% CI 0.01-0.52, p=0.009). In conclusion, darunavir-cobicistat therapy was found to be associated with a significant survival benefit in critically ill patients with SARS-CoV-2 infection.
C1 [Kim, Eun Jin] Daegu Catholic Univ, Div Pulm & Crit Care Med, Med Ctr, Daegu, South Korea.
   [Choi, Sun Ha; Lee, Shin Yup] Kyungpook Natl Univ, Div Pulm & Crit Care Med, Chilgok Hosp, Daegu, South Korea.
   [Park, Jae Seok; Kwon, Yong Shik] Keimyung Univ, Dongsan Hosp, Dept Internal Med, Div Pulmonol,Sch Med, Daegu, South Korea.
   [Lee, Jaehee] Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea.
   [Kim, Yeonjae] Daegu Fatima Hosp, Div Pulm & Crit Care Med, Daegu, South Korea.
   [Choi, Eun Young] Yeungnam Univ, Div Pulm & Crit Care Med, Med Ctr, 170 Hyeonchung Ro, Daegu 42415, South Korea.
RP Choi, EY (corresponding author), Yeungnam Univ, Div Pulm & Crit Care Med, Med Ctr, 170 Hyeonchung Ro, Daegu 42415, South Korea.
EM letact@yu.ac.kr
RI ; Kim, Eun Jin/L-6480-2018
OI CHOI, SUNHA/0000-0002-9665-7466; Kwon, Yong Shik/0000-0002-8003-7668;
   Kim, Eun Jin/0000-0001-9791-8077
FU Research Program of Medicity Daegu Council - Daegu Metropolitan City
   [COVID19-DM18]
FX This work was supported by the Research Program of Medicity Daegu
   Council funded by Daegu Metropolitan City (fund code COVID19-DM18).
CR Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   China News Network, CHINA NEWS NETWORK
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Curran A, 2015, AIDS REV, V17, P114
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Putcharoen O, 2015, DRUG DES DEV THER, V9, P5763, DOI 10.2147/DDDT.S63989
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Zanon D, 2020, DATA BRIEF, V30, DOI 10.1016/j.dib.2020.105552
NR 8
TC 0
Z9 0
U1 0
U2 0
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD SEP
PY 2020
VL 61
IS 9
BP 826
EP 830
DI 10.3349/ymj.2020.61.9.826
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA NU2WK
UT WOS:000573503600011
PM 32882767
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Marmarosh, CL
   Forsyth, DR
   Strauss, B
   Burlingame, GM
AF Marmarosh, Cheri L.
   Forsyth, Donelson R.
   Strauss, Bernhard
   Burlingame, Gary M.
TI The Psychology of the COVID-19 Pandemic: A Group-Level Perspective
SO GROUP DYNAMICS-THEORY RESEARCH AND PRACTICE
LA English
DT Article
DE group therapy; COVID-19; pandemic; group dynamics
ID RANDOMIZED CONTROLLED-TRIAL; SOCIAL SUPPORT; GROUP-PSYCHOTHERAPY;
   COMPLICATED GRIEF; MENTAL-HEALTH; GROUP CLIMATE; GROUP-THERAPY; STRESS;
   METAANALYSIS; DISORDER
AB Objective: The coronavirus disease (COVID-19) threatened not only people's physical health but also every aspect of their psychological well-being: from their struggle to avoid contracting the disease, to their coping with the disruption of the normal course of their lives, to the trauma they endured when the virus took the lives of those they loved. The objective of this article is to consider the group-level processes that sustain people's physical and psychological well-being during COVID-19. Method: Applying group dynamic and group therapy theory and research, we explore why COVID-19 spread so rapidly. We also explore how people cope with prolonged social isolation, distress, and social inequities, as well as how people deal with the psychological trauma of the disease, which includes heightened levels of depression, anxiety, substance abuse, and complicated bereavement. Results: Researchers and theorists suggest that human beings are fundamentally social, and the need to gather with others is extremely important, especially during times of distress. The need to belong as well as the importance of reducing loneliness during uncertain times often encourages people to connect, despite recommendations to remain socially distant. Conclusions: Group treatment options developed by group psychotherapists are effective at reducing depression, anxiety, complicated grief, and stress. We conclude by examining the growing impact of online groups and the many ways that these groups help people improve their psychological well-being during the COVID-19 crisis.
C1 [Marmarosh, Cheri L.] George Washington Univ, Dept Psychol, 1922 F St, Washington, DC 20008 USA.
   [Forsyth, Donelson R.] Univ Richmond, Jepson Sch Leadership Studies, Richmond, VA 23173 USA.
   [Strauss, Bernhard] Univ Hosp, Inst Psychosocial Med Psychotherapy & Plycho Onco, Jena, Germany.
   [Burlingame, Gary M.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA.
RP Marmarosh, CL (corresponding author), George Washington Univ, Dept Psychol, 1922 F St, Washington, DC 20008 USA.
EM cmarmarosh@gmail.com
OI Marmarosh, Cheri/0000-0001-9601-7752; , Gary/0000-0002-1280-6904;
   Forsyth, Donelson/0000-0002-2388-2953
CR Doorn KAV, 2020, COUNS PSYCHOL Q, DOI 10.1080/09515070.2020.1773404
   American Psychiatric Association, 2020, PSYCH EMBR TEL PREV
   Aspinwall LG, 1997, PSYCHOL BULL, V121, P417, DOI 10.1037//0033-2909.121.3.417
   Backhaus A, 2012, PSYCHOL SERV, V9, P111, DOI 10.1037/a0027924
   Bai Y, 2004, PSYCHIAT SERV, V55, P1055, DOI 10.1176/appi.ps.55.9.1055
   BAUMEISTER RF, 1995, PSYCHOL BULL, V117, P497, DOI 10.1037/0033-2909.117.3.497
   BRAATEN LJ, 1989, INT J GROUP PSYCHOTH, V39, P377, DOI 10.1080/00207284.1989.11491175
   Brauner J. M., 2020, EFFECTIVENESS PERCEI
   Brindley P. G., 2020, J INTENSIVE CARE SOC, DOI [10.1177/1751143720, DOI 10.1177/1751143720]
   Brooks SK, 2020, LANCET, V395, P912, DOI [10.1016/S0140-6736(20)30460-8, 10.1016/S0140-6736(20)30460-8.]
   Burke L.A, 2013, COMPLICATED GRIEF SC, P145
   Burlingame G. M., 2013, BERGIN GARFIELDS HDB, P640
   Burlingame G. M., BERGIN GARFIELDS HDB
   Burlingame G. M., 2002, PSYCHOTHERAPY RELATI, P71
   Burlingame GM, 2018, PSYCHOTHERAPY, V55, P384, DOI 10.1037/pst0000173
   Burlingame GM, 2016, PSYCHOTHERAPY, V53, P446, DOI 10.1037/pst0000090
   Caravan M, 2020, J APPL GERONTOL, DOI 10.1177/0733464820921082
   Carter RT, 2010, PSYCHOL TRAUMA-US, V2, P183, DOI 10.1037/a0020102
   Cialdini RB, 2005, PSYCHOL INQ, V16, P158, DOI 10.1207/s15327965pli1604_03
   Clay JM, 2020, LANCET PUBLIC HEALTH, V5, pE259, DOI 10.1016/S2468-2667(20)30088-8
   COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310
   COOPER CL, 1981, SMALL GROUP BEHAV, V12, P285, DOI 10.1177/104649648101200304
   Crisp D, 2014, PSYCHIAT RES, V216, P60, DOI 10.1016/j.psychres.2014.01.041
   Davidovitz R, 2007, J PERS SOC PSYCHOL, V93, P632, DOI 10.1037/0022-3514.93.4.632
   Dehkordi MK, 2020, PSYCHIAT RES, V290, DOI 10.1016/j.psychres.2020.113034
   DeLluciaWaack J., 2011, OXFORD HDB GROUP COU, P83, DOI [10.1093/oxfordhb/9780195394450.013.0006, DOI 10.1093/OXFORDHB/9780195394450.013.0006]
   Erceg N., 2020, MISBEHAVING CORONA C
   Floyd DL, 2000, J APPL SOC PSYCHOL, V30, P407, DOI 10.1111/j.1559-1816.2000.tb02323.x
   Forsyth D. R., 2018, GROUP DYNAMICS
   Forsyth D. R., 1999, SOCIAL PSYCHOL EMOTI, P339
   Forsyth DR, 2020, GROUP DYN-THEOR RES, V24, P139, DOI 10.1037/gdn0000132
   Forsyth R., 2020, ROLE STRESS RE UNPUB
   Frantell KA, 2019, SMALL GR RES, V50, P654, DOI 10.1177/1046496419835923
   Fujimori A., 2017, PSYCHOLOGY, V8, P654, DOI [10.4236/psych.2017.84042, DOI 10.4236/PSYCH.2017.84042]
   Furman D, 2019, NAT MED, V25, P1822, DOI 10.1038/s41591-019-0675-0
   Galea S, 2020, JAMA INTERN MED, V180, P817, DOI 10.1001/jamainternmed.2020.1562
   Harper CA, 2020, INT J MENT HEALTH AD, DOI 10.1007/s11469-020-00281-5
   HILL CA, 1987, J PERS SOC PSYCHOL, V52, P1008, DOI 10.1037/0022-3514.52.5.1008
   Hogg MA, 1998, J PERS SOC PSYCHOL, V75, P1248, DOI 10.1037/0022-3514.75.5.1248
   Holmes EA, 2020, LANCET PSYCHIAT, V7, P547, DOI 10.1016/S2215-0366(20)30168-1
   Holt-Lunstad J, 2015, PERSPECT PSYCHOL SCI, V10, P227, DOI 10.1177/1745691614568352
   Hopf RBB, 2013, EUR EAT DISORD REV, V21, P215, DOI 10.1002/erv.2196
   Huang Y, 2020, PSYCHIAT RES, V290, DOI 10.1016/j.psychres.2020.112963
   Janis R., PSYCHOTHERAPY RES
   Johnson JE, 2005, J COUNS PSYCHOL, V52, P310, DOI 10.1037/0022-0167.52.3.310
   Kim SW, 2020, BRAIN BEHAV IMMUN, V87, P4, DOI 10.1016/j.bbi.2020.03.025
   Knowles LM, 2017, COMPUT HUM BEHAV, V73, P650, DOI 10.1016/j.chb.2017.04.005
   Kumar A, 2020, ASIAN J PSYCHIATR, V51, DOI 10.1016/j.ajp.2020.102053
   Larson J.R., 2010, SEARCH SYNERGY SMALL
   Liu S, 2020, LANCET PSYCHIAT, V7, pE17, DOI 10.1016/S2215-0366(20)30077-8
   Lo Coco G, 2019, J SUBST ABUSE TREAT, V99, P104, DOI 10.1016/j.jsat.2019.01.016
   Maass U, 2020, DEATH STUD, DOI 10.1080/07481187.2020.1772410
   Mayland CR, 2020, J PAIN SYMPTOM MANAG, V60, pE33, DOI 10.1016/j.jpainsymman.2020.05.012
   McKelvey T., 2020, BBC NEWS
   Mihashi M, 2009, HEALTH PSYCHOL, V28, P91, DOI 10.1037/a0013674
   Mikulincer M., 2016, ATTACHMENT ADULTHOOD
   Murali V., 2004, ADV PSYCHIAT TREAT, V10, P216, DOI DOI 10.1192/APT.10.3.216
   Nowak B, 2020, PERS INDIV DIFFER, V167, DOI 10.1016/j.paid.2020.110232
   O'Connor RC, 2020, LANCET PSYCHIAT, V7, pE44, DOI 10.1016/S2215-0366(20)30247-9
   Ornell F, 2020, PSYCHIAT RES, V289, DOI 10.1016/j.psychres.2020.113096
   Pan PJD, 2005, J SPEC GROUP WORK, V30, P363, DOI 10.1080/01933920500186951
   Pascoe EA, 2009, PSYCHOL BULL, V135, P531, DOI 10.1037/a0016059
   Piper W. E., 2011, SHORT TERM GROUP THE, DOI [10.1037/12344-000, DOI 10.1037/12344-000]
   Qiu JY, 2020, GEN PSYCHIAT, V33, DOI 10.1136/gpsych-2020-100213
   Radloff R., 1968, GROUPS STRESS PSYCHO
   Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066
   Rees CS, 2015, AUST PSYCHOL, V50, P259, DOI 10.1111/ap.12122
   ROFE Y, 1984, PSYCHOL REV, V91, P235
   Russell G. I., 2015, SCREEN RELATIONS
   Sacker A, 2009, PSYCHOSOM MED, V71, P763, DOI 10.1097/PSY.0b013e3181b1e45e
   Sapolsky RM, 2004, ANNU REV ANTHROPOL, V33, P393, DOI 10.1146/annurev.anthro.33.070203.144000
   Schulz A, 2016, BEHAV RES THER, V84, P14, DOI 10.1016/j.brat.2016.07.001
   Schwartz JA, 2017, SOC SCI MED, V187, P184, DOI 10.1016/j.socscimed.2017.06.006
   Schwartze D, 2019, PSYCHOTHER RES, V29, P415, DOI 10.1080/10503307.2017.1405168
   Schwartze D, 2016, J OBSESS-COMPULS REL, V10, P49, DOI 10.1016/j.jocrd.2016.05.001
   Schwartze D, 2017, GROUP DYN-THEOR RES, V21, P77, DOI 10.1037/gdn0000064
   Segerstrom SC, 2004, PSYCHOL BULL, V130, P601, DOI 10.1037/0033-2909.130.4.601
   Shepperd JA, 2013, PERSPECT PSYCHOL SCI, V8, P395, DOI 10.1177/1745691613485247
   Shields G. S., 2020, JAMA PSYCHIAT, DOI [10.1001/jamapsychiatry.2020.0431, DOI 10.1001/JAMAPSYCHIATRY.2020.0431]
   Shor E, 2013, SOC NETWORKS, V35, P626, DOI 10.1016/j.socnet.2013.08.004
   Slavich GM, 2014, PSYCHOL BULL, V140, P774, DOI 10.1037/a0035302
   Smokowski PR, 1999, RES SOCIAL WORK PRAC, V9, P555, DOI 10.1177/104973159900900503
   Stasser G, 2020, ANNU REV PSYCHOL, V71, P589, DOI 10.1146/annurev-psych-010418-103211
   Stephen J, 2013, CURR ONCOL, V20, P39, DOI 10.3747/co.20.1210
   Stewart AE, 2015, J MAR SCI ENG, V3, P630, DOI 10.3390/jmse3030630
   Sun YK, 2020, PSYCHIAT CLIN NEUROS, V74, P406, DOI 10.1111/pcn.13008
   Supiano KP, 2017, DEATH STUD, V41, P553, DOI 10.1080/07481187.2017.1320339
   Supiano KP, 2014, GERONTOLOGIST, V54, P840, DOI 10.1093/geront/gnt076
   Sweeny K, 2010, REV GEN PSYCHOL, V14, P340, DOI 10.1037/a0021288
   Tang WJ, 2020, J AFFECT DISORDERS, V274, P1, DOI 10.1016/j.jad.2020.05.009
   Tate DF, 2017, INT J BEHAV NUTR PHY, V14, DOI 10.1186/s12966-017-0599-3
   Taylor S. E., 2011, OXFORD HDB STRESS HL, P86
   TSCHUSCHKE V, 1994, INT J GROUP PSYCHOTH, V44, P185, DOI 10.1080/00207284.1994.11490742
   Uchino BN, 2006, J BEHAV MED, V29, P377, DOI 10.1007/s10865-006-9056-5
   van der Zanden R, 2012, J MED INTERNET RES, V14, P274, DOI 10.2196/jmir.2033
   Wallace CL, 2020, J PAIN SYMPTOM MANAG, V60, pE70, DOI 10.1016/j.jpainsymman.2020.04.012
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Weinberg H., 2020, GROUP DYNAMICS
   Weinberg H., 2019, THEORY PRACTICE ONLI, DOI [10.4324/9781315545530, DOI 10.4324/9781315545530]
   Yalom ID, 2005, THEORY PRACTICE GROU
   Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548
   Zell E, 2010, PERS SOC PSYCHOL REV, V14, P368, DOI 10.1177/1088868310366144
   Zhang WR, 2020, PSYCHOTHER PSYCHOSOM, V89, P242, DOI 10.1159/000507639
NR 103
TC 1
Z9 1
U1 14
U2 14
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1089-2699
EI 1930-7802
J9 GROUP DYN-THEOR RES
JI Group Dyn.-Theory Res. Pract.
PD SEP
PY 2020
VL 24
IS 3
SI SI
BP 122
EP 138
DI 10.1037/gdn0000142
PG 17
WC Psychology, Social
SC Psychology
GA NT3OI
UT WOS:000572854200002
DA 2021-01-01
ER

PT J
AU Kun-Darbois, JD
   Kahn, A
   Corre, P
AF Kun-Darbois, J. D.
   Kahn, A.
   Corre, P.
TI Influence of the containment on the epidemiology of maxillo-facial
   emergencies during the COVID-19 pandemic. Why no more cellulites of
   odontogenic origin?
SO JOURNAL OF STOMATOLOGY ORAL AND MAXILLOFACIAL SURGERY
LA English
DT Letter
DE Cellulitis; Coronavirus; Non-steroidal anti-inflammatory drugs
C1 [Kun-Darbois, J. D.; Kahn, A.] Angers Univ Hosp, Dept Oral & Maxillofacial Surg, 4 Rue Larrey, F-49933 Angers, France.
   [Corre, P.] Nantes Univ Hosp, Dept Oral & Maxillofacial Surg, 1 Pl Alexis Ricordeau, F-44093 Nantes 1, France.
RP Kun-Darbois, JD (corresponding author), Angers Univ Hosp, Dept Oral & Maxillofacial Surg, 4 Rue Larrey, F-49933 Angers, France.
EM daniel.kun-darbois@univ-angers.fr
RI Kun-Darbois, Jean-Daniel/AAD-6194-2019; CORRE, Pierre/P-1307-2014
OI Kun-Darbois, Jean-Daniel/0000-0002-0818-7856; CORRE,
   Pierre/0000-0003-4587-2163; KAHN, Alexis/0000-0002-4667-8621
CR Bennani-Baiti AA, 2015, EUR ANN OTORHINOLARY, V132, P181, DOI 10.1016/j.anorl.2015.06.004
   Giollo Alessandro, 2020, Ann Rheum Dis, DOI [10.1136/annrheumdis-2020-218830, 10.1136/annrheumdis-2020-218845, 10.1136/annrheumdis-2020-217598]
   Guo Huaqiu, 2020, J Dent Sci, V15, P564, DOI 10.1016/j.jds.2020.02.002
   Little P, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1185
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Nicot R, 2014, REV STOMATOL CHIR, V115, P31, DOI 10.1016/j.revsto.2013.07.020
   Weill A, 2020, USAGE MED VILLE FRAN, P1
NR 7
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2468-8509
EI 2468-7855
J9 J STOMATOL ORAL MAXI
JI J. Stomatol. Oral Maxillofac. Surg.
PD SEP
PY 2020
VL 121
IS 4
BP 467
EP 468
DI 10.1016/j.jormas.2020.05.005
PG 2
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA NT1EF
UT WOS:000572692400030
PM 32405606
OA Green Published
DA 2021-01-01
ER

PT J
AU Kim, EA
AF Kim, Eun-A
TI Social Distancing and Public Health Guidelines at Workplaces in Korea:
   Responses to Coronavirus Disease-19
SO SAFETY AND HEALTH AT WORK
LA English
DT Article
DE COVID-19; Public health; Public health surveillance; Social distance;
   Workplace
ID COVID-19
AB Background: In the absence of a vaccine or treatment, the most pragmatic strategies against an infectious disease pandemic are extensive early detection testing and social distancing. This study aimed to summarize public and workplace responses to Coronavirus Disease-19 (COVID-19) and show how the Korean system has operated during the COVID-19 pandemic.
   Method: Daily briefings from the Korean Center for Disease Control and the Central Disaster Management Headquarters were assembled from January 20 to May 15, 2020.
   Results: By May 15, 2020, 11,018 COVID-19 cases were identified, of which 15.7% occurred in workplaces such as health-care facilities, call centers, sports clubs, coin karaoke, and nightlife destinations. When the first confirmed case was diagnosed, the Korean Center for Disease Control and Central Disaster Management Headquarters responded quickly, emphasizing early detection with numerous tests and a social distancing policy. This slowed the spread of infection without intensive containment, shut down, or mitigation interventions. After entering the public health blue alert level, a business continuity plan was distributed. After entering the orange level, the Ministry of Employment and Labor developed workplace guidelines for COVID-19 consisting of social distancing, flexible working schedules, early identification of workers with suspected infections, and disinfection of workplaces. Owing to the intensive workplace social distancing policy, workplaces remained safe with only small sporadic group infections.
   Conclusion: The workplace social distancing policy with timely implementation of specific guidelines was a key to preventing a large outbreak of COVID-19 in Korean workplaces. However, sporadic incidents of COVID-19 are still ongoing, and risk assessment in vulnerable workplaces should be continued. (C) 2020 Occupational Safety and Health Research Institute, Published by Elsevier Korea LLC.
C1 [Kim, Eun-A] Occupat Safety & Hlth Res Inst, Occupat Safety & Hlth Agcy, Jonggaro 400, Ulsan, South Korea.
RP Kim, EA (corresponding author), Occupat Safety & Hlth Res Inst, Occupat Safety & Hlth Agcy, Jonggaro 400, Ulsan, South Korea.
EM toxneuro@gmail.com
CR [Anonymous], 2020, COR DIS COVID 19 DAS
   Dalton C, 2020, 3549276 SOC SCI RES
   Delirrad M, 2020, ALCOHOL ALCOHOL
   Fiorillo A, 2020, EUROPEAN PSYCHIAT, V63
   Government of Republic of Korea, 2020, KOR RESP PAND US ICT
   Greenstone M, 2020, 3561244 SOC SCI RES
   Herald TK, 2020, COVID 19 PATIENT WEN
   Herald TK, 2020, SEOUL SUSPENDS COIN
   Issac A, 2020, J PREVENT MED PUBL H
   Jang S, 2020, EMERGING INFECT  AUG, V26
   Jeon MH, 2016, INFECT CHEMOTHER, V48, P75, DOI 10.3947/ic.2016.48.2.75
   Kang S-K, 2020, SAF HLTH WORK
   Kang Y-J, DISASTER MED PUBL HL, P1
   KCDC, FREQ ASK QUEST KCDC
   Kim HJ, 2016, NEUROCHEM INT, V101, P56, DOI 10.1016/j.neuint.2016.10.006
   Kim Y, 2016, J KOREAN MED ASSOC, V59, P668, DOI 10.5124/jkma.2016.59.9.668
   Koh D, 2020, OCCUP MED-OXFORD, V70, P3, DOI 10.1093/occmed/kqaa036
   Korea Center for Disease Control, 2020, DAIL BRIEF
   Korean Soc Infect Dis, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e112
   Lee J-SA, 2018, STUDY IMPROVEMENT IN
   Lewnard JA, 2020, LANCET INFECT DIS, V20, P631, DOI 10.1016/S1473-3099(20)30190-0
   Ministry of Health and Welfare, 2016, INF DIS CONTR PREV A
   Ministry of Health and Welfare, 2016, STAND MAN INF DIS RI
   Ministry of Health and Welfare, 2018, INF DIS PREV MAN BAS
   Park C., 2019, J GLOB HLTH REP, V3
   Park SY, 2020, EMERG INFECT DIS CDC, V26
   Public Safety and Security, 2010, FRAM ACT MAN DIS SAF
   Shim E, 2020, INT J INFECT DIS, V93, P339, DOI 10.1016/j.ijid.2020.03.031
   Sook Jeong， Ihn, 2017, [Korean Journal of Occupational Health Nursing, 한국직업건강간호학회지], V26, P207, DOI 10.5807/kjohn.2017.26.4.207
   The Government of the Republic of Korea, 2020, TACKL COVID 19 HLTH
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   Woo Jung Hyun, 2019, [Health Policy and Mangemnet, 보건행정학회지], V29, P112
   World Health Organization, COR DIS COVID 19 ADV
   Yang CH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61133-9
NR 34
TC 0
Z9 0
U1 7
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2093-7911
EI 2093-7997
J9 SAF HEALTH WORK-KR
JI Saf. Health Work
PD SEP
PY 2020
VL 11
IS 3
BP 275
EP 283
DI 10.1016/j.shaw.2020.07.006
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA NT0YZ
UT WOS:000572678800004
PM 32837740
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Crisa, FM
   Leocata, F
   Arienti, VM
   Picano, M
   Berta, L
   Mainardi, HS
   Monti, AF
   Musca, F
   Colombo, S
   Palazzi, M
   La Camera, A
AF Crisa, Francesco Maria
   Leocata, Filippo
   Arienti, Virginia Maria
   Picano, Marco
   Berta, Luca
   Mainardi, Hae Song
   Monti, Angelo Filippo
   Musca, Francesco
   Colombo, Silvia
   Palazzi, Mauro
   La Camera, Alessandro
TI Gamma Knife Radiosurgery for Treatment of Brain Metastases during the
   COVID-19 Outbreak
SO STEREOTACTIC AND FUNCTIONAL NEUROSURGERY
LA English
DT Article
DE COVID-19; Gamma Knife; Radiosurgery; Brain metastases
AB Introduction:The WHO declared 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) a public health emergency of international concern. The National and Regional Health System has been reorganized, and many oncological patients died during this period or had to interrupt their therapies. This study summarizes a single-centre experience, during the COVID-19 period in Italy, in the treatment of brain metastases with Gamma Knife stereotactic radiosurgery (GKRS).Methods:We retrospectively analysed our series of patients with brain metastases who underwent GKRS at the Niguarda Hospital from February 24 to April 24, 2020.Results:We treated 30 patients with 66 brain metastases. A total of 22 patients came from home and 8 patients were admitted to the emergency room for urgent neurological symptoms. Duration of stay was limited to 0-1 day in 17 patients. We chose to treat a cluster of 9 patients, whose greater lesion exceeded 10 cm(3), with 2-stage modality GKRS to minimize tumour recurrence and radiation necrosis.Conclusion:Due to the COVID-19 pandemic, the whole world is at a critical crossroads about the use of health care resources. During the COVID-19 outbreak, the deferral of diagnostic and therapeutic procedures and a work backlog in every medical specialty are the natural consequences of reservation of resources for COVID-19 patients. GKRS improved symptoms and reduced the need for open surgeries, allowing many patients to continue their therapeutic path and sparing beds in ICUs. Neurosurgeons have to take into account the availability of stereotactic radiosurgery to reduce hospital stay, conciliating safety for patients and operators with the request for health care coming from the oncological patients and their families.
C1 [Crisa, Francesco Maria; Leocata, Filippo; Picano, Marco; La Camera, Alessandro] ASST Grande Osped Metropolitano Niguarda, Neurosurg, Milan, Italy.
   [Crisa, Francesco Maria] Univ Milan, Milan, Italy.
   [Arienti, Virginia Maria; Palazzi, Mauro] ASST Grande Osped Metropolitano Niguarda, Radiotherapy, Milan, Italy.
   [Berta, Luca; Mainardi, Hae Song; Monti, Angelo Filippo] ASST Grande Osped Metropolitano Niguarda, Med Phys, Milan, Italy.
   [Musca, Francesco] ASST Grande Osped Metropolitano Niguarda, A De Gasperis Cardioctr, Cardiol 4, Milan, Italy.
   [Colombo, Silvia] ASST Grande Osped Metropolitano Niguarda, Milan, Italy.
RP Crisa, FM (corresponding author), Univ Milan, ASST Grande Osped Metropolitano Niguarda, IT-20162 Milan, Italy.
EM francesco.crisa@unimi.it
OI Crisa, Francesco Maria/0000-0002-9408-5281
CR Muhammad S, 2020, NEUROSURGERY, V87, pE220, DOI 10.1093/neuros/nyaa184
   Pannullo SC, 2020, CUREUS, V12, DOI 10.7759/cureus.7671
   Ramakrishna R, 2020, J NEURO-ONCOL, V147, P525, DOI 10.1007/s11060-020-03488-7
   Remuzzi A, 2020, LANCET, V395, P1225, DOI 10.1016/S0140-6736(20)30627-9
   Serizawa T, 2019, J NEUROSURG, V131, P227, DOI 10.3171/2018.4.JNS172596
   The Lancet Oncology, 2020, Lancet Oncol, V21, P467, DOI 10.1016/S1470-2045(20)30175-3
   WHO, RAT US PERS PROT EQU
   Zoia C, 2020, ACTA NEUROCHIR, V162, P1221, DOI 10.1007/s00701-020-04305-w
NR 8
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1011-6125
EI 1423-0372
J9 STEREOT FUNCT NEUROS
JI Stereotact. Funct. Neurosurg.
PD SEP
PY 2020
VL 98
IS 5
BP 319
EP 323
DI 10.1159/000510271
PG 5
WC Neurosciences; Neuroimaging; Surgery
SC Neurosciences & Neurology; Surgery
GA NS9AQ
UT WOS:000572547900005
PM 32726792
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Grayson, JW
   McCormick, JP
   Thompson, HM
   Miller, PL
   Cho, YO
   Woodworth, BA
AF Grayson, Jessica W.
   McCormick, Justin P.
   Thompson, Harrison M.
   Miller, Peter L.
   Cho, Yeon
   Woodworth, Bradford A.
TI The SARS-CoV-2 pandemic impact on rhinology research: A survey of the
   American Rhinologic Society
SO AMERICAN JOURNAL OF OTOLARYNGOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; Coronavirus; Pandemic; Basic science; Clinical
   trial; Resident education; Research; Rhinology
AB Background: The COVID-19 pandemic has radically shifted healthcare operations within hospitals and universities across the globe. However, the effect of the COVID-19 pandemic on research endeavors and clinical trials is unclear.
   Objective: This study investigates the impact of the COVID-19 pandemic on basic science and clinical research within the rhinology community.
   Methods: A cross-sectional study was designed utilizing an 8-question survey to identify changes to rhinology research. Questions evaluated the impact of the COVID-19 pandemic on administrative research support and staffing, basic science research, clinical trials and resident research involvement.
   Results: Seventy-one participants responded to the survey (8.5% response rate). Most respondents noted changes in IACUC/IRB approval (faster, 33%; slower, 31%). Of those who employed laboratory personnel, 64% were able to continue staff employment with full salary. The majority of animal research and in vitro studies were halted (64% and 56%, respectively), but animal care and cell line maintenance were allowed to continue. Clinical trial enrollment was most commonly limited to COVID derived studies (51%). Forty-seven percent of respondents noted increased resident research participation.
   Conclusion: The rapid spread of the SARS-CoV-2 virus has markedly impacted rhinology-related research. Maintaining safe workplace practices as restrictions are lifted will hopefully mitigate the spread of the virus and allow research productivity to resume.
C1 [Grayson, Jessica W.; McCormick, Justin P.; Thompson, Harrison M.; Miller, Peter L.; Cho, Yeon; Woodworth, Bradford A.] Univ Alabama Birmingham, Dept Otolaryngol Head & Neck Surg, 1720 2nd Ave South FOT 1155, Birmingham, AL 35294 USA.
RP Grayson, JW (corresponding author), Univ Alabama Birmingham, Dept Otolaryngol Head & Neck Surg, 1720 2nd Ave South FOT 1155, Birmingham, AL 35294 USA.
EM jgrayson@uabmc.edu
RI McCormick, Justin/ABC-5578-2020
OI CHO, DO YEON/0000-0002-5173-8959
CR Apuzzo M., COVID 19 CHANGED WOR
   Crosby DL, 2020, OTOLARYNGOL HEAD NEC
   Gewin V., SAFELY CONDUCTING ES
   Goldman RA, 2020, OTOLARYNGOL HEAD NEC
   Grimm CA, 2020, HOSP EXPERIENCES RES
   Liu Z, 2020, INT FORUM ALLERGY RH, V10, P584, DOI 10.1002/alr.22585
   Noel JE, 2020, OTOLARYNGOL HEAD NEC
   Patel ZM, 2020, NEUROSURGERY, V87, pE66, DOI 10.1093/neuros/nyaa125
   Ranasinghe V, 2020, HEAD NECK-J SCI SPEC, V42, P1243, DOI 10.1002/hed.26207
   Setzen M, 2020, AM J OTOLARYNG, V41, DOI 10.1016/j.amjoto.2020.102491
   Skoog H, 2020, HEAD NECK-J SCI SPEC, V42, P1392, DOI 10.1002/hed.26214
   Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034
   Workman AD, 2020, INT FORUM ALLERGY RH
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 14
TC 0
Z9 0
U1 2
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0196-0709
EI 1532-818X
J9 AM J OTOLARYNG
JI Am. J. Otolaryngol.
PD SEP-OCT
PY 2020
VL 41
IS 5
AR 102617
DI 10.1016/j.amjoto.2020.102617
PG 5
WC Otorhinolaryngology
SC Otorhinolaryngology
GA NS6CF
UT WOS:000572346400019
PM 32574897
OA Green Published
DA 2021-01-01
ER

PT J
AU Khan, MM
   Parab, SR
   Paranjape, M
AF Khan, Mubarak Muhamed
   Parab, Sapna Ramkrishna
   Paranjape, Mandar
TI Repurposing 0.5% povidone iodine solution in otorhinolaryngology
   practice in Covid 19 pandemic
SO AMERICAN JOURNAL OF OTOLARYNGOLOGY
LA English
DT Article
DE Povidone iodine; SARS Cov; SARS CoV 2; MERS; Prophylaxis; Gargles; Nasal
   spray
ID CORONAVIRUS; ANTISEPSIS
AB SARS CoV 2 is very much homologous in structure to SARS CoV. Review of literature suggests the in-vitro virucidal action of povidone iodine in SARS CoV and MFRS. The oropharynx and nasopharynx are target sites of SARS CoV 2. A significant proportion of COVID 19 sufferers are asymptomatic, but shedding these viral particles, PVP-I has been shown to be a safe therapy when used as a mouthwash or taken nasally or used during ophthalmic surgeries.
   Aims:
   1. To propose the use of 0.5% Povidone iodine gargles and nasal drops as prerequisite for office based nose and throat examination and procedures during COVID 19 pandemic.
   2. To assess tolerability of 0.5% PVP-I in patients and in healthcare workers.
   Materials and methods: 0.5% PVP-I solution is prepared from commercially available 10% PVP-I solution. Patients were instructed to put 0.5% PVP-I drops in nose and rinse mouth with gargle prior examinations for 30 s. For endoscopic procedure (nasal and throat) nasal douching and gargling to be started one day prior. Douching and rinsing to be repeated just before procedures. Nasal packing with 0.5% PVP-I along with 4% xylocaine/adrenaline solution, tolerability and any allergic reaction noted.
   Results: The patient and health care workers tolerated the 0.5%. No allergy was noted.
   Conclusion: We propose the use of 0.5% PVP-I in healthcare workers and their patients to minimise the risk of spread of the disease in addition to the recommended PPE.
C1 [Khan, Mubarak Muhamed; Parab, Sapna Ramkrishna] Sushrut ENT Hosp, Talegaon Dabhade, India.
   [Khan, Mubarak Muhamed; Parab, Sapna Ramkrishna] Dr Khans ENT Res Ctr, Talegaon Dabhade, India.
RP Parab, SR (corresponding author), Sushrut ENT Hosp, Talegaon Dabhade, India.; Parab, SR (corresponding author), Dr Khans ENT Res Ctr, Talegaon Dabhade, India.
EM ent.khan@gmail.com; drsapnaparab@gmail.com
CR ADER AW, 1988, J CLIN ENDOCR METAB, V66, P632, DOI 10.1210/jcem-66-3-632
   BERKELMAN RL, 1982, J CLIN MICROBIOL, V15, P635, DOI 10.1128/JCM.15.4.635-639.1982
   da Silveira Teixeira Dieni, 2019, Stomatologija, V21, P35
   Domingo M A, 1996, J Philipp Dent Assoc, V48, P31
   Eggers M, 2018, INFECT DIS THER, V7, P249, DOI 10.1007/s40121-018-0200-7
   Eggers M, 2015, INFECT DIS THER, V4, P491, DOI 10.1007/s40121-015-0091-9
   Gonzalez-Martin-Moro J, 2019, Arch Soc Esp Oftalmol, V94, P521, DOI 10.1016/j.oftal.2019.07.013
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Kariwa H, 2006, DERMATOLOGY, V212, P119, DOI 10.1159/000089211
   Kawana A, 1999, Kansenshogaku Zasshi, V73, P429
   Koerner JC, 2018, SURV OPHTHALMOL, V63, P862, DOI 10.1016/j.survophthal.2018.05.002
   KUNZE J, 1983, Z HAUTKRANKHEITEN, V58, P255
   Lachapelle JM, 2005, CONTACT DERMATITIS, V52, P9, DOI 10.1111/j.0105-1873.2005.00479.x
   Mullings W, 2019, EUROPEAN J RHINOLOGY, DOI [10.5152/ejra.2019.166, DOI 10.5152/EJRA.2019.166]
   Panchmatia R, 2019, EUR ARCH OTO-RHINO-L, V276, P3373, DOI 10.1007/s00405-019-05628-w
   RAHN R, 1993, POSTGRAD MED J, V69, pS4
   Rezapoor M, 2017, J ARTHROPLASTY, V32, P2815, DOI 10.1016/j.arth.2017.04.039
   Silas MR, 2017, J CATARACT REFR SURG, V43, P400, DOI 10.1016/j.jcrs.2017.01.007
   To KK, 2020, CLIN INFECT DIS, P12
   Urias DS, 2018, EUR J TRAUMA EMERG S, V44, P787, DOI 10.1007/s00068-017-0896-1
   Wada H, 2016, BIOCONTROL SCI, V21, P21, DOI 10.4265/bio.21.21
   Zheng J, 2020, INT J BIOL SCI, V16, P1678, DOI 10.7150/ijbs.45053
NR 22
TC 2
Z9 2
U1 2
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0196-0709
EI 1532-818X
J9 AM J OTOLARYNG
JI Am. J. Otolaryngol.
PD SEP-OCT
PY 2020
VL 41
IS 5
AR 102618
DI 10.1016/j.amjoto.2020.102618
PG 4
WC Otorhinolaryngology
SC Otorhinolaryngology
GA NS6CF
UT WOS:000572346400038
PM 32574894
OA Green Published
DA 2021-01-01
ER

PT J
AU Lee, VS
   Pottinger, PS
   Davis, GE
AF Lee, Victoria S.
   Pottinger, Paul S.
   Davis, Greg E.
TI Tolerability and effectiveness of povidone-iodine or mupirocin versus
   saline sinus irrigations for chronic rhinosinusitis
SO AMERICAN JOURNAL OF OTOLARYNGOLOGY
LA English
DT Article; Proceedings Paper
CT 119th Annual Spring Meeting of the American-Rhinologic-Society (ARS)
   during the Combined-Otolaryngologic-Societies Spring Meetings (COSM)
CY MAY 16-22, 2016
CL Chicago, IL
SP Amer Rhinol Soc, Combined Otolaryngol Soc
DE Sinusitis; Microbiota; Anti-infective agents; Therapeutic irrigation;
   Sino-nasal outcome test; Endoscopy; Quality of life
ID STAPHYLOCOCCUS-AUREUS; CORONAVIRUS; MANAGEMENT; EFFICACY; UPDATE; TRIAL
AB Objectives: The role of topical anti-infectives in acute exacerbations of chronic rhinosinusitis is controversial. Povidone-iodine is an anti-bacterial and anti-viral that is affordable and available over-the-counter and may demonstrate advantages over mupirocin as a sinus irrigation therapy. The objective was to compare povidone-iodine or mupirocin versus saline sinus irrigations for sinusitis exacerbations in post-surgery subjects as well as to assess tolerability of povidone-iodine sinus irrigations.
   Materials and methods: This was a prospective single-blinded (clinician only) randomized controlled trial. Subjects were post-surgery with acute exacerbations of chronic rhinosinusitis and gram-positive bacteria on culture. They received povidone-iodine, mupirocin, or saline sinus irrigations, twice daily for 30 days. Outcomes were post-treatment culture negativity (primary) and Sinonasal Outcome Test-20 and Lund-Kennedy endoscopic score change (secondary).
   Results: Of the 62 subjects analyzed, post-treatment culture negativity rate was higher in the MUP (14/20, 70%) group compared to the PI (9/21, 43%) and SAL (9/19, 47%) groups, although this was not significant (p = 0.29). Povidone-iodine sinus irrigations at the 1% concentration were very well-tolerated, similar to saline irrigations. There were no significant differences in Sinonasal Outcome Test-20 score (povidone-iodine -0.3 [ - 0.6, 0.05] vs. mupirocin - 0.3 [ - 0.7, 0.05] vs. saline - 0.4 [ - 0.8, 0.05]; p = 0.86) or Lund-Kennedy endoscopic score (povidone-iodine - 3.5 [ - 7, - 0.5] vs. mupirocin - 2 [ - 4, 2] vs. saline - 3 [ -5, 0]; p = 0.45) change. No serious adverse effects were reported.
   Conclusions: In patients who have had prior sinus surgery with acute exacerbations of CRS and gram-positive bacteria on culture, mupirocin sinus irrigations achieved a better post-treatment culture "control" rate compared to saline and povidone-iodine. In addition, 1% povidone-iodine solution was well-tolerated as a sinus irrigation and may represent a feasible method for temporarily disinfecting the sinonasal cavity of bacteria and viruses such as COVID-19.
C1 [Lee, Victoria S.; Davis, Greg E.] Univ Washington, Dept Otolaryngol Head & Neck Surg, Box 356515, Seattle, WA 98195 USA.
   [Pottinger, Paul S.] Univ Washington, Dept Med, Div Allergy & Infect Dis, 1959 NE Pacific St,POB 356130,Courier BB 302, Seattle, WA 98195 USA.
   [Lee, Victoria S.] Univ Illinois, Dept Otolaryngol Head & Neck Surg, 1855 W Taylor St,Room 2-42 MC 648, Chicago, IL 60612 USA.
   [Davis, Greg E.] Univ Washington, Seattle, WA 98195 USA.
   [Davis, Greg E.] Proliance Surg, Seattle, WA USA.
   [Davis, Greg E.] Proliance Surg, Puyallup, WA USA.
RP Lee, VS (corresponding author), Univ Illinois, Dept Otolaryngol Head & Neck Surg, 1855 W Taylor St,Room 2-42 MC 648, Chicago, IL 60612 USA.
EM vlee39@uic.edu
OI Davis, Greg/0000-0002-5373-5559
FU National Institutes of Health National Institute on Deafness and Other
   Communication DisordersUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Deafness & Other Communication Disorders (NIDCD) [T32 DC000018]
FX Dr. Lee was supported by the National Institutes of Health National
   Institute on Deafness and Other Communication Disorders T32 DC000018
   Research Training Grant. The funding source had no involvement in the
   project.
CR Birk R, 2016, EUR ARCH OTO-RHINO-L, V273, P4335, DOI 10.1007/s00405-016-4161-8
   Chundamala J, 2007, CAN J SURG, V50, P473
   Durani P, 2008, INT WOUND J, V5, P376, DOI 10.1111/j.1742-481X.2007.00405.x
   Eggers M, 2018, INFECT DIS THER, V7, P249, DOI 10.1007/s40121-018-0200-7
   Eggers M, 2015, INFECT DIS THER, V4, P491, DOI 10.1007/s40121-015-0091-9
   Greenstein G, 1999, J PERIODONTOL, V70, P1397, DOI 10.1902/jop.1999.70.11.1397
   Jervis-Bardy J, 2012, LARYNGOSCOPE, V122, P2148, DOI 10.1002/lary.23486
   Jervis-Bardy J, 2012, INT FORUM ALLERGY RH, V2, P111, DOI 10.1002/alr.20106
   Kariwa H, 2006, DERMATOLOGY, V212, P119, DOI 10.1159/000089211
   Kim JH, 2015, J LARYNGOL OTOL, V129, pS45, DOI 10.1017/S0022215114002746
   Li B, 2013, J CATARACT REFR SURG, V39, P994, DOI 10.1016/j.jcrs.2013.02.039
   Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183
   Lund VJ, 1997, OTOLARYNG HEAD NECK, V117, pS35, DOI 10.1016/S0194-5998(97)70005-6
   Mady LJ, 2020, ORAL ONCOL, V105, DOI 10.1016/j.oraloncology.2020.104724
   Mahdavinia M, 2016, CLIN EXP ALLERGY, V46, P21, DOI 10.1111/cea.12666
   Moein ST, 2020, INT FORUM ALLERGY RH, V10, P944, DOI 10.1002/alr.22587
   Orlandi RR, 2016, INT FORUM ALLERGY RH, V6, pS22, DOI 10.1002/alr.21695
   Orlandi RR, 2014, INT FORUM ALLERGY RH, V4, pS1, DOI 10.1002/alr.21344
   Phillips M, 2014, INFECT CONT HOSP EP, V35, P826, DOI 10.1086/676872
   Piccirillo JF, 2002, OTOLARYNG HEAD NECK, V126, P41, DOI 10.1067/mhn.2002.121022
   Pynnonen MA, 2007, ARCH OTOLARYNGOL, V133, P1115, DOI 10.1001/archotol.133.11.1115
   Ramezanpour M, 2020, INT FORUM ALLERGY RH, P1
   Rosenfeld RM, 2007, OTOLARYNG HEAD NECK, V137, pS1, DOI 10.1016/j.otohns.2007.06.726
   Rosenfeld RM, 2015, OTOLARYNG HEAD NECK, V152, P598, DOI 10.1177/0194599815574247
   Rudmik L, 2013, INT FORUM ALLERGY RH, V3, P281, DOI 10.1002/alr.21096
   Solares CA, 2006, AM J OTOLARYNG, V27, P161, DOI 10.1016/j.amjoto.2005.09.006
   Uren B, 2008, LARYNGOSCOPE, V118, P1677, DOI 10.1097/MLG.0b013e31817aec47
   van Rijen M, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006216.pub2
NR 28
TC 2
Z9 2
U1 1
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0196-0709
EI 1532-818X
J9 AM J OTOLARYNG
JI Am. J. Otolaryngol.
PD SEP-OCT
PY 2020
VL 41
IS 5
AR 102604
DI 10.1016/j.amjoto.2020.102604
PG 6
WC Otorhinolaryngology
SC Otorhinolaryngology
GA NS6CF
UT WOS:000572346400029
PM 32563787
DA 2021-01-01
ER

PT J
AU Russo, M
   Moccia, S
   Spagnuolo, C
   Tedesco, I
   Russo, GL
AF Russo, Maria
   Moccia, Stefania
   Spagnuolo, Carmela
   Tedesco, Idolo
   Russo, Gian Luigi
TI Roles of flavonoids against coronavirus infection
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Coronavirus; Flavonoids; SARS-CoV; MERS-CoV; SARS-CoV-2
ID RESPIRATORY SYNDROME CORONAVIRUS; SARS-COV 3CL(PRO); PROTEASE
   INHIBITION; IN-VITRO; VIRUS; IDENTIFICATION; POLYPHENOLS; DERIVATIVES;
   PREVENTION; MOLECULES
AB In terms of public health, the 21st century has been characterized by coronavirus pandemics: in 2002-03 the virus SARS-CoV caused SARS; in 2012 MERS-CoV emerged and in 2019 a new human betacoronavirus strain, called SARS-CoV-2, caused the unprecedented COVID-19 outbreak. During the course of the current epidemic, medical challenges to save lives and scientific research aimed to reveal the genetic evolution and the biochemistry of the vital cycle of the new pathogen could lead to new preventive and therapeutic strategies against SARS-CoV-2. Up to now, there is no cure for COVID-19 and waiting for an efficacious vaccine, the development of "savage" protocols, based on "old" anti-inflammatory and anti-viral drugs represents a valid and alternative therapeutic approach. As an alternative or additional therapeutic/preventive option, different in silico and in vitro studies demonstrated that small natural molecules, belonging to polyphenol family, can interfere with various stages of coronavirus entry and replication cycle. Here, we reviewed the capacity of wellknown (e.g. quercetin, baicalin, luteolin, hesperetin, gallocatechin gallate, epigallocatechin gallate) and uncommon (e.g. scutellarein, amentoflavone, papyriflavonol A) flavonoids, secondary metabolites widely present in plant tissues with antioxidant and anti-microbial functions, to inhibit key proteins involved in coronavirus infective cycle, such as PLpro, 3CL(pro), NTPase/helicase. Due to their pleiotropic activities and lack of systemic toxicity, flavonoids and their derivative may represent target compounds to be tested in future clinical trials to enrich the drug arsenal against coronavirus infections.
C1 [Russo, Maria; Moccia, Stefania; Spagnuolo, Carmela; Tedesco, Idolo; Russo, Gian Luigi] CNR, Inst Food Sci, Via Roma 64, I-83100 Avellino, Italy.
RP Russo, GL (corresponding author), CNR, Inst Food Sci, Via Roma 64, I-83100 Avellino, Italy.
EM glrusso@isa.cnr.it
RI moccia, stefania/ABE-3470-2020
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   BELADI I, 1977, ANN NY ACAD SCI, V284, P358, DOI 10.1111/j.1749-6632.1977.tb21971.x
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   Chen LL, 2006, BIOORGAN MED CHEM, V14, P8295, DOI 10.1016/j.bmc.2006.09.014
   Cho JK, 2013, BIOORGAN MED CHEM, V21, P3051, DOI 10.1016/j.bmc.2013.03.027
   Choi HJ, 2009, ANTIVIR RES, V81, P77, DOI 10.1016/j.antiviral.2008.10.002
   Clark KJ, 1998, VET MICROBIOL, V63, P147, DOI 10.1016/S0378-1135(98)00242-9
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   CUTTING W C, 1951, Stanford Med Bull, V9, P236
   Dai WH, 2020, SCIENCE, V368, P1331, DOI 10.1126/science.abb4489
   de Groot RJ, 2013, J VIROL, V87, P7790, DOI 10.1128/JVI.01244-13
   DEBIAGGI M, 1990, MICROBIOLOGICA, V13, P207
   Dubey K, 2020, BIOMED J, V43, P363, DOI 10.1016/j.bj.2020.05.002
   Ferrer JL, 2008, PLANT PHYSIOL BIOCH, V46, P356, DOI 10.1016/j.plaphy.2007.12.009
   Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Guy RK, 2020, SCIENCE, V368, P829, DOI 10.1126/science.abb9332
   Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004
   Haslberger GA, 2020, FUNCT FOODS HEALTH D, V10, P195, DOI 10.31989/ffhd.v10i5.707
   Hatakeyama S, 2008, VIROLOGY, V380, P99, DOI 10.1016/j.virol.2008.07.012
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Iddir M., 2020, NUTRIENTS, V12
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jo S, 2020, J ENZYM INHIB MED CH, V35, P145, DOI 10.1080/14756366.2019.1690480
   Jo S, 2019, CHEM BIOL DRUG DES, V94, P2023, DOI 10.1111/cbdd.13604
   Johnson RM, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2648
   Joshi RS, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1760137
   KAPIKIAN AZ, 1969, J INFECT DIS, V119, P282, DOI 10.1093/infdis/119.3.282
   KAUL TN, 1985, J MED VIROL, V15, P71, DOI 10.1002/jmv.1890150110
   Keum YS, 2012, BIOCHEM PHARMACOL, V84, P1351, DOI 10.1016/j.bcp.2012.08.012
   Kim DW, 2014, J ENZYM INHIB MED CH, V29, P59, DOI 10.3109/14756366.2012.753591
   Lalani S., 2020, VIRUSES, P12
   Lee C, 2009, BIOORG MED CHEM LETT, V19, P4538, DOI 10.1016/j.bmcl.2009.07.009
   Lim YL, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.00060-16
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Lung JH, 2020, J MED VIROL, V92, P693, DOI 10.1002/jmv.25761
   Lye D.C.B., 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2015301, DOI 10.1056/NEJMOA2015301]
   Magro G, 2020, VIRUS RES, V286, DOI 10.1016/j.virusres.2020.198070
   Mani JS, 2020, VIRUS RES, V284, DOI 10.1016/j.virusres.2020.197989
   Messina G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093104
   Mierziak J, 2014, MOLECULES, V19, P16240, DOI 10.3390/molecules191016240
   Nabavi SM, 2020, BIOTECHNOL ADV, V38, DOI 10.1016/j.biotechadv.2018.11.005
   Osadchuk T V, 2016, Ukr Biochem J, V88, P5, DOI 10.15407/ubj88.06.005
   Park HR, 2012, ARCH PHARM RES, V35, P77, DOI 10.1007/s12272-012-0108-9
   Park JY, 2017, J ENZYM INHIB MED CH, V32, P504, DOI 10.1080/14756366.2016.1265519
   Park JY, 2016, J ENZYM INHIB MED CH, V31, P23, DOI 10.3109/14756366.2014.1003215
   Pillay TS, 2020, J CLIN PATHOL, V73, P366, DOI 10.1136/jclinpath-2020-206658
   Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2011400, 10.1056/NEJMc2013400]
   PUSZTAI R, 1966, ACTA MICROBIOL HUNG, V13, P113
   Qian SH, 2015, VIRUSES-BASEL, V7, P1613, DOI 10.3390/v7041613
   Rahman N., 2020, MOLECULES, P25
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Rodriguez-Mateos A, 2014, ARCH TOXICOL, V88, P1803, DOI 10.1007/s00204-014-1330-7
   Roh C, 2012, INT J NANOMED, V7, P2173, DOI 10.2147/IJN.S31379
   Russo GL, 2017, SEMIN CANCER BIOL, V46, P1, DOI 10.1016/j.semcancer.2017.05.005
   Russo M, 2010, TOXINS, V2, P517, DOI 10.3390/toxins2040517
   Ryu YB, 2010, BIOORGAN MED CHEM, V18, P7940, DOI 10.1016/j.bmc.2010.09.035
   Sargiacomo C, 2020, AGING-US, V12, P6511, DOI 10.18632/aging.103001
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Soukhova N, 2004, CLIN CHIM ACTA, V343, P185, DOI 10.1016/j.cccn.2004.01.007
   Spagnuolo C, 2018, EUR J MED CHEM, V153, P105, DOI 10.1016/j.ejmech.2017.09.001
   Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775
   Steinmann J, 2013, BRIT J PHARMACOL, V168, P1059, DOI 10.1111/bph.12009
   Thi THN, 2012, BIOTECHNOL LETT, V34, P831, DOI 10.1007/s10529-011-0845-8
   Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   VLIETINCK AJ, 1991, J ETHNOPHARMACOL, V32, P141, DOI 10.1016/0378-8741(91)90112-Q
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang RC, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104820
   Yi L, 2004, J VIROL, V78, P11334, DOI 10.1128/JVI.78.20.11334-11339.2004
   Yin WC, 2020, SCIENCE, V368, P1499, DOI 10.1126/science.abc1560
   Yu MS, 2012, BIOORG MED CHEM LETT, V22, P4049, DOI 10.1016/j.bmcl.2012.04.081
   Yu R, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106012
   Zabetakis I, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051466
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhong NS, 2003, LANCET, V362, P1353, DOI 10.1016/S0140-6736(03)14630-2
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhuang M, 2009, ANTIVIR RES, V82, P73, DOI 10.1016/j.antiviral.2009.02.001
   Ziebuhr J, 2005, CURR TOP MICROBIOL, V287, P57, DOI 10.1007/3-540-26765-4_3
NR 82
TC 7
Z9 7
U1 22
U2 22
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD SEP 1
PY 2020
VL 328
AR 109211
DI 10.1016/j.cbi.2020.109211
PG 13
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA NS7CP
UT WOS:000572415700007
PM 32735799
OA Green Published
DA 2021-01-01
ER

PT J
AU Chatterjee, AN
   Al Basir, F
AF Chatterjee, Amar Nath
   Al Basir, Fahad
TI A Model for SARS-CoV-2 Infection with Treatment
SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE
LA English
DT Article
ID HIV-1 INFECTION; CORONAVIRUS; DYNAMICS
AB The current emergence of coronavirus (SARS-CoV-2) puts the world in threat. The structural research on the receptor recognition by SARS-CoV-2 has identified the key interactions between SARS-CoV-2 spike protein and its host (epithelial cell) receptor, also known as angiotensin-converting enzyme 2 (ACE2). It controls both the cross-species and human-to-human transmissions of SARS-CoV-2. In view of this, we propose and analyze a mathematical model for investigating the effect of CTL responses over the viral mutation to control the viral infection when a postinfection immunostimulant drug (pidotimod) is administered at regular intervals. Dynamics of the system with and without impulses have been analyzed using the basic reproduction number. This study shows that the proper dosing interval and drug dose both are important to eradicate the viral infection.
C1 [Chatterjee, Amar Nath] Magadh Univ, Dept Math, KLS Coll, Bodh Gaya 805110, Bihar, India.
   [Al Basir, Fahad] Asansol Girls Coll, Dept Math, Asansol 4, Asansol 713304, W Bengal, India.
RP Al Basir, F (corresponding author), Asansol Girls Coll, Dept Math, Asansol 4, Asansol 713304, W Bengal, India.
EM anchaterji@gmail.com; fahadalbasir@yahoo.com
RI Chatterjee, Amar Nath/AAL-6571-2020
OI Chatterjee, Amar Nath/0000-0002-3007-0144
CR Adhya SP, 2015, EPJ WEB CONF, V95, DOI 10.1051/epjconf/20159504001
   Chatterjee Amar Nath, 2015, World J Virol, V4, P356, DOI 10.5501/wjv.v4.i4.356
   Chen Jiajia, 2020, Engineering (Beijing), V6, P1153, DOI 10.1016/j.eng.2020.02.006
   Hsueh PR, 2004, CLIN MICROBIOL INFEC, V10, P1062, DOI 10.1111/j.1469-0691.2004.01009.x
   Lakshmikantham V., 1989, SERIES MODERN APPL M, V6
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Lou J, 2011, J THEOR BIOL, V268, P1, DOI 10.1016/j.jtbi.2010.09.039
   Lou J, 2009, J BIOL SYST, V17, P659, DOI 10.1142/S0218339009002934
   Miron RE, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-6
   Nowak M, 2000, VIRUS DYNAMICS MATH
   Oh HLJ, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.26
   Perelson AS, 1999, SIAM REV, V41, P3, DOI 10.1137/S0036144598335107
   Puggioni F., 2019, MULTIDISCIPLINARY RE, V14, P1
   Qing E, 2020, TRENDS IMMUNOL, V41, P271, DOI 10.1016/j.it.2020.02.007
   Qureshi S, 2019, PHYSICA A, V534, DOI 10.1016/j.physa.2019.122149
   Qureshi S, 2019, EUR PHYS J PLUS, V134, DOI 10.1140/epjp/i2019-12661-7
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Roy PK, 2013, NONLINEAR ANAL-REAL, V14, P1621, DOI 10.1016/j.nonrwa.2012.10.021
   Smith RJ, 2005, B MATH BIOL, V67, P783, DOI 10.1016/j.bulm.2004.10.004
   Smith RJ, 2008, J THEOR BIOL, V251, P227, DOI 10.1016/j.jtbi.2007.11.032
   Smith RJ, 2009, J MATH BIOL, V59, P697, DOI 10.1007/s00285-008-0245-4
   Tang SM, 2017, COMPUT MATH METHOD M, DOI 10.1155/2017/5285810
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   World Health Organization, 2020, LAB TEST COR DIS 201
   World Health Organization (WHO), 2020, CONS QUAR IND CONT C
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Yu HG, 2011, COMMUN NONLINEAR SCI, V16, P776, DOI 10.1016/j.cnsns.2010.04.017
   Zheng MJ, 2020, CELL MOL IMMUNOL, V17, P533, DOI 10.1038/s41423-020-0402-2
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 32
TC 0
Z9 0
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1748-670X
EI 1748-6718
J9 COMPUT MATH METHOD M
JI Comput. Math. Method Med.
PD SEP 1
PY 2020
VL 2020
AR 1352982
DI 10.1155/2020/1352982
PG 11
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA NS6BS
UT WOS:000572345100004
PM 32908574
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Joyner, MJ
   Bruno, KA
   Klassen, SA
   Kunze, KL
   Johnson, PW
   Lesser, ER
   Wiggins, CC
   Senefeld, JW
   Klompas, AM
   Hodge, DO
   Shepherd, JRA
   Rea, RF
   Whelan, ER
   Clayburn, AJ
   Spiegel, MR
   Baker, SE
   Larson, KF
   Ripoll, JG
   Andersen, KJ
   Buras, MR
   Vogt, MNP
   Herasevich, V
   Dennis, JJ
   Regimbal, RJ
   Bauer, PR
   Blair, JE
   van Buskirk, CM
   Winters, JL
   Stubbs, JR
   van Helmond, N
   Butterfield, BP
   Sexton, MA
   Soto, JCD
   Paneth, NS
   Verdun, NC
   Marks, P
   Casadevall, A
   Fairweather, D
   Carter, RE
   Wright, RS
AF Joyner, Michael J.
   Bruno, Katelyn A.
   Klassen, Stephen A.
   Kunze, Katie L.
   Johnson, Patrick W.
   Lesser, Elizabeth R.
   Wiggins, Chad C.
   Senefeld, Jonathon W.
   Klompas, Allan M.
   Hodge, David O.
   Shepherd, John R. A.
   Rea, Robert F.
   Whelan, Emily R.
   Clayburn, Andrew J.
   Spiegel, Matthew R.
   Baker, Sarah E.
   Larson, Kathryn F.
   Ripoll, Juan G.
   Andersen, Kylie J.
   Buras, Matthew R.
   Vogt, Matthew N. P.
   Herasevich, Vitaly
   Dennis, Joshua J.
   Regimbal, Riley J.
   Bauer, Philippe R.
   Blair, Janis E.
   van Buskirk, Camille M.
   Winters, Jeffrey L.
   Stubbs, James R.
   van Helmond, Noud
   Butterfield, Brian P.
   Sexton, Matthew A.
   Soto, Juan C. Diaz
   Paneth, Nigel S.
   Verdun, Nicole C.
   Marks, Peter
   Casadevall, Arturo
   Fairweather, DeLisa
   Carter, Rickey E.
   Wright, R. Scott
TI Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized
   Patients
SO MAYO CLINIC PROCEEDINGS
LA English
DT Article
AB Objective: To provide an update on key safety metrics after transfusion of convalescent plasma in hospitalized coronavirus 2019 (COVID-19) patients, having previously demonstrated safety in 5000 hospitalized patients.
   Patients and Methods: From April 3 to June 2, 2020, the US Food and Drug Administration Expanded Access Program for COVID-19 convalescent plasma transfused a convenience sample of 20,000 hospitalized patients with COVID-19 convalescent plasma.
   Results: The incidence of all serious adverse events was low; these included transfusion reactions (n=78; <1%), thromboembolic or thrombotic events (n=113; <1%), and cardiac events (n=677, similar to 3%). Notably, the vast majority of the thromboembolic or thrombotic events (n=75) and cardiac events (n=597) were judged to be unrelated to the plasma transfusion per se. The 7-day mortality rate was 13.0% (12.5%, 13.4%), and was higher among more critically ill patients relative to less ill counterparts, including patients admitted to the intensive care unit versus those not admitted (15.6 vs 9.3%), mechanically ventilated versus not ventilated (18.3% vs 9.9%), and with septic shock or multiple organ dysfunction/failure versus those without dysfunction/failure (21.7% vs 11.5%).
   Conclusion: These updated data provide robust evidence that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19, and support the notion that earlier administration of plasma within the clinical course of COVID-19 is more likely to reduce mortality. (C) 2020 Mayo Foundation for Medical Education and Research
C1 [Joyner, Michael J.; Klassen, Stephen A.; Wiggins, Chad C.; Senefeld, Jonathon W.; Klompas, Allan M.; Shepherd, John R. A.; Clayburn, Andrew J.; Baker, Sarah E.; Larson, Kathryn F.; Ripoll, Juan G.; Andersen, Kylie J.; Vogt, Matthew N. P.; Herasevich, Vitaly; Dennis, Joshua J.; Regimbal, Riley J.; Butterfield, Brian P.; Sexton, Matthew A.; Soto, Juan C. Diaz] Mayo Clin, Dept Anesthesiol & Perioperat Med, Rochester, MN 55905 USA.
   [Rea, Robert F.; Wright, R. Scott] Mayo Clin, Dept Cardiovasc Med, Rochester, MN 55905 USA.
   [Bauer, Philippe R.] Mayo Clin, Dept Internal Med, Div Pulm & Crit Care, Rochester, MN 55905 USA.
   [van Buskirk, Camille M.; Winters, Jeffrey L.; Stubbs, James R.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA.
   [Wright, R. Scott] Mayo Clin, Human Res Protect Program, Rochester, MN 55905 USA.
   [Bruno, Katelyn A.; Whelan, Emily R.; Fairweather, DeLisa] Mayo Clin, Dept Cardiovasc Med, Jacksonville, FL 32224 USA.
   [Johnson, Patrick W.; Lesser, Elizabeth R.; Hodge, David O.; Spiegel, Matthew R.; Carter, Rickey E.] Mayo Clin, Dept Hlth Sci Res, Jacksonville, FL 32224 USA.
   [Kunze, Katie L.; Buras, Matthew R.] Mayo Clin, Dept Hlth Sci Res, Scottsdale, AZ USA.
   [Blair, Janis E.] Mayo Clin, Dept Internal Med, Div Infect Dis, Phoenix, AZ USA.
   [van Helmond, Noud] Rowan Univ, Cooper Univ Hlth Care, Cooper Med Sch, Dept Anesthesiol, Camden, NJ USA.
   [Paneth, Nigel S.] Michigan State Univ, Coll Human Med, Dept Epidemiol & Biostat, E Lansing, MI 48824 USA.
   [Paneth, Nigel S.] Michigan State Univ, Coll Human Med, Dept Pediat, E Lansing, MI 48824 USA.
   [Paneth, Nigel S.] Michigan State Univ, Coll Human Med, Dept Human Dev, E Lansing, MI 48824 USA.
   [Verdun, Nicole C.; Marks, Peter] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA.
   [Casadevall, Arturo] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA.
RP Joyner, MJ (corresponding author), Mayo Clin, 200 First St SW,Joseph Bldg 4-184, Rochester, MN 55905 USA.
RI Senefeld, Jack/ABF-1286-2020; Johnson, Patrick/ABE-9597-2020
OI Johnson, Patrick/0000-0001-8365-1375; Kunze, Katie/0000-0001-6850-6823;
   Klompas, Allan/0000-0001-8852-4666; Andersen, Kylie/0000-0001-8668-2871;
   Bruno, Katelyn/0000-0001-8980-6059
FU U.S. Department of Health and Human Services (HHS); Biomedical Advanced
   Research and Development Authority (BARDA) [75A50120C00096]; National
   Center for Advancing Translational Sciences (NCATS)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS)
   [UL1TR002377]; National Heart, Lung, and Blood Institute (NHLBI)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)
   [5R35HL139854]; National Institute of Diabetes and Digestive and Kidney
   Diseases (NIDDK)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [5T32DK07352]; Natural
   Sciences and Engineering Research Council of Canada (NSERC)Natural
   Sciences and Engineering Research Council of Canada [PDF-532926-2019];
   National Institute of Allergy and Infectious Disease (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R21 AI145356, R21 AI152318, R01 AI152078 9]; National
   Heart, Lung, and Blood InstituteUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Heart Lung & Blood Institute (NHLBI) [RO1 HL059842]; National Institute
   on Aging (NIA)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   on Aging (NIA) [U54AG044170]; Schwab Charitable Fund; United Health
   Group; National Basketball Association (NBA); Millennium
   PharmaceuticalsTakeda Pharmaceutical Company Ltd; Octapharma USA, Inc.;
   Mayo Clinic
FX This study was supported in part by a U.S. Department of Health and
   Human Services (HHS), Biomedical Advanced Research and Development
   Authority (BARDA) contract 75A50120C00096 (to M.J.J.), National Center
   for Advancing Translational Sciences (NCATS) grant UL1TR002377, National
   Heart, Lung, and Blood Institute (NHLBI) grant 5R35HL139854 (to MJJ),
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
   5T32DK07352 (to J.W.S. and C.C.W.), Natural Sciences and Engineering
   Research Council of Canada (NSERC) PDF-532926-2019 (to S.A.K.), National
   Institute of Allergy and Infectious Disease (NIAID) grants R21 AI145356
   and R21 AI152318 (to D.F.), R01 AI152078 9 (to A.C.), National Heart,
   Lung, and Blood Institute RO1 HL059842 (to A.C.), National Institute on
   Aging (NIA) U54AG044170 (to S.E.B.), Schwab Charitable Fund (Eric E.
   Schmidt, Wendy Schmidt donors), United Health Group, National Basketball
   Association (NBA), Millennium Pharmaceuticals, Octapharma USA, Inc., and
   the Mayo Clinic.
CR Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Casadevall A, 2020, J CLIN INVEST, V130, P1545, DOI 10.1172/JCI138003
   Centers for Disease Control and Prevention, COR DIS 2019 COVID 1
   Dzik S, 2020, TRANSFUS MED REV, V34, P141, DOI 10.1016/j.tmrv.2020.04.002
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Inciardi RM, 2020, JAMA CARDIOL, V5, P819, DOI 10.1001/jamacardio.2020.1096
   Joyner MJ, 2020, J CLIN INVEST, V130, P4791, DOI 10.1172/JCI140200
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Luke TC, 2006, ANN INTERN MED, V145, P599, DOI 10.7326/0003-4819-145-8-200610170-00139
   Rajgor DD, 2020, LANCET INFECT DIS, V20, P776, DOI 10.1016/S1473-3099(20)30244-9
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Roubinian Nareg, 2018, Hematology Am Soc Hematol Educ Program, V2018, P585, DOI 10.1182/asheducation-2018.1.585
   US Centers for Disease Control and Prevention, 2018, NAT HEALTHC SAF NETW
   Wang K, 2020, INTENS CARE MED, V46, P1472, DOI 10.1007/s00134-020-06047-w
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wright FL, 2020, J AM COLL SURGEONS, V231, P193, DOI 10.1016/j.jamcollsurg.2020.05.007
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang JS, 2005, J MED VIROL, V77, P147, DOI 10.1002/jmv.20431
NR 23
TC 27
Z9 26
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0025-6196
EI 1942-5546
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD SEP
PY 2020
VL 95
IS 9
BP 1888
EP 1897
DI 10.1016/j.mayocp.2020.06.028
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA NS7WL
UT WOS:000572468100019
PM 32861333
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Lim, S
   DeBruin, DA
   Leider, JP
   Sederstrom, N
   Lynfield, R
   Baker, JV
   Kline, S
   Kesler, S
   Rizza, S
   Wu, J
   Sharp, RR
   Wolf, SM
AF Lim, Sarah
   DeBruin, Debra A.
   Leider, Jonathon P.
   Sederstrom, Nneka
   Lynfield, Ruth
   Baker, Jason, V
   Kline, Susan
   Kesler, Sarah
   Rizza, Stacey
   Wu, Joel
   Sharp, Richard R.
   Wolf, Susan M.
TI Developing an Ethics Framework for Allocating Remdesivir in the COVID-19
   Pandemic
SO MAYO CLINIC PROCEEDINGS
LA English
DT Article
AB On May 1, 2020, the US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) to allow use of the antiviral drug remdesivir to treat patients with severe coronavirus disease-2019 (COVID-19). Remdesivir is an investigational drug studied in clinical trials for COVID-19 and is available to children and pregnant women through compassionate-use access but is not yet FDA approved. In early May, the US Department of Health and Human Services began to distribute remdesivir, donated by Gilead Sciences, Inc., to hospitals and state health departments for emergency use; multiple shipments have since been distributed. This process has raised questions of how remdesivir should be allocated. The Minnesota Department of Health has collaborated with the Minnesota COVID Ethics Collaborative and multiple clinical experts to issue an Ethical Framework for May 2020 Allocation of Remdesivir in the COVID-19 Pandemic. The framework builds on extensive ethical guidance developed for public health emergencies in Minnesota before the COVID-19 crisis. The Minnesota remdesivir allocation framework specifies an ethical approach to distributing the drug to facilities across the state and then among COVID-19 patients within each facility. This article describes the process of developing the framework and adjustments in the framework over time with emergence of new data, analyzes key issues addressed, and suggests next steps. Sharing this framework and the development process can encourage transparency and may be useful to other states formulating and refining their approach to remdesivir EUA allocation. (C) 2020 Mayo Foundation for Medical Education and Research
C1 [Lim, Sarah; Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA.
   [DeBruin, Debra A.; Leider, Jonathon P.; Kline, Susan; Kesler, Sarah; Wu, Joel; Wolf, Susan M.] Univ Minnesota, Minneapolis, MN USA.
   [Sederstrom, Nneka] Childrens Minnesota, Minneapolis, MN USA.
   [Baker, Jason, V] Hennepin Healthcare, Minneapolis, MN USA.
   [Rizza, Stacey; Sharp, Richard R.] Mayo Clin, Rochester, MN USA.
RP Wolf, SM (corresponding author), Univ Minnesota, Consortium Law & Values Heahh Environm & Life Sci, 316 Johnston Hall,101 Pleast St SE, Minneapolis, MN 55455 USA.
EM swolf@umn.edu
OI Leider, JP/0000-0001-9905-476X
FU Gilead SciencesGilead Sciences [GS-US-540-5773, GS-US-540-5774];
   NIAIDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID); NCIUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [75N910D00024, 75N91019F00130]
FX Drs Baker and Rizza receive research support from Gilead Sciences
   (GS-US-540-5773; GS-US-540-5774). Dr Kline participated in the ACTT-1
   trial, which was funded by NIAID and NCI (contract 75N910D00024, task
   order number 75N91019F00130). Dr Leider owns 30 unit equivalents of
   Gilead Sciences stock. Prof Wolf owns shares in Vanguard Health Care
   ETF, which includes Gliead Sciences Inc among its stock holdings as of
   May 31. The other authors report no competing interests.
CR [Anonymous], 2020, DAILY CHRONICLE
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Boodman E, 2020, LITTLE DATA DOCTORS
   Burns G., 2020, EXPT CORONAVIRUS DRU
   California Department of Public Health, 2020, CAL DEP PUBL HLTH RE
   COVID-19 Treatment Guidelines Panel, 2020, COVID 19 TREATM GUID
   DeBruin DA, 2010, IMPLEMENTING ETHICAL
   Eastman RT, 2020, ACS CENTRAL SCI, V6, P672, DOI 10.1021/acscentsci.0c00489
   Georgia Department of Public Health Coastal Health District, 2020, GEORG DPH DISTR REMD
   Gilead, EM ACC REMD OUTS CLI
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Infectious Disease Society of America (IDSA), 2020, IDSA HIVMA CALL TRAN
   Minnesota Department of Health ( MDH), ETH FRAM MAY 2020 AL
   Minnesota Department of Health (MDH), MINN PAND ETH PROJ
   Minnesota Department of Health (MDH), ETH CONS CRIS STAND
   Minnesota Department of Health (MDH), ALL VENT REL SCARC C
   Pennsylvania Department of Health, 2020, SUMM REMD ALL
   U.S. Department of Health and Human Services (HHS), 2020, HHS ANN SHIPM DON RE
   U.S. Food and Drug Administration (FDA), 2020, COMMUNICATION   0501
   University of Minnesota, MINN COVID ETH COLL
   US Food And Drug Administration, FACT SHEET PAT PAR C
   US Food Drug and Administration, FACT SHEET HLTH CAR
   Vawter DE, 2010, GOOD US ALL ETHICALL
   Virginia Department of Health, 2020, REMD US REC ALL VIRG
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
NR 26
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0025-6196
EI 1942-5546
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD SEP
PY 2020
VL 95
IS 9
BP 1946
EP 1954
DI 10.1016/j.mayocp.2020.06.016
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA NS7WL
UT WOS:000572468100026
PM 32861338
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Baughn, LB
   Sharma, N
   Elhaik, E
   Sekulic, A
   Bryce, AH
   Fonseca, R
AF Baughn, Linda B.
   Sharma, Neeraj
   Elhaik, Eran
   Sekulic, Aleksandar
   Bryce, Alan H.
   Fonseca, Rafael
TI Targeting TMPRSS2 in SARS-CoV-2 Infection
SO MAYO CLINIC PROCEEDINGS
LA English
DT Article
ID RESPIRATORY SYNDROME CORONAVIRUS; PNEUMONIA; OUTBREAK
AB Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has rapidly caused a global pandemic associated with a novel respiratory infection: coronavirus disease-19 (COVID-19). Angiotensin-converting enzyme-2 (ACE2) is necessary to facilitate SARS-CoV-2 infection, but-owing to its essential metabolic roles-it may be difficult to target it in therapies. Transmembrane protease serine 2 (TMPRSS2), which interacts with ACE2, may be a better candidate for targeted therapies. Using publicly available expression data, we show that both ACE2 and TMPRSS2 are expressed in many host tissues, including lung. The highest expression of ACE2 is found in the testes, whereas the prostate displays the highest expression of TMPRSS2. Given the increased severity of disease among older men with SARS-CoV-2 infection, we address the potential roles of ACE2 and TMPRSS2 in their contribution to the sex differences in severity of disease. We show that expression levels of ACE2 and TMPRSS2 are overall comparable between men and women in multiple tissues, suggesting that differences in the expression levels of TMPRSS2 and ACE2 in the lung and other non-sex-specific tissues may not explain the gender disparities in severity of SARS CoV-2. However, given their instrumental roles for SARS-CoV-2 infection and their pleiotropic expression, targeting the activity and expression levels of TMPRSS2 is a rational approach to treat COVID-19. (C) 2020 Mayo Foundation for Medical Education and Research.
C1 [Baughn, Linda B.; Sharma, Neeraj] Mayo Clin, Div Lab Genet, Dept Lab Med & Pathol, Rochester, MN USA.
   [Elhaik, Eran] Lund Univ, Dept Biol, Lund, Sweden.
   [Sekulic, Aleksandar] Mayo Clin, Dept Dermatol, Scottsdale, AZ USA.
   [Bryce, Alan H.; Fonseca, Rafael] Mayo Clin, Div Hematol & Med Oncol, Phoenix, AZ USA.
RP Fonseca, R (corresponding author), Mayo Clin, 5777 East Mayo Blvd, Phoenix, AZ 85054 USA.
EM fonseca.rafael@mayo.edu
CR Alghamdi IG, 2014, INT J GEN MED, V7, P417, DOI 10.2147/IJGM.S67061
   Asselta R, 2020, ACE2 TMPRSS2 VARIANT, DOI [10.1101/2020.03.30.20047878, DOI 10.1101/2020.03.30.20047878]
   Badawi A, 2016, INT J INFECT DIS, V49, P129, DOI 10.1016/j.ijid.2016.06.015
   Butler D. J., 2020, HOST VIRAL ENV TRANS, DOI [10.1101/2020.04.20.048066, DOI 10.1101/2020.04.20.048066]
   Cai G., 2020, BULK SINGLE CELL TRA, DOI [10.1101/2020.02.05.20020107, DOI 10.1101/2020.02.05.20020107]
   Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Crackower MA, 2002, NATURE, V417, P822, DOI 10.1038/nature00786
   Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1
   Du YZ, 2020, AM J RESP CRIT CARE, V201, P1372, DOI 10.1164/rccm.202003-0543OC
   Gibo J, 2005, LAB INVEST, V85, P75, DOI 10.1038/labinvest.3700203
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Iwata-Yoshikawa N, 2019, J VIROL, V93, DOI 10.1128/JVI.01815-18
   Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152
   Kim TS, 2006, MOL CELL BIOL, V26, P965, DOI 10.1128/MCB.26.3.965-975.2006
   Kryuchkova-Mostacci N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131673
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lin BY, 1999, CANCER RES, V59, P4180
   Linn DE, 2016, CANCER RES, V76, P1869, DOI 10.1158/0008-5472.CAN-15-1911
   Lucas JM, 2014, CANCER DISCOV, V4, P1310, DOI 10.1158/2159-8290.CD-13-1010
   Marcus JH, 2017, BIOINFORMATICS, V33, P594, DOI 10.1093/bioinformatics/btw643
   Marzano AV, 2020, J AM ACAD DERMATOL, V83, P280, DOI 10.1016/j.jaad.2020.04.044
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   Shastri A, 2020, DELAYED CLEARANCE SA, DOI [10.1101/2020.04.16.20060566., 10.1101/2020.04.16.20060566, DOI 10.1101/2020.04.16.20060566]
   Shen LW, 2017, BIOCHIMIE, V142, P1, DOI 10.1016/j.biochi.2017.07.016
   Shi Y, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2833-7
   Stopsack KH, 2020, CANCER DISCOV, V10, P779, DOI 10.1158/2159-8290.CD-20-0451
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8
   Tukiainen T, 2017, NATURE, V550, P244, DOI 10.1038/nature24265
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Xie J, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8147
   Xydakis MS, 2020, LANCET INFECT DIS, V20, P1015, DOI 10.1016/S1473-3099(20)30293-0
   Yamamoto M, 2016, ANTIMICROB AGENTS CH, V60, P6532, DOI 10.1128/AAC.01043-16
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 46
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0025-6196
EI 1942-5546
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD SEP
PY 2020
VL 95
IS 9
BP 1989
EP 1999
DI 10.1016/j.mayocp.2020.06.018
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA NS7WL
UT WOS:000572468100030
PM 32861340
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Hartman, AL
   Nambulli, S
   McMillen, CM
   White, AG
   Tilston-Lunel, NL
   Albe, JR
   Cottle, E
   Dunn, MD
   Frye, LJ
   Gilliland, TH
   Olsen, EL
   O'Malley, KJ
   Schwarz, MM
   Tomko, JA
   Walker, RC
   Xia, MY
   Hartman, MS
   Klein, E
   Scanga, CA
   Flynn, JL
   Klimstra, WB
   McElroy, AK
   Reed, DS
   Duprex, WP
AF Hartman, Amy L.
   Nambulli, Sham
   McMillen, Cynthia M.
   White, Alexander G.
   Tilston-Lunel, Natasha L.
   Albe, Joseph R.
   Cottle, Emily
   Dunn, Matthew D.
   Frye, L. James
   Gilliland, Theron H.
   Olsen, Emily L.
   O'Malley, Katherine J.
   Schwarz, Madeline M.
   Tomko, Jaime A.
   Walker, Reagan C.
   Xia, Mengying
   Hartman, Matthew S.
   Klein, Edwin
   Scanga, Charles A.
   Flynn, JoAnne L.
   Klimstra, William B.
   McElroy, Anita K.
   Reed, Douglas S.
   Duprex, W. Paul
TI SARS-CoV-2 infection of African green monkeys results in mild
   respiratory disease discernible by PET/CT imaging and shedding of
   infectious virus from both respiratory and gastrointestinal tracts
SO PLOS PATHOGENS
LA English
DT Article
ID SARS; TRANSMISSION; PATHOGENESIS; COVID-19; MODEL
AB Author summary SARS-CoV-2 infection can result in asymptomatic, mild or severe disease in humans. Vaccines against SARS-CoV-2 are paramount for combating COVID-19 disease and curtailing the pandemic. Large animal models are critical for early vaccine testing before human clinical trials. Here, we found that infection of African green monkeys (AGM) with SARS-CoV-2 resulted in mild disease yet lesions were detectable by PET/CT imaging of the lungs. Shedding of infectious virus from both respiratory and gastrointestinal tracts was also documented. This study provides a detailed account of the pathogenesis of a low-passage SARS-CoV-2 isolate in the AGM model and suggests that AGM can be used for preclinical evaluation of candidate vaccines and therapeutic interventions.
   Vaccines are urgently needed to combat the global coronavirus disease 2019 (COVID-19) pandemic, and testing of candidate vaccines in an appropriate non-human primate (NHP) model is a critical step in the process. Infection of African green monkeys (AGM) with a low passage human isolate of SARS-CoV-2 by aerosol or mucosal exposure resulted in mild clinical infection with a transient decrease in lung tidal volume. Imaging with human clinical-grade(18)F-fluoro-2-deoxy-D-glucose positron emission tomography (F-18-FDG PET) co-registered with computed tomography (CT) revealed pulmonary lesions at 4 days post-infection (dpi) that resolved over time. Infectious virus was shed from both respiratory and gastrointestinal (GI) tracts in all animals in a biphasic manner, first between 2-7 dpi followed by a recrudescence at 14-21 dpi. Viral RNA (vRNA) was found throughout both respiratory and gastrointestinal systems at necropsy with higher levels of vRNA found within the GI tract tissues. All animals seroconverted simultaneously for IgM and IgG, which has also been documented in human COVID-19 cases. Young AGM represent an species to study mild/subclinical COVID-19 disease and with possible insights into live virus shedding. Future vaccine evaluation can be performed in AGM with correlates of efficacy being lung lesions by PET/CT, virus shedding, and tissue viral load.
C1 [Hartman, Amy L.; Nambulli, Sham; McMillen, Cynthia M.; Tilston-Lunel, Natasha L.; Albe, Joseph R.; Cottle, Emily; Dunn, Matthew D.; Gilliland, Theron H.; Olsen, Emily L.; O'Malley, Katherine J.; Schwarz, Madeline M.; Xia, Mengying; Scanga, Charles A.; Flynn, JoAnne L.; Klimstra, William B.; McElroy, Anita K.; Reed, Douglas S.; Duprex, W. Paul] Univ Pittsburgh, Sch Med, Ctr Vaccine Res, Pittsburgh, PA 15260 USA.
   [Hartman, Amy L.; McMillen, Cynthia M.; Schwarz, Madeline M.] Univ Pittsburgh, Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15260 USA.
   [Nambulli, Sham; White, Alexander G.; Tilston-Lunel, Natasha L.; Frye, L. James; Tomko, Jaime A.; Scanga, Charles A.; Flynn, JoAnne L.; Duprex, W. Paul] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15260 USA.
   [Walker, Reagan C.; Klein, Edwin] Univ Pittsburgh, Div Lab Anim Resources, Pittsburgh, PA USA.
   [Hartman, Matthew S.] Allegheny Hlth Network, Dept Radiol, Pittsburgh, PA USA.
   [Klimstra, William B.; Reed, Douglas S.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA.
   [McElroy, Anita K.] Univ Pittsburgh, Dept Pediat, Div Pediat Infect Dis, Pittsburgh, PA 15260 USA.
RP Hartman, AL; Duprex, WP (corresponding author), Univ Pittsburgh, Sch Med, Ctr Vaccine Res, Pittsburgh, PA 15260 USA.; Hartman, AL (corresponding author), Univ Pittsburgh, Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15260 USA.; Duprex, WP (corresponding author), Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15260 USA.
EM hartman2@pitt.edu; pduprex@pitt.edu
RI Flynn, JoAnne/ABC-7371-2020; Scanga, Charles/L-2353-2019
OI Scanga, Charles/0000-0003-3654-5603; Tilston-Lunel,
   Natasha/0000-0002-5290-9350; Schwarz, Madeline/0000-0002-9038-4655;
   Dunn, Matthew/0000-0003-0378-5838; McElroy, Anita/0000-0001-6764-7536;
   Hartman, Amy/0000-0002-0857-2973; Nambulli, Sham/0000-0002-9781-9703
FU University of PittsburghUniversity of Pittsburgh; Center for Vaccine
   Research; Bill and Melinda Gates FoundationBill & Melinda Gates
   Foundation [OPP1130668]; Burroughs Wellcome career award for medical
   scientistsBurroughs Wellcome Fund [1013362]; NIHUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32
   AI060525]
FX Funding for this study was generously provided by Dr. Patrick Gallagher,
   Chancellor of the University of Pittsburgh and by the Center for Vaccine
   Research. Funding for the PET/CT Reading Core was through the Bill and
   Melinda Gates Foundation (OPP1130668). A.M. was funded through a
   Burroughs Wellcome career award for medical scientists (award 1013362)
   C.M. was funded through NIH T32 AI060525. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Bowling JD, 2019, APPL ENVIRON MICROB, V85, DOI 10.1128/AEM.00747-19
   Cadena AM, 2016, COMPARATIVE MED, V66, P412
   Chao S., 2020, INFECT NOVEL CORONAV, DOI [10.21203/rs.2.25200/v1, DOI 10.21203/RS.2.25200/V1]
   Chen C, 2020, ANN INTERN MED, V172, P832, DOI 10.7326/M20-0991
   Chen YF, 2020, J MED VIROL, V92, P833, DOI 10.1002/jmv.25825
   Du RH, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00524-2020
   Durbin AP, 2000, VACCINE, V18, P2462, DOI 10.1016/S0264-410X(99)00575-7
   Fairbanks LA, 2004, BIOL PSYCHIAT, V55, P642, DOI 10.1016/j.biopsych.2003.12.005
   Finch CL, 2020, CHARACTERISTIC QUANT, DOI [10.1101/2020.05.14.096727, DOI 10.1101/2020.05.14.096727]
   Freeman MC, 2014, MBIO, V5, DOI 10.1128/mBio.01340-14
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020
   Huang L, 2020, J INFECTION, V80, pE1, DOI 10.1016/j.jinf.2020.03.006
   Jasinska AJ, 2013, ILAR J, V54, P122, DOI 10.1093/ilar/ilt049
   Johnston SC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117817
   Kim GU, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.04.040
   Klimstra William B, 2020, J Gen Virol, V101, P1156, DOI 10.1099/jgv.0.001481
   Kuri-Cervantes Leticia, 2020, bioRxiv, DOI 10.1101/2020.05.18.101717
   Layton RC, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000959
   Lin PL, 2014, NAT MED, V20, P75, DOI 10.1038/nm.3412
   Lin PL, 2013, ANTIMICROB AGENTS CH, V57, P4237, DOI 10.1128/AAC.00277-13
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Lutje S, 2020, NUKLEARMED-NUCL MED, V59, P276, DOI 10.1055/a-1152-2341
   Maiello P, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00505-17
   Martin CJ, 2017, MBIO, V8, DOI 10.1128/mBio.00312-17
   Mathew Divij, 2020, bioRxiv, DOI 10.1101/2020.05.20.106401
   McAuliffe J, 2004, VIROLOGY, V330, P8, DOI 10.1016/j.virol.2004.09.030
   McKinney K. R, 2006, J ENV HLTH, V68, P51
   McKinney KR, 2006, J ENVIRON HEALTH, V68, P26
   Munster VJ, 2020, NATURE, DOI 10.1038/s41586-020-2324-7
   Pandrea I, 2006, J VIROL, V80, P4858, DOI 10.1128/JVI.80.10.4858-4867.2006
   Polverari G, 2020, J THORAC ONCOL, V15, P1078, DOI 10.1016/j.jtho.2020.03.022
   Rhoads MK, 2017, AM J PHYSIOL-REG I, V313, pR211, DOI 10.1152/ajpregu.00026.2017
   Riley S, 2003, SCIENCE, V300, P1961, DOI 10.1126/science.1086478
   Rockx B, 2020, SCIENCE, V368, P1012, DOI 10.1126/science.abb7314
   Roy CJ, 2005, BIODEFENSE RES METHO, P61
   Smits SL, 2011, J VIROL, V85, P4234, DOI 10.1128/JVI.02395-10
   Stadlbauer Daniel, 2020, Curr Protoc Microbiol, V57, pe100, DOI 10.1002/cpmc.100
   Suhandynata RT, 2020, J APPL LAB MED, V5, P908, DOI 10.1093/jalm/jfaa079
   Tulchinsky M, 2020, CLIN NUCL MED, V45, P531, DOI 10.1097/RLU.0000000000003100
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   White AG, 2017, JOVE-J VIS EXP, DOI 10.3791/56375
   Wonderlich ER, 2018, J VIROL, V92, DOI 10.1128/JVI.01662-17
   Woolsey Courtney, 2020, bioRxiv, DOI 10.1101/2020.05.17.100289
   Xiang F, 2020, CLIN INFECT DIS, V71, P1930, DOI 10.1093/cid/ciaa461
   Xu X, 2020, NAT MED, V26, P1193, DOI 10.1038/s41591-020-0949-6
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
NR 46
TC 1
Z9 1
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD SEP
PY 2020
VL 16
IS 9
AR e1008903
DI 10.1371/journal.ppat.1008903
PG 24
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA NU7KZ
UT WOS:000573820300001
PM 32946524
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mohan, M
   Cherian, JJ
   Sharma, A
AF Mohan, Mradul
   Cherian, Jerin Jose
   Sharma, Amit
TI Exploring links between vitamin D deficiency and COVID-19
SO PLOS PATHOGENS
LA English
DT Article
ID INFECTIONS
AB Coronavirus Disease 2019 (COVID-19) pandemic remains a major public health threat in most countries. The causative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus can lead to acute respiratory distress syndrome and result in mortality in COVID-19 patients. Vitamin D is an immunomodulator hormone with established effectiveness against various upper respiratory infections. Vitamin D can stall hyper-inflammatory responses and expedite healing process of the affected areas, primarily in the lung tissue. Thus, there are ecological and mechanistic reasons to promote exploration of vitamin D action in COVID-19 patients. As no curative drugs are available currently for COVID-19, we feel that the potential of vitamin D to alter the course of disease severity needs to be investigated. Clinical studies may be undertaken to address the value of vitamin D supplementation in deficient, high-risk COVID-19 patients.
C1 [Mohan, Mradul; Sharma, Amit] Natl Inst Malaria Res, Parasite Host Biol Grp, New Delhi, India.
   [Cherian, Jerin Jose] Indian Council Med Res, Div Basic Med Sci, New Delhi, India.
   [Sharma, Amit] Int Ctr Genet Engn & Biotechnol, Struct Parasitol Grp, New Delhi, India.
RP Sharma, A (corresponding author), Natl Inst Malaria Res, Parasite Host Biol Grp, New Delhi, India.; Sharma, A (corresponding author), Int Ctr Genet Engn & Biotechnol, Struct Parasitol Grp, New Delhi, India.
EM directornimr@gmail.com
CR Alipio M., 2020, VITAMIN D SUPPLEMENT
   Amrein K, 2020, EUR J CLIN NUTR, V74, P1498, DOI 10.1038/s41430-020-0558-y
   Aparna P, 2018, J Family Med Prim Care, V7, P324, DOI 10.4103/jfmpc.jfmpc_78_18
   Arboleda JF, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01523
   Azrielant S, 2017, ISR MED ASSOC J, V19, P510
   Beard JA, 2011, J CLIN VIROL, V50, P194, DOI 10.1016/j.jcv.2010.12.006
   Bergman P, 2020, J INTERN MED, DOI 10.1111/joim.13158
   Bikle DD, 2014, CHEM BIOL, V21, P319, DOI 10.1016/j.chembiol.2013.12.016
   Carter SJ, 2020, OBESITY, V28, P1176, DOI 10.1002/oby.22838
   Chen Y, 2013, J BIOL CHEM, V288, P19450, DOI 10.1074/jbc.M113.467670
   Daniel C, 2008, J PHARMACOL EXP THER, V324, P23, DOI 10.1124/jpet.107.127209
   Dauber A, 2012, J CLIN ENDOCR METAB, V97, pE268, DOI 10.1210/jc.2011-1972
   Fields Jessica, 2011, Curr Osteoporos Rep, V9, P243, DOI 10.1007/s11914-011-0071-2
   Greiller CL, 2015, NUTRIENTS, V7, P4240, DOI 10.3390/nu7064240
   Holick MF, 2003, J CELL BIOCHEM, V88, P296, DOI 10.1002/jcb.10338
   Jain SK, 2020, J HYDROL ENG, V25, DOI 10.1061/(ASCE)HE.1943-5584.0001989
   Lips P, 2019, EUR J ENDOCRINOL, V180, pP23, DOI 10.1530/EJE-18-0736
   Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Manuel A., 2020, LANCET RESP MED
   Martineau AR, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6583
   MATSUOKA LY, 1991, ARCH DERMATOL, V127, P536, DOI 10.1001/archderm.127.4.536
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Merzon E, 2020, FEBS J, V287, P3693, DOI 10.1111/febs.15495
   Mitchell F., 2020, LANCET DIABETES ENDO
   Nguyen NL, 2015, ASTHMA RES PRACT, V1
   Panarese A, 2020, ALIMENT PHARM THER, V51, P993, DOI 10.1111/apt.15752
   Raisi-Estabragh Z, 2020, J PUBLIC HEALTH-UK, V42, P451, DOI 10.1093/pubmed/fdaa095
   Rhodes JM, 2020, J INTERN MED, DOI 10.1111/joim.13149
   Robertsen S, 2014, PUBLIC HEALTH NUTR, V17, P780, DOI 10.1017/S1368980013001134
   Robien K, 2013, NUTR CLIN PRACT, V28, P194, DOI 10.1177/0884533612467824
   Sly LM, 2001, J BIOL CHEM, V276, P35482, DOI 10.1074/jbc.M102876200
   Verweij Paul E, 2020, Lancet Microbe, V1, pe53, DOI 10.1016/S2666-5247(20)30027-6
   Wu D, 2020, J MICROBIOL IMMUNOL
   Zittermann A, 2016, EUR J MED RES, V21, DOI 10.1186/s40001-016-0208-y
NR 35
TC 0
Z9 0
U1 5
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD SEP
PY 2020
VL 16
IS 9
AR e1008874
DI 10.1371/journal.ppat.1008874
PG 6
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA NU7KZ
UT WOS:000573820300003
PM 32946517
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Attanasi, M
   Pasini, S
   Caronni, A
   Pellegrino, GM
   Faverio, P
   Di Pillo, S
   Cimino, MM
   Cipolla, G
   Chiarelli, F
   Centanni, S
   Papa, GFS
AF Attanasi, Marina
   Pasini, Simone
   Caronni, Antonio
   Pellegrino, Giulia Michela
   Faverio, Paola
   Di Pillo, Sabrina
   Cimino, Matteo Maria
   Cipolla, Giuseppe
   Chiarelli, Francesco
   Centanni, Stefano
   Papa, Giuseppe Francesco Sferrazza
CA Collaborators RECOVER Investigator
TI Inpatient Care during the COVID-19 Pandemic: A Survey of Italian
   Physicians
SO RESPIRATION
LA English
DT Article
DE COVID-19; Acute respiratory failure; Pandemic; Pneumonia; Mechanical
   ventilation; Rehabilitation; Steroid; Pandemic
ID ULTRASOUND; LUNG
AB Background:Coronavirus disease 2019 (COVID-19) is a potentially fatal disease that is of great global public health concern.Objective:We explored the clinical management of inpatients with COVID-19 in Italy.Methods:A self-administered survey was sent by email to Italian physicians caring for adult patients with COVID-19. A panel of experts was selected according to their clinical curricula and their responses were analyzed.Results:A total of 1,215 physicians completed the survey questionnaire (17.4% response rate). Of these, 188 (15.5%) were COVID-19 experts. Chest computed tomography was the most used method to detect and monitor COVID-19 pneumonia. Most of the experts managed acute respiratory failure with CPAP (56.4%), high flow nasal cannula (18.6%), and non-invasive mechanical ventilation (8%), while an intensivist referral for early intubation was requested in 17% of the cases. Hydroxychloroquine was prescribed as an antiviral in 90% of cases, both as monotherapy (11.7%), and combined with protease inhibitors (43.6%) or azithromycin (36.2%). The experts unanimously prescribed low-molecular-weight heparin to patients with severe COVID-19 pneumonia, and half of them (51.6%) used a dose higher than standard. The respiratory burden in patients who survived the acute phase was estimated as relevant in 28.2% of the cases, modest in 39.4%, and negligible in 9%.Conclusions:In our survey some major topics, such as the role of non-invasive respiratory support and drug treatments, show disagreement between experts, likely reflecting the absence of high-quality evidence studies. Considering the significant respiratory sequelae reported following COVID-19, proper respiratory and physical therapy programs should be promptly made available.
C1 [Attanasi, Marina; Di Pillo, Sabrina; Chiarelli, Francesco] Univ G dAnnunzio, Res Ctr Excellence Aging, Dept Pediat, Pediat Allergy & Pulmonol Unit, Chieti, Italy.
   [Pasini, Simone] ASST Lodi, Internal Med Unit, Osped Maggiore Lodi, UOC Med, Lodi, Italy.
   [Caronni, Antonio] IRCCS Fdn Don Carlo Gnocchi Onlus, UO Recupero & Rieduc Funz, Milan, Italy.
   [Pellegrino, Giulia Michela; Centanni, Stefano; Papa, Giuseppe Francesco Sferrazza] Univ Milan, Dipartimento Sci Salute, Via Rudini 8, IT-20146 Milan, Italy.
   [Pellegrino, Giulia Michela; Papa, Giuseppe Francesco Sferrazza] Casa Cura Policlin, Dept Neurorehabil Sci, Milan, Italy.
   [Faverio, Paola] Univ Milano Bicocca, Sch Med & Surg, Monza, Italy.
   [Faverio, Paola] ASST Monza, Resp Unit, San Gerardo Hosp, Monza, Italy.
   [Cimino, Matteo Maria] Humanitas Univ, Humanitas Clin & Res Hosp Ctr, Dept Surg, Div Hepatobiliary & Gen Surg,IRCCS, Rozzano, Italy.
   [Cipolla, Giuseppe] ASST Lodi, UOC Pneumol, Lodi, Italy.
RP Papa, GFS (corresponding author), Univ Milan, Dipartimento Sci Salute, Via Rudini 8, IT-20146 Milan, Italy.
EM giuseppe.sferrazza@unimi.it
RI Papa, Giuseppe Francesco Sferrazza/ABC-5984-2020
OI Papa, Giuseppe Francesco Sferrazza/0000-0002-5245-4843; Pasini,
   Simone/0000-0002-8009-6182
FU University of Milan
FX G.F.S.P. is the recipient of a grant from the University of Milan
   (Unitech for research on COVID-19) for the RECOVER study
   (recovernet.org), a multicenter clinical registry of hospitalized
   patients affected by COVID-19. This survey stems from the expert opinion
   drawn by the analysis of the clinical features of patients and their
   hospital management, and is the result of the networking of the project.
CR [Anonymous], 2020, LANCET, V395, P311, DOI 10.1016/S0140-6736(20)30186-0
   [Anonymous], 2020, LANCET RESP MED, V2600, p[30128, 2213]
   Bai HX, 2020, RADIOLOGY, V296, pE46, DOI 10.1148/radiol.2020200823
   Beasley TM, 1995, J EXP EDUC, V64, P79, DOI 10.1080/00220973.1995.9943797
   Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0
   Burns KEA, 2008, CAN MED ASSOC J, V179, P245, DOI 10.1503/cmaj.080372
   Cunningham AC, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2818-6
   DesRoches CM, 2008, NEW ENGL J MED, V359, P50, DOI 10.1056/NEJMsa0802005
   Di Marco F, 2019, INT J CHRONIC OBSTR, V14, P353, DOI 10.2147/COPD.S176662
   Ehrmann S, 2013, INTENS CARE MED, V39, P1048, DOI 10.1007/s00134-013-2872-5
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Klok FA, 2020, THROMB RES
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mondoni M, 2016, INT J TUBERC LUNG D, V20, P1135, DOI [10.5588/ijtld.16.0379, 10.55888/ijtld.16.0379]
   Nacoti M, 2020, NEJM CATALYST, DOI [10.1056/CAT.20.0080, DOI 10.1056/CAT.20.0080, 10.1056/CAT.20.0080#]
   Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
   Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Soldati G, 2020, J ULTRAS MED, V39, P1413, DOI 10.1002/jum.15285
   Soldati G, 2020, J ULTRAS MED, V39, P1459, DOI 10.1002/jum.15284
   Sotgiu G, 2020, ALLERGY, V75, P1813, DOI 10.1111/all.14327
   Tobin MJ, 2020, AM J RESP CRIT CARE, V201, P1319, DOI 10.1164/rccm.202004-1076ED
   Wang RC, 2020, J INFECTION, V80, P354, DOI 10.1016/j.jinf.2020.01.017
   World Health Organization Regional Office for Europe, 2020, STRENGTH HLTH SYST R
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Xu J, REV RESP RES BMC
   Yoon SH, 2020, KOREAN J RADIOL, V21, P494, DOI 10.3348/kjr.2020.0132
   Zanforlin A, 2020, RESPIRATION, V99, P171, DOI 10.1159/000504632
   Zanforlin A, 2018, CHEST, V154, P357, DOI 10.1016/j.chest.2018.02.011
NR 32
TC 1
Z9 2
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0025-7931
EI 1423-0356
J9 RESPIRATION
JI Respiration
PD SEP
PY 2020
VL 99
IS 8
BP 667
EP 677
DI 10.1159/000509007
PG 11
WC Respiratory System
SC Respiratory System
GA NS9AX
UT WOS:000572548600007
PM 32756065
OA Green Published
DA 2021-01-01
ER

PT J
AU Vaysse, J
   Poli, A
AF Vaysse, Jocelyne
   Poli, Antonella
TI Jail incarceration, social sanitary confinement and ways of escape
SO ANNALES MEDICO-PSYCHOLOGIQUES
LA French
DT Article
DE Art-therapy; Dance; Imaginary; Incarceration; Pandemic; Self-esteem;
   Socialization
AB Jail incarceration and social confinement due to a sanitary stay-at-home law against the ongoing COVID-19 pandemic are compared to the introduction of dance workshops for imprisoned women charged with long sentences, then followed by an outside performance Soul Kitchen. The whole experience, organized by a famous contemporary choreographer Angelin Preljocaj, is filmed by Valerie Muller, producing Danser sa peine (To dance her sentence/her sorrow), nominated for an award. The sessions are planned: two hours and a half, 2 times a week, for four months, no technique required. A group of five women start with ordinary easy functional movements, gaining in innovative and expressive qualities, spatial perceptions, feelings and interpersonal interactions, lead by A. Preljocaj in a helpful and empathic mood. At the same time, he discovers the cooking authorization in their jail cell. The relevant results shift into a dynamic successful piece Soul Kitchen (2019) performed in town (Dance Festival in Montpellier, south of France) with dancing and cooking occurrences on stage. It makes sense, specially about self-esteem, body image and positive opinion from the audience. The women's physical and psychological states linked with a long lack of space and sensitivity... move to a better self-balance and feelings of well-being. In a similar state of mind, the French confined population - youth to elderly - try to find different and imaginative strategies at home as moving in a restrictive area, enjoying family cooking... through trainings provided by Internet, looking for reducing anxiety, depressive disorders and other social problems. A panel of situations goes from deleterious conflictual relationships, dramatic isolation, to funny and positive ones using creativeness to escape, facing the disruption of daily life. (C) 2020 Elsevier Masson SAS. All rights reserved.
C1 [Vaysse, Jocelyne] 5 Rue Foucault, F-92110 Clichy, France.
   [Poli, Antonella] 7 Rue Thorigny, Paris, France.
RP Vaysse, J (corresponding author), 5 Rue Foucault, F-92110 Clichy, France.
EM jocelynevaysse@orange.fr
CR Andrieu B., 2016, MOMENTS PHILOS
   Foucault M., 1975, SURVEILLER PUNIR NAI
   Girardin-Gantier O., 2018, COMMENT ART THERAPIE
   Poli A., 2019, CRITIQUE SOUL KITCHE
   Prinzhorn H., 1984, EXPRESSIONS FOLIE
   Vaysse J., 2014, EVOLUTIONS PSYCHOMOT, V26, P38
   Vaysse J, 2006, HIST TECHNIQUES THEO
   Vaysse J., 2020, MOUVEMENTS DANSES MO
   Watzlawick P, 1972, LOGIQUE COMMUNICATIO
NR 9
TC 0
Z9 0
U1 1
U2 1
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0003-4487
EI 1769-6631
J9 ANN MED-PSYCHOL
JI Ann. Med.-Psychol.
PD SEP
PY 2020
VL 178
IS 7
BP 743
EP 746
DI 10.1016/j.amp.2020.05.002
PG 4
WC Pharmacology & Pharmacy; Psychiatry; Psychology; Psychology,
   Multidisciplinary
SC Pharmacology & Pharmacy; Psychiatry; Psychology
GA NR2UV
UT WOS:000571419000014
PM 32836295
OA Green Published
DA 2021-01-01
ER

PT J
AU Nenchev, V
AF Nenchev, Vladislav
TI Optimal quarantine control of an infectious outbreak
SO CHAOS SOLITONS & FRACTALS
LA English
DT Article
DE Quarantine control; Constrained optimization; COVID-19
ID OPTIMAL ISOLATION POLICY
AB This paper studies the optimal control of an infectious spread based on common epidemic models with permanent immunity and no vaccine availability. Assuming limited isolation control and capacity con-straints on the number of infections, an optimal quarantine control strategy that balances between the total number of infections and the overall isolation effort is derived from necessary optimality conditions. The specific optimal policy is then obtained by optimizing the switching times of this generalized strat-egy. In the case of a newly emerged disease, these results can be used in a data-driven receding horizon manner to improve actions as more data becomes available.
   The proposed approach is applied to publicly available data from the outbreak of SARS-CoV-2 in Germany. In particular, for minimizing the total number of infections or the number of isolated individuals, the simulations indicate that a sufficiently delayed and controlled release of the lock-down are optimal for overcoming the outbreak. The approach can support public health authorities to plan quarantine control policies. (c) 2020 Elsevier Ltd. All rights reserved.
EM vladislav.nenchev@gmail.com
CR ABAKUKS A, 1973, J APPL PROBAB, V10, P247, DOI 10.2307/3212343
   An der Heiden M., 2020, MODELLIERUNG BEISPIE, DOI [10.25646/6571.2, DOI 10.25646/6571.2]
   ANDERSON R M, 1991
   Bolzoni L, 2017, MATH BIOSCI, V292, P86, DOI 10.1016/j.mbs.2017.07.011
   Clancy D, 2005, APPL MATH COMPUT, V163, P1109, DOI 10.1016/j.amc.2004.06.028
   Dandekar R, 2020, QUANTIFYING EFFECT Q
   Deutsche Krankenhausgesellschaft, FAKT INF 2020 REP
   Donsimoni J.R., 2020, PROJECTING SPREAD CO, DOI [10.1101/2020.03.26.20044214, DOI 10.1101/2020.03.26.20044214]
   Fang H, 2006, 27 IEEE ANN C ENG ME, P7470
   Hansen E, 2011, J MATH BIOL, V62, P423, DOI 10.1007/s00285-010-0341-0
   HARTL RF, 1995, SIAM REV, V37, P181, DOI 10.1137/1037043
   Jacobsen EW, 2011, J PROCESS CONTR, V21, P1517, DOI 10.1016/j.jprocont.2011.05.009
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Ledzewicz U, 2004, IEEE DECIS CONTR P, P923, DOI 10.1109/CDC.2004.1428803
   Maier BF, 2020, SCIENCE, V368, P742, DOI 10.1126/science.abb4557
   Maurer H, 2005, P 44 IEEE C DEC CONT
   Read J., 2020, NOVEL CORONA VIRUS 2
   Saito MM, 2013, MATH BIOSCI, V246, P47, DOI 10.1016/j.mbs.2013.08.009
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
   WICKWIRE K H, 1975, Mathematical Biosciences, V26, P325, DOI 10.1016/0025-5564(75)90020-6
   Wu JT, 2020, LANCET, V395, P689, DOI 10.1016/S0140-6736(20)30260-9
   Xue L, 2020, MATH BIOSCI, V326, DOI 10.1016/j.mbs.2020.108391
   Yan L, 2020, PREDICTION CRITICALI
   Yousefpour A, 2020, CHAOS SOLITON FRACT, V136, DOI 10.1016/j.chaos.2020.109883
   Zhang Y., 2020, STRATEGIC RELEASE LO
NR 25
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0779
EI 1873-2887
J9 CHAOS SOLITON FRACT
JI Chaos Solitons Fractals
PD SEP
PY 2020
VL 138
AR 110139
DI 10.1016/j.chaos.2020.110139
PG 7
WC Mathematics, Interdisciplinary Applications; Physics, Multidisciplinary;
   Physics, Mathematical
SC Mathematics; Physics
GA NR7LY
UT WOS:000571743400003
PM 32834584
OA Green Published
DA 2021-01-01
ER

PT J
AU Pietrantonio, F
   Morano, F
   Niger, M
   Corallo, S
   Antista, M
   Raimondi, A
   Prisciandaro, M
   Pagani, F
   Prinzi, N
   Nichetti, F
   Randon, G
   Torchio, M
   Corti, F
   Ambrosini, M
   Palermo, F
   Palazzo, M
   Biamonte, L
   Platania, M
   Sposito, C
   Cosimelli, M
   Mazzaferro, V
   Pusceddu, S
   Cremolini, C
   de Braud, F
   Di Bartolomeo, M
AF Pietrantonio, Filippo
   Morano, Federica
   Niger, Monica
   Corallo, Salvatore
   Antista, Maria
   Raimondi, Alessandra
   Prisciandaro, Michele
   Pagani, Filippo
   Prinzi, Natalie
   Nichetti, Federico
   Randon, Giovanni
   Torchio, Martina
   Corti, Francesca
   Ambrosini, Margherita
   Palermo, Federica
   Palazzo, Michele
   Biamonte, Lavinia
   Platania, Marco
   Sposito, Carlo
   Cosimelli, Maurizio
   Mazzaferro, Vincenzo
   Pusceddu, Sara
   Cremolini, Chiara
   de Braud, Filippo
   Di Bartolomeo, Maria
TI Systemic Treatment of Patients With Gastrointestinal Cancers During the
   COVID-19 Outbreak: COVID-19-adapted Recommendations of the National
   Cancer Institute of Milan
SO CLINICAL COLORECTAL CANCER
LA English
DT Article
DE Colorectal cancer; Gastric cancer; Hepatobiliary cancer; Pancreatic
   cancer; SARS-CoV-2 pandemic
ID METASTATIC COLORECTAL-CANCER; CAPECITABINE PLUS OXALIPLATIN; RANDOMIZED
   PHASE-III; OPEN-LABEL; 2ND-LINE CHEMOTHERAPY; GASTRIC-CANCER;
   DOUBLE-BLIND; HEPATOCELLULAR-CARCINOMA; PANCREATIC-CANCER; 1ST-LINE
   THERAPY
AB The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak poses a major challenge in the treatment decision-making of patients with cancer, who may be at higher risk of developing a severe and deadly SARS-CoV-2 infection compared with the general population. The healthcare emergency is forcing the reshaping of the daily assessment between risks and benefits expected from the administration of immune-suppressive and potentially toxic treatments. To guide our clinical decisions at the National Cancer Institute of Milan (Lombardy region, the epicenter of the outbreak in Italy), we formulated Coronavirus-adapted institutional recommendations for the systemic treatment of patients with gastrointestinal cancers. Here, we describe how our daily clinical practice has changed due to the pandemic outbreak, with the aim of providing useful suggestions for physicians that are facing the same challenges worldwide. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Pietrantonio, Filippo; Sposito, Carlo; Mazzaferro, Vincenzo; de Braud, Filippo] Univ Milan, Oncol & Hematooncol Dept, Via Giacomo Venezian 1, I-20133 Milan, Italy.
   [Pietrantonio, Filippo; Morano, Federica; Niger, Monica; Corallo, Salvatore; Antista, Maria; Raimondi, Alessandra; Prisciandaro, Michele; Pagani, Filippo; Prinzi, Natalie; Nichetti, Federico; Randon, Giovanni; Torchio, Martina; Corti, Francesca; Ambrosini, Margherita; Palermo, Federica; Palazzo, Michele; Biamonte, Lavinia; Platania, Marco; Pusceddu, Sara; de Braud, Filippo; Di Bartolomeo, Maria] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Via Giacomo Venezian 1, I-20133 Milan, Italy.
   [Sposito, Carlo; Mazzaferro, Vincenzo] Fdn IRCCS Ist Nazl Tumori, Hepatobiliary Pancreat Surg & Liver Transplantat, Milan, Italy.
   [Cosimelli, Maurizio] Fdn IRCCS Ist Nazl Tumori, Colorectal Canc Surg Dept, Milan, Italy.
   [Cremolini, Chiara] Univ Hosp Pisa, Dept Oncol, Pisa, Italy.
   [Cremolini, Chiara] Univ Pisa, Dept Translat Res & New Technol Med, Pisa, Italy.
RP Pietrantonio, F (corresponding author), Univ Milan, Oncol & Hematooncol Dept, Via Giacomo Venezian 1, I-20133 Milan, Italy.; Pietrantonio, F (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Via Giacomo Venezian 1, I-20133 Milan, Italy.
EM filippo.pietrantonio@istitutotumori.mi.it
RI ; Di Bartolomeo, Maria/D-1655-2017
OI Nichetti, Federico/0000-0001-8044-4207; Niger,
   Monica/0000-0002-9055-5338; Di Bartolomeo, Maria/0000-0002-7954-6609
CR Abou-Alfa GK, 2018, NEW ENGL J MED, V379, P54, DOI 10.1056/NEJMoa1717002
   AJANI JA, 1989, AM J MED, V87, P221
   Al-Batran SE, 2008, J CLIN ONCOL, V26, P1435, DOI 10.1200/JCO.2007.13.9378
   Al-Batran SE, 2019, LANCET, V393, P1948, DOI 10.1016/S0140-6736(18)32557-1
   Aparicio T, 2018, J CLIN ONCOL, V36, P674, DOI 10.1200/JCO.2017.75.2931
   Ay C, 2017, THROMB HAEMOSTASIS, V117, P219, DOI 10.1160/TH16-08-0615
   Bang YJ, 2010, LANCET, V376, P1302
   Bartelink H, 1997, J CLIN ONCOL, V15, P2040, DOI 10.1200/JCO.1997.15.5.2040
   Bekaii-Saab TS, 2019, LANCET ONCOL, V20, P1070, DOI 10.1016/S1470-2045(19)30272-4
   Bruix J, 2017, LANCET, V389, P56, DOI 10.1016/S0140-6736(16)32453-9
   Catalano V, 2008, BRIT J CANCER, V99, P1402, DOI 10.1038/sj.bjc.6604732
   Conroy T, 2018, NEW ENGL J MED, V379, P2395, DOI 10.1056/NEJMoa1809775
   Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923
   Cremolini C, 2020, LANCET ONCOL, V21, P497, DOI 10.1016/S1470-2045(19)30862-9
   Cremolini C, 2018, JAMA ONCOL, V4, P529, DOI 10.1001/jamaoncol.2017.5314
   Cunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149
   Diaz JA, 2017, J ONCOL PRACT, V13, P44, DOI 10.1200/JOP.2016.010843
   Falvella FS, 2015, BRIT J CLIN PHARMACO, V80, P581, DOI 10.1111/bcp.12631
   Ford HER, 2014, LANCET ONCOL, V15, P78, DOI 10.1016/S1470-2045(13)70549-7
   Fuchs CS, 2003, J CLIN ONCOL, V21, P807, DOI 10.1200/JCO.2003.08.058
   Garcia-Carbonero R, 2016, NEUROENDOCRINOLOGY, V103, P186, DOI 10.1159/000443172
   Gill S, 2016, J CLIN ONCOL, V34, P3914, DOI 10.1200/JCO.2016.68.5776
   Grothey A, 2018, NEW ENGL J MED, V378, P1177, DOI 10.1056/NEJMoa1713709
   Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017
   Hadoux J, 2015, ENDOCR-RELAT CANCER, V22, P289, DOI 10.1530/ERC-15-0075
   Hanna TP, 2020, NAT REV CLIN ONCOL, V17, P268, DOI 10.1038/s41571-020-0362-6
   Hentic O, 2012, ENDOCR-RELAT CANCER, V19, P751, DOI 10.1530/ERC-12-0002
   Hyder O, 2013, ANN SURG ONCOL, V20, P3779, DOI 10.1245/s10434-013-3127-y
   Kattan MW, 2003, J CLIN ONCOL, V21, P3647, DOI 10.1200/JCO.2003.01.240
   Kim ST, 2019, ANN ONCOL, V30, P788, DOI 10.1093/annonc/mdz058
   Kokkali S, 2018, Ann Oncol, V29 Suppl 5, pv39, DOI 10.1093/annonc/mdy151.141
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Kraaijpoel N, 2018, THROMB HAEMOSTASIS, V118, P1439, DOI 10.1055/s-0038-1667001
   Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1
   Lala M, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.3062
   Lamarca A, 2014, ANN ONCOL, V25, P2328, DOI 10.1093/annonc/mdu162
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Li J, 2010, EXPERT OPIN DRUG SAF, V9, P207, DOI 10.1517/14740330903555181
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lowery MA, 2019, LANCET GASTROENTEROL, V4, P711, DOI 10.1016/S2468-1253(19)30189-X
   Marmorino F, 2019, ANN ONCOL, V30, P1969, DOI 10.1093/annonc/mdz403
   Mazzaferro V, 2019, BRIT J CANCER, V120, P165, DOI 10.1038/s41416-018-0334-0
   National Institute for Health Care and Excellence, COR COVID 19
   Noh SH, 2014, LANCET ONCOL, V15, P1389, DOI 10.1016/S1470-2045(14)70473-5
   Oehler-Jaenne C, 2008, J CLIN ONCOL, V26, P2550, DOI 10.1200/JCO.2007.15.2348
   Oliveira Suilane Coelho Ribeiro, 2016, J Gastrointest Cancer, V47, P75, DOI 10.1007/s12029-015-9790-4
   Pelzer U, 2011, EUR J CANCER, V47, P1676, DOI 10.1016/j.ejca.2011.04.011
   Pietrantonio F, 2017, ANN ONCOL, V28, P555, DOI 10.1093/annonc/mdw627
   Pietrantonio F, 2019, J CLIN ONCOL, V37, P3392, DOI 10.1200/JCO.19.01124
   Pietrantonio F, 2019, JAMA ONCOL, V5, P1268, DOI 10.1001/jamaoncol.2019.1467
   Pietrantonio F, 2018, ONCOLOGY-BASEL, V95, P344, DOI 10.1159/000491753
   Primrose JN, 2019, LANCET ONCOL, V20, P663, DOI 10.1016/S1470-2045(18)30915-X
   Pusceddu S, 2019, CANCERS, V11, DOI 10.3390/cancers11040484
   Rao S, 2018, ANN ONCOL, V29
   Raymond E, 2011, NEW ENGL J MED, V364, P501, DOI 10.1056/NEJMoa1003825
   Rivera F, 2019, CANCER CHEMOTH PHARM, V83, P1175, DOI 10.1007/s00280-019-03820-7
   Rogers JE, 2020, J GASTROINTEST ONCOL, V11, P55, DOI 10.21037/jgo.2019.10.05
   Rogers JE, 2019, ONCOLOGY-BASEL, V96, P252, DOI 10.1159/000496978
   Ryu MH, 2015, EUR J CANCER, V51, P482, DOI 10.1016/j.ejca.2014.12.015
   Simkens LHJ, 2015, LANCET, V385, P1843, DOI 10.1016/S0140-6736(14)62004-3
   Solinas G, 2017, J VASC ACCESS, V18, P325, DOI 10.5301/jva.5000740
   Sorbye H, 2013, ANN ONCOL, V24, P152, DOI 10.1093/annonc/mds276
   Stein A, 2016, CLIN COLORECTAL CANC, V15, pE29, DOI 10.1016/j.clcc.2015.12.005
   Strosberg J, 2017, NEW ENGL J MED, V376, P125, DOI 10.1056/NEJMoa1607427
   Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
   Thuss-Patience PC, 2011, EUR J CANCER, V47, P2306, DOI 10.1016/j.ejca.2011.06.002
   Tong HX, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26811-9
   Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369
   Wagner AD, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub3
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang-Gillam A, 2016, LANCET, V387, P545, DOI 10.1016/S0140-6736(15)00986-1
   Welin S, 2011, CANCER-AM CANCER SOC, V117, P4617, DOI 10.1002/cncr.26124
   Wilke H, 2014, LANCET ONCOL, V15, P1224, DOI 10.1016/S1470-2045(14)70420-6
   Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290
   Yu J, 2020, JAMA ONCOL, V6, P1108, DOI 10.1001/jamaoncol.2020.0980
NR 77
TC 4
Z9 4
U1 0
U2 0
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1533-0028
EI 1938-0674
J9 CLIN COLORECTAL CANC
JI Clin. Colorectal Canc.
PD SEP
PY 2020
VL 19
IS 3
BP 156
EP 164
DI 10.1016/j.clcc.2020.05.004
PG 9
WC Oncology
SC Oncology
GA NR3UU
UT WOS:000571489500018
PM 32513593
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Burdick, H
   Lam, C
   Mataraso, S
   Siefkas, A
   Braden, G
   Dellinger, RP
   McCoy, A
   Vincent, JL
   Green-Saxena, A
   Barnes, G
   Hoffman, J
   Calvert, J
   Pellegrini, E
   Das, R
AF Burdick, Hoyt
   Lam, Carson
   Mataraso, Samson
   Siefkas, Anna
   Braden, Gregory
   Dellinger, R. Phillip
   McCoy, Andrea
   Vincent, Jean-Louis
   Green-Saxena, Abigail
   Barnes, Gina
   Hoffman, Jana
   Calvert, Jacob
   Pellegrini, Emily
   Das, Ritankar
TI Prediction of respiratory decompensation in Covid-19 patients using
   machine learning: The READY trial
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE Machine learning; COVID-19; Mechanical ventilation; Prediction
ID TRACHEAL INTUBATION; LUNG INJURY; MANAGEMENT; FAILURE
AB Background: Currently, physicians are limited in their ability to provide an accurate prognosis for COVID-19 positive patients. Existing scoring systems have been ineffective for identifying patient decompensation. Machine learning (ML) may offer an alternative strategy. A prospectively validated method to predict the need for ventilation in COVID-19 patients is essential to help triage patients, allocate resources, and prevent emergency intubations and their associated risks.
   Methods: In a multicenter clinical trial, we evaluated the performance of a machine learning algorithm for prediction of invasive mechanical ventilation of COVID-19 patients within 24 h of an initial encounter. We enrolled patients with a COVID-19 diagnosis who were admitted to five United States health systems between March 24 and May 4, 2020.
   Results: 197 patients were enrolled in the REspirAtory Decompensation and model for the triage of covid-19 patients: a prospective studY (READY) clinical trial. The algorithm had a higher diagnostic odds ratio (DOR, 12.58) for predicting ventilation than a comparator early warning system, the Modified Early Warning Score (MEWS). The algorithm also achieved significantly higher sensitivity (0.90) than MEWS, which achieved a sensitivity of 0.78, while maintaining a higher specificity (p < 0.05).
   Conclusions: In the first clinical trial of a machine learning algorithm for ventilation needs among COVID-19 patients, the algorithm demonstrated accurate prediction of the need for mechanical ventilation within 24 h. This algorithm may help care teams effectively triage patients and allocate resources. Further, the algorithm is capable of accurately identifying 16% more patients than a widely used scoring system while minimizing false positive results.
C1 [Burdick, Hoyt] Cabell Huntington Hosp, Huntington, WV USA.
   [Burdick, Hoyt] Marshall Univ, Sch Med, Huntington, WV USA.
   [Lam, Carson; Mataraso, Samson; Siefkas, Anna; Green-Saxena, Abigail; Barnes, Gina; Hoffman, Jana; Calvert, Jacob; Pellegrini, Emily; Das, Ritankar] Dascena Inc, San Francisco, CA USA.
   [Braden, Gregory] Kidney Care & Transplant Associates New England, Springfield, MA USA.
   [Dellinger, R. Phillip] Rowan Univ, Cooper Med Sch, Cooper Univ Hosp, Div Crit Care Med, Camden, NJ USA.
   [McCoy, Andrea] Cape Reg Med Ctr, Cape May Court House, NJ USA.
   [Vincent, Jean-Louis] Univ Libre Bruxelles, Erasme Univ Hosp, Dept Intens Care, Brussels, Belgium.
RP Siefkas, A (corresponding author), POB 156572, San Francisco, CA 94115 USA.
EM anna@dascena.com
OI Lam, Carson/0000-0002-8255-4423
CR Ahsan W, 2020, DRUG DISCOV THER, V14, P67, DOI 10.5582/ddt.2020.03008
   Avellar SA, 2017, EVALUATION REV, V41, P283, DOI 10.1177/0193841X16665199
   Brochard L, 2017, AM J RESP CRIT CARE, V195, P438, DOI 10.1164/rccm.201605-1081CP
   Calvert JS, 2017, J AM MED INFORM ASSN, V24, P24, DOI 10.1093/jamia/ocw014
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Che ZP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24271-9
   Chen TQ, 2016, KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P785, DOI 10.1145/2939672.2939785
   Cook TM, 2011, BRIT J ANAESTH, V106, P632, DOI 10.1093/bja/aer059
   Divatia JV, 2011, INDIAN J ANAESTH, V55, P470, DOI 10.4103/0019-5049.89872
   Fong S.J., 2020, ARXIV200310776
   Fong SJ, 2020, APPL SOFT COMPUT, V93, DOI 10.1016/j.asoc.2020.106282
   Grieco DL, 2019, MINERVA ANESTESIOL, V85, P1014, DOI 10.23736/S0375-9393.19.13418-9
   Hartman ME, 2020, ASAIO J, V66, P603, DOI 10.1097/MAT.0000000000001177
   Higgs A, 2018, BRIT J ANAESTH, V120, P323, DOI 10.1016/j.bja.2017.10.021
   Hu H, 2020, ACAD EMERG MED, DOI 10.1111/acem.13992
   Jacobs JP, 2020, ASAIO J, V66, P722, DOI 10.1097/MAT.0000000000001185
   Kissler SM, 2020, SCIENCE
   Lalkhen AG, 2008, BJA EDUC, V8, P221, DOI 10.1093/bjaceaccp/mkn041
   Leviton LC, 2017, ANNU REV PUBL HEALTH, V38, P371, DOI 10.1146/annurev-publhealth-031816-044509
   Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033
   Marini JJ, 2020, JAMA-J AM MED ASSOC, V323, P2329, DOI 10.1001/jama.2020.6825
   Moghadas SM, 2020, P NATL ACAD SCI USA, V117, P9122, DOI 10.1073/pnas.2004064117
   Mohamadlou H, 2020, HEALTH INFORM J, V26, P1912, DOI 10.1177/1460458219894494
   Mohamadlou Hamid, 2018, Can J Kidney Health Dis, V5, p2054358118776326, DOI 10.1177/2054358118776326
   Natt BS, 2016, BRIT J ANAESTH, V117, P60, DOI 10.1093/bja/aew061
   Pathak Y., 2020, DEEP TRANSFER LEARNI
   Shimabukuro DW, 2017, BMJ OPEN RESPIR RES, V4, DOI 10.1136/bmjresp-2017-000234
   Shinde GR, 2020, COMPUT SCI, V1, P197, DOI [10.1007/s42979-020-00209-9, DOI 10.1007/S42979-020-00209-9]
   Singh D, 2020, EUR J CLIN MICROBIOL, V39, P1379, DOI 10.1007/s10096-020-03901-z
   Singh K., 2020, VALIDATING WIDELY IM
   Smith M E Beth, 2014, Ann Am Thorac Soc, V11, P1454, DOI 10.1513/AnnalsATS.201403-102OC
   Su Y, 2020, J INFECTION, V81, P664, DOI 10.1016/j.jinf.2020.05.007
   Subbe CP, 2006, EMERG MED J, V23, P841, DOI 10.1136/emj.2006.035816
   Tofthagen Cindy, 2012, J Adv Pract Oncol, V3, P181
   Trochim W., 2005, RES METHODS CONCISE
   Vaid A, 2020, MACHINE LEARNING PRE, DOI [10.1101/2020.04.26.20073411, DOI 10.1101/2020.04.26.20073411]
   Yoon U, 2019, BMC ANESTHESIOL, V19, DOI 10.1186/s12871-019-0894-4
   Zou XJ, 2020, CRIT CARE MED, V48, pE657, DOI 10.1097/CCM.0000000000004411
NR 38
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD SEP
PY 2020
VL 124
AR 103949
DI 10.1016/j.compbiomed.2020.103949
PG 6
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA NR9OD
UT WOS:000571891000007
PM 32798922
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Rakib, A
   Sami, SA
   Mimi, NJ
   Chowdhury, MM
   Eva, TA
   Nainu, F
   Paul, A
   Shahriar, A
   Tareq, A
   Emon, NU
   Chakraborty, S
   Shil, S
   Mily, SJ
   Ben Hadda, T
   Almalki, FA
   Bin Emran, T
AF Rakib, Ahmed
   Sami, Saad Ahmed
   Mimi, Nusrat Jahan
   Chowdhury, Md Mustafiz
   Eva, Taslima Akter
   Nainu, Firzan
   Paul, Arkajyoti
   Shahriar, Asif
   Tareq, Abu Montakim
   Emon, Nazim Uddin
   Chakraborty, Sajal
   Shil, Sagar
   Mily, Sabrina Jahan
   Ben Hadda, Taibi
   Almalki, Faisal A.
   Bin Emran, Talha
TI Immunoinformatics-guided design of an epitope-based vaccine against
   severe acute respiratory syndrome coronavirus 2 spike glycoprotein
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE COVID-19; SARS-CoV-2; Spike glycoprotein; Immunoinformatics; Epitope
ID RECEPTOR-BINDING DOMAIN; CELL; PROTEIN; PREDICTION; VIRUS; PNEUMONIA;
   ANTIBODIES; RESPONSES; SELECTION; CHINA
AB Aims: With a large number of fatalities, coronavirus disease-2019 (COVID-19) has greatly affected human health worldwide. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus that causes COVID-19. The World Health Organization has declared a global pandemic of this contagious disease. Researchers across the world are collaborating in a quest for remedies to combat this deadly virus. It has recently been demonstrated that the spike glycoprotein (SGP) of SARS-CoV-2 is the mediator by which the virus enters host cells.
   Main methods: Our group comprehensibly analyzed the SGP of SARS-CoV-2 through multiple sequence analysis and a phylogenetic analysis. We predicted the strongest immunogenic epitopes of the SGP for both B cells and T cells.
   Key findings: We focused on predicting peptides that would bind major histocompatibility complex class I. Two optimal epitopes were identified, WTAGAAAYY and GAAAYYVGY. They interact with the HLA-B*15:01 allele, which was further validated by molecular docking simulation. This study also found that the selected epitopes are able to be recognized in a large percentage of the world's population. Furthermore, we predicted CD4(+) T-cell epitopes and B-cell epitopes.
   Significance: Our study provides a strong basis for designing vaccine candidates against SARS-CoV-2. However, laboratory work is required to validate our theoretical results, which would lay the foundation for the appropriate vaccine manufacturing and testing processes.
C1 [Rakib, Ahmed; Sami, Saad Ahmed; Mimi, Nusrat Jahan; Chowdhury, Md Mustafiz; Eva, Taslima Akter] Univ Chittagong, Fac Biol Sci, Dept Pharm, Chittagong 4331, Bangladesh.
   [Nainu, Firzan] Hasanuddin Univ, Fac Pharm, Kota Makassar 90245, Sulawesi Selata, Indonesia.
   [Paul, Arkajyoti] GUSTO A Res Grp, Drug Discovery, Chittagong 4203, Bangladesh.
   [Paul, Arkajyoti; Chakraborty, Sajal; Shil, Sagar; Bin Emran, Talha] BGC Trust Univ Bangladesh, Dept Pharm, Chittagong 4381, Bangladesh.
   [Shahriar, Asif] Stamford Univ Bangladesh, Dept Microbiol, 51 Siddeswari Rd, Dhaka 1217, Bangladesh.
   [Tareq, Abu Montakim; Emon, Nazim Uddin] Int Islamic Univ Chittagong, Dept Pharm, Chittagong 4318, Bangladesh.
   [Mily, Sabrina Jahan] Banshkhali Upazila Hlth Complex, Dept Gynaecol & Obstet, Chittagong 4390, Bangladesh.
   [Ben Hadda, Taibi] Univ Mohammed First, Fac Sci, Lab Appl Chem & Environm, BP 524, Oujda 60000, Morocco.
   [Ben Hadda, Taibi; Almalki, Faisal A.] Umm Al Qura Univ, Fac Pharm, Dept Pharmaceut Chem, Makkah El Mukarramah 21955, Saudi Arabia.
RP Bin Emran, T (corresponding author), BGC Trust Univ Bangladesh, Dept Pharm, Chittagong 4381, Bangladesh.; Ben Hadda, T (corresponding author), Univ Mohammed First, Fac Sci, Lab Appl Chem & Environm, BP 524, Oujda 60000, Morocco.
EM taibi.ben.hadda@gmail.com; talhabmb@bgctub.ac.bd
RI Paul, Arkajyoti/N-5429-2016; , Abu Montakim Tareq/AAM-4692-2020; Emon,
   Nazim Uddin/AAV-6026-2020; Nainu, Firzan/E-2447-2017; Bin Emran,
   Talha/P-9184-2016
OI Paul, Arkajyoti/0000-0002-2767-2646; , Abu Montakim
   Tareq/0000-0003-2704-7610; Emon, Nazim Uddin/0000-0001-7567-4796; Nainu,
   Firzan/0000-0003-0989-4023; Bin Emran, Talha/0000-0003-3188-2272; JAHAN
   MILY, SABRINA/0000-0002-1840-7613; Rakib, Ahmed/0000-0003-3335-0368
FU Deanship of Scientific Research at Umm Al-Qura University
   [18-MED-1-02-0003]
FX The authors would like to thank Cambridge Proofreading & Editing LLC.
   (https://proofreading.org/) for editing a draft of this manuscript.
   Prof. T. Ben Hadda acknowledges the offer of the bioinformatics
   facilities by Prof Y. Zarhloule even in this critical situation of
   COVID-19, and the financially support by the Deanship of Scientific
   Research at Umm Al-Qura University to Prof. F.A. Almalki
   (18-MED-1-02-0003).
CR Abdelmageed MI, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2683286
   Peele KA, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1770127
   Ahmed S, 2019, CLIN PHYTOSCIENCE, V5, P1, DOI [DOI 10.1186/S40816-019-0127-X, 10.1186/s40816-019-0127-x]
   AHMED SF, 2020, PRELIMINARY IDENTIFI, V12, DOI DOI 10.3390/V12030254
   Alam A, 2016, IMMUNOLOGY, V149, P386, DOI 10.1111/imm.12656
   Alberts B, 2002, MOL BIOL CELL
   Bateman A, 2017, NUCLEIC ACIDS RES, V45, pD158, DOI 10.1093/nar/gkw1099
   Bevan MJ, 2004, NAT REV IMMUNOL, V4, P595, DOI 10.1038/nri1413
   Bhattacharya M, 2020, J MED VIROL, V92, P618, DOI 10.1002/jmv.25736
   Briney B, 2016, CELL, V166, P1459, DOI 10.1016/j.cell.2016.08.005
   Bugembe DL, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-4876-4
   Bui HH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-361
   Bui HH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-153
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chiou SS, 2012, J GEN VIROL, V93, P1185, DOI 10.1099/vir.0.040238-0
   CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343
   Christie JML, 1999, HEPATOLOGY, V30, P1037, DOI 10.1002/hep.510300403
   Dallakyan S., 2008, PYRX PYTHON PRESCRIP, P2010
   Dalsass M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00113
   Dimitrov I, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S6-S4
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Du L., 2013, PLOS ONE, V8
   Du LY, 2009, BIOCHEM BIOPH RES CO, V384, P486, DOI 10.1016/j.bbrc.2009.05.003
   EMINI EA, 1985, J VIROL, V55, P836, DOI 10.1128/JVI.55.3.836-839.1985
   Giguere S, 2013, J IMMUNOL METHODS, V400, P30, DOI 10.1016/j.jim.2013.10.003
   Gralinski LE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020135
   Greenbaum J, 2011, IMMUNOGENETICS, V63, P325, DOI 10.1007/s00251-011-0513-0
   Grifoni A, 2020, CELL HOST MICROBE
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Hasan MM, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-S4-S3
   He YX, 2004, BIOCHEM BIOPH RES CO, V324, P773, DOI 10.1016/j.bbrc.2004.09.106
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hughes EE, 1995, VACCINE, V13, P1750, DOI 10.1016/0264-410X(95)00166-X
   Kallinich T, 2007, EUR RESPIR J, V29, P1246, DOI 10.1183/09031936.00094306
   Kanne JP, 2020, FINDINGS 2019 NOVEL
   KARPLUS PA, 1985, NATURWISSENSCHAFTEN, V72, P212, DOI 10.1007/BF01195768
   Khan MK, 2014, MOL IMMUNOL, V61, P16, DOI 10.1016/j.molimm.2014.04.009
   Khanolkar A, 2007, IMMUNOL RES, V39, P94, DOI 10.1007/s12026-007-0081-4
   KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q
   Larsen Jens Erik Pontoppidan, 2006, Immunome Res, V2, P2, DOI 10.1186/1745-7580-2-2
   Lee C.H., 2020, F1000RESEARCH
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Li WZ, 2015, NUCLEIC ACIDS RES, V43, pW580, DOI 10.1093/nar/gkv279
   Liu J, 2011, EXP BIOL MED, V236, P253, DOI 10.1258/ebm.2010.010278
   Maupetit J, 2009, NUCLEIC ACIDS RES, V37, pW498, DOI 10.1093/nar/gkp323
   Moutaftsi M, 2006, NAT BIOTECHNOL, V24, P817, DOI 10.1038/nbt1215
   Nardin EH, 2001, J IMMUNOL, V166, P481, DOI 10.4049/jimmunol.166.1.481
   Nielsen M, 2003, PROTEIN SCI, V12, P1007, DOI 10.1110/ps.0239403
   Novy P, 2007, J IMMUNOL, V179, P8243, DOI 10.4049/jimmunol.179.12.8243
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Oleg T., 2010, J COMPUT CHEM, DOI [10.1002/jcc.21334., DOI 10.1002/JCC.21334, 10.1002/jcc.21334]
   Ong E., 2020, COVID 19 CORONAVIRUS
   Ortega JT, 2020, EXCLI J, V19, P410, DOI 10.17179/excli2020-1167
   Oyarzun P., 2013, BMC BIOINFORMATICS, V14, P1
   Patel S.K., VACCINE IS NOT TOO F
   Poland GA, 2011, OMICS, V15, P625, DOI 10.1089/omi.2011.0032
   Rakib A., 2020, EPITOPE BASED IMMUNO
   Ramaiah A, 2020, INSIGHTS CROSS SPECI
   Rosa DS, 2010, ARCH IMMUNOL THER EX, V58, P121, DOI 10.1007/s00005-010-0067-0
   Sanche S., EARLY RELEASE HIGH C, V2
   Schellekens GA, 2000, ARTHRITIS RHEUM-US, V43, P155, DOI 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3
   Shey RA, 2019, SCI REPORTS, V9, p1~18, DOI [10.1038/s41598-018-37186-2., DOI 10.1038/S41598-018-37186-2]
   Sinha SK, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1762741
   Suarez DL, 2000, DEV COMP IMMUNOL, V24, P269, DOI 10.1016/S0145-305X(99)00078-6
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   TYRRELL DA, 1966, LANCET, V1, P76
   Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006
   W.H. Organization, 2020, MENT HLTH PSYCH CONS, P2020
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang H, 2020, CELL
   Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0
   WHO, 2020, Q A COR COVID 19
   World Health Organization, 2020, COR DIS 2019 COVID 1, V72
   Wu F., 2020, COMPLETE GENOME CHAR
   Xiong C., 2020, EVOLUTION VARIATION
   Xu ZJ, 2020, GEROSCIENCE, DOI 10.1007/s11357-020-00209-w
   Yang D, 2015, VIRUS RES, V206, P120, DOI 10.1016/j.virusres.2015.02.025
   Zhang JY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020153
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu XJ, 2013, J THORAC DIS, V5, pS142, DOI 10.3978/j.issn.2072-1439.2013.06.06
NR 83
TC 3
Z9 3
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD SEP
PY 2020
VL 124
AR 103967
DI 10.1016/j.compbiomed.2020.103967
PG 16
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA NR8YM
UT WOS:000571849200001
PM 32828069
OA Green Published
DA 2021-01-01
ER

PT J
AU Vardhan, S
   Sahoo, SK
AF Vardhan, Seshu
   Sahoo, Suban K.
TI In silico ADMET and molecular docking study on searching potential
   inhibitors from limonoids and triterpenoids for COVID-19
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE Coronavirus; COVID-19; Molecular docking; ADMET; Limonoids;
   Triterpenoids
ID RESPIRATORY SYNDROME-CORONAVIRUS; PAPAIN-LIKE PROTEASE; ACID; LIMONIN;
   DOMAIN; FRUITS
AB Virtual screening of phytochemicals was performed through molecular docking, simulations, in silico ADMET and drug-likeness prediction to identify the potential hits that can inhibit the effects of SARS-CoV-2. Considering the published literature on medicinal importance, 154 phytochemicals with analogous structure from limonoids and triterpenoids were selected to search potential inhibitors for the five therapeutic protein targets of SARS-CoV-2, i. e., 3CLpro (main protease), PLpro (papain-like protease), SGp-RBD (spike glycoprotein-receptor binding domain), RdRp (RNA dependent RNA polymerase) and ACE2 (angiotensin-converting enzyme 2). The in silico computational results revealed that the phytochemicals such as glycyrrhizic acid, limonin, 7-deacetyl-7-benzoylgedunin, maslinic acid, corosolic acid, obacunone and ursolic acid were found to be effective against the target proteins of SARS-CoV-2. The protein-ligand interaction study revealed that these phytochemicals bind with the amino acid residues at the active site of the target proteins. Therefore, the core structure of these potential hits can be used for further lead optimization to design drugs for SARS-CoV-2. Also, the medicinal plants containing these phytochemicals like licorice, neem, tulsi, citrus and olives can be used to formulate suitable therapeutic approaches in traditional medicines.
C1 [Vardhan, Seshu; Sahoo, Suban K.] SV Natl Inst Technol SVNIT, Dept Appl Chem, Surat 395007, Gujarat, India.
RP Sahoo, SK (corresponding author), SV Natl Inst Technol SVNIT, Dept Appl Chem, Surat 395007, Gujarat, India.
EM sks@chem.svnit.ac.in
CR Abdelgaleil SAM, 2004, FITOTERAPIA, V75, P566, DOI 10.1016/j.fitote.2004.06.001
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Baez-Santos YM, 2014, J VIROL, V88, P12511, DOI 10.1128/JVI.01294-14
   Barretto N, 2005, J VIROL, V79, P15189, DOI 10.1128/JVI.79.24.15189-15198.2005
   Battinelli L, 2003, PLANTA MED, V69, P910, DOI 10.1055/s-2003-45099
   Miranda RNC, 2012, J ETHNOPHARMACOL, V142, P679, DOI 10.1016/j.jep.2012.05.037
   Chianese G, 2010, J NAT PROD, V73, P1448, DOI 10.1021/np100325q
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Fiore C, 2008, PHYTOTHER RES, V22, P141, DOI 10.1002/ptr.2295
   Frisch M. J., 2009, GAUSSIAN 09W REVISIO
   Fuzimoto Andrea D, 2020, J Tradit Complement Med, V10, P405, DOI 10.1016/j.jtcme.2020.05.003
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Graebin CS, 2010, J BRAZIL CHEM SOC, V21, P1595, DOI 10.1590/S0103-50532010000900002
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Guy JL, 2005, FEBS J, V272, P3512, DOI 10.1111/j.1742-4658.2005.04756.x
   Ho LTF, 2020, EUR J INTEGR MED, V36, DOI 10.1016/j.eujim.2020.101116
   Jamroz M, 2014, BIOINFORMATICS, V30, P2150, DOI 10.1093/bioinformatics/btu184
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kikuchi T, 2011, J NAT PROD, V74, P866, DOI 10.1021/np100783k
   Kilianski A, 2013, J VIROL, V87, P11955, DOI 10.1128/JVI.02105-13
   Kingston DGI, 2011, J NAT PROD, V74, P496, DOI 10.1021/np100550t
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Laura C, 2015, NEURAL REGEN RES, V10, P540, DOI 10.4103/1673-5374.155414
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li JY, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/872139
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Liu M, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104896
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Murthy KNC, 2011, FOOD CHEM TOXICOL, V49, P1616, DOI 10.1016/j.fct.2011.04.014
   Murthy KNC, 2011, J AGR FOOD CHEM, V59, P2314, DOI 10.1021/jf104498p
   Parikh NR, 2014, PHYTOCHEM REV, V13, P793, DOI 10.1007/s11101-014-9337-5
   Pillaiyar T, 2016, J MED CHEM, V59, P6595, DOI 10.1021/acs.jmedchem.5b01461
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Ramos-Hryb AB, 2017, CNS DRUGS, V31, P1029, DOI 10.1007/s40263-017-0474-4
   Rodell C., 2020, SCI TRANS MED, V12, P541
   Ryu YB, 2010, BIOORG MED CHEM LETT, V20, P1873, DOI 10.1016/j.bmcl.2010.01.152
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Singh AK, 2020, DIABETES METAB SYND, V14, P241, DOI 10.1016/j.dsx.2020.03.011
   Takagi M, 2014, CHEM BIODIVERS, V11, P451, DOI 10.1002/cbdv.201300348
   Thillainayagam M., 2018, J BIOMOL STRUCT DYN, V37
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vardhan S., 2020, ARXIV200408095
   Wang HH, 2020, EUR J CLIN MICROBIOL, V39, P1629, DOI 10.1007/s10096-020-03899-4
   World Health Organization, 2020, 165 WHO
   Wu KL, 2009, P NATL ACAD SCI USA, V106, P19970, DOI 10.1073/pnas.0908837106
   Xiao SL, 2018, MED RES REV, V38, P951, DOI 10.1002/med.21484
   Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538
   Yap WH, 2015, BIOCHEM RES INT, V2015, DOI 10.1155/2015/279356
   Yu R, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106012
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu Z, 2020, J INFECTION, V81, pE21, DOI 10.1016/j.jinf.2020.03.060
NR 54
TC 1
Z9 2
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD SEP
PY 2020
VL 124
AR 103936
DI 10.1016/j.compbiomed.2020.103936
PG 12
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA NR9EF
UT WOS:000571865200003
PM 32738628
OA Green Published
DA 2021-01-01
ER

PT J
AU Stephen-Victor, E
   Das, M
   Karnam, A
   Pitard, B
   Gautier, JF
   Bayry, J
AF Stephen-Victor, Emmanuel
   Das, Mrinmoy
   Karnam, Anupama
   Pitard, Bruno
   Gautier, Jean-Francois
   Bayry, Jagadeesh
TI Potential of regulatory T-cell-based therapies in the management of
   severe COVID-19
SO EUROPEAN RESPIRATORY JOURNAL
LA English
DT Letter
ID ABATACEPT
C1 [Stephen-Victor, Emmanuel; Das, Mrinmoy] Harvard Med Sch, Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA.
   [Karnam, Anupama; Gautier, Jean-Francois; Bayry, Jagadeesh] INSERM, Paris, France.
   [Karnam, Anupama; Gautier, Jean-Francois; Bayry, Jagadeesh] Univ Paris, Sorbonne Univ, Ctr Rech Cordeliers, Paris, France.
   [Pitard, Bruno] Univ Nantes, CNRS, ERL6001, Inserm 1232,CRCINA, Nantes, France.
   [Gautier, Jean-Francois] Univ Paris Diderot Paris 7, Hop Lariboisiere, Ctr Univ Diabet & Ses Complicat, Serv Diabetol,Endocrinol,Nutr, Paris, France.
RP Bayry, J (corresponding author), Ctr Rech Cordeliers, INSERM, Unite 1138, 15 Rue Ecole Med, F-75006 Paris, France.
EM jagadeesh.bayry@crc.jussieu.fr
RI Bayry, Jagadeesh/A-6589-2011
OI Bayry, Jagadeesh/0000-0003-0498-9808; Reis,
   AlessanRSS/0000-0001-8486-7469
FU Agence Nationale de la Recherche, FranceFrench National Research Agency
   (ANR) [ANR-19-CE17-0021(BASIN)]
FX Partly supported by grants from Agence Nationale de la Recherche, France
   (Appel Flash COVID-19-COVIMUNE and ANR-19-CE17-0021(BASIN)). Funding
   information for this article has been deposited with the Crossref Funder
   Registry.
CR Anghelina D, 2009, VIROLOGY, V385, P358, DOI 10.1016/j.virol.2008.12.014
   Arpaia N, 2015, CELL, V162, P1078, DOI 10.1016/j.cell.2015.08.021
   Bluestone JA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad4134
   Bonam Srinivasa Reddy, 2020, Cell Rep Med, V1, P100016, DOI 10.1016/j.xcrm.2020.100016
   Bonelli M, 2018, CURR OPIN RHEUMATOL, V30, P295, DOI 10.1097/BOR.0000000000000491
   Bonelli M, 2016, RHEUMATOLOGY, V55, P710, DOI 10.1093/rheumatology/kev403
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chu H, 2016, J INFECT DIS, V213, P904, DOI 10.1093/infdis/jiv380
   Conticini Edoardo, 2020, Ann Rheum Dis, DOI [10.1136/annrheumdis-2020-217681, 10.1136/annrheumdis-2020-218761]
   Fernandez-Gutierrez B, 2020, HOSP ADMISSIONS INFL, DOI [10.1101/2020.05.21.20108696, DOI 10.1101/2020.05.21.20108696]
   Feuerer M, 2009, NAT MED, V15, P930, DOI 10.1038/nm.2002
   Genovese MC, 2005, NEW ENGL J MED, V353, P1114, DOI 10.1056/NEJMoa050524
   Gladstone DE, 2020, ANN INTERN MED, V173, P852, DOI 10.7326/L20-0681
   Hartemann A, 2013, LANCET DIABETES ENDO, V1, P295, DOI 10.1016/S2213-8587(13)70113-X
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kalfaoglu B, 2020, T CELL HYPERACTIVATI, DOI [10.1101/2020.05.26.1159230, DOI 10.1101/2020.05.26.1159230]
   Langdon K, 2018, INT REV IMMUNOL, V37, P206, DOI 10.1080/08830185.2018.1465943
   Lythgoe MP, 2020, TRENDS PHARMACOL SCI, V41, P363, DOI 10.1016/j.tips.2020.03.006
   Michelena X, 2020, SEMIN ARTHRITIS RHEU, V50, P564, DOI 10.1016/j.semarthrit.2020.05.001
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Qureshi OS, 2011, SCIENCE, V332, P600, DOI 10.1126/science.1202947
   Romano M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00043
   Trotta E, 2018, NAT MED, V24, P1005, DOI 10.1038/s41591-018-0070-2
   Wagner NM, 2013, OBESITY, V21, P461, DOI 10.1002/oby.20087
   Wang F, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137799
   Wang WJ, 2020, CELL MOL IMMUNOL, V17, P650, DOI 10.1038/s41423-020-0447-2
   Webster KE, 2009, J EXP MED, V206, P751, DOI 10.1084/jem.20082824
   Wing JB, 2019, IMMUNITY, V50, P302, DOI 10.1016/j.immuni.2019.01.020
NR 28
TC 4
Z9 4
U1 1
U2 1
PU EUROPEAN RESPIRATORY SOC JOURNALS LTD
PI SHEFFIELD
PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND
SN 0903-1936
EI 1399-3003
J9 EUR RESPIR J
JI Eur. Resp. J.
PD SEP 1
PY 2020
VL 56
IS 3
AR 2002182
DI 10.1183/13993003.02182-2020
PG 4
WC Respiratory System
SC Respiratory System
GA NR4ZJ
UT WOS:000571572000013
PM 32616599
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Vangelista, L
   Secchi, M
AF Vangelista, Luca
   Secchi, Massimiliano
TI Prepare for the Future: Dissecting the Spike to Seek Broadly
   Neutralizing Antibodies and Universal Vaccine for Pandemic Coronaviruses
SO FRONTIERS IN MOLECULAR BIOSCIENCES
LA English
DT Article
DE COVID-19; SARS-CoV-2; coronavirus; spike; conserved regions; broadly
   neutralizing antibodies; universal vaccine; antibody-dependent
   enhancement
ID MONOCLONAL-ANTIBODIES; VULNERABILITY; LESSONS; SITE
AB Learning from the lengthy fight against HIV-1, influenza, and Ebola virus infection, broadly neutralizing antibodies (bnAbs), directed at conserved regions of surface proteins crucial to virus entry (Env, hemagglutinin, and GP, respectively), are an essential resource for passive as well as active immunization. Rare in their emergence and antigen recognition mode, bnAbs are active toward a large set of different viral strains. Isolation, characterization and production of bnAbs lead to their possible use in passive immunotherapy and form the basis for an educated effort in the development of vaccines for universal coverage. SARS-CoV-2-specific antibodies targeting the spike receptor binding domain (RBD) may lead to antibody dependent enhancement (ADE) of infection, possibly hampering the field of vaccine development. This perspective points to the identification of conserved regions in the spike of SARS-CoV-2, SARS-CoV, and MERS-CoV through investigation, dissection and recombinant production of isolated moieties. These spike moieties should be capable of independent folding and allow the detection as well as the elicitation of bnAbs, thus setting the basis for an effective passive immunotherapy and the development of a universal vaccine against human epidemic coronaviruses (HCoVs). SARS, MERS and, most of all, COVID-19 demonstrate that humanity is the target of HCoV, preparedness for future hits is thus no longer an option.
C1 [Vangelista, Luca] Nazarbayev Univ, Dept Biomed Sci, Sch Med, Nur Sultan, Kazakhstan.
   [Secchi, Massimiliano] IRCCS San Raffaele Hosp, Diabet Res Inst, Milan, Italy.
RP Vangelista, L (corresponding author), Nazarbayev Univ, Dept Biomed Sci, Sch Med, Nur Sultan, Kazakhstan.
EM luca.vangelista@nu.edu.kz
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Bangaru S, 2019, CELL, V177, P1136, DOI 10.1016/j.cell.2019.04.011
   Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3
   Chary MA, 2020, J MED TOXICOL, V16, P284, DOI 10.1007/s13181-020-00777-5
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Elshabrawy HA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050366
   Fan PF, 2020, MABS-AUSTIN, V12, DOI 10.1080/19420862.2020.1742457
   Fatima K, 2018, J GLOB HEALTH, V8, DOI [10.7189/jogh.08.020312, 10.7189/jogh.08-020312]
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Flyak AI, 2018, NAT MICROBIOL, V3, P670, DOI 10.1038/s41564-018-0157-z
   Gilchuk P, 2020, IMMUNITY, V52, P388, DOI 10.1016/j.immuni.2020.01.001
   Gilchuk P, 2018, IMMUNITY, V49, P363, DOI 10.1016/j.immuni.2018.06.018
   Gudi SK, 2020, INT J OCCUP ENV MED, V11, P108, DOI 10.34172/ijoem.2020.1977
   Hotez PJ, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0323-4
   Huisman W, 2009, VACCINE, V27, P505, DOI 10.1016/j.vaccine.2008.10.087
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Jacobsen KH, 2020, LANCET, V395, P1013, DOI 10.1016/S0140-6736(20)30559-6
   Jang YH, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00344
   Kallewaard NL, 2016, CELL, V166, P596, DOI 10.1016/j.cell.2016.05.073
   King LB, 2019, CURR OPIN VIROL, V34, P140, DOI 10.1016/j.coviro.2019.01.003
   Krammer F, 2019, NAT REV IMMUNOL, V19, P383, DOI 10.1038/s41577-019-0143-6
   Krammer F, 2016, CURR OPIN VIROL, V17, P95, DOI 10.1016/j.coviro.2016.02.002
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Lanzavecchia A, 2007, CURR OPIN BIOTECH, V18, P523, DOI 10.1016/j.copbio.2007.10.011
   Lurie N, 2020, NEW ENGL J MED, V382, P1969, DOI 10.1056/NEJMp2005630
   Malvy D, 2019, LANCET, V393, P936, DOI 10.1016/S0140-6736(18)33132-5
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Pinto D, 2020, NATURE, V583, P290, DOI 10.1038/s41586-020-2349-y
   Raj VS, 2013, NATURE, V495, P251, DOI 10.1038/nature12005
   Raoult D, 2020, CELL STRESS, V4, P66, DOI 10.15698/cst2020.04.216
   Rey FA, 2018, EMBO REP, V19, P206, DOI 10.15252/embr.201745302
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sanders RW, 2017, IMMUNOL REV, V275, P161, DOI 10.1111/imr.12481
   Saphire EO, 2020, CELL, V181, P6, DOI 10.1016/j.cell.2020.03.011
   Saphire EO, 2018, CELL, V174, P938, DOI 10.1016/j.cell.2018.07.033
   Seabright GE, 2019, J MOL BIOL, V431, P2223, DOI 10.1016/j.jmb.2019.04.016
   Sedeyn K, 2019, ANTIVIR RES, V170, DOI 10.1016/j.antiviral.2019.104562
   Stephenson KE, 2020, ANNU REV IMMUNOL, V38, P673, DOI 10.1146/annurev-immunol-080219-023629
   TANNE JH, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1256
   Taubenberger JK, 2010, CELL HOST MICROBE, V7, P440, DOI 10.1016/j.chom.2010.05.009
   Tetro JA, 2020, MICROBES INFECT, V22, P72, DOI 10.1016/j.micinf.2020.02.006
   Thorp HH, 2020, SCIENCE, V367, P1283, DOI 10.1126/science.abb7248
   Thorp HH, 2020, SCIENCE, V367, P959, DOI 10.1126/science.abb4420
   Turner HL, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000139
   Vanderven HA, 2020, IMMUNOL CELL BIOL, V98, P253, DOI 10.1111/imcb.12312
   Vogel OA, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00135
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang Q, 2020, FRONT MED-PRC, V14, P30, DOI 10.1007/s11684-019-0721-9
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Wang YL, 2020, FRONT MED-PRC, V14, P149, DOI 10.1007/s11684-020-0764-y
   Wec AZ, 2017, CELL, V169, P878, DOI 10.1016/j.cell.2017.04.037
   Weiss SR, 2020, J EXP MED, V217, DOI 10.1084/jem.20200537
   West BR, 2019, NAT STRUCT MOL BIOL, V26, P204, DOI 10.1038/s41594-019-0191-4
   Wolfe DN, 2020, HUM VACC IMMUNOTHER, V16, P2855, DOI 10.1080/21645515.2020.1741313
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xia S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4580
   Xu JY, 2019, EMERG MICROBES INFEC, V8, P841, DOI 10.1080/22221751.2019.1624482
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092
   Zhang T, 2020, CURR BIOL, V30, P1578, DOI 10.1016/j.cub.2020.03.063
   Zhang YZ, 2020, CELL, V181, P223, DOI 10.1016/j.cell.2020.03.035
   Zhao XL, 2017, CELL, V169, P891, DOI 10.1016/j.cell.2017.04.038
NR 67
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-889X
J9 FRONT MOL BIOSCI
JI Front. Mol. Biosci.
PD SEP 1
PY 2020
VL 7
AR 226
DI 10.3389/fmolb.2020.00226
PG 7
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA NS7UN
UT WOS:000572462800001
PM 33033717
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Xiong, WZ
   Wang, G
   Du, J
   Ai, W
AF Xiong, Wu-zhong
   Wang, Gang
   Du, Juan
   Ai, Wang
TI Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with
   conventional drug in treating COVID-19: a pilot randomized clinical
   trial
SO INTEGRATIVE MEDICINE RESEARCH
LA English
DT Article
DE COVID-19; Herbalmedicine; Randomizedcontrolledtrial;
   Integrativemedicine; Chinesemedicine
ID TRADITIONAL CHINESE MEDICINE
AB Background: The aim of this study was to evaluate the clinical efficacy of Xuanfei Baidu Decoction (XBD) combined with conventional drug therapy compared with conventional medicine alone in patients with coronavirus disease 2019 (COVID-19).
   Methods: Forty-two patients with COVID-19 were randomly assigned to XBD plus conventional medicine (n = 22) and conventional medicine alone (n = 20). Both groups were treated for 1 week. The primary endpoint was the disappearance rate of main symptoms (fever, cough, and fatigue).
   Results: Compared with the conventional medicine, the disappearance rate of clinical symptoms such as fever, cough, fatigue and loss of appetite in the experimental group were significantly reduced (P < 0.05). The number of white blood cells and lymphocytes in the experimental group increased significantly (P < 0.05), which all returned to normal parameters. Meanwhile, the C-reactive protein and erythrocyte sedimentation rate in the experimental group were significantly reduced (P < 0.05).
   Conclusion: XBD combined with conventional medicine may significantly improve patient's clinical symptoms, increase the number of white blood cells and lymphocytes to improve immunity, and also significantly reduce C-reactive protein and erythrocyte sedimentation rate to play an anti-inflammatory effect. However, it needs to be confirmed by a large sample study. Clinical trial registration: China Clinical Trial Registry (ChiCTR2000034795). (c) 2020 Korea Institute of Oriental Medicine. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Xiong, Wu-zhong; Wang, Gang; Ai, Wang] Wuhan Hosp Tradit Chinese Med, Wuhan, Peoples R China.
   [Du, Juan] Wuhan Pulm Hosp, Wuhan, Peoples R China.
RP Wang, G (corresponding author), Wuhan Hosp Tradit Chinese Med, Wuhan, Peoples R China.
EM 2401610965@qq.com
OI , Wu-zhong/0000-0002-4897-4256
CR [刘菊 Liu Ju], 2020, [中草药, Chinese Traditional and Herbal Drugs], V51, P860
   Miao Q, 2020, J TRADIT CHIN MED, V61, P286, DOI DOI 10.13288/J.11-2166/R.2020.04.003.4
   National Health Commission of China, 2020, DIAGN TREATM PROT FO
   Pan XQ, 2020, VIRUS RES, V286, DOI 10.1016/j.virusres.2020.198057
   Tong T, 2020, CHIN MED-UK, V15, DOI 10.1186/s13020-020-00326-w
   [夏文广 Xia Wenguang], 2020, [中医杂志, Journal of Traditional Chinese Medicine], V61, P375
   Xu J, 2020, COMPLEMENT THER CLIN, V39, DOI 10.1016/j.ctcp.2020.101165
NR 7
TC 1
Z9 1
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-4220
EI 2213-4239
J9 INTEGR MED RES
JI Integr. Med. Res.
PD SEP
PY 2020
VL 9
IS 3
SI SI
AR 100489
DI 10.1016/j.imr.2020.100489
PG 4
WC Integrative & Complementary Medicine
SC Integrative & Complementary Medicine
GA NR5DK
UT WOS:000571582500022
PM 32874913
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dobson, GP
AF Dobson, Geoffrey P.
TI Trauma of major surgery: A global problem that is not going away
SO INTERNATIONAL JOURNAL OF SURGERY
LA English
DT Article
DE Surgery; Perioperative; Mortality; Morbidity; Trauma; Global
ID NONCARDIAC SURGERY; STRESS-RESPONSE; NACL ADENOSINE; ADVERSE EVENTS;
   MG2+ ALM; LIDOCAINE; COMPLICATIONS; DYSFUNCTION; MORTALITY; VOLUME
AB Globally, a staggering 310 million major surgeries are performed each year; around 40 to 50 million in USA and 20 million in Europe. It is estimated that 1-4% of these patients will die, up to 15% will have serious postoperative morbidity, and 5-15% will be readmitted within 30 days. An annual global mortality of around 8 million patients places major surgery comparable with the leading causes of death from cardiovascular disease and stroke, cancer and injury. If surgical complications were classified as a pandemic, like HIV/AIDS or coronavirus (COVID-19), developed countries would work together and devise an immediate action plan and allocate resources to address it. Seeking to reduce preventable deaths and post-surgical complications would save billions of dollars in healthcare costs. Part of the global problem resides in differences in institutional practice patterns in high- and low-income countries, and part from a lack of effective perioperative drug therapies to protect the patient from surgical stress. We briefly review the history of surgical stress and provide a path forward from a systems-based approach. Key to progress is recognizing that the anesthetized brain is still physiologically 'awake' and responsive to the sterile stressors of surgery. New intravenous drug therapies are urgently required after anesthesia and before the first incision to prevent the brain from switching to sympathetic overdrive and activating secondary injury progression such as hyperinflammation, coagulopathy, immune activation and metabolic dysfunction. A systems-based approach targeting central nervous system-mitochondrial coupling may help drive research to improve outcomes following major surgery in civilian and military medicine.
C1 [Dobson, Geoffrey P.] James Cook Univ, Coll Med & Dent, Heart Trauma & Sepsis Res Lab, Townsville, Qld 4811, Australia.
RP Dobson, GP (corresponding author), James Cook Univ, Coll Med & Dent, Heart Trauma & Sepsis Res Lab, Townsville, Qld 4811, Australia.
EM geoffrey.dobson@jcu.edu.au
FU USSOCOM; IACUC [A2118, A2296]; USAMRMCU.S. Army Medical Research &
   Materiel Command (USAMRMC) [SO150053, W81XWH-USSOCOM-BAA-15-1]
FX This work was supported by USSOCOM, IACUC protocol A2118 and A2296,
   USAMRMC proposal SO150053 under Award No. W81XWH-USSOCOM-BAA-15-1. The
   opinions, interpretations, conclusions are those of the author and are
   not necessarily endorsed by the US Department of Defense.
CR Abdelmalak BB, 2013, ANESTH ANALG, V116, P1116, DOI 10.1213/ANE.0b013e318288416d
   Aird WC, 2005, J THROMB HAEMOST, V3, P1392, DOI 10.1111/j.1538-7836.2005.01328.x
   Anderson DJ, 2008, INFECT CONT HOSP EP, V29, P941, DOI 10.1086/591457
   Anderson O, 2013, AM J SURG, V206, P253, DOI 10.1016/j.amjsurg.2012.11.009
   Astapenko D, 2019, BMC ANESTHESIOL, V19, DOI 10.1186/s12871-019-0896-2
   Axell RG, 2017, PHYSL REP, V5, P7
   Barman SM, 2020, AM J PHYSIOL-REG I, V318, pR191, DOI 10.1152/ajpregu.00298.2019
   Berthelsen PG, 2015, ACTA ANAESTH SCAND, V59, P246, DOI 10.1111/aas.12444
   Biccard BM, 2018, LANCET, V391, P1589, DOI [10.1016/S0140-6736(18)30001-1, 10.1016/s0140-6736(18)30001-1]
   Blessberger H, 2015, JAMA-J AM MED ASSOC, V313, P2070, DOI 10.1001/jama.2015.1883
   Botto F, 2014, ANESTHESIOLOGY, V120, P564, DOI 10.1097/ALN.0000000000000113
   Boudreau LH, 2014, BLOOD, V124, P2173, DOI 10.1182/blood-2014-05-573543
   Burford NG, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102150
   Burton D, 2004, CEACCP, V4, P144, DOI DOI 10.1093/BJACEACCP/MKH040
   Cannon WB, 1914, AM J PHYSIOL, V33, P356
   Cannon WB, 1929, PHYSIOL REV, V9, P399
   Cannon WB, 1932, WISDOM BODY
   Cannon WB, 1923, TRAUMATIC SHOCK
   Cap A, 2014, CURR OPIN CRIT CARE, V20, P638, DOI 10.1097/MCC.0000000000000158
   Charkoudian N, 2014, COMPR PHYSIOL, V4, P827, DOI 10.1002/cphy.c130038
   Cherry Anne D, 2019, Anesthesiol Clin, V37, P769, DOI 10.1016/j.anclin.2019.08.003
   Choileain N.N., 2006, ARCH SURG, V141
   Cholley B, 2016, J THORAC DIS, V8, P2287, DOI 10.21037/jtd.2016.08.34
   Coote JH, 2016, AUTON NEUROSCI-BASIC, V199, P17, DOI 10.1016/j.autneu.2016.08.014
   Coote JH, 2007, EXP PHYSIOL, V92, P3, DOI 10.1113/expphysiol.2006.035378
   Crile GW, 1911, SURG GYNECOL OBSTET, V13, P170
   Crile GW, 1913, LANCET, V2, P7
   Curry N, 2020, SEMIN THROMB HEMOST, V46, P73, DOI 10.1055/s-0039-1697932
   Cushing H, 1902, ANN SURG, V36, P321
   CUTHBERTSON DP, 1980, P NUTR SOC, V39, P101, DOI 10.1079/PNS19800017
   Danelich IM, 2014, J AM COLL SURGEONS, V219, P831, DOI 10.1016/j.jamcollsurg.2014.02.038
   Davenport L, 2017, INNATE IMMUN-LONDON, V23, P482, DOI 10.1177/1753425917718921
   Delogu G, 2001, ARCH SURG-CHICAGO, V136, P1190, DOI 10.1001/archsurg.136.10.1190
   Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109
   Devereaux PJ, 2015, NEW ENGL J MED, V373, P2258, DOI 10.1056/NEJMra1502824
   Devereaux PJ, 2014, NEW ENGL J MED, V370, P1494, DOI 10.1056/NEJMoa1401105
   Devereaux PJ, 2012, JAMA-J AM MED ASSOC, V307, P2295, DOI 10.1001/jama.2012.5502
   Dimick JB, 2015, JAMA-J AM MED ASSOC, V313, P512, DOI 10.1001/jama.2014.14179
   Dobson GP, 2020, SEMIN THROMB HEMOST, V46, P199, DOI 10.1055/s-0039-1701018
   Dobson GP, 2019, EBIOMEDICINE, V41, P42, DOI 10.1016/j.ebiom.2019.02.038
   Dobson GP, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00824
   Dobson GP, 2015, FRONT SURG, V2, DOI 10.3389/fsurg.2015.00043
   Dobson GP, 2016, J TRAUMA ACUTE CARE, V80, P135, DOI 10.1097/TA.0000000000000881
   Downing NS, 2017, JAMA-J AM MED ASSOC, V317, P1854, DOI 10.1001/jama.2017.5150
   Dragos Dorin, 2010, J Med Life, V3, P10
   Ekeloef S, 2017, BRIT J ANAESTH, V118, P200, DOI 10.1093/bja/aew410
   Elenkov IJ, 2006, NEUROIMMUNOMODULAT, V13, P257, DOI 10.1159/000104853
   Eyob B, 2019, INT J SURG, V72, P27, DOI 10.1016/j.ijsu.2019.07.036
   Farmer PE, 2008, WORLD J SURG, V32, P533, DOI 10.1007/s00268-008-9525-9
   Filho IPT, 2017, SHOCK, V48, P583, DOI 10.1097/SHK.0000000000000895
   Fink G, 2016, NATURE, V539, P175, DOI 10.1038/nature20473
   GEBBER GL, 1995, CLIN EXP HYPERTENS, V17, P181, DOI 10.3109/10641969509087064
   Giannoudis PV, 2006, INJURY, V37, pS3, DOI 10.1016/S0020-1383(07)70005-0
   Goldstein DS, 2007, STRESS, V10, P109, DOI 10.1080/10253890701288935
   Granfeldt A, 2014, CRIT CARE MED, V42, pE329, DOI 10.1097/CCM.0000000000000225
   Grill HJ, 2009, INT J OBESITY, V33, pS11, DOI 10.1038/ijo.2009.10
   Guarracino F, 2013, CRIT CARE, V17, DOI 10.1186/cc12522
   HALL GM, 1985, ANN ROY COLL SURG, V67, P25
   HARRIS GW, 1950, BRIT MED BULL, V6, P345, DOI 10.1093/oxfordjournals.bmb.a073628
   Hauser CJ, 2018, EUR J TRAUMA EMERG S, V44, P317, DOI 10.1007/s00068-018-0963-2
   Healey MA, 2002, ARCH SURG-CHICAGO, V137, P611, DOI 10.1001/archsurg.137.5.611
   Herman JP, 2018, CELL MOL NEUROBIOL, V38, P25, DOI 10.1007/s10571-017-0543-8
   Hollmann C, 2018, ANESTH ANALG, V127, P678, DOI 10.1213/ANE.0000000000002837
   Huang ML, 2016, GLYCOBIOLOGY, V26, P797, DOI 10.1093/glycob/cww022
   Kass DA, 2005, HYPERTENSION, V46, P185, DOI 10.1161/01.HYP.0000168053.34306.d4
   Kelkar KV, 2015, INDIAN J ANAESTH, V59, P599, DOI 10.4103/0019-5049.165857
   Kheterpal S, 2007, ANESTHESIOLOGY, V107, P892, DOI 10.1097/01.anes.0000290588.29668.38
   Kohl BA, 2006, CURR OPIN CRIT CARE, V12, P325, DOI 10.1097/01.ccx.0000235210.85073.fc
   Kristensen SD, 2014, EUR HEART J, V35, P2383, DOI 10.1093/eurheartj/ehu282
   Ky B, 2013, J AM COLL CARDIOL, V62, P1165, DOI 10.1016/j.jacc.2013.03.085
   Leape LL, 2015, JAMA-J AM MED ASSOC, V313, P467, DOI 10.1001/jama.2014.18666
   Lederer AK, 2017, BMC SURG, V17, DOI 10.1186/s12893-017-0325-8
   Letson HL, 2020, J SURG RES, V253, P127, DOI 10.1016/j.jss.2020.03.048
   Letson HL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45871-z
   Letson HL, 2017, J TRAUMA ACUTE CARE, V82, P1063, DOI 10.1097/TA.0000000000001454
   Letson HL, 2019, J TRAUMA ACUTE CARE, V87, P606, DOI 10.1097/TA.0000000000002397
   Levy JH, 2015, BLOOD, V125, P1387, DOI 10.1182/blood-2014-08-552000
   Li L, 2009, TRENDS ENDOCRIN MET, V20, P429, DOI 10.1016/j.tem.2009.06.004
   Lin E, 2000, SURGERY, V127, P117, DOI 10.1067/msy.2000.101584
   Lin E., 2013, ISRN OBESITY, V2013, P1
   London GM, 2005, AM J HYPERTENS, V18, p19S, DOI 10.1016/j.amjhyper.2004.10.001
   LUFT JH, 1976, INT REV CYTOL, V45, P291, DOI 10.1016/S0074-7696(08)60081-9
   Maggio PM, 2005, SURG CLIN N AM, V85, P1091, DOI 10.1016/j.suc.2005.09.016
   Marik PE, 2012, J TRAUMA ACUTE CARE, V73, P801, DOI 10.1097/TA.0b013e318265cf87
   Mayer EA, 2015, J CLIN INVEST, V125, P926, DOI 10.1172/JCI76304
   Menger MD, 2004, LANGENBECK ARCH SURG, V389, P475, DOI 10.1007/s00423-004-0472-0
   Miller TE, 2019, ANESTHESIOLOGY, V130, P825, DOI 10.1097/ALN.0000000000002603
   MOORE FD, 1953, ANN SURG, V137, P289, DOI 10.1097/00000658-195303000-00001
   Morris JL, 2019, SEMIN ARTHRITIS RHEU, V49, P331, DOI 10.1016/j.semarthrit.2019.03.008
   Mrkobrada M, 2019, LANCET, V394, P1022, DOI 10.1016/S0140-6736(19)31795-7
   Nathoo N, 2005, J NEUROSURG, V103, P378, DOI 10.3171/jns.2005.103.2.0378
   Naumann DN, 2018, SHOCK, V49, P420, DOI 10.1097/SHK.0000000000000999
   Neale G, 2001, J ROY SOC MED, V94, P322
   O'Connor TM, 2000, QJM-INT J MED, V93, P323, DOI 10.1093/qjmed/93.6.323
   OKA Y, 1992, CYTOKINE, V4, P298, DOI 10.1016/1043-4666(92)90070-8
   Olshansky B, 2016, TRENDS CARDIOVAS MED, V26, P1, DOI 10.1016/j.tcm.2015.03.016
   Onorati F, 2013, INT J CARDIOL, V167, P2739, DOI 10.1016/j.ijcard.2012.06.099
   Patel AY, 2015, J AM COLL CARDIOL, V66, P2140, DOI 10.1016/j.jacc.2015.09.026
   Pearse RM, 2012, LANCET, V380, P1059, DOI 10.1016/S0140-6736(12)61148-9
   Picard M, 2015, P NATL ACAD SCI USA, V112, pE6614, DOI 10.1073/pnas.1515733112
   Pongratz G, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0504-2
   Prete A, 2018, CLIN ENDOCRINOL, V89, P554, DOI 10.1111/cen.13820
   Price CC, 2008, ANESTHESIOLOGY, V108, P8, DOI 10.1097/01.anes.0000296072.02527.18
   Riedel B., 2013, CURRENT ANESTHESIOLO, V3, P151
   Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]
   SELYE H, 1973, AM SCI, V61, P692
   Semel ME, 2012, SURGERY, V151, P171, DOI 10.1016/j.surg.2011.07.021
   Sessler DI, 2016, ANESTH ANALG, V123, P359, DOI 10.1213/ANE.0000000000001450
   Shoemaker WC, 2010, ACP-APPL CARDIOPUL P, V14, P5
   Smith S.M., 2006, DIALOGUES CLIN NEURO, V8
   Song JW, 2018, KOREAN J ANESTHESIOL, V71, P92, DOI 10.4097/kjae.2018.71.2.92
   Soto-Ruiz KM, 2009, RESUSCITATION, V80, P6, DOI 10.1016/j.resuscitation.2008.09.008
   SUGA H, 1993, BASIC RES CARDIOL, V88, P43
   Thayer Julian F, 2009, Cleve Clin J Med, V76 Suppl 2, pS23, DOI 10.3949/ccjm.76.s2.05
   Thurairajah K, 2018, EUR J TRAUMA EMERG S, V44, P325, DOI 10.1007/s00068-018-0954-3
   Tillisch K, 2014, GUT MICROBES, V5, P404, DOI 10.4161/gmic.29232
   Torrance HDT, 2016, CURR OPIN ANESTHESIO, V29, P376, DOI 10.1097/ACO.0000000000000331
   Tracey KJ, 2009, NAT REV IMMUNOL, V9, P418, DOI 10.1038/nri2566
   Turnbull AV, 1995, BRAIN BEHAV IMMUN, V9, P253, DOI 10.1006/brbi.1995.1026
   Ueda Kazuki, 2004, HPB (Oxford), V6, P247, DOI 10.1080/13651820410023987
   Vaara ST, 2017, CURR OPIN CRIT CARE, V23, P440, DOI 10.1097/MCC.0000000000000439
   Weinberg RL, 2017, JAMA INTERN MED, V177, P242, DOI 10.1001/jamainternmed.2016.8037
   Weiser TG, 2008, LANCET, V372, P139, DOI 10.1016/S0140-6736(08)60878-8
   Weiser TG, 2015, LANCET, V385, P11, DOI 10.1016/S0140-6736(15)60806-6
   Xu Jiaquan, 2020, NCHS Data Brief, P1
   Zeng Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086249
NR 126
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1743-9191
EI 1743-9159
J9 INT J SURG
JI Int. J. Surg.
PD SEP
PY 2020
VL 81
BP 47
EP 54
DI 10.1016/j.ijsu.2020.07.017
PG 8
WC Surgery
SC Surgery
GA NS3YD
UT WOS:000572200300013
PM 32738546
OA Green Published
DA 2021-01-01
ER

PT J
AU Hu, YF
   Ma, JT
   Huang, HJ
   Vermund, SH
AF Hu, Yifei
   Ma, Juntao
   Huang, Haojie
   Vermund, Sten H.
TI Coinfection With HIV and SARS-CoV-2 in Wuhan, China: A 12-Person Case
   Series
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV; COVID-19; SARS-CoV-2; coinfection; antiretroviral treatment; China
ID COVID-19
AB Background: Given the magnitude of the global COVID-19 pandemic, persons living with HIV (PLWH) may become coinfected with SARS-CoV-2. Setting: We conducted a survey in Wuhan, China, to characterize the status of coinfected PLWH, their time to clinical improvement, and clinical prognoses. Methods: Using a Wuhan shipping service for antiretroviral medications, the Wuhan LGBT Center screened 2900 PLWH shipping addresses and cross-referenced 36 of them to quarantine sites or hospitals, suggesting possible COVID-19 cases. Through telephone calls and WeChat (social media) messaging, we conducted a survey after obtaining online informed consent. Results: We had 12 HIV-infected respondents (10 men and 2 women) who also reported COVID-19. The median age was 36 years (interquartile range: 33.0-56.3), mean age 42.4 years, and range 25-66 years of age. Nine of 10 persons on antiretroviral therapy (ART) presented with only mild COVID-19 symptoms. The 10th person on ART was a 56-year-old man who died at home early in the outbreak when health care services were overwhelmed. Two additional cases who had been in intensive care with acute COVID-19 were both men, aged 25 and 37 years; both were ART-naive until this hospitalization. Excluding the deceased man, 6 of 11 coinfected persons reported feeling depressed even after clinical improvements. Conclusion: Twelve coinfected persons were identified in Wuhan; 9 of 10 were on long-term ART and had favorable outcomes. Two men identified as having started ART only recently were found to have severe symptoms. Our case series suggests the value of ART for potential mitigation of COVID-19 coinfection.
C1 [Hu, Yifei] Capital Med Univ, Sch Publ Hlth, Dept Child & Adolescent Hlth & Maternal Care, Beijing, Peoples R China.
   [Ma, Juntao] Yisheng Yishi Med Beijing Technol Co Ltd, Beijing, Peoples R China.
   [Huang, Haojie] Wuhan LGBT Ctr, Wuhan, Peoples R China.
   [Vermund, Sten H.] Yale Sch Med, Yale Sch Publ Hlth, Depr Epidemiol Microbial Dis & Pediat, New Haven, CT USA.
RP Hu, YF (corresponding author), 10 Youanmenwai Xitoutiao, Beijing 100069, Peoples R China.
EM huyifei@yahoo.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81673232]; Beijing Natural Science
   FoundationBeijing Natural Science Foundation [7202009]; National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P30MH062294]
FX Y. Hu is supported in part by the National Natural Science Foundation of
   China (81673232) and Beijing Natural Science Foundation (7202009). S. H.
   Vermund is supported in part by the National Institutes of Health grant
   (P30MH062294). The sponsors have no role in study design; in the
   collection, analysis, and interpretation of data; in the writing of the
   report; and in the decision to submit the paper for publication.
CR Ashcroft J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1511
   Baluku JB, 2020, J MED VIROL, V92, P2351, DOI 10.1002/jmv.26044
   Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Ford N, 2020, J INT AIDS SOC, V23, DOI 10.1002/jia2.25489
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Lily Lee BW, 2020, CNN
   Logie CH, 2020, AIDS BEHAV, V24, P2003, DOI 10.1007/s10461-020-02856-8
   Nakamoto T, 2020, J MED VIROL, DOI 10.1002/jmv.26102
   Ridgway JP, 2020, AIDS PATIENT CARE ST, V34, P331, DOI 10.1089/apc.2020.0103
   Suwanwongse K, 2020, J MED VIROL, V92, P2387, DOI 10.1002/jmv.26077
   Tao J, 2017, AIDS, V31, P401, DOI 10.1097/QAD.0000000000001287
   Vizcarra P, 2020, LANCET HIV, V7, pE554, DOI 10.1016/S2352-3018(20)30164-8
   Wang MM, 2020, INT J INFECT DIS, V96, P148, DOI 10.1016/j.ijid.2020.04.060
   Wang N, 2019, AIDS CARE, V31, P629, DOI 10.1080/09540121.2018.1549721
   Wang X, 2020, CLIN MICROBIOL INFEC, V26, P1063, DOI 10.1016/j.cmi.2020.03.032
   Zhao Juanjuan, 2020, Clin Infect Dis, V71, P2233, DOI 10.1093/cid/ciaa408
   Zhu F, 2020, J MED VIROL, V92, P529, DOI 10.1002/jmv.25732
NR 18
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD SEP 1
PY 2020
VL 85
IS 1
BP 1
EP 5
DI 10.1097/QAI.0000000000002424
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA NQ8PN
UT WOS:000571130000002
PM 32568771
OA Green Published
DA 2021-01-01
ER

PT J
AU Karmen-Tuohy, S
   Carlucci, PM
   Zervou, FN
   Zacharioudakis, IM
   Rebick, G
   Klein, E
   Reich, J
   Jones, S
   Rahimian, J
AF Karmen-Tuohy, Savannah
   Carlucci, Philip M.
   Zervou, Fainareti N.
   Zacharioudakis, Ioannis M.
   Rebick, Gabriel
   Klein, Elizabeth
   Reich, Jenna
   Jones, Simon
   Rahimian, Joseph
TI Outcomes Among HIV-Positive Patients Hospitalized With COVID-19
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV; COVID-19; SARS-CoV-2; coronavirus
ID BACTERIAL PNEUMONIA; THERAPY
AB Background: SARS-CoV-2 infection continues to cause significant morbidity and mortality worldwide. Preliminary data on SARS-CoV-2 infection suggest that some immunocompromised hosts experience worse outcomes. We performed a retrospective matched cohort study to characterize outcomes in HIV-positive patients with SARS-CoV-2 infection. Methods: Leveraging data collected from electronic medical records for all patients hospitalized at NYU Langone Health with COVID-19 between March 2, 2020, and April 23, 2020, we matched 21 HIV-positive patients with 42 non-HIV patients using a greedy nearest-neighbor algorithm. Admission characteristics, laboratory test results, and hospital outcomes were recorded and compared between the 2 groups. Results: Although there was a trend toward increased rates of intensive care unit admission, mechanical ventilation, and mortality in HIV-positive patients, these differences were not statistically significant. Rates for these outcomes in our cohort are similar to those previously published for all patients hospitalized with COVID-19. HIV-positive patients had significantly higher admission and peak C-reactive protein values. Other inflammatory markers did not differ significantly between groups, although HIV-positive patients tended to have higher peak values during their clinical course. Three HIV-positive patients had superimposed bacterial pneumonia with positive sputum cultures, and all 3 patients died during hospitalization. There was no difference in frequency of thrombotic events or myocardial infarction between these groups. Conclusions: This study provides evidence that HIV coinfection does not significantly impact presentation, hospital course, or outcomes of patients infected with SARS-CoV-2, when compared with matched non-HIV patients. A larger study is required to determine whether the trends we observed apply to all HIV-positive patients.
C1 [Karmen-Tuohy, Savannah; Carlucci, Philip M.; Zervou, Fainareti N.; Zacharioudakis, Ioannis M.; Rebick, Gabriel; Klein, Elizabeth; Reich, Jenna; Rahimian, Joseph] NYU, Dept Med, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Jones, Simon] NYU Grossman Sch Med, Dept Populat Hlth, Div Healthcare Delivery Sci, New York, NY USA.
   [Jones, Simon] NYU Langone Hlth, Ctr Healthcare Innovat & Delivery Sci, New York, NY USA.
RP Rahimian, J (corresponding author), NYU Grossman Sch Med, Dept Med, 31 Washington Sq West,Floor 4, New York, NY 10011 USA.
EM Joseph.Rahimian@nyulangone.org
OI Jones, Simon/0000-0002-8267-5647
CR Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cilloniz C, 2018, EXPERT REV ANTI-INFE, V16, P579, DOI 10.1080/14787210.2018.1495560
   Collin A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152970
   Croxford S, 2017, LANCET PUBLIC HEALTH, V2, pE35, DOI 10.1016/S2468-2667(16)30020-2
   Feikin DR, 2004, LANCET INFECT DIS, V4, P445, DOI 10.1016/S1473-3099(04)01060-6
   Ho D, 2011, J STAT SOFTW, V42, P28, DOI DOI 10.18637/JSS.V042.I08
   Kohli R, 2006, CLIN INFECT DIS, V43, P90, DOI 10.1086/504871
   Liang WH, 2020, LANCET ONCOL, V21, P335, DOI 10.1016/S1470-2045(20)30096-6
   Lomoro Pascal, 2020, Eur J Radiol Open, V7, P100231, DOI 10.1016/j.ejro.2020.100231
   Mahy M, 2019, AIDS, V33, pS203, DOI 10.1097/QAD.0000000000002321
   Petrilli CM, 2020, FACTORS ASS HOSP CRI
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sogaard OS, 2013, J INFECTION, V66, P439, DOI 10.1016/j.jinf.2012.12.012
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu F, 2020, J MED VIROL, V92, P529, DOI 10.1002/jmv.25732
NR 17
TC 6
Z9 6
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD SEP 1
PY 2020
VL 85
IS 1
BP 6
EP 10
DI 10.1097/QAI.0000000000002423
PG 5
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA NQ8PN
UT WOS:000571130000005
PM 32568770
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Kalichman, SC
   Eaton, LA
   Berman, M
   Kalichman, MO
   Katner, H
   Sam, SS
   Caliendo, AM
AF Kalichman, Seth C.
   Eaton, Lisa A.
   Berman, Marcie
   Kalichman, Moira O.
   Katner, Harold
   Sam, Soya S.
   Caliendo, Angela M.
TI Intersecting Pandemics: Impact of SARS-CoV-2 (COVID-19) Protective
   Behaviors on People Living With HIV, Atlanta, Georgia
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV continuum of care; COVID-19; coronavirus; food insecurity
ID ANTIRETROVIRAL THERAPY; ALCOHOL-CONSUMPTION; INFECTION; SMOKING; URINE;
   BLOOD
AB Background: COVID-19 and its social responses threaten the health of people living with HIV. We conducted a rapid-response interview to assess COVID-19 protective behaviors of people living with HIV and the impact of their responses on HIV-related health care. Method: Men and women living with HIV (N = 162) aged 20-37 years participating in a longitudinal study of HIV treatment and care completed routine study measures and an assessment of COVID-19-related experiences. Results: At baseline, most participants demonstrated HIV viremia, markers indicative of renal disorders, and biologically confirmed substance use. At follow-up, in the first month of responding to COVID-19, engaging in more social distancing behaviors was related to difficulty accessing food and medications and increased cancelation of health care appointments, both by self and providers. We observed antiretroviral therapy adherence had improved during the initial month of COVID-19 response. Conclusions: Factors that may pose added risk for COVID-19 severity were prevalent among people living with HIV, and those with greater risk factors did not practice more COVID-19 protective behaviors. Social distancing and other practices intended to mitigate the spread of COVID-19 interfered with HIV care, and impeded access to food and medications, although an immediate adverse impact on medication adherence was not evident. These results suggest social responses to COVID-19 adversely impacted the health care of people living with HIV, supporting continued monitoring to determine the long-term effects of co-occurring HIV and COVID-19 pandemics.
C1 [Kalichman, Seth C.; Eaton, Lisa A.; Berman, Marcie; Kalichman, Moira O.] Univ Connecticut, Inst Collaborat Hlth Intervent & Policy, Storrs, CT USA.
   [Katner, Harold] Mercer Univ, Sch Med, Infect Dis, Macon, GA 31207 USA.
   [Sam, Soya S.] Miriam Hosp, Div Infect Dis, Providence, RI 02906 USA.
   [Caliendo, Angela M.] Brown Univ, Dept Med, Warren Alpert Med Sch, Providence, RI 02912 USA.
RP Kalichman, SC (corresponding author), Univ Connecticut, Dept Psychol, 406 Babbidge Rd, Storrs, CT 06269 USA.
EM seth.k@uconn.edu
FU National Institute on Drug AbuseUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute on Drug Abuse (NIDA) [R01-DA033067]
FX Supported by the National Institute on Drug Abuse Grant R01-DA033067.
CR Adepoju P, 2020, LANCET HIV, V7, pE319, DOI 10.1016/S2352-3018(20)30109-0
   Algarin AB, 2020, AIDS BEHAV, V24, P2236, DOI 10.1007/s10461-020-02869-3
   Anderson BL, 2008, CLIN INFECT DIS, V47, P1216, DOI 10.1086/592303
   [Anonymous], 2020, MOL REALTIME HIV 1 A
   Atlanta Co, 2020, CIT ATL COR DIS 2019
   Barr T, 2016, PROG NEURO-PSYCHOPH, V65, DOI 10.1016/j.pnpbp.2015.09.001
   Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9
   Carrico AW, 2020, AIDS BEHAV, V24, P3020, DOI 10.1007/s10461-020-02854-w
   Cook JT, 2008, ANN NY ACAD SCI, V1136, P193, DOI 10.1196/annals.1425.001
   Cunningham WE, 2000, J ACQ IMMUN DEF SYND, V25, P115, DOI 10.1097/00126334-200010010-00005
   de Pee S, 2010, FOOD NUTR BULL, V31, pS313, DOI 10.1177/15648265100314S403
   Drain Paul K, 2020, EClinicalMedicine, V22, P100342, DOI 10.1016/j.eclinm.2020.100342
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Gaydos J, 2016, AM J PHYSIOL-LUNG C, V310, pL507, DOI 10.1152/ajplung.00242.2015
   Health GDoP, GEORG DEP PUBL HLTH
   Humeniuk R, 2008, ADDICTION, V103, P1039, DOI 10.1111/j.1360-0443.2007.02114.x
   Jiang HB, 2020, LANCET HIV, V7, pE308, DOI 10.1016/S2352-3018(20)30105-3
   Jiang W, 2018, CURR HIV RES, V16, P143, DOI [10.2174/1570162X16666180703151208, 10.2174/1570162x16666180703151208]
   Karoly HC, 2018, ALCOHOL CLIN EXP RES, V42, P531, DOI 10.1111/acer.13592
   Kay ES, 2020, AIDS BEHAV, V24, P2461, DOI 10.1007/s10461-020-02879-1
   Kretchy I. A., 2020, RES SOC ADM PHARM
   Kummer N, 2016, DRUG ALCOHOL DEPEN, V165, P191, DOI 10.1016/j.drugalcdep.2016.06.012
   KUTTER D, 1974, DEUT MED WOCHENSCHR, V99, P2332, DOI 10.1055/s-0028-1108134
   Laisaar KT, 2013, AIDS CARE, V25, P863, DOI 10.1080/09540121.2013.764393
   Liu R, 2020, CLIN CHEM LAB MED, V58, P1121, DOI 10.1515/cclm-2020-0220
   Maisto SA, 2000, PSYCHOL ASSESSMENT, V12, P346, DOI 10.1037/1040-3590.12.3.346
   Marasca C, 2020, CLIN EXP DERMATOL, V45, P749, DOI 10.1111/ced.14245
   Marhefka S, 2020, AIDS BEHAV, V24, P1983, DOI 10.1007/s10461-020-02837-x
   McLinden T, 2020, AIDS BEHAV, V24, P2766, DOI 10.1007/s10461-020-02904-3
   Monnig MA, 2017, AM J DRUG ALCOHOL AB, V43, P7, DOI 10.1080/00952990.2016.1211667
   Ozma Mahdi Asghari, 2020, Infez Med, V28, P153
   Ridgway JP, 2020, AIDS BEHAV, V24, P2770, DOI 10.1007/s10461-020-02905-2
   SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x
   Shiau S, 2020, AIDS BEHAV, V24, P2244, DOI 10.1007/s10461-020-02871-9
   Shoptaw S, 2012, INT J STD AIDS, V23, P576, DOI 10.1258/ijsa.2012.011322
   Stein MB, 2020, DEPRESS ANXIETY, V37, P302, DOI 10.1002/da.23014
   Tang N, 2017, J CLIN VIROL, V92, P56, DOI 10.1016/j.jcv.2017.05.002
   Today U., 3 MONTHS TIMELINE CO
   Valdiserri RO, 2020, AIDS BEHAV, V24, P1980, DOI 10.1007/s10461-020-02859-5
   Volkow ND, 2020, ANN INTERN MED, V173, P61, DOI 10.7326/M20-1212
   Wang RR, 2020, INT J INFECT DIS, V95, P421, DOI 10.1016/j.ijid.2020.03.070
   Wilson IB, 2014, AIDS BEHAV, V18, P2349, DOI 10.1007/s10461-013-0610-1
   Zhao QW, 2020, J MED VIROL, V92, P1915, DOI 10.1002/jmv.25889
   2020, MMWR MORBID MORTAL W, V69, P343
NR 44
TC 1
Z9 1
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD SEP 1
PY 2020
VL 85
IS 1
BP 66
EP 72
DI 10.1097/QAI.0000000000002414
PG 7
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA NQ8PN
UT WOS:000571130000015
PM 32530862
OA Green Published
DA 2021-01-01
ER

PT J
AU Shekhar, R
   Barton, A
   Sheikh, A
   Upadhyay, S
   Salas, NM
AF Shekhar, Rahul
   Barton, Ashley
   Sheikh, Abu Baker
   Upadhyay, Shubhra
   Salas, Natalie M.
TI Coronavirus Disease of 2019 in Patients With Well-Controlled Human
   Immunodeficiency Virus on Antiretroviral Therapy
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Letter
ID HIV; COVID-19
AB Supplemental Digital Content is Available in the Text.
C1 [Shekhar, Rahul; Sheikh, Abu Baker; Upadhyay, Shubhra] Univ New Mexico, Dept Internal Med, Hlth Sci Ctr, Albuquerque, NM 87131 USA.
   [Barton, Ashley] Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA.
   [Salas, Natalie M.] Univ New, Hlth Sci Ctr, Dept Infect Dis, Albuquerque, NM USA.
RP Shekhar, R (corresponding author), Univ New Mexico, Dept Internal Med, Hlth Sci Ctr, Albuquerque, NM 87131 USA.
CR Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Drain PK, 2020, ECLINICALMEDICINE, V22
   Guo W, 2020, SURVEY COVID 19 HIV, DOI [10.2139/ssrn.3550029, DOI 10.2139/SSRN.3550029]
   Jackson BS, 2019, SEMIN THROMB HEMOST, V45, P132, DOI 10.1055/s-0038-1676374
   Martinez MA, 2020, ANTIMICROB AGENTS CH, V64
   Mascolo S, 2020, J MED VIROL, V92, P1777, DOI 10.1002/jmv.25881
   Micieli E, 2007, BLOOD COAGUL FIBRIN, V18, P259, DOI 10.1097/MBC.0b013e32808738a3
   Nordling L, 2020, SCIENCE, V368, P117, DOI 10.1126/science.368.6487.117
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Shiau S, 2020, AIDS BEHAV, V24, P2244, DOI 10.1007/s10461-020-02871-9
   Wang MM, 2020, INT J INFECT DIS, V96, P148, DOI 10.1016/j.ijid.2020.04.060
   Wang T, 2020, LANCET HAEMATOL, V7, pE362, DOI 10.1016/S2352-3026(20)30109-5
   Zhao Juanjuan, 2020, Clin Infect Dis, V71, P2233, DOI 10.1093/cid/ciaa408
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 15
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD SEP 1
PY 2020
VL 85
IS 1
BP E1
EP E4
DI 10.1097/QAI.0000000000002415
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA NQ8PN
UT WOS:000571130000001
PM 32568765
OA Green Published
DA 2021-01-01
ER

PT J
AU Roca-Gines, J
   Torres-Navarro, I
   Sanchez-Arraez, J
   Abril-Perez, C
   Sabalza-Baztan, O
   Pardo-Granell, S
   Cozar, VMI
   Botella-Estrada, R
   Evole-Buselli, M
AF Roca-Gines, Juncal
   Torres-Navarro, Ignacio
   Sanchez-Arraez, Javier
   Abril-Perez, Carlos
   Sabalza-Baztan, Oihana
   Pardo-Granell, Sergio
   Cozar, Vicent Martinez i
   Botella-Estrada, Rafael
   Evole-Buselli, Montserrat
TI Assessment of Acute Acral Lesions in a Case Series of Children and
   Adolescents During the COVID-19 Pandemic
SO JAMA DERMATOLOGY
LA English
DT Article
AB Importance A novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has recently been identified as the cause of a pandemic called coronavirus disease 2019 (COVID-19). In this context, some associated skin diseases have been described. Cutaneous lesions referred to as acute acro-ischemia have been reported as a possible sign of COVID-19 in adolescents and children. Objective To evaluate the pathogenesis of these newly described acute acral lesions. Design, Setting, and Participants This prospective case series was conducted at La Fe University Hospital, a tertiary referral hospital in Valencia, Spain, between April 9 and April 15, 2020. Among 32 referred patients, 20 children and adolescents with new-onset inflammatory lesions did not have a diagnosis. Exposures Patients were not exposed to any drug or other intervention. Main Outcomes and Measures We performed reverse transcriptase-polymerase chain reaction for SARS-CoV-2 and a range of blood tests for possible origins of the lesions. Skin biopsies were performed in 6 patients. Results Of the 20 patients enrolled, 7 were female and 13 were male, with an age range of 1 to 18 years. Clinical findings fit into the following patterns: acral erythema (6 patients), dactylitis (4 patients), purpuric maculopapules (7 patients), and a mixed pattern (3 patients). None of the patients had remarkable hematologic or serologic abnormalities, including negative antibodies to SARS-CoV-2. Biopsies performed in 6 patients showed histologic findings characteristic of perniosis. Conclusions and Relevance The clinical, histologic, and laboratory test results were compatible with a diagnosis of perniosis, and no evidence was found to support the implication of SARS-CoV-2 infection.
   This case series describes 20 children and adolescents who presented with new-onset acral inflammatory lesions during the COVID-19 pandemic.
   Question What is the association between acute acral lesions and coronavirus disease 2019 (COVID-19) in children and adolescents? Findings In this case series of 20 patients aged 1 to 18 years with new-onset acral inflammatory lesions, all lacked systemic manifestations of COVID-19. Both reverse transcriptase-polymerase chain reaction and serologic test results were negative for severe acute respiratory syndrome coronavirus 2. Meaning An association between acral skin disease and COVID-19 has yet to be proved.
C1 [Roca-Gines, Juncal; Torres-Navarro, Ignacio; Sanchez-Arraez, Javier; Abril-Perez, Carlos; Botella-Estrada, Rafael; Evole-Buselli, Montserrat] Hosp Univ & Politecn La Fe, Dept Dermatol, 106 Fernando Abril Martorell Ave, Valencia 46026, Spain.
   [Sabalza-Baztan, Oihana; Pardo-Granell, Sergio] Hosp Univ & Politecn La Fe, Dept Microbiol, Valencia, Spain.
   [Cozar, Vicent Martinez i] Hosp Univ & Politecn La Fe, Dept Pathol, Valencia, Spain.
   [Botella-Estrada, Rafael] Univ Valencia, Sch Med, Dept Med, Valencia, Spain.
RP Torres-Navarro, I (corresponding author), Hosp Univ & Politecn La Fe, Dept Dermatol, 106 Fernando Abril Martorell Ave, Valencia 46026, Spain.
EM nacho.torres.navarro@gmall.com
FU Department of Dermatology of La Fe University Hospital
FX This study was funded by the Department of Dermatology of La Fe
   University Hospital.
CR Cribier B, 2001, J AM ACAD DERMATOL, V45, P924, DOI 10.1067/mjd.2001.117861
   Fernandez-Nieto D, 2020, J AM ACAD DERMATOL, V83, pE61, DOI 10.1016/j.jaad.2020.04.093
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hedou M, 2020, J EUR ACAD DERMATOL, V34, pE299, DOI 10.1111/jdv.16519
   Landa N, 2020, INT J DERMATOL, V59, P739, DOI 10.1111/ijd.14937
   Lechien JR, 2020, EUR ARCH OTO-RHINO-L, V277, P2251, DOI 10.1007/s00405-020-05965-1
   Magro C, 2020, TRANSL RES, V220, P1, DOI 10.1016/j.trsl.2020.04.007
   Mazzotta F, 2020, DERMATOLOGIA PEDIAT
   McIntosh K., 2020, CORONAVIRUS DIS 2019
   Piccolo V, 2020, J EUR ACAD DERMATOL, V34, pE291, DOI 10.1111/jdv.16526
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE346, DOI 10.1111/jdv.16533
   Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
   Romani J, 2020, ACTAS DERMOSIFILIOGR
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wu F., 2020, NEUTRALIZING ANTIBOD, DOI [10.2139/ssrn.3566211, DOI 10.2139/SSRN.3566211]
NR 15
TC 10
Z9 10
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6068
EI 2168-6084
J9 JAMA DERMATOL
JI JAMA Dermatol.
PD SEP
PY 2020
VL 156
IS 9
BP 992
EP 997
DI 10.1001/jamadermatol.2020.2340
PG 6
WC Dermatology
SC Dermatology
GA NR9KJ
UT WOS:000571881200009
PM 32584397
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Shekerdemian, LS
   Mahmood, NR
   Wolfe, KK
   Riggs, BJ
   Ross, CE
   McKiernan, CA
   Heidemann, SM
   Kleinman, LC
   Sen, AI
   Hall, MW
   Priestley, MA
   McGuire, JK
   Boukas, K
   Sharron, MP
   Burns, JP
AF Shekerdemian, Lara S.
   Mahmood, Nabihah R.
   Wolfe, Katie K.
   Riggs, Becky J.
   Ross, Catherine E.
   McKiernan, Christine A.
   Heidemann, Sabrina M.
   Kleinman, Lawrence C.
   Sen, Anita I.
   Hall, Mark W.
   Priestley, Margaret A.
   McGuire, John K.
   Boukas, Konstantinos
   Sharron, Matthew P.
   Burns, Jeffrey P.
CA Int COVID 19 PICU Collaborative
TI Characteristics and Outcomes of Children With Coronavirus Disease 2019
   (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive
   Care Units
SO JAMA PEDIATRICS
LA English
DT Article
AB Question What has been the early experience of coronavirus disease 2019 (COVID-19) in pediatric intensive care units (PICUs)? Findings In this cross-sectional study of 46 North American PICUs, between March 14 and April 3, 2020, 48 children were admitted to 14 PICUs in the US and none in Canada. A total of 40 children (83%) had preexisting underlying medical conditions, 35 (73%) presented with respiratory symptoms, and 18 (38%) required invasive ventilation, and the hospital mortality rate was 4.2%. Meaning This early study shows that COVID-19 can result in a significant disease burden in children but confirms that severe illness is less frequent, and early hospital outcomes in children are better than in adults.
   This cross-sectional study describes and characterizes coronavirus disease 2019 (COVID-19) infection in North American pediatric intensive care units, including mode of presentation, presence of comorbidities, severity of disease, therapeutic interventions, clinical trajectory, and early outcomes.
   Importance The recent and ongoing coronavirus disease 2019 (COVID-19) pandemic has taken an unprecedented toll on adults critically ill with COVID-19 infection. While there is evidence that the burden of COVID-19 infection in hospitalized children is lesser than in their adult counterparts, to date, there are only limited reports describing COVID-19 in pediatric intensive care units (PICUs). Objective To provide an early description and characterization of COVID-19 infection in North American PICUs, focusing on mode of presentation, presence of comorbidities, severity of disease, therapeutic interventions, clinical trajectory, and early outcomes. Design, Setting, and Participants This cross-sectional study included children positive for COVID-19 admitted to 46 North American PICUs between March 14 and April 3, 2020. with follow-up to April 10, 2020. Main Outcomes and Measures Prehospital characteristics, clinical trajectory, and hospital outcomes of children admitted to PICUs with confirmed COVID-19 infection. Results Of the 48 children with COVID-19 admitted to participating PICUs, 25 (52%) were male, and the median (range) age was 13 (4.2-16.6) years. Forty patients (83%) had significant preexisting comorbidities; 35 (73%) presented with respiratory symptoms and 18 (38%) required invasive ventilation. Eleven patients (23%) had failure of 2 or more organ systems. Extracorporeal membrane oxygenation was required for 1 patient (2%). Targeted therapies were used in 28 patients (61%), with hydroxychloroquine being the most commonly used agent either alone (11 patients) or in combination (10 patients). At the completion of the follow-up period, 2 patients (4%) had died and 15 (31%) were still hospitalized, with 3 still requiring ventilatory support and 1 receiving extracorporeal membrane oxygenation. The median (range) PICU and hospital lengths of stay for those who had been discharged were 5 (3-9) days and 7 (4-13) days, respectively. Conclusions and Relevance This early report describes the burden of COVID-19 infection in North American PICUs and confirms that severe illness in children is significant but far less frequent than in adults. Prehospital comorbidities appear to be an important factor in children. These preliminary observations provide an important platform for larger and more extensive studies of children with COVID-19 infection.
C1 [Shekerdemian, Lara S.] Baylor Coll Med, Texas Childrens Hosp, 6651 Main St, Houston, TX 77030 USA.
   [Mahmood, Nabihah R.] Childrens Healthcare Atlanta, Atlanta, GA USA.
   [Wolfe, Katie K.] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp, Chicago, IL 60611 USA.
   [Riggs, Becky J.] Johns Hopkins Sch Med, Johns Hopkins Childrens Ctr, Baltimore, MD USA.
   [Ross, Catherine E.] Harvard Med Sch, Boston Childrens Hosp, Boston, MA 02115 USA.
   [McKiernan, Christine A.] Baystate Childrens Hosp, UMass Med Sch, Baystate Campus, Springfield, MA USA.
   [Heidemann, Sabrina M.] Wayne State Univ, Childrens Hosp Michigan, Detroit, MI USA.
   [Kleinman, Lawrence C.] Rutgers State Univ, Robert Wood Johnson Med Sch, Bristol Myers Squibb Hosp, New Brunswick, NJ USA.
   [Sen, Anita I.] Columbia Univ, Med Ctr, NewYork Presbyterian Morgan Stanley Childrens Hos, New York, NY USA.
   [Hall, Mark W.] Ohio State Univ, Coll Med, Nationwide Childrens Hosp, Columbus, OH 43210 USA.
   [Priestley, Margaret A.] Univ Penn, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
   [McGuire, John K.] Univ Washington, Seattle Childrens Hosp, Seattle, WA 98195 USA.
   [Boukas, Konstantinos] Univ Texas Houston, Childrens Mem Hermann Hosp, Houston, TX USA.
   [Sharron, Matthew P.] George Washington Sch Med, Childrens Natl Med Ctr, Washington, DC USA.
   [Burns, Jeffrey P.] Harvard Med Sch, Boston Childrens Hosp, Boston, MA 02115 USA.
RP Shekerdemian, LS (corresponding author), Baylor Coll Med, Texas Childrens Hosp, 6651 Main St, Houston, TX 77030 USA.
EM lssheker@texaschildrens.org
CR Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500
   Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Costanzo M, 2020, CURR MED CHEM, V27, P4536, DOI 10.2174/0929867327666200416131117
   Di Giambenedetto S, 2020, J MED VIROL, V92, P1787, DOI 10.1002/jmv.25897
   Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3
   Infectious Diseases Society of America, INF DIS SOC AM GUID
   Johns Hopkins University of Medicine, COVID 19 DASHB CTR S
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   National Vital Statistics System, PROV DEATH COUNTS CO
   OPENPediatrics, COR DIS COVID 19
   Sturrock BRH, 2020, CLIN MED, V20, P278, DOI 10.7861/clinmed.2020-0129
   U.S. Centers for Disease Control and Prevention, CAS US
   US Centers for Disease Control and Prevention, WEEKL US INFL SURV R
   Wu Z, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI [10.1001/jama.2020.2648, DOI 10.1001/JAMA.2020.2648]
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 15
TC 94
Z9 97
U1 4
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6203
EI 2168-6211
J9 JAMA PEDIATR
JI JAMA Pediatr.
PD SEP
PY 2020
VL 174
IS 9
BP 868
EP 873
DI 10.1001/jamapediatrics.2020.1948
PG 6
WC Pediatrics
SC Pediatrics
GA NR9FJ
UT WOS:000571868200011
PM 32392288
DA 2021-01-01
ER

PT J
AU Parra-Lara, LG
   Martinez-Arboleda, JJ
   Rosso, F
AF Parra-Lara, Luis Gabriel
   Jose Martinez-Arboleda, Juan
   Rosso, Fernando
TI Azithromycin and SARS-CoV-2 infection: Where we are now and where we are
   going
SO JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
LA English
DT Article
DE Azithromycin; Severe acute respiratory syndrome corona-virus 2;
   SARS-CoV-2; COVID-19; Clinical trial
ID HYDROXYCHLOROQUINE; PROLONGATION; COVID-19
C1 [Parra-Lara, Luis Gabriel; Jose Martinez-Arboleda, Juan; Rosso, Fernando] Univ Icesi, Fac Ciencias Salud, Calle 18 122135, Cali 760031, Colombia.
   [Rosso, Fernando] Fdn Valle Lili, Dept Med Interna, Serv Infectol, Cali 760032, Colombia.
   [Rosso, Fernando] Fdn Valle Lili, Ctr Invest Clin CIC, Cali 760032, Colombia.
RP Parra-Lara, LG (corresponding author), Univ Icesi, Fac Ciencias Salud, Calle 18 122135, Cali 760031, Colombia.
EM luisgabrielparralara@hotmail.com
RI Lara, Luis Gabriel Parra/X-3966-2018
OI Lara, Luis Gabriel Parra/0000-0002-4877-1117; Martinez, Juan
   Jose/0000-0002-7525-1520
CR Banjanac M, 2012, PHARMACOL RES, V66, P357, DOI 10.1016/j.phrs.2012.06.011
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   EMA, 2020, COVID 19 REM RISK SE
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Hancox JC, 2013, THER ADV INFECT DIS, V1, P155, DOI 10.1177/2049936113501816
   Kagkelaris KA, 2018, THER ADV OPHTHALMOL, V10, DOI 10.1177/2515841418783622
   Mercuro NJ, 2020, JAMA CARDIOL, V5, P1036, DOI 10.1001/jamacardio.2020.1834
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Ohe M, 2020, BIOSCI TRENDS, V14, P159, DOI 10.5582/bst.2020.03058
   Sargiacomo C, 2020, AGING-US, V12, P6511, DOI 10.18632/aging.103001
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
NR 13
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-7165
EI 2213-7173
J9 J GLOB ANTIMICROB RE
JI J. Glob. Antimicrob. Resist.
PD SEP
PY 2020
VL 22
BP 680
EP 684
DI 10.1016/j.jgar.2020.06.016
PG 5
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA NS4CB
UT WOS:000572210500035
PM 32622008
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Alkholy, UM
   Salama, ME
   Mahmoud, H
   Taher, A
   Elsayes, KM
AF Alkholy, Usama M.
   Salama, Mohamed E.
   Mahmoud, Hagar
   Taher, Ahmed
   Elsayes, Khaled M.
TI Could Bordetella pertussis vaccine protect against coronavirus COVID-19?
SO JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
LA English
DT Article
AB According to the World Health Organization (WHO), as of today, there are 2.165.500 confirmed cases of the novel coronavirus disease (COVID-19) and 145.705 deaths in over 185 countries. Unfortunately, despite the tremendous efforts to develop a vaccine initiated by various leading health institutions all over the world, it may be 18 months before a vaccine against the coronavirus is publicly available. We are proposing a theory about testing the use of the Bordetella pertussis vaccine to protect against COVID-19. We deliver this theory to the scientific community, aiming to raise the concern about it, and to provide us with support by realistic and experimental evidence. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.
C1 [Alkholy, Usama M.] Zagazig Univ, Zagazig, Egypt.
   [Salama, Mohamed E.] Mayo Clin, 200 First St SW, Rochester, MN USA.
   [Mahmoud, Hagar; Taher, Ahmed; Elsayes, Khaled M.] Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.
RP Elsayes, KM (corresponding author), Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM usamaalkoly@yahoo.com; Salama.Mohamed@mayo.edu;
   HSMahmoud@mdanderson.org; artaher@mdanderson.org;
   KMElsayes@mdanderson.org
CR Fischer JE, 1999, J INFECT DIS, V180, P714, DOI 10.1086/314947
   Kline JM, 2013, AM FAM PHYSICIAN, V88, P507
   Li R, 2010, J VIROL, V84, P7105, DOI 10.1128/JVI.02542-09
   Roser M, 2020, CORONAVIRUS DIS COVI
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Schnoeller C, 2014, AM J RESP CRIT CARE, V189, P194, DOI [10.1164/rccm.201307-227OC, 10.1164/rccm.201307-1227OC]
NR 6
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-7165
EI 2213-7173
J9 J GLOB ANTIMICROB RE
JI J. Glob. Antimicrob. Resist.
PD SEP
PY 2020
VL 22
BP 803
EP 805
DI 10.1016/j.jgar.2020.07.005
PG 3
WC Infectious Diseases; Pharmacology & Pharmacy
SC Infectious Diseases; Pharmacology & Pharmacy
GA NS4CB
UT WOS:000572210500049
PM 32682930
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Shi, W
   Lv, JG
   Lin, L
AF Shi, Wei
   Lv, Jiagao
   Lin, Li
TI Coagulopathy in COVID-19: Focus on vascular thrombotic events
SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
LA English
DT Article
DE COVID-19; SARS-CoV-2; Hypercoagulability; Thrombosis
ID ACUTE RESPIRATORY SYNDROME; CLINICAL CHARACTERISTICS; SARS-CORONAVIRUS;
   CYTOKINE STORM; PNEUMONIA; COMPLEMENT; OUTBREAK; ANGIOTENSIN-(1-7);
   INFECTIONS; HYDROXYCHLOROQUINE
AB SARS-CoV-2 causes a phenotype of pneumonia with diverse manifestation, which is termed as coronavirus disease 2019 (COVID-19). An impressive high transmission rate allows COVID-19 conferring enormous challenge for clinicians worldwide, and developing to a pandemic level. Combined with a series of complications, a part of COVID-19 patients progress into severe cases, which critically contributes to the risk of fatality. To date, coagulopathy has been found as a prominent feature of COVID-19 and severe coagulation dysfunction may be associated with poor prognosis. Coagulopathy in COVID-19 may predispose patients to hypercoagulability-related disorders including thrombosis and even fatal vascular events. Inflammatory storm, uncontrolled inflammation-mediated endothelial injury and renin angiotensin system (RAS) dysregulation are the potential mechanisms. Ongoing efforts made to develop promising therapies provide several potential strategies for hypercoagulability in COVID-19. In this review, we introduce the clinical features of coagulation and the increased vascular thrombotic risk conferred by coagulopathy according to present reports about COVID-19. The potential underlying mechanisms and emerging therapeutic avenues are discussed, emphasizing an urgent need for effective interventions.
C1 [Shi, Wei; Lv, Jiagao; Lin, Li] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Internal Med,Div Cardiol, Jiefang Ave 1095, Wuhan 430030, Peoples R China.
RP Lv, JG; Lin, L (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Internal Med,Div Cardiol, Jiefang Ave 1095, Wuhan 430030, Peoples R China.
EM shwetjmu@163.com; lujiagao@tjh.tjmu.edu.cn; linlee271227@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81570416]; Fundamental Research Fund for the
   Central Universities (HUST) [2017KFYXJJ099]; Science and Technology
   Project Foundation of Wuhan [2017060201010175]; Hubei Province health
   and family planning scientific research project [WJ2019M120]
FX This review was supported by National Natural Science Foundation of
   China to Li Lin (81570416), the Fundamental Research Fund for the
   Central Universities (HUST) to Jiagao Lv (2017KFYXJJ099), the Science
   and Technology Project Foundation of Wuhan to Jiagao Lv
   (2017060201010175), Hubei Province health and family planning scientific
   research project to Jiagao Lv (WJ2019M120).
CR Akhmerov A, 2020, CIRC RES, V126, P1443, DOI 10.1161/CIRCRESAHA.120.317055
   Al-Abdallat MM, 2014, CLIN INFECT DIS, V59, P1225, DOI 10.1093/cid/ciu359
   Amgalan A, 2020, J THROMB HAEMOST, V18, P1514, DOI 10.1111/jth.14832
   Martinez-Rojas MA, 2020, AM J PHYSIOL-RENAL, V318, pF1454, DOI 10.1152/ajprenal.00160.2020
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Barrett CD, 2020, J TRAUMA ACUTE CARE, V89, P453, DOI 10.1097/TA.0000000000002786
   Bendapudi PK, 2017, LANCET HAEMATOL, V4, pE157, DOI 10.1016/S2352-3026(17)30026-1
   Benucci M, 2020, J MED VIROL, V92, P2368, DOI 10.1002/jmv.26062
   Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876
   Bray MA, 2020, TRANSL RES, V225, P105, DOI 10.1016/j.trsl.2020.05.006
   Callaway E, 2020, NATURE, V579, P482, DOI 10.1038/d41586-020-00758-2
   Campbell CM, 2020, CIRCULATION, V141, P1739, DOI 10.1161/CIRCULATIONAHA.120.047419
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chaturvedi S, 2020, BLOOD, V135, P239, DOI 10.1182/blood.2019003863
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cheng ZY, 2020, ACTA CARDIOL, DOI [10.2214/AJR.20.22959, 10.1080/00015385.2020.1746497]
   Chong PY, 2004, ARCH PATHOL LAB MED, V128, P195
   Christie DB, 2020, J TRAUMA ACUTE CARE, V89, P448, DOI 10.1097/TA.0000000000002787
   Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Danzi GB, 2020, EUR HEART J, V41, P1858, DOI 10.1093/eurheartj/ehaa254
   Du LY, 2007, BIOCHEM BIOPH RES CO, V359, P174, DOI 10.1016/j.bbrc.2007.05.092
   Fontes JA, 2015, CYTOKINE, V74, P62, DOI 10.1016/j.cyto.2014.12.024
   Fox SE, 2020, LANCET RESP MED, V8, P681, DOI 10.1016/S2213-2600(20)30243-5
   Fraga-Silva RA, 2012, THROMB HAEMOSTASIS, V108, P1089, DOI 10.1160/TH12-06-0396
   Fraga-Silva RA, 2010, MOL MED, V16, P210, DOI 10.2119/molmed.2009.00160
   Fraga-Silva RA, 2008, MOL MED, V14, P28, DOI 10.2119/2007-00073.Fraga-Silva
   Fraga-Silva RA, 2011, CLINICS, V66, P837, DOI 10.1590/S1807-59322011000500021
   Galeano-Valle F, 2020, THROMB RES, V192, P113, DOI 10.1016/j.thromres.2020.05.017
   Gao T., 2020, HIGHLY PATHOGENIC CO
   Gao Y, 2020, SCIENCE, V368, P779, DOI 10.1126/science.abb7498
   Gao Y, 2020, J MED VIROL, V92, P791, DOI 10.1002/jmv.25770
   George JN, 2006, NEW ENGL J MED, V354, P1927, DOI 10.1056/NEJMcp053024
   Giannis D, 2020, J CLIN VIROL, V127, DOI 10.1016/j.jcv.2020.104362
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   Gralinski LE, 2013, MBIO, V4, DOI 10.1128/mBio.00271-13
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Gu JG, 2020, P I MECH ENG C-J MEC, DOI 10.1177/0954406220937038
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han H, 2020, CLIN CHEM LAB MED, V58, P1116, DOI 10.1515/cclm-2020-0188
   Harzallah I, 2020, J THROMB HAEMOST, V18, P2064, DOI 10.1111/jth.14867
   Henry BM, 2020, CLIN CHEM LAB MED, V58, P1021, DOI 10.1515/cclm-2020-0369
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   HUISMAN A, 2020, INT J LAB HEMAT 0522, DOI DOI 10.1111/IJLH.13230
   Ji HL, 2020, PHYSIOL REV, V100, P1065, DOI 10.1152/physrev.00013.2020
   Jiang YT, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0063-8
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Kwong JC, 2018, NEW ENGL J MED, V378, P345, DOI 10.1056/NEJMoa1702090
   Le Berre A, 2020, DIAGN INTERV IMAG, V101, P321, DOI 10.1016/j.diii.2020.04.003
   Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Levi M, 2020, LANCET HAEMATOL, V7, pE438, DOI 10.1016/S2352-3026(20)30145-9
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li HM, 2014, J MED CHEM, V57, P632, DOI 10.1021/jm401144z
   Li X, 2020, INT J INFECT DIS, V94, P128, DOI 10.1016/j.ijid.2020.03.053
   Li YY, 2020, BIOCHEM BIOPH RES CO, V526, P947, DOI 10.1016/j.bbrc.2020.04.010
   Lippi G, 2020, THROMB HAEMOSTASIS, V120, P876, DOI 10.1055/s-0040-1709650
   Lippi G, 2020, CLIN CHIM ACTA, V506, P145, DOI 10.1016/j.cca.2020.03.022
   Liu M, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE016, DOI [10.3760/cma.j.issn.1001-0939.2020.03.014, 10.3760/cma.j.issn.1001-0939.2020.0016]
   Liu PP, 2020, CIRCULATION, V142, P68, DOI 10.1161/CIRCULATIONAHA.120.047549
   Luo P, 2020, J ENVIRON SCI HEAL A, V55, P1349, DOI [10.1002/jmv.25801, 10.1080/10934529.2020.1794444]
   Ma HY, 2019, CANCER SCI, V110, P950, DOI 10.1111/cas.13940
   Maatman TK, 2020, CRIT CARE MED, V48, pE783, DOI 10.1097/CCM.0000000000004466
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Matsuyama T, 2009, THROMB HAEMOSTASIS, V102, P371, DOI 10.1160/TH08-12-0825
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mei H, 2020, Zhonghua Xue Ye Xue Za Zhi, V41, P185, DOI 10.3760/cma.j.issn.0253-2727.2020.0002
   Mendoza-Pinto C, 2018, CURR RHEUMATOL REP, V20, DOI 10.1007/s11926-018-0773-x
   Meroni PL, 2011, NAT REV RHEUMATOL, V7, P330, DOI 10.1038/nrrheum.2011.52
   Meyerowitz EA, 2020, FASEB J, V34, P6027, DOI 10.1096/fj.202000919
   Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Ng WF, 2006, PATHOLOGY, V38, P210, DOI 10.1080/00313020600696280
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   PAN YY, 2020, CLIN INFECT DIS, V20, DOI DOI 10.1093/CID/CIAA237
   Pedersen KB, 2015, ENDOCRINOLOGY, V156, P4411, DOI 10.1210/en.2015-1556
   Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5
   Peng Y D, 2020, Zhonghua Xin Xue Guan Bing Za Zhi, V48, P450, DOI 10.3760/cma.j.cn112148-20200220-00105
   Pengo V, 2010, J THROMB HAEMOST, V8, P237, DOI 10.1111/j.1538-7836.2009.03674.x
   Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430
   Poor HD, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.44
   Qu R, 2020, J MED VIROL, V92, P1533, DOI 10.1002/jmv.25767
   Ramlall V, 2020, IDENTIFICATION IMMUN
   Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914
   Rondeau E, 2020, KIDNEY INT, V97, P1287, DOI 10.1016/j.kint.2020.01.035
   Rossi R, 2020, EUR J INTERN MED, V77, P158, DOI 10.1016/j.ejim.2020.06.006
   Russo V, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104965
   Sampaio WO, 2007, HYPERTENSION, V49, P185, DOI 10.1161/01.HYP.0000251865.35728.2f
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Sartain SE, 2018, J BIOL CHEM, V293, P7195, DOI 10.1074/jbc.RA118.002639
   Schreiber K, 2018, RHEUMATOLOGY, V57, P120, DOI 10.1093/rheumatology/kex378
   Shi S, 2020, JAMA CARDIOL, P802, DOI [10.1001/jamacardio.2020.0950., DOI 10.1001/JAMACARDI0.2020.0950, 10.1001/jamacardio.2020.0950]
   Shi W, 2020, J CELL MOL MED, V24, P4748, DOI 10.1111/jcmm.15147
   Shi W, 2017, BIOCHEM BIOPH RES CO, V491, P159, DOI 10.1016/j.bbrc.2017.07.067
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287
   Skendros P, 2020, COMPLEMENT TISSUE FA
   South AM, 2020, AM J PHYSIOL-HEART C, V318, pH1084, DOI 10.1152/ajpheart.00217.2020
   Spiezia L, 2020, THROMB HAEMOSTASIS, V120, P998, DOI 10.1055/s-0040-1710018
   Sridharan M, 2018, MAYO CLIN PROC, V93, P1351, DOI 10.1016/j.mayocp.2018.07.008
   Stefanini GG, 2020, CIRCULATION, V141, P2113, DOI 10.1161/CIRCULATIONAHA.120.047525
   Tanaka T, 2016, IMMUNOTHERAPY-UK, V8, P959, DOI 10.2217/imt-2016-0020
   Tanaka T, 2014, CANCER IMMUNOL RES, V2, P288, DOI 10.1158/2326-6066.CIR-14-0022
   Tavazzi G, 2020, EUR J HEART FAIL, V22, P911, DOI 10.1002/ejhf.1828
   Thachil J, 2020, J THROMB HAEMOST, V18, P1020, DOI 10.1111/jth.14821
   Urbanski G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206814
   Uthman IW, 2002, SEMIN ARTHRITIS RHEU, V31, P256, DOI 10.1053/sarh.2002.28303
   van der Poll T, 2017, NAT REV IMMUNOL, V17, P407, DOI 10.1038/nri.2017.36
   Viecca M, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104950
   Wada H, 2014, J INTENSIVE CARE, V2, DOI 10.1186/2052-0492-2-15
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wan SX, 2020, J MED VIROL, V92, P797, DOI 10.1002/jmv.25783
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang J, 2020, J THROMB HAEMOST, V18, P1752, DOI 10.1111/jth.14828
   Wang XL, 2020, CELL MOL IMMUNOL, DOI 10.1038/s41423-020-0424-9
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xiong M, 2020, BRIT J HAEMATOL, V189, P1050, DOI 10.1111/bjh.16725
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Yan D, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00392
   Yang H, 2013, J INFECT DIS, V207, P50, DOI 10.1093/infdis/jis651
   Yang ZW, 2020, J INFECTION, V81, pE13, DOI 10.1016/j.jinf.2020.03.062
   Yin SY, 2020, J THROMB THROMBOLYS, DOI 10.1007/s11239-020-02105-8
   Yip R.M.L., 2019, JCR-J CLIN RHEUMATOL, DOI [10.1097/RHU., DOI 10.1097/RHU]
   Zhang GM, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01338-8
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang Y, 2020, Zhonghua Xue Ye Xue Za Zhi, V41, pE006, DOI [10.3760/cma.j.issn.0253-2727.2020.008, 10.3760/cma.j.issn.0253-2727.2020.0006]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zuo Mingzhang, 2020, Chinese Medical Sciences Journal, V35, P105, DOI 10.24920/003724
NR 137
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0022-2828
EI 1095-8584
J9 J MOL CELL CARDIOL
JI J. Mol. Cell. Cardiol.
PD SEP
PY 2020
VL 146
BP 32
EP 40
DI 10.1016/j.yjmcc.2020.07.003
PG 9
WC Cardiac & Cardiovascular Systems; Cell Biology
SC Cardiovascular System & Cardiology; Cell Biology
GA NR3MD
UT WOS:000571466000004
PM 32681845
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Wang, YB
   Foo, R
   Thum, T
AF Wang, Yibin
   Foo, Roger
   Thum, Thomas
TI Using "old" medications to fight new COVID-19: Re-purposing with a
   purpose
SO JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
LA English
DT Letter
DE COVID-19; SARS-CoV-2; Drug treatment; Inflammation; ACE inhibitors
C1 [Wang, Yibin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Anesthesiol Med & Physiol, Los Angeles, CA 90095 USA.
   [Foo, Roger] Natl Univ Singapore, Genome Inst Singapore, Cardiovasc Res Inst, Ctr Translat Med, Singapore, Singapore.
   [Thum, Thomas] Hannover Med Sch, Inst Mol & Translat Therapeut Strategies, Hannover, Germany.
   [Thum, Thomas] Hannover Med Sch, REBIRTH Ctr Translat Regenerat Med, Hannover, NH, Germany.
RP Wang, YB (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Anesthesiol Med & Physiol, Los Angeles, CA 90095 USA.; Thum, T (corresponding author), Hannover Med Sch, Inst Mol & Translat Therapeut Strategies, Hannover, Germany.
EM thum.thomas@mh-hannover.de
CR Beigel J. H., 2020, N ENGL J MED
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Cannata F., 2020, EUR HEART J CARDIOVA, DOI [10.1093/ehjcvp/pvaa056pvaa056, DOI 10.1093/EHJCVP/PVAA056PVAA056]
   Foo R, 2020, J MOL CELL CARDIOL, V141, P107, DOI 10.1016/j.yjmcc.2020.04.010
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Goldman Jason D, 2020, N Engl J Med, V383, P1827, DOI 10.1056/NEJMoa2015301
   Gross S, 2020, J MOL CELL CARDIOL, V144, P47, DOI 10.1016/j.yjmcc.2020.04.031
   Johnson Kyle, 2020, medRxiv, DOI 10.1101/2020.05.31.20118802
   Zhang P, 2020, CIRC RES, V126, P1671, DOI 10.1161/CIRCRESAHA.120.317134
   Zhang XJ, 2020, CELL METAB, V32, P176, DOI 10.1016/j.cmet.2020.06.015
NR 10
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0022-2828
EI 1095-8584
J9 J MOL CELL CARDIOL
JI J. Mol. Cell. Cardiol.
PD SEP
PY 2020
VL 146
BP 41
EP 42
DI 10.1016/j.yjmcc.2020.07.005
PG 2
WC Cardiac & Cardiovascular Systems; Cell Biology
SC Cardiovascular System & Cardiology; Cell Biology
GA NR3MD
UT WOS:000571466000005
PM 32687852
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Xia, P
   Wen, YB
   Duan, YQ
   Su, H
   Cao, W
   Xiao, M
   Ma, J
   Zhou, YZ
   Chen, G
   Jiang, W
   Wu, HN
   Hu, Y
   Xu, SP
   Cai, HH
   Liu, ZY
   Zhou, X
   Du, B
   Wang, JL
   Li, TS
   Yan, XW
   Chen, LM
   Liang, ZY
   Zhang, SY
   Zhang, C
   Qin, Y
   Wang, GP
   Li, XM
AF Xia, Peng
   Wen, Yubing
   Duan, Yaqi
   Su, Hua
   Cao, Wei
   Xiao, Meng
   Ma, Jie
   Zhou, Yangzhong
   Chen, Gang
   Jiang, Wei
   Wu, Huanwen
   Hu, Yan
   Xu, Sanpeng
   Cai, Hanghang
   Liu, Zhengyin
   Zhou, Xiang
   Du, Bin
   Wang, Jinglan
   Li, Taisheng
   Yan, Xiaowei
   Chen, Limeng
   Liang, Zhiyong
   Zhang, Shuyang
   Zhang, Chun
   Qin, Yan
   Wang, Guoping
   Li, Xuemei
TI Clinicopathological Features and Outcomes of Acute Kidney Injury in
   Critically Ill COVID-19 with Prolonged Disease Course: A Retrospective
   Cohort
SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
DE renal pathology; acute renal failure; kidney disease; COVID-19;
   critically ill
ID CORONAVIRUS; SARS-COV-2; WUHAN
AB Background The incidence, severity, and outcomes of AKI in COVID-19 varied in different reports. In patients critically ill with COVID-19, the clinicopathologic characteristics of AKI have not been described in detail.
   Methods This is a retrospective cohort study of 81 patients critically ill with COVID-19 in an intensive care unit. The incidence, etiologies, and outcomes of AKI were analyzed. Pathologic studies were performed in kidney tissues from ten deceased patients with AKI.
   Results A total of 41 (50.6%) patients experienced AKI in this study. The median time from illness to AKI was 21.0 (IQR, 9.5-26.0) days. The proportion of Kidney Disease Improving Global Outcomes (KDIGO) stage 1, stage 2, and stage 3 AKI were 26.8%, 31.7%, and 41.5%, respectively. The leading causes of AKI included septic shock (25 of 41, 61.0%), volume insufficiency (eight of 41, 19.5%), and adverse drug effects (five of 41, 12.2%). The risk factors for AKI included age (per 10 years) (HR, 1.83; 95% CI, 1.24 to 2.69; P=0.002) and serum IL-6 level (HR, 1.83; 95% CI, 1.23 to 2.73; P=0.003). KDIGO stage 3 AKI predicted death. Other potential risk factors for death included male sex, elevated D-dimer, serum IL-6 level, and higher Sequential Organ Failure Assessment score. The predominant pathologic finding was acute tubular injury. Nucleic acid tests and immunohistochemistry failed to detect the virus in kidney tissues.
   Conclusions AKI was a common and multifactorial complication in patients critically ill with COVID-19 at the late stage of the disease course. The predominant pathologic finding was acute tubular injury. Older age and higher serum IL-6 level were risk factors of AKI, and KDIGO stage 3 AKI independently predicted death.
C1 [Xia, Peng; Wen, Yubing; Ma, Jie; Zhou, Yangzhong; Chen, Gang; Hu, Yan; Chen, Limeng; Qin, Yan; Li, Xuemei] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Nephrol, 1 Shuaifuyuan,Wangfujing St, Beijing 100730, Peoples R China.
   [Duan, Yaqi; Xu, Sanpeng; Cai, Hanghang; Wang, Guoping] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Inst Pathol, 1095 Jie Fang Ave, Wuhan 430030, Peoples R China.
   [Duan, Yaqi; Wang, Guoping] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med Sci, Dept Pathol, Wuhan 430030, Peoples R China.
   [Su, Hua; Zhang, Chun] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Nephrol, Wuhan, Peoples R China.
   [Cao, Wei; Liu, Zhengyin; Li, Taisheng] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Infect Dis, Beijing, Peoples R China.
   [Xiao, Meng] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Lab Med, Beijing, Peoples R China.
   [Jiang, Wei; Du, Bin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Med ICU, Beijing, Peoples R China.
   [Wu, Huanwen; Liang, Zhiyong] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pathol, Beijing, Peoples R China.
   [Zhou, Xiang] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Intens Care Med, Beijing, Peoples R China.
   [Wang, Jinglan] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Pulm & Crit Care Med, Beijing, Peoples R China.
   [Yan, Xiaowei; Zhang, Shuyang] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Cardiol, Beijing, Peoples R China.
RP Qin, Y (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Nephrol, 1 Shuaifuyuan,Wangfujing St, Beijing 100730, Peoples R China.; Wang, GP (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Inst Pathol, 1095 Jie Fang Ave, Wuhan 430030, Peoples R China.; Wang, GP (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med Sci, Dept Pathol, Wuhan 430030, Peoples R China.
FU National Natural Sciences Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81970621]; Foundation of Tongji Hospital of
   Tongji Medical College, Huazhong University of Science and Technology
   [XXGZBDYJ010]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [3332019029]
FX This work was supported by National Natural Sciences Foundation of China
   grant 81970621 (to Y. Qin); Foundation of Tongji Hospital of Tongji
   Medical College, Huazhong University of Science and Technology grant
   XXGZBDYJ010 (to G. Wang); and Fundamental Research Funds for the Central
   Universities grant 3332019029 (to P. Xia).
CR Calomeni E, 2020, KIDNEY INT, V98, P233, DOI 10.1016/j.kint.2020.05.003
   Chanchal S, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00073
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen T, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m1091, 10.1136/bmj.m1295]
   Cheng YC, 2020, KIDNEY INT, V97, P829, DOI 10.1016/j.kint.2020.03.005
   Fan E, 2018, JAMA-J AM MED ASSOC, V319, P698, DOI 10.1001/jama.2017.21907
   Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913
   Goldsmith CS, 2020, LANCET, V395, pE99, DOI 10.1016/S0140-6736(20)31188-0
   Griffin BR, 2020, AM J KIDNEY DIS, V75, P435, DOI 10.1053/j.ajkd.2019.10.010
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hirsch JS, 2020, KIDNEY INT, V98, P209, DOI 10.1016/j.kint.2020.05.006
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789
   Li TH, 2020, EMERG MICROBES INFEC, V9, P687, DOI 10.1080/22221751.2020.1741327
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Ling Y, 2020, CHINESE MED J-PEKING, V133, P1039, DOI 10.1097/CM9.0000000000000774
   Ma J, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108408
   McNicholas BA, 2019, CRIT CARE MED, V47, P1216, DOI 10.1097/CCM.0000000000003832
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Miller SE, 2020, KIDNEY INT, V98, P231, DOI 10.1016/j.kint.2020.05.004
   Naicker S, 2020, KIDNEY INT, V97, P824, DOI 10.1016/j.kint.2020.03.001
   National Health Commission of China, GUID MAN COVID 19
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Panitchote A, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0552-5
   Pei GC, 2020, J AM SOC NEPHROL, V31, P1157, DOI 10.1681/ASN.2020030276
   Puelles VG, 2020, NEW ENGL J MED, V383, P590, DOI [10.1056/NEJMc2011400, 10.1056/NEJMc2013400]
   Shankar-Hari M, 2016, JAMA-J AM MED ASSOC, V315, P775, DOI 10.1001/jama.2016.0289
   Su H, 2020, KIDNEY INT, V98, P219, DOI 10.1016/j.kint.2020.04.003
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang LW, 2020, AM J NEPHROL, V51, P343, DOI 10.1159/000507471
   Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   WHO, COR DIS COVID 19 PAN
   Xie CB, 2020, INT J INFECT DIS, V93, P264, DOI 10.1016/j.ijid.2020.02.050
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Yao XH, 2020, ZHONGHUA BING LI XUE, V49, P411, DOI [DOI 10.3760/CMA.J.CN112151-20200312-00193, 10.3760/cma.j.cn112151-20200312-00193]
   Yao XH, 2020, CELL RES, V30, P541, DOI 10.1038/s41422-020-0318-5
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 42
TC 2
Z9 2
U1 1
U2 1
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1046-6673
EI 1533-3450
J9 J AM SOC NEPHROL
JI J. Am. Soc. Nephrol.
PD SEP
PY 2020
VL 31
IS 9
BP 2205
EP 2221
DI 10.1681/ASN.2020040426
PG 17
WC Urology & Nephrology
SC Urology & Nephrology
GA NR8KY
UT WOS:000571810200022
PM 32826326
OA Bronze
DA 2021-01-01
ER

PT J
AU Goel, S
   Hawi, S
   Goel, G
   Thakur, VK
   Agrawal, A
   Hoskins, C
   Pearce, O
   Hussain, T
   Upadhyaya, HM
   Cross, G
   Barber, AH
AF Goel, Saurav
   Hawi, Sara
   Goel, Gaurav
   Thakur, Vijay Kumar
   Agrawal, Anupam
   Hoskins, Clare
   Pearce, Oliver
   Hussain, Tanvir
   Upadhyaya, Hari M.
   Cross, Graham
   Barber, Asa H.
TI Resilient and agile engineering solutions to address societal challenges
   such as coronavirus pandemic
SO MATERIALS TODAY CHEMISTRY
LA English
DT Article
DE SARS CoV-2; Manufacturing; Sensing; Climate change; Nanotechnology; PPE
ID ACUTE RESPIRATORY SYNDROME; INFLUENZA-VIRUS; COATINGS; NANOPARTICLES;
   INACTIVATION; COVID-19; NANOSTRUCTURES; ANTIBACTERIAL; MEMBRANES; RATIO
AB The world is witnessing tumultuous times as major economic powers including the US, UK, Russia, India, and most of Europe continue to be in a state of lockdown. The worst-hit sectors due to this lockdown are sales, production (manufacturing), transport (aerospace and automotive) and tourism. Lockdowns became necessary as a preventive measure to avoid the spread of the contagious and infectious "Coronavirus Disease 2019" (COVID-19). This newly identified disease is caused by a new strain of the virus being referred to as Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS CoV-2; formerly called 2019-nCoV). We review the current medical and manufacturing response to COVID-19, including advances in instrumentation, sensing, use of lasers, fumigation chambers and development of novel tools such as lab-on-the-chip using combinatorial additive and subtractive manufacturing techniques and use of molecular modelling and molecular docking in drug and vaccine discovery. We also offer perspectives on future considerations on climate change, outsourced versus indigenous manufacturing, automation, and antimicrobial resistance. Overall, this paper attempts to identify key areas where manufacturing can be employed to address societal challenges such as COVID-19. (c) 2020 The Authors. Published by Elsevier Ltd.
C1 [Goel, Saurav; Goel, Gaurav; Upadhyaya, Hari M.; Barber, Asa H.] London South Bank Univ, Sch Engn, 103 Borough Rd, London SE1 0AA, England.
   [Goel, Saurav; Hawi, Sara] Cranfield Univ, Sch Aerosp Transport & Mfg, Bedford MK43 0AL, England.
   [Goel, Saurav; Thakur, Vijay Kumar] Shiv Nadar Univ, Dept Mech Engn, Greater Noida 201314, India.
   [Thakur, Vijay Kumar] Scotlands Rural Coll SRUC, Biorefining & Adv Mat Res Ctr, Kings Bldg, Edinburgh EH9 3JG, Midlothian, Scotland.
   [Agrawal, Anupam] Texas A&M Univ, Mays Business Sch, College Stn, TX USA.
   [Hoskins, Clare] Univ Strathclyde, Pure & Appl Chem, Glasgow G1 1RD, Lanark, Scotland.
   [Pearce, Oliver] Milton Keynes Univ Hosp, Orthopaed Dept, Milton Keynes MK6 5LD, Bucks, England.
   [Hussain, Tanvir] Univ Nottingham, Fac Engn, Nottingham NG7 2RD, England.
   [Cross, Graham] Adama Innovat Ltd, Dublin 2, Ireland.
   [Cross, Graham] Trinity Coll Dublin, Sch Phys, CRANN Nanosci Inst, Dublin 2, Ireland.
RP Goel, S (corresponding author), London South Bank Univ, Sch Engn, 103 Borough Rd, London SE1 0AA, England.
EM GoeLs@Lsbu.ac.uk
RI Thakur, Vijay Kumar/J-1691-2015; Goel, Gaurav/F-7136-2011; Cross,
   Graham/B-9447-2008; Hussain, Tanvir/A-5006-2011; Goel,
   Saurav/C-9714-2011
OI Thakur, Vijay Kumar/0000-0002-0790-2264; Goel,
   Gaurav/0000-0002-7656-1272; Cross, Graham/0000-0003-2299-6091; Hoskins,
   Clare/0000-0002-7200-0566; Hussain, Tanvir/0000-0001-8024-829X; Goel,
   Saurav/0000-0002-8694-332X
FU UKRI [EP/K503241/1, EP/L016567/1, EP/S013652/1, EP/T001100/1,
   EP/S036180/1, EP/T024607/1]; Royal Academy of EngineeringRoyal Academy
   of Engineering - UK [IAPP18-19\295, TSP1332]; Royal SocietyRoyal Society
   of London [NIF\R1\191571]; GCRF/EPSRC [EP/P032591/1]; H2020 (Cost
   Actions) [CA18125, CA18224, CA17136, CA16235]; H2020 (EURAMET EMPIR
   (2018)) [A185]
FX Authors are very much thankful to the Research support provided by the
   UKRI via Grants No.: (EP/K503241/1, EP/L016567/1, EP/S013652/1,
   EP/T001100/1, EP/S036180/1 and EP/T024607/1) as well as the GCRF/EPSRC
   supported SUNRISE program (EP/P032591/1). Additionally, we acknowledge
   the support received from H2020 (Cost Actions (CA18125, CA18224, CA17136
   and CA16235) and EURAMET EMPIR A185 (2018)), Royal Academy of
   Engineering Grant No. IAPP18-19\295 (Indo-UK partnership), Royal Academy
   of Engineering Grant No. TSP1332 (South Africa-UK partnership) and
   Newton Fellowship award from the Royal Society (NIF\R1\191571). Also,
   numerical calculations performed on the Isambard Bristol, UK and ARCHER
   HPC were made available by the EPSRC Resource Allocation Panel (RAP).
CR Ahmed SR, 2017, RSC ADV, V7, P40849, DOI 10.1039/c7ra07175b
   Ai T, 2020, RADIOLOGY, V296, pE32, DOI 10.1148/radiol.2020200642
   Aimi MF, 2004, NAT MATER, V3, P103, DOI 10.1038/nmat1058
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Angione MD, 2012, P NATL ACAD SCI USA, V109, P6429, DOI 10.1073/pnas.1200549109
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P1204, DOI 10.1021/acschemneuro.0c00181
   Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122
   Borkow G., 2010, PLOS ONE, P5
   Bourouiba L, 2020, JAMA-J AM MED ASSOC, V323, P1837, DOI 10.1001/jama.2020.4756
   Callaway E, 2020, NATURE, V579, P482, DOI 10.1038/d41586-020-00758-2
   Chan WCW, 2020, ACS NANO, V14, P3719, DOI 10.1021/acsnano.0c02540
   Chavoshi SZ, 2017, MATER DESIGN, V127, P37, DOI 10.1016/j.matdes.2017.04.057
   Cheang P, 1996, BIOMATERIALS, V17, P537, DOI 10.1016/0142-9612(96)82729-3
   Chellamani KP, 2013, J ACAD IND RES, V2, P320
   Chen YN, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13040430
   Chin Alex W H, 2020, Lancet Microbe, V1, pe10, DOI 10.1016/S2666-5247(20)30003-3
   Chouirfa H, 2019, ACTA BIOMATER, V83, P37, DOI 10.1016/j.actbio.2018.10.036
   Cross GLW, 2006, J PHYS D APPL PHYS, V39, pR363, DOI 10.1088/0022-3727/39/20/R01
   Darnell MER, 2004, J VIROL METHODS, V121, P85, DOI 10.1016/j.jviromet.2004.06.006
   Darnell MER, 2006, TRANSFUSION, V46, P1770, DOI 10.1111/j.1537-2995.2006.00976.x
   Das G, 2020, ACS CHEM NEUROSCI, V11, P1206, DOI 10.1021/acschemneuro.0c00201
   de Kraker M.E., 2016, PLOS MED, P13
   Eastman RT, 2020, ACS CENTRAL SCI, V6, P672, DOI 10.1021/acscentsci.0c00489
   Forster P., 2020, P NATL ACAD SCI USA
   Gaikwad S, 2013, INT J NANOMED, V8, P4303, DOI 10.2147/IJN.S50070
   GEESINK RGT, 1987, CLIN ORTHOP RELAT R, P147
   Ghani AC, 2005, AM J EPIDEMIOL, V162, P479, DOI 10.1093/aje/kwi230
   Hai WF, 2018, SENSOR ACTUAT B-CHEM, V260, P635, DOI 10.1016/j.snb.2018.01.081
   Haldar J, 2007, NAT PROTOC, V2, P2412, DOI 10.1038/nprot.2007.353
   Haldar J, 2008, BIOTECHNOL LETT, V30, P475, DOI 10.1007/s10529-007-9565-5
   Haldar J, 2006, P NATL ACAD SCI USA, V103, P17667, DOI 10.1073/pnas.0608803103
   Hallema DW, 2020, ECOL PROCESS, V9, DOI 10.1186/s13717-020-00231-y
   Han S, 1997, POLYMER, V38, P317, DOI 10.1016/S0032-3861(97)88175-X
   Hsu BB, 2011, P NATL ACAD SCI USA, V108, P61, DOI 10.1073/pnas.1017012108
   Jin S, 2020, ACS ENERGY LETT, V5, P1709, DOI 10.1021/acsenergylett.0c00910
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kerry RG, 2019, NANOMED-NANOTECHNOL, V18, P196, DOI 10.1016/j.nano.2019.03.004
   Kim D, 2020, CELL, V181, P914, DOI 10.1016/j.cell.2020.04.011
   Leung Nancy H L, 2020, Nat Med, V26, P676, DOI 10.1038/s41591-020-0843-2
   Li Y, 2018, RSC ADV, V8, P18272, DOI 10.1039/c8ra01985a
   Liao JJ, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19020218
   Lin N, 2018, ADV COLLOID INTERFAC, V252, P55, DOI 10.1016/j.cis.2017.12.007
   LIU Y, 2020, NATURE, DOI DOI 10.1080/14786419.2020.1815740
   Loeffelholz MJ, 2020, EMERG MICROBES INFEC, V9, P747, DOI 10.1080/22221751.2020.1745095
   Maxmen Amy, 2020, Nature, V580, P16, DOI 10.1038/d41586-020-00895-8
   McKenzie W, 2011, DIAM RELAT MATER, V20, P707, DOI 10.1016/j.diamond.2011.03.008
   Mukherjee M, 2018, ENVIRON SCI-WAT RES, V4, P1078, DOI [10.1039/c8ew00206a, 10.1039/C8EW00206A]
   Nakamura S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153620
   Pardee K, 2016, CELL, V165, P1255, DOI 10.1016/j.cell.2016.04.059
   Peng L, 2020, J MED VIROL, V92, P1676, DOI 10.1002/jmv.25936
   Quan F. S., 2017, SCI REPORTS, V7, P1, DOI DOI 10.HTTPS://D0I.0RG/10.1038/SREP39956
   Robbins T., 2020, COVID 19 NEW DIGITAL
   Sang P, 2020, RSC ADV, V10, P15775, DOI 10.1039/d0ra01899f
   Schroder I, 2020, ACS CHEM HEALTH SAFE, V27, P160, DOI 10.1021/acs.chas.0c00035
   Seo G, 2020, ACS NANO, V14, P5135, DOI 10.1021/acsnano.0c02823
   Speshock Janice L., 2010, Journal of Nanobiotechnology, V8, P19, DOI 10.1186/1477-3155-8-19
   Sun LM, 2001, J BIOMED MATER RES, V58, P570, DOI 10.1002/jbm.1056.abs
   Sundberg K., 2015, J BIOTECHNOL BIOMATE, V5, P2
   Te Velthuis A.J., 2010, PLOS PATHOG, V6
   Tiliket G, 2011, CHEM ENG J, V173, P341, DOI 10.1016/j.cej.2011.07.059
   Torsi L, 2013, CHEM SOC REV, V42, P8612, DOI 10.1039/c3cs60127g
   Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y
   Udugama B, 2020, ACS NANO, V14, P3822, DOI 10.1021/acsnano.0c02624
   Valitutto MT, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230802
   van Doremalen N, 2020, N ENGL J MED
   Vardelle A, 2016, J THERM SPRAY TECHN, V25, P1376, DOI 10.1007/s11666-016-0473-x
   Vincent M, 2018, J APPL MICROBIOL, V124, P1032, DOI 10.1111/jam.13681
   Wadman M, 2020, SCIENCE, V368, P356, DOI 10.1126/science.368.6489.356
   Wang JM, 2020, J CHEM INF MODEL, V60, P3277, DOI 10.1021/acs.jcim.0c00179
   Warnes S.L., 2013, PLOS ONE, P8
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xia JH, 2020, J MED VIROL, V92, P589, DOI 10.1002/jmv.25725
   Xie D, 2018, J BIOMATER APPL, V33, P340, DOI 10.1177/0885328218792687
   Xing YG, 2016, INT J POLYM SCI, V2016, DOI 10.1155/2016/4851730
   Yang SY, 2008, ADV FUNCT MATER, V18, P1371, DOI 10.1002/adfm.200700832
   Yao H., 2020, PATIENT DERIVED MUTA, DOI [10.1101/2020.04.14.20060160, DOI 10.1101/2020.04.14.20060160]
   Yu Y., 2020, MATER CHEM FRONT
   Zeitlin C, 2019, SPACE WEATHER, V17, P1011, DOI 10.1029/2019SW002223
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
NR 80
TC 3
Z9 3
U1 7
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2468-5194
J9 MATER TODAY CHEM
JI Mater. Today Chem.
PD SEP
PY 2020
VL 17
AR 100300
DI 10.1016/j.mtchem.2020.100300
PG 23
WC Chemistry, Multidisciplinary; Materials Science, Multidisciplinary
SC Chemistry; Materials Science
GA NR4FH
UT WOS:000571518700005
PM 32835154
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Mujawar, MA
   Gohel, H
   Bhardwaj, SK
   Srinivasan, S
   Hickman, N
   Kaushik, A
AF Mujawar, M. A.
   Gohel, H.
   Bhardwaj, S. K.
   Srinivasan, S.
   Hickman, N.
   Kaushik, A.
TI Nano-enabled biosensing systems for intelligent healthcare: towards
   COVID-19 management
SO MATERIALS TODAY CHEMISTRY
LA English
DT Article
DE Nano-sensors; Smart diagnostics; Point-of-care systems; Disease
   management; Personalized health care; COVID-19 diagnostics
ID WEARABLE SENSOR; LABEL-FREE; INTERNET; IOT; INFECTION; DISEASE; THINGS
AB Biosensors are emerging as efficient (sensitive and selective) and affordable analytical diagnostic tools for early-stage disease detection, as required for personalized health wellness management. Low-level detection of a targeted disease biomarker (pM level) has emerged extremely useful to evaluate the progression of disease under therapy. Such collected bioinformatics and its multi-aspects-oriented analytics is in demand to explore the effectiveness of a prescribed treatment, optimize therapy, and correlate biomarker level with disease pathogenesis. Owing to nanotechnology-enabled advancements in sensing unit fabrication, device integration, interfacing, packaging, and sensing performance at point of-care (POC) has rendered diagnostics according to the requirements of disease management and patient disease profile i.e. in a personalized manner. Efforts are continuously being made to promote the state of art biosensing technology as a next-generation non-invasive disease diagnostics methodology. Keeping this in view, this progressive opinion article describes personalized health care management related analytical tools which can provide access to better health for everyone, with overreaching aim to manage healthy tomorrow timely. Considering accomplishments and predictions, such affordable intelligent diagnostics tools are urgently required to manage COVID-19 pandemic, a life-threatening respiratory infectious disease, where a rapid, selective and sensitive detection of human beta severe acute respiratory system coronavirus (SARS-COoV-2) protein is the key factor. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Mujawar, M. A.] Florida Int Univ, Coll Engn & Comp, Dept Elect & Comp Engn, Miami, FL 33174 USA.
   [Gohel, H.] Univ Houston, Sch Art & Sci, Dept Comp Sci, Victoria, TX USA.
   [Bhardwaj, S. K.] Univ Amsterdam, Vant Hoff Inst Mol Sci, Sci Pk 904, NL-1098 XH Amsterdam, Netherlands.
   [Srinivasan, S.; Hickman, N.; Kaushik, A.] Florida Polytech Univ, Div Sci Art & Math, Dept Nat Sci, NnaoBioTech Lab, Lakeland, FL 33805 USA.
RP Kaushik, A (corresponding author), Florida Polytech Univ, Div Sci Art & Math, Dept Nat Sci, NnaoBioTech Lab, Lakeland, FL 33805 USA.
EM akaushik@floridapoly.edu
RI ; Kaushik, Ajeet/K-1289-2018
OI Mujawar, Mubarak Ajmuddin/0000-0003-2857-8309; Kaushik,
   Ajeet/0000-0003-4206-1541
FU Florida Polytechnic University, Lakeland, FL, USA [GR-2000024]
FX Authors acknowledges respective institutions and department for
   providing facilities and support. AK acknowledges a research grant
   (GR-2000024) funded by Florida Polytechnic University, Lakeland, FL,
   USA.
CR Akyildiz IF, 2015, IEEE COMMUN MAG, V53, P32, DOI 10.1109/MCOM.2015.7060516
   Ali F, 2018, COMPUT COMMUN, V119, P138, DOI 10.1016/j.comcom.2017.10.005
   Ali MA, 2020, J ELECTROCHEM SOC, V167, DOI 10.1149/1945-7111/ab69fe
   Berrouiguet S, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.7412
   Bhardwaj SK, 2019, BIOMATER SCI-UK, V7, P1598, DOI 10.1039/c8bm01406j
   Bhardwaj SK, 2018, THIN SOLID FILMS, V645, P10, DOI 10.1016/j.tsf.2017.10.021
   Bhardwaj SK, 2016, ACS APPL MATER INTER, V8, P24350, DOI 10.1021/acsami.6b04562
   Bhardwaj V, 2017, MICROMACHINES-BASEL, V8, DOI 10.3390/mi8100298
   Bianchi V, 2019, IEEE INTERNET THINGS, V6, P8553, DOI 10.1109/JIOT.2019.2920283
   Cruz AFD, 2014, BIOSENS BIOELECTRON, V62, P249, DOI 10.1016/j.bios.2014.06.053
   de Chazal P, 2004, IEEE T BIO-MED ENG, V51, P1196, DOI 10.1109/TBME.2004.827359
   Dimitrov DV, 2016, HEALTHC INFORM RES, V22, P156, DOI 10.4258/hir.2016.22.3.156
   Dixit C., 2016, MICROFLUIDICS BIOL
   Fallmann S, 2019, IEEE ACCESS, V7, P142421, DOI 10.1109/ACCESS.2019.2944801
   Gohel H. A., 2014, CSI COMMUNICATIONS K, V38, P23
   Gohel H.A., 2015, CSI COMMUNICATIONS K, V39
   Gohel HA, 2020, NUCL ENG TECHNOL, V52, P1436, DOI 10.1016/j.net.2019.12.029
   Gubbi J, 2013, FUTURE GENER COMP SY, V29, P1645, DOI 10.1016/j.future.2013.01.010
   Kaushik A., 2019, FRONT NANOTECHNOL, V1
   Kaushik A.K., 2016, NANOBIOTECHNOLOGY SE
   Kaushik A, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18124303
   Kaushik A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28035-3
   Kaushik A, 2017, TRENDS BIOTECHNOL, V35, P308, DOI 10.1016/j.tibtech.2016.10.001
   Kaushik A, 2016, ANAL METHODS-UK, V8, P6115, DOI 10.1039/c6ay01910b
   Kaushik A, 2016, BIOSENS BIOELECTRON, V86, P426, DOI 10.1016/j.bios.2016.06.086
   Kaushik A, 2016, BIOSENS BIOELECTRON, V80, P273, DOI 10.1016/j.bios.2016.01.065
   Kaushik A, 2016, BIOSENS BIOELECTRON, V75, P254, DOI 10.1016/j.bios.2015.08.040
   Kaushik A, 2015, INT J NANOMED, V10, P677, DOI 10.2147/IJN.S75514
   Kaushik A, 2014, BIOSENS BIOELECTRON, V53, P499, DOI 10.1016/j.bios.2013.09.060
   Kaushik A, 2013, BIOSENS BIOELECTRON, V50, P35, DOI 10.1016/j.bios.2013.06.012
   Krause A, 2006, IEEE T MOBILE COMPUT, V5, P113, DOI 10.1109/TMC.2006.18
   Kumar S, 2019, SENSORS-BASEL, V19, DOI 10.3390/s19204476
   Levy D'Mita, 2017, 2017 IEEE 4th International Conference on Cyber-Security and Cloud Computing (CSCloud), P316, DOI 10.1109/CSCloud.2017.18
   McCall B, 2020, LANCET DIGIT HEALTH, V2, pE166, DOI 10.1016/S2589-7500(20)30054-6
   Morales-Narvaez E, 2020, BIOSENS BIOELECTRON, V163, DOI 10.1016/j.bios.2020.112274
   Mostafalu P, 2016, MICROSYST NANOENG, V2, DOI 10.1038/micronano.2016.39
   Mouly J., BIOMEMS NONINVASIVE
   Park SW, 2015, IEEE T BIOMED CIRC S, V9, P838, DOI 10.1109/TBCAS.2015.2504563
   Polastre J., 2004, P 2 INT C EMB NETW S, P95, DOI [10.1145/1031495.1031508, DOI 10.1145/1031495.1031508]
   Prather KA, 2020, SCIENCE, V368, P1422, DOI 10.1126/science.abc6197
   Ravi D, 2017, IEEE J BIOMED HEALTH, V21, P4, DOI 10.1109/JBHI.2016.2636665
   Ravi D, 2016, INT CONF WEARAB IMPL, P71, DOI 10.1109/BSN.2016.7516235
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Sang SB, 2016, CRIT REV BIOTECHNOL, V36, P465, DOI 10.3109/07388551.2014.991270
   Shah P, 2014, ANALYST, V139, P2088, DOI 10.1039/c3an02280c
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Shinde RB, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00325
   Solanki PR, 2011, NPG ASIA MATER, V3, P17, DOI 10.1038/asiamat.2010.137
   Song JZ, 2018, ANAL CHEM, V90, P4823, DOI 10.1021/acs.analchem.8b00283
   Sony S, 2019, STRUCT CONTROL HLTH, V26, DOI 10.1002/stc.2321
   Stoica L, 2006, ANAL CHEM, V78, P393, DOI 10.1021/ac050327o
   Ting DSW, 2020, NAT MED, DOI 10.1038/s41591-020-0824-5
   Tolga AC, 2020, SOCIO-ECON PLAN SCI, V69, DOI 10.1016/j.seps.2019.02.008
   Vabbina PK, 2015, BIOSENS BIOELECTRON, V63, P124, DOI 10.1016/j.bios.2014.07.026
   Vasudev A, 2013, SENSOR ACTUAT B-CHEM, V182, P139, DOI 10.1016/j.snb.2013.02.096
   Xia Y., 2016, IEEE ACCESS, V6, P16529
   Yager P, 2008, ANNU REV BIOMED ENG, V10, P107, DOI 10.1146/annurev.bioeng.10.061807.160524
   Yang G H, 2008, METALLURGICAL EQUIPM, V6, P1
   Yang LT, 2019, NANO LETT, V19, P8138, DOI 10.1021/acs.nanolett.9b03402
   Yang SQ, 2018, MOBILE NETW APPL, V23, P216, DOI 10.1007/s11036-017-0929-3
NR 60
TC 6
Z9 6
U1 8
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2468-5194
J9 MATER TODAY CHEM
JI Mater. Today Chem.
PD SEP
PY 2020
VL 17
AR 100306
DI 10.1016/j.mtchem.2020.100306
PG 9
WC Chemistry, Multidisciplinary; Materials Science, Multidisciplinary
SC Chemistry; Materials Science
GA NR4FH
UT WOS:000571518700006
PM 32835155
OA Green Published
DA 2021-01-01
ER

PT J
AU Huang, MX
   Li, M
   Xiao, F
   Pang, PF
   Liang, JB
   Tang, TT
   Liu, SX
   Chen, BH
   Shu, JX
   You, YY
   Li, Y
   Tang, MW
   Zhou, JH
   Jiang, GM
   Xiang, JF
   Hong, WX
   He, SM
   Wang, ZQ
   Feng, JH
   Lin, CQ
   Ye, YN
   Wu, ZL
   Li, YC
   Zhong, B
   Sun, RL
   Hong, ZS
   Liu, J
   Chen, HL
   Wang, XH
   Li, ZH
   Pei, DQ
   Tian, L
   Xia, JY
   Jiang, SP
   Zhong, NS
   Shan, H
AF Huang, Mingxing
   Li, Man
   Xiao, Fei
   Pang, Pengfei
   Liang, Jiabi
   Tang, Tiantian
   Liu, Shaoxuan
   Chen, Binghui
   Shu, Jingxian
   You, Yingying
   Li, Yang
   Tang, Meiwen
   Zhou, Jianhui
   Jiang, Guanmin
   Xiang, Jingfen
   Hong, Wenxin
   He, Songmei
   Wang, Zhaoqin
   Feng, Jianhua
   Lin, Changqing
   Ye, Yinong
   Wu, Zhilong
   Li, Yaocai
   Zhong, Bei
   Sun, Ruilin
   Hong, Zhongsi
   Liu, Jing
   Chen, Huili
   Wang, Xiaohua
   Li, Zhonghe
   Pei, Duanqing
   Tian, Lin
   Xia, Jinyu
   Jiang, Shanping
   Zhong, Nanshan
   Shan, Hong
TI Preliminary evidence from a multicenter prospective observational study
   of the safety and efficacy of chloroquine for the treatment of COVID-19
SO NATIONAL SCIENCE REVIEW
LA English
DT Article
DE COVID-19; SARS-CoV-2; treatment; chloroquine
ID CORONAVIRUS; PHARMACOKINETICS; INHIBITION; AUTOPHAGY; HEALTH
AB Effective therapies are urgently needed for the SARS-CoV-2 pandemic. Chloroquine has been proved to have antiviral effect against coronavirus in vitro. In this study, we aimed to assess the efficacy and safety of chloroquine with different doses in COVID-19. In this multicenter prospective observational study, we enrolled patients older than 18 years old with confirmed SARS-CoV-2 infection excluding critical cases from 12 hospitals in Guangdong and Hubei Provinces. Eligible patients received chloroquine phosphate 500 mg, orally, once (half dose) or twice (full dose) daily. Patients treated with non-chloroquine therapy were included as historical controls. The primary endpoint is the time to undetectable viral RNA. Secondary outcomes include the proportion of patients with undetectable viral RNA by day 10 and 14, hospitalization time, duration of fever, and adverse events. A total of 197 patients completed chloroquine treatment, and 176 patients were included as historical controls. The median time to achieve an undetectable viral RNA was shorter in chloroquine than in non-chloroquine (absolute difference in medians -6.0 days; 95% CI -6.0 to -4.0). The duration of fever is shorter in chloroquine (geometric mean ratio 0.6; 95% CI 0.5 to 0.8). No serious adverse events were observed in the chloroquine group. Patients treated with half dose experienced lower rate of adverse events than with full dose. Although randomized trials are needed for further evaluation, this study provides evidence for safety and efficacy of chloroquine in COVID-19 and suggests that chloroquine can be a cost-effective therapy for combating the COVID-19 pandemic.
C1 [Huang, Mingxing; Xiao, Fei; Hong, Zhongsi; Chen, Huili; Xia, Jinyu] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Infect Dis, Zhuhai 519000, Peoples R China.
   [Li, Man; Xiao, Fei; Pang, Pengfei; Li, Yang; Shan, Hong] Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Key Lab Biomed Imaging, Zhuhai 519000, Peoples R China.
   [Li, Man; Xiao, Fei; Pang, Pengfei; Li, Yang; Shan, Hong] Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Engn Res Ctr Mol Imaging, Zhuhai 519000, Peoples R China.
   [Li, Man; Pang, Pengfei; Li, Yang; Tian, Lin; Shan, Hong] Sun Yat Sen Univ, Affiliated Hosp 5, Ctr Intervent Med, Zhuhai 519000, Peoples R China.
   [Liang, Jiabi; Shu, Jingxian] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Pharm, Zhuhai 519000, Peoples R China.
   [Tang, Tiantian; Jiang, Shanping] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Resp & Crit Care Med, Guangzhou 510120, Peoples R China.
   [Liu, Shaoxuan] Sun Yat Sen Univ, Affiliated Hosp 5, Clin Res Ctr Off, Zhuhai 519000, Peoples R China.
   [Chen, Binghui] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Radiol, Zhuhai 519000, Peoples R China.
   [You, Yingying] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Stomatol, Zhuhai 519000, Peoples R China.
   [Tang, Meiwen] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Hematol, Zhuhai 519000, Peoples R China.
   [Zhou, Jianhui; Jiang, Guanmin] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Clin Lab, Zhuhai 519000, Peoples R China.
   [Xiang, Jingfen] Wuhan East West Lake Mobile Cabin Hosp, Dept Emergency, Wuhan 430040, Peoples R China.
   [Hong, Wenxin] Guangzhou Eighth Peoples Hosp, Dept Infect Dis, Guangzhou 510060, Peoples R China.
   [He, Songmei] Dongguan Ninth Peoples Hosp, Dept Infect Dis, Dongguan 532016, Peoples R China.
   [Wang, Zhaoqin] Shenzhen Third Peoples Hosp, Dept Infect Dis, Shenzhen 518100, Peoples R China.
   [Feng, Jianhua] Zhongshan Second Peoples Hosp, Dept Infect Dis, Zhongshan 528447, Peoples R China.
   [Lin, Changqing] Huizhou Cent Peoples Hosp, Dept Resp & Crit Care Med, Huizhou 516001, Peoples R China.
   [Ye, Yinong] Foshan First peoples Hosp, Dept Infect Dis, Foshan 528000, Peoples R China.
   [Wu, Zhilong] Fourth Peoples Hosp Foshan City, Dept Resp & Crit Care Med, Foshan 528000, Peoples R China.
   [Li, Yaocai] Maoming Peoples Hosp, Dept Infect Dis, Maoming 525000, Peoples R China.
   [Zhong, Bei] Guangzhou Med Univ, Affiliated Hosp 6, Dept Infect Dis, Qingyuan Peoples Hosp, Qingyuan 511518, Peoples R China.
   [Sun, Ruilin] Guangdong Second Prov Gen Hosp, Pulm & Crit Care Med Dept, Guangzhou 510317, Peoples R China.
   [Liu, Jing] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Resp & Crit Care Med, Zhuhai 519099, Peoples R China.
   [Wang, Xiaohua] Sun Yat Sen Univ, Affiliated Hosp 5, Intens Care Unit, Zhuhai 519099, Peoples R China.
   [Li, Zhonghe] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Nephrol, Zhuhai 519099, Peoples R China.
   [Pei, Duanqing] Guangzhou Regenerat Med & Hlth Guangdong Lab, Guangzhou 510700, Peoples R China.
   [Pei, Duanqing] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangzhou 510700, Peoples R China.
   [Zhong, Nanshan] Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou Inst Resp Hlth, Guangzhou 510120, Peoples R China.
RP Xia, JY (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Dept Infect Dis, Zhuhai 519000, Peoples R China.; Shan, H (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Key Lab Biomed Imaging, Zhuhai 519000, Peoples R China.; Shan, H (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Guangdong Prov Engn Res Ctr Mol Imaging, Zhuhai 519000, Peoples R China.; Tian, L; Shan, H (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Ctr Intervent Med, Zhuhai 519000, Peoples R China.; Jiang, SP (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Resp & Crit Care Med, Guangzhou 510120, Peoples R China.; Pei, DQ (corresponding author), Guangzhou Regenerat Med & Hlth Guangdong Lab, Guangzhou 510700, Peoples R China.; Pei, DQ (corresponding author), Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Guangzhou 510700, Peoples R China.; Zhong, NS (corresponding author), Guangzhou Med Univ, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou Inst Resp Hlth, Guangzhou 510120, Peoples R China.
EM pei_duanqing@gibh.ac.cn; tianlin@mail.sysu.edu.cn;
   xiajinyu@mail.sysu.edu.cn; jiangshp@mail.sysu.edu.cn;
   nanshan@vip.163.com; shanhong@mail.sysu.edu.cn
FU National Key Research and Development Plan for the Emergency Management
   of Novel Coronavirus Pneumonia [2020YFC082400]; Special Project of
   Guangdong Science and Technology Department [2020B111105001]; Emergency
   Research Project on SARS-CoV-2 from Guangzhou Regenerative Medicine and
   Health Guangdong Laboratory [2020GZR110106003]; Cultivation project of
   Scientific Research Plan from `Three Major Constructions of Sun Yat-sen
   University in 2020': Emergency Management of Novel Coronavirus Pneumonia
   in Science and Technology Development; Emergency Project of Novel
   Coronavirus Pneumonia in Science and Technology Development of Zhuhai in
   2020
FX This work was supported in part by the National Key Research and
   Development Plan for the Emergency Management of Novel Coronavirus
   Pneumonia (2020YFC082400), the Special Project of Guangdong Science and
   Technology Department (2020B111105001), the Emergency Research Project
   on SARS-CoV-2 from Guangzhou Regenerative Medicine and Health Guangdong
   Laboratory (2020GZR110106003), the Cultivation project of Scientific
   Research Plan from `Three Major Constructions of Sun Yat-sen University
   in 2020': Emergency Management of Novel Coronavirus Pneumonia in Science
   and Technology Development, and the Emergency Project of Novel
   Coronavirus Pneumonia in Science and Technology Development of Zhuhai in
   2020.
CR Akpovwa H, 2016, CELL BIOCHEM FUNCT, V34, P191, DOI 10.1002/cbf.3182
   AUGUSTIJNS P, 1992, EUR J CLIN PHARMACOL, V42, P429
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chung M, 2020, RADIOLOGY, V295, P202, DOI 10.1148/radiol.2020200230
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Ducharme J, 1996, CLIN PHARMACOKINET, V31, P257, DOI 10.2165/00003088-199631040-00003
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   GUSTAFSSON LL, 1987, BRIT J CLIN PHARMACO, V24, P221, DOI 10.1111/j.1365-2125.1987.tb03165.x
   Hage MP, 2014, THER ADV ENDOCRINOL, V5, P10, DOI 10.1177/2042018813517522
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Keene ON, 2002, STAT MED, V21, P3687, DOI 10.1002/sim.1312
   Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
   Kono M, 2008, ANTIVIR RES, V77, P150, DOI 10.1016/j.antiviral.2007.10.011
   Kormelink TG, 2010, ANN RHEUM DIS, V69, P2137, DOI 10.1136/ard.2009.126441
   Krishna S, 1996, CLIN PHARMACOKINET, V30, P263, DOI 10.2165/00003088-199630040-00002
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Magagnoli J, 2020, MED, DOI [10.1016/j.medj.2020.06.001, DOI 10.1016/J.MEDJ.2020.06.001]
   MARKS JS, 1982, ANN RHEUM DIS, V41, P52, DOI 10.1136/ard.41.1.52
   Organization WH, 2020, CLIN MAN SEV AC RESP
   R Core Team, 2020, R LANG ENV STAT COMP
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Sun J, 2020, CLIN PHARMACOL THER, V108, P791, DOI 10.1002/cpt.1866
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yang ND, 2020, INT J BIOL SCI, V16, P1724, DOI 10.7150/ijbs.45498
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 25
TC 11
Z9 11
U1 5
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2095-5138
EI 2053-714X
J9 NATL SCI REV
JI Natl. Sci. Rev.
PD SEP
PY 2020
VL 7
IS 9
BP 1428
EP 1436
DI 10.1093/nsr/nwaa113
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NT3UW
UT WOS:000572871200005
OA DOAJ Gold, Green Accepted
DA 2021-01-01
ER

PT J
AU Chen, YX
   Tong, X
   Li, Y
   Gu, B
   Yan, JW
   Liu, Y
   Shen, H
   Huang, R
   Wu, C
AF Chen, Yuxin
   Tong, Xin
   Li, Yang
   Gu, Bin
   Yan, Jiawei
   Liu, Yong
   Shen, Han
   Huang, Rui
   Wu, Chao
TI A comprehensive, longitudinal analysis of humoral responses specific to
   four recombinant antigens of SARS-CoV-2 in severe and non-severe
   COVID-19 patients
SO PLOS PATHOGENS
LA English
DT Article
ID CORONAVIRUS SARS-COV; ANTIBODIES; INFECTION; DOMAIN
AB Author summary The world is facing an unprecedented challenge with communities and economies affected by the growing pandemic of coronavirus disease 2019 (COVID-19). Currently, there is no vaccine or effective drugs have been approved to treat or prevent COVID-19. The development of antibody response to SARS-CoV-2, the virus that causes COVID-19, started to be reported but remained largely elusive. Understanding the adaptive responses where the body makes antibodies that specifically bind to the SARS-CoV-2 among COVID-19 patients provides fundamental information for developing effective treatment and preventive vaccine. In this study, we not only successively analyzed the specificity and magnitude of antibody responses using four SARS-CoV-2 related antigens, but also monitored the neutralization potency of the convalescent sera from COVID-19 patients at the time point of hospital discharge and follow-up visit. Our results indicated that most patients generated humoral responses against nucleoprotein and three spike protein-related antigens with their distinct kinetics profiles. Additionally, most convalescent sera had the varying extents of neutralization activities against SARS-CoV-2. Of note, we identified that IgA antibody responses specific to S1 and ECD were strongly correlated with neutralization activities in non-severe patients, but not in severe patients. Furthermore, we identified a significant reduction of neutralizing activities of the convalescent sera within one month. Our data provide a collective basis of serological testing, antibody-based intervention, and vaccine design of COVID-19.
   There is an urgent need for effective treatment and preventive vaccine to contain this devastating global pandemic, which requires a comprehensive understanding of humoral responses specific to SARS-CoV-2 during the disease progression and convalescent phase of COVID-19 patients. We continuously monitored the serum IgM and IgG responses specific to four SARS-CoV-2 related antigens, including the nucleoprotein (NP), receptor binding domain (RBD), S1 protein, and ectodomain (ECD) of the spike protein among non-severe and severe COVID-19 patients for seven weeks since disease onset. Most patients generated humoral responses against NP and spike protein-related antigens but with their distinct kinetics profiles. Combined detection of NP and ECD antigens as detecting antigen synergistically improved the sensitivity of the serological assay, compared to that of using NP or RBD as detection antigen. 80.7% of convalescent sera from COVID-19 patients revealed that the varying extents of neutralization activities against SARS-CoV-2. S1-specific and ECD-specific IgA responses were strongly correlated with the neutralization activities in non-severe patients, but not in severe patients. Moreover, the neutralizing activities of the convalescent sera were shown to significantly decline during the period between 21 days to 28 days after hospital discharge, accompanied by a substantial drop in RBD-specific IgA response. Our data provide evidence that are crucial for serological testing, antibody-based intervention, and vaccine design of COVID-19.
C1 [Chen, Yuxin; Li, Yang; Shen, Han] Nanjing Univ, Dept Lab Med, Med Sch, Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China.
   [Tong, Xin; Huang, Rui; Wu, Chao] Nanjing Univ, Dept Infect Dis, Med Sch, Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China.
   [Gu, Bin] Xuzhou Med Univ, Xuzhou Key Lab Lab Diagnost, Med Technol Sch, Xuzhou, Jiangsu, Peoples R China.
   [Gu, Bin] Xuzhou Med Univ, Dept Lab Med, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China.
   [Yan, Jiawei] Xuzhou Med Univ, Dept Lab Med, Xuzhou Infect Dis Hosp, Xuzhou, Jiangsu, Peoples R China.
   [Liu, Yong] Nanjing Univ, Dept Expt Med, Med Sch, Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China.
RP Huang, R; Wu, C (corresponding author), Nanjing Univ, Dept Infect Dis, Med Sch, Nanjing Drum Tower Hosp, Nanjing, Jiangsu, Peoples R China.
EM doctor_hr@126.com; dr.wu@nju.edu.cn
OI Reis, AlessanRSS/0000-0001-8486-7469
FU Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [14380459]; Medical Science
   and technology Development Foundation, Nanjing Department of Health
   [YKK19056]; Nanjing Medical Science and Technique Development Foundation
   [QRX17141]
FX This study was supported by the Fundamental Research Funds for the
   Central Universities (No. 14380459 to CW). the Medical Science and
   technology Development Foundation, Nanjing Department of Health
   (YKK19056 to YC), Nanjing Medical Science and Technique Development
   Foundation (QRX17141 to YC). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Amanat F, 2020, NAT MED, V26, P1033, DOI 10.1038/s41591-020-0913-5
   [Anonymous], 2019, JMIR PUBLIC HLTH SUR, V4, pe53, DOI 10.2196/publichealth.9932
   Arabi YM, 2016, EMERG INFECT DIS, V22, P1554, DOI 10.3201/eid2209.151164
   Cao WCC, 2007, NEW ENGL J MED, V357, P1162, DOI 10.1056/NEJMc070348
   Chi X, 2020, SCIENCE
   China NHCotPsRo, 2020, CHIN MAN GUID COVID
   Du LY, 2008, J IMMUNOL, V180, P948, DOI 10.4049/jimmunol.180.2.948
   Duan K, 2020, P NATL ACAD SCI US
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Guo L., 2020, CLIN INFECT DIS
   Iwasaki A, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0321-6
   Juanjuan Zhao Jr .QY, 2020, MEDRXIV2020030220030
   Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836
   Long Q.-X., 2020, NAT MED
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Okba NMA, 2020, EMERG INFECT DIS, V26
   Perera RAPM, 2020, EUROSURVEILLANCE, V25, P14, DOI 10.2807/1560-7917.ES.2020.25.16.2000421
   Shen C, 2020, JAMA
   STOCKERT RJ, 1982, P NATL ACAD SCI-BIOL, V79, P6229, DOI 10.1073/pnas.79.20.6229
   Tan XM, 2021, MAGN RESON CHEM, V59, P16, DOI 10.1002/mrc.5098
   To KK, 2020, LANCET INFECT DIS
   Wang QD, 2016, ACS INFECT DIS, V2, P361, DOI 10.1021/acsinfecdis.6b00006
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Wu F, 2020, NEUTRALIZING ANTIBOD
   Wu YL, 2020, CELL HOST MICROBE, V27, P891, DOI 10.1016/j.chom.2020.04.023
   Wu YJ, 2020, LANCET GASTROENTEROL, V5, P434, DOI 10.1016/S2468-1253(20)30083-2
   Yasui F, 2008, J IMMUNOL, V181, P6337, DOI 10.4049/jimmunol.181.9.6337
   Yongchen Zhang, 2020, Emerg Microbes Infect, V9, P833, DOI 10.1080/22221751.2020.1756699
   Zhang B, 2020, J INFECTION, V81, pE49, DOI 10.1016/j.jinf.2020.04.023
   Zhang B, 2020, J CHEM RES, V44, P571, DOI 10.1177/1747519820912675
   Zhang X, 2020, NATURE
   Zhao B, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202002019
NR 32
TC 3
Z9 3
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7366
EI 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD SEP
PY 2020
VL 16
IS 9
AR e1008796
DI 10.1371/journal.ppat.1008796
PG 16
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA NS1XX
UT WOS:000572058700001
PM 32913364
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Lund, LC
   Kristensen, KB
   Reilev, M
   Christensen, S
   Thomsen, RW
   Christiansen, CF
   Stovring, H
   Johansen, NB
   Brun, NC
   Hallas, J
   Pottegard, A
AF Lund, Lars Christian
   Kristensen, Kasper Bruun
   Reilev, Mette
   Christensen, Steffen
   Thomsen, Reimar Wernich
   Christiansen, Christian Fynbo
   Stovring, Henrik
   Johansen, Nanna Borup
   Brun, Nikolai Constantin
   Hallas, Jesper
   Pottegard, Anton
TI Adverse outcomes and mortality in users of non-steroidal
   anti-inflammatory drugs who tested positive for SARS-CoV-2: A Danish
   nationwide cohort study
SO PLOS MEDICINE
LA English
DT Article
ID PROPENSITY SCORE; ASPIRIN; HEALTH
AB Background
   Concerns over the safety of non-steroidal anti-inflammatory drug (NSAID) use during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been raised. We studied whether use of NSAIDs was associated with adverse outcomes and mortality during SARS-CoV-2 infection.
   Methods and findings
   We conducted a population-based cohort study using Danish administrative and health registries. We included individuals who tested positive for SARS-CoV-2 during the period 27 February 2020 to 29 April 2020. NSAID users (defined as individuals having filled a prescription for NSAIDs up to 30 days before the SARS-CoV-2 test) were matched to up to 4 non-users on calendar week of the test date and propensity scores based on age, sex, relevant comorbidities, and use of selected prescription drugs. The main outcome was 30-day mortality, and NSAID users were compared to non-users using risk ratios (RRs) and risk differences (RDs). Secondary outcomes included hospitalization, intensive care unit (ICU) admission, mechanical ventilation, and acute renal replacement therapy. A total of 9,236 SARS-CoV-2 PCR-positive individuals were eligible for inclusion. The median age in the study cohort was 50 years, and 58% were female. Of these, 248 (2.7%) had filled a prescription for NSAIDs, and 535 (5.8%) died within 30 days. In the matched analyses, treatment with NSAIDs was not associated with 30-day mortality (RR 1.02, 95% CI 0.57 to 1.82,p= 0.95; RD 0.1%, 95% CI -3.5% to 3.7%,p= 0.95), risk of hospitalization (RR 1.16, 95% CI 0.87 to 1.53,p= 0.31; RD 3.3%, 95% CI -3.4% to 10%,p= 0.33), ICU admission (RR 1.04, 95% CI 0.54 to 2.02,p= 0.90; RD 0.2%, 95% CI -3.0% to 3.4%,p= 0.90), mechanical ventilation (RR 1.14, 95% CI 0.56 to 2.30,p= 0.72; RD 0.5%, 95% CI -2.5% to 3.6%,p= 0.73), or renal replacement therapy (RR 0.86, 95% CI 0.24 to 3.09,p= 0.81; RD -0.2%, 95% CI -2.0% to 1.6%,p= 0.81). The main limitations of the study are possible exposure misclassification, as not all individuals who fill an NSAID prescription use the drug continuously, and possible residual confounding by indication, as NSAIDs may generally be prescribed to healthier individuals due to their side effects, but on the other hand may also be prescribed for early symptoms of severe COVID-19.
   Conclusions
   Use of NSAIDs was not associated with 30-day mortality, hospitalization, ICU admission, mechanical ventilation, or renal replacement therapy in Danish individuals who tested positive for SARS-CoV-2.
C1 [Lund, Lars Christian; Kristensen, Kasper Bruun; Reilev, Mette; Stovring, Henrik; Hallas, Jesper; Pottegard, Anton] Univ Southern Denmark, Dept Publ Hlth, Clin Pharmacol & Pharm, Odense, Denmark.
   [Christensen, Steffen] Aarhus Univ Hosp, Dept Anaesthesia & Intens Care Med, Aarhus, Denmark.
   [Thomsen, Reimar Wernich; Christiansen, Christian Fynbo] Aarhus Univ Hosp, Dept Clin Epidemiol, Aarhus, Denmark.
   [Stovring, Henrik] Aarhus Univ, Dept Publ Hlth, Biostat, Aarhus, Denmark.
   [Johansen, Nanna Borup; Brun, Nikolai Constantin] Danish Med Agcy, Dept Med Evaluat & Biostat, Copenhagen, Denmark.
RP Pottegard, A (corresponding author), Univ Southern Denmark, Dept Publ Hlth, Clin Pharmacol & Pharm, Odense, Denmark.
EM apottegaard@health.sdu.dk
RI ; Christiansen, Christian/B-5870-2014
OI Pottegard, Anton/0000-0001-9314-5679; Christiansen,
   Christian/0000-0002-0727-953X; Kristensen, Kasper
   Bruun/0000-0001-6373-1386; Thomsen, Reimar/0000-0001-9135-3474; Hallas,
   Jesper/0000-0002-8097-8708
CR Basille D, 2018, AM J RESP CRIT CARE, V198, P128, DOI 10.1164/rccm.201802-0229LE
   Blichert-Hansen Linea, 2013, Clin Epidemiol, V5, P9, DOI 10.2147/CLEP.S37763
   Day M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1086
   Epperly H, 2016, JPN J INFECT DIS, V69, P248, DOI 10.7883/yoken.JJID.2014.577
   European Medicines agency, 2020, EMA1368502020
   European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, 2020, EUPAS34734 EUR NETW
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Franklin JM, 2014, STAT MED, V33, P1685, DOI 10.1002/sim.6058
   Glynn RJ, 2001, EPIDEMIOLOGY, V12, P682, DOI 10.1097/00001648-200111000-00017
   Gribsholt SB, 2019, CLIN EPIDEMIOL, V11, P845, DOI 10.2147/CLEP.S214909
   Helweg-Larsen K, 2011, SCAND J PUBLIC HEALT, V39, P26, DOI 10.1177/1403494811399958
   Kristensen KB, 2019, PHARMACOTHERAPY, V39, P150, DOI 10.1002/phar.2217
   Leuven Edwin, 2018, PSMATCH2 STATA MODUL
   Lund LC, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13880
   Mancia G, 2020, NEW ENGL J MED, V382, P2431, DOI 10.1056/NEJMoa2006923
   Meganathan P, 2019, INDIAN J PEDIATR, V86, P140, DOI 10.1007/s12098-018-2769-y
   Mehta N, 2020, JAMA CARDIOL, V5, P1020, DOI 10.1001/jamacardio.2020.1855
   Messika J, 2014, J CRIT CARE, V29, P733, DOI 10.1016/j.jcrc.2014.05.021
   Pottegard A, CLIN EPIDEMIOL
   Pottegard A, 2020, PHARMACOEPIDEM DR S, V29, P825, DOI 10.1002/pds.5029
   Pottegard A, 2017, INT J EPIDEMIOL, V46, P798, DOI 10.1093/ije/dyw213
   Qiao WL, 2015, CARDIOLOGY, V131, P97, DOI 10.1159/000375362
   Rassen JA, 2012, PHARMACOEPIDEM DR S, V21, P697, DOI 10.1002/pds.2256
   Reynolds HR, 2020, NEW ENGL J MED, V382, P2441, DOI 10.1056/NEJMoa2008975
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   Schmidt M, 2019, CLIN EPIDEMIOL, V11, P563, DOI 10.2147/CLEP.S179083
   Schmidt M, 2016, INT J EPIDEMIOL, V45, P1401, DOI 10.1093/ije/dyw116
   Schmidt M, 2016, EUR HEART J-CARD PHA, V2, P108, DOI 10.1093/ehjcvp/pvv054
   Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125
   Schmidt M, 2014, CLIN EPIDEMIOL, V6, P155, DOI 10.2147/CLEP.S59156
   Sturmer T, 2010, AM J EPIDEMIOL, V172, P843, DOI 10.1093/aje/kwq198
   Thygesen LC, 2011, SCAND J PUBLIC HEALT, V39, P12, DOI 10.1177/1403494811399956
   Voiriot G, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060786
   Voldstedlund M, 2014, EUROSURVEILLANCE, V19, P29, DOI 10.2807/1560-7917.ES2014.19.1.20667
NR 34
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1277
EI 1549-1676
J9 PLOS MED
JI PLos Med.
PD SEP
PY 2020
VL 17
IS 9
AR e1003308
DI 10.1371/journal.pmed.1003308
PG 16
WC Medicine, General & Internal
SC General & Internal Medicine
GA NQ6LG
UT WOS:000570982500001
PM 32898149
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gkogkou, E
   Barnasas, G
   Vougas, K
   Trougakos, IP
AF Gkogkou, Eirini
   Barnasas, Grigoris
   Vougas, Konstantinos
   Trougakos, Ioannis P.
TI Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative
   anti-inflammatory receptor and priming protease of SARS-CoV-2 in human
   cells, and identification of putative modulators
SO REDOX BIOLOGY
LA English
DT Article
DE ACE2; COVID-19; CTSB/L; Gene expression; SARS-CoV-2; TMPRSS2
ID ENZYME 2 ACE2; SARS CORONAVIRUS; SPIKE PROTEIN; INHIBITORS; COVID-19;
   INFECTION
AB Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and has resulted in hundreds of thousands of deaths worldwide. While the majority of people with COVID-19 won't require hospitalization, those who do may experience severe life-threatening complications, including acute respiratory distress syndrome. SARS-CoV-2 infects human cells by binding to the cellular surface protein angiotensin-converting enzyme 2 (ACE2); in addition, the cellular transmembrane serine protease 2 (TMPRSS2) is needed for priming of the spike (S) protein of the virus. Virus entry may also depend on the activity of the endosomal/lysosomal cysteine proteases cathepsin B, L (CTSB, CTSL) although their activity is likely dispensable. Given that the uncertainty of how COVID-19 kills, hampers doctors' ability to choose treatments the need for a deep understanding of COVID-19 biology is urgent. Herein, we performed an expression profiling meta-analysis of ACE2, TMPRSS2 and CTSB/L genes (and proteins) in public repository databases and found that all are widely expressed in human tissues; also, the ACE2 and TMPRSS2 genes tend to be co-regulated. The ACE2 and TMPRSS genes expression is (among others) suppressed by TNF, and is induced by pro-inflammatory conditions including obesity, Barrett's esophagus, stomach infection by helicobacter pylori, diabetes, autoimmune diseases and oxidized LDL; by exercise, as well as by growth factors, viruses' infections, cigarette smoke, interferons and androgens. Regarding currently investigated therapies interferon-beta induced ACE2 gene expression in bronchial epithelial cells, while chloroquine tends to upregulate CTSB/L genes. Finally, we analyzed KEGG pathways modulated by ACE2, TMPRSS2 and CTSB/L and probed DrugBank for drugs that target modules of the affected pathways. Our data indicate possible novel high-risk groups for COVID-19; provide a rich resource for future investigations of its pathogenesis and highlight the therapeutic challenges we face.
C1 [Gkogkou, Eirini; Barnasas, Grigoris; Trougakos, Ioannis P.] Natl & Kapodistrian Univ Athens, Fac Biol, Dept Cell Biol & Biophys, Athens 15784, Greece.
   [Vougas, Konstantinos] Acad Athens, Biomed Res Fdn, Ctr Basic Res 2, Genom & Prote Res Units, Athens 11527, Greece.
   [Vougas, Konstantinos] DeepMed IO Ltd, 49 Peter St, Manchester M2 3NG, Lancs, England.
RP Trougakos, IP (corresponding author), Natl & Kapodistrian Univ Athens, Fac Biol, Dept Cell Biol & Biophys, Athens 15784, Greece.
EM itrougakos@biol.uoa.gr
FU Hellenic GSRT project BIOIMAGING-GR [MIS 5002755]; Hellenic GSRT project
   PlantUP-GR [MIS 5002803]
FX IPT acknowledges funding from the Hellenic GSRT projects BIOIMAGING-GR
   (MIS 5002755) and PlantUP-GR (MIS 5002803).
CR Adedeji AO, 2013, J VIROL, V87, P8017, DOI 10.1128/JVI.00998-13
   Alenina N, 2008, EXP PHYSIOL, V93, P528, DOI 10.1113/expphysiol.2007.040345
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Bennion DM, 2015, CURR HYPERTENS REP, V17, DOI 10.1007/s11906-014-0512-2
   Bindom SM, 2009, MOL CELL ENDOCRINOL, V302, P193, DOI 10.1016/j.mce.2008.09.020
   Chang L, 2020, EMERG INFECT DIS, V26, P1631, DOI 10.3201/eid2607.200839
   Chen WL, 2020, EMERG MICROBES INFEC, V9, P469, DOI 10.1080/22221751.2020.1732837
   Deftereos SG, 2020, HELL J CARDIOL, V61, P42, DOI 10.1016/j.hjc.2020.03.002
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   Elkin SR, 2016, TRAFFIC, V17, P1139, DOI 10.1111/tra.12425
   Frlan R, 2006, CURR MED CHEM, V13, P2309, DOI 10.2174/092986706777935122
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Hashimoto T, 2012, NATURE, V487, P477, DOI 10.1038/nature11228
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, MOL CELL, V78, P779, DOI 10.1016/j.molcel.2020.04.022
   Huang C, 2019, LANCET, V2020, P395
   Huang IC, 2006, J BIOL CHEM, V281, P3198, DOI 10.1074/jbc.M508381200
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Imai Y, 2010, CIRC J, V74, P405, DOI 10.1253/circj.CJ-10-0045
   Kaur R, 2014, EUR J MED CHEM, V87, P89, DOI 10.1016/j.ejmech.2014.09.051
   Keller CW, 2018, CURR OPIN IMMUNOL, V52, P68, DOI 10.1016/j.coi.2018.04.014
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Kuba K, 2006, CURR OPIN PHARMACOL, V6, P271, DOI 10.1016/j.coph.2006.03.001
   Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5
   Li XC, 2017, PHARMACOL RES, V125, P21, DOI 10.1016/j.phrs.2017.06.005
   Lukassen S, 2020, EMBO J, DOI 10.15252/embj.20105114
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1252
   Mareti A, 2019, EUR J PREV CARDIOL, DOI 10.1177/2047487319893042
   Marin GH, 2020, DRUG DISCOV THER, V14, P105, DOI 10.5582/ddt.2020.01017
   Matsuyama S, 2020, P NATL ACAD SCI USA, V117, P7001, DOI 10.1073/pnas.2002589117
   Matsuyama S, 2010, J VIROL, V84, P12658, DOI 10.1128/JVI.01542-10
   McCluskey A, 2013, TRAFFIC, V14, P1272, DOI 10.1111/tra.12119
   Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b2535]
   Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925
   Pasanen L, 2019, J PHYSIOL PHARMACOL, V70, P199, DOI 10.26402/jpp.2019.2.03
   Passos-Silva DG, 2013, CLIN SCI, V124, P443, DOI 10.1042/CS20120461
   Patel VB, 2016, CIRC RES, V119
   Ritchie AI, 2020, LANCET, V395, P1111, DOI 10.1016/S0140-6736(20)30691-7
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Stratford FLL, 2006, FEBS LETT, V580, P3989, DOI 10.1016/j.febslet.2006.06.029
   Sun Y, 2015, PART FIBRE TOXICOL, V12, DOI 10.1186/s12989-015-0080-x
   Sungnak W, 2020, NAT MED, V26, P681, DOI 10.1038/s41591-020-0868-6
   Tsakiri EN, 2015, INT REV CEL MOL BIO, V314, P171, DOI 10.1016/bs.ircmb.2014.09.002
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Weir DL, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-40
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wyczalkowska-Tomasik A, 2012, ARCH GERONTOL GERIAT, V55, P735, DOI 10.1016/j.archger.2012.05.007
   Zanker D, 2014, EUR J IMMUNOL, V44, P3500, DOI 10.1002/eji.201445272
   Zhang K, 2015, KIDNEY INT, V87, P359, DOI 10.1038/ki.2014.274
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhao Y., 2020, 919985 BIORXIV
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 53
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2317
J9 REDOX BIOL
JI Redox Biol.
PD SEP
PY 2020
VL 36
AR 101615
DI 10.1016/j.redox.2020.101615
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA NQ7ZR
UT WOS:000571088500004
PM 32863223
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Long, EF
   Chen, MK
   Rohla, R
AF Long, Elisa F.
   Chen, M. Keith
   Rohla, Ryne
TI Political storms: Emergent partisan skepticism of hurricane risks
SO SCIENCE ADVANCES
LA English
DT Article
ID SCIENCE LITERACY
AB Mistrust of scientific evidence and government-issued guidelines is increasingly correlated with political affiliation. Survey evidence has documented skepticism in a diverse set of issues including climate change, vaccine hesitancy, and, most recently, COVID-19 risks. Less well understood is whether these beliefs alter high-stakes behavior. Combining GPS data for 2.7 million smartphone users in Florida and Texas with 2016 U.S. presidential election precinct-level results, we examine how conservative-media dismissals of hurricane advisories in 2017 influenced evacuation decisions. Likely Trump-voting Florida residents were 10 to 11 percentage points less likely to evacuate Hurricane Irma than Clinton voters (34% versus 45%), a gap not present in prior hurricanes. Results are robust to fine-grain geographic controls, which compare likely Clinton and Trump voters living within 150 m of each other. The rapid surge in media-led suspicion of hurricane forecasts-and the resulting divide in self-protective measures-illustrates a large behavioral consequence of science denialism.
C1 [Long, Elisa F.; Chen, M. Keith; Rohla, Ryne] Univ Calif Los Angeles, Anderson Sch Management, Los Angeles, CA 90095 USA.
RP Long, EF (corresponding author), Univ Calif Los Angeles, Anderson Sch Management, Los Angeles, CA 90095 USA.
EM elisa.long@anderson.ucla.edu
CR Allcott H, 2017, J ECON PERSPECT, V31, P211, DOI 10.1257/jep.31.2.211
   Altonji JG, 2005, J POLIT ECON, V113, P151, DOI 10.1086/426036
   Chen MK, 2018, SCIENCE, V360, P1020, DOI 10.1126/science.aaq1433
   Darcy O., 2017, CNN
   Drummond C, 2017, P NATL ACAD SCI USA, V114, P9587, DOI 10.1073/pnas.1704882114
   Federal Emergency Management Agency (FEMA), 2018, HURR FLOR RUM CONTR
   Huang SK, 2016, ENVIRON BEHAV, V48, P991, DOI 10.1177/0013916515578485
   Kahan DM, 2012, NAT CLIM CHANGE, V2, P732, DOI 10.1038/NCLIMATE1547
   Lazo JK, 2015, RISK ANAL, V35, P1837, DOI 10.1111/risa.12407
   Malhotra N, 2008, J POLIT, V70, P120, DOI 10.1017/S0022381607080097
   Morss RE, 2016, WEATHER FORECAST, V31, P395, DOI 10.1175/WAF-D-15-0066.1
   National Aeronautics Space Administration (NASA), 2009, DIST NEAR COAST
   National Oceanic Atmospheric Administration (NOAA), 2018, FAQ WHY DONT WE TRY
   Ohlheiser A., 2018, WASHINGTON POST
   Oster E, 2019, J BUS ECON STAT, V37, P187, DOI 10.1080/07350015.2016.1227711
   Patricola CM, 2018, NATURE, V563, P339, DOI 10.1038/s41586-018-0673-2
   Pennycook G, 2019, P NATL ACAD SCI USA, V116, P2521, DOI 10.1073/pnas.1806781116
   Pew Research Center, 2016, POL CLIM
   Selk Avi, 2017, WASHINGTON POST
   Snider MUT, 2017, US TODAY
   Stenhouse N, 2014, B AM METEOROL SOC, V95, P1029, DOI 10.1175/BAMS-D-13-00091.1
   Stephens NM, 2009, PSYCHOL SCI, V20, P878, DOI 10.1111/j.1467-9280.2009.02386.x
   United States Geological Survey (USGS), 2018, NAT MAP DAT DEL
   Webster PJ, 2005, SCIENCE, V309, P1844, DOI 10.1126/science.1116448
   World Meteorological Organization, 2018, CAR 2017 HURR SEAS E
NR 25
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD SEP
PY 2020
VL 6
IS 37
AR eabb7906
DI 10.1126/sciadv.abb7906
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NR1XL
UT WOS:000571356100026
PM 32917709
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Menendez, CA
   Bylehn, F
   Perez-Lemus, GR
   Alvarado, W
   de Pablo, JJ
AF Menendez, Cintia A.
   Bylehn, Fabian
   Perez-Lemus, Gustavo R.
   Alvarado, Walter
   de Pablo, Juan J.
TI Molecular characterization of ebselen binding activity to SARS-CoV-2
   main protease
SO SCIENCE ADVANCES
LA English
DT Article
ID CORONAVIRUS; DYNAMICS; PREVENTION
AB There is an urgent need to repurpose drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recent computational-experimental screenings have identified several existing drugs that could serve as effective inhibitors of the virus' main protease, M-pro, which is involved in gene expression and replication. Among these, ebselen (2-phenyl-1,2-benzoselenazol-3-one) appears to be particularly promising. Here, we examine, at a molecular level, the potential of ebselen to decrease Mpro activity. We find that it exhibits a distinct affinity for the catalytic region. Our results reveal a higher-affinity, previously unknown binding site localized between the II and III domains of the protein. A detailed strain analysis indicates that, on such a site, ebselen exerts a pronounced allosteric effect that regulates catalytic site access through surface-loop interactions, thereby inducing a reconfiguration of water hotspots. Together, these findings highlight the promise of ebselen as a repurposed drug against SARS-CoV-2.
C1 [Menendez, Cintia A.; Bylehn, Fabian; Perez-Lemus, Gustavo R.; Alvarado, Walter; de Pablo, Juan J.] Univ Chicago, Pritzker Sch Mol Engn, 5640 S Ellis Ave, Chicago, IL 60637 USA.
   [de Pablo, Juan J.] Argonne Natl Lab, Lemont, IL 60439 USA.
RP de Pablo, JJ (corresponding author), Univ Chicago, Pritzker Sch Mol Engn, 5640 S Ellis Ave, Chicago, IL 60637 USA.; de Pablo, JJ (corresponding author), Argonne Natl Lab, Lemont, IL 60439 USA.
EM depablo@uchicago.edu
OI Bylehn, Fabian/0000-0001-9331-6773
FU NSFNational Science Foundation (NSF) [EFRI CEE 1830969, DMR-1828629];
   Department of Energy, Office of Science, Basic Energy Sciences, Division
   of Materials Science and EngineeringUnited States Department of Energy
   (DOE); BIO/MCB [BIO/MCB 1818328];  [MURI: W911NF-15-1-0568]
FX The authors are grateful to Andrzej Joachimiak and Rick Stevens for
   helpful discussions. The study of protein-DNA complexes in epigenetics
   is supported by the NSF, under grant EFRI CEE 1830969, and the
   development of new DNA models is supported by BIO/MCB 1818328. The study
   of allostery and its role in triggerable materials is supported by MURI:
   W911NF-15-1-0568. The development of advanced sampling simulation
   algorithms and efficient software is supported by the Department of
   Energy, Office of Science, Basic Energy Sciences, Division of Materials
   Science and Engineering. The simulations reported here were carried out
   on the GPU cluster supported by the NSF through grant DMR-1828629.
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327
   Bzowka M., 2020, BIORXIV
   Case D., 2018, AMBER 2018
   DeLano W.L., 2002, PROTEIN CRYST, V40, P82, DOI DOI 10.1038/S41598-017-03842-2
   Dube D, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006665
   Eckmann JP, 2019, REV MOD PHYS, V91, DOI 10.1103/RevModPhys.91.031001
   Falk ML, 1998, PHYS REV E, V57, P7192, DOI 10.1103/PhysRevE.57.7192
   Gullett PM, 2008, MODEL SIMUL MATER SC, V16, DOI 10.1088/0965-0393/16/1/015001
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Kaus JW, 2013, J CHEM THEORY COMPUT, V9, P4131, DOI 10.1021/ct400340s
   Kil J, 2017, LANCET, V390, P969, DOI 10.1016/S0140-6736(17)31791-9
   Knight JDR, 2009, PROTEINS, V76, P527, DOI 10.1002/prot.22451
   Li CM, 2010, J BIOL CHEM, V285, P28134, DOI 10.1074/jbc.M109.095851
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Lynch Eric, 2009, Seminars in Hearing, V30, P47, DOI 10.1055/s-0028-1111106
   Magdziarz T, 2020, BIOINFORMATICS, V36, P2599, DOI 10.1093/bioinformatics/btz946
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Masaki C, 2016, PSYCHOPHARMACOLOGY, V233, P2655, DOI 10.1007/s00213-016-4319-5
   Mitchell MR, 2016, P NATL ACAD SCI USA, V113, pE5847, DOI 10.1073/pnas.1609462113
   Papakonstantopoulos GJ, 2007, PHYS REV E, V75, DOI 10.1103/PhysRevE.75.031803
   R. P. D. Bank, RCSB PDB 6M03 CRYST
   Renson M., 1982, 2 PHENYL 1 2 BENZISO
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Singh N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2320
   Steinbrecher T, 2011, J COMPUT CHEM, V32, P3253, DOI 10.1002/jcc.21909
   Thangamani S, 2015, SCI REP-UK, V5, DOI 10.1038/srep11596
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LL, 2017, EMBO MOL MED, V9, P1165, DOI 10.15252/emmm.201707661
   Zumla A, 2016, NAT REV DRUG DISCOV, V15, P327, DOI 10.1038/nrd.2015.37
NR 37
TC 1
Z9 1
U1 8
U2 8
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 2375-2548
J9 SCI ADV
JI Sci. Adv.
PD SEP
PY 2020
VL 6
IS 37
AR eabd0345
DI 10.1126/sciadv.abd0345
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA NR1XL
UT WOS:000571356100041
PM 32917717
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Al-Rasheed, M
AF Al-Rasheed, Malak
TI Protective Behavior against COVID-19 among the Public in Kuwait: An
   Examination of the Protection Motivation Theory, Trust in Government,
   and Sociodemographic Factors
SO SOCIAL WORK IN PUBLIC HEALTH
LA English
DT Article
DE Protective behaviors; Kuwait; protection motivation theory; trust in
   government; COVID-19; social work
ID HEALTH-EDUCATION; VULNERABILITY; INTERVENTION; SARS
AB With the COVID-19 pandemic threatening millions of lives around the world with no clear promises for treatment or vaccine yet, motivating the public to change their behaviors to prevent the spread of the disease becomes crucial and moral imperative. The current study investigated the associations between self-reported intentions to perform protective behaviors against COVID-19, the seven constructs of the Protection Motivation Theory PMT, trust in government, and sociodemographic factors within the general population in Kuwait. A cross-sectional design was adapted to explore the associations between study factors in a nonprobability voluntary response sample of 679 participants who completed an online public survey. Results indicate that the scores of trust in government and the severity, vulnerability, response efficacy, and self-efficacy subconstructs of the PMT were positively related to protective behavior intention, whereas intrinsic and extrinsic reward and response cost subconstructs were negatively associated with protective behavior intention. The results were discussed considering previous literature and future applications.
C1 [Al-Rasheed, Malak] Kuwait Univ, Dept Sociol & Social Work, Kuwait, Kuwait.
RP Al-Rasheed, M (corresponding author), POB 49, Kuwait 72861, Kuwait.
EM malak.alrasheed@ku.edu.kw
CR Ali I, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138861
   Amadasun S, 2020, SOC WORK EDUC, DOI 10.1080/02615479.2020.1771300
   [Anonymous], 2020, KUWAIT COVID 19
   Barati M., J HOSP INFECT, DOI [10.1016/j.jhin.2020.04.035, DOI 10.1016/J.JHIN.2020.04.035]
   Barrios M, 2011, SOC SCI COMPUT REV, V29, P208, DOI 10.1177/0894439310368031
   Bouckaert G, 2003, INT REV ADM SCI, V69, P329, DOI 10.1177/0020852303693003
   Council on Social Work Education, 2008, ED POL ACCR STAND
   Dasgupta P., 2009, ANN BANK C DEV EC AB
   Fukuyama F., 1995, TRUST SOCIAL VIRTUES
   Fung ICH, 2006, TROP MED INT HEALTH, V11, P1749, DOI 10.1111/j.1365-3156.2006.01734.x
   Gerrard M, 1996, PSYCHOL BULL, V119, P390, DOI 10.1037/0033-2909.119.3.390
   Ghahremani L, 2014, INT J PREVENTIVE MED, V5, P463
   Gong J, 2009, PEDIATRICS, V123, pE917, DOI 10.1542/peds.2008-2363
   Jiang XY, 2009, INT J BEHAV MED, V16, P58, DOI 10.1007/s12529-008-9005-5
   Kampen Jarl K., 2006, PUBLIC PERFORM MANAG, V29, P387, DOI DOI 10.1080/15309576.2006.11051881
   Macdonell Karen, 2013, J Addict Res Ther, V4, P154
   Milne S, 2000, J APPL SOC PSYCHOL, V30, P106, DOI 10.1111/j.1559-1816.2000.tb02308.x
   National Association of Social Work, 2017, BYL NAT ASS SOC WORK
   Rimer BK, 2001, HEALTH EDUC BEHAV, V28, P231, DOI 10.1177/109019810102800208
   Rosas SR, 2005, AM J EVAL, V26, P389, DOI 10.1177/1098214005278760
   Rubin GJ, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2651
   Sharifirad Gholamreza, 2014, J Educ Health Promot, V3, P7, DOI 10.4103/2277-9531.127556
   STEIN KB, 1974, PSYCHOL REP, V35, P999, DOI 10.2466/pr0.1974.35.2.999
   van der Pligt J, 1998, BRIT J HEALTH PSYCH, V3, P1
   WHO, 2020, COR DIS COVID 19 PAN
   Williams L, 2015, PSYCHOL HEALTH MED, V20, P832, DOI 10.1080/13548506.2015.1028946
   Wu CST, 2014, INT J ENV RES PUB HE, V11, P671, DOI 10.3390/ijerph110100671
   Xiao H., 2016, IEEE T IND ELECTRON, V1, P1, DOI DOI 10.1109/TIE.2016.2558138
   Zare Sakhvidi Mohammad Javad, 2015, Adv Prev Med, V2015, P467498, DOI 10.1155/2015/467498
NR 29
TC 0
Z9 0
U1 10
U2 10
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1937-1918
EI 1937-190X
J9 SOC WORK PUBLIC HLTH
JI Soc. Work Public Health
PD SEP 1
PY 2020
VL 35
IS 7
SI SI
BP 546
EP 556
DI 10.1080/19371918.2020.1806171
PG 11
WC Public, Environmental & Occupational Health; Social Work
SC Public, Environmental & Occupational Health; Social Work
GA NS7WJ
UT WOS:000572467900004
PM 32970542
DA 2021-01-01
ER

PT J
AU Paez, YM
   Bennett, JL
   Subramanian, PS
   Pelak, VS
AF Martin Paez, Yosbelkys
   Bennett, Jeffrey L.
   Subramanian, Prem S.
   Pelak, Victoria S.
TI Considerations for the Treatment of Inflammatory Neuro-Ophthalmologic
   Disorders During the COVID-19 Pandemic
SO JOURNAL OF NEURO-OPHTHALMOLOGY
LA English
DT Article
ID PLASMA-EXCHANGE; MULTIPLE; INFECTIONS; TRIAL; SARS; OCRELIZUMAB;
   RELAPSES; SAFETY; RISK
AB The initiation and continuation of immune-based therapies to treat and prevent complications of inflammatory neuro-ophthalmologic disorders during the 2019 novel coronavirus (COVID-19) pandemic is the subject of considerable debate. In each case, a treatment decision must be reached based on best clinical practices for the disorder, patient comorbidities, the current state of knowledge about the pathogenesis and infectivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the utilization of hospital and community resources. Unfortunately, the evidence needed to standardize the decision-making process for each neuro-ophthalmologic disorder is currently absent and is likely to require months or years to develop based on the accrual of robust international data sets. In this article, we review the current understanding of SARS-CoV-2 and COVID-19 complications to provide a framework for approaching the treatment of inflammatory neuro-ophthalmic disorders during the COVID-19 viral pandemic.
C1 [Martin Paez, Yosbelkys; Bennett, Jeffrey L.; Subramanian, Prem S.; Pelak, Victoria S.] Univ Colorado, Sch Med, Dept Ophthalmol, Aurora, CO USA.
   [Martin Paez, Yosbelkys; Bennett, Jeffrey L.; Subramanian, Prem S.; Pelak, Victoria S.] Univ Colorado, Sch Med, Dept Neurol, Aurora, CO USA.
   [Subramanian, Prem S.] Univ Colorado, Sch Med, Dept Neurosurg, Aurora, CO USA.
   [Bennett, Jeffrey L.] Univ Colorado, Sch Med, Program Neurosci, Aurora, CO USA.
   [Bennett, Jeffrey L.] Univ Colorado, Sch Med, Program Immunol, Aurora, CO USA.
RP Paez, YM (corresponding author), UCHlth Sue Anschutz Rodgers Eye Ctr, 1675 Aurora Ct, Aurora, CO 80045 USA.
EM yosbelkys.martin-paez@cuanschutz.edu
CR Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   ANDERSEN O, 1993, J NEUROL, V240, P417, DOI 10.1007/BF00867354
   Baker D, 2017, NEUROL-NEUROIMMUNOL, V4, DOI 10.1212/NXI.0000000000000360
   BECK RW, 1992, NEW ENGL J MED, V326, P581, DOI 10.1056/NEJM199202273260901
   Bonnan M, 2018, J NEUROL NEUROSUR PS, V89, P346, DOI 10.1136/jnnp-2017-316286
   Brufsky A, 2020, J MED VIROL, V92, P770, DOI 10.1002/jmv.25887
   Buljevac D, 2002, BRAIN, V125, P952, DOI 10.1093/brain/awf098
   CABIRAC GF, 1994, MICROB PATHOGENESIS, V16, P349, DOI 10.1006/mpat.1994.1035
   Centers for Disease Control and Prevention, 2020, INF IMM PERS
   Centers for Disease Control and Prevention, 2020, HEALTHC PROF FREQ AS
   Centers for Disease Control and Prevention, 2020, INT CLIN GUID MAN PA
   Confavreux C, 2001, NEW ENGL J MED, V344, P319, DOI 10.1056/NEJM200102013440501
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Coutinho AE, 2011, MOL CELL ENDOCRINOL, V335, P2, DOI 10.1016/j.mce.2010.04.005
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Desforges M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010014
   Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
   Edwards S, 1998, J NEUROL NEUROSUR PS, V64, P736, DOI 10.1136/jnnp.64.6.736
   Fraser J Alexander, 2008, Rev Neurol Dis, V5, P140
   Gu J, 2005, J EXP MED, V202, P415, DOI 10.1084/jem.20050828
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Haga S, 2008, P NATL ACAD SCI USA, V105, P7809, DOI 10.1073/pnas.0711241105
   Helms J, 2020, NEW ENGL J MED, V382
   Ho JC, 2003, AM J RESP CRIT CARE, V168, P1449, DOI 10.1164/rccm.200306-766OC
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Jacob S, 2020, J NEUROL SCI, V412, DOI 10.1016/j.jns.2020.116803
   Juanatey A, 2018, REV NEUROLOGIA, V66, P423, DOI 10.33588/rn.6612.2018132
   Lanini S, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-36
   Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
   Mao L, 2020, JAMA NEUROL
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Merle H, 2012, ARCH OPHTHALMOL-CHIC, V130, P858, DOI 10.1001/archophthalmol.2012.1126
   Montalban X, 2017, NEW ENGL J MED, V376, P209, DOI 10.1056/NEJMoa1606468
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Morrow SA, 2018, JAMA NEUROL, V75, P690, DOI 10.1001/jamaneurol.2018.0024
   Nath A, 2020, NEUROLOGY, V94, P809, DOI 10.1212/WNL.0000000000009455
   Noseworthy JH, 2001, NEUROLOGY, V56, P1514, DOI 10.1212/WNL.56.11.1514
   Oxley TJ, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009787
   Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187
   Prompetchara E, 2020, ASIAN PAC J ALLERGY, V38, P1, DOI 10.12932/AP-200220-0772
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   Robinson PC, 2020, NAT REV RHEUMATOL, V16, P293, DOI 10.1038/s41584-020-0418-0
   SITC, 2020, J IMMUNOTHER CANC, V8
   Sormani MP, 2020, LANCET NEUROL, V19, P481, DOI 10.1016/S1474-4422(20)30147-2
   Tajfirouz DA, 2019, CURR NEUROL NEUROSCI, V19, DOI 10.1007/s11910-019-1014-z
   Thomas K, 2016, NEUROL-NEUROIMMUNOL, V3, DOI 10.1212/NXI.0000000000000228
   Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Vollono C, 2020, SEIZURE-EUR J EPILEP, V78, P109, DOI 10.1016/j.seizure.2020.04.009
   World Health Organization, 2020, DIAGN TREATM PROT NO
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Yamamura T, 2019, NEW ENGL J MED, V381, P2114, DOI 10.1056/NEJMoa1901747
   Youssef J, 2016, RHEUM DIS CLIN N AM, V42, P157, DOI 10.1016/j.rdc.2015.08.004
   Zhang C, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105954
   Zheng YY, 2020, NAT REV CARDIOL, DOI 10.1038/s41569-020-0360-5
   Zhu L, 2020, AM J TRANSPLANT, V20, P1859, DOI 10.1111/ajt.15869
NR 57
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1070-8022
EI 1536-5166
J9 J NEURO-OPHTHALMOL
JI J. Neuro-Ophthal.
PD SEP
PY 2020
VL 40
IS 3
BP 305
EP 314
DI 10.1097/WNO.0000000000001016
PG 10
WC Clinical Neurology; Ophthalmology
SC Neurosciences & Neurology; Ophthalmology
GA NQ9CC
UT WOS:000571163200012
PM 32804456
OA Green Published
DA 2021-01-01
ER

PT J
AU Christie, DB
   Nemec, HM
   Scott, AM
   Buchanan, JT
   Franklin, CM
   Ahmed, A
   Khan, MS
   Callender, CW
   James, EA
   Christie, AB
   Ashley, DW
AF Christie, D. Benjamin, III
   Nemec, Hannah M.
   Scott, Anthony M.
   Buchanan, John T.
   Franklin, Christopher M.
   Ahmed, Aftab
   Khan, Muhammad S.
   Callender, Charles W.
   James, Erskine A.
   Christie, Amy B.
   Ashley, Dennis W.
TI Early outcomes with utilization of tissue plasminogen activator in
   COVID-19-associated respiratory distress: A series of five cases
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
DE COVID-19; tissue plasminogen activator; thrombolytic; respiratory
   failure
AB BACKGROUND Coronavirus patients demonstrate varying degrees of respiratory insufficiency; many will progress to respiratory failure with a severe version of acute respiratory distress syndrome refractory to traditional supportive strategies. Providers must consider alternative therapies to deter or prevent the cascade of decompensation to fulminant respiratory failure. METHODS This is a case-series of five COVID-19 positive patients who demonstrated severe hypoxemia, declining respiratory performance, and escalating oxygen requirements. Patients met the following criteria: COVID-19 positivity, worsening respiratory performance, severe hypoxemia (Pao(2)<= 80) despite traditional supportive measures, escalating supplemental oxygen requirements, and D-dimer greater than 1.5 mu g/mL. All patients received protocol directed thrombolytic therapy with tissue plasminogen activator (tPA). RESULTS All five patients improved without deleterious effects of thrombolytic therapy. Patient one was on maximum ventilator support, paralytics, and prone positioning without improvement. During tPA administration his Pao(2)/FIO(2)ratio improved from 69 to 127. Ventilator support was weaned immediately on posttreatment day 1, and he was extubated on posttreatment day 12. Our second through fifth patients were not intubated at time of initiation of tPA therapy. These patients each required significant oxygen supplementation trending toward intubation. After tPA therapy, all patients demonstrated a noticeable increase in Pao(2)values overtime. Three of these patients avoided intubation due to COVID-19-associated respiratory failure. CONCLUSION Administration of thrombolytics was followed by overall improvement in patients' oxygen requirements, and in three cases, prevented progression to mechanical ventilation, without deleterious effects. Clinical trials of thrombolytic therapy would further serve to underscore the efficacy and utility of this therapy.
C1 [Christie, D. Benjamin, III; Nemec, Hannah M.; Scott, Anthony M.; Buchanan, John T.; Franklin, Christopher M.; Ahmed, Aftab; Khan, Muhammad S.; Callender, Charles W.; James, Erskine A.; Christie, Amy B.; Ashley, Dennis W.] Mercer Univ, Sch Med, Med Ctr Navicent Hlth, Dept Trauma Crit Care, Macon, GA 31207 USA.
RP Christie, DB (corresponding author), 777 Hemlock St,MSC 140, Macon, GA 31201 USA.
EM christie.dudley@navicenthealth.org
CR [Anonymous], COVID 19 MAP
   [Anonymous], COR COVID 19 UPD FAI
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Fox SE., PULMONARY CARDIAC PA, DOI [10.1101/2020.04.06.20050575, DOI 10.1101/2020.04.06.20050575]
   Gattinoni L, 2020, INTENS CARE MED, V46, P1099, DOI 10.1007/s00134-020-06033-2
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Greco E, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102200
   Grommes J, 2012, AM J RESP CRIT CARE, V185, P628, DOI 10.1164/rccm.201108-1533OC
   HARDAWAY RM, 1990, RESUSCITATION, V19, P61, DOI 10.1016/0300-9572(90)90099-Z
   Hardaway RM, 2001, AM SURGEON, V67, P377
   HARDAWAY RM, 1990, CRIT CARE MED, V18, P1413, DOI 10.1097/00003246-199012000-00021
   Hardaway RM, 1996, J SURG RES, V61, P311, DOI 10.1006/jsre.1996.0122
   Idell S, 2003, CRIT CARE MED, V31, pS213, DOI 10.1097/01.CCM.0000057846.21303.AB
   Moore HB, 2020, RES PRACT THROMB HAE, V4, P984, DOI 10.1002/rth2.12395
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang J, 2020, J THROMB HAEMOST, V18, P1752, DOI 10.1111/jth.14828
   WHO, 2020, 84 WHO
NR 19
TC 8
Z9 8
U1 3
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2163-0755
EI 2163-0763
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD SEP
PY 2020
VL 89
IS 3
BP 448
EP 452
DI 10.1097/TA.0000000000002787
PG 5
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA NQ7RJ
UT WOS:000571066500017
PM 32427774
OA Bronze
DA 2021-01-01
ER

PT J
AU Barrett, CD
   Oren-Grinberg, A
   Chao, ED
   Moraco, AH
   Martin, MJ
   Reddy, SH
   Ilg, AM
   Jhunjhunwala, R
   Uribe, M
   Moore, HB
   Moore, EE
   Baedorf-Kassis, EN
   Krajewski, ML
   Talmor, DS
   Shaefi, S
   Yaffe, MB
AF Barrett, Christopher D.
   Oren-Grinberg, Achikam
   Chao, Edward
   Moraco, Andrew H.
   Martin, Matthew J.
   Reddy, Srinivas H.
   Ilg, Annette M.
   Jhunjhunwala, Rashi
   Uribe, Marco
   Moore, Hunter B.
   Moore, Ernest E.
   Baedorf-Kassis, Elias N.
   Krajewski, Megan L.
   Talmor, Daniel S.
   Shaefi, Shahzad
   Yaffe, Michael B.
TI Rescue therapy for severe COVID-19-associated acute respiratory distress
   syndrome with tissue plasminogen activator: A case series
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
DE COVID-19; acute respiratory distress syndrome; tissue plasminogen
   activator; pulmonary failure; fibrinolysis
AB The coronavirus disease 2019 (COVID-19) pandemic has led to unprecedented stresses on modern medical systems, overwhelming the resource infrastructure in numerous countries while presenting a unique series of pathophysiologic clinical findings. Thrombotic coagulopathy is common in critically ill patients suffering from COVID-19, with associated high rates of respiratory failure requiring prolonged periods of mechanical ventilation. Here, we report a case series of five patients suffering from profound, medically refractory COVID-19-associated respiratory failure who were treated with fibrinolytic therapy using tissue plasminogen activator (tPA; alteplase). All five patients appeared to have an improved respiratory status following tPA administration: one patient had an initial marked improvement that partially regressed after several hours, one patient had transient improvements that were not sustained, and three patients had sustained clinical improvements following tPA administration.
C1 [Barrett, Christopher D.; Jhunjhunwala, Rashi; Yaffe, Michael B.] Harvard Med Sch, Div Acute Care Surg Trauma & Surg Crit Care, Dept Surg, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
   [Barrett, Christopher D.; Yaffe, Michael B.] MIT, Dept Biol Engn, Koch Inst Integrat Canc Res, Ctr Precis Canc Med, 76-363,500 Main St, Cambridge, MA 02139 USA.
   [Barrett, Christopher D.; Yaffe, Michael B.] MIT, Dept Biol, Koch Inst Integrat Canc Res, Ctr Precis Canc Med, 76-363,500 Main St, Cambridge, MA 02139 USA.
   [Oren-Grinberg, Achikam; Ilg, Annette M.; Krajewski, Megan L.; Talmor, Daniel S.; Shaefi, Shahzad] Harvard Med Sch, Dept Anesthesia Crit Care & Pain Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
   [Chao, Edward; Reddy, Srinivas H.; Uribe, Marco] Albert Einstein Coll Med, Div Trauma & Surg Crit Care, Dept Surg, Jacobi Med Ctr, Bronx, NY 10467 USA.
   [Moraco, Andrew H.] Tufts Univ, Sch Med, Dept Med, Div Pulm & Crit Care,St Elizabeths Med Ctr, Boston, MA 02111 USA.
   [Martin, Matthew J.] Scripps Mercy Hosp, Dept Surg, San Diego, CA USA.
   [Ilg, Annette M.] Harvard Med Sch, Dept Emergency Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
   [Moore, Hunter B.; Moore, Ernest E.] Univ Colorado Denver, Dept Surg, Aurora, CO USA.
   [Moore, Ernest E.] Denver Hlth, Dept Surg, Ernest E Moore Shock Trauma Ctr, Denver, CO USA.
   [Baedorf-Kassis, Elias N.] Harvard Med Sch, Dept Med, Beth Israel Deaconess Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02115 USA.
RP Yaffe, MB (corresponding author), MIT, Dept Biol Engn, Koch Inst Integrat Canc Res, Ctr Precis Canc Med, 76-363,500 Main St, Cambridge, MA 02139 USA.; Yaffe, MB (corresponding author), MIT, Dept Biol, Koch Inst Integrat Canc Res, Ctr Precis Canc Med, 76-363,500 Main St, Cambridge, MA 02139 USA.
EM myaffe@mit.edu
FU NIA NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)
   [R03 AG060179] Funding Source: Medline; NIGMS NIH HHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS) [K08
   GM134220] Funding Source: Medline
CR Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Fox SE., PULMONARY CARDIAC PA, DOI [10.1101/2020.04.06.20050575, DOI 10.1101/2020.04.06.20050575]
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Han H, 2020, CLIN CHEM LAB MED
   Hardaway RM, 2001, AM SURGEON, V67, P377
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Konstantinides S, 2002, NEW ENGL J MED, V347, P1143, DOI 10.1056/NEJMoa021274
   Liu C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01898
   Moore HB, 2020, J TRAUMA ACUTE CARE, V88, P713, DOI 10.1097/TA.0000000000002694
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Wang J, 2020, J THROMB HAEMOST, V18, P1752, DOI 10.1111/jth.14828
   Ware LB, 2007, CRIT CARE MED, V35, P1821, DOI 10.1097/01.CCM.0000275386.95968.5F
   Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288
NR 13
TC 4
Z9 4
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2163-0755
EI 2163-0763
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD SEP
PY 2020
VL 89
IS 3
BP 453
EP 457
DI 10.1097/TA.0000000000002786
PG 5
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA NQ7RJ
UT WOS:000571066500018
PM 32427773
OA Green Accepted, Green Published
DA 2021-01-01
ER

PT J
AU Dalakas, MC
AF Dalakas, Marinos C.
TI Guillain-Barre syndrome: The first documented COVID-19-triggered
   autoimmune neurologic disease: More to come with myositis in the offing
SO NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
LA English
DT Article
ID INFLAMMATORY MYOPATHIES; NEUROPATHY; IMMUNOGLOBULIN
AB Objective
   To present the COVID-19-associated GBS, the prototypic viral-triggered autoimmune disease, in the context of other emerging COVID-19-triggered autoimmunities, and discuss potential concerns with ongoing neuroimmunotherapies.
   Methods
   Eleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids. Emerging cases of COVID-19-triggered autoimmune necrotizing myositis (NAM) and encephalopathies are also reviewed in the context of viral invasion, autoimmunity and ongoing immunotherapies.
   Results
   Collective data indicate that in this pandemic any patient presenting with an acute paralytic disease-like GBS, encephalomyelitis or myositis-even without systemic symptoms, may represent the first manifestation of COVID-19. Anosmia, ageusia, other cranial neuropathies and lymphocytopenia are red flags enhancing early diagnostic suspicion. In Miller-Fisher Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19-bearing gangliosides and peripheral nerve glycolipids was addressed. Elevated Creatine Kinase (>10,000) is reported in 10% of COVID-19-infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19-triggered NAM is an overlooked entity. Cases of acute necrotizing brainstem encephalitis, cranial neuropathies with leptomeningeal enhancement, and tumefactive postgadolinium-enhanced demyelinating lesions are now emerging with the need to explore neuroinvasion and autoimmunity. Concerns for modifications-if any-of chronic immunotherapies with steroids, mycophenolate, azathioprine, IVIg, and anti-B-cell agents were addressed; the role of complement in innate immunity to viral responses and anti-complement therapeutics (i.e. eculizumab) were reviewed.
   Conclusions
   Emerging data indicate that COVID-19 can trigger not only GBS but other autoimmune neurological diseases necessitating vigilance for early diagnosis and therapy initiation. Although COVID-19 infection, like most other viruses, can potentially worsen patients with pre-existing autoimmunity, there is no evidence that patients with autoimmune neurological diseases stable on common immunotherapies are facing increased risks of infection.
C1 [Dalakas, Marinos C.] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA.
   [Dalakas, Marinos C.] Natl & Kapodistrian Univ Athens, Neuroimmunol Unit, Sch Med, Athens, Greece.
RP Dalakas, MC (corresponding author), Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA.; Dalakas, MC (corresponding author), Natl & Kapodistrian Univ Athens, Neuroimmunol Unit, Sch Med, Athens, Greece.
EM marinos.dalakas@jefferson.edu
CR Alberti P, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000741
   Armangue T, 2018, LANCET NEUROL, V17, P760, DOI 10.1016/S1474-4422(18)30244-8
   Bigaut K, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000785
   Brun G, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000777
   Cabello-Verrugio C, 2015, MED RES REV, V35, P437, DOI 10.1002/med.21343
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Dalakas MC, 2008, NEUROLOGY, V70, P2252, DOI 10.1212/01.wnl.0000313840.27060.bf
   Dalakas MC, 2007, ANN NEUROL, V61, P466, DOI 10.1002/ana.21103
   Dalakas MC, 2018, NAT REV RHEUMATOL, V14, P251, DOI 10.1038/nrrheum.2018.54
   Dalakas MC, 2015, NEW ENGL J MED, V372, P1734, DOI 10.1056/NEJMra1402225
   Dalakas MC, 2015, BBA-MOL BASIS DIS, V1852, P658, DOI 10.1016/j.bbadis.2014.06.013
   DALAKAS MC, 1986, JAMA-J AM MED ASSOC, V256, P2381, DOI 10.1001/jama.256.17.2381
   Dalakas MC, 1996, ANN NEUROL, V39, P419, DOI 10.1002/ana.410390402
   Dalakas MC, 2001, J PERIPHER NERV SYST, V6, P14, DOI 10.1046/j.1529-8027.2001.006001014.x
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   DAUNE GC, 1992, ANN NEUROL, V31, P683, DOI 10.1002/ana.410310621
   Desforges M, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010014
   Dixon L, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000789
   Fan ML, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000787
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Gutierrez-Ortiz C, 2020, NEUROLOGY, V95, pE601, DOI 10.1212/WNL.0000000000009619
   Habernan R, COVID 19 IMMUNE MEDI, DOI [10.1056/NEJMc2009567, DOI 10.1056/NEJMC2009567]
   ILLA I, 1991, ANN NEUROL, V29, P474, DOI 10.1002/ana.410290505
   Kusunoki S, 1996, ANN NEUROL, V39, P424, DOI 10.1002/ana.410390404
   LEFF RL, 1992, LANCET, V339, P1192, DOI 10.1016/0140-6736(92)91134-T
   LEONMONZON M, 1993, MUSCLE NERVE, V16, P408, DOI 10.1002/mus.880160411
   Lv PP, 2020, BMC ENDOCR DISORD, V20, DOI 10.1186/s12902-020-00569-6
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Moriguchi T, 2020, INT J INFECT DIS, V94, P55, DOI 10.1016/j.ijid.2020.03.062
   Risitano AM, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0320-7
   Stein M, 2000, J RHEUMATOL, V27, P2927
   Suwanwongse K, 2020, CUREUS, V12, DOI 10.7759/cureus.7561
   Toscano G, 2020, NEW ENGL J MED, V382, P2574, DOI 10.1056/NEJMc2009191
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   van Schaik IN, 2018, LANCET NEUROL, V17, P35, DOI 10.1016/S1474-4422(17)30378-2
   Wakerley BR, 2013, EXPERT REV CLIN IMMU, V9, P627, DOI 10.1586/1744666X.2013.811119
   Watanabe Y, 2016, J NEUROL NEUROSUR PS, V87, P1038, DOI 10.1136/jnnp-2016-313166
   Yan CH, 2020, INT FORUM ALLERGY RH, V10, P806, DOI 10.1002/alr.22579
   Zhao H, 2020, LANCET NEUROL, V19, P383, DOI 10.1016/S1474-4422(20)30109-5
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 41
TC 24
Z9 24
U1 2
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2332-7812
J9 NEUROL-NEUROIMMUNOL
JI Neurol.-Neuroimmunol. Neuroinflammation
PD SEP
PY 2020
VL 7
IS 5
AR e781
DI 10.1212/NXI.0000000000000781
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NQ9PP
UT WOS:000571198600030
PM 32518172
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dixon, L
   Varley, J
   Gontsarova, A
   Mallon, D
   Tona, F
   Muir, D
   Luqmani, A
   Jenkins, IH
   Nicholas, R
   Jones, B
   Everitt, A
AF Dixon, Luke
   Varley, James
   Gontsarova, Anastassia
   Mallon, Dermot
   Tona, Francesca
   Muir, David
   Luqmani, Asad
   Jenkins, Ieuan Harri
   Nicholas, Richard
   Jones, Brynmor
   Everitt, Alex
TI COVID-19-related acute necrotizing encephalopathy with brain stem
   involvement in a patient with aplastic anemia
SO NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
LA English
DT Article
ID ENCEPHALITIS; CHILDHOOD; JAPAN
AB Objective
   To describe a novel case of coronavirus disease 2019 (COVID-19)-associated acute necrotizing encephalopathy (ANE) in a patient with aplastic anemia where there was early brain stem-predominant involvement.
   Methods
   Evaluation of cause, clinical symptoms, and treatment response.
   Results
   A 59-year-old woman with a background of transfusion-dependent aplastic anemia presented with seizures and reduced level of consciousness 10 days after the onset of subjective fever, cough, and headache. Nasopharyngeal swab testing for severe acute respiratory syndrome coronavirus (SARS-CoV-2) was positive, and CT during admission demonstrated diffuse swelling of the brain stem. She required intubation and mechanical ventilation for airway protection, given her reduced level of consciousness. The patient's condition deteriorated, and MRI on day 6 demonstrated worsening brain stem swelling with symmetrical hemorrhagic lesions in the brain stem, amygdalae, putamina, and thalamic nuclei. Appearances were consistent with hemorrhagic ANE with early brain stem involvement. The patient showed no response to steroid therapy and died on the eighth day of admission.
   Conclusions
   COVID-19 may be associated with an acute severe encephalopathy and, in this case, was considered most likely to represent an immune-mediated phenomenon. As the pandemic continues, we anticipate that the spectrum of neurologic presentation will broaden. It will be important to delineate the full clinical range of emergent COVID-19-related neurologic disease.
C1 [Dixon, Luke; Gontsarova, Anastassia; Mallon, Dermot; Tona, Francesca; Jones, Brynmor] Imperial Coll Healthcare NHS Trust, Dept Imaging, London, England.
   [Varley, James; Jenkins, Ieuan Harri; Everitt, Alex] Imperial Coll Healthcare NHS Trust, Dept Neurosci, London, England.
   [Muir, David] Imperial Coll Healthcare NHS Trust, Northwest London Pathol, London, England.
   [Luqmani, Asad] Imperial Coll Healthcare NHS Trust, Dept Hematol, London, England.
   [Nicholas, Richard] Imperial Coll London, Fac Med, Ctr Neuroinflammat & Neurodegenerat, London, England.
   [Nicholas, Richard] UCL Inst Ophthalmol, Dept Visual Neurosci, London, England.
RP Dixon, L (corresponding author), Imperial Coll Healthcare NHS Trust, Dept Imaging, London, England.
EM Luke.dixon1@nhs.net
OI Mallon, Dermot/0000-0001-7434-1201; nicholas,
   richard/0000-0003-0414-1225
FU Imperial College London University
FX The Article Processing Charge was funded by the Imperial College London
   University.
CR Ito Y, 1999, J MED VIROL, V58, P420, DOI 10.1002/(SICI)1096-9071(199908)58:4&lt;420::AID-JMV16&gt;3.0.CO;2-T
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Mashima K, 2017, INTERNAL MED, V56, P701, DOI 10.2169/internalmedicine.56.7722
   McGonagle D, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102537
   Mizuguchi M, 1997, BRAIN DEV-JPN, V19, P81, DOI 10.1016/S0387-7604(96)00063-0
   Offiah C, 2013, J PEDIATR NEURORADIO, V2, P319, DOI 10.3233/PNR-13075
   Poyiadji N, 2020, RADIOLOGY, V296, pE119, DOI 10.1148/radiol.2020201187
   Sugaya N, 2000, PEDIATR INT, V42, P215, DOI 10.1046/j.1442-200x.2000.01200.x
   Tam DYS, 2012, J PEDIAT HEMATOL ONC, V34, P472, DOI 10.1097/MPH.0b013e318243501b
   Wong AM, 2006, AM J NEURORADIOL, V27, P1919
NR 10
TC 26
Z9 25
U1 2
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2332-7812
J9 NEUROL-NEUROIMMUNOL
JI Neurol.-Neuroimmunol. Neuroinflammation
PD SEP
PY 2020
VL 7
IS 5
AR e789
DI 10.1212/NXI.0000000000000789
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NQ9PP
UT WOS:000571198600026
PM 32457227
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fan, ML
   Qiu, W
   Bu, BT
   Xu, Y
   Yang, H
   Huang, DH
   Lau, AY
   Guo, J
   Zhang, MN
   Zhang, XH
   Yang, CS
   Chen, JS
   Zheng, P
   Liu, Q
   Zhang, C
   Shi, FD
AF Fan, Moli
   Qiu, Wei
   Bu, Bitao
   Xu, Yan
   Yang, Huan
   Huang, Dehui
   Lau, Alexander Y.
   Guo, Jun
   Zhang, Mei-Ni
   Zhang, Xinghu
   Yang, Chun-Sheng
   Chen, Jingshan
   Zheng, Pei
   Liu, Qiang
   Zhang, Chao
   Shi, Fu-Dong
TI Risk of COVID-19 infection in MS and neuromyelitis optica spectrum
   disorders
SO NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
LA English
DT Article
AB Objective
   Disease-modifying drugs (DMDs) may alter the immune status and thus increase the susceptibility to coronavirus disease 2019 (COVID-19) in patients with MS or neuromyelitis optica spectrum disorders (NMOSD). However, evidence supporting this notion is currently lacking. In this study, we conducted a survey on the risk of COVID-19 in patients with MS and NMOSD.
   Methods
   The survey was conducted through the Chinese Medical Network for Neuroinflammation. Patients in 10 MS centers from 8 cities including Wuhan were included. Information about MS and NMOSD disease duration and the usage of DMDs were collected. Data of suspected cases of COVID-19 were obtained from hospital visits, questionnaires, and patient self-reporting. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was confirmed through clinical evaluation by a panel of experts in conjunction with chest CT and viral RNA detection.
   Results
   Eight hundred eighty-two of 1,804 (48.89%) patients with MS and 2,129 of 3,060 (69.58%) patients with NMOSD were receiving DMDs. There were no alterations in the patients' DMD regimen during January 15, 2020, to March 15, 2020, the 3-month period. None of the patients with MS treated with DMDs had COVID-19. However, 2 patients with relapsing NMOSD were diagnosed with COVID-19-related pneumonia. After treatment, both patients recovered from pneumonia and neither patient experienced new attacks due to predisposing SARS-CoV-2 infection in the following 2 months.
   Conclusions
   No increased risk of COVID-19 infection was observed in patients with MS or NMOSD, irrespective of whether these patients received DMDs. A battery of stringent preventive measures adopted by neurologists to reduce COVID-19 infection in these patients may have contributed to low risk of COVID-19 infection.
C1 [Fan, Moli; Yang, Huan; Chen, Jingshan; Zheng, Pei; Zhang, Chao; Shi, Fu-Dong] Tianjin Med Univ Gen Hosp, Dept Neurol, Tianjin, Peoples R China.
   [Zhang, Xinghu; Shi, Fu-Dong] Capital Med Univ, Beijing Tiantan Hosp, Jing Jin Ctr Neuroinfalmmat, China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
   [Qiu, Wei] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Neurol, Guangzhou, Peoples R China.
   [Bu, Bitao] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Neurol, Wuhan, Peoples R China.
   [Xu, Yan] Peking Union Med Coll Hosp, Dept Neurol, Beijing, Peoples R China.
   [Yang, Huan] Cent South Univ, Xiangya Hosp, Changsha, Peoples R China.
   [Huang, Dehui] Gen Hosp Chinese Peoples Liberat Army, Dept Neurol, Beijing, Peoples R China.
   [Lau, Alexander Y.] Chinese Univ Hong Kong, Div Neurol, Dept Med & Therapeut, Prince Wales Hosp, Hong Kong, Peoples R China.
   [Guo, Jun] Air Force Mil Med Univ, Dept Neurol, Tangdu Hosp, Xian, Peoples R China.
   [Zhang, Mei-Ni] Shanxi Med Univ, Dept Neurol, Affiliated Hosp 1, Taiyuan, Peoples R China.
RP Shi, FD (corresponding author), Tianjin Med Univ Gen Hosp, Dept Neurol, Tianjin, Peoples R China.; Shi, FD (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Jing Jin Ctr Neuroinfalmmat, China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
EM fshi@tmu.edu.cn
FU Advanced Innovation Center for Human Brain Protection (Neuroimmune)
   [01]; National Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [91642205, 81830038, 81601019]
FX This study was supported by the Advanced Innovation Center for Human
   Brain Protection (Neuroimmune 01), and the National Science Foundation
   of China (91642205, 81830038, and 81601019).
CR Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Luna G, 2020, JAMA NEUROL, V77, P184, DOI 10.1001/jamaneurol.2019.3365
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4
NR 6
TC 7
Z9 7
U1 3
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2332-7812
J9 NEUROL-NEUROIMMUNOL
JI Neurol.-Neuroimmunol. Neuroinflammation
PD SEP
PY 2020
VL 7
IS 5
AR e787
DI 10.1212/NXI.0000000000000787
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NQ9PP
UT WOS:000571198600032
PM 32503092
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Maguire, C
   Frohman, T
   Zamvil, SS
   Frohman, E
   Melamed, E
AF Maguire, Cole
   Frohman, Teresa
   Zamvil, Scott S.
   Frohman, Elliot
   Melamed, Esther
TI Should interferons take front stage as an essential MS disease-modifying
   therapy in the era of coronavirus disease 2019?
SO NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
LA English
DT Article
AB In the unprecedented pandemic of the coronavirus disease 2019 (COVID-19) along with a limited clinical understanding on effective vaccines and therapies, there are currently many unknowns for patients with autoimmune conditions, such as MS, who require ongoing treatment with immunotherapies. As information is currently lacking on the immune effects of COVID-19 in the context of MS disease-modifying therapies (DMTs), a challenging clinical question being faced by patients and neurologists is whether to continue current DMTs for patients with MS and risk potentially greater morbidity and mortality due to COVID-19 infection vs discontinue DMT therapy and risk MS disease relapse. At this time, we desperately need data to guide which DMTs may best treat both COVID-19 and MS.
C1 [Maguire, Cole; Frohman, Teresa; Frohman, Elliot; Melamed, Esther] Dell Med Sch, Dept Neurol, Austin, TX 78712 USA.
   [Zamvil, Scott S.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
   [Zamvil, Scott S.] Univ Calif San Francisco, Program Immunol, San Francisco, CA 94143 USA.
RP Melamed, E (corresponding author), Dell Med Sch, Dept Neurol, Austin, TX 78712 USA.
EM esther.melamed@austin.utexas.edu
OI Maguire, Cole/0000-0001-8986-9762
FU University of Texas Dell Medical School
FX This work was supported by the University of Texas Dell Medical School
   Start Up funding to E. Melamed. The corresponding author, E. Melamed,
   had the final responsibility for the decision to submit this manuscript
   for publication.
CR Axtell RC, 2008, IMMUNITY, V28, P600, DOI 10.1016/j.immuni.2008.04.006
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Gilli F, 2017, J NEUROVIROL, V23, P825, DOI 10.1007/s13365-017-0570-8
   Huang L., 2020, INFECT DIS HIV AIDS, DOI [10.1101/2020.03.15.20033472, DOI 10.1101/2020.03.15.20033472]
   Kupferschmidt K., 2020, SCIENCE
   Myhr KM, 1999, NEUROLOGY, V52, P1049, DOI 10.1212/WNL.52.5.1049
   Wei L, CELLD2000887, DOI [10.2139/ssrn.3564998, DOI 10.2139/SSRN.3564998]
NR 7
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2332-7812
J9 NEUROL-NEUROIMMUNOL
JI Neurol.-Neuroimmunol. Neuroinflammation
PD SEP
PY 2020
VL 7
IS 5
AR e811
DI 10.1212/NXI.0000000000000811
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NQ9PP
UT WOS:000571198600014
PM 32527763
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Parrotta, E
   Kister, I
   Charvet, L
   Sammarco, C
   Saha, V
   Charlson, RE
   Howard, J
   Gutman, JM
   Gottesman, M
   Abou-Fayssal, N
   Wolintz, R
   Keilson, M
   Fernandez-Carbonell, C
   Krupp, LB
   Ryerson, LZ
AF Parrotta, Erica
   Kister, Ilya
   Charvet, Leigh
   Sammarco, Carrie
   Saha, Valerie
   Charlson, Robert Erik
   Howard, Jonathan
   Gutman, Josef Maxwell
   Gottesman, Malcolm
   Abou-Fayssal, Nada
   Wolintz, Robyn
   Keilson, Marshall
   Fernandez-Carbonell, Cristina
   Krupp, Lauren B.
   Ryerson, Lana Zhovtis
TI COVID-19 outcomes in MS Observational study of early experience from NYU
   Multiple Sclerosis Comprehensive Care Center
SO NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
LA English
DT Article
AB Objective
   To report outcomes on patients with multiple sclerosis (MS) and related disorders with coronavirus disease 2019 (COVID-19) illness.
   Methods
   From March 16 to April 30, 2020, patients with MS or related disorders at NYU Langone MS Comprehensive Care Center were identified with laboratory-confirmed or suspected COVID-19. The diagnosis was established using a standardized questionnaire or by review of in-patient hospital records.
   Results
   We identified 76 patients (55 with relapsing MS, of which 9 had pediatric onset; 17 with progressive MS; and 4 with related disorders). Thirty-seven underwent PCR testing and were confirmed positive. Of the entire group, 64 (84%) patients were on disease-modifying therapy (DMT) including anti-CD20 therapies (n = 34, 44.7%) and sphingosine-1-phosphate receptor modulators (n = 10, 13.5%). The most common COVID-19 symptoms were fever and cough, but 21.1% of patients had neurologic symptom recrudescence preceding or coinciding with the infection. A total of 18 (23.7%) were hospitalized; 8 (10.5%) had COVID-19 critical illness or related death. Features more common among those hospitalized or with critical illness or death were older age, presence of comorbidities, progressive disease, and a nonambulatory status. No DMT class was associated with an increased risk of hospitalization or fatal outcome.
   Conclusions
   Most patients with MS with COVID-19 do not require hospitalization despite being on DMTs. Factors associated with critical illness were similar to the general at-risk patient population. DMT use did not emerge as a predictor of poor COVID-19 outcome in this preliminary sample.
C1 [Parrotta, Erica; Kister, Ilya; Charvet, Leigh; Sammarco, Carrie; Saha, Valerie; Charlson, Robert Erik; Howard, Jonathan; Gutman, Josef Maxwell; Gottesman, Malcolm; Abou-Fayssal, Nada; Wolintz, Robyn; Keilson, Marshall; Krupp, Lauren B.; Ryerson, Lana Zhovtis] NYU Langone Multiple Sclerosis Comprehens Care Ct, New York, NY 10016 USA.
   [Fernandez-Carbonell, Cristina] Cohens Children Med Ctr Northwell Hlth, Lake Success, NY USA.
RP Ryerson, LZ (corresponding author), NYU Langone Multiple Sclerosis Comprehens Care Ct, New York, NY 10016 USA.
EM lana.zhovtisryerson@nyulangone.org
OI keilson, marshall/0000-0001-7145-9108; krupp,
   lauren/0000-0001-7003-807X; Charvet, Leigh/0000-0003-4429-9713; Kister,
   Ilya/0000-0003-3549-949X; Gutman, Josef/0000-0002-7931-3098;
   Abou-Fayssal, Nada/0000-0002-3426-7040; Howard,
   Jonathan/0000-0003-2658-3219
CR Lighter J, 2020, CLIN INFECT DIS
   Luna G, 2020, JAMA NEUROL, V77, P184, DOI 10.1001/jamaneurol.2019.3365
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Petrilli CM, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1966
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2098, DOI [10.1001/jama.2020.7681, 10.1001/jama.2020.6775]
   Sormani MP, 2020, LANCET NEUROL, V19, P481, DOI 10.1016/S1474-4422(20)30147-2
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 7
TC 6
Z9 6
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2332-7812
J9 NEUROL-NEUROIMMUNOL
JI Neurol.-Neuroimmunol. Neuroinflammation
PD SEP
PY 2020
VL 7
IS 5
AR e835
DI 10.1212/NXI.0000000000000835
PG 9
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA NQ9PP
UT WOS:000571198600003
PM 32646885
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dwarka, D
   Agoni, C
   Mellem, JJ
   Soliman, ME
   Baijnath, H
AF Dwarka, Depika
   Agoni, Clement
   Mellem, John Jason
   Soliman, Mahmoud E.
   Baijnath, Himansu
TI Identification of potential SARS-CoV-2 inhibitors from South African
   medicinal plant extracts using molecular modelling approaches
SO SOUTH AFRICAN JOURNAL OF BOTANY
LA English
DT Article
DE COVID-19; SARS-CoV-2 3C-like main protease; SARS-CoV-2 receptor binding
   domain; SARS-CoV-2 RNA-dependent polymerase; Molecular dynamics
   simulations
ID ANTIVIRAL ACTIVITY; MAIN PROTEASE; UCSF CHIMERA; CORONAVIRUS; DYNAMICS;
   OPTIMIZATION; ACCURACY; SOFTWARE; DOCKING; VIRUS
AB The coronavirus is a group of viruses found in animals as well as humans and have been detected since the 1960s. However, a newly identified form, SARS-CoV-2, has triggered a recent pandemic of respiratory disease now called COVID-19. There is currently no specific antiviral drug for the treatment of this pandemic, with most treatment strategies focused on symptomatic management and supportive therapy. As such, several drug discovery efforts are ongoing for potent treatment agents, with medicinal plants gradually gaining prominence. Approximately 80% of the South African population use traditional medicines to meet their primary health care needs. The current study aimed to identify potential COVID-19 therapeutic agents from a list of 29 bioactive compounds isolated from commonly used South African medicinal plants using molecular docking and molecular dynamics. Molecular docking identified arabic acid from Acacia senegal and L-canavanine found in Sutherlandia frutescens as a potential inhibitor of SARS-CoV-2 3C-like main protease. Similarly, hypoxoside isolated from Hypoxis hemerocallidea and uzarin from Xysmalobium undulatum, were identified as a potential inhibitor of SARS-CoV-2 receptor binding domain and SARS-CoV-2 RNA-dependent polymerase. These four bioactive compounds exhibited favourable binding orientations characterized by strong molecular interactions within respective inhibitors binding pockets of the target enzymes. Molecular dynamics simulations revealed that the binding of the identified inhibitors are characterized by structural perturbations which favour the inhibitory potency of these bioactive compounds. Additionally, in silico pharmacokinetic assessment of the compounds demonstrated favourable anti-SARS-CoV-2 properties. Although not conclusive, further experimental exploration of these compounds could serve as a starting point for the discovery of novel SARS-CoV-2 therapeutic. (C) 2020 SAAB. Published by Elsevier B.V. All rights reserved.
C1 [Dwarka, Depika; Mellem, John Jason] Durban Univ Technol, Dept Biotechnol & Food Technol, Kwa Zulu, South Africa.
   [Agoni, Clement; Soliman, Mahmoud E.] Univ KwaZulu Natal, Discipline Pharmaceut Sci, Sch Hlth Sci, Mol Biocomputat & Drug Design Lab, Kwa Zulu, South Africa.
   [Agoni, Clement] Dream Lab Consult, Cape Coast, Ghana.
   [Baijnath, Himansu] Univ KwaZulu Natal, Sch Life Sci, Ward Herbarium, Kwa Zulu, South Africa.
RP Dwarka, D (corresponding author), Durban Univ Technol, Dept Biotechnol & Food Technol, Kwa Zulu, South Africa.
OI Mellem, John/0000-0002-4784-699X; AGONI, CLEMENT/0000-0001-6130-8031
FU Durban University of Technology; University of KwaZulu-Natal
FX Durban University of Technology and University of KwaZulu-Natal.
CR Agbabiaka TB, 2008, PHYTOMEDICINE, V15, P378, DOI 10.1016/j.phymed.2007.11.023
   Agoni C, 2020, CELL BIOCHEM BIOPHYS, V78, P3, DOI 10.1007/s12013-019-00896-z
   Agoni C, 2019, CHEM BIODIVERS, V16, DOI 10.1002/cbdv.201900365
   Agoni C, 2018, COMB CHEM HIGH T SCR, V21, P453, DOI 10.2174/1386207321666180716093617
   Agoni C, 2018, FUTURE MED CHEM, V10, P1665, DOI 10.4155/fmc-2017-0197
   ALBRECHT CF, 1995, S AFR MED J, V85, P853
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Andersen KG, 2020, NAT MED, DOI 10.1038/s41591-020-0820-9
   Astani A, 2010, PHYTOTHER RES, V24, P673, DOI 10.1002/ptr.2955
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451
   BIOVIA D.S., 2015, DASSAULT SYSTEMES DI
   Bornot A, 2011, PROTEINS, V79, P839, DOI 10.1002/prot.22922
   Brendler T., 2010, AFRICAN HERBAL PHARM
   Cai GJ, 2020, STEEL RES INT, DOI 10.1002/srin.202000269
   Case DA, 2005, J COMPUT CHEM, V26, P1668, DOI 10.1002/jcc.20290
   Chu Chung K., 2006, Antiviral Chemistry & Chemotherapy, V17, P285
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   DEKKER TG, 1988, S AFR J CHEM, V41, P33
   Duke J, 2012, HDB LEGUMES WORLD EC
   Dwarka Depika, 2017, Afr J Tradit Complement Altern Med, V14, P147, DOI 10.21010/ajtcam.v14i3.16
   Faleschini M.T., 2011, PHYTOCHEMICAL BIOL I
   Gao Y., 2020, STRUCTURE RNA DEPEND, DOI [10.1101/2020.03.16.993386, DOI 10.1101/2020.03.16.993386]
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Hall J, 2020, SUSTAINABILITY-BASEL, V12, DOI 10.3390/su12051980
   Hanwell MD, 2012, J CHEMINFORMATICS, V4, DOI 10.1186/1758-2946-4-17
   Hutchings A, 1996, ZULU MED PLANTS INVE
   Imbert I, 2006, EMBO J, V25, P4933, DOI 10.1038/sj.emboj.7601368
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Kirchdoerfer RN, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10280-3
   Kolodziej H, 2002, MED AROM PLANTS, V27, P262
   Krautler V, 2001, J COMPUT CHEM, V22, P501, DOI 10.1002/1096-987X(20010415)22:5<501::AID-JCC1021>3.0.CO;2-V
   Lategan CA, 2009, J ETHNOPHARMACOL, V121, P92, DOI 10.1016/j.jep.2008.10.007
   Leonard CM, 2015, J ETHNOPHARMACOL, V165, P260, DOI 10.1016/j.jep.2015.02.021
   Liebenberg R.W., 1997, U.S. Patent, Patent No. [5,609,874, 5609874]
   Liu NQ, 2009, S AFR J BOT, V75, P185, DOI 10.1016/j.sajb.2008.11.001
   Liu X., 2020, CRYTAL STRUCTURE 201
   Lobanov MY, 2008, MOL BIOL+, V42, P623, DOI 10.1134/S0026893308040195
   MAENO K, 1979, VIROLOGY, V94, P128, DOI 10.1016/0042-6822(79)90443-4
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   MAIOROV VN, 1994, J MOL BIOL, V235, P625, DOI 10.1006/jmbi.1994.1017
   Mamidala E., 2020, ARXIV200412055
   Mehrbod P, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2184-y
   Oguntade S, 2017, FUTURE VIROL, V12, P261, DOI 10.2217/fvl-2017-0014
   Okhale E., 2016, INT J PHARMACOGN, V3, P201
   Olotu FA, 2018, COMPUT STRUCT BIOTEC, V16, P573, DOI 10.1016/j.csbj.2018.11.005
   Olotu FA, 2019, APPL BIOCHEM BIOTECH, V187, P1061, DOI 10.1007/s12010-018-2863-7
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pitera JW, 2014, J PHYS CHEM B, V118, P6526, DOI 10.1021/jp412776d
   Rahmasari R, 2017, NAT PROD COMMUN, V12, P599
   Rezazadeh Fahimeh, 2016, J Dent (Shiraz), V17, P49
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101623
   Rodriguez-Morales AJ, 2020, TRAVEL MED INFECT DI, V33, DOI 10.1016/j.tmaid.2020.101578
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p
   Roy DC, 2013, MED PLANT RES, V3, P20, DOI DOI 10.5376/MPR.2013.03.0004
   Salmaso V, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00923
   Salomon-Ferrer R, 2013, J CHEM THEORY COMPUT, V9, P3878, DOI 10.1021/ct400314y
   Sang P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020254
   Seifert E, 2014, J CHEM INF MODEL, V54, P1552, DOI 10.1021/ci500161d
   Sharma VK, 2015, INT J INDIGENOUS MED, V48, P1871
   Sneha P., 2016, CGPD SCI DIRECT TOPI
   Spiteri G, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.9.2000178
   Stokes Trevor, 2002, Trends Plant Sci, V7, P57, DOI 10.1016/S1360-1385(02)02238-0
   Subissi L, 2014, ANTIVIR RES, V101, P122, DOI 10.1016/j.antiviral.2013.11.006
   Thring TSA, 2006, J ETHNOPHARMACOL, V103, P261, DOI 10.1016/j.jep.2005.08.013
   Ticha LA, 2015, NAT PROD COMMUN, V10, P1185
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   ul Qamar MT, 2019, SCI REP, V9, P1
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Van Wyk B., 2000, PEOPLES PLANTS GUIDE
   Van Wyk BE, 2011, S AFR J BOT, V77, P812, DOI 10.1016/j.sajb.2011.08.011
   VAN WYK B. E., 2018, MED PLANTS WORLD
   Vermaak I, 2014, J ETHNOPHARMACOL, V156, P135, DOI 10.1016/j.jep.2014.08.016
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   WANG JM, 2001, ABSTR PAP AM CHEM 1, V222
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yan R-H, 2020, BIORXIV, DOI [10.1101/2020.02.19.956946., DOI 10.1101/2020.02.19.956946]
   Yang HB, 2019, BIOINFORMATICS, V35, P1067, DOI 10.1093/bioinformatics/bty707
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yang Z, 2012, J STRUCT BIOL, V179, P269, DOI 10.1016/j.jsb.2011.09.006
   Yin W., 2020, SCIENCE
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 85
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0254-6299
EI 1727-9321
J9 S AFR J BOT
JI S. Afr. J. Bot.
PD SEP
PY 2020
VL 133
BP 273
EP 284
DI 10.1016/j.sajb.2020.07.035
PG 12
WC Plant Sciences
SC Plant Sciences
GA NQ9KS
UT WOS:000571185800015
PM 32839635
OA Green Published
DA 2021-01-01
ER

PT J
AU Wong, AW
   Fidler, L
   Marcoux, V
   Johannson, KA
   Assayag, D
   Fisher, JH
   Hambly, N
   Kolb, M
   Morisset, J
   Shapera, S
   Ryerson, CJ
AF Wong, Alyson W.
   Fidler, Lee
   Marcoux, Veronica
   Johannson, Kerri A.
   Assayag, Deborah
   Fisher, Jolene H.
   Hambly, Nathan
   Kolb, Martin
   Morisset, Julie
   Shapera, Shane
   Ryerson, Christopher J.
TI Practical Considerations for the Diagnosis and Treatment of Fibrotic
   Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic
SO CHEST
LA English
DT Article
DE coronavirus disease; diagnosis; interstitial lung disease; treatment
ID IDIOPATHIC PULMONARY-FIBROSIS; CORTICOSTEROID-THERAPY; PIRFENIDONE;
   NINTEDANIB; CAPACITY; COVID-19; EFFICACY; SAFETY; SARS
AB The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, has affected virtually all aspects of patient care. Health-care systems around the world are trying simultaneously to treat patients with COVID-19, prepare for its long-term impacts, and treat patients with other acute and chronic diseases. There are multiple ways that the COVID-19 pandemic will directly affect patients with fibrotic interstitial lung disease (ILD), particularly given their common risk factors for poor outcomes. Major issues for patients with ILD will include restricted access to key components of the diagnostic process, new uncertainties in the use of common ILD pharmacotherapies, limited ability to monitor both disease severity and the presence of medication adverse effects, and significantly curtailed research activities. The purpose of this review is to summarize how COVID-19 has impacted key components of the diagnosis and management of fibrotic ILD as well as to provide strategies to mitigate these challenges. We further review major obstacles for researchers and identify priority areas for future ILD research related to COVID-19. Our goals are to provide practical considerations to support the care of patients with ILD during the COVID-19 pandemic and to provide a road map for clinicians caring for these patients during future infectious disease outbreaks.
C1 [Wong, Alyson W.; Ryerson, Christopher J.] Univ British Columbia, Dept Med, 8B Providence Wing,1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
   [Wong, Alyson W.; Ryerson, Christopher J.] St Pauls Hosp, Ctr Heart Lung Innovat, Vancouver, BC, Canada.
   [Fidler, Lee] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Toronto, ON, Canada.
   [Marcoux, Veronica] Univ Saskatchewan, Dept Med, Saskatoon, SK, Canada.
   [Johannson, Kerri A.] Univ Calgary, Dept Med, Calgary, AB, Canada.
   [Assayag, Deborah] McGill Univ, Dept Med, Montreal, PQ, Canada.
   [Fisher, Jolene H.; Shapera, Shane] Univ Toronto, Univ Hlth Network, Dept Med, Toronto, ON, Canada.
   [Hambly, Nathan; Kolb, Martin] McMaster Univ, Firestone Inst Resp Hlth, Dept Med, Hamilton, ON, Canada.
   [Morisset, Julie] Ctr Hosp Univ Montreal, Dept Med, Montreal, PQ, Canada.
RP Ryerson, CJ (corresponding author), Univ British Columbia, Dept Med, 8B Providence Wing,1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.; Ryerson, CJ (corresponding author), Univ British Columbia, Ctr Heart Lung Innovat, 8B Providence Wing,1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.
EM chris.ryerson@hli.ubc.ca
CR Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   American Thoracic Society, 2020, PULM FUNCT LAB ADV R
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI 10.1001/jama.2020.2565
   Brown KK, 2019, RESP MED, V146, P42, DOI 10.1016/j.rmed.2018.11.012
   Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID 1
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   D'Antiga L, 2020, LIVER TRANSPLANT, V26, P832, DOI 10.1002/lt.25756
   Distler O, 2019, NEW ENGL J MED, V380, P2518, DOI 10.1056/NEJMoa1903076
   Du Plessis JP, 2018, RESPIROLOGY, V23, P392, DOI 10.1111/resp.13226
   Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114
   Fernandez-Perez ER, 2008, CHEST, V133, P1113, DOI 10.1378/chest.07-1481
   Fisher JH, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01164-2018
   Flaherty KR, 2019, NEW ENGL J MED, V381, P1718, DOI 10.1056/NEJMoa1908681
   Gattinoni L, 2020, AM J RESP CRIT CARE, V201, P1299, DOI 10.1164/rccm.202003-0817LE
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hoyer N, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1076-0
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hui DS, 2018, AM J RESP CRIT CARE, V197, P700, DOI 10.1164/rccm.201712-2371ED
   Hui DSC, 2019, INFECT DIS CLIN N AM, V33, P869, DOI 10.1016/j.idc.2019.07.001
   Hutchinson JP, 2016, EUR RESPIR J, V48, P1453, DOI 10.1183/13993003.00378-2016
   Kaltsas A, 2012, CURR OPIN INFECT DIS, V25, P423, DOI 10.1097/QCO.0b013e328355660b
   Khoury M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00858-2020
   King TE, 2014, NEW ENGL J MED, V370, P2083, DOI 10.1056/NEJMoa1402582
   Kreuter M, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01760-2019
   Lamas DJ, 2011, AM J RESP CRIT CARE, V184, P842, DOI 10.1164/rccm.201104-0668OC
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Leuschner G, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00176
   Li XP, 2008, AM J PHYSIOL-LUNG C, V295, pL178, DOI 10.1152/ajplung.00009.2008
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Long CQ, 2020, EUR J RADIOL, V126, DOI 10.1016/j.ejrad.2020.108961
   Maher TM, 2020, LANCET RESP MED, V8, P147, DOI 10.1016/S2213-2600(19)30341-8
   Maher TM, 2019, ANN AM THORAC SOC, V16, P927, DOI 10.1513/AnnalsATS.201810-720RL
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Nathan SD, 2019, RESP MED, V153, P44, DOI 10.1016/j.rmed.2019.04.016
   Noble PW, 2011, LANCET, V377, P1760, DOI 10.1016/S0140-6736(11)60405-4
   Pan Y, 2020, LANCET INFECT DIS, V20, P411, DOI 10.1016/S1473-3099(20)30113-4
   Patel AB, 2020, JAMA-J AM MED ASSOC, V323, P1769, DOI 10.1001/jama.2020.4812
   Raghu G, 2018, AM J RESP CRIT CARE, V198, pE44, DOI 10.1164/rccm.201807-1255ST
   Raghu G, 2017, AM J RESP CRIT CARE, V195, P78, DOI 10.1164/rccm.201602-0402OC
   Ren X, 2020, SSRN ELECT J, DOI [10.2139/ssrn.3546086, DOI 10.2139/SSRN.3546086]
   Richeldi L, 2014, NEW ENGL J MED, V370, P2071, DOI 10.1056/NEJMoa1402584
   Rubin GD, 2020, CHEST, V158, P106, DOI 10.1016/j.chest.2020.04.003
   Ryerson CJ, 2017, AM J RESP CRIT CARE, V196, P1249, DOI 10.1164/rccm.201702-0400PP
   Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
   Sprunger DB, 2012, EUR RESPIR J, V39, P125, DOI 10.1183/09031936.00041411
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST
   Wang HJ, 2003, NEW ENGL J MED, V349, P507, DOI 10.1056/NEJM200307313490519
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Wuyts WA, 2016, LUNG, V194, P739, DOI 10.1007/s00408-016-9912-1
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zumla A, 2020, LANCET, V395, pE35, DOI 10.1016/S0140-6736(20)30305-6
NR 56
TC 5
Z9 5
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0012-3692
EI 1931-3543
J9 CHEST
JI Chest
PD SEP
PY 2020
VL 158
IS 3
BP 1069
EP 1078
DI 10.1016/j.chest.2020.04.019
PG 10
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA NQ3ZD
UT WOS:000570802000019
PM 32333929
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Moores, LK
   Tritschler, T
   Brosnahan, S
   Carrier, M
   Collen, JF
   Doerschug, K
   Holley, AB
   Jimenez, D
   Le Gal, G
   Rali, P
   Wells, P
AF Moores, Lisa K.
   Tritschler, Tobias
   Brosnahan, Shari
   Carrier, Marc
   Collen, Jacob F.
   Doerschug, Kevin
   Holley, Aaron B.
   Jimenez, David
   Le Gal, Gregoire
   Rali, Parth
   Wells, Philip
TI Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus
   Disease 2019 CHEST Guideline and Expert Panel Report
SO CHEST
LA English
DT Article
DE COVID-19; DIC; DVT; hypercoagulability; pulmonary embolism; VTE
ID HOSPITALIZED MEDICAL PATIENTS; MOLECULAR-WEIGHT HEPARIN; VENOUS
   THROMBOEMBOLISM PROPHYLAXIS; CRITICALLY-ILL PATIENTS; RISK-ASSESSMENT
   MODEL; ACUTELY-ILL; ANTITHROMBOTIC THERAPY; ORAL RIVAROXABAN;
   DOSE-ESCALATION; MANAGEMENT
AB BACKGROUND: Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated by a significant coagulopathy, that likely manifests in the form of both microthrombosis and VTE. This recognition has led to the urgent need for practical guidance regarding prevention, diagnosis, and treatment of VTE.
   METHODS: A group of approved panelists developed key clinical questions by using the PICO (Population, Intervention, Comparator, Outcome) format that addressed urgent clinical questions regarding the prevention, diagnosis, and treatment of VTE in patients with COVID-19. MEDLINE (via PubMed or Ovid), Embase, and Cochrane Controlled Register of Trials were systematically searched for relevant literature, and references were screened for inclusion. Validated evaluation tools were used to grade the level of evidence to support each recommendation. When evidence did not exist, guidance was developed based on consensus using the modified Delphi process.
   RESULTS: The systematic review and critical analysis of the literature based on 13 Population, Intervention, Comparator, Outcome questions resulted in 22 statements. Very little evidence exists in the COVID-19 population. The panel thus used expert consensus and existing evidence-based guidelines to craft the guidance statements.
   CONCLUSIONS: The evidence on the optimal strategies to prevent, diagnose, and treat VTE in patients with COVID-19 is sparse but rapidly evolving.
C1 [Moores, Lisa K.; Collen, Jacob F.; Holley, Aaron B.] Uniformed Serv Univ Hlth Sci, Dept Med, F Edward Hebert Sch Med, Bethesda, MD 20814 USA.
   [Tritschler, Tobias; Carrier, Marc; Le Gal, Gregoire; Wells, Philip] Univ Ottawa, Ottawa Hosp, Dept Med, Res Inst, Ottawa, ON, Canada.
   [Tritschler, Tobias] Univ Bern, Bern Univ Hosp, Dept Gen Internal Med, Inselspital, Bern, Switzerland.
   [Brosnahan, Shari] New York Univ Langone Hlth Syst, Div Pulm Crit Care & Sleep Med, New York, NY USA.
   [Collen, Jacob F.; Holley, Aaron B.] Walter Reed Natl Mil Med Ctr, Pulm Crit Care & Sleep Med Serv, Bethesda, MD USA.
   [Doerschug, Kevin] Univ Iowa, Pulm Crit Care & Occupat Med, Iowa City, IA USA.
   [Jimenez, David] Ramon Y Cajal Hosp IRYCIS, Resp Med, Madrid, Spain.
   [Jimenez, David] CIBER Enfermedades Resp CIBERES, Madrid, Spain.
   [Rali, Parth] Temple Univ, Dept Thorac Med & Surg, Lewis Katz Sch Med, Philadelphia, PA 19122 USA.
RP Moores, LK (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, 4301 Jones Bridge Rd,A 1005a, Bethesda, MD 20814 USA.
EM lisa.moores@usuhes.edu
RI Brosnahan, Shari/ABG-7864-2020
OI Brosnahan, Shari/0000-0002-2092-3633; Tritschler,
   Tobias/0000-0002-8775-0511
CR Agnelli G, 2013, NEW ENGL J MED, V369, P799, DOI 10.1056/NEJMoa1302507
   Alhazzani W, 2013, CRIT CARE MED, V41, P2088, DOI 10.1097/CCM.0b013e31828cf104
   Amin AN, 2012, J HOSP MED, V7, P231, DOI 10.1002/jhm.1002
   [Anonymous], 1994, BMJ, V308, P235
   Arabi YM, 2019, NEW ENGL J MED, V380, P1305, DOI 10.1056/NEJMoa1816150
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Bajaj NS, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002797
   Barbar S, 2010, J THROMB HAEMOST, V8, P2450, DOI 10.1111/j.1538-7836.2010.04044.x
   Barnes GD, 2020, J THROMB THROMBOLYS, V50, P72, DOI 10.1007/s11239-020-02138-z
   Bauersachs R, 2010, NEW ENGL J MED, V363, P2499, DOI 10.1056/NEJMoa1007903
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Buller HR, 2013, NEW ENGL J MED, V369, P1406, DOI 10.1056/NEJMoa1306638
   Buller HR, 2012, NEW ENGL J MED, V366, P1287, DOI 10.1056/NEJMoa1113572
   Carrier M, 2009, J THROMB HAEMOST, V7, P760, DOI 10.1111/j.1538-7836.2009.03326.x
   Casini Alessandro, 2020, Swiss Med Wkly, V150, pw20247, DOI 10.4414/smw.2020.20247
   Cobben MRR, 2019, RES PRACT THROMB HAE, V3, P217, DOI 10.1002/rth2.12181
   Cohen AT, 2014, J THROMB HAEMOST, V12, P479, DOI 10.1111/jth.12515
   Cohen AT, 2006, BMJ-BRIT MED J, V332, P325, DOI 10.1136/bmj.38733.466748.7C
   Cook D, 2011, NEW ENGL J MED, V364, P1305, DOI 10.1056/NEJMoa1014475
   Cui SP, 2020, J THROMB HAEMOST, V18, P1421, DOI 10.1111/jth.14830
   Darzi AJ, 2020, BLOOD, V135, P1788, DOI 10.1182/blood.2019003603
   Djulbegovic B, 2019, JAMA-J AM MED ASSOC, V322, P725, DOI 10.1001/jama.2019.9751
   Escher R, 2020, THROMB RES, V190, P62, DOI 10.1016/j.thromres.2020.04.014
   Fraisse F, 2000, AM J RESP CRIT CARE, V161, P1109, DOI 10.1164/ajrccm.161.4.9807025
   Gibson C Michael, 2017, TH Open, V1, pe56, DOI 10.1055/s-0037-1603929
   Greene MT, 2016, AM J MED, V129, DOI 10.1016/j.amjmed.2016.03.031
   Helms J, 2020, INTENS CARE MED, V46, P1089, DOI 10.1007/s00134-020-06062-x
   Hirsh J, 2004, CHEST, V126, p188S, DOI 10.1378/chest.126.3_suppl.188S
   Hunt B, 2020, PRACTICAL GUIDANCE P
   Iba T, 2019, J THROMB HAEMOST, V17, P1989, DOI 10.1111/jth.14578
   Ihaddadene R, 2014, THROMB RES, V134, P93, DOI 10.1016/j.thromres.2014.04.028
   Kahn SR, 2012, CHEST, V141, pE195S, DOI 10.1378/chest.11-2296
   Kaplan D, 2015, CHEST, V148, P1224, DOI 10.1378/chest.15-0287
   Kearon C, 2016, CHEST, V149, P315, DOI 10.1016/j.chest.2015.11.026
   Klok FA, 2020, THROMB RES, V191, P148, DOI 10.1016/j.thromres.2020.04.041
   Klok FA, 2020, THROMB RES, V191, P145, DOI 10.1016/j.thromres.2020.04.013
   Konstantinides SV, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.01647-2019
   Leizorovicz A, 2004, CIRCULATION, V110, P874, DOI 10.1161/01.CIR.0000138928.83266.24
   Lillicrap D, 2020, J THROMB HAEMOST, V18, P786, DOI 10.1111/jth.14781
   Llitjos JF, 2020, J THROMB HAEMOST, V18, P1743, DOI 10.1111/jth.14869
   Lodigiani C, 2020, THROMB RES, V191, P9, DOI 10.1016/j.thromres.2020.04.024
   Long B, AM J EMERG MED, DOI [10.1016/j.ajem.2020.04., DOI 10.1016/J.AJEM.2020.04.]
   Luk C, 2001, AM J MED, V111, P270, DOI 10.1016/S0002-9343(01)00840-3
   Mahan CE, 2014, THROMB HAEMOSTASIS, V112, P692, DOI 10.1160/TH14-03-0239
   Marietta M, 2020, BLOOD TRANSFUS-ITALY, V18, P167, DOI 10.2450/2020.0083-20
   Marone EM, 2020, J VASC SURG-VENOUS L, V8, P694, DOI 10.1016/j.jvsv.2020.04.004
   Middeldorp S, 2020, J THROMB HAEMOST, V18, P1995, DOI 10.1111/jth.14888
   Moumneh T, 2020, J THROMB HAEMOST, V18, P1398, DOI 10.1111/jth.14796
   Nendaz M, 2014, THROMB HAEMOSTASIS, V111, P531, DOI 10.1160/TH13-05-0427
   Neumann I, 2020, BLOOD ADV, V4, P1512, DOI 10.1182/bloodadvances.2019000840
   Oudkerk M, RADIOLOGY, DOI [10.1148/radiol.2020201629, DOI 10.1148/RADIOL.2020201629.]
   Paranjpe I, 2020, J AM COLL CARDIOL, V76, P122, DOI 10.1016/j.jacc.2020.05.001
   Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430
   Porres-Aguilar M, 2014, NEW ENGL J MED, V371, P580, DOI 10.1056/NEJMc1406283
   Ranucci M, 2020, J THROMB HAEMOST, V18, P1747, DOI 10.1111/jth.14854
   Rosenberg D, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001152
   Samama MM, 1999, NEW ENGL J MED, V341, P793, DOI 10.1056/NEJM199909093411103
   Schulman S, 2015, J THROMB HAEMOST, V13, P1010, DOI 10.1111/jth.12955
   Schunemann HJ, 2018, BLOOD ADV, V2, P3198, DOI 10.1182/bloodadvances.2018022954
   Shorr AF, 2009, THROMB HAEMOSTASIS, V101, P139, DOI 10.1160/TH08-07-0468
   Smythe MA, 2016, J THROMB THROMBOLYS, V41, P165, DOI 10.1007/s11239-015-1315-2
   Spiezia L, 2020, THROMB HAEMOSTASIS, V120, P998, DOI 10.1055/s-0040-1710018
   Spyropoulos Alex C, 2020, TH Open, V4, pe59, DOI 10.1055/s-0040-1705137
   Spyropoulos AC, 2018, NEW ENGL J MED, V379, P1118, DOI 10.1056/NEJMoa1805090
   Spyropoulos AC, 2011, CHEST, V140, P706, DOI 10.1378/chest.10-1944
   Testa S, 2020, J THROMB HAEMOST, V18, P1320, DOI 10.1111/jth.14871
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Thomas W, 2020, THROMB RES, V191, P76, DOI 10.1016/j.thromres.2020.04.028
   Tian SF, 2020, MODERN PATHOL, V33, P1007, DOI 10.1038/s41379-020-0536-x
   Vardi M, 2013, J THROMB HAEMOST, V11, P467, DOI 10.1111/jth.12108
   Vivas D, REV ESP CARDIOL, DOI [10.1016/j.recesp.2020.04.006., DOI 10.1016/J.RECESP.2020.04.006.]
   Wang T, 2020, LANCET HAEMATOL, V7, pE362, DOI 10.1016/S2352-3026(20)30109-5
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Xu JF, RISK ASSESSMENT VENO, DOI [10.21203/rs.3.rs-18340/v1., DOI 10.21203/RS.3.RS-18340/V1.]
   Zagury-Orly I, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2009405
   Zhai ZG, 2020, THROMB HAEMOSTASIS, V120, P937, DOI 10.1055/s-0040-1710019
NR 76
TC 48
Z9 48
U1 2
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0012-3692
EI 1931-3543
J9 CHEST
JI Chest
PD SEP
PY 2020
VL 158
IS 3
BP 1143
EP 1163
DI 10.1016/j.chest.2020.05.559
PG 21
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA NQ3ZD
UT WOS:000570802000027
PM 32502594
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Knell, G
   Robertson, MC
   Dooley, EE
   Burford, K
   Mendez, KS
AF Knell, Gregory
   Robertson, Michael C.
   Dooley, Erin E.
   Burford, Katie
   Mendez, Karla S.
TI Health Behavior Changes During COVID-19 Pandemic and Subsequent
   "Stay-at-Home" Orders
SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
LA English
DT Article
DE COVID-19; physical activity; sleep; health behaviors; alcohol use;
   marijuana use; tobacco use
ID UNITED-STATES; RISK-FACTORS; SLEEP; QUALITY; STRESS; ADULTS
AB The COVID-19 pandemic, and resultant "Stay-at-Home" orders, may have impacted adults' positive health behaviors (sleep, physical activity) and negative health behaviors (alcohol consumption, drug use, and tobacco use). The purpose of this study was to investigate how these health behaviors changed (increased/improved or decreased/worsened) at the early stages of the pandemic, what participant characteristics were associated with health behavior changes, and why these behavioral changes may have occurred. A convenience sample of 1809 adults residing in the United States completed a 15-min self-report questionnaire in April and May 2020. Multinomial logistic regressions and descriptive statistics were used to evaluate how, for whom, and why these health behaviors changed. Participants were primarily female (67.4%), aged 35-49 years (39.8%), college graduates (83.3%), non-tobacco users (74.7%), and had previously used marijuana (48.6%). Overall, participants primarily reported a decrease in physical activity, while sleep and all of the negative health behaviors remained the same. Changes in negative health behaviors were related (p< 0.05) to sex, age, parental status, educational status, job status, BMI, and depression scores. Changes in positive health behaviors were related (p< 0.05) to sex, parental status, job status, and depression scores. Having more time available during the pandemic was the most commonly cited reason for changing health behaviors (negative and positive). Public health efforts should address the potential for long-term health consequences due to behavior change during COVID-19.
C1 [Knell, Gregory; Mendez, Karla S.] Univ Texas Hlth Sci Ctr Houston UTHlth, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA.
   [Knell, Gregory] Univ Texas Hlth Sci Ctr Houston UTHlth, Ctr Pediat Populat Hlth, Dallas, TX 75390 USA.
   [Knell, Gregory] Childrens Hlth Andrews Inst Orthopaed & Sports Me, Plano, TX 75024 USA.
   [Robertson, Michael C.; Dooley, Erin E.; Burford, Katie] Univ Texas Hlth Sci Ctr Houston UTHlth, Dept Hlth Promot & Behav Sci, Houston, TX 77030 USA.
   [Robertson, Michael C.] Univ Texas MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA.
   [Dooley, Erin E.; Burford, Katie] Univ Texas Hlth Sci Ctr Houston UTHlth, Michael & Susan Ctr Hlth Living, Austin, TX 78701 USA.
RP Knell, G (corresponding author), Univ Texas Hlth Sci Ctr Houston UTHlth, Dept Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA.; Knell, G (corresponding author), Univ Texas Hlth Sci Ctr Houston UTHlth, Ctr Pediat Populat Hlth, Dallas, TX 75390 USA.; Knell, G (corresponding author), Childrens Hlth Andrews Inst Orthopaed & Sports Me, Plano, TX 75024 USA.
EM gregory.knell@uth.tmc.edu; michael.c.robertson@uth.tmc.edu;
   erin.dooley@uth.tmc.edu; kathryn.burford@uth.tmc.edu;
   karla.mendez@uth.tmc.edu
OI Dooley, Erin/0000-0001-9881-5053; Burford, Katie/0000-0001-5500-9609;
   Knell, Gregory/0000-0002-5067-544X
FU National Cancer Institute of the National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [F31 CA236433]
FX Michael C. Robertson was supported by the National Cancer Institute of
   the National Institutes of Health, grant number F31 CA236433. The
   content of this paper is solely the responsibility of the authors and
   does not necessarily represent the o fficial views of the National
   Institutes of Health.
CR [Anonymous], 2020, BAT WORK PAR AR KEY
   [Anonymous], 2020, US CENS BUR HOUS PUL
   [Anonymous], 2020, BBC NEWS
   BELISLE M, 1987, HEALTH PSYCHOL, V6, P159, DOI 10.1037/0278-6133.6.2.159
   Breiman L, 2001, RANDOM FORESTS MACHI
   BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4
   Cappuccio FP, 2010, DIABETES CARE, V33, P414, DOI 10.2337/dc09-1124
   Carpenter JS, 1998, J PSYCHOSOM RES, V45, P5, DOI 10.1016/S0022-3999(97)00298-5
   Ciupijus Z, 2020, POPUL SPACE PLACE, V26, DOI 10.1002/psp.2300
   Clay JM, 2020, LANCET PUBLIC HEALTH, V5, pE259, DOI 10.1016/S2468-2667(20)30088-8
   Collins C, 2020, GENDER WORK ORGAN, DOI 10.1111/gwao.12506
   Cox RC, 2016, J ANXIETY DISORD, V37, P104, DOI 10.1016/j.janxdis.2015.12.001
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Du Y, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.7597
   Dunton G., EARLY EFFECTS COVID
   Ezzati M, 2013, NEW ENGL J MED, V369, P954, DOI 10.1056/NEJMra1203528
   Gostin LO, 2020, JAMA-J AM MED ASSOC, V323, P2137, DOI 10.1001/jama.2020.5460
   Guan HY, 2020, LANCET CHILD ADOLESC, V4, P416, DOI 10.1016/S2352-4642(20)30131-0
   Hall G., 2020, PROG CARDIOVASC DIS, DOI [10.1016/j.pcad.2020.04.00532277997, DOI 10.1016/J.PCAD.2020.04.00532277997]
   Han Benjamin H, 2018, Prev Med Rep, V12, P214, DOI 10.1016/j.pmedr.2018.10.007
   Harris PA, 2019, J BIOMED INFORM, V95, DOI 10.1016/j.jbi.2019.103208
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Huang YE, 2020, PSYCHIAT RES, V288, DOI 10.1016/j.psychres.2020.112954
   Gimenez-Nadal JI, 2018, J TRANSP GEOGR, V66, P19, DOI 10.1016/j.jtrangeo.2017.10.011
   Juliano LM, 2006, J ABNORM PSYCHOL, V115, P166, DOI 10.1037/0021-843X.115.1.166
   Kirshenbaum AP, 2009, J SUBST ABUSE TREAT, V36, P8, DOI 10.1016/j.jsat.2008.04.001
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Lantz PM, 2010, SOC SCI MED, V70, P1558, DOI 10.1016/j.socscimed.2010.02.003
   Lee PH, 2011, INT J BEHAV NUTR PHY, V8, DOI 10.1186/1479-5868-8-115
   LePera N., 2011, NEW SCH PSYCHOL B, V8, P15
   Liu Y, 2016, MMWR-MORBID MORTAL W, V65, P137, DOI 10.15585/mmwr.mm6506a1
   Magee L, 2012, SLEEP MED REV, V16, P231, DOI 10.1016/j.smrv.2011.05.005
   Marsden J, 2020, ADDICTION, V115, P1007, DOI 10.1111/add.15080
   McCance-Katz EF, NATL SURVEY DRUG USE
   National Center for Immunization and Respiratory Diseases (NCIRD), 2020, DIV VIR DIS COP STRE
   Office of Disease Prevention and Health Promotion US Department of Health and Human Services, 2010, HLTH PEOPL 2020
   Rajkumar RP, 2020, ASIAN J PSYCHIATR, V52, DOI 10.1016/j.ajp.2020.102066
   Sharma M, 2014, J EVID-BASED INTEGR, V19, P59, DOI 10.1177/2156587213503344
   Sinha R, 2008, ANN NY ACAD SCI, V1141, P105, DOI 10.1196/annals.1441.030
   Smialek J., 2020, NY TIMES
   Smith Joshua P, 2008, Psychiatr Times, V25, P19
   Stanton R, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17114065
   Stekhoven DJ, 2012, BIOINFORMATICS, V28, P112, DOI 10.1093/bioinformatics/btr597
   Thakur V, 2020, BRAIN BEHAV IMMUN, V88, P952, DOI 10.1016/j.bbi.2020.04.062
   The National Bureau of Economic Research, 2020, IMP COVID 19 GEND EQ
   U.S. Bureau of Labor Statistics, 2020, CIV UN RAT
   U.S. Bureau of Labor Statistics, 2020, AM TIM US SURV 2019
   U.S. Department of Health and Human Services, 2018, PHYS ACT GUID ADV CO
   U.S. Department of Health and Human Services, 2020, SMOK CESS REP SURG G
   United States Department of Health and Human Services (HHS) Office of the Surgeon General, 2016, FAC ADD AM SURG GEN
   US Department of Health and Human Services, 2017, DIET GUID AM 2015 20
   Volkow ND, 2020, ANN INTERN MED, V173, P61, DOI 10.7326/M20-1212
   Waljee AK, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002847
   Wallace A., 2020, WASHINGTON POST
   Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729
   Wang TW, 2018, MMWR-MORBID MORTAL W, V67, P1225, DOI 10.15585/mmwr.mm6744a2
   Watson NF, 2015, SLEEP, V38, P843, DOI 10.5665/sleep.4716
NR 57
TC 2
Z9 2
U1 5
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1660-4601
J9 INT J ENV RES PUB HE
JI Int. J. Environ. Res. Public Health
PD SEP
PY 2020
VL 17
IS 17
AR 6268
DI 10.3390/ijerph17176268
PG 16
WC Environmental Sciences; Public, Environmental & Occupational Health
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
   Health
GA NR0CN
UT WOS:000571232400001
PM 32872179
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Gotzinger, F
   Santiago-Garcia, B
   Noguera-Julian, A
   Lanaspa, M
   Lancella, L
   Carducci, FIC
   Gabrovska, N
   Velizarova, S
   Prunk, P
   Osterman, V
   Krivec, U
   Lo Vecchio, A
   Shingadia, D
   Soriano-Arandes, A
   Melendo, S
   Lanari, M
   Pierantoni, L
   Wagner, N
   L'Huillier, AG
   Heininger, U
   Ritz, N
   Bandi, S
   Krajcar, N
   Roglic, S
   Santos, M
   Christiaens, C
   Creuven, M
   Buonsenso, D
   Welch, SB
   Bogyi, M
   Brinkmann, F
   Tebruegge, M
AF Goetzinger, Florian
   Santiago-Garcia, Begona
   Noguera-Julian, Antoni
   Lanaspa, Miguel
   Lancella, Laura
   Carducci, Francesca I. Calo
   Gabrovska, Natalia
   Velizarova, Svetlana
   Prunk, Petra
   Osterman, Veronika
   Krivec, Uros
   Lo Vecchio, Andrea
   Shingadia, Delane
   Soriano-Arandes, Antoni
   Melendo, Susana
   Lanari, Marcello
   Pierantoni, Luca
   Wagner, Noemie
   L'Huillier, Arnaud G.
   Heininger, Ulrich
   Ritz, Nicole
   Bandi, Srini
   Krajcar, Nina
   Roglic, Srdan
   Santos, Mar
   Christiaens, Christelle
   Creuven, Marine
   Buonsenso, Danilo
   Welch, Steven B.
   Bogyi, Matthias
   Brinkmann, Folke
   Tebruegge, Marc
CA COVID-19 Study Grp
TI COVID-19 in children and adolescents in Europe: a multinational,
   multicentre cohort study
SO LANCET CHILD & ADOLESCENT HEALTH
LA English
DT Article
ID SHORTAGE
AB Background To date, few data on paediatric COVID-19 have been published, and most reports originate from China. This study aimed to capture key data on children and adolescents with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection across Europe to inform physicians and health-care service planning during the ongoing pandemic.
   Methods This multicentre cohort study involved 82 participating health-care institutions across 25 European countries, using a well established research network-the Paediatric Tuberculosis Network European Trials Group (ptbnet)-that mainly comprises paediatric infectious diseases specialists and paediatric pulmonologists. We included all individuals aged 18 years or younger with confirmed SARS-CoV-2 infection, detected at any anatomical site by RT-PCR, between April 1 and April 24, 2020, during the initial peak of the European COVID-19 pandemic. We explored factors associated with need for intensive care unit (ICU) admission and initiation of drug treatment for COVID-19 using univariable analysis, and applied multivariable logistic regression with backwards stepwise analysis to further explore those factors significantly associated with ICU admission.
   Findings 582 individuals with PCR-confirmed SARS-CoV-2 infection were included, with a median age of 5.0 years (IQR 0.5-12.0) and a sex ratio of 1.15 males per female. 145 (25%) had pre-existing medical conditions. 363 (62%) individuals were admitted to hospital. 48 (8%) individuals required ICU admission, 25 (4%) mechanical ventilation (median duration 7 days, IQR 2-11, range 1-34), 19 (3%) inotropic support, and one (<1%) extracorporeal membrane oxygenation. Significant risk factors for requiring ICU admission in multivariable analyses were being younger than 1 month (odds ratio 5.06, 95% CI 1.72-14.87; p=0.0035), male sex (2.12, 1.06-4.21; p=0.033), pre-existing medical conditions (3.27, 1.67-6.42; p=0.0015), and presence of lower respiratory tract infection signs or symptoms at presentation (10.46, 5.16-21.23; p<0.0001). The most frequently used drug with antiviral activity was hydroxychloroquine (40 [7%] patients), followed by remdesivir (17 [3%] patients), lopinavir-ritonavir (six [1%] patients), and oseltamivir (three [1%] patients). Immunomodulatory medication used included corticosteroids (22 [4%] patients), intravenous immunoglobulin (seven [1%] patients), tocilizumab (four [1%] patients), anakinra (three [1%] patients), and siltuximab (one [<1%] patient). Four children died (case-fatality rate 0.69%, 95% CI 0.20-1.82); at study end, the remaining 578 were alive and only 25 (4%) were still symptomatic or requiring respiratory support.
   Interpretation COVID-19 is generally a mild disease in children, including infants. However, a small proportion develop severe disease requiring ICU admission and prolonged ventilation, although fatal outcome is overall rare. The data also reflect the current uncertainties regarding specific treatment options, highlighting that additional data on antiviral and immunomodulatory drugs are urgently needed. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Goetzinger, Florian; Bogyi, Matthias] Wilhelminenspital Stadt Wien, Dept Paediat & Adolescent Med, Natl Reference Ctr Childhood TB, Vienna, Austria.
   [Santiago-Garcia, Begona; Santos, Mar] Univ Hosp Gregorio Maranon, Dept Paediat Infect Dis, Madrid, Spain.
   [Santiago-Garcia, Begona; Santos, Mar] Gregorio Maranon Res Inst, Madrid, Spain.
   [Noguera-Julian, Antoni; Lanaspa, Miguel] Hosp St Joan Deu, Unitat Infecc, Malalties Infeccioses & Resposta Inflamatoria Sis, Serv Pediat,Inst Recerca Pediat, Barcelona, Spain.
   [Noguera-Julian, Antoni] Univ Barcelona, Dept Pediat, Barcelona, Spain.
   [Noguera-Julian, Antoni] Ctr Invest Biomed Red Epidemiol & Salud Publ, Madrid, Spain.
   [Santiago-Garcia, Begona; Noguera-Julian, Antoni; Santos, Mar] Red Invest Translac Infectol Pediat, Madrid, Spain.
   [Lancella, Laura; Carducci, Francesca I. Calo] Bambino Gesu Pediat Hosp, Acad Dept Paediat, Rome, Italy.
   [Gabrovska, Natalia; Velizarova, Svetlana] Med Univ Sofia, Dept Pulm Dis, Childrens Clin, MHATLD St Sofia, Sofia, Bulgaria.
   [Prunk, Petra; Osterman, Veronika] Univ Med Ctr Ljubljana, Dept Infect Dis, Ljubljana, Slovenia.
   [Krivec, Uros] Univ Med Ctr Ljubljana, Dept Paediat Pulmonol, Ljubljana, Slovenia.
   [Lo Vecchio, Andrea] Univ Naples Federico II, Dept Translat Med Sci, Sect Paediat, Naples, Italy.
   [Shingadia, Delane] Great Ormond St Hosp Sick Children, Dept Paediat Infect Dis, London, England.
   [Shingadia, Delane; Tebruegge, Marc] UCL, Dept Infect Immun & Inflammat, UCL Great Ormond St Inst Child Hlth, London WC1N 1EH, England.
   [Soriano-Arandes, Antoni; Melendo, Susana] Hosp Univ Vall dHebron, Vall dHebron Res Inst, Paediat Infect Dis & Immunodeficiencies Unit, Barcelona, Spain.
   [Lanari, Marcello; Pierantoni, Luca] S Orsola Univ Hosp, Med & Surg Sci Dept, Bologna, Italy.
   [Wagner, Noemie; L'Huillier, Arnaud G.] Geneva Univ Hosp, Paediat Infect Dis Unit, Geneva, Switzerland.
   [Wagner, Noemie; L'Huillier, Arnaud G.] Fac Med, Geneva, Switzerland.
   [Heininger, Ulrich; Ritz, Nicole] Univ Basel, Dept Paediat Infect Dis & Vaccinol, Childrens Hosp, Basel, Switzerland.
   [Ritz, Nicole; Tebruegge, Marc] Univ Melbourne, Royal Childrens Hosp Melbourne, Dept Paediat, Melbourne, Vic, Australia.
   [Bandi, Srini] Leicester Childrens Hosp, Dept Paediat, Leicester, Leics, England.
   [Krajcar, Nina; Roglic, Srdan] Univ Hosp Infect Dis, Dept Paediat Infect Dis, Zagreb, Croatia.
   [Christiaens, Christelle; Creuven, Marine] CHC Montlegia, Dept Paediat Infect Dis, Liege, Belgium.
   [Buonsenso, Danilo] Fdn Policlin Univ A Gemelli IRCCS, Dept Woman & Child Hlth & Publ Hlth, Rome, Italy.
   [Welch, Steven B.] Univ Hosp Birmingham, Birmingham Chest Clin, Birmingham, W Midlands, England.
   [Welch, Steven B.] Univ Hosp Birmingham, Heartlands Hosp, Birmingham, W Midlands, England.
   [Brinkmann, Folke] Ruhr Univ Bochum, Dept Paediat Pulmonol, Bochum, Germany.
   [Tebruegge, Marc] Guys & St Thomas NHS Fdn Trust, Dept Paediat Infect Dis & Immunol, Evelina London Childrens Hosp, London, England.
RP Tebruegge, M (corresponding author), UCL, Dept Infect Immun & Inflammat, UCL Great Ormond St Inst Child Hlth, London WC1N 1EH, England.
EM m.tebruegge@ucl.ac.uk
RI Zimmermann, Petra/I-4670-2019; Arandes, Antonio Soriano/Q-3348-2016;
   L'Huillier, Arnaud/AAI-1872-2019
OI Zimmermann, Petra/0000-0002-2388-4318; Arandes, Antonio
   Soriano/0000-0001-9613-7228; L'Huillier, Arnaud/0000-0001-9230-7285;
   Berger, Angelika/0000-0001-8775-2405; Santos-Sebastian,
   Mar/0000-0003-1986-9016; Whittaker, Elizabeth/0000-0002-7944-8793; Lo
   Vecchio, Andrea/0000-0003-4181-6842; Perez-Butragueno,
   Mario/0000-0002-8850-2878
FU Deutsche Gesellschaft fur Internationale Zusammenarbeit; Spanish
   Ministry of HealthInstituto de Salud Carlos IIIInstituto de Salud Carlos
   IIISpanish Government; European Union (FEDER)European Union (EU)
   [JR16/00036]; "Subvencions per a la Intensificacio de Facultatius
   Especialistes"Departament de Salut de la Generalitat de Catalunya,
   Programa PERIS 2016-2020 [SLT008/18/00193]
FX We express our gratitude to all colleagues and research personnel
   involved in the data collection for this study, as well as the members
   of the human research ethics committees and institutional review boards
   that have kindly fast-tracked this study. We are also grateful for the
   kind support of the Clinical Microbiology & Infectious Diseases
   Department and the COVID-19 Group at Hospital General Universitario
   Gregorio Maranon, Madrid, Spain. This project did not receive specific
   funding. ptbnet is supported by the Deutsche Gesellschaft fur
   Internationale Zusammenarbeit. BS-G is funded by the Spanish Ministry of
   HealthInstituto de Salud Carlos III and co-funded by the European Union
   (FEDER; Contrato Juan Rodes, Grant JR16/00036). AN-J was supported by
   "Subvencions per a la Intensificacio de Facultatius
   Especialistes"Departament de Salut de la Generalitat de Catalunya,
   Programa PERIS 2016-2020 (SLT008/18/00193).
CR Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Castagnoli R, 2020, JAMA PEDIAT, DOI [10.1001/jamapediatrics.2020.1467, DOI 10.1001/JAMAPEDIATRICS.2020.1467.]
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chiotos Kathleen, 2020, J Pediatric Infect Dis Soc, DOI 10.1093/jpids/piaa045
   COVID-19 National Incident Room Surveillance Team, 2020, COMMUN DIS INTELL, P44
   Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702
   Epidemiology Working Group for NCIP Epidemic Response Chinese Center for Disease Control and Prevention, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P145, DOI 10.3760/cma.j.issn.0254-6450.2020.02.003
   European Centre for Disease Prevention and Control, 2020, RAP RISK ASS PAED IN
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Gudbjartsson DF, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2006100, DOI 10.1056/NEJMOA2006100.]
   Kollmann TR, 2017, IMMUNITY, V46, P350, DOI 10.1016/j.immuni.2017.03.009
   Kollmann TR, 2009, J IMMUNOL, V183, P7150, DOI 10.4049/jimmunol.0901481
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liu WY, 2020, NEW ENGL J MED, V382, P1370, DOI 10.1056/NEJMc2003717
   Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073
   Malaguarnera L, 2001, ARCH GERONTOL GERIAT, V32, P1, DOI 10.1016/S0167-4943(00)00086-8
   McKiernan C, 2010, J PEDIATR-US, V156, P634, DOI 10.1016/j.jpeds.2009.10.039
   Noguera-Julian Antoni, 2019, Clin Infect Dis, DOI 10.1093/cid/ciz1138
   Parri N, 2020, NEW ENGL J MED, V383, P187, DOI 10.1056/NEJMc2007617
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Roy RB, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.02004-2019
   Tagarro A, 2020, JAMA PEDIAT, DOI [10.1001/jamapediatrics.2020.1346, DOI 10.1001/01445]
   Tebruegge M, 2016, INT J TUBERC LUNG D, V20, P1293, DOI 10.5588/ijtld.15.0975
   Tebruegge M, 2014, LANCET, V384, P2026, DOI 10.1016/S0140-6736(14)62335-7
   Tebruegge M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099129
   The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, EP CHAR OUTBR 2019 N
   Villanueva P, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.00346-2018
   von der Beck D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180920
   World Health Organization, NOV COR 2019 NCOV SI
   World Health Organization, NOVEL CORONAVIRUS 20
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Zhu L, 2020, PEDIATR PULM, V55, P1430, DOI 10.1002/ppul.24767
   Zimmermann P, JAMA PEDIAT
NR 35
TC 64
Z9 66
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2352-4642
J9 LANCET CHILD ADOLESC
JI Lancet Child. Adolesc. Health
PD SEP
PY 2020
VL 4
IS 9
BP 653
EP 661
DI 10.1016/S2352-4642(20)30177-2
PG 9
WC Pediatrics
SC Pediatrics
GA NQ3NX
UT WOS:000570772300010
PM 32593339
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Davies, P
   Evans, C
   Kanthimathinathan, HK
   Lillie, J
   Brierley, J
   Waters, G
   Johnson, M
   Griffiths, B
   du Pre, P
   Mohammad, Z
   Deep, A
   Playfor, S
   Singh, D
   Inwald, D
   Jardine, M
   Ross, O
   Shetty, N
   Worrall, M
   Sinha, R
   Koul, A
   Whittaker, E
   Vyas, H
   Scholefield, BR
   Ramnarayan, P
AF Davies, Patrick
   Evans, Claire
   Kanthimathinathan, Hari Krishnan
   Lillie, Jon
   Brierley, Joseph
   Waters, Gareth
   Johnson, Mae
   Griffiths, Benedict
   du Pre, Pascale
   Mohammad, Zoha
   Deep, Akash
   Playfor, Stephen
   Singh, Davinder
   Inwald, David
   Jardine, Michelle
   Ross, Oliver
   Shetty, Nayan
   Worrall, Mark
   Sinha, Ruchi
   Koul, Ashwani
   Whittaker, Elizabeth
   Vyas, Harish
   Scholefield, Barnaby R.
   Ramnarayan, Padmanabhan
TI Intensive care admissions of children with paediatric inflammatory
   multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in
   the UK: a multicentre observational study
SO LANCET CHILD & ADOLESCENT HEALTH
LA English
DT Article
ID DISEASE
AB Background In April, 2020, clinicians in the UK observed a cluster of children with unexplained inflammation requiring admission to paediatric intensive care units (PICUs). We aimed to describe the clinical characteristics, course, management, and outcomes of patients admitted to PICUs with this condition, which is now known as paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS).
   Methods We did a multicentre observational study of children (aged <18 years), admitted to PICUs in the UK between April 1 and May 10, 2020, fulfilling the case definition of PIMS-TS published by the Royal College of Paediatrics and Child Health. We analysed routinely collected, de-identified data, including demographic details, presenting clinical features, underlying comorbidities, laboratory markers, echocardiographic findings, interventions, treatments, and outcomes; serology information was collected if available. PICU admission rates of PIMS-TS were compared with historical trends of PICU admissions for four similar inflammatory conditions (Kawasaki disease, toxic shock syndrome, haemophagocytic lymphohistiocytosis, and macrophage activation syndrome).
   Findings 78 cases of PIMS-TS were reported by 21 of 23 PICUs in the UK. Historical data for similar inflammatory conditions showed a mean of one (95% CI 0.85-1.22) admission per week, compared to an average of 14 admissions per week for PIMS-TS and a peak of 32 admissions per week during the study period. The median age of patients was 11 years (IQR 8-14). Male patients (52 [67%] of 78) and those from ethnic minority backgrounds (61 [78%] of 78) were over-represented. Fever (78 [100%] patients), shock (68 [87%]), abdominal pain (48 [62%]), vomiting (49 [63%]), and diarrhoea (50 [64%]) were common presenting features. Longitudinal data over the first 4 days of admission showed a serial reduction in C-reactive protein (from a median of 264 mg/L on day 1 to 96 mg/L on day 4), D-dimer (4030 mu g/L to 1659 mu g/L), and ferritin (1042 mu g/L to 757 mu g/L), whereas the lymphocyte count increased to more than 1.0 x 10. cells per L by day 3 and troponin increased over the 4 days (from a median of 157 ng/mL to 358 ng/mL). 36 (46%) of 78 patients were invasively ventilated and 65 (83%) needed vasoactive infusions; 57 (73%) received steroids, 59 (76%) received intravenous immunoglobulin, and 17 (22%) received biologic therapies. 28 (36%) had evidence of coronary artery abnormalities (18 aneurysms and ten echogenicity). Three children needed extracorporeal membrane oxygenation, and two children died.
   Interpretation During the study period, the rate of PICU admissions for PIMS-TS was at least 11-fold higher than historical trends for similar inflammatory conditions. Clinical presentations and treatments varied. Coronary artery aneurysms appear to be an important complication. Although immediate survival is high, the long-term outcomes of children with PIMS-TS are unknown. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Davies, Patrick; Evans, Claire; Vyas, Harish] Nottingham Childrens Hosp, Paediat Crit Care Unit, Nottingham NG7 2UH, England.
   [Kanthimathinathan, Hari Krishnan; Scholefield, Barnaby R.] Birmingham Womens & Childrens NHS Fdn Trust, Paediat Intens Care Unit, Birmingham, W Midlands, England.
   [Lillie, Jon; Waters, Gareth; Griffiths, Benedict] Evelina Childrens Hosp, Paediat Intens Care Unit, London, England.
   [Brierley, Joseph; Johnson, Mae; du Pre, Pascale] Great Ormond St Hosp Sick Children, Paediat Intens Care Unit, London, England.
   [Mohammad, Zoha] Leicester Royal Infirm, Paediat Intens Care Unit, Leicester, Leics, England.
   [Deep, Akash] Kings Coll Hosp London, Paediat Intens Care Unit, London, England.
   [Playfor, Stephen] Royal Manchester Childrens Hosp, Paediat Intens Care Unit, Manchester, Lancs, England.
   [Singh, Davinder] Leeds Royal Infirm, Paediat Intens Care Unit, Leeds, W Yorkshire, England.
   [Inwald, David] Addenbrookes Hosp, Paediat Intens Care Unit, Cambridge, England.
   [Jardine, Michelle] Childrens Hosp Wales, Paediat Crit Care Unit, Cardiff, Wales.
   [Ross, Oliver] Southampton Childrens Hosp, Paediat Intens Care Unit, Southampton, Hants, England.
   [Shetty, Nayan] Alder Hey Childrens Hosp, Paediat Intens Care Unit, Liverpool, Merseyside, England.
   [Worrall, Mark] Royal Hosp Children, Paediat Intens Care Unit, Glasgow, Lanark, Scotland.
   [Sinha, Ruchi; Ramnarayan, Padmanabhan] St Marys Hosp, Paediat Intens Care Unit, London, England.
   [Koul, Ashwani] John Radcliffe Hosp, Paediat Crit Care Unit, Oxford, England.
   [Whittaker, Elizabeth] Imperial Coll Healthcare NHS Trust, Paediat Infect Dis Dept, London, England.
   [Scholefield, Barnaby R.] Univ Birmingham, Inst Inflammat & Ageing, Birmingham Acute Care Res Grp, Birmingham, W Midlands, England.
   [Ramnarayan, Padmanabhan] Great Ormond St Hosp NHS Fdn Trust, Childrens Acute Transport Serv, London, England.
   [Ramnarayan, Padmanabhan] NIHR Biomed Res Ctr, London, England.
RP Davies, P (corresponding author), Nottingham Childrens Hosp, Paediat Crit Care Unit, Nottingham NG7 2UH, England.
EM patrick.davies@nuh.nhs.uk
RI Krishnan, Hari/ABH-5848-2020
OI Krishnan, Hari/0000-0001-5170-1534; Scholefield,
   Barney/0000-0002-6198-4985; Whittaker, Elizabeth/0000-0002-7944-8793
FU paediatric intensive care community; Healthcare Quality Improvement
   Partnership
FX Data were provided by the Paediatric Intensive Care Audit Network
   (PICANet) in collaboration with the University of Leeds and University
   of Leicester, and with the support of the paediatric intensive care
   community. PICANet is funded by the Healthcare Quality Improvement
   Partnership. We thank the following for their assistance in collecting
   data for this manuscript: Liz Draper, PICANet; Nicholas Lanyon and
   Salmas Watad, Great Ormond St Hospital for Children, London, UK; Craig
   Stewart, Karan Gagneja, Nicholas Richens, and Sanket Sontakke,
   Birmingham Children's Hospital, Birmingham, UK; Khuen Ng, Leicester
   Royal Infirmary, Leicester, UK; Michael Griksaitis, Andrew Baldock,
   Christine Jones and John Pappachan, Southampton Children's Hospital,
   Southampton, UK; Lynda Verhulst and Vijayasree Sana, King's College
   Hospital, London, UK; Rebecca Mitting, St Marys Hospital, London, UK;
   Louise Woodgate, Chantelle Lilley, and Alice Eade, Royal Hospital for
   Children, Glasgow, UK; Chin Eyton-Chong, Alder Hey Childrens' Hospital,
   Liverpool, UK; Shelley Riphagen, Marilyn McDougall, Xabier Frier-Gomez,
   Owen Miller, and Julia Kenny, Evelina Children's Hospital, London, UK;
   and Jo Lumsden, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
CR Arons MM, 2020, NEW ENGL J MED, V382, P2081, DOI 10.1056/NEJMoa2008457
   BBC, 2020, BBC
   Burns JHR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072466
   CDC, 2020, COR DIS 2019 CHILDR
   Center for Disease Control, 2020, SEV OUTC PAT COR DIS
   Centers for Disease Control and Prevention (CDC), 2020, MULT INFL SYNDR CHIL
   Chang LY, 2014, J FORMOS MED ASSOC, V113, P148, DOI 10.1016/j.jfma.2013.12.008
   European Centre for Disease Prevention and Control, 2020, RAP RISK ASS PAED IN
   Hall GC, 2016, BRIT J GEN PRACT, V66, pE271, DOI 10.3399/bjgp16X684325
   Intensive Care National Audit and Research Centre, INCARC REP COVID 19
   Jones Veena G, 2020, Hosp Pediatr, V10, P537, DOI 10.1542/hpeds.2020-0123
   Kanegaye JT, 2009, PEDIATRICS, V123, pE783, DOI 10.1542/peds.2008-1871
   Khunti K, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1548
   Li H, 2020, LANCET, V395, P1517, DOI 10.1016/S0140-6736(20)30920-X
   Office for National Statistics ; National Records of Scotland; Northern Ireland Statistics and Research Agency, 2017, 2011 CENS AGGR DAT, DOI [10.5257/census/aggregate-2011-2, DOI 10.5257/CENSUS/AGGREGATE-2011-2]
   Paediatric Intensive Care Society, 2020, PICS STATEMENT INCRE
   Parri N, 2020, NEW ENGL J MED, V383, P187, DOI 10.1056/NEJMc2007617
   Parslow RC, 2009, ARCH DIS CHILD, V94, P210, DOI 10.1136/adc.2007.134403
   Ramcharan T, 2020, PEDIATR CARDIOL, V41, P1391, DOI 10.1007/s00246-020-02391-2
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Royal College of Paediatrics and Child Health, BPSU STUDY MULTISYST
   Royal College of Paediatrics and Child Health, 2020, GUIDANCE PAEDIATRIC
   Shekerdemian LS, 2020, JAMA PEDIATR, V174, P868, DOI 10.1001/jamapediatrics.2020.1948
   Stewart DJ, 2020, LANCET CHILD ADOLESC, V4, pE28, DOI 10.1016/S2352-4642(20)30178-4
   Tagarro Alfredo, 2020, JAMA Pediatr, DOI 10.1001/jamapediatrics.2020.1346
   Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X
   Whittaker E, 2020, JAMA-J AM MED ASSOC, V324, P259, DOI 10.1001/jama.2020.10369
   World Health Organization, 2020, CORONAVIRUS DISEASE
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
NR 29
TC 22
Z9 22
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2352-4642
J9 LANCET CHILD ADOLESC
JI Lancet Child. Adolesc. Health
PD SEP
PY 2020
VL 4
IS 9
BP 669
EP 677
DI 10.1016/S2352-4642(20)30215-7
PG 9
WC Pediatrics
SC Pediatrics
GA NQ3NX
UT WOS:000570772300013
PM 32653054
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Chapple, LAS
   Fetterplace, K
   Asrani, V
   Burrell, A
   Cheng, AC
   Collins, P
   Doola, R
   Ferrie, S
   Marshall, AP
   Ridley, EJ
AF Chapple, Lee-anne S.
   Fetterplace, Kate
   Asrani, Varsha
   Burrell, Aidan
   Cheng, Allen C.
   Collins, Peter
   Doola, Ra'eesa
   Ferrie, Suzie
   Marshall, Andrea P.
   Ridley, Emma J.
TI Nutrition management for critically and acutely unwell hospitalised
   patients with coronavirus disease 2019 (COVID-19) in Australia and New
   Zealand
SO NUTRITION & DIETETICS
LA English
DT Article
DE Artificial feeding; COVID-19; Critical illness; Nutrition; Pandemic
ID ENTERAL NUTRITION; ICU
AB Coronavirus disease 2019 (COVID-19) results from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical features and subsequent medical treatment, combined with the impact of a global pandemic, require specific nutritional therapy in hospitalised adults. This document aims to provide Australian and New Zealand clinicians with guidance on managing critically and acutely unwell adult patients hospitalised with COVID-19. These recommendations were developed using expert consensus, incorporating the documented clinical signs and metabolic processes associated with COVID-19, the literature from other respiratory illnesses, in particular acute respiratory distress syndrome, and published guidelines for medical management of COVID-19 and general nutrition and intensive care. Patients hospitalised with COVID-19 are likely to have preexisting comorbidities, and the ensuing inflammatory response may result in increased metabolic demands, protein catabolism, and poor glycaemic control. Common medical interventions, including deep sedation, early mechanical ventilation, fluid restriction, and management in the prone position, may exacerbate gastrointestinal dysfunction and affect nutritional intake. Nutrition care should be tailored to pandemic capacity, with early gastric feeding commenced using an algorithm to provide nutrition for the first 5-7 days in lower-nutritional-risk patients and individualised care for high-nutritional-risk patients where capacity allows. Indirect calorimetry should be avoided owing to potential aerosol exposure and therefore infection risk to healthcare providers. Use of a volume-controlled, higher-protein enteral formula and gastric residual volume monitoring should be initiated. Careful monitoring, particularly after intensive care unit stay, is required to ensure appropriate nutrition delivery to prevent muscle deconditioning and aid recovery. The infectious nature of SARS-CoV-2 and the expected high volume of patient admissions will require contingency planning to optimise staffing resources including upskilling, ensure adequate nutrition supplies, facilitate remote consultations, and optimise food service management. These guidelines provide recommendations on how to manage the aforementioned aspects when providing nutrition support to patients during the SARS-CoV-2 pandemic.
C1 [Chapple, Lee-anne S.] Royal Adelaide Hosp, Intens Care Res, Adelaide, SA, Australia.
   [Chapple, Lee-anne S.] Univ Adelaide, Discipline Acute Care Med, Adelaide, SA, Australia.
   [Fetterplace, Kate] Royal Melbourne Hosp, Allied Hlth Clin Nutr, Melbourne, Vic, Australia.
   [Fetterplace, Kate] Univ Melbourne, Dept Med, Melbourne, Vic, Australia.
   [Asrani, Varsha] Auckland City Hosp, Nutr & Dietet, Auckland, New Zealand.
   [Asrani, Varsha] Univ Auckland, Surg & Translat Res STaR Ctr, Auckland, New Zealand.
   [Asrani, Varsha] Auckland City Hosp, Dept Crit Care Med, Auckland, New Zealand.
   [Burrell, Aidan] Alfred Hosp, Intens Care Unit, Melbourne, Vic, Australia.
   [Burrell, Aidan; Ridley, Emma J.] Monash Univ, Sch Publ Hlth & Preventat Med, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia.
   [Cheng, Allen C.] Alfred Hlth, Dept Infect & Epidemiol, Melbourne, Vic, Australia.
   [Collins, Peter] Griffith Univ, Sch Allied Hlth Sci, Nutr & Dietet, Gold Coast, Qld, Australia.
   [Collins, Peter] Menzies Hlth Inst, Patient Ctr Hlth Serv, Brisbane, Qld, Australia.
   [Doola, Ra'eesa] Princess Alexandra Hosp, Dietet Dept, Brisbane, Qld, Australia.
   [Doola, Ra'eesa] Univ Queensland, Mater Res Inst, Brisbane, Qld, Australia.
   [Ferrie, Suzie] Royal Prince Alfred Hosp, Nutr & Dietet Dept, Sydney, NSW, Australia.
   [Ferrie, Suzie] Univ Sydney, Sydney, NSW, Australia.
   [Marshall, Andrea P.] Griffith Univ, Sch Nursing & Midwifery, Gold Coast, Qld, Australia.
   [Marshall, Andrea P.] Griffith Univ, Menzies Hlth Inst, Gold Coast, Qld, Australia.
   [Marshall, Andrea P.] Gold Coast Hlth, Southport, Qld, Australia.
   [Ridley, Emma J.] Alfred Hosp, Nutr Dept, Melbourne, Vic, Australia.
RP Ridley, EJ (corresponding author), Level 3,553 St Kilda Rd, Melbourne, Vic 3004, Australia.
EM emma.ridley@monash.edu
OI Marshall, Andrea/0000-0001-7692-403X; Chapple, Lee-anne
   S/0000-0002-9818-2484
CR Australian and New Zealand intensive care society, ANZICS COVID 19 GUID
   Chapman M, 2018, NEW ENGL J MED, V379, P1823, DOI 10.1056/NEJMoa1811687
   Chapple Lee-Anne, 2020, Aust Crit Care, V33, P300, DOI 10.1016/j.aucc.2020.02.008
   Chapple LAS, 2016, CLIN NUTR, V35, P1315, DOI 10.1016/j.clnu.2016.02.009
   DelBene V.E., 1990, TEMPERATURE CLIN MET
   McClave SA, 2016, JPEN-PARENTER ENTER, V40, P159, DOI 10.1177/0148607115621863
   Merriweather J, 2014, J CLIN NURS, V23, P654, DOI 10.1111/jocn.12241
   Reignier J, 2004, CRIT CARE MED, V32, P94, DOI 10.1097/01.CCM.0000104208.23542.A8
   Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P795, DOI 10.1001/jama.2012.137
   Ridley EJ, 2020, CURR OPIN CLIN NUTR, V23, P111, DOI 10.1097/MCO.0000000000000637
   Ridley EJ, 2019, JPEN-PARENTER ENTER, V43, P88, DOI 10.1002/jpen.1196
   Singer P, 2019, CLIN NUTR, V38, P48, DOI 10.1016/j.clnu.2018.08.037
   Wittholz K, 2020, J HUM NUTR DIET, V33, P414, DOI 10.1111/jhn.12719
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Xiao F, 2020, SCI TECHNOL BUILT EN, V26, P1, DOI 10.1080/23744731.2019.1707955
   Yan CH, 2020, INT FORUM ALLERGY RH, V10, P806, DOI 10.1002/alr.22579
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
NR 17
TC 2
Z9 2
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1446-6368
EI 1747-0080
J9 NUTR DIET
JI Nutr. Diet.
PD SEP
PY 2020
VL 77
IS 4
BP 426
EP 436
DI 10.1111/1747-0080.12636
PG 11
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA NP5EL
UT WOS:000570199200004
PM 32945085
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Fusi, F
   Romano, G
AF Fusi, Franco
   Romano, Giovanni
TI Shedding light on the restart
SO PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS
LA English
DT Letter
DE Antimicrobic phototherapy; Germicidal UV; UV safety; UVC; COVID-19
ID ANTIMICROBIAL APPROACH; PHOTODYNAMIC THERAPY; ULTRAVIOLET; PHOTOTHERAPY;
   INACTIVATION; IRRADIATION; RADIATION
C1 [Fusi, Franco; Romano, Giovanni] Univ Florence, Dept Expt & Clin Biomed Sci Mario Serio, Med Phys Unit, Viale G Pieraccini 6, I-50139 Florence, Italy.
RP Fusi, F (corresponding author), Univ Florence, Dept Expt & Clin Biomed Sci Mario Serio, Med Phys Unit, Viale G Pieraccini 6, I-50139 Florence, Italy.
EM franco.fusi@unifi.it; giovanni.romano@unifi.it
CR Bai Yu, 2019, Cereal & Food Industry, P1
   Bourouiba L, 2014, J FLUID MECH, V745, P537, DOI 10.1017/jfm.2014.88
   Buonanno M, 2020, FAR UVC LIGHT EFFICI, DOI [10.21203/rs.3.rs-25728/v1, DOI 10.21203/RS.3.RS-25728/V1]
   Buonanno M, 2017, RADIAT RES, V187, P483, DOI 10.1667/RR0010CC.1
   Calzavara-Pinton P, 1998, J AM ACAD DERMATOL, V38, P687, DOI 10.1016/S0190-9622(98)70214-2
   Calzavara-Pinton P, 2012, PHOTOCHEM PHOTOBIOL, V88, P512, DOI 10.1111/j.1751-1097.2012.01107.x
   COLELLA CM, 1986, PHOTOCHEM PHOTOBIOL, V43, P437, DOI 10.1111/j.1751-1097.1986.tb05626.x
   Dai TH, 2012, EXPERT REV ANTI-INFE, V10, P185, DOI [10.1586/eri.11.166, 10.1586/ERI.11.166]
   Diffey Brian L, 2002, J Cosmet Dermatol, V1, P124, DOI 10.1046/j.1473-2165.2002.00060.x
   DUGUID JP, 1946, J HYG-CAMBRIDGE, V44, P471, DOI 10.1017/S0022172400019288
   Erbil HY, 2012, ADV COLLOID INTERFAC, V170, P67, DOI 10.1016/j.cis.2011.12.006
   FEATHER J W, 1990, Lasers in Medical Science, V5, P345, DOI 10.1007/BF02032590
   Gallagher RP, 2006, PROG BIOPHYS MOL BIO, V92, P119, DOI 10.1016/j.pbiomolbio.2006.02.011
   Gazso LG, 2005, RAD INACTIVATION BIO
   Hamblin MR, 2004, PHOTOCH PHOTOBIO SCI, V3, P436, DOI 10.1039/b311900a
   Hamblin MR, 2013, HDB PHOTOMEDICINE, DOI [10.1201/b15582, DOI 10.1201/B15582]
   Honigsmann H, 2009, DERMATOLOGICAL PHOTO, DOI [10.1007/978-3-540-36693-5, DOI 10.1007/978-3-540-36693-5]
   Juzeniene A, 2010, INT J INFECT DIS, V14, pE1099, DOI 10.1016/j.ijid.2010.09.002
   Kneissl M, 2019, NAT PHOTONICS, V13, P233, DOI 10.1038/s41566-019-0359-9
   Lembo AJ, 2009, LASER SURG MED, V41, P337, DOI 10.1002/lsm.20770
   Liu L, 2017, INDOOR AIR, V27, P179, DOI 10.1111/ina.12297
   Lytle CD, 2005, J VIROL, V79, P14244, DOI 10.1128/JVI.79.22.14244-14252.2005
   Marr LC, 2019, J R SOC INTERFACE, V16, DOI 10.1098/rsif.2018.0298
   Munoz B, 1999, ANN EPIDEMIOL, V9, P53, DOI 10.1016/S1047-2797(98)00026-X
   Reed NG, 2010, PUBLIC HEALTH REP, V125, P15, DOI 10.1177/003335491012500105
   Robertson CA, 2009, J PHOTOCH PHOTOBIO B, V96, P1, DOI 10.1016/j.jphotobiol.2009.04.001
   Shaman J, 2009, P NATL ACAD SCI USA, V106, P3243, DOI 10.1073/pnas.0806852106
   Tamerius JD, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003194
   Tortora G, 2016, IEEE-ASME T MECH, V21, P1935, DOI 10.1109/TMECH.2016.2536944
   Tseng CC, 2005, AEROSOL SCI TECH, V39, P1136, DOI 10.1080/02786820500428575
   Wainwright M, 2017, LANCET INFECT DIS, V17, pE49, DOI 10.1016/S1473-3099(16)30268-7
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1120-1797
EI 1724-191X
J9 PHYS MEDICA
JI Phys. Medica
PD SEP
PY 2020
VL 77
BP 18
EP 20
DI 10.1016/j.ejmp.2020.07.018
PG 3
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA NP4MM
UT WOS:000570151800003
PM 32768916
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Brickman, D
   Greenway, A
   Sobocinski, K
   Thai, H
   Turick, A
   Xuereb, K
   Zambardino, D
   Barie, PS
   Liu, SI
AF Brickman, Diana
   Greenway, Andrew
   Sobocinski, Kathryn
   Hanh Thai
   Turick, Ashley
   Xuereb, Kevin
   Zambardino, Danielle
   Barie, Philip S.
   Liu, Susan, I
TI RAPID CRITICAL CARE TRAINING OF NURSES IN THE SURGE RESPONSE TO THE
   CORONAVIRUS PANDEMIC
SO AMERICAN JOURNAL OF CRITICAL CARE
LA English
DT Article
AB Background In response to the coronavirus pandemic, New York State mandated that all hospitals double the capacity of their adult intensive care units In this facility, resources were mobilized to increase from 104 to 283 beds.
   Objective To create and implement a 3-hour curriculum to prepare several hundred non-critical care staff nurses to manage critically ill patients with coronavirus disease 2019.
   Methods Critical care nursing leaders and staff developed and implemented a flexible critical care nursing curriculum tailored to the diverse experience, expertise, and learning needs of non-critical care nursing staff who were being redeployed to critical care units during the surge response to the pandemic. Curricular elements included respiratory failure and ventilator management, shock and hemodynamics, pharmacotherapy for critical illnesses, and renal replacement therapy. A skills station allowed hands-on practice with common critical care equipment.
   Results A total of 413 nurses completed training within 10 days. As of June 2020, 151 patients with coronavirus disease 2019 still required mechanical ventilation at our institution, and 7 of 10 temporary intensive care units remained operational. Thus most of the nurses who received this training continued to practice critical care. A unique feature of this curriculum was the tailored instruction, adapted to learners' needs, which improved the efficiency of content delivery.
   Conclusions Program evaluation is ongoing. As recovery and restoration proceed and normal operations resume, detailed feedback from program participants and patient care managers will help the institution maintain high operational readiness should a second wave of critically ill patients with coronavirus disease 2019 be admitted.
C1 [Brickman, Diana; Greenway, Andrew; Sobocinski, Kathryn; Hanh Thai; Turick, Ashley; Xuereb, Kevin; Zambardino, Danielle; Liu, Susan, I] Weill Cornell Med Ctr, New York Presbyterian Hosp, Dept Nursing, Surg Intens Care Unit, New York, NY 10065 USA.
   [Barie, Philip S.] Weill Cornell Med, Dept Surg, Div Trauma Burns Acute & Crit Care, New York, NY USA.
   [Barie, Philip S.] Weill Cornell Med, Dept Med, Div Med Eth, New York, NY USA.
RP Liu, SI (corresponding author), Weill Cornell Med Ctr, NewYork Presbyterian Hosp, Dept Nursing, 525 E 68th St,Box 137, New York, NY 10065 USA.
EM sul9025@nyp.org
CR Barie PS, 2020, SURG INFECT, V21, P726, DOI 10.1089/sur.2020.146
   Nibbelink CW, 2018, J CLIN NURS, V27, P917, DOI 10.1111/jocn.14151
   Peters AW, 2020, NEW ENGL J MED, V382, pE52, DOI 10.1056/NEJMc2010853
   Poor AD, 2020, AM J CRIT CARE, V29, pE52, DOI 10.4037/ajcc2020992
NR 4
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC CRITICAL CARE NURSES
PI ALISO VIEJO
PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA
SN 1062-3264
EI 1937-710X
J9 AM J CRIT CARE
JI Am. J. Crit. Care
PD SEP
PY 2020
VL 29
IS 5
BP E104
EP E107
DI 10.4037/ajcc2020142
PG 4
WC Critical Care Medicine; Nursing
SC General & Internal Medicine; Nursing
GA NO3HL
UT WOS:000569376100002
PM 32666088
OA Bronze
DA 2021-01-01
ER

PT J
AU Ben Fredj, H
   Cherif, F
AF Ben Fredj, Haifa
   Cherif, Farouk
TI Novel Corona virus disease infection in Tunisia: Mathematical model and
   the impact of the quarantine strategy
SO CHAOS SOLITONS & FRACTALS
LA English
DT Article
DE Mathematical modelling; Nonlinear differential systems; Qualitative
   study; Simulation
AB Corona virus disease (COVID-19) is an extremely serious infection with an extremely high death rate worldwide. In March, the disease was declared a "global pandemic" by the World Health Organization (WHO). Until now, there is no known vaccine or drug, since the unknown things related to the disease are more important than our theoretical and empirical knowledge. However, mathematical modeling and the estimation of the basic number of reproductions can provide clarifications in order to determine the potential and severity of this epidemic and therefore provide essential information to identify the type of measures and interventions to be taken to control the intensity of the spread of the disease. Hence, in this paper, we propose a new deterministic compartmental model based on the clinical progression of the disease, the epidemiological state of the individuals and the intervention for the dynamics of COVID-19 infections. Our approach consists of seven phenotypes: the susceptible humans, exposed humans, infectious humans, the recovered humans, the quarantine population, there recovered-exposed and deceased population. We proved first through mathematical approach the positivity, boundness and existence of a solution to the considered model. We also studied the existence of the disease free equilibrium and corresponding stability. Our work shows, in particular, that the disease will decrease if the number of re-production R-0 was less than one. Moreover, the impact of the quarantine strategies to reduce the spread of this disease is discussed. The theoretical results are validated by some numerical simulations of the system of the epidemic's differential equations. It should be mentioned that, the error between the considered model and the official data curve is quite small. (c) 2020 Elsevier Ltd. All rights reserved.
C1 [Ben Fredj, Haifa; Cherif, Farouk] Univ Sousse Tunisia, ESSTHS, MaPSFA, Sousse, Tunisia.
   [Cherif, Farouk] Univ Sousse Tunisia, ESSTHS, ISSATs, Sousse, Tunisia.
RP Ben Fredj, H (corresponding author), Univ Sousse Tunisia, ESSTHS, MaPSFA, Sousse, Tunisia.
EM haifabenfredjh@gmail.com
CR Boccaletti S, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109794
   Coddington EA, 1989, INTRO ORDINARY DIFFE
   DIEKMANN O, 1990, J MATH BIOL, V28, P365
   Fanelli D, 2020, CHAOS SOLITON FRACT, V134, DOI 10.1016/j.chaos.2020.109761
   Hethcote HW, 2000, SIAM REV, V42, P599, DOI 10.1137/S0036144500371907
   Jiwei J, 2020, ELECT J DIFFERENTIAL, V2020, P1
   Kucharski AJ, 2020, LANCET INFECT DIS, V20, P553, DOI 10.1016/S1473-3099(20)30144-4
   Ndairoua F, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109846
   Tang B, 2020, INT J INFECT DIS, V95, P288, DOI 10.1016/j.ijid.2020.03.018
   Tang B, 2020, INFECT DIS MODEL, V5, P248, DOI 10.1016/j.idm.2020.02.001
   Teo AKJ, 2020, TRIALS, V21, DOI 10.1186/s13063-020-4138-1
   van den Driessche P, 2002, MATH BIOSCI, V180, P29, DOI 10.1016/S0025-5564(02)00108-6
   Wilson ME, 2020, J TRAVEL MED, V27
   World. Health organization, 2020, COR DIS 2019 COVID 1
   Zhang XL, 2020, CHAOS SOLITON FRACT, V135, DOI 10.1016/j.chaos.2020.109829
NR 15
TC 0
Z9 0
U1 11
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0779
EI 1873-2887
J9 CHAOS SOLITON FRACT
JI Chaos Solitons Fractals
PD SEP
PY 2020
VL 138
AR 109969
DI 10.1016/j.chaos.2020.109969
PG 10
WC Mathematics, Interdisciplinary Applications; Physics, Multidisciplinary;
   Physics, Mathematical
SC Mathematics; Physics
GA NP0RE
UT WOS:000569890000007
PM 32536761
OA Green Published
DA 2021-01-01
ER

PT J
AU Mishra, BK
   Keshri, AK
   Rao, YS
   Mishra, BK
   Mahato, B
   Ayesha, S
   Rukhaiyyar, BP
   Saini, DK
   Singh, AK
AF Mishra, Bimal Kumar
   Keshri, Ajit Kumar
   Rao, Yerra Shankar
   Mishra, Binay Kumar
   Mahato, Buddhadeo
   Ayesha, Syeda
   Rukhaiyyar, Bansidhar Prasad
   Saini, Dinesh Kumar
   Singh, Aditya Kumar
TI COVID-19 created chaos across the globe: Three novel quarantine epidemic
   models
SO CHAOS SOLITONS & FRACTALS
LA English
DT Article
DE Mathematical models; Pandemic disease; COVID-19; Reproduction number;
   Home isolation; Quarantine
ID CORONAVIRUS; TRANSMISSION; 2019-NCOV; WUHAN
AB The latest version of human coronavirus said to be COVID-19 came out as a sudden pandemic disease within human population and in the absence of vaccination and proper treatment till date, it daunting threats heavily to human lives, infecting more than 12, 11, 214 people and death more than 67, 666 people in 208 countries across the globe as on April 06, 2020, which is highly alarming. When no treatment or vaccine is available till date and to avoid COVID-19 to be transmitted in the community, social distancing is the only way to prevent the disease, which is well taken into account in our novel epidemic models as a special compartment, that is, home isolation. Based on the transmitting behavior of COVID-19 in the human population, we develop three quarantine models of this pandemic taking into account the compartments: susceptible population, immigrant population, home isolation population, infectious population, hospital quarantine population, and recovered population. Local and global asymptotic stability is proved for all the three models. Extensive numerical simulations are performed to establish the analytical results with suitable examples. Our research reveals that home isolation and quarantine to hospitals are the two pivot force-control policies under the present situation when no treatment is available for this pandemic. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Mishra, Bimal Kumar] Markham Coll Commerce, Hazaribagh, India.
   [Keshri, Ajit Kumar] Birla Inst Technol, Patna Extens Ctr, Dept Comp Sci & Engn, Patna, Bihar, India.
   [Rao, Yerra Shankar] Gandhi Inst Excellent Technocrats, Dept Math, Bhubaneswar, India.
   [Mishra, Binay Kumar] Veer Kunwar Singh Univ, Dept Phys, Ara, Bihar, India.
   [Mahato, Buddhadeo] Univ Coll Engn & Technol, Dept Math, Hazaribagh, India.
   [Ayesha, Syeda] Wollongong Univ, Dept Financial Management, Dubai, U Arab Emirates.
   [Rukhaiyyar, Bansidhar Prasad] Vinoba Bhave Univ, Hazaribagh, India.
   [Saini, Dinesh Kumar] Sohar Univ, Fac Comp Sci & Informat Technol, Sohar, Oman.
   [Singh, Aditya Kumar] Ramgarh Engn Coll, Dept Math, Ramgarh, India.
RP Mishra, BK (corresponding author), Markham Coll Commerce, Hazaribagh, India.
EM drbimalmishra@gmail.com; ajitkeshri@bit.mesra.ac.in
RI ; Mishra, Bimal Kumar/L-7718-2017
OI saini, Dinesh/0000-0002-5140-1731; Mishra, Bimal
   Kumar/0000-0002-7979-4995; RAO, YERRA SHANKAR/0000-0002-2481-9585
CR Althaus Christian L, 2014, PLoS Curr, V6, DOI 10.1371/currents.outbreaks.91afb5e0f279e7f29e7056095255b288
   Bauch CT, 2005, EPIDEMIOLOGY, V16, P791, DOI 10.1097/01.ede.0000181633.80269.4c
   Chen L, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009226
   Coburn BJ, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-30
   Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747
   Ferguson NM, 2006, NATURE, V442, P448, DOI 10.1038/nature04795
   Fielding B.C., 2020, BRIEF HIST CORONAVIR
   Fraser C, 2009, SCIENCE, V324, P1557, DOI 10.1126/science.1176062
   Gani R, 2001, NATURE, V414, P748, DOI 10.1038/414748a
   Guerra FM, 2017, LANCET INFECT DIS, V17, pE420, DOI 10.1016/S1473-3099(17)30307-9
   Ireland's Health Services, HLTH CAR WORK INF PD
   Kahn Jeffrey S, 2005, Pediatr Infect Dis J, V24, pS223, DOI 10.1097/01.inf.0000188166.17324.60
   Kretzschmar M, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000291
   Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781
   Kucharski AJ, 2015, EUROSURVEILLANCE, V20, P14, DOI 10.2807/1560-7917.ES2015.20.25.21167
   Last J, 2001, DICT EPIDEMIOLOGY
   Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Liu T, 2020, TIME VARYING TRANSMI, DOI [10.1101/2020.01.25.919787, DOI 10.1101/2020.01.25.919787]
   Milligan GN, 2015, VACCINOLOGY ESSENTIA, P310
   Peiris JSM, 2003, LANCET, V361, P1319, DOI 10.1016/S0140-6736(03)13077-2
   Read J. M., 2020, NOVEL CORONAVIRUS 20, DOI [10.1101/2020.01.23.20018549, DOI 10.1101/2020.01.23.20018549]
   Riou J, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.4.2000058
   Shereen MA, 2020, J ADV RES, V1232
   Truelove SA, 2020, CLIN INFECT DIS, V71, P89, DOI 10.1093/cid/ciz808
   TYRRELL DA, 1966, LANCET, V1, P76
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Wallinga J, 2004, AM J EPIDEMIOL, V160, P509, DOI 10.1093/aje/kwh255
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
NR 30
TC 1
Z9 1
U1 8
U2 26
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0779
EI 1873-2887
J9 CHAOS SOLITON FRACT
JI Chaos Solitons Fractals
PD SEP
PY 2020
VL 138
AR 109928
DI 10.1016/j.chaos.2020.109928
PG 34
WC Mathematics, Interdisciplinary Applications; Physics, Multidisciplinary;
   Physics, Mathematical
SC Mathematics; Physics
GA NP0RA
UT WOS:000569889600010
PM 32501378
OA Green Published
DA 2021-01-01
ER

PT J
AU Yousaf, M
   Zahir, S
   Riaz, M
   Hussain, SM
   Shah, K
AF Yousaf, Muhammad
   Zahir, Samiha
   Riaz, Muhammad
   Hussain, Sardar Muhammad
   Shah, Kamal
TI Statistical analysis of forecasting COVID-19 for upcoming month in
   Pakistan
SO CHAOS SOLITONS & FRACTALS
LA English
DT Article
DE COVID-19 Pandemic; Confirmed Cases; Deaths; Recoveries; Forecast; ARIMA
AB In this paper, we have conducted analysis based on data obtained from National Institute of Health (NIH) - Islamabad and produced a forecast of COVID-19 confirmed cases as well as the number of deaths and recoveries in Pakistan using the Auto-Regressive Integrated Moving Average Model (ARIMA). The fitted forecasting models revealed high exponential growth in the number of confirmed cases, deaths and recoveries in Pakistan. Based on our model prediction the number of confirmed cases will be increased by 2.7 times, 95% prediction interval for the number of cases at the end of May 2020 = (5681 to 33079). There could be up to 500 deaths, 95% prediction interval = (168 to 885) and there could be eightfold increase in the number of recoveries, 95% prediction interval = (2391 to 16126). The forecasting results of COVID-19 are alarming for May in Pakistan. The health officials and government should adopt new strategies to control the pandemic from further spread until a proper treatment or vaccine is developed. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Yousaf, Muhammad; Zahir, Samiha; Riaz, Muhammad] Quaid I Azam Univ Islamabad, Dept Stat, Islamabad 45320, Pakistan.
   [Hussain, Sardar Muhammad] Balochistan Univ Informat Technol Engn & Manageme, Dept Math Sci, Quetta 87300, Pakistan.
   [Shah, Kamal] Univ Malakand, Dept Math, Chakdara Dir L, Kpk, Pakistan.
RP Hussain, SM (corresponding author), Balochistan Univ Informat Technol Engn & Manageme, Dept Math Sci, Quetta 87300, Pakistan.
EM yousafmuhammad480@gmail.com; samihazaheer11@gmail.com; mriaz@qau.edu.pk;
   smhussain01@gmail.com; kamalshah408@gmail.com
RI ; Shah, Kamal/S-8662-2016
OI Riaz, Muhammad/0000-0002-5512-1745; Shah, Kamal/0000-0002-8851-4844
CR [Anonymous], PAKISTAN GULF NEWS
   Chatfield C., 1984, ANAL TIME SERIES INT, DOI [10.1007/978-1-4899-2921-1., DOI 10.1007/978-1-4899-2921-1]
   Chen P, 2008, FIFTH INTERNATIONAL CONFERENCE ON FUZZY SYSTEMS AND KNOWLEDGE DISCOVERY, VOL 5, PROCEEDINGS, P627, DOI 10.1109/FSKD.2008.222
   Fong SJ, 2020, INT J INTERACT MULTI, V6, P132, DOI 10.9781/ijimai.2020.02.002
   Kumar P, 2020, FORECASTING DYNAMICS, DOI [10.1101/2020.03.30.20046227, DOI 10.1101/2020.03.30.20046227]
   Pais RJ, PREDICTING EVOLUTION, DOI [10.1101/2020.03.28.20046250., DOI 10.1101/2020.03.28.20046250V2]
   Paules CI, 2020, JAMA-J AM MED ASSOC, V323, P707, DOI 10.1001/jama.2020.0757
   Peng YJ, 2020, STRUCT CONCRETE, DOI 10.1002/suco.201900466
   Petropoulos F, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231236
   Roosa K, 2020, INFECT DIS MODEL, V5, P256, DOI 10.1016/j.idm.2020.02.002
   Shearer FM, ASSESSING RISK SPREA
   Sohail Raza, 2020, TRANSMISSION POTENTI, DOI 10.20944 /preprints202004.0004.v1
NR 12
TC 8
Z9 8
U1 5
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0779
EI 1873-2887
J9 CHAOS SOLITON FRACT
JI Chaos Solitons Fractals
PD SEP
PY 2020
VL 138
AR 109926
DI 10.1016/j.chaos.2020.109926
PG 4
WC Mathematics, Interdisciplinary Applications; Physics, Multidisciplinary;
   Physics, Mathematical
SC Mathematics; Physics
GA NP0RA
UT WOS:000569889600002
PM 32501377
OA Green Published
DA 2021-01-01
ER

PT J
AU Guinart, M
AF Guinart, M.
TI Drug Information Association (DIA) Europe-32nd Annual Meeting, Virtual
   (June 29-July 3, 2020)
SO DRUGS OF TODAY
LA English
DT Article
DE ICMRA; Big data; Clinical Trial Regulation; Medical Device Regulation;
   Patient engagement; Digital therapeutics
AB The Drug Information Association (DIA) Europe 2020 brought together multiple stakeholders from around the world including regulatory agencies, industry, patients and academia, to discuss the most innovative topics in healthcare. Main subjects covered were regulatory science, data and data standards, clinical safety and pharmacovigilance, translational medicines and science, patient engagement in clinical development, value and access, medical affairs and scientific communication, health policy, and public affairs and legal issues. The meeting, which was initially intended to take place in Brussels, was finally held virtually due to the COVID-19 situation. This report covers some of the sessions held on these 5 days of state-of-the-art topic discussions.
C1 [Guinart, M.] Clarivate, Barcelona, Spain.
RP Guinart, M (corresponding author), Clarivate, Barcelona, Spain.
EM marta.guinartvidal@clarivate.com
NR 0
TC 0
Z9 0
U1 4
U2 4
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 1699-3993
EI 1699-4019
J9 DRUG TODAY
JI Drugs Today
PD SEP
PY 2020
VL 56
IS 9
BP 609
EP 614
DI 10.1358/dot.2020.56.9.3208177
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NO2KN
UT WOS:000569313600005
PM 33025954
DA 2021-01-01
ER

PT J
AU Adamu, AA
   Jalo, RI
   Habonimana, D
   Wiysonge, CS
AF Adamu, Abdu A.
   Jalo, Rabiu, I
   Habonimana, Desire
   Wiysonge, Charles S.
TI COVID-19 and routine childhood immunization in Africa: Leveraging
   systems thinking and implementation science to improve immunization
   system performance
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Implementation science; Systems thinking; Immunization; Africa; COVID-19
ID HEALTH
AB One of the routine health services that is being disrupted by coronavirus disease 2019 (COVID-19) in Africa is childhood immunization. This is because the immunization system relies on functioning health facilities and stable communities to be effective. Its disruption increases the risk of epidemics of vaccine-preventable diseases, which could increase child mortality. Therefore, policymakers must quickly identify robust and context-specific strategies to rapidly scale-up routine immunization in order to mitigate the impact of COVID-19 on their national immunization performance. To achieve this, we propose a paradigm shift towards systems thinking and use of implementation science in immunization decision-making. Systems thinking can inform a more nuanced and holistic understanding of the interrelationship between COVID-19, its control strategies, and childhood immunization. Tools like causal loop diagrams can be used to explicitly illustrate the systems structure by identifying feedback loops. Once mapped and leverage points for interventions have been identified, implementation science can be used to guide the rapid uptake and utilization of multifaceted evidence-based innovations in complex practice settings. As Africa re-strategizes for the post-2020 era, these emerging fields could contribute significantly in accelerating progress towards universal access to vaccines for all children on the continent despite COVID-19. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Adamu, Abdu A.; Wiysonge, Charles S.] South African Med Res Council, Cochrane South Africa, Francie Van Zijl Dr, ZA-7505 Cape Town, South Africa.
   [Adamu, Abdu A.; Wiysonge, Charles S.] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Global Hlth, Div Epidemiol & Biostat, Francie Van Zijl Dr, ZA-7505 Cape Town, South Africa.
   [Jalo, Rabiu, I] Bayero Univ, Aminu Kano Teaching Hosp, Dept Community Med, Zaria Rd, Kano, Kano State, Nigeria.
   [Habonimana, Desire] Univ Burundi, Fac Med, Dept Community Med, Res & Innovat Unit, Bujumbura, Burundi.
   [Wiysonge, Charles S.] Univ Cape Town, Sch Publ Hlth & Family Med, ZA-7925 Cape Town, South Africa.
RP Adamu, AA (corresponding author), Stellenbosch Univ, Fac Med & Hlth Sci, Dept Global Hlth, Div Epidemiol & Biostat, Francie Van Zijl Dr, ZA-7505 Cape Town, South Africa.
EM abdu.adamu@gmail.com
OI Habonimana, Desire/0000-0003-0832-5558
CR Adamu AA, 2020, EXPERT REV VACCINES, V19, P395, DOI 10.1080/14760584.2020.1750379
   [Anonymous], 2019, WKLY EPIDEMIOL REC, V94, P541
   Ataguba JE, 2016, HEALTH POLICY PLANN, V31, P1212, DOI 10.1093/heapol/czw053
   Cabore JW, 2020, BMJ GLOB HEALTH, V5
   Carey G, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009002
   Chen JL, 2020, MICROBES INFECT, V22, P69, DOI 10.1016/j.micinf.2020.01.004
   CMMID nCov working group, 2020, BEN RISK AN HLTH BEN
   Eccles M. P., 2006, WELCOME IMPLEMENTATI
   Elston JWT, 2017, PUBLIC HEALTH, V143, P60, DOI 10.1016/j.puhe.2016.10.020
   Emanuel EJ, 2020, MASS MED SOC
   Gilbert M, 2020, LANCET, V395, P871, DOI 10.1016/S0140-6736(20)30411-6
   Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z
   Hamzelou J, 2020, NEW SCI, V245, P7, DOI 10.1016/S0262-4079(20)30611-4
   He X, 2020, NAT MED, V26, P672, DOI 10.1038/s41591-020-0869-5
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Lau H, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa037
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Luke DA, 2012, ANNU REV PUBL HEALTH, V33, P357, DOI 10.1146/annurev-publhealth-031210-101222
   McLaughlin CP, 2004, J BARTLETT LEARN
   Moullin JC, 2019, IMPLEMENT SCI, V14, DOI 10.1186/s13012-018-0842-6
   Nkengasong JN, 2020, LANCET, V395, P841, DOI 10.1016/S0140-6736(20)30464-5
   Peters DH, 2014, HEALTH RES POLICY SY, V12, DOI 10.1186/1478-4505-12-51
   Powell BJ, 2012, MED CARE RES REV, V69, P123, DOI 10.1177/1077558711430690
   Prem K, 2020, LANCET PUBLIC HEALTH, V5, pE261, DOI 10.1016/S2468-2667(20)30073-6
   Suk JE, 2016, EMERG INFECT DIS, V22, P1106, DOI 10.3201/eid2206.151652
   Wilhelm JA, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.010406
   World Health Organisation, 2020, STAT 2 M INT HLTH RE
   World Health Organization, 2019, WHO UNICEF COV AG ES
   World Health Organization, WORLD HLTH STAT 2020
   World Health Organization, 2019, GLOB VACC ACT PLAN 2
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
   World Health Organization, WHO COR DIS COVID 19
   World Health Organization, 2020, GUID PRINC IMM ACT C
NR 33
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD SEP
PY 2020
VL 98
BP 161
EP 165
DI 10.1016/j.ijid.2020.06.072
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA NN8VF
UT WOS:000569065100025
PM 32592908
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tariq, A
   Mateen, RM
   Afzal, MS
   Saleem, M
AF Tariq, Asma
   Mateen, Rana Muhammad
   Afzal, Muhammad Sohail
   Saleem, Mahjabeen
TI Paromomycin: A potential dual targeted drug effectively inhibits both
   spike (S1) and main protease of COVID-19
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; Drug repurposing; Chloroquine; Protease; Spike; MD simulation
ID MOLECULAR-DYNAMICS; CORONAVIRUS; CHARMM; GUI; SIMULATIONS; PREDICTION;
   PNEUMONIA
AB Objectives: With the increasing number of people suffering from coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is a dire need to look for effective remedies against this pandemic. Drug repurposing seems to be the solution for the current situation.
   Methods: In a quest to find a potential drug against this virus, 15 antimalarial drugs (including chloroquine) and 2413 US Food and Drug Administration-approved drugs were investigated for activity against both the protease and spike proteins of SARS-CoV-2 using an in silico approach. Molecular docking analysis followed by molecular dynamics simulation was performed to estimate the binding and stability of the complexes.
   Results: This study identified a single drug - paromomycin - with activity against two targets of SARS-CoV-2, i.e., spike protein (S1) and protease domain. Paromomycin was found to have strong binding affinity for both targets of coronavirus. The results also showed that no antimalarial drug exhibited effective binding for either S1 or protease.
   Conclusions: This study found that paromomycin may be an effective dual targeting drug against coronavirus, as it binds not only to the protease domain of the virion, but also to the spike domain, with high stability. Furthermore, none of the antimalarial drugs showed strong binding affinity for either protease or the receptor binding domain (RBD). (C) 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Tariq, Asma; Saleem, Mahjabeen] Univ Punjab, Inst Biochem & Biotechnol, Lahore, Pakistan.
   [Mateen, Rana Muhammad; Afzal, Muhammad Sohail] Univ Management & Technol, Sch Sci, Dept Life Sci, Lahore, Pakistan.
RP Tariq, A (corresponding author), Univ Punjab, Inst Biochem & Biotechnol, Lahore, Pakistan.
EM asmi_mahmood@yahoo.com; mateenibb@yahoo.com; sohail.ncvi@gmail.com;
   mahjabeen.ibb@pu.edu.pk
CR [Anonymous], 2020, SCHRODINGER RELEASE
   Brooks BR, 2009, J COMPUT CHEM, V30, P1545, DOI 10.1002/jcc.21287
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen YK, 2018, MOLECULES, V23, DOI 10.3390/molecules23051040
   Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
   Duan K Bc, 2020, P NATL ACAD SCI USA, P1
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hu TY, 2020, NAT NANOTECHNOL, V15, P247, DOI 10.1038/s41565-020-0674-9
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Jo S, 2008, J COMPUT CHEM, V29, P1859, DOI 10.1002/jcc.20945
   Jo SW, 2014, ADV PROTEIN CHEM STR, V96, P235, DOI 10.1016/bs.apcsb.2014.06.002
   Kim S, 2017, J COMPUT CHEM, V38, P1879, DOI 10.1002/jcc.24829
   Lee J, 2016, J CHEM THEORY COMPUT, V12, P405, DOI 10.1021/acs.jctc.5b00935
   Li YC, 2018, STRUCT DYNAM-US, V5, DOI 10.1063/1.5058172
   Liu H, 2016, BIOINFORMATICS, V32, P2216, DOI 10.1093/bioinformatics/btw215
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Ortega JT, 2020, EXCLI J, V19, P400, DOI 10.17179/excli2020-1189
   Phillips JC, 2005, J COMPUT CHEM, V26, P1781, DOI 10.1002/jcc.20289
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Vankadari N, 2020, EMERG MICROBES INFEC, V9, P601, DOI 10.1080/22221751.2020.1739565
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang W, 2000, J MOL BIOL, V303, P567, DOI 10.1006/jmbi.2000.4057
   WHO, 2020, 83 WHO
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhang L, 2020, SCIENCE, V3405, P1
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 34
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD SEP
PY 2020
VL 98
BP 166
EP 175
DI 10.1016/j.ijid.2020.06.063
PG 10
WC Infectious Diseases
SC Infectious Diseases
GA NN8VF
UT WOS:000569065100026
PM 32579907
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shen, CX
   Yue, XF
   Wang, JW
   Shi, CM
   Li, WB
AF Shen, Chongxing
   Yue, Xiaofeng
   Wang, Jianwu
   Shi, Chunmeng
   Li, Weibing
TI Nocturnal oxygen therapy as an option for early COVID-19
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Coronavirus; Nocturnal oxygen therapy; COVID-19; SARS-CoV-2;
   Immunomodulation
ID GLUCOSE-METABOLISM; ACE2 EXPRESSION; GENE-EXPRESSION; SARS-COV; VIRUS;
   PD-L1; CORONAVIRUS; HIF-1-ALPHA
AB There is currently no effective antiviral therapy or immune-based treatment for coronavirus disease (COVID-19). The urgent challenge is to prevent the transition of COVID-19 from mild to severe infection. This paper discussed nocturnal oxygen therapy as a new option for people with COVID-19 under home quarantine. It suggested that nocturnal oxygen therapy in the early stages may be helpful in preventing disease progression by inhibiting the rapid replication of the virus and improving the body's antiviral ability. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Shen, Chongxing; Yue, Xiaofeng; Wang, Jianwu; Li, Weibing] Chongqing Med Univ, Dept Urol, Affiliated Hosp 3, Gen Hosp, Chongqing, Peoples R China.
   [Shi, Chunmeng] Third Mil Med Univ, Inst Rocket Force Med, State Key Lab Trauma Burns & Combined Injury, Chongqing, Peoples R China.
RP Li, WB (corresponding author), Chongqing Med Univ, Dept Urol, Affiliated Hosp 3, Gen Hosp, Chongqing, Peoples R China.; Shi, CM (corresponding author), Third Mil Med Univ, Inst Rocket Force Med, State Key Lab Trauma Burns & Combined Injury, Chongqing, Peoples R China.
EM shicm@tmmu.edu.cn; liweibing63@cqmu.edu.cn
OI Wang, Yuhan/0000-0001-9134-0091
FU Chongqing Research Program of Technology Innovation and Application
   Development on 2019 Novel Coronavirus-Infected Pneumonia
   [cstc2020jscx-fyzxX0013]
FX This work was partially funded by Chongqing Research Program of
   Technology Innovation and Application Development on 2019 Novel
   Coronavirus-Infected Pneumonia (cstc2020jscx-fyzxX0013).
CR Alamili M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087413
   Atkuri KR, 2005, P NATL ACAD SCI USA, V102, P3756, DOI 10.1073/pnas.0409910102
   Avendano-Ortiz J, 2018, J INFECT DIS, V217, P393, DOI 10.1093/infdis/jix279
   BAUDOUIN SV, 1992, THORAX, V47, P550, DOI 10.1136/thx.47.7.550
   Bracken CP, 2003, CELL MOL LIFE SCI, V60, P1376, DOI 10.1007/s00018-003-2370-y
   Chen Y, 2013, LANCET, V381, P1916, DOI 10.1016/S0140-6736(13)60903-4
   Clarke NE, 2014, CLIN SCI, V126, P507, DOI 10.1042/CS20130291
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Edgar RS, 2016, P NATL ACAD SCI USA, V113, P10085, DOI 10.1073/pnas.1601895113
   Gagnidze K, 2016, P NATL ACAD SCI USA, V113, P5730, DOI 10.1073/pnas.1520489113
   Guo Y, 2014, INT J MOL SCI, V15, P7974, DOI 10.3390/ijms15057974
   Hatfield SM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1260
   Hou Y. J, 2020, CELL
   Hu WC, 2012, VIRAL IMMUNOL, V25, P277, DOI 10.1089/vim.2011.0099
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Hunt L, 2015, LANCET INFECT DIS, V15, P1292, DOI 10.1016/S1473-3099(15)00144-9
   Joshi S, 2019, J CELL PHYSIOL, V234, P20420, DOI 10.1002/jcp.28643
   Kang D, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004979
   KELLY RF, 1995, AM HEART J, V130, P957, DOI 10.1016/0002-8703(95)90194-9
   Kindler E, 2016, CELL HOST MICROBE, V19, P139, DOI 10.1016/j.chom.2016.01.012
   Li Z, 2020, 20021212 MEDRXIV, V2020
   Manning AM, 2002, VET CLIN N AM-SMALL, V32, P1005, DOI 10.1016/S0195-5616(02)00043-8
   Mazzon M, 2015, J GEN VIROL, V96, P395, DOI 10.1099/vir.0.069591-0
   Moon EJ, 2003, FASEB J, V17, P382, DOI 10.1096/fj.03-0153fje
   Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916
   Ottestad W, 2020, TIDSSKRIFT, V140
   Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
   Petrovsky N, 1998, Int Rev Immunol, V16, P635, DOI 10.3109/08830189809043012
   Petrovsky N, 1998, CYTOKINE, V10, P307, DOI 10.1006/cyto.1997.0289
   Pillet S, 2004, VIROLOGY, V327, P1, DOI 10.1016/j.virol.2004.06.020
   Popescu CR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082421
   Qian X, 2019, AM J CANCER RES, V9, P529
   Reddy R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213096
   Ren LH, 2019, VIROLOGY, V530, P51, DOI 10.1016/j.virol.2019.02.010
   Roberts A, 2007, PLOS PATHOG, V3, P23, DOI 10.1371/journal.ppat.0030005
   Schonrich G, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00207
   Thai M, 2014, CELL METAB, V19, P694, DOI 10.1016/j.cmet.2014.03.009
   TRASK CH, 1962, NEW ENGL J MED, V266, P639, DOI 10.1056/NEJM196203292661303
   Vassilaki N, 2013, J VIROL, V87, P2935, DOI 10.1128/JVI.02534-12
   Wan S., 2020, CHARACTERISTICS LYMP, DOI [10.20021832, DOI 10.1101/2020.02.10.20021832, 10.1101/2020.02. 10.20021832, 10.1101/2020.02.10.20021832]
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang YG, 2019, ADV SCI, V6, DOI 10.1002/advs.201901278
   Wang ZW, 2020, BIOSCI TRENDS, V14, P64, DOI 10.5582/bst.2020.01030
   Waskowska A, 2017, FOLIA HISTOCHEM CYTO, V55, P26, DOI 10.5603/FHC.a2017.0006
   Yu YJ, 2014, P NATL ACAD SCI USA, V111, P1951, DOI 10.1073/pnas.1310779111
   Zhang RF, 2009, AM J PHYSIOL-LUNG C, V297, pL631, DOI 10.1152/ajplung.90415.2008
   Zhang WN, 2019, CELL, V178, P176, DOI 10.1016/j.cell.2019.05.003
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 48
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD SEP
PY 2020
VL 98
BP 176
EP 179
DI 10.1016/j.ijid.2020.06.080
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA NN8VF
UT WOS:000569065100027
PM 32599285
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ebrahim, SH
   Zhuo, JT
   Gozzer, E
   Ahmed, QA
   Imtiaz, R
   Ahmed, Y
   Doumbia, S
   Rahman, NMM
   Elachola, H
   Wilder-Smith, A
   Memish, ZA
AF Ebrahim, Shahul H.
   Zhuo, Jiatong
   Gozzer, Ernesto
   Ahmed, Qanta A.
   Imtiaz, Rubina
   Ahmed, Yusuf
   Doumbia, Seydou
   Rahman, N. M. Mujeeb
   Elachola, Habida
   Wilder-Smith, A.
   Memish, Ziad A.
TI All Hands on Deck: A synchronized whole-of-world approach for COVID-19
   mitigation
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE COVID-19; SARS-COV-2; Pandemic; Mitigation
AB The COVID-19 pandemic can no longer be mitigated by a nationwide approach of individual nations alone. Given its scale and accelerating expansion, COVID-19 requires a coordinated and simultaneous Whole- of-World approach that galvanizes clear global leadership and solidarity from all governments of the world. Considering an 'all hands-on deck concept, we present a comprehensive list of tools and entities responsible for enabling them, as well a conceptual framework to achieve the maximum impact. The list is drawn from pandemic mitigation tools developed in response to past outbreaks including influenza, coronaviruses, and Ebola, and includes tools to minimize transmission in various settings including person-to-person, crowd, funerals, travel, workplace, and events and gatherings including business, social and religious venues. Included are the roles of individuals, communities, government and other sectors such as school systems, health, institutions, and business. While individuals and communities have significant responsibilities to prevent person-to-person transmission, other entities can play a significant role to enable individuals and communities to make use of the tools. Historic and current data indicate the role of political will, whole-of-government approach, and the role of early introduction of mitigation measures. There is also an urgent need to further elucidate the immunologic mechanisms underlying the epidemiological characteristics such as the low disease burden among women, and the role of COVID-19 in inducing Kawasaki-like syndromes in children. Understanding the role of and development of anti-inflammatory strategies based on our understanding of pro-inflammatory cytokines (ILl, IL-6) is also critical. Similarly, the role of oxygen therapyas an anti-inflammatory strategy is evident and access to oxygen therapy should be prioritized to avoid the aggravation of COVID-19 infection. We highlight the need for global solidarity to share both mitigation commodities and infrastructure between countries. Given the global reach of COVID-19 and potential for repeat waves of outbreaks, we call on all countries and communities to act synergistically and emphasize the need for synchronized pan-global mitigation efforts to minimize everyone's risk, to maximize collaboration, and to commit to shared progress. (C) 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Ebrahim, Shahul H.] Univ Sci Tech & Technol, Bamako, Mali.
   [Zhuo, Jiatong] Guangxi Ctr Dis Control Prevent, Nanning, Peoples R China.
   [Gozzer, Ernesto] Univ Peruana Cayetano Heredia, Lima, Peru.
   [Ahmed, Qanta A.] Winthrop Univ Hosp, Dept Med, Div Pulm Dis & Crit Care Med, Mineola, NY 11501 USA.
   [Imtiaz, Rubina] Task Force Global Hlth, Children Worms, Decatur, GA USA.
   [Ahmed, Yusuf] Levy Mwanawasa Med Univ, Univ Teaching Hosp Associate Prof, Lusaka, Zambia.
   [Doumbia, Seydou] Univ Sci Tech & Technol, Fac Med & Odontostomatol, Bamako, Mali.
   [Doumbia, Seydou] Univ Sci Tech & Technol, Univ Clin Res Ctr, Bamako, Mali.
   [Rahman, N. M. Mujeeb] MES Med Coll Hosp, Perinthalmanna, India.
   [Elachola, Habida] Mercer Univ, Atlanta, GA USA.
   [Wilder-Smith, A.] London Sch Hyg & Trop Med, Dept Dis Control, London, England.
   [Memish, Ziad A.] Alfaisal Univ, Res Innovat Ctr, King Saud Med City, Minist Hlth, Riyadh, Saudi Arabia.
   [Memish, Ziad A.] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia.
   [Memish, Ziad A.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA.
RP Memish, ZA (corresponding author), Alfaisal Univ, Res Innovat Ctr, King Saud Med City, Minist Hlth, Riyadh, Saudi Arabia.; Memish, ZA (corresponding author), Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia.
EM ebrahimsh2@gmail.com; Zjta28@168.com; Ernesto.gozzer@upch.pe;
   qanta.ahmed@gmail.com; rimtiaz@taskforce.org; Yusufahmed03@hotmail.com;
   sdoumbi@gmail.com; drnmmujeeb@mesams.com; habidaec@gmail.com;
   anneliesws@gmail.com; zmemish@yahoo.com
CR Abiad A. A., 2020, EC IMPACT COVID 19 O
   Anzai A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020601
   Baird Robert P, 2020, WHY WIDESPREAD CORON
   Barrett C., 2019, 3 SHEETS WIND NAUTIC
   Centers for Disease Control and Prevention (CDC), IMPL MIT STRAT COMM, P10
   Christensen T, 2007, PUBLIC ADMIN REV, V67, P1059, DOI 10.1111/j.1540-6210.2007.00797.x
   Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E
   Ebrahim SH, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1066
   Ebrahim SH, 2020, LANCET, V395, pE48, DOI 10.1016/S0140-6736(20)30466-9
   Ferguson NM, IMPACT NONPHARMACEUT, P20
   Fisher D, 2020, LANCET, V395, P1109, DOI 10.1016/S0140-6736(20)30679-6
   Gawande Atul A, 2020, KEEPING CORONAVIRUS
   Global News, 2020, GLOBAL NEWS
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Hamzah F. A., 2020, CORONATRACKER WORLD, DOI 10.2471/BLT.20.255695
   Kelly L, 2020, 100S AM STRANDED PER
   Knaus C., 2020, GUARDIAN
   Lan L, 2020, JAMA
   Madhav N, 2017, DIS CONTROL PRIORITI
   McKinsey and Company, COVID 19 BRIEF NOT G
   Neher RA, 2020, SWISS MED WKLY, V150
   Nuclear Threat Initiative Johns Hopkins University, 2019, ECONOMIST, P324
   OCarroll DCL, 2020, GUARDIAN
   Pandey A, 2014, SCIENCE, V346, P991, DOI 10.1126/science.1260612
   Poole DN, 2020, INT J EQUITY HEALTH, V19, DOI 10.1186/s12939-020-01162-y
   Public Health Agency of Canada, 2020, COMM BAS MEAS MIT SP
   Ronconi G, 2020, J Biol Regul Homeost Agents, V34, P767, DOI 10.23812/EDITORIAL-RONCONI-E-59
   The World Bank, 2018, URB POP TOT POP DAT
   United Nations Conference on Trade and Development, 2020, COR SHOCK STOR AN GL
   Wang CJ, 2020, JAMA-J AM MED ASSOC, V323, P1341, DOI 10.1001/jama.2020.3151
   WHO, 2005, INT HLTH REG
   WHO, 2019, PREV HIV AD AG 15 49
   (WHO) WHO, 2020, COR DIS COVID 19 OUT
   Wilder-Smith A, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa020
   World Health Organization, 2007, GLOB PUBL HLTH SEC 2
   World Health Organization, 2020, COR DIS 2019 COVID 1
   Zastrow M., 2020, NATURE
NR 37
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD SEP
PY 2020
VL 98
BP 208
EP 215
DI 10.1016/j.ijid.2020.06.049
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA NN8VF
UT WOS:000569065100035
PM 32565364
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Dubert, M
   Visseaux, B
   Isernia, V
   Bouadma, L
   Deconinck, L
   Patrier, J
   Wicky, PH
   Le Pluart, D
   Kramer, L
   Rioux, C
   Le Hingrat, Q
   Houhou-Fidouh, N
   Yazdanpanah, Y
   Ghosn, J
   Lescure, FX
AF Dubert, Marie
   Visseaux, Benoit
   Isernia, Valentina
   Bouadma, Lila
   Deconinck, Laurene
   Patrier, Juliette
   Wicky, Paul-Henri
   Le Pluart, Diane
   Kramer, Laura
   Rioux, Christophe
   Le Hingrat, Quentin
   Houhou-Fidouh, Nadhira
   Yazdanpanah, Yazdan
   Ghosn, Jade
   Lescure, Francois-Xavier
TI Case report study of the first five COVID-19 patients treated with
   remdesivir in France
SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE SARS-CoV-2 viral load; Remdesivir; Antiviral therapy; Viral pneumonia;
   Case reports
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been identified as the virus responsible for the coronavirus disease 2019 (COVID-19 ) outbreak worldwide. Data on treatment are scare and parallels have been made between SARS-CoV-2 and other coronaviruses. Remdesivir is a broad-spectrum antiviral with efficient in vitro activity against SARS-CoV-2. Evidence of clinical improvement in patients with severe COVID-19 treated with remdesivir is controversial. The aim of this study was to describe the clinical outcomes and virological monitoring of the first five COVID-19 patients admitted to the intensive care unit of Bichat-Claude Bernard University Hospital, Paris, France, for severe pneumonia related to SARS-CoV-2 and treated with remdesivir. Quantitative reverse transcription PCR was used to monitor SARS-CoV-2 in blood plasma and the lower and upper respiratory tract. Among the five patients treated, two needed mechanical ventilation and one needed high-flow cannula oxygen. A significant decrease in SARS-CoV-2 viral load in the upper respiratory tract was observed in most cases, but two patients died with active SARS-CoV-2 replication in the lower respiratory tract. Plasma samples were positive for SARS-CoV-2 in only one patient. Remdesivir was interrupted before the initialy planned duration in four patients, two because of alanine aminotransferase elevations (3 to 5 normal range) and two because of renal failure requiring renal replacement. This case series of five COVID-19 patients requiring intensive care unit treatment for respiratory distress and treated with remdesivir, highlights the complexity of remdesivir use in such critically ill patients. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
C1 [Dubert, Marie; Isernia, Valentina; Deconinck, Laurene; Le Pluart, Diane; Rioux, Christophe; Yazdanpanah, Yazdan; Ghosn, Jade; Lescure, Francois-Xavier] Bichat Claude Bernard Univ Hosp, AP HP Nord, Infect & Trop Dis Dept, Paris, France.
   [Visseaux, Benoit; Le Hingrat, Quentin; Houhou-Fidouh, Nadhira] Bichat Claude Bernard Univ Hosp, AP HP Nord, Virol Dept, Paris, France.
   [Visseaux, Benoit; Bouadma, Lila; Patrier, Juliette; Wicky, Paul-Henri; Le Hingrat, Quentin; Yazdanpanah, Yazdan; Ghosn, Jade; Lescure, Francois-Xavier] Univ Paris, French Inst Hlth & Med Res INSERM, Team DesCID, IAME,U1137, Paris, France.
   [Bouadma, Lila; Patrier, Juliette; Wicky, Paul-Henri] Bichat Claude Bernard Univ Hosp, AP HP Nord, Med & Infect Dis Intens Care Unit, Paris, France.
   [Kramer, Laura] Bichat Claude Bernard Univ Hosp, AP HP Nord, Pharm Unit, Paris, France.
RP Dubert, M (corresponding author), Hop Bichat Claude Bernard, SMIT, 46 Rue Henri Huchard, F-75018 Paris, France.
EM marie.dubert@aphp.fr
CR Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Arabi YM, 2020, TRIALS, V21, DOI 10.1186/s13063-019-3846-x
   Chen Z, 2020, EFFICACY HYDROXYCHLO
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Corman V, 2020, DIAGNOSTIC DETECTION
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Grein J, 2020, NEW ENGL J MED, V382
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Kujawski SA, 2020, 1 12 PATIENTS CORONA, V2020
   Lescure F.X., 2020, LANCET INFECT DIS
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang Y., 2020, LANCET
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 16
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1201-9712
EI 1878-3511
J9 INT J INFECT DIS
JI Int. J. Infect. Dis.
PD SEP
PY 2020
VL 98
BP 290
EP 293
DI 10.1016/j.ijid.2020.06.093
PG 4
WC Infectious Diseases
SC Infectious Diseases
GA NN8VI
UT WOS:000569065400011
PM 32619764
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Shamshina, JL
   Rogers, RD
AF Shamshina, Julia L.
   Rogers, Robin D.
TI Are Myths and Preconceptions Preventing Us from Applying Ionic Liquid
   Forms of Antiviral Medicines to the Current Health Crisis?
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE ionic liquids of active pharmaceutical ingredients (API-ILs); antiviral
   API-ILs; solubility; polymorphism; cocrystals; pharmaceutical salts;
   acyclovir; GSK2838232
ID SALT SELECTION; DRUGS; STABILITY; CRYSTAL; POLYMORPHISM; SOLUBILITY;
   RELEVANCE; FORMULATION; COCRYSTALS; CHALLENGES
AB At the moment, there are no U.S. Food and Drug Administration (U.S. FDA)-approved drugs for the treatment of COVID-19, although several antiviral drugs are available for repurposing. Many of these drugs suffer from polymorphic transformations with changes in the drug's safety and efficacy; many are poorly soluble, poorly bioavailable drugs. Current tools to reformulate antiviral APIs into safer and more bioavailable forms include pharmaceutical salts and cocrystals, even though it is difficult to classify solid forms into these regulatory-wise mutually exclusive categories. Pure liquid salt forms of APIs, ionic liquids that incorporate APIs into their structures (API-ILs) present all the advantages that salt forms provide from a pharmaceutical standpoint, without being subject to solid-state matter problems. In this perspective article, the myths and the most voiced concerns holding back implementation of API-ILs are examined, and two case studies of API-ILs antivirals (the amphoteric acyclovir and GSK2838232) are presented in detail, with a focus on drug property improvement. We advocate that the industry should consider the advantages of API-ILs which could be the genesis of disruptive innovation and believe that in order for the industry to grow and develop, the industry should be comfortable with a certain element of risk because progress often only comes from trying something different.
C1 [Shamshina, Julia L.; Rogers, Robin D.] 525 Solut Inc, POB 2206, Tuscaloosa, AL 35403 USA.
RP Shamshina, JL; Rogers, RD (corresponding author), 525 Solut Inc, POB 2206, Tuscaloosa, AL 35403 USA.
EM shams002@gmail.com; Robin.Rogers@525Solutions.com
RI ; Rogers, Robin D./C-8265-2013
OI Shamshina, Julia/0000-0003-0708-764X; Rogers, Robin
   D./0000-0001-9843-7494
CR AHFS, DRUG INF, P765
   AHLNECK C, 1990, INT J PHARMACEUT, V62, P87, DOI 10.1016/0378-5173(90)90221-O
   Aitipamula S, 2012, CRYST GROWTH DES, V12, P2147, DOI 10.1021/cg3002948
   Akhavein N., 2018, P HIV RES PREV C PD0
   Alves F, 2013, J PHARM SCI-US, V102, P1504, DOI 10.1002/jps.23487
   Araujo JMM, 2014, RSC ADV, V4, P28126, DOI 10.1039/c3ra47615d
   Balk A, 2015, EUR J PHARM BIOPHARM, V94, P291, DOI 10.1016/j.ejpb.2015.05.027
   Bandi P.P.R, 2009, U.S. Patent, Patent No. [13,121,505, 13121505]
   Banerjee R, 2005, CRYST GROWTH DES, V5, P2299, DOI 10.1021/cg050125l
   Barr G, 2004, J APPL CRYSTALLOGR, V37, P243, DOI 10.1107/S0021889804000391
   Bergstrom CAS, 2002, PHARMACEUT RES, V19, P182, DOI 10.1023/A:1014224900524
   Bernstein J., 2002, IUCR MONOGRAPHS CRYS, V14
   Bhattacharya S., 2009, DRUGS PHARM SCI SERI, V192, P318
   Bica K, 2012, CHEM COMMUN, V48, P5422, DOI 10.1039/c2cc30959a
   Bica K, 2010, PHYS CHEM CHEM PHYS, V12, P2011, DOI 10.1039/b923855g
   Bica K, 2010, CHEM COMMUN, V46, P1215, DOI 10.1039/b925147b
   Budavari S., 1996, MERCK INDEX, P27
   Burke M.D., 2018, P AM ASS PHARM SCI A
   Chang RK, 2013, AAPS J, V15, P41, DOI 10.1208/s12248-012-9411-0
   Chatel G, 2014, GREEN CHEM, V16, P2051, DOI 10.1039/c3gc41389f
   Chawla G, 2004, CRIPS, V5, P9
   Cole MR, 2011, CHEM BIOL DRUG DES, V78, P33, DOI 10.1111/j.1747-0285.2011.01114.x
   Cutaia Kara, 2018, Int J Pharm Compd, V22, P480
   Daniel CI, 2013, J PHYS CHEM B, V117, P11877, DOI 10.1021/jp4078536
   De Savi C, 2020, ORG PROCESS RES DEV, V24, P940, DOI 10.1021/acs.oprd.0c00233
   DeJesus E, 2020, CLIN INFECT DIS, V71, P1255, DOI 10.1093/cid/ciz938
   Desiraju GR, 2003, CRYSTENGCOMM, V5, P466, DOI 10.1039/b313552g
   Di L, 2006, DRUG DISCOV TODAY, V11, P446, DOI 10.1016/j.drudis.2006.03.004
   Egorova K.S., 2019, ENCY IONIC LIQUIDS, P1, DOI [10.1007/978-981-10-6739-6_1-1, DOI 10.1007/978-981-10-6739-6_1-1]
   Egorova KS, 2017, CHEM REV, V117, P7132, DOI 10.1021/acs.chemrev.6b00562
   FDA, GUID DOC OR SOL SUSP
   FDA, GUID IND ANDAS PHARM
   Ferraz R, 2012, MEDCHEMCOMM, V3, P494, DOI 10.1039/c2md00269h
   Florence A. J., 2009, POLYMORPHISM PHARM S, P139
   Florindo C, 2013, INT J PHARMACEUT, V456, P553, DOI 10.1016/j.ijpharm.2013.08.010
   Frizzo CP, 2013, IONIC LIQUIDS - NEW ASPECTS FOR THE FUTURE, P557, DOI 10.5772/51655
   Gala U, 2013, J DEV DRUG, V2, pe130, DOI [DOI 10.4172/2329-6631.1000E130, 10.4172/2329-6631.1000e130]
   Giesler KE, 2016, J MED CHEM, V59, P7097, DOI 10.1021/acs.jmedchem.6b00428
   GOULD PL, 1986, INT J PHARM, V33, P201, DOI 10.1016/0378-5173(86)90055-4
   Gupta D, 2018, MOLECULES, V23, DOI 10.3390/molecules23071719
   Hatcher M.A, 2013, Patent WO, Patent No. 2013090664A1
   Hough WL, 2007, NEW J CHEM, V31, P1429, DOI 10.1039/b706677p
   Hough-Troutman WL, 2009, NEW J CHEM, V33, P26, DOI 10.1039/b813213p
   Jensen AF, 2005, ACTA CRYSTALLOGR A, V61, pC292, DOI 10.1107/S0108767305087532
   Johns B.A, 2015, Patent US, Patent No. [9,102,685 B2, 9102685B2]
   Johnson M, 2020, CLIN PHARM DRUG DEV, V9, P972, DOI 10.1002/cpdd.820
   Karimi-Jafari M, 2018, CRYST GROWTH DES, V18, P6370, DOI 10.1021/acs.cgd.8b00933
   Karpinski PH, 2006, CHEM ENG TECHNOL, V29, P233, DOI 10.1002/ceat.200500397
   Kelley SP, 2013, CRYST GROWTH DES, V13, P965, DOI 10.1021/cg4000439
   Koi ZK, 2019, NEW J CHEM, V43, P16207, DOI 10.1039/c9nj03436f
   Kristl A, 1996, INT J PHARM, V139, P231, DOI 10.1016/0378-5173(96)04601-7
   Lutker KM, 2011, J PHARM SCI-US, V100, P949, DOI 10.1002/jps.22336
   Makary P., 2014, UK J PHARM BIOSCI, V2, P1, DOI [10.20510/ukjpb/2/i4/91101, DOI 10.20510/UKJPB/2/I4/91101, 10. 20510/ukjpb/2/i4/91101]
   McCrary PD, 2013, NEW J CHEM, V37, P2196, DOI 10.1039/c3nj00454f
   Megwa S.A., 2010, J PHARM PHARMACOL, V52, P919, DOI [10.1211/002235700177480411007062, DOI 10.1211/002235700177480411007062]
   Miwa Y, 2016, EUR J PHARM BIOPHARM, V102, P92, DOI 10.1016/j.ejpb.2016.03.003
   Morissette SL, 2003, P NATL ACAD SCI USA, V100, P2180, DOI 10.1073/pnas.0437744100
   Mrestani-Klaus C, 2012, CHEMPHYSCHEM, V13, P1836, DOI 10.1002/cphc.201100927
   Mwesigwa E, 2016, INT J PHARMACEUT, V497, P70, DOI 10.1016/j.ijpharm.2015.10.068
   Nagappa A. N., 2016, AM J ADV DRUG DELIV, V4, P78
   Nair AB, 2014, DRUG DELIV, V21, P540, DOI 10.3109/10717544.2013.853213
   Noonan TJ, 2016, CRYSTENGCOMM, V18, P8172, DOI 10.1039/c6ce01975g
   Odendaal R.W., 2012, THESIS
   Ostadjoo S, 2018, TOXICOL SCI, V161, P249, DOI 10.1093/toxsci/kfx172
   Paduszynski K, 2014, J CHEM INF MODEL, V54, P1311, DOI [10.1021/ci500206u, 10.1021/ci500706u]
   Pannu J., RUNNING AHEAD PANDEM
   Paulekuhn GS, 2007, J MED CHEM, V50, P6665, DOI 10.1021/jm701032y
   Peplow M., 2005, WARNING SHOT GREEN C, DOI [10.1038/news051031-8, DOI 10.1038/NEWS051031-8]
   Pernak J, 2007, CHEM-EUR J, V13, P3106, DOI 10.1002/chem.200601243
   PITHA J, 1988, LIFE SCI, V43, P493, DOI 10.1016/0024-3205(88)90150-6
   Pouton CW, 2006, EUR J PHARM SCI, V29, P278, DOI 10.1016/j.ejps.2006.04.016
   Prohotsky DL, 2012, J PHARM SCI-US, V101, P1, DOI 10.1002/jps.22735
   Raza K, 2014, SOJ PHARM PHARM SCI, V1, P10, DOI DOI 10.15226/2374-6866/1/2/00111
   Riebesehl B.U., 2015, PRACTICE MED CHEM, P699, DOI DOI 10.1016/B978-0-12-417205-0.00029-8
   Riisager A, 2011, Patent WO, Patent No. 2011110662A1
   Rogers R, 2009, U.S. Patent, Patent No. [9,278,134, 9278134]
   Roque-Flores RL, 2017, ACTA CRYSTALLOGR C, V73, P1116, DOI 10.1107/S2053229617016059
   Sarbajna RM, 2011, MOL CRYST LIQ CRYST, V537, P141, DOI 10.1080/15421406.2011.556472
   Schade D, 2015, J PHARM SCI-US, V104, P3208, DOI 10.1002/jps.24508
   Schuster D, 2005, CURR PHARM DESIGN, V11, P3545, DOI 10.2174/138161205774414510
   Shadid M, 2015, MEDCHEMCOMM, V6, P1837, DOI 10.1039/c5md00290g
   Shamshina J.L., 2018, GREEN TECHNIQUES ORG, P541, DOI 10.1002/9781119288152.ch20
   Shamshina JL, 2017, ACS OMEGA, V2, P3483, DOI 10.1021/acsomega.7b00554
   Shamshina JL, 2015, NATURE, V528, P188, DOI 10.1038/528188a
   Shamshina JL, 2013, EXPERT OPIN DRUG DEL, V10, P1367, DOI 10.1517/17425247.2013.808185
   Smith DJ, 2015, MOL PHARMACEUT, V12, P1893, DOI 10.1021/mp5005993
   Sopyan I., 2019, INT J RES PHARM SCI, V10, P3013, DOI [10.26452/ijrps.v10i4.1589, DOI 10.26452/IJRPS.V10I4.1589]
   Stoimenovski J, 2011, CHEM COMMUN, V47, P11429, DOI 10.1039/c1cc14314j
   Stoimenovski J, 2010, PHARM RES-DORDR, V27, P521, DOI 10.1007/s11095-009-0030-0
   Suitthimeathegorn O, 2005, INT J PHARMACEUT, V298, P367, DOI 10.1016/j.ijpharm.2005.03.028
   Szilagyi I, 2014, PHYS CHEM CHEM PHYS, V16, P9515, DOI 10.1039/c4cp00804a
   Thi PTP, 2010, WATER RES, V44, P352, DOI 10.1016/j.watres.2009.09.030
   Tuffin J, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201900698
   Von Raumer M, 2006, CHIM OGGI, V24, P41
   Wang H, 2014, CHEM SCI, V5, P3449, DOI 10.1039/c4sc01036a
   Welton T, 1999, CHEM REV, V99, P2071, DOI 10.1021/cr980032t
   Wiedemann C, 2019, RSC ADV, V9, P35735, DOI 10.1039/c9ra07731f
   Wojnarowska Z, 2009, J CHEM PHYS, V131, DOI 10.1063/1.3223540
   Yoshizawa M, 2003, J AM CHEM SOC, V125, P15411, DOI 10.1021/ja035783d
NR 99
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2020
VL 21
IS 17
AR 6002
DI 10.3390/ijms21176002
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA NP7LF
UT WOS:000570353800001
PM 32825444
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Copaescu, A
   Smibert, O
   Gibson, A
   Phillips, EJ
   Trubiano, JA
AF Copaescu, Ana
   Smibert, Olivia
   Gibson, Andrew
   Phillips, Elizabeth J.
   Trubiano, Jason A.
TI The role of IL-6 and other mediators in the cytokine storm associated
   with SARS-CoV-2 infection
SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
LA English
DT Article
DE IL-6; sepsis; cytokine storm; cytokines; COVID-19; SARS-CoV-2;
   TNF-alpha; JAK; STING; proinflammatory; hyperinflammatory;
   hemophagocytic lymphohistiocytosis
ID MACROPHAGE ACTIVATION SYNDROME; CRITICALLY ILL PATIENTS; CONVALESCENT
   PLASMA; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; PROGNOSTIC MARKER;
   DIAGNOSTIC MARKER; ORGAN FAILURE; SEVERE SEPSIS; SARS-COV; INTERLEUKIN-6
AB The coronavirus disease 2019 pandemic caused by severe acute respiratory syndrome coronavirus 2 presents with a spectrum of clinical manifestations from asymptomatic or mild, self-limited constitutional symptoms to a hyperinflammatory state ("cytokine storm") followed by acute respiratory distress syndrome and death. The objective of this study was to provide an evidence-based review of the associated pathways and potential treatment of the hyperinflammatory state associated with severe acute respiratory syndrome coronavirus 2 infection. Dysregulated immune responses have been reported to occur in a smaller subset of those infected with severe acute respiratory syndrome coronavirus 2, leading to clinical deterioration 7 to 10 days after initial presentation. A hyperinflammatory state referred to as cytokine storm in its severest form has been marked by elevation of IL-6, IL-10, TNF-alpha, and other cytokines and severe CD4(+) and CD8(+) T-cell lymphopenia and coagulopathy. Recognition of at-risk patients could permit early institution of aggressive intensive care and antiviral and immune treatment to reduce the complications related to this proinflammatory state. Several reports and ongoing clinical trials provide hope that available immunomodulatory therapies could have therapeutic potential in these severe cases. This review highlights our current state of knowledge of immune mechanisms and targeted immunomodulatory treatment options for the current coronavirus disease 2019 pandemic.
C1 [Copaescu, Ana; Smibert, Olivia; Trubiano, Jason A.] Austin Hlth, Ctr Antibiot Allergy & Res, Dept Infect Dis, Heidelberg, Vic, Australia.
   [Gibson, Andrew; Phillips, Elizabeth J.] Murdoch Univ, Inst Immunol & Infect Dis, Murdoch, WA, Australia.
   [Phillips, Elizabeth J.] Vanderbilt Univ, Med Ctr, Dept Infect Dis, Nashville, TN USA.
   [Trubiano, Jason A.] Univ Melbourne, Dept Oncol, Sir Peter MacCallum Canc Ctr, Parkville, Vic, Australia.
   [Trubiano, Jason A.] Univ Melbourne, Austin Hlth, Dept Med, Heidelberg, Vic, Australia.
   [Trubiano, Jason A.] Peter MacCallum Canc Ctr, Natl Ctr Infect Canc, Parkville, Vic, Australia.
RP Copaescu, A (corresponding author), Austin Hlth, Ctr Antibiot Allergy & Res, Dept Infect Dis, Heidelberg, Vic, Australia.
EM ana.copaescu@gmail.com
OI Copaescu, Ana-Maria/0000-0002-9183-5032
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [1P50GM115305,
   R21AI139021, 1 R01 HG010863, 1R01AI152183]
FX E.J.P. receives support from National Institutes of Health grants
   1P50GM115305, R21AI139021, 1 R01 HG010863, and 1R01AI152183.
CR Acharya D, 2020, NAT REV IMMUNOL, V20, P397, DOI 10.1038/s41577-020-0346-x
   Adam N, 2009, J VIROL, V83, P5117, DOI 10.1128/JVI.01601-08
   Azhar EI, 2019, INFECT DIS CLIN N AM, V33, P891, DOI 10.1016/j.idc.2019.08.001
   Behrens EM, 2017, ARTHRITIS RHEUMATOL, V69, P1135, DOI 10.1002/art.40071
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Beutel G, 2011, CRIT CARE, V15, DOI 10.1186/cc10073
   Billeter A, 2009, WORLD J SURG, V33, P558, DOI 10.1007/s00268-008-9896-y
   Bloch EM, 2020, J CLIN INVEST, V130, P2757, DOI 10.1172/JCI138745
   Campbell CM, 2020, CIRCULATION, V141, P1739, DOI 10.1161/CIRCULATIONAHA.120.047419
   Cao Y, 2020, J ALLERGY CLIN IMMUN, V146, P137, DOI 10.1016/j.jaci.2020.05.019
   Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2
   Chalmers Sarah, 2019, World J Crit Care Med, V8, P59, DOI 10.5492/wjccm.v8.i5.59
   Channappanavar R, 2017, SEMIN IMMUNOPATHOL, V39, P529, DOI 10.1007/s00281-017-0629-x
   Chen G, 2020, J CLIN INVEST, DOI [10.1172/JCI137244, DOI 10.1172/JCI137244]
   Chen L, 2020, LANCET INFECT DIS, V20, P398, DOI 10.1016/S1473-3099(20)30141-9
   Chen X, 2020, DETECTABLE SERUM SAR, DOI [10.1101/2020.02.29.2002952., DOI 10.1101/2020.02.29.2002952]
   Cheng Y, 2005, EUR J CLIN MICROBIOL, V24, P44, DOI 10.1007/s10096-004-1271-9
   Choi WS, 2016, INFECT CHEMOTHER, V48, P118, DOI 10.3947/ic.2016.48.2.118
   Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8
   Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410
   Cohen SB, 2004, RHEUM DIS CLIN N AM, V30, P365, DOI 10.1016/j.rdc.2004.01.005
   de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477
   Diao B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00827
   Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417
   Faix JD, 2013, CRIT REV CL LAB SCI, V50, P23, DOI 10.3109/10408363.2013.764490
   Fala Loretta, 2016, Am Health Drug Benefits, V9, P60
   Filipovich A, 2010, BIOL BLOOD MARROW TR, V16, pS82, DOI [10.1016/j.bbmt.2009.11.014, 10.1016/j.bbmt.2010.05.002]
   Fraietta JA, 2018, NAT MED, V24, P563, DOI 10.1038/s41591-018-0010-1
   Gao Y, 2020, J MED VIROL, V92, P791, DOI 10.1002/jmv.25770
   Gouel-Cheron A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033095
   Gralinski LE, 2018, MBIO, V9, DOI 10.1128/mBio.01753-18
   Gudbjartsson DF, 2020, NEW ENGL J MED, V382, P2302, DOI 10.1056/NEJMoa2006100
   Haga S, 2008, P NATL ACAD SCI USA, V105, P7809, DOI 10.1073/pnas.0711241105
   Harbarth S, 2001, AM J RESP CRIT CARE, V164, P396, DOI 10.1164/ajrccm.164.3.2009052
   Herold T, 2020, LEVEL IL 6 PREDICTS, V2020, DOI [10.1101/2020.04.01.20047381, DOI 10.1101/2020.04.01.20047381, 10.1101/2020.04.01.20047381,04.01.20047381.]
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang KJ, 2005, J MED VIROL, V75, P185, DOI 10.1002/jmv.20255
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Jekarl DW, 2013, DIAGN MICR INFEC DIS, V75, P342, DOI 10.1016/j.diagmicrobio.2012.12.011
   Jones AE, 2009, CRIT CARE MED, V37, P1649, DOI 10.1097/CCM.0b013e31819def97
   Jones Veena G, 2020, Hosp Pediatr, V10, P537, DOI 10.1542/hpeds.2020-0123
   Kellum JA, 2007, ARCH INTERN MED, V167, P1655, DOI 10.1001/archinte.167.15.1655
   Klaver Y, 2016, CLIN IMMUNOL, V169, P107, DOI 10.1016/j.clim.2016.06.014
   Kumar B, 2017, J CLIN IMMUNOL, V37, P638, DOI 10.1007/s10875-017-0439-x
   Le RQ, 2018, ONCOLOGIST, V23, P943, DOI 10.1634/theoncologist.2018-0028
   Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729
   Leon MPD, 2020, J PEDIAT INF DIS SOC, V9, P407, DOI 10.1093/jpids/piaa061
   Li L, 2020, JAMA-J AM MED ASSOC, V324, P460, DOI 10.1001/jama.2020.10044
   Li XC, 2020, J ALLERGY CLIN IMMUN, V146, P110, DOI [10.1016/j.jaci.2020.04.006, 10.1002/jmv.25731]
   Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625
   Ma L, 2016, CYTOKINE, V88, P126, DOI 10.1016/j.cyto.2016.08.033
   Maier B, 2007, SHOCK, V28, P668, DOI 10.1097/shk.0b013e318123e64e
   Mat-Nor MB, 2016, J CRIT CARE, V33, P245, DOI 10.1016/j.jcrc.2016.01.002
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Merad M, 2020, NAT REV IMMUNOL, V20, P355, DOI 10.1038/s41577-020-0331-4
   Miettunen PM, 2011, RHEUMATOLOGY, V50, P417, DOI 10.1093/rheumatology/keq218
   Miossec P, 2009, NEW ENGL J MED, V361, P888, DOI 10.1056/NEJMra0707449
   Mors K, 2016, IMMUNOBIOLOGY, V221, P904, DOI 10.1016/j.imbio.2016.03.005
   NIH, 2020, NAT I HLTH COVID 19
   Nishimoto N, 2008, BLOOD, V112, P3959, DOI 10.1182/blood-2008-05-155846
   OBrien TR, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa453., DOI 10.1093/CID/CIAA453.]
   Ogata A, 2019, MOD RHEUMATOL, V29, P258, DOI [10.1080/14397595.2018.1533514, 10.1080/14397595.2018.1546357]
   Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647
   Pei JW, 2019, CANCER LETT, V450, P110, DOI 10.1016/j.canlet.2019.02.029
   Petrosillo N, 2020, CLIN MICROBIOL INFEC, V26, P729, DOI 10.1016/j.cmi.2020.03.026
   Pettila V, 2002, INTENS CARE MED, V28, P1220, DOI 10.1007/s00134-002-1416-1
   Price CC, 2020, CHEST, V158, P1397, DOI 10.1016/j.chest.2020.06.006
   Rajendran K, 2020, J MED VIROL, V92, P1475, DOI 10.1002/jmv.25961
   Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]
   Risitano AM, 2020, NAT REV IMMUNOL, DOI 10.1038/s41577-020-0320-7
   Rojas M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102554
   Roumier M, 2020, INTERLEUKIN 6 BLOCKA
   Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x
   Saad M, 2014, INT J INFECT DIS, V29, P301, DOI 10.1016/j.ijid.2014.09.003
   Scheller J, 2006, SCAND J IMMUNOL, V63, P321, DOI 10.1111/j.1365-3083.2006.01750.x
   Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034
   Schulert GS, 2016, J INFECT DIS, V213, P1180, DOI 10.1093/infdis/jiv550
   Schulert GS, 2015, ANNU REV MED, V66, P145, DOI 10.1146/annurev-med-061813-012806
   Schulert GS, 2014, BEST PRACT RES CL RH, V28, P277, DOI 10.1016/j.berh.2014.03.002
   Schumacher N, 2019, CANCERS, V11, DOI 10.3390/cancers11111736
   Shakoory B, 2016, CRIT CARE MED, V44, P275, DOI 10.1097/CCM.0000000000001402
   Shen CG, 2020, JAMA-J AM MED ASSOC, V323, P1582, DOI 10.1001/jama.2020.4783
   Song J, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4618-7
   Soo YOY, 2004, CLIN MICROBIOL INFEC, V10, P676, DOI 10.1111/j.1469-0691.2004.00956.x
   Spencer S, 2019, J EXP MED, V216, P1986, DOI 10.1084/jem.20190344
   Stensballe J, 2009, ACTA ANAESTH SCAND, V53, P515, DOI 10.1111/j.1399-6576.2008.01801.x
   Takahashi W, 2016, SHOCK, V46, P254, DOI 10.1097/SHK.0000000000000616
   Tanaka T, 2014, CANCER IMMUNOL RES, V2, P288, DOI 10.1158/2326-6066.CIR-14-0022
   Tisoncik JR, 2012, MICROBIOL MOL BIOL R, V76, P16, DOI 10.1128/MMBR.05015-11
   Uciechowski P, 2020, ONCOLOGY-BASEL, V98, P131, DOI 10.1159/000505099
   Uusitalo-Seppala R, 2011, SCAND J INFECT DIS, V43, P883, DOI 10.3109/00365548.2011.600325
   Wan S, 2020, CHARACTERISTICS LYMP, DOI [10.1101/2020.02.10.20021832, DOI 10.1101/2020.02.10.20021832.]
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Wang Z, 2020, CLIN INFECT DIS, DOI [10.1093/cid/ciaa272, DOI 10.1093/CID/CIAA272.]
   Weber ANR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01454
   Wen W, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0168-9
   Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Wu HP, 2009, INFLAMM RES, V58, P385, DOI 10.1007/s00011-009-0003-0
   Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang D, 2020, COVID 19 INFECT INDU, DOI [10.1101/2020.03.24.20042655., DOI 10.1101/2020.03.24.20042655.]
   Zhang W, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108393
   Zhang X, 2007, VIROLOGY, V365, P324, DOI 10.1016/j.virol.2007.04.009
   Zhang YC, 2004, INFECT IMMUN, V72, P4410, DOI 10.1128/IAI.72.8.4410-4415.2004
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041
NR 109
TC 1
Z9 1
U1 1
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0091-6749
EI 1097-6825
J9 J ALLERGY CLIN IMMUN
JI J. Allergy Clin. Immunol.
PD SEP
PY 2020
VL 146
IS 3
BP 518
EP +
DI 10.1016/j.jaci.2020.07.001
PG 18
WC Allergy; Immunology
SC Allergy; Immunology
GA NO0HS
UT WOS:000569168900014
PM 32896310
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Braithwaite, R
   McKeown, HL
   Lawrence, VJ
   Cramer, O
AF Braithwaite, Richard
   McKeown, Hollie L.
   Lawrence, Victor J.
   Cramer, Oliver
TI Successful Electroconvulsive Therapy in a Patient With Confirmed,
   Symptomatic COVID-19
SO JOURNAL OF ECT
LA English
DT Letter
C1 [Braithwaite, Richard] St Marys Hosp, Dept Psychiat, Isle Wight NHS Trust, Isle Of Wight, England.
   [McKeown, Hollie L.; Lawrence, Victor J.] St Marys Hosp, Dept Gen Med, Isle Wight NHS Trust, Isle Of Wight, England.
   [Cramer, Oliver] St Marys Hosp, Dept Anaesthesia, Isle Wight NHS Trust, Isle Of Wight, England.
RP Braithwaite, R (corresponding author), St Marys Hosp, Dept Psychiat, Isle Wight NHS Trust, Isle Of Wight, England.
EM richard.braithwaite@nhs.net
CR Coccolini F, 2020, WORLD J EMERG SURG, V15, DOI 10.1186/s13017-020-00307-2
   Flexman AM, 2020, J NEUROSURG ANESTH, V32, P202, DOI 10.1097/ANA.0000000000000691
   Sienaert P, 2020, AM J GERIATR PSYCHIA
   Tenenbein M, 2020, COVID 19 GUIDELINES
   Tor PC, 2020, J ECT, V36, P80, DOI 10.1097/YCT.0000000000000690
NR 5
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1095-0680
EI 1533-4112
J9 J ECT
JI J. ECT
PD SEP
PY 2020
VL 36
IS 3
BP 222
EP 223
DI 10.1097/YCT.0000000000000706
PG 2
WC Behavioral Sciences; Psychiatry
SC Behavioral Sciences; Psychiatry
GA NO7JA
UT WOS:000569663000020
PM 32453191
OA Green Published
DA 2021-01-01
ER

PT J
AU Boland, X
   Dratcu, L
AF Boland, Xavier
   Dratcu, Luiz
TI Electroconvulsive Therapy and COVID-19 in Acute Inpatient Psychiatry
   More Than Clinical Issues Alone
SO JOURNAL OF ECT
LA English
DT Letter
C1 [Boland, Xavier; Dratcu, Luiz] Maudsley Hosp & Inst Psychiat, South London, England.
   [Boland, Xavier; Dratcu, Luiz] Maudsley NHS Trust, Denmark Hill, London, England.
RP Boland, X (corresponding author), Maudsley Hosp & Inst Psychiat, South London, England.; Boland, X (corresponding author), Maudsley NHS Trust, Denmark Hill, London, England.
EM XBoland@slam.nhs.uk
CR Espinoza RT, 2020, J ECT, V36, P78, DOI 10.1097/YCT.0000000000000689
   Kellner CH, 2012, AM J PSYCHIAT, V169, P1238, DOI 10.1176/appi.ajp.2012.12050648
   Sienaert P, 2020, AM J GERIATR PSYCHIA
   Tor PC, 2020, J ECT, V36, P80, DOI 10.1097/YCT.0000000000000690
NR 4
TC 2
Z9 2
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1095-0680
EI 1533-4112
J9 J ECT
JI J. ECT
PD SEP
PY 2020
VL 36
IS 3
BP 223
EP 224
DI 10.1097/YCT.0000000000000708
PG 2
WC Behavioral Sciences; Psychiatry
SC Behavioral Sciences; Psychiatry
GA NO7JA
UT WOS:000569663000021
PM 32826545
OA Green Published
DA 2021-01-01
ER

PT J
AU Abu Sufian
   Ghosh, A
   Sadiq, AS
   Smarandache, F
AF Abu Sufian
   Ghosh, Anirudha
   Sadiq, Ali Safaa
   Smarandache, Florentin
TI A Survey on Deep Transfer Learning to Edge Computing for Mitigating the
   COVID-19 Pandemic
SO JOURNAL OF SYSTEMS ARCHITECTURE
LA English
DT Article
DE AI for Good; COVID-19; Deep Learning; Edge Computing; Pandemic; Review;
   Transfer Learning
ID CONVOLUTIONAL NEURAL-NETWORKS; ARTIFICIAL-INTELLIGENCE; INFLUENZA
   PANDEMICS; INTERNET; SYSTEMS; THINGS; IOT
AB Global Health sometimes faces pandemics as are currently facing COVID-19 disease. The spreading and infection factors of this disease are very high. A huge number of people from most of the countries are infected within six months from its first report of appearance and it keeps spreading. The required systems are not ready up to some stages for any pandemic; therefore, mitigation with existing capacity becomes necessary. On the other hand, modern-era largely depends on Artificial Intelligence(AI) including Data Science; and Deep Learning(DL) is one of the current flag-bearer of these techniques. It could use to mitigate COVID-19 like pandemics in terms of stop spread, diagnosis of the disease, drug & vaccine discovery, treatment, patient care, and many more. But this DL requires large datasets as well as powerful computing resources. A shortage of reliable datasets of a running pandemic is a common phenomenon. So, Deep Transfer Learning(DTL) would be effective as it learns from one task and could work on another task. In addition, Edge Devices(ED) such as IoT, Webcam, Drone, Intelligent Medical Equipment, Robot, etc. are very useful in a pandemic situation. These types of equipment make the infrastructures sophisticated and automated which helps to cope with an outbreak. But these are equipped with low computing resources, so, applying DL is also a bit challenging; therefore, DTL also would be effective there. This article scholarly studies the potentiality and challenges of these issues. It has described relevant technical backgrounds and reviews of the related recent state-of-the-art. This article also draws a pipeline of DTL over Edge Computing as a future scope to assist the mitigation of any pandemic.
C1 [Abu Sufian; Ghosh, Anirudha] Univ Gour Banga, Dept Comp Sci, Malda, India.
   [Sadiq, Ali Safaa] Univ Wolverhampton, Sch Math & Comp Sci, Wolverhampton Cyber Res Inst, Wolverhampton, England.
   [Sadiq, Ali Safaa] Torrens Univ, Ctr Artificial Intelligence Res & Optimizat, Brisbane, Qld, Australia.
   [Smarandache, Florentin] Univ New Mexico, Math Dept, Albuquerque, NM 87131 USA.
RP Abu Sufian (corresponding author), Univ Gour Banga, Dept Comp Sci, Malda, India.
EM sufian.csa@gmail.com
OI Sufian, Abu/0000-0003-2035-2938
CR Abdellatif A.A., 2020, ENERGY EFFICIENCY ME, P53
   Al-Zinati M, 2019, SIMUL MODEL PRACT TH, V93, P65, DOI 10.1016/j.simpat.2018.10.013
   Alamo T, 2020, ARXIV200406111
   Altman RB, 2017, CLIN PHARMACOL THER, V101, P585, DOI 10.1002/cpt.650
   Apostolopoulos I.D., 2020, PHYS ENG SCI MED, P1
   Ayyoubzadeh SM, 2020, JMIR PUBLIC HLTH SUR, V6, P192, DOI 10.2196/18828
   Baldini I., 2017, RES ADV CLOUD COMPUT, P1, DOI DOI 10.1007/978-981-10-5026-8_1
   Basu S, 2020, ARXIV200410507
   Beck BR, 2020, COMPUT STRUCT BIOTEC
   Chae S, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15081596
   Chen E, 2020, ARXIV200307372
   Chen JS, 2019, P IEEE, V107, P1655, DOI 10.1109/JPROC.2019.2921977
   Chen M, 2018, FUTURE GENER COMP SY, V86, P403, DOI 10.1016/j.future.2018.03.054
   Chen Q., 2020, IEEE T PARALL DISTR, V31, P1357
   Chen Q, 2019, INT CON DISTR COMP S, P1040, DOI 10.1109/ICDCS.2019.00107
   Chen Y., 2019, ARXIV190709173
   Cohen J. P., 2020, ARXIV200511856
   Cohen JP, 2020, ARXIV200311597
   Daga H., 2019, P ACM S CLOUD COMP, P25
   Das D, 2020, PHYS ENG SCI MED, V43, P915, DOI 10.1007/s13246-020-00888-x
   Daszak P., 2020, STRATEGY PREVENT FUT
   Deng J, 2009, PROC CVPR IEEE, P248, DOI 10.1109/CVPRW.2009.5206848
   Ding W, 2019, J SYST ARCHITECT, V97, P278, DOI 10.1016/j.sysarc.2018.12.008
   Escamilla-Ambrosio P. J., 2018, NEO 2016, P87
   Fanelli D, 2020, CHAOS SOLITON FRACT, V134, DOI 10.1016/j.chaos.2020.109761
   Fauci A.S., 2020, COVID 19 NAVIGATING
   Fong SJ, 2020, APPL SOFT COMPUT, V93, DOI 10.1016/j.asoc.2020.106282
   Gao YQ, 2018, COMPUT-AIDED CIV INF, V33, P748, DOI 10.1111/mice.12363
   Garcia-Valls M, 2018, J SYST ARCHITECT, V91, P83, DOI 10.1016/j.sysarc.2018.05.007
   Ghosh A., 2020, RECENT TRENDS ADV AR, P519, DOI DOI 10.1007/978-3-030-32644-9_36
   Goodfellow I., 2016, DEEP LEARNING
   Goodfellow IJ, 2014, ADV NEUR IN, V27, P2672
   Gozes O., 2020, ARXIV200305037
   Grubaugh ND, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0690-4
   Han T, 2020, ISA T, V97, P269, DOI 10.1016/j.isatra.2019.08.012
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Hegde C., 2020, AUTOTRIAGEAN OPEN SO
   Hinton G, 2018, JAMA-J AM MED ASSOC, V320, P1101, DOI 10.1001/jama.2018.11100
   Hou TT, 2018, INT J COMMUN SYST, V31, DOI 10.1002/dac.3706
   Hsieh YC, 2006, J FORMOS MED ASSOC, V105, P1, DOI 10.1016/S0929-6646(09)60102-9
   Hu S., 2020, ARXIV200406689
   Huang G, 2017, PROC CVPR IEEE, P2261, DOI 10.1109/CVPR.2017.243
   Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372
   Khalifa N.E.M., 2020, SYMMETRY
   Khalifa NEM, 2020, ARXIV200401184
   Khan WZ, 2019, FUTURE GENER COMP SY, V97, P219, DOI 10.1016/j.future.2019.02.050
   Kilbourne ED, 2006, EMERG INFECT DIS, V12, P9, DOI 10.3201/eid1201.051254
   Killeen B. D., 2020, ARXIV200400756
   Koitka S., 2016, P WORKSH CLEF2016 WO, V1609, P304
   Krizhevsky A, 2017, COMMUN ACM, V60, P84, DOI 10.1145/3065386
   Ksentini A, 2020, IEEE NETWORK, V34, P99, DOI 10.1109/MNET.001.1900261
   Kucharski AJ, 2020, LANCET INFECT DIS
   Kumar A, 2017, IEEE J BIOMED HEALTH, V21, P31, DOI 10.1109/JBHI.2016.2635663
   LeCun Y, 1995, HDB BRAIN THEORY NEU, V3361, P1995, DOI DOI 10.1007/S13398-014-0173-7.2
   Lecun Y, 2019, ISSCC DIG TECH PAP I, V62, P12, DOI 10.1109/ISSCC.2019.8662396
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Li GS, 2020, EURASIP J WIREL COMM, V2020, DOI 10.1186/s13638-019-1624-9
   Li H, 2018, IEEE NETWORK, V32, P96, DOI 10.1109/MNET.2018.1700202
   Li L., 2020, RADIOLOGY, DOI [10.1148/radiol.2020200905 ., DOI 10.1148/RADI0L.2020200905]
   Li X.-H., 2020, IEEE T KNOW DATA ENG
   Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005
   Loey M, 2020, SYMMETRY-BASEL, V12, DOI 10.3390/sym12040651
   Long M., 2017, P 34 INT C MACH LEAR, V70, P2208
   Lopez-Rincon A., 2020, BIORXIV
   Luz E, 2020, ARXIV200405717
   Mandic D.P., 2001, ADAPT LEARN SYST SIG
   Minaee S., 2020, ARXIV200409363
   Mittal S, 2019, J SYST ARCHITECT, V99, DOI 10.1016/j.sysarc.2019.101635
   Mittal S, 2019, J SYST ARCHITECT, V97, P428, DOI 10.1016/j.sysarc.2019.01.011
   Mohammadi M, 2018, IEEE COMMUN SURV TUT, V20, P2923, DOI 10.1109/COMST.2018.2844341
   Mukherjee Himadri, 2020, SHALLOW CONVOLUTIONA
   Murray CJL, 2006, LANCET, V368, P2211, DOI 10.1016/S0140-6736(06)69895-4
   Nanni L, 2017, PATTERN RECOGN, V71, P158, DOI 10.1016/j.patcog.2017.05.025
   Narin A, 2020, ARXIV200310849
   Nishiura H, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-111
   Pace P, 2019, IEEE T IND INFORM, V15, P481, DOI 10.1109/TII.2018.2843169
   Pan SJ, 2010, IEEE T KNOWL DATA EN, V22, P1345, DOI 10.1109/TKDE.2009.191
   Phan Trung V., 2020, 2020 International Conference on Artificial Intelligence in Information and Communication (ICAIIC), P146, DOI 10.1109/ICAIIC48513.2020.9065240
   Premsankar G, 2018, IEEE INTERNET THINGS, V5, P1275, DOI 10.1109/JIOT.2018.2805263
   Preuveneers D, 2020, SENSORS-BASEL, V20, DOI 10.3390/s20041176
   Redmon J., 2018, ARXIV180402767
   Roman R, 2018, FUTURE GENER COMP SY, V78, P680, DOI 10.1016/j.future.2016.11.009
   Rothan HA, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102433
   Rumelhart D.E., 1985, TECHNICAL REPORT
   Sak H., 2014, LONG SHORT TERM MEMO
   Santosh T.S., 2020, REV SALIVARY DIAGNOS, V12
   Satyanarayanan M, 2017, COMPUTER, V50, P30, DOI 10.1109/MC.2017.9
   Sharma R, 2018, 2018 IEEE INTERNATIONAL CONFERENCE ON EDGE COMPUTING (IEEE EDGE), P42, DOI 10.1109/EDGE.2018.00013
   She C., 2020, ARXIV200211045
   Shen Z, 2020, CLIN INFECT DIS
   Shi F., 2020, ARXIV200402731
   Shi WS, 2016, IEEE INTERNET THINGS, V3, P637, DOI 10.1109/JIOT.2016.2579198
   Simonyan K., 2014, 14091556 ARXIV, DOI DOI 10.1109/CVPR.2015.7298594
   Sodhro AH, 2019, INT J INFORM MANAGE, V45, P308, DOI 10.1016/j.ijinfomgt.2018.08.004
   Sohrabi C., 2020, INT J SURG
   Subirana B., 2020, ARXIV200406510
   Sultana F, 2018, 2018 FOURTH IEEE INTERNATIONAL CONFERENCE ON RESEARCH IN COMPUTATIONAL INTELLIGENCE AND COMMUNICATION NETWORKS (ICRCICN), P122, DOI 10.1109/ICRCICN.2018.8718718
   Sun W, 2019, IEEE NETWORK, V33, P68, DOI 10.1109/MNET.001.1800510
   Sun X, 2016, IEEE COMMUN MAG, V54, P22, DOI 10.1109/MCOM.2016.1600492CM
   Szegedy C, 2015, PROC CVPR IEEE, P1, DOI 10.1109/CVPR.2015.7298594
   Talo M, 2019, COGN SYST RES, V54, P176, DOI 10.1016/j.cogsys.2018.12.007
   Tan CQ, 2018, LECT NOTES COMPUT SC, V11141, P270, DOI 10.1007/978-3-030-01424-7_27
   Ting DS, 2020, DIGITAL TECHNOLOGY C, P1
   Tobore I, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/11966
   Ucar F, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109761
   Vaishya R, 2020, DIABETES METAB SYND, V14, P337, DOI 10.1016/j.dsx.2020.04.012
   Valerio L, 2016, 2016 IEEE 2ND INTERNATIONAL FORUM ON RESEARCH AND TECHNOLOGIES FOR SOCIETY AND INDUSTRY LEVERAGING A BETTER TOMORROW (RTSI), P467
   W.H. Organization, 2020, COR DIS 2019 COV 19, V74
   W.H. Organization, 2020, TECHNICAL REPORT
   Wan SH, 2020, COMPUT COMMUN, V149, P99, DOI 10.1016/j.comcom.2019.10.012
   Wang F, 2018, IEEE T WIREL COMMUN, V17, P1784, DOI 10.1109/TWC.2017.2785305
   Wang JJ, 2018, 2018 THIRD IEEE/ACM SYMPOSIUM ON EDGE COMPUTING (SEC), P159, DOI 10.1109/SEC.2018.00019
   Wang L. D., 2020, ARXIV200309871
   Wang S., 2020, DEEP LEARNING ALGORI, DOI 10.1101/2020.02.14.20023028
   Wang SG, 2019, J PARALLEL DISTR COM, V127, P160, DOI 10.1016/j.jpdc.2018.06.008
   Wang X., 2020, IEEE COMMUN SURV TUT
   White G, 2020, IEEE ACCESS, V8, P7518, DOI 10.1109/ACCESS.2020.2963912
   Wilson A.C., 2017, P ADV NEUR INF PROC, P4148
   Wu RT, 2019, COMPUT-AIDED CIV INF, V34, P774, DOI 10.1111/mice.12449
   Xu B, 2020, SCI DATA, V7, DOI 10.1038/s41597-020-0448-0
   Xu X, 2020, AM J NEPHROL, V51, P453, DOI 10.1159/000506664
   Yang J., 2020, IEEE INTERNET THINGS
   Yao X, 1999, P IEEE, V87, P1423, DOI 10.1109/5.784219
   Yi S., 2015, P 2015 WORKSH MOB BI, P37, DOI DOI 10.1145/2757384.2757397
   Yousefpour A, 2019, J SYST ARCHITECT, V98, P289, DOI 10.1016/j.sysarc.2019.02.009
   Zamir AR, 2018, PROC CVPR IEEE, P3712, DOI 10.1109/CVPR.2018.00391
   Zeiler MD, 2014, LECT NOTES COMPUT SC, V8689, P818, DOI 10.1007/978-3-319-10590-1_53
   Zhang F, 2018, IEEE INTERNET THINGS, V5, P4262, DOI 10.1109/JIOT.2018.2845412
   Zhang HB, 2018, IEEE INTERNET THINGS, V5, P1550, DOI 10.1109/JIOT.2018.2792423
   Zhang XZ, 2019, INT CON DISTR COMP S, P1840, DOI 10.1109/ICDCS.2019.00182
   Zhao J., 2020, ARXIV200313865
   Zhou M., 2020, IMPROVED DEEP LEARNI
   Zhu HL, 2020, SENSOR ACTUAT B-CHEM, V303, DOI 10.1016/j.snb.2019.127098
NR 133
TC 0
Z9 0
U1 10
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1383-7621
EI 1873-6165
J9 J SYST ARCHITECT
JI J. Syst. Architect.
PD SEP
PY 2020
VL 108
AR 101830
DI 10.1016/j.sysarc.2020.101830
PG 11
WC Computer Science, Hardware & Architecture; Computer Science, Software
   Engineering
SC Computer Science
GA NO2QF
UT WOS:000569328400011
DA 2021-01-01
ER

PT J
AU de Lusignan, S
   Dorward, J
   Correa, A
   Jones, N
   Akinyemi, O
   Amirthalingam, G
   Andrews, N
   Byford, R
   Dabrera, G
   Elliot, A
   Ellis, J
   Ferreira, F
   Bernal, JL
   Okusi, C
   Ramsay, M
   Sherlock, J
   Smith, G
   Williams, J
   Howsam, G
   Zambon, M
   Joy, M
   Hobbs, FDR
AF de Lusignan, Simon
   Dorward, Jienchi
   Correa, Ana
   Jones, Nicholas
   Akinyemi, Oluwafunmi
   Amirthalingam, Gayatri
   Andrews, Nick
   Byford, Rachel
   Dabrera, Gavin
   Elliot, Alex
   Ellis, Joanna
   Ferreira, Filipa
   Bernal, Jamie Lopez
   Okusi, Cecilia
   Ramsay, Mary
   Sherlock, Julian
   Smith, Gillian
   Williams, John
   Howsam, Gary
   Zambon, Maria
   Joy, Mark
   Hobbs, F. D. Richard
TI Risk factors for SARS-CoV-2 among patients in the Oxford Royal College
   of General Practitioners Research and Surveillance Centre primary care
   network: a cross-sectional study
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID INFLUENZA VACCINE EFFECTIVENESS; INFECTIONS; COVID-19; ADULTS
AB Background There are few primary care studies of the COVID-19 pandemic. We aimed to identify demographic and clinical risk factors for testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within the Oxford Royal College of General Practitioners (RCGP) Research and Surveillance Centre primary care network.
   Methods We analysed routinely collected, pseudonymised data for patients in the RCGP Research and Surveillance Centre primary care sentinel network who were tested for SARS-CoV-2 between Jan 28 and April 4, 2020. We used multivariable logistic regression models with multiple imputation to identify risk factors for positive SARS-CoV-2 tests within this surveillance network.
   Findings We identified 3802 SARS-CoV-2 test results, of which 587 were positive. In multivariable analysis, male sex was independently associated with testing positive for SARS-CoV-2 (296 [18.4%] of 1612 men vs 291 [13.3%] of 2190 women; adjusted odds ratio [OR] 1.55, 95% CI 1.27-1.89). Adults were at increased risk of testing positive for SARS-CoV-2 compared with children, and people aged 40-64 years were at greatest risk in the multivariable model (243 [18.5%] of 1316 adults aged 40-64 years vs 23 [4.6%] of 499 children; adjusted OR 5.36, 95% CI 3.28-8.76). Compared with white people, the adjusted odds of a positive test were greater in black people (388 [15.5%] of 2497 white people vs 36 [62.1%] of 58 black people; adjusted OR 4.75, 95% CI 2.65-8.51). People living in urban areas versus rural areas (476 [26.2%] of 1816 in urban areas vs 111 [5.6%] of 1986 in rural areas; adjusted OR 4.59, 95% CI 3.57-5.90) and in more deprived areas (197 [29.5%] of 668 in most deprived vs 143 [7.7%] of 1855 in least deprived; adjusted OR 2.03, 95% CI 1.51-2.71) were more likely to test positive. People with chronic kidney disease were more likely to test positive in the adjusted analysis (68 [32.9%] of 207 with chronic kidney disease vs 519 [14.4%] of 3595 without; adjusted OR 1.91, 95% CI 1.31-2.78), but there was no significant association with other chronic conditions in that analysis. We found increased odds of a positive test among people who are obese (142 [20.9%] of 680 people with obesity vs 171 [13.2%] of 1296 normal-weight people; adjusted OR 1.41, 95% CI 1.04-1.91). Notably, active smoking was linked with decreased odds of a positive test result (47 [11.4%] of 413 active smokers vs 201 [17.9%] of 1125 non-smokers; adjusted OR 0.49, 95% CI 0.34-0.71).
   Interpretation A positive SARS-CoV-2 test result in this primary care cohort was associated with similar risk factors as observed for severe outcomes of COVID-19 in hospital settings, except for smoking. We provide evidence of potential sociodemographic factors associated with a positive test, including deprivation, population density, ethnicity, and chronic kidney disease. Copyright (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [de Lusignan, Simon; Dorward, Jienchi; Jones, Nicholas; Akinyemi, Oluwafunmi; Byford, Rachel; Ferreira, Filipa; Okusi, Cecilia; Sherlock, Julian; Williams, John; Joy, Mark; Hobbs, F. D. Richard] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford OX2 6ED, England.
   [de Lusignan, Simon; Howsam, Gary] Royal Coll Gen Practitioners Res & Surveillance C, London, England.
   [Dorward, Jienchi] Univ KwaZulu Natal, Ctr AIDS Programme Res South Africa, Durban, South Africa.
   [Correa, Ana] UCL, Inst Global Hlth, London, England.
   [Correa, Ana] Univ Surrey, Sect Clin Med, Guildford, Surrey, England.
   [Amirthalingam, Gayatri; Andrews, Nick; Dabrera, Gavin; Elliot, Alex; Ellis, Joanna; Bernal, Jamie Lopez; Ramsay, Mary; Smith, Gillian; Zambon, Maria] Publ Hlth England, London, England.
RP de Lusignan, S (corresponding author), Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford OX2 6ED, England.
EM simon.delusignan@phc.ox.ac.uk
RI Dorward, Jienchi/P-7100-2019; ramsay, mary elizabeth/S-8281-2016
OI Dorward, Jienchi/0000-0001-6072-1430; ramsay, mary
   elizabeth/0000-0002-7156-7640; Correa, Ana/0000-0002-0988-061X; Elliot,
   Alex/0000-0002-6414-3065; Okusi, Cecilia/0000-0002-5575-8527
FU Public Health England; Nuffield Department of Primary Care Health
   Sciences; Wellcome Biomedical resources grant [212763/Z/18/Z]; Wellcome
   TrustWellcome Trust [216421/Z/19/Z]; National Institute for Health
   Research (NIHR) School for Primary Care ResearchNational Institute for
   Health Research (NIHR); NIHR Collaboration for Leadership in Health
   Research and Care Oxford; NIHR Oxford Biomedical Research CentreNational
   Institute for Health Research (NIHR); NIHR Oxford Medtech and In-Vitro
   Diagnostics Co-operative
FX We thank the participating practices and patients for providing the data
   for this cohort. We acknowledge our collaboration with the general
   practitioner computer system suppliers-EMIS Health, The Phoenix
   Partnership, and InPractice Systems-Apollo Medical Systems, Public
   Health England, Wellcome Trust, and our other funders and collaborators.
   Public Health England provides the core funding for the Royal College of
   General Practitioners (RCGP) Research and Surveillance Centre; no
   specific funding was provided for this analysis but the Nuffield
   Department of Primary Care Health Sciences has supported the rapid
   expansion of the network. SdL is the Director of the Oxford RCGP
   Research and Surveillance Centre. RB, JS, FF, and JW are part funded by
   Public Health England, and CO and AC by a Wellcome Biomedical resources
   grant (212763/Z/18/Z). JD and NJ are funded by the Wellcome Trust
   (216421/Z/19/Z). FDRH is part funded by the National Institute for
   Health Research (NIHR) School for Primary Care Research, the NIHR
   Collaboration for Leadership in Health Research and Care Oxford, the
   NIHR Oxford Biomedical Research Centre, and the NIHR Oxford Medtech and
   In-Vitro Diagnostics Co-operative.
CR Bi QF, 2020, LANCET INFECT DIS, V20, P911, DOI 10.1016/S1473-3099(20)30287-5
   Cai GS, 2020, AM J RESP CRIT CARE, V201, P1557, DOI 10.1164/rccm.202003-0693LE
   Carson AP, 2011, HYPERTENSION, V57, P1101, DOI 10.1161/HYPERTENSIONAHA.110.168005
   Chow N, 2020, MMWR-MORBID MORTAL W, V69, P382, DOI 10.15585/mmwr.mm6913e2
   Cole SR, 2010, INT J EPIDEMIOL, V39, P417, DOI 10.1093/ije/dyp334
   Corman VM, 2019, EUROSURVEILLANCE, V2020, P25, DOI DOI 10.2807/1560-7917.ES.2020.25.3.2000045.PUBMED
   Correa A, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011092
   de Lusignan S, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-08525-8
   de Lusignan S, 2020, JMIR PUBLIC HLTH SUR, V6, P126, DOI 10.2196/18606
   de Lusignan S, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024285
   de Lusignan S, 2018, JMIR PUBLIC HLTH SUR, V4, P3, DOI 10.2196/11354
   de Lusignan S, 2017, BRIT J GEN PRACT, V67, P440, DOI 10.3399/bjgp17X692645
   Elliot AJ, 2015, EUROSURVEILLANCE, V20, DOI 10.2807/1560-7917.ES2015.20.10.21058
   Fleming DM, 2010, J PUBLIC HEALTH-UK, V32, P90, DOI 10.1093/pubmed/fdp087
   Fleming D M, 1999, Commun Dis Public Health, V2, P96
   Fleming DM, 2012, HUM VACC IMMUNOTHER, V8, P138, DOI 10.4161/hv.8.1.18808
   Godoy P, 2018, EUR J PUBLIC HEALTH, V28, P150, DOI 10.1093/eurpub/ckx130
   Health Research Authority, 2017, DEF RES TABL
   Hughes RA, 2019, INT J EPIDEMIOL, V48, P1294, DOI 10.1093/ije/dyz032
   Intensive Care National Audit and Research Centre, 2020, ICNARC REP COVID 19
   Karalekas G, 2020, SENSORS-BASEL, V20, DOI 10.3390/s20092469
   Kinross P, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.11.2000285
   Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924
   Leung JM, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00688-2020
   Lipsitch M, 2020, NEW ENGL J MED, V382, P1194, DOI 10.1056/NEJMp2002125
   Mancia G., 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2006923, DOI 10.1056/NEJM0A2006923]
   McDonald HI, 2015, AM J KIDNEY DIS, V66, P60, DOI 10.1053/j.ajkd.2014.11.027
   Mehta N, 2020, JAMA CARDIOL, DOI [10.1001/jamacardio.2020.1855, DOI 10.1001/JAMACARDI0.2020.1855]
   Mertens BJA, 2020, BIOMETRICAL J, V62, P724, DOI 10.1002/bimj.201800289
   NHS England and NHS Improvement, 2020, GUID STAND OP PROC C
   Oakes JM, 2018, AM J PHYSIOL-REG I, V315, pR895, DOI 10.1152/ajpregu.00099.2018
   Parascandola M, 2019, TRANSL LUNG CANCER R, V8, pS21, DOI 10.21037/tlcr.2019.03.12
   Pareek M, 2020, LANCET, V395, P1421, DOI 10.1016/S0140-6736(20)30922-3
   Pebody RG, 2020, VACCINE, V38, P489, DOI 10.1016/j.vaccine.2019.10.071
   Pebody RG, 2018, EUROSURVEILLANCE, V23, P20, DOI 10.2807/1560-7917.ES.2018.23.39.1800092
   Reynolds HR, 2020, NEW ENGL J MED, DOI [10.1056/NEJMoa2008975, DOI 10.1056/NEJM0A2008975]
   Smith Sue, 2020, J Public Health (Oxf), DOI 10.1093/pubmed/fdaa014
   Su GB, 2020, NEPHROL DIAL TRANSPL, V35, P1894, DOI 10.1093/ndt/gfz119
   Tippu Zayd, 2017, J Innov Health Inform, V23, P920, DOI 10.14236/jhi.v23i4.920
   Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760
   van Buuren S, 2011, J STAT SOFTW, V45, P1
   Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324
   Wang KW, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101654
   WHO . World Health organization expert Committee, 1995, PHYS STAT US INT ANT
   Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Yi Y, 2020, INT J BIOL SCI, V16, P1753, DOI 10.7150/ijbs.45134
   Zammit C, 2010, INT J GEN MED, V3, P335, DOI 10.2147/IJGM.S11926
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 49
TC 37
Z9 37
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD SEP
PY 2020
VL 20
IS 9
BP 1034
EP 1042
DI 10.1016/S1473-3099(20)30371-6
PG 9
WC Infectious Diseases
SC Infectious Diseases
GA NK5EK
UT WOS:000566754000046
PM 32422204
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Tabata, S
   Imai, K
   Kawano, S
   Ikeda, M
   Kodama, T
   Miyoshi, K
   Obinata, H
   Mimura, S
   Kodera, T
   Kitagaki, M
   Sato, M
   Suzuki, S
   Ito, T
   Uwabe, Y
   Tamura, K
AF Tabata, Sakiko
   Imai, Kazuo
   Kawano, Shuichi
   Ikeda, Mayu
   Kodama, Tatsuya
   Miyoshi, Kazuyasu
   Obinata, Hirofumi
   Mimura, Satoshi
   Kodera, Tsutomu
   Kitagaki, Manabu
   Sato, Michiya
   Suzuki, Satoshi
   Ito, Toshimitsu
   Uwabe, Yasuhide
   Tamura, Kaku
TI Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2
   infection on the Diamond Princess cruise ship: a retrospective analysis
SO LANCET INFECTIOUS DISEASES
LA English
DT Article
ID LACTATE-DEHYDROGENASE; PNEUMONIA; WUHAN; CHINA
AB Background The ongoing COVID-19 pandemic is a global threat. Identification of markers for symptom onset and disease progression is a pressing issue. We described the clinical features of people infected on board the Diamond Princess cruise ship who were diagnosed with asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or mild or severe COVID-19, on admission to the Self-Defense Forces Central Hospital (Tokyo, Japan) and at the end of observation.
   Methods This retrospective, single-centre study included participants with laboratory-detected SARS-CoV-2 infection who were admitted to the Self-Defense Forces Central Hospital from Feb 11 to Feb 25, 2020. Clinical records, laboratory data, and radiological findings were analysed. Clinical outcomes were followed up until discharge or Feb 26, 2020, whichever came first. We defined asymptomatic infection as SARS-CoV-2 infection with no history of clinical signs and symptoms, severe COVID-19 as clinical symptoms of pneumonia (dyspnoea, tachypnoea, peripheral capillary oxygen saturation <93%, and need for oxygen therapy), and mild COVID-19 as all other symptoms. Clinical features on admission were compared among patients with different disease severity, including asymptomatic infection, at the end of observation. We used univariable analysis to identify factors associated with symptomatic illness among asymptomatic people infected with SARS-CoV-2 and disease progression in patients with COVID-19.
   Findings Among the 104 participants included in the final analysis, the median age was 68 years (IQR 47-75) and 54 (52%) were male. On admission, 43 (41%) participants were classified as asymptomatic, 41 (39%) as having mild COVID-10, and 20 (19%) as having severe COVID-19. At the end of observation, 33 (32%) participants were confirmed as being asymptomatic, 43 (41%) as having mild COVID-19, and 28 (27%) as having severe COVID-19. Serum lactate hydrogenase concentrations were significantly higher in the ten participants who were asymptomatic on admission but developed symptomatic COVID-19 compared with the 33 participants who remained asymptomatic throughout the observation period (five [50%] vs four [12%] participants; odds ratio 7.25, 95% CI 1.43-36.70; p=0.020). Compared with patients with mild disease at the end of observation, patients with severe COVID-19 were older (median age 73 years [IQR 55-77] vs 60 years [40-71]; p=0.028) and had more frequent consolidation on chest CT (13 [46%] of 28 vs nine [21%] of 43; p=0.035) and lymphopenia (16 [57%] vs ten [23%]; p=0.0055) on admission.
   Interpretation Older age, consolidation on chest CT images, and lymphopenia might be risk factors for disease progression of COVID-19 and contribute to improved clinical management. Copyright (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Tabata, Sakiko; Imai, Kazuo; Kawano, Shuichi; Ikeda, Mayu; Kodama, Tatsuya; Miyoshi, Kazuyasu; Obinata, Hirofumi; Mimura, Satoshi; Kodera, Tsutomu; Kitagaki, Manabu; Sato, Michiya; Suzuki, Satoshi; Ito, Toshimitsu; Uwabe, Yasuhide; Tamura, Kaku] Self Def Forces Cent Hosp, Tokyo 1540001, Japan.
   [Imai, Kazuo] Saitama Med Univ, Dept Infect Dis & Infect Control, Saitama, Japan.
   [Obinata, Hirofumi] Nippon Med Sch, Dept Emergency & Crit Care Med, Tokyo, Japan.
   [Kawano, Shuichi] Japan Ground Self Def Force Med Serv Sch, Tokyo, Japan.
RP Imai, K (corresponding author), Self Def Forces Cent Hosp, Tokyo 1540001, Japan.
EM k_imai@saitama-med.ac.jp
CR Bai H, 2020, MEMBRANES-BASEL, V10, DOI 10.3390/membranes10080180
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Drent M, 1996, EUR RESPIR J, V9, P1736, DOI 10.1183/09031936.96.09081736
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Inui S, 2020, RADIOL CARDIOTHORAC, V2, DOI [10.1148/ryct.2020200110, DOI 10.1148/RYCT.2020200110]
   Kakimoto K, 2020, MMWR-MORBID MORTAL W, V69, P312, DOI 10.15585/mmwr.mm6911e2
   Kim GU, 2020, CLIN MICROBIOL INFEC, V26, DOI 10.1016/j.cmi.2020.04.040
   Lechien JR, 2020, J INTERN MED, V288, P335, DOI 10.1111/joim.13089
   Li KH, 2020, INVEST RADIOL, V55, P327, DOI 10.1097/RLI.0000000000000672
   Lu AZ, 2015, RESP CARE, V60, P1469, DOI 10.4187/respcare.03920
   Nao N, 2020, DETECTION 2 CASE 201
   National Institute of Infectious Diseases, 2020, FIELD BRIEF DIAM PRI
   Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370
   Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248
   QUIST J, 1995, CHEST, V108, P415, DOI 10.1378/chest.108.2.415
   Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017
   Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238
   Zhang JN, 2020, LANCET RESP MED, V8, pE11, DOI 10.1016/S2213-2600(20)30071-0
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 23
TC 19
Z9 19
U1 2
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1473-3099
EI 1474-4457
J9 LANCET INFECT DIS
JI Lancet Infect. Dis.
PD SEP
PY 2020
VL 20
IS 9
BP 1043
EP 1050
DI 10.1016/S1473-3099(20)30482-5
PG 8
WC Infectious Diseases
SC Infectious Diseases
GA NK5EK
UT WOS:000566754000047
PM 32539988
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Rakib, A
   Paul, A
   Chy, MNU
   Sami, SA
   Baral, SK
   Majumder, M
   Tareq, A
   Amin, MN
   Shahriar, A
   Uddin, MZ
   Dutta, M
   Tallei, TE
   Bin Emran, T
   Simal-Gandara, J
AF Rakib, Ahmed
   Paul, Arkajyoti
   Chy, Md Nazim Uddin
   Sami, Saad Ahmed
   Baral, Sumit Kumar
   Majumder, Mohuya
   Tareq, Abu Montakim
   Amin, Mohammad Nurul
   Shahriar, Asif
   Uddin, Md Zia
   Dutta, Mycal
   Tallei, Trina Ekawati
   Bin Emran, Talha
   Simal-Gandara, Jesus
TI Biochemical and Computational Approach of Selected Phytocompounds
   fromTinospora crispain the Management of COVID-19
SO MOLECULES
LA English
DT Article
DE SARS-CoV-2; COVID-19; Tinospora crispa; natural products;
   phytochemicals; secondary metabolites; molecular docking
ID DOCKING; PHYTOCHEMICALS; MECHANISM; PLANT; GLIDE; SITE
AB A pandemic caused by the novel coronavirus (SARS-CoV-2 or COVID-19) began in December 2019 in Wuhan, China, and the number of newly reported cases continues to increase. More than 19.7 million cases have been reported globally and about 728,000 have died as of this writing (10 August 2020). Recently, it has been confirmed that the SARS-CoV-2 main protease (M(pro))enzyme is responsible not only for viral reproduction but also impedes host immune responses. The M(pro)provides a highly favorable pharmacological target for the discovery and design of inhibitors. Currently, no specific therapies are available, and investigations into the treatment of COVID-19 are lacking. Therefore, herein, we analyzed the bioactive phytocompounds isolated by gas chromatography-mass spectroscopy (GC-MS) fromTinospora crispaas potential COVID-19 M(pro)inhibitors, using molecular docking study. Our analyses unveiled that the top nine hits might serve as potential anti-SARS-CoV-2 lead molecules, with three of them exerting biological activity and warranting further optimization and drug development to combat COVID-19.
C1 [Rakib, Ahmed; Sami, Saad Ahmed] Univ Chittagong, Fac Biol Sci, Dept Pharm, Chittagong 4331, Bangladesh.
   [Paul, Arkajyoti; Chy, Md Nazim Uddin; Majumder, Mohuya] GUSTO A Res Grp, Drug Discovery, Chittagong 4000, Bangladesh.
   [Paul, Arkajyoti; Uddin, Md Zia; Dutta, Mycal; Bin Emran, Talha] BGC Trust Univ Bangladesh, Dept Pharm, Chittagong 4381, Bangladesh.
   [Paul, Arkajyoti; Baral, Sumit Kumar] Jagannath Univ, Dept Microbiol, Dhaka 1100, Bangladesh.
   [Chy, Md Nazim Uddin; Tareq, Abu Montakim] Int Islamic Univ Chittagong, Dept Pharm, Chittagong 4318, Bangladesh.
   [Amin, Mohammad Nurul] Atish Dipankar Univ Sci & Technol, Dept Pharm, Dhaka 1230, Bangladesh.
   [Shahriar, Asif] Stamford Univ Bangladesh, Dept Microbiol, 51 Siddeswari Rd, Dhaka 1217, Bangladesh.
   [Uddin, Md Zia; Dutta, Mycal] Jahangirnagar Univ, Dept Pharm, Dhaka 1342, Bangladesh.
   [Tallei, Trina Ekawati] Sam Ratulangi Univ, Fac Math & Nat Sci, Dept Biol, Manado 95115, Indonesia.
   [Simal-Gandara, Jesus] Univ Vigo, Fac Food Sci & Technol, Dept Analyt & Food Chem, Nutr & Bromatol Grp, Ourense Campus, E-32004 Orense, Spain.
RP Bin Emran, T (corresponding author), BGC Trust Univ Bangladesh, Dept Pharm, Chittagong 4381, Bangladesh.; Simal-Gandara, J (corresponding author), Univ Vigo, Fac Food Sci & Technol, Dept Analyt & Food Chem, Nutr & Bromatol Grp, Ourense Campus, E-32004 Orense, Spain.
EM rakib.pharmacy.cu@gmail.com; arka.bgctub@gmail.com;
   nazim107282@gmail.com; s.a.sami18pharm@gmail.com; akbaiub6@gmail.com;
   mohuyamajumderbgctub@gmail.com; montakim0.abu@gmail.com;
   amin.pharma07@gmail.com; abasifbl@gmail.com; zia@bgctub.ac.bd;
   mycal@bgctub.ac.bd; trina_tallei@unsrat.ac.id; talhabmb@bgctub.ac.bd;
   jsimal@uvigo.es
RI Chy, Nazim Uddin/G-8438-2015; , Abu Montakim Tareq/AAM-4692-2020;
   Simal-Gandara, Jesus/A-9533-2009; Bin Emran, Talha/P-9184-2016; Paul,
   Arkajyoti/N-5429-2016
OI Chy, Nazim Uddin/0000-0003-2329-0867; , Abu Montakim
   Tareq/0000-0003-2704-7610; Simal-Gandara, Jesus/0000-0001-9215-9737; Bin
   Emran, Talha/0000-0003-3188-2272; Paul, Arkajyoti/0000-0002-2767-2646;
   Sami, Saad Ahmed/0000-0002-0621-4523; Rakib, Ahmed/0000-0003-3335-0368
CR Adem S., 2020, IDENTIFICATION POTEN, V46, P1, DOI [10.20944/preprints202003.0333.v1., 10.20944/preprints202003.0333.v1, DOI 10.20944/PREPRINTS202003.0333.V1]
   Agbowuro AA, 2018, MED RES REV, V38, P1295, DOI 10.1002/med.21475
   Ahmed S, 2019, CLIN PHYTOSCIENCE, V5, P1, DOI [DOI 10.1186/S40816-019-0127-X, 10.1186/s40816-019-0127-x]
   Al Mahmud Zobaer, 2016, Journal of Basic and Clinical Physiology and Pharmacology, V27, P63, DOI 10.1515/jbcpp-2015-0056
   Al-Mahmud Z., 2017, BMC Research Notes, V10, DOI 10.1186/s13104-017-2503-2
   Ashraf MA, 2014, BIOINFORMATION, V10, P384, DOI 10.6026/97320630010384
   Barua Niloy, 2020, Biochem Biophys Rep, V23, P100772, DOI 10.1016/j.bbrep.2020.100772
   Bin Emran T, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0643-2
   Brooijmans N, 2003, ANNU REV BIOPH BIOM, V32, P335, DOI 10.1146/annurev.biophys.32.110601.142532
   Chang D, 2020, JAMA-J AM MED ASSOC, V323, P1092, DOI 10.1001/jama.2020.1623
   Chen YPP, 2008, EXPERT OPIN THER TAR, V12, P383, DOI [10.1517/14728222.12.4.383 , 10.1517/14728222.12.4.383]
   Cheng J., 2020, EXPLORING ACTIVE COM
   Chhikara B. S., 2020, CHEM BIOL LETT, V7, P63, DOI DOI 10.1007/s00058-020-1496-8
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   Diao K, 2020, PREC CLIN MED, V3, P9, DOI [10.1093/pcmedi/pbaa004, DOI 10.1093/PCMEDI/PBAA004]
   Direkbusarakom S, 1996, FISH PATHOL, V31, P209, DOI 10.3147/jsfp.31.209
   Du QS, 2004, PEPTIDES, V25, P1857, DOI 10.1016/j.peptides.2004.06.018
   Dutta T, 2020, BIOCH BIOPHYS REP, V21, P715
   EMRAN TB, 2018, J APPL LIFE SCI INT, V16, P1, DOI DOI 10.9734/JALSI/2018/39073
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Goyal B, 2020, ACS COMB SCI, V22, P297, DOI 10.1021/acscombsci.0c00058
   Hegyi A, 2002, J GEN VIROL, V83, P595, DOI 10.1099/0022-1317-83-3-595
   Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191
   Hsu MF, 2005, J BIOL CHEM, V280, P31257, DOI 10.1074/jbc.M502577200
   Jahan I, 2020, MOLECULES, V25, DOI 10.3390/molecules25153536
   Kang CK, 2020, KOREAN J INTERN MED, V35, P782, DOI 10.3904/kjim.2020.157
   Khaerunnisa S, 2020, POTENTIAL INHIBITOR
   Khanam B.H., 2020, J PLANT SCI, V8, P12
   KORKINA L, 2018, COSMETICS, V5, P32, DOI DOI 10.3390/COSMETICS5020032
   Lee KW, 2011, NAT REV CANCER, V11, P211, DOI 10.1038/nrc3017
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Liu X., 2020, CRYTAL STRUCTURE 201
   Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021
   Lu HZ, 2020, BIOSCI TRENDS, V14, P69, DOI 10.5582/bst.2020.01020
   Lubomirov R, 2010, PHARMACOGENET GENOM, V20, P217, DOI 10.1097/FPC.0b013e328336eee4
   MAHASE E, 2020, BMJ-BRIT MED J, V368, P48071, DOI DOI 10.1136/BMJ.M641
   Mondal S, 2020, METALS-BASEL, V10, DOI 10.3390/met10050683
   Muramatsu T, 2016, P NATL ACAD SCI USA, V113, P12997, DOI 10.1073/pnas.1601327113
   Niljan J, 2014, J HEALTH RES, V28, P199
   Oyebode O, 2016, HEALTH POLICY PLANN, V31, P984, DOI 10.1093/heapol/czw022
   Rakib A., 2020, EPITOPE BASED IMMUNO
   Rakib A, 2020, COMPUT BIOL MED, V124, DOI 10.1016/j.compbiomed.2020.103967
   Rakib A, 2020, PHYTOTHER RES, V34, P2978, DOI 10.1002/ptr.6725
   Rakib A, 2020, FOOD SCI NUTR, V8, P547, DOI 10.1002/fsn3.1339
   Saha S, 2012, ANC SCI LIFE, V31, P151, DOI 10.4103/0257-7941.107344
   Sermakkani M., 2012, ASIAN J PHARM CLIN R, V5, P90
   Shifah F, 2020, J ADV BIOTECHNOL EXP, P11, DOI [10.5455/jabet.2020.d110, DOI 10.5455/JABET.2020.D110]
   Singh R, 2014, INT J SCI STUDY, V1, P6
   Tareq A, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04061
   Thiel V, 2003, J GEN VIROL, V84, P2305, DOI 10.1099/vir.0.19424-0
   Uddin M. M. N., 2017, Journal of Applied Pharmaceutical Science, V7, P104, DOI 10.7324/japs.2017.70114
   Uddin MZ, 2019, INT SYM MED INFORM, P1
   ul Qamar MT, 2020, J PHARM ANAL, V10, P313, DOI 10.1016/j.jpha.2020.03.009
   Ullrich S, 2020, BIOORG MED CHEM LETT, V30, DOI 10.1016/j.bmcl.2020.127377
   Vasanthi HR, 2012, CURR MED CHEM, V19, P2242
   Volkamer A, 2012, BIOINFORMATICS, V28, P2074, DOI 10.1093/bioinformatics/bts310
   Wagner H.K, 2012, P 1 INT C MED PLANT, P6
   Xu Z., 2020, NELFINAVIR WAS PREDI, DOI [10.1101/2020.01.27.921627, DOI 10.1101/2020.01.27.921627]
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Yamamoto N., 2020, BIORXIV, DOI [DOI 10.1101/2020.04.06.026476, 10.1101/ 2020.04.06.026476]
   Yang Y, 2020, INT J BIOL SCI, V16, P1708, DOI 10.7150/ijbs.45538
   Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853
NR 64
TC 2
Z9 2
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD SEP
PY 2020
VL 25
IS 17
AR 3936
DI 10.3390/molecules25173936
PG 16
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA NP7FW
UT WOS:000570339300001
PM 32872217
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Vivek-Ananth, RP
   Rana, A
   Rajan, N
   Biswal, HS
   Samal, A
AF Vivek-Ananth, R. P.
   Rana, Abhijit
   Rajan, Nithin
   Biswal, Himansu S.
   Samal, Areejit
TI In Silico Identification of Potential Natural Product Inhibitors of
   Human Proteases Key to SARS-CoV-2 Infection
SO MOLECULES
LA English
DT Article
DE COVID-19; TMPRSS2; cathepsin L; molecular docking; molecular dynamics;
   non-covalent interactions; phytochemical inhibitors
ID MOLECULAR-DYNAMICS; SILYBUM-MARIANUM; SERINE-PROTEASE; HYDROGEN-BONDS;
   BINDING; FLOWER; PHYTOCHEMISTRY; PHARMACOLOGY; ETHNOBOTANY; BICUCULLINE
AB Presently, there are no approved drugs or vaccines to treat COVID-19, which has spread to over 200 countries and at the time of writing was responsible for over 650,000 deaths worldwide. Recent studies have shown that two human proteases, TMPRSS2 and cathepsin L, play a key role in host cell entry of SARS-CoV-2. Importantly, inhibitors of these proteases were shown to block SARS-CoV-2 infection. Here, we perform virtual screening of 14,011 phytochemicals produced by Indian medicinal plants to identify natural product inhibitors of TMPRSS2 and cathepsin L. AutoDock Vina was used to perform molecular docking of phytochemicals against TMPRSS2 and cathepsin L. Potential phytochemical inhibitors were filtered by comparing their docked binding energies with those of known inhibitors of TMPRSS2 and cathepsin L. Further, the ligand binding site residues and non-covalent interactions between protein and ligand were used as an additional filter to identify phytochemical inhibitors that either bind to or form interactions with residues important for the specificity of the target proteases. This led to the identification of 96 inhibitors of TMPRSS2 and 9 inhibitors of cathepsin L among phytochemicals of Indian medicinal plants. Further, we have performed molecular dynamics (MD) simulations to analyze the stability of the protein-ligand complexes for the three top inhibitors of TMPRSS2 namely, qingdainone, edgeworoside C and adlumidine, and of cathepsin L namely, ararobinol, (+)-oxoturkiyenine and 3 alpha,17 alpha-cinchophylline. Interestingly, several herbal sources of identified phytochemical inhibitors have antiviral or anti-inflammatory use in traditional medicine. Further in vitro and in vivo testing is needed before clinical trials of the promising phytochemical inhibitors identified here.
C1 [Vivek-Ananth, R. P.; Rajan, Nithin; Samal, Areejit] Inst Math Sci IMSc, Chennai 600113, Tamil Nadu, India.
   [Vivek-Ananth, R. P.; Rana, Abhijit; Biswal, Himansu S.; Samal, Areejit] Homi Bhabha Natl Inst HBNI, Mumbai 400094, Maharashtra, India.
   [Rana, Abhijit; Biswal, Himansu S.] Natl Inst Sci Educ & Res NISER, Sch Chem Sci, Bhubaneswar 752050, India.
RP Samal, A (corresponding author), Inst Math Sci IMSc, Chennai 600113, Tamil Nadu, India.; Biswal, HS; Samal, A (corresponding author), Homi Bhabha Natl Inst HBNI, Mumbai 400094, Maharashtra, India.; Biswal, HS (corresponding author), Natl Inst Sci Educ & Res NISER, Sch Chem Sci, Bhubaneswar 752050, India.
EM vivekananth@imsc.res.in; abhijit.rana@niser.ac.in;
   nithinofficial2912@gmail.com; himansu@niser.ac.in; asamal@imsc.res.in
OI Rajan, Nithin/0000-0002-8115-6634; Biswal, Himansu
   S./0000-0003-0791-2259; Rana, Abhijit/0000-0001-5854-0710; Samal,
   Areejit/0000-0002-6796-9604; R.P., Vivek Ananth/0000-0002-3232-3299
FU Science and Engineering Research Board (SERB) India through the award of
   a Ramanujan fellowship [SB/S2/RJN-006/2014]; Max Planck Society Germany
   through the award of a Max Planck Partner Group in Mathematical Biology;
   Abdus SalamInternational Centre for Theoretical Physics Italy
FX Authors thank S. Krishnaswamy for guidance and help with MD simulations.
   Authors also thank Dhiraj Kumar, Vinay Nandicoori and Pinaki Saha for
   discussions. A.S. and R.P.V.-A. Thank the computational staff of IMSc
   for maintaining resources during the Covid-19 associated lockdown.
   H.S.B. and A.R. acknowledge the computational facilities of NISER. A.S.
   would like to acknowledge financial support from the Science and
   Engineering Research Board (SERB) India through the award of a Ramanujan
   fellowship (SB/S2/RJN-006/2014), Max Planck Society Germany through the
   award of a Max Planck Partner Group in Mathematical Biology, and the
   Abdus SalamInternational Centre for Theoretical Physics Italy for the
   award of a Simons Associateship. The funders have no role in study
   design, data collection, data analysis, manuscript preparation or
   decision to publish.
CR Abhimany Yadav, 2010, Journal of Chemical and Pharmaceutical Research, V2, P255
   Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   Acharya R., 2011, AYU INT Q J RES AYUR, V32, P402, DOI [10.4103/0974-8520.93923, DOI 10.4103/0974-8520.93923]
   Adams-Cioaba MA, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1204
   Ahmad M, 2020, ACS OMEGA, V5, P18356, DOI 10.1021/acsomega.0c02096
   [Anonymous], 2000, WEALTH IND WEALTH S, V2
   [Anonymous], 2000, WEALTH IND WEALTH S, V1
   [Anonymous], 2000, WEALTH IND WEALTH S, V3
   [Anonymous], 2000, WEALTH IND WEALTH S, V5
   [Anonymous], 2000, WEALTH IND WEALTH S, V4
   Bahmani M, 2015, J EVID-BASED INTEGR, V20, P292, DOI 10.1177/2156587215571116
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Borozan SZ, 2013, COMPUT BIOL CHEM, V47, P231, DOI 10.1016/j.compbiolchem.2013.10.002
   BOSISIO E, 1992, PHARMACOL RES, V25, P147, DOI 10.1016/1043-6618(92)91383-R
   Cadelis MM, 2016, BIOORGAN MED CHEM, V24, P3102, DOI 10.1016/j.bmc.2016.05.024
   Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9
   Chand A, 2020, ACCOUNTS CHEM RES, V53, P1580, DOI 10.1021/acs.accounts.0c00289
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   de Freitas RF, 2017, MEDCHEMCOMM, V8, P1970, DOI 10.1039/c7md00381a
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81
   Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592
   EVNIN LB, 1990, P NATL ACAD SCI USA, V87, P6659, DOI 10.1073/pnas.87.17.6659
   Fujishima A, 1997, FEBS LETT, V407, P47, DOI 10.1016/S0014-5793(97)00216-0
   Gao D, 2016, J ETHNOPHARMACOL, V191, P379, DOI 10.1016/j.jep.2016.06.059
   Gao D, 2015, J ETHNOPHARMACOL, V162, P14, DOI 10.1016/j.jep.2014.12.034
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Gupta Prakash Chandra, 2012, Asian Pacific Journal of Tropical Biomedicine, V2, P665, DOI 10.1016/S2221-1691(12)60117-8
   Gurung P, 2017, J PHARMACOGN PHYTOCH, V6, P162
   Herter S, 2005, BIOCHEM J, V390, P125, DOI 10.1042/BJ20041955
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Hoffmann M, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00754-20
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Islam R, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1761883
   Jain Mahendra, 2012, Asian Pacific Journal of Tropical Biomedicine, V2, pS1918
   KARDOS J, 1984, BIOCHEM PHARMACOL, V33, P3537, DOI 10.1016/0006-2952(84)90134-5
   Khare C.P, 2007, INDIAN MED PLANTS IL
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Kriz K, 2018, CHEMPHYSCHEM, V19, P2540, DOI 10.1002/cphc.201800409
   Kuhn B, 2017, J MED CHEM, V60, P2485, DOI 10.1021/acs.jmedchem.6b01881
   Kumar A, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1772112
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Liu S, 2020, BIOINFORMATICS, V36, P1066, DOI 10.1093/bioinformatics/btz725
   Liu TX, 2020, PHARMACOL THERAPEUT, V213, DOI 10.1016/j.pharmthera.2020.107587
   METE IE, 1988, J NAT PROD, V51, P272, DOI 10.1021/np50056a013
   Mohanraj K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22631-z
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Olubiyi OO, 2020, MOLECULES, V25, DOI 10.3390/molecules25143193
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   PaoloniGiacobino A, 1997, GENOMICS, V44, P309, DOI 10.1006/geno.1997.4845
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Rahman N, 2020, MOLECULES, V25, DOI 10.3390/molecules25102271
   Rastogi R.P., 1993, COMPENDIUM INDIAN ME, V3, P1980
   Rastogi R.P., 1991, COMPENDIUM INDIAN ME, V2, p1970 
   Rastogi R.P., 1990, COMPENDIUM INDIAN ME, V1, P1960
   Rastogi R.P., 1998, COMPENDIUM INDIAN ME, V5, P1990
   Rastogi R.P., 1995, COMPENDIUM INDIAN ME, V4, P1985
   Ren JL, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104743
   Rodrigues Joao P G L M, 2018, F1000Res, V7, P1961, DOI 10.12688/f1000research.17456.1
   Sarkhel S, 2004, PROTEINS, V54, P247, DOI 10.1002/prot.10567
   Schmid N, 2011, EUR BIOPHYS J BIOPHY, V40, P843, DOI 10.1007/s00249-011-0700-9
   Schmidt T, 2011, PROTEINS, V79, P126, DOI 10.1002/prot.23174
   Schyman P, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00889
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y
   Stroet M, 2018, J CHEM THEORY COMPUT, V14, P5834, DOI 10.1021/acs.jctc.8b00768
   Sumthong P, 2008, J WOOD CHEM TECHNOL, V28, P247, DOI 10.1080/02773810802452592
   TRIPATHI YC, 1989, PHYTOCHEMISTRY, V28, P1563, DOI 10.1016/S0031-9422(00)97797-5
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tsai YC, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030366
   Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629
   Turk V, 2012, BBA-PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002
   Ueno S, 1997, J NEUROSCI, V17, P625
   Vellingiri B, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138277
   Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9
   Wang Jin-Hui, 2018, J Tradit Complement Med, V8, P24, DOI 10.1016/j.jtcme.2017.04.001
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001
   Wu CR, 2020, ACTA PHARMACOL SIN B, V10, P766, DOI 10.1016/j.apsb.2020.02.008
   Yadav JP, 2010, FITOTERAPIA, V81, P223, DOI 10.1016/j.fitote.2009.09.008
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yuan XH, 2016, MOLECULES, V21, DOI 10.3390/molecules21050559
   Zhao DG, 2015, FITOTERAPIA, V107, P122, DOI 10.1016/j.fitote.2015.10.012
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhou P, 2009, PROTEINS, V76, P151, DOI 10.1002/prot.22327
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zhu S.H, 2005, China Patent, Patent No. [CN20051134677, 20051134677]
NR 95
TC 1
Z9 1
U1 5
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD SEP
PY 2020
VL 25
IS 17
AR 3822
DI 10.3390/molecules25173822
PG 28
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA NO7XM
UT WOS:000569702200001
PM 32842606
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Grazioli, E
   Cerulli, C
   Dimauro, I
   Moretti, E
   Murri, A
   Parisi, A
AF Grazioli, Elisa
   Cerulli, Claudia
   Dimauro, Ivan
   Moretti, Elisa
   Murri, Arianna
   Parisi, Attilio
TI New Strategy of Home-Based Exercise during Pandemic COVID-19 in Breast
   Cancer Patients: A Case Study
SO SUSTAINABILITY
LA English
DT Article
DE QoL; breast Cancer; physical activity; treatments; COVID-19
ID QUALITY-OF-LIFE; PHYSICAL-ACTIVITY; HEALTH; STRENGTH; FATIGUE; FITNESS;
   CHEMOTHERAPY; SURVIVORS; PROTOCOL; SCALE
AB The COVID-19 pandemic has posed several challenges for the oncology health care system. The need to improve patients' Quality of Life (QoL) through exercise, which is related to survival and healing, has increased, especially during lockdowns. Technologies are often used to help with patient care as well as to monitor exercise training. This case study, developed during the pandemic period, aims to evaluate the effectiveness of a proposed home-based combined training (CT) regimen, supervised through online lessons, in increasing QoL and fatigue in breast cancer patients undergoing adjuvant therapy. Additionally, we evaluated the effect of exercise on psychological and functional parameters. Methods: Two breast cancer (BC) survivors were required to participate in 2 h/week of supervised and home-based CT for 16 weeks. Results: Improvements were found in the emotional function of QoL (10% in patient A; 70% in patient B) and in all variables of fatigue (physical fatigue 66% in patient A; 33% in patient B). Conclusion: The findings from this study revealed positive effects of CT on QoL and fatigue perception in BC women undergoing therapy. Both patients attended all training sessions with no adverse events, showing the sustainability of this training as an alternative and affordable method that is capable of improving patients' wellbeing.
C1 [Grazioli, Elisa; Cerulli, Claudia; Dimauro, Ivan; Moretti, Elisa; Murri, Arianna; Parisi, Attilio] Univ Rome Foro Italico, Dept Movement Human & Hlth Sci, I-00135 Rome, Italy.
RP Grazioli, E (corresponding author), Univ Rome Foro Italico, Dept Movement Human & Hlth Sci, I-00135 Rome, Italy.
EM elisa.grazioli@uniroma4.it; claudia.cerulli@uniroma4.it;
   ivan.dimauro@uniroma4.it; elisa.moretti1@studenti.uniroma4.it;
   ariannamurri@hotmail.it; attilio.parisi@uniroma4.it
RI Dimauro, Ivan/AAG-1178-2019
OI Dimauro, Ivan/0000-0003-0577-3144; Grazioli, Elisa/0000-0003-4245-1320
FU Il Research Grant of University of Rome "Foro Italico"
   [19/001873-GEN-13/03/2019]
FX This research was funded by Il Research Grant of University of Rome
   "Foro Italico" Prot. 19/001873-GEN-13/03/2019.
CR Armfield NR, 2015, INT J MED INFORM, V84, P737, DOI 10.1016/j.ijmedinf.2015.06.006
   Bertucci F, 2019, CANCERS, V11, DOI 10.3390/cancers11020219
   Cantarero-Villanueva I, 2012, AM J PHYS MED REHAB, V91, P774, DOI 10.1097/PHM.0b013e31825f1538
   Cerulli C, 2019, MED SPORT, V72, P295, DOI 10.23736/S0025-7826.19.03530-0
   Cheli S., 2016, PSICOTERAPIA COGNITI, DOI [10.13140/RG.2.2.20830.64328, DOI 10.13140/RG.2.2.20830.64328]
   Curigliano G, 2020, BREAST, V52, P8, DOI 10.1016/j.breast.2020.04.006
   De Luca V, 2016, PUBLIC HEALTH, V136, P126, DOI 10.1016/j.puhe.2016.03.028
   Fong DYT, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e70
   Galiano-Castillo N, 2016, J AGING PHYS ACTIV, V24, P508, DOI 10.1123/japa.2015-0056
   Galiano-Castillo N, 2016, CANCER-AM CANCER SOC, V122, P3166, DOI 10.1002/cncr.30172
   Groenvold M, 1997, J CLIN EPIDEMIOL, V50, P441, DOI 10.1016/S0895-4356(96)00428-3
   Hofman M, 2007, ONCOLOGIST, V12, P4, DOI 10.1634/theoncologist.12-S1-4
   Hopwood P, 2001, EUR J CANCER, V37, P189, DOI 10.1016/S0959-8049(00)00353-1
   Iqbal S, 2019, HEALTH TECHNOL-GER, V9, P93, DOI 10.1007/s12553-018-0252-4
   Jones CJ, 1999, RES Q EXERCISE SPORT, V70, P113, DOI 10.1080/02701367.1999.10608028
   Kirkham AA, 2019, J NATL COMPR CANC NE, V17, P695, DOI 10.6004/jnccn.2018.7276
   Mijwel S, 2019, J CANCER SURVIV, V13, P244, DOI 10.1007/s11764-019-00747-z
   Mijwel S, 2018, BREAST CANCER RES TR, V168, P79, DOI 10.1007/s10549-017-4571-3
   Peterson LL, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912-018-0702-1
   Reis AD, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-0882-2
   Richards LG, 1996, AM J OCCUP THER, V50, P133, DOI 10.5014/ajot.50.2.133
   Schinkothe T, 2019, BREAST CARE, V14, P130, DOI 10.1159/000500900
   Schulz SVW, 2018, DISABIL REHABIL, V40, P1501, DOI 10.1080/09638288.2017.1300688
   Spei ME, 2019, BREAST, V44, P144, DOI 10.1016/j.breast.2019.02.001
   Thorsen L, 2005, J CLIN ONCOL, V23, P2378, DOI 10.1200/JCO.2005.04.106
   Travier N, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0362-z
   van Waart H, 2015, J CLIN ONCOL, V33, P1918, DOI 10.1200/JCO.2014.59.1081
   Vasankari Ville, 2019, BMJ Open Sport Exerc Med, V5, pe000539, DOI 10.1136/bmjsem-2019-000539
NR 28
TC 0
Z9 0
U1 6
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2071-1050
J9 SUSTAINABILITY-BASEL
JI Sustainability
PD SEP
PY 2020
VL 12
IS 17
AR 6940
DI 10.3390/su12176940
PG 9
WC Green & Sustainable Science & Technology; Environmental Sciences;
   Environmental Studies
SC Science & Technology - Other Topics; Environmental Sciences & Ecology
GA NO7XI
UT WOS:000569701800001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Balakrishnan, JM
   Kunju, SA
   Wilson, W
   Sujir, SN
   Bhat, R
   Vandana, KE
AF Balakrishnan, Jayaraj M.
   Kunju, Sanjan Asanaru
   Wilson, William
   Sujir, Sachin Nayak
   Bhat, Rachana
   Vandana, K. E.
TI MIST (Modified Intubating Sequence for Transmissibility) Bundle for
   Infectious Diseases with Aerosol Hazard
SO WESTERN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
AB The current global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has magnified the risk to healthcare providers when inititiating airway management, and safe tracheal intubation has become of paramount importance. Mitigation of risk to frontline providers requires airway management to be an orchestrated exercise based on training and purposeful simulation. Role allocation and closed-loop communication form the foundation of this exercise. We describe a methodical, 10-step approach from decision-making and meticulous drug and equipment choices to donning of personal protective equipment, and procedural concerns. This bundled approach will help reduce unplanned actions, which in turn may reduce the risk of aerosol transmission during airway management in resource-limited settings.
C1 [Balakrishnan, Jayaraj M.; Kunju, Sanjan Asanaru; Wilson, William; Sujir, Sachin Nayak; Bhat, Rachana] Manipal Acad Higher Educ, Kasturba Med Coll, Dept Emergency Med, Manipal, Karnataka, India.
   [Vandana, K. E.] Manipal Acad Higher Educ, Kasturba Med Coll, Dept Microbiol, Manipal, Karnataka, India.
RP Kunju, SA (corresponding author), Kasturba Med Coll & Hosp, Dept Emergency Med, Tiger Circle Rd, Manipal 576104, Karnataka, India.
EM sanjan.a@manipal.edu
CR Cheung JCH, 2020, LANCET RESP MED, V8, pE19, DOI 10.1016/S2213-2600(20)30084-9
   Detsky ME, 2019, JAMA-J AM MED ASSOC, V321, P493, DOI 10.1001/jama.2018.21413
   Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316
   Peng PWH, 2020, BRIT J ANAESTH, V124, P497, DOI 10.1016/j.bja.2020.02.008
   Tang JW, 2020, J INFECTION, V80, P350, DOI 10.1016/j.jinf.2020.01.014
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   World Health Organization, CLIN MAN SEV AC RESP
   World Health Organization, SAF MAN WAST HLTH CA
NR 8
TC 0
Z9 0
U1 0
U2 0
PU WESTJEM
PI ORANGE
PA C/O SHAHRAM LOTFIPOUR, MD, MPH, 333 CITY BLVD W STE 640, RT 128-01,
   ORANGE, CA 92868 USA
SN 1936-900X
EI 1936-9018
J9 WEST J EMERG MED
JI West. J. Emerg. Med.
PD SEP
PY 2020
VL 21
IS 5
BP 1076
EP 1079
DI 10.5811/westjem.2020.7.47473
PG 4
WC Emergency Medicine
SC Emergency Medicine
GA NO6FZ
UT WOS:000569586300009
PM 32970557
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Conzelmann, C
   Gilg, A
   Gross, R
   Schutz, D
   Preising, N
   Standker, L
   Jahrsdorfer, B
   Schrezenmeier, H
   Sparrer, KMJ
   Stamminger, T
   Stenger, S
   Munch, J
   Muller, JA
AF Conzelmann, Carina
   Gilg, Andrea
   Gross, Ruediger
   Schuetz, Desiree
   Preising, Nico
   Staendker, Ludger
   Jahrsdoerfer, Bernd
   Schrezenmeier, Hubert
   Sparrer, Konstantin M. J.
   Stamminger, Thomas
   Stenger, Steffen
   Muench, Jan
   Mueller, Janis A.
TI An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE SARS-CoV-2; In-cell ELISA; Antiviral testing; Neutralization; Drug
   screening
ID ZIKA VIRUS
AB SARS-CoV-2 is a novel pandemic coronavirus that caused a global health and economic crisis. The development of efficient drugs and vaccines against COVID-19 requires detailed knowledge about SARS-CoV-2 biology. Several techniques to detect SARS-CoV-2 infection have been established, mainly based on counting infected cells by staining plaques or foci, or by quantifying the viral genome by PCR. These methods are laborious, timeconsuming and expensive and therefore not suitable for a high sample throughput or rapid diagnostics. We here report a novel enzyme-based immunodetection assay that directly quantifies the amount of de novo synthesized viral spike protein within fixed and permeabilized cells. This in-cell ELISA enables a rapid and quantitative detection of SARS-CoV-2 infection in microtiter format, regardless of the virus isolate or target cell culture. It follows the established method of performing ELISA assays and does not require expensive instrumentation. Utilization of the in-cell ELISA allows to e.g. determine TCID50 of virus stocks, antiviral efficiencies (IC50 values) of drugs or neutralizing activity of sera. Thus, the in-cell spike ELISA represents a promising alternative to study SARS-CoV-2 infection and inhibition and may facilitate future research.
C1 [Conzelmann, Carina; Gilg, Andrea; Gross, Ruediger; Schuetz, Desiree; Sparrer, Konstantin M. J.; Muench, Jan; Mueller, Janis A.] Ulm Univ, Med Ctr, Inst Mol Virol, D-89081 Ulm, Germany.
   [Preising, Nico; Staendker, Ludger; Muench, Jan] Ulm Univ, Med Ctr, Core Facil Funct Peptid, D-89081 Ulm, Germany.
   [Jahrsdoerfer, Bernd; Schrezenmeier, Hubert] Ulm Univ, Inst Transfus Med, D-89081 Ulm, Germany.
   [Jahrsdoerfer, Bernd; Schrezenmeier, Hubert] German Red Cross Blood Serv Baden Wurttemberg, Inst Clin Transfus Med & Immunogenet Ulm, D-89081 Ulm, Germany.
   [Jahrsdoerfer, Bernd; Schrezenmeier, Hubert] Univ Hosp Ulm, D-89081 Ulm, Germany.
   [Stamminger, Thomas] Ulm Univ, Med Ctr, Inst Virol, D-89081 Ulm, Germany.
   [Stenger, Steffen] Ulm Univ, Med Ctr, Inst Med Microbiol & Hyg, D-89081 Ulm, Germany.
RP Muller, JA (corresponding author), Ulm Univ, Med Ctr, Inst Mol Virol, D-89081 Ulm, Germany.
EM Janis.mueller@uni-ulm.de
OI Sparrer, Konstantin/0000-0002-8682-1779
FU European UnionEuropean Union (EU) [101003555]; German Research
   FoundationGerman Research Foundation (DFG) [CRC1279]; Baden-Wurttemberg
   Stiftung; International Graduate School in Molecular Medicine Ulm;
   German Ministry of Health [EudraCT 2020-001310-38]
FX We thank Daniela Krnavek, Nicola Schrott, Merve Karacan, Carolin Ludwig,
   Tirza Braun and Vivien Prex for experimental assistance. This project
   has received funding from the European Union's Horizon 2020 research and
   innovation programme under grant agreement No 101003555 (Fight-nCoV) to
   J.M., the German Research Foundation (CRC1279) to J.M., S.S. and
   K.M.J.S., and an individual research grant (to J.A.M.). J.A.M. is
   indebted to the Baden-Wurttemberg Stiftung for the financial support of
   this research project by the Eliteprogramme for Postdocs. C.C., R.G.,
   and D.S. are part of and R.G. is funded by a scholarship from the
   International Graduate School in Molecular Medicine Ulm. H.S. and B.J.
   receive funding from the German Ministry of Health for a randomized
   prospective trial of convalescent plasma for treatment of patients with
   severe COVID-19 (CAPSID, EudraCT 2020-001310-38 and
   ClinicalTrials.gov-Identifier: NCT04433910).
CR Aubry M, 2016, TRANSFUSION, V56, P33, DOI 10.1111/trf.13271
   Chin Alex W H, 2020, Lancet Microbe, V1, pe10, DOI 10.1016/S2666-5247(20)30003-3
   Chu Hin, 2020, Lancet Microbe, V1, pe14, DOI 10.1016/S2666-5247(20)30004-5
   Conzelmann C, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11070591
   Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jeon S, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00819-20
   Keil SD, 2020, VOX SANG, V115, P495, DOI 10.1111/vox.12937
   Li RF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104761
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Liu XY, 2020, ACTA PHARMACOL SIN B, V10, P1205, DOI 10.1016/j.apsb.2020.04.008
   Ma QH, 2020, PHARMACOL RES, V158, DOI 10.1016/j.phrs.2020.104850
   Manenti A, 2020, J MED VIROL, V92, P2096, DOI 10.1002/jmv.25986
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Monteil V, 2020, CELL, V181, P905, DOI 10.1016/j.cell.2020.04.004
   Muller JA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04442-y
   Muller JA, 2017, MED MICROBIOL IMMUN, V206, P175, DOI 10.1007/s00430-017-0493-2
   Ng OW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102415
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Rocker AE, 2018, ANTIVIR RES, V152, P26, DOI 10.1016/j.antiviral.2018.02.003
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Yao X, 2020, CLIN INFECT DIS, V2, P1, DOI DOI 10.1093/CID/CIAA237
   Zheng Z., 2020, BIORXIV, DOI [10.110 1/2020.03.06.980037, DOI 10.1101/2020.03.06.980037, 10.1101/2020.03.06.980037]
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 29
TC 1
Z9 1
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD SEP
PY 2020
VL 181
AR 104882
DI 10.1016/j.antiviral.2020.104882
PG 8
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA NN5HP
UT WOS:000568819900002
PM 32738255
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Pizzorno, A
   Padey, B
   Dubois, J
   Julien, T
   Traversier, A
   Duliere, V
   Brun, P
   Lina, B
   Rosa-Calatrava, M
   Terrier, O
AF Pizzorno, Andres
   Padey, Blandine
   Dubois, Julia
   Julien, Thomas
   Traversier, Aurelien
   Duliere, Victoria
   Brun, Pauline
   Lina, Bruno
   Rosa-Calatrava, Manuel
   Terrier, Olivier
TI In vitro evaluation of antiviral activity of single and combined
   repurposable drugs against SARS-CoV-2
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE COVID-19; Antivirals; Drug combination; Remdesivir; Berberine; Diltiazem
AB In response to the current pandemic caused by the novel SARS-CoV-2, identifying and validating effective therapeutic strategies is more than ever necessary. We evaluated the in vitro antiviral activities of a shortlist of compounds, known for their cellular broad-spectrum activities, together with drugs that are currently under evaluation in clinical trials for COVID-19 patients. We report the antiviral effect of remdesivir, lopinavir, chloroquine, umifenovir, berberine and cyclosporine A in Vero E6 cells model of SARS-CoV-2 infection, with estimated 50% inhibitory concentrations of 0.99, 5.2, 1.38, 3.5, 10.6 and 3 mu M, respectively. Virus-directed plus host-directed drug combinations were also investigated. We report a strong antagonism between remdesivir and berberine, in contrast with remdesivir/diltiazem, for which we describe high levels of synergy, with mean Loewe synergy scores of 12 and peak values above 50. Combination of host-directed drugs with direct acting antivirals underscore further validation in more physiological models, yet they open up interesting avenues for the treatment of COVID-19.
C1 [Pizzorno, Andres; Padey, Blandine; Dubois, Julia; Julien, Thomas; Traversier, Aurelien; Duliere, Victoria; Brun, Pauline; Lina, Bruno; Rosa-Calatrava, Manuel; Terrier, Olivier] Univ Claude Bernard Lyon 1, Univ Lyon, Ctr Int Rech Infectiol Team VirPath, CIRI,INSERM,U1111,CNRS,UMR5308,ENS Lyon, F-69007 Lyon, France.
   [Padey, Blandine] Signia Therapeut SAS, Lyon, France.
   [Julien, Thomas; Duliere, Victoria; Brun, Pauline; Rosa-Calatrava, Manuel] Univ Lyon, Univ Claude Bernard Lyon 1, Fac Med RTH Laennec, VirNext, Lyon, France.
   [Lina, Bruno] Hosp Civils Lyon, Grp Hosp Nord, Ctr Natl Reference Virus Influenza Sud, Lab Virol,Inst Agents Infect, Lyon, France.
RP Rosa-Calatrava, M; Terrier, O (corresponding author), Univ Claude Bernard Lyon 1, Univ Lyon, Ctr Int Rech Infectiol Team VirPath, CIRI,INSERM,U1111,CNRS,UMR5308,ENS Lyon, F-69007 Lyon, France.
EM manuel.rosa-calatrava@univ-lyon1.fr; olivier.terrier@univ-lyon1.fr
RI Terrier, Olivier/B-6301-2009; Pizzorno, Mario Andres/L-7810-2017
OI Terrier, Olivier/0000-0001-9393-7684; Pizzorno, Mario
   Andres/0000-0002-0918-6804; lina, bruno/0000-0002-8959-2123
FU INSERM REACTing (REsearch & ACtion emergING infectious diseases);
   CNRSCentre National de la Recherche Scientifique (CNRS); Merieux
FX This work was funded by INSERM REACTing (REsearch & ACtion emergING
   infectious diseases), CNRS, and Merieux research grants. AP, BP, TJ, AT,
   OT and MRC are co-inventors of a patent application filed by INSERM,
   CNRS, Universite Claude Bernard Lyon 1 and Signia Therapeutics for the
   repurposing of diltiazem for the treatment of SARS-CoV-2 infections (FR
   20/02351).
CR Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   [Anonymous], 2020, COVID 19 LIVING DATA
   Blaising J, 2014, ANTIVIR RES, V107, P84, DOI 10.1016/j.antiviral.2014.04.006
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen C., 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Choy KT, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104786
   Chu CM, 2004, THORAX, V59, P252, DOI 10.1136/thorax.2003.012658
   Crotty S, 2000, NAT MED, V6, P1375
   de Wilde AH, 2011, J GEN VIROL, V92, P2542, DOI 10.1099/vir.0.034983-0
   Dunning J, 2014, LANCET INFECT DIS, V14, P1259, DOI 10.1016/S1473-3099(14)70821-7
   Furuta Y, 2002, ANTIMICROB AGENTS CH, V46, P977, DOI 10.1128/AAC.46.4.977-981.2002
   Furuta Y, 2013, ANTIVIR RES, V100, P446, DOI 10.1016/j.antiviral.2013.09.015
   Haviernik J, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040184
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Ianevski A, 2017, BIOINFORMATICS, V33, P2413, DOI 10.1093/bioinformatics/btx162
   Liu Q, 2020, EFFECT ARBIDOL HYDRO, DOI [10.1101/2020.04.11.20056523, DOI 10.1101/2020.04.11.20056523]
   Liu Y, 2020, LANCET INFECT DIS, V20, P656, DOI 10.1016/S1473-3099(20)30232-2
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Pizzorno A, 2020, BIORXIV, DOI [10.1101/2020.03.31.017889, DOI 10.1101/2020.03.31.017889]
   Pizzorno A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00060
   Prescott J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011159
   SIDWELL RW, 1972, SCIENCE, V177, P705, DOI 10.1126/science.177.4050.705
   Solidarity, 2020, CLIN TRIAL COVID 19
   Varghese FS, 2016, J VIROL, V90, P9743, DOI 10.1128/JVI.01382-16
   Varghese FS, 2016, ANTIVIR RES, V126, P117, DOI 10.1016/j.antiviral.2015.12.012
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Yan YQ, 2018, PHYTOTHER RES, V32, P2560, DOI 10.1002/ptr.6196
   Zheng SF, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1443
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 32
TC 4
Z9 4
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD SEP
PY 2020
VL 181
AR 104878
DI 10.1016/j.antiviral.2020.104878
PG 6
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA NN5HP
UT WOS:000568819900006
PM 32679055
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Kumar, Y
   Singh, H
   Patel, CN
AF Kumar, Yogesh
   Singh, Harvijay
   Patel, Chirag N.
TI In silico prediction of potential inhibitors for the Main protease of
   SARS-CoV-2 using molecular docking and dynamics simulation based
   drug-repurposing
SO JOURNAL OF INFECTION AND PUBLIC HEALTH
LA English
DT Article
DE Coronavirus; SARS-CoV-2; COVID-19; Drug repurposing; Docking
ID SARS; DESIGN; SCREEN; WUHAN
AB Background: The rapidly enlarging COVID-19 pandemic caused by the novel SARS-corona virus-2 is a global public health emergency of an unprecedented level. Unfortunately no treatment therapy or vaccine is yet available to counter the SARS-CoV-2 infection, which substantiates the need to expand research efforts in this direction. The indispensable function of the main protease in virus replication makes this enzyme a promising target for inhibitors screening and drug discovery to treat novel coronavirus infection. The recently concluded alpha-ketoamide ligand-bound X-ray crystal structure of SARS-CoV-2 M-pro (PDB ID: 6Y2F) from Zhang et al. has revealed the potential inhibitor binding mechanism and the molecular determinants responsible for substrate binding.
   Methods: For the study, we have targeted the SARS-CoV-2 M-pro for the screening of FDA approved antiviral drugs and carried out molecular docking based virtual screening. Further molecular dynamic simulation studies of the top three selected drugs carried out to investigated for their binding affinity and stability in the SARS-CoV-2 M-pro active site. The phylogenetic analysis was also performed to know the relatedness between the SARS-CoV-2 genomes isolated from different countries.
   Results: The phylogenetic analysis of the SARS-CoV-2 genome reveals that the virus is closely related to the Bat-SL-CoV and does not exhibit any divergence at the genomic level. Molecular docking studies revealed that among the 77 drugs, screened top ten drugs shows good binding affinities, whereas the top three drugs: Lopinavir-Ritonavir, Tipranavir, and Raltegravir were undergone for molecular dynamics simulation studies for their conformational stability in the active site of the SARS-CoV-2 M-pro protein.
   Conclusions: In the present study among the library of FDA approved antiviral drugs, the top three inhibitors Lopinavir-Ritonavir, Tipranavir, and Raltegravir show the best molecular interaction with the main protease of SARS-CoV-2. However, the in-vitro efficacy of the drug molecules screened in this study further needs to be corroborated by carrying out a biochemical and structural investigation. (c) 2020 Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.
C1 [Kumar, Yogesh] Cent Inst Med & Aromat Plants, CSIR, Dept Metab & Struct Biol, Lucknow 226015, Uttar Pradesh, India.
   [Kumar, Yogesh] Univ Med Ctr Hamburg Eppendorf, Dept Med, D-20246 Hamburg, Germany.
   [Singh, Harvijay] Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.
   [Patel, Chirag N.] Gujarat Univ, Univ Sch Sci, Dept Bot Bioinformat & Climate Impacts Management, Ahmadabad 280009, Gujarat, India.
RP Kumar, Y (corresponding author), Cent Inst Med & Aromat Plants, CSIR, Dept Metab & Struct Biol, Lucknow 226015, Uttar Pradesh, India.; Singh, H (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA.
EM kumar.yogesh601@gmail.com; hsingh@umn.edu
RI Singh, Harvijay/AAU-6952-2020
OI Kumar, Dr. Yogesh/0000-0001-7835-7972
CR Agarwal A, 2018, INT CONF IND INF SYS, P96
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   [Anonymous], 2020, REUTERS
   Barrows NJ, 2016, CELL HOST MICROBE, V20, P259, DOI 10.1016/j.chom.2016.07.004
   Blair HA, 2018, DRUGS, V78, P1741, DOI 10.1007/s40265-018-1005-4
   Brites C, 2018, HIV CLIN TRIALS, V19, P94, DOI 10.1080/15284336.2018.1459343
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Cottrell ML, 2013, CLIN PHARMACOKINET, V52, P981, DOI 10.1007/s40262-013-0093-2
   Cui J, 2019, NAT REV MICROBIOL, V17, P181, DOI 10.1038/s41579-018-0118-9
   De Luca A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225381
   Del Puente F, 2020, J ANTIMICROB CHEMOTH, V75, P3698, DOI 10.1093/jac/dkaa120
   Desai VH, 2015, APPL BIOCHEM BIOTECH, V177, P861, DOI 10.1007/s12010-015-1784-y
   Doyon L, 2005, ANTIVIR RES, V68, P27, DOI 10.1016/j.antiviral.2005.07.003
   Fan HH, 2020, CHINESE MED J-PEKING, V133, P1051, DOI [10.1097/CM9.0000000000000797, 10.1080/15384047.2020.1792218]
   Foolad F, 2018, EXPERT REV CLIN PHAR, V11, P931, DOI 10.1080/17512433.2018.1500897
   Forster P, 2020, P NATL ACAD SCI USA, V117, P9241, DOI 10.1073/pnas.2004999117
   Hayden FG, 2018, NEW ENGL J MED, V379, P913, DOI 10.1056/NEJMoa1716197
   He SS, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010286
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Hui DS, 2020, INT J INFECT DIS, V91, P264, DOI 10.1016/j.ijid.2020.01.009
   Hung IF-N, 2020, LANCET, DOI [10.1016/S0140-6736(20)31042-8, DOI 10.1016/S0140-6736(20)31042-8.]
   Hussain S, 2005, J VIROL, V79, P5288, DOI 10.1128/JVI.79.9.5288-5295.2005
   Kiemer L, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-72
   Kouznetsova J., 2014, EMERG MICROBES INFEC, V3, P1
   Krieger E, 2004, PROTEINS, V57, P678, DOI 10.1002/prot.20251
   Krieger E, 2015, J COMPUT CHEM, V36, P996, DOI 10.1002/jcc.23899
   Larder BA, 2000, AIDS, V14, P1943, DOI 10.1097/00002030-200009080-00009
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Marty FM, 2017, NEW ENGL J MED, V377, P2433, DOI 10.1056/NEJMoa1706640
   Plosker GL, 2003, DRUGS, V63, P1611, DOI 10.2165/00003495-200363150-00009
   Sun W, 2016, DRUG DISCOV TODAY, V21, P1189, DOI 10.1016/j.drudis.2016.05.015
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI [10.1093/molbev/msr121, 10.1093/molbev/mst197]
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Walmsley SL, 2013, NEW ENGL J MED, V369, P1807, DOI 10.1056/NEJMoa1215541
   Wong SK, 2004, J BIOL CHEM, V279, P3197, DOI 10.1074/jbc.C300520200
   Woo PCY, 2010, VIRUSES-BASEL, V2, P1804, DOI 10.3390/v2081803
   Yamamoto N, 2004, BIOCHEM BIOPH RES CO, V318, P719, DOI 10.1016/j.bbrc.2004.04.083
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yang YM, 2013, CELL STEM CELL, V12, P713, DOI 10.1016/j.stem.2013.04.003
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 45
TC 16
Z9 16
U1 4
U2 5
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1876-0341
EI 1876-035X
J9 J INFECT PUBLIC HEAL
JI J. Infect. Public Health
PD SEP
PY 2020
VL 13
IS 9
BP 1210
EP 1223
DI 10.1016/j.jiph.2020.06.016
PG 14
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA NN3AA
UT WOS:000568662900004
PM 32561274
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Ahlen, G
   Frelin, L
   Nikouyan, N
   Weber, F
   Hoglund, U
   Larsson, O
   Westman, M
   Tuvesson, O
   Gidlund, EK
   Cadossi, M
   Appelberg, S
   Mirazimi, A
   Sallberg, M
AF Ahlen, Gustaf
   Frelin, Lars
   Nikouyan, Negin
   Weber, Friedemann
   Hoglund, Urban
   Larsson, Olivia
   Westman, Marie
   Tuvesson, Ola
   Gidlund, Eva-karin
   Cadossi, Matteo
   Appelberg, Sofia
   Mirazimi, Ali
   Sallberg, Matti
CA OPENCORONA Consortium
TI The SARS-CoV-2 N Protein Is a Good Component in a Vaccine
SO JOURNAL OF VIROLOGY
LA English
DT Letter
DE COVID-19; DNA vaccine; SARS-CoV-2; vaccine
C1 [Ahlen, Gustaf; Frelin, Lars; Nikouyan, Negin; Mirazimi, Ali; Sallberg, Matti] Karolinska Inst, Div Clin Microbiol, Dept Lab Med, Stockholm, Sweden.
   [Weber, Friedemann] Justus Liebig Univ Giessen, Giessen, Germany.
   [Hoglund, Urban; Larsson, Olivia] Adlego Biomed AB, Uppsala, Sweden.
   [Westman, Marie] Karolinska Univ Hosp, Karolinska Trial Alliance, Stockholm, Sweden.
   [Tuvesson, Ola; Gidlund, Eva-karin] Cobra Biol, Matfors, Sweden.
   [Cadossi, Matteo] IGEA Spa, Carpi, Italy.
   [Appelberg, Sofia; Mirazimi, Ali] Publ Hlth Agcy Sweden, Solna, Sweden.
RP Sallberg, M (corresponding author), Karolinska Inst, Div Clin Microbiol, Dept Lab Med, Stockholm, Sweden.
EM matti.sallberg@ki.se
FU Swedish Research CouncilSwedish Research Council; Region Stockholm;
   Horizon 2020 grant OPENCORONA
FX The study was supported by the Horizon 2020 grant OPENCORONA, by
   donations to Karolinska Institutet for COVID-19 research, and by grants
   from the Swedish Research Council and Region Stockholm to M.S.
CR Chandrashekar A, 2020, SCIENCE, V369, P812, DOI 10.1126/science.abc4776
   Dutta NK, 2020, J VIROL, V94, DOI 10.1128/JVI.00647-20
   Gao Q, 2020, SCIENCE, V369, P77, DOI 10.1126/science.abc1932
   IWARSON S, 1985, GASTROENTEROLOGY, V88, P763, DOI 10.1016/0016-5085(85)90148-9
   Maravelia Panagiota, 2020, J Infect Dis, DOI 10.1093/infdis/jiaa036
   van Doremalen Neeltje, 2020, bioRxiv, DOI 10.1101/2020.05.13.093195
   Yu JY, 2020, SCIENCE, V369, P806, DOI 10.1126/science.abc6284
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 8
TC 1
Z9 1
U1 4
U2 4
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
EI 1098-5514
J9 J VIROL
JI J. Virol.
PD SEP
PY 2020
VL 94
IS 18
AR e01279-20
DI 10.1128/JVI.01279-20.
PG 2
WC Virology
SC Virology
GA NN3WF
UT WOS:000568720800005
DA 2021-01-01
ER

PT J
AU Jewell, BL
   Mudimu, E
   Stover, J
   ten Brink, D
   Phillips, AN
   Smith, JA
   Martin-Hughes, R
   Teng, Y
   Glaubius, R
   Mahiane, SG
   Bansi-Matharu, L
   Taramusi, I
   Chagoma, N
   Morrison, M
   Doherty, M
   Marsh, K
   Bershteyn, A
   Hallett, TB
   Kelly, SL
AF Jewell, Britta L.
   Mudimu, Edinah
   Stover, John
   Brink, Debra ten
   Phillips, Andrew N.
   Smith, Jennifer A.
   Martin-Hughes, Rowan
   Teng, Yu
   Glaubius, Robert
   Mahiane, Severin Guy
   Bansi-Matharu, Loveleen
   Taramusi, Isaac
   Chagoma, Newton
   Morrison, Michelle
   Doherty, Meg
   Marsh, Kimberly
   Bershteyn, Anna
   Hallett, Timothy B.
   Kelly, Sherrie L.
CA HIV Modelling Consortium
TI Potential effects of disruption to HIV programmes in sub-Saharan Africa
   caused by COVID-19: results from multiple mathematical models
SO LANCET HIV
LA English
DT Article
ID POSTELECTION CRISIS; EPIDEMIC; IMPACT
AB Background The COVID-19 pandemic could lead to disruptions to provision of HIV services for people living with HIV and those at risk of acquiring HIV in sub-Saharan Africa, where UNAIDS estimated that more than two-thirds of the approximately 38 million people living with HIV resided in 2018. We aimed to predict the potential effects of such disruptions on HIV-related deaths and new infections in sub-Saharan Africa.
   Methods In this modelling study, we used five well described models of HIV epidemics (Goals, Optima HIV, HIV Synthesis, an Imperial College London model, and Epidemiological MODeling software [EMOD]) to estimate the effect of various potential disruptions to HIV prevention, testing, and treatment services on HIV-related deaths and new infections in sub-Saharan Africa lasting 6 months over 1 year from April 1, 2020. We considered scenarios in which disruptions affected 20%, 50%, and 100% of the population.
   Findings A 6-month interruption of supply of antiretroviral therapy (ART) drugs across 50% of the population of people living with HIV who are on treatment would be expected to lead to a 1.63 times (median across models; range 1.39-1.87) increase in HIV-related deaths over a 1-year period compared with no disruption. In sub-Saharan Africa, this increase amounts to a median excess of HIV deaths, across all model estimates, of 296 000 (range 229023-420000) if such a high level of disruption occurred. Interruption of ART would increase mother-to-child transmission of HIV by approximately 1.6 times. Although an interruption in the supply of ART drugs would have the largest impact of any potential disruptions, effects of poorer clinical care due to overstretched health facilities, interruptions of supply of other drugs such as co-trimoxazole, and suspension of HIV testing would all have a substantial effect on population-level mortality (up to a 1.06 times increase in HIV-related deaths over a 1-year period due to disruptions affecting 50% of the population compared with no disruption). Interruption to condom supplies and peer education would make populations more susceptible to increases in HIV incidence, although physical distancing measures could lead to reductions in risky sexual behaviour (up to 1.19 times increase in new HIV infections over a 1-year period if 50% of people are affected).
   Interpretation During the COVID-19 pandemic, the primary priority for governments, donors, suppliers, and communities should focus on maintaining uninterrupted supply of ART drugs for people with HIV to avoid additional HIV-related deaths. The provision of other HIV prevention measures is also important to prevent any increase in HIV incidence. Copyright (c) 2020 World Health Organization; licensee Elsevier.
C1 [Jewell, Britta L.; Smith, Jennifer A.; Hallett, Timothy B.] Imperial Coll London, Med Res Council Ctr Global Infect Dis Anal, Abdul Latif Jameel Inst Dis & Emergency Analyt, London, England.
   [Mudimu, Edinah] Univ South Africa, Dept Decis Sci, Pretoria, South Africa.
   [Stover, John; Teng, Yu; Glaubius, Robert; Mahiane, Severin Guy] Avenir Hlth, Glastonbury, CT USA.
   [Brink, Debra ten; Martin-Hughes, Rowan; Kelly, Sherrie L.] Burnet Inst, Melbourne, Vic, Australia.
   [Phillips, Andrew N.; Bansi-Matharu, Loveleen] UCL, Inst Global Hlth, London NW3 2PF, England.
   [Taramusi, Isaac] Natl AIDS Council Zimbabwe, Harare, Zimbabwe.
   [Chagoma, Newton] Natl AIDS Council Malawi, Lilongwe, Malawi.
   [Morrison, Michelle] Bill & Melinda Gates Fdn, Seattle, WA USA.
   [Doherty, Meg] WHO, Geneva, Switzerland.
   [Marsh, Kimberly] UNAIDS, Geneva, Switzerland.
   [Bershteyn, Anna] NYU, Sch Med, New York, NY USA.
RP Phillips, AN (corresponding author), UCL, Inst Global Hlth, London NW3 2PF, England.
EM andrew.phillips@ucl.ac.uk
OI Smith, Jennifer/0000-0002-8809-8553; Hallett,
   Timothy/0000-0002-9681-0424
FU Bill & Melinda Gates FoundationBill & Melinda Gates Foundation
FX Bill & Melinda Gates Foundation.
CR [Anonymous], 2020, LANCET HIV, V7, pE301, DOI 10.1016/S2352-3018(20)30113-2
   [Anonymous], 2020, NEWS DESK
   [Anonymous], 2020, PEPFAR TECHN GUID CO
   [Anonymous], 2020, COVID 19 DSD RES COM
   Beacroft L, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25414
   Bershteyn A, 2018, PATHOG DIS, V76, DOI 10.1093/femspd/fty059
   Drain PK, 2020, ECLINICALMEDICINE, V22
   El-Sadr WM, 2020, NEW ENGL J MED, V383, DOI 10.1056/NEJMp2008193
   Ferreyra C, 2018, CONFL HEALTH, V12, DOI 10.1186/s13031-018-0161-1
   Finmark Trust, 2020, LIV IMP COVID 19 KEN
   Glaziou P, 2020, PREDICTED IMPACT COV, DOI [10.1101/2020.04.28.20079582, DOI 10.1101/2020.04.28.20079582]
   Grund B, 2006, INT AIDS C TOR ON CA
   Hogan AB, 2020, LANCET GLOB HLTH
   Hosken Graeme, 2020, SUNDAY TIMES
   Jobanputra Kiran, 2014, Journal of acquired immune deficiency syndromes (1999), V67, P45, DOI 10.1097/QAI.0000000000000224
   Joint United Nations Programme on HIV/AIDS (UNAIDS), 2019, UNAIDS DAT 2019
   Kerr CC, 2015, JAIDS-J ACQ IMM DEF, V69, P365, DOI 10.1097/QAI.0000000000000605
   Leuenberger D, 2015, AIDS, V29, P1883, DOI 10.1097/QAD.0000000000000784
   Mann M, 2013, JAIDS-J ACQ IMM DEF, V64, P220, DOI 10.1097/QAI.0b013e31829ec485
   Mutasa-Apollo T, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.5.21647
   Nyoni T, 2020, AIDS BEHAV, V24, P2473, DOI 10.1007/s10461-020-02888-0
   Rattner I, 2019, INT J QUAL METH, V18
   Stop TB Partnership, 2020, POT IMP COVID 19 RES
   Stover J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154893
   Todd J, 2007, AIDS, V21, pS55, DOI 10.1097/01.aids.0000299411.75269.e8
   WHO, 2020, WHO ACC HIV MED SEV
   Wit FWNM, 2005, AIDS, V19, P345
   World Health Organization (WHO), 2020, POT IMP HLTH SERV DI
   Yoder RB, 2012, JAIDS-J ACQ IMM DEF, V59, P199, DOI 10.1097/QAI.0b013e31823b4448
   Young S, 2014, AIDS BEHAV, V18, pS505, DOI 10.1007/s10461-013-0547-4
NR 30
TC 8
Z9 8
U1 3
U2 3
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 2352-3018
J9 LANCET HIV
JI Lancet HIV
PD SEP
PY 2020
VL 7
IS 9
BP E629
EP E640
DI 10.1016/S2352-3018(20)30211-3
PG 12
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA NN2VN
UT WOS:000568651100010
PM 32771089
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Fennelly, KP
AF Fennelly, Kevin P.
TI Particle sizes of infectious aerosols: implications for infection
   control
SO LANCET RESPIRATORY MEDICINE
LA English
DT Article
ID EXHALED BREATH CONDENSATE; AIRBORNE MYCOBACTERIUM-TUBERCULOSIS; ACUTE
   RESPIRATORY SYNDROME; RANDOMIZED CLINICAL-TRIAL; HEALTH-CARE WORKERS;
   INFLUENZA-A VIRUS; N95 RESPIRATORS; PNEUMOCYSTIS-JIROVECII; MEDICAL
   MASKS; PSEUDOMONAS-AERUGINOSA
AB The global pandemic of COVID-19 has been associated with infections and deaths among health-care workers. This Viewpoint of infectious aerosols is intended to inform appropriate infection control measures to protect health-care workers. Studies of cough aerosols and of exhaled breath from patients with various respiratory infections have shown striking similarities in aerosol size distributions, with a predominance of pathogens in small particles (<5 mu m). These are immediately respirable, suggesting the need for personal respiratory protection (respirators) for individuals in close proximity to patients with potentially virulent pathogens. There is no evidence that some pathogens are carried only in large droplets. Surgical masks might offer some respiratory protection from inhalation of infectious aerosols, but not as much as respirators. However, surgical masks worn by patients reduce exposures to infectious aerosols to health-care workers and other individuals. The variability of infectious aerosol production, with some socalled super-emitters producing much higher amounts of infectious aerosol than most, might help to explain the epidemiology of super-spreading. Airborne infection control measures are indicated for potentially lethal respiratory pathogens such as severe acute respiratory syndrome coronavirus 2.
C1 [Fennelly, Kevin P.] NHLBI, Pulm Branch, Div Intramural Res, NIH, Bethesda, MD 20892 USA.
RP Fennelly, KP (corresponding author), NHLBI, Pulm Branch, Div Intramural Res, NIH, Bethesda, MD 20892 USA.
EM kevin.fennelly@nih.gov
FU Division of Intramural Research, Pulmonary Branch, National Heart, Lung
   and Blood Institute (NHLBI), National Institutes of Health (NIH),
   Bethesda, MD, USA
FX I am funded entirely by the Division of Intramural Research, Pulmonary
   Branch, National Heart, Lung and Blood Institute (NHLBI), National
   Institutes of Health (NIH), Bethesda, MD, USA. I conceived this paper,
   and did all the searches, manuscript drafts, and revisions. No medical
   writers were used. The views presented here are mine alone and do not
   represent official policy of the NIH, NHLBI, or any other organisation.
CR Acuna-Villaorduna C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206384
   Acuna-Villaorduna C, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01578-2017
   ALFORD RH, 1966, P SOC EXP BIOL MED, V122, P800, DOI 10.3181/00379727-122-31255
   [Anonymous], 2014, RAP RESP REP
   Bahl Prateek, 2020, J Infect Dis, DOI 10.1093/infdis/jiaa189
   Bake B, 2019, RESP RES, V20, DOI 10.1186/s12931-019-0970-9
   Bartlett MS, 1997, J CLIN MICROBIOL, V35, P2511, DOI 10.1128/JCM.35.10.2511-2513.1997
   Bartoszko JJ, 2020, INFLUENZA OTHER RESP, V14, P365, DOI 10.1111/irv.12745
   bin-Reza F, 2012, INFLUENZA OTHER RESP, V6, P257, DOI 10.1111/j.1750-2659.2011.00307.x
   Bischoff WE, 2016, J INFECT DIS, V213, P600, DOI 10.1093/infdis/jiv465
   Bischoff WE, 2013, J INFECT DIS, V207, P1037, DOI 10.1093/infdis/jis773
   Blachere FM, 2009, CLIN INFECT DIS, V48, P438, DOI 10.1086/596478
   Booth C. M., 2013, Journal of Hospital Infection, V84, P22, DOI 10.1016/j.jhin.2013.02.007
   Booth TF, 2005, J INFECT DIS, V191, P1472, DOI 10.1086/429634
   Bourouiba L, 2020, JAMA-J AM MED ASSOC, V323, P1837, DOI 10.1001/jama.2020.4756
   Brankston G, 2007, LANCET INFECT DIS, V7, P257, DOI 10.1016/S1473-3099(07)70029-4
   BROWN JH, 1950, AM J PUBLIC HEALTH, V40, P450
   Carpagnano GE, 2011, BRIT J CANCER, V105, P1183, DOI 10.1038/bjc.2011.354
   Carpagnano GE, 2018, CLIN RESPIR J, V12, P418, DOI 10.1111/crj.12531
   Carpagnano GE, 2016, ALLERGY ASTHMA PROC, V37, pE41, DOI 10.2500/aap.2016.37.3943
   Cheng VCC, 2020, INFECT CONT HOSP EP, V41, P493, DOI [10.1017/ice.2020.58, 10.1017/ice.2020.282]
   Chikasue K, 2012, ACTA MED OKAYAMA, V66, P387
   Chou R, 2020, ANN INTERN MED, V173, P120, DOI 10.7326/M20-1632
   Choukri F, 2010, CLIN INFECT DIS, V51, P259, DOI 10.1086/653933
   Coffey CC, 2004, J OCCUP ENVIRON HYG, V1, P262, DOI 10.1080/15459620490433799
   Costa C, 2011, J VIROL METHODS, V173, P384, DOI 10.1016/j.jviromet.2011.02.004
   COX CS, 1989, SCI PROG, V73, P469
   Dharmadhikari AS, 2012, AM J RESP CRIT CARE, V185, P1104, DOI 10.1164/rccm.201107-1190OC
   DRUETT HA, 1953, J HYG-CAMBRIDGE, V51, P359, DOI 10.1017/S0022172400015795
   Duling MG, 2007, J OCCUP ENVIRON HYG, V4, P420, DOI 10.1080/15459620701346925
   Elmashae Reported By Yousef, 2017, J Occup Environ Hyg, V14, pD145, DOI 10.1080/15459624.2017.1319571
   Fabian P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002691
   Faridi S, 2020, SCI TOTAL ENVIRON, V725, DOI 10.1016/j.scitotenv.2020.138401
   Fennelly K, 2014, VIRUS ADAPT TREAT, V7, P1
   Fennelly KP, 2007, CLIN INFECT DIS, V44, P1358, DOI 10.1086/516617
   Fennelly KP, 2012, AM J RESP CRIT CARE, V186, P450, DOI 10.1164/rccm.201203-0444OC
   Fennelly KP, 1998, INFECT CONT HOSP EP, V19, P754
   Fennelly KP, 2004, AM J RESP CRIT CARE, V169, P604, DOI 10.1164/rccm.200308-1101OC
   Fennelly KP, 1997, CLIN CHEST MED, V18, P1, DOI 10.1016/S0272-5231(05)70352-X
   Fennelly KP, 2015, FRONT IMMUNOL, V6, P1
   Frealle E, 2017, MED MYCOL, V55, P568, DOI 10.1093/mmy/myw113
   Galvani AP, 2005, NATURE, V438, P293, DOI 10.1038/438293a
   Gammaitoni L, 1997, EMERG INFECT DIS, V3, P335, DOI 10.3201/eid0303.970310
   Gao S, 2016, ANN OCCUP HYG, V60, P608, DOI 10.1093/annhyg/mew006
   Gawn JM, 2008, EVALUATING PROTECTIO
   Gralton J, 2013, J MED VIROL, V85, P2151, DOI 10.1002/jmv.23698
   Gralton J, 2011, J INFECTION, V62, P1, DOI 10.1016/j.jinf.2010.11.010
   Grinshpun SA, 2009, J OCCUP ENVIRON HYG, V6, P593, DOI 10.1080/15459620903120086
   Guo ZD, 2020, EMERG INFECT DIS, V26, P1586, DOI 10.3201/eid2607.200885
   Hamner L, 2020, MMWR-MORBID MORTAL W, V69, P606, DOI 10.15585/mmwr.mm6919e6
   HARPER GJ, 1953, J HYG-CAMBRIDGE, V51, P372, DOI 10.1017/S0022172400015801
   Hemmink JD, 2016, VET RES, V47, DOI 10.1186/s13567-016-0390-5
   Houspie L, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-98
   HUTTON MD, 1990, J INFECT DIS, V161, P286, DOI 10.1093/infdis/161.2.286
   Huynh KN, 2008, CLIN INFECT DIS, V46, P93, DOI 10.1086/523000
   Jain R, 2007, RESPIRATION, V74, P329, DOI 10.1159/000101786
   Johnson DF, 2009, CLIN INFECT DIS, V49, P275, DOI 10.1086/600041
   Jones-Lopez EC, 2013, AM J RESP CRIT CARE, V187, P1007, DOI 10.1164/rccm.201208-1422OC
   Kawada Hiroshi, 2008, Kekkaku, V83, P387
   Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501
   Kim SH, 2016, CLIN INFECT DIS, V63, P363, DOI 10.1093/cid/ciw239
   Knibbs LD, 2014, THORAX, V69, P740, DOI 10.1136/thoraxjnl-2014-205213
   Kulkarni H, 2016, AM J RESP CRIT CARE, V194, P308, DOI 10.1164/rccm.201509-1833OC
   Le Gal S, 2015, DIAGN MICR INFEC DIS, V82, P137, DOI 10.1016/j.diagmicrobio.2015.01.004
   Leung Nancy H L, 2020, Nat Med, V26, P676, DOI 10.1038/s41591-020-0843-2
   Leung NHL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148669
   Li Y, 2005, INDOOR AIR, V15, P83, DOI 10.1111/j.1600-0668.2004.00317.x
   Lindsley WG, 2016, INFLUENZA OTHER RESP, V10, P404, DOI 10.1111/irv.12390
   Lindsley WG, 2015, J OCCUP ENVIRON HYG, V12, P107, DOI 10.1080/15459624.2014.973113
   Lindsley WG, 2014, J OCCUP ENVIRON HYG, V11, P509, DOI 10.1080/15459624.2013.877591
   Lindsley WG, 2012, J OCCUP ENVIRON HYG, V9, P443, DOI 10.1080/15459624.2012.684582
   Lindsley WG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015100
   Lindsley WG, 2010, CLIN INFECT DIS, V50, P693, DOI 10.1086/650457
   Liu LT, 2000, INT J TUBERC LUNG D, V4, P275
   Liu Y, 2020, NATURE, V582, P557, DOI 10.1038/s41586-020-2271-3
   Lloyd-Smith JO, 2005, NATURE, V438, P355, DOI 10.1038/nature04153
   Loeb M, 2009, JAMA-J AM MED ASSOC, V302, P1865, DOI 10.1001/jama.2009.1466
   Long Youlin, 2020, J Evid Based Med, V13, P93, DOI 10.1111/jebm.12381
   MacIntyre CR, 2013, AM J RESP CRIT CARE, V187, P960, DOI 10.1164/rccm.201207-1164OC
   MacIntyre CR, 2011, INFLUENZA OTHER RESP, V5, P170, DOI 10.1111/j.1750-2659.2011.00198.x
   MacIntyre CR, 1999, EPIDEMIOL INFECT, V123, P445, DOI 10.1017/S095026889900312X
   Mandalakas AM, 2012, INT J TUBERC LUNG D, V16, P1033, DOI 10.5588/ijtld.12.0027
   Mastorides SM, 1997, CLIN INFECT DIS, V25, P756, DOI 10.1086/516953
   Matuka O, 2015, J HOSP INFECT, V89, P192, DOI 10.1016/j.jhin.2014.11.013
   McIntosh AI, 2017, STAT MED, V36, P2522, DOI 10.1002/sim.7303
   Milton DK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003205
   Morawska L, 2020, ENVIRON INT, V142, DOI 10.1016/j.envint.2020.105832
   Morilla R, 2018, MED MYCOL, DOI [10.1093/mmy/myy093., DOI 10.1093/MMY/MYY093.]
   Myatt TA, 2004, AM J RESP CRIT CARE, V169, P1187, DOI 10.1164/rccm.200306-760OC
   NICAS M, 1995, AM J IND MED, V27, P317, DOI 10.1002/ajim.4700270302
   Oliphant K, 2020, MSYSTEMS, V5, DOI 10.1128/mSystems.00404-19
   Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227
   Pan M, 2019, J APPL MICROBIOL, V127, P1596, DOI 10.1111/jam.14278
   Patterson B, 2018, GATES OPEN RES, V1, P11
   Patterson B, 2019, TUBERCULOSIS, V117, P31, DOI 10.1016/j.tube.2019.05.003
   Pougnet L, 2018, INFECT CONT HOSP EP, V39, P627, DOI 10.1017/ice.2018.45
   Prather KA, 2020, SCIENCE, V368, P1422, DOI 10.1126/science.abc6197
   Public Health England, 2020, GUID INF PREV CONTR
   Qian YG, 1998, AM IND HYG ASSOC J, V59, P128, DOI 10.1080/15428119891010389
   Radonovich LJ, 2019, JAMA-J AM MED ASSOC, V322, P824, DOI 10.1001/jama.2019.11645
   Riou J, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.4.2000058
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Roxby AC, 2020, MMWR-MORBID MORTAL W, V69, P416, DOI 10.15585/mmwr.mm6914e2
   Rule AM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203223
   Santarpia JL, 2020, AEROSOL SURFACE TRAN
   SAWYER MH, 1994, J INFECT DIS, V169, P91, DOI 10.1093/infdis/169.1.91
   Schreiber J, 2002, EUR J MED RES, V7, P290
   Shaikh A, 2019, INT J INFECT DIS, V86, P5, DOI 10.1016/j.ijid.2019.06.006
   Shiu EYC, 2020, INDOOR AIR, V30, P805, DOI 10.1111/ina.12669
   Sia SF, 2020, NATURE, V583, P834, DOI 10.1038/s41586-020-2342-5
   Siegel JD, 2007, AM J INFECT CONTROL, V35, pS65, DOI 10.1016/j.ajic.2007.10.007
   Smith JD, 2016, CAN MED ASSOC J, V188, P567, DOI 10.1503/cmaj.150835
   Somsen GA, 2020, LANCET RESP MED, V8, P658, DOI 10.1016/S2213-2600(20)30245-9
   St George K, 2010, J VIROL METHODS, V163, P144, DOI 10.1016/j.jviromet.2009.08.019
   Stelzer-Braid S, 2016, J MED VIROL, V88, P578, DOI 10.1002/jmv.24371
   Stelzer-Braid S, 2009, J MED VIROL, V81, P1674, DOI 10.1002/jmv.21556
   Tang JW, 2008, NEW ENGL J MED, V359, pE19, DOI 10.1056/NEJMicm072576
   Tellier R, 2007, LANCET INFECT DIS, V7, P759, DOI 10.1016/S1473-3099(07)70269-4
   Theron G, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0940-2
   Tovey ER, 2015, J ALLERGY CLIN IMMUN, V135, P663, DOI 10.1016/j.jaci.2014.10.020
   Tseng CC, 2010, J ENVIRON HEALTH, V73, P22
   Turchiarelli V, 2011, ALLERGY, V66, P1099, DOI 10.1111/j.1398-9995.2011.02600.x
   United States Centers for Disease Control and Prevention (CDC), 2020, INT INF PREV CONTR R
   Vadrot C, 2004, J HOSP INFECT, V58, P262, DOI 10.1016/j.jhin.2004.04.026
   Valade S, 2015, INTENS CARE MED, V41, P1716, DOI 10.1007/s00134-015-3835-9
   van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI 10.1056/NEJMc2004973
   Verani M, 2014, AM J INFECT CONTROL, V42, P758, DOI 10.1016/j.ajic.2014.03.026
   Verbeek JH, 2020, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD011621.pub4, 10.1002/14651858.CD011621.pub5]
   Wainwright CE, 2009, THORAX, V64, P926, DOI 10.1136/thx.2008.112466
   Wallace M, 2020, MMWR-MORBID MORTAL W, V69, P587, DOI 10.15585/mmwr.mm6919e1
   Wan GH, 2004, AM J INFECT CONTROL, V32, P17, DOI 10.1016/S0196-6553(03)00090-7
   Wan GH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033974
   Wells WF, 1955, AIRBORNE CONTAGION A, P13
   WHO, 2020, MOD TRANSM VIR CAUS
   Williams CM, 2020, LANCET INFECT DIS, V20, P607, DOI [10.1016/S1473-3099(19)30707-8, 10.1016/S1473-3099(19)30307-8]
   Wong TW, 2004, EMERG INFECT DIS, V10, P269, DOI 10.3201/eid1002.030452
   Wood ME, 2018, AM J RESP CRIT CARE, V197, P348, DOI 10.1164/rccm.201707-1457OC
   Xie X, 2007, INDOOR AIR, V17, P211, DOI 10.1111/j.1600-0668.2007.00469.x
   Yadana S, 2019, J PUBLIC HEALTH RES, V8, P100, DOI 10.4081/jphr.2019.1407
   Yan J, 2018, P NATL ACAD SCI USA, V115, P1081, DOI 10.1073/pnas.1716561115
   Yip L, 2019, J OCCUP ENVIRON HYG, V16, P341, DOI 10.1080/15459624.2019.1591626
   Yu ITS, 2014, CLIN INFECT DIS, V58, P683, DOI 10.1093/cid/cit797
   Yu ITS, 2004, NEW ENGL J MED, V350, P1731, DOI 10.1056/NEJMoa032867
   Zakharkina T, 2011, RESPIROLOGY, V16, P932, DOI 10.1111/j.1440-1843.2011.01977.x
   Zhang B, 1997, Zhonghua Jie He He Hu Xi Za Zhi, V20, P101
   Zheng YH, 2018, J AEROSOL SCI, V117, P224, DOI 10.1016/j.jaerosci.2017.12.009
NR 146
TC 20
Z9 20
U1 10
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-2600
J9 LANCET RESP MED
JI Lancet Resp. Med.
PD SEP
PY 2020
VL 8
IS 9
BP 914
EP 924
DI 10.1016/S2213-2600(20)30323-4
PG 11
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA NN2ZX
UT WOS:000568662600023
PM 32717211
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Sencanski, M
   Perovic, V
   Pajovic, SB
   Adzic, M
   Paessler, S
   Glisic, S
AF Sencanski, Milan
   Perovic, Vladimir
   Pajovic, Snezana B.
   Adzic, Miroslav
   Paessler, Slobodan
   Glisic, Sanja
TI Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a
   NovelIn SilicoMethod
SO MOLECULES
LA English
DT Article
DE SARS-CoV-2; main protease M-pro; drug repurposing; virtual screening;
   ISM
ID OPTIMIZATION; DOCKING
AB The SARS-CoV-2 outbreak caused an unprecedented global public health threat, having a high transmission rate with currently no drugs or vaccines approved. An alternative powerful additional approach to counteract COVID-19 isin silicodrug repurposing. The SARS-CoV-2 main protease is essential for viral replication and an attractive drug target. In this study, we used the virtual screening protocol with both long-range and short-range interactions to select candidate SARS-CoV-2 main protease inhibitors. First, the Informational spectrum method applied for small molecules was used for searching the Drugbank database and further followed by molecular docking. Afterin silicoscreening of drug space, we identified 57 drugs as potential SARS-CoV-2 main protease inhibitors that we propose for further experimental testing.
C1 [Sencanski, Milan; Perovic, Vladimir; Glisic, Sanja] Univ Belgrade, Inst Nucl Sci Vinca, Natl Inst Republ Serbia, Lab Bioinformat & Computat Chem, Belgrade 11001, Serbia.
   [Pajovic, Snezana B.; Adzic, Miroslav] Univ Belgrade, VINCA Inst Nucl Sci, Natl Inst Republ Serbia, Dept Mol Biol & Endocrinol, Belgrade 11001, Serbia.
   [Paessler, Slobodan] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.
   [Paessler, Slobodan] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA.
RP Glisic, S (corresponding author), Univ Belgrade, Inst Nucl Sci Vinca, Natl Inst Republ Serbia, Lab Bioinformat & Computat Chem, Belgrade 11001, Serbia.
EM sencanski@vinca.rs; vladaper@vinca.rs; pajovic@vinca.rs;
   miraz@vin.bg.ac.rs; slpaessl@utmb.edu; sanja@vinca.rs
OI Pajovic, Snezana/0000-0002-3524-2814; Sencanski,
   Milan/0000-0002-7296-3223
FU Ministry of Education, Science and Technological Development of the
   Republic of Serbia
FX This work was supported by the Ministry of Education, Science and
   Technological Development of the Republic of Serbia.
CR Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   [Anonymous], 2012, OR VERS 9
   Bean D., 2020, TREATMENT ACE INHIBI, DOI [10.1101/2020.04.07.20056788, DOI 10.1101/2020.04.07.20056788]
   Biovia D.S., 2016, DISCOVERY STUDIO MOD
   Dallakyan S, 2015, METHODS MOL BIOL, V1263, P243, DOI 10.1007/978-1-4939-2269-7_19
   DELUCCA GV, 1992, BIOORG MED CHEM LETT, V2, P1639, DOI 10.1016/S0960-894X(00)80447-3
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Duarte RR., 2020, REPURPOSING FDA APPR, DOI [10.26434/chemrxiv.12148764.v1, DOI 10.26434/CHEMRXIV.12148764.V1]
   Durdagi S., 2020, SCREENING CLIN APPRO, DOI [10.26434/chemrxiv.12032712.v2., DOI 10.26434/CHEMRXIV.12032712.V2]
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Gul S., 2020, SILICO IDENTIFICATIO, DOI [10.26434/chemrxiv.12123204.v1, DOI 10.26434/CHEMRXIV.12123204.V1]
   Hosseini M., 2020, COMPUTATIONAL MOL DO, DOI [10.26434/chemrxiv.12237995.v1, DOI 10.26434/CHEMRXIV.12237995.V1]
   Iwabuchi K, 2020, J INFECT CHEMOTHER, V26, P625, DOI 10.1016/j.jiac.2020.04.007
   Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Kumar V, 2020, RES SQ, DOI [10.21203/rs.3.rs-31775/v1, DOI 10.21203/RS.3.RS-31775/V1]
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Maestro V., 2016, SCHRODINGER RELEASE
   Mahanta S, 2020, J BIOMOL STRUCT DYN, DOI 10.1080/07391102.2020.1768902
   Matsuyama S., 2020, INHALED CORTICOSTERO, DOI [10.1101/2020.03.11.987016, DOI 10.1101/2020.03.11.987016]
   Mitja O, 2020, LANCET GLOB HEALTH, V8, pE639, DOI 10.1016/S2214-109X(20)30114-5
   Nakajima K., 2020, CASE CORONAVIRUS DIS, DOI [10.1016/j.mayocp.2020.04.007, DOI 10.1016/J.MAYOCP.2020.04.007]
   Omar A., 2020, MOL DOCKING REVEALS, DOI [10.26434/chemrxiv.12061302.v1., DOI 10.26434/CHEMRXIV.12061302.V1]
   Sencanski M., 2019, ARXIV190702713
   Smyth LJ, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026777
   Stewart J., 2016, MOPAC2016 STEWART CO
   Stewart JJP, 2013, J MOL MODEL, V19, P1, DOI 10.1007/s00894-012-1667-x
   Strodel B, 2020, HIGH THROUGHPUT VIRT, DOI [10.20944/preprints202004.0161.v1, DOI 10.20944/PREPRINTS202004.0161.V1]
   Tariq A, 2020, INT J INFECT DIS, V98, P166, DOI 10.1016/j.ijid.2020.06.063
   Thenin-Houssier S, 2016, ANTIMICROB AGENTS CH, V60, P2195, DOI 10.1128/AAC.02574-15
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Tsuji M, 2020, FEBS OPEN BIO, V10, P995, DOI 10.1002/2211-5463.12875
   Tu YF, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072657
   Vafaei S., 2019, CORONAVIRUS DIS, DOI [10.2139/ssrn.3569866, DOI 10.2139/SSRN.3569866]
   Vatansever Erol C, 2020, bioRxiv, DOI 10.1101/2020.05.23.112235
   VELJKOVIC V, 1985, IEEE T BIO-MED ENG, V32, P337, DOI 10.1109/TBME.1985.325549
   VELJKOVIC V, 1972, PHYS REV LETT, V29, P105, DOI 10.1103/PhysRevLett.29.105
   Veljkovic V., 2020, RES SQ, DOI [10.21203/rs.2.24483/v1+, DOI 10.21203/RS.2.24483/V1+]
   Veljkovic Veljko, 2020, F1000Res, V9, P52, DOI 10.12688/f1000research.22149.1
   Verbalis JG, 2011, EUR J ENDOCRINOL, V164, P725, DOI 10.1530/EJE-10-1078
   Verma D., 2020, POTENTIAL INHIBITORS, DOI [10.20944/preprints202004.0149.v1, DOI 10.20944/PREPRINTS202004.0149.V1]
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   World Health Organization, 2020, COR DIS
   Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3
   Yamanishi Y, 2008, BIOINFORMATICS, V24, pI232, DOI 10.1093/bioinformatics/btn162
   Yamey G., 2020, VACCINES, DOI [10.2139/ssrn.3575660, DOI 10.2139/SSRN.3575660]
   Yousaf Z, 2020, AM J PHYSIOL-ENDOC M, V318, pE882, DOI 10.1152/ajpendo.00178.2020
   Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405
NR 50
TC 1
Z9 1
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD SEP
PY 2020
VL 25
IS 17
AR 3830
DI 10.3390/molecules25173830
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA NO8BU
UT WOS:000569713700001
PM 32842509
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Romeo, A
   Iacovelli, F
   Falconi, M
AF Romeo, Alice
   Iacovelli, Federico
   Falconi, Mattia
TI Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation:
   virtual screening and molecular dynamics simulations applied to the
   identification of potential fusion inhibitors
SO VIRUS RESEARCH
LA English
DT Article
DE SARS-CoV-2; Virtual screening; Molecular dynamics; Spike glycoprotein;
   Sequence alignment; Fusion inhibitors
ID RESPIRATORY SYNCYTIAL VIRUS; PHOTODYNAMIC INACTIVATION; HIV-1 INFECTION;
   ROSE-BENGAL; HYPERICIN; OPTIMIZATION; INTEGRATION; MECHANISM; DISCOVERY;
   TMC647055
AB The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a renewed interest in studying the role of the spike S glycoprotein in regulating coronavirus infections in the natural host. Taking advantage of the cryo-electron microscopy structure of SARS-CoV-2 S trimer in the prefusion conformation, we performed a virtual screening simulation with the aim to identify novel molecules that could be used as fusion inhibitors. The spike glycoprotein structure has been completed using modeling techniques and its inner cavity, needful for the postfusion transition of the trimer, has been scanned for the identification of strongly interacting available drugs. Finally, the stability of the protein-drug top complexes has been tested using classical molecular dynamics simulations. The free energy of interaction of the molecules to the spike protein has been evaluated through the MM/GBSA method and per-residue decomposition analysis. Results have been critically discussed considering previous scientific knowledge concerning the selected compounds and sequence alignments have been carried out to evaluate the spike glycoprotein similarity among the betacoronavirus family members. Finally, a cocktail of drugs that may be used as SARS-CoV-2 fusion inhibitors has been suggested.
C1 [Romeo, Alice; Iacovelli, Federico; Falconi, Mattia] Univ Roma Tor Vergata, Dept Biol, Struct Bioinformat Grp, Rome, Italy.
RP Falconi, M (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci 1, I-00133 Rome, Italy.
EM falconi@uniroma2.it
RI Iacovelli, Federico/T-9193-2019
OI Iacovelli, Federico/0000-0001-7511-6575; FALCONI,
   MATTIA/0000-0002-3990-4758; Romeo, Alice/0000-0001-6162-6814
FU ENEAENEA, Italy; Italian National Agency for New Technologies, Energy
   and Sustainable Economic DevelopmentENEA, Italy; European research
   programme; Italian research programme
FX The computing resources and the related technical support were provided
   by CRESCO/ENEAGRID High Performance Computing infrastructure (Ponti et
   al., 2014). CRESCO/ENEAGRID High Performance Computing infrastructure is
   funded by ENEA, the Italian National Agency for New Technologies, Energy
   and Sustainable Economic Development and by Italian and European
   research programmes, see http://www.cresco.enea.it/english for
   information.
CR Abraham Mark James, 2015, SoftwareX, V1-2, P19, DOI 10.1016/j.softx.2015.06.001
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   [Anonymous], PYMOL MOL GRAPH SYST
   Aoki KM, 2004, MOL CRYST LIQ CRYST, V413, P2245, DOI 10.1080/15421400490437259
   Balasubramanian S, 2011, NAT REV DRUG DISCOV, V10, P261, DOI 10.1038/nrd3428
   Battles MB, 2019, NAT REV MICROBIOL, V17, P233, DOI 10.1038/s41579-019-0149-x
   Battles MB, 2016, NAT CHEM BIOL, V12, P87, DOI [10.1038/NCHEMBIO.1982, 10.1038/nchembio.1982]
   Bosch BJ, 2003, J VIROL, V77, P8801, DOI 10.1128/JVI.77.16.8801-8811.2003
   Bourgeois S, 2017, BMC GASTROENTEROL, V17, DOI 10.1186/s12876-017-0580-2
   Case D., 2018, AMBER 2018
   Chen HJ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01272
   Chen HJ, 2019, POULTRY SCI, V98, P6367, DOI 10.3382/ps/pez465
   Clark K, 2016, NUCLEIC ACIDS RES, V44, pD67, DOI 10.1093/nar/gkv1276
   Cummings MD, 2014, J MED CHEM, V57, P1880, DOI 10.1021/jm401396p
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117
   DeVincenzo JP, 2014, NEW ENGL J MED, V371, P711, DOI 10.1056/NEJMoa1401184
   Devogelaere B, 2012, ANTIMICROB AGENTS CH, V56, P4676, DOI 10.1128/AAC.00245-12
   Drygin D, 2009, CANCER RES, V69, P7653, DOI 10.1158/0008-5472.CAN-09-1304
   Francois KO, 2009, ANTIMICROB AGENTS CH, V53, P4852, DOI 10.1128/AAC.00811-09
   Genheden S, 2015, EXPERT OPIN DRUG DIS, V10, P449, DOI 10.1517/17460441.2015.1032936
   Goga N, 2012, J CHEM THEORY COMPUT, V8, P3637, DOI 10.1021/ct3000876
   Hatcher EL, 2017, NUCLEIC ACIDS RES, V45, pD482, DOI 10.1093/nar/gkw1065
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Jendzelovska Z, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.00560
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Karioti A, 2010, INT J MOL SCI, V11, P562, DOI 10.3390/ijms11020562
   Korneev D, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100955
   Kubin A, 2005, CURR PHARM DESIGN, V11, P233, DOI 10.2174/1381612053382287
   Kupferschmidt K, 2020, SCIENCE, V367, P1412, DOI 10.1126/science.367.6485.1412
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Lavezzo E, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006675
   LENARD J, 1993, P NATL ACAD SCI USA, V90, P158, DOI 10.1073/pnas.90.1.158
   Li F, 2016, ANNU REV VIROL, V3, P237, DOI 10.1146/annurev-virology-110615-042301
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nikolaeva-Glomb L, 2017, ACTA VIROL, V61, P341, DOI 10.4149/av_2017_313
   Lopes BRP, 2020, VIRUS RES, V276, DOI 10.1016/j.virusres.2019.197805
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Ponti G, 2014, 2014 INTERNATIONAL CONFERENCE ON HIGH PERFORMANCE COMPUTING & SIMULATION (HPCS), P1030, DOI 10.1109/HPCSim.2014.6903807
   Ruggiero E, 2018, NUCLEIC ACIDS RES, V46, P3270, DOI 10.1093/nar/gky187
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5
   Samuel D, 2015, ANTIMICROB AGENTS CH, V59, P7109, DOI 10.1128/AAC.00761-15
   Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57
   SMETANA Z, 1994, J PHOTOCH PHOTOBIO B, V22, P37, DOI 10.1016/1011-1344(93)06949-4
   Sorokin AB, 2013, CHEM REV, V113, P8152, DOI 10.1021/cr4000072
   Stevens M, 2018, J INFECT DIS, V218, P748, DOI 10.1093/infdis/jiy227
   STEVENSON NR, 1993, ANTIVIR RES, V21, P119, DOI 10.1016/0166-3542(93)90048-N
   Styczynski AR, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0358-5
   Tian C, 2020, J CHEM THEORY COMPUT, V16, P528, DOI 10.1021/acs.jctc.9b00591
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vendeville S, 2012, BIOORG MED CHEM LETT, V22, P4437, DOI 10.1016/j.bmcl.2012.04.113
   Vijgen L, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0760-2
   Vzorov AN, 2003, ANTIVIR RES, V59, P99, DOI 10.1016/S0166-3542(03)00035-4
   Vzorov AN, 2007, ANTIVIR RES, V73, P60, DOI 10.1016/j.antiviral.2006.07.008
   Walls AC, 2017, P NATL ACAD SCI USA, V114, P11157, DOI 10.1073/pnas.1708727114
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Wright J.D., 2001, ENCY MAT SCI TECHNOL, P6987, DOI DOI 10.1016/B0-08-043152-6/01238-9
   Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x
   Yan D, 2014, P NATL ACAD SCI USA, V111, pE3441, DOI 10.1073/pnas.1405198111
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
NR 63
TC 1
Z9 1
U1 7
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-1702
EI 1872-7492
J9 VIRUS RES
JI Virus Res.
PD SEP
PY 2020
VL 286
AR 198068
DI 10.1016/j.virusres.2020.198068
PG 10
WC Virology
SC Virology
GA NN4RK
UT WOS:000568777000009
PM 32565126
OA Green Published
DA 2021-01-01
ER

PT J
AU White, NJ
   Watson, JA
   Hoglund, RM
   Chan, XHS
   Cheah, PY
   Tarning, J
AF White, Nicholas J.
   Watson, James A.
   Hoglund, Richard M.
   Chan, Xin Hui S.
   Cheah, Phaik Yeong
   Tarning, Joel
TI COVID-19 prevention and treatment: A critical analysis of chloroquine
   and hydroxychloroquine clinical pharmacology
SO PLOS MEDICINE
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; POPULATION PHARMACOKINETICS; VIVAX
   MALARIA; DESETHYLCHLOROQUINE; DRUG; FALCIPARUM; TOXICITY; BLOOD; SAFETY;
   CHEMOPROPHYLAXIS
AB Nicholas White and coauthors discuss chloroquine and hydroxychloroquine pharmacology in the context of possible treatment of SARS-CoV-2 infection.
C1 [White, Nicholas J.; Watson, James A.; Hoglund, Richard M.; Chan, Xin Hui S.; Cheah, Phaik Yeong; Tarning, Joel] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand.
   [White, Nicholas J.; Watson, James A.; Hoglund, Richard M.; Chan, Xin Hui S.; Cheah, Phaik Yeong; Tarning, Joel] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, England.
   [Chan, Xin Hui S.] Univ Coll London Hosp NHS Fdn Trust, Hosp Trop Dis, London, England.
RP White, NJ (corresponding author), Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand.; White, NJ (corresponding author), Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, England.
EM nickw@tropmedres.ac
OI Cheah, Phaik Yeong/0000-0001-6327-3266; Tarning,
   Joel/0000-0003-4566-4030; Chan, Xin Hui/0000-0002-9941-6975
CR ADEROUNMU AF, 1986, BRIT J CLIN PHARMACO, V22, P559, DOI 10.1111/j.1365-2125.1986.tb02935.x
   Ajayi AAL, 2019, INT J DERMATOL, V58, P880, DOI 10.1111/ijd.14252
   Al-Rawi H, 2018, LUPUS, V27, P847, DOI 10.1177/0961203317727601
   ARORA R. B., 1955, INDIAN JOUR MED RES, V43, P659
   Balevic SJ, 2019, CLIN PHARMACOKINET, V58, P525, DOI 10.1007/s40262-018-0712-z
   Ball DE, 2002, J APPL TOXICOL, V22, P311, DOI 10.1002/jat.864
   BERGQVIST Y, 1988, J CHROMATOGR-BIOMED, V434, P1, DOI 10.1016/0378-4347(88)80057-4
   BERLINER RW, 1948, J CLIN INVEST, V27, P98, DOI 10.1172/JCI101980
   Bethell DB, 1996, T ROY SOC TROP MED H, V90, P266, DOI 10.1016/S0035-9203(96)90241-2
   BEUTLER E, 1994, BLOOD, V84, P3613, DOI 10.1182/blood.V84.11.3613.bloodjournal84113613
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638
   Bourke L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143771
   Capel RA, 2015, HEART RHYTHM, V12, P2186, DOI 10.1016/j.hrthm.2015.05.027
   Cardoso CD, 2005, J PHARMACEUT BIOMED, V37, P703, DOI 10.1016/j.jpba.2004.11.048
   Carmichael SJ, 2003, THER DRUG MONIT, V25, P671, DOI 10.1097/00007691-200312000-00005
   CEIC, 2020, CHIN CN PROD
   Chairat K, 2018, J ANTIMICROB CHEMOTH, V73, P3102, DOI 10.1093/jac/dky297
   Chan XHS, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003040
   Chan XHS, 2018, LANCET INFECT DIS, V18, P913, DOI 10.1016/S1473-3099(18)30297-4
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   CHEEMA N, 2013, CLIN TOXICOL, V51, P712
   Chen CY, 2006, CLIN TOXICOL, V44, P173, DOI 10.1080/15563650500514558
   Chorin E, 2020, HEART RHYTHM, V17, P1425, DOI 10.1016/j.hrthm.2020.05.014
   Clemessy JL, 1996, PRESSE MED, V25, P1435
   CLEMESSY JL, 1995, LANCET, V346, P877, DOI 10.1016/S0140-6736(95)92711-5
   Clemessy JL, 1996, CRIT CARE MED, V24, P1189, DOI 10.1097/00003246-199607000-00021
   Clemessy JL, 1996, INTENS CARE MED, V22, P1400, DOI 10.1007/BF01709558
   COATNEY GR, 1963, AM J TROP MED HYG, V12, P121, DOI 10.4269/ajtmh.1963.12.121
   Cohen MS, 2020, NEW ENGL J MED, V383, P585, DOI 10.1056/NEJMe2020388
   COHEN RJ, 1968, NEW ENGL J MED, V279, P1127, DOI 10.1056/NEJM196811212792102
   Collins R, 2020, NEW ENGL J MED, V382, P674, DOI 10.1056/NEJMsb1901642
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   CONAN NJ, 1949, AM J MED, V6, P309, DOI 10.1016/0002-9343(49)90167-9
   Cunha C, 2018, NEPHROL DIAL TRANSPL, V33, P1604, DOI 10.1093/ndt/gfx318
   de Olano J, 2019, AM J EMERG MED, V37, DOI 10.1016/j.ajem.2019.158387
   Durcan L, 2015, J RHEUMATOL, V42, P2092, DOI 10.3899/jrheum.150379
   EASTERBROOK M, 1988, AM J MED, V85, P23, DOI 10.1016/0002-9343(88)90358-0
   Fantini J, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.106020
   FAZEKAS T, 1988, ACTA PHYSIOL HUNG, V72, P191
   Filgueiras-Rama D, 2012, CIRC-ARRHYTHMIA ELEC, V5, P561, DOI 10.1161/CIRCEP.111.966820
   Food US, 2020, MEM EXPL BAS REV EM
   FRISKHOLMBERG M, 1984, EUR J CLIN PHARMACOL, V26, P521, DOI 10.1007/BF00542151
   FU S, 1986, BRIT J CLIN PHARMACO, V22, P93
   Furst DE, 1996, LUPUS, V5, pS11, DOI 10.1177/096120339600500104
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geraldino-Pardilla L, 2019, LUPUS, V28, P862, DOI 10.1177/0961203319851558
   Ginsburg H, 2003, REDOX REP, V8, P276, DOI 10.1179/135100003225002907
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   GUSTAFSSON LL, 1983, LANCET, V1, P126
   GUSTAFSSON LL, 1983, BRIT J CLIN PHARMACO, V15, P471, DOI 10.1111/j.1365-2125.1983.tb01532.x
   Haeusler IL, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1188-2
   Han YS, 2019, J MED VIROL, V91, P1182, DOI 10.1002/jmv.25440
   HARRIS L, 1988, CAN J CARDIOL, V4, P295
   HESS ME, 1959, CIRC RES, V7, P86, DOI 10.1161/01.RES.7.1.86
   Hoglund R, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1181-1
   Huzly, 1996, J Travel Med, V3, P148, DOI 10.1111/j.1708-8305.1996.tb00729.x
   Indian Council for Medical Research, 2020, REC EMP US HYDR PROP
   Jallouli M, 2015, ARTHRITIS RHEUMATOL, V67, P2176, DOI 10.1002/art.39194
   James Watson on the behalf of 201 signatories, 2020, COMMUNICATION, DOI 10.5281/zenodo.3871094
   Jordan P, 1999, J TOXICOL-CLIN TOXIC, V37, P861, DOI 10.1081/CLT-100102466
   Keshtkar-Jahromi M, 2020, AM J TROP MED HYG, V102, P932, DOI 10.4269/ajtmh.20-0230
   Lane J.C., 2020, SAFETY HYDROXYCHLORO, DOI [10.1101/2020.04.08.20054551, DOI 10.1101/2020.04.08.20054551]
   Lee JY, 2017, ARTHRIT CARE RES, V69, P536, DOI 10.1002/acr.22962
   Lee JY, 2016, ARTHRITIS RHEUMATOL, V68, P184, DOI 10.1002/art.39402
   Lee SJ, 2008, EUR J CLIN PHARMACOL, V64, P987, DOI 10.1007/s00228-008-0500-z
   Lenzer J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1335
   Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   LOOAREESUWAN S, 1986, BRIT J CLIN PHARMACO, V22, P31, DOI 10.1111/j.1365-2125.1986.tb02876.x
   Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
   MCCHESNEY EW, 1967, J PHARMACOL EXP THER, V158, P323
   MCCHESNEY EW, 1983, AM J MED, V75, P11, DOI 10.1016/0002-9343(83)91265-2
   MCCHESNEY EW, 1967, TOXICOL APPL PHARM, V10, P501, DOI 10.1016/0041-008X(67)90089-0
   McGready R, 2012, LANCET INFECT DIS, V12, P388, DOI 10.1016/S1473-3099(11)70339-5
   MCLACHLAN AJ, 1994, BRIT J RHEUMATOL, V33, P235
   Megarbane B, 2010, CLIN TOXICOL, V48, P904, DOI 10.3109/15563650.2010.518969
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Melles RB, 2014, JAMA OPHTHALMOL, V132, P1453, DOI 10.1001/jamaophthalmol.2014.3459
   Mok CC, 2016, ARTHRIT CARE RES, V68, P1295, DOI 10.1002/acr.22837
   Morita S, 2016, THER DRUG MONIT, V38, P259, DOI 10.1097/FTD.0000000000000261
   Newton PN, 2020, LANCET GLOB HEALTH, V8, pE754, DOI 10.1016/S2214-109X(20)30136-4
   Pasadhika S, 2010, EYE, V24, P340, DOI 10.1038/eye.2009.65
   Pedrosa TN, 2020, LUPUS, V29, P560, DOI 10.1177/0961203320912832
   PERCIVAL SP, 1968, BMJ-BRIT MED J, V3, P579, DOI 10.1136/bmj.3.5618.579
   Petersen E, 2000, J TRAVEL MED, V7, P79
   PHILLIPSHOWARD PA, 1995, DRUG SAFETY, V12, P370, DOI 10.2165/00002018-199512060-00003
   Ponticelli C, 2017, EXPERT OPIN DRUG SAF, V16, P411, DOI 10.1080/14740338.2017.1269168
   POWRIE JK, 1993, METABOLISM, V42, P415, DOI 10.1016/0026-0495(93)90096-7
   POWRIE JK, 1991, AM J PHYSIOL, V260, pE897
   Projean D, 2003, DRUG METAB DISPOS, V31, P748, DOI 10.1124/dmd.31.6.748
   Pukrittayakamee S, 2014, ANTIMICROB AGENTS CH, V58, P3354, DOI 10.1128/AAC.02794-13
   PUSSARD E, 1991, ANTIMICROB AGENTS CH, V35, P406, DOI 10.1128/AAC.35.3.406
   QUATRARO A, 1990, ANN INTERN MED, V112, P678, DOI 10.7326/0003-4819-112-9-678
   RIOU B, 1988, NEW ENGL J MED, V318, P1, DOI 10.1056/NEJM198801073180101
   Rodriguez-Menchaca AA, 2008, P NATL ACAD SCI USA, V105, P1364, DOI 10.1073/pnas.0708153105
   ROMBO L, 1985, THER DRUG MONIT, V7, P211, DOI 10.1097/00007691-198506000-00013
   ROMBO L, 1987, B WORLD HEALTH ORGAN, V65, P879
   ROSENTHAL AR, 1978, INVEST OPHTH VIS SCI, V17, P1158
   Ross LS, 2019, CELL HOST MICROBE, V26, P35, DOI 10.1016/j.chom.2019.06.001
   RYNES RI, 1988, AM J MED, V85, P18, DOI 10.1016/0002-9343(88)90357-9
   Saleh M, 2020, CIRC-ARRHYTHMIA ELEC, V13, DOI 10.1161/CIRCEP.120.008662
   Sanchez-Capula JA, 2001, J PHARMACOL EXP THER, V297, P437
   SANGHVI LM, 1956, AM HEART J, V52, P908, DOI 10.1016/0002-8703(56)90159-4
   Sanson C, 2019, ASSAY DRUG DEV TECHN, V17, P89, DOI 10.1089/adt.2018.882
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950
   STAIGER MA, 1981, J CHROMATOGR, V225, P139, DOI 10.1016/S0378-4347(00)80253-4
   SUPANARANOND W, 1993, EUR J CLIN PHARMACOL, V44, P325, DOI 10.1007/BF00316467
   Szekely Y, 2020, HEART RHYTHM, V17, P1452, DOI 10.1016/j.hrthm.2020.04.046
   Taylor WRJ, 2004, DRUG SAFETY, V27, P25, DOI 10.2165/00002018-200427010-00003
   Teixeira RA, 2014, EUROPACE, V16, P887, DOI 10.1093/europace/eut290
   Tett S, 1996, BRIT J CLIN PHARMACO, V41, P244, DOI 10.1111/j.1365-2125.1996.tb00190.x
   TETT SE, 1988, BRIT J CLIN PHARMACO, V26, P303, DOI 10.1111/j.1365-2125.1988.tb05281.x
   TETT SE, 1993, CLIN PHARMACOKINET, V25, P392, DOI 10.2165/00003088-199325050-00005
   TETT SE, 1989, BRIT J CLIN PHARMACO, V27, P771, DOI 10.1111/j.1365-2125.1989.tb03439.x
   Tett SE, 2000, J RHEUMATOL, V27, P1656
   Tonnesmann E, 2013, IMMUNOPHARM IMMUNOT, V35, P434, DOI 10.3109/08923973.2013.780078
   Ursing J, 2009, ANTIMICROB AGENTS CH, V53, P180, DOI 10.1128/AAC.01111-08
   Vicente J, 2019, CLIN PHARMACOL THER, V105, P943, DOI 10.1002/cpt.1303
   Vigdor N, 2020, NY TIMES
   Villegas L, 2007, TROP MED INT HEALTH, V12, P209, DOI [10.1111/j.1365-3165.2006.01778.x, 10.1111/j.1365-3156.2006.01778.x]
   WALKER O, 1987, BRIT J CLIN PHARMACO, V23, P295, DOI 10.1111/j.1365-2125.1987.tb03048.x
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Watson JA, 2020, ELIFE, V9, DOI 10.7554/eLife.58631
   WETSTEYN JCFM, 1995, BRIT J CLIN PHARMACO, V39, P696, DOI 10.1111/j.1365-2125.1995.tb05731.x
   White NJ, 2007, LANCET INFECT DIS, V7, P549, DOI 10.1016/S1473-3099(07)70187-1
   WHITE NJ, 1988, NEW ENGL J MED, V319, P1493, DOI 10.1056/NEJM198812083192301
   WHITE NJ, 1987, J INFECT DIS, V155, P192, DOI 10.1093/infdis/155.2.192
   World Health Organisation Scientific Group on the Chemotherapy of Malaria, 1984, ADV MAL CHEM REP WHO, V711
   World Health Organization, 2017, WHO EV REV GROUP CAR
   World Health Organization, 2015, GUID TREATM MAL
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yee TH, 2020, STRAITS TIMES
NR 134
TC 4
Z9 4
U1 2
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1549-1277
EI 1549-1676
J9 PLOS MED
JI PLos Med.
PD SEP
PY 2020
VL 17
IS 9
AR e1003252
DI 10.1371/journal.pmed.1003252
PG 24
WC Medicine, General & Internal
SC General & Internal Medicine
GA NM8LK
UT WOS:000568344200001
PM 32881895
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU He, T
   Qu, RD
   Qin, CM
   Wang, ZY
   Zhang, Y
   Shao, XM
   Lu, T
AF He, Tian
   Qu, Rendong
   Qin, Caimeng
   Wang, Zheyi
   Zhang, Yue
   Shao, Xiangming
   Lu, Tao
TI Potential mechanisms of Chinese Herbal Medicine that implicated in the
   treatment of COVID-19 related renal injury
SO SAUDI PHARMACEUTICAL JOURNAL
LA English
DT Article
DE COVID-19; Association rules; Network pharmacology; Renal/kidney injury;
   Chinese Herbal Medicine; Traditional Chinese Medicine
ID ANGIOTENSIN-CONVERTING ENZYME-2; PROTEIN; NEPHROTOXICITY; EXPRESSION;
   RECEPTOR; DIOSCIN; COX2
AB Clinical studies have shown that renal injury in Corona Virus Disease 2019 (COVID-19) patients has been a real concern, which is associated with high mortality and an inflammation/apoptosis-related causality. Effective target therapy for renal injury has yet been developed. Besides, potential anti-COVID-19 medicines have also been reported to cause adverse side effects to kidney. Chinese Herbal Medicine (CHM), however, has rich experience in treating renal injury and has successfully applied in China in the battle of COVID-19. Nevertheless, the molecular mechanisms of CHM treatment are still unclear. In this study, we searched prescriptions in the treatment of renal injury extensively and the potential mechanisms to treat COVID-19 related renal injury were investigated. The association rules analysis showed that the core herbs includes Huang Qi, Fu Ling, Bai Zhu, Di Huang, Shan Yao. TCM herbs regulate core pathways, such as AGE-RAGE, PI3K-AKT, TNF and apoptosis pathway, etc. The ingredients (quercetin, formononetin, kaempferol, etc.,) from core herbs could modulate targets (PTGS2 (COX2), PTGS1 (COX1), IL6, CASP3, NOS2, and TNF, etc.), and thereby prevent the pharmacological and non-pharmacological renal injury comparable to that from COVID-19 infection. This study provides therapeutic potentials of CHM to combat COVID-19 related renal injury to reduce complications and mortality. (C) 2020 The Authors. Published by Elsevier B.V. on behalf of King Saud University.
C1 [He, Tian; Qu, Rendong; Qin, Caimeng; Wang, Zheyi; Zhang, Yue; Shao, Xiangming; Lu, Tao] Beijing Univ Chinese Med, Sch Life Sci, Beijing, Peoples R China.
RP Lu, T (corresponding author), Beijing Univ Chinese Med, Sch Life Sci, Beijing, Peoples R China.
EM taolu@bucm.edu.cn
FU Beijing research fund for double first-class and high-level talents
   [1000041510053]
FX This work was supported by the Beijing research fund for double
   first-class and high-level talents (No. 1000041510053).
CR Agatonovic-Kustrin S, 2018, S AFR J BOT, V115, P94, DOI 10.1016/j.sajb.2017.12.011
   Basudhar D, 2017, P NATL ACAD SCI USA, V114, P13030, DOI 10.1073/pnas.1709119114
   Bellomo R, 2012, LANCET, V380, P756, DOI 10.1016/S0140-6736(11)61454-2
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chen J., 2020, CHINESE J INFECT DIS, V38, pE008, DOI [10.3760/cma.j.cn311365-20200210-00050, DOI 10.3760/CMA.J.CN311365-20200210-00050]
   Chen J, 2018, MOL CARCINOGEN, V57, P817, DOI 10.1002/mc.22531
   Chen RQ, 2013, CELL, V155, P1154, DOI 10.1016/j.cell.2013.10.042
   Chen Y, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2656-8
   Chen Y, 2020, BIOCHEM BIOPH RES CO, V525, P135, DOI 10.1016/j.bbrc.2020.02.071
   Chu KH, 2005, KIDNEY INT, V67, P698, DOI 10.1111/j.1523-1755.2005.67130.x
   Douros A, 2018, CLIN NEPHROL, V89, P18, DOI 10.5414/CN109212
   Eckerle I, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-359
   Fan C, 2020, ACE2 EXPRESSION KIDN, DOI [10.1101/2020.02.12.20022418, DOI 10.1101/2020.02.12.20022418]
   Fan X., 2005, J IMMUNOL, V21, P430
   Fei ZW, 2016, CHIN J INTEGR MED, V22, P674, DOI 10.1007/s11655-015-2048-y
   Feng YL, 2019, CELL MOL LIFE SCI, V76, P4961, DOI 10.1007/s00018-019-03155-9
   Gan L, 2018, RENAL FAILURE, V40, P364, DOI 10.1080/0886022X.2018.1450762
   Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016
   Gu J, 2007, AM J PATHOL, V170, P1136, DOI 10.2353/ajpath.2007.061088
   Guo L, 2012, MOL BIOL REP, V39, P9285, DOI 10.1007/s11033-012-1677-x
   Han HY, 2017, CELL PHYSIOL BIOCHEM, V42, P1934, DOI 10.1159/000479834
   Han X.X., 2020, EVAL ANAL DRUGUSE HO, V20, P129, DOI [10.14009/j.issn.1672-2124.2020.02.001., DOI 10.14009/J.ISSN.1672-2124.2020.02.001]
   Hsieh MJ, 2017, ARCH TOXICOL, V91, P2495, DOI 10.1007/s00204-017-1973-2
   Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
   Ishii T, 2020, J NAT MED-TOKYO, V74, P51, DOI 10.1007/s11418-019-01342-3
   Kang DR, 2018, IRAN J ALLERGY ASTHM, V17, P428
   Kuba K, 2005, NAT MED, V11, P875, DOI 10.1038/nm1267
   Lee D, 2017, BIOORG MED CHEM LETT, V27, P2881, DOI 10.1016/j.bmcl.2017.04.084
   Lee S.M., 2013, FASEB J, V27, DOI 10.1016/j.jep.2012.02.048.
   Lee SC, 2002, ACTA PHARMACOL SIN, V23, P503
   Li HD, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00376
   Li L, 2017, FUND CLIN PHARMACOL, V31, P17, DOI 10.1111/fcp.12232
   [李璐 Li Lu], 2020, [中国现代应用药学, Chinese Journal of Modern Applied Pharmacy], V37, P257
   Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145
   Li Z, 2020, CAUTION KIDNEY DYSFU, DOI [10.1101/2020.02.08.20021212, DOI 10.1101/2020.02.08.20021212]
   Liu J, 2020, J MED VIROL, V92, P491, DOI 10.1002/jmv.25709
   Liu YZ, 2017, PHARMACOGN MAG, V13, P413, DOI 10.4103/pm.pm_394_16
   Ma Xiao-Lin, 2018, Zhongguo Zhong Yao Za Zhi, V43, P1844, DOI 10.19540/j.cnki.cjcmm.20180307.008
   Ma Y, 2017, IMMUNOPHARM IMMUNOT, V39, P148, DOI 10.1080/08923973.2017.1306868
   Ming W., 2017, PHYTOMEDICINE, V36, DOI [10.1016/j.phymed.2017.10.008., DOI 10.1016/J.PHYMED.2017.10.008]
   Niu Ming, 2020, Zhongguo Zhong Yao Za Zhi, V45, P1213, DOI 10.19540/j.cnki.cjcmm.20200206.501
   Pannu N, 2008, CRIT CARE MED, V36, pS216, DOI 10.1097/CCM.0b013e318168e375
   Qiao YJ, 2019, TOXICOL LETT, V315, P117, DOI 10.1016/j.toxlet.2019.08.011
   Spagnuolo C, 2018, EUR J MED CHEM, V153, P105, DOI 10.1016/j.ejmech.2017.09.001
   Visconti L, 2016, J NEPHROL, V29, P341, DOI 10.1007/s40620-016-0276-7
   Wang L, 2020, J XINXIANG MED U, V2002, P20025288, DOI [10.1101/2020.02.19.20025288, DOI 10.7683/XXYXYXB.2019.08.004]
   Wang L., 2020, SARS COV 2 INFECT DO, DOI [10.1101/2020.02.19.20025288., DOI 10.1101/2020.02.19.20025288]
   Wang MQ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/1875471
   [王饶琼 Wang Raoqiong], 2020, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V36, P13
   Wang SQ, 2020, NAT REV UROL, V17, P314, DOI 10.1038/s41585-020-0319-7
   Xu WJ, 2014, J PHARMACOL EXP THER, V350, P552, DOI 10.1124/jpet.114.214205
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Yang DH, 2014, J NAT MED-TOKYO, V68, P11, DOI 10.1007/s11418-013-0756-1
   Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5
   Zhang B, 2020, CLIN CHARACTERISTICS, DOI [10.1101/2020.02.26.20028191, DOI 10.1101/2020.02.26.20028191]
   Zhang YM, 2017, TOXICOLOGY, V378, P53, DOI 10.1016/j.tox.2017.01.007
   Zhao XR, 2018, INT IMMUNOPHARMACOL, V65, P458, DOI 10.1016/j.intimp.2018.10.036
   Zheng X.F., 2020, HLTH RES, V40, P137, DOI [10.3969/j.issn.1674-6449.2020.02.005., DOI 10.3969/J.ISSN.1674-6449.2020.02.005]
   Zhou P., DISCOVERY NOVEL CORO, DOI [DOI 10.1101/2020.01.22.914952, 10.1101/2020.01.22.914952v2., DOI 10.1101/2020.01.22.914952V2]
   Zuk A, 2016, ANNU REV MED, V67, P293, DOI 10.1146/annurev-med-050214-013407
   Zumla A, 2015, LANCET RESP MED, V3, P100, DOI 10.1016/S2213-2600(14)70316-9
NR 61
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1319-0164
EI 2213-7475
J9 SAUDI PHARM J
JI Saudi Pharm. J.
PD SEP
PY 2020
VL 28
IS 9
BP 1138
EP 1148
DI 10.1016/j.jsps.2020.08.002
PG 11
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA NN0AE
UT WOS:000568450600012
PM 32837217
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

PT J
AU Cohen, MA
   Powell, AM
   Coleman, JS
   Keller, JM
   Livingston, A
   Anderson, JR
AF Cohen, Megan A.
   Powell, Anna M.
   Coleman, Jenell S.
   Keller, Jean M.
   Livingston, Alison
   Anderson, Jean R.
TI Special ambulatory gynecologic considerations in the era of coronavirus
   disease 2019 (COVID-19) and implications for future practice
SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
LA English
DT Article
DE abortion; cervical cancer screening; contraception; coronavirus disease
   2019; health equity; intimate partner violence; reproductive healthcare
   access; telemedicine
ID SEXUALLY-TRANSMITTED INFECTIONS; INTIMATE PARTNER VIOLENCE; MEDICAL
   ABORTION; UNITED-STATES; WOMEN; DEPRESSION; PREGNANCY; HEALTH; SAMPLE
AB The coronavirus disease 2019 pandemic has altered medical practice in unprecedented ways. Although much of the emphasis in ob-stetrics and gynecology to date has been on the as yet uncertain effects of coronavirus disease 2019 in pregnancy and on changes to surgical management, the pandemic has broad implications for ambulatory gynecologic care. In this article, we review important ambulatory gynecologic topics such as safety and mental health, reproductive life planning, sexually transmitted infections, and routine screening for breast and cervical cancer. For each topic, we review how care may be modified during the pandemic, provide recom-mendations when possible on how to ensure continued access to comprehensive healthcare at this time, and discuss ways that future practice may change. Social distancing requirements may place patients at higher risk for intimate partner violence and mental health concerns, threaten continued access to contraception and abortion services, affect prepregnancy planning, interrupt routine screening for breast and cervical cancer, increase risk of sexually transmitted infection acquisition and decrease access to treatment, and exacerbate already underlying racial and minority disparities in care and health outcomes. We advocate for increased use of telemedicine services with increased screening for intimate partner violence and depression using validated questionnaires. Appointments for long-acting contra-ceptive insertions can be prioritized. Easier access to patient-controlled injectable contraception and pharmacist-provided hormonal contraception can be facilitated. Reproductive healthcare access can be ensured through reducing needs for ultrasonography and lab-oratory testing for certain eligible patients desiring abortion and conducting phone follow-up for medication abortions. Priority for in-person appointments should be given to patients with sexually transmitted infection symptoms, particularly if at risk for complications, while also offering expedited partner therapy. Although routine mammography screening and cervical cancer screening may be safely delayed, we discuss society guideline recommendations for higher-risk populations. There may be an increasing role for patient-collected human papillomavirus self-samples using new cervical cancer screening guidelines that can be expanded considering the pandemic situation. Although the pandemic has strained our healthcare system, it also affords ambulatory clinicians with opportunities to expand care to vulnerable populations in ways that were previously underutilized to improve health equity.
C1 [Cohen, Megan A.; Powell, Anna M.; Coleman, Jenell S.; Keller, Jean M.; Livingston, Alison; Anderson, Jean R.] Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Baltimore, MD 21205 USA.
   [Cohen, Megan A.; Powell, Anna M.; Coleman, Jenell S.; Keller, Jean M.; Livingston, Alison; Anderson, Jean R.] Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Johns Hopkins HIV Womens Hlth Program, Baltimore, MD 21205 USA.
RP Cohen, MA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Baltimore, MD 21205 USA.; Cohen, MA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Johns Hopkins HIV Womens Hlth Program, Baltimore, MD 21205 USA.
EM mcohen82@jhu.edu
CR ACOG Committee Opinion no 595, 2014, OBSTET GYNECOL, V123, P1133, DOI DOI 10.1097/01.AOG.0000446855.78026.21
   [Anonymous], 2019, Obstet Gynecol, V134, P886, DOI 10.1097/AOG.0000000000003474
   [Anonymous], 2018, Obstet Gynecol, V132, P1314, DOI 10.1097/AOG.0000000000002928
   [Anonymous], 2019, Obstet Gynecol, V133, pe78, DOI 10.1097/AOG.0000000000003013
   [Anonymous], 2018, Obstet Gynecol, V131, P1180, DOI 10.1097/AOG.0000000000002622
   [Anonymous], 2015, Obstet Gynecol, V126, pe130, DOI 10.1097/AOG.0000000000001213
   [Anonymous], 2012, Obstet Gynecol, V119, P412, DOI 10.1097/AOG.0b013e318249ff74
   [Anonymous], 2010, Sentinel Event Alert, P1
   [Anonymous], COVID 19 MAP
   Arbyn M, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4823
   ASCCP, COVID 19 ASCCP
   Basile KC, 2007, INTIMATE PARTNER VIO
   Bayefsky MJ, 2020, NEW ENGL J MED, V382, pE47, DOI 10.1056/NEJMp2008006
   Bhat A, 2017, OBSTET GYNECOL, V129, P157, DOI 10.1097/AOG.0000000000001809
   Bishop E, 2019, BIORESEARCH OPEN ACC, V8, P65, DOI 10.1089/biores.2018.0040
   Bloom-Feshbach K, 2011, J INFECT DIS, V204, P1157, DOI 10.1093/infdis/jir510
   Brady M, 2020, BEST PRACT RES CLIN
   Campbell AM, 2020, INCREASING RISK FAMI
   Centers for Disease Control and Prevention, 2020, HIV WOM
   Centers for Disease Control and Prevention, 2020, STD CAR PREV GUID DI
   Centers for Disease Control and Prevention, 2018, SEX TRANSM DIS SURV
   Chandra S, 2018, AM J EPIDEMIOL, V187, P2585, DOI 10.1093/aje/kwy153
   Chen MJ, 2016, CONTRACEPTION, V94, P122, DOI 10.1016/j.contraception.2016.04.007
   Chisholm CA, 2017, AM J OBSTET GYNECOL, V217, P141, DOI 10.1016/j.ajog.2017.05.042
   Curry SJ, 2018, JAMA-J AM MED ASSOC, V320, P674, DOI 10.1001/jama.2018.10897
   Dietz JR, 2020, BREAST CANCER RES TR, V181, P487, DOI 10.1007/s10549-020-05644-z
   Dzuba IG, 2020, CONTRACEPTION, V101, P302, DOI 10.1016/j.contraception.2020.01.009
   El-Zein M, 2019, CANCER EPIDEM BIOMAR, V28, P1134, DOI 10.1158/1055-9965.EPI-18-1338
   Finer LB, 2016, NEW ENGL J MED, V374, P843, DOI 10.1056/NEJMsa1506575
   Goldstein Zil, 2020, Transgend Health, V5, P10, DOI 10.1089/trgh.2019.0019
   Hall KS, 2020, LANCET, V395, P1175, DOI 10.1016/S0140-6736(20)30801-1
   Havens JP, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz365
   Hess KL, 2012, SEX TRANSM DIS, V39, P366, DOI 10.1097/OLQ.0b013e3182478fa5
   International Planned Parenthood Federation, 2020, IMAP STAT COVID 19 S
   IPV Health, ED HLTH PROV RESP IN
   Jamison CD, 2019, OBSTET GYNECOL, V133, P416, DOI 10.1097/AOG.0000000000003088
   Kapp N, 2019, CONTRACEPTION, V99, P77, DOI 10.1016/j.contraception.2018.11.002
   Kennedy CE, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2018-001350
   Kohn JE, 2019, OBSTET GYNECOL, V134, P343, DOI 10.1097/AOG.0000000000003357
   Kooner M, 2003, J AM PHARM ASS, P2020
   Kuehner C, 2017, LANCET PSYCHIAT, V4, P146, DOI 10.1016/S2215-0366(16)30263-2
   Laurencin CT, 2020, J RACIAL ETHN HEALTH, V7, P398, DOI 10.1007/s40615-020-00756-0
   McDowell M, 2017, LGBT HEALTH, V4, P252, DOI 10.1089/lgbt.2016.0187
   McNicholas C, 2017, AM J OBSTET GYNECOL, V216, P586
   Miller E, 2019, NEW ENGL J MED, V380, P850, DOI 10.1056/NEJMra1807166
   Mmeje OO, 2020, AM J OBSTET GYNECOL
   Nouri S, NEJM CATALYST, DOI 10.1056/CAT.20.0123
   O'Connor E, 2016, JAMA-J AM MED ASSOC, V315, P388, DOI 10.1001/jama.2015.18948
   Osborne LM, 2017, MOOD ANXIETY DISORDE
   Park LT, 2019, NEW ENGL J MED, V380, P559, DOI 10.1056/NEJMcp1712493
   Perkins RB, 2020, J LOW GENIT TRACT DI, V24, P102, DOI 10.1097/LGT.0000000000000525
   Perriera LK, 2010, CONTRACEPTION, V81, P143, DOI 10.1016/j.contraception.2009.08.008
   Raifman M, 2020, AM J PREV MED
   Rajkumar RP, 2020, ASIAN J PSYCHIAT, V52
   Raymond E, 2019, CONTRACEPTION, V100, P173, DOI 10.1016/j.contraception.2019.05.013
   Raymond EG, 2020, CONTRACEPTION, V101, P361, DOI 10.1016/j.contraception.2020.04.005
   Raymond EG, 2018, CONTRACEPTION, V97, P324, DOI 10.1016/j.contraception.2017.12.004
   Reisner SL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190172
   Sharpe TT, 2012, J WOMENS HEALTH, V21, P249, DOI 10.1089/jwh.2011.3350
   Siu AL, 2016, JAMA-J AM MED ASSOC, V315, P380, DOI 10.1001/jama.2015.18392
   SOBEL L., 2020, STATE ACTION LIMIT A
   The American College of Obstetricians and Gynecologists, COVID 19 FAQS OBST G
   The American College of Obstetricians and Gynecologists, 2020, JOINT STAT AB ACC CO
   Ti AJ, 2020, AM J OBSTET GYNECOL
   United Nations Population Fund, 2020, SEX REPR HLTH RIGHTS
   Wong Keith Yiu Kei, 2020, Mhealth, V6, P21, DOI 10.21037/mhealth.2019.12.06
NR 66
TC 3
Z9 3
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9378
EI 1097-6868
J9 AM J OBSTET GYNECOL
JI Am. J. Obstet. Gynecol.
PD SEP
PY 2020
VL 223
IS 3
BP 372
EP 378
DI 10.1016/j.ajog.2020.06.006
PG 7
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA NM0NK
UT WOS:000567801700008
PM 32522513
OA Bronze
DA 2021-01-01
ER

PT J
AU Casey, JD
   Johnson, NJ
   Semler, MW
   Collins, SP
   Aggarwal, NR
   Brower, RG
   Chang, SY
   Eppensteiner, J
   Filbin, M
   Gibbs, KW
   Ginde, AA
   Gong, MN
   Harrell, F
   Hayden, DL
   Hough, CL
   Khan, A
   Leither, LM
   Moss, M
   Oldmixon, CF
   Park, PK
   Reineck, LA
   Ringwood, NJ
   Robinson, BRH
   Schoenfeld, DA
   Shapiro, NI
   Steingrub, JS
   Torr, DK
   Weissman, A
   Lindsell, CJ
   Rice, TW
   Thompson, BT
   Brown, SM
   Self, WH
AF Casey, Jonathan D.
   Johnson, Nicholas J.
   Semler, Matthew W.
   Collins, Sean P.
   Aggarwal, Neil R.
   Brower, Roy G.
   Chang, Steven Y.
   Eppensteiner, John
   Filbin, Michael
   Gibbs, Kevin W.
   Ginde, Adit A.
   Gong, Michelle N.
   Harrell, Frank
   Hayden, Douglas L.
   Hough, Catherine L.
   Khan, Akram
   Leither, Lindsay M.
   Moss, Marc
   Oldmixon, Cathryn F.
   Park, Pauline K.
   Reineck, Lora A.
   Ringwood, Nancy J.
   Robinson, Bryce R. H.
   Schoenfeld, David A.
   Shapiro, Nathan, I
   Steingrub, Jay S.
   Torr, Donna K.
   Weissman, Alexandra
   Lindsell, Christopher J.
   Rice, Todd W.
   Thompson, B. Taylor
   Brown, Samuel M.
   Self, Wesley H.
TI Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical
   Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19
SO ANNALS OF THE AMERICAN THORACIC SOCIETY
LA English
DT Article
DE COVID-19; SARS-CoV-2; ARDS; hydroxychloroquine; ORCHID
ID CHLOROQUINE
AB The ORCHID (Outcomes Related to COVID-19 treated with Hydroxychloroquine among In-patients with symptomatic Disease) trial is a multicenter, blinded, randomized trial of hydroxychloroquine versus placebo for the treatment of adults hospitalized with coronavirus disease (COVID-19). This document provides the rationale and background for the trial and highlights key design features. We discuss five novel challenges to the design and conduct of a large, multicenter, randomized trial during a pandemic, including 1) widespread, off-label use of the study drug before the availability of safety and efficacy data; 2) the need to adapt traditional procedures for documentation of informed consent during an infectious pandemic; 3) developing a flexible and robust Bayesian analysis incorporating significant uncertainty about the disease, outcomes, and treatment; 4) obtaining indistinguishable drug and placebo without delaying enrollment; and 5) rapidly obtaining administrative and regulatory approvals. Our goals in describing how the ORCHID trial progressed from study conception to enrollment of the first patient in 15 days are to inform the development of other high-quality, multicenter trials targeting COVID-19. We describe lessons learned to improve the efficiency of future clinical trials, particularly in the setting of pandemics. The ORCHID trial will provide high-quality, clinically relevant data on the safety and efficacy of hydroxychloroquine for the treatment of COVID-19 among hospitalized adults.
C1 [Casey, Jonathan D.; Semler, Matthew W.; Rice, Todd W.] Vanderbilt Univ, Sch Med, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37212 USA.
   [Collins, Sean P.; Self, Wesley H.] Vanderbilt Univ, Sch Med, Dept Emergency Med, Nashville, TN 37212 USA.
   [Harrell, Frank; Lindsell, Christopher J.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA.
   [Johnson, Nicholas J.] Univ Washington, Dept Emergency Med, Seattle, WA 98195 USA.
   [Johnson, Nicholas J.; Hough, Catherine L.] Univ Washington, Div Pulm Crit Care & Sleep Med, Harborview Med Ctr, Seattle, WA 98195 USA.
   [Robinson, Bryce R. H.] Univ Washington, Dept Surg, Seattle, WA 98195 USA.
   [Aggarwal, Neil R.; Reineck, Lora A.] NHLBI, Div Lung Dis, Bldg 10, Bethesda, MD 20892 USA.
   [Brower, Roy G.] Johns Hopkins Univ, Crit Care Med, Baltimore, MD USA.
   [Chang, Steven Y.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA.
   [Eppensteiner, John] Duke Univ, Dept Surg, Durham, NC USA.
   [Filbin, Michael] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
   [Hayden, Douglas L.; Oldmixon, Cathryn F.; Ringwood, Nancy J.; Schoenfeld, David A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
   [Thompson, B. Taylor] Massachusetts Gen Hosp, Div Pulm & Crit Care Med, Dept Med, Boston, MA 02114 USA.
   [Gibbs, Kevin W.] Wake Forest Sch Med, Dept Med, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC 27101 USA.
   [Ginde, Adit A.] Univ Colorado, Sch Med, Dept Emergency Med, Aurora, CO USA.
   [Moss, Marc] Univ Colorado, Sch Med, Div Pulm Sci & Crit Care Med, Aurora, CO USA.
   [Gong, Michelle N.] Albert Einstein Coll Med, Montefiore Med Ctr, Dept Med, Div Epidemiol & Populat Hlth, New York, NY USA.
   [Khan, Akram] Oregon Hlth & Sci Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Portland, OR 97201 USA.
   [Leither, Lindsay M.; Brown, Samuel M.] Intermt Med Ctr, Div Pulm & Crit Care Med, Salt Lake City, UT USA.
   [Leither, Lindsay M.; Brown, Samuel M.] Univ Utah, Salt Lake City, UT USA.
   [Park, Pauline K.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA.
   [Shapiro, Nathan, I] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA.
   [Shapiro, Nathan, I] Harvard Med Sch, Boston, MA 02115 USA.
   [Steingrub, Jay S.] Univ Massachusetts, Dept Med, Med Sch Baystate, Springfield, MA USA.
   [Torr, Donna K.] Vanderbilt Univ, Med Ctr, Dept Pharm Serv, Nashville, TN USA.
   [Weissman, Alexandra] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA USA.
RP Self, WH (corresponding author), 1313 21st Ave South,312 Oxford House, Nashville, TN 37232 USA.
EM wesley.self@vumc.org
RI Leither, Lindsay/ABG-4892-2020; Brown, Samuel/E-6846-2015
OI , Neil/0000-0002-0922-8824; Casey, Jonathan/0000-0002-0977-290X; Semler,
   Matthew/0000-0002-7664-8263; Brown, Samuel/0000-0003-1206-6261
FU U.S. National Heart, Lung and Blood Institute (NHLBI)United States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL123009,
   U01HL122998, U01HL123018, U01HL123023, U01HL123008, U01HL123031,
   U01HL123004, U01HL123027, U01HL123010, U01HL123033, U01HL122989,
   U01HL123022, U01HL123020]; Massachusetts General Hospital; NHLBIUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)
   [K12HL133117, K23HL143053, 1R01HL144624]; Clinical and Translational
   Science Awards from the National Center for Advancing Translational
   Sciences [UL1 TR002243]
FX Supported by grants from the U.S. National Heart, Lung and Blood
   Institute (NHLBI): U01HL123009, U01HL122998, U01HL123018, U01HL123023,
   U01HL123008, U01HL123031, U01HL123004, U01HL123027, U01HL123010,
   U01HL123033, U01HL122989, U01HL123022, and U01HL123020. Massachusetts
   General Hospital was the sponsor. J.D.C. was supported in part by the
   NHLBI (K12HL133117). M.W.S. was supported in part by the NHLBI
   (K23HL143053). S.M.B. was supported in part by the NHLBI (1R01HL144624).
   F.H. and C.J.L.'s work on this paper was supported by Clinical and
   Translational Science Awards (UL1 TR002243) from the National Center for
   Advancing Translational Sciences. The content of this manuscript is the
   responsibility of the authors alone and does not necessarily reflect the
   views or policies of the National Institutes of Health, the NHLBI, the
   National Center for Advancing Translational Sciences, the Department of
   Health and Human Services, or the United States Government.
CR Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   Angus DC, 2020, JAMA-J AM MED ASSOC, V323, P1895, DOI 10.1001/jama.2020.4984
   Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bhimraj A, 2020, INFECT DIS SOC AM GU
   Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857
   Briel Matthias, 2012, J Bone Joint Surg Am, V94 Suppl 1, P56, DOI 10.2106/JBJS.K.01412
   Brigham and Women's Hospital, 2020, BRIGH WOM HOSP COVID
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI DOI 10.1101/2020.03.22.20040758V3
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105932
   COVID-19 Treatment Guidelines Panel, 2020, COVID 19 TREATM GUID
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1339, DOI 10.1001/jama.2020.3072
   DrugBank, 2020, HYDR
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Food and Drug Administration (FDA), 2020, EM AUTH US CHLOR PHO
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Ginde AA, 2019, NEW ENGL J MED, V381, P2529, DOI 10.1056/NEJMoa1911124
   Goodman JL, 2020, JAMA-J AM MED ASSOC, V323, P1899, DOI 10.1001/jama.2020.6434
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Harhay MO, 2020, INTENS CARE MED, V46, P930, DOI 10.1007/s00134-020-05934-6
   Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang DT, 2017, ANN AM THORAC SOC, V14, P124, DOI 10.1513/AnnalsATS.201608-629OT
   Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
   Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Massachusetts General Hospital, 2020, MASS GEN HOSP COVID
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   POCOCK SJ, 1989, CONTROL CLIN TRIALS, V10, pS209
   Ponticelli C, 2017, EXPERT OPIN DRUG SAF, V16, P411, DOI 10.1080/14740338.2017.1269168
   Rice TW, 2020, ANN AM THORAC SOC, V17, P787, DOI 10.1513/AnnalsATS.202004-325IP
   Roden DM, 2020, CIRCULATION, V141, pE906, DOI 10.1161/CIRCULATIONAHA.120.047521
   Rojek AM, 2018, CLIN INFECT DIS, V66, P1454, DOI 10.1093/cid/cix1061
   Rojek AM, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0294
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Self WH, 2018, ANN EMERG MED, V72, P457, DOI 10.1016/j.annemergmed.2018.03.039
   Singer BD, 2020, AM J RESP CELL MOL, V63, P132, DOI 10.1165/rcmb.2020-0151LE
   U.S. Food and Drug Administration, 2019, RES C DE US EL INF C
   U.S. Food and Drug Administration, 2020, FDA GUID COND CLIN T
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Waterer GW, 2020, AM J RESP CRIT CARE, V201, P1324, DOI 10.1164/rccm.202004-1153ED
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
   Wilson KC, 2020, BEHALF INT TASK FORC
   World Health Organization, 2020, COR DIS COVID 2019 R
   Yale School of Medicine, 2020, YNHHS IN TREATM ALG
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Zhao M, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105982
   Ziehr DR, 2020, AM J RESP CRIT CARE, V201, P1560, DOI 10.1164/rccm.202004-1163LE
NR 55
TC 5
Z9 5
U1 1
U2 1
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1546-3222
EI 2325-6621
J9 ANN AM THORAC SOC
JI Ann. Am. Thoracic Society
PD SEP
PY 2020
VL 17
IS 9
BP 1144
EP 1153
DI 10.1513/AnnalsATS.202005-478SD
PG 10
WC Respiratory System
SC Respiratory System
GA NM0AX
UT WOS:000567769200017
PM 32492354
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Vancini, RL
   de Lira, CAB
   Andrade, MS
   Arida, RM
AF Vancini, Rodrigo Luiz
   Lira, Claudio Andre Barbosa de
   Andrade, Marilia Santos
   Arida, Ricardo Mario
TI CoVID-19 vs. epilepsy: It is time tomove, act, and encourage physical
   exercise
SO EPILEPSY & BEHAVIOR
LA English
DT Letter
ID COPING STRATEGY; ANTIEPILEPTIC DRUGS; PEOPLE; DEPRESSION; MEDICINE
C1 [Vancini, Rodrigo Luiz] Univ Fed Espirito Santo, Ctr Educ Fis & Desportos, Campus Univ,Ave Fernando Ferrari 514, BR-29075810 Vitoria, ES, Brazil.
   [Lira, Claudio Andre Barbosa de] Univ Fed Goias, Setor Fisiol Humana & Exercicio, Lab Avaliacao Movimento, Humano,Fac Educ Fis & Danca, Goiania, Go, Brazil.
   [Andrade, Marilia Santos; Arida, Ricardo Mario] Univ Fed Sao Paulo, Dept Fisiol, Sao Paulo, Brazil.
RP Vancini, RL (corresponding author), Univ Fed Espirito Santo, Ctr Educ Fis & Desportos, Campus Univ,Ave Fernando Ferrari 514, BR-29075810 Vitoria, ES, Brazil.
EM rodrigoluizvancini@gmail.com
RI Andrade, Marilia S/J-2333-2014; Arida, Ricardo Mario/P-7408-2016; de
   Lira, Claudio/V-2480-2019; Vancini, Rodrigo Luiz/F-1012-2016
OI Andrade, Marilia S/0000-0002-7004-4565; Arida, Ricardo
   Mario/0000-0002-7771-6133; de Lira, Claudio/0000-0001-5749-6877;
   Vancini, Rodrigo Luiz/0000-0003-1981-1092
FU Fundacao de Amparo a Pesquisa e Inovacao do Espirito Santo (FAPES)
   agency
FX To all health professionals and scientists who donate their knowledge
   and experience to save lives. To all people, victims, patients,
   families, parents, and friends who have lost loved ones. RLV receives a
   productivity fellowship at the Fundacao de Amparo a Pesquisa e Inovacao
   do Espirito Santo (FAPES) agency (Edital No. 18/2018-Bolsa Pesquisador
   Capixaba).
CR Althoff T, 2017, NATURE, V547, P336, DOI 10.1038/nature23018
   [Anonymous], 2018, NAT REV DIS PRIMERS, V4, P18025
   Arida RM, 2008, SPORTS MED, V38, P607, DOI 10.2165/00007256-200838070-00006
   Arida RM, 2012, EPILEPSY RES, V99, P1, DOI 10.1016/j.eplepsyres.2011.10.012
   Arida RM, 2003, EPILEPSY BEHAV, V4, P507, DOI 10.1016/S1525-5050(03)00184-7
   Beghi E, 2011, EPILEPSIA, V52, P40, DOI 10.1111/j.1528-1167.2011.03035.x
   Cairney J, 2014, J PHYS ACT HEALTH, V11, P908, DOI 10.1123/jpah.2012-0107
   Cascella M, FEATURES EVALUATION
   Center for Disease Control and Prevention (CDC), 2020, STRESS COPING
   Centers for diasease control and prevention, 2020, PROT YOURS
   Duncan JS, 2006, LANCET, V367, P1087, DOI 10.1016/S0140-6736(06)68477-8
   Elger CE, 2017, SEIZURE-EUR J EPILEP, V44, P184, DOI 10.1016/j.seizure.2016.10.018
   Epilepsy Society, EP COR COVID 19 FAQS
   ERIKSEN HR, 1994, EPILEPSIA, V35, P1256, DOI 10.1111/j.1528-1157.1994.tb01797.x
   Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550
   Godhwani N, 2016, ANN ALLERG ASTHMA IM, V117, P634, DOI 10.1016/j.anai.2016.09.443
   Hall G, 2020, PROG CARDIOVASC DIS
   Hamed SA, 2014, EPILEPSY BEHAV, V41, P290, DOI 10.1016/j.yebeh.2014.07.003
   HEISE J, 2002, CLIN EXERC PHYSL, V4, P79
   Jimenez-Pavon D., 2020, PROG CARDIOVASC DIS
   Keezer MR, 2016, LANCET NEUROL, V15, P106, DOI 10.1016/S1474-4422(15)00225-2
   Li SJ, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17062032
   Livneh H, 2001, EPILEPSY BEHAV, V2, P533, DOI 10.1006/ebeh.2001.0284
   MAGUIRE MJ, 2020, COCHRANE DB SYST REV, V4
   McAuley JW, 2001, EPILEPSY BEHAV, V2, P592, DOI 10.1006/ebeh.2001.0271
   NAKKEN KO, 1990, EPILEPSIA, V31, P88, DOI 10.1111/j.1528-1157.1990.tb05365.x
   Oni T, 2015, INT HEALTH, V7, P390, DOI 10.1093/inthealth/ihv040
   Pedersen BK, 2015, SCAND J MED SCI SPOR, V25, P1, DOI 10.1111/sms.12581
   Phua J, 2020, LANCET RESP MED
   Vancini RL, 2016, SCAND J MED SCI SPOR, V26, P856, DOI 10.1111/sms.12708
   Vancini RL, 2018, ARQ NEURO-PSIQUIAT, V76, P209, DOI [10.1590/0004-282x20180014, 10.1590/0004-282X20180014]
   Vancini RL, 2015, ARQ NEURO-PSIQUIAT, V73, P7, DOI 10.1590/0004-282X20140188
   Vancini RL, 2014, EPILEPSY BEHAV, V31, P194, DOI 10.1016/j.yebeh.2013.12.019
   Vancini RL, 2013, EPILEPSY BEHAV, V29, P431, DOI 10.1016/j.yebeh.2013.08.023
   Vancini RL, 2013, EPILEPSY BEHAV, V28, P133, DOI 10.1016/j.yebeh.2013.04.004
   World Health Organization, 2020, COR DIS COVID 2019 S
   World Health Organization, 2020, MENT HLTH PSYCH CONS
   Zaccara G, 2009, ACTA NEUROL SCAND, V120, P1, DOI 10.1111/j.1600-0404.2008.01146.x
NR 38
TC 3
Z9 3
U1 1
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1525-5050
EI 1525-5069
J9 EPILEPSY BEHAV
JI Epilepsy Behav.
PD SEP
PY 2020
VL 110
AR 107154
DI 10.1016/j.yebeh.2020.107154
PG 3
WC Behavioral Sciences; Clinical Neurology; Psychiatry
SC Behavioral Sciences; Neurosciences & Neurology; Psychiatry
GA NM0NY
UT WOS:000567803100027
PM 32451251
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Deprest, J
   Choolani, M
   Chervenak, F
   Farmer, D
   Lagrou, K
   Lopriore, E
   McCullough, L
   Olutoye, O
   Simpson, L
   Van Mieghem, T
   Ryan, G
AF Deprest, Jan
   Choolani, Mahesh
   Chervenak, Frank
   Farmer, Diana
   Lagrou, Katrien
   Lopriore, Enrico
   McCullough, Laurence
   Olutoye, Olutoyin
   Simpson, Lynn
   Van Mieghem, Tim
   Ryan, Greg
TI Fetal Diagnosis and Therapy during the COVID-19 Pandemic: Guidance on
   Behalf of the International Fetal Medicine and Surgery Society
SO FETAL DIAGNOSIS AND THERAPY
LA English
DT Article
DE COVID-19; SARS-CoV-2; Vertical transmission; Fetal anomaly; Fetal
   surgery; Fetoscopy; Fetal medicine
ID MIRROR SYNDROME; INFECTION
AB The COVID-19 pandemic has stressed patients and healthcare givers alike and challenged our practice of antenatal care, including fetal diagnosis and therapy. This document aims to review relevant recent information to allow us to optimize prenatal care delivery. We discuss potential modifications to obstetric management and fetal procedures in SARS-CoV2-negative and SARS-CoV2-positive patients with fetal anomalies or disorders. Most fetal therapies are time sensitive and cannot be delayed. If personnel and resources are available, we should continue to offer procedures of proven benefit, acknowledging any fetal and maternal risks, including those to health care workers. There is, to date, minimal, unconfirmed evidence of spontaneous vertical transmission, though it may theoretically be increased with some procedures. Knowing a mother's preoperative SARS-CoV-2 status would enable us to avoid or defer certain procedures while she is contagious and to protect health care workers appropriately. Some fetal conditions may alternatively be managed neonatally. Counseling regarding fetal interventions which have a possibility of additional intra- or postoperative morbidity must be performed in the context of local resource availability. Procedures of unproven benefit should not be offered. We encourage participation in registries and trials that may help us to understand the impact of COVID-19 on pregnant women, their fetuses, and neonates.
C1 [Deprest, Jan] UZ Leuven, Dept Obstet & Gynecol, Campus Gasthuisberg,Herestr 49, BE-3000 Leuven, Belgium.
   [Deprest, Jan] Katholieke Univ Leuven, Dept Dev & Regenerat, Leuven, Belgium.
   [Deprest, Jan] UCL, Inst Womens Hlth, London, England.
   [Choolani, Mahesh] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Obstet & Gynecol, Singapore, Singapore.
   [Chervenak, Frank; McCullough, Laurence] Lenox Hill Hosp, Zucker Sch Med Hofstra Northwell, New York, NY 10021 USA.
   [Farmer, Diana] Univ Calif Davis, Sch Med, Dept Surg, Sacramento, CA USA.
   [Lagrou, Katrien] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Leuven, Belgium.
   [Lagrou, Katrien] UZ Leuven, Dept Clin Lab Med, Leuven, Belgium.
   [Lagrou, Katrien] UZ Leuven, Natl Reference Ctr Resp Pathogens, Leuven, Belgium.
   [Lopriore, Enrico] Leiden Univ, Med Ctr, Dept Pediat, Div Neonatol, Leiden, Netherlands.
   [Olutoye, Olutoyin] Baylor Coll Med, Texas Childrens Hosp, Dept Anesthesiol, Houston, TX 77030 USA.
   [Simpson, Lynn] Columbia Univ, Dept Obstet & Gynecol, Maternal Fetal Med, New York, NY USA.
   [Van Mieghem, Tim; Ryan, Greg] Univ Toronto, Mt Sinai Hosp, Dept Obstet & Gynaecol, Fetal Med Unit,Ontario Fetal Ctr, Toronto, ON, Canada.
   [Farmer, Diana] Univ Calif Davis, Childrens Hosp, Sacramento, CA USA.
RP Deprest, J (corresponding author), UZ Leuven, Dept Obstet & Gynecol, Campus Gasthuisberg,Herestr 49, BE-3000 Leuven, Belgium.
EM jan.deprest@uzleuven.be
OI Farmer, Diana/0000-0002-3530-5993
CR Abdulai I, 2020, AGR SYST, V181, DOI 10.1016/j.agsy.2020.102812
   Abu-Rustum RS, 2020, ULTRASOUND OBST GYN, V55, P863, DOI 10.1002/uog.22029
   [Anonymous], 2020, NHS SPEC GUID COR
   Ashokka B, 2020, AM J OBSTET GYNECOL, V223, P66, DOI 10.1016/j.ajog.2020.04.005
   Boelig RC, 2020, BJOG-INT J OBSTET GY, V127, P1438, DOI 10.1111/1471-0528.16335
   Braun T, 2010, FETAL DIAGN THER, V27, P191, DOI 10.1159/000305096
   Cascella M, 2020, FEATURES EVALUATION
   Chen DJ, 2020, INT J GYNECOL OBSTET, V149, P130, DOI 10.1002/ijgo.13146
   Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3
   Chen Y, 2020, J MED VIROL, V92, P731, DOI 10.1002/jmv.25787
   Chimenea A, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1718-0
   Cook TM, 2020, ANAESTHESIA, V75, P785, DOI 10.1111/anae.15054
   Dashraath P, 2020, AM J OBSTET GYNECOL, V222, P521, DOI 10.1016/j.ajog.2020.03.021
   David JB, 2020, MED J AUST
   Deprest J, 2020, PRENATAL DIAG, DOI 10.1002/pd.5702
   Dong L, 2020, JAMA-J AM MED ASSOC, V323, P1846, DOI 10.1001/jama.2020.4621
   Fan Cuifang, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa226
   Favre G, 2020, LANCET INFECT DIS, V20, P652, DOI 10.1016/S1473-3099(20)30157-2
   Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang LS, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2841-7
   IACOBUCCI G, 2020, BMJ-BRIT MED J, V369, DOI DOI 10.1136/BMJ.M1339
   Kimberlin DW, 2020, JAMA
   Lei Shaoqing, 2020, EClinicalMedicine, V21, P100331, DOI 10.1016/j.eclinm.2020.100331
   Levy A, 2008, AM J PHYSIOL-REG I, V295, pR1953, DOI 10.1152/ajpregu.90592.2008
   Li YK, 2020, CURR MED SCI, V40, P295, DOI 10.1007/s11596-020-2176-2
   Ling L, 2020, ANAESTH CRIT CARE PA, V39, P163, DOI 10.1016/j.accpm.2020.02.002
   Liu HH, 2020, J INFECTION, V80, pE7, DOI 10.1016/j.jinf.2020.03.007
   Lu Q, 2020, J MED VIROL, V92, P564, DOI 10.1002/jmv.25740
   McCullough LB, 2020, PROFESSIONAL ETHICS
   Melamed N, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031197
   Musso D, 2019, NEW ENGL J MED, V381, P1444, DOI 10.1056/NEJMra1808246
   ObGproject, 2020, COVID 19 SMFM SOAP G
   PAN COVID, 2020, INT REG PREGN NEON O
   Peralta CFA, 2020, PRENATAL DIAG, V40, P689, DOI 10.1002/pd.5675
   Poon LC, 2020, ULTRASOUND OBST GYN, V55, P700, DOI 10.1002/uog.22013
   prevention Cfdca, 2020, SYMPT COR
   Qiao J, 2020, LANCET, V395, P760, DOI 10.1016/S0140-6736(20)30365-2
   Rasmussen SA, 2020, AM J OBSTET GYNECOL, V222, P415, DOI 10.1016/j.ajog.2020.02.017
   Rothe C, 2020, NEW ENGL J MED, V382, P970, DOI 10.1056/NEJMc2001468
   Sacco A, 2019, PRENATAL DIAG, V39, P251, DOI 10.1002/pd.5421
   Schwartz David A, 2020, Arch Pathol Lab Med, DOI 10.5858/arpa.2020-0901-SA
   SMFM, 2020, JOINT STATM EL SURG
   Sutton D, 2020, NEW ENGL J MED, V382, P2163, DOI 10.1056/NEJMc2009316
   TO KKW, 2020, LANCET INFECT DIS, DOI DOI 10.1016/S1473-3099(20)30196-1
   Tsao KB, 2020, AM J OBSTET GYNECOL
   Van Damme E, 2015, J GEN VIROL, V96, P131, DOI 10.1099/vir.0.069872-0
   Wang DM, 2020, J INFECTION, V80, pE25, DOI 10.1016/j.jinf.2020.03.008
   Wang WL, 2020, JAMA-J AM MED ASSOC, V323, P1843, DOI 10.1001/jama.2020.3786
   Wei WE, 2020, MMWR-MORBID MORTAL W, V69, P411, DOI 10.15585/mmwr.mm6914e1
   WHO, 2020, REP WHO CHIN JOINT M
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Yu N, 2020, LANCET INFECT DIS, V20, P559, DOI 10.1016/S1473-3099(20)30176-6
   Zeng L, 2020, JAMA PEDIAT
   Zhang JC, 2020, J MED VIROL, V92, P680, DOI 10.1002/jmv.25742
   Zhang L, 2020, Zhonghua Fu Chan Ke Za Zhi, V55, P166, DOI 10.3760/cma.j.cn112141-20200218-00111
   Zhang Wei, 2020, Emerg Microbes Infect, V9, P386, DOI 10.1080/22221751.2020.1729071
   Zhao J., 2020, CLIN INFECT DIS, V71, P2027, DOI [10.1093/cid/ciaa344, DOI 10.1093/CID/CIAA344]
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu HP, 2020, TRANSL PEDIATR, V9, P51, DOI 10.21037/tp.2020.02.06
NR 61
TC 4
Z9 4
U1 2
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-3837
EI 1421-9964
J9 FETAL DIAGN THER
JI Fetal Diagn. Ther.
PD SEP
PY 2020
VL 47
IS 9
BP 689
EP 698
DI 10.1159/000508254
PG 10
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA NM2XG
UT WOS:000567964200005
PM 32375144
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Scaldaferri, F
   Ianiro, G
   Privitera, G
   Lopetuso, LR
   Vetrone, LM
   Petito, V
   Pugliese, D
   Neri, M
   Cammarota, G
   Ringel, Y
   Costamagna, G
   Gasbarrini, A
   Boskoski, I
   Armuzzi, A
AF Scaldaferri, Franco
   Ianiro, Gianluca
   Privitera, Giuseppe
   Lopetuso, Loris Riccardo
   Vetrone, Lorenzo Maria
   Petito, Valentina
   Pugliese, Daniela
   Neri, Matteo
   Cammarota, Giovanni
   Ringel, Yehuda
   Costamagna, Guido
   Gasbarrini, Antonio
   Boskoski, Ivo
   Armuzzi, Alessandro
TI The Thrilling Journey of SARS-CoV-2 into the Intestine: From
   Pathogenesis to Future Clinical Implications
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE immune-mediated disease; lung-gut axis; microbiota; immunomodulators
ID INFLAMMATORY-BOWEL-DISEASE; MICROBIOTA; LUNG; INFECTION; MANAGEMENT;
   INJURY; RISK; GUT
AB Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has a direct impact on the gastrointestinal system, as up to 50% of fecal samples from coronavirus disease 2019 (COVID-19) patients contain detectable viral RNA despite a negative rhino-pharyngeal swab. This finding, together with an intestinal expression of angiotensin conversion enzyme 2 protein, suggests a possible fecal-oral transmission for SARS-CoV-2. Furthermore, gastrointestinal (GI) symptoms are common in COVID-19 patients including watery diarrhea, vomiting-particularly in children-nausea, and abdominal pain.
   Pathogenesis of SARS-CoV-2 infection presents significant similarities to those of some immune-mediated diseases, such as inflammatory bowel diseases or rheumatoid arthritis, leading to the hypothesis that targeted therapies used for the treatment of immune-mediated disease could be effective to treat (and possibly prevent) the main complications of COVID-19.
   In this review, we synthesize the present and future impact of SARS-CoV-2 infection on the gastrointestinal system and on gastroenterology practice, hypothesizing a potential role of the "gut-lung axis" and perhaps of the gut and lung microbiota into the interindividual differential susceptibility to COVID-19 19 disease.
   Finally, we speculate on the reorganization of outpatient gastroenterology services, which need to consider, among other factors, the major psychological impact of strict lockdown measures on the whole population.
C1 [Scaldaferri, Franco; Ianiro, Gianluca; Lopetuso, Loris Riccardo; Pugliese, Daniela; Cammarota, Giovanni; Gasbarrini, Antonio; Boskoski, Ivo; Armuzzi, Alessandro] Fdn Policlin Univ A Gemelli IRCCS, Dipartimento Sci Med & Chirurg, Unita Operat Complesse Med Interne & Gastroentero, CEMAD IBD Unit, Rome, Italy.
   [Scaldaferri, Franco; Ianiro, Gianluca; Privitera, Giuseppe; Vetrone, Lorenzo Maria; Petito, Valentina; Cammarota, Giovanni; Costamagna, Guido; Gasbarrini, Antonio; Armuzzi, Alessandro] Univ Cattolica Sacro Cuore, Dipartimento Univ Med & Chirurg Traslazionale, Rome, Italy.
   [Lopetuso, Loris Riccardo; Neri, Matteo] G dAnnunzio Univ Chieti Pescara, Dept Med & Ageing Scie, Chieti, Italy.
   [Lopetuso, Loris Riccardo; Neri, Matteo] G dAnnunzio Univ Chieti Pescara, Ctr Adv Studies & Technol CAST, Chieti, Italy.
   [Ringel, Yehuda] Meir Med Ctr, Div Gastroenterol & Hepatol, Kefar Sava, Israel.
   [Ringel, Yehuda] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA.
   [Costamagna, Guido; Boskoski, Ivo] Fdn Policlin Univ Agostino Gemelli IRCCS, Digest Adoscopy Unit, Rome, Italy.
RP Armuzzi, A (corresponding author), Fdn Policlin Univ Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, I-00168 Rome, RM, Italy.
EM alessandro.armuzzi@unicatt.it
RI Boskoski, Ivo/A-9629-2014
OI Boskoski, Ivo/0000-0001-8194-2670; Privitera,
   Giuseppe/0000-0002-7020-5808; Vetrone, Lorenzo Maria/0000-0002-9845-0004
CR Agarwal S, 2017, EXPERT REV CLIN IMMU, V13, P247, DOI 10.1080/1744666X.2017.1232165
   An P, 2020, SSRN ELECT J
   Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC
   Beilenhoff U, 2018, ENDOSCOPY, V50, P1205, DOI 10.1055/a-0759-1629
   Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011
   Bingula R, 2017, J ONCOL, V2017, DOI 10.1155/2017/5035371
   Boettler Tobias, 2020, JHEP Rep, V2, P100113, DOI 10.1016/j.jhepr.2020.100113
   Bonovas S, 2016, CLIN GASTROENTEROL H, V14, P1385, DOI 10.1016/j.cgh.2016.04.039
   Bowman LJ, 2018, TRANSPLANTATION, V102, pS50, DOI [10.1097/TP.0000000000001777, 10.1097/tp.0000000000001777]
   Bradley KC, 2019, CELL REP, V28, P245, DOI 10.1016/j.celrep.2019.05.105
   Brake SJ, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030841
   Brenner EJ, 2020, GASTROENTEROLOGY, V159, P481, DOI 10.1053/j.gastro.2020.05.032
   Buscarini E, 2020, GUT, V69, P1547, DOI 10.1136/gutjnl-2020-321434
   Cammarota G, 2019, GUT, V68, P2111, DOI 10.1136/gutjnl-2019-319548
   Chai X, 2020, SPECIFIC ACE2 EXPRES
   Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244
   Cheung KS, 2020, GASTROENTEROLOGY
   Choi WS, 2016, INFECT CHEMOTHER, V48, P118, DOI 10.3947/ic.2016.48.2.118
   DAmico F, 2020, CLIN GASTROENTEROL H
   Danese S, 2020, NAT REV GASTRO HEPAT, V17, P253, DOI 10.1038/s41575-020-0294-8
   Effenberger M, 2020, GUT, V69, P1543, DOI 10.1136/gutjnl-2020-321388
   Enaud R, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00009
   Ercolini AM, 2009, CLIN EXP IMMUNOL, V155, P1, DOI 10.1111/j.1365-2249.2008.03834.x
   Favalli EG, 2020, LANCET INFECT DIS
   Fragoulis GE, 2019, WORLD J GASTROENTERO, V25, P2162, DOI 10.3748/wjg.v25.i18.2162
   Gao QY, 2020, J DIGEST DIS, V21, P125, DOI 10.1111/1751-2980.12851
   Garg M, 2020, GUT, V69, P841, DOI 10.1136/gutjnl-2019-318512
   Garg M, 2015, J RENIN-ANGIO-ALDO S, V16, P559, DOI 10.1177/1470320314521086
   Ghosh S, 2019, DRUG SAFETY, V42, P809, DOI 10.1007/s40264-019-00816-3
   Gollwitzer ES, 2014, NAT MED, V20, P642, DOI 10.1038/nm.3568
   Gralnek IM, 2020, ENDOSCOPY, V52, P483, DOI 10.1055/a-1155-6229
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031
   Gu J., 2020, GASTROENTEROLOGY
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Han C, 2020, AM J GASTROENTEROL, P1
   Hashimoto T, 2012, NATURE, V487, P477, DOI 10.1038/nature11228
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang YF, 2018, SCIENCE, V359, P114, DOI 10.1126/science.aam5809
   Huffnagle GB., MICROBIOTA ALLERGIES
   Iacucci M, 2020, LANCET GASTROENTEROL, V5, P598, DOI 10.1016/S2468-1253(20)30119-9
   Ianiro G, 2019, ANN INTERN MED, V171, P695, DOI 10.7326/M18-3635
   Ianiro G, 2018, UNITED EUR GASTROENT, V6, P1232, DOI 10.1177/2050640618780762
   Jablaoui A, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00021
   Jin Y, 2020, VIRUSES, V12
   Jones Veena G, 2020, Hosp Pediatr, V10, P537, DOI 10.1542/hpeds.2020-0123
   Lee KH, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102469
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Leung WK, 2003, GASTROENTEROLOGY, V125, P1011, DOI 10.1053/S0016-5085(03)01215-0
   Lin L, 2020, EMERG MICROBES INFEC, V9, P727, DOI 10.1080/22221751.2020.1746199
   Madan JC, 2012, MBIO, V3, DOI 10.1128/mBio.00251-12
   Mao R, 2020, LANCET GASTROENTEROL, V5, P426, DOI 10.1016/S2468-1253(20)30076-5
   McAleer JP, 2018, EUR J IMMUNOL, V48, P39, DOI 10.1002/eji.201646721
   Mehta AK, 2018, CYTOKINE, V101, P14, DOI 10.1016/j.cyto.2016.08.003
   Motwani K, 2020, CLIN J GASTROENTEROL, V13, P732, DOI 10.1007/s12328-020-01141-4
   Mukherjee S, 2018, YALE J BIOL MED, V91, P143
   Neurath MF, 2020, GUT, V69, P1335, DOI 10.1136/gutjnl-2020-321269
   Ng SC, 2018, INFLAMM BOWEL DIS, V24, P2431, DOI 10.1093/ibd/izy153
   Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8
   Norsa L, 2020, GASTROENTEROLOGY
   O'Connor A, 2010, THER ADV CHRONIC DIS, V1, P7, DOI 10.1177/2040622310368736
   Ortiz-Martinez Y., 2020, TRAVEL MED INFECT DI
   OTTMAN KE, 2020, J CLIN INVEST, V130
   Peyrin-Biroulet L, 2015, AM J GASTROENTEROL, V110, P1324, DOI 10.1038/ajg.2015.233
   Qin C, 2020, CLIN INFECT DIS, V2019, P4, DOI [10.2139/ssrn.3541136, DOI 10.2139/SSRN.3541136]
   Richardson P, 2020, LANCET, V395, pE30, DOI 10.1016/S0140-6736(20)30304-4
   Rowley AH, 2010, EXPERT REV ANTI-INFE, V8, P197, DOI 10.1586/ERI.09.109
   Samuelson DR, 2015, FRONT MICROBIOL, V6, DOI [10.5389/fmicb.2015.01085, 10.3389/fmicb.2015.01085]
   Sandborn WJ, 2012, NEW ENGL J MED, V367, P616, DOI 10.1056/NEJMoa1112168
   Sani G, 2020, PSYCHIAT CLIN NEUROS, V74, P372, DOI 10.1111/pcn.13004
   Scaldaferri F, 2020, UNITED EUR GASTROENT, V8, P775, DOI 10.1177/2050640620929133
   Schett G, 2020, NAT REV IMMUNOL, V20, P271, DOI 10.1038/s41577-020-0312-7
   Siddiqi HK, 2020, J HEART LUNG TRANSPL, V39, P405, DOI 10.1016/j.healun.2020.03.012
   Sneller MC, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax3447
   Sze MA, 2012, AM J RESP CRIT CARE, V185, P1073, DOI 10.1164/rccm.201111-2075OC
   Tanaka Y, 2013, VIRUSES-BASEL, V5, P1250, DOI 10.3390/v5051250
   Tapper EB, 2020, J HEPATOL
   Tian Y, 2020, ALIMENT PHARM THER, V51, P843, DOI 10.1111/apt.15731
   Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444
   Turnier JL, 2015, PEDIATRICS, V136, pE609, DOI 10.1542/peds.2015-0950
   Tursi A, 2020, GUT, V69, P1364, DOI 10.1136/gutjnl-2020-321240
   Ungaro RC, 2020, GASTROENTEROLOGY
   Verdecchia P, 2020, EUR J INTERN MED, P1
   Wan Y, 2020, LANCET GASTROENTEROL
   Wang J, 2014, J EXP MED, V211, P2397, DOI 10.1084/jem.20140625
   Wang W., 2020, JAMA
   Wolfel R, 2020, NATURE, P1, DOI [10.1038/s41586-020-2196-x, 10.1038/s41586-020-2984-3]
   Wong E, 2016, SCI REP-UK, V6, DOI 10.1038/srep35598
   Wu C, 2020, JAMA INT MED, DOI 10.1001/jamainternmed.2020.0994
   Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005
   Xiao F, 2020, GASTROENTEROLOGY
   Xing Y.-H., 2020, J MICROBIOL IMMUNOL
   Xu Y, 2020, NAT MED, DOI 10.1038/s41591-020-0817-4
   Yang Z, 2020, J INFECT
   Ye Q., 2020, J INFECT
   Zhang C, 2020, LANCET GASTROENTEROL, V5, P428, DOI 10.1016/S2468-1253(20)30057-1
   Zhang H, 2020, INT J INFECT DIS, V96, P19, DOI 10.1016/j.ijid.2020.04.027
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
NR 98
TC 1
Z9 1
U1 6
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1078-0998
EI 1536-4844
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD SEP
PY 2020
VL 26
IS 9
BP 1306
EP 1314
DI 10.1093/ibd/izaa181
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA NO0ZN
UT WOS:000569215300012
PM 32720978
OA Green Published
DA 2021-01-01
ER

PT J
AU Braz, HLB
   Silveira, JAD
   Marinho, AD
   de Moraes, MEA
   de Moraes, MO
   Monteiro, HSA
   Jorge, RJB
AF Bezerra Braz, Helyson Lucas
   de Moraes Silveira, Joao Alison
   Marinho, Aline Diogo
   Amaral de Moraes, Maria Elisabete
   de Moraes Filho, Manoel Odorico
   Azul Monteiro, Helena Serra
   Bezerra Jorge, Roberta Jeane
TI In silico study of azithromycin, chloroquine and hydroxychloroquine and
   their potential mechanisms of action against SARS-CoV-2 infection
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE COVID-19; Coronavirus; Molecular docking; Azithromycin; Chloroquine;
   Hydroxychloroquine
ID CORONAVIRUS MAIN PROTEINASE; EAST RESPIRATORY SYNDROME; PROTEASE; SARS;
   INHIBIT; VIRUS; DESIGN; DRUGS; ENTRY; SPIKE
AB Coronavirus disease 2019 (COVID-19) is a highly transmissible viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical trials have reported improved outcomes resulting from an effective reduction or absence of viral load when patients were treated with chloroquine (CQ) or hydroxychloroquine (HCQ). In addition, the effects of these drugs were improved by simultaneous administration of azithromycin (AZM). The receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein binds to the cell surface angiotensin-converting enzyme 2 (ACE2) receptor, allowing virus entry and replication in host cells. The viral main protease (Mpro) and host cathepsin L (CTSL) are among the proteolytic systems involved in SARS-CoV-2 S protein activation. Hence, molecular docking studies were performed to test the binding performance of these three drugs against four targets. The findings showed AZM affinity scores ( AG) with strong interactions with ACE2, CTSL, Mpro and RBD. CQ affinity scores showed three low-energy results (less negative) with ACE2, CTSL and RBD, and a firm bond score with Mpro. For HCQ, two results (ACE2 and Mpro) were firmly bound to the receptors, however CTSL and RBD showed low interaction energies. The differences in better interactions and affinity between HCQ and CQ with ACE2 and Mpro were probably due to structural differences between the drugs. On other hand, AZM not only showed more negative (better) values in affinity, but also in the number of interactions in all targets. Nevertheless, further studies are needed to investigate the antiviral properties of these drugs against SARS-CoV-2. (c) 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.
C1 [Bezerra Braz, Helyson Lucas] Univ Fed Ceara, Sch Med, Dept Morphol, Postgrad Program Morphol Sci, Delmiro de Farias St, BR-60430170 Fortaleza, Ceara, Brazil.
   [Bezerra Braz, Helyson Lucas; de Moraes Silveira, Joao Alison; Marinho, Aline Diogo; Amaral de Moraes, Maria Elisabete; de Moraes Filho, Manoel Odorico; Azul Monteiro, Helena Serra; Bezerra Jorge, Roberta Jeane] Univ Fed Ceara, Drug Res & Dev Ctr, Coronel Nunes de Melo St,1000, BR-60430275 Fortaleza, Ceara, Brazil.
   [de Moraes Silveira, Joao Alison; Marinho, Aline Diogo; Amaral de Moraes, Maria Elisabete; de Moraes Filho, Manoel Odorico; Azul Monteiro, Helena Serra; Bezerra Jorge, Roberta Jeane] Univ Fed Ceara, Sch Med, Dept Physiol & Pharmacol, Coronel Nunes de Melo St,1127, BR-60430275 Fortaleza, Ceara, Brazil.
RP Jorge, RJB (corresponding author), Univ Fed Ceara, Drug Res & Dev Ctr, Coronel Nunes de Melo St,1000, BR-60430275 Fortaleza, Ceara, Brazil.; Jorge, RJB (corresponding author), Univ Fed Ceara, Sch Med, Dept Physiol & Pharmacol, Coronel Nunes de Melo St,1127, BR-60430275 Fortaleza, Ceara, Brazil.
EM robertajeane@ufc.br
OI Bezerra Braz, Helyson Lucas/0000-0003-1996-8831
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq), BrazilNational Council for Scientific and
   Technological Development (CNPq)
FX This work was supported by the Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior (CAPES) and the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Brazil.
CR Abdoli A, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1973
   Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
   Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   Anand K, 2003, SCIENCE, V300, P1763, DOI 10.1126/science.1085658
   Ton AT, 2020, MOL INFORM, DOI 10.1002/minf.202000028
   Asada M, 2009, ANTIVIR RES, V83, P191, DOI 10.1016/j.antiviral.2009.05.003
   Baez-Santos YM, 2015, ANTIVIR RES, V115, P21, DOI 10.1016/j.antiviral.2014.12.015
   Bosseboeuf E., 2018, J ANTIVIR ANTIRETROV, V10, P6, DOI [10.4172/1948-5964.1000173, DOI 10.4172/1948-5964.1000173]
   Catapang JK, 2020, CHEMRXIV, DOI [10.26434/chemrxiv.12011157.v1., DOI 10.26434/CHEMRXIV.12011157.V1]
   Choi Y, 2018, NAT REV MICROBIOL, V16, P340, DOI 10.1038/s41579-018-0003-6
   Chou KC, 2003, BIOCHEM BIOPH RES CO, V308, P148, DOI 10.1016/S0006-291X(03)01342-1
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   D'Alessandro S, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8010085
   Tran DH, 2019, J ANTIBIOT, V72, P759, DOI 10.1038/s41429-019-0204-x
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477
   Fantini J, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105960
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gierer S, 2013, J VIROL, V87, P5502, DOI 10.1128/JVI.00128-13
   Golden EB, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2014.12.FOCUS14748
   Guo DY, 2020, VIROL SIN, V35, P253, DOI 10.1007/s12250-020-00204-7
   Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0
   Hilgenfeld R, 2014, FEBS J, V281, P4085, DOI 10.1111/febs.12936
   Jelic D, 2016, ANTIBIOTICS-BASEL, V5, DOI 10.3390/antibiotics5030029
   Kawase M, 2012, J VIROL, V86, P6537, DOI 10.1128/JVI.00094-12
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218
   Kuster GM, 2020, EUR HEART J, V41, P1801, DOI 10.1093/eurheartj/ehaa235
   Letko M, 2020, NAT MICROBIOL, DOI 10.1038/s41564-020-0688-y
   Li CF, 2019, ANTIMICROB AGENTS CH, V63, DOI 10.1128/AAC.00394-19
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Morse JS, 2020, CHEMBIOCHEM, V21, P730, DOI 10.1002/cbic.202000047
   Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9
   Patel PH, 2020, STATPEARLS
   Paz Ocaranza Maria, 2020, Nat Rev Cardiol, V17, P116, DOI 10.1038/s41569-019-0244-8
   Pence HE, 2010, J CHEM EDUC, V87, P1123, DOI 10.1021/ed100697w
   Rabaan AA, 2017, J MED MICROBIOL, V66, P1261, DOI 10.1099/jmm.0.000565
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Sheahan TP, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13940-6
   Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005
   Sun YJ, 2020, CHEM COMMUN, V56, P6484, DOI 10.1039/d0cc02245d
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   Tortorici MA, 2019, ADV VIRUS RES, V105, P93, DOI 10.1016/bs.aivir.2019.08.002
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Rosa SGV, 2020, REV PANAM SALUD PUBL, V44, DOI 10.26633/RPSP.2020.40
   Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]
   Xia S, 2020, CELL MOL IMMUNOL, V17, P765, DOI 10.1038/s41423-020-0374-2
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yang HT, 2003, P NATL ACAD SCI USA, V100, P13190, DOI 10.1073/pnas.1835675100
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Ye G, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12020240
   Yu B, 2020, SCI CHINA LIFE SCI, V63, P1515, DOI 10.1007/s11427-020-1732-2
   Zhang HB, 2020, INTENS CARE MED, V46, P586, DOI 10.1007/s00134-020-05985-9
   Zhou N, 2016, J BIOL CHEM, V291, P9218, DOI 10.1074/jbc.M116.716100
   Zhou Y, 2015, ANTIVIR RES, V116, P76, DOI 10.1016/j.antiviral.2015.01.011
   Zhuang WR, 2019, J CONTROL RELEASE, V294, P311, DOI 10.1016/j.jconrel.2018.12.014
NR 65
TC 0
Z9 0
U1 15
U2 15
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD SEP
PY 2020
VL 56
IS 3
AR 106119
DI 10.1016/j.ijantimicag.2020.106119
PG 8
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA NM0CS
UT WOS:000567773900029
PM 32738306
OA Green Published
DA 2021-01-01
ER

PT J
AU Khuroo, MS
AF Khuroo, Mohammad Sultan
TI Chloroquine and hydroxychloroquine in coronavirus disease 2019
   (COVID-19). Facts, fiction and the hype: a critical appraisal
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE Chloroquine; Hydroxychloroquine; COVID-19; SARS-CoV-2; Coronavirus;
   Pandemic
ID QT INTERVAL PROLONGATION; COVID-19; MECHANISMS; PHARMACOKINETICS;
   ANTIMALARIALS; AZITHROMYCIN; MANAGEMENT; DRUGS; RISK
AB The coronavirus infection (COVID-19) has turned into a global catastrophe and there is an intense search for effective drug therapy. Of all the potential therapies, chloroquine and hydroxychloroquine have been the focus of tremendous public attention. Both drugs have been used in the treatment and prophylaxis of malaria. Long-term use of hydroxychloroquine is the cornerstone in the treatment of several auto -immune disorders. There is convincing evidence that hydroxychloroquine has strong in vitro antiviral activity against SARS-CoV-2. A few small uncontrolled trials and several anecdotal reports have shown conflicting results of such drug therapy in COVID-19. However, the results of preliminary large-scale ran-domized controlled trials have failed to show any survival benefit of such drug therapy in COVID-19. De-spite the lack of such evidence, hydroxychloroquine has been used as a desperate attempt for prophylaxis and treatment of COVID-19. The drug has wide-ranging drug interactions and potential cardiotoxicity. In-discriminate unsupervised use can expose the public to serious adverse drug effects. (c) 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.
C1 [Khuroo, Mohammad Sultan] Dr Khuroos Med Clin, Digest Dis Ctr, Srinagar, Jammu & Kashmir, India.
RP Khuroo, MS (corresponding author), Dr Khuroos Med Clin, Digest Dis Ctr, Sect 1, Kashmir 190010, Jammu & Kashmir, India.
EM khuroo@yahoo.com
OI Khuroo, Mohammad Sultan/0000-0003-2823-8814
FU Dr. Khuroo Medical Trust [273 CD 314]
FX Professor MS Khuroo received grants from Dr. Khuroo Medical Trust
   (Registration number 273 CD 314), sponsored by Dr. Khuroo's family meant
   to help the needy, promote medical education and support cutting-edge
   scientific research.
CR Abdel-Hamid H, 2008, MUSCLE NERVE, V38, P1206, DOI 10.1002/mus.21091
   Acharjee S., 2020, INDIA TODAY     0324
   Alhazzani W, 2020, INTENS CARE MED, V46, P854, DOI [10.1097/CCM.0000000000004363, 10.1007/s00134-020-06022-5]
   An J, 2017, ANNU REV MED, V68, P317, DOI 10.1146/annurev-med-043015-123453
   [Anonymous], 2020, JAIPUR NEWS TIM 0322
   [Anonymous], 2020, TIMES INDIA
   [Anonymous], 2020, TREATMENTS COVID 19
   Antony Hiasindh Ashmi, 2016, Trop Parasitol, V6, P30, DOI 10.4103/2229-5070.175081
   Arguin PM, 2011, INFECT DIS RELATED T
   Bennett ML, 2000, CURR PROBL DERM-US, V12, P257, DOI 10.1016/S1040-0486(00)90019-X
   Borba MG, 2020, CHLOROQUINE DIPHOSPH
   Boulware D.R., 2020, N ENGL J MED
   Caly L, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104787
   Casado E, 2006, ANN RHEUM DIS, V65, P385, DOI 10.1136/ard.2004.023200
   CDC, 2020, INF CLIN THER OPT CO
   CDC, 2020, INT CLIN GUID MAN PA
   Chandna H., 2020, INDIAN FIRMS IPCA ZY
   Chandra H., 2020, THE PRINT       0325
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chatterjee P, 2020, HEALTHCARE WORKERS S
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen XT, 2020, CLIN TRIALS, V17, P507, DOI 10.1177/1740774520928614
   Cherney K, 2016, RHEUMATOID ARTHRITIS
   Chorin E, 2020, NAT MED, V26, P808, DOI 10.1038/s41591-020-0888-2
   Cohen MS, 2020, NEW ENGL J MED, V383, P585, DOI 10.1056/NEJMe2020388
   Cortez MF, 2020, MALARIA DRUG CHLOROQ
   Costedoat-Chalumeau N, 2007, RHEUMATOLOGY, V46, P808, DOI 10.1093/rheumatology/kel402
   Diamond D., 2020, CORONAVIRUS FDA ISSU
   Diederich S., 2020, PREVENTING SPREAD SA
   Ducharme J, 1996, CLIN PHARMACOKINET, V31, P257, DOI 10.2165/00003088-199631040-00003
   Ebrahim SH, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1066
   Ecker A, 2012, TRENDS PARASITOL, V28, P504, DOI 10.1016/j.pt.2012.08.002
   FDA, 2020, COR DIS 2019 COVID 1
   FINBLOOM DS, 1985, J RHEUMATOL, V12, P692
   Foley M, 1998, PHARMACOL THERAPEUT, V79, P55, DOI 10.1016/S0163-7258(98)00012-6
   Fossa AA, 2007, AM J TROP MED HYG, V77, P929, DOI 10.4269/ajtmh.2007.77.929
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Gates B., 2020, NEW ENGL J MED
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Goodman J., 2020, BBC
   Gordon C, 2018, RHEUMATOLOGY, V57, pE1, DOI 10.1093/rheumatology/kex286
   Guastalegname M, 2020, CLIN INFECT DIS
   Haseltine WA, 2020, HYDROXYCHLOROQUINE I
   Herman B., 2020, MAN DIES SELF MED CH
   Horby P, 2020, 20151852 MEDRXIV
   Jorge A, 2018, NAT REV RHEUMATOL, V14, P693, DOI 10.1038/s41584-018-0111-8
   Kannan S, 2020, EUR REV MED PHARMACO, V24, P2006, DOI 10.26355/eurrev_202002_20378
   Khuroo MS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121450
   Kishimoto M, 2012, J RHEUMATOL, V39, P1296, DOI 10.3899/jrheum.111569
   Krause DW, 2020, NATURE, V581, P421, DOI 10.1038/s41586-020-2234-8
   Kumar C., 2020, BUSINESS TODAY
   Lazarus MN, 2006, RHEUMATOLOGY, V45, P1012, DOI 10.1093/rheumatology/kei281
   Legido-Quigley H, 2020, LANCET, V395, P848, DOI 10.1016/S0140-6736(20)30551-1
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lu ZK, 2015, EXPERT OPIN DRUG SAF, V14, P295, DOI 10.1517/14740338.2015.989210
   Magagnoli J, 2010, OUTCOMES HYDROXYCHLO
   MAHASE E, 2020, BMJ-BRIT MED J, V368, DOI DOI 10.1136/BMJ.M1166
   Mahevas M., 2020, 20060699 MEDRXIV
   MCCHESNEY EW, 1983, AM J MED, V75, P11, DOI 10.1016/0002-9343(83)91265-2
   McLaughlin EC, 2020, CHLOROQUINE HYDROXYC
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Moore T, 2020, HARRISONS PRINCIPLES, V1, P1556
   Nachimuthu S, 2012, THER ADV DRUG SAF, V3, P241, DOI 10.1177/2042098612454283
   Natarajan D., 2020, INDIANS ARE BUYING C
   Nordqvist J., 2013, MED NEWS TODAY
   Owens B, 2020, LANCET RHEUMATOL
   Price RN, 1999, ANTIMICROB AGENTS CH, V43, P2943, DOI 10.1128/AAC.43.12.2943
   Rathi S, 2020, LANCET INFECT DIS
   Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833
   RECOVERY Collaborative Group, 2020, N Engl J Med, DOI 10.1056/NEJMoa2021436
   Richardson V., 2020, WASHINGTON TIME 0330
   Rodriguez-Menchaca AA, 2008, P NATL ACAD SCI USA, V105, P1364, DOI 10.1073/pnas.0708153105
   Ruiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766
   Schneider L., 2020, CHLOROQUINE GENIUS D
   Schrezenmeier E, 2020, NAT REV RHEUMATOL, V16, P155, DOI 10.1038/s41584-020-0372-x
   Simpson TF, 2020, AM COLL CARDIOL
   Singh AK, 2020, DIABETES METAB SYND, V14, P241, DOI 10.1016/j.dsx.2020.03.011
   Smith T., 2020, COVID 19 DRUG THERAP
   Smolen JS, 2014, ANN RHEUM DIS, V73, P492, DOI 10.1136/annrheumdis-2013-204573
   Srinivasa Amar, 2017, J Rheumatol, V44, P398, DOI 10.3899/jrheum.161063
   Streetman DS, 2020, DRUG INTERACTION POT
   Taccone FS, 2020, LANCET RESP MED
   TANENBAUM L, 1980, ARCH DERMATOL, V116, P587, DOI 10.1001/archderm.116.5.587
   Tang W, 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]
   Tektonidou MG, 2019, ANN RHEUM DIS, V78, P1296, DOI 10.1136/annrheumdis-2019-215213
   Tisdale JE, 2013, CIRC-CARDIOVASC QUAL, V6, P479, DOI 10.1161/CIRCOUTCOMES.113.000152
   Ursing J, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01846-19
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Viswanath A., 2020, CORONAVIRUS CRISIS D
   Vivino FB, 2016, RHEUM DIS CLIN N AM, V42, P531, DOI 10.1016/j.rdc.2016.03.010
   WALLACE DJ, 1994, J RHEUMATOL, V21, P375
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   WHO, 2020, COR DIS COVID 19 PAN
   WHO, 2017, WHO EV REV GROUP M 1
   WHO, 2019, LICENSE
   WHO, 2020, CLIN MAN SEV AC RESP
   Woosley RL, 2020, CARDIAC COMPLICATION
   World Health Organization, 2020, SOL CLIN TRIAL COVID
   World Health Organization, 2017, WHO MAL POL ADV COMM
   World Health Organization, 2020, NAM COR DIS COVID 19
   Yao X, 2020, CLIN INFECT DIS
NR 102
TC 3
Z9 3
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD SEP
PY 2020
VL 56
IS 3
AR 106101
DI 10.1016/j.ijantimicag.2020.106101
PG 12
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA NM0CS
UT WOS:000567773900004
PM 32687949
OA Green Published
DA 2021-01-01
ER

PT J
AU Oscanoa, TJ
   Romero-Ortuno, R
   Carvajal, A
   Savarino, A
AF Oscanoa, Teodoro J.
   Romero-Ortuno, Roman
   Carvajal, Alfonso
   Savarino, Andrea
TI A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An
   old drug for the fight against a new coronavirus?
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE SARS-CoV-2; COVID-19; Chloroquine; Hydroxychloroquine; Antiviral
ID TUMOR-NECROSIS-FACTOR; RETINAL TOXICITY; FACTOR-ALPHA;
   HYDROXYCHLOROQUINE; VIRUS; PHARMACOKINETICS; MALARIA; INHIBITION;
   ENDOCYTOSIS; CARDIOTOXICITY
AB The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is having serious consequences on health and the economy worldwide. All evidence-based treatment strategies need to be considered to combat this new virus. Drugs need to be considered on scientific grounds of efficacy, safety and cost. Chloroquine (CQ) and hydroxychloroquine (HCQ) are old drugs used in the treatment of malaria. Moreover, their antiviral properties have been previously studied, including against coronaviruses, where evidence of efficacy has been found. In the current race against time triggered by the COVID-19 pandemic, the search for new antivirals is very important. However, consideration should be given to old drugs with known anti-coronavirus activity, such as CQ and HCQ. These could be integrated into current treatment strategies while novel treatments are awaited, also in light of the fact that they display an anticoagulant effect that facilitates the activity of low-molecular-weight heparin, aimed at preventing acute respiratory distress syndrome (ARDS)associated thrombotic events. The safety of CQ and HCQ has been studied for over 50 years, however recently published data raise concerns for cardiac toxicity of CQ/HCQ in patients with COVID-19. This review also re-examines the real information provided by some of the published alarming reports, although concluding that cardiac toxicity should in any case be stringently monitored in patients receiving CQ/HCQ. (c) 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
C1 [Oscanoa, Teodoro J.] Univ Nacl Mayor San Marcos, Fac Med, Dept Pharmacol, Lima, Peru.
   [Oscanoa, Teodoro J.] Univ San Martin de Porres, Hosp Almenara, Fac Med Humana, Drug Safety Res Ctr,ESSALUD, Lima, Peru.
   [Romero-Ortuno, Roman] St James Hosp, Mercers Inst Successful Ageing, Discipline Med Gerontol, Dublin, Ireland.
   [Romero-Ortuno, Roman] Trinity Coll Dublin, Global Brain Hlth Inst, Dublin, Ireland.
   [Carvajal, Alfonso] Univ Valladolid, Ctr Estudios Seguridad Med CESME, Valladolid, Spain.
   [Savarino, Andrea] Ist Super Sanita, Dept Infect Dis, Rome, Italy.
RP Oscanoa, TJ (corresponding author), Univ Nacl Mayor San Marcos, Fac Med, Dept Pharmacol, Lima, Peru.; Oscanoa, TJ (corresponding author), Univ San Martin de Porres, Hosp Almenara, Fac Med Humana, Drug Safety Res Ctr,ESSALUD, Lima, Peru.
EM tjoscanoae2017@gmail.com
CR Accapezzato D, 2005, J EXP MED, V202, P817, DOI 10.1084/jem.20051106
   Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS), TRAT DISP MAN INF RE
   Agenzie Italiana del Farmaco (AIFA), COVID 19 AGG SCHED I
   Agenzie Italiana del Farmaco (AIFA), 2020, AIFA SOSP AUT ALL ID
   Ahmad I, 2020, DOXYCYCLINE HYDROXYC, DOI [10.1101/2020.05.18.20066902, DOI 10.1101/2020.05.18.20066902]
   Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   Arya R, 2020, POTENTIAL INHIBITORS, DOI [10.26434/chemrxiv.11860011.v2, DOI 10.26434/CHEMRXIV.11860011.V2, 10.26434/chemrxiv.11860011.v2.]
   Barrow E, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-177
   Bondeson J, 1998, GEN PHARMACOL, V30, P357, DOI 10.1016/S0306-3623(97)00269-3
   Boonyasuppayakorn S, 2014, ANTIVIR RES, V106, P125, DOI 10.1016/j.antiviral.2014.03.014
   Borba MGS, 2020, CHLOROQUINE DIPHOSPH, DOI [10.1101/2020.04.07.20056424, DOI 10.1101/2020.04.07.20056424]
   Broder A, 2013, J RHEUMATOL, V40, P30, DOI 10.3899/jrheum.120157
   Buyue Y, 2012, J THROMB HAEMOST, V10, P2086, DOI 10.1111/j.1538-7836.2012.04892.x
   Cabrera M, 2009, BIOCHEMISTRY-US, V48, P9471, DOI 10.1021/bi901034r
   Chamberlain AM, 2011, HEART RHYTHM, V8, P1160, DOI 10.1016/j.hrthm.2011.03.038
   Chan-Yeung M, 2003, RESPIROLOGY, V8, pS9, DOI 10.1046/j.1440-1843.2003.00518.x
   Channappanavar R, 2014, IMMUNOL RES, V59, P118, DOI 10.1007/s12026-014-8534-z
   Chatre C, 2018, DRUG SAFETY, V41, P919, DOI 10.1007/s40264-018-0689-4
   Chen Jun, 2020, Zhejiang Da Xue Xue Bao Yi Xue Ban, V49, P215, DOI 10.3785/j.issn.1008-9292.2020.03.03
   Chen X., 2020, PREPRINT MEDRXIV, DOI [10.1101/2020.03.03.20030353, DOI 10.1101/2020.03.03.20030353]
   Chen Z, 2020, EFFICACY HYDROXYCHLO, DOI [10.1101/2020.03.22.20040758., 10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]
   Chu CS, 2018, CLIN INFECT DIS, V67, P1543, DOI 10.1093/cid/ciy319
   Colaneri M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8050695
   Cortegiani A, 2020, J CRIT CARE, V57, P279, DOI 10.1016/j.jcrc.2020.03.005
   Costedoat-Chalumeau N, 2007, RHEUMATOLOGY, V46, P808, DOI 10.1093/rheumatology/kel402
   D'Alessandro S, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8010085
   Daher A, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2950-4
   Delvecchio R, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8120322
   Devaux CA, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105938
   Diaz-Griffero F, 2002, J VIROL, V76, P12866, DOI 10.1128/JVI.76.24.12866-12876.2002
   Ding HJ, 2016, RHEUMATOLOGY, V55, P957, DOI 10.1093/rheumatology/kev357
   Ducharme J, 1996, CLIN PHARMACOKINET, V31, P257, DOI 10.2165/00003088-199631040-00003
   Elandaloussi LM, 2006, CHEMOTHERAPY, V52, P50, DOI 10.1159/000090245
   FERRARI V, 1990, BIOCHEM PHARMACOL, V39, P753, DOI 10.1016/0006-2952(90)90155-E
   Ferreira DF, 2000, J MED MICROBIOL, V49, P313, DOI 10.1099/0022-1317-49-4-313
   FINBLOOM DS, 1985, J RHEUMATOL, V12, P692
   FRISKHOLMBERG M, 1983, EUR J CLIN PHARMACOL, V24, P837, DOI 10.1007/BF00607097
   Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
   Garulli B, 2013, VACCINE, V31, P1717, DOI 10.1016/j.vaccine.2013.01.037
   Gautret P, 2020, INT J ANTIMICROB AG, V56, DOI 10.1016/j.ijantimicag.2020.105949
   Gautret P, 2020, TRAVEL MED INFECT DI, V34, DOI 10.1016/j.tmaid.2020.101663
   Geleris J, 2020, NEW ENGL J MED, V382, P2411, DOI 10.1056/NEJMoa2012410
   Gerard A, 2020, THERAPIE, V75, P371, DOI 10.1016/j.therap.2020.05.002
   Giudicessi JR, 2020, MAYO CLIN PROC, V95, P1213, DOI 10.1016/j.mayocp.2020.03.024
   Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10
   Goncalves Antonio, 2020, medRxiv, DOI 10.1101/2020.04.04.20047886
   GonzalezDunia D, 1998, J VIROL, V72, P783, DOI 10.1128/JVI.72.1.783-788.1998
   Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015
   Han YS, 2019, J MED VIROL, V91, P1182, DOI 10.1002/jmv.25440
   Harley CA, 2001, J VIROL, V75, P1236, DOI 10.1128/JVI.75.3.1236-1251.2001
   Health Service Executive (HSE) National Clinical Advisor and Group Lead Acute Hospitals, 2020, INT GUID US ANT THER
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Huang M, 2020, PRELIMINARY EVIDENCE, DOI [10.1101/2020.04.26.20081059, DOI 10.1101/2020.04.26.20081059]
   Jeong JY, 1997, J IMMUNOL, V158, P4901
   Joyce E, 2013, EUR HEART J-ACUTE CA, V2, P77, DOI 10.1177/2048872612471215
   Kanvinde S, 2018, ACTA BIOMATER, V82, P158, DOI 10.1016/j.actbio.2018.10.027
   Karimi A, 2020, ARCH PEDIATR INFECT, V8, DOI 10.5812/pedinfect.102400
   Keyaerts E, 2009, ANTIMICROB AGENTS CH, V53, P3416, DOI 10.1128/AAC.01509-08
   Kong SL, 2009, VIRUS RES, V145, P260, DOI 10.1016/j.virusres.2009.07.014
   Kono M, 2008, ANTIVIR RES, V77, P150, DOI 10.1016/j.antiviral.2007.10.011
   Krishna S, 1996, CLIN PHARMACOKINET, V30, P263, DOI 10.2165/00003088-199630040-00002
   Kshirsagar NA, 2017, RES REP TROP MED, V8, P85, DOI [10.2147/RRTM.S129741, 10.2147/rrtm.s129741]
   Kwiek JJ, 2004, BIOCHEMISTRY-US, V43, P4538, DOI 10.1021/bi035923w
   Lancet G, 2020, LANCET
   Lane J.C., 2020, SAFETY HYDROXYCHLORO, DOI [10.1101/2020.04.08.20054551, DOI 10.1101/2020.04.08.20054551]
   Lee JE, 2020, RES SQUARE      0508, DOI [10.21203/rs.3.rs-27372/v1, DOI 10.21203/RS.3.RS-27372/V1]
   Lee JY, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2576-5
   Lee J, 2016, J THEOR BIOL, V408, P118, DOI 10.1016/j.jtbi.2016.08.009
   Lee SH, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105988
   Levy GD, 1997, ARTHRITIS RHEUM, V40, P1482, DOI 10.1002/art.1780400817
   Lim HS, 2009, ANTIMICROB AGENTS CH, V53, P1468, DOI 10.1128/AAC.00339-08
   Lin HX, 2008, J GEN VIROL, V89, P1015, DOI 10.1099/vir.0.83331-0
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Lother SA, 2020, CAN J ANESTH, V67, P1201, DOI 10.1007/s12630-020-01684-7
   Lu HZ, 2020, J MED VIROL, V92, P401, DOI [10.1002/jmv.25678, 10.1002/jmv.2567]
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Magagnoli Joseph, 2020, Med (N Y), V1, P114, DOI [10.1101/2020.04.16.20065920, 10.1016/j.medj.2020.06.001]
   Mahevas M, 2020, NO EVIDENCE CLIN EFF, P369, DOI [10.1101/2020.04.10.20060699, DOI 10.1101/2020.04.10.20060699]
   Mallat J, 2020, HYDROXYCHLOROQUINE I, DOI [10.1101/2020.04.27.20082180, DOI 10.1101/2020.04.27.20082180]
   MANDEL EDWARD H., 1962, JOUR MT SINAI HOSP, V29, P71
   Mavrikakis I, 2003, OPHTHALMOLOGY, V110, P1321, DOI 10.1016/S0161-6420(03)00409-3
   MCCHESNEY EW, 1983, AM J MED, V75, P11, DOI 10.1016/0002-9343(83)91265-2
   McMichael TM, 2020, MMWR-MORBID MORTAL W, V69, P339, DOI 10.15585/mmwr.mm6912e1
   Mehra MR, 2020, LANCET, V395, P1820, DOI [10.1016/S0140-6736(20)31324-6, 10.1016/S0140-6736(20)31180-6]
   Membrillo de Novales FJ, 2020, PREPRINT, DOI [10.20944/preprints202005.0057.v1, DOI 10.20944/PREPRINTS202005.0057.V1]
   Meyerowitz EA, 2020, FASEB J, V34, P6027, DOI 10.1096/fj.202000919
   Million M, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101738
   Miranda S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212614
   Molina JM, 2020, MED MALADIES INFECT, V50, P384, DOI 10.1016/j.medmal.2020.03.006
   Moreno G, 2020, RESEARCHGATE
   Morita S, 2016, THER DRUG MONIT, V38, P259, DOI 10.1097/FTD.0000000000000261
   multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia, 2020, Zhonghua Jie He He Hu Xi Za Zhi, V43, pE019, DOI [10.3760/cma.j.issn.1001-0939.2020.03.009, 10.3760/cma.j.issn.1001-0939.2020.0019]
   Naarding MA, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-6
   Nicastri E, 2020, INFECT DIS REP, V12, P3, DOI 10.4081/idr.2020.8543
   OHKUMA S, 1981, J CELL BIOL, V90, P656, DOI 10.1083/jcb.90.3.656
   Oikonomopoulou K, 2012, SEMIN IMMUNOPATHOL, V34, P151, DOI 10.1007/s00281-011-0280-x
   Ooi EE, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-39
   Parhizgar AR, 2017, IRAN J MED SCI, V42, P115
   Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143
   Perlman S, 2005, NAT REV IMMUNOL, V5, P917, DOI 10.1038/nri1732
   RAMANATHAN VD, 1985, INT J IMMUNOPHARMACO, V7, P769, DOI 10.1016/0192-0561(85)90164-X
   RANDOLPH VB, 1990, VIROLOGY, V174, P450, DOI 10.1016/0042-6822(90)90099-D
   Rosenberg ES, 2020, JAMA-J AM MED ASSOC, V323, P2493, DOI 10.1001/jama.2020.8630
   Ruiz-Irastorza G, 2010, ANN RHEUM DIS, V69, P20, DOI 10.1136/ard.2008.101766
   Ruiz-Irastorza G, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2764
   Sagara I, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-458
   Savarino A, 2006, LANCET INFECT DIS, V6, P67, DOI 10.1016/S1473-3099(06)70361-9
   Savarino A, 2005, J CLIN VIROL, V34, P170, DOI 10.1016/j.jcv.2005.03.005
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Savarino A, 2020, PHARMACOKINETIC BASE, DOI [10.1101/2020.04.23.20076471, DOI 10.1101/2020.04.23.20076471]
   Savarino A, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0178-0
   Shabrawishi MH, 2020, NEGATIVE NASOPHARYNG, DOI [10.1101/2020.05.08.20095679, DOI 10.1101/2020.05.08.20095679]
   Shanmugaraj B, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9020148
   Shen L, 2016, ANTIMICROB AGENTS CH, V60, P5492, DOI 10.1128/AAC.00814-16
   Farias KJS, 2013, SCI WORLD J, DOI 10.1155/2013/282734
   SIMIT-Italian Society of Infectious and Tropical Diseases, 2020, HDB CAR PEOPL DIS CO
   Smit C, 2020, CLIN PHARMACOKINET, V59, P659, DOI 10.1007/s40262-020-00891-1
   Sun YP, 2013, CRIT REV MICROBIOL, V39, P166, DOI 10.3109/1040841X.2012.694412
   Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849
   TSAI WP, 1990, AIDS RES HUM RETROV, V6, P481, DOI 10.1089/aid.1990.6.481
   vandenBorne BEEM, 1997, J RHEUMATOL, V24, P55
   Vezmar M, 1998, BIOCHEM PHARMACOL, V56, P733, DOI 10.1016/S0006-2952(98)00217-2
   Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
   Wang ML, 2020, CELL RES, V30, P269, DOI 10.1038/s41422-020-0282-0
   Wang PH, 2020, BIORXIV, DOI [10.1101/2020.02.24.963348, DOI 10.1101/2020.02.24.963348]
   Weiss SR, 2011, ADV VIRUS RES, V81, P85, DOI 10.1016/B978-0-12-385885-6.00009-2
   White NJ, 2007, LANCET INFECT DIS, V7, P549, DOI 10.1016/S1473-3099(07)70187-1
   Wiacek MP, 2017, NIGER J CLIN PRACT, V20, P919, DOI 10.4103/njcp.njcp_380_16
   Winzeler EA, 2008, NATURE, V455, P751, DOI 10.1038/nature07361
   Wolfe F, 2010, ARTHRIT CARE RES, V62, P775, DOI 10.1002/acr.20133
   World Health Organization, 1995, WHO MOD PRESCR INF D
   Wu CI, 2020, HEART RHYTHM, V17, P1456, DOI 10.1016/j.hrthm.2020.03.024
   Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
   Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762
   Yan YW, 2013, CELL RES, V23, P300, DOI 10.1038/cr.2012.165
   Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
   Yu B, 2020, HYDROXYCHLOROQUINE A, DOI [10.1101/2020.04.27.20073379, DOI 10.1101/2020.04.27.20073379]
   Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721
   Zhang SN, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104547
   Zhao YX, 2020, SCI CHINA CHEM, DOI 10.1007/s11426-020-9864-7
   Zhu RF, 2020, SYSTEMATIC REV REGIS, DOI [10.1101/2020.03.01.20029611, DOI 10.1101/2020.03.01.20029611]
   Zhu YZ, 2012, J VIROL, V86, P13407, DOI 10.1128/JVI.00903-12
NR 142
TC 3
Z9 3
U1 7
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD SEP
PY 2020
VL 56
IS 3
AR 106078
DI 10.1016/j.ijantimicag.2020.106078
PG 16
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA NM0CS
UT WOS:000567773900019
PM 32629115
OA Green Published
DA 2021-01-01
ER

PT J
AU Tong, S
   Su, Y
   Yu, Y
   Wu, CY
   Chen, JL
   Wang, SH
   Jiang, JJ
AF Tong, Song
   Su, Yuan
   Yu, Yuan
   Wu, Chuangyan
   Chen, Jiuling
   Wang, Sihua
   Jiang, Jinjun
TI Ribavirin therapy for severe COVID-19: a retrospective cohort study
SO INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
LA English
DT Article
DE 2019 novel coronavirus; SARS-CoV-2; COVID-19; Respiratory infection;
   Treatment; Ribavirin
ID ACUTE RESPIRATORY SYNDROME; SARS; CORONAVIRUS
AB The aim of this study was to compare ribavirin therapy versus supportive therapy only for patients with severe coronavirus disease 2019 (COVID-19). A total of 115 patients with laboratory-confirmed COVID19 were retrospectively analysed. All patients received supportive care as well as regular laboratory and clinical monitoring. The 115 patients comprised 44 patients who received intravenous ribavirin (treatment group) and 71 who did not (control group). Baseline laboratory and clinical characteristics were similar between the two groups. The negative conversion time for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR in the ribavirin group was 12.8 +/- 4.1 days compared with 14.1 +/- 3.5 days in the control group ( P = 0.314). Moreover, 7/41 patients (17.1%) in the ribavirin group died compared with 17/69 (24.6%) in the control group ( P = 0.475). Adverse effects were similar between the two groups. In conclusion, in patients with severe COVID-19, ribavirin therapy is not associated with improved negative conversion time for SARS-CoV-2 test and is not associated with an improved mortality rate. Further assessment in designed randomised controlled trials is recommended. (c) 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.
C1 [Tong, Song; Wu, Chuangyan; Chen, Jiuling; Wang, Sihua] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Thorac Surg, Wuhan 430022, Peoples R China.
   [Su, Yuan] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Resp & Crit Care Med, Wuhan 430022, Peoples R China.
   [Yu, Yuan] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Crit Care Med, Wuhan 430022, Peoples R China.
   [Jiang, Jinjun] Fudan Univ, Zhongshan Hosp, Dept Resp & Crit Care Med, Shanghai 200032, Peoples R China.
RP Wang, SH (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Thorac Surg, Wuhan 430022, Peoples R China.; Jiang, JJ (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Resp & Crit Care Med, Shanghai 200032, Peoples R China.
EM sihua_wang@126.com; jiang.jinjun@zs-hospital.sh.cn
CR Arabi YM, 2020, CLIN INFECT DIS, V70, P1837, DOI 10.1093/cid/ciz544
   Barnard DL, 2006, ANTIVIR RES, V71, P53, DOI 10.1016/j.antiviral.2006.03.001
   Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
   Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
   Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5
   Knowles SR, 2003, CLIN INFECT DIS, V37, P1139, DOI 10.1086/378304
   Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006
   Li KH, 2020, INVEST RADIOL, V55, P327, DOI 10.1097/RLI.0000000000000672
   Muller MP, 2007, PHARMACOTHERAPY, V27, P494, DOI 10.1592/phco.27.4.494
   Omrani AS, 2014, LANCET INFECT DIS, V14, P1090, DOI 10.1016/S1473-3099(14)70920-X
   Saijo M, 2005, ANTIVIR RES, V66, P159, DOI 10.1016/j.antiviral.2005.01.003
   Shalhoub S, 2015, J ANTIMICROB CHEMOTH, V70, P2129, DOI 10.1093/jac/dkv085
   Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585
   Zhang JN, 2020, LANCET RESP MED, V8, pE11, DOI 10.1016/S2213-2600(20)30071-0
NR 14
TC 6
Z9 6
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0924-8579
EI 1872-7913
J9 INT J ANTIMICROB AG
JI Int. J. Antimicrob. Agents
PD SEP
PY 2020
VL 56
IS 3
AR 106114
DI 10.1016/j.ijantimicag.2020.106114
PG 5
WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy
GA NM0CS
UT WOS:000567773900005
PM 32712334
OA Green Published
DA 2021-01-01
ER

PT J
AU Al-Zahrani, AA
AF Al-Zahrani, Ateeq Ahmed
TI Rutin as a Promising Inhibitor of Main Protease and Other Protein
   Targets of COVID-19: In Silico Study
SO NATURAL PRODUCT COMMUNICATIONS
LA English
DT Article
DE antiviral; rutin; lopinavir; protein docking; natural products;
   Juniperus procera Hochst
AB The process of investigating a possible cure for coronavirus disease 2019 (COVID-19) in vitro and in vivo may take a long time. For this reason, several in silico studies were performed in order to produce preliminary results that could lead to treatment. Extract of Juniperus procera Hochst is used as a traditional medicine for recovery from flu in Saudi Arabia. In the present study, more than 51 phytochemicals of J. procera were docked against the main protease of COVID-19. Rutin gave the highest interaction score among all the phytochemicals and the commercially available antiviral drugs. Lopinavir showed the second highest binding score. Rutin and lopinavir were further investigated using homology models of COVID-19. Rutin showed a better inhibition score in 9 of the 11 of homology models compared with lopinavir. Analysis of ligand-protein interaction contacts revealed that 3 residues (Glu166, Gly143, and Thr45) of the main protease formed hydrogen bonds with rutin. This simulation study suggests that rutin could be a possible effective inhibitor of several COVID-19 protein targets, including the main protease. Rutin, already available for commercial use, was evaluated for its ability as a possible drug. To our knowledge, this is the first study that suggests rutin having a possible strong inhibitory role against several protein targets of COVID-19.
C1 [Al-Zahrani, Ateeq Ahmed] Umm Al Qura Univ, Univ Coll Al Qunfudhah, Biol & Chem Dept, POB 1109, Mecca 21912, Saudi Arabia.
RP Al-Zahrani, AA (corresponding author), Umm Al Qura Univ, Univ Coll Al Qunfudhah, Biol & Chem Dept, POB 1109, Mecca 21912, Saudi Arabia.
EM aaalzahrani@uqu.edu.sa
FU Deanship of Scientific Research at Umm Al-Qura University
   [18-SCI-1-01-0028]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: this work
   was supported financially by the Deanship of Scientific Research at Umm
   Al-Qura University (Grant Code. 18-SCI-1-01-0028).
CR Al-Zahrani Ateeq Ahmed, 2019, International Journal of Computational Biology and Drug Design, V12, P362
   Boligon AA, 2013, ACTA PHYSIOL PLANT, V35, P2229, DOI 10.1007/s11738-013-1259-0
   Chaman S, 2019, TROP J PHARM RES, V18, P1507, DOI 10.4314/tjpr.v18i7.21
   Chang YC, 2020, POTENTIAL THERAPEUTI, DOI [10.20944/preprints202002.0242.v2., 10.20944/preprints202002.0242.v1, DOI 10.20944/PREPRINTS202002.0242.V1]
   Gashash A., 2012, PLANTS MOUNTAINS SAR
   Ghazanfar S.A., 1994, HDB ARABIAN MED PLAN
   Hospital A, 2012, BIOINFORMATICS, V28, P1278, DOI 10.1093/bioinformatics/bts139
   Hsu KC, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S1-S33
   Karunamoorthi Kaliyaperumal, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, pS99, DOI 10.12980/APJTB.4.2014C687
   Keivan Zandi, 2014, Journal of Medicinal Plants Research, V8, P307
   Khaerunnisa S., 2020, POTENTIAL INHIBITOR, DOI [10.20944/preprints202003.0226.v1, DOI 10.20944/PREPRINTS202003.0226.V1, 10.20944/preprints202003.0226.v1.]
   Kong R., 2020, ARXIV200300163
   Lin YJ, 2012, J VIROL METHODS, V182, P93, DOI 10.1016/j.jviromet.2012.03.020
   Samaha HAM, 2017, WORLD J PHARM PHARM, V6, P232, DOI [10.20959/wjpps20172-8579, DOI 10.20959/WJPPS20172-8579]
   Sampangi-Ramaiah MH, 2020, CURR SCI INDIA, V118, P1087, DOI 10.18520/cs/v118/i7/1087-1092
   Shah B, 2020, LIFE SCI, V252, DOI 10.1016/j.lfs.2020.117652
NR 16
TC 1
Z9 1
U1 3
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1934-578X
EI 1555-9475
J9 NAT PROD COMMUN
JI Nat. Prod. Commun.
PD SEP
PY 2020
VL 15
IS 9
DI 10.1177/1934578X20953951
PG 4
WC Chemistry, Medicinal; Food Science & Technology
SC Pharmacology & Pharmacy; Food Science & Technology
GA NM1UW
UT WOS:000567890300001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Yang, JS
   Chiang, JH
   Tsai, SC
   Hsu, YM
   Bau, DT
   Lee, KH
   Tsai, FJ
AF Yang, Jai-Sing
   Chiang, Jo-Hua
   Tsai, Shih-Chang
   Hsu, Yuan-Man
   Bau, Da-Tian
   Lee, Kuo-Hsiung
   Tsai, Fuu-Jen
TI In Silico De Novo Curcuminoid Derivatives From the Compound Library of
   Natural Products Research Laboratories Inhibit COVID-19 3CL(pro)
   Activity
SO NATURAL PRODUCT COMMUNICATIONS
LA English
DT Article
DE curcuminoid derivatives; 2019-nCoV; COVID-19 3CL(pro)polyprotein;
   Natural Products Research Laboratories compound library; in silico study
ID CORONAVIRUS; PROTEASE; SARS; PNEUMONIA; INFECTION; OUTBREAK; RECEPTOR;
   LIGHT; HIV-1
AB The coronavirus disease 2019 (COVID-19) outbreak caused by the 2019 novel coronavirus (2019-nCOV) is becoming increasingly serious. In March 2019, the Food and Drug Administration (FDA) designated remdesivir for compassionate use to treat COVID-19. Thus, the development of novel antiviral agents, antibodies, and vaccines against COVID-19 is an urgent research subject. Many laboratories and research organizations are actively investing in the development of new compounds for COVID-19. Through in silico high-throughput virtual screening, we have recently identified compounds from the compound library of Natural Products Research Laboratories (NPRL) that can bind to COVID-19 3L(pro) polyprotein and block COVID-19 3L(pro) activity through in silico high-throughput virtual screening. Curcuminoid derivatives (including NPRL334, NPRL339, NPRL342, NPRL346, NPRL407, NPRL415, NPRL420, NPRL472, and NPRL473) display strong binding affinity to COVID-19 3L(pro) polyprotein. The binding site of curcuminoid derivatives to COVID-19 3L(pro) polyprotein is the same as that of the FDA-approved human immunodeficiency virus protease inhibitor (lopinavir) to COVID-19 3L(pro) polyprotein. The binding affinity of curcuminoid derivatives to COVID-19 3Lpro is stronger than that of lopinavir and curcumin. Among curcuminoid derivatives, NPRL-334 revealed the strongest binding affinity to COVID-19 3L(pro) polyprotein and is speculated to have an anti-COVID-19 effect. In vitro and in vivo ongoing experiments are currently underway to confirm the present findings. This study sheds light on the drug design for COVID-19 3L(pro) polyprotein. Basing on lead compound development, we provide new insights on inhibiting COVID-19 attachment to cells, reducing COVID-19 infection rate and drug side effects, and increasing therapeutic success rate.
C1 [Yang, Jai-Sing; Tsai, Fuu-Jen] China Med Univ Hosp, Dept Med Res, Taichung 40447, Taiwan.
   [Chiang, Jo-Hua] Chung Jen Jr Coll Nursing Hlth Sci & Management, Dept Nursing, Chiayi, Taiwan.
   [Tsai, Shih-Chang; Hsu, Yuan-Man] China Med Univ, Dept Biol Sci & Technol, Taichung, Taiwan.
   [Bau, Da-Tian] China Med Univ, Grad Inst Biomed Sci, Taichung, Taiwan.
   [Bau, Da-Tian] China Med Univ Hosp, Dept Med Res, Terry Fox Canc Res Lab, Taichung, Taiwan.
   [Bau, Da-Tian] Asia Univ, Dept Bioinformat & Med Engn, Taichung, Taiwan.
   [Lee, Kuo-Hsiung] Univ N Carolina, UNC Eshelman Sch Pharm, Nat Prod Res Labs, Chapel Hill, NC USA.
   [Lee, Kuo-Hsiung] China Med Univ Hosp, Chinese Med Res & Dev Ctr, Taichung, Taiwan.
   [Tsai, Fuu-Jen] China Med Univ Hosp, Human Genet Ctr, Dept Med Res, Taichung, Taiwan.
   [Tsai, Fuu-Jen] China Med Univ Hosp, Dept Med Genet, Taichung, Taiwan.
   [Tsai, Fuu-Jen] China Med Univ, Sch Chinese Med, Taichung, Taiwan.
RP Tsai, FJ (corresponding author), China Med Univ Hosp, Dept Med Res, Taichung 40447, Taiwan.; Yang, JS (corresponding author), China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung 40447, Taiwan.
EM jaisingyang@gmail.com; d0704@mail.cmuh.org.tw
FU compound library of Natural Products Research Laboratories (NPRL) of
   China Medical University Hospital (CMUH); University of North Carolina
   (UNC), Chapel Hill Eshelman School of Pharmacy; China Medical University
   Hospital, Taichung, Taiwan [DMR-109-147]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This study
   was supported by the project from the compound library of Natural
   Products Research Laboratories (NPRL) of China Medical University
   Hospital (CMUH) and University of North Carolina (UNC), Chapel Hill
   Eshelman School of Pharmacy. This work was also supported by a grant
   from China Medical University Hospital, Taichung, Taiwan (DMR-109-147).
CR Martinez MA, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00399-20
   Bacha U, 2004, BIOCHEMISTRY-US, V43, P4906, DOI 10.1021/bi0361766
   Bhatnagar T, 2020, INDIAN J MED RES, DOI [10.4103/ijmr.IJMR_502_20, DOI 10.4103/IJMR.IJMR_502_20]
   Bose Subhasish, 2020, J Clin Med Res, V12, P329, DOI 10.14740/jocmr4201
   Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282
   Cascella M, 2020, FEATURES EVALUATION
   Chai H, 2005, J AM COLL SURGEONS, V200, P820, DOI 10.1016/j.jamcollsurg.2005.02.030
   Chainoglou E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061975
   Chan JFW, 2020, EMERG MICROBES INFEC, V9, P221, DOI 10.1080/22221751.2020.1719902
   Chen GL, 2018, CELL MOL NEUROBIOL, V38, P1465, DOI 10.1007/s10571-018-0616-3
   Chen Yu Wai, 2020, F1000Res, V9, P129, DOI 10.12688/f1000research.22457.2
   Colson P, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105923
   Containing KEH, 2020, HEALTH CARE MANAG SC, V23, P311
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
   Fernandez-Sanchez A, 2013, EPIGENETICS-US, V8, P66, DOI 10.4161/epi.23115
   Ferreira VH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124903
   Goel A, 2010, NUTR CANCER, V62, P919, DOI 10.1080/01635581.2010.509835
   Guo LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070565
   Gurwitz D, 2020, DRUG DEVELOP RES, V81, P537, DOI 10.1002/ddr.21656
   Hong ZC, 2020, NAT PROD COMMUN, V15, DOI 10.1177/1934578X20934219
   Huang WH, 2020, J MICROBIOL IMMUNOL, V53, P481, DOI 10.1016/j.jmii.2020.02.009
   Jordan WC, 1996, J NATL MED ASSOC, V88, P333
   Kandeel M, 2020, LIFE SCI, V251, DOI 10.1016/j.lfs.2020.117627
   Khan Z, 2020, ADV THER, V37, P2575, DOI 10.1007/s12325-020-01351-9
   Kutluay SB, 2008, VIROLOGY, V373, P239, DOI 10.1016/j.virol.2007.11.028
   Lai CC, 2020, J MICROBIOL IMMUNOL, V53, P404, DOI 10.1016/j.jmii.2020.02.012
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li R, 2020, J INFECTION, V80, P469, DOI 10.1016/j.jinf.2020.02.013
   Liang CY, 2020, EUR J MED CHEM, V201, DOI 10.1016/j.ejmech.2020.112527
   Liew MF, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2828-4
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1070, DOI 10.1515/cclm-2020-0285
   Liu JP, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003937.pub2
   Liu LM, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8592921
   Lopez-Malo D, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9010048
   Luca SV, 2020, CRIT REV FOOD SCI, V60, P626, DOI 10.1080/10408398.2018.1546669
   Lupia T, 2020, J GLOB ANTIMICROB RE, V21, P22, DOI 10.1016/j.jgar.2020.02.021
   Mounce BC, 2017, ANTIVIR RES, V142, P148, DOI 10.1016/j.antiviral.2017.03.014
   Nelson CW, 2020, NATURE, V579, P193, DOI 10.1038/d41586-020-00693-2
   Nukoolkarn V, 2008, J THEOR BIOL, V254, P861, DOI 10.1016/j.jtbi.2008.07.030
   Pavli A, 2014, TRAVEL MED INFECT DI, V12, P602, DOI 10.1016/j.tmaid.2014.10.006
   Peeri NC, 2020, INT J EPIDEMIOL, V49, P717, DOI 10.1093/ije/dyaa033
   Perico Luca, 2020, Nephron, V144, P213, DOI 10.1159/000507305
   Prasad S, 2015, FOOD FUNCT, V6, P3412, DOI [10.1039/c5fo00485c, 10.1039/C5FO00485C]
   Qian SJ, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010079
   Rocha FAC, 2020, PHYTOTHER RES, V34, P2085, DOI 10.1002/ptr.6745
   Roussel Y, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105947
   Rzymski P, 2020, SCIENCE, V367, P1313, DOI 10.1126/science.abb4870
   Sahraei Z, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105945
   Shen KL, 2020, WORLD J PEDIATR, V16, P223, DOI 10.1007/s12519-020-00343-7
   Sinha R, 2003, J Postgrad Med, V49, P222
   Stohs SJ, 2020, MOLECULES, V25, DOI 10.3390/molecules25061397
   Sui Z, 1993, Bioorg Med Chem, V1, P415, DOI 10.1016/S0968-0896(00)82152-5
   Taguchi Fumihiro, 2011, Virus (Nagoya), V61, P205
   Taher MM, 2003, MOL CELL BIOCHEM, V254, P289, DOI 10.1023/A:1027393719610
   Tai DYH, 2007, ANN ACAD MED SINGAP, V36, P438
   Vajragupta O, 2005, BIOORG MED CHEM LETT, V15, P3364, DOI 10.1016/j.bmcl.2005.05.032
   Vlietinck AJ, 1998, PLANTA MED, V64, P97, DOI 10.1055/s-2006-957384
   Vora J, 2020, CURR HIV RES, V18, P132, DOI 10.2174/1570162X18666200129112509
   Wen CC, 2007, J MED CHEM, V50, P4087, DOI 10.1021/jm070295s
   Weng Wenhao, 2020, Semin Cancer Biol, DOI 10.1016/j.semcancer.2020.02.011
   Wu YC, 2020, J CHIN MED ASSOC, V83, P217, DOI 10.1097/JCMA.0000000000000270
   Xiao-Yu Xu, 2018, Nutrients, V10, P1553, DOI 10.3390/nu10101553
   Xu H, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0074-x
   Yang XX, 2017, NANOSCALE, V9, P16086, DOI 10.1039/c7nr06520e
   Yang XX, 2016, NANOSCALE, V8, P3040, DOI 10.1039/c5nr07918g
   Yu LC, 2017, CANC RES FRONT, V3, P1, DOI DOI 10.17980/2017.1
   Zahedipour F, 2020, PHYTOTHER RES, V34, P2911, DOI 10.1002/ptr.6738
   Zhao DH, 2020, CLIN INFECT DIS, V71, P756, DOI 10.1093/cid/ciaa247
   Zhao SH, 2017, BRAIN RES BULL, V135, P53, DOI 10.1016/j.brainresbull.2017.09.011
   Zhao Wenming, 2020, Yichuan, V42, P212, DOI 10.16288/j.yczz.20-030
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zou X, 2020, FRONT MED-PRC, V14, P185, DOI 10.1007/s11684-020-0754-0
NR 73
TC 0
Z9 0
U1 1
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1934-578X
EI 1555-9475
J9 NAT PROD COMMUN
JI Nat. Prod. Commun.
PD SEP
PY 2020
VL 15
IS 9
DI 10.1177/1934578X20953262
PG 15
WC Chemistry, Medicinal; Food Science & Technology
SC Pharmacology & Pharmacy; Food Science & Technology
GA NM1TA
UT WOS:000567885500001
OA DOAJ Gold
DA 2021-01-01
ER

PT J
AU Schulze-Koops, H
   Iking-Konert, C
   Leipe, J
   Hoyer, BF
   Holle, J
   Moosig, F
   Aries, P
   Burmester, G
   Fiehn, C
   Krause, A
   Lorenz, HM
   Schneider, M
   Sewerin, P
   Voormann, A
   Wagner, U
   Kruger, K
   Specker, C
AF Schulze-Koops, Hendrik
   Iking-Konert, Christof
   Leipe, Jan
   Hoyer, Bimba Franziska
   Holle, Julia
   Moosig, Frank
   Aries, Peer
   Burmester, Gerd
   Fiehn, Christoph
   Krause, Andreas
   Lorenz, Hanns-Martin
   Schneider, Matthias
   Sewerin, Philipp
   Voormann, Anna
   Wagner, Ulf
   Krueger, Klaus
   Specker, Christof
CA Deutsch Gesell Rheumatologie
TI Recommendations of the German Society for Rheumatology for management of
   patients with inflammatory rheumatic diseases in the context of the
   SARS-CoV-2/COVID-19 pandemic - Update July 2020
SO ZEITSCHRIFT FUR RHEUMATOLOGIE
LA German
DT Article
DE SARS-CoV-2; COVID-19; Treatment management; Recommendations;
   Inflammatory diseases
ID COVID-19; RISK
AB A few days after the SARS-CoV-2 infectionwas declared a pandemic, the German Society for Rheumatology (DGRh) compiled first recommendations for the care of patients with inflammatory rheumatic diseases (IRD). These first recommendations were based on an expert consensus and were largely non-evidence-based. Now that the first scientific data from registers, cross-sectional studies, case reports and case series are available, the present update is intended to update the previous recommendations and to add new findings. The current recommendations are based on a literature search of publications available up to 15 June 2020 and address preventive measures (such as hygiene measures or vaccinations) and the use of immunomodulatory/immunosuppressive drugs. An important goal of the current recommendations is also to prevent harm to patients with IRD through unjustified restriction of care. The DGRh will continue to update its recommendations in the case of new aspects and will publish them as well as further information on the COVID-19 pandemic on its homepage (www.dgrh.de) in an ongoing process.
C1 [Schulze-Koops, Hendrik; Krause, Andreas; Lorenz, Hanns-Martin; Voormann, Anna; Wagner, Ulf; Specker, Christof] Deutsch Gesell Rheumatol eV, Berlin, Germany.
   [Schulze-Koops, Hendrik] Ludwig Maximilians Univ Munchen, Sekt Rheumatol & Klin Immunol, Med Klin & Poliklin 4, Pettenkoferstr 8a, D-80336 Munich, Germany.
   [Iking-Konert, Christof] Univ Klinikum Hamburg Eppendorf, Med Klin & Poliklin 3, Sekt Rheumatol, Hamburg, Germany.
   [Leipe, Jan] Univ Krankenhaus Mannheim, Abt Rheumatol, Med Klin 5, Mannheim, Germany.
   [Hoyer, Bimba Franziska] Univ Krankenhaus Schleswig Holstein, Abt Rheumatol, Med Klin 1, Campus Kiel, Kiel, Germany.
   [Holle, Julia; Moosig, Frank] Rheumazentrum Schleswig Holstein Mitte, Neumunster, Germany.
   [Aries, Peer] Rheumatol Struenseehaus, Hamburg, Germany.
   [Burmester, Gerd] Freie Univ, Charite Univ Med Berlin, Klin Rheumatol & Klin Immunol, Berlin, Germany.
   [Burmester, Gerd] Humboldt Univ, Berlin, Germany.
   [Fiehn, Christoph] Med Ctr Baden Baden, Praxis Rheumatol & Klin Immunol, Baden Baden, Germany.
   [Fiehn, Christoph] ViDia Kliniken Karlsruhe, Baden Baden, Germany.
   [Krause, Andreas] Immanuel Krankenhaus Berlin, Abt Rheumatol Osteol & Klin Immunol, Berlin, Germany.
   [Lorenz, Hanns-Martin] Univ Klinikum Heidelberg, Abt Rheumatol, Med Klin 5, Heidelberg, Germany.
   [Schneider, Matthias; Sewerin, Philipp] Heinrich Heine Univ Dusseldorf, Univ Klinikum Dusseldorf, Poliklin, Funktionsbereich & Hiller Forschungszentrum Rheum, Dusseldorf, Germany.
   [Wagner, Ulf] Univ Klinikum Leipzig, Abt Rheumatol, Klin & Poliklin Endokrinol, Nephrol,Rheumatol, Leipzig, Germany.
   [Krueger, Klaus] Rheumatol Praxiszentrum Munchen, St Bonifatius Str 5, D-81541 Munich, Germany.
   [Specker, Christof] Kliniken Essen Mitte, Klin Rheumatol & Klin Immunol, Essen, Germany.
   [Krueger, Klaus] DGRh eV, Kommiss Pharmakotherapie, Berlin, Germany.
RP Schulze-Koops, H (corresponding author), Ludwig Maximilians Univ Munchen, Sekt Rheumatol & Klin Immunol, Med Klin & Poliklin 4, Pettenkoferstr 8a, D-80336 Munich, Germany.; Kruger, K (corresponding author), Rheumatol Praxiszentrum Munchen, St Bonifatius Str 5, D-81541 Munich, Germany.
EM Hendrik.Schulze-Koops@med.uni-muenchen.de;
   Klaus.Krueger@med.uni-muenchen.de
RI Burmester, Gerd R./AAY-7514-2020; Aries, Peer/AAE-6166-2020
CR Au K, 2011, ANN RHEUM DIS, V70, P785, DOI 10.1136/ard.2010.128637
   D'Silva KM, 2020, AM J RESP CRIT CARE, V201
   Damiani G, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13475
   Ferguson LD, 2019, NAT REV RHEUMATOL, V15, P461, DOI 10.1038/s41584-019-0256-0
   Freudenberg S, 2020, Z RHEUMATOL, V79, P584, DOI 10.1007/s00393-020-00833-z
   Furer V, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2019-001041
   Gianfrancesco M, 2020, ANN RHEUM DIS, V79, P859, DOI [10.1136/annrheumdis-2020-217871, 10.1136/annrheumdis-2020-218328, 10.1136/annrheumdis-2020-218713]
   Gianfrancesco MA, 2020, LANCET RHEUMATOL, V2, pE250, DOI 10.1016/S2665-9913(20)30095-3
   Gonzalez C, 2020, ANN RHEUM DIS, V79, P214
   Haberman R, 2020, NEW ENGL J MED, V383, P85, DOI 10.1056/NEJMc2009567
   Hasseli R, 2020, RMD OPEN
   Jordan RE, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1198
   Leipe J, 2020, SEMIN ARTHRITIS RHEU
   Listing J, 2005, ARTHRITIS RHEUM-US, V52, P3403, DOI 10.1002/art.21386
   Mehta B, 2019, RMD OPEN, V5, DOI 10.1136/rmdopen-2019-000935
   Michelena X, 2020, SEMIN ARTHRITIS RHEU, V50, P564, DOI 10.1016/j.semarthrit.2020.05.001
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
   Nurmohamed MT, 2015, NAT REV RHEUMATOL, V11, P693, DOI 10.1038/nrrheum.2015.112
   Schulze-Koops H, 2020, Z RHEUMATOL, V79, P385, DOI 10.1007/s00393-020-00799-y
   Schulze-Koops H, 2020, ANN RHEUM DIS
   Stone JH, 2017, NEW ENGL J MED, V377, P317, DOI 10.1056/NEJMoa1613849
   Walsh M, 2020, NEW ENGL J MED, V382, P622, DOI 10.1056/NEJMoa1803537
   Ye C, 2020, ANN RHEUM DIS
NR 23
TC 2
Z9 2
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-1855
EI 1435-1250
J9 Z RHEUMATOL
JI Z. Rheumatol.
PD SEP
PY 2020
VL 79
IS 7
SI SI
BP 679
EP 685
DI 10.1007/s00393-020-00851-x
PG 7
WC Rheumatology
SC Rheumatology
GA NM0LL
UT WOS:000567796600011
PM 32757030
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Janda, A
   Schuetz, C
   Heeg, M
   Minden, K
   Hedrich, CM
   Kallinich, T
   Hinze, C
   Schulz, A
   Speth, F
AF Janda, A.
   Schuetz, C.
   Heeg, M.
   Minden, K.
   Hedrich, C. M.
   Kallinich, T.
   Hinze, C.
   Schulz, A.
   Speth, F.
TI COVID-19: treatment strategies of German-speaking pediatric
   rheumatologists Results of an online survey
SO ZEITSCHRIFT FUR RHEUMATOLOGIE
LA German
DT Article
DE Children; Rheumatic diseases; COVID-19; Therapy; SARS-CoV-2
ID INTENSIFIED IMMUNOSUPPRESSION; CHILDREN
AB Background Reliable data on the course and treatment of pediatric COVID-19 ("corona virus disease 2019") in immunosuppressed patients with rheumatic diseases are missing. Aim Delineation of individual strategies of the members of the Society for Pediatric Rheumatology (GKJR) in cases of COVID-19. Methods In May 2020 all GKJR members were invited to take part in an online survey. Opinion data regarding an approach using disease-modifying anti-rheumatic drugs (DMARD) in cases of COVID-19 as well as the readiness to use new therapeutic agents in patients in different stages of the disease were collected. Results A total of 71 respondents (27.3% of all contacted pediatric rheumatologists) took part in the survey. Of these 28.2% had treated patients with COVID-19. Over 95% of the respondents did not support a preventive adaptation of the anti-rheumatic treatment during the SARS-CoV-2 pandemic. In the case of outpatients under immunosuppression with proven COVID-19 more than 50% of the respondents would refrain from administering intravenous high-dose steroids, cyclophosphamide, anti-CD20 antibodies as well as BAFF, CTLA-4 and TNF-alpha blockades. Conversely, >70% of the respondents would continue the treatment with nonsteroidal anti-inflammatory drugs, hydroxychloroquine (HCQ), oral steroids, mycophenolate, IL-1 blockade and immunoglobulins (Ig). In the case of inpatients 74.6% of respondents would consider targeted COVID-19 treatment. In stable patients with oxygen treatment (stage I) HCQ (18.3%), azithromycin (16.9%) and Ig (9.9%) were most frequently used. In cases of early signs (stage II) or a manifest cytokine storm (stage III) anakinra (40.8% for stage II and 46.5% for stage III), tocilizumab (26.8% and 40.8%, respectively), steroids (25.4% and 33.8%, respectively) and remdesivir (29.6% and 38.0%, respectively) were most frequently used. The need for a personalized approach based on the current clinical situation was emphasized by many respondents. Conclusion The currently low prevalence of COVID-19 in Germany limits the general clinical experience. Therefore, the presented results have to be interpreted with caution and mostly as hypothetical treatment considerations. It is to be expected that there will always be a limited amount of evidence on pediatric COVID-19; therefore, a continuous and critical exchange of expert opinions on the treatment strategies is important.
C1 [Janda, A.; Schulz, A.] Univ Klinikum Ulm, Klin Kinder & Jugendmed, Eythstr 24, D-89075 Ulm, Germany.
   [Schuetz, C.] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Klin & Poliklin Kinder & Jugendmed, Dresden, Germany.
   [Heeg, M.] Univ Klinikum Freiburg, Inst Immundefizienz, Freiburg, Germany.
   [Heeg, M.] Univ Klinikum Freiburg, Zentrum Kinder & Jugendmed, Freiburg, Germany.
   [Minden, K.; Kallinich, T.] Charite Univ Med Berlin, Berlin, Germany.
   [Minden, K.; Kallinich, T.] Deutsch Rheuma Forschungszentrum Berlin, Berlin, Germany.
   [Hedrich, C. M.] Univ Liverpool, Dept Womens & Childrens Hlth, Inst Life Course & Med Sci, Liverpool, Merseyside, England.
   [Hedrich, C. M.] Alder Hey Childrens NHS Fdn Trust Hosp, Dept Paediat Rheumatol, Liverpool, Merseyside, England.
   [Hinze, C.] Univ Klinikum Munster, Klin Padiatr Rheumatol & Immunol, Munster, Germany.
   [Speth, F.] Univ Klinikum Hamburg Eppendorf, Zentrum Geburtshilfe Kinder & Jugendmed, Abt Kinderrheumatol, Sekt Padiatr Stammzelltransplantat & Immunol, Hamburg, Germany.
RP Janda, A (corresponding author), Univ Klinikum Ulm, Klin Kinder & Jugendmed, Eythstr 24, D-89075 Ulm, Germany.
EM ales.janda@uniklinik-ulm.de
FU Projekt DEAL
FX Open Access funding provided by Projekt DEAL.
CR American Academy of Pediatrics, 2020, CRIT UPD COVID 19
   [Anonymous], 2020, Drug Ther Bull, V58, P69, DOI 10.1136/dtb.2020.000021
   API, 2020, NEUART COR
   Armann JP, 2020, DTSCH ARZTEBL INT, V117, P373, DOI 10.3238/arztebl.2020.0373
   Castagnoli R, 2020, JAMA PEDIAT
   Deutsche Gesellschaft fur Kinder- und Jugendmedizin, 2020, COVID 19 MED THER BE
   Deutsche Gesellschaft fur Rheumatologie, 2020, EMPF WAHR SARS COV 2
   DGPI: Deutsche Gesellschaft fur Padiatrische Infektiologie, 2020, COVID 19 SURV UPD KW
   DGPI: Deutsche Gesellschaft fur Padiatrische Infektiologie, 2020, STELL DGPI GPP API G
   European Centre for Disease Prevention and Control (ECDC), 2020, PAED INFL MULT SYNDR
   Fajgenbaum DC, 2020, INFECT DIS THER, V9, P435, DOI 10.1007/s40121-020-00303-8
   Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448
   Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P175
   Franzetti M., 2020, INT J INFECT DIS
   Gesellschaft fur Kinder- und Jugendrheumatologie, 2020, SARS COV 2 BEI KIND
   Goldbach-Mansky R, 2006, NEW ENGL J MED, V355, P581, DOI 10.1056/NEJMoa055137
   Hedrich CM, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108420
   Konig MF, 2020, ANN RHEUM DIS
   Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270
   Minotti C, 2020, J INFECT
   National Institutes of Health, 2020, COR DIS 2019 COVID 1
   Nationale Plattform fur geographische Daten (NPGEO), 2020, CORONA
   Ortiz-Alvarez O, 2004, J RHEUMATOL, V31, P2501
   Paediatric Rheumatology European Society, 2020, UPD PRES REC COR OUT
   Pain CE, 2020, LANCET RHEUMATOL
   Speth F, 2013, Z RHEUMATOL, V72, P896, DOI 10.1007/s00393-013-1203-0
   Speth F, 2013, Z RHEUMATOL, V72, P814, DOI 10.1007/s00393-013-1200-3
   Streng A, 2020, MONATSSCHR KINDERH, V168, P615, DOI 10.1007/s00112-020-00919-7
   Whittaker E, 2020, JAMA
   Zhang J, 2020, SURG INFECT, DOI 10.1089/sur.2020.245
NR 30
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-1855
EI 1435-1250
J9 Z RHEUMATOL
JI Z. Rheumatol.
PD SEP
PY 2020
VL 79
IS 7
SI SI
BP 710
EP 717
DI 10.1007/s00393-020-00854-8
PG 8
WC Rheumatology
SC Rheumatology
GA NM0LL
UT WOS:000567796600020
PM 32809050
OA Other Gold, Green Published
DA 2021-01-01
ER

PT J
AU Migaud, M
   Gandotra, S
   Chand, HS
   Gillespie, MN
   Thannickal, VJ
   Langley, RJ
AF Migaud, Marie
   Gandotra, Sheetal
   Chand, Hitendra S.
   Gillespie, Mark N.
   Thannickal, Victor J.
   Langley, Raymond J.
TI Metabolomics to Predict Antiviral Drug Efficacy in COVID-19
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Letter
C1 [Migaud, Marie; Gillespie, Mark N.; Langley, Raymond J.] Univ S Alabama, Mobile, AL 36688 USA.
   [Gandotra, Sheetal; Thannickal, Victor J.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Chand, Hitendra S.] Florida Int Univ, Miami, FL 33199 USA.
RP Langley, RJ (corresponding author), Univ S Alabama, Mobile, AL 36688 USA.
EM rlangley@southalabama.edu
OI Chand, Hitendra/0000-0002-0574-9307; migaud, marie/0000-0002-9626-2405
FU Elysium Health; U.S. National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA; National Center for Advancing Translational SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Center for Advancing Translational Sciences (NCATS); 
   [1KL2TR003097];  [R21AI144374];  [R01 HL113614];  [R01 GM127823];  [UL1
   TR001417]
FX Supported by 1KL2TR003097 (R.J.L.), R21AI144374 (H.S.C.), in part by
   Elysium Health (M.M.), and R01 HL113614, R01 GM127823, and UL1 TR001417
   (M.N.G.). All grants are funded by the U.S. National Institutes of
   Health. The KL2 and UL1 grants are funded by the National Center for
   Advancing Translational Sciences.
CR Beigel John H, 2020, N Engl J Med, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bojkova D., 2020, RES SQUARE, DOI [10.21203/rs.3.rs-17218/v1, DOI 10.21203/RS.3.RS-17218/V1]
   Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1
   Frederick DW, 2016, CELL METAB, V24, P269, DOI 10.1016/j.cmet.2016.07.005
   Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4
   Langley RJ, 2015, AM J RESP CRIT CARE, V191
   Langley RJ, 2014, AM J RESP CRIT CARE, V190, P445, DOI 10.1164/rccm.201404-0624OC
   Langley RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005893
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859
   Naesens L, 2013, MOL PHARMACOL, V84, P615, DOI 10.1124/mol.113.087247
   Rogers AJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087538
   Shen B., 2020, CELL
   Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 15
TC 1
Z9 1
U1 4
U2 4
PU AMER THORACIC SOC
PI NEW YORK
PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA
SN 1044-1549
EI 1535-4989
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD SEP
PY 2020
VL 63
IS 3
BP 396
EP 398
DI 10.1165/rcmb.2020-0206LE
PG 3
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA NM0AG
UT WOS:000567767500015
PM 32574504
OA Green Published, Other Gold
DA 2021-01-01
ER

PT J
AU Lax, SF
   Skok, K
   Zechner, P
   Kessler, HH
   Kaufmann, N
   Koelblinger, C
   Vander, K
   Bargfrieder, U
   Trauner, M
AF Lax, Sigurd F.
   Skok, Kristijan
   Zechner, Peter
   Kessler, Harald H.
   Kaufmann, Norbert
   Koelblinger, Camillo
   Vander, Klaus
   Bargfrieder, Ute
   Trauner, Michael
TI Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome Results
   From a Prospective, Single-Center, Clinicopathologic Case Series
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
AB Background: Coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become pandemic, with substantial mortality.
   Objective: To evaluate the pathologic changes of organ systems and the clinicopathologic basis for severe and fatal outcomes.
   Design: Prospective autopsy study.
   Setting: Single pathology department.
   Participants: 11 deceased patients with COVID-19 (10 of whom were selected at random for autopsy).
   Measurements: Systematic macroscopic, histopathologic, and viral analysis (SARS-CoV-2 on real-time polymerase chain reaction assay), with correlation of pathologic and clinical features, including comorbidities, comedication, and laboratory values.
   Results: Patients' age ranged from 66 to 91 years (mean, 80.5 years; 8 men, 3 women). Ten of the 11 patients received prophylactic anticoagulant therapy; venous thromboembolism was not clinically suspected antemortem in any of the patients. Both lungs showed various stages of diffuse alveolar damage (DAD), including edema, hyaline membranes, and proliferation of pneumocytes and fibroblasts. Thrombosis of small and mid-sized pulmonary arteries was found in various degrees in all 11 patients and was associated with infarction in 8 patients and bronchopneumonia in 6 patients. Kupffer cell proliferation was seen in all patients, and chronic hepatic congestion in 8 patients. Other changes in the liver included hepatic steatosis, portal fibrosis, lymphocytic infiltrates and ductular proliferation, lobular cholestasis, and acute liver cell necrosis, together with central vein thrombosis. Additional frequent findings included renal proximal tubular injury, focal pancreatitis, adrenocortical hyperplasia, and lymphocyte depletion of spleen and lymph nodes. Viral RNA was detectable in pharyngeal, bronchial, and colonic mucosa but not bile.
   Limitation: The sample was small.
   Conclusion: COVID-19 predominantly involves the lungs, causing DAD and leading to acute respiratory insufficiency. Death may be caused by the thrombosis observed in segmental and subsegmental pulmonary arterial vessels despite the use of prophylactic anticoagulation. Studies are needed to further understand the thrombotic complications of COVID-19, together with the roles for strict thrombosis prophylaxis, laboratory and imaging studies, and early anticoagulant therapy for suspected pulmonary arterial thrombosis or thromboembolism.
C1 [Lax, Sigurd F.; Skok, Kristijan; Zechner, Peter; Kaufmann, Norbert; Koelblinger, Camillo; Bargfrieder, Ute] Med Univ Graz, Acad Teaching Hosp, Hosp Graz 2, Graz, Austria.
   [Lax, Sigurd F.] Johannes Kepler Univ Linz, Sch Med, Inst Pathol, Linz, Austria.
   [Kessler, Harald H.] Med Univ Graz, Diagnost & Res Inst Hyg Microbiol & Environm Med, Graz, Austria.
   [Vander, Klaus] Styrian Hosp Corp, Inst Hosp Hyg & Microbiol, Graz, Austria.
   [Trauner, Michael] Med Univ Vienna, Vienna, Austria.
RP Lax, SF (corresponding author), Hosp Graz II, Dept Pathol, Goestingerstr 22, A-8020 Graz, Austria.; Lax, SF (corresponding author), Johannes Kepler Univ Linz, Inst Pathol & Mol Pathol, Huemerstr 3-5, AT-4020 Linz, Austria.
EM sigurd.lax@kages.at
RI Skok, Kristijan/AAH-9899-2019
OI Skok, Kristijan/0000-0002-3027-8164; Trauner,
   Michael/0000-0002-1275-6425
CR Antommaria AHM, 2020, ANN INTERN MED, V173, P188, DOI 10.7326/M20-1738
   Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
   Barrett CD, 2020, J THROMB HAEMOST, V18, P2060, DOI 10.1111/jth.14860
   Barton LM, 2020, AM J CLIN PATHOL, V153, P725, DOI [10.1093/AJCP/AQAA062, 10.1093/ajcp/aqaa062]
   Bikdeli B, 2020, J AM COLL CARDIOL, V75, P2950, DOI 10.1016/j.jacc.2020.04.031
   Chong PY, 2004, ARCH PATHOL LAB MED, V128, P195
   Ciceri F., 2020, CRIT CARE RESUSC
   Cunningham CO, 2020, ANN INTERN MED, V172, P764, DOI 10.7326/M20-1715
   Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
   Dolhnikoff M, 2020, J THROMB HAEMOST, V18, P1517, DOI 10.1111/jth.14844
   Grillet F, 2020, RADIOLOGY, V296, pE186, DOI 10.1148/radiol.2020201544
   Harmer D, 2002, FEBS LETT, V532, P107, DOI 10.1016/S0014-5793(02)03640-2
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Horvatits T, 2019, HEPATOLOGY, V70, P2204, DOI 10.1002/hep.30824
   Idell S, 2003, CRIT CARE MED, V31, pS213, DOI 10.1097/01.CCM.0000057846.21303.AB
   Jiang XG, 2020, CMC-COMPUT MATER CON, V63, P537, DOI 10.32604/cmc.2020.010691
   Jin X, 2020, GUT, V69, P1002, DOI 10.1136/gutjnl-2020-320926
   Leonard-Lorant I, 2020, RADIOLOGY, V296, pE189, DOI 10.1148/radiol.2020201561
   Lin L, 2020, GUT, V69, P997, DOI 10.1136/gutjnl-2020-321013
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Nicholls JM, 2003, LANCET, V361, P1773, DOI 10.1016/S0140-6736(03)13413-7
   Panesar NS, 2008, MED HYPOTHESES, V71, P453, DOI 10.1016/j.mehy.2008.04.005
   Pfefferle S, 2020, EUROSURVEILLANCE, V25, P18, DOI 10.2807/1560-7917.ES.2020.25.9.2000152
   Phua J, 2020, LANCET RESP MED, V8, P506, DOI 10.1016/S2213-2600(20)30161-2
   Poljak M, 2020, J CLIN MICROBIOL, V58, DOI 10.1128/JCM.00599-20
   Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019
   Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831
   Sun J, 2020, LIVER INT, V40, P1278, DOI 10.1111/liv.14470
   Sverzellati N, 2013, DIAGN INTERV RADIOL, V19, P355, DOI 10.5152/dir.2013.149
   Thachil J, 2020, J THROMB HAEMOST, V18, P1023, DOI 10.1111/jth.14810
   Tian SF, 2020, MODERN PATHOL, V33, P1007, DOI 10.1038/s41379-020-0536-x
   Tian SF, 2020, J THORAC ONCOL, V15, P700, DOI 10.1016/j.jtho.2020.02.010
   TOMASHEFSKI JF, 1983, AM J PATHOL, V112, P112
   Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5
   Wang J, 2020, J THROMB HAEMOST, V18, P1752, DOI 10.1111/jth.14828
   Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003
   Wolf MS, 2020, ANN INTERN MED, V173, P100, DOI 10.7326/M20-1239
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Xie Y, 2020, RADIOL CARDIOTHORAC, V2, pe200067, DOI [10.1148/ryct.2020200067, DOI 10.1148/RYCT.2020200067]
   Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
   Zhang HL, 2020, ANN INTERN MED, V172, P629, DOI 10.7326/M20-0533
   Zhang YF, 2020, LIVER INT, V40, P1791, DOI 10.1111/liv.14497
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
   Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7
   Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 48
TC 106
Z9 105
U1 11
U2 12
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD SEP 1
PY 2020
VL 173
IS 5
BP 350
EP +
DI 10.7326/M20-2566
PG 15
WC Medicine, General & Internal
SC General & Internal Medicine
GA NK9XI
UT WOS:000567080900009
PM 32422076
OA Green Published
DA 2021-01-01
ER

PT J
AU Pablos, JL
   Abasolo, L
   Alvaro-Gracia, JM
   Blanco, FJ
   Blanco, R
   Castrejon, I
   Fernandez-Fernandez, D
   Fernandez-Gutierrez, B
   Galindo-Izquierdo, M
   Gonzalez-Gay, MA
   Manrique-Arija, S
   Vazquez, NM
   Varela, AM
   Retuerto, M
   Seijas-Lopez, A
AF Pablos, Jose L.
   Abasolo, Lydia
   Alvaro-Gracia, Jose M.
   Blanco, Francisco J.
   Blanco, Ricardo
   Castrejon, Isabel
   Fernandez-Fernandez, David
   Fernandez-Gutierrez, Benjamin
   Galindo-Izquierdo, Maria
   Gonzalez-Gay, Miguel A.
   Manrique-Arija, Sara
   Mena Vazquez, Natalia
   Mera Varela, Antonio
   Retuerto, Miriam
   Seijas-Lopez, Alvaro
CA RIER Investigators Grp
TI Prevalence of hospital PCR-confirmed COVID-19 cases in patients with
   chronic inflammatory and autoimmune rheumatic diseases
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
AB Background The susceptibility of patients with rheumatic diseases and the risks or benefits of immunosuppressive therapies for COVID-19 are unknown.
   Methods We performed a retrospective study with patients under follow-up in rheumatology departments from seven hospitals in Spain. We matched updated databases of rheumatology patients with severe acute respiratory syndrome coronavirus 2-positive PCR tests performed in the hospital to the same reference populations. Rates of PCR+ confirmed COVID-19 were compared among groups.
   Results Patients with chronic inflammatory diseases had 1.32-fold higher prevalence of hospital PCR+ COVID-19 than the reference population (0.76% vs 0.58%). Patients with systemic autoimmune or immune-mediated disease (AI/IMID) showed a significant increase, whereas patients with inflammatory arthritis (IA) or systemic lupus erythematosus did not. COVID-19 cases in some but not all diagnostic groups had older ages than cases in the reference population. Patients with IA on targeted-synthetic or biological disease-modifying antirheumatic drugs (DMARDs), but not those on conventional-synthetic DMARDs, had a greater prevalence despite a similar age distribution.
   Conclusion Patients with AI/IMID show a variable risk of hospital-diagnosed COVID-19. Interplay of ageing, therapies and disease-specific factors seem to contribute. These data provide a basis to improve preventive recommendations to rheumatic patients and to analyse the specific factors involved in COVID-19 susceptibility.
C1 [Pablos, Jose L.; Galindo-Izquierdo, Maria; Retuerto, Miriam] Inst Invest Hosp 12 Octubre, Serv Reumatol, Madrid 28041, Spain.
   [Pablos, Jose L.; Galindo-Izquierdo, Maria] Univ Complutense Madrid, Dept Med, Madrid, Comunidad Madri, Spain.
   [Abasolo, Lydia; Fernandez-Gutierrez, Benjamin] Hosp Clin San Carlos, Inst Invest Sanitaria San Carlos IdISSC, Serv Reumatol, Madrid, Spain.
   [Alvaro-Gracia, Jose M.; Castrejon, Isabel] Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon IISGM, Serv Reumatol, Madrid, Spain.
   [Blanco, Francisco J.] INIBIC Hosp Univ A Coruna, Serv Reumatol, La Coruna, Spain.
   [Blanco, Francisco J.] Univ A Coruna, Dept Fisioterapia Med & Ciencias Biomed, La Coruna, Spain.
   [Blanco, Ricardo; Gonzalez-Gay, Miguel A.] Hosp Univ Marques de Valdecilla IDIVAL, Serv Reumatol, Santander, Spain.
   [Fernandez-Fernandez, David; Mera Varela, Antonio; Seijas-Lopez, Alvaro] Hosp Clin Univ Santiago, Inst Invest Sanitaria Santiago IDIS, Serv Reumatol, Santiago De Compostela, Spain.
   [Manrique-Arija, Sara; Mena Vazquez, Natalia] Inst Invest Biomed Malaga IBIMA, Malaga, Spain.
   [Manrique-Arija, Sara; Mena Vazquez, Natalia] Hosp Reg Univ Malaga, UGC Reumatol, Malaga, Spain.
RP Pablos, JL (corresponding author), Inst Invest Hosp 12 Octubre, Serv Reumatol, Madrid 28041, Spain.
EM jlpablos@h12o.es
RI Castrejon, Isabel/ABH-5293-2020; Gonzalez, Antonio/C-4444-2008; VARELA,
   ANTONIO MERA/ABH-1886-2020; Fernandez, David Fernandez/AAW-3710-2020;
   Gonzalez-Gay, Miguel/B-2306-2008; Blanco Garcia, Francisco J/C-3192-2014
OI Gonzalez, Antonio/0000-0002-2624-0606; VARELA, ANTONIO
   MERA/0000-0001-9380-6975; Fernandez, David
   Fernandez/0000-0003-4590-7821; Gonzalez-Gay, Miguel/0000-0002-7924-7406;
   Blanco Garcia, Francisco J/0000-0001-9821-7635; Pablos, Jose
   L./0000-0001-7229-6005; Blanco, Ricardo/0000-0003-2344-2285
FU Fondo de Investigacion Sanitaria, Instituto de Salud Carlos IIIInstituto
   de Salud Carlos III [RD16/0012]; European Regional Development
   FundEuropean Union (EU)
FX The RIER network was supported by the Fondo de Investigacion Sanitaria,
   Instituto de Salud Carlos III (RD16/0012 RETICS Program) and cofinanced
   by the European Regional Development Fund.
CR Gianfrancesco MA, 2020, LANCET RHEUMATOL, V2, pE250, DOI 10.1016/S2665-9913(20)30095-3
   Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394
   Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032
   Henderson LA, ARTHRITIS RHEUMATOL, V17
   Liu J, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0156-0
   Luo P, J MED VIROL
   McInnes IB, 2020, ANN RHEUM DIS, V79, DOI 10.1136/annrheumdis-2020-217494
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Ritchie AI, 2020, LANCET, V395, P1111, DOI 10.1016/S0140-6736(20)30691-7
   Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2
   Vassilopoulos D, 2007, CURR OPIN RHEUMATOL, V19, P619, DOI 10.1097/BOR.0b013e3282f05b63
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Winthrop KL, 2017, NAT REV RHEUMATOL, V13, P234, DOI 10.1038/nrrheum.2017.23
   Wu JT, 2020, NAT MED, DOI 10.1038/s41591-020-0822-7
   Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
NR 15
TC 10
Z9 10
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD SEP
PY 2020
VL 79
IS 9
BP 1170
EP 1173
DI 10.1136/annrheumdis-2020-217763
PG 4
WC Rheumatology
SC Rheumatology
GA NK9FL
UT WOS:000567034400027
PM 32796045
OA Green Published, Bronze
DA 2021-01-01
ER

PT J
AU Moutsopoulos, HM
AF Moutsopoulos, Haralampos M.
TI Anti-inflammatory therapy may ameliorate the clinical picture of
   COVID-19
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Letter
C1 [Moutsopoulos, Haralampos M.] Acad Athens, Med Sci Immunol, Athens 11527, Greece.
RP Moutsopoulos, HM (corresponding author), Acad Athens, Med Sci Immunol, Athens 11527, Greece.
EM hmoutsop@med.uoa.gr
CR Mihai C, 2020, ANN RHEUM DIS, V79, P668, DOI 10.1136/annrheumdis-2020-217442
   Monti S, 2020, ANN RHEUM DIS, V79, P667, DOI 10.1136/annrheumdis-2020-217424
NR 2
TC 4
Z9 4
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD SEP
PY 2020
VL 79
IS 9
BP 1253
EP +
DI 10.1136/annrheumdis-2020-217562
PG 2
WC Rheumatology
SC Rheumatology
GA NK9FL
UT WOS:000567034400040
PM 32345616
OA Bronze, Green Published
DA 2021-01-01
ER

PT J
AU Soler, M
   Scholtz, A
   Zeto, R
   Armani, AM
AF Soler, Maria
   Scholtz, Alexis
   Zeto, Rene
   Armani, Andrea M.
TI Engineering photonics solutions for COVID-19
SO APL PHOTONICS
LA English
DT Article
ID LABEL-FREE; DISINFECTION METHODS; SENSITIVE DETECTION; RAPID DETECTION;
   SPR BIOSENSOR; UV; VIRUS; INACTIVATION; SARS-COV-2; ASSAY
AB As the impact of COVID-19 on society became apparent, the engineering and scientific community recognized the need for innovative solutions. Two potential roadmaps emerged: developing short-term solutions to address the immediate needs of the healthcare communities and developing mid/long-term solutions to eliminate the over-arching threat. However, in a truly global effort, researchers from all backgrounds came together in tackling this challenge. Short-term efforts have focused on re-purposing existing technologies and leveraging additive manufacturing techniques to address shortages in personal protective equipment and disinfection. More basic research efforts with mid-term and long-term impact have emphasized developing novel diagnostics and accelerating vaccines. As a foundational technology, photonics has contributed directly and indirectly to all efforts. This perspective will provide an overview of the critical role that the photonics field has played in efforts to combat the immediate COVID-19 pandemic as well as how the photonics community could anticipate contributing to future pandemics of this nature.
C1 [Soler, Maria] BIST, Nanobiosensors & Bioanalyt Applicat Grp NanoB2A, Catalan Inst Nanosci & Nanotechnol ICN2, CSIC, Barcelona, Spain.
   [Soler, Maria] CIBER BBN, Barcelona, Spain.
   [Scholtz, Alexis; Armani, Andrea M.] Univ Southern Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA.
   [Zeto, Rene; Armani, Andrea M.] Univ Southern Calif, Mork Family Dept Chem Engn & Mat Sci, Los Angeles, CA 90089 USA.
RP Armani, AM (corresponding author), Univ Southern Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA.; Armani, AM (corresponding author), Univ Southern Calif, Mork Family Dept Chem Engn & Mat Sci, Los Angeles, CA 90089 USA.
EM armani@usc.edu
RI Armani, Andrea/A-8132-2010
OI Armani, Andrea/0000-0001-9890-5104
FU National Science FoundationNational Science Foundation (NSF) [2028446];
   CoNVaT project from the H2020 research and innovation programme of the
   European Commission [101003544]; CERCA programme/Generalitat de
   Catalunya; Severo Ochoa Centres of Excellence programme - AEI
   [SEV-2017-0706]
FX The authors thank Fakhar Singhera for assistance in preparing the
   figures in Biorender. The authors would like to thank the National
   Science Foundation (Grant No. 2028446) and the CoNVaT project from the
   H2020 research and innovation programme of the European Commission
   (Project Grant No. 101003544). The ICN2 was funded by the CERCA
   programme/Generalitat de Catalunya. The ICN2 was supported by the Severo
   Ochoa Centres of Excellence programme, funded by AEI (Grant No.
   SEV-2017-0706).
CR Ackerman E, 2020, IEEE SPECTRUM, V57, P50, DOI 10.1109/MSPEC.2020.8946313
   Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254
   Alijotas-Reig J, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102569
   Altay O, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101303
   Andersen B. M., 2019, PREVENTION CONTROL I, P815
   [Anonymous], 2018, AM J TRANSPLANT S1, V18, P10, DOI DOI 10.1109/JSEN.2018.2870228
   Armani AM, 2020, NAT REV MATER, V5, P403, DOI 10.1038/s41578-020-0205-1
   Beal A, 2016, J HOSP INFECT, V93, P164, DOI 10.1016/j.jhin.2016.03.016
   Bergmann K., 2014, AM PHARM REV
   Berney M, 2006, APPL ENVIRON MICROB, V72, P2586, DOI 10.1128/AEM.72.4.2586-2593.2006
   Card K. J., 2020, MEDRXIV
   Carter LJ, 2020, ACS CENTRAL SCI, V6, P591, DOI 10.1021/acscentsci.0c00501
   Casini B, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16193572
   Celina MC, 2020, POLYM DEGRAD STABIL, V179, DOI 10.1016/j.polymdegradstab.2020.109251
   Cereda D, 2020, ARXIV200309320QBIO
   Chang YF, 2018, ANAL CHEM, V90, P1861, DOI 10.1021/acs.analchem.7b03934
   Chemaly RF, 2014, THER ADV INFECT DIS, V2, P79, DOI 10.1177/2049936114543287
   Ciminelli C, 2019, IET OPTOELECTRON, V13, P48, DOI 10.1049/iet-opt.2018.5082
   Daaboul GG, 2014, ACS NANO, V8, P6047, DOI 10.1021/nn501312q
   Darnell MER, 2004, J VIROL METHODS, V121, P85, DOI 10.1016/j.jviromet.2004.06.006
   de Anda J, 2017, ACS NANO, V11, P9340, DOI 10.1021/acsnano.7b04738
   del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1339, DOI 10.1001/jama.2020.3072
   Derraik J. G. B., 2020, MEDRXIV, DOI [10.1101/2020.04.02.20051409, DOI 10.1101/2020.04.02.20051409]
   Dias R, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0689-8
   Duval D, 2012, LAB CHIP, V12, P1987, DOI [10.1039/c2lc40054e, 10.1039/c21c40054e]
   El Haddad L, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2792-z
   Fauci AS, 2020, NEW ENGL J MED, V382, P1268, DOI 10.1056/NEJMe2002387
   Gavela AF, 2016, SENSORS-BASEL, V16, DOI 10.3390/s16030285
   Ferrari D, 2020, CLIN CHEM LAB MED, V58, P1095, DOI 10.1515/cclm-2020-0398
   Frustaci S, 2019, CURR OPIN CHEM BIOL, V51, P66, DOI 10.1016/j.cbpa.2019.05.003
   Fuentes S, 2017, SCI REP-UK, V7, DOI 10.1038/srep42428
   Gauger PC, 2014, VIROLOGY, V471, P93, DOI 10.1016/j.virol.2014.10.003
   Grossman J, 2020, J AM COLL SURGEONS, V231, P275, DOI 10.1016/j.jamcollsurg.2020.04.029
   Guridi A, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16234747
   Hamzavi IH, 2020, J AM ACAD DERMATOL, V82, P1511, DOI 10.1016/j.jaad.2020.03.085
   Han X, 2019, MATERIALS, V12, DOI 10.3390/ma12091411
   Hawk RM, 2015, BIOSENS BIOELECTRON, V65, P198, DOI 10.1016/j.bios.2014.10.041
   Hijnen WAM, 2006, WATER RES, V40, P3, DOI 10.1016/j.watres.2005.10.030
   Huertas CS, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00724
   Hunt HK, 2014, IEEE J SEL TOP QUANT, V20, DOI 10.1109/JSTQE.2013.2272916
   Hunt HK, 2010, NANOSCALE, V2, P1544, DOI 10.1039/c0nr00201a
   Ishige T, 2020, CLIN CHIM ACTA, V507, P139, DOI 10.1016/j.cca.2020.04.023
   Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007
   Jobin A, 2019, NAT MACH INTELL, V1, P389, DOI 10.1038/s42256-019-0088-2
   Jouffroy R, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03036-9
   Kim YJ, 2020, ANN LAB MED, V40, P349, DOI 10.3343/alm.2020.40.5.349
   Koivunen J, 2005, WATER RES, V39, P1519, DOI 10.1016/j.watres.2005.01.021
   Koo B, 2017, BIOSENS BIOELECTRON, V90, P187, DOI 10.1016/j.bios.2016.11.051
   Kovach A, 2020, ADV OPT PHOTONICS, V12, P135, DOI 10.1364/AOP.376924
   Lam TTY, 2020, NATURE, V583, P282, DOI 10.1038/s41586-020-2169-0
   Lee CYP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00879
   Lee ME, 2016, ACS SENSORS, V1, P1251, DOI 10.1021/acssensors.6b00491
   Li GD, 2020, NAT REV DRUG DISCOV, V19, P149, DOI 10.1038/d41573-020-00016-0
   Li XL, 2019, SCI TOTAL ENVIRON, V659, P1415, DOI 10.1016/j.scitotenv.2018.12.344
   Li ZT, 2020, J MED VIROL, V92, P1518, DOI 10.1002/jmv.25727
   Liao L, 2020, ACS NANO, V14, P6348, DOI 10.1021/acsnano.0c03597
   Lippi G, 2020, CLIN CHEM LAB MED, V58, P1063, DOI 10.1515/cclm-2020-0240
   Liu C, 2020, ACS CENTRAL SCI, V6, P315, DOI 10.1021/acscentsci.0c00272
   Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1
   Lopez CA, 2011, BIOSENS BIOELECTRON, V26, P3432, DOI 10.1016/j.bios.2011.01.019
   Luan EX, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18103519
   Lukin DM, 2020, NAT PHOTONICS, V14, P330, DOI 10.1038/s41566-019-0556-6
   Luks AM, 2020, ANN AM THORAC SOC, V17, P918, DOI 10.1513/AnnalsATS.202004-327CME
   Maldonado J, 2020, ANALYST, V145, P497, DOI 10.1039/c9an01485c
   Marra AR, 2018, INFECT CONT HOSP EP, V39, P20, DOI 10.1017/ice.2017.226
   Marsh R, 2007, J MED VIROL, V79, P829, DOI 10.1002/jmv.20892
   Mauriz E, 2019, ANALYST, V144, P7105, DOI 10.1039/c9an00701f
   McBirney SE, 2018, ACS SENSORS, V3, P1264, DOI 10.1021/acssensors.8b00269
   McBirney SE, 2016, BIOMED OPT EXPRESS, V7, P4034, DOI 10.1364/BOE.7.004034
   Mehrabani S, 2014, SENSORS-BASEL, V14, P5890, DOI 10.3390/s140405890
   Michard F, 2020, J CLIN MONIT COMPUT, DOI 10.1007/s10877-020-00550-7
   Mustapha A, 2018, AM J INFECT CONTROL, V46, P584, DOI [10.1016/j.ajic.2017.10.025, 10.1016/j.ajic.2017.09.019]
   Nerandzic MM, 2015, INFECT CONT HOSP EP, V36, P192, DOI 10.1017/ice.2014.36
   Nerandzic MM, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-197
   Nie JH, 2020, EMERG MICROBES INFEC, V9, P680, DOI 10.1080/22221751.2020.1743767
   Nilsson CE, 2010, VACCINE, V28, P759, DOI 10.1016/j.vaccine.2009.10.070
   Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236
   Nunayon SS, 2019, INDOOR AIR, DOI 10.1111/ina.12619
   Nwachuku N, 2005, APPL ENVIRON MICROB, V71, P5633, DOI 10.1128/AEM.71.9.5633-5636.2005
   Ozkumur E, 2008, P NATL ACAD SCI USA, V105, P7988, DOI 10.1073/pnas.0711421105
   Ozkumur AY, 2019, IEEE J SEL TOP QUANT, V25, DOI 10.1109/JSTQE.2018.2854548
   Padoan A, 2020, CLIN CHEM LAB MED, V58, P1081, DOI 10.1515/cclm-2020-0443
   Prabowo BA, 2017, BIOSENS BIOELECTRON, V92, P186, DOI 10.1016/j.bios.2017.01.043
   Qiu GG, 2020, ACS NANO, V14, P5268, DOI 10.1021/acsnano.0c02439
   Raj A, 2018, ENERGY ENV SUSTAIN, P389, DOI 10.1007/978-981-10-7751-7_17
   Santiago I, 2020, CHEMBIOCHEM, V21, P2880, DOI 10.1002/cbic.202000250
   Satyanarayana M., 2020, CHEM ENG NEWS
   Scherr SM, 2017, LAB CHIP, V17, P917, DOI 10.1039/c6lc01528j
   Scherr SM, 2016, ACS NANO, V10, P2827, DOI 10.1021/acsnano.5b07948
   Schroeder HW, 2010, J ALLERGY CLIN IMMUN, V125, pS41, DOI 10.1016/j.jaci.2009.09.046
   Setlow P, 2001, ENVIRON MOL MUTAGEN, V38, P97, DOI 10.1002/em.1058
   Sevenler D, 2017, BIOMED OPT EXPRESS, V8, P2976, DOI 10.1364/BOE.8.002976
   Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117
   She RC, 2020, BIOMED OPT EXPRESS, V11, P4326, DOI 10.1364/BOE.395659
   Shen MZ, 2020, J PHARM ANAL, V10, P97, DOI 10.1016/j.jpha.2020.02.010
   Shi L, 2015, BIO-MED MATER ENG, V26, pS2207, DOI 10.3233/BME-151526
   Singh P., 2017, REFERENCE MODULE LIF
   Sinha RP, 2002, PHOTOCH PHOTOBIO SCI, V1, P225, DOI 10.1039/b201230h
   Soler M, 2019, EXPERT REV MOL DIAGN, V19, P71, DOI 10.1080/14737159.2019.1554435
   Stadler K, 2003, NAT REV MICROBIOL, V1, P209, DOI 10.1038/nrmicro775
   Sun SY, 2020, CLIN CHIM ACTA, V507, P174, DOI 10.1016/j.cca.2020.04.024
   Tang XL, 2020, NATL SCI REV, V7, P1012, DOI 10.1093/nsr/nwaa036
   To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1
   U.S. Centers for Disease Control and Prevention, 2019, ANT RES THREATS US 2
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Nguyen VT, 2016, BIOSENS BIOELECTRON, V86, P293, DOI 10.1016/j.bios.2016.06.064
   VanGuilder HD, 2008, BIOTECHNIQUES, V44, P619, DOI 10.2144/000112776
   Vashist SK, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10040202
   Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7
   Walls AC, 2020, CELL, V181, P281, DOI 10.1016/j.cell.2020.02.058
   Wang CY, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-16452-w, 10.1038/s41467-020-16256-y]
   Wang FF, 2019, NAT METHODS, V16, P545, DOI 10.1038/s41592-019-0398-7
   Washburn AL, 2009, ANAL CHEM, V81, P9499, DOI 10.1021/ac902006p
   Weissleder R, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc1931
   Wilkerson R Gentry, 2020, Am J Emerg Med, V38, DOI 10.1016/j.ajem.2020.05.044
   Willner AN, 2018, OPT LETT, V43, P5563, DOI 10.1364/OL.43.005563
   Winfield A, 2019, NAT ELECTRON, V2, P46, DOI 10.1038/s41928-019-0213-6
   Wong CL, 2017, SENSORS-BASEL, V17, DOI 10.3390/s17102363
   Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328
   Xu J, 2007, ANAL BIOANAL CHEM, V389, P1193, DOI 10.1007/s00216-007-1525-3
   Yong SK, 2020, BIOTECHNOL J, V15, DOI 10.1002/biot.202000152
   Young BE, 2020, JAMA-J AM MED ASSOC, V323, P1488, DOI 10.1001/jama.2020.3204
   Yuan M, 2020, SCIENCE, V368, P630, DOI 10.1126/science.abb7269
   Yurt A, 2012, NANOSCALE, V4, P715, DOI 10.1039/c2nr11562j
   Zhang HY, 2019, BIOSENS BIOELECTRON, V141, DOI 10.1016/j.bios.2019.111476
   Zhang YN, 2018, NANOSCALE, V10, P13832, DOI 10.1039/c8nr03709d
   Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575
   Zipfel WR, 2003, NAT BIOTECHNOL, V21, P1368, DOI 10.1038/nbt899
   Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737
NR 129
TC 0
Z9 0
U1 3
U2 3
PU AMER INST PHYSICS
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
SN 2378-0967
J9 APL PHOTONICS
JI APL Phontonics
PD SEP 1
PY 2020
VL 5
IS 9
AR 090901
DI 10.1063/5.0021270
PG 14
WC Optics; Physics, Applied
SC Optics; Physics
GA NL5PE
UT WOS:000567466700001
PM 33015361
OA DOAJ Gold, Green Published
DA 2021-01-01
ER

EF